det||features-5/NNS||the-1/DT	amod||features-5/NNS||clinical-2/JJ	conj_and||clinical-2/JJ||pathological-4/JJ	amod||features-5/NNS||pathological-4/JJ	nsubjpass||analyzed-19/VBN||features-5/NNS	num||specimens-11/NNS||61-7/CD	amod||specimens-11/NNS||formalin-fixed-8/JJ	amod||specimens-11/NNS||pancreatic-9/JJ	nn||specimens-11/NNS||cancer-10/NN	prep_of||features-5/NNS||specimens-11/NNS	num||pancreases-15/NNS||10-13/CD	amod||pancreases-15/NNS||normal-14/JJ	conj_and||features-5/NNS||pancreases-15/NNS	nsubjpass||analyzed-19/VBN||pancreases-15/NNS	prep_as||pancreases-15/NNS||controls-17/NNS	auxpass||analyzed-19/VBN||were-18/VBD	root||ROOT-0/null||analyzed-19/VBN	cancer-10||formalin--1||no_rel||the clinical and pathological features of 61 formalin-fixed pancreatic cancer specimens and 10 normal pancreases as controls were analyzed.
nsubj||reservoirs-3/NNS||bats-1/NNS	cop||reservoirs-3/NNS||are-2/VBP	root||ROOT-0/null||reservoirs-3/NNS	amod||viruses-7/NNS||emerging-5/VBG	amod||viruses-7/NNS||zoonotic-6/JJ	prep_for||reservoirs-3/NNS||viruses-7/NNS	nsubj||have-10/VB||viruses-7/NNS	aux||have-10/VB||can-9/MD	rcmod||viruses-7/NNS||have-10/VB	det||impact-13/NN||a-11/DT	amod||impact-13/NN||profound-12/JJ	dobj||have-10/VB||impact-13/NN	nn||health-18/NN||human-15/NN	conj_and||human-15/NN||animal-17/NN	nn||health-18/NN||animal-17/NN	prep_on||impact-13/NN||health-18/NN	nn||paramyxoviruses-25/NNS||lyssaviruses-21/NNS	dep||paramyxoviruses-25/NNS||filoviruses-23/NNS	prep_including||impact-13/NN||paramyxoviruses-25/NNS	nn||coronaviruses-29/NNS||severeacuterespiratorysyndrome-28/NN	prep_including||impact-13/NN||coronaviruses-29/NNS	conj_and||paramyxoviruses-25/NNS||coronaviruses-29/NNS	appos||reservoirs-3/NNS||sars-covs-31/NNS	severeacuterespiratorysyndrome-28||coronaviruses-29||no||bats are reservoirs for emerging zoonotic viruses that can have a profound impact on human and animal health, including lyssaviruses, filoviruses, paramyxoviruses, and severeacuterespiratorysyndrome coronaviruses (sars-covs).
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||significance-5/NN||the-3/DT	amod||significance-5/NN||clinical-4/JJ	dobj||investigated-2/VBD||significance-5/NN	amod||immunoglobulin-9/NN||serum-7/JJ	amod||immunoglobulin-9/NN||specific-8/JJ	prep_of||significance-5/NN||immunoglobulin-9/NN	dep||significance-5/NN||e-10/SYM	appos||significance-5/NN||lge-12/NN	det||enterotoxin-19/NN||the-15/DT	amod||enterotoxin-19/NN||staphylococcal-16/JJ	nn||enterotoxin-19/NN||superantigens-17/NNS	nn||enterotoxin-19/NN||staphylococcal-18/NN	prep_to||investigated-2/VBD||enterotoxin-19/NN	det||sea-22/NN||a-20/DT	dep||enterotoxin-19/NN||sea-22/NN	amod||enterotoxin-26/NN||staphylococcal-25/JJ	prep_to||investigated-2/VBD||enterotoxin-26/NN	conj_and||enterotoxin-19/NN||enterotoxin-26/NN	dep||enterotoxin-26/NN||b-27/SYM	appos||b-27/SYM||seb-29/NN	amod||toxin-34/NN||toxicshocksyndrome-33/JJ	prep_to||investigated-2/VBD||toxin-34/NN	conj_and||enterotoxin-19/NN||toxin-34/NN	appos||toxin-34/NN||tsst-36/NN	dep||toxin-34/NN||-1-38/CD	prep_in||investigated-2/VBD||patients-40/NNS	amod||urticaria-43/NN||chronic-42/JJ	prep_with||patients-40/NNS||urticaria-43/NN	appos||urticaria-43/NN||cu-45/NN	vmod||investigated-2/VBD||focusing-48/VBG	det||differences-51/NNS||the-50/DT	prep_on||focusing-48/VBG||differences-51/NNS	det||prevalences-54/NNS||these-53/DT	prep_in||differences-51/NNS||prevalences-54/NNS	amod||cu-57/NN||aspirin-intolerant-56/JJ	prep_between||prevalences-54/NNS||cu-57/NN	appos||cu-57/NN||aicu-59/NNP	amod||patients-67/NNS||aspirin-tolerant-62/JJ	nn||patients-67/NNS||cu-63/NN	appos||patients-67/NNS||atcu-65/NNP	prep_between||prevalences-54/NNS||patients-67/NNS	conj_and||cu-57/NN||patients-67/NNS	cu-63||urticaria-43||no_rel||we investigated the clinical significance of serum specific immunoglobulin e (lge) to the staphylococcal superantigens staphylococcal enterotoxin a (sea), staphylococcal enterotoxin b (seb), and toxicshocksyndrome toxin (tsst)-1 in patients with chronic urticaria (cu), focusing on the differences in these prevalences between aspirin-intolerant cu (aicu) and aspirin-tolerant cu (atcu) patients.
det||plurality-2/NN||a-1/DT	nsubjpass||treated-8/VBN||plurality-2/NN	prep_of||plurality-2/NN||patients-4/NNS	prep_with||patients-4/NNS||schizophrenia-6/NN	auxpass||treated-8/VBN||was-7/VBD	root||ROOT-0/null||treated-8/VBN	prep_with||treated-8/VBN||clozapine-10/NN	num||%-13/NN||39-12/CD	appos||clozapine-10/NN||%-13/NN	nsubjpass||followed-18/VBN||this-16/DT	auxpass||followed-18/VBN||was-17/VBD	parataxis||treated-8/VBN||followed-18/VBN	agent||followed-18/VBN||risperidone-20/JJ	agent||followed-18/VBN||sulpride-22/JJ	conj_and||risperidone-20/JJ||sulpride-22/JJ	agent||followed-18/VBN||chlorpromazine-24/JJ	conj_and||risperidone-20/JJ||chlorpromazine-24/JJ	agent||followed-18/VBN||perphenazine-26/JJ	conj_and||risperidone-20/JJ||perphenazine-26/JJ	agent||followed-18/VBN||haloperidol-29/JJ	conj_and||risperidone-20/JJ||haloperidol-29/JJ	schizophrenia-6||perphenazine-26||yes||a plurality of patients with schizophrenia was treated with clozapine (39%); this was followed by risperidone, sulpride, chlorpromazine, perphenazine, and haloperidol.
nsubj||equivalent-7/JJ||growth-1/NN	nsubjpass||reduced-20/VBN||growth-1/NN	det||viruses-5/NNS||both-3/DT	amod||viruses-5/NNS||recombinant-4/JJ	prep_of||growth-1/NN||viruses-5/NNS	cop||equivalent-7/JJ||was-6/VBD	root||ROOT-0/null||equivalent-7/JJ	prep_to||equivalent-7/JJ||that-9/DT	amod||virus-13/NN||wild-11/JJ	nn||virus-13/NN||type-12/NN	prep_of||that-9/DT||virus-13/NN	nn||cells-16/NNS||vero-15/NN	prep_in||equivalent-7/JJ||cells-16/NNS	auxpass||reduced-20/VBN||was-19/VBD	conj_but||equivalent-7/JJ||reduced-20/VBN	amod||cells-24/NNS||human-22/JJ	amod||cells-24/NNS||epithelial-23/JJ	prep_in||reduced-20/VBN||cells-24/NNS	prep_like||cells-24/NNS||hep-2-26/CD	virus-13||viruses-5||no||growth of both recombinant viruses was equivalent to that of wild type virus in vero cells, but was reduced in human epithelial cells like hep-2.
det||contrary-3/NN||the-2/DT	prep_on||tgf-î-40/VBZ||contrary-3/NN	amod||injections-7/NNS||triple-5/JJ	nn||injections-7/NNS||i.p.-6/NN	nsubj||tgf-î-40/VBZ||injections-7/NNS	num||hours-10/NNS||24-9/CD	npadvmod||apart-11/RB||hours-10/NNS	advmod||injections-7/NNS||apart-11/RB	num||î-15/NN||10-14/CD	prep_of||injections-7/NNS||î-15/NN	num||ejhe-18/NN||1/4-16/CD	nn||ejhe-18/NN||g-17/NN	nsubj||increased-19/VBD||ejhe-18/NN	rcmod||î-15/NN||increased-19/VBD	advmod||ifn-î-21/JJ||significantly-20/RB	amod||production-23/NN||ifn-î-21/JJ	amod||production-23/NN||³-22/JJ	dobj||increased-19/VBD||production-23/NN	det||p-28/NN||the-25/DT	amod||p-28/NN||spleen-26/JJ	amod||p-28/NN||-lrb--27/JJ	prep_in||increased-19/VBD||p-28/NN	vmod||p-28/NN||<-29/VBG	num||-rrb--31/NNS||0.02-30/CD	dobj||<-29/VBG||-rrb--31/NNS	mark||increased-35/VBD||while-32/IN	advmod||ejhe-wr-34/NN||only-33/RB	nsubj||increased-35/VBD||ejhe-wr-34/NN	advcl||<-29/VBG||increased-35/VBD	advmod||ifn-î-37/JJ||significantly-36/RB	amod||³-38/NNS||ifn-î-37/JJ	dobj||increased-35/VBD||³-38/NNS	root||ROOT-0/null||tgf-î-40/VBZ	number||1-42/CD||²-41/CD	dobj||tgf-î-40/VBZ||1-42/CD	amod||<-47/NNS||il-17-44/JJ	amod||<-47/NNS||-lrb--45/JJ	nn||<-47/NNS||p-46/NN	dobj||tgf-î-40/VBZ||<-47/NNS	conj_and||1-42/CD||<-47/NNS	dep||<-47/NNS||0.03-48/CD	num||production-52/NN||0.005-50/CD	amod||production-52/NN||-rrb--51/JJ	dep||<-47/NNS||production-52/NN	det||microenvironment-56/NN||the-54/DT	nn||microenvironment-56/NN||tumor-55/NN	prep_within||production-52/NN||microenvironment-56/NN	amod||fibrosarcoma-59/NN||meth-a-58/JJ	prep_of||microenvironment-56/NN||fibrosarcoma-59/NN	ifn--1||fibrosarcoma-59||no_rel||on the contrary , triple i.p. injections , 24 hours apart ; of 10 î 1/4 g ejhe increased significantly ifn-î ³ production in the spleen -lrb- p < 0.02 -rrb- while only ejhe-wr increased significantly ifn-î ³ , tgf-î ² 1 and il-17 -lrb- p < 0.03 - 0.005 -rrb- production within the tumor microenvironment of meth-a fibrosarcoma .
amod||shortstature-2/NN||idiopathic-1/JJ	nsubj||term-8/NN||shortstature-2/NN	appos||shortstature-2/NN||iss-4/NN	cop||term-8/NN||is-6/VBZ	det||term-8/NN||a-7/DT	root||ROOT-0/null||term-8/NN	nsubj||describes-10/VBZ||term-8/NN	rcmod||term-8/NN||describes-10/VBZ	dobj||describes-10/VBZ||shortstature-11/NN	prep_in||describes-10/VBZ||children-13/NNS	nsubj||have-17/VB||children-13/NNS	aux||have-17/VB||do-15/VBP	neg||have-17/VB||not-16/RB	rcmod||children-13/NNS||have-17/VB	amod||deficiency-22/NN||growthhormone-18/JJ	dep||growthhormone-18/JJ||gh-20/NN	dobj||have-17/VB||deficiency-22/NN	dobj||identified-33/VBN||whom-25/WP	det||etiology-27/NN||the-26/DT	nsubjpass||identified-33/VBN||etiology-27/NN	det||shortstature-30/NN||the-29/DT	prep_of||etiology-27/NN||shortstature-30/NN	auxpass||identified-33/VBN||is-31/VBZ	neg||identified-33/VBN||not-32/RB	prep_in||describes-10/VBZ||identified-33/VBN	conj_and||children-13/NNS||identified-33/VBN	nsubj||have-17/VB||identified-33/VBN	shortstature-30||growthhormone-18||yes||idiopathic shortstature (iss) is a term that describes shortstature in children who do not have growthhormone (gh) deficiency and in whom the etiology of the shortstature is not identified.
nsubj||components-12/NNS||collagen-1/NN	conj_and||collagen-1/NN||fibronectin-3/NN	nsubj||components-12/NNS||fibronectin-3/NN	appos||collagen-1/NN||fn-5/NN	cop||components-12/NNS||are-7/VBP	num||components-12/NNS||two-8/CD	amod||components-12/NNS||abundant-9/JJ	conj_and||abundant-9/JJ||essential-11/JJ	amod||components-12/NNS||essential-11/JJ	root||ROOT-0/null||components-12/NNS	det||matrix-17/NN||the-14/DT	amod||matrix-17/NN||vertebrate-15/JJ	nn||matrix-17/NN||extracellular-16/NN	prep_of||components-12/NNS||matrix-17/NN	nsubj||interact-20/VB||they-19/PRP	nsubj||affect-26/VB||they-19/PRP	parataxis||components-12/NNS||interact-20/VB	advmod||interact-20/VB||directly-21/RB	amod||receptors-24/NNS||cellular-23/JJ	prep_with||interact-20/VB||receptors-24/NNS	parataxis||components-12/NNS||affect-26/VB	conj_and||interact-20/VB||affect-26/VB	nn||adhesion-28/NN||cell-27/NN	dobj||affect-26/VB||adhesion-28/NN	dobj||affect-26/VB||migration-30/NN	conj_and||adhesion-28/NN||migration-30/NN	collagen-1||adhesion-28||no_rel||collagen and fibronectin (fn) are two abundant and essential components of the vertebrate extracellular matrix; they interact directly with cellular receptors and affect cell adhesion and migration.
advmod||investigated-25/VBN||sulphadoxine-pyrimethamine-1/RB	dep||investigated-25/VBN||sp-3/VB	det||treatment-8/NN||a-5/DT	advmod||used-7/VBN||widely-6/RB	amod||treatment-8/NN||used-7/VBN	nsubjpass||investigated-25/VBN||treatment-8/NN	amod||malaria-11/NN||uncomplicated-10/JJ	prep_for||treatment-8/NN||malaria-11/NN	prep_for||treatment-8/NN||recommended-13/VBN	conj_and||malaria-11/NN||recommended-13/VBN	amod||treatment-17/NN||intermittent-15/JJ	nn||treatment-17/NN||preventive-16/NN	prep_for||recommended-13/VBN||treatment-17/NN	prep_of||recommended-13/VBN||malaria-19/NN	prep_in||recommended-13/VBN||pregnancy-21/NN	aux||investigated-25/VBN||is-23/VBZ	auxpass||investigated-25/VBN||being-24/VBG	root||ROOT-0/null||investigated-25/VBN	amod||treatment-29/NN||intermittent-27/JJ	nn||treatment-29/NN||preventive-28/NN	prep_for||investigated-25/VBN||treatment-29/NN	prep_of||treatment-29/NN||malaria-31/NN	prep_in||malaria-31/NN||infants-33/NNS	appos||infants-33/NNS||ipti-35/NNP	malaria-31||pyrimethamine--1||no||sulphadoxine-pyrimethamine (sp) a widely used treatment for uncomplicated malaria and recommended for intermittent preventive treatment of malaria in pregnancy, is being investigated for intermittent preventive treatment of malaria in infants (ipti).
poss||data-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||data-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||likely-8/JJ||that-4/IN	amod||pathogenesis-6/NNS||hereditaryferritinopathy-5/JJ	nsubj||likely-8/JJ||pathogenesis-6/NNS	nsubj||result-10/VB||pathogenesis-6/NNS	cop||likely-8/JJ||is-7/VBZ	ccomp||suggest-3/VBP||likely-8/JJ	aux||result-10/VB||to-9/TO	xcomp||likely-8/JJ||result-10/VB	det||combination-13/NN||a-12/DT	prep_from||result-10/VB||combination-13/NN	prep_of||combination-13/NN||reduction-15/NN	nn||function-19/NN||iron-17/NN	nn||function-19/NN||storage-18/NN	prep_in||result-10/VB||function-19/NN	amod||toxicity-22/NN||enhanced-21/JJ	prep_in||result-10/VB||toxicity-22/NN	conj_and||function-19/NN||toxicity-22/NN	vmod||function-19/NN||associated-23/VBN	amod||aggregates-27/NNS||iron-induced-25/JJ	nn||aggregates-27/NNS||ferritin-26/NN	prep_with||associated-23/VBN||aggregates-27/NNS	iron-17||hereditaryferritinopathy-5||no_rel||our data suggest that hereditaryferritinopathy pathogenesis is likely to result from a combination of reduction in iron storage function and enhanced toxicity associated with iron-induced ferritin aggregates.
nsubjpass||discussed-6/VBN||treatment-1/NN	amod||malaria-4/NN||chloroquine-resistant-3/JJ	prep_of||treatment-1/NN||malaria-4/NN	auxpass||discussed-6/VBN||is-5/VBZ	root||ROOT-0/null||discussed-6/VBN	malaria-4||chloroquine--1||yes||treatment of chloroquine-resistant malaria is discussed.
nsubj||received-16/VBN||janumettm-1/NN	nsubj||received-16/VBN||janumettm-1/NN	nsubj||received-16/VBN||janumettm-1/NN	det||combination-6/NN||a-3/DT	amod||combination-6/NN||fixed-4/VBN	nn||combination-6/NN||dose-5/NN	appos||janumettm-1/NN||combination-6/NN	nn||hcl-9/NN||sitagliptin/metformin-8/NN	prep_of||combination-6/NN||hcl-9/NN	vmod||combination-6/NN||manufactured-10/VBN	nn||pharmaceuticals-13/NNS||merck-12/NN	agent||manufactured-10/VBN||pharmaceuticals-13/NNS	aux||received-16/VBN||has-15/VBZ	root||ROOT-0/null||received-16/VBN	conj_or||received-16/VBN||received-16/VBN	conj_or||received-16/VBN||received-16/VBN	nsubj||approval-22/NN||us-17/PRP	nn||approval-22/NN||food-18/NN	conj_and||food-18/NN||drug-20/NN	nn||approval-22/NN||drug-20/NN	nn||approval-22/NN||administration-21/NN	xcomp||received-16/VBN||approval-22/NN	prep_for||approval-22/NN||treatment-24/NN	prep_of||treatment-24/NN||patients-26/NNS	prep_with||received-16/VBN||type2diabetes-28/NNS	nsubjpass||controlled-33/VBN||type2diabetes-28/NNS	auxpass||controlled-33/VBN||are-31/VBP	advmod||controlled-33/VBN||inadequately-32/RB	rcmod||type2diabetes-28/NNS||controlled-33/VBN	preconj||received-16/VBN||either-35/CC	prep_by||received-16/VBN||sitagliptin-37/NN	prep_by||received-16/VBN||metformin-39/NN	conj_or||sitagliptin-37/NN||metformin-39/NN	advmod||received-16/VBN||alone-40/RB	advmod||received-16/VBN||together-42/RB	amod||form-46/NN||free-dose-44/JJ	nn||form-46/NN||combination-45/NN	prep_in||received-16/VBN||form-46/NN	type2diabetes-28||sitagliptin-37||yes||janumettm, a fixed dose combination of sitagliptin/metformin hcl manufactured by merck pharmaceuticals, has received us food and drug administration approval for treatment of patients with type2diabetes, that are inadequately controlled, either by sitagliptin or metformin alone or together in free-dose combination form.
nsubj||demonstration-5/NN||this-1/DT	cop||demonstration-5/NN||is-2/VBZ	det||demonstration-5/NN||the-3/DT	amod||demonstration-5/NN||first-4/JJ	root||ROOT-0/null||demonstration-5/NN	mark||induces-8/VBZ||that-6/IN	nsubj||induces-8/VBZ||stroke-7/NN	ccomp||demonstration-5/NN||induces-8/VBZ	amod||changes-10/NNS||immediate-9/JJ	dobj||induces-8/VBZ||changes-10/NNS	det||timing-13/NN||the-12/DT	prep_in||induces-8/VBZ||timing-13/NN	amod||secretion-17/NN||pineal-15/JJ	nn||secretion-17/NN||melatonin-16/NN	prep_of||timing-13/NN||secretion-17/NN	vmod||induces-8/VBZ||indicating-19/VBG	mark||impacts-26/VBZ||that-20/IN	amod||infarction-25/NNS||cortical-21/JJ	conj_and||cortical-21/JJ||basal-23/JJ	amod||infarction-25/NNS||basal-23/JJ	nn||infarction-25/NNS||ganglia-24/NN	nsubj||impacts-26/VBZ||infarction-25/NNS	ccomp||indicating-19/VBG||impacts-26/VBZ	det||timing-28/NN||the-27/DT	dobj||impacts-26/VBZ||timing-28/NN	nn||rhythms-31/NNS||melatonin-30/NN	prep_of||timing-28/NN||rhythms-31/NNS	stroke-7||melatonin-30||no_rel||this is the first demonstration that stroke induces immediate changes in the timing of pineal melatonin secretion, indicating that cortical and basal ganglia infarction impacts the timing of melatonin rhythms.
poss||analyses-2/NNS||our-1/PRP$	nsubj||indicated-3/VBD||analyses-2/NNS	ccomp||attached-24/VBN||indicated-3/VBD	mark||deserves-12/VBZ||that-4/IN	det||prevalence-6/NN||the-5/DT	nsubj||deserves-12/VBZ||prevalence-6/NN	amod||co-infection-9/NN||hiv/tb-8/JJ	prep_of||prevalence-6/NN||co-infection-9/NN	prep_in||co-infection-9/NN||china-11/NN	ccomp||indicated-3/VBD||deserves-12/VBZ	amod||attention-14/NN||special-13/JJ	dobj||deserves-12/VBZ||attention-14/NN	nsubjpass||attached-24/VBN||screening-16/NN	prep_of||screening-16/NN||tb-18/NN	amod||populations-21/NNS||hiv/aids-20/JJ	prep_among||tb-18/NN||populations-21/NNS	aux||attached-24/VBN||should-22/MD	auxpass||attached-24/VBN||be-23/VB	root||ROOT-0/null||attached-24/VBN	amod||importance-26/NN||more-25/JJR	dobj||attached-24/VBN||importance-26/NN	nsubj||helpful-33/JJ||importance-26/NN	aux||helpful-33/JJ||would-29/MD	cop||helpful-33/JJ||be-30/VB	advmod||helpful-33/JJ||much-31/RB	advmod||helpful-33/JJ||more-32/RBR	rcmod||importance-26/NN||helpful-33/JJ	prep_for||helpful-33/JJ||treatment-35/NN	det||diseases-38/NNS||both-37/DT	prep_of||treatment-35/NN||diseases-38/NNS	aids--1||hiv--1||no||our analyses indicated that the prevalence of hiv/tb co-infection in china deserves special attention, screening of tb among hiv/aids populations should be attached more importance, which would be much more helpful for treatment of both diseases.
nsubj||showed-5/VBD||mice-1/NNS	vmod||mice-1/NNS||bearing-2/VBG	amod||tumors-4/NNS||subcutaneous-3/JJ	dobj||bearing-2/VBG||tumors-4/NNS	root||ROOT-0/null||showed-5/VBD	det||growth-9/NN||a-6/DT	amod||growth-9/NN||reduced-7/JJ	nn||growth-9/NN||tumor-8/NN	dobj||showed-5/VBD||growth-9/NN	prep_upon||showed-5/VBD||treatment-11/NN	prep_with||showed-5/VBD||dox-13/NN	nsubj||induced-17/VBN||dox-13/NN	nsubj||revealed-22/VBD||dox-13/NN	advmod||induced-17/VBN||effectively-16/RB	rcmod||dox-13/NN||induced-17/VBN	dobj||induced-17/VBN||shrna-18/NN	prep_against||induced-17/VBN||psca-20/NN	mark||revealed-22/VBD||as-21/IN	advcl||induced-17/VBN||revealed-22/VBD	nn||expression-25/NN||gfp-24/NN	prep_by||revealed-22/VBD||expression-25/NN	tumors-4||dox-13||no_rel||mice bearing subcutaneous tumors showed a reduced tumor growth upon treatment with dox, which effectively induced shrna against psca as revealed by gfp expression.
aux||determine-2/VB||to-1/TO	advcl||tested-16/VBD||determine-2/VB	nn||prevalence-4/NN||hiv-3/NN	dobj||determine-2/VB||prevalence-4/NN	dobj||determine-2/VB||place-6/NN	conj_and||prevalence-4/NN||place-6/NN	prep_of||prevalence-4/NN||exposure-8/NN	amod||migrants-11/NNS||illegal-10/JJ	prep_for||determine-2/VB||migrants-11/NNS	prep_in||migrants-11/NNS||italy-13/NN	nsubj||tested-16/VBD||we-15/PRP	root||ROOT-0/null||tested-16/VBD	num||migrants-20/NNS||3,003-17/CD	amod||migrants-20/NNS||illegal-18/JJ	nn||migrants-20/NNS||adult-19/NN	dobj||tested-16/VBD||migrants-20/NNS	prep_for||tested-16/VBD||hiv-22/NN	nsubj||hivpositive-30/JJ||29-24/CD	num||%-27/NN||0.97-26/CD	appos||29-24/CD||%-27/NN	cop||hivpositive-30/JJ||were-29/VBD	parataxis||tested-16/VBD||hivpositive-30/JJ	hivpositive-30||hiv-22||no||to determine hiv prevalence and place of exposure for illegal migrants in italy, we tested 3,003 illegal adult migrants for hiv; 29 (0.97%) were hivpositive.
nsubj||provides-12/VBZ||lapatinib-1/NN	prep_in||lapatinib-1/NN||combination-4/NN	prep_with||combination-4/NN||chemotherapeuticagents-6/NNS	prep_such_as||combination-4/NN||capecitabine-10/NN	root||ROOT-0/null||provides-12/VBZ	amod||benefits-14/NNS||clinical-13/JJ	dobj||provides-12/VBZ||benefits-14/NNS	prep_to||provides-12/VBZ||patients-16/NNS	amod||cancer-21/NN||erbb2-18/JJ	amod||cancer-21/NN||+-19/JJ	nn||cancer-21/NN||breast-20/NN	prep_with||patients-16/NNS||cancer-21/NN	prep_including||patients-16/NNS||patients-24/NNS	nsubj||develop-26/VBP||patients-24/NNS	rcmod||patients-24/NNS||develop-26/VBP	amod||disease-28/NN||progressive-27/JJ	dobj||develop-26/VBP||disease-28/NN	prep_on||develop-26/VBP||trastuzumab-30/NN	cancer-21||chemotherapeuticagents-6||no_rel||lapatinib, in combination with chemotherapeuticagents, such as capecitabine, provides clinical benefits to patients with erbb2+ breast cancer, including patients who develop progressive disease on trastuzumab.
det||effect-2/NN||this-1/DT	nsubj||independent-4/JJ||effect-2/NN	nsubj||attenuate-12/VB||effect-2/NN	cop||independent-4/JJ||is-3/VBZ	root||ROOT-0/null||independent-4/JJ	amod||capacity-10/NN||atropineâ-6/JJ	amod||capacity-10/NN||$-7/$	number||s-9/CD||-8/CD	num||$-7/$||s-9/CD	prep_of||independent-4/JJ||capacity-10/NN	aux||attenuate-12/VB||to-11/TO	xcomp||independent-4/JJ||attenuate-12/VB	dobj||attenuate-12/VB||bradycardia-13/NN	prep_during||attenuate-12/VB||intubation-15/NN	nsubj||occurred-17/VBD||intubation-15/NN	rcmod||intubation-15/NN||occurred-17/VBD	advmod||occurred-17/VBD||similarly-18/RB	prep_in||occurred-17/VBD||neonates-20/NNS	amod||children-23/NNS||older-22/JJR	prep_in||occurred-17/VBD||children-23/NNS	conj_and||neonates-20/NNS||children-23/NNS	bradycardia-13||atropine--1||yes||this effect is independent of atropineâs capacity to attenuate bradycardia during intubation which occurred similarly in neonates and older children.
amod||analyses-5/NNS||classical-1/JJ	conj_and||classical-1/JJ||quantitative-3/JJ	amod||analyses-5/NNS||quantitative-3/JJ	nn||analyses-5/NNS||linkage-4/NN	nsubjpass||used-12/VBN||analyses-5/NNS	amod||crosses-8/NNS||genetic-7/JJ	prep_of||analyses-5/NNS||crosses-8/NNS	aux||used-12/VBN||have-9/VBP	advmod||used-12/VBN||traditionally-10/RB	auxpass||used-12/VBN||been-11/VBN	root||ROOT-0/null||used-12/VBN	nn||genes-15/NNS||map-14/NN	prep_to||used-12/VBN||genes-15/NNS	prep_of||genes-15/NNS||interest-17/NN	prep_such_as||genes-15/NNS||those-21/DT	vmod||those-21/DT||conferring-22/VBG	amod||resistance-26/NN||chloroquine-23/JJ	conj_or||chloroquine-23/JJ||quinine-25/JJ	amod||resistance-26/NN||quinine-25/JJ	dobj||conferring-22/VBG||resistance-26/NN	nn||parasites-29/NNS||malaria-28/NN	prep_in||resistance-26/NN||parasites-29/NNS	malaria-28||quinine-25||yes||classical and quantitative linkage analyses of genetic crosses have traditionally been used to map genes of interest, such as those conferring chloroquine or quinine resistance in malaria parasites.
det||data-2/NNS||these-1/DT	nsubj||established-4/VBN||data-2/NNS	aux||established-4/VBN||have-3/VBP	root||ROOT-0/null||established-4/VBN	mark||prion-9/VBN||that-5/IN	amod||prions-7/NNS||kuru-6/JJ	nsubj||prion-9/VBN||prions-7/NNS	aux||prion-9/VBN||have-8/VBP	ccomp||established-4/VBN||prion-9/VBN	nn||properties-11/NNS||strain-10/NN	nsubj||equivalent-12/JJ||properties-11/NNS	xcomp||prion-9/VBN||equivalent-12/JJ	prep_to||equivalent-12/JJ||those-14/DT	amod||prions-29/NNS||classical-16/JJ	dep||prions-29/NNS||sporadic-18/JJ	conj_and||sporadic-18/JJ||iatrogenic-20/JJ	dep||prions-29/NNS||iatrogenic-20/JJ	amod||prions-29/NNS||cjd-22/JJ	nn||prions-29/NNS||prions-23/NNS	conj_but||prions-23/NNS||distinct-25/JJ	nn||prions-29/NNS||distinct-25/JJ	amod||cjd-28/NN||variant-27/JJ	prep_from||distinct-25/JJ||cjd-28/NN	prep_of||those-14/DT||prions-29/NNS	prions-29||cjd-28||no_rel||these data have established that kuru prions have prion strain properties equivalent to those of classical (sporadic and iatrogenic) cjd prions but distinct from variant cjd prions.
amod||women-3/NNS||older-1/JJR	nn||women-3/NNS||aa-2/NN	nsubj||have-6/VBP||women-3/NNS	prep_with||women-3/NNS||tnbc-5/NN	root||ROOT-0/null||have-6/VBP	det||survival-13/NN||a-7/DT	advmod||worse-9/JJR||significantly-8/RB	amod||survival-13/NN||worse-9/JJR	nn||survival-13/NN||breast-10/NN	nn||survival-13/NN||cancer-11/NN	amod||survival-13/NN||specific-12/JJ	dobj||have-6/VBP||survival-13/NN	mark||counterparts-17/VB||than-14/IN	nsubj||counterparts-17/VB||their-15/PRP$	aux||counterparts-17/VB||ca-16/MD	advcl||survival-13/NN||counterparts-17/VB	cancer-11||ca-16||no_rel||older aa women with tnbc have a significantly worse breast cancer specific survival than their ca counterparts.
nsubj||describe-2/VBP||we-1/PRP	root||ROOT-0/null||describe-2/VBP	det||outcomes-5/NNS||the-3/DT	amod||outcomes-5/NNS||long-term-4/JJ	dobj||describe-2/VBP||outcomes-5/NNS	num||patients-9/NNS||510-7/CD	amod||patients-9/NNS||diabetic-8/JJ	prep_of||outcomes-5/NNS||patients-9/NNS	amod||ischemia-13/NN||critical-11/JJ	nn||ischemia-13/NN||limb-12/NN	prep_with||patients-9/NNS||ischemia-13/NN	appos||ischemia-13/NN||cli-15/NN	det||footulcer-20/NN||an-18/DT	amod||footulcer-20/NN||active-19/JJ	prep_with||patients-9/NNS||footulcer-20/NN	conj_and||ischemia-13/NN||footulcer-20/NN	conj_and||ischemia-13/NN||gangrene-22/NN	conj_or||footulcer-20/NN||gangrene-22/NN	vmod||patients-9/NNS||seen-24/VBN	det||hospital-28/NN||the-26/DT	nn||hospital-28/NN||university-27/NN	prep_at||seen-24/VBN||hospital-28/NN	amod||vergata-32/NN||rome-30/JJ	nn||vergata-32/NN||tor-31/NN	prep_of||hospital-28/NN||vergata-32/NN	det||clinic-37/NN||a-34/DT	amod||clinic-37/NN||tertiary-35/JJ	nn||clinic-37/NN||care-36/NN	appos||vergata-32/NN||clinic-37/NN	tor-31||ischemia-13||no_rel||we describe the long-term outcomes of 510 diabetic patients with critical limb ischemia (cli) and an active footulcer or gangrene, seen at the university hospital of rome tor vergata, a tertiary care clinic.
det||purpose-2/NN||the-1/DT	nsubj||assessment-7/NN||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	cop||assessment-7/NN||was-6/VBD	root||ROOT-0/null||assessment-7/NN	det||influence-10/NN||the-9/DT	prep_of||assessment-7/NN||influence-10/NN	amod||phase-14/NN||acute-12/JJ	amod||phase-14/NN||manic-13/JJ	prep_of||influence-10/NN||phase-14/NN	det||pharmacokinetics-19/NNS||the-16/DT	amod||pharmacokinetics-19/NNS||steady-17/JJ	nn||pharmacokinetics-19/NNS||state-18/NN	prep_on||phase-14/NN||pharmacokinetics-19/NNS	amod||vpa-23/NN||valproicacid-21/JJ	prep_of||pharmacokinetics-19/NNS||vpa-23/NN	amod||patients-27/NNS||bipolar-26/JJ	prep_in||vpa-23/NN||patients-27/NNS	prep_in||patients-27/NNS||comparison-29/NN	prep_with||assessment-7/NN||those-31/DT	amod||patients-34/NNS||epileptic-33/JJ	prep_of||those-31/DT||patients-34/NNS	epileptic-33||valproicacid-21||yes||the purpose of this study was assessment of the influence of acute manic phase on the steady state pharmacokinetics of valproicacid (vpa) in bipolar patients in comparison with those of epileptic patients.
det||mixture-5/NN||the-1/DT	amod||mixture-5/NN||lidocaine-2/JJ	conj_and||lidocaine-2/JJ||propofol-4/JJ	amod||mixture-5/NN||propofol-4/JJ	nsubj||effective-7/JJ||mixture-5/NN	cop||effective-7/JJ||is-6/VBZ	root||ROOT-0/null||effective-7/JJ	prepc_in||effective-7/JJ||alleviating-9/VBG	dobj||alleviating-9/VBG||pain-10/NN	vmod||pain-10/NN||associated-11/VBN	amod||injection-15/NN||microemulsion-13/JJ	amod||injection-15/NN||propofol-14/JJ	prep_with||associated-11/VBN||injection-15/NN	pain-10||lidocaine-2||yes||the lidocaine and propofol mixture is effective in alleviating pain associated with microemulsion propofol injection.
amod||hydrochloride-2/NN||landiolol-1/JJ	nsubj||²-7/NN||hydrochloride-2/NN	cop||²-7/NN||is-3/VBZ	det||²-7/NN||a-4/DT	amod||²-7/NN||new-5/JJ	nn||²-7/NN||î-6/NN	root||ROOT-0/null||²-7/NN	dep||²-7/NN||adrenergicblocker-9/NN	nsubj||suggests-15/VBZ||adrenergicblocker-9/NN	det||profile-13/NN||a-11/DT	amod||profile-13/NN||pharmacological-12/JJ	prep_with||adrenergicblocker-9/NN||profile-13/NN	rcmod||adrenergicblocker-9/NN||suggests-15/VBZ	nsubjpass||administered-19/VBN||it-16/PRP	aux||administered-19/VBN||can-17/MD	auxpass||administered-19/VBN||be-18/VB	dep||suggests-15/VBZ||administered-19/VBN	advmod||administered-19/VBN||safely-20/RB	prep_to||administered-19/VBN||patients-22/NNS	nsubj||have-24/VBP||patients-22/NNS	rcmod||patients-22/NNS||have-24/VBP	amod||tachycardia-26/NN||sinus-25/JJ	dobj||have-24/VBP||tachycardia-26/NN	dobj||have-24/VBP||tachyarrhythmia-28/NN	conj_or||tachycardia-26/NN||tachyarrhythmia-28/NN	nsubj||require-31/VBP||who-30/WP	dep||suggests-15/VBZ||require-31/VBP	conj_and||administered-19/VBN||require-31/VBP	nn||reduction-34/NN||heart-32/NN	nn||reduction-34/NN||rate-33/NN	dobj||require-31/VBP||reduction-34/NN	adrenergicblocker-9||tachycardia-26||no_rel||landiolol hydrochloride is a new î²-adrenergicblocker with a pharmacological profile that suggests it can be administered safely to patients who have sinus tachycardia or tachyarrhythmia and who require heart rate reduction.
det||paper-2/NN||this-1/DT	nsubj||aims-3/VBZ||paper-2/NN	nsubj||provide-5/VB||paper-2/NN	nsubj||ward-27/VB||paper-2/NN	root||ROOT-0/null||aims-3/VBZ	aux||provide-5/VB||to-4/TO	xcomp||aims-3/VBZ||provide-5/VB	det||review-9/NN||a-6/DT	amod||systematic-8/JJ||descriptive-7/JJ	amod||review-9/NN||systematic-8/JJ	dobj||provide-5/VB||review-9/NN	det||effects-12/NNS||the-11/DT	prep_regarding||review-9/NN||effects-12/NNS	amod||hyperglycemia-15/NN||pn-induced-14/JJ	prep_of||effects-12/NNS||hyperglycemia-15/NN	amod||patients-18/NNS||hospitalized-17/JJ	prep_in||provide-5/VB||patients-18/NNS	dep||provide-5/VB||either-20/CC	xcomp||aims-3/VBZ||in-21/IN	conj_or||provide-5/VB||in-21/IN	det||unit-25/NN||the-22/DT	amod||unit-25/NN||intensive-23/JJ	nn||unit-25/NN||care-24/NN	pobj||in-21/IN||unit-25/NN	xcomp||aims-3/VBZ||ward-27/VB	conj_or||provide-5/VB||ward-27/VB	dep||formulating-30/VBG||while-29/IN	parataxis||ward-27/VB||formulating-30/VBG	parataxis||ward-27/VB||complementing-32/VBG	conj_and||formulating-30/VBG||complementing-32/VBG	amod||guidelines-34/NNS||existing-33/VBG	dobj||formulating-30/VBG||guidelines-34/NNS	det||administration-37/NN||the-36/DT	prep_on||guidelines-34/NNS||administration-37/NN	nn||monitoring-42/NN||pn-39/NN	conj_and||pn-39/NN||glucose-41/NN	nn||monitoring-42/NN||glucose-41/NN	prep_of||administration-37/NN||monitoring-42/NN	amod||patients-45/NNS||hospitalized-44/JJ	prep_in||ward-27/VB||patients-45/NNS	hyperglycemia-15||glucose-41||no||this paper aims to provide a descriptive systematic review regarding the effects of pn-induced hyperglycemia in hospitalized patients, either in the intensive care unit or ward, while formulating and complementing existing guidelines on the administration of pn and glucose monitoring in hospitalized patients.
prep_to||approved-7/VBN||date-2/NN	nsubjpass||approved-7/VBN||posaconazole-4/NN	aux||approved-7/VBN||has-5/VBZ	auxpass||approved-7/VBN||been-6/VBN	root||ROOT-0/null||approved-7/VBN	prep_for||approved-7/VBN||prophylaxis-9/NNS	amod||fungalinfections-12/NNS||invasive-11/JJ	prep_of||prophylaxis-9/NNS||fungalinfections-12/NNS	nn||recipients-17/NNS||stem-14/NN	nn||recipients-17/NNS||cell-15/NN	nn||recipients-17/NNS||transplant-16/NN	prep_in||approved-7/VBN||recipients-17/NNS	amod||graftversushostdisease-20/NN||acute-19/JJ	prep_with||recipients-17/NNS||graftversushostdisease-20/NN	dep||recipients-17/NNS||gvhd-22/VBN	amod||patients-26/NNS||neutropenic-25/JJ	prep_in||approved-7/VBN||patients-26/NNS	conj_and||recipients-17/NNS||patients-26/NNS	vmod||patients-26/NNS||receiving-27/VBG	amod||induction-29/NN||intensive-28/JJ	dobj||receiving-27/VBG||induction-29/NN	advmod||receiving-27/VBG||chemotherapy-30/RB	amod||leukemia-34/NN||acute-32/JJ	nn||leukemia-34/NN||myelogenous-33/NNS	prep_for||receiving-27/VBG||leukemia-34/NN	amod||syndrome-37/NN||myelodys-plastic-36/JJ	prep_for||receiving-27/VBG||syndrome-37/NN	conj_and||leukemia-34/NN||syndrome-37/NN	fungalinfections-12||posaconazole-4||yes||to date, posaconazole has been approved for prophylaxis of invasive fungalinfections in stem cell transplant recipients with acute graftversushostdisease (gvhd) and neutropenic patients receiving intensive induction chemotherapy for acute myelogenous leukemia and myelodys-plastic syndrome.
nsubj||recorded-2/VBD||we-1/PRP	nsubj||examined-22/VBD||we-1/PRP	root||ROOT-0/null||recorded-2/VBD	amod||data-4/NNS||demographic-3/JJ	dobj||recorded-2/VBD||data-4/NNS	amod||prescription-7/NN||antenatal-6/JJ	appos||data-4/NNS||prescription-7/NN	amod||therapy-11/NN||intermittent-9/JJ	nn||therapy-11/NN||preventive-10/NN	prep_of||prescription-7/NN||therapy-11/NN	prep_during||recorded-2/VBD||pregnancy-13/NN	nn||use-19/NN||sulfadoxine-pyrimethamine-15/NN	conj_and||sulfadoxine-pyrimethamine-15/NN||bed-17/NN	nn||use-19/NN||bed-17/NN	amod||use-19/NN||net-18/JJ	prep_with||recorded-2/VBD||use-19/NN	conj_and||recorded-2/VBD||examined-22/VBD	amod||blood-24/NN||finger-prick-23/JJ	dobj||examined-22/VBD||blood-24/NN	nn||parasites-27/NNS||malaria-26/NN	prep_for||examined-22/VBD||parasites-27/NNS	nn||concentration-30/NN||hemoglobin-29/NN	prep_for||examined-22/VBD||concentration-30/NN	conj_and||parasites-27/NNS||concentration-30/NN	malaria-26||pyrimethamine--1||yes||we recorded demographic data, antenatal prescription of intermittent preventive therapy during pregnancy with sulfadoxine-pyrimethamine and bed net use, and examined finger-prick blood for malaria parasites and hemoglobin concentration.
det||lack-2/NN||the-1/DT	nsubj||hindered-12/VBN||lack-2/NN	amod||trials-7/NNS||adequate-4/JJ	amod||trials-7/NNS||randomized-5/JJ	amod||trials-7/NNS||clinical-6/JJ	prep_of||lack-2/NN||trials-7/NNS	appos||trials-7/NNS||rct-9/NN	aux||hindered-12/VBN||has-11/VBZ	root||ROOT-0/null||hindered-12/VBN	dobj||hindered-12/VBN||identification-13/NN	nsubj||safe-19/JJ||identification-13/NN	nsubj||effective-21/JJ||identification-13/NN	amod||therapies-16/NNS||new-15/JJ	prep_of||identification-13/NN||therapies-16/NNS	cop||safe-19/JJ||are-18/VBP	rcmod||identification-13/NN||safe-19/JJ	rcmod||identification-13/NN||effective-21/JJ	conj_and||safe-19/JJ||effective-21/JJ	prep_for||safe-19/JJ||patients-23/NNS	amod||focalsegmentalglomerulosclerosis-26/NNS||primary-25/JJ	prep_with||patients-23/NNS||focalsegmentalglomerulosclerosis-26/NNS	appos||focalsegmentalglomerulosclerosis-26/NNS||fsgs-28/NNS	dep||safe-19/JJ||especially-31/RB	prep_in||safe-19/JJ||patients-33/NNS	nsubj||fail-35/VBP||patients-33/NNS	nsubj||respond-37/VB||patients-33/NNS	rcmod||patients-33/NNS||fail-35/VBP	aux||respond-37/VB||to-36/TO	xcomp||fail-35/VBP||respond-37/VB	prep_to||respond-37/VB||corticosteroids-39/NNS	nn||therapies-42/NNS||immunosuppressive-41/NN	prep_to||respond-37/VB||therapies-42/NNS	conj_and||corticosteroids-39/NNS||therapies-42/NNS	immunosuppressive-41||focalsegmentalglomerulosclerosis-26||no_rel||the lack of adequate randomized clinical trials (rct) has hindered identification of new therapies that are safe and effective for patients with primary focalsegmentalglomerulosclerosis (fsgs), especially in patients who fail to respond to corticosteroids and immunosuppressive therapies.
aux||evaluate-2/VB||to-1/TO	advcl||conducted-18/VBD||evaluate-2/VB	det||effects-4/NNS||the-3/DT	dobj||evaluate-2/VB||effects-4/NNS	prep_of||effects-4/NNS||hivinfection-6/NN	amod||precursors-9/NNS||intra-thymic-8/JJ	prep_on||evaluate-2/VB||precursors-9/NNS	nn||cells-12/NNS||t-11/NN	prep_of||precursors-9/NNS||cells-12/NNS	amod||adults-15/NNS||hiv-infected-14/JJ	prep_in||evaluate-2/VB||adults-15/NNS	nsubj||conducted-18/VBD||we-17/PRP	root||ROOT-0/null||conducted-18/VBD	det||study-22/NN||a-19/DT	amod||study-22/NN||detailed-20/JJ	amod||study-22/NN||immunophenotypic-21/JJ	dobj||conducted-18/VBD||study-22/NN	amod||tissue-25/NN||thymic-24/JJ	prep_of||study-22/NN||tissue-25/NN	vmod||tissue-25/NN||isolated-26/VBN	num||hiv-infected-29/NN||7-28/CD	prep_from||isolated-26/VBN||hiv-infected-29/NN	num||adults-33/NNS||10-31/CD	amod||adults-33/NNS||hiv-negative-32/JJ	prep_from||isolated-26/VBN||adults-33/NNS	conj_and||hiv-infected-29/NN||adults-33/NNS	nsubj||were-35/VBD||adults-33/NNS	nsubj||undergo-37/VB||adults-33/NNS	rcmod||adults-33/NNS||were-35/VBD	aux||undergo-37/VB||to-36/TO	xcomp||were-35/VBD||undergo-37/VB	nn||surgery-39/NN||heart-38/NN	dobj||undergo-37/VB||surgery-39/NN	hivinfection-6||hiv--1||no||to evaluate the effects of hivinfection on intra-thymic precursors of t cells in hiv-infected adults, we conducted a detailed immunophenotypic study of thymic tissue isolated from 7 hiv-infected and 10 hiv-negative adults who were to undergo heart surgery.
det||fear-2/NN||the-1/DT	nsubj||challenge-24/VB||fear-2/NN	nn||milk-5/NN||breast-4/NN	prep_of||fear-2/NN||milk-5/NN	nsubj||seems-7/VBZ||milk-5/NN	nsubj||developed-10/VBN||milk-5/NN	rcmod||milk-5/NN||seems-7/VBZ	aux||developed-10/VBN||to-8/TO	aux||developed-10/VBN||have-9/VB	xcomp||seems-7/VBZ||developed-10/VBN	prep_among||developed-10/VBN||counselors-12/NNS	nn||mothers-15/NNS||hivpositive-14/NN	prep_among||developed-10/VBN||mothers-15/NNS	conj_and||counselors-12/NNS||mothers-15/NNS	det||wake-18/NN||the-17/DT	prep_in||developed-10/VBN||wake-18/NN	det||epidemic-22/NN||the-20/DT	nn||epidemic-22/NN||hiv-21/NN	prep_of||wake-18/NN||epidemic-22/NN	aux||challenge-24/VB||may-23/MD	root||ROOT-0/null||challenge-24/VB	det||culture-29/NN||a-25/DT	advmod||established-27/VBN||well-26/RB	amod||culture-29/NN||established-27/VBN	amod||culture-29/NN||breastfeeding-28/VBG	dobj||challenge-24/VB||culture-29/NN	dobj||challenge-24/VB||calls-31/NNS	conj_and||culture-29/NN||calls-31/NNS	amod||action-35/NN||public-33/JJ	nn||action-35/NN||health-34/NN	prep_for||calls-31/NNS||action-35/NN	hivpositive-14||hiv-21||no||the fear of breast milk that seems to have developed among counselors and hivpositive mothers in the wake of the hiv epidemic may challenge a well established breastfeeding culture and calls for public health action.
det||study-3/NN||this-2/DT	prep_in||investigated-6/VBD||study-3/NN	nsubj||investigated-6/VBD||we-5/PRP	root||ROOT-0/null||investigated-6/VBD	det||effect-8/NN||the-7/DT	dobj||investigated-6/VBD||effect-8/NN	det||mixture-12/NN||a-10/DT	amod||mixture-12/NN||lidocaine-11/JJ	prep_of||effect-8/NN||mixture-12/NN	prep_on||investigated-6/VBD||pain-14/NN	dep||pain-14/NN||induced-15/VBN	amod||injection-19/NN||microemulsion-17/JJ	amod||injection-19/NN||propofol-18/JJ	prep_by||induced-15/VBN||injection-19/NN	dep||pain-14/NN||sought-22/VBN	conj_and||induced-15/VBN||sought-22/VBN	aux||determine-24/VB||to-23/TO	xcomp||sought-22/VBN||determine-24/VB	det||dose-27/NN||the-25/DT	amod||dose-27/NN||optimal-26/JJ	dobj||determine-24/VB||dose-27/NN	nsubj||reduce-32/VB||dose-27/NN	prep_of||dose-27/NN||lidocaine-29/NN	aux||reduce-32/VB||could-31/MD	rcmod||dose-27/NN||reduce-32/VB	dobj||reduce-32/VB||pain-33/NN	prepc_on||reduce-32/VB||injecting-35/VBG	det||mixture-38/NN||a-36/DT	amod||mixture-38/NN||propofol-lidocaine-37/JJ	dobj||injecting-35/VBG||mixture-38/NN	pain-33||propofol-18||yes||in this study, we investigated the effect of a lidocaine mixture on pain induced by microemulsion propofol injection, and sought to determine the optimal dose of lidocaine that could reduce pain on injecting a propofol-lidocaine mixture.
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubj||consists-11/VBZ||treatment-3/NN	prep_of||treatment-3/NN||malaria-5/NN	prep_in||malaria-5/NN||infants-7/NNS	appos||infants-7/NNS||ipti-9/NNP	root||ROOT-0/null||consists-11/VBZ	det||administration-14/NN||the-13/DT	prep_of||consists-11/VBZ||administration-14/NN	det||dose-18/NN||a-16/DT	nn||dose-18/NN||treatment-17/NN	prep_of||administration-14/NN||dose-18/NN	amod||sp-22/NN||sulphadoxine-pyrimethamine-20/JJ	prep_of||dose-18/NN||sp-22/NN	det||time-26/NN||the-25/DT	prep_at||sp-22/NN||time-26/NN	amod||vaccinations-29/NNS||routine-28/JJ	prep_of||time-26/NN||vaccinations-29/NNS	malaria-5||pyrimethamine--1||no||intermittent preventive treatment of malaria in infants (ipti) consists of the administration of a treatment dose of sulphadoxine-pyrimethamine (sp) at the time of routine vaccinations.
prep_in||similar-24/JJ||patients-2/NNS	advmod||resectable-5/JJ||initially-4/RB	amod||tumors-6/NNS||resectable-5/JJ	prep_with||patients-2/NNS||tumors-6/NNS	det||$-13/NN||â-8/DT	amod||$-13/NN||$-9/$	dep||$-9/$||resectable-10/JJ	dep||$-9/$||tumor-11/NN	amod||$-13/NN||patientsâ-12/JJ	appos||tumors-6/NNS||$-13/NN	nn||frequencies-17/NNS||resection-16/NN	nsubj||similar-24/JJ||frequencies-17/NNS	conj_and||frequencies-17/NNS||survival-19/NN	nsubj||similar-24/JJ||survival-19/NN	amod||therapy-22/NN||neoadjuvant-21/JJ	prep_after||frequencies-17/NNS||therapy-22/NN	cop||similar-24/JJ||are-23/VBP	root||ROOT-0/null||similar-24/JJ	prep_to||similar-24/JJ||those-26/DT	prep_of||those-26/DT||patients-28/NNS	advmod||tumors-32/NNS||primarily-30/RB	amod||tumors-32/NNS||resected-31/VBN	prep_with||patients-28/NNS||tumors-32/NNS	amod||therapy-35/NN||adjuvant-34/JJ	prep_with||patients-28/NNS||therapy-35/NN	conj_and||tumors-32/NNS||therapy-35/NN	tumors-32||adjuvant-34||no_rel||in patients with initially resectable tumors (âresectable tumor patientsâ?), resection frequencies and survival after neoadjuvant therapy are similar to those of patients with primarily resected tumors and adjuvant therapy.
nn||epidemica-2/NN||nephropathia-1/NN	nsubj||type-9/NN||epidemica-2/NN	appos||epidemica-2/NN||ne-4/NN	cop||type-9/NN||is-6/VBZ	det||type-9/NN||a-7/DT	nn||type-9/NN||scandinavian-8/NN	root||ROOT-0/null||type-9/NN	prep_of||type-9/NN||hemorrhagicfeverwithrenalsyndrome-11/NN	vmod||hemorrhagicfeverwithrenalsyndrome-11/NN||caused-12/VBN	agent||caused-12/VBN||puumalahantavirus-14/NNS	hemorrhagicfeverwithrenalsyndrome-11||puumalahantavirus-14||no||nephropathia epidemica (ne) is a scandinavian type of hemorrhagicfeverwithrenalsyndrome caused by puumalahantavirus.
nsubj||raised-2/VBD||genetically-1/NNP	root||ROOT-0/null||raised-2/VBD	xcomp||raised-2/VBD||circulating-3/VBG	amod||levels-5/NNS||triglyceride-4/JJ	nsubj||increase-8/VB||levels-5/NNS	nsubj||raise-14/VB||levels-5/NNS	aux||increase-8/VB||do-6/VBP	neg||increase-8/VB||not-7/RB	ccomp||circulating-3/VBG||increase-8/VB	det||risk-10/NN||the-9/DT	dobj||increase-8/VB||risk-10/NN	prep_of||risk-10/NN||type2diabetes-12/CD	ccomp||circulating-3/VBG||raise-14/VB	conj_or||increase-8/VB||raise-14/VB	ccomp||raise-14/VB||fasting-15/VBG	dobj||fasting-15/VBG||glucose-16/NN	ccomp||raise-14/VB||fasting-18/VBG	conj_or||fasting-15/VBG||fasting-18/VBG	nn||levels-20/NNS||insulin-19/NN	dobj||fasting-18/VBG||levels-20/NNS	amod||individuals-23/NNS||nondiabetic-22/JJ	prep_in||fasting-18/VBG||individuals-23/NNS	type2diabetes-12||insulin-19||yes||genetically raised circulating triglyceride levels do not increase the risk of type2diabetes or raise fasting glucose or fasting insulin levels in nondiabetic individuals.
nsubj||aimed-2/VBD||we-1/PRP	nsubj||analyze-4/VB||we-1/PRP	nsubj||hcv/hiv-11/VB||we-1/PRP	root||ROOT-0/null||aimed-2/VBD	aux||analyze-4/VB||to-3/TO	xcomp||aimed-2/VBD||analyze-4/VB	nn||transaminases-6/NNS||liver-5/NN	dobj||analyze-4/VB||transaminases-6/NNS	nn||monoinfected-9/NN||hcv-8/NN	prep_in||analyze-4/VB||monoinfected-9/NN	xcomp||aimed-2/VBD||hcv/hiv-11/VB	conj_and||analyze-4/VB||hcv/hiv-11/VB	amod||patients-13/NNS||co-infected-12/JJ	dobj||hcv/hiv-11/VB||patients-13/NNS	aux||assess-15/VB||to-14/TO	vmod||hcv/hiv-11/VB||assess-15/VB	det||effect-17/NN||the-16/DT	dobj||assess-15/VB||effect-17/NN	prep_of||effect-17/NN||hivinfection-19/NN	nn||elevations-23/NNS||liver-21/NN	nn||elevations-23/NNS||enzyme-22/NN	prep_on||assess-15/VB||elevations-23/NNS	hivinfection-19||hiv--1||no||we aimed to analyze liver transaminases in hcv monoinfected and hcv/hiv co-infected patients to assess the effect of hivinfection on liver enzyme elevations.
det||dipeptidase-7/NN||another-1/DT	amod||family-4/NN||non-s28-3/JJ	appos||dipeptidase-7/NN||family-4/NN	amod||dipeptidase-7/NN||dipeptidyl-6/JJ	nsubj||target-15/NN||dipeptidase-7/NN	appos||dipeptidase-7/NN||dpp4-9/NNP	cop||target-15/NN||is-11/VBZ	det||target-15/NN||a-12/DT	amod||target-15/NN||major-13/JJ	nn||target-15/NN||drug-14/NN	root||ROOT-0/null||target-15/NN	prep_in||target-15/NN||type2diabetes-17/CD	nsubj||developed-23/VBN||merck-20/NN	aux||developed-23/VBN||has-21/VBZ	advmod||developed-23/VBN||already-22/RB	conj_and||target-15/NN||developed-23/VBN	det||inhibitor-26/NN||a-24/DT	amod||inhibitor-26/NN||successful-25/JJ	dobj||developed-23/VBN||inhibitor-26/NN	prep_of||inhibitor-26/NN||dpp4-28/NNS	det||sitagliptin-33/NN||the-30/DT	amod||sitagliptin-33/NN||anti-hyperglycemic-31/JJ	nn||sitagliptin-33/NN||drug-32/NN	appos||dpp4-28/NNS||sitagliptin-33/NN	det||treatment-37/NN||the-36/DT	prep_for||developed-23/VBN||treatment-37/NN	prep_of||treatment-37/NN||type2diabetes-39/CD	type2diabetes-39||sitagliptin-33||yes||another (non-s28 family) dipeptidyl dipeptidase (dpp4) is a major drug target in type2diabetes, and merck has already developed a successful inhibitor of dpp4, the anti-hyperglycemic drug sitagliptin, for the treatment of type2diabetes.
amod||lake-2/NN||qinghai-1/JJ	nsubj||been-7/VBN||lake-2/NN	amod||china-5/NN||central-4/JJ	prep_in||lake-2/NN||china-5/NN	aux||been-7/VBN||has-6/VBZ	root||ROOT-0/null||been-7/VBN	det||center-10/NN||the-9/DT	prep_at||been-7/VBN||center-10/NN	prep_of||center-10/NN||debate-12/NN	mark||play-17/VBP||whether-14/IN	amod||birds-16/NNS||wild-15/JJ	nsubj||play-17/VBP||birds-16/NNS	prepc_on||been-7/VBN||play-17/VBP	det||role-19/NN||a-18/DT	dobj||play-17/VBP||role-19/NN	prep_in||role-19/NN||circulation-21/NN	advmod||pathogenic-24/JJ||highly-23/RB	amod||h5n1-26/NNS||pathogenic-24/JJ	nn||h5n1-26/NNS||avianinfluenzavirus-25/NN	prep_of||circulation-21/NN||h5n1-26/NNS	h5n1-26||avianinfluenzavirus-25||no||qinghai lake in central china has been at the center of debate on whether wild birds play a role in circulation of highly pathogenic avianinfluenzavirus h5n1.
nn||smegmati-2/NNS||mycobacterium-1/NN	nsubj||s-3/VBZ||smegmati-2/NNS	root||ROOT-0/null||s-3/VBZ	nsubj||mycobacteria-10/NN||ms-5/NN	cop||mycobacteria-10/NN||is-7/VBZ	det||mycobacteria-10/NN||a-8/DT	amod||mycobacteria-10/NN||nonpathogenic-9/JJ	ccomp||s-3/VBZ||mycobacteria-10/NN	amod||growth-13/NN||rapid-12/JJ	prep_of||mycobacteria-10/NN||growth-13/NN	nsubj||shares-16/VBZ||growth-13/NN	rcmod||growth-13/NN||shares-16/VBZ	amod||characteristics-18/NNS||many-17/JJ	dobj||shares-16/VBZ||characteristics-18/NNS	prep_with||shares-16/VBZ||mycobacteriumtuberculosis-20/NNS	appos||mycobacteriumtuberculosis-20/NNS||mtb-22/NN	det||agent-28/NN||the-25/DT	amod||agent-28/NN||major-26/JJ	nn||agent-28/NN||causative-27/NN	appos||mycobacteriumtuberculosis-20/NNS||agent-28/NN	prep_of||agent-28/NN||tuberculosis-30/NNP	tuberculosis-30||mycobacteriumtuberculosis-20||no||mycobacterium smegmati s (ms) is a nonpathogenic mycobacteria of rapid growth, which shares many characteristics with mycobacteriumtuberculosis (mtb), the major causative agent of tuberculosis.
det||findings-2/NNS||these-1/DT	nsubj||suggest-3/VBP||findings-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||experiencing-14/VBG||that-4/IN	nsubj||experiencing-14/VBG||adults-5/NNS	nsubj||be-30/VB||adults-5/NNS	amod||levels-8/NNS||decreased-7/VBN	prep_with||adults-5/NNS||levels-8/NNS	nn||cholesterol-11/NN||hdl-10/NN	prep_of||levels-8/NNS||cholesterol-11/NN	aux||experiencing-14/VBG||may-12/MD	aux||experiencing-14/VBG||be-13/VB	ccomp||suggest-3/VBP||experiencing-14/VBG	amod||changes-16/NNS||cognitive-15/JJ	dobj||experiencing-14/VBG||changes-16/NNS	nn||reductions-19/NNS||gm-18/NN	dobj||experiencing-14/VBG||reductions-19/NNS	conj_and||changes-16/NNS||reductions-19/NNS	prep_in||experiencing-14/VBG||regions-21/NNS	vmod||regions-21/NNS||associated-22/VBN	amod||disease-25/NN||neurodegenerative-24/JJ	prep_with||associated-22/VBN||disease-25/NN	advmod||be-30/VB||therefore-27/RB	aux||be-30/VB||may-29/MD	ccomp||suggest-3/VBP||be-30/VB	conj_and||experiencing-14/VBG||be-30/VB	amod||risk-33/NN||greater-32/JJR	prep_at||be-30/VB||risk-33/NN	amod||cognitivedecline-36/NN||future-35/JJ	prep_for||risk-33/NN||cognitivedecline-36/NN	cholesterol-11||cognitivedecline-36||no_rel||these findings suggest that adults with decreased levels of hdl cholesterol may be experiencing cognitive changes and gm reductions in regions associated with neurodegenerative disease and therefore, may be at greater risk for future cognitivedecline.
det||model-3/NN||a-1/DT	amod||model-3/NN||deterministic-2/JJ	nsubjpass||adapted-10/VBN||model-3/NN	nsubj||allow-12/VB||model-3/NN	nn||processes-8/NNS||mosquito-5/NN	nn||processes-8/NNS||life-6/NN	nn||processes-8/NNS||cycle-7/NN	prep_of||model-3/NN||processes-8/NNS	auxpass||adapted-10/VBN||was-9/VBD	root||ROOT-0/null||adapted-10/VBN	aux||allow-12/VB||to-11/TO	xcomp||adapted-10/VBN||allow-12/VB	dobj||allow-12/VB||parameterization-13/NN	prep_with||allow-12/VB||results-15/NNS	amod||trials-19/NNS||experimental-17/JJ	nn||trials-19/NNS||hut-18/NN	prep_from||results-15/NNS||trials-19/NNS	amod||combinations-22/NNS||various-21/JJ	prep_of||trials-19/NNS||combinations-22/NNS	amod||nets-25/NNS||untreated-24/JJ	prep_of||combinations-22/NNS||nets-25/NNS	prep_of||combinations-22/NNS||llins-27/NNS	conj_or||nets-25/NNS||llins-27/NNS	nn||®-30/NNP||olysetâ-29/NNP	appos||nets-25/NNS||®-30/NNP	amod||®-35/NNP||permanet-32/JJ	nn||®-35/NNP||2.0-33/NNP	nn||®-35/NNP||â-34/NN	dep||®-30/NNP||®-35/NNP	num||nets-40/NNS||icon-37/CD	nn||nets-40/NNS||lifeâ-38/NNP	nn||nets-40/NNS||®-39/NN	dep||®-30/NNP||nets-40/NNS	prep_with||allow-12/VB||irs-43/NN	amod||methyl-46/NN||pirimiphos-45/JJ	appos||irs-43/NN||methyl-46/NN	amod||ddt-51/NN||lambda-48/JJ	nn||ddt-51/NN||cyhalothrin-49/NN	dep||methyl-46/NN||ddt-51/NN	det||setting-56/NN||a-55/DT	prep_in||irs-43/NN||setting-56/NN	advmod||dominated-61/VBN||where-57/WRB	nn||populations-59/NNS||vector-58/NN	nsubjpass||dominated-61/VBN||populations-59/NNS	auxpass||dominated-61/VBN||are-60/VBP	rcmod||setting-56/NN||dominated-61/VBN	amod||arabiensis-64/NNS||anopheles-63/JJ	agent||dominated-61/VBN||arabiensis-64/NNS	advmod||predicted-79/VBN||so-66/RB	mark||predicted-79/VBN||that-67/IN	nn||impact-70/NN||community-68/NN	nn||impact-70/NN||level-69/NN	nsubjpass||predicted-79/VBN||impact-70/NN	nn||transmission-73/NN||malaria-72/NN	prep_upon||impact-70/NN||transmission-73/NN	amod||coverage-76/NN||high-75/JJ	prep_at||transmission-73/NN||coverage-76/NN	aux||predicted-79/VBN||could-77/MD	auxpass||predicted-79/VBN||be-78/VB	advcl||allow-12/VB||predicted-79/VBN	ddt-51||malaria-72||no_rel||a deterministic model of mosquito life cycle processes was adapted to allow parameterization with results from experimental hut trials of various combinations of untreated nets or llins (olysetâ®, permanet 2.0â®, icon lifeâ® nets) with irs (pirimiphos methyl, lambda cyhalothrin, ddt), in a setting where vector populations are dominated by anopheles arabiensis , so that community level impact upon malaria transmission at high coverage could be predicted.
amod||understanding-2/NN||greater-1/JJR	nsubj||help-20/VB||understanding-2/NN	det||interplay-5/NN||the-4/DT	prep_of||understanding-2/NN||interplay-5/NN	det||factors-9/NNS||the-7/DT	amod||factors-9/NNS||key-8/JJ	prep_between||interplay-5/NN||factors-9/NNS	vmod||factors-9/NNS||involved-10/VBN	det||regulation-13/NN||the-12/DT	prep_in||involved-10/VBN||regulation-13/NN	nn||metabolism-16/NN||iron-15/NN	prep_of||regulation-13/NN||metabolism-16/NN	prep_of||regulation-13/NN||erythropoiesis-18/NNS	conj_and||metabolism-16/NN||erythropoiesis-18/NNS	aux||help-20/VB||will-19/MD	root||ROOT-0/null||help-20/VB	xcomp||help-20/VB||develop-21/VB	advmod||effective-23/JJ||more-22/RBR	amod||therapies-24/NNS||effective-23/JJ	dobj||develop-21/VB||therapies-24/NNS	prep_for||develop-21/VB||disorders-26/NNS	nn||irondeficiency-30/NN||ironoverload-28/NN	prep_of||disorders-26/NNS||irondeficiency-30/NN	nn||synthesis-34/NN||hemoglobin-33/NN	prep_of||disorders-26/NNS||synthesis-34/NN	conj_and||irondeficiency-30/NN||synthesis-34/NN	irondeficiency-30||iron-15||yes||greater understanding of the interplay between the key factors involved in the regulation of iron metabolism and erythropoiesis will help develop more effective therapies for disorders of ironoverload, irondeficiency, and hemoglobin synthesis.
amod||disrupts-7/NNS||parkinson-1/JJ	nn||disrupts-7/NNS||sdisease-3/NN	appos||disrupts-7/NNS||pd-5/NN	nsubjpass||understood-28/VBN||disrupts-7/NNS	amod||processing-9/NN||temporal-8/JJ	dep||disrupts-7/NNS||processing-9/NN	det||sources-14/NNS||the-12/DT	amod||sources-14/NNS||neuronal-13/JJ	conj_but||disrupts-7/NNS||sources-14/NNS	nsubjpass||understood-28/VBN||sources-14/NNS	prep_of||sources-14/NNS||deficits-16/NNS	poss||response-19/NN||their-18/PRP$	prep_of||sources-14/NNS||response-19/NN	conj_and||deficits-16/NNS||response-19/NN	aux||dopamine-21/VB||to-20/TO	vmod||response-19/NN||dopamine-21/VB	dep||understood-28/VBN||da-23/NNP	nsubjpass||understood-28/VBN||therapy-25/NN	auxpass||understood-28/VBN||are-26/VBP	neg||understood-28/VBN||not-27/RB	root||ROOT-0/null||understood-28/VBN	parkinson'sdisease--1||dopamine-21||no_rel||parkinson'sdisease (pd) disrupts temporal processing, but the neuronal sources of deficits and their response to dopamine (da) therapy are not understood.
det||study-7/NN||a-2/DT	advmod||published-4/VBN||recently-3/RB	amod||study-7/NN||published-4/VBN	nn||study-7/NN||24-week-5/NN	nn||study-7/NN||maintenance-6/NN	prep_in||noted-29/VBN||study-7/NN	amod||injection-11/NN||olanzapine-9/JJ	amod||injection-11/NN||long-acting-10/JJ	prep_of||study-7/NN||injection-11/NN	appos||injection-11/NN||lai-13/NN	prep_in||injection-11/NN||schizophrenia-16/NN	appos||schizophrenia-16/NN||kane-18/NNP	appos||schizophrenia-16/NN||al.-20/NNP	conj_et||kane-18/NNP||al.-20/NNP	dep||kane-18/NNP||2010-22/CD	amod||changes-27/NNS||apparent-25/JJ	amod||changes-27/NNS||dose-associated-26/JJ	nsubjpass||noted-29/VBN||changes-27/NNS	auxpass||noted-29/VBN||were-28/VBD	root||ROOT-0/null||noted-29/VBN	preconj||parameters-35/NNS||both-31/DT	nn||parameters-35/NNS||efficacy-32/NN	conj_and||efficacy-32/NN||safety-34/NN	nn||parameters-35/NNS||safety-34/NN	prep_in||noted-29/VBN||parameters-35/NNS	schizophrenia-16||olanzapine-9||yes||in a recently published 24-week maintenance study of olanzapine long-acting injection (lai) in schizophrenia (kane et al., 2010), apparent dose-associated changes were noted in both efficacy and safety parameters.
advmod||lesion-12/NN||early-1/RB	det||epidemic-5/NN||the-3/DT	nn||epidemic-5/NN||aids-4/NNS	prep_in||early-1/RB||epidemic-5/NN	nsubj||lesion-12/NN||hivan-7/NN	cop||lesion-12/NN||was-8/VBD	det||lesion-12/NN||the-9/DT	amod||lesion-12/NN||predominant-10/JJ	nn||lesion-12/NN||glomerular-11/NN	root||ROOT-0/null||lesion-12/NN	vmod||lesion-12/NN||observed-13/VBN	amod||patients-16/NNS||hiv-infected-15/JJ	prep_in||observed-13/VBN||patients-16/NNS	aids-4||hiv--1||no||early in the aids epidemic, hivan was the predominant glomerular lesion observed in hiv-infected patients.
amod||prophylaxis-3/NNS||post-transplant-1/JJ	nn||prophylaxis-3/NNS||hbv-2/NN	nsubj||effective-31/JJ||prophylaxis-3/NNS	prep_with||prophylaxis-3/NNS||lamivudine-5/NN	prep_with||prophylaxis-3/NNS||intramuscular-7/NN	conj_and||lamivudine-5/NN||intramuscular-7/NN	vmod||prophylaxis-3/NNS||hbig-8/VBG	amod||dosage-11/NN||appropriate-10/JJ	prep_with||hbig-8/VBG||dosage-11/NN	aux||keep-13/VB||to-12/TO	xcomp||hbig-8/VBG||keep-13/VB	amod||titer-16/NN||anti-hbs-14/JJ	nn||titer-16/NN||antibody-15/NN	dobj||keep-13/VB||titer-16/NN	num||iu/l-19/NN||300-18/CD	prep_above||keep-13/VB||iu/l-19/NN	det||months-24/NNS||the-21/DT	amod||months-24/NNS||first-22/JJ	num||months-24/NNS||six-23/CD	prep_in||iu/l-19/NN||months-24/NNS	num||iu/l-28/NN||100-27/CD	prep_above||keep-13/VB||iu/l-28/NN	conj_and||iu/l-19/NN||iu/l-28/NN	dep||keep-13/VB||afterwards-29/RB	cop||effective-31/JJ||is-30/VBZ	root||ROOT-0/null||effective-31/JJ	prep_for||effective-31/JJ||prevention-33/NN	nn||recurrence-36/NN||hbv-35/NN	prep_of||prevention-33/NN||recurrence-36/NN	prep_after||effective-31/JJ||lt.-38/NN	hbv-35||lamivudine-5||yes||post-transplant hbv prophylaxis with lamivudine and intramuscular hbig with appropriate dosage to keep anti-hbs antibody titer above 300 iu/l in the first six months and above 100 iu/l afterwards is effective for prevention of hbv recurrence after lt.
det||zn-3/NN||a-1/DT	amod||zn-3/NN||size-controlled-2/JJ	nsubjpass||used-10/VBN||zn-3/NN	nsubj||explain-16/VB||zn-3/NN	discourse||zn-3/NN||oh-5/UH	number||template-8/JJ||2-7/CD	amod||zn-3/NN||template-8/JJ	auxpass||used-10/VBN||is-9/VBZ	root||ROOT-0/null||used-10/VBN	det||study-14/NN||a-12/DT	nn||study-14/NN||case-13/NN	prep_as||used-10/VBN||study-14/NN	aux||explain-16/VB||to-15/TO	xcomp||used-10/VBN||explain-16/VB	det||strategy-19/NN||the-17/DT	amod||strategy-19/NN||chemical-18/JJ	dobj||explain-16/VB||strategy-19/NN	nsubjpass||executed-23/VBN||strategy-19/NN	aux||executed-23/VBN||can-21/MD	auxpass||executed-23/VBN||be-22/VB	rcmod||strategy-19/NN||executed-23/VBN	advmod||engineering-26/VBG||chemically-25/RB	prepc_to||executed-23/VBN||engineering-26/VBG	amod||cavities-29/NNS||various-27/JJ	nn||cavities-29/NNS||nanoscale-28/NN	dobj||engineering-26/VBG||cavities-29/NNS	zn-3||cavities-29||no_rel||a size-controlled zn(oh)2 template is used as a case study to explain the chemical strategy that can be executed to chemically engineering various nanoscale cavities.
nsubj||anaemia-7/VBN||one-1/CD	nsubj||deficiencyoffolicacid-9/VBN||one-1/CD	det||women-5/NNS||every-3/DT	num||women-5/NNS||three-4/CD	prep_in||one-1/CD||women-5/NNS	aux||anaemia-7/VBN||had-6/VBD	root||ROOT-0/null||anaemia-7/VBN	conj_and||anaemia-7/VBN||deficiencyoffolicacid-9/VBN	mark||had-15/VBD||while-10/IN	nsubj||had-15/VBD||one-11/CD	det||two-14/CD||every-13/DT	prep_in||one-11/CD||two-14/CD	advcl||anaemia-7/VBN||had-15/VBD	dobj||had-15/VBD||irondeficiency-16/NN	vmod||had-15/VBD||suggesting-18/VBG	mark||constitute-26/VBP||that-19/IN	nsubj||constitute-26/VBP||deficiencies-20/NNS	preconj||folicacid-23/NN||both-22/DT	prep_of||deficiencies-20/NNS||folicacid-23/NN	prep_of||deficiencies-20/NNS||iron-25/NN	conj_and||folicacid-23/NN||iron-25/NN	ccomp||suggesting-18/VBG||constitute-26/VBP	det||deficiencies-30/NNS||the-27/DT	amod||deficiencies-30/NNS||major-28/JJ	nn||deficiencies-30/NNS||micronutrient-29/NN	dobj||constitute-26/VBP||deficiencies-30/NNS	nn||women-33/NNS||ethiopian-32/NN	prep_in||deficiencies-30/NNS||women-33/NNS	deficiencyoffolicacid-9||folicacid-23||yes||one in every three women had anaemia and deficiencyoffolicacid while one in every two had irondeficiency, suggesting that deficiencies of both folicacid and iron constitute the major micronutrient deficiencies in ethiopian women.
nsubj||is-9/VBZ||epratuzumab-1/NN	det||antibody-7/NN||a-3/DT	amod||antibody-7/NN||humanized-4/JJ	amod||antibody-7/NN||anti-cd22-5/JJ	nn||antibody-7/NN||monoclonal-6/NN	appos||epratuzumab-1/NN||antibody-7/NN	root||ROOT-0/null||is-9/VBZ	prep_under||is-9/VBZ||investigation-11/NN	det||antibody-15/NN||a-13/DT	amod||antibody-15/NN||therapeutic-14/JJ	prep_as||investigation-11/NN||antibody-15/NN	poss||lymphoma-19/NN||non-hodgkin-17/NN	prep_in||antibody-15/NN||lymphoma-19/NN	amod||lupuserythematosus-22/NNS||systemic-21/JJ	prep_in||antibody-15/NN||lupuserythematosus-22/NNS	conj_and||lymphoma-19/NN||lupuserythematosus-22/NNS	appos||lupuserythematosus-22/NNS||sle-24/NN	poss||mechanism-29/NN||its-28/PRP$	nsubj||remains-34/VBZ||mechanism-29/NN	prep_of||mechanism-29/NN||action-31/NN	prep_on||action-31/NN||b-cells-33/NNS	conj_but||is-9/VBZ||remains-34/VBZ	acomp||remains-34/VBZ||elusive-35/JJ	antibody-15||sle-24||no_rel||epratuzumab, a humanized anti-cd22 monoclonal antibody, is under investigation as a therapeutic antibody in non-hodgkin's lymphoma and systemic lupuserythematosus (sle), but its mechanism of action on b-cells remains elusive.
det||possibility-2/NN||the-1/DT	nsubj||allow-14/VB||possibility-2/NN	nsubj||help-27/VB||possibility-2/NN	prepc_of||possibility-2/NN||extracting-4/VBG	dobj||extracting-4/VBG||rna-5/NN	prepc_of||possibility-2/NN||measuring-7/VBG	conj_and||extracting-4/VBG||measuring-7/VBG	nn||expression-9/NN||rna-8/NN	dobj||measuring-7/VBG||expression-9/NN	nn||sections-12/NNS||paraffin-11/NN	prep_from||measuring-7/VBG||sections-12/NNS	aux||allow-14/VB||can-13/MD	root||ROOT-0/null||allow-14/VB	amod||investigations-16/NNS||extensive-15/JJ	dobj||allow-14/VB||investigations-16/NNS	amod||samples-20/NNS||stored-18/JJ	nn||samples-20/NNS||paraffin-19/NN	prep_on||allow-14/VB||samples-20/NNS	vmod||samples-20/NNS||obtained-21/VBN	amod||livers-24/NNS||diseased-23/JJ	prep_from||obtained-21/VBN||livers-24/NNS	aux||help-27/VB||could-26/MD	conj_and||allow-14/VB||help-27/VB	conj_and||allow-14/VB||help-27/VB	conj_and||help-27/VB||help-27/VB	prep_with||help-27/VB||studies-29/NNS	det||history-33/NN||the-31/DT	amod||history-33/NN||natural-32/JJ	prep_of||studies-29/NNS||history-33/NN	nn||fibrosis-36/NN||liver-35/NN	prep_of||history-33/NN||fibrosis-36/NN	prep_of||history-33/NN||inflammation-38/NN	conj_and||fibrosis-36/NN||inflammation-38/NN	amod||mechanisms-46/NNS||particular-42/JJ	amod||mechanisms-46/NNS||correlate-44/JJ	amod||mechanisms-46/NNS||basic-45/JJ	prep_in||help-27/VB||mechanisms-46/NNS	amod||outcomes-49/NNS||clinical-48/JJ	prep_to||help-27/VB||outcomes-49/NNS	paraffin-19||inflammation-38||no_rel||the possibility of extracting rna and measuring rna expression from paraffin sections can allow extensive investigations on stored paraffin samples obtained from diseased livers and could help with studies of the natural history of liver fibrosis and inflammation, and in particular, correlate basic mechanisms to clinical outcomes.
nsubj||conducted-2/VBD||we-1/PRP	root||ROOT-0/null||conducted-2/VBD	amod||analyses-6/NNS||phylogenetic-3/JJ	conj_and||phylogenetic-3/JJ||epidemiologic-5/JJ	amod||analyses-6/NNS||epidemiologic-5/JJ	dobj||conducted-2/VBD||analyses-6/NNS	aux||determine-8/VB||to-7/TO	vmod||conducted-2/VBD||determine-8/VB	dobj||determine-8/VB||sources-9/NNS	prep_of||sources-9/NNS||outbreaks-11/NNS	advmod||pathogenic-14/JJ||highly-13/RB	amod||avianinfluenzavirus-15/NNS||pathogenic-14/JJ	prep_of||outbreaks-11/NNS||avianinfluenzavirus-15/NNS	appos||sources-9/NNS||hpaiv-17/NNP	amod||h5n1-21/NNS||subtype-20/JJ	appos||sources-9/NNS||h5n1-21/NNS	nn||holdings-25/NNS||poultry-24/NN	prep_in||sources-9/NNS||holdings-25/NNS	prep_in||holdings-25/NNS||2007-27/CD	prep_in||sources-9/NNS||germany-29/NN	det||incursion-34/NN||a-32/DT	amod||incursion-34/NN||suspected-33/VBN	dobj||determine-8/VB||incursion-34/NN	conj_and||sources-9/NNS||incursion-34/NN	prep_of||incursion-34/NN||hpaiv-36/NNP	det||chain-40/NN||the-38/DT	nn||chain-40/NN||food-39/NN	prep_into||determine-8/VB||chain-40/NN	amod||carcasses-45/NNS||contaminated-42/JJ	amod||carcasses-45/NNS||deep-frozen-43/JJ	nn||carcasses-45/NNS||duck-44/NN	prep_through||determine-8/VB||carcasses-45/NNS	h5n1-21||avianinfluenzavirus-15||no||we conducted phylogenetic and epidemiologic analyses to determine sources of outbreaks of highly pathogenic avianinfluenzavirus (hpaiv), subtype h5n1, in poultry holdings in 2007 in germany, and a suspected incursion of hpaiv into the food chain through contaminated deep-frozen duck carcasses.
det||patient-2/NN||the-1/DT	nsubjpass||treated-4/VBN||patient-2/NN	auxpass||treated-4/VBN||was-3/VBD	ccomp||dipropionate-20/VBP||treated-4/VBN	amod||mg-9/NN||oral-6/JJ	amod||mg-9/NN||methylprednisolone-7/JJ	dep||methylprednisolone-7/JJ||48-8/CD	prep_with||treated-4/VBN||mg-9/NN	nn||®-12/NNP||prednolâ-11/NNP	dep||mg-9/NN||®-12/NNP	nn||nevzat-15/NN||mustafa-14/NN	dep||®-12/NNP||nevzat-15/NN	amod||clobetasol-19/NN||topical-18/JJ	nsubj||dipropionate-20/VBP||clobetasol-19/NN	root||ROOT-0/null||dipropionate-20/VBP	num||cream-23/NN||0.05-21/CD	nn||cream-23/NN||%-22/NN	dobj||dipropionate-20/VBP||cream-23/NN	nn||®-26/NNP||dermovateâ-25/NNP	dep||cream-23/NN||®-26/NNP	nn||smithkline-29/NN||glaxo-28/NN	dep||®-26/NNP||smithkline-29/NN	amod||urea-36/NN||topical-33/JJ	number||%-35/NN||4-34/CD	amod||urea-36/NN||%-35/NN	dobj||dipropionate-20/VBP||urea-36/NN	conj_and||cream-23/NN||urea-36/NN	dep||cream-23/NN||lotion-37/NN	amod||®-41/NNS||excipial-39/JJ	amod||®-41/NNS||lipoâ-40/JJ	dep||lotion-37/NN||®-41/NNS	dep||®-41/NNS||orva-43/NN	amod||bullouspemphigoid-47/NN||presumptive-46/JJ	prep_for||lotion-37/NN||bullouspemphigoid-47/NN	bullouspemphigoid-47||methylprednisolone-7||no_rel||the patient was treated with oral methylprednisolone 48 mg (prednolâ®; mustafa nevzat), topical clobetasol dipropionate 0.05% cream (dermovateâ®; glaxo smithkline), and topical 4% urea lotion (excipial lipoâ®; orva) for presumptive bullouspemphigoid.
amod||factors-3/NNS||independent-1/JJ	nn||factors-3/NNS||risk-2/NN	nsubj||weight-18/NN||factors-3/NNS	det||development-6/NN||the-5/DT	prep_for||factors-3/NNS||development-6/NN	prep_of||development-6/NN||diabetes-8/NN	nn||women-11/NNS||korean-10/NN	prep_in||diabetes-8/NN||women-11/NNS	amod||gdm-14/NN||previous-13/JJ	prep_with||women-11/NNS||gdm-14/NN	cop||weight-18/NN||are-15/VBP	amod||weight-18/NN||pre-pregnancy-16/JJ	nn||weight-18/NN||body-17/NN	root||ROOT-0/null||weight-18/NN	amod||age-21/NN||gestational-20/JJ	appos||weight-18/NN||age-21/NN	prep_at||age-21/NN||diagnosis-23/NN	nn||hyperglycemia-26/NN||antepartum-25/NN	conj_and||weight-18/NN||hyperglycemia-26/NN	amod||test-31/NN||oral-28/JJ	nn||test-31/NN||glucose-29/NN	nn||test-31/NN||tolerance-30/NN	prep_on||hyperglycemia-26/NN||test-31/NN	amod||response-35/NN||low-33/JJ	nn||response-35/NN||insulin-34/NN	conj_and||weight-18/NN||response-35/NN	amod||load-39/NN||oral-37/JJ	nn||load-39/NN||glucose-38/NN	prep_to||response-35/NN||load-39/NN	nn||history-43/NN||family-42/NN	conj_and||weight-18/NN||history-43/NN	prep_of||history-43/NN||diabetes-45/NN	hyperglycemia-26||glucose-38||no||independent risk factors for the development of diabetes in korean women with previous gdm are pre-pregnancy body weight, gestational age at diagnosis, antepartum hyperglycemia on oral glucose tolerance test, low insulin response to oral glucose load, and family history of diabetes.
advmod||exists-6/VBZ||however-1/RB	advmod||information-5/NN||virtually-3/RB	neg||information-5/NN||no-4/DT	nsubj||exists-6/VBZ||information-5/NN	root||ROOT-0/null||exists-6/VBZ	xcomp||exists-6/VBZ||regarding-7/VBG	det||effects-9/NNS||the-8/DT	dobj||regarding-7/VBG||effects-9/NNS	prep_of||effects-9/NNS||fluoxetine-11/NN	amod||responses-16/NNS||integrated-13/JJ	amod||responses-16/NNS||physiological-14/JJ	nn||responses-16/NNS||counterregulatory-15/NN	prep_on||regarding-7/VBG||responses-16/NNS	prep_during||regarding-7/VBG||hypoglycemia-18/NN	prep_in||hypoglycemia-18/NN||type1diabetes-20/CD	hypoglycemia-18||fluoxetine-11||no_rel||however, virtually no information exists regarding the effects of fluoxetine on integrated physiological counterregulatory responses during hypoglycemia in type1diabetes.
det||relationship-2/NN||the-1/DT	nsubjpass||supported-8/VBN||relationship-2/NN	prep_between||relationship-2/NN||ngf-4/NN	prep_between||relationship-2/NN||pain-6/NN	conj_and||ngf-4/NN||pain-6/NN	auxpass||supported-8/VBN||is-7/VBZ	root||ROOT-0/null||supported-8/VBN	amod||mutations-12/NNS||genetic-10/JJ	nn||mutations-12/NNS||evidence-11/NN	agent||supported-8/VBN||mutations-12/NNS	det||receptor-17/NN||the-14/DT	nn||receptor-17/NN||ngf-15/NN	nn||receptor-17/NN||trka-16/NN	prep_in||mutations-12/NNS||receptor-17/NN	prep_in||supported-8/VBN||patients-19/NNS	vmod||patients-19/NNS||affected-20/VBN	det||disease-25/NN||an-22/DT	advmod||rare-24/JJ||hereditary-23/RB	amod||disease-25/NN||rare-24/JJ	agent||affected-20/VBN||disease-25/NN	number||sensory-28/JJ||hereditary-27/CD	dep||disease-25/NN||sensory-28/JJ	amod||iv-33/NN||autonomic-30/JJ	nn||iv-33/NN||neuropathy-31/NNP	nn||iv-33/NN||type-32/NN	dep||disease-25/NN||iv-33/NN	conj_and||sensory-28/JJ||iv-33/NN	nn||iv-36/NN||hsan-35/NN	appos||sensory-28/JJ||iv-36/NN	ccomp||affected-20/VBN||determine-38/VB	det||form-41/NN||a-39/DT	amod||form-41/NN||congenital-40/JJ	dobj||determine-38/VB||form-41/NN	amod||pain-44/NN||severe-43/JJ	prep_of||form-41/NN||pain-44/NN	advmod||determine-38/VB||insensitivity-45/RB	amod||retardation-49/NN||mental-48/JJ	prep_with||determine-38/VB||retardation-49/NN	mark||determines-68/VBZ||while-51/IN	det||mutation-53/NN||a-52/DT	nsubj||determines-68/VBZ||mutation-53/NN	amod||gene-56/NN||ngfb-55/JJ	prep_in||mutation-53/NN||gene-56/NN	vmod||determines-68/VBZ||leading-58/VBG	det||r100w-63/NN||the-60/DT	amod||r100w-63/NN||aminoacid-61/JJ	nn||r100w-63/NN||substitution-62/NN	prep_to||leading-58/VBG||r100w-63/NN	amod||ngf-66/NN||mature-65/JJ	prep_in||r100w-63/NN||ngf-66/NN	dep||retardation-49/NN||determines-68/VBZ	det||loss-71/NN||a-69/DT	amod||loss-71/NN||similar-70/JJ	dobj||determines-68/VBZ||loss-71/NN	nn||perception-74/NN||pain-73/NN	prep_of||loss-71/NN||perception-74/NN	amod||cognitive-78/JJ||overt-77/JJ	amod||defects-80/NNS||cognitive-78/JJ	amod||defects-80/NNS||neurological-79/JJ	prep_without||determines-68/VBZ||defects-80/NNS	nn||v-83/NN||hsan-82/NN	appos||defects-80/NNS||v-83/NN	pain-73||aminoacid-61||no_rel||the relationship between ngf and pain is supported by genetic evidence mutations in the ngf trka receptor in patients affected by an hereditary rare disease (hereditary sensory and autonomic neuropathy type iv, hsan iv) determine a congenital form of severe pain insensitivity, with mental retardation, while a mutation in ngfb gene, leading to the aminoacid substitution r100w in mature ngf, determines a similar loss of pain perception, without overt cognitive neurological defects (hsan v).
aux||determine-2/VB||to-1/TO	advcl||analyzed-14/VBD||determine-2/VB	det||structure-5/NN||the-3/DT	nn||structure-5/NN||population-4/NN	dobj||determine-2/VB||structure-5/NN	det||agents-9/NNS||the-7/DT	amod||agents-9/NNS||cryptococcosis-8/JJ	prep_of||structure-5/NN||agents-9/NNS	prep_in||agents-9/NNS||china-11/NN	nsubj||analyzed-14/VBD||we-13/PRP	root||ROOT-0/null||analyzed-14/VBD	det||genotype-16/NN||the-15/DT	nsubj||isolated-25/VBD||genotype-16/NN	num||cryptococcusneoformans-19/NNS||120-18/CD	prep_of||genotype-16/NN||cryptococcusneoformans-19/NNS	num||strains-24/NNS||9-21/CD	amod||strains-24/NNS||cryptococcus-22/JJ	nn||strains-24/NNS||gattii-23/NN	prep_of||genotype-16/NN||strains-24/NNS	conj_and||cryptococcusneoformans-19/NNS||strains-24/NNS	ccomp||analyzed-14/VBD||isolated-25/VBD	prep_from||isolated-25/VBD||1980-27/CD	prep_through||isolated-25/VBD||2006-29/CD	amod||patients-32/NNS||cryptococcosis-31/JJ	prep_from||isolated-25/VBD||patients-32/NNS	vmod||patients-32/NNS||residing-33/VBG	num||provinces-36/NNS||16-35/CD	prep_in||residing-33/VBG||provinces-36/NNS	amod||china-39/NN||mainland-38/JJ	prep_of||provinces-36/NNS||china-39/NN	cryptococcosis-31||cryptococcus-22||no||to determine the population structure of the cryptococcosis agents in china, we analyzed the genotype of 120 cryptococcusneoformans and 9 cryptococcus gattii strains isolated from 1980 through 2006 from cryptococcosis patients residing in 16 provinces of mainland china.
nsubj||emerged-8/VBN||variants-1/NNS	nsubjpass||known-13/VBN||variants-1/NNS	amod||biotype-6/NN||vibriocholeraeo1-3/JJ	nn||biotype-6/NN||el-4/NN	nn||biotype-6/NN||tor-5/NN	prep_of||variants-1/NNS||biotype-6/NN	aux||emerged-8/VBN||have-7/VBP	root||ROOT-0/null||emerged-8/VBN	advmod||little-11/RB||very-10/RB	advmod||emerged-8/VBN||little-11/RB	conj_but||emerged-8/VBN||little-11/RB	auxpass||known-13/VBN||is-12/VBZ	conj_but||emerged-8/VBN||known-13/VBN	prep_about||known-13/VBN||strains-15/NNS	vmod||strains-15/NNS||causing-16/VBG	nn||outbreaks-18/NNS||cholera-17/NN	dobj||causing-16/VBG||outbreaks-18/NNS	amod||africa-21/NN||west-20/JJ	prep_in||causing-16/VBG||africa-21/NN	nsubj||crucial-25/JJ||africa-21/NN	nsubj||control-32/VB||africa-21/NN	cop||crucial-25/JJ||is-24/VBZ	rcmod||africa-21/NN||crucial-25/JJ	det||implementation-28/NN||the-27/DT	prep_for||crucial-25/JJ||implementation-28/NN	prep_of||implementation-28/NN||interventions-30/NNS	aux||control-32/VB||to-31/TO	xcomp||crucial-25/JJ||control-32/VB	dobj||control-32/VB||epidemiccholera-33/NN	cholera-17||vibriocholeraeo1-3||no||variants of vibriocholeraeo1 el tor biotype have emerged but very little is known about strains causing cholera outbreaks in west africa, which is crucial for the implementation of interventions to control epidemiccholera.
det||total-2/NN||a-1/DT	nsubjpass||enrolled-15/VBN||total-2/NN	num||animals-5/NNS||197-4/CD	prep_of||total-2/NN||animals-5/NNS	num||practices-9/NNS||150-7/CD	amod||practices-9/NNS||veterinary-8/JJ	prep_from||animals-5/NNS||practices-9/NNS	det||kingdom-13/NN||the-11/DT	amod||kingdom-13/NN||united-12/VBN	prep_across||practices-9/NNS||kingdom-13/NN	auxpass||enrolled-15/VBN||was-14/VBD	root||ROOT-0/null||enrolled-15/VBN	prep||enrolled-15/VBN||including-17/VBG	num||cases-20/NNS||105-18/CD	nn||cases-20/NNS||mrsa-19/NN	npadvmod||with-24/IN||cases-20/NNS	num||controls-23/NNS||92-22/CD	conj_and||cases-20/NNS||controls-23/NNS	npadvmod||with-24/IN||controls-23/NNS	pcomp||including-17/VBG||with-24/IN	amod||infection-30/NN||methicillin-susceptible-25/JJ	nn||infection-30/NN||s.aureus-26/NNS	nn||infection-30/NN||-lrb--27/NN	nn||infection-30/NN||mssa-28/NN	nn||infection-30/NN||-rrb--29/NN	pobj||with-24/IN||infection-30/NN	mrsa-19||s.aureus-26||no||a total of 197 animals from 150 veterinary practices across the united kingdom was enrolled , including 105 mrsa cases and 92 controls with methicillin-susceptible s.aureus -lrb- mssa -rrb- infection .
amod||endpoints-3/NNS||secondary-1/JJ	nn||endpoints-3/NNS||efficacy-2/NN	nsubj||included-4/VBD||endpoints-3/NNS	root||ROOT-0/null||included-4/VBD	det||change-6/NN||the-5/DT	dobj||included-4/VBD||change-6/NN	prep_from||included-4/VBD||baseline-8/NN	amod||bp-13/NN||mean-10/JJ	amod||bp-13/NN||seated-11/VBN	amod||bp-13/NN||systolic-12/JJ	prep_in||included-4/VBD||bp-13/NN	appos||bp-13/NN||sbp-15/NN	prep_in||included-4/VBD||proportions-18/NNS	conj_and||bp-13/NN||proportions-18/NNS	prep_of||proportions-18/NNS||patients-20/NNS	vmod||patients-20/NNS||achieving-21/VBG	nn||goal-23/NN||bp-22/NN	dobj||achieving-21/VBG||goal-23/NN	number||140/90-26/CD||<-25/CD	num||â-27/NN||140/90-26/CD	dep||proportions-18/NNS||â-27/NN	num||$-31/$||$-28/$	number||mmâ-30/CD||-29/CD	num||$-28/$||mmâ-30/CD	nsubj||mmâ-40/VBP||$-31/$	number||hg-33/CD||-32/CD	num||$-31/$||hg-33/CD	number||130/80-36/CD||<-35/CD	num||â-37/NN||130/80-36/CD	conj_or||$-31/$||â-37/NN	nsubj||mmâ-40/VBP||â-37/NN	dep||â-37/NN||$-38/$	num||$-38/$||-39/CD	rcmod||â-27/NN||mmâ-40/VBP	dobj||mmâ-40/VBP||$-41/$	number||hg-43/CD||-42/CD	num||$-41/$||hg-43/CD	prep_in||$-41/$||patients-45/NNS	prep_with||â-27/NN||diabetes-47/NN	det||number-52/NN||the-51/DT	prep_in||included-4/VBD||number-52/NN	conj_and||bp-13/NN||number-52/NN	conj_and||bp-13/NN||percentage-54/NN	conj_and||number-52/NN||percentage-54/NN	prep_of||number-52/NN||patients-56/NNS	vmod||patients-56/NNS||achieving-57/VBG	det||range-59/NN||a-58/DT	dobj||achieving-57/VBG||range-59/NN	nn||targets-62/NNS||bp-61/NN	prep_of||range-59/NN||targets-62/NNS	hg-43||secondary-1||no_rel||secondary efficacy endpoints included the change from baseline in mean seated systolic bp (sbp), proportions of patients achieving bp goal (<140/90âmmâhg or <130/80âmmâhg in patients with diabetes), and the number and percentage of patients achieving a range of bp targets.
nsubj||hope-2/VBP||we-1/PRP	root||ROOT-0/null||hope-2/VBP	nsubj||constitutes-4/VBZ||this-3/DT	ccomp||hope-2/VBP||constitutes-4/VBZ	det||beginning-6/NN||a-5/DT	dobj||constitutes-4/VBZ||beginning-6/NN	nsubj||groundswell-12/NN||what-8/WP	aux||groundswell-12/NN||could-9/MD	cop||groundswell-12/NN||be-10/VB	det||groundswell-12/NN||a-11/DT	prepc_of||beginning-6/NN||groundswell-12/NN	prep_of||groundswell-12/NN||interest-14/NN	amod||services-17/NNS||family-centred-16/JJ	prep_in||interest-14/NN||services-17/NNS	prep_for||services-17/NNS||children-19/NNS	vmod||children-19/NNS||affected-20/VBN	agent||affected-20/VBN||hiv-22/NN	agent||affected-20/VBN||aids-24/NNS	conj_and||hiv-22/NN||aids-24/NNS	aids-24||hiv-22||no||we hope this constitutes a beginning of what could be a groundswell of interest in family-centred services for children affected by hiv and aids.
nsubjpass||associated-17/VBN||isotretinoin-1/NN	det||retinoid-6/NN||a-3/DT	amod||retinoid-6/NN||synthetic-4/JJ	amod||retinoid-6/NN||oral-5/JJ	appos||isotretinoin-1/NN||retinoid-6/NN	nsubjpass||used-9/VBN||retinoid-6/NN	auxpass||used-9/VBN||is-8/VBZ	rcmod||retinoid-6/NN||used-9/VBN	amod||acne-13/NN||severe-11/JJ	amod||acne-13/NN||nodulocystic-12/JJ	prep_against||used-9/VBN||acne-13/NN	aux||associated-17/VBN||has-15/VBZ	auxpass||associated-17/VBN||been-16/VBN	root||ROOT-0/null||associated-17/VBN	amod||effects-22/NNS||various-19/JJ	amod||effects-22/NNS||psychiatric-20/JJ	nn||effects-22/NNS||side-21/NN	prep_with||associated-17/VBN||effects-22/NNS	nn||symptoms-30/NNS||depression-25/NN	conj_and||depression-25/NN||suicidality-27/NN	nn||symptoms-30/NNS||suicidality-27/NN	conj_and||depression-25/NN||psychotic-29/NN	nn||symptoms-30/NNS||psychotic-29/NN	prep_such_as||effects-22/NNS||symptoms-30/NNS	acne-13||isotretinoin-1||yes||isotretinoin, a synthetic oral retinoid that is used against severe nodulocystic acne, has been associated with various psychiatric side effects such as depression, suicidality and psychotic symptoms.
nsubj||increases-3/VBZ||hivinfection-1/NN	advmod||increases-3/VBZ||significantly-2/RB	root||ROOT-0/null||increases-3/VBZ	det||risk-5/NN||the-4/DT	dobj||increases-3/VBZ||risk-5/NN	prep_of||risk-5/NN||tuberculosis-7/NNP	det||disease-10/NN||this-9/DT	nsubj||one-12/CD||disease-10/NN	cop||one-12/CD||is-11/VBZ	conj_and||increases-3/VBZ||one-12/CD	det||infections-18/NNS||the-14/DT	advmod||common-16/JJ||most-15/RBS	amod||infections-18/NNS||common-16/JJ	amod||infections-18/NNS||opportunistic-17/JJ	prep_of||one-12/CD||infections-18/NNS	nn||patients-21/NNS||hiv-20/NN	prep_in||infections-18/NNS||patients-21/NNS	hivinfection-1||hiv-20||no||hivinfection significantly increases the risk of tuberculosis and this disease is one of the most common opportunistic infections in hiv patients.
amod||insulin-3/NN||total-1/JJ	amod||insulin-3/NN||mean-2/JJ	nsubj||use-4/VBP||insulin-3/NN	root||ROOT-0/null||use-4/VBP	dep||use-4/VBP||increased-5/VBN	amod||patients-8/NNS||type2diabetes-7/JJ	prep_in||increased-5/VBN||patients-8/NNS	dep||increased-5/VBN||from-10/IN	number||â-12/CD||0.67-11/CD	num||â-18/NN||â-12/CD	nn||â-18/NN||±-13/NNP	num||â-18/NN||1.35-14/CD	amod||â-18/NN||u/kg-15/JJ	prep_to||u/kg-15/JJ||0.88-17/CD	pobj||from-10/IN||â-18/NN	dep||u/kg-21/JJ||±-19/NNP	num||±-19/NNP||1.33-20/CD	amod||â-18/NN||u/kg-21/JJ	vmod||â-18/NN||p-23/VBN	num||0.001-25/CD||<-24/CD	dobj||p-23/VBN||0.001-25/CD	det||decrease-30/NN||a-28/DT	amod||decrease-30/NN||slight-29/JJ	prep_with||increased-5/VBN||decrease-30/NN	amod||patients-33/NNS||type1diabetes-32/JJ	prep_in||decrease-30/NN||patients-33/NNS	number||â-37/CD||1.04-36/CD	num||â-43/NN||â-37/CD	nn||â-43/NN||±-38/NNP	num||â-43/NN||2.51-39/CD	amod||â-43/NN||u/kg-40/JJ	prep_to||u/kg-40/JJ||0.98-42/CD	prep_from||decrease-30/NN||â-43/NN	number||2.58-45/CD||±-44/CD	dep||u/kg-46/JJ||2.58-45/CD	dep||â-43/NN||u/kg-46/JJ	vmod||â-43/NN||p-48/VBN	num||0.001-50/CD||<-49/CD	dobj||p-48/VBN||0.001-50/CD	type1diabetes-32||insulin-3||yes||total mean insulin use increased in type2diabetes patients (from 0.67 â± 1.35 u/kg to 0.88 â± 1.33 u/kg, p < 0.001) with a slight decrease in type1diabetes patients (from 1.04 â± 2.51 u/kg to 0.98 â± 2.58 u/kg, p < 0.001).
det||value-2/NN||the-1/DT	nsubj||vs-22/VBP||value-2/NN	amod||³-6/NNS||standard-4/JJ	nn||³-6/NNS||î-5/NN	prep_of||value-2/NN||³-6/NNS	dep||value-2/NN||globulin-8/NN	det||titer-12/NN||a-10/DT	amod||titer-12/NN||low-11/JJ	prep_with||globulin-8/NN||titer-12/NN	prep_of||titer-12/NN||antibody-14/NN	amod||antigen-18/NN||hepatitisb-16/JJ	nn||antigen-18/NN||surface-17/NN	prep_to||antibody-14/NN||antigen-18/NN	appos||value-2/NN||anti-hbs-20/NNS	root||ROOT-0/null||vs-22/VBP	amod||immuneglobulin-24/NN||hepatitisb-23/JJ	nsubj||unclear-37/JJ||immuneglobulin-24/NN	appos||immuneglobulin-24/NN||hbig-26/NN	prep_in||immuneglobulin-24/NN||prevention-29/NN	amod||hepatitisb-32/NN||icteric-31/JJ	prep_of||prevention-29/NN||hepatitisb-32/NN	det||military-35/NN||the-34/DT	prep_in||hepatitisb-32/NN||military-35/NN	cop||unclear-37/JJ||is-36/VBZ	ccomp||vs-22/VBP||unclear-37/JJ	hepatitisb-32||hepatitisbimmuneglobulin--1||yes||the value of standard î³-globulin with a low titer of antibody to hepatitisb surface antigen (anti-hbs) vs hepatitisb immuneglobulin (hbig) in prevention of icteric hepatitisb in the military is unclear.
prep_in||involved-16/VBN||addition-2/NN	nsubjpass||involved-16/VBN||transport-4/NN	conj_and||transport-4/NN||diffusion-6/NN	nsubjpass||involved-16/VBN||diffusion-6/NN	prep_of||transport-4/NN||ions-8/NNS	det||epithelium-14/NN||the-10/DT	nn||epithelium-14/NN||bbb-11/NN	conj_and||bbb-11/NN||cp-13/NN	nn||epithelium-14/NN||cp-13/NN	prep_by||ions-8/NNS||epithelium-14/NN	auxpass||involved-16/VBN||are-15/VBP	root||ROOT-0/null||involved-16/VBN	det||formation-19/NN||the-18/DT	prep_in||involved-16/VBN||formation-19/NN	prep_of||formation-19/NN||fluid-21/NN	det||isf-24/NN||the-23/DT	prep_of||formation-19/NN||isf-24/NN	conj_and||fluid-21/NN||isf-24/NN	prep_of||formation-19/NN||csf-26/NN	conj_and||fluid-21/NN||csf-26/NN	advmod||involved-16/VBN||respectively-28/RB	dep||involved-16/VBN||so-30/IN	det||part-33/NN||the-31/DT	amod||part-33/NN||last-32/JJ	nsubj||discusses-37/VBZ||part-33/NN	nsubj||cp-51/VBP||part-33/NN	det||review-36/NN||this-35/DT	prep_of||part-33/NN||review-36/NN	parataxis||involved-16/VBN||discusses-37/VBZ	amod||biology-39/NN||molecular-38/JJ	dobj||discusses-37/VBZ||biology-39/NN	nn||transporters/exchangers-42/NNS||ion-41/NN	prep_of||biology-39/NN||transporters/exchangers-42/NNS	nn||channels-45/NNS||ion-44/NN	prep_of||biology-39/NN||channels-45/NNS	conj_and||transporters/exchangers-42/NNS||channels-45/NNS	det||endothelial-49/NN||the-47/DT	nn||endothelial-49/NN||brain-48/NN	prep_in||discusses-37/VBZ||endothelial-49/NN	parataxis||involved-16/VBN||cp-51/VBP	conj_and||discusses-37/VBZ||cp-51/VBP	amod||cells-53/NNS||epithelial-52/JJ	dobj||cp-51/VBP||cells-53/NNS	ion-44||cp-51||no_rel||in addition, transport and diffusion of ions by the bbb and cp epithelium are involved in the formation of fluid, the isf and csf, respectively, so the last part of this review discusses molecular biology of ion transporters/exchangers and ion channels in the brain endothelial and cp epithelial cells.
advmod||attributed-10/VBN||recently-1/RB	det||cases-4/NNS||some-3/DT	nsubjpass||attributed-10/VBN||cases-4/NNS	amod||anaphylaxis-7/NNS||non-allergic-6/JJ	prep_of||cases-4/NNS||anaphylaxis-7/NNS	aux||attributed-10/VBN||could-8/MD	auxpass||attributed-10/VBN||be-9/VB	root||ROOT-0/null||attributed-10/VBN	amod||contaminants-14/NNS||undesirable-12/JJ	nn||contaminants-14/NNS||heparin-13/NN	prep_to||attributed-10/VBN||contaminants-14/NNS	heparin-13||anaphylaxis-7||no_rel||recently, some cases of non-allergic anaphylaxis could be attributed to undesirable heparin contaminants.
nsubj||performed-2/VBD||we-1/PRP	nsubj||determined-28/VBD||we-1/PRP	root||ROOT-0/null||performed-2/VBD	det||analysis-6/NN||a-3/DT	nn||analysis-6/NN||population-4/NN	amod||analysis-6/NN||pharmacokinetic-5/JJ	dobj||performed-2/VBD||analysis-6/NN	prep_of||analysis-6/NN||phenytoin-8/NN	amod||administration-11/NN||intravenous-10/JJ	prep_after||performed-2/VBD||administration-11/NN	prep_of||administration-11/NN||fosphenytoinsodium-13/NN	amod||subjects-21/NNS||healthy-15/JJ	amod||subjects-21/NNS||neurosurgical-17/JJ	conj_and||neurosurgical-17/JJ||epileptic-20/JJ	amod||subjects-21/NNS||epileptic-20/JJ	prep_in||fosphenytoinsodium-13/NN||subjects-21/NNS	amod||patients-25/NNS||pediatric-24/JJ	prep_including||administration-11/NN||patients-25/NNS	conj_and||performed-2/VBD||determined-28/VBD	det||dose-31/NN||the-29/DT	amod||dose-31/NN||optimal-30/JJ	dobj||determined-28/VBD||dose-31/NN	nn||rate-34/NN||infusion-33/NN	dobj||determined-28/VBD||rate-34/NN	conj_and||dose-31/NN||rate-34/NN	prepc_for||determined-28/VBD||achieving-36/VBG	det||range-39/NN||the-37/DT	amod||range-39/NN||therapeutic-38/JJ	dobj||achieving-36/VBG||range-39/NN	epileptic-20||phenytoin-8||yes||we performed a population pharmacokinetic analysis of phenytoin after intravenous administration of fosphenytoinsodium in healthy, neurosurgical, and epileptic subjects, including pediatric patients, and determined the optimal dose and infusion rate for achieving the therapeutic range.
mark||seems-5/VBZ||as-1/IN	amod||signalling-4/NN||a2b-2/JJ	nn||signalling-4/NN||ar-3/NN	nsubj||seems-5/VBZ||signalling-4/NN	nsubjpass||associated-8/VBN||signalling-4/NN	advcl||represent-19/VB||seems-5/VBZ	aux||associated-8/VBN||to-6/TO	auxpass||associated-8/VBN||be-7/VB	xcomp||seems-5/VBZ||associated-8/VBN	prepc_with||associated-8/VBN||pre/postconditioning-10/VBG	amod||mechanisms-14/NNS||cardioprotective-11/JJ	conj_and||cardioprotective-11/JJ||anti-inflammatory-13/JJ	amod||mechanisms-14/NNS||anti-inflammatory-13/JJ	dobj||pre/postconditioning-10/VBG||mechanisms-14/NNS	amod||agonists-17/NNS||selective-16/JJ	nsubj||represent-19/VB||agonists-17/NNS	aux||represent-19/VB||may-18/MD	root||ROOT-0/null||represent-19/VB	det||group-23/NN||a-20/DT	amod||group-23/NN||new-21/JJ	amod||group-23/NN||therapeutic-22/JJ	dobj||represent-19/VB||group-23/NN	prep_for||represent-19/VB||patients-25/NNS	vmod||patients-25/NNS||suffering-26/VBG	prep_from||suffering-26/VBG||coronaryarterydisease-28/NN	coronaryarterydisease-28||anti-inflammatory-13||no_rel||as a2b ar signalling seems to be associated with pre/postconditioning cardioprotective and anti-inflammatory mechanisms, selective agonists may represent a new therapeutic group for patients suffering from coronaryarterydisease.
det||basis-3/NN||the-2/DT	prep_on||updated-62/VBN||basis-3/NN	det||results-8/NNS||the-5/DT	advmod||published-7/VBN||recently-6/RB	amod||results-8/NNS||published-7/VBN	prep_of||basis-3/NN||results-8/NNS	det||trial-12/NN||a-10/DT	amod||trial-12/NN||clinical-11/JJ	prep_of||results-8/NNS||trial-12/NN	vmod||trial-12/NN||comparing-13/VBG	nn||months-17/NNS||12-14/CD	conj_and||12-14/CD||36â-16/CD	nn||months-17/NNS||36â-16/CD	dobj||comparing-13/VBG||months-17/NNS	prep_of||months-17/NNS||imatinib-19/NN	amod||therapy-22/NN||adjuvant-21/JJ	prep_in||comparing-13/VBG||therapy-22/NN	amod||tumors-26/NNS||gastrointestinal-24/JJ	amod||tumors-26/NNS||stromal-25/JJ	prep_for||therapy-22/NN||tumors-26/NNS	nsubj||demonstrated-32/VBD||tumors-26/NNS	appos||tumors-26/NNS||gists-28/NNS	rcmod||tumors-26/NNS||demonstrated-32/VBD	amod||benefit-34/NN||clinical-33/JJ	dobj||demonstrated-32/VBD||benefit-34/NN	amod||treatment-38/NN||longer-36/JJR	nn||treatment-38/NN||imatinib-37/NN	prep_of||benefit-34/NN||treatment-38/NN	prep_in||treatment-38/NN||terms-40/NNS	prepc_of||terms-40/NNS||delaying-42/VBG	dobj||delaying-42/VBG||recurrences-43/NNS	prepc_of||terms-40/NNS||improving-45/VBG	conj_and||delaying-42/VBG||improving-45/VBG	amod||survival-47/NN||overall-46/JJ	dobj||improving-45/VBG||survival-47/NN	dep||survival-47/NN||both-49/CC	det||us-51/PRP||the-50/DT	conj||survival-47/NN||us-51/PRP	nn||administration-55/NN||food-52/NN	conj_and||food-52/NN||drug-54/NN	nn||administration-55/NN||drug-54/NN	nsubj||updated-62/VBN||administration-55/NN	nsubj||approved-66/VBN||administration-55/NN	det||agency-60/NN||the-57/DT	nn||agency-60/NN||european-58/NN	nn||agency-60/NN||medicines-59/NNS	conj_and||administration-55/NN||agency-60/NN	nsubj||updated-62/VBN||agency-60/NN	aux||updated-62/VBN||have-61/VBP	root||ROOT-0/null||updated-62/VBN	poss||recommendations-64/NNS||their-63/PRP$	dobj||updated-62/VBN||recommendations-64/NNS	conj_and||updated-62/VBN||approved-66/VBN	amod||months-68/NNS||36â-67/JJ	dobj||approved-66/VBN||months-68/NNS	amod||treatment-71/NN||imatinib-70/JJ	prep_of||months-68/NNS||treatment-71/NN	prep_in||approved-66/VBN||patients-73/NNS	amod||homolog-82/NN||v-kit-75/JJ	amod||homolog-82/NN||hardy-zuckerman-76/JJ	dep||hardy-zuckerman-76/JJ||4-77/CD	nn||homolog-82/NN||feline-78/NN	nn||homolog-82/NN||sarcoma-79/NN	amod||homolog-82/NN||viral-80/JJ	nn||homolog-82/NN||oncogene-81/NN	prep_with||patients-73/NNS||homolog-82/NN	appos||homolog-82/NN||kit-84/NN	amod||gists-88/NNS||positive-87/JJ	parataxis||approved-66/VBN||gists-88/NNS	advmod||known-91/VBN||also-90/RB	dep||gists-88/NNS||known-91/VBN	amod||gists-94/NNS||cd117-positive-93/JJ	prep_as||known-91/VBN||gists-94/NNS	amod||risk-98/NN||high-97/JJ	prep_at||gists-88/NNS||risk-98/NN	prep_of||risk-98/NN||recurrence-100/NN	amod||resection-103/NN||surgical-102/JJ	prep_after||updated-62/VBN||resection-103/NN	det||tumor-107/NN||a-105/DT	amod||tumor-107/NN||primary-106/JJ	prep_of||resection-103/NN||tumor-107/NN	sarcoma-79||adjuvant-21||no_rel||on the basis of the recently published results of a clinical trial comparing 12 and 36â months of imatinib in adjuvant therapy for gastrointestinal stromal tumors (gists), which demonstrated clinical benefit of longer imatinib treatment in terms of delaying recurrences and improving overall survival, both the us food and drug administration and the european medicines agency have updated their recommendations and approved 36â months of imatinib treatment in patients with v-kit hardy-zuckerman 4 feline sarcoma viral oncogene homolog (kit)-positive gists (also known as cd117-positive gists) at high risk of recurrence after surgical resection of a primary tumor.
amod||adults-2/NNS||overweight-1/JJ	nsubj||±-10/VBD||adults-2/NNS	advmod||controlled-5/VBN||inadequately-4/RB	amod||type2diabetes-6/NNS||controlled-5/VBN	prep_with||adults-2/NNS||type2diabetes-6/NNS	nn||â-9/NN||metformin-8/NN	prep_on||type2diabetes-6/NNS||â-9/NN	root||ROOT-0/null||±-10/VBD	det||thiazolidinedione-12/NN||a-11/DT	nsubjpass||randomized-14/VBN||thiazolidinedione-12/NN	nsubj||subcutaneous-16/VB||thiazolidinedione-12/NN	nsubj||taspoglutide-27/VB||thiazolidinedione-12/NN	nsubj||exenatide-38/VB||thiazolidinedione-12/NN	auxpass||randomized-14/VBN||were-13/VBD	ccomp||±-10/VBD||randomized-14/VBN	aux||subcutaneous-16/VB||to-15/TO	xcomp||randomized-14/VBN||subcutaneous-16/VB	nn||weekly-20/NN||taspoglutide-17/NN	num||weekly-20/NN||10-18/CD	nn||weekly-20/NN||mg-19/NN	dobj||subcutaneous-16/VB||weekly-20/NN	dep||weekly-20/NN||n-22/VBN	dep||399-24/CD||=-23/SYM	ccomp||n-22/VBN||399-24/CD	xcomp||randomized-14/VBN||taspoglutide-27/VB	conj_or||subcutaneous-16/VB||taspoglutide-27/VB	num||weekly-30/NN||20-28/CD	nn||weekly-30/NN||mg-29/NN	dobj||taspoglutide-27/VB||weekly-30/NN	dep||weekly-30/NN||n-32/VBN	dep||398-34/CD||=-33/SYM	ccomp||n-32/VBN||398-34/CD	xcomp||randomized-14/VBN||exenatide-38/VB	conj_or||subcutaneous-16/VB||exenatide-38/VB	number||âµg-40/CD||10-39/CD	num||daily-42/RB||âµg-40/CD	advmod||daily-42/RB||twice-41/RB	dobj||exenatide-38/VB||daily-42/RB	dep||daily-42/RB||n-44/VBN	dep||392-46/CD||=-45/SYM	ccomp||n-44/VBN||392-46/CD	det||trial-53/NN||an-49/DT	amod||trial-53/NN||open-label-50/JJ	amod||trial-53/NN||multicenter-52/JJ	prep_in||exenatide-38/VB||trial-53/NN	type2diabetes-6||exenatide-38||yes||overweight adults with inadequately controlled type2diabetes on metformin â± a thiazolidinedione were randomized to subcutaneous taspoglutide 10 mg weekly ( n = 399), taspoglutide 20 mg weekly ( n = 398), or exenatide 10 âµg twice daily ( n = 392) in an open-label, multicenter trial.
det||findings-2/NNS||these-1/DT	nsubj||provide-3/VBP||findings-2/NNS	root||ROOT-0/null||provide-3/VBP	amod||support-5/NN||further-4/JJ	dobj||provide-3/VBP||support-5/NN	det||hypothesis-8/NNS||the-7/DT	prep_for||provide-3/VBP||hypothesis-8/NNS	nsubj||increased-10/VBN||hypothesis-8/NNS	rcmod||hypothesis-8/NNS||increased-10/VBN	nn||metabolism-12/NN||drug-11/NN	nsubj||mediate-15/VB||metabolism-12/NN	nsubj||highlight-24/VB||metabolism-12/NN	conj_and||metabolism-12/NN||efflux-14/NN	nsubj||mediate-15/VB||efflux-14/NN	ccomp||increased-10/VBN||mediate-15/VB	nn||resistance-19/NN||permethrin-16/NN	conj_and||permethrin-16/NN||ivermectin-18/NN	nn||resistance-19/NN||ivermectin-18/NN	dobj||mediate-15/VB||resistance-19/NN	amod||mites-22/NNS||scabies-21/JJ	prep_in||mediate-15/VB||mites-22/NNS	ccomp||increased-10/VBN||highlight-24/VB	conj_and||mediate-15/VB||highlight-24/VB	det||threat-26/NN||the-25/DT	dobj||highlight-24/VB||threat-26/NN	amod||resistance-30/NN||emerging-28/VBG	amod||resistance-30/NN||acaricide-29/JJ	prep_of||threat-26/NN||resistance-30/NN	det||treatment-33/NN||the-32/DT	prep_to||increased-10/VBN||treatment-33/NN	prep_of||treatment-33/NN||scabies-35/NNS	advmod||increased-10/VBN||worldwide-36/RB	scabies-35||ivermectin-18||yes||these findings provide further support for the hypothesis that increased drug metabolism and efflux mediate permethrin and ivermectin resistance in scabies mites and highlight the threat of emerging acaricide resistance to the treatment of scabies worldwide.
det||kinase-4/NN||the-1/DT	nn||kinase-4/NN||receptor-2/NN	nn||kinase-4/NN||tyrosine-3/NN	nsubj||met-5/VBD||kinase-4/NN	root||ROOT-0/null||met-5/VBD	auxpass||involved-7/VBN||is-6/VBZ	ccomp||met-5/VBD||involved-7/VBN	det||progression-10/NN||the-9/DT	prep_in||involved-7/VBN||progression-10/NN	prep_in||involved-7/VBN||metastasis-12/NNS	conj_and||progression-10/NN||metastasis-12/NNS	amod||cancers-16/NNS||numerous-14/JJ	amod||cancers-16/NNS||human-15/JJ	prep_of||progression-10/NN||cancers-16/NNS	tyrosine-3||metastasis-12||no_rel||the receptor tyrosine kinase met is involved in the progression and metastasis of numerous human cancers.
mark||multifold-10/VBN||since-1/IN	det||cause-4/NN||the-2/DT	amod||cause-4/NN||underlying-3/VBG	nsubjpass||multifold-10/VBN||cause-4/NN	prep_for||cause-4/NN||obesity-6/NN	prep_for||cause-4/NN||type2diabetes-8/NNS	conj_and||obesity-6/NN||type2diabetes-8/NNS	auxpass||multifold-10/VBN||is-9/VBZ	advcl||investigated-14/VBD||multifold-10/VBN	nsubj||investigated-14/VBD||we-12/PRP	nsubj||explored-29/VBD||we-12/PRP	advmod||investigated-14/VBD||further-13/RBR	root||ROOT-0/null||investigated-14/VBD	amod||effects-16/NNS||metabolic-15/JJ	dobj||investigated-14/VBD||effects-16/NNS	amod||supplementation-19/NN||leucine-18/JJ	prep_of||effects-16/NNS||supplementation-19/NN	amod||models-23/NNS||obese/diabetes-21/JJ	nn||models-23/NNS||mouse-22/NN	prep_in||supplementation-19/NN||models-23/NNS	amod||etiologies-26/NNS||different-25/JJ	prep_with||investigated-14/VBD||etiologies-26/NNS	conj_and||investigated-14/VBD||explored-29/VBD	det||mechanisms-33/NNS||the-30/DT	amod||mechanisms-33/NNS||underlying-31/JJ	amod||mechanisms-33/NNS||molecular-32/JJ	dobj||explored-29/VBD||mechanisms-33/NNS	leucine-18||type2diabetes-8||no_rel||since the underlying cause for obesity and type2diabetes is multifold, we further investigated metabolic effects of leucine supplementation in obese/diabetes mouse models with different etiologies, and explored the underlying molecular mechanisms.
advmod||co-localized-4/VBD||furthermore-1/RB	nsubj||co-localized-4/VBD||fmnl2-3/NNS	root||ROOT-0/null||co-localized-4/VBD	prep_with||co-localized-4/VBD||f-actin-6/NN	det||tips-9/NNS||the-8/DT	prep_to||co-localized-4/VBD||tips-9/NNS	amod||protrusions-12/NNS||cellular-11/JJ	prep_of||tips-9/NNS||protrusions-12/NNS	amod||cells-17/NNS||wm164-14/JJ	amod||cells-17/NNS||human-15/JJ	nn||cells-17/NNS||melanoma-16/NN	prep_in||protrusions-12/NNS||cells-17/NNS	melanoma-16||f---1||no_rel||furthermore, fmnl2 co-localized with f-actin to the tips of cellular protrusions in wm164 human melanoma cells.
amod||target-3/NN||aberrant-1/JJ	amod||target-3/NN||mammalian-2/JJ	nsubjpass||implicated-12/VBN||target-3/NN	nsubj||chemotherapy-27/VB||target-3/NN	amod||activation-9/NNS||rapamycin-5/JJ	appos||activation-9/NNS||mtor-7/NN	prep_of||target-3/NN||activation-9/NNS	aux||implicated-12/VBN||has-10/VBZ	auxpass||implicated-12/VBN||been-11/VBN	root||ROOT-0/null||implicated-12/VBN	prep_in||implicated-12/VBN||oncogenesis-14/NNS	prep_in||implicated-12/VBN||angiogenesis-16/NNS	conj_and||oncogenesis-14/NNS||angiogenesis-16/NNS	det||development-20/NN||the-19/DT	prep_in||implicated-12/VBN||development-20/NN	conj_and||oncogenesis-14/NNS||development-20/NN	nn||independence-23/NN||estrogen-22/NN	prep_of||development-20/NN||independence-23/NN	prep_of||development-20/NN||resistance-25/NN	conj_and||independence-23/NN||resistance-25/NN	aux||chemotherapy-27/VB||to-26/TO	xcomp||implicated-12/VBN||chemotherapy-27/VB	prep_in||chemotherapy-27/VB||breasttumors-29/NNS	breasttumors-29||estrogen-22||no||aberrant mammalian target of rapamycin (mtor) activation has been implicated in oncogenesis, angiogenesis, and the development of estrogen independence and resistance to chemotherapy in breasttumors.
amod||people-3/NNS||thai-2/JJ	prep_as||important-19/JJ||people-3/NNS	vmod||people-3/NNS||living-4/VBG	amod||access-9/NN||hiv/aids-6/JJ	nn||access-9/NN||gain-7/NN	amod||access-9/NN||increasing-8/VBG	prep_with||living-4/VBG||access-9/NN	nn||therapy-15/NN||antiretroviral-11/NNP	appos||therapy-15/NN||arv-13/NN	prep_to||access-9/NN||therapy-15/NN	nsubj||important-19/JJ||it-17/PRP	nsubj||evaluate-21/VB||it-17/PRP	cop||important-19/JJ||is-18/VBZ	root||ROOT-0/null||important-19/JJ	aux||evaluate-21/VB||to-20/TO	xcomp||important-19/JJ||evaluate-21/VB	det||impact-23/NN||the-22/DT	dobj||evaluate-21/VB||impact-23/NN	nsubj||has-25/VBZ||this-24/DT	rcmod||impact-23/NN||has-25/VBZ	neg||only-27/JJ||not-26/RB	preconj||on-28/IN||only-27/JJ	dep||has-25/VBZ||on-28/IN	amod||outcomes-30/NNS||clinical-29/JJ	pobj||on-28/IN||outcomes-30/NNS	dep||has-25/VBZ||on-34/IN	conj_and||on-28/IN||on-34/IN	poss||status-38/NN||patients-35/NNS	nn||status-38/NN||functional-37/NN	pobj||on-34/IN||status-38/NN	pobj||on-34/IN||well-being-40/NN	conj_and||status-38/NN||well-being-40/NN	aids--1||hiv--1||no||as thai people living with hiv/aids gain increasing access to antiretroviral (arv) therapy, it is important to evaluate the impact this has not only on clinical outcomes, but also on patients' functional status and well-being.
advmod||frequent-10/JJ||however-1/RB	det||â-4/NN||the-3/DT	poss||variant-7/NN||â-4/NN	amod||variant-7/NN||336a-6/JJ	nsubj||frequent-10/JJ||variant-7/NN	cop||frequent-10/JJ||was-8/VBD	advmod||frequent-10/JJ||more-9/RBR	root||ROOT-0/null||frequent-10/JJ	amod||patients-13/NNS||htlv-1-infected-12/JJ	prep_in||frequent-10/JJ||patients-13/NNS	amod||tropicalspasticparaparesis-17/NNS||-LSB--14/JJ	amod||tropicalspasticparaparesis-17/NNS||htlv-1-associatedmyelopathy-15/JJ	amod||tropicalspasticparaparesis-17/NNS||/-16/JJ	dep||patients-13/NNS||tropicalspasticparaparesis-17/NNS	appos||tropicalspasticparaparesis-17/NNS||ham/tsp-19/NN	quantmod||$-23/$||80â-22/RB	num||%-25/NN||$-23/$	num||$-23/$||-24/CD	appos||tropicalspasticparaparesis-17/NNS||%-25/NN	amod||asymptomatic-28/JJ||healthy-27/JJ	amod||carriers-30/NNS||asymptomatic-28/JJ	amod||carriers-30/NNS||htlv-1-29/JJ	appos||tropicalspasticparaparesis-17/NNS||carriers-30/NNS	amod||-RSB--36/NNS||90â-32/JJ	dep||%-35/NN||$-33/$	num||$-33/$||-34/CD	amod||-RSB--36/NNS||%-35/NN	appos||tropicalspasticparaparesis-17/NNS||-RSB--36/NNS	mark||70â-43/NNS||than-37/IN	det||group-41/NN||the-39/DT	nn||group-41/NN||control-40/NN	prep_in||70â-43/NNS||group-41/NN	dep||-RSB--36/NNS||70â-43/NNS	dep||%-46/NN||$-44/$	num||$-44/$||-45/CD	amod||70â-43/NNS||%-46/NN	dep||70â-43/NNS||-LSB--48/FW	dep||70â-43/NNS||p-49/NN	dep||0.0197-51/CD||=-50/SYM	rcmod||p-49/NN||0.0197-51/CD	nn||ratio-54/NN||odds-53/NNS	appos||tropicalspasticparaparesis-17/NNS||ratio-54/NN	cc||=-58/NNP||or-56/CC	dep||ratio-54/NN||=-58/NNP	num||=-58/NNP||2.511-59/CD	num||=-58/NNP||95â-61/CD	dep||%-64/NN||$-62/$	num||$-62/$||-63/CD	amod||interval-66/NN||%-64/NN	nn||interval-66/NN||confidence-65/NN	nsubj||=-70/VBZ||interval-66/NN	discourse||interval-66/NN||ci-68/UH	rcmod||=-58/NNP||=-70/VBZ	num||â-72/NNS||1.218-71/CD	dobj||=-70/VBZ||â-72/NNS	num||â-72/NNS||$-73/$	num||$-73/$||5.179-75/CD	htlv-1-associatedmyelopathy-15||htlv-1-29||no||however, the â336a variant was more frequent in htlv-1-infected patients [htlv-1-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp), 80â%; healthy asymptomatic htlv-1 carriers, 90â%] than in the control group (70â%) [ p =0.0197, odds ratio (or)=2.511, 95â% confidence interval (ci)=1.218â5.179).
nsubj||affect-7/VB||use-1/NN	det||drugs-4/NNS||both-3/DT	prep_of||use-1/NN||drugs-4/NNS	aux||affect-7/VB||will-5/MD	advmod||affect-7/VB||positively-6/RB	root||ROOT-0/null||affect-7/VB	dobj||affect-7/VB||many-8/JJ	det||abnormalities-13/NNS||the-10/DT	amod||abnormalities-13/NNS||underlying-11/JJ	amod||abnormalities-13/NNS||metabolic-12/JJ	prep_of||many-8/JJ||abnormalities-13/NNS	vmod||abnormalities-13/NNS||associated-14/VBN	prep_with||associated-14/VBN||type2diabetes-16/CD	det||secretion-21/NN||the-19/DT	amod||secretion-21/NN||disordered-20/JJ	prep_including||abnormalities-13/NNS||secretion-21/NN	prep_of||secretion-21/NN||insulin-23/NN	prep_of||secretion-21/NN||glucagon-25/NN	conj_and||insulin-23/NN||glucagon-25/NN	amod||sensitivity-30/NN||impaired-29/VBN	dobj||affect-7/VB||sensitivity-30/NN	conj_and||many-8/JJ||sensitivity-30/NN	nsubjpass||known-35/VBN||sensitivity-30/NN	nsubj||accompany-37/VB||sensitivity-30/NN	prep_to||sensitivity-30/NN||insulin-32/NN	auxpass||known-35/VBN||are-34/VBP	rcmod||sensitivity-30/NN||known-35/VBN	aux||accompany-37/VB||to-36/TO	xcomp||known-35/VBN||accompany-37/VB	det||disease-39/NN||this-38/DT	dobj||accompany-37/VB||disease-39/NN	type2diabetes-16||insulin-32||yes||use of both drugs will positively affect many of the underlying metabolic abnormalities associated with type2diabetes, including the disordered secretion of insulin and glucagon as well as impaired sensitivity to insulin which are known to accompany this disease.
nsubj||collected-2/VBD||we-1/PRP	root||ROOT-0/null||collected-2/VBD	amod||records-4/NNS||medical-3/JJ	dobj||collected-2/VBD||records-4/NNS	num||men-8/NNS||170-6/CD	amod||men-8/NNS||adult-7/JJ	prep_of||records-4/NNS||men-8/NNS	dep||men-8/NNS||diagnosed-9/VBN	prep_with||diagnosed-9/VBN||chronichepatitisc-11/NN	nsubj||started-13/VBD||chronichepatitisc-11/NN	rcmod||chronichepatitisc-11/NN||started-13/VBD	dobj||started-13/VBD||treatment-14/NN	det||combination-17/NN||a-16/DT	prep_with||started-13/VBD||combination-17/NN	amod||interferon-alpha-20/NN||pegylated-19/JJ	prep_of||combination-17/NN||interferon-alpha-20/NN	prep_with||started-13/VBD||ribavirin-22/NNP	conj_and||combination-17/NN||ribavirin-22/NNP	prep_between||ribavirin-22/NNP||january-24/NNP	num||january-24/NNP||2003-25/CD	dep||men-8/NNS||june-27/NNP	conj_and||diagnosed-9/VBN||june-27/NNP	num||june-27/NNP||2009-28/CD	det||centre-33/NN||the-30/DT	amod||centre-33/NN||croatian-31/JJ	nn||centre-33/NN||reference-32/NN	prep_at||june-27/NNP||centre-33/NN	amod||hepatitis-36/NN||viral-35/JJ	prep_for||centre-33/NN||hepatitis-36/NN	chronichepatitisc-11||interferon--1||yes||we collected medical records of 170 adult men diagnosed with chronichepatitisc who started treatment with a combination of pegylated interferon-alpha and ribavirin between january 2003 and june 2009 at the croatian reference centre for viral hepatitis.
nsubj||obstructivepulmonarydisease-21/VBP||objectives-1/NNS	aux||compare-3/VB||to-2/TO	vmod||objectives-1/NNS||compare-3/VB	amod||treatment-8/NN||standard-4/JJ	amod||treatment-8/NN||high-5/JJ	nn||treatment-8/NN||flow-6/NN	nn||treatment-8/NN||oxygen-7/NN	dobj||compare-3/VB||treatment-8/NN	amod||treatment-12/NN||titrated-10/JJ	nn||treatment-12/NN||oxygen-11/NN	prep_with||compare-3/VB||treatment-12/NN	prep_for||treatment-12/NN||patients-14/NNS	det||exacerbation-18/NN||an-16/DT	amod||exacerbation-18/NN||acute-17/JJ	prep_with||compare-3/VB||exacerbation-18/NN	prep_of||exacerbation-18/NN||chronic-20/NN	root||ROOT-0/null||obstructivepulmonarydisease-21/VBP	det||setting-25/NN||the-23/DT	amod||setting-25/NN||prehospital-24/JJ	prep_in||obstructivepulmonarydisease-21/VBP||setting-25/NN	obstructivepulmonarydisease-21||oxygen-11||yes||objectives to compare standard high flow oxygen treatment with titrated oxygen treatment for patients with an acute exacerbation of chronic obstructivepulmonarydisease in the prehospital setting.
advmod||appearance-12/NN||nowadays-1/RB	det||problem-5/NN||the-2/DT	advmod||difficult-4/JJ||most-3/RBS	amod||problem-5/NN||difficult-4/JJ	nsubj||appearance-12/NN||problem-5/NN	prep_in||problem-5/NN||treatment-7/NN	prep_of||treatment-7/NN||bacterialinfections-9/NNS	cop||appearance-12/NN||is-10/VBZ	det||appearance-12/NN||the-11/DT	root||ROOT-0/null||appearance-12/NN	amod||bacteria-15/NNS||resistant-14/JJ	prep_of||appearance-12/NN||bacteria-15/NNS	det||agents-19/NNS||the-17/DT	amod||agents-19/NNS||antimicrobial-18/JJ	prep_to||bacteria-15/NNS||agents-19/NNS	advmod||drawn-26/VBN||so-20/RB	mark||drawn-26/VBN||that-21/IN	det||attention-23/NN||the-22/DT	nsubjpass||drawn-26/VBN||attention-23/NN	aux||drawn-26/VBN||is-24/VBZ	auxpass||drawn-26/VBN||being-25/VBG	advcl||appearance-12/NN||drawn-26/VBN	amod||targets-30/NNS||other-28/JJ	amod||targets-30/NNS||potential-29/JJ	prep_to||drawn-26/VBN||targets-30/NNS	bacterialinfections-9||bacteria-15||no||nowadays the most difficult problem in treatment of bacterialinfections is the appearance of resistant bacteria to the antimicrobial agents so that the attention is being drawn to other potential targets.
amod||acetate-2/NN||bazedoxifene-1/JJ	nsubj||modulator-12/NN||acetate-2/NN	cop||modulator-12/NN||is-3/VBZ	det||modulator-12/NN||a-4/DT	amod||modulator-12/NN||novel-5/JJ	advmod||distinct-8/JJ||chemically-7/RB	amod||modulator-12/NN||distinct-8/JJ	amod||modulator-12/NN||selective-9/JJ	nn||modulator-12/NN||estrogen-10/NN	nn||modulator-12/NN||receptor-11/NN	root||ROOT-0/null||modulator-12/NN	nsubjpass||developed-20/VBN||modulator-12/NN	nsubj||obtain-29/VB||modulator-12/NN	nsubj||obtain-29/VB||modulator-12/NN	appos||modulator-12/NN||serm-14/NNP	aux||developed-20/VBN||has-17/VBZ	auxpass||developed-20/VBN||been-18/VBN	advmod||developed-20/VBN||specifically-19/RB	rcmod||modulator-12/NN||developed-20/VBN	det||screening-25/NN||a-22/DT	amod||screening-25/NN||stringent-23/JJ	amod||screening-25/NN||preclinical-24/JJ	prep_after||developed-20/VBN||screening-25/NN	prep_in||screening-25/NN||order-27/NN	aux||obtain-29/VB||to-28/TO	xcomp||developed-20/VBN||obtain-29/VB	xcomp||developed-20/VBN||obtain-29/VB	conj_and||obtain-29/VB||obtain-29/VB	amod||effects-31/NNS||favorable-30/JJ	dobj||obtain-29/VB||effects-31/NNS	det||metabolism-37/NN||the-33/DT	nn||metabolism-37/NN||skeleton-34/NN	conj_and||skeleton-34/NN||lipid-36/NN	nn||metabolism-37/NN||lipid-36/NN	prep_on||obtain-29/VB||metabolism-37/NN	det||improvement-41/NN||the-39/DT	amod||improvement-41/NN||additional-40/JJ	prep_with||obtain-29/VB||improvement-41/NN	det||effect-45/NN||a-43/DT	amod||effect-45/NN||neutral-44/JJ	prep_of||improvement-41/NN||effect-45/NN	prep_on||effect-45/NN||hotflushes-47/NNS	prepc_without||obtain-29/VB||stimulating-50/VBG	det||uterus-52/NN||the-51/DT	dobj||stimulating-50/VBG||uterus-52/NN	det||breast-55/NN||the-54/DT	dobj||stimulating-50/VBG||breast-55/NN	conj_or||uterus-52/NN||breast-55/NN	hotflushes-47||estrogen-10||yes||bazedoxifene acetate is a novel, chemically distinct selective estrogen receptor modulator (serm) that has been specifically developed after a stringent preclinical screening in order to obtain favorable effects on the skeleton and lipid metabolism with the additional improvement of a neutral effect on hotflushes and without stimulating the uterus or the breast.
det||study-2/NN||this-1/DT	nsubj||demonstrated-3/VBD||study-2/NN	root||ROOT-0/null||demonstrated-3/VBD	mark||higher-18/JJR||that-4/IN	csubj||higher-18/JJR||circulating-5/VBG	nn||plasmablasts-8/NNS||igg-6/NN	nn||plasmablasts-8/NNS||+-7/NN	dobj||circulating-5/VBG||plasmablasts-8/NNS	amod||secretion-11/NN||spontaneous-10/JJ	dobj||circulating-5/VBG||secretion-11/NN	conj_and||plasmablasts-8/NNS||secretion-11/NN	amod||antibodies-15/NNS||bcg-specific-13/JJ	nn||antibodies-15/NNS||igg-14/NN	prep_of||secretion-11/NN||antibodies-15/NNS	cop||higher-18/JJR||were-16/VBD	advmod||higher-18/JJR||significantly-17/RB	ccomp||demonstrated-3/VBD||higher-18/JJR	prep_in||higher-18/JJR||patients-20/NNS	amod||tb-23/NN||active-22/JJ	prep_with||patients-20/NNS||tb-23/NN	prepc_compared_with||higher-18/JJR||with-25/IN	nn||cases-28/NNS||latent-26/NN	nn||cases-28/NNS||tb-27/NN	pobj||higher-18/JJR||cases-28/NNS	amod||controls-31/NNS||non-tb-30/JJ	pobj||higher-18/JJR||controls-31/NNS	conj_and||cases-28/NNS||controls-31/NNS	tb-27||bcg--1||yes||this study demonstrated that circulating igg+ plasmablasts and spontaneous secretion of bcg-specific igg antibodies were significantly higher in patients with active tb compared with latent tb cases and non-tb controls.
nsubj||were-9/VBD||patients-1/NNS	vmod||patients-1/NNS||enrolled-2/VBN	det||trial-8/NN||the-4/DT	nn||trial-8/NN||asthma-5/NN	nn||trial-8/NN||intervention-6/NN	nn||trial-8/NN||research-7/NN	prep_in||enrolled-2/VBN||trial-8/NN	root||ROOT-0/null||were-9/VBD	amod||corticosteroids-12/NNS||inhaled-11/JJ	prep_on||were-9/VBD||corticosteroids-12/NNS	dep||corticosteroids-12/NNS||â-13/VBN	xcomp||â-13/VBN||-14/VBG	number||200-16/CD||¥-15/CD	num||+-23/NNS||200-16/CD	nn||+-23/NNS||î-17/NNP	num||+-23/NNS||1/4-18/CD	amod||+-23/NNS||g-19/JJ	amod||+-23/NNS||beclomethasone-20/JJ	conj_or||beclomethasone-20/JJ||equivalent-22/JJ	amod||+-23/NNS||equivalent-22/JJ	nsubj||long-acting-beta2-agonists-24/JJ||+-23/NNS	xcomp||-14/VBG||long-acting-beta2-agonists-24/JJ	dep||corticosteroids-12/NNS||demonstrated-26/VBN	conj_and||â-13/VBN||demonstrated-26/VBN	dobj||demonstrated-26/VBN||worsening-27/VBG	prep_of||worsening-27/VBG||asthma-29/NN	nn||withdrawal-34/NN||long-acting-î-31/NNP	nn||withdrawal-34/NN||²-32/NNP	amod||withdrawal-34/NN||2-agonist-33/JJ	prep_on||asthma-29/NN||withdrawal-34/NN	asthma-29||beclomethasone-20||yes||patients enrolled in the asthma intervention research trial were on inhaled corticosteroids â¥200 î¼g beclomethasone or equivalent + long-acting-beta2-agonists and demonstrated worsening of asthma on long-acting-î²2-agonist withdrawal.
nsubjpass||recovered-6/VBN||epstein-barrvirus-1/NNS	appos||epstein-barrvirus-1/NNS||ebv-3/NN	auxpass||recovered-6/VBN||was-5/VBD	root||ROOT-0/null||recovered-6/VBN	amod||cells-9/NNS||cerebrospinal-8/JJ	prep_from||recovered-6/VBN||cells-9/NNS	cc||not-12/RB||but-11/CC	dep||cells-9/NNS||not-12/RB	amod||fluid-15/NN||cell-free-14/JJ	prep_from||not-12/RB||fluid-15/NN	det||patient-19/NN||a-18/DT	prep_of||cells-9/NNS||patient-19/NN	amod||infectiousmononucleosis-23/NNS||meningoencephalitis-21/JJ	amod||infectiousmononucleosis-23/NNS||complicating-22/VBG	prep_with||recovered-6/VBN||infectiousmononucleosis-23/NNS	infectiousmononucleosis-23||ebv-3||no||epstein-barrvirus (ebv) was recovered from cerebrospinal cells (but not from cell-free fluid) of a patient with meningoencephalitis complicating infectiousmononucleosis.
nn||equivalence-2/NNS||conclusion-1/NN	nsubjpass||found-4/VBN||equivalence-2/NNS	auxpass||found-4/VBN||was-3/VBD	root||ROOT-0/null||found-4/VBN	amod||bcgvaccine-7/NN||intradermal-6/JJ	prep_between||found-4/VBN||bcgvaccine-7/NN	nn||bcg-10/NN||percutaneous-9/NNS	prep_between||found-4/VBN||bcg-10/NN	conj_and||bcgvaccine-7/NN||bcg-10/NN	det||incidence-13/NN||the-12/DT	prep_in||bcgvaccine-7/NN||incidence-13/NN	prep_of||incidence-13/NN||tuberculosis-15/NNP	amod||infants-19/NNS||south-17/JJ	nn||infants-19/NNS||african-18/NN	prep_in||found-4/VBN||infants-19/NNS	dep||infants-19/NNS||vaccinated-20/VBN	prep_at||vaccinated-20/VBN||birth-22/NN	dep||infants-19/NNS||followed-24/VBN	conj_and||vaccinated-20/VBN||followed-24/VBN	prt||followed-24/VBN||up-25/RP	num||years-28/NNS||two-27/CD	prep_for||followed-24/VBN||years-28/NNS	tuberculosis-15||bcgvaccine-7||yes||conclusion equivalence was found between intradermal bcgvaccine and percutaneous bcg in the incidence of tuberculosis in south african infants vaccinated at birth and followed up for two years.
poss||work-2/NN||our-1/PRP$	nsubj||provides-3/VBZ||work-2/NN	nsubj||suggests-17/VBZ||work-2/NN	root||ROOT-0/null||provides-3/VBZ	amod||insight-5/NN||valuable-4/JJ	dobj||provides-3/VBZ||insight-5/NN	det||drug-8/NN||the-7/DT	prep_into||provides-3/VBZ||drug-8/NN	vmod||drug-8/NN||induced-9/VBN	nn||event-12/NN||cell-10/NN	nn||event-12/NN||fusion-11/NN	dobj||induced-9/VBN||event-12/NN	dobj||induced-9/VBN||outcome-14/NN	conj_and||event-12/NN||outcome-14/NN	conj_and||provides-3/VBZ||suggests-17/VBZ	nsubj||targets-28/NNS||yb-1-18/JJ	conj_and||yb-1-18/JJ||gst-20/NN	nsubj||targets-28/NNS||gst-20/NN	conj_and||yb-1-18/JJ||abcb5-22/NNS	nsubj||targets-28/NNS||abcb5-22/NNS	conj_and||yb-1-18/JJ||erk3-24/NNS	nsubj||targets-28/NNS||erk3-24/NNS	aux||targets-28/NNS||could-25/MD	cop||targets-28/NNS||be-26/VB	amod||targets-28/NNS||potential-27/JJ	ccomp||suggests-17/VBZ||targets-28/NNS	det||development-32/NN||the-30/DT	amod||development-32/NN||anti-cancerdrug-31/JJ	prep_for||targets-28/NNS||development-32/NN	nn||cells-38/NNS||drug-34/NN	amod||breast-36/JJ||resistant-35/JJ	amod||cells-38/NNS||breast-36/JJ	nn||cells-38/NNS||cancer-37/NN	prep_against||development-32/NN||cells-38/NNS	cancer-37||cancerdrug--1||no_rel||our work provides valuable insight into the drug induced cell fusion event and outcome, and suggests yb-1, gst, abcb5 and erk3 could be potential targets for the anti-cancerdrug development against drug resistant breast cancer cells.
nsubj||enzyme-10/NN||glucokinase-1/NN	appos||glucokinase-1/NN||gck-3/NN	cop||enzyme-10/NN||is-5/VBZ	det||enzyme-10/NN||the-6/DT	amod||enzyme-10/NN||key-7/JJ	nn||enzyme-10/NN||glucose-8/NN	nn||enzyme-10/NN||phosphorylation-9/NN	root||ROOT-0/null||enzyme-10/NN	nsubj||attracted-13/VBN||enzyme-10/NN	nsubj||regulates-40/VBZ||enzyme-10/NN	aux||attracted-13/VBN||has-12/VBZ	rcmod||enzyme-10/NN||attracted-13/VBN	amod||attention-15/NN||considerable-14/JJ	dobj||attracted-13/VBN||attention-15/NN	det||gene-19/NN||a-17/DT	nn||gene-19/NN||candidate-18/NN	prep_as||attracted-13/VBN||gene-19/NN	amod||t2d-23/NNS||type2diabetes-21/JJ	prep_for||gene-19/NN||t2d-23/NNS	vmod||t2d-23/NNS||based-25/VBN	poss||function-29/NN||its-27/PRP$	amod||function-29/NN||enzyme-28/JJ	prep_on||based-25/VBN||function-29/NN	det||step-34/NN||the-31/DT	amod||step-34/NN||first-32/JJ	amod||step-34/NN||rate-limiting-33/JJ	prep_as||based-25/VBN||step-34/NN	det||pathway-38/NN||the-36/DT	amod||pathway-38/NN||glycolysis-37/JJ	prep_in||step-34/NN||pathway-38/NN	rcmod||enzyme-10/NN||regulates-40/VBZ	conj_and||attracted-13/VBN||regulates-40/VBZ	amod||secretion-43/NN||glucose-stimulated-41/JJ	nn||secretion-43/NN||insulin-42/NN	dobj||regulates-40/VBZ||secretion-43/NN	type2diabetes-21||insulin-42||yes||glucokinase ( gck ) is the key glucose phosphorylation enzyme which has attracted considerable attention as a candidate gene for type2diabetes (t2d) based on its enzyme function as the first rate-limiting step in the glycolysis pathway and regulates glucose-stimulated insulin secretion.
amod||infection-7/NN||posttransfusion-1/JJ	amod||infection-7/NN||hepatitisb-2/JJ	nn||infection-7/NN||virus-3/NN	appos||infection-7/NN||hbv-5/NN	nsubj||occurs-9/VBZ||infection-7/NN	advmod||occurs-9/VBZ||still-8/RB	root||ROOT-0/null||occurs-9/VBZ	mark||reduced-16/VBN||although-10/IN	poss||incidence-12/NN||its-11/PRP$	nsubjpass||reduced-16/VBN||incidence-12/NN	aux||reduced-16/VBN||has-13/VBZ	auxpass||reduced-16/VBN||been-14/VBN	advmod||reduced-16/VBN||substantially-15/RB	advcl||occurs-9/VBZ||reduced-16/VBN	det||introduction-19/NN||the-18/DT	prep_since||reduced-16/VBN||introduction-19/NN	prep_of||introduction-19/NN||screening-21/NN	amod||antigen-25/NN||hepatitisb-23/JJ	nn||antigen-25/NN||surface-24/NN	prep_of||screening-21/NN||antigen-25/NN	appos||antigen-25/NN||hbsag-27/NN	nn||donors-31/NNS||blood-30/NN	prep_in||antigen-25/NN||donors-31/NNS	hbv-5||hbsag-27||yes||posttransfusion hepatitisb virus (hbv) infection still occurs although its incidence has been substantially reduced since the introduction of screening of hepatitisb surface antigen (hbsag) in blood donors.
nsubj||pathogen-19/NN||mycobacteriumtuberculosis-1/NNS	appos||mycobacteriumtuberculosis-1/NNS||mtb-3/NN	det||agent-8/NN||the-6/DT	amod||agent-8/NN||causative-7/JJ	appos||mycobacteriumtuberculosis-1/NNS||agent-8/NN	prep_of||agent-8/NN||tuberculosis-10/NNP	appos||tuberculosis-10/NNP||tb-12/NN	cop||pathogen-19/NN||is-15/VBZ	det||pathogen-19/NN||a-16/DT	amod||pathogen-19/NN||facultative-17/JJ	nn||pathogen-19/NN||intracellular-18/NN	root||ROOT-0/null||pathogen-19/NN	nsubj||persist-22/VB||pathogen-19/NN	aux||persist-22/VB||can-21/MD	rcmod||pathogen-19/NN||persist-22/VB	det||host-25/NN||the-24/DT	prep_within||persist-22/VB||host-25/NN	tb-12||mycobacteriumtuberculosis-1||no||mycobacteriumtuberculosis ( mtb ), the causative agent of tuberculosis (tb), is a facultative intracellular pathogen that can persist within the host.
nsubjpass||made-4/VBN||consideration-1/NN	nsubj||avoid-6/VB||consideration-1/NN	nsubj||change-10/VB||consideration-1/NN	nsubj||premedicate-15/VB||consideration-1/NN	aux||made-4/VBN||should-2/MD	auxpass||made-4/VBN||be-3/VB	root||ROOT-0/null||made-4/VBN	aux||avoid-6/VB||to-5/TO	xcomp||made-4/VBN||avoid-6/VB	dobj||avoid-6/VB||fluorescein-7/NN	advmod||avoid-6/VB||angiography-8/RB	xcomp||made-4/VBN||change-10/VB	conj_or||avoid-6/VB||change-10/VB	nn||route-12/NN||administration-11/NN	dobj||change-10/VB||route-12/NN	xcomp||made-4/VBN||premedicate-15/VB	conj_or||avoid-6/VB||premedicate-15/VB	prep_with||premedicate-15/VB||antihistamines-17/NNS	prep_in||antihistamines-17/NNS||patients-19/NNS	amod||albuminsolutionallergy-23/NN||known-21/JJ	amod||albuminsolutionallergy-23/NN||human-22/JJ	prep_with||patients-19/NNS||albuminsolutionallergy-23/NN	fluorescein-7||albuminsolutionallergy-23||no_rel||consideration should be made to avoid fluorescein angiography, change administration route, or premedicate with antihistamines in patients with known human albuminsolutionallergy.
det||hand-4/NN||the-2/DT	amod||hand-4/NN||other-3/JJ	prep_on||promote-24/VB||hand-4/NN	amod||hyporesponsiveness-8/NNS||uc-mscs-6/JJ	amod||hyporesponsiveness-8/NNS||induced-7/JJ	nsubj||promote-24/VB||hyporesponsiveness-8/NNS	nn||cells-11/NNS||t-10/NN	prep_of||hyporesponsiveness-8/NNS||cells-11/NNS	vmod||cells-11/NNS||mediated-12/VBN	agent||mediated-12/VBN||pge2-14/NNS	num||²-17/NNP||tgf-î-16/CD	agent||mediated-12/VBN||²-17/NNP	conj_and||pge2-14/NNS||²-17/NNP	num||²-17/NNP||1-18/CD	agent||mediated-12/VBN||no-20/DT	conj_and||pge2-14/NNS||no-20/DT	conj_and||pge2-14/NNS||uc-mscs-22/NN	conj_and||no-20/DT||uc-mscs-22/NN	aux||promote-24/VB||could-23/MD	root||ROOT-0/null||promote-24/VB	det||expansion-26/NN||the-25/DT	dobj||promote-24/VB||expansion-26/NN	amod||cells-34/NNS||cd4-28/JJ	amod||cells-34/NNS||+-29/JJ	amod||cells-34/NNS||foxp3-30/JJ	amod||cells-34/NNS||+-31/JJ	amod||cells-34/NNS||regulatory-32/JJ	nn||cells-34/NNS||t-33/NN	prep_of||expansion-26/NN||cells-34/NNS	nn||patients-37/NNS||ra-36/NN	prep_from||cells-34/NNS||patients-37/NNS	pge2-14||uc--1||no_rel||on the other hand, uc-mscs induced hyporesponsiveness of t cells mediated by pge2, tgf-î²1 and no and uc-mscs could promote the expansion of cd4+ foxp3+ regulatory t cells from ra patients.
amod||studies-2/NNS||clinical-1/JJ	nsubj||indicate-3/VBP||studies-2/NNS	root||ROOT-0/null||indicate-3/VBP	mark||option-13/NN||that-4/IN	det||implant-7/NN||this-5/DT	amod||implant-7/NN||dexamethasone-6/JJ	nsubj||option-13/NN||implant-7/NN	cop||option-13/NN||is-8/VBZ	det||option-13/NN||a-9/DT	amod||option-13/NN||promising-10/JJ	amod||option-13/NN||new-11/JJ	nn||option-13/NN||treatment-12/NN	ccomp||indicate-3/VBP||option-13/NN	prep_for||option-13/NN||patients-15/NNS	amod||macularedema-18/NN||persistent-17/JJ	prep_with||patients-15/NNS||macularedema-18/NN	vmod||macularedema-18/NN||resulting-19/VBG	amod||occlusion-23/NN||retinal-21/JJ	nn||occlusion-23/NN||vein-22/NN	prep_from||resulting-19/VBG||occlusion-23/NN	advmod||resulting-19/VBG||diabeticretinopathy-25/RB	ccomp||indicate-3/VBP||uveitis-28/NNS	conj_and||option-13/NN||uveitis-28/NNS	amod||syndrome-31/NN||irvine-gass-30/JJ	conj_and||option-13/NN||syndrome-31/NN	conj_or||uveitis-28/NNS||syndrome-31/NN	uveitis-28||dexamethasone-6||no_rel||clinical studies indicate that this dexamethasone implant is a promising new treatment option for patients with persistent macularedema resulting from retinal vein occlusion, diabeticretinopathy, and uveitis or irvine-gass syndrome.
prep||propose-6/VBP||given-1/VBN	det||findings-3/NNS||these-2/DT	pobj||given-1/VBN||findings-3/NNS	nsubj||propose-6/VBP||we-5/PRP	root||ROOT-0/null||propose-6/VBP	mark||rxr-12/VBP||that-7/IN	det||modulation-9/NN||the-8/DT	nsubj||rxr-12/VBP||modulation-9/NN	prep_of||modulation-9/NN||endogenous-11/NNS	ccomp||propose-6/VBP||rxr-12/VBP	nn||²-15/NNS||î-14/NN	prep_in||rxr-12/VBP||²-15/NNS	nsubj||approach-23/NN||cells-17/NNS	aux||approach-23/NN||may-18/MD	cop||approach-23/NN||be-19/VB	det||approach-23/NN||a-20/DT	amod||approach-23/NN||new-21/JJ	amod||approach-23/NN||therapeutic-22/JJ	parataxis||propose-6/VBP||approach-23/NN	prepc_for||approach-23/NN||improving-25/VBG	amod||secretion-28/NN||impaired-26/VBN	nn||secretion-28/NN||insulin-27/NN	dobj||improving-25/VBG||secretion-28/NN	prep_in||secretion-28/NN||type2diabetes-30/CD	insulin-27||type2diabetes-30||no_rel||given these findings, we propose that the modulation of endogenous rxr in î²-cells may be a new therapeutic approach for improving impaired insulin secretion in type2diabetes.
poss||data-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||data-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||endogenous-9/VBZ||that-4/IN	nn||tissues-6/NNS||cancer-5/NN	nsubj||endogenous-9/VBZ||tissues-6/NNS	advmod||secrete-8/JJ||directly-7/RB	amod||tissues-6/NNS||secrete-8/JJ	ccomp||suggest-3/VBP||endogenous-9/VBZ	dobj||endogenous-9/VBZ||formaldehyde-10/NN	det||formaldehyde-14/NN||this-13/DT	nsubj||induces-18/VBZ||formaldehyde-14/NN	amod||concentration-17/NN||low-16/JJ	prep_at||formaldehyde-14/NN||concentration-17/NN	conj_and||suggest-3/VBP||induces-18/VBZ	amod||pain-22/NN||metastatic-19/JJ	nn||pain-22/NN||bone-20/NN	nn||pain-22/NN||cancer-21/NN	dobj||induces-18/VBZ||pain-22/NN	amod||activation-25/NN||trpv1-24/JJ	prep_through||induces-18/VBZ||activation-25/NN	advmod||induces-18/VBZ||especially-26/RB	nn||environment-30/NN||tumor-28/NN	amod||environment-30/NN||acidic-29/JJ	prep_under||induces-18/VBZ||environment-30/NN	pain-22||formaldehyde-14||no_rel||our data suggest that cancer tissues directly secrete endogenous formaldehyde, and this formaldehyde at low concentration induces metastatic bone cancer pain through trpv1 activation especially under tumor acidic environment.
nsubj||appear-4/VBP||prochlorperazine-1/NN	nsubj||effective-8/JJ||prochlorperazine-1/NN	conj_and||prochlorperazine-1/NN||ondansetron-3/NN	nsubj||appear-4/VBP||ondansetron-3/NN	nsubj||effective-8/JJ||ondansetron-3/NN	root||ROOT-0/null||appear-4/VBP	aux||effective-8/JJ||to-5/TO	cop||effective-8/JJ||be-6/VB	advmod||effective-8/JJ||equally-7/RB	xcomp||appear-4/VBP||effective-8/JJ	prepc_at||effective-8/JJ||treating-10/VBG	dobj||treating-10/VBG||vomiting-11/NN	det||department-15/NN||the-13/DT	nn||department-15/NN||emergency-14/NN	prep_in||treating-10/VBG||department-15/NN	vomiting-11||ondansetron-3||yes||prochlorperazine and ondansetron appear to be equally effective at treating vomiting in the emergency department.
nn||enzyme-2/NN||restriction-1/NN	nsubjpass||utilized-8/VBN||enzyme-2/NN	nsubj||continue-17/VB||enzyme-2/NN	nsubj||have-19/VB||enzyme-2/NN	vmod||enzyme-2/NN||based-3/VBN	dobj||based-3/VBN||approaches-4/NNS	aux||utilized-8/VBN||have-5/VBP	auxpass||utilized-8/VBN||been-6/VBN	advmod||utilized-8/VBN||widely-7/RB	root||ROOT-0/null||utilized-8/VBN	nn||profiling-11/NN||methylation-10/NN	prep_for||utilized-8/VBN||profiling-11/NN	nn||genomes-14/NNS||cancer-13/NN	prep_of||profiling-11/NN||genomes-14/NNS	aux||continue-17/VB||will-16/MD	conj_and||utilized-8/VBN||continue-17/VB	aux||have-19/VB||to-18/TO	xcomp||continue-17/VB||have-19/VB	dobj||have-19/VB||importance-20/NN	prep_in||importance-20/NN||combination-22/NN	amod||microarrays-26/NNS||higher-24/JJR	nn||microarrays-26/NNS||density-25/NN	prep_with||have-19/VB||microarrays-26/NNS	cancer-13||enzyme-2||no_rel||restriction enzyme based approaches have been widely utilized for methylation profiling of cancer genomes and will continue to have importance in combination with higher density microarrays.
det||technique-3/NN||this-1/DT	amod||technique-3/NN||simple-2/JJ	nsubjpass||used-6/VBN||technique-3/NN	nsubj||identify-8/VB||technique-3/NN	nsubj||classify-10/VB||technique-3/NN	aux||used-6/VBN||has-4/VBZ	auxpass||used-6/VBN||been-5/VBN	root||ROOT-0/null||used-6/VBN	aux||identify-8/VB||to-7/TO	xcomp||used-6/VBN||identify-8/VB	xcomp||used-6/VBN||classify-10/VB	conj_and||identify-8/VB||classify-10/VB	nn||viruses-12/NNS||dna-11/NN	dobj||identify-8/VB||viruses-12/NNS	det||herpes-15/NNS||the-14/DT	prep_of||viruses-12/NNS||herpes-15/NNS	prep_of||viruses-12/NNS||adeno-17/NN	conj_and||herpes-15/NNS||adeno-17/NN	nn||groups-22/NNS||papova-20/NN	nn||groups-22/NNS||virus-21/NN	prep_of||viruses-12/NNS||groups-22/NNS	conj_and||herpes-15/NNS||groups-22/NNS	virus-21||viruses-12||no||this simple technique has been used to identify and classify dna viruses of the herpes, adeno, and papova virus groups.
nn||events-3/NNS||understanding-1/NN	nn||events-3/NNS||recombination-2/NN	nsubj||helps-4/VBZ||events-3/NNS	root||ROOT-0/null||helps-4/VBZ	det||study-7/NN||the-6/DT	prep_with||helps-4/VBZ||study-7/NN	det||evolution-10/NN||the-9/DT	prep_of||study-7/NN||evolution-10/NN	amod||strains-14/NNS||new-12/JJ	nn||strains-14/NNS||virus-13/NN	prep_of||evolution-10/NN||strains-14/NNS	amod||viruses-17/NNS||new-16/JJ	prep_of||evolution-10/NN||viruses-17/NNS	conj_or||strains-14/NNS||viruses-17/NNS	virus-13||viruses-17||no||understanding recombination events helps with the study of the evolution of new virus strains or new viruses.
nn||intake-2/NN||gluten-1/NN	nsubj||provokes-7/VBZ||intake-2/NN	prep_by||intake-2/NN||patients-4/NNS	prep_with||patients-4/NNS||coeliacdisease-6/NN	root||ROOT-0/null||provokes-7/VBZ	det||reaction-10/NN||a-8/DT	amod||reaction-10/NN||strong-9/JJ	dobj||provokes-7/VBZ||reaction-10/NN	amod||lymphocytes-14/NNS||intestinal-12/JJ	amod||lymphocytes-14/NNS||intraepithelial-13/JJ	prep_by||provokes-7/VBZ||lymphocytes-14/NNS	nsubj||normalises-20/VBZ||lymphocytes-14/NNS	appos||lymphocytes-14/NNS||iels-16/NNS	rcmod||lymphocytes-14/NNS||normalises-20/VBZ	det||diet-24/NN||a-22/DT	amod||diet-24/NN||gluten-free-23/JJ	prep_on||normalises-20/VBZ||diet-24/NN	coeliacdisease-6||gluten-1||no||gluten intake by patients with coeliacdisease provokes a strong reaction by intestinal intraepithelial lymphocytes (iels), which normalises on a gluten-free diet.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||association-7/NN||the-3/DT	amod||association-7/NN||independent-4/JJ	conj_and||independent-4/JJ||joint-6/JJ	amod||association-7/NN||joint-6/JJ	dobj||investigated-2/VBD||association-7/NN	amod||activity-12/NN||adiposity-9/JJ	conj_and||adiposity-9/JJ||physical-11/JJ	amod||activity-12/NN||physical-11/JJ	prep_of||association-7/NN||activity-12/NN	amod||glucose-16/NN||fasting-14/VBG	nn||glucose-16/NN||plasma-15/NN	prep_with||investigated-2/VBD||glucose-16/NN	amod||glucose-20/NN||impaired-18/VBN	amod||glucose-20/NN||fasting-19/JJ	prep_with||investigated-2/VBD||glucose-20/NN	conj_and||glucose-16/NN||glucose-20/NN	prep_with||investigated-2/VBD||type2diabetes-23/NNS	conj_and||glucose-16/NN||type2diabetes-23/NNS	det||population-27/NN||a-25/DT	amod||population-27/NN||chinese-26/JJ	prep_in||type2diabetes-23/NNS||population-27/NN	glucose-20||type2diabetes-23||no_rel||we investigated the independent and joint association of adiposity and physical activity with fasting plasma glucose, impaired fasting glucose, and type2diabetes in a chinese population.
amod||washing-5/NNS||deep-1/JJ	conj_and||deep-1/JJ||thorough-3/JJ	amod||washing-5/NNS||thorough-3/JJ	nn||washing-5/NNS||biliary-4/NN	nsubj||covered-18/VBD||washing-5/NNS	conj_and||washing-5/NNS||stenting-8/VBG	nsubj||covered-18/VBD||stenting-8/VBG	det||polytetrafluoroethylene-13/NN||a-10/DT	amod||polytetrafluoroethylene-13/NN||new-11/JJ	amod||polytetrafluoroethylene-13/NN||removable-12/JJ	prep_with||stenting-8/VBG||polytetrafluoroethylene-13/NN	appos||polytetrafluoroethylene-13/NN||ptfe-15/NN	root||ROOT-0/null||covered-18/VBD	amod||stent-20/NN||flared-type-19/JJ	nsubj||led-21/VBD||stent-20/NN	nsubj||complete-23/VB||stent-20/NN	ccomp||covered-18/VBD||led-21/VBD	aux||complete-23/VB||to-22/TO	xcomp||led-21/VBD||complete-23/VB	dobj||complete-23/VB||resolution-24/NN	det||jaundice-28/NN||the-26/DT	amod||jaundice-28/NN||obstructive-27/JJ	prep_of||resolution-24/NN||jaundice-28/NN	polytetrafluoroethylene-13||jaundice-28||no_rel||deep and thorough biliary washing, and stenting with a new removable polytetrafluoroethylene (ptfe)-covered flared-type stent led to complete resolution of the obstructive jaundice.
dep||mp-20/VBP||r-2/LS	conj_or||--4/JJ||racemic-6/JJ	amod||formoterol-17/NN||albuterol-7/JJ	cc||albuterol-7/JJ||and-8/CC	dep||albuterol-7/JJ||r-10/SYM	appos||r-10/SYM||r-12/SYM	conj_or||--14/JJ||racemic-16/JJ	nsubj||mp-20/VBP||formoterol-17/NN	advmod||decreased-19/VBN||significantly-18/RB	vmod||formoterol-17/NN||decreased-19/VBN	root||ROOT-0/null||mp-20/VBP	dobj||mp-20/VBP||levels-21/NNS	amod||cells-27/NNS||normal-23/JJ	conj_and||normal-23/JJ||asthma-25/NN	amod||cells-27/NNS||asthma-25/NN	nn||cells-27/NNS||epithelial-26/NN	prep_in||levels-21/NNS||cells-27/NNS	asthma-25||formoterol-17||yes||(r)- or racemic albuterol and (r,r)- or racemic formoterol significantly decreased mp levels in normal and asthma epithelial cells.
det||study-5/NN||a-2/DT	amod||study-5/NN||one-year-3/JJ	nn||study-5/NN||follow-up-4/NN	prep_in||tb-70/VBP||study-5/NN	nsubj||tb-70/VBP||11-7/CD	num||%-10/NN||19.3-9/CD	appos||11-7/CD||%-10/NN	num||test-16/NN||57-13/CD	nn||test-16/NN||tuberculin-14/NN	nn||test-16/NN||skin-15/NN	prep_of||11-7/CD||test-16/NN	appos||test-16/NN||tst-18/NN	amod||inmates-23/NNS||hiv-negative-22/JJ	conj_and||11-7/CD||inmates-23/NNS	nsubj||tb-70/VBP||inmates-23/NNS	vmod||inmates-23/NNS||became-24/VBD	nsubj||hiv-positive-32/JJ||tst-positive-25/NN	conj_and||tst-positive-25/NN||one-27/NN	nsubj||hiv-positive-32/JJ||one-27/NN	num||%-30/NN||1.8-29/CD	appos||tst-positive-25/NN||%-30/NN	xcomp||became-24/VBD||hiv-positive-32/JJ	conj_and||11-7/CD||eight-34/CD	conj_and||inmates-23/NNS||eight-34/CD	num||%-37/NN||13.8-36/CD	appos||eight-34/CD||%-37/NN	det||inmates-45/NNS||the-40/DT	num||inmates-45/NNS||58-41/CD	amod||inmates-45/NNS||tst-positive-42/JJ	conj_but||tst-positive-42/JJ||hiv-negative-44/JJ	amod||inmates-45/NNS||hiv-negative-44/JJ	prep_of||eight-34/CD||inmates-45/NNS	vmod||inmates-45/NNS||developed-46/VBN	dobj||developed-46/VBN||tb-47/NN	conj_and||11-7/CD||one-50/CD	conj_and||inmates-23/NNS||one-50/CD	num||%-53/NN||1.7-52/CD	appos||one-50/CD||%-53/NN	rcmod||one-50/CD||became-55/VBD	amod||six-57/CD||hiv-infected-56/JJ	xcomp||became-55/VBD||six-57/CD	num||%-60/NN||24.0-59/CD	appos||six-57/CD||%-60/NN	num||tst-64/NN||25-63/CD	prep_of||six-57/CD||tst-64/NN	amod||inmates-68/NNS||hiv-positive-67/JJ	conj_and||inmates-23/NNS||inmates-68/NNS	conj_and||one-50/CD||inmates-68/NNS	vmod||inmates-68/NNS||developed-69/VBN	root||ROOT-0/null||tb-70/VBP	mark||became-83/VBD||while-71/IN	nsubj||became-83/VBD||five-72/CD	num||%-75/NN||33.3-74/CD	appos||five-72/CD||%-75/NN	num||inmates-82/NNS||15-78/CD	amod||inmates-82/NNS||tst-negative-79/JJ	conj_but||tst-negative-79/JJ||hiv-positive-81/JJ	amod||inmates-82/NNS||hiv-positive-81/JJ	prep_of||five-72/CD||inmates-82/NNS	advcl||tb-70/VBP||became-83/VBD	acomp||became-83/VBD||tst-positive-84/JJ	nsubj||progressed-92/VBD||one-87/CD	num||%-90/NN||6.7-89/CD	appos||one-87/CD||%-90/NN	conj_and||tb-70/VBP||progressed-92/VBD	prep_to||progressed-92/VBD||aids-94/NNS	aids-94||hiv--1||no||in a one-year follow-up study, 11 (19.3%) of 57 tuberculin skin test (tst)- and hiv-negative inmates became tst-positive and one (1.8%) hiv-positive, eight (13.8%) of the 58 tst-positive but hiv-negative inmates developed tb, and one (1.7%) became hiv-infected six (24.0%) of 25 tst- and hiv-positive inmates developed tb while five (33.3%) of 15 tst-negative but hiv-positive inmates became tst-positive, and one (6.7%) progressed to aids.
nsubj||assessed-2/VBD||we-1/PRP	root||ROOT-0/null||assessed-2/VBD	nsubj||enrolled-7/VBD||nvp-resistance-3/NN	nn||infants-6/NNS||indian-5/NN	prep_in||nvp-resistance-3/NN||infants-6/NNS	dep||assessed-2/VBD||enrolled-7/VBD	det||transmission-34/NN||the-9/DT	amod||transmission-34/NN||â-10/JJ	amod||transmission-34/NN||$-11/$	dep||$-11/$||six-week-12/JJ	nn||transmission-34/NN||extended-dose-13/NN	dep||$-15/$||nevirapineâ-14/RB	dep||transmission-34/NN||$-15/$	amod||trial-19/NN||swen-17/JJ	npadvmod||of-31/RB||trial-19/NN	npadvmod||nvp-23/JJ||who-20/WP	npadvmod||single-dose-22/JJ||received-21/JJ	amod||who-20/WP||single-dose-22/JJ	advmod||trial-19/NN||nvp-23/JJ	dep||nvp-23/JJ||sd-nvp-25/NN	advmod||trial-19/NN||swen-28/JJ	conj_or||nvp-23/JJ||swen-28/JJ	prep_for||nvp-23/JJ||prevention-30/NN	dep||breast-milk-32/CD||of-31/RB	num||$-15/$||breast-milk-32/CD	amod||transmission-34/NN||hiv-33/JJ	prep_in||enrolled-7/VBD||transmission-34/NN	nsubj||acquired-38/VBD||who-36/WP	advmod||acquired-38/VBD||also-37/RB	dep||assessed-2/VBD||acquired-38/VBD	conj_but||enrolled-7/VBD||acquired-38/VBD	amod||hivinfection-41/NN||subtype-39/JJ	nn||hivinfection-41/NN||c-40/NN	dobj||acquired-38/VBD||hivinfection-41/NN	det||year-45/NN||the-43/DT	amod||year-45/NN||first-44/JJ	prep_during||acquired-38/VBD||year-45/NN	prep_of||year-45/NN||life-47/NN	hivinfection-41||nvp-23||yes||we assessed nvp-resistance in indian infants enrolled in the âsix-week extended-dose nevirapineâ? (swen) trial who received single-dose nvp (sd-nvp) or swen for prevention of breast-milk hiv transmission but who also acquired subtype c hivinfection during the first year of life.
nsubj||shown-4/VBN||we-1/PRP	aux||shown-4/VBN||have-2/VBP	advmod||shown-4/VBN||recently-3/RB	root||ROOT-0/null||shown-4/VBN	amod||prevalence-6/NN||high-5/JJ	dobj||shown-4/VBN||prevalence-6/NN	prep_of||prevalence-6/NN||bat-8/NN	amod||humans-11/NNS||adult-10/JJ	prep_in||bat-8/NN||humans-11/NNS	nsubjpass||related-16/VBN||humans-11/NNS	auxpass||related-16/VBN||was-14/VBD	advmod||related-16/VBN||inversely-15/RB	rcmod||humans-11/NNS||related-16/VBN	nn||index-20/NN||body-18/NN	nn||index-20/NN||mass-19/NN	prep_to||related-16/VBN||index-20/NN	appos||index-20/NN||bmi-22/NN	nn||percentage-27/NN||body-25/NN	amod||percentage-27/NN||fat-26/JJ	prep_to||related-16/VBN||percentage-27/NN	conj_and||index-20/NN||percentage-27/NN	num||%-30/NN||bf-29/CD	appos||index-20/NN||%-30/NN	vmod||shown-4/VBN||suggesting-33/VBG	mark||associated-37/VBN||that-34/IN	nsubjpass||associated-37/VBN||obesity-35/NN	auxpass||associated-37/VBN||is-36/VBZ	ccomp||suggesting-33/VBG||associated-37/VBN	amod||activity-41/NN||lower-39/JJR	nn||activity-41/NN||bat-40/NN	prep_with||associated-37/VBN||activity-41/NN	fat-26||obesity-35||no_rel||we have recently shown high prevalence of bat in adult humans, which was inversely related to body mass index (bmi) and body fat percentage (bf%), suggesting that obesity is associated with lower bat activity.
nn||assays-2/NNS||plaque-1/NN	nsubj||showed-23/VBD||assays-2/NNS	cc||assays-2/NNS||and-3/CC	number||--5/CD||3-4/CD	appos||--5/CD||4,5-7/CD	dep||--5/CD||dimethylthiahiazo-10/NN	dep||dimethylthiahiazo-10/NN||z-y1-13/JJ	dep||dimethylthiahiazo-10/NN||-3,5-15/CD	amod||tetrazoliumbromide-18/NN||di-phenyl-17/JJ	dep||--5/CD||tetrazoliumbromide-18/NN	appos||tetrazoliumbromide-18/NN||mtt-20/NN	dep||tetrazoliumbromide-18/NN||assays-22/NNS	root||ROOT-0/null||showed-23/VBD	mark||inhibited-31/VBN||that-24/IN	det||infection-27/NN||the-25/DT	nn||infection-27/NN||cell-26/NN	nsubjpass||inhibited-31/VBN||infection-27/NN	prep_by||infection-27/NN||tgev-29/NNP	auxpass||inhibited-31/VBN||was-30/VBD	ccomp||showed-23/VBD||inhibited-31/VBN	det||manner-35/NN||a-33/DT	amod||manner-35/NN||dose-dependent-34/JJ	prep_in||inhibited-31/VBN||manner-35/NN	tmod||added-40/VBN||manner-35/NN	advmod||added-40/VBN||when-37/WRB	nsubjpass||added-40/VBN||licl-38/NN	auxpass||added-40/VBN||was-39/VBD	rcmod||manner-35/NN||added-40/VBN	amod||cells-43/NNS||virus-infected-42/JJ	prep_to||added-40/VBN||cells-43/NNS	det||infection-47/NN||the-45/DT	nn||infection-47/NN||cell-46/NN	nsubjpass||affected-50/VBN||infection-47/NN	auxpass||affected-50/VBN||was-48/VBD	neg||affected-50/VBN||not-49/RB	parataxis||showed-23/VBD||affected-50/VBN	advmod||pretreated-57/VBN||when-51/WRB	preconj||cells-53/NNS||either-52/DT	nsubjpass||pretreated-57/VBN||cells-53/NNS	conj_or||cells-53/NNS||viruses-55/NNS	nsubjpass||pretreated-57/VBN||viruses-55/NNS	auxpass||pretreated-57/VBN||were-56/VBD	advcl||affected-50/VBN||pretreated-57/VBN	det||drug-60/NN||the-59/DT	prep_with||pretreated-57/VBN||drug-60/NN	virus--1||viruses-55||no||plaque assays and 3-(4,5)-dimethylthiahiazo(-z-y1)-3,5-di-phenyl tetrazoliumbromide (mtt) assays showed that the cell infection by tgev was inhibited in a dose-dependent manner, when licl was added to virus-infected cells; the cell infection was not affected when either cells or viruses were pretreated with the drug.
cc||describe-22/VBP||in-1/IN	advmod||described-5/VBD||previously-4/RB	dep||describe-22/VBP||described-5/VBD	dobj||described-5/VBD||cases-6/NNS	amod||â-15/NN||flinders-8/JJ	nn||â-15/NN||island-9/NN	nn||â-15/NN||spottedfever-10/NN	nn||â-15/NN||-lrb--11/NN	nn||â-15/NN||rickettsia-12/NN	nn||â-15/NN||honei-13/NN	nn||â-15/NN||strain-14/NN	prep_of||cases-6/NNS||â-15/NN	nsubj||described-5/VBD||$-16/$	num||$-16/$||marmioniiâ-17/CD	amod||$-16/$||$-18/$	dep||$-18/$||-rrb--19/JJ	nsubj||describe-22/VBP||we-21/PRP	root||ROOT-0/null||describe-22/VBP	num||case-24/NN||1-23/CD	nsubj||typhus-28/VBZ||case-24/NN	amod||tick-27/NN||queensland-26/JJ	prep_of||case-24/NN||tick-27/NN	dep||describe-22/VBP||typhus-28/VBZ	amod||australis-31/NNS||-lrb--29/JJ	nn||australis-31/NNS||r.-30/NN	dobj||typhus-28/VBZ||australis-31/NNS	advmod||typhus-28/VBZ||-rrb--32/RB	num||cases-35/NNS||2-34/CD	nsubj||caused-38/VBD||cases-35/NNS	prep_of||cases-35/NNS||scrubtyphus-37/NNS	dep||describe-22/VBP||caused-38/VBD	conj_and||typhus-28/VBZ||caused-38/VBD	det||strain-42/NN||a-40/DT	amod||strain-42/NN||unique-41/JJ	prep_by||caused-38/VBD||strain-42/NN	num||orientiatsutsugamushi-44/NNS||-lrb--43/CD	npadvmod||-rrb--45/JJ||orientiatsutsugamushi-44/NNS	amod||strain-42/NN||-rrb--45/JJ	scrubtyphus-37||orientiatsutsugamushi-44||no||in addition to previously described cases of flinders island spottedfever -lrb- rickettsia honei strain â $ marmioniiâ $ -rrb- , we describe 1 case of queensland tick typhus -lrb- r. australis -rrb- and 2 cases of scrubtyphus caused by a unique strain -lrb- orientiatsutsugamushi -rrb- .
nsubj||had-5/VBD||they-1/PRP	advmod||had-5/VBD||also-2/RB	advmod||frequently-4/RB||more-3/RBR	advmod||had-5/VBD||frequently-4/RB	root||ROOT-0/null||had-5/VBD	dobj||had-5/VBD||parkinsonism-6/NN	nsubjpass||correlated-11/VBN||parkinsonism-6/NN	auxpass||correlated-11/VBN||was-9/VBD	advmod||correlated-11/VBN||significantly-10/RB	rcmod||parkinsonism-6/NN||correlated-11/VBN	det||treatment-15/NN||both-13/DT	amod||treatment-15/NN||haloperidol-14/JJ	prep_with||correlated-11/VBN||treatment-15/NN	num||month-18/NN||1-17/CD	prep_at||treatment-15/NN||month-18/NN	nn||â-21/NN||p-20/NN	dep||month-18/NN||â-21/NN	nsubj||â-25/VBP||$-22/$	number||<-24/CD||-23/CD	num||$-22/$||<-24/CD	rcmod||â-21/NN||â-25/VBP	dobj||â-25/VBP||$-26/$	number||0.001-28/CD||-27/CD	num||$-26/$||0.001-28/CD	num||months-32/NNS||6-31/CD	prep_at||treatment-15/NN||months-32/NNS	conj_and||month-18/NN||months-32/NNS	nn||â-35/NN||p-34/NN	dep||months-32/NNS||â-35/NN	nsubj||â-39/VBP||$-36/$	number||=-38/CD||-37/CD	num||$-36/$||=-38/CD	rcmod||â-35/NN||â-39/VBP	dobj||â-39/VBP||$-40/$	number||0.016-42/CD||-41/CD	num||$-40/$||0.016-42/CD	amod||treatment-46/NN||olanzapine-45/JJ	prep_at||treatment-15/NN||treatment-46/NN	conj_and||month-18/NN||treatment-46/NN	prep_at||treatment-46/NN||baseline-48/NN	nn||â-51/NN||p-50/NN	dep||treatment-46/NN||â-51/NN	nsubj||â-55/VBP||$-52/$	number||=-54/CD||-53/CD	num||$-52/$||=-54/CD	rcmod||â-51/NN||â-55/VBP	dobj||â-55/VBP||$-56/$	number||0.016-58/CD||-57/CD	num||$-56/$||0.016-58/CD	num||months-62/NNS||3-61/CD	prep_with||correlated-11/VBN||months-62/NNS	conj_and||treatment-15/NN||months-62/NNS	nn||â-65/NN||p-64/NN	dep||months-62/NNS||â-65/NN	dep||â-69/NN||$-66/$	num||â-69/NN||-67/CD	amod||â-69/NN||=-68/JJ	dep||â-65/NN||â-69/NN	dep||â-69/NN||$-70/$	number||0.019-72/CD||-71/CD	num||$-70/$||0.019-72/CD	num||months-77/NNS||6-76/CD	prep_with||correlated-11/VBN||months-77/NNS	conj_and||treatment-15/NN||months-77/NNS	nn||â-80/NN||p-79/NN	dep||months-77/NNS||â-80/NN	dep||â-84/NN||$-81/$	num||â-84/NN||-82/CD	amod||â-84/NN||=-83/JJ	dep||â-80/NN||â-84/NN	dep||â-84/NN||$-85/$	number||0.021-87/CD||-86/CD	num||$-85/$||0.021-87/CD	haloperidol-14||parkinsonism-6||no_rel||they also more frequently had parkinsonism, which was significantly correlated with both haloperidol treatment at 1 month ( p â<â0.001) and 6 months ( p â=â0.016) and olanzapine treatment at baseline ( p â=â0.016), 3 months ( p â=â0.019), and 6 months ( p â=â0.021).
nsubj||suggest-5/VBP||results-1/NNS	det||study-4/NN||this-3/DT	prep_from||results-1/NNS||study-4/NN	root||ROOT-0/null||suggest-5/VBP	mark||investigated-16/VBN||that-6/IN	amod||treatment-9/NN||nutrient-7/JJ	nn||treatment-9/NN||starvation-8/NN	nsubjpass||investigated-16/VBN||treatment-9/NN	amod||bcgvaccines-12/NNS||live-11/JJ	prep_of||treatment-9/NN||bcgvaccines-12/NNS	aux||investigated-16/VBN||should-13/MD	auxpass||investigated-16/VBN||be-14/VB	advmod||investigated-16/VBN||further-15/RBR	ccomp||suggest-5/VBP||investigated-16/VBN	det||way-19/NN||a-18/DT	prep_as||investigated-16/VBN||way-19/NN	aux||increase-21/VB||to-20/TO	vmod||way-19/NN||increase-21/VB	nn||induction-23/NN||host-22/NN	dobj||increase-21/VB||induction-23/NN	amod||cytokines-27/NNS||th-1-25/JJ	amod||cytokines-27/NNS||related-26/JJ	prep_of||induction-23/NN||cytokines-27/NNS	det||development-30/NN||the-29/DT	prep_in||increase-21/VB||development-30/NN	amod||vaccines-34/NNS||experimental-32/JJ	amod||vaccines-34/NNS||anti-tb-33/JJ	prep_of||development-30/NN||vaccines-34/NNS	tb--1||bcgvaccines-12||yes||results from this study suggest that nutrient starvation treatment of live bcgvaccines should be further investigated as a way to increase host induction of th-1 related cytokines in the development of experimental anti-tb vaccines.
amod||vasculitis-4/NNS||anti-neutrophil-1/JJ	amod||vasculitis-4/NNS||cytoplasmic-2/JJ	amod||vasculitis-4/NNS||antibody-associated-3/JJ	nsubjpass||associated-7/VBN||vasculitis-4/NNS	aux||associated-7/VBN||has-5/VBZ	auxpass||associated-7/VBN||been-6/VBN	root||ROOT-0/null||associated-7/VBN	amod||drugs-10/NNS||many-9/JJ	prep_with||associated-7/VBN||drugs-10/NNS	nsubj||effect-18/NN||it-12/PRP	cop||effect-18/NN||is-13/VBZ	det||effect-18/NN||a-14/DT	advmod||rare-16/JJ||relatively-15/RB	amod||effect-18/NN||rare-16/JJ	nn||effect-18/NN||side-17/NN	conj_and||associated-7/VBN||effect-18/NN	det||hydralazine-23/NN||the-20/DT	amod||hydralazine-23/NN||antihypertensive-21/JJ	nn||hydralazine-23/NN||drug-22/NN	prep_of||effect-18/NN||hydralazine-23/NN	vasculitis-4||antibody--1||no_rel||anti-neutrophil cytoplasmic antibody-associated vasculitis has been associated with many drugs and it is a relatively rare side effect of the antihypertensive drug hydralazine.
det||therapeutics-2/NNS||the-1/DT	nsubj||narrows-6/VBZ||therapeutics-2/NNS	amod||entericfever-5/NN||ciprofloxacin-resistant-4/JJ	prep_of||therapeutics-2/NNS||entericfever-5/NN	root||ROOT-0/null||narrows-6/VBZ	prt||narrows-6/VBZ||down-7/RP	prep_to||narrows-6/VBZ||third-9/JJ	amod||cephalosporins-13/NNS||fourth-generation-12/JJ	prep_to||narrows-6/VBZ||cephalosporins-13/NNS	conj_and||third-9/JJ||cephalosporins-13/NNS	acomp||narrows-6/VBZ||azithromycin-15/JJ	acomp||narrows-6/VBZ||tigecycline-17/JJ	conj_and||azithromycin-15/JJ||tigecycline-17/JJ	acomp||narrows-6/VBZ||penems-19/JJ	conj_and||azithromycin-15/JJ||penems-19/JJ	entericfever-5||ciprofloxacin--1||yes||the therapeutics of ciprofloxacin-resistant entericfever narrows down to third- and fourth-generation cephalosporins, azithromycin, tigecycline and penems.
nsubjpass||matched-3/VBN||they-1/PRP	auxpass||matched-3/VBN||were-2/VBD	root||ROOT-0/null||matched-3/VBN	prep_on||matched-3/VBN||age-5/NN	prep_on||matched-3/VBN||sex-7/NN	conj_and||age-5/NN||sex-7/NN	prep_with||matched-3/VBN||controls-9/NNS	nsubj||attendants-18/NNS||controls-9/NNS	dep||controls-9/NNS||n-11/VBN	dep||296-13/CD||=-12/SYM	ccomp||n-11/VBN||296-13/CD	cop||attendants-18/NNS||were-17/VBD	rcmod||controls-9/NNS||attendants-18/NNS	vmod||attendants-18/NNS||sitting-19/VBG	det||department-25/NN||the-21/DT	amod||department-25/NN||medical-22/JJ	advmod||patient-24/JJ||out-23/RB	amod||department-25/NN||patient-24/JJ	prep_in||sitting-19/VBG||department-25/NN	det||hospital-29/NN||the-27/DT	amod||hospital-29/NN||same-28/JJ	prep_of||department-25/NN||hospital-29/NN	vmod||department-25/NN||recruited-31/VBN	det||basis-34/NN||the-33/DT	prep_on||recruited-31/VBN||basis-34/NN	prep_of||basis-34/NN||absence-36/NN	amod||symptoms-39/NNS||classical-38/JJ	prep_of||basis-34/NN||symptoms-39/NNS	prep_of||symptoms-39/NNS||polyuria-41/NN	prep_of||symptoms-39/NNS||polydispia-43/NN	conj_and||polyuria-41/NN||polydispia-43/NN	amod||level-48/NN||random-46/JJ	nn||level-48/NN||bloodglucose-47/NN	prep_along_with||basis-34/NN||level-48/NN	number||200-51/CD||<-50/CD	num||mg/dl-52/NN||200-51/CD	prep_of||level-48/NN||mg/dl-52/NN	vmod||mg/dl-52/NN||measured-53/VBN	det||glucometer-56/NN||a-55/DT	agent||measured-53/VBN||glucometer-56/NN	polyuria-41||glucose--1||no_rel||they were matched on age and sex with controls (n = 296), who were attendants sitting in the medical out patient department of the same hospital, recruited on the basis of absence of classical symptoms of polyuria and polydispia along with random bloodglucose level of <200 mg/dl measured by a glucometer.
det||context-3/NN||this-2/DT	prep_in||be-15/VB||context-3/NN	nsubj||be-15/VB||one-5/CD	nsubj||investigate-17/VB||one-5/CD	det||control-13/NN||the-7/DT	amod||control-13/NN||pathways-8/JJ	amod||control-13/NN||available-9/JJ	nn||vector-12/NN||malaria-11/NN	prep_for||available-9/JJ||vector-12/NN	prep_of||one-5/CD||control-13/NN	aux||be-15/VB||would-14/MD	root||ROOT-0/null||be-15/VB	aux||investigate-17/VB||to-16/TO	xcomp||be-15/VB||investigate-17/VB	amod||classes-19/NNS||alternative-18/JJ	dobj||investigate-17/VB||classes-19/NNS	prep_of||classes-19/NNS||insecticides-21/NNS	amod||mode-24/NN||different-23/JJ	prep_with||investigate-17/VB||mode-24/NN	prep_of||mode-24/NN||action-26/NN	prep_than||investigate-17/VB||that-28/DT	prep_of||that-28/DT||pyrethroids-30/NNS	insecticides-21||malaria-11||no_rel||in this context, one of the pathways available for malaria vector control would be to investigate alternative classes of insecticides with different mode of action than that of pyrethroids.
nsubj||tested-2/VBD||we-1/PRP	root||ROOT-0/null||tested-2/VBD	poss||hypothesis-4/NNS||our-3/PRP$	dobj||tested-2/VBD||hypothesis-4/NNS	prepc_by||tested-2/VBD||compiling-6/VBG	nn||shuffling-8/NN||exon-7/NN	dobj||compiling-6/VBG||shuffling-8/NN	nn||data-11/NNS||ppi-10/NN	dobj||compiling-6/VBG||data-11/NNS	conj_and||shuffling-8/NN||data-11/NNS	num||sapiens-17/NNS||six-13/CD	amod||sapiens-17/NNS||eukaryotic-14/JJ	nn||sapiens-17/NNS||species-15/NN	nn||sapiens-17/NNS||homo-16/NN	prep_from||compiling-6/VBG||sapiens-17/NNS	nn||musculus-20/NNS||mus-19/NN	prep_from||compiling-6/VBG||musculus-20/NNS	conj_and||sapiens-17/NNS||musculus-20/NNS	nn||melanogaster-23/NN||drosophila-22/NN	prep_from||compiling-6/VBG||melanogaster-23/NN	conj_and||sapiens-17/NNS||melanogaster-23/NN	amod||elegans-26/NNS||caenorhabditis-25/JJ	prep_from||compiling-6/VBG||elegans-26/NNS	conj_and||sapiens-17/NNS||elegans-26/NNS	prep_from||compiling-6/VBG||cryptococcusneoformans-28/NNS	conj_and||sapiens-17/NNS||cryptococcusneoformans-28/NNS	amod||thaliana-31/NN||arabidopsis-30/JJ	prep_from||compiling-6/VBG||thaliana-31/NN	conj_and||sapiens-17/NNS||thaliana-31/NN	ppi-10||cryptococcusneoformans-28||no_rel||we tested our hypothesis by compiling exon shuffling and ppi data from six eukaryotic species homo sapiens , mus musculus , drosophila melanogaster , caenorhabditis elegans , cryptococcusneoformans and arabidopsis thaliana .
nsubjpass||injected-4/VBN||animals-1/NNS	nsubj||showed-20/VBD||animals-1/NNS	auxpass||injected-4/VBN||were-3/VBD	rcmod||animals-1/NNS||injected-4/VBN	det||dose-8/NN||a-6/DT	amod||dose-8/NN||low-7/JJ	prep_with||injected-4/VBN||dose-8/NN	num||î-11/NN||10-10/CD	dep||dose-8/NN||î-11/NN	num||g-13/NN||1/4-12/CD	dep||î-11/NN||g-13/NN	nn||transposon-18/NN||statin-16/NN	nn||transposon-18/NN||ae-17/NN	prep_of||dose-8/NN||transposon-18/NN	vmod||transposon-18/NN||plasmid-19/VBN	root||ROOT-0/null||showed-20/VBD	det||decrease-23/NN||a-21/DT	amod||decrease-23/NN||significant-22/JJ	dobj||showed-20/VBD||decrease-23/NN	nn||formation-26/NN||tumor-25/NN	prep_in||showed-20/VBD||formation-26/NN	advmod||plasmid-33/VBD||only-27/RB	advmod||plasmid-33/VBD||when-28/WRB	nsubj||plasmid-33/VBD||co-injected-29/JJ	nn||transposase-encoding-32/NN||sb-31/NN	prep_with||co-injected-29/JJ||transposase-encoding-32/NN	advcl||showed-20/VBD||plasmid-33/VBD	mark||affect-62/VB||while-35/IN	prep_for||affect-62/VB||animals-37/NNS	vmod||animals-37/NNS||injected-38/VBN	det||dose-42/NN||a-40/DT	amod||dose-42/NN||higher-41/JJR	prep_with||injected-38/VBN||dose-42/NN	num||î-45/NN||25-44/CD	dep||dose-42/NN||î-45/NN	num||g-47/NN||1/4-46/CD	dep||î-45/NN||g-47/NN	amod||transposon-52/NN||statin-50/JJ	nn||transposon-52/NN||ae-51/NN	prep_of||dose-42/NN||transposon-52/NN	nsubj||affect-62/VB||co-injection-54/NN	amod||plasmid-58/NN||sb-56/JJ	amod||plasmid-58/NN||transposase-encoding-57/JJ	prep_of||co-injection-54/NN||plasmid-58/NN	aux||affect-62/VB||did-59/VBD	neg||affect-62/VB||not-60/RB	advmod||affect-62/VB||significantly-61/RB	dep||plasmid-33/VBD||affect-62/VB	nn||load-64/NN||tumor-63/NN	dobj||affect-62/VB||load-64/NN	statin-50||tumor-63||no_rel||animals that were injected with a low dose (10 î¼g) of statin ae transposon plasmid showed a significant decrease in tumor formation only when co-injected with sb transposase-encoding plasmid, while for animals injected with a higher dose (25 î¼g) of statin ae transposon, co-injection of sb transposase-encoding plasmid did not significantly affect tumor load.
nn||acetylsalicylicacid-4/NN||background-1/NN	conj_and||background-1/NN||aim-3/NN	nn||acetylsalicylicacid-4/NN||aim-3/NN	nsubj||drug-16/NN||acetylsalicylicacid-4/NN	num||-RSB--9/NNS||asa-6/CD	nn||-RSB--9/NNS||-LSB--7/NNP	nn||-RSB--9/NNS||aspirin-8/NN	appos||acetylsalicylicacid-4/NN||-RSB--9/NNS	cop||drug-16/NN||is-11/VBZ	det||drug-16/NN||a-12/DT	advmod||used-14/VBN||commonly-13/RB	amod||drug-16/NN||used-14/VBN	amod||drug-16/NN||over-the-counter-15/JJ	root||ROOT-0/null||drug-16/NN	det||treatment-19/NN||the-18/DT	prep_for||drug-16/NN||treatment-19/NN	prep_of||treatment-19/NN||pain-21/NN	prep_of||treatment-19/NN||fever-23/NN	conj_or||pain-21/NN||fever-23/NN	prep_of||treatment-19/NN||colds-26/NNS	conj_or||pain-21/NN||colds-26/NNS	nsubj||limited-38/JJ||data-29/NNS	det||safety-32/NN||the-31/DT	prep_on||data-29/NNS||safety-32/NN	det||use-35/NN||this-34/DT	prep_of||safety-32/NN||use-35/NN	cop||limited-38/JJ||are-36/VBP	advmod||limited-38/JJ||very-37/RB	conj_but||drug-16/NN||limited-38/JJ	pain-21||acetylsalicylicacid-4||yes||background and aim acetylsalicylicacid (asa [aspirin]) is a commonly used over-the-counter drug for the treatment of pain, fever, or colds, but data on the safety of this use are very limited.
nn||tb-3/NN||tuberculosis-1/NNP	nsubj||one-12/CD||tb-3/NN	vmod||tb-3/NN||caused-5/VBN	agent||caused-5/VBN||mycobacteriumtuberculosis-7/NNS	appos||tb-3/NN||mtb-9/NN	cop||one-12/CD||is-11/VBZ	root||ROOT-0/null||one-12/CD	det||causes-18/NNS||the-14/DT	amod||causes-18/NNS||leading-15/VBG	amod||causes-18/NNS||infectious-16/JJ	nn||causes-18/NNS||disease-17/NN	prep_of||one-12/CD||causes-18/NNS	nn||worldwide-23/NNS||morbidity-20/NN	conj_and||morbidity-20/NN||mortality-22/NN	nn||worldwide-23/NNS||mortality-22/NN	prep_of||causes-18/NNS||worldwide-23/NNS	tuberculosis-1||mtb-9||no||tuberculosis (tb) caused by mycobacteriumtuberculosis ( mtb ) is one of the leading infectious disease causes of morbidity and mortality worldwide.
det||isolates-2/NN||all-1/DT	nsubjpass||reidentified-4/VBN||isolates-2/NN	nsubjpass||retested-17/VBN||isolates-2/NN	nsubj||methicillin-21/VB||isolates-2/NN	auxpass||reidentified-4/VBN||were-3/VBD	root||ROOT-0/null||reidentified-4/VBN	agent||reidentified-4/VBN||culturing-6/VBG	amod||agar-10/NN||mannitol-8/JJ	nn||agar-10/NN||salt-9/NN	prep_on||culturing-6/VBG||agar-10/NN	nn||system-15/NN||api-12/NN	num||system-15/NN||20-13/CD	nn||system-15/NN||staph-14/NN	appos||agar-10/NN||system-15/NN	conj_and||reidentified-4/VBN||retested-17/VBN	prep_for||retested-17/VBN||resistance-19/NN	aux||methicillin-21/VB||to-20/TO	xcomp||retested-17/VBN||methicillin-21/VB	xcomp||methicillin-21/VB||using-22/VBG	det||test-28/NN||the-23/DT	nn||test-28/NN||cefoxitin-24/NN	nn||test-28/NN||disk-25/NN	nn||test-28/NN||diffusion-26/NN	nn||test-28/NN||susceptibility-27/NN	dobj||using-22/VBG||test-28/NN	dobj||using-22/VBG||pbp2a-30/NNS	conj_and||test-28/NN||pbp2a-30/NNS	staph-14||cefoxitin-24||yes||all isolates were reidentified by culturing on mannitol salt agar, api 20 staph system and retested for resistance to methicillin using the cefoxitin disk diffusion susceptibility test and pbp2a.
poss||recommendations-2/NNS||their-1/PRP$	nsubj||included-3/VBD||recommendations-2/NNS	root||ROOT-0/null||included-3/VBD	dep||make-12/VB||1-5/LS	det||country-10/NN||every-7/DT	amod||country-10/NN||dengue-8/JJ	amod||country-10/NN||endemic-9/JJ	nsubj||make-12/VB||country-10/NN	aux||make-12/VB||should-11/MD	dep||included-3/VBD||make-12/VB	dobj||make-12/VB||reporting-13/NN	amod||cases-16/NNS||dengue-15/JJ	prep_of||reporting-13/NN||cases-16/NNS	det||government-19/NN||the-18/DT	prep_to||make-12/VB||government-19/NN	amod||government-19/NN||mandatory-20/JJ	dep||developed-30/VBN||2-23/LS	amod||systems-27/NNS||electronic-25/JJ	nn||systems-27/NNS||reporting-26/NN	nsubjpass||developed-30/VBN||systems-27/NNS	nsubjpass||used-32/VBN||systems-27/NNS	aux||developed-30/VBN||should-28/MD	auxpass||developed-30/VBN||be-29/VB	parataxis||make-12/VB||developed-30/VBN	parataxis||make-12/VB||used-32/VBN	conj_and||developed-30/VBN||used-32/VBN	nsubj||include-43/VB||3-35/NNP	amod||data-41/NNS||minimum-38/JJ	nn||data-41/NNS||dengue-39/NN	nn||data-41/NNS||surveillance-40/NN	prep_at||3-35/NNP||data-41/NNS	aux||include-43/VB||should-42/MD	conj_and||included-3/VBD||include-43/VB	dobj||include-43/VB||incidence-44/NN	nn||rates-47/NNS||hospitalization-46/NN	appos||incidence-44/NN||rates-47/NNS	appos||rates-47/NNS||deaths-49/NNS	nn||group-52/NN||age-51/NN	prep_by||include-43/VB||group-52/NN	dep||completed-61/VBN||4-55/LS	amod||studies-58/NNS||additional-57/JJ	nsubjpass||completed-61/VBN||studies-58/NNS	nsubj||check-63/VB||studies-58/NNS	aux||completed-61/VBN||should-59/MD	auxpass||completed-61/VBN||be-60/VB	conj_and||included-3/VBD||completed-61/VBN	aux||check-63/VB||to-62/TO	xcomp||completed-61/VBN||check-63/VB	det||sensitivity-65/NN||the-64/DT	dobj||check-63/VB||sensitivity-65/NN	det||system-68/NN||the-67/DT	prep_of||sensitivity-65/NN||system-68/NN	dep||share-75/VB||5-71/CD	nsubj||share-75/VB||laboratories-73/NNS	aux||share-75/VB||should-74/MD	conj_and||included-3/VBD||share-75/VB	dobj||share-75/VB||expertise-76/NN	dobj||share-75/VB||data-78/NNS	conj_and||expertise-76/NN||data-78/NNS	appos||tests-83/NNS||6-81/CD	dep||expertise-76/NN||tests-83/NNS	nsubj||identify-85/VBP||tests-83/NNS	rcmod||tests-83/NNS||identify-85/VBP	nsubjpass||used-89/VBN||denguevirus-86/NNS	aux||used-89/VBN||should-87/MD	auxpass||used-89/VBN||be-88/VB	ccomp||identify-85/VBP||used-89/VBN	prep_in||used-89/VBN||patients-91/NNS	prep_with||patients-91/NNS||fever-93/NN	num||days-96/NNS||four-95/CD	prep_for||fever-93/NN||days-96/NNS	cc||less-98/JJR||or-97/CC	num||days-96/NNS||less-98/JJR	nn||tests-101/NNS||antibody-100/NN	nsubjpass||used-104/VBN||tests-101/NNS	nsubj||diagnose-109/VB||tests-101/NNS	aux||used-104/VBN||should-102/MD	auxpass||used-104/VBN||be-103/VB	conj_and||included-3/VBD||used-104/VBN	prep_after||used-104/VBN||day-106/NN	num||day-106/NN||4-107/CD	aux||diagnose-109/VB||to-108/TO	xcomp||used-104/VBN||diagnose-109/VB	dobj||diagnose-109/VB||dengue-110/NN	appos||detection-117/NN||7-114/CD	amod||detection-117/NN||early-116/JJ	nsubj||goals-125/NNS||detection-117/NN	conj_and||detection-117/NN||prediction-119/NN	nsubj||goals-125/NNS||prediction-119/NN	amod||outbreaks-122/NNS||dengue-121/JJ	prep_of||prediction-119/NN||outbreaks-122/NNS	aux||goals-125/NNS||should-123/MD	cop||goals-125/NNS||be-124/VB	conj_and||included-3/VBD||goals-125/NNS	amod||systems-129/NNS||national-127/JJ	nn||systems-129/NNS||surveillance-128/NN	prep_for||goals-125/NNS||systems-129/NNS	dengue-121||denguevirus-86||no||their recommendations included (1) every dengue endemic country should make reporting of dengue cases to the government mandatory; (2) electronic reporting systems should be developed and used; (3) at minimum dengue surveillance data should include incidence, hospitalization rates, deaths by age group; (4) additional studies should be completed to check the sensitivity of the system; (5) laboratories should share expertise and data; (6) tests that identify denguevirus should be used in patients with fever for four days or less and antibody tests should be used after day 4 to diagnose dengue; and (7) early detection and prediction of dengue outbreaks should be goals for national surveillance systems.
det||findings-2/NNS||these-1/DT	nsubj||suggest-3/VBP||findings-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||modulate-8/VB||that-4/IN	nsubj||modulate-8/VB||pde5inhibitors-5/NNS	nsubj||enhance-13/VB||pde5inhibitors-5/NNS	aux||modulate-8/VB||may-6/MD	advmod||modulate-8/VB||effectively-7/RB	ccomp||suggest-3/VBP||modulate-8/VB	dobj||modulate-8/VB||btb-9/NN	advmod||modulate-8/VB||permeability-10/RB	ccomp||suggest-3/VBP||enhance-13/VB	conj_and||modulate-8/VB||enhance-13/VB	nn||efficacy-17/NN||delivery-14/NN	conj_and||delivery-14/NN||therapeutic-16/JJ	nn||efficacy-17/NN||therapeutic-16/JJ	dobj||enhance-13/VB||efficacy-17/NN	amod||antibodies-20/NNS||monoclonal-19/JJ	prep_of||efficacy-17/NN||antibodies-20/NNS	amod||metastases-24/NNS||hard-to-treat-22/JJ	nn||metastases-24/NNS||brain-23/NN	prep_in||antibodies-20/NNS||metastases-24/NNS	amod||tumors-28/NNS||different-26/JJ	amod||tumors-28/NNS||primary-27/JJ	prep_from||enhance-13/VB||tumors-28/NNS	nsubj||metastasized-31/VBN||tumors-28/NNS	aux||metastasized-31/VBN||had-30/VBD	rcmod||tumors-28/NNS||metastasized-31/VBN	det||brain-34/NN||the-33/DT	prep_to||metastasized-31/VBN||brain-34/NN	antibodies-20||metastasized-31||no_rel||these findings suggest that pde5inhibitors may effectively modulate btb permeability, and enhance delivery and therapeutic efficacy of monoclonal antibodies in hard-to-treat brain metastases from different primary tumors that had metastasized to the brain.
nsubj||continues-12/VBZ||pertussis-1/NN	nsubj||threat-19/NN||pertussis-1/NN	appos||pertussis-1/NN||whoopingcough-3/NN	dep||continues-12/VBZ||caused-5/VBN	prep_by||caused-5/VBN||bordetellapertussis-7/NNS	appos||bordetellapertussis-7/NNS||b.p-9/NN	root||ROOT-0/null||continues-12/VBZ	aux||threat-19/NN||to-13/TO	cop||threat-19/NN||be-14/VB	det||threat-19/NN||a-15/DT	amod||threat-19/NN||serious-16/JJ	amod||threat-19/NN||public-17/JJ	nn||threat-19/NN||health-18/NN	xcomp||continues-12/VBZ||threat-19/NN	whoopingcough-3||pertussis-1||yes||pertussis (whoopingcough) caused by bordetellapertussis ( b.p ), continues to be a serious public health threat.
det||tick-2/NN||this-1/DT	nsubj||vector-5/NN||tick-2/NN	cop||vector-5/NN||is-3/VBZ	det||vector-5/NN||a-4/DT	root||ROOT-0/null||vector-5/NN	amod||organisms-8/NNS||life-threatening-7/JJ	prep_for||vector-5/NN||organisms-8/NNS	prep_including||organisms-8/NNS||rickettsiarickettsii-10/NNS	det||agent-13/NN||the-12/DT	appos||rickettsiarickettsii-10/NNS||agent-13/NN	prep_of||agent-13/NN||rockymountainspottedfever-15/NN	nn||conorii-18/NNS||r.-17/NN	prep_of||agent-13/NN||conorii-18/NNS	conj_and||rockymountainspottedfever-15/NN||conorii-18/NNS	det||agent-21/NN||the-20/DT	prep_of||agent-13/NN||agent-21/NN	conj_and||rockymountainspottedfever-15/NN||agent-21/NN	nn||spottedfever-24/NN||mediterranean-23/NN	prep_of||agent-21/NN||spottedfever-24/NN	det||pathogen-30/NN||the-27/DT	amod||pathogen-30/NN||ubiquitous-28/JJ	amod||pathogen-30/NN||emerging-29/VBG	prep_of||agent-13/NN||pathogen-30/NN	conj_and||rockymountainspottedfever-15/NN||pathogen-30/NN	advmod||massiliae-32/JJ||r.-31/RB	amod||pathogen-30/NN||massiliae-32/JJ	rockymountainspottedfever-15||rickettsiarickettsii-10||no||this tick is a vector for life-threatening organisms including rickettsiarickettsii , the agent of rockymountainspottedfever , r. conorii , the agent of mediterranean spottedfever , and the ubiquitous emerging pathogen r. massiliae .
amod||subjects-5/NNS||objective-1/JJ	nn||subjects-5/NNS||â-2/NN	nn||subjects-5/NNS||$-3/NN	nsubj||prone-20/JJ||subjects-5/NNS	nsubj||need-22/VB||subjects-5/NNS	det||diagnosis-8/NN||the-7/DT	prep_with||subjects-5/NNS||diagnosis-8/NN	nn||diabetes-12/NN||latent-10/NN	amod||diabetes-12/NN||autoimmune-11/JJ	prep_of||diagnosis-8/NN||diabetes-12/NN	prep_in||diabetes-12/NN||adults-14/NNS	appos||adults-14/NNS||lada-16/NNP	cop||prone-20/JJ||are-18/VBP	advmod||prone-20/JJ||more-19/RBR	root||ROOT-0/null||prone-20/JJ	aux||need-22/VB||to-21/TO	xcomp||prone-20/JJ||need-22/VB	nn||treatment-24/NN||insulin-23/NN	dobj||need-22/VB||treatment-24/NN	prep_than||need-22/VB||those-26/DT	prep_with||those-26/DT||type2diabetes-28/CD	type2diabetes-28||insulin-23||yes||objective âsubjects with the diagnosis of latent autoimmune diabetes in adults (lada) are more prone to need insulin treatment than those with type2diabetes.
amod||dst-3/NN||conventional-2/JJ	agent||classified-8/VBN||dst-3/NN	num||strains-6/NNS||55-5/CD	nsubjpass||classified-8/VBN||strains-6/NNS	auxpass||classified-8/VBN||were-7/VBD	root||ROOT-0/null||classified-8/VBN	prep_as||classified-8/VBN||mdr-tb-10/NN	num||strains-13/NNS||four-12/CD	nsubjpass||rifampicin-15/VBN||strains-13/NNS	auxpass||rifampicin-15/VBN||were-14/VBD	conj_and||classified-8/VBN||rifampicin-15/VBN	xcomp||rifampicin-15/VBN||mono-resistant-16/JJ	num||strains-19/NNS||52-18/CD	nsubj||susceptible-21/JJ||strains-19/NNS	cop||susceptible-21/JJ||were-20/VBD	conj_and||classified-8/VBN||susceptible-21/JJ	det||drugs-25/NNS||all-23/DT	amod||drugs-25/NNS||first-line-24/JJ	prep_to||susceptible-21/JJ||drugs-25/NNS	tb--1||rifampicin-15||yes||by conventional dst, 55 strains were classified as mdr-tb, four strains were rifampicin mono-resistant and 52 strains were susceptible to all first-line drugs.
nsubj||found-3/VBD||we-1/PRP	advmod||found-3/VBD||also-2/RB	root||ROOT-0/null||found-3/VBD	mark||decrease-10/VB||that-4/IN	nn||use-6/NN||insulin-5/NN	nsubj||decrease-10/VB||use-6/NN	prep_in||use-6/NN||type2diabetes-8/CD	aux||decrease-10/VB||might-9/MD	ccomp||found-3/VBD||decrease-10/VB	det||risk-12/NN||this-11/DT	dobj||decrease-10/VB||risk-12/NN	type2diabetes-8||insulin-5||yes||we also found that insulin use in type2diabetes might decrease this risk.
det||hypersensitivityreaction-2/NN||a-1/DT	nsubj||occurs-12/VBZ||hypersensitivityreaction-2/NN	vmod||hypersensitivityreaction-2/NN||initiated-3/VBN	amod||mechanisms-6/NNS||immunologic-5/JJ	agent||initiated-3/VBN||mechanisms-6/NNS	vmod||mechanisms-6/NNS||mediated-8/VBN	nn||antibodies-11/NNS||ige-10/NN	agent||mediated-8/VBN||antibodies-11/NNS	root||ROOT-0/null||occurs-12/VBZ	prep_in||occurs-12/VBZ||allergicasthma-14/NN	aux||estimate-16/VB||to-15/TO	ccomp||occurs-12/VBZ||estimate-16/VB	ccomp||occurs-12/VBZ||compare-18/VB	conj_and||estimate-16/VB||compare-18/VB	nn||levels-21/NNS||serum-19/NN	nn||levels-21/NNS||ige-20/NN	dobj||estimate-16/VB||levels-21/NNS	amod||asthmatics-29/NNS||mild-23/JJ	amod||asthmatics-29/NNS||moderate-25/JJ	conj_and||moderate-25/JJ||severe-28/JJ	amod||asthmatics-29/NNS||severe-28/JJ	prep_in||estimate-16/VB||asthmatics-29/NNS	amod||subjects-33/NNS||normal-32/JJ	prep_in||estimate-16/VB||subjects-33/NNS	conj_and||asthmatics-29/NNS||subjects-33/NNS	aux||obtain-36/VB||to-35/TO	ccomp||occurs-12/VBZ||obtain-36/VB	conj_and||estimate-16/VB||obtain-36/VB	det||model-39/NN||a-37/DT	amod||model-39/NN||mathematical-38/JJ	dobj||obtain-36/VB||model-39/NN	vmod||model-39/NN||describing-40/VBG	det||relationship-42/NN||the-41/DT	dobj||describing-40/VBG||relationship-42/NN	nn||levels-46/NNS||serum-44/NN	nn||levels-46/NNS||ige-45/NN	prep_between||relationship-42/NN||levels-46/NNS	dobj||describing-40/VBG||severity-48/NN	conj_and||relationship-42/NN||severity-48/NN	prep_of||severity-48/NN||asthma-50/NN	allergicasthma-14||hypersensitivityreaction-2||no||a hypersensitivityreaction initiated by immunologic mechanisms, mediated by ige antibodies occurs in allergicasthma to estimate and compare serum ige levels in mild, moderate, and severe asthmatics and in normal subjects and to obtain a mathematical model describing the relationship between serum ige levels and severity of asthma.
nsubj||treated-4/VBD||prednisone-1/NN	conj_and||prednisone-1/NN||combination-3/NN	nsubj||treated-4/VBD||combination-3/NN	root||ROOT-0/null||treated-4/VBD	nsubj||showed-6/VBD||groups-5/NNS	ccomp||treated-4/VBD||showed-6/VBD	dobj||showed-6/VBD||alterations-7/NNS	det||expression-10/NN||the-9/DT	prep_in||showed-6/VBD||expression-10/NN	prep_of||expression-10/NN||genes-12/NNS	nsubj||control-14/VBP||genes-12/NNS	rcmod||genes-12/NNS||control-14/VBP	dobj||control-14/VBP||fibrosis-15/NN	dobj||control-14/VBP||inflammation-17/NN	conj_and||fibrosis-15/NN||inflammation-17/NN	dobj||control-14/VBP||myogenesis-19/NN	conj_and||fibrosis-15/NN||myogenesis-19/NN	dobj||control-14/VBP||atrophy-21/NN	conj_and||fibrosis-15/NN||atrophy-21/NN	inflammation-17||prednisone-1||yes||prednisone and combination treated groups showed alterations in the expression of genes that control fibrosis, inflammation, myogenesis and atrophy.
det||use-3/NN||the-1/DT	amod||use-3/NN||chronic-2/JJ	nsubj||patientâ-21/VBD||use-3/NN	amod||agents-6/NNS||antifungal-5/JJ	prep_of||use-3/NN||agents-6/NNS	det||treatment-9/NN||the-8/DT	prep_in||agents-6/NNS||treatment-9/NN	amod||infection-12/NN||fungal-11/JJ	prep_of||treatment-9/NN||infection-12/NN	amod||candidiasis-17/NNS||general-14/JJ	conj_and||general-14/JJ||oropharyngeal-16/JJ	amod||candidiasis-17/NNS||oropharyngeal-16/JJ	prep_in||infection-12/NN||candidiasis-17/NNS	advmod||candidiasis-17/NNS||mainly-18/RB	prep_in||candidiasis-17/NNS||aids-20/NNS	root||ROOT-0/null||patientâ-21/VBD	num||leads-25/NNS||$-22/$	number||s-24/CD||-23/CD	num||$-22/$||s-24/CD	dobj||patientâ-21/VBD||leads-25/NNS	det||selection-28/NN||the-27/DT	prep_to||patientâ-21/VBD||selection-28/NN	prep_of||selection-28/NN||strain-30/NN	amod||strain-30/NN||resistant-31/JJ	det||therapies-34/NNS||these-33/DT	prep_to||resistant-31/JJ||therapies-34/NNS	det||shift-37/NN||a-36/DT	prep_to||resistant-31/JJ||shift-37/NN	conj_and||therapies-34/NNS||shift-37/NN	det||spectrum-40/NN||the-39/DT	prep_in||patientâ-21/VBD||spectrum-40/NN	nn||species-43/NNS||candida-42/NN	prep_of||spectrum-40/NN||species-43/NNS	candidiasis-17||candida-42||no||the chronic use of antifungal agents in the treatment of fungal infection in general and oropharyngeal candidiasis mainly in aids patientâs leads to the selection of strain resistant to these therapies and a shift in the spectrum of candida species.
nn||cells-3/NNS||cancer-2/NN	prep_in||controls-7/VBZ||cells-3/NNS	nsubj||controls-7/VBZ||lh/hcg-5/NN	nsubj||apoptosis-11/VBZ||lh/hcg-5/NN	advmod||controls-7/VBZ||mainly-6/RB	root||ROOT-0/null||controls-7/VBZ	nn||proliferation-9/NN||cell-8/NN	dobj||controls-7/VBZ||proliferation-9/NN	conj_and||controls-7/VBZ||apoptosis-11/VBZ	cancer-2||hcg--1||no_rel||in cancer cells, lh/hcg mainly controls cell proliferation and apoptosis.
nsubj||capable-13/JJ||mycobacteriumtuberculosis-1/NNS	appos||mycobacteriumtuberculosis-1/NNS||m.tb-3/NN	det||pathogen-7/NN||the-6/DT	appos||mycobacteriumtuberculosis-1/NNS||pathogen-7/NN	nsubj||causes-9/VBZ||pathogen-7/NN	rcmod||pathogen-7/NN||causes-9/VBZ	dobj||causes-9/VBZ||tuberculosis-10/NNP	cop||capable-13/JJ||is-12/VBZ	root||ROOT-0/null||capable-13/JJ	prepc_of||capable-13/JJ||staying-15/VBG	advmod||staying-15/VBG||asymptomatically-16/RB	det||form-20/NN||a-18/DT	nn||form-20/NN||latent-19/NN	prep_in||staying-15/VBG||form-20/NN	dep||staying-15/VBG||persisting-22/VBG	prep_for||persisting-22/VBG||years-24/NNS	advmod||low-27/JJ||very-26/RB	amod||state-29/NN||low-27/JJ	amod||state-29/NN||replicating-28/JJ	prep_in||years-24/NNS||state-29/NN	advmod||getting-32/VBG||before-31/RB	dep||staying-15/VBG||getting-32/VBG	advmod||getting-32/VBG||reactivated-33/RB	aux||cause-35/VB||to-34/TO	xcomp||getting-32/VBG||cause-35/VB	amod||infection-37/NN||active-36/JJ	dobj||cause-35/VB||infection-37/NN	tb--1||mycobacteriumtuberculosis-1||no||mycobacteriumtuberculosis ( m.tb ), the pathogen that causes tuberculosis, is capable of staying asymptomatically in a latent form, persisting for years in very low replicating state, before getting reactivated to cause active infection.
advmod||lower-2/JJR||significantly-1/RB	amod||performance-3/NN||lower-2/JJR	nsubjpass||seen-5/VBN||performance-3/NN	auxpass||seen-5/VBN||was-4/VBD	root||ROOT-0/null||seen-5/VBN	det||sample-10/NN||the-7/DT	nn||sample-10/NN||hiv-8/NN	nn||sample-10/NN||+-9/NN	prep_in||seen-5/VBN||sample-10/NN	prep_on||seen-5/VBN||tests-12/NNS	amod||function-15/NN||executive-14/JJ	prep_of||tests-12/NNS||function-15/NN	prep_of||tests-12/NNS||speed-17/NN	conj_and||function-15/NN||speed-17/NN	nn||processing-20/NN||information-19/NN	prep_of||speed-17/NN||processing-20/NN	amod||memory-23/NN||working-22/JJ	prep_of||tests-12/NNS||memory-23/NN	conj_and||function-15/NN||memory-23/NN	nn||speed-27/NN||psychomotor-26/NN	prep_of||tests-12/NNS||speed-27/NN	conj_and||function-15/NN||speed-27/NN	hiv+--1||speed-27||no_rel||significantly lower performance was seen in the hiv+ sample on tests of executive function, speed of information processing, working memory, and psychomotor speed.
amod||ifn-gamma-responses-2/NNS||increased-1/VBN	nsubj||represents-15/VBZ||ifn-gamma-responses-2/NNS	amod||proliferation-7/NN||antigen-specific-4/JJ	nn||proliferation-7/NN||t-5/NN	nn||proliferation-7/NN||cell-6/NN	conj_and||ifn-gamma-responses-2/NNS||proliferation-7/NN	nsubj||represents-15/VBZ||proliferation-7/NN	det||subset-14/NN||the-9/DT	amod||subset-14/NN||cd8alpha/alpha-10/JJ	amod||subset-14/NN||+-11/JJ	nn||subset-14/NN||t-12/NN	nn||subset-14/NN||cell-13/NN	prep_in||proliferation-7/NN||subset-14/NN	root||ROOT-0/null||represents-15/VBZ	det||marker-18/NN||a-16/DT	amod||marker-18/NN||valuable-17/JJ	dobj||represents-15/VBZ||marker-18/NN	prep_for||marker-18/NN||vaccine-take-20/NN	amod||trials-25/NNS||bcg-based-22/JJ	nn||trials-25/NNS||tb-23/NN	nn||trials-25/NNS||vaccine-24/NN	prep_in||vaccine-take-20/NN||trials-25/NNS	tb-23||bcg--1||no||increased ifn-gamma-responses and antigen-specific t cell proliferation in the cd8alpha/alpha+ t cell subset represents a valuable marker for vaccine-take in bcg-based tb vaccine trials
amod||shortstature-2/NN||idiopathic-1/JJ	nsubj||term-8/NN||shortstature-2/NN	appos||shortstature-2/NN||iss-4/NN	cop||term-8/NN||is-6/VBZ	det||term-8/NN||a-7/DT	root||ROOT-0/null||term-8/NN	nsubj||describes-10/VBZ||term-8/NN	rcmod||term-8/NN||describes-10/VBZ	dobj||describes-10/VBZ||shortstature-11/NN	prep_in||describes-10/VBZ||children-13/NNS	nsubj||have-17/VB||children-13/NNS	aux||have-17/VB||do-15/VBP	neg||have-17/VB||not-16/RB	rcmod||children-13/NNS||have-17/VB	amod||deficiency-22/NN||growthhormone-18/JJ	dep||growthhormone-18/JJ||gh-20/NN	dobj||have-17/VB||deficiency-22/NN	dobj||identified-33/VBN||whom-25/WP	det||etiology-27/NN||the-26/DT	nsubjpass||identified-33/VBN||etiology-27/NN	det||shortstature-30/NN||the-29/DT	prep_of||etiology-27/NN||shortstature-30/NN	auxpass||identified-33/VBN||is-31/VBZ	neg||identified-33/VBN||not-32/RB	prep_in||describes-10/VBZ||identified-33/VBN	conj_and||children-13/NNS||identified-33/VBN	nsubj||have-17/VB||identified-33/VBN	shortstature-30||growthhormone-18||yes||idiopathic shortstature (iss) is a term that describes shortstature in children who do not have growthhormone (gh) deficiency and in whom the etiology of the shortstature is not identified.
advmod||choice-6/NN||even-1/RB	advmod||choice-6/NN||though-2/RB	det||choice-6/NN||a-3/DT	advmod||pharmacoeconomical-5/JJ||better-4/RBR	amod||choice-6/NN||pharmacoeconomical-5/JJ	advcl||likely-22/JJ||choice-6/NN	prep_than||choice-6/NN||amphotericinb-8/NN	det||cost-12/NN||the-10/DT	amod||cost-12/NN||higher-11/JJR	nsubj||likely-22/JJ||cost-12/NN	nsubj||limit-24/VB||cost-12/NN	nsubj||limit-24/VB||cost-12/NN	nsubj||limit-24/VB||cost-12/NN	det||drugs-15/NNS||these-14/DT	prep_of||cost-12/NN||drugs-15/NNS	prep_in||drugs-15/NNS||comparison-17/NN	amod||antifungals-20/NNS||azole-19/JJ	prep_to||comparison-17/NN||antifungals-20/NNS	cop||likely-22/JJ||is-21/VBZ	root||ROOT-0/null||likely-22/JJ	aux||limit-24/VB||to-23/TO	xcomp||likely-22/JJ||limit-24/VB	xcomp||likely-22/JJ||limit-24/VB	xcomp||likely-22/JJ||limit-24/VB	conj_and||limit-24/VB||limit-24/VB	conj_negcc||limit-24/VB||limit-24/VB	poss||use-26/NN||their-25/PRP$	dobj||limit-24/VB||use-26/NN	amod||resistant-29/JJ||azole-28/JJ	amod||cases-30/NNS||resistant-29/JJ	prep_to||limit-24/VB||cases-30/NNS	amod||infections-33/NNS||candidial-32/JJ	prep_of||cases-30/NNS||infections-33/NNS	nn||therapy-37/NN||salvage-36/NN	prep_as||limit-24/VB||therapy-37/NN	amod||aspergillosis-40/NNS||invasive-39/JJ	prep_in||limit-24/VB||aspergillosis-40/NNS	amod||drugs-46/NNS||first-44/JJ	nn||drugs-46/NNS||line-45/NN	prep_as||limit-24/VB||drugs-46/NNS	aspergillosis-40||amphotericinb-8||yes||even though a better pharmacoeconomical choice than amphotericinb, the higher cost of these drugs in comparison to azole antifungals is likely to limit their use to azole resistant cases of candidial infections and as salvage therapy in invasive aspergillosis rather than as first line drugs.
nsubj||genome-5/VBP||sars-coronavirus-1/NNS	appos||sars-coronavirus-1/NNS||sars-cov-3/NNP	root||ROOT-0/null||genome-5/VBP	nsubj||depends-7/VBZ||expression-6/NN	ccomp||genome-5/VBP||depends-7/VBZ	det||synthesis-10/NN||the-9/DT	prep_on||depends-7/VBZ||synthesis-10/NN	det||set-13/NN||a-12/DT	prep_of||synthesis-10/NN||set-13/NN	prep_of||set-13/NN||mrnas-15/NNS	nsubjpass||capped-20/VBN||mrnas-15/NNS	advmod||capped-20/VBN||presumably-18/RB	auxpass||capped-20/VBN||are-19/VBP	rcmod||mrnas-15/NNS||capped-20/VBN	poss||end-26/NN||their-22/PRP$	amod||end-26/NN||5â-23/JJ	amod||end-26/NN||$-24/$	num||$-24/$||²-25/CD	prep_at||capped-20/VBN||end-26/NN	amod||synthesis-30/NN||direct-28/JJ	det||synthesis-30/NN||the-29/DT	prep_at||capped-20/VBN||synthesis-30/NN	conj_and||end-26/NN||synthesis-30/NN	det||proteins-34/NNS||all-32/DT	amod||proteins-34/NNS||viral-33/JJ	prep_of||synthesis-30/NN||proteins-34/NNS	det||cell-38/NN||the-36/DT	amod||cell-38/NN||infected-37/JJ	prep_in||proteins-34/NNS||cell-38/NN	sars--1||sars-cov-3||no||sars-coronavirus (sars-cov) genome expression depends on the synthesis of a set of mrnas, which presumably are capped at their 5â² end and direct the synthesis of all viral proteins in the infected cell.
amod||diodes-5/NNS||phosphor-free-1/JJ	amod||diodes-5/NNS||apple-white-2/JJ	amod||diodes-5/NNS||light-3/JJ	nn||diodes-5/NNS||emitting-4/NN	nsubjpass||fabricated-8/VBN||diodes-5/NNS	aux||fabricated-8/VBN||have-6/VBP	auxpass||fabricated-8/VBN||been-7/VBN	root||ROOT-0/null||fabricated-8/VBN	xcomp||fabricated-8/VBN||using-9/VBG	det||wells-16/NNS||a-10/DT	amod||wells-16/NNS||dual-11/JJ	amod||wells-16/NNS||stacked-12/JJ	amod||wells-16/NNS||ingan/gan-13/JJ	amod||wells-16/NNS||multiple-14/JJ	nn||wells-16/NNS||quantum-15/NN	dobj||using-9/VBG||wells-16/NNS	vmod||wells-16/NNS||comprising-17/VBG	det||set-21/NN||a-19/DT	amod||set-21/NN||lower-20/JJR	prep_of||comprising-17/VBG||set-21/NN	amod||wavelength-24/NN||long-23/JJ	prep_of||set-21/NN||wavelength-24/NN	vmod||comprising-17/VBG||emitting-25/VBG	amod||nanostructures-27/NNS||indium-rich-26/JJ	dobj||emitting-25/VBG||nanostructures-27/NNS	vmod||nanostructures-27/NNS||incorporated-28/VBN	amod||wells-32/NNS||multiple-30/JJ	nn||wells-32/NNS||quantum-31/NN	prep_in||incorporated-28/VBN||wells-32/NNS	det||set-36/NN||an-34/DT	amod||set-36/NN||upper-35/JJ	nsubj||emitting-39/VBG||set-36/NN	prep_of||set-36/NN||cyan-green-38/NN	prepc_with||incorporated-28/VBN||emitting-39/VBG	amod||wells-42/NNS||multiple-40/JJ	nn||wells-42/NNS||quantum-41/NN	dobj||emitting-39/VBG||wells-42/NNS	gan--1||wells-42||no_rel||phosphor-free apple-white light emitting diodes have been fabricated using a dual stacked ingan/gan multiple quantum wells comprising of a lower set of long wavelength emitting indium-rich nanostructures incorporated in multiple quantum wells with an upper set of cyan-green emitting multiple quantum wells.
nsubj||had-11/VBD||patients-1/NNS	vmod||patients-1/NNS||using-2/VBG	amod||n-7/NN||insulinglargine-3/JJ	conj_or||insulinglargine-3/JJ||detemir-5/JJ	amod||n-7/NN||detemir-5/JJ	amod||n-7/NN||-lrb--6/JJ	dobj||using-2/VBG||n-7/NN	dep||-rrb--10/NNS||=-8/SYM	num||-rrb--10/NNS||5,317-9/CD	dep||using-2/VBG||-rrb--10/NNS	ccomp||±-27/VBZ||had-11/VBD	det||incidence-15/NN||a-12/DT	amod||incidence-15/NN||higher-13/JJR	nn||incidence-15/NN||dka-14/NN	dobj||had-11/VBD||incidence-15/NN	mark||5,365-23/CD||than-16/IN	nsubj||5,365-23/CD||individuals-17/NNS	vmod||individuals-17/NNS||using-18/VBG	amod||n-21/NN||nphinsulin-19/JJ	amod||n-21/NN||-lrb--20/JJ	dobj||using-18/VBG||n-21/NN	dep||5,365-23/CD||=-22/SYM	advcl||had-11/VBD||5,365-23/CD	num||â-26/NN||6.6-25/CD	nsubj||±-27/VBZ||â-26/NN	root||ROOT-0/null||±-27/VBZ	dobj||±-27/VBZ||0.4-28/CD	num||-rrb--38/NNS||3.6-30/CD	nn||-rrb--38/NNS||â-31/NNP	nn||-rrb--38/NNS||±-32/NNP	num||-rrb--38/NNS||0.3-33/CD	dep||-rrb--38/NNS||p-35/NNP	nn||-rrb--38/NNS||<-36/NNP	num||-rrb--38/NNS||0.001-37/CD	prep_vs.||0.4-28/CD||-rrb--38/NNS	insulinglargine-3||dka-14||no_rel||patients using insulinglargine or detemir -lrb- n = 5,317 -rrb- had a higher dka incidence than individuals using nphinsulin -lrb- n = 5,365 , 6.6 â ± 0.4 vs. 3.6 â ± 0.3 , p < 0.001 -rrb- .
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||effect-4/NN||the-3/DT	dobj||investigated-2/VBD||effect-4/NN	amod||mice-36/NNS||varying-6/VBG	det||rates-10/NNS||the-7/DT	amod||rates-10/NNS||intraperitoneal-8/JJ	nn||rates-10/NNS||infusion-9/NN	nn||mice-36/NNS||rates-10/NNS	amod||dose50-19/NNS||bupropionhcl-12/JJ	num||mg/kg-14/NN||120-13/CD	dep||bupropionhcl-12/JJ||mg/kg-14/NN	det||convulsive-18/NN||a-16/DT	amod||convulsive-18/NN||known-17/JJ	appos||mg/kg-14/NN||convulsive-18/NN	prep_of||rates-10/NNS||dose50-19/NNS	appos||dose50-19/NNS||cd50-21/NNP	conj_and||rates-10/NNS||on-24/IN	nn||mice-36/NNS||on-24/IN	det||incidence-26/NN||the-25/DT	prep_on||rates-10/NNS||incidence-26/NN	conj_and||rates-10/NNS||severity-28/NN	nn||mice-36/NNS||severity-28/NN	amod||convulsions-31/NNS||bupropion-induced-30/JJ	prep_of||severity-28/NN||convulsions-31/NNS	det||albino-35/NN||the-33/DT	amod||albino-35/NN||swiss-34/JJ	prep_in||convulsions-31/NNS||albino-35/NN	prep_of||effect-4/NN||mice-36/NNS	convulsions-31||bupropionhcl-12||no||we investigated the effect of varying the intraperitoneal infusion rates of bupropionhcl 120 mg/kg, a known convulsive dose50 (cd50), on the incidence and severity of bupropion-induced convulsions in the swiss albino mice.
det||lack-4/NN||this-1/DT	nn||lack-4/NN||study-2/NN	nn||lack-4/NN||shows-3/NNS	nsubj||ca-44/MD||lack-4/NN	amod||activity-8/NN||co2-6/JJ	nn||activity-8/NN||hydration-7/NN	prep_of||lack-4/NN||activity-8/NN	det||protein-12/NN||a-10/DT	amod||protein-12/NN||recombinant-11/JJ	prep_in||activity-8/NN||protein-12/NN	vmod||protein-12/NN||expressed-13/VBN	det||gene-16/NN||a-15/DT	prep_from||expressed-13/VBN||gene-16/NN	vmod||gene-16/NN||predicted-17/VBN	aux||encode-19/VB||to-18/TO	xcomp||predicted-17/VBN||encode-19/VB	det||³-22/NN||a-20/DT	nn||³-22/NN||î-21/NN	dobj||encode-19/VB||³-22/NN	amod||anhydrase-25/NN||carbonic-24/JJ	dep||cross-31/VBP||anhydrase-25/NN	nn||brasilense-28/NN||a.-27/NN	prep_in||anhydrase-25/NN||brasilense-28/NN	mark||cross-31/VBP||although-29/IN	nsubj||cross-31/VBP||it-30/PRP	dep||lack-4/NN||cross-31/VBP	ccomp||cross-31/VBP||reacts-32/VBZ	amod||antibody-35/NN||anti-cam-34/JJ	prep_with||reacts-32/VBZ||antibody-35/NN	vmod||antibody-35/NN||raised-36/VBN	det||³-42/NN||a-38/DT	advmod||characterized-40/JJ||well-39/RB	amod||³-42/NN||characterized-40/JJ	nn||³-42/NN||î-41/NN	prep_against||raised-36/VBN||³-42/NN	root||ROOT-0/null||ca-44/MD	cross-31||antibody-35||no_rel||this study shows lack of co2 hydration activity in a recombinant protein expressed from a gene predicted to encode a î ³ - carbonic anhydrase in a. brasilense although it cross reacts with anti-cam antibody raised against a well characterized î ³ - ca .
poss||study-3/NN||our-1/PRP$	amod||study-3/NN||previous-2/JJ	nsubj||shown-5/VBN||study-3/NN	aux||shown-5/VBN||has-4/VBZ	root||ROOT-0/null||shown-5/VBN	mark||transactivate-9/VB||that-6/IN	nsubj||transactivate-9/VB||igf-1r-7/JJ	aux||transactivate-9/VB||can-8/MD	ccomp||shown-5/VBN||transactivate-9/VB	dobj||transactivate-9/VB||cxcr4-10/NNS	det||association-14/NN||a-12/DT	amod||association-14/NN||physical-13/JJ	prep_via||cxcr4-10/NNS||association-14/NN	det||line-23/NN||the-16/DT	amod||line-23/NN||human-17/JJ	amod||line-23/NN||mda-mb-231-18/JJ	amod||line-23/NN||metastatic-19/JJ	nn||line-23/NN||breast-20/NN	nn||line-23/NN||cancer-21/NN	nn||line-23/NN||cell-22/NN	prep_in||association-14/NN||line-23/NN	mark||plays-27/VBZ||that-25/IN	nsubj||plays-27/VBZ||this-26/DT	ccomp||shown-5/VBN||plays-27/VBZ	conj_and||transactivate-9/VB||plays-27/VBZ	det||role-30/NN||a-28/DT	amod||role-30/NN||key-29/JJ	dobj||plays-27/VBZ||role-30/NN	amod||migration-33/NN||igf-i-induced-32/JJ	prep_in||role-30/NN||migration-33/NN	det||cells-36/NNS||these-35/DT	prep_of||migration-33/NN||cells-36/NNS	cancer-21||i---1||no_rel||our previous study has shown that igf-1r can transactivate cxcr4 via a physical association in the human mda-mb-231 metastatic breast cancer cell line and that this plays a key role in igf-i-induced migration of these cells.
det||progression-2/NN||the-1/DT	nsubj||involves-14/VBZ||progression-2/NN	amod||tuberculosis-5/NNP||human-4/JJ	prep_of||progression-2/NN||tuberculosis-5/NNP	appos||progression-2/NN||tb-7/NN	amod||disease-11/NN||active-10/JJ	prep_to||progression-2/NN||disease-11/NN	prep_to||progression-2/NN||transmission-13/NN	conj_and||disease-11/NN||transmission-13/NN	root||ROOT-0/null||involves-14/VBZ	det||development-16/NN||the-15/DT	dobj||involves-14/VBZ||development-16/NN	det||granuloma-20/NN||a-18/DT	amod||granuloma-20/NN||caseous-19/JJ	prep_of||development-16/NN||granuloma-20/NN	nsubj||cavitates-22/VBZ||granuloma-20/NN	nsubj||releases-24/VBZ||granuloma-20/NN	rcmod||granuloma-20/NN||cavitates-22/VBZ	rcmod||granuloma-20/NN||releases-24/VBZ	conj_and||cavitates-22/VBZ||releases-24/VBZ	amod||bacilli-27/NNS||infectious-25/JJ	nn||bacilli-27/NNS||mycobacteriumtuberculosis-26/NN	dobj||cavitates-22/VBZ||bacilli-27/NNS	tb-7||mycobacteriumtuberculosis-26||no||the progression of human tuberculosis (tb) to active disease and transmission involves the development of a caseous granuloma that cavitates and releases infectious mycobacteriumtuberculosis bacilli.
amod||studies-2/NNS||recent-1/JJ	nsubj||indicate-3/VBP||studies-2/NNS	root||ROOT-0/null||indicate-3/VBP	mark||reduced-13/VBN||that-4/IN	prep_during||reduced-13/VBN||hantavirusinfection-6/NN	amod||responses-11/NNS||proinflammatory-8/JJ	conj_and||proinflammatory-8/JJ||antiviral-10/JJ	amod||responses-11/NNS||antiviral-10/JJ	nsubjpass||reduced-13/VBN||responses-11/NNS	auxpass||reduced-13/VBN||are-12/VBP	ccomp||indicate-3/VBP||reduced-13/VBN	amod||responses-16/NNS||regulatory-15/JJ	nsubj||elevated-18/JJ||responses-16/NNS	cop||elevated-18/JJ||are-17/VBP	ccomp||indicate-3/VBP||elevated-18/JJ	conj_and||reduced-13/VBN||elevated-18/JJ	prep_at||elevated-18/JJ||sites-20/NNS	amod||replication-24/NN||increased-22/VBN	nn||replication-24/NN||virus-23/NN	prep_of||sites-20/NNS||replication-24/NN	prep_in||replication-24/NN||rodents-26/NNS	antiviral-10||hantavirusinfection-6||no_rel||recent studies indicate that during hantavirusinfection, proinflammatory and antiviral responses are reduced and regulatory responses are elevated at sites of increased virus replication in rodents.
nsubj||developed-6/VBN||viruses-1/NNS	prep_such_as||viruses-1/NNS||influenza-4/NN	aux||developed-6/VBN||have-5/VBP	root||ROOT-0/null||developed-6/VBN	dobj||developed-6/VBN||mechanisms-7/NNS	aux||evade-9/VB||to-8/TO	vmod||developed-6/VBN||evade-9/VB	det||mechanism-12/NN||this-10/DT	nn||mechanism-12/NN||defense-11/NN	dobj||evade-9/VB||mechanism-12/NN	prep_during||viruses-19/NNS||infection-15/NN	prep_with||infection-15/NN||influenza-17/NN	det||viruses-19/NNS||a-18/DT	conj_and||developed-6/VBN||viruses-19/NNS	det||ns1-26/NN||the-21/DT	amod||ns1-26/NN||non-structural-22/JJ	nn||ns1-26/NN||protein-23/NN	num||ns1-26/NN||1-24/CD	appos||viruses-19/NNS||ns1-26/NN	vmod||ns1-26/NN||encoded-28/VBN	det||induction-34/NN||the-30/DT	nn||induction-34/NN||virus-31/NN	amod||induction-34/NN||genome-32/JJ	nn||induction-34/NN||suppresses-33/NNS	agent||encoded-28/VBN||induction-34/NN	nn||²-40/NNP||ifns-î-36/NNP	nn||²-40/NNP||±-37/NNP	nn||²-40/NNP||/-38/NNP	nn||²-40/NNP||î-39/NNP	prep_of||induction-34/NN||²-40/NNP	virus-31||viruses-19||no||viruses such as influenza have developed mechanisms to evade this defense mechanism and during infection with influenza a viruses, the non-structural protein 1 (ns1) encoded by the virus genome suppresses induction of ifns-î±/î².
dep||administered-16/VBN||using-1/VBG	det||rat-3/NN||the-2/DT	dobj||using-1/VBG||rat-3/NN	amod||model-6/NN||collagen-induced-4/JJ	nn||model-6/NN||arthritis-5/NN	nsubjpass||administered-16/VBN||model-6/NN	amod||combinations-9/NNS||different-8/JJ	appos||model-6/NN||combinations-9/NNS	prep_of||combinations-9/NNS||ect-11/NN	prep_of||combinations-9/NNS||dex-13/NN	conj_and||ect-11/NN||dex-13/NN	auxpass||administered-16/VBN||were-15/VBD	root||ROOT-0/null||administered-16/VBN	nn||onset-19/NN||disease-18/NN	prep_from||administered-16/VBN||onset-19/NN	prep_to||administered-16/VBN||peak-21/NN	dep||peak-21/NN||day-23/NN	num||day-23/NN||11-24/CD	prep_to||day-23/NN||18-26/CD	collagen--1||arthritis-5||no_rel||using the rat collagen-induced arthritis model, different combinations of ect and dex, were administered from disease onset to peak (day 11 to 18).
det||effects-2/NNS||the-1/DT	nsubjpass||investigated-28/VBN||effects-2/NNS	det||treatment-6/NN||an-4/DT	amod||treatment-6/NN||analgesic-5/JJ	prep_of||effects-2/NNS||treatment-6/NN	prep_of||effects-2/NNS||treatment-6/NN	conj_and||treatment-6/NN||treatment-6/NN	amod||patches-9/NNS||lidocaine-8/JJ	appos||treatment-6/NN||patches-9/NNS	nn||activity-13/NN||brain-12/NN	prep_on||treatment-6/NN||activity-13/NN	amod||lowbackpain-16/NN||chronic-15/JJ	prep_in||activity-13/NN||lowbackpain-16/NN	appos||lowbackpain-16/NN||cbp-18/NN	nn||osteoarthritis-23/NNS||knee-22/NN	prep_in||treatment-6/NN||osteoarthritis-23/NNS	appos||effects-2/NNS||oa-25/NN	auxpass||investigated-28/VBN||were-27/VBD	root||ROOT-0/null||investigated-28/VBN	xcomp||investigated-28/VBN||using-29/VBG	amod||fmri-31/NNS||serial-30/JJ	dobj||using-29/VBG||fmri-31/NNS	dep||fmri-31/NNS||contrasting-33/VBG	dobj||contrasting-33/VBG||fmri-34/NNS	advmod||weeks-40/NNS||before-36/RB	conj_and||before-36/RB||after-38/IN	advmod||weeks-40/NNS||after-38/IN	pobj||after-38/IN||two-39/CD	prep_between||fmri-34/NNS||weeks-40/NNS	prep_of||fmri-34/NNS||treatment-42/NN	oa-25||lidocaine-8||no_rel||the effects of an analgesic treatment (lidocaine patches) on brain activity in chronic lowbackpain (cbp) and in knee osteoarthritis (oa) were investigated using serial fmri (contrasting fmri between before and after two weeks of treatment).
mark||upstream-5/JJ||because-1/IN	nsubj||upstream-5/JJ||cvl-2/NN	cop||upstream-5/JJ||is-3/VBZ	advmod||upstream-5/JJ||temporally-4/RB	advcl||consider-12/VB||upstream-5/JJ	amod||hivinfections-8/NNS||new-7/JJ	prep_of||upstream-5/JJ||hivinfections-8/NNS	nsubj||consider-12/VB||jurisdictions-10/NNS	aux||consider-12/VB||should-11/MD	root||ROOT-0/null||consider-12/VB	dep||consider-12/VB||adding-13/VBG	dobj||adding-13/VBG||cvl-14/NN	amod||surveillance-18/NN||routine-16/JJ	nn||surveillance-18/NN||hiv-17/NN	prep_to||adding-13/VBG||surveillance-18/NN	aux||track-20/VB||to-19/TO	vmod||adding-13/VBG||track-20/VB	det||epidemic-22/NN||the-21/DT	dobj||track-20/VB||epidemic-22/NN	dep||consider-12/VB||allocate-24/VB	ccomp||adding-13/VBG||allocate-24/VB	conj_and||adding-13/VBG||allocate-24/VB	dobj||allocate-24/VB||resources-25/NNS	aux||evaluate-29/VB||to-28/TO	dep||consider-12/VB||evaluate-29/VB	conj_and||adding-13/VBG||evaluate-29/VB	det||effectiveness-31/NN||the-30/DT	dobj||evaluate-29/VB||effectiveness-31/NN	nn||prevention-34/NN||hiv-33/NN	prep_of||effectiveness-31/NN||prevention-34/NN	nn||efforts-37/NNS||treatment-36/NN	prep_of||effectiveness-31/NN||efforts-37/NNS	conj_and||prevention-34/NN||efforts-37/NNS	hivinfections-8||hiv-33||no||because cvl is temporally upstream of new hivinfections, jurisdictions should consider adding cvl to routine hiv surveillance to track the epidemic, allocate resources, and to evaluate the effectiveness of hiv prevention and treatment efforts.
nsubj||emerging-12/VBG||il2ra/cd25-1/NNS	det||gene-4/NN||the-3/DT	appos||il2ra/cd25-1/NNS||gene-4/NN	nn||±-9/NNS||interleukin-2-6/NN	nn||±-9/NNS||receptor-7/NN	nn||±-9/NNS||î-8/NN	prep_for||gene-4/NN||±-9/NNS	aux||emerging-12/VBG||is-11/VBZ	root||ROOT-0/null||emerging-12/VBG	det||gene-17/NN||a-14/DT	amod||gene-17/NN||general-15/JJ	nn||gene-17/NN||susceptibility-16/NN	prep_as||emerging-12/VBG||gene-17/NN	prep_for||gene-17/NN||autoimmunediseases-19/NNS	poss||role-23/NN||its-22/PRP$	prep_because_of||autoimmunediseases-19/NNS||role-23/NN	det||development-26/NN||the-25/DT	prep_in||emerging-12/VBG||development-26/NN	prep_in||emerging-12/VBG||function-28/NN	conj_and||development-26/NN||function-28/NN	amod||cells-32/NNS||regulatory-30/JJ	nn||cells-32/NNS||t-31/NN	prep_of||development-26/NN||cells-32/NNS	det||association-35/NN||the-34/DT	prep_in||emerging-12/VBG||association-35/NN	conj_and||development-26/NN||association-35/NN	amod||polymorphisms-38/NNS||single-nucleotide-37/JJ	prep_of||association-35/NN||polymorphisms-38/NNS	parataxis||emerging-12/VBG||snps-40/VBZ	det||gene-44/NN||this-43/DT	prep_within||emerging-12/VBG||gene-44/NN	prep_with||gene-44/NN||type1diabetesmellitus-46/NNS	appos||type1diabetesmellitus-46/NNS||dm-48/NN	poss||disease-53/NN||graves-51/NNS	prep_with||gene-44/NN||disease-53/NN	conj_and||type1diabetesmellitus-46/NNS||disease-53/NN	prep_with||gene-44/NN||rheumatoidarthritis-55/NNS	conj_and||type1diabetesmellitus-46/NNS||rheumatoidarthritis-55/NNS	appos||rheumatoidarthritis-55/NNS||ra-57/NN	prep_with||gene-44/NN||multiplesclerosis-61/NNS	conj_and||type1diabetesmellitus-46/NNS||multiplesclerosis-61/NNS	appos||multiplesclerosis-61/NNS||ms-63/NN	multiplesclerosis-61||dm-48||no_rel||il2ra/cd25 , the gene for interleukin-2 receptor î±, is emerging as a general susceptibility gene for autoimmunediseases because of its role in the development and function of regulatory t cells and the association of single-nucleotide polymorphisms (snps) within this gene with type1diabetesmellitus (dm), graves' disease, rheumatoidarthritis (ra), and multiplesclerosis (ms).
nsubj||tested-2/VBD||we-1/PRP	root||ROOT-0/null||tested-2/VBD	det||hypothesis-4/NNS||the-3/DT	dobj||tested-2/VBD||hypothesis-4/NNS	mark||suppresses-21/VBZ||that-5/IN	det||increase-7/NN||an-6/DT	nsubj||suppresses-21/VBZ||increase-7/NN	prep_in||increase-7/NN||insulin-9/NN	nn||se-11/FW||per-10/FW	advmod||insulin-9/NN||se-11/FW	dep||se-11/FW||i.e.-13/CD	det||absence-17/NN||the-16/DT	prep_in||se-11/FW||absence-17/NN	prep_of||absence-17/NN||zinc-19/NN	ccomp||tested-2/VBD||suppresses-21/VBZ	nn||secretion-23/NN||glucagon-22/NN	dobj||suppresses-21/VBZ||secretion-23/NN	prep_during||suppresses-21/VBZ||euglycemia-25/NN	mark||stimulates-34/VBZ||that-27/IN	det||decrease-29/NN||a-28/DT	nsubj||stimulates-34/VBZ||decrease-29/NN	prep_in||decrease-29/NN||insulin-31/NN	nn||se-33/FW||per-32/FW	advmod||stimulates-34/VBZ||se-33/FW	ccomp||tested-2/VBD||stimulates-34/VBZ	conj_and||suppresses-21/VBZ||stimulates-34/VBZ	nn||secretion-36/NN||glucagon-35/NN	dobj||stimulates-34/VBZ||secretion-36/NN	prep_during||stimulates-34/VBZ||hypoglycemia-38/NN	prep_in||hypoglycemia-38/NN||humans-40/NNS	insulin-31||hypoglycemia-38||no_rel||we tested the hypothesis that an increase in insulin per se, i.e., in the absence of zinc, suppresses glucagon secretion during euglycemia and that a decrease in insulin per se stimulates glucagon secretion during hypoglycemia in humans.
amod||causes-2/NNS||potential-1/JJ	nsubj||include-12/VBP||causes-2/NNS	amod||deterioration-5/NN||clinical-4/JJ	prep_for||causes-2/NNS||deterioration-5/NN	prep_in||deterioration-5/NN||settings-7/NNS	amod||prevalence-11/NN||high-9/JJ	amod||prevalence-11/NN||hiv-1-10/JJ	prep_of||settings-7/NNS||prevalence-11/NN	root||ROOT-0/null||include-12/VBP	npadvmod||resistant-14/JJ||drug-13/NN	amod||mycobacteriumtuberculosis-15/NNS||resistant-14/JJ	dobj||include-12/VBP||mycobacteriumtuberculosis-15/NNS	appos||mycobacteriumtuberculosis-15/NNS||m.tb-17/NN	amod||illnesses-21/NNS||co-morbid-20/JJ	dobj||include-12/VBP||illnesses-21/NNS	conj_and||mycobacteriumtuberculosis-15/NNS||illnesses-21/NNS	amod||adherence-24/NN||poor-23/JJ	dobj||include-12/VBP||adherence-24/NN	conj_and||mycobacteriumtuberculosis-15/NNS||adherence-24/NN	nn||syndrome-32/NN||therapy-26/NN	nn||syndrome-32/NN||tuberculosis-28/NNP	amod||syndrome-32/NN||associated-immune-29/JJ	amod||syndrome-32/NN||reconstitution-30/JJ	amod||syndrome-32/NN||inflammatory-31/JJ	prep_to||adherence-24/NN||syndrome-32/NN	appos||syndrome-32/NN||tb-iris-34/NNS	amod||levels-40/NNS||subtherapeutic-37/JJ	nn||levels-40/NNS||antitubercular-38/NN	nn||levels-40/NNS||drug-39/NN	dobj||include-12/VBP||levels-40/NNS	conj_and||mycobacteriumtuberculosis-15/NNS||levels-40/NNS	tb--1||mycobacteriumtuberculosis-15||no||potential causes for clinical deterioration in settings of high hiv-1 prevalence include drug resistant mycobacteriumtuberculosis (m.tb) , co-morbid illnesses, poor adherence to therapy, tuberculosis associated-immune reconstitution inflammatory syndrome (tb-iris) and subtherapeutic antitubercular drug levels.
amod||interactions-2/NNS||multiple-1/JJ	nsubj||make-10/VBP||interactions-2/NNS	det||region-6/NN||the-4/DT	nn||region-6/NN||neck-5/NN	prep_between||interactions-2/NNS||region-6/NN	det||crds-9/NNS||the-8/DT	prep_between||interactions-2/NNS||crds-9/NNS	conj_and||region-6/NN||crds-9/NNS	root||ROOT-0/null||make-10/VBP	det||trimer-12/NN||the-11/DT	nsubj||unit-15/NN||trimer-12/NN	det||unit-15/NN||a-13/DT	amod||unit-15/NN||rigid-14/JJ	xcomp||make-10/VBP||unit-15/NN	det||crds-19/NNS||the-17/DT	num||crds-19/NNS||three-18/CD	prep_with||unit-15/NN||crds-19/NNS	amod||positions-22/NNS||fixed-21/VBN	prep_in||crds-19/NNS||positions-22/NNS	det||sites-27/NNS||the-24/DT	amod||sites-27/NNS||primary-25/JJ	amod||sites-27/NNS||sugar-binding-26/JJ	prep_in||crds-19/NNS||sites-27/NNS	conj_and||positions-22/NNS||sites-27/NNS	vmod||sites-27/NNS||separated-28/VBN	det||distance-31/NN||a-30/DT	agent||separated-28/VBN||distance-31/NN	num||``-35/NNS||42-33/CD	nn||``-35/NNS||â-34/NN	prep_of||distance-31/NN||``-35/NNS	sugar--1||rigid-14||no_rel||multiple interactions between the neck region and the crds make the trimer a rigid unit with the three crds in fixed positions and the primary sugar-binding sites separated by a distance of 42 â«.
advmod||associated-7/VBN||also-1/RB	nn||methylation-5/NN||erî-3/NN	nn||methylation-5/NN||±-4/NN	nsubj||associated-7/VBN||methylation-5/NN	nsubj||progesterone-9/VB||methylation-5/NN	nsubj||double-18/VB||methylation-5/NN	aux||associated-7/VBN||has-6/VBZ	root||ROOT-0/null||associated-7/VBN	aux||progesterone-9/VB||to-8/TO	xcomp||associated-7/VBN||progesterone-9/VB	nn||negativity-11/NN||receptor-10/NN	dobj||progesterone-9/VB||negativity-11/NN	dep||progesterone-9/VB||p-13/NNP	number||0.008-15/CD||<-14/CD	num||p-13/NNP||0.008-15/CD	xcomp||associated-7/VBN||double-18/VB	conj_and||progesterone-9/VB||double-18/VB	nn||status-21/NN||receptor-19/NN	amod||status-21/NN||negative-20/JJ	dobj||double-18/VB||status-21/NN	appos||status-21/NN||p-23/NNP	number||0.0001-25/CD||<-24/CD	num||p-23/NNP||0.0001-25/CD	prep_in||status-21/NN||breasttumors-28/NNS	breasttumors-28||progesterone-9||no||also, erî± methylation has associated to progesterone receptor negativity (p<0.008) and double receptor negative status (p<0.0001) in breasttumors.
aux||evaluate-2/VB||to-1/TO	advcl||etoposide-23/VBP||evaluate-2/VB	dobj||evaluate-2/VB||tolerability-3/NN	dobj||evaluate-2/VB||maintenance-5/NN	conj_and||tolerability-3/NN||maintenance-5/NN	nn||intensity-8/NN||dose-7/NN	prep_of||tolerability-3/NN||intensity-8/NN	num||treatment-12/NN||2-10/CD	amod||treatment-12/NN||weekly-11/JJ	prep_of||intensity-8/NN||treatment-12/NN	prep_with||treatment-12/NN||vincristine-14/NN	nsubj||etoposide-23/VBP||doxorubicin-16/NN	appos||doxorubicin-16/NN||cyclophosphamide-18/NN	vmod||cyclophosphamide-18/NN||alternating-19/VBG	prep_with||alternating-19/VBG||ifosfamide-21/NN	root||ROOT-0/null||etoposide-23/VBP	parataxis||etoposide-23/VBP||vdc/ie-25/VB	prep_in||etoposide-23/VBP||patients-28/NNS	amod||sarcomas-34/NNS||advanced-30/JJ	amod||sarcomas-34/NNS||small-31/JJ	nn||sarcomas-34/NNS||round-32/NN	nn||sarcomas-34/NNS||cell-33/NN	prep_with||patients-28/NNS||sarcomas-34/NNS	amod||tumours-38/NNS||ewing-36/JJ	nn||tumours-38/NNS||family-37/NN	prep_including||etoposide-23/VBP||tumours-38/NNS	appos||tumours-38/NNS||eft-40/NN	amod||tumours-47/NNS||desmoplastic-43/JJ	amod||tumours-47/NNS||small-44/JJ	nn||tumours-47/NNS||round-45/NN	nn||tumours-47/NNS||cell-46/NN	prep_including||etoposide-23/VBP||tumours-47/NNS	conj_and||tumours-38/NNS||tumours-47/NNS	appos||tumours-47/NNS||dsrct-49/NN	amod||sarcomas-57/NNS||undifferentiated-52/JJ	amod||sarcomas-57/NNS||high-53/JJ	nn||sarcomas-57/NNS||grade-54/NN	nn||sarcomas-57/NNS||round-55/NN	nn||sarcomas-57/NNS||cell-56/NN	prep_including||etoposide-23/VBP||sarcomas-57/NNS	conj_and||tumours-38/NNS||sarcomas-57/NNS	appos||sarcomas-57/NNS||uhgrcs-59/NNS	sarcomas-57||ifosfamide-21||yes||to evaluate tolerability and maintenance of dose intensity of 2 weekly treatment with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide, etoposide (vdc/ie) in patients with advanced small round cell sarcomas including ewing family tumours (eft), desmoplastic small round cell tumours (dsrct) and undifferentiated high grade round cell sarcomas (uhgrcs).
advmod||had-7/VBD||furthermore-1/RB	nsubj||had-7/VBD||those-3/DT	nsubj||able-14/JJ||those-3/DT	nsubj||seek-16/VB||those-3/DT	nsubj||have-27/VBP||those-3/DT	det||clozapine-user-6/NN||the-5/DT	prep_in||those-3/DT||clozapine-user-6/NN	root||ROOT-0/null||had-7/VBD	amod||incomes-10/NNS||lower-8/JJR	nn||incomes-10/NNS||family-9/NN	dobj||had-7/VBD||incomes-10/NNS	cop||able-14/JJ||were-12/VBD	advmod||able-14/JJ||less-13/RBR	conj_and||had-7/VBD||able-14/JJ	aux||seek-16/VB||to-15/TO	xcomp||able-14/JJ||seek-16/VB	amod||services-18/NNS||psychiatric-17/JJ	dobj||seek-16/VB||services-18/NNS	advmod||likely-22/JJ||more-21/RBR	conj_and||had-7/VBD||likely-22/JJ	conj_and||able-14/JJ||likely-22/JJ	aux||male-25/JJ||to-23/TO	cop||male-25/JJ||be-24/VB	xcomp||likely-22/JJ||male-25/JJ	conj_and||had-7/VBD||have-27/VBP	det||history-31/NN||a-28/DT	amod||history-31/NN||positive-29/JJ	nn||history-31/NN||family-30/NN	dobj||have-27/VBP||history-31/NN	prep_of||history-31/NN||schizophrenia-33/NN	schizophrenia-33||clozapine--1||yes||furthermore, those in the clozapine-user had lower family incomes, were less able to seek psychiatric services, and more likely to be male and have a positive family history of schizophrenia.
det||emergence-2/NN||the-1/DT	nsubj||undermines-8/VBZ||emergence-2/NN	nsubj||undermines-8/VBZ||emergence-2/NN	nn||resistance-5/NN||drug-4/NN	prep_of||emergence-2/NN||resistance-5/NN	prep_in||resistance-5/NN||m.tuberculosis-7/NNS	root||ROOT-0/null||undermines-8/VBZ	conj_and||undermines-8/VBZ||undermines-8/VBZ	det||efficacy-10/NN||the-9/DT	dobj||undermines-8/VBZ||efficacy-10/NN	nn||treatment-16/NN||tuberculosis-12/NNP	nn||treatment-16/NN||-lrb--13/NNP	nn||treatment-16/NN||tb-14/NNP	nn||treatment-16/NN||-rrb--15/NNP	prep_of||efficacy-10/NN||treatment-16/NN	prep_in||undermines-8/VBZ||individuals-18/NNS	nn||programs-23/NNS||tb-21/NN	nn||programs-23/NNS||control-22/NN	prep_of||undermines-8/VBZ||programs-23/NNS	prep_in||programs-23/NNS||populations-25/NNS	tb-21||m.tuberculosis-7||no||the emergence of drug resistance in m.tuberculosis undermines the efficacy of tuberculosis -lrb- tb -rrb- treatment in individuals and of tb control programs in populations .
nsubj||conclude-2/VBP||we-1/PRP	nsubj||effective-15/JJ||we-1/PRP	nsubjpass||tolerated-19/VBN||we-1/PRP	root||ROOT-0/null||conclude-2/VBP	mark||administered-11/VBN||that-3/IN	num||carboxymaltose-7/NN||1000â-4/CD	nn||carboxymaltose-7/NN||mg-5/NN	amod||carboxymaltose-7/NN||ferric-6/JJ	nsubjpass||administered-11/VBN||carboxymaltose-7/NN	aux||administered-11/VBN||can-8/MD	auxpass||administered-11/VBN||be-9/VB	advmod||administered-11/VBN||rapidly-10/RB	ccomp||conclude-2/VBP||administered-11/VBN	cop||effective-15/JJ||is-13/VBZ	advmod||effective-15/JJ||more-14/RBR	conj_and||conclude-2/VBP||effective-15/JJ	auxpass||tolerated-19/VBN||is-17/VBZ	advmod||tolerated-19/VBN||better-18/RBR	conj_and||conclude-2/VBP||tolerated-19/VBN	amod||iron-22/NN||oral-21/JJ	prep_than||tolerated-19/VBN||iron-22/NN	prep_for||iron-22/NN||treatment-24/NN	prep_of||treatment-24/NN||irondeficiency-26/NN	amod||patients-29/NNS||nd-ckd-28/JJ	prep_in||tolerated-19/VBN||patients-29/NNS	irondeficiency-26||iron-22||yes||we conclude that 1000â mg ferric carboxymaltose can be rapidly administered, is more effective and is better tolerated than oral iron for treatment of irondeficiency in nd-ckd patients.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||investigate-8/VB||aim-2/NN	nsubj||secretion-18/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||investigate-8/VB||to-7/TO	xcomp||was-6/VBD||investigate-8/VB	det||differences-10/NNS||the-9/DT	dobj||investigate-8/VB||differences-10/NNS	nn||sensitivity-13/NN||insulin-12/NN	prep_in||investigate-8/VB||sensitivity-13/NN	dep||sensitivity-13/NN||is-15/VBZ	xcomp||was-6/VBD||secretion-18/VB	conj_and||investigate-8/VB||secretion-18/VB	amod||adolescents-21/NNS||obese-20/JJ	prep_in||secretion-18/VB||adolescents-21/NNS	prep_with||adolescents-21/NNS||igt-23/NN	prepc_compared_with||secretion-18/VB||with-25/IN	pobj||secretion-18/VB||those-26/DT	amod||tolerance-30/NN||normal-28/JJ	nn||tolerance-30/NN||glucose-29/NN	prep_with||those-26/DT||tolerance-30/NN	appos||tolerance-30/NN||ngt-32/NN	prep_with||those-26/DT||type2diabetes-35/NNS	conj_and||tolerance-30/NN||type2diabetes-35/NNS	type2diabetes-35||insulin-12||yes||the aim of this study was to investigate the differences in insulin sensitivity (is) and secretion in obese adolescents with igt compared with those with normal glucose tolerance (ngt) and type2diabetes.
det||combination-3/NN||a-1/DT	amod||combination-3/NN||fixed-dose-2/JJ	nsubj||shown-13/VBN||combination-3/NN	prep_of||combination-3/NN||artemether-lumefantrine-5/NN	appos||combination-3/NN||al-7/NNP	nn||®-10/NNP||coartemâ-9/NNP	dep||al-7/NNP||®-10/NNP	aux||shown-13/VBN||has-12/VBZ	root||ROOT-0/null||shown-13/VBN	amod||efficacy-15/NN||high-14/JJ	dobj||shown-13/VBN||efficacy-15/NN	amod||tolerability-18/NN||good-17/JJ	dobj||shown-13/VBN||tolerability-18/NN	conj_and||efficacy-15/NN||tolerability-18/NN	dobj||shown-13/VBN||cost-effectiveness-20/NNS	conj_and||efficacy-15/NN||cost-effectiveness-20/NNS	prep_in||shown-13/VBN||adults-22/NNS	prep_in||shown-13/VBN||children-24/NNS	conj_and||adults-22/NNS||children-24/NNS	amod||malaria-27/NN||uncomplicated-26/JJ	prep_with||shown-13/VBN||malaria-27/NN	vmod||malaria-27/NN||caused-28/VBN	nn||falciparum-31/NN||plasmodium-30/NN	agent||caused-28/VBN||falciparum-31/NN	malaria-27||artemether--1||yes||a fixed-dose combination of artemether-lumefantrine (al, coartemâ®) has shown high efficacy, good tolerability and cost-effectiveness in adults and children with uncomplicated malaria caused by plasmodium falciparum .
aux||illustrate-2/VB||to-1/TO	advcl||focused-8/VBN||illustrate-2/VB	det||approach-4/NN||this-3/DT	dobj||illustrate-2/VB||approach-4/NN	nsubj||focused-8/VBN||we-6/PRP	aux||focused-8/VBN||have-7/VBP	root||ROOT-0/null||focused-8/VBN	det||detection-11/NN||the-10/DT	prep_on||focused-8/VBN||detection-11/NN	prep_of||detection-11/NN||viruses-13/NNS	nsubj||cause-15/VBP||viruses-13/NNS	rcmod||viruses-13/NNS||cause-15/VBP	nsubj||using-20/VBG||hemorrhagicfever-16/NN	appos||hemorrhagicfever-16/NN||hf-18/NN	dep||cause-15/VBP||using-20/VBG	det||hf-virus-23/NNS||a-21/DT	nn||hf-virus-23/NNS||custom-22/NN	dobj||using-20/VBG||hf-virus-23/NNS	advmod||using-20/VBG||microarray-24/RB	virus--1||viruses-13||no||to illustrate this approach, we have focused on the detection of viruses that cause hemorrhagicfever (hf) using a custom hf-virus microarray.
num||patient-2/NN||one-1/CD	nsubj||developed-3/VBD||patient-2/NN	root||ROOT-0/null||developed-3/VBD	nn||reactivation-5/NN||hbv-4/NN	dobj||developed-3/VBD||reactivation-5/NN	amod||withdrawal-8/NN||lamivudine-7/JJ	prep_after||developed-3/VBD||withdrawal-8/NN	num||patients-12/NNS||4-11/CD	nsubj||developed-13/VBD||patients-12/NNS	conj_and||developed-3/VBD||developed-13/VBD	det||mutation-19/NN||the-14/DT	amod||mutation-19/NN||ymdd-15/JJ	dep||ymdd-15/JJ||tyrosine-methionine-aspartate-aspartate-17/JJ	dobj||developed-13/VBD||mutation-19/NN	amod||therapy-22/NN||lamivudine-21/JJ	prep_during||developed-13/VBD||therapy-22/NN	hbv-4||lamivudine-21||yes||one patient developed hbv reactivation after lamivudine withdrawal, and 4 patients developed the ymdd (tyrosine-methionine-aspartate-aspartate) mutation during lamivudine therapy.
advmod||show-12/VBP||simultaneously-1/RB	prepc_compared_with||show-12/VBP||with-4/IN	nn||rats-7/NNS||zucker-5/NN	nn||rats-7/NNS||obese-6/NN	pobj||show-12/VBP||rats-7/NNS	det||rats-11/NNS||the-9/DT	nn||rats-11/NNS||gk-10/NN	nsubj||show-12/VBP||rats-11/NNS	root||ROOT-0/null||show-12/VBP	amod||levels-14/NNS||decreased-13/VBN	dobj||show-12/VBP||levels-14/NNS	prep_of||levels-14/NNS||trimethylamine-16/JJ	prep_of||levels-14/NNS||acetate-18/JJ	conj_and||trimethylamine-16/JJ||acetate-18/JJ	prep_of||levels-14/NNS||choline-21/JJ	conj_and||trimethylamine-16/JJ||choline-21/JJ	amod||levels-27/NNS||increased-26/VBN	dobj||show-12/VBP||levels-27/NNS	conj_and||levels-14/NNS||levels-27/NNS	prep_of||levels-27/NNS||creatine/creatinine-29/JJ	prep_of||levels-27/NNS||acetoacetate-31/JJ	conj_and||creatine/creatinine-29/JJ||acetoacetate-31/JJ	prep_of||levels-27/NNS||alanine-33/JJ	conj_and||creatine/creatinine-29/JJ||alanine-33/JJ	prep_of||levels-27/NNS||citrate-35/JJ	conj_and||creatine/creatinine-29/JJ||citrate-35/JJ	prep_of||levels-27/NNS||2-ketoglutarate-37/JJ	conj_and||creatine/creatinine-29/JJ||2-ketoglutarate-37/JJ	prep_of||levels-27/NNS||succinate-39/JJ	conj_and||creatine/creatinine-29/JJ||succinate-39/JJ	prep_of||levels-27/NNS||lactate-41/JJ	conj_and||creatine/creatinine-29/JJ||lactate-41/JJ	prep_of||levels-27/NNS||hippurate-44/JJ	conj_and||creatine/creatinine-29/JJ||hippurate-44/JJ	obese-6||choline-21||no_rel||simultaneously, compared with zucker obese rats, the gk rats show decreased levels of trimethylamine, acetate, and choline, as well as increased levels of creatine/creatinine, acetoacetate, alanine, citrate, 2-ketoglutarate, succinate, lactate, and hippurate.
amod||trials-3/NNS||published-1/VBN	amod||trials-3/NNS||double-blind-2/JJ	nsubj||show-4/VBP||trials-3/NNS	root||ROOT-0/null||show-4/VBP	mark||achieves-12/VBZ||that-5/IN	amod||therapy-7/NN||budesonide/formoterol-6/JJ	nsubj||achieves-12/VBZ||therapy-7/NN	vmod||therapy-7/NN||delivered-8/VBN	amod||fashion-11/NN||smart-10/JJ	prep_in||delivered-8/VBN||fashion-11/NN	ccomp||show-4/VBP||achieves-12/VBZ	amod||outcomes-15/NNS||better-13/JJR	nn||outcomes-15/NNS||asthma-14/NN	dobj||achieves-12/VBZ||outcomes-15/NNS	amod||monotherapy-18/NN||budesonide-17/JJ	prep_than||achieves-12/VBZ||monotherapy-18/NN	amod||doses-21/NNS||lower-20/JJR	prep_than||achieves-12/VBZ||doses-21/NNS	conj_or||monotherapy-18/NN||doses-21/NNS	amod||therapy-24/NN||budesonide/formoterol-23/JJ	prep_of||doses-21/NNS||therapy-24/NN	vmod||therapy-24/NN||delivered-25/VBN	amod||dosage-28/NN||constant-27/JJ	prep_in||delivered-25/VBN||dosage-28/NN	asthma-14||budesonide-17||no||published double-blind trials show that budesonide/formoterol therapy delivered in smart fashion achieves better asthma outcomes than budesonide monotherapy or lower doses of budesonide/formoterol therapy delivered in constant dosage.
mark||analyze-4/VB||in-1/IN	dep||analyze-4/VB||order-2/NN	aux||analyze-4/VB||to-3/TO	advcl||studied-19/VBD||analyze-4/VB	amod||cells-6/NNS||dendritic-5/JJ	dobj||analyze-4/VB||cells-6/NNS	appos||cells-6/NNS||dcs-8/NN	vmod||cells-6/NNS||activation-10/VBN	prep_following||activation-10/VBN||infection-12/NN	amod||strains-16/NNS||different-14/JJ	amod||strains-16/NNS||mycobacterial-15/JJ	prep_with||infection-12/NN||strains-16/NNS	nsubj||studied-19/VBD||we-18/PRP	ccomp||mycobacteriumtuberculosis-36/VBZ||studied-19/VBD	det||profiles-22/NNS||the-20/DT	nn||profiles-22/NNS||expression-21/NN	dobj||studied-19/VBD||profiles-22/NNS	num||genes-25/NNS||165-24/CD	prep_of||profiles-22/NNS||genes-25/NNS	amod||dcs-29/NN||human-27/JJ	amod||dcs-29/NN||monocyte-derived-28/JJ	prep_of||genes-25/NNS||dcs-29/NN	vmod||dcs-29/NN||infected-30/VBN	prep_with||infected-30/VBN||h37rv-32/CD	det||virulent-35/NN||a-34/DT	nsubj||mycobacteriumtuberculosis-36/VBZ||virulent-35/NN	root||ROOT-0/null||mycobacteriumtuberculosis-36/VBZ	dep||mycobacteriumtuberculosis-36/VBZ||mtb-38/NN	nn||strain-41/NN||laboratory-40/NN	dobj||mycobacteriumtuberculosis-36/VBZ||strain-41/NN	dobj||mycobacteriumtuberculosis-36/VBZ||cmt97-43/NNS	conj_and||strain-41/NN||cmt97-43/NNS	det||isolate-48/NN||a-45/DT	amod||isolate-48/NN||clinical-46/JJ	nn||isolate-48/NN||mtb-47/NN	dobj||mycobacteriumtuberculosis-36/VBZ||isolate-48/NN	conj_and||strain-41/NN||isolate-48/NN	amod||bacillus-51/NNS||mycobacteriumbovis-50/JJ	dobj||mycobacteriumtuberculosis-36/VBZ||bacillus-51/NNS	conj_and||strain-41/NN||bacillus-51/NNS	nn||rin-54/NNP||calmette-guã-52/NNP	nn||rin-54/NNP||©-53/NNP	dep||bacillus-51/NNS||rin-54/NNP	appos||rin-54/NNP||bcg-56/NN	amod||pasteur-60/NN||aventis-59/JJ	dobj||mycobacteriumtuberculosis-36/VBZ||pasteur-60/NN	conj_and||strain-41/NN||pasteur-60/NN	nn||japan-64/NN||bcg-63/NN	dobj||mycobacteriumtuberculosis-36/VBZ||japan-64/NN	conj_and||strain-41/NN||japan-64/NN	nsubj||employed-67/VBN||both-66/DT	rcmod||japan-64/NN||employed-67/VBN	prep_as||employed-67/VBN||vaccine-69/NN	prep_against||vaccine-69/NN||tuberculosis-71/NNP	tuberculosis-71||bcg-63||yes||in order to analyze dendritic cells (dcs) activation following infection with different mycobacterial strains, we studied the expression profiles of 165 genes of human monocyte-derived dcs infected with h37rv, a virulent mycobacteriumtuberculosis (mtb) laboratory strain, cmt97, a clinical mtb isolate, mycobacteriumbovis bacillus calmette-guã©rin (bcg), aventis pasteur, and bcg japan, both employed as vaccine against tuberculosis.
nsubj||evident-3/JJ||this-1/DT	cop||evident-3/JJ||was-2/VBD	root||ROOT-0/null||evident-3/JJ	prep_from||evident-3/JJ||inhibition-5/NN	amod||formation-9/NN||estrogen-induced-7/JJ	nn||formation-9/NN||breasttumor-8/NN	prep_of||inhibition-5/NN||formation-9/NN	det||model-13/NN||the-11/DT	amod||model-13/NN||xenograft-12/JJ	prep_in||formation-9/NN||model-13/NN	det||overexpression-16/NN||both-15/DT	prep_by||evident-3/JJ||overexpression-16/NN	prep_of||overexpression-16/NN||catalase-18/NN	prep_by||evident-3/JJ||co-treatment-23/NN	conj_and||overexpression-16/NN||co-treatment-23/NN	prep_with||co-treatment-23/NN||ebselen-25/NN	breasttumor-8||estrogen--1||no||this was evident from inhibition of estrogen-induced breasttumor formation in the xenograft model by both overexpression of catalase as well as by co-treatment with ebselen.
num||specimens-3/NNS||33-2/CD	prep_of||%-27/NN||specimens-3/NNS	amod||results-7/NNS||concurrent-5/JJ	nn||results-7/NNS||dst-6/NN	prep_with||specimens-3/NNS||results-7/NNS	nsubj||%-27/NN||sensitivity-9/NN	det||assay-13/NN||the-11/DT	amod||assay-13/NN||mods-12/JJ	prep_of||sensitivity-9/NN||assay-13/NN	prep_for||assay-13/NN||detection-15/NN	prep_of||detection-15/NN||resistance-17/NN	prep_to||resistance-17/NN||isoniazid-19/NN	prep_to||resistance-17/NN||rifampin-21/NN	conj_and||isoniazid-19/NN||rifampin-21/NN	prep_to||resistance-17/NN||mdr-tb-24/NN	conj_and||isoniazid-19/NN||mdr-tb-24/NN	cop||%-27/NN||was-25/VBD	num||%-27/NN||88-26/CD	root||ROOT-0/null||%-27/NN	num||%-30/NN||95-29/CD	npadvmod||ci-31/JJ||%-30/NN	dep||68â-33/NNS||ci-31/JJ	dep||%-27/NN||68â-33/NNS	dep||%-37/NN||$-34/$	num||$-34/$||97-36/CD	amod||68â-33/NNS||%-37/NN	num||%-41/NN||96-40/CD	conj_and||%-27/NN||%-41/NN	num||%-44/NN||95-43/CD	npadvmod||ci-45/JJ||%-44/NN	dep||79â-47/NNS||ci-45/JJ	dep||%-41/NN||79â-47/NNS	dep||%-51/NN||$-48/$	num||$-48/$||100-50/CD	amod||79â-47/NNS||%-51/NN	num||%-56/NN||91-55/CD	conj_and||%-27/NN||%-56/NN	num||%-59/NN||95-58/CD	npadvmod||ci-60/JJ||%-59/NN	dep||72â-62/NNS||ci-60/JJ	dep||%-56/NN||72â-62/NNS	dep||%-66/NN||$-63/$	num||$-63/$||99-65/CD	amod||72â-62/NNS||%-66/NN	advmod||%-27/NN||respectively-69/RB	nsubj||%-74/NN||specificity-71/NN	cop||%-74/NN||was-72/VBD	num||%-74/NN||89-73/CD	parataxis||%-27/NN||%-74/NN	num||%-77/NN||95-76/CD	npadvmod||ci-78/JJ||%-77/NN	dep||52â-80/NNS||ci-78/JJ	dep||%-74/NN||52â-80/NNS	dep||%-84/NN||$-81/$	num||$-81/$||100-83/CD	amod||52â-80/NNS||%-84/NN	num||%-88/NN||89-87/CD	parataxis||%-27/NN||%-88/NN	conj_and||%-74/NN||%-88/NN	num||%-91/NN||95-90/CD	npadvmod||ci-92/JJ||%-91/NN	dep||52â-94/NNS||ci-92/JJ	dep||%-88/NN||52â-94/NNS	dep||%-98/NN||$-95/$	num||$-95/$||100-97/CD	amod||52â-94/NNS||%-98/NN	num||%-103/NN||90-102/CD	parataxis||%-27/NN||%-103/NN	conj_and||%-74/NN||%-103/NN	num||%-106/NN||95-105/CD	npadvmod||ci-107/JJ||%-106/NN	dep||56â-109/NNS||ci-107/JJ	dep||%-103/NN||56â-109/NNS	dep||%-113/NN||$-110/$	num||$-110/$||100-112/CD	amod||56â-109/NNS||%-113/NN	advmod||%-74/NN||respectively-116/RB	tb--1||isoniazid-19||yes||of 33 specimens with concurrent dst results, sensitivity of the mods assay for detection of resistance to isoniazid, rifampin, and mdr-tb was 88% (95% ci, 68â97%), 96% (95% ci, 79â100%), and 91% (95% ci, 72â99%), respectively; specificity was 89% (95% ci, 52â100%), 89% (95% ci, 52â100%), and 90% (95% ci, 56â100%), respectively.
nsubj||assists-10/VBZ||sitagliptin-1/NN	det||inhibitor-4/NN||an-3/DT	appos||sitagliptin-1/NN||inhibitor-4/NN	det||ddp-4-8/NN||the-6/DT	amod||ddp-4-8/NN||enzyme-7/JJ	prep_of||inhibitor-4/NN||ddp-4-8/NN	root||ROOT-0/null||assists-10/VBZ	dobj||assists-10/VBZ||patients-11/NNS	prep_with||assists-10/VBZ||type2diabetesmellitus-13/CD	aux||achieve-15/VB||to-14/TO	vmod||assists-10/VBZ||achieve-15/VB	amod||control-17/NN||glycemic-16/JJ	dobj||achieve-15/VB||control-17/NN	type2diabetesmellitus-13||sitagliptin-1||yes||sitagliptin, an inhibitor of the enzyme ddp-4, assists patients with type2diabetesmellitus to achieve glycemic control.
det||injection-3/NN||a-1/DT	amod||injection-3/NN||single-2/JJ	nsubj||sufficient-10/JJ||injection-3/NN	nsubj||inhibit-12/VB||injection-3/NN	num||precursor-8/NN||0.5-5/CD	amod||precursor-8/NN||nm-6/JJ	amod||precursor-8/NN||mir-200b-7/JJ	prep_of||injection-3/NN||precursor-8/NN	cop||sufficient-10/JJ||was-9/VBD	root||ROOT-0/null||sufficient-10/JJ	aux||inhibit-12/VB||to-11/TO	xcomp||sufficient-10/JJ||inhibit-12/VB	det||increase-14/NN||the-13/DT	nsubj||i-18/JJ||increase-14/NN	nsubj||iii-20/JJ||increase-14/NN	nsubj||fibronectin-22/JJ||increase-14/NN	nn||types-17/NNS||collagen-16/NN	prep_of||increase-14/NN||types-17/NNS	xcomp||inhibit-12/VB||i-18/JJ	xcomp||inhibit-12/VB||iii-20/JJ	conj_and||i-18/JJ||iii-20/JJ	xcomp||inhibit-12/VB||fibronectin-22/JJ	conj_and||i-18/JJ||fibronectin-22/JJ	amod||kidneys-25/NNS||obstructed-24/VBN	prep_in||inhibit-12/VB||kidneys-25/NNS	nsubjpass||confirmed-32/VBN||amelioration-28/NN	prep_of||amelioration-28/NN||fibrosis-30/NN	auxpass||confirmed-32/VBN||was-31/VBD	conj_and||sufficient-10/JJ||confirmed-32/VBN	agent||confirmed-32/VBN||observation-34/NN	det||kidneys-37/NNS||the-36/DT	prep_of||observation-34/NN||kidneys-37/NNS	nn||staining-40/NN||azan-39/NN	prep_with||confirmed-32/VBN||staining-40/NN	nm-6||fibrosis-30||no_rel||a single injection of 0.5 nm mir-200b precursor was sufficient to inhibit the increase of collagen types i, iii and fibronectin in obstructed kidneys, and amelioration of fibrosis was confirmed by observation of the kidneys with azan staining.
nsubjpass||used-8/VBN||supplementation-1/NN	nsubj||treat-10/VB||supplementation-1/NN	prep_of||supplementation-1/NN||l-3/NN	dep||l-3/NN||arginine-5/NN	aux||used-8/VBN||has-6/VBZ	auxpass||used-8/VBN||been-7/VBN	ccomp||caused-27/VBD||used-8/VBN	aux||treat-10/VB||to-9/TO	xcomp||used-8/VBN||treat-10/VB	dobj||treat-10/VB||melas-11/NNS	amod||encephalopathy-14/NN||mitochondrial-13/JJ	dep||melas-11/NNS||encephalopathy-14/NN	amod||acidosis-17/NNS||lactic-16/JJ	prep_with||encephalopathy-14/NN||acidosis-17/NNS	dep||melas-11/NNS||stroke-19/NN	conj_and||encephalopathy-14/NN||stroke-19/NN	prep_like||stroke-19/NN||syndrome-21/NN	det||disease-26/NN||a-24/DT	amod||disease-26/NN||mitochondrial-25/JJ	nsubj||caused-27/VBD||disease-26/NN	root||ROOT-0/null||caused-27/VBD	det||mutation-34/NN||the-29/DT	amod||mutation-34/NN||m.-30/JJ	amod||mutation-34/NN||3243a-31/JJ	nn||mutation-34/NN||>-32/NN	nn||mutation-34/NN||g-33/NN	prep_by||caused-27/VBD||mutation-34/NN	acidosis-17||arginine-5||yes||supplementation of l -arginine has been used to treat melas (mitochondrial encephalopathy with lactic acidosis and stroke like syndrome), a mitochondrial disease caused by the m.3243a>g mutation.
nsubj||identified-3/VBD||we-1/PRP	nsubj||characterized-5/VBD||we-1/PRP	advmod||identified-3/VBD||also-2/RB	root||ROOT-0/null||identified-3/VBD	conj_and||identified-3/VBD||characterized-5/VBD	det||lineage-11/NN||a-6/DT	amod||lineage-11/NN||v.cholerae-7/JJ	amod||lineage-11/NN||non-o1-8/JJ	amod||lineage-11/NN||/-9/JJ	amod||lineage-11/NN||non-o139-10/JJ	dobj||characterized-5/VBD||lineage-11/NN	amod||cases-15/NNS||cholera-like-13/JJ	nn||cases-15/NNS||diarrhea-14/NN	prep_from||lineage-11/NN||cases-15/NNS	prep_in||characterized-5/VBD||nigeria-17/NN	cholera--1||v.cholerae-7||no||we also identified and characterized a v.cholerae non-o1 / non-o139 lineage from cholera-like diarrhea cases in nigeria .
nsubj||tested-2/VBD||we-1/PRP	root||ROOT-0/null||tested-2/VBD	det||hypothesis-4/NNS||the-3/DT	dobj||tested-2/VBD||hypothesis-4/NNS	mark||suppresses-21/VBZ||that-5/IN	det||increase-7/NN||an-6/DT	nsubj||suppresses-21/VBZ||increase-7/NN	prep_in||increase-7/NN||insulin-9/NN	nn||se-11/FW||per-10/FW	advmod||insulin-9/NN||se-11/FW	dep||se-11/FW||i.e.-13/CD	det||absence-17/NN||the-16/DT	prep_in||se-11/FW||absence-17/NN	prep_of||absence-17/NN||zinc-19/NN	ccomp||tested-2/VBD||suppresses-21/VBZ	nn||secretion-23/NN||glucagon-22/NN	dobj||suppresses-21/VBZ||secretion-23/NN	prep_during||suppresses-21/VBZ||euglycemia-25/NN	mark||stimulates-34/VBZ||that-27/IN	det||decrease-29/NN||a-28/DT	nsubj||stimulates-34/VBZ||decrease-29/NN	prep_in||decrease-29/NN||insulin-31/NN	nn||se-33/FW||per-32/FW	advmod||stimulates-34/VBZ||se-33/FW	ccomp||tested-2/VBD||stimulates-34/VBZ	conj_and||suppresses-21/VBZ||stimulates-34/VBZ	nn||secretion-36/NN||glucagon-35/NN	dobj||stimulates-34/VBZ||secretion-36/NN	prep_during||stimulates-34/VBZ||hypoglycemia-38/NN	prep_in||hypoglycemia-38/NN||humans-40/NNS	hypoglycemia-38||glucagon-35||yes||we tested the hypothesis that an increase in insulin per se, i.e., in the absence of zinc, suppresses glucagon secretion during euglycemia and that a decrease in insulin per se stimulates glucagon secretion during hypoglycemia in humans.
det||study-6/NN||the-1/DT	amod||study-6/NN||alpha-tocopherol-2/JJ	amod||study-6/NN||beta-carotene-3/JJ	nn||study-6/NN||cancer-4/NN	nn||study-6/NN||prevention-5/NN	nsubj||examined-7/VBD||study-6/NN	root||ROOT-0/null||examined-7/VBD	det||effects-9/NNS||the-8/DT	dobj||examined-7/VBD||effects-9/NNS	amod||carotene-22/NN||vitamine-11/JJ	num||mg-14/NN||50-13/CD	dep||vitamine-11/JJ||mg-14/NN	prep_per||mg-14/NN||day-16/NN	npadvmod||²-20/JJ||î-19/NN	conj_and||vitamine-11/JJ||²-20/JJ	amod||carotene-22/NN||²-20/JJ	prep_of||effects-9/NNS||carotene-22/NN	num||mg-25/NN||20-24/CD	dep||carotene-22/NN||mg-25/NN	prep_per||mg-25/NN||day-27/NN	nn||cancer-31/NN||lung-30/NN	prep_on||examined-7/VBD||cancer-31/NN	num||smokers-35/NNS||29,133-33/CD	amod||smokers-35/NNS||male-34/JJ	prep_in||cancer-31/NN||smokers-35/NNS	vmod||smokers-35/NNS||aged-36/VBN	xcomp||aged-36/VBN||50â-37/VBG	num||years-41/NNS||$-38/$	num||$-38/$||69-40/CD	tmod||50â-37/VBG||years-41/NNS	vmod||50â-37/VBG||using-42/VBG	det||ã-45/NN||a-43/DT	num||ã-45/NN||2-44/CD	dobj||using-42/VBG||ã-45/NN	num||design-49/NN||2-47/CD	amod||design-49/NN||factorial-48/JJ	dep||ã-45/NN||design-49/NN	cancer-31||carotene-22||no_rel||the alpha-tocopherol beta-carotene cancer prevention study examined the effects of vitamine (50 mg per day) and î²-carotene (20 mg per day) on lung cancer in 29,133 male smokers aged 50â69 years using a 2 ã 2 factorial design.
amod||sensitivities-2/NNS||analytical-1/JJ	nsubj||reduce-10/VB||sensitivities-2/NNS	prep_for||sensitivities-2/NNS||hbsag-4/NN	number||1-7/CD||>-6/CD	num||iu/ml-8/NN||1-7/CD	prep_of||hbsag-4/NN||iu/ml-8/NN	advmod||reduce-10/VB||significantly-9/RB	root||ROOT-0/null||reduce-10/VB	det||length-12/NN||the-11/DT	dobj||reduce-10/VB||length-12/NN	det||period-17/NN||the-14/DT	amod||period-17/NN||hbsag-15/JJ	amod||period-17/NN||positive-16/JJ	prep_of||length-12/NN||period-17/NN	nsubj||renders-19/VBZ||period-17/NN	rcmod||period-17/NN||renders-19/VBZ	nsubj||reliable-22/JJ||them-20/PRP	advmod||reliable-22/JJ||less-21/RBR	xcomp||renders-19/VBZ||reliable-22/JJ	prepc_for||renders-19/VBZ||detecting-24/VBG	vmod||detecting-24/VBG||hbsag-25/VBG	amod||infections-29/NNS||asymptomatic-27/JJ	nn||infections-29/NNS||hbv-28/NN	prep_in||hbsag-25/VBG||infections-29/NNS	hbv-28||hbsag-25||yes||analytical sensitivities for hbsag of >1 iu/ml significantly reduce the length of the hbsag positive period which renders them less reliable for detecting hbsag in asymptomatic hbv infections.
det||mycobacteria-3/NN||the-1/DT	amod||mycobacteria-3/NN||recombinant-2/JJ	nsubj||grew-4/VBD||mycobacteria-3/NN	nsubj||sensitive-10/JJ||mycobacteria-3/NN	root||ROOT-0/null||grew-4/VBD	prep_in||grew-4/VBD||length-6/NN	cop||sensitive-10/JJ||were-8/VBD	advmod||sensitive-10/JJ||more-9/RBR	conj_and||grew-4/VBD||sensitive-10/JJ	num||drugs-14/NNS||two-12/CD	amod||drugs-14/NNS||anti-tuberculosis-13/JJ	prep_to||sensitive-10/JJ||drugs-14/NNS	vmod||drugs-14/NNS||isoniazid-16/VBN	vmod||drugs-14/NNS||streptomycin-18/VBN	conj_and||isoniazid-16/VBN||streptomycin-18/VBN	tuberculosis--1||isoniazid-16||yes||the recombinant mycobacteria grew in length and were more sensitive to two anti-tuberculosis drugs, isoniazid and streptomycin.
amod||conjugates-4/NNS||vivo-2/JJ	nn||conjugates-4/NNS||antibody-3/NN	prep_in||caused-5/VBD||conjugates-4/NNS	root||ROOT-0/null||caused-5/VBD	dobj||caused-5/VBD||suppression-6/NN	amod||growth-11/NN||human-8/JJ	nn||growth-11/NN||lovo-9/NN	nn||growth-11/NN||tumour-10/NN	prep_of||suppression-6/NN||growth-11/NN	amod||nih-14/NN||immunodeficient-13/JJ	prep_in||caused-5/VBD||nih-14/NN	nn||mice-16/NNS||iii-15/NN	nsubj||caused-5/VBD||mice-16/NNS	amod||doses-35/NNS||similar-18/JJ	det||therapy-23/NN||the-20/DT	amod||therapy-23/NN||commercial-21/JJ	amod||therapy-23/NN||photodynamic-22/JJ	prep_to||similar-18/JJ||therapy-23/NN	appos||therapy-23/NN||pdt-25/NN	nn||doses-35/NNS||agent-27/NN	amod||doses-35/NNS||photofrinâ-28/JJ	amod||doses-35/NNS||®-29/JJ	conj_but||®-29/JJ||at-32/IN	amod||doses-35/NNS||at-32/IN	amod||doses-35/NNS||administered-33/JJ	nn||doses-35/NNS||photosensitizer-34/NN	appos||mice-16/NNS||doses-35/NNS	nsubj||lower-44/JJR||doses-35/NNS	cop||lower-44/JJR||were-37/VBD	mwe||than-39/IN||more-38/JJR	quantmod||two-40/CD||than-39/IN	num||orders-41/NNS||two-40/CD	npadvmod||lower-44/JJR||orders-41/NNS	prep_of||orders-41/NNS||magnitude-43/NN	rcmod||doses-35/NNS||lower-44/JJR	photosensitizer-34||tumour-10||no_rel||in vivo antibody conjugates caused suppression of human lovo tumour growth in immunodeficient nih iii mice, similar to the commercial photodynamic therapy (pdt) agent photofrinâ®, but at administered photosensitizer doses that were more than two orders of magnitude lower.
nn||caregivers-2/NNS||volunteer-1/NN	nsubj||source-6/NN||caregivers-2/NNS	cop||source-6/NN||are-3/VBP	det||source-6/NN||a-4/DT	amod||source-6/NN||critical-5/JJ	root||ROOT-0/null||source-6/NN	prep_of||source-6/NN||support-8/NN	det||majority-11/NN||the-10/DT	prep_for||support-8/NN||majority-11/NN	prep_of||majority-11/NN||people-13/NNS	vmod||people-13/NNS||living-14/VBG	prep_with||living-14/VBG||hiv-16/NN	prep_with||living-14/VBG||aids-18/NNS	conj_and||hiv-16/NN||aids-18/NNS	amod||africa-21/NN||southern-20/JJ	prep_in||living-14/VBG||africa-21/NN	nsubj||has-24/VBZ||africa-21/NN	rcmod||africa-21/NN||has-24/VBZ	advmod||high-26/JJ||extremely-25/RB	amod||rates-29/NNS||high-26/JJ	amod||rates-29/NNS||hiv/aids-27/JJ	nn||rates-29/NNS||prevalence-28/NN	dobj||has-24/VBZ||rates-29/NNS	aids-18||hiv-16||no||volunteer caregivers are a critical source of support for the majority of people living with hiv and aids in southern africa, which has extremely high hiv/aids prevalence rates.
nn||syndrome-3/NN||introduction-1/NN	nn||syndrome-3/NN||brugada-2/NN	nsubjpass||associated-8/VBN||syndrome-3/NN	appos||syndrome-3/NN||brs-5/NN	auxpass||associated-8/VBN||is-7/VBZ	root||ROOT-0/null||associated-8/VBN	prep_with||associated-8/VBN||loss-10/NN	aux||+-13/VB||na-12/TO	prep_of||loss-10/NN||+-13/VB	nn||function-15/NN||channel-14/NN	dobj||+-13/VB||function-15/NN	amod||risks-18/NNS||increased-17/VBN	prep_of||loss-10/NN||risks-18/NNS	conj_and||+-13/VB||risks-18/NNS	det||ventriculartachycardia-21/NN||a-20/DT	prep_of||risks-18/NNS||ventriculartachycardia-21/NN	dep||ventriculartachycardia-21/NN||exacerbated-22/VBN	prep_by||exacerbated-22/VBN||flecainide-24/NN	dep||ventriculartachycardia-21/NN||reduced-26/VBN	conj_but||exacerbated-22/VBN||reduced-26/VBN	prep_by||reduced-26/VBN||quinidine-28/NN	ventriculartachycardia-21||flecainide-24||yes||introduction brugada syndrome (brs) is associated with loss of na+ channel function and increased risks of a ventriculartachycardia exacerbated by flecainide but reduced by quinidine.
mark||performed-6/VBN||although-1/IN	amod||studies-3/NNS||many-2/JJ	nsubjpass||performed-6/VBN||studies-3/NNS	aux||performed-6/VBN||have-4/VBP	auxpass||performed-6/VBN||been-5/VBN	advcl||known-26/VBN||performed-6/VBN	prep_on||performed-6/VBN||efficacy-8/NN	prep_on||performed-6/VBN||tolerability-10/NN	conj_and||efficacy-8/NN||tolerability-10/NN	det||arthemeter-lumefantrine-14/NN||the-12/DT	nn||arthemeter-lumefantrine-14/NN||combination-13/NN	prep_of||efficacy-8/NN||arthemeter-lumefantrine-14/NN	appos||arthemeter-lumefantrine-14/NN||al-16/NNP	prep_of||efficacy-8/NN||dihydroartemisinin-piperaquine-19/NN	conj_or||arthemeter-lumefantrine-14/NN||dihydroartemisinin-piperaquine-19/NN	appos||arthemeter-lumefantrine-14/NN||dp-21/NN	nsubjpass||known-26/VBN||less-24/JJR	auxpass||known-26/VBN||is-25/VBZ	root||ROOT-0/null||known-26/VBN	det||effect-29/NN||the-28/DT	prep_of||known-26/VBN||effect-29/NN	det||drugs-32/NNS||these-31/DT	prep_of||effect-29/NN||drugs-32/NNS	amod||development-35/NN||gametocyte-34/JJ	prep_on||known-26/VBN||development-35/NN	nsubj||issue-41/NN||development-35/NN	cop||issue-41/NN||is-38/VBZ	det||issue-41/NN||an-39/DT	amod||issue-41/NN||important-40/JJ	rcmod||development-35/NN||issue-41/NN	nn||control-44/NN||malaria-43/NN	prep_in||issue-41/NN||control-44/NN	malaria-43||lumefantrine--1||yes||although many studies have been performed on efficacy and tolerability of the combination arthemeter-lumefantrine (al) or dihydroartemisinin-piperaquine (dp), less is known of the effect of these drugs on gametocyte development, which is an important issue in malaria control.
nsubj||endocrinedisease-5/NN||endogenous-1/NNS	advmod||endocrinedisease-5/NN||cushingsyndrome-2/RB	cop||endocrinedisease-5/NN||is-3/VBZ	det||endocrinedisease-5/NN||an-4/DT	root||ROOT-0/null||endocrinedisease-5/NN	vmod||endocrinedisease-5/NN||caused-6/VBN	amod||secretion-9/NN||excessive-8/JJ	agent||caused-6/VBN||secretion-9/NN	nn||hormone-12/NN||adrenocorticotropin-11/NN	prep_of||secretion-9/NN||hormone-12/NN	quantmod||80-15/CD||approximately-14/RB	num||%-16/NN||80-15/CD	prep_in||caused-6/VBN||%-16/NN	prep_of||%-16/NN||cases-18/NNS	advmod||caused-6/VBN||usually-20/RB	det||adenoma-25/NN||a-22/DT	advmod||corticotroph-24/JJ||pituitary-23/RB	amod||adenoma-25/NN||corticotroph-24/JJ	agent||caused-6/VBN||adenoma-25/NN	amod||-RSB--30/NNP||cushingdisease-27/JJ	nn||-RSB--30/NNP||-LSB--28/NNP	nn||-RSB--30/NNP||cd-29/NN	appos||adenoma-25/NN||-RSB--30/NNP	cd-29||cushingdisease-27||no_rel||endogenous cushingsyndrome is an endocrinedisease caused by excessive secretion of adrenocorticotropin hormone in approximately 80% of cases, usually by a pituitary corticotroph adenoma (cushingdisease [cd]).
nn||detemir-2/NN||insulin-1/NN	nsubj||appears-3/VBZ||detemir-2/NN	nsubj||provide-5/VB||detemir-2/NN	root||ROOT-0/null||appears-3/VBZ	aux||provide-5/VB||to-4/TO	xcomp||appears-3/VBZ||provide-5/VB	advmod||glycemic-7/JJ||better-6/RBR	amod||control-8/NN||glycemic-7/JJ	dobj||provide-5/VB||control-8/NN	det||risk-12/NN||a-10/DT	amod||risk-12/NN||lower-11/JJR	prep_with||provide-5/VB||risk-12/NN	prep_of||risk-12/NN||hypoglycemia-14/NN	amod||gain-18/NN||less-16/JJR	nn||gain-18/NN||weight-17/NN	prep_with||provide-5/VB||gain-18/NN	conj_and||risk-12/NN||gain-18/NN	det||treatment-21/NN||the-20/DT	prep_in||gain-18/NN||treatment-21/NN	prep_of||treatment-21/NN||patients-23/NNS	prep_with||provide-5/VB||type-25/NN	num||type-25/NN||1-26/CD	prep_with||provide-5/VB||type2diabetes-28/NNS	conj_and||type-25/NN||type2diabetes-28/NNS	type2diabetes-28||insulin-1||yes||insulin detemir appears to provide better glycemic control with a lower risk of hypoglycemia and less weight gain in the treatment of patients with type 1 and type2diabetes.
advmod||was-9/VBD||therefore-1/RB	det||aim-4/NN||the-3/DT	nsubj||was-9/VBD||aim-4/NN	nsubj||evaluate-11/VB||aim-4/NN	det||study-8/NN||the-6/DT	amod||study-8/NN||present-7/JJ	prep_of||aim-4/NN||study-8/NN	root||ROOT-0/null||was-9/VBD	aux||evaluate-11/VB||to-10/TO	xcomp||was-9/VBD||evaluate-11/VB	det||response-15/NN||the-12/DT	amod||response-15/NN||ifn-î-13/JJ	amod||response-15/NN||³-14/JJ	dobj||evaluate-11/VB||response-15/NN	amod||hbha-18/NN||methylated-17/JJ	prep_to||evaluate-11/VB||hbha-18/NN	prep_of||hbha-18/NN||mtb-20/NN	vmod||mtb-20/NN||produced-21/VBN	nn||smegmatis-24/NNS||m.-23/NN	prep_in||produced-21/VBN||smegmatis-24/NNS	num||rhbhams-26/NNS||-lrb--25/CD	npadvmod||-rrb--27/JJ||rhbhams-26/NNS	amod||smegmatis-24/NNS||-rrb--27/JJ	prep_in||produced-21/VBN||individuals-29/NNS	nsubj||scored-36/VBD||individuals-29/NNS	amod||stages-32/NNS||different-31/JJ	prep_at||individuals-29/NNS||stages-32/NNS	prep_of||stages-32/NNS||tb-34/NN	rcmod||individuals-29/NNS||scored-36/VBD	acomp||scored-36/VBD||positive-37/JJ	aux||qft-it-39/VB||to-38/TO	xcomp||positive-37/JJ||qft-it-39/VB	tb-34||mtb-20||no||therefore , the aim of the present study was to evaluate the ifn-î ³ response to methylated hbha of mtb produced in m. smegmatis -lrb- rhbhams -rrb- in individuals at different stages of tb who scored positive to qft-it .
nn||injection-2/NN||lps-1/NN	root||ROOT-0/null||injection-2/NN	vmod||injection-2/NN||induced-3/VBN	det||increase-6/NN||a-4/DT	amod||increase-6/NN||rapid-5/JJ	dobj||induced-3/VBN||increase-6/NN	nn||concentrations-9/NNS||plasma-8/NN	prep_in||increase-6/NN||concentrations-9/NNS	amod||metabolites-12/NNS||nitricoxide-11/JJ	prep_of||concentrations-9/NNS||metabolites-12/NNS	amod||concentrations-9/NNS||nitrite-14/JJ	amod||concentrations-9/NNS||nitrate-16/JJ	conj_and||nitrite-14/JJ||nitrate-16/JJ	appos||concentrations-9/NNS||nom-18/NN	amod||acidâ-23/NNS||thiobarbituric-22/JJ	dobj||induced-3/VBN||acidâ-23/NNS	conj_and||increase-6/NN||acidâ-23/NNS	dep||acidâ-23/NNS||$-24/$	advmod||substances-27/RB||reacting-26/RB	dep||generation-41/CD||substances-27/RB	pobj||substances-27/RB||tbars-29/NN	det||increase-33/NN||an-32/DT	appos||tbars-29/NN||increase-33/NN	amod||species-37/NNS||reactive-35/JJ	nn||species-37/NNS||oxygen-36/NN	prep_in||increase-33/NN||species-37/NNS	appos||species-37/NNS||ros-39/NN	num||$-24/$||generation-41/CD	nn||leukocytes-44/NNS||polymorphonuclear-43/NN	agent||induced-3/VBN||leukocytes-44/NNS	dep||injection-2/NN||pmnls-46/NNS	amod||increases-51/NNS||marked-50/VBN	conj_and||injection-2/NN||increases-51/NNS	amod||fattyacids-55/NNS||plasma-53/JJ	amod||fattyacids-55/NNS||free-54/JJ	prep_in||increases-51/NNS||fattyacids-55/NNS	nn||necrosis-58/NNS||tumor-57/NN	appos||fattyacids-55/NNS||necrosis-58/NNS	nn||±-60/NNP||factor-î-59/NNP	dep||injection-2/NN||±-60/NNP	nn||±-63/NNP||tnf-î-62/NNP	appos||±-60/NNP||±-63/NNP	dep||injection-2/NN||interleukin-6-66/JJ	conj_and||±-60/NNP||interleukin-6-66/JJ	dep||interleukin-6-66/JJ||il-6-68/JJ	amod||protein-1-73/NN||monocyte-71/JJ	nn||protein-1-73/NN||chemoattractant-72/NN	dep||injection-2/NN||protein-1-73/NN	conj_and||±-60/NNP||protein-1-73/NN	dep||protein-1-73/NN||mcp-1-75/JJ	amod||factor-81/NN||macrophage-78/JJ	nn||factor-81/NN||migration-79/NN	nn||factor-81/NN||inhibition-80/NN	appos||protein-1-73/NN||factor-81/NN	appos||factor-81/NN||mif-83/NN	amod||protein-87/NN||c-reactive-86/JJ	appos||protein-1-73/NN||protein-87/NN	appos||protein-87/NN||resistin-89/NN	vmod||protein-1-73/NN||visfatin-91/VBN	nn||protein-95/NN||lipopolysaccharide-93/NN	amod||protein-95/NN||binding-94/VBG	appos||protein-1-73/NN||protein-95/NN	appos||protein-95/NN||lbp-97/NN	advmod||group-b1-102/JJ||high-100/RB	advmod||group-b1-102/JJ||mobility-101/RB	dep||injection-2/NN||group-b1-102/JJ	amod||±-60/NNP||group-b1-102/JJ	conj_and||±-60/NNP||group-b1-102/JJ	dep||group-b1-102/JJ||hmg-b1-104/JJ	nn||concentrations-109/NNS||myoglobin-108/NN	dep||injection-2/NN||concentrations-109/NNS	conj_and||±-60/NNP||concentrations-109/NNS	nitricoxide-11||tumor-57||no_rel||lps injection induced a rapid increase in plasma concentrations of nitricoxide metabolites, nitrite and nitrate (nom), and thiobarbituric acidâreacting substances (tbars), an increase in reactive oxygen species (ros) generation by polymorphonuclear leukocytes (pmnls), and marked increases in plasma free fattyacids, tumor necrosis factor-î± (tnf-î±), interleukin-6 (il-6), monocyte chemoattractant protein-1 (mcp-1), macrophage migration inhibition factor (mif), c-reactive protein, resistin, visfatin, lipopolysaccharide binding protein (lbp), high mobility group-b1 (hmg-b1), and myoglobin concentrations.
nn||detemir-2/NN||insulin-1/NN	nsubj||analog-7/NN||detemir-2/NN	cop||analog-7/NN||is-3/VBZ	det||analog-7/NN||a-4/DT	amod||analog-7/NN||basal-5/JJ	nn||analog-7/NN||insulin-6/NN	root||ROOT-0/null||analog-7/NN	nsubj||provides-9/VBZ||analog-7/NN	rcmod||analog-7/NN||provides-9/VBZ	amod||options-12/NNS||effective-10/JJ	amod||options-12/NNS||therapeutic-11/JJ	dobj||provides-9/VBZ||options-12/NNS	prep_for||options-12/NNS||patients-14/NNS	prep_with||patients-14/NNS||type-16/NN	num||type-16/NN||1-17/CD	prep_with||patients-14/NNS||type2diabetes-19/NNS	conj_and||type-16/NN||type2diabetes-19/NNS	type2diabetes-19||insulin-6||yes||insulin detemir is a basal insulin analog that provides effective therapeutic options for patients with type 1 and type2diabetes.
advmod||diagnosed-3/JJ||newly-2/RB	amod||patients-4/NNS||diagnosed-3/JJ	prep_in||documented-31/VBN||patients-4/NNS	prep_with||patients-4/NNS||hodgkinlymphoma-6/NN	dep||documented-31/VBN||hl-8/VB	det||effect-11/NN||the-10/DT	nsubjpass||documented-31/VBN||effect-11/NN	prep_of||effect-11/NN||doxorubicin-13/NN	prep_of||effect-11/NN||bleomycin-15/NN	conj_and||doxorubicin-13/NN||bleomycin-15/NN	prep_of||effect-11/NN||vinblastine-17/NN	conj_and||doxorubicin-13/NN||vinblastine-17/NN	prep_of||effect-11/NN||dacarbazine-19/NN	conj_and||doxorubicin-13/NN||dacarbazine-19/NN	dep||doxorubicin-13/NN||abvd-21/VBN	amod||neutropenia-25/NN||related-24/VBN	dep||doxorubicin-13/NN||neutropenia-25/NN	amod||delivery-28/NN||chemotherapy-27/JJ	prep_on||neutropenia-25/NN||delivery-28/NN	auxpass||documented-31/VBN||is-29/VBZ	advmod||documented-31/VBN||poorly-30/RB	root||ROOT-0/null||documented-31/VBN	hl-8||vinblastine-17||yes||in newly diagnosed patients with hodgkinlymphoma (hl) the effect of doxorubicin, bleomycin, vinblastine and dacarbazine (abvd)-related neutropenia on chemotherapy delivery is poorly documented.
amod||acid-2/NN||tauroursodeoxycholic-1/JJ	nsubjpass||used-16/VBN||acid-2/NN	nsubj||study-18/VB||acid-2/NN	appos||acid-2/NN||tudca-4/NNP	det||chaperone-9/NN||a-7/DT	amod||chaperone-9/NN||chemical-8/JJ	appos||acid-2/NN||chaperone-9/NN	nsubj||alleviates-11/VBZ||chaperone-9/NN	rcmod||chaperone-9/NN||alleviates-11/VBZ	nn||stress-13/NN||er-12/NN	dobj||alleviates-11/VBZ||stress-13/NN	auxpass||used-16/VBN||was-15/VBD	root||ROOT-0/null||used-16/VBN	aux||study-18/VB||to-17/TO	xcomp||used-16/VBN||study-18/VB	det||mechanism-20/NN||the-19/DT	dobj||study-18/VB||mechanism-20/NN	vmod||mechanism-20/NN||underlying-21/VBG	amod||downregulation-24/NN||obesity-induced-22/JJ	nn||downregulation-24/NN||adiponectin-23/NN	dobj||underlying-21/VBG||downregulation-24/NN	amod||mice-27/NNS||db/db-26/JJ	prep_in||underlying-21/VBG||mice-27/NNS	amod||mice-32/NNS||high-fat-29/JJ	amod||mice-32/NNS||diet-induced-30/JJ	nn||mice-32/NNS||obese-31/NN	appos||mice-27/NNS||mice-32/NNS	amod||adipocytes-38/NNS||er-stressed-36/JJ	amod||adipocytes-38/NNS||3t3-l1-37/JJ	prep_in||underlying-21/VBG||adipocytes-38/NNS	conj_and||mice-27/NNS||adipocytes-38/NNS	fat--1||obese-31||no_rel||tauroursodeoxycholic acid (tudca), a chemical chaperone that alleviates er stress, was used to study the mechanism underlying obesity-induced adiponectin downregulation in db/db mice, high-fat diet-induced obese mice, and in er-stressed 3t3-l1 adipocytes.
det||ratio-4/NN||the-2/DT	nn||ratio-4/NN||benefit/risk-3/NN	prep_in||be-21/VB||ratio-4/NN	det||use-7/NN||the-6/DT	nsubj||be-21/VB||use-7/NN	nn||unsaponifiables-17/NNS||chondroitinsulfate-9/NN	prep_of||use-7/NN||diacereine-11/NN	conj_and||unsaponifiables-17/NNS||diacereine-11/NN	prep_of||use-7/NN||glucosamine-13/NN	conj_and||unsaponifiables-17/NNS||glucosamine-13/NN	nn||unsaponifiables-17/NNS||sulfate-14/NN	prep_of||use-7/NN||avocado/soybean-16/NN	conj_and||unsaponifiables-17/NNS||avocado/soybean-16/NN	prep_of||use-7/NN||unsaponifiables-17/NNS	prep_of||use-7/NN||hyaluronicacid-19/NN	conj_and||unsaponifiables-17/NNS||hyaluronicacid-19/NN	aux||be-21/VB||could-20/MD	root||ROOT-0/null||be-21/VB	amod||interest-24/NN||potential-23/JJ	prep_of||be-21/VB||interest-24/NN	det||management-28/NN||the-26/DT	amod||management-28/NN||symptomatic-27/JJ	prep_for||be-21/VB||management-28/NN	prep_of||management-28/NN||oa-30/NN	oa-30||glucosamine-13||yes||in the benefit/risk ratio, the use of chondroitinsulfate, diacereine, glucosamine sulfate, avocado/soybean unsaponifiables and hyaluronicacid could be of potential interest for the symptomatic management of oa.
det||combination-3/NN||the-1/DT	amod||combination-3/NN||budesonide/formoterol-2/JJ	nsubjpass||used-6/VBN||combination-3/NN	auxpass||used-6/VBN||is-4/VBZ	advmod||used-6/VBN||successfully-5/RB	root||ROOT-0/null||used-6/VBN	amod||relief-9/NN||fast-8/JJ	prep_for||used-6/VBN||relief-9/NN	nn||symptoms-12/NNS||asthma-11/NN	prep_of||relief-9/NN||symptoms-12/NNS	prep_in||symptoms-12/NNS||addition-14/NN	poss||use-17/NN||its-16/PRP$	prep_to||used-6/VBN||use-17/NN	nn||therapy-20/NN||maintenance-19/NN	prep_as||used-6/VBN||therapy-20/NN	asthma-11||formoterol--1||no||the budesonide/formoterol combination is successfully used for fast relief of asthma symptoms in addition to its use as maintenance therapy.
advmod||agent-9/NN||therefore-1/RB	nsubj||agent-9/NN||bumetanide-3/NN	cop||agent-9/NN||is-4/VBZ	det||agent-9/NN||a-5/DT	amod||agent-9/NN||promising-6/JJ	amod||agent-9/NN||novel-7/JJ	amod||agent-9/NN||therapeutic-8/JJ	root||ROOT-0/null||agent-9/NN	aux||treat-11/VB||to-10/TO	vmod||agent-9/NN||treat-11/VB	dobj||treat-11/VB||autism-12/NN	autism-12||bumetanide-3||no_rel||therefore, bumetanide is a promising novel therapeutic agent to treat autism.
nsubj||bacterium-7/NN||francisellatularensis-1/NNS	cop||bacterium-7/NN||is-2/VBZ	det||bacterium-7/NN||a-3/DT	amod||bacterium-7/NN||gram-negative-4/JJ	amod||bacterium-7/NN||facultative-5/JJ	nn||bacterium-7/NN||intracellular-6/NN	root||ROOT-0/null||bacterium-7/NN	det||agent-11/NN||the-9/DT	amod||agent-11/NN||causative-10/JJ	conj_and||bacterium-7/NN||agent-11/NN	det||tularemia-16/NN||the-13/DT	amod||tularemia-16/NN||lethal-14/JJ	nn||tularemia-16/NN||disease-15/NN	prep_of||agent-11/NN||tularemia-16/NN	tularemia-16||francisellatularensis-1||no||francisellatularensis is a gram-negative facultative intracellular bacterium and the causative agent of the lethal disease tularemia.
nsubj||multiplies-11/VBZ||francisellatularensis-1/NNS	det||agent-5/NN||the-3/DT	amod||agent-5/NN||etiological-4/JJ	appos||francisellatularensis-1/NNS||agent-5/NN	det||tularemia-9/NN||the-7/DT	nn||tularemia-9/NN||inhalation-8/NN	prep_of||agent-5/NN||tularemia-9/NN	root||ROOT-0/null||multiplies-11/VBZ	det||variety-14/NN||a-13/DT	prep_in||multiplies-11/VBZ||variety-14/NN	amod||cells-18/NNS||cultured-16/JJ	amod||cells-18/NNS||mammalian-17/JJ	prep_of||variety-14/NN||cells-18/NNS	tularemia-9||francisellatularensis-1||no||francisellatularensis , the etiological agent of the inhalation tularemia, multiplies in a variety of cultured mammalian cells.
root||ROOT-0/null||irinotecan-1/VB	nsubj||result-8/VB||cisplatin-3/NN	conj_and||cisplatin-3/NN||paclitaxel-5/NN	nsubj||result-8/VB||paclitaxel-5/NN	conj_plus||cisplatin-3/NN||cisplatin-7/NN	nsubj||result-8/VB||cisplatin-7/NN	ccomp||irinotecan-1/VB||result-8/VB	amod||survival-11/NN||similar-10/JJ	prep_in||result-8/VB||survival-11/NN	advmod||combined-13/VBN||when-12/WRB	advcl||result-8/VB||combined-13/VBN	prep_with||combined-13/VBN||radiotherapy-15/NN	prep_for||radiotherapy-15/NN||esophagealcancer-17/NN	esophagealcancer-17||cisplatin-7||yes||irinotecan plus cisplatin and paclitaxel plus cisplatin result in similar survival when combined with radiotherapy for esophagealcancer.
nsubj||added-2/VBD||aliskiren-1/NN	nsubj||losartan-4/VB||aliskiren-1/NN	nsubj||tolerated-13/JJ||aliskiren-1/NN	root||ROOT-0/null||added-2/VBD	aux||losartan-4/VB||to-3/TO	xcomp||added-2/VBD||losartan-4/VB	amod||albuminuria-6/NN||reduced-5/VBN	dobj||losartan-4/VB||albuminuria-6/NN	amod||dysfunction-9/NN||renal-8/JJ	dobj||losartan-4/VB||dysfunction-9/NN	conj_and||albuminuria-6/NN||dysfunction-9/NN	cop||tolerated-13/JJ||was-11/VBD	advmod||tolerated-13/JJ||well-12/RB	conj_and||added-2/VBD||tolerated-13/JJ	prep_except_for||independent-23/JJ||hyperkalemia-17/NN	appos||hyperkalemia-17/NN||stage-19/NN	num||stage-19/NN||3-20/CD	dep||tolerated-13/JJ||independent-23/JJ	amod||stage-27/NN||baseline-25/JJ	nn||stage-27/NN||ckd-26/NN	prep_of||independent-23/JJ||stage-27/NN	prep_in||stage-27/NN||patients-29/NNS	prep_with||patients-29/NNS||type2diabetes-31/NNS	appos||type2diabetes-31/NNS||hypertension-33/NN	conj_and||added-2/VBD||nephropathy-36/JJ	conj_and||tolerated-13/JJ||nephropathy-36/JJ	hypertension-33||losartan-4||yes||aliskiren added to losartan reduced albuminuria and renal dysfunction and was well tolerated, except for hyperkalemia (stage 3), independent of baseline ckd stage in patients with type2diabetes, hypertension, and nephropathy.
amod||cmv-3/NN||human-2/JJ	prep_unlike||profile-39/VB||cmv-3/NN	appos||cmv-3/NN||hcmv-5/NNP	dep||reduced-12/VBN||whose-8/WP$	nsubjpass||reduced-12/VBN||growth-9/NN	auxpass||reduced-12/VBN||was-10/VBD	advmod||reduced-12/VBN||significantly-11/RB	dep||cmv-3/NN||reduced-12/VBN	advmod||tagged-25/VBN||when-13/WRB	nsubjpass||tagged-25/VBN||ie2-14/NNS	det||homologue-18/NN||the-16/DT	amod||homologue-18/NN||hcmv-17/JJ	dep||ie2-14/NNS||homologue-18/NN	prep_of||homologue-18/NN||ie3-20/NNS	prep_in||ie3-20/NNS||mcmv-22/NNP	auxpass||tagged-25/VBN||was-24/VBD	advcl||reduced-12/VBN||tagged-25/VBN	prep_with||tagged-25/VBN||egfp-27/NN	nsubj||profile-39/VB||mcmvs-29/NNS	prepc_with||mcmvs-29/NNS||ie3â-31/VBG	dobj||ie3â-31/VBG||$-32/$	npadvmod||unchanged-37/RB||egfp-34/NN	num||egfp-34/NN||presented-35/CD	advmod||egfp-34/NN||an-36/DT	dep||replication-38/CD||unchanged-37/RB	num||$-32/$||replication-38/CD	root||ROOT-0/null||profile-39/VB	cmv-3||hcmv-17||no||unlike human cmv (hcmv), whose growth was significantly reduced when ie2 (the hcmv homologue of ie3 in mcmv) was tagged with egfp, mcmvs with ie3âegfp presented an unchanged replication profile.
det||treatment-2/NN||the-1/DT	nsubj||long-10/JJ||treatment-2/NN	nsubjpass||complicated-14/VBN||treatment-2/NN	prep_of||treatment-2/NN||tb-4/NN	cop||long-10/JJ||is-5/VBZ	quantmod||six-8/CD||at-6/IN	mwe||at-6/IN||least-7/JJS	pobj||at-6/IN||least-7/JJS	num||months-9/NNS||six-8/CD	tmod||long-10/JJ||months-9/NNS	root||ROOT-0/null||long-10/JJ	aux||complicated-14/VBN||may-12/MD	auxpass||complicated-14/VBN||be-13/VB	conj_and||long-10/JJ||complicated-14/VBN	det||burden-19/NN||a-16/DT	amod||burden-19/NN||high-17/JJ	nn||burden-19/NN||pill-18/NN	agent||complicated-14/VBN||burden-19/NN	pill-18||tb-4||no_rel||the treatment of tb is at least six months long and may be complicated by a high pill burden.
det||woman-3/NN||a-1/DT	amod||woman-3/NN||75-year-old-2/JJ	nsubj||developed-10/VBD||woman-3/NN	amod||adenocarcinoma-6/NN||serous-5/JJ	prep_with||woman-3/NN||adenocarcinoma-6/NN	det||ovary-9/NN||the-8/DT	prep_of||adenocarcinoma-6/NN||ovary-9/NN	root||ROOT-0/null||developed-10/VBD	amod||pancolitis-12/NNS||lethal-11/JJ	nsubj||caused-13/VBD||pancolitis-12/NNS	ccomp||developed-10/VBD||caused-13/VBD	nn||difficile-16/NN||c.-15/NN	prep_by||caused-13/VBD||difficile-16/NN	num||cycles-19/NNS||five-18/CD	prep_after||caused-13/VBD||cycles-19/NNS	amod||chemotherapy-25/NN||paclitaxel-21/JJ	conj_and||paclitaxel-21/JJ||carboplatin-based-24/JJ	amod||chemotherapy-25/NN||carboplatin-based-24/JJ	prep_of||cycles-19/NNS||chemotherapy-25/NN	adenocarcinoma-6||paclitaxel-21||no_rel||a 75-year-old woman with serous adenocarcinoma of the ovary developed lethal pancolitis caused by c. difficile after five cycles of paclitaxel - and carboplatin-based chemotherapy .
quantmod||51-2/CD||only-1/RB	nsubj||reported-11/VBD||51-2/CD	det||tba-6/NN||the-4/DT	amod||tba-6/NN||417-5/JJ	prep_of||51-2/CD||tba-6/NN	num||%-9/NN||12-8/CD	appos||51-2/CD||%-9/NN	root||ROOT-0/null||reported-11/VBD	dobj||reported-11/VBD||hearing-12/NN	prep_about||reported-11/VBD||hiv/aids-14/NNS	aids--1||hiv--1||no||only 51 of the 417 tba (12%) reported hearing about hiv/aids.
amod||dehydrogenase-2/NN||glucose-6-phosphate-1/JJ	nsubj||enzyme-9/NN||dehydrogenase-2/NN	appos||dehydrogenase-2/NN||g6pd-4/NNP	cop||enzyme-9/NN||is-6/VBZ	det||enzyme-9/NN||a-7/DT	amod||enzyme-9/NN||key-8/JJ	root||ROOT-0/null||enzyme-9/NN	det||pathway-14/NN||the-11/DT	amod||pathway-14/NN||pentose-12/JJ	nn||pathway-14/NN||monophosphate-13/NN	prep_of||enzyme-9/NN||pathway-14/NN	poss||deficiency-18/NN||its-17/PRP$	nsubj||worldwide-25/NN||deficiency-18/NN	cop||worldwide-25/NN||is-19/VBZ	det||worldwide-25/NN||the-20/DT	advmod||common-22/JJ||most-21/RBS	amod||worldwide-25/NN||common-22/JJ	amod||worldwide-25/NN||inherited-23/VBN	nn||worldwide-25/NN||enzymopathy-24/NN	conj_and||enzyme-9/NN||worldwide-25/NN	glucose--1||enzymopathy-24||no_rel||glucose-6-phosphate dehydrogenase (g6pd) is a key enzyme of the pentose monophosphate pathway, and its deficiency is the most common inherited enzymopathy worldwide.
root||ROOT-0/null||basal-1/NN	conj_and||basal-1/NN||interferon-alpha-3/NN	nn||±-6/NNP||ifn-î-5/NNP	appos||basal-1/NN||±-6/NNP	conj_or||basal-1/NN||interferon-gamma-9/NN	nn||³-12/NNP||ifn-î-11/NNP	appos||interferon-gamma-9/NN||³-12/NNP	amod||expression-16/NN||induced-15/JJ	nsubjpass||evaluated-23/VBN||expression-16/NN	amod||proteins-21/NNS||socs1-18/JJ	conj_and||socs1-18/JJ||socs3-20/JJ	amod||proteins-21/NNS||socs3-20/JJ	prep_of||expression-16/NN||proteins-21/NNS	auxpass||evaluated-23/VBN||was-22/VBD	dep||basal-1/NN||evaluated-23/VBN	amod||analysis-26/NN||immunoblot-25/JJ	agent||evaluated-23/VBN||analysis-26/NN	det||panel-29/NN||a-28/DT	prep_in||analysis-26/NN||panel-29/NN	prep_of||panel-29/NN||n-31/NN	dep||lines-38/NNS||=-32/SYM	num||lines-38/NNS||10-33/CD	amod||lines-38/NNS||metastatic-34/JJ	amod||lines-38/NNS||human-35/JJ	nn||lines-38/NNS||melanoma-36/NNP	nn||lines-38/NNS||cell-37/NN	ccomp||evaluated-23/VBN||lines-38/NNS	amod||melanocytes-43/NNS||human-41/JJ	amod||melanocytes-43/NNS||embryonic-42/JJ	prep_in||basal-1/NN||melanocytes-43/NNS	appos||melanocytes-43/NNS||hem-45/NN	prep_in||basal-1/NN||radial-49/NN	conj_and||melanocytes-43/NNS||radial-49/NN	amod||cells-55/NNS||vertical-51/JJ	nn||cells-55/NNS||growth-52/NN	nn||cells-55/NNS||phase-53/NN	nn||cells-55/NNS||melanoma-54/NN	conj_and||melanocytes-43/NNS||cells-55/NNS	conj_or||radial-49/NN||cells-55/NNS	interferon--1||melanoma-54||no_rel||basal and interferon-alpha (ifn-î±) or interferon-gamma (ifn-î³)-induced expression of socs1 and socs3 proteins was evaluated by immunoblot analysis in a panel of n = 10 metastatic human melanoma cell lines, in human embryonic melanocytes (hem), and radial or vertical growth phase melanoma cells.
nsubj||heard-5/VBN||those-2/DT	prep_of||reported-16/VBD||those-2/DT	aux||heard-5/VBN||had-4/VBD	rcmod||those-2/DT||heard-5/VBN	prep_about||heard-5/VBN||hiv/aids-7/NNS	quantmod||36-10/CD||only-9/RB	num||%-13/NN||36-10/CD	num||%-13/NN||72-12/CD	nsubj||reported-16/VBD||%-13/NN	advmod||reported-16/VBD||correctly-15/RB	root||ROOT-0/null||reported-16/VBD	mark||spread-22/VBN||that-17/IN	det||virus-19/NN||the-18/DT	nsubjpass||spread-22/VBN||virus-19/NN	aux||spread-22/VBN||could-20/MD	auxpass||spread-22/VBN||be-21/VB	ccomp||reported-16/VBD||spread-22/VBN	prep_from||spread-22/VBN||mother-24/NN	prep_to||spread-22/VBN||child-26/NN	nsubj||identified-33/VBD||37-28/CD	num||%-31/NN||74-30/CD	appos||37-28/CD||%-31/NN	conj_and||reported-16/VBD||identified-33/VBD	amod||sex-35/NN||unprotected-34/JJ	dobj||identified-33/VBD||sex-35/NN	det||mode-38/NN||a-37/DT	prep_as||identified-33/VBD||mode-38/NN	prep_of||mode-38/NN||transmission-40/NN	nsubj||said-49/VBD||26-43/CD	num||%-46/NN||51-45/CD	appos||26-43/CD||%-46/NN	advmod||said-49/VBD||correctly-48/RB	conj_and||reported-16/VBD||said-49/VBD	acomp||said-49/VBD||healthy-50/JJ	dep||healthy-50/JJ||looking-51/VBG	nsubj||spread-54/VB||people-52/NNS	aux||spread-54/VB||could-53/MD	ccomp||looking-51/VBG||spread-54/VB	dobj||spread-54/VB||hiv-55/NN	aids--1||hiv-55||no||of those who had heard about hiv/aids, only 36 (72%) correctly reported that the virus could be spread from mother to child; 37 (74%) identified unprotected sex as a mode of transmission; and 26 (51%) correctly said healthy looking people could spread hiv.
mark||analyze-4/VB||in-1/IN	dep||analyze-4/VB||order-2/NN	aux||analyze-4/VB||to-3/TO	advcl||studied-19/VBD||analyze-4/VB	amod||cells-6/NNS||dendritic-5/JJ	dobj||analyze-4/VB||cells-6/NNS	appos||cells-6/NNS||dcs-8/NN	vmod||cells-6/NNS||activation-10/VBN	prep_following||activation-10/VBN||infection-12/NN	amod||strains-16/NNS||different-14/JJ	amod||strains-16/NNS||mycobacterial-15/JJ	prep_with||infection-12/NN||strains-16/NNS	nsubj||studied-19/VBD||we-18/PRP	ccomp||mycobacteriumtuberculosis-36/VBZ||studied-19/VBD	det||profiles-22/NNS||the-20/DT	nn||profiles-22/NNS||expression-21/NN	dobj||studied-19/VBD||profiles-22/NNS	num||genes-25/NNS||165-24/CD	prep_of||profiles-22/NNS||genes-25/NNS	amod||dcs-29/NN||human-27/JJ	amod||dcs-29/NN||monocyte-derived-28/JJ	prep_of||genes-25/NNS||dcs-29/NN	vmod||dcs-29/NN||infected-30/VBN	prep_with||infected-30/VBN||h37rv-32/CD	det||virulent-35/NN||a-34/DT	nsubj||mycobacteriumtuberculosis-36/VBZ||virulent-35/NN	root||ROOT-0/null||mycobacteriumtuberculosis-36/VBZ	dep||mycobacteriumtuberculosis-36/VBZ||mtb-38/NN	nn||strain-41/NN||laboratory-40/NN	dobj||mycobacteriumtuberculosis-36/VBZ||strain-41/NN	dobj||mycobacteriumtuberculosis-36/VBZ||cmt97-43/NNS	conj_and||strain-41/NN||cmt97-43/NNS	det||isolate-48/NN||a-45/DT	amod||isolate-48/NN||clinical-46/JJ	nn||isolate-48/NN||mtb-47/NN	dobj||mycobacteriumtuberculosis-36/VBZ||isolate-48/NN	conj_and||strain-41/NN||isolate-48/NN	amod||bacillus-51/NNS||mycobacteriumbovis-50/JJ	dobj||mycobacteriumtuberculosis-36/VBZ||bacillus-51/NNS	conj_and||strain-41/NN||bacillus-51/NNS	nn||rin-54/NNP||calmette-guã-52/NNP	nn||rin-54/NNP||©-53/NNP	dep||bacillus-51/NNS||rin-54/NNP	appos||rin-54/NNP||bcg-56/NN	amod||pasteur-60/NN||aventis-59/JJ	dobj||mycobacteriumtuberculosis-36/VBZ||pasteur-60/NN	conj_and||strain-41/NN||pasteur-60/NN	nn||japan-64/NN||bcg-63/NN	dobj||mycobacteriumtuberculosis-36/VBZ||japan-64/NN	conj_and||strain-41/NN||japan-64/NN	nsubj||employed-67/VBN||both-66/DT	rcmod||japan-64/NN||employed-67/VBN	prep_as||employed-67/VBN||vaccine-69/NN	prep_against||vaccine-69/NN||tuberculosis-71/NNP	tuberculosis-71||mtb-47||no||in order to analyze dendritic cells (dcs) activation following infection with different mycobacterial strains, we studied the expression profiles of 165 genes of human monocyte-derived dcs infected with h37rv, a virulent mycobacteriumtuberculosis (mtb) laboratory strain, cmt97, a clinical mtb isolate, mycobacteriumbovis bacillus calmette-guã©rin (bcg), aventis pasteur, and bcg japan, both employed as vaccine against tuberculosis.
det||system-3/NN||the-1/DT	nn||system-3/NN||mdlap-2/NN	nsubj||tool-7/NN||system-3/NN	cop||tool-7/NN||is-4/VBZ	det||tool-7/NN||a-5/DT	amod||tool-7/NN||promising-6/JJ	root||ROOT-0/null||tool-7/NN	amod||control-11/NN||individualized-9/JJ	nn||control-11/NN||glucose-10/NN	prep_for||tool-7/NN||control-11/NN	prep_in||control-11/NN||patients-13/NNS	prep_with||patients-13/NNS||type1diabetes-15/CD	type1diabetes-15||glucose-10||no_rel||the mdlap system is a promising tool for individualized glucose control in patients with type1diabetes.
advmod||reduced-10/VBD||recently-1/RB	det||thienopyridine-5/NN||a-3/DT	amod||thienopyridine-5/NN||new-4/JJ	nsubj||reduced-10/VBD||thienopyridine-5/NN	appos||thienopyridine-5/NN||prasugrel-7/NN	advmod||reduced-10/VBD||significantly-9/RB	root||ROOT-0/null||reduced-10/VBD	det||endpoint-13/NN||the-11/DT	amod||endpoint-13/NN||primary-12/JJ	dobj||reduced-10/VBD||endpoint-13/NN	amod||death-16/NN||cardiovascular-15/JJ	prep_of||endpoint-13/NN||death-16/NN	amod||myocardialinfarction-19/NN||non-fatal-18/JJ	prep_of||endpoint-13/NN||myocardialinfarction-19/NN	conj_or||death-16/NN||myocardialinfarction-19/NN	amod||stroke-22/NN||non-fatal-21/JJ	prep_of||endpoint-13/NN||stroke-22/NN	conj_or||death-16/NN||stroke-22/NN	num||%-25/NN||9.9-24/CD	prep_to||reduced-10/VBD||%-25/NN	prepc_compared_to||%-25/NN||to-27/TO	num||%-29/NN||12.1-28/CD	pobj||%-25/NN||%-29/NN	prep_for||%-29/NN||clopidogrel-31/NN	myocardialinfarction-19||clopidogrel-31||yes||recently, a new thienopyridine, prasugrel, significantly reduced the primary endpoint of cardiovascular death, non-fatal myocardialinfarction or non-fatal stroke to 9.9% compared to 12.1% for clopidogrel.
det||study-3/NN||this-2/DT	prep_in||ascertain-5/VBP||study-3/NN	nsubj||ascertain-5/VBP||we-4/PRP	root||ROOT-0/null||ascertain-5/VBP	det||role-9/NN||the-6/DT	advmod||role-9/NN||in-7/RB	amod||role-9/NN||vivo-8/JJ	dobj||ascertain-5/VBP||role-9/NN	prep_of||role-9/NN||sr-a-11/NN	det||recognition-14/NN||the-13/DT	prep_in||ascertain-5/VBP||recognition-14/NN	amod||-rrb--20/NNS||n.meningitidis-16/JJ	amod||-rrb--20/NNS||mc58-17/JJ	amod||-rrb--20/NNS||-lrb--18/JJ	nn||-rrb--20/NNS||serogroupb-19/NN	prep_of||recognition-14/NN||-rrb--20/NNS	det||model-24/NN||a-22/DT	amod||model-24/NN||murine-23/JJ	prep_in||-rrb--20/NNS||model-24/NN	prep_of||model-24/NN||meningococcalsepticaemia-26/NN	meningococcalsepticaemia-26||n.meningitidis-16||no||in this study we ascertain the in vivo role of sr-a in the recognition of n.meningitidis mc58 -lrb- serogroupb -rrb- in a murine model of meningococcalsepticaemia .
det||adhesion-2/NN||the-1/DT	nsubj||observed-16/JJ||adhesion-2/NN	conj_and||adhesion-2/NN||spreading-4/NN	nsubj||observed-16/JJ||spreading-4/NN	amod||cells-9/NNS||rmg-i-6/JJ	conj_and||rmg-i-6/JJ||rmg-i-h-8/JJ	amod||cells-9/NNS||rmg-i-h-8/JJ	prep_of||adhesion-2/NN||cells-9/NNS	prep_on||adhesion-2/NN||hyaluronicacid-11/NN	appos||adhesion-2/NN||ha-13/NN	cop||observed-16/JJ||were-15/VBD	root||ROOT-0/null||observed-16/JJ	i---1||adhesion-2||no_rel||the adhesion and spreading of rmg-i and rmg-i-h cells on hyaluronicacid (ha) were observed.
advmod||compared-4/VBD||here-1/RB	nsubj||compared-4/VBD||we-3/PRP	root||ROOT-0/null||compared-4/VBD	det||characteristics-9/NNS||the-5/DT	nn||characteristics-9/NNS||cell-6/NN	nn||characteristics-9/NNS||culture-7/NN	nn||characteristics-9/NNS||growth-8/NN	dobj||compared-4/VBD||characteristics-9/NNS	nn||viruses-12/NNS||haemorrhagicfever-11/NN	prep_of||characteristics-9/NNS||viruses-12/NNS	appos||viruses-12/NNS||hfv-14/NN	det||arenaviridae-19/NN||the-18/DT	prep_of||viruses-12/NNS||arenaviridae-19/NN	prep_of||viruses-12/NNS||filoviridae-21/NN	conj_and||arenaviridae-19/NN||filoviridae-21/NN	prep_of||viruses-12/NNS||bunyaviridae-23/NN	conj_and||arenaviridae-19/NN||bunyaviridae-23/NN	amod||families-28/NNS||flavivridae-26/JJ	nn||families-28/NNS||virus-27/NN	prep_of||viruses-12/NNS||families-28/NNS	conj_and||arenaviridae-19/NN||families-28/NNS	prepc_by||compared-4/VBD||performing-30/VBG	amod||analysis-32/NN||quantitative-31/JJ	dobj||performing-30/VBG||analysis-32/NN	nn||supernatants-36/NNS||cell-34/NN	nn||supernatants-36/NNS||culture-35/NN	prep_of||analysis-32/NN||supernatants-36/NNS	appos||microscopy-42/NN||i-39/NNP	amod||microscopy-42/NN||electron-41/JJ	prep_by||performing-30/VBG||microscopy-42/NN	det||quantification-45/NN||the-44/DT	prep_for||performing-30/VBG||quantification-45/NN	nn||particles-48/NNS||virus-47/NN	prep_of||quantification-45/NN||particles-48/NNS	appos||particles-48/NNS||ii-51/NN	amod||time-55/NN||quantitative-53/JJ	amod||time-55/NN||real-54/JJ	dep||particles-48/NNS||time-55/NN	vmod||time-55/NN||pcr-56/VBN	det||quantification-59/NN||the-58/DT	prep_for||pcr-56/VBN||quantification-59/NN	prep_of||quantification-59/NN||genomes-61/NNS	amod||determination-67/NN||iii-65/JJ	prep_of||quantification-45/NN||determination-67/NN	conj_and||particles-48/NNS||determination-67/NN	prep_of||determination-67/NN||focus-69/NN	vmod||determination-67/NN||forming-70/VBG	dobj||forming-70/VBG||units-71/NNS	agent||forming-70/VBG||coating-73/VBG	amod||antibodies-75/NNS||fluorescent-74/JJ	dobj||coating-73/VBG||antibodies-75/NNS	amod||monolayers-79/NNS||infected-77/JJ	nn||monolayers-79/NNS||cell-78/NN	prep_to||coating-73/VBG||monolayers-79/NNS	det||quantification-82/NN||the-81/DT	prep_for||determination-67/NN||quantification-82/NN	nn||infectivity-85/NN||virus-84/NN	prep_of||quantification-82/NN||infectivity-85/NN	virus-84||viruses-12||no||here, we compared the cell culture growth characteristics of haemorrhagicfever viruses (hfv), of the arenaviridae , filoviridae , bunyaviridae , and flavivridae virus families by performing quantitative analysis of cell culture supernatants by (i) electron microscopy for the quantification of virus particles, (ii) quantitative real time pcr for the quantification of genomes, and (iii) determination of focus forming units by coating fluorescent antibodies to infected cell monolayers for the quantification of virus infectivity.
amod||access-2/NN||improved-1/VBN	nsubj||seems-9/VBZ||access-2/NN	nsubjpass||associated-12/VBN||access-2/NN	nn||care-5/NN||hiv-4/NN	prep_to||access-2/NN||care-5/NN	nn||services-8/NNS||treatment-7/NN	prep_to||access-2/NN||services-8/NNS	conj_and||care-5/NN||services-8/NNS	root||ROOT-0/null||seems-9/VBZ	aux||associated-12/VBN||to-10/TO	auxpass||associated-12/VBN||be-11/VB	xcomp||seems-9/VBZ||associated-12/VBN	poss||presentation-17/NN||patients-14/NNS	amod||presentation-17/NN||early-16/JJ	prep_with||associated-12/VBN||presentation-17/NN	det||clinics-20/NNS||the-19/DT	prep_to||associated-12/VBN||clinics-20/NNS	det||course-23/NN||the-22/DT	prep_in||clinics-20/NNS||course-23/NN	prep_of||course-23/NN||hivdisease-25/NN	hivdisease-25||hiv-4||no||improved access to hiv care and treatment services seems to be associated with patients' early presentation to the clinics in the course of hivdisease.
nsubj||improve-15/VB||addition-1/NN	amod||diet-9/NN||ezetimibe-3/JJ	det||loss-8/NN||a-5/DT	amod||loss-8/NN||moderate-6/JJ	nn||loss-8/NN||weight-7/NN	prep_to||ezetimibe-3/JJ||loss-8/NN	prep_of||addition-1/NN||diet-9/NN	amod||subjects-12/NNS||obese-11/JJ	prep_in||diet-9/NN||subjects-12/NNS	aux||improve-15/VB||can-13/MD	advmod||improve-15/VB||significantly-14/RB	root||ROOT-0/null||improve-15/VB	amod||steatosis-17/NNS||hepatic-16/JJ	dobj||improve-15/VB||steatosis-17/NNS	dobj||improve-15/VB||inflammation-19/NNS	conj_and||steatosis-17/NNS||inflammation-19/NNS	amod||metabolism-26/NN||ldlâ-22/JJ	amod||metabolism-26/NN||$-23/$	amod||metabolism-26/NN||apob-100-25/JJ	dobj||improve-15/VB||metabolism-26/NN	conj_and||steatosis-17/NNS||metabolism-26/NN	ezetimibe-3||inflammation-19||no_rel||addition of ezetimibe to a moderate weight loss diet in obese subjects can significantly improve hepatic steatosis, inflammation, and ldlâapob-100 metabolism.
root||ROOT-0/null||hereditary-1/VBG	amod||deficiency-5/NN||combined-2/VBN	amod||deficiency-5/NN||vitamink-dependent-3/JJ	nn||deficiency-5/NN||clottingfactors-4/NN	dobj||hereditary-1/VBG||deficiency-5/NN	dep||deficiency-5/NN||vkcfd-7/VBN	cop||bleedingdisorder-13/NN||is-9/VBZ	det||bleedingdisorder-13/NN||a-10/DT	amod||bleedingdisorder-13/NN||rare-11/JJ	amod||bleedingdisorder-13/NN||congenital-12/JJ	aux||hereditary-1/VBG||bleedingdisorder-13/NN	vmod||bleedingdisorder-13/NN||resulting-14/VBG	amod||levels-18/NNS||variably-16/JJ	amod||levels-18/NNS||decreased-17/VBN	prep_from||resulting-14/VBG||levels-18/NNS	amod||ii-21/NN||coagulationfactors-20/JJ	prep_of||levels-18/NNS||ii-21/NN	prep_of||levels-18/NNS||vii-23/NN	conj_and||ii-21/NN||vii-23/NN	prep_of||levels-18/NNS||ix-25/NN	conj_and||ii-21/NN||ix-25/NN	prep_of||levels-18/NNS||x-27/SYM	conj_and||ii-21/NN||x-27/SYM	amod||anticoagulants-32/NNS||natural-31/JJ	aux||hereditary-1/VBG||anticoagulants-32/NNS	conj_and||bleedingdisorder-13/NN||anticoagulants-32/NNS	dep||anticoagulants-32/NNS||protein-33/NN	nsubj||hereditary-1/VBG||c-34/SYM	nn||s-37/NNS||protein-36/NN	appos||c-34/SYM||s-37/NNS	nn||z.-40/NN||protein-39/NN	appos||c-34/SYM||z.-40/NN	conj_and||s-37/NNS||z.-40/NN	bleedingdisorder-13||vitamink--1||no_rel||hereditary combined vitamink-dependent clottingfactors deficiency (vkcfd) is a rare congenital bleedingdisorder resulting from variably decreased levels of coagulationfactors ii, vii, ix and x as well as natural anticoagulants protein c, protein s and protein z.
nsubj||tool-8/NN||genotyping-1/NN	prep_of||genotyping-1/NN||mycobacteriumtuberculosis-3/NNS	dep||mycobacteriumtuberculosis-3/NNS||isolates-4/VBZ	cop||tool-8/NN||is-5/VBZ	det||tool-8/NN||a-6/DT	amod||tool-8/NN||powerful-7/JJ	root||ROOT-0/null||tool-8/NN	amod||control-11/NN||epidemiological-10/JJ	prep_for||tool-8/NN||control-11/NN	prep_of||control-11/NN||tuberculosis-13/NNP	appos||tuberculosis-13/NNP||tb-15/NN	amod||exploration-19/NN||phylogenetic-18/JJ	prep_for||tool-8/NN||exploration-19/NN	conj_and||control-11/NN||exploration-19/NN	det||pathogen-22/NN||the-21/DT	prep_of||exploration-19/NN||pathogen-22/NN	tuberculosis-13||mycobacteriumtuberculosis-3||no||genotyping of mycobacteriumtuberculosis isolates is a powerful tool for epidemiological control of tuberculosis (tb) and phylogenetic exploration of the pathogen.
amod||therapy-5/NN||hivinfection-2/JJ	amod||therapy-5/NN||and/or-3/JJ	amod||therapy-5/NN||antiretroviral-4/JJ	prep_during||exhibit-13/VB||therapy-5/NN	appos||therapy-5/NN||art-7/NN	nsubj||exhibit-13/VB||monocytes-10/NNS	conj_and||monocytes-10/NNS||macrophages-12/NNS	nsubj||exhibit-13/VB||macrophages-12/NNS	root||ROOT-0/null||exhibit-13/VB	det||range-16/NN||a-14/DT	amod||range-16/NN||wide-15/JJ	dobj||exhibit-13/VB||range-16/NN	prep_of||range-16/NN||dysfunctions-18/NNS	nsubj||contribute-20/VBP||dysfunctions-18/NNS	rcmod||dysfunctions-18/NNS||contribute-20/VBP	advmod||contribute-20/VBP||significantly-21/RB	nn||pathogenesis-24/NNS||hiv-23/NN	prep_to||contribute-20/VBP||pathogenesis-24/NNS	amod||complications-27/NNS||therapy-associated-26/JJ	prep_to||contribute-20/VBP||complications-27/NNS	conj_and||pathogenesis-24/NNS||complications-27/NNS	hivinfection-2||hiv-23||no||during hivinfection and/or antiretroviral therapy (art), monocytes and macrophages exhibit a wide range of dysfunctions which contribute significantly to hiv pathogenesis and therapy-associated complications.
amod||diagnosed-10/NN||anonymized-2/JJ	amod||diagnosed-10/NN||linkage-3/JJ	det||survey-6/NN||the-5/DT	prep_with||linkage-3/JJ||survey-6/NN	amod||hivinfections-9/NNS||prevalent-8/JJ	prep_of||survey-6/NN||hivinfections-9/NNS	prep_through||categorized-35/VBN||diagnosed-10/NN	nn||scotland-14/NN||health-12/NN	nn||scotland-14/NN||protection-13/NN	conj_and||diagnosed-10/NN||scotland-14/NN	prep_through||categorized-35/VBN||scotland-14/NN	amod||databases-17/NNS||national-16/JJ	appos||diagnosed-10/NN||databases-17/NNS	det||patients-21/NNS||all-19/DT	nn||patients-21/NNS||hiv-20/NN	prep_of||databases-17/NNS||patients-21/NNS	prep_in||patients-21/NNS||care-23/NN	det||uk-26/NN||the-25/DT	prep_in||care-23/NN||uk-26/NN	advmod||uk-26/NN||up-27/RB	prep_to||up-27/RB||december-29/NNP	num||december-29/NNP||2006-30/CD	amod||patients-33/NNS||loss-to-follow-up-32/JJ	nsubjpass||categorized-35/VBN||patients-33/NNS	auxpass||categorized-35/VBN||were-34/VBD	root||ROOT-0/null||categorized-35/VBN	prep_as||categorized-35/VBN||transfers-37/NNS	advmod||received-40/VBN||subsequently-39/RB	dep||transfers-37/NNS||received-40/VBN	dobj||received-40/VBN||care-41/NN	det||clinic-46/NN||another-43/DT	nn||clinic-46/NN||uk-44/NN	nn||clinic-46/NN||hiv-45/NN	prep_at||received-40/VBN||clinic-46/NN	prep_as||categorized-35/VBN||uklfu-49/VBG	conj_or||transfers-37/NNS||uklfu-49/VBG	neg||record-52/NN||no-51/DT	dep||uklfu-49/VBG||record-52/NN	amod||attendance-55/NN||subsequent-54/JJ	prep_of||record-52/NN||attendance-55/NN	det||clinic-59/NN||any-57/DT	nn||clinic-59/NN||hiv-58/NN	prep_at||attendance-55/NN||clinic-59/NN	det||uk-62/NN||the-61/DT	prep_in||clinic-59/NN||uk-62/NN	hivinfections-9||hiv-58||no||through anonymized linkage with the survey of prevalent hivinfections diagnosed and health protection scotland, national databases of all hiv patients in care in the uk up to december 2006, loss-to-follow-up patients were categorized as transfers (subsequently received care at another uk hiv clinic) or uklfu (no record of subsequent attendance at any hiv clinic in the uk).
det||study-2/NN||this-1/DT	nsubj||aimed-3/VBD||study-2/NN	nsubj||examine-5/VB||study-2/NN	root||ROOT-0/null||aimed-3/VBD	aux||examine-5/VB||to-4/TO	xcomp||aimed-3/VBD||examine-5/VB	det||hypothesis-7/NNS||the-6/DT	dobj||examine-5/VB||hypothesis-7/NNS	mark||relate-19/VBP||that-8/IN	det||factors-10/NNS||some-9/DT	nsubj||relate-19/VBP||factors-10/NNS	prep_of||factors-10/NNS||ptg-12/NN	amod||strength-17/NN||personal-16/JJ	prep_such_as||factors-10/NNS||strength-17/NN	ccomp||examine-5/VB||relate-19/VBP	prep_to||relate-19/VBP||resilience-21/NN	mark||relate-33/VBP||whereas-23/IN	amod||factors-25/NNS||other-24/JJ	nsubj||relate-33/VBP||factors-25/NNS	nsubj||ptsd-35/VB||factors-25/NNS	prep_such_as||factors-25/NNS||appreciation-29/NN	prep_of||appreciation-29/NN||life-31/NN	advcl||relate-19/VBP||relate-33/VBP	aux||ptsd-35/VB||to-34/TO	xcomp||relate-33/VBP||ptsd-35/VB	dobj||ptsd-35/VB||symptoms-36/NNS	amod||survivors-45/NNS||japanese-38/JJ	nn||survivors-45/NNS||motor-39/NN	nn||survivors-45/NNS||vehicle-40/NN	nn||survivors-45/NNS||accident-41/NN	nn||survivors-45/NNS||mva-43/NN	prep_among||ptsd-35/VB||survivors-45/NNS	ptsd-35||ptg-12||no_rel||this study aimed to examine the hypothesis that some factors of ptg, such as personal strength, relate to resilience, whereas other factors, such as appreciation of life, relate to ptsd symptoms among japanese motor vehicle accident (mva) survivors.
amod||modulation-2/NN||immune-1/JJ	nsubj||improved-7/VBD||modulation-2/NN	nsubj||resulted-11/VBD||modulation-2/NN	prep||modulation-2/NN||combined-3/VBN	pcomp||combined-3/VBN||with-4/IN	nn||treatment-6/NN||inh-5/NN	pobj||with-4/IN||treatment-6/NN	root||ROOT-0/null||improved-7/VBD	amod||clearance-9/NN||bacillary-8/JJ	dobj||improved-7/VBD||clearance-9/NN	conj_and||improved-7/VBD||resulted-11/VBD	amod||granulomas-14/NNS||smaller-13/JJR	prep_in||resulted-11/VBD||granulomas-14/NNS	amod||pathology-18/NN||less-16/JJR	nn||pathology-18/NN||lung-17/NN	prep_in||resulted-11/VBD||pathology-18/NN	conj_and||granulomas-14/NNS||pathology-18/NN	prepc_compared_to||improved-7/VBD||to-21/TO	pobj||improved-7/VBD||treatment-22/NN	prep_with||treatment-22/NN||inh-24/NN	advmod||inh-24/NN||alone-25/RB	granulomas-14||inh-24||no_rel||immune modulation combined with inh treatment improved bacillary clearance and resulted in smaller granulomas and less lung pathology, compared to treatment with inh alone.
nsubj||identified-2/VBD||we-1/PRP	root||ROOT-0/null||identified-2/VBD	nn||monacensis-4/NNS||rickettsia-3/NN	dobj||identified-2/VBD||monacensis-4/NNS	det||cause-7/NN||a-6/DT	prep_as||identified-2/VBD||cause-7/NN	amod||rickettsiosis-11/NNS||acute-9/JJ	nn||rickettsiosis-11/NNS||tickborne-10/NN	prep_of||cause-7/NN||rickettsiosis-11/NNS	num||humans-14/NNS||2-13/CD	prep_in||identified-2/VBD||humans-14/NNS	rickettsiosis-11||rickettsia-3||no||we identified rickettsia monacensis as a cause of acute tickborne rickettsiosis in 2 humans.
nsubj||demonstrate-2/VBP||we-1/PRP	root||ROOT-0/null||demonstrate-2/VBP	mark||have-12/VBP||that-3/IN	det||influenza-7/NN||the-4/DT	amod||influenza-7/NN||novel-5/JJ	amod||influenza-7/NN||pandemic-6/JJ	nn||viruses-11/NNS||influenza-7/NN	appos||viruses-11/NNS||h1n1-9/NNP	nsubj||have-12/VBP||viruses-11/NNS	ccomp||demonstrate-2/VBP||have-12/VBP	amod||virusâ-14/NNS||human-13/JJ	dobj||have-12/VBP||virusâ-14/NNS	npadvmod||virusâ-14/NNS||$-15/$	amod||specificity-19/NNS||like-17/JJ	conj_and||specificity-19/NNS||like-17/JJ	npadvmod||longer-23/RB||like-17/JJ	nn||specificity-19/NNS||receptor-18/NN	npadvmod||longer-23/RB||specificity-19/NNS	conj_and||specificity-19/NNS||can-21/NN	npadvmod||longer-23/RB||can-21/NN	advmod||specificity-19/NNS||no-22/DT	dep||replicate-24/CD||longer-23/RB	num||$-15/$||replicate-24/CD	amod||waterfowl-27/NN||aquatic-26/JJ	prep_in||virusâ-14/NNS||waterfowl-27/NN	poss||reservoir-32/NN||their-29/PRP$	amod||reservoir-32/NN||historic-30/JJ	amod||reservoir-32/NN||natural-31/JJ	appos||waterfowl-27/NN||reservoir-32/NN	virus--1||viruses-11||no||we demonstrate that the novel pandemic influenza (h1n1) viruses have human virusâlike receptor specificity and can no longer replicate in aquatic waterfowl, their historic natural reservoir.
det||relationship-2/NN||the-1/DT	nsubjpass||supported-8/VBN||relationship-2/NN	prep_between||relationship-2/NN||ngf-4/NN	prep_between||relationship-2/NN||pain-6/NN	conj_and||ngf-4/NN||pain-6/NN	auxpass||supported-8/VBN||is-7/VBZ	root||ROOT-0/null||supported-8/VBN	amod||mutations-12/NNS||genetic-10/JJ	nn||mutations-12/NNS||evidence-11/NN	agent||supported-8/VBN||mutations-12/NNS	det||receptor-17/NN||the-14/DT	nn||receptor-17/NN||ngf-15/NN	nn||receptor-17/NN||trka-16/NN	prep_in||mutations-12/NNS||receptor-17/NN	prep_in||supported-8/VBN||patients-19/NNS	vmod||patients-19/NNS||affected-20/VBN	det||disease-25/NN||an-22/DT	advmod||rare-24/JJ||hereditary-23/RB	amod||disease-25/NN||rare-24/JJ	agent||affected-20/VBN||disease-25/NN	number||sensory-28/JJ||hereditary-27/CD	dep||disease-25/NN||sensory-28/JJ	amod||iv-33/NN||autonomic-30/JJ	nn||iv-33/NN||neuropathy-31/NNP	nn||iv-33/NN||type-32/NN	dep||disease-25/NN||iv-33/NN	conj_and||sensory-28/JJ||iv-33/NN	nn||iv-36/NN||hsan-35/NN	appos||sensory-28/JJ||iv-36/NN	ccomp||affected-20/VBN||determine-38/VB	det||form-41/NN||a-39/DT	amod||form-41/NN||congenital-40/JJ	dobj||determine-38/VB||form-41/NN	amod||pain-44/NN||severe-43/JJ	prep_of||form-41/NN||pain-44/NN	advmod||determine-38/VB||insensitivity-45/RB	amod||retardation-49/NN||mental-48/JJ	prep_with||determine-38/VB||retardation-49/NN	mark||determines-68/VBZ||while-51/IN	det||mutation-53/NN||a-52/DT	nsubj||determines-68/VBZ||mutation-53/NN	amod||gene-56/NN||ngfb-55/JJ	prep_in||mutation-53/NN||gene-56/NN	vmod||determines-68/VBZ||leading-58/VBG	det||r100w-63/NN||the-60/DT	amod||r100w-63/NN||aminoacid-61/JJ	nn||r100w-63/NN||substitution-62/NN	prep_to||leading-58/VBG||r100w-63/NN	amod||ngf-66/NN||mature-65/JJ	prep_in||r100w-63/NN||ngf-66/NN	dep||retardation-49/NN||determines-68/VBZ	det||loss-71/NN||a-69/DT	amod||loss-71/NN||similar-70/JJ	dobj||determines-68/VBZ||loss-71/NN	nn||perception-74/NN||pain-73/NN	prep_of||loss-71/NN||perception-74/NN	amod||cognitive-78/JJ||overt-77/JJ	amod||defects-80/NNS||cognitive-78/JJ	amod||defects-80/NNS||neurological-79/JJ	prep_without||determines-68/VBZ||defects-80/NNS	nn||v-83/NN||hsan-82/NN	appos||defects-80/NNS||v-83/NN	pain-73||aminoacid-61||no_rel||the relationship between ngf and pain is supported by genetic evidence mutations in the ngf trka receptor in patients affected by an hereditary rare disease (hereditary sensory and autonomic neuropathy type iv, hsan iv) determine a congenital form of severe pain insensitivity, with mental retardation, while a mutation in ngfb gene, leading to the aminoacid substitution r100w in mature ngf, determines a similar loss of pain perception, without overt cognitive neurological defects (hsan v).
nsubj||demonstrated-4/VBN||we-1/PRP	aux||demonstrated-4/VBN||have-2/VBP	advmod||demonstrated-4/VBN||previously-3/RB	root||ROOT-0/null||demonstrated-4/VBN	mark||promoted-12/VBD||that-5/IN	det||quercetin-8/NN||the-6/DT	amod||quercetin-8/NN||bioflavonoid-7/JJ	nsubj||promoted-12/VBD||quercetin-8/NN	nsubj||sensitized-17/VBD||quercetin-8/NN	appos||quercetin-8/NN||qct-10/NN	ccomp||demonstrated-4/VBN||promoted-12/VBD	det||response-15/NN||a-13/DT	amod||response-15/NN||p53-mediated-14/JJ	dobj||promoted-12/VBD||response-15/NN	ccomp||demonstrated-4/VBN||sensitized-17/VBD	conj_and||promoted-12/VBD||sensitized-17/VBD	dobj||sensitized-17/VBD||melanoma-18/NN	prep_to||sensitized-17/VBD||dtic-20/NN	melanoma-18||dtic-20||yes||we have previously demonstrated that the bioflavonoid quercetin (qct) promoted a p53-mediated response and sensitized melanoma to dtic.
nsubjpass||concluded-3/VBN||it-1/PRP	auxpass||concluded-3/VBN||was-2/VBD	root||ROOT-0/null||concluded-3/VBN	mark||favor-7/VBP||that-4/IN	amod||nitrates-6/NNS||organic-5/JJ	nsubj||favor-7/VBP||nitrates-6/NNS	ccomp||concluded-3/VBN||favor-7/VBP	dobj||favor-7/VBP||regression-8/NN	prep_of||regression-8/NN||lvh-10/NN	amod||patients-13/NNS||hypertensive-12/JJ	prep_in||favor-7/VBP||patients-13/NNS	amod||dialysis-17/NN||chronic-15/JJ	amod||dialysis-17/NN||peritoneal-16/JJ	prep_on||patients-13/NNS||dialysis-17/NN	nsubjpass||considered-23/VBN||nitrates-20/NNS	aux||considered-23/VBN||may-21/MD	auxpass||considered-23/VBN||be-22/VB	conj_and||concluded-3/VBN||considered-23/VBN	prep_for||considered-23/VBN||use-25/NN	prepc_before||considered-23/VBN||employing-27/VBG	det||antihypertensiveagents-31/NNS||the-28/DT	num||antihypertensiveagents-31/NNS||five-29/CD	amod||antihypertensiveagents-31/NNS||other-30/JJ	dobj||employing-27/VBG||antihypertensiveagents-31/NNS	amod||antihypertensiveagents-31/NNS||other-32/JJ	prep_than||employing-27/VBG||nitrates-34/NNS	lvh-10||nitrates-34||no_rel||it was concluded that organic nitrates favor regression of lvh in hypertensive patients on chronic peritoneal dialysis, and nitrates may be considered for use before employing the five other antihypertensiveagents other than nitrates.
root||ROOT-0/null||study-1/VB	det||effects-3/NNS||the-2/DT	dobj||study-1/VB||effects-3/NNS	iobj||study-1/VB||effects-3/NNS	prep_of||effects-3/NNS||exenatide-5/NN	appos||exenatide-5/NN||exe-7/NN	amod||effects-3/NNS||plus-9/IN	amod||rosi-12/NNS||rosiglitazone-10/JJ	dep||effects-3/NNS||rosi-12/NNS	nn||²-16/NNS||î-15/NN	prep_on||rosi-12/NNS||²-16/NNS	nn||function-19/NN||cell-18/NN	dep||rosi-12/NNS||function-19/NN	nn||sensitivity-22/NN||insulin-21/NN	dep||rosi-12/NNS||sensitivity-22/NN	conj_and||function-19/NN||sensitivity-22/NN	vmod||function-19/NN||using-23/VBG	amod||techniques-29/NNS||hyperglycemic-24/JJ	conj_and||hyperglycemic-24/JJ||euglycemic-26/JJ	amod||techniques-29/NNS||euglycemic-26/JJ	nn||techniques-29/NNS||insulin-27/NN	nn||techniques-29/NNS||clamp-28/NN	dobj||using-23/VBG||techniques-29/NNS	prep_in||techniques-29/NNS||participants-31/NNS	prep_with||participants-31/NNS||type2diabetes-33/NNS	prep_on||type2diabetes-33/NNS||metformin-35/NN	type2diabetes-33||metformin-35||yes||study the effects of exenatide (exe) plus rosiglitazone (rosi) on î²-cell function and insulin sensitivity using hyperglycemic and euglycemic insulin clamp techniques in participants with type2diabetes on metformin.
nsubj||antipsychoticdrug-5/NN||aripiprazole-1/NN	cop||antipsychoticdrug-5/NN||is-2/VBZ	det||antipsychoticdrug-5/NN||an-3/DT	amod||antipsychoticdrug-5/NN||atypical-4/JJ	root||ROOT-0/null||antipsychoticdrug-5/NN	vmod||antipsychoticdrug-5/NN||approved-6/VBN	det||treatment-9/NN||the-8/DT	prep_for||approved-6/VBN||treatment-9/NN	amod||disorders-12/NNS||psychiatric-11/JJ	prep_of||treatment-9/NN||disorders-12/NNS	nn||depressivedisorder-20/NN||schizophrenia-15/NN	prep_such_as||disorders-12/NNS||bipolardisorder-17/NN	conj_and||depressivedisorder-20/NN||bipolardisorder-17/NN	prep_such_as||disorders-12/NNS||major-19/JJ	amod||depressivedisorder-20/NN||major-19/JJ	conj_and||depressivedisorder-20/NN||major-19/JJ	prep_such_as||disorders-12/NNS||depressivedisorder-20/NN	prep_such_as||disorders-12/NNS||autism-22/NN	conj_and||depressivedisorder-20/NN||autism-22/NN	antipsychoticdrug-5||depressivedisorder-20||no_rel||aripiprazole is an atypical antipsychoticdrug approved for the treatment of psychiatric disorders such as schizophrenia, bipolardisorder, major depressivedisorder and autism.
aux||evaluate-2/VB||to-1/TO	root||ROOT-0/null||evaluate-2/VB	det||efficacy-5/NN||the-3/DT	amod||efficacy-5/NN||long-term-4/JJ	dobj||evaluate-2/VB||efficacy-5/NN	dobj||evaluate-2/VB||safety-7/NN	conj_and||efficacy-5/NN||safety-7/NN	num||combinations-13/NNS||3-9/CD	advmod||available-11/JJ||commercially-10/RB	amod||combinations-13/NNS||available-11/JJ	amod||combinations-13/NNS||fixed-12/VBN	prep_of||efficacy-5/NN||combinations-13/NNS	nn||analogs-16/NNS||prostaglandin-15/NN	prep_of||evaluate-2/VB||analogs-16/NNS	det||prostamide-19/NN||a-18/DT	prep_of||evaluate-2/VB||prostamide-19/NN	conj_or||analogs-16/NNS||prostamide-19/NN	prep_with||evaluate-2/VB||timololmaleate-21/NN	prep_in||timololmaleate-21/NN||patients-23/NNS	amod||openangleglaucoma-26/NN||primary-25/JJ	prep_with||patients-23/NNS||openangleglaucoma-26/NN	prep_with||patients-23/NNS||ocularhypertension-28/NN	conj_or||openangleglaucoma-26/NN||ocularhypertension-28/NN	timololmaleate-21||ocularhypertension-28||no_rel||to evaluate the long-term efficacy and safety of 3 commercially available fixed combinations of prostaglandin analogs or a prostamide with timololmaleate in patients with primary openangleglaucoma or ocularhypertension.
amod||status-2/NN||hiv/aids-1/JJ	nsubjpass||known-4/VBN||status-2/NN	auxpass||known-4/VBN||was-3/VBD	ccomp||reported-19/VBD||known-4/VBN	amod||children-11/NNS||68-6/CD	num||%-9/NN||17.4-8/CD	appos||children-11/NNS||%-9/NN	agent||known-4/VBN||children-11/NNS	nn||caretakers-18/NNS||93-13/CD	num||%-16/NN||29-15/CD	appos||caretakers-18/NNS||%-16/NN	nsubj||reported-19/VBD||caretakers-18/NNS	root||ROOT-0/null||reported-19/VBD	xcomp||reported-19/VBD||knowing-20/VBG	det||child-22/NN||the-21/DT	poss||status-48/NN||child-22/NN	amod||status-48/NN||serostatus-24/JJ	num||years-26/NNS||two-25/CD	npadvmod||serostatus-24/JJ||years-26/NNS	poss||survey-30/NN||our-29/PRP$	prep_prior_to||serostatus-24/JJ||survey-30/NN	appos||survey-30/NN||180-32/CD	mark||told-44/VBN||180-32/CD	num||%-35/NN||46.2-34/CD	appos||180-32/CD||%-35/NN	nsubj||said-38/VBD||respondents-37/NNS	rcmod||180-32/CD||said-38/VBD	det||child-41/NN||the-40/DT	nsubjpass||told-44/VBN||child-41/NN	aux||told-44/VBN||should-42/MD	auxpass||told-44/VBN||be-43/VB	ccomp||said-38/VBD||told-44/VBN	nn||hiv/aids-47/NNS||his/her-46/NN	prep_about||told-44/VBN||hiv/aids-47/NNS	dobj||knowing-20/VBG||status-48/NN	advmod||older-52/JJR||when-49/WRB	nsubj||older-52/JJR||he/she-50/NN	cop||older-52/JJR||is-51/VBZ	rcmod||child-22/NN||older-52/JJR	ccomp||status-48/NN||older-52/JJR	num||years-55/NNS||14-54/CD	prep_than||older-52/JJR||years-55/NNS	prep_of||years-55/NNS||age-57/NN	aids--1||hiv--1||no||hiv/aids status was known by 68 (17.4%) children, 93 (29%) caretakers reported knowing the child's serostatus two years prior to our survey, 180 (46.2%) respondents said that the child should be told about his/her hiv/aids status when he/she is older than 14 years of age.
amod||brachytherapy-2/NN||electronic-1/JJ	nsubj||provides-3/VBZ||brachytherapy-2/NN	nsubj||provides-3/VBZ||brachytherapy-2/NN	root||ROOT-0/null||provides-3/VBZ	conj_and||provides-3/VBZ||provides-3/VBZ	det||option-7/NN||a-4/DT	amod||option-7/NN||feasible-5/JJ	nn||option-7/NN||treatment-6/NN	dobj||provides-3/VBZ||option-7/NN	amod||brachytherapy-12/NN||postoperative-9/JJ	amod||brachytherapy-12/NN||adjuvant-10/JJ	amod||brachytherapy-12/NN||vaginal-11/JJ	prep_for||option-7/NN||brachytherapy-12/NN	amod||therapy-16/NN||sole-14/JJ	nn||therapy-16/NN||radiation-15/NN	prep_as||provides-3/VBZ||therapy-16/NN	prep_in||provides-3/VBZ||combination-19/NN	prep_with||combination-19/NN||ebrt-21/NN	amod||cancer-25/NN||primary-23/JJ	amod||cancer-25/NN||endometrial-24/JJ	prep_for||ebrt-21/NN||cancer-25/NN	cancer-25||adjuvant-10||no_rel||electronic brachytherapy provides a feasible treatment option for postoperative adjuvant vaginal brachytherapy as sole radiation therapy and in combination with ebrt for primary endometrial cancer.
advmod||increased-11/VBD||however-1/RB	amod||administration-4/NN||fluoxetine-3/JJ	nsubj||increased-11/VBD||administration-4/NN	advmod||increased-11/VBD||significantly-5/RB	dep||<-8/JJ||p-7/RB	dep||significantly-5/RB||<-8/JJ	dep||<-8/JJ||0.05-9/CD	root||ROOT-0/null||increased-11/VBD	amod||ans-13/NN||key-12/JJ	nn||responses-40/NNS||ans-13/NN	dep||ans-13/NN||epinephrine-15/NN	dep||ans-13/NN||norepinephrine-17/NN	conj_and||epinephrine-15/NN||norepinephrine-17/NN	dep||ans-13/NN||msna-20/NN	conj_and||epinephrine-15/NN||msna-20/NN	conj_and||ans-13/NN||metabolic-23/NN	nn||responses-40/NNS||metabolic-23/NN	amod||production-27/NN||endogenous-25/JJ	nn||production-27/NN||glucose-26/NN	dep||metabolic-23/NN||production-27/NN	dep||metabolic-23/NN||lipolysis-29/NNS	conj_and||production-27/NN||lipolysis-29/NNS	amod||counterregulatory-39/NN||cardiovascular-33/JJ	amod||pressure-37/NN||systolic-35/JJ	nn||pressure-37/NN||blood-36/NN	appos||counterregulatory-39/NN||pressure-37/NN	conj_and||ans-13/NN||counterregulatory-39/NN	nn||responses-40/NNS||counterregulatory-39/NN	dobj||increased-11/VBD||responses-40/NNS	prep_during||increased-11/VBD||hypoglycemia-42/NN	epinephrine-15||hypoglycemia-42||no_rel||however, fluoxetine administration significantly ( p < 0.05) increased key ans (epinephrine, norepinephrine, and msna), metabolic (endogenous glucose production and lipolysis), and cardiovascular (systolic blood pressure) counterregulatory responses during hypoglycemia.
amod||children-2/NNS||thirty-four-1/JJ	nsubjpass||screened-25/VBN||children-2/NNS	num||males-5/NNS||25-4/CD	dep||children-2/NNS||males-5/NNS	amod||age-8/NN||median-7/JJ	dep||males-5/NNS||age-8/NN	number||â-10/CD||10.8-9/CD	num||yrs-13/NN||â-10/CD	nn||yrs-13/NN||±-11/NNP	num||yrs-13/NN||3.4-12/CD	dep||age-8/NN||yrs-13/NN	amod||obesity-17/NN||severe-16/JJ	prep_with||children-2/NNS||obesity-17/NN	dep||children-2/NNS||bmi-19/VBN	xcomp||bmi-19/VBN||>-20/VBG	num||%-22/NN||95-21/CD	dobj||>-20/VBG||%-22/NN	auxpass||screened-25/VBN||were-24/VBD	root||ROOT-0/null||screened-25/VBN	prep_for||screened-25/VBN||diabetes-27/NN	amod||test-32/NN||oral-29/JJ	nn||test-32/NN||glucose-30/NN	nn||test-32/NN||tolerance-31/NN	prep_with||diabetes-27/NN||test-32/NN	appos||test-32/NN||ogtt-34/NN	amod||inflammation-38/NN||systemic-37/JJ	prep_for||screened-25/VBN||inflammation-38/NN	conj_and||diabetes-27/NN||inflammation-38/NN	amod||protein-41/NN||c-reactive-40/JJ	prep_with||inflammation-38/NN||protein-41/NN	appos||protein-41/NN||crp-43/NN	nn||inflammation-47/NN||gut-46/NN	prep_for||screened-25/VBN||inflammation-47/NN	conj_and||diabetes-27/NN||inflammation-47/NN	amod||nitricoxide-50/NN||rectal-49/JJ	prep_with||inflammation-47/NN||nitricoxide-50/NN	discourse||nitricoxide-50/NN||no-52/UH	amod||calprotectin-56/NN||faecal-55/JJ	prep_with||inflammation-47/NN||calprotectin-56/NN	conj_and||nitricoxide-50/NN||calprotectin-56/NN	inflammation-47||glucose-30||no_rel||thirty-four children (25 males; median age 10.8 â± 3.4 yrs) with severe obesity (bmi >95%) were screened for diabetes with oral glucose tolerance test (ogtt), systemic inflammation with c-reactive protein (crp) and gut inflammation with rectal nitricoxide (no) and faecal calprotectin.
aux||assess-2/VB||to-1/TO	csubj||study-35/VBP||assess-2/VB	det||effect-4/NN||the-3/DT	dobj||assess-2/VB||effect-4/NN	amod||variability-8/NN||intraday-6/JJ	nn||variability-8/NN||glucose-7/NN	prep_of||effect-4/NN||variability-8/NN	appos||variability-8/NN||gv-10/NN	amod||outcomes-14/NNS||cardiovascular-13/JJ	prep_on||assess-2/VB||outcomes-14/NNS	det||reanalysis-17/NNS||a-16/DT	prep_in||outcomes-14/NNS||reanalysis-17/NNS	prep_of||reanalysis-17/NNS||hyperglycemia-19/NN	poss||effect-22/NN||its-21/PRP$	prep_of||reanalysis-17/NNS||effect-22/NN	conj_and||hyperglycemia-19/NN||effect-22/NN	prep_after||assess-2/VB||acutemyocardialinfarction-24/NN	amod||outcomes-27/NNS||cardiovascular-26/JJ	prep_on||acutemyocardialinfarction-24/NN||outcomes-27/NNS	prep_in||outcomes-27/NNS||patients-29/NNS	prep_with||patients-29/NNS||type2diabetesmellitus-31/NNS	appos||type2diabetesmellitus-31/NNS||heart2d-33/NNP	root||ROOT-0/null||study-35/VBP	dobj||study-35/VBP||data-36/NNS	hyperglycemia-19||glucose-7||no||to assess the effect of intraday glucose variability (gv) on cardiovascular outcomes in a reanalysis of hyperglycemia and its effect after acutemyocardialinfarction on cardiovascular outcomes in patients with type2diabetesmellitus (heart2d) study data.
amod||programs-3/NNS||similar-1/JJ	amod||programs-3/NNS||task-shifting-2/JJ	nsubj||help-5/VB||programs-3/NNS	aux||help-5/VB||might-4/MD	root||ROOT-0/null||help-5/VB	amod||clinics-8/NNS||large-6/JJ	nn||clinics-8/NNS||hiv/aids-7/NNS	dobj||help-5/VB||clinics-8/NNS	nn||countries-14/NNS||uganda-10/NN	conj_and||uganda-10/NN||other-12/JJ	nn||countries-14/NNS||other-12/JJ	amod||countries-14/NNS||low-income-13/JJ	prep_in||clinics-8/NNS||countries-14/NNS	aux||cope-16/VB||to-15/TO	vmod||help-5/VB||cope-16/VB	amod||numbers-19/NNS||increasing-18/VBG	prep_with||cope-16/VB||numbers-19/NNS	prep_of||numbers-19/NNS||patients-21/NNS	vmod||patients-21/NNS||seeking-22/VBG	dobj||seeking-22/VBG||care-23/NN	aids--1||hiv--1||no||similar task-shifting programs might help large hiv/aids clinics in uganda and other low-income countries to cope with increasing numbers of patients seeking care.
expl||is-2/VBZ||there-1/EX	root||ROOT-0/null||is-2/VBZ	det||need-4/NN||a-3/DT	nsubj||is-2/VBZ||need-4/NN	amod||attempts-7/NNS||greater-6/JJR	prep_for||need-4/NN||attempts-7/NNS	prepc_toward||attempts-7/NNS||making-9/VBG	dobj||making-9/VBG||information-10/NN	prep_regarding||information-10/NN||hiv/aids-12/NNS	amod||hiv/aids-12/NNS||available-13/JJ	det||individual-16/NN||every-15/DT	prep_to||available-13/JJ||individual-16/NN	det||society-19/NN||the-18/DT	prep_of||individual-16/NN||society-19/NN	aids--1||hiv--1||no||there is a need for greater attempts toward making information regarding hiv/aids available to every individual of the society.
det||results-2/NNS||the-1/DT	nsubjpass||confirmed-4/VBN||results-2/NNS	auxpass||confirmed-4/VBN||were-3/VBD	root||ROOT-0/null||confirmed-4/VBN	amod||assay-8/NN||quantitative-6/JJ	nn||assay-8/NN||enzyme-7/NN	agent||confirmed-4/VBN||assay-8/NN	det||cases-11/NNS||the-10/DT	prep_for||assay-8/NN||cases-11/NNS	nsubj||showed-13/VBD||cases-11/NNS	rcmod||cases-11/NNS||showed-13/VBD	dobj||showed-13/VBD||g6pddeficiency-14/NNS	g6pddeficiency-14||enzyme-7||no_rel||the results were confirmed by quantitative enzyme assay for the cases that showed g6pddeficiency.
nsubjpass||reported-18/VBN||infliximab-1/NN	nsubj||effective-21/JJ||infliximab-1/NN	det||factor-6/NN||an-3/DT	amod||factor-6/NN||anti-tumor-4/JJ	nn||factor-6/NN||necrosis-5/NNS	appos||infliximab-1/NN||factor-6/NN	appos||factor-6/NN||tnf-8/NN	advmod||±-12/JJ||î-11/RB	amod||antibody-14/NN||±-12/JJ	amod||antibody-14/NN||monoclonal-13/JJ	dep||factor-6/NN||antibody-14/NN	aux||reported-18/VBN||has-16/VBZ	auxpass||reported-18/VBN||been-17/VBN	root||ROOT-0/null||reported-18/VBN	aux||effective-21/JJ||to-19/TO	cop||effective-21/JJ||be-20/VB	xcomp||reported-18/VBN||effective-21/JJ	amod||uveoretinitis-24/NNS||refractory-23/JJ	prep_in||effective-21/JJ||uveoretinitis-24/NNS	prepc_in||effective-21/JJ||behã-26/VBG	nn||et-28/NNP||§-27/NNP	dep||sdisease-30/JJ||et-28/NNP	dep||behã-26/VBG||sdisease-30/JJ	behã§et'sdisease--1||antibody-14||no_rel||infliximab, an anti-tumor necrosis factor (tnf)-î± monoclonal antibody, has been reported to be effective in refractory uveoretinitis in behã§et'sdisease.
det||study-3/NN||this-2/DT	prep_in||demonstrate-6/VBP||study-3/NN	nsubj||demonstrate-6/VBP||we-5/PRP	root||ROOT-0/null||demonstrate-6/VBP	mark||elicits-15/VBZ||that-7/IN	nsubj||elicits-15/VBZ||vaccination-8/NN	det||vaccine-14/NN||the-10/DT	num||vaccine-14/NN||2009-11/CD	amod||vaccine-14/NN||pandemic-12/JJ	nn||vaccine-14/NN||h1n1-13/NN	prep_with||vaccination-8/NN||vaccine-14/NN	ccomp||demonstrate-6/VBP||elicits-15/VBZ	num||antibodies-19/NNS||1918-16/CD	nn||antibodies-19/NNS||virus-17/NN	nn||antibodies-19/NNS||cross-protective-18/NN	dobj||elicits-15/VBZ||antibodies-19/NNS	prep_in||antibodies-19/NNS||mice-21/NNS	prep_in||antibodies-19/NNS||humans-23/NNS	conj_and||mice-21/NNS||humans-23/NNS	mark||reduced-34/VBD||that-26/IN	nn||transfer-30/NN||vaccination-27/NN	conj_or||vaccination-27/NN||passive-29/JJ	nn||transfer-30/NN||passive-29/JJ	nsubj||reduced-34/VBD||transfer-30/NN	nsubj||conferred-37/VBD||transfer-30/NN	amod||sera-33/NN||human-positive-32/JJ	prep_of||transfer-30/NN||sera-33/NN	ccomp||demonstrate-6/VBP||reduced-34/VBD	conj_and||elicits-15/VBZ||reduced-34/VBD	dobj||reduced-34/VBD||morbidity-35/NN	conj_and||elicits-15/VBZ||conferred-37/VBD	conj_and||reduced-34/VBD||conferred-37/VBD	amod||protection-39/NN||full-38/JJ	dobj||conferred-37/VBD||protection-39/NN	amod||challenge-42/NN||lethal-41/JJ	prep_from||conferred-37/VBD||challenge-42/NN	det||virus-46/NN||the-44/DT	num||virus-46/NN||1918-45/CD	prep_with||challenge-42/NN||virus-46/NN	prep_in||conferred-37/VBD||mice-48/NNS	cross--1||antibodies-19||no_rel||in this study, we demonstrate that vaccination with the 2009 pandemic h1n1 vaccine elicits 1918 virus cross-protective antibodies in mice and humans, and that vaccination or passive transfer of human-positive sera reduced morbidity and conferred full protection from lethal challenge with the 1918 virus in mice.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||case-5/NN||a-3/DT	amod||case-5/NN||rare-4/JJ	dobj||report-2/VBP||case-5/NN	amod||vasculitis-11/NNS||hydralazine-induced-7/JJ	amod||vasculitis-11/NNS||anti-neutrophil-8/JJ	amod||vasculitis-11/NNS||cytoplasmic-9/JJ	amod||vasculitis-11/NNS||antibody-associated-10/JJ	prep_of||case-5/NN||vasculitis-11/NNS	det||woman-16/NN||a-13/DT	amod||woman-16/NN||62-year-old-14/JJ	amod||woman-16/NN||caucasian-15/JJ	prep_in||vasculitis-11/NNS||woman-16/NN	nsubj||presented-18/VBD||woman-16/NN	rcmod||woman-16/NN||presented-18/VBD	det||syndrome-22/NN||a-20/DT	amod||syndrome-22/NN||vasculitic-21/JJ	prep_with||presented-18/VBD||syndrome-22/NN	det||sorethroat-25/NN||a-24/DT	prep_with||syndrome-22/NN||sorethroat-25/NN	prep_with||syndrome-22/NN||mouthulcers-27/NNS	conj_and||sorethroat-25/NN||mouthulcers-27/NNS	prep_with||syndrome-22/NN||otalgia-29/NN	conj_and||sorethroat-25/NN||otalgia-29/NN	amod||months-32/NNS||several-31/JJ	prep_after||presented-18/VBD||months-32/NNS	amod||symptoms-35/NNS||constitutional-34/JJ	prep_of||months-32/NNS||symptoms-35/NNS	otalgia-29||antibody--1||no_rel||we report a rare case of hydralazine-induced anti-neutrophil cytoplasmic antibody-associated vasculitis in a 62-year-old caucasian woman who presented with a vasculitic syndrome with a sorethroat, mouthulcers and otalgia after several months of constitutional symptoms.
det||meta-analyses-2/NNS||these-1/DT	nsubj||reveal-5/VB||meta-analyses-2/NNS	aux||reveal-5/VB||did-3/VBD	neg||reveal-5/VB||not-4/RB	root||ROOT-0/null||reveal-5/VB	det||increase-8/NN||a-6/DT	amod||increase-8/NN||significant-7/JJ	dobj||reveal-5/VB||increase-8/NN	det||risk-11/NN||the-10/DT	prep_in||increase-8/NN||risk-11/NN	amod||infections-14/NNS||serious-13/JJ	prep_of||risk-11/NN||infections-14/NNS	nn||treatments-19/NNS||rituximab-16/NN	conj_or||rituximab-16/NN||abatacept-18/NN	nn||treatments-19/NNS||abatacept-18/NN	prep_during||reveal-5/VB||treatments-19/NNS	prep_in||reveal-5/VB||patients-21/NNS	prep_with||patients-21/NNS||rheumatoidarthritis-23/NNS	advmod||increase-32/VB||however-25/RB	amod||doses-28/NNS||high-27/JJ	nsubj||increase-32/VB||doses-28/NNS	prep_of||doses-28/NNS||anakinra-30/NN	aux||increase-32/VB||may-31/MD	parataxis||reveal-5/VB||increase-32/VB	det||risk-34/NN||this-33/DT	dobj||increase-32/VB||risk-34/NN	tmod||have-39/VBP||risk-34/NN	advmod||when-37/WRB||especially-36/RB	advmod||have-39/VBP||when-37/WRB	nsubj||have-39/VBP||patients-38/NNS	rcmod||risk-34/NN||have-39/VBP	amod||factors-41/NNS||comorbidity-40/JJ	dobj||have-39/VBP||factors-41/NNS	rheumatoidarthritis-23||anakinra-30||yes||these meta-analyses did not reveal a significant increase in the risk of serious infections during rituximab or abatacept treatments in patients with rheumatoidarthritis; however, high doses of anakinra may increase this risk, especially when patients have comorbidity factors.
det||trial-8/NN||a-2/DT	amod||trial-8/NN||large-3/JJ	amod||trial-8/NN||acute-4/JJ	amod||trial-8/NN||coronary-5/JJ	nn||trial-8/NN||syndrome-6/NN	amod||trial-8/NN||clinical-7/JJ	prep_in||reduced-11/VBD||trial-8/NN	nsubj||reduced-11/VBD||ranolazine-10/NN	root||ROOT-0/null||reduced-11/VBD	det||incidence-13/NN||the-12/DT	dobj||reduced-11/VBD||incidence-13/NN	prep_of||incidence-13/NN||supraventriculartachycardia-15/NN	prep_of||incidence-13/NN||ventriculartachycardia-17/NN	conj_and||supraventriculartachycardia-15/NN||ventriculartachycardia-17/NN	amod||atrialfibrillation-20/NN||new-onset-19/JJ	prep_of||incidence-13/NN||atrialfibrillation-20/NN	conj_and||supraventriculartachycardia-15/NN||atrialfibrillation-20/NN	amod||events-24/NNS||bradycardic-23/JJ	prep_of||incidence-13/NN||events-24/NNS	conj_and||supraventriculartachycardia-15/NN||events-24/NNS	ranolazine-10||supraventriculartachycardia-15||no_rel||in a large acute coronary syndrome clinical trial, ranolazine reduced the incidence of supraventriculartachycardia, ventriculartachycardia, new-onset atrialfibrillation, and bradycardic events.
amod||dysfunction-2/NN||endothelial-1/JJ	nsubj||present-5/JJ||dysfunction-2/NN	nsubjpass||induced-15/VBN||dysfunction-2/NN	cop||present-5/JJ||is-3/VBZ	advmod||present-5/JJ||frequently-4/RB	root||ROOT-0/null||present-5/JJ	prep_in||present-5/JJ||individuals-7/NNS	prep_with||individuals-7/NNS||insulinresistance-9/NN	prep_with||individuals-7/NNS||type2diabetes-11/NNS	conj_or||insulinresistance-9/NN||type2diabetes-11/NNS	aux||induced-15/VBN||can-13/MD	auxpass||induced-15/VBN||be-14/VB	conj_and||present-5/JJ||induced-15/VBN	amod||meals-20/NNS||high-fat-17/JJ	conj_or||high-fat-17/JJ||high-carbohydrate-19/JJ	amod||meals-20/NNS||high-carbohydrate-19/JJ	agent||induced-15/VBN||meals-20/NNS	carbohydrate--1||insulinresistance-9||no_rel||endothelial dysfunction is frequently present in individuals with insulinresistance or type2diabetes and can be induced by high-fat or high-carbohydrate meals.
nsubjpass||used-3/VBN||eflornithine-1/NN	auxpass||used-3/VBN||is-2/VBZ	root||ROOT-0/null||used-3/VBN	det||treatment-8/NN||a-5/DT	amod||treatment-8/NN||first-6/JJ	nn||treatment-8/NN||line-7/NN	prep_as||used-3/VBN||treatment-8/NN	amod||africantrypanosomiasis-11/NNS||human-10/JJ	prep_for||treatment-8/NN||africantrypanosomiasis-11/NNS	expl||is-15/VBZ||there-14/EX	conj_but||used-3/VBN||is-15/VBZ	det||risk-17/NN||a-16/DT	nsubj||is-15/VBZ||risk-17/NN	mark||thwart-21/VB||that-18/IN	nsubj||thwart-21/VB||resistance-19/NN	aux||thwart-21/VB||could-20/MD	ccomp||is-15/VBZ||thwart-21/VB	poss||use-23/NN||its-22/PRP$	dobj||thwart-21/VB||use-23/NN	advmod||used-27/VBN||even-25/RB	advmod||used-27/VBN||when-26/WRB	advcl||is-15/VBZ||used-27/VBN	nn||therapy-30/NN||combination-29/NN	prep_in||used-27/VBN||therapy-30/NN	prep_with||used-27/VBN||nifurtimox-32/NN	africantrypanosomiasis-11||eflornithine-1||yes||eflornithine is used as a first line treatment for human africantrypanosomiasis, but there is a risk that resistance could thwart its use, even when used in combination therapy with nifurtimox.
vmod||determined-26/VBD||based-1/VBN	advmod||successful-4/JJ||highly-3/RB	amod||demonstrations-5/NNS||successful-4/JJ	prep_on||based-1/VBN||demonstrations-5/NNS	prep_in||based-1/VBN||israel-7/NN	mark||decimate-18/VB||that-8/IN	amod||bait-12/NN||attractive-9/JJ	amod||bait-12/NN||toxic-10/JJ	nn||bait-12/NN||sugar-11/NN	nn||methods-16/NNS||bait-12/NN	appos||methods-16/NNS||atsb-14/NN	nsubj||decimate-18/VB||methods-16/NNS	aux||decimate-18/VB||can-17/MD	ccomp||based-1/VBN||decimate-18/VB	amod||populations-20/NNS||local-19/JJ	dobj||decimate-18/VB||populations-20/NNS	prep_of||populations-20/NNS||mosquitoes-22/NNS	det||study-25/NN||this-24/DT	nsubj||determined-26/VBD||study-25/NN	root||ROOT-0/null||determined-26/VBD	det||effectiveness-28/NN||the-27/DT	dobj||determined-26/VBD||effectiveness-28/NN	amod||methods-31/NNS||atsb-30/JJ	prep_of||effectiveness-28/NN||methods-31/NNS	nn||control-35/NN||malaria-33/NN	nn||control-35/NN||vector-34/NN	prep_for||determined-26/VBD||control-35/NN	det||district-40/NN||the-37/DT	amod||district-40/NN||semi-arid-38/JJ	nn||district-40/NN||bandiagara-39/NN	prep_in||control-35/NN||district-40/NN	prep_of||district-40/NN||mali-42/NNS	amod||africa-45/NN||west-44/JJ	appos||mali-42/NNS||africa-45/NN	sugar-11||west-44||no_rel||based on highly successful demonstrations in israel that attractive toxic sugar bait (atsb) methods can decimate local populations of mosquitoes, this study determined the effectiveness of atsb methods for malaria vector control in the semi-arid bandiagara district of mali, west africa.
advmod||increased-14/JJ||however-1/RB	det||frequency-4/NN||the-3/DT	nsubj||increased-14/JJ||frequency-4/NN	nn||cells-11/NNS||total-6/NN	conj_and||total-6/NN||cd8-8/JJ	nn||cells-11/NNS||cd8-8/JJ	nn||cells-11/NNS||+-9/NN	nn||cells-11/NNS||nkt-10/NN	prep_of||frequency-4/NN||cells-11/NNS	cop||increased-14/JJ||is-12/VBZ	advmod||increased-14/JJ||remarkably-13/RB	dep||infectiousmononucleosis-19/VBZ||increased-14/JJ	det||ebv-18/NN||the-16/DT	amod||ebv-18/NN||acute-17/JJ	prep_in||increased-14/JJ||ebv-18/NN	root||ROOT-0/null||infectiousmononucleosis-19/VBZ	dobj||infectiousmononucleosis-19/VBZ||patients-20/NNS	prep_at||infectiousmononucleosis-19/VBZ||year-22/NN	num||post-onset-24/NN||1-23/CD	nsubj||infectiousmononucleosis-19/VBZ||post-onset-24/NN	infectiousmononucleosis-19||ebv-18||no||however, the frequency of total and cd8+ nkt cells is remarkably increased in the acute ebv infectiousmononucleosis patients at year 1 post-onset.
nsubj||conclude-2/VBP||we-1/PRP	root||ROOT-0/null||conclude-2/VBP	det||³-5/NN||that-3/DT	nn||³-5/NN||î-4/NN	dobj||conclude-2/VBP||³-5/NN	amod||results-9/NNS||secretase-7/JJ	nn||results-9/NNS||inhibition-8/NN	nsubj||kinases-15/VBZ||results-9/NNS	nsubj||enhances-24/VBZ||results-9/NNS	prep_in||results-9/NNS||activation-11/NN	det||map-14/NN||the-13/DT	prep_of||activation-11/NN||map-14/NN	parataxis||conclude-2/VBP||kinases-15/VBZ	dobj||kinases-15/VBZ||erk1/2-16/NNS	advmod||used-20/VBN||when-19/WRB	parataxis||kinases-15/VBZ||used-20/VBN	parataxis||enhances-24/VBZ||used-20/VBN	prep_in||used-20/VBN||conjunction-22/NN	parataxis||conclude-2/VBP||enhances-24/VBZ	conj_and||kinases-15/VBZ||enhances-24/VBZ	nn||death-26/NN||cell-25/NN	dobj||enhances-24/VBZ||death-26/NN	vmod||death-26/NN||induced-27/VBN	nn||compounds-30/NNS||platinum-29/NN	agent||induced-27/VBN||compounds-30/NNS	det||subset-34/NN||a-32/DT	amod||subset-34/NN||large-33/JJ	prep_in||compounds-30/NNS||subset-34/NN	amod||lines-39/NNS||colorectal-36/JJ	nn||lines-39/NNS||cancer-37/NN	nn||lines-39/NNS||cell-38/NN	prep_of||subset-34/NN||lines-39/NNS	cancer-37||platinum-29||no_rel||we conclude that î³-secretase inhibition results in activation of the map kinases erk1/2 and, when used in conjunction, enhances cell death induced by platinum compounds in a large subset of colorectal cancer cell lines.
det||study-3/NN||this-2/DT	prep_in||investigated-6/VBD||study-3/NN	nsubj||investigated-6/VBD||we-5/PRP	root||ROOT-0/null||investigated-6/VBD	det||role-8/NN||the-7/DT	dobj||investigated-6/VBD||role-8/NN	amod||sensitivity-17/NN||caspase-3-10/JJ	nn||line-16/NN||breast-12/NN	conj_and||breast-12/NN||lungtumor-14/NN	nn||line-16/NN||lungtumor-14/NN	nn||line-16/NN||cell-15/NN	prep_in||caspase-3-10/JJ||line-16/NN	prep_of||role-8/NN||sensitivity-17/NN	prep_to||investigated-6/VBD||paclitaxel-19/NN	lungtumor-14||paclitaxel-19||yes||in this study, we investigated the role of caspase-3 in breast and lungtumor cell line sensitivity to paclitaxel.
nsubj||introduced-2/VBD||we-1/PRP	root||ROOT-0/null||introduced-2/VBD	amod||opioids-4/NNS||strong-3/JJ	nsubj||tolerable-26/JJ||opioids-4/NNS	amod||patches-8/NNS||transdermal-6/JJ	amod||patches-8/NNS||fentanyl-7/JJ	dep||opioids-4/NNS||patches-8/NNS	det||pain-12/NN||the-10/DT	nn||pain-12/NN||background-11/NN	prep_for||patches-8/NNS||pain-12/NN	det||opioid-16/NN||a-14/DT	amod||opioid-16/NN||short-acting-15/JJ	dep||opioids-4/NNS||opioid-16/NN	conj_and||patches-8/NNS||opioid-16/NN	det||pain-20/NN||the-18/DT	nn||pain-20/NN||breakthrough-19/NN	prep_for||opioid-16/NN||pain-20/NN	poss||pain-24/NN||his-23/PRP$	conj_and||opioids-4/NNS||pain-24/NN	nsubj||tolerable-26/JJ||pain-24/NN	cop||tolerable-26/JJ||was-25/VBD	ccomp||introduced-2/VBD||tolerable-26/JJ	num||hr-31/NN||250-28/CD	nn||hr-31/NN||âµg-29/NN	nn||hr-31/NN||/-30/NN	prep_on||tolerable-26/JJ||hr-31/NN	amod||patches-34/NNS||fentanyl-33/JJ	prep_of||hr-31/NN||patches-34/NNS	num||months-37/NNS||3-36/CD	prep_for||tolerable-26/JJ||months-37/NNS	pain-24||fentanyl-33||yes||we introduced strong opioids (transdermal fentanyl patches for the background pain and a short-acting opioid for the breakthrough pain) and his pain was tolerable on 250 âµg/hr of fentanyl patches for 3 months.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||simplify-8/VB||to-7/TO	dep||was-6/VBD||simplify-8/VB	det||test-16/NN||the-9/DT	amod||test-16/NN||intravenous-10/JJ	amod||test-16/NN||gonadotropin-releasinghormone-11/JJ	appos||test-16/NN||gnrh-13/NN	nn||test-16/NN||stimulation-15/NN	dobj||simplify-8/VB||test-16/NN	det||diagnosis-19/NN||the-18/DT	prep_in||test-16/NN||diagnosis-19/NN	prep_of||diagnosis-19/NN||precociouspuberty-21/NN	dep||was-6/VBD||in-23/IN	conj_and||simplify-8/VB||in-23/IN	det||assessment-25/NN||the-24/DT	pobj||in-23/IN||assessment-25/NN	amod||suppression-28/NN||pubertal-27/JJ	prep_of||assessment-25/NN||suppression-28/NN	precociouspuberty-21||gonadotropin-releasinghormone-11||yes||the aim of this study was to simplify the intravenous gonadotropin-releasinghormone (gnrh) stimulation test in the diagnosis of precociouspuberty and in the assessment of pubertal suppression.
amod||tension-3/NN||arterial-1/JJ	nn||tension-3/NN||oxygen-2/NN	nsubjpass||recognized-14/VBN||tension-3/NN	nn||delivery-6/NN||oxygen-5/NN	appos||tension-3/NN||delivery-6/NN	prep_to||delivery-6/NN||tissue-8/NN	amod||inflammation-12/NN||systemic-11/JJ	conj_and||tension-3/NN||inflammation-12/NN	nsubjpass||recognized-14/VBN||inflammation-12/NN	auxpass||recognized-14/VBN||are-13/VBP	root||ROOT-0/null||recognized-14/VBN	amod||factors-17/NNS||pivotal-16/JJ	prep_as||recognized-14/VBN||factors-17/NNS	det||progression-20/NN||the-19/DT	prep_in||factors-17/NNS||progression-20/NN	amod||obstructivepulmonarydisease-23/NN||chronic-22/JJ	prep_of||progression-20/NN||obstructivepulmonarydisease-23/NN	dep||progression-20/NN||copd-25/VBN	obstructivepulmonarydisease-23||oxygen-5||yes||arterial oxygen tension, oxygen delivery to tissue, and systemic inflammation are recognized as pivotal factors in the progression of chronic obstructivepulmonarydisease (copd).
nsubjpass||associated-4/VBN||colesevelam-1/NN	nsubjpass||associated-10/VBN||colesevelam-1/NN	nsubjpass||combined-22/VBN||colesevelam-1/NN	auxpass||associated-4/VBN||was-2/VBD	neg||associated-4/VBN||not-3/RB	root||ROOT-0/null||associated-4/VBN	nn||gain-7/NN||weight-6/NN	prep_with||associated-4/VBN||gain-7/NN	auxpass||associated-10/VBN||was-9/VBD	conj_and||associated-4/VBN||associated-10/VBN	det||incidence-14/NN||a-12/DT	amod||incidence-14/NN||low-13/JJ	prep_with||associated-10/VBN||incidence-14/NN	prep_of||incidence-14/NN||hypoglycaemia-16/NN	aux||combined-22/VBN||can-19/MD	auxpass||combined-22/VBN||be-20/VB	advmod||combined-22/VBN||safely-21/RB	conj_and||associated-4/VBN||combined-22/VBN	det||range-26/NN||a-24/DT	amod||range-26/NN||broad-25/JJ	prep_with||combined-22/VBN||range-26/NN	amod||agents-29/NNS||glucose-lowering-28/JJ	prep_of||range-26/NN||agents-29/NNS	dep||agents-29/NNS||metformin-31/NN	dep||agents-29/NNS||sulfonylureas-33/NNS	conj_and||metformin-31/NN||sulfonylureas-33/NNS	dep||agents-29/NNS||insulin-35/NN	conj_and||metformin-31/NN||insulin-35/NN	amod||statins-39/NNS||lipid-lowering-38/JJ	prep_of||range-26/NN||statins-39/NNS	conj_and||agents-29/NNS||statins-39/NNS	hypoglycaemia-16||glucose--1||yes||colesevelam was not associated with weight gain, was associated with a low incidence of hypoglycaemia, and can be safely combined with a broad range of glucose-lowering agents (metformin, sulfonylureas and insulin) and lipid-lowering statins.
vmod||demonstrated-30/VBD||using-1/VBG	det||model-5/NN||an-2/DT	dep||vitro-4/NN||in-3/IN	amod||model-5/NN||vitro-4/NN	dobj||using-1/VBG||model-5/NN	vmod||model-5/NN||designed-6/VBN	aux||recapitulate-8/VB||to-7/TO	xcomp||designed-6/VBN||recapitulate-8/VB	amod||events-10/NNS||cellular-9/JJ	dobj||recapitulate-8/VB||events-10/NNS	vmod||events-10/NNS||implicated-11/VBN	prep_in||implicated-11/VBN||mycobacterialinfection-13/NN	prep_in||implicated-11/VBN||dissemination-15/NN	conj_and||mycobacterialinfection-13/NN||dissemination-15/NN	prep_in||implicated-11/VBN||vivo-17/NN	dep||phagocytosis-21/JJ||i.e.-19/FW	dep||vivo-17/NN||phagocytosis-21/JJ	amod||mycobacteria-26/NN||apoptotic-23/JJ	amod||mycobacteria-26/NN||macrophages-24/JJ	amod||mycobacteria-26/NN||containing-25/JJ	prep_of||phagocytosis-21/JJ||mycobacteria-26/NN	nsubj||demonstrated-30/VBD||we-29/PRP	root||ROOT-0/null||demonstrated-30/VBD	amod||recovery-32/NN||reduced-31/VBN	dobj||demonstrated-30/VBD||recovery-32/NN	amod||mycobacteria-35/NN||viable-34/JJ	prep_of||recovery-32/NN||mycobacteria-35/NN	amod||macrophages-41/NNS||cd36-37/JJ	dep||macrophages-41/NNS||/-39/NNP	prep_within||mycobacteria-35/NN||macrophages-41/NNS	mycobacterialinfection-13||mycobacteria-35||no||using an in vitro model designed to recapitulate cellular events implicated in mycobacterialinfection and dissemination in vivo (i.e., phagocytosis of apoptotic macrophages containing mycobacteria), we demonstrated reduced recovery of viable mycobacteria within cd36 -/- macrophages.
mark||knew-4/VBD||although-1/IN	num||%-3/NN||91.4-2/CD	nsubj||knew-4/VBD||%-3/NN	advcl||know-15/VB||knew-4/VBD	nsubjpass||transmitted-7/VBN||tb-5/NN	auxpass||transmitted-7/VBN||was-6/VBD	ccomp||knew-4/VBD||transmitted-7/VBN	prep_via||transmitted-7/VBN||aerosols-9/NNS	quantmod||one-third-12/NN||about-11/RB	nsubj||know-15/VB||one-third-12/NN	aux||know-15/VB||did-13/VBD	neg||know-15/VB||not-14/RB	root||ROOT-0/null||know-15/VB	det||method-17/NN||the-16/DT	dobj||know-15/VB||method-17/NN	prepc_for||know-15/VB||administering-19/VBG	dobj||administering-19/VBG||tuberculin-20/NN	det||vaccine-28/NN||that-23/DT	amod||vaccine-28/NN||bacilluscalmette-guerin-24/JJ	nn||vaccine-28/NN||bcg-26/NN	nsubj||contraindication-32/NN||vaccine-28/NN	cop||contraindication-32/NN||was-29/VBD	neg||contraindication-32/NN||not-30/RB	det||contraindication-32/NN||a-31/DT	conj_or||know-15/VB||contraindication-32/NN	aux||tb-34/VB||to-33/TO	vmod||contraindication-32/NN||tb-34/VB	nn||testing-36/NN||skin-35/NN	dobj||tb-34/VB||testing-36/NN	tb-34||bcg-26||yes||although 91.4% knew tb was transmitted via aerosols, about one-third did not know the method for administering tuberculin, or that bacilluscalmette-guerin (bcg) vaccine was not a contraindication to tb skin testing.
mark||result-8/VB||while-1/IN	nn||treatments-3/NNS||stimulant-2/NN	nsubj||result-8/VB||treatments-3/NNS	prep_for||treatments-3/NNS||adhd-5/NN	aux||result-8/VB||could-6/MD	advmod||result-8/VB||certainly-7/RB	advcl||reports-23/NNS||result-8/VB	det||result-12/NN||a-10/DT	amod||result-12/NN||positive-11/JJ	prep_in||result-8/VB||result-12/NN	nn||screen-15/NN||urine-14/NN	prep_on||result-12/NN||screen-15/NN	prep_for||screen-15/NN||amphetamines-17/NNS	expl||reports-23/NNS||there-19/EX	aux||reports-23/NNS||have-20/VBP	cop||reports-23/NNS||been-21/VBN	neg||reports-23/NNS||no-22/DT	root||ROOT-0/null||reports-23/NNS	amod||results-26/NNS||false-positive-25/JJ	prep_of||reports-23/NNS||results-26/NNS	prep_for||results-26/NNS||amphetamines-28/NNS	amod||amphetamines-28/NNS||secondary-29/JJ	prep_to||secondary-29/JJ||patients-31/NNS	vmod||patients-31/NNS||using-32/VBG	dobj||using-32/VBG||atomoxetine-33/NN	adhd-5||atomoxetine-33||yes||while stimulant treatments for adhd could certainly result in a positive result on urine screen for amphetamines, there have been no reports of false-positive results for amphetamines secondary to patients using atomoxetine.
nn||cancer-2/NN||breast-1/NN	nsubj||cancer-8/NN||cancer-2/NN	cop||cancer-8/NN||is-3/VBZ	advmod||cancer-8/NN||frequently-4/RB	det||cancer-8/NN||a-5/DT	advmod||dependent-7/JJ||hormonally-6/RB	amod||cancer-8/NN||dependent-7/JJ	root||ROOT-0/null||cancer-8/NN	nsubjpass||established-24/VBN||associations-11/NNS	prepc_of||associations-11/NNS||circulating-13/VBG	dobj||circulating-13/VBG||estrogens-14/NNS	dobj||circulating-13/VBG||androgens-16/NNS	conj_and||estrogens-14/NNS||androgens-16/NNS	amod||risk-21/NN||subsequent-18/JJ	nn||risk-21/NN||breast-19/NN	nn||risk-21/NN||cancer-20/NN	prep_with||circulating-13/VBG||risk-21/NN	auxpass||established-24/VBN||are-22/VBP	advmod||established-24/VBN||well-23/RB	conj_and||cancer-8/NN||established-24/VBN	amod||women-27/NNS||postmenopausal-26/JJ	prep_in||established-24/VBN||women-27/NNS	estrogens-14||cancer-20||no_rel||breast cancer is frequently a hormonally dependent cancer, and associations of circulating estrogens and androgens with subsequent breast cancer risk are well established in postmenopausal women.
aux||compare-2/VB||to-1/TO	root||ROOT-0/null||compare-2/VB	det||safety-4/NN||the-3/DT	dobj||compare-2/VB||safety-4/NN	dobj||compare-2/VB||efficacy-6/NN	conj_and||safety-4/NN||efficacy-6/NN	amod||ointment-10/NN||loteprednoletabonate-8/JJ	amod||ointment-10/NN||ophthalmic-9/JJ	prep_of||safety-4/NN||ointment-10/NN	number||%-12/NN||0.5-11/CD	amod||ointment-10/NN||%-12/NN	amod||ointment-15/NN||le-14/JJ	appos||ointment-10/NN||ointment-15/NN	det||formulation-22/NN||a-18/DT	amod||formulation-22/NN||new-19/JJ	amod||formulation-22/NN||topical-20/JJ	nn||formulation-22/NN||ointment-21/NN	appos||ointment-10/NN||formulation-22/NN	prep_with||compare-2/VB||vehicle-25/NN	det||treatment-28/NN||the-27/DT	prep_for||vehicle-25/NN||treatment-28/NN	prep_of||treatment-28/NN||inflammation-30/NN	prep_of||treatment-28/NN||pain-32/NN	conj_and||inflammation-30/NN||pain-32/NN	nn||surgery-35/NN||cataract-34/NN	prep_following||vehicle-25/NN||surgery-35/NN	loteprednoletabonate-8||pain-32||no_rel||to compare the safety and efficacy of loteprednoletabonate ophthalmic ointment 0.5% (le ointment), a new topical ointment formulation, with vehicle for the treatment of inflammation and pain following cataract surgery.
poss||mutations-7/NNS||conclusions-1/NNS	amod||mutations-7/NNS||$-3/$	nn||mutations-7/NNS||insulin-5/NN	nn||mutations-7/NNS||gene-6/NN	nsubj||rare-9/JJ||mutations-7/NNS	nsubjpass||identified-27/VBN||mutations-7/NNS	cop||rare-9/JJ||are-8/VBP	root||ROOT-0/null||rare-9/JJ	amod||terms-12/NNS||absolute-11/JJ	prep_in||rare-9/JJ||terms-12/NNS	prep_in||terms-12/NNS||patients-14/NNS	vmod||patients-14/NNS||classified-15/VBN	nn||diabetic-19/NN||type-17/NN	num||diabetic-19/NN||1-18/CD	prep_as||classified-15/VBN||diabetic-19/NN	num||%-22/NN||0.6-21/CD	appos||diabetic-19/NN||%-22/NN	aux||identified-27/VBN||can-25/MD	auxpass||identified-27/VBN||be-26/VB	conj_but||rare-9/JJ||identified-27/VBN	det||screening-31/NN||a-29/DT	amod||screening-31/NN||thorough-30/JJ	prep_after||identified-27/VBN||screening-31/NN	amod||autoantibodies-34/NNS||type1diabetes-33/JJ	prep_of||screening-31/NN||autoantibodies-34/NNS	type1diabetes-33||insulin-5||yes||conclusions âinsulin gene mutations are rare in absolute terms in patients classified as type 1 diabetic (0.6%) but can be identified after a thorough screening of type1diabetes autoantibodies.
det||contrary-3/NN||the-2/DT	prep_on||tgf-î-40/VBZ||contrary-3/NN	amod||injections-7/NNS||triple-5/JJ	nn||injections-7/NNS||i.p.-6/NN	nsubj||tgf-î-40/VBZ||injections-7/NNS	num||hours-10/NNS||24-9/CD	npadvmod||apart-11/RB||hours-10/NNS	advmod||injections-7/NNS||apart-11/RB	num||î-15/NN||10-14/CD	prep_of||injections-7/NNS||î-15/NN	num||ejhe-18/NN||1/4-16/CD	nn||ejhe-18/NN||g-17/NN	nsubj||increased-19/VBD||ejhe-18/NN	rcmod||î-15/NN||increased-19/VBD	advmod||ifn-î-21/JJ||significantly-20/RB	amod||production-23/NN||ifn-î-21/JJ	amod||production-23/NN||³-22/JJ	dobj||increased-19/VBD||production-23/NN	det||p-28/NN||the-25/DT	amod||p-28/NN||spleen-26/JJ	amod||p-28/NN||-lrb--27/JJ	prep_in||increased-19/VBD||p-28/NN	vmod||p-28/NN||<-29/VBG	num||-rrb--31/NNS||0.02-30/CD	dobj||<-29/VBG||-rrb--31/NNS	mark||increased-35/VBD||while-32/IN	advmod||ejhe-wr-34/NN||only-33/RB	nsubj||increased-35/VBD||ejhe-wr-34/NN	advcl||<-29/VBG||increased-35/VBD	advmod||ifn-î-37/JJ||significantly-36/RB	amod||³-38/NNS||ifn-î-37/JJ	dobj||increased-35/VBD||³-38/NNS	root||ROOT-0/null||tgf-î-40/VBZ	number||1-42/CD||²-41/CD	dobj||tgf-î-40/VBZ||1-42/CD	amod||<-47/NNS||il-17-44/JJ	amod||<-47/NNS||-lrb--45/JJ	nn||<-47/NNS||p-46/NN	dobj||tgf-î-40/VBZ||<-47/NNS	conj_and||1-42/CD||<-47/NNS	dep||<-47/NNS||0.03-48/CD	num||production-52/NN||0.005-50/CD	amod||production-52/NN||-rrb--51/JJ	dep||<-47/NNS||production-52/NN	det||microenvironment-56/NN||the-54/DT	nn||microenvironment-56/NN||tumor-55/NN	prep_within||production-52/NN||microenvironment-56/NN	amod||fibrosarcoma-59/NN||meth-a-58/JJ	prep_of||microenvironment-56/NN||fibrosarcoma-59/NN	meth--1||fibrosarcoma-59||no_rel||on the contrary , triple i.p. injections , 24 hours apart ; of 10 î 1/4 g ejhe increased significantly ifn-î ³ production in the spleen -lrb- p < 0.02 -rrb- while only ejhe-wr increased significantly ifn-î ³ , tgf-î ² 1 and il-17 -lrb- p < 0.03 - 0.005 -rrb- production within the tumor microenvironment of meth-a fibrosarcoma .
amod||characteristics-2/NNS||patient-related-1/JJ	nsubjpass||evaluated-56/VBN||characteristics-2/NNS	dep||characteristics-2/NNS||age-4/NN	amod||status-7/NN||menopausal-6/JJ	dep||characteristics-2/NNS||status-7/NN	conj_and||age-4/NN||status-7/NN	amod||size-11/NN||pathological-9/JJ	nn||size-11/NN||stage/tumor-10/NN	dep||characteristics-2/NNS||size-11/NN	conj_and||age-4/NN||size-11/NN	nn||location-14/NN||tumor-13/NN	dep||characteristics-2/NNS||location-14/NN	conj_and||age-4/NN||location-14/NN	dep||characteristics-2/NNS||histology-16/NN	conj_and||age-4/NN||histology-16/NN	amod||status-20/NN||estrogen/progesterone-18/JJ	nn||status-20/NN||receptor-19/NN	dep||characteristics-2/NNS||status-20/NN	conj_and||age-4/NN||status-20/NN	amod||grade-23/NN||histological-22/JJ	dep||characteristics-2/NNS||grade-23/NN	conj_and||age-4/NN||grade-23/NN	amod||grade-26/NN||nuclear-25/JJ	dep||characteristics-2/NNS||grade-26/NN	conj_and||age-4/NN||grade-26/NN	nn||extension-29/NN||extracapsular-28/NN	dep||characteristics-2/NNS||extension-29/NN	conj_and||age-4/NN||extension-29/NN	nn||invasion-36/NN||lymphatic-31/JJ	conj_and||lymphatic-31/JJ||vascular-33/NN	nn||invasion-36/NN||vascular-33/NN	conj_and||lymphatic-31/JJ||perineural-35/NN	nn||invasion-36/NN||perineural-35/NN	dep||characteristics-2/NNS||invasion-36/NN	conj_and||age-4/NN||invasion-36/NN	dep||characteristics-2/NNS||ratio-38/NN	conj_and||age-4/NN||ratio-38/NN	amod||nodes/dissected-41/JJ||involved-40/JJ	amod||nodes-42/NNS||nodes/dissected-41/JJ	prep_of||ratio-38/NN||nodes-42/NNS	amod||factors-46/NNS||treatment-related-45/JJ	conj_and||characteristics-2/NNS||factors-46/NNS	nsubjpass||evaluated-56/VBN||factors-46/NNS	nn||therapy-53/NN||pmrt-48/NN	conj_and||pmrt-48/NN||chemotherapy-50/NN	nn||therapy-53/NN||chemotherapy-50/NN	conj_and||pmrt-48/NN||hormonal-52/NN	nn||therapy-53/NN||hormonal-52/NN	appos||factors-46/NNS||therapy-53/NN	auxpass||evaluated-56/VBN||were-55/VBD	root||ROOT-0/null||evaluated-56/VBN	prep_in||evaluated-56/VBN||terms-58/NNS	nn||rate-63/NN||lrr-60/NN	conj_and||lrr-60/NN||dm-62/NN	nn||rate-63/NN||dm-62/NN	prep_of||terms-58/NNS||rate-63/NN	tumor-13||dm-62||yes||patient-related characteristics (age, menopausal status, pathological stage/tumor size, tumor location, histology, estrogen/progesterone receptor status, histological grade, nuclear grade, extracapsular extension, lymphatic, vascular and perineural invasion and ratio of involved nodes/dissected nodes) and treatment-related factors (pmrt, chemotherapy and hormonal therapy) were evaluated in terms of lrr and dm rate.
nsubj||improves-2/VBZ||exenatide-1/NN	root||ROOT-0/null||improves-2/VBZ	amod||excursions-5/NNS||postprandial-3/JJ	amod||excursions-5/NNS||glycemic-4/JJ	dobj||improves-2/VBZ||excursions-5/NNS	prep_in||excursions-5/NNS||type2diabetes-7/CD	type2diabetes-7||exenatide-1||yes||exenatide improves postprandial glycemic excursions in type2diabetes.
nsubj||classified-9/VBD||two-thirds-1/NNS	det||plhiv-4/NN||the-3/DT	prep_of||two-thirds-1/NNS||plhiv-4/NN	num||%-7/NN||66-6/CD	appos||plhiv-4/NN||%-7/NN	root||ROOT-0/null||classified-9/VBD	dobj||classified-9/VBD||themselves-10/PRP	auxpass||given-13/VBN||being-12/VBG	prepc_with||classified-9/VBD||given-13/VBN	det||aids-15/NNS||an-14/DT	iobj||given-13/VBN||aids-15/NNS	amod||stage-18/NN||advanced-17/JJ	dep||aids-15/NNS||stage-18/NN	prep_of||stage-18/NN||hiv-20/NN	dobj||given-13/VBN||diagnosis-22/NN	num||%-25/NN||48-24/CD	nsubj||were-26/VBD||%-25/NN	ccomp||classified-9/VBD||were-26/VBD	conj_and||classified-9/VBD||were-26/VBD	advmod||were-26/VBD||currently-27/RB	prep_on||were-26/VBD||art-29/NN	num||%-32/NN||35-31/CD	nsubj||were-33/VBD||%-32/NN	conj_and||classified-9/VBD||were-33/VBD	advmod||were-33/VBD||currently-34/RB	det||grant-38/NN||a-36/DT	nn||grant-38/NN||disability-37/NN	prep_on||were-33/VBD||grant-38/NN	prep_for||grant-38/NN||hiv/aids-40/NNS	num||%-44/NN||13-43/CD	prep_for||stopped-50/VBN||%-44/NN	det||grant-47/NN||the-45/DT	nn||grant-47/NN||disability-46/NN	nsubjpass||stopped-50/VBN||grant-47/NN	aux||stopped-50/VBN||had-48/VBD	auxpass||stopped-50/VBN||been-49/VBN	conj_and||classified-9/VBD||stopped-50/VBN	aids-15||hiv-20||no||two-thirds of the plhiv (66%) classified themselves with being given an aids (advanced stage of hiv) diagnosis, 48% were currently on art, 35% were currently on a disability grant for hiv/aids and for 13% the disability grant had been stopped.
nsubj||triggered-20/VBD||antimycin-1/NN	dep||antimycin-1/NN||a-2/DT	det||inducer-8/NN||an-4/DT	amod||inducer-8/NN||alternative-5/JJ	amod||inducer-8/NN||respiratory-6/JJ	nn||inducer-8/NN||pathway-7/NN	dep||antimycin-1/NN||inducer-8/NN	advmod||inducer-12/NN||also-10/RB	det||inducer-12/NN||an-11/DT	dep||antimycin-1/NN||inducer-12/NN	conj_and||inducer-8/NN||inducer-12/NN	prep_of||inducer-12/NN||resistance-14/NN	prep_to||inducer-8/NN||viruses-16/NNS	conj_and||antimycin-1/NN||sa-19/NN	nsubj||triggered-20/VBD||sa-19/NN	root||ROOT-0/null||triggered-20/VBD	dobj||triggered-20/VBD||resistance-21/NN	nn||virus-25/NN||tobacco-23/NN	amod||virus-25/NN||mosaic-24/JJ	prep_to||triggered-20/VBD||virus-25/NN	appos||virus-25/NN||tmv-27/NN	virus-25||viruses-16||no||antimycin a (an alternative respiratory pathway inducer and also an inducer of resistance to viruses) and sa triggered resistance to tobacco mosaic virus (tmv).
det||study-3/NN||this-2/DT	prep_in||investigated-6/VBD||study-3/NN	nsubj||investigated-6/VBD||we-5/PRP	root||ROOT-0/null||investigated-6/VBD	det||effect-8/NN||the-7/DT	dobj||investigated-6/VBD||effect-8/NN	det||mixture-12/NN||a-10/DT	amod||mixture-12/NN||lidocaine-11/JJ	prep_of||effect-8/NN||mixture-12/NN	prep_on||investigated-6/VBD||pain-14/NN	dep||pain-14/NN||induced-15/VBN	amod||injection-19/NN||microemulsion-17/JJ	amod||injection-19/NN||propofol-18/JJ	prep_by||induced-15/VBN||injection-19/NN	dep||pain-14/NN||sought-22/VBN	conj_and||induced-15/VBN||sought-22/VBN	aux||determine-24/VB||to-23/TO	xcomp||sought-22/VBN||determine-24/VB	det||dose-27/NN||the-25/DT	amod||dose-27/NN||optimal-26/JJ	dobj||determine-24/VB||dose-27/NN	nsubj||reduce-32/VB||dose-27/NN	prep_of||dose-27/NN||lidocaine-29/NN	aux||reduce-32/VB||could-31/MD	rcmod||dose-27/NN||reduce-32/VB	dobj||reduce-32/VB||pain-33/NN	prepc_on||reduce-32/VB||injecting-35/VBG	det||mixture-38/NN||a-36/DT	amod||mixture-38/NN||propofol-lidocaine-37/JJ	dobj||injecting-35/VBG||mixture-38/NN	pain-33||lidocaine-29||yes||in this study, we investigated the effect of a lidocaine mixture on pain induced by microemulsion propofol injection, and sought to determine the optimal dose of lidocaine that could reduce pain on injecting a propofol-lidocaine mixture.
det||result-2/NN||this-1/DT	nsubj||suggested-3/VBD||result-2/NN	root||ROOT-0/null||suggested-3/VBD	det||regimen-8/NN||the-4/DT	amod||regimen-8/NN||general-5/JJ	nn||regimen-8/NN||tb-6/NN	nn||regimen-8/NN||treatment-7/NN	dobj||suggested-3/VBD||regimen-8/NN	prep_including||regimen-8/NN||pyrazinamide-10/NN	aux||choice-15/NN||to-11/TO	cop||choice-15/NN||be-12/VB	det||choice-15/NN||the-13/DT	amod||choice-15/NN||first-14/JJ	vmod||pyrazinamide-10/NN||choice-15/NN	prep_in||choice-15/NN||bangladesh-17/NN	tb-6||pyrazinamide-10||yes||this result suggested the general tb treatment regimen including pyrazinamide to be the first choice in bangladesh.
det||patient-3/NN||each-2/DT	prep_in||graded-12/JJ||patient-3/NN	nsubj||graded-12/JJ||pain-5/NN	nsubj||mild-16/JJ||pain-5/NN	nsubj||moderate-18/JJ||pain-5/NN	nsubj||severe-21/JJ||pain-5/NN	amod||injection-10/NN||microemulsion-7/JJ	amod||injection-10/NN||propofol-8/JJ	nn||injection-10/NN||solution-9/NN	prep_on||pain-5/NN||injection-10/NN	cop||graded-12/JJ||was-11/VBD	root||ROOT-0/null||graded-12/JJ	prep_as||graded-12/JJ||none-14/NN	conj_or||graded-12/JJ||mild-16/JJ	conj_or||graded-12/JJ||moderate-18/JJ	conj_or||graded-12/JJ||severe-21/JJ	pain-5||propofol-8||yes||in each patient, pain on microemulsion propofol solution injection was graded as none, mild, moderate, or severe.
mark||applied-7/VBN||after-1/IN	number||%-3/NN||5-2/CD	amod||patches-5/NNS||%-3/NN	nn||patches-5/NNS||lidocaine-4/NN	nsubjpass||applied-7/VBN||patches-5/NNS	auxpass||applied-7/VBN||were-6/VBD	advcl||exhibited-19/VBD||applied-7/VBN	det||part-12/NN||the-9/DT	amod||part-12/NN||painful-10/JJ	nn||part-12/NN||body-11/NN	prep_to||applied-7/VBN||part-12/NN	num||weeks-15/NNS||two-14/CD	prep_for||part-12/NN||weeks-15/NNS	nn||patients-18/NNS||cbp-17/NN	nsubj||exhibited-19/VBD||patients-18/NNS	root||ROOT-0/null||exhibited-19/VBD	det||decrease-22/NN||a-20/DT	amod||decrease-22/NN||significant-21/JJ	dobj||exhibited-19/VBD||decrease-22/NN	amod||measures-26/NNS||clinical-24/JJ	nn||measures-26/NNS||pain-25/NN	prep_in||exhibited-19/VBD||measures-26/NNS	mark||showed-35/VBD||while-28/IN	nn||questionnaire-32/NN||oa-30/NN	amod||questionnaire-32/NN||clinical-31/JJ	prep_in||showed-35/VBD||questionnaire-32/NN	vmod||questionnaire-32/NN||based-33/VBN	nsubj||showed-35/VBD||outcomes-34/NNS	advcl||exhibited-19/VBD||showed-35/VBD	neg||effect-38/NN||no-36/DT	nn||effect-38/NN||treatment-37/NN	nsubj||evoked-41/VBD||effect-38/NN	prep||effect-38/NN||but-39/CC	pobj||but-39/CC||stimulus-40/NN	ccomp||showed-35/VBD||evoked-41/VBD	nsubj||showed-43/VBD||pain-42/NN	ccomp||evoked-41/VBD||showed-43/VBD	det||decrease-46/NN||a-44/DT	amod||decrease-46/NN||borderline-45/JJ	dobj||showed-43/VBD||decrease-46/NN	lidocaine-4||oa-30||no_rel||after 5% lidocaine patches were applied to the painful body part for two weeks, cbp patients exhibited a significant decrease in clinical pain measures, while in oa clinical questionnaire based outcomes showed no treatment effect but stimulus evoked pain showed a borderline decrease.
nsubj||1.9-22/CD||incidence-1/NN	amod||pancreatitis-4/NNS||acute-3/JJ	prep_of||incidence-1/NN||pancreatitis-4/NNS	det||group-9/NN||the-6/DT	amod||group-9/NN||nondiabetic-7/JJ	nn||group-9/NN||control-8/NN	prep_in||pancreatitis-4/NNS||group-9/NN	amod||group-13/NN||diabetic-11/JJ	nn||group-13/NN||control-12/NN	prep_in||pancreatitis-4/NNS||group-13/NN	conj_and||group-9/NN||group-13/NN	amod||group-16/NN||exenatide-15/JJ	prep_in||pancreatitis-4/NNS||group-16/NN	conj_and||group-9/NN||group-16/NN	nn||group-20/NN||sitagliptin-19/NN	prep_in||pancreatitis-4/NNS||group-20/NN	conj_and||group-9/NN||group-20/NN	cop||1.9-22/CD||was-21/VBD	root||ROOT-0/null||1.9-22/CD	conj_and||1.9-22/CD||5.6-24/CD	conj_and||1.9-22/CD||5.7-26/CD	num||cases-30/NNS||5.6-29/CD	conj_and||1.9-22/CD||cases-30/NNS	num||years-34/NNS||1,000-32/CD	amod||years-34/NNS||patient-33/JJ	prep_per||cases-30/NNS||years-34/NNS	advmod||1.9-22/CD||respectively-36/RB	exenatide-15||pancreatitis-4||no_rel||incidence of acute pancreatitis in the nondiabetic control group, diabetic control group, exenatide group, and sitagliptin group was 1.9, 5.6, 5.7, and 5.6 cases per 1,000 patient years, respectively.
det||features-3/NNS||the-1/DT	nn||features-3/NNS||tissue-2/NN	nsubj||help-5/VB||features-3/NNS	aux||help-5/VB||may-4/MD	root||ROOT-0/null||help-5/VB	amod||reactions-7/NNS||distinguish-6/JJ	dobj||help-5/VB||reactions-7/NNS	amod||wear-10/NN||high-9/JJ	prep_to||help-5/VB||wear-10/NN	prep_from||help-5/VB||those-12/DT	amod||hypersensitivity-16/NN||suspected-14/VBN	nn||hypersensitivity-16/NN||metal-15/NN	prep_with||those-12/DT||hypersensitivity-16/NN	metal-15||hypersensitivity-16||no_rel||the tissue features may help distinguish reactions to high wear from those with suspected metal hypersensitivity.
aux||characterize-2/VB||to-1/TO	csubj||randomized-38/VBD||characterize-2/VB	det||amount-4/NN||the-3/DT	dobj||characterize-2/VB||amount-4/NN	amod||hypoglycemia-7/NN||nocturnal-6/JJ	prep_of||amount-4/NN||hypoglycemia-7/NN	conj_and||characterize-2/VB||evaluate-9/VB	csubj||randomized-38/VBD||evaluate-9/VB	dobj||evaluate-9/VB||factors-10/NNS	vmod||factors-10/NNS||associated-11/VBN	amod||hypoglycemia-14/NN||nocturnal-13/JJ	prep_with||associated-11/VBN||hypoglycemia-14/NN	vmod||hypoglycemia-14/NN||assessed-15/VBN	amod||monitoring-19/NN||continuous-17/JJ	nn||monitoring-19/NN||glucose-18/NN	prep_with||assessed-15/VBN||monitoring-19/NN	appos||monitoring-19/NN||cgm-21/NN	prep_in||monitoring-19/NN||adults-24/NNS	prep_in||monitoring-19/NN||children-26/NNS	conj_and||adults-24/NNS||children-26/NNS	prep_with||assessed-15/VBN||type1diabetes-28/NNS	nsubj||participated-30/VBD||type1diabetes-28/NNS	rcmod||type1diabetes-28/NNS||participated-30/VBD	det||cgm-37/NN||the-32/DT	amod||cgm-37/NN||juvenile-33/JJ	nn||cgm-37/NN||diabetes-34/NN	nn||cgm-37/NN||research-35/NN	nn||cgm-37/NN||foundation-36/NN	prep_in||participated-30/VBD||cgm-37/NN	root||ROOT-0/null||randomized-38/VBD	amod||trial-40/NN||clinical-39/JJ	dobj||randomized-38/VBD||trial-40/NN	hypoglycemia-14||glucose-18||yes||to characterize the amount of nocturnal hypoglycemia and evaluate factors associated with nocturnal hypoglycemia assessed with continuous glucose monitoring (cgm) in adults and children with type1diabetes who participated in the juvenile diabetes research foundation cgm randomized clinical trial.
advmod||had-6/VBD||also-1/RB	nsubj||had-6/VBD||patients-3/NNS	vmod||patients-3/NNS||receiving-4/VBG	acomp||receiving-4/VBG||haloperidol-5/JJ	root||ROOT-0/null||had-6/VBD	amod||correlation-8/NN||significant-7/JJ	dobj||had-6/VBD||correlation-8/NN	nn||lactate-11/NN||blood-10/NN	prep_between||correlation-8/NN||lactate-11/NN	prep_between||correlation-8/NN||dystonia-13/NN	conj_and||lactate-11/NN||dystonia-13/NN	num||month-16/NN||1-15/CD	prep_at||had-6/VBD||month-16/NN	nn||â-19/NN||p-18/NN	dep||month-16/NN||â-19/NN	nsubj||â-23/VBP||$-20/$	number||<-22/CD||-21/CD	num||$-20/$||<-22/CD	rcmod||â-19/NN||â-23/VBP	dobj||â-23/VBP||$-24/$	number||0.001-26/CD||-25/CD	num||$-24/$||0.001-26/CD	num||months-30/NNS||6-29/CD	prep_at||had-6/VBD||months-30/NNS	conj_and||month-16/NN||months-30/NNS	nn||â-33/NN||p-32/NN	dep||months-30/NNS||â-33/NN	nsubj||â-37/VBP||$-34/$	number||=-36/CD||-35/CD	num||$-34/$||=-36/CD	rcmod||â-33/NN||â-37/VBP	dobj||â-37/VBP||$-38/$	number||0.012-40/CD||-39/CD	num||$-38/$||0.012-40/CD	amod||dyskinesia-44/NN||tardive-43/JJ	prep_at||had-6/VBD||dyskinesia-44/NN	conj_and||month-16/NN||dyskinesia-44/NN	num||month-47/NN||1-46/CD	prep_at||dyskinesia-44/NN||month-47/NN	nn||â-50/NN||p-49/NN	dep||month-47/NN||â-50/NN	nsubj||â-54/VBP||$-51/$	number||=-53/CD||-52/CD	num||$-51/$||=-53/CD	rcmod||â-50/NN||â-54/VBP	dobj||â-54/VBP||$-55/$	number||0.032-57/CD||-56/CD	num||$-55/$||0.032-57/CD	haloperidol-5||dyskinesia-44||no_rel||also, patients receiving haloperidol had significant correlation between blood lactate and dystonia at 1 month ( p â<â0.001) and 6 months ( p â=â0.012) and tardive dyskinesia at 1 month ( p â=â0.032).
nn||analysis-3/NN||glycan-1/NN	nn||analysis-3/NN||microarray-2/NN	nsubj||reassortantâ-11/VBD||analysis-3/NN	det||â-8/NN||a-5/DT	amod||â-8/NN||high-6/JJ	nn||â-8/NN||infectivity-7/NN	prep_with||analysis-3/NN||â-8/NN	amod||â-8/NN||$-9/$	dep||$-9/$||triple-10/JJ	root||ROOT-0/null||reassortantâ-11/VBD	nsubj||spread-24/VBN||$-12/$	nsubj||showed-51/VBD||$-12/$	num||$-12/$||virus-13/CD	amod||/-17/NN||a/swine/mn-16/JJ	dep||$-12/$||/-17/NN	num||/-17/NN||593/99-18/CD	appos||$-12/$||h3n2-20/NNP	rcmod||$-12/$||spread-24/VBN	advmod||spread-24/VBN||widely-25/RB	det||population-31/NN||the-27/DT	nn||population-31/NN||north-28/NN	nn||population-31/NN||american-29/NN	nn||population-31/NN||swine-30/NNS	prep_throughout||spread-24/VBN||population-31/NN	det||virus-37/NN||a-33/DT	dep||human-36/JJ||lower-34/JJR	advmod||human-36/JJ||infectivity-35/RB	amod||virus-37/NN||human-36/JJ	conj_and||$-12/$||virus-37/NN	nsubj||spread-24/VBN||virus-37/NN	nsubj||showed-51/VBD||virus-37/NN	vmod||virus-37/NN||isolated-38/VBN	det||pig-42/NN||a-40/DT	amod||pig-42/NN||single-41/JJ	prep_from||isolated-38/VBN||pig-42/NN	dep||virus-37/NN||a/swine/ont-44/VB	number||00130/97-46/CD||/-45/CD	dobj||a/swine/ont-44/VB||00130/97-46/CD	appos||00130/97-46/CD||h3n2-48/NNP	ccomp||reassortantâ-11/VBD||showed-51/VBD	mark||viruses-54/VBZ||that-52/IN	nsubj||viruses-54/VBZ||both-53/DT	ccomp||showed-51/VBD||viruses-54/VBZ	acomp||viruses-54/VBZ||bound-55/VBN	advmod||bound-55/VBN||exclusively-56/RB	prep_to||bound-55/VBN||glycans-58/NNS	vmod||glycans-58/NNS||containing-59/VBG	nn||±-61/NNP||neuacî-60/NNP	dobj||containing-59/VBG||±-61/NNP	vmod||±-61/NNP||2â-62/VBG	dobj||2â-62/VBG||$-63/$	npadvmod||polylactosamine-72/JJ||6-65/CD	prep_with||6-65/CD||strong-68/JJ	amod||6-65/CD||binding-69/JJ	dep||sialylated-71/CD||to-70/TO	num||6-65/CD||sialylated-71/CD	amod||n-75/NNS||polylactosamine-72/JJ	conj_and||polylactosamine-72/JJ||sialylated-74/JJ	amod||n-75/NNS||sialylated-74/JJ	npadvmod||--76/RB||n-75/NNS	num||$-63/$||glycans-77/CD	virus-37||mn--1||no_rel||glycan microarray analysis with a high infectivity âtriple reassortantâ? virus ((a/swine/mn/593/99 (h3n2)) that spread widely throughout the north american swine population and a lower infectivity human virus isolated from a single pig (a/swine/ont/00130/97 (h3n2)) showed that both viruses bound exclusively to glycans containing neuacî±2â6, with strong binding to sialylated polylactosamine and sialylated n -glycans.
advmod||review-21/VBP||here-1/RB	det||attempt-5/NN||an-4/DT	prep_in||review-21/VBP||attempt-5/NN	aux||understand-7/VB||to-6/TO	vmod||attempt-5/NN||understand-7/VB	det||role-9/NN||the-8/DT	dobj||understand-7/VB||role-9/NN	nn||interferons-13/NNS||type-11/FW	nn||interferons-13/NNS||i-12/FW	prep_of||role-9/NN||interferons-13/NNS	det||pathogenesis-16/NNS||the-15/DT	prep_in||interferons-13/NNS||pathogenesis-16/NNS	prep_of||pathogenesis-16/NNS||autoimmunity-18/NN	nsubj||review-21/VBP||we-20/PRP	root||ROOT-0/null||review-21/VBP	det||advances-24/NNS||the-22/DT	amod||advances-24/NNS||recent-23/JJ	dobj||review-21/VBP||advances-24/NNS	det||genetics-27/NNS||the-26/DT	prep_in||advances-24/NNS||genetics-27/NNS	prep_of||genetics-27/NNS||autoimmunediseases-29/NNS	vmod||autoimmunediseases-29/NNS||focusing-30/VBG	det||association-33/NN||the-32/DT	prep_on||focusing-30/VBG||association-33/NN	prep_of||association-33/NN||genes-35/NNS	vmod||genes-35/NNS||involved-36/VBN	nn||pathways-41/NNS||type-38/NN	nn||pathways-41/NNS||i-39/NN	nn||pathways-41/NNS||interferon-40/NN	prep_in||involved-36/VBN||pathways-41/NNS	autoimmunediseases-29||interferons-13||no||here, in an attempt to understand the role of type i interferons in the pathogenesis of autoimmunity, we review the recent advances in the genetics of autoimmunediseases focusing on the association of genes involved in type i interferon pathways.
nsubjpass||asked-14/VBN||physicians-1/NNS	nsubj||grade-16/VB||physicians-1/NNS	vmod||physicians-1/NNS||selected-2/VBN	prep_from||selected-2/VBN||malaysia-4/NN	prep_from||selected-2/VBN||taiwan-6/NN	conj_and||malaysia-4/NN||taiwan-6/NN	prep_from||selected-2/VBN||philippines-8/NNS	conj_and||malaysia-4/NN||philippines-8/NNS	prep_from||selected-2/VBN||korea-10/NN	conj_and||malaysia-4/NN||korea-10/NN	prep_from||selected-2/VBN||singapore-12/NN	conj_and||malaysia-4/NN||singapore-12/NN	auxpass||asked-14/VBN||were-13/VBD	root||ROOT-0/null||asked-14/VBN	aux||grade-16/VB||to-15/TO	xcomp||asked-14/VBN||grade-16/VB	det||significance-18/NN||the-17/DT	dobj||grade-16/VB||significance-18/NN	prep_of||significance-18/NN||vitamind-20/NN	prep_of||significance-18/NN||calcium-22/NN	conj_and||vitamind-20/NN||calcium-22/NN	det||treatment-25/NN||the-24/DT	prep_in||grade-16/VB||treatment-25/NN	prep_of||treatment-25/NN||osteoporosis-27/NN	poss||patients-30/NNS||their-29/PRP$	poss||use-32/NN||patients-30/NNS	prep_in||grade-16/VB||use-32/NN	conj_and||treatment-25/NN||use-32/NN	det||supplements-35/NNS||these-34/DT	prep_of||use-32/NN||supplements-35/NNS	osteoporosis-27||vitamind-20||yes||physicians selected from malaysia, taiwan, philippines, korea and singapore were asked to grade the significance of vitamind and calcium in the treatment of osteoporosis and their patients' use of these supplements.
det||insulinresistance-3/NN||the-1/DT	amod||insulinresistance-3/NN||aggravated-2/JJ	nsubjpass||associated-5/VBN||insulinresistance-3/NN	auxpass||associated-5/VBN||was-4/VBD	root||ROOT-0/null||associated-5/VBN	amod||signaling-9/NNS||impaired-7/VBN	nn||signaling-9/NNS||insulin-8/NN	prep_with||associated-5/VBN||signaling-9/NNS	amod||content-13/NN||increased-11/VBN	amod||content-13/NN||diacylglycerol-12/JJ	prep_with||associated-5/VBN||content-13/NN	conj_and||signaling-9/NNS||content-13/NN	amod||muscle-16/NN||skeletal-15/JJ	prep_in||content-13/NN||muscle-16/NN	insulin-8||insulinresistance-3||no_rel||the aggravated insulinresistance was associated with impaired insulin signaling and increased diacylglycerol content in skeletal muscle.
nsubj||lorazepam-4/VBP||treatment-1/NN	nsubj||prevent-11/VB||treatment-1/NN	prep_with||treatment-1/NN||intravenous-3/NNP	root||ROOT-0/null||lorazepam-4/VBP	amod||vomiting-6/NN||aborted-5/JJ	dobj||lorazepam-4/VBP||vomiting-6/NN	aux||prevent-11/VB||could-9/MD	neg||prevent-11/VB||not-10/RB	conj_but||lorazepam-4/VBP||prevent-11/VB	dobj||prevent-11/VB||recurrences-12/NNS	nn||pain-17/NN||vomiting-14/NN	conj_and||vomiting-14/NN||epigastric-16/JJ	nn||pain-17/NN||epigastric-16/JJ	prep_of||recurrences-12/NNS||pain-17/NN	vomiting-14||lorazepam-4||yes||treatment with intravenous lorazepam aborted vomiting, but could not prevent recurrences of vomiting and epigastric pain.
det||aim-2/NN||the-1/DT	nsubj||was-7/VBD||aim-2/NN	nsubj||examine-9/VB||aim-2/NN	det||study-6/NN||the-4/DT	amod||study-6/NN||present-5/JJ	prep_of||aim-2/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||examine-9/VB||to-8/TO	xcomp||was-7/VBD||examine-9/VB	prep_in||examine-9/VB||humans-11/NNS	det||role-14/NN||the-12/DT	amod||role-14/NN||potential-13/JJ	dobj||examine-9/VB||role-14/NN	amod||sensors-19/NNS||portal-16/JJ	nn||sensors-19/NNS||vein-17/NN	nn||sensors-19/NNS||glucose-18/NN	prep_of||role-14/NN||sensors-19/NNS	amod||responses-22/NNS||physiological-21/JJ	prep_in||sensors-19/NNS||responses-22/NNS	amod||hypoglycemia-25/NN||insulin-induced-24/JJ	prep_to||responses-22/NNS||hypoglycemia-25/NN	vmod||hypoglycemia-25/NN||mimicking-26/VBG	det||fall-29/NN||the-27/DT	amod||fall-29/NN||slow-28/JJ	dobj||mimicking-26/VBG||fall-29/NN	amod||subjects-33/NNS||insulin-treated-31/JJ	amod||subjects-33/NNS||diabetic-32/JJ	prep_of||fall-29/NN||subjects-33/NNS	hypoglycemia-25||glucose-18||yes||the aim of the present study was to examine in humans the potential role of portal vein glucose sensors in physiological responses to insulin-induced hypoglycemia mimicking the slow fall of insulin-treated diabetic subjects.
nsubjpass||reported-4/VBN||dieldrin-1/NN	nsubj||one-7/CD||dieldrin-1/NN	nsubj||destroy-20/VB||dieldrin-1/NN	aux||reported-4/VBN||has-2/VBZ	auxpass||reported-4/VBN||been-3/VBN	root||ROOT-0/null||reported-4/VBN	aux||one-7/CD||to-5/TO	cop||one-7/CD||be-6/VB	xcomp||reported-4/VBN||one-7/CD	det||factors-11/NNS||the-9/DT	amod||factors-11/NNS||environmental-10/JJ	prep_of||one-7/CD||factors-11/NNS	vmod||factors-11/NNS||correlated-12/VBN	nn||sdisease-16/NN||parkinson-14/NN	prep_with||correlated-12/VBN||sdisease-16/NN	aux||destroy-20/VB||may-18/MD	advmod||destroy-20/VB||selectively-19/RB	conj_and||reported-4/VBN||destroy-20/VB	amod||neurons-22/NNS||dopaminergic-21/JJ	dobj||destroy-20/VB||neurons-22/NNS	parkinson'sdisease--1||dieldrin-1||no_rel||dieldrin has been reported to be one of the environmental factors correlated with parkinson'sdisease and may selectively destroy dopaminergic neurons.
det||beginning-3/NN||the-2/DT	prep_since||provided-16/VBN||beginning-3/NN	det||century-7/NN||the-5/DT	amod||century-7/NN||21st-6/JJ	prep_of||beginning-3/NN||century-7/NN	nn||assistance-10/NN||development-9/NN	nsubjpass||provided-16/VBN||assistance-10/NN	prep_for||assistance-10/NN||hiv/aids-12/NNS	aux||provided-16/VBN||has-13/VBZ	advmod||provided-16/VBN||increasingly-14/RB	auxpass||provided-16/VBN||been-15/VBN	root||ROOT-0/null||provided-16/VBN	amod||initiatives-20/NNS||global-18/JJ	nn||initiatives-20/NNS||health-19/NN	prep_through||provided-16/VBN||initiatives-20/NNS	advmod||plan-28/VBP||specifically-22/RB	det||emergency-27/NN||the-23/DT	amod||emergency-27/NN||united-24/VBN	nn||emergency-27/NN||states-25/NNS	amod||emergency-27/NN||presidential-26/JJ	nsubj||plan-28/VBP||emergency-27/NN	nsubj||fight-37/VB||emergency-27/NN	parataxis||provided-16/VBN||plan-28/VBP	nn||relief-31/NN||aids-30/NNS	prep_for||plan-28/VBP||relief-31/NN	det||fund-35/NN||the-33/DT	amod||fund-35/NN||global-34/JJ	appos||relief-31/NN||fund-35/NN	aux||fight-37/VB||to-36/TO	xcomp||plan-28/VBP||fight-37/VB	dobj||fight-37/VB||hiv-38/NN	dobj||fight-37/VB||tb-40/NN	conj_and||hiv-38/NN||tb-40/NN	dobj||fight-37/VB||malaria-42/NN	conj_and||hiv-38/NN||malaria-42/NN	det||multi-country-47/NN||the-44/DT	nn||multi-country-47/NN||world-45/NN	nn||multi-country-47/NN||bank-46/NN	nsubj||aids-48/VBZ||multi-country-47/NN	conj_and||provided-16/VBN||aids-48/VBZ	dobj||aids-48/VBZ||programme-49/NN	aids-48||hiv-38||no||since the beginning of the 21st century, development assistance for hiv/aids has increasingly been provided through global health initiatives, specifically the united states presidential emergency plan for aids relief, the global fund to fight hiv, tb and malaria and the world bank multi-country aids programme.
mark||identified-7/VBN||although-1/IN	neg||bacterium-4/NN||no-2/DT	amod||bacterium-4/NN||single-3/JJ	nsubjpass||identified-7/VBN||bacterium-4/NN	aux||identified-7/VBN||could-5/MD	auxpass||identified-7/VBN||be-6/VB	advcl||associated-50/VBN||identified-7/VBN	det||marker-11/NN||a-9/DT	amod||marker-11/NN||specific-10/JJ	prep_as||identified-7/VBN||marker-11/NN	amod||bacteroidetes-21/NNS||healthy-13/JJ	amod||conditions-16/NNS||diseased-15/JJ	prep_over||healthy-13/JJ||conditions-16/NNS	npadvmod||phyla-19/JJ||three-18/CD	dep||healthy-13/JJ||phyla-19/JJ	prep_for||marker-11/NN||bacteroidetes-21/NNS	prep_for||marker-11/NN||actinobacteria-23/NN	conj_and||bacteroidetes-21/NNS||actinobacteria-23/NN	conj_and||bacteroidetes-21/NNS||fusobacteria-25/NN	conj_and||actinobacteria-23/NN||fusobacteria-25/NN	num||genera-29/NN||eight-28/CD	prep_for||marker-11/NN||genera-29/NN	conj_and||bacteroidetes-21/NNS||genera-29/NN	nn||sneathia-43/NN||gardnerella-31/NN	dep||sneathia-43/NN||atopobium-33/NN	dep||sneathia-43/NN||megasphaera-35/NN	dep||sneathia-43/NN||eggerthella-37/NN	dep||sneathia-43/NN||aerococcus-39/NNS	dep||sneathia-43/NN||leptotrichia-41/NN	num||sneathia-43/NN||/-42/CD	prep_including||genera-29/NN||sneathia-43/NN	nsubjpass||associated-50/VBN||prevotella-45/NN	conj_and||prevotella-45/NN||papillibacter-47/NN	nsubjpass||associated-50/VBN||papillibacter-47/NN	auxpass||associated-50/VBN||were-48/VBD	advmod||associated-50/VBN||strongly-49/RB	root||ROOT-0/null||associated-50/VBN	prep_with||associated-50/VBN||bv-52/NN	dep||<-55/JJ||p-54/RB	dep||associated-50/VBN||<-55/JJ	dep||<-55/JJ||0.05-56/CD	gardnerella-31||bacterium-4||no||although no single bacterium could be identified as a specific marker for healthy over diseased conditions, three phyla - bacteroidetes , actinobacteria and fusobacteria , and eight genera including gardnerella , atopobium , megasphaera , eggerthella , aerococcus , leptotrichia / sneathia , prevotella and papillibacter were strongly associated with bv ( p < 0.05).
det||decisions-2/NNS||all-1/DT	nsubj||include-20/VB||decisions-2/NNS	prepc_about||decisions-2/NNS||initiating-4/VBG	prepc_about||decisions-2/NNS||continuing-6/VBG	conj_or||initiating-4/VBG||continuing-6/VBG	prepc_about||decisions-2/NNS||stopping-9/VBG	conj_or||initiating-4/VBG||stopping-9/VBG	dobj||stopping-9/VBG||therapy-10/NN	det||hepatitisbvirus-13/NNS||the-12/DT	prep_of||therapy-10/NN||hepatitisbvirus-13/NNS	appos||hepatitisbvirus-13/NNS||hbv-15/NN	prep_during||stopping-9/VBG||pregnancy-18/NN	aux||include-20/VB||must-19/MD	root||ROOT-0/null||include-20/VB	det||analysis-22/NN||an-21/DT	dobj||include-20/VB||analysis-22/NN	det||risks-25/NNS||the-24/DT	prep_of||analysis-22/NN||risks-25/NNS	prep_of||analysis-22/NN||benefits-27/NNS	conj_and||risks-25/NNS||benefits-27/NNS	prep_for||risks-25/NNS||mother-29/NN	prep_for||risks-25/NNS||fetus-31/NN	conj_and||mother-29/NN||fetus-31/NN	hbv-15||hepatitisbvirus-13||no||all decisions about initiating, continuing, or stopping therapy of the hepatitisbvirus (hbv) during pregnancy must include an analysis of the risks and benefits for mother and fetus.
amod||m.tb-2/NN||rifampin-resistant-1/JJ	nsubjpass||found-37/VBN||m.tb-2/NN	dep||m.tb-2/NN||nâ-4/NN	num||â-8/NN||$-5/$	number||=-7/CD||-6/CD	num||$-5/$||=-7/CD	dep||nâ-4/NN||â-8/NN	dep||â-8/NN||$-9/$	num||$-9/$||41-10/CD	conj_and||m.tb-2/NN||tb-iris-13/NNS	nsubjpass||found-37/VBN||tb-iris-13/NNS	dep||tb-iris-13/NNS||nâ-15/NN	num||â-19/NN||$-16/$	number||=-18/CD||-17/CD	num||$-16/$||=-18/CD	dep||nâ-15/NN||â-19/NN	dep||â-19/NN||$-20/$	num||$-20/$||51-21/CD	npadvmod||resistant-25/JJ||drug-24/NN	amod||bacterialinfections-26/NNS||resistant-25/JJ	conj_and||m.tb-2/NN||bacterialinfections-26/NNS	nsubjpass||found-37/VBN||bacterialinfections-26/NNS	dep||m.tb-2/NN||nâ-28/NN	num||â-32/NN||$-29/$	number||=-31/CD||-30/CD	num||$-29/$||=-31/CD	dep||nâ-28/NN||â-32/NN	dep||â-32/NN||$-33/$	num||$-33/$||12-34/CD	auxpass||found-37/VBN||were-36/VBD	root||ROOT-0/null||found-37/VBN	num||%-40/NN||12-39/CD	prep_in||found-37/VBN||%-40/NN	num||%-43/NN||14-42/CD	prep_in||found-37/VBN||%-43/NN	conj_and||%-40/NN||%-43/NN	num||%-46/NN||3.4-45/CD	prep_in||found-37/VBN||%-46/NN	conj_and||%-40/NN||%-46/NN	det||cases-50/NNS||the-48/DT	amod||cases-50/NNS||352-49/JJ	prep_of||%-46/NN||cases-50/NNS	advmod||found-37/VBN||respectively-52/RB	bacterialinfections-26||rifampin--1||yes||rifampin-resistant m.tb (nâ=â41), tb-iris (nâ=â51) and drug resistant bacterialinfections (nâ=â12) were found in 12%, 14% and 3.4% of the 352 cases, respectively.
aux||review-2/VB||to-1/TO	root||ROOT-0/null||review-2/VB	det||literature-4/NN||the-3/DT	dobj||review-2/VB||literature-4/NN	det||treatment-7/NN||the-6/DT	prep_on||literature-4/NN||treatment-7/NN	prep_of||treatment-7/NN||gastroesophagealrefluxdisease-9/NN	dep||treatment-7/NN||gerd-11/VBN	prep_with||review-2/VB||emphasis-14/NN	prep_on||emphasis-14/NN||protonpumpinhibitors-16/NNS	appos||protonpumpinhibitors-16/NNS||ppis-18/NNS	advmod||review-2/VB||particularly-21/RB	amod||esomeprazole-24/NN||delayed-release-23/JJ	prep_on||review-2/VB||esomeprazole-24/NN	aux||identify-28/VB||to-27/TO	conj_and||review-2/VB||identify-28/VB	dobj||identify-28/VB||properties-29/NNS	amod||effects-32/NNS||adverse-31/JJ	nsubj||observed-35/VBD||effects-32/NNS	prep_of||effects-32/NNS||ppis-34/NNS	conj_and||review-2/VB||observed-35/VBD	det||treatment-38/NN||the-37/DT	prep_in||observed-35/VBD||treatment-38/NN	prep_of||treatment-38/NN||gerd-40/NN	prep_in||observed-35/VBD||children-42/NNS	prep_in||observed-35/VBD||adolescents-44/NNS	conj_and||children-42/NNS||adolescents-44/NNS	gastroesophagealrefluxdisease-9||protonpumpinhibitors-16||no_rel||to review the literature on the treatment of gastroesophagealrefluxdisease (gerd) with emphasis on protonpumpinhibitors (ppis), particularly on delayed-release esomeprazole, and to identify properties and adverse effects of ppis observed in the treatment of gerd in children and adolescents.
det||therapy-4/NN||the-1/DT	amod||therapy-4/NN||gold-2/JJ	amod||therapy-4/NN||standard-3/JJ	nsubjpass||pegylated-9/VBN||therapy-4/NN	amod||patients-7/NNS||chronichepatitisc-6/JJ	prep_for||therapy-4/NN||patients-7/NNS	auxpass||pegylated-9/VBN||is-8/VBZ	root||ROOT-0/null||pegylated-9/VBN	dobj||pegylated-9/VBN||interferon-10/NN	prep||pegylated-9/VBN||combined-11/VBN	pcomp||combined-11/VBN||with-12/IN	det||drug-15/NN||an-13/DT	amod||drug-15/NN||anti-viral-14/JJ	pobj||with-12/IN||drug-15/NN	appos||drug-15/NN||ribavirin-17/NNP	chronichepatitisc-6||ribavirin-17||yes||the gold standard therapy for chronichepatitisc patients is pegylated interferon combined with an anti-viral drug (ribavirin).
det||data-2/NNS||these-1/DT	nsubj||suggest-3/VBP||data-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||leads-10/VBZ||that-4/IN	nsubj||leads-10/VBZ||administration-5/NN	prep_of||administration-5/NN||cannabinoids-7/NNS	prep_during||cannabinoids-7/NNS||adolescence-9/NN	ccomp||suggest-3/VBP||leads-10/VBZ	det||phenotype-14/NN||a-12/DT	amod||phenotype-14/NN||behavioral-13/JJ	prep_to||leads-10/VBZ||phenotype-14/NN	vmod||phenotype-14/NN||associated-15/VBN	det||model-19/NN||a-17/DT	amod||model-19/NN||rodent-18/JJ	prep_with||associated-15/VBN||model-19/NN	prep_of||model-19/NN||schizophrenia-21/NN	mark||indexed-24/VBN||as-23/IN	advcl||associated-15/VBN||indexed-24/VBN	prep_by||indexed-24/VBN||alterations-26/NNS	nn||gating-29/NN||sensorimotor-28/NN	prep_in||alterations-26/NNS||gating-29/NN	amod||learning-32/NN||hippocampal-dependent-31/JJ	prep_in||alterations-26/NNS||learning-32/NN	conj_and||gating-29/NN||learning-32/NN	nn||deficits-35/NNS||memory-34/NN	prep_in||alterations-26/NNS||deficits-35/NNS	conj_and||gating-29/NN||deficits-35/NNS	cannabinoids-7||schizophrenia-21||no_rel||these data suggest that administration of cannabinoids during adolescence leads to a behavioral phenotype associated with a rodent model of schizophrenia, as indexed by alterations in sensorimotor gating and hippocampal-dependent learning and memory deficits.
det||change-3/NN||the-1/DT	amod||change-3/NN||recent-2/JJ	nsubjpass||accompanied-20/VBN||change-3/NN	nn||policy-6/NN||treatment-5/NN	prep_of||change-3/NN||policy-6/NN	amod||malaria-9/NN||uncomplicated-8/JJ	prep_for||policy-6/NN||malaria-9/NN	prep_from||malaria-9/NN||sulfadoxine-pyrime-thamine-11/NN	prep_to||sulfadoxine-pyrime-thamine-11/NN||artemether-lumefantrine-13/NN	appos||artemether-lumefantrine-13/NN||al-15/NNP	prep_in||artemether-lumefantrine-13/NN||kenya-18/NN	auxpass||accompanied-20/VBN||was-19/VBD	root||ROOT-0/null||accompanied-20/VBN	amod||recommendations-25/NNS||revised-22/VBN	nn||recommendations-25/NNS||malaria-23/NN	nn||recommendations-25/NNS||diagnosis-24/NN	nsubj||promoting-26/VBG||recommendations-25/NNS	agent||accompanied-20/VBN||promoting-26/VBG	amod||treatment-29/NN||presumptive-27/JJ	amod||treatment-29/NN||antimalarial-28/JJ	dobj||promoting-26/VBG||treatment-29/NN	amod||children-32/NNS||young-31/JJ	prep_in||treatment-29/NN||children-32/NNS	amod||diagnosis-35/NN||parasitological-34/JJ	dobj||promoting-26/VBG||diagnosis-35/NN	conj_and||treatment-29/NN||diagnosis-35/NN	prep_in||diagnosis-35/NN||patients-37/NNS	num||years-39/NNS||5-38/CD	dep||promoting-26/VBG||years-39/NNS	dep||promoting-26/VBG||older-41/JJR	conj_and||years-39/NNS||older-41/JJR	malaria-23||lumefantrine--1||yes||the recent change of treatment policy for uncomplicated malaria from sulfadoxine-pyrime-thamine to artemether-lumefantrine (al) in kenya was accompanied by revised malaria diagnosis recommendations promoting presumptive antimalarial treatment in young children and parasitological diagnosis in patients 5 years and older.
nsubj||agent-5/NN||yersiniapestis-1/NNS	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||the-3/DT	amod||agent-5/NN||causative-4/JJ	root||ROOT-0/null||agent-5/NN	prep_of||agent-5/NN||pneumonicplague-7/NN	advmod||reported-14/VBD||recently-9/RB	nsubj||reported-14/VBD||we-11/PRP	conj_and||we-11/PRP||others-13/NNS	nsubj||reported-14/VBD||others-13/NNS	parataxis||agent-5/NN||reported-14/VBD	dobj||reported-14/VBD||that-15/DT	det||hours-20/NNS||the-17/DT	amod||hours-20/NNS||first-18/JJ	num||hours-20/NNS||24-36-19/CD	prep_during||reported-14/VBD||hours-20/NNS	mark||undetectable-30/JJ||after-21/IN	amod||infection-23/NN||pulmonary-22/JJ	nsubj||undetectable-30/JJ||infection-23/NN	amod||expression-28/NN||y.pestis-25/JJ	amod||expression-28/NN||pro-inflammatory-26/JJ	nn||expression-28/NN||cytokine-27/NN	prep_with||infection-23/NN||expression-28/NN	cop||undetectable-30/JJ||is-29/VBZ	advcl||reported-14/VBD||undetectable-30/JJ	nn||tissues-33/NNS||lung-32/NN	prep_in||undetectable-30/JJ||tissues-33/NNS	pneumonicplague-7||yersiniapestis-1||no||yersiniapestis is the causative agent of pneumonicplague ; recently , we and others reported that during the first 24-36 hours after pulmonary infection with y.pestis pro-inflammatory cytokine expression is undetectable in lung tissues .
amod||causes-2/NNS||potential-1/JJ	nsubj||include-12/VBP||causes-2/NNS	amod||deterioration-5/NN||clinical-4/JJ	prep_for||causes-2/NNS||deterioration-5/NN	prep_in||deterioration-5/NN||settings-7/NNS	amod||prevalence-11/NN||high-9/JJ	amod||prevalence-11/NN||hiv-1-10/JJ	prep_of||settings-7/NNS||prevalence-11/NN	root||ROOT-0/null||include-12/VBP	npadvmod||resistant-14/JJ||drug-13/NN	amod||mycobacteriumtuberculosis-15/NNS||resistant-14/JJ	dobj||include-12/VBP||mycobacteriumtuberculosis-15/NNS	appos||mycobacteriumtuberculosis-15/NNS||m.tb-17/NN	amod||illnesses-21/NNS||co-morbid-20/JJ	dobj||include-12/VBP||illnesses-21/NNS	conj_and||mycobacteriumtuberculosis-15/NNS||illnesses-21/NNS	amod||adherence-24/NN||poor-23/JJ	dobj||include-12/VBP||adherence-24/NN	conj_and||mycobacteriumtuberculosis-15/NNS||adherence-24/NN	nn||syndrome-32/NN||therapy-26/NN	nn||syndrome-32/NN||tuberculosis-28/NNP	amod||syndrome-32/NN||associated-immune-29/JJ	amod||syndrome-32/NN||reconstitution-30/JJ	amod||syndrome-32/NN||inflammatory-31/JJ	prep_to||adherence-24/NN||syndrome-32/NN	appos||syndrome-32/NN||tb-iris-34/NNS	amod||levels-40/NNS||subtherapeutic-37/JJ	nn||levels-40/NNS||antitubercular-38/NN	nn||levels-40/NNS||drug-39/NN	dobj||include-12/VBP||levels-40/NNS	conj_and||mycobacteriumtuberculosis-15/NNS||levels-40/NNS	tuberculosis-28||antitubercular-38||yes||potential causes for clinical deterioration in settings of high hiv-1 prevalence include drug resistant mycobacteriumtuberculosis (m.tb) , co-morbid illnesses, poor adherence to therapy, tuberculosis associated-immune reconstitution inflammatory syndrome (tb-iris) and subtherapeutic antitubercular drug levels.
aux||determine-2/VB||to-1/TO	advcl||studied-28/VBN||determine-2/VB	det||prevalence-4/NN||the-3/DT	dobj||determine-2/VB||prevalence-4/NN	amod||dysfunction-7/NN||pulmonary-6/JJ	prep_of||prevalence-4/NN||dysfunction-7/NN	prep_in||determine-2/VB||lupuserythematosus-9/NNS	num||patients-12/NNS||24-11/CD	nsubjpass||studied-28/VBN||patients-12/NNS	amod||lupuserythematosus-15/NNS||systemic-14/JJ	prep_with||patients-12/NNS||lupuserythematosus-15/NNS	appos||lupuserythematosus-15/NNS||sle-17/NN	num||patients-21/NNS||5-20/CD	prep_with||patients-12/NNS||patients-21/NNS	conj_and||lupuserythematosus-15/NNS||patients-21/NNS	prep_with||patients-21/NNS||discoidlupuserythematosus-23/NNS	appos||discoidlupuserythematosus-23/NNS||dle-25/NN	auxpass||studied-28/VBN||were-27/VBD	root||ROOT-0/null||studied-28/VBN	discoidlupuserythematosus-23||lupuserythematosus-15||no||to determine the prevalence of pulmonary dysfunction in lupuserythematosus, 24 patients with systemic lupuserythematosus (sle) and 5 patients with discoidlupuserythematosus (dle) were studied.
det||warfarin-4/NN||the-1/DT	amod||warfarin-4/NN||anticoagulant-2/JJ	nn||warfarin-4/NN||drug-3/NN	nsubjpass||prescribed-7/VBN||warfarin-4/NN	auxpass||prescribed-7/VBN||is-5/VBZ	advmod||prescribed-7/VBN||widely-6/RB	root||ROOT-0/null||prescribed-7/VBN	prepc_for||prescribed-7/VBN||reducing-9/VBG	det||risk-11/NN||the-10/DT	dobj||reducing-9/VBG||risk-11/NN	prep_of||risk-11/NN||stroke-13/NN	prep_of||risk-11/NN||thrombosis-15/NNS	conj_and||stroke-13/NN||thrombosis-15/NNS	prep_of||risk-11/NN||pulmonaryembolism-17/NN	conj_and||stroke-13/NN||pulmonaryembolism-17/NN	amod||malfunction-21/NN||coronary-20/JJ	prep_of||risk-11/NN||malfunction-21/NN	conj_and||stroke-13/NN||malfunction-21/NN	pulmonaryembolism-17||warfarin-4||yes||the anticoagulant drug warfarin is widely prescribed for reducing the risk of stroke, thrombosis, pulmonaryembolism, and coronary malfunction.
det||study-9/NN||this-1/DT	amod||study-9/NN||open-label-2/JJ	amod||study-9/NN||26-week-4/JJ	amod||study-9/NN||multi-centre-6/JJ	amod||study-9/NN||randomised-8/JJ	nsubj||aripiprazole-11/VBP||study-9/NN	nsubj||soc-13/VB||study-9/NN	vmod||study-9/NN||compared-10/VBN	root||ROOT-0/null||aripiprazole-11/VBP	aux||soc-13/VB||to-12/TO	xcomp||aripiprazole-11/VBP||soc-13/VB	dobj||soc-13/VB||olanzapine-15/NN	dobj||soc-13/VB||quetiapine-17/NN	conj_or||olanzapine-15/NN||quetiapine-17/NN	dobj||soc-13/VB||risperidone-19/NN	conj_or||olanzapine-15/NN||risperidone-19/NN	prep_in||soc-13/VB||patients-22/NNS	prep_with||patients-22/NNS||schizophrenia-24/NN	amod||criteria-27/NNS||dsm-iv-tr-26/JJ	appos||schizophrenia-24/NN||criteria-27/NNS	schizophrenia-24||risperidone-19||yes||this open-label, 26-week, multi-centre, randomised study compared aripiprazole to soc (olanzapine, quetiapine or risperidone) in patients with schizophrenia (dsm-iv-tr criteria).
nsubj||aimed-2/VBD||we-1/PRP	nsubj||evaluate-4/VB||we-1/PRP	root||ROOT-0/null||aimed-2/VBD	aux||evaluate-4/VB||to-3/TO	xcomp||aimed-2/VBD||evaluate-4/VB	advmod||evaluate-4/VB||retrospectively-5/RB	det||correlation-7/NN||the-6/DT	dobj||evaluate-4/VB||correlation-7/NN	iobj||evaluate-4/VB||correlation-7/NN	amod||relapse-10/NN||loco-regional-9/JJ	prep_of||correlation-7/NN||relapse-10/NN	appos||correlation-7/NN||lrr-12/NN	dep||correlation-7/NN||rate-14/NN	amod||metastasis-17/NNS||distant-16/JJ	dep||correlation-7/NN||metastasis-17/NNS	conj_and||rate-14/NN||metastasis-17/NNS	appos||metastasis-17/NNS||dm-19/NN	dep||metastasis-17/NNS||rate-21/NN	nn||survival-25/NN||disease-23/NN	amod||survival-25/NN||free-24/JJ	dep||correlation-7/NN||survival-25/NN	conj_and||rate-14/NN||survival-25/NN	dep||survival-25/NN||dfs-27/VBN	amod||survival-31/NN||overall-30/JJ	dep||correlation-7/NN||survival-31/NN	conj_and||rate-14/NN||survival-31/NN	nsubj||are-46/VBP||survival-31/NN	appos||survival-31/NN||os-33/NN	det||group-37/NN||a-36/DT	prep_in||survival-31/NN||group-37/NN	nn||patients-44/NNS||breast-39/NN	nn||patients-44/NNS||cancer-40/NN	nn||patients-44/NNS||bc-42/NN	prep_of||group-37/NN||patients-44/NNS	rcmod||survival-31/NN||are-46/VBP	amod||risk-49/NN||intermediate-48/JJ	prep_at||are-46/VBP||risk-49/NN	prep_for||risk-49/NN||lrr-51/NN	amod||tumor-54/NN||t1-2-53/JJ	dep||lrr-51/NN||tumor-54/NN	num||nodes-59/NNS||1-3-56/CD	amod||nodes-59/NNS||positive-57/JJ	nn||nodes-59/NNS||axillary-58/NN	dep||lrr-51/NN||nodes-59/NNS	conj_and||tumor-54/NN||nodes-59/NNS	vmod||lrr-51/NN||treated-61/VBN	vmod||lrr-51/NN||treated-61/VBN	conj_or||treated-61/VBN||treated-61/VBN	amod||radiotherapy-66/NN||postmastectomy-65/JJ	prep_with||treated-61/VBN||radiotherapy-66/NN	prep_without||treated-61/VBN||radiotherapy-66/NN	appos||radiotherapy-66/NN||pmrt-68/NN	amod||mastectomy-73/NN||modified-71/VBN	amod||mastectomy-73/NN||radical-72/JJ	prep_following||treated-61/VBN||mastectomy-73/NN	appos||mastectomy-73/NN||mrm-75/NN	tumor-54||dm-19||yes||we aimed to evaluate retrospectively the correlation of loco-regional relapse (lrr) rate, distant metastasis (dm) rate, disease free survival (dfs) and overall survival (os) in a group of breast cancer (bc) patients who are at intermediate risk for lrr (t1-2 tumor and 1-3 positive axillary nodes) treated with or without postmastectomy radiotherapy (pmrt) following modified radical mastectomy (mrm).
nsubj||found-2/VBD||we-1/PRP	nsubj||observed-19/VBD||we-1/PRP	nsubj||promoted-38/VBD||we-1/PRP	root||ROOT-0/null||found-2/VBD	det||correlation-4/NN||a-3/DT	dobj||found-2/VBD||correlation-4/NN	amod||expression-7/NN||erbb2-6/JJ	prep_between||correlation-4/NN||expression-7/NN	prep_between||correlation-4/NN||activation-9/NN	conj_and||expression-7/NN||activation-9/NN	prep_of||correlation-4/NN||pak-11/NN	amod||samples-17/NNS||estrogen-receptor-13/JJ	amod||samples-17/NNS||positive-14/JJ	amod||samples-17/NNS||human-15/JJ	nn||samples-17/NNS||breasttumor-16/NN	prep_in||found-2/VBD||samples-17/NNS	conj_and||found-2/VBD||observed-19/VBD	dobj||observed-19/VBD||that-20/DT	amod||cultures-23/NNS||3d-22/JJ	prep_in||that-20/DT||cultures-23/NNS	appos||cultures-23/NNS||activation-25/NN	amod||pathway-28/NN||rac-pak1-27/JJ	prep_of||activation-25/NN||pathway-28/NN	amod||homodimers-31/NNS||erbb2-30/JJ	prep_by||observed-19/VBD||homodimers-31/NNS	vmod||homodimers-31/NNS||induced-32/VBN	nn||factor-34/NN||growth-33/NN	dobj||induced-32/VBN||factor-34/NN	amod||proliferation-36/NN||independent-35/JJ	dobj||found-2/VBD||proliferation-36/NN	conj_and||found-2/VBD||promoted-38/VBD	dobj||promoted-38/VBD||disruption-39/NN	amod||structures-44/NNS||three-dimensional-41/JJ	amod||structures-44/NNS||mammary-42/JJ	amod||structures-44/NNS||acinar-like-43/JJ	prep_of||disruption-39/NN||structures-44/NNS	prep_through||promoted-38/VBD||activation-46/NN	det||pathways-52/NNS||the-48/DT	nn||pathways-52/NNS||erk-49/NN	conj_and||erk-49/NN||akt-51/NN	nn||pathways-52/NNS||akt-51/NN	prep_of||activation-46/NN||pathways-52/NNS	breasttumor-16||estrogen--1||yes||we found a correlation between erbb2 expression and activation of pak in estrogen-receptor positive human breasttumor samples and observed that in 3d cultures, activation of rac-pak1 pathway by erbb2 homodimers induced growth factor independent proliferation and promoted disruption of three-dimensional mammary acinar-like structures through activation of the erk and akt pathways.
nn||g-3/NN||paracetamol-1/NNP	num||g-3/NN||1-2/CD	nsubj||reduced-9/VBD||g-3/NN	vmod||g-3/NN||taken-4/VBN	advmod||taken-4/VBN||orally-5/RB	det||hours-8/NNS||every-6/DT	num||hours-8/NNS||6-7/CD	dobj||taken-4/VBN||hours-8/NNS	root||ROOT-0/null||reduced-9/VBD	amod||anglerecessionglaucoma-12/NN||openangleglaucoma-10/JJ	amod||anglerecessionglaucoma-12/NN||and/or-11/JJ	dobj||reduced-9/VBD||anglerecessionglaucoma-12/NN	det||groups-15/NNS||both-14/DT	prep_in||reduced-9/VBD||groups-15/NNS	prep_of||groups-15/NNS||patients-17/NNS	det||way-21/NN||a-20/DT	prep_in||reduced-9/VBD||way-21/NN	amod||way-21/NN||comparable-22/JJ	prep_with||comparable-22/JJ||that-24/DT	vmod||that-24/DT||achieved-25/VBN	det||beta-adrenergicreceptorantagonist-29/NN||a-27/DT	amod||beta-adrenergicreceptorantagonist-29/NN||topical-28/JJ	agent||achieved-25/VBN||beta-adrenergicreceptorantagonist-29/NN	openangleglaucoma-10||paracetamol-1||no_rel||paracetamol 1 g taken orally every 6 hours reduced openangleglaucoma and/or anglerecessionglaucoma in both groups of patients, in a way comparable with that achieved by a topical beta-adrenergicreceptorantagonist.
mark||affects-6/VBZ||although-1/IN	nsubj||affects-6/VBZ||chronichepatitisb-2/NN	appos||chronichepatitisb-2/NN||chb-4/NN	advcl||is-15/VBZ||affects-6/VBZ	quantmod||million-9/CD||approximately-7/RB	number||million-9/CD||2-8/CD	dobj||affects-6/VBZ||million-9/CD	vmod||million-9/CD||united-10/VBN	nn||residents-12/NNS||states-11/NNS	dobj||united-10/VBN||residents-12/NNS	expl||is-15/VBZ||there-14/EX	root||ROOT-0/null||is-15/VBZ	neg||screening-18/NN||no-16/DT	amod||screening-18/NN||systematic-17/JJ	nsubj||is-15/VBZ||screening-18/NN	amod||individuals-21/NNS||at-risk-20/JJ	prep_of||screening-18/NN||individuals-21/NNS	nsubj||remain-25/VBP||most-24/JJS	conj_and||is-15/VBZ||remain-25/VBP	acomp||remain-25/VBP||unaware-26/JJ	poss||infection-33/NN||their-28/PRP$	amod||infection-33/NN||hepatitisbvirus-29/JJ	appos||infection-33/NN||hbv-31/NN	prep_of||remain-25/VBP||infection-33/NN	chronichepatitisb-2||hepatitisbvirus-29||no||although chronichepatitisb (chb) affects approximately 2 million united states residents, there is no systematic screening of at-risk individuals, and most remain unaware of their hepatitisbvirus (hbv) infection.
prep_despite||lack-12/VBP||progress-2/NN	prepc_in||progress-2/NN||deciphering-4/VBG	amod||determinants-6/NNS||viral-5/JJ	dobj||deciphering-4/VBG||determinants-6/NNS	prep_of||determinants-6/NNS||pathogenicity-8/NN	nsubj||lack-12/VBP||we-10/PRP	advmod||lack-12/VBP||still-11/RB	root||ROOT-0/null||lack-12/VBP	amod||information-14/NN||crucial-13/JJ	dobj||lack-12/VBP||information-14/NN	amod||interactions-18/NNS||virus/immune-16/JJ	nn||interactions-18/NNS||system-17/NN	prep_on||lack-12/VBP||interactions-18/NNS	vmod||interactions-18/NNS||pertaining-19/VBG	amod||disease-22/NN||severe-21/JJ	prep_to||pertaining-19/VBG||disease-22/NN	amod||mortality-25/NN||high-24/JJ	prep_to||pertaining-19/VBG||mortality-25/NN	conj_and||disease-22/NN||mortality-25/NN	vmod||disease-22/NN||associated-26/VBN	amod||influenzavirusinfections-30/NNS||human-28/JJ	amod||influenzavirusinfections-30/NNS||h5n1-29/JJ	prep_with||associated-26/VBN||influenzavirusinfections-30/NNS	h5n1-29||influenzavirus--1||no||despite progress in deciphering viral determinants of pathogenicity, we still lack crucial information on virus/immune system interactions pertaining to severe disease and high mortality associated with human h5n1 influenzavirusinfections.
advmod||cultured-4/VBN||when-1/WRB	nsubjpass||cultured-4/VBN||viruses-2/NNS	auxpass||cultured-4/VBN||are-3/VBP	advcl||cause-20/VB||cultured-4/VBN	amod||passage-7/NN||serial-6/JJ	agent||cultured-4/VBN||passage-7/NN	amod||cells-11/NNS||susceptible-9/JJ	nn||cells-11/NNS||host-10/NN	prep_on||passage-7/NN||cells-11/NNS	det||presence-14/NN||the-13/DT	nsubj||cause-20/VB||presence-14/NN	amod||particles-18/NNS||virus-like-16/JJ	nn||particles-18/NNS||di-17/NNP	prep_of||presence-14/NN||particles-18/NNS	aux||cause-20/VB||can-19/MD	root||ROOT-0/null||cause-20/VB	nn||populations-22/NNS||virus-21/NN	dobj||cause-20/VB||populations-22/NNS	aux||rise-24/VB||to-23/TO	vmod||cause-20/VB||rise-24/VB	vmod||cause-20/VB||fall-26/VB	conj_and||rise-24/VB||fall-26/VB	xcomp||cause-20/VB||reflecting-28/VBG	amod||interactions-30/NNS||predator-prey-29/JJ	dobj||reflecting-28/VBG||interactions-30/NNS	prep_between||interactions-30/NNS||di-32/FW	nn||particles-35/NNS||virus-34/NN	prep_between||interactions-30/NNS||particles-35/NNS	conj_and||di-32/FW||particles-35/NNS	virus-34||viruses-2||no||when viruses are cultured by serial passage on susceptible host cells, the presence of virus-like di particles can cause virus populations to rise and fall, reflecting predator-prey interactions between di and virus particles.
expl||was-2/VBD||there-1/EX	root||ROOT-0/null||was-2/VBD	det||paucity-4/NN||a-3/DT	nsubj||was-2/VBD||paucity-4/NN	prep_of||paucity-4/NN||evidence-6/NN	prep_on||evidence-6/NN||behaviour-8/NN	aux||avoid-10/VB||to-9/TO	vmod||paucity-4/NN||avoid-10/VB	dobj||avoid-10/VB||hccccccccccccccccccccccccccccccccypoglycaemia-11/NN	expl||were-15/VBD||there-14/EX	conj_but||was-2/VBD||were-15/VBD	det||suggestions-17/NNS||some-16/DT	nsubj||were-15/VBD||suggestions-17/NNS	mark||permitted-26/VBN||that-18/IN	dep||desirable-21/JJ||higher-19/JJR	dep||desirable-21/JJ||than-20/IN	amod||levels-23/NNS||desirable-21/JJ	nn||levels-23/NNS||bloodglucose-22/NN	nsubjpass||permitted-26/VBN||levels-23/NNS	nsubj||avoid-30/VB||levels-23/NNS	aux||permitted-26/VBN||might-24/MD	auxpass||permitted-26/VBN||be-25/VB	ccomp||were-15/VBD||permitted-26/VBN	prep_in||permitted-26/VBN||order-28/NN	aux||avoid-30/VB||to-29/TO	xcomp||permitted-26/VBN||avoid-30/VB	dobj||avoid-30/VB||hypoglycaemia-31/NN	hypoglycaemia-31||glucose--1||yes||there was a paucity of evidence on behaviour to avoid hccccccccccccccccccccccccccccccccypoglycaemia, but there were some suggestions that higher than desirable bloodglucose levels might be permitted in order to avoid hypoglycaemia.
nsubj||present-2/VBP||we-1/PRP	root||ROOT-0/null||present-2/VBP	nsubj||drawn-4/VBN||data-3/NNS	dep||present-2/VBP||drawn-4/VBN	num||irondeficiency-11/NN||four-6/CD	amod||irondeficiency-11/NN||different-7/JJ	amod||irondeficiency-11/NN||conditionsâ-8/JJ	nn||irondeficiency-11/NN||$-9/NN	prep_from||drawn-4/VBN||irondeficiency-11/NN	amod||hypotransferrinemia-14/NN||congenital-13/JJ	prep_from||drawn-4/VBN||hypotransferrinemia-14/NN	conj_and||irondeficiency-11/NN||hypotransferrinemia-14/NN	prep_from||drawn-4/VBN||beta-thalassemia-16/NN	conj_and||irondeficiency-11/NN||beta-thalassemia-16/NN	nn||$-20/NNP||hereditaryhemochromatosisâ-19/NNP	prep_from||drawn-4/VBN||$-20/NNP	conj_and||irondeficiency-11/NN||$-20/NNP	dep||irondeficiency-11/NN||both-22/DT	prep_from||drawn-4/VBN||in-23/IN	conj_and||irondeficiency-11/NN||in-23/IN	amod||models-27/NNS||human-24/JJ	conj_and||human-24/JJ||non-human-26/JJ	amod||models-27/NNS||non-human-26/JJ	prep_in||irondeficiency-11/NN||models-27/NNS	prep_of||models-27/NNS||disease-29/NN	advmod||suggesting-32/VBG||together-31/RB	xcomp||present-2/VBP||suggesting-32/VBG	mark||exerts-37/VBZ||that-33/IN	amod||demand-36/NN||erythroid-34/VBN	nn||demand-36/NN||iron-35/NN	nsubj||exerts-37/VBZ||demand-36/NN	ccomp||suggesting-32/VBG||exerts-37/VBZ	det||influence-40/NN||a-38/DT	amod||influence-40/NN||stronger-39/JJR	dobj||exerts-37/VBZ||influence-40/NN	prepc_on||exerts-37/VBZ||circulating-42/VBG	nn||supply-44/NN||iron-43/NN	dobj||circulating-42/VBG||supply-44/NN	amod||stores-48/NNS||systemic-46/JJ	nn||stores-48/NNS||iron-47/NN	prep_than||circulating-42/VBG||stores-48/NNS	irondeficiency-11||iron-47||yes||we present data drawn from four different conditionsâirondeficiency, congenital hypotransferrinemia, beta-thalassemia, and hereditaryhemochromatosisâboth in human and non-human models of disease, together suggesting that erythroid iron demand exerts a stronger influence on circulating iron supply than systemic iron stores.
num||patients-5/NNS||101-2/CD	amod||patients-5/NNS||adult-3/JJ	amod||patients-5/NNS||epileptic-4/JJ	prep_in||evaluated-27/VBN||patients-5/NNS	vmod||patients-5/NNS||treated-6/VBN	prep_with||treated-6/VBN||valproicacid-8/NN	prep_in||valproicacid-8/NN||monotherapy-10/NN	dep||valproicacid-8/NN||n-12/VBN	dep||75-14/CD||=-13/SYM	ccomp||n-12/VBN||75-14/CD	prep_with||treated-6/VBN||polytherapy-17/NN	conj_and||valproicacid-8/NN||polytherapy-17/NN	dep||polytherapy-17/NN||n-19/VBN	dep||26-21/CD||=-20/SYM	ccomp||n-19/VBN||26-21/CD	det||availability-25/NN||the-23/DT	nn||availability-25/NN||copper-24/NN	nsubjpass||evaluated-27/VBN||availability-25/NN	auxpass||evaluated-27/VBN||was-26/VBD	root||ROOT-0/null||evaluated-27/VBN	xcomp||evaluated-27/VBN||using-28/VBG	det||activity-32/NN||the-29/DT	amod||activity-32/NN||specific-30/JJ	nn||activity-32/NN||oxidase-31/NN	dobj||using-28/VBG||activity-32/NN	prep_of||activity-32/NN||ceruloplasmin-34/NN	dep||ceruloplasmin-34/NN||activity-36/NN	nn||mass-39/NN||unit-38/NN	prep_per||activity-36/NN||mass-39/NN	amod||protein-42/NN||enzyme-41/JJ	prep_of||mass-39/NN||protein-42/NN	det||ratio-47/NN||the-45/DT	nn||ratio-47/NN||copper/ceruloplasmin-46/NN	prep_of||activity-32/NN||ratio-47/NN	conj_and||ceruloplasmin-34/NN||ratio-47/NN	epileptic-4||valproicacid-8||yes||in 101 adult epileptic patients treated with valproicacid in monotherapy ( n = 75) and polytherapy ( n = 26) the copper availability was evaluated using the specific oxidase activity of ceruloplasmin (activity per unit mass of enzyme protein) and the copper/ceruloplasmin ratio.
nn||t3-2/NNS||serum-1/NN	nsubjpass||decreased-6/VBN||t3-2/NNS	conj_and||t3-2/NNS||t4-4/NNS	nsubjpass||decreased-6/VBN||t4-4/NNS	auxpass||decreased-6/VBN||were-5/VBD	root||ROOT-0/null||decreased-6/VBN	num||children-9/NNS||34/78-8/CD	prep_in||decreased-6/VBN||children-9/NNS	nn||infections-12/NNS||cns-11/NN	prep_with||children-9/NNS||infections-12/NNS	nsubj||lower-19/JJR||t3-14/NNS	nsubj||higher-33/JJR||t3-14/NNS	conj_and||t3-14/NNS||t4-16/NNS	nsubj||lower-19/JJR||t4-16/NNS	cop||lower-19/JJR||were-17/VBD	advmod||lower-19/JJR||much-18/RB	dep||decreased-6/VBN||lower-19/JJR	prep_than||lower-19/JJR||those-21/DT	amod||adult-24/NN||healthy-23/JJ	prep_of||those-21/DT||adult-24/NN	dep||<-27/JJ||p-26/RB	dep||lower-19/JJR||<-27/JJ	dep||<-27/JJ||0.05-28/CD	advmod||higher-33/JJR||still-32/RB	dep||decreased-6/VBN||higher-33/JJR	conj_but||lower-19/JJR||higher-33/JJR	prep_than||higher-33/JJR||that-35/DT	det||hypothyroidism-39/NN||the-37/DT	amod||hypothyroidism-39/NN||primary-38/JJ	prep_of||that-35/DT||hypothyroidism-39/NN	dep||<-42/JJ||p-41/RB	dep||higher-33/JJR||<-42/JJ	dep||<-42/JJ||0.05-43/CD	nn||levels-48/NNS||tsh-47/NN	nsubj||differences-52/NNS||levels-48/NNS	cop||differences-52/NNS||were-49/VBD	neg||differences-52/NNS||not-50/RB	amod||differences-52/NNS||significant-51/JJ	conj_and||decreased-6/VBN||differences-52/NNS	prep_among||differences-52/NNS||children-54/NNS	nn||infections-57/NNS||cns-56/NN	prep_with||children-54/NNS||infections-57/NNS	prep_with||children-54/NNS||children-59/NNS	conj_and||infections-57/NNS||children-59/NNS	amod||infections-62/NNS||non-cns-61/JJ	prep_with||children-54/NNS||infections-62/NNS	dep||children-54/NNS||p-64/VBN	num||0.05-66/CD||>-65/CD	dobj||p-64/VBN||0.05-66/CD	hypothyroidism-39||t3-14||yes||serum t3 and t4 were decreased in 34/78 children with cns infections, t3 and t4 were much lower than those of healthy adult (p < 0.05), but still higher than that of the primary hypothyroidism (p < 0.05), and tsh levels were not significant differences among children with cns infections and children with non-cns infections (p > 0.05).
det||purpose-2/NN||the-1/DT	nsubj||is-6/VBZ||purpose-2/NN	nsubj||review-8/VB||purpose-2/NN	det||article-5/NN||this-4/DT	prep_of||purpose-2/NN||article-5/NN	root||ROOT-0/null||is-6/VBZ	aux||review-8/VB||to-7/TO	xcomp||is-6/VBZ||review-8/VB	det||effectiveness-10/NN||the-9/DT	dobj||review-8/VB||effectiveness-10/NN	dobj||review-8/VB||tolerability-12/NN	conj_and||effectiveness-10/NN||tolerability-12/NN	prep_of||effectiveness-10/NN||pioglitazone-14/NN	det||prevention-17/NN||the-16/DT	prep_in||review-8/VB||prevention-17/NN	prep_in||review-8/VB||management-19/NN	conj_and||prevention-17/NN||management-19/NN	prep_of||prevention-17/NN||atherosclerosis-21/NNS	prep_in||atherosclerosis-21/NNS||patients-23/NNS	prep_with||patients-23/NNS||type2diabetes-25/CD	type2diabetes-25||pioglitazone-14||yes||the purpose of this article is to review the effectiveness and tolerability of pioglitazone in the prevention and management of atherosclerosis in patients with type2diabetes.
det||study-4/NN||the-2/DT	amod||study-4/NN||current-3/JJ	prep_in||exploited-7/VBN||study-4/NN	nsubj||exploited-7/VBN||we-6/PRP	root||ROOT-0/null||exploited-7/VBN	amod||analysis-10/NN||genome-wide-8/JJ	amod||analysis-10/NN||microarray-9/JJ	dobj||exploited-7/VBN||analysis-10/NN	aux||determine-12/VB||to-11/TO	vmod||analysis-10/NN||determine-12/VB	mark||expressed-22/VBN||that-13/IN	nsubjpass||expressed-22/VBN||genes-14/NNS	nn||sequestration-17/NN||lipid-16/NN	prep_for||genes-14/NNS||sequestration-17/NN	prep_for||genes-14/NNS||metabolism-19/NN	conj_and||sequestration-17/NN||metabolism-19/NN	auxpass||expressed-22/VBN||were-20/VBD	advmod||expressed-22/VBN||highly-21/RB	ccomp||determine-12/VB||expressed-22/VBN	amod||granulomas-26/NNS||caseous-24/JJ	nn||granulomas-26/NNS||tb-25/NN	prep_in||expressed-22/VBN||granulomas-26/NNS	tb-25||lipid-16||no_rel||in the current study, we exploited genome-wide microarray analysis to determine that genes for lipid sequestration and metabolism were highly expressed in caseous tb granulomas.
amod||response-2/NN||flush-1/JJ	nsubj||impaired-9/JJ||response-2/NN	amod||patch-6/NN||niacin-4/JJ	nn||patch-6/NN||skin-5/NN	prep_to||response-2/NN||patch-6/NN	cop||impaired-9/JJ||is-7/VBZ	advmod||impaired-9/JJ||more-8/RBR	root||ROOT-0/null||impaired-9/JJ	nn||patients-12/NNS||schizophrenia-11/NN	prep_in||impaired-9/JJ||patients-12/NNS	poss||relatives-15/NNS||their-14/PRP$	prep_in||impaired-9/JJ||relatives-15/NNS	conj_and||patients-12/NNS||relatives-15/NNS	prep_from||impaired-9/JJ||families-17/NNS	amod||loading-21/NN||higher-19/JJR	amod||loading-21/NN||genetic-20/JJ	prep_with||families-17/NNS||loading-21/NN	prep_for||loading-21/NN||schizophrenia-23/NN	det||finding-27/NN||this-26/DT	nsubj||has-28/VBZ||finding-27/NN	conj_and||impaired-9/JJ||has-28/VBZ	dobj||has-28/VBZ||implications-29/NNS	amod||dissection-33/NN||future-31/JJ	amod||dissection-33/NN||genetic-32/JJ	prep_for||implications-29/NNS||dissection-33/NN	prep_of||dissection-33/NN||schizophrenia-35/NN	flush-1||niacin-4||no||flush response to niacin skin patch is more impaired in schizophrenia patients and their relatives from families with higher genetic loading for schizophrenia, and this finding has implications for future genetic dissection of schizophrenia.
nsubj||causes-7/VBZ||aquafol-1/NN	det||propofol-5/NN||a-3/DT	nn||propofol-5/NN||microemulsion-4/NN	appos||aquafol-1/NN||propofol-5/NN	root||ROOT-0/null||causes-7/VBZ	advmod||severe-9/JJ||more-8/RBR	amod||pain-12/NN||severe-9/JJ	conj_and||severe-9/JJ||frequent-11/JJ	amod||pain-12/NN||frequent-11/JJ	dobj||causes-7/VBZ||pain-12/NN	prep_on||causes-7/VBZ||injection-14/NN	prep_than||injection-14/NN||propofol-16/NN	pain-12||propofol-16||yes||aquafol, a microemulsion propofol, causes more severe and frequent pain on injection than propofol.
nn||levels-2/NNS||glucagon-1/NN	nsubj||remained-3/VBD||levels-2/NNS	root||ROOT-0/null||remained-3/VBD	acomp||remained-3/VBD||suppressed-4/VBN	det||decrease-7/NN||a-6/DT	prep_following||suppressed-4/VBN||decrease-7/NN	amod||insulin-10/NN||zinc-free-9/JJ	prep_in||decrease-7/NN||insulin-10/NN	prep_in||decrease-7/NN||insulin-10/NN	conj_and||insulin-10/NN||insulin-10/NN	prep_with||insulin-10/NN||euglycemia-12/NN	dep||insulin-10/NN||â-14/VB	num||±-17/NN||14-15/CD	nn||±-17/NN||â-16/NN	nsubj||-LSB--20/VBG||±-17/NN	number||pg/ml-19/JJ||3-18/CD	dep||-LSB--20/VBG||pg/ml-19/JJ	xcomp||â-14/VB||-LSB--20/VBG	poss||-RSB--28/NN||â-21/NNP	number||â-24/CD||4.0-23/CD	num||-RSB--28/NN||â-24/CD	nn||-RSB--28/NN||±-25/NN	num||-RSB--28/NN||0.9-26/CD	nn||-RSB--28/NN||pmol/l-27/NN	dobj||-LSB--20/VBG||-RSB--28/NN	amod||hyperinsulinemia-33/NN||sustained-32/VBN	prep_during||insulin-10/NN||hyperinsulinemia-33/NN	prep_with||hyperinsulinemia-33/NN||hypoglycemia-35/NN	nn||±-40/NN||â-37/NN	num||±-40/NN||14-38/CD	nn||±-40/NN||â-39/NN	dep||hypoglycemia-35/NN||±-40/NN	num||-LSB--43/NNS||2-41/CD	amod||-LSB--43/NNS||pg/ml-42/JJ	dep||±-40/NN||-LSB--43/NNS	poss||-RSB--51/NN||â-44/NNP	amod||-RSB--51/NN||4.0-46/JJ	nn||-RSB--51/NN||â-47/NN	nn||-RSB--51/NN||±-48/NN	num||-RSB--51/NN||0.6-49/CD	amod||-RSB--51/NN||pmol/l-50/JJ	dep||-LSB--43/NNS||-RSB--51/NN	acomp||remained-3/VBD||increased-54/VBN	conj_but||suppressed-4/VBN||increased-54/VBN	poss||pg/ml-62/NN||â-56/NNP	number||â-59/CD||3-58/CD	num||pg/ml-62/NN||â-59/CD	amod||pg/ml-62/NN||±-60/JJ	num||pg/ml-62/NN||3-61/CD	prep_to||increased-54/VBN||pg/ml-62/NN	poss||â-67/NN||â-64/NNP	num||â-67/NN||0.9-66/CD	npadvmod||pmol/l-70/JJ||â-67/NN	number||0.9-69/CD||±-68/CD	num||â-67/NN||0.9-69/CD	dep||pg/ml-62/NN||pmol/l-70/JJ	parataxis||increased-54/VBN||p-73/VB	num||0.01-75/CD||<-74/CD	dobj||p-73/VB||0.01-75/CD	det||decrease-79/NN||a-78/DT	prep_following||increased-54/VBN||decrease-79/NN	amod||insulin-82/NN||zinc-free-81/JJ	prep_in||decrease-79/NN||insulin-82/NN	prep_with||insulin-82/NN||hypoglycemia-84/NN	det||min-89/NNS||the-86/DT	amod||min-89/NNS||next-87/JJ	num||min-89/NNS||120-88/CD	prep_over||hypoglycemia-84/NN||min-89/NNS	glucagon-1||hypoglycemia-84||no_rel||glucagon levels remained suppressed following a decrease in zinc-free insulin with euglycemia (â14 â± 3 pg/ml [â4.0 â± 0.9 pmol/l]) and during sustained hyperinsulinemia with hypoglycemia (â14 â± 2 pg/ml [â4.0 â± 0.6 pmol/l]) but increased to â3 â± 3 pg/ml (â0.9 â± 0.9 pmol/l) ( p < 0.01) following a decrease in zinc-free insulin with hypoglycemia over the next 120 min.
nsubj||provide-4/VB||bevacizumab-1/NN	aux||provide-4/VB||did-2/VBD	neg||provide-4/VB||not-3/RB	root||ROOT-0/null||provide-4/VB	amod||benefit-6/NN||additional-5/JJ	dobj||provide-4/VB||benefit-6/NN	aux||chemotherapy-8/VB||to-7/TO	vmod||provide-4/VB||chemotherapy-8/VB	amod||chemotherapy-11/NN||adjuvant-10/JJ	prep_in||chemotherapy-8/VB||chemotherapy-11/NN	nn||ii-14/NN||stage-13/NN	prep_for||chemotherapy-11/NN||ii-14/NN	nn||cancer-18/NN||iii-16/NN	nn||cancer-18/NN||colon-17/NN	prep_for||chemotherapy-11/NN||cancer-18/NN	conj_or||ii-14/NN||cancer-18/NN	cancer-18||adjuvant-10||no_rel||bevacizumab did not provide additional benefit to chemotherapy in adjuvant chemotherapy for stage ii or iii colon cancer.
advmod||administrated-14/VBN||even-1/RB	mark||administrated-14/VBN||though-2/IN	nsubjpass||administrated-14/VBN||immunoprophylaxis-3/NNS	amod||immunoglobulin-6/NN||hepatitisb-5/JJ	prep_with||immunoprophylaxis-3/NNS||immunoglobulin-6/NN	appos||immunoglobulin-6/NN||hbig-8/NN	amod||vaccine-12/NN||hepatitisb-11/JJ	prep_with||immunoprophylaxis-3/NNS||vaccine-12/NN	conj_and||immunoglobulin-6/NN||vaccine-12/NN	auxpass||administrated-14/VBN||is-13/VBZ	advcl||suffer-34/VBP||administrated-14/VBN	prep_to||administrated-14/VBN||neonates-16/NNS	poss||mothers-18/NNS||neonates-16/NNS	nsubj||antigen-22/NN||mothers-18/NNS	cop||antigen-22/NN||are-19/VBP	amod||antigen-22/NN||hepatitisb-20/JJ	nn||antigen-22/NN||surface-21/NN	rcmod||neonates-16/NNS||antigen-22/NN	appos||antigen-22/NN||hbsag-24/NN	amod||antigen-22/NN||positive-26/JJ	quantmod||10-29/CD||about-28/RB	num||%-30/NN||10-29/CD	nsubj||suffer-34/VBP||%-30/NN	det||neonates-33/NNS||the-32/DT	prep_of||%-30/NN||neonates-33/NNS	root||ROOT-0/null||suffer-34/VBP	nn||infection-37/NN||hbv-36/NN	prep_from||suffer-34/VBP||infection-37/NN	poss||life-41/NN||their-39/PRP$	amod||life-41/NN||early-40/JJ	prep_in||infection-37/NN||life-41/NN	hbv-36||hbig-8||yes||even though immunoprophylaxis with hepatitisb immunoglobulin (hbig) and hepatitisb vaccine is administrated to neonates whose mothers are hepatitisb surface antigen (hbsag) positive, about 10% of the neonates suffer from hbv infection in their early life.
nsubj||effective-4/JJ||montelukast-1/NN	aux||effective-4/JJ||might-2/MD	cop||effective-4/JJ||be-3/VB	root||ROOT-0/null||effective-4/JJ	amod||urticaria-7/NN||chronic-6/JJ	prep_in||effective-4/JJ||urticaria-7/NN	vmod||urticaria-7/NN||associated-8/VBN	prep_with||associated-8/VBN||aspirin-10/NN	appos||urticaria-7/NN||asa-12/NN	nn||-RSB--64/NN||food-15/NN	amod||-RSB--64/NN||additive-16/JJ	advmod||additive-16/JJ||hypersensitivity-17/RB	conj_or||additive-16/JJ||with-19/IN	amod||-RSB--64/NN||with-19/IN	pobj||with-19/IN||autoreactivity-20/NN	pobj||with-19/IN||autoreactivity-20/NN	conj_negcc||autoreactivity-20/NN||autoreactivity-20/NN	amod||injection-24/NN||intradermal-22/JJ	nn||injection-24/NN||serum-23/NN	prep_to||autoreactivity-20/NN||injection-24/NN	appos||injection-24/NN||asst-26/NN	advmod||taken-29/VBN||when-28/WRB	rcmod||injection-24/NN||taken-29/VBN	det||antihistamine-32/NN||an-31/DT	prep_with||taken-29/VBN||antihistamine-32/NN	amod||urticaria-43/NN||mild-36/JJ	conj_or||mild-36/JJ||moderate-38/JJ	amod||urticaria-43/NN||moderate-38/JJ	amod||urticaria-43/NN||chronic-39/JJ	amod||urticaria-43/NN||idiopathic-40/JJ	nn||urticaria-43/NN||urticaria-41/NN	amod||urticaria-43/NN||-LSB--42/VBG	prep_in||autoreactivity-20/NN||urticaria-43/NN	det||causes-48/NNS||any-45/DT	amod||causes-48/NNS||possible-46/JJ	amod||causes-48/NNS||secondary-47/JJ	prep_without||urticaria-43/NN||causes-48/NNS	dep||autoreactivity-20/NN||ie-50/NN	nn||additive-53/NN||food-52/NN	dep||autoreactivity-20/NN||additive-53/NN	conj_or||ie-50/NN||additive-53/NN	conj_or||ie-50/NN||asa-55/NN	conj_or||additive-53/NN||asa-55/NN	amod||hypersensitivity-59/NN||other-57/JJ	amod||hypersensitivity-59/NN||nsaid-58/JJ	conj_or||ie-50/NN||hypersensitivity-59/NN	conj_and||additive-53/NN||hypersensitivity-59/NN	dep||autoreactivity-20/NN||asst-62/NN	conj_or||ie-50/NN||asst-62/NN	prep_in||effective-4/JJ||-RSB--64/NN	conj_or||urticaria-7/NN||-RSB--64/NN	hypersensitivity-59||hypersensitivity-59||no||montelukast might be effective in chronic urticaria associated with aspirin (asa) or food additive hypersensitivity or with autoreactivity to intradermal serum injection (asst) when taken with an antihistamine but not in mild or moderate chronic idiopathic urticaria [urticaria without any possible secondary causes (ie, food additive or asa and other nsaid hypersensitivity, or asst)].
advmod||was-8/VBD||therefore-1/RB	det||aim-4/NN||the-3/DT	nsubj||was-8/VBD||aim-4/NN	nsubj||assess-10/VB||aim-4/NN	det||study-7/NN||this-6/DT	prep_of||aim-4/NN||study-7/NN	root||ROOT-0/null||was-8/VBD	aux||assess-10/VB||to-9/TO	xcomp||was-8/VBD||assess-10/VB	det||effectiveness-12/NN||the-11/DT	dobj||assess-10/VB||effectiveness-12/NN	amod||-rrb--43/NN||chloroquine-14/JJ	nn||strains-18/NNS||p.-16/NN	nn||strains-18/NNS||vivax-17/NN	prep_against||chloroquine-14/JJ||strains-18/NNS	prep_in||strains-18/NNS||one-20/CD	det||areas-25/NNS||the-22/DT	amod||areas-25/NNS||malaria-23/JJ	amod||areas-25/NNS||endemic-24/JJ	prep_of||one-20/CD||areas-25/NNS	nn||district-31/NN||ethiopia-27/NN	advmod||district-31/NN||namely-29/RB	nn||district-31/NN||halaba-30/NN	prep_of||areas-25/NNS||district-31/NN	vmod||strains-18/NNS||located-33/VBN	amod||nations-36/NNS||south-35/JJ	prep_in||located-33/VBN||nations-36/NNS	prep_in||located-33/VBN||nationalities-38/NNS	conj_and||nations-36/NNS||nationalities-38/NNS	nn||-rrb--43/NN||peoples-39/NNS	nn||-rrb--43/NN||region-40/NN	amod||-rrb--43/NN||-lrb--41/VBG	nn||-rrb--43/NN||snnpr-42/NN	prep_of||effectiveness-12/NN||-rrb--43/NN	amod||ethiopia-46/NN||south-45/JJ	prep_of||effectiveness-12/NN||ethiopia-46/NN	num||patients-50/NNS||87-48/CD	nn||patients-50/NNS||malaria-49/NN	prep_among||ethiopia-46/NN||patients-50/NNS	vmod||patients-50/NNS||enrolled-51/VBN	det||study-54/NN||the-53/DT	prep_in||enrolled-51/VBN||study-54/NN	quantmod||80-57/CD||only-56/RB	appos||study-54/NN||80-57/CD	prep_of||80-57/CD||them-59/PRP	vmod||80-57/CD||completed-60/VBN	det||follow-up-63/NN||the-61/DT	amod||follow-up-63/NN||28-days-62/JJ	dobj||completed-60/VBN||follow-up-63/NN	malaria-49||chloroquine-14||yes||therefore , the aim of this study was to assess the effectiveness of chloroquine against p. vivax strains in one of the malaria endemic areas of ethiopia , namely halaba district , located in south nations and nationalities peoples region -lrb- snnpr -rrb- of south ethiopia among 87 malaria patients enrolled in the study , only 80 of them completed the 28-days follow-up .
nsubj||provided-11/VBD||analysis-1/NN	det||protein-5/NN||the-3/DT	amod||protein-5/NN||capsid-4/JJ	prep_of||analysis-1/NN||protein-5/NN	det||virus-10/NN||this-7/DT	amod||virus-10/NN||new-8/JJ	nn||virus-10/NN||leafhopper-9/NN	prep_of||protein-5/NN||virus-10/NN	root||ROOT-0/null||provided-11/VBD	amod||evidence-13/NN||significant-12/JJ	dobj||provided-11/VBD||evidence-13/NN	mark||related-17/VBN||that-14/IN	nsubjpass||related-17/VBN||it-15/PRP	auxpass||related-17/VBN||is-16/VBZ	ccomp||provided-11/VBD||related-17/VBN	amod||viruses-22/NNS||other-19/JJ	nn||viruses-22/NNS||ssrna-20/NN	nn||viruses-22/NNS||insect-21/NN	prep_to||related-17/VBN||viruses-22/NNS	det||family-25/NN||the-24/DT	prep_within||related-17/VBN||family-25/NN	appos||family-25/NN||dicistroviridae-27/NN	virus-10||viruses-22||no||analysis of the capsid protein of this new leafhopper virus provided significant evidence that it is related to other ssrna insect viruses within the family, dicistroviridae.
aux||review-2/VB||to-1/TO	csubj||use-7/VBP||review-2/VB	nn||detemir-4/NN||insulin-3/NN	dobj||review-2/VB||detemir-4/NN	prep_for||review-2/VB||clinical-6/JJ	root||ROOT-0/null||use-7/VBP	aux||manage-10/VB||to-8/TO	advmod||manage-10/VB||better-9/RBR	xcomp||use-7/VBP||manage-10/VB	dobj||manage-10/VB||patients-11/NNS	prep_with||manage-10/VB||type-13/NN	num||type-13/NN||1-14/CD	prep_with||manage-10/VB||type2diabetes-16/NNS	conj_and||type-13/NN||type2diabetes-16/NNS	type2diabetes-16||insulin-3||yes||to review insulin detemir for clinical use to better manage patients with type 1 and type2diabetes.
det||control-3/NN||the-1/DT	amod||control-3/NN||profound-2/JJ	nsubj||oxidant-9/VB||control-3/NN	nsubj||ros-32/VB||control-3/NN	prep_of||control-3/NN||aunps-5/NNS	det||anti-8/NN||the-7/DT	prep_over||aunps-5/NNS||anti-8/NN	root||ROOT-0/null||oxidant-9/VB	dobj||oxidant-9/VB||enzymes-10/NNS	prep_such_as||enzymes-10/NNS||gsh-13/NN	prep_such_as||enzymes-10/NNS||sod-15/NN	conj_and||gsh-13/NN||sod-15/NN	prep_such_as||enzymes-10/NNS||catalase-17/NN	conj_and||gsh-13/NN||catalase-17/NN	prep_such_as||enzymes-10/NNS||gpx-19/NN	conj_and||gsh-13/NN||gpx-19/NN	amod||mice-22/NNS||diabetic-21/JJ	prep_in||oxidant-9/VB||mice-22/NNS	prep_to||oxidant-9/VB||normal-24/JJ	prep_by||oxidant-9/VB||inhibition-27/NN	nn||peroxidation-30/NN||lipid-29/NN	prep_of||inhibition-27/NN||peroxidation-30/NN	conj_and||oxidant-9/VB||ros-32/VB	dobj||ros-32/VB||generation-33/NN	nn||evidence-36/NN||hyperglycemia-35/NN	prep_during||ros-32/VB||evidence-36/NN	poss||effect-39/NN||their-37/PRP$	amod||effect-39/NN||anti-oxidant-38/JJ	dobj||oxidant-9/VB||effect-39/NN	prep_during||oxidant-9/VB||hyperglycemia-41/NN	lipid-29||hyperglycemia-41||no_rel||the profound control of aunps over the anti oxidant enzymes such as gsh, sod, catalase and gpx in diabetic mice to normal, by inhibition of lipid peroxidation and ros generation during hyperglycemia evidence their anti-oxidant effect during hyperglycemia.
nsubjpass||classified-3/VBN||deaths-1/NNS	auxpass||classified-3/VBN||were-2/VBD	root||ROOT-0/null||classified-3/VBN	advmod||hiv/aids-related-5/JJ||as-4/RB	acomp||classified-3/VBN||hiv/aids-related-5/JJ	acomp||classified-3/VBN||not-7/RB	conj_or||hiv/aids-related-5/JJ||not-7/RB	neg||hiv/aids-related-5/JJ||not-7/RB	amod||autopsy-10/NN||verbal-9/JJ	prep_by||hiv/aids-related-5/JJ||autopsy-10/NN	aids--1||hiv--1||no||deaths were classified as hiv/aids-related or not by verbal autopsy.
det||combination-3/NN||a-1/DT	amod||combination-3/NN||fixed-dose-2/JJ	nsubj||shown-13/VBN||combination-3/NN	prep_of||combination-3/NN||artemether-lumefantrine-5/NN	appos||combination-3/NN||al-7/NNP	nn||®-10/NNP||coartemâ-9/NNP	dep||al-7/NNP||®-10/NNP	aux||shown-13/VBN||has-12/VBZ	root||ROOT-0/null||shown-13/VBN	amod||efficacy-15/NN||high-14/JJ	dobj||shown-13/VBN||efficacy-15/NN	amod||tolerability-18/NN||good-17/JJ	dobj||shown-13/VBN||tolerability-18/NN	conj_and||efficacy-15/NN||tolerability-18/NN	dobj||shown-13/VBN||cost-effectiveness-20/NNS	conj_and||efficacy-15/NN||cost-effectiveness-20/NNS	prep_in||shown-13/VBN||adults-22/NNS	prep_in||shown-13/VBN||children-24/NNS	conj_and||adults-22/NNS||children-24/NNS	amod||malaria-27/NN||uncomplicated-26/JJ	prep_with||shown-13/VBN||malaria-27/NN	vmod||malaria-27/NN||caused-28/VBN	nn||falciparum-31/NN||plasmodium-30/NN	agent||caused-28/VBN||falciparum-31/NN	malaria-27||lumefantrine--1||yes||a fixed-dose combination of artemether-lumefantrine (al, coartemâ®) has shown high efficacy, good tolerability and cost-effectiveness in adults and children with uncomplicated malaria caused by plasmodium falciparum .
nsubj||disease-7/NN||tetanus-1/NN	cop||disease-7/NN||is-2/VBZ	det||disease-7/NN||an-3/DT	amod||disease-7/NN||acute-4/JJ	advmod||fatal-6/JJ||often-5/RB	amod||disease-7/NN||fatal-6/JJ	root||ROOT-0/null||disease-7/NN	vmod||disease-7/NN||produced-8/VBN	det||clostridiumtetani-16/NN||the-10/DT	amod||clostridiumtetani-16/NN||gram-positive-11/JJ	amod||clostridiumtetani-16/NN||obligate-13/JJ	amod||clostridiumtetani-16/NN||anaerobic-14/JJ	nn||clostridiumtetani-16/NN||bacterium-15/NN	agent||produced-8/VBN||clostridiumtetani-16/NN	tetanus-1||clostridiumtetani-16||no||tetanus is an acute often fatal disease produced by the gram-positive, obligate anaerobic bacterium clostridiumtetani.
nsubj||disease-5/NN||malaria-1/NN	cop||disease-5/NN||is-2/VBZ	det||disease-5/NN||the-3/DT	amod||disease-5/NN||infectious-4/JJ	ccomp||changed-28/VBN||disease-5/NN	vmod||disease-5/NN||causing-6/VBG	det||morbidity-9/NN||the-7/DT	amod||morbidity-9/NN||highest-8/JJS	dobj||causing-6/VBG||morbidity-9/NN	dobj||causing-6/VBG||mortality-11/NN	conj_and||morbidity-9/NN||mortality-11/NN	prep_in||mortality-11/NN||angola-13/NN	amod||widespread-17/JJ||due-15/JJ	dep||widespread-17/JJ||to-16/TO	amod||resistance-22/NN||widespread-17/JJ	amod||resistance-22/NN||chloroquine-18/JJ	dep||resistance-22/NN||cq-20/VBN	dobj||causing-6/VBG||resistance-22/NN	conj_and||morbidity-9/NN||resistance-22/NN	det||country-25/NN||the-24/DT	nsubj||changed-28/VBN||country-25/NN	aux||changed-28/VBN||has-26/VBZ	advmod||changed-28/VBN||recently-27/RB	root||ROOT-0/null||changed-28/VBN	poss||recommendations-32/NNS||its-29/PRP$	amod||recommendations-32/NNS||first-line-30/JJ	nn||recommendations-32/NNS||treatment-31/NN	dobj||changed-28/VBN||recommendations-32/NNS	amod||malaria-35/NN||uncomplicated-34/JJ	prep_for||changed-28/VBN||malaria-35/NN	prep_from||changed-28/VBN||cq-38/NN	aux||artemisinin-40/VB||to-39/TO	vmod||cq-38/NN||artemisinin-40/VB	nn||therapies-42/NNS||combination-41/NN	dobj||artemisinin-40/VB||therapies-42/NNS	appos||therapies-42/NNS||act-44/NN	prep_in||therapies-42/NNS||adults-47/NNS	prep_in||therapies-42/NNS||sulphadoxine/pyrimethamine-50/NN	conj_and||adults-47/NNS||sulphadoxine/pyrimethamine-50/NN	appos||adults-47/NNS||s/p-52/NN	amod||women-56/NNS||pregnant-55/JJ	prep_in||artemisinin-40/VB||women-56/NNS	malaria-35||pyrimethamine--1||yes||malaria is the infectious disease causing the highest morbidity and mortality in angola and due to widespread chloroquine (cq) resistance, the country has recently changed its first-line treatment recommendations for uncomplicated malaria, from cq to artemisinin combination therapies (act) in adults, and sulphadoxine/pyrimethamine (s/p) in pregnant women.
amod||administration-2/NN||leflunomide-1/JJ	nsubj||reduced-3/VBD||administration-2/NN	root||ROOT-0/null||reduced-3/VBD	dobj||reduced-3/VBD||cycling-4/NN	amod||cells-8/NNS||cd4-6/JJ	nn||cells-8/NNS||t-7/NN	prep_of||cycling-4/NN||cells-8/NNS	amod||uptake-14/NN||ex-11/JJ	nn||uptake-14/NN||vivo-12/NN	nn||uptake-14/NN||bromodeoxyuridine-13/NN	prep_by||cells-8/NNS||uptake-14/NN	amod||expression-17/NN||ki67-16/JJ	prep_by||cells-8/NNS||expression-17/NN	conj_and||uptake-14/NN||expression-17/NN	amod||expression-21/NN||decreased-20/VBN	dobj||reduced-3/VBD||expression-21/NN	conj_and||cycling-4/NN||expression-21/NN	nn||markers-24/NNS||activation-23/NN	prep_of||expression-21/NN||markers-24/NNS	amod||co-expression-27/NN||hla-dr/cd38-26/JJ	appos||markers-24/NNS||co-expression-27/NN	amod||cells-32/NNS||cd8-30/JJ	nn||cells-32/NNS||t-31/NN	prep_on||expression-21/NN||cells-32/NNS	amod||blood-35/NN||peripheral-34/JJ	prep_in||expression-21/NN||blood-35/NN	dr--1||leflunomide-1||no_rel||leflunomide administration reduced cycling of cd4 t cells (by ex vivo bromodeoxyuridine uptake and ki67 expression) and decreased expression of activation markers (hla-dr/cd38 co-expression) on cd8 t cells in peripheral blood.
nsubj||conclude-2/VBP||we-1/PRP	root||ROOT-0/null||conclude-2/VBP	mark||accurate-7/JJ||that-3/IN	det||tests-5/NNS||both-4/DT	nsubj||accurate-7/JJ||tests-5/NNS	nsubj||detect-9/VB||tests-5/NNS	cop||accurate-7/JJ||are-6/VBP	ccomp||conclude-2/VBP||accurate-7/JJ	aux||detect-9/VB||to-8/TO	xcomp||accurate-7/JJ||detect-9/VB	nn||tuberculosis-11/NNP||latent-10/NNP	dobj||detect-9/VB||tuberculosis-11/NNP	mark||have-17/VBP||although-13/IN	amod||assays-16/NNS||interferon-gamma-14/JJ	nn||assays-16/NNS||release-15/NN	nsubj||have-17/VBP||assays-16/NNS	dep||tuberculosis-11/NNP||have-17/VBP	amod||specificity-19/NN||higher-18/JJR	dobj||have-17/VBP||specificity-19/NN	nn||testing-23/NN||tuberculin-21/NN	nn||testing-23/NN||skin-22/NN	prep_than||have-17/VBP||testing-23/NN	amod||populations-26/NNS||bcg-vaccinated-25/JJ	prep_in||testing-23/NN||populations-26/NNS	advmod||received-32/VBN||particularly-28/RB	mark||received-32/VBN||if-29/IN	nsubjpass||received-32/VBN||bcg-30/NN	auxpass||received-32/VBN||is-31/VBZ	advcl||have-17/VBP||received-32/VBN	prep_after||received-32/VBN||infancy-34/NN	tuberculosis-11||bcg-30||yes||we conclude that both tests are accurate to detect latent tuberculosis, although interferon-gamma release assays have higher specificity than tuberculin skin testing in bcg-vaccinated populations, particularly if bcg is received after infancy.
amod||model-5/NN||castoroil-2/JJ	amod||model-5/NN||induced-3/JJ	nn||model-5/NN||diarrhea-4/NN	prep_in||reduced-33/VBD||model-5/NN	det||extract-12/NN||the-7/DT	number||%-9/NN||80-8/CD	amod||extract-12/NN||%-9/NN	nn||extract-12/NN||methanol-10/NN	nn||extract-12/NN||leaf-11/NN	nsubj||reduced-33/VBD||extract-12/NN	nn||aurea-15/NN||c.-14/NN	prep_of||extract-12/NN||aurea-15/NN	prep_at||aurea-15/NN||100-17/CD	num||100-17/CD||200-19/CD	prep_at||aurea-15/NN||400-21/CD	conj_and||100-17/CD||400-21/CD	amod||aurea-15/NN||mg/kg-22/JJ	det||drug-26/NN||the-24/DT	amod||drug-26/NN||standard-25/JJ	amod||aurea-15/NN||drug-26/NN	conj_and||mg/kg-22/JJ||drug-26/NN	advmod||drug-26/NN||loperamide-27/RB	number||3-29/CD||-lrb--28/CD	num||-rrb--31/NNS||3-29/CD	amod||-rrb--31/NNS||mg/kg-30/JJ	dep||mg/kg-22/JJ||-rrb--31/NNS	advmod||reduced-33/VBD||significantly-32/RB	root||ROOT-0/null||reduced-33/VBD	det||time-35/NN||the-34/DT	dobj||reduced-33/VBD||time-35/NN	prep_of||time-35/NN||onset-37/NN	prep_of||onset-37/NN||diarrhea-39/NN	det||frequency-42/NN||the-41/DT	prep_of||time-35/NN||frequency-42/NN	conj_and||onset-37/NN||frequency-42/NN	nn||number-47/NN||defecation-44/NN	nn||number-47/NN||-lrb--45/NNP	amod||number-47/NN||total-46/JJ	prep_of||frequency-42/NN||number-47/NN	amod||-rrb--51/NNS||faecal-49/JJ	nn||-rrb--51/NNS||output-50/NN	prep_of||frequency-42/NN||-rrb--51/NNS	prep_of||time-35/NN||weight-53/NN	conj_and||onset-37/NN||weight-53/NN	prep_of||weight-53/NN||faeces-55/NNS	diarrhea-39||loperamide-27||yes||in castoroil induced diarrhea model , the 80 % methanol leaf extract of c. aurea at 100 , 200 and 400 mg/kg and the standard drug loperamide -lrb- 3 mg/kg -rrb- significantly reduced the time of onset of diarrhea , the frequency of defecation -lrb- total number of faecal output -rrb- and weight of faeces .
amod||publications-2/NNS||recent-1/JJ	nsubj||put-3/VBD||publications-2/NNS	root||ROOT-0/null||put-3/VBD	det||warning-6/NN||a-4/DT	amod||warning-6/NN||serious-5/JJ	dobj||put-3/VBD||warning-6/NN	det||inefficacy-9/NN||the-8/DT	prep_regarding||warning-6/NN||inefficacy-9/NN	amod||sp-13/NN||sulphadoxine-pyrimethamine-11/JJ	prep_of||inefficacy-9/NN||sp-13/NN	det||treatment-19/NN||the-16/DT	amod||treatment-19/NN||intermittent-17/JJ	nn||treatment-19/NN||preventive-18/NN	prep_for||sp-13/NN||treatment-19/NN	prep_of||treatment-19/NN||malaria-21/NN	amod||children-24/NNS||young-23/JJ	prep_in||malaria-21/NN||children-24/NNS	appos||children-24/NNS||ipti-26/NNP	malaria-21||pyrimethamine--1||yes||recent publications put a serious warning regarding the inefficacy of sulphadoxine-pyrimethamine (sp) for the intermittent preventive treatment of malaria in young children (ipti).
nsubjpass||spread-3/VBN||vzv-1/NN	nsubj||cause-7/VB||vzv-1/NN	auxpass||spread-3/VBN||is-2/VBZ	root||ROOT-0/null||spread-3/VBN	agent||spread-3/VBN||aerosol-5/NN	aux||cause-7/VB||to-6/TO	xcomp||spread-3/VBN||cause-7/VB	dobj||cause-7/VB||chickenpox-8/NN	nsubj||infection-21/NN||chickenpox-8/NN	amod||countries-14/NNS||temperate-13/JJ	prep_in||infection-21/NN||countries-14/NNS	cop||infection-21/NN||is-16/VBZ	det||infection-21/NN||a-17/DT	advmod||benign-19/JJ||relatively-18/RB	amod||infection-21/NN||benign-19/JJ	nn||infection-21/NN||childhood-20/NN	rcmod||chickenpox-8/NN||infection-21/NN	advmod||tends-28/VBZ||yet-23/RB	amod||countries-26/NNS||tropical-25/JJ	prep_in||tends-28/VBZ||countries-26/NNS	nsubj||tends-28/VBZ||it-27/PRP	nsubj||occur-30/VB||it-27/PRP	parataxis||spread-3/VBN||tends-28/VBZ	aux||occur-30/VB||to-29/TO	xcomp||tends-28/VBZ||occur-30/VB	advmod||age-33/NN||later-32/RB	prep_at||occur-30/VB||age-33/NN	det||trend-36/NN||a-35/DT	appos||age-33/NN||trend-36/NN	vmod||trend-36/NN||associated-37/VBN	advmod||increased-40/JJ||markedly-39/RB	amod||severity-41/NN||increased-40/JJ	prep_with||associated-37/VBN||severity-41/NN	prep_including||severity-41/NN||complications-43/NNS	prep_including||severity-41/NN||hospitalization-45/NN	conj_and||complications-43/NNS||hospitalization-45/NN	amod||burden-49/NN||overall-48/JJ	prep_including||severity-41/NN||burden-49/NN	conj_and||complications-43/NNS||burden-49/NN	prep_of||burden-49/NN||care-51/NN	chickenpox-8||vzv-1||no||vzv is spread by aerosol to cause chickenpox, which, in temperate countries, is a relatively benign childhood infection; yet in tropical countries it tends to occur at later age, a trend associated with markedly increased severity including complications, hospitalization, and overall burden of care.
amod||vaccines-3/NNS||replicon-1/JJ	nn||vaccines-3/NNS||particle-2/NN	nsubj||induce-14/VB||vaccines-3/NNS	nsubj||reduce-18/VB||vaccines-3/NNS	nsubj||mitigate-24/VB||vaccines-3/NNS	vmod||vaccines-3/NNS||administered-4/VBN	det||regimen-8/NN||a-6/DT	amod||regimen-8/NN||prime/boost-7/JJ	prep_in||administered-4/VBN||regimen-8/NN	vmod||regimen-8/NN||expressing-9/VBG	amod||glycoprotein-12/NN||bvdv-10/JJ	amod||glycoprotein-12/NN||e2-11/JJ	dobj||expressing-9/VBG||glycoprotein-12/NN	aux||induce-14/VB||can-13/MD	root||ROOT-0/null||induce-14/VB	amod||titers-16/NNS||cross-neutralizing-15/JJ	dobj||induce-14/VB||titers-16/NNS	conj_and||induce-14/VB||reduce-18/VB	amod||challenge-21/NN||leukopenia-19/JJ	nn||challenge-21/NN||post-20/NN	dobj||reduce-18/VB||challenge-21/NN	conj_and||induce-14/VB||mitigate-24/VB	amod||disease-26/NN||clinical-25/JJ	dobj||mitigate-24/VB||disease-26/NN	prep_in||mitigate-24/VB||calves-28/NNS	leukopenia-19||vaccines-3||no_rel||replicon particle vaccines administered in a prime/boost regimen expressing bvdv e2 glycoprotein can induce cross-neutralizing titers, reduce leukopenia post challenge, and mitigate clinical disease in calves.
det||sublineage-4/NN||a-1/DT	amod||sublineage-4/NN||proposed-2/VBN	amod||sublineage-4/NN||new-3/JJ	nsubj||virus-13/NN||sublineage-4/NN	prep_of||sublineage-4/NN||ev71-6/NNS	appos||ev71-6/NNS||c4a-2-8/JJ	cop||virus-13/NN||was-10/VBD	det||virus-13/NN||the-11/DT	amod||virus-13/NN||predominant-12/JJ	root||ROOT-0/null||virus-13/NN	vmod||virus-13/NN||associated-14/VBN	det||beijing-17/NN||the-16/DT	prep_with||associated-14/VBN||beijing-17/NN	amod||outbreaks-21/NNS||nationwide-19/JJ	amod||outbreaks-21/NNS||hfmd-20/JJ	prep_with||associated-14/VBN||outbreaks-21/NNS	conj_and||beijing-17/NN||outbreaks-21/NNS	prep_since||associated-14/VBN||2008-23/CD	amod||substitution-26/NN||aminoacid-25/JJ	nsubj||link-30/VBP||substitution-26/NN	nsubjpass||found-41/VBN||substitution-26/NN	advmod||link-30/VBP||possibly-29/RB	rcmod||substitution-26/NN||link-30/VBP	det||tropism-36/NN||the-32/DT	amod||tropism-36/NN||central-33/JJ	amod||tropism-36/NN||nervous-34/JJ	nn||tropism-36/NN||system-35/NN	prep_to||link-30/VBP||tropism-36/NN	prep_of||tropism-36/NN||ev71-38/CD	auxpass||found-41/VBN||was-40/VBD	conj_and||virus-13/NN||found-41/VBN	amod||viruses-45/NN||genotype-43/JJ	det||viruses-45/NN||a-44/DT	prep_in||found-41/VBN||viruses-45/NN	virus-13||viruses-45||no||a proposed new sublineage of ev71, c4a-2, was the predominant virus associated with the beijing and nationwide hfmd outbreaks since 2008 and aminoacid substitution, which possibly link to the central nervous system tropism of ev71, was found in genotype a viruses.
nsubjpass||associated-6/VBN||diabetesmellitus-1/NNS	appos||diabetesmellitus-1/NNS||dm-3/NN	auxpass||associated-6/VBN||is-5/VBZ	root||ROOT-0/null||associated-6/VBN	nn||complications-9/NNS||microvascular-8/NN	prep_with||associated-6/VBN||complications-9/NNS	prep_such_as||complications-9/NNS||diabeticretinopathy-13/NN	appos||diabeticretinopathy-13/NN||dr-15/NN	dr-15||diabetesmellitus-1||no||diabetesmellitus (dm) is associated with microvascular complications, such as diabeticretinopathy (dr).
amod||so2-4/NNS||mycobacteriumtuberculosis-1/JJ	amod||so2-4/NNS||phop-2/JJ	amod||so2-4/NNS||mutant-3/JJ	nsubjpass||shown-11/VBN||so2-4/NNS	nsubjpass||attenuated-14/VBN||so2-4/NNS	nsubjpass||demonstrated-28/VBN||so2-4/NNS	vmod||so2-4/NNS||derived-5/VBN	det||isolate-9/NN||a-7/DT	amod||isolate-9/NN||clinical-8/JJ	prep_from||derived-5/VBN||isolate-9/NN	auxpass||shown-11/VBN||was-10/VBD	root||ROOT-0/null||shown-11/VBN	aux||attenuated-14/VBN||to-12/TO	auxpass||attenuated-14/VBN||be-13/VB	xcomp||shown-11/VBN||attenuated-14/VBN	nn||macrophages-19/NNS||mouse-16/NN	nn||macrophages-19/NNS||bone-17/NN	amod||macrophages-19/NNS||marrow-derived-18/JJ	nn||model-25/NN||macrophages-19/NNS	conj_and||macrophages-19/NNS||in-21/IN	nn||model-25/NN||in-21/IN	nn||mouse-23/NN||vivo-22/NN	pobj||in-21/IN||mouse-23/NN	nn||model-25/NN||infection-24/NN	prep_in||attenuated-14/VBN||model-25/NN	aux||demonstrated-28/VBN||has-27/VBZ	conj_and||shown-11/VBN||demonstrated-28/VBN	det||potential-31/NN||a-29/DT	amod||potential-31/NN||high-30/JJ	dobj||demonstrated-28/VBN||potential-31/NN	amod||candidate-35/NN||attenuated-33/JJ	nn||candidate-35/NN||vaccine-34/NN	prep_as||demonstrated-28/VBN||candidate-35/NN	prep_against||candidate-35/NN||tuberculosis-37/NNP	tuberculosis-37||mycobacteriumtuberculosis-1||no||mycobacteriumtuberculosis phop mutant so2 derived from a clinical isolate was shown to be attenuated in mouse bone marrow-derived macrophages and in vivo mouse infection model and has demonstrated a high potential as attenuated vaccine candidate against tuberculosis.
advmod||apply-4/VBP||finally-1/RB	nsubj||apply-4/VBP||we-3/PRP	root||ROOT-0/null||apply-4/VBP	poss||method-6/NN||our-5/PRP$	dobj||apply-4/VBP||method-6/NN	aux||predict-8/VB||to-7/TO	vmod||method-6/NN||predict-8/VB	amod||reactions-10/NNS||new-9/JJ	dobj||predict-8/VB||reactions-10/NNS	amod||targets-14/NNS||possible-12/JJ	nn||targets-14/NNS||enzyme-13/NN	dobj||predict-8/VB||targets-14/NNS	conj_and||reactions-10/NNS||targets-14/NNS	prep_for||predict-8/VB||cancerdrugs-16/NNS	enzyme-13||cancer--1||no_rel||finally, we apply our method to predict new reactions and possible enzyme targets for cancerdrugs.
det||challenge-2/NN||a-1/DT	nsubj||is-9/VBZ||challenge-2/NN	nsubj||develop-11/VB||challenge-2/NN	nn||research-8/NN||tuberculosis-4/NNP	appos||research-8/NN||tb-6/NN	prep_in||challenge-2/NN||research-8/NN	root||ROOT-0/null||is-9/VBZ	aux||develop-11/VB||to-10/TO	xcomp||is-9/VBZ||develop-11/VB	det||test-15/NN||a-12/DT	amod||test-15/NN||new-13/JJ	amod||test-15/NN||immunological-14/JJ	dobj||develop-11/VB||test-15/NN	nsubj||help-18/VB||test-15/NN	aux||help-18/VB||can-17/MD	rcmod||test-15/NN||help-18/VB	ccomp||help-18/VB||distinguish-19/VB	prep_among||distinguish-19/VB||subjects-22/NNS	amod||subjects-22/NNS||responsive-23/JJ	nn||gold-27/NN||quantiferon-25/NN	nn||gold-27/NN||tb-26/NN	prep_to||responsive-23/JJ||gold-27/NN	prep_in||gold-27/NN||tube-29/NN	appos||subjects-22/NNS||qft-it-31/NN	dobj||distinguish-19/VB||those-34/DT	nsubj||able-37/JJ||those-34/DT	nsubj||control-39/VB||those-34/DT	cop||able-37/JJ||are-36/VBP	rcmod||those-34/DT||able-37/JJ	aux||control-39/VB||to-38/TO	xcomp||able-37/JJ||control-39/VB	nn||replication-41/NN||mtb-40/NN	dobj||control-39/VB||replication-41/NN	amod||ltbi-44/NNS||remote-43/JJ	dep||replication-41/NN||ltbi-44/NNS	amod||infection-47/NN||recent-46/JJ	dep||replication-41/NN||infection-47/NN	conj_and||ltbi-44/NNS||infection-47/NN	amod||tb-50/NN||past-49/JJ	dep||replication-41/NN||tb-50/NN	conj_and||ltbi-44/NNS||tb-50/NN	prep_from||control-39/VB||those-53/DT	nsubj||can-55/MD||those-53/DT	rcmod||those-53/DT||can-55/MD	neg||can-55/MD||not-56/RB	amod||disease-60/NN||active-58/JJ	nn||disease-60/NN||tb-59/NN	appos||those-53/DT||disease-60/NN	tb-59||mtb-40||no||a challenge in tuberculosis (tb) research is to develop a new immunological test that can help distinguish, among subjects responsive to quantiferon tb gold in tube (qft-it), those who are able to control mtb replication (remote ltbi, recent infection and past tb) from those who cannot (active tb disease).
mark||immunization-3/NN||upon-1/IN	nn||immunization-3/NN||rabbit-2/NN	advcl||elicited-8/VBD||immunization-3/NN	det||proteins-7/NNS||both-5/DT	nn||proteins-7/NNS||ha-6/NN	nsubj||elicited-8/VBD||proteins-7/NNS	root||ROOT-0/null||elicited-8/VBD	amod||antibodies-10/NNS||neutralizing-9/VBG	dobj||elicited-8/VBD||antibodies-10/NNS	det||virus-14/NN||the-12/DT	amod||virus-14/NN||homologous-13/JJ	prep_against||antibodies-10/NNS||virus-14/NN	dep||virus-14/NN||a/vietnam/1203-16/NNP	punct||a/vietnam/1203-16/NNP||/-17/:	dep||a/vietnam/1203-16/NNP||2004-18/CD	appos||2004-18/CD||clade-20/NN	num||clade-20/NN||1-21/CD	amod||antibodies-27/NNS||cross-neutralizing-26/JJ	dobj||elicited-8/VBD||antibodies-27/NNS	conj_and||antibodies-10/NNS||antibodies-27/NNS	amod||h5n1-30/NNS||heterologous-29/JJ	prep_against||antibodies-27/NNS||h5n1-30/NNS	amod||h5n1-30/NNS||clade-31/JJ	num||strains-33/NNS||2-32/CD	dep||clade-31/JJ||strains-33/NNS	amod||/-37/NNP||a/indonesia/5-36/JJ	prep_including||h5n1-30/NNS||/-37/NNP	num||/-37/NNP||2005-38/CD	h5n1-30||antibodies-27||no_rel||upon rabbit immunization, both ha proteins elicited neutralizing antibodies against the homologous virus (a/vietnam/1203/2004, clade 1) as well as cross-neutralizing antibodies against heterologous h5n1 clade 2 strains, including a/indonesia/5/2005.
num||characteristics-4/NNS||six-1/CD	nn||characteristics-4/NNS||baseline-2/NN	nn||characteristics-4/NNS||participant-3/NN	nsubjpass||designated-6/VBN||characteristics-4/NNS	nsubj||participantsâ-60/VBZ||characteristics-4/NNS	auxpass||designated-6/VBN||were-5/VBD	root||ROOT-0/null||designated-6/VBN	amod||predictors-9/NNS||putative-8/JJ	prep_as||designated-6/VBN||predictors-9/NNS	nn||response-12/NN||treatment-11/NN	prep_of||predictors-9/NNS||response-12/NN	appos||response-12/NN||1-14/CD	dep||response-12/NN||gender-16/NN	appos||gender-16/NN||2-19/CD	dep||gender-16/NN||education-21/NN	dep||use-27/NN||3-24/LS	amod||use-27/NN||internet-26/VBN	appos||education-21/NN||use-27/NN	amod||sociodemographics-30/NNS||competence-28/JJ	dep||use-27/NN||sociodemographics-30/NNS	appos||sociodemographics-30/NNS||4-34/CD	amod||consumption-39/NN||mean-36/JJ	amod||consumption-39/NN||weekly-37/JJ	nn||consumption-39/NN||alcohol-38/NN	dep||sociodemographics-30/NNS||consumption-39/NN	appos||consumption-39/NN||5-42/CD	amod||help-46/NN||prior-44/JJ	amod||help-46/NN||professional-45/JJ	dep||consumption-39/NN||help-46/NN	nn||problems-49/NNS||alcohol-48/NN	prep_for||help-46/NN||problems-49/NNS	dep||problems-49/NNS||level-51/NN	prep_of||level-51/NN||problemdrinking-53/VBG	dep||participantsâ-60/VBZ||6-58/CD	conj_and||designated-6/VBN||participantsâ-60/VBZ	dep||expectancies-63/NNS||$-61/$	num||expectancies-63/NNS||-62/CD	dobj||participantsâ-60/VBZ||expectancies-63/NNS	amod||interventions-66/NNS||web-based-65/JJ	prep_of||expectancies-63/NNS||interventions-66/NNS	prep_for||interventions-66/NNS||problemdrinking-68/VBG	problemdrinking-68||alcohol-48||no||six baseline participant characteristics were designated as putative predictors of treatment response (1) gender, (2) education, (3) internet use competence (sociodemographics), (4) mean weekly alcohol consumption, (5) prior professional help for alcohol problems (level of problemdrinking), and (6) participantsâ expectancies of web-based interventions for problemdrinking.
aux||determine-2/VB||to-1/TO	advcl||analyzed-14/VBD||determine-2/VB	det||structure-5/NN||the-3/DT	nn||structure-5/NN||population-4/NN	dobj||determine-2/VB||structure-5/NN	det||agents-9/NNS||the-7/DT	amod||agents-9/NNS||cryptococcosis-8/JJ	prep_of||structure-5/NN||agents-9/NNS	prep_in||agents-9/NNS||china-11/NN	nsubj||analyzed-14/VBD||we-13/PRP	root||ROOT-0/null||analyzed-14/VBD	det||genotype-16/NN||the-15/DT	nsubj||isolated-25/VBD||genotype-16/NN	num||cryptococcusneoformans-19/NNS||120-18/CD	prep_of||genotype-16/NN||cryptococcusneoformans-19/NNS	num||strains-24/NNS||9-21/CD	amod||strains-24/NNS||cryptococcus-22/JJ	nn||strains-24/NNS||gattii-23/NN	prep_of||genotype-16/NN||strains-24/NNS	conj_and||cryptococcusneoformans-19/NNS||strains-24/NNS	ccomp||analyzed-14/VBD||isolated-25/VBD	prep_from||isolated-25/VBD||1980-27/CD	prep_through||isolated-25/VBD||2006-29/CD	amod||patients-32/NNS||cryptococcosis-31/JJ	prep_from||isolated-25/VBD||patients-32/NNS	vmod||patients-32/NNS||residing-33/VBG	num||provinces-36/NNS||16-35/CD	prep_in||residing-33/VBG||provinces-36/NNS	amod||china-39/NN||mainland-38/JJ	prep_of||provinces-36/NNS||china-39/NN	cryptococcosis-31||cryptococcus-22||no||to determine the population structure of the cryptococcosis agents in china, we analyzed the genotype of 120 cryptococcusneoformans and 9 cryptococcus gattii strains isolated from 1980 through 2006 from cryptococcosis patients residing in 16 provinces of mainland china.
nn||diagnoses-2/NNS||differential-1/NN	nsubj||include-3/VBP||diagnoses-2/NNS	ccomp||discolouration-40/VBP||include-3/VBP	amod||forms-5/NNS||hypocalcified-4/JJ	dobj||include-3/VBP||forms-5/NNS	amod||imperfecta-8/NN||amelogenesis-7/JJ	prep_of||forms-5/NNS||imperfecta-8/NN	amod||porphyria-12/NN||congenital-10/JJ	amod||porphyria-12/NN||erythropoietic-11/JJ	appos||imperfecta-8/NN||porphyria-12/NN	appos||porphyria-12/NN||conditions-14/NNS	amod||conditions-14/NNS||leading-15/VBG	amod||loss-19/NN||early-17/JJ	nn||loss-19/NN||tooth-18/NN	prep_to||conditions-14/NNS||loss-19/NN	poss||disease-23/NN||kostmann-21/NN	nsubj||histiocytosis-31/VBZ||disease-23/NN	amod||neutropenia-26/NN||cyclic-25/JJ	appos||disease-23/NN||neutropenia-26/NN	nn||syndrome-29/NN||chediak-hegashi-28/NN	appos||disease-23/NN||syndrome-29/NN	dep||conditions-14/NNS||histiocytosis-31/VBZ	dobj||histiocytosis-31/VBZ||x-32/SYM	amod||syndrome-35/NN||papillon-lefevre-34/JJ	appos||x-32/SYM||syndrome-35/NN	amod||teeth-39/NNS||permanent-38/JJ	nsubj||discolouration-40/VBP||teeth-39/NNS	root||ROOT-0/null||discolouration-40/VBP	acomp||discolouration-40/VBP||due-41/JJ	nn||rickets-48/NNS||tetracyclines-43/NNS	conj_and||tetracyclines-43/NNS||vitamind-dependent-45/NN	nn||rickets-48/NNS||vitamind-dependent-45/NN	conj_and||tetracyclines-43/NNS||vitamind-resistant-47/NN	nn||rickets-48/NNS||vitamind-resistant-47/NN	prep_to||due-41/JJ||rickets-48/NNS	rickets-48||vitamind--1||yes||differential diagnoses include hypocalcified forms of amelogenesis imperfecta, congenital erythropoietic porphyria, conditions leading to early tooth loss (kostmann's disease, cyclic neutropenia, chediak-hegashi syndrome, histiocytosis x, papillon-lefevre syndrome), permanent teeth discolouration due to tetracyclines, vitamind-dependent and vitamind-resistant rickets.
nsubj||placed-12/VBD||comparison-1/NN	num||genes-4/NNS||3691-3/CD	prep_of||comparison-1/NN||genes-4/NNS	vmod||genes-4/NNS||shared-5/VBN	det||strains-11/NNS||all-7/DT	num||strains-11/NNS||six-8/CD	amod||strains-11/NNS||sequenced-9/JJ	nn||strains-11/NNS||salmonella-10/NN	agent||shared-5/VBN||strains-11/NNS	root||ROOT-0/null||placed-12/VBD	nn||c-15/NN||s.-13/NN	nn||c-15/NN||paratyphi-14/NN	dobj||placed-12/VBD||c-15/NN	nn||choleraesuis-18/NNS||s.-17/NN	dobj||placed-12/VBD||choleraesuis-18/NNS	conj_and||c-15/NN||choleraesuis-18/NNS	advmod||placed-12/VBD||together-19/RB	num||end-22/NN||one-21/CD	prep_at||placed-12/VBD||end-22/NN	prep_at||placed-12/VBD||s.typhi-25/NNS	conj_and||end-22/NN||s.typhi-25/NNS	det||end-29/NN||the-27/DT	amod||end-29/NN||opposite-28/JJ	prep_at||s.typhi-25/NNS||end-29/NN	det||tree-34/NN||the-32/DT	amod||tree-34/NN||phylogenetic-33/JJ	prep_of||end-22/NN||tree-34/NN	vmod||placed-12/VBD||demonstrating-36/VBG	amod||ancestries-38/NNS||separate-37/JJ	dobj||demonstrating-36/VBG||ancestries-38/NNS	det||agents-43/NNS||the-40/DT	amod||agents-43/NNS||human-adapted-41/JJ	amod||agents-43/NNS||typhoid-42/JJ	prep_of||ancestries-38/NNS||agents-43/NNS	typhoid-42||s.typhi-25||no||comparison of 3691 genes shared by all six sequenced salmonella strains placed s. paratyphi c and s. choleraesuis together at one end , and s.typhi at the opposite end , of the phylogenetic tree , demonstrating separate ancestries of the human-adapted typhoid agents .
nsubj||disease-5/NN||lymeborreliosis-1/NNS	cop||disease-5/NN||is-2/VBZ	det||disease-5/NN||a-3/DT	amod||disease-5/NN||zoonotic-4/JJ	root||ROOT-0/null||disease-5/NN	vmod||disease-5/NN||caused-6/VBN	amod||bacteria-11/NNS||borreliaburgdorferi-8/JJ	amod||bacteria-11/NNS||sensu-9/JJ	nn||bacteria-11/NNS||lato-10/NN	agent||caused-6/VBN||bacteria-11/NNS	vmod||bacteria-11/NNS||transmitted-12/VBN	prep_to||transmitted-12/VBN||humans-14/NNS	amod||animals-17/NNS||domestic-16/JJ	prep_to||transmitted-12/VBN||animals-17/NNS	conj_and||humans-14/NNS||animals-17/NNS	det||bite-20/NN||the-19/DT	agent||transmitted-12/VBN||bite-20/NN	det||spp-24/NN||an-22/DT	amod||spp-24/NN||ixodes-23/JJ	prep_of||bite-20/NN||spp-24/NN	lymeborreliosis-1||borreliaburgdorferi-8||no||lymeborreliosis is a zoonotic disease caused by borreliaburgdorferi sensu lato bacteria transmitted to humans and domestic animals by the bite of an ixodes spp.
mark||suggested-6/VBN||although-1/IN	det||studies-4/NNS||some-2/DT	amod||studies-4/NNS||previous-3/JJ	nsubj||suggested-6/VBN||studies-4/NNS	aux||suggested-6/VBN||have-5/VBP	advcl||examined-24/VBN||suggested-6/VBN	mark||comprised-14/VBN||that-7/IN	amod||growth-9/NN||posttraumatic-8/JJ	nsubjpass||comprised-14/VBN||growth-9/NN	appos||growth-9/NN||ptg-11/NN	auxpass||comprised-14/VBN||is-13/VBZ	ccomp||suggested-6/VBN||comprised-14/VBN	amod||factors-17/NNS||several-16/JJ	prep_of||comprised-14/VBN||factors-17/NNS	amod||properties-20/NNS||different-19/JJ	prep_with||comprised-14/VBN||properties-20/NNS	nsubj||examined-24/VBN||few-22/JJ	aux||examined-24/VBN||have-23/VBP	root||ROOT-0/null||examined-24/VBN	predet||association-27/NN||both-25/PDT	det||association-27/NN||the-26/DT	dobj||examined-24/VBN||association-27/NN	prep_between||examined-24/VBN||ptg-29/NN	prep_between||examined-24/VBN||posttraumaticstressdisorder-31/NN	conj_and||ptg-29/NN||posttraumaticstressdisorder-31/NN	dep||examined-24/VBN||ptsd-33/VBN	prep_between||examined-24/VBN||ptg-37/NN	conj_and||ptg-29/NN||ptg-37/NN	conj_and||ptg-29/NN||resilience-39/NN	conj_and||ptg-37/NN||resilience-39/NN	vmod||ptg-37/NN||focusing-41/VBG	prep_on||focusing-41/VBG||each-43/DT	det||factors-46/NNS||the-45/DT	prep_of||each-43/DT||factors-46/NNS	prep_of||factors-46/NNS||ptg-48/NN	ptg-48||posttraumaticstressdisorder-31||no_rel||although some previous studies have suggested that posttraumatic growth (ptg) is comprised of several factors with different properties, few have examined both the association between ptg and posttraumaticstressdisorder (ptsd) and between ptg and resilience, focusing on each of the factors of ptg.
amod||events-2/NNS||hypoglycemic-1/JJ	nsubj||occurred-3/VBD||events-2/NNS	root||ROOT-0/null||occurred-3/VBD	num||%-6/NN||8.5-5/CD	prep_during||occurred-3/VBD||%-6/NN	prep_of||%-6/NN||nights-8/NNS	det||percentage-13/NN||the-11/DT	amod||percentage-13/NN||median-12/JJ	nsubj||%-22/NN||percentage-13/NN	prep_of||percentage-13/NN||nights-15/NNS	prep_with||nights-15/NNS||hypoglycemia-17/NN	prep_per||hypoglycemia-17/NN||subject-19/NN	cop||%-22/NN||being-20/VBG	num||%-22/NN||7.4-21/CD	prepc_with||occurred-3/VBD||%-22/NN	dep||range-25/VB||interquartile-24/NN	dep||%-22/NN||range-25/VB	num||â-27/NN||3.7-26/CD	dobj||range-25/VB||â-27/NN	dep||%-31/NN||$-28/$	num||$-28/$||12.1-30/CD	amod||â-27/NN||%-31/NN	hypoglycemia-17||hypoglycemic-1||no_rel||hypoglycemic events occurred during 8.5% of nights, with the median percentage of nights with hypoglycemia per subject being 7.4% (interquartile range 3.7â12.1%).
nsubjpass||complicated-14/VBN||treatment-1/NN	nn||patients-4/NNS||cancer-3/NN	prep_of||treatment-1/NN||patients-4/NNS	amod||doxorubicin-8/NN||anthracycline-6/JJ	amod||doxorubicin-8/NN||antibiotic-7/JJ	prep_with||patients-4/NNS||doxorubicin-8/NN	appos||treatment-1/NN||dox-10/NN	aux||complicated-14/VBN||may-12/MD	auxpass||complicated-14/VBN||be-13/VB	root||ROOT-0/null||complicated-14/VBN	agent||complicated-14/VBN||development-16/NN	amod||congestiveheartfailure-21/NN||acute-18/JJ	conj_and||acute-18/JJ||chronic-20/JJ	amod||congestiveheartfailure-21/NN||chronic-20/JJ	prep_of||development-16/NN||congestiveheartfailure-21/NN	appos||congestiveheartfailure-21/NN||chf-23/NN	amod||arrhythmias-27/NNS||malignant-26/JJ	prep_of||development-16/NN||arrhythmias-27/NNS	conj_and||congestiveheartfailure-21/NN||arrhythmias-27/NNS	prep_of||development-16/NN||death-29/NN	conj_and||congestiveheartfailure-21/NN||death-29/NN	congestiveheartfailure-21||doxorubicin-8||no||treatment of cancer patients with anthracycline antibiotic doxorubicin (dox) may be complicated by development of acute and chronic congestiveheartfailure (chf), malignant arrhythmias and death.
prep_in||involved-16/VBN||addition-2/NN	nsubjpass||involved-16/VBN||transport-4/NN	conj_and||transport-4/NN||diffusion-6/NN	nsubjpass||involved-16/VBN||diffusion-6/NN	prep_of||transport-4/NN||ions-8/NNS	det||epithelium-14/NN||the-10/DT	nn||epithelium-14/NN||bbb-11/NN	conj_and||bbb-11/NN||cp-13/NN	nn||epithelium-14/NN||cp-13/NN	prep_by||ions-8/NNS||epithelium-14/NN	auxpass||involved-16/VBN||are-15/VBP	root||ROOT-0/null||involved-16/VBN	det||formation-19/NN||the-18/DT	prep_in||involved-16/VBN||formation-19/NN	prep_of||formation-19/NN||fluid-21/NN	det||isf-24/NN||the-23/DT	prep_of||formation-19/NN||isf-24/NN	conj_and||fluid-21/NN||isf-24/NN	prep_of||formation-19/NN||csf-26/NN	conj_and||fluid-21/NN||csf-26/NN	advmod||involved-16/VBN||respectively-28/RB	dep||involved-16/VBN||so-30/IN	det||part-33/NN||the-31/DT	amod||part-33/NN||last-32/JJ	nsubj||discusses-37/VBZ||part-33/NN	nsubj||cp-51/VBP||part-33/NN	det||review-36/NN||this-35/DT	prep_of||part-33/NN||review-36/NN	parataxis||involved-16/VBN||discusses-37/VBZ	amod||biology-39/NN||molecular-38/JJ	dobj||discusses-37/VBZ||biology-39/NN	nn||transporters/exchangers-42/NNS||ion-41/NN	prep_of||biology-39/NN||transporters/exchangers-42/NNS	nn||channels-45/NNS||ion-44/NN	prep_of||biology-39/NN||channels-45/NNS	conj_and||transporters/exchangers-42/NNS||channels-45/NNS	det||endothelial-49/NN||the-47/DT	nn||endothelial-49/NN||brain-48/NN	prep_in||discusses-37/VBZ||endothelial-49/NN	parataxis||involved-16/VBN||cp-51/VBP	conj_and||discusses-37/VBZ||cp-51/VBP	amod||cells-53/NNS||epithelial-52/JJ	dobj||cp-51/VBP||cells-53/NNS	ion-44||cp-51||no_rel||in addition, transport and diffusion of ions by the bbb and cp epithelium are involved in the formation of fluid, the isf and csf, respectively, so the last part of this review discusses molecular biology of ion transporters/exchangers and ion channels in the brain endothelial and cp epithelial cells.
det||test-4/NN||the-1/DT	amod||test-4/NN||tuberculin-2/JJ	nn||test-4/NN||skin-3/NN	nsubjpass||used-10/VBN||test-4/NN	nsubj||aid-15/VB||test-4/NN	appos||test-4/NN||tst-6/NN	auxpass||used-10/VBN||is-8/VBZ	advmod||used-10/VBN||widely-9/RB	root||ROOT-0/null||used-10/VBN	nn||clinics-13/NNS||tb-12/NN	prep_in||used-10/VBN||clinics-13/NNS	aux||aid-15/VB||to-14/TO	xcomp||used-10/VBN||aid-15/VB	amod||diagnosis-20/NN||mycobacteriumtuberculosis-16/JJ	dep||mycobacteriumtuberculosis-16/JJ||m.tb-18/JJ	dobj||aid-15/VB||diagnosis-20/NN	det||definition-24/NN||the-23/DT	nsubj||unclear-38/JJ||definition-24/NN	det||significance-27/NN||the-26/DT	conj_and||definition-24/NN||significance-27/NN	nsubj||unclear-38/JJ||significance-27/NN	det||test-31/NN||a-29/DT	amod||test-31/NN||positive-30/JJ	prep_of||significance-27/NN||test-31/NN	advmod||young-34/JJ||very-33/RB	amod||children-35/NNS||young-34/JJ	prep_in||test-31/NN||children-35/NNS	cop||unclear-38/JJ||is-36/VBZ	advmod||unclear-38/JJ||still-37/RB	conj_but||used-10/VBN||unclear-38/JJ	tb-12||mycobacteriumtuberculosis-16||no||the tuberculin skin test (tst) is widely used in tb clinics to aid mycobacteriumtuberculosis ( m.tb ) diagnosis, but the definition and the significance of a positive test in very young children is still unclear.
det||rgcs-2/NNS||the-1/DT	nsubj||exposed-3/VBD||rgcs-2/NNS	ccomp||revealed-21/VBD||exposed-3/VBD	prep_to||exposed-3/VBD||hypoxia-5/NN	dep||exposed-3/VBD||either-6/CC	number||%-9/NN||1-8/CD	amod||oxygen-10/NN||%-9/NN	prep_with||exposed-3/VBD||oxygen-10/NN	amod||chloride-13/NN||cobalt-12/JJ	prep_with||exposed-3/VBD||chloride-13/NN	conj_or||oxygen-10/NN||chloride-13/NN	num||î-16/NN||0-400-15/CD	dep||chloride-13/NN||î-16/NN	num||m-18/NN||1/4-17/CD	dep||î-16/NN||m-18/NN	root||ROOT-0/null||revealed-21/VBD	number||30-23/CD||~-22/CD	num||%-24/NN||30-23/CD	dobj||revealed-21/VBD||%-24/NN	num||%-26/NN||-70-25/CD	npadvmod||apoptotic-27/JJ||%-26/NN	amod||%-24/NN||apoptotic-27/JJ	nn||death-29/NN||cell-28/NN	nsubj||revealed-21/VBD||death-29/NN	prep_after||death-29/NN||48-31/CD	num||h-34/NN||72-33/CD	nsubj||revealed-21/VBD||h-34/NN	conj_and||death-29/NN||h-34/NN	prep_of||h-34/NN||exposure-36/NN	cobalt-12||hypoxia-5||no_rel||the rgcs exposed to hypoxia either with 1% oxygen or cobalt chloride (0-400 î¼m), revealed ~30%-70% apoptotic cell death after 48 and 72 h of exposure.
det||findings-3/NNS||the-1/DT	nn||findings-3/NNS||interview-2/NN	nsubj||pointed-4/VBD||findings-3/NNS	root||ROOT-0/null||pointed-4/VBD	prep_to||pointed-4/VBD||obstacles-6/NNS	amod||linkages-9/NNS||strengthening-8/JJ	prep_to||pointed-4/VBD||linkages-9/NNS	nn||planning-12/NN||family-11/NN	prep_between||linkages-9/NNS||planning-12/NN	prep_between||linkages-9/NNS||hiv/aids-14/NNS	conj_and||planning-12/NN||hiv/aids-14/NNS	det||need-18/NN||the-17/DT	prep_including||pointed-4/VBD||need-18/NN	prep_for||need-18/NN||resources-20/NNS	aux||integrate-22/VB||to-21/TO	vmod||resources-20/NNS||integrate-22/VB	nn||planning-24/NN||family-23/NN	dobj||integrate-22/VB||planning-24/NN	vmod||resources-20/NNS||hiv-26/VB	conj_and||integrate-22/VB||hiv-26/VB	dobj||hiv-26/VB||services-27/NNS	dobj||hiv-26/VB||infrastructure-29/NN	conj_or||services-27/NNS||infrastructure-29/NN	dobj||hiv-26/VB||capacity-31/NN	conj_or||services-27/NNS||capacity-31/NN	aux||provide-33/VB||to-32/TO	vmod||hiv-26/VB||provide-33/VB	amod||services-35/NNS||integrated-34/VBN	dobj||provide-33/VB||services-35/NNS	det||level-39/NN||the-37/DT	nn||level-39/NN||facility-38/NN	prep_at||services-35/NNS||level-39/NN	amod||leadership-42/NN||national-41/JJ	dobj||provide-33/VB||leadership-42/NN	conj_and||services-35/NNS||leadership-42/NN	conj_and||services-35/NNS||coordination-44/NN	conj_and||leadership-42/NN||coordination-44/NN	amod||advocacy-48/NN||targeted-47/JJ	dobj||provide-33/VB||advocacy-48/NN	conj_and||services-35/NNS||advocacy-48/NN	amod||decision-makers-51/NNS||key-50/JJ	prep_to||advocacy-48/NN||decision-makers-51/NNS	aids--1||hiv-26||no||the interview findings pointed to obstacles to strengthening linkages between family planning and hiv/aids, including the need for resources to integrate family planning and hiv services, infrastructure or capacity to provide integrated services at the facility level, national leadership and coordination, and targeted advocacy to key decision-makers.
det||contrary-3/NN||the-2/DT	prep_on||tgf-î-40/VBZ||contrary-3/NN	amod||injections-7/NNS||triple-5/JJ	nn||injections-7/NNS||i.p.-6/NN	nsubj||tgf-î-40/VBZ||injections-7/NNS	num||hours-10/NNS||24-9/CD	npadvmod||apart-11/RB||hours-10/NNS	advmod||injections-7/NNS||apart-11/RB	num||î-15/NN||10-14/CD	prep_of||injections-7/NNS||î-15/NN	num||ejhe-18/NN||1/4-16/CD	nn||ejhe-18/NN||g-17/NN	nsubj||increased-19/VBD||ejhe-18/NN	rcmod||î-15/NN||increased-19/VBD	advmod||ifn-î-21/JJ||significantly-20/RB	amod||production-23/NN||ifn-î-21/JJ	amod||production-23/NN||³-22/JJ	dobj||increased-19/VBD||production-23/NN	det||p-28/NN||the-25/DT	amod||p-28/NN||spleen-26/JJ	amod||p-28/NN||-lrb--27/JJ	prep_in||increased-19/VBD||p-28/NN	vmod||p-28/NN||<-29/VBG	num||-rrb--31/NNS||0.02-30/CD	dobj||<-29/VBG||-rrb--31/NNS	mark||increased-35/VBD||while-32/IN	advmod||ejhe-wr-34/NN||only-33/RB	nsubj||increased-35/VBD||ejhe-wr-34/NN	advcl||<-29/VBG||increased-35/VBD	advmod||ifn-î-37/JJ||significantly-36/RB	amod||³-38/NNS||ifn-î-37/JJ	dobj||increased-35/VBD||³-38/NNS	root||ROOT-0/null||tgf-î-40/VBZ	number||1-42/CD||²-41/CD	dobj||tgf-î-40/VBZ||1-42/CD	amod||<-47/NNS||il-17-44/JJ	amod||<-47/NNS||-lrb--45/JJ	nn||<-47/NNS||p-46/NN	dobj||tgf-î-40/VBZ||<-47/NNS	conj_and||1-42/CD||<-47/NNS	dep||<-47/NNS||0.03-48/CD	num||production-52/NN||0.005-50/CD	amod||production-52/NN||-rrb--51/JJ	dep||<-47/NNS||production-52/NN	det||microenvironment-56/NN||the-54/DT	nn||microenvironment-56/NN||tumor-55/NN	prep_within||production-52/NN||microenvironment-56/NN	amod||fibrosarcoma-59/NN||meth-a-58/JJ	prep_of||microenvironment-56/NN||fibrosarcoma-59/NN	ifn--1||tumor-55||no_rel||on the contrary , triple i.p. injections , 24 hours apart ; of 10 î 1/4 g ejhe increased significantly ifn-î ³ production in the spleen -lrb- p < 0.02 -rrb- while only ejhe-wr increased significantly ifn-î ³ , tgf-î ² 1 and il-17 -lrb- p < 0.03 - 0.005 -rrb- production within the tumor microenvironment of meth-a fibrosarcoma .
det||reorientation-3/NN||the-1/DT	amod||reorientation-3/NN||tcr-dependent-2/JJ	nsubj||explain-16/VB||reorientation-3/NN	det||sugar-6/NN||the-5/DT	prep_of||reorientation-3/NN||sugar-6/NN	advmod||with-9/IN||together-8/RB	rcmod||reorientation-3/NN||with-9/IN	det||fit-13/NN||the-10/DT	amod||fit-13/NN||induced-11/JJ	amod||fit-13/NN||cd1d-12/JJ	pobj||with-9/IN||fit-13/NN	aux||explain-16/VB||may-15/MD	root||ROOT-0/null||explain-16/VB	det||potency-19/NN||the-17/DT	amod||potency-19/NN||weaker-18/JJR	dobj||explain-16/VB||potency-19/NN	det||antigens-23/NNS||the-21/DT	amod||antigens-23/NNS||microbial-22/JJ	prep_of||potency-19/NN||antigens-23/NNS	prepc_compared_with||explain-16/VB||with-25/IN	nn||±-27/NNS||î-26/NN	pobj||explain-16/VB||±-27/NNS	dep||±-27/NNS||galcer-29/NN	sugar-6||fit-13||no_rel||the tcr-dependent reorientation of the sugar, together with the induced cd1d fit, may explain the weaker potency of the microbial antigens compared with î±-galcer.
nsubj||report-5/NN||this-1/DT	cop||report-5/NN||is-2/VBZ	det||report-5/NN||the-3/DT	amod||report-5/NN||first-4/JJ	root||ROOT-0/null||report-5/NN	amod||antibodies-9/NNS||autoreactive-7/JJ	amod||antibodies-9/NNS||anti-actin-8/JJ	prep_of||report-5/NN||antibodies-9/NNS	vmod||antibodies-9/NNS||involved-10/VBN	det||pathogenesis-13/NNS||the-12/DT	prep_in||involved-10/VBN||pathogenesis-13/NNS	prep_of||pathogenesis-13/NNS||autoimmunehaemolyticanaemia-15/NN	autoimmunehaemolyticanaemia-15||antibodies-9||no||this is the first report of autoreactive anti-actin antibodies involved in the pathogenesis of autoimmunehaemolyticanaemia.
nsubj||cause-7/VB||stress-1/NN	conj_and||stress-1/NN||anxiety-3/NN	nsubj||cause-7/VB||anxiety-3/NN	conj_and||stress-1/NN||depression-5/NN	nsubj||cause-7/VB||depression-5/NN	aux||cause-7/VB||can-6/MD	root||ROOT-0/null||cause-7/VB	amod||changes-12/NNS||complex-8/JJ	amod||changes-12/NNS||physiological-9/JJ	conj_and||physiological-9/JJ||neuroendocrine-11/JJ	amod||changes-12/NNS||neuroendocrine-11/JJ	dobj||cause-7/VB||changes-12/NNS	vmod||changes-12/NNS||resulting-14/VBG	amod||level-17/NN||increased-16/VBN	prep_in||resulting-14/VBG||level-17/NN	prep_of||level-17/NN||stress-19/NN	vmod||stress-19/NN||related-20/VBN	nn||catecholamine-22/NN||hormone-21/NN	dobj||related-20/VBN||catecholamine-22/NN	nsubj||constitute-26/VB||catecholamine-22/NN	aux||constitute-26/VB||may-25/MD	rcmod||catecholamine-22/NN||constitute-26/VB	det||mechanism-29/NN||a-27/DT	amod||mechanism-29/NN||primary-28/JJ	dobj||constitute-26/VB||mechanism-29/NN	dobj||impact-34/VB||which-31/WDT	amod||factors-33/NNS||physiological-32/JJ	nsubj||impact-34/VB||factors-33/NNS	prepc_by||constitute-26/VB||impact-34/VB	nn||expression-36/NN||gene-35/NN	dobj||impact-34/VB||expression-36/NN	prep_in||impact-34/VB||tumors-38/NNS	tumors-38||hormone-21||no_rel||stress, anxiety and depression can cause complex physiological and neuroendocrine changes, resulting in increased level of stress related hormone catecholamine, which may constitute a primary mechanism by which physiological factors impact gene expression in tumors.
aux||evaluate-2/VB||to-1/TO	root||ROOT-0/null||evaluate-2/VB	amod||levels-5/NNS||serum-3/JJ	amod||levels-5/NNS||il-33-4/JJ	dobj||evaluate-2/VB||levels-5/NNS	det||group-8/NN||a-7/DT	prep_in||evaluate-2/VB||group-8/NN	prep_of||group-8/NN||patients-10/NNS	amod||1b-17/NN||chronichepatitisc-12/JJ	nn||1b-17/NN||chc-14/NN	amod||1b-17/NN||genotype-16/JJ	prep_with||patients-10/NNS||1b-17/NN	prep_at||1b-17/NN||enrolment-19/NN	cc||evaluate-2/VB||and-20/CC	dep||evaluate-2/VB||after-21/IN	det||course-23/NN||a-22/DT	pobj||after-21/IN||course-23/NN	prep_of||course-23/NN||pegylated-25/NN	appos||pegylated-25/NN||peg-27/NNP	dep||pegylated-25/NN||ifn-30/NNP	dep||pegylated-25/NN||ribavirin-32/NNP	conj_plus||ifn-30/NNP||ribavirin-32/NNP	chronichepatitisc-12||ribavirin-32||yes||to evaluate serum il-33 levels in a group of patients with chronichepatitisc (chc) genotype 1b at enrolment and after a course of pegylated (peg)-ifn plus ribavirin.
poss||role-5/NN||its-3/PRP$	amod||role-5/NN||principal-4/JJ	prep_apart_from||attributed-16/VBN||role-5/NN	nn||metabolism-8/NN||bone-7/NN	prep_in||role-5/NN||metabolism-8/NN	nn||homeostasis-11/NNS||calcium-10/NN	prep_in||role-5/NN||homeostasis-11/NNS	conj_and||metabolism-8/NN||homeostasis-11/NNS	nsubjpass||attributed-16/VBN||vitamind-13/NN	aux||attributed-16/VBN||has-14/VBZ	auxpass||attributed-16/VBN||been-15/VBN	root||ROOT-0/null||attributed-16/VBN	amod||effects-18/NNS||additional-17/JJ	dobj||attributed-16/VBN||effects-18/NNS	det||capacity-29/NN||an-20/DT	amod||capacity-29/NN||immunomodulatory-21/JJ	amod||capacity-29/NN||anti-inflammatory-23/JJ	advmod||neuroprotective-28/JJ||possibly-26/RB	advmod||neuroprotective-28/JJ||even-27/RB	conj_and||anti-inflammatory-23/JJ||neuroprotective-28/JJ	amod||capacity-29/NN||neuroprotective-28/JJ	prep_including||effects-18/NNS||capacity-29/NN	nsubj||implicates-31/VBZ||which-30/WDT	ccomp||capacity-29/NN||implicates-31/VBZ	det||role-34/NN||a-32/DT	amod||role-34/NN||possible-33/JJ	dobj||implicates-31/VBZ||role-34/NN	prep_of||role-34/NN||vitamind-36/NN	prep_in||implicates-31/VBZ||autoimmunediseases-38/NNS	prep_like||autoimmunediseases-38/NNS||multiplesclerosis-40/NNS	appos||multiplesclerosis-40/NNS||ms-42/NN	calcium-10||multiplesclerosis-40||no_rel||apart from its principal role in bone metabolism and calcium homeostasis, vitamind has been attributed additional effects including an immunomodulatory, anti-inflammatory, and possibly even neuroprotective capacity which implicates a possible role of vitamind in autoimmunediseases like multiplesclerosis (ms).
nn||rates-2/NNS||success-1/NN	nsubj||%-9/NN||rates-2/NNS	prep_for||rates-2/NNS||daptomycin-4/NN	prep_versus||daptomycin-4/NN||vancomycin/gentamicin-6/NN	cop||%-9/NN||were-7/VBD	num||%-9/NN||45-8/CD	root||ROOT-0/null||%-9/NN	num||%-12/NN||27-11/CD	prep_versus||%-9/NN||%-12/NN	amod||bacteraemia-15/NN||complicated-14/JJ	prep_in||%-12/NN||bacteraemia-15/NN	num||%-18/NN||60-17/CD	prep_versus||%-9/NN||%-18/NN	conj_and||%-12/NN||%-18/NN	num||%-21/NN||45-20/CD	prep_versus||%-18/NN||%-21/NN	amod||bacteraemia-24/NN||uncomplicated-23/JJ	prep_in||%-21/NN||bacteraemia-24/NN	num||%-27/NN||50-26/CD	prep_versus||%-9/NN||%-27/NN	conj_and||%-12/NN||%-27/NN	num||%-30/NN||50-29/CD	prep_versus||%-27/NN||%-30/NN	amod||endocarditis-34/NNS||right-sided-32/JJ	nn||endocarditis-34/NNS||mrsa-33/NN	prep_in||%-30/NN||endocarditis-34/NNS	vancomycin--1||bacteraemia-24||no_rel||success rates for daptomycin versus vancomycin/gentamicin were 45% versus 27% in complicated bacteraemia, 60% versus 45% in uncomplicated bacteraemia and 50% versus 50% in right-sided mrsa endocarditis.
nsubj||fluoroquinolone-6/NN||levofloxacin-1/NN	cop||fluoroquinolone-6/NN||is-2/VBZ	det||fluoroquinolone-6/NN||a-3/DT	advmod||used-5/VBN||widely-4/RB	amod||fluoroquinolone-6/NN||used-5/VBN	root||ROOT-0/null||fluoroquinolone-6/NN	vmod||fluoroquinolone-6/NN||approved-7/VBN	det||treatment-10/NN||the-9/DT	prep_for||approved-7/VBN||treatment-10/NN	amod||pyelonephritis-16/NNS||complicated-12/JJ	amod||pyelonephritis-16/NNS||urinarytractinfections-13/JJ	conj_and||urinarytractinfections-13/JJ||acute-15/JJ	amod||pyelonephritis-16/NNS||acute-15/JJ	prep_of||treatment-10/NN||pyelonephritis-16/NNS	urinarytractinfections-13||levofloxacin-1||yes||levofloxacin is a widely used fluoroquinolone approved for the treatment of complicated urinarytractinfections and acute pyelonephritis.
amod||countries-4/NNS||sub-saharan-2/JJ	nn||countries-4/NNS||african-3/NN	prep_in||prevented-23/VBN||countries-4/NNS	amod||rates-8/NNS||high-6/JJ	nn||rates-8/NNS||prevalence-7/NN	prep_with||countries-4/NNS||rates-8/NNS	amod||hiv/aids-11/NNS||pediatric-10/JJ	nsubjpass||prevented-23/VBN||hiv/aids-11/NNS	vmod||hiv/aids-11/NNS||acquired-12/VBN	amod||transmission-15/NN||mother-to-child-14/JJ	prep_through||acquired-12/VBN||transmission-15/NN	appos||hiv/aids-11/NNS||mtct-17/NN	aux||prevented-23/VBN||can-19/MD	advmod||prevented-23/VBN||in-20/IN	advmod||in-20/IN||largely-21/RB	auxpass||prevented-23/VBN||be-22/VB	root||ROOT-0/null||prevented-23/VBN	agent||prevented-23/VBN||using-25/VBG	amod||interventions-28/NNS||well-established-26/JJ	amod||interventions-28/NNS||biomedical-27/JJ	dobj||using-25/VBG||interventions-28/NNS	aids--1||hiv--1||no||in sub-saharan african countries with high prevalence rates, pediatric hiv/aids acquired through mother-to-child transmission (mtct) can in largely be prevented by using well-established biomedical interventions.
expl||were-2/VBD||there-1/EX	root||ROOT-0/null||were-2/VBD	amod||cases-4/NNS||295-3/JJ	nsubj||were-2/VBD||cases-4/NNS	prep_of||diagnosed-31/VBN||cases-4/NNS	prep_of||cases-4/NNS||ibd-6/NN	dep||cases-4/NNS||uc-8/VBN	dep||240-10/CD||=-9/SYM	ccomp||uc-8/VBN||240-10/CD	ccomp||uc-8/VBN||cd-12/VB	dep||55-14/CD||=-13/SYM	ccomp||cd-12/VB||55-14/CD	nsubjpass||diagnosed-31/VBN||34-19/CD	dep||34-19/CD||uc-21/VBN	dep||30-23/CD||=-22/SYM	ccomp||uc-21/VBN||30-23/CD	ccomp||uc-21/VBN||cd-25/VB	dep||4-27/CD||=-26/SYM	ccomp||cd-25/VB||4-27/CD	auxpass||diagnosed-31/VBN||were-29/VBD	advmod||diagnosed-31/VBN||newly-30/RB	rcmod||cases-4/NNS||diagnosed-31/VBN	det||year-35/NN||the-33/DT	nn||year-35/NN||study-34/NN	prep_during||diagnosed-31/VBN||year-35/NN	uc-21||cd-25||no_rel||there were 295 cases of ibd (uc = 240, cd = 55), of which 34 (uc = 30, cd = 4) were newly diagnosed during the study year.
nn||rates-2/NNS||conversion-1/NN	nsubj||differ-14/VB||rates-2/NNS	amod||microscopy-6/NN||standard-4/JJ	nn||microscopy-6/NN||smear-5/NN	prep_of||rates-2/NNS||microscopy-6/NN	amod||microscopy-9/NN||fluorescence-8/JJ	prep_of||rates-2/NNS||microscopy-9/NN	conj_and||microscopy-6/NN||microscopy-9/NN	prep_of||rates-2/NNS||culture-11/NN	conj_and||microscopy-6/NN||culture-11/NN	aux||differ-14/VB||did-12/VBD	neg||differ-14/VB||not-13/RB	root||ROOT-0/null||differ-14/VB	amod||patients-21/NNS||hivpositive-16/JJ	conj_and||hivpositive-16/JJ||hiv-18/JJ	amod||patients-21/NNS||hiv-18/JJ	amod||patients-21/NNS||negative-19/JJ	nn||patients-21/NNS||pulmonarytuberculosis-20/NN	prep_between||differ-14/VB||patients-21/NNS	hivpositive-16||hiv-18||no||conversion rates of standard smear microscopy, fluorescence microscopy and culture did not differ between hivpositive and hiv negative pulmonarytuberculosis patients.
aux||assess-2/VB||to-1/TO	root||ROOT-0/null||assess-2/VB	nn||users-4/NNS||drug-3/NN	poss||knowledge-6/NN||users-4/NNS	dobj||assess-2/VB||knowledge-6/NN	prep_of||knowledge-6/NN||hiv/aids-8/NNS	det||association-12/NN||the-10/DT	amod||association-12/NN||possible-11/JJ	dobj||assess-2/VB||association-12/NN	conj_and||knowledge-6/NN||association-12/NN	nn||testing-17/NN||knowledge-14/NN	conj_and||knowledge-14/NN||hiv-16/NN	nn||testing-17/NN||hiv-16/NN	prep_between||association-12/NN||testing-17/NN	aids--1||hiv-16||no||to assess drug users' knowledge of hiv/aids and the possible association between knowledge and hiv testing.
det||ulcer-2/NN||the-1/DT	nsubj||improved-3/VBD||ulcer-2/NN	root||ROOT-0/null||improved-3/VBD	advmod||slightly-5/RB||only-4/RB	dobj||improved-3/VBD||slightly-5/RB	num||months-8/NNS||2-7/CD	prep_after||improved-3/VBD||months-8/NNS	amod||ointment-12/NN||povidone-iodine-10/JJ	nn||ointment-12/NN||sugar-11/NN	prep_with||improved-3/VBD||ointment-12/NN	amod||nausea-16/NN||severe-15/JJ	prep_because_of||ointment-12/NN||nausea-16/NN	prep_because_of||ointment-12/NN||anorexia-18/NN	conj_and||nausea-16/NN||anorexia-18/NN	anorexia-18||povidone-iodine-10||no_rel||the ulcer improved only slightly after 2 months with povidone-iodine sugar ointment because of severe nausea and anorexia.
advmod||report-4/VBP||here-1/RB	nsubj||report-4/VBP||we-3/PRP	root||ROOT-0/null||report-4/VBP	det||case-6/NN||a-5/DT	dobj||report-4/VBP||case-6/NN	prep_of||case-6/NN||5-8/CD	nn||â-11/NN||fu-10/NN	dep||case-6/NN||â-11/NN	dep||â-11/NN||$-12/$	advmod||encephalopathy-15/JJ||induced-14/RB	amod||manifesting-17/NNS||encephalopathy-15/JJ	npadvmod||as-18/RB||manifesting-17/NNS	dep||seizures-19/CD||as-18/RB	num||$-12/$||seizures-19/CD	dobj||report-4/VBP||delirium-21/NN	conj_and||case-6/NN||delirium-21/NN	det||era-25/NN||an-24/DT	prep_in||delirium-21/NN||era-25/NN	amod||chemotherapy-28/NN||oxaliplatin-containing-27/JJ	prep_of||era-25/NN||chemotherapy-28/NN	seizures-19||fu-10||no_rel||here, we report a case of 5- fu âinduced encephalopathy, manifesting as seizures and delirium, in an era of oxaliplatin-containing chemotherapy.
det||china-2/NN||each-1/DT	nsubj||cares-3/VBZ||china-2/NN	root||ROOT-0/null||cares-3/VBZ	nsubjpass||required-6/VBN||site-4/NN	nsubj||carry-8/VB||site-4/NN	auxpass||required-6/VBN||was-5/VBD	ccomp||cares-3/VBZ||required-6/VBN	aux||carry-8/VB||to-7/TO	xcomp||required-6/VBN||carry-8/VB	prt||carry-8/VB||out-9/RP	dobj||carry-8/VB||surveillance-10/NN	dobj||carry-8/VB||surveys-12/NNS	conj_and||surveillance-10/NN||surveys-12/NNS	aux||understand-14/VB||to-13/TO	vmod||carry-8/VB||understand-14/VB	det||epidemic-18/NN||the-15/DT	amod||epidemic-18/NN||local-16/JJ	nn||epidemic-18/NN||hiv/aids-17/NN	dobj||understand-14/VB||epidemic-18/NN	aux||deliver-21/VB||to-20/TO	vmod||carry-8/VB||deliver-21/VB	amod||interventions-23/NNS||primary-22/JJ	dobj||deliver-21/VB||interventions-23/NNS	aux||reduce-25/VB||to-24/TO	vmod||deliver-21/VB||reduce-25/VB	vmod||deliver-21/VB||reduce-25/VB	conj_and||reduce-25/VB||reduce-25/VB	amod||hivinfections-27/NNS||new-26/JJ	dobj||reduce-25/VB||hivinfections-27/NNS	amod||groups-32/NNS||high-risk-31/JJ	prep_among||reduce-25/VB||groups-32/NNS	prep_from||reduce-25/VB||groups-32/NNS	aux||prevent-35/VB||to-34/TO	dep||reduce-25/VB||prevent-35/VB	amod||transmission-37/NN||mother-to-child-36/JJ	dobj||prevent-35/VB||transmission-37/NN	aux||treat-40/VB||to-39/TO	dep||reduce-25/VB||treat-40/VB	conj_and||prevent-35/VB||treat-40/VB	nn||patients-42/NNS||aids-41/NNS	dobj||treat-40/VB||patients-42/NNS	amod||medicines-45/NNS||antiretroviral-44/JJ	prep_with||treat-40/VB||medicines-45/NNS	aux||provide-48/VB||to-47/TO	dep||reduce-25/VB||provide-48/VB	conj_and||prevent-35/VB||provide-48/VB	nn||services-50/NNS||support-49/NN	dobj||provide-48/VB||services-50/NNS	prep_to||provide-48/VB||families-52/NNS	vmod||families-52/NNS||affected-53/VBN	agent||affected-53/VBN||hiv/aids-55/NNS	aids-41||hiv--1||no||each china cares site was required to carry out surveillance and surveys to understand the local hiv/aids epidemic, to deliver primary interventions to reduce new hivinfections among and from high-risk groups, to prevent mother-to-child transmission, to treat aids patients with antiretroviral medicines and to provide support services to families affected by hiv/aids.
det||investigation-4/NN||the-2/DT	amod||investigation-4/NN||present-3/JJ	prep_in||used-44/VBN||investigation-4/NN	vmod||investigation-4/NN||using-6/VBG	amod||rt-pcr-9/NN||real-7/JJ	nn||rt-pcr-9/NN||time-8/NN	dobj||using-6/VBG||rt-pcr-9/NN	amod||immunoblot-13/JJ||immunofluorescence-11/JJ	dobj||using-6/VBG||immunoblot-13/JJ	amod||rt-pcr-9/NN||immunoblot-13/JJ	conj_and||rt-pcr-9/NN||immunoblot-13/JJ	nn||assay-17/NN||plaque-16/NN	dobj||using-6/VBG||assay-17/NN	conj_and||rt-pcr-9/NN||assay-17/NN	det||rna-26/NN||assay-17/NN	nsubj||show-19/VBP||we-18/PRP	rcmod||assay-17/NN||show-19/VBP	num||rna-26/NN||5-21/CD	amod||rna-26/NN||ppp-containing-23/JJ	amod||rna-26/NN||single-24/JJ	amod||rna-26/NN||stranded-25/JJ	dobj||show-19/VBP||rna-26/NN	num||ppp-rna-30/NNS||5-28/CD	dep||investigation-4/NN||ppp-rna-30/NNS	det||sensor-39/NN||a-33/DT	amod||sensor-39/NN||ligand-34/JJ	det||rna-38/NN||the-36/DT	amod||rna-38/NN||intracytoplasmic-37/JJ	prep_for||ligand-34/JJ||rna-38/NN	appos||investigation-4/NN||sensor-39/NN	nsubjpass||used-44/VBN||rig-i-41/NNP	aux||used-44/VBN||can-42/MD	auxpass||used-44/VBN||be-43/VB	root||ROOT-0/null||used-44/VBN	det||agent-48/NN||a-46/DT	amod||agent-48/NN||prophylactic-47/JJ	prep_as||used-44/VBN||agent-48/NN	amod||h5n1-53/NNS||known-50/JJ	amod||h5n1-53/NNS||drug-resistant-51/JJ	nn||h5n1-53/NNS||avian-52/NN	prep_against||agent-48/NN||h5n1-53/NNS	amod||influenzaviruses-56/NNS||pandemic-55/JJ	prep_against||agent-48/NN||influenzaviruses-56/NNS	conj_and||h5n1-53/NNS||influenzaviruses-56/NNS	h5n1-53||influenzaviruses-56||no||in the present investigation, using real time rt-pcr, immunofluorescence, immunoblot, and plaque assay we show that 5'ppp-containing single stranded rna (5'ppp-rna), a ligand for the intracytoplasmic rna sensor, rig-i can be used as a prophylactic agent against known drug-resistant avian h5n1 and pandemic influenzaviruses.
advmod||m.tuberculosis-5/VBZ||furthermore-1/RB	det||xdr-4/NN||the-3/DT	nsubj||m.tuberculosis-5/VBZ||xdr-4/NN	root||ROOT-0/null||m.tuberculosis-5/VBZ	nsubj||likely-9/JJ||strains-6/NNS	nsubjpass||clustered-20/VBN||strains-6/NNS	cop||likely-9/JJ||were-7/VBD	advmod||likely-9/JJ||more-8/RBR	ccomp||m.tuberculosis-5/VBZ||likely-9/JJ	det||$-13/NN||the-11/DT	amod||$-13/NN||nonâ-12/JJ	prep_than||likely-9/JJ||$-13/NN	nn||strains-17/NNS||xdr-15/FW	nn||strains-17/NNS||mdr-16/FW	dep||$-13/NN||strains-17/NNS	aux||clustered-20/VBN||to-18/TO	auxpass||clustered-20/VBN||be-19/VB	xcomp||likely-9/JJ||clustered-20/VBN	number||71-22/CD||-lrb--21/CD	num||%-23/NN||71-22/CD	dobj||clustered-20/VBN||%-23/NN	num||%-26/NN||24-25/CD	prep_vs.||%-23/NN||%-26/NN	vmod||%-26/NN||p-28/VBN	dep||-rrb--31/NNS||=-29/SYM	num||-rrb--31/NNS||0.003-30/CD	ccomp||p-28/VBN||-rrb--31/NNS	xcomp||p-28/VBN||suggesting-33/VBG	mark||plays-36/VBZ||that-34/IN	nsubj||plays-36/VBZ||transmission-35/NN	ccomp||suggesting-33/VBG||plays-36/VBZ	det||role-39/NN||a-37/DT	amod||role-39/NN||critical-38/JJ	dobj||plays-36/VBZ||role-39/NN	det||incidence-43/NN||the-41/DT	amod||incidence-43/NN||new-42/JJ	prep_in||role-39/NN||incidence-43/NN	nn||tb-46/FW||xdr-45/FW	prep_of||incidence-43/NN||tb-46/FW	tb-46||m.tuberculosis-5||no||furthermore , the xdr m.tuberculosis strains were more likely than the nonâ $ `` xdr mdr strains to be clustered -lrb- 71 % vs. 24 % ; p = 0.003 -rrb- , suggesting that transmission plays a critical role in the new incidence of xdr tb .
det||paper-2/NN||this-1/DT	nsubj||provides-3/VBZ||paper-2/NN	ccomp||ironoverload-11/VBD||provides-3/VBZ	det||overview-5/NN||an-4/DT	dobj||provides-3/VBZ||overview-5/NN	amod||metabolism-9/NN||normal-7/JJ	nn||metabolism-9/NN||iron-8/NN	prep_of||overview-5/NN||metabolism-9/NN	root||ROOT-0/null||ironoverload-11/VBD	amod||patients-14/NNS||transfused-13/JJ	prep_in||ironoverload-11/VBD||patients-14/NNS	amod||disease-18/NN||sickle-16/JJ	nn||disease-18/NN||cell-17/NN	prep_with||ironoverload-11/VBD||disease-18/NN	appos||disease-18/NN||patterns-20/NNS	nn||organ-23/NN||end-22/NN	prep_of||patterns-20/NNS||organ-23/NN	nsubj||ironoverload-11/VBD||damage-24/NN	nsubj||ironoverload-11/VBD||diagnosis-26/NN	conj_and||damage-24/NN||diagnosis-26/NN	nsubj||ironoverload-11/VBD||treatment-28/NN	conj_and||damage-24/NN||treatment-28/NN	nsubj||ironoverload-11/VBD||prevention-31/NN	conj_and||damage-24/NN||prevention-31/NN	prep_of||damage-24/NN||ironoverload-33/NN	ironoverload-33||iron-8||no||this paper provides an overview of normal iron metabolism, ironoverload in transfused patients with sickle cell disease, patterns of end organ damage, diagnosis, treatment, and prevention of ironoverload.
det||analysis-4/NN||the-2/DT	amod||analysis-4/NN||case-control-3/JJ	prep_in||associated-13/VBN||analysis-4/NN	amod||use-7/NN||current-6/JJ	nsubjpass||associated-13/VBN||use-7/NN	det||contraceptive-11/NN||the-9/DT	amod||contraceptive-11/NN||drospirenone-10/JJ	prep_of||use-7/NN||contraceptive-11/NN	auxpass||associated-13/VBN||was-12/VBD	root||ROOT-0/null||associated-13/VBN	det||risk-18/NN||a-15/DT	amod||risk-18/NN||threefold-16/JJ	amod||risk-18/NN||higher-17/JJR	prep_with||associated-13/VBN||risk-18/NN	amod||thromboembolism-23/NN||non-fatal-20/JJ	amod||thromboembolism-23/NN||idiopathic-21/JJ	nn||thromboembolism-23/NN||venous-22/NNS	prep_of||risk-18/NN||thromboembolism-23/NN	prepc_compared_with||thromboembolism-23/NN||with-25/IN	amod||use-27/NN||levonorgestrel-26/JJ	pobj||thromboembolism-23/NN||use-27/NN	det||ratio-31/NN||the-29/DT	nn||ratio-31/NN||odds-30/NNS	nsubj||3.3-38/CD||ratio-31/NN	vmod||ratio-31/NN||adjusted-32/VBN	nn||index-36/NN||body-34/NN	nn||index-36/NN||mass-35/NN	prep_for||adjusted-32/VBN||index-36/NN	cop||3.3-38/CD||was-37/VBD	parataxis||associated-13/VBN||3.3-38/CD	num||%-41/NN||95-40/CD	dep||3.3-38/CD||%-41/NN	nn||interval-43/NN||confidence-42/NN	dep||%-41/NN||interval-43/NN	number||7.6-46/CD||1.4-44/CD	dep||7.6-46/CD||to-45/TO	dep||interval-43/NN||7.6-46/CD	thromboembolism-23||drospirenone-10||no||in the case-control analysis, current use of the drospirenone contraceptive was associated with a threefold higher risk of non-fatal idiopathic venous thromboembolism compared with levonorgestrel use; the odds ratio adjusted for body mass index was 3.3 (95% confidence interval 1.4 to 7.6).
nsubj||agent-10/NN||bortezomib-1/NN	det||inhibitor-5/NN||an-3/DT	amod||inhibitor-5/NN||nfkb-4/JJ	appos||bortezomib-1/NN||inhibitor-5/NN	cop||agent-10/NN||is-7/VBZ	det||agent-10/NN||an-8/DT	amod||agent-10/NN||active-9/JJ	root||ROOT-0/null||agent-10/NN	det||treatment-13/NN||the-12/DT	prep_for||agent-10/NN||treatment-13/NN	prep_of||treatment-13/NN||myeloma-15/NN	appos||myeloma-15/NN||mm-17/NN	myeloma-15||bortezomib-1||yes||bortezomib, an nfkb inhibitor, is an active agent for the treatment of myeloma (mm).
amod||study-2/NN||case-control-1/JJ	nsubj||english-5/VBP||study-2/NN	nsubj||dutch-7/VBP||study-2/NN	nsubj||irish-10/VBP||study-2/NN	prep_of||study-2/NN||71-4/CD	root||ROOT-0/null||english-5/VBP	conj_and||english-5/VBP||dutch-7/VBP	conj_and||english-5/VBP||irish-10/VBP	amod||food-12/NN||oral-11/JJ	dobj||english-5/VBP||food-12/NN	vmod||food-12/NN||challengeâ-13/VBG	dobj||challengeâ-13/VBG||$-14/$	advmod||patients-17/NNS||positive-16/RB	dep||non-22/CD||patients-17/NNS	prep_with||patients-17/NNS||peanutallergy-19/CD	prep_with||patients-17/NNS||1000-21/CD	conj_and||peanutallergy-19/CD||1000-21/CD	num||$-14/$||non-22/CD	amod||controls-26/NNS||peanut-sensitized-23/JJ	nn||controls-26/NNS||english-24/NN	nn||controls-26/NNS||population-25/NN	dep||challengeâ-13/VBG||controls-26/NNS	peanutallergy-19||peanut--1||no||case-control study of 71 english, dutch, and irish oral food challengeâpositive patients with peanutallergy and 1000 non peanut-sensitized english population controls.
aux||determine-2/VB||to-1/TO	csubj||use-21/VBP||determine-2/VB	mark||decrease-17/VB||whether-3/IN	amod||administration-8/NN||pre-4/JJ	conj_and||pre-4/JJ||post-operative-7/JJ	amod||administration-8/NN||post-operative-7/JJ	nsubj||decrease-17/VB||administration-8/NN	amod||ibuprofen-11/NN||intravenous-10/JJ	prep_of||administration-8/NN||ibuprofen-11/NN	appos||ibuprofen-11/NN||iv-ibuprofen-13/NN	aux||decrease-17/VB||can-15/MD	advmod||decrease-17/VB||significantly-16/RB	ccomp||determine-2/VB||decrease-17/VB	dobj||decrease-17/VB||pain-18/NN	dobj||decrease-17/VB||morphine-20/NN	conj_and||pain-18/NN||morphine-20/NN	root||ROOT-0/null||use-21/VBP	advmod||compared-23/VBN||when-22/WRB	advcl||use-21/VBP||compared-23/VBN	prep_with||compared-23/VBN||placebo-25/NN	amod||patients-30/NNS||adult-27/JJ	amod||patients-30/NNS||orthopedic-28/JJ	amod||patients-30/NNS||surgical-29/JJ	prep_in||placebo-25/NN||patients-30/NNS	pain-18||ibuprofen-11||yes||to determine whether pre- and post-operative administration of intravenous ibuprofen (iv-ibuprofen) can significantly decrease pain and morphine use when compared with placebo in adult orthopedic surgical patients.
det||findings-2/NNS||the-1/DT	nsubj||obtained-3/VBD||findings-2/NNS	root||ROOT-0/null||obtained-3/VBD	det||show-7/NN||this-5/DT	nn||show-7/NN||study-6/NN	prep_in||obtained-3/VBD||show-7/NN	mark||due-14/JJ||that-8/IN	nn||transmission-10/NNP||tuberculosis-9/NNP	nsubj||due-14/JJ||transmission-10/NNP	prep_in||transmission-10/NNP||honduras-12/NNS	cop||due-14/JJ||is-13/VBZ	ccomp||obtained-3/VBD||due-14/JJ	amod||lineages-18/NNS||modern-16/JJ	nn||lineages-18/NNS||m.tuberculosis-17/NNS	prep_to||due-14/JJ||lineages-18/NNS	amod||level-21/NN||high-20/JJ	prep_with||lineages-18/NNS||level-21/NN	prep_of||level-21/NN||biodiversity-23/NN	tuberculosis-9||m.tuberculosis-17||no||the findings obtained in this study show that tuberculosis transmission in honduras is due to modern m.tuberculosis lineages with high level of biodiversity .
det||point-3/NN||this-2/DT	prep_at||demonstrates-9/VBZ||point-3/NN	det||evidence-7/NN||the-5/DT	amod||evidence-7/NN||best-6/JJS	nsubj||demonstrates-9/VBZ||evidence-7/NN	advmod||demonstrates-9/VBZ||powerfully-8/RB	root||ROOT-0/null||demonstrates-9/VBZ	nn||patients-13/NNS||stroke-10/NN	conj_and||stroke-10/NN||tia-12/NN	nn||patients-13/NNS||tia-12/NN	nsubjpass||prescribed-16/VBN||patients-13/NNS	aux||prescribed-16/VBN||should-14/MD	auxpass||prescribed-16/VBN||be-15/VB	ccomp||demonstrates-9/VBZ||prescribed-16/VBN	amod||therapy-20/NN||high-17/JJ	nn||therapy-20/NN||dose-18/NN	nn||therapy-20/NN||statin-19/NN	dobj||prescribed-16/VBN||therapy-20/NN	amod||prevention-24/NN||secondary-22/JJ	nn||prevention-24/NN||stroke-23/NN	prep_for||therapy-20/NN||prevention-24/NN	statin-19||stroke-23||no_rel||at this point, the best evidence powerfully demonstrates stroke and tia patients should be prescribed high dose statin therapy for secondary stroke prevention.
advmod||refractory-22/VBN||conversely-1/RB	det||pc-3-8/NN||the-3/DT	nn||pc-3-8/NN||prostate-4/NN	nn||pc-3-8/NN||cancer-5/NN	nn||pc-3-8/NN||cell-6/NN	nn||pc-3-8/NN||line-7/NN	nsubjpass||refractory-22/VBN||pc-3-8/NN	nsubj||support-31/VB||pc-3-8/NN	amod||negative-12/NN||androgen-10/JJ	nn||negative-12/NN||receptor-11/NN	appos||pc-3-8/NN||negative-12/NN	det||line-19/NN||the-15/DT	amod||line-19/NN||pancreatic-16/JJ	nn||line-19/NN||cancer-17/NN	nn||line-19/NN||cell-18/NN	conj_and||pc-3-8/NN||line-19/NN	nsubjpass||refractory-22/VBN||line-19/NN	amod||line-19/NN||panc-1-20/JJ	auxpass||refractory-22/VBN||were-21/VBD	root||ROOT-0/null||refractory-22/VBN	det||effect-27/NN||the-24/DT	amod||effect-27/NN||viral-25/JJ	amod||effect-27/NN||cytopathic-26/JJ	prep_to||refractory-22/VBN||effect-27/NN	aux||support-31/VB||did-29/VBD	neg||support-31/VB||not-30/RB	conj_and||refractory-22/VBN||support-31/VB	amod||replication-33/NN||viral-32/JJ	dobj||support-31/VB||replication-33/NN	androgen-10||cancer-17||no_rel||conversely, the prostate cancer cell line pc-3 (androgen receptor negative) and the pancreatic cancer cell line panc-1 were refractory to the viral cytopathic effect and did not support viral replication.
advmod||utilized-5/VBD||therefore-1/RB	det||study-4/NN||this-3/DT	nsubj||utilized-5/VBD||study-4/NN	nsubj||combined-30/VBD||study-4/NN	root||ROOT-0/null||utilized-5/VBD	amod||spectrometry-7/NN||mass-6/JJ	dobj||utilized-5/VBD||spectrometry-7/NN	det||analysis-13/NN||a-9/DT	amod||analysis-13/NN||structure-specific-10/JJ	conj_and||structure-specific-10/JJ||quantitative-12/JJ	amod||analysis-13/NN||quantitative-12/JJ	prep_for||utilized-5/VBD||analysis-13/NN	det||types-16/NNS||the-15/DT	prep_of||analysis-13/NN||types-16/NNS	prep_of||analysis-13/NN||amounts-18/NNS	conj_and||types-16/NNS||amounts-18/NNS	nn||localization-22/NN||tissue-21/NN	prep_of||analysis-13/NN||localization-22/NN	conj_and||types-16/NNS||localization-22/NN	prep_of||localization-22/NN||st-24/NN	nn||cancer-27/NN||ovarian-26/NN	prep_in||utilized-5/VBD||cancer-27/NN	conj_and||utilized-5/VBD||combined-30/VBD	det||findings-32/NNS||these-31/DT	dobj||combined-30/VBD||findings-32/NNS	prep_with||combined-30/VBD||analysis-34/NN	prep_of||analysis-34/NN||mrnas-36/NNS	det||enzymes-40/NNS||the-38/DT	amod||enzymes-40/NNS||relevant-39/JJ	prep_for||mrnas-36/NNS||enzymes-40/NNS	nn||metabolism-43/NN||st-42/NN	prep_of||enzymes-40/NNS||metabolism-43/NN	aux||explore-45/VB||to-44/TO	vmod||combined-30/VBD||explore-45/VB	amod||mechanisms-47/NNS||possible-46/JJ	dobj||explore-45/VB||mechanisms-47/NNS	enzymes-40||cancer-27||no_rel||therefore, this study utilized mass spectrometry for a structure-specific and quantitative analysis of the types, amounts, and tissue localization of st in ovarian cancer, and combined these findings with analysis of mrnas for the relevant enzymes of st metabolism to explore possible mechanisms.
det||woman-3/NN||a-1/DT	amod||woman-3/NN||32-year-old-2/JJ	nsubj||presented-10/VBD||woman-3/NN	det||history-6/NN||a-5/DT	prep_with||woman-3/NN||history-6/NN	amod||use-9/NN||oralcontraceptive-8/JJ	prep_of||history-6/NN||use-9/NN	root||ROOT-0/null||presented-10/VBD	nn||abdominalpain-15/NN||nausea-12/NN	conj_and||nausea-12/NN||severe-14/JJ	nn||abdominalpain-15/NN||severe-14/JJ	prep_with||presented-10/VBD||abdominalpain-15/NN	prep||abdominalpain-15/NN||but-16/CC	neg||ascites-18/NN||no-17/DT	pobj||but-16/CC||ascites-18/NN	pobj||but-16/CC||stigmata-20/NN	conj_or||ascites-18/NN||stigmata-20/NN	prep_of||ascites-18/NN||cirrhosis-22/NNS	abdominalpain-15||oralcontraceptive-8||no_rel||a 32-year-old woman with a history of oralcontraceptive use presented with nausea and severe abdominalpain but no ascites or stigmata of cirrhosis.
amod||mutants-2/NNS||spontaneous-1/JJ	nsubjpass||isolated-16/VBN||mutants-2/NNS	nsubjpass||found-18/VBN||mutants-2/NNS	prep_of||mutants-2/NNS||mycobacteriumtuberculosis-4/NNS	nsubj||resistant-7/JJ||mycobacteriumtuberculosis-4/NNS	cop||resistant-7/JJ||were-6/VBD	rcmod||mycobacteriumtuberculosis-4/NNS||resistant-7/JJ	det||drugs-11/NNS||the-9/DT	amod||drugs-11/NNS||anti-tuberculosis-10/JJ	prep_to||resistant-7/JJ||drugs-11/NNS	amod||drugs-11/NNS||ethionamide-12/JJ	amod||drugs-11/NNS||isoniazid-14/JJ	conj_and||ethionamide-12/JJ||isoniazid-14/JJ	auxpass||isolated-16/VBN||were-15/VBD	root||ROOT-0/null||isolated-16/VBN	conj_and||isolated-16/VBN||found-18/VBN	prep_to||isolated-16/VBN||map-20/NN	prep_to||isolated-16/VBN||msha-22/NN	det||gene-25/NN||a-24/DT	appos||msha-22/NN||gene-25/NN	vmod||gene-25/NN||encoding-26/VBG	det||enzyme-29/NN||the-27/DT	amod||enzyme-29/NN||first-28/JJ	dobj||encoding-26/VBG||enzyme-29/NN	vmod||enzyme-29/NN||involved-30/VBN	det||biosynthesis-33/NNS||the-32/DT	prep_in||involved-30/VBN||biosynthesis-33/NNS	prep_of||biosynthesis-33/NNS||mycothiol-35/NN	det||thiol-40/NN||a-37/DT	amod||thiol-40/NN||major-38/JJ	amod||thiol-40/NN||low-molecular-weight-39/JJ	appos||mycothiol-35/NN||thiol-40/NN	prep_in||thiol-40/NN||m.tuberculosis-42/NNS	tuberculosis--1||isoniazid-14||yes||spontaneous mutants of mycobacteriumtuberculosis that were resistant to the anti-tuberculosis drugs ethionamide and isoniazid were isolated and found to map to msha , a gene encoding the first enzyme involved in the biosynthesis of mycothiol , a major low-molecular-weight thiol in m.tuberculosis .
det||impact-2/NN||the-1/DT	nsubj||occur-11/VB||impact-2/NN	amod||incidence-6/NN||hpv-related-4/JJ	nn||incidence-6/NN||disease-5/NN	prep_on||impact-2/NN||incidence-6/NN	prep_on||impact-2/NN||costs-8/NNS	conj_and||incidence-6/NN||costs-8/NNS	vmod||costs-8/NNS||avoided-9/VBN	aux||occur-11/VB||would-10/MD	root||ROOT-0/null||occur-11/VB	advmod||soon-13/RB||relatively-12/RB	advmod||occur-11/VB||soon-13/RB	prepc_after||occur-11/VB||initiating-15/VBG	det||programme-18/NN||the-16/DT	nn||programme-18/NN||vaccine-17/NN	dobj||initiating-15/VBG||programme-18/NN	nsubj||due-27/JJ||much-21/RB	det||impact-25/NN||the-23/DT	amod||impact-25/NN||early-24/JJ	prep_of||much-21/RB||impact-25/NN	cop||due-27/JJ||being-26/VBG	prepc_with||occur-11/VB||due-27/JJ	det||prevention-30/NN||the-29/DT	prep_to||due-27/JJ||prevention-30/NN	amod||genitalwarts-33/NNS||hpv6/11-related-32/JJ	prep_of||prevention-30/NN||genitalwarts-33/NNS	genitalwarts-33||hpv--1||no||the impact on hpv-related disease incidence and costs avoided would occur relatively soon after initiating the vaccine programme, with much of the early impact being due to the prevention of hpv6/11-related genitalwarts.
vmod||present-16/VBP||using-1/VBG	det||$-10/FW||the-2/DT	nn||$-10/FW||caenorhabditis-3/FW	nn||$-10/FW||elegans-4/FW	nn||$-10/FW||â-5/FW	nn||$-10/FW||$-6/FW	nn||$-10/FW||pseudomonasaeruginosa-8/FW	nn||$-10/FW||hostâ-9/FW	dobj||using-1/VBG||$-10/FW	iobj||using-1/VBG||$-10/FW	nn||system-13/NN||pathogen-12/NN	dep||$-10/FW||system-13/NN	nsubj||present-16/VBP||we-15/PRP	root||ROOT-0/null||present-16/VBP	amod||evidence-18/NN||genetic-17/JJ	dobj||present-16/VBP||evidence-18/NN	mark||required-72/VBN||that-19/IN	det||fat-3-24/NNS||a-20/DT	nn||fat-3-24/NNS||î-21/NN	amod||fat-3-24/NNS||6-desaturase-23/JJ	nsubjpass||required-72/VBN||fat-3-24/NNS	poss||productsâ-30/NNS||its-27/PRP$	num||productsâ-30/NNS||two-28/CD	amod||productsâ-30/NNS||18-carbon-29/JJ	prep_through||fat-3-24/NNS||productsâ-30/NNS	dep||fat-3-24/NNS||$-31/$	num||$-31/$||gamma-linolenicacid-33/CD	dep||$-31/$||gla-35/NN	appos||gla-35/NN||183n6-37/NNS	amod||acid-41/NN||stearidonic-40/JJ	dep||fat-3-24/NNS||acid-41/NN	conj_and||$-31/$||acid-41/NN	dep||acid-41/NN||sda-43/NN	appos||sda-43/NN||184n3-45/NNS	det||acid-54/NN||the-50/DT	num||pufas-52/NNS||20-carbon-51/CD	npadvmod||arachidonic-53/JJ||pufas-52/NNS	amod||acid-54/NN||arachidonic-53/JJ	dep||fat-3-24/NNS||acid-54/NN	conj_negcc||$-31/$||acid-54/NN	dep||acid-54/NN||aa-56/NN	appos||aa-56/NN||204n6-58/NNS	amod||$-69/NNS||eicosapentaenoic-61/JJ	amod||$-69/NNS||acid-62/JJ	dep||$-69/NNS||epa-64/NN	appos||epa-64/NN||205n3-66/NNS	nn||$-69/NNS||â-68/NN	conj_negcc||$-31/$||$-69/NNS	conj_and||acid-54/NN||$-69/NNS	auxpass||required-72/VBN||is-71/VBZ	ccomp||present-16/VBP||required-72/VBN	amod||immunity-76/NN||basal-74/JJ	nn||immunity-76/NN||innate-75/NN	prep_for||required-72/VBN||immunity-76/NN	prep_in||immunity-76/NN||vivo-78/NN	sda-43||gamma-linolenicacid-33||no_rel||using the caenorhabditis elegans â pseudomonasaeruginosa hostâpathogen system, we present genetic evidence that a î6-desaturase fat-3, through its two 18-carbon productsâgamma-linolenicacid (gla, 183n6) and stearidonic acid (sda, 184n3), but not the 20-carbon pufas arachidonic acid (aa, 204n6) and eicosapentaenoic acid (epa, 205n3)âis required for basal innate immunity in vivo.
det||effects-2/NNS||the-1/DT	nsubjpass||evaluated-28/VBN||effects-2/NNS	amod||species-5/NNS||other-4/JJ	prep_of||effects-2/NNS||species-5/NNS	amod||bacteria-8/NNS||oral-7/JJ	prep_of||species-5/NNS||bacteria-8/NNS	nn||formation-11/NN||biofilm-10/NN	prep_on||bacteria-8/NNS||formation-11/NN	nn||expression-15/NN||virulence-13/NN	nn||expression-15/NN||gene-14/NN	prep_on||bacteria-8/NNS||expression-15/NN	conj_and||formation-11/NN||expression-15/NN	amod||mutans-18/NNS||streptococcus-17/JJ	prep_by||formation-11/NN||mutans-18/NNS	det||agent-23/NN||the-20/DT	amod||agent-23/NN||primary-21/JJ	amod||agent-23/NN||etiologic-22/JJ	appos||effects-2/NNS||agent-23/NN	prep_of||agent-23/NN||dentalcaries-25/NNS	auxpass||evaluated-28/VBN||were-27/VBD	root||ROOT-0/null||evaluated-28/VBN	xcomp||evaluated-28/VBN||using-29/VBG	det||model-33/NN||a-30/DT	amod||model-33/NN||dual-species-31/JJ	nn||model-33/NN||biofilm-32/NN	dobj||using-29/VBG||model-33/NN	nn||analysis-36/NN||realtime-pcr-35/NN	dobj||using-29/VBG||analysis-36/NN	conj_and||model-33/NN||analysis-36/NN	dentalcaries-25||bacteria-8||no||the effects of other species of oral bacteria on biofilm formation and virulence gene expression by streptococcus mutans , the primary etiologic agent of dentalcaries, were evaluated using a dual-species biofilm model and realtime-pcr analysis.
num||strains-5/NNS||six-1/CD	amod||strains-5/NNS||vancomycin-2/JJ	amod||strains-5/NNS||intermediate-3/JJ	nn||strains-5/NNS||s.aureus-4/NN	nsubjpass||detected-7/VBN||strains-5/NNS	auxpass||detected-7/VBN||were-6/VBD	root||ROOT-0/null||detected-7/VBN	amod||-rrb--10/NNS||-lrb--8/JJ	nn||-rrb--10/NNS||visa-9/NN	dobj||detected-7/VBN||-rrb--10/NNS	prep_with||detected-7/VBN||mic-12/NN	dep||ml-16/NN||=-13/SYM	amod||ml-16/NN||4âµg-14/JJ	amod||ml-16/NN||/-15/JJ	rcmod||mic-12/NN||ml-16/NN	appos||mic-12/NN||5-18/CD	nsubj||mrsa-22/JJ||them-20/PRP	cop||mrsa-22/JJ||being-21/VBG	prepc_of||5-18/CD||mrsa-22/JJ	mrsa-22||s.aureus-4||no||six vancomycin intermediate s.aureus strains were detected -lrb- visa -rrb- with mic = 4âµg / ml , 5 of them being mrsa .
prep||undertaken-7/VBN||given-1/VBN	det||scenario-3/NN||these-2/DT	pobj||given-1/VBN||scenario-3/NN	det||study-5/NN||the-4/DT	nsubjpass||undertaken-7/VBN||study-5/NN	nsubj||examine-9/VB||study-5/NN	nsubj||aids-14/VBZ||study-5/NN	nsubj||identify-18/VB||study-5/NN	auxpass||undertaken-7/VBN||was-6/VBD	root||ROOT-0/null||undertaken-7/VBN	aux||examine-9/VB||to-8/TO	xcomp||undertaken-7/VBN||examine-9/VB	dobj||examine-9/VB||trends-10/NNS	prep_in||examine-9/VB||hiv-12/NN	xcomp||undertaken-7/VBN||aids-14/VBZ	conj_and||examine-9/VB||aids-14/VBZ	amod||knowledge-16/NN||comprehensive-15/JJ	dobj||aids-14/VBZ||knowledge-16/NN	xcomp||undertaken-7/VBN||identify-18/VB	conj_and||examine-9/VB||identify-18/VB	det||correlates-21/NNS||the-19/DT	amod||correlates-21/NNS||main-20/JJ	dobj||identify-18/VB||correlates-21/NNS	amod||hiv-24/NN||comprehensive-23/JJ	prep_of||correlates-21/NNS||hiv-24/NN	nn||knowledge-27/NN||aids-26/NNS	prep_of||correlates-21/NNS||knowledge-27/NN	conj_and||hiv-24/NN||knowledge-27/NN	amod||women-32/NNS||kenyan-29/JJ	amod||women-32/NNS||urban-30/JJ	amod||women-32/NNS||young-31/JJ	prep_among||identify-18/VB||women-32/NNS	aids-26||hiv-24||no||given these scenario the study was undertaken to examine trends in hiv and aids comprehensive knowledge and identify the main correlates of comprehensive hiv and aids knowledge among kenyan urban young women.
prep_in||demonstrated-17/VBD||type1diabetes-2/CD	prepc_compared_with||demonstrated-17/VBD||with-5/IN	pobj||demonstrated-17/VBD||insulinglargine-6/NN	nsubj||demonstrated-17/VBD||ly2605541-8/NNS	nsubj||lowered-39/VBD||ly2605541-8/NNS	det||novel-11/NN||a-10/DT	appos||ly2605541-8/NNS||novel-11/NN	amod||insulin-15/NN||long-acting-13/JJ	amod||insulin-15/NN||basal-14/JJ	appos||novel-11/NN||insulin-15/NN	root||ROOT-0/null||demonstrated-17/VBD	amod||improvements-19/NNS||greater-18/JJR	dobj||demonstrated-17/VBD||improvements-19/NNS	amod||control-22/NN||glycemic-21/JJ	prep_in||demonstrated-17/VBD||control-22/NN	amod||hypoglycemia-26/NN||increased-24/VBN	amod||hypoglycemia-26/NN||total-25/JJ	prep_in||demonstrated-17/VBD||hypoglycemia-26/NN	conj_and||control-22/NN||hypoglycemia-26/NN	amod||hypoglycemia-31/NN||reduced-29/VBN	amod||hypoglycemia-31/NN||nocturnal-30/JJ	prep_in||demonstrated-17/VBD||hypoglycemia-31/NN	conj_and||control-22/NN||hypoglycemia-31/NN	amod||weight-37/NN||reduced-36/VBN	prep_in||demonstrated-17/VBD||weight-37/NN	conj_and||control-22/NN||weight-37/NN	conj_and||demonstrated-17/VBD||lowered-39/VBD	amod||doses-42/NNS||mealtime-40/JJ	nn||doses-42/NNS||insulin-41/NN	dobj||lowered-39/VBD||doses-42/NNS	type1diabetes-2||insulinglargine-6||yes||in type1diabetes, compared with insulinglargine, ly2605541, a novel, long-acting basal insulin, demonstrated greater improvements in glycemic control, increased total hypoglycemia, and reduced nocturnal hypoglycemia, as well as reduced weight and lowered mealtime insulin doses.
amod||monitoring-3/NN||continuous-1/JJ	nn||monitoring-3/NN||glucose-2/NN	nsubjpass||associated-5/VBN||monitoring-3/NN	auxpass||associated-5/VBN||was-4/VBD	root||ROOT-0/null||associated-5/VBN	amod||time-8/NN||reduced-7/VBN	prep_with||associated-5/VBN||time-8/NN	vmod||time-8/NN||spent-9/VBN	prep_in||spent-9/VBN||hypoglycemia-11/NN	det||decrease-15/NN||a-13/DT	amod||decrease-15/NN||concomitant-14/JJ	prep_in||spent-9/VBN||decrease-15/NN	conj_and||hypoglycemia-11/NN||decrease-15/NN	prep_in||spent-9/VBN||hba1c-17/NNS	prep_in||hba1c-17/NNS||children-19/NNS	prep_in||hba1c-17/NNS||adults-21/NNS	conj_and||children-19/NNS||adults-21/NNS	prep_with||spent-9/VBN||type1diabetes-23/CD	hypoglycemia-11||glucose-2||yes||continuous glucose monitoring was associated with reduced time spent in hypoglycemia and a concomitant decrease in hba1c in children and adults with type1diabetes.
nsubjpass||associated-13/VBN||s100a12-1/NNS	det||protein-6/NN||a-3/DT	amod||protein-6/NN||calcium-binding-4/JJ	nn||protein-6/NN||proinflammatory-5/NN	appos||s100a12-1/NNS||protein-6/NN	vmod||protein-6/NN||secreted-7/VBN	agent||secreted-7/VBN||granulocytes-9/NNS	aux||associated-13/VBN||has-11/VBZ	auxpass||associated-13/VBN||been-12/VBN	root||ROOT-0/null||associated-13/VBN	amod||diseases-16/NNS||different-15/JJ	prep_with||associated-13/VBN||diseases-16/NNS	amod||origin-19/NN||inflammatory-18/JJ	prep_of||diseases-16/NNS||origin-19/NN	prep_including||diseases-16/NNS||inflammatoryboweldisease-22/NN	appos||inflammatoryboweldisease-22/NN||ibd-24/NN	calcium--1||ibd-24||no_rel||s100a12, a calcium-binding proinflammatory protein secreted by granulocytes, has been associated with different diseases of inflammatory origin, including inflammatoryboweldisease (ibd).
det||study-2/NN||this-1/DT	nsubj||indicates-3/VBZ||study-2/NN	root||ROOT-0/null||indicates-3/VBZ	mark||important-16/JJ||that-4/IN	amod||turnover-7/NN||increased-5/JJ	nn||turnover-7/NN||bone-6/NN	nsubj||important-16/JJ||turnover-7/NN	conj_and||turnover-7/NN||inflammation-9/NN	nsubj||important-16/JJ||inflammation-9/NN	amod||levels-14/NNS||low-12/JJ	amod||levels-14/NNS||vitamind-13/JJ	conj_and||turnover-7/NN||levels-14/NNS	nsubj||important-16/JJ||levels-14/NNS	cop||important-16/JJ||are-15/VBP	ccomp||indicates-3/VBZ||important-16/JJ	det||pathophysiology-19/NN||the-18/DT	prep_in||important-16/JJ||pathophysiology-19/NN	amod||osteoporosis-22/NNS||as-related-21/JJ	prep_of||pathophysiology-19/NN||osteoporosis-22/NNS	mark||markers-34/NNS||that-25/IN	nn||markers-28/NNS||bone-26/NN	nn||markers-28/NNS||turnover-27/NN	nsubj||markers-34/NNS||markers-28/NNS	appos||markers-28/NNS||btm-30/NN	cop||markers-34/NNS||are-32/VBP	amod||markers-34/NNS||valuable-33/JJ	ccomp||indicates-3/VBZ||markers-34/NNS	conj_and||important-16/JJ||markers-34/NNS	aux||detect-36/VB||to-35/TO	vmod||markers-34/NNS||detect-36/VB	nn||loss-38/NN||bone-37/NN	dobj||detect-36/VB||loss-38/NN	prep||detect-36/VB||in-39/IN	dep||in-39/IN||as-40/RB	osteoporosis-22||vitamind-13||yes||this study indicates that increased bone turnover, inflammation, and low vitamind levels are important in the pathophysiology of as-related osteoporosis, and that bone turnover markers (btm) are valuable markers to detect bone loss in as.
det||exclusion-2/NN||the-1/DT	nsubj||is-8/VBZ||exclusion-2/NN	amod||routes-5/NNS||alternative-4/JJ	prep_of||exclusion-2/NN||routes-5/NNS	prep_of||routes-5/NNS||transmission-7/NN	root||ROOT-0/null||is-8/VBZ	prep_of||is-8/VBZ||importance-10/NN	vmod||importance-10/NN||owing-11/VBG	det||exposure-15/NN||the-13/DT	amod||exposure-15/NN||dietary-14/JJ	prep_to||owing-11/VBG||exposure-15/NN	det||uk-18/NN||the-17/DT	prep_of||exposure-15/NN||uk-18/NN	amod||populations-21/NNS||other-20/JJ	prep_of||exposure-15/NN||populations-21/NNS	conj_and||uk-18/NN||populations-21/NNS	amod||prions-24/NNS||bovinespongiformencephalopathy-23/JJ	prep_to||owing-11/VBG||prions-24/NNS	bovinespongiformencephalopathy-23||prions-24||no_rel||the exclusion of alternative routes of transmission is of importance owing to the dietary exposure of the uk and other populations to bovinespongiformencephalopathy prions.
nn||granulomas-5/NNS||tuberculosis-1/NNP	appos||granulomas-5/NNS||tb-3/NN	nsubj||collections-8/NNS||granulomas-5/NNS	cop||collections-8/NNS||are-6/VBP	amod||collections-8/NNS||organized-7/VBN	root||ROOT-0/null||collections-8/NNS	amod||cells-11/NNS||immune-10/JJ	prep_of||collections-8/NNS||cells-11/NNS	vmod||cells-11/NNS||comprised-12/VBN	prep_of||comprised-12/VBN||macrophages-14/NNS	prep_of||comprised-12/VBN||lymphocytes-16/NNS	conj_and||macrophages-14/NNS||lymphocytes-16/NNS	amod||cells-19/NNS||other-18/JJ	prep_of||comprised-12/VBN||cells-19/NNS	conj_and||macrophages-14/NNS||cells-19/NNS	nsubj||form-21/VBP||cells-19/NNS	rcmod||cells-19/NNS||form-21/VBP	det||lung-24/NN||the-23/DT	prep_in||form-21/VBP||lung-24/NN	det||result-27/NN||a-26/DT	prep_as||lung-24/NN||result-27/NN	amod||response-30/NN||immune-29/JJ	prep_of||result-27/NN||response-30/NN	nn||infection-36/NN||mycobacteriumtuberculosis-32/NNP	appos||infection-36/NN||mtb-34/NN	prep_to||form-21/VBP||infection-36/NN	tb-3||mtb-34||no||tuberculosis (tb) granulomas are organized collections of immune cells comprised of macrophages, lymphocytes and other cells that form in the lung as a result of immune response to mycobacteriumtuberculosis (mtb) infection.
det||study-2/NN||the-1/DT	nsubj||shows-3/VBZ||study-2/NN	root||ROOT-0/null||shows-3/VBZ	mark||willing-11/JJ||that-4/IN	amod||women-6/NNS||hivpositive-5/JJ	nsubj||willing-11/JJ||women-6/NNS	nsubj||screen-13/VB||women-6/NNS	poss||environment-9/NN||our-8/PRP$	prep_in||women-6/NNS||environment-9/NN	cop||willing-11/JJ||are-10/VBP	ccomp||shows-3/VBZ||willing-11/JJ	aux||screen-13/VB||to-12/TO	xcomp||willing-11/JJ||screen-13/VB	amod||cancer-16/NN||cervical-15/JJ	prep_for||screen-13/VB||cancer-16/NN	mark||strengthen-30/VB||that-18/IN	det||integration-20/NN||the-19/DT	nsubj||strengthen-30/VB||integration-20/NN	nsubj||disrupt-33/VB||integration-20/NN	amod||service-24/NN||reproductive-22/JJ	nn||service-24/NN||health-23/NN	prep_of||integration-20/NN||service-24/NN	amod||programmes-28/NNS||existing-26/VBG	nn||programmes-28/NNS||hiv-27/NN	prep_into||service-24/NN||programmes-28/NNS	aux||strengthen-30/VB||will-29/MD	ccomp||shows-3/VBZ||strengthen-30/VB	conj_and||willing-11/JJ||strengthen-30/VB	conj_and||willing-11/JJ||disrupt-33/VB	conj_negcc||strengthen-30/VB||disrupt-33/VB	det||services-35/NNS||the-34/DT	dobj||disrupt-33/VB||services-35/NNS	hivpositive-5||hiv-27||no||the study shows that hivpositive women in our environment are willing to screen for cervical cancer and that the integration of reproductive health service into existing hiv programmes will strengthen rather than disrupt the services.
nsubj||designed-2/VBD||we-1/PRP	nsubj||participate-50/VB||we-1/PRP	root||ROOT-0/null||designed-2/VBD	num||cascades-5/NNS||two-3/CD	amod||cascades-5/NNS||pmtct-4/JJ	dobj||designed-2/VBD||cascades-5/NNS	xcomp||designed-2/VBD||using-6/VBG	dobj||using-6/VBG||studies-7/NNS	prep_with||using-6/VBG||outcomes-9/NNS	nsubj||showed-16/VBD||outcomes-9/NNS	det||interventions-14/NNS||all-11/DT	amod||interventions-14/NNS||perinatal-12/JJ	amod||interventions-14/NNS||pmtct-13/JJ	prep_for||outcomes-9/NNS||interventions-14/NNS	rcmod||outcomes-9/NNS||showed-16/VBD	mark||notified-42/VBN||that-17/IN	det||%-21/NN||an-18/DT	amod||%-21/NN||estimated-19/VBN	num||%-21/NN||22-20/CD	nsubjpass||notified-42/VBN||%-21/NN	det||women-25/NNS||all-23/DT	amod||women-25/NNS||hivpositive-24/JJ	prep_of||%-21/NN||women-25/NNS	vmod||%-21/NN||attending-26/VBG	amod||care-28/NN||antenatal-27/JJ	dobj||attending-26/VBG||care-28/NN	num||%-31/NN||11-30/CD	dobj||attending-26/VBG||%-31/NN	conj_and||care-28/NN||%-31/NN	det||women-35/NNS||all-33/DT	amod||women-35/NNS||hivpositive-34/JJ	prep_of||%-31/NN||women-35/NNS	vmod||women-35/NNS||delivering-36/VBG	nn||ward-39/NN||labor-38/NN	prep_at||delivering-36/VBG||ward-39/NN	auxpass||notified-42/VBN||were-40/VBD	neg||notified-42/VBN||not-41/RB	ccomp||showed-16/VBD||notified-42/VBN	poss||status-46/NN||their-44/PRP$	nn||status-46/NN||hiv-45/NN	prep_about||notified-42/VBN||status-46/NN	aux||participate-50/VB||did-48/VBD	neg||participate-50/VB||not-49/RB	conj_and||designed-2/VBD||participate-50/VB	amod||program-53/NN||pmtct-52/JJ	prep_in||participate-50/VB||program-53/NN	hivpositive-34||hiv-45||no||we designed two pmtct cascades using studies with outcomes for all perinatal pmtct interventions which showed that an estimated 22% of all hivpositive women attending antenatal care and 11% of all hivpositive women delivering at labor ward were not notified about their hiv status and did not participate in pmtct program.
det||introduction-2/NN||the-1/DT	nsubj||step-9/NN||introduction-2/NN	amod||antipsychotics-5/NNS||atypical-4/JJ	prep_of||introduction-2/NN||antipsychotics-5/NNS	cop||step-9/NN||was-6/VBD	det||step-9/NN||a-7/DT	amod||step-9/NN||big-8/JJ	root||ROOT-0/null||step-9/NN	advmod||step-9/NN||forward-10/RB	det||treatment-13/NN||the-12/DT	prep_in||step-9/NN||treatment-13/NN	nn||psychoses-18/NNS||schizophrenia-15/NN	conj_and||schizophrenia-15/NN||other-17/JJ	nn||psychoses-18/NNS||other-17/JJ	prep_of||treatment-13/NN||psychoses-18/NNS	antipsychotics-5||schizophrenia-15||no_rel||the introduction of atypical antipsychotics was a big step forward in the treatment of schizophrenia and other psychoses.
amod||parallel-group-7/NN||randomized-1/JJ	amod||parallel-group-7/NN||double-blind-3/JJ	amod||parallel-group-7/NN||placebo-controlled-5/JJ	nsubj||î-66/VBP||parallel-group-7/NN	nsubj||placebo-75/VBZ||parallel-group-7/NN	num||study-11/NN||13-9/CD	nn||study-11/NN||week-10/NN	nsubj||treated-53/VBN||study-11/NN	num||patients-14/NNS||542-13/CD	prep_of||study-11/NN||patients-14/NNS	amod||7.0-28/NNS||type2diabetes-16/JJ	advmod||controlled-18/VBN||inadequately-17/RB	amod||7.0-28/NNS||controlled-18/VBN	nn||7.0-28/NNS||-LSB--19/NNP	advmod||haemoglobin-21/JJ||glycated-20/RB	amod||7.0-28/NNS||haemoglobin-21/JJ	dep||haemoglobin-21/JJ||hba1c-23/CD	amod||7.0-28/NNS||â-25/JJ	amod||7.0-28/NNS||-26/JJ	nn||7.0-28/NNS||¥-27/NN	prep_with||patients-14/NNS||7.0-28/NNS	number||9.0-31/CD||<-30/CD	num||%-32/NN||9.0-31/CD	prep_with||patients-14/NNS||%-32/NN	conj_and||7.0-28/NNS||%-32/NN	num||53-37/CD||â-34/CD	num||53-37/CD||-35/CD	num||53-37/CD||¥-36/CD	npadvmod||mmol/mol-41/JJ||53-37/CD	num||75-40/CD||<-39/CD	conj_and||53-37/CD||75-40/CD	npadvmod||mmol/mol-41/JJ||75-40/CD	dep||%-32/NN||mmol/mol-41/JJ	vmod||%-32/NN||-RSB--43/VBN	prep_on||-RSB--43/VBN||metformin-45/NN	dep||%-32/NN||â-47/VBN	xcomp||â-47/VBN||-48/VBG	num||1000-50/CD||¥-49/CD	dobj||-48/VBG||1000-50/CD	advmod||-48/VBG||mg/day-51/RB	rcmod||parallel-group-7/NN||treated-53/VBN	prep_with||treated-53/VBN||subcutaneous-55/NNS	amod||subcutaneous-55/NNS||lixisenatide-56/JJ	dep||of-58/IN||doses-57/NN	advmod||lixisenatide-56/JJ||of-58/IN	dep||lixisenatide-56/JJ||5-59/CD	num||5-59/CD||10-61/CD	num||5-59/CD||20-63/CD	dep||lixisenatide-56/JJ||30-65/CD	conj_or||5-59/CD||30-65/CD	root||ROOT-0/null||î-66/VBP	number||g-68/CD||1/4-67/CD	dobj||î-66/VBP||g-68/CD	advmod||daily-70/JJ||once-69/RB	advmod||î-66/VBP||daily-70/JJ	advmod||daily-73/JJ||twice-72/RB	advmod||î-66/VBP||daily-73/JJ	conj_or||daily-70/JJ||daily-73/JJ	conj_or||î-66/VBP||placebo-75/VBZ	type2diabetes-16||metformin-45||yes||randomized, double-blind, placebo-controlled, parallel-group, 13 week study of 542 patients with type2diabetes inadequately controlled [glycated haemoglobin (hba1c) â¥ 7.0 and < 9.0% (â¥ 53 and < 75 mmol/mol)] on metformin (â¥ 1000 mg/day) treated with subcutaneous lixisenatide doses of 5, 10, 20 or 30 î¼g once daily or twice daily or placebo.
amod||rats-5/NNS||goto-kakizaki-1/JJ	appos||rats-5/NNS||gk-3/NN	nsubj||model-9/NN||rats-5/NNS	cop||model-9/NN||are-6/VBP	det||model-9/NN||a-7/DT	amod||model-9/NN||polygenic-8/JJ	root||ROOT-0/null||model-9/NN	amod||bloodglucose-12/NN||elevated-11/JJ	prep_with||model-9/NN||bloodglucose-12/NN	amod||insulinresistance-15/NN||peripheral-14/JJ	prep_with||model-9/NN||insulinresistance-15/NN	conj_and||bloodglucose-12/NN||insulinresistance-15/NN	det||phenotype-19/NN||a-17/DT	amod||phenotype-19/NN||non-obese-18/JJ	prep_with||model-9/NN||phenotype-19/NN	conj_and||bloodglucose-12/NN||phenotype-19/NN	prep_with||model-9/NN||exhibit-22/NN	conj_and||bloodglucose-12/NN||exhibit-22/NN	amod||changes-25/NNS||many-23/JJ	nn||changes-25/NNS||degenerative-24/NN	nsubj||observed-26/VBD||changes-25/NNS	rcmod||model-9/NN||observed-26/VBD	amod||t2dm-29/NNS||human-28/JJ	prep_in||observed-26/VBD||t2dm-29/NNS	glucose--1||obese--1||no_rel||goto-kakizaki (gk) rats are a polygenic model with elevated bloodglucose, peripheral insulinresistance, a non-obese phenotype, and exhibit many degenerative changes observed in human t2dm.
det||warfarin-4/NN||the-1/DT	amod||warfarin-4/NN||anticoagulant-2/JJ	nn||warfarin-4/NN||drug-3/NN	nsubjpass||prescribed-7/VBN||warfarin-4/NN	auxpass||prescribed-7/VBN||is-5/VBZ	advmod||prescribed-7/VBN||widely-6/RB	root||ROOT-0/null||prescribed-7/VBN	prepc_for||prescribed-7/VBN||reducing-9/VBG	det||risk-11/NN||the-10/DT	dobj||reducing-9/VBG||risk-11/NN	prep_of||risk-11/NN||stroke-13/NN	prep_of||risk-11/NN||thrombosis-15/NNS	conj_and||stroke-13/NN||thrombosis-15/NNS	prep_of||risk-11/NN||pulmonaryembolism-17/NN	conj_and||stroke-13/NN||pulmonaryembolism-17/NN	amod||malfunction-21/NN||coronary-20/JJ	prep_of||risk-11/NN||malfunction-21/NN	conj_and||stroke-13/NN||malfunction-21/NN	stroke-13||warfarin-4||yes||the anticoagulant drug warfarin is widely prescribed for reducing the risk of stroke, thrombosis, pulmonaryembolism, and coronary malfunction.
nsubj||introduced-2/VBD||we-1/PRP	root||ROOT-0/null||introduced-2/VBD	amod||opioids-4/NNS||strong-3/JJ	nsubj||tolerable-26/JJ||opioids-4/NNS	amod||patches-8/NNS||transdermal-6/JJ	amod||patches-8/NNS||fentanyl-7/JJ	dep||opioids-4/NNS||patches-8/NNS	det||pain-12/NN||the-10/DT	nn||pain-12/NN||background-11/NN	prep_for||patches-8/NNS||pain-12/NN	det||opioid-16/NN||a-14/DT	amod||opioid-16/NN||short-acting-15/JJ	dep||opioids-4/NNS||opioid-16/NN	conj_and||patches-8/NNS||opioid-16/NN	det||pain-20/NN||the-18/DT	nn||pain-20/NN||breakthrough-19/NN	prep_for||opioid-16/NN||pain-20/NN	poss||pain-24/NN||his-23/PRP$	conj_and||opioids-4/NNS||pain-24/NN	nsubj||tolerable-26/JJ||pain-24/NN	cop||tolerable-26/JJ||was-25/VBD	ccomp||introduced-2/VBD||tolerable-26/JJ	num||hr-31/NN||250-28/CD	nn||hr-31/NN||âµg-29/NN	nn||hr-31/NN||/-30/NN	prep_on||tolerable-26/JJ||hr-31/NN	amod||patches-34/NNS||fentanyl-33/JJ	prep_of||hr-31/NN||patches-34/NNS	num||months-37/NNS||3-36/CD	prep_for||tolerable-26/JJ||months-37/NNS	pain-24||fentanyl-33||yes||we introduced strong opioids (transdermal fentanyl patches for the background pain and a short-acting opioid for the breakthrough pain) and his pain was tolerable on 250 âµg/hr of fentanyl patches for 3 months.
nsubjpass||known-8/VBN||resistance-1/NN	nsubjpass||associated-11/VBN||resistance-1/NN	prep_to||resistance-1/NN||chloroquine-3/NN	nn||strains-6/NNS||malaria-5/NN	prep_of||chloroquine-3/NN||strains-6/NNS	auxpass||known-8/VBN||is-7/VBZ	root||ROOT-0/null||known-8/VBN	aux||associated-11/VBN||to-9/TO	auxpass||associated-11/VBN||be-10/VB	xcomp||known-8/VBN||associated-11/VBN	det||protein-15/NN||a-13/DT	nn||protein-15/NN||parasite-14/NN	prep_with||associated-11/VBN||protein-15/NN	vmod||protein-15/NN||named-16/VBN	dobj||named-16/VBN||pfcrt-17/NN	det||form-21/NN||the-19/DT	amod||form-21/NN||mutated-20/JJ	appos||pfcrt-17/NN||form-21/NN	nsubj||able-25/JJ||which-23/WDT	nsubj||reduce-27/VB||which-23/WDT	cop||able-25/JJ||is-24/VBZ	prepc_of||form-21/NN||able-25/JJ	aux||reduce-27/VB||to-26/TO	xcomp||able-25/JJ||reduce-27/VB	amod||accumulation-29/NN||chloroquine-28/JJ	dobj||reduce-27/VB||accumulation-29/NN	det||vacuole-33/NN||the-31/DT	amod||vacuole-33/NN||digestive-32/JJ	prep_in||reduce-27/VB||vacuole-33/NN	det||pathogen-36/NN||the-35/DT	prep_of||vacuole-33/NN||pathogen-36/NN	malaria-5||chloroquine-28||yes||resistance to chloroquine of malaria strains is known to be associated with a parasite protein named pfcrt, the mutated form of which is able to reduce chloroquine accumulation in the digestive vacuole of the pathogen.
det||introduction-2/NN||the-1/DT	nsubj||step-9/NN||introduction-2/NN	amod||antipsychotics-5/NNS||atypical-4/JJ	prep_of||introduction-2/NN||antipsychotics-5/NNS	cop||step-9/NN||was-6/VBD	det||step-9/NN||a-7/DT	amod||step-9/NN||big-8/JJ	root||ROOT-0/null||step-9/NN	advmod||step-9/NN||forward-10/RB	det||treatment-13/NN||the-12/DT	prep_in||step-9/NN||treatment-13/NN	nn||psychoses-18/NNS||schizophrenia-15/NN	conj_and||schizophrenia-15/NN||other-17/JJ	nn||psychoses-18/NNS||other-17/JJ	prep_of||treatment-13/NN||psychoses-18/NNS	antipsychotics-5||psychoses-18||no_rel||the introduction of atypical antipsychotics was a big step forward in the treatment of schizophrenia and other psychoses.
mark||immunization-3/NN||upon-1/IN	nn||immunization-3/NN||rabbit-2/NN	advcl||elicited-8/VBD||immunization-3/NN	det||proteins-7/NNS||both-5/DT	nn||proteins-7/NNS||ha-6/NN	nsubj||elicited-8/VBD||proteins-7/NNS	root||ROOT-0/null||elicited-8/VBD	amod||antibodies-10/NNS||neutralizing-9/VBG	dobj||elicited-8/VBD||antibodies-10/NNS	det||virus-14/NN||the-12/DT	amod||virus-14/NN||homologous-13/JJ	prep_against||antibodies-10/NNS||virus-14/NN	dep||virus-14/NN||a/vietnam/1203-16/NNP	punct||a/vietnam/1203-16/NNP||/-17/:	dep||a/vietnam/1203-16/NNP||2004-18/CD	appos||2004-18/CD||clade-20/NN	num||clade-20/NN||1-21/CD	amod||antibodies-27/NNS||cross-neutralizing-26/JJ	dobj||elicited-8/VBD||antibodies-27/NNS	conj_and||antibodies-10/NNS||antibodies-27/NNS	amod||h5n1-30/NNS||heterologous-29/JJ	prep_against||antibodies-27/NNS||h5n1-30/NNS	amod||h5n1-30/NNS||clade-31/JJ	num||strains-33/NNS||2-32/CD	dep||clade-31/JJ||strains-33/NNS	amod||/-37/NNP||a/indonesia/5-36/JJ	prep_including||h5n1-30/NNS||/-37/NNP	num||/-37/NNP||2005-38/CD	cross--1||antibodies-27||no_rel||upon rabbit immunization, both ha proteins elicited neutralizing antibodies against the homologous virus (a/vietnam/1203/2004, clade 1) as well as cross-neutralizing antibodies against heterologous h5n1 clade 2 strains, including a/indonesia/5/2005.
amod||drugs-2/NNS||anti-epileptic-1/JJ	nsubjpass||prescribed-8/VBN||drugs-2/NNS	appos||drugs-2/NNS||aeds-4/NNS	auxpass||prescribed-8/VBN||are-6/VBP	advmod||prescribed-8/VBN||frequently-7/RB	root||ROOT-0/null||prescribed-8/VBN	prep_to||prescribed-8/VBN||persons-10/NNS	prep_with||prescribed-8/VBN||hiv/aids-12/NNS	vmod||hiv/aids-12/NNS||receiving-13/VBG	nn||therapy-16/NN||combination-14/NN	amod||therapy-16/NN||antiretroviral-15/JJ	dobj||receiving-13/VBG||therapy-16/NN	appos||therapy-16/NN||cart-18/NN	mark||uncertain-32/JJ||although-20/IN	det||extent-22/NN||the-21/DT	nsubj||uncertain-32/JJ||extent-22/NN	nn||use-25/NN||aed-24/NN	prep_of||extent-22/NN||use-25/NN	poss||interactions-28/NNS||their-27/PRP$	conj_and||extent-22/NN||interactions-28/NNS	nsubj||uncertain-32/JJ||interactions-28/NNS	prep_with||interactions-28/NNS||cart-30/NN	cop||uncertain-32/JJ||are-31/VBP	dep||therapy-16/NN||uncertain-32/JJ	aids--1||hiv--1||no||anti-epileptic drugs (aeds) are frequently prescribed to persons with hiv/aids receiving combination antiretroviral therapy (cart) although the extent of aed use and their interactions with cart are uncertain.
nsubj||provide-3/VB||it-1/PRP	aux||provide-3/VB||could-2/MD	root||ROOT-0/null||provide-3/VB	det||alternative-10/NN||a-4/DT	advmod||efficient-6/JJ||more-5/RBR	amod||alternative-10/NN||efficient-6/JJ	advmod||painful-9/JJ||less-8/RBR	conj_and||efficient-6/JJ||painful-9/JJ	amod||alternative-10/NN||painful-9/JJ	dobj||provide-3/VB||alternative-10/NN	advmod||tests-16/NNS||traditionally-12/RB	amod||tests-16/NNS||used-13/JJ	nn||tests-16/NNS||skin-14/NN	nn||tests-16/NNS||prick-15/NN	prep_to||provide-3/VB||tests-16/NNS	vmod||provide-3/VB||making-18/VBG	nsubj||compare-23/VB||it-19/PRP	nsubj||monitor-30/VB||it-19/PRP	nsubj||facilitate-37/VB||it-19/PRP	advmod||feasible-21/JJ||economically-20/RB	dep||compare-23/VB||feasible-21/JJ	aux||compare-23/VB||to-22/TO	xcomp||making-18/VBG||compare-23/VB	nn||sensitivity-25/NN||allergen-24/NN	dobj||compare-23/VB||sensitivity-25/NN	amod||populations-28/NNS||different-27/JJ	prep_of||sensitivity-25/NN||populations-28/NNS	xcomp||making-18/VBG||monitor-30/VB	conj_and||compare-23/VB||monitor-30/VB	amod||responses-32/NNS||individual-31/JJ	dobj||monitor-30/VB||responses-32/NNS	prep_over||monitor-30/VB||time-34/NN	xcomp||making-18/VBG||facilitate-37/VB	conj_and||compare-23/VB||facilitate-37/VB	amod||studies-39/NNS||genetic-38/JJ	dobj||facilitate-37/VB||studies-39/NNS	prep_on||facilitate-37/VB||pollenallergy-41/NN	allergen-24||painful-9||no_rel||it could provide a more efficient and less painful alternative to traditionally used skin prick tests, making it economically feasible to compare allergen sensitivity of different populations, monitor individual responses over time, and facilitate genetic studies on pollenallergy.
nsubj||antipsychotic-5/NN||olanzapine-1/NN	cop||antipsychotic-5/NN||is-2/VBZ	det||antipsychotic-5/NN||an-3/DT	amod||antipsychotic-5/NN||atypical-4/JJ	root||ROOT-0/null||antipsychotic-5/NN	advmod||antipsychotic-5/NN||currently-6/RB	prep_with||antipsychotic-5/NN||indications-8/NNS	det||treatment-11/NN||the-10/DT	prep_for||indications-8/NNS||treatment-11/NN	prep_of||treatment-11/NN||schizophrenia-13/NN	amod||mania-16/NN||acute-15/JJ	prep_of||treatment-11/NN||mania-16/NN	conj_and||schizophrenia-13/NN||mania-16/NN	det||prevention-19/NN||the-18/DT	prep_of||treatment-11/NN||prevention-19/NN	conj_and||schizophrenia-13/NN||prevention-19/NN	prep_of||prevention-19/NN||relapse-21/NN	prep_in||antipsychotic-5/NN||bipolardisorder-23/NN	schizophrenia-13||olanzapine-1||yes||olanzapine is an atypical antipsychotic currently with indications for the treatment of schizophrenia, acute mania and the prevention of relapse in bipolardisorder.
nsubj||affects-5/VBZ||denguevirus-1/NNS	appos||denguevirus-1/NNS||denv-3/NNP	root||ROOT-0/null||affects-5/VBZ	quantmod||half-7/PDT||over-6/IN	num||population-13/NN||half-7/PDT	det||population-13/NN||the-8/DT	amod||population-13/NN||worldâ-9/JJ	amod||population-13/NN||$-10/$	number||s-12/CD||-11/CD	num||$-10/$||s-12/CD	dobj||affects-5/VBZ||population-13/NN	num||countries-16/NNS||112-15/CD	prep_in||affects-5/VBZ||countries-16/NNS	nsubj||arthropod-27/NN||denguefever-19/NN	appos||denguefever-19/NN||df-21/NN	cop||arthropod-27/NN||is-23/VBZ	det||arthropod-27/NN||the-24/DT	amod||arthropod-27/NN||second-25/JJ	dep||second-25/JJ||largest-26/JJS	conj_and||affects-5/VBZ||arthropod-27/NN	vmod||arthropod-27/NN||borne-28/VBN	amod||hazard-31/NN||infectious-29/JJ	amod||hazard-31/NN||global-30/JJ	dobj||borne-28/VBN||hazard-31/NN	prep_after||borne-28/VBN||malaria-33/NN	prep_with||borne-28/VBN||complications-35/NNS	prep_like||complications-35/NNS||denguehemorrhagicfever-37/NN	appos||denguehemorrhagicfever-37/NN||dhf-39/NN	prep_like||complications-35/NNS||dengueshocksyndrome-42/NN	conj_and||denguehemorrhagicfever-37/NN||dengueshocksyndrome-42/NN	appos||denguehemorrhagicfever-37/NN||dss-44/NN	prep||borne-28/VBN||accounting-47/VBG	pcomp||accounting-47/VBG||for-48/IN	amod||morbidity-50/NN||significant-49/JJ	pobj||for-48/IN||morbidity-50/NN	nn||world-over-53/NN||mortality-52/NN	pobj||for-48/IN||world-over-53/NN	conj_and||morbidity-50/NN||world-over-53/NN	denguehemorrhagicfever-37||denguevirus-1||no||denguevirus (denv) affects over half the worldâs population in 112 countries, and denguefever (df) is the second largest arthropod borne infectious global hazard after malaria with complications like denguehemorrhagicfever (dhf) and dengueshocksyndrome (dss), accounting for significant morbidity and mortality world-over.
det||domain-3/NN||the-1/DT	amod||domain-3/NN||outer-2/JJ	nsubj||represents-14/VBZ||domain-3/NN	appos||domain-3/NN||od-5/NN	prep_of||domain-3/NN||humanimmunodeficiencyvirus-8/NNS	dep||domain-3/NN||hiv-10/VBN	num||gp120-13/NNS||-1-12/CD	dep||domain-3/NN||gp120-13/NNS	root||ROOT-0/null||represents-14/VBZ	det||target-21/NN||an-15/DT	amod||difficult-19/JJ||attractive-16/JJ	dep||difficult-19/JJ||if-18/IN	amod||target-21/NN||difficult-19/JJ	dobj||represents-14/VBZ||target-21/NN	det||response-26/NN||a-23/DT	amod||response-26/NN||beneficial-24/JJ	amod||response-26/NN||immune-25/JJ	prep_for||target-21/NN||response-26/NN	prep_to||represents-14/VBZ||hivinfection-28/NN	hivinfection-28||humanimmunodeficiencyvirus-8||no||the outer domain (od) of humanimmunodeficiencyvirus (hiv)-1 gp120 represents an attractive, if difficult, target for a beneficial immune response to hivinfection.
amod||outcome-2/NN||main-1/JJ	nsubj||measures-3/VBZ||outcome-2/NN	root||ROOT-0/null||measures-3/VBZ	dobj||measures-3/VBZ||risk-4/NN	amod||variable-36/NN||coronaryheartdisease-6/JJ	prep||coronaryheartdisease-6/JJ||in-7/IN	dep||in-7/IN||treated-8/VBN	dep||in-7/IN||â-10/VBN	conj_and||treated-8/VBN||â-10/VBN	amod||patients-21/NNS||$-11/$	number||$-13/CD||untreatedâ-12/CD	num||$-11/$||$-13/CD	dep||$-11/$||delay-15/NN	amod||treatment-19/NN||starting-17/JJ	nn||treatment-19/NN||statin-18/NN	prep_in||delay-15/NN||treatment-19/NN	dobj||treated-8/VBN||patients-21/NNS	prepc_compared_with||treated-8/VBN||with-23/IN	det||model-27/NN||a-24/DT	nn||model-27/NN||cox-25/NN	nn||model-27/NN||regression-26/NN	pobj||treated-8/VBN||model-27/NN	prep_in||time-34/NN||model-27/NN	nn||use-31/NN||statin-30/NN	nsubj||time-34/NN||use-31/NN	cop||time-34/NN||was-32/VBD	det||time-34/NN||a-33/DT	rcmod||model-27/NN||time-34/NN	amod||variable-36/NN||dependent-35/JJ	prep_of||risk-4/NN||variable-36/NN	statin-30||coronaryheartdisease-6||no_rel||main outcome measures risk of coronaryheartdisease in treated and âuntreatedâ? (delay in starting statin treatment) patients compared with a cox regression model in which statin use was a time dependent variable.
prep_in||correlated-8/VBN||addition-2/NN	amod||concentration-5/NN||formate-4/JJ	nsubjpass||correlated-8/VBN||concentration-5/NN	nsubjpass||correlated-38/VBN||concentration-5/NN	auxpass||correlated-8/VBN||was-6/VBD	advmod||correlated-8/VBN||negatively-7/RB	root||ROOT-0/null||correlated-8/VBN	amod||pc20-11/NNS||methacholine-10/JJ	prep_with||correlated-8/VBN||pc20-11/NNS	num||0.39-21/NNS||râ-13/CD	amod||0.39-21/NNS||$-14/$	number||=-16/CD||-15/CD	num||$-14/$||=-16/CD	amod||0.39-21/NNS||â-17/JJ	amod||0.39-21/NNS||$-18/$	dep||$-18/$||â-19/JJ	nsubj||asthmatics-32/VBZ||0.39-21/NNS	nn||â-27/NN||pâ-23/NN	amod||â-27/NN||$-24/$	dep||$-24/$||-25/JJ	nn||â-27/NN||=-26/NNP	appos||0.39-21/NNS||â-27/NN	dep||â-27/NN||$-28/$	num||$-28/$||0-29/CD	num||$-28/$||.002-30/CD	dep||pc20-11/NNS||asthmatics-32/VBZ	advmod||asthmatics-32/VBZ||only-33/RB	advmod||correlated-38/VBN||positively-37/RB	conj_and||correlated-8/VBN||correlated-38/VBN	det||nitrite-43/NN||the-40/DT	amod||nitrite-43/NN||no-derived-41/JJ	nn||nitrite-43/NN||ion-42/NN	prep_with||correlated-38/VBN||nitrite-43/NN	dep||nitrite-43/NN||râ-45/VBN	dobj||râ-45/VBN||$-46/$	number||=-48/CD||-47/CD	num||$-46/$||=-48/CD	dep||râ-45/VBN||â-49/VB	dobj||â-49/VB||$-50/$	number||.46-52/CD||0-51/CD	num||$-50/$||.46-52/CD	appos||$-50/$||p-54/NN	number||0.0001-56/CD||<-55/CD	dep||p-54/NN||0.0001-56/CD	amod||ige-64/NN||total-62/JJ	nn||ige-64/NN||serum-63/NN	prep_with||correlated-38/VBN||ige-64/NN	conj_and||nitrite-43/NN||ige-64/NN	dep||ige-64/NN||râ-66/VBN	num||â-70/NN||$-67/$	number||=-69/CD||-68/CD	num||$-67/$||=-69/CD	dobj||râ-66/VBN||â-70/NN	nsubj||asthmatics-84/VBZ||$-71/$	num||$-71/$||0-72/CD	num||$-71/$||.28-73/CD	nn||â-79/NN||pâ-75/NN	amod||â-79/NN||$-76/$	dep||$-76/$||-77/JJ	nn||â-79/NN||=-78/NNP	appos||$-71/$||â-79/NN	dep||â-79/NN||$-80/$	num||$-80/$||0-81/CD	num||$-80/$||.016-82/CD	rcmod||â-70/NN||asthmatics-84/VBZ	advmod||asthmatics-84/VBZ||only-85/RB	asthmatics-84||nitrite-43||no_rel||in addition, formate concentration was negatively correlated with methacholine pc20 (râ=ââ0.39, pâ=â0.002, asthmatics only), and positively correlated with the no-derived ion nitrite (râ=â0.46, p<0.0001) as well as with total serum ige (râ=â0.28, pâ=â0.016, asthmatics only).
nsubj||drug-4/NN||disulfiram-1/NN	cop||drug-4/NN||is-2/VBZ	det||drug-4/NN||the-3/DT	root||ROOT-0/null||drug-4/NN	nsubjpass||prescribed-8/VBN||drug-4/NN	auxpass||prescribed-8/VBN||is-6/VBZ	advmod||prescribed-8/VBN||commonly-7/RB	rcmod||drug-4/NN||prescribed-8/VBN	det||treatment-11/NN||the-10/DT	prep_for||prescribed-8/VBN||treatment-11/NN	prep_of||treatment-11/NN||alcoholdependencesyndrome-13/NN	amod||psychosis-18/NNS||transient-16/JJ	nn||psychosis-18/NNS||functional-17/NN	nsubjpass||reported-21/VBN||psychosis-18/NNS	aux||reported-21/VBN||has-19/VBZ	auxpass||reported-21/VBN||been-20/VBN	conj_and||drug-4/NN||reported-21/VBN	nsubjpass||prescribed-8/VBN||reported-21/VBN	prep_as||reported-21/VBN||one-23/CD	poss||side-effects-26/NNS||its-25/PRP$	prep_of||one-23/CD||side-effects-26/NNS	psychosis-18||disulfiram-1||no||disulfiram is the drug that is commonly prescribed for the treatment of alcoholdependencesyndrome, and transient functional psychosis has been reported as one of its side-effects.
nsubj||enrolled-27/VBD||objective-1/NN	aux||improve-3/VB||to-2/TO	vmod||objective-1/NN||improve-3/VB	nn||treatment-5/NN||hiv-4/NN	dobj||improve-3/VB||treatment-5/NN	prep_in||treatment-5/NN||china-7/NN	prepc_by||improve-3/VB||determining-9/VBG	dobj||determining-9/VBG||changes-10/NNS	prep_over||determining-9/VBG||time-12/NN	amod||characteristics-15/NNS||patient-14/JJ	prep_of||time-12/NN||characteristics-15/NNS	dep||objective-1/NN||geographic-17/JJ	dep||objective-1/NN||clinical-19/JJ	conj_and||geographic-17/JJ||clinical-19/JJ	dep||objective-1/NN||route-21/NN	conj_and||geographic-17/JJ||route-21/NN	prep_of||route-21/NN||hivinfection-23/NN	prep_among||objective-1/NN||patients-26/NNS	root||ROOT-0/null||enrolled-27/VBD	det||program-35/NN||the-29/DT	nn||program-35/NN||china-30/NNP	amod||program-35/NN||national-31/JJ	amod||program-35/NN||free-32/JJ	nn||program-35/NN||antiretroviral-33/NN	nn||program-35/NN||treatment-34/NN	prep_in||enrolled-27/VBD||program-35/NN	hivinfection-23||hiv-4||no||objective to improve hiv treatment in china by determining changes over time of patient characteristics (geographic, clinical and route of hivinfection) among patients enrolled in the china national free antiretroviral treatment program.
nsubjpass||assumed-12/VBN||sorption-1/NN	nsubj||negligible-15/JJ||sorption-1/NN	nsubj||higher-26/JJR||sorption-1/NN	prep_of||sorption-1/NN||venlafaxine-3/NN	prep_of||sorption-1/NN||desmethylvenlafaxine-5/NN	conj_and||venlafaxine-3/NN||desmethylvenlafaxine-5/NN	prep_of||sorption-1/NN||carbamazepine-8/NN	conj_and||venlafaxine-3/NN||carbamazepine-8/NN	prep_on||venlafaxine-3/NN||sludge-10/NN	auxpass||assumed-12/VBN||was-11/VBD	root||ROOT-0/null||assumed-12/VBN	aux||negligible-15/JJ||to-13/TO	cop||negligible-15/JJ||be-14/VB	xcomp||assumed-12/VBN||negligible-15/JJ	dep||negligible-15/JJ||log-17/VB	nn||-20/NNS||kd-18/NN	nn||-20/NNS||â-19/NN	dobj||log-17/VB||-20/NNS	amod||-20/NNS||$-21/$	number||$-21/$||2-22/CD	xcomp||assumed-12/VBN||higher-26/JJR	conj_but||negligible-15/JJ||higher-26/JJR	nn||behavior-28/NN||sorption-27/NN	nsubjpass||expected-31/VBN||behavior-28/NN	aux||expected-31/VBN||can-29/MD	auxpass||expected-31/VBN||be-30/VB	ccomp||higher-26/JJR||expected-31/VBN	prep_for||expected-31/VBN||sertraline-33/NN	dep||negligible-15/JJ||log-35/VB	nn||â-37/NN||kd-36/NN	dobj||log-35/VB||â-37/NN	vmod||â-37/NN||-38/VBG	number||4-40/CD||¥-39/CD	dobj||-38/VBG||4-40/CD	kd-36||venlafaxine-3||no_rel||sorption of venlafaxine, desmethylvenlafaxine, and carbamazepine on sludge was assumed to be negligible (log kd â¤ 2), but higher sorption behavior can be expected for sertraline (log kd â¥ 4).
amod||evidence-2/NN||recent-1/JJ	nsubj||demonstrated-4/VBN||evidence-2/NN	aux||demonstrated-4/VBN||has-3/VBZ	root||ROOT-0/null||demonstrated-4/VBN	mark||becoming-9/VBG||that-5/IN	nn||mites-7/NNS||scabies-6/NNS	nsubj||becoming-9/VBG||mites-7/NNS	aux||becoming-9/VBG||are-8/VBP	ccomp||demonstrated-4/VBN||becoming-9/VBG	advmod||tolerant-11/JJ||increasingly-10/RB	acomp||becoming-9/VBG||tolerant-11/JJ	amod||permethrin-14/NN||topical-13/JJ	prep_to||tolerant-11/JJ||permethrin-14/NN	amod||ivermectin-17/NN||oral-16/JJ	prep_to||tolerant-11/JJ||ivermectin-17/NN	conj_and||permethrin-14/NN||ivermectin-17/NN	scabies-6||ivermectin-17||yes||recent evidence has demonstrated that scabies mites are becoming increasingly tolerant to topical permethrin and oral ivermectin.
num||mssa-2/NN||46-1/CD	nsubjpass||misidentified-6/VBN||mssa-2/NN	vmod||mssa-2/NN||containing-3/VBG	dobj||containing-3/VBG||samples-4/NNS	auxpass||misidentified-6/VBN||were-5/VBD	root||ROOT-0/null||misidentified-6/VBN	prep_as||misidentified-6/VBN||mrsa-8/NN	prep_as||misidentified-6/VBN||9-10/CD	conj_and||mrsa-8/NN||9-10/CD	amod||-rrb--34/NNS||other-12/JJ	prep_than||other-12/JJ||s.aureus-14/NNS	vmod||s.aureus-14/NNS||ending-15/VBG	amod||positive-18/JJ||low-17/JJ	amod||-rrb--25/NNS||positive-18/JJ	amod||-rrb--25/NNS||predicted-19/JJ	nn||-rrb--25/NNS||value-20/NN	nn||-rrb--25/NNS||-lrb--21/NNP	nn||-rrb--25/NNS||<-22/NNP	number||%-24/NN||85-23/CD	amod||-rrb--25/NNS||%-24/NN	prep_with||ending-15/VBG||-rrb--25/NNS	advmod||low-28/JJ||very-27/RB	amod||-lrb--30/NNS||low-28/JJ	nn||-lrb--30/NNS||specificity-29/NN	prep_with||ending-15/VBG||-lrb--30/NNS	conj_and||-rrb--25/NNS||-lrb--30/NNS	vmod||ending-15/VBG||<-31/VBG	num||%-33/NN||62-32/CD	dobj||<-31/VBG||%-33/NN	prep_as||misidentified-6/VBN||-rrb--34/NNS	mrsa-8||s.aureus-14||no||46 mssa containing samples were misidentified as mrsa and 9 as other than s.aureus ending with low positive predicted value -lrb- < 85 % -rrb- and very low specificity -lrb- < 62 % -rrb- .
nsubj||describe-2/VBP||we-1/PRP	root||ROOT-0/null||describe-2/VBP	advmod||describe-2/VBP||here-3/RB	det||patient-5/NN||a-4/DT	dobj||describe-2/VBP||patient-5/NN	nsubj||obtained-7/VBD||patient-5/NN	rcmod||patient-5/NN||obtained-7/VBD	det||effect-11/NN||a-8/DT	amod||effect-11/NN||good-9/JJ	amod||effect-11/NN||analgesic-10/JJ	dobj||obtained-7/VBD||effect-11/NN	amod||patches-15/NNS||high-dose-13/JJ	amod||patches-15/NNS||fentanyl-14/JJ	prep_with||obtained-7/VBD||patches-15/NNS	amod||pain-19/NN||controlling-17/JJ	nn||pain-19/NN||cancer-18/NN	prep_for||obtained-7/VBD||pain-19/NN	pain-19||fentanyl-14||yes||we describe here a patient who obtained a good analgesic effect with high-dose fentanyl patches for controlling cancer pain.
amod||subjects-2/NNS||eighty-three-1/JJ	nsubjpass||enrolled-15/VBN||subjects-2/NNS	nsubjpass||received-17/VBN||subjects-2/NNS	dep||subjects-2/NNS||mean-4/VB	nsubj||10.78-10/NNS||age-5/NN	dep||10.78-10/NNS||=-6/SYM	num||10.78-10/NNS||57.87-7/CD	nn||10.78-10/NNS||â-8/NN	nn||10.78-10/NNS||±-9/NN	ccomp||mean-4/VB||10.78-10/NNS	prep_with||subjects-2/NNS||type2diabetesmellitus-13/CD	auxpass||enrolled-15/VBN||were-14/VBD	root||ROOT-0/null||enrolled-15/VBN	conj_and||enrolled-15/VBN||received-17/VBN	advmod||dose-20/NN||daily-18/RB	num||dose-20/NN||one-19/CD	dobj||enrolled-15/VBN||dose-20/NN	prep_of||dose-20/NN||rosiglitazone-22/NN	number||mg-25/CD||4-24/CD	dep||rosiglitazone-22/NN||mg-25/CD	prep_of||dose-20/NN||pioglitazone-28/NN	conj_or||rosiglitazone-22/NN||pioglitazone-28/NN	number||mg-31/CD||15-30/CD	dep||rosiglitazone-22/NN||mg-31/CD	type2diabetesmellitus-13||rosiglitazone-22||yes||eighty-three subjects (mean age = 57.87 â± 10.78) with type2diabetesmellitus were enrolled and received daily one dose of rosiglitazone (4 mg) or pioglitazone (15 mg).
nsubj||resulted-6/VBD||deletion-1/NN	nsubj||grow-14/VB||deletion-1/NN	det||gene-5/NN||the-3/DT	amod||gene-5/NN||sap-4/JJ	prep_of||deletion-1/NN||gene-5/NN	root||ROOT-0/null||resulted-6/VBD	det||capacity-10/NN||a-8/DT	amod||capacity-10/NN||reduced-9/JJ	prep_in||resulted-6/VBD||capacity-10/NN	prep_of||capacity-10/NN||bacteria-12/NNS	aux||grow-14/VB||to-13/TO	xcomp||resulted-6/VBD||grow-14/VB	prep_in||grow-14/VB||medium-16/NN	vmod||medium-16/NN||containing-17/VBG	dobj||containing-17/VBG||pullulan-18/NN	dobj||containing-17/VBG||glycogen-20/NN	conj_or||pullulan-18/NN||glycogen-20/NN	neg||glucose-24/NN||not-23/RB	nsubj||glucans-41/VBZ||glucose-24/NN	conj_or||glucose-24/NN||maltose-26/NN	nsubj||glucans-41/VBZ||maltose-26/NN	vmod||glucans-41/VBZ||confirming-28/VBG	det||role-31/NN||the-29/DT	amod||role-31/NN||pivotal-30/JJ	dobj||confirming-28/VBG||role-31/NN	prep_of||role-31/NN||sap-33/NNP	nn||metabolism-36/NN||gbs-35/NN	prep_in||confirming-28/VBG||metabolism-36/NN	nn||±-39/NNS||î-38/NN	prep_of||metabolism-36/NN||±-39/NNS	conj_but||resulted-6/VBD||glucans-41/VBZ	gbs-35||glucose-24||no_rel||deletion of the sap gene resulted in a reduced capacity of bacteria to grow in medium containing pullulan or glycogen, but not glucose or maltose, confirming the pivotal role of sap in gbs metabolism of î±-glucans.
mark||indicated-8/VBN||while-1/IN	nn||studies-6/NNS||human-2/NN	conj_and||human-2/NN||animal-4/NN	nn||studies-6/NNS||animal-4/NN	nn||studies-6/NNS||model-5/NN	nsubj||indicated-8/VBN||studies-6/NNS	aux||indicated-8/VBN||have-7/VBP	advcl||shown-29/VBN||indicated-8/VBN	det||role-11/NN||a-9/DT	amod||role-11/NN||protective-10/JJ	dobj||indicated-8/VBN||role-11/NN	prep_for||role-11/NN||estrogen-13/NN	prep_against||indicated-8/VBN||cardiovasculardisease-15/NN	prep_against||indicated-8/VBN||glomerulosclerosis-17/NNS	conj_and||cardiovasculardisease-15/NN||glomerulosclerosis-17/NNS	amod||studies-20/NNS||clinical-19/JJ	nsubj||shown-29/VBN||studies-20/NNS	nn||therapy-24/NN||hormone-22/NN	nn||therapy-24/NN||replacement-23/NN	prep_of||studies-20/NNS||therapy-24/NN	amod||women-27/NNS||postmenopausal-26/JJ	prep_in||therapy-24/NN||women-27/NNS	aux||shown-29/VBN||have-28/VBP	root||ROOT-0/null||shown-29/VBN	amod||results-31/NNS||polar-30/JJ	dobj||shown-29/VBN||results-31/NNS	det||improvement-34/NN||some-33/DT	prep_with||shown-29/VBN||improvement-34/NN	prep_in||improvement-34/NN||hypertension-36/NN	prep_with||shown-29/VBN||worsening-38/VBG	conj_but||improvement-34/NN||worsening-38/VBG	amod||kidneydisease-41/NN||hypertensive-40/JJ	prep_of||worsening-38/VBG||kidneydisease-41/NN	neg||effect-45/NN||no-44/DT	prep_with||shown-29/VBN||effect-45/NN	conj_or||improvement-34/NN||effect-45/NN	prep_at||effect-45/NN||all-47/DT	hypertension-36||estrogen-13||no_rel||while human and animal model studies have indicated a protective role for estrogen against cardiovasculardisease and glomerulosclerosis, clinical studies of hormone replacement therapy in postmenopausal women have shown polar results with some improvement in hypertension but worsening of hypertensive kidneydisease, or no effect at all.
nn||design-2/NN||research-1/NN	nsubj||â-5/VBP||design-2/NN	conj_and||design-2/NN||methods-4/NNS	nsubj||â-5/VBP||methods-4/NNS	root||ROOT-0/null||â-5/VBP	dobj||â-5/VBP||$-6/$	nsubj||sample-12/NN||this-8/DT	cop||sample-12/NN||was-9/VBD	det||sample-12/NN||a-10/DT	amod||sample-12/NN||cross-sectional-11/JJ	rcmod||$-6/$||sample-12/NN	amod||individuals-15/NNS||281-14/JJ	prep_of||sample-12/NN||individuals-15/NNS	amod||metabolism-19/NN||normal-17/JJ	nn||metabolism-19/NN||glucose-18/NN	prep_with||individuals-15/NNS||metabolism-19/NN	discourse||metabolism-19/NN||ngm-21/UH	num||individuals-25/NNS||181-24/CD	dobj||â-5/VBP||individuals-25/NNS	conj_and||$-6/$||individuals-25/NNS	amod||metabolism-29/NN||impaired-27/VBN	nn||metabolism-29/NN||glucose-28/NN	prep_with||individuals-25/NNS||metabolism-29/NN	discourse||metabolism-29/NN||igm-31/UH	num||subjects-36/NNS||107-35/CD	dobj||â-5/VBP||subjects-36/NNS	conj_and||$-6/$||subjects-36/NNS	prep_with||subjects-36/NNS||type2diabetes-38/CD	type2diabetes-38||glucose-28||no_rel||research design and methods âthis was a cross-sectional sample of 281 individuals with normal glucose metabolism (ngm), 181 individuals with impaired glucose metabolism (igm), and 107 subjects with type2diabetes.
nsubj||agent-5/NN||mycobacteriumbovis-1/NNS	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||the-3/DT	amod||agent-5/NN||aetiological-4/JJ	root||ROOT-0/null||agent-5/NN	prep_of||agent-5/NN||bovinetuberculosis-7/NNS	appos||bovinetuberculosis-7/NNS||btb-9/NN	det||zoonosis-15/NNS||an-12/DT	amod||zoonosis-15/NNS||important-13/JJ	nn||zoonosis-15/NNS||recrudescent-14/NN	appos||bovinetuberculosis-7/NNS||zoonosis-15/NNS	advmod||increasing-18/VBG||significantly-17/RB	vmod||agent-5/NN||increasing-18/VBG	amod||herds-21/NNS||british-20/JJ	prep_in||increasing-18/VBG||herds-21/NNS	amod||years-24/NNS||recent-23/JJ	prep_in||herds-21/NNS||years-24/NNS	bovinetuberculosis-7||mycobacteriumbovis-1||no||mycobacteriumbovis is the aetiological agent of bovinetuberculosis (btb), an important recrudescent zoonosis, significantly increasing in british herds in recent years.
amod||lar-2/NN||octreotide-1/JJ	nsubj||lengthened-4/VBN||lar-2/NN	advmod||lengthened-4/VBN||significantly-3/RB	root||ROOT-0/null||lengthened-4/VBN	amod||time-6/NN||median-5/JJ	dobj||lengthened-4/VBN||time-6/NN	nn||progression-9/NN||tumor-8/NN	prep_to||lengthened-4/VBN||progression-9/NN	prepc_compared_with||lengthened-4/VBN||with-11/IN	pobj||lengthened-4/VBN||placebo-12/NN	prep_in||placebo-12/NN||patients-14/NNS	amod||tumors-18/NNS||metastatic-16/JJ	nn||tumors-18/NNS||neuroendocrine-17/NN	prep_with||patients-14/NNS||tumors-18/NNS	det||midgut-21/NN||the-20/DT	prep_of||tumors-18/NNS||midgut-21/NN	octreotide-1||tumors-18||no_rel||octreotide lar significantly lengthened median time to tumor progression compared with placebo in patients with metastatic neuroendocrine tumors of the midgut.
det||man-4/NN||a-1/DT	amod||man-4/NN||42-year-old-2/JJ	nn||man-4/NN||indian-3/NN	nsubj||received-5/VBD||man-4/NN	root||ROOT-0/null||received-5/VBD	num||rifampicin-8/NN||450-6/CD	nn||rifampicin-8/NN||mg-7/NN	dobj||received-5/VBD||rifampicin-8/NN	appos||rifampicin-8/NN||rif-10/NN	num||mg-14/NN||150-13/CD	dobj||received-5/VBD||mg-14/NN	conj_and||rifampicin-8/NN||mg-14/NN	vmod||mg-14/NN||isoniazid-15/VBN	dep||isoniazid-15/VBN||inh-17/NN	advmod||inh-17/NN||daily-19/RB	auxpass||diagnosed-22/VBN||being-21/VBG	prepc_after||received-5/VBD||diagnosed-22/VBN	det||tuberculosisinfection-26/NN||a-24/DT	nn||tuberculosisinfection-26/NN||latent-25/NN	prep_of||diagnosed-22/VBN||tuberculosisinfection-26/NN	tuberculosisinfection-26||rifampicin-8||yes||a 42-year-old indian man received 450 mg rifampicin (rif) and 150 mg isoniazid (inh) daily after being diagnosed of a latent tuberculosisinfection.
det||factors-2/NNS||some-1/DT	nsubjpass||correlated-7/VBN||factors-2/NNS	prep_of||factors-2/NNS||ptg-4/NN	auxpass||correlated-7/VBN||were-5/VBD	advmod||correlated-7/VBN||positively-6/RB	root||ROOT-0/null||correlated-7/VBN	prep_with||correlated-7/VBN||resilience-9/NN	nsubjpass||regarded-14/VBN||resilience-9/NN	aux||regarded-14/VBN||can-12/MD	auxpass||regarded-14/VBN||be-13/VB	rcmod||resilience-9/NN||regarded-14/VBN	det||outcome-17/NN||an-16/DT	prep_as||regarded-14/VBN||outcome-17/NN	prepc_of||outcome-17/NN||coping-19/VBG	dobj||coping-19/VBG||success-20/NN	mark||correlated-29/VBN||whereas-22/IN	amod||factors-24/NNS||other-23/JJ	nsubjpass||correlated-29/VBN||factors-24/NNS	prep_of||factors-24/NNS||ptg-26/NN	auxpass||correlated-29/VBN||were-27/VBD	advmod||correlated-29/VBN||positively-28/RB	advcl||correlated-7/VBN||correlated-29/VBN	amod||symptoms-32/NNS||ptsd-31/JJ	prep_with||correlated-29/VBN||symptoms-32/NNS	nsubjpass||regarded-37/VBN||symptoms-32/NNS	aux||regarded-37/VBN||can-35/MD	auxpass||regarded-37/VBN||be-36/VB	rcmod||symptoms-32/NNS||regarded-37/VBN	prepc_as||regarded-37/VBN||signifying-39/VBG	vmod||signifying-39/VBG||coping-40/VBG	dobj||coping-40/VBG||effort-41/NN	det||face-44/NN||the-43/DT	prep_in||coping-40/VBG||face-44/NN	amod||distress-47/NN||enduring-46/VBG	prep_of||face-44/NN||distress-47/NN	ptsd-31||ptg-26||no_rel||some factors of ptg were positively correlated with resilience, which can be regarded as an outcome of coping success, whereas other factors of ptg were positively correlated with ptsd symptoms, which can be regarded as signifying coping effort in the face of enduring distress.
prep_in||remained-9/VBD||contrast-2/NN	amod||cytokines-5/NNS||th1/th2-4/JJ	nsubj||remained-9/VBD||cytokines-5/NNS	vmod||cytokines-5/NNS||producing-6/VBG	nn||cells-8/NNS||t-7/NN	dobj||producing-6/VBG||cells-8/NNS	root||ROOT-0/null||remained-9/VBD	advmod||remained-9/VBD||lower-10/RBR	num||patient-13/NN||one-12/CD	prep_in||remained-9/VBD||patient-13/NN	vmod||patient-13/NN||detected-14/VBN	amod||resistant-17/JJ||adefovirdipivoxil-16/JJ	amod||mutation-20/NN||resistant-17/JJ	amod||mutation-20/NN||hbv-18/JJ	amod||mutation-20/NN||a181t/v-19/JJ	prep_with||detected-14/VBN||mutation-20/NN	hbv-18||adefovirdipivoxil-16||yes||in contrast, th1/th2 cytokines producing t cells remained lower in one patient detected with adefovirdipivoxil resistant hbv a181t/v mutation.
nsubj||employs-9/VBZ||yersiniapestis-1/NNS	det||agent-5/NN||the-3/DT	amod||agent-5/NN||causative-4/JJ	appos||yersiniapestis-1/NNS||agent-5/NN	prep_of||agent-5/NN||bubonicplague-7/NN	root||ROOT-0/null||employs-9/VBZ	poss||system-14/NN||its-10/PRP$	nn||system-14/NN||type-11/NN	nn||system-14/NN||iii-12/NN	nn||system-14/NN||secretion-13/NN	dobj||employs-9/VBZ||system-14/NN	aux||inject-16/VB||to-15/TO	vmod||employs-9/VBZ||inject-16/VB	dobj||inject-16/VB||toxins-17/NNS	nn||cells-20/NNS||target-19/NN	prep_into||inject-16/VB||cells-20/NNS	det||step-24/NN||a-22/DT	amod||step-24/NN||crucial-23/JJ	appos||cells-20/NNS||step-24/NN	nn||establishment-27/NN||infection-26/NN	prep_in||step-24/NN||establishment-27/NN	bubonicplague-7||yersiniapestis-1||no||yersiniapestis , the causative agent of bubonicplague, employs its type iii secretion system to inject toxins into target cells, a crucial step in infection establishment.
det||results-2/NNS||these-1/DT	nsubj||encourage-4/VB||results-2/NNS	aux||encourage-4/VB||should-3/MD	root||ROOT-0/null||encourage-4/VB	det||association-6/NN||the-5/DT	dobj||encourage-4/VB||association-6/NN	predet||the-9/DT||all-8/PDT	nsubj||involved-10/VBD||the-9/DT	conj_and||encourage-4/VB||involved-10/VBD	dobj||involved-10/VBD||actors-11/NNS	det||hiv/aids-14/NNS||the-13/DT	poss||program-16/NN||hiv/aids-14/NNS	prep_in||involved-10/VBD||program-16/NN	aux||strengthen-18/VB||to-17/TO	vmod||program-16/NN||strengthen-18/VB	nn||interventions-24/NNS||counseling-19/NN	conj_and||counseling-19/NN||education-21/NN	nn||interventions-24/NNS||education-21/NN	conj_and||counseling-19/NN||information-23/NN	nn||interventions-24/NNS||information-23/NN	dobj||strengthen-18/VB||interventions-24/NNS	amod||patients-27/NNS||hiv-infected-26/JJ	prep_for||strengthen-18/VB||patients-27/NNS	mark||overcome-31/VB||in-28/IN	dep||overcome-31/VB||order-29/NN	aux||overcome-31/VB||to-30/TO	advcl||strengthen-18/VB||overcome-31/VB	det||barriers-34/NNS||the-32/DT	amod||barriers-34/NNS||potential-33/JJ	dobj||overcome-31/VB||barriers-34/NNS	amod||adherence-37/NN||poor-36/JJ	prep_of||barriers-34/NNS||adherence-37/NN	aids--1||hiv--1||no||these results should encourage the association and all the involved actors in the hiv/aids's program to strengthen counseling, education and information interventions for hiv-infected patients in order to overcome the potential barriers of poor adherence.
nsubj||demonstrate-2/VBP||we-1/PRP	root||ROOT-0/null||demonstrate-2/VBP	xcomp||demonstrate-2/VBP||using-3/VBG	amod||anaphylaxis-6/NNS||passive-4/JJ	nn||anaphylaxis-6/NNS||cutaneous-5/NNS	dobj||using-3/VBG||anaphylaxis-6/NNS	det||model-11/NN||a-8/DT	amod||model-11/NN||mast-9/JJ	amod||model-11/NN||cell-dependent-10/JJ	appos||anaphylaxis-6/NNS||model-11/NN	mark||ablated-24/VBD||that-13/IN	nsubj||ablated-24/VBD||deficiency-14/NN	amod||blockage-19/NN||st2-16/JJ	conj_or||st2-16/JJ||antibody-18/NN	amod||blockage-19/NN||antibody-18/NN	prep_in||deficiency-14/NN||blockage-19/NN	prep_of||blockage-19/NN||st2-21/CD	prep_of||blockage-19/NN||il-33-23/CD	conj_or||st2-21/CD||il-33-23/CD	dep||anaphylaxis-6/NNS||ablated-24/VBD	det||response-29/NN||the-25/DT	amod||response-29/NN||late-26/JJ	nn||response-29/NN||phase-27/NN	amod||response-29/NN||inflammatory-28/JJ	dobj||ablated-24/VBD||response-29/NN	mark||unaffected-37/JJ||that-31/IN	det||response-35/NN||the-32/DT	amod||response-35/NN||immediate-33/JJ	nn||response-35/NN||phase-34/NN	nsubj||unaffected-37/JJ||response-35/NN	cop||unaffected-37/JJ||was-36/VBD	dep||anaphylaxis-6/NNS||unaffected-37/JJ	conj_but||ablated-24/VBD||unaffected-37/JJ	anaphylaxis-6||antibody-18||no_rel||we demonstrate using passive cutaneous anaphylaxis, a mast cell-dependent model, that deficiency in st2 or antibody blockage of st2 or il-33 ablated the late phase inflammatory response but that the immediate phase response was unaffected.
amod||reliance-3/NN||heavy-2/JJ	prep_despite||known-14/VBN||reliance-3/NN	amod||primates-6/NNS||non-human-5/JJ	prep_on||reliance-3/NN||primates-6/NNS	prep_as||primates-6/NNS||models-8/NNS	prep_for||models-8/NNS||hiv/aids-10/NNS	nsubjpass||known-14/VBN||little-12/RB	auxpass||known-14/VBN||is-13/VBZ	root||ROOT-0/null||known-14/VBN	det||host-17/NN||which-16/WDT	prep_about||shared-20/VBN||host-17/NN	nsubjpass||shared-20/VBN||factors-18/NNS	auxpass||shared-20/VBN||are-19/VBP	dep||known-14/VBN||shared-20/VBN	nsubj||unique-24/JJ||which-22/WDT	cop||unique-24/JJ||are-23/VBP	dep||known-14/VBN||unique-24/JJ	conj_and||shared-20/VBN||unique-24/JJ	det||lineage-29/NN||a-26/DT	amod||lineage-29/NN||given-27/VBN	nn||lineage-29/NN||primate-28/NN	prep_to||unique-24/JJ||lineage-29/NN	aids--1||hiv--1||no||despite heavy reliance on non-human primates as models for hiv/aids, little is known about which host factors are shared and which are unique to a given primate lineage.
amod||virus-2/NN||varicellar-zoster-1/JJ	nsubjpass||detected-22/VBN||virus-2/NN	appos||virus-2/NN||vzv-4/NN	conj_and||virus-2/NN||cytomegalovirus-7/NNS	nsubjpass||detected-22/VBN||cytomegalovirus-7/NNS	appos||cytomegalovirus-7/NNS||cmv-9/NN	amod||types-15/NNS||herpes-13/JJ	nn||types-15/NNS||simplex-14/NN	conj_and||virus-2/NN||types-15/NNS	nsubjpass||detected-22/VBN||types-15/NNS	dep||types-15/NNS||1,2-16/CD	dep||virus-2/NN||hsv-1-18/JJ	dep||hsv-1-18/JJ||,2-19/CD	auxpass||detected-22/VBN||were-21/VBD	root||ROOT-0/null||detected-22/VBN	det||humor-26/NN||the-24/DT	amod||humor-26/NN||aqueous-25/JJ	prep_in||detected-22/VBN||humor-26/NN	agent||detected-22/VBN||pcr-28/NN	zoster--1||vzv-4||no||varicellar-zoster virus (vzv), cytomegalovirus (cmv), and herpes simplex types 1,2 (hsv-1,2) were detected in the aqueous humor by pcr.
advmod||present-4/VBP||here-1/RB	nsubj||present-4/VBP||we-3/PRP	root||ROOT-0/null||present-4/VBP	det||analysis-7/NN||a-5/DT	amod||analysis-7/NN||bioinformatic-6/JJ	dobj||present-4/VBP||analysis-7/NN	amod||populations-10/NNS||hcv-1a-9/JJ	prep_of||analysis-7/NN||populations-10/NNS	vmod||populations-10/NNS||isolated-11/VBN	num||children-14/NNS||23-13/CD	prep_from||isolated-11/VBN||children-14/NNS	prep_with||isolated-11/VBN||chronichepatitisc-16/NN	discourse||chronichepatitisc-16/NN||chc-18/UH	vmod||chronichepatitisc-16/NN||subjected-20/VBN	aux||interferonâ-22/VB||to-21/TO	xcomp||subjected-20/VBN||interferonâ-22/VB	num||therapy-26/NN||$-23/$	num||$-23/$||ribavirin-25/CD	dobj||interferonâ-22/VB||therapy-26/NN	chronichepatitisc-16||ribavirin-25||yes||here, we present a bioinformatic analysis of hcv-1a populations isolated from 23 children with chronichepatitisc (chc) subjected to interferonâribavirin therapy.
amod||concentrations-3/NNS||free-1/JJ	nn||concentrations-3/NNS||testosterone-2/NN	nsubjpass||analyzed-24/VBN||concentrations-3/NNS	num||men-6/NNS||1,849-5/CD	prep_of||concentrations-3/NNS||men-6/NNS	num||nondiabetic-9/NN||1,451-8/CD	dep||men-6/NNS||nondiabetic-9/NN	num||diabetic-12/NN||398-11/CD	dep||men-6/NNS||diabetic-12/NN	conj_and||nondiabetic-9/NN||diabetic-12/NN	det||hypogonadism-16/NN||the-15/DT	prep_in||men-6/NNS||hypogonadism-16/NN	nn||study-22/NN||males-18/NNP	dep||study-22/NN||him-20/PRP	prep_in||hypogonadism-16/NN||study-22/NN	auxpass||analyzed-24/VBN||were-23/VBD	root||ROOT-0/null||analyzed-24/VBN	hypogonadism-16||testosterone-2||yes||free testosterone concentrations of 1,849 men (1,451 nondiabetic and 398 diabetic) in the hypogonadism in males (him) study were analyzed.
nsubj||result-3/VB||this-1/DT	aux||result-3/VB||may-2/MD	root||ROOT-0/null||result-3/VB	amod||transmission-6/NN||enhanced-5/JJ	prep_in||result-3/VB||transmission-6/NN	amod||parasites-10/NNS||mutant-8/JJ	nn||parasites-10/NNS||malaria-9/NN	prep_of||transmission-6/NN||parasites-10/NNS	mark||shown-14/VBN||as-12/IN	advmod||shown-14/VBN||previously-13/RB	advcl||result-3/VB||shown-14/VBN	amod||resistant-17/JJ||chloroquine-16/JJ	amod||parasites-18/NNS||resistant-17/JJ	prep_for||shown-14/VBN||parasites-18/NNS	malaria-9||chloroquine-16||yes||this may result in enhanced transmission of mutant malaria parasites, as previously shown for chloroquine resistant parasites.
det||study-2/NN||this-1/DT	nsubj||first-5/JJ||study-2/NN	cop||first-5/JJ||is-3/VBZ	det||first-5/JJ||the-4/DT	root||ROOT-0/null||first-5/JJ	det||uae-8/NN||the-7/DT	prep_in||first-5/JJ||uae-8/NN	aux||report-10/VB||to-9/TO	vmod||uae-8/NN||report-10/VB	amod||levels-13/NNS||such-11/JJ	amod||levels-13/NNS||high-12/JJ	dobj||report-10/VB||levels-13/NNS	prep_of||levels-13/NNS||resistance-15/NN	amod||drugs-18/NNS||anti-tb-17/JJ	prep_to||report-10/VB||drugs-18/NNS	num||%-21/NN||27.7-20/CD	nsubj||are-30/VBP||%-21/NN	nsubj||achieve-35/VB||%-21/NN	amod||drugs-24/NNS||anti-tuberculosis-23/JJ	prep_for||%-21/NN||drugs-24/NNS	prep_such_as||drugs-24/NNS||isoniazid-27/NN	prep_such_as||drugs-24/NNS||pyrazinamide-29/NN	conj_and||isoniazid-27/NN||pyrazinamide-29/NN	parataxis||first-5/JJ||are-30/VBP	amod||significance-33/NN||great-32/JJ	prep_of||are-30/VBP||significance-33/NN	aux||achieve-35/VB||to-34/TO	xcomp||are-30/VBP||achieve-35/VB	amod||treatment-37/NN||proper-36/JJ	dobj||achieve-35/VB||treatment-37/NN	prep_in||achieve-35/VB||m.tuberculosisinfections-39/NNS	prep_in||m.tuberculosisinfections-39/NNS||future-41/NN	tb--1||pyrazinamide-29||yes||this study is the first in the uae to report such high levels of resistance to anti-tb drugs ; 27.7 % for anti-tuberculosis drugs such as isoniazid and pyrazinamide are of great significance to achieve proper treatment in m.tuberculosisinfections in future .
amod||ablation-2/NN||mfge8-1/JJ	nsubj||derived-37/VBD||ablation-2/NN	vmod||ablation-2/NN||induced-3/VBN	amod||priondisease-5/NN||accelerated-4/JJ	dobj||induced-3/VBN||priondisease-5/NN	amod||clearance-8/NN||reduced-7/VBN	dobj||induced-3/VBN||clearance-8/NN	conj_and||priondisease-5/NN||clearance-8/NN	amod||bodies-12/NNS||cerebellar-10/JJ	amod||bodies-12/NNS||apoptotic-11/JJ	prep_of||clearance-8/NN||bodies-12/NNS	prep_in||clearance-8/NN||vivo-14/NN	amod||accumulation-21/NN||excessive-19/JJ	amod||accumulation-21/NN||prpsc-20/JJ	dobj||induced-3/VBN||accumulation-21/NN	conj_and||priondisease-5/NN||accumulation-21/NN	amod||titers-25/NNS||increased-23/VBN	nn||titers-25/NNS||prion-24/NN	conj_and||priondisease-5/NN||titers-25/NNS	conj_and||accumulation-21/NN||titers-25/NNS	amod||ã-29/NN||prion-infected-27/JJ	amod||ã-29/NN||c57bl/6-28/JJ	prep_in||titers-25/NNS||ã-29/NN	amod||mice-32/NNS||129sv-31/JJ	conj_and||priondisease-5/NN||mice-32/NNS	conj_and||accumulation-21/NN||mice-32/NNS	amod||slices-36/NNS||organotypic-34/JJ	nn||slices-36/NNS||cerebellar-35/NN	conj_and||accumulation-21/NN||slices-36/NNS	conj_and||mice-32/NNS||slices-36/NNS	root||ROOT-0/null||derived-37/VBD	dobj||derived-37/VBD||therefrom-38/NN	priondisease-5||prion-24||no||mfge8 ablation induced accelerated priondisease and reduced clearance of cerebellar apoptotic bodies in vivo, as well as excessive prpsc accumulation and increased prion titers in prion-infected c57bl/6 ã 129sv mice and organotypic cerebellar slices derived therefrom.
number||hundred-2/CD||one-1/CD	num||isolates-5/NNS||hundred-2/CD	amod||isolates-5/NNS||eighty-3/JJ	num||isolates-5/NNS||three-4/CD	nsubjpass||fingerprinted-17/VBN||isolates-5/NNS	prep_of||isolates-5/NNS||mycobacteriumtuberculosis-7/NNS	num||hivseropositive-10/NN||80-9/CD	prep_from||mycobacteriumtuberculosis-7/NNS||hivseropositive-10/NN	num||patients-15/NNS||103-12/CD	nn||patients-15/NNS||hiv-13/NN	nn||patients-15/NNS||seronegative-14/NN	prep_from||mycobacteriumtuberculosis-7/NNS||patients-15/NNS	conj_and||hivseropositive-10/NN||patients-15/NNS	auxpass||fingerprinted-17/VBN||were-16/VBD	root||ROOT-0/null||fingerprinted-17/VBN	agent||fingerprinted-17/VBN||standard-19/NN	cop||6110-21/CD||is-20/VBZ	dep||standard-19/NN||6110-21/CD	dep||6110-21/CD||rflp-23/NN	hivseropositive-10||hiv-13||no||one hundred eighty three isolates of mycobacteriumtuberculosis from 80 hivseropositive and 103 hiv seronegative patients were fingerprinted by standard is 6110 -rflp.
det||phase-4/NN||the-2/DT	amod||phase-4/NN||acute-3/JJ	prep_in||targets-13/VBZ||phase-4/NN	prep_of||phase-4/NN||infectionwithfelineimmunodeficiencyvirus-6/NNS	appos||infectionwithfelineimmunodeficiencyvirus-6/NNS||fiv-8/NN	det||virus-12/NN||the-11/DT	nsubj||targets-13/VBZ||virus-12/NN	root||ROOT-0/null||targets-13/VBZ	amod||cells-18/NNS||activated-14/VBN	amod||cells-18/NNS||cd4-15/JJ	amod||cells-18/NNS||+-16/JJ	nn||cells-18/NNS||t-17/NN	dobj||targets-13/VBZ||cells-18/NNS	prepc_by||cells-18/NNS||utilising-20/VBG	amod||ox40-23/NNS||cd134-21/JJ	dobj||utilising-20/VBG||ox40-23/NNS	det||receptor-29/NN||a-26/DT	amod||receptor-29/NN||primary-27/JJ	nn||receptor-29/NN||attachment-28/NN	prep_as||ox40-23/NNS||receptor-29/NN	prep_as||ox40-23/NNS||cxcr4-31/NNS	conj_and||receptor-29/NN||cxcr4-31/NNS	det||co-receptor-34/NN||a-33/DT	prep_as||utilising-20/VBG||co-receptor-34/NN	infectionwithfelineimmunodeficiencyvirus-6||fiv-8||no||in the acute phase of infectionwithfelineimmunodeficiencyvirus (fiv), the virus targets activated cd4+ t cells by utilising cd134 (ox40) as a primary attachment receptor and cxcr4 as a co-receptor.
amod||advances-2/NNS||newer-1/JJR	nsubj||include-3/VBP||advances-2/NNS	ccomp||revolutionized-63/VBD||include-3/VBP	dobj||include-3/VBP||introduction-4/NN	amod||techniques-7/NNS||newer-6/JJR	prep_of||introduction-4/NN||techniques-7/NNS	amod||epidurals-11/NNS||combined-9/VBN	amod||epidurals-11/NNS||spinal-10/JJ	prep_like||techniques-7/NNS||epidurals-11/NNS	amod||epidurals-14/NNS||low-dose-13/JJ	dobj||include-3/VBP||epidurals-14/NNS	conj_and||introduction-4/NN||epidurals-14/NNS	vmod||epidurals-14/NNS||facilitating-15/VBG	dobj||facilitating-15/VBG||ambulation-16/NN	amod||advances-19/NNS||pharmacological-18/JJ	dobj||include-3/VBP||advances-19/NNS	conj_and||introduction-4/NN||advances-19/NNS	prep_like||advances-19/NNS||introduction-21/NN	prep_of||introduction-21/NN||remifentanil-23/NN	amod||analgesia-27/NN||patient-controlled-25/JJ	amod||analgesia-27/NN||intravenous-26/JJ	prep_for||remifentanil-23/NN||analgesia-27/NN	dobj||include-3/VBP||introduction-29/NN	conj_and||introduction-4/NN||introduction-29/NN	amod||anaesthetics-33/NNS||newer-31/JJR	amod||anaesthetics-33/NNS||local-32/JJ	prep_of||introduction-29/NN||anaesthetics-33/NNS	dobj||include-3/VBP||adjuvants-35/NNS	conj_and||introduction-4/NN||adjuvants-35/NNS	prep_like||adjuvants-35/NNS||ropivacaine-37/JJ	prep_like||adjuvants-35/NNS||levobupivacaine-39/JJ	conj_and||ropivacaine-37/JJ||levobupivacaine-39/JJ	prep_like||adjuvants-35/NNS||sufentanil-41/JJ	conj_and||ropivacaine-37/JJ||sufentanil-41/JJ	prep_like||adjuvants-35/NNS||clonidine-43/JJ	conj_and||ropivacaine-37/JJ||clonidine-43/JJ	prep_like||adjuvants-35/NNS||neostigmine-45/JJ	conj_and||ropivacaine-37/JJ||neostigmine-45/JJ	appos||introduction-4/NN||use-47/NN	amod||agents-50/NNS||inhalational-49/JJ	prep_of||use-47/NN||agents-50/NNS	prep_like||agents-50/NNS||sevoflourane-52/NN	amod||analgesia-56/NN||patient-controlled-54/JJ	amod||analgesia-56/NN||inhalational-55/JJ	prep_for||sevoflourane-52/NN||analgesia-56/NN	vmod||analgesia-56/NN||using-57/VBG	amod||vaporizers-59/NNS||special-58/JJ	dobj||using-57/VBG||vaporizers-59/NNS	nsubj||revolutionized-63/VBD||all-61/DT	aux||revolutionized-63/VBD||have-62/VBP	root||ROOT-0/null||revolutionized-63/VBD	det||practice-65/NN||the-64/DT	dobj||revolutionized-63/VBD||practice-65/NN	nn||management-68/NN||pain-67/NN	prep_of||practice-65/NN||management-68/NN	prepc_in||revolutionized-63/VBD||labouring-70/VBG	dobj||labouring-70/VBG||parturients-71/NNS	pain-67||sufentanil-41||yes||newer advances include introduction of newer techniques like combined spinal epidurals, low-dose epidurals facilitating ambulation, pharmacological advances like introduction of remifentanil for patient-controlled intravenous analgesia, introduction of newer local anaesthetics and adjuvants like ropivacaine, levobupivacaine, sufentanil, clonidine and neostigmine, use of inhalational agents like sevoflourane for patient-controlled inhalational analgesia using special vaporizers, all have revolutionized the practice of pain management in labouring parturients.
aux||investigate-2/VB||to-1/TO	root||ROOT-0/null||investigate-2/VB	mark||produce-18/VB||whether-3/IN	ccomp||investigate-2/VB||not-5/RB	conj_or||produce-18/VB||not-5/RB	nsubj||produce-18/VB||coadministration-6/NN	prep_of||coadministration-6/NN||tacrolimus-8/NNS	appos||tacrolimus-8/NNS||tac-10/NN	prep_with||tacrolimus-8/NNS||prednisolone-13/NN	appos||prednisolone-13/NN||psl-15/NN	aux||produce-18/VB||can-17/MD	ccomp||investigate-2/VB||produce-18/VB	det||effect-21/NN||a-19/DT	amod||effect-21/NN||beneficial-20/JJ	dobj||produce-18/VB||effect-21/NN	det||treatment-24/NN||the-23/DT	prep_in||produce-18/VB||treatment-24/NN	amod||dermatomyositis-28/NNS||polymyositis-26/JJ	amod||dermatomyositis-28/NNS||/-27/JJ	prep_of||treatment-24/NN||dermatomyositis-28/NNS	appos||dermatomyositis-28/NNS||pm/dm-30/NNP	prednisolone-13||polymyositis-26||no_rel||to investigate whether or not coadministration of tacrolimus (tac) with prednisolone (psl) can produce a beneficial effect in the treatment of polymyositis/ dermatomyositis (pm/dm).
num||assays-3/NNS||two-1/CD	nn||assays-3/NNS||blood-2/NN	nsubj||add-5/VB||assays-3/NNS	aux||add-5/VB||might-4/MD	root||ROOT-0/null||add-5/VB	dobj||add-5/VB||information-6/NN	vmod||information-6/NN||characterising-7/VBG	vmod||information-6/NN||characterising-7/VBG	vmod||information-6/NN||characterising-7/VBG	conj_or||characterising-7/VBG||characterising-7/VBG	conj_or||characterising-7/VBG||characterising-7/VBG	det||evolution-9/NN||the-8/DT	dobj||characterising-7/VBG||evolution-9/NN	prep_from||evolution-9/NN||ltbi-11/NNS	amod||tb-14/NN||active-13/JJ	prep_to||characterising-7/VBG||tb-14/NN	preconj||characterising-7/VBG||either-15/CC	agent||characterising-7/VBG||losing-17/VBG	amod||immunity-19/NN||protective-18/JJ	dobj||losing-17/VBG||immunity-19/NN	mark||demonstrated-22/VBD||as-21/IN	dep||immunity-19/NN||demonstrated-22/VBD	det||blood-26/NN||the-24/DT	amod||blood-26/NN||whole-25/JJ	prep_by||demonstrated-22/VBD||blood-26/NN	vmod||blood-26/NN||killing-27/VBG	advmod||killing-27/VBG||assay-28/RB	agent||characterising-7/VBG||evaluating-32/VBG	det||kinetics-34/NNS||the-33/DT	dobj||evaluating-32/VBG||kinetics-34/NNS	det||antibodies-37/NNS||the-36/DT	prep_of||kinetics-34/NNS||antibodies-37/NNS	vmod||antibodies-37/NNS||synthesized-38/VBN	amod||antigens-42/NNS||m.tuberculosis-40/JJ	amod||antigens-42/NNS||specific-41/JJ	prep_against||synthesized-38/VBN||antigens-42/NNS	tb-14||m.tuberculosis-40||no||two blood assays might add information characterising the evolution from ltbi to active tb either by losing protective immunity , as demonstrated by the whole blood killing assay , or by evaluating the kinetics of the antibodies synthesized against m.tuberculosis specific antigens .
amod||aes-2/NN||placebo-adjusted-1/JJ	nsubj||insomnia-9/JJ||aes-2/NN	advmod||common-4/JJ||more-3/RBR	amod||aes-2/NN||common-4/JJ	amod||er-7/NN||paliperidone-6/JJ	prep_with||common-4/JJ||er-7/NN	cop||insomnia-9/JJ||were-8/VBD	ccomp||congestion-36/NN||insomnia-9/JJ	nn||tachycardia-12/NN||sinus-11/NNS	nsubj||congestion-36/NN||tachycardia-12/NN	conj_and||tachycardia-12/NN||tachycardia-14/NN	nsubj||congestion-36/NN||tachycardia-14/NN	advmod||common-17/JJ||more-16/RBR	amod||tachycardia-12/NN||common-17/JJ	prep_with||tachycardia-12/NN||risperidone-19/NN	cop||congestion-36/NN||were-20/VBD	nn||congestion-36/NN||somnolence-21/NN	conj_and||somnolence-21/NN||restlessness-23/NNS	nn||congestion-36/NN||restlessness-23/NNS	conj_and||somnolence-21/NN||nausea-25/NN	nn||congestion-36/NN||nausea-25/NN	conj_and||somnolence-21/NN||anxiety-27/NN	nn||congestion-36/NN||anxiety-27/NN	conj_and||somnolence-21/NN||salivaryhypersecretion-29/NN	nn||congestion-36/NN||salivaryhypersecretion-29/NN	conj_and||somnolence-21/NN||akathisia-31/NN	nn||congestion-36/NN||akathisia-31/NN	conj_and||somnolence-21/NN||dizziness-33/NN	nn||congestion-36/NN||dizziness-33/NN	conj_and||somnolence-21/NN||nasal-35/NN	nn||congestion-36/NN||nasal-35/NN	root||ROOT-0/null||congestion-36/NN	paliperidone-6||tachycardia-14||no_rel||placebo-adjusted aes more common with paliperidone er were insomnia, sinus tachycardia and tachycardia; more common with risperidone were somnolence, restlessness, nausea, anxiety, salivaryhypersecretion, akathisia, dizziness and nasal congestion.
det||markers-3/NNS||these-1/DT	amod||markers-3/NNS||molecular-2/JJ	nsubj||indicate-4/VBP||markers-3/NNS	nsubj||high-14/JJ||markers-3/NNS	nsubj||rely-16/VB||markers-3/NNS	root||ROOT-0/null||indicate-4/VBP	mark||increasing-9/VBG||that-5/IN	amod||resistance-7/NN||pyrimethamine/sulfadoxine-6/JJ	nsubj||increasing-9/VBG||resistance-7/NN	aux||increasing-9/VBG||is-8/VBZ	ccomp||indicate-4/VBP||increasing-9/VBG	cop||high-14/JJ||is-11/VBZ	advmod||high-14/JJ||now-12/RB	advmod||high-14/JJ||too-13/RB	conj_and||indicate-4/VBP||high-14/JJ	aux||rely-16/VB||to-15/TO	xcomp||high-14/JJ||rely-16/VB	det||drug-19/NN||this-18/DT	prep_on||rely-16/VB||drug-19/NN	det||agent-24/NN||a-21/DT	amod||agent-24/NN||routine-22/JJ	amod||agent-24/NN||therapeutic-23/JJ	prep_as||drug-19/NN||agent-24/NN	aux||treat-26/VB||to-25/TO	xcomp||rely-16/VB||treat-26/VB	dobj||treat-26/VB||malaria-27/NN	prep_in||treat-26/VB||travelers-29/NNS	malaria-27||pyrimethamine--1||no||these molecular markers indicate that pyrimethamine/sulfadoxine resistance is increasing and is now too high to rely on this drug as a routine therapeutic agent to treat malaria in travelers.
nsubj||describe-2/VBP||we-1/PRP	root||ROOT-0/null||describe-2/VBP	det||creation-4/NN||the-3/DT	dobj||describe-2/VBP||creation-4/NN	det||system-13/NN||a-6/DT	amod||system-13/NN||unified-7/JJ	amod||system-13/NN||web-based-9/JJ	amod||system-13/NN||national-10/JJ	nn||system-13/NN||hiv/aids-11/NNS	nn||system-13/NN||information-12/NN	prep_of||creation-4/NN||system-13/NN	vmod||system-13/NN||designed-14/VBN	aux||streamline-16/VB||to-15/TO	xcomp||designed-14/VBN||streamline-16/VB	nn||collection-18/NN||data-17/NN	dobj||streamline-16/VB||collection-18/NN	xcomp||designed-14/VBN||facilitate-20/VB	conj_and||streamline-16/VB||facilitate-20/VB	nn||use-22/NN||data-21/NN	dobj||facilitate-20/VB||use-22/NN	aids--1||hiv--1||no||we describe the creation of a unified, web-based national hiv/aids information system designed to streamline data collection and facilitate data use.
prep_in||causes-5/VBZ||humans-2/NNS	nsubj||causes-5/VBZ||c.neoformans-4/NNS	nsubj||cutaneouscryptococcosis-17/VBZ||c.neoformans-4/NNS	root||ROOT-0/null||causes-5/VBZ	num||types-7/NNS||three-6/CD	dobj||causes-5/VBZ||types-7/NNS	nn||cryptococcosis-11/NNS||infections-9/NNS	nn||cryptococcosis-11/NNS||pulmonary-10/NNS	prep_of||types-7/NNS||cryptococcosis-11/NNS	prep_of||types-7/NNS||cryptococcalmeningitis-13/NNS	conj_and||cryptococcosis-11/NNS||cryptococcalmeningitis-13/NNS	prep_of||types-7/NNS||wound-15/NN	conj_and||cryptococcosis-11/NNS||wound-15/NN	conj_or||causes-5/VBZ||cutaneouscryptococcosis-17/VBZ	cutaneouscryptococcosis-17||c.neoformans-4||no||in humans , c.neoformans causes three types of infections pulmonary cryptococcosis , cryptococcalmeningitis and wound or cutaneouscryptococcosis .
det||accumulation-2/NN||the-1/DT	nsubj||feature-17/NN||accumulation-2/NN	amod||resistant-5/JJ||protease-4/JJ	amod||conformers-6/NNS||resistant-5/JJ	prep_of||accumulation-2/NN||conformers-6/NNS	det||prionprotein-9/NN||the-8/DT	prep_of||conformers-6/NNS||prionprotein-9/NN	appos||prionprotein-9/NN||prpres-11/NNS	cop||feature-17/NN||is-13/VBZ	det||feature-17/NN||a-14/DT	amod||feature-17/NN||key-15/JJ	amod||feature-17/NN||pathological-16/JJ	root||ROOT-0/null||feature-17/NN	prep_of||feature-17/NN||priondiseases-19/NNS	priondiseases-19||prionprotein-9||no||the accumulation of protease resistant conformers of the prionprotein (prpres) is a key pathological feature of priondiseases.
nsubjpass||recognised-5/VBN||hantaviruses-1/NNS	nsubj||cause-7/VB||hantaviruses-1/NNS	aux||recognised-5/VBN||have-2/VBP	advmod||recognised-5/VBN||previously-3/RB	auxpass||recognised-5/VBN||been-4/VBN	root||ROOT-0/null||recognised-5/VBN	aux||cause-7/VB||to-6/TO	xcomp||recognised-5/VBN||cause-7/VB	num||syndromes-10/NNS||two-8/CD	amod||syndromes-10/NNS||separate-9/JJ	dobj||cause-7/VB||syndromes-10/NNS	amod||syndromes-10/NNS||hemorrhagicfeverwithrenalsyndrome-11/JJ	prep_in||hemorrhagicfeverwithrenalsyndrome-11/JJ||eurasia-13/NN	amod||syndromes-10/NNS||hantaviruspulmonarysyndrome-16/JJ	conj_and||hemorrhagicfeverwithrenalsyndrome-11/JJ||hantaviruspulmonarysyndrome-16/JJ	appos||syndromes-10/NNS||hps-18/NN	det||americas-22/NNS||the-21/DT	prep_in||cause-7/VB||americas-22/NNS	hps-18||hantaviruses-1||no||hantaviruses have previously been recognised to cause two separate syndromes hemorrhagicfeverwithrenalsyndrome in eurasia, and hantaviruspulmonarysyndrome (hps) in the americas.
amod||analyses-2/NNS||multivariable-1/JJ	nsubj||type-8/VBZ||analyses-2/NNS	nn||response-5/NN||treatment-4/NN	prep_of||analyses-2/NNS||response-5/NN	prep_in||response-5/NN||1,229-7/CD	root||ROOT-0/null||type-8/VBZ	num||patients-11/NNS||2-9/CD	amod||patients-11/NNS||diabetic-10/JJ	dobj||type-8/VBZ||patients-11/NNS	prep_with||type-8/VBZ||hypercholesterolemia-13/NN	nsubj||received-15/VBD||hypercholesterolemia-13/NN	rcmod||hypercholesterolemia-13/NN||received-15/VBD	dobj||received-15/VBD||ezetimibe/simvastatin-16/NN	dobj||received-15/VBD||atorvastatin-18/NN	conj_or||ezetimibe/simvastatin-16/NN||atorvastatin-18/NN	det||study-24/NN||a-20/DT	amod||study-24/NN||randomized-21/JJ	amod||study-24/NN||double-blind-22/JJ	amod||study-24/NN||6-week-23/JJ	prep_in||received-15/VBD||study-24/NN	hypercholesterolemia-13||atorvastatin-18||yes||multivariable analyses of treatment response in 1,229 type 2 diabetic patients with hypercholesterolemia who received ezetimibe/simvastatin or atorvastatin in a randomized double-blind 6-week study.
det||understanding-3/NN||a-1/DT	amod||understanding-3/NN||better-2/JJR	nsubj||help-12/VB||understanding-3/NN	nsubj||develop-14/VB||understanding-3/NN	det||anorexia-10/NN||the-5/DT	amod||anorexia-10/NN||neurobiological-6/JJ	nn||anorexia-10/NN||mechanisms-7/NNP	amod||anorexia-10/NN||underlying-8/JJ	amod||anorexia-10/NN||inflammation-associated-9/JJ	prep_of||understanding-3/NN||anorexia-10/NN	aux||help-12/VB||will-11/MD	root||ROOT-0/null||help-12/VB	aux||develop-14/VB||to-13/TO	xcomp||help-12/VB||develop-14/VB	nn||stimulants-16/NNS||appetite-15/NN	dobj||develop-14/VB||stimulants-16/NNS	nn||patients-21/NNS||cancer-18/NN	conj_and||cancer-18/NN||aids-20/NNS	nn||patients-21/NNS||aids-20/NNS	prep_for||develop-14/VB||patients-21/NNS	anorexia-10||stimulants-16||no_rel||a better understanding of the neurobiological mechanisms underlying inflammation-associated anorexia will help to develop appetite stimulants for cancer and aids patients.
nsubj||represents-14/VBZ||development-1/NN	amod||-lrb--5/NNS||recombinant-3/JJ	nn||-lrb--5/NNS||bcg-4/NN	prep_of||development-1/NN||-lrb--5/NNS	vmod||-lrb--5/NNS||rbcg-6/VBG	amod||antigens-11/NNS||-rrb--7/JJ	amod||antigens-11/NNS||over-expressing-8/JJ	amod||antigens-11/NNS||promising-9/JJ	nn||antigens-11/NNS||immunodominant-10/NN	dobj||rbcg-6/VBG||antigens-11/NNS	prep_of||antigens-11/NNS||m.tuberculosis-13/NNS	root||ROOT-0/null||represents-14/VBZ	dobj||represents-14/VBZ||one-15/CD	det||approaches-19/NNS||the-17/DT	amod||approaches-19/NNS||potential-18/JJ	prep_of||one-15/CD||approaches-19/NNS	det||development-22/NN||the-21/DT	prep_for||approaches-19/NNS||development-22/NN	prep_of||development-22/NN||vaccines-24/NNS	prep_against||vaccines-24/NNS||tb-26/NN	tb-26||bcg-4||no||development of recombinant bcg -lrb- rbcg -rrb- over-expressing promising immunodominant antigens of m.tuberculosis represents one of the potential approaches for the development of vaccines against tb .
det||results-2/NNS||these-1/DT	nsubj||indicated-3/VBD||results-2/NNS	nsubj||contribute-17/VB||results-2/NNS	root||ROOT-0/null||indicated-3/VBD	mark||involved-7/VBN||that-4/IN	nsubjpass||involved-7/VBN||vpbd-5/NN	auxpass||involved-7/VBN||was-6/VBD	ccomp||indicated-3/VBD||involved-7/VBN	det||response-12/NN||the-9/DT	nn||response-12/NN||host-10/NN	amod||response-12/NN||immune-11/JJ	prep_in||involved-7/VBN||response-12/NN	prep_against||response-12/NN||bacterialinfection-14/NN	aux||contribute-17/VB||might-16/MD	conj_and||indicated-3/VBD||contribute-17/VB	det||clearance-20/NN||the-19/DT	prep_to||contribute-17/VB||clearance-20/NN	prepc_of||clearance-20/NN||invading-22/VBG	dobj||invading-22/VBG||bacteria-23/NNS	bacterialinfection-14||bacteria-23||no||these results indicated that vpbd was involved in the host immune response against bacterialinfection and might contribute to the clearance of invading bacteria.
nn||design-2/NN||research-1/NN	nsubjpass||enrolled-20/VBN||design-2/NN	conj_and||design-2/NN||methods-4/NNS	nsubjpass||enrolled-20/VBN||methods-4/NNS	advmod||hospitalized-10/VBN||â-5/RB	num||patients-9/NNS||$-6/$	num||$-6/$||diabetic-8/CD	pobj||â-5/RB||patients-9/NNS	vmod||design-2/NN||hospitalized-10/VBN	det||department-14/NN||a-12/DT	amod||department-14/NN||diabeticfoot-13/JJ	prep_in||hospitalized-10/VBN||department-14/NN	det||footulcer-17/NN||a-16/DT	prep_with||department-14/NN||footulcer-17/NN	auxpass||enrolled-20/VBN||were-18/VBD	advmod||enrolled-20/VBN||prospectively-19/RB	root||ROOT-0/null||enrolled-20/VBN	mark||free-25/JJ||if-21/IN	nsubj||free-25/JJ||they-22/PRP	aux||free-25/JJ||had-23/VBD	cop||free-25/JJ||been-24/VBN	advcl||enrolled-20/VBN||free-25/JJ	amod||treatment-28/NN||antibiotic-27/JJ	prep_of||free-25/JJ||treatment-28/NN	det||months-33/NNS||the-30/DT	amod||months-33/NNS||previous-31/JJ	num||months-33/NNS||6-32/CD	prep_over||free-25/JJ||months-33/NNS	antibiotic-27||diabeticfoot-13||no_rel||research design and methods âdiabetic patients hospitalized in a diabeticfoot department with a footulcer were prospectively enrolled if they had been free of antibiotic treatment over the previous 6 months.
nsubj||disease-5/NN||malaria-1/NN	cop||disease-5/NN||is-2/VBZ	det||disease-5/NN||the-3/DT	amod||disease-5/NN||infectious-4/JJ	ccomp||changed-28/VBN||disease-5/NN	vmod||disease-5/NN||causing-6/VBG	det||morbidity-9/NN||the-7/DT	amod||morbidity-9/NN||highest-8/JJS	dobj||causing-6/VBG||morbidity-9/NN	dobj||causing-6/VBG||mortality-11/NN	conj_and||morbidity-9/NN||mortality-11/NN	prep_in||mortality-11/NN||angola-13/NN	amod||widespread-17/JJ||due-15/JJ	dep||widespread-17/JJ||to-16/TO	amod||resistance-22/NN||widespread-17/JJ	amod||resistance-22/NN||chloroquine-18/JJ	dep||resistance-22/NN||cq-20/VBN	dobj||causing-6/VBG||resistance-22/NN	conj_and||morbidity-9/NN||resistance-22/NN	det||country-25/NN||the-24/DT	nsubj||changed-28/VBN||country-25/NN	aux||changed-28/VBN||has-26/VBZ	advmod||changed-28/VBN||recently-27/RB	root||ROOT-0/null||changed-28/VBN	poss||recommendations-32/NNS||its-29/PRP$	amod||recommendations-32/NNS||first-line-30/JJ	nn||recommendations-32/NNS||treatment-31/NN	dobj||changed-28/VBN||recommendations-32/NNS	amod||malaria-35/NN||uncomplicated-34/JJ	prep_for||changed-28/VBN||malaria-35/NN	prep_from||changed-28/VBN||cq-38/NN	aux||artemisinin-40/VB||to-39/TO	vmod||cq-38/NN||artemisinin-40/VB	nn||therapies-42/NNS||combination-41/NN	dobj||artemisinin-40/VB||therapies-42/NNS	appos||therapies-42/NNS||act-44/NN	prep_in||therapies-42/NNS||adults-47/NNS	prep_in||therapies-42/NNS||sulphadoxine/pyrimethamine-50/NN	conj_and||adults-47/NNS||sulphadoxine/pyrimethamine-50/NN	appos||adults-47/NNS||s/p-52/NN	amod||women-56/NNS||pregnant-55/JJ	prep_in||artemisinin-40/VB||women-56/NNS	malaria-35||chloroquine-18||yes||malaria is the infectious disease causing the highest morbidity and mortality in angola and due to widespread chloroquine (cq) resistance, the country has recently changed its first-line treatment recommendations for uncomplicated malaria, from cq to artemisinin combination therapies (act) in adults, and sulphadoxine/pyrimethamine (s/p) in pregnant women.
nn||patients-4/NNS||uc-1/NN	conj_and||uc-1/NN||cd-3/NN	nn||patients-4/NNS||cd-3/NN	nsubj||had-5/VBD||patients-4/NNS	root||ROOT-0/null||had-5/VBD	advmod||higher-7/JJR||significantly-6/RB	amod||levels-10/NNS||higher-7/JJR	amod||levels-10/NNS||serum-8/JJ	amod||levels-10/NNS||s100a12-9/JJ	dobj||had-5/VBD||levels-10/NNS	prepc_compared_to||levels-10/NNS||to-12/TO	nn||patients-14/NNS||ibs-13/NN	pobj||levels-10/NNS||patients-14/NNS	dep||patients-14/NNS||p-16/VBN	dep||0.001-18/CD||=-17/SYM	ccomp||p-16/VBN||0.001-18/CD	det||comparisons-21/NNS||both-20/DT	prep_for||p-16/VBN||comparisons-21/NNS	uc-1||cd-3||no_rel||uc and cd patients had significantly higher serum s100a12 levels compared to ibs patients ( p = 0.001 for both comparisons).
nsubj||antiemeticdrug-6/NN||ondansetronhydrochloride-1/NN	cop||antiemeticdrug-6/NN||is-2/VBZ	det||antiemeticdrug-6/NN||an-3/DT	advmod||bitter-5/JJ||intensely-4/RB	amod||antiemeticdrug-6/NN||bitter-5/JJ	root||ROOT-0/null||antiemeticdrug-6/NN	vmod||antiemeticdrug-6/NN||used-7/VBN	aux||treat-9/VB||to-8/TO	xcomp||used-7/VBN||treat-9/VB	dobj||treat-9/VB||nausea-10/NN	dobj||treat-9/VB||vomiting-12/NN	conj_and||nausea-10/NN||vomiting-12/NN	prep_following||nausea-10/NN||chemotherapy-14/NN	ondansetronhydrochloride-1||nausea-10||no_rel||ondansetronhydrochloride is an intensely bitter antiemeticdrug used to treat nausea and vomiting following chemotherapy.
nsubjpass||known-8/VBN||resistance-1/NN	nsubjpass||associated-11/VBN||resistance-1/NN	prep_to||resistance-1/NN||chloroquine-3/NN	nn||strains-6/NNS||malaria-5/NN	prep_of||chloroquine-3/NN||strains-6/NNS	auxpass||known-8/VBN||is-7/VBZ	root||ROOT-0/null||known-8/VBN	aux||associated-11/VBN||to-9/TO	auxpass||associated-11/VBN||be-10/VB	xcomp||known-8/VBN||associated-11/VBN	det||protein-15/NN||a-13/DT	nn||protein-15/NN||parasite-14/NN	prep_with||associated-11/VBN||protein-15/NN	vmod||protein-15/NN||named-16/VBN	dobj||named-16/VBN||pfcrt-17/NN	det||form-21/NN||the-19/DT	amod||form-21/NN||mutated-20/JJ	appos||pfcrt-17/NN||form-21/NN	nsubj||able-25/JJ||which-23/WDT	nsubj||reduce-27/VB||which-23/WDT	cop||able-25/JJ||is-24/VBZ	prepc_of||form-21/NN||able-25/JJ	aux||reduce-27/VB||to-26/TO	xcomp||able-25/JJ||reduce-27/VB	amod||accumulation-29/NN||chloroquine-28/JJ	dobj||reduce-27/VB||accumulation-29/NN	det||vacuole-33/NN||the-31/DT	amod||vacuole-33/NN||digestive-32/JJ	prep_in||reduce-27/VB||vacuole-33/NN	det||pathogen-36/NN||the-35/DT	prep_of||vacuole-33/NN||pathogen-36/NN	malaria-5||chloroquine-28||yes||resistance to chloroquine of malaria strains is known to be associated with a parasite protein named pfcrt, the mutated form of which is able to reduce chloroquine accumulation in the digestive vacuole of the pathogen.
det||findings-2/NNS||these-1/DT	nsubj||extend-3/VB||findings-2/NNS	nsubj||possess-12/VB||findings-2/NNS	nsubj||highlight-18/VB||findings-2/NNS	root||ROOT-0/null||extend-3/VB	det||range-6/NN||the-4/DT	nn||range-6/NN||host-5/NN	dobj||extend-3/VB||range-6/NN	det||influenzavirus-10/NNS||the-8/DT	amod||influenzavirus-10/NNS||h5n1-9/JJ	prep_of||range-6/NN||influenzavirus-10/NNS	conj_and||extend-3/VB||possess-12/VB	dobj||possess-12/VB||implications-13/NNS	prep_for||implications-13/NNS||influenzavirus-15/NNS	advmod||possess-12/VB||epidemiology-16/RB	conj_and||extend-3/VB||highlight-18/VB	det||need-20/NN||the-19/DT	dobj||highlight-18/VB||need-20/NN	det||surveillance-24/NN||the-22/DT	amod||surveillance-24/NN||systematic-23/JJ	prep_for||need-20/NN||surveillance-24/NN	prep_of||surveillance-24/NN||h5n1-26/CD	prep_in||highlight-18/VB||animals-28/NNS	det||vicinity-31/NN||the-30/DT	prep_in||animals-28/NNS||vicinity-31/NN	nn||units-35/NNS||backyard-33/NN	nn||units-35/NNS||poultry-34/NN	prep_of||vicinity-31/NN||units-35/NNS	advmod||highlight-18/VB||especially-36/RB	amod||areas-39/NNS||endemic-38/JJ	prep_in||highlight-18/VB||areas-39/NNS	h5n1-26||influenzavirus-15||no||these findings extend the host range of the h5n1 influenzavirus, possess implications for influenzavirus epidemiology and highlight the need for the systematic surveillance of h5n1 in animals in the vicinity of backyard poultry units especially in endemic areas.
det||results-2/NNS||the-1/DT	nsubj||suggest-3/VBP||results-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||provide-8/VBP||that-4/IN	det||r5-7/NNS||the-5/DT	nn||r5-7/NNS||group-6/NN	nsubj||provide-8/VBP||r5-7/NNS	nsubj||showed-21/VBD||r5-7/NNS	ccomp||suggest-3/VBP||provide-8/VBP	amod||relief-10/NN||more-9/JJR	dobj||provide-8/VBP||relief-10/NN	amod||pain-14/NN||propofol-12/JJ	amod||pain-14/NN||induced-13/JJ	prep_in||provide-8/VBP||pain-14/NN	det||r3-18/NN||the-16/DT	nn||r3-18/NN||group-17/NN	prep_than||pain-14/NN||r3-18/NN	ccomp||suggest-3/VBP||showed-21/VBD	conj_but||provide-8/VBP||showed-21/VBD	amod||possibility-23/NN||great-22/JJ	dobj||showed-21/VBD||possibility-23/NN	prep_of||possibility-23/NN||hypotension-25/NN	prep_of||possibility-23/NN||bradycardia-27/NN	conj_and||hypotension-25/NN||bradycardia-27/NN	det||groups-30/NNS||both-29/DT	prep_in||showed-21/VBD||groups-30/NNS	nsubj||means-33/VBZ||groups-30/NNS	rcmod||groups-30/NNS||means-33/VBZ	nsubjpass||used-37/VBN||it-34/PRP	aux||used-37/VBN||should-35/MD	auxpass||used-37/VBN||be-36/VB	ccomp||means-33/VBZ||used-37/VBN	prep_with||used-37/VBN||cautions-39/NNP	det||patients-43/NNS||the-41/DT	amod||patients-43/NNS||elderly-42/JJ	prep_in||used-37/VBN||patients-43/NNS	pain-14||propofol-12||yes||the results suggest that the group r5 provide more relief in propofol induced pain than the group r3, but showed great possibility of hypotension and bradycardia in both groups, which means it should be used with cautions in the elderly patients.
vmod||examined-17/VBN||going-1/VBG	prt||going-1/VBG||back-2/RP	det||century-7/NN||the-4/DT	amod||century-7/NN||late-5/JJ	amod||century-7/NN||19th-6/JJ	prep_to||going-1/VBG||century-7/NN	det||histories-11/NNS||the-9/DT	amod||histories-11/NNS||evolutionary-10/JJ	nsubjpass||examined-17/VBN||histories-11/NNS	nsubj||understand-23/VB||histories-11/NNS	amod||viruses-15/NNS||past-13/JJ	amod||viruses-15/NNS||pandemic-14/JJ	prep_of||histories-11/NNS||viruses-15/NNS	auxpass||examined-17/VBN||are-16/VBP	root||ROOT-0/null||examined-17/VBN	det||effort-20/NN||an-19/DT	prep_in||examined-17/VBN||effort-20/NN	aux||understand-23/VB||to-21/TO	advmod||understand-23/VB||better-22/RBR	xcomp||examined-17/VBN||understand-23/VB	det||nature-25/NN||the-24/DT	dobj||understand-23/VB||nature-25/NN	dobj||understand-23/VB||extent-27/NN	conj_and||nature-25/NN||extent-27/NN	det||pressures-31/NNS||the-29/DT	amod||pressures-31/NNS||immune-30/JJ	prep_of||nature-25/NN||pressures-31/NNS	vmod||pressures-31/NNS||faced-32/VBN	det||virus-37/NN||the-34/DT	num||virus-37/NN||2009-35/CD	amod||virus-37/NN||pandemic-36/JJ	agent||faced-32/VBN||virus-37/NN	det||future-41/NN||the-39/DT	amod||future-41/NN||immediate-40/JJ	prep_in||faced-32/VBN||future-41/NN	virus-37||viruses-15||no||going back to the late 19th century, the evolutionary histories of past pandemic viruses are examined in an effort to better understand the nature and extent of the immune pressures faced by the 2009 pandemic virus in the immediate future.
nsubjpass||approved-9/VBN||atomoxetine-1/NN	dep||atomoxetine-1/NN||atomoxetinehydrochloride-3/NN	nn||®-6/NNP||stratteraâ-5/NNP	dep||atomoxetinehydrochloride-3/NN||®-6/NNP	auxpass||approved-9/VBN||was-8/VBD	root||ROOT-0/null||approved-9/VBN	prep_in||approved-9/VBN||2002-11/CD	prep_for||approved-9/VBN||treatment-13/NN	prep_of||treatment-13/NN||adhd-15/NN	cop||medication-22/NN||was-18/VBD	det||medication-22/NN||the-19/DT	amod||medication-22/NN||first-20/JJ	nn||medication-22/NN||nonstimulant-21/NN	conj_and||approved-9/VBN||medication-22/NN	vmod||medication-22/NN||approved-23/VBN	det||disorder-26/NN||this-25/DT	prep_for||approved-23/VBN||disorder-26/NN	adhd-15||atomoxetinehydrochloride-3||yes||atomoxetine (atomoxetinehydrochloride; stratteraâ®) was approved in 2002 for treatment of adhd, and was the first nonstimulant medication approved for this disorder.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||significance-5/NN||the-3/DT	amod||significance-5/NN||clinical-4/JJ	dobj||investigated-2/VBD||significance-5/NN	amod||immunoglobulin-9/NN||serum-7/JJ	amod||immunoglobulin-9/NN||specific-8/JJ	prep_of||significance-5/NN||immunoglobulin-9/NN	dep||significance-5/NN||e-10/SYM	appos||significance-5/NN||lge-12/NN	det||enterotoxin-19/NN||the-15/DT	amod||enterotoxin-19/NN||staphylococcal-16/JJ	nn||enterotoxin-19/NN||superantigens-17/NNS	nn||enterotoxin-19/NN||staphylococcal-18/NN	prep_to||investigated-2/VBD||enterotoxin-19/NN	det||sea-22/NN||a-20/DT	dep||enterotoxin-19/NN||sea-22/NN	amod||enterotoxin-26/NN||staphylococcal-25/JJ	prep_to||investigated-2/VBD||enterotoxin-26/NN	conj_and||enterotoxin-19/NN||enterotoxin-26/NN	dep||enterotoxin-26/NN||b-27/SYM	appos||b-27/SYM||seb-29/NN	amod||toxin-34/NN||toxicshocksyndrome-33/JJ	prep_to||investigated-2/VBD||toxin-34/NN	conj_and||enterotoxin-19/NN||toxin-34/NN	appos||toxin-34/NN||tsst-36/NN	dep||toxin-34/NN||-1-38/CD	prep_in||investigated-2/VBD||patients-40/NNS	amod||urticaria-43/NN||chronic-42/JJ	prep_with||patients-40/NNS||urticaria-43/NN	appos||urticaria-43/NN||cu-45/NN	vmod||investigated-2/VBD||focusing-48/VBG	det||differences-51/NNS||the-50/DT	prep_on||focusing-48/VBG||differences-51/NNS	det||prevalences-54/NNS||these-53/DT	prep_in||differences-51/NNS||prevalences-54/NNS	amod||cu-57/NN||aspirin-intolerant-56/JJ	prep_between||prevalences-54/NNS||cu-57/NN	appos||cu-57/NN||aicu-59/NNP	amod||patients-67/NNS||aspirin-tolerant-62/JJ	nn||patients-67/NNS||cu-63/NN	appos||patients-67/NNS||atcu-65/NNP	prep_between||prevalences-54/NNS||patients-67/NNS	conj_and||cu-57/NN||patients-67/NNS	aspirin--1||toxicshocksyndrome-33||no_rel||we investigated the clinical significance of serum specific immunoglobulin e (lge) to the staphylococcal superantigens staphylococcal enterotoxin a (sea), staphylococcal enterotoxin b (seb), and toxicshocksyndrome toxin (tsst)-1 in patients with chronic urticaria (cu), focusing on the differences in these prevalences between aspirin-intolerant cu (aicu) and aspirin-tolerant cu (atcu) patients.
expl||was-2/VBD||there-1/EX	root||ROOT-0/null||was-2/VBD	det||incidence-6/NN||a-3/DT	advmod||lower-5/JJR||significantly-4/RB	amod||incidence-6/NN||lower-5/JJR	nsubj||was-2/VBD||incidence-6/NN	prep_of||incidence-6/NN||microemulsion-8/NN	amod||pain-11/NN||propofol-9/JJ	nn||pain-11/NN||injection-10/NN	npadvmod||than-26/IN||pain-11/NN	dep||pain-11/NN||severity-13/$	num||severity-13/$||2-14/CD	dep||pain-11/NN||more-16/JJR	conj_or||severity-13/$||more-16/JJR	det||group-21/NN||the-19/DT	nn||group-21/NN||combination-20/NN	prep_in||severity-13/$||group-21/NN	num||%-24/NN||12.5-23/CD	appos||pain-11/NN||%-24/NN	advmod||was-2/VBD||than-26/IN	det||groups-32/NNS||the-28/DT	amod||groups-32/NNS||remifentanil-29/JJ	conj_and||remifentanil-29/JJ||lidocaine-31/JJ	amod||groups-32/NNS||lidocaine-31/JJ	prep_in||than-26/IN||groups-32/NNS	num||%-35/NN||90-34/CD	nsubj||p-42/VBP||%-35/NN	num||%-38/NN||65-37/CD	conj_and||%-35/NN||%-38/NN	nsubj||p-42/VBP||%-38/NN	advmod||%-38/NN||respectively-40/RB	dep||groups-32/NNS||p-42/VBP	num||0.05-44/CD||<-43/CD	dobj||p-42/VBP||0.05-44/CD	pain-11||propofol-9||yes||there was a significantly lower incidence of microemulsion propofol injection pain (severity 2 or more) in the combination group (12.5%) than in the remifentanil and lidocaine groups (90% and 65%, respectively, p < 0.05).
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||identify-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||identify-8/VB||to-7/TO	xcomp||was-6/VBD||identify-8/VB	det||presence-10/NN||the-9/DT	dobj||identify-8/VB||presence-10/NN	iobj||identify-8/VB||presence-10/NN	amod||inh-14/NN||isoniazid-12/JJ	prep_of||presence-10/NN||inh-14/NN	prep_of||presence-10/NN||rifampicin-17/NN	conj_and||inh-14/NN||rifampicin-17/NN	appos||presence-10/NN||rif-19/NN	nn||resistance-22/NN||drug-21/NN	dep||presence-10/NN||resistance-22/NN	amod||cases-32/NNS||new-24/JJ	advmod||treated-27/JJ||previously-26/RB	conj_and||new-24/JJ||treated-27/JJ	amod||cases-32/NNS||treated-27/JJ	nn||cases-32/NNS||tuberculosis-28/NNP	appos||cases-32/NNS||tb-30/NN	prep_in||resistance-22/NN||cases-32/NNS	vmod||cases-32/NNS||using-33/VBG	nn||sequencing-35/NN||dna-34/NN	dobj||using-33/VBG||sequencing-35/NN	tb-30||isoniazid-12||yes||the aim of this study was to identify the presence of isoniazid (inh) and rifampicin(rif) drug resistance in new and previously treated tuberculosis (tb) cases using dna sequencing.
nsubjpass||allocated-17/VBN||patients-1/NNS	nsubj||receive-19/VB||patients-1/NNS	conj_and||patients-1/NNS||methods-3/NNS	nsubjpass||allocated-17/VBN||methods-3/NNS	nsubj||receive-19/VB||methods-3/NNS	number||hundred-5/CD||two-4/CD	dep||patients-1/NNS||hundred-5/CD	amod||patients-9/NNS||thirty-six-7/JJ	amod||patients-9/NNS||chemotherapy-naive-8/JJ	conj_and||patients-1/NNS||patients-9/NNS	nsubjpass||allocated-17/VBN||patients-9/NNS	nsubj||receive-19/VB||patients-9/NNS	amod||cancer-14/NN||inoperable-11/JJ	amod||cancer-14/NN||non-small-cell-12/JJ	nn||cancer-14/NN||lung-13/NN	prep_with||patients-9/NNS||cancer-14/NN	auxpass||allocated-17/VBN||were-15/VBD	advmod||allocated-17/VBN||randomly-16/RB	root||ROOT-0/null||allocated-17/VBN	aux||receive-19/VB||to-18/TO	xcomp||allocated-17/VBN||receive-19/VB	preconj||mg/m2-22/NNS||either-20/CC	num||mg/m2-22/NNS||200-21/CD	dobj||receive-19/VB||mg/m2-22/NNS	amod||cisplatin-25/NN||liposomal-24/JJ	prep_of||mg/m2-22/NNS||cisplatin-25/NN	num||paclitaxel-29/NN||135-27/CD	amod||paclitaxel-29/NN||mg/m2-28/JJ	prep_of||mg/m2-22/NNS||paclitaxel-29/NN	conj_and||cisplatin-25/NN||paclitaxel-29/NN	dep||paclitaxel-29/NN||arm-31/NN	dep||arm-31/NN||a-32/DT	num||cisplatin-37/NN||75-35/CD	amod||cisplatin-37/NN||mg/m2-36/JJ	dobj||receive-19/VB||cisplatin-37/NN	conj_or||mg/m2-22/NNS||cisplatin-37/NN	num||paclitaxel-41/NN||135-39/CD	amod||paclitaxel-41/NN||mg/m2-40/JJ	conj_or||mg/m2-22/NNS||paclitaxel-41/NN	conj_and||cisplatin-37/NN||paclitaxel-41/NN	appos||paclitaxel-41/NN||arm-43/NN	num||arm-43/NN||b-44/CD	advmod||mg/m2-22/NNS||once-47/RB	det||weeks-50/NNS||every-48/DT	num||weeks-50/NNS||2-49/CD	tmod||receive-19/VB||weeks-50/NNS	det||basis-54/NN||an-52/DT	nn||basis-54/NN||outpatient-53/NN	prep_on||receive-19/VB||basis-54/NN	cancer-14||cisplatin-37||no_rel||patients and methods two hundred and thirty-six chemotherapy-naive patients with inoperable non-small-cell lung cancer were randomly allocated to receive either 200 mg/m2 of liposomal cisplatin and 135 mg/m2 paclitaxel (arm a) or 75 mg/m2 cisplatin and 135 mg/m2 paclitaxel (arm b), once every 2 weeks on an outpatient basis.
amod||melanoma-3/NN||b16f10-2/JJ	prep_in||reduced-13/VBD||melanoma-3/NN	amod||association-9/NN||web2170-5/JJ	advmod||association-9/NN||alone-6/RB	conj_or||alone-6/RB||in-8/IN	advmod||association-9/NN||in-8/IN	nsubj||reduced-13/VBD||association-9/NN	prep_with||association-9/NN||dtic-11/NN	advmod||reduced-13/VBD||significantly-12/RB	root||ROOT-0/null||reduced-13/VBD	nn||volume-15/NN||tumour-14/NN	dobj||reduced-13/VBD||volume-15/NN	melanoma-3||dtic-11||yes||in b16f10 melanoma, web2170 alone or in association with dtic significantly reduced tumour volume.
amod||men-2/NNS||fifty-nine-1/JJ	nsubjpass||studied-14/VBN||men-2/NNS	advmod||controlled-5/VBN||well-4/RB	amod||type2diabetes-6/NNS||controlled-5/VBN	prep_with||men-2/NNS||type2diabetes-6/NNS	num||men-12/NNS||18-8/CD	amod||men-12/NNS||age-matched-9/JJ	amod||men-12/NNS||healthy-10/JJ	amod||men-12/NNS||normoglycemic-11/JJ	prep_with||men-2/NNS||men-12/NNS	conj_and||type2diabetes-6/NNS||men-12/NNS	auxpass||studied-14/VBN||were-13/VBD	root||ROOT-0/null||studied-14/VBN	xcomp||studied-14/VBN||using-15/VBG	amod||tomography-18/NN||positron-16/JJ	nn||tomography-18/NN||emission-17/NN	dobj||using-15/VBG||tomography-18/NN	aux||assess-20/VB||to-19/TO	vmod||using-15/VBG||assess-20/VB	amod||perfusion-23/NN||hepatic-21/JJ	nn||perfusion-23/NN||tissue-22/NN	dobj||assess-20/VB||perfusion-23/NN	amod||glucose-26/NN||insulin-stimulated-25/JJ	dobj||assess-20/VB||glucose-26/NN	amod||metabolism-31/NN||fasting-29/JJ	amod||metabolism-31/NN||fattyacid-30/JJ	dobj||assess-20/VB||metabolism-31/NN	conj_and||glucose-26/NN||metabolism-31/NN	dobj||assess-20/VB||respectively-33/RB	advmod||glucose-26/NN||respectively-33/RB	conj_and||glucose-26/NN||respectively-33/RB	prep_in||assess-20/VB||relation-36/NN	amod||content-40/NN||hepatic-38/JJ	nn||content-40/NN||triglyceride-39/NN	prep_to||relation-36/NN||content-40/NN	vmod||content-40/NN||quantified-42/VBN	amod||spectroscopy-47/NN||proton-44/JJ	amod||spectroscopy-47/NN||magnetic-45/JJ	nn||spectroscopy-47/NN||resonance-46/NN	agent||quantified-42/VBN||spectroscopy-47/NN	insulin--1||type2diabetes-6||no_rel||fifty-nine men with well controlled type2diabetes and 18 age-matched healthy normoglycemic men were studied using positron emission tomography to assess hepatic tissue perfusion, insulin-stimulated glucose, and fasting fattyacid metabolism, respectively, in relation to hepatic triglyceride content, quantified by proton magnetic resonance spectroscopy.
advmod||administrated-14/VBN||even-1/RB	mark||administrated-14/VBN||though-2/IN	nsubjpass||administrated-14/VBN||immunoprophylaxis-3/NNS	amod||immunoglobulin-6/NN||hepatitisb-5/JJ	prep_with||immunoprophylaxis-3/NNS||immunoglobulin-6/NN	appos||immunoglobulin-6/NN||hbig-8/NN	amod||vaccine-12/NN||hepatitisb-11/JJ	prep_with||immunoprophylaxis-3/NNS||vaccine-12/NN	conj_and||immunoglobulin-6/NN||vaccine-12/NN	auxpass||administrated-14/VBN||is-13/VBZ	advcl||suffer-34/VBP||administrated-14/VBN	prep_to||administrated-14/VBN||neonates-16/NNS	poss||mothers-18/NNS||neonates-16/NNS	nsubj||antigen-22/NN||mothers-18/NNS	cop||antigen-22/NN||are-19/VBP	amod||antigen-22/NN||hepatitisb-20/JJ	nn||antigen-22/NN||surface-21/NN	rcmod||neonates-16/NNS||antigen-22/NN	appos||antigen-22/NN||hbsag-24/NN	amod||antigen-22/NN||positive-26/JJ	quantmod||10-29/CD||about-28/RB	num||%-30/NN||10-29/CD	nsubj||suffer-34/VBP||%-30/NN	det||neonates-33/NNS||the-32/DT	prep_of||%-30/NN||neonates-33/NNS	root||ROOT-0/null||suffer-34/VBP	nn||infection-37/NN||hbv-36/NN	prep_from||suffer-34/VBP||infection-37/NN	poss||life-41/NN||their-39/PRP$	amod||life-41/NN||early-40/JJ	prep_in||infection-37/NN||life-41/NN	hbv-36||hbsag-24||yes||even though immunoprophylaxis with hepatitisb immunoglobulin (hbig) and hepatitisb vaccine is administrated to neonates whose mothers are hepatitisb surface antigen (hbsag) positive, about 10% of the neonates suffer from hbv infection in their early life.
det||pin-3/NN||a-1/DT	nn||pin-3/NN||titanium-2/NN	nsubjpass||implanted-5/VBN||pin-3/NN	nsubj||mimic-11/VB||pin-3/NN	auxpass||implanted-5/VBN||was-4/VBD	root||ROOT-0/null||implanted-5/VBN	nn||tibia-9/NN||mouse-7/NN	nn||tibia-9/NN||proximal-8/NN	prep_into||implanted-5/VBN||tibia-9/NN	aux||mimic-11/VB||to-10/TO	xcomp||implanted-5/VBN||mimic-11/VB	det||arthroplasty-15/NN||a-12/DT	amod||arthroplasty-15/NN||weight-bearing-13/JJ	nn||arthroplasty-15/NN||knee-14/NN	dobj||mimic-11/VB||arthroplasty-15/NN	vmod||arthroplasty-15/NN||followed-17/VBN	amod||challenge-20/NN||titanium-particles-19/JJ	agent||followed-17/VBN||challenge-20/NN	aux||induce-22/VB||to-21/TO	xcomp||followed-17/VBN||induce-22/VB	amod||osteolysis-24/NNS||periprosthetic-23/JJ	dobj||induce-22/VB||osteolysis-24/NNS	titanium-2||osteolysis-24||no_rel||a titanium pin was implanted into mouse proximal tibia to mimic a weight-bearing knee arthroplasty, followed by titanium-particles challenge to induce periprosthetic osteolysis.
det||results-2/NNS||the-1/DT	nsubj||indicated-3/VBD||results-2/NNS	root||ROOT-0/null||indicated-3/VBD	mark||showed-27/VBD||that-4/IN	mark||had-10/VBD||although-5/IN	amod||children-9/NNS||adhd-6/JJ	advmod||adhd-6/JJ||as-8/RB	conj_and||adhd-6/JJ||as-8/RB	amod||children-9/NNS||as-8/RB	nsubj||had-10/VBD||children-9/NNS	nsubj||took-19/VBD||children-9/NNS	nsubj||complete-22/VB||children-9/NNS	advcl||showed-27/VBD||had-10/VBD	det||tendency-12/NN||a-11/DT	dobj||had-10/VBD||tendency-12/NN	prepc_of||tendency-12/NN||repeating-14/VBG	det||errors-17/NNS||the-15/DT	amod||errors-17/NNS||same-16/JJ	dobj||repeating-14/VBG||errors-17/NNS	conj_and||had-10/VBD||took-19/VBD	advcl||showed-27/VBD||took-19/VBD	advmod||took-19/VBD||longer-20/RBR	aux||complete-22/VB||to-21/TO	xcomp||took-19/VBD||complete-22/VB	det||sequence-24/NN||a-23/DT	dobj||complete-22/VB||sequence-24/NN	nsubj||showed-27/VBD||both-26/DT	ccomp||indicated-3/VBD||showed-27/VBD	det||degree-29/NN||a-28/DT	nsubj||similar-38/JJ||degree-29/NN	conj_and||degree-29/NN||pattern-31/NN	nsubj||similar-38/JJ||pattern-31/NN	prep_of||degree-29/NN||improvement-33/NN	prep_in||improvement-33/NN||accuracy-35/NN	prep_in||improvement-33/NN||speed-37/NN	conj_and||accuracy-35/NN||speed-37/NN	xcomp||showed-27/VBD||similar-38/JJ	prep_to||similar-38/JJ||that-40/DT	advmod||developing-43/VBG||typically-42/RB	prepc_of||that-40/DT||developing-43/VBG	dobj||developing-43/VBG||children-44/NNS	adhd-6||speed-37||yes||the results indicated that although adhd and as children had a tendency of repeating the same errors and took longer to complete a sequence, both showed a degree and pattern of improvement in accuracy and speed similar to that of typically developing children.
advmod||analyzed-5/VBN||here-1/RB	nsubj||analyzed-5/VBN||we-3/PRP	aux||analyzed-5/VBN||have-4/VBP	root||ROOT-0/null||analyzed-5/VBN	nn||reactivity-8/NN||t-6/NN	nn||reactivity-8/NN||cell-7/NN	dobj||analyzed-5/VBN||reactivity-8/NN	prep_against||reactivity-8/NN||ppd-10/NN	prep_against||reactivity-8/NN||ag85-12/NNS	conj_and||ppd-10/NN||ag85-12/NNS	amod||individuals-15/NNS||hiv-infected-14/JJ	prep_in||analyzed-5/VBN||individuals-15/NNS	prep||analyzed-5/VBN||without-17/IN	prep||analyzed-5/VBN||with-19/IN	conj_or||without-17/IN||with-19/IN	amod||symptoms-21/NNS||clinical-20/JJ	pobj||with-19/IN||symptoms-21/NNS	prep_of||symptoms-21/NNS||tuberculosis-23/NNP	prep||analyzed-5/VBN||in-26/IN	conj_and||without-17/IN||in-26/IN	nn||patients-28/NNS||aids-27/NNS	pobj||in-26/IN||patients-28/NNS	prep_with||patients-28/NNS||disease-30/NN	vmod||disease-30/NN||caused-31/VBN	amod||mycobacteria-34/NN||nontuberculous-33/JJ	agent||caused-31/VBN||mycobacteria-34/NN	aids-27||hiv--1||no||here, we have analyzed t cell reactivity against ppd and ag85 in hiv-infected individuals, without or with clinical symptoms of tuberculosis, and in aids patients with disease caused by nontuberculous mycobacteria.
amod||analysis-4/NN||multivariate-1/JJ	amod||analysis-4/NN||logistic-2/JJ	nn||analysis-4/NN||regression-3/NN	nsubjpass||performed-6/VBN||analysis-4/NN	nsubj||assess-8/VB||analysis-4/NN	auxpass||performed-6/VBN||was-5/VBD	root||ROOT-0/null||performed-6/VBN	aux||assess-8/VB||to-7/TO	xcomp||performed-6/VBN||assess-8/VB	advmod||associated-12/VBN||how-9/WRB	nsubjpass||associated-12/VBN||religion-10/NN	auxpass||associated-12/VBN||was-11/VBD	ccomp||assess-8/VB||associated-12/VBN	prep_with||associated-12/VBN||perceptions-14/NNS	prep_about||perceptions-14/NNS||hiv-16/NN	nn||treatment-19/NN||hiv-18/NN	prep_about||perceptions-14/NNS||treatment-19/NN	conj_and||hiv-16/NN||treatment-19/NN	prep_about||perceptions-14/NNS||people-22/NNS	conj_and||hiv-16/NN||people-22/NNS	xcomp||associated-12/VBN||living-23/VBG	prep_with||living-23/VBG||hiv/aids-25/NNS	aids--1||hiv-18||no||multivariate logistic regression analysis was performed to assess how religion was associated with perceptions about hiv, hiv treatment, and people living with hiv/aids.
nn||review-4/NN||retrospective-1/NN	nn||review-4/NN||case-2/NN	nn||review-4/NN||notes-3/NNS	nsubj||admitted-8/VBD||review-4/NN	det||children-7/NNS||all-6/DT	prep_of||review-4/NN||children-7/NNS	root||ROOT-0/null||admitted-8/VBD	prep_to||admitted-8/VBD||hospital-10/NN	amod||falciparummalaria-13/NN||severe-12/JJ	prep_with||admitted-8/VBD||falciparummalaria-13/NN	prep_between||falciparummalaria-13/NN||april-15/NNP	num||april-15/NNP||2002-16/CD	tmod||admitted-8/VBD||july-18/NNP	num||july-18/NNP||2009-19/CD	prep||admitted-8/VBD||before-21/IN	prep||admitted-8/VBD||after-23/IN	conj_and||before-21/IN||after-23/IN	det||introduction-25/NN||the-24/DT	pobj||after-23/IN||introduction-25/NN	det||new-28/JJ||the-27/DT	prep_of||introduction-25/NN||new-28/JJ	nsubj||quinine-30/VBP||new-28/JJ	rcmod||new-28/JJ||quinine-30/VBP	dobj||quinine-30/VBP||regimen-31/NN	falciparummalaria-13||quinine-30||yes||retrospective case notes review of all children admitted to hospital with severe falciparummalaria between april 2002 - july 2009, before and after the introduction of the new who quinine regimen.
nsubj||affects-5/VBZ||denguevirus-1/NNS	appos||denguevirus-1/NNS||denv-3/NNP	root||ROOT-0/null||affects-5/VBZ	quantmod||half-7/PDT||over-6/IN	num||population-13/NN||half-7/PDT	det||population-13/NN||the-8/DT	amod||population-13/NN||worldâ-9/JJ	amod||population-13/NN||$-10/$	number||s-12/CD||-11/CD	num||$-10/$||s-12/CD	dobj||affects-5/VBZ||population-13/NN	num||countries-16/NNS||112-15/CD	prep_in||affects-5/VBZ||countries-16/NNS	nsubj||arthropod-27/NN||denguefever-19/NN	appos||denguefever-19/NN||df-21/NN	cop||arthropod-27/NN||is-23/VBZ	det||arthropod-27/NN||the-24/DT	amod||arthropod-27/NN||second-25/JJ	dep||second-25/JJ||largest-26/JJS	conj_and||affects-5/VBZ||arthropod-27/NN	vmod||arthropod-27/NN||borne-28/VBN	amod||hazard-31/NN||infectious-29/JJ	amod||hazard-31/NN||global-30/JJ	dobj||borne-28/VBN||hazard-31/NN	prep_after||borne-28/VBN||malaria-33/NN	prep_with||borne-28/VBN||complications-35/NNS	prep_like||complications-35/NNS||denguehemorrhagicfever-37/NN	appos||denguehemorrhagicfever-37/NN||dhf-39/NN	prep_like||complications-35/NNS||dengueshocksyndrome-42/NN	conj_and||denguehemorrhagicfever-37/NN||dengueshocksyndrome-42/NN	appos||denguehemorrhagicfever-37/NN||dss-44/NN	prep||borne-28/VBN||accounting-47/VBG	pcomp||accounting-47/VBG||for-48/IN	amod||morbidity-50/NN||significant-49/JJ	pobj||for-48/IN||morbidity-50/NN	nn||world-over-53/NN||mortality-52/NN	pobj||for-48/IN||world-over-53/NN	conj_and||morbidity-50/NN||world-over-53/NN	denguefever-19||denguevirus-1||no||denguevirus (denv) affects over half the worldâs population in 112 countries, and denguefever (df) is the second largest arthropod borne infectious global hazard after malaria with complications like denguehemorrhagicfever (dhf) and dengueshocksyndrome (dss), accounting for significant morbidity and mortality world-over.
amod||aim-3/NN||objective-1/JJ	det||aim-3/NN||the-2/DT	nsubj||was-7/VBD||aim-3/NN	nsubj||assess-9/VB||aim-3/NN	det||analysis-6/NN||this-5/DT	prep_of||aim-3/NN||analysis-6/NN	root||ROOT-0/null||was-7/VBD	aux||assess-9/VB||to-8/TO	xcomp||was-7/VBD||assess-9/VB	det||effect-11/NN||the-10/DT	dobj||assess-9/VB||effect-11/NN	amod||pressurized-14/JJ||budesonide/formoterol-13/JJ	amod||inhaler-16/NN||pressurized-14/JJ	amod||inhaler-16/NN||metered-dose-15/JJ	prep_of||effect-11/NN||inhaler-16/NN	nn||pmdi-19/NNS||bud/fm-18/NN	appos||inhaler-16/NN||pmdi-19/NNS	dobj||assess-9/VB||bud-22/NN	conj_and||effect-11/NN||bud-22/NN	amod||criteria-25/NNS||predefined-24/JJ	prep_on||bud-22/NN||criteria-25/NNS	prep_for||criteria-25/NNS||asthma-27/NN	amod||asthma-27/NN||worsening-28/VBG	det||metric-33/NN||an-30/DT	nn||metric-33/NN||asthma-31/NN	nn||metric-33/NN||control-32/NN	appos||bud-22/NN||metric-33/NN	advmod||aligned-35/VBN||generally-34/RB	vmod||metric-33/NN||aligned-35/VBN	prep_with||aligned-35/VBN||definitions-37/NNS	amod||exacerbations-41/NNS||moderate-39/JJ	nn||exacerbations-41/NNS||asthma-40/NN	prep_of||definitions-37/NNS||exacerbations-41/NNS	num||populations-46/NNS||four-44/CD	amod||populations-46/NNS||different-45/JJ	prep_across||bud-22/NN||populations-46/NNS	asthma-40||formoterol--1||yes||objective the aim of this analysis was to assess the effect of budesonide/formoterol pressurized metered-dose inhaler (bud/fm pmdi) and bud on predefined criteria for asthma worsening, an asthma control metric generally aligned with definitions of moderate asthma exacerbations, across four different populations.
advmod||report-4/VBP||here-1/RB	nsubj||report-4/VBP||we-3/PRP	root||ROOT-0/null||report-4/VBP	det||switch-7/NN||an-5/DT	nn||switch-7/NN||rna-6/NN	nsubj||utr-21/VBP||switch-7/NN	amod||3â-18/NNS||human-9/JJ	nn||3â-18/NNS||vascular-10/NN	nn||3â-18/NNS||endothelial-11/NN	nn||3â-18/NNS||growth-12/NN	amod||3â-18/NNS||factor-a-13/JJ	appos||3â-18/NNS||vegf-15/NN	nn||3â-18/NNS||mrna-17/NN	prep_in||switch-7/NN||3â-18/NNS	amod||3â-18/NNS||$-19/$	dep||$-19/$||-20/JJ	ccomp||report-4/VBP||utr-21/VBP	mark||signals-24/VBZ||that-22/IN	nsubj||signals-24/VBZ||integrates-23/NNS	ccomp||utr-21/VBP||signals-24/VBZ	prep_from||signals-24/VBZ||interferon-26/NN	appos||interferon-26/NN||ifn-28/NN	nn||³-32/NNS||î-31/NN	dobj||signals-24/VBZ||³-32/NNS	nsubj||regulate-36/VB||³-32/NNS	dobj||signals-24/VBZ||hypoxia-34/NN	conj_and||³-32/NNS||hypoxia-34/NN	nsubj||regulate-36/VB||hypoxia-34/NN	aux||regulate-36/VB||to-35/TO	parataxis||signals-24/VBZ||regulate-36/VB	xcomp||signals-24/VBZ||regulate-36/VB	nn||translation-38/NN||vegf-37/NN	dobj||regulate-36/VB||translation-38/NN	amod||cells-41/NNS||myeloid-40/JJ	prep_in||regulate-36/VB||cells-41/NNS	hypoxia-34||ifn-28||no_rel||here, we report an rna switch in human vascular endothelial growth factor-a (vegf) mrna 3âutr that integrates signals from interferon (ifn)-î³ and hypoxia to regulate vegf translation in myeloid cells.
nsubj||revealed-2/VBD||studies-1/NNS	root||ROOT-0/null||revealed-2/VBD	mark||appeared-31/VBD||that-3/IN	det||dose-6/NN||a-5/DT	nsubj||mg/kg-11/VBG||dose-6/NN	prep_of||dose-6/NN||25-8/CD	prep_of||dose-6/NN||75-10/CD	conj_and||25-8/CD||75-10/CD	prepc_at||appeared-31/VBD||mg/kg-11/VBG	det||reduction-14/NN||a-12/DT	amod||reduction-14/NN||considerable-13/JJ	nsubjpass||observed-21/VBN||reduction-14/NN	det||extent-17/NN||the-16/DT	prep_in||reduction-14/NN||extent-17/NN	prep_of||extent-17/NN||diarrhoea-19/NN	auxpass||observed-21/VBN||was-20/VBD	ccomp||mg/kg-11/VBG||observed-21/VBN	cc||observed-21/VBN||but-22/CC	det||dose-25/NN||a-24/DT	prep_at||observed-21/VBN||dose-25/NN	num||mg/kg-28/NN||100-27/CD	prep_of||dose-25/NN||mg/kg-28/NN	det||animals-30/NNS||the-29/DT	nsubj||appeared-31/VBD||animals-30/NNS	ccomp||revealed-2/VBD||appeared-31/VBD	advmod||constipated-33/JJ||completely-32/RB	acomp||appeared-31/VBD||constipated-33/JJ	advmod||subjected-35/VBN||when-34/WRB	advcl||appeared-31/VBD||subjected-35/VBN	amod||diarrhoea-39/NN||castoroil-37/JJ	amod||diarrhoea-39/NN||induced-38/JJ	prep_to||subjected-35/VBN||diarrhoea-39/NN	amod||model-43/NN||intestinal-41/JJ	nn||model-43/NN||motility-42/NN	prep_to||subjected-35/VBN||model-43/NN	conj_and||diarrhoea-39/NN||model-43/NN	constipated-33||castoroil-37||yes||studies revealed that at a dose of 25 and 75 mg/kg a considerable reduction in the extent of diarrhoea was observed but at a dose of 100 mg/kg the animals appeared completely constipated when subjected to castoroil induced diarrhoea and intestinal motility model.
det||docetaxel/axitinib-5/NN||the-1/DT	amod||docetaxel/axitinib-5/NN||cp-868-2/JJ	dep||cp-868-2/JJ||,596-3/CD	amod||docetaxel/axitinib-5/NN||/-4/JJ	nsubj||dose-8/NN||docetaxel/axitinib-5/NN	cop||dose-8/NN||was-6/VBD	neg||dose-8/NN||not-7/RB	root||ROOT-0/null||dose-8/NN	vmod||dose-8/NN||escalated-9/VBN	amod||incidence-13/NN||increased-12/VBN	prep_because_of||escalated-9/VBN||incidence-13/NN	amod||events-17/NNS||mucositis-like-15/JJ	amod||events-17/NNS||adverse-16/JJ	prep_of||incidence-13/NN||events-17/NNS	appos||events-17/NNS||aes-19/NN	amod||neutropenia-23/NN||concurrent-22/JJ	prep_with||incidence-13/NN||neutropenia-23/NN	advmod||incidence-13/NN||relative-24/JJ	prep_to||relative-24/JJ||that-26/DT	vmod||that-26/DT||expected-27/VBN	prep_for||expected-27/VBN||docetaxel-29/NN	neutropenia-23||docetaxel-29||no||the cp-868,596/docetaxel/axitinib was not dose escalated because of increased incidence of mucositis-like adverse events (aes) with concurrent neutropenia relative to that expected for docetaxel.
nsubj||952-3/CD||participants-1/NNS	cop||952-3/CD||were-2/VBD	root||ROOT-0/null||952-3/CD	nsubj||received-20/VBD||952-3/CD	nsubj||drank-25/VBD||952-3/CD	num||%-6/NN||78-5/CD	dep||952-3/CD||%-6/NN	det||sample-12/NN||the-8/DT	amod||sample-12/NN||total-9/JJ	amod||sample-12/NN||combine-10/JJ	nn||sample-12/NN||study-11/NN	prep_of||%-6/NN||sample-12/NN	amod||men-16/NNS||treatment-seeking-14/JJ	amod||men-16/NNS||alcohol-dependent-15/JJ	dep||952-3/CD||men-16/NNS	dep||952-3/CD||women-18/NNS	conj_and||men-16/NNS||women-18/NNS	rcmod||952-3/CD||received-20/VBD	advmod||received-20/VBD||pharmacotherapy-21/RB	prep_for||received-20/VBD||alcoholism-23/NN	rcmod||952-3/CD||drank-25/VBD	conj_and||received-20/VBD||drank-25/VBD	advmod||drank-25/VBD||at-26/IN	pobj||at-26/IN||least-27/JJS	advmod||at-26/IN||once-28/RB	det||trial-32/NN||the-30/DT	amod||trial-32/NN||16-week-31/JJ	prep_during||at-26/IN||trial-32/NN	alcoholism-23||alcohol--1||no||participants were 952 (78% of the total combine study sample) treatment-seeking alcohol-dependent men and women who received pharmacotherapy for alcoholism and drank at least once during the 16-week trial.
num||outpatients-2/NNS||seventeen-1/CD	nsubj||underwent-18/VBD||outpatients-2/NNS	prep_with||outpatients-2/NNS||schizophrenia-4/NN	num||aripiprazole-8/NN||9-6/CD	nn||aripiprazole-8/NN||taking-7/NN	dep||schizophrenia-4/NN||aripiprazole-8/NN	num||risperidone-12/NN||8-10/CD	nn||risperidone-12/NN||taking-11/NN	dep||schizophrenia-4/NN||risperidone-12/NN	conj_and||aripiprazole-8/NN||risperidone-12/NN	num||controls-17/NNS||18-15/CD	amod||controls-17/NNS||healthy-16/JJ	prep_with||outpatients-2/NNS||controls-17/NNS	conj_and||schizophrenia-4/NN||controls-17/NNS	root||ROOT-0/null||underwent-18/VBD	amod||pet-20/NN||18f-fluoroflumazenil-19/JJ	dobj||underwent-18/VBD||pet-20/NN	nn||receptor-24/NN||gabaa-23/NN	nsubjpass||compared-28/VBN||receptor-24/NN	amod||potential-26/JJ||binding-25/JJ	amod||receptor-24/NN||potential-26/JJ	auxpass||compared-28/VBN||was-27/VBD	conj_and||underwent-18/VBD||compared-28/VBN	det||groups-32/NNS||the-30/DT	num||groups-32/NNS||three-31/CD	prep_between||compared-28/VBN||groups-32/NNS	schizophrenia-4||aripiprazole-8||yes||seventeen outpatients with schizophrenia (9 taking aripiprazole and 8 taking risperidone) and 18 healthy controls underwent 18f-fluoroflumazenil pet, and gabaa receptor binding potential was compared between the three groups.
amod||samples-2/NNS||biopsy-1/JJ	nsubjpass||investigated-24/VBN||samples-2/NNS	num||patients-5/NNS||122-4/CD	prep_from||samples-2/NNS||patients-5/NNS	amod||melanoma-8/NN||metastatic-7/JJ	prep_with||patients-5/NNS||melanoma-8/NN	auxpass||treated-10/VBN||being-9/VBG	vmod||melanoma-8/NN||treated-10/VBN	prep_with||treated-10/VBN||tmz-12/NN	num||studies-16/NNS||two-14/CD	nn||studies-16/NNS||multicenter-15/NN	prep_in||treated-10/VBN||studies-16/NNS	det||group-22/NN||the-18/DT	amod||group-22/NN||dermatologic-19/JJ	amod||group-22/NN||cooperative-20/JJ	nn||group-22/NN||oncology-21/NN	prep_of||studies-16/NNS||group-22/NN	auxpass||investigated-24/VBN||were-23/VBD	root||ROOT-0/null||investigated-24/VBN	amod||methylation-28/NN||mgmt-26/JJ	nn||methylation-28/NN||promoter-27/NN	prep_for||investigated-24/VBN||methylation-28/NN	melanoma-8||tmz-12||yes||biopsy samples from 122 patients with metastatic melanoma being treated with tmz in two multicenter studies of the dermatologic cooperative oncology group were investigated for mgmt promoter methylation.
expl||was-2/VBD||there-1/EX	root||ROOT-0/null||was-2/VBD	neg||association-4/NN||no-3/DT	nsubj||was-2/VBD||association-4/NN	amod||alleles-10/NNS||functional-6/JJ	dep||functional-6/JJ||cyp2c19-7/CD	dep||functional-6/JJ||cyp2d6-9/CD	conj_and||cyp2c19-7/CD||cyp2d6-9/CD	prep_between||association-4/NN||alleles-10/NNS	nn||outcome-13/NN||treatment-12/NN	nsubj||was-2/VBD||outcome-13/NN	conj_and||association-4/NN||outcome-13/NN	nn||patients-16/NNS||multiplemyeloma-15/NN	prep_in||outcome-13/NN||patients-16/NNS	vmod||patients-16/NNS||treated-17/VBN	prep_with||treated-17/VBN||cyclophosphamide-19/NN	prep_with||treated-17/VBN||thalidomide-21/NN	conj_or||cyclophosphamide-19/NN||thalidomide-21/NN	prep_with||treated-17/VBN||bortezomib-23/NN	conj_or||cyclophosphamide-19/NN||bortezomib-23/NN	multiplemyeloma-15||cyclophosphamide-19||yes||there was no association between functional cyp2c19 and cyp2d6 alleles and treatment outcome in multiplemyeloma patients treated with cyclophosphamide, thalidomide or bortezomib.
amod||borrelia-2/NN||lymedisease-1/JJ	nsubj||infect-4/VB||borrelia-2/NN	aux||infect-4/VB||can-3/MD	root||ROOT-0/null||infect-4/VB	dobj||infect-4/VB||humans-5/NNS	dobj||infect-4/VB||animals-7/NNS	conj_and||humans-5/NNS||animals-7/NNS	prep_for||humans-5/NNS||months-9/NNS	prep_to||infect-4/VB||years-11/NNS	det||presence-15/NN||the-14/DT	prep_despite||infect-4/VB||presence-15/NN	det||response-21/NN||an-17/DT	amod||response-21/NN||active-18/JJ	nn||response-21/NN||host-19/NN	amod||response-21/NN||immune-20/JJ	prep_of||presence-15/NN||response-21/NN	lymedisease-1||borrelia-2||no||lymedisease borrelia can infect humans and animals for months to years, despite the presence of an active host immune response.
det||trial-6/NN||a-2/DT	amod||trial-6/NN||prospective-3/JJ	amod||trial-6/NN||randomized-5/JJ	prep_in||non-inferior-10/JJ||trial-6/NN	nsubj||non-inferior-10/JJ||daptomycin-8/NN	cop||non-inferior-10/JJ||was-9/VBD	root||ROOT-0/null||non-inferior-10/JJ	amod||therapy-13/NN||standard-12/JJ	prep_to||non-inferior-10/JJ||therapy-13/NN	amod||bacteraemia-16/NN||staphylococcusaureus-15/JJ	prep_for||therapy-13/NN||bacteraemia-16/NN	amod||endocarditis-19/NNS||right-sided-18/JJ	prep_for||therapy-13/NN||endocarditis-19/NNS	conj_and||bacteraemia-16/NN||endocarditis-19/NNS	endocarditis-19||daptomycin-8||no_rel||in a prospective, randomized trial, daptomycin was non-inferior to standard therapy for staphylococcusaureus bacteraemia and right-sided endocarditis.
nsubj||had-5/VBD||none-1/NN	det||patients-4/NNS||the-3/DT	prep_of||none-1/NN||patients-4/NNS	root||ROOT-0/null||had-5/VBD	amod||pain-7/NN||severe-6/JJ	dobj||had-5/VBD||pain-7/NN	det||procedure-10/NN||the-9/DT	prep_during||pain-7/NN||procedure-10/NN	quantmod||2-13/CD||only-12/RB	num||%-14/NN||2-13/CD	nsubj||required-20/VBD||%-14/NN	number||300-18/CD||six-16/CD	quantmod||300-18/CD||of-17/IN	dep||%-14/NN||300-18/CD	parataxis||had-5/VBD||required-20/VBD	nsubj||high-42/JJ||use-21/NN	amod||sedation-24/NN||intravenous-23/JJ	prep_of||use-21/NN||sedation-24/NN	dep||sedation-24/NN||propofol-26/JJ	preconj||sedation-24/NN||both-29/CC	det||$-32/$||the-30/DT	amod||$-32/$||surgeonâ-31/JJ	prep_of||use-21/NN||$-32/$	conj_and||sedation-24/NN||$-32/$	number||s-34/CD||-33/CD	num||$-32/$||s-34/CD	det||satisfaction-40/NN||the-36/DT	amod||satisfaction-40/NN||patientsâ-37/JJ	amod||satisfaction-40/NN||$-38/$	dep||$-38/$||-39/JJ	prep_of||use-21/NN||satisfaction-40/NN	conj_and||sedation-24/NN||satisfaction-40/NN	cop||high-42/JJ||were-41/VBD	ccomp||required-20/VBD||high-42/JJ	pain-7||propofol-26||yes||none of the patients had severe pain during the procedure; only 2% (six of 300) required use of intravenous sedation (propofol), both the surgeonâs and the patientsâ satisfaction were high.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||investigate-8/VB||aim-2/NN	det||study-5/NN||the-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||investigate-8/VB||to-7/TO	xcomp||was-6/VBD||investigate-8/VB	det||effect-10/NN||the-9/DT	dobj||investigate-8/VB||effect-10/NN	amod||patients-37/NNS||bortezomib-12/JJ	nn||proliferation-15/NN||osteoblast-14/NN	prep_on||bortezomib-12/JJ||proliferation-15/NN	prep_on||bortezomib-12/JJ||differentiation-17/NN	conj_and||proliferation-15/NN||differentiation-17/NN	nn||deposition-25/NN||bone-23/NN	nn||deposition-25/NN||matrix-24/NN	prep_on||bortezomib-12/JJ||deposition-25/NN	conj_and||proliferation-15/NN||deposition-25/NN	det||time-29/NN||the-27/DT	amod||time-29/NN||first-28/JJ	prep_for||deposition-25/NN||time-29/NN	prep_in||time-29/NN||bisphosphonate-naã-31/NNP	amod||patients-37/NNS||¯-32/JJ	amod||patients-37/NNS||ve-33/JJ	advmod||untreated-36/JJ||previously-35/RB	amod||patients-37/NNS||untreated-36/JJ	prep_of||effect-10/NN||patients-37/NNS	prep_with||investigate-8/VB||myeloma-39/NN	myeloma-39||bortezomib-12||yes||the aim of the study was to investigate the effect of bortezomib on osteoblast proliferation and differentiation, as well as on bone matrix deposition for the first time in bisphosphonate-naã¯ve, previously untreated patients with myeloma.
det||study-3/NN||the-1/DT	amod||study-3/NN||present-2/JJ	nsubjpass||designed-6/VBN||study-3/NN	nsubj||evaluate-8/VB||study-3/NN	auxpass||designed-6/VBN||was-4/VBD	advmod||designed-6/VBN||thus-5/RB	root||ROOT-0/null||designed-6/VBN	aux||evaluate-8/VB||to-7/TO	xcomp||designed-6/VBN||evaluate-8/VB	det||effect-10/NN||the-9/DT	dobj||evaluate-8/VB||effect-10/NN	det||use-13/NN||the-12/DT	prep_of||effect-10/NN||use-13/NN	prep_of||use-13/NN||acupuncture-15/NN	det||alleviation-18/NN||the-17/DT	prep_in||acupuncture-15/NN||alleviation-18/NN	det||symptoms-21/NNS||the-20/DT	prep_of||alleviation-18/NN||symptoms-21/NNS	prep_of||symptoms-21/NNS||patients-23/NNS	amod||patients-27/NNS||ms.-25/JJ	amod||patients-27/NNS||thirty-one-26/JJ	prep_with||patients-23/NNS||patients-27/NNS	prep_with||evaluate-8/VB||relapsing-remittingmultiplesclerosis-29/NNS	vmod||relapsing-remittingmultiplesclerosis-29/NNS||undergoing-30/VBG	dobj||undergoing-30/VBG||treatment-31/NN	mark||distributed-36/VBN||with-32/IN	nsubjpass||distributed-36/VBN||immunomodulators-33/NNS	auxpass||distributed-36/VBN||were-34/VBD	advmod||distributed-36/VBN||randomly-35/RB	advcl||undergoing-30/VBG||distributed-36/VBN	amod||experimental-39/JJ||sex-stratified-38/JJ	prep_into||distributed-36/VBN||experimental-39/JJ	nn||groups-42/NNS||placebo-41/NN	prep_into||distributed-36/VBN||groups-42/NNS	conj_and||experimental-39/JJ||groups-42/NNS	det||design-49/NN||a-44/DT	amod||design-49/NN||patient-45/JJ	conj_and||patient-45/JJ||evaluator-blind-48/JJ	amod||design-49/NN||evaluator-blind-48/JJ	prep_in||distributed-36/VBN||design-49/NN	nsubj||received-52/VBD||they-51/PRP	parataxis||designed-6/VBN||received-52/VBD	det||electroacupuncture-57/NN||either-53/DT	amod||electroacupuncture-57/NN||true-54/JJ	conj_or||true-54/JJ||sham-56/JJ	amod||electroacupuncture-57/NN||sham-56/JJ	dobj||received-52/VBD||electroacupuncture-57/NN	amod||visits-60/NNS||regular-59/JJ	prep_during||received-52/VBD||visits-60/NNS	det||doctor-63/NN||the-62/DT	prep_to||received-52/VBD||doctor-63/NN	det||clinic-69/NN||the-65/DT	nn||clinic-69/NN||university-66/NN	nn||clinic-69/NN||hospital-67/NN	nn||clinic-69/NN||outpatient-68/NN	prep_in||doctor-63/NN||clinic-69/NN	immunomodulators-33||relapsing-remittingmultiplesclerosis-29||no_rel||the present study was thus designed to evaluate the effect of the use of acupuncture in the alleviation of the symptoms of patients with ms. thirty-one patients with relapsing-remittingmultiplesclerosis undergoing treatment with immunomodulators were randomly distributed into sex-stratified experimental and placebo groups in a patient - and evaluator-blind design ; they received either true or sham electroacupuncture during regular visits to the doctor in the university hospital outpatient clinic .
nsubj||used-2/VBD||we-1/PRP	root||ROOT-0/null||used-2/VBD	dobj||used-2/VBD||2000â-3/NNS	prep||2000â-3/NNS||$-4/$	advmod||data-7/NNS||2004-6/RB	dep||¥-28/CD||data-7/NNS	det||supplement-10/NN||the-9/DT	prep_from||data-7/NNS||supplement-10/NN	nn||project-17/NN||hiv/aids-12/NNS	nn||project-17/NN||surveillance-13/NN	nn||project-17/NN||shas-15/NN	prep_to||data-7/NNS||project-17/NN	det||project-22/NN||a-19/DT	amod||project-22/NN||cross-sectional-20/JJ	nn||project-22/NN||interview-21/NN	appos||project-17/NN||project-22/NN	amod||-27/NNS||hiv-infected-24/JJ	nn||-27/NNS||persons-25/NNS	nn||-27/NNS||â-26/NN	prep_of||project-22/NN||-27/NNS	num||$-4/$||¥-28/CD	num||years-30/NNS||18-29/CD	dep||$-4/$||years-30/NNS	vmod||years-30/NNS||conducted-31/VBN	num||states-34/NNS||18-33/CD	prep_in||conducted-31/VBN||states-34/NNS	aids--1||hiv--1||no||we used 2000â2004 data from the supplement to hiv/aids surveillance (shas) project, a cross-sectional interview project of hiv-infected persons â¥18 years conducted in 18 states.
aux||investigate-2/VB||to-1/TO	csubj||argentipes-10/VBZ||investigate-2/VB	det||susceptibility-7/NN||the-3/DT	nn||susceptibility-7/NN||ddt-4/NN	conj_and||ddt-4/NN||deltamethrin-6/NN	nn||susceptibility-7/NN||deltamethrin-6/NN	dobj||investigate-2/VB||susceptibility-7/NN	prep_of||susceptibility-7/NN||phlebotomus-9/NNS	root||ROOT-0/null||argentipes-10/VBZ	det||vector-13/NN||the-12/DT	dep||countries-27/NNS||vector-13/NN	nn||donovani-16/NNS||leishmania-15/NN	prep_of||vector-13/NN||donovani-16/NNS	amod||countries-27/NNS||responsible-18/JJ	prep_for||responsible-18/JJ||visceralleishmaniasis-20/NNS	appos||visceralleishmaniasis-20/NNS||vl-22/NN	prep_in||visceralleishmaniasis-20/NNS||two-26/CD	dobj||argentipes-10/VBZ||countries-27/NNS	dep||countries-27/NNS||india-29/JJ	dep||countries-27/NNS||nepal-31/JJ	conj_and||india-29/JJ||nepal-31/JJ	amod||histories-35/NNS||different-34/JJ	prep_with||argentipes-10/VBZ||histories-35/NNS	amod||exposure-38/NN||insecticide-37/JJ	prep_of||histories-35/NNS||exposure-38/NN	visceralleishmaniasis-20||ddt-4||no_rel||to investigate the ddt and deltamethrin susceptibility of phlebotomus argentipes , the vector of leishmania donovani , responsible for visceralleishmaniasis (vl), in two countries (india and nepal) with different histories of insecticide exposure.
nsubj||high-8/JJ||misconceptions-1/NNS	det||transmission-4/NN||the-3/DT	prep_about||misconceptions-1/NNS||transmission-4/NN	prep_of||transmission-4/NN||hiv-6/NN	cop||high-8/JJ||were-7/VBD	root||ROOT-0/null||high-8/JJ	amod||knowledge-11/NN||comprehensive-10/JJ	nsubj||low-17/JJ||knowledge-11/NN	prep_about||knowledge-11/NN||hiv-13/NNP	prep_about||knowledge-11/NN||aids-15/NNP	conj_and||hiv-13/NNP||aids-15/NNP	cop||low-17/JJ||was-16/VBD	conj_and||high-8/JJ||low-17/JJ	advmod||low-17/JJ||particularly-19/RB	prep_among||low-17/JJ||pastoralists-21/NNS	aids-15||hiv-13||no||misconceptions about the transmission of hiv were high and comprehensive knowledge about hiv & aids was low, particularly among pastoralists.
det||properties-3/NNS||the-1/DT	amod||properties-3/NNS||genetic-2/JJ	nsubj||due-8/JJ||properties-3/NNS	prep_of||properties-3/NNS||st75/st883-mrsa-5/CD	aux||due-8/JJ||may-6/MD	cop||due-8/JJ||be-7/VB	root||ROOT-0/null||due-8/JJ	det||series-11/NN||a-10/DT	prep_to||due-8/JJ||series-11/NN	amod||events-14/NNS||evolutionary-13/JJ	prep_of||series-11/NN||events-14/NNS	amod||strains-19/NNS||ancient-16/JJ	amod||strains-19/NNS||insulated-17/JJ	amod||strains-19/NNS||s.aureus-18/JJ	prep_in||due-8/JJ||strains-19/NNS	det||evolution-23/NN||a-21/DT	amod||evolution-23/NN||convergent-22/JJ	prep_including||strains-19/NNS||evolution-23/NN	vmod||evolution-23/NN||leading-24/VBG	aux||agr-26/VB||to-25/TO	xcomp||leading-24/VBG||agr-26/VB	dobj||agr-26/VB||group-27/NN	amod||sequences-33/NNS||i-28/JJ	conj_or||i-28/JJ||iv-like-31/JJ	amod||sequences-33/NNS||iv-like-31/JJ	nn||sequences-33/NNS||aip-32/NN	dep||group-27/NN||sequences-33/NNS	det||acquisition-37/NN||a-35/DT	amod||acquisition-37/NN||recent-36/JJ	dobj||agr-26/VB||acquisition-37/NN	conj_and||group-27/NN||acquisition-37/NN	nn||elements-42/NNS||scc-39/NN	nn||elements-42/NNS||mec-40/NN	nn||elements-42/NNS||iv-41/NN	prep_of||acquisition-37/NN||elements-42/NNS	mrsa--1||s.aureus-18||no||the genetic properties of st75/st883-mrsa may be due to a series of evolutionary events in ancient insulated s.aureus strains including a convergent evolution leading to agr group i - or iv-like aip sequences and a recent acquisition of scc mec iv elements .
prep_in||examines-4/VBZ||particular-2/JJ	nsubj||examines-4/VBZ||it-3/PRP	root||ROOT-0/null||examines-4/VBZ	det||steps-6/NNS||the-5/DT	dobj||examines-4/VBZ||steps-6/NNS	prepc_to||examines-4/VBZ||achieving-8/VBG	amod||availability-10/NN||wider-9/JJR	dobj||achieving-8/VBG||availability-10/NN	prep_of||availability-10/NN||opioids-12/NNS	nn||management-15/NN||pain-14/NN	prep_for||opioids-12/NNS||management-15/NN	prep_for||achieving-8/VBG||those-17/DT	advmod||advanced-20/VBN||far-19/RB	amod||disease-21/NN||advanced-20/VBN	prep_with||those-17/DT||disease-21/NN	opioids-12||pain-14||no_rel||in particular it examines the steps to achieving wider availability of opioids for pain management for those with far advanced disease.
amod||induced-2/NNS||gp120-1/JJ	nsubj||caspase-3/VBP||induced-2/NNS	root||ROOT-0/null||caspase-3/VBP	num||activation-7/NN||8-4/CD	amod||activation-7/NN||dependent-5/JJ	amod||activation-7/NN||nf-îºb-6/JJ	nsubj||pathway-11/NN||activation-7/NN	cop||pathway-11/NN||is-8/VBZ	det||pathway-11/NN||a-9/DT	nn||pathway-11/NN||novel-10/NN	ccomp||caspase-3/VBP||pathway-11/NN	nsubj||increases-16/VBZ||pathway-11/NN	nn||replication-14/NN||hiv-13/NN	prep_of||pathway-11/NN||replication-14/NN	rcmod||pathway-11/NN||increases-16/VBZ	ccomp||increases-16/VBZ||understanding-17/VBG	det||biology-20/NN||the-19/DT	prep_of||understanding-17/VBG||biology-20/NN	amod||death-23/NN||t-cell-22/JJ	prep_of||biology-20/NN||death-23/NN	ccomp||increases-16/VBZ||having-28/VBG	conj_and||understanding-17/VBG||having-28/VBG	dobj||having-28/VBG||implications-29/NNS	nn||treatment-32/NN||understanding-31/NN	prep_for||implications-29/NNS||treatment-32/NN	prep_for||implications-29/NNS||prevention-34/NN	conj_and||treatment-32/NN||prevention-34/NN	prep_of||implications-29/NNS||hivinfection-36/NN	hivinfection-36||hiv-13||no||gp120 induced caspase 8 dependent nf-îºb activation is a novel pathway of hiv replication which increases understanding of the biology of t-cell death, as well as having implications for understanding treatment and prevention of hivinfection.
det||woman-3/NN||a-1/DT	amod||woman-3/NN||75-year-old-2/JJ	nsubj||developed-10/VBD||woman-3/NN	amod||adenocarcinoma-6/NN||serous-5/JJ	prep_with||woman-3/NN||adenocarcinoma-6/NN	det||ovary-9/NN||the-8/DT	prep_of||adenocarcinoma-6/NN||ovary-9/NN	root||ROOT-0/null||developed-10/VBD	amod||pancolitis-12/NNS||lethal-11/JJ	nsubj||caused-13/VBD||pancolitis-12/NNS	ccomp||developed-10/VBD||caused-13/VBD	nn||difficile-16/NN||c.-15/NN	prep_by||caused-13/VBD||difficile-16/NN	num||cycles-19/NNS||five-18/CD	prep_after||caused-13/VBD||cycles-19/NNS	amod||chemotherapy-25/NN||paclitaxel-21/JJ	conj_and||paclitaxel-21/JJ||carboplatin-based-24/JJ	amod||chemotherapy-25/NN||carboplatin-based-24/JJ	prep_of||cycles-19/NNS||chemotherapy-25/NN	adenocarcinoma-6||carboplatin--1||no_rel||a 75-year-old woman with serous adenocarcinoma of the ovary developed lethal pancolitis caused by c. difficile after five cycles of paclitaxel - and carboplatin-based chemotherapy .
aux||evaluate-2/VB||to-1/TO	advcl||conducted-18/VBD||evaluate-2/VB	det||effects-4/NNS||the-3/DT	dobj||evaluate-2/VB||effects-4/NNS	prep_of||effects-4/NNS||hivinfection-6/NN	amod||precursors-9/NNS||intra-thymic-8/JJ	prep_on||evaluate-2/VB||precursors-9/NNS	nn||cells-12/NNS||t-11/NN	prep_of||precursors-9/NNS||cells-12/NNS	amod||adults-15/NNS||hiv-infected-14/JJ	prep_in||evaluate-2/VB||adults-15/NNS	nsubj||conducted-18/VBD||we-17/PRP	root||ROOT-0/null||conducted-18/VBD	det||study-22/NN||a-19/DT	amod||study-22/NN||detailed-20/JJ	amod||study-22/NN||immunophenotypic-21/JJ	dobj||conducted-18/VBD||study-22/NN	amod||tissue-25/NN||thymic-24/JJ	prep_of||study-22/NN||tissue-25/NN	vmod||tissue-25/NN||isolated-26/VBN	num||hiv-infected-29/NN||7-28/CD	prep_from||isolated-26/VBN||hiv-infected-29/NN	num||adults-33/NNS||10-31/CD	amod||adults-33/NNS||hiv-negative-32/JJ	prep_from||isolated-26/VBN||adults-33/NNS	conj_and||hiv-infected-29/NN||adults-33/NNS	nsubj||were-35/VBD||adults-33/NNS	nsubj||undergo-37/VB||adults-33/NNS	rcmod||adults-33/NNS||were-35/VBD	aux||undergo-37/VB||to-36/TO	xcomp||were-35/VBD||undergo-37/VB	nn||surgery-39/NN||heart-38/NN	dobj||undergo-37/VB||surgery-39/NN	hivinfection-6||hiv--1||no||to evaluate the effects of hivinfection on intra-thymic precursors of t cells in hiv-infected adults, we conducted a detailed immunophenotypic study of thymic tissue isolated from 7 hiv-infected and 10 hiv-negative adults who were to undergo heart surgery.
det||patients-4/NNS||the-3/DT	prep_due_to||undertook-19/VBD||patients-4/NNS	amod||record-7/NN||clean-5/JJ	amod||record-7/NN||medical-6/JJ	dep||patients-4/NNS||record-7/NN	det||diagnosis-13/NN||the-11/DT	amod||diagnosis-13/NN||radiologic-12/JJ	conj_and||patients-4/NNS||diagnosis-13/NN	prep_due_to||undertook-19/VBD||diagnosis-13/NN	prep_of||diagnosis-13/NN||intussusception-15/NN	nsubj||undertook-19/VBD||we-17/PRP	nsubj||established-27/VBD||we-17/PRP	advmod||undertook-19/VBD||promptly-18/RB	root||ROOT-0/null||undertook-19/VBD	amod||tests-22/NNS||further-20/JJ	amod||tests-22/NNS||serologic-21/JJ	dobj||undertook-19/VBD||tests-22/NNS	prep_for||undertook-19/VBD||humanimmunodeficiencyvirus-24/NNS	advmod||established-27/VBD||eventually-26/RB	conj_and||undertook-19/VBD||established-27/VBD	det||diagnosis-29/NN||the-28/DT	dobj||established-27/VBD||diagnosis-29/NN	prep_of||diagnosis-29/NN||acquiredimmunedeficiencysyndrome-31/NN	acquiredimmunedeficiencysyndrome-31||humanimmunodeficiencyvirus-24||no||due to the patients clean medical record as well as the radiologic diagnosis of intussusception, we promptly undertook further serologic tests for humanimmunodeficiencyvirus and eventually established the diagnosis of acquiredimmunedeficiencysyndrome.
prep_in||introduced-10/VBD||2001-2/CD	det||service-6/NN||the-3/DT	amod||service-6/NN||national-4/JJ	nn||service-6/NN||health-5/NN	nsubj||introduced-10/VBD||service-6/NN	det||uk-9/NN||the-8/DT	prep_in||service-6/NN||uk-9/NN	root||ROOT-0/null||introduced-10/VBD	det||scheme-15/NN||a-11/DT	amod||scheme-15/NN||mandatory-12/JJ	nn||scheme-15/NN||bacteraemia-13/NN	nn||scheme-15/NN||surveillance-14/NN	dobj||introduced-10/VBD||scheme-15/NN	det||reporting-18/NN||the-17/DT	prep_for||introduced-10/VBD||reporting-18/NN	prep_of||reporting-18/NN||s.aureus-20/NNS	amod||s.aureus-23/NNS||methicillin-resistant-22/JJ	prep_for||introduced-10/VBD||s.aureus-23/NNS	conj_and||reporting-18/NN||s.aureus-23/NNS	nn||-rrb--26/NNP||-lrb--24/NNP	nn||-rrb--26/NNP||mrsa-25/NNP	dep||s.aureus-23/NNS||-rrb--26/NNP	mrsa-25||s.aureus-23||no||in 2001 the national health service in the uk introduced a mandatory bacteraemia surveillance scheme for the reporting of s.aureus and methicillin-resistant s.aureus -lrb- mrsa -rrb- .
nsubj||combined-25/VBD||objective-1/NN	aux||compare-3/VB||to-2/TO	vmod||objective-1/NN||compare-3/VB	det||costs-6/NNS||the-4/DT	nn||costs-6/NNS||treatment-5/NN	dobj||compare-3/VB||costs-6/NNS	prep_of||costs-6/NNS||insulinglargine-8/NN	dep||insulinglargine-8/NN||ig-10/NN	nn||®-13/NNP||lantusâ-12/NNP	dep||ig-10/NN||®-13/NNP	aux||detemir-16/VB||to-15/TO	vmod||insulinglargine-8/NN||detemir-16/VB	dep||combined-25/VBD||id-18/NN	nn||®-21/NNP||levemirâ-20/NNP	dep||id-18/NN||®-21/NNP	nsubj||combined-25/VBD||both-24/DT	root||ROOT-0/null||combined-25/VBD	amod||insulinaspart-28/NN||bolus-27/JJ	prep_with||combined-25/VBD||insulinaspart-28/NN	nn||®-31/NNP||novorapidâ-30/NNP	appos||insulinaspart-28/NN||®-31/NNP	amod||t2d-36/NNS||type2diabetes-34/JJ	prep_in||combined-25/VBD||t2d-36/NNS	prep_in||t2d-36/NNS||germany-39/NN	t2d-36||insulinaspart-28||yes||objective to compare the treatment costs of insulinglargine (ig; lantusâ®) to detemir (id; levemirâ®), both combined with bolus insulinaspart (novorapidâ®) in type2diabetes (t2d) in germany.
det||protection-3/NN||the-1/DT	amod||protection-3/NN||acute-2/JJ	nsubj||supports-19/VBZ||protection-3/NN	amod||stimuli-7/NNS||subsequent-5/JJ	nn||stimuli-7/NNS||bronchoconstrictor-6/NN	prep_against||protection-3/NN||stimuli-7/NNS	amod||amp-11/NN||inhaled-10/JJ	prep_such_as||stimuli-7/NNS||amp-11/NN	det||reversal-15/NN||the-13/DT	amod||reversal-15/NN||rapid-14/JJ	prep_such_as||stimuli-7/NNS||reversal-15/NN	conj_and||amp-11/NN||reversal-15/NN	amod||obstruction-18/NN||airway-17/JJ	prep_of||reversal-15/NN||obstruction-18/NN	root||ROOT-0/null||supports-19/VBZ	det||use-21/NN||the-20/DT	dobj||supports-19/VBZ||use-21/NN	prep_of||use-21/NN||budesonide/formoterol-23/NN	preconj||relief-26/NN||both-25/DT	prep_for||supports-19/VBZ||relief-26/NN	prep_for||supports-19/VBZ||prevention-28/NN	conj_and||relief-26/NN||prevention-28/NN	det||treatment-31/NN||the-30/DT	prep_in||relief-26/NN||treatment-31/NN	prep_of||treatment-31/NN||asthma-33/NN	asthma-33||formoterol--1||no||the acute protection against subsequent bronchoconstrictor stimuli such as inhaled amp and the rapid reversal of airway obstruction supports the use of budesonide/formoterol for both relief and prevention in the treatment of asthma.
det||majority-2/NN||the-1/DT	nsubj||experience-6/VBP||majority-2/NN	nn||patients-5/NNS||cancer-4/NN	prep_of||majority-2/NN||patients-5/NNS	root||ROOT-0/null||experience-6/VBP	amod||loss-9/NN||dramatic-7/JJ	nn||loss-9/NN||weight-8/NN	dobj||experience-6/VBP||loss-9/NN	prep_due_to||loss-9/NN||cachexia-13/NN	dobj||experience-6/VBP||consisting-15/VBG	conj_and||loss-9/NN||consisting-15/VBG	amod||muscle-18/NN||skeletal-17/JJ	prep_of||consisting-15/VBG||muscle-18/NN	amod||wasting-22/NN||fat-20/JJ	nn||wasting-22/NN||tissue-21/NN	prep_of||consisting-15/VBG||wasting-22/NN	conj_and||muscle-18/NN||wasting-22/NN	wasting-22||fat-20||no_rel||the majority of cancer patients experience dramatic weight loss, due to cachexia and consisting of skeletal muscle and fat tissue wasting.
advmod||brought-16/VBN||however-1/RB	nsubj||brought-16/VBN||knowledge-3/NN	det||risk-6/NN||the-5/DT	prep_of||knowledge-3/NN||risk-6/NN	amod||transmission-12/NN||humanimmunodeficiencyvirus-8/JJ	appos||transmission-12/NN||hiv-10/NN	prep_of||risk-6/NN||transmission-12/NN	prep_through||transmission-12/NN||breastfeeding-14/NN	aux||brought-16/VBN||has-15/VBZ	root||ROOT-0/null||brought-16/VBN	prep_to||brought-16/VBN||attention-18/NN	det||controversy-20/NN||the-19/DT	dobj||brought-16/VBN||controversy-20/NN	mark||practiced-27/VBN||whether-22/IN	nsubjpass||practiced-27/VBN||breastfeeding-23/NN	aux||practiced-27/VBN||can-24/MD	auxpass||practiced-27/VBN||be-25/VB	advmod||practiced-27/VBN||safely-26/RB	prepc_of||controversy-20/NN||practiced-27/VBN	amod||mothers-30/NNS||hivpositive-29/JJ	agent||practiced-27/VBN||mothers-30/NNS	hivpositive-29||humanimmunodeficiencyvirus-8||no||however, knowledge of the risk of humanimmunodeficiencyvirus (hiv) transmission through breastfeeding has brought to attention the controversy of whether breastfeeding can be safely practiced by hivpositive mothers.
num||lines-4/NNS||four-1/CD	nn||lines-4/NNS||neuroblastoma-2/NN	nn||lines-4/NNS||cell-3/NN	nsubjpass||used-6/VBN||lines-4/NNS	auxpass||used-6/VBN||were-5/VBD	root||ROOT-0/null||used-6/VBN	xcomp||used-6/VBN||ukf-nb-3-7/JJ	dep||used-6/VBN||sk-n-as-9/JJ	prep||used-6/VBN||plus-11/CC	num||subline-14/NN||one-12/CD	amod||subline-14/NN||cisplatin-resistant-13/JJ	pobj||plus-11/CC||subline-14/NN	vmod||subline-14/NN||derived-15/VBN	prep_from||derived-15/VBN||each-17/DT	det||lines-23/NNS||the-19/DT	num||lines-23/NNS||two-20/CD	amod||lines-23/NNS||original-21/JJ	amod||lines-23/NNS||sensitive-22/JJ	prep_of||each-17/DT||lines-23/NNS	neuroblastoma-2||cisplatin--1||yes||four neuroblastoma cell lines were used ukf-nb-3, sk-n-as, plus one cisplatin-resistant subline derived from each of the two original sensitive lines.
nsubj||assessed-2/VBD||we-1/PRP	root||ROOT-0/null||assessed-2/VBD	nsubj||enrolled-7/VBD||nvp-resistance-3/NN	nn||infants-6/NNS||indian-5/NN	prep_in||nvp-resistance-3/NN||infants-6/NNS	dep||assessed-2/VBD||enrolled-7/VBD	det||transmission-34/NN||the-9/DT	amod||transmission-34/NN||â-10/JJ	amod||transmission-34/NN||$-11/$	dep||$-11/$||six-week-12/JJ	nn||transmission-34/NN||extended-dose-13/NN	dep||$-15/$||nevirapineâ-14/RB	dep||transmission-34/NN||$-15/$	amod||trial-19/NN||swen-17/JJ	npadvmod||of-31/RB||trial-19/NN	npadvmod||nvp-23/JJ||who-20/WP	npadvmod||single-dose-22/JJ||received-21/JJ	amod||who-20/WP||single-dose-22/JJ	advmod||trial-19/NN||nvp-23/JJ	dep||nvp-23/JJ||sd-nvp-25/NN	advmod||trial-19/NN||swen-28/JJ	conj_or||nvp-23/JJ||swen-28/JJ	prep_for||nvp-23/JJ||prevention-30/NN	dep||breast-milk-32/CD||of-31/RB	num||$-15/$||breast-milk-32/CD	amod||transmission-34/NN||hiv-33/JJ	prep_in||enrolled-7/VBD||transmission-34/NN	nsubj||acquired-38/VBD||who-36/WP	advmod||acquired-38/VBD||also-37/RB	dep||assessed-2/VBD||acquired-38/VBD	conj_but||enrolled-7/VBD||acquired-38/VBD	amod||hivinfection-41/NN||subtype-39/JJ	nn||hivinfection-41/NN||c-40/NN	dobj||acquired-38/VBD||hivinfection-41/NN	det||year-45/NN||the-43/DT	amod||year-45/NN||first-44/JJ	prep_during||acquired-38/VBD||year-45/NN	prep_of||year-45/NN||life-47/NN	hivinfection-41||nvp-23||yes||we assessed nvp-resistance in indian infants enrolled in the âsix-week extended-dose nevirapineâ? (swen) trial who received single-dose nvp (sd-nvp) or swen for prevention of breast-milk hiv transmission but who also acquired subtype c hivinfection during the first year of life.
advmod||shown-8/VBN||however-1/RB	amod||analyses-6/NNS||proteomic-3/JJ	conj_and||proteomic-3/JJ||transcriptomic-5/JJ	amod||analyses-6/NNS||transcriptomic-5/JJ	nsubj||shown-8/VBN||analyses-6/NNS	aux||shown-8/VBN||have-7/VBP	root||ROOT-0/null||shown-8/VBN	mark||upregulated-17/VBN||that-9/IN	det||number-11/NN||a-10/DT	nsubjpass||upregulated-17/VBN||number-11/NN	nsubjpass||upregulated-17/VBN||number-11/NN	nsubjpass||upregulated-17/VBN||number-11/NN	nn||genes-14/NNS||usp-13/NN	prep_of||number-11/NN||genes-14/NNS	auxpass||upregulated-17/VBN||are-15/VBP	advmod||upregulated-17/VBN||significantly-16/RB	ccomp||shown-8/VBN||upregulated-17/VBN	ccomp||shown-8/VBN||upregulated-17/VBN	ccomp||shown-8/VBN||upregulated-17/VBN	conj_and||upregulated-17/VBN||upregulated-17/VBN	conj_and||upregulated-17/VBN||upregulated-17/VBN	amod||conditions-20/NNS||hypoxic-19/JJ	prep_under||upregulated-17/VBN||conditions-20/NNS	prep_in||upregulated-17/VBN||response-23/NN	prep_to||upregulated-17/VBN||nitricoxide-25/NN	prep_to||upregulated-17/VBN||carbonmonoxide-27/NN	conj_and||nitricoxide-25/NN||carbonmonoxide-27/NN	prep_during||upregulated-17/VBN||m.tuberculosisinfection-33/NN	amod||lines-37/NNS||macrophage-35/JJ	nn||lines-37/NNS||cell-36/NN	prep_of||m.tuberculosisinfection-33/NN||lines-37/NNS	carbonmonoxide-27||hypoxic-19||no_rel||however , proteomic and transcriptomic analyses have shown that a number of usp genes are significantly upregulated under hypoxic conditions and in response to nitricoxide and carbonmonoxide , as well as during m.tuberculosisinfection of macrophage cell lines .
nsubj||conclude-2/VBP||we-1/PRP	root||ROOT-0/null||conclude-2/VBP	mark||used-17/VBN||that-3/IN	vmod||used-17/VBN||owing-4/VBG	prep_to||owing-4/VBG||complexity-6/NN	nn||metabolism-9/NN||iron-8/NN	prep_of||complexity-6/NN||metabolism-9/NN	prep_in||metabolism-9/NN||ckd-11/NN	nsubjpass||used-17/VBN||stfr-13/NN	aux||used-17/VBN||can-14/MD	neg||used-17/VBN||not-15/RB	auxpass||used-17/VBN||be-16/VB	ccomp||conclude-2/VBP||used-17/VBN	det||marker-21/NN||a-19/DT	amod||marker-21/NN||reliable-20/JJ	prep_as||used-17/VBN||marker-21/NN	prep_of||marker-21/NN||irondeficiencyanemia-23/NN	irondeficiencyanemia-23||iron-8||yes||we conclude that owing to complexity of iron metabolism in ckd, stfr can not be used as a reliable marker of irondeficiencyanemia.
nn||design-2/NN||research-1/NN	nsubj||stages-46/VBZ||design-2/NN	nn||â-5/NN||methods-4/NNS	conj_and||design-2/NN||â-5/NN	nsubj||stages-46/VBZ||â-5/NN	nsubjpass||divided-21/VBN||$-6/$	vmod||$-6/$||based-8/VBN	prep_on||based-8/VBN||values-10/NNS	vmod||values-10/NNS||obtained-11/VBN	amod||patients-19/NNS||iothalamate-13/JJ	num||patients-19/NNS||118-15/CD	nn||patients-19/NNS||type-16/NN	num||patients-19/NNS||2-17/CD	amod||patients-19/NNS||diabetic-18/JJ	prep_with||obtained-11/VBN||patients-19/NNS	auxpass||divided-21/VBN||were-20/VBD	rcmod||design-2/NN||divided-21/VBN	num||groups-24/NNS||three-23/CD	prep_into||divided-21/VBN||groups-24/NNS	prepc_according_to||divided-21/VBN||to-26/TO	amod||hyperfiltration-29/NN||renal-27/JJ	nn||hyperfiltration-29/NN||function-28/NN	pobj||divided-21/VBN||hyperfiltration-29/NN	appos||hyperfiltration-29/NN||26-31/CD	amod||function-35/NN||normal-34/JJ	pobj||divided-21/VBN||function-35/NN	conj_or||hyperfiltration-29/NN||function-35/NN	appos||function-35/NN||56-37/CD	amod||kidneydisease-42/NN||chronic-41/JJ	pobj||divided-21/VBN||kidneydisease-42/NN	conj_or||hyperfiltration-29/NN||kidneydisease-42/NN	discourse||kidneydisease-42/NN||ckd-44/UH	root||ROOT-0/null||stages-46/VBZ	amod||$-48/$||3â-47/JJ	dobj||stages-46/VBZ||$-48/$	num||$-48/$||4-50/CD	appos||$-48/$||36-52/CD	iothalamate-13||kidneydisease-42||no_rel||research design and methods âbased on values obtained with iothalamate, 118 type 2 diabetic patients were divided into three groups according to renal function hyperfiltration (26), normal function (56), or chronic kidneydisease (ckd) stages 3â4 (36).
amod||searches-2/NNS||pubmed-1/JJ	nsubjpass||conducted-4/VBN||searches-2/NNS	auxpass||conducted-4/VBN||were-3/VBD	root||ROOT-0/null||conducted-4/VBN	prep_for||conducted-4/VBN||olanzapine-6/NN	prep||conducted-4/VBN||combined-7/VBN	pcomp||combined-7/VBN||with-8/IN	pobj||with-8/IN||pharmacology-9/NN	pobj||with-8/IN||schizophrenia-11/NN	conj_or||pharmacology-9/NN||schizophrenia-11/NN	pobj||with-8/IN||bipolardisorder-14/NN	conj_or||pharmacology-9/NN||bipolardisorder-14/NN	bipolardisorder-14||olanzapine-6||yes||pubmed searches were conducted for olanzapine combined with pharmacology, schizophrenia, or bipolardisorder.
nsubj||disease-5/NN||leptospirosis-1/NNS	cop||disease-5/NN||is-2/VBZ	det||disease-5/NN||a-3/DT	nn||disease-5/NN||multisystem-4/NN	root||ROOT-0/null||disease-5/NN	vmod||disease-5/NN||caused-6/VBN	amod||strains-9/NNS||pathogenic-8/JJ	agent||caused-6/VBN||strains-9/NNS	det||genusleptospira-12/NN||the-11/DT	prep_of||strains-9/NNS||genusleptospira-12/NN	leptospirosis-1||genusleptospira-12||no||leptospirosis is a multisystem disease caused by pathogenic strains of the genusleptospira .
nsubj||influence-12/VBP||genotypes-1/NNS	dep||genotypes-1/NNS||a-3/DT	aux||h-5/VB||to-4/TO	dep||a-3/DT||h-5/VB	prep_of||genotypes-1/NNS||hepatitisbvirus-8/NNS	appos||hepatitisbvirus-8/NNS||hbv-10/NN	root||ROOT-0/null||influence-12/VBP	amod||progression-14/NN||liverdisease-13/JJ	dobj||influence-12/VBP||progression-14/NN	dobj||influence-12/VBP||response-16/NN	conj_and||progression-14/NN||response-16/NN	amod||therapy-19/NN||antiviral-18/JJ	prep_to||influence-12/VBP||therapy-19/NN	amod||patients-22/NNS||hbv-infected-21/JJ	prep_in||therapy-19/NN||patients-22/NNS	hbv-10||hepatitisbvirus-8||no||genotypes (a to h) of hepatitisbvirus (hbv) influence liverdisease progression and response to antiviral therapy in hbv-infected patients.
nsubj||conclude-2/VBP||we-1/PRP	nsubj||effective-15/JJ||we-1/PRP	nsubjpass||tolerated-19/VBN||we-1/PRP	root||ROOT-0/null||conclude-2/VBP	mark||administered-11/VBN||that-3/IN	num||carboxymaltose-7/NN||1000â-4/CD	nn||carboxymaltose-7/NN||mg-5/NN	amod||carboxymaltose-7/NN||ferric-6/JJ	nsubjpass||administered-11/VBN||carboxymaltose-7/NN	aux||administered-11/VBN||can-8/MD	auxpass||administered-11/VBN||be-9/VB	advmod||administered-11/VBN||rapidly-10/RB	ccomp||conclude-2/VBP||administered-11/VBN	cop||effective-15/JJ||is-13/VBZ	advmod||effective-15/JJ||more-14/RBR	conj_and||conclude-2/VBP||effective-15/JJ	auxpass||tolerated-19/VBN||is-17/VBZ	advmod||tolerated-19/VBN||better-18/RBR	conj_and||conclude-2/VBP||tolerated-19/VBN	amod||iron-22/NN||oral-21/JJ	prep_than||tolerated-19/VBN||iron-22/NN	prep_for||iron-22/NN||treatment-24/NN	prep_of||treatment-24/NN||irondeficiency-26/NN	amod||patients-29/NNS||nd-ckd-28/JJ	prep_in||tolerated-19/VBN||patients-29/NNS	irondeficiency-26||iron-22||yes||we conclude that 1000â mg ferric carboxymaltose can be rapidly administered, is more effective and is better tolerated than oral iron for treatment of irondeficiency in nd-ckd patients.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||effects-4/NNS||the-3/DT	dobj||investigated-2/VBD||effects-4/NNS	prep_on||effects-4/NNS||hemodynamics-6/NNS	nn||exchange-9/NN||gas-8/NN	prep_on||effects-4/NNS||exchange-9/NN	conj_and||hemodynamics-6/NNS||exchange-9/NN	det||emulsion-13/NN||a-11/DT	nn||emulsion-13/NN||lipid-12/NN	prep_of||effects-4/NNS||emulsion-13/NN	vmod||emulsion-13/NN||enriched-14/VBN	amod||fattyacids-17/NNS||omega-3-16/JJ	prep_with||enriched-14/VBN||fattyacids-17/NNS	prep_in||fattyacids-17/NNS||patients-19/NNS	prep_with||patients-19/NNS||ards-21/NNS	ards-21||lipid-12||no_rel||we investigated the effects on hemodynamics and gas exchange of a lipid emulsion enriched with omega-3 fattyacids in patients with ards.
nsubj||conclude-2/VBP||we-1/PRP	root||ROOT-0/null||conclude-2/VBP	mark||accurate-7/JJ||that-3/IN	det||tests-5/NNS||both-4/DT	nsubj||accurate-7/JJ||tests-5/NNS	nsubj||detect-9/VB||tests-5/NNS	cop||accurate-7/JJ||are-6/VBP	ccomp||conclude-2/VBP||accurate-7/JJ	aux||detect-9/VB||to-8/TO	xcomp||accurate-7/JJ||detect-9/VB	nn||tuberculosis-11/NNP||latent-10/NNP	dobj||detect-9/VB||tuberculosis-11/NNP	mark||have-17/VBP||although-13/IN	amod||assays-16/NNS||interferon-gamma-14/JJ	nn||assays-16/NNS||release-15/NN	nsubj||have-17/VBP||assays-16/NNS	dep||tuberculosis-11/NNP||have-17/VBP	amod||specificity-19/NN||higher-18/JJR	dobj||have-17/VBP||specificity-19/NN	nn||testing-23/NN||tuberculin-21/NN	nn||testing-23/NN||skin-22/NN	prep_than||have-17/VBP||testing-23/NN	amod||populations-26/NNS||bcg-vaccinated-25/JJ	prep_in||testing-23/NN||populations-26/NNS	advmod||received-32/VBN||particularly-28/RB	mark||received-32/VBN||if-29/IN	nsubjpass||received-32/VBN||bcg-30/NN	auxpass||received-32/VBN||is-31/VBZ	advcl||have-17/VBP||received-32/VBN	prep_after||received-32/VBN||infancy-34/NN	tuberculosis-11||bcg-30||no||we conclude that both tests are accurate to detect latent tuberculosis, although interferon-gamma release assays have higher specificity than tuberculin skin testing in bcg-vaccinated populations, particularly if bcg is received after infancy.
amod||models-4/NNS||multiple-1/JJ	amod||models-4/NNS||logistic-2/JJ	nn||models-4/NNS||regression-3/NN	nsubjpass||used-6/VBN||models-4/NNS	nsubj||determine-8/VB||models-4/NNS	auxpass||used-6/VBN||were-5/VBD	root||ROOT-0/null||used-6/VBN	aux||determine-8/VB||to-7/TO	xcomp||used-6/VBN||determine-8/VB	nn||factors-10/NNS||risk-9/NN	dobj||determine-8/VB||factors-10/NNS	amod||stress-13/NN||psychosocial-12/JJ	prep_for||determine-8/VB||stress-13/NN	appos||stress-13/NN||demoralization-15/NN	nn||consumption-18/NN||tobacco-17/NN	appos||demoralization-15/NN||consumption-18/NN	nn||¹-22/NNP||â-20/NNP	nn||¹-22/NNP||-21/NNP	dep||consumption-18/NN||¹-22/NNP	num||items/day-24/NN||10-23/CD	dep||¹-22/NNP||items/day-24/NN	amod||consumption-29/NN||high-risk-27/JJ	nn||consumption-29/NN||alcohol-28/NN	appos||consumption-18/NN||consumption-29/NN	dep||consumption-29/NN||men-31/NNS	number||20-33/CD||>-32/CD	dep||men-31/NNS||20-33/CD	nn||alcohol/day-36/NN||g-34/NN	amod||alcohol/day-36/NN||pure-35/JJ	dep||20-33/CD||alcohol/day-36/NN	dep||men-31/NNS||women-38/NNS	number||10-40/CD||>-39/CD	dep||women-38/NNS||10-40/CD	nn||alcohol/day-43/NN||g-41/NN	amod||alcohol/day-43/NN||pure-42/JJ	dep||10-40/CD||alcohol/day-43/NN	appos||consumption-18/NN||binge-46/NN	vmod||binge-46/NN||drinking-47/VBG	vmod||consumption-18/NN||problemdrinking-49/VBG	prepc_according_to||problemdrinking-49/VBG||to-51/TO	pobj||problemdrinking-49/VBG||cage-52/NN	amod||intake-57/NN||regular-54/JJ	amod||intake-57/NN||medical-55/JJ	nn||intake-57/NN||drug-56/NN	pobj||problemdrinking-49/VBG||intake-57/NN	conj_and||cage-52/NN||intake-57/NN	quantmod||weekly-61/CD||at-59/IN	mwe||at-59/IN||least-60/JJS	pobj||at-59/IN||least-60/JJS	dep||consumption-18/NN||weekly-61/CD	problemdrinking-49||alcohol-28||no||multiple logistic regression models were used to determine risk factors for psychosocial stress, demoralization, tobacco consumption (â¹ 10 items/day), high-risk alcohol consumption (men > 20 g pure alcohol/day, women > 10 g pure alcohol/day), binge drinking, problemdrinking according to cage and regular medical drug intake (at least weekly).
advmod||suggest-7/VBP||together-1/RB	det||findings-6/NNS||these-3/DT	amod||findings-6/NNS||multimodal-4/JJ	nn||findings-6/NNS||imaging-5/NN	nsubj||suggest-7/VBP||findings-6/NNS	root||ROOT-0/null||suggest-7/VBP	det||involvement-10/NN||a-8/DT	nn||involvement-10/NN||novel-9/NN	dobj||suggest-7/VBP||involvement-10/NN	det||midbrain-14/NN||the-12/DT	amod||midbrain-14/NN||dopaminergic-13/JJ	prep_of||involvement-10/NN||midbrain-14/NN	prepc_in||suggest-7/VBP||sustaining-16/VBG	dobj||sustaining-16/VBG||motivation-17/NN	prep_during||sustaining-16/VBG||fatigue-19/NN	fatigue-19||dopaminergic-13||no_rel||together, these multimodal imaging findings suggest a novel involvement of the dopaminergic midbrain in sustaining motivation during fatigue.
root||ROOT-0/null||conclusions-1/NNS	vmod||conclusions-1/NNS||â-2/VBN	dobj||â-2/VBN||$-3/$	mark||linked-19/VBN||$-3/$	poss||conclusions-6/NNS||our-5/PRP$	nsubj||are-7/VBP||conclusions-6/NNS	rcmod||$-3/$||are-7/VBP	dep||need-12/NN||1-9/LS	det||need-12/NN||the-11/DT	nsubjpass||linked-19/VBN||need-12/NN	nn||treatment-15/NN||insulin-14/NN	prep_for||need-12/NN||treatment-15/NN	prep_in||need-12/NN||lada-17/NN	auxpass||linked-19/VBN||is-18/VBZ	ccomp||are-7/VBP||linked-19/VBN	det||degree-22/NN||the-21/DT	prep_to||linked-19/VBN||degree-22/NN	prep_of||degree-22/NN||autoimmunity-24/NN	prep_of||degree-22/NN||î-26/NN	conj_and||autoimmunity-24/NN||î-26/NN	punct||autoimmunity-24/NN||²-27/''	nn||failure-30/NN||cell-29/NN	prep_of||degree-22/NN||failure-30/NN	conj_and||autoimmunity-24/NN||failure-30/NN	dep||subjects-34/NNS||2-32/LS	appos||failure-30/NN||subjects-34/NNS	nsubj||similar-47/JJ||lada-36/NN	conj_and||lada-36/NN||type2diabetes-38/NNS	nsubj||similar-47/JJ||type2diabetes-38/NNS	det||need-41/NN||the-40/DT	prep_without||lada-36/NN||need-41/NN	nn||treatment-44/NN||insulin-43/NN	prep_for||need-41/NN||treatment-44/NN	cop||similar-47/JJ||are-45/VBP	advmod||similar-47/JJ||phenotypically-46/RB	prepc_with||subjects-34/NNS||similar-47/JJ	dep||treatment-53/NN||3-50/LS	nn||treatment-53/NN||insulin-52/NN	prep_of||degree-22/NN||treatment-53/NN	conj_and||autoimmunity-24/NN||treatment-53/NN	prep_in||treatment-53/NN||type-55/NN	num||patients-58/NNS||2-56/CD	amod||patients-58/NNS||diabetic-57/JJ	nsubjpass||associated-60/VBN||patients-58/NNS	auxpass||associated-60/VBN||is-59/VBZ	rcmod||type-55/NN||associated-60/VBN	preconj||insulinresistance-63/NN||both-62/DT	prep_with||associated-60/VBN||insulinresistance-63/NN	prep_with||associated-60/VBN||î-65/NN	conj_and||insulinresistance-63/NN||î-65/NN	dep||insufficiency-69/NN||²-66/SYM	nn||insufficiency-69/NN||cell-68/NN	dep||conclusions-1/NNS||insufficiency-69/NN	type2diabetes-38||insulin-52||yes||conclusions âour conclusions are that 1 ) the need for insulin treatment in lada is linked to the degree of autoimmunity and î²-cell failure, 2 ) subjects with lada and type2diabetes without the need for insulin treatment are phenotypically similar, and 3 ) insulin treatment in type 2 diabetic patients is associated with both insulinresistance and î²-cell insufficiency.
det||2003-3/CD||the-2/DT	prep_during||randomised-26/VBN||2003-3/CD	num||seasons-8/NNS||2004-5/CD	nn||seasons-8/NNS||malaria-6/NN	nn||seasons-8/NNS||transmission-7/NN	conj_and||2003-3/CD||seasons-8/NNS	prep_during||randomised-26/VBN||seasons-8/NNS	num||children-12/NNS||1200-10/CD	nn||children-12/NNS||gambian-11/NN	nsubjpass||randomised-26/VBN||children-12/NNS	nsubj||receive-28/VB||children-12/NNS	amod||anaemia-17/NN||moderate-14/JJ	conj_or||moderate-14/JJ||severe-16/JJ	amod||anaemia-17/NN||severe-16/JJ	prep_with||children-12/NNS||anaemia-17/NN	nn||<-21/NNS||hb-19/NN	nn||<-21/NNS||concentration-20/NN	dep||g/dl-23/JJ||<-21/NNS	number||g/dl-23/JJ||7-22/CD	dep||anaemia-17/NN||g/dl-23/JJ	auxpass||randomised-26/VBN||were-25/VBD	root||ROOT-0/null||randomised-26/VBN	aux||receive-28/VB||to-27/TO	xcomp||randomised-26/VBN||receive-28/VB	det||sulfadoxine-pyrimethamine-31/NN||either-29/DT	amod||sulfadoxine-pyrimethamine-31/NN||monthly-30/JJ	dobj||receive-28/VB||sulfadoxine-pyrimethamine-31/NN	appos||sulfadoxine-pyrimethamine-31/NN||sp-33/NN	dobj||receive-28/VB||placebo-36/NN	conj_or||sulfadoxine-pyrimethamine-31/NN||placebo-36/NN	det||end-39/NN||the-38/DT	prep_until||receive-28/VB||end-39/NN	det||season-44/NN||the-41/DT	nn||season-44/NN||malaria-42/NN	nn||season-44/NN||transmission-43/NN	prep_of||end-39/NN||season-44/NN	prep_in||enrolled-49/VBN||season-44/NN	nsubjpass||enrolled-49/VBN||they-47/PRP	auxpass||enrolled-49/VBN||were-48/VBD	rcmod||season-44/NN||enrolled-49/VBN	det||trial-54/NN||a-52/DT	amod||trial-54/NN||double-blind-53/JJ	prep_in||enrolled-49/VBN||trial-54/NN	malaria-42||pyrimethamine--1||yes||during the 2003 and 2004 malaria transmission seasons, 1200 gambian children with moderate or severe anaemia (hb concentration <7 g/dl) were randomised to receive either monthly sulfadoxine-pyrimethamine (sp) or placebo until the end of the malaria transmission season in which they were enrolled, in a double-blind trial.
det||training-4/NN||some-2/DT	nn||training-4/NN||skills-3/NNS	prep_with||avenue-15/NN||training-4/NN	prep_on||training-4/NN||communication-6/NN	prep_on||training-4/NN||srh-8/NN	conj_and||communication-6/NN||srh-8/NN	nsubj||avenue-15/NN||parents-10/NNS	aux||avenue-15/NN||may-11/MD	cop||avenue-15/NN||be-12/VB	det||avenue-15/NN||a-13/DT	amod||avenue-15/NN||natural-14/JJ	root||ROOT-0/null||avenue-15/NN	prepc_for||avenue-15/NN||channeling-17/VBG	prepc_for||avenue-15/NN||reinforcing-19/VBG	conj_and||channeling-17/VBG||reinforcing-19/VBG	amod||messages-22/NNS||hiv/aids-20/JJ	nn||messages-22/NNS||prevention-21/NN	dobj||channeling-17/VBG||messages-22/NNS	poss||children-25/NNS||their-24/PRP$	prep_to||channeling-17/VBG||children-25/NNS	aids--1||hiv--1||no||with some skills training on communication and srh, parents may be a natural avenue for channeling and reinforcing hiv/aids prevention messages to their children.
det||therapy-3/NN||a-1/DT	nn||therapy-3/NN||salvage-2/NN	nsubjpass||performed-15/VBN||therapy-3/NN	prep_including||therapy-3/NN||osmotherapy-6/NN	prep_including||therapy-3/NN||corticosteroids-8/NN	conj_and||osmotherapy-6/NN||corticosteroids-8/NN	prep_including||therapy-3/NN||treatment-10/NN	conj_and||osmotherapy-6/NN||treatment-10/NN	prep_of||osmotherapy-6/NN||epilepticseizures-12/NNS	auxpass||performed-15/VBN||was-14/VBD	root||ROOT-0/null||performed-15/VBN	det||patient-19/NN||the-18/DT	nsubj||died-20/VBD||patient-19/NN	conj_but||performed-15/VBN||died-20/VBD	nn||herniation-23/NN||brainstem-22/NN	prep_from||died-20/VBD||herniation-23/NN	num||hours-25/NNS||48-24/CD	dobj||died-20/VBD||hours-25/NNS	prep_after||died-20/VBD||admission-27/NN	corticosteroids-8||epilepticseizures-12||no_rel||a salvage therapy, including osmotherapy, corticosteroids and treatment of epilepticseizures, was performed, but the patient died from brainstem herniation 48 hours after admission.
nsubjpass||defined-5/VBN||entry-1/NN	prep_into||entry-1/NN||care-3/NN	auxpass||defined-5/VBN||was-4/VBD	root||ROOT-0/null||defined-5/VBN	prepc_as||defined-5/VBN||having-7/VBG	quantmod||one-10/CD||at-8/IN	mwe||at-8/IN||least-9/JJS	pobj||at-8/IN||least-9/JJS	num||visit-11/NN||one-10/CD	dobj||having-7/VBG||visit-11/NN	det||provider-17/NN||a-13/DT	amod||provider-17/NN||primary-14/JJ	nn||provider-17/NN||hiv-15/NN	nn||provider-17/NN||care-16/NN	prep_to||visit-11/NN||provider-17/NN	det||diagnosis-21/NN||the-19/DT	amod||diagnosis-21/NN||initial-20/JJ	prep_after||having-7/VBG||diagnosis-21/NN	prep_of||diagnosis-21/NN||hivinfection-23/NN	hivinfection-23||hiv-15||no||entry into care was defined as having at least one visit to a primary hiv care provider after the initial diagnosis of hivinfection.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||association-7/NN||the-3/DT	amod||association-7/NN||independent-4/JJ	conj_and||independent-4/JJ||joint-6/JJ	amod||association-7/NN||joint-6/JJ	dobj||investigated-2/VBD||association-7/NN	amod||activity-12/NN||adiposity-9/JJ	conj_and||adiposity-9/JJ||physical-11/JJ	amod||activity-12/NN||physical-11/JJ	prep_of||association-7/NN||activity-12/NN	amod||glucose-16/NN||fasting-14/VBG	nn||glucose-16/NN||plasma-15/NN	prep_with||investigated-2/VBD||glucose-16/NN	amod||glucose-20/NN||impaired-18/VBN	amod||glucose-20/NN||fasting-19/JJ	prep_with||investigated-2/VBD||glucose-20/NN	conj_and||glucose-16/NN||glucose-20/NN	prep_with||investigated-2/VBD||type2diabetes-23/NNS	conj_and||glucose-16/NN||type2diabetes-23/NNS	det||population-27/NN||a-25/DT	amod||population-27/NN||chinese-26/JJ	prep_in||type2diabetes-23/NNS||population-27/NN	glucose-20||adiposity-9||no_rel||we investigated the independent and joint association of adiposity and physical activity with fasting plasma glucose, impaired fasting glucose, and type2diabetes in a chinese population.
amod||anaesthesia-2/NN||general-1/JJ	nsubj||seems-22/VBZ||anaesthesia-2/NN	nsubj||generate-24/VB||anaesthesia-2/NN	vmod||anaesthesia-2/NN||combined-3/VBN	amod||glucocorticoids-6/NNS||intraoperative-5/JJ	prep_with||combined-3/VBN||glucocorticoids-6/NNS	amod||care-10/NN||accelerated-8/VBN	amod||care-10/NN||postoperative-9/JJ	prep_with||combined-3/VBN||care-10/NN	conj_and||glucocorticoids-6/NNS||care-10/NN	prepc_compared_with||anaesthesia-2/NN||with-13/IN	amod||blockade-16/NN||intrathecal-15/JJ	pobj||anaesthesia-2/NN||blockade-16/NN	amod||care-20/NN||traditional-18/JJ	nn||care-20/NN||postoperative-19/NN	pobj||anaesthesia-2/NN||care-20/NN	conj_and||blockade-16/NN||care-20/NN	root||ROOT-0/null||seems-22/VBZ	aux||generate-24/VB||to-23/TO	xcomp||seems-22/VBZ||generate-24/VB	det||ratings-29/NNS||the-25/DT	amod||ratings-29/NNS||same-26/JJ	amod||ratings-29/NNS||overall-27/JJ	nn||ratings-29/NNS||pain-28/NN	dobj||generate-24/VB||ratings-29/NNS	det||decrease-32/NN||a-31/DT	dobj||generate-24/VB||decrease-32/NN	conj_and||ratings-29/NNS||decrease-32/NN	amod||stay-35/NN||length-of-hospital-34/JJ	prep_in||generate-24/VB||stay-35/NN	prep_in||generate-24/VB||patients-38/NNS	vmod||patients-38/NNS||undergoing-39/VBG	amod||knee-42/NN||elective-40/JJ	amod||knee-42/NN||total-41/JJ	dobj||undergoing-39/VBG||knee-42/NN	advmod||undergoing-39/VBG||arthroplasty-43/RB	glucocorticoids-6||pain-28||no_rel||general anaesthesia combined with intraoperative glucocorticoids and accelerated postoperative care, compared with, intrathecal blockade and traditional postoperative care, seems to generate the same overall pain ratings and a decrease in length-of-hospital stay, in patients undergoing elective total knee arthroplasty.
nsubj||consisted-2/VBD||treatment-1/NN	root||ROOT-0/null||consisted-2/VBD	advmod||consisted-2/VBD||primarily-3/RB	prep_of||consisted-2/VBD||methyleneblue-5/NN	num||mg/kg-8/NN||1-7/CD	dep||methyleneblue-5/NN||mg/kg-8/NN	nn||doses-13/NNS||one-10/CD	conj_or||one-10/CD||two-12/CD	nn||doses-13/NNS||two-12/CD	prep_for||mg/kg-8/NN||doses-13/NNS	nn||transfusion-17/NN||exchange-16/NN	prep_of||consisted-2/VBD||transfusion-17/NN	conj_and||methyleneblue-5/NN||transfusion-17/NN	amod||care-20/NN||supportive-19/JJ	prep_of||consisted-2/VBD||care-20/NN	conj_and||methyleneblue-5/NN||care-20/NN	advmod||diagnosed-24/VBN||when-21/WRB	nsubjpass||diagnosed-24/VBN||methaemoglobinaemia-22/NN	auxpass||diagnosed-24/VBN||was-23/VBD	advcl||consisted-2/VBD||diagnosed-24/VBN	xcomp||diagnosed-24/VBN||clinically-25/JJ	methaemoglobinaemia-22||methyleneblue-5||no||treatment consisted primarily of methyleneblue (1 mg/kg for one or two doses), exchange transfusion and supportive care when methaemoglobinaemia was diagnosed clinically.
nsubj||inducer-15/NN||rifampicin-1/NN	det||component-5/NN||a-3/DT	amod||component-5/NN||critical-4/JJ	appos||rifampicin-1/NN||component-5/NN	nn||therapy-11/NN||tuberculosis-7/NNP	appos||therapy-11/NN||tb-9/NN	prep_of||component-5/NN||therapy-11/NN	cop||inducer-15/NN||is-12/VBZ	det||inducer-15/NN||a-13/DT	amod||inducer-15/NN||potent-14/JJ	root||ROOT-0/null||inducer-15/NN	nn||activity-19/NN||cyp-17/NN	nn||activity-19/NN||enzyme-18/NN	prep_of||inducer-15/NN||activity-19/NN	tb-9||rifampicin-1||yes||rifampicin, a critical component of tuberculosis (tb) therapy is a potent inducer of cyp enzyme activity.
amod||studies-2/NNS||forty-nine-1/JJ	nsubj||met-3/VBD||studies-2/NNS	root||ROOT-0/null||met-3/VBD	det||criteria-6/NNS||the-4/DT	nn||criteria-6/NNS||inclusion-5/NN	dobj||met-3/VBD||criteria-6/NNS	num||indicators-10/NNS||30-8/CD	amod||indicators-10/NNS||different-9/JJ	nsubjpass||extracted-12/VBN||indicators-10/NNS	nsubjpass||categorized-14/VBN||indicators-10/NNS	auxpass||extracted-12/VBN||were-11/VBD	parataxis||met-3/VBD||extracted-12/VBN	parataxis||met-3/VBD||categorized-14/VBN	conj_and||extracted-12/VBN||categorized-14/VBN	num||categories-18/NNS||four-16/CD	amod||categories-18/NNS||nonorthogonal-17/JJ	prep_into||extracted-12/VBN||categories-18/NNS	amod||zones-20/NNS||bloodglucose-19/JJ	dep||categories-18/NNS||zones-20/NNS	prep_for||zones-20/NNS||example-23/NN	dep||example-23/NN||hypoglycaemia-26/NN	amod||levels-31/NNS||bloodglucose-30/JJ	prep_into||extracted-12/VBN||levels-31/NNS	conj_and||categories-18/NNS||levels-31/NNS	prep_for||levels-31/NNS||example-34/NN	amod||level-39/NN||mean-37/JJ	nn||level-39/NN||bloodglucose-38/NN	dep||example-34/NN||level-39/NN	nn||intervals-44/NNS||time-43/NN	prep_into||extracted-12/VBN||intervals-44/NNS	conj_and||categories-18/NNS||intervals-44/NNS	prep_for||intervals-44/NNS||example-47/NN	dep||example-47/NN||time-50/NN	prep_to||time-50/NN||occurrence-52/NN	det||event-55/NN||an-54/DT	prep_of||occurrence-52/NN||event-55/NN	nn||characteristics-61/NNS||protocol-60/NN	prep_into||extracted-12/VBN||characteristics-61/NNS	conj_and||categories-18/NNS||characteristics-61/NNS	prep_for||categories-18/NNS||example-64/NN	nsubj||sampling-68/VBG||bloodglucose-67/NN	dep||example-64/NN||sampling-68/VBG	dobj||sampling-68/VBG||frequency-69/NN	hypoglycaemia-26||glucose--1||yes||forty-nine studies met the inclusion criteria; 30 different indicators were extracted and categorized into four nonorthogonal categories bloodglucose zones (for example, 'hypoglycaemia'); bloodglucose levels (for example, 'mean bloodglucose level'); time intervals (for example, 'time to occurrence of an event'); and protocol characteristics (for example, 'bloodglucose sampling frequency').
nn||inhibitors-2/NNS||tnf-1/NN	nsubjpass||considered-5/VBN||inhibitors-2/NNS	auxpass||considered-5/VBN||are-3/VBP	advmod||considered-5/VBN||currently-4/RB	root||ROOT-0/null||considered-5/VBN	preconj||effective-7/JJ||both-6/DT	advmod||considered-5/VBN||effective-7/JJ	advmod||considered-5/VBN||cost-effective-9/JJ	conj_and||effective-7/JJ||cost-effective-9/JJ	prep_in||effective-7/JJ||patients-11/NNS	amod||rheumatoidarthritis-14/NNS||active-13/JJ	prep_with||patients-11/NNS||rheumatoidarthritis-14/NNS	appos||rheumatoidarthritis-14/NNS||ra-16/NN	advmod||effective-7/JJ||particularly-19/RB	prep_in||effective-7/JJ||patients-21/NNS	nsubj||responded-25/VBN||patients-21/NNS	nsubj||methotrexate-28/VB||patients-21/NNS	aux||responded-25/VBN||have-23/VBP	neg||responded-25/VBN||not-24/RB	rcmod||patients-21/NNS||responded-25/VBN	advmod||responded-25/VBN||fully-26/RB	aux||methotrexate-28/VB||to-27/TO	xcomp||responded-25/VBN||methotrexate-28/VB	rheumatoidarthritis-14||methotrexate-28||yes||tnf inhibitors are currently considered both effective and cost-effective in patients with active rheumatoidarthritis (ra), particularly in patients who have not responded fully to methotrexate.
nn||techniques-2/NNS||immobilization-1/NN	nsubj||involve-4/VB||techniques-2/NNS	aux||involve-4/VB||can-3/MD	root||ROOT-0/null||involve-4/VB	nn||bonding-10/NN||adsorption-5/NN	conj_or||adsorption-5/NN||entrapment-7/NN	nn||bonding-10/NN||entrapment-7/NN	conj_or||adsorption-5/NN||covalent-9/NN	nn||bonding-10/NN||covalent-9/NN	dobj||involve-4/VB||bonding-10/NN	det||support-17/NN||the-12/DT	amod||support-17/NN||enzyme-13/JJ	det||insoluble-16/NN||an-15/DT	prep_into||enzyme-13/JJ||insoluble-16/NN	prep_of||bonding-10/NN||support-17/NN	amod||methods-21/NNS||carrier-free-20/JJ	prep_of||bonding-10/NN||methods-21/NNS	conj_or||support-17/NN||methods-21/NNS	prep_of||bonding-10/NN||usually-23/RB	advmod||support-17/NN||usually-23/RB	conj_or||support-17/NN||usually-23/RB	prepc_based_on||involve-4/VB||on-25/IN	det||formation-27/NN||the-26/DT	pobj||involve-4/VB||formation-27/NN	amod||aggregates-31/NNS||cross-linked-29/JJ	nn||aggregates-31/NNS||enzyme-30/NN	prep_of||formation-27/NN||aggregates-31/NNS	appos||aggregates-31/NNS||cleas-33/NNS	cross--1||enzyme-30||no_rel||immobilization techniques can involve adsorption, entrapment or covalent bonding of the enzyme into an insoluble support, or carrier-free methods, usually based on the formation of cross-linked enzyme aggregates (cleas).
det||use-2/NN||the-1/DT	nsubj||gained-18/VBN||use-2/NN	amod||conjugates-5/NNS||antibody-drug-4/JJ	prep_of||use-2/NN||conjugates-5/NNS	appos||use-2/NN||adcs-7/NNS	det||platform-12/NN||a-10/DT	amod||platform-12/NN||therapeutic-11/JJ	prep_as||use-2/NN||platform-12/NN	aux||treat-14/VB||to-13/TO	vmod||platform-12/NN||treat-14/VB	dobj||treat-14/VB||cancer-15/NN	aux||gained-18/VBN||has-16/VBZ	advmod||gained-18/VBN||recently-17/RB	root||ROOT-0/null||gained-18/VBN	amod||momentum-20/NN||substantial-19/JJ	dobj||gained-18/VBN||momentum-20/NN	cancer-15||antibody--1||no_rel||the use of antibody-drug conjugates (adcs) as a therapeutic platform to treat cancer has recently gained substantial momentum.
amod||illnesses-2/NNS||atopy-related-1/JJ	nsubj||illnesses-10/NNS||illnesses-2/NNS	prep_such_as||illnesses-2/NNS||atopicdermatitis-5/NNS	prep_such_as||illnesses-2/NNS||asthma-7/NN	conj_and||atopicdermatitis-5/NNS||asthma-7/NN	cop||illnesses-10/NNS||are-8/VBP	amod||illnesses-10/NNS||chronic-9/JJ	root||ROOT-0/null||illnesses-10/NNS	nsubjpass||subjected-19/VBN||children-13/NNS	vmod||children-13/NNS||suffering-14/VBG	amod||illnesses-17/NNS||such-16/JJ	prep_from||suffering-14/VBG||illnesses-17/NNS	auxpass||subjected-19/VBN||are-18/VBP	conj_and||illnesses-10/NNS||subjected-19/VBN	amod||absenteeism-22/NN||frequent-21/JJ	prep_to||subjected-19/VBN||absenteeism-22/NN	prep_from||subjected-19/VBN||school-24/NN	atopicdermatitis-5||atopy--1||no||atopy-related illnesses such as atopicdermatitis and asthma are chronic illnesses, and children suffering from such illnesses are subjected to frequent absenteeism from school.
nsubj||effective-18/JJ||methotrexate-1/NN	nsubj||brings-20/VBZ||methotrexate-1/NN	appos||methotrexate-1/NN||mtx-3/NN	det||treatment-8/NN||the-6/DT	amod||treatment-8/NN||primary-7/JJ	appos||methotrexate-1/NN||treatment-8/NN	det||juvenileidiopathicarthritis-12/NNS||the-10/DT	amod||juvenileidiopathicarthritis-12/NNS||articular-type-11/JJ	prep_for||treatment-8/NN||juvenileidiopathicarthritis-12/NNS	appos||juvenileidiopathicarthritis-12/NNS||jia-14/NN	cop||effective-18/JJ||is-17/VBZ	root||ROOT-0/null||effective-18/JJ	conj_and||effective-18/JJ||brings-20/VBZ	amod||improvement-23/NN||radiological-22/JJ	prep_about||brings-20/VBZ||improvement-23/NN	juvenileidiopathicarthritis-12||methotrexate-1||yes||methotrexate (mtx), the primary treatment for the articular-type juvenileidiopathicarthritis (jia), is effective and brings about radiological improvement.
nsubj||infection-6/NN||plague-1/NNP	cop||infection-6/NN||is-2/VBZ	det||infection-6/NN||an-3/DT	amod||infection-6/NN||ectoparasite-borne-4/JJ	amod||infection-6/NN||deadly-5/JJ	root||ROOT-0/null||infection-6/NN	vmod||infection-6/NN||caused-7/VBN	agent||caused-7/VBN||yersiniapestis-9/NNS	det||bacterium-12/NN||a-11/DT	appos||yersiniapestis-9/NNS||bacterium-12/NN	vmod||bacterium-12/NN||classified-13/VBN	det||group-16/NN||the-15/DT	prep_among||classified-13/VBN||group-16/NN	det||agents-19/NNS||a-17/DT	nn||agents-19/NNS||bioterrorism-18/NN	dep||group-16/NN||agents-19/NNS	plague-1||yersiniapestis-9||no||plague is an ectoparasite-borne deadly infection caused by yersiniapestis , a bacterium classified among the group a bioterrorism agents.
nn||samples-2/NNS||blood-1/NN	nsubjpass||tested-4/VBN||samples-2/NNS	auxpass||tested-4/VBN||were-3/VBD	root||ROOT-0/null||tested-4/VBN	amod||antigen-8/NN||hepatitisb-6/JJ	nn||antigen-8/NN||surface-7/NN	prep_for||tested-4/VBN||antigen-8/NN	appos||antigen-8/NN||hbsag-10/NN	amod||hbeag-17/NN||hepatitisb-13/JJ	nn||hbeag-17/NN||e-14/NN	nn||hbeag-17/NN||antigen-15/NN	prep_for||tested-4/VBN||hbeag-17/NN	conj_and||antigen-8/NN||hbeag-17/NN	amod||antibody-25/NN||hepatitisc-20/JJ	nn||antibody-25/NN||virus-21/NN	nn||antibody-25/NN||hcv-23/NN	prep_for||tested-4/VBN||antibody-25/NN	conj_and||antigen-8/NN||antibody-25/NN	nn||rna-28/NN||hcv-27/NN	prep_for||tested-4/VBN||rna-28/NN	conj_and||antigen-8/NN||rna-28/NN	det||mutation-35/NN||the-31/DT	amod||mutation-35/NN||aflatoxin-associated-32/JJ	amod||mutation-35/NN||249ser-33/JJ	amod||mutation-35/NN||tp53-34/JJ	prep_for||tested-4/VBN||mutation-35/NN	conj_and||antigen-8/NN||mutation-35/NN	hepatitisb-13||hbsag-10||yes||blood samples were tested for hepatitisb surface antigen (hbsag), hepatitisb e antigen (hbeag), hepatitisc virus (hcv) antibody, hcv rna, and the aflatoxin-associated 249ser tp53 mutation.
nsubj||therapy-7/NN||tamoxifen-1/NN	cop||therapy-7/NN||is-2/VBZ	det||therapy-7/NN||the-3/DT	advmod||prescribed-6/JJ||most-4/RBS	advmod||prescribed-6/JJ||commonly-5/RB	amod||therapy-7/NN||prescribed-6/JJ	root||ROOT-0/null||therapy-7/NN	prep_for||therapy-7/NN||patients-9/NNS	nn||receptor-12/NN||estrogen-11/NN	prep_with||patients-9/NNS||receptor-12/NN	dep||therapy-7/NN||er-14/VBN	nn||±-17/NNS||î-16/NN	dep||therapy-7/NN||±-17/NNS	amod||breasttumors-20/NNS||positive-19/JJ	dep||±-17/NNS||breasttumors-20/NNS	breasttumors-20||estrogen-11||yes||tamoxifen is the most commonly prescribed therapy for patients with estrogen receptor (er)î±-positive breasttumors.
nsubj||disorder-8/NN||celiacdisease-1/NN	cop||disorder-8/NN||is-2/VBZ	det||disorder-8/NN||a-3/DT	amod||disorder-8/NN||t-cell-4/JJ	amod||disorder-8/NN||mediated-5/JJ	amod||disorder-8/NN||chronic-6/JJ	amod||disorder-8/NN||inflammatory-7/JJ	root||ROOT-0/null||disorder-8/NN	det||gut-11/NN||the-10/DT	prep_of||disorder-8/NN||gut-11/NN	nsubjpass||induced-14/VBN||gut-11/NN	auxpass||induced-14/VBN||is-13/VBZ	rcmod||gut-11/NN||induced-14/VBN	amod||exposure-17/NN||dietary-16/JJ	agent||induced-14/VBN||exposure-17/NN	nn||proteins-20/NNS||gluten-19/NN	prep_to||induced-14/VBN||proteins-20/NNS	celiacdisease-1||gluten-19||no||celiacdisease is a t-cell mediated chronic inflammatory disorder of the gut that is induced by dietary exposure to gluten proteins.
det||pathophysiology-2/NN||the-1/DT	nsubj||remain-17/VBP||pathophysiology-2/NN	prep_of||pathophysiology-2/NN||hfe-4/NN	vmod||hfe-4/NN||derived-6/VBN	dobj||derived-6/VBN||hereditaryhemochromatosis-7/NNS	det||function-10/NN||the-9/DT	dobj||derived-6/VBN||function-10/NN	conj_and||hereditaryhemochromatosis-7/NNS||function-10/NN	nn||protein-13/NN||hfe-12/NN	prep_of||function-10/NN||protein-13/NN	nn||homeostasis-16/NNS||iron-15/NN	prep_in||derived-6/VBN||homeostasis-16/NNS	root||ROOT-0/null||remain-17/VBP	acomp||remain-17/VBP||uncertain-18/JJ	hereditaryhemochromatosis-7||iron-15||no||the pathophysiology of hfe -derived hereditaryhemochromatosis and the function of hfe protein in iron homeostasis remain uncertain.
amod||studies-2/NNS||clinical-1/JJ	nsubj||indicate-3/VBP||studies-2/NNS	root||ROOT-0/null||indicate-3/VBP	mark||option-13/NN||that-4/IN	det||implant-7/NN||this-5/DT	amod||implant-7/NN||dexamethasone-6/JJ	nsubj||option-13/NN||implant-7/NN	cop||option-13/NN||is-8/VBZ	det||option-13/NN||a-9/DT	amod||option-13/NN||promising-10/JJ	amod||option-13/NN||new-11/JJ	nn||option-13/NN||treatment-12/NN	ccomp||indicate-3/VBP||option-13/NN	prep_for||option-13/NN||patients-15/NNS	amod||macularedema-18/NN||persistent-17/JJ	prep_with||patients-15/NNS||macularedema-18/NN	vmod||macularedema-18/NN||resulting-19/VBG	amod||occlusion-23/NN||retinal-21/JJ	nn||occlusion-23/NN||vein-22/NN	prep_from||resulting-19/VBG||occlusion-23/NN	advmod||resulting-19/VBG||diabeticretinopathy-25/RB	ccomp||indicate-3/VBP||uveitis-28/NNS	conj_and||option-13/NN||uveitis-28/NNS	amod||syndrome-31/NN||irvine-gass-30/JJ	conj_and||option-13/NN||syndrome-31/NN	conj_or||uveitis-28/NNS||syndrome-31/NN	dexamethasone-6||diabeticretinopathy-25||no_rel||clinical studies indicate that this dexamethasone implant is a promising new treatment option for patients with persistent macularedema resulting from retinal vein occlusion, diabeticretinopathy, and uveitis or irvine-gass syndrome.
amod||evidence-2/NN||available-1/JJ	nsubj||shows-8/VBZ||evidence-2/NN	amod||treatment-5/NN||symptomatic-4/JJ	prep_on||evidence-2/NN||treatment-5/NN	prep_of||treatment-5/NN||vomiting-7/NN	root||ROOT-0/null||shows-8/VBZ	det||efficacy-10/NN||the-9/DT	dobj||shows-8/VBZ||efficacy-10/NN	det||molecule-16/NN||the-12/DT	advmod||registered-15/VBN||most-13/RBS	advmod||registered-15/VBN||recently-14/RB	amod||molecule-16/NN||registered-15/VBN	prep_of||efficacy-10/NN||molecule-16/NN	appos||molecule-16/NN||ondansetron-18/NN	det||evaluation-23/NN||a-21/DT	amod||evaluation-23/NN||proper-22/JJ	nsubj||lacking-38/VBG||evaluation-23/NN	amod||drugs-26/NNS||antiemetics-25/JJ	prep_of||evaluation-23/NN||drugs-26/NNS	advmod||used-28/VBN||largely-27/RB	vmod||drugs-26/NNS||used-28/VBN	amod||practice-31/NN||clinical-30/JJ	prep_in||used-28/VBN||practice-31/NN	prep_such_as||evaluation-23/NN||domperidone-35/NN	aux||lacking-38/VBG||is-37/VBZ	conj_but||shows-8/VBZ||lacking-38/VBG	vomiting-7||ondansetron-18||yes||available evidence on symptomatic treatment of vomiting shows the efficacy of the most recently registered molecule (ondansetron) but a proper evaluation of antiemetics drugs largely used in clinical practice, such as domperidone, is lacking.
amod||ligands-2/NNS||nonribose-1/JJ	nsubjpass||represented-4/VBN||ligands-2/NNS	auxpass||represented-4/VBN||are-3/VBP	root||ROOT-0/null||represented-4/VBN	amod||dicarbonitrilepyridines-8/NNS||conveniently-6/JJ	amod||dicarbonitrilepyridines-8/NNS||substituted-7/JJ	agent||represented-4/VBN||dicarbonitrilepyridines-8/NNS	dobj||is-65/VBZ||which-11/WDT	num||-LSB--14/CD||2-12/CD	nsubj||is-65/VBZ||-LSB--14/CD	amod||-LSB--14/CD||6-amino-3-15/JJ	dep||6-amino-3-15/JJ||,5-16/CD	dep||-LSB--14/CD||dicyano-4-18/JJ	number||4-21/CD||-LSB--20/CD	dep||dicyano-4-18/JJ||4-21/CD	appos||-RSB--27/NN||cyclopropylmethoxy-24/NN	amod||-RSB--27/NN||phenyl-26/JJ	dep||-LSB--14/CD||-RSB--27/NN	amod||acetamide-30/NN||pyridin-2-ylsulfanyl-28/JJ	amod||acetamide-30/NN||-RSB--29/JJ	dep||-RSB--27/NN||acetamide-30/NN	dep||-LSB--14/CD||bay-60â-32/JJ	dep||bay-60â-32/JJ||$-33/$	nn||ha2a-39/NN||6583-35/NNP	dep||ha2a-39/NN||ha1-37/NNS	npadvmod||=-58/RB||ha2a-39/NN	dep||î-50/NNS||ha3-41/RB	num||î-50/NNS||ec50â-42/CD	amod||î-50/NNS||$-43/$	number||>-45/CD||-44/CD	num||$-43/$||>-45/CD	amod||î-50/NNS||â-46/JJ	num||î-50/NNS||$-47/$	number||10â-49/CD||-48/CD	num||$-47/$||10â-49/CD	dep||ha2a-39/NN||î-50/NNS	num||m-52/NN||1/4-51/CD	dep||î-50/NNS||m-52/NN	amod||ec50â-55/NNS||ha2b-54/JJ	dep||î-50/NNS||ec50â-55/NNS	dep||î-50/NNS||$-56/$	num||$-56/$||-57/CD	dep||â-59/CD||=-58/RB	num||$-33/$||â-59/CD	dep||nm-63/NN||$-60/$	num||nm-63/NN||-61/CD	amod||nm-63/NN||3â-62/JJ	dep||$-33/$||nm-63/NN	prepc_among||represented-4/VBN||is-65/VBZ	advmod||is-65/VBZ||currently-66/RB	amod||investigation-69/NN||preclinical-phase-68/JJ	prep_under||is-65/VBZ||investigation-69/NN	prepc_for||is-65/VBZ||treating-71/VBG	dobj||treating-71/VBG||coronaryarterydisorders-72/NNS	dobj||treating-71/VBG||atherosclerosis-74/NNS	conj_and||coronaryarterydisorders-72/NNS||atherosclerosis-74/NNS	nm-63||coronaryarterydisorders-72||no_rel||nonribose ligands are represented by conveniently substituted dicarbonitrilepyridines, among which 2-[6-amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-ylsulfanyl]acetamide ( bay-60â6583 , ha1, ha2a, ha3 ec50â>â10â î¼m; ha2b ec50â=â3â nm) is currently under preclinical-phase investigation for treating coronaryarterydisorders and atherosclerosis.
amod||retinopathy-2/NN||oxygen-induced-1/JJ	nsubj||model-10/NN||retinopathy-2/NN	appos||retinopathy-2/NN||oir-4/NN	cop||model-10/NN||is-6/VBZ	det||model-10/NN||a-7/DT	amod||model-10/NN||robust-8/JJ	nn||model-10/NN||animal-9/NN	root||ROOT-0/null||model-10/NN	nsubj||allows-16/VBZ||model-10/NN	amod||retinopathyofprematurity-13/NN||human-12/JJ	prep_of||model-10/NN||retinopathyofprematurity-13/NN	advmod||allows-16/VBZ||readily-15/RB	rcmod||model-10/NN||allows-16/VBZ	dobj||allows-16/VBZ||changes-17/NNS	nsubjpass||studied-36/VBN||changes-17/NNS	amod||gene-20/NN||retinal-19/JJ	prep_in||changes-17/NNS||gene-20/NN	amod||expression-26/NN||microrna-22/JJ	appos||expression-26/NN||mirna-24/NNP	dobj||allows-16/VBZ||expression-26/NN	conj_and||changes-17/NNS||expression-26/NN	nsubjpass||studied-36/VBN||expression-26/NN	prep_in||expression-26/NN||response-28/NN	prep_to||allows-16/VBZ||fluctuations-30/NNS	nn||levels-33/NNS||oxygen-32/NN	prep_in||fluctuations-30/NNS||levels-33/NNS	aux||studied-36/VBN||to-34/TO	auxpass||studied-36/VBN||be-35/VB	xcomp||allows-16/VBZ||studied-36/VBN	retinopathyofprematurity-13||oxygen-32||no||oxygen-induced retinopathy (oir) is a robust animal model of human retinopathyofprematurity that readily allows changes in retinal gene and microrna (mirna) expression in response to fluctuations in oxygen levels to be studied.
det||combination-2/NN||the-1/DT	nsubj||effective-8/JJ||combination-2/NN	prep_of||combination-2/NN||remifentanil-4/NN	prep_of||combination-2/NN||lidocaine-6/NN	conj_and||remifentanil-4/NN||lidocaine-6/NN	cop||effective-8/JJ||is-7/VBZ	root||ROOT-0/null||effective-8/JJ	prepc_in||effective-8/JJ||alleviating-10/VBG	dobj||alleviating-10/VBG||pain-11/NN	vmod||pain-11/NN||associated-12/VBN	det||injection-17/NN||a-14/DT	amod||injection-17/NN||microemulsion-15/JJ	amod||injection-17/NN||propofol-16/JJ	prep_with||associated-12/VBN||injection-17/NN	prepc_compared_with||associated-12/VBN||with-19/IN	advmod||lidocaine-21/NN||just-20/RB	pobj||associated-12/VBN||lidocaine-21/NN	pain-11||lidocaine-21||yes||the combination of remifentanil and lidocaine is effective in alleviating pain associated with a microemulsion propofol injection compared with just lidocaine.
prep_in||propose-10/VB||light-2/NN	det||data-7/NNS||the-4/DT	amod||data-7/NNS||most-5/JJS	amod||data-7/NNS||recent-6/JJ	prep_of||light-2/NN||data-7/NNS	nsubj||propose-10/VB||we-9/PRP	nsubj||discuss-19/VB||we-9/PRP	root||ROOT-0/null||propose-10/VB	det||model-12/NN||a-11/DT	dobj||propose-10/VB||model-12/NN	det||complex-17/NN||the-14/DT	amod||complex-17/NN||htlv-1-15/JJ	nn||complex-17/NN||receptor-16/NN	prep_of||model-12/NN||complex-17/NN	conj_and||propose-10/VB||discuss-19/VB	poss||impact-22/NN||its-20/PRP$	amod||impact-22/NN||potential-21/JJ	dobj||discuss-19/VB||impact-22/NN	prep_on||discuss-19/VB||htlv-1infection-24/JJ	htlv-1infection-24||htlv-1-15||no||in light of the most recent data, we propose a model of the htlv-1 receptor complex and discuss its potential impact on htlv-1infection.
amod||estimates-3/NNS||reliable-1/JJ	amod||estimates-3/NNS||quantitative-2/JJ	nsubjpass||needed-14/VBN||estimates-3/NNS	nsubj||understand-16/VB||estimates-3/NNS	det||role-7/NN||the-5/DT	nn||role-7/NN||indian-6/NN	prep_of||estimates-3/NNS||role-7/NN	amod||supply-12/NN||generic-9/JJ	amod||supply-12/NN||global-10/JJ	nn||supply-12/NN||arv-11/NN	prep_in||role-7/NN||supply-12/NN	auxpass||needed-14/VBN||are-13/VBP	root||ROOT-0/null||needed-14/VBN	aux||understand-16/VB||to-15/TO	xcomp||needed-14/VBN||understand-16/VB	amod||impacts-18/NNS||potential-17/JJ	dobj||understand-16/VB||impacts-18/NNS	amod||measures-21/NNS||such-20/JJ	prep_of||impacts-18/NNS||measures-21/NNS	amod||treatment-24/NN||hiv/aids-23/JJ	prep_on||understand-16/VB||treatment-24/NN	amod||countries-27/NNS||developing-26/VBG	prep_in||treatment-24/NN||countries-27/NNS	aids--1||hiv--1||no||reliable quantitative estimates of the indian role in generic global arv supply are needed to understand potential impacts of such measures on hiv/aids treatment in developing countries.
amod||therapy-3/NN||antibiotic-2/JJ	prep_in||considered-12/VBN||therapy-3/NN	det||use-6/NN||the-5/DT	nsubjpass||considered-12/VBN||use-6/NN	prep_of||use-6/NN||thirdgenerationcephalosporins-8/NNS	aux||considered-12/VBN||should-9/MD	advmod||considered-12/VBN||only-10/RB	auxpass||considered-12/VBN||be-11/VB	root||ROOT-0/null||considered-12/VBN	prep_in||considered-12/VBN||cases-14/NNS	prep_of||cases-14/NNS||lymedisease-16/NN	lymedisease-16||thirdgenerationcephalosporins-8||no_rel||in antibiotic therapy, the use of thirdgenerationcephalosporins should only be considered in cases of lymedisease.
nn||therapy-3/NN||nicotine-1/NN	nn||therapy-3/NN||replacement-2/NN	nsubj||form-11/NN||therapy-3/NN	nsubj||proven-18/VBN||therapy-3/NN	appos||therapy-3/NN||nrt-5/NN	cop||form-11/NN||is-7/VBZ	det||form-11/NN||the-8/DT	advmod||common-10/JJ||most-9/RBS	amod||form-11/NN||common-10/JJ	root||ROOT-0/null||form-11/NN	nn||pharmacotherapy-15/NN||smoking-13/NN	nn||pharmacotherapy-15/NN||cessation-14/NN	prep_of||form-11/NN||pharmacotherapy-15/NN	aux||proven-18/VBN||has-17/VBZ	conj_and||form-11/NN||proven-18/VBN	advmod||proven-18/VBN||efficacy-19/RB	det||treatment-22/NN||the-21/DT	prep_for||proven-18/VBN||treatment-22/NN	prep_of||treatment-22/NN||tobaccodependence-24/NN	tobaccodependence-24||nicotine-1||no||nicotine replacement therapy (nrt) is the most common form of smoking cessation pharmacotherapy and has proven efficacy for the treatment of tobaccodependence.
amod||prednisolone-2/NN||low-dose-1/JJ	nsubj||counteracts-6/VBZ||prednisolone-2/NN	amod||ra-5/NN||early-4/JJ	prep_in||prednisolone-2/NN||ra-5/NN	root||ROOT-0/null||counteracts-6/VBZ	det||impact-9/NN||the-7/DT	amod||impact-9/NN||negative-8/JJ	dobj||counteracts-6/VBZ||impact-9/NN	amod||inflammation-12/NN||rheumatoid-11/JJ	prep_of||impact-9/NN||inflammation-12/NN	nn||tissue-15/NN||bone-14/NN	prep_on||counteracts-6/VBZ||tissue-15/NN	det||hip-18/NN||the-17/DT	prep_in||tissue-15/NN||hip-18/NN	det||localisation-22/NN||a-20/DT	amod||localisation-22/NN||juxta-articular-21/JJ	appos||hip-18/NN||localisation-22/NN	inflammation-12||prednisolone-2||yes||low-dose prednisolone in early ra counteracts the negative impact of rheumatoid inflammation on bone tissue in the hip, a juxta-articular localisation.
det||activity-5/NN||the-1/DT	dep||vitro-3/NN||in-2/IN	amod||activity-5/NN||vitro-3/NN	amod||activity-5/NN||anticandidal-4/JJ	nsubj||racemosus-8/VBZ||activity-5/NN	prep_of||activity-5/NN||asparagus-7/NNS	dep||investigated-14/VBN||racemosus-8/VBZ	nsubj||extract-12/VB||roots-9/NNS	conj_and||roots-9/NNS||tubers-11/NNS	nsubj||extract-12/VB||tubers-11/NNS	ccomp||racemosus-8/VBZ||extract-12/VB	auxpass||investigated-14/VBN||was-13/VBD	root||ROOT-0/null||investigated-14/VBN	prep_against||investigated-14/VBN||candidaalbicans-16/NNS	nn||tropicalis-19/NNS||candida-18/NN	prep_against||investigated-14/VBN||tropicalis-19/NNS	conj_and||candidaalbicans-16/NNS||tropicalis-19/NNS	nn||krusei-22/NNS||candida-21/NN	prep_against||investigated-14/VBN||krusei-22/NNS	conj_and||candidaalbicans-16/NNS||krusei-22/NNS	nn||guillermondii-25/NNS||candida-24/NN	prep_against||investigated-14/VBN||guillermondii-25/NNS	conj_and||candidaalbicans-16/NNS||guillermondii-25/NNS	nn||parapsilosis-28/NNS||candida-27/NN	prep_against||investigated-14/VBN||parapsilosis-28/NNS	conj_and||candidaalbicans-16/NNS||parapsilosis-28/NNS	prep_against||investigated-14/VBN||candida-30/NN	conj_and||candidaalbicans-16/NNS||candida-30/NN	nsubjpass||investigated-14/VBN||stellatoida-31/NN	nsubjpass||isolated-35/VBN||stellatoida-31/NN	auxpass||isolated-35/VBN||are-34/VBP	rcmod||stellatoida-31/NN||isolated-35/VBN	amod||patients-38/NNS||vaginalthrush-37/JJ	prep_from||isolated-35/VBN||patients-38/NNS	vaginalthrush-37||candidaalbicans-16||no||the in vitro anticandidal activity of asparagus racemosus roots and tubers extract was investigated against candidaalbicans, candida tropicalis, candida krusei, candida guillermondii, candida parapsilosis and candida stellatoida, which are isolated from vaginalthrush patients.
det||woman-4/NN||a-1/DT	amod||woman-4/NN||54-year-old-2/JJ	amod||woman-4/NN||caucasian-3/JJ	nsubj||developed-19/VBN||woman-4/NN	amod||multiplemyeloma-9/NN||immunoglobulin-6/JJ	nn||multiplemyeloma-9/NN||g-7/NN	nn||multiplemyeloma-9/NN||kappa-8/NN	prep_with||woman-4/NN||multiplemyeloma-9/NN	amod||bortezomib-12/NN||single-agent-11/JJ	prep_on||multiplemyeloma-9/NN||bortezomib-12/NN	prep||bortezomib-12/NN||given-13/VBN	pcomp||given-13/VBN||by-14/IN	amod||push-16/NN||intravenous-15/JJ	pobj||by-14/IN||push-16/NN	advmod||developed-19/VBN||once-17/RB	advmod||developed-19/VBN||weekly-18/RB	root||ROOT-0/null||developed-19/VBN	amod||palsy-28/NN||isolated-20/JJ	amod||palsy-28/NN||unilateral-21/JJ	advmod||left-24/NN||partially-22/RB	dep||left-24/NN||reversible-23/JJ	amod||palsy-28/NN||left-24/NN	nn||palsy-28/NN||sided-25/NNP	nn||palsy-28/NN||oculomotor-26/NN	nn||palsy-28/NN||nerve-27/NN	dobj||developed-19/VBN||palsy-28/NN	det||cycle-32/NN||the-30/DT	amod||cycle-32/NN||first-31/JJ	prep_during||developed-19/VBN||cycle-32/NN	prep_of||cycle-32/NN||treatment-34/NN	multiplemyeloma-9||bortezomib-12||yes||a 54-year-old caucasian woman with immunoglobulin g kappa multiplemyeloma on single-agent bortezomib given by intravenous push once weekly developed isolated unilateral partially reversible left sided oculomotor nerve palsy during the first cycle of treatment.
nsubj||prominent-4/JJ||hyperprolactinemia-1/NN	cop||prominent-4/JJ||is-2/VBZ	advmod||prominent-4/JJ||especially-3/RB	root||ROOT-0/null||prominent-4/JJ	amod||antipsychotics-7/NNS||first-generation-6/JJ	prep_with||prominent-4/JJ||antipsychotics-7/NNS	prep_such_as||antipsychotics-7/NNS||haloperidol-10/NN	det||drugs-14/NNS||the-12/DT	amod||drugs-14/NNS||second-generation-13/JJ	prep_such_as||antipsychotics-7/NNS||drugs-14/NNS	conj_and||haloperidol-10/NN||drugs-14/NNS	advmod||risperidone-18/JJ||most-16/RBS	advmod||risperidone-18/JJ||commonly-17/RB	amod||antipsychotics-7/NNS||risperidone-18/JJ	det||patients-22/NNS||some-21/DT	prep_with||antipsychotics-7/NNS||patients-22/NNS	vmod||patients-22/NNS||developing-23/VBG	dobj||developing-23/VBG||gynecomastia-24/NN	dobj||developing-23/VBG||galactorrhea-26/NN	conj_or||gynecomastia-24/NN||galactorrhea-26/NN	det||result-31/NN||a-30/DT	prep_as||gynecomastia-24/NN||result-31/NN	nn||inhibition-34/NN||prolactin-33/NN	prep_of||result-31/NN||inhibition-34/NN	prep_of||inhibition-34/NN||gonadotropinreleasinghormone-36/NN	det||hypothalamus-39/NNS||the-38/DT	prep_from||gonadotropinreleasinghormone-36/NN||hypothalamus-39/NNS	dobj||developing-23/VBG||amenorrhea-41/NN	conj_or||gynecomastia-24/NN||amenorrhea-41/NN	amenorrhea-41||gonadotropinreleasinghormone-36||yes||hyperprolactinemia is especially prominent with first-generation antipsychotics such as haloperidol and the second-generation drugs, most commonly risperidone, with some patients developing gynecomastia or galactorrhea or, as a result of prolactin inhibition of gonadotropinreleasinghormone from the hypothalamus, amenorrhea.
amod||insulinresistance-2/NN||increasing-1/VBG	nsubj||maintains-6/VBZ||insulinresistance-2/NN	det||mother-5/NN||the-4/DT	prep_in||insulinresistance-2/NN||mother-5/NN	root||ROOT-0/null||maintains-6/VBZ	amod||flow-8/NN||nutrient-7/JJ	dobj||maintains-6/VBZ||flow-8/NN	det||fetus-12/NN||the-10/DT	amod||fetus-12/NN||growing-11/VBG	prep_to||maintains-6/VBZ||fetus-12/NN	mark||counterbalance-19/VB||while-14/IN	nn||lactogen-18/NNS||prolactin-15/NN	conj_and||prolactin-15/NN||placental-17/NN	nn||lactogen-18/NNS||placental-17/NN	nsubj||counterbalance-19/VB||lactogen-18/NNS	nsubj||prevent-23/VB||lactogen-18/NNS	dep||fetus-12/NN||counterbalance-19/VB	det||resistance-21/NN||this-20/DT	dobj||counterbalance-19/VB||resistance-21/NN	dep||fetus-12/NN||prevent-23/VB	conj_and||counterbalance-19/VB||prevent-23/VB	amod||hyperglycemia-25/NN||maternal-24/JJ	dobj||prevent-23/VB||hyperglycemia-25/NN	amod||expansion-28/NN||driving-27/VBG	prep_by||prevent-23/VB||expansion-28/NN	det||population-32/NN||the-30/DT	amod||population-32/NN||maternal-31/JJ	prep_of||expansion-28/NN||population-32/NN	amod||î-35/NN||insulin-producing-34/JJ	prep_of||population-32/NN||î-35/NN	dep||population-32/NN||²-36/SYM	dep||population-32/NN||cells-38/NNS	number||â-40/CD||1-39/CD	num||$-41/$||â-40/CD	dep||cells-38/NNS||$-41/$	num||$-41/$||3-43/CD	hyperglycemia-25||insulin--1||yes||increasing insulinresistance in the mother maintains nutrient flow to the growing fetus, while prolactin and placental lactogen counterbalance this resistance and prevent maternal hyperglycemia by driving expansion of the maternal population of insulin-producing î²-cells 1 â 3 .
amod||acid-2/NN||tauroursodeoxycholic-1/JJ	nsubjpass||used-16/VBN||acid-2/NN	nsubj||study-18/VB||acid-2/NN	appos||acid-2/NN||tudca-4/NNP	det||chaperone-9/NN||a-7/DT	amod||chaperone-9/NN||chemical-8/JJ	appos||acid-2/NN||chaperone-9/NN	nsubj||alleviates-11/VBZ||chaperone-9/NN	rcmod||chaperone-9/NN||alleviates-11/VBZ	nn||stress-13/NN||er-12/NN	dobj||alleviates-11/VBZ||stress-13/NN	auxpass||used-16/VBN||was-15/VBD	root||ROOT-0/null||used-16/VBN	aux||study-18/VB||to-17/TO	xcomp||used-16/VBN||study-18/VB	det||mechanism-20/NN||the-19/DT	dobj||study-18/VB||mechanism-20/NN	vmod||mechanism-20/NN||underlying-21/VBG	amod||downregulation-24/NN||obesity-induced-22/JJ	nn||downregulation-24/NN||adiponectin-23/NN	dobj||underlying-21/VBG||downregulation-24/NN	amod||mice-27/NNS||db/db-26/JJ	prep_in||underlying-21/VBG||mice-27/NNS	amod||mice-32/NNS||high-fat-29/JJ	amod||mice-32/NNS||diet-induced-30/JJ	nn||mice-32/NNS||obese-31/NN	appos||mice-27/NNS||mice-32/NNS	amod||adipocytes-38/NNS||er-stressed-36/JJ	amod||adipocytes-38/NNS||3t3-l1-37/JJ	prep_in||underlying-21/VBG||adipocytes-38/NNS	conj_and||mice-27/NNS||adipocytes-38/NNS	chemical-8||obese-31||no_rel||tauroursodeoxycholic acid (tudca), a chemical chaperone that alleviates er stress, was used to study the mechanism underlying obesity-induced adiponectin downregulation in db/db mice, high-fat diet-induced obese mice, and in er-stressed 3t3-l1 adipocytes.
nsubjpass||considered-25/VBN||elimination-1/NN	prep_of||elimination-1/NN||onchocerciasis-3/NNS	nn||blindness-6/NN||river-5/NN	appos||elimination-1/NN||blindness-6/NN	amod||administration-10/NN||mass-9/JJ	prep_through||elimination-1/NN||administration-10/NN	prep_of||administration-10/NN||ivermectin-12/NN	det||countries-16/NNS||the-14/DT	num||countries-16/NNS||six-15/CD	prep_in||ivermectin-12/NN||countries-16/NNS	nn||america-19/NN||latin-18/NN	prep_in||countries-16/NNS||america-19/NN	advmod||endemic-23/JJ||where-20/WRB	nsubj||endemic-23/JJ||it-21/PRP	cop||endemic-23/JJ||is-22/VBZ	rcmod||administration-10/NN||endemic-23/JJ	auxpass||considered-25/VBN||is-24/VBZ	root||ROOT-0/null||considered-25/VBN	xcomp||considered-25/VBN||feasible-26/JJ	acomp||considered-25/VBN||due-27/JJ	det||size-32/NN||the-29/DT	advmod||small-31/JJ||relatively-30/RB	amod||size-32/NN||small-31/JJ	prep_to||due-27/JJ||size-32/NN	amod||isolation-35/NN||geographic-34/JJ	prep_to||due-27/JJ||isolation-35/NN	conj_and||size-32/NN||isolation-35/NN	amod||foci-38/NNS||endemic-37/JJ	prep_of||isolation-35/NN||foci-38/NNS	onchocerciasis-3||ivermectin-12||yes||elimination of onchocerciasis (river blindness) through mass administration of ivermectin in the six countries in latin america where it is endemic is considered feasible due to the relatively small size and geographic isolation of endemic foci.
aux||investigate-2/VB||to-1/TO	root||ROOT-0/null||investigate-2/VB	mark||produce-18/VB||whether-3/IN	ccomp||investigate-2/VB||not-5/RB	conj_or||produce-18/VB||not-5/RB	nsubj||produce-18/VB||coadministration-6/NN	prep_of||coadministration-6/NN||tacrolimus-8/NNS	appos||tacrolimus-8/NNS||tac-10/NN	prep_with||tacrolimus-8/NNS||prednisolone-13/NN	appos||prednisolone-13/NN||psl-15/NN	aux||produce-18/VB||can-17/MD	ccomp||investigate-2/VB||produce-18/VB	det||effect-21/NN||a-19/DT	amod||effect-21/NN||beneficial-20/JJ	dobj||produce-18/VB||effect-21/NN	det||treatment-24/NN||the-23/DT	prep_in||produce-18/VB||treatment-24/NN	amod||dermatomyositis-28/NNS||polymyositis-26/JJ	amod||dermatomyositis-28/NNS||/-27/JJ	prep_of||treatment-24/NN||dermatomyositis-28/NNS	appos||dermatomyositis-28/NNS||pm/dm-30/NNP	dermatomyositis-28||dm--1||no_rel||to investigate whether or not coadministration of tacrolimus (tac) with prednisolone (psl) can produce a beneficial effect in the treatment of polymyositis/ dermatomyositis (pm/dm).
nsubjpass||considered-4/VBN||phentermine-1/NN	aux||considered-4/VBN||has-2/VBZ	auxpass||considered-4/VBN||been-3/VBN	root||ROOT-0/null||considered-4/VBN	det||drug-8/NN||a-5/DT	advmod||safe-7/JJ||relatively-6/RB	amod||drug-8/NN||safe-7/JJ	dobj||considered-4/VBN||drug-8/NN	aux||treat-10/VB||to-9/TO	vmod||considered-4/VBN||treat-10/VB	advmod||treat-10/VB||obesity-11/RB	amod||investigation-15/NN||further-14/JJ	nsubjpass||needed-17/VBN||investigation-15/NN	nsubj||decide-19/VB||investigation-15/NN	auxpass||needed-17/VBN||is-16/VBZ	conj_and||considered-4/VBN||needed-17/VBN	aux||decide-19/VB||to-18/TO	xcomp||needed-17/VBN||decide-19/VB	det||safety-21/NN||the-20/DT	dobj||decide-19/VB||safety-21/NN	dobj||decide-19/VB||dosage-23/NN	conj_and||safety-21/NN||dosage-23/NN	prep_of||safety-21/NN||phentermine-25/NN	obesity-11||phentermine-25||yes||phentermine has been considered a relatively safe drug to treat obesity, and further investigation is needed to decide the safety and dosage of phentermine.
prep_after||insulin-11/NN||accounting-2/NN	prep_for||accounting-2/NN||adiposity-4/NN	amod||factors-8/NNS||other-6/JJ	nn||factors-8/NNS||risk-7/NN	nsubj||insulin-11/NN||factors-8/NNS	cop||insulin-11/NN||were-9/VBD	amod||insulin-11/NN||high-10/JJ	root||ROOT-0/null||insulin-11/NN	conj_and||insulin-11/NN||insulinresistance-13/NN	amod||triglycerides-16/NNPS||high-15/JJ	conj_and||insulin-11/NN||triglycerides-16/NNPS	conj_and||insulin-11/NN||smoking-19/NN	nsubj||amenable-22/JJ||factors-21/NNS	nsubj||lifestyle-24/VB||factors-21/NNS	xcomp||insulin-11/NN||amenable-22/JJ	aux||lifestyle-24/VB||to-23/TO	xcomp||amenable-22/JJ||lifestyle-24/VB	dobj||lifestyle-24/VB||intervention-25/NN	adiposity-4||insulin-11||no_rel||after accounting for adiposity, other risk factors were high insulin, insulinresistance, high triglycerides, and smoking, factors amenable to lifestyle intervention.
amod||years-3/NNS||recent-2/JJ	prep_in||discussed-21/VBN||years-3/NNS	det||ways-6/NNS||the-5/DT	prep_in||interact-11/VBP||ways-6/NNS	nsubjpass||discussed-21/VBN||ways-6/NNS	amod||programs-10/NNS||hiv/aids-focused-9/JJ	nsubj||interact-11/VBP||programs-10/NNS	rcmod||ways-6/NNS||interact-11/VBP	det||delivery-14/NN||the-13/DT	prep_with||interact-11/VBP||delivery-14/NN	amod||services-18/NNS||other-16/JJ	nn||services-18/NNS||health-17/NN	prep_of||delivery-14/NN||services-18/NNS	auxpass||discussed-21/VBN||is-19/VBZ	advmod||discussed-21/VBN||often-20/RB	root||ROOT-0/null||discussed-21/VBN	det||evidence-25/NN||the-24/DT	nsubj||limited-38/JJ||evidence-25/NN	mark||strengthen-31/VBP||whether-28/IN	nn||programs-30/NNS||hiv/aids-29/NNS	nsubj||strengthen-31/VBP||programs-30/NNS	nsubj||distort-33/VBP||programs-30/NNS	prepc_as_to||evidence-25/NN||strengthen-31/VBP	prepc_as_to||evidence-25/NN||distort-33/VBP	conj_or||strengthen-31/VBP||distort-33/VBP	amod||services-36/NNS||overall-34/JJ	nn||services-36/NNS||health-35/NN	dobj||strengthen-31/VBP||services-36/NNS	cop||limited-38/JJ||is-37/VBZ	conj_but||discussed-21/VBN||limited-38/JJ	aids--1||hiv--1||no||in recent years, the ways in which hiv/aids-focused programs interact with the delivery of other health services is often discussed, but the evidence as to whether hiv/aids programs strengthen or distort overall health services is limited.
det||review-2/NN||this-1/DT	nsubj||discusses-3/VBZ||review-2/NN	root||ROOT-0/null||discusses-3/VBZ	amod||trials-5/NNS||several-4/JJ	dobj||discusses-3/VBZ||trials-5/NNS	advmod||used-10/VBN||where-6/WRB	nsubjpass||used-10/VBN||bortezomib-7/NN	aux||used-10/VBN||has-8/VBZ	auxpass||used-10/VBN||been-9/VBN	rcmod||trials-5/NNS||used-10/VBN	det||agent-14/NN||a-12/DT	nn||agent-14/NN||single/combination-13/NN	prep_as||used-10/VBN||agent-14/NN	amod||treatment-17/NN||front-line-16/JJ	prep_for||agent-14/NN||treatment-17/NN	prep_of||treatment-17/NN||multiplemyeloma-19/NN	multiplemyeloma-19||bortezomib-7||yes||this review discusses several trials where bortezomib has been used as a single/combination agent for front-line treatment of multiplemyeloma.
nsubj||compared-2/VBD||we-1/PRP	nsubj||isolates-47/VBZ||we-1/PRP	root||ROOT-0/null||compared-2/VBD	det||performance-4/NN||the-3/DT	dobj||compared-2/VBD||performance-4/NN	det||mtbdr-9/NN||the-6/DT	nn||mtbdr-9/NN||genotypeâ-7/NNP	nn||mtbdr-9/NN||®-8/NNP	prep_of||performance-4/NN||mtbdr-9/NN	amod||specimens-45/NNS||assay-11/JJ	amod||tube-16/NN||mycobacterial-13/JJ	nn||tube-16/NN||growth-14/NN	nn||tube-16/NN||indicator-15/NN	prep_to||assay-11/JJ||tube-16/NN	amod||testing-20/NN||antimycobacterial-18/JJ	nn||testing-20/NN||susceptibility-19/NN	prep_for||tube-16/NN||testing-20/NN	amod||ast-23/NN||mgit-22/JJ	appos||testing-20/NN||ast-23/NN	nn||resistance-28/NN||detection-26/NN	nn||resistance-28/NN||inh-27/NN	prep_for||testing-20/NN||resistance-28/NN	nn||resistance-31/NN||rif-30/NN	appos||resistance-28/NN||resistance-31/NN	conj_and||assay-11/JJ||mdr-tb-34/JJ	amod||specimens-45/NNS||mdr-tb-34/JJ	amod||bacilli-38/NNS||stored-36/JJ	amod||bacilli-38/NNS||acid-fast-37/JJ	prep_in||mdr-tb-34/JJ||bacilli-38/NNS	appos||bacilli-38/NNS||afb-40/NN	amod||specimens-45/NNS||positive-43/JJ	nn||specimens-45/NNS||sputum-44/NN	dobj||compared-2/VBD||specimens-45/NNS	conj_plus||performance-4/NN||specimens-45/NNS	conj_and||compared-2/VBD||isolates-47/VBZ	det||laboratory-52/NN||a-49/DT	amod||laboratory-52/NN||public-50/JJ	nn||laboratory-52/NN||tb-51/NN	prep_at||isolates-47/VBZ||laboratory-52/NN	prep_in||laboratory-52/NN||bangkok-54/NN	dep||compared-2/VBD||thailand-56/VBD	tb-51||inh-27||yes||we compared the performance of the genotypeâ® mtbdr plus assay to mycobacterial growth indicator tube for antimycobacterial susceptibility testing (mgit ast) for detection inh resistance, rif resistance, and mdr-tb in stored acid-fast bacilli (afb)-positive sputum specimens and isolates at a public tb laboratory in bangkok, thailand.
det||expression-2/NN||the-1/DT	nsubj||able-8/JJ||expression-2/NN	nsubj||predict-10/VB||expression-2/NN	det||micrornas-5/NNS||some-4/DT	prep_of||expression-2/NN||micrornas-5/NNS	cop||able-8/JJ||was-6/VBD	advmod||able-8/JJ||also-7/RB	root||ROOT-0/null||able-8/JJ	aux||predict-10/VB||to-9/TO	xcomp||able-8/JJ||predict-10/VB	amod||resistance-12/NN||fludarabine-11/JJ	dobj||predict-10/VB||resistance-12/NN	num||patients-17/NNS||12-14/CD	amod||patients-17/NNS||independent-15/JJ	nn||patients-17/NNS||cll-16/NN	prep_of||resistance-12/NN||patients-17/NNS	cll-16||fludarabine-11||yes||the expression of some micrornas was also able to predict fludarabine resistance of 12 independent cll patients.
amod||effects-2/NNS||direct-1/JJ	nsubjpass||evaluated-9/VBN||effects-2/NNS	prep_of||effects-2/NNS||calcitonin-4/NN	nn||cartilage-7/NN||articular-6/NN	prep_on||calcitonin-4/NN||cartilage-7/NN	auxpass||evaluated-9/VBN||were-8/VBD	root||ROOT-0/null||evaluated-9/VBN	dep||measurement-13/NN||1-11/LS	agent||evaluated-9/VBN||measurement-13/NN	nn||synthesis-16/NN||proteoglycan-15/NN	prep_of||measurement-13/NN||synthesis-16/NN	prep_by||synthesis-16/NN||incorporation-18/NN	prep_of||incorporation-18/NN||radioactive-20/NN	vmod||radioactive-20/NN||labeled-21/VBN	amod||ci-27/NN||35so4-22/JJ	amod||ci-27/NN||-LSB--23/JJ	num||ci-27/NN||5-24/CD	nn||ci-27/NN||î-25/NN	num||ci-27/NN||1/4-26/CD	dobj||labeled-21/VBN||ci-27/NN	xcomp||labeled-21/VBN||-RSB--28/VBG	dep||quantification-31/NN||2-29/LS	dobj||-RSB--28/VBG||quantification-31/NN	nn||formation-34/NN||collagen-type-ii-33/NN	prep_of||quantification-31/NN||formation-34/NN	prep_by||formation-34/NN||pro-peptides-36/NNS	nn||elisa-44/NN||collagen-38/NN	nn||elisa-44/NN||type-39/NN	nn||elisa-44/NN||ii-40/NN	nn||elisa-44/NN||piinp-42/NN	prep_of||pro-peptides-36/NNS||elisa-44/NN	dep||expression-49/NN||3-46/LS	nn||expression-49/NN||qpcr-48/NN	appos||elisa-44/NN||expression-49/NN	det||receptor-53/NN||the-51/DT	nn||receptor-53/NN||calcitonin-52/NN	prep_of||expression-49/NN||receptor-53/NN	nn||chondrocytes-56/NNS||oa-55/NN	prep_in||receptor-53/NN||chondrocytes-56/NNS	vmod||chondrocytes-56/NNS||using-57/VBG	num||pairs-61/NNS||four-58/CD	amod||pairs-61/NNS||individual-59/JJ	nn||pairs-61/NNS||primer-60/NN	dobj||using-57/VBG||pairs-61/NNS	dep||activation-65/NN||4-63/LS	appos||quantification-31/NN||activation-65/NN	det||camp-68/NN||the-67/DT	prep_of||activation-65/NN||camp-68/NN	vmod||camp-68/NN||signaling-69/VBG	advmod||signaling-69/VBG||pathway-70/RB	agent||signaling-69/VBG||eia-72/NN	dep||investigations-77/NNS||5-75/CD	agent||evaluated-9/VBN||investigations-77/NNS	conj_and||measurement-13/NN||investigations-77/NNS	amod||activity-80/NN||metabolic-79/JJ	prep_of||investigations-77/NNS||activity-80/NN	prep_by||activity-80/NN||alamarblue-82/NN	calcitonin-52||oa-55||no_rel||direct effects of calcitonin on articular cartilage were evaluated by 1) measurement of proteoglycan synthesis by incorporation of radioactive labeled 35so4 [5 î¼ci] 2) quantification of collagen-type-ii formation by pro-peptides of collagen type ii (piinp) elisa, 3) qpcr expression of the calcitonin receptor in oa chondrocytes using four individual primer pairs, 4) activation of the camp signaling pathway by eia and, 5) investigations of metabolic activity by alamarblue.
det||incidence-2/NN||the-1/DT	nsubj||lower-9/JJR||incidence-2/NN	conj_and||incidence-2/NN||severity-4/NN	nsubj||lower-9/JJR||severity-4/NN	prep_of||incidence-2/NN||pain-6/NN	cop||lower-9/JJR||was-7/VBD	advmod||lower-9/JJR||significantly-8/RB	root||ROOT-0/null||lower-9/JJR	nn||lk-12/NN||group-11/NN	prep_in||lower-9/JJR||lk-12/NN	prep_than||lower-9/JJR||group-14/NN	dep||lower-9/JJR||l-15/NN	dep||lower-9/JJR||group-17/NN	conj_or||l-15/NN||group-17/NN	xcomp||lower-9/JJR||k-18/VBG	num||seconds-21/NNS||10-20/CD	prep_at||k-18/VBG||seconds-21/NNS	det||injection-24/NN||the-23/DT	prep_after||k-18/VBG||injection-24/NN	amod||mg-29/NN||microemulsion-26/JJ	nn||mg-29/NN||propofol-27/NN	num||mg-29/NN||30-28/CD	prep_of||injection-24/NN||mg-29/NN	parataxis||k-18/VBG||p-31/VB	num||0.05-33/CD||<-32/CD	dobj||p-31/VB||0.05-33/CD	pain-6||propofol-27||yes||the incidence and severity of pain was significantly lower in group lk than group l or group k at 10 seconds after the injection of microemulsion propofol 30 mg (p < 0.05).
nsubj||promote-12/VB||presence-1/NN	prep_of||presence-1/NN||denture-3/NN	det||cavity-7/NN||the-5/DT	amod||cavity-7/NN||oral-6/JJ	prep_in||denture-3/NN||cavity-7/NN	amod||patients-10/NNS||diabetic-9/JJ	prep_of||cavity-7/NN||patients-10/NNS	aux||promote-12/VB||can-11/MD	root||ROOT-0/null||promote-12/VB	nn||colonization-14/NNS||candida-13/NN	dobj||promote-12/VB||colonization-14/NNS	dobj||promote-12/VB||results-16/NNS	conj_and||colonization-14/NNS||results-16/NNS	det||incidence-20/NN||the-18/DT	amod||incidence-20/NN||higher-19/JJR	prep_in||promote-12/VB||incidence-20/NN	prep_of||incidence-20/NN||oral-22/JJ	prep_of||incidence-20/NN||systemiccandidiasis-24/NNS	conj_and||oral-22/JJ||systemiccandidiasis-24/NNS	systemiccandidiasis-24||candida-13||no||presence of denture in the oral cavity of diabetic patients can promote candida colonization and results in the higher incidence of oral and systemiccandidiasis.
advmod||cultured-2/VBD||when-1/WRB	advcl||showed-19/VBD||cultured-2/VBD	nn||selenium-7/NN||insulin-4/NN	dep||selenium-7/NN||transferrin-6/NN	prep_in||cultured-2/VBD||selenium-7/NN	nn||media-10/NNS||fibronectin-9/NN	prep_in||cultured-2/VBD||media-10/NNS	conj_and||selenium-7/NN||media-10/NNS	amod||factors-15/NNS||basic-12/JJ	nn||factors-15/NNS||fibroblast-13/NN	nn||factors-15/NNS||growth-14/NN	prep_with||cultured-2/VBD||factors-15/NNS	nn||cells-18/NNS||tumour-17/NN	nsubj||showed-19/VBD||cells-18/NNS	nsubj||phenotypes-23/VBZ||cells-18/NNS	root||ROOT-0/null||showed-19/VBD	amod||morphology-21/NN||neuronal-20/JJ	dobj||showed-19/VBD||morphology-21/NN	conj_and||showed-19/VBD||phenotypes-23/VBZ	selenium-7||tumour-17||no_rel||when cultured in insulin, transferrin selenium and fibronectin media with basic fibroblast growth factors, tumour cells showed neuronal morphology and phenotypes.
aux||develop-2/VB||to-1/TO	root||ROOT-0/null||develop-2/VB	det||formulation-5/NN||an-3/DT	amod||formulation-5/NN||oral-4/JJ	dobj||develop-2/VB||formulation-5/NN	nsubj||stable-13/JJ||formulation-5/NN	prep_of||formulation-5/NN||amphotericinb-7/NN	appos||formulation-5/NN||amb-9/NN	cop||stable-13/JJ||is-12/VBZ	rcmod||formulation-5/NN||stable-13/JJ	det||temperatures-16/NNS||the-15/DT	prep_at||stable-13/JJ||temperatures-16/NNS	nsubj||climatic-19/VBZ||who-18/WP	prepc_of||temperatures-16/NNS||climatic-19/VBZ	dobj||climatic-19/VBZ||zones-20/NNS	num||zones-20/NNS||3-21/CD	dobj||climatic-19/VBZ||4-23/CD	conj_and||zones-20/NNS||4-23/CD	dep||zones-20/NNS||30â-25/NNS	dep||30â-25/NNS||$-26/$	num||c-30/NN||43â-28/CD	amod||c-30/NN||°-29/JJ	npadvmod||of-41/RB||c-30/NN	cc||c-30/NN||and-32/CC	nn||efficacy-36/NN||evaluate-34/NN	poss||efficacy-36/NN||its-35/PRP$	prep_to||c-30/NN||efficacy-36/NN	det||model-40/NN||a-38/DT	amod||model-40/NN||murine-39/JJ	prep_in||efficacy-36/NN||model-40/NN	dep||visceralleishmaniasis-42/CD||of-41/RB	num||$-26/$||visceralleishmaniasis-42/CD	appos||zones-20/NNS||vl-44/NN	visceralleishmaniasis-42||amb-9||yes||to develop an oral formulation of amphotericinb (amb) that is stable at the temperatures of who climatic zones 3 and 4 (30â43â°c) and to evaluate its efficacy in a murine model of visceralleishmaniasis (vl).
advmod||predisposed-11/VBN||thereby-1/RB	nn||carriers-4/NNS||risk-2/NN	nn||carriers-4/NNS||allele-3/NN	nsubjpass||predisposed-11/VBN||carriers-4/NNS	amod||levels-8/NNS||low-6/JJ	nn||levels-8/NNS||cholesterol-7/NN	prep_with||carriers-4/NNS||levels-8/NNS	aux||predisposed-11/VBN||may-9/MD	auxpass||predisposed-11/VBN||be-10/VB	root||ROOT-0/null||predisposed-11/VBN	det||risk-15/NN||an-13/DT	amod||risk-15/NN||increased-14/VBN	prep_to||predisposed-11/VBN||risk-15/NN	amod||cvd-18/NN||developing-17/VBG	prep_of||risk-15/NN||cvd-18/NN	nsubj||seems-21/VBZ||cvd-18/NN	nsubjpass||abolished-24/VBN||cvd-18/NN	rcmod||cvd-18/NN||seems-21/VBZ	aux||abolished-24/VBN||to-22/TO	auxpass||abolished-24/VBN||be-23/VB	xcomp||seems-21/VBZ||abolished-24/VBN	nn||carriers-28/NNS||risk-26/NN	nn||carriers-28/NNS||allele-27/NN	prep_among||abolished-24/VBN||carriers-28/NNS	amod||levels-32/NNS||high-30/JJ	nn||levels-32/NNS||cholesterol-31/NN	prep_with||abolished-24/VBN||levels-32/NNS	cholesterol-31||cvd-18||no_rel||thereby risk allele carriers with low cholesterol levels may be predisposed to an increased risk of developing cvd, which seems to be abolished among risk allele carriers with high cholesterol levels.
amod||use-3/NN||early-onset-1/JJ	nn||use-3/NN||methamphetamine-2/NN	nsubj||increases-4/VBZ||use-3/NN	root||ROOT-0/null||increases-4/VBZ	det||prevalence-7/NN||the-5/DT	nn||prevalence-7/NN||lifetime-6/NN	dobj||increases-4/VBZ||prevalence-7/NN	prep_of||prevalence-7/NN||methamphetaminedependence-9/NN	methamphetaminedependence-9||methamphetamine-2||no||early-onset methamphetamine use increases the lifetime prevalence of methamphetaminedependence.
det||man-3/NN||a-1/DT	amod||man-3/NN||29-year-old-2/JJ	nsubjpass||readmitted-26/VBN||man-3/NN	vmod||man-3/NN||suffering-4/VBG	prep_from||suffering-4/VBG||dyspnea-6/NN	amod||effusion-10/NN||eosinophilic-8/JJ	amod||effusion-10/NN||pleural-9/JJ	prep_from||suffering-4/VBG||effusion-10/NN	conj_and||dyspnea-6/NN||effusion-10/NN	prepc_after||suffering-4/VBG||being-12/VBG	prep_on||being-12/VBG||warfarin-14/NN	amod||thromboembolism-17/NN||pulmonary-16/JJ	prep_for||warfarin-14/NN||thromboembolism-17/NN	det||period-20/NN||a-19/DT	prep_for||being-12/VBG||period-20/NN	num||month-23/NN||one-22/CD	prep_of||period-20/NN||month-23/NN	auxpass||readmitted-26/VBN||was-25/VBD	root||ROOT-0/null||readmitted-26/VBN	poss||hospital-29/NN||our-28/PRP$	prep_to||readmitted-26/VBN||hospital-29/NN	thromboembolism-17||warfarin-14||yes||a 29-year-old man suffering from dyspnea and eosinophilic pleural effusion after being on warfarin for pulmonary thromboembolism for a period of one month, was readmitted to our hospital.
amod||progress-2/NN||considerable-1/JJ	nsubjpass||made-4/VBN||progress-2/NN	auxpass||made-4/VBN||was-3/VBD	root||ROOT-0/null||made-4/VBN	det||introduction-7/NN||the-6/DT	agent||made-4/VBN||introduction-7/NN	prep_of||introduction-7/NN||interferon-9/NN	det||treatment-12/NN||the-11/DT	prep_to||made-4/VBN||treatment-12/NN	amod||virusinfection-15/NN||chronichepatitisc-14/JJ	prep_of||treatment-12/NN||virusinfection-15/NN	chronichepatitisc-14||interferon-9||yes||considerable progress was made by the introduction of interferon to the treatment of chronichepatitisc virusinfection.
det||absence-3/NN||the-1/DT	amod||absence-3/NN||near-2/JJ	nsubj||make-12/VBP||absence-3/NN	prep_of||absence-3/NN||hypoglycemia-5/NN	det||mechanism-9/NN||an-7/DT	amod||mechanism-9/NN||insulin-independent-8/JJ	conj_and||absence-3/NN||mechanism-9/NN	nsubj||make-12/VBP||mechanism-9/NN	prep_of||mechanism-9/NN||action-11/NN	root||ROOT-0/null||make-12/VBP	xcomp||make-12/VBP||dapagliflozin-13/VB	det||addition-16/NN||a-14/DT	amod||addition-16/NN||unique-15/JJ	dobj||dapagliflozin-13/VB||addition-16/NN	amod||options-20/NNS||existing-18/VBG	nn||options-20/NNS||treatment-19/NN	prep_to||dapagliflozin-13/VB||options-20/NNS	prep_for||options-20/NNS||type2diabetes-22/CD	type2diabetes-22||insulin--1||yes||the near absence of hypoglycemia and an insulin-independent mechanism of action make dapagliflozin a unique addition to existing treatment options for type2diabetes.
nsubj||undergoing-3/VBG||patients-2/NNS	prepc_among||safe-21/JJ||undergoing-3/VBG	amod||stenting-5/NN||primary-4/JJ	dobj||undergoing-3/VBG||stenting-5/NN	amod||administration-8/NN||abciximab-7/JJ	prep_with||undergoing-3/VBG||administration-8/NN	amod||reversal-12/NN||immediate-10/JJ	nn||reversal-12/NN||post-pci-11/NN	nsubjpass||safe-21/JJ||reversal-12/NN	nsubjpass||associated-23/VBN||reversal-12/NN	vmod||reversal-12/NN||anticoagulation-13/VBN	agent||anticoagulation-13/VBN||protamine-15/NN	amod||infusion-19/NN||associated-17/VBN	nn||infusion-19/NN||heparin-18/NN	prep_without||anticoagulation-13/VBN||infusion-19/NN	auxpass||safe-21/JJ||is-20/VBZ	cop||safe-21/JJ||is-20/VBZ	root||ROOT-0/null||safe-21/JJ	conj_and||safe-21/JJ||associated-23/VBN	det||reduction-27/NN||a-25/DT	amod||reduction-27/NN||significant-26/JJ	prep_with||associated-23/VBN||reduction-27/NN	amod||complications-31/NNS||major-29/JJ	amod||complications-31/NNS||bleeding-30/VBG	prep_in||reduction-27/NN||complications-31/NNS	abciximab-7||bleeding-30||no_rel||among patients undergoing primary stenting with abciximab administration, immediate post-pci reversal anticoagulation by protamine without associated heparin infusion is safe and associated with a significant reduction in major bleeding complications.
det||delay-3/NN||some-2/DT	prep_after||became-14/VBD||delay-3/NN	nn||observation-9/NN||deâ-5/NN	amod||observation-9/NN||$-6/$	dep||$-6/$||-7/JJ	nn||observation-9/NN||s-8/NNP	nsubj||became-14/VBD||observation-9/NN	det||exotoxin-13/NN||a-11/DT	amod||exotoxin-13/NN||diarrhoeagenic-12/JJ	prep_of||observation-9/NN||exotoxin-13/NN	root||ROOT-0/null||became-14/VBD	det||principle-17/NN||the-15/DT	amod||principle-17/NN||founding-16/VBG	xcomp||became-14/VBD||principle-17/NN	amod||research-21/NN||modern-19/JJ	nn||research-21/NN||cholera-20/NN	prep_of||principle-17/NN||research-21/NN	prep_of||principle-17/NN||vaccination-23/NN	conj_and||research-21/NN||vaccination-23/NN	prep_of||principle-17/NN||treatment-26/NN	conj_and||research-21/NN||treatment-26/NN	det||burst-30/NN||a-29/DT	nsubj||saw-33/VBD||burst-30/NN	prep_of||burst-30/NN||discovery-32/NN	conj_and||became-14/VBD||saw-33/VBD	dobj||saw-33/VBD||v.cholerae-34/NN	vmod||v.cholerae-34/NN||transformed-35/VBN	det||pathogen-39/NN||the-37/DT	amod||pathogen-39/NN||enteric-38/JJ	prep_into||transformed-35/VBN||pathogen-39/NN	advmod||understood-41/VBN||best-40/RBS	vmod||pathogen-39/NN||understood-41/VBN	det||level-45/NN||the-43/DT	amod||level-45/NN||molecular-44/JJ	prep_at||understood-41/VBN||level-45/NN	cholera-20||v.cholerae-34||no||after some delay , deâ $  s observation of a diarrhoeagenic exotoxin became the founding principle of modern cholera research , vaccination , and treatment ; and a burst of discovery saw v.cholerae transformed into the enteric pathogen best understood at the molecular level .
nsubj||vaccinated-13/VBD||objective-1/NN	aux||compare-3/VB||to-2/TO	vmod||objective-1/NN||compare-3/VB	det||incidence-5/NN||the-4/DT	dobj||compare-3/VB||incidence-5/NN	prep_of||incidence-5/NN||tuberculosis-7/NNP	num||years-10/NNS||two-9/CD	prep_over||compare-3/VB||years-10/NNS	prep_in||years-10/NNS||infants-12/NNS	root||ROOT-0/null||vaccinated-13/VBD	prep_at||vaccinated-13/VBD||birth-15/NN	amod||bcg-18/NN||intradermal-17/JJ	prep_with||vaccinated-13/VBD||bcg-18/NN	amod||bcg-22/NN||percutaneous-21/JJ	prep_with||vaccinated-13/VBD||bcg-22/NN	conj_or||bcg-18/NN||bcg-22/NN	tuberculosis-7||bcg-22||yes||objective to compare the incidence of tuberculosis over two years in infants vaccinated at birth with intradermal bcg or with percutaneous bcg.
amod||ssarcoma-4/NN||aids-associated-1/JJ	nn||ssarcoma-4/NN||kaposi-2/NN	nsubj||infection-11/NN||ssarcoma-4/NN	cop||infection-11/NN||is-5/VBZ	det||infection-11/NN||an-6/DT	amod||life-threatening-9/JJ||important-7/JJ	amod||infection-11/NN||life-threatening-9/JJ	amod||infection-11/NN||opportunistic-10/JJ	root||ROOT-0/null||infection-11/NN	prep_among||infection-11/NN||people-13/NNS	vmod||people-13/NNS||living-14/VBG	prep_with||living-14/VBG||hiv/aids-16/NNS	amod||settings-19/NNS||resource-limited-18/JJ	prep_in||hiv/aids-16/NNS||settings-19/NNS	aids--1||hiv--1||no||aids-associated kaposi'ssarcoma is an important, life-threatening opportunistic infection among people living with hiv/aids in resource-limited settings.
nn||methods-2/NNS||review-1/NN	nsubj||randomised-3/VBD||methods-2/NNS	root||ROOT-0/null||randomised-3/VBD	amod||trials-5/NNS||controlled-4/JJ	nsubj||eligible-23/JJ||trials-5/NNS	vmod||trials-5/NNS||comparing-6/VBG	dobj||comparing-6/VBG||fibre-7/NN	dobj||comparing-6/VBG||antispasmodics-9/NN	conj_and||fibre-7/NN||antispasmodics-9/NN	dobj||comparing-6/VBG||peppermintoil-12/NN	conj_and||fibre-7/NN||peppermintoil-12/NN	prep_with||comparing-6/VBG||placebo-14/NN	neg||treatment-17/NN||no-16/DT	prep_with||comparing-6/VBG||treatment-17/NN	conj_or||placebo-14/NN||treatment-17/NN	prep_in||comparing-6/VBG||adults-19/NNS	prep_with||adults-19/NNS||irritablebowelsyndrome-21/NN	cop||eligible-23/JJ||were-22/VBD	ccomp||randomised-3/VBD||eligible-23/JJ	prep_for||eligible-23/JJ||inclusion-25/NN	peppermintoil-12||irritablebowelsyndrome-21||no_rel||review methods randomised controlled trials comparing fibre, antispasmodics, and peppermintoil with placebo or no treatment in adults with irritablebowelsyndrome were eligible for inclusion.
nn||studies-2/NNS||animal-1/NN	nsubj||revealed-5/VBN||studies-2/NNS	aux||revealed-5/VBN||have-3/VBP	advmod||revealed-5/VBN||further-4/RBR	root||ROOT-0/null||revealed-5/VBN	mark||induces-10/VBZ||that-6/IN	amod||treatment-9/NN||chronic-7/JJ	nn||treatment-9/NN||antidepressant-8/NN	nsubj||induces-10/VBZ||treatment-9/NN	nsubj||contributes-19/VBZ||treatment-9/NN	ccomp||revealed-5/VBN||induces-10/VBZ	amod||changes-12/NNS||robust-11/JJ	dobj||induces-10/VBZ||changes-12/NNS	nn||metabolism-16/NN||brain-14/NN	nn||metabolism-16/NN||fa-15/NN	prep_in||induces-10/VBZ||metabolism-16/NN	ccomp||revealed-5/VBN||contributes-19/VBZ	conj_but||induces-10/VBZ||contributes-19/VBZ	amod||part-21/NN||only-20/JJ	dobj||contributes-19/VBZ||part-21/NN	det||abnormalities-24/NNS||the-23/DT	prep_of||part-21/NN||abnormalities-24/NNS	vmod||abnormalities-24/NNS||found-25/VBN	det||brains-29/NNS||the-27/DT	nn||brains-29/NNS||affectivedisorder-28/NN	prep_in||found-25/VBN||brains-29/NNS	antidepressant-8||affectivedisorder-28||no_rel||animal studies have further revealed that chronic antidepressant treatment induces robust changes in brain fa metabolism, but contributes only part of the abnormalities found in the affectivedisorder brains.
det||study-4/NN||an-1/DT	amod||study-4/NN||observational-2/JJ	nn||study-4/NN||retrospective-3/NN	root||ROOT-0/null||study-4/NN	amod||follow-up-7/NN||1-year-6/JJ	appos||study-4/NN||follow-up-7/NN	num||patients-11/NNS||104-10/CD	prep_on||study-4/NN||patients-11/NNS	prep_with||patients-11/NNS||oa-13/NN	nsubjpass||treated-38/VBN||oa-13/NN	nn||osteoarthritis-16/NNS||nodular-15/NN	dep||oa-13/NN||osteoarthritis-16/NNS	det||hand-19/NN||the-18/DT	prep_of||osteoarthritis-16/NNS||hand-19/NN	amod||osteoarthritis-22/NNS||erosive-21/JJ	appos||osteoarthritis-16/NNS||osteoarthritis-22/NNS	det||hand-25/NN||the-24/DT	prep_of||osteoarthritis-22/NNS||hand-25/NN	appos||osteoarthritis-16/NNS||eoa-27/NN	appos||osteoarthritis-16/NNS||osteoarthritis-29/NNS	det||knee-32/NN||the-31/DT	prep_of||osteoarthritis-29/NNS||knee-32/NN	prep_of||osteoarthritis-29/NNS||hip-34/NN	conj_or||knee-32/NN||hip-34/NN	auxpass||treated-38/VBN||were-37/VBD	rcmod||oa-13/NN||treated-38/VBN	nn||chondroitinsulfate-44/NN||gc-40/NN	conj_or||gc-40/NN||glucosamine-42/NN	nn||chondroitinsulfate-44/NN||glucosamine-42/NN	prep_with||treated-38/VBN||chondroitinsulfate-44/NN	nn||ii-48/NNS||collagen-46/NN	nn||ii-48/NNS||type-47/NN	prep_with||treated-38/VBN||ii-48/NNS	conj_and||chondroitinsulfate-44/NN||ii-48/NNS	appos||patients-11/NNS||gcc-50/NN	osteoarthritis-29||glucosamine-42||yes||an observational retrospective study, 1-year follow-up, on 104 patients with oa (nodular osteoarthritis of the hand, erosive osteoarthritis of the hand, eoa, osteoarthritis of the knee or hip) who were treated with gc or glucosamine, chondroitinsulfate and collagen type ii (gcc).
amod||guidelines-2/NNS||current-1/JJ	nsubj||recommend-3/VBP||guidelines-2/NNS	root||ROOT-0/null||recommend-3/VBP	amod||use-5/NN||prophylactic-4/JJ	nsubj||%-22/NN||use-5/NN	prep_of||use-5/NN||granulocyte-colonystimulatingfactors-7/NNS	tmod||risk-17/VBP||granulocyte-colonystimulatingfactors-7/NNS	dep||granulocyte-colonystimulatingfactors-7/NNS||g-csf-9/JJ	advmod||risk-17/VBP||when-11/WRB	amod||neutropenia-13/NN||febrile-12/JJ	nsubj||risk-17/VBP||neutropenia-13/NN	appos||neutropenia-13/NN||fn-15/NN	rcmod||granulocyte-colonystimulatingfactors-7/NNS||risk-17/VBP	cop||%-22/NN||is-18/VBZ	mwe||than-20/IN||greater-19/JJR	quantmod||20-21/CD||than-20/IN	num||%-22/NN||20-21/CD	ccomp||recommend-3/VBP||%-22/NN	neutropenia-13||colonystimulatingfactors--1||no_rel||current guidelines recommend prophylactic use of granulocyte-colonystimulatingfactors (g-csf) when febrile neutropenia (fn) risk is greater than 20%.
nsubj||showed-7/VBD||none-1/NN	det||swine-4/NNS||the-3/DT	prep_of||none-1/NN||swine-4/NNS	prep_of||none-1/NN||avianinfluenzaviruses-6/NNS	conj_and||swine-4/NNS||avianinfluenzaviruses-6/NNS	root||ROOT-0/null||showed-7/VBD	advmod||showed-7/VBD||transmissibility-8/RB	nn||pigs-11/NNS||guinea-10/NN	prep_among||showed-7/VBD||pigs-11/NNS	prep_in||transmit-36/VB||contrast-14/NN	amod||h1n1-18/NNS||pandemic-16/JJ	nsubj||transmit-36/VB||h1n1-18/NNS	num||virus-21/NN||2009-20/CD	nsubj||transmitted-22/VBD||virus-21/NN	rcmod||h1n1-18/NNS||transmitted-22/VBD	amod||pigs-26/NNS||infected-24/JJ	nn||pigs-26/NNS||guinea-25/NN	prep_from||transmitted-22/VBD||pigs-26/NNS	det||animals-29/NNS||all-28/DT	prep_to||transmitted-22/VBD||animals-29/NNS	amod||humaninfluenzaviruses-32/NNS||seasonal-31/JJ	prep_to||transmitted-22/VBD||humaninfluenzaviruses-32/NNS	conj_and||animals-29/NNS||humaninfluenzaviruses-32/NNS	aux||transmit-36/VB||could-33/MD	advmod||transmit-36/VB||also-34/RB	advmod||transmit-36/VB||horizontally-35/RB	parataxis||showed-7/VBD||transmit-36/VB	nn||pigs-39/NNS||guinea-38/NN	prep_in||transmit-36/VB||pigs-39/NNS	humaninfluenza--1||influenzaviruses--1||no||none of the swine and avianinfluenzaviruses showed transmissibility among guinea pigs; in contrast, pandemic (h1n1) 2009 virus transmitted from infected guinea pigs to all animals and seasonal humaninfluenzaviruses could also horizontally transmit in guinea pigs.
root||ROOT-0/null||antibody-1/NN	appos||antibody-1/NN||ab-3/NN	amod||inhibition-7/NN||mediated-6/JJ	dep||antibody-1/NN||inhibition-7/NN	det||serum-12/NN||the-9/DT	advmod||abundant-11/JJ||most-10/RBS	amod||serum-12/NN||abundant-11/JJ	prep_of||inhibition-7/NN||serum-12/NN	amod||ligand-14/NN||cxcr3-13/JJ	nsubj||decreased-20/VBD||ligand-14/NN	nsubj||lowered-38/VBD||ligand-14/NN	appos||ligand-14/NN||cxcl10-16/NNS	prep_in||decreased-20/VBD||mice-19/NNS	rcmod||serum-12/NN||decreased-20/VBD	det||production-23/NN||the-21/DT	amod||production-23/NN||local-22/JJ	dobj||decreased-20/VBD||production-23/NN	amod||ligands-26/NNS||cxcr3-25/JJ	prep_of||production-23/NN||ligands-26/NNS	amod||cytokines-31/NNS||th1-30/JJ	dobj||decreased-20/VBD||cytokines-31/NNS	conj_and||production-23/NN||cytokines-31/NNS	vmod||cytokines-31/NNS||expressed-32/VBN	amod||leukocytes-35/NNS||local-34/JJ	agent||expressed-32/VBN||leukocytes-35/NNS	rcmod||serum-12/NN||lowered-38/VBD	conj_and||decreased-20/VBD||lowered-38/VBD	amod||levels-41/NNS||corresponding-39/JJ	nn||levels-41/NNS||serum-40/NN	dobj||lowered-38/VBD||levels-41/NNS	aux||reduce-43/VB||to-42/TO	vmod||lowered-38/VBD||reduce-43/VB	det||severity-45/NN||the-44/DT	dobj||reduce-43/VB||severity-45/NN	amod||cystitis-48/NNS||cyp-induced-47/JJ	prep_of||severity-45/NN||cystitis-48/NNS	cystitis-48||antibody-1||no_rel||antibody (ab)-mediated inhibition of the most abundant serum cxcr3 ligand, cxcl10, in mice decreased the local production of cxcr3 ligands as well as th1 cytokines expressed by local leukocytes, and lowered corresponding serum levels to reduce the severity of cyp-induced cystitis.
root||ROOT-0/null||irinotecan-1/VB	nsubj||result-8/VB||cisplatin-3/NN	conj_and||cisplatin-3/NN||paclitaxel-5/NN	nsubj||result-8/VB||paclitaxel-5/NN	conj_plus||cisplatin-3/NN||cisplatin-7/NN	nsubj||result-8/VB||cisplatin-7/NN	ccomp||irinotecan-1/VB||result-8/VB	amod||survival-11/NN||similar-10/JJ	prep_in||result-8/VB||survival-11/NN	advmod||combined-13/VBN||when-12/WRB	advcl||result-8/VB||combined-13/VBN	prep_with||combined-13/VBN||radiotherapy-15/NN	prep_for||radiotherapy-15/NN||esophagealcancer-17/NN	esophagealcancer-17||cisplatin-7||yes||irinotecan plus cisplatin and paclitaxel plus cisplatin result in similar survival when combined with radiotherapy for esophagealcancer.
det||research-3/NN||the-1/DT	amod||research-3/NN||proposed-2/VBN	nsubj||seeks-4/VBZ||research-3/NN	nsubj||answer-6/VB||research-3/NN	dep||explain-23/VB||seeks-4/VBZ	aux||answer-6/VB||to-5/TO	xcomp||seeks-4/VBZ||answer-6/VB	det||questions-9/NNS||the-7/DT	amod||questions-9/NNS||following-8/JJ	nsubj||i-10/VBZ||questions-9/NNS	parataxis||answer-6/VB||i-10/VBZ	advmod||assessed-13/VBN||when-12/WRB	advcl||answer-6/VB||assessed-13/VBN	advmod||assessed-13/VBN||systematically-14/RB	aux||explain-23/VB||do-16/VBP	nsubj||explain-23/VB||patients-17/NNS	conj_and||patients-17/NNS||clinicians-20/NNS	nsubj||explain-23/VB||clinicians-20/NNS	dep||patients-17/NNS||preferences-22/NNS	root||ROOT-0/null||explain-23/VB	det||utilization-25/NN||the-24/DT	dobj||explain-23/VB||utilization-25/NN	prep_of||utilization-25/NN||warfarin-27/NN	aux||prevent-29/VB||to-28/TO	vmod||explain-23/VB||prevent-29/VB	dobj||prevent-29/VB||strokes-30/NNS	vmod||strokes-30/NNS||associated-31/VBN	prep_with||associated-31/VBN||atrialfibrillation-33/NN	strokes-30||warfarin-27||yes||the proposed research seeks to answer the following questions i) when assessed systematically, do patients' and clinicians' preferences explain the utilization of warfarin to prevent strokes associated with atrialfibrillation?
det||propagation-2/NN||the-1/DT	nsubj||requires-17/VBZ||propagation-2/NN	prep_of||propagation-2/NN||prions-4/NNS	det||agents-8/NNS||the-6/DT	amod||agents-8/NNS||causative-7/JJ	appos||propagation-2/NN||agents-8/NNS	amod||disease-11/NN||creutzfeldt-jakob-10/JJ	prep_of||agents-8/NNS||disease-11/NN	amod||priondiseases-15/NNS||other-13/JJ	amod||priondiseases-15/NNS||human-14/JJ	prep_of||agents-8/NNS||priondiseases-15/NNS	conj_and||disease-11/NN||priondiseases-15/NNS	root||ROOT-0/null||requires-17/VBZ	amod||conversion-19/NN||post-translational-18/JJ	dobj||requires-17/VBZ||conversion-19/NN	amod||prionprotein-23/NN||normal-21/JJ	amod||prionprotein-23/NN||cellular-22/JJ	prep_of||conversion-19/NN||prionprotein-23/NN	amod||forms-26/NNS||disease-associated-25/JJ	prep_to||requires-17/VBZ||forms-26/NNS	priondiseases-15||prions-4||no||the propagation of prions, the causative agents of creutzfeldt-jakob disease and other human priondiseases, requires post-translational conversion of normal cellular prionprotein to disease-associated forms.
nsubj||has-2/VBZ||oxaliplatin/docetaxel-1/NN	root||ROOT-0/null||has-2/VBZ	dobj||has-2/VBZ||activity-3/NN	amod||non-smallcelllungcancer-6/NN||metastatic-5/JJ	prep_in||activity-3/NN||non-smallcelllungcancer-6/NN	nsubj||seems-10/VBZ||it-9/PRP	nsubj||inferior-13/JJ||it-9/PRP	nsubj||cisplatin/docetaxel-15/VB||it-9/PRP	conj_but||has-2/VBZ||seems-10/VBZ	aux||inferior-13/JJ||to-11/TO	cop||inferior-13/JJ||be-12/VB	xcomp||seems-10/VBZ||inferior-13/JJ	aux||cisplatin/docetaxel-15/VB||to-14/TO	xcomp||inferior-13/JJ||cisplatin/docetaxel-15/VB	non-smallcelllungcancer-6||docetaxel--1||yes||oxaliplatin/docetaxel has activity in metastatic non-smallcelllungcancer, but it seems to be inferior to cisplatin/docetaxel.
det||research-7/NN||some-1/DT	cc||all-5/DT||not-4/RB	dep||research-7/NN||all-5/DT	nsubj||indicates-8/VBZ||research-7/NN	root||ROOT-0/null||indicates-8/VBZ	mark||linked-20/VBN||that-9/IN	amod||administration-11/NN||antibiotic-10/JJ	nsubjpass||linked-20/VBN||administration-11/NN	prep_in||administration-11/NN||pregnancy-13/NN	prep_in||administration-11/NN||childbirth-15/NN	conj_or||pregnancy-13/NN||childbirth-15/NN	prep_in||administration-11/NN||infancy-17/NN	conj_or||pregnancy-13/NN||infancy-17/NN	aux||linked-20/VBN||may-18/MD	auxpass||linked-20/VBN||be-19/VB	ccomp||indicates-8/VBZ||linked-20/VBN	nn||asthma-23/NN||childhood-22/NN	prep_to||linked-20/VBN||asthma-23/NN	prep_to||linked-20/VBN||eczema-25/NN	conj_and||asthma-23/NN||eczema-25/NN	amod||uncertainty-29/NN||much-28/JJ	nsubj||remains-30/VBZ||uncertainty-29/NN	conj_but||indicates-8/VBZ||remains-30/VBZ	asthma-23||antibiotic-10||no_rel||some, but not all, research indicates that antibiotic administration in pregnancy, childbirth or infancy may be linked to childhood asthma and eczema, but much uncertainty remains.
nsubj||has-2/VBZ||insulin-1/NN	root||ROOT-0/null||has-2/VBZ	amod||effects-4/NNS||mitogenic-3/JJ	dobj||has-2/VBZ||effects-4/NNS	mark||factor-12/NN||although-6/IN	nsubj||factor-12/NN||hyperglycemia-7/NN	aux||factor-12/NN||may-8/MD	cop||factor-12/NN||be-9/VB	det||factor-12/NN||a-10/DT	nn||factor-12/NN||risk-11/NN	advcl||has-2/VBZ||factor-12/NN	prep_for||factor-12/NN||cancer-14/NN	prep_in||cancer-14/NN||type2diabetes-16/CD	hyperglycemia-7||insulin-1||yes||insulin has mitogenic effects, although hyperglycemia may be a risk factor for cancer in type2diabetes.
amod||evidence-2/NN||available-1/JJ	nsubj||shows-8/VBZ||evidence-2/NN	amod||treatment-5/NN||symptomatic-4/JJ	prep_on||evidence-2/NN||treatment-5/NN	prep_of||treatment-5/NN||vomiting-7/NN	root||ROOT-0/null||shows-8/VBZ	det||efficacy-10/NN||the-9/DT	dobj||shows-8/VBZ||efficacy-10/NN	det||molecule-16/NN||the-12/DT	advmod||registered-15/VBN||most-13/RBS	advmod||registered-15/VBN||recently-14/RB	amod||molecule-16/NN||registered-15/VBN	prep_of||efficacy-10/NN||molecule-16/NN	appos||molecule-16/NN||ondansetron-18/NN	det||evaluation-23/NN||a-21/DT	amod||evaluation-23/NN||proper-22/JJ	nsubj||lacking-38/VBG||evaluation-23/NN	amod||drugs-26/NNS||antiemetics-25/JJ	prep_of||evaluation-23/NN||drugs-26/NNS	advmod||used-28/VBN||largely-27/RB	vmod||drugs-26/NNS||used-28/VBN	amod||practice-31/NN||clinical-30/JJ	prep_in||used-28/VBN||practice-31/NN	prep_such_as||evaluation-23/NN||domperidone-35/NN	aux||lacking-38/VBG||is-37/VBZ	conj_but||shows-8/VBZ||lacking-38/VBG	vomiting-7||antiemetics-25||no_rel||available evidence on symptomatic treatment of vomiting shows the efficacy of the most recently registered molecule (ondansetron) but a proper evaluation of antiemetics drugs largely used in clinical practice, such as domperidone, is lacking.
det||incidence-3/NN||the-1/DT	amod||incidence-3/NN||reported-2/JJ	nsubj||growing-10/VBG||incidence-3/NN	amod||isolates-6/NNS||drug-resistant-5/JJ	prep_of||incidence-3/NN||isolates-6/NNS	prep_of||isolates-6/NNS||m.tuberculosis-8/NNS	aux||growing-10/VBG||is-9/VBZ	root||ROOT-0/null||growing-10/VBG	advmod||growing-10/VBG||steadily-11/RB	advmod||reported-52/VBN||however-13/RB	nsubjpass||reported-52/VBN||data-15/NNS	det||variation-19/NN||the-17/DT	amod||variation-19/NN||genetic-18/JJ	prep_on||data-15/NNS||variation-19/NN	prep_of||variation-19/NN||isolates-21/NNP	prep_of||isolates-21/NNP||m.tuberculosis-23/NNS	vmod||m.tuberculosis-23/NNS||circulating-24/VBG	vmod||m.tuberculosis-23/NNS||circulating-24/VBG	conj_and||circulating-24/VBG||circulating-24/VBG	amod||ukraine-27/NN||northern-26/JJ	prep_in||circulating-24/VBG||ukraine-27/NN	det||spectrum-31/NN||the-30/DT	prep_on||circulating-24/VBG||spectrum-31/NN	prep_on||circulating-24/VBG||frequency-33/NN	conj_and||spectrum-31/NN||frequency-33/NN	prep_of||spectrum-31/NN||occurrence-35/NN	prep_of||occurrence-35/NN||mutations-37/NNS	vmod||mutations-37/NNS||determining-38/VBG	dobj||determining-38/VBG||resistance-39/NN	det||drugs-44/NNS||the-41/DT	amod||drugs-44/NNS||principal-42/JJ	amod||drugs-44/NNS||anti-tuberculosis-43/JJ	prep_to||determining-38/VBG||drugs-44/NNS	amod||drugs-44/NNS||isoniazid-45/JJ	amod||drugs-44/NNS||rifampicin-47/JJ	conj_and||isoniazid-45/JJ||rifampicin-47/JJ	aux||reported-52/VBN||have-48/VBP	neg||reported-52/VBN||not-49/RB	advmod||reported-52/VBN||yet-50/RB	auxpass||reported-52/VBN||been-51/VBN	parataxis||growing-10/VBG||reported-52/VBN	tuberculosis--1||isoniazid-45||yes||the reported incidence of drug-resistant isolates of m.tuberculosis is growing steadily ; however , data on the genetic variation of isolates of m.tuberculosis circulating in northern ukraine and on the spectrum and frequency of occurrence of mutations determining resistance to the principal anti-tuberculosis drugs isoniazid and rifampicin have not yet been reported .
advmod||distinctive-4/JJ||apparently-2/RB	advmod||distinctive-4/JJ||quite-3/RB	amod||profiles-7/NNS||distinctive-4/JJ	amod||profiles-7/NNS||venom-5/JJ	nn||profiles-7/NNS||protein-6/NN	prep_despite||observed-10/VBD||profiles-7/NNS	nsubj||observed-10/VBD||we-9/PRP	root||ROOT-0/null||observed-10/VBD	amod||similarity-13/NN||extensive-11/JJ	amod||similarity-13/NN||cross-species-12/JJ	dobj||observed-10/VBD||similarity-13/NN	det||profiles-17/NNS||the-15/DT	amod||profiles-17/NNS||immuno-reactivity-16/JJ	prep_in||observed-10/VBD||profiles-17/NNS	amod||antisera-21/NN||echis-19/JJ	amod||antisera-21/NN||species-specific-20/JJ	prep_of||profiles-17/NNS||antisera-21/NN	antisera-21||cross--1||no_rel||despite apparently quite distinctive venom protein profiles, we observed extensive cross-species similarity in the immuno-reactivity profiles of echis species-specific antisera.
nsubj||drug-6/NN||praziquantel-1/NN	cop||drug-6/NN||is-2/VBZ	advmod||drug-6/NN||currently-3/RB	det||drug-6/NN||the-4/DT	amod||drug-6/NN||only-5/JJ	root||ROOT-0/null||drug-6/NN	nsubj||effective-9/JJ||drug-6/NN	cop||effective-9/JJ||is-8/VBZ	rcmod||drug-6/NN||effective-9/JJ	det||worms-12/NNS||the-11/DT	prep_against||effective-9/JJ||worms-12/NNS	worms-12||praziquantel-1||yes||praziquantel is currently the only drug that is effective against the worms.
num||mechanisms-2/NNS||three-1/CD	nsubj||seem-3/VBP||mechanisms-2/NNS	nsubj||operate-5/VB||mechanisms-2/NNS	root||ROOT-0/null||seem-3/VBP	aux||operate-5/VB||to-4/TO	xcomp||seem-3/VBP||operate-5/VB	prep_in||operate-5/VB||il-6â-7/JJ	dep||il-6â-7/JJ||$-8/$	advmod||activation-12/NN||induced-10/RB	amod||activation-12/NN||insulinresistance-11/JJ	dep||1/2-17/CD||activation-12/NN	amod||kinase-16/NN||c-jun-14/JJ	amod||kinase-16/NN||nh2-terminal-15/JJ	prep_of||activation-12/NN||kinase-16/NN	num||$-8/$||1/2-17/CD	appos||$-8/$||jnk1/2-19/NNP	prep_in||operate-5/VB||accumulation-22/NN	conj_and||il-6â-7/JJ||accumulation-22/NN	prep_of||accumulation-22/NN||suppressor-24/NN	amod||mrna-32/NNS||cytokine-26/JJ	dep||cytokine-26/JJ||signaling-27/NNP	num||signaling-27/NNP||3-28/CD	appos||mrna-32/NNS||socs3-30/NNP	prep_of||suppressor-24/NN||mrna-32/NNS	det||increase-36/NN||an-35/DT	prep_in||operate-5/VB||increase-36/NN	conj_and||il-6â-7/JJ||increase-36/NN	amod||activity-39/NN||ptp1b-38/JJ	prep_in||increase-36/NN||activity-39/NN	nh2--1||insulinresistance-11||no_rel||three mechanisms seem to operate in il-6âinduced insulinresistance activation of c-jun nh2-terminal kinase 1/2 (jnk1/2), accumulation of suppressor of cytokine signaling 3 ( socs3 ) mrna, and an increase in ptp1b activity.
det||period-5/NN||the-2/DT	amod||period-5/NN||6-month-3/JJ	nn||period-5/NN||study-4/NN	prep_following||decreased-20/VBN||period-5/NN	det||glucose-13/NN||the-7/DT	nn||glucose-13/NN||plasma-8/NN	nn||glucose-13/NN||tbars-9/NNS	nn||glucose-13/NN||levels-10/NNS	conj_and||glucose-13/NN||fasting-12/NN	nsubjpass||decreased-20/VBN||fasting-12/NN	nsubjpass||decreased-20/VBN||glucose-13/NN	nsubjpass||decreased-20/VBN||glucose-13/NN	conj_and||glucose-13/NN||hba1c-15/NN	nsubjpass||decreased-20/VBN||hba1c-15/NN	conj_and||glucose-13/NN||insulinresistance-17/NN	nsubjpass||decreased-20/VBN||insulinresistance-17/NN	auxpass||decreased-20/VBN||were-18/VBD	advmod||decreased-20/VBN||significantly-19/RB	root||ROOT-0/null||decreased-20/VBN	conj_but||decreased-20/VBN||decreased-20/VBN	det||cr-23/NN||the-22/DT	prep_in||decreased-20/VBN||cr-23/NN	nn||groups-32/NNS||crâ-25/NN	nn||groups-32/NNS||+-26/NNP	nn||groups-32/NNS||â-27/NN	nn||groups-32/NNS||câ-28/NN	nn||groups-32/NNS||+-29/NN	nn||groups-32/NNS||â-30/NN	amod||groups-32/NNS||e-31/JJ	prep_in||decreased-20/VBN||groups-32/NNS	conj_and||cr-23/NN||groups-32/NNS	neg||decreased-20/VBN||not-35/RB	det||group-39/NN||the-37/DT	nn||group-39/NN||placebo-38/NN	prep_for||decreased-20/VBN||group-39/NN	insulinresistance-17||cr-23||no_rel||following the 6-month study period, the plasma tbars levels, fasting glucose, hba1c and insulinresistance were significantly decreased in the cr and crâ +â câ +â e groups, but not for the placebo group.
nsubj||mechanism-12/NN||the-1/DT	amod||the-1/DT||binding-2/VBG	prep_of||the-1/DT||bacteria-4/NNS	amod||platelets-7/NNS||human-6/JJ	prep_to||bacteria-4/NNS||platelets-7/NNS	cop||mechanism-12/NN||is-8/VBZ	det||mechanism-12/NN||a-9/DT	amod||central-11/JJ||likely-10/JJ	amod||mechanism-12/NN||central-11/JJ	root||ROOT-0/null||mechanism-12/NN	det||pathogenesis-15/NNS||the-14/DT	prep_in||mechanism-12/NN||pathogenesis-15/NNS	prep_of||pathogenesis-15/NNS||infectiveendocarditis-17/NNS	infectiveendocarditis-17||bacteria-4||no||the binding of bacteria to human platelets is a likely central mechanism in the pathogenesis of infectiveendocarditis.
det||study-2/NN||this-1/DT	nsubj||aims-3/VBZ||study-2/NN	nsubj||compare-5/VB||study-2/NN	root||ROOT-0/null||aims-3/VBZ	aux||compare-5/VB||to-4/TO	xcomp||aims-3/VBZ||compare-5/VB	num||vasoconstrictors-7/NNS||two-6/CD	dobj||compare-5/VB||vasoconstrictors-7/NNS	dobj||compare-5/VB||$-9/$	conj_â||vasoconstrictors-7/NNS||$-9/$	amod||$-9/$||norepinephrine-11/JJ	amod||$-9/$||phenylephrine-13/JJ	conj_and||norepinephrine-11/JJ||phenylephrine-13/JJ	advmod||$-9/$||â-14/RB	pobj||â-14/RB||$-15/$	det||management-19/NN||the-18/DT	prep_in||â-14/RB||management-19/NN	prep_of||management-19/NN||dopamineâ-21/NNP	amod||septicshock-25/NN||$-22/$	dep||$-22/$||resistant-24/NN	dep||$-9/$||septicshock-25/NN	septicshock-25||phenylephrine-13||yes||this study aims to compare two vasoconstrictors â norepinephrine and phenylephrine â in the management of dopamineâresistant septicshock.
nsubjpass||associated-7/VBN||total-1/NN	amod||estradiol-4/NN||non-shbg-bound-3/JJ	conj_and||total-1/NN||estradiol-4/NN	nsubjpass||associated-7/VBN||estradiol-4/NN	auxpass||associated-7/VBN||were-5/VBD	neg||associated-7/VBN||not-6/RB	root||ROOT-0/null||associated-7/VBN	nn||cancer-10/NN||breast-9/NN	prep_with||associated-7/VBN||cancer-10/NN	amod||variation-14/NN||extreme-13/JJ	nsubj||coupled-21/VBN||variation-14/NN	prep_in||variation-14/NN||levels-16/NNS	det||cycle-20/NN||the-18/DT	amod||cycle-20/NN||menstrual-19/JJ	prep_across||levels-16/NNS||cycle-20/NN	conj_but||associated-7/VBN||coupled-21/VBN	advmod||small-24/JJ||relatively-23/RB	amod||numbers-25/NNS||small-24/JJ	prep_with||coupled-21/VBN||numbers-25/NNS	advmod||coupled-21/VBN||particularly-27/RB	prep_for||coupled-21/VBN||analyses-29/NNS	amod||analyses-29/NNS||stratified-30/JJ	nn||phase-33/NN||cycle-32/NN	prep_by||stratified-30/JJ||phase-33/NN	vmod||analyses-29/NNS||limited-35/VBN	det||power-37/NN||the-36/DT	dobj||limited-35/VBN||power-37/NN	aux||detect-39/VB||to-38/TO	vmod||power-37/NN||detect-39/VB	dobj||detect-39/VB||associations-40/NNS	estradiol-4||cancer-10||no_rel||total and non-shbg-bound estradiol were not associated with breast cancer, but extreme variation in levels across the menstrual cycle coupled with relatively small numbers, particularly for analyses stratified by cycle phase, limited the power to detect associations.
amod||vascular-2/NN||increased-1/VBN	nsubj||infection-14/NN||vascular-2/NN	advmod||infection-14/NN||permeability-3/RB	cop||infection-14/NN||is-4/VBZ	det||feature-7/NN||a-5/DT	nn||feature-7/NN||hallmark-6/NN	nn||infection-14/NN||feature-7/NN	amod||denguevirus-10/NNS||severe-9/JJ	prep_in||feature-7/NN||denguevirus-10/NNS	appos||denguevirus-10/NNS||dv-12/NN	root||ROOT-0/null||infection-14/NN	nsubjpass||speculated-23/VBN||dysfunction-17/NN	nsubj||contribute-25/VB||dysfunction-17/NN	amod||cells-20/NNS||endothelial-19/JJ	prep_of||dysfunction-17/NN||cells-20/NNS	aux||speculated-23/VBN||has-21/VBZ	auxpass||speculated-23/VBN||been-22/VBN	conj_and||infection-14/NN||speculated-23/VBN	aux||contribute-25/VB||to-24/TO	xcomp||speculated-23/VBN||contribute-25/VB	det||pathogenesis-28/NNS||the-27/DT	prep_in||contribute-25/VB||pathogenesis-28/NNS	prep_of||pathogenesis-28/NNS||denguehemorrhagicfever/dengueshocksyndrome-30/NN	appos||denguehemorrhagicfever/dengueshocksyndrome-30/NN||dhf/dss-32/NNS	dengueshocksyndrome--1||denguevirus-10||no||increased vascular permeability is a hallmark feature in severe denguevirus (dv) infection, and dysfunction of endothelial cells has been speculated to contribute in the pathogenesis of denguehemorrhagicfever/dengueshocksyndrome (dhf/dss).
nsubjpass||associated-4/VBN||phn-1/NN	auxpass||associated-4/VBN||was-2/VBD	advmod||associated-4/VBN||significantly-3/RB	root||ROOT-0/null||associated-4/VBN	nn||intensity-7/NN||pain-6/NN	prep_with||associated-4/VBN||intensity-7/NN	nn||smoking-13/NN||presentation-9/NN	dep||smoking-13/NN||age-11/NN	prep_at||intensity-7/NN||smoking-13/NN	dep||smoking-13/NN||trauma-15/FW	amod||prescription-19/NN||missed-17/VBN	amod||prescription-19/NN||antiviral-18/JJ	prep_with||associated-4/VBN||prescription-19/NN	conj_and||intensity-7/NN||prescription-19/NN	amod||model-24/NN||generalized-21/JJ	nn||model-24/NN||estimating-22/NN	nn||model-24/NN||equations-23/NNS	appos||prescription-19/NN||model-24/NN	phn-1||antiviral-18||no_rel||phn was significantly associated with pain intensity at presentation, age, smoking, trauma and missed antiviral prescription (generalized estimating equations model).
det||analysis-2/NN||the-1/DT	nsubj||included-3/VBD||analysis-2/NN	root||ROOT-0/null||included-3/VBD	num||studies-8/NNS||three-4/CD	amod||studies-8/NNS||randomized-5/JJ	amod||studies-8/NNS||double-blind-7/JJ	dobj||included-3/VBD||studies-8/NNS	prep_in||studies-8/NNS||patients-10/NNS	nn||schizoaffectivedisorder-14/NN||schizophrenia-12/NN	prep_with||patients-10/NNS||schizoaffectivedisorder-14/NN	nn||disorder-18/NN||schizophreniform-17/NN	prep_with||patients-10/NNS||disorder-18/NN	conj_or||schizoaffectivedisorder-14/NN||disorder-18/NN	dep||patients-10/NNS||diagnosed-19/VBN	prepc_according_to||diagnosed-19/VBN||to-21/TO	det||manual-26/NN||the-22/DT	amod||manual-26/NN||diagnostic-23/JJ	conj_and||diagnostic-23/JJ||statistical-25/JJ	amod||manual-26/NN||statistical-25/JJ	pobj||diagnosed-19/VBN||manual-26/NN	amod||disorders-29/NNS||mental-28/JJ	npadvmod||4th-30/JJ||disorders-29/NNS	amod||edition-31/NN||4th-30/JJ	prep_of||manual-26/NN||edition-31/NN	advmod||assigned-34/VBN||randomly-33/RB	dep||patients-10/NNS||assigned-34/VBN	conj_and||diagnosed-19/VBN||assigned-34/VBN	prep_to||assigned-34/VBN||treatment-36/NN	poss||mg/day-43/NN||olanzapine-38/PRP$	amod||mg/day-43/NN||5â-39/JJ	amod||mg/day-43/NN||$-40/$	num||$-40/$||20-42/CD	prep_with||assigned-34/VBN||mg/day-43/NN	det||antipsychotic-46/NN||another-45/DT	prep_with||assigned-34/VBN||antipsychotic-46/NN	conj_or||mg/day-43/NN||antipsychotic-46/NN	amod||2â-49/NNS||haloperidol-48/JJ	dep||antipsychotic-46/NN||2â-49/NNS	num||mg/day-53/NN||$-50/$	num||$-50/$||20-52/CD	dep||2â-49/NNS||mg/day-53/NN	poss||mg/day-60/NN||risperidone-55/PRP$	amod||mg/day-60/NN||2â-56/JJ	amod||mg/day-60/NN||$-57/$	num||$-57/$||10-59/CD	dep||2â-49/NNS||mg/day-60/NN	conj_or||mg/day-53/NN||mg/day-60/NN	poss||mg/day-68/NN||ziprasidone-63/PRP$	amod||mg/day-68/NN||80â-64/JJ	amod||mg/day-68/NN||$-65/$	num||$-65/$||160-67/CD	dep||2â-49/NNS||mg/day-68/NN	conj_or||mg/day-53/NN||mg/day-68/NN	haloperidol-48||schizophrenia-12||no_rel||the analysis included three randomized, double-blind studies in patients with schizophrenia, schizoaffectivedisorder, or schizophreniform disorder diagnosed according to the diagnostic and statistical manual of mental disorders 4th edition and randomly assigned to treatment with olanzapine 5â20 mg/day or another antipsychotic (haloperidol 2â20 mg/day, risperidone 2â10 mg/day, or ziprasidone 80â160 mg/day).
det||standard-3/NN||the-1/DT	nn||standard-3/NN||reference-2/NN	nsubj||comprised-4/VBN||standard-3/NN	nsubj||suggestive-11/JJ||standard-3/NN	root||ROOT-0/null||comprised-4/VBN	nn||positivity-6/NN||culture-5/NN	dobj||comprised-4/VBN||positivity-6/NN	prep_for||positivity-6/NN||m.tuberculosis-8/NNS	advmod||suggestive-11/JJ||histology-10/RB	conj_or||comprised-4/VBN||suggestive-11/JJ	prep_of||suggestive-11/JJ||tuberculosis-13/NNP	tuberculosis-13||m.tuberculosis-8||no||the reference standard comprised culture positivity for m.tuberculosis or histology suggestive of tuberculosis .
prep_in||included-16/VBN||all-2/DT	num||patients-5/NNS||99-4/CD	nsubjpass||included-16/VBN||patients-5/NNS	det||breasttumour-9/NN||an-7/DT	amod||breasttumour-9/NN||her-2-amplified-8/JJ	prep_with||patients-5/NNS||breasttumour-9/NN	vmod||breasttumour-9/NN||treated-10/VBN	amod||therapy-14/NN||trastuzumab-based-12/JJ	nn||therapy-14/NN||neoadjuvant-13/NN	prep_with||treated-10/VBN||therapy-14/NN	auxpass||included-16/VBN||were-15/VBD	root||ROOT-0/null||included-16/VBN	breasttumour-9||trastuzumab--1||yes||in all, 99 patients with an her-2-amplified breasttumour treated with trastuzumab-based neoadjuvant therapy were included.
nsubj||found-2/VBD||we-1/PRP	root||ROOT-0/null||found-2/VBD	mark||suggesting-25/VBG||that-3/IN	amod||cells-5/NNS||phototrophic-4/JJ	nsubj||suggesting-25/VBG||cells-5/NNS	cop||suggesting-25/VBG||are-6/VBP	advmod||impacted-8/JJ||less-7/RBR	acomp||suggesting-25/VBG||impacted-8/JJ	prep_by||impacted-8/JJ||irondeficiency-10/NN	det||correlates-13/NNS||this-12/DT	prep_by||impacted-8/JJ||correlates-13/NNS	conj_and||irondeficiency-10/NN||correlates-13/NNS	poss||content-18/NN||their-15/PRP$	amod||content-18/NN||higher-16/JJR	nn||content-18/NN||iron-17/NN	prep_with||suggesting-25/VBG||content-18/NN	det||basis-23/NN||a-20/DT	amod||basis-23/NN||per-21/IN	nn||basis-23/NN||cell-22/NN	prep_on||content-18/NN||basis-23/NN	ccomp||found-2/VBD||suggesting-25/VBG	det||capacity/ability-28/NN||a-26/DT	amod||capacity/ability-28/NN||greater-27/JJR	dobj||suggesting-25/VBG||capacity/ability-28/NN	nn||assimilation-31/NN||iron-30/NN	prep_for||suggesting-25/VBG||assimilation-31/NN	det||state-35/NN||this-33/DT	amod||state-35/NN||metabolic-34/JJ	prep_in||assimilation-31/NN||state-35/NN	irondeficiency-10||iron-30||yes||we found that phototrophic cells are less impacted by irondeficiency and this correlates with their higher iron content on a per cell basis, suggesting a greater capacity/ability for iron assimilation in this metabolic state.
nn||visits-2/NNS||follow-up-1/NN	nsubj||increased-9/VBD||visits-2/NNS	prep_to||visits-2/NNS||people-4/NNS	prep_with||people-4/NNS||hiv-6/NN	prep_with||people-4/NNS||aids-8/NNS	conj_and||hiv-6/NN||aids-8/NNS	root||ROOT-0/null||increased-9/VBD	num||%-14/NN||32.8-11/CD	conj_and||32.8-11/CD||34.0-13/CD	num||%-14/NN||34.0-13/CD	prep_from||increased-9/VBD||%-14/NN	num||74.6-18/CD||2007-16/CD	dep||74.6-18/CD||to-17/TO	prep_in||%-14/NN||74.6-18/CD	num||%-21/NN||78.5-20/CD	prep_from||increased-9/VBD||%-21/NN	conj_and||%-14/NN||%-21/NN	prep_in||%-21/NN||2009-23/CD	advmod||increased-9/VBD||respectively-25/RB	det||p-28/NN||both-27/DT	nsubj||<-29/VBZ||p-28/NN	dep||increased-9/VBD||<-29/VBZ	dobj||<-29/VBZ||0.0001-30/CD	aids-8||hiv-6||no||follow-up visits to people with hiv and aids increased from 32.8 and 34.0% in 2007 to 74.6 and 78.5% in 2009, respectively (both p < 0.0001).
det||analysis-4/NN||the-2/DT	amod||analysis-4/NN||case-control-3/JJ	prep_in||associated-13/VBN||analysis-4/NN	amod||use-7/NN||current-6/JJ	nsubjpass||associated-13/VBN||use-7/NN	det||contraceptive-11/NN||the-9/DT	amod||contraceptive-11/NN||drospirenone-10/JJ	prep_of||use-7/NN||contraceptive-11/NN	auxpass||associated-13/VBN||was-12/VBD	root||ROOT-0/null||associated-13/VBN	det||risk-18/NN||a-15/DT	amod||risk-18/NN||threefold-16/JJ	amod||risk-18/NN||higher-17/JJR	prep_with||associated-13/VBN||risk-18/NN	amod||thromboembolism-23/NN||non-fatal-20/JJ	amod||thromboembolism-23/NN||idiopathic-21/JJ	nn||thromboembolism-23/NN||venous-22/NNS	prep_of||risk-18/NN||thromboembolism-23/NN	prepc_compared_with||thromboembolism-23/NN||with-25/IN	amod||use-27/NN||levonorgestrel-26/JJ	pobj||thromboembolism-23/NN||use-27/NN	det||ratio-31/NN||the-29/DT	nn||ratio-31/NN||odds-30/NNS	nsubj||3.3-38/CD||ratio-31/NN	vmod||ratio-31/NN||adjusted-32/VBN	nn||index-36/NN||body-34/NN	nn||index-36/NN||mass-35/NN	prep_for||adjusted-32/VBN||index-36/NN	cop||3.3-38/CD||was-37/VBD	parataxis||associated-13/VBN||3.3-38/CD	num||%-41/NN||95-40/CD	dep||3.3-38/CD||%-41/NN	nn||interval-43/NN||confidence-42/NN	dep||%-41/NN||interval-43/NN	number||7.6-46/CD||1.4-44/CD	dep||7.6-46/CD||to-45/TO	dep||interval-43/NN||7.6-46/CD	thromboembolism-23||levonorgestrel-26||no||in the case-control analysis, current use of the drospirenone contraceptive was associated with a threefold higher risk of non-fatal idiopathic venous thromboembolism compared with levonorgestrel use; the odds ratio adjusted for body mass index was 3.3 (95% confidence interval 1.4 to 7.6).
nsubj||measured-2/VBD||we-1/PRP	root||ROOT-0/null||measured-2/VBD	nn||levels-5/NNS||gene-3/NN	nn||levels-5/NNS||expression-4/NN	dobj||measured-2/VBD||levels-5/NNS	number||38,500-8/CD||>-7/CD	num||genes-9/NNS||38,500-8/CD	prep_of||levels-5/NNS||genes-9/NNS	amod||mtb-13/NN||ex-11/JJ	nn||mtb-13/NN||vivo-12/NN	prep_from||genes-9/NNS||mtb-13/NN	vmod||mtb-13/NN||stimulated-15/VBN	dobj||stimulated-15/VBN||macrophages-16/NNS	num||subjects-19/NNS||12-18/CD	prep_in||macrophages-16/NNS||subjects-19/NNS	num||phenotypes-23/NNS||3-21/CD	amod||phenotypes-23/NNS||clinical-22/JJ	prep_with||stimulated-15/VBN||phenotypes-23/NNS	amod||pulmonary-26/JJ||latent-24/JJ	amod||genes-9/NNS||pulmonary-26/JJ	prep_of||levels-5/NNS||meningealtb-29/NN	conj_and||genes-9/NNS||meningealtb-29/NN	dep||genes-9/NNS||nâ-31/VBN	dobj||nâ-31/VBN||$-32/$	number||=-34/CD||-33/CD	num||$-32/$||=-34/CD	dep||nâ-31/VBN||â-35/VB	dobj||â-35/VB||$-36/$	num||$-36/$||4-37/CD	prep_per||$-36/$||group-39/NN	meningealtb-29||mtb-13||no||we measured gene expression levels of >38,500 genes from ex vivo mtb -stimulated macrophages in 12 subjects with 3 clinical phenotypes latent, pulmonary, and meningealtb (nâ=â4 per group).
mark||have-6/VBP||since-1/IN	det||majority-3/NN||a-2/DT	nsubj||have-6/VBP||majority-3/NN	prep_of||majority-3/NN||humans-5/NNS	advcl||crucial-28/JJ||have-6/VBP	neg||antibody-9/NN||no-7/DT	amod||antibody-9/NN||neutralizing-8/VBG	dobj||have-6/VBP||antibody-9/NN	det||virus-22/NN||the-11/DT	amod||virus-22/NN||pandemic-12/JJ	dep||pandemic-12/JJ||h1n1-14/CD	amod||virus-22/NN||2009-16/JJ	nn||virus-22/NN||influenza-17/NN	appos||virus-22/NN||pandemic-19/NN	num||pandemic-19/NN||2009-20/CD	prep_against||antibody-9/NN||virus-22/NN	amod||immunity-25/NN||innate-24/JJ	nsubj||crucial-28/JJ||immunity-25/NN	aux||crucial-28/JJ||may-26/MD	cop||crucial-28/JJ||be-27/VB	root||ROOT-0/null||crucial-28/JJ	nsubj||influence-34/VB||mbl-30/NN	advmod||influence-34/VB||susceptibility-31/RB	aux||influence-34/VB||may-32/MD	advmod||influence-34/VB||therefore-33/RB	conj_and||crucial-28/JJ||influence-34/VB	amod||pathogenesis-36/NNS||viral-35/JJ	dobj||influence-34/VB||pathogenesis-36/NNS	influenza-17||antibody-9||no_rel||since a majority of humans have no neutralizing antibody against the pandemic (h1n1) 2009 influenza (pandemic 2009) virus, innate immunity may be crucial and mbl susceptibility may therefore influence viral pathogenesis.
mark||disrupted-6/VBN||since-1/IN	det||equilibrium-3/NN||this-2/DT	nsubjpass||disrupted-6/VBN||equilibrium-3/NN	auxpass||disrupted-6/VBN||is-4/VBZ	advmod||disrupted-6/VBN||frequently-5/RB	advcl||hypothesize-18/VBP||disrupted-6/VBN	prep_in||disrupted-6/VBN||individuals-8/NNS	vmod||individuals-8/NNS||infected-9/VBN	det||humanimmunodeficiencyvirus-12/NNS||the-11/DT	prep_with||infected-9/VBN||humanimmunodeficiencyvirus-12/NNS	appos||humanimmunodeficiencyvirus-12/NNS||hiv-14/NN	nsubj||hypothesize-18/VBP||we-17/PRP	root||ROOT-0/null||hypothesize-18/VBP	mark||hamper-23/VB||that-19/IN	poss||deregulation-21/NN||its-20/PRP$	nsubj||hamper-23/VB||deregulation-21/NN	aux||hamper-23/VB||could-22/MD	ccomp||hypothesize-18/VBP||hamper-23/VB	amod||reconstitution-25/NN||immune-24/JJ	dobj||hamper-23/VB||reconstitution-25/NN	prep_in||hamper-23/VB||patients-27/NNS	amod||recovery-34/NN||poor-29/JJ	amod||recovery-34/NN||cd4-30/JJ	amod||recovery-34/NN||+-31/JJ	nn||recovery-34/NN||t-32/NN	nn||recovery-34/NN||cell-33/NN	prep_with||patients-27/NNS||recovery-34/NN	advmod||active-37/JJ||highly-36/RB	amod||therapy-39/NN||active-37/JJ	amod||therapy-39/NN||antiretroviral-38/JJ	prep_under||hamper-23/VB||therapy-39/NN	appos||therapy-39/NN||haart-41/NN	hiv)--1||humanimmunodeficiencyvirus-12||no||since this equilibrium is frequently disrupted in individuals infected with the humanimmunodeficiencyvirus (hiv), we hypothesize that its deregulation could hamper immune reconstitution in patients with poor cd4+ t cell recovery under highly active antiretroviral therapy (haart).
amod||lupuserythematosus-2/NNS||systemic-1/JJ	nsubj||autoimmunedisease-9/NN||lupuserythematosus-2/NNS	appos||lupuserythematosus-2/NNS||sle-4/NN	cop||autoimmunedisease-9/NN||is-6/VBZ	det||autoimmunedisease-9/NN||a-7/DT	amod||autoimmunedisease-9/NN||systemic-8/JJ	root||ROOT-0/null||autoimmunedisease-9/NN	vmod||autoimmunedisease-9/NN||characterized-10/VBN	amod||interferons-15/NNS||increased-12/VBN	nn||interferons-15/NNS||type-13/NN	amod||interferons-15/NNS||i-14/VBG	agent||characterized-10/VBN||interferons-15/NNS	dep||autoimmunedisease-9/NN||ifns-17/NNS	nn||inflammation-21/NN||multiorgan-20/NN	conj_and||autoimmunedisease-9/NN||inflammation-21/NN	advmod||targeting-23/VBG||frequently-22/RB	vmod||inflammation-21/NN||targeting-23/VBG	det||skin-25/NN||the-24/DT	dobj||targeting-23/VBG||skin-25/NN	interferons-15||sle-4||no_rel||systemic lupuserythematosus (sle) is a systemic autoimmunedisease characterized by increased type i interferons (ifns) and multiorgan inflammation frequently targeting the skin.
nsubj||appears-3/VBZ||hypersensitivity-1/NN	advmod||appears-3/VBZ||usually-2/RB	root||ROOT-0/null||appears-3/VBZ	amod||infusions-6/NNS||multiple-5/JJ	prep_after||appears-3/VBZ||infusions-6/NNS	xcomp||appears-3/VBZ||suggesting-8/VBG	nn||allergicreactions-11/NNS||type-9/NN	nn||allergicreactions-11/NNS||i-10/NN	dobj||suggesting-8/VBG||allergicreactions-11/NNS	advmod||seem-20/VBP||however-13/RB	amod||types-16/NNS||other-15/JJ	nsubj||seem-20/VBP||types-16/NNS	nsubjpass||implicated-23/VBN||types-16/NNS	prep_of||types-16/NNS||hypersensitivity-18/NN	advmod||seem-20/VBP||also-19/RB	parataxis||appears-3/VBZ||seem-20/VBP	aux||implicated-23/VBN||to-21/TO	auxpass||implicated-23/VBN||be-22/VB	xcomp||seem-20/VBP||implicated-23/VBN	hypersensitivity-18||hypersensitivity-18||no||hypersensitivity usually appears after multiple infusions, suggesting type i allergicreactions; however, other types of hypersensitivity also seem to be implicated.
nsubj||disease-5/NN||malaria-1/NN	cop||disease-5/NN||is-2/VBZ	det||disease-5/NN||the-3/DT	amod||disease-5/NN||infectious-4/JJ	ccomp||changed-28/VBN||disease-5/NN	vmod||disease-5/NN||causing-6/VBG	det||morbidity-9/NN||the-7/DT	amod||morbidity-9/NN||highest-8/JJS	dobj||causing-6/VBG||morbidity-9/NN	dobj||causing-6/VBG||mortality-11/NN	conj_and||morbidity-9/NN||mortality-11/NN	prep_in||mortality-11/NN||angola-13/NN	amod||widespread-17/JJ||due-15/JJ	dep||widespread-17/JJ||to-16/TO	amod||resistance-22/NN||widespread-17/JJ	amod||resistance-22/NN||chloroquine-18/JJ	dep||resistance-22/NN||cq-20/VBN	dobj||causing-6/VBG||resistance-22/NN	conj_and||morbidity-9/NN||resistance-22/NN	det||country-25/NN||the-24/DT	nsubj||changed-28/VBN||country-25/NN	aux||changed-28/VBN||has-26/VBZ	advmod||changed-28/VBN||recently-27/RB	root||ROOT-0/null||changed-28/VBN	poss||recommendations-32/NNS||its-29/PRP$	amod||recommendations-32/NNS||first-line-30/JJ	nn||recommendations-32/NNS||treatment-31/NN	dobj||changed-28/VBN||recommendations-32/NNS	amod||malaria-35/NN||uncomplicated-34/JJ	prep_for||changed-28/VBN||malaria-35/NN	prep_from||changed-28/VBN||cq-38/NN	aux||artemisinin-40/VB||to-39/TO	vmod||cq-38/NN||artemisinin-40/VB	nn||therapies-42/NNS||combination-41/NN	dobj||artemisinin-40/VB||therapies-42/NNS	appos||therapies-42/NNS||act-44/NN	prep_in||therapies-42/NNS||adults-47/NNS	prep_in||therapies-42/NNS||sulphadoxine/pyrimethamine-50/NN	conj_and||adults-47/NNS||sulphadoxine/pyrimethamine-50/NN	appos||adults-47/NNS||s/p-52/NN	amod||women-56/NNS||pregnant-55/JJ	prep_in||artemisinin-40/VB||women-56/NNS	malaria-35||pyrimethamine--1||yes||malaria is the infectious disease causing the highest morbidity and mortality in angola and due to widespread chloroquine (cq) resistance, the country has recently changed its first-line treatment recommendations for uncomplicated malaria, from cq to artemisinin combination therapies (act) in adults, and sulphadoxine/pyrimethamine (s/p) in pregnant women.
det||duration-3/NN||the-1/DT	amod||duration-3/NN||optimal-2/JJ	nsubj||remain-22/VBP||duration-3/NN	nn||therapy-6/NN||warfarin-5/NN	prep_of||duration-3/NN||therapy-6/NN	det||thromboembolicevent-11/NN||a-8/DT	amod||thromboembolicevent-11/NN||first-9/JJ	nn||thromboembolicevent-11/NN||venous-10/NNS	nsubj||matter-15/NN||thromboembolicevent-11/NN	cop||matter-15/NN||is-12/VBZ	advmod||matter-15/NN||however-13/RB	det||matter-15/NN||a-14/DT	prepc_after||therapy-6/NN||matter-15/NN	det||controversy-18/NN||some-17/DT	prep_of||matter-15/NN||controversy-18/NN	amod||questions-21/NNS||many-20/JJ	prep_of||matter-15/NN||questions-21/NNS	conj_and||controversy-18/NN||questions-21/NNS	root||ROOT-0/null||remain-22/VBP	acomp||remain-22/VBP||unanswered-23/JJ	thromboembolicevent-11||warfarin-5||yes||the optimal duration of warfarin therapy after a first venous thromboembolicevent is however a matter of some controversy and many questions remain unanswered.
amod||tuberculosis-2/NNS||multidrug-resistant-1/JJ	nsubj||is-6/VBZ||tuberculosis-2/NNS	appos||tuberculosis-2/NNS||mdr-tb-4/NNP	root||ROOT-0/null||is-6/VBZ	dep||resistant-9/NN||vitro-8/NN	prep_in||is-6/VBZ||resistant-9/NN	prep_to||is-6/VBZ||isoniazid-11/NN	appos||isoniazid-11/NN||h-13/NN	prep_to||is-6/VBZ||rifampicin-16/NN	conj_and||isoniazid-11/NN||rifampicin-16/NN	appos||isoniazid-11/NN||r-18/NN	tb--1||isoniazid-11||yes||multidrug-resistant tuberculosis (mdr-tb) is in vitro resistant to isoniazid (h) and rifampicin (r).
amod||analyses-5/NNS||case-control-2/JJ	conj_and||case-control-2/JJ||case-series-4/JJ	amod||analyses-5/NNS||case-series-4/JJ	prep_in||examined-8/VBD||analyses-5/NNS	nsubj||examined-8/VBD||we-7/PRP	root||ROOT-0/null||examined-8/VBD	nn||concentrations-10/NNS||serum-9/NN	dobj||examined-8/VBD||concentrations-10/NNS	amod||25ohd-14/NNS||25-hydroxyvitamind-12/JJ	prep_of||concentrations-10/NNS||25ohd-14/NNS	prep_in||25ohd-14/NNS||relation-17/NN	nn||characteristics-22/NNS||breast-19/NN	nn||characteristics-22/NNS||cancer-20/NN	amod||characteristics-22/NNS||prognostic-21/JJ	prep_to||examined-8/VBD||characteristics-22/NNS	amod||grade-26/NN||histologic-25/JJ	prep_including||examined-8/VBD||grade-26/NN	nn||receptor-29/NN||estrogen-28/NN	appos||grade-26/NN||receptor-29/NN	appos||receptor-29/NN||er-31/NN	amod||subtypes-36/NNS||molecular-35/JJ	nsubj||enrolled-67/VBD||subtypes-36/NNS	vmod||subtypes-36/NNS||defined-37/VBN	agent||defined-37/VBN||er-39/NN	amod||pr-44/NN||progesterone-41/JJ	nn||pr-44/NN||receptor-42/NN	agent||defined-37/VBN||pr-44/NN	conj_and||er-39/NN||pr-44/NN	agent||defined-37/VBN||her2-47/NNS	conj_and||er-39/NN||her2-47/NNS	num||women-51/NNS||579-50/CD	prep_among||defined-37/VBN||women-51/NNS	nn||cancer-55/NN||incident-53/NN	nn||cancer-55/NN||breast-54/NN	prep_with||women-51/NNS||cancer-55/NN	num||controls-58/NNS||574-57/CD	prep_among||defined-37/VBN||controls-58/NNS	conj_and||women-51/NNS||controls-58/NNS	vmod||controls-58/NNS||matched-59/VBN	prep_on||matched-59/VBN||age-61/NN	prep_on||matched-59/VBN||time-63/NN	conj_and||age-61/NN||time-63/NN	nn||draw-66/NN||blood-65/NN	prep_of||age-61/NN||draw-66/NN	conj_and||examined-8/VBD||enrolled-67/VBD	det||institute-73/NN||the-69/DT	amod||institute-73/NN||roswell-70/JJ	nn||institute-73/NN||park-71/NN	nn||institute-73/NN||cancer-72/NN	prep_in||enrolled-67/VBD||institute-73/NN	num||2008-77/CD||2003-75/CD	dep||2008-77/CD||to-76/TO	prep_from||enrolled-67/VBD||2008-77/CD	cancer-72||progesterone-41||no_rel||in case-control and case-series analyses, we examined serum concentrations of 25-hydroxyvitamind (25ohd) in relation to breast cancer prognostic characteristics, including histologic grade, estrogen receptor (er), and molecular subtypes defined by er, progesterone receptor (pr) and her2, among 579 women with incident breast cancer and 574 controls matched on age and time of blood draw enrolled in the roswell park cancer institute from 2003 to 2008.
nsubj||superior-3/JJ||entecavir-1/NN	nsubj||adefovir-5/VB||entecavir-1/NN	cop||superior-3/JJ||is-2/VBZ	root||ROOT-0/null||superior-3/JJ	aux||adefovir-5/VB||to-4/TO	xcomp||superior-3/JJ||adefovir-5/VB	amod||dna-10/NN||decreasing-7/VBG	nn||dna-10/NN||serum-8/NN	nn||dna-10/NN||hbv-9/NN	prep_in||adefovir-5/VB||dna-10/NN	amod||alt-13/NN||normalizing-12/VBG	prep_in||adefovir-5/VB||alt-13/NN	conj_and||dna-10/NN||alt-13/NN	amod||adefovir-38/NN||similar-15/JJ	prep_with||similar-15/JJ||adefovir-17/NN	prepc_in||adefovir-17/NN||clearing-19/VBG	vmod||clearing-19/VBG||hbeag-20/VBG	prepc_in||adefovir-17/NN||encouraging-22/VBG	conj_and||clearing-19/VBG||encouraging-22/VBG	amod||seroconversion-24/NN||hbeag-23/VBG	dobj||encouraging-22/VBG||seroconversion-24/NN	det||nucleos-28/NNS||the-26/DT	amod||nucleos-28/NNS||hbeag-positive-27/JJ	prep_for||seroconversion-24/NN||nucleos-28/NNS	amod||t-30/NN||-lrb--29/JJ	dep||encouraging-22/VBG||t-30/NN	dep||t-30/NN||-rrb--31/VBG	amod||patients-34/NNS||ide-naive-32/JJ	nn||patients-34/NNS||asian-33/NN	dobj||-rrb--31/VBG||patients-34/NNS	prep_with||-rrb--31/VBG||chronichepatitisb-36/NN	nsubjpass||used-42/VBN||adefovir-38/NN	aux||used-42/VBN||can-39/MD	auxpass||used-42/VBN||be-40/VB	advmod||used-42/VBN||still-41/RB	conj_but||superior-3/JJ||used-42/VBN	amod||therapy-45/NN||first-line-44/JJ	prep_for||used-42/VBN||therapy-45/NN	det||patients-48/NNS||these-47/DT	prep_in||therapy-45/NN||patients-48/NNS	hbv-9||adefovir-38||yes||entecavir is superior to adefovir in decreasing serum hbv dna and normalizing alt but similar with adefovir in clearing hbeag and encouraging hbeag seroconversion for the hbeag-positive nucleos -lrb- t -rrb- ide-naive asian patients with chronichepatitisb. adefovir can be still used for first-line therapy in these patients .
det||end-3/NN||the-2/DT	prep_at||lower-25/JJR||end-3/NN	det||period-7/NN||the-5/DT	amod||period-7/NN||24-week-6/JJ	prep_of||end-3/NN||period-7/NN	nn||prevalence-14/NN||bp-9/NN	dep||prevalence-14/NN||lvmi-11/NN	dep||prevalence-14/NN||lvh-13/NN	nsubj||lower-25/JJR||prevalence-14/NN	nn||levels-18/NNS||plasma-16/NN	nn||levels-18/NNS||adma-17/NN	conj_and||prevalence-14/NN||levels-18/NNS	nsubj||lower-25/JJR||levels-18/NNS	det||group-22/NN||the-20/DT	amod||group-22/NN||nitrate-21/JJ	prep_in||prevalence-14/NN||group-22/NN	cop||lower-25/JJR||were-23/VBD	advmod||lower-25/JJR||significantly-24/RB	root||ROOT-0/null||lower-25/JJR	prep_than||lower-25/JJR||those-27/DT	det||group-31/NN||the-29/DT	amod||group-31/NN||non-nitrate-30/JJ	prep_in||those-27/DT||group-31/NN	lvh-13||nitrate-21||no_rel||at the end of the 24-week period, bp, lvmi, lvh prevalence and plasma adma levels in the nitrate group were significantly lower than those in the non-nitrate group.
nsubj||conducted-5/VBD||we-1/PRP	advmod||conducted-5/VBD||therefore-3/RB	root||ROOT-0/null||conducted-5/VBD	det||evaluation-8/NN||a-6/DT	amod||evaluation-8/NN||comprehensive-7/JJ	dobj||conducted-5/VBD||evaluation-8/NN	advmod||resistant-11/JJ||inh-10/RB	amod||levels-54/NNS||resistant-11/JJ	amod||strains-13/NNS||m.tuberculosis-12/JJ	nn||n-15/NN||strains-13/NNS	amod||n-15/NN||-lrb--14/JJ	npadvmod||resistant-11/JJ||n-15/NN	dep||-rrb--18/NNS||=-16/SYM	num||-rrb--18/NNS||224-17/CD	dep||n-15/NN||-rrb--18/NNS	npadvmod||south-21/RB||three-20/CD	advmod||countries-23/NNS||south-21/RB	amod||countries-23/NNS||american-22/JJ	prep_from||resistant-11/JJ||countries-23/NNS	amod||burden-26/NN||high-25/JJ	prep_with||resistant-11/JJ||burden-26/NN	prep_of||burden-26/NN||drug-28/NN	amod||levels-54/NNS||resistant-29/JJ	advmod||resistant-29/JJ||tb-30/RB	aux||characterize-32/VB||to-31/TO	xcomp||resistant-29/JJ||characterize-32/VB	dobj||characterize-32/VB||mutations-33/NNS	nn||g-36/NN||kat-35/NN	prep_in||characterize-32/VB||g-36/NN	xcomp||resistant-29/JJ||ahp-38/VB	conj_and||characterize-32/VB||ahp-38/VB	dep||ahp-38/VB||c-39/SYM	xcomp||resistant-29/JJ||inh-41/VB	conj_and||characterize-32/VB||inh-41/VB	det||loci-44/NN||a-42/DT	nn||loci-44/NN||gene-43/NN	dobj||inh-41/VB||loci-44/NN	conj_and||characterize-32/VB||correlate-46/VB	conj_and||inh-41/VB||correlate-46/VB	amod||concentrations-50/NNS||minimal-48/JJ	nn||concentrations-50/NNS||inhibitory-49/NN	prep_with||correlate-46/VB||concentrations-50/NNS	amod||levels-54/NNS||-lrb--51/JJ	amod||levels-54/NNS||mic-52/JJ	nn||levels-54/NNS||-rrb--53/NN	prep_of||evaluation-8/NN||levels-54/NNS	amod||family-58/NN||spoligotype-56/JJ	nn||family-58/NN||strain-57/NN	prep_of||evaluation-8/NN||family-58/NN	conj_and||levels-54/NNS||family-58/NN	tb-30||inh-41||yes||we , therefore , conducted a comprehensive evaluation of inh resistant m.tuberculosis strains -lrb- n = 224 -rrb- from three south american countries with high burden of drug resistant tb to characterize mutations in kat g , ahp c and inh a gene loci and correlate with minimal inhibitory concentrations -lrb- mic -rrb- levels and spoligotype strain family .
root||ROOT-0/null||hereditary-1/VBG	amod||deficiency-5/NN||combined-2/VBN	amod||deficiency-5/NN||vitamink-dependent-3/JJ	nn||deficiency-5/NN||clottingfactors-4/NN	dobj||hereditary-1/VBG||deficiency-5/NN	dep||deficiency-5/NN||vkcfd-7/VBN	cop||bleedingdisorder-13/NN||is-9/VBZ	det||bleedingdisorder-13/NN||a-10/DT	amod||bleedingdisorder-13/NN||rare-11/JJ	amod||bleedingdisorder-13/NN||congenital-12/JJ	aux||hereditary-1/VBG||bleedingdisorder-13/NN	vmod||bleedingdisorder-13/NN||resulting-14/VBG	amod||levels-18/NNS||variably-16/JJ	amod||levels-18/NNS||decreased-17/VBN	prep_from||resulting-14/VBG||levels-18/NNS	amod||ii-21/NN||coagulationfactors-20/JJ	prep_of||levels-18/NNS||ii-21/NN	prep_of||levels-18/NNS||vii-23/NN	conj_and||ii-21/NN||vii-23/NN	prep_of||levels-18/NNS||ix-25/NN	conj_and||ii-21/NN||ix-25/NN	prep_of||levels-18/NNS||x-27/SYM	conj_and||ii-21/NN||x-27/SYM	amod||anticoagulants-32/NNS||natural-31/JJ	aux||hereditary-1/VBG||anticoagulants-32/NNS	conj_and||bleedingdisorder-13/NN||anticoagulants-32/NNS	dep||anticoagulants-32/NNS||protein-33/NN	nsubj||hereditary-1/VBG||c-34/SYM	nn||s-37/NNS||protein-36/NN	appos||c-34/SYM||s-37/NNS	nn||z.-40/NN||protein-39/NN	appos||c-34/SYM||z.-40/NN	conj_and||s-37/NNS||z.-40/NN	bleedingdisorder-13||coagulationfactors-20||no_rel||hereditary combined vitamink-dependent clottingfactors deficiency (vkcfd) is a rare congenital bleedingdisorder resulting from variably decreased levels of coagulationfactors ii, vii, ix and x as well as natural anticoagulants protein c, protein s and protein z.
amod||forms-4/NNS||attractive-1/JJ	conj_and||attractive-1/JJ||novel-3/JJ	amod||forms-4/NNS||novel-3/JJ	nsubj||include-7/VBP||forms-4/NNS	prep_of||forms-4/NNS||therapy-6/NN	root||ROOT-0/null||include-7/VBP	dobj||include-7/VBP||strategies-8/NNS	aux||eliminate-10/VB||to-9/TO	vmod||strategies-8/NNS||eliminate-10/VB	amod||peptides-13/NNS||detrimental-11/JJ	nn||peptides-13/NNS||gluten-12/NN	dobj||eliminate-10/VB||peptides-13/NNS	det||diet-17/NN||the-15/DT	amod||diet-17/NN||celiac-16/JJ	prep_from||eliminate-10/VB||diet-17/NN	advmod||neutralized-29/VBN||so-18/RB	mark||neutralized-29/VBN||that-19/IN	det||effect-22/NN||the-20/DT	amod||effect-22/NN||immunogenic-21/JJ	nsubjpass||neutralized-29/VBN||effect-22/NN	det||epitopes-26/NNS||the-24/DT	nn||epitopes-26/NNS||gluten-25/NN	prep_of||effect-22/NN||epitopes-26/NNS	aux||neutralized-29/VBN||can-27/MD	auxpass||neutralized-29/VBN||be-28/VB	advcl||eliminate-10/VB||neutralized-29/VBN	dobj||include-7/VBP||strategies-34/NNS	conj_and||strategies-8/NNS||strategies-34/NNS	aux||block-36/VB||to-35/TO	vmod||strategies-34/NNS||block-36/VB	det||response-40/NN||the-37/DT	amod||response-40/NN||gluten-induced-38/JJ	amod||response-40/NN||inflammatory-39/JJ	dobj||block-36/VB||response-40/NN	gluten-25||celiac-16||no_rel||attractive and novel forms of therapy include strategies to eliminate detrimental gluten peptides from the celiac diet so that the immunogenic effect of the gluten epitopes can be neutralized, as well as strategies to block the gluten-induced inflammatory response.
advmod||become-23/VBN||recently-1/RB	det||association-4/NN||the-3/DT	nsubj||become-23/VBN||association-4/NN	amod||therapy-7/NN||antineoplastic-6/JJ	prep_between||association-4/NN||therapy-7/NN	nn||difficile-10/NN||c.-9/NN	prep_between||association-4/NN||difficile-10/NN	conj_and||therapy-7/NN||difficile-10/NN	amod||diarrhea-13/NN||associated-12/VBN	dep||therapy-7/NN||diarrhea-13/NN	det||absence-16/NN||the-15/DT	prep_in||diarrhea-13/NN||absence-16/NN	det||therapy-21/NN||a-18/DT	amod||therapy-21/NN||prior-19/JJ	amod||therapy-21/NN||antibiotic-20/JJ	prep_of||absence-16/NN||therapy-21/NN	aux||become-23/VBN||has-22/VBZ	root||ROOT-0/null||become-23/VBN	advmod||apparent-25/JJ||more-24/RBR	acomp||become-23/VBN||apparent-25/JJ	antineoplastic-6||diarrhea-13||no_rel||recently , the association between antineoplastic therapy and c. difficile - associated diarrhea in the absence of a prior antibiotic therapy has become more apparent .
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	det||effects-4/NNS||the-3/DT	dobj||evaluated-2/VBN||effects-4/NNS	prep_of||effects-4/NNS||bosentan-6/NN	det||antagonist-12/NN||a-8/DT	amod||antagonist-12/NN||dual-9/JJ	nn||antagonist-12/NN||endothelin-10/NN	nn||antagonist-12/NN||receptor-11/NN	dep||effects-4/NNS||antagonist-12/NN	prep_in||effects-4/NNS||patients-15/NNS	vmod||effects-4/NNS||receiving-16/VBG	amod||therapy-19/NN||first-line-17/JJ	nn||therapy-19/NN||dacarbazine-18/NN	dobj||receiving-16/VBG||therapy-19/NN	nn||cutaneousmelanoma-24/NN||stage-21/NN	nn||cutaneousmelanoma-24/NN||iv-22/NN	amod||cutaneousmelanoma-24/NN||metastatic-23/JJ	prep_for||therapy-19/NN||cutaneousmelanoma-24/NN	det||phase-27/NN||a-26/DT	prep_in||evaluated-2/VBN||phase-27/NN	num||phase-27/NN||2-28/CD	amod||study-31/NN||proof-of-concept-30/JJ	dobj||evaluated-2/VBN||study-31/NN	dacarbazine-18||cutaneousmelanoma-24||no_rel||we evaluated the effects of bosentan - a dual endothelin receptor antagonist - in patients receiving first-line dacarbazine therapy for stage iv metastatic cutaneousmelanoma in a phase 2, proof-of-concept study.
nn||studies-3/NNS||dna-1/NN	nn||studies-3/NNS||reannealing-2/NN	nsubj||demonstrated-4/VBD||studies-3/NNS	root||ROOT-0/null||demonstrated-4/VBD	mark||represent-8/VBP||that-5/IN	amod||spirochetes-7/NNS||lymedisease-6/JJ	nsubj||represent-8/VBP||spirochetes-7/NNS	ccomp||demonstrated-4/VBD||represent-8/VBP	det||species-11/NN||a-9/DT	amod||species-11/NN||new-10/JJ	dobj||represent-8/VBP||species-11/NN	prep_of||species-11/NN||borrelia-13/NN	vmod||represent-8/VBP||exhibiting-15/VBG	det||homology-20/NN||a-16/DT	num||homology-20/NN||31-59-17/CD	nn||homology-20/NN||percent-18/NN	nn||homology-20/NN||dna-19/NN	dobj||exhibiting-15/VBG||homology-20/NN	det||species-24/NNS||the-22/DT	num||species-24/NNS||three-23/CD	prep_with||exhibiting-15/VBG||species-24/NNS	nn||borreliae-28/NN||north-26/NN	nn||borreliae-28/NN||american-27/NN	prep_of||species-24/NNS||borreliae-28/NN	lymedisease-6||borrelia-13||no||dna reannealing studies demonstrated that lymedisease spirochetes represent a new species of borrelia, exhibiting a 31-59 percent dna homology with the three species of north american borreliae.
nsubj||appears-2/VBZ||it-1/PRP	root||ROOT-0/null||appears-2/VBZ	mark||shadows-9/VBD||that-3/IN	det||distribution-6/NN||the-4/DT	nn||distribution-6/NN||age-5/NN	nsubj||shadows-9/VBD||distribution-6/NN	prep_of||distribution-6/NN||hd-8/NN	ccomp||appears-2/VBZ||shadows-9/VBD	dobj||shadows-9/VBD||that-10/DT	prep_of||that-10/DT||susceptibility-12/NN	amod||infections-16/NNS||common-14/JJ	nn||infections-16/NNS||childhood-15/NN	prep_to||shadows-9/VBD||infections-16/NNS	det||epstein-barrvirus-21/NNS||the-20/DT	prep_such_as||shadows-9/VBD||epstein-barrvirus-21/NNS	dep||epstein-barrvirus-21/NNS||ebv-23/VBN	advmod||increased-33/VBN||furthermore-26/RB	det||risk-29/NN||that-28/DT	nsubjpass||increased-33/VBN||risk-29/NN	prep_of||risk-29/NN||hd-31/NN	auxpass||increased-33/VBN||is-32/VBZ	parataxis||appears-2/VBZ||increased-33/VBN	det||parallel-44/NN||those-35/DT	amod||parallel-44/NN||susceptible-36/JJ	det||infection-41/NN||a-38/DT	advmod||late-40/JJ||relatively-39/RB	amod||infection-41/NN||late-40/JJ	prep_to||susceptible-36/JJ||infection-41/NN	advmod||infection-41/NN||in-43/RB	prep_among||increased-33/VBN||parallel-44/NN	prep_with||parallel-44/NN||infectiousmononucleosis-46/NNS	appos||infectiousmononucleosis-46/NNS||im-48/NN	nsubjpass||found-55/VBN||it-52/PRP	aux||found-55/VBN||has-53/VBZ	auxpass||found-55/VBN||been-54/VBN	parataxis||appears-2/VBZ||found-55/VBN	conj_and||increased-33/VBN||found-55/VBN	mark||have-62/VBP||that-56/IN	nsubj||had-60/VBN||people-57/NNS	nsubj||have-62/VBP||people-57/NNS	aux||had-60/VBN||have-59/VBP	rcmod||people-57/NNS||had-60/VBN	dobj||had-60/VBN||im-61/NN	ccomp||found-55/VBN||have-62/VBP	quantmod||times-65/NNS||about-63/RB	number||times-65/NNS||three-64/CD	num||rate-68/NN||times-65/NNS	det||rate-68/NN||the-66/DT	amod||rate-68/NN||expected-67/JJ	dobj||have-62/VBP||rate-68/NN	prep_of||rate-68/NN||hd-70/NN	infectiousmononucleosis-46||ebv-23||no||it appears that the age distribution of hd shadows that of susceptibility to common childhood infections, such as the epstein-barrvirus (ebv); furthermore, that risk of hd is increased among those susceptible to a relatively late infection, in parallel with infectiousmononucleosis (im), and it has been found that people who have had im have about three times the expected rate of hd.
amod||prevalence-2/NN||increasing-1/VBG	nsubj||worsening-17/VBG||prevalence-2/NN	nn||resistance-5/NN||inh-4/NN	prep_of||prevalence-2/NN||resistance-5/NN	advmod||resistance-5/NN||especially-7/RB	amod||tb-12/NN||high-9/JJ	nn||tb-12/NN||tuberculosis-10/NNP	nn||tb-12/NN||-lrb--11/NNP	prep_in||especially-7/RB||tb-12/NN	advmod||prevalent-14/JJ||-rrb--13/RB	amod||countries-15/NNS||prevalent-14/JJ	dep||resistance-5/NN||countries-15/NNS	aux||worsening-17/VBG||is-16/VBZ	root||ROOT-0/null||worsening-17/VBG	det||burden-19/NN||the-18/DT	dobj||worsening-17/VBG||burden-19/NN	nn||programs-23/NNS||tb-21/NN	nn||programs-23/NNS||control-22/NN	prep_of||burden-19/NN||programs-23/NNS	mark||noted-30/VBN||since-25/IN	amod||rates-28/NNS||similar-26/JJ	nn||rates-28/NNS||transmission-27/NN	nsubjpass||noted-30/VBN||rates-28/NNS	auxpass||noted-30/VBN||are-29/VBP	advcl||worsening-17/VBG||noted-30/VBN	nn||strains-37/NNS||inh-32/NN	amod||strains-37/NNS||susceptible-33/JJ	conj_and||susceptible-33/JJ||resistant-35/JJ	amod||strains-37/NNS||resistant-35/JJ	nn||strains-37/NNS||m.tuberculosis-36/NN	prep_for||noted-30/VBN||strains-37/NNS	tuberculosis-10||inh-32||yes||increasing prevalence of inh resistance , especially in high tuberculosis -lrb- tb -rrb- prevalent countries is worsening the burden of tb control programs , since similar transmission rates are noted for inh susceptible and resistant m.tuberculosis strains .
amod||analgesics-2/NNS||opioid-1/JJ	nsubjpass||used-10/VBN||analgesics-2/NNS	nsubj||control-12/VB||analgesics-2/NNS	prep_such_as||analgesics-2/NNS||morphine-5/NN	prep_such_as||analgesics-2/NNS||meperidine-7/NN	conj_and||morphine-5/NN||meperidine-7/NN	aux||used-10/VBN||have-8/VBP	auxpass||used-10/VBN||been-9/VBN	root||ROOT-0/null||used-10/VBN	aux||control-12/VB||to-11/TO	xcomp||used-10/VBN||control-12/VB	acomp||control-12/VB||moderate-13/JJ	amod||pain-16/NN||severe-15/JJ	prep_to||moderate-13/JJ||pain-16/NN	amod||years-19/NNS||many-18/JJ	prep_for||pain-16/NN||years-19/NNS	pain-16||meperidine-7||yes||opioid analgesics such as morphine and meperidine have been used to control moderate to severe pain for many years.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||contribution-4/NN||the-3/DT	dobj||investigated-2/VBD||contribution-4/NN	amod||s-transferase-7/JJ||glutathione-6/JJ	amod||enzymes-11/NNS||s-transferase-7/JJ	appos||enzymes-11/NNS||gst-9/NN	prep_of||contribution-4/NN||enzymes-11/NNS	nn||tolerance-16/NN||permethrin-13/NN	conj_and||permethrin-13/NN||ivermectin-15/NN	nn||tolerance-16/NN||ivermectin-15/NN	prep_to||investigated-2/VBD||tolerance-16/NN	amod||mites-19/NNS||scabies-18/JJ	prep_in||tolerance-16/NN||mites-19/NNS	vmod||mites-19/NNS||using-20/VBG	amod||approaches-24/NNS||biochemical-21/JJ	conj_and||biochemical-21/JJ||molecular-23/JJ	amod||approaches-24/NNS||molecular-23/JJ	dobj||using-20/VBG||approaches-24/NNS	scabies-18||permethrin-13||yes||we investigated the contribution of glutathione s-transferase (gst) enzymes to permethrin and ivermectin tolerance in scabies mites using biochemical and molecular approaches.
amod||cells-4/NNS||cd8-1/JJ	amod||cells-4/NNS||+-2/JJ	nn||cells-4/NNS||t-3/NN	nsubj||contribute-5/VBP||cells-4/NNS	root||ROOT-0/null||contribute-5/VBP	det||clearance-8/NN||the-7/DT	prep_to||contribute-5/VBP||clearance-8/NN	nn||infection-14/NN||hepatitisbvirus-10/NNP	appos||infection-14/NN||hbv-12/NN	prep_of||clearance-8/NN||infection-14/NN	det||response-22/NN||an-16/DT	amod||response-22/NN||insufficient-17/JJ	amod||response-22/NN||cd8-18/JJ	amod||response-22/NN||+-19/JJ	nn||response-22/NN||t-20/NN	nn||response-22/NN||cell-21/NN	nsubj||one-25/CD||response-22/NN	aux||one-25/CD||may-23/MD	cop||one-25/CD||be-24/VB	conj_and||contribute-5/VBP||one-25/CD	det||factors-29/NNS||the-27/DT	amod||factors-29/NNS||major-28/JJ	prep_of||one-25/CD||factors-29/NNS	vmod||factors-29/NNS||leading-30/VBG	amod||infection-34/NN||chronic-32/JJ	nn||infection-34/NN||hbv-33/NN	prep_to||leading-30/VBG||infection-34/NN	hbv-33||hepatitisbvirus-10||no||cd8+ t cells contribute to the clearance of hepatitisbvirus (hbv) infection and an insufficient cd8+ t cell response may be one of the major factors leading to chronic hbv infection.
det||length-2/NN||neither-1/DT	nsubj||predictor-13/NN||length-2/NN	amod||infection-10/NN||stay-4/JJ	conj_nor||stay-4/JJ||methicillin-resistantstaphylococcusaureus-6/JJ	amod||infection-10/NN||methicillin-resistantstaphylococcusaureus-6/JJ	nn||infection-10/NN||-lrb--7/NN	nn||infection-10/NN||mrsa-8/NN	nn||infection-10/NN||-rrb--9/NN	prep_of||length-2/NN||infection-10/NN	cop||predictor-13/NN||was-11/VBD	det||predictor-13/NN||a-12/DT	root||ROOT-0/null||predictor-13/NN	amod||bacteriuria-16/NN||s.aureus-15/JJ	prep_of||predictor-13/NN||bacteriuria-16/NN	prep_of||predictor-13/NN||death-18/NN	conj_or||bacteriuria-16/NN||death-18/NN	mrsa-8||s.aureus-15||no||neither length of stay nor methicillin-resistantstaphylococcusaureus -lrb- mrsa -rrb- infection was a predictor of s.aureus bacteriuria or death .
aux||estimate-2/VB||to-1/TO	advcl||took-10/VBD||estimate-2/VB	amod||risks-7/NNS||subtype-specific-3/JJ	nn||risks-7/NNS||lifetime-4/NN	nn||risks-7/NNS||breast-5/NN	nn||risks-7/NNS||cancer-6/NN	dobj||estimate-2/VB||risks-7/NNS	nsubj||took-10/VBD||we-9/PRP	root||ROOT-0/null||took-10/VBD	dobj||took-10/VBD||advantage-11/NN	prep_for||available-40/JJ||advantage-11/NN	amod||data-14/NNS||population-based-13/JJ	prep_of||advantage-11/NN||data-14/NNS	nsubj||available-40/JJ||information-17/NN	nn||expression-20/NN||tumor-19/NN	prep_regarding||information-17/NN||expression-20/NN	nn||receptor-23/NN||estrogen-22/NN	prep_of||expression-20/NN||receptor-23/NN	appos||receptor-23/NN||er-25/NN	amod||receptor-29/NN||progesterone-28/JJ	prep_of||expression-20/NN||receptor-29/NN	conj_and||receptor-23/NN||receptor-29/NN	appos||receptor-29/NN||pr-31/NN	prep_of||expression-20/NN||her2/neu-34/NNS	conj_and||receptor-23/NN||her2/neu-34/NNS	appos||her2/neu-34/NNS||her2-36/NNP	cop||available-40/JJ||was-38/VBD	advmod||available-40/JJ||newly-39/RB	rcmod||advantage-11/NN||available-40/JJ	cancer-6||progesterone-28||no_rel||to estimate subtype-specific lifetime breast cancer risks, we took advantage of population-based data for which information regarding tumor expression of estrogen receptor (er), progesterone receptor (pr) and her2/neu (her2) was newly available.
advmod||identified-3/VBD||here-1/RB	nsubj||identified-3/VBD||we-2/PRP	root||ROOT-0/null||identified-3/VBD	nn||signatures-7/NNS||dna-4/NN	conj_and||dna-4/NN||protein-6/NN	nn||signatures-7/NNS||protein-6/NN	nsubj||specific-8/JJ||signatures-7/NNS	xcomp||identified-3/VBD||specific-8/JJ	prep_for||specific-8/JJ||y.pestis-10/NNS	nsubjpass||associated-26/VBN||y.pestis-10/NNS	amod||skeletons-13/NNS||human-12/JJ	prep_in||y.pestis-10/NNS||skeletons-13/NNS	amod||graves-16/NNS||mass-15/JJ	prep_from||skeletons-13/NNS||graves-16/NNS	amod||europe-23/NN||northern-18/JJ	conj_and||northern-18/JJ||central-20/JJ	amod||europe-23/NN||central-20/JJ	conj_and||northern-18/JJ||southern-22/JJ	amod||europe-23/NN||southern-22/JJ	prep_in||graves-16/NNS||europe-23/NN	auxpass||associated-26/VBN||were-25/VBD	rcmod||y.pestis-10/NNS||associated-26/VBN	advmod||associated-26/VBN||archaeologically-27/RB	det||blackdeath-30/NN||the-29/DT	prep_with||associated-26/VBN||blackdeath-30/NN	amod||resurgences-33/NNS||subsequent-32/JJ	prep_with||associated-26/VBN||resurgences-33/NNS	conj_and||blackdeath-30/NN||resurgences-33/NNS	blackdeath-30||y.pestis-10||no||here we identified dna and protein signatures specific for y.pestis in human skeletons from mass graves in northern , central and southern europe that were associated archaeologically with the blackdeath and subsequent resurgences .
det||studies-3/NNS||both-2/DT	prep_in||induced-20/VBN||studies-3/NNS	num||min-7/NN||60-6/CD	prep_after||induced-20/VBN||min-7/NN	amod||concentrations-12/NNS||normal-9/JJ	nn||concentrations-12/NNS||plasma-10/NN	nn||concentrations-12/NNS||glucose-11/NN	prep_of||min-7/NN||concentrations-12/NNS	nsubjpass||induced-20/VBN||hypoglycemia-14/NN	nsubjpass||maintained-27/VBN||hypoglycemia-14/NN	num||mg/dl-17/NN||47-16/CD	appos||hypoglycemia-14/NN||mg/dl-17/NN	auxpass||induced-20/VBN||was-19/VBD	root||ROOT-0/null||induced-20/VBN	advmod||induced-20/VBN||slowly-21/RB	number||min-24/CD||60-23/CD	dep||induced-20/VBN||min-24/CD	conj_and||induced-20/VBN||maintained-27/VBN	num||min-30/NN||60-29/CD	prep_for||maintained-27/VBN||min-30/NN	hypoglycemia-14||glucose-11||yes||in both studies, after 60 min of normal plasma glucose concentrations, hypoglycemia (47 mg/dl) was induced slowly (60 min) and maintained for 60 min.
det||analysis-2/NN||the-1/DT	nsubj||included-3/VBD||analysis-2/NN	root||ROOT-0/null||included-3/VBD	num||studies-8/NNS||three-4/CD	amod||studies-8/NNS||randomized-5/JJ	amod||studies-8/NNS||double-blind-7/JJ	dobj||included-3/VBD||studies-8/NNS	prep_in||studies-8/NNS||patients-10/NNS	nn||schizoaffectivedisorder-14/NN||schizophrenia-12/NN	prep_with||patients-10/NNS||schizoaffectivedisorder-14/NN	nn||disorder-18/NN||schizophreniform-17/NN	prep_with||patients-10/NNS||disorder-18/NN	conj_or||schizoaffectivedisorder-14/NN||disorder-18/NN	dep||patients-10/NNS||diagnosed-19/VBN	prepc_according_to||diagnosed-19/VBN||to-21/TO	det||manual-26/NN||the-22/DT	amod||manual-26/NN||diagnostic-23/JJ	conj_and||diagnostic-23/JJ||statistical-25/JJ	amod||manual-26/NN||statistical-25/JJ	pobj||diagnosed-19/VBN||manual-26/NN	amod||disorders-29/NNS||mental-28/JJ	npadvmod||4th-30/JJ||disorders-29/NNS	amod||edition-31/NN||4th-30/JJ	prep_of||manual-26/NN||edition-31/NN	advmod||assigned-34/VBN||randomly-33/RB	dep||patients-10/NNS||assigned-34/VBN	conj_and||diagnosed-19/VBN||assigned-34/VBN	prep_to||assigned-34/VBN||treatment-36/NN	poss||mg/day-43/NN||olanzapine-38/PRP$	amod||mg/day-43/NN||5â-39/JJ	amod||mg/day-43/NN||$-40/$	num||$-40/$||20-42/CD	prep_with||assigned-34/VBN||mg/day-43/NN	det||antipsychotic-46/NN||another-45/DT	prep_with||assigned-34/VBN||antipsychotic-46/NN	conj_or||mg/day-43/NN||antipsychotic-46/NN	amod||2â-49/NNS||haloperidol-48/JJ	dep||antipsychotic-46/NN||2â-49/NNS	num||mg/day-53/NN||$-50/$	num||$-50/$||20-52/CD	dep||2â-49/NNS||mg/day-53/NN	poss||mg/day-60/NN||risperidone-55/PRP$	amod||mg/day-60/NN||2â-56/JJ	amod||mg/day-60/NN||$-57/$	num||$-57/$||10-59/CD	dep||2â-49/NNS||mg/day-60/NN	conj_or||mg/day-53/NN||mg/day-60/NN	poss||mg/day-68/NN||ziprasidone-63/PRP$	amod||mg/day-68/NN||80â-64/JJ	amod||mg/day-68/NN||$-65/$	num||$-65/$||160-67/CD	dep||2â-49/NNS||mg/day-68/NN	conj_or||mg/day-53/NN||mg/day-68/NN	schizophrenia-12||antipsychotic-46||no_rel||the analysis included three randomized, double-blind studies in patients with schizophrenia, schizoaffectivedisorder, or schizophreniform disorder diagnosed according to the diagnostic and statistical manual of mental disorders 4th edition and randomly assigned to treatment with olanzapine 5â20 mg/day or another antipsychotic (haloperidol 2â20 mg/day, risperidone 2â10 mg/day, or ziprasidone 80â160 mg/day).
det||study-2/NN||this-1/DT	nsubj||examined-3/VBD||study-2/NN	root||ROOT-0/null||examined-3/VBD	mark||associated-13/VBN||whether-4/IN	nsubjpass||associated-13/VBN||performance-5/NN	det||test-11/NN||an-7/DT	amod||test-11/NN||8-ft-8/JJ	nn||test-11/NN||walking-9/NN	nn||test-11/NN||speed-10/NN	prep_in||performance-5/NN||test-11/NN	auxpass||associated-13/VBN||is-12/VBZ	ccomp||examined-3/VBD||associated-13/VBN	amod||factors-17/NNS||metabolic-15/JJ	nn||factors-17/NNS||risk-16/NN	prep_with||associated-13/VBN||factors-17/NNS	amod||atherosclerosis-20/NNS||subclinical-19/JJ	prep_with||associated-13/VBN||atherosclerosis-20/NNS	conj_and||factors-17/NNS||atherosclerosis-20/NNS	atherosclerosis-20||speed-10||no||this study examined whether performance in an 8-ft walking speed test is associated with metabolic risk factors and subclinical atherosclerosis.
det||correlation-3/NN||a-1/DT	amod||correlation-3/NN||significant-2/JJ	nsubj||estimated-9/VBD||correlation-3/NN	nsubj||mr-15/VBP||correlation-3/NN	advmod||visible-6/JJ||microscopically-5/RB	amod||droplets-8/NNS||visible-6/JJ	nn||droplets-8/NNS||lipid-7/NN	prep_between||correlation-3/NN||droplets-8/NNS	root||ROOT-0/null||estimated-9/VBD	amod||staining-13/NN||nile-11/JJ	amod||staining-13/NN||red-12/JJ	prep_by||estimated-9/VBD||staining-13/NN	conj_and||estimated-9/VBD||mr-15/VBP	amod||signals-18/NNS||visible-16/JJ	nn||signals-18/NNS||lipid-17/NN	nsubjpass||observed-20/VBN||signals-18/NNS	auxpass||observed-20/VBN||was-19/VBD	ccomp||mr-15/VBP||observed-20/VBN	amod||carcinomas-24/NNS||metastatic-22/JJ	nn||carcinomas-24/NNS||lung-23/NN	prep_in||observed-20/VBN||carcinomas-24/NNS	dep||carcinomas-24/NNS||p-26/VBN	dep||0.01-28/CD||=-27/SYM	ccomp||p-26/VBN||0.01-28/CD	vmod||estimated-9/VBD||indicating-31/VBG	mark||mr-35/VBP||that-32/IN	det||proton-34/NN||the-33/DT	nsubj||mr-35/VBP||proton-34/NN	ccomp||indicating-31/VBG||mr-35/VBP	amod||signals-38/NNS||visible-36/JJ	nn||signals-38/NNS||lipid-37/NN	nsubj||arise-39/VBP||signals-38/NNS	ccomp||mr-35/VBP||arise-39/VBP	amod||droplets-43/NNS||cytoplasmic-41/JJ	nn||droplets-43/NNS||lipid-42/NN	prep_from||arise-39/VBP||droplets-43/NNS	lipid-42||carcinomas-24||no_rel||a significant correlation between microscopically visible lipid droplets estimated by nile red staining and mr visible lipid signals was observed in metastatic lung carcinomas ( p = 0.01), indicating that the proton mr visible lipid signals arise from cytoplasmic lipid droplets.
det||study-2/NN||this-1/DT	nsubj||examined-3/VBD||study-2/NN	root||ROOT-0/null||examined-3/VBD	det||prevention-5/NN||the-4/DT	dobj||examined-3/VBD||prevention-5/NN	prep_of||prevention-5/NN||pain-7/NN	amod||injection-11/NN||microemulsion-9/JJ	amod||injection-11/NN||propofol-10/JJ	prep_during||examined-3/VBD||injection-11/NN	prep_by||examined-3/VBD||pretreatment-13/NN	amod||doses-16/NNS||different-15/JJ	prep_with||examined-3/VBD||doses-16/NNS	prep_of||doses-16/NNS||remifentanil-18/JJ	prep_of||doses-16/NNS||saline-20/JJ	conj_or||remifentanil-18/JJ||saline-20/JJ	prep_of||doses-16/NNS||premixing-23/NN	conj_and||remifentanil-18/JJ||premixing-23/NN	prep_of||premixing-23/NN||lidocaine-25/NN	pain-7||propofol-10||yes||this study examined the prevention of pain during microemulsion propofol injection by pretreatment with different doses of remifentanil or saline, and premixing of lidocaine.
det||study-2/NN||the-1/DT	nsubj||suggests-3/VBZ||study-2/NN	ccomp||interpreted-29/VBN||suggests-3/VBZ	det||utility-5/NN||the-4/DT	dobj||suggests-3/VBZ||utility-5/NN	nn||mannan-8/NN||candida-7/NN	prep_of||utility-5/NN||mannan-8/NN	nn||dna-11/NN||candida-10/NN	prep_of||utility-5/NN||dna-11/NN	conj_or||mannan-8/NN||dna-11/NN	det||diagnosis-14/NN||the-13/DT	prep_in||mannan-8/NN||diagnosis-14/NN	prep_of||diagnosis-14/NN||invasivecandidiasis-16/NNS	advmod||suggests-3/VBZ||however-18/RB	det||levels-22/NNS||the-20/DT	nn||levels-22/NNS||bdg-21/NN	nsubjpass||interpreted-29/VBN||levels-22/NNS	amod||subjects-26/NNS||pediatric-24/JJ	nn||subjects-26/NNS||cancer-25/NN	prep_in||levels-22/NNS||subjects-26/NNS	aux||interpreted-29/VBN||should-27/MD	auxpass||interpreted-29/VBN||be-28/VB	root||ROOT-0/null||interpreted-29/VBN	prep_with||interpreted-29/VBN||caution-31/NN	invasivecandidiasis-16||candida-10||no||the study suggests the utility of candida mannan or candida dna in the diagnosis of invasivecandidiasis, however, the bdg levels in pediatric cancer subjects should be interpreted with caution.
det||baculovirus-5/NNS||a-1/DT	amod||baculovirus-5/NNS||recombinant-2/JJ	nn||baculovirus-5/NNS||bombyx-3/NN	nn||baculovirus-5/NNS||mori-4/NN	nsubjpass||constructed-10/VBN||baculovirus-5/NNS	appos||baculovirus-5/NNS||bmg64ha-7/NNS	auxpass||constructed-10/VBN||was-9/VBD	root||ROOT-0/null||constructed-10/VBN	det||expression-13/NN||the-12/DT	prep_for||constructed-10/VBN||expression-13/NN	nn||protein-16/NN||ha-15/NN	prep_of||expression-13/NN||protein-16/NN	amod||influenzavirus-19/NNS||h5n1-18/JJ	prep_of||protein-16/NN||influenzavirus-19/NNS	xcomp||constructed-10/VBN||displaying-20/VBG	det||surface-25/NN||the-22/DT	amod||surface-25/NN||viral-23/JJ	nn||surface-25/NN||envelope-24/NN	prep_on||displaying-20/VBG||surface-25/NN	h5n1-18||influenzavirus-19||no||a recombinant bombyx mori baculovirus, bmg64ha, was constructed for the expression of ha protein of h5n1 influenzavirus displaying on the viral envelope surface.
det||discovery-2/NN||the-1/DT	nsubj||raised-28/VBN||discovery-2/NN	amod||viruses-5/NNS||giant-4/JJ	prep_of||discovery-2/NN||viruses-5/NNS	amod||size-10/NN||genome-7/JJ	conj_and||genome-7/JJ||physical-9/JJ	amod||size-10/NN||physical-9/JJ	prep_with||viruses-5/NNS||size-10/NN	amod||size-10/NN||comparable-11/JJ	amod||organisms-14/NNS||cellular-13/JJ	prep_to||comparable-11/JJ||organisms-14/NNS	appos||organisms-14/NNS||remnants-16/NNS	nn||machinery-20/NN||protein-18/NN	nn||machinery-20/NN||translation-19/NN	prep_of||remnants-16/NNS||machinery-20/NN	amod||parasites-23/NNS||virus-specific-22/JJ	prep_of||remnants-16/NNS||parasites-23/NNS	conj_and||machinery-20/NN||parasites-23/NNS	appos||size-10/NN||virophages-25/NNS	aux||raised-28/VBN||have-27/VBP	root||ROOT-0/null||raised-28/VBN	amod||questions-30/NNS||intriguing-29/JJ	dobj||raised-28/VBN||questions-30/NNS	poss||origin-33/NN||their-32/PRP$	prep_about||raised-28/VBN||origin-33/NN	virus--1||viruses-5||no||the discovery of giant viruses with genome and physical size comparable to cellular organisms, remnants of protein translation machinery and virus-specific parasites (virophages) have raised intriguing questions about their origin.
nn||levels-2/NNS||glucagon-1/NN	nsubj||remained-3/VBD||levels-2/NNS	root||ROOT-0/null||remained-3/VBD	acomp||remained-3/VBD||suppressed-4/VBN	det||decrease-7/NN||a-6/DT	prep_following||suppressed-4/VBN||decrease-7/NN	amod||insulin-10/NN||zinc-free-9/JJ	prep_in||decrease-7/NN||insulin-10/NN	prep_in||decrease-7/NN||insulin-10/NN	conj_and||insulin-10/NN||insulin-10/NN	prep_with||insulin-10/NN||euglycemia-12/NN	dep||insulin-10/NN||â-14/VB	num||±-17/NN||14-15/CD	nn||±-17/NN||â-16/NN	nsubj||-LSB--20/VBG||±-17/NN	number||pg/ml-19/JJ||3-18/CD	dep||-LSB--20/VBG||pg/ml-19/JJ	xcomp||â-14/VB||-LSB--20/VBG	poss||-RSB--28/NN||â-21/NNP	number||â-24/CD||4.0-23/CD	num||-RSB--28/NN||â-24/CD	nn||-RSB--28/NN||±-25/NN	num||-RSB--28/NN||0.9-26/CD	nn||-RSB--28/NN||pmol/l-27/NN	dobj||-LSB--20/VBG||-RSB--28/NN	amod||hyperinsulinemia-33/NN||sustained-32/VBN	prep_during||insulin-10/NN||hyperinsulinemia-33/NN	prep_with||hyperinsulinemia-33/NN||hypoglycemia-35/NN	nn||±-40/NN||â-37/NN	num||±-40/NN||14-38/CD	nn||±-40/NN||â-39/NN	dep||hypoglycemia-35/NN||±-40/NN	num||-LSB--43/NNS||2-41/CD	amod||-LSB--43/NNS||pg/ml-42/JJ	dep||±-40/NN||-LSB--43/NNS	poss||-RSB--51/NN||â-44/NNP	amod||-RSB--51/NN||4.0-46/JJ	nn||-RSB--51/NN||â-47/NN	nn||-RSB--51/NN||±-48/NN	num||-RSB--51/NN||0.6-49/CD	amod||-RSB--51/NN||pmol/l-50/JJ	dep||-LSB--43/NNS||-RSB--51/NN	acomp||remained-3/VBD||increased-54/VBN	conj_but||suppressed-4/VBN||increased-54/VBN	poss||pg/ml-62/NN||â-56/NNP	number||â-59/CD||3-58/CD	num||pg/ml-62/NN||â-59/CD	amod||pg/ml-62/NN||±-60/JJ	num||pg/ml-62/NN||3-61/CD	prep_to||increased-54/VBN||pg/ml-62/NN	poss||â-67/NN||â-64/NNP	num||â-67/NN||0.9-66/CD	npadvmod||pmol/l-70/JJ||â-67/NN	number||0.9-69/CD||±-68/CD	num||â-67/NN||0.9-69/CD	dep||pg/ml-62/NN||pmol/l-70/JJ	parataxis||increased-54/VBN||p-73/VB	num||0.01-75/CD||<-74/CD	dobj||p-73/VB||0.01-75/CD	det||decrease-79/NN||a-78/DT	prep_following||increased-54/VBN||decrease-79/NN	amod||insulin-82/NN||zinc-free-81/JJ	prep_in||decrease-79/NN||insulin-82/NN	prep_with||insulin-82/NN||hypoglycemia-84/NN	det||min-89/NNS||the-86/DT	amod||min-89/NNS||next-87/JJ	num||min-89/NNS||120-88/CD	prep_over||hypoglycemia-84/NN||min-89/NNS	glucagon-1||hypoglycemia-84||no_rel||glucagon levels remained suppressed following a decrease in zinc-free insulin with euglycemia (â14 â± 3 pg/ml [â4.0 â± 0.9 pmol/l]) and during sustained hyperinsulinemia with hypoglycemia (â14 â± 2 pg/ml [â4.0 â± 0.6 pmol/l]) but increased to â3 â± 3 pg/ml (â0.9 â± 0.9 pmol/l) ( p < 0.01) following a decrease in zinc-free insulin with hypoglycemia over the next 120 min.
amod||infection-3/NN||acute-1/JJ	nn||infection-3/NN||hav-2/NN	nsubjpass||confirmed-6/VBN||infection-3/NN	auxpass||confirmed-6/VBN||is-4/VBZ	advmod||confirmed-6/VBN||usually-5/RB	root||ROOT-0/null||confirmed-6/VBN	amod||detection-10/NN||anti-hav-8/JJ	nn||detection-10/NN||igm-9/NN	agent||confirmed-6/VBN||detection-10/NN	anti-hav-8||hav-2||no_rel||acute hav infection is usually confirmed by anti-hav igm detection.
det||three-dose-4/NN||the-1/DT	advmod||three-dose-4/NN||once-2/RB	amod||three-dose-4/NN||daily-3/JJ	nsubj||superior-14/JJ||three-dose-4/NN	nsubj||six-dose-16/VB||three-dose-4/NN	amod||suspension-7/NN||artemether-lumefantrine-6/JJ	prep_of||three-dose-4/NN||suspension-7/NN	nn||®-10/NNP||co-artesianeâ-9/NNP	appos||three-dose-4/NN||®-10/NNP	cop||superior-14/JJ||was-12/VBD	neg||superior-14/JJ||not-13/RB	root||ROOT-0/null||superior-14/JJ	aux||six-dose-16/VB||to-15/TO	xcomp||superior-14/JJ||six-dose-16/VB	amod||tablets-18/NNS||artemether-lumefantrine-17/JJ	dobj||six-dose-16/VB||tablets-18/NNS	nn||®-21/NNP||coartemâ-20/NNP	appos||tablets-18/NNS||®-21/NNP	det||treatment-25/NN||the-24/DT	prep_for||six-dose-16/VB||treatment-25/NN	amod||malaria-28/NN||uncomplicated-27/JJ	prep_of||treatment-25/NN||malaria-28/NN	prep_in||malaria-28/NN||children-30/NNS	num||years-33/NNS||five-32/CD	prep_below||six-dose-16/VB||years-33/NNS	prep_of||years-33/NNS||age-35/NN	amod||kenya-38/NN||western-37/JJ	prep_in||age-35/NN||kenya-38/NN	malaria-28||artemether--1||yes||the once daily three-dose of artemether-lumefantrine suspension (co-artesianeâ®) was not superior to six-dose artemether-lumefantrine tablets (coartemâ®) for the treatment of uncomplicated malaria in children below five years of age in western kenya.
amod||risks-4/NNS||gastrointestinal-3/JJ	prep_because_of||propose-30/VBP||risks-4/NNS	nn||complications-8/NNS||ulcer-7/NN	prep_including||risks-4/NNS||complications-8/NNS	amod||risks-12/NNS||cardiovascular-11/JJ	conj_and||risks-4/NNS||risks-12/NNS	prep_because_of||propose-30/VBP||risks-12/NNS	nn||events-18/NNS||hypertension-15/NN	conj_and||hypertension-15/NN||thrombotic-17/JJ	nn||events-18/NNS||thrombotic-17/JJ	prep_including||risks-12/NNS||events-18/NNS	vmod||events-18/NNS||associated-19/VBN	amod||anti-inflammatorydrugs-22/NNS||nonsteroidal-21/JJ	prep_with||associated-19/VBN||anti-inflammatorydrugs-22/NNS	num||nsaids-24/NNS||-LSB--23/CD	npadvmod||-RSB--25/JJ||nsaids-24/NNS	amod||anti-inflammatorydrugs-22/NNS||-RSB--25/JJ	det||guidelines-29/NNS||these-28/DT	nsubj||propose-30/VBP||guidelines-29/NNS	root||ROOT-0/null||propose-30/VBP	dobj||propose-30/VBP||acetaminophen-31/NN	det||anti-inflammatoryagents-36/NNS||the-33/DT	amod||anti-inflammatoryagents-36/NNS||first-34/JJ	nn||anti-inflammatoryagents-36/NNS||choice-35/NN	prep_as||propose-30/VBP||anti-inflammatoryagents-36/NNS	hypertension-15||acetaminophen-31||no_rel||because of gastrointestinal risks (including ulcer complications) and cardiovascular risks (including hypertension and thrombotic events associated with nonsteroidal anti-inflammatorydrugs [nsaids]), these guidelines propose acetaminophen as the first choice anti-inflammatoryagents.
det||study-3/NN||a-1/DT	amod||study-3/NN||cross-sectional-2/JJ	nsubjpass||conducted-5/VBN||study-3/NN	auxpass||conducted-5/VBN||was-4/VBD	root||ROOT-0/null||conducted-5/VBN	num||patients-9/NNS||1143-7/CD	nn||patients-9/NNS||hiv-8/NN	prep_among||conducted-5/VBN||patients-9/NNS	prep_under||conducted-5/VBN||follow-up-11/NN	det||center-17/NN||a-13/DT	amod||center-17/NN||hiv/aids-14/JJ	nn||center-17/NN||outpatient-15/NN	nn||center-17/NN||reference-16/NN	prep_in||follow-up-11/NN||center-17/NN	det||system-23/NN||the-19/DT	amod||system-23/NN||brazilian-20/JJ	amod||system-23/NN||public-21/JJ	nn||system-23/NN||health-22/NN	prep_of||center-17/NN||system-23/NN	aids--1||hiv-8||no||a cross-sectional study was conducted among 1143 hiv patients under follow-up in a hiv/aids outpatient reference center of the brazilian public health system.
aux||select-2/VB||to-1/TO	advcl||matched-16/VBD||select-2/VB	amod||compartments-4/NNS||cellular-3/JJ	dobj||select-2/VB||compartments-4/NNS	advmod||likely-6/JJ||most-5/RBS	amod||compartments-4/NNS||likely-6/JJ	aux||give-8/VB||to-7/TO	xcomp||likely-6/JJ||give-8/VB	dobj||give-8/VB||rise-9/NN	prep_to||give-8/VB||subgroups-11/NNS	prep_of||subgroups-11/NNS||ependymoma-13/NN	nsubj||matched-16/VBD||we-15/PRP	root||ROOT-0/null||matched-16/VBD	det||transcriptomes-18/NNS||the-17/DT	nsubj||stem-27/VBP||transcriptomes-18/NNS	amod||tumors-21/NNS||human-20/JJ	prep_of||transcriptomes-18/NNS||tumors-21/NNS	prep_to||tumors-21/NNS||those-23/DT	nn||neural-26/NN||mouse-25/NN	prep_of||those-23/DT||neural-26/NN	ccomp||matched-16/VBD||stem-27/VBP	dobj||stem-27/VBP||cells-28/NNS	appos||cells-28/NNS||nscs-30/NNS	vmod||cells-28/NNS||isolated-33/VBN	amod||regions-36/NNS||different-35/JJ	prep_from||isolated-33/VBN||regions-36/NNS	det||cns-39/NN||the-38/DT	prep_of||regions-36/NNS||cns-39/NN	amod||stages-43/NNS||different-41/JJ	amod||stages-43/NNS||developmental-42/JJ	prep_at||cns-39/NN||stages-43/NNS	det||locus-51/NNS||an-46/DT	amod||locus-51/NNS||intact-47/JJ	conj_or||intact-47/JJ||deleted-49/JJ	amod||locus-51/NNS||deleted-49/JJ	amod||locus-51/NNS||ink4a/arf-50/JJ	prep_with||cells-28/NNS||locus-51/NNS	rise-9||tumors-21||no_rel||to select cellular compartments most likely to give rise to subgroups of ependymoma, we matched the transcriptomes of human tumors to those of mouse neural stem cells (nscs), isolated from different regions of the cns at different developmental stages, with an intact or deleted ink4a/arf locus.
root||ROOT-0/null||retinoicacid-1/NN	prep_including||retinoicacid-1/NN||all-4/DT	dep||retinoicacid-1/NN||transretinoicacid-6/NN	amod||transretinoicacid-6/NN||9-8/CD	dep||retinoicacid-1/NN||cis-10/NN	dep||retinoicacid-1/NN||13-12/CD	conj_and||cis-10/NN||13-12/CD	nn||retinoicacid-15/NN||cis-14/NN	dep||retinoicacid-1/NN||retinoicacid-15/NN	nn||roles-19/NNS||play-17/NN	amod||roles-19/NNS||important-18/JJ	appos||retinoicacid-15/NN||roles-19/NNS	amod||processes-23/NNS||various-21/JJ	amod||processes-23/NNS||physiological-22/JJ	prep_in||roles-19/NNS||processes-23/NNS	prepc_such_as||retinoicacid-15/NN||in-27/IN	amod||growth-36/NN||embryonic-28/JJ	nn||growth-36/NN||development-29/NN	pobj||in-27/IN||reproduction-31/NN	conj_and||growth-36/NN||reproduction-31/NN	pobj||in-27/IN||vision-33/NN	conj_and||growth-36/NN||vision-33/NN	pobj||in-27/IN||cell-35/NN	conj_and||growth-36/NN||cell-35/NN	pobj||in-27/IN||growth-36/NN	pobj||in-27/IN||differentiation-38/NN	conj_and||growth-36/NN||differentiation-38/NN	pobj||in-27/IN||apoptosis-40/NNS	conj_and||growth-36/NN||apoptosis-40/NNS	pobj||in-27/IN||inflammation-42/NN	conj_and||growth-36/NN||inflammation-42/NN	inflammation-42||transretinoicacid-6||no_rel||retinoicacid, including all- transretinoicacid, 9- cis and 13- cis retinoicacid, play important roles in various physiological processes, such as in embryonic development, reproduction, vision, cell growth, differentiation, apoptosis and inflammation.
advmod||exhibited-8/VBN||worldwide-1/RB	nsubj||exhibited-8/VBN||organisms-3/NNS	det||mycobacteriumtuberculosiscomplex-6/NN||the-5/DT	prep_within||organisms-3/NNS||mycobacteriumtuberculosiscomplex-6/NN	aux||exhibited-8/VBN||have-7/VBP	root||ROOT-0/null||exhibited-8/VBN	det||ability-10/NN||the-9/DT	dobj||exhibited-8/VBN||ability-10/NN	aux||develop-12/VB||to-11/TO	vmod||ability-10/NN||develop-12/VB	dobj||develop-12/VB||resistance-13/NN	amod||agents-16/NNS||antimicrobial-15/JJ	prep_to||develop-12/VB||agents-16/NNS	dep||exhibited-8/VBN||resulting-18/VBG	predet||multidrug-resistant-22/NN||both-20/PDT	det||multidrug-resistant-22/NN||the-21/DT	prep_in||resulting-18/VBG||multidrug-resistant-22/NN	appos||multidrug-resistant-22/NN||mdr-24/NN	dep||exhibited-8/VBN||extensively-27/VBG	conj_and||resulting-18/VBG||extensively-27/VBG	amod||strains-32/NNS||drug-resistant-28/JJ	appos||strains-32/NNS||xdr-30/NN	dobj||extensively-27/VBG||strains-32/NNS	amod||tuberculosis-35/NNP||human-34/JJ	prep_of||extensively-27/VBG||tuberculosis-35/NNP	tuberculosis-35||mycobacteriumtuberculosiscomplex-6||no||worldwide, organisms within the mycobacteriumtuberculosiscomplex have exhibited the ability to develop resistance to antimicrobial agents, resulting in both the multidrug-resistant (mdr) and extensively drug-resistant (xdr) strains of human tuberculosis.
nsubj||antibiotic-4/JJ||minocycline-1/NN	cop||antibiotic-4/JJ||is-2/VBZ	det||antibiotic-4/JJ||an-3/DT	root||ROOT-0/null||antibiotic-4/JJ	nsubjpass||used-11/VBN||antibiotic-4/JJ	amod||derivatives-7/NNS||tetracycline-6/JJ	prep_of||antibiotic-4/JJ||derivatives-7/NNS	auxpass||used-11/VBN||is-9/VBZ	advmod||used-11/VBN||commonly-10/RB	rcmod||antibiotic-4/JJ||used-11/VBN	det||treatment-14/NN||the-13/DT	prep_in||used-11/VBN||treatment-14/NN	amod||severe-18/JJ||moderate-16/JJ	dep||severe-18/JJ||to-17/TO	amod||acnevulgaris-19/NNS||severe-18/JJ	prep_of||treatment-14/NN||acnevulgaris-19/NNS	acnevulgaris-19||minocycline-1||yes||minocycline is an antibiotic of tetracycline derivatives that is commonly used in the treatment of moderate to severe acnevulgaris.
nn||diagnosis-2/NN||laboratory-1/NN	nsubj||relies-9/VBZ||diagnosis-2/NN	prep_of||diagnosis-2/NN||tuberculosis-4/NNP	appos||diagnosis-2/NN||tb-6/NN	advmod||relies-9/VBZ||traditionally-8/RB	root||ROOT-0/null||relies-9/VBZ	nn||microscopy-12/NN||smear-11/NN	prep_on||relies-9/VBZ||microscopy-12/NN	prep_on||relies-9/VBZ||culture-14/NN	conj_and||microscopy-12/NN||culture-14/NN	prep_of||microscopy-12/NN||mycobacteriumtuberculosis-16/NNS	amod||samples-19/NNS||clinical-18/JJ	prep_from||relies-9/VBZ||samples-19/NNS	tuberculosis-4||mycobacteriumtuberculosis-16||no||laboratory diagnosis of tuberculosis (tb) traditionally relies on smear microscopy and culture of mycobacteriumtuberculosis from clinical samples.
det||review-2/NN||this-1/DT	nsubj||presents-3/VBZ||review-2/NN	root||ROOT-0/null||presents-3/VBZ	amod||findings-5/NNS||recent-4/JJ	dobj||presents-3/VBZ||findings-5/NNS	amod||formulations-8/NNS||topical-7/JJ	prep_regarding||findings-5/NNS||formulations-8/NNS	det||drugs-14/NNS||the-10/DT	advmod||used-13/VBN||most-11/RBS	advmod||used-13/VBN||widely-12/RB	amod||drugs-14/NNS||used-13/VBN	prep_of||formulations-8/NNS||drugs-14/NNS	nn||treatment-17/NN||pain-16/NN	prep_for||drugs-14/NNS||treatment-17/NN	prep_of||formulations-8/NNS||as-20/IN	conj_and||drugs-14/NNS||as-20/IN	amod||anti-inflammatoryagents-22/NNS||nonsteroidal-21/JJ	prep_such_as||drugs-14/NNS||anti-inflammatoryagents-22/NNS	prep_such_as||drugs-14/NNS||anesthetics-24/NNS	conj_and||anti-inflammatoryagents-22/NNS||anesthetics-24/NNS	prep_such_as||drugs-14/NNS||capsaicin-27/NN	conj_and||anti-inflammatoryagents-22/NNS||capsaicin-27/NN	det||role-31/NN||the-30/DT	prep_of||formulations-8/NNS||role-31/NN	conj_and||drugs-14/NNS||role-31/NN	amod||agents-34/NNS||physical-33/JJ	prep_of||role-31/NN||agents-34/NNS	nn||enhancers-37/NNS||delivery-36/NN	prep_as||agents-34/NNS||enhancers-37/NNS	dep||enhancers-37/NNS||phonophoresis-39/NNS	dep||enhancers-37/NNS||iontophoresis-41/NNS	conj_and||phonophoresis-39/NNS||iontophoresis-41/NNS	pain-16||capsaicin-27||yes||this review presents recent findings regarding topical formulations of the most widely used drugs for pain treatment, such as nonsteroidal anti-inflammatoryagents, anesthetics, and capsaicin, and the role of physical agents as delivery enhancers (phonophoresis and iontophoresis).
det||incidence-2/NN||the-1/DT	nsubj||disappeared-6/VBD||incidence-2/NN	amod||pain-5/NN||moderate-4/JJ	prep_of||incidence-2/NN||pain-5/NN	root||ROOT-0/null||disappeared-6/VBD	advmod||disappeared-6/VBD||completely-7/RB	det||group-11/NN||the-9/DT	nn||group-11/NN||combination-10/NN	prep_in||disappeared-6/VBD||group-11/NN	num||%-14/NN||0-13/CD	appos||group-11/NN||%-14/NN	prepc_compared_to||disappeared-6/VBD||to-17/TO	pobj||disappeared-6/VBD||that-18/DT	det||group-24/NN||the-20/DT	amod||group-24/NN||remifentanil-21/JJ	conj_and||remifentanil-21/JJ||lidocaine-23/JJ	amod||group-24/NN||lidocaine-23/JJ	prep_in||that-18/DT||group-24/NN	num||%-27/NN||32.5-26/CD	dep||group-24/NN||%-27/NN	num||%-30/NN||20-29/CD	dep||group-24/NN||%-30/NN	conj_and||%-27/NN||%-30/NN	advmod||%-27/NN||respectively-32/RB	nn||0.05-36/NNP||p-34/NNP	nn||0.05-36/NNP||<-35/NNP	appos||%-27/NN||0.05-36/NNP	pain-5||lidocaine-23||yes||the incidence of moderate pain disappeared completely in the combination group (0%) compared to that in the remifentanil and lidocaine group (32.5% and 20%, respectively, p < 0.05).
amod||populations-10/NNS||untreated-1/JJ	amod||populations-10/NNS||humanimmunodeficiencyvirus-2/JJ	appos||populations-10/NNS||hiv-4/NN	nn||populations-10/NNS||disease-6/NN	nn||populations-10/NNS||disrupts-7/NNS	nn||populations-10/NNS||b-8/NN	nn||populations-10/NNS||cell-9/NN	nsubj||resting-19/VBD||populations-10/NNS	vmod||populations-10/NNS||causing-11/VBG	amod||memory-13/NN||reduced-12/VBN	dobj||causing-11/VBG||memory-13/NN	amod||ve-18/NN||reduced-15/VBN	nn||ve-18/NN||naã-16/NN	nn||ve-18/NN||¯-17/NN	dobj||causing-11/VBG||ve-18/NN	conj_and||memory-13/NN||ve-18/NN	root||ROOT-0/null||resting-19/VBD	dep||cells-21/NNS||b-20/SYM	dep||resting-19/VBD||cells-21/NNS	vmod||cells-21/NNS||leading-22/VBG	prep_to||leading-22/VBG||increases-24/NNS	amod||co-infections-27/NNS||specific-26/JJ	prep_in||increases-24/NNS||co-infections-27/NNS	amod||responses-30/NNS||impaired-29/VBN	dep||resting-19/VBD||responses-30/NNS	conj_and||cells-21/NNS||responses-30/NNS	prep_to||responses-30/NNS||vaccines-32/NNS	hiv)--1||humanimmunodeficiencyvirus-2||no||untreated humanimmunodeficiencyvirus (hiv) disease disrupts b cell populations causing reduced memory and reduced naã¯ve resting b cells leading to increases in specific co-infections and impaired responses to vaccines.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	advmod||report-2/VBP||here-3/RB	mark||polyunsaturated-12/VBD||that-4/IN	nsubj||polyunsaturated-12/VBD||incubation-5/NN	nsubj||triggered-21/VBD||incubation-5/NN	nsubj||caused-28/VBD||incubation-5/NN	amod||cells-8/NNS||endothelial-7/JJ	prep_of||incubation-5/NN||cells-8/NNS	prep_with||cells-8/NNS||n-10/NN	num||n-10/NN||-3-11/CD	ccomp||report-2/VBP||polyunsaturated-12/VBD	amod||migration-16/NN||fattyacids-13/JJ	amod||migration-16/NN||impaired-14/VBN	nn||migration-16/NN||cell-15/NN	dobj||polyunsaturated-12/VBD||migration-16/NN	det||wound-19/NN||a-18/DT	prep_into||polyunsaturated-12/VBD||wound-19/NN	ccomp||report-2/VBP||triggered-21/VBD	conj_and||polyunsaturated-12/VBD||triggered-21/VBD	amod||distribution-23/NN||peripheral-22/JJ	dobj||triggered-21/VBD||distribution-23/NN	amod||adhesions-26/NNS||focal-25/JJ	prep_of||distribution-23/NN||adhesions-26/NNS	ccomp||report-2/VBP||caused-28/VBD	conj_and||polyunsaturated-12/VBD||caused-28/VBD	amod||disassembly-30/NN||partial-29/JJ	dobj||caused-28/VBD||disassembly-30/NN	nn||filaments-33/NNS||actin-32/NN	prep_of||disassembly-30/NN||filaments-33/NNS	fattyacids-13||adhesions-26||no_rel||we report here that incubation of endothelial cells with n -3 polyunsaturated fattyacids impaired cell migration into a wound, triggered peripheral distribution of focal adhesions and caused partial disassembly of actin filaments.
poss||profiling-3/NN||our-1/PRP$	amod||profiling-3/NN||systematic-2/JJ	nsubj||advanced-14/VBD||profiling-3/NN	nsubj||identified-29/VBD||profiling-3/NN	nn||changes-6/NNS||phosphorylation-5/NN	prep_of||profiling-3/NN||changes-6/NNS	prep_in||changes-6/NNS||response-8/NN	amod||treatment-11/NN||bortezomib-10/JJ	prep_to||response-8/NN||treatment-11/NN	neg||only-13/JJ||not-12/RB	preconj||advanced-14/VBD||only-13/JJ	root||ROOT-0/null||advanced-14/VBD	det||understanding-18/NN||the-15/DT	amod||understanding-18/NN||global-16/JJ	amod||understanding-18/NN||mechanistic-17/JJ	dobj||advanced-14/VBD||understanding-18/NN	det||action-21/NN||the-20/DT	prep_of||understanding-18/NN||action-21/NN	prep_of||action-21/NN||bortezomib-23/NN	nn||cells-26/NNS||myeloma-25/NN	prep_on||advanced-14/VBD||cells-26/NNS	advmod||identified-29/VBD||also-28/RB	conj_but||advanced-14/VBD||identified-29/VBD	advmod||uncharacterized-31/JJ||previously-30/RB	acomp||signaling-32/VBG||uncharacterized-31/JJ	ccomp||identified-29/VBD||signaling-32/VBG	xcomp||identified-29/VBD||signaling-32/VBG	dobj||signaling-32/VBG||proteins-33/NNS	nn||cells-36/NNS||myeloma-35/NN	prep_in||signaling-32/VBG||cells-36/NNS	myeloma-35||bortezomib-23||yes||our systematic profiling of phosphorylation changes in response to bortezomib treatment not only advanced the global mechanistic understanding of the action of bortezomib on myeloma cells but also identified previously uncharacterized signaling proteins in myeloma cells.
nsubj||phagocytosed-12/JJ||studies-1/NNS	nsubj||revealed-14/VBD||studies-1/NNS	amod||cells-6/NNS||murine-3/JJ	amod||cells-6/NNS||min6-4/JJ	nn||cells-6/NNS||insuloma-5/NN	prep_with||studies-1/NNS||cells-6/NNS	cop||phagocytosed-12/JJ||were-9/VBD	advmod||phagocytosed-12/JJ||also-10/RB	advmod||also-10/RB||efficiently-11/RB	rcmod||studies-1/NNS||phagocytosed-12/JJ	root||ROOT-0/null||revealed-14/VBD	det||expression-18/NN||that-15/DT	amod||expression-18/NN||increased-16/JJ	nn||expression-18/NN||isg-17/NN	dobj||revealed-14/VBD||expression-18/NN	prep_in||revealed-14/VBD||dcs-20/NN	prepc_upon||revealed-14/VBD||encountering-22/VBG	amod||cells-24/NNS||cvb-infected-23/JJ	dobj||encountering-22/VBG||cells-24/NNS	vmod||cells-24/NNS||resulted-25/VBN	det||state-29/NN||an-27/DT	amod||state-29/NN||antiviral-28/JJ	prep_in||resulted-25/VBN||state-29/NN	nsubj||protected-31/VBD||state-29/NN	rcmod||state-29/NN||protected-31/VBD	dobj||protected-31/VBD||dcs-32/NN	amod||enterovirusinfection-35/NN||subsequent-34/JJ	prep_from||protected-31/VBD||enterovirusinfection-35/NN	antiviral-28||insuloma-5||no_rel||studies with murine min6 insuloma cells, which were also efficiently phagocytosed, revealed that increased isg expression in dcs upon encountering cvb-infected cells resulted in an antiviral state that protected dcs from subsequent enterovirusinfection.
amod||family-2/NN||high-1/JJ	nsubj||increase-21/VB||family-2/NN	vmod||family-2/NN||loading-3/VBG	prep_for||loading-3/VBG||alcoholism-5/NN	amod||onset-8/NN||early-7/JJ	nsubj||increase-21/VB||onset-8/NN	nn||use-11/NN||alcohol-10/NN	prep_of||onset-8/NN||use-11/NN	nn||behaviors-15/NNS||childhood-13/NN	nn||behaviors-15/NNS||disinhibitory-14/NN	prep_of||onset-8/NN||behaviors-15/NNS	conj_and||use-11/NN||behaviors-15/NNS	vmod||onset-8/NN||persisting-17/VBG	prep_into||persisting-17/VBG||adulthood-19/NN	root||ROOT-0/null||increase-21/VB	det||susceptibility-23/NN||the-22/DT	dobj||increase-21/VB||susceptibility-23/NN	prep_to||increase-21/VB||alcoholism-25/NN	alcoholism-25||alcohol-10||no||high family loading for alcoholism, early onset of alcohol use and childhood disinhibitory behaviors, persisting into adulthood, increase the susceptibility to alcoholism.
nsubjpass||assumed-12/VBN||sorption-1/NN	nsubj||negligible-15/JJ||sorption-1/NN	nsubj||higher-26/JJR||sorption-1/NN	prep_of||sorption-1/NN||venlafaxine-3/NN	prep_of||sorption-1/NN||desmethylvenlafaxine-5/NN	conj_and||venlafaxine-3/NN||desmethylvenlafaxine-5/NN	prep_of||sorption-1/NN||carbamazepine-8/NN	conj_and||venlafaxine-3/NN||carbamazepine-8/NN	prep_on||venlafaxine-3/NN||sludge-10/NN	auxpass||assumed-12/VBN||was-11/VBD	root||ROOT-0/null||assumed-12/VBN	aux||negligible-15/JJ||to-13/TO	cop||negligible-15/JJ||be-14/VB	xcomp||assumed-12/VBN||negligible-15/JJ	dep||negligible-15/JJ||log-17/VB	nn||-20/NNS||kd-18/NN	nn||-20/NNS||â-19/NN	dobj||log-17/VB||-20/NNS	amod||-20/NNS||$-21/$	number||$-21/$||2-22/CD	xcomp||assumed-12/VBN||higher-26/JJR	conj_but||negligible-15/JJ||higher-26/JJR	nn||behavior-28/NN||sorption-27/NN	nsubjpass||expected-31/VBN||behavior-28/NN	aux||expected-31/VBN||can-29/MD	auxpass||expected-31/VBN||be-30/VB	ccomp||higher-26/JJR||expected-31/VBN	prep_for||expected-31/VBN||sertraline-33/NN	dep||negligible-15/JJ||log-35/VB	nn||â-37/NN||kd-36/NN	dobj||log-35/VB||â-37/NN	vmod||â-37/NN||-38/VBG	number||4-40/CD||¥-39/CD	dobj||-38/VBG||4-40/CD	kd-36||carbamazepine-8||no_rel||sorption of venlafaxine, desmethylvenlafaxine, and carbamazepine on sludge was assumed to be negligible (log kd â¤ 2), but higher sorption behavior can be expected for sertraline (log kd â¥ 4).
mark||factor-6/NN||since-1/IN	nsubj||factor-6/NN||inflammation-2/NN	cop||factor-6/NN||is-3/VBZ	det||factor-6/NN||an-4/DT	amod||factor-6/NN||important-5/JJ	advcl||explored-14/VBD||factor-6/NN	det||development-9/NN||the-8/DT	prep_in||factor-6/NN||development-9/NN	amod||tumors-12/NNS||pancreatic-11/JJ	prep_of||development-9/NN||tumors-12/NNS	nsubj||explored-14/VBD||we-13/PRP	root||ROOT-0/null||explored-14/VBD	det||potential-16/NN||the-15/DT	dobj||explored-14/VBD||potential-16/NN	amod||orthotopically-29/NN||diclofenac-18/JJ	aux||inhibit-20/VB||to-19/TO	xcomp||diclofenac-18/JJ||inhibit-20/VB	nn||growth-22/NN||tumor-21/NN	dobj||inhibit-20/VB||growth-22/NN	prep_in||inhibit-20/VB||mice-24/NNS	vmod||mice-24/NNS||inoculated-25/VBN	amod||cells-28/NNS||panco2-27/JJ	prep_with||inoculated-25/VBN||cells-28/NNS	prep_of||potential-16/NN||orthotopically-29/NN	inflammation-2||diclofenac-18||yes||since inflammation is an important factor in the development of pancreatic tumors we explored the potential of diclofenac to inhibit tumor growth in mice inoculated with panco2 cells orthotopically.
det||compound-3/NN||the-1/DT	nn||compound-3/NN||title-2/NN	nsubj||contains-12/VBZ||compound-3/NN	nn||-RSB--10/NNP||-LSB--5/NNP	nn||-RSB--10/NNP||zni2-6/NNP	appos||-RSB--10/NNP||c10h8n2s-8/NNP	appos||compound-3/NN||-RSB--10/NNP	root||ROOT-0/null||contains-12/VBZ	det||ring-16/NN||a-13/DT	amod||ring-16/NN||six-membered-14/JJ	nn||ring-16/NN||chelate-15/NN	dobj||contains-12/VBZ||ring-16/NN	vmod||ring-16/NN||adopting-17/VBG	vmod||ring-16/NN||adopting-17/VBG	conj_and||adopting-17/VBG||adopting-17/VBG	det||conformation-20/NN||a-18/DT	nn||conformation-20/NN||boat-19/NN	dobj||adopting-17/VBG||conformation-20/NN	dobj||coordinated-27/VBN||which-22/WDT	det||atom-25/NN||the-23/DT	nn||atom-25/NN||zn-24/NN	nsubjpass||coordinated-27/VBN||atom-25/NN	auxpass||coordinated-27/VBN||is-26/VBZ	prepc_in||adopting-17/VBG||coordinated-27/VBN	num||ions-31/NNS||two-29/CD	amod||ions-31/NNS||iodide-30/JJ	agent||coordinated-27/VBN||ions-31/NNS	det||atoms-38/NNS||the-34/DT	num||atoms-38/NNS||two-35/CD	amod||atoms-38/NNS||pyridyl-36/JJ	nn||atoms-38/NNS||n-37/NN	agent||adopting-17/VBG||atoms-38/NNS	det||sulfide-43/NN||a-40/DT	amod||sulfide-43/NN||single-41/JJ	amod||sulfide-43/NN||di-2-pyridyl-42/JJ	prep_of||atoms-38/NNS||sulfide-43/NN	vmod||sulfide-43/NN||ligand-44/VBN	det||tetraâhedron-49/NN||a-46/DT	advmod||distorted-48/JJ||slightly-47/RB	amod||tetraâhedron-49/NN||distorted-48/JJ	prep_within||ligand-44/VBN||tetraâhedron-49/NN	sulfide-43||di--1||no_rel||the title compound, [zni2(c10h8n2s)], contains a six-membered chelate ring adopting a boat conformation in which the zn atom is coordinated by two iodide ions and by the two pyridyl n atoms of a single di-2-pyridyl sulfide ligand within a slightly distorted tetraâ­hedron.
nsubj||due-3/JJ||this-1/DT	cop||due-3/JJ||is-2/VBZ	root||ROOT-0/null||due-3/JJ	prep_in||due-3/JJ||part-5/NN	amod||suppression-9/NN||impaired-7/VBN	amod||suppression-9/NN||insulin-induced-8/JJ	prep_to||due-3/JJ||suppression-9/NN	amod||production-13/NN||endogenous-11/JJ	nn||production-13/NN||glucose-12/NN	prep_of||suppression-9/NN||production-13/NN	nsubjpass||observed-17/VBN||production-13/NN	auxpass||observed-17/VBN||is-16/VBZ	rcmod||production-13/NN||observed-17/VBN	advmod||observed-17/VBN||early-18/RB	det||evolution-21/NN||the-20/DT	prep_in||observed-17/VBN||evolution-21/NN	prep_of||evolution-21/NN||type2diabetes-23/CD	insulin--1||type2diabetes-23||no_rel||this is due in part to impaired insulin-induced suppression of endogenous glucose production, which is observed early in the evolution of type2diabetes.
det||study-2/NN||the-1/DT	nsubjpass||undertaken-4/VBN||study-2/NN	nsubj||investigate-6/VB||study-2/NN	nsubj||basal-19/VB||study-2/NN	nsubj||precore-26/VB||study-2/NN	auxpass||undertaken-4/VBN||was-3/VBD	root||ROOT-0/null||undertaken-4/VBN	aux||investigate-6/VB||to-5/TO	xcomp||undertaken-4/VBN||investigate-6/VB	det||features-8/NNS||the-7/DT	dobj||investigate-6/VB||features-8/NNS	amod||implications-11/NNS||clinical-10/JJ	dobj||investigate-6/VB||implications-11/NNS	conj_and||features-8/NNS||implications-11/NNS	amod||genotypes-17/NNS||hepatitisbvirus-13/JJ	appos||genotypes-17/NNS||hbv-15/NN	prep_of||implications-11/NNS||genotypes-17/NNS	xcomp||undertaken-4/VBN||basal-19/VB	conj_and||investigate-6/VB||basal-19/VB	nn||promoter-21/NN||core-20/NN	dobj||basal-19/VB||promoter-21/NN	appos||promoter-21/NN||bcp-23/NN	xcomp||undertaken-4/VBN||precore-26/VB	conj_and||investigate-6/VB||precore-26/VB	appos||mutations-30/NNS||pc-28/NN	dobj||precore-26/VB||mutations-30/NNS	amod||liverfailure-34/NN||hepatitisb-related-32/JJ	amod||liverfailure-34/NN||acute-on-chronic-33/JJ	prep_in||precore-26/VB||liverfailure-34/NN	dep||liverfailure-34/NN||hb-aclf-36/JJ	hbv-15||hepatitisbvirus-13||no||the study was undertaken to investigate the features and clinical implications of hepatitisbvirus (hbv) genotypes, basal core promoter (bcp) and precore (pc) mutations in hepatitisb-related acute-on-chronic liverfailure (hb-aclf).
amod||treatment-3/NN||closed-loop-2/JJ	prep_during||decreased-13/VBD||treatment-3/NN	prep_in||treatment-3/NN||subjects-5/NNS	prep_with||subjects-5/NNS||type1diabetes-7/CD	amod||pulses-10/NNS||high-gain-9/JJ	nsubj||decreased-13/VBD||pulses-10/NNS	prep_of||pulses-10/NNS||glucagon-12/NN	root||ROOT-0/null||decreased-13/VBD	det||frequency-15/NN||the-14/DT	dobj||decreased-13/VBD||frequency-15/NN	prep_of||frequency-15/NN||hypoglycemia-17/NN	hypoglycemia-17||glucagon-12||yes||during closed-loop treatment in subjects with type1diabetes, high-gain pulses of glucagon decreased the frequency of hypoglycemia.
nsubj||medication-6/NN||ranolazine-1/NN	nsubjpass||considered-16/VBN||ranolazine-1/NN	cop||medication-6/NN||is-2/VBZ	det||medication-6/NN||a-3/DT	amod||medication-6/NN||proven-4/JJ	amod||medication-6/NN||antianginal-5/JJ	root||ROOT-0/null||medication-6/NN	prep_in||medication-6/NN||patients-8/NNS	amod||coronaryheartdisease-11/NN||symptomatic-10/JJ	prep_with||patients-8/NNS||coronaryheartdisease-11/NN	aux||considered-16/VBN||should-14/MD	auxpass||considered-16/VBN||be-15/VB	conj_and||medication-6/NN||considered-16/VBN	det||agent-21/NN||an-18/DT	amod||agent-21/NN||initial-19/JJ	amod||agent-21/NN||antianginal-20/JJ	prep_as||considered-16/VBN||agent-21/NN	prep_for||agent-21/NN||those-23/DT	prep_with||those-23/DT||hypotension-25/NN	prep_with||those-23/DT||bradycardia-27/NN	conj_or||hypotension-25/NN||bradycardia-27/NN	coronaryheartdisease-11||antianginal-20||no_rel||ranolazine is a proven antianginal medication in patients with symptomatic coronaryheartdisease, and should be considered as an initial antianginal agent for those with hypotension or bradycardia.
nsubj||was-6/VBD||objective-1/NN	nsubj||investigate-8/VB||objective-1/NN	det||study-5/NN||this-3/DT	amod||study-5/NN||prospective-4/JJ	prep_of||objective-1/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||investigate-8/VB||to-7/TO	xcomp||was-6/VBD||investigate-8/VB	amod||use-10/NN||clinical-9/JJ	dobj||investigate-8/VB||use-10/NN	amod||value-13/NN||prognostic-12/JJ	dobj||investigate-8/VB||value-13/NN	conj_and||use-10/NN||value-13/NN	amod||angle-17/NN||bia-derived-15/JJ	nn||angle-17/NN||phase-16/NN	prep_of||use-10/NN||angle-17/NN	dobj||investigate-8/VB||alterations-19/NNS	conj_and||use-10/NN||alterations-19/NNS	nn||composition-22/NN||body-21/NN	prep_in||alterations-19/NNS||composition-22/NN	prep_for||investigate-8/VB||hepatitiscinfection-24/NN	appos||hepatitiscinfection-24/NN||hcv-26/NN	amod||therapy-30/NN||antiviral-29/JJ	prep_following||hepatitiscinfection-24/NN||therapy-30/NN	hepatitiscinfection-24||hcv-26||no||objective of this prospective study was to investigate clinical use and prognostic value of bia-derived phase angle and alterations in body composition for hepatitiscinfection (hcv) following antiviral therapy.
nsubj||antipsychoticdrug-5/NN||aripiprazole-1/NN	cop||antipsychoticdrug-5/NN||is-2/VBZ	det||antipsychoticdrug-5/NN||an-3/DT	amod||antipsychoticdrug-5/NN||atypical-4/JJ	root||ROOT-0/null||antipsychoticdrug-5/NN	vmod||antipsychoticdrug-5/NN||approved-6/VBN	det||treatment-9/NN||the-8/DT	prep_for||approved-6/VBN||treatment-9/NN	amod||disorders-12/NNS||psychiatric-11/JJ	prep_of||treatment-9/NN||disorders-12/NNS	nn||depressivedisorder-20/NN||schizophrenia-15/NN	prep_such_as||disorders-12/NNS||bipolardisorder-17/NN	conj_and||depressivedisorder-20/NN||bipolardisorder-17/NN	prep_such_as||disorders-12/NNS||major-19/JJ	amod||depressivedisorder-20/NN||major-19/JJ	conj_and||depressivedisorder-20/NN||major-19/JJ	prep_such_as||disorders-12/NNS||depressivedisorder-20/NN	prep_such_as||disorders-12/NNS||autism-22/NN	conj_and||depressivedisorder-20/NN||autism-22/NN	autism-22||aripiprazole-1||no_rel||aripiprazole is an atypical antipsychoticdrug approved for the treatment of psychiatric disorders such as schizophrenia, bipolardisorder, major depressivedisorder and autism.
amod||advances-2/NNS||recent-1/JJ	nsubjpass||based-10/VBN||advances-2/NNS	det||virology-6/NN||the-4/DT	amod||virology-6/NN||clinical-5/JJ	prep_in||advances-2/NNS||virology-6/NN	prep_of||virology-6/NN||influenza-8/NN	auxpass||based-10/VBN||are-9/VBP	root||ROOT-0/null||based-10/VBN	amod||research-14/NN||non-pragmatically-12/JJ	amod||research-14/NN||oriented-13/JJ	prep_on||based-10/VBN||research-14/NN	det||genetics-17/NNS||the-16/DT	prep_on||based-10/VBN||genetics-17/NNS	prep_on||based-10/VBN||biochemistry-19/NN	conj_and||genetics-17/NNS||biochemistry-19/NN	det||influenzavirus-22/NNS||the-21/DT	prep_of||genetics-17/NNS||influenzavirus-22/NNS	influenza-8||influenzavirus-22||no||recent advances in the clinical virology of influenza are based on non-pragmatically oriented research on the genetics and biochemistry of the influenzavirus.
mark||likely-14/JJ||since-1/IN	det||part-4/NN||a-2/DT	amod||part-4/NN||significant-3/JJ	nsubj||likely-14/JJ||part-4/NN	nsubj||relate-16/VB||part-4/NN	det||diversity-8/NN||the-6/DT	amod||diversity-8/NN||clinicopathological-7/JJ	prep_of||part-4/NN||diversity-8/NN	vmod||diversity-8/NN||seen-9/VBN	amod||priondisease-12/NN||human-11/JJ	prep_in||seen-9/VBN||priondisease-12/NN	cop||likely-14/JJ||is-13/VBZ	advcl||compared-28/VBN||likely-14/JJ	aux||relate-16/VB||to-15/TO	xcomp||likely-14/JJ||relate-16/VB	det||propagation-19/NN||the-18/DT	prep_to||relate-16/VB||propagation-19/NN	amod||strains-24/NNS||distinct-21/JJ	amod||strains-24/NNS||human-22/JJ	nn||strains-24/NNS||prion-23/NN	prep_of||propagation-19/NN||strains-24/NNS	nsubj||compared-28/VBN||we-26/PRP	aux||compared-28/VBN||have-27/VBP	root||ROOT-0/null||compared-28/VBN	det||properties-31/NNS||the-29/DT	nn||properties-31/NNS||transmission-30/NN	dobj||compared-28/VBN||properties-31/NNS	amod||prions-34/NNS||kuru-33/JJ	prep_of||properties-31/NNS||prions-34/NNS	prep_with||compared-28/VBN||those-36/DT	vmod||those-36/DT||isolated-37/VBN	prep_from||isolated-37/VBN||patients-39/NNS	amod||cjd-46/NN||sporadic-41/JJ	conj_and||sporadic-41/JJ||iatrogenic-43/JJ	amod||cjd-46/NN||iatrogenic-43/JJ	conj_and||sporadic-41/JJ||variant-45/JJ	amod||cjd-46/NN||variant-45/JJ	prep_with||patients-39/NNS||cjd-46/NN	preconj||transgenic-49/JJ||both-48/DT	amod||mice-52/NNS||transgenic-49/JJ	conj_and||transgenic-49/JJ||wild-type-51/JJ	amod||mice-52/NNS||wild-type-51/JJ	prep_in||cjd-46/NN||mice-52/NNS	prion-23||kuru-33||no_rel||since a significant part of the clinicopathological diversity seen in human priondisease is likely to relate to the propagation of distinct human prion strains, we have compared the transmission properties of kuru prions with those isolated from patients with sporadic, iatrogenic and variant cjd in both transgenic and wild-type mice.
nn||ebvinfection-2/NN||recurrent-1/NN	nsubjpass||demonstrated-4/VBN||ebvinfection-2/NN	auxpass||demonstrated-4/VBN||was-3/VBD	root||ROOT-0/null||demonstrated-4/VBN	det||presence-7/NN||the-6/DT	agent||demonstrated-4/VBN||presence-7/NN	amod||antibodies-13/NNS||anti-ebv-9/JJ	amod||antibodies-13/NNS||early-10/JJ	nn||antibodies-13/NNS||antigen-11/NN	nn||antibodies-13/NNS||igm-12/NN	prep_of||presence-7/NN||antibodies-13/NNS	amod||antibodies-19/NNS||anti-ebv-15/JJ	amod||antibodies-19/NNS||nuclear-16/JJ	nn||antibodies-19/NNS||antigen-17/NN	nn||antibodies-19/NNS||igg-18/NN	prep_of||presence-7/NN||antibodies-19/NNS	conj_and||antibodies-13/NNS||antibodies-19/NNS	ebvinfection-2||ebv--1||no||recurrent ebvinfection was demonstrated by the presence of anti-ebv early antigen igm antibodies and anti-ebv nuclear antigen igg antibodies.
nsubj||had-11/VBN||efforts-1/NNS	prep_at||efforts-1/NNS||prevention-3/NN	prep_of||prevention-3/NN||pre-eclampsia-5/NN	prep_with||pre-eclampsia-5/NN||aspirin-7/NN	prep_with||pre-eclampsia-5/NN||calcium-9/NN	conj_and||aspirin-7/NN||calcium-9/NN	aux||had-11/VBN||have-10/VBP	root||ROOT-0/null||had-11/VBN	amod||success-13/NN||limited-12/JJ	dobj||had-11/VBN||success-13/NN	nsubj||encouraging-28/VBG||research-16/NN	amod||factors-20/NNS||modifiable-18/JJ	nn||factors-20/NNS||risk-19/NN	prep_on||research-16/NN||factors-20/NNS	amod||surgery-25/NN||obesity-24/JJ	prep_such_as||research-16/NN||surgery-25/NN	cop||encouraging-28/VBG||are-27/VBP	conj_but||had-11/VBN||encouraging-28/VBG	pre-eclampsia-5||aspirin-7||yes||efforts at prevention of pre-eclampsia with aspirin and calcium have had limited success, but research on modifiable risk factors, such as obesity surgery, are encouraging.
advmod||report-15/VBP||here-1/RB	det||coexistence-6/NN||a-4/DT	amod||coexistence-6/NN||unique-5/JJ	prep_as||report-15/VBP||coexistence-6/NN	det||entities-12/NNS||these-8/DT	num||entities-12/NNS||two-9/CD	amod||entities-12/NNS||seperated-10/JJ	amod||entities-12/NNS||clinical-11/JJ	prep_of||coexistence-6/NN||entities-12/NNS	nsubj||report-15/VBP||we-14/PRP	root||ROOT-0/null||report-15/VBP	det||woman-18/NN||a-16/DT	amod||woman-18/NN||30-yr-old-17/JJ	dobj||report-15/VBP||woman-18/NN	vmod||woman-18/NN||presenting-19/VBG	amod||spasm-22/NN||carpal-21/JJ	prep_with||presenting-19/VBG||spasm-22/NN	vmod||spasm-22/NN||related-23/VBN	amod||preparation-42/NN||hypocalcemia-25/JJ	amod||calcium-28/NN||ionized-27/JJ	dep||preparation-42/NN||calcium-28/NN	num||mm/l-31/NN||1.90-30/CD	prep_of||calcium-28/NN||mm/l-31/NN	amod||preparation-42/NN||due-33/JJ	aux||acute-35/VB||to-34/TO	xcomp||due-33/JJ||acute-35/VB	amod||poisoning-37/NN||phosphate-36/JJ	dobj||acute-35/VB||poisoning-37/NN	amod||bowel-41/NN||oral-39/JJ	nn||bowel-41/NN||sodiumphosphate-40/NN	prep_after||acute-35/VB||bowel-41/NN	prep_to||related-23/VBN||preparation-42/NN	nsubj||resolved-45/VBN||preparation-42/NN	rcmod||preparation-42/NN||resolved-45/VBN	advmod||resolved-45/VBN||rapidly-46/RB	nn||gluconate-49/NN||calcium-48/NN	prep_after||resolved-45/VBN||gluconate-49/NN	advmod||resolved-45/VBN||intravenously-50/RB	hypocalcemia-25||sodiumphosphate-40||no_rel||here, as a unique coexistence of these two seperated clinical entities, we report a 30-yr-old woman presenting with carpal spasm related to hypocalcemia (ionized calcium of 1.90 mm/l) due to acute phosphate poisoning after oral sodiumphosphate bowel preparation, which resolved rapidly after calcium gluconate intravenously.
det||model-5/NN||the-2/DT	nn||model-5/NN||nod-3/NN	nn||model-5/NN||mouse-4/NN	prep_in||induces-15/VBZ||model-5/NN	prep_of||model-5/NN||type1diabetes-7/CD	amod||administration-12/NN||oral-9/JJ	conj_or||oral-9/JJ||nasal-11/JJ	amod||administration-12/NN||nasal-11/JJ	nsubj||induces-15/VBZ||administration-12/NN	nsubj||protects-21/VBZ||administration-12/NN	prep_of||administration-12/NN||insulin-14/NN	root||ROOT-0/null||induces-15/VBZ	amod||tolerance-17/NN||immune-16/JJ	dobj||induces-15/VBZ||tolerance-17/NN	prep_to||induces-15/VBZ||insulin-19/NN	conj_and||induces-15/VBZ||protects-21/VBZ	amod||diabetes-24/NN||autoimmune-23/JJ	prep_against||protects-21/VBZ||diabetes-24/NN	type1diabetes-7||insulin-19||yes||in the nod mouse model of type1diabetes, oral or nasal administration of insulin induces immune tolerance to insulin and protects against autoimmune diabetes.
nsubj||continues-4/VBZ||background-1/NN	nsubj||commit-6/VB||background-1/NN	prep_as||background-1/NN||china-3/NN	ccomp||become-23/VBN||continues-4/VBZ	aux||commit-6/VB||to-5/TO	xcomp||continues-4/VBZ||commit-6/VB	amod||access-9/NN||universal-8/JJ	prep_to||commit-6/VB||access-9/NN	amod||services-17/NNS||hiv/aids-11/JJ	nn||services-17/NNS||prevention-12/NN	conj_and||prevention-12/NN||treatment-14/NN	nn||services-17/NNS||treatment-14/NN	conj_and||prevention-12/NN||care-16/NN	nn||services-17/NNS||care-16/NN	prep_to||commit-6/VB||services-17/NNS	poss||policies-21/NNS||its-19/PRP$	amod||policies-21/NNS||hiv/aids-20/JJ	nsubj||become-23/VBN||policies-21/NNS	aux||become-23/VBN||have-22/VBP	root||ROOT-0/null||become-23/VBN	advmod||information-25/NN||increasingly-24/RB	xcomp||become-23/VBN||information-25/NN	vmod||information-25/NN||driven-26/VBN	aids--1||hiv--1||no||background as china continues to commit to universal access to hiv/aids prevention, treatment and care services, its hiv/aids policies have become increasingly information driven.
prep_objectiveâ||suggested-7/VBN||$-2/$	nsubjpass||suggested-7/VBN||it-4/PRP	aux||suggested-7/VBN||has-5/VBZ	auxpass||suggested-7/VBN||been-6/VBN	root||ROOT-0/null||suggested-7/VBN	mark||links-15/VBZ||that-8/IN	amod||protein-10/NN||retinol-binding-9/JJ	nsubj||links-15/VBZ||protein-10/NN	num||protein-10/NN||4-11/CD	appos||protein-10/NN||rbp4-13/NNP	ccomp||suggested-7/VBN||links-15/VBZ	dobj||links-15/VBZ||adiposity-16/NN	dobj||links-15/VBZ||insulinresistance-18/NN	conj_and||adiposity-16/NN||insulinresistance-18/NN	dobj||links-15/VBZ||type2diabetes-21/NN	conj_and||adiposity-16/NN||type2diabetes-21/NN	retinol--1||type2diabetes-21||no_rel||objectiveâ it has been suggested that retinol-binding protein 4 (rbp4) links adiposity, insulinresistance, and type2diabetes.
amod||trials-3/NNS||published-1/VBN	amod||trials-3/NNS||double-blind-2/JJ	nsubj||show-4/VBP||trials-3/NNS	root||ROOT-0/null||show-4/VBP	mark||achieves-12/VBZ||that-5/IN	amod||therapy-7/NN||budesonide/formoterol-6/JJ	nsubj||achieves-12/VBZ||therapy-7/NN	vmod||therapy-7/NN||delivered-8/VBN	amod||fashion-11/NN||smart-10/JJ	prep_in||delivered-8/VBN||fashion-11/NN	ccomp||show-4/VBP||achieves-12/VBZ	amod||outcomes-15/NNS||better-13/JJR	nn||outcomes-15/NNS||asthma-14/NN	dobj||achieves-12/VBZ||outcomes-15/NNS	amod||monotherapy-18/NN||budesonide-17/JJ	prep_than||achieves-12/VBZ||monotherapy-18/NN	amod||doses-21/NNS||lower-20/JJR	prep_than||achieves-12/VBZ||doses-21/NNS	conj_or||monotherapy-18/NN||doses-21/NNS	amod||therapy-24/NN||budesonide/formoterol-23/JJ	prep_of||doses-21/NNS||therapy-24/NN	vmod||therapy-24/NN||delivered-25/VBN	amod||dosage-28/NN||constant-27/JJ	prep_in||delivered-25/VBN||dosage-28/NN	asthma-14||formoterol--1||no||published double-blind trials show that budesonide/formoterol therapy delivered in smart fashion achieves better asthma outcomes than budesonide monotherapy or lower doses of budesonide/formoterol therapy delivered in constant dosage.
amod||virus-3/NN||feline-1/JJ	nn||virus-3/NN||immunodeficiency-2/NN	nsubj||lentivirus-9/NNS||virus-3/NN	appos||virus-3/NN||fiv-5/NN	cop||lentivirus-9/NNS||is-7/VBZ	det||lentivirus-9/NNS||a-8/DT	root||ROOT-0/null||lentivirus-9/NNS	dep||lentivirus-9/NNS||associated-10/VBN	amod||illnesses-13/NNS||aids-like-12/JJ	prep_with||associated-10/VBN||illnesses-13/NNS	prep_in||illnesses-13/NNS||cats-15/NNS	aux||used-19/VBN||has-17/VBZ	auxpass||used-19/VBN||been-18/VBN	dep||lentivirus-9/NNS||used-19/VBN	conj_and||associated-10/VBN||used-19/VBN	det||model-22/NN||a-21/DT	prep_as||used-19/VBN||model-22/NN	det||study-25/NN||the-24/DT	prep_for||model-22/NN||study-25/NN	prep_of||study-25/NN||humanimmunodeficiencyvirus-27/NNS	appos||humanimmunodeficiencyvirus-27/NNS||hiv-29/NN	aids--1||hiv-29||no||feline immunodeficiency virus (fiv) is a lentivirus associated with aids-like illnesses in cats and has been used as a model for the study of humanimmunodeficiencyvirus (hiv).
amod||profiles-4/NNS||multiple-1/JJ	amod||profiles-4/NNS||antibiotic-2/JJ	nn||profiles-4/NNS||resistance-3/NN	nsubjpass||determined-9/VBN||profiles-4/NNS	det||countries-7/NNS||both-6/DT	prep_from||profiles-4/NNS||countries-7/NNS	auxpass||determined-9/VBN||were-8/VBD	root||ROOT-0/null||determined-9/VBN	det||total-12/NN||a-11/DT	nsubjpass||seen-19/VBN||total-12/NN	amod||profiles-17/NNS||forty-two-14/JJ	conj_and||forty-two-14/JJ||forty-five-16/JJ	amod||profiles-17/NNS||forty-five-16/JJ	prep_of||total-12/NN||profiles-17/NNS	auxpass||seen-19/VBN||were-18/VBD	conj_and||determined-9/VBN||seen-19/VBN	det||cohort-23/NN||the-21/DT	nn||cohort-23/NN||uk-22/NN	prep_in||seen-19/VBN||cohort-23/NN	nn||respectively-28/NN||mrsa-25/NN	conj_and||mrsa-25/NN||mssa-27/NN	nn||respectively-28/NN||mssa-27/NN	appos||cohort-23/NN||respectively-28/NN	amod||profiles-36/NNS||comparatively-31/JJ	conj_and||comparatively-31/JJ||sixty-two-33/JJ	amod||profiles-36/NNS||sixty-two-33/JJ	conj_and||comparatively-31/JJ||fifty-two-35/JJ	amod||profiles-36/NNS||fifty-two-35/JJ	nsubjpass||shown-38/VBN||profiles-36/NNS	auxpass||shown-38/VBN||were-37/VBD	conj_and||determined-9/VBN||shown-38/VBN	det||group-42/NN||the-40/DT	amod||group-42/NN||maltese-41/JJ	prep_in||shown-38/VBN||group-42/NN	mrsa-25||antibiotic-2||no_rel||multiple antibiotic resistance profiles from both countries were determined, a total of forty-two and forty-five profiles were seen in the uk cohort (mrsa and mssa respectively) and comparatively, sixty-two and fifty-two profiles were shown in the maltese group.
nn||content-3/NN||bone-1/NN	nn||content-3/NN||mineral-2/NN	nsubj||different-21/JJ||content-3/NN	appos||content-3/NN||bmc-5/NN	nn||density-10/NN||bone-8/NN	nn||density-10/NN||mineral-9/NN	conj_and||content-3/NN||density-10/NN	nsubj||different-21/JJ||density-10/NN	appos||density-10/NN||bmd-12/NN	det||group-17/NN||the-15/DT	nn||group-17/NN||sle-16/NN	prep_in||density-10/NN||group-17/NN	cop||different-21/JJ||was-18/VBD	neg||different-21/JJ||not-19/RB	advmod||different-21/JJ||significantly-20/RB	root||ROOT-0/null||different-21/JJ	det||controls-24/NNS||the-23/DT	prep_from||different-21/JJ||controls-24/NNS	neg||relationship-28/NN||no-27/DT	nsubjpass||found-30/VBN||relationship-28/NN	auxpass||found-30/VBN||was-29/VBD	conj_and||different-21/JJ||found-30/VBN	det||exposure-34/NN||the-32/DT	amod||exposure-34/NN||glucocorticoid-33/JJ	prep_between||found-30/VBN||exposure-34/NN	det||bmc/bmd-37/NN||the-36/DT	prep_between||found-30/VBN||bmc/bmd-37/NN	conj_and||exposure-34/NN||bmc/bmd-37/NN	sle-16||glucocorticoid-33||no_rel||bone mineral content (bmc) and bone mineral density (bmd) in the sle group was not significantly different from the controls, and no relationship was found between the glucocorticoid exposure and the bmc/bmd.
amod||model-5/NN||castoroil-2/JJ	amod||model-5/NN||induced-3/JJ	nn||model-5/NN||diarrhea-4/NN	prep_in||reduced-33/VBD||model-5/NN	det||extract-12/NN||the-7/DT	number||%-9/NN||80-8/CD	amod||extract-12/NN||%-9/NN	nn||extract-12/NN||methanol-10/NN	nn||extract-12/NN||leaf-11/NN	nsubj||reduced-33/VBD||extract-12/NN	nn||aurea-15/NN||c.-14/NN	prep_of||extract-12/NN||aurea-15/NN	prep_at||aurea-15/NN||100-17/CD	num||100-17/CD||200-19/CD	prep_at||aurea-15/NN||400-21/CD	conj_and||100-17/CD||400-21/CD	amod||aurea-15/NN||mg/kg-22/JJ	det||drug-26/NN||the-24/DT	amod||drug-26/NN||standard-25/JJ	amod||aurea-15/NN||drug-26/NN	conj_and||mg/kg-22/JJ||drug-26/NN	advmod||drug-26/NN||loperamide-27/RB	number||3-29/CD||-lrb--28/CD	num||-rrb--31/NNS||3-29/CD	amod||-rrb--31/NNS||mg/kg-30/JJ	dep||mg/kg-22/JJ||-rrb--31/NNS	advmod||reduced-33/VBD||significantly-32/RB	root||ROOT-0/null||reduced-33/VBD	det||time-35/NN||the-34/DT	dobj||reduced-33/VBD||time-35/NN	prep_of||time-35/NN||onset-37/NN	prep_of||onset-37/NN||diarrhea-39/NN	det||frequency-42/NN||the-41/DT	prep_of||time-35/NN||frequency-42/NN	conj_and||onset-37/NN||frequency-42/NN	nn||number-47/NN||defecation-44/NN	nn||number-47/NN||-lrb--45/NNP	amod||number-47/NN||total-46/JJ	prep_of||frequency-42/NN||number-47/NN	amod||-rrb--51/NNS||faecal-49/JJ	nn||-rrb--51/NNS||output-50/NN	prep_of||frequency-42/NN||-rrb--51/NNS	prep_of||time-35/NN||weight-53/NN	conj_and||onset-37/NN||weight-53/NN	prep_of||weight-53/NN||faeces-55/NNS	diarrhea-39||castoroil-2||no||in castoroil induced diarrhea model , the 80 % methanol leaf extract of c. aurea at 100 , 200 and 400 mg/kg and the standard drug loperamide -lrb- 3 mg/kg -rrb- significantly reduced the time of onset of diarrhea , the frequency of defecation -lrb- total number of faecal output -rrb- and weight of faeces .
advmod||found-4/VBD||recently-1/RB	nsubj||found-4/VBD||we-3/PRP	root||ROOT-0/null||found-4/VBD	mark||enhanced-20/VBD||that-5/IN	det||model-12/NN||a-7/DT	nn||model-12/NN||chemically-8/NNP	nn||model-12/NN||induced-9/NNP	nn||model-12/NN||skin-10/NN	nn||model-12/NN||carcinoma-11/NN	prep_in||enhanced-20/VBD||model-12/NN	amod||drainage-16/NN||increased-14/VBN	amod||drainage-16/NN||vegf-c-15/JJ	nsubj||enhanced-20/VBD||drainage-16/NN	nsubj||facilitated-28/VBD||drainage-16/NN	det||tumor-19/NN||the-18/DT	prep_from||drainage-16/NN||tumor-19/NN	ccomp||found-4/VBD||enhanced-20/VBD	dobj||enhanced-20/VBD||lymphangiogenesis-21/NNS	det||node-26/NN||the-23/DT	amod||node-26/NN||sentinel-24/JJ	nn||node-26/NN||lymph-25/NN	prep_in||enhanced-20/VBD||node-26/NN	ccomp||found-4/VBD||facilitated-28/VBD	conj_and||enhanced-20/VBD||facilitated-28/VBD	amod||spread-30/NN||metastatic-29/JJ	dobj||facilitated-28/VBD||spread-30/NN	nn||cells-33/NNS||cancer-32/NN	prep_of||spread-30/NN||cells-33/NNS	det||lymphatics-36/NNS||the-35/DT	prep_via||cells-33/NNS||lymphatics-36/NNS	carcinoma-11||chemically-8||no_rel||recently, we found that in a chemically induced skin carcinoma model, increased vegf-c drainage from the tumor enhanced lymphangiogenesis in the sentinel lymph node and facilitated metastatic spread of cancer cells via the lymphatics.
nsubjpass||computed-10/VBN||association-1/NN	amod||survival-4/NN||overall-3/JJ	prep_between||association-1/NN||survival-4/NN	nn||levels-8/NNS||serum-6/NN	nn||levels-8/NNS||25ohd-7/NNS	prep_between||association-1/NN||levels-8/NNS	conj_and||survival-4/NN||levels-8/NNS	auxpass||computed-10/VBN||were-9/VBD	ccomp||adjuvant-49/VBD||computed-10/VBN	xcomp||computed-10/VBN||using-11/VBG	det||model-16/NN||the-12/DT	amod||model-16/NN||cox-13/JJ	amod||model-16/NN||proportional-14/JJ	nn||model-16/NN||hazard-15/NN	dobj||using-11/VBG||model-16/NN	vmod||model-16/NN||adjusted-17/VBN	prep_for||adjusted-17/VBN||month-19/NN	nn||sampling-22/NN||serum-21/NN	prep_of||month-19/NN||sampling-22/NN	dobj||using-11/VBG||age-26/NN	conj_and||model-16/NN||age-26/NN	prep_at||age-26/NN||diagnosis-28/NN	nsubj||adjuvant-49/VBD||gender-30/NN	nn||stage-33/NN||cancer-32/NN	appos||gender-30/NN||stage-33/NN	amod||tumor-36/NN||residual-35/JJ	appos||gender-30/NN||tumor-36/NN	prep_after||tumor-36/NN||surgery-38/NN	nn||period-41/NN||time-40/NN	appos||gender-30/NN||period-41/NN	prep_of||period-41/NN||surgery-43/NN	appos||gender-30/NN||location-45/NN	prep_of||location-45/NN||tumor-47/NN	root||ROOT-0/null||adjuvant-49/VBD	dobj||adjuvant-49/VBD||chemotherapy-50/NN	dobj||adjuvant-49/VBD||number-52/NN	conj_and||chemotherapy-50/NN||number-52/NN	nn||nodes-55/NNS||lymph-54/NN	prep_of||chemotherapy-50/NN||nodes-55/NNS	prep_with||adjuvant-49/VBD||metastasis-57/NNS	prep_at||metastasis-57/NNS||surgery-59/NN	tumor-47||adjuvant-49||no_rel||association between overall survival and serum 25ohd levels were computed using the cox proportional hazard model adjusted for month of serum sampling as well as age at diagnosis, gender, cancer stage, residual tumor after surgery, time period of surgery, location of tumor, adjuvant chemotherapy and number of lymph nodes with metastasis at surgery.
poss||use-3/NN||their-1/PRP$	amod||use-3/NN||tramadol-2/JJ	nsubj||begun-5/VBN||use-3/NN	nsubj||begun-5/VBN||use-3/NN	aux||begun-5/VBN||had-4/VBD	root||ROOT-0/null||begun-5/VBN	conj_and||begun-5/VBN||begun-5/VBN	det||prescription-8/NN||a-7/DT	prep_with||begun-5/VBN||prescription-8/NN	prep_of||prescription-8/NN||tramadol-10/NN	amod||detoxification-13/NN||opioid-12/JJ	prep_for||begun-5/VBN||detoxification-13/NN	nn||pains-19/NNS||headache-16/NN	conj_and||headache-16/NN||body-18/NN	nn||pains-19/NNS||body-18/NN	prep_for||begun-5/VBN||pains-19/NNS	det||alternative-24/NN||an-23/DT	prep_as||begun-5/VBN||alternative-24/NN	aux||injectable-26/VB||to-25/TO	vmod||alternative-24/NN||injectable-26/VB	dobj||injectable-26/VB||opioids-27/NNS	pains-19||tramadol-10||yes||their tramadol use had begun with a prescription of tramadol for opioid detoxification, for headache and body pains, and as an alternative to injectable opioids.
det||group-4/NN||the-2/DT	amod||group-4/NN||met-anov-3/JJ	prep_in||observed-10/VBN||group-4/NN	neg||correlation-8/NN||no-6/DT	amod||correlation-8/NN||significant-7/JJ	nsubjpass||observed-10/VBN||correlation-8/NN	auxpass||observed-10/VBN||was-9/VBD	root||ROOT-0/null||observed-10/VBN	nn||concentrations-13/NNS||amh-12/NN	prep_between||observed-10/VBN||concentrations-13/NNS	det||fluid-17/NN||the-15/DT	nn||fluid-17/NN||follicular-16/NN	prep_in||concentrations-13/NNS||fluid-17/NN	prep_in||concentrations-13/NNS||variation-19/NN	conj_and||fluid-17/NN||variation-19/NN	nn||androgens-22/NNS||serum-21/NN	prep_in||fluid-17/NN||androgens-22/NNS	amod||indexes-27/NNS||amh-24/JJ	conj_and||amh-24/JJ||insulinresistance-26/JJ	amod||indexes-27/NNS||insulinresistance-26/JJ	appos||fluid-17/NN||indexes-27/NNS	mark||detected-36/VBN||whereas-29/IN	amod||group-32/NN||met-ov-31/JJ	prep_in||detected-36/VBN||group-32/NN	amod||correlations-34/NNS||significant-33/JJ	nsubjpass||detected-36/VBN||correlations-34/NNS	auxpass||detected-36/VBN||were-35/VBD	advcl||observed-10/VBN||detected-36/VBN	nn||levels-39/NNS||amh-38/NN	prep_between||detected-36/VBN||levels-39/NNS	det||fluid-43/NN||the-41/DT	nn||fluid-43/NN||follicular-42/NN	prep_in||levels-39/NNS||fluid-43/NN	prep_in||levels-39/NNS||variation-45/NN	conj_and||fluid-43/NN||variation-45/NN	amod||indexes-53/NNS||serum-47/JJ	nn||indexes-53/NNS||androgens-48/NNS	conj_and||androgens-48/NNS||amh-50/NN	nn||indexes-53/NNS||amh-50/NN	conj_and||androgens-48/NNS||insulinresistance-52/NN	nn||indexes-53/NNS||insulinresistance-52/NN	prep_in||fluid-43/NN||indexes-53/NNS	androgens-48||insulinresistance-52||no_rel||in the met-anov group, no significant correlation was observed between amh concentrations in the follicular fluid and variation in serum androgens, amh and insulinresistance indexes; whereas in met-ov group significant correlations were detected between amh levels in the follicular fluid and variation in serum androgens, amh and insulinresistance indexes.
nsubjpass||reviewed-33/VBN||statements-1/NNS	det||effects-4/NNS||the-3/DT	prep_regarding||statements-1/NNS||effects-4/NNS	amod||use-9/NN||preoperative-6/JJ	nn||use-9/NN||somatostatin-7/NN	nn||use-9/NN||analog-8/NN	prep_of||effects-4/NNS||use-9/NN	amod||outcomes-13/NNS||pituitary-11/JJ	amod||outcomes-13/NNS||surgical-12/JJ	prep_on||use-9/NN||outcomes-13/NNS	poss||effects-16/NNS||their-15/PRP$	prep_of||effects-4/NNS||effects-16/NNS	conj_and||use-9/NN||effects-16/NNS	nn||control-21/NN||hormone-18/NN	conj_and||hormone-18/NN||symptom-20/NN	nn||control-21/NN||symptom-20/NN	prep_on||effects-16/NNS||control-21/NN	prep_in||control-21/NN||carcinoidsyndrome-23/NN	det||efficacy-27/NN||the-26/DT	prep_of||effects-4/NNS||efficacy-27/NN	conj_and||use-9/NN||efficacy-27/NN	amod||intervals-31/NNS||extended-29/JJ	nn||intervals-31/NNS||dosing-30/NN	prep_of||efficacy-27/NN||intervals-31/NNS	auxpass||reviewed-33/VBN||were-32/VBD	root||ROOT-0/null||reviewed-33/VBN	pituitary-11||hormone-18||no_rel||statements regarding the effects of preoperative somatostatin analog use on pituitary surgical outcomes, their effects on hormone and symptom control in carcinoidsyndrome, and the efficacy of extended dosing intervals were reviewed.
nsubj||safe-3/JJ||dorzolamide-1/NN	nsubj||effective-5/JJ||dorzolamide-1/NN	cop||safe-3/JJ||is-2/VBZ	root||ROOT-0/null||safe-3/JJ	conj_and||safe-3/JJ||effective-5/JJ	advmod||used-7/VBD||when-6/WRB	advcl||safe-3/JJ||used-7/VBD	num||months-10/NNS||twelve-9/CD	prep_for||used-7/VBD||months-10/NNS	amod||therapy-13/NN||add-on-12/JJ	prep_as||months-10/NNS||therapy-13/NN	aux||latanoprost-15/VB||to-14/TO	xcomp||used-7/VBD||latanoprost-15/VB	prep_for||latanoprost-15/VB||open-angleglaucoma-17/NN	open-angleglaucoma-17||latanoprost-15||yes||dorzolamide is safe and effective when used for twelve months as add-on therapy to latanoprost for open-angleglaucoma.
quantmod||49-2/CD||about-1/RB	num||%-3/NN||49-2/CD	nsubj||isolates-7/VBZ||%-3/NN	nn||negatives-6/NNS||gram-5/NN	prep_of||%-3/NN||negatives-6/NNS	root||ROOT-0/null||isolates-7/VBZ	cop||resistant-9/JJ||were-8/VBD	ccomp||isolates-7/VBZ||resistant-9/JJ	prep_to||resistant-9/JJ||thirdgenerationcephalosporins-11/NNS	num||%-14/NN||28-13/CD	nsubjpass||found-18/VBN||%-14/NN	nsubj||staphylococcusaureus-23/NNS||%-14/NN	prep_of||%-14/NN||staphylococcusaureus-16/NNS	auxpass||found-18/VBN||were-17/VBD	conj_and||isolates-7/VBZ||found-18/VBN	aux||staphylococcusaureus-23/NNS||to-19/TO	cop||staphylococcusaureus-23/NNS||be-20/VB	amod||resistant-22/JJ||methicillin-21/JJ	amod||staphylococcusaureus-23/NNS||resistant-22/JJ	xcomp||found-18/VBN||staphylococcusaureus-23/NNS	appos||staphylococcusaureus-23/NNS||mrsa-25/NNP	mrsa-25||staphylococcusaureus-23||no||about 49% of gram negatives isolates were resistant to thirdgenerationcephalosporins and 28% of staphylococcusaureus were found to be methicillin resistant staphylococcusaureus (mrsa).
advmod||diminished-13/VBN||moreover-1/RB	amod||responses-4/NNS||anorectic-3/JJ	nsubjpass||diminished-13/VBN||responses-4/NNS	prep_to||responses-4/NNS||leptin-6/NN	prep_to||responses-4/NNS||insulin-8/NN	conj_and||leptin-6/NN||insulin-8/NN	prep_to||responses-4/NNS||glucose-11/NN	conj_and||leptin-6/NN||glucose-11/NN	auxpass||diminished-13/VBN||were-12/VBD	root||ROOT-0/null||diminished-13/VBN	amod||mice-16/NNS||angptl4-null-15/JJ	prep_in||diminished-13/VBN||mice-16/NNS	insulin-8||anorectic-3||no_rel||moreover, anorectic responses to leptin, insulin, and glucose were diminished in angptl4-null mice.
nsubjpass||triggered-14/VBN||events-1/NNS	amod||events-1/NNS||similar-2/JJ	prep_to||similar-2/JJ||those-4/DT	vmod||those-4/DT||occurring-5/VBG	prep_in||occurring-5/VBG||er-7/NN	amod||events-12/NNS||stress-induced-10/JJ	nn||events-12/NNS||mh-11/NN	prep_in||occurring-5/VBG||events-12/NNS	conj_and||er-7/NN||events-12/NNS	auxpass||triggered-14/VBN||are-13/VBP	root||ROOT-0/null||triggered-14/VBN	prep_after||triggered-14/VBN||exposure-16/NN	prep_to||triggered-14/VBN||anestheticagents-18/NNS	amod||patients-24/NNS||mh-susceptible-20/JJ	appos||patients-24/NNS||mhs-22/NN	prep_in||anestheticagents-18/NNS||patients-24/NNS	mh-11||anestheticagents-18||no||events similar to those occurring in er and in stress-induced mh events are triggered after exposure to anestheticagents in mh-susceptible (mhs) patients.
amod||patients-2/NNS||asymptomatic-1/JJ	nsubjpass||enrolled-64/VBN||patients-2/NNS	appos||patients-2/NNS||n-4/NNP	number||485-6/CD||=-5/CD	num||n-4/NNP||485-6/CD	vmod||patients-2/NNS||aged-8/VBN	nn||-10/NNS||â-9/NN	dobj||aged-8/VBN||-10/NNS	number||50-12/CD||¥-11/CD	num||years-13/NNS||50-12/CD	npadvmod||aged-8/VBN||years-13/NNS	advmod||thickness-21/NN||either-15/RB	det||thickness-21/NN||a-16/DT	amod||carotid-18/JJ||maximal-17/JJ	amod||thickness-21/NN||carotid-18/JJ	nn||thickness-21/NN||artery-19/NN	nn||thickness-21/NN||intima-media-20/NN	prep_with||aged-8/VBN||thickness-21/NN	nn||-24/NNS||â-23/NN	prep_of||thickness-21/NN||-24/NNS	amod||thickness-21/NN||¥-25/JJ	num||mm-27/NNS||1.1-26/CD	dep||¥-25/JJ||mm-27/NNS	det||creatinine-38/NN||a-30/DT	advmod||albumin-32/JJ||urinary-31/RB	amod||creatinine-38/NN||albumin-32/JJ	nn||creatinine-38/NN||â-33/NNP	nn||creatinine-38/NN||-34/NNP	nn||creatinine-38/NN||¥-35/NNP	num||creatinine-38/NN||30-36/CD	nn||creatinine-38/NN||mg/g-37/NN	prep_with||aged-8/VBN||creatinine-38/NN	conj_or||thickness-21/NN||creatinine-38/NN	nsubj||had-41/VBD||who-40/WP	prep_with||aged-8/VBN||had-41/VBD	conj_or||thickness-21/NN||had-41/VBD	quantmod||two-44/CD||at-42/IN	mwe||at-42/IN||least-43/JJS	pobj||at-42/IN||least-43/JJS	dobj||had-41/VBD||two-44/CD	det||obesity-50/NN||the-46/DT	amod||obesity-50/NN||following-47/JJ	amod||obesity-50/NN||abdominal-49/JJ	prep_of||two-44/CD||obesity-50/NN	amod||cholesterol-54/NN||low-52/JJ	nn||cholesterol-54/NN||hdl-53/NN	prep_of||two-44/CD||cholesterol-54/NN	conj_and||obesity-50/NN||cholesterol-54/NN	amod||levels-58/NNS||high-56/JJ	nn||levels-58/NNS||triglyceride-57/NN	prep_of||two-44/CD||levels-58/NNS	conj_and||obesity-50/NN||levels-58/NNS	prep_of||two-44/CD||hypertension-61/NN	conj_and||obesity-50/NN||hypertension-61/NN	auxpass||enrolled-64/VBN||were-63/VBD	root||ROOT-0/null||enrolled-64/VBN	num||institutions-67/NNS||50-66/CD	prep_at||enrolled-64/VBN||institutions-67/NNS	hypertension-61||albumin-32||no_rel||asymptomatic patients ( n = 485) aged â¥50 years with either a maximal carotid artery intima-media thickness of â¥1.1 mm, or a urinary albumin â¥30 mg/g creatinine or who had at least two of the following, abdominal obesity, low hdl cholesterol, high triglyceride levels, and hypertension, were enrolled at 50 institutions.
amod||rhinitis-2/NNS||allergic-1/JJ	nsubj||prevalent-10/JJ||rhinitis-2/NNS	conj_and||rhinitis-2/NNS||atopic/non-atopicasthma-4/NN	nsubj||prevalent-10/JJ||atopic/non-atopicasthma-4/NN	conj_and||rhinitis-2/NNS||atopicdermatitis-7/NNS	nsubj||prevalent-10/JJ||atopicdermatitis-7/NNS	cop||prevalent-10/JJ||were-8/VBD	advmod||prevalent-10/JJ||equally-9/RB	root||ROOT-0/null||prevalent-10/JJ	det||groups-14/NNS||the-12/DT	nn||groups-14/NNS||study-13/NN	prep_among||prevalent-10/JJ||groups-14/NNS	det||group-19/NN||the-17/DT	nn||group-19/NN||crs/rom-18/NN	prep_except_for||prevalent-10/JJ||group-19/NN	prep_in||prevalent-25/JJ||group-19/NN	nsubj||prevalent-25/JJ||non-atopicasthma-22/NN	cop||prevalent-25/JJ||was-23/VBD	advmod||prevalent-25/JJ||more-24/RBR	rcmod||group-19/NN||prevalent-25/JJ	num||%-28/NN||52.6-27/CD	appos||group-19/NN||%-28/NN	atopicasthma--1||atopic--1||no||allergic rhinitis, atopic/non-atopicasthma, and atopicdermatitis were equally prevalent among the study groups except for the crs/rom group in which non-atopicasthma was more prevalent (52.6%).
det||mechanism-2/NN||this-1/DT	nsubj||has-9/VBZ||mechanism-2/NN	mark||finds-6/VBZ||if-4/IN	nsubj||finds-6/VBZ||it-5/PRP	dep||mechanism-2/NN||finds-6/VBZ	dobj||finds-6/VBZ||support-7/NN	root||ROOT-0/null||has-9/VBZ	amod||implications-11/NNS||important-10/JJ	dobj||has-9/VBZ||implications-11/NNS	amod||research-14/NN||future-13/JJ	prep_for||implications-11/NNS||research-14/NN	det||hazard-18/NN||the-16/DT	nn||hazard-18/NN||mesothelioma-17/NN	prep_into||has-9/VBZ||hazard-18/NN	prep_into||has-9/VBZ||hazard-18/NN	conj_and||hazard-18/NN||hazard-18/NN	prep_from||hazard-18/NN||harn-20/NN	advmod||hazard-18/NN||also-22/RB	poss||view-26/NN||our-24/PRP$	amod||view-26/NN||current-25/JJ	prep_for||hazard-18/NN||view-26/NN	det||origins-29/NNS||the-28/DT	prep_of||view-26/NN||origins-29/NNS	amod||mesothelioma-33/NN||asbestos-initiated-31/JJ	amod||mesothelioma-33/NN||pleural-32/JJ	prep_of||origins-29/NNS||mesothelioma-33/NN	det||use-37/NN||the-35/DT	amod||use-37/NN||common-36/JJ	prep_of||view-26/NN||use-37/NN	conj_and||origins-29/NNS||use-37/NN	prep_of||use-37/NN||lung-39/NN	amod||burden-43/NN||parenchymal-40/JJ	nn||burden-43/NN||asbestos-41/NN	nn||burden-43/NN||fibre-42/NN	pobj||hazard-18/NN||burden-43/NN	det||correlate-46/NN||a-45/DT	prep_as||has-9/VBZ||correlate-46/NN	det||tumour-49/NN||this-48/DT	prep_of||correlate-46/NN||tumour-49/NN	nsubj||arises-53/VBZ||tumour-49/NN	advmod||arises-53/VBZ||actually-52/RB	rcmod||tumour-49/NN||arises-53/VBZ	det||pleura-57/NN||the-55/DT	amod||pleura-57/NN||parietal-56/JJ	prep_in||arises-53/VBZ||pleura-57/NN	asbestos-41||tumour-49||no_rel||this mechanism, if it finds support, has important implications for future research into the mesothelioma hazard from harn and also for our current view of the origins of asbestos-initiated pleural mesothelioma and the common use of lung parenchymal asbestos fibre burden as a correlate of this tumour, which actually arises in the parietal pleura.
det||cb-3/NN||the-1/DT	amod||cb-3/NN||high-fat-2/JJ	nsubj||induced-10/VBN||cb-3/NN	conj_and||cb-3/NN||oo-5/NN	nsubj||induced-10/VBN||oo-5/NN	advmod||diets-9/NNS||so-8/RB	conj_and||cb-3/NN||diets-9/NNS	nsubj||induced-10/VBN||diets-9/NNS	root||ROOT-0/null||induced-10/VBN	dobj||induced-10/VBN||hyperglycemia-11/NN	det||increase-15/NN||a-13/DT	amod||increase-15/NN||2-fold-14/JJ	dobj||induced-10/VBN||increase-15/NN	conj_and||hyperglycemia-11/NN||increase-15/NN	amod||content-19/NN||hepatic-17/JJ	amod||content-19/NN||fat-18/JJ	prep_in||induced-10/VBN||content-19/NN	amod||mice-27/NNS||male-21/JJ	neg||female-25/JJ||not-24/RB	conj_but||male-21/JJ||female-25/JJ	amod||mice-27/NNS||female-25/JJ	amod||mice-27/NNS||wild-type-26/JJ	prep_in||content-19/NN||mice-27/NNS	prep_in||content-34/NN||females-30/NNS	amod||content-34/NN||hepatic-32/JJ	amod||content-34/NN||fat-33/JJ	dep||mice-27/NNS||content-34/NN	prep_to||similar-36/JJ||content-34/NN	cop||similar-36/JJ||was-35/VBD	rcmod||content-34/NN||similar-36/JJ	prep_in||that-38/DT||males-40/NNS	vmod||males-40/NNS||fed-41/VBN	det||diet-44/NN||a-42/DT	amod||diet-44/NN||high-fat-43/JJ	dobj||fed-41/VBN||diet-44/NN	hyperglycemia-11||fat-33||no_rel||the high-fat cb, oo, and so diets induced hyperglycemia and a 2-fold increase in hepatic fat content in male, but not female wild-type mice (in females, hepatic fat content was similar to that in males fed a high-fat diet).
num||percent-2/NN||fourteen-1/CD	nsubj||positive-20/JJ||percent-2/NN	amod||subjects-5/NNS||hivpositive-4/JJ	prep_of||percent-2/NN||subjects-5/NNS	appos||subjects-5/NNS||8/57-7/CD	num||%-11/NN||4.3-10/CD	prep_of||percent-2/NN||%-11/NN	conj_and||subjects-5/NNS||%-11/NN	appos||subjects-5/NNS||14/327-13/CD	amod||subjects-18/NNS||hiv-16/JJ	amod||subjects-18/NNS||negative-17/JJ	prep_of||percent-2/NN||subjects-18/NNS	cop||positive-20/JJ||were-19/VBD	root||ROOT-0/null||positive-20/JJ	prepc_for||positive-20/JJ||hbsag-22/VBG	hivpositive-4||hiv-16||no||fourteen percent of hivpositive subjects (8/57) and 4.3% (14/327) of hiv negative subjects were positive for hbsag.
det||study-3/NN||the-1/DT	amod||study-3/NN||present-2/JJ	nsubj||tested-4/VBD||study-3/NN	root||ROOT-0/null||tested-4/VBD	det||effect-6/NN||the-5/DT	dobj||tested-4/VBD||effect-6/NN	nn||administration-9/NN||midazolam-8/NN	prep_of||effect-6/NN||administration-9/NN	amod||anesthesia-12/NN||sevoflurane-11/JJ	prep_after||tested-4/VBD||anesthesia-12/NN	nn||agitation-15/NN||emergence-14/NN	prep_against||anesthesia-12/NN||agitation-15/NN	prep_in||tested-4/VBD||children-17/NNS	det||phase-21/NN||the-19/DT	nn||phase-21/NN||recovery-20/NN	prep_in||children-17/NNS||phase-21/NN	agitation-15||midazolam-8||yes||the present study tested the effect of midazolam administration after sevoflurane anesthesia against emergence agitation in children in the recovery phase.
aux||assess-2/VB||to-1/TO	root||ROOT-0/null||assess-2/VB	det||effects-4/NNS||the-3/DT	dobj||assess-2/VB||effects-4/NNS	prep_of||effects-4/NNS||topiramate-6/NN	amod||function-9/NN||c-fiber-8/JJ	prep_on||topiramate-6/NN||function-9/NN	nn||morphology-13/NN||nerve-11/NN	nn||morphology-13/NN||fiber-12/NN	prep_on||topiramate-6/NN||morphology-13/NN	conj_and||function-9/NN||morphology-13/NN	prep_on||topiramate-6/NN||metabolism-16/NN	conj_and||function-9/NN||metabolism-16/NN	nn||sensitivity-20/NN||insulin-19/NN	prep_including||effects-4/NNS||sensitivity-20/NN	prep_including||effects-4/NNS||obesity-22/NN	conj_and||sensitivity-20/NN||obesity-22/NN	prep_including||effects-4/NNS||dyslipidemia-25/NN	conj_and||sensitivity-20/NN||dyslipidemia-25/NN	prep_in||effects-4/NNS||type2diabetes-28/CD	type2diabetes-28||insulin-19||yes||to assess the effects of topiramate on c-fiber function, nerve fiber morphology, and metabolism (including insulin sensitivity, obesity, and dyslipidemia) in type2diabetes.
det||disparity-2/NN||the-1/DT	nsubj||result-8/VB||disparity-2/NN	amod||incidence-6/NN||human-4/JJ	nn||incidence-6/NN||lymedisease-5/NN	prep_in||disparity-2/NN||incidence-6/NN	aux||result-8/VB||may-7/MD	root||ROOT-0/null||result-8/VB	det||disparity-11/NN||a-10/DT	prep_from||result-8/VB||disparity-11/NN	det||invasiveness-15/NNS||the-13/DT	amod||invasiveness-15/NNS||human-14/JJ	prep_in||disparity-11/NN||invasiveness-15/NNS	det||bacteria-18/NNS||the-17/DT	prep_of||invasiveness-15/NNS||bacteria-18/NNS	det||northeast-21/NN||the-20/DT	prep_in||result-8/VB||northeast-21/NN	prep_in||result-8/VB||midwest-23/NN	conj_and||northeast-21/NN||midwest-23/NN	vmod||northeast-21/NN||caused-24/VBN	advmod||different-27/JJ||fundamentally-26/RB	amod||histories-29/NNS||different-27/JJ	amod||histories-29/NNS||evolutionary-28/JJ	agent||caused-24/VBN||histories-29/NNS	lymedisease-5||bacteria-18||no||the disparity in human lymedisease incidence may result from a disparity in the human invasiveness of the bacteria in the northeast and midwest caused by fundamentally different evolutionary histories.
amod||surgery-2/NN||combined-1/VBN	nsubj||allow-12/VB||surgery-2/NN	amod||administration-5/NN||continuous-4/JJ	conj_and||surgery-2/NN||administration-5/NN	nsubj||allow-12/VB||administration-5/NN	prep_of||administration-5/NN||albendazole-7/NN	amod||dosage-10/NN||high-9/JJ	prep_at||albendazole-7/NN||dosage-10/NN	aux||allow-12/VB||may-11/MD	root||ROOT-0/null||allow-12/VB	nn||echinococcosis-14/NNS||alveolar-13/NN	iobj||allow-12/VB||echinococcosis-14/NNS	dobj||allow-12/VB||patients-15/NNS	aux||survive-17/VB||to-16/TO	vmod||patients-15/NNS||survive-17/VB	mwe||than-19/IN||more-18/JJR	quantmod||30â-20/CD||than-19/IN	num||years-23/NNS||30â-20/CD	amod||years-23/NNS||$-21/$	dep||$-21/$||-22/JJ	dobj||survive-17/VB||years-23/NNS	prep_after||years-23/NNS||diagnosis-25/NN	amod||involvement-28/NN||multi-organ-27/JJ	prep_despite||survive-17/VB||involvement-28/NN	echinococcosis-14||albendazole-7||yes||combined surgery and continuous administration of albendazole at high dosage may allow alveolar echinococcosis patients to survive more than 30âyears after diagnosis despite multi-organ involvement.
amod||virus-2/NN||hepatitisb-1/JJ	nn||reactivation-6/NNS||virus-2/NN	appos||reactivation-6/NNS||hbv-4/NN	nsubj||complication-10/NN||reactivation-6/NNS	cop||complication-10/NN||is-7/VBZ	det||complication-10/NN||the-8/DT	amod||complication-10/NN||frequent-9/JJ	root||ROOT-0/null||complication-10/NN	amod||chemotherapy-13/NN||cytotoxic-12/JJ	prep_after||complication-10/NN||chemotherapy-13/NN	amod||non-hodgkin-16/NN||hbsag-positive-15/JJ	poss||patients-22/NNS||non-hodgkin-16/NN	amod||patients-22/NNS||lymphoma-18/JJ	appos||patients-22/NNS||nhl-20/NN	prep_in||chemotherapy-13/NN||patients-22/NNS	hbv-4||hbsag--1||yes||hepatitisb virus (hbv) reactivation is the frequent complication after cytotoxic chemotherapy in hbsag-positive non-hodgkin's lymphoma (nhl) patients.
nsubj||increased-2/VBD||lps-1/NN	ccomp||necrosis-18/VBZ||increased-2/VBD	mark||decreased-6/VBD||whereas-4/IN	nsubj||decreased-6/VBD||igf-i-5/NNP	parataxis||increased-2/VBD||decreased-6/VBD	dobj||increased-2/VBD||expression-8/NN	amod||markers-11/JJ||inflammatory-10/JJ	prep_of||expression-8/NN||markers-11/JJ	amod||markers-11/JJ||interleukin-1ãÿ-12/JJ	dep||markers-11/JJ||il-1ãÿ-14/JJ	nsubj||necrosis-18/VBZ||tumor-17/NN	root||ROOT-0/null||necrosis-18/VBZ	dobj||necrosis-18/VBZ||factor-19/NN	appos||±-25/NNP||tnf-22/NN	nn||±-25/NNP||î-24/NNP	dep||factor-19/NN||±-25/NNP	amod||synthase-29/NN||inducible-27/JJ	nn||synthase-29/NN||nitricoxide-28/NN	dep||factor-19/NN||synthase-29/NN	conj_and||±-25/NNP||synthase-29/NN	appos||synthase-29/NN||inos-31/NNS	amod||protein-37/NN||glial-34/JJ	amod||protein-37/NN||fibrillary-35/JJ	amod||protein-37/NN||acidic-36/JJ	dep||factor-19/NN||protein-37/NN	conj_and||±-25/NNP||protein-37/NN	appos||protein-37/NN||gfap-39/NN	tumor-17||nitricoxide-28||no_rel||lps increased, whereas igf-i decreased, expression of inflammatory markers interleukin-1ãÿ (il-1ãÿ), tumor necrosis factor-(tnf)î±, inducible nitricoxide synthase (inos) and glial fibrillary acidic protein (gfap).
nsubj||alternative-7/NN||febuxostat-1/NN	cop||alternative-7/NN||is-2/VBZ	det||alternative-7/NN||the-3/DT	amod||alternative-7/NN||first-4/JJ	amod||alternative-7/NN||major-5/JJ	nn||alternative-7/NN||treatment-6/NN	root||ROOT-0/null||alternative-7/NN	prep_for||alternative-7/NN||gout-9/NN	mwe||than-12/IN||more-11/JJR	quantmod||40-13/CD||than-12/IN	num||years-14/NNS||40-13/CD	prep_in||gout-9/NN||years-14/NNS	cop||alternative-19/NN||is-16/VBZ	det||alternative-19/NN||a-17/DT	amod||alternative-19/NN||promising-18/JJ	conj_and||alternative-7/NN||alternative-19/NN	prep_to||alternative-19/NN||allopurinol-21/NN	mark||required-32/VBN||although-23/IN	amod||surveillance-26/NN||continued-24/VBN	amod||surveillance-26/NN||long-term-25/JJ	nsubjpass||required-32/VBN||surveillance-26/NN	prep_on||surveillance-26/NN||safety-28/NN	prep_on||surveillance-26/NN||efficacy-30/NN	conj_and||safety-28/NN||efficacy-30/NN	auxpass||required-32/VBN||is-31/VBZ	advcl||alternative-19/NN||required-32/VBN	gout-9||allopurinol-21||yes||febuxostat is the first major treatment alternative for gout in more than 40 years and is a promising alternative to allopurinol, although continued long-term surveillance on safety and efficacy is required.
det||data-2/NNS||these-1/DT	nsubj||established-4/VBN||data-2/NNS	aux||established-4/VBN||have-3/VBP	root||ROOT-0/null||established-4/VBN	mark||prion-9/VBN||that-5/IN	amod||prions-7/NNS||kuru-6/JJ	nsubj||prion-9/VBN||prions-7/NNS	aux||prion-9/VBN||have-8/VBP	ccomp||established-4/VBN||prion-9/VBN	nn||properties-11/NNS||strain-10/NN	nsubj||equivalent-12/JJ||properties-11/NNS	xcomp||prion-9/VBN||equivalent-12/JJ	prep_to||equivalent-12/JJ||those-14/DT	amod||prions-29/NNS||classical-16/JJ	dep||prions-29/NNS||sporadic-18/JJ	conj_and||sporadic-18/JJ||iatrogenic-20/JJ	dep||prions-29/NNS||iatrogenic-20/JJ	amod||prions-29/NNS||cjd-22/JJ	nn||prions-29/NNS||prions-23/NNS	conj_but||prions-23/NNS||distinct-25/JJ	nn||prions-29/NNS||distinct-25/JJ	amod||cjd-28/NN||variant-27/JJ	prep_from||distinct-25/JJ||cjd-28/NN	prep_of||those-14/DT||prions-29/NNS	prions-29||kuru-6||no_rel||these data have established that kuru prions have prion strain properties equivalent to those of classical (sporadic and iatrogenic) cjd prions but distinct from variant cjd prions.
amod||insulinresistance-2/NN||peripheral-1/JJ	nsubjpass||linked-4/VBN||insulinresistance-2/NN	auxpass||linked-4/VBN||is-3/VBZ	root||ROOT-0/null||linked-4/VBN	det||increase-7/NN||an-6/DT	prep_to||linked-4/VBN||increase-7/NN	amod||species-11/NNS||reactive-9/JJ	nn||species-11/NNS||oxygen-10/NN	prep_in||increase-7/NN||species-11/NNS	appos||species-11/NNS||ros-13/NN	vmod||increase-7/NN||leading-16/VBG	prep_in||leading-16/VBG||part-18/NN	det||production-21/NN||the-20/DT	prep_to||part-18/NN||production-21/NN	amod||aldehydes-25/NNS||reactive-23/JJ	nn||aldehydes-25/NNS||lipid-24/NN	prep_of||production-21/NN||aldehydes-25/NNS	mark||termed-37/VBD||that-26/IN	csubj||termed-37/VBD||modify-27/VB	det||chains-30/NNS||the-28/DT	nn||chains-30/NNS||side-29/NN	dobj||modify-27/VB||chains-30/NNS	nn||aminoacids-33/NNS||protein-32/NN	prep_of||chains-30/NNS||aminoacids-33/NNS	det||reaction-36/NN||a-35/DT	prep_in||aminoacids-33/NNS||reaction-36/NN	ccomp||leading-16/VBG||termed-37/VBD	nn||carbonylation-39/NN||protein-38/NN	dobj||termed-37/VBD||carbonylation-39/NN	oxygen-10||insulinresistance-2||no_rel||peripheral insulinresistance is linked to an increase in reactive oxygen species (ros), leading in part to the production of reactive lipid aldehydes that modify the side chains of protein aminoacids in a reaction termed protein carbonylation.
amod||course-2/NN||postoperative-1/JJ	nsubjpass||complicated-4/VBN||course-2/NN	auxpass||complicated-4/VBN||was-3/VBD	root||ROOT-0/null||complicated-4/VBN	amod||thrombosis-8/NNS||tricuspid-6/JJ	nn||thrombosis-8/NNS||valve-7/NN	agent||complicated-4/VBN||thrombosis-8/NNS	amod||pulmonaryembolism-11/NN||secondary-10/JJ	agent||complicated-4/VBN||pulmonaryembolism-11/NN	conj_and||thrombosis-8/NNS||pulmonaryembolism-11/NN	xcomp||complicated-4/VBN||requiring-12/VBG	nn||thrombolysis-14/NNS||tpa-13/NN	dobj||requiring-12/VBG||thrombolysis-14/NNS	nsubj||successful-18/JJ||thrombolysis-14/NNS	cop||successful-18/JJ||was-16/VBD	advmod||successful-18/JJ||instantly-17/RB	rcmod||thrombolysis-14/NNS||successful-18/JJ	pulmonaryembolism-11||tpa-13||yes||postoperative course was complicated by tricuspid valve thrombosis and secondary pulmonaryembolism requiring tpa thrombolysis which was instantly successful.
det||hand-4/NN||the-2/DT	amod||hand-4/NN||other-3/JJ	prep_on||promote-24/VB||hand-4/NN	amod||hyporesponsiveness-8/NNS||uc-mscs-6/JJ	amod||hyporesponsiveness-8/NNS||induced-7/JJ	nsubj||promote-24/VB||hyporesponsiveness-8/NNS	nn||cells-11/NNS||t-10/NN	prep_of||hyporesponsiveness-8/NNS||cells-11/NNS	vmod||cells-11/NNS||mediated-12/VBN	agent||mediated-12/VBN||pge2-14/NNS	num||²-17/NNP||tgf-î-16/CD	agent||mediated-12/VBN||²-17/NNP	conj_and||pge2-14/NNS||²-17/NNP	num||²-17/NNP||1-18/CD	agent||mediated-12/VBN||no-20/DT	conj_and||pge2-14/NNS||no-20/DT	conj_and||pge2-14/NNS||uc-mscs-22/NN	conj_and||no-20/DT||uc-mscs-22/NN	aux||promote-24/VB||could-23/MD	root||ROOT-0/null||promote-24/VB	det||expansion-26/NN||the-25/DT	dobj||promote-24/VB||expansion-26/NN	amod||cells-34/NNS||cd4-28/JJ	amod||cells-34/NNS||+-29/JJ	amod||cells-34/NNS||foxp3-30/JJ	amod||cells-34/NNS||+-31/JJ	amod||cells-34/NNS||regulatory-32/JJ	nn||cells-34/NNS||t-33/NN	prep_of||expansion-26/NN||cells-34/NNS	nn||patients-37/NNS||ra-36/NN	prep_from||cells-34/NNS||patients-37/NNS	pge2-14||uc--1||no_rel||on the other hand, uc-mscs induced hyporesponsiveness of t cells mediated by pge2, tgf-î²1 and no and uc-mscs could promote the expansion of cd4+ foxp3+ regulatory t cells from ra patients.
nsubj||interesting-4/JJ||it-1/PRP	nsubj||investigate-6/VB||it-1/PRP	aux||interesting-4/JJ||will-2/MD	cop||interesting-4/JJ||be-3/VB	root||ROOT-0/null||interesting-4/JJ	aux||investigate-6/VB||to-5/TO	xcomp||interesting-4/JJ||investigate-6/VB	mark||has-22/VBZ||whether-7/IN	nsubjpass||used-15/VBN||mefloquine-8/NN	nsubj||has-22/VBZ||mefloquine-8/NN	auxpass||used-15/VBN||is-11/VBZ	advmod||used-15/VBN||widely-12/RB	conj_and||widely-12/RB||effectively-14/RB	advmod||used-15/VBN||effectively-14/RB	rcmod||mefloquine-8/NN||used-15/VBN	det||treatment-18/NN||the-17/DT	prep_for||used-15/VBN||treatment-18/NN	prep_of||treatment-18/NN||malaria-20/NN	ccomp||investigate-6/VB||has-22/VBZ	det||impact-24/NN||an-23/DT	dobj||has-22/VBZ||impact-24/NN	prep_on||impact-24/NN||schistosomiasis-26/NNS	prep_in||schistosomiasis-26/NNS||areas-28/NNS	advmod||co-exist-34/VB||where-29/WRB	det||malaria-31/NN||both-30/DT	nsubj||co-exist-34/VB||malaria-31/NN	conj_and||malaria-31/NN||schistosomiasis-33/NNS	nsubj||co-exist-34/VB||schistosomiasis-33/NNS	advcl||interesting-4/JJ||co-exist-34/VB	malaria-31||mefloquine-8||yes||it will be interesting to investigate whether mefloquine, which is widely and effectively used for the treatment of malaria, has an impact on schistosomiasis in areas where both malaria and schistosomiasis co-exist.
nsubj||have-9/VBP||adults-1/NNS	amod||living-5/NN||african-caribbean-3/JJ	nn||living-5/NN||origin-4/NN	prep_of||adults-1/NNS||living-5/NN	det||uk-8/NN||the-7/DT	prep_in||living-5/NN||uk-8/NN	root||ROOT-0/null||have-9/VBP	amod||increases-11/NNS||smaller-10/JJR	dobj||have-9/VBP||increases-11/NNS	amod||risk-14/NN||type2diabetes-13/JJ	prep_in||increases-11/NNS||risk-14/NN	vmod||increases-11/NNS||raised-16/VBN	xcomp||raised-16/VBN||circulating-17/VBG	dobj||circulating-17/VBG||insulin-18/NN	dobj||circulating-17/VBG||hdl-cholesterol-20/NN	conj_and||insulin-18/NN||hdl-cholesterol-20/NN	amod||triglyceride-24/NN||low-23/JJ	dobj||have-9/VBP||triglyceride-24/NN	conj_and||increases-11/NNS||triglyceride-24/NN	amod||concentrations-28/NNS||c-reactive-26/JJ	nn||concentrations-28/NNS||protein-27/NN	conj_and||increases-11/NNS||concentrations-28/NNS	conj_and||triglyceride-24/NN||concentrations-28/NNS	type2diabetes-13||insulin-18||yes||adults of african-caribbean origin living in the uk have smaller increases in type2diabetes risk, raised circulating insulin and hdl-cholesterol, and low triglyceride and c-reactive protein concentrations.
det||report-2/NN||this-1/DT	nsubj||discusses-3/VBZ||report-2/NN	root||ROOT-0/null||discusses-3/VBZ	det||case-5/NN||a-4/DT	dobj||discusses-3/VBZ||case-5/NN	amod||psychosis-8/NNS||acute-7/JJ	prep_of||case-5/NN||psychosis-8/NNS	prep_of||case-5/NN||enuresis-10/NNS	conj_and||psychosis-8/NNS||enuresis-10/NNS	det||alcohol-19/NN||a-12/DT	amod||alcohol-19/NN||patient-13/JJ	prep_on||patient-13/JJ||disulfiram-15/NN	nsubj||ingested-18/VBN||disulfiram-15/NN	aux||ingested-18/VBN||had-17/VBD	rcmod||disulfiram-15/NN||ingested-18/VBN	prep_in||case-5/NN||alcohol-19/NN	psychosis-8||disulfiram-15||no||this report discusses a case of acute psychosis and enuresis in a patient on disulfiram who had ingested alcohol.
det||study-3/NN||this-2/DT	prep_in||investigated-6/VBD||study-3/NN	nsubj||investigated-6/VBD||we-5/PRP	root||ROOT-0/null||investigated-6/VBD	det||effect-8/NN||the-7/DT	dobj||investigated-6/VBD||effect-8/NN	det||mixture-12/NN||a-10/DT	amod||mixture-12/NN||lidocaine-11/JJ	prep_of||effect-8/NN||mixture-12/NN	prep_on||investigated-6/VBD||pain-14/NN	dep||pain-14/NN||induced-15/VBN	amod||injection-19/NN||microemulsion-17/JJ	amod||injection-19/NN||propofol-18/JJ	prep_by||induced-15/VBN||injection-19/NN	dep||pain-14/NN||sought-22/VBN	conj_and||induced-15/VBN||sought-22/VBN	aux||determine-24/VB||to-23/TO	xcomp||sought-22/VBN||determine-24/VB	det||dose-27/NN||the-25/DT	amod||dose-27/NN||optimal-26/JJ	dobj||determine-24/VB||dose-27/NN	nsubj||reduce-32/VB||dose-27/NN	prep_of||dose-27/NN||lidocaine-29/NN	aux||reduce-32/VB||could-31/MD	rcmod||dose-27/NN||reduce-32/VB	dobj||reduce-32/VB||pain-33/NN	prepc_on||reduce-32/VB||injecting-35/VBG	det||mixture-38/NN||a-36/DT	amod||mixture-38/NN||propofol-lidocaine-37/JJ	dobj||injecting-35/VBG||mixture-38/NN	pain-33||lidocaine-29||yes||in this study, we investigated the effect of a lidocaine mixture on pain induced by microemulsion propofol injection, and sought to determine the optimal dose of lidocaine that could reduce pain on injecting a propofol-lidocaine mixture.
det||literature-3/NN||the-1/DT	amod||literature-3/NN||available-2/JJ	nsubjpass||reviewed-5/VBN||literature-3/NN	nsubj||examine-7/VB||literature-3/NN	auxpass||reviewed-5/VBN||was-4/VBD	root||ROOT-0/null||reviewed-5/VBN	aux||examine-7/VB||to-6/TO	xcomp||reviewed-5/VBN||examine-7/VB	det||links-9/NNS||the-8/DT	dobj||examine-7/VB||links-9/NNS	amod||antibiotics-12/NNS||prescribed-11/JJ	prep_between||links-9/NNS||antibiotics-12/NNS	nn||eczema-15/NN||childhood-14/NN	prep_between||links-9/NNS||eczema-15/NN	conj_and||antibiotics-12/NNS||eczema-15/NN	conj_and||antibiotics-12/NNS||asthma-17/NN	conj_and||eczema-15/NN||asthma-17/NN	eczema-15||antibiotics-12||no_rel||the available literature was reviewed to examine the links between prescribed antibiotics and childhood eczema and asthma.
nsubj||candidate-8/NN||humanimmunodeficiencyvirus-1/NNS	appos||humanimmunodeficiencyvirus-1/NNS||hiv-3/NN	cop||candidate-8/NN||is-5/VBZ	det||candidate-8/NN||a-6/DT	amod||candidate-8/NN||prime-7/JJ	root||ROOT-0/null||candidate-8/NN	aux||impose-10/VB||to-9/TO	vmod||candidate-8/NN||impose-10/VB	amod||selection-13/NN||such-11/JJ	amod||selection-13/NN||genetic-12/JJ	dobj||impose-10/VB||selection-13/NN	vmod||selection-13/NN||owing-14/VBG	det||number-18/NN||the-16/DT	amod||number-18/NN||vast-17/JJ	prep_to||owing-14/VBG||number-18/NN	prep_of||number-18/NN||people-20/NNS	nsubj||infects-22/VBZ||it-21/PRP	rcmod||people-20/NNS||infects-22/VBZ	det||susceptibility-26/NN||the-24/DT	amod||susceptibility-26/NN||varying-25/VBG	dobj||impose-10/VB||susceptibility-26/NN	conj_and||selection-13/NN||susceptibility-26/NN	amod||types-35/NNS||different-28/JJ	amod||types-35/NNS||human-29/JJ	nn||types-35/NNS||leucocyte-30/NN	nn||types-35/NNS||antigen-31/NN	appos||types-35/NNS||hla-33/NN	prep_of||susceptibility-26/NN||types-35/NNS	amod||progression-38/NN||hivdisease-37/JJ	prep_to||types-35/NNS||progression-38/NN	hivdisease-37||humanimmunodeficiencyvirus-1||no||humanimmunodeficiencyvirus (hiv) is a prime candidate to impose such genetic selection owing to the vast number of people it infects and the varying susceptibility of different human leucocyte antigen (hla) types to hivdisease progression.
nsubjpass||administered-23/VBN||questionnaires-1/NNS	aux||ascertain-3/VB||to-2/TO	vmod||questionnaires-1/NNS||ascertain-3/VB	det||presence-5/NN||the-4/DT	dobj||ascertain-3/VB||presence-5/NN	amod||conditions-8/NNS||atopy-associated-7/JJ	prep_of||presence-5/NN||conditions-8/NNS	prep_such_as||conditions-8/NNS||hayfever-11/NN	prep_such_as||conditions-8/NNS||atopicdermatitis-13/NNS	conj_and||hayfever-11/NN||atopicdermatitis-13/NNS	prep_such_as||conditions-8/NNS||asthma-15/NN	conj_and||hayfever-11/NN||asthma-15/NN	amod||rhinitis-18/NNS||allergic-17/JJ	prep_such_as||conditions-8/NNS||rhinitis-18/NNS	conj_and||hayfever-11/NN||rhinitis-18/NNS	prep_such_as||conditions-8/NNS||allergicconjunctivitis-21/NNS	conj_and||hayfever-11/NN||allergicconjunctivitis-21/NNS	auxpass||administered-23/VBN||were-22/VBD	root||ROOT-0/null||administered-23/VBN	det||parents-26/NNS||the-25/DT	prep_to||administered-23/VBN||parents-26/NNS	num||pupils-29/NNS||128-28/CD	prep_of||parents-26/NNS||pupils-29/NNS	det||3rd-32/NNS||the-31/DT	prep_in||pupils-29/NNS||3rd-32/NNS	amod||grades-35/NNS||6th-34/JJ	prep_to||administered-23/VBN||grades-35/NNS	amod||school-38/NN||elementary-37/JJ	prep_of||grades-35/NNS||school-38/NN	hayfever-11||atopy--1||no||questionnaires to ascertain the presence of atopy-associated conditions such as hayfever, atopicdermatitis, asthma, allergic rhinitis, and allergicconjunctivitis were administered to the parents of 128 pupils in the 3rd to 6th grades of elementary school.
det||objectives-3/NNS||the-1/DT	amod||objectives-3/NNS||primary-2/JJ	nsubj||were-4/VBD||objectives-3/NNS	nsubj||evaluate-6/VB||objectives-3/NNS	root||ROOT-0/null||were-4/VBD	aux||evaluate-6/VB||to-5/TO	xcomp||were-4/VBD||evaluate-6/VB	det||safety-8/NN||the-7/DT	dobj||evaluate-6/VB||safety-8/NN	det||vaccine-13/NN||a-10/DT	amod||vaccine-13/NN||tetravalent-11/JJ	nn||vaccine-13/NN||dengue-12/NN	prep_of||safety-8/NN||vaccine-13/NN	appos||safety-8/NN||tdv-15/NN	vmod||safety-8/NN||comprising-17/VBG	num||viruses-24/NNS||four-18/CD	amod||viruses-24/NNS||recombinant-19/JJ	amod||viruses-24/NNS||live-21/JJ	amod||viruses-24/NNS||attenuated-23/JJ	dobj||comprising-17/VBG||viruses-24/NNS	appos||safety-8/NN||cyd-tdv-26/NNP	det||responses-33/NNS||the-29/DT	amod||responses-33/NNS||denguevirus-30/JJ	amod||responses-33/NNS||serotype-specific-31/JJ	nn||responses-33/NNS||antibody-32/NN	xcomp||were-4/VBD||responses-33/NNS	conj_and||evaluate-6/VB||responses-33/NNS	cc||28-36/CD||and-35/CC	num||d-37/SYM||28-36/CD	prep_before||responses-33/NNS||d-37/SYM	det||vaccination-40/NN||each-39/DT	prep_after||d-37/SYM||vaccination-40/NN	dengue-12||denguevirus-30||no||the primary objectives were to evaluate the safety of a tetravalent dengue vaccine (tdv) comprising four recombinant, live, attenuated viruses (cyd-tdv) and the denguevirus serotype-specific antibody responses before and 28 d after each vaccination.
amod||dependent-2/JJ||vitamind-1/JJ	amod||i-5/NNS||dependent-2/JJ	amod||i-5/NNS||rickets-3/JJ	nn||i-5/NNS||type-4/NN	nsubj||disorder-29/NN||i-5/NNS	appos||i-5/NNS||vddr-i-7/NNP	advmod||referred-11/VBN||also-10/RB	vmod||i-5/NNS||referred-11/VBN	advmod||vitamind-14/JJ||as-13/RB	amod||±-16/NNS||vitamind-14/JJ	amod||±-16/NNS||1î-15/JJ	prep_to||referred-11/VBN||±-16/NNS	amod||deficiency-19/NN||hydroxylase-18/JJ	dep||±-16/NNS||deficiency-19/NN	amod||rickets-23/NNS||pseudovitamind-21/JJ	nn||rickets-23/NNS||deficiency-22/NN	dep||±-16/NNS||rickets-23/NNS	conj_or||deficiency-19/NN||rickets-23/NNS	cop||disorder-29/NN||is-25/VBZ	det||disorder-29/NN||an-26/DT	amod||disorder-29/NN||autosomal-27/JJ	nn||disorder-29/NN||recessive-28/NN	root||ROOT-0/null||disorder-29/NN	vmod||disorder-29/NN||characterized-30/VBN	dep||characterized-30/VBN||clinically-31/RB	prep_by||clinically-31/RB||hypotonia-33/NN	nn||weakness-36/NN||muscle-35/NN	conj_and||disorder-29/NN||weakness-36/NN	nn||failure-39/NN||growth-38/NN	appos||weakness-36/NN||failure-39/NN	amod||seizures-42/NNS||hypocalcemic-41/JJ	conj_and||disorder-29/NN||seizures-42/NNS	amod||infancy-45/NN||early-44/JJ	prep_in||seizures-42/NNS||infancy-45/NN	amod||findings-49/NNS||radiographic-48/JJ	conj_and||disorder-29/NN||findings-49/NNS	prep_of||findings-49/NNS||rickets-51/NNS	rickets-51||vitamind-14||yes||vitamind dependent rickets type i (vddr-i), also referred to as vitamind 1î±-hydroxylase deficiency or pseudovitamind deficiency rickets, is an autosomal recessive disorder characterized clinically by hypotonia, muscle weakness, growth failure, hypocalcemic seizures in early infancy, and radiographic findings of rickets.
prep||used-18/VBN||given-1/VBN	det||safety-3/NN||the-2/DT	pobj||given-1/VBN||safety-3/NN	pobj||given-1/VBN||effectiveness-5/NN	conj_and||safety-3/NN||effectiveness-5/NN	amod||costs-9/NNS||low-8/JJ	pobj||given-1/VBN||costs-9/NNS	conj_and||safety-3/NN||costs-9/NNS	prep_of||costs-9/NNS||albendazole-11/NN	det||drug-14/NN||this-13/DT	nsubjpass||used-18/VBN||drug-14/NN	aux||used-18/VBN||could-15/MD	auxpass||used-18/VBN||be-16/VB	advmod||used-18/VBN||potentially-17/RB	root||ROOT-0/null||used-18/VBN	mark||and/or-22/VBZ||as-19/IN	det||alternative-21/NN||an-20/DT	nsubj||and/or-22/VBZ||alternative-21/NN	advcl||used-18/VBN||and/or-22/VBZ	det||replacement-24/NN||a-23/DT	dobj||and/or-22/VBZ||replacement-24/NN	det||protocols-30/NNS||the-26/DT	amod||protocols-30/NNS||existing-27/VBG	amod||protocols-30/NNS||metronidazole-28/JJ	nn||protocols-30/NNS||therapy-29/NN	prep_for||replacement-24/NN||protocols-30/NNS	det||treatment-33/NN||the-32/DT	prep_in||protocols-30/NNS||treatment-33/NN	prep_of||treatment-33/NN||giardiasis-35/NNS	prep_in||giardiasis-35/NNS||humans-37/NNS	giardiasis-35||metronidazole-28||yes||given the safety, effectiveness, and low costs of albendazole, this drug could be potentially used as an alternative and/or a replacement for the existing metronidazole therapy protocols in the treatment of giardiasis in humans.
prep_in||reduced-7/VBD||addition-2/NN	nn||supplement-5/NN||zinc-4/NN	nsubj||reduced-7/VBD||supplement-5/NN	advmod||reduced-7/VBD||significantly-6/RB	root||ROOT-0/null||reduced-7/VBD	det||severity-9/NN||the-8/DT	dobj||reduced-7/VBD||severity-9/NN	prep_of||severity-9/NN||diarrhea-11/NN	prep_of||severity-9/NN||duration-13/NN	conj_and||diarrhea-11/NN||duration-13/NN	det||episode-16/NN||the-15/DT	prep_of||severity-9/NN||episode-16/NN	zinc-4||diarrhea-11||no_rel||in addition, zinc supplement significantly reduced the severity of diarrhea and duration of the episode.
num||third-2/NN||one-1/CD	nsubjpass||estimated-9/VBN||third-2/NN	nsubjpass||infected-12/VBN||third-2/NN	det||world-5/NN||the-4/DT	poss||population-7/NN||world-5/NN	prep_of||third-2/NN||population-7/NN	auxpass||estimated-9/VBN||is-8/VBZ	root||ROOT-0/null||estimated-9/VBN	aux||infected-12/VBN||to-10/TO	auxpass||infected-12/VBN||be-11/VB	xcomp||estimated-9/VBN||infected-12/VBN	prep_with||infected-12/VBN||mycobacteriumtuberculosis-14/NNS	xcomp||estimated-9/VBN||representing-16/VBG	det||reservoir-19/NN||a-17/DT	amod||reservoir-19/NN||huge-18/JJ	dobj||representing-16/VBG||reservoir-19/NN	amod||disease-26/NNP||potential-21/JJ	nn||disease-26/NNP||tuberculosis-22/NNP	appos||disease-26/NNP||tb-24/NN	prep_of||reservoir-19/NN||disease-26/NNP	tb-24||mycobacteriumtuberculosis-14||no||one third of the world's population is estimated to be infected with mycobacteriumtuberculosis , representing a huge reservoir of potential tuberculosis (tb) disease.
nsubj||tested-2/VBD||we-1/PRP	root||ROOT-0/null||tested-2/VBD	det||hypothesis-4/NNS||the-3/DT	dobj||tested-2/VBD||hypothesis-4/NNS	mark||prevents-9/VBZ||that-5/IN	num||terbutaline-8/NN||2.5-6/CD	nn||terbutaline-8/NN||mg-7/NN	nsubj||prevents-9/VBZ||terbutaline-8/NN	ccomp||tested-2/VBD||prevents-9/VBZ	amod||hypoglycemia-11/NN||nocturnal-10/JJ	dobj||prevents-9/VBZ||hypoglycemia-11/NN	prepc_without||prevents-9/VBZ||causing-13/VBG	nn||hyperglycemia-15/NN||morning-14/NN	dobj||causing-13/VBG||hyperglycemia-15/NN	terbutaline-8||hyperglycemia-15||no_rel||we tested the hypothesis that 2.5 mg terbutaline prevents nocturnal hypoglycemia without causing morning hyperglycemia.
nsubjpass||perceived-9/VBN||conflict-1/NN	amod||practices-7/NNS||risky-3/JJ	amod||practices-7/NNS||sexual-4/JJ	amod||practices-7/NNS||related-5/JJ	amod||practices-7/NNS||cultural-6/JJ	conj_and||conflict-1/NN||practices-7/NNS	nsubjpass||perceived-9/VBN||practices-7/NNS	auxpass||perceived-9/VBN||were-8/VBD	root||ROOT-0/null||perceived-9/VBN	agent||perceived-9/VBN||communities-11/NNS	amod||drivers-14/NNS||major-13/JJ	prep_as||communities-11/NNS||drivers-14/NNS	prep_of||drivers-14/NNS||hiv-16/NN	prep_of||drivers-14/NNS||aids-18/NNS	conj_and||hiv-16/NN||aids-18/NNS	det||district-21/NN||the-20/DT	prep_in||perceived-9/VBN||district-21/NN	aids-18||hiv-16||no||conflict and risky sexual related cultural practices were perceived by communities as major drivers of hiv and aids in the district.
prep_in||explored-19/VBN||addition-2/NN	amod||tests-5/NNS||immunological-4/JJ	nsubjpass||explored-19/VBN||tests-5/NNS	nsubj||identify-21/VB||tests-5/NNS	det||detection-8/NN||the-7/DT	prep_for||tests-5/NNS||detection-8/NN	amod||antigens-11/NNS||m.tuberculosis-10/JJ	prep_of||detection-8/NN||antigens-11/NNS	prep_of||detection-8/NN||antibodies-13/NNS	conj_and||antigens-11/NNS||antibodies-13/NNS	det||antigens-16/NNS||the-15/DT	prep_to||antigens-11/NNS||antigens-16/NNS	aux||explored-19/VBN||have-17/VBP	auxpass||explored-19/VBN||been-18/VBN	root||ROOT-0/null||explored-19/VBN	aux||identify-21/VB||to-20/TO	xcomp||explored-19/VBN||identify-21/VB	dobj||identify-21/VB||individuals-22/NNS	prep_at||identify-21/VB||risk-24/NN	amod||-rrb--35/NNS||developing-26/VBG	advmod||-rrb--35/NNS||tb-27/RB	conj_or||tb-27/RB||with-29/IN	advmod||-rrb--35/NNS||with-29/IN	nn||ltbi-34/NNS||latent-30/NN	nn||ltbi-34/NNS||tb-31/NN	nn||ltbi-34/NNS||infection-32/NN	amod||ltbi-34/NNS||-lrb--33/JJ	pobj||with-29/IN||ltbi-34/NNS	prep_of||risk-24/NN||-rrb--35/NNS	tb-31||m.tuberculosis-10||no||in addition , immunological tests for the detection of m.tuberculosis antigens and antibodies to the antigens have been explored to identify individuals at risk of developing tb or with latent tb infection -lrb- ltbi -rrb- .
nn||hbp-2/NN||baseline-1/NN	nsubj||â-18/NN||hbp-2/NN	nn||s.d.-6/NNP||meanâ-4/NNP	nn||s.d.-6/NNP||±-5/NNP	appos||hbp-2/NN||s.d.-6/NNP	det||morning-10/NN||the-9/DT	prep_in||hbp-2/NN||morning-10/NN	det||measurement-14/NN||the-12/DT	amod||measurement-14/NN||first-13/JJ	appos||morning-10/NN||measurement-14/NN	cop||â-18/NN||was-16/VBD	num||â-18/NN||151.6-17/CD	root||ROOT-0/null||â-18/NN	number||16.4-20/CD||±-19/CD	dep||â-18/NN||16.4-20/CD	punct||â-38/NNS||/-21/:	number||â-23/CD||87.1-22/CD	num||â-26/NNS||â-23/CD	nn||â-26/NNS||±-24/NNP	num||â-26/NNS||11.8-25/CD	nsubj||â-38/NNS||â-26/NNS	num||â-26/NNS||$-27/$	number||mmâ-29/CD||-28/CD	num||$-27/$||mmâ-29/CD	amod||â-26/NNS||$-30/$	number||hg-32/CD||-31/CD	num||$-30/$||hg-32/CD	advmod||bedtime-35/JJ||at-34/IN	amod||â-26/NNS||bedtime-35/JJ	conj_and||$-30/$||bedtime-35/JJ	cop||â-38/NNS||was-36/VBD	num||â-38/NNS||144.3-37/CD	dep||â-18/NN||â-38/NNS	number||16.8-40/CD||±-39/CD	num||â-38/NNS||16.8-40/CD	punct||â-38/NNS||/-41/:	number||â-43/CD||82.8-42/CD	num||â-46/NN||â-43/CD	nn||â-46/NN||±-44/NNP	num||â-46/NN||11.9-45/CD	dep||â-18/NN||â-46/NN	dep||â-18/NN||$-47/$	num||$-47/$||-48/CD	vmod||$-47/$||mmâ-49/VBN	dobj||mmâ-49/VBN||$-50/$	number||hg-52/CD||-51/CD	num||$-50/$||hg-52/CD	mark||â-58/NN||whereas-54/IN	nsubj||â-58/NN||cbp-55/NN	cop||â-58/NN||was-56/VBD	num||â-58/NN||153.6-57/CD	dep||â-18/NN||â-58/NN	num||19.0-60/CD||±-59/CD	dep||â-58/NN||19.0-60/CD	punct||19.0-60/CD||/-61/:	number||â-63/CD||87.1-62/CD	num||â-66/NN||â-63/CD	nn||â-66/NN||±-64/NNP	num||â-66/NN||13.4-65/CD	nsubj||mmâ-69/VBP||â-66/NN	amod||â-66/NN||$-67/$	dep||$-67/$||-68/JJ	dep||19.0-60/CD||mmâ-69/VBP	dobj||mmâ-69/VBP||$-70/$	number||hg-72/CD||-71/CD	num||$-70/$||hg-72/CD	hg-72||hbp-2||no_rel||baseline hbp (meanâ±s.d.) in the morning (the first measurement) was 151.6â±16.4/87.1â±11.8âmmâhg and at bedtime was 144.3â±16.8/82.8â±11.9âmmâhg, whereas cbp was 153.6â±19.0/87.1â±13.4âmmâhg.
mark||suggested-6/VBN||although-1/IN	det||studies-4/NNS||some-2/DT	amod||studies-4/NNS||previous-3/JJ	nsubj||suggested-6/VBN||studies-4/NNS	aux||suggested-6/VBN||have-5/VBP	advcl||examined-24/VBN||suggested-6/VBN	mark||comprised-14/VBN||that-7/IN	amod||growth-9/NN||posttraumatic-8/JJ	nsubjpass||comprised-14/VBN||growth-9/NN	appos||growth-9/NN||ptg-11/NN	auxpass||comprised-14/VBN||is-13/VBZ	ccomp||suggested-6/VBN||comprised-14/VBN	amod||factors-17/NNS||several-16/JJ	prep_of||comprised-14/VBN||factors-17/NNS	amod||properties-20/NNS||different-19/JJ	prep_with||comprised-14/VBN||properties-20/NNS	nsubj||examined-24/VBN||few-22/JJ	aux||examined-24/VBN||have-23/VBP	root||ROOT-0/null||examined-24/VBN	predet||association-27/NN||both-25/PDT	det||association-27/NN||the-26/DT	dobj||examined-24/VBN||association-27/NN	prep_between||examined-24/VBN||ptg-29/NN	prep_between||examined-24/VBN||posttraumaticstressdisorder-31/NN	conj_and||ptg-29/NN||posttraumaticstressdisorder-31/NN	dep||examined-24/VBN||ptsd-33/VBN	prep_between||examined-24/VBN||ptg-37/NN	conj_and||ptg-29/NN||ptg-37/NN	conj_and||ptg-29/NN||resilience-39/NN	conj_and||ptg-37/NN||resilience-39/NN	vmod||ptg-37/NN||focusing-41/VBG	prep_on||focusing-41/VBG||each-43/DT	det||factors-46/NNS||the-45/DT	prep_of||each-43/DT||factors-46/NNS	prep_of||factors-46/NNS||ptg-48/NN	ptsd-33||ptg-48||no_rel||although some previous studies have suggested that posttraumatic growth (ptg) is comprised of several factors with different properties, few have examined both the association between ptg and posttraumaticstressdisorder (ptsd) and between ptg and resilience, focusing on each of the factors of ptg.
mark||inactive-5/JJ||while-1/IN	nn||monotherapy-3/NN||cisplatin-2/NN	nsubj||inactive-5/JJ||monotherapy-3/NN	cop||inactive-5/JJ||was-4/VBD	advcl||abrogated-16/VBD||inactive-5/JJ	nsubj||abrogated-16/VBD||combination-7/NN	amod||silencing-10/NN||bmi-1-9/JJ	prep_of||combination-7/NN||silencing-10/NN	prep_along_with||completely-15/RB||cisplatin-13/NN	advmod||completely-15/RB||almost-14/RB	advmod||abrogated-16/VBD||completely-15/RB	root||ROOT-0/null||abrogated-16/VBD	nn||growth-18/NN||ovariantumor-17/NN	dobj||abrogated-16/VBD||growth-18/NN	ovariantumor-17||cisplatin-13||yes||while cisplatin monotherapy was inactive, combination of bmi-1 silencing along with cisplatin almost completely abrogated ovariantumor growth.
nsubjpass||studied-19/VBN||properties-1/NNS	amod||´-5/NNS||mutant-3/JJ	nn||´-5/NNS||î-4/NN	prep_of||properties-1/NNS||´-5/NNS	amod||dehydratase-8/NN||aminolevulinate-7/JJ	dep||´-5/NNS||dehydratase-8/NN	dep||´-5/NNS||alad-10/VBN	vmod||´-5/NNS||found-12/VBN	prep_in||found-12/VBN||patients-14/NNS	amod||porphyria-17/NN||alad-16/JJ	prep_with||patients-14/NNS||porphyria-17/NN	auxpass||studied-19/VBN||were-18/VBD	root||ROOT-0/null||studied-19/VBN	amod||analyses-24/NNS||enzymological-21/JJ	conj_and||enzymological-21/JJ||immunological-23/JJ	amod||analyses-24/NNS||immunological-23/JJ	agent||studied-19/VBN||analyses-24/NNS	det||synthesis-27/NN||the-26/DT	nsubj||using-31/VBG||synthesis-27/NN	amod||complexes-30/NNS||enzyme-29/JJ	prep_of||synthesis-27/NN||complexes-30/NNS	prepc_after||studied-19/VBN||using-31/VBG	det||system-34/NN||a-32/DT	amod||system-34/NN||cell-free-33/JJ	dobj||using-31/VBG||system-34/NN	porphyria-17||enzyme-29||no_rel||properties of mutant î´-aminolevulinate dehydratase (alad) found in patients with alad porphyria were studied by enzymological and immunological analyses after the synthesis of enzyme complexes using a cell-free system.
det||review-2/NN||this-1/DT	nsubj||discusses-3/VBZ||review-2/NN	root||ROOT-0/null||discusses-3/VBZ	amod||niches-6/NNS||potential-4/JJ	amod||niches-6/NNS||therapeutic-5/JJ	dobj||discusses-3/VBZ||niches-6/NNS	amod||applications-9/NNS||future-8/JJ	dobj||discusses-3/VBZ||applications-9/NNS	conj_and||niches-6/NNS||applications-9/NNS	prep_of||applications-9/NNS||alemtuzumab-11/NN	det||focus-14/NN||a-13/DT	prep_with||discusses-3/VBZ||focus-14/NN	amod||treatment-18/NN||cll-16/JJ	amod||treatment-18/NN||front-line-17/JJ	prep_on||focus-14/NN||treatment-18/NN	cll-16||alemtuzumab-11||yes||this review discusses potential therapeutic niches and future applications of alemtuzumab with a focus on cll front-line treatment.
vmod||performed-9/VBD||using-1/VBG	amod||methods-3/NNS||statistical-2/JJ	dobj||using-1/VBG||methods-3/NNS	amod||evolution-6/NN||molecular-5/JJ	prep_of||methods-3/NNS||evolution-6/NN	nsubj||performed-9/VBD||we-8/PRP	nsubj||found-33/VBD||we-8/PRP	root||ROOT-0/null||performed-9/VBD	det||analysis-12/NN||a-10/DT	amod||analysis-12/NN||comprehensive-11/JJ	dobj||performed-9/VBD||analysis-12/NN	amod||sequences-16/NNS||jcvirus-14/JJ	amod||sequences-16/NNS||vp1-15/JJ	prep_of||analysis-12/NN||sequences-16/NNS	vmod||sequences-16/NNS||isolated-17/VBN	num||patients-21/NNS||55-19/CD	nn||patients-21/NNS||pml-20/NN	prep_from||isolated-17/VBN||patients-21/NNS	num||sequences-24/NNS||253-23/CD	prep_from||isolated-17/VBN||sequences-24/NNS	conj_and||patients-21/NNS||sequences-24/NNS	vmod||sequences-24/NNS||isolated-25/VBN	det||urine-28/NN||the-27/DT	prep_from||isolated-25/VBN||urine-28/NN	amod||individuals-31/NNS||healthy-30/JJ	prep_of||urine-28/NN||individuals-31/NNS	conj_and||performed-9/VBD||found-33/VBD	mark||acquired-46/VBN||that-34/IN	det||subset-36/NN||a-35/DT	nsubjpass||acquired-46/VBN||subset-36/NN	prep_of||subset-36/NN||aminoacids-38/NNS	vmod||aminoacids-38/NNS||found-39/VBN	advmod||found-39/VBN||exclusively-40/RB	amod||sequences-44/NNS||pml-42/JJ	amod||sequences-44/NNS||vp1-43/JJ	prep_among||found-39/VBN||sequences-44/NNS	auxpass||acquired-46/VBN||is-45/VBZ	ccomp||found-33/VBD||acquired-46/VBN	amod||evolution-49/NN||adaptive-48/JJ	prep_via||acquired-46/VBN||evolution-49/NN	pml-42||jcvirus-14||no||using statistical methods of molecular evolution, we performed a comprehensive analysis of jcvirus vp1 sequences isolated from 55 pml patients and 253 sequences isolated from the urine of healthy individuals and found that a subset of aminoacids found exclusively among pml vp1 sequences is acquired via adaptive evolution.
mark||were-3/VBD||although-1/IN	expl||were-3/VBD||there-2/EX	advcl||decreased-26/VBN||were-3/VBD	neg||differences-6/NNS||no-4/DT	amod||differences-6/NNS||significant-5/JJ	nsubj||were-3/VBD||differences-6/NNS	det||-rrb--14/NN||the-8/DT	amod||-rrb--14/NN||vibriocidal-9/JJ	conj_or||vibriocidal-9/JJ||lipopolysaccharide-11/JJ	amod||-rrb--14/NN||lipopolysaccharide-11/JJ	amod||-rrb--14/NN||-lrb--12/JJ	nn||-rrb--14/NN||lps-13/NN	prep_in||differences-6/NNS||-rrb--14/NN	amod||responses-18/NNS||specific-16/JJ	amod||responses-18/NNS||immune-17/JJ	dep||-rrb--14/NN||responses-18/NNS	prep_to||responses-18/NNS||v.cholerae-20/NN	amod||patients-24/NNS||helminth-infected-22/JJ	nn||patients-24/NNS||cholera-23/NN	nsubj||decreased-26/VBN||patients-24/NNS	aux||decreased-26/VBN||had-25/VBD	root||ROOT-0/null||decreased-26/VBN	amod||responses-32/NNS||fecal-27/JJ	conj_and||fecal-27/JJ||serum-29/JJ	amod||responses-32/NNS||serum-29/JJ	amod||responses-32/NNS||iga-30/JJ	amod||responses-32/NNS||immune-31/JJ	dobj||decreased-26/VBN||responses-32/NNS	det||subunit-36/NN||the-34/DT	amod||subunit-36/NN||b-35/JJ	prep_to||responses-32/NNS||subunit-36/NN	nn||-rrb--42/NNP||cholera-38/NN	nn||-rrb--42/NNP||toxin-39/NN	nn||-rrb--42/NNP||-lrb--40/NNP	nn||-rrb--42/NNP||ctb-41/NNP	prep_of||subunit-36/NN||-rrb--42/NNP	det||decrease-49/NN||a-46/DT	advmod||modest-48/JJ||more-47/RBR	amod||decrease-49/NN||modest-48/JJ	dobj||decreased-26/VBN||decrease-49/NN	conj_and||responses-32/NNS||decrease-49/NN	nn||response-53/NN||serum-51/NN	nn||response-53/NN||igg-52/NN	prep_in||decrease-49/NN||response-53/NN	prep_to||decreased-26/VBN||ctb-55/NN	cholera-38||v.cholerae-20||no||although there were no significant differences in the vibriocidal or lipopolysaccharide -lrb- lps -rrb- - specific immune responses to v.cholerae , helminth-infected cholera patients had decreased fecal and serum iga immune responses to the b subunit of cholera toxin -lrb- ctb -rrb- as well as a more modest decrease in serum igg response to ctb .
det||injection-3/NN||a-1/DT	amod||injection-3/NN||monthly-2/JJ	nsubjpass||used-8/VBN||injection-3/NN	prep_of||injection-3/NN||palivizumab-5/NN	aux||used-8/VBN||has-6/VBZ	auxpass||used-8/VBN||been-7/VBN	root||ROOT-0/null||used-8/VBN	prep_for||used-8/VBN||prophylaxis-10/NNS	amod||rsvinfections-13/NNS||serious-12/JJ	prep_of||prophylaxis-10/NNS||rsvinfections-13/NNS	amod||children-16/NNS||high-risk-15/JJ	prep_among||used-8/VBN||children-16/NNS	num||countries-19/NNS||71-18/CD	prep_in||children-16/NNS||countries-19/NNS	prep_since||countries-19/NNS||1998-21/CD	nsubjpass||obtained-31/VBN||approval-23/NN	prep_for||approval-23/NN||use-25/NN	det||federation-29/NN||the-27/DT	nn||federation-29/NN||russian-28/NN	prep_in||use-25/NN||federation-29/NN	auxpass||obtained-31/VBN||was-30/VBD	conj_and||used-8/VBN||obtained-31/VBN	prep_in||obtained-31/VBN||february-33/NNP	num||february-33/NNP||2010-34/CD	rsvinfections-13||palivizumab-5||yes||a monthly injection of palivizumab has been used for prophylaxis of serious rsvinfections among high-risk children in 71 countries since 1998 and approval for use in the russian federation was obtained in february 2010.
det||background-4/NN||the-2/DT	amod||background-4/NN||db/db-3/JJ	prep_on||prevented-8/VBD||background-4/NN	amod||deletion-7/NN||sglt2-6/JJ	nsubj||prevented-8/VBD||deletion-7/NN	root||ROOT-0/null||prevented-8/VBD	xcomp||prevented-8/VBD||fasting-9/VBG	dobj||fasting-9/VBG||hyperglycemia-10/NN	nn||levels-15/NNS||plasma-13/NN	nn||levels-15/NNS||insulin-14/NN	nsubj||improved-19/JJ||levels-15/NNS	cop||improved-19/JJ||were-16/VBD	advmod||improved-19/JJ||also-17/RB	advmod||improved-19/JJ||dramatically-18/RB	conj_and||prevented-8/VBD||improved-19/JJ	hyperglycemia-10||insulin-14||yes||on the db/db background, sglt2 deletion prevented fasting hyperglycemia, and plasma insulin levels were also dramatically improved.
nsubj||raises-2/VBZ||this-1/DT	root||ROOT-0/null||raises-2/VBZ	det||issue-4/NN||the-3/DT	dobj||raises-2/VBZ||issue-4/NN	det||appropriateness-7/NN||the-6/DT	prep_of||issue-4/NN||appropriateness-7/NN	det||values-12/NNS||the-9/DT	amod||values-12/NNS||present-10/JJ	nn||values-12/NNS||reference-11/NN	prep_of||appropriateness-7/NN||values-12/NNS	prep_of||appropriateness-7/NN||guidelines-14/NNS	conj_and||values-12/NNS||guidelines-14/NNS	prepc_for||values-12/NNS||monitoring-16/VBG	amod||patients-18/NNS||hiv/aids-17/JJ	dobj||monitoring-16/VBG||patients-18/NNS	prep_in||monitoring-16/VBG||tanzania-20/NN	aids--1||hiv--1||no||this raises the issue of the appropriateness of the present reference values and guidelines for monitoring hiv/aids patients in tanzania.
nn||nn414-4/NNS||resultsâ-1/NNP	nn||nn414-4/NNS||$-2/NNP	nsubj||delivered-5/VBD||nn414-4/NNS	nsubj||showed-14/VBD||nn414-4/NNS	root||ROOT-0/null||delivered-5/VBD	amod||responses-9/NNS||systemically-6/JJ	amod||responses-9/NNS||amplified-7/JJ	nn||responses-9/NNS||epinephrine-8/NN	dobj||delivered-5/VBD||responses-9/NNS	amod||hypoglycemia-12/NN||acute-11/JJ	prep_during||delivered-5/VBD||hypoglycemia-12/NN	conj_and||delivered-5/VBD||showed-14/VBD	det||effect-17/NN||a-15/DT	amod||effect-17/NN||persisting-16/JJ	dobj||showed-14/VBD||effect-17/NN	aux||amplify-19/VB||to-18/TO	vmod||showed-14/VBD||amplify-19/VB	det||response-22/NN||the-20/DT	amod||response-22/NN||epinephrine-21/JJ	dobj||amplify-19/VB||response-22/NN	advmod||given-24/VBN||when-23/WRB	advcl||amplify-19/VB||given-24/VBN	number||h-26/CD||24-25/CD	dobj||given-24/VBN||h-26/CD	det||study-30/NN||the-28/DT	amod||study-30/NN||hypoglycemic-29/JJ	prep_before||given-24/VBN||study-30/NN	hypoglycemia-12||epinephrine-21||no_rel||resultsâ nn414 delivered systemically amplified epinephrine responses during acute hypoglycemia and showed a persisting effect to amplify the epinephrine response when given 24 h before the hypoglycemic study.
amod||concentrations-2/NNS||low-1/JJ	nsubjpass||enhanced-25/VBN||concentrations-2/NNS	dep||concentrations-2/NNS||1â-4/NNS	number||5-6/CD||1/4-5/CD	dep||1â-4/NNS||5-6/CD	dep||5-6/CD||mm-7/NN	prep_of||concentrations-2/NNS||formaldehyde-10/NN	vmod||formaldehyde-10/NN||induced-11/VBN	nn||responses-13/NNS||pain-12/NN	dobj||induced-11/VBN||responses-13/NNS	prep_in||induced-11/VBN||rat-15/NN	prep_via||rat-15/NN||trpv1-17/NNS	det||response-21/NN||this-19/DT	nn||response-21/NN||pain-20/NN	prep_via||rat-15/NN||response-21/NN	conj_and||trpv1-17/NNS||response-21/NN	aux||enhanced-25/VBN||could-22/MD	auxpass||enhanced-25/VBN||be-23/VB	advmod||enhanced-25/VBN||significantly-24/RB	root||ROOT-0/null||enhanced-25/VBN	agent||enhanced-25/VBN||ph-27/NN	num||ph-27/NN||6.0-28/CD	dep||ph-27/NN||mimicking-30/VBG	det||microenvironment-34/NN||the-31/DT	amod||microenvironment-34/NN||acidic-32/JJ	nn||microenvironment-34/NN||tumor-33/NN	dobj||mimicking-30/VBG||microenvironment-34/NN	pain-20||formaldehyde-10||no_rel||low concentrations (1â¼5 mm) of formaldehyde induced pain responses in rat via trpv1 and this pain response could be significantly enhanced by ph 6.0 (mimicking the acidic tumor microenvironment).
det||protein-4/NN||the-1/DT	amod||protein-4/NN||interferon-induced-2/JJ	amod||protein-4/NN||bst-2-3/JJ	nsubj||has-5/VBZ||protein-4/NN	ccomp||ssarcomaâ-18/VBZ||has-5/VBZ	det||ability-8/NN||the-6/DT	amod||ability-8/NN||unique-7/JJ	dobj||has-5/VBZ||ability-8/NN	aux||restrict-10/VB||to-9/TO	vmod||ability-8/NN||restrict-10/VB	det||egress-12/NNS||the-11/DT	dobj||restrict-10/VB||egress-12/NNS	prep_of||egress-12/NNS||hiv-1-14/CD	nsubj||ssarcomaâ-18/VBZ||kaposi-16/NNS	root||ROOT-0/null||ssarcomaâ-18/VBZ	dobj||ssarcomaâ-18/VBZ||$-19/$	advmod||herpesvirus-22/RB||associated-21/RB	dep||viruses-33/CD||herpesvirus-22/RB	nn||ebola-27/NNP||kshv-24/NNP	dep||virus-28/IN||ebola-27/NNP	prep||herpesvirus-22/RB||virus-28/IN	prep||herpesvirus-22/RB||other-31/JJ	conj_and||virus-28/IN||other-31/JJ	dep||other-31/JJ||enveloped-32/JJ	num||$-19/$||viruses-33/CD	kaposi'ssarcoma--1||interferon--1||yes||the interferon-induced bst-2 protein has the unique ability to restrict the egress of hiv-1, kaposi'ssarcomaâassociated herpesvirus (kshv), ebola virus, and other enveloped viruses.
nn||design-2/NN||research-1/NN	nsubj||gain-8/VB||design-2/NN	nn||$-5/NNP||methodsâ-4/NNP	conj_and||design-2/NN||$-5/NNP	nsubj||gain-8/VB||$-5/NNP	aux||gain-8/VB||to-7/TO	advcl||measured-24/VBD||gain-8/VB	dobj||gain-8/VB||insight-9/NN	det||role-12/NN||the-11/DT	prep_into||gain-8/VB||role-12/NN	prep_of||role-12/NN||pref-1-14/JJ	det||onset-17/NN||the-16/DT	prep_on||pref-1-14/JJ||onset-17/NN	prep_of||onset-17/NN||insulinresistance-19/NN	prep_of||onset-17/NN||type2diabetes-21/NNS	conj_and||insulinresistance-19/NN||type2diabetes-21/NNS	nsubj||measured-24/VBD||we-23/PRP	root||ROOT-0/null||measured-24/VBD	nn||composition-26/NN||body-25/NN	dobj||measured-24/VBD||composition-26/NN	amod||metabolism-31/NN||whole-body-28/JJ	amod||metabolism-31/NN||insulin-stimulated-29/JJ	nn||metabolism-31/NN||glucose-30/NN	dobj||measured-24/VBD||metabolism-31/NN	conj_and||composition-26/NN||metabolism-31/NN	det||clamp-35/NN||a-33/DT	amod||clamp-35/NN||hyperinsulinemic-euglycemic-34/JJ	prep_during||measured-24/VBD||clamp-35/NN	amod||transgenic-38/JJ||pref-1-37/JJ	prep_in||clamp-35/NN||transgenic-38/JJ	amod||mice-42/NNS||wild-type-40/JJ	nn||mice-42/NNS||control-41/NN	prep_in||clamp-35/NN||mice-42/NNS	conj_and||transgenic-38/JJ||mice-42/NNS	vmod||clamp-35/NN||fed-43/VBN	det||diet-46/NN||a-44/DT	amod||diet-46/NN||high-fat-45/JJ	dobj||fed-43/VBN||diet-46/NN	fat--1||insulinresistance-19||no_rel||research design and methodsâ to gain insight into the role of pref-1 on the onset of insulinresistance and type2diabetes, we measured body composition and whole-body insulin-stimulated glucose metabolism during a hyperinsulinemic-euglycemic clamp in pref-1 transgenic and wild-type control mice fed a high-fat diet.
amod||response-2/NN||humoral-1/JJ	nsubjpass||evaluated-4/VBN||response-2/NN	auxpass||evaluated-4/VBN||was-3/VBD	root||ROOT-0/null||evaluated-4/VBN	agent||evaluated-4/VBN||elisa-6/NN	num||patients-10/NNS||117-8/CD	nn||patients-10/NNS||tb-9/NN	prep_in||evaluated-4/VBN||patients-10/NNS	num||ltbi-13/NNS||45-12/CD	prep_in||evaluated-4/VBN||ltbi-13/NNS	conj_and||patients-10/NNS||ltbi-13/NNS	num||controls-17/NNS||67-15/CD	amod||controls-17/NNS||bcg-vaccinated-16/JJ	prep_in||evaluated-4/VBN||controls-17/NNS	conj_and||patients-10/NNS||controls-17/NNS	predet||those-21/DT||all-20/PDT	prep_including||evaluated-4/VBN||those-21/DT	nsubj||had-23/VBD||those-21/DT	rcmod||those-21/DT||had-23/VBD	amod||assay-25/NN||t-cell-24/JJ	dobj||had-23/VBD||assay-25/NN	prep_in||had-23/VBD||comparison-28/NN	det||kit-33/NN||a-30/DT	amod||kit-33/NN||commercial-31/JJ	nn||kit-33/NN||igg-32/NN	prep_with||comparison-28/NN||kit-33/NN	tb-9||bcg--1||no||humoral response was evaluated by elisa in 117 tb patients, 45 ltbi and 67 bcg-vaccinated controls, including all those who had t-cell assay, in comparison with a commercial igg kit.
det||increase-3/NN||a-1/DT	amod||increase-3/NN||significant-2/JJ	nsubjpass||reported-10/VBN||increase-3/NN	prep_in||increase-3/NN||congestiveheartfailure-5/NN	appos||increase-3/NN||chf-7/NN	auxpass||reported-10/VBN||was-9/VBD	root||ROOT-0/null||reported-10/VBN	advmod||used-17/VBN||when-11/WRB	det||trastuzumab-15/NN||the-12/DT	amod||trastuzumab-15/NN||anti-erbb2-13/JJ	nn||trastuzumab-15/NN||antibody-14/NN	nsubjpass||used-17/VBN||trastuzumab-15/NN	auxpass||used-17/VBN||was-16/VBD	advcl||reported-10/VBN||used-17/VBN	prep_in||used-17/VBN||combination-19/NN	det||doxorubicin-24/NN||the-21/DT	amod||doxorubicin-24/NN||chemotherapy-22/JJ	nn||doxorubicin-24/NN||drug-23/NN	prep_with||used-17/VBN||doxorubicin-24/NN	appos||doxorubicin-24/NN||dox-26/NN	congestiveheartfailure-5||doxorubicin-24||no||a significant increase in congestiveheartfailure (chf) was reported when the anti-erbb2 antibody trastuzumab was used in combination with the chemotherapy drug doxorubicin (dox).
nsubj||bacillus-2/VBZ||mycobacteriumbovis-1/NNS	ccomp||matter-30/NN||bacillus-2/VBZ	amod||rin-6/NN||calmette-3/JJ	nn||rin-6/NN||guã-4/NN	nn||rin-6/NN||©-5/NN	nsubj||vaccine-13/NN||rin-6/NN	appos||rin-6/NN||bcg-8/NN	cop||vaccine-13/NN||is-10/VBZ	det||vaccine-13/NN||a-11/DT	amod||vaccine-13/NN||sole-12/JJ	ccomp||bacillus-2/VBZ||vaccine-13/NN	advmod||used-15/VBN||currently-14/RB	vmod||vaccine-13/NN||used-15/VBN	prep_for||used-15/VBN||tb-17/NN	advmod||used-15/VBN||however-19/RB	det||efficacy-22/NN||the-21/DT	nsubj||matter-30/NN||efficacy-22/NN	prep_of||efficacy-22/NN||bcg-24/NN	prep_in||bcg-24/NN||adults-26/NNS	cop||matter-30/NN||is-27/VBZ	advmod||matter-30/NN||still-28/RB	det||matter-30/NN||a-29/DT	root||ROOT-0/null||matter-30/NN	prep_of||matter-30/NN||debate-32/NN	tb-17||bcg-24||yes||mycobacteriumbovis bacillus calmette guã©rin (bcg) is a sole vaccine currently used for tb, however, the efficacy of bcg in adults is still a matter of debate.
nsubj||mg-8/VBP||dabigatran-1/NN	prep||dabigatran-1/NN||given-2/VBN	pcomp||given-2/VBN||at-3/IN	det||dose-5/NN||a-4/DT	pobj||at-3/IN||dose-5/NN	prep_of||dose-5/NN||150-7/CD	root||ROOT-0/null||mg-8/VBP	advmod||mg-8/VBP||twice-9/RB	advmod||mg-8/VBP||daily-10/RB	mark||associated-18/VBN||as-12/IN	prepc_compared_with||associated-18/VBN||with-14/IN	pobj||associated-18/VBN||warfarin-15/NN	auxpass||associated-18/VBN||was-17/VBD	advcl||mg-8/VBP||associated-18/VBN	amod||rates-21/NNS||lower-20/JJR	prep_with||associated-18/VBN||rates-21/NNS	prep_of||rates-21/NNS||stroke-23/NN	amod||embolism-26/NN||systemic-25/JJ	prep_with||associated-18/VBN||embolism-26/NN	conj_and||rates-21/NNS||embolism-26/NN	prep||embolism-26/NN||but-27/CC	amod||rates-29/NNS||similar-28/JJ	pobj||but-27/CC||rates-29/NNS	amod||hemorrhage-32/NN||major-31/JJ	prep_of||rates-29/NNS||hemorrhage-32/NN	stroke-23||warfarin-15||yes||dabigatran given at a dose of 150 mg twice daily, as compared with warfarin, was associated with lower rates of stroke and systemic embolism but similar rates of major hemorrhage.
amod||advances-4/NNS||recent-1/JJ	amod||advances-4/NNS||basic-2/JJ	nn||advances-4/NNS||science-3/NN	nsubj||led-6/VBN||advances-4/NNS	aux||led-6/VBN||have-5/VBP	root||ROOT-0/null||led-6/VBN	prep_to||led-6/VBN||development-8/NN	nsubj||target-14/VBP||development-8/NN	amod||treatments-11/NNS||alternative-10/JJ	prep_of||development-8/NN||treatments-11/NNS	advmod||target-14/VBP||specifically-13/RB	rcmod||development-8/NN||target-14/VBP	amod||pathways-16/NNS||aberrant-15/JJ	dobj||target-14/VBP||pathways-16/NNS	nsubj||relevant-21/JJ||pathways-16/NNS	prep_of||pathways-16/NNS||fibrosis-18/NN	cop||relevant-21/JJ||are-20/VBP	rcmod||pathways-16/NNS||relevant-21/JJ	nn||progression-24/NN||disease-23/NN	prep_to||relevant-21/JJ||progression-24/NN	prep_in||progression-24/NN||fsgs-26/NNS	basic-2||fibrosis-18||no_rel||recent basic science advances have led to development of alternative treatments that specifically target aberrant pathways of fibrosis which are relevant to disease progression in fsgs.
poss||results-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||results-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||key-14/JJ||that-4/IN	det||combination-6/NN||a-5/DT	nsubj||key-14/JJ||combination-6/NN	amod||genes-11/NNS||suppressed-8/JJ	conj_and||suppressed-8/JJ||up-regulated-10/JJ	amod||genes-11/NNS||up-regulated-10/JJ	prep_of||combination-6/NN||genes-11/NNS	aux||key-14/JJ||may-12/MD	cop||key-14/JJ||be-13/VB	ccomp||suggest-3/VBP||key-14/JJ	prepc_in||key-14/JJ||determining-16/VBG	dobj||determining-16/VBG||development-17/NN	amod||immunity-20/NN||protective-19/JJ	prep_of||development-17/NN||immunity-20/NN	prep_to||determining-16/VBG||tb-22/NN	vmod||tb-22/NN||induced-23/VBN	agent||induced-23/VBN||vaccination-25/NN	prep_with||induced-23/VBN||bcg-27/NN	tb-22||bcg-27||no||our results suggest that a combination of suppressed and up-regulated genes may be key in determining development of protective immunity to tb induced by vaccination with bcg.
nsubj||share-5/VBP||cr-1/NN	amod||exercise-4/NN||endurance-3/JJ	conj_and||cr-1/NN||exercise-4/NN	nsubj||share-5/VBP||exercise-4/NN	root||ROOT-0/null||share-5/VBP	det||function-9/NN||a-6/DT	amod||function-9/NN||potent-7/JJ	amod||function-9/NN||anti-inflammatory-8/JJ	dobj||share-5/VBP||function-9/NN	amod||tissues-12/NNS||adipose-11/JJ	prep_in||function-9/NN||tissues-12/NNS	prepc_in||share-5/VBP||ameliorating-14/VBG	amod||obesity-16/NN||diet-induced-15/JJ	dobj||ameliorating-14/VBG||obesity-16/NN	dobj||ameliorating-14/VBG||insulinresistance-18/NN	conj_and||obesity-16/NN||insulinresistance-18/NN	obesity-16||anti-inflammatory-8||no_rel||cr and endurance exercise share a potent anti-inflammatory function in adipose tissues in ameliorating diet-induced obesity and insulinresistance.
nn||xenografts-2/NNS||tumor-1/NN	nsubjpass||established-4/VBN||xenografts-2/NNS	auxpass||established-4/VBN||were-3/VBD	root||ROOT-0/null||established-4/VBN	det||pad-9/NN||the-6/DT	advmod||fat-8/JJ||mammary-7/RB	amod||pad-9/NN||fat-8/JJ	prep_in||established-4/VBN||pad-9/NN	amod||mice-12/NNS||nu/nu-11/JJ	prep_of||pad-9/NN||mice-12/NNS	xcomp||established-4/VBN||using-13/VBG	amod||cells-17/NNS||human-14/JJ	nn||cells-17/NNS||breast-15/NN	nn||cells-17/NNS||cancer-16/NN	dobj||using-13/VBG||cells-17/NNS	nsubjpass||pre-exposed-20/VBN||cells-17/NNS	auxpass||pre-exposed-20/VBN||were-19/VBD	rcmod||cells-17/NNS||pre-exposed-20/VBN	preconj||hypoxic-23/JJ||either-22/DT	amod||conditions-26/NNS||hypoxic-23/JJ	conj_or||hypoxic-23/JJ||normoxic-25/JJ	amod||conditions-26/NNS||normoxic-25/JJ	prep_to||pre-exposed-20/VBN||conditions-26/NNS	hypoxic-23||fat-8||no_rel||tumor xenografts were established in the mammary fat pad of nu/nu mice using human breast cancer cells that were pre-exposed to either hypoxic or normoxic conditions.
det||mtx-12/NN||a-1/DT	amod||mtx-12/NN||24-week-2/JJ	amod||mtx-12/NN||double-blind-4/JJ	amod||mtx-12/NN||double-dummy-6/JJ	amod||mtx-12/NN||randomized-8/JJ	dep||mtx-12/NN||methotrexate-10/NN	root||ROOT-0/null||mtx-12/NN	amod||study-16/NN||controlled-15/JJ	nsubjpass||conducted-18/VBN||study-16/NN	nsubj||evaluate-20/VB||study-16/NN	auxpass||conducted-18/VBN||was-17/VBD	dep||mtx-12/NN||conducted-18/VBN	aux||evaluate-20/VB||to-19/TO	xcomp||conducted-18/VBN||evaluate-20/VB	det||efficacy-22/NN||the-21/DT	dobj||evaluate-20/VB||efficacy-22/NN	dobj||evaluate-20/VB||safety-24/NN	conj_and||efficacy-22/NN||safety-24/NN	prep_of||efficacy-22/NN||ccii-26/NNS	det||treatment-29/NN||the-28/DT	prep_in||ccii-26/NNS||treatment-29/NN	prep_of||treatment-29/NN||rheumatoidarthritis-31/NNS	appos||rheumatoidarthritis-31/NNS||ra-33/NN	rheumatoidarthritis-31||mtx-12||yes||a 24-week, double-blind, double-dummy, randomized, methotrexate (mtx)-controlled study was conducted to evaluate the efficacy and safety of ccii in the treatment of rheumatoidarthritis (ra).
det||adults-3/NNS||these-2/DT	prep_of||had-10/VBD||adults-3/NNS	nsubj||hiv-infected-7/JJ||56-5/CD	cop||hiv-infected-7/JJ||were-6/VBD	dep||had-10/VBD||hiv-infected-7/JJ	nsubj||had-10/VBD||120-9/CD	root||ROOT-0/null||had-10/VBD	det||member-13/NN||a-11/DT	nn||member-13/NN||family-12/NN	dobj||had-10/VBD||member-13/NN	prep_with||member-13/NN||hiv/aids-15/NNS	nsubj||were-19/VBD||146-18/CD	conj_and||had-10/VBD||were-19/VBD	prep_in||were-19/VBD||households-21/NNS	amod||members-24/NNS||hiv-infected-23/JJ	prep_without||were-19/VBD||members-24/NNS	aids--1||hiv--1||no||of these adults, 56 were hiv-infected, 120 had a family member with hiv/aids, and 146 were in households without hiv-infected members.
aux||investigate-2/VB||to-1/TO	root||ROOT-0/null||investigate-2/VB	mark||produce-18/VB||whether-3/IN	ccomp||investigate-2/VB||not-5/RB	conj_or||produce-18/VB||not-5/RB	nsubj||produce-18/VB||coadministration-6/NN	prep_of||coadministration-6/NN||tacrolimus-8/NNS	appos||tacrolimus-8/NNS||tac-10/NN	prep_with||tacrolimus-8/NNS||prednisolone-13/NN	appos||prednisolone-13/NN||psl-15/NN	aux||produce-18/VB||can-17/MD	ccomp||investigate-2/VB||produce-18/VB	det||effect-21/NN||a-19/DT	amod||effect-21/NN||beneficial-20/JJ	dobj||produce-18/VB||effect-21/NN	det||treatment-24/NN||the-23/DT	prep_in||produce-18/VB||treatment-24/NN	amod||dermatomyositis-28/NNS||polymyositis-26/JJ	amod||dermatomyositis-28/NNS||/-27/JJ	prep_of||treatment-24/NN||dermatomyositis-28/NNS	appos||dermatomyositis-28/NNS||pm/dm-30/NNP	tacrolimus-8||dermatomyositis-28||no_rel||to investigate whether or not coadministration of tacrolimus (tac) with prednisolone (psl) can produce a beneficial effect in the treatment of polymyositis/ dermatomyositis (pm/dm).
det||study-7/NN||this-1/DT	amod||study-7/NN||26-week-2/JJ	amod||study-7/NN||double-blind-4/JJ	amod||study-7/NN||parallel-group-6/JJ	root||ROOT-0/null||study-7/NN	vmod||study-7/NN||randomized-8/VBN	amod||patients-10/NNS||655-9/JJ	dobj||randomized-8/VBN||patients-10/NNS	advmod||controlled-13/JJ||inadequately-12/RB	amod||monotherapy-25/NNS||controlled-13/JJ	amod||monotherapy-25/NNS||type2diabetes-14/JJ	num||arms-17/NNS||four-16/CD	prep_to||type2diabetes-14/JJ||arms-17/NNS	num||alogliptin-20/NN||25-18/CD	nn||alogliptin-20/NN||mg-19/NN	nsubj||-lrb--21/VBZ||alogliptin-20/NN	rcmod||arms-17/NNS||-lrb--21/VBZ	amod||monotherapy-25/NNS||a25-22/JJ	amod||monotherapy-25/NNS||-rrb--23/JJ	nn||monotherapy-25/NNS||q.d.-24/NN	prep_with||randomized-8/VBN||monotherapy-25/NNS	number||mg-28/CD||30-27/CD	num||monotherapy-34/NN||mg-28/CD	amod||monotherapy-34/NN||pioglitazone-29/JJ	amod||monotherapy-34/NN||-lrb--30/JJ	amod||monotherapy-34/NN||p30-31/JJ	amod||monotherapy-34/NN||-rrb--32/JJ	nn||monotherapy-34/NN||q.d.-33/NN	prep_with||randomized-8/VBN||monotherapy-34/NN	conj_or||monotherapy-25/NNS||monotherapy-34/NN	num||a12-39/NNS||12.5-37/CD	amod||a12-39/NNS||-lrb--38/JJ	prep_with||randomized-8/VBN||a12-39/NNS	conj_or||monotherapy-25/NNS||a12-39/NNS	num||-rrb--41/NNS||.5-40/CD	dep||a12-39/NNS||-rrb--41/NNS	num||q.d.-46/NN||25-43/CD	nn||q.d.-46/NN||mg-44/NN	nn||q.d.-46/NN||alogliptin-45/NN	prep_with||randomized-8/VBN||q.d.-46/NN	conj_or||monotherapy-25/NNS||q.d.-46/NN	prep||q.d.-46/NN||plus-47/CC	amod||therapy-54/NN||pioglitazone-48/JJ	nn||therapy-54/NN||-lrb--49/NNP	amod||therapy-54/NN||p30-50/JJ	amod||therapy-54/NN||-rrb--51/JJ	nn||therapy-54/NN||q.d.-52/NN	nn||therapy-54/NN||combination-53/NN	pobj||plus-47/CC||therapy-54/NN	pioglitazone-48||type2diabetes-14||no_rel||this 26-week , double-blind , parallel-group study randomized 655 patients with inadequately controlled type2diabetes to four arms 25 mg alogliptin -lrb- a25 -rrb- q.d. monotherapy , 30 mg pioglitazone -lrb- p30 -rrb- q.d. monotherapy , or 12.5 -lrb- a12 .5 -rrb- or 25 mg alogliptin q.d. plus pioglitazone -lrb- p30 -rrb- q.d. combination therapy .
amod||objectives-2/NNS||major-1/JJ	nsubj||were-6/VBD||objectives-2/NNS	nsubj||extract-8/VB||objectives-2/NNS	nsubj||evaluate-31/VB||objectives-2/NNS	nsubj||generate-50/VB||objectives-2/NNS	det||study-5/NN||this-4/DT	prep_of||objectives-2/NNS||study-5/NN	root||ROOT-0/null||were-6/VBD	aux||extract-8/VB||to-7/TO	xcomp||were-6/VBD||extract-8/VB	det||database-19/NN||the-9/DT	amod||database-19/NN||canadian-10/JJ	amod||database-19/NN||adverse-11/JJ	nn||database-19/NN||drug-12/NN	nn||database-19/NN||reaction-13/NN	nn||database-19/NN||monitoring-14/NN	nn||database-19/NN||program-15/NN	nn||database-19/NN||cadrmp-17/NN	dobj||extract-8/VB||database-19/NN	amod||detection-24/NN||possible-21/JJ	amod||detection-24/NN||toxic-22/JJ	nn||detection-24/NN||signal-23/NN	prep_for||database-19/NN||detection-24/NN	appos||detection-24/NN||sd-26/NN	prep_of||detection-24/NN||propranololhydrochloride-29/NN	xcomp||were-6/VBD||evaluate-31/VB	conj_and||extract-8/VB||evaluate-31/VB	det||frequency-33/NN||the-32/DT	dobj||evaluate-31/VB||frequency-33/NN	det||bradycardia-36/NN||the-35/DT	prep_of||frequency-33/NN||bradycardia-36/NN	vmod||bradycardia-36/NN||associated-37/VBN	prep_with||associated-37/VBN||it-39/PRP	amod||stratified-42/JJ||different-41/JJ	amod||groups-43/NNS||stratified-42/JJ	prep_in||associated-37/VBN||groups-43/NNS	det||signal-47/NN||a-45/DT	amod||signal-47/NN||putative-46/JJ	prep_for||groups-43/NNS||signal-47/NN	xcomp||were-6/VBD||generate-50/VB	conj_and||extract-8/VB||generate-50/VB	dobj||generate-50/VB||awareness-51/NN	nn||professionals-54/NNS||healthcare-53/NN	prep_in||generate-50/VB||professionals-54/NNS	prep_regarding||professionals-54/NNS||usefulness-56/NN	prep_of||usefulness-56/NN||sd-58/NN	bradycardia-36||propranololhydrochloride-29||no||major objectives of this study were to extract the canadian adverse drug reaction monitoring program (cadrmp) database for possible toxic signal detection (sd) of propranololhydrochloride, evaluate the frequency of the bradycardia associated with it in different stratified groups for a putative signal, and generate awareness in healthcare professionals regarding usefulness of sd.
det||beginning-3/NN||the-2/DT	prep_since||provided-16/VBN||beginning-3/NN	det||century-7/NN||the-5/DT	amod||century-7/NN||21st-6/JJ	prep_of||beginning-3/NN||century-7/NN	nn||assistance-10/NN||development-9/NN	nsubjpass||provided-16/VBN||assistance-10/NN	prep_for||assistance-10/NN||hiv/aids-12/NNS	aux||provided-16/VBN||has-13/VBZ	advmod||provided-16/VBN||increasingly-14/RB	auxpass||provided-16/VBN||been-15/VBN	root||ROOT-0/null||provided-16/VBN	amod||initiatives-20/NNS||global-18/JJ	nn||initiatives-20/NNS||health-19/NN	prep_through||provided-16/VBN||initiatives-20/NNS	advmod||plan-28/VBP||specifically-22/RB	det||emergency-27/NN||the-23/DT	amod||emergency-27/NN||united-24/VBN	nn||emergency-27/NN||states-25/NNS	amod||emergency-27/NN||presidential-26/JJ	nsubj||plan-28/VBP||emergency-27/NN	nsubj||fight-37/VB||emergency-27/NN	parataxis||provided-16/VBN||plan-28/VBP	nn||relief-31/NN||aids-30/NNS	prep_for||plan-28/VBP||relief-31/NN	det||fund-35/NN||the-33/DT	amod||fund-35/NN||global-34/JJ	appos||relief-31/NN||fund-35/NN	aux||fight-37/VB||to-36/TO	xcomp||plan-28/VBP||fight-37/VB	dobj||fight-37/VB||hiv-38/NN	dobj||fight-37/VB||tb-40/NN	conj_and||hiv-38/NN||tb-40/NN	dobj||fight-37/VB||malaria-42/NN	conj_and||hiv-38/NN||malaria-42/NN	det||multi-country-47/NN||the-44/DT	nn||multi-country-47/NN||world-45/NN	nn||multi-country-47/NN||bank-46/NN	nsubj||aids-48/VBZ||multi-country-47/NN	conj_and||provided-16/VBN||aids-48/VBZ	dobj||aids-48/VBZ||programme-49/NN	aids-48||hiv-38||no||since the beginning of the 21st century, development assistance for hiv/aids has increasingly been provided through global health initiatives, specifically the united states presidential emergency plan for aids relief, the global fund to fight hiv, tb and malaria and the world bank multi-country aids programme.
mark||express-4/VBP||because-1/IN	det||neurons-3/NNS||these-2/DT	nsubj||express-4/VBP||neurons-3/NNS	advcl||sought-17/VBD||express-4/VBP	det||isoform-10/NN||the-5/DT	amod||isoform-10/NN||kir6-6/JJ	num||/-8/NNS||.2-7/CD	npadvmod||sur-1-9/JJ||/-8/NNS	amod||isoform-10/NN||sur-1-9/JJ	dobj||express-4/VBP||isoform-10/NN	det||channel-14/NN||the-12/DT	nn||channel-14/NN||katp-13/NN	prep_of||isoform-10/NN||channel-14/NN	nsubj||sought-17/VBD||we-16/PRP	nsubj||examine-19/VB||we-16/PRP	root||ROOT-0/null||sought-17/VBD	aux||examine-19/VB||to-18/TO	xcomp||sought-17/VBD||examine-19/VB	det||potential-22/NN||the-20/DT	amod||potential-22/NN||therapeutic-21/JJ	dobj||examine-19/VB||potential-22/NN	det||sur-1â-25/NN||the-24/DT	prep_of||potential-22/NN||sur-1â-25/NN	dep||sur-1â-25/NN||$-26/$	advmod||channel-30/RB||selective-28/RB	npadvmod||channel-30/RB||potassium-29/CD	dep||opener-31/CD||channel-30/RB	num||$-26/$||opener-31/CD	appos||sur-1â-25/NN||kco-33/NN	appos||sur-1â-25/NN||nn414-36/NNS	aux||amplify-39/VB||to-38/TO	vmod||examine-19/VB||amplify-39/VB	amod||response-41/NN||counterregulatory-40/JJ	dobj||amplify-39/VB||response-41/NN	prep_to||amplify-39/VB||hypoglycemia-43/NN	hypoglycemia-43||potassium-29||no_rel||because these neurons express the kir6.2/sur-1 isoform of the katp channel, we sought to examine the therapeutic potential of the sur-1âselective potassium channel opener (kco), nn414, to amplify counterregulatory response to hypoglycemia.
nsubj||showed-24/VBD||antisera-1/NN	vmod||antisera-1/NN||raised-2/VBN	det||virus-6/NN||the-4/DT	amod||virus-6/NN||parental-5/JJ	prep_against||raised-2/VBN||virus-6/NN	vmod||virus-6/NN||reacted-7/VBN	advmod||reacted-7/VBN||equally-8/RB	preconj||homologous-11/JJ||both-10/DT	amod||viruses-14/NNS||homologous-11/JJ	conj_and||homologous-11/JJ||heterlogous-13/JJ	amod||viruses-14/NNS||heterlogous-13/JJ	prep_to||reacted-7/VBN||viruses-14/NNS	advmod||showed-24/VBD||however-16/RB	nsubj||showed-24/VBD||antisera-18/NN	vmod||antisera-18/NN||raised-19/VBN	det||virus-23/NN||the-21/DT	amod||virus-23/NN||mutant-22/JJ	prep_against||raised-19/VBN||virus-23/NN	root||ROOT-0/null||showed-24/VBD	num||folds-26/NNS||4-8-25/CD	npadvmod||lower-27/JJR||folds-26/NNS	amod||reactivity-28/NN||lower-27/JJR	dobj||showed-24/VBD||reactivity-28/NN	det||virus-32/NN||the-30/DT	amod||virus-32/NN||parental-31/JJ	prep_to||showed-24/VBD||virus-32/NN	virus-32||viruses-14||no||antisera raised against the parental virus reacted equally to both homologous and heterlogous viruses, however, antisera raised against the mutant virus showed 4-8 folds lower reactivity to the parental virus.
nsubj||had-12/VBD||patients-1/NNS	dobj||isolated-7/VBN||whom-3/WP	nsubjpass||isolated-7/VBN||m.tuberculosis-4/NNS	aux||isolated-7/VBN||had-5/VBD	auxpass||isolated-7/VBN||been-6/VBN	prepc_from||patients-1/NNS||isolated-7/VBN	agent||isolated-7/VBN||bactec-9/NN	advmod||often-11/RB||more-10/RBR	advmod||had-12/VBD||often-11/RB	root||ROOT-0/null||had-12/VBD	dobj||had-12/VBD||tuberculomas-13/NNS	nn||imaging-16/NN||ct-15/NN	nn||p-18/NN||imaging-16/NN	amod||p-18/NN||-lrb--17/JJ	prep_in||tuberculomas-13/NNS||p-18/NN	dep||-rrb--21/NNS||=-19/SYM	num||-rrb--21/NNS||0.018-20/CD	dep||p-18/NN||-rrb--21/NNS	tuberculomas-13||m.tuberculosis-4||no||patients from whom m.tuberculosis had been isolated by bactec more often had tuberculomas in ct imaging -lrb- p = 0.018 -rrb- .
num||groups-3/NNS||two-1/CD	nn||groups-3/NNS||treatment-2/NN	nsubjpass||compared-11/VBN||groups-3/NNS	amod||patients-7/NNS||resuscitated-5/JJ	nn||patients-7/NNS||trauma-6/NN	prep_of||groups-3/NNS||patients-7/NNS	prep_in||patients-7/NNS||cardiacarrest-9/NN	auxpass||compared-11/VBN||were-10/VBD	root||ROOT-0/null||compared-11/VBN	det||patients-16/NNS||the-13/DT	amod||patients-16/NNS||epinephrine-14/JJ	nn||patients-16/NNS||group-15/NN	prep_in||compared-11/VBN||patients-16/NNS	dep||patients-16/NNS||received-17/VBN	amod||mg-20/NN||epinephrine-18/JJ	amod||mg-20/NN||1â-19/JJ	nsubj||iv-21/VB||mg-20/NN	ccomp||received-17/VBN||iv-21/VB	det||min-24/NN||every-22/DT	amod||min-24/NN||3â-23/JJ	dobj||iv-21/VB||min-24/NN	advmod||iv-21/VB||only-25/RB	det||vasopressin-29/NN||the-28/DT	prep_in||iv-21/VB||vasopressin-29/NN	nn||patients-31/NNS||group-30/NN	nsubj||received-33/VBD||patients-31/NNS	advmod||received-33/VBD||first-32/RB	rcmod||vasopressin-29/NN||received-33/VBD	amod||hhs-35/NN||hypertonic-34/JJ	dobj||received-33/VBD||hhs-35/NN	nn||vasopressin-38/NN||arginine-37/NN	dobj||received-33/VBD||vasopressin-38/NN	conj_and||hhs-35/NN||vasopressin-38/NN	num||units-40/NNS||40-39/CD	npadvmod||iv-41/JJ||units-40/NNS	amod||hhs-35/NN||iv-41/JJ	advmod||received-33/VBD||only-42/RB	dep||patients-16/NNS||followed-44/VBN	conj_or||received-17/VBN||followed-44/VBN	amod||mg-48/NN||epinephrine-46/JJ	amod||mg-48/NN||1â-47/JJ	prep_by||followed-44/VBN||mg-48/NN	det||min-51/NN||every-49/DT	amod||min-51/NN||3â-50/JJ	dobj||received-17/VBN||min-51/NN	prep_until||received-17/VBN||cessation-53/NN	prep_of||cessation-53/NN||cpr-55/NN	cardiacarrest-9||epinephrine-46||yes||two treatment groups of resuscitated trauma patients in cardiacarrest were compared in the epinephrine group patients received epinephrine 1â mg iv every 3â min only; in the vasopressin group patients first received hypertonic hhs and arginine vasopressin 40 units iv only or followed by epinephrine 1â mg every 3â min until cessation of cpr.
nsubj||have-12/VBP||fluticasone/salmeterol-1/NN	conj_and||fluticasone/salmeterol-1/NN||budesonide/formoterol-3/NN	nsubj||have-12/VBP||budesonide/formoterol-3/NN	det||products-10/NNS||the-5/DT	advmod||available-7/JJ||currently-6/RB	amod||products-10/NNS||available-7/JJ	nn||products-10/NNS||ics/laba-8/NN	nn||products-10/NNS||combination-9/NN	appos||fluticasone/salmeterol-1/NN||products-10/NNS	root||ROOT-0/null||have-12/VBP	amod||efficacy-14/NN||similar-13/JJ	dobj||have-12/VBP||efficacy-14/NN	dobj||have-12/VBP||tolerability-16/NN	conj_and||efficacy-14/NN||tolerability-16/NN	prepc_based_on||have-12/VBP||on-18/IN	det||meta-analysis-21/NNS||a-19/DT	amod||meta-analysis-21/NNS||recent-20/JJ	pobj||have-12/VBP||meta-analysis-21/NNS	nn||trials-24/NNS||asthma-23/NN	prep_of||meta-analysis-21/NNS||trials-24/NNS	asthma-23||formoterol--1||no||fluticasone/salmeterol and budesonide/formoterol, the currently available ics/laba combination products, have similar efficacy and tolerability based on a recent meta-analysis of asthma trials.
nsubj||suspect-2/VBP||all-1/DT	root||ROOT-0/null||suspect-2/VBP	amod||cases-4/NNS||h5n1-3/JJ	nsubjpass||tested-6/VBN||cases-4/NNS	auxpass||tested-6/VBN||were-5/VBD	ccomp||suspect-2/VBP||tested-6/VBN	nn||assays-14/NNS||polymerase-8/NN	nn||assays-14/NNS||chain-9/NN	nn||assays-14/NNS||reaction-10/NN	nn||assays-14/NNS||pcr-12/NN	prep_with||tested-6/VBN||assays-14/NNS	prepc_for||tested-6/VBN||influenza-16/VBG	det||h5n1-19/NNS||a-17/DT	dobj||influenza-16/VBG||h5n1-19/NNS	dobj||influenza-16/VBG||humaninfluenzaviruses-22/NNS	conj_and||h5n1-19/NNS||humaninfluenzaviruses-22/NNS	influenza-16||influenzaviruses--1||no||all suspect h5n1 cases were tested with polymerase chain reaction (pcr) assays for influenza a(h5n1) and humaninfluenzaviruses.
mark||²-3/VBZ||although-1/IN	nsubj||²-3/VBZ||î-2/NN	advcl||display-14/VBP||²-3/VBZ	nn||numbers-6/NNS||cell-5/NN	nsubj||recover-7/VB||numbers-6/NNS	ccomp||²-3/VBZ||recover-7/VB	parataxis||²-3/VBZ||recover-7/VB	prep_by||recover-7/VB||birth-9/NN	amod||mice-13/NNS||adult-11/JJ	amod||mice-13/NNS||smo-deficient-12/JJ	nsubj||display-14/VBP||mice-13/NNS	root||ROOT-0/null||display-14/VBP	dobj||display-14/VBP||glucoseintolerance-15/NN	amod||sensitivity-19/NN||increased-17/VBN	nn||sensitivity-19/NN||insulin-18/NN	dobj||display-14/VBP||sensitivity-19/NN	conj_and||glucoseintolerance-15/NN||sensitivity-19/NN	amod||production-25/NN||reduced-22/VBN	amod||production-25/NN||total-23/JJ	nn||production-25/NN||insulin-24/NN	dobj||display-14/VBP||production-25/NN	conj_and||glucoseintolerance-15/NN||production-25/NN	insulin-24||glucoseintolerance-15||no_rel||although î²-cell numbers recover by birth, adult smo-deficient mice display glucoseintolerance, increased insulin sensitivity, and reduced total insulin production.
det||settings-3/NNS||these-2/DT	prep_in||continue-10/VBP||settings-3/NNS	nsubj||continue-10/VBP||babies-5/NNS	nsubj||added-13/VBN||babies-5/NNS	vmod||babies-5/NNS||born-6/VBN	amod||women-9/NNS||hiv-positive-8/JJ	prep_to||born-6/VBN||women-9/NNS	root||ROOT-0/null||continue-10/VBP	aux||added-13/VBN||to-11/TO	aux||added-13/VBN||have-12/VB	xcomp||continue-10/VBP||added-13/VBN	dobj||added-13/VBN||risks-14/NNS	prepc_of||risks-14/NNS||acquiring-16/VBG	dobj||acquiring-16/VBG||hivinfection-17/NN	prepc_of||risks-14/NNS||dying-19/VBG	conj_and||acquiring-16/VBG||dying-19/VBG	prep_from||dying-19/VBG||it-21/PRP	poss||birthdays-25/NNS||their-23/PRP$	amod||birthdays-25/NNS||fifth-24/JJ	prep_before||dying-19/VBG||birthdays-25/NNS	mark||employed-30/VBN||if-26/IN	neg||interventions-28/NNS||no-27/DT	nsubjpass||employed-30/VBN||interventions-28/NNS	auxpass||employed-30/VBN||are-29/VBP	advcl||added-13/VBN||employed-30/VBN	hivinfection-17||hiv--1||no||in these settings, babies born to hiv-positive women continue to have added risks of acquiring hivinfection and dying from it before their fifth birthdays if no interventions are employed.
amod||years-2/NNS||twenty-five-1/JJ	npadvmod||made-21/VBN||years-2/NNS	det||discovery-5/NN||the-4/DT	prep_after||made-21/VBN||discovery-5/NN	conj_and||discovery-5/NN||isolation-7/NN	prep_after||made-21/VBN||isolation-7/NN	det||humanimmunodeficiencyvirus-10/NNS||the-9/DT	prep_of||discovery-5/NN||humanimmunodeficiencyvirus-10/NNS	amod||scientists-15/NNS||french-12/JJ	conj_and||french-12/JJ||american-14/JJ	amod||scientists-15/NNS||american-14/JJ	prep_by||humanimmunodeficiencyvirus-10/NNS||scientists-15/NNS	amod||progress-18/NN||much-17/JJ	nsubjpass||made-21/VBN||progress-18/NN	aux||made-21/VBN||has-19/VBZ	auxpass||made-21/VBN||been-20/VBN	root||ROOT-0/null||made-21/VBN	amod||research-24/NN||basic-23/JJ	prep_in||made-21/VBN||research-24/NN	amod||treatment-27/NN||clinical-26/JJ	prep_in||made-21/VBN||treatment-27/NN	conj_and||research-24/NN||treatment-27/NN	amod||measures-33/NNS||public-30/JJ	nn||measures-33/NNS||health-31/NN	nn||measures-33/NNS||prevention-32/NN	prep_in||made-21/VBN||measures-33/NNS	conj_and||research-24/NN||measures-33/NNS	prep_for||measures-33/NNS||acquiredimmunodeficiencysyndrome-35/NN	acquiredimmunodeficiencysyndrome-35||humanimmunodeficiencyvirus-10||no||twenty-five years after the discovery and isolation of the humanimmunodeficiencyvirus by french and american scientists, much progress has been made in basic research, clinical treatment, and public health prevention measures for acquiredimmunodeficiencysyndrome.
det||prevention-3/NN||the-1/DT	nn||prevention-3/NN||stroke-2/NN	nsubj||reduced-33/VBD||prevention-3/NN	amod||reduction-6/NN||aggressive-5/JJ	prep_by||prevention-3/NN||reduction-6/NN	nn||levels-9/NNS||cholesterol-8/NN	prep_of||reduction-6/NN||levels-9/NNS	dep||levels-9/NNS||sparcl-11/JJ	nsubj||showed-14/VBD||trial-13/NN	rcmod||levels-9/NNS||showed-14/VBD	amod||treatment-16/NN||daily-15/JJ	dobj||showed-14/VBD||treatment-16/NN	num||mg-19/NN||80-18/CD	prep_with||showed-14/VBD||mg-19/NN	prep_of||mg-19/NN||atorvastatin-21/NN	prep_in||showed-14/VBD||patients-23/NNS	det||stroke-27/NN||a-25/DT	amod||stroke-27/NN||recent-26/JJ	prep_with||patients-23/NNS||stroke-27/NN	prep_with||patients-23/NNS||transientischemicattack-29/NN	conj_or||stroke-27/NN||transientischemicattack-29/NN	appos||stroke-27/NN||tia-31/NN	root||ROOT-0/null||reduced-33/VBD	det||incidence-35/NN||the-34/DT	dobj||reduced-33/VBD||incidence-35/NN	amod||stroke-40/NN||fatal-37/JJ	conj_or||fatal-37/JJ||nonfatal-39/JJ	amod||stroke-40/NN||nonfatal-39/JJ	prep_of||incidence-35/NN||stroke-40/NN	num||%-43/NN||16-42/CD	prep_by||reduced-33/VBD||%-43/NN	atorvastatin-21||stroke-40||no_rel||the stroke prevention by aggressive reduction of cholesterol levels (sparcl) trial showed daily treatment with 80 mg of atorvastatin in patients with a recent stroke or transientischemicattack (tia) reduced the incidence of fatal or nonfatal stroke by 16%.
nsubj||investigated-15/VBD||aims-1/NNS	det||trial-14/NN||this-2/DT	amod||trial-14/NN||52-week-3/JJ	amod||trial-14/NN||randomized-5/JJ	amod||trial-14/NN||multinational-7/JJ	amod||trial-14/NN||open-label-9/JJ	amod||trial-14/NN||parallel-group-11/JJ	amod||trial-14/NN||non-inferiority-13/JJ	dep||aims-1/NNS||trial-14/NN	root||ROOT-0/null||investigated-15/VBD	det||efficacy-17/NN||the-16/DT	nsubj||bolus-24/VBZ||efficacy-17/NN	conj_and||efficacy-17/NN||safety-19/NN	nsubj||bolus-24/VBZ||safety-19/NN	nn||$-22/NNP||basalâ-21/NNP	prep_of||efficacy-17/NN||$-22/NNP	ccomp||investigated-15/VBD||bolus-24/VBZ	dobj||bolus-24/VBZ||treatment-25/NN	prep_with||bolus-24/VBZ||insulin-27/NN	nn||insulin-27/NN||detemir-28/FW	nn||insulin-27/NN||vs.-29/FW	nn||insulin-27/NN||nph-30/FW	nn||insulin-27/NN||-lrb--31/FW	nn||insulin-27/NN||neutral-32/FW	nn||insulin-27/NN||protamine-33/FW	nn||insulin-27/NN||hagedorn-34/FW	nn||insulin-27/NN||-rrb--35/FW	dep||insulin-27/NN||insulin-36/FW	prep_in||insulin-27/NN||combination-39/NN	prep_with||combination-39/NN||insulinaspart-41/NN	prep_in||combination-39/NN||subjects-44/NNS	vmod||subjects-44/NNS||aged-45/VBN	dobj||aged-45/VBN||2â-46/NNS	num||years-50/NNS||$-47/$	num||$-47/$||16-49/CD	npadvmod||aged-45/VBN||years-50/NNS	prep_with||aged-45/VBN||type1diabetesmellitus-52/CD	type1diabetesmellitus-52||insulinaspart-41||yes||aims this 52-week , randomized , multinational , open-label , parallel-group , non-inferiority trial investigated the efficacy and safety of basalâ $ `` bolus treatment with insulin detemir vs. nph -lrb- neutral protamine hagedorn -rrb- insulin , in combination with insulinaspart , in subjects aged 2â $ `` 16 years with type1diabetesmellitus .
amod||colony-stimulatingfactors-3/NNS||recombinant-1/JJ	nn||colony-stimulatingfactors-3/NNS||granulocyte-2/NN	nsubjpass||used-11/VBN||colony-stimulatingfactors-3/NNS	nsubj||treat-13/VB||colony-stimulatingfactors-3/NNS	appos||colony-stimulatingfactors-3/NNS||g-csfs-5/NNS	prep_such_as||colony-stimulatingfactors-3/NNS||filgrastim-9/NN	auxpass||used-11/VBN||are-10/VBP	root||ROOT-0/null||used-11/VBN	aux||treat-13/VB||to-12/TO	xcomp||used-11/VBN||treat-13/VB	amod||neutropenia-15/NN||chemotherapy-induced-14/JJ	dobj||treat-13/VB||neutropenia-15/NN	neutropenia-15||filgrastim-9||yes||recombinant granulocyte colony-stimulatingfactors (g-csfs) such as filgrastim are used to treat chemotherapy-induced neutropenia.
det||subclinical-3/NN||a-1/DT	amod||subclinical-3/NN||higher-2/JJR	nsubjpass||associated-6/VBN||subclinical-3/NN	advmod||associated-6/VBN||vitaminadeficiency-4/RB	auxpass||associated-6/VBN||was-5/VBD	root||ROOT-0/null||associated-6/VBN	neg||receiving-9/VBG||not-8/RB	prepc_with||associated-6/VBN||receiving-9/VBG	nn||supplement-11/NN||vitamina-10/NN	dobj||receiving-9/VBG||supplement-11/NN	det||year-14/NN||the-13/DT	prep_over||receiving-9/VBG||year-14/NN	aux||ill-18/JJ||having-16/VBG	cop||ill-18/JJ||been-17/VBN	vmod||receiving-9/VBG||ill-18/JJ	det||weeks-22/NNS||the-20/DT	num||weeks-22/NNS||two-21/CD	prep_during||ill-18/JJ||weeks-22/NNS	xcomp||ill-18/JJ||preceding-23/VBG	det||survey-25/NN||the-24/DT	nsubj||belonging-32/VBG||survey-25/NN	amod||vaccination-30/NN||no-27/DT	conj_or||no-27/DT||incomplete-29/JJ	amod||vaccination-30/NN||incomplete-29/JJ	appos||survey-25/NN||vaccination-30/NN	vmod||preceding-23/VBG||belonging-32/VBG	det||mother-35/NN||a-34/DT	prep_to||belonging-32/VBG||mother-35/NN	amod||parity-38/NN||high-37/JJ	prep_with||ill-18/JJ||parity-38/NN	amod||levels-42/NNS||low-41/JJ	nsubjpass||associated-56/VBN||levels-42/NNS	nsubj||being-50/VBG||awareness-44/NN	prep_of||awareness-44/NN||vitamina-46/NNP	advmod||vitamina-46/NNP||moreover-48/RB	prepc_of||levels-42/NNS||being-50/VBG	nn||household-53/NN||muslim-52/NN	prep_from||being-50/VBG||household-53/NN	auxpass||associated-56/VBN||was-54/VBD	advmod||associated-56/VBN||strongly-55/RB	conj_and||associated-6/VBN||associated-56/VBN	amod||levels-59/NNS||higher-58/JJR	prep_with||associated-56/VBN||levels-59/NNS	amod||vitaminadeficiency-62/NN||subclinical-61/JJ	prep_of||levels-59/NNS||vitaminadeficiency-62/NN	vitaminadeficiency-62||vitamina-46||yes||a higher subclinical vitaminadeficiency was associated with not receiving vitamina supplement over the year , having been ill during the two weeks preceding the survey , no or incomplete vaccination , belonging to a mother with high parity , and low levels of awareness of vitamina. moreover , being from muslim household was strongly associated with higher levels of subclinical vitaminadeficiency .
num||patients-2/NNS||230-1/CD	nsubjpass||investigated-41/VBN||patients-2/NNS	prep_with||patients-2/NNS||melanoma-4/NN	det||control-group-7/NN||a-6/DT	prep_with||patients-2/NNS||control-group-7/NN	conj_and||melanoma-4/NN||control-group-7/NN	num||patients-10/NNS||625-9/CD	prep_of||melanoma-4/NN||patients-10/NNS	amod||melanoma-4/NN||consistent-11/JJ	amod||patients-14/NNS||212-13/JJ	prep_of||consistent-11/JJ||patients-14/NNS	nn||hepatitisb-17/NN||virus-16/NN	prep_with||patients-14/NNS||hepatitisb-17/NN	amod||melanoma-4/NN||c-19/SYM	conj_or||consistent-11/JJ||c-19/SYM	num||patients-22/NNS||149-21/CD	conj_and||patients-2/NNS||patients-22/NNS	nsubjpass||investigated-41/VBN||patients-22/NNS	prep_with||patients-22/NNS||allergies-24/NNS	num||patients-27/NNS||78-26/CD	conj_and||patients-2/NNS||patients-27/NNS	nsubjpass||investigated-41/VBN||patients-27/NNS	prep_with||patients-27/NNS||psoriasis-29/NNS	num||patients-32/NNS||46-31/CD	conj_and||patients-2/NNS||patients-32/NNS	nsubjpass||investigated-41/VBN||patients-32/NNS	prep_with||patients-32/NNS||plasmocytoma-34/NN	num||donors-39/NNS||140-36/CD	amod||donors-39/NNS||healthy-37/JJ	nn||donors-39/NNS||blood-38/NN	conj_and||patients-2/NNS||donors-39/NNS	nsubjpass||investigated-41/VBN||donors-39/NNS	auxpass||investigated-41/VBN||were-40/VBD	root||ROOT-0/null||investigated-41/VBN	det||occurrence-44/NN||the-43/DT	prep_for||investigated-41/VBN||occurrence-44/NN	amod||antibodies-47/NNS||cd28-46/JJ	prep_of||occurrence-44/NN||antibodies-47/NNS	psoriasis-29||allergies-24||no||230 patients with melanoma and a control-group of 625 patients consistent of 212 patients with virus hepatitisb or c, 149 patients with allergies, 78 patients with psoriasis, 46 patients with plasmocytoma and 140 healthy blood donors were investigated for the occurrence of cd28 antibodies.
det||study-2/NN||the-1/DT	nsubj||indicated-3/VBD||study-2/NN	nsubj||highlights-13/VBZ||study-2/NN	root||ROOT-0/null||indicated-3/VBD	det||prevalence-6/NN||a-4/DT	amod||prevalence-6/NN||high-5/JJ	dobj||indicated-3/VBD||prevalence-6/NN	prep_of||prevalence-6/NN||g6pddeficiency-8/CD	amod||province-11/NN||isabel-10/JJ	prep_in||indicated-3/VBD||province-11/NN	conj_and||indicated-3/VBD||highlights-13/VBZ	det||need-16/NN||the-14/DT	amod||need-16/NN||critical-15/JJ	dobj||highlights-13/VBZ||need-16/NN	aux||consider-18/VB||to-17/TO	vmod||need-16/NN||consider-18/VB	dobj||consider-18/VB||g6pddeficiency-19/NNS	det||context-22/NN||the-21/DT	prep_in||g6pddeficiency-19/NNS||context-22/NN	nn||strategies-27/NNS||p.-24/NN	nn||strategies-27/NNS||vivaxmalaria-25/NN	nn||strategies-27/NNS||elimination-26/NN	prep_of||context-22/NN||strategies-27/NNS	nn||islands-30/NNS||solomon-29/NN	prep_in||consider-18/VB||islands-30/NNS	dep||consider-18/VB||particularly-32/RB	prep_in||consider-18/VB||light-34/NN	det||role-38/NN||the-36/DT	amod||role-38/NN||potential-37/JJ	prep_of||light-34/NN||role-38/NN	amod||administration-43/NN||primaquine-40/JJ	nn||administration-43/NN||mass-41/NN	nn||administration-43/NN||drug-42/NN	prep_of||role-38/NN||administration-43/NN	vivaxmalaria-25||primaquine-40||yes||the study indicated a high prevalence of g6pddeficiency in isabel province and highlights the critical need to consider g6pddeficiency in the context of p. vivaxmalaria elimination strategies in solomon islands , particularly in light of the potential role of primaquine mass drug administration .
num||data-5/NNS||objectiveâ-1/CD	amod||data-5/NNS||$-2/JJ	amod||data-5/NNS||experimental-4/JJ	nsubj||indicate-9/VBP||data-5/NNS	nn||studies-8/NNS||animal-7/NN	prep_from||data-5/NNS||studies-8/NNS	root||ROOT-0/null||indicate-9/VBP	mark||play-15/VBP||that-10/IN	amod||sensors-14/NNS||portal-11/JJ	nn||sensors-14/NNS||vein-12/NN	nn||sensors-14/NNS||glucose-13/NN	nsubj||play-15/VBP||sensors-14/NNS	ccomp||indicate-9/VBP||play-15/VBP	det||role-18/NN||a-16/DT	amod||role-18/NN||key-17/JJ	dobj||play-15/VBP||role-18/NN	det||responses-21/NNS||the-20/DT	prep_in||role-18/NN||responses-21/NNS	amod||hypoglycemia-24/NN||slow-fall-23/JJ	prep_to||play-15/VBP||hypoglycemia-24/NN	hypoglycemia-24||glucose-13||yes||objectiveâ experimental data from animal studies indicate that portal vein glucose sensors play a key role in the responses to slow-fall hypoglycemia.
prep_in||involved-16/VBN||addition-2/NN	nsubjpass||involved-16/VBN||transport-4/NN	conj_and||transport-4/NN||diffusion-6/NN	nsubjpass||involved-16/VBN||diffusion-6/NN	prep_of||transport-4/NN||ions-8/NNS	det||epithelium-14/NN||the-10/DT	nn||epithelium-14/NN||bbb-11/NN	conj_and||bbb-11/NN||cp-13/NN	nn||epithelium-14/NN||cp-13/NN	prep_by||ions-8/NNS||epithelium-14/NN	auxpass||involved-16/VBN||are-15/VBP	root||ROOT-0/null||involved-16/VBN	det||formation-19/NN||the-18/DT	prep_in||involved-16/VBN||formation-19/NN	prep_of||formation-19/NN||fluid-21/NN	det||isf-24/NN||the-23/DT	prep_of||formation-19/NN||isf-24/NN	conj_and||fluid-21/NN||isf-24/NN	prep_of||formation-19/NN||csf-26/NN	conj_and||fluid-21/NN||csf-26/NN	advmod||involved-16/VBN||respectively-28/RB	dep||involved-16/VBN||so-30/IN	det||part-33/NN||the-31/DT	amod||part-33/NN||last-32/JJ	nsubj||discusses-37/VBZ||part-33/NN	nsubj||cp-51/VBP||part-33/NN	det||review-36/NN||this-35/DT	prep_of||part-33/NN||review-36/NN	parataxis||involved-16/VBN||discusses-37/VBZ	amod||biology-39/NN||molecular-38/JJ	dobj||discusses-37/VBZ||biology-39/NN	nn||transporters/exchangers-42/NNS||ion-41/NN	prep_of||biology-39/NN||transporters/exchangers-42/NNS	nn||channels-45/NNS||ion-44/NN	prep_of||biology-39/NN||channels-45/NNS	conj_and||transporters/exchangers-42/NNS||channels-45/NNS	det||endothelial-49/NN||the-47/DT	nn||endothelial-49/NN||brain-48/NN	prep_in||discusses-37/VBZ||endothelial-49/NN	parataxis||involved-16/VBN||cp-51/VBP	conj_and||discusses-37/VBZ||cp-51/VBP	amod||cells-53/NNS||epithelial-52/JJ	dobj||cp-51/VBP||cells-53/NNS	ions-8||cp-51||no_rel||in addition, transport and diffusion of ions by the bbb and cp epithelium are involved in the formation of fluid, the isf and csf, respectively, so the last part of this review discusses molecular biology of ion transporters/exchangers and ion channels in the brain endothelial and cp epithelial cells.
advmod||focuses-5/VBZ||finally-1/RB	det||review-4/NN||this-3/DT	nsubj||focuses-5/VBZ||review-4/NN	root||ROOT-0/null||focuses-5/VBZ	det||functions-11/NNS||the-7/DT	advmod||reported-9/VBN||recently-8/RB	amod||functions-11/NNS||reported-9/VBN	amod||functions-11/NNS||regulatory-10/JJ	prep_on||focuses-5/VBZ||functions-11/NNS	mark||exerts-20/VBZ||that-12/IN	amod||protein-15/NN||adipocyte-13/JJ	amod||protein-15/NN||enhancer-binding-14/JJ	nsubj||exerts-20/VBZ||protein-15/NN	num||protein-15/NN||1-16/CD	appos||protein-15/NN||aebp1-18/NNP	dep||functions-11/NNS||exerts-20/VBZ	nn||activity-29/NN||pparî-22/NNP	amod||activity-29/NN||³-23/JJ	dep||³-23/JJ||1-24/CD	dep||³-23/JJ||lxrî-26/CD	conj_and||1-24/CD||lxrî-26/CD	amod||activity-29/NN||±-27/JJ	amod||activity-29/NN||transcriptional-28/JJ	prep_on||exerts-20/VBZ||activity-29/NN	det||context-32/NN||the-31/DT	prep_in||exerts-20/VBZ||context-32/NN	amod||homeostasis-36/NNS||macrophage-34/JJ	nn||homeostasis-36/NNS||cholesterol-35/NN	prep_of||context-32/NN||homeostasis-36/NNS	prep_of||context-32/NN||inflammation-38/NN	conj_and||homeostasis-36/NNS||inflammation-38/NN	cholesterol-35||inflammation-38||no_rel||finally, this review focuses on the recently reported regulatory functions that adipocyte enhancer-binding protein 1 (aebp1) exerts on pparî³1 and lxrî± transcriptional activity in the context of macrophage cholesterol homeostasis and inflammation.
det||factors-5/NNS||the-1/DT	num||factors-5/NNS||two-2/CD	advmod||consistent-4/JJ||most-3/RBS	amod||factors-5/NNS||consistent-4/JJ	nsubj||having-14/VBG||factors-5/NNS	vmod||factors-5/NNS||associated-6/VBN	nn||testing-9/NN||hiv-8/NN	prep_with||associated-6/VBN||testing-9/NN	det||countries-12/NNS||the-11/DT	prep_across||associated-6/VBN||countries-12/NNS	aux||having-14/VBG||were-13/VBD	root||ROOT-0/null||having-14/VBG	dep||having-14/VBG||heard-15/VBN	prep_about||heard-15/VBN||hiv/aids-17/NNS	det||centre-23/NN||a-19/DT	nn||centre-23/NN||clinic-20/NN	conj_or||clinic-20/NN||health-22/NN	nn||centre-23/NN||health-22/NN	prep_from||hiv/aids-17/NNS||centre-23/NN	aux||talked-27/VBN||having-26/VBG	dep||having-14/VBG||talked-27/VBN	conj_and||heard-15/VBN||talked-27/VBN	prep_to||talked-27/VBN||someone-29/NN	prep_about||someone-29/NN||hiv-31/NN	prep_about||someone-29/NN||aids-33/NNS	conj_and||hiv-31/NN||aids-33/NNS	aids-33||hiv-31||no||the two most consistent factors associated with hiv testing across the countries were having heard about hiv/aids from a clinic or health centre, and having talked to someone about hiv and aids.
nsubjpass||used-19/VBN||some-1/DT	nsubj||effective-25/JJ||some-1/DT	det||metabolites-6/NNS||these-3/DT	amod||metabolites-6/NNS||bioactive-4/JJ	amod||metabolites-6/NNS||secondary-5/JJ	prep_of||some-1/DT||metabolites-6/NNS	amod||origin-9/NN||microbial-8/JJ	prep_of||metabolites-6/NNS||origin-9/NN	amod||activities-15/NNS||strong-11/JJ	amod||activities-15/NNS||antibacterial-12/JJ	conj_and||antibacterial-12/JJ||antifungal-14/JJ	amod||activities-15/NNS||antifungal-14/JJ	prep_with||origin-9/NN||activities-15/NNS	aux||used-19/VBN||are-16/VBP	auxpass||used-19/VBN||being-17/VBG	advmod||used-19/VBN||intensely-18/RB	root||ROOT-0/null||used-19/VBN	prep_as||used-19/VBN||antibiotics-21/NNS	aux||effective-25/JJ||may-23/MD	cop||effective-25/JJ||be-24/VB	conj_and||used-19/VBN||effective-25/JJ	amod||diseases-28/NNS||infectious-27/JJ	prep_against||effective-25/JJ||diseases-28/NNS	prep_such_as||diseases-28/NNS||hiv-31/NN	prep_such_as||diseases-28/NNS||conditions-33/NNS	conj_or||hiv-31/NN||conditions-33/NNS	amod||bacterialinfections-36/NNS||multiple-35/JJ	prep_of||conditions-33/NNS||bacterialinfections-36/NNS	dep||bacterialinfections-36/NNS||penicillin-38/NN	dep||bacterialinfections-36/NNS||cephalosporines-40/NNS	conj_and||penicillin-38/NN||cephalosporines-40/NNS	dep||bacterialinfections-36/NNS||streptomycin-42/NN	conj_and||penicillin-38/NN||streptomycin-42/NN	dep||bacterialinfections-36/NNS||vancomycin-45/NN	conj_and||penicillin-38/NN||vancomycin-45/NN	amod||sequelae-49/NN||neuropsychiatric-48/JJ	prep_such_as||diseases-28/NNS||sequelae-49/NN	conj_or||hiv-31/NN||sequelae-49/NN	bacterialinfections-36||vancomycin-45||yes||some of these bioactive secondary metabolites of microbial origin with strong antibacterial and antifungal activities are being intensely used as antibiotics and may be effective against infectious diseases such as hiv, conditions of multiple bacterialinfections (penicillin, cephalosporines, streptomycin, and vancomycin) or neuropsychiatric sequelae.
advmod||investigated-25/VBN||sulphadoxine-pyrimethamine-1/RB	dep||investigated-25/VBN||sp-3/VB	det||treatment-8/NN||a-5/DT	advmod||used-7/VBN||widely-6/RB	amod||treatment-8/NN||used-7/VBN	nsubjpass||investigated-25/VBN||treatment-8/NN	amod||malaria-11/NN||uncomplicated-10/JJ	prep_for||treatment-8/NN||malaria-11/NN	prep_for||treatment-8/NN||recommended-13/VBN	conj_and||malaria-11/NN||recommended-13/VBN	amod||treatment-17/NN||intermittent-15/JJ	nn||treatment-17/NN||preventive-16/NN	prep_for||recommended-13/VBN||treatment-17/NN	prep_of||recommended-13/VBN||malaria-19/NN	prep_in||recommended-13/VBN||pregnancy-21/NN	aux||investigated-25/VBN||is-23/VBZ	auxpass||investigated-25/VBN||being-24/VBG	root||ROOT-0/null||investigated-25/VBN	amod||treatment-29/NN||intermittent-27/JJ	nn||treatment-29/NN||preventive-28/NN	prep_for||investigated-25/VBN||treatment-29/NN	prep_of||treatment-29/NN||malaria-31/NN	prep_in||malaria-31/NN||infants-33/NNS	appos||infants-33/NNS||ipti-35/NNP	malaria-31||pyrimethamine--1||no||sulphadoxine-pyrimethamine (sp) a widely used treatment for uncomplicated malaria and recommended for intermittent preventive treatment of malaria in pregnancy, is being investigated for intermittent preventive treatment of malaria in infants (ipti).
prep_at||made-16/VBN||6â-2/NNS	num||years-6/NNS||$-3/$	num||$-3/$||7-5/CD	npadvmod||6â-2/NNS||years-6/NNS	prep_of||6â-2/NNS||age-8/NN	det||comparison-11/NN||the-10/DT	nsubjpass||made-16/VBN||comparison-11/NN	amod||factors-14/NNS||various-13/JJ	prep_of||comparison-11/NN||factors-14/NNS	auxpass||made-16/VBN||was-15/VBD	root||ROOT-0/null||made-16/VBN	number||lga-19/NN||31-18/CD	amod||children-26/NNS||lga-19/NN	number||appropriate-for-gestational-age-22/NN||34-21/CD	conj_and||lga-19/NN||appropriate-for-gestational-age-22/NN	amod||children-26/NNS||appropriate-for-gestational-age-22/NN	discourse||children-26/NNS||aga-24/UH	prep_between||made-16/VBN||children-26/NNS	dobj||made-16/VBN||fibrinogen-27/NN	dobj||made-16/VBN||antithrombiniii-29/NNS	conj_and||fibrinogen-27/NN||antithrombiniii-29/NNS	nn||c-32/NN||protein-31/NN	dobj||made-16/VBN||c-32/NN	conj_and||fibrinogen-27/NN||c-32/NN	dobj||made-16/VBN||s-34/PRP	conj_and||fibrinogen-27/NN||s-34/PRP	amod||model-43/NN||fasting-36/VBG	nn||model-43/NN||insulin-37/NN	dep||model-43/NN||glucose-39/NN	dep||model-43/NN||homeostasis-41/NN	nn||model-43/NN||assessment-42/NN	dobj||made-16/VBN||model-43/NN	conj_and||fibrinogen-27/NN||model-43/NN	prep_of||model-43/NN||insulinresistance-45/NN	appos||model-43/NN||homa-ir-47/NN	nn||protein-60/NN||index-49/NN	dep||protein-60/NN||adiponectin-51/NN	dep||protein-60/NN||leptin-53/NN	dep||protein-60/NN||visfatin-55/NN	amod||protein-60/NN||igf-1-57/JJ	amod||protein-60/NN||igf-binding-59/JJ	dep||fibrinogen-27/NN||protein-60/NN	appos||protein-60/NN||igfbp-62/NN	nsubj||lipids-68/VBZ||-1-64/CD	amod||-1-64/CD||igfbp-3-66/JJ	rcmod||protein-60/NN||lipids-68/VBZ	det||factors-73/NNS||the-71/DT	amod||factors-73/NNS||genetic-72/JJ	poss||mutation-77/NN||factors-73/NNS	nn||mutation-77/NN||leiden-75/NN	amod||mutation-77/NN||g1691a-76/VBD	dobj||made-16/VBN||mutation-77/NN	conj_and||fibrinogen-27/NN||mutation-77/NN	amod||20210a/g-80/JJ||prothrombin-79/JJ	amod||polymorphism-81/NN||20210a/g-80/JJ	conj_and||fibrinogen-27/NN||polymorphism-81/NN	conj_and||mutation-77/NN||polymorphism-81/NN	conj_and||fibrinogen-27/NN||mutation-84/NN	conj_and||mutation-77/NN||mutation-84/NN	det||gene-89/NN||the-86/DT	amod||5,10-methylenetetrahydrofolate-reductase-88/JJ||enzyme-87/JJ	amod||gene-89/NN||5,10-methylenetetrahydrofolate-reductase-88/JJ	prep_in||mutation-84/NN||gene-89/NN	dep||gene-89/NN||mthfr-c677t-91/JJ	insulin-37||insulinresistance-45||no_rel||at 6â7 years of age, the comparison of various factors was made between 31 lga and 34 appropriate-for-gestational-age (aga) children fibrinogen, antithrombiniii, protein c and s, fasting insulin, glucose, homeostasis assessment model of insulinresistance (homa-ir) index, adiponectin, leptin, visfatin, igf-1, igf-binding protein (igfbp)-1, igfbp-3, lipids, and the genetic factors v leiden g1691a mutation, prothrombin 20210a/g polymorphism, and mutation in the enzyme 5,10-methylenetetrahydrofolate-reductase gene (mthfr-c677t).
amod||surveys-2/NNS||epidemiological-1/JJ	nsubj||demonstrated-7/VBN||surveys-2/NNS	nn||experiments-5/NNS||laboratory-4/NN	conj_and||surveys-2/NNS||experiments-5/NNS	nsubj||demonstrated-7/VBN||experiments-5/NNS	aux||demonstrated-7/VBN||have-6/VBP	root||ROOT-0/null||demonstrated-7/VBN	mark||-lrb--21/VBZ||that-8/IN	det||virulence-12/NN||the-9/DT	advmod||acquired-11/VBN||newly-10/RB	amod||virulence-12/NN||acquired-11/VBN	nsubj||-lrb--21/VBZ||virulence-12/NN	amod||viruses-15/NNS||several-14/JJ	prep_of||virulence-12/NN||viruses-15/NNS	vmod||viruses-15/NNS||belonging-16/VBG	det||dicistroviridae-20/NN||the-18/DT	nn||dicistroviridae-20/NN||family-19/NN	prep_to||belonging-16/VBG||dicistroviridae-20/NN	ccomp||demonstrated-7/VBN||-lrb--21/VBZ	amod||virus-29/NN||acute-22/JJ	nn||virus-29/NN||bee-23/NN	nn||virus-29/NN||paralysis-24/NN	nn||virus-29/NN||virus-25/NN	dep||virus-29/NN||kashmir-27/NN	nn||virus-29/NN||bee-28/NN	dobj||-lrb--21/VBZ||virus-29/NN	amod||-rrb--35/NNS||israeli-31/JJ	amod||-rrb--35/NNS||acute-32/JJ	nn||-rrb--35/NNS||paralysis-33/NN	nn||-rrb--35/NNS||virus-34/NN	dobj||-lrb--21/VBZ||-rrb--35/NNS	conj_and||virus-29/NN||-rrb--35/NNS	prep_in||virus-29/NN||europe-37/NN	det||usa-40/NN||the-39/DT	nsubjpass||observed-43/VBN||usa-40/NN	nsubjpass||observed-43/VBN||usa-40/NN	aux||observed-43/VBN||had-41/VBD	auxpass||observed-43/VBN||been-42/VBN	conj_and||demonstrated-7/VBN||observed-43/VBN	conj_and||demonstrated-7/VBN||observed-43/VBN	conj_and||observed-43/VBN||observed-43/VBN	prep_in||observed-43/VBN||relation-45/NN	conj_and||demonstrated-7/VBN||destructor-48/NN	conj_v.||observed-43/VBN||destructor-48/NN	prep_with||observed-43/VBN||destructor-48/NN	vmod||destructor-48/NN||acting-49/VBG	vmod||destructor-48/NN||acting-49/VBG	conj_and||acting-49/VBG||acting-49/VBG	det||disseminator-52/NN||a-51/DT	prep_as||acting-49/VBG||disseminator-52/NN	det||viruses-55/NNS||these-54/DT	prep_of||disseminator-52/NN||viruses-55/NNS	nn||colonies-60/NNS||bee-59/NN	prep_between||acting-49/VBG||colonies-60/NNS	prep_within||acting-49/VBG||colonies-60/NNS	det||activator-64/NN||an-63/DT	prep_as||observed-43/VBN||activator-64/NN	prep_of||activator-64/NN||virus-66/NN	vmod||virus-66/NN||multiplication-67/VBN	det||larvae-73/NN||the-69/DT	amod||larvae-73/NN||infected-70/JJ	nn||larvae-73/NN||individuals-71/NNS	nn||larvae-73/NN||bee-72/NN	prep_in||multiplication-67/VBN||larvae-73/NN	prep_in||multiplication-67/VBN||adults-75/NNS	conj_and||larvae-73/NN||adults-75/NNS	virus-66||viruses-55||no||epidemiological surveys and laboratory experiments have demonstrated that the newly acquired virulence of several viruses belonging to the family dicistroviridae -lrb- acute bee paralysis virus , kashmir bee virus and israeli acute paralysis virus -rrb- in europe and the usa had been observed in relation with v. destructor acting as a disseminator of these viruses between and within bee colonies and as an activator of virus multiplication in the infected individuals bee larvae and adults .
nsubj||one-6/CD||valproicacid-1/NN	appos||valproicacid-1/NN||vpa-3/NN	cop||one-6/CD||is-5/VBZ	root||ROOT-0/null||one-6/CD	det||anticonvulsant-12/NN||the-8/DT	advmod||used-11/VBN||most-9/RBS	advmod||used-11/VBN||widely-10/RB	amod||anticonvulsant-12/NN||used-11/VBN	prep_of||one-6/CD||anticonvulsant-12/NN	amod||agents-15/NNS||mood-stabilizing-14/JJ	prep_of||one-6/CD||agents-15/NNS	conj_and||anticonvulsant-12/NN||agents-15/NNS	prepc_for||agents-15/NNS||treating-17/VBG	dobj||treating-17/VBG||epilepsy-18/NN	dobj||treating-17/VBG||bipolardisorder-20/NN	conj_and||epilepsy-18/NN||bipolardisorder-20/NN	bipolardisorder-20||valproicacid-1||yes||valproicacid (vpa) is one of the most widely used anticonvulsant and mood-stabilizing agents for treating epilepsy and bipolardisorder.
det||analysis-4/NN||this-1/DT	amod||analysis-4/NN||post-2/FW	dep||post-2/FW||hoc-3/FW	nsubj||assessed-5/VBD||analysis-4/NN	root||ROOT-0/null||assessed-5/VBD	det||efficacy-7/NN||the-6/DT	nsubj||added-12/VBD||efficacy-7/NN	conj_and||efficacy-7/NN||safety-9/NN	nsubj||added-12/VBD||safety-9/NN	prep_of||efficacy-7/NN||aliskiren-11/NN	ccomp||assessed-5/VBD||added-12/VBD	det||dose-17/NN||the-14/DT	amod||dose-17/NN||maximal-15/JJ	amod||dose-17/NN||recommended-16/JJ	prep_to||added-12/VBD||dose-17/NN	prep_of||dose-17/NN||losartan-19/NN	prepc_according_to||added-12/VBD||to-21/TO	amod||gfr-24/NN||baseline-22/JJ	amod||gfr-24/NN||estimated-23/JJ	pobj||added-12/VBD||gfr-24/NN	appos||gfr-24/NN||egfr-26/NN	nn||1â-30/NNS||stage-29/NN	dep||gfr-24/NN||1â-30/NNS	dep||1â-30/NNS||$-31/$	num||$-31/$||3-33/CD	dep||$-31/$||chronic-34/NN	nn||chronic-34/NN||kidneydisease-35/FW	nn||chronic-34/NN||-LSB--36/FW	nn||chronic-34/NN||ckd-37/FW	dep||chronic-34/NN||-RSB--38/FW	kidneydisease-35||losartan-19||no_rel||this post hoc analysis assessed the efficacy and safety of aliskiren added to the maximal recommended dose of losartan according to baseline estimated gfr (egfr) (stage 1â3 chronic kidneydisease [ckd]).
poss||role-5/NN||its-3/PRP$	amod||role-5/NN||principal-4/JJ	prep_apart_from||attributed-16/VBN||role-5/NN	nn||metabolism-8/NN||bone-7/NN	prep_in||role-5/NN||metabolism-8/NN	nn||homeostasis-11/NNS||calcium-10/NN	prep_in||role-5/NN||homeostasis-11/NNS	conj_and||metabolism-8/NN||homeostasis-11/NNS	nsubjpass||attributed-16/VBN||vitamind-13/NN	aux||attributed-16/VBN||has-14/VBZ	auxpass||attributed-16/VBN||been-15/VBN	root||ROOT-0/null||attributed-16/VBN	amod||effects-18/NNS||additional-17/JJ	dobj||attributed-16/VBN||effects-18/NNS	det||capacity-29/NN||an-20/DT	amod||capacity-29/NN||immunomodulatory-21/JJ	amod||capacity-29/NN||anti-inflammatory-23/JJ	advmod||neuroprotective-28/JJ||possibly-26/RB	advmod||neuroprotective-28/JJ||even-27/RB	conj_and||anti-inflammatory-23/JJ||neuroprotective-28/JJ	amod||capacity-29/NN||neuroprotective-28/JJ	prep_including||effects-18/NNS||capacity-29/NN	nsubj||implicates-31/VBZ||which-30/WDT	ccomp||capacity-29/NN||implicates-31/VBZ	det||role-34/NN||a-32/DT	amod||role-34/NN||possible-33/JJ	dobj||implicates-31/VBZ||role-34/NN	prep_of||role-34/NN||vitamind-36/NN	prep_in||implicates-31/VBZ||autoimmunediseases-38/NNS	prep_like||autoimmunediseases-38/NNS||multiplesclerosis-40/NNS	appos||multiplesclerosis-40/NNS||ms-42/NN	vitamind-36||multiplesclerosis-40||no_rel||apart from its principal role in bone metabolism and calcium homeostasis, vitamind has been attributed additional effects including an immunomodulatory, anti-inflammatory, and possibly even neuroprotective capacity which implicates a possible role of vitamind in autoimmunediseases like multiplesclerosis (ms).
nsubj||displayed-6/VBD||replacement-1/NN	prep_of||replacement-1/NN||lamivudine-3/NN	prep_by||lamivudine-3/NN||adefovir-5/NN	root||ROOT-0/null||displayed-6/VBD	neg||advantage-8/NN||no-7/DT	dobj||displayed-6/VBD||advantage-8/NN	det||lack-11/NN||the-10/DT	prep_despite||displayed-6/VBD||lack-11/NN	nn||mutations-14/NNS||resistance-13/NN	prep_of||lack-11/NN||mutations-14/NNS	advmod||displayed-6/VBD||thus-16/RB	neg||decrease-18/NN||no-17/DT	nsubjpass||observed-22/VBN||decrease-18/NN	prep_in||decrease-18/NN||viremia-20/NN	auxpass||observed-22/VBN||was-21/VBD	parataxis||displayed-6/VBD||observed-22/VBN	nn||treatment-25/NN||adefovir-24/NN	prep_under||observed-22/VBN||treatment-25/NN	viremia-20||lamivudine-3||no_rel||replacement of lamivudine by adefovir displayed no advantage despite the lack of resistance mutations, thus no decrease in viremia was observed under adefovir treatment.
det||organizations-2/NNS||these-1/DT	nsubj||include-3/VBP||organizations-2/NNS	root||ROOT-0/null||include-3/VBP	det||center-5/NN||the-4/DT	dobj||include-3/VBP||center-5/NN	amod||-rrb--12/NNP||hiv/aids-7/JJ	nn||-rrb--12/NNP||vaccine-8/NN	nn||-rrb--12/NNP||immunology-9/NN	nn||-rrb--12/NNP||-lrb--10/NNP	nn||-rrb--12/NNP||chavi-11/NNP	prep_for||center-5/NN||-rrb--12/NNP	det||network-17/NN||the-14/DT	amod||network-17/NN||immune-15/JJ	nn||network-17/NN||tolerance-16/NN	dobj||include-3/VBP||network-17/NN	conj_and||center-5/NN||network-17/NN	nn||-rrb--20/NNP||-lrb--18/NNP	nn||-rrb--20/NNP||itn-19/NNP	dep||network-17/NN||-rrb--20/NNP	det||hiv-23/NN||the-22/DT	dobj||include-3/VBP||hiv-23/NN	conj_and||center-5/NN||hiv-23/NN	nn||-rrb--29/NNP||vaccine-24/NN	nn||-rrb--29/NNP||trials-25/NNS	nn||-rrb--29/NNP||network-26/NN	nn||-rrb--29/NNP||-lrb--27/NNP	nn||-rrb--29/NNP||hvtn-28/NNP	dep||hiv-23/NN||-rrb--29/NNP	det||program-36/NN||the-31/DT	amod||program-36/NN||u.s.-32/JJ	amod||program-36/NN||military-33/JJ	nn||program-36/NN||hiv-34/NN	nn||program-36/NN||research-35/NN	dobj||include-3/VBP||program-36/NN	conj_and||center-5/NN||program-36/NN	amod||-rrb--39/NNS||-lrb--37/JJ	nn||-rrb--39/NNS||mhrp-38/NN	dep||program-36/NN||-rrb--39/NNS	det||network-43/NN||the-42/DT	dobj||include-3/VBP||network-43/NN	conj_and||center-5/NN||network-43/NN	amod||donors-47/NNS||pancreatic-45/JJ	nn||donors-47/NNS||organ-46/NN	prep_for||network-43/NN||donors-47/NNS	nn||-rrb--52/NN||diabetes-49/NN	nn||-rrb--52/NN||-lrb--50/NNP	amod||-rrb--52/NN||npod-51/JJ	prep_with||include-3/VBP||-rrb--52/NN	aids--1||hiv-34||no||these organizations include the center for hiv/aids vaccine immunology -lrb- chavi -rrb- , the immune tolerance network -lrb- itn -rrb- , the hiv vaccine trials network -lrb- hvtn -rrb- , the u.s. military hiv research program -lrb- mhrp -rrb- , and the network for pancreatic organ donors with diabetes -lrb- npod -rrb- .
nsubj||decreased-8/VBD||consumption-1/NN	det||hpmc-7/NN||the-3/DT	amod||hpmc-7/NN||viscous-4/JJ	amod||hpmc-7/NN||non-fermentable-5/JJ	nn||hpmc-7/NN||fiber-6/NN	prep_of||consumption-1/NN||hpmc-7/NN	root||ROOT-0/null||decreased-8/VBD	amod||wasting-10/NN||diabetic-9/JJ	dobj||decreased-8/VBD||wasting-10/NN	amod||control-14/NN||improved-12/VBN	nn||control-14/NN||glucose-13/NN	dobj||decreased-8/VBD||control-14/NN	conj_and||wasting-10/NN||control-14/NN	amod||insulinresistance-17/NN||reduced-16/VBN	dobj||decreased-8/VBD||insulinresistance-17/NN	conj_and||wasting-10/NN||insulinresistance-17/NN	nn||liver-20/NN||fatty-19/NN	conj_and||wasting-10/NN||liver-20/NN	conj_and||insulinresistance-17/NN||liver-20/NN	det||model-23/NN||a-22/DT	prep_in||insulinresistance-17/NN||model-23/NN	prep_of||insulinresistance-17/NN||obesity-25/NN	prep_with||insulinresistance-17/NN||diabetes-27/NN	wasting-10||glucose-13||no_rel||consumption of the viscous non-fermentable fiber hpmc decreased diabetic wasting, improved glucose control and reduced insulinresistance and fatty liver in a model of obesity with diabetes.
nsubj||reported-4/VBN||we-1/PRP	nsubj||aminoacid-32/VBN||we-1/PRP	aux||reported-4/VBN||have-2/VBP	advmod||reported-4/VBN||previously-3/RB	root||ROOT-0/null||reported-4/VBN	amod||strains-9/NNS||g10p-5/JJ	amod||strains-9/NNS||-LSB--6/JJ	num||strains-9/NNS||11-7/CD	amod||strains-9/NNS||-RSB--8/JJ	nsubj||associated-10/VBN||strains-9/NNS	dep||reported-4/VBN||associated-10/VBN	det||gastrointestinaldisease-16/NN||both-12/DT	amod||gastrointestinaldisease-16/NN||asymptomaticinfections-13/JJ	conj_and||asymptomaticinfections-13/JJ||severe-15/JJ	amod||gastrointestinaldisease-16/NN||severe-15/JJ	prep_with||associated-10/VBN||gastrointestinaldisease-16/NN	prep_in||gastrointestinaldisease-16/NN||neonates-18/NNS	prep_from||associated-10/VBN||vellore-20/NN	amod||india-23/NN||southern-22/JJ	prep_in||vellore-20/NN||india-23/NN	prepc_with||associated-10/VBN||>-26/VBG	number||%-28/NN||90-27/CD	amod||nucleotide-30/NN||%-28/NN	amod||nucleotide-30/NN||partial-29/JJ	dobj||>-26/VBG||nucleotide-30/NN	conj_and||reported-4/VBN||aminoacid-32/VBN	dobj||aminoacid-32/VBN||identity-33/NN	det||genes-43/NNS||the-35/DT	amod||genes-43/NNS||vp4-36/JJ	conj_and||vp4-36/JJ||vp6-38/JJ	amod||genes-43/NNS||vp6-38/JJ	conj_and||vp4-36/JJ||vp7-40/JJ	amod||genes-43/NNS||vp7-40/JJ	conj_and||vp4-36/JJ||nsp4-42/JJ	amod||genes-43/NNS||nsp4-42/JJ	prep_to||aminoacid-32/VBN||genes-43/NNS	det||-LSB--49/NN||the-45/DT	advmod||asymptomatic-47/JJ||exclusively-46/RB	amod||-LSB--49/NN||asymptomatic-47/JJ	amod||-LSB--49/NN||g10p-48/JJ	prep_of||genes-43/NNS||-LSB--49/NN	num||i321-53/NNS||11-50/CD	amod||i321-53/NNS||-RSB--51/JJ	nn||i321-53/NNS||strain-52/NN	dobj||reported-4/VBN||i321-53/NNS	gastrointestinaldisease-16||aminoacid-32||no_rel||we have previously reported g10p[11] strains associated with both asymptomaticinfections and severe gastrointestinaldisease in neonates from vellore in southern india, with >90% partial nucleotide and aminoacid identity to the vp4, vp6, vp7 and nsp4 genes of the exclusively asymptomatic g10p[11] strain i321.
det||results-3/NNS||the-1/DT	amod||results-3/NNS||clinical-2/JJ	nsubj||show-4/VBP||results-3/NNS	root||ROOT-0/null||show-4/VBP	mark||effective-9/JJ||that-5/IN	nsubj||effective-9/JJ||amoxicillin-6/NNP	cop||effective-9/JJ||is-7/VBZ	advmod||effective-9/JJ||highly-8/RB	ccomp||show-4/VBP||effective-9/JJ	prepc_in||effective-9/JJ||reducing-11/VBG	amod||bacteremia-13/NN||postoperative-12/JJ	dobj||reducing-11/VBG||bacteremia-13/NN	amod||surgery-17/NN||periodontal-15/JJ	nn||surgery-17/NN||flap-16/NN	prep_in||reducing-11/VBG||surgery-17/NN	advmod||effective-9/JJ||thus-19/RB	prepc_in||effective-9/JJ||preventing-21/VBG	conj_and||reducing-11/VBG||preventing-21/VBG	det||sequelae-24/NN||the-22/DT	amod||sequelae-24/NN||possible-23/JJ	dobj||preventing-21/VBG||sequelae-24/NN	dep||sequelae-24/NN||infectiveendocarditis-26/NNS	amod||maladies-30/NNS||other-28/JJ	amod||maladies-30/NNS||systemic-29/JJ	dep||sequelae-24/NN||maladies-30/NNS	conj_and||infectiveendocarditis-26/NNS||maladies-30/NNS	amod||patients-34/NNS||susceptible-33/JJ	prep_in||sequelae-24/NN||patients-34/NNS	infectiveendocarditis-26||amoxicillin-6||yes||the clinical results show that amoxicillin is highly effective in reducing postoperative bacteremia in periodontal flap surgery and thus in preventing the possible sequelae (infectiveendocarditis and other systemic maladies) in susceptible patients.
advmod||observed-17/VBN||importantly-1/RB	neg||evidence-4/NN||no-3/DT	nsubjpass||observed-17/VBN||evidence-4/NN	nn||colonization-7/NN||lymphoreticular-6/NN	prep_for||evidence-4/NN||colonization-7/NN	prep_with||colonization-7/NN||prions-9/NNS	vmod||evidence-4/NN||seen-11/VBN	advmod||seen-11/VBN||uniformly-12/RB	prep_in||uniformly-12/RB||vcjd-14/JJ	auxpass||observed-17/VBN||was-16/VBD	root||ROOT-0/null||observed-17/VBN	det||patient-20/NN||a-19/DT	prep_in||observed-17/VBN||patient-20/NN	prep_with||patient-20/NN||kuru-22/NN	amod||biopsy-25/NN||tonsil-24/JJ	prep_at||observed-17/VBN||biopsy-25/NN	vcjd-14||prions-9||no_rel||importantly, no evidence for lymphoreticular colonization with prions, seen uniformly in vcjd, was observed in a patient with kuru at tonsil biopsy.
neg||differences-3/NNS||no-1/DT	amod||differences-3/NNS||significant-2/JJ	nsubjpass||found-5/VBN||differences-3/NNS	auxpass||found-5/VBN||were-4/VBD	root||ROOT-0/null||found-5/VBN	nn||subjects-10/NNS||smoking-7/NN	conj_and||smoking-7/NN||non-smoking-9/NN	nn||subjects-10/NNS||non-smoking-9/NN	prep_between||found-5/VBN||subjects-10/NNS	amod||asthma-13/NN||mild-12/JJ	prep_with||subjects-10/NNS||asthma-13/NN	prep_in||asthma-13/NN||regard-15/NN	amod||changes-18/NNS||clinical-17/JJ	prep_to||found-5/VBN||changes-18/NNS	nn||control-21/NN||asthma-20/NN	prep_in||changes-18/NNS||control-21/NN	amod||function-24/NN||pulmonary-23/JJ	appos||control-21/NN||function-24/NN	nn||inflammation-27/NN||airway-26/NN	appos||control-21/NN||inflammation-27/NN	conj_and||function-24/NN||inflammation-27/NN	det||period-32/NN||a-29/DT	amod||period-32/NN||2-month-30/JJ	nn||period-32/NN||treatment-31/NN	prep_following||function-24/NN||period-32/NN	prep_with||period-32/NN||budesonide-34/NN	det||association-37/NN||the-36/DT	prep_following||function-24/NN||association-37/NN	conj_or||period-32/NN||association-37/NN	prep_of||association-37/NN||budesonide-39/NN	prep_of||association-37/NN||formoterol-41/NN	conj_and||budesonide-39/NN||formoterol-41/NN	det||period-44/NN||a-43/DT	prep_for||association-37/NN||period-44/NN	num||months-47/NNS||2-46/CD	prep_of||period-44/NN||months-47/NNS	asthma-20||formoterol-41||no||no significant differences were found between smoking and non-smoking subjects with mild asthma in regard to clinical changes in asthma control, pulmonary function and airway inflammation following a 2-month treatment period with budesonide or the association of budesonide and formoterol for a period of 2 months.
cc||describe-22/VBP||in-1/IN	advmod||described-5/VBD||previously-4/RB	dep||describe-22/VBP||described-5/VBD	dobj||described-5/VBD||cases-6/NNS	amod||â-15/NN||flinders-8/JJ	nn||â-15/NN||island-9/NN	nn||â-15/NN||spottedfever-10/NN	nn||â-15/NN||-lrb--11/NN	nn||â-15/NN||rickettsia-12/NN	nn||â-15/NN||honei-13/NN	nn||â-15/NN||strain-14/NN	prep_of||cases-6/NNS||â-15/NN	nsubj||described-5/VBD||$-16/$	num||$-16/$||marmioniiâ-17/CD	amod||$-16/$||$-18/$	dep||$-18/$||-rrb--19/JJ	nsubj||describe-22/VBP||we-21/PRP	root||ROOT-0/null||describe-22/VBP	num||case-24/NN||1-23/CD	nsubj||typhus-28/VBZ||case-24/NN	amod||tick-27/NN||queensland-26/JJ	prep_of||case-24/NN||tick-27/NN	dep||describe-22/VBP||typhus-28/VBZ	amod||australis-31/NNS||-lrb--29/JJ	nn||australis-31/NNS||r.-30/NN	dobj||typhus-28/VBZ||australis-31/NNS	advmod||typhus-28/VBZ||-rrb--32/RB	num||cases-35/NNS||2-34/CD	nsubj||caused-38/VBD||cases-35/NNS	prep_of||cases-35/NNS||scrubtyphus-37/NNS	dep||describe-22/VBP||caused-38/VBD	conj_and||typhus-28/VBZ||caused-38/VBD	det||strain-42/NN||a-40/DT	amod||strain-42/NN||unique-41/JJ	prep_by||caused-38/VBD||strain-42/NN	num||orientiatsutsugamushi-44/NNS||-lrb--43/CD	npadvmod||-rrb--45/JJ||orientiatsutsugamushi-44/NNS	amod||strain-42/NN||-rrb--45/JJ	scrubtyphus-37||rickettsia-12||no||in addition to previously described cases of flinders island spottedfever -lrb- rickettsia honei strain â $ marmioniiâ $ -rrb- , we describe 1 case of queensland tick typhus -lrb- r. australis -rrb- and 2 cases of scrubtyphus caused by a unique strain -lrb- orientiatsutsugamushi -rrb- .
prep_in||antigen-8/NN||conclusion-2/NN	nsubj||antigen-8/NN||rv1985c-4/NNS	cop||antigen-8/NN||is-5/VBZ	det||antigen-8/NN||a-6/DT	nn||antigen-8/NN||novel-7/NN	root||ROOT-0/null||antigen-8/NN	nsubjpass||used-12/VBN||antigen-8/NN	nsubj||diagnose-15/VB||antigen-8/NN	aux||used-12/VBN||can-10/MD	auxpass||used-12/VBN||be-11/VB	rcmod||antigen-8/NN||used-12/VBN	aux||diagnose-15/VB||to-13/TO	advmod||diagnose-15/VB||immunologically-14/RB	xcomp||used-12/VBN||diagnose-15/VB	nn||infection-17/NN||tb-16/NN	dobj||diagnose-15/VB||infection-17/NN	amod||antigens-22/NNS||other-20/JJ	nn||antigens-22/NNS||immunodominant-21/NN	prep_along_with||diagnose-15/VB||antigens-22/NNS	amod||population-25/NN||bcg-vaccinated-24/JJ	prep_among||antigens-22/NNS||population-25/NN	tb-16||bcg--1||yes||in conclusion, rv1985c is a novel antigen which can be used to immunologically diagnose tb infection along with other immunodominant antigens among bcg-vaccinated population.
det||change-3/NN||the-1/DT	amod||change-3/NN||recent-2/JJ	nsubjpass||accompanied-20/VBN||change-3/NN	nn||policy-6/NN||treatment-5/NN	prep_of||change-3/NN||policy-6/NN	amod||malaria-9/NN||uncomplicated-8/JJ	prep_for||policy-6/NN||malaria-9/NN	prep_from||malaria-9/NN||sulfadoxine-pyrime-thamine-11/NN	prep_to||sulfadoxine-pyrime-thamine-11/NN||artemether-lumefantrine-13/NN	appos||artemether-lumefantrine-13/NN||al-15/NNP	prep_in||artemether-lumefantrine-13/NN||kenya-18/NN	auxpass||accompanied-20/VBN||was-19/VBD	root||ROOT-0/null||accompanied-20/VBN	amod||recommendations-25/NNS||revised-22/VBN	nn||recommendations-25/NNS||malaria-23/NN	nn||recommendations-25/NNS||diagnosis-24/NN	nsubj||promoting-26/VBG||recommendations-25/NNS	agent||accompanied-20/VBN||promoting-26/VBG	amod||treatment-29/NN||presumptive-27/JJ	amod||treatment-29/NN||antimalarial-28/JJ	dobj||promoting-26/VBG||treatment-29/NN	amod||children-32/NNS||young-31/JJ	prep_in||treatment-29/NN||children-32/NNS	amod||diagnosis-35/NN||parasitological-34/JJ	dobj||promoting-26/VBG||diagnosis-35/NN	conj_and||treatment-29/NN||diagnosis-35/NN	prep_in||diagnosis-35/NN||patients-37/NNS	num||years-39/NNS||5-38/CD	dep||promoting-26/VBG||years-39/NNS	dep||promoting-26/VBG||older-41/JJR	conj_and||years-39/NNS||older-41/JJR	malaria-23||lumefantrine--1||yes||the recent change of treatment policy for uncomplicated malaria from sulfadoxine-pyrime-thamine to artemether-lumefantrine (al) in kenya was accompanied by revised malaria diagnosis recommendations promoting presumptive antimalarial treatment in young children and parasitological diagnosis in patients 5 years and older.
amod||time-2/NN||median-1/JJ	nsubj||days-13/NNS||time-2/NN	prep_to||time-2/NN||detection-4/NN	prep_of||detection-4/NN||tuberculosis-6/NNP	det||test-10/NN||the-8/DT	nn||test-10/NN||mtb/rif-9/NN	prep_for||tuberculosis-6/NNP||test-10/NN	cop||days-13/NNS||was-11/VBD	num||days-13/NNS||0-12/CD	root||ROOT-0/null||days-13/NNS	dep||$-17/$||iqr-15/RB	pobj||iqr-15/RB||0â-16/CD	dep||days-13/NNS||$-17/$	num||$-17/$||1-19/CD	prepc_compared_with||days-13/NNS||with-23/IN	num||day-25/NN||1-24/CD	pobj||days-13/NNS||day-25/NN	appos||day-25/NN||0â-27/NNP	num||0â-27/NNP||$-28/$	num||$-28/$||1-30/CD	prep_for||day-25/NN||microscopy-33/NN	num||days-36/NNS||30-35/CD	pobj||days-13/NNS||days-36/NNS	conj_and||day-25/NN||days-36/NNS	appos||days-36/NNS||23â-38/NNP	num||23â-38/NNP||$-39/$	num||$-39/$||43-41/CD	amod||culture-45/NN||solid-44/JJ	prep_for||days-36/NNS||culture-45/NN	num||days-49/NNS||16-48/CD	pobj||days-13/NNS||days-49/NNS	conj_and||day-25/NN||days-49/NNS	appos||days-49/NNS||13â-51/NNP	num||13â-51/NNP||$-52/$	num||$-52/$||21-54/CD	amod||culture-58/NN||liquid-57/JJ	prep_for||days-49/NNS||culture-58/NN	tuberculosis-6||rif--1||yes||median time to detection of tuberculosis for the mtb/rif test was 0 days (iqr 0â1), compared with 1 day (0â1) for microscopy, 30 days (23â43) for solid culture, and 16 days (13â21) for liquid culture.
det||study-3/NN||this-2/DT	prep_in||investigated-10/VBD||study-3/NN	amod||monkeys-7/NNS||common-5/JJ	nn||monkeys-7/NNS||marmoset-6/NN	prep_with||study-3/NN||monkeys-7/NNS	nsubj||investigated-10/VBD||we-9/PRP	root||ROOT-0/null||investigated-10/VBD	amod||effects-15/NNS||neonatal-12/JJ	conj_and||neonatal-12/JJ||adulthood-14/JJ	amod||effects-15/NNS||adulthood-14/JJ	prep_for||investigated-10/VBD||effects-15/NNS	amod||treatment-19/NN||antenatal-17/JJ	nn||treatment-19/NN||dex-18/NN	prep_of||effects-15/NNS||treatment-19/NN	det||expression-22/NN||the-21/DT	prep_on||investigated-10/VBD||expression-22/NN	det||receptors-26/NNS||the-24/DT	amod||receptors-26/NNS||corticosteroid-25/JJ	prep_of||expression-22/NN||receptors-26/NNS	advmod||calcyon-29/NN||also-28/RB	prep_on||investigated-10/VBD||calcyon-29/NN	conj_and||expression-22/NN||calcyon-29/NN	det||gene-33/NN||a-31/DT	nn||gene-33/NN||risk-32/NN	appos||calcyon-29/NN||gene-33/NN	prep_for||gene-33/NN||attention-deficit/hyperactivitydisorder-35/NN	det||cortex-40/NN||the-38/DT	amod||cortex-40/NN||prefrontal-39/JJ	prep_in||calcyon-29/NN||cortex-40/NN	appos||cortex-40/NN||pfc-42/NN	corticosteroid-25||hyperactivitydisorder--1||no_rel||in this study with common marmoset monkeys, we investigated for neonatal and adulthood effects of antenatal dex treatment on the expression of the corticosteroid receptors and also calcyon, a risk gene for attention-deficit/hyperactivitydisorder, in the prefrontal cortex (pfc).
nsubj||decreased-8/VBD||consumption-1/NN	det||hpmc-7/NN||the-3/DT	amod||hpmc-7/NN||viscous-4/JJ	amod||hpmc-7/NN||non-fermentable-5/JJ	nn||hpmc-7/NN||fiber-6/NN	prep_of||consumption-1/NN||hpmc-7/NN	root||ROOT-0/null||decreased-8/VBD	amod||wasting-10/NN||diabetic-9/JJ	dobj||decreased-8/VBD||wasting-10/NN	amod||control-14/NN||improved-12/VBN	nn||control-14/NN||glucose-13/NN	dobj||decreased-8/VBD||control-14/NN	conj_and||wasting-10/NN||control-14/NN	amod||insulinresistance-17/NN||reduced-16/VBN	dobj||decreased-8/VBD||insulinresistance-17/NN	conj_and||wasting-10/NN||insulinresistance-17/NN	nn||liver-20/NN||fatty-19/NN	conj_and||wasting-10/NN||liver-20/NN	conj_and||insulinresistance-17/NN||liver-20/NN	det||model-23/NN||a-22/DT	prep_in||insulinresistance-17/NN||model-23/NN	prep_of||insulinresistance-17/NN||obesity-25/NN	prep_with||insulinresistance-17/NN||diabetes-27/NN	obesity-25||glucose-13||no_rel||consumption of the viscous non-fermentable fiber hpmc decreased diabetic wasting, improved glucose control and reduced insulinresistance and fatty liver in a model of obesity with diabetes.
nn||g-3/NN||paracetamol-1/NNP	num||g-3/NN||1-2/CD	nsubj||reduced-9/VBD||g-3/NN	vmod||g-3/NN||taken-4/VBN	advmod||taken-4/VBN||orally-5/RB	det||hours-8/NNS||every-6/DT	num||hours-8/NNS||6-7/CD	dobj||taken-4/VBN||hours-8/NNS	root||ROOT-0/null||reduced-9/VBD	amod||anglerecessionglaucoma-12/NN||openangleglaucoma-10/JJ	amod||anglerecessionglaucoma-12/NN||and/or-11/JJ	dobj||reduced-9/VBD||anglerecessionglaucoma-12/NN	det||groups-15/NNS||both-14/DT	prep_in||reduced-9/VBD||groups-15/NNS	prep_of||groups-15/NNS||patients-17/NNS	det||way-21/NN||a-20/DT	prep_in||reduced-9/VBD||way-21/NN	amod||way-21/NN||comparable-22/JJ	prep_with||comparable-22/JJ||that-24/DT	vmod||that-24/DT||achieved-25/VBN	det||beta-adrenergicreceptorantagonist-29/NN||a-27/DT	amod||beta-adrenergicreceptorantagonist-29/NN||topical-28/JJ	agent||achieved-25/VBN||beta-adrenergicreceptorantagonist-29/NN	adrenergicreceptorantagonist--1||anglerecessionglaucoma-12||no_rel||paracetamol 1 g taken orally every 6 hours reduced openangleglaucoma and/or anglerecessionglaucoma in both groups of patients, in a way comparable with that achieved by a topical beta-adrenergicreceptorantagonist.
det||virus-2/NN||the-1/DT	nsubj||had-3/VBD||virus-2/NN	root||ROOT-0/null||had-3/VBD	det||distribution-6/NN||a-4/DT	amod||distribution-6/NN||widespread-5/JJ	dobj||had-3/VBD||distribution-6/NN	det||diversity-11/NN||a-8/DT	amod||diversity-11/NN||low-9/JJ	amod||diversity-11/NN||genetic-10/JJ	prep_with||distribution-6/NN||diversity-11/NN	advmod||associated-19/VBN||however-13/RB	num||isolates-17/NNS||three-15/CD	amod||isolates-17/NNS||divergent-16/JJ	nsubjpass||associated-19/VBN||isolates-17/NNS	auxpass||associated-19/VBN||were-18/VBD	parataxis||had-3/VBD||associated-19/VBN	amod||symptoms-23/NNS||atypical-21/JJ	nn||symptoms-23/NNS||cbd-22/NN	prep_with||associated-19/VBN||symptoms-23/NNS	cbd-22||virus-2||no_rel||the virus had a widespread distribution with a low genetic diversity; however, three divergent isolates were associated with atypical cbd symptoms.
nsubj||believe-2/VBP||we-1/PRP	root||ROOT-0/null||believe-2/VBP	dobj||believe-2/VBP||this-3/DT	nsubj||report-8/NN||this-3/DT	aux||report-8/NN||to-4/TO	cop||report-8/NN||be-5/VB	det||report-8/NN||the-6/DT	amod||report-8/NN||first-7/JJ	xcomp||believe-2/VBP||report-8/NN	amod||abnormalities-12/NNS||spinal-10/JJ	nn||abnormalities-12/NNS||cord-11/NN	prep_of||report-8/NN||abnormalities-12/NNS	det||patient-15/NN||a-14/DT	prep_in||abnormalities-12/NNS||patient-15/NN	prep_with||patient-15/NN||multiplemyeloma-17/NN	vmod||multiplemyeloma-17/NN||treated-18/VBN	prep_with||treated-18/VBN||bortezomib-20/NN	multiplemyeloma-17||bortezomib-20||yes||we believe this to be the first report of spinal cord abnormalities in a patient with multiplemyeloma treated with bortezomib.
neg||differences-3/NNS||no-1/DT	amod||differences-3/NNS||significant-2/JJ	nsubjpass||found-5/VBN||differences-3/NNS	auxpass||found-5/VBN||were-4/VBD	root||ROOT-0/null||found-5/VBN	nn||subjects-10/NNS||smoking-7/NN	conj_and||smoking-7/NN||non-smoking-9/NN	nn||subjects-10/NNS||non-smoking-9/NN	prep_between||found-5/VBN||subjects-10/NNS	amod||asthma-13/NN||mild-12/JJ	prep_with||subjects-10/NNS||asthma-13/NN	prep_in||asthma-13/NN||regard-15/NN	amod||changes-18/NNS||clinical-17/JJ	prep_to||found-5/VBN||changes-18/NNS	nn||control-21/NN||asthma-20/NN	prep_in||changes-18/NNS||control-21/NN	amod||function-24/NN||pulmonary-23/JJ	appos||control-21/NN||function-24/NN	nn||inflammation-27/NN||airway-26/NN	appos||control-21/NN||inflammation-27/NN	conj_and||function-24/NN||inflammation-27/NN	det||period-32/NN||a-29/DT	amod||period-32/NN||2-month-30/JJ	nn||period-32/NN||treatment-31/NN	prep_following||function-24/NN||period-32/NN	prep_with||period-32/NN||budesonide-34/NN	det||association-37/NN||the-36/DT	prep_following||function-24/NN||association-37/NN	conj_or||period-32/NN||association-37/NN	prep_of||association-37/NN||budesonide-39/NN	prep_of||association-37/NN||formoterol-41/NN	conj_and||budesonide-39/NN||formoterol-41/NN	det||period-44/NN||a-43/DT	prep_for||association-37/NN||period-44/NN	num||months-47/NNS||2-46/CD	prep_of||period-44/NN||months-47/NNS	asthma-20||budesonide-39||yes||no significant differences were found between smoking and non-smoking subjects with mild asthma in regard to clinical changes in asthma control, pulmonary function and airway inflammation following a 2-month treatment period with budesonide or the association of budesonide and formoterol for a period of 2 months.
ccomp||herpesvirus-27/VBZ||marek-1/VB	amod||md-5/NN||sdisease-3/JJ	nsubj||disease-12/NN||md-5/NN	cop||disease-12/NN||is-7/VBZ	det||disease-12/NN||an-8/DT	advmod||important-10/JJ||economically-9/RB	amod||disease-12/NN||important-10/JJ	amod||disease-12/NN||viral-11/JJ	ccomp||marek-1/VB||disease-12/NN	prep_of||disease-12/NN||chickens-14/NNS	vmod||chickens-14/NNS||caused-15/VBN	agent||caused-15/VBN||marek-17/NN	amod||virus-20/NN||sdisease-19/JJ	dep||marek-17/NN||virus-20/NN	appos||marek-17/NN||mdv-22/NN	det||oncogenic-26/NN||an-25/DT	nsubj||herpesvirus-27/VBZ||oncogenic-26/NN	root||ROOT-0/null||herpesvirus-27/VBZ	marek'sdisease--1||herpesvirus-27||no||marek'sdisease (md) is an economically important viral disease of chickens caused by marek'sdisease virus (mdv), an oncogenic herpesvirus.
det||2003-3/CD||the-2/DT	prep_during||randomised-26/VBN||2003-3/CD	num||seasons-8/NNS||2004-5/CD	nn||seasons-8/NNS||malaria-6/NN	nn||seasons-8/NNS||transmission-7/NN	conj_and||2003-3/CD||seasons-8/NNS	prep_during||randomised-26/VBN||seasons-8/NNS	num||children-12/NNS||1200-10/CD	nn||children-12/NNS||gambian-11/NN	nsubjpass||randomised-26/VBN||children-12/NNS	nsubj||receive-28/VB||children-12/NNS	amod||anaemia-17/NN||moderate-14/JJ	conj_or||moderate-14/JJ||severe-16/JJ	amod||anaemia-17/NN||severe-16/JJ	prep_with||children-12/NNS||anaemia-17/NN	nn||<-21/NNS||hb-19/NN	nn||<-21/NNS||concentration-20/NN	dep||g/dl-23/JJ||<-21/NNS	number||g/dl-23/JJ||7-22/CD	dep||anaemia-17/NN||g/dl-23/JJ	auxpass||randomised-26/VBN||were-25/VBD	root||ROOT-0/null||randomised-26/VBN	aux||receive-28/VB||to-27/TO	xcomp||randomised-26/VBN||receive-28/VB	det||sulfadoxine-pyrimethamine-31/NN||either-29/DT	amod||sulfadoxine-pyrimethamine-31/NN||monthly-30/JJ	dobj||receive-28/VB||sulfadoxine-pyrimethamine-31/NN	appos||sulfadoxine-pyrimethamine-31/NN||sp-33/NN	dobj||receive-28/VB||placebo-36/NN	conj_or||sulfadoxine-pyrimethamine-31/NN||placebo-36/NN	det||end-39/NN||the-38/DT	prep_until||receive-28/VB||end-39/NN	det||season-44/NN||the-41/DT	nn||season-44/NN||malaria-42/NN	nn||season-44/NN||transmission-43/NN	prep_of||end-39/NN||season-44/NN	prep_in||enrolled-49/VBN||season-44/NN	nsubjpass||enrolled-49/VBN||they-47/PRP	auxpass||enrolled-49/VBN||were-48/VBD	rcmod||season-44/NN||enrolled-49/VBN	det||trial-54/NN||a-52/DT	amod||trial-54/NN||double-blind-53/JJ	prep_in||enrolled-49/VBN||trial-54/NN	malaria-42||pyrimethamine--1||yes||during the 2003 and 2004 malaria transmission seasons, 1200 gambian children with moderate or severe anaemia (hb concentration <7 g/dl) were randomised to receive either monthly sulfadoxine-pyrimethamine (sp) or placebo until the end of the malaria transmission season in which they were enrolled, in a double-blind trial.
amod||morphine-3/NN||oral-1/JJ	amod||morphine-3/NN||affordable-2/JJ	nsubjpass||brought-5/VBN||morphine-3/NN	nsubjpass||brought-5/VBN||morphine-3/NN	auxpass||brought-5/VBN||was-4/VBD	root||ROOT-0/null||brought-5/VBN	conj_and||brought-5/VBN||brought-5/VBN	prep_to||brought-5/VBN||kenya-7/NN	amod||hospice-10/NN||nairobi-9/JJ	prep_through||brought-5/VBN||hospice-10/NN	det||year-12/NN||that-11/DT	dep||hospice-10/NN||year-12/NN	prep_to||brought-5/VBN||uganda-16/NN	amod||uganda-20/NN||hospice-18/JJ	nn||uganda-20/NN||africa-19/NN	prep_through||brought-5/VBN||uganda-20/NN	prep_in||uganda-20/NN||1993-22/CD	morphine-3||nairobi-9||no_rel||oral affordable morphine was brought to kenya through nairobi hospice that year, and to uganda through hospice africa uganda in 1993.
det||gene-3/NN||the-1/DT	amod||gene-3/NN||akt2-2/JJ	nsubjpass||chosen-5/VBN||gene-3/NN	auxpass||chosen-5/VBN||was-4/VBD	root||ROOT-0/null||chosen-5/VBN	det||candidate-8/NN||a-7/DT	prep_as||chosen-5/VBN||candidate-8/NN	prep_for||candidate-8/NN||pcos-10/NNS	mark||affects-14/VBZ||because-11/IN	poss||product-13/NN||its-12/PRP$	nsubj||affects-14/VBZ||product-13/NN	advcl||chosen-5/VBN||affects-14/VBZ	nn||metabolism-16/NN||glucose-15/NN	dobj||affects-14/VBZ||metabolism-16/NN	amod||signaling-19/NNS||mitogenic-18/JJ	dobj||affects-14/VBZ||signaling-19/NNS	conj_and||metabolism-16/NN||signaling-19/NNS	dobj||affects-14/VBZ||interacts-21/NNS	conj_and||metabolism-16/NN||interacts-21/NNS	amod||²-24/NNS||gsk3î-23/JJ	prep_with||interacts-21/NNS||²-24/NNS	amod||survival-29/NN||mediates-27/JJ	nn||survival-29/NN||cell-28/NN	dobj||affects-14/VBZ||survival-29/NN	conj_and||metabolism-16/NN||survival-29/NN	det||ovary-32/NN||the-31/DT	prep_in||survival-29/NN||ovary-32/NN	pcos-10||glucose-15||no_rel||the akt2 gene was chosen as a candidate for pcos because its product affects glucose metabolism and mitogenic signaling, interacts with gsk3î², and mediates cell survival in the ovary.
preconj||met-anov-3/JJ||both-2/DT	amod||groups-6/NNS||met-anov-3/JJ	conj_and||met-anov-3/JJ||met-ov-5/JJ	amod||groups-6/NNS||met-ov-5/JJ	prep_in||improved-30/VBN||groups-6/NNS	prep_without||improved-30/VBN||difference-10/NN	prep_between||difference-10/NN||them-12/PRP	nn||androgens-15/NNS||serum-14/NN	nsubjpass||improved-30/VBN||androgens-15/NNS	nsubjpass||improved-30/VBN||androgens-15/NNS	conj_and||androgens-15/NNS||amh-17/NN	nsubjpass||improved-30/VBN||amh-17/NN	conj_and||androgens-15/NNS||indices-20/NNS	nsubjpass||improved-30/VBN||indices-20/NNS	prep_of||indices-20/NNS||insulinresistance-22/NN	auxpass||improved-30/VBN||were-23/VBD	advmod||improved-30/VBN||significantly-24/RB	dep||<-27/JJ||p-26/RB	dep||significantly-24/RB||<-27/JJ	dep||<-27/JJ||0.05-28/CD	root||ROOT-0/null||improved-30/VBN	conj_and||improved-30/VBN||improved-30/VBN	prep_after||improved-30/VBN||treatment-32/NN	androgens-15||insulinresistance-22||no_rel||in both met-anov and met-ov groups, and without difference between them, serum androgens and amh, and indices of insulinresistance were significantly ( p < 0.05) improved after treatment.
det||ability-2/NN||the-1/DT	nsubj||important-10/JJ||ability-2/NN	aux||give-4/VB||to-3/TO	vmod||ability-2/NN||give-4/VB	amod||doses-6/NNS||high-5/JJ	dobj||give-4/VB||doses-6/NNS	prep_of||doses-6/NNS||iron-8/NN	cop||important-10/JJ||is-9/VBZ	root||ROOT-0/null||important-10/JJ	det||context-13/NN||the-12/DT	prep_in||important-10/JJ||context-13/NN	amod||irondeficiencyanemia-16/NN||managing-15/VBG	prep_of||context-13/NN||irondeficiencyanemia-16/NN	det||number-19/NN||a-18/DT	prep_in||irondeficiencyanemia-16/NN||number-19/NN	amod||conditions-22/NNS||clinical-21/JJ	prep_of||number-19/NN||conditions-22/NNS	advmod||high-28/JJ||where-23/WRB	nsubj||high-28/JJ||demands-24/NNS	prep_for||demands-24/NNS||iron-26/NN	cop||high-28/JJ||are-27/VBP	rcmod||irondeficiencyanemia-16/NN||high-28/JJ	dep||important-10/JJ||including-30/VBG	amod||bloodloss-32/NNS||chronic-31/JJ	pobj||including-30/VBG||bloodloss-32/NNS	vmod||bloodloss-32/NNS||associated-33/VBN	nn||menorrhagia-37/NN||inflammatoryboweldisease-35/NN	prep_with||associated-33/VBN||menorrhagia-37/NN	nn||kidneydisease-41/NN||chronic-40/NN	prep_with||associated-33/VBN||kidneydisease-41/NN	conj_and||menorrhagia-37/NN||kidneydisease-41/NN	irondeficiencyanemia-16||iron-26||yes||the ability to give high doses of iron is important in the context of managing irondeficiencyanemia in a number of clinical conditions where demands for iron are high (including chronic bloodloss associated with inflammatoryboweldisease, menorrhagia, and chronic kidneydisease).
amod||analyses-2/NNS||secondary-1/JJ	nsubj||suggest-3/VBP||analyses-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||due-11/JJ||that-4/IN	nsubj||due-11/JJ||some-5/DT	nsubj||use-13/VB||some-5/DT	det||improvement-8/NN||this-7/DT	prep_of||some-5/DT||improvement-8/NN	aux||due-11/JJ||may-9/MD	cop||due-11/JJ||be-10/VB	ccomp||suggest-3/VBP||due-11/JJ	aux||use-13/VB||to-12/TO	xcomp||due-11/JJ||use-13/VB	prep_of||use-13/VB||recombinanthumandnase-15/NN	recombinanthumandnase-15||secondary-1||no_rel||secondary analyses suggest that some of this improvement may be due to use of recombinanthumandnase.
nsubj||induced-6/VBN||statusepilepticus-1/NNS	appos||statusepilepticus-1/NNS||se-3/NNP	aux||induced-6/VBN||was-5/VBD	root||ROOT-0/null||induced-6/VBN	amod||adenosine5-38/NNS||pilocarpine-8/JJ	prep_in||pilocarpine-8/JJ||rats-10/NNS	nsubjpass||infused-14/VBN||rats-10/NNS	auxpass||infused-14/VBN||were-12/VBD	advmod||infused-14/VBN||intracerebroventricularly-13/RB	rcmod||rats-10/NNS||infused-14/VBN	det||saline-17/NN||either-16/DT	prep_with||infused-14/VBN||saline-17/NN	appos||saline-17/NN||2-19/CD	poss||adenosine5-30/NN||,3-21/CD	dep||adenosine5-30/NN||o-24/NN	appos||o-24/NN||4-benzoylbenzoyl-27/NN	dep||2-19/CD||adenosine5-30/NN	dep||adenosine5-30/NN||triphosphate-33/NN	appos||triphosphate-33/NN||bzatp-35/NN	prep_by||induced-6/VBN||adenosine5-38/NNS	dep||induced-6/VBN||triphosphate-2-41/VBN	dobj||triphosphate-2-41/VBN||,3-43/CD	dep||induced-6/VBN||dialdehyde-46/JJ	dep||dialdehyde-46/JJ||oxatp-48/VB	dep||induced-6/VBN||il-1ra-52/JJ	conj_or||dialdehyde-46/JJ||il-1ra-52/JJ	dep||dialdehyde-46/JJ||interleukin-54/VB	num||antagonist-57/NN||1-55/CD	nn||antagonist-57/NN||receptor-56/NN	dobj||interleukin-54/VB||antagonist-57/NN	amod||induction-62/NN||se-61/JJ	prep_prior_to||dialdehyde-46/JJ||induction-62/NN	statusepilepticus-1||adenosine5'-triphosphate--1||no_rel||statusepilepticus (se) was induced by pilocarpine in rats that were intracerebroventricularly infused with either saline, 2',3'-o-(4-benzoylbenzoyl)-adenosine5'-triphosphate (bzatp), adenosine5'-triphosphate-2',3'-dialdehyde (oxatp), or il-1ra (interleukin 1 receptor antagonist) prior to se induction.
det||matrices-3/NNS||these-1/DT	amod||matrices-3/NNS||synthetic-2/JJ	nsubjpass||validated-6/VBN||matrices-3/NNS	auxpass||validated-6/VBN||are-4/VBP	advmod||validated-6/VBN||then-5/RB	root||ROOT-0/null||validated-6/VBN	prep||validated-6/VBN||against-7/IN	pobj||against-7/IN||recently-8/RB	vmod||recently-8/RB||collected-9/VBN	amod||data-12/NNS||italian-10/JJ	amod||data-12/NNS||serological-11/JJ	dobj||collected-9/VBN||data-12/NNS	prep_for||data-12/NNS||varicella-14/NN	appos||varicella-14/NN||vzv-16/NN	prep_for||data-12/NNS||parvovirus-19/NNS	conj_and||varicella-14/NN||parvovirus-19/NNS	appos||varicella-14/NN||b19-21/NNP	varicella-14||vzv-16||no||these synthetic matrices are then validated against recently collected italian serological data for varicella (vzv) and parvovirus (b19).
amod||prophylaxis-3/NNS||post-transplant-1/JJ	nn||prophylaxis-3/NNS||hbv-2/NN	nsubj||effective-31/JJ||prophylaxis-3/NNS	prep_with||prophylaxis-3/NNS||lamivudine-5/NN	prep_with||prophylaxis-3/NNS||intramuscular-7/NN	conj_and||lamivudine-5/NN||intramuscular-7/NN	vmod||prophylaxis-3/NNS||hbig-8/VBG	amod||dosage-11/NN||appropriate-10/JJ	prep_with||hbig-8/VBG||dosage-11/NN	aux||keep-13/VB||to-12/TO	xcomp||hbig-8/VBG||keep-13/VB	amod||titer-16/NN||anti-hbs-14/JJ	nn||titer-16/NN||antibody-15/NN	dobj||keep-13/VB||titer-16/NN	num||iu/l-19/NN||300-18/CD	prep_above||keep-13/VB||iu/l-19/NN	det||months-24/NNS||the-21/DT	amod||months-24/NNS||first-22/JJ	num||months-24/NNS||six-23/CD	prep_in||iu/l-19/NN||months-24/NNS	num||iu/l-28/NN||100-27/CD	prep_above||keep-13/VB||iu/l-28/NN	conj_and||iu/l-19/NN||iu/l-28/NN	dep||keep-13/VB||afterwards-29/RB	cop||effective-31/JJ||is-30/VBZ	root||ROOT-0/null||effective-31/JJ	prep_for||effective-31/JJ||prevention-33/NN	nn||recurrence-36/NN||hbv-35/NN	prep_of||prevention-33/NN||recurrence-36/NN	prep_after||effective-31/JJ||lt.-38/NN	hbv-35||lamivudine-5||yes||post-transplant hbv prophylaxis with lamivudine and intramuscular hbig with appropriate dosage to keep anti-hbs antibody titer above 300 iu/l in the first six months and above 100 iu/l afterwards is effective for prevention of hbv recurrence after lt.
expl||was-2/VBD||there-1/EX	root||ROOT-0/null||was-2/VBD	neg||association-4/NN||no-3/DT	nsubj||was-2/VBD||association-4/NN	prep_between||association-4/NN||intensity-6/NN	nn||prescription-11/NN||pain-8/NN	conj_and||pain-8/NN||nsaid-10/NN	nn||prescription-11/NN||nsaid-10/NN	prep_of||intensity-6/NN||prescription-11/NN	amod||prescription-16/NN||previous-14/JJ	amod||prescription-16/NN||nsaid-15/JJ	nsubj||predicted-17/VBD||prescription-16/NN	conj_but||was-2/VBD||predicted-17/VBD	det||prescription-20/NN||another-18/DT	amod||prescription-20/NN||such-19/JJ	dobj||predicted-17/VBD||prescription-20/NN	nsaid-15||pain-8||no_rel||there was no association between intensity of pain and nsaid prescription, but previous nsaid prescription predicted another such prescription.
det||rt-pcr/esi-ms-2/NNS||the-1/DT	nsubj||tool-10/NN||rt-pcr/esi-ms-2/NNS	advmod||tool-10/NN||assay-3/RB	cop||tool-10/NN||is-4/VBZ	det||tool-10/NN||a-5/DT	amod||tool-10/NN||broad-6/JJ	nn||tool-10/NN||range-7/NN	nn||tool-10/NN||influenza-8/NN	nn||tool-10/NN||identification-9/NN	root||ROOT-0/null||tool-10/NN	nsubjpass||used-14/VBN||tool-10/NN	aux||used-14/VBN||can-12/MD	auxpass||used-14/VBN||be-13/VB	rcmod||tool-10/NN||used-14/VBN	advmod||used-14/VBN||directly-15/RB	amod||specimens-18/NNS||clinical-17/JJ	prep_on||used-14/VBN||specimens-18/NNS	amod||detection-23/NN||rapid-20/JJ	conj_and||rapid-20/JJ||accurate-22/JJ	amod||detection-23/NN||accurate-22/JJ	prep_for||specimens-18/NNS||detection-23/NN	amod||genes-26/NNS||influenzavirus-25/JJ	prep_of||detection-23/NN||genes-26/NNS	influenza-8||influenzavirus-25||no||the rt-pcr/esi-ms assay is a broad range influenza identification tool that can be used directly on clinical specimens for rapid and accurate detection of influenzavirus genes.
amod||protocol-3/NN||post-transplant-1/JJ	nn||protocol-3/NN||prophylaxis-2/NNS	nsubjpass||based-8/VBN||protocol-3/NN	nsubj||keep-28/VB||protocol-3/NN	nn||recurrence-6/NN||hbv-5/NN	prep_against||protocol-3/NN||recurrence-6/NN	auxpass||based-8/VBN||was-7/VBD	root||ROOT-0/null||based-8/VBN	det||milligrams-12/NNS||a-10/DT	num||milligrams-12/NNS||hundred-11/CD	prep_on||based-8/VBN||milligrams-12/NNS	prep_of||milligrams-12/NNS||lamivudine-14/NN	amod||lamivudine-14/NN||daily-15/JJ	amod||lamivudine-14/NN||plus-16/IN	nn||injections-18/NNS||intramuscular-17/NN	dep||lamivudine-14/NN||injections-18/NNS	prep_of||injections-18/NNS||hepatitisbimmuneglobulin-20/NN	appos||injections-18/NNS||hbig-22/NN	amod||dosage-26/NN||appropriate-25/JJ	prep_with||based-8/VBN||dosage-26/NN	aux||keep-28/VB||to-27/TO	xcomp||based-8/VBN||keep-28/VB	amod||titer-31/NN||anti-hbs-29/JJ	nn||titer-31/NN||antibody-30/NN	dobj||keep-28/VB||titer-31/NN	num||iu/l-34/NN||300-33/CD	prep_above||titer-31/NN||iu/l-34/NN	num||iu/l-37/NN||100-36/CD	prep_above||titer-31/NN||iu/l-37/NN	conj_and||iu/l-34/NN||iu/l-37/NN	prep||keep-28/VB||in-38/IN	det||months-42/NNS||the-39/DT	amod||months-42/NNS||first-40/JJ	num||months-42/NNS||six-41/CD	pobj||in-38/IN||months-42/NNS	prep||keep-28/VB||afterwards-44/RB	conj_and||in-38/IN||afterwards-44/RB	prep||keep-28/VB||respectively-46/RB	conj_and||in-38/IN||respectively-46/RB	hbv-5||hbig-22||yes||post-transplant prophylaxis protocol against hbv recurrence was based on a hundred milligrams of lamivudine daily plus intramuscular injections of hepatitisbimmuneglobulin (hbig) with appropriate dosage to keep anti-hbs antibody titer above 300 iu/l and 100 iu/l in the first six months and afterwards, respectively.
nsubj||hypothesized-2/VBN||we-1/PRP	root||ROOT-0/null||hypothesized-2/VBN	mark||have-18/VB||that-3/IN	amod||infection-16/NN||macrophages-4/JJ	prep_from||macrophages-4/JJ||individuals-6/NNS	amod||manifestations-10/NNS||different-8/JJ	amod||manifestations-10/NNS||clinical-9/JJ	prep_with||individuals-6/NNS||manifestations-10/NNS	prep_of||manifestations-10/NNS||mycobacteriumtuberculosis-12/NNS	appos||mycobacteriumtuberculosis-12/NNS||mtb-14/NN	nsubj||have-18/VB||infection-16/NN	aux||have-18/VB||would-17/MD	ccomp||hypothesized-2/VBN||have-18/VB	amod||profiles-22/NNS||distinct-19/JJ	nn||profiles-22/NNS||gene-20/NN	nn||profiles-22/NNS||expression-21/NN	dobj||have-18/VB||profiles-22/NNS	mark||associated-32/VBN||that-24/IN	nsubjpass||associated-32/VBN||polymorphisms-25/NNS	det||genes-28/NNS||these-27/DT	prep_in||polymorphisms-25/NNS||genes-28/NNS	aux||associated-32/VBN||may-29/MD	advmod||associated-32/VBN||also-30/RB	auxpass||associated-32/VBN||be-31/VB	ccomp||hypothesized-2/VBN||associated-32/VBN	conj_and||have-18/VB||associated-32/VBN	prep_with||associated-32/VBN||susceptibility-34/NN	prep_to||associated-32/VBN||tb-36/NN	tb-36||mtb-14||no||we hypothesized that macrophages from individuals with different clinical manifestations of mycobacteriumtuberculosis ( mtb ) infection would have distinct gene expression profiles and that polymorphisms in these genes may also be associated with susceptibility to tb.
predet||patients-3/NNS||both-1/PDT	det||patients-3/NNS||the-2/DT	nsubj||were-4/VBD||patients-3/NNS	root||ROOT-0/null||were-4/VBD	prep_on||were-4/VBD||anticoagulants-6/NNS	prep_on||were-4/VBD||warfarin-8/NN	conj_and||anticoagulants-6/NNS||warfarin-8/NN	prep_on||were-4/VBD||heparin-10/NN	conj_and||anticoagulants-6/NNS||heparin-10/NN	prep_in||were-4/VBD||one-12/CD	prep_in||were-4/VBD||aspirin-14/NN	conj_and||one-12/CD||aspirin-14/NN	conj_and||one-12/CD||clopidogrel-16/NN	conj_and||aspirin-14/NN||clopidogrel-16/NN	det||other-19/JJ||the-18/DT	prep_in||aspirin-14/NN||other-19/JJ	nn||profile-23/NN||abnormalcoagulation-22/NN	prep_with||were-4/VBD||profile-23/NN	det||former-26/JJ||the-25/DT	prep_in||profile-23/NN||former-26/JJ	abnormalcoagulation-22||aspirin-14||no||both the patients were on anticoagulants, warfarin and heparin in one and aspirin and clopidogrel in the other, with abnormalcoagulation profile in the former.
advmod||lower-2/JJR||somewhat-1/RB	amod||doses-6/NNS||lower-2/JJR	conj_or||lower-2/JJR||higher-4/JJR	amod||doses-6/NNS||higher-4/JJR	nn||doses-6/NNS||insulin-5/NN	nsubj||best-9/JJS||doses-6/NNS	aux||best-9/JJS||may-7/MD	cop||best-9/JJS||be-8/VB	root||ROOT-0/null||best-9/JJS	amod||hyperglycemia-14/NN||lesser-11/JJR	conj_or||lesser-11/JJR||greater-13/JJR	amod||hyperglycemia-14/NN||greater-13/JJR	prep_for||best-9/JJS||hyperglycemia-14/NN	hyperglycemia-14||insulin-5||yes||somewhat lower or higher insulin doses may be best for lesser or greater hyperglycemia.
det||study-2/NN||this-1/DT	nsubj||draws-3/VBZ||study-2/NN	root||ROOT-0/null||draws-3/VBZ	dobj||draws-3/VBZ||attention-4/NN	det||phenotype-8/NN||a-6/DT	amod||phenotype-8/NN||particular-7/JJ	prep_to||draws-3/VBZ||phenotype-8/NN	advmod||leads-14/VBZ||where-9/WRB	nsubj||leads-14/VBZ||na-10/NNP	nsubj||irondeficiency-16/VB||na-10/NNP	amod||paradoxically-13/NN||excess-12/JJ	prep_in||na-10/NNP||paradoxically-13/NN	rcmod||phenotype-8/NN||leads-14/VBZ	aux||irondeficiency-16/VB||to-15/TO	xcomp||leads-14/VBZ||irondeficiency-16/VB	advmod||irondeficiency-16/VB||probably-18/RB	det||increase-22/NN||an-21/DT	prep_because_of||irondeficiency-16/VB||increase-22/NN	det||iron-29/NN||the-24/DT	amod||iron-29/NN||na-25/JJ	amod||iron-29/NN||apoplastic-26/JJ	nn||iron-29/NN||pool-27/NN	nn||iron-29/NN||sequestering-28/NN	prep_of||increase-22/NN||iron-29/NN	irondeficiency-16||iron-29||yes||this study draws attention to a particular phenotype where na in excess paradoxically leads to irondeficiency, probably because of an increase of the na apoplastic pool sequestering iron.
nsubj||diseases-9/NNS||priondiseases-1/NNS	conj_or||priondiseases-1/NNS||transmissiblespongiformencephalopathies-3/NNS	nsubj||diseases-9/NNS||transmissiblespongiformencephalopathies-3/NNS	appos||priondiseases-1/NNS||tses-5/NNS	cop||diseases-9/NNS||are-7/VBP	amod||diseases-9/NNS||fatal-8/JJ	root||ROOT-0/null||diseases-9/NNS	vmod||diseases-9/NNS||associated-10/VBN	det||conversion-13/NN||the-12/DT	prep_with||associated-10/VBN||conversion-13/NN	det||prionprotein-17/NN||the-15/DT	amod||prionprotein-17/NN||cellular-16/JJ	prep_of||conversion-13/NN||prionprotein-17/NN	dep||prionprotein-17/NN||prpc-19/JJ	det||prionprotein-24/NN||the-22/DT	amod||prionprotein-24/NN||abnormal-23/JJ	prep_to||associated-10/VBN||prionprotein-24/NN	dep||prionprotein-24/NN||prpsc-26/JJ	priondiseases-1||prionprotein-24||no||priondiseases or transmissiblespongiformencephalopathies (tses) are fatal diseases associated with the conversion of the cellular prionprotein (prpc) to the abnormal prionprotein (prpsc).
nsubjpass||concluded-3/VBN||it-1/PRP	auxpass||concluded-3/VBN||was-2/VBD	root||ROOT-0/null||concluded-3/VBN	mark||were-6/VBD||that-4/IN	expl||were-6/VBD||there-5/EX	ccomp||concluded-3/VBN||were-6/VBD	neg||issues-10/NNS||no-7/DT	advmod||significant-9/JJ||clinically-8/RB	amod||issues-10/NNS||significant-9/JJ	nsubj||were-6/VBD||issues-10/NNS	prep_in||issues-10/NNS||terms-12/NNS	prep_of||terms-12/NNS||safety-14/NN	prep_of||terms-12/NNS||efficacy-16/NN	conj_or||safety-14/NN||efficacy-16/NN	det||treatment-20/NN||the-18/DT	amod||treatment-20/NN||long-term-19/JJ	prep_with||were-6/VBD||treatment-20/NN	prep_of||treatment-20/NN||carvedilol-22/NN	prep_in||carvedilol-22/NN||patients-24/NNS	prep_with||patients-24/NNS||hypertension-26/NN	hypertension-26||carvedilol-22||yes||it was concluded that there were no clinically significant issues in terms of safety or efficacy with the long-term treatment of carvedilol in patients with hypertension.
det||aim-2/NN||the-1/DT	nsubj||is-6/VBZ||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	det||paper-5/NN||this-4/DT	prep_of||aim-2/NN||paper-5/NN	root||ROOT-0/null||is-6/VBZ	aux||evaluate-8/VB||to-7/TO	xcomp||is-6/VBZ||evaluate-8/VB	det||effect-10/NN||the-9/DT	dobj||evaluate-8/VB||effect-10/NN	prep_of||effect-10/NN||antipsychotics-12/NNS	det||treatment-15/NN||the-14/DT	prep_for||antipsychotics-12/NNS||treatment-15/NN	prep_of||treatment-15/NN||schizophrenia-17/NN	det||community-20/NN||a-19/DT	prep_in||evaluate-8/VB||community-20/NN	vmod||community-20/NN||based-21/VBN	dobj||based-21/VBN||study-22/NN	amod||function-25/NN||sexual-24/JJ	prep_on||based-21/VBN||function-25/NN	nn||levels-28/NNS||prolactin-27/NN	prep_on||based-21/VBN||levels-28/NNS	conj_and||function-25/NN||levels-28/NNS	vmod||function-25/NN||comparing-29/VBG	det||use-31/NN||the-30/DT	dobj||comparing-29/VBG||use-31/NN	prep_of||use-31/NN||aripiprazole-33/NN	prep_of||use-31/NN||standard-35/NN	conj_and||aripiprazole-33/NN||standard-35/NN	prep_of||use-31/NN||care-37/NN	nsubj||choice-46/NN||care-37/NN	appos||care-37/NN||soc-39/NN	cop||choice-46/NN||was-43/VBD	det||choice-46/NN||a-44/DT	amod||choice-46/NN||limited-45/JJ	rcmod||care-37/NN||choice-46/NN	num||antipsychotics-53/NNS||three-48/CD	advmod||used-50/JJ||widely-49/RB	amod||antipsychotics-53/NNS||used-50/JJ	conj_and||used-50/JJ||available-52/JJ	amod||antipsychotics-53/NNS||available-52/JJ	prep_of||choice-46/NN||antipsychotics-53/NNS	dep||antipsychotics-53/NNS||olanzapine-55/NN	dep||olanzapine-55/NN||quetiapine-57/JJ	dep||olanzapine-55/NN||risperidone-59/JJ	conj_or||quetiapine-57/JJ||risperidone-59/JJ	det||trial-64/NN||the-62/DT	nn||trial-64/NN||schizophrenia-63/NN	dep||antipsychotics-53/NNS||trial-64/NN	amod||-RSB--73/NNS||aripiprazole-66/JJ	nn||-RSB--73/NNS||-LSB--67/NNP	nn||-RSB--73/NNS||star-68/NN	nn||-RSB--73/NNS||-RSB--69/NN	nn||-RSB--73/NNS||study-70/NN	nn||-RSB--73/NNS||-LSB--71/NN	amod||-RSB--73/NNS||nct00237913-72/JJ	prep_of||trial-64/NN||-RSB--73/NNS	schizophrenia-63||aripiprazole-66||yes||the aim of this paper is to evaluate the effect of antipsychotics for the treatment of schizophrenia in a community based study on sexual function and prolactin levels comparing the use of aripiprazole and standard of care (soc), which was a limited choice of three widely used and available antipsychotics (olanzapine, quetiapine or risperidone) (the schizophrenia trial of aripiprazole [star] study [nct00237913]).
nn||design-2/NN||research-1/NN	nsubj||gain-8/VB||design-2/NN	nn||$-5/NNP||methodsâ-4/NNP	conj_and||design-2/NN||$-5/NNP	nsubj||gain-8/VB||$-5/NNP	aux||gain-8/VB||to-7/TO	advcl||measured-24/VBD||gain-8/VB	dobj||gain-8/VB||insight-9/NN	det||role-12/NN||the-11/DT	prep_into||gain-8/VB||role-12/NN	prep_of||role-12/NN||pref-1-14/JJ	det||onset-17/NN||the-16/DT	prep_on||pref-1-14/JJ||onset-17/NN	prep_of||onset-17/NN||insulinresistance-19/NN	prep_of||onset-17/NN||type2diabetes-21/NNS	conj_and||insulinresistance-19/NN||type2diabetes-21/NNS	nsubj||measured-24/VBD||we-23/PRP	root||ROOT-0/null||measured-24/VBD	nn||composition-26/NN||body-25/NN	dobj||measured-24/VBD||composition-26/NN	amod||metabolism-31/NN||whole-body-28/JJ	amod||metabolism-31/NN||insulin-stimulated-29/JJ	nn||metabolism-31/NN||glucose-30/NN	dobj||measured-24/VBD||metabolism-31/NN	conj_and||composition-26/NN||metabolism-31/NN	det||clamp-35/NN||a-33/DT	amod||clamp-35/NN||hyperinsulinemic-euglycemic-34/JJ	prep_during||measured-24/VBD||clamp-35/NN	amod||transgenic-38/JJ||pref-1-37/JJ	prep_in||clamp-35/NN||transgenic-38/JJ	amod||mice-42/NNS||wild-type-40/JJ	nn||mice-42/NNS||control-41/NN	prep_in||clamp-35/NN||mice-42/NNS	conj_and||transgenic-38/JJ||mice-42/NNS	vmod||clamp-35/NN||fed-43/VBN	det||diet-46/NN||a-44/DT	amod||diet-46/NN||high-fat-45/JJ	dobj||fed-43/VBN||diet-46/NN	type2diabetes-21||insulin--1||yes||research design and methodsâ to gain insight into the role of pref-1 on the onset of insulinresistance and type2diabetes, we measured body composition and whole-body insulin-stimulated glucose metabolism during a hyperinsulinemic-euglycemic clamp in pref-1 transgenic and wild-type control mice fed a high-fat diet.
nn||dynamics-2/NNS||dm-1/NN	nsubj||displays-3/VBZ||dynamics-2/NNS	root||ROOT-0/null||displays-3/VBZ	det||pattern-7/NN||the-4/DT	amod||pattern-7/NN||same-5/JJ	amod||pattern-7/NN||bimodal-6/JJ	dobj||displays-3/VBZ||pattern-7/NN	amod||peak-11/NN||first-9/JJ	amod||peak-11/NN||early-10/JJ	dep||displays-3/VBZ||peak-11/NN	quantmod||24-14/CD||about-13/RB	num||months-15/NNS||24-14/CD	prep_at||peak-11/NN||months-15/NNS	amod||peak-19/NN||second-17/JJ	amod||peak-19/NN||late-18/JJ	appos||months-15/NNS||peak-19/NN	det||year-23/NN||the-21/DT	amod||year-23/NN||sixth-seventh-22/JJ	prep_at||peak-19/NN||year-23/NN	det||receptor-28/NN||both-26/DT	nn||receptor-28/NN||estrogen-27/NN	prep_for||displays-3/VBZ||receptor-28/NN	appos||receptor-28/NN||er-30/NN	amod||receptor-28/NN||positive-32/JJ	appos||receptor-28/NN||p-34/NN	amod||tumours-41/NNS||negative-37/JJ	dep||negative-37/JJ||n-39/NN	prep_for||displays-3/VBZ||tumours-41/NNS	conj_and||receptor-28/NN||tumours-41/NNS	dep||treatments-46/NNS||all-44/PDT	amod||treatments-46/NNS||local-45/JJ	prep_for||displays-3/VBZ||treatments-46/NNS	conj_and||receptor-28/NN||treatments-46/NNS	amod||sites-49/NNS||metastatic-48/JJ	conj_and||receptor-28/NN||sites-49/NNS	conj_and||treatments-46/NNS||sites-49/NNS	tumours-41||dm-1||yes||dm dynamics displays the same bimodal pattern (first early peak at about 24 months, second late peak at the sixth-seventh year) for both estrogen receptor (er) positive (p) and negative (n) tumours and for all local treatments and metastatic sites.
amod||mortality-2/NN||overall-1/JJ	nsubj||%-5/NN||mortality-2/NN	cop||%-5/NN||was-3/VBD	num||%-5/NN||9-4/CD	root||ROOT-0/null||%-5/NN	num||deaths-8/NNS||21-7/CD	appos||%-5/NN||deaths-8/NNS	det||arm-15/NN||the-11/DT	amod||arm-15/NN||high-12/JJ	nn||arm-15/NN||flow-13/NN	nn||arm-15/NN||oxygen-14/NN	prep_in||%-5/NN||arm-15/NN	prep||arm-15/NN||compared-16/VBN	pcomp||compared-16/VBN||with-17/IN	num||%-19/NN||4-18/CD	pobj||with-17/IN||%-19/NN	num||deaths-22/NNS||7-21/CD	appos||%-19/NN||deaths-22/NNS	det||arm-28/NN||the-25/DT	amod||arm-28/NN||titrated-26/JJ	nn||arm-28/NN||oxygen-27/NN	prep_in||%-19/NN||arm-28/NN	nsubj||%-40/NN||mortality-30/NN	det||subgroup-33/NN||the-32/DT	prep_in||mortality-30/NN||subgroup-33/NN	amod||obstructivepulmonarydisease-37/NN||confirmed-35/JJ	amod||obstructivepulmonarydisease-37/NN||chronic-36/JJ	prep_with||subgroup-33/NN||obstructivepulmonarydisease-37/NN	cop||%-40/NN||was-38/VBD	num||%-40/NN||9-39/CD	parataxis||%-5/NN||%-40/NN	num||deaths-43/NNS||11-42/CD	appos||%-40/NN||deaths-43/NNS	det||arm-49/NN||the-46/DT	amod||arm-49/NN||high-47/JJ	nn||arm-49/NN||flow-48/NN	prep_in||%-40/NN||arm-49/NN	prepc_compared_with||arm-49/NN||with-51/IN	num||%-53/NN||2-52/CD	pobj||arm-49/NN||%-53/NN	num||deaths-56/NNS||2-55/CD	appos||%-53/NN||deaths-56/NNS	det||arm-62/NN||the-59/DT	amod||arm-62/NN||titrated-60/JJ	nn||arm-62/NN||oxygen-61/NN	prep_in||%-53/NN||arm-62/NN	obstructivepulmonarydisease-37||oxygen-61||yes||overall mortality was 9% (21 deaths) in the high flow oxygen arm compared with 4% (7 deaths) in the titrated oxygen arm; mortality in the subgroup with confirmed chronic obstructivepulmonarydisease was 9% (11 deaths) in the high flow arm compared with 2% (2 deaths) in the titrated oxygen arm.
nn||composition-2/NN||body-1/NN	nsubjpass||measured-30/VBN||composition-2/NN	prep_including||composition-2/NN||anthropometrics-5/NNS	amod||assessment-10/NN||visceral-7/JJ	amod||assessment-10/NN||adipose-8/JJ	nn||assessment-10/NN||tissue-9/NN	prep_including||composition-2/NN||assessment-10/NN	conj_and||anthropometrics-5/NNS||assessment-10/NN	prep_by||assessment-10/NN||ct-12/NN	amod||parameters-16/NNS||metabolic-15/JJ	prep_including||composition-2/NN||parameters-16/NNS	conj_and||anthropometrics-5/NNS||parameters-16/NNS	prep_including||composition-2/NN||lipids-19/NNS	prep_including||composition-2/NN||cimt-21/NN	conj_and||lipids-19/NNS||cimt-21/NN	amod||test-27/NN||oral-24/JJ	nn||test-27/NN||glucose-25/NN	nn||test-27/NN||tolerance-26/NN	prep_including||composition-2/NN||test-27/NN	conj_and||lipids-19/NNS||test-27/NN	auxpass||measured-30/VBN||were-29/VBD	root||ROOT-0/null||measured-30/VBN	num||men-33/NNS||174-32/CD	prep_in||measured-30/VBN||men-33/NNS	prep_in||measured-30/VBN||women-35/NNS	conj_and||men-33/NNS||women-35/NNS	num||$-41/NNS||hivinfection-37/NN	num||nonâ-40/CD||154-39/CD	conj_and||hivinfection-37/NN||nonâ-40/CD	num||$-41/NNS||nonâ-40/CD	prep_with||measured-30/VBN||$-41/NNS	amod||subjects-44/NNS||hiv-infected-43/JJ	dep||$-41/NNS||subjects-44/NNS	hivinfection-37||hiv--1||no||body composition, including anthropometrics, visceral adipose tissue assessment by ct, and metabolic parameters, including lipids, cimt, and oral glucose tolerance test, were measured in 174 men and women with hivinfection and 154 nonâhiv-infected subjects.
nn||treatment-3/NN||gancyclovir-2/NN	prep_following||went-11/VBD||treatment-3/NN	amod||viremia-7/NN||subsequent-5/JJ	nn||viremia-7/NN||cytomegalovirus-6/NNS	prep_of||treatment-3/NN||viremia-7/NN	det||patient-10/NN||the-9/DT	nsubj||went-11/VBD||patient-10/NN	nsubj||receive-14/VB||patient-10/NN	root||ROOT-0/null||went-11/VBD	prt||went-11/VBD||on-12/RP	aux||receive-14/VB||to-13/TO	xcomp||went-11/VBD||receive-14/VB	det||course-16/NN||a-15/DT	dobj||receive-14/VB||course-16/NN	prep_of||course-16/NN||epoch-18/NN	advmod||mg/m2/day-52/NN||etoposide-20/RB	num||mg/m2/day-22/NNS||50-21/CD	pobj||etoposide-20/RB||mg/m2/day-22/NNS	prep_on||etoposide-20/RB||days-24/NNS	amod||mg/m2/day-52/NN||1â-25/JJ	amod||mg/m2/day-52/NN||$-26/$	num||$-26/$||4-28/CD	amod||mg/m2/day-52/NN||vincristine-30/JJ	num||mg/m2/day-32/NNS||0.4-31/CD	dep||vincristine-30/JJ||mg/m2/day-32/NNS	prep_on||mg/m2/day-32/NNS||days-34/NNS	amod||mg/m2/day-52/NN||1â-35/JJ	amod||mg/m2/day-52/NN||$-36/$	num||$-36/$||4-38/CD	amod||mg/m2/day-52/NN||doxorubicin-40/JJ	num||mg/m2/day-42/NNS||10-41/CD	dep||doxorubicin-40/JJ||mg/m2/day-42/NNS	prep_on||mg/m2/day-42/NNS||days-44/NNS	amod||mg/m2/day-52/NN||1â-45/JJ	amod||mg/m2/day-52/NN||$-46/$	num||$-46/$||4-48/CD	amod||mg/m2/day-52/NN||cyclophosphamide-50/JJ	number||cyclophosphamide-50/JJ||750-51/CD	dep||epoch-18/NN||mg/m2/day-52/NN	prep_on||mg/m2/day-52/NN||day-54/NN	num||day-54/NN||6-55/CD	advmod||1â-63/JJ||prednisolone-58/RB	num||mg/m2/day-60/NNS||60-59/CD	pobj||prednisolone-58/RB||mg/m2/day-60/NNS	prep_on||prednisolone-58/RB||days-62/NNS	prep_on||mg/m2/day-52/NN||1â-63/JJ	conj_and||day-54/NN||1â-63/JJ	dep||1â-63/JJ||$-64/$	num||$-64/$||6-66/CD	viremia-7||vincristine-30||no_rel||following gancyclovir treatment of subsequent cytomegalovirus viremia, the patient went on to receive a course of epoch (etoposide 50 mg/m2/day on days 1â4, vincristine 0.4 mg/m2/day on days 1â4, doxorubicin 10 mg/m2/day on days 1â4, cyclophosphamide 750 mg/m2/day on day 6, and prednisolone 60 mg/m2/day on days 1â6).
nsubj||â-2/VBP||conclusions-1/NNS	nsubj||lowered-22/VBD||conclusions-1/NNS	root||ROOT-0/null||â-2/VBP	dobj||â-2/VBP||$-3/$	prep_in||â-2/VBP||subjects-6/NNS	amod||liraglutide-11/NN||type2diabetes-8/JJ	amod||liraglutide-11/NN||once-daily-10/JJ	prep_with||subjects-6/NNS||liraglutide-11/NN	vmod||liraglutide-11/NN||induced-12/VBN	amod||control-15/NN||similar-13/JJ	amod||control-15/NN||glycemic-14/JJ	dobj||induced-12/VBN||control-15/NN	amod||weight-19/NN||reduced-17/VBN	nn||weight-19/NN||body-18/NN	appos||control-15/NN||weight-19/NN	conj_and||â-2/VBP||lowered-22/VBD	det||occurrence-24/NN||the-23/DT	dobj||lowered-22/VBD||occurrence-24/NN	prep_of||occurrence-24/NN||hypoglycemia-26/NN	prepc_compared_with||lowered-22/VBD||with-28/IN	pobj||lowered-22/VBD||glimepiride-29/NN	tmod||had-33/VBD||glimepiride-29/NN	advmod||had-33/VBD||when-31/WRB	nsubj||had-33/VBD||both-32/DT	rcmod||glimepiride-29/NN||had-33/VBD	nn||therapy-35/NN||background-34/NN	dobj||had-33/VBD||therapy-35/NN	prep_of||therapy-35/NN||metformin-37/NN	type2diabetes-8||metformin-37||yes||conclusions âin subjects with type2diabetes, once-daily liraglutide induced similar glycemic control, reduced body weight, and lowered the occurrence of hypoglycemia compared with glimepiride, when both had background therapy of metformin.
vmod||present-16/VBP||using-1/VBG	det||$-10/FW||the-2/DT	nn||$-10/FW||caenorhabditis-3/FW	nn||$-10/FW||elegans-4/FW	nn||$-10/FW||â-5/FW	nn||$-10/FW||$-6/FW	nn||$-10/FW||pseudomonasaeruginosa-8/FW	nn||$-10/FW||hostâ-9/FW	dobj||using-1/VBG||$-10/FW	iobj||using-1/VBG||$-10/FW	nn||system-13/NN||pathogen-12/NN	dep||$-10/FW||system-13/NN	nsubj||present-16/VBP||we-15/PRP	root||ROOT-0/null||present-16/VBP	amod||evidence-18/NN||genetic-17/JJ	dobj||present-16/VBP||evidence-18/NN	mark||required-72/VBN||that-19/IN	det||fat-3-24/NNS||a-20/DT	nn||fat-3-24/NNS||î-21/NN	amod||fat-3-24/NNS||6-desaturase-23/JJ	nsubjpass||required-72/VBN||fat-3-24/NNS	poss||productsâ-30/NNS||its-27/PRP$	num||productsâ-30/NNS||two-28/CD	amod||productsâ-30/NNS||18-carbon-29/JJ	prep_through||fat-3-24/NNS||productsâ-30/NNS	dep||fat-3-24/NNS||$-31/$	num||$-31/$||gamma-linolenicacid-33/CD	dep||$-31/$||gla-35/NN	appos||gla-35/NN||183n6-37/NNS	amod||acid-41/NN||stearidonic-40/JJ	dep||fat-3-24/NNS||acid-41/NN	conj_and||$-31/$||acid-41/NN	dep||acid-41/NN||sda-43/NN	appos||sda-43/NN||184n3-45/NNS	det||acid-54/NN||the-50/DT	num||pufas-52/NNS||20-carbon-51/CD	npadvmod||arachidonic-53/JJ||pufas-52/NNS	amod||acid-54/NN||arachidonic-53/JJ	dep||fat-3-24/NNS||acid-54/NN	conj_negcc||$-31/$||acid-54/NN	dep||acid-54/NN||aa-56/NN	appos||aa-56/NN||204n6-58/NNS	amod||$-69/NNS||eicosapentaenoic-61/JJ	amod||$-69/NNS||acid-62/JJ	dep||$-69/NNS||epa-64/NN	appos||epa-64/NN||205n3-66/NNS	nn||$-69/NNS||â-68/NN	conj_negcc||$-31/$||$-69/NNS	conj_and||acid-54/NN||$-69/NNS	auxpass||required-72/VBN||is-71/VBZ	ccomp||present-16/VBP||required-72/VBN	amod||immunity-76/NN||basal-74/JJ	nn||immunity-76/NN||innate-75/NN	prep_for||required-72/VBN||immunity-76/NN	prep_in||immunity-76/NN||vivo-78/NN	gamma-linolenicacid-33||gla-35||no_rel||using the caenorhabditis elegans â pseudomonasaeruginosa hostâpathogen system, we present genetic evidence that a î6-desaturase fat-3, through its two 18-carbon productsâgamma-linolenicacid (gla, 183n6) and stearidonic acid (sda, 184n3), but not the 20-carbon pufas arachidonic acid (aa, 204n6) and eicosapentaenoic acid (epa, 205n3)âis required for basal innate immunity in vivo.
det||study-2/NN||this-1/DT	nsubjpass||designed-4/VBN||study-2/NN	auxpass||designed-4/VBN||was-3/VBD	root||ROOT-0/null||designed-4/VBN	aux||evaluate-6/VB||to-5/TO	ccomp||designed-4/VBN||evaluate-6/VB	det||role-8/NN||the-7/DT	dobj||evaluate-6/VB||role-8/NN	amod||methadone-lidocaine-11/NN||epidural-10/JJ	prep_of||role-8/NN||methadone-lidocaine-11/NN	nn||pain-14/NN||cancer-13/NN	prep_in||evaluate-6/VB||pain-14/NN	vmod||pain-14/NN||combined-15/VBN	neg||epidural-19/VB||not-17/RB	aux||epidural-19/VB||to-18/TO	ccomp||designed-4/VBN||epidural-19/VB	conj_or||evaluate-6/VB||epidural-19/VB	dobj||epidural-19/VB||dexamethasone-20/NN	pain-14||lidocaine--1||yes||this study was designed to evaluate the role of epidural methadone-lidocaine in cancer pain combined or not to epidural dexamethasone.
advmod||increased-11/VBD||however-1/RB	amod||administration-4/NN||fluoxetine-3/JJ	nsubj||increased-11/VBD||administration-4/NN	advmod||increased-11/VBD||significantly-5/RB	dep||<-8/JJ||p-7/RB	dep||significantly-5/RB||<-8/JJ	dep||<-8/JJ||0.05-9/CD	root||ROOT-0/null||increased-11/VBD	amod||ans-13/NN||key-12/JJ	nn||responses-40/NNS||ans-13/NN	dep||ans-13/NN||epinephrine-15/NN	dep||ans-13/NN||norepinephrine-17/NN	conj_and||epinephrine-15/NN||norepinephrine-17/NN	dep||ans-13/NN||msna-20/NN	conj_and||epinephrine-15/NN||msna-20/NN	conj_and||ans-13/NN||metabolic-23/NN	nn||responses-40/NNS||metabolic-23/NN	amod||production-27/NN||endogenous-25/JJ	nn||production-27/NN||glucose-26/NN	dep||metabolic-23/NN||production-27/NN	dep||metabolic-23/NN||lipolysis-29/NNS	conj_and||production-27/NN||lipolysis-29/NNS	amod||counterregulatory-39/NN||cardiovascular-33/JJ	amod||pressure-37/NN||systolic-35/JJ	nn||pressure-37/NN||blood-36/NN	appos||counterregulatory-39/NN||pressure-37/NN	conj_and||ans-13/NN||counterregulatory-39/NN	nn||responses-40/NNS||counterregulatory-39/NN	dobj||increased-11/VBD||responses-40/NNS	prep_during||increased-11/VBD||hypoglycemia-42/NN	hypoglycemia-42||norepinephrine-17||no_rel||however, fluoxetine administration significantly ( p < 0.05) increased key ans (epinephrine, norepinephrine, and msna), metabolic (endogenous glucose production and lipolysis), and cardiovascular (systolic blood pressure) counterregulatory responses during hypoglycemia.
nsubj||disease-6/NN||buruliulcer-1/NN	cop||disease-6/NN||is-2/VBZ	det||disease-6/NN||a-3/DT	amod||disease-6/NN||necrotizing-4/VBG	nn||disease-6/NN||skin-5/NN	root||ROOT-0/null||disease-6/NN	dep||disease-6/NN||caused-7/VBN	prep_by||caused-7/VBN||mycobacteriumulcerans-9/NNS	dep||disease-6/NN||associated-11/VBN	conj_and||caused-7/VBN||associated-11/VBN	prep_with||associated-11/VBN||exposure-13/NN	amod||habitats-16/NNS||aquatic-15/JJ	prep_to||associated-11/VBN||habitats-16/NNS	buruliulcer-1||mycobacteriumulcerans-9||no||buruliulcer is a necrotizing skin disease caused by mycobacteriumulcerans and associated with exposure to aquatic habitats.
det||effects-3/NNS||the-1/DT	amod||effects-3/NNS||therapeutic-2/JJ	nsubjpass||explored-21/VBN||effects-3/NNS	amod||infusion-6/NN||systemic-5/JJ	prep_of||effects-3/NNS||infusion-6/NN	amod||uc-mscs-9/NNS||human-8/JJ	prep_of||infusion-6/NN||uc-mscs-9/NNS	amod||arthritis-12/NN||collagen-induced-11/JJ	prep_on||uc-mscs-9/NNS||arthritis-12/NN	appos||arthritis-12/NN||cia-14/NN	det||model-19/NN||a-17/DT	nn||model-19/NN||mouse-18/NN	prep_in||arthritis-12/NN||model-19/NN	auxpass||explored-21/VBN||were-20/VBD	root||ROOT-0/null||explored-21/VBN	arthritis-12||collagen--1||no_rel||the therapeutic effects of systemic infusion of human uc-mscs on collagen-induced arthritis (cia) in a mouse model were explored.
nsubj||test-15/VBP||rhinoconjunctivitis-1/NNS	amod||symptoms-4/NNS||asthma-like-3/JJ	conj_and||rhinoconjunctivitis-1/NNS||symptoms-4/NNS	nsubj||test-15/VBP||symptoms-4/NNS	conj_and||rhinoconjunctivitis-1/NNS||fev1-6/NNS	nsubj||test-15/VBP||fev1-6/NNS	amod||challenge-11/NN||ar-8/JJ	amod||challenge-11/NN||post-methacholine-9/JJ	amod||challenge-11/NN||bronchial-10/JJ	conj_and||rhinoconjunctivitis-1/NNS||challenge-11/NN	nsubj||test-15/VBP||challenge-11/NN	appos||rhinoconjunctivitis-1/NNS||mbc-13/NN	root||ROOT-0/null||test-15/VBP	nn||measurements-19/NNS||results-16/NNS	conj_and||measurements-19/NNS||feno-18/NN	nsubjpass||investigated-24/VBN||feno-18/NN	nsubjpass||investigated-24/VBN||measurements-19/NNS	conj_and||measurements-19/NNS||ep-21/NN	nsubjpass||investigated-24/VBN||ep-21/NN	auxpass||investigated-24/VBN||were-22/VBD	advmod||investigated-24/VBN||all-23/RB	ccomp||test-15/VBP||investigated-24/VBN	amod||bakers-27/NNS||apprentice-26/JJ	prep_in||investigated-24/VBN||bakers-27/NNS	prep_in||investigated-24/VBN||pastry-makers-29/NNS	conj_and||bakers-27/NNS||pastry-makers-29/NNS	prep_in||investigated-24/VBN||hairdressers-31/NNS	conj_and||bakers-27/NNS||hairdressers-31/NNS	neg||suffering-33/VBG||not-32/RB	vmod||bakers-27/NNS||suffering-33/VBG	prep_from||suffering-33/VBG||asthma-35/NN	methacholine--1||asthma-35||no_rel||rhinoconjunctivitis, asthma-like symptoms, fev1 and ar post-methacholine bronchial challenge (mbc) test results, feno measurements and ep were all investigated in apprentice bakers, pastry-makers and hairdressers not suffering from asthma.
det||elisa-3/NN||the-1/DT	amod||elisa-3/NN||epitope-blocking-2/JJ	nsubj||provided-10/VBD||elisa-3/NN	prepc_based_on||elisa-3/NN||on-5/IN	det||mab-9/NN||a-6/DT	amod||mab-9/NN||unique-7/JJ	amod||mab-9/NN||5f8-8/JJ	pobj||elisa-3/NN||mab-9/NN	root||ROOT-0/null||provided-10/VBD	advmod||sensitive-12/JJ||highly-11/RB	amod||detection-17/NN||sensitive-12/JJ	num||%-15/NN||100-14/CD	npadvmod||specific-16/JJ||%-15/NN	conj_and||sensitive-12/JJ||specific-16/JJ	amod||detection-17/NN||specific-16/JJ	dobj||provided-10/VBD||detection-17/NN	prep_of||detection-17/NN||antibodies-19/NNS	amod||influenzaviruses-22/NNS||h5n1-21/JJ	prep_to||provided-10/VBD||influenzaviruses-22/NNS	amod||sera-25/NN||human-24/JJ	prep_in||influenzaviruses-22/NNS||sera-25/NN	h5n1-21||influenzaviruses-22||no||the epitope-blocking elisa based on a unique 5f8 mab provided highly sensitive and 100% specific detection of antibodies to h5n1 influenzaviruses in human sera.
vmod||assessed-6/VBD||using-1/VBG	det||elisa-3/NN||this-2/DT	dobj||using-1/VBG||elisa-3/NN	nsubj||assessed-6/VBD||we-5/PRP	root||ROOT-0/null||assessed-6/VBD	xcomp||assessed-6/VBD||circulating-7/VBG	xcomp||assessed-6/VBD||circulating-7/VBG	conj_and||circulating-7/VBG||circulating-7/VBG	dobj||circulating-7/VBG||progranulin-8/NN	det||study-12/NN||a-10/DT	amod||study-12/NN||cross-sectional-11/JJ	prep_in||circulating-7/VBG||study-12/NN	num||subjects-15/NNS||209-14/CD	prep_of||study-12/NN||subjects-15/NNS	det||range-19/NN||a-17/DT	amod||range-19/NN||wide-18/JJ	prep_with||subjects-15/NNS||range-19/NN	prep_of||range-19/NN||obesity-21/NN	nn||distribution-25/NN||body-23/NN	amod||distribution-25/NN||fat-24/JJ	prep_of||range-19/NN||distribution-25/NN	conj_and||obesity-21/NN||distribution-25/NN	nn||sensitivity-28/NN||insulin-27/NN	prep_of||range-19/NN||sensitivity-28/NN	conj_and||obesity-21/NN||sensitivity-28/NN	nn||tolerance-32/NN||glucose-31/NN	prep_of||range-19/NN||tolerance-32/NN	conj_and||obesity-21/NN||tolerance-32/NN	num||individuals-36/NNS||60-35/CD	prep_in||circulating-7/VBG||individuals-36/NNS	conj_and||study-12/NN||individuals-36/NNS	amod||tolerance-48/NN||normal-38/JJ	dep||normal-38/JJ||ngt-40/NN	conj_or||normal-38/JJ||impaired-43/JJ	amod||tolerance-48/NN||impaired-43/JJ	dep||impaired-43/JJ||igt-45/NN	nn||tolerance-48/NN||glucose-47/NN	prep_with||individuals-36/NNS||tolerance-48/NN	prep_with||individuals-36/NNS||type2diabetes-50/NNS	conj_or||tolerance-48/NN||type2diabetes-50/NNS	det||program-58/NN||a-54/DT	amod||program-58/NN||4-week-55/JJ	amod||program-58/NN||physical-56/JJ	nn||program-58/NN||training-57/NN	prep_after||circulating-7/VBG||program-58/NN	prep_before||circulating-7/VBG||program-58/NN	type2diabetes-50||insulin-27||yes||using this elisa, we assessed circulating progranulin in a cross-sectional study of 209 subjects with a wide range of obesity, body fat distribution, insulin sensitivity, and glucose tolerance and in 60 individuals with normal (ngt) or impaired (igt) glucose tolerance or type2diabetes before and after a 4-week physical training program.
det||organization-4/NN||the-1/DT	nn||organization-4/NN||world-2/NN	nn||organization-4/NN||health-3/NN	nsubj||estimated-6/VBN||organization-4/NN	aux||estimated-6/VBN||has-5/VBZ	root||ROOT-0/null||estimated-6/VBN	mark||develop-12/VBP||that-7/IN	number||million-9/CD||8-8/CD	nsubj||develop-12/VBP||million-9/CD	prep_of||million-9/CD||people-11/NNS	ccomp||estimated-6/VBN||develop-12/VBP	amod||tb-14/NN||active-13/JJ	dobj||develop-12/VBP||tb-14/NN	det||year-16/NN||every-15/DT	tmod||develop-12/VBP||year-16/NN	det||situation-19/NN||the-18/DT	nsubjpass||complicated-21/VBN||situation-19/NN	auxpass||complicated-21/VBN||is-20/VBZ	ccomp||estimated-6/VBN||complicated-21/VBN	conj_and||develop-12/VBP||complicated-21/VBN	det||increase-24/NN||an-23/DT	agent||complicated-21/VBN||increase-24/NN	amod||strains-27/NNS||mycobacteriumtuberculosis-26/JJ	prep_of||increase-24/NN||strains-27/NNS	amod||strains-27/NNS||resistant-28/JJ	prep_to||resistant-28/JJ||drugs-30/NNS	vmod||drugs-30/NNS||used-31/VBN	nn||mdr-35/NN||antitubercular-33/NN	nn||mdr-35/NN||therapy-34/NN	prep_in||used-31/VBN||mdr-35/NN	amod||strains-27/NNS||xdr-tb-37/JJ	conj_and||resistant-28/JJ||xdr-tb-37/JJ	xdr-tb-37||antitubercular-33||no_rel||the world health organization has estimated that 8 million of people develop active tb every year and the situation is complicated by an increase of mycobacteriumtuberculosis strains resistant to drugs used in antitubercular therapy mdr and xdr-tb.
det||observation-2/NN||this-1/DT	nsubj||is-3/VBZ||observation-2/NN	root||ROOT-0/null||is-3/VBZ	nn||significance-6/NN||public-health-5/NN	prep_of||is-3/VBZ||significance-6/NN	advmod||is-3/VBZ||particularly-8/RB	det||era-11/NN||the-10/DT	prep_in||is-3/VBZ||era-11/NN	prep_of||era-11/NN||hiv/aids-13/NNS	aids--1||hiv--1||no||this observation is of public-health significance, particularly in the era of hiv/aids.
det||warfarin-4/NN||the-1/DT	amod||warfarin-4/NN||anticoagulant-2/JJ	nn||warfarin-4/NN||drug-3/NN	nsubjpass||prescribed-7/VBN||warfarin-4/NN	auxpass||prescribed-7/VBN||is-5/VBZ	advmod||prescribed-7/VBN||widely-6/RB	root||ROOT-0/null||prescribed-7/VBN	prepc_for||prescribed-7/VBN||reducing-9/VBG	det||risk-11/NN||the-10/DT	dobj||reducing-9/VBG||risk-11/NN	prep_of||risk-11/NN||stroke-13/NN	prep_of||risk-11/NN||thrombosis-15/NNS	conj_and||stroke-13/NN||thrombosis-15/NNS	prep_of||risk-11/NN||pulmonaryembolism-17/NN	conj_and||stroke-13/NN||pulmonaryembolism-17/NN	amod||malfunction-21/NN||coronary-20/JJ	prep_of||risk-11/NN||malfunction-21/NN	conj_and||stroke-13/NN||malfunction-21/NN	stroke-13||warfarin-4||yes||the anticoagulant drug warfarin is widely prescribed for reducing the risk of stroke, thrombosis, pulmonaryembolism, and coronary malfunction.
amod||--3/NNS||compounds-1/JJ	amod||--3/NNS||1-deoxy-1-2/JJ	dep||--3/NNS||6-5/CD	amod||â-9/NN||-LSB--7/JJ	nn||â-9/NN||n-8/NN	dep||--3/NNS||â-9/NN	dep||â-9/NN||$-10/$	num||$-10/$||²-11/CD	dep||â-9/NN||furan-2-carbonyl-14/NN	nn||-RSB--18/NNS||hydrazino-17/NN	dep||furan-2-carbonyl-14/NN||-RSB--18/NNS	num||h-20/NN||-9-19/CD	dep||-RSB--18/NNS||h-20/NN	dep||furan-2-carbonyl-14/NN||purin-9-yl-22/JJ	amod||d-ribofuranuronamide-30/NN||n-ethyl-25/JJ	nn||²-28/NNP||î-27/NNP	dep||d-ribofuranuronamide-30/NN||²-28/NNP	dep||--3/NNS||d-ribofuranuronamide-30/NN	dep||d-ribofuranuronamide-30/NN||19-32/CD	amod||k-35/JJ||ha1-34/JJ	amod||iâ-71/NN||k-35/JJ	amod||iâ-71/NN||iâ-36/JJ	amod||iâ-71/NN||$-37/$	number||=-39/CD||-38/CD	num||$-37/$||=-39/CD	amod||iâ-71/NN||â-40/JJ	amod||iâ-71/NN||$-41/$	number||1050â-43/CD||-42/CD	num||$-41/$||1050â-43/CD	amod||iâ-71/NN||nm-44/JJ	amod||iâ-71/NN||ha2a-46/JJ	amod||iâ-71/NN||k-47/JJ	amod||iâ-71/NN||iâ-48/JJ	amod||iâ-71/NN||$-49/$	number||=-51/CD||-50/CD	num||$-49/$||=-51/CD	amod||iâ-71/NN||â-52/JJ	amod||iâ-71/NN||$-53/$	number||1550â-55/CD||-54/CD	num||$-53/$||1550â-55/CD	amod||iâ-71/NN||nm-56/JJ	amod||iâ-71/NN||ha2b-58/JJ	amod||iâ-71/NN||ec50â-59/JJ	amod||iâ-71/NN||$-60/$	number||=-62/CD||-61/CD	num||$-60/$||=-62/CD	amod||iâ-71/NN||â-63/JJ	amod||iâ-71/NN||$-64/$	number||82â-66/CD||-65/CD	num||$-64/$||82â-66/CD	amod||iâ-71/NN||nm-67/JJ	amod||iâ-71/NN||ha3-69/JJ	nn||iâ-71/NN||k-70/NN	appos||19-32/CD||iâ-71/NN	dep||iâ-71/NN||$-72/$	number||>-74/CD||-73/CD	num||$-72/$||>-74/CD	vmod||$-72/$||â-75/VBN	dep||m-81/NN||$-76/$	num||m-81/NN||-77/CD	num||m-81/NN||5â-78/CD	nn||m-81/NN||î-79/NN	num||m-81/NN||1/4-80/CD	dobj||â-75/VBN||m-81/NN	poss||analogue-86/NN||its-84/PRP$	amod||analogue-86/NN||2-chloro-85/JJ	dep||--3/NNS||analogue-86/NN	conj_and||d-ribofuranuronamide-30/NN||analogue-86/NN	nsubjpass||confirmed-139/VBN||23-87/CD	nsubj||agonists-146/NNS||23-87/CD	amod||iâ-91/NN||ha1-89/JJ	nn||iâ-91/NN||k-90/NN	dep||23-87/CD||iâ-91/NN	num||â-95/NN||$-92/$	number||=-94/CD||-93/CD	num||$-92/$||=-94/CD	prep||iâ-91/NN||â-95/NN	amod||î-134/NN||$-96/$	dep||$-96/$||-97/JJ	amod||î-134/NN||3500â-98/JJ	amod||î-134/NN||nm-99/JJ	amod||î-134/NN||ha2a-101/JJ	amod||î-134/NN||k-102/JJ	amod||î-134/NN||iâ-103/JJ	amod||î-134/NN||$-104/$	number||=-106/CD||-105/CD	num||$-104/$||=-106/CD	amod||î-134/NN||â-107/JJ	amod||î-134/NN||$-108/$	number||4950â-110/CD||-109/CD	num||$-108/$||4950â-110/CD	amod||î-134/NN||nm-111/JJ	amod||î-134/NN||ha2b-113/JJ	amod||î-134/NN||ec50â-114/JJ	amod||î-134/NN||$-115/$	number||=-117/CD||-116/CD	num||$-115/$||=-117/CD	amod||î-134/NN||â-118/JJ	amod||î-134/NN||$-119/$	number||210â-121/CD||-120/CD	num||$-119/$||210â-121/CD	amod||î-134/NN||nm-122/JJ	amod||î-134/NN||ha3-124/JJ	amod||î-134/NN||k-125/JJ	amod||î-134/NN||iâ-126/JJ	amod||î-134/NN||$-127/$	number||>-129/CD||-128/CD	num||$-127/$||>-129/CD	amod||î-134/NN||â-130/JJ	amod||î-134/NN||$-131/$	num||$-131/$||-132/CD	amod||î-134/NN||5â-133/JJ	dep||â-95/NN||î-134/NN	number||m-136/JJ||1/4-135/CD	amod||î-134/NN||m-136/JJ	auxpass||confirmed-139/VBN||were-138/VBD	rcmod||analogue-86/NN||confirmed-139/VBN	aux||agonists-146/NNS||to-140/TO	cop||agonists-146/NNS||be-141/VB	amod||agonists-146/NNS||potent-142/JJ	conj_and||potent-142/JJ||selective-144/JJ	amod||agonists-146/NNS||selective-144/JJ	amod||agonists-146/NNS||full-145/JJ	xcomp||confirmed-139/VBN||agonists-146/NNS	det||adenosinemonophosphate-150/NN||a-148/DT	amod||adenosinemonophosphate-150/NN||cyclic-149/JJ	prep_in||agonists-146/NNS||adenosinemonophosphate-150/NN	appos||adenosinemonophosphate-150/NN||camp-152/NN	amod||assay-155/JJ||functional-154/JJ	amod||adenosinemonophosphate-150/NN||assay-155/JJ	amod||cells-163/NNS||chinese-157/JJ	nn||cells-163/NNS||hamster-158/NN	nn||cells-163/NNS||ovary-159/NN	appos||cells-163/NNS||cho-161/NN	prep_in||agonists-146/NNS||cells-163/NNS	vmod||cells-163/NNS||expressing-164/VBG	amod||ar-166/NN||ha2b-165/JJ	dobj||expressing-164/VBG||ar-166/NN	nm-122||ar-166||no_rel||compounds 1-deoxy-1-{6-[ n â²-(furan-2-carbonyl)-hydrazino]-9 h -purin-9-yl}-n-ethyl- î² -d-ribofuranuronamide ( 19 , ha1 k iâ=â1050â nm, ha2a k iâ=â1550â nm, ha2b ec50â=â82â nm, ha3 k iâ>â5â î¼m) and its 2-chloro analogue 23 (ha1 k iâ=â3500â nm, ha2a k iâ=â4950â nm, ha2b ec50â=â210â nm, ha3 k iâ>â5â î¼m) were confirmed to be potent and selective full agonists in a cyclic adenosinemonophosphate (camp) functional assay in chinese hamster ovary (cho) cells expressing ha2b ar.
nn||cancer-5/NN||stage-2/NN	nn||cancer-5/NN||iv-3/NN	amod||cancer-5/NN||colorectal-4/JJ	prep_in||supported-9/VBN||cancer-5/NN	nsubj||supported-9/VBN||data-7/NNS	aux||supported-9/VBN||have-8/VBP	root||ROOT-0/null||supported-9/VBN	det||use-12/NN||the-10/DT	amod||use-12/NN||routine-11/JJ	dobj||supported-9/VBN||use-12/NN	amod||treatment-16/NN||prophylactic-14/JJ	nn||treatment-16/NN||skin-15/NN	prep_of||use-12/NN||treatment-16/NN	prep_in||supported-9/VBN||patients-18/NNS	dep||patients-18/NNS||receiving-19/VBG	dobj||receiving-19/VBG||antibody-20/NN	amod||receptor-25/NN||epidermal-22/JJ	nn||receptor-25/NN||growth-23/NN	nn||receptor-25/NN||factor-24/NN	prep_against||antibody-20/NN||receptor-25/NN	det||use-29/NN||the-28/DT	dobj||receiving-19/VBG||use-29/NN	conj_and||antibody-20/NN||use-29/NN	amod||chemotherapy-32/NN||upfront-31/JJ	prep_of||use-29/NN||chemotherapy-32/NN	amod||management-35/NN||initial-34/JJ	prep_as||receiving-19/VBG||management-35/NN	prep_in||receiving-19/VBG||patients-37/NNS	amod||metastasis-40/NNS||synchronous-39/JJ	prep_with||patients-37/NNS||metastasis-40/NNS	prep_without||receiving-19/VBG||obstruction-42/NN	dep||patients-18/NNS||bleeding-44/VBG	conj_or||receiving-19/VBG||bleeding-44/VBG	det||site-48/NN||the-46/DT	amod||site-48/NN||primary-47/JJ	prep_from||bleeding-44/VBG||site-48/NN	cancer-5||antibody-20||no_rel||in stage iv colorectal cancer, data have supported the routine use of prophylactic skin treatment in patients receiving antibody against epidermal growth factor receptor, and the use of upfront chemotherapy as initial management in patients with synchronous metastasis without obstruction or bleeding from the primary site.
advmod||achieved-25/VBN||moreover-1/RB	advmod||added-6/VBN||when-3/WRB	nsubjpass||added-6/VBN||thioridazine-4/NN	auxpass||added-6/VBN||was-5/VBD	advcl||achieved-25/VBN||added-6/VBN	det||regimen-9/NN||a-8/DT	prep_to||added-6/VBN||regimen-9/NN	vmod||regimen-9/NN||containing-10/VBG	dobj||containing-10/VBG||rifampicin-11/NN	dobj||containing-10/VBG||isoniazid-13/NN	conj_and||rifampicin-11/NN||isoniazid-13/NN	dobj||containing-10/VBG||pyrazinamide-15/NN	conj_and||rifampicin-11/NN||pyrazinamide-15/NN	nn||tuberculosis-18/NNP||susceptible-17/NNP	prep_for||containing-10/VBG||tuberculosis-18/NNP	det||effect-23/NN||a-20/DT	amod||effect-23/NN||significant-21/JJ	amod||effect-23/NN||synergistic-22/JJ	nsubjpass||achieved-25/VBN||effect-23/NN	auxpass||achieved-25/VBN||was-24/VBD	root||ROOT-0/null||achieved-25/VBN	poss||â-31/NNP||â-27/NNP	nn||â-31/NNP||6.2-29/NNP	nn||â-31/NNP||vs-30/NNP	poss||cfu-35/NN||â-31/NNP	number||log-34/CD||5.9-33/CD	num||cfu-35/NN||log-34/CD	dep||achieved-25/VBN||cfu-35/NN	nn||0.01-39/NNP||p-37/NNP	nn||0.01-39/NNP||<-38/NNP	appos||cfu-35/NN||0.01-39/NNP	tuberculosis-18||pyrazinamide-15||yes||moreover, when thioridazine was added to a regimen containing rifampicin, isoniazid and pyrazinamide for susceptible tuberculosis, a significant synergistic effect was achieved (â6.2 vs â5.9 log cfu, p<0.01).
nsubj||developed-2/VBD||we-1/PRP	root||ROOT-0/null||developed-2/VBD	det||method-11/NN||a-3/DT	amod||method-11/NN||fast-4/JJ	advmod||sensitive-7/JJ||highly-6/RB	conj_and||fast-4/JJ||sensitive-7/JJ	amod||method-11/NN||sensitive-7/JJ	nn||method-11/NN||blood-8/NN	nn||method-11/NN||culture-9/NN	nn||method-11/NN||pcr-10/NN	dobj||developed-2/VBD||method-11/NN	prep_for||method-11/NN||detection-13/NN	prep_of||detection-13/NN||salmonellatyphi-15/NNS	vmod||developed-2/VBD||allowing-17/VBG	amod||initiation-19/NN||same-day-18/JJ	dobj||allowing-17/VBG||initiation-19/NN	prep_of||initiation-19/NN||treatment-21/NN	amod||diagnosis-24/NN||accurate-23/JJ	prep_after||allowing-17/VBG||diagnosis-24/NN	prep_of||diagnosis-24/NN||typhoid-26/NN	typhoid-26||salmonellatyphi-15||no||we developed a fast and highly sensitive blood culture pcr method for detection of salmonellatyphi, allowing same-day initiation of treatment after accurate diagnosis of typhoid.
amod||quotient-14/NN||white-1/JJ	nn||quotient-14/NN||blood-2/NN	nn||quotient-14/NN||cell-3/NN	nn||quotient-14/NN||count-4/NN	dep||quotient-14/NN||csf/serum-6/NN	nn||quotient-14/NN||glucose-7/NN	nn||quotient-14/NN||ratio-8/NN	dep||quotient-14/NN||protein-10/NN	dep||quotient-14/NN||csf/serum-12/NN	nn||quotient-14/NN||albumin-13/NN	nsubjpass||analyzed-25/VBN||quotient-14/NN	nn||indices-17/NNS||immunoglobulin-16/NN	conj_and||quotient-14/NN||indices-17/NNS	nsubjpass||analyzed-25/VBN||indices-17/NNS	prep_for||quotient-14/NN||igg-19/NN	prep_for||quotient-14/NN||iga-21/NN	conj_and||igg-19/NN||iga-21/NN	prep_for||quotient-14/NN||igm-23/NN	conj_and||igg-19/NN||igm-23/NN	auxpass||analyzed-25/VBN||were-24/VBD	root||ROOT-0/null||analyzed-25/VBN	num||patients-28/NNS||90-27/CD	prep_in||analyzed-25/VBN||patients-28/NNS	prep_with||patients-28/NNS||bacterialmeningitis-30/NNS	num||patients-33/NNS||117-32/CD	prep_in||analyzed-25/VBN||patients-33/NNS	conj_and||patients-28/NNS||patients-33/NNS	prep_with||patients-33/NNS||viralmeningoencephalitis-35/NNS	num||patients-38/NNS||36-37/CD	prep_in||analyzed-25/VBN||patients-38/NNS	conj_and||patients-28/NNS||patients-38/NNS	prep_with||patients-38/NNS||leptomeningealmetastases-40/NNS	det||total-43/NN||a-42/DT	prep_in||leptomeningealmetastases-40/NNS||total-43/NN	num||samples-47/NNS||480-45/CD	nn||samples-47/NNS||csf-46/NN	prep_of||total-43/NN||samples-47/NNS	viralmeningoencephalitis-35||glucose-7||no_rel||white blood cell count, csf/serum glucose ratio, protein, csf/serum albumin quotient and immunoglobulin indices for igg, iga and igm were analyzed in 90 patients with bacterialmeningitis, 117 patients with viralmeningoencephalitis and 36 patients with leptomeningealmetastases in a total of 480 csf samples.
det||form-4/NN||the-1/DT	amod||form-4/NN||primary-2/JJ	amod||form-4/NN||circulating-3/JJ	nsubj||-RSB--15/VBZ||form-4/NN	prep_of||form-4/NN||vitamind-6/NN	amod||-LSB--9/NN||25-hydroxy-vitamind-8/JJ	appos||vitamind-6/NN||-LSB--9/NN	num||-LSB--9/NN||25-10/CD	discourse||vitamind-6/NN||oh-12/UH	dep||vitamind-6/NN||d-14/SYM	root||ROOT-0/null||-RSB--15/VBZ	auxpass||associated-18/VBN||is-17/VBZ	dep||-RSB--15/VBZ||associated-18/VBN	amod||outcomes-22/NNS||multiple-20/JJ	amod||outcomes-22/NNS||medical-21/JJ	prep_with||associated-18/VBN||outcomes-22/NNS	prep_including||-RSB--15/VBZ||rickets-25/NNS	prep_including||-RSB--15/VBZ||osteoporosis-27/NNS	conj_and||rickets-25/NNS||osteoporosis-27/NNS	prep_including||-RSB--15/VBZ||multiplesclerosis-29/NNS	conj_and||rickets-25/NNS||multiplesclerosis-29/NNS	prep_including||-RSB--15/VBZ||cancer-31/NN	conj_and||rickets-25/NNS||cancer-31/NN	osteoporosis-27||vitamind-6||yes||the primary circulating form of vitamind, 25-hydroxy-vitamind [25(oh)d], is associated with multiple medical outcomes, including rickets, osteoporosis, multiplesclerosis and cancer.
amod||infection-5/NNS||humantcelllymphotropicvirustype1-1/JJ	dep||infection-5/NNS||htlv-1-3/JJ	nsubj||lead-7/VB||infection-5/NNS	aux||lead-7/VB||can-6/MD	root||ROOT-0/null||lead-7/VB	prep_to||lead-7/VB||development-9/NN	amod||leukemia/lymphoma-14/NN||adult-11/JJ	nn||leukemia/lymphoma-14/NN||t-12/NN	nn||leukemia/lymphoma-14/NN||cell-13/NN	prep_of||development-9/NN||leukemia/lymphoma-14/NN	appos||leukemia/lymphoma-14/NN||atl-16/NN	amod||tropicalspasticparaparesis-21/NNS||htlv-1-associatedmyelopathy-19/JJ	amod||tropicalspasticparaparesis-21/NNS||/-20/JJ	prep_of||development-9/NN||tropicalspasticparaparesis-21/NNS	conj_or||leukemia/lymphoma-14/NN||tropicalspasticparaparesis-21/NNS	appos||leukemia/lymphoma-14/NN||ham/tsp-23/NN	det||subset-27/NN||a-26/DT	prep_in||lead-7/VB||subset-27/NN	amod||subjects-30/NNS||infected-29/JJ	prep_of||subset-27/NN||subjects-30/NNS	htlv-1-associatedmyelopathy-19||humantcelllymphotropicvirustype1-1||no||humantcelllymphotropicvirustype1 (htlv-1) infection can lead to development of adult t cell leukemia/lymphoma (atl) or htlv-1-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp) in a subset of infected subjects.
det||adhesion-2/NN||the-1/DT	nsubjpass||enhanced-12/VBN||adhesion-2/NN	conj_and||adhesion-2/NN||spreading-4/NN	nsubjpass||enhanced-12/VBN||spreading-4/NN	amod||cells-7/NNS||rmg-i-h-6/JJ	prep_of||adhesion-2/NN||cells-7/NNS	prep_on||cells-7/NNS||ha-9/NN	auxpass||enhanced-12/VBN||were-10/VBD	advmod||enhanced-12/VBN||significantly-11/RB	root||ROOT-0/null||enhanced-12/VBN	prep||enhanced-12/VBN||as-13/IN	prepc_compared_to||enhanced-12/VBN||to-15/TO	pobj||enhanced-12/VBN||those-16/DT	amod||cells-19/NNS||rmg-i-18/JJ	prep_of||those-16/DT||cells-19/NNS	nn||0.01-23/NNP||p-21/NNP	nn||0.01-23/NNP||<-22/NNP	appos||cells-19/NNS||0.01-23/NNP	det||enhancement-28/NN||this-27/DT	nsubjpass||inhibited-30/VBN||enhancement-28/NN	auxpass||inhibited-30/VBN||was-29/VBD	conj_and||enhanced-12/VBN||inhibited-30/VBN	amod||antibody-35/NN||lewis-32/JJ	nn||antibody-35/NN||y-33/NN	nn||antibody-35/NN||monoclonal-34/NN	agent||inhibited-30/VBN||antibody-35/NN	dep||<-38/JJ||p-37/RB	dep||inhibited-30/VBN||<-38/JJ	dep||<-38/JJ||0.01-39/CD	i---1||adhesion-2||no_rel||the adhesion and spreading of rmg-i-h cells on ha were significantly enhanced as compared to those of rmg-i cells ( p < 0.01), and this enhancement was inhibited by lewis y monoclonal antibody ( p < 0.01).
num||type-3/NN||ten-1/CD	amod||type-3/NN||obese-2/JJ	nsubj||-lrb--11/VBD||type-3/NN	num||patients-6/NNS||2-4/CD	amod||patients-6/NNS||diabetic-5/JJ	nsubjpass||infused-8/VBN||patients-6/NNS	auxpass||infused-8/VBN||were-7/VBD	rcmod||type-3/NN||infused-8/VBN	prep_with||infused-8/VBN||insulin-10/NN	root||ROOT-0/null||-lrb--11/VBD	num||units/h-13/NN||2-12/CD	nsubjpass||infused-34/VBN||units/h-13/NN	nsubjpass||served-51/VBN||units/h-13/NN	num||ml-16/NN||100-15/CD	prep_with||units/h-13/NN||ml-16/NN	number||%-19/NN||5-18/CD	amod||-rrb--21/NNS||%-19/NN	nn||-rrb--21/NNS||dextrose/h-20/NN	prep_of||ml-16/NN||-rrb--21/NNS	number||h.-24/CD||4-23/CD	num||8-26/CD||h.-24/CD	quantmod||8-26/CD||another-25/DT	prep_for||-rrb--21/NNS||8-26/CD	num||type-29/NN||6-28/CD	prep_of||ml-16/NN||type-29/NN	conj_and||-rrb--21/NNS||type-29/NN	num||patients-32/NNS||2-30/CD	amod||patients-32/NNS||diabetic-31/JJ	dep||type-29/NN||patients-32/NNS	auxpass||infused-34/VBN||were-33/VBD	ccomp||-lrb--11/VBD||infused-34/VBN	num||ml-37/NN||100-36/CD	prep_with||infused-34/VBN||ml-37/NN	number||%-40/NN||5-39/CD	amod||dextrose/h-41/NN||%-40/NN	prep_of||ml-37/NN||dextrose/h-41/NN	prep_of||ml-37/NN||saline-43/NN	conj_or||dextrose/h-41/NN||saline-43/NN	num||h-46/NN||4-45/CD	prep_for||ml-37/NN||h-46/NN	advmod||infused-34/VBN||respectively-48/RB	ccomp||-lrb--11/VBD||served-51/VBN	conj_and||infused-34/VBN||served-51/VBN	nn||subjects-54/NNS||control-53/NN	prep_as||served-51/VBN||subjects-54/NNS	dextrose--1||obese-2||no_rel||ten obese type 2 diabetic patients were infused with insulin -lrb- 2 units/h with 100 ml of 5 % dextrose/h -rrb- for 4 h. another 8 and 6 type 2 diabetic patients were infused with 100 ml of 5 % dextrose/h or saline for 4 h , respectively , and served as control subjects .
aux||characterize-2/VB||to-1/TO	csubj||randomized-38/VBD||characterize-2/VB	det||amount-4/NN||the-3/DT	dobj||characterize-2/VB||amount-4/NN	amod||hypoglycemia-7/NN||nocturnal-6/JJ	prep_of||amount-4/NN||hypoglycemia-7/NN	conj_and||characterize-2/VB||evaluate-9/VB	csubj||randomized-38/VBD||evaluate-9/VB	dobj||evaluate-9/VB||factors-10/NNS	vmod||factors-10/NNS||associated-11/VBN	amod||hypoglycemia-14/NN||nocturnal-13/JJ	prep_with||associated-11/VBN||hypoglycemia-14/NN	vmod||hypoglycemia-14/NN||assessed-15/VBN	amod||monitoring-19/NN||continuous-17/JJ	nn||monitoring-19/NN||glucose-18/NN	prep_with||assessed-15/VBN||monitoring-19/NN	appos||monitoring-19/NN||cgm-21/NN	prep_in||monitoring-19/NN||adults-24/NNS	prep_in||monitoring-19/NN||children-26/NNS	conj_and||adults-24/NNS||children-26/NNS	prep_with||assessed-15/VBN||type1diabetes-28/NNS	nsubj||participated-30/VBD||type1diabetes-28/NNS	rcmod||type1diabetes-28/NNS||participated-30/VBD	det||cgm-37/NN||the-32/DT	amod||cgm-37/NN||juvenile-33/JJ	nn||cgm-37/NN||diabetes-34/NN	nn||cgm-37/NN||research-35/NN	nn||cgm-37/NN||foundation-36/NN	prep_in||participated-30/VBD||cgm-37/NN	root||ROOT-0/null||randomized-38/VBD	amod||trial-40/NN||clinical-39/JJ	dobj||randomized-38/VBD||trial-40/NN	hypoglycemia-14||glucose-18||yes||to characterize the amount of nocturnal hypoglycemia and evaluate factors associated with nocturnal hypoglycemia assessed with continuous glucose monitoring (cgm) in adults and children with type1diabetes who participated in the juvenile diabetes research foundation cgm randomized clinical trial.
poss||study-2/NN||our-1/PRP$	nsubj||identified-3/VBD||study-2/NN	root||ROOT-0/null||identified-3/VBD	dobj||identified-3/VBD||gaps-4/NNS	dobj||identified-3/VBD||determinants-6/NNS	conj_and||gaps-4/NNS||determinants-6/NNS	prep_of||gaps-4/NNS||knowledge-8/NN	prep_about||identified-3/VBD||hiv/aids-10/NNS	amod||adults-13/NNS||older-12/JJR	prep_in||hiv/aids-10/NNS||adults-13/NNS	prep_among||adults-13/NNS||clinicians-15/NNS	nn||district-18/NN||kampala-17/NN	prep_in||clinicians-15/NNS||district-18/NN	appos||district-18/NN||uganda-20/NN	aids--1||hiv--1||no||our study identified gaps and determinants of knowledge about hiv/aids in older adults among clinicians in kampala district, uganda.
det||centers-3/NNS||the-1/DT	num||centers-3/NNS||2006-2/CD	nsubj||hiv-12/VBP||centers-3/NNS	nn||control-6/NN||disease-5/NN	prep_for||centers-3/NNS||control-6/NN	prep_for||centers-3/NNS||prevention-8/NN	conj_and||control-6/NN||prevention-8/NN	appos||centers-3/NNS||cdc-10/NN	root||ROOT-0/null||hiv-12/VBP	nn||guidelines-14/NNS||testing-13/NN	nsubj||recommend-15/VBP||guidelines-14/NNS	ccomp||hiv-12/VBP||recommend-15/VBP	xcomp||recommend-15/VBP||screening-16/VBG	prep_for||screening-16/VBG||hivinfection-18/NN	det||settings-22/NNS||all-20/DT	nn||settings-22/NNS||healthcare-21/NN	prep_in||hivinfection-18/NN||settings-22/NNS	det||department-27/NN||the-25/DT	nn||department-27/NN||emergency-26/NN	prep_including||hivinfection-18/NN||department-27/NN	appos||department-27/NN||ed-29/NN	hivinfection-18||hiv-12||no||the 2006 centers for disease control and prevention (cdc) hiv testing guidelines recommend screening for hivinfection in all healthcare settings, including the emergency department (ed).
amod||idus-4/NNS||current-1/JJ	conj_and||current-1/JJ||former-3/JJ	amod||idus-4/NNS||former-3/JJ	nsubjpass||recruited-6/VBN||idus-4/NNS	auxpass||recruited-6/VBN||were-5/VBD	root||ROOT-0/null||recruited-6/VBN	agent||recruited-6/VBN||respondent-8/NN	dep||respondent-8/NN||driven-9/VBN	xcomp||driven-9/VBN||sampling-10/VBG	det||setting-14/NN||an-12/DT	amod||setting-14/NN||urban-13/JJ	prep_in||sampling-10/VBG||setting-14/NN	prep_in||setting-14/NN||java-16/NN	dep||respondent-8/NN||interviewed-19/VBN	conj_and||driven-9/VBN||interviewed-19/VBN	nn||use-22/NN||drug-21/NN	prep_regarding||interviewed-19/VBN||use-22/NN	nn||behavior-26/NN||hiv-24/NN	nn||behavior-26/NN||risk-25/NN	prep_regarding||interviewed-19/VBN||behavior-26/NN	conj_and||use-22/NN||behavior-26/NN	vmod||use-22/NN||using-27/VBG	det||index-32/NN||the-28/DT	amod||index-32/NN||european-29/JJ	nn||index-32/NN||addiction-30/NN	nn||index-32/NN||severity-31/NN	dobj||using-27/VBG||index-32/NN	det||questionnaire-39/NN||the-34/DT	nn||questionnaire-39/NN||blood-35/NN	num||questionnaire-39/NN||borne-36/CD	nn||questionnaire-39/NN||virus-37/NN	nn||questionnaire-39/NN||transmission-38/NN	dobj||using-27/VBG||questionnaire-39/NN	conj_and||index-32/NN||questionnaire-39/NN	virus-37||idus-4||yes||current and former idus were recruited by respondent driven sampling in an urban setting in java, and interviewed regarding drug use and hiv risk behavior using the european addiction severity index and the blood borne virus transmission questionnaire.
det||title-2/NN||the-1/DT	nsubj||nitroâphenyl-3/VBP||title-2/NN	ccomp||synthesized-9/VBN||nitroâphenyl-3/VBP	amod||compound-5/NN||pyridine-4/JJ	dobj||nitroâphenyl-3/VBP||compound-5/NN	nsubjpass||synthesized-9/VBN||c20h22n2o6-7/NNS	auxpass||synthesized-9/VBN||was-8/VBD	root||ROOT-0/null||synthesized-9/VBN	det||product-13/NN||a-11/DT	nn||product-13/NN||degradation-12/NN	prep_as||synthesized-9/VBN||product-13/NN	det||nisoldipine-18/NN||the-15/DT	nn||nisoldipine-18/NN||hypertension-16/NN	nn||nisoldipine-18/NN||medication-17/NN	prep_of||product-13/NN||nisoldipine-18/NN	hypertension-16||nisoldipine-18||yes||the title nitroâ­phenyl pyridine compound, c20h22n2o6 was synthesized as a degradation product of the hypertension medication nisoldipine.
nsubjpass||determined-3/VBN||fcu-1/NN	auxpass||determined-3/VBN||was-2/VBD	root||ROOT-0/null||determined-3/VBN	num||patients-6/NNS||36-5/CD	prep_in||determined-3/VBN||patients-6/NNS	prep_with||determined-3/VBN||gout-8/NN	auxpass||treated-10/VBN||being-9/VBG	vmod||gout-8/NN||treated-10/VBN	prep_with||treated-10/VBN||allopurinol-12/NN	gout-8||allopurinol-12||yes||fcu was determined in 36 patients with gout being treated with allopurinol.
nsubj||allowed-5/VBD||analysis-1/NN	nn||constants-4/NNS||rate-3/NN	prep_of||analysis-1/NN||constants-4/NNS	root||ROOT-0/null||allowed-5/VBD	dobj||allowed-5/VBD||determination-6/NN	prep_of||determination-6/NN||kd-8/NN	det||complex-13/NN||each-10/DT	amod||complex-13/NN||non-covalent-11/JJ	amod||complex-13/NN||enzyme-dtnb-12/JJ	prep_for||allowed-5/VBD||complex-13/NN	det||rate-16/NN||the-15/DT	prep_for||allowed-5/VBD||rate-16/NN	conj_and||complex-13/NN||rate-16/NN	amod||rate-16/NN||constant-17/JJ	prep_for||constant-17/JJ||reaction-19/NN	aux||form-21/VB||to-20/TO	vmod||reaction-19/NN||form-21/VB	det||adduct-25/NN||the-22/DT	amod||adduct-25/NN||inactive-23/JJ	amod||adduct-25/NN||enzyme-thionitrobenzoate-24/JJ	dobj||form-21/VB||adduct-25/NN	enzyme--1||kd-8||no_rel||analysis of rate constants allowed determination of kd for each non-covalent enzyme-dtnb complex and the rate constant for reaction to form the inactive enzyme-thionitrobenzoate adduct.
amod||force-2/NN||single-cell-1/JJ	nsubjpass||used-5/VBN||force-2/NN	nsubj||investigate-7/VB||force-2/NN	advmod||used-5/VBN||spectroscopy-3/RB	auxpass||used-5/VBN||was-4/VBD	root||ROOT-0/null||used-5/VBN	aux||investigate-7/VB||to-6/TO	xcomp||used-5/VBN||investigate-7/VB	det||adhesion-10/NN||the-8/DT	amod||adhesion-10/NN||initial-9/JJ	dobj||investigate-7/VB||adhesion-10/NN	amod||fibroblasts-13/NNS||l929-12/JJ	prep_of||adhesion-10/NN||fibroblasts-13/NNS	advmod||grooved-16/JJ||periodically-15/RB	amod||microstructures-18/NNS||grooved-16/JJ	nn||microstructures-18/NNS||titanium-17/NN	prep_onto||investigate-7/VB||microstructures-18/NNS	nn||~-21/NNS||height-20/NN	dep||microstructures-18/NNS||~-21/NNS	amod||î-23/NN||6â-22/JJ	dep||~-21/NNS||î-23/NN	number||m-25/CD||1/4-24/CD	num||m-32/NN||m-25/CD	amod||width-28/JJ||groove-27/JJ	amod||m-32/NN||width-28/JJ	amod||m-32/NN||20â-29/JJ	nn||m-32/NN||î-30/NN	num||m-32/NN||1/4-31/CD	dep||î-23/NN||m-32/NN	titanium-17||adhesion-10||no_rel||single-cell force spectroscopy was used to investigate the initial adhesion of l929 fibroblasts onto periodically grooved titanium microstructures (height ~6â î¼m, groove width 20â î¼m).
nsubjpass||associated-9/VBN||access-1/NN	det||template-7/NN||a-3/DT	nn||template-7/NN||computer-4/NN	nn||template-7/NN||insulin-5/NN	nn||template-7/NN||order-6/NN	prep_to||access-1/NN||template-7/NN	auxpass||associated-9/VBN||was-8/VBD	root||ROOT-0/null||associated-9/VBN	amod||levels-14/NNS||improved-11/JJ	amod||levels-14/NNS||mean-12/JJ	nn||levels-14/NNS||glucose-13/NN	prep_with||associated-9/VBN||levels-14/NNS	amod||hypoglycemia-17/NN||increasing-16/VBG	prep_without||associated-9/VBN||hypoglycemia-17/NN	prep_in||hypoglycemia-17/NN||patients-19/NNS	prep_with||patients-19/NNS||type2diabetes-21/CD	type2diabetes-21||insulin-5||yes||access to a computer insulin order template was associated with improved mean glucose levels without increasing hypoglycemia in patients with type2diabetes.
amod||subjects-2/NNS||forty-nine-1/JJ	nsubjpass||enrolled-66/VBN||subjects-2/NNS	amod||renalcellcarcinoma-5/NN||metastatic-4/JJ	prep_with||subjects-2/NNS||renalcellcarcinoma-5/NN	nsubj||underwent-17/VBD||renalcellcarcinoma-5/NN	num||recipients-10/NNS||21-7/CD	nn||recipients-10/NNS||target-8/NN	nn||recipients-10/NNS||therapy-9/NN	dep||renalcellcarcinoma-5/NN||recipients-10/NNS	num||recipients-14/NNS||28-12/CD	amod||recipients-14/NNS||immunochemotherapy-13/JJ	dep||renalcellcarcinoma-5/NN||recipients-14/NNS	conj_and||recipients-10/NNS||recipients-14/NNS	rcmod||renalcellcarcinoma-5/NN||underwent-17/VBD	det||cycles-20/NNS||either-18/DT	amod||cycles-20/NNS||6-week-19/JJ	dobj||underwent-17/VBD||cycles-20/NNS	amod||treatment-23/NN||sunitinib-22/JJ	prep_of||cycles-20/NNS||treatment-23/NN	dep||subjects-2/NNS||50-25/CD	vmod||50-25/CD||mg-26/VBN	advmod||daily-28/JJ||once-27/RB	advmod||mg-26/VBN||daily-28/JJ	prep||daily-28/JJ||for-29/IN	num||weeks-31/NNS||4-30/CD	npadvmod||on-32/IN||weeks-31/NNS	pcomp||for-29/IN||on-32/IN	num||weeks-35/NNS||2-34/CD	npadvmod||off-36/RB||weeks-35/NNS	advmod||mg-26/VBN||off-36/RB	conj_and||daily-28/JJ||off-36/RB	amod||cycles-40/NNS||8-week-39/JJ	conj_or||subjects-2/NNS||cycles-40/NNS	nsubjpass||enrolled-66/VBN||cycles-40/NNS	prep_of||cycles-40/NNS||immunochemotherapy-42/NN	dep||cycles-40/NNS||combination-44/NN	amod||il-48/NN||interleukin-46/JJ	amod||il-48/NN||-LSB--47/JJ	prep_of||combination-44/NN||il-48/NN	vmod||combination-44/NN||-RSB--49/VBN	dobj||-RSB--49/VBN||-2-50/CD	amod||-RSB--55/NNS||interferon-52/JJ	amod||-RSB--55/NNS||-LSB--53/JJ	nn||-RSB--55/NNS||ifn-54/NN	appos||-2-50/CD||-RSB--55/NNS	amod||-2-50/CD||alpha-57/NN	amod||-2-50/CD||5-fluorouracil-60/VBG	conj_and||alpha-57/NN||5-fluorouracil-60/VBG	amod||-RSB--63/NNS||-LSB--61/JJ	nn||-RSB--63/NNS||fu-62/NN	dobj||5-fluorouracil-60/VBG||-RSB--63/NNS	auxpass||enrolled-66/VBN||were-65/VBD	root||ROOT-0/null||enrolled-66/VBN	renalcellcarcinoma-5||interferon-52||yes||forty-nine subjects with metastatic renalcellcarcinoma (21 target therapy recipients and 28 immunochemotherapy recipients) who underwent either 6-week cycles of sunitinib treatment (50 mg once daily for 4 weeks on and 2 weeks off) or 8-week cycles of immunochemotherapy (combination of interleukin [il]-2, interferon [ifn]-alpha, and 5-fluorouracil [fu]) were enrolled.
det||decades-5/NNS||the-2/DT	amod||decades-5/NNS||first-3/JJ	num||decades-5/NNS||two-4/CD	prep_during||lower-22/JJR||decades-5/NNS	det||epidemic-10/NN||the-7/DT	nn||epidemic-10/NN||u.s.-8/NN	nn||epidemic-10/NN||aids-9/NNS	prep_of||decades-5/NNS||epidemic-10/NN	det||malignancies-15/NNS||some-14/DT	prep_unlike||lower-22/JJR||malignancies-15/NNS	nn||risk-19/NN||breast-17/NN	nn||risk-19/NN||cancer-18/NN	nsubj||lower-22/JJR||risk-19/NN	nsubj||lower-22/JJR||risk-19/NN	cop||lower-22/JJR||was-20/VBD	advmod||lower-22/JJR||significantly-21/RB	root||ROOT-0/null||lower-22/JJR	conj_and||lower-22/JJR||lower-22/JJR	prep_for||lower-22/JJR||women-24/NNS	amod||infection-30/NN||humanimmunodeficiencyvirus-26/JJ	nn||infection-30/NN||-lrb--27/NNP	nn||infection-30/NN||hiv-28/NN	nn||infection-30/NN||-rrb--29/NN	prep_with||women-24/NNS||infection-30/NN	prepc_compared_to||lower-22/JJR||to-32/TO	det||population-35/NN||the-33/DT	amod||population-35/NN||general-34/JJ	pobj||lower-22/JJR||population-35/NN	aids-9||humanimmunodeficiencyvirus-26||no||during the first two decades of the u.s. aids epidemic , and unlike some malignancies , breast cancer risk was significantly lower for women with humanimmunodeficiencyvirus -lrb- hiv -rrb- infection compared to the general population .
nsubj||assessed-2/VBD||we-1/PRP	ccomp||exhaled-6/VBD||assessed-2/VBD	nn||dimethylarginines-4/NNS||plasma-3/NN	dobj||assessed-2/VBD||dimethylarginines-4/NNS	root||ROOT-0/null||exhaled-6/VBD	neg||concentrations-8/NNS||no-7/DT	nsubj||exhaled-6/VBD||concentrations-8/NNS	nn||function-11/NN||endothelial-10/NN	nsubj||exhaled-6/VBD||function-11/NN	conj_and||concentrations-8/NNS||function-11/NN	num||patients-14/NNS||49-13/CD	prep_in||concentrations-8/NNS||patients-14/NNS	prep_with||patients-14/NNS||sm-16/NN	prep_with||patients-14/NNS||78-18/CD	conj_and||sm-16/NN||78-18/CD	advmod||severe-21/JJ||moderately-20/RB	amod||malaria-22/NN||severe-21/JJ	prep_with||78-18/CD||malaria-22/NN	appos||malaria-22/NN||msm-24/NN	num||controls-29/NNS||19-27/CD	amod||controls-29/NNS||healthy-28/JJ	prep_with||patients-14/NNS||controls-29/NNS	conj_and||sm-16/NN||controls-29/NNS	appos||controls-29/NNS||hc-31/NN	hc-31||malaria-22||no_rel||we assessed plasma dimethylarginines, exhaled no concentrations and endothelial function in 49 patients with sm, 78 with moderately severe malaria (msm) and 19 healthy controls (hc).
amod||quotient-14/NN||white-1/JJ	nn||quotient-14/NN||blood-2/NN	nn||quotient-14/NN||cell-3/NN	nn||quotient-14/NN||count-4/NN	dep||quotient-14/NN||csf/serum-6/NN	nn||quotient-14/NN||glucose-7/NN	nn||quotient-14/NN||ratio-8/NN	dep||quotient-14/NN||protein-10/NN	dep||quotient-14/NN||csf/serum-12/NN	nn||quotient-14/NN||albumin-13/NN	nsubjpass||analyzed-25/VBN||quotient-14/NN	nn||indices-17/NNS||immunoglobulin-16/NN	conj_and||quotient-14/NN||indices-17/NNS	nsubjpass||analyzed-25/VBN||indices-17/NNS	prep_for||quotient-14/NN||igg-19/NN	prep_for||quotient-14/NN||iga-21/NN	conj_and||igg-19/NN||iga-21/NN	prep_for||quotient-14/NN||igm-23/NN	conj_and||igg-19/NN||igm-23/NN	auxpass||analyzed-25/VBN||were-24/VBD	root||ROOT-0/null||analyzed-25/VBN	num||patients-28/NNS||90-27/CD	prep_in||analyzed-25/VBN||patients-28/NNS	prep_with||patients-28/NNS||bacterialmeningitis-30/NNS	num||patients-33/NNS||117-32/CD	prep_in||analyzed-25/VBN||patients-33/NNS	conj_and||patients-28/NNS||patients-33/NNS	prep_with||patients-33/NNS||viralmeningoencephalitis-35/NNS	num||patients-38/NNS||36-37/CD	prep_in||analyzed-25/VBN||patients-38/NNS	conj_and||patients-28/NNS||patients-38/NNS	prep_with||patients-38/NNS||leptomeningealmetastases-40/NNS	det||total-43/NN||a-42/DT	prep_in||leptomeningealmetastases-40/NNS||total-43/NN	num||samples-47/NNS||480-45/CD	nn||samples-47/NNS||csf-46/NN	prep_of||total-43/NN||samples-47/NNS	leptomeningealmetastases-40||albumin-13||no_rel||white blood cell count, csf/serum glucose ratio, protein, csf/serum albumin quotient and immunoglobulin indices for igg, iga and igm were analyzed in 90 patients with bacterialmeningitis, 117 patients with viralmeningoencephalitis and 36 patients with leptomeningealmetastases in a total of 480 csf samples.
root||ROOT-0/null||study-1/VB	det||effects-3/NNS||the-2/DT	dobj||study-1/VB||effects-3/NNS	iobj||study-1/VB||effects-3/NNS	prep_of||effects-3/NNS||exenatide-5/NN	appos||exenatide-5/NN||exe-7/NN	amod||effects-3/NNS||plus-9/IN	amod||rosi-12/NNS||rosiglitazone-10/JJ	dep||effects-3/NNS||rosi-12/NNS	nn||²-16/NNS||î-15/NN	prep_on||rosi-12/NNS||²-16/NNS	nn||function-19/NN||cell-18/NN	dep||rosi-12/NNS||function-19/NN	nn||sensitivity-22/NN||insulin-21/NN	dep||rosi-12/NNS||sensitivity-22/NN	conj_and||function-19/NN||sensitivity-22/NN	vmod||function-19/NN||using-23/VBG	amod||techniques-29/NNS||hyperglycemic-24/JJ	conj_and||hyperglycemic-24/JJ||euglycemic-26/JJ	amod||techniques-29/NNS||euglycemic-26/JJ	nn||techniques-29/NNS||insulin-27/NN	nn||techniques-29/NNS||clamp-28/NN	dobj||using-23/VBG||techniques-29/NNS	prep_in||techniques-29/NNS||participants-31/NNS	prep_with||participants-31/NNS||type2diabetes-33/NNS	prep_on||type2diabetes-33/NNS||metformin-35/NN	insulin-27||type2diabetes-33||no_rel||study the effects of exenatide (exe) plus rosiglitazone (rosi) on î²-cell function and insulin sensitivity using hyperglycemic and euglycemic insulin clamp techniques in participants with type2diabetes on metformin.
nsubj||contributes-2/VBZ||this-1/DT	root||ROOT-0/null||contributes-2/VBZ	det||return-8/NN||the-4/DT	nn||return-8/NN||persistence-5/NN	conj_and||persistence-5/NN||gradual-7/JJ	nn||return-8/NN||gradual-7/JJ	prep_to||contributes-2/VBZ||return-8/NN	prep_of||return-8/NN||trachoma-10/NN	amod||treatment-13/NN||community-wide-12/JJ	prep_after||contributes-2/VBZ||treatment-13/NN	prep_with||treatment-13/NN||antibiotics-15/NNS	trachoma-10||antibiotics-15||no_rel||this contributes to the persistence and gradual return of trachoma after community-wide treatment with antibiotics.
advmod||reported-15/VBN||bartonellahenselae-1/RB	det||agent-5/NN||the-3/DT	amod||agent-5/NN||causative-4/JJ	nsubjpass||reported-15/VBN||agent-5/NN	prep_of||agent-5/NN||catscratchdisease-7/NN	amod||species-12/NNS||other-10/JJ	nn||species-12/NNS||bartonella-11/NN	prep_of||agent-5/NN||species-12/NNS	conj_and||catscratchdisease-7/NN||species-12/NNS	aux||reported-15/VBN||have-13/VBP	auxpass||reported-15/VBN||been-14/VBN	root||ROOT-0/null||reported-15/VBN	prep_in||reported-15/VBN||fleas-17/NNS	prep_in||reported-15/VBN||ticks-19/NNS	conj_and||fleas-17/NNS||ticks-19/NNS	catscratchdisease-7||bartonellahenselae-1||no||bartonellahenselae , the causative agent of catscratchdisease, and other bartonella species have been reported in fleas and ticks.
mark||exhibit-6/VB||because-1/IN	amod||proteins-4/NNS||internal-2/JJ	nn||proteins-4/NNS||influenza-3/NN	nsubj||exhibit-6/VB||proteins-4/NNS	aux||exhibit-6/VB||may-5/MD	advcl||possible-13/JJ||exhibit-6/VB	advmod||antigenic-8/JJ||less-7/RBR	amod||variation-9/NN||antigenic-8/JJ	dobj||exhibit-6/VB||variation-9/NN	nsubj||possible-13/JJ||it-11/PRP	cop||possible-13/JJ||is-12/VBZ	root||ROOT-0/null||possible-13/JJ	mark||provide-22/VBP||that-14/IN	amod||exposure-16/NN||prior-15/JJ	nsubj||provide-22/VBP||exposure-16/NN	amod||strains-19/NNS||diverse-18/JJ	prep_to||exposure-16/NN||strains-19/NNS	prep_of||strains-19/NNS||influenzavirus-21/NNS	ccomp||possible-13/JJ||provide-22/VBP	det||immunity-24/NN||some-23/DT	dobj||provide-22/VBP||immunity-24/NN	nn||strains-27/NNS||novel-26/NN	prep_to||provide-22/VBP||strains-27/NNS	det||strain-33/NN||the-30/DT	amod||strain-33/NN||recent-31/JJ	amod||strain-33/NN||pandemic-32/JJ	prep_including||provide-22/VBP||strain-33/NN	amod||a/h1n1-36/NNS||swine-avian-35/JJ	appos||strain-33/NN||a/h1n1-36/NNS	influenza-3||influenzavirus-21||no||because internal influenza proteins may exhibit less antigenic variation, it is possible that prior exposure to diverse strains of influenzavirus provide some immunity to novel strains, including the recent pandemic strain (swine-avian a/h1n1).
det||netb-5/NN||the-1/DT	amod||netb-5/NN||secreted-2/JJ	amod||netb-5/NN||pore-forming-3/JJ	nn||netb-5/NN||toxin-4/NN	nsubj||factor-10/NN||netb-5/NN	nsubj||similar-18/JJ||netb-5/NN	cop||factor-10/NN||is-6/VBZ	det||factor-10/NN||a-7/DT	amod||factor-10/NN||key-8/JJ	nn||factor-10/NN||virulence-9/NN	root||ROOT-0/null||factor-10/NN	det||pathogenesis-13/NNS||the-12/DT	prep_in||factor-10/NN||pathogenesis-13/NNS	prep_of||pathogenesis-13/NNS||aviannecroticenteritis-15/NNS	cop||similar-18/JJ||is-17/VBZ	conj_and||factor-10/NN||similar-18/JJ	prep_to||similar-18/JJ||alpha-hemolysin-20/NN	det||²-24/NN||a-22/DT	nn||²-24/NN||î-23/NN	appos||alpha-hemolysin-20/NN||²-24/NN	nn||toxin-28/NN||barrel-26/NN	amod||toxin-28/NN||pore-forming-27/JJ	dep||²-24/NN||toxin-28/NN	prep_from||toxin-28/NN||staphylococcusaureus-30/NNS	aviannecroticenteritis-15||hemolysin--1||no_rel||the secreted pore-forming toxin netb is a key virulence factor in the pathogenesis of aviannecroticenteritis and is similar to alpha-hemolysin, a î²-barrel pore-forming toxin from staphylococcusaureus .
prep_at||observed-12/JJ||check-up-2/NN	det||level-7/NN||a-4/DT	amod||level-7/NN||high-5/JJ	nn||level-7/NN||psa-6/NN	nsubj||observed-12/JJ||level-7/NN	amod||ng/ml-10/NN||515-9/JJ	prep_of||level-7/NN||ng/ml-10/NN	cop||observed-12/JJ||was-11/VBD	root||ROOT-0/null||observed-12/JJ	det||patient-15/NN||the-14/DT	nsubjpass||diagnosed-17/VBN||patient-15/NN	auxpass||diagnosed-17/VBN||was-16/VBD	conj_and||observed-12/JJ||diagnosed-17/VBN	prepc_with||diagnosed-17/VBN||having-19/VBG	amod||cancer-24/NN||clinical-20/JJ	nn||cancer-24/NN||stage-21/NN	nn||cancer-24/NN||d-22/NN	nn||cancer-24/NN||prostate-23/NN	dobj||having-19/VBG||cancer-24/NN	det||blockade-29/NN||a-26/DT	amod||blockade-29/NN||maximum-27/JJ	nn||blockade-29/NN||androgen-28/NN	nsubjpass||started-35/VBN||blockade-29/NN	nn||therapy-32/NN||mab-31/NN	appos||blockade-29/NN||therapy-32/NN	auxpass||started-35/VBN||was-34/VBD	conj_and||observed-12/JJ||started-35/VBN	androgen-28||cancer-24||no_rel||at check-up, a high psa level of 515 ng/ml was observed, the patient was diagnosed with having clinical stage d prostate cancer and a maximum androgen blockade (mab therapy) was started.
nsubj||receiving-12/VBG||resistance-1/NN	amod||insecticides-4/NNS||pyrethroid-3/JJ	prep_to||resistance-1/NN||insecticides-4/NNS	det||gambiae-10/NN||the-6/DT	nn||gambiae-10/NN||malaria-7/NN	nn||gambiae-10/NN||vector-8/NN	nn||gambiae-10/NN||anopheles-9/NNS	prep_in||insecticides-4/NNS||gambiae-10/NN	aux||receiving-12/VBG||is-11/VBZ	root||ROOT-0/null||receiving-12/VBG	vmod||receiving-12/VBG||increasing-13/VBG	dobj||increasing-13/VBG||attention-14/NN	mark||threatens-17/VBZ||because-15/IN	nsubj||threatens-17/VBZ||it-16/PRP	advcl||increasing-13/VBG||threatens-17/VBZ	det||sustainability-19/NN||the-18/DT	dobj||threatens-17/VBZ||sustainability-19/NN	nn||programs-24/NNS||malaria-21/NN	nn||programs-24/NNS||vector-22/NN	nn||programs-24/NNS||control-23/NN	prep_of||sustainability-19/NN||programs-24/NNS	amod||africa-27/NN||sub-saharan-26/JJ	prep_in||threatens-17/VBZ||africa-27/NN	malaria-21||pyrethroid-3||no_rel||resistance to pyrethroid insecticides in the malaria vector anopheles gambiae is receiving increasing attention because it threatens the sustainability of malaria vector control programs in sub-saharan africa.
nsubj||introduced-2/VBD||we-1/PRP	root||ROOT-0/null||introduced-2/VBD	amod||opioids-4/NNS||strong-3/JJ	nsubj||tolerable-26/JJ||opioids-4/NNS	amod||patches-8/NNS||transdermal-6/JJ	amod||patches-8/NNS||fentanyl-7/JJ	dep||opioids-4/NNS||patches-8/NNS	det||pain-12/NN||the-10/DT	nn||pain-12/NN||background-11/NN	prep_for||patches-8/NNS||pain-12/NN	det||opioid-16/NN||a-14/DT	amod||opioid-16/NN||short-acting-15/JJ	dep||opioids-4/NNS||opioid-16/NN	conj_and||patches-8/NNS||opioid-16/NN	det||pain-20/NN||the-18/DT	nn||pain-20/NN||breakthrough-19/NN	prep_for||opioid-16/NN||pain-20/NN	poss||pain-24/NN||his-23/PRP$	conj_and||opioids-4/NNS||pain-24/NN	nsubj||tolerable-26/JJ||pain-24/NN	cop||tolerable-26/JJ||was-25/VBD	ccomp||introduced-2/VBD||tolerable-26/JJ	num||hr-31/NN||250-28/CD	nn||hr-31/NN||âµg-29/NN	nn||hr-31/NN||/-30/NN	prep_on||tolerable-26/JJ||hr-31/NN	amod||patches-34/NNS||fentanyl-33/JJ	prep_of||hr-31/NN||patches-34/NNS	num||months-37/NNS||3-36/CD	prep_for||tolerable-26/JJ||months-37/NNS	pain-24||fentanyl-33||yes||we introduced strong opioids (transdermal fentanyl patches for the background pain and a short-acting opioid for the breakthrough pain) and his pain was tolerable on 250 âµg/hr of fentanyl patches for 3 months.
det||female-5/NN||an-1/DT	advmod||healthy-3/JJ||otherwise-2/RB	amod||female-5/NN||healthy-3/JJ	amod||female-5/NN||27-year-old-4/JJ	nsubj||had-17/VBD||female-5/NN	det||history-8/NN||a-7/DT	prep_with||female-5/NN||history-8/NN	prep_of||history-8/NN||attentiondeficithyperactivitydisorder-10/NN	dep||history-8/NN||adhd-12/VBN	vmod||history-8/NN||treated-14/VBN	prep_with||treated-14/VBN||atomoxetine-16/NN	root||ROOT-0/null||had-17/VBD	det||seizure-22/NN||an-18/DT	amod||onset-20/JJ||acute-19/JJ	amod||seizure-22/NN||onset-20/JJ	amod||seizure-22/NN||tonic-clonic-21/JJ	dobj||had-17/VBD||seizure-22/NN	attentiondeficithyperactivitydisorder-10||atomoxetine-16||yes||an otherwise healthy 27-year-old female with a history of attentiondeficithyperactivitydisorder (adhd) treated with atomoxetine had an acute onset tonic-clonic seizure.
nsubjpass||mentioned-4/VBN||it-1/PRP	nsubjpass||divided-23/VBN||it-1/PRP	auxpass||mentioned-4/VBN||was-2/VBD	advmod||mentioned-4/VBN||first-3/RB	root||ROOT-0/null||mentioned-4/VBN	agent||mentioned-4/VBN||maurice-6/NN	vmod||maurice-6/NN||raynaud-7/VBN	prep_in||raynaud-7/VBN||1862-9/CD	xcomp||raynaud-7/VBN||describing-10/VBG	quantmod||$-12/$||â-11/RB	num||asphyxia-15/FW||$-12/$	num||$-12/$||a-13/CD	amod||asphyxia-15/FW||local-14/JJ	dobj||describing-10/VBG||asphyxia-15/FW	det||$-19/NN||the-17/DT	amod||$-19/NN||extremitiesâ-18/JJ	prep_of||asphyxia-15/FW||$-19/NN	auxpass||divided-23/VBN||was-21/VBD	advmod||divided-23/VBN||further-22/RBR	conj_and||mentioned-4/VBN||divided-23/VBN	amod||raynaudâ-26/NNS||primary-25/JJ	prep_into||divided-23/VBN||raynaudâ-26/NNS	nsubjpass||related-42/VBN||raynaudâ-26/NNS	num||disease-30/NN||$-27/$	number||s-29/CD||-28/CD	num||$-27/$||s-29/CD	nsubj||phenomenon-37/NN||disease-30/NN	amod||raynaudâ-33/NNS||secondary-32/JJ	conj_and||disease-30/NN||raynaudâ-33/NNS	nsubj||phenomenon-37/NN||raynaudâ-33/NNS	amod||disease-30/NN||$-34/$	number||$-34/$||-35/CD	cop||phenomenon-37/NN||s-36/VBZ	rcmod||raynaudâ-26/NNS||phenomenon-37/NN	auxpass||related-42/VBN||is-40/VBZ	advmod||related-42/VBN||often-41/RB	rcmod||phenomenon-37/NN||related-42/VBN	prep_to||related-42/VBN||connectivetissuediseases-44/NNS	amod||strain-51/NN||physical-48/NN	conj_or||physical-48/NN||chemical-50/NN	amod||strain-51/NN||chemical-50/NN	rcmod||raynaudâ-26/NNS||strain-51/NN	conj_and||phenomenon-37/NN||strain-51/NN	chemical-50||asphyxia-15||no_rel||it was first mentioned by maurice raynaud in 1862 describing âa local asphyxia of the extremitiesâ? and was further divided into primary raynaudâs disease and secondary raynaudâs phenomenon, which is often related to connectivetissuediseases, but also physical or chemical strain.
nsubj||constitutes-2/VBZ||tuberculosis-1/NNP	root||ROOT-0/null||constitutes-2/VBZ	tmod||constitutes-2/VBZ||today-3/NN	det||threat-6/NN||a-4/DT	amod||threat-6/NN||serious-5/JJ	dep||constitutes-2/VBZ||threat-6/NN	amod||worldwide-10/NNS||human-8/JJ	nn||worldwide-10/NNS||health-9/NN	prep_to||threat-6/NN||worldwide-10/NNS	vmod||constitutes-2/VBZ||aggravated-12/VBN	det||number-16/NN||the-14/DT	amod||number-16/NN||increasing-15/VBG	agent||aggravated-12/VBN||number-16/NN	amod||strains-20/NNS||identified-18/VBN	amod||strains-20/NNS||multi-resistant-19/JJ	prep_of||number-16/NN||strains-20/NNS	prep_of||strains-20/NNS||mycobacteriumtuberculosis-22/NNS	poss||agent-26/NN||its-24/PRP$	amod||agent-26/NN||causative-25/JJ	appos||mycobacteriumtuberculosis-22/NNS||agent-26/NN	det||lack-33/NN||the-32/DT	agent||aggravated-12/VBN||lack-33/NN	conj_and||number-16/NN||lack-33/NN	prep_of||lack-33/NN||development-35/NN	amod||compounds-39/NNS||novel-37/JJ	amod||compounds-39/NNS||mycobactericidal-38/JJ	prep_of||development-35/NN||compounds-39/NNS	det||decades-44/NNS||the-41/DT	amod||decades-44/NNS||last-42/JJ	amod||decades-44/NNS||few-43/JJ	prep_for||compounds-39/NNS||decades-44/NNS	tuberculosis-1||mycobacteriumtuberculosis-22||no||tuberculosis constitutes today a serious threat to human health worldwide, aggravated by the increasing number of identified multi-resistant strains of mycobacteriumtuberculosis , its causative agent, as well as by the lack of development of novel mycobactericidal compounds for the last few decades.
det||study-2/NN||this-1/DT	nsubj||aims-3/VBZ||study-2/NN	nsubj||test-5/VB||study-2/NN	root||ROOT-0/null||aims-3/VBZ	aux||test-5/VB||to-4/TO	xcomp||aims-3/VBZ||test-5/VB	det||efficacy-7/NN||the-6/DT	dobj||test-5/VB||efficacy-7/NN	prepc_of||efficacy-7/NN||adding-9/VBG	det||dose-12/NN||a-10/DT	amod||dose-12/NN||low-11/JJ	dobj||adding-9/VBG||dose-12/NN	amod||orally-15/NN||ketamine-14/JJ	prep_of||dose-12/NN||orally-15/NN	det||supplement-19/NN||a-18/DT	prep_as||test-5/VB||supplement-19/NN	det||premedication-24/NN||the-21/DT	amod||premedication-24/NN||midazolam-based-22/JJ	amod||premedication-24/NN||oral-23/JJ	prep_to||supplement-19/NN||premedication-24/NN	prepc_for||premedication-24/NN||reducing-26/VBG	amod||agitation-29/NN||sevoflurane-related-27/JJ	nn||agitation-29/NN||emergence-28/NN	dobj||reducing-26/VBG||agitation-29/NN	agitation-29||midazolam--1||yes||this study aims to test the efficacy of adding a low dose of ketamine orally, as a supplement to the midazolam-based oral premedication for reducing sevoflurane-related emergence agitation.
det||treatment-3/NN||the-2/DT	prep_in||modality-15/NN||treatment-3/NN	prepc_of||treatment-3/NN||gravesâ-5/VBG	dep||basedowdisease-8/JJ||$-6/NNP	dep||gravesâ-5/VBG||basedowdisease-8/JJ	nsubj||modality-15/NN||radiotherapy-10/NN	cop||modality-15/NN||is-11/VBZ	det||modality-15/NN||a-12/DT	amod||modality-15/NN||well-tolerated-13/JJ	nn||modality-15/NN||treatment-14/NN	root||ROOT-0/null||modality-15/NN	graves--1||basedowdisease-8||no||in the treatment of gravesâbasedowdisease, radiotherapy is a well-tolerated treatment modality.
amod||analysis-2/NN||multivariate-1/JJ	nsubj||identified-3/VBD||analysis-2/NN	ccomp||transfusion-52/VBP||identified-3/VBD	det||factors-8/NNS||the-4/DT	amod||factors-8/NNS||following-5/JJ	amod||factors-8/NNS||independent-6/JJ	nn||factors-8/NNS||risk-7/NN	dobj||identified-3/VBD||factors-8/NNS	amod||catheterization-13/NN||candidemia-10/JJ	amod||catheterization-13/NN||central-11/JJ	nn||catheterization-13/NN||venous-12/NNS	prep_for||identified-3/VBD||catheterization-13/NN	dep||catheterization-13/NN||odds-15/NNS	nn||-LSB--17/NNS||ratio-16/NN	dep||odds-15/NNS||-LSB--17/NNS	nn||-RSB--29/NNS||-RSB--19/NNP	nn||-RSB--29/NNS||=-20/NNP	num||-RSB--29/NNS||3.2-21/CD	num||-RSB--29/NNS||95-23/CD	nn||-RSB--29/NNS||%-24/NN	nn||-RSB--29/NNS||confidence-25/NN	amod||-RSB--29/NNS||interval-26/JJ	amod||-RSB--29/NNS||-LSB--27/JJ	nn||-RSB--29/NNS||ci-28/NN	dep||odds-15/NNS||-RSB--29/NNS	conj_or||-LSB--17/NNS||-RSB--29/NNS	dep||.0-32/CD||=-30/SYM	num||.0-32/CD||1.2-9-31/CD	rcmod||-LSB--17/NNS||.0-32/CD	amod||therapy-37/NN||previous-35/JJ	amod||therapy-37/NN||steroid-36/JJ	appos||catheterization-13/NN||therapy-37/NN	cc||=-40/VBG||or-39/CC	dep||identified-3/VBD||=-40/VBG	nn||ci-45/NN||4.7-41/CD	number||%-44/NN||95-43/CD	amod||ci-45/NN||%-44/NN	dobj||=-40/VBG||ci-45/NN	dep||.1-48/CD||=-46/SYM	num||.1-48/CD||1.8-12-47/CD	dep||=-40/VBG||.1-48/CD	nsubj||transfusion-52/VBP||blood-51/NN	nsubj||hepaticfailure-72/VBP||blood-51/NN	root||ROOT-0/null||transfusion-52/VBP	det||period-57/NN||the-54/DT	amod||period-57/NN||same-55/JJ	nn||period-57/NN||admission-56/NN	prep_during||transfusion-52/VBP||period-57/NN	cc||=-60/VBG||or-59/CC	dep||transfusion-52/VBP||=-60/VBG	nn||ci-65/NN||6.3-61/CD	number||%-64/NN||95-63/CD	amod||ci-65/NN||%-64/NN	dobj||=-60/VBG||ci-65/NN	dep||.7-68/CD||=-66/SYM	num||.7-68/CD||2.4-16-67/CD	dep||=-60/VBG||.7-68/CD	conj_and||transfusion-52/VBP||hepaticfailure-72/VBP	amod||admission-75/NN||micu-74/JJ	prep_upon||transfusion-52/VBP||admission-75/NN	cc||=-78/VBG||or-77/CC	dep||transfusion-52/VBP||=-78/VBG	nn||ci-83/NN||6.9-79/CD	number||%-82/NN||95-81/CD	amod||ci-83/NN||%-82/NN	dobj||=-78/VBG||ci-83/NN	dep||.4-86/CD||=-84/SYM	num||.4-86/CD||1.7-28-85/CD	dep||=-78/VBG||.4-86/CD	steroid-36||hepaticfailure-72||no_rel||multivariate analysis identified the following independent risk factors for candidemia central venous catheterization (odds ratio [or] = 3.2, 95% confidence interval [ci]=1.2-9.0), previous steroid therapy (or=4.7, 95% ci=1.8-12.1), blood transfusion during the same admission period (or=6.3, 95% ci=2.4-16.7), and hepaticfailure upon micu admission (or=6.9, 95% ci=1.7-28.4).
num||kinds-2/NNS||two-1/CD	nsubj||viruses-7/NNS||kinds-2/NNS	prep_of||kinds-2/NNS||them-4/PRP	cop||viruses-7/NNS||are-5/VBP	amod||viruses-7/NNS||mosquito-borne-6/JJ	root||ROOT-0/null||viruses-7/NNS	nsubj||lead-16/VBP||viruses-7/NNS	nsubj||denguefever/denguehemorrhagicfever-21/VBP||viruses-7/NNS	advmod||virus-11/NN||namely-9/RB	amod||virus-11/NN||japaneseencephalitis-10/JJ	appos||viruses-7/NNS||virus-11/NN	appos||viruses-7/NNS||denguevirus-13/NNS	conj_and||virus-11/NN||denguevirus-13/NNS	rcmod||viruses-7/NNS||lead-16/VBP	prep_to||lead-16/VBP||japaneseencephalitis-18/NNS	rcmod||viruses-7/NNS||denguefever/denguehemorrhagicfever-21/VBP	conj_and||lead-16/VBP||denguefever/denguehemorrhagicfever-21/VBP	advmod||denguefever/denguehemorrhagicfever-21/VBP||respectively-22/RB	det||two-26/CD||the-24/DT	amod||two-26/CD||other-25/JJ	nsubj||viruses-29/NNS||two-26/CD	cop||viruses-29/NNS||are-27/VBP	amod||viruses-29/NNS||tick-borne-28/JJ	parataxis||viruses-7/NNS||viruses-29/NNS	nsubj||contribute-48/VBP||viruses-29/NNS	advmod||virus-33/NN||namely-31/RB	amod||virus-33/NN||tick-borneencephalitis-32/JJ	parataxis||viruses-7/NNS||virus-33/NN	conj_and||viruses-29/NNS||virus-33/NN	nsubj||contribute-48/VBP||virus-33/NN	amod||virus-37/NN||crimean-congo-35/JJ	nn||virus-37/NN||hemorrhagicfever-36/NN	parataxis||viruses-7/NNS||virus-37/NN	conj_and||viruses-29/NNS||virus-37/NN	nsubj||contribute-48/VBP||virus-37/NN	advmod||known-40/VBN||also-39/RB	dep||viruses-29/NNS||known-40/VBN	prepc_as||known-40/VBN||xinjiang-42/VBG	nn||virus-44/NN||hemorrhagicfever-43/NN	dobj||xinjiang-42/VBG||virus-44/NN	rcmod||viruses-29/NNS||contribute-48/VBP	prep_to||contribute-48/VBP||tick-borneencephalitis-50/NNS	nn||hemorrhagicfever-53/NN||xinjiang-52/NN	prep_to||contribute-48/VBP||hemorrhagicfever-53/NN	conj_and||tick-borneencephalitis-50/NNS||hemorrhagicfever-53/NN	advmod||contribute-48/VBP||respectively-54/RB	virus-44||viruses-29||no||two kinds of them are mosquito-borne viruses, namely japaneseencephalitis virus and denguevirus, which lead to japaneseencephalitis, and denguefever/denguehemorrhagicfever respectively; the other two are tick-borne viruses, namely tick-borneencephalitis virus and crimean-congo hemorrhagicfever virus (also known as xinjiang hemorrhagicfever virus), which contribute to tick-borneencephalitis and xinjiang hemorrhagicfever respectively.
nsubj||form-11/VBP||points-1/NNS	vmod||points-1/NNS||belonging-2/VBG	det||constituents-7/NNS||the-4/DT	amod||constituents-7/NNS||same-5/JJ	nn||constituents-7/NNS||lipid-6/NN	prep_to||belonging-2/VBG||constituents-7/NNS	amod||conditions-10/NNS||experimental-9/JJ	prep_to||belonging-2/VBG||conditions-10/NNS	conj_and||constituents-7/NNS||conditions-10/NNS	root||ROOT-0/null||form-11/VBP	det||curve-13/NN||a-12/DT	dobj||form-11/VBP||curve-13/NN	det||plane-16/NN||the-15/DT	prep_on||form-11/VBP||plane-16/NN	advmod||belongs-21/VBZ||where-18/WRB	det||point-20/NN||each-19/DT	nsubj||belongs-21/VBZ||point-20/NN	rcmod||plane-16/NN||belongs-21/VBZ	det||fraction-26/NN||a-23/DT	amod||fraction-26/NN||different-24/JJ	nn||fraction-26/NN||mole-25/NN	prep_to||belongs-21/VBZ||fraction-26/NN	lipid-6||mole-25||no_rel||points belonging to the same lipid constituents and experimental conditions form a curve on the plane, where each point belongs to a different mole fraction.
det||1,25-dihydroxyvitamind3-5/NN||the-1/DT	amod||1,25-dihydroxyvitamind3-5/NN||active-2/JJ	amod||1,25-dihydroxyvitamind3-5/NN||vitamind-3/JJ	nn||1,25-dihydroxyvitamind3-5/NN||metabolite-4/NN	nsubj||inhibits-13/VBZ||1,25-dihydroxyvitamind3-5/NN	nsubj||promotes-16/VBZ||1,25-dihydroxyvitamind3-5/NN	dep||1,25-dihydroxyvitamind3-5/NN||1,25-7/CD	discourse||1,25-7/CD||oh-9/UH	dep||1,25-7/CD||2d3-11/NNS	root||ROOT-0/null||inhibits-13/VBZ	dobj||inhibits-13/VBZ||proliferation-14/NN	conj_and||inhibits-13/VBZ||promotes-16/VBZ	dobj||promotes-16/VBZ||differentiation-17/NN	nn||cells-21/NNS||colon-19/NN	nn||cells-21/NNS||cancer-20/NN	prep_of||differentiation-17/NN||cells-21/NNS	det||activation-24/NN||the-23/DT	prep_through||promotes-16/VBZ||activation-24/NN	amod||receptor-27/NN||vitamind-26/JJ	prep_of||activation-24/NN||receptor-27/NN	appos||receptor-27/NN||vdr-29/NN	det||factor-34/NN||a-32/DT	nn||factor-34/NN||transcription-33/NN	appos||receptor-27/NN||factor-34/NN	det||superfamily-39/NN||the-36/DT	amod||superfamily-39/NN||nuclear-37/JJ	nn||superfamily-39/NN||receptor-38/NN	prep_of||factor-34/NN||superfamily-39/NN	cancer-20||vitamind-26||no_rel||the active vitamind metabolite 1,25-dihydroxyvitamind3 (1,25(oh)2d3) inhibits proliferation and promotes differentiation of colon cancer cells through the activation of vitamind receptor (vdr), a transcription factor of the nuclear receptor superfamily.
nsubj||compared-3/VBD||we-1/PRP	advmod||compared-3/VBD||directly-2/RB	root||ROOT-0/null||compared-3/VBD	det||efficacy-5/NN||the-4/DT	dobj||compared-3/VBD||efficacy-5/NN	dobj||compared-3/VBD||safety-7/NN	conj_and||efficacy-5/NN||safety-7/NN	num||formulations-11/NNS||two-9/CD	amod||formulations-11/NNS||mesalamine-10/JJ	prep_of||efficacy-5/NN||formulations-11/NNS	det||induction-14/NN||the-13/DT	prep_for||formulations-11/NNS||induction-14/NN	prep_of||induction-14/NN||remission-16/NN	prep_in||compared-3/VBD||patients-18/NNS	prep_with||patients-18/NNS||uc-20/NN	uc-20||mesalamine-10||yes||we directly compared the efficacy and safety of two mesalamine formulations for the induction of remission in patients with uc.
poss||properties-6/NNS||its-3/PRP$	amod||properties-6/NNS||unique-4/JJ	amod||properties-6/NNS||pharmacodynamic-5/JJ	prep_due_to||aripiprazole-23/NN||properties-6/NNS	amod||activity-11/NN||dopamine-8/JJ	amod||activity-11/NN||partial-9/JJ	nn||activity-11/NN||agonist-10/NN	prep_of||properties-6/NNS||activity-11/NN	poss||association-15/NN||its-14/PRP$	prep_of||properties-6/NNS||association-15/NN	conj_and||activity-11/NN||association-15/NN	amod||effects-21/NNS||few-17/JJ	conj_and||few-17/JJ||mild-19/JJ	amod||effects-21/NNS||mild-19/JJ	nn||effects-21/NNS||side-20/NN	prep_with||association-15/NN||effects-21/NNS	nsubj||antipsychotic-28/NN||aripiprazole-23/NN	cop||antipsychotic-28/NN||is-24/VBZ	det||antipsychotic-28/NN||a-25/DT	nn||antipsychotic-28/NN||candidate-26/NN	nn||antipsychotic-28/NN||atypical-27/NN	root||ROOT-0/null||antipsychotic-28/NN	prep_for||antipsychotic-28/NN||patients-30/NNS	prep_with||patients-30/NNS||ticdisorders-32/NNS	ticdisorders-32||aripiprazole-23||no_rel||due to its unique pharmacodynamic properties of dopamine partial agonist activity, and its association with few and mild side effects, aripiprazole is a candidate atypical antipsychotic for patients with ticdisorders.
det||vaccine-2/NN||the-1/DT	nsubj||consisted-6/VBD||vaccine-2/NN	dep||vaccine-2/NN||idd-3-4/JJ	root||ROOT-0/null||consisted-6/VBD	num||doses-8/NNS||8-7/CD	dobj||consisted-6/VBD||doses-8/NNS	amod||dc-13/NN||autologous-10/JJ	amod||dc-13/NN||monocyte-derived-11/JJ	nn||dc-13/NN||matured-12/NN	prep_of||doses-8/NNS||dc-13/NN	dep||dc-13/NN||generated-14/VBN	amod||medium-17/NN||serum-free-16/JJ	prep_in||generated-14/VBN||medium-17/NN	amod||colonystimulatingfactor-21/NN||granulocyte-19/JJ	nn||colonystimulatingfactor-21/NN||macrophage-20/NN	prep_with||generated-14/VBN||colonystimulatingfactor-21/NN	dep||colonystimulatingfactor-21/NN||gm-csf-23/JJ	prep_with||generated-14/VBN||interleukin-13-26/JJ	conj_and||colonystimulatingfactor-21/NN||interleukin-13-26/JJ	dep||colonystimulatingfactor-21/NN||il-13-28/JJ	dep||dc-13/NN||pulsed-31/VBN	conj_and||generated-14/VBN||pulsed-31/VBN	prep_with||pulsed-31/VBN||lysates-33/NNS	num||lines-39/NNS||three-35/CD	amod||lines-39/NNS||allogeneic-36/JJ	nn||lines-39/NNS||melanoma-37/NN	nn||lines-39/NNS||cell-38/NN	prep_of||lysates-33/NNS||lines-39/NNS	dep||dc-13/NN||matured-42/VBN	conj_and||generated-14/VBN||matured-42/VBN	nn||gamma-45/NN||interferon-44/NN	prep_with||matured-42/VBN||gamma-45/NN	melanoma-37||interferon-44||yes||the vaccine (idd-3) consisted 8 doses of autologous monocyte-derived matured dc generated in serum-free medium with granulocyte macrophage colonystimulatingfactor (gm-csf) and interleukin-13 (il-13), pulsed with lysates of three allogeneic melanoma cell lines, and matured with interferon gamma.
nsubjpass||determined-66/VBN||levels-1/NNS	amod||factor-7/NN||angiopoietin-2-3/JJ	nn||factor-7/NN||von-5/NNP	amod||factor-7/NN||willebrand-6/JJ	prep_of||levels-1/NNS||factor-7/NN	appos||factor-7/NN||vwf-9/NN	nn||propeptide-13/NN||vwf-12/NN	appos||levels-1/NNS||propeptide-13/NN	amod||molecule-1-21/NN||soluble-15/JJ	amod||molecule-1-21/NN||p-selectin-16/JJ	amod||molecule-1-21/NN||soluble-18/JJ	nn||molecule-1-21/NN||intercellular-19/NN	nn||molecule-1-21/NN||adhesion-20/NN	appos||levels-1/NNS||molecule-1-21/NN	dep||molecule-1-21/NN||icam-1-23/JJ	amod||kinase-1-32/NN||soluble-26/JJ	amod||kinase-1-32/NN||endoglin-27/JJ	amod||kinase-1-32/NN||soluble-29/JJ	amod||kinase-1-32/NN||fms-like-30/JJ	nn||kinase-1-32/NN||tyrosine-31/NN	appos||molecule-1-21/NN||kinase-1-32/NN	dep||kinase-1-32/NN||flt-1-34/JJ	amod||protein-41/NN||soluble-37/JJ	amod||protein-41/NN||tie-2-38/JJ	amod||protein-41/NN||c-reactive-40/JJ	appos||molecule-1-21/NN||protein-41/NN	appos||protein-41/NN||procalcitonin-43/NN	num||protein-49/NN||10-45/CD	amod||protein-49/NN||kda-46/JJ	amod||protein-49/NN||interferon-47/JJ	amod||protein-49/NN||gamma-induced-48/JJ	appos||molecule-1-21/NN||protein-49/NN	dep||protein-49/NN||ip-10-51/JJ	amod||receptor-57/NN||soluble-55/JJ	amod||receptor-57/NN||triggering-56/VBG	appos||molecule-1-21/NN||receptor-57/NN	conj_and||protein-49/NN||receptor-57/NN	vmod||receptor-57/NN||expressed-58/VBN	amod||cells-1-61/NN||myeloid-60/JJ	prep_on||expressed-58/VBN||cells-1-61/NN	dep||protein-49/NN||trem-1-63/JJ	auxpass||determined-66/VBN||were-65/VBD	root||ROOT-0/null||determined-66/VBN	agent||determined-66/VBN||elisa-68/NN	adhesion-20||vwf-12||no_rel||levels of angiopoietin-2, von willebrand factor (vwf), vwf propeptide, soluble p-selectin, soluble intercellular adhesion molecule-1 (icam-1), soluble endoglin, soluble fms-like tyrosine kinase-1 (flt-1), soluble tie-2, c-reactive protein, procalcitonin, 10 kda interferon gamma-induced protein (ip-10), and soluble triggering receptor expressed on myeloid cells-1 (trem-1) were determined by elisa.
det||decrease-2/NN||the-1/DT	nsubjpass||caused-13/VBN||decrease-2/NN	amod||synthesis-6/NN||mitochondrial-4/JJ	nn||synthesis-6/NN||atp-5/NN	prep_in||decrease-2/NN||synthesis-6/NN	det||patients-10/NNS||the-8/DT	amod||patients-10/NNS||cfs/me-9/JJ	prep_in||synthesis-6/NN||patients-10/NNS	auxpass||caused-13/VBN||is-11/VBZ	neg||caused-13/VBN||not-12/RB	root||ROOT-0/null||caused-13/VBN	det||defect-16/NN||a-15/DT	agent||caused-13/VBN||defect-16/NN	det||complexes-20/NNS||the-18/DT	amod||complexes-20/NNS||enzyme-19/JJ	prep_in||defect-16/NN||complexes-20/NNS	vmod||complexes-20/NNS||catalyzing-21/VBG	amod||phosphorylation-23/NN||oxidative-22/JJ	dobj||catalyzing-21/VBG||phosphorylation-23/NN	det||factor-28/NN||another-27/DT	prep_in||defect-16/NN||factor-28/NN	conj_but||complexes-20/NNS||factor-28/NN	enzyme-19||cfs--1||no_rel||the decrease in mitochondrial atp synthesis in the cfs/me patients is not caused by a defect in the enzyme complexes catalyzing oxidative phosphorylation, but in another factor.
amod||spraying-4/NNS||indoor-1/JJ	amod||spraying-4/NNS||residual-2/JJ	nn||spraying-4/NNS||insecticide-3/NN	nsubjpass||used-18/VBN||spraying-4/NNS	appos||spraying-4/NNS||irs-6/NN	amod||nets-12/NNS||long-lasting-9/JJ	amod||nets-12/NNS||insecticide-10/JJ	amod||nets-12/NNS||treated-11/JJ	conj_and||spraying-4/NNS||nets-12/NNS	nsubjpass||used-18/VBN||nets-12/NNS	appos||nets-12/NNS||llins-14/NNS	auxpass||used-18/VBN||are-16/VBP	advmod||used-18/VBN||commonly-17/RB	root||ROOT-0/null||used-18/VBN	advmod||used-18/VBN||together-19/RB	advmod||inconsistent-36/JJ||even-20/RB	mark||inconsistent-36/JJ||though-21/IN	nsubj||inconsistent-36/JJ||evidence-22/NN	mark||confer-26/VBP||that-23/IN	amod||combinations-25/NNS||such-24/JJ	nsubj||confer-26/VBP||combinations-25/NNS	dep||evidence-22/NN||confer-26/VBP	amod||protection-28/NN||greater-27/JJR	dobj||confer-26/VBP||protection-28/NN	prep_against||confer-26/VBP||malaria-30/NN	det||method-33/NN||either-32/DT	prep_than||malaria-30/NN||method-33/NN	advmod||inconsistent-36/JJ||alone-34/RB	cop||inconsistent-36/JJ||is-35/VBZ	advcl||used-18/VBN||inconsistent-36/JJ	insecticide-10||malaria-30||no_rel||indoor residual insecticide spraying (irs) and long-lasting insecticide treated nets (llins) are commonly used together even though evidence that such combinations confer greater protection against malaria than either method alone is inconsistent.
amod||influenza-2/NN||swine-origin-1/JJ	nsubjpass||caused-8/VBN||influenza-2/NN	det||h1n1-5/NNS||a-3/DT	dep||influenza-2/NN||h1n1-5/NNS	auxpass||caused-8/VBN||is-7/VBZ	root||ROOT-0/null||caused-8/VBN	det||strain-12/NN||a-10/DT	amod||strain-12/NN||new-11/JJ	agent||caused-8/VBN||strain-12/NN	det||influenzavirus-15/NNS||the-14/DT	prep_of||strain-12/NN||influenzavirus-15/NNS	influenza-2||influenzavirus-15||no||swine-origin influenza a (h1n1) is caused by a new strain of the influenzavirus.
amod||loads-3/NNS||hbv-1/JJ	amod||loads-3/NNS||viral-2/JJ	root||ROOT-0/null||loads-3/NNS	amod||mutations-12/NNS||genotypes-5/JJ	conj_and||genotypes-5/JJ||precore-7/JJ	amod||mutations-12/NNS||precore-7/JJ	conj_and||genotypes-5/JJ||basal-9/JJ	amod||mutations-12/NNS||basal-9/JJ	nn||mutations-12/NNS||core-10/NN	nn||mutations-12/NNS||promotor-11/NN	appos||loads-3/NNS||mutations-12/NNS	amod||antigen-16/NN||serumhepatitisb-14/JJ	nn||antigen-16/NN||surface-15/NN	appos||loads-3/NNS||antigen-16/NN	conj_and||mutations-12/NNS||antigen-16/NN	dep||antigen-16/NN||hbsag-18/VBG	amod||protein-23/NN||interferon-gamma-21/JJ	nn||protein-23/NN||inducible-22/NN	appos||loads-3/NNS||protein-23/NN	conj_and||mutations-12/NNS||protein-23/NN	dobj||determined-37/VBN||10-24/CD	dep||10-24/CD||ip-10-26/JJ	nsubjpass||determined-37/VBN||levels-28/NNS	num||snps-33/NNS||four-32/CD	conj_and||levels-28/NNS||snps-33/NNS	nsubjpass||determined-37/VBN||snps-33/NNS	prep_of||snps-33/NNS||il28b-35/CD	auxpass||determined-37/VBN||were-36/VBD	rcmod||protein-23/NN||determined-37/VBN	hbv-1||hbsag-18||yes||hbv viral loads, genotypes, precore and basal core promotor mutations, serumhepatitisb surface antigen (hbsag) and interferon-gamma inducible protein 10 (ip-10) levels as well as four snps of il28b were determined.
nn||rates-2/NNS||mortality-1/NN	nsubj||-lrb--8/VBD||rates-2/NNS	nn||s.aureus-7/NNS||mrsa-4/NN	conj_and||mrsa-4/NN||methicillin-susceptible-6/NN	nn||s.aureus-7/NNS||methicillin-susceptible-6/NN	prep_for||rates-2/NNS||s.aureus-7/NNS	root||ROOT-0/null||-lrb--8/VBD	nn||-rrb--10/NNP||mssa-9/NNP	nsubj||%-13/NN||-rrb--10/NNP	cop||%-13/NN||were-11/VBD	num||%-13/NN||67-12/CD	ccomp||-lrb--8/VBD||%-13/NN	number||18/27-15/CD||-lrb--14/CD	num||-rrb--16/NNS||18/27-15/CD	dep||%-13/NN||-rrb--16/NNS	number||%-19/NN||46-18/CD	amod||-rrb--22/NNS||%-19/NN	amod||-rrb--22/NNS||-lrb--20/JJ	num||-rrb--22/NNS||33/71-21/CD	dep||%-13/NN||-rrb--22/NNS	conj_and||-rrb--16/NNS||-rrb--22/NNS	advmod||pâ-26/NN||respectively-24/RB	amod||pâ-26/NN||-lrb--25/JJ	dep||%-13/NN||pâ-26/NN	conj_and||-rrb--16/NNS||pâ-26/NN	num||-rrb--34/NNS||$-27/$	number||=-29/CD||-28/CD	num||$-27/$||=-29/CD	amod||-rrb--34/NNS||â-30/JJ	num||-rrb--34/NNS||$-31/$	number||.11-33/CD||0-32/CD	num||$-31/$||.11-33/CD	dep||pâ-26/NN||-rrb--34/NNS	mrsa-4||s.aureus-7||no||mortality rates for mrsa and methicillin-susceptible s.aureus -lrb- mssa -rrb- were 67 % -lrb- 18/27 -rrb- and 46 % -lrb- 33/71 -rrb- , respectively -lrb- pâ $  = â $ 0 .11 -rrb- .
poss||results-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||results-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||associated-20/VBN||that-4/IN	amod||inflammation-6/NN||colonic-5/JJ	nsubjpass||associated-20/VBN||inflammation-6/NN	amod||mice-12/NNS||il10-8/JJ	dep||mice-12/NNS||/-10/NNP	prep_in||inflammation-6/NN||mice-12/NNS	vmod||inflammation-6/NN||inoculated-13/VBN	prep_with||inoculated-13/VBN||solutions-15/NNS	vmod||solutions-15/NNS||containing-16/VBG	amod||strains-18/NNS||enterococcus-17/JJ	dobj||containing-16/VBG||strains-18/NNS	auxpass||associated-20/VBN||is-19/VBZ	ccomp||suggest-3/VBP||associated-20/VBN	nn||changes-24/NNS||gene-22/NN	nn||changes-24/NNS||expression-23/NN	prep_with||associated-20/VBN||changes-24/NNS	amod||changes-24/NNS||similar-25/JJ	prep_to||similar-25/JJ||those-27/DT	amod||ibd-30/NN||human-29/JJ	prep_of||those-27/DT||ibd-30/NN	advmod||cd-33/VBN||specifically-32/RB	vmod||changes-24/NNS||cd-33/VBN	mark||model-49/NN||that-36/IN	det||inoculum-42/NN||the-38/DT	amod||inoculum-42/NN||efâ-39/JJ	amod||inoculum-42/NN||·-40/JJ	nn||inoculum-42/NN||cif-41/NN	prep_with||model-49/NN||inoculum-42/NN	prep_in||inoculum-42/NN||particular-44/NN	nsubj||model-49/NN||this-45/DT	cop||model-49/NN||is-46/VBZ	det||model-49/NN||an-47/DT	amod||model-49/NN||appropriate-48/JJ	ccomp||suggest-3/VBP||model-49/NN	conj_and||associated-20/VBN||model-49/NN	aux||investigate-51/VB||to-50/TO	vmod||model-49/NN||investigate-51/VB	amod||interactions-53/NNS||food-gene-52/JJ	nsubj||relevant-54/JJ||interactions-53/NNS	xcomp||investigate-51/VB||relevant-54/JJ	amod||cd-57/NN||human-56/JJ	prep_to||relevant-54/JJ||cd-57/NN	inflammation-6||cd-57||no_rel||our results suggest that colonic inflammation in il10 -/- mice inoculated with solutions containing enterococcus strains is associated with gene expression changes similar to those of human ibd, specifically cd, and that with the efâ·cif inoculum in particular this is an appropriate model to investigate food-gene interactions relevant to human cd.
nsubj||illness-9/NN||severeacuterespiratorysyndrome-1/NN	appos||severeacuterespiratorysyndrome-1/NN||sars-3/NNS	cop||illness-9/NN||is-5/VBZ	det||illness-9/NN||a-6/DT	amod||illness-9/NN||severe-7/JJ	nn||illness-9/NN||respiratory-8/NN	root||ROOT-0/null||illness-9/NN	vmod||illness-9/NN||caused-10/VBN	det||virus-14/NN||a-12/DT	nn||virus-14/NN||novel-13/NN	agent||caused-10/VBN||virus-14/NN	det||sarscoronavirus-17/NNS||the-16/DT	appos||virus-14/NN||sarscoronavirus-17/NNS	appos||sarscoronavirus-17/NNS||sars-cov-19/NNP	sars-3||sarscoronavirus-17||no||severeacuterespiratorysyndrome (sars) is a severe respiratory illness caused by a novel virus, the sarscoronavirus (sars-cov).
nn||tb-3/NN||tuberculosis-1/NNP	nsubj||one-12/CD||tb-3/NN	vmod||tb-3/NN||caused-5/VBN	agent||caused-5/VBN||mycobacteriumtuberculosis-7/NNS	appos||tb-3/NN||mtb-9/NN	cop||one-12/CD||is-11/VBZ	root||ROOT-0/null||one-12/CD	det||causes-18/NNS||the-14/DT	amod||causes-18/NNS||leading-15/VBG	amod||causes-18/NNS||infectious-16/JJ	nn||causes-18/NNS||disease-17/NN	prep_of||one-12/CD||causes-18/NNS	nn||worldwide-23/NNS||morbidity-20/NN	conj_and||morbidity-20/NN||mortality-22/NN	nn||worldwide-23/NNS||mortality-22/NN	prep_of||causes-18/NNS||worldwide-23/NNS	tb-3||mtb-9||no||tuberculosis (tb) caused by mycobacteriumtuberculosis ( mtb ) is one of the leading infectious disease causes of morbidity and mortality worldwide.
nsubjpass||found-13/VBN||c-yes-1/NNS	det||member-4/NN||a-3/DT	appos||c-yes-1/NNS||member-4/NN	det||family-10/NN||the-6/DT	nn||family-10/NN||src-7/NN	nn||family-10/NN||tyrosine-8/NN	nn||family-10/NN||kinase-9/NN	prep_of||member-4/NN||family-10/NN	auxpass||found-13/VBN||is-12/VBZ	root||ROOT-0/null||found-13/VBN	advmod||activated-15/JJ||highly-14/RB	acomp||found-13/VBN||activated-15/JJ	nn||carcinoma-18/NN||colon-17/NN	prep_in||found-13/VBN||carcinoma-18/NN	poss||importance-21/NN||its-20/PRP$	nsubj||remained-26/VBN||importance-21/NN	advmod||remained-26/VBN||relative-22/JJ	prep_to||relative-22/JJ||c-src-24/JJ	aux||remained-26/VBN||has-25/VBZ	conj_but||found-13/VBN||remained-26/VBN	acomp||remained-26/VBN||unclear-27/JJ	carcinoma-18||tyrosine-8||no_rel||c-yes, a member of the src tyrosine kinase family, is found highly activated in colon carcinoma but its importance relative to c-src has remained unclear.
nsubj||lower-3/VB||exercise-1/NN	aux||lower-3/VB||can-2/MD	root||ROOT-0/null||lower-3/VB	xcomp||lower-3/VB||circulating-4/VBG	nsubj||responsible-12/JJ||levels-5/NNS	prep_of||levels-5/NNS||estrogen-7/NN	det||hormone-11/NN||the-9/DT	amod||hormone-11/NN||female-10/JJ	appos||estrogen-7/NN||hormone-11/NN	xcomp||circulating-4/VBG||responsible-12/JJ	nn||proliferation-15/NN||tumor-14/NN	prep_for||responsible-12/JJ||proliferation-15/NN	det||form-19/NN||the-17/DT	amod||form-19/NN||estrogen-sensitive-18/JJ	prep_in||proliferation-15/NN||form-19/NN	det||disease-22/NN||the-21/DT	prep_of||form-19/NN||disease-22/NN	estrogen-7||tumor-14||no_rel||exercise can lower circulating levels of estrogen, the female hormone responsible for tumor proliferation in the estrogen-sensitive form of the disease.
nsubj||remained-9/VBD||changes-1/NNS	nn||control-6/NN||adiposity-3/NN	conj_and||adiposity-3/NN||glucose-5/NN	nn||control-6/NN||glucose-5/NN	prep_in||changes-1/NNS||control-6/NN	prep_with||control-6/NN||ili-8/NN	root||ROOT-0/null||remained-9/VBD	amod||predictors-11/NNS||independent-10/JJ	xcomp||remained-9/VBD||predictors-11/NNS	amod||change-14/NN||hs-crp-13/JJ	prep_of||predictors-11/NNS||change-14/NN	num||year-17/NN||1-16/CD	prep_at||change-14/NN||year-17/NN	dep||year-17/NN||p-19/VBN	number||0.0001-21/CD||<-20/CD	dobj||p-19/VBN||0.0001-21/CD	prep_for||0.0001-21/CD||each-23/DT	prep_after||remained-9/VBD||adjustment-26/NN	prep_for||adjustment-26/NN||demographics-28/NNS	prep_for||adjustment-26/NN||smoking-30/NN	conj_and||demographics-28/NNS||smoking-30/NN	amod||use-38/NN||cardiovascular-32/JJ	nn||use-38/NN||history-33/NN	conj_and||history-33/NN||statin-35/NN	nn||use-38/NN||statin-35/NN	conj_and||history-33/NN||thiazolidinedione-37/NN	nn||use-38/NN||thiazolidinedione-37/NN	prep_for||adjustment-26/NN||use-38/NN	conj_and||demographics-28/NNS||use-38/NN	prep_for||adjustment-26/NN||changes-41/NNS	conj_and||demographics-28/NNS||changes-41/NNS	nn||control-46/NN||fitness-43/NN	conj_and||fitness-43/NN||lipid-45/NN	nn||control-46/NN||lipid-45/NN	prep_in||remained-9/VBD||control-46/NN	adiposity-3||lipid-45||no_rel||changes in adiposity and glucose control with ili remained independent predictors of hs-crp change at 1 year ( p < 0.0001 for each) after adjustment for demographics, smoking, cardiovascular history, statin and thiazolidinedione use, and changes in fitness and lipid control.
advmod||demonstrate-3/VBP||here-1/RB	nsubj||demonstrate-3/VBP||we-2/PRP	root||ROOT-0/null||demonstrate-3/VBP	det||ability-5/NN||the-4/DT	dobj||demonstrate-3/VBP||ability-5/NN	det||mag1-10/NN||the-7/DT	amod||mag1-10/NN||monoclonal-8/JJ	nn||mag1-10/NN||antibody-9/NN	prep_of||ability-5/NN||mag1-10/NN	vmod||mag1-10/NN||directed-11/VBN	det||end-15/NN||the-13/DT	amod||end-15/NN||c-terminal-14/JJ	prep_against||directed-11/VBN||end-15/NN	prep_of||end-15/NN||proavp-17/NN	aux||identify-19/VB||to-18/TO	xcomp||directed-11/VBN||identify-19/VB	dobj||identify-19/VB||proavp-20/NN	det||cases-23/NNS||all-22/DT	prep_in||identify-19/VB||cases-23/NNS	vmod||cases-23/NNS||examined-24/VBN	amod||cancer-28/NN||human-26/JJ	nn||cancer-28/NN||invasive-27/NN	prep_of||examined-24/VBN||cancer-28/NN	prep_of||examined-24/VBN||dcis-30/NNS	conj_and||cancer-28/NN||dcis-30/NNS	dep||identify-19/VB||35-32/CD	dep||identify-19/VB||26-34/CD	conj_and||35-32/CD||26-34/CD	advmod||35-32/CD||respectively-36/RB	cancer-28||antibody-9||no_rel||here we demonstrate the ability of the monoclonal antibody mag1 directed against the c-terminal end of proavp to identify proavp in all cases examined of human invasive cancer and dcis (35 and 26, respectively).
amod||-rrb--4/NNS||methicillin-resistantstaphylococcusaureus-1/JJ	amod||-rrb--4/NNS||-lrb--2/JJ	nn||-rrb--4/NNS||mrsa-3/NN	nsubj||-lrb--8/VBD||-rrb--4/NNS	amod||s.aureus-7/NNS||methicillin-sensitive-6/JJ	conj_and||-rrb--4/NNS||s.aureus-7/NNS	nsubj||-lrb--8/VBD||s.aureus-7/NNS	root||ROOT-0/null||-lrb--8/VBD	nn||-rrb--10/NNP||mssa-9/NNP	nsubjpass||used-12/VBN||-rrb--10/NNP	auxpass||used-12/VBN||were-11/VBD	ccomp||-lrb--8/VBD||used-12/VBN	prep_in||used-12/VBN||vitro-14/NN	prep_in||used-12/VBN||for-16/IN	conj_and||vitro-14/NN||for-16/IN	amod||mice-18/NNS||infecting-17/VBG	pobj||for-16/IN||mice-18/NNS	mark||studied-25/VBN||while-20/IN	amod||infection-23/NN||natural-21/JJ	nn||infection-23/NN||mssa-22/NN	nsubjpass||studied-25/VBN||infection-23/NN	auxpass||studied-25/VBN||was-24/VBD	advcl||used-12/VBN||studied-25/VBN	prep_in||studied-25/VBN||humans-27/NNS	methicillin-resistantstaphylococcusaureus-1||s.aureus-7||no||methicillin-resistantstaphylococcusaureus -lrb- mrsa -rrb- and methicillin-sensitive s.aureus -lrb- mssa -rrb- were used in vitro and for infecting mice , while natural mssa infection was studied in humans .
det||end-3/NN||the-2/DT	prep_at||superior-10/JJ||end-3/NN	amod||treatment-6/NN||48-week-5/JJ	prep_of||end-3/NN||treatment-6/NN	nsubj||superior-10/JJ||tenofovir-8/NN	nsubj||adefovir-12/VB||tenofovir-8/NN	cop||superior-10/JJ||was-9/VBD	root||ROOT-0/null||superior-10/JJ	aux||adefovir-12/VB||to-11/TO	xcomp||superior-10/JJ||adefovir-12/VB	det||suppression-16/NN||the-14/DT	amod||suppression-16/NN||hbv-dna-15/JJ	prep_at||adefovir-12/VB||suppression-16/NN	nn||rr-20/NN||patients-18/NNS	amod||rr-20/NN||-LSB--19/JJ	prep_in||suppression-16/NN||rr-20/NN	dep||2.59-22/NNS||=-21/SYM	dep||rr-20/NN||2.59-22/NNS	number||%-25/NN||95-24/CD	amod||ci-26/NN||%-25/NN	dep||suppression-16/NN||ci-26/NN	number||.67-29/CD||1.01-6-28/CD	dep||ci-26/NN||.67-29/CD	vmod||ci-26/NN||p-32/VBN	dep||-RSB--35/NNS||=-33/SYM	num||-RSB--35/NNS||0.05-34/CD	ccomp||p-32/VBN||-RSB--35/NNS	hbv--1||tenofovir-8||yes||at the end of 48-week treatment, tenofovir was superior to adefovir at the hbv-dna suppression in patients[rr = 2.59; 95%ci(1.01-6.67), p = 0.05].
nsubjpass||used-11/VBN||clonidine-1/NN	det||agonist-8/NN||an-3/DT	nn||agonist-8/NN||î-4/NN	num||agonist-8/NN||±-5/CD	num||agonist-8/NN||-2-6/CD	amod||agonist-8/NN||adrenergic-7/JJ	appos||clonidine-1/NN||agonist-8/NN	auxpass||used-11/VBN||is-10/VBZ	root||ROOT-0/null||used-11/VBN	det||period-15/NN||the-13/DT	amod||period-15/NN||perioperative-14/JJ	prep_in||used-11/VBN||period-15/NN	amod||care-19/NN||intensive-18/JJ	prep_in||used-11/VBN||care-19/NN	conj_and||period-15/NN||care-19/NN	det||management-22/NN||the-21/DT	prep_for||care-19/NN||management-22/NN	prep_of||management-22/NN||hypertension-24/NN	hypertension-24||clonidine-1||yes||clonidine, an î±-2 adrenergic agonist, is used in the perioperative period and in intensive care for the management of hypertension.
det||aim-2/NN||the-1/DT	nsubj||is-6/VBZ||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	det||paper-5/NN||this-4/DT	prep_of||aim-2/NN||paper-5/NN	root||ROOT-0/null||is-6/VBZ	aux||evaluate-8/VB||to-7/TO	xcomp||is-6/VBZ||evaluate-8/VB	det||effect-10/NN||the-9/DT	dobj||evaluate-8/VB||effect-10/NN	prep_of||effect-10/NN||antipsychotics-12/NNS	det||treatment-15/NN||the-14/DT	prep_for||antipsychotics-12/NNS||treatment-15/NN	prep_of||treatment-15/NN||schizophrenia-17/NN	det||community-20/NN||a-19/DT	prep_in||evaluate-8/VB||community-20/NN	vmod||community-20/NN||based-21/VBN	dobj||based-21/VBN||study-22/NN	amod||function-25/NN||sexual-24/JJ	prep_on||based-21/VBN||function-25/NN	nn||levels-28/NNS||prolactin-27/NN	prep_on||based-21/VBN||levels-28/NNS	conj_and||function-25/NN||levels-28/NNS	vmod||function-25/NN||comparing-29/VBG	det||use-31/NN||the-30/DT	dobj||comparing-29/VBG||use-31/NN	prep_of||use-31/NN||aripiprazole-33/NN	prep_of||use-31/NN||standard-35/NN	conj_and||aripiprazole-33/NN||standard-35/NN	prep_of||use-31/NN||care-37/NN	nsubj||choice-46/NN||care-37/NN	appos||care-37/NN||soc-39/NN	cop||choice-46/NN||was-43/VBD	det||choice-46/NN||a-44/DT	amod||choice-46/NN||limited-45/JJ	rcmod||care-37/NN||choice-46/NN	num||antipsychotics-53/NNS||three-48/CD	advmod||used-50/JJ||widely-49/RB	amod||antipsychotics-53/NNS||used-50/JJ	conj_and||used-50/JJ||available-52/JJ	amod||antipsychotics-53/NNS||available-52/JJ	prep_of||choice-46/NN||antipsychotics-53/NNS	dep||antipsychotics-53/NNS||olanzapine-55/NN	dep||olanzapine-55/NN||quetiapine-57/JJ	dep||olanzapine-55/NN||risperidone-59/JJ	conj_or||quetiapine-57/JJ||risperidone-59/JJ	det||trial-64/NN||the-62/DT	nn||trial-64/NN||schizophrenia-63/NN	dep||antipsychotics-53/NNS||trial-64/NN	amod||-RSB--73/NNS||aripiprazole-66/JJ	nn||-RSB--73/NNS||-LSB--67/NNP	nn||-RSB--73/NNS||star-68/NN	nn||-RSB--73/NNS||-RSB--69/NN	nn||-RSB--73/NNS||study-70/NN	nn||-RSB--73/NNS||-LSB--71/NN	amod||-RSB--73/NNS||nct00237913-72/JJ	prep_of||trial-64/NN||-RSB--73/NNS	schizophrenia-63||olanzapine-55||yes||the aim of this paper is to evaluate the effect of antipsychotics for the treatment of schizophrenia in a community based study on sexual function and prolactin levels comparing the use of aripiprazole and standard of care (soc), which was a limited choice of three widely used and available antipsychotics (olanzapine, quetiapine or risperidone) (the schizophrenia trial of aripiprazole [star] study [nct00237913]).
det||goal-2/NN||the-1/DT	nsubj||was-6/VBD||goal-2/NN	nsubj||see-8/VB||goal-2/NN	det||study-5/NN||this-4/DT	prep_of||goal-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||see-8/VB||to-7/TO	xcomp||was-6/VBD||see-8/VB	mark||used-14/VBN||whether-9/IN	amod||fungi-11/NNS||entomopathogenic-10/JJ	nsubjpass||used-14/VBN||fungi-11/NNS	aux||used-14/VBN||could-12/MD	auxpass||used-14/VBN||be-13/VB	ccomp||see-8/VB||used-14/VBN	aux||infect-16/VB||to-15/TO	ccomp||used-14/VBN||infect-16/VB	amod||vectors-19/NNS||insecticide-resistant-17/JJ	nn||vectors-19/NNS||malaria-18/NN	dobj||infect-16/VB||vectors-19/NNS	nn||conditions-22/NNS||field-21/NN	prep_under||infect-16/VB||conditions-22/NNS	aux||see-26/VB||to-25/TO	ccomp||used-14/VBN||see-26/VB	conj_and||infect-16/VB||see-26/VB	mark||decreased-36/VBD||whether-27/IN	det||virulence-29/NN||the-28/DT	nsubj||decreased-36/VBD||virulence-29/NN	nsubj||ambient-40/VB||virulence-29/NN	conj_and||virulence-29/NN||viability-31/NN	nsubj||decreased-36/VBD||viability-31/NN	nsubj||ambient-40/VB||viability-31/NN	det||conidia-35/NN||the-33/DT	amod||conidia-35/NN||fungal-34/JJ	prep_of||virulence-29/NN||conidia-35/NN	ccomp||see-26/VB||decreased-36/VBD	prep_after||decreased-36/VBD||exposure-38/NN	aux||ambient-40/VB||to-39/TO	xcomp||decreased-36/VBD||ambient-40/VB	amod||conditions-43/NNS||african-41/JJ	nn||conditions-43/NNS||field-42/NN	dobj||ambient-40/VB||conditions-43/NNS	insecticide--1||malaria-18||no_rel||the goal of this study was to see whether entomopathogenic fungi could be used to infect insecticide-resistant malaria vectors under field conditions, and to see whether the virulence and viability of the fungal conidia decreased after exposure to ambient african field conditions.
det||study-9/NN||this-1/DT	amod||study-9/NN||open-label-2/JJ	amod||study-9/NN||26-week-4/JJ	amod||study-9/NN||multi-centre-6/JJ	amod||study-9/NN||randomised-8/JJ	nsubj||aripiprazole-11/VBP||study-9/NN	nsubj||soc-13/VB||study-9/NN	vmod||study-9/NN||compared-10/VBN	root||ROOT-0/null||aripiprazole-11/VBP	aux||soc-13/VB||to-12/TO	xcomp||aripiprazole-11/VBP||soc-13/VB	dobj||soc-13/VB||olanzapine-15/NN	dobj||soc-13/VB||quetiapine-17/NN	conj_or||olanzapine-15/NN||quetiapine-17/NN	dobj||soc-13/VB||risperidone-19/NN	conj_or||olanzapine-15/NN||risperidone-19/NN	prep_in||soc-13/VB||patients-22/NNS	prep_with||patients-22/NNS||schizophrenia-24/NN	amod||criteria-27/NNS||dsm-iv-tr-26/JJ	appos||schizophrenia-24/NN||criteria-27/NNS	schizophrenia-24||olanzapine-15||yes||this open-label, 26-week, multi-centre, randomised study compared aripiprazole to soc (olanzapine, quetiapine or risperidone) in patients with schizophrenia (dsm-iv-tr criteria).
mark||established-11/VBN||although-1/IN	amod||countries-5/NNS||western-4/JJ	prep_in||established-11/VBN||countries-5/NNS	amod||regimens-8/NNS||oxaliplatin-based-7/JJ	nsubjpass||established-11/VBN||regimens-8/NNS	aux||established-11/VBN||have-9/VBP	auxpass||established-11/VBN||been-10/VBN	advcl||accepted-40/VBN||established-11/VBN	det||treatment-16/NN||a-13/DT	amod||treatment-16/NN||gold-14/JJ	amod||treatment-16/NN||standard-15/JJ	prep_as||established-11/VBN||treatment-16/NN	prep_for||treatment-16/NN||patients-18/NNS	nn||iii-21/NN||stage-20/NN	prep_with||patients-18/NNS||iii-21/NN	amod||cancer-28/NN||high-23/JJ	nn||cancer-28/NN||risk-24/NN	nn||cancer-28/NN||stage-25/NN	nn||cancer-28/NN||ii-26/NN	nn||cancer-28/NN||colon-27/NN	prep_with||patients-18/NNS||cancer-28/NN	conj_or||iii-21/NN||cancer-28/NN	amod||resection-31/NN||curative-30/JJ	prep_after||established-11/VBN||resection-31/NN	prep_in||established-11/VBN||japan-34/NN	amod||regimens-36/NNS||fluorouracil-based-35/JJ	nsubjpass||accepted-40/VBN||regimens-36/NNS	nsubjpass||recommended-42/VBN||regimens-36/NNS	aux||accepted-40/VBN||have-37/VBP	auxpass||accepted-40/VBN||been-38/VBN	advmod||accepted-40/VBN||widely-39/RB	root||ROOT-0/null||accepted-40/VBN	conj_and||accepted-40/VBN||recommended-42/VBN	det||guidelines-45/NNS||the-44/DT	prep_in||accepted-40/VBN||guidelines-45/NNS	amod||settings-48/NNS||adjuvant-47/JJ	prep_for||guidelines-45/NNS||settings-48/NNS	prep_in||accepted-40/VBN||patients-50/NNS	nn||cancer-55/NN||stage-52/NN	nn||cancer-55/NN||iii-53/NN	nn||cancer-55/NN||colon-54/NN	prep_with||patients-50/NNS||cancer-55/NN	oxaliplatin--1||cancer-55||no_rel||although, in western countries, oxaliplatin-based regimens have been established as a gold standard treatment for patients with stage iii or high risk stage ii colon cancer after curative resection, in japan fluorouracil-based regimens have been widely accepted and recommended in the guidelines for adjuvant settings in patients with stage iii colon cancer.
prep_since||shifted-13/VBN||2004-2/CD	nsubj||shifted-13/VBN||treatment-4/NN	amod||disease-7/NN||mycobacteriumulcerans-6/JJ	prep_of||treatment-4/NN||disease-7/NN	prep_of||treatment-4/NN||buruliulcer-10/NN	conj_or||disease-7/NN||buruliulcer-10/NN	aux||shifted-13/VBN||has-12/VBZ	root||ROOT-0/null||shifted-13/VBN	prep_from||shifted-13/VBN||surgery-15/NN	amod||treatment-18/NN||daily-17/JJ	prep_to||shifted-13/VBN||treatment-18/NN	amod||rifampin-25/NN||streptomycin-20/JJ	nn||rifampin-25/NN||str-22/NN	amod||rifampin-25/NN||+-24/JJ	prep_with||shifted-13/VBN||rifampin-25/NN	appos||rifampin-25/NN||rif-27/NN	num||weeks-31/NNS||8-30/CD	prep_for||rifampin-25/NN||weeks-31/NNS	buruliulcer-10||mycobacteriumulcerans-6||no||since 2004, treatment of mycobacteriumulcerans disease, or buruliulcer, has shifted from surgery to daily treatment with streptomycin (str) + rifampin (rif) for 8 weeks.
aux||maximize-2/VB||to-1/TO	root||ROOT-0/null||maximize-2/VB	amod||use-4/NN||effective-3/JJ	dobj||maximize-2/VB||use-4/NN	amod||drugs-7/NNS||mydriatic-6/JJ	prep_of||use-4/NN||drugs-7/NNS	prepc_through||maximize-2/VB||comparing-9/VBG	det||effects-12/NNS||the-10/DT	nn||effects-12/NNS||pupillarydilation-11/NN	dobj||comparing-9/VBG||effects-12/NNS	number||%-15/NN||1-14/CD	amod||tropicamide-16/NN||%-15/NN	prep_between||effects-12/NNS||tropicamide-16/NN	number||%-19/NN||2.5-18/CD	amod||phenylephrine-20/NN||%-19/NN	prep_between||effects-12/NNS||phenylephrine-20/NN	conj_and||tropicamide-16/NN||phenylephrine-20/NN	pupillarydilation-11||phenylephrine-20||no||to maximize effective use of mydriatic drugs through comparing the pupillarydilation effects between 1% tropicamide and 2.5% phenylephrine.
advmod||attenuated-2/JJ||more-1/RBR	amod||response-4/NN||attenuated-2/JJ	amod||response-4/NN||flush-3/JJ	nsubjpass||shown-9/VBN||response-4/NN	amod||niacin-7/NN||topical-6/JJ	prep_to||response-4/NN||niacin-7/NN	auxpass||shown-9/VBN||was-8/VBD	root||ROOT-0/null||shown-9/VBN	nn||probands-12/NNS||schizophrenia-11/NN	prep_in||shown-9/VBN||probands-12/NNS	poss||relatives-15/NNS||their-14/PRP$	prep_in||shown-9/VBN||relatives-15/NNS	conj_and||probands-12/NNS||relatives-15/NNS	nn||families-18/NNS||multiplex-17/NN	prep_from||shown-9/VBN||families-18/NNS	dep||shown-9/VBN||than-19/IN	poss||counterparts-22/NNS||their-21/PRP$	prep_in||shown-9/VBN||counterparts-22/NNS	nn||families-25/NNS||simplex-24/NN	prep_from||counterparts-22/NNS||families-25/NNS	det||differentiation-29/NN||the-28/DT	nsubjpass||revealed-32/VBN||differentiation-29/NN	auxpass||revealed-32/VBN||was-30/VBD	advmod||revealed-32/VBN||better-31/RBR	conj_and||shown-9/VBN||revealed-32/VBN	xcomp||revealed-32/VBN||using-33/VBG	num||concentration-36/NN||0.1-34/CD	nn||concentration-36/NN||m-35/NN	dobj||using-33/VBG||concentration-36/NN	prep_of||concentration-36/NN||niacin-38/NN	num||m-41/NN||0.01-40/CD	prep_than||using-33/VBG||m-41/NN	num||m.-44/NN||0.001-43/CD	prep_than||using-33/VBG||m.-44/NN	conj_or||m-41/NN||m.-44/NN	det||concentration-48/NN||the-46/DT	amod||concentration-48/NN||highest-47/JJS	prep_for||using-33/VBG||concentration-48/NN	num||m-51/NN||0.1-50/CD	prep_of||concentration-48/NN||m-51/NN	det||lag-56/NN||the-53/DT	amod||lag-56/NN||longest-54/JJS	nn||lag-56/NN||time-55/NN	prep_for||using-33/VBG||lag-56/NN	conj_and||concentration-48/NN||lag-56/NN	num||minutes-59/NNS||15-58/CD	prep_of||lag-56/NN||minutes-59/NNS	det||subgroup-62/NN||a-61/DT	nsubj||-lrb--65/VBZ||subgroup-62/NN	prep_of||subgroup-62/NN||probands-64/NNS	ccomp||shown-9/VBN||-lrb--65/VBZ	conj_and||shown-9/VBN||-lrb--65/VBZ	num||%-67/NN||23-66/CD	dobj||-lrb--65/VBZ||%-67/NN	advmod||-lrb--65/VBZ||-rrb--68/RB	nsubj||-lrb--71/VBZ||parents-70/NNS	ccomp||shown-9/VBN||-lrb--71/VBZ	conj_and||shown-9/VBN||-lrb--71/VBZ	num||%-73/NN||27-72/CD	dobj||-lrb--71/VBZ||%-73/NN	advmod||-lrb--71/VBZ||-rrb--74/RB	nsubj||-lrb--78/VBZ||siblings-77/NNS	conj_and||shown-9/VBN||-lrb--78/VBZ	number||%-80/NN||19-79/CD	amod||response-85/NN||%-80/NN	amod||response-85/NN||-rrb--81/JJ	advmod||exhibited-83/JJ||still-82/RB	amod||response-85/NN||exhibited-83/JJ	nn||response-85/NN||nonflush-84/NN	dobj||-lrb--78/VBZ||response-85/NN	flush-3||niacin-38||no||more attenuated flush response to topical niacin was shown in schizophrenia probands and their relatives from multiplex families than in their counterparts from simplex families , and the differentiation was better revealed using 0.1 m concentration of niacin than 0.01 m or 0.001 m. for the highest concentration of 0.1 m and the longest time lag of 15 minutes , a subgroup of probands -lrb- 23 % -rrb- , parents -lrb- 27 % -rrb- , and siblings -lrb- 19 % -rrb- still exhibited nonflush response .
det||indices-3/NNS||the-1/DT	amod||indices-3/NNS||insulinresistance-2/JJ	nsubj||value-8/NN||indices-3/NNS	vmod||indices-3/NNS||used-4/VBN	cop||value-8/NN||were-5/VBD	det||value-8/NN||the-6/DT	nn||value-8/NN||m-7/NN	root||ROOT-0/null||value-8/NN	nsubj||rate-17/NN||value-8/NN	cop||rate-17/NN||is-11/VBZ	det||rate-17/NN||the-12/DT	amod||rate-17/NN||total-13/JJ	nn||rate-17/NN||body-14/NN	nn||rate-17/NN||glucose-15/NN	nn||rate-17/NN||disposal-16/NN	rcmod||value-8/NN||rate-17/NN	det||value-22/NN||the-20/DT	nn||value-22/NN||m/i-21/NN	conj_and||value-8/NN||value-22/NN	nsubj||value-28/NN||value-22/NN	cop||value-28/NN||is-25/VBZ	det||value-28/NN||the-26/DT	nn||value-28/NN||m-27/NN	rcmod||value-22/NN||value-28/NN	vmod||value-28/NN||adjusted-29/VBN	det||level-36/NN||the-31/DT	amod||level-36/NN||steady-32/JJ	nn||level-36/NN||state-33/NN	nn||level-36/NN||plasma-34/NN	nn||level-36/NN||insulin-35/NN	prep_for||adjusted-29/VBN||level-36/NN	insulin-35||insulinresistance-2||no_rel||the insulinresistance indices used were the m value, which is the total body glucose disposal rate, and the m/i value, which is the m value adjusted for the steady state plasma insulin level.
nsubjpass||recovered-3/VBN||respiratoryinfection-1/NN	auxpass||recovered-3/VBN||was-2/VBD	root||ROOT-0/null||recovered-3/VBN	amod||care-6/NN||supportive-5/JJ	agent||recovered-3/VBN||care-6/NN	nsubjpass||improved-11/VBN||cholestasis-9/NNS	auxpass||improved-11/VBN||was-10/VBD	conj_and||recovered-3/VBN||improved-11/VBN	advmod||improved-11/VBN||slowly-12/RB	amod||feeding-15/NN||sufficient-14/JJ	prep_with||improved-11/VBN||feeding-15/NN	prep_with||improved-11/VBN||supplementation-17/NN	conj_and||feeding-15/NN||supplementation-17/NN	amod||enzymes-21/NNS||pancreatic-19/JJ	nn||enzymes-21/NNS||exocrine-20/NN	prep_of||feeding-15/NN||enzymes-21/NNS	enzymes-21||respiratoryinfection-1||no_rel||respiratoryinfection was recovered by supportive care, and cholestasis was improved slowly with sufficient feeding and supplementation of pancreatic exocrine enzymes.
prep_in||likely-9/JJ||patients-2/NNS	amod||partialepilepsy-5/NN||refractory-4/JJ	prep_with||patients-2/NNS||partialepilepsy-5/NN	nsubj||likely-9/JJ||pregabalin-7/NN	nsubj||effective-13/JJ||pregabalin-7/NN	cop||likely-9/JJ||is-8/VBZ	root||ROOT-0/null||likely-9/JJ	aux||effective-13/JJ||to-10/TO	cop||effective-13/JJ||be-11/VB	advmod||effective-13/JJ||more-12/RBR	xcomp||likely-9/JJ||effective-13/JJ	prep_than||effective-13/JJ||gabapentin-15/NN	amod||effective-18/JJ||comparable-17/JJ	amod||doses-19/NNS||effective-18/JJ	prep_at||effective-13/JJ||doses-19/NNS	prepc_based_on||effective-13/JJ||on-22/IN	amod||response-24/NN||clinical-23/JJ	pobj||effective-13/JJ||response-24/NN	det||number-27/NN||the-26/DT	pobj||effective-13/JJ||number-27/NN	conj_and||response-24/NN||number-27/NN	prep_of||number-27/NN||sfd-29/NN	partialepilepsy-5||gabapentin-15||yes||in patients with refractory partialepilepsy, pregabalin is likely to be more effective than gabapentin at comparable effective doses, based on clinical response and the number of sfd.
amod||expression-4/NN||mpges-1-1/JJ	conj_and||mpges-1-1/JJ||cox-3/JJ	amod||expression-4/NN||cox-3/JJ	nsubjpass||evaluated-6/VBN||expression-4/NN	nsubjpass||evaluated-6/VBN||expression-4/NN	auxpass||evaluated-6/VBN||was-5/VBD	root||ROOT-0/null||evaluated-6/VBN	conj_and||evaluated-6/VBN||evaluated-6/VBN	agent||evaluated-6/VBN||immunohistochemistry-8/NN	nn||tissue-11/NN||muscle-10/NN	prep_in||immunohistochemistry-8/NN||tissue-11/NN	amod||individuals-14/NNS||healthy-13/JJ	prep_from||evaluated-6/VBN||individuals-14/NNS	prep_from||evaluated-6/VBN||patients-17/NNS	conj_and||individuals-14/NNS||patients-17/NNS	prep_with||patients-17/NNS||polymyositis-19/NNS	prep_with||patients-17/NNS||dermatomyositis-21/NNS	conj_or||polymyositis-19/NNS||dermatomyositis-21/NNS	amod||treatment-27/NN||conventional-25/JJ	nn||treatment-27/NN||immunosuppressive-26/NN	prep_after||evaluated-6/VBN||treatment-27/NN	prep_before||evaluated-6/VBN||treatment-27/NN	dermatomyositis-21||immunosuppressive-26||no_rel||mpges-1 and cox expression was evaluated by immunohistochemistry in muscle tissue from healthy individuals and from patients with polymyositis or dermatomyositis before and after conventional immunosuppressive treatment.
nn||treatment-3/NN||gancyclovir-2/NN	prep_following||went-11/VBD||treatment-3/NN	amod||viremia-7/NN||subsequent-5/JJ	nn||viremia-7/NN||cytomegalovirus-6/NNS	prep_of||treatment-3/NN||viremia-7/NN	det||patient-10/NN||the-9/DT	nsubj||went-11/VBD||patient-10/NN	nsubj||receive-14/VB||patient-10/NN	root||ROOT-0/null||went-11/VBD	prt||went-11/VBD||on-12/RP	aux||receive-14/VB||to-13/TO	xcomp||went-11/VBD||receive-14/VB	det||course-16/NN||a-15/DT	dobj||receive-14/VB||course-16/NN	prep_of||course-16/NN||epoch-18/NN	advmod||mg/m2/day-52/NN||etoposide-20/RB	num||mg/m2/day-22/NNS||50-21/CD	pobj||etoposide-20/RB||mg/m2/day-22/NNS	prep_on||etoposide-20/RB||days-24/NNS	amod||mg/m2/day-52/NN||1â-25/JJ	amod||mg/m2/day-52/NN||$-26/$	num||$-26/$||4-28/CD	amod||mg/m2/day-52/NN||vincristine-30/JJ	num||mg/m2/day-32/NNS||0.4-31/CD	dep||vincristine-30/JJ||mg/m2/day-32/NNS	prep_on||mg/m2/day-32/NNS||days-34/NNS	amod||mg/m2/day-52/NN||1â-35/JJ	amod||mg/m2/day-52/NN||$-36/$	num||$-36/$||4-38/CD	amod||mg/m2/day-52/NN||doxorubicin-40/JJ	num||mg/m2/day-42/NNS||10-41/CD	dep||doxorubicin-40/JJ||mg/m2/day-42/NNS	prep_on||mg/m2/day-42/NNS||days-44/NNS	amod||mg/m2/day-52/NN||1â-45/JJ	amod||mg/m2/day-52/NN||$-46/$	num||$-46/$||4-48/CD	amod||mg/m2/day-52/NN||cyclophosphamide-50/JJ	number||cyclophosphamide-50/JJ||750-51/CD	dep||epoch-18/NN||mg/m2/day-52/NN	prep_on||mg/m2/day-52/NN||day-54/NN	num||day-54/NN||6-55/CD	advmod||1â-63/JJ||prednisolone-58/RB	num||mg/m2/day-60/NNS||60-59/CD	pobj||prednisolone-58/RB||mg/m2/day-60/NNS	prep_on||prednisolone-58/RB||days-62/NNS	prep_on||mg/m2/day-52/NN||1â-63/JJ	conj_and||day-54/NN||1â-63/JJ	dep||1â-63/JJ||$-64/$	num||$-64/$||6-66/CD	gancyclovir-2||viremia-7||no_rel||following gancyclovir treatment of subsequent cytomegalovirus viremia, the patient went on to receive a course of epoch (etoposide 50 mg/m2/day on days 1â4, vincristine 0.4 mg/m2/day on days 1â4, doxorubicin 10 mg/m2/day on days 1â4, cyclophosphamide 750 mg/m2/day on day 6, and prednisolone 60 mg/m2/day on days 1â6).
nsubj||are-5/VBP||patients-1/NNS	nsubj||benefit-16/VB||patients-1/NNS	amod||syndrome-4/NN||antiphospholipid-3/JJ	prep_with||patients-1/NNS||syndrome-4/NN	root||ROOT-0/null||are-5/VBP	amod||risk-8/NN||increased-7/VBN	prep_at||are-5/VBP||risk-8/NN	amod||arterial-11/NN||recurrent-10/JJ	prep_for||risk-8/NN||arterial-11/NN	prep_for||risk-8/NN||venousthrombosis-13/NNS	conj_and||arterial-11/NN||venousthrombosis-13/NNS	advmod||benefit-16/VB||therefore-15/RB	conj_and||are-5/VBP||benefit-16/VB	amod||therapy-21/NN||long-18/JJ	nn||therapy-21/NN||term-19/NN	nn||therapy-21/NN||warfarin-20/NN	prep_from||benefit-16/VB||therapy-21/NN	venousthrombosis-13||warfarin-20||yes||patients with antiphospholipid syndrome are at increased risk for recurrent arterial and venousthrombosis and therefore benefit from long term warfarin therapy.
poss||macroglobulinemia-3/NN||waldenstrom-1/NNP	nsubj||b-celllymphoma-7/NN||macroglobulinemia-3/NN	cop||b-celllymphoma-7/NN||is-4/VBZ	det||b-celllymphoma-7/NN||a-5/DT	amod||b-celllymphoma-7/NN||low-grade-6/JJ	root||ROOT-0/null||b-celllymphoma-7/NN	vmod||b-celllymphoma-7/NN||characterized-8/VBN	det||presence-11/NN||the-10/DT	agent||characterized-8/VBN||presence-11/NN	amod||cells-14/NNS||lymphoplasmacytic-13/JJ	prep_of||presence-11/NN||cells-14/NNS	det||marrow-18/NN||the-16/DT	nn||marrow-18/NN||bone-17/NN	prep_in||cells-14/NNS||marrow-18/NN	det||m-23/NN||a-20/DT	amod||m-23/NN||monoclonal-21/JJ	nn||m-23/NN||immunoglobulin-22/NN	prep_of||presence-11/NN||m-23/NN	conj_and||cells-14/NNS||m-23/NN	det||circulation-26/NN||the-25/DT	prep_in||m-23/NN||circulation-26/NN	b-celllymphoma-7||immunoglobulin-22||no_rel||waldenstrom's macroglobulinemia is a low-grade b-celllymphoma characterized by the presence of lymphoplasmacytic cells in the bone marrow and a monoclonal immunoglobulin m in the circulation.
nsubj||form-4/NN||neurosyphilis-1/NNS	cop||form-4/NN||is-2/VBZ	det||form-4/NN||a-3/DT	root||ROOT-0/null||form-4/NN	amod||infection-7/NN||tertiarysyphilis-6/JJ	prep_of||form-4/NN||infection-7/NN	vmod||infection-7/NN||caused-8/VBN	det||treponemapallidum-13/NN||the-10/DT	amod||treponemapallidum-13/NN||spirochete-11/JJ	nn||treponemapallidum-13/NN||bacterium-12/NN	agent||caused-8/VBN||treponemapallidum-13/NN	neurosyphilis-1||treponemapallidum-13||no||neurosyphilis is a form of tertiarysyphilis infection caused by the spirochete bacterium treponemapallidum.
amod||programmes-2/NNS||many-1/JJ	nsubj||focused-10/VBN||programmes-2/NNS	nsubj||channeled-15/VBD||programmes-2/NNS	amod||people-5/NNS||young-4/JJ	prep_on||programmes-2/NNS||people-5/NNS	nn||prevention-8/NN||hiv/aids-7/NNS	prep_on||programmes-2/NNS||prevention-8/NN	conj_and||people-5/NNS||prevention-8/NN	aux||focused-10/VBN||have-9/VBP	root||ROOT-0/null||focused-10/VBN	det||in-school-13/NN||the-12/DT	prep_on||focused-10/VBN||in-school-13/NN	conj_and||focused-10/VBN||channeled-15/VBD	amod||messages-20/NNS||sexual-16/JJ	conj_and||sexual-16/JJ||reproductive-18/JJ	amod||messages-20/NNS||reproductive-18/JJ	nn||messages-20/NNS||health-19/NN	dobj||channeled-15/VBD||messages-20/NNS	prep_through||messages-20/NNS||schools-22/NNS	amod||activities-25/NNS||limited-24/JJ	prep_with||channeled-15/VBD||activities-25/NNS	det||people-29/NNS||the-27/DT	amod||people-29/NNS||young-28/JJ	poss||families-31/NNS||people-29/NNS	prep_for||activities-25/NNS||families-31/NNS	aids--1||hiv--1||no||many programmes on young people and hiv/aids prevention have focused on the in-school and channeled sexual and reproductive health messages through schools with limited activities for the young people's families.
nn||india-2/NN||northeast-1/NN	nsubj||source-6/NN||india-2/NN	cop||source-6/NN||is-3/VBZ	det||source-6/NN||a-4/DT	amod||source-6/NN||major-5/JJ	root||ROOT-0/null||source-6/NN	nn||users-10/NNS||injection-8/NN	nn||users-10/NNS||drug-9/NN	prep_of||source-6/NN||users-10/NNS	appos||users-10/NNS||idus-12/NNS	amod||hiv/aids-16/NNS||associated-15/VBN	prep_of||source-6/NN||hiv/aids-16/NNS	conj_and||users-10/NNS||hiv/aids-16/NNS	aids--1||hiv--1||no||northeast india is a major source of injection drug users (idus) and associated hiv/aids.
det||wake-3/NN||the-2/DT	prep_in||classified-20/VBD||wake-3/NN	det||revolution-7/NN||the-5/DT	amod||revolution-7/NN||bacterial-6/JJ	prep_of||wake-3/NN||revolution-7/NN	amod||koch-10/NN||robert-9/JJ	prep_after||revolution-7/NN||koch-10/NN	vmod||koch-10/NN||identified-11/VBN	det||tuberculosisbacillus-13/NNS||the-12/DT	dobj||identified-11/VBN||tuberculosisbacillus-13/NNS	amod||professionals-19/NNS||medical-15/JJ	conj_and||medical-15/JJ||public-17/JJ	amod||professionals-19/NNS||public-17/JJ	nn||professionals-19/NNS||health-18/NN	nsubj||classified-20/VBD||professionals-19/NNS	root||ROOT-0/null||classified-20/VBD	det||forms-23/NNS||the-21/DT	amod||forms-23/NNS||various-22/JJ	dobj||classified-20/VBD||forms-23/NNS	prep_of||forms-23/NNS||consumption-25/NN	prep_of||forms-23/NNS||phthisis-27/NNS	conj_and||consumption-25/NN||phthisis-27/NNS	det||disease-31/NN||a-29/DT	amod||disease-31/NN||single-30/JJ	prep_as||classified-20/VBD||disease-31/NN	dep||disease-31/NN||tuberculosis-33/NNP	tuberculosis-33||tuberculosisbacillus-13||no||in the wake of the bacterial revolution after robert koch identified the tuberculosisbacillus, medical and public health professionals classified the various forms of consumption and phthisis as a single disease--tuberculosis.
nsubj||aware-5/JJ||laboratories-1/NNS	nsubj||check-13/VB||laboratories-1/NNS	aux||aware-5/JJ||should-2/MD	advmod||aware-5/JJ||therefore-3/RB	cop||aware-5/JJ||be-4/VB	root||ROOT-0/null||aware-5/JJ	det||sensitivity-9/NN||the-7/DT	amod||sensitivity-9/NN||analytical-8/JJ	prep_of||aware-5/JJ||sensitivity-9/NN	prep_for||sensitivity-9/NN||hbsag-11/VBG	conj_and||aware-5/JJ||check-13/VB	det||variants-18/NNS||the-15/DT	amod||variants-18/NNS||relevant-16/JJ	nn||variants-18/NNS||hbv-17/NN	prep_for||check-13/VB||variants-18/NNS	vmod||variants-18/NNS||circulating-19/VBG	det||population-23/NN||the-21/DT	amod||population-23/NN||relevant-22/JJ	prep_in||circulating-19/VBG||population-23/NN	hbv-17||hbsag-11||yes||laboratories should therefore be aware of the analytical sensitivity for hbsag and check for the relevant hbv variants circulating in the relevant population.
nsubj||provides-2/VBZ||oxymorphone-1/NN	root||ROOT-0/null||provides-2/VBZ	amod||relief-5/NN||excellent-3/JJ	nn||relief-5/NN||pain-4/NN	dobj||provides-2/VBZ||relief-5/NN	amod||pain-8/NN||significant-7/JJ	prep_for||relief-5/NN||pain-8/NN	amod||effects-14/NNS||typical-11/JJ	amod||effects-14/NNS||opioid-12/JJ	nn||effects-14/NNS||side-13/NN	prep_with||provides-2/VBZ||effects-14/NNS	nsubj||mild-18/JJ||effects-14/NNS	nsubj||moderate-20/JJ||effects-14/NNS	cop||mild-18/JJ||are-16/VBP	advmod||mild-18/JJ||usually-17/RB	rcmod||effects-14/NNS||mild-18/JJ	rcmod||effects-14/NNS||moderate-20/JJ	conj_or||mild-18/JJ||moderate-20/JJ	prep_in||mild-18/JJ||intensity-22/NN	pain-8||oxymorphone-1||yes||oxymorphone provides excellent pain relief for significant pain, with typical opioid side effects that are usually mild or moderate in intensity.
advmod||investigated-4/VBD||here-1/RB	nsubj||investigated-4/VBD||we-3/PRP	root||ROOT-0/null||investigated-4/VBD	det||ability-6/NN||the-5/DT	dobj||investigated-4/VBD||ability-6/NN	prep_of||ability-6/NN||quercetin-8/NN	aux||sensitise-10/VB||to-9/TO	vmod||investigated-4/VBD||sensitise-10/VB	vmod||investigated-4/VBD||sensitise-10/VB	conj_and||sensitise-10/VB||sensitise-10/VB	amod||cells-12/NNS||primary-11/JJ	dobj||sensitise-10/VB||cells-12/NNS	amod||leukaemia-16/NN||chronic-14/JJ	amod||leukaemia-16/NN||lymphocytic-15/JJ	prep_from||sensitise-10/VB||leukaemia-16/NN	appos||leukaemia-16/NN||cll-18/NN	nn||agonists-26/NNS||death-21/NN	nn||agonists-26/NNS||receptor-22/NN	nn||agonists-26/NNS||dr-24/NN	prep_to||leukaemia-16/NN||agonists-26/NNS	amod||ligand-30/NN||recombinant-28/JJ	amod||ligand-30/NN||tnf-related-apoptosis-inducing-29/JJ	prep_from||sensitise-10/VB||ligand-30/NN	conj_and||leukaemia-16/NN||ligand-30/NN	dep||ligand-30/NN||rtrail-32/JJ	prep_from||sensitise-10/VB||anti-cd95-35/JJ	conj_and||leukaemia-16/NN||anti-cd95-35/JJ	prep_to||sensitise-10/VB||fludarabine-39/NN	det||drug-45/NN||a-41/DT	advmod||used-43/VBN||widely-42/RB	amod||drug-45/NN||used-43/VBN	amod||drug-45/NN||chemotherapeutic-44/JJ	appos||fludarabine-39/NN||drug-45/NN	prep_against||investigated-4/VBD||cll-47/NN	cll-47||fludarabine-39||yes||here, we investigated the ability of quercetin to sensitise primary cells from chronic lymphocytic leukaemia (cll) to death receptor (dr) agonists, recombinant tnf-related-apoptosis-inducing ligand (rtrail) and anti-cd95, and to fludarabine, a widely used chemotherapeutic drug against cll.
nsubjpass||induced-3/VBN||allergy-1/NN	auxpass||induced-3/VBN||was-2/VBD	root||ROOT-0/null||induced-3/VBN	det||series-6/NN||a-5/DT	agent||induced-3/VBN||series-6/NN	prep_of||series-6/NN||subcutaneous-8/NNS	amod||sensitizations-11/NNS||intratracheal-10/JJ	prep_of||series-6/NN||sensitizations-11/NNS	conj_and||subcutaneous-8/NNS||sensitizations-11/NNS	amod||allergen-15/NN||ascaris-13/JJ	nn||allergen-15/NN||suum-14/NN	prep_with||induced-3/VBN||allergen-15/NN	appos||allergen-15/NN||asa-17/NN	det||frame-24/NN||a-20/DT	num||frame-24/NN||six-21/CD	nn||frame-24/NN||week-22/NN	nn||frame-24/NN||time-23/NN	prep_during||induced-3/VBN||frame-24/NN	amod||pigs-27/NNS||post-weanling-26/JJ	prep_in||induced-3/VBN||pigs-27/NNS	vmod||pigs-27/NNS||supplemented-28/VBN	vmod||pigs-27/NNS||supplemented-28/VBN	conj_or||supplemented-28/VBN||supplemented-28/VBN	advmod||supplemented-28/VBN||daily-29/RB	prep_with||supplemented-28/VBN||hn001-31/CD	prep_without||supplemented-28/VBN||supplementation-35/NN	allergen-15||allergy-1||no_rel||allergy was induced by a series of subcutaneous and intratracheal sensitizations with ascaris suum allergen (asa) during a six week time frame in post-weanling pigs supplemented daily with hn001, or without supplementation.
nsubj||show-2/VBP||results-1/NNS	root||ROOT-0/null||show-2/VBP	mark||induces-8/VBZ||that-3/IN	num||falciparum-7/NN||1-4/CD	amod||falciparum-7/NN||-rrb--5/JJ	nn||falciparum-7/NN||p.-6/NN	nsubj||induces-8/VBZ||falciparum-7/NN	ccomp||show-2/VBP||induces-8/VBZ	det||inflammation-11/NN||a-9/DT	amod||inflammation-11/NN||strong-10/JJ	dobj||induces-8/VBZ||inflammation-11/NN	vmod||inflammation-11/NN||characterized-12/VBN	det||increase-15/NN||an-14/DT	agent||characterized-12/VBN||increase-15/NN	prepc_in||characterized-12/VBN||circulating-17/VBG	dobj||circulating-17/VBG||leukocytes-18/NNS	det||release-21/NN||the-20/DT	dobj||induces-8/VBZ||release-21/NN	conj_and||inflammation-11/NN||release-21/NN	amod||cytokines-24/NNS||inflammatory-23/JJ	prep_of||release-21/NN||cytokines-24/NNS	num||-rrb--27/NNS||2-26/CD	nsubj||induces-37/VBZ||-rrb--27/NNS	prep_in||-rrb--27/NNS||contrast-29/NN	det||yoelii-35/NN||the-31/DT	amod||yoelii-35/NN||rodent-32/JJ	nn||yoelii-35/NN||parasite-33/NN	nn||yoelii-35/NN||p.-34/NN	appos||contrast-29/NN||yoelii-35/NN	conj_and||show-2/VBP||induces-37/VBZ	det||inflammation-42/NN||a-38/DT	advmod||moderate-41/JJ||far-39/RB	advmod||moderate-41/JJ||more-40/RBR	amod||inflammation-42/NN||moderate-41/JJ	dobj||induces-37/VBZ||inflammation-42/NN	number||-rrb--45/CD||3-44/CD	num||cells-49/NNS||-rrb--45/CD	amod||cells-49/NNS||human-46/JJ	amod||cells-49/NNS||red-47/JJ	nn||cells-49/NNS||blood-48/NN	nsubj||induce-54/VB||cells-49/NNS	det||anti-inflammatoryagents-52/NNS||the-51/DT	conj_and||cells-49/NNS||anti-inflammatoryagents-52/NNS	nsubj||induce-54/VB||anti-inflammatoryagents-52/NNS	vmod||anti-inflammatoryagents-52/NNS||employed-53/VBN	conj_and||show-2/VBP||induce-54/VB	amod||inflammation-56/NN||low-grade-55/JJ	dobj||induce-54/VB||inflammation-56/NN	num||macrophages-61/NNS||4-59/CD	amod||macrophages-61/NNS||-rrb--60/JJ	nsubj||seem-62/VBP||macrophages-61/NNS	nsubj||bear-64/VB||macrophages-61/NNS	conj_and||show-2/VBP||seem-62/VBP	aux||bear-64/VB||to-63/TO	xcomp||seem-62/VBP||bear-64/VB	det||function-68/NN||the-65/DT	advmod||critical-67/JJ||most-66/RBS	amod||function-68/NN||critical-67/JJ	dobj||bear-64/VB||function-68/NN	amod||survival-73/NN||controlling-70/JJ	nn||survival-73/NN||p.-71/NN	nn||survival-73/NN||falciparum-72/NN	prep_in||bear-64/VB||survival-73/NN	det||mice-76/NNS||those-75/DT	prep_in||survival-73/NN||mice-76/NNS	mark||have-83/VBP||whereas-78/IN	nn||cells-82/NNS||polymorphonuclear-79/NN	conj_and||polymorphonuclear-79/NN||nk-81/NN	nn||cells-82/NNS||nk-81/NN	nsubj||have-83/VBP||cells-82/NNS	advcl||bear-64/VB||have-83/VBP	advmod||role-87/NN||only-84/RB	det||role-87/NN||a-85/DT	amod||role-87/NN||minor-86/JJ	dobj||have-83/VBP||role-87/NN	anti-inflammatoryagents-52||inflammation-56||no_rel||results show that 1 -rrb- p. falciparum induces a strong inflammation characterized by an increase in circulating leukocytes and the release of inflammatory cytokines ; 2 -rrb- in contrast , the rodent parasite p. yoelii , induces a far more moderate inflammation ; 3 -rrb- human red blood cells and the anti-inflammatoryagents employed induce low-grade inflammation ; and 4 -rrb- macrophages seem to bear the most critical function in controlling p. falciparum survival in those mice , whereas polymorphonuclear and nk cells have only a minor role .
amod||assays-2/NNS||bioactivity-1/JJ	nsubj||showed-3/VBD||assays-2/NNS	root||ROOT-0/null||showed-3/VBD	mark||efficient-14/JJ||that-4/IN	det||drug-8/NN||the-5/DT	amod||drug-8/NN||first-line-6/JJ	nn||drug-8/NN||tuberculosis-7/NNP	nsubj||efficient-14/JJ||drug-8/NN	appos||drug-8/NN||ethambutol-10/NN	cop||efficient-14/JJ||was-12/VBD	advmod||efficient-14/JJ||as-13/RB	ccomp||showed-3/VBD||efficient-14/JJ	prepc_in||efficient-14/JJ||treating-16/VBG	amod||macrophages-19/NNS||mycobacteria-17/JJ	amod||macrophages-19/NNS||infected-18/JJ	dobj||treating-16/VBG||macrophages-19/NNS	advmod||loaded-21/VBD||when-20/WRB	advcl||efficient-14/JJ||loaded-21/VBD	nn||-LSB--24/NNS||cb-23/NN	prep_into||loaded-21/VBD||-LSB--24/NNS	num||-RSB--26/NNS||7-25/CD	npadvmod||as-27/RB||-RSB--26/NNS	advmod||loaded-21/VBD||as-27/RB	advmod||given-29/VBN||when-28/WRB	advcl||loaded-21/VBD||given-29/VBN	det||form-33/NN||the-31/DT	amod||form-33/NN||unbound-32/JJ	prep_in||given-29/VBN||form-33/NN	tuberculosis-7||ethambutol-10||yes||bioactivity assays showed that the first-line tuberculosis drug, ethambutol, was as efficient in treating mycobacteria infected macrophages when loaded into cb [7] as when given in the unbound form.
amod||options-2/NNS||several-1/JJ	nsubjpass||licensed-10/VBN||options-2/NNS	det||treatment-5/NN||the-4/DT	prep_for||options-2/NNS||treatment-5/NN	prep_of||treatment-5/NN||hepatitisb-7/NN	aux||licensed-10/VBN||have-8/VBP	auxpass||licensed-10/VBN||been-9/VBN	root||ROOT-0/null||licensed-10/VBN	det||interferon-15/NN||the-12/DT	amod||interferon-15/NN||last-13/JJ	nn||interferon-15/NN||years-14/NNS	prep_in||licensed-10/VBN||interferon-15/NN	amod||interferon-18/NN||pegylated-17/JJ	prep_in||licensed-10/VBN||interferon-18/NN	conj_and||interferon-15/NN||interferon-18/NN	prep_in||licensed-10/VBN||lamivudine-20/NN	conj_and||interferon-15/NN||lamivudine-20/NN	prep_in||licensed-10/VBN||adefovir-22/NN	conj_and||interferon-15/NN||adefovir-22/NN	prep_in||licensed-10/VBN||entecavir-24/NN	conj_and||interferon-15/NN||entecavir-24/NN	prep_in||licensed-10/VBN||telbivudine-27/NN	conj_and||interferon-15/NN||telbivudine-27/NN	hepatitisb-7||lamivudine-20||yes||several options for the treatment of hepatitisb have been licensed in the last years interferon, pegylated interferon, lamivudine, adefovir, entecavir, and telbivudine.
det||role-2/NN||the-1/DT	nsubj||lineage-12/VBP||role-2/NN	amod||birds-5/NNS||wild-4/JJ	prep_of||role-2/NN||birds-5/NNS	det||epidemiology-8/NN||the-7/DT	prep_in||birds-5/NNS||epidemiology-8/NN	det||asian-11/NN||the-10/DT	prep_of||epidemiology-8/NN||asian-11/NN	root||ROOT-0/null||lineage-12/VBP	advmod||pathogenic-14/JJ||highly-13/RB	amod||h5n1-21/NNS||pathogenic-14/JJ	amod||h5n1-21/NNS||avianinfluenza-15/JJ	appos||h5n1-21/NNS||hpai-17/NNP	nn||h5n1-21/NNS||virus-19/NN	nn||h5n1-21/NNS||subtype-20/NN	dobj||lineage-12/VBP||h5n1-21/NNS	amod||h5n1-21/NNS||epizootic-22/JJ	poss||contribution-25/NN||their-24/PRP$	nsubj||unclear-38/JJ||contribution-25/NN	det||spread-28/NN||the-27/DT	prep_to||contribution-25/NN||spread-28/NN	det||viruses-32/NNS||the-30/DT	amod||viruses-32/NNS||responsible-31/JJ	prep_of||spread-28/NN||viruses-32/NNS	prep_in||viruses-32/NNS||eurasia-34/NN	prep_in||viruses-32/NNS||africa-36/NN	conj_and||eurasia-34/NN||africa-36/NN	cop||unclear-38/JJ||are-37/VBP	conj_and||lineage-12/VBP||unclear-38/JJ	virus-19||viruses-32||no||the role of wild birds in the epidemiology of the asian lineage highly pathogenic avianinfluenza (hpai) virus subtype h5n1 epizootic and their contribution to the spread of the responsible viruses in eurasia and africa are unclear.
advmod||report-4/VBP||here-1/RB	nsubj||report-4/VBP||we-3/PRP	root||ROOT-0/null||report-4/VBP	det||case-6/NN||a-5/DT	dobj||report-4/VBP||case-6/NN	prep_of||case-6/NN||5-8/CD	nn||â-11/NN||fu-10/NN	dep||case-6/NN||â-11/NN	dep||â-11/NN||$-12/$	advmod||encephalopathy-15/JJ||induced-14/RB	amod||manifesting-17/NNS||encephalopathy-15/JJ	npadvmod||as-18/RB||manifesting-17/NNS	dep||seizures-19/CD||as-18/RB	num||$-12/$||seizures-19/CD	dobj||report-4/VBP||delirium-21/NN	conj_and||case-6/NN||delirium-21/NN	det||era-25/NN||an-24/DT	prep_in||delirium-21/NN||era-25/NN	amod||chemotherapy-28/NN||oxaliplatin-containing-27/JJ	prep_of||era-25/NN||chemotherapy-28/NN	oxaliplatin--1||delirium-21||no_rel||here, we report a case of 5- fu âinduced encephalopathy, manifesting as seizures and delirium, in an era of oxaliplatin-containing chemotherapy.
nsubj||state-7/NN||diabeticketoacidosis-1/NNS	appos||diabeticketoacidosis-1/NNS||dka-3/NN	cop||state-7/NN||is-5/VBZ	det||state-7/NN||a-6/DT	root||ROOT-0/null||state-7/NN	amod||deficiency-11/NN||severe-9/JJ	nn||deficiency-11/NN||insulin-10/NN	nsubj||resulting-18/VBG||deficiency-11/NN	preconj||absolute-14/JJ||either-13/DT	amod||deficiency-11/NN||absolute-14/JJ	amod||deficiency-11/NN||relative-16/JJ	conj_or||absolute-14/JJ||relative-16/JJ	prepc_of||state-7/NN||resulting-18/VBG	prep_in||resulting-18/VBG||hyperglycemia-20/NN	prep_in||resulting-18/VBG||ketonemia-22/NN	conj_and||hyperglycemia-20/NN||ketonemia-22/NN	hyperglycemia-20||insulin-10||yes||diabeticketoacidosis (dka) is a state of severe insulin deficiency, either absolute or relative, resulting in hyperglycemia and ketonemia.
det||scores-4/NNS||the-1/DT	amod||scores-4/NNS||highest-2/JJS	amod||scores-4/NNS||alval-3/JJ	nsubj||occurred-5/VBD||scores-4/NNS	root||ROOT-0/null||occurred-5/VBD	prep_in||occurred-5/VBD||patients-7/NNS	nsubjpass||revised-10/VBN||patients-7/NNS	auxpass||revised-10/VBN||were-9/VBD	rcmod||patients-7/NNS||revised-10/VBN	prep_for||revised-10/VBN||pain-12/NN	amod||hypersensitivity-16/NN||suspected-14/VBN	nn||hypersensitivity-16/NN||metal-15/NN	prep_for||revised-10/VBN||hypersensitivity-16/NN	conj_and||pain-12/NN||hypersensitivity-16/NN	pain-12||metal-15||no_rel||the highest alval scores occurred in patients who were revised for pain and suspected metal hypersensitivity.
det||result-2/NN||the-1/DT	nsubj||showed-3/VBD||result-2/NN	root||ROOT-0/null||showed-3/VBD	mark||had-17/VBD||that-4/IN	nsubj||had-17/VBD||c-5/SYM	num||mg/l-8/NN||128-7/CD	appos||c-5/SYM||mg/l-8/NN	prep||c-5/SYM||combined-10/VBN	pcomp||combined-10/VBN||with-11/IN	pobj||with-11/IN||ecg-12/NN	num||mg/l-15/NN||16-14/CD	appos||ecg-12/NN||mg/l-15/NN	ccomp||showed-3/VBD||had-17/VBD	det||effect-20/NN||the-18/DT	amod||effect-20/NN||greatest-19/JJS	dobj||had-17/VBD||effect-20/NN	det||combination-23/NN||the-22/DT	nsubj||reduced-25/VBD||combination-23/NN	advmod||reduced-25/VBD||also-24/RB	conj_and||showed-3/VBD||reduced-25/VBD	det||load-28/NN||the-26/DT	amod||load-28/NN||bacterial-27/JJ	dobj||reduced-25/VBD||load-28/NN	prep_in||reduced-25/VBD||blood-30/NN	amod||mice-33/NNS||septic-32/JJ	prep_of||blood-30/NN||mice-33/NNS	dep||mice-33/NNS||challenged-34/VBN	det||dose-38/NN||a-36/DT	amod||dose-38/NN||sublethal-37/JJ	prep_with||challenged-34/VBN||dose-38/NN	prep_of||dose-38/NN||mrsa-40/NN	dep||mice-33/NNS||increased-42/VBN	conj_and||challenged-34/VBN||increased-42/VBN	nn||accumulation-44/NN||daunomycin-43/NN	dobj||increased-42/VBN||accumulation-44/NN	prep_within||increased-42/VBN||mrsa-46/NN	dep||mice-33/NNS||down-regulated-48/VBN	conj_and||challenged-34/VBN||down-regulated-48/VBN	det||expression-51/NN||the-49/DT	nn||expression-51/NN||mrna-50/NN	dobj||down-regulated-48/VBN||expression-51/NN	prep_of||expression-51/NN||nora-53/NN	prep_of||expression-51/NN||norc-55/NN	conj_and||nora-53/NN||norc-55/NN	prep_of||expression-51/NN||abca-57/NN	conj_and||nora-53/NN||abca-57/NN	num||pumps-62/NNS||three-59/CD	amod||pumps-62/NNS||important-60/JJ	nn||pumps-62/NNS||efflux-61/NN	dobj||reduced-25/VBD||pumps-62/NNS	prep_of||pumps-62/NNS||mrsa-64/NN	daunomycin-43||mrsa-64||no_rel||the result showed that c (128 mg/l) combined with ecg (16 mg/l) had the greatest effect and the combination also reduced the bacterial load in blood of septic mice challenged with a sublethal dose of mrsa, increased daunomycin accumulation within mrsa and down-regulated the mrna expression of nora , norc and abca , three important efflux pumps of mrsa.
det||pathophysiology-2/NN||the-1/DT	nsubj||multifactorial-6/JJ||pathophysiology-2/NN	nsubj||related-8/VBN||pathophysiology-2/NN	prep_of||pathophysiology-2/NN||anemia-4/NN	cop||multifactorial-6/JJ||is-5/VBZ	root||ROOT-0/null||multifactorial-6/JJ	conj_and||multifactorial-6/JJ||related-8/VBN	amod||factors-11/NNS||various-10/JJ	prep_to||related-8/VBN||factors-11/NNS	prep_including||factors-11/NNS||hemodilution-14/NN	nn||losses-17/NNS||iron-16/NN	appos||hemodilution-14/NN||losses-17/NNS	amod||drugs-20/NNS||anti-platelet-19/JJ	prep_from||losses-17/NNS||drugs-20/NNS	appos||hemodilution-14/NN||activation-22/NN	det||cascade-26/NN||the-24/DT	amod||cascade-26/NN||inflammatory-25/JJ	prep_of||activation-22/NN||cascade-26/NN	amod||losses-29/NNS||urinary-28/JJ	appos||hemodilution-14/NN||losses-29/NNS	prep_of||losses-29/NNS||erythropoietin-31/NN	conj_and||multifactorial-6/JJ||associated-33/VBN	conj_and||related-8/VBN||associated-33/VBN	advmod||associated-33/VBN||renalinsufficiency-34/RB	iron-16||renalinsufficiency-34||no_rel||the pathophysiology of anemia is multifactorial and related to various factors including; hemodilution, iron losses from anti-platelet drugs, activation of the inflammatory cascade, urinary losses of erythropoietin and associated renalinsufficiency.
nsubjpass||used-19/VBN||some-1/DT	nsubj||effective-25/JJ||some-1/DT	det||metabolites-6/NNS||these-3/DT	amod||metabolites-6/NNS||bioactive-4/JJ	amod||metabolites-6/NNS||secondary-5/JJ	prep_of||some-1/DT||metabolites-6/NNS	amod||origin-9/NN||microbial-8/JJ	prep_of||metabolites-6/NNS||origin-9/NN	amod||activities-15/NNS||strong-11/JJ	amod||activities-15/NNS||antibacterial-12/JJ	conj_and||antibacterial-12/JJ||antifungal-14/JJ	amod||activities-15/NNS||antifungal-14/JJ	prep_with||origin-9/NN||activities-15/NNS	aux||used-19/VBN||are-16/VBP	auxpass||used-19/VBN||being-17/VBG	advmod||used-19/VBN||intensely-18/RB	root||ROOT-0/null||used-19/VBN	prep_as||used-19/VBN||antibiotics-21/NNS	aux||effective-25/JJ||may-23/MD	cop||effective-25/JJ||be-24/VB	conj_and||used-19/VBN||effective-25/JJ	amod||diseases-28/NNS||infectious-27/JJ	prep_against||effective-25/JJ||diseases-28/NNS	prep_such_as||diseases-28/NNS||hiv-31/NN	prep_such_as||diseases-28/NNS||conditions-33/NNS	conj_or||hiv-31/NN||conditions-33/NNS	amod||bacterialinfections-36/NNS||multiple-35/JJ	prep_of||conditions-33/NNS||bacterialinfections-36/NNS	dep||bacterialinfections-36/NNS||penicillin-38/NN	dep||bacterialinfections-36/NNS||cephalosporines-40/NNS	conj_and||penicillin-38/NN||cephalosporines-40/NNS	dep||bacterialinfections-36/NNS||streptomycin-42/NN	conj_and||penicillin-38/NN||streptomycin-42/NN	dep||bacterialinfections-36/NNS||vancomycin-45/NN	conj_and||penicillin-38/NN||vancomycin-45/NN	amod||sequelae-49/NN||neuropsychiatric-48/JJ	prep_such_as||diseases-28/NNS||sequelae-49/NN	conj_or||hiv-31/NN||sequelae-49/NN	bacterialinfections-36||vancomycin-45||yes||some of these bioactive secondary metabolites of microbial origin with strong antibacterial and antifungal activities are being intensely used as antibiotics and may be effective against infectious diseases such as hiv, conditions of multiple bacterialinfections (penicillin, cephalosporines, streptomycin, and vancomycin) or neuropsychiatric sequelae.
nsubj||found-2/VBD||we-1/PRP	root||ROOT-0/null||found-2/VBD	amod||results-4/NNS||similar-3/JJ	dobj||found-2/VBD||results-4/NNS	prep_after||found-2/VBD||trabeculectomy-6/NN	amod||implantation-13/NN||mitomycinc-8/JJ	conj_and||mitomycinc-8/JJ||ahmed-10/JJ	amod||implantation-13/NN||ahmed-10/JJ	amod||implantation-13/NN||glaucoma-11/JJ	nn||implantation-13/NN||valve-12/NN	prep_with||trabeculectomy-6/NN||implantation-13/NN	prep_in||found-2/VBD||eyes-15/NNS	nn||glaucoma-18/NN||neovascular-17/NN	prep_with||eyes-15/NNS||glaucoma-18/NN	glaucoma-18||mitomycinc-8||yes||we found similar results after trabeculectomy with mitomycinc and ahmed glaucoma valve implantation in eyes with neovascular glaucoma.
det||frequency-3/NN||an-1/DT	amod||frequency-3/NN||increased-2/VBN	nsubj||occurs-7/VBZ||frequency-3/NN	amod||flares-6/NNS||gout-5/JJ	prep_of||frequency-3/NN||flares-6/NNS	root||ROOT-0/null||occurs-7/VBZ	det||period-11/NN||a-9/DT	amod||period-11/NN||prolonged-10/VBN	prep_for||occurs-7/VBZ||period-11/NN	nn||initiation-14/NN||treatment-13/NN	prep_after||period-11/NN||initiation-14/NN	dep||period-11/NN||as-16/RB	det||lowering-20/NN||any-18/DT	amod||lowering-20/NN||aggressive-19/JJ	prep_with||period-11/NN||lowering-20/NN	nn||urate-23/NN||serum-22/NN	prep_of||lowering-20/NN||urate-23/NN	amod||prophylaxis-27/NNS||prolonged-26/VBN	nsubjpass||required-34/VBN||prophylaxis-27/NNS	prep_with||prophylaxis-27/NNS||colchicine-29/NN	prep_with||prophylaxis-27/NNS||nsaids-31/NNS	conj_or||colchicine-29/NN||nsaids-31/NNS	auxpass||required-34/VBN||is-32/VBZ	advmod||required-34/VBN||usually-33/RB	conj_and||occurs-7/VBZ||required-34/VBN	gout-5||colchicine-29||yes||an increased frequency of gout flares occurs for a prolonged period after treatment initiation, as with any aggressive lowering of serum urate, and prolonged prophylaxis with colchicine or nsaids is usually required.
advmod||overwhelmed-7/VBN||when-1/WRB	det||level-5/NN||this-2/DT	amod||level-5/NN||first-3/JJ	amod||level-5/NN||regulatory-4/JJ	nsubjpass||overwhelmed-7/VBN||level-5/NN	auxpass||overwhelmed-7/VBN||is-6/VBZ	advcl||occurs-20/VBZ||overwhelmed-7/VBN	nsubj||is-10/VBZ||that-9/WDT	parataxis||overwhelmed-7/VBN||is-10/VBZ	prep_by||is-10/VBZ||exogenous-13/NNS	xcomp||is-10/VBZ||glucose-14/VBG	dobj||glucose-14/VBG||supplementation-15/NN	amod||hyperglycaemia-19/NN||persistent-18/JJ	nsubj||occurs-20/VBZ||hyperglycaemia-19/NN	root||ROOT-0/null||occurs-20/VBZ	amod||consequences-23/NNS||intricate-22/JJ	prep_with||occurs-20/VBZ||consequences-23/NNS	vmod||consequences-23/NNS||related-24/VBN	det||glucose-27/NN||the-26/DT	prep_to||related-24/VBN||glucose-27/NN	vmod||glucose-27/NN||acting-28/VBG	det||substrate-32/NN||a-30/DT	amod||substrate-32/NN||metabolic-31/JJ	prep_as||acting-28/VBG||substrate-32/NN	det||mediator-37/NN||an-35/DT	nn||mediator-37/NN||intracellular-36/NN	prep_as||acting-28/VBG||mediator-37/NN	conj_and||substrate-32/NN||mediator-37/NN	hyperglycaemia-19||glucose-27||no||when this first regulatory level is overwhelmed (that is, by exogenous glucose supplementation), persistent hyperglycaemia occurs with intricate consequences related to the glucose acting as a metabolic substrate and as an intracellular mediator.
nsubj||immunomodulator-5/NN||tacrolimus-1/NNS	cop||immunomodulator-5/NN||is-2/VBZ	det||immunomodulator-5/NN||a-3/DT	amod||immunomodulator-5/NN||potent-4/JJ	root||ROOT-0/null||immunomodulator-5/NN	nsubj||effective-8/JJ||immunomodulator-5/NN	cop||effective-8/JJ||is-7/VBZ	rcmod||immunomodulator-5/NN||effective-8/JJ	det||treatment-11/NN||the-10/DT	prep_in||effective-8/JJ||treatment-11/NN	prep_of||treatment-11/NN||inflammatoryboweldisease-13/NN	appos||inflammatoryboweldisease-13/NN||ibd-15/NN	immunomodulator-5||ibd-15||no_rel||tacrolimus is a potent immunomodulator that is effective in the treatment of inflammatoryboweldisease (ibd).
nsubj||treatment-4/NN||warfarin-1/NN	cop||treatment-4/NN||is-2/VBZ	det||treatment-4/NN||the-3/DT	root||ROOT-0/null||treatment-4/NN	prep_of||treatment-4/NN||choice-6/NN	amod||patients-9/NNS||high-risk-8/JJ	prep_in||choice-6/NN||patients-9/NNS	prep_with||patients-9/NNS||af-11/NN	poss||efficacy-16/NN||its-14/PRP$	amod||efficacy-16/NN||superior-15/JJ	nsubjpass||recognized-27/VBN||efficacy-16/NN	prep_over||efficacy-16/NN||aspirin-18/NN	prepc_for||aspirin-18/NN||preventing-20/VBG	dobj||preventing-20/VBG||stroke-21/NN	det||patients-24/NNS||these-23/DT	prep_in||preventing-20/VBG||patients-24/NNS	auxpass||recognized-27/VBN||is-25/VBZ	advmod||recognized-27/VBN||widely-26/RB	conj_and||treatment-4/NN||recognized-27/VBN	stroke-21||warfarin-1||yes||warfarin is the treatment of choice in high-risk patients with af, and its superior efficacy over aspirin for preventing stroke in these patients is widely recognized.
poss||role-5/NN||its-3/PRP$	amod||role-5/NN||principal-4/JJ	prep_apart_from||attributed-16/VBN||role-5/NN	nn||metabolism-8/NN||bone-7/NN	prep_in||role-5/NN||metabolism-8/NN	nn||homeostasis-11/NNS||calcium-10/NN	prep_in||role-5/NN||homeostasis-11/NNS	conj_and||metabolism-8/NN||homeostasis-11/NNS	nsubjpass||attributed-16/VBN||vitamind-13/NN	aux||attributed-16/VBN||has-14/VBZ	auxpass||attributed-16/VBN||been-15/VBN	root||ROOT-0/null||attributed-16/VBN	amod||effects-18/NNS||additional-17/JJ	dobj||attributed-16/VBN||effects-18/NNS	det||capacity-29/NN||an-20/DT	amod||capacity-29/NN||immunomodulatory-21/JJ	amod||capacity-29/NN||anti-inflammatory-23/JJ	advmod||neuroprotective-28/JJ||possibly-26/RB	advmod||neuroprotective-28/JJ||even-27/RB	conj_and||anti-inflammatory-23/JJ||neuroprotective-28/JJ	amod||capacity-29/NN||neuroprotective-28/JJ	prep_including||effects-18/NNS||capacity-29/NN	nsubj||implicates-31/VBZ||which-30/WDT	ccomp||capacity-29/NN||implicates-31/VBZ	det||role-34/NN||a-32/DT	amod||role-34/NN||possible-33/JJ	dobj||implicates-31/VBZ||role-34/NN	prep_of||role-34/NN||vitamind-36/NN	prep_in||implicates-31/VBZ||autoimmunediseases-38/NNS	prep_like||autoimmunediseases-38/NNS||multiplesclerosis-40/NNS	appos||multiplesclerosis-40/NNS||ms-42/NN	calcium-10||autoimmunediseases-38||no_rel||apart from its principal role in bone metabolism and calcium homeostasis, vitamind has been attributed additional effects including an immunomodulatory, anti-inflammatory, and possibly even neuroprotective capacity which implicates a possible role of vitamind in autoimmunediseases like multiplesclerosis (ms).
amod||prophylaxis-3/NNS||post-transplant-1/JJ	nn||prophylaxis-3/NNS||hbv-2/NN	nsubj||effective-31/JJ||prophylaxis-3/NNS	prep_with||prophylaxis-3/NNS||lamivudine-5/NN	prep_with||prophylaxis-3/NNS||intramuscular-7/NN	conj_and||lamivudine-5/NN||intramuscular-7/NN	vmod||prophylaxis-3/NNS||hbig-8/VBG	amod||dosage-11/NN||appropriate-10/JJ	prep_with||hbig-8/VBG||dosage-11/NN	aux||keep-13/VB||to-12/TO	xcomp||hbig-8/VBG||keep-13/VB	amod||titer-16/NN||anti-hbs-14/JJ	nn||titer-16/NN||antibody-15/NN	dobj||keep-13/VB||titer-16/NN	num||iu/l-19/NN||300-18/CD	prep_above||keep-13/VB||iu/l-19/NN	det||months-24/NNS||the-21/DT	amod||months-24/NNS||first-22/JJ	num||months-24/NNS||six-23/CD	prep_in||iu/l-19/NN||months-24/NNS	num||iu/l-28/NN||100-27/CD	prep_above||keep-13/VB||iu/l-28/NN	conj_and||iu/l-19/NN||iu/l-28/NN	dep||keep-13/VB||afterwards-29/RB	cop||effective-31/JJ||is-30/VBZ	root||ROOT-0/null||effective-31/JJ	prep_for||effective-31/JJ||prevention-33/NN	nn||recurrence-36/NN||hbv-35/NN	prep_of||prevention-33/NN||recurrence-36/NN	prep_after||effective-31/JJ||lt.-38/NN	hbv-35||lamivudine-5||yes||post-transplant hbv prophylaxis with lamivudine and intramuscular hbig with appropriate dosage to keep anti-hbs antibody titer above 300 iu/l in the first six months and above 100 iu/l afterwards is effective for prevention of hbv recurrence after lt.
nsubj||conducted-2/VBD||we-1/PRP	root||ROOT-0/null||conducted-2/VBD	det||trial-8/NN||an-3/DT	amod||trial-8/NN||open-4/JJ	amod||trial-8/NN||randomized-6/JJ	amod||trial-8/NN||clinical-7/JJ	dobj||conducted-2/VBD||trial-8/NN	amod||dihydroartemisinin-piperaquine-11/NN||oral-10/JJ	prep_of||trial-8/NN||dihydroartemisinin-piperaquine-11/NN	appos||dihydroartemisinin-piperaquine-11/NN||dp-13/NN	prep_versus||dihydroartemisinin-piperaquine-11/NN||artesunate-mefloquine-16/NN	dep||dihydroartemisinin-piperaquine-11/NN||am-18/VBP	num||patients-22/NNS||300-21/CD	prep_in||conducted-2/VBD||patients-22/NNS	prep_in||patients-22/NNS||laos-24/NNS	amod||plasmodiumfalciparummalaria-27/NN||uncomplicated-26/JJ	prep_with||laos-24/NNS||plasmodiumfalciparummalaria-27/NN	prep_as||conducted-2/VBD||part-29/NN	det||study-33/NN||a-31/DT	amod||study-33/NN||multicentre-32/JJ	prep_of||part-29/NN||study-33/NN	prep_in||study-33/NN||asia-35/NN	plasmodiumfalciparummalaria-27||mefloquine--1||yes||we conducted an open, randomized clinical trial of oral dihydroartemisinin-piperaquine (dp) versus artesunate-mefloquine (am) in 300 patients in laos with uncomplicated plasmodiumfalciparummalaria as part of a multicentre study in asia.
amod||weight-4/NN||epididymal-1/JJ	amod||weight-4/NN||fat-2/JJ	nn||weight-4/NN||pad-3/NN	nsubjpass||reduced-11/VBN||weight-4/NN	prep_as||weight-4/NN||percent-6/NN	nn||weight-9/NN||body-8/NN	prep_of||percent-6/NN||weight-9/NN	auxpass||reduced-11/VBN||was-10/VBD	root||ROOT-0/null||reduced-11/VBN	det||group-15/NN||the-13/DT	amod||group-15/NN||hv-hpmc-14/JJ	prep_in||reduced-11/VBN||group-15/NN	prepc_compared_to||reduced-11/VBN||to-17/TO	det||group-21/NN||the-18/DT	amod||group-21/NN||obese-19/JJ	nn||group-21/NN||control-20/NN	pobj||reduced-11/VBN||group-21/NN	obese-19||fat-2||no_rel||epididymal fat pad weight as percent of body weight was reduced in the hv-hpmc group compared to the obese control group.
nsubj||lack-2/VBP||we-1/PRP	root||ROOT-0/null||lack-2/VBP	det||understanding-4/NN||the-3/DT	dobj||lack-2/VBP||understanding-4/NN	advmod||progress-12/VB||why-6/WRB	amod||individuals-8/NNS||hiv-infected-7/JJ	nsubj||progress-12/VB||individuals-8/NNS	amod||africa-11/NN||south-10/JJ	prep_in||individuals-8/NNS||africa-11/NN	prepc_of||understanding-4/NN||progress-12/VB	prep_to||progress-12/VB||aids-14/NNS	aids-14||hiv--1||no||we lack the understanding of why hiv-infected individuals in south africa progress to aids.
num||means-3/NNS||one-1/CD	amod||means-3/NNS||recommended-2/VBN	nsubj||therapy-12/NN||means-3/NNS	prepc_of||means-3/NNS||preventing-5/VBG	dobj||preventing-5/VBG||malaria-6/NN	prep_during||preventing-5/VBG||pregnancy-8/NN	cop||therapy-12/NN||is-9/VBZ	amod||therapy-12/NN||intermittent-10/JJ	nn||therapy-12/NN||preventive-11/NN	root||ROOT-0/null||therapy-12/NN	appos||therapy-12/NN||iptp-14/NN	prep_with||therapy-12/NN||sulfadoxine/pyrimethamine-17/NN	appos||sulfadoxine/pyrimethamine-17/NN||sp-19/NN	malaria-6||pyrimethamine--1||yes||one recommended means of preventing malaria during pregnancy is intermittent preventive therapy (iptp) with sulfadoxine/pyrimethamine (sp).
nsubj||injected-25/VBN||adults-1/NNS	amod||type1diabetes-4/NNS||recent-onset-3/JJ	prep_with||adults-1/NNS||type1diabetes-4/NNS	prep_in||subacute-11/JJ||type1diabetes-4/NNS	det||process-9/NN||the-7/DT	nn||process-9/NN||disease-8/NN	nsubj||subacute-11/JJ||process-9/NN	cop||subacute-11/JJ||is-10/VBZ	rcmod||type1diabetes-4/NNS||subacute-11/JJ	ccomp||subacute-11/JJ||afford-12/VB	det||opportunity-14/NN||an-13/DT	dobj||afford-12/VB||opportunity-14/NN	aux||determine-16/VB||to-15/TO	vmod||opportunity-14/NN||determine-16/VB	mark||induces-20/VBZ||whether-17/IN	amod||insulin-19/NN||mucosal-18/JJ	nsubj||induces-20/VBZ||insulin-19/NN	ccomp||determine-16/VB||induces-20/VBZ	dobj||induces-20/VBZ||tolerance-21/NN	prep_to||induces-20/VBZ||insulin-23/NN	advmod||injected-25/VBN||subsequently-24/RB	root||ROOT-0/null||injected-25/VBN	prep_for||injected-25/VBN||treatment-27/NN	type1diabetes-4||insulin-23||yes||adults with recent-onset type1diabetes in whom the disease process is subacute afford an opportunity to determine whether mucosal insulin induces tolerance to insulin subsequently injected for treatment.
nsubj||examined-2/VBD||we-1/PRP	root||ROOT-0/null||examined-2/VBD	dobj||examined-2/VBD||correlates-3/NNS	amod||rna-7/NN||genital-5/JJ	amod||rna-7/NN||hiv-1-6/JJ	prep_of||correlates-3/NNS||rna-7/NN	prep_in||rna-7/NN||women-9/NNS	nsubj||seropositive-12/JJ||who-10/WP	cop||seropositive-12/JJ||were-11/VBD	dep||examined-2/VBD||seropositive-12/JJ	det||-rrb--20/NNP||both-14/DT	amod||-rrb--20/NNP||herpes-15/JJ	nn||-rrb--20/NNP||simplex-16/NN	nn||-rrb--20/NNP||virus-17/NN	nn||-rrb--20/NNP||-lrb--18/NNP	nn||-rrb--20/NNP||hsv-19/NNP	prep_for||seropositive-12/JJ||-rrb--20/NNP	dep||seropositive-12/JJ||-2-21/CD	dep||seropositive-12/JJ||hiv-1-23/CD	conj_and||-2-21/CD||hiv-1-23/CD	dep||enrolled-27/VBN||who-25/WP	auxpass||enrolled-27/VBN||were-26/VBD	dep||examined-2/VBD||enrolled-27/VBN	conj_and||seropositive-12/JJ||enrolled-27/VBN	det||trial-32/NN||a-29/DT	amod||trial-32/NN||randomised-30/JJ	amod||trial-32/NN||controlled-31/JJ	prep_in||enrolled-27/VBN||trial-32/NN	nn||therapy-36/NN||hsv-34/NN	nn||therapy-36/NN||suppressive-35/NN	prep_of||trial-32/NN||therapy-36/NN	num||aciclovir-38/NN||-lrb--37/CD	nsubjpass||enrolled-27/VBN||aciclovir-38/NN	num||-rrb--44/NN||400-39/CD	amod||-rrb--44/NN||mg-40/JJ	amod||-rrb--44/NN||b.i.d-41/JJ	nn||-rrb--44/NN||vs.-42/FW	nn||-rrb--44/NN||placebo-43/FW	dep||enrolled-27/VBN||-rrb--44/NN	prep_in||enrolled-27/VBN||tanzania-46/NN	hsv-34||aciclovir-38||yes||we examined correlates of genital hiv-1 rna in women who were seropositive for both herpes simplex virus -lrb- hsv -rrb- -2 and hiv-1 and who were enrolled in a randomised controlled trial of hsv suppressive therapy -lrb- aciclovir 400 mg b.i.d vs. placebo -rrb- in tanzania .
nn||gain-3/NN||body-1/NN	nn||gain-3/NN||weight-2/NN	nsubjpass||suppressed-20/VBN||gain-3/NN	amod||accumulation-7/NN||fat-5/JJ	nn||accumulation-7/NN||pad-6/NN	conj_and||gain-3/NN||accumulation-7/NN	nsubjpass||suppressed-20/VBN||accumulation-7/NN	det||development-10/NN||the-9/DT	conj_and||gain-3/NN||development-10/NN	nsubjpass||suppressed-20/VBN||development-10/NN	prep_of||development-10/NN||hyperlipidemia-12/NN	conj_and||gain-3/NN||hyperglycemia-14/NN	nsubjpass||suppressed-20/VBN||hyperglycemia-14/NN	conj_and||gain-3/NN||insulinresistance-17/NN	nsubjpass||suppressed-20/VBN||insulinresistance-17/NN	auxpass||suppressed-20/VBN||were-18/VBD	advmod||suppressed-20/VBN||significantly-19/RB	root||ROOT-0/null||suppressed-20/VBN	amod||polyphenols-23/NNS||lemon-22/JJ	agent||suppressed-20/VBN||polyphenols-23/NNS	hyperlipidemia-12||fat-5||no_rel||body weight gain, fat pad accumulation, the development of hyperlipidemia, hyperglycemia, and insulinresistance were significantly suppressed by lemon polyphenols.
nsubj||treatment-11/NN||valproicacid-1/NN	appos||valproicacid-1/NN||vpa-3/NN	cop||treatment-11/NN||is-5/VBZ	det||treatment-11/NN||a-6/DT	advmod||prescribed-8/VBN||commonly-7/RB	amod||treatment-11/NN||prescribed-8/VBN	conj_and||prescribed-8/VBN||approved-10/VBN	amod||treatment-11/NN||approved-10/VBN	root||ROOT-0/null||treatment-11/NN	prep_for||treatment-11/NN||epilepsy-13/NN	nn||syndrome-17/NN||angelman-16/NN	prep_including||treatment-11/NN||syndrome-17/NN	amod||syndrome-17/NN||throughout-19/IN	det||world-21/NN||the-20/DT	dep||syndrome-17/NN||world-21/NN	epilepsy-13||valproicacid-1||yes||valproicacid (vpa) is a commonly prescribed and approved treatment for epilepsy, including angelman syndrome, throughout the world.
amod||mice-3/NNS||swiss-1/JJ	nn||mice-3/NNS||albino-2/NN	nsubjpass||divided-8/VBN||mice-3/NNS	det||sex-6/NN||either-5/DT	prep_of||mice-3/NNS||sex-6/NN	auxpass||divided-8/VBN||were-7/VBD	root||ROOT-0/null||divided-8/VBN	num||groups-11/NNS||five-10/CD	prep_into||divided-8/VBN||groups-11/NNS	vmod||groups-11/NNS||-lrb--12/VBG	nn||group-15/NN||five/group-13/NN	nn||group-15/NN||-rrb--14/NN	dobj||-lrb--12/VBG||group-15/NN	nsubj||served-17/VBD||i-16/FW	nsubj||received-21/VBD||i-16/FW	rcmod||group-15/NN||served-17/VBD	prep_as||served-17/VBD||control-19/NN	rcmod||group-15/NN||received-21/VBD	conj_and||served-17/VBD||received-21/VBD	nn||-lrb--23/NNS||vehicle-22/NN	dobj||received-21/VBD||-lrb--23/NNS	number||%-25/NN||1-24/CD	amod||tween-26/NN||%-25/NN	dep||group-15/NN||tween-26/NN	number||-rrb--28/CD||80-27/CD	dep||group-15/NN||-rrb--28/CD	det||dose-31/NN||a-30/DT	prep_at||-rrb--28/CD||dose-31/NN	prep_of||dose-31/NN||10-33/CD	vmod||-rrb--28/CD||ml/kg-34/VBG	advmod||ml/kg-34/VBG||orally-35/RB	nn||ii-38/NN||group-37/NN	dep||group-15/NN||ii-38/NN	dep||ii-38/NN||served-39/VBN	prep_as||served-39/VBN||standard-41/NN	dep||ii-38/NN||received-43/VBN	conj_and||served-39/VBN||received-43/VBN	dobj||received-43/VBN||loperamide-44/NN	det||dose-47/NN||the-46/DT	prep_at||received-43/VBN||dose-47/NN	prep_of||dose-47/NN||3-49/CD	dep||received-43/VBN||mg/kg-50/VBG	advmod||mg/kg-50/VBG||orally-51/RB	dep||group-15/NN||groups-53/NNS	nsubj||served-59/VBD||iii-54/NN	nsubj||received-64/VBD||iii-54/NN	conj_and||iii-54/NN||iv-56/NN	nsubj||served-59/VBD||iv-56/NN	conj_and||iii-54/NN||v-58/NN	nsubj||served-59/VBD||v-58/NN	rcmod||groups-53/NNS||served-59/VBD	nn||groups-62/NNS||test-61/NN	prep_as||served-59/VBD||groups-62/NNS	rcmod||groups-53/NNS||received-64/VBD	conj_and||served-59/VBD||received-64/VBD	det||extract-70/NN||the-65/DT	number||%-67/NN||80-66/CD	amod||extract-70/NN||%-67/NN	amod||extract-70/NN||meoh-68/JJ	nn||extract-70/NN||leaf-69/NN	dobj||received-64/VBD||extract-70/NN	nn||aurea-73/NN||c.-72/NN	prep_of||extract-70/NN||aurea-73/NN	prep_at||received-64/VBD||doses-75/NNS	prep_of||doses-75/NNS||100-77/CD	num||100-77/CD||200-79/CD	prep_of||doses-75/NNS||400-81/CD	conj_and||100-77/CD||400-81/CD	amod||orally-83/NN||mg/kg-82/JJ	dep||group-15/NN||orally-83/NN	amod||group-15/NN||respectively-85/RB	albino-2||loperamide-44||no_rel||swiss albino mice of either sex were divided into five groups -lrb- five/group -rrb- group i served as control and received vehicle -lrb- 1 % tween 80 -rrb- at a dose of 10 ml/kg orally ; group ii served as standard and received loperamide at the dose of 3 mg/kg orally ; groups iii , iv and v served as test groups and received the 80 % meoh leaf extract of c. aurea at doses of 100 , 200 and 400 mg/kg orally , respectively .
nsubjpass||treated-7/VBN||pmvec-1/NN	vmod||pmvec-1/NN||isolated-2/VBN	amod||lung-5/NN||human-4/JJ	prep_from||isolated-2/VBN||lung-5/NN	auxpass||treated-7/VBN||were-6/VBD	root||ROOT-0/null||treated-7/VBN	amod||albumin-45/NN||vitro-9/NN	amod||stimulation-12/NN||septic-11/JJ	prep_with||vitro-9/NN||stimulation-12/NN	amod||-RSB--17/NNS||lipopolysaccharide-14/JJ	amod||-RSB--17/NNS||-LSB--15/JJ	nn||-RSB--17/NNS||lps-16/NN	dep||stimulation-12/NN||-RSB--17/NNS	det||mixture-20/NN||a-19/DT	dep||stimulation-12/NN||mixture-20/NN	conj_or||-RSB--17/NNS||mixture-20/NN	amod||-RSB--26/NNS||clinically-relevant-22/JJ	nn||-RSB--26/NNS||cytokines-23/NNS	nn||-RSB--26/NNS||-LSB--24/NN	nn||-RSB--26/NNS||cytomix-25/NN	prep_of||mixture-20/NN||-RSB--26/NNS	dep||stimulation-12/NN||plasma-29/NN	conj_or||-RSB--17/NNS||plasma-29/NN	prep_from||plasma-29/NN||patients-31/NNS	amod||sepsis-34/NN||severe-33/JJ	prep_with||patients-31/NNS||sepsis-34/NN	det||leak-40/NN||the-38/DT	amod||leak-40/NN||trans-pmvec-39/JJ	prep_with||vitro-9/NN||leak-40/NN	conj_and||stimulation-12/NN||leak-40/NN	prep_of||leak-40/NN||evans-42/NNS	amod||albumin-45/NN||blue-43/JJ	amod||albumin-45/NN||dye-labeled-44/JJ	prep_in||treated-7/VBN||albumin-45/NN	vmod||albumin-45/NN||assessed-46/VBN	dye--1||evans-42||no_rel||pmvec isolated from human lung were treated in vitro with septic stimulation (lipopolysaccharide [lps], a mixture of clinically-relevant cytokines [cytomix], or plasma from patients with severe sepsis), and the trans-pmvec leak of evans blue dye-labeled albumin assessed.
prep_at||increased-13/VBD||center-2/NN	dep||center-2/NN||a-3/DT	det||proportion-6/NN||the-5/DT	nsubj||increased-13/VBD||proportion-6/NN	amod||infections-9/NNS||s.aureus-8/JJ	prep_of||proportion-6/NN||infections-9/NNS	vmod||infections-9/NNS||caused-10/VBN	agent||caused-10/VBN||ca-mrsa-12/NN	root||ROOT-0/null||increased-13/VBD	number||%-19/NN||4-15/CD	dep||%-19/NN||%-16/NN	dep||%-19/NN||to-17/TO	number||%-19/NN||23-18/CD	prep_from||increased-13/VBD||%-19/NN	num||years-22/NNS||2-21/CD	prep_over||increased-13/VBD||years-22/NNS	det||proportion-25/NN||the-24/DT	nsubj||decreased-33/VBD||proportion-25/NN	vmod||proportion-25/NN||caused-26/VBN	amod||-rrb--32/NNS||healthcare-associated-28/JJ	nn||-rrb--32/NNS||mrsa-29/NN	nn||-rrb--32/NNS||-lrb--30/NN	amod||-rrb--32/NNS||ha-mrsa-31/JJ	agent||caused-26/VBN||-rrb--32/NNS	parataxis||increased-13/VBD||decreased-33/VBD	number||%-39/NN||25-35/CD	dep||%-39/NN||%-36/NN	dep||%-39/NN||to-37/TO	number||%-39/NN||5-38/CD	prep_from||decreased-33/VBD||%-39/NN	mrsa-29||s.aureus-8||no||at center a , the proportion of s.aureus infections caused by ca-mrsa increased from 4 % to 23 % over 2 years ; the proportion caused by healthcare-associated mrsa -lrb- ha-mrsa -rrb- decreased from 25 % to 5 % .
det||stoichiometries-3/NNS||the-2/DT	nsubj||produce-8/VBP||stoichiometries-3/NNS	nsubj||consume-10/VBP||stoichiometries-3/NNS	prep_from||support-31/VBP||stoichiometries-3/NNS	amod||pathways-6/NNS||metabolic-5/JJ	prep_of||stoichiometries-3/NNS||pathways-6/NNS	rcmod||stoichiometries-3/NNS||produce-8/VBP	rcmod||stoichiometries-3/NNS||consume-10/VBP	conj_or||produce-8/VBP||consume-10/VBP	number||+-12/CD||h-11/CD	dobj||produce-8/VBP||+-12/CD	det||availability-17/NN||the-15/DT	amod||availability-17/NN||greater-16/JJR	dobj||produce-8/VBP||availability-17/NN	conj_and||+-12/CD||availability-17/NN	prep_of||availability-17/NN||glucose-19/NN	prepc_compared_to||produce-8/VBP||to-21/TO	pobj||produce-8/VBP||oxygen-22/NN	amod||parts-25/NNS||most-24/JJS	prep_in||oxygen-22/NN||parts-25/NNS	det||tumor-28/NN||a-27/DT	prep_of||parts-25/NNS||tumor-28/NN	nsubj||support-31/VBP||we-30/PRP	root||ROOT-0/null||support-31/VBP	det||view-34/NN||the-32/DT	amod||view-34/NN||classic-33/JJ	dobj||support-31/VBP||view-34/NN	mark||originates-45/VBZ||that-35/IN	nsubj||originates-45/VBZ||most-36/JJS	nsubj||add-59/VBP||most-36/JJS	det||efflux-41/NN||the-38/DT	amod||efflux-41/NN||net-39/JJ	nn||efflux-41/NN||proton-40/NN	prep_of||most-36/JJS||efflux-41/NN	amod||gliomas-44/NNS||c6-43/JJ	prep_from||efflux-41/NN||gliomas-44/NNS	ccomp||support-31/VBP||originates-45/VBZ	amod||formation-48/NN||glycolytic-47/JJ	prep_in||originates-45/VBZ||formation-48/NN	nn||+-53/NNS||lactate-50/NN	conj_and||lactate-50/NN||h-52/NN	nn||+-53/NNS||h-52/NN	prep_of||formation-48/NN||+-53/NNS	det||tumor-56/NN||the-55/DT	prep_inside||originates-45/VBZ||tumor-56/NN	ccomp||support-31/VBP||add-59/VBP	conj_but||originates-45/VBZ||add-59/VBP	mark||taken-64/VBN||that-60/IN	det||lactate-62/NN||some-61/DT	nsubjpass||taken-64/VBN||lactate-62/NN	auxpass||taken-64/VBN||is-63/VBZ	ccomp||add-59/VBP||taken-64/VBN	prt||taken-64/VBN||up-65/RP	prep_into||taken-64/VBN||cells-67/NNS	det||rim-70/NN||the-69/DT	prep_in||cells-67/NNS||rim-70/NN	prep_on||rim-70/NN||mct1-72/CD	det||lactate-76/NN||some-75/DT	nsubj||diffuses-77/VBZ||lactate-76/NN	ccomp||add-59/VBP||diffuses-77/VBZ	conj_and||taken-64/VBN||diffuses-77/VBZ	prt||diffuses-77/VBZ||away-78/RP	xcomp||diffuses-77/VBZ||leaving-80/VBG	poss||protons-83/NNS||its-81/PRP$	amod||protons-83/NNS||associated-82/JJ	dobj||leaving-80/VBG||protons-83/NNS	acomp||originates-45/VBZ||available-84/JJ	aux||re-enter-86/VB||to-85/TO	xcomp||available-84/JJ||re-enter-86/VB	dobj||re-enter-86/VB||cells-87/NNS	prep_for||cells-87/NNS||extrusion-89/NN	prep_on||re-enter-86/VB||nhe1-91/CD	tumor-56||add-59||no_rel||from the stoichiometries of metabolic pathways that produce or consume h+, and the greater availability of glucose compared to oxygen in most parts of a tumor, we support the classic view that most of the net proton efflux from c6 gliomas originates in glycolytic formation of lactate and h+ inside the tumor, but add that some lactate is taken up into cells in the rim on mct1, and some lactate diffuses away, leaving its associated protons available to re-enter cells for extrusion on nhe1.
nsubj||conditions-51/NNS||malignancy-1/NN	num||%-4/NN||76.7-3/CD	appos||malignancy-1/NN||%-4/NN	conj_and||malignancy-1/NN||neutropenia-7/NN	nsubj||conditions-51/NNS||neutropenia-7/NN	num||%-10/NN||64.1-9/CD	appos||neutropenia-7/NN||%-10/NN	amod||transplantation-17/NN||allogeneic-13/JJ	nn||transplantation-17/NN||hematopoietic-14/NN	nn||transplantation-17/NN||stem-15/NN	nn||transplantation-17/NN||cell-16/NN	conj_and||malignancy-1/NN||transplantation-17/NN	nsubj||conditions-51/NNS||transplantation-17/NN	appos||transplantation-17/NN||hsct-19/NN	num||%-22/NN||22.3-21/CD	dep||hsct-19/NN||%-22/NN	amod||transplantation-27/NN||solid-25/JJ	nn||transplantation-27/NN||organ-26/NN	conj_and||malignancy-1/NN||transplantation-27/NN	nsubj||conditions-51/NNS||transplantation-27/NN	num||%-30/NN||8.7-29/CD	appos||transplantation-27/NN||%-30/NN	amod||hsct-34/NN||autologous-33/JJ	conj_and||malignancy-1/NN||hsct-34/NN	nsubj||conditions-51/NNS||hsct-34/NN	num||%-37/NN||4.9-36/CD	appos||hsct-34/NN||%-37/NN	conj_and||malignancy-1/NN||hiv/aids-41/NNS	nsubj||conditions-51/NNS||hiv/aids-41/NNS	num||%-44/NN||2.9-43/CD	appos||malignancy-1/NN||%-44/NN	cop||conditions-51/NNS||were-46/VBD	det||conditions-51/NNS||the-47/DT	advmod||common-49/JJ||most-48/RBS	amod||conditions-51/NNS||common-49/JJ	amod||conditions-51/NNS||underlying-50/JJ	root||ROOT-0/null||conditions-51/NNS	aids--1||hiv--1||no||malignancy (76.7%), neutropenia (64.1%), allogeneic hematopoietic stem cell transplantation (hsct, 22.3%), solid organ transplantation (8.7%), autologous hsct (4.9%), and hiv/aids (2.9%) were the most common underlying conditions.
amod||follow-2/NNS||long-term-1/JJ	nsubjpass||needed-5/VBN||follow-2/NNS	nsubj||evaluate-7/VB||follow-2/NNS	advmod||needed-5/VBN||up-3/RB	auxpass||needed-5/VBN||is-4/VBZ	root||ROOT-0/null||needed-5/VBN	aux||evaluate-7/VB||to-6/TO	xcomp||needed-5/VBN||evaluate-7/VB	det||effect-9/NN||the-8/DT	dobj||evaluate-7/VB||effect-9/NN	amod||prophylaxis-14/NNS||early-11/JJ	amod||prophylaxis-14/NNS||anti-hpv-12/JJ	amod||prophylaxis-14/NNS||targeted-13/JJ	prep_of||effect-9/NN||prophylaxis-14/NNS	det||development-17/NN||the-16/DT	prep_on||prophylaxis-14/NNS||development-17/NN	prep_of||development-17/NN||skin-19/NN	prep_of||development-17/NN||genitalwarts-21/NNS	conj_and||skin-19/NN||genitalwarts-21/NNS	genitalwarts-21||hpv--1||no||long-term follow up is needed to evaluate the effect of early anti-hpv targeted prophylaxis on the development of skin and genitalwarts.
amod||factors-3/NNS||numerous-1/JJ	nn||factors-3/NNS||risk-2/NN	nsubjpass||established-11/VBN||factors-3/NNS	det||development-6/NN||the-5/DT	prep_for||factors-3/NNS||development-6/NN	prep_of||development-6/NN||gout-8/NN	aux||established-11/VBN||have-9/VBP	auxpass||established-11/VBN||been-10/VBN	root||ROOT-0/null||established-11/VBN	prep_including||established-11/VBN||hyperuricaemia-14/NN	amod||factors-17/NNS||genetic-16/JJ	prep_including||established-11/VBN||factors-17/NNS	conj_and||hyperuricaemia-14/NN||factors-17/NNS	amod||factors-20/NNS||dietary-19/JJ	prep_including||established-11/VBN||factors-20/NNS	conj_and||hyperuricaemia-14/NN||factors-20/NNS	nn||consumption-23/NN||alcohol-22/NN	prep_including||established-11/VBN||consumption-23/NN	conj_and||hyperuricaemia-14/NN||consumption-23/NN	amod||syndrome-26/NN||metabolic-25/JJ	prep_including||established-11/VBN||syndrome-26/NN	conj_and||hyperuricaemia-14/NN||syndrome-26/NN	prep_including||established-11/VBN||hypertension-28/NN	conj_and||hyperuricaemia-14/NN||hypertension-28/NN	prep_including||established-11/VBN||obesity-30/NN	conj_and||hyperuricaemia-14/NN||obesity-30/NN	amod||use-33/NN||diuretic-32/JJ	prep_including||established-11/VBN||use-33/NN	conj_and||hyperuricaemia-14/NN||use-33/NN	prep_including||established-11/VBN||chronicrenaldisease-35/NN	conj_and||hyperuricaemia-14/NN||chronicrenaldisease-35/NN	hyperuricaemia-14||diuretic-32||no_rel||numerous risk factors for the development of gout have been established, including hyperuricaemia, genetic factors, dietary factors, alcohol consumption, metabolic syndrome, hypertension, obesity, diuretic use and chronicrenaldisease.
num||lidocaine-3/NN||five-1/CD	nn||lidocaine-3/NN||percent-2/NN	nsubj||medicated-4/VBD||lidocaine-3/NN	root||ROOT-0/null||medicated-4/VBD	nsubj||efficacious-9/NNS||plaster-5/NN	aux||efficacious-9/NNS||has-6/VBZ	cop||efficacious-9/NNS||been-7/VBN	amod||efficacious-9/NNS||proven-8/VBN	ccomp||medicated-4/VBD||efficacious-9/NNS	det||relief-13/NN||the-11/DT	amod||relief-13/NN||symptomatic-12/JJ	prep_for||efficacious-9/NNS||relief-13/NN	prep_of||relief-13/NN||neuropathicpain-15/NN	amod||conditions-19/NNS||diverse-17/JJ	nn||conditions-19/NNS||pain-18/NN	prep_in||efficacious-9/NNS||conditions-19/NNS	nsubjpass||attributed-23/VBN||conditions-19/NNS	aux||attributed-23/VBN||might-21/MD	auxpass||attributed-23/VBN||be-22/VB	rcmod||conditions-19/NNS||attributed-23/VBN	det||symptomatology-28/NN||a-25/DT	amod||symptomatology-28/NN||common-26/JJ	amod||symptomatology-28/NN||localized-27/VBN	prep_to||attributed-23/VBN||symptomatology-28/NN	det||indications-31/NNS||these-30/DT	prep_in||symptomatology-28/NN||indications-31/NNS	advmod||attributed-23/VBN||possibly-33/RB	amod||predictors-36/NNS||common-35/JJ	prep_with||attributed-23/VBN||predictors-36/NNS	nn||success-39/NN||treatment-38/NN	prep_of||predictors-36/NNS||success-39/NN	pain-18||lidocaine-3||yes||five percent lidocaine medicated plaster has been proven efficacious for the symptomatic relief of neuropathicpain in diverse pain conditions which might be attributed to a common localized symptomatology in these indications, possibly with common predictors of treatment success.
csubj||frequency-13/NN||aa-1/VBN	aux||patients-4/VB||ca-3/MD	conj_and||aa-1/VBN||patients-4/VB	csubj||frequency-13/NN||patients-4/VB	dep||patients-4/VB||treated-5/VBN	amod||prostatectomy-8/NN||radical-7/JJ	prep_with||treated-5/VBN||prostatectomy-8/NN	appos||prostatectomy-8/NN||rp-10/NN	cop||frequency-13/NN||were-12/VBD	root||ROOT-0/null||frequency-13/NN	vmod||frequency-13/NN||matched-14/VBN	prep_for||matched-14/VBN||age-16/NN	prep_at||matched-14/VBN||rp-18/NN	nn||grade-21/NN||gleason-20/NN	prep_at||matched-14/VBN||grade-21/NN	conj_and||rp-18/NN||grade-21/NN	nn||stage-25/NN||tumor-24/NN	prep_at||matched-14/VBN||stage-25/NN	conj_and||rp-18/NN||stage-25/NN	ca-3||tumor-24||no_rel||aa and ca patients treated with radical prostatectomy (rp) were frequency matched for age at rp, gleason grade, and tumor stage.
det||possibility-2/NN||the-1/DT	nsubj||allow-14/VB||possibility-2/NN	nsubj||help-27/VB||possibility-2/NN	prepc_of||possibility-2/NN||extracting-4/VBG	dobj||extracting-4/VBG||rna-5/NN	prepc_of||possibility-2/NN||measuring-7/VBG	conj_and||extracting-4/VBG||measuring-7/VBG	nn||expression-9/NN||rna-8/NN	dobj||measuring-7/VBG||expression-9/NN	nn||sections-12/NNS||paraffin-11/NN	prep_from||measuring-7/VBG||sections-12/NNS	aux||allow-14/VB||can-13/MD	root||ROOT-0/null||allow-14/VB	amod||investigations-16/NNS||extensive-15/JJ	dobj||allow-14/VB||investigations-16/NNS	amod||samples-20/NNS||stored-18/JJ	nn||samples-20/NNS||paraffin-19/NN	prep_on||allow-14/VB||samples-20/NNS	vmod||samples-20/NNS||obtained-21/VBN	amod||livers-24/NNS||diseased-23/JJ	prep_from||obtained-21/VBN||livers-24/NNS	aux||help-27/VB||could-26/MD	conj_and||allow-14/VB||help-27/VB	conj_and||allow-14/VB||help-27/VB	conj_and||help-27/VB||help-27/VB	prep_with||help-27/VB||studies-29/NNS	det||history-33/NN||the-31/DT	amod||history-33/NN||natural-32/JJ	prep_of||studies-29/NNS||history-33/NN	nn||fibrosis-36/NN||liver-35/NN	prep_of||history-33/NN||fibrosis-36/NN	prep_of||history-33/NN||inflammation-38/NN	conj_and||fibrosis-36/NN||inflammation-38/NN	amod||mechanisms-46/NNS||particular-42/JJ	amod||mechanisms-46/NNS||correlate-44/JJ	amod||mechanisms-46/NNS||basic-45/JJ	prep_in||help-27/VB||mechanisms-46/NNS	amod||outcomes-49/NNS||clinical-48/JJ	prep_to||help-27/VB||outcomes-49/NNS	paraffin-19||inflammation-38||no_rel||the possibility of extracting rna and measuring rna expression from paraffin sections can allow extensive investigations on stored paraffin samples obtained from diseased livers and could help with studies of the natural history of liver fibrosis and inflammation, and in particular, correlate basic mechanisms to clinical outcomes.
advmod||8-6/CD||whenever-1/WRB	nn||score-3/NN||pain-2/NN	nsubj||8-6/CD||score-3/NN	cop||8-6/CD||was-4/VBD	number||8-6/CD||>-5/CD	advcl||given-15/VBN||8-6/CD	nn||mg.kgâ-9/NNP||0.5-8/NNP	nsubjpass||given-15/VBN||mg.kgâ-9/NNP	dep||mg.kgâ-9/NNP||1-11/CD	prep_of||mg.kgâ-9/NNP||pethidine-13/NN	auxpass||given-15/VBN||was-14/VBD	root||ROOT-0/null||given-15/VBN	advmod||given-15/VBN||intravenously-16/RB	nn||analgesia-19/NN||rescue-18/NN	prep_for||given-15/VBN||analgesia-19/NN	det||groups-22/NNS||both-21/DT	prep_in||analgesia-19/NN||groups-22/NNS	pain-2||pethidine-13||yes||whenever pain score was >8, 0.5mg.kgâ1 of pethidine was given intravenously for rescue analgesia in both groups.
advmod||assessing-2/VBG||when-1/WRB	advcl||predominated-17/VBD||assessing-2/VBG	amod||profiles-4/NNS||cytokine-3/JJ	dobj||assessing-2/VBG||profiles-4/NNS	amod||cells-10/NNS||ppd-6/JJ	amod||cells-10/NNS||specific-7/JJ	amod||cells-10/NNS||cd4-8/JJ	nn||cells-10/NNS||t-9/NN	nsubj||predominated-17/VBD||cells-10/NNS	vmod||cells-10/NNS||secreting-11/VBG	preconj||³-14/JJ||both-12/DT	amod||³-14/JJ||ifn-î-13/JJ	dobj||secreting-11/VBG||³-14/JJ	dobj||secreting-11/VBG||il-2-16/JJ	conj_and||³-14/JJ||il-2-16/JJ	root||ROOT-0/null||predominated-17/VBD	prepc_in||predominated-17/VBD||treated-19/VBN	dobj||treated-19/VBN||tb-20/NN	nn||infection-23/NN||latent-22/NN	dobj||treated-19/VBN||infection-23/NN	conj_and||tb-20/NN||infection-23/NN	dobj||treated-19/VBN||bcg-vaccination-25/NN	conj_and||tb-20/NN||bcg-vaccination-25/NN	mark||shifted-35/VBN||whilst-27/IN	amod||tb-30/NN||active-29/JJ	prep_in||shifted-35/VBN||tb-30/NN	det||profile-33/NN||the-31/DT	amod||profile-33/NN||cytokine-32/JJ	nsubjpass||shifted-35/VBN||profile-33/NN	auxpass||shifted-35/VBN||was-34/VBD	dep||treated-19/VBN||shifted-35/VBN	prep_towards||shifted-35/VBN||cells-37/NNS	xcomp||shifted-35/VBN||secreting-38/VBG	amod||³-40/NNS||ifn-î-39/JJ	dobj||secreting-38/VBG||³-40/NNS	advmod||secreting-38/VBG||only-41/RB	dep||secreting-38/VBG||p-43/NNP	number||0.0001-45/CD||<-44/CD	num||p-43/NNP||0.0001-45/CD	tb-30||bcg--1||yes||when assessing cytokine profiles, ppd specific cd4 t cells secreting both ifn-î³ and il-2 predominated in treated tb, latent infection and bcg-vaccination, whilst in active tb the cytokine profile was shifted towards cells secreting ifn-î³ only (p<0.0001).
det||consequence-3/NN||a-2/DT	prep_as||display-15/VBP||consequence-3/NN	det||reduction-6/NN||the-5/DT	prep_of||consequence-3/NN||reduction-6/NN	amod||currents-10/NNS||ttx-r-8/JJ	amod||currents-10/NNS||vgsc-9/JJ	prep_of||reduction-6/NN||currents-10/NNS	amod||mice-14/NNS||t-mrvia-12/JJ	amod||mice-14/NNS||transgenic-13/JJ	nsubj||display-15/VBP||mice-14/NNS	root||ROOT-0/null||display-15/VBP	ccomp||display-15/VBP||decreased-16/VBD	amod||hypersensitivity-19/NN||inflammatory-17/JJ	amod||hypersensitivity-19/NN||mechanical-18/JJ	dobj||decreased-16/VBD||hypersensitivity-19/NN	amod||insensitivity-23/NN||cold-21/JJ	nn||insensitivity-23/NN||pain-22/NN	dobj||decreased-16/VBD||insensitivity-23/NN	conj_and||hypersensitivity-19/NN||insensitivity-23/NN	amod||firing-26/NN||reduced-25/VBN	dobj||decreased-16/VBD||firing-26/NN	conj_and||hypersensitivity-19/NN||firing-26/NN	amod||c-fibres-29/NNS||cutaneous-28/JJ	prep_of||firing-26/NN||c-fibres-29/NNS	amod||c-fibres-29/NNS||sensitive-30/JJ	amod||temperatures-34/NNS||noxious-32/JJ	amod||temperatures-34/NNS||cold-33/JJ	prep_to||sensitive-30/JJ||temperatures-34/NNS	hypersensitivity-19||fibres--1||no||as a consequence of the reduction of ttx-r vgsc currents, t-mrvia transgenic mice display decreased inflammatory mechanical hypersensitivity, cold pain insensitivity and reduced firing of cutaneous c-fibres sensitive to noxious cold temperatures.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||simplify-8/VB||to-7/TO	dep||was-6/VBD||simplify-8/VB	det||test-16/NN||the-9/DT	amod||test-16/NN||intravenous-10/JJ	amod||test-16/NN||gonadotropin-releasinghormone-11/JJ	appos||test-16/NN||gnrh-13/NN	nn||test-16/NN||stimulation-15/NN	dobj||simplify-8/VB||test-16/NN	det||diagnosis-19/NN||the-18/DT	prep_in||test-16/NN||diagnosis-19/NN	prep_of||diagnosis-19/NN||precociouspuberty-21/NN	dep||was-6/VBD||in-23/IN	conj_and||simplify-8/VB||in-23/IN	det||assessment-25/NN||the-24/DT	pobj||in-23/IN||assessment-25/NN	amod||suppression-28/NN||pubertal-27/JJ	prep_of||assessment-25/NN||suppression-28/NN	precociouspuberty-21||gnrh-13||yes||the aim of this study was to simplify the intravenous gonadotropin-releasinghormone (gnrh) stimulation test in the diagnosis of precociouspuberty and in the assessment of pubertal suppression.
amod||sbp-2/NN||mean-1/JJ	nsubj||predictive-7/JJ||sbp-2/NN	conj_and||sbp-2/NN||sd.sbp-4/NN	nsubj||predictive-7/JJ||sd.sbp-4/NN	cop||predictive-7/JJ||were-5/VBD	advmod||predictive-7/JJ||independently-6/RB	root||ROOT-0/null||predictive-7/JJ	prep_of||predictive-7/JJ||albuminuria-9/NN	nn||ratio-12/NN||odds-11/NNS	dep||albuminuria-9/NN||ratio-12/NN	num||-LSB--14/NNS||1.005-13/CD	dep||ratio-12/NN||-LSB--14/NNS	number||%-16/NN||95-15/CD	amod||-LSB--14/NNS||%-16/NN	advmod||-LSB--14/NNS||ci-17/RB	num||â-19/NN||1.002-18/CD	pobj||ci-17/RB||â-19/NN	num||-RSB--23/NNS||$-20/$	num||$-20/$||1.008-22/CD	dep||-LSB--14/NNS||-RSB--23/NNS	dep||-LSB--14/NNS||p-25/FW	punct||0.001-27/CD||<-26/``	dep||-LSB--14/NNS||0.001-27/CD	num||-RSB--36/NNS||1.093-29/CD	number||1.069-31/CD||-LSB--30/CD	num||-RSB--36/NNS||1.069-31/CD	amod||-RSB--36/NNS||â-32/JJ	num||-RSB--36/NNS||$-33/$	num||$-33/$||1.117-35/CD	dep||-LSB--14/NNS||-RSB--36/NNS	conj_and||0.001-27/CD||-RSB--36/NNS	dep||0.001-27/CD||p-38/FW	dep||0.001-27/CD||<-39/NNP	num||<-39/NNP||0.001-40/CD	advmod||<-39/NNP||respectively-42/RB	num||change-47/NN||1-45/CD	nn||change-47/NN||mmhg-46/NN	prep_for||-LSB--14/NNS||change-47/NN	mark||add-55/VB||although-50/IN	nsubj||add-55/VB||sbp-51/PRP	nsubj||mean-57/VB||sbp-51/PRP	advmod||add-55/VB||variability-52/RB	aux||add-55/VB||did-53/VBD	neg||add-55/VB||not-54/RB	advcl||predictive-7/JJ||add-55/VB	aux||mean-57/VB||to-56/TO	xcomp||add-55/VB||mean-57/VB	dobj||mean-57/VB||sbp-58/NN	prepc_in||mean-57/VB||predicting-60/VBG	advmod||predicting-60/VBG||retinopathy-61/RB	num||-RSB--70/NNS||0.999-63/CD	number||0.985-65/CD||-LSB--64/CD	num||-RSB--70/NNS||0.985-65/CD	amod||-RSB--70/NNS||â-66/JJ	num||-RSB--70/NNS||$-67/$	num||$-67/$||1.013-69/CD	dep||mean-57/VB||-RSB--70/NNS	nn||0.93-74/NN||p-72/FW	nn||0.93-74/NN||=-73/FW	appos||-RSB--70/NNS||0.93-74/NN	add-55||retinopathy-61||no_rel||mean sbp and sd.sbp were independently predictive of albuminuria (odds ratio 1.005 [95% ci 1.002â1.008], p < 0.001 and 1.093 [1.069â1.117], p < 0.001, respectively, for 1 mmhg change), although sbp variability did not add to mean sbp in predicting retinopathy (0.999 [0.985â1.013], p = 0.93).
nsubj||classified-9/VBD||two-thirds-1/NNS	det||plhiv-4/NN||the-3/DT	prep_of||two-thirds-1/NNS||plhiv-4/NN	num||%-7/NN||66-6/CD	appos||plhiv-4/NN||%-7/NN	root||ROOT-0/null||classified-9/VBD	dobj||classified-9/VBD||themselves-10/PRP	auxpass||given-13/VBN||being-12/VBG	prepc_with||classified-9/VBD||given-13/VBN	det||aids-15/NNS||an-14/DT	iobj||given-13/VBN||aids-15/NNS	amod||stage-18/NN||advanced-17/JJ	dep||aids-15/NNS||stage-18/NN	prep_of||stage-18/NN||hiv-20/NN	dobj||given-13/VBN||diagnosis-22/NN	num||%-25/NN||48-24/CD	nsubj||were-26/VBD||%-25/NN	ccomp||classified-9/VBD||were-26/VBD	conj_and||classified-9/VBD||were-26/VBD	advmod||were-26/VBD||currently-27/RB	prep_on||were-26/VBD||art-29/NN	num||%-32/NN||35-31/CD	nsubj||were-33/VBD||%-32/NN	conj_and||classified-9/VBD||were-33/VBD	advmod||were-33/VBD||currently-34/RB	det||grant-38/NN||a-36/DT	nn||grant-38/NN||disability-37/NN	prep_on||were-33/VBD||grant-38/NN	prep_for||grant-38/NN||hiv/aids-40/NNS	num||%-44/NN||13-43/CD	prep_for||stopped-50/VBN||%-44/NN	det||grant-47/NN||the-45/DT	nn||grant-47/NN||disability-46/NN	nsubjpass||stopped-50/VBN||grant-47/NN	aux||stopped-50/VBN||had-48/VBD	auxpass||stopped-50/VBN||been-49/VBN	conj_and||classified-9/VBD||stopped-50/VBN	aids-15||hiv-20||no||two-thirds of the plhiv (66%) classified themselves with being given an aids (advanced stage of hiv) diagnosis, 48% were currently on art, 35% were currently on a disability grant for hiv/aids and for 13% the disability grant had been stopped.
amod||practices-3/NNS||unsafe-1/JJ	nn||practices-3/NNS||injection-2/NN	nsubj||prevalent-5/JJ||practices-3/NNS	nsubj||resulted-15/VBN||practices-3/NNS	cop||prevalent-5/JJ||are-4/VBP	root||ROOT-0/null||prevalent-5/JJ	nn||users-9/NNS||injection-7/NN	nn||users-9/NNS||drug-8/NN	prep_among||prevalent-5/JJ||users-9/NNS	appos||users-9/NNS||idu-11/NN	aux||resulted-15/VBN||have-14/VBP	conj_and||prevalent-5/JJ||resulted-15/VBN	amod||forms-18/NNS||numerous-17/JJ	prep_in||resulted-15/VBN||forms-18/NNS	amod||harm-21/NN||drug-related-20/JJ	prep_of||forms-18/NNS||harm-21/NN	amod||transmission-24/NN||hiv/hcv-23/JJ	prep_including||harm-21/NN||transmission-24/NN	amod||bacterial-27/NNS||other-26/JJ	prep_including||harm-21/NN||bacterial-27/NNS	conj_and||transmission-24/NN||bacterial-27/NNS	conj_and||transmission-24/NN||viralinfections-29/NNS	conj_and||bacterial-27/NNS||viralinfections-29/NNS	viralinfections-29||idu-11||yes||unsafe injection practices are prevalent among injection drug users (idu) and have resulted in numerous forms of drug-related harm including hiv/hcv transmission and other bacterial and viralinfections.
nsubj||represents-5/VBZ||culture-1/NN	prep_of||culture-1/NN||mycobacteriumtuberculosis-3/NNS	advmod||represents-5/VBZ||currently-4/RB	root||ROOT-0/null||represents-5/VBZ	det||â-8/NN||the-6/DT	amod||â-8/NN||closest-7/JJS	dobj||represents-5/VBZ||â-8/NN	amod||â-8/NN||$-9/$	dep||$-9/$||gold-10/JJ	vmod||â-8/NN||standardâ-11/VBG	dobj||standardâ-11/VBG||$-12/$	quantmod||diagnosis-14/CD||for-13/IN	num||$-12/$||diagnosis-14/CD	prep_of||$-12/$||tuberculosis-16/NNP	appos||â-8/NN||tb-18/NN	amod||data-23/NNS||operational-22/JJ	nsubj||scant-25/JJ||data-23/NNS	cop||scant-25/JJ||are-24/VBP	conj_but||represents-5/VBZ||scant-25/JJ	det||impact-28/NN||the-27/DT	prep_on||scant-25/JJ||impact-28/NN	prep_on||scant-25/JJ||cost-effectiveness-30/NNS	conj_and||impact-28/NN||cost-effectiveness-30/NNS	nn||culture-33/NN||tb-32/NN	prep_of||impact-28/NN||culture-33/NN	amod||immunodeficiency-36/NN||human-35/JJ	prep_for||culture-33/NN||immunodeficiency-36/NN	dep||scant-25/JJ||hiv-38/RB	amod||individuals-42/NNS||infected-41/JJ	npadvmod||scant-25/JJ||individuals-42/NNS	amod||settings-45/NNS||resource-limited-44/JJ	prep_in||scant-25/JJ||settings-45/NNS	tb-32||mycobacteriumtuberculosis-3||no||culture of mycobacteriumtuberculosis currently represents the closest âgold standardâ? for diagnosis of tuberculosis (tb), but operational data are scant on the impact and cost-effectiveness of tb culture for human immunodeficiency (hiv-) infected individuals in resource-limited settings.
preconj||artemether-2/NN||both-1/DT	nsubjpass||shown-7/VBN||artemether-2/NN	nsubj||superior-10/JJ||artemether-2/NN	nsubj||quinine-12/VB||artemether-2/NN	conj_and||artemether-2/NN||artesunate-4/NN	nsubjpass||shown-7/VBN||artesunate-4/NN	nsubj||superior-10/JJ||artesunate-4/NN	nsubj||quinine-12/VB||artesunate-4/NN	aux||shown-7/VBN||have-5/VBP	auxpass||shown-7/VBN||been-6/VBN	root||ROOT-0/null||shown-7/VBN	aux||superior-10/JJ||to-8/TO	cop||superior-10/JJ||be-9/VB	xcomp||shown-7/VBN||superior-10/JJ	aux||quinine-12/VB||to-11/TO	xcomp||superior-10/JJ||quinine-12/VB	det||treatment-15/NN||the-14/DT	prep_for||quinine-12/VB||treatment-15/NN	amod||falciparummalaria-18/NN||severe-17/JJ	prep_of||treatment-15/NN||falciparummalaria-18/NN	nn||adults-22/NNS||southeast-20/NN	nn||adults-22/NNS||asian-21/NN	prep_in||quinine-12/VB||adults-22/NNS	mark||greater-32/JJR||although-24/IN	det||magnitude-26/NN||the-25/DT	nsubj||greater-32/JJR||magnitude-26/NN	det||superiority-29/NN||the-28/DT	prep_of||magnitude-26/NN||superiority-29/NN	aux||greater-32/JJR||has-30/VBZ	cop||greater-32/JJR||been-31/VBN	advcl||quinine-12/VB||greater-32/JJR	prep_for||greater-32/JJR||artesunate-34/NN	prep_than||greater-32/JJR||artemether-36/NN	falciparummalaria-18||quinine-12||yes||both artemether and artesunate have been shown to be superior to quinine for the treatment of severe falciparummalaria in southeast asian adults, although the magnitude of the superiority has been greater for artesunate than artemether.
nn||cells-2/NNS||cancer-1/NN	nsubj||utilize-4/VB||cells-2/NNS	advmod||utilize-4/VB||predominantly-3/RB	root||ROOT-0/null||utilize-4/VB	dobj||utilize-4/VB||glycolysis-5/NNS	nn||production-8/NN||atp-7/NN	prep_for||glycolysis-5/NNS||production-8/NN	advmod||utilize-4/VB||even-9/RB	det||presence-12/NN||the-11/DT	prep_in||utilize-4/VB||presence-12/NN	amod||oxygen-15/NN||abundant-14/JJ	prep_of||presence-12/NN||oxygen-15/NN	det||environment-18/NN||an-17/DT	dobj||utilize-4/VB||environment-18/NN	nsubj||result-22/VB||environment-18/NN	aux||result-22/VB||would-20/MD	advmod||result-22/VB||normally-21/RB	rcmod||environment-18/NN||result-22/VB	nn||production-25/NN||energy-24/NN	prep_in||result-22/VB||production-25/NN	amod||phosphorylation-28/NN||oxidative-27/JJ	prep_through||result-22/VB||phosphorylation-28/NN	atp-7||cancer-1||no_rel||cancer cells predominantly utilize glycolysis for atp production even in the presence of abundant oxygen, an environment that would normally result in energy production through oxidative phosphorylation.
nsubj||reduced-6/VBD||use-1/NN	det||test-5/NN||the-3/DT	nn||test-5/NN||mtb/rif-4/NN	prep_of||use-1/NN||test-5/NN	root||ROOT-0/null||reduced-6/VBD	amod||time-8/NN||median-7/JJ	dobj||reduced-6/VBD||time-8/NN	prep_to||reduced-6/VBD||treatment-10/NN	amod||tuberculosis-13/NNP||smear-negative-12/JJ	prep_for||treatment-10/NN||tuberculosis-13/NNP	num||days-16/NNS||56-15/CD	prep_from||reduced-6/VBD||days-16/NNS	appos||days-16/NNS||39â-18/NNP	num||39â-18/NNP||$-19/$	num||$-19/$||81-21/CD	dep||days-16/NNS||to-23/TO	num||days-25/NNS||5-24/CD	dep||days-16/NNS||days-25/NNS	appos||days-25/NNS||2â-27/NNP	num||2â-27/NNP||$-28/$	num||$-28/$||8-30/CD	tuberculosis-13||rif--1||yes||use of the mtb/rif test reduced median time to treatment for smear-negative tuberculosis from 56 days (39â81) to 5 days (2â8).
det||study-2/NN||this-1/DT	nsubj||shows-3/VBZ||study-2/NN	root||ROOT-0/null||shows-3/VBZ	mark||are-36/VBP||that-4/IN	advmod||established-9/VBN||when-5/WRB	det||collaboration-7/NN||a-6/DT	nsubjpass||established-9/VBN||collaboration-7/NN	nsubj||strengthen-11/VB||collaboration-7/NN	auxpass||established-9/VBN||is-8/VBZ	advcl||are-36/VBP||established-9/VBN	aux||strengthen-11/VB||to-10/TO	xcomp||established-9/VBN||strengthen-11/VB	amod||systems-14/NNS||existing-12/JJ	nn||systems-14/NNS||health-13/NN	dobj||strengthen-11/VB||systems-14/NNS	prepc_in_addition_to||established-9/VBN||providing-19/VBG	amod||services-21/NNS||hiv/aids-20/JJ	dobj||providing-19/VBG||services-21/NNS	det||setting-24/NN||a-23/DT	prep_in||providing-19/VBG||setting-24/NN	prep_in||delivered-33/VBN||setting-24/NN	amod||care-30/NN||other-27/JJ	amod||care-30/NN||primary-28/JJ	nn||care-30/NN||health-29/NN	nsubjpass||delivered-33/VBN||care-30/NN	aux||delivered-33/VBN||is-31/VBZ	auxpass||delivered-33/VBN||being-32/VBG	rcmod||setting-24/NN||delivered-33/VBN	expl||are-36/VBP||there-35/EX	ccomp||shows-3/VBZ||are-36/VBP	amod||effects-38/NNS||positive-37/JJ	nsubj||are-36/VBP||effects-38/NNS	neg||only-40/JJ||not-39/RB	preconj||are-36/VBP||only-40/JJ	amod||services-43/NNS||hiv/aids-42/JJ	prep_on||are-36/VBP||services-43/NNS	amod||services-51/NNS||many-48/JJ	amod||services-51/NNS||other-49/JJ	amod||services-51/NNS||essential-50/JJ	prep_on||are-36/VBP||services-51/NNS	conj_and||services-43/NNS||services-51/NNS	aids--1||hiv--1||no||this study shows that when a collaboration is established to strengthen existing health systems, in addition to providing hiv/aids services in a setting in which other primary health care is being delivered, there are positive effects not only on hiv/aids services, but also on many other essential services.
nn||patients-2/NNS||tb-1/NN	prep_for||%-13/NN||patients-2/NNS	nsubjpass||found-28/VBN||patients-2/NNS	nsubj||population-34/NN||patients-2/NNS	det||prevalence-8/NN||the-6/DT	nn||prevalence-8/NN||summary-7/NN	nsubj||%-13/NN||prevalence-8/NN	prep_of||prevalence-8/NN||hivinfection-10/NN	cop||%-13/NN||was-11/VBD	number||%-13/NN||0.9-12/CD	rcmod||patients-2/NNS||%-13/NN	num||%-16/NN||0.6-15/CD	npadvmod||â-17/RB||%-16/NN	dep||%-21/NN||â-17/RB	dep||%-21/NN||$-18/$	num||$-18/$||1.4-20/CD	dep||%-13/NN||%-21/NN	amod||china-25/NN||mainland-24/JJ	prep_in||%-13/NN||china-25/NN	auxpass||found-28/VBN||were-27/VBD	root||ROOT-0/null||found-28/VBN	aux||population-34/NN||to-29/TO	cop||population-34/NN||be-30/VB	det||population-34/NN||a-31/DT	amod||population-34/NN||potential-32/JJ	nn||population-34/NN||target-33/NN	xcomp||found-28/VBN||population-34/NN	nn||screening-37/NN||hiv-36/NN	prep_for||population-34/NN||screening-37/NN	hivinfection-10||hiv-36||no||tb patients, for whom the summary prevalence of hivinfection was 0.9% (0.6%â1.4%) in mainland china, were found to be a potential target population for hiv screening.
det||report-3/NN||this-1/DT	nn||report-3/NN||case-2/NN	nsubj||demonstrates-4/VBZ||report-3/NN	root||ROOT-0/null||demonstrates-4/VBZ	det||response-7/NN||a-5/DT	amod||response-7/NN||satisfying-6/JJ	nsubj||had-24/VBD||response-7/NN	nsubjpass||discontinued-27/VBN||response-7/NN	aux||topiramate-9/VB||to-8/TO	vmod||response-7/NN||topiramate-9/VB	det||patient-13/NN||a-11/DT	amod||patient-13/NN||79-year-old-12/JJ	prep_in||topiramate-9/VB||patient-13/NN	amod||essentialtremor-16/NN||disabling-15/VBG	prep_with||topiramate-9/VB||essentialtremor-16/NN	nsubj||propranolol-19/VBP||whom-18/WP	nsubj||primidone-23/VBP||whom-18/WP	prepc_in||essentialtremor-16/NN||propranolol-19/VBP	prepc_in||essentialtremor-16/NN||primidone-23/VBP	conj_and||propranolol-19/VBP||primidone-23/VBP	ccomp||demonstrates-4/VBZ||had-24/VBD	aux||discontinued-27/VBN||to-25/TO	auxpass||discontinued-27/VBN||be-26/VB	xcomp||had-24/VBD||discontinued-27/VBN	xcomp||discontinued-27/VBN||due-28/JJ	amod||effects-32/NNS||severe-30/JJ	nn||effects-32/NNS||side-31/NN	prep_to||due-28/JJ||effects-32/NNS	essentialtremor-16||propranolol-19||yes||this case report demonstrates a satisfying response to topiramate in a 79-year-old patient with disabling essentialtremor in whom propranolol as well as primidone had to be discontinued due to severe side effects.
nsubjpass||performed-3/VBN||bioassay-1/NN	auxpass||performed-3/VBN||were-2/VBD	root||ROOT-0/null||performed-3/VBN	prep_on||performed-3/VBN||adults-5/NNS	vmod||adults-5/NNS||collected-6/VBN	det||field-9/NN||the-8/DT	prep_from||collected-6/VBN||field-9/NN	aux||assess-11/VB||to-10/TO	xcomp||collected-6/VBN||assess-11/VB	det||susceptibility-13/NN||the-12/DT	dobj||assess-11/VB||susceptibility-13/NN	nn||vectors-16/NNS||malaria-15/NN	prep_of||susceptibility-13/NN||vectors-16/NNS	amod||papers-19/NNS||insecticide-impregnated-18/JJ	prep_to||assess-11/VB||papers-19/NNS	dep||performed-3/VBN||permethrin-21/VB	num||%-23/NN||0.75-22/CD	dobj||permethrin-21/VB||%-23/NN	dep||performed-3/VBN||delthamethrin-25/VB	conj_and||permethrin-21/VB||delthamethrin-25/VB	num||%-27/NN||0.05-26/CD	dobj||delthamethrin-25/VB||%-27/NN	dep||performed-3/VBN||ddt-29/VB	conj_and||permethrin-21/VB||ddt-29/VB	num||%-31/NN||4-30/CD	dobj||ddt-29/VB||%-31/NN	dep||performed-3/VBN||bendiocarb-34/VB	conj_and||permethrin-21/VB||bendiocarb-34/VB	num||%-36/NN||0.1-35/CD	dobj||bendiocarb-34/VB||%-36/NN	amod||guidelines-40/NNS||whopes-39/JJ	prep_following||performed-3/VBN||guidelines-40/NNS	permethrin-21||malaria-15||no_rel||bioassay were performed on adults collected from the field to assess the susceptibility of malaria vectors to insecticide-impregnated papers (permethrin 0.75%, delthamethrin 0.05%, ddt 4%, and bendiocarb 0.1%) following whopes guidelines.
amod||mg-3/NN||tegaserod-1/JJ	dep||tegaserod-1/JJ||6-2/CD	nsubj||improved-7/VBD||mg-3/NN	vmod||mg-3/NN||given-4/VBN	advmod||given-4/VBN||twice-5/RB	advmod||improved-7/VBD||daily-6/RB	root||ROOT-0/null||improved-7/VBD	det||qol-9/NN||the-8/DT	dobj||improved-7/VBD||qol-9/NN	det||symptoms-15/NNS||the-13/DT	nn||symptoms-15/NNS||bowel-14/NN	dobj||improved-7/VBD||symptoms-15/NNS	conj_and||qol-9/NN||symptoms-15/NNS	amod||patients-20/NNS||korean-17/JJ	amod||patients-20/NNS||female-18/JJ	nn||patients-20/NNS||ibs-19/NN	prep_in||improved-7/VBD||patients-20/NNS	prep_with||patients-20/NNS||constipation-22/NN	constipation-22||tegaserod-1||yes||tegaserod 6 mg given twice daily improved the qol as well as the bowel symptoms in korean female ibs patients with constipation.
amod||artesunate-2/NN||monthly-1/JJ	nsubj||reduced-5/VBD||artesunate-2/NN	prep||artesunate-2/NN||plus-3/CC	pobj||plus-3/CC||amodiaquine-4/NN	root||ROOT-0/null||reduced-5/VBD	det||incidence-7/NN||the-6/DT	dobj||reduced-5/VBD||incidence-7/NN	prep_of||incidence-7/NN||malaria-9/NN	num||%-12/NN||69-11/CD	prep_by||reduced-5/VBD||%-12/NN	number||%-15/NN||95-14/CD	amod||ci-16/NN||%-15/NN	dep||%-12/NN||ci-16/NN	number||%-18/NN||63-17/CD	amod||ci-16/NN||%-18/NN	num||%-21/NN||74-20/CD	appos||ci-16/NN||%-21/NN	prep_by||reduced-5/VBD||anaemia-24/NN	conj_and||%-12/NN||anaemia-24/NN	num||%-27/NN||45-26/CD	prep_by||reduced-5/VBD||%-27/NN	number||%-30/NN||95-29/CD	amod||ci-31/NN||%-30/NN	dep||%-27/NN||ci-31/NN	number||%-33/NN||25-32/CD	amod||ci-31/NN||%-33/NN	num||%-35/NN||,60-34/CD	dep||ci-31/NN||%-35/NN	amod||sulphadoxine-pyrimethamine-39/NN||bimonthly-38/JJ	nsubj||reduced-40/VBD||sulphadoxine-pyrimethamine-39/NN	conj_and||reduced-5/VBD||reduced-40/VBD	det||incidence-42/NN||the-41/DT	dobj||reduced-40/VBD||incidence-42/NN	prep_of||incidence-42/NN||malaria-44/NN	num||%-47/NN||24-46/CD	prep_by||reduced-40/VBD||%-47/NN	number||%-50/NN||95-49/CD	amod||ci-51/NN||%-50/NN	dep||%-47/NN||ci-51/NN	number||%-53/NN||14-52/CD	amod||ci-51/NN||%-53/NN	num||%-55/NN||,33-54/CD	dep||ci-51/NN||%-55/NN	prep_by||reduced-40/VBD||anaemia-58/NN	conj_and||%-47/NN||anaemia-58/NN	num||%-61/NN||30-60/CD	prep_by||reduced-40/VBD||%-61/NN	number||%-64/NN||95-63/CD	amod||ci-65/NN||%-64/NN	dep||%-61/NN||ci-65/NN	number||%-67/NN||6-66/CD	amod||ci-65/NN||%-67/NN	num||%-70/NN||49-69/CD	appos||ci-65/NN||%-70/NN	amod||artesunate-74/NN||bimonthly-73/JJ	nsubj||reduced-77/VBD||artesunate-74/NN	prep||artesunate-74/NN||plus-75/CC	pobj||plus-75/CC||amodiaquine-76/NN	conj_and||reduced-5/VBD||reduced-77/VBD	det||incidence-79/NN||the-78/DT	dobj||reduced-77/VBD||incidence-79/NN	prep_of||incidence-79/NN||malaria-81/NN	num||%-84/NN||17-83/CD	prep_by||reduced-77/VBD||%-84/NN	number||%-87/NN||95-86/CD	amod||ci-88/NN||%-87/NN	dep||%-84/NN||ci-88/NN	number||%-90/NN||6-89/CD	amod||ci-88/NN||%-90/NN	num||%-93/NN||27-92/CD	appos||ci-88/NN||%-93/NN	prep_by||reduced-77/VBD||anaemia-96/NN	conj_and||%-84/NN||anaemia-96/NN	num||%-99/NN||32-98/CD	prep_by||reduced-77/VBD||%-99/NN	number||%-102/NN||95-101/CD	amod||ci-103/NN||%-102/NN	dep||%-99/NN||ci-103/NN	number||%-105/NN||7-104/CD	amod||ci-103/NN||%-105/NN	num||%-108/NN||50-107/CD	appos||ci-103/NN||%-108/NN	prepc_compared_to||reduced-77/VBD||to-111/TO	pobj||reduced-77/VBD||placebo-112/NN	malaria-81||pyrimethamine--1||yes||monthly artesunate plus amodiaquine reduced the incidence of malaria by 69% (95% ci 63%, 74%) and anaemia by 45% (95% ci 25%,60%), bimonthly sulphadoxine-pyrimethamine reduced the incidence of malaria by 24% (95% ci 14%,33%) and anaemia by 30% (95% ci 6%, 49%) and bimonthly artesunate plus amodiaquine reduced the incidence of malaria by 17% (95% ci 6%, 27%) and anaemia by 32% (95% ci 7%, 50%) compared to placebo.
nsubj||exist-2/VBP||differences-1/NNS	root||ROOT-0/null||exist-2/VBP	nn||recommendations-5/NNS||treatment-4/NN	prep_between||exist-2/VBP||recommendations-5/NNS	det||choice-8/NN||the-7/DT	prep_regarding||recommendations-5/NNS||choice-8/NN	prep_of||choice-8/NN||metformin-10/NN	amod||therapy-13/NN||first-line-12/JJ	prep_as||metformin-10/NN||therapy-13/NN	amod||patients-16/NNS||type2diabetes-15/JJ	prep_for||therapy-13/NN||patients-16/NNS	prepc_according_to||exist-2/VBP||to-18/TO	nn||index-21/NN||body-19/NN	nn||index-21/NN||mass-20/NN	pobj||exist-2/VBP||index-21/NN	appos||index-21/NN||bmi-23/NN	type2diabetes-15||metformin-10||yes||differences exist between treatment recommendations regarding the choice of metformin as first-line therapy for type2diabetes patients according to body mass index (bmi).
det||study-9/NN||a-1/DT	amod||double-blind-8/JJ||4-week-2/JJ	amod||double-blind-8/JJ||multicentre-4/JJ	amod||double-blind-8/JJ||randomised-6/JJ	amod||study-9/NN||double-blind-8/JJ	nsubj||compared-11/VBN||study-9/NN	aux||compared-11/VBN||has-10/VBZ	root||ROOT-0/null||compared-11/VBN	det||effects-13/NNS||the-12/DT	dobj||compared-11/VBN||effects-13/NNS	nn||mg-17/NN||lumiracoxib-15/NN	num||mg-17/NN||100-16/CD	prep_of||effects-13/NNS||mg-17/NN	advmod||od-21/NN||once-18/RB	amod||od-21/NN||daily-19/JJ	dep||mg-17/NN||od-21/NN	dep||mg-17/NN||n-24/VBN	dep||394-26/NNS||=-25/SYM	ccomp||n-24/VBN||394-26/NNS	prep_of||effects-13/NNS||ibuprofen-29/NN	conj_and||mg-17/NN||ibuprofen-29/NN	num||ibuprofen-29/NN||600-30/CD	vmod||ibuprofen-29/NN||mg-31/VBN	num||times-33/NNS||three-32/CD	dobj||mg-31/VBN||times-33/NNS	advmod||times-33/NNS||daily-34/RB	appos||ibuprofen-29/NN||tid-36/NN	dep||effects-13/NNS||n-39/VBN	dep||393-41/CD||=-40/SYM	ccomp||n-39/VBN||393-41/CD	amod||bp-45/NN||ambulatory-44/JJ	prep_on||compared-11/VBN||bp-45/NN	amod||patients-51/NNS||osteoarthritis-47/JJ	appos||patients-51/NNS||oa-49/NN	prep_in||bp-45/NN||patients-51/NNS	amod||hypertension-54/NN||controlled-53/JJ	prep_with||bp-45/NN||hypertension-54/NN	oa-49||ibuprofen-29||yes||a 4-week, multicentre, randomised, double-blind study has compared the effects of lumiracoxib 100 mg once daily (od) ( n = 394) and ibuprofen 600 mg three times daily (tid) ( n = 393) on ambulatory bp in osteoarthritis (oa) patients with controlled hypertension.
nsubj||genotyped-2/VBD||we-1/PRP	root||ROOT-0/null||genotyped-2/VBD	num||type2diabetesâ-4/NNS||34-3/CD	dobj||genotyped-2/VBD||type2diabetesâ-4/NNS	prep||type2diabetesâ-4/NNS||$-5/$	advmod||in-9/IN||associated-7/RB	npadvmod||in-9/IN||variants-8/NNS	dep||2,843-10/CD||in-9/IN	num||$-5/$||2,843-10/CD	nn||participants-12/NNS||dpp-11/NN	dep||$-5/$||participants-12/NNS	amod||risk-15/NN||high-14/JJ	prep_at||participants-12/NNS||risk-15/NN	amod||representative-22/NN||type2diabetes-17/JJ	num||groups-21/NNS||five-19/CD	amod||groups-21/NNS||ethnic-20/JJ	prep_from||type2diabetes-17/JJ||groups-21/NNS	prep_of||risk-15/NN||representative-22/NN	nsubjpass||randomized-31/VBN||representative-22/NN	det||population-26/NN||the-24/DT	nn||population-26/NN||u.s.-25/NN	prep_of||representative-22/NN||population-26/NN	aux||randomized-31/VBN||had-29/VBD	auxpass||randomized-31/VBN||been-30/VBN	rcmod||representative-22/NN||randomized-31/VBN	nn||metformin-35/NN||placebo-33/NN	prep_to||randomized-31/VBN||metformin-35/NN	nn||intervention-39/NN||lifestyle-38/NN	prep_to||randomized-31/VBN||intervention-39/NN	conj_or||metformin-35/NN||intervention-39/NN	type2diabetes-17||metformin-35||yes||we genotyped 34 type2diabetesâ $ `` associated variants in 2,843 dpp participants at high risk of type2diabetes from five ethnic groups representative of the u.s. population , who had been randomized to placebo , metformin , or lifestyle intervention .
advmod||remain-4/VBP||nevertheless-1/RB	nsubj||remain-4/VBP||hiv/aids-3/NNS	root||ROOT-0/null||remain-4/VBP	det||threat-7/NN||a-5/DT	amod||threat-7/NN||serious-6/JJ	xcomp||remain-4/VBP||threat-7/NN	nn||health-10/NN||population-9/NN	prep_to||remain-4/VBP||health-10/NN	prep_to||remain-4/VBP||economic-12/JJ	conj_and||health-10/NN||economic-12/JJ	advmod||remain-4/VBP||well-13/RB	dep||well-13/RB||being-14/VBG	det||region-17/NN||this-16/DT	prep_in||being-14/VBG||region-17/NN	aids--1||hiv--1||no||nevertheless, hiv/aids remain a serious threat to population health and economic well being in this region.
amod||â-2/NN||objective-1/JJ	nsubj||was-10/VBD||â-2/NN	nsubj||determine-12/VB||â-2/NN	dep||â-2/NN||$-3/$	det||purpose-6/NN||the-5/DT	dep||â-2/NN||purpose-6/NN	det||study-9/NN||this-8/DT	prep_of||purpose-6/NN||study-9/NN	root||ROOT-0/null||was-10/VBD	aux||determine-12/VB||to-11/TO	xcomp||was-10/VBD||determine-12/VB	det||associations-14/NNS||the-13/DT	dobj||determine-12/VB||associations-14/NNS	amod||distress-18/NN||diabetes-related-16/JJ	nn||distress-18/NN||symptom-17/NN	prep_between||associations-14/NNS||distress-18/NN	nn||status-22/NN||glucose-20/NN	nn||status-22/NN||metabolism-21/NN	prep_between||associations-14/NNS||status-22/NN	conj_and||distress-18/NN||status-22/NN	prep_between||associations-14/NNS||comorbidities-25/NNS	conj_and||distress-18/NN||comorbidities-25/NNS	prep_of||comorbidities-25/NNS||type2diabetes-27/CD	glucose-20||type2diabetes-27||no_rel||objective âthe purpose of this study was to determine the associations between diabetes-related symptom distress, glucose metabolism status, and comorbidities of type2diabetes.
prep_in||changed-11/VBN||2002-2/CD	det||treatment-6/NN||the-4/DT	amod||treatment-6/NN||first-line-5/JJ	nsubjpass||changed-11/VBN||treatment-6/NN	amod||malaria-9/NN||uncomplicated-8/JJ	prep_for||treatment-6/NN||malaria-9/NN	auxpass||changed-11/VBN||was-10/VBD	root||ROOT-0/null||changed-11/VBN	prep_to||changed-11/VBN||artemether-lumefantrine-13/NN	nsubj||proved-19/VBN||artemether-lumefantrine-13/NN	nsubj||efficacious-23/JJ||artemether-lumefantrine-13/NN	appos||artemether-lumefantrine-13/NN||al-15/NNP	aux||proved-19/VBN||has-18/VBZ	rcmod||artemether-lumefantrine-13/NN||proved-19/VBN	aux||efficacious-23/JJ||to-20/TO	cop||efficacious-23/JJ||be-21/VB	advmod||efficacious-23/JJ||highly-22/RB	xcomp||proved-19/VBN||efficacious-23/JJ	prepc_against||efficacious-23/JJ||multidrug-25/VBG	amod||falciparum-28/NN||resistant-26/JJ	nn||falciparum-28/NN||plasmodium-27/NN	dobj||multidrug-25/VBG||falciparum-28/NN	malaria-9||lumefantrine--1||yes||in 2002, the first-line treatment for uncomplicated malaria was changed to artemether-lumefantrine (al) that has proved to be highly efficacious against multidrug resistant plasmodium falciparum .
prep||propose-6/VBP||given-1/VBN	det||findings-3/NNS||these-2/DT	pobj||given-1/VBN||findings-3/NNS	nsubj||propose-6/VBP||we-5/PRP	root||ROOT-0/null||propose-6/VBP	mark||rxr-12/VBP||that-7/IN	det||modulation-9/NN||the-8/DT	nsubj||rxr-12/VBP||modulation-9/NN	prep_of||modulation-9/NN||endogenous-11/NNS	ccomp||propose-6/VBP||rxr-12/VBP	nn||²-15/NNS||î-14/NN	prep_in||rxr-12/VBP||²-15/NNS	nsubj||approach-23/NN||cells-17/NNS	aux||approach-23/NN||may-18/MD	cop||approach-23/NN||be-19/VB	det||approach-23/NN||a-20/DT	amod||approach-23/NN||new-21/JJ	amod||approach-23/NN||therapeutic-22/JJ	parataxis||propose-6/VBP||approach-23/NN	prepc_for||approach-23/NN||improving-25/VBG	amod||secretion-28/NN||impaired-26/VBN	nn||secretion-28/NN||insulin-27/NN	dobj||improving-25/VBG||secretion-28/NN	prep_in||secretion-28/NN||type2diabetes-30/CD	type2diabetes-30||insulin-27||yes||given these findings, we propose that the modulation of endogenous rxr in î²-cells may be a new therapeutic approach for improving impaired insulin secretion in type2diabetes.
nsubj||included-8/VBD||factors-1/NNS	vmod||factors-1/NNS||related-2/VBN	det||reappearance-5/NN||the-4/DT	prep_to||related-2/VBN||reappearance-5/NN	prep_of||reappearance-5/NN||vivaxmalaria-7/NN	root||ROOT-0/null||included-8/VBD	amod||dosage-12/NN||inadequate-9/JJ	amod||dosage-12/NN||total-10/JJ	nn||dosage-12/NN||primaquine-11/NN	dobj||included-8/VBD||dosage-12/NN	vmod||dosage-12/NN||received-13/VBN	xcomp||received-13/VBN||-lrb--14/VBG	num||-rrb--18/NNS||<-15/CD	num||-rrb--18/NNS||2.75-16/CD	amod||-rrb--18/NNS||mg/kg-17/JJ	nsubj||-24/VB||-rrb--18/NNS	appos||-rrb--18/NNS||duration-20/NN	nn||â-23/NN||fever-22/NN	prep_of||duration-20/NN||â-23/NN	ccomp||-lrb--14/VBG||-24/VB	amod||days-27/NNS||$-25/$	number||$-25/$||2-26/CD	tmod||-24/VB||days-27/NNS	prep_before||-24/VB||initiation-29/NN	prep_of||initiation-29/NN||treatment-31/NN	nn||count-34/NN||parasite-33/NN	dep||-24/VB||count-34/NN	nn||¥-39/NNP||admission-36/NN	nn||¥-39/NNP||â-37/NN	nn||¥-39/NNP||-38/NNP	prep_on||count-34/NN||¥-39/NNP	num||¥-39/NNP||10,000-40/CD	punct||count-34/NN||/-41/:	dep||count-34/NN||âµl-42/NN	amod||vivax-46/NN||multiple-44/JJ	nn||vivax-46/NN||p.-45/NN	appos||âµl-42/NN||vivax-46/NN	amod||infection-49/NN||genotype-48/JJ	dep||âµl-42/NN||infection-49/NN	dobj||included-8/VBD||presence-52/NN	conj_and||dosage-12/NN||presence-52/NN	nn||infection-56/NN||p.-54/NN	nn||infection-56/NN||falciparum-55/NN	prep_of||presence-52/NN||infection-56/NN	det||period-60/NN||the-58/DT	nn||period-60/NN||follow-up-59/NN	prep_during||infection-56/NN||period-60/NN	vivaxmalaria-7||primaquine-11||yes||factors related to the reappearance of vivaxmalaria included inadequate total primaquine dosage received -lrb- < 2.75 mg/kg -rrb- , duration of fever â  $ 2 days before initiation of treatment , parasite count on admission â  ¥ 10,000 / âµl , multiple p. vivax - genotype infection , and presence of p. falciparum infection during the follow-up period .
prep_in||reduce-33/VB||people-2/NNS	nn||oa-7/NN||hip-4/NN	conj_or||hip-4/NN||knee-6/NN	nn||oa-7/NN||knee-6/NN	prep_with||people-2/NNS||oa-7/NN	dep||reduce-33/VB||walking-9/VBG	det||minimum-11/NN||a-10/DT	dobj||walking-9/VBG||minimum-11/NN	num||steps-14/NNS||3000-13/CD	prep_of||minimum-11/NN||steps-14/NNS	dep||steps-14/NNS||~-16/NNP	num||minutes-18/NNS||30-17/CD	dep||~-16/NNP||minutes-18/NNS	quantmod||3-23/CD||at-21/IN	mwe||at-21/IN||least-22/JJS	pobj||at-21/IN||least-22/JJS	num||days/week-24/NN||3-23/CD	appos||steps-14/NNS||days/week-24/NN	prep_in||steps-14/NNS||combination-27/NN	amod||sulphate-30/NN||glucosamine-29/JJ	prep_with||steps-14/NNS||sulphate-30/NN	aux||reduce-33/VB||may-32/MD	root||ROOT-0/null||reduce-33/VB	nn||symptoms-35/NNS||oa-34/NN	dobj||reduce-33/VB||symptoms-35/NNS	oa-34||glucosamine-29||yes||in people with hip or knee oa, walking a minimum of 3000 steps (~30 minutes), at least 3 days/week, in combination with glucosamine sulphate, may reduce oa symptoms.
det||â-5/NN||the-1/DT	advmod||famous-3/JJ||now-2/RB	amod||â-5/NN||famous-3/JJ	amod||â-5/NN||bland-sutton-4/JJ	nsubjpass||cured-20/VBN||â-5/NN	amod||â-5/NN||$-6/$	dep||$-6/$||experiment-7/JJ	prep_of||â-5/NN||nature-9/NN	amod||rickets-14/NNS||â-11/JJ	amod||rickets-14/NNS||$-12/$	dep||$-12/$||fatal-13/JJ	appos||â-5/NN||rickets-14/NNS	nn||cubs-17/NNS||lion-16/NN	prep_in||rickets-14/NNS||cubs-17/NNS	auxpass||cured-20/VBN||was-19/VBD	root||ROOT-0/null||cured-20/VBN	agent||cured-20/VBN||addition-22/NN	prep_of||addition-22/NN||minerals-24/NNS	agent||cured-20/VBN||vitamind-26/NNP	conj_and||addition-22/NN||vitamind-26/NNP	amod||salts-30/NNS||taurine-conjugated-28/JJ	nn||salts-30/NNS||bile-29/NN	nsubj||permitted-32/VBD||salts-30/NNS	advmod||permitted-32/VBD||undoubtedly-31/RB	rcmod||vitamind-26/NNP||permitted-32/VBD	dobj||permitted-32/VBD||absorption-33/NN	amod||a-36/DT||vitamins-35/JJ	prep_of||absorption-33/NN||a-36/DT	prep_of||absorption-33/NN||d-38/SYM	conj_and||a-36/DT||d-38/SYM	advmod||preventing-41/VBG||thus-40/RB	vmod||permitted-32/VBD||preventing-41/VBG	det||occurrence-43/NN||the-42/DT	dobj||preventing-41/VBG||occurrence-43/NN	amod||bonedisease-46/NN||metabolic-45/JJ	prep_of||occurrence-43/NN||bonedisease-46/NN	prep_of||occurrence-43/NN||rickets-48/NNS	conj_and||bonedisease-46/NN||rickets-48/NNS	rickets-48||vitamind-26||yes||the now famous bland-sutton â $ experiment of nature , â $ fatal rickets in lion cubs , was cured by addition of minerals and vitamind. taurine-conjugated bile salts undoubtedly permitted absorption of vitamins a and d , thus preventing the occurrence of metabolic bonedisease and rickets .
advmod||noted-4/VBD||therefore-1/RB	nsubj||noted-4/VBD||we-3/PRP	nsubj||propose-24/VBP||we-3/PRP	root||ROOT-0/null||noted-4/VBD	det||increases-6/NNS||the-5/DT	dobj||noted-4/VBD||increases-6/NNS	prep_of||increases-6/NNS||gal-9-8/NN	prep_of||increases-6/NNS||opn-10/NN	conj_and||gal-9-8/NN||opn-10/NN	prep_in||noted-4/VBD||plasma-12/NN	det||time-16/NN||the-14/DT	amod||time-16/NN||first-15/JJ	prep_for||plasma-12/NN||time-16/NN	det||patient-19/NN||a-18/DT	prep_in||time-16/NN||patient-19/NN	nn||allergy-22/NN||insulin-21/NN	prep_with||patient-19/NN||allergy-22/NN	conj_and||noted-4/VBD||propose-24/VBP	mark||reflects-27/VBZ||that-25/IN	nsubj||reflects-27/VBZ||gal-9-26/JJ	ccomp||propose-24/VBP||reflects-27/VBZ	det||conditions-29/NNS||the-28/DT	dobj||reflects-27/VBZ||conditions-29/NNS	prep_of||conditions-29/NNS||allergy-31/NN	advmod||accurately-33/RB||more-32/RBR	advmod||reflects-27/VBZ||accurately-33/RB	allergy-31||allergy-31||no||therefore, we noted the increases of gal-9 and opn in plasma for the first time in a patient with insulin allergy and propose that gal-9 reflects the conditions of allergy more accurately.
amod||model-5/NN||castoroil-2/JJ	amod||model-5/NN||induced-3/JJ	nn||model-5/NN||diarrhea-4/NN	prep_in||reduced-33/VBD||model-5/NN	det||extract-12/NN||the-7/DT	number||%-9/NN||80-8/CD	amod||extract-12/NN||%-9/NN	nn||extract-12/NN||methanol-10/NN	nn||extract-12/NN||leaf-11/NN	nsubj||reduced-33/VBD||extract-12/NN	nn||aurea-15/NN||c.-14/NN	prep_of||extract-12/NN||aurea-15/NN	prep_at||aurea-15/NN||100-17/CD	num||100-17/CD||200-19/CD	prep_at||aurea-15/NN||400-21/CD	conj_and||100-17/CD||400-21/CD	amod||aurea-15/NN||mg/kg-22/JJ	det||drug-26/NN||the-24/DT	amod||drug-26/NN||standard-25/JJ	amod||aurea-15/NN||drug-26/NN	conj_and||mg/kg-22/JJ||drug-26/NN	advmod||drug-26/NN||loperamide-27/RB	number||3-29/CD||-lrb--28/CD	num||-rrb--31/NNS||3-29/CD	amod||-rrb--31/NNS||mg/kg-30/JJ	dep||mg/kg-22/JJ||-rrb--31/NNS	advmod||reduced-33/VBD||significantly-32/RB	root||ROOT-0/null||reduced-33/VBD	det||time-35/NN||the-34/DT	dobj||reduced-33/VBD||time-35/NN	prep_of||time-35/NN||onset-37/NN	prep_of||onset-37/NN||diarrhea-39/NN	det||frequency-42/NN||the-41/DT	prep_of||time-35/NN||frequency-42/NN	conj_and||onset-37/NN||frequency-42/NN	nn||number-47/NN||defecation-44/NN	nn||number-47/NN||-lrb--45/NNP	amod||number-47/NN||total-46/JJ	prep_of||frequency-42/NN||number-47/NN	amod||-rrb--51/NNS||faecal-49/JJ	nn||-rrb--51/NNS||output-50/NN	prep_of||frequency-42/NN||-rrb--51/NNS	prep_of||time-35/NN||weight-53/NN	conj_and||onset-37/NN||weight-53/NN	prep_of||weight-53/NN||faeces-55/NNS	diarrhea-39||loperamide-27||yes||in castoroil induced diarrhea model , the 80 % methanol leaf extract of c. aurea at 100 , 200 and 400 mg/kg and the standard drug loperamide -lrb- 3 mg/kg -rrb- significantly reduced the time of onset of diarrhea , the frequency of defecation -lrb- total number of faecal output -rrb- and weight of faeces .
nsubj||necessary-9/JJ||methylation-1/NN	det||ar-4/NN||the-3/DT	prep_of||methylation-1/NN||ar-4/NN	amod||632-7/NNS||lysine-6/JJ	prep_on||ar-4/NN||632-7/NNS	cop||necessary-9/JJ||is-8/VBZ	root||ROOT-0/null||necessary-9/JJ	prepc_for||necessary-9/JJ||enhancing-11/VBG	amod||activity-13/NN||transcriptional-12/JJ	dobj||enhancing-11/VBG||activity-13/NN	det||receptor-16/NN||the-15/DT	prep_of||activity-13/NN||receptor-16/NN	prepc_by||enhancing-11/VBG||facilitating-18/VBG	det||communication-21/NN||both-19/DT	amod||communication-21/NN||inter-domain-20/JJ	dobj||facilitating-18/VBG||communication-21/NN	det||n-24/NN||the-23/DT	prep_between||communication-21/NN||n-24/NN	dobj||facilitating-18/VBG||c-termini-27/NN	conj_and||communication-21/NN||c-termini-27/NN	conj_and||communication-21/NN||recruitment-29/NN	conj_and||c-termini-27/NN||recruitment-29/NN	amod||genes-32/NNS||androgen-target-31/JJ	prep_to||c-termini-27/NN||genes-32/NNS	lysine-6||ar-4||no_rel||methylation of the ar on lysine 632 is necessary for enhancing transcriptional activity of the receptor by facilitating both inter-domain communication between the n- and c-termini and recruitment to androgen-target genes.
aux||elucidate-2/VB||to-1/TO	advcl||analyzed-15/VBD||elucidate-2/VB	mark||involved-6/VBN||whether-3/IN	nsubjpass||involved-6/VBN||micrornas-4/NNS	auxpass||involved-6/VBN||are-5/VBP	ccomp||elucidate-2/VB||involved-6/VBN	det||development-9/NN||the-8/DT	prep_in||involved-6/VBN||development-9/NN	amod||resistance-12/NN||fludarabine-11/JJ	prep_of||development-9/NN||resistance-12/NN	nsubj||analyzed-15/VBD||we-14/PRP	root||ROOT-0/null||analyzed-15/VBD	det||expression-17/NN||the-16/DT	dobj||analyzed-15/VBD||expression-17/NN	num||mirnas-21/NNS||723-19/CD	amod||mirnas-21/NNS||human-20/JJ	prep_of||expression-17/NN||mirnas-21/NNS	advmod||mirnas-21/NNS||before-22/RB	advmod||mirnas-21/NNS||5-days-24/JJ	conj_and||before-22/RB||5-days-24/JJ	amod||mono-therapy-27/NN||fludarabine-26/JJ	prep_after||5-days-24/JJ||mono-therapy-27/NN	num||patients-31/NNS||17-29/CD	nn||patients-31/NNS||cll-30/NN	prep_in||analyzed-15/VBD||patients-31/NNS	nsubjpass||classified-34/VBN||patients-31/NNS	nsubj||fludarabine-40/VB||patients-31/NNS	auxpass||classified-34/VBN||were-33/VBD	rcmod||patients-31/NNS||classified-34/VBN	prep_as||classified-34/VBN||responder-36/NN	prep_as||classified-34/VBN||refractory-38/NN	conj_or||responder-36/NN||refractory-38/NN	aux||fludarabine-40/VB||to-39/TO	xcomp||classified-34/VBN||fludarabine-40/VB	dobj||fludarabine-40/VB||treatment-41/NN	prepc_based_on||fludarabine-40/VB||on-43/IN	nn||criteria-45/NNS||nci-44/NN	pobj||fludarabine-40/VB||criteria-45/NNS	cll-30||fludarabine-40||yes||to elucidate whether micrornas are involved in the development of fludarabine resistance, we analyzed the expression of 723 human mirnas before and 5-days after fludarabine mono-therapy in 17 cll patients which were classified as responder or refractory to fludarabine treatment based on nci criteria.
aux||use-2/VB||to-1/TO	advcl||necessary-16/JJ||use-2/VB	dobj||use-2/VB||pyrimethamine-3/NN	det||drug-8/NN||an-5/DT	amod||drug-8/NN||alternative-6/JJ	amod||drug-8/NN||anti-malarial-7/JJ	prep_as||use-2/VB||drug-8/NN	amod||parasites-12/NNS||chloroquine-resistant-10/JJ	nn||parasites-12/NNS||malaria-11/NN	prep_for||drug-8/NN||parasites-12/NNS	nsubj||necessary-16/JJ||it-14/PRP	nsubj||determine-18/VB||it-14/PRP	cop||necessary-16/JJ||was-15/VBD	root||ROOT-0/null||necessary-16/JJ	aux||determine-18/VB||to-17/TO	xcomp||necessary-16/JJ||determine-18/VB	det||enzyme-20/NN||the-19/DT	poss||variation-23/NN||enzyme-20/NN	amod||variation-23/NN||genetic-22/JJ	dobj||determine-18/VB||variation-23/NN	amod||syntase-27/NN||dihydrofolate-25/JJ	amod||syntase-27/NN||reductase-thymidylate-26/JJ	prep_in||variation-23/NN||syntase-27/NN	appos||syntase-27/NN||dhfr-ts-29/NNS	nn||strains-33/NNS||korean-32/NN	prep_among||determine-18/VB||strains-33/NNS	malaria-11||chloroquine--1||yes||to use pyrimethamine as an alternative anti-malarial drug for chloroquine-resistant malaria parasites, it was necessary to determine the enzyme's genetic variation in dihydrofolate reductase-thymidylate syntase (dhfr-ts) among korean strains.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	mwe||than-4/IN||more-3/JJR	quantmod||460-5/CD||than-4/IN	num||lines-8/NNS||460-5/CD	amod||lines-8/NNS||primate-6/JJ	nn||lines-8/NNS||cell-7/NN	dobj||investigated-2/VBD||lines-8/NNS	prep_for||lines-8/NNS||epstein-barr-10/NN	appos||epstein-barr-10/NN||ebv-12/NN	prep_for||lines-8/NNS||hepatitisb-15/NN	conj_and||epstein-barr-10/NN||hepatitisb-15/NN	appos||hepatitisb-15/NN||hbv-17/NN	prep_for||lines-8/NNS||hepatitisc-20/NN	conj_and||epstein-barr-10/NN||hepatitisc-20/NN	appos||hepatitisc-20/NN||hcv-22/NN	amod||type-26/NN||humanimmunodeficiencyvirus-25/JJ	prep_for||lines-8/NNS||type-26/NN	conj_and||epstein-barr-10/NN||type-26/NN	num||type-26/NN||1-27/CD	dep||type-26/NN||hiv-1-29/JJ	amod||i-36/NNS||human-32/JJ	amod||i-36/NNS||t-cell-33/JJ	nn||i-36/NNS||leukemia/lymphoma-34/NN	nn||i-36/NNS||virus-35/NN	prep_for||lines-8/NNS||i-36/NNS	conj_and||epstein-barr-10/NN||i-36/NNS	prep_for||lines-8/NNS||ii-38/NN	conj_and||epstein-barr-10/NN||ii-38/NN	nn||/-41/NNP||htlv-i-40/NNP	dep||ii-38/NN||/-41/NNP	dep||/-41/NNP||ii-43/NN	amod||retrovirus-49/NNS||squirrel-47/JJ	nn||retrovirus-49/NNS||monkey-48/NN	prep_for||lines-8/NNS||retrovirus-49/NNS	conj_and||epstein-barr-10/NN||retrovirus-49/NNS	appos||retrovirus-49/NNS||smrv-51/NNP	dep||retrovirus-49/NNS||infections-53/NNS	nn||assessment-56/NN||risk-55/NN	prep_for||investigated-2/VBD||assessment-56/NN	hepatitisc-20||hcv-22||no||we investigated more than 460 primate cell lines for epstein-barr (ebv), hepatitisb (hbv), hepatitisc (hcv), humanimmunodeficiencyvirus type 1 (hiv-1), human t-cell leukemia/lymphoma virus i and ii (htlv-i/-ii), and squirrel monkey retrovirus (smrv) infections for risk assessment.
nsubj||drug-9/NN||chondroitinsulfate-1/NN	appos||chondroitinsulfate-1/NN||cs-3/NN	cop||drug-9/NN||is-5/VBZ	det||drug-9/NN||a-6/DT	amod||drug-9/NN||symptomatic-7/JJ	amod||drug-9/NN||slow-acting-8/JJ	root||ROOT-0/null||drug-9/NN	prep_for||drug-9/NN||osteoarthritis-11/NNS	appos||osteoarthritis-11/NNS||oa-13/NN	advmod||used-16/VBN||widely-15/RB	vmod||osteoarthritis-11/NNS||used-16/VBN	det||clinic-19/NN||the-18/DT	prep_in||used-16/VBN||clinic-19/NN	oa-13||chondroitinsulfate-1||yes||chondroitinsulfate (cs) is a symptomatic slow-acting drug for osteoarthritis (oa) widely used in the clinic.
amod||sleepapnea-2/NN||obstructive-1/JJ	nsubj||common-4/JJ||sleepapnea-2/NN	cop||common-4/JJ||is-3/VBZ	root||ROOT-0/null||common-4/JJ	prep_in||common-4/JJ||patients-6/NNS	prep_with||patients-6/NNS||type2diabetes-8/CD	poss||association-12/NN||its-11/PRP$	nsubjpass||examined-19/VBN||association-12/NN	prep_with||association-12/NN||insulin-14/NN	prep_with||association-12/NN||insulinresistance-16/NN	conj_and||insulin-14/NN||insulinresistance-16/NN	aux||examined-19/VBN||has-17/VBZ	auxpass||examined-19/VBN||been-18/VBN	conj_and||common-4/JJ||examined-19/VBN	amod||studies-22/NNS||cross-sectional-21/JJ	prep_in||examined-19/VBN||studies-22/NNS	insulin-14||insulinresistance-16||no_rel||obstructive sleepapnea is common in patients with type2diabetes, and its association with insulin and insulinresistance has been examined in cross-sectional studies.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||decipher-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||decipher-8/VB||to-7/TO	xcomp||was-6/VBD||decipher-8/VB	det||role-11/NN||the-9/DT	amod||role-11/NN||specific-10/JJ	dobj||decipher-8/VB||role-11/NN	amod||stimulation-14/NN||ecb-system-13/JJ	prep_of||role-11/NN||stimulation-14/NN	amod||endotoxaemia-17/NN||metabolic-16/JJ	dobj||decipher-8/VB||endotoxaemia-17/NN	conj_or||role-11/NN||endotoxaemia-17/NN	det||onset-20/NN||the-19/DT	prep_in||endotoxaemia-17/NN||onset-20/NN	prep_of||onset-20/NN||glucoseintolerance-22/NN	amod||inflammation-25/NN||metabolic-24/JJ	prep_of||onset-20/NN||inflammation-25/NN	conj_and||glucoseintolerance-22/NN||inflammation-25/NN	amod||metabolism-29/NN||altered-27/JJ	nn||metabolism-29/NN||lipid-28/NN	prep_of||onset-20/NN||metabolism-29/NN	conj_and||glucoseintolerance-22/NN||metabolism-29/NN	lipid-28||glucoseintolerance-22||no_rel||the aim of this study was to decipher the specific role of ecb-system stimulation or metabolic endotoxaemia in the onset of glucoseintolerance, metabolic inflammation and altered lipid metabolism.
nn||deficiency-2/NN||insulin-1/NN	nsubjpass||induced-6/VBN||deficiency-2/NN	conj_and||deficiency-2/NN||hyperglycemia-4/NN	nsubjpass||induced-6/VBN||hyperglycemia-4/NN	auxpass||induced-6/VBN||were-5/VBD	root||ROOT-0/null||induced-6/VBN	prep_with||induced-6/VBN||streptozotocin-8/NN	appos||streptozotocin-8/NN||stz-10/NN	amod||mice-16/NNS||c57bl/6-13/JJ	nn||mice-16/NNS||fxr-14/NN	nn||mice-16/NNS||ko-15/NN	prep_in||streptozotocin-8/NN||mice-16/NNS	hyperglycemia-4||stz-10||no_rel||insulin deficiency and hyperglycemia were induced with streptozotocin (stz) in c57bl/6 fxr ko mice.
nsubj||disease-5/NN||malaria-1/NN	cop||disease-5/NN||is-2/VBZ	det||disease-5/NN||the-3/DT	amod||disease-5/NN||infectious-4/JJ	ccomp||changed-28/VBN||disease-5/NN	vmod||disease-5/NN||causing-6/VBG	det||morbidity-9/NN||the-7/DT	amod||morbidity-9/NN||highest-8/JJS	dobj||causing-6/VBG||morbidity-9/NN	dobj||causing-6/VBG||mortality-11/NN	conj_and||morbidity-9/NN||mortality-11/NN	prep_in||mortality-11/NN||angola-13/NN	amod||widespread-17/JJ||due-15/JJ	dep||widespread-17/JJ||to-16/TO	amod||resistance-22/NN||widespread-17/JJ	amod||resistance-22/NN||chloroquine-18/JJ	dep||resistance-22/NN||cq-20/VBN	dobj||causing-6/VBG||resistance-22/NN	conj_and||morbidity-9/NN||resistance-22/NN	det||country-25/NN||the-24/DT	nsubj||changed-28/VBN||country-25/NN	aux||changed-28/VBN||has-26/VBZ	advmod||changed-28/VBN||recently-27/RB	root||ROOT-0/null||changed-28/VBN	poss||recommendations-32/NNS||its-29/PRP$	amod||recommendations-32/NNS||first-line-30/JJ	nn||recommendations-32/NNS||treatment-31/NN	dobj||changed-28/VBN||recommendations-32/NNS	amod||malaria-35/NN||uncomplicated-34/JJ	prep_for||changed-28/VBN||malaria-35/NN	prep_from||changed-28/VBN||cq-38/NN	aux||artemisinin-40/VB||to-39/TO	vmod||cq-38/NN||artemisinin-40/VB	nn||therapies-42/NNS||combination-41/NN	dobj||artemisinin-40/VB||therapies-42/NNS	appos||therapies-42/NNS||act-44/NN	prep_in||therapies-42/NNS||adults-47/NNS	prep_in||therapies-42/NNS||sulphadoxine/pyrimethamine-50/NN	conj_and||adults-47/NNS||sulphadoxine/pyrimethamine-50/NN	appos||adults-47/NNS||s/p-52/NN	amod||women-56/NNS||pregnant-55/JJ	prep_in||artemisinin-40/VB||women-56/NNS	malaria-35||pyrimethamine--1||yes||malaria is the infectious disease causing the highest morbidity and mortality in angola and due to widespread chloroquine (cq) resistance, the country has recently changed its first-line treatment recommendations for uncomplicated malaria, from cq to artemisinin combination therapies (act) in adults, and sulphadoxine/pyrimethamine (s/p) in pregnant women.
det||suppression-3/NN||the-2/DT	prep_through||improves-17/VBZ||suppression-3/NN	det||chemokines-6/NN||these-5/DT	prep_of||suppression-3/NN||chemokines-6/NN	prep_of||suppression-3/NN||maintenance-8/NN	conj_and||chemokines-6/NN||maintenance-8/NN	amod||levels-12/NNS||effective-10/JJ	nn||levels-12/NNS||theophylline-11/NN	prep_of||chemokines-6/NN||levels-12/NNS	amod||therapy-16/NN||low-dose-14/JJ	nn||therapy-16/NN||em-15/NN	nsubj||improves-17/VBZ||therapy-16/NN	root||ROOT-0/null||improves-17/VBZ	det||symptoms-19/NNS||the-18/DT	dobj||improves-17/VBZ||symptoms-19/NNS	prep_of||symptoms-19/NNS||bronchialasthma-21/NN	bronchialasthma-21||theophylline-11||yes||through the suppression of these chemokines and maintenance of effective theophylline levels, low-dose em therapy improves the symptoms of bronchialasthma.
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||examine-8/VB||purpose-2/NN	det||study-5/NN||the-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||examine-8/VB||to-7/TO	xcomp||was-6/VBD||examine-8/VB	dobj||examine-8/VB||factors-9/NNS	vmod||factors-9/NNS||associated-10/VBN	amod||presentation-13/NN||late-12/JJ	prep_with||associated-10/VBN||presentation-13/NN	amod||care-16/NN||hiv/aids-15/JJ	prep_to||associated-10/VBN||care-16/NN	aids--1||hiv--1||no||the purpose of the study was to examine factors associated with late presentation to hiv/aids care.
amod||-rrb--4/NNS||vibriocholerae-1/JJ	amod||-rrb--4/NNS||-lrb--2/JJ	nn||-rrb--4/NNS||v.cholerae-3/NN	nsubj||causes-5/VBZ||-rrb--4/NNS	root||ROOT-0/null||causes-5/VBZ	det||disease-9/NN||a-6/DT	advmod||lethal-8/JJ||potentially-7/RB	amod||disease-9/NN||lethal-8/JJ	dobj||causes-5/VBZ||disease-9/NN	vmod||disease-9/NN||named-10/VBN	dobj||named-10/VBN||cholera-11/NN	cholera-11||v.cholerae-3||no||vibriocholerae -lrb- v.cholerae -rrb- causes a potentially lethal disease named cholera .
nsubj||component-5/NN||permethrin-1/NN	cop||component-5/NN||is-2/VBZ	det||component-5/NN||the-3/DT	amod||component-5/NN||active-4/JJ	root||ROOT-0/null||component-5/NN	amod||creams-8/NNS||topical-7/JJ	prep_of||component-5/NN||creams-8/NNS	advmod||used-10/VBN||widely-9/RB	vmod||creams-8/NNS||used-10/VBN	aux||treat-12/VB||to-11/TO	xcomp||used-10/VBN||treat-12/VB	amod||scabies-14/NNS||human-13/JJ	dobj||treat-12/VB||scabies-14/NNS	scabies-14||permethrin-1||yes||permethrin is the active component of topical creams widely used to treat human scabies.
nsubj||showed-5/VBD||sera-1/NN	amod||animals-4/NNS||immunized-3/JJ	prep_of||sera-1/NN||animals-4/NNS	root||ROOT-0/null||showed-5/VBD	amod||response-8/NN||high-6/JJ	nn||response-8/NN||igg-7/NN	nsubj||showed-17/VBD||response-8/NN	amod||cross-reactivity-11/NN||strong-10/JJ	conj_and||response-8/NN||cross-reactivity-11/NN	nsubj||showed-17/VBD||cross-reactivity-11/NN	amod||results-16/NNS||different-13/JJ	nn||results-16/NNS||mtb-14/NN	nn||results-16/NNS||antigens.these-15/NN	prep_against||response-8/NN||results-16/NNS	ccomp||showed-5/VBD||showed-17/VBD	mark||candidates-25/NNS||that-18/IN	nn||pls-20/NN||bcg-19/NN	nsubj||candidates-25/NNS||pls-20/NN	aux||candidates-25/NNS||could-21/MD	cop||candidates-25/NNS||be-22/VB	amod||candidates-25/NNS||potential-23/JJ	nn||candidates-25/NNS||vaccine-24/NN	ccomp||showed-17/VBD||candidates-25/NNS	prep_against||candidates-25/NNS||tb-27/NN	tb-27||mtb-14||no||sera of immunized animals showed high igg response and strong cross-reactivity against different mtb antigens.these results showed that bcg pls could be potential vaccine candidates against tb.
det||success-4/NN||the-2/DT	amod||success-4/NN||emerging-3/VBG	prep_despite||seems-24/VBZ||success-4/NN	amod||inhibitors-13/NNS||multi-targeted-6/JJ	nn||inhibitors-13/NNS||protein-7/NN	nn||inhibitors-13/NNS||tyrosine-8/NN	nn||inhibitors-13/NNS||kinase-9/NN	appos||inhibitors-13/NNS||ptk-11/NN	prep_of||success-4/NN||inhibitors-13/NNS	nn||therapy-16/NN||cancer-15/NN	prep_in||inhibitors-13/NNS||therapy-16/NN	amod||effects-20/NNS||significant-18/JJ	nn||effects-20/NNS||side-19/NN	nsubj||seems-24/VBZ||effects-20/NNS	nsubjpass||avoided-27/VBN||effects-20/NNS	nn||concerns-23/NNS||resistance-22/NN	conj_and||effects-20/NNS||concerns-23/NNS	nsubj||seems-24/VBZ||concerns-23/NNS	nsubjpass||avoided-27/VBN||concerns-23/NNS	root||ROOT-0/null||seems-24/VBZ	aux||avoided-27/VBN||to-25/TO	auxpass||avoided-27/VBN||be-26/VB	xcomp||seems-24/VBZ||avoided-27/VBN	xcomp||avoided-27/VBN||unlikely-28/JJ	cancer-15||tyrosine-8||no_rel||despite the emerging success of multi-targeted protein tyrosine kinase (ptk) inhibitors in cancer therapy, significant side effects and resistance concerns seems to be avoided unlikely.
nsubj||included-2/VBD||these-1/DT	root||ROOT-0/null||included-2/VBD	det||role-4/NN||the-3/DT	dobj||included-2/VBD||role-4/NN	prep_of||role-4/NN||statins-6/NNS	det||agent-10/NN||an-8/DT	amod||agent-10/NN||anti-lipid-9/JJ	appos||statins-6/NNS||agent-10/NN	prepc_in||included-2/VBD||reducing-13/VBG	amod||morbidity-15/NN||post-stroke-14/JJ	dobj||reducing-13/VBG||morbidity-15/NN	dobj||reducing-13/VBG||mortality-17/NN	conj_and||morbidity-15/NN||mortality-17/NN	prepc_in||included-2/VBD||decreasing-20/VBG	conj_and||reducing-13/VBG||decreasing-20/VBG	det||plaque-24/NN||the-21/DT	amod||plaque-24/NN||carotid-22/JJ	amod||plaque-24/NN||atherosclerotic-23/JJ	dobj||decreasing-20/VBG||plaque-24/NN	prep_in||plaque-24/NN||middle-26/NN	vmod||middle-26/NN||aged-27/VBN	dobj||aged-27/VBN||patients-28/NNS	amod||risk-31/NN||increased-30/VBN	prep_at||aged-27/VBN||risk-31/NN	prep_of||risk-31/NN||cardiovasculardisease-33/NN	amod||infusion-36/NN||glucose-potassium-insulin-35/JJ	dobj||decreasing-20/VBG||infusion-36/NN	conj_and||plaque-24/NN||infusion-36/NN	amod||acute-39/JJ||hyperglyceamic-38/JJ	amod||patients-41/NNS||acute-39/JJ	nn||patients-41/NNS||stroke-40/NN	prep_in||infusion-36/NN||patients-41/NNS	dep||infusion-36/NN||pioglitazone-43/VB	det||medication-47/NN||an-45/DT	amod||medication-47/NN||anti-diabetic-46/JJ	dobj||pioglitazone-43/VB||medication-47/NN	nsubj||reduce-50/VB||medication-47/NN	aux||reduce-50/VB||to-49/TO	xcomp||pioglitazone-43/VB||reduce-50/VB	dobj||reduce-50/VB||recurrence-51/NN	prep_of||recurrence-51/NN||stroke-53/NN	nn||patients-58/NNS||type-55/NN	num||patients-58/NNS||2-56/CD	nn||patients-58/NNS||diabetic-57/NN	prep_in||reduce-50/VB||patients-58/NNS	parataxis||pioglitazone-43/VB||administration-60/NN	amod||urokinase-63/NN||intra-arterial-62/JJ	prep_of||administration-60/NN||urokinase-63/NN	det||agent-67/NN||a-65/DT	amod||agent-67/NN||thrombolytic-66/JJ	appos||urokinase-63/NN||agent-67/NN	det||role-71/NN||the-70/DT	prep_of||administration-60/NN||role-71/NN	conj_and||urokinase-63/NN||role-71/NN	nn||therapy-74/NN||laser-73/NN	prep_of||role-71/NN||therapy-74/NN	amod||dissolution-77/NN||clot-76/JJ	prep_in||therapy-74/NN||dissolution-77/NN	dep||administration-60/NN||given-78/VBN	mark||is-83/VBZ||that-79/IN	prep_at||is-83/VBZ||present-81/JJ	expl||is-83/VBZ||there-82/EX	pcomp||given-78/VBN||is-83/VBZ	advmod||fda-86/NN||only-84/RB	num||fda-86/NN||one-85/CD	nsubj||is-83/VBZ||fda-86/NN	vmod||fda-86/NN||approved-87/VBN	amod||agent-89/NN||thrombolytic-88/JJ	dobj||approved-87/VBN||agent-89/NN	nn||tpa-92/NN||r-91/NN	dep||administration-60/NN||tpa-92/NN	parataxis||pioglitazone-43/VB||benefit-95/VB	prep_of||benefit-95/VB||warfarin-97/NN	det||anticoagulant-100/NN||an-99/DT	appos||warfarin-97/NN||anticoagulant-100/NN	amod||patients-104/NNS||elderly-103/JJ	prep_in||warfarin-97/NN||patients-104/NNS	prep_with||benefit-95/VB||atrialfibrillation-106/NN	det||community-109/NN||the-108/DT	prep_in||atrialfibrillation-106/NN||community-109/NN	parataxis||pioglitazone-43/VB||nxy-111/VB	det||agent-117/NN||a-113/DT	amod||radical-115/JJ||free-114/JJ	amod||agent-117/NN||radical-115/JJ	amod||agent-117/NN||trapping-116/JJ	dep||nxy-111/VB||agent-117/NN	parataxis||pioglitazone-43/VB||minocycline-120/VB	conj_and||nxy-111/VB||minocycline-120/VB	det||tested-122/NN||both-121/DT	dobj||nxy-111/VB||tested-122/NN	prep_as||nxy-111/VB||neuroprotectants-124/NNS	dobj||decreasing-20/VBG||zoledronate-127/NN	conj_and||plaque-24/NN||zoledronate-127/NN	det||bisphosphonate-131/NN||an-129/DT	amod||bisphosphonate-131/NN||intravenous-130/JJ	appos||zoledronate-127/NN||bisphosphonate-131/NN	aux||prevent-134/VB||to-133/TO	vmod||zoledronate-127/NN||prevent-134/VB	dobj||prevent-134/VB||loss-135/NN	nn||density-139/NN||bone-137/NN	nn||density-139/NN||mineral-138/NN	prep_of||loss-135/NN||density-139/NN	det||extremity-143/NN||the-141/DT	amod||extremity-143/NN||affected-142/VBN	prep_of||density-139/NN||extremity-143/NN	advmod||role-148/NN||finally-146/RB	det||role-148/NN||the-147/DT	prep_of||density-139/NN||role-148/NN	conj_and||extremity-143/NN||role-148/NN	prep_of||role-148/NN||nicardipine-150/NN	det||calciumchannelblocker-153/NN||a-152/DT	appos||nicardipine-150/NN||calciumchannelblocker-153/NN	det||prevention-157/NN||the-156/DT	prep_in||nicardipine-150/NN||prevention-157/NN	prep_of||prevention-157/NN||vasospasm-159/NN	vmod||zoledronate-127/NN||hydrocortisone-162/VB	conj_and||prevent-134/VB||hydrocortisone-162/VB	aux||prevent-164/VB||to-163/TO	xcomp||hydrocortisone-162/VB||prevent-164/VB	dobj||prevent-164/VB||hyponatraemia-165/NN	amod||hemorrhage-168/NN||sub-arachnoid-167/JJ	prep_after||prevent-164/VB||hemorrhage-168/NN	stroke-53||warfarin-97||yes||these included the role of statins (an anti-lipid agent) in reducing post-stroke morbidity and mortality, and decreasing the carotid atherosclerotic plaque in middle aged patients at increased risk of cardiovasculardisease; glucose-potassium-insulin infusion in hyperglyceamic acute stroke patients; pioglitazone (an anti-diabetic medication) to reduce recurrence of stroke in type 2 diabetic patients; administration of intra-arterial urokinase (a thrombolytic agent) and the role of laser therapy in clot dissolution given that at present there is only one fda approved thrombolytic agent (r tpa); benefit of warfarin (an anticoagulant) in elderly patients with atrialfibrillation in the community; nxy (a free radical trapping agent) and minocycline both tested as neuroprotectants; and zoledronate (an intravenous bisphosphonate) to prevent loss of bone mineral density of the affected extremity, and finally the role of nicardipine (a calciumchannelblocker) in the prevention of vasospasm, and hydrocortisone to prevent hyponatraemia after sub-arachnoid hemorrhage.
nsubjpass||collected-16/VBN||data-1/NNS	det||incidence-4/NN||the-3/DT	prep_on||data-1/NNS||incidence-4/NN	nn||infection-7/NN||vzv-6/NN	prep_of||incidence-4/NN||infection-7/NN	appos||infection-7/NN||chickenpox-9/NN	poss||period-14/NN||their-12/PRP$	amod||period-14/NN||undergraduate-13/JJ	prep_during||infection-7/NN||period-14/NN	auxpass||collected-16/VBN||was-15/VBD	root||ROOT-0/null||collected-16/VBN	xcomp||collected-16/VBN||using-17/VBG	det||questionnaire-21/NN||a-18/DT	amod||questionnaire-21/NN||self-administered-19/JJ	amod||questionnaire-21/NN||structured-20/JJ	dobj||using-17/VBG||questionnaire-21/NN	chickenpox-9||vzv-6||no||data on the incidence of vzv infection (chickenpox) during their undergraduate period was collected using a self-administered structured questionnaire.
det||risk-2/NN||the-1/DT	nsubjpass||thought-16/VBN||risk-2/NN	nsubjpass||increased-19/VBN||risk-2/NN	nn||tb-6/NN||tuberculosis-4/NNP	prep_of||risk-2/NN||tb-6/NN	prep_in||tb-6/NN||patients-9/NNS	prep_with||patients-9/NNS||rheumatoidarthritis-11/NNS	appos||rheumatoidarthritis-11/NNS||ra-13/NN	auxpass||thought-16/VBN||is-15/VBZ	root||ROOT-0/null||thought-16/VBN	aux||increased-19/VBN||to-17/TO	auxpass||increased-19/VBN||be-18/VB	xcomp||thought-16/VBN||increased-19/VBN	amod||therapy-27/NN||anti-tumour-21/JJ	nn||therapy-27/NN||necrosis-22/NNS	nn||therapy-27/NN||factor-23/NN	dep||therapy-27/NN||anti-tnf-25/JJ	prep_following||increased-19/VBN||therapy-27/NN	det||risk-33/NN||a-30/DT	amod||risk-33/NN||proposed-31/VBN	nn||risk-33/NN||differential-32/NN	prep_with||thought-16/VBN||risk-33/NN	det||etanercept-38/NN||the-35/DT	amod||etanercept-38/NN||anti-tnf-36/JJ	nn||etanercept-38/NN||drugs-37/NNS	prep_between||risk-33/NN||etanercept-38/NN	appos||etanercept-38/NN||eta-40/NN	prep_between||risk-33/NN||infliximab-43/NN	conj_and||etanercept-38/NN||infliximab-43/NN	appos||infliximab-43/NN||inf-45/NN	prep_between||risk-33/NN||adalimumab-48/NN	conj_and||etanercept-38/NN||adalimumab-48/NN	appos||adalimumab-48/NN||ada-50/NN	rheumatoidarthritis-11||etanercept-38||yes||the risk of tuberculosis (tb) in patients with rheumatoidarthritis (ra) is thought to be increased following anti-tumour necrosis factor (anti-tnf) therapy, with a proposed differential risk between the anti-tnf drugs etanercept (eta), infliximab (inf) and adalimumab (ada).
det||role-3/NN||an-1/DT	amod||role-3/NN||important-2/JJ	nsubjpass||recognized-20/VBN||role-3/NN	amod||metabolism-7/NN||altered-5/JJ	nn||metabolism-7/NN||lipid-6/NN	prep_for||role-3/NN||metabolism-7/NN	amod||proteins-13/NNS||sterol-9/JJ	amod||proteins-13/NNS||regulatory-10/JJ	nn||proteins-13/NNS||element-11/NN	amod||proteins-13/NNS||binding-12/VBG	prep_via||metabolism-7/NN||proteins-13/NNS	dep||role-3/NN||srebps-15/VBZ	aux||recognized-20/VBN||has-17/VBZ	auxpass||recognized-20/VBN||been-18/VBN	advmod||recognized-20/VBN||recently-19/RB	root||ROOT-0/null||recognized-20/VBN	prep_in||recognized-20/VBN||diabetickidneydisease-22/NN	lipid-6||diabetickidneydisease-22||no_rel||an important role for altered lipid metabolism via sterol regulatory element binding proteins (srebps) has been recently recognized in diabetickidneydisease.
num||strain-2/NN||one-1/CD	nsubj||promising-8/JJ||strain-2/NN	appos||strain-2/NN||m44-4/NNP	aux||promising-8/JJ||was-6/VBD	advmod||promising-8/JJ||particularly-7/RB	root||ROOT-0/null||promising-8/JJ	poss||activity-11/NN||its-10/PRP$	prep_since||promising-8/JJ||activity-11/NN	vmod||activity-11/NN||counteracted-12/VBN	det||effect-15/NN||the-13/DT	amod||effect-15/NN||protective-14/JJ	dobj||counteracted-12/VBN||effect-15/NN	prep_of||effect-15/NN||ledgf/p75-17/NNS	dep||ledgf/p75-17/NNS||overexpressed-18/VBN	nn||cells-21/NNS||aml-20/NN	prep_in||overexpressed-18/VBN||cells-21/NNS	dep||ledgf/p75-17/NNS||acted-23/VBN	conj_and||overexpressed-18/VBN||acted-23/VBN	advmod||acted-23/VBN||synergistically-24/RB	det||daunorubicin-29/NN||the-26/DT	amod||daunorubicin-29/NN||anthracycline-27/JJ	amod||daunorubicin-29/NN||anticancerdrug-28/VBG	prep_with||acted-23/VBN||daunorubicin-29/NN	nn||cells-32/NNS||aml-31/NN	prep_in||daunorubicin-29/NN||cells-32/NNS	dep||ledgf/p75-17/NNS||protected-35/VBN	conj_and||overexpressed-18/VBN||protected-35/VBN	dobj||protected-35/VBN||cardiomyoblasts-36/NNS	det||effect-40/NN||the-38/DT	amod||effect-40/NN||toxic-39/JJ	prep_against||protected-35/VBN||effect-40/NN	prep_of||effect-40/NN||anthracyclines-42/NNS	aml-31||daunorubicin-29||yes||one strain (m44) was particularly promising since its activity counteracted the protective effect of ledgf/p75 overexpressed in aml cells, acted synergistically with the anthracycline anticancerdrug daunorubicin in aml cells, and protected cardiomyoblasts against the toxic effect of anthracyclines.
mark||implicated-14/VBN||although-1/IN	det||death-receptor-4/NN||both-2/DT	amod||death-receptor-4/NN||extrinsic-3/JJ	nsubjpass||implicated-14/VBN||death-receptor-4/NN	vmod||death-receptor-4/NN||signaling-5/VBG	amod||pathways-9/NNS||pathways-6/JJ	conj_and||pathways-6/JJ||intrinsic-8/JJ	amod||pathways-9/NNS||intrinsic-8/JJ	dobj||signaling-5/VBG||pathways-9/NNS	vmod||signaling-5/VBG||involving-10/VBG	amod||injury-12/NN||mitochondrial-11/JJ	dobj||involving-10/VBG||injury-12/NN	auxpass||implicated-14/VBN||are-13/VBP	advcl||unknown-37/JJ||implicated-14/VBN	amod||apoptosis-17/NNS||reovirus-induced-16/JJ	prep_in||implicated-14/VBN||apoptosis-17/NNS	agent||activated-27/VBN||mechanisms-19/NNS	nsubj||unknown-37/JJ||mechanisms-19/NNS	nsubjpass||activated-27/VBN||either-22/DT	det||pathways-25/NNS||these-24/DT	prep_of||either-22/DT||pathways-25/NNS	auxpass||activated-27/VBN||are-26/VBP	rcmod||mechanisms-19/NNS||activated-27/VBN	poss||relationship-30/NN||their-29/PRP$	conj_and||mechanisms-19/NNS||relationship-30/NN	agent||activated-27/VBN||relationship-30/NN	nsubj||unknown-37/JJ||relationship-30/NN	aux||nf-îºb-32/VB||to-31/TO	vmod||relationship-30/NN||nf-îºb-32/VB	xcomp||nf-îºb-32/VB||signaling-33/VBG	amod||reovirusinfection-35/NN||following-34/JJ	dobj||signaling-33/VBG||reovirusinfection-35/NN	cop||unknown-37/JJ||are-36/VBP	root||ROOT-0/null||unknown-37/JJ	reovirusinfection-35||reovirus--1||no||although both extrinsic death-receptor signaling pathways and intrinsic pathways involving mitochondrial injury are implicated in reovirus-induced apoptosis, mechanisms by which either of these pathways are activated and their relationship to nf-îºb signaling following reovirusinfection are unknown.
nsubj||caused-5/VBD||variolavirus-1/NNS	appos||variolavirus-1/NNS||varv-3/NNP	root||ROOT-0/null||caused-5/VBD	dobj||caused-5/VBD||smallpox-6/NN	dobj||caused-5/VBD||one-8/CD	conj_and||smallpox-6/NN||one-8/CD	det||diseases-14/NNS||the-10/DT	advmod||devastating-12/JJ||most-11/RBS	amod||diseases-14/NNS||devastating-12/JJ	amod||diseases-14/NNS||human-13/JJ	prep_of||one-8/CD||diseases-14/NNS	det||first-17/JJ||the-16/DT	dobj||caused-5/VBD||first-17/JJ	conj_and||smallpox-6/NN||first-17/JJ	aux||eradicated-20/VBN||to-18/TO	auxpass||eradicated-20/VBN||be-19/VB	vmod||caused-5/VBD||eradicated-20/VBN	poss||release-25/NN||its-23/PRP$	amod||release-25/NN||deliberate-24/JJ	nsubj||represents-26/VBZ||release-25/NN	conj_but||caused-5/VBD||represents-26/VBZ	det||threat-29/NN||a-27/DT	amod||threat-29/NN||dangerous-28/JJ	dobj||represents-26/VBZ||threat-29/NN	smallpox-6||variolavirus-1||no||variolavirus (varv) caused smallpox, one of the most devastating human diseases and the first to be eradicated, but its deliberate release represents a dangerous threat.
det||total-2/NN||a-1/DT	nsubjpass||assigned-27/VBN||total-2/NN	nsubjpass||assigned-27/VBN||total-2/NN	num||men-5/NNS||83-4/CD	prep_of||total-2/NN||men-5/NNS	prep_of||total-2/NN||women-7/NNS	conj_and||men-5/NNS||women-7/NNS	prep_with||men-5/NNS||type2diabetes-9/CD	dep||total-2/NN||aged-11/VBN	number||â-13/CD||56.1-12/CD	num||±-14/NNS||â-13/CD	dobj||aged-11/VBN||±-14/NNS	number||years-16/NNS||7.5-15/CD	amod||±-14/NNS||years-16/NNS	number||35.4-19/CD||bmi-18/CD	num||â-20/NN||35.4-19/CD	npadvmod||±-21/JJ||â-20/NN	dep||years-16/NNS||±-21/JJ	num||kg/m2-23/NNS||4.6-22/CD	dep||years-16/NNS||kg/m2-23/NNS	auxpass||assigned-27/VBN||were-25/VBD	advmod||assigned-27/VBN||randomly-26/RB	root||ROOT-0/null||assigned-27/VBN	conj_or||assigned-27/VBN||assigned-27/VBN	det||diet-33/NN||an-29/DT	amod||diet-33/NN||isocaloric-30/JJ	amod||diet-33/NN||energy-restricted-32/JJ	prep_to||assigned-27/VBN||diet-33/NN	amod||subjects-36/NNS||female-35/JJ	dep||diet-33/NN||subjects-36/NNS	num||subjects-41/NNS||6-37/CD	amod||subjects-41/NNS||mj/day-38/JJ	amod||subjects-41/NNS||male-40/JJ	dep||subjects-36/NNS||subjects-41/NNS	number||mj/day-43/JJ||7-42/CD	amod||subjects-41/NNS||mj/day-43/JJ	det||carbohydrate-48/NN||either-46/DT	amod||carbohydrate-48/NN||standard-47/JJ	prep_of||diet-33/NN||carbohydrate-48/NN	dep||carbohydrate-48/NN||con-50/NN	dep||con-50/NN||carbohydrateproteinfat-52/NN	num||carbohydrateproteinfat-52/NN||531926-53/CD	amod||protein-57/NN||high-56/JJ	prep_of||diet-33/NN||protein-57/NN	conj_or||carbohydrate-48/NN||protein-57/NN	dep||carbohydrate-48/NN||hp-59/NN	dep||hp-59/NN||433322-61/CD	amod||rt-68/NN||supervised-67/JJ	prep_with||assigned-27/VBN||rt-68/NN	prep_without||assigned-27/VBN||rt-68/NN	num||days/week-71/NN||3-70/CD	appos||rt-68/NN||days/week-71/NN	num||weeks-75/NNS||16-74/CD	prep_for||assigned-27/VBN||weeks-75/NNS	type2diabetes-9||fat--1||no_rel||a total of 83 men and women with type2diabetes (aged 56.1 â± 7.5 years, bmi 35.4 â± 4.6 kg/m2) were randomly assigned to an isocaloric, energy-restricted diet (female subjects 6 mj/day, male subjects 7 mj/day) of either standard carbohydrate (con; carbohydrateproteinfat 531926) or high protein (hp; 433322), with or without supervised rt (3 days/week) for 16 weeks.
aux||study-2/VB||to-1/TO	advcl||genotyped-16/VBN||study-2/VB	det||associations-4/NNS||the-3/DT	dobj||study-2/VB||associations-4/NNS	prep_between||associations-4/NNS||aia-6/NN	prep_between||associations-4/NNS||polymorphisms-8/NNS	conj_and||aia-6/NN||polymorphisms-8/NNS	amod||gene-11/NN||cacng6-10/JJ	prep_in||study-2/VB||gene-11/NN	num||variants-14/NNS||eight-13/CD	nsubjpass||genotyped-16/VBN||variants-14/NNS	auxpass||genotyped-16/VBN||were-15/VBD	root||ROOT-0/null||genotyped-16/VBN	number||aia-19/CD||102-18/CD	num||cases-20/NNS||aia-19/CD	prep_in||genotyped-16/VBN||cases-20/NNS	num||controls-28/NNS||429-22/CD	amod||controls-28/NNS||aspirin-tolerant-23/JJ	nn||controls-28/NNS||asthma-24/NN	appos||controls-28/NNS||ata-26/NN	prep_in||genotyped-16/VBN||controls-28/NNS	conj_and||cases-20/NNS||controls-28/NNS	asthma-24||aspirin--1||no||to study the associations between aia and polymorphisms in cacng6 gene, eight variants were genotyped in 102 aia cases and 429 aspirin-tolerant asthma (ata) controls.
nsubj||anticipate-2/VBP||we-1/PRP	root||ROOT-0/null||anticipate-2/VBP	mark||contribute-9/VB||that-3/IN	det||study-5/NN||this-4/DT	nsubj||contribute-9/VB||study-5/NN	nsubj||stimulate-23/VB||study-5/NN	aux||contribute-9/VB||will-6/MD	neg||contribute-9/VB||not-7/RB	advmod||contribute-9/VB||only-8/RB	ccomp||anticipate-2/VBP||contribute-9/VB	det||development-12/NN||the-11/DT	prep_toward||contribute-9/VB||development-12/NN	det||alternative-16/NN||a-14/DT	amod||alternative-16/NN||superior-15/JJ	prep_of||development-12/NN||alternative-16/NN	prep_to||contribute-9/VB||bcg-18/NN	aux||stimulate-23/VB||will-21/MD	advmod||stimulate-23/VB||also-22/RB	ccomp||anticipate-2/VBP||stimulate-23/VB	conj_but||contribute-9/VB||stimulate-23/VB	xcomp||stimulate-23/VB||designing-24/VBG	nn||vaccines-27/NNS||tb-26/NN	prep_of||designing-24/VBG||vaccines-27/NNS	prepc_based_on||designing-24/VBG||on-29/IN	amod||antigens-31/NNS||latency-30/JJ	pobj||designing-24/VBG||antigens-31/NNS	tb-26||bcg-18||no||we anticipate that this study will not only contribute toward the development of a superior alternative to bcg, but will also stimulate designing of tb vaccines based on latency antigens.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||relationship-4/NN||the-3/DT	dobj||investigated-2/VBD||relationship-4/NN	prep_between||relationship-4/NN||maternal-6/NN	vmod||maternal-6/NN||circulating-7/VBG	dobj||circulating-7/VBG||fattyacids-8/NNS	appos||fattyacids-8/NNS||fas-10/NN	amod||intake-15/NN||dietary-13/JJ	nn||intake-15/NN||fa-14/NN	dobj||circulating-7/VBG||intake-15/NN	conj_and||fattyacids-8/NNS||intake-15/NN	amod||women-18/NNS||pregnant-17/JJ	prep_in||intake-15/NN||women-18/NNS	amod||diabetesmellitus-21/NNS||gestational-20/JJ	prep_with||women-18/NNS||diabetesmellitus-21/NNS	dep||diabetesmellitus-21/NNS||gdm-23/NN	dep||gdm-23/NN||n-25/NN	dep||49-27/CD||=-26/SYM	rcmod||n-25/NN||49-27/CD	dobj||circulating-7/VBG||women-30/NNS	conj_and||fattyacids-8/NNS||women-30/NNS	prep_with||women-30/NNS||hyperglycemia-32/NN	advmod||severe-34/JJ||less-33/RBR	amod||hyperglycemia-32/NN||severe-34/JJ	prep_than||hyperglycemia-32/NN||gdm-36/NN	dep||fattyacids-8/NNS||impaired-38/VBN	nn||test-41/NN||glucose-39/NN	nn||test-41/NN||challenge-40/NN	dobj||impaired-38/VBN||test-41/NN	nn||non-gdm-45/NNP||-LSB--42/NNP	nn||non-gdm-45/NNP||gct-43/NNP	nn||non-gdm-45/NNP||-RSB--44/NNP	dep||test-41/NN||non-gdm-45/NNP	dep||test-41/NN||n-47/NN	dep||80-49/CD||=-48/SYM	rcmod||n-47/NN||80-49/CD	amod||subjects-55/NNS||normal-53/JJ	nn||subjects-55/NNS||control-54/NN	dobj||circulating-7/VBG||subjects-55/NNS	conj_and||fattyacids-8/NNS||subjects-55/NNS	dep||subjects-55/NNS||n-57/VBN	dep||98-59/CD||=-58/SYM	ccomp||n-57/VBN||98-59/CD	hyperglycemia-32||glucose-39||no||we investigated the relationship between maternal circulating fattyacids (fas) and dietary fa intake in pregnant women with gestational diabetesmellitus (gdm; n = 49), women with hyperglycemia less severe than gdm (impaired glucose challenge test [gct] non-gdm; n = 80), and normal control subjects ( n = 98).
nsubj||reduced-9/VBD||conclusions-1/NNS	det||regimen-7/NN||an-2/DT	amod||regimen-7/NN||olmesartanmedoxomilâ-3/JJ	amod||regimen-7/NN||±-4/JJ	nn||regimen-7/NN||hctz-5/NN	nn||regimen-7/NN||treatment-6/NN	dep||conclusions-1/NNS||regimen-7/NN	advmod||reduced-9/VBD||significantly-8/RB	root||ROOT-0/null||reduced-9/VBD	dobj||reduced-9/VBD||bp-10/NN	prep_from||reduced-9/VBD||baseline-12/NN	prep_in||reduced-9/VBD||patients-14/NNS	prep_with||patients-14/NNS||hypertension-16/NN	prep_with||patients-14/NNS||type2diabetes-18/NNS	conj_and||hypertension-16/NN||type2diabetes-18/NNS	hypertension-16||hctz-5||yes||conclusions an olmesartanmedoxomilâ±hctz treatment regimen significantly reduced bp from baseline in patients with hypertension and type2diabetes.
aux||identify-2/VB||to-1/TO	advcl||performed-18/VBN||identify-2/VB	amod||locations-5/NNS||new-3/JJ	amod||locations-5/NNS||genomic-4/JJ	dobj||identify-2/VB||locations-5/NNS	vmod||locations-5/NNS||associated-6/VBN	prep_with||associated-6/VBN||irondeficiency-8/NN	det||study-13/NN||a-10/DT	amod||study-13/NN||genome-wide-11/JJ	nn||study-13/NN||association-12/NN	nsubjpass||performed-18/VBN||study-13/NN	appos||study-13/NN||gwas-15/NNS	auxpass||performed-18/VBN||was-17/VBD	root||ROOT-0/null||performed-18/VBN	xcomp||performed-18/VBN||using-19/VBG	dobj||using-19/VBG||dna-20/NN	vmod||dna-20/NN||collected-21/VBN	amod||men-24/NNS||white-23/JJ	prep_from||collected-21/VBN||men-24/NNS	vmod||men-24/NNS||aged-25/VBN	number||-27/CD||â-26/CD	num||y-30/NN||-27/CD	nn||y-30/NN||¥-28/NNP	num||y-30/NN||25-29/CD	dobj||aged-25/VBN||y-30/NN	nn||-34/NN||women-32/NNS	nn||-34/NN||â-33/NN	dobj||aged-25/VBN||-34/NN	conj_and||y-30/NN||-34/NN	vmod||y-30/NN||¥-35/VBG	num||y-37/NN||50-36/CD	dobj||¥-35/VBG||y-37/NN	det||study-47/NN||the-39/DT	amod||study-47/NN||hemochromatosis-40/JJ	conj_and||hemochromatosis-40/JJ||ironoverload-42/JJ	amod||study-47/NN||ironoverload-42/JJ	nn||study-47/NN||screening-43/NN	appos||study-47/NN||heirs-45/NNS	prep_in||y-37/NN||study-47/NN	amod||controls-67/NNS||serum-49/JJ	amod||controls-67/NNS||ferritin-50/JJ	appos||controls-67/NNS||sf-52/NN	nn||controls-67/NNS||â-54/NN	amod||controls-67/NNS||-55/JJ	amod||controls-67/NNS||$-56/$	number||$-56/$||12-57/CD	nn||controls-67/NNS||âµg-58/NN	punct||replete-66/JJ||/-59/:	amod||cases-62/NNS||l-60/JJ	dep||replete-66/JJ||cases-62/NNS	conj_and||cases-62/NNS||iron-65/NN	dep||replete-66/JJ||iron-65/NN	dep||controls-67/NNS||replete-66/JJ	prep_with||¥-35/VBG||controls-67/NNS	dep||controls-67/NNS||sf-69/VBN	number||100-71/CD||>-70/CD	num||âµg-72/NN||100-71/CD	iobj||sf-69/VBN||âµg-72/NN	punct||l-74/NN||/-73/:	dep||âµg-72/NN||l-74/NN	prep_in||l-74/NN||men-76/NNS	advmod||50-80/CD||sf-78/RB	number||50-80/CD||>-79/CD	appos||l-74/NN||50-80/CD	dep||50-80/CD||âµg-81/NN	punct||l-74/NN||/-82/:	dobj||sf-69/VBN||l-83/NN	prep_in||sf-69/VBN||women-85/NNS	irondeficiency-8||iron-65||yes||to identify new genomic locations associated with irondeficiency, a genome-wide association study (gwas) was performed using dna collected from white men aged â¥25 y and women â¥50 y in the hemochromatosis and ironoverload screening (heirs) study with serum ferritin (sf) â¤ 12 âµg/l (cases) and iron replete controls (sf>100 âµg/l in men, sf>50 âµg/l in women).
advmod||play-5/VB||therefore-1/RB	nsubj||play-5/VB||inflammation-3/NN	aux||play-5/VB||may-4/MD	root||ROOT-0/null||play-5/VB	det||role-8/NN||a-6/DT	amod||role-8/NN||causal-7/JJ	dobj||play-5/VB||role-8/NN	det||pathogenesis-11/NNS||the-10/DT	prep_in||play-5/VB||pathogenesis-11/NNS	prep_of||pathogenesis-11/NNS||t2dm-13/CD	csubj||lead-29/VB||reducing-16/VBG	dobj||reducing-16/VBG||it-17/PRP	prep_via||reducing-16/VBG||modulation-19/NN	amod||stress-22/NN||oxidative-21/JJ	prep_of||modulation-19/NN||stress-22/NN	det||response-27/NN||the-24/DT	amod||response-27/NN||innate-25/JJ	amod||response-27/NN||immune-26/JJ	prep_of||modulation-19/NN||response-27/NN	conj_and||stress-22/NN||response-27/NN	aux||lead-29/VB||could-28/MD	conj_and||play-5/VB||lead-29/VB	det||status-32/NN||a-31/DT	prep_to||lead-29/VB||status-32/NN	amod||sensitivity-36/NN||improved-34/VBN	nn||sensitivity-36/NN||insulin-35/NN	prep_of||status-32/NN||sensitivity-36/NN	amod||onset-40/NN||delayed-38/VBN	nn||onset-40/NN||disease-39/NN	prep_of||status-32/NN||onset-40/NN	conj_and||sensitivity-36/NN||onset-40/NN	insulin-35||inflammation-3||no_rel||therefore, inflammation may play a causal role in the pathogenesis of t2dm, and reducing it via modulation of oxidative stress and the innate immune response could lead to a status of improved insulin sensitivity and delayed disease onset.
nn||design-2/NN||research-1/NN	dep||conducted-8/VBD||design-2/NN	nn||$-5/NNP||methodsâ-4/NNP	conj_and||design-2/NN||$-5/NNP	dep||conducted-8/VBD||$-5/NNP	nsubj||conducted-8/VBD||we-7/PRP	root||ROOT-0/null||conducted-8/VBD	amod||studies-10/NNS||case-control-9/JJ	dobj||conducted-8/VBD||studies-10/NNS	num||adults-13/NNS||764-12/CD	prep_in||conducted-8/VBD||adults-13/NNS	num||samples-18/NNS||two-16/CD	amod||samples-18/NNS||independent-17/JJ	prep_from||adults-13/NNS||samples-18/NNS	num||individuals-25/NNS||289-20/CD	amod||individuals-25/NNS||nonobese-21/JJ	conj_and||nonobese-21/JJ||485-23/JJ	amod||individuals-25/NNS||485-23/JJ	amod||individuals-25/NNS||obese-24/JJ	prep_of||samples-18/NNS||individuals-25/NNS	num||children-30/NNS||240-28/CD	amod||children-30/NNS||overweight/obese-29/JJ	prep_in||conducted-8/VBD||children-30/NNS	conj_and||adults-13/NNS||children-30/NNS	vmod||children-30/NNS||undergoing-31/VBG	amod||testing-35/NN||oral-32/JJ	nn||testing-35/NN||glucose-33/NN	nn||testing-35/NN||tolerance-34/NN	dobj||undergoing-31/VBG||testing-35/NN	appos||testing-35/NN||ogtt-37/NN	obese-24||glucose-33||no_rel||research design and methodsâ we conducted case-control studies in 764 adults (from two independent samples of 289 nonobese and 485 obese individuals) and 240 overweight/obese children undergoing oral glucose tolerance testing (ogtt).
prep_in||displayed-9/VBD||vietnam-2/NN	det||population-8/NN||the-4/DT	advmod||diversified-6/VBN||highly-5/RB	amod||population-8/NN||diversified-6/VBN	nn||population-8/NN||gonococcal-7/NN	nsubj||displayed-9/VBD||population-8/NN	root||ROOT-0/null||displayed-9/VBD	amod||resistance-13/NN||high-10/JJ	dep||vitro-12/NN||in-11/IN	amod||resistance-13/NN||vitro-12/NN	dobj||displayed-9/VBD||resistance-13/NN	prep_to||displayed-9/VBD||antimicrobials-15/NNS	advmod||recommended-17/VBN||previously-16/RB	vmod||antimicrobials-15/NNS||recommended-17/VBN	nn||treatment-20/NN||gonorrhoea-19/NN	prep_for||recommended-17/VBN||treatment-20/NN	prep_with||treatment-20/NN||exception-23/NN	prep_of||exception-23/NN||spectinomycin-25/NN	nsubjpass||found-37/VBN||resistance-29/NN	advmod||resistance-29/NN||also-30/RB	det||escs-35/NN||the-32/DT	advmod||escs-35/NN||currently-33/RB	amod||escs-35/NN||recommended-34/VBN	prep_to||resistance-29/NN||escs-35/NN	auxpass||found-37/VBN||were-36/VBD	conj_but||displayed-9/VBD||found-37/VBN	gonococcal-7||spectinomycin-25||yes||in vietnam, the highly diversified gonococcal population displayed high in vitro resistance to antimicrobials previously recommended for gonorrhoea treatment (with exception of spectinomycin), but resistance also to the currently recommended escs were found.
nsubj||agent-5/NN||exenatide-1/NN	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||a-3/DT	amod||agent-5/NN||unique-4/JJ	root||ROOT-0/null||agent-5/NN	nsubj||control-9/VB||agent-5/NN	aux||control-9/VB||can-7/MD	advmod||control-9/VB||effectively-8/RB	rcmod||agent-5/NN||control-9/VB	amod||levels-11/NNS||bloodglucose-10/JJ	dobj||control-9/VB||levels-11/NNS	prep_in||levels-11/NNS||type2diabetesmellitus-13/CD	prepc_without||control-9/VB||producing-15/VBG	amod||effects-18/NNS||dangerous-16/JJ	amod||effects-18/NNS||adverse-17/JJ	dobj||producing-15/VBG||effects-18/NNS	type2diabetesmellitus-13||exenatide-1||yes||exenatide is a unique agent which can effectively control bloodglucose levels in type2diabetesmellitus without producing dangerous adverse effects.
expl||increasing-3/VBG||there-1/EX	aux||increasing-3/VBG||is-2/VBZ	root||ROOT-0/null||increasing-3/VBG	dobj||increasing-3/VBG||evidence-4/NN	nsubj||increasing-3/VBG||evidence-4/NN	amod||effects-7/NNS||anti-tumour-6/JJ	prep_of||evidence-4/NN||effects-7/NNS	prep_of||effects-7/NNS||bisphosphonates-9/NNS	amod||studies-12/NNS||pre-clinical-11/JJ	prep_from||increasing-3/VBG||studies-12/NNS	vmod||increasing-3/VBG||supporting-14/VBG	det||role-16/NN||a-15/DT	dobj||supporting-14/VBG||role-16/NN	det||drugs-19/NNS||these-18/DT	prep_for||role-16/NN||drugs-19/NNS	poss||use-23/NN||their-21/PRP$	amod||use-23/NN||traditional-22/JJ	prep_beyond||supporting-14/VBG||use-23/NN	prep_in||use-23/NN||treatment-25/NN	amod||bonedisease-28/NN||cancer-induced-27/JJ	prep_of||treatment-25/NN||bonedisease-28/NN	bisphosphonates-9||bonedisease-28||no_rel||there is increasing evidence of anti-tumour effects of bisphosphonates from pre-clinical studies, supporting a role for these drugs beyond their traditional use in treatment of cancer-induced bonedisease.
amod||standard-2/NN||gold-1/JJ	nsubj||was-9/VBD||standard-2/NN	det||diagnosis-5/NN||the-4/DT	prep_for||standard-2/NN||diagnosis-5/NN	nn||infection-8/NN||malaria-7/NN	prep_of||diagnosis-5/NN||infection-8/NN	root||ROOT-0/null||was-9/VBD	advmod||was-9/VBD||microscopy-10/RB	gold-1||malaria-7||no_rel||gold standard for the diagnosis of malaria infection was microscopy.
aux||advance-2/VB||to-1/TO	advcl||performed-7/VBD||advance-2/VB	det||studies-4/NNS||these-3/DT	dobj||advance-2/VB||studies-4/NNS	nsubj||performed-7/VBD||we-6/PRP	nsubj||completed-19/VBD||we-6/PRP	root||ROOT-0/null||performed-7/VBD	amod||analysis-10/NN||n-linked-8/JJ	nn||analysis-10/NN||glycan-9/NN	dobj||performed-7/VBD||analysis-10/NN	det||isoforms-15/NNS||the-12/DT	num||isoforms-15/NNS||five-13/CD	amod||isoforms-15/NNS||major-14/JJ	prep_on||performed-7/VBD||isoforms-15/NNS	prep_of||isoforms-15/NNS||a1at-17/CD	conj_and||performed-7/VBD||completed-19/VBD	det||study-22/NN||a-20/DT	amod||study-22/NN||comprehensive-21/JJ	dobj||completed-19/VBD||study-22/NN	det||glycosylation-25/NN||the-24/DT	prep_of||study-22/NN||glycosylation-25/NN	prep_of||glycosylation-25/NN||a1at-27/NNS	vmod||a1at-27/NNS||found-28/VBN	amod||controls-31/NNS||healthy-30/JJ	prep_in||found-28/VBN||controls-31/NNS	appos||controls-31/NNS||patients-33/NNS	amod||livercirrhosis-41/NNS||hepatitisc-35/JJ	dep||hepatitisc-35/JJ||hcv-38/NN	vmod||hcv-38/NN||induced-40/VBN	prep_with||patients-33/NNS||livercirrhosis-41/NNS	prep_in||found-28/VBN||patients-45/NNS	conj_and||controls-31/NNS||patients-45/NNS	vmod||patients-45/NNS||infected-46/VBN	prep_with||infected-46/VBN||hcv-48/NN	det||diagnosis-51/NN||a-50/DT	prep_with||infected-46/VBN||diagnosis-51/NN	nn||carcinoma-54/NN||hepatocellular-53/NN	prep_of||diagnosis-51/NN||carcinoma-54/NN	appos||carcinoma-54/NN||hcc-56/NN	hepatitisc-35||hcv-48||no||to advance these studies, we performed n-linked glycan analysis on the five major isoforms of a1at and completed a comprehensive study of the glycosylation of a1at found in healthy controls, patients with hepatitisc- (hcv) induced livercirrhosis, and in patients infected with hcv with a diagnosis of hepatocellular carcinoma (hcc).
amod||priondiseases-2/NNS||genetic-1/JJ	nsubj||develop-5/VBP||priondiseases-2/NNS	nsubj||account-18/VBP||priondiseases-2/NNS	rcmod||priondiseases-2/NNS||develop-5/VBP	acomp||develop-5/VBP||due-6/JJ	det||mutations-9/NNS||a-8/DT	prep_to||due-6/JJ||mutations-9/NNS	det||gene-13/NN||the-11/DT	nn||gene-13/NN||prionprotein-12/NN	prep_in||mutations-9/NNS||gene-13/NN	appos||gene-13/NN||prnp-15/NN	root||ROOT-0/null||account-18/VBP	det||10-22/CD||an-20/DT	amod||10-22/CD||estimated-21/VBN	prep_for||account-18/VBP||10-22/CD	num||%-25/NN||15-24/CD	prep_to||10-22/CD||%-25/NN	det||cases-29/NNS||all-27/DT	nn||cases-29/NNS||cjd-28/NN	prep_of||%-25/NN||cases-29/NNS	priondiseases-2||prionprotein-12||no||genetic priondiseases, which develop due to a mutations in the prionprotein gene (prnp), account for an estimated 10 to 15% of all cjd cases.
amod||analysis-3/NN||multivariate-2/JJ	prep_in||associated-11/VBN||analysis-3/NN	det||use-7/NN||the-5/DT	amod||use-7/NN||concomitant-6/JJ	nsubjpass||associated-11/VBN||use-7/NN	prep_of||use-7/NN||cy-9/NN	auxpass||associated-11/VBN||was-10/VBD	root||ROOT-0/null||associated-11/VBN	det||age-15/NN||a-13/DT	amod||age-15/NN||younger-14/JJR	prep_with||associated-11/VBN||age-15/NN	amod||hemorrhage-18/NN||pulmonary-17/JJ	prep_with||associated-11/VBN||hemorrhage-18/NN	conj_and||age-15/NN||hemorrhage-18/NN	nn||patients-21/NNS||mpa-20/NN	prep_in||associated-11/VBN||patients-21/NNS	det||avoidance-25/NN||the-24/DT	nsubjpass||associated-29/VBN||avoidance-25/NN	prep_of||avoidance-25/NN||cy-27/NN	auxpass||associated-29/VBN||was-28/VBD	conj_and||associated-11/VBN||associated-29/VBN	amod||symptoms-33/NNS||nervous-31/JJ	nn||symptoms-33/NNS||system-32/NN	nn||glomerulonephritis-37/NNS||symptoms-33/NNS	advmod||symptoms-33/NNS||rapidly-35/RB	conj_and||symptoms-33/NNS||rapidly-35/RB	nn||glomerulonephritis-37/NNS||rapidly-35/RB	amod||glomerulonephritis-37/NNS||progressive-36/JJ	prep_with||associated-29/VBN||glomerulonephritis-37/NNS	nn||patients-40/NNS||gpa-39/NN	prep_in||associated-29/VBN||patients-40/NNS	hemorrhage-18||mpa-20||no||in multivariate analysis, the concomitant use of cy was associated with a younger age and pulmonary hemorrhage in mpa patients, and the avoidance of cy was associated with nervous system symptoms and rapidly progressive glomerulonephritis in gpa patients.
nsubj||analyzed-2/VBD||we-1/PRP	root||ROOT-0/null||analyzed-2/VBD	nsubj||retrieved-4/VBD||data-3/NNS	nsubj||compare-38/VB||data-3/NNS	ccomp||analyzed-2/VBD||retrieved-4/VBD	det||search-8/NN||a-6/DT	amod||search-8/NN||pubmed-7/JJ	prep_through||retrieved-4/VBD||search-8/NN	amod||trials-13/NNS||randomized-10/JJ	amod||trials-13/NNS||placebo-controlled-12/JJ	prep_of||search-8/NN||trials-13/NNS	amod||injectables-18/NNS||first-generation-15/JJ	amod||injectables-18/NNS||antipsychotic-16/JJ	amod||injectables-18/NNS||long-acting-17/JJ	prep_of||trials-13/NNS||injectables-18/NNS	dep||injectables-18/NNS||haloperidoldecanoate-20/NN	amod||decanoate-23/NN||bromperidol-22/JJ	dep||injectables-18/NNS||decanoate-23/NN	conj_and||haloperidoldecanoate-20/NN||decanoate-23/NN	dep||injectables-18/NNS||fluphenazinedecanoate-26/NN	conj_and||haloperidoldecanoate-20/NN||fluphenazinedecanoate-26/NN	det||database-32/NN||a-30/DT	nn||database-32/NN||company-31/NN	prep_of||trials-13/NNS||database-32/NN	conj_and||injectables-18/NNS||database-32/NN	amod||palmitate-35/NN||paliperidone-34/JJ	prep_of||database-32/NN||palmitate-35/NN	aux||compare-38/VB||to-37/TO	xcomp||retrieved-4/VBD||compare-38/VB	det||ratio-41/NN||the-39/DT	amod||ratio-41/NN||benefit-risk-40/JJ	dobj||compare-38/VB||ratio-41/NN	prep_in||compare-38/VB||patients-43/NNS	prep_with||patients-43/NNS||schizophrenia-45/NN	schizophrenia-45||haloperidoldecanoate-20||yes||we analyzed data retrieved through a pubmed search of randomized, placebo-controlled trials of first-generation antipsychotic long-acting injectables (haloperidoldecanoate, bromperidol decanoate, and fluphenazinedecanoate), and a company database of paliperidone palmitate, to compare the benefit-risk ratio in patients with schizophrenia.
amod||response-2/NN||virological-1/JJ	nsubjpass||predicted-15/VBN||response-2/NN	amod||therapy-5/NN||antiviral-4/JJ	prep_to||response-2/NN||therapy-5/NN	prep_in||therapy-5/NN||patients-7/NNS	prep_with||patients-7/NNS||hepatitisc-9/JJ	amod||hepatitisc-9/JJ||recurring-10/VBG	prep_after||hepatitisc-9/JJ||ldlt-12/NN	aux||predicted-15/VBN||can-13/MD	auxpass||predicted-15/VBN||be-14/VB	root||ROOT-0/null||predicted-15/VBN	prep_prior_to||predicted-15/VBN||transplant-18/NN	prepc_based_on||predicted-15/VBN||on-21/IN	amod||levels-25/NNS||pretransplant-22/JJ	nn||levels-25/NNS||serum-23/NN	nn||levels-25/NNS||hcv-rna-24/NN	pobj||predicted-15/VBN||levels-25/NNS	nn||genotype-28/NN||hcv-27/NN	pobj||predicted-15/VBN||genotype-28/NN	conj_and||levels-25/NNS||genotype-28/NN	hepatitisc-9||hcv-27||no||virological response to antiviral therapy in patients with hepatitisc recurring after ldlt can be predicted prior to transplant, based on pretransplant serum hcv-rna levels and hcv genotype.
det||study-4/NN||this-2/DT	amod||study-4/NN||prospective-3/JJ	prep_in||associated-14/VBN||study-4/NN	prep_of||study-4/NN||women-6/NNS	nn||size-10/NN||nmr-8/NN	nn||size-10/NN||lipoprotein-9/NN	nsubjpass||associated-14/VBN||size-10/NN	nsubjpass||remained-19/VBD||size-10/NN	conj_and||size-10/NN||concentrations-12/NNS	nsubjpass||associated-14/VBN||concentrations-12/NNS	auxpass||associated-14/VBN||were-13/VBD	root||ROOT-0/null||associated-14/VBN	nn||type2diabetes-17/NNS||incident-16/NN	prep_with||associated-14/VBN||type2diabetes-17/NNS	conj_and||associated-14/VBN||remained-19/VBD	acomp||remained-19/VBD||significant-20/JJ	prep_after||significant-20/JJ||adjustment-22/NN	amod||factors-26/NNS||established-24/VBN	nn||factors-26/NNS||risk-25/NN	prep_for||adjustment-22/NN||factors-26/NNS	nn||cholesterol-30/NN||hdl-29/NN	prep_including||associated-14/VBN||cholesterol-30/NN	prep_including||associated-14/VBN||triglycerides-32/NNPS	conj_and||cholesterol-30/NN||triglycerides-32/NNPS	type2diabetes-17||triglycerides-32||no_rel||in this prospective study of women, nmr lipoprotein size and concentrations were associated with incident type2diabetes and remained significant after adjustment for established risk factors, including hdl cholesterol and triglycerides.
nsubj||examined-3/VBD||we-1/PRP	advmod||examined-3/VBD||therefore-2/RB	root||ROOT-0/null||examined-3/VBD	det||integrity-7/NN||the-4/DT	amod||integrity-7/NN||synovial-5/JJ	nn||integrity-7/NN||lining-6/NN	nsubj||wear-19/VBP||integrity-7/NN	amod||infiltrates-11/NNS||inflammatory-9/JJ	nn||infiltrates-11/NNS||cell-10/NN	conj_and||integrity-7/NN||infiltrates-11/NNS	nsubj||wear-19/VBP||infiltrates-11/NNS	nn||organization-14/NN||tissue-13/NN	conj_and||integrity-7/NN||organization-14/NN	nsubj||wear-19/VBP||organization-14/NN	conj_and||integrity-7/NN||necrosis-16/NNS	nsubj||wear-19/VBP||necrosis-16/NNS	conj_and||integrity-7/NN||metal-18/NN	nsubj||wear-19/VBP||metal-18/NN	ccomp||examined-3/VBD||wear-19/VBP	nsubj||causes-37/VBZ||particles-20/NNS	amod||tissues-23/NNS||pseudotumor-like-22/JJ	prep_of||particles-20/NNS||tissues-23/NNS	amod||hips-26/NNS||m-m-25/JJ	prep_from||tissues-23/NNS||hips-26/NNS	vmod||hips-26/NNS||revised-27/VBN	amod||wear-31/NN||suspected-29/VBN	amod||wear-31/NN||high-30/JJ	prep_for||revised-27/VBN||wear-31/NN	amod||wear-31/NN||related-32/VBN	amod||metal-35/NN||suspected-34/VBN	prep_for||revised-27/VBN||metal-35/NN	conj_and||wear-31/NN||metal-35/NN	advmod||causes-37/VBZ||hypersensitivity-36/RB	ccomp||wear-19/VBP||causes-37/VBZ	metal-35||hypersensitivity-36||no_rel||we therefore examined the synovial lining integrity, inflammatory cell infiltrates, tissue organization, necrosis and metal wear particles of pseudotumor-like tissues from m-m hips revised for suspected high wear related and suspected metal hypersensitivity causes.
nsubj||remained-7/VBN||hepatitisbvirus-1/NNS	appos||hepatitisbvirus-1/NNS||hbv-3/NN	advmod||remained-7/VBN||infection-5/RB	aux||remained-7/VBN||has-6/VBZ	root||ROOT-0/null||remained-7/VBN	det||problem-12/NN||a-8/DT	amod||problem-12/NN||significant-9/JJ	amod||problem-12/NN||public-10/JJ	nn||problem-12/NN||health-11/NN	xcomp||remained-7/VBN||problem-12/NN	hbv-3||hepatitisbvirus-1||no||hepatitisbvirus (hbv) infection has remained a significant public health problem.
root||ROOT-0/null||basal-1/NN	conj_and||basal-1/NN||interferon-alpha-3/NN	nn||±-6/NNP||ifn-î-5/NNP	appos||basal-1/NN||±-6/NNP	conj_or||basal-1/NN||interferon-gamma-9/NN	nn||³-12/NNP||ifn-î-11/NNP	appos||interferon-gamma-9/NN||³-12/NNP	amod||expression-16/NN||induced-15/JJ	nsubjpass||evaluated-23/VBN||expression-16/NN	amod||proteins-21/NNS||socs1-18/JJ	conj_and||socs1-18/JJ||socs3-20/JJ	amod||proteins-21/NNS||socs3-20/JJ	prep_of||expression-16/NN||proteins-21/NNS	auxpass||evaluated-23/VBN||was-22/VBD	dep||basal-1/NN||evaluated-23/VBN	amod||analysis-26/NN||immunoblot-25/JJ	agent||evaluated-23/VBN||analysis-26/NN	det||panel-29/NN||a-28/DT	prep_in||analysis-26/NN||panel-29/NN	prep_of||panel-29/NN||n-31/NN	dep||lines-38/NNS||=-32/SYM	num||lines-38/NNS||10-33/CD	amod||lines-38/NNS||metastatic-34/JJ	amod||lines-38/NNS||human-35/JJ	nn||lines-38/NNS||melanoma-36/NNP	nn||lines-38/NNS||cell-37/NN	ccomp||evaluated-23/VBN||lines-38/NNS	amod||melanocytes-43/NNS||human-41/JJ	amod||melanocytes-43/NNS||embryonic-42/JJ	prep_in||basal-1/NN||melanocytes-43/NNS	appos||melanocytes-43/NNS||hem-45/NN	prep_in||basal-1/NN||radial-49/NN	conj_and||melanocytes-43/NNS||radial-49/NN	amod||cells-55/NNS||vertical-51/JJ	nn||cells-55/NNS||growth-52/NN	nn||cells-55/NNS||phase-53/NN	nn||cells-55/NNS||melanoma-54/NN	conj_and||melanocytes-43/NNS||cells-55/NNS	conj_or||radial-49/NN||cells-55/NNS	melanoma-54||interferon--1||yes||basal and interferon-alpha (ifn-î±) or interferon-gamma (ifn-î³)-induced expression of socs1 and socs3 proteins was evaluated by immunoblot analysis in a panel of n = 10 metastatic human melanoma cell lines, in human embryonic melanocytes (hem), and radial or vertical growth phase melanoma cells.
nsubj||represents-2/VBZ||insulin-resistance-1/NN	root||ROOT-0/null||represents-2/VBZ	det||mechanism-5/NN||the-3/DT	amod||mechanism-5/NN||common-4/JJ	dobj||represents-2/VBZ||mechanism-5/NN	nsubj||leads-7/VBZ||mechanism-5/NN	rcmod||mechanism-5/NN||leads-7/VBZ	prep_to||leads-7/VBZ||type2diabetes-9/NNS	amod||subjects-12/NNS||obese-11/JJ	prep_in||type2diabetes-9/NNS||subjects-12/NNS	type2diabetes-9||insulin--1||yes||insulin-resistance represents the common mechanism that leads to type2diabetes in obese subjects.
nsubj||unknown-4/JJ||it-1/PRP	cop||unknown-4/JJ||is-2/VBZ	advmod||unknown-4/JJ||yet-3/RB	root||ROOT-0/null||unknown-4/JJ	advmod||have-10/VBP||why-5/WRB	det||patients-8/NNS||some-6/DT	nn||patients-8/NNS||gbs-7/NN	nsubj||have-10/VBP||patients-8/NNS	advmod||have-10/VBP||only-9/RB	advcl||unknown-4/JJ||have-10/VBP	det||increase-13/NN||a-11/DT	amod||increase-13/NN||minor-12/JJ	dobj||have-10/VBP||increase-13/NN	amod||treatment-17/NN||standard-15/JJ	nn||treatment-17/NN||ivig-16/NN	prep_after||have-10/VBP||treatment-17/NN	gbs-7||ivig-16||yes||it is yet unknown why some gbs patients only have a minor increase after standard ivig treatment.
nsubj||are-8/VBP||patients-1/NNS	nn||infection-7/NN||humanimmunodeficiencyvirus-3/NNP	appos||infection-7/NN||hiv-5/NN	prep_with||patients-1/NNS||infection-7/NN	root||ROOT-0/null||are-8/VBP	prep_at||are-8/VBP||risk-10/NN	prep_for||risk-10/NN||mycobacteriumtuberculosis-12/NNS	appos||mycobacteriumtuberculosis-12/NNS||tb-14/NN	vmod||mycobacteriumtuberculosis-12/NNS||coinfection-16/VBN	tb-14||mycobacteriumtuberculosis-12||no||patients with humanimmunodeficiencyvirus (hiv) infection are at risk for mycobacteriumtuberculosis (tb) coinfection.
nsubj||lungdisease-5/NN||silicosis-1/NNS	cop||lungdisease-5/NN||is-2/VBZ	det||lungdisease-5/NN||an-3/DT	amod||lungdisease-5/NN||occupational-4/JJ	root||ROOT-0/null||lungdisease-5/NN	vmod||lungdisease-5/NN||caused-6/VBN	agent||caused-6/VBN||inhalation-8/NN	prep_of||inhalation-8/NN||silicadust-10/NN	vmod||silicadust-10/NN||characterized-11/VBN	agent||characterized-11/VBN||lunginflammation-13/NN	agent||characterized-11/VBN||fibrosis-15/NN	conj_and||lunginflammation-13/NN||fibrosis-15/NN	silicosis-1||silicadust-10||no||silicosis is an occupational lungdisease caused by inhalation of silicadust characterized by lunginflammation and fibrosis.
nsubj||investigated-15/VBD||aims-1/NNS	det||trial-14/NN||this-2/DT	amod||trial-14/NN||52-week-3/JJ	amod||trial-14/NN||randomized-5/JJ	amod||trial-14/NN||multinational-7/JJ	amod||trial-14/NN||open-label-9/JJ	amod||trial-14/NN||parallel-group-11/JJ	amod||trial-14/NN||non-inferiority-13/JJ	dep||aims-1/NNS||trial-14/NN	root||ROOT-0/null||investigated-15/VBD	det||efficacy-17/NN||the-16/DT	nsubj||bolus-24/VBZ||efficacy-17/NN	conj_and||efficacy-17/NN||safety-19/NN	nsubj||bolus-24/VBZ||safety-19/NN	nn||$-22/NNP||basalâ-21/NNP	prep_of||efficacy-17/NN||$-22/NNP	ccomp||investigated-15/VBD||bolus-24/VBZ	dobj||bolus-24/VBZ||treatment-25/NN	prep_with||bolus-24/VBZ||insulin-27/NN	nn||insulin-27/NN||detemir-28/FW	nn||insulin-27/NN||vs.-29/FW	nn||insulin-27/NN||nph-30/FW	nn||insulin-27/NN||-lrb--31/FW	nn||insulin-27/NN||neutral-32/FW	nn||insulin-27/NN||protamine-33/FW	nn||insulin-27/NN||hagedorn-34/FW	nn||insulin-27/NN||-rrb--35/FW	dep||insulin-27/NN||insulin-36/FW	prep_in||insulin-27/NN||combination-39/NN	prep_with||combination-39/NN||insulinaspart-41/NN	prep_in||combination-39/NN||subjects-44/NNS	vmod||subjects-44/NNS||aged-45/VBN	dobj||aged-45/VBN||2â-46/NNS	num||years-50/NNS||$-47/$	num||$-47/$||16-49/CD	npadvmod||aged-45/VBN||years-50/NNS	prep_with||aged-45/VBN||type1diabetesmellitus-52/CD	type1diabetesmellitus-52||insulin-36||yes||aims this 52-week , randomized , multinational , open-label , parallel-group , non-inferiority trial investigated the efficacy and safety of basalâ $ `` bolus treatment with insulin detemir vs. nph -lrb- neutral protamine hagedorn -rrb- insulin , in combination with insulinaspart , in subjects aged 2â $ `` 16 years with type1diabetesmellitus .
nsubj||titrated-2/VBD||conclusions-1/NNS	root||ROOT-0/null||titrated-2/VBD	nn||treatment-4/NN||oxygen-3/NN	nsubj||reduced-6/VBD||treatment-4/NN	advmod||reduced-6/VBD||significantly-5/RB	ccomp||titrated-2/VBD||reduced-6/VBD	dobj||reduced-6/VBD||mortality-7/NN	dobj||reduced-6/VBD||hypercapnia-9/NN	conj_and||mortality-7/NN||hypercapnia-9/NN	dobj||reduced-6/VBD||respiratoryacidosis-12/NN	conj_and||mortality-7/NN||respiratoryacidosis-12/NN	prepc_compared_with||reduced-6/VBD||with-14/IN	amod||oxygen-17/NN||high-15/JJ	nn||oxygen-17/NN||flow-16/NN	pobj||reduced-6/VBD||oxygen-17/NN	amod||exacerbations-20/NNS||acute-19/JJ	prep_in||oxygen-17/NN||exacerbations-20/NNS	amod||obstructivepulmonarydisease-23/NN||chronic-22/JJ	prep_of||exacerbations-20/NNS||obstructivepulmonarydisease-23/NN	obstructivepulmonarydisease-23||oxygen-17||yes||conclusions titrated oxygen treatment significantly reduced mortality, hypercapnia, and respiratoryacidosis compared with high flow oxygen in acute exacerbations of chronic obstructivepulmonarydisease.
det||manuscript-2/NN||this-1/DT	nsubj||reviews-3/VBZ||manuscript-2/NN	root||ROOT-0/null||reviews-3/VBZ	det||evidence-6/NN||the-4/DT	amod||evidence-6/NN||available-5/JJ	dobj||reviews-3/VBZ||evidence-6/NN	nn||searches-11/NNS||medline-8/NN	conj_and||medline-8/NN||embase-10/NN	nn||searches-11/NNS||embase-10/NN	prep_including||evidence-6/NN||searches-11/NNS	prep_including||evidence-6/NN||abstracts-13/NNS	conj_and||searches-11/NNS||abstracts-13/NNS	amod||meetings-17/NNS||international-15/JJ	nn||meetings-17/NNS||allergy-16/NN	prep_of||abstracts-13/NNS||meetings-17/NNS	nn||papers-20/NNS||position-19/NN	prep_including||evidence-6/NN||papers-20/NNS	conj_and||searches-11/NNS||papers-20/NNS	det||literature-25/NN||the-22/DT	nn||literature-25/NN||world-23/NN	nn||literature-25/NN||allergy-24/NN	prep_from||papers-20/NNS||literature-25/NN	allergy-24||allergy-24||no||this manuscript reviews the available evidence including medline and embase searches, abstracts of international allergy meetings and position papers from the world allergy literature.
advmod||hbsag-24/VBG||furthermore-1/RB	mark||expressed-12/VBD||while-3/IN	nsubj||expressed-12/VBD||most-4/JJS	det||controls-7/NNS||the-6/DT	prep_of||most-4/JJS||controls-7/NNS	amod||infection-11/NN||ongoing-9/JJ	nn||infection-11/NN||hbv-10/NN	prep_with||controls-7/NNS||infection-11/NN	advcl||hbsag-24/VBG||expressed-12/VBD	xcomp||expressed-12/VBD||hbsag-13/VBG	det||majority-16/NN||the-15/DT	nsubj||hbsag-24/VBG||majority-16/NN	nn||patients-22/NNS||hcv-18/NN	conj_and||hcv-18/NN||hbv-20/JJ	nn||patients-22/NNS||hbv-20/JJ	amod||patients-22/NNS||positive-21/JJ	prep_of||majority-16/NN||patients-22/NNS	aux||hbsag-24/VBG||were-23/VBD	root||ROOT-0/null||hbsag-24/VBG	amod||positive-29/NN||negative-25/JJ	conj_and||negative-25/JJ||hbv-27/NN	amod||positive-29/NN||hbv-27/NN	nn||positive-29/NN||dna-28/NN	dobj||hbsag-24/VBG||positive-29/NN	hbv-27||hbsag-24||yes||furthermore, while most of the controls with ongoing hbv infection expressed hbsag, the majority of hcv and hbv positive patients were hbsag negative and hbv dna positive.
nsubjpass||studied-17/VBN||associations-1/NNS	nn||estrogens-4/NNS||serum-3/NN	prep_of||associations-1/NNS||estrogens-4/NNS	prep_of||associations-1/NNS||androgens-6/NNS	conj_and||estrogens-4/NNS||androgens-6/NNS	nn||risk-10/NN||breast-8/NN	nn||risk-10/NN||cancer-9/NN	prep_with||estrogens-4/NNS||risk-10/NN	amod||women-13/NNS||premenopausal-12/JJ	prep_in||risk-10/NN||women-13/NNS	auxpass||studied-17/VBN||are-14/VBP	advmod||well-16/RB||less-15/RBR	advmod||studied-17/VBN||well-16/RB	root||ROOT-0/null||studied-17/VBN	androgens-6||cancer-9||no_rel||associations of serum estrogens and androgens with breast cancer risk in premenopausal women are less well studied.
advmod||pathogenic-2/JJ||highly-1/RB	amod||a/h5n1-4/NNS||pathogenic-2/JJ	nn||a/h5n1-4/NNS||avianinfluenzavirus-3/NN	nsubjpass||reported-8/VBN||a/h5n1-4/NNS	auxpass||reported-8/VBN||was-5/VBD	advmod||reported-8/VBN||first-6/RB	advmod||reported-8/VBN||officially-7/RB	root||ROOT-0/null||reported-8/VBN	prep_in||reported-8/VBN||africa-10/NN	amod||2006-13/CD||early-12/JJ	prep_in||africa-10/NN||2006-13/CD	h5n1--1||avianinfluenzavirus-3||no||highly pathogenic avianinfluenzavirus a/h5n1 was first officially reported in africa in early 2006.
det||herpesviruses-2/NNS||some-1/DT	nsubj||integrate-26/VB||herpesviruses-2/NNS	advmod||lymphotropic-5/JJ||particularly-4/RB	amod||viruses-6/NNS||lymphotropic-5/JJ	appos||herpesviruses-2/NNS||viruses-6/NNS	prepc_such_as||viruses-6/NNS||marekâ-9/VBG	amod||virus-14/NN||$-10/$	number||s-12/CD||-11/CD	num||$-10/$||s-12/CD	nn||virus-14/NN||disease-13/NN	dobj||marekâ-9/VBG||virus-14/NN	appos||virus-14/NN||mdv-16/NN	amod||herpesvirus-20/NNS||human-19/JJ	dobj||marekâ-9/VBG||herpesvirus-20/NNS	conj_and||virus-14/NN||herpesvirus-20/NNS	dep||herpesvirus-20/NNS||6-21/CD	dep||6-21/CD||hhv-6-23/JJ	root||ROOT-0/null||integrate-26/VB	poss||dna-28/NN||their-27/PRP$	dobj||integrate-26/VB||dna-28/NN	nn||chromosomes-31/NNS||host-30/NN	prep_into||integrate-26/VB||chromosomes-31/NNS	virus-14||viruses-6||no||some herpesviruses, particularly lymphotropic viruses such as marekâs disease virus (mdv) and human herpesvirus 6 (hhv-6), integrate their dna into host chromosomes.
amod||changes-2/NNS||monthly-1/JJ	nsubjpass||analyzed-12/VBN||changes-2/NNS	det||volume-5/NN||the-4/DT	prep_in||changes-2/NNS||volume-5/NN	amod||services-10/NNS||hiv-7/JJ	conj_and||hiv-7/JJ||non-hiv-9/JJ	amod||services-10/NNS||non-hiv-9/JJ	prep_of||volume-5/NN||services-10/NNS	auxpass||analyzed-12/VBN||were-11/VBD	root||ROOT-0/null||analyzed-12/VBN	agent||analyzed-12/VBN||using-14/VBG	amod||models-16/NNS||multilevel-15/JJ	dobj||using-14/VBG||models-16/NNS	aux||examine-18/VB||to-17/TO	vmod||using-14/VBG||examine-18/VB	det||effect-20/NN||the-19/DT	dobj||examine-18/VB||effect-20/NN	det||program-24/NN||an-22/DT	amod||program-24/NN||hiv/aids-23/JJ	prep_of||effect-20/NN||program-24/NN	nn||delivery-28/NN||health-26/NN	nn||delivery-28/NN||service-27/NN	prep_on||examine-18/VB||delivery-28/NN	aids--1||hiv-7||no||monthly changes in the volume of hiv and non-hiv services were analyzed by using multilevel models to examine the effect of an hiv/aids program on health service delivery.
num||patients-2/NNS||six-1/CD	nsubj||had-7/VBD||patients-2/NNS	amod||results-6/NNS||discordant-4/JJ	nn||results-6/NNS||test-5/NN	prep_with||patients-2/NNS||results-6/NNS	root||ROOT-0/null||had-7/VBD	preconj||tst-14/NN||either-8/DT	dep||tst-14/NN||1-10/LS	det||tst-14/NN||a-12/DT	amod||tst-14/NN||negative-13/JJ	dobj||had-7/VBD||tst-14/NN	amod||igra-17/NN||positive-16/JJ	dobj||had-7/VBD||igra-17/NN	conj_and||tst-14/NN||igra-17/NN	prep_in||tst-14/NN||combination-19/NN	det||history-23/NN||a-21/DT	amod||history-23/NN||medical-22/JJ	prep_with||combination-19/NN||history-23/NN	nn||exposure-26/NN||tuberculosis-25/NNP	prep_of||history-23/NN||exposure-26/NN	nn||â-29/NN||n-28/NN	dep||combination-19/NN||â-29/NN	nsubj||â-33/VBP||$-30/$	number||=-32/CD||-31/CD	num||$-30/$||=-32/CD	rcmod||â-29/NN||â-33/VBP	dobj||â-33/VBP||$-34/$	number||1-36/CD||-35/CD	num||$-34/$||1-36/CD	dep||tst-44/NN||2-40/LS	det||tst-44/NN||a-42/DT	amod||tst-44/NN||positive-43/JJ	prep_in||tst-14/NN||tst-44/NN	conj_or||combination-19/NN||tst-44/NN	amod||igra-47/NN||negative-46/JJ	conj_or||combination-19/NN||igra-47/NN	conj_and||tst-44/NN||igra-47/NN	prep_in||tst-44/NN||combination-49/NN	nn||vaccination-52/NN||bcg-51/NN	prep_with||combination-49/NN||vaccination-52/NN	nn||â-55/NN||n-54/NN	dep||combination-49/NN||â-55/NN	nsubj||â-59/VBP||$-56/$	number||=-58/CD||-57/CD	num||$-56/$||=-58/CD	rcmod||â-55/NN||â-59/VBP	dobj||â-59/VBP||$-60/$	number||3-62/CD||-61/CD	num||$-60/$||3-62/CD	det||history-67/NN||a-65/DT	amod||history-67/NN||medical-66/JJ	dobj||had-7/VBD||history-67/NN	conj_or||tst-14/NN||history-67/NN	nn||exposure-70/NN||tuberculosis-69/NNP	prep_of||history-67/NN||exposure-70/NN	nn||â-73/NN||n-72/NN	dep||history-67/NN||â-73/NN	nsubj||â-77/VBP||$-74/$	number||=-76/CD||-75/CD	num||$-74/$||=-76/CD	rcmod||â-73/NN||â-77/VBP	dobj||â-77/VBP||$-78/$	number||2-80/CD||-79/CD	num||$-78/$||2-80/CD	tuberculosis-69||bcg-51||yes||six patients with discordant test results had either (1) a negative tst and positive igra in combination with a medical history of tuberculosis exposure ( n â=â1) or (2) a positive tst and negative igra in combination with bcg vaccination ( n â=â3) or a medical history of tuberculosis exposure ( n â=â2).
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	det||factors-5/NNS||the-3/DT	amod||factors-5/NNS||clinical-4/JJ	dobj||evaluated-2/VBN||factors-5/NNS	nsubj||affect-7/VBP||factors-5/NNS	rcmod||factors-5/NNS||affect-7/VBP	det||pain-9/NN||the-8/DT	dobj||affect-7/VBP||pain-9/NN	prep_on||affect-7/VBP||injection-11/NN	prep_of||injection-11/NN||propofol-13/NN	aux||develop-15/VB||to-14/TO	vmod||evaluated-2/VBN||develop-15/VB	det||strategy-17/NN||a-16/DT	dobj||develop-15/VB||strategy-17/NN	aux||prevent-19/VB||to-18/TO	vmod||strategy-17/NN||prevent-19/VB	vmod||strategy-17/NN||reduce-21/VB	conj_or||prevent-19/VB||reduce-21/VB	dobj||prevent-19/VB||pain-22/NN	pain-22||propofol-13||yes||we evaluated the clinical factors that affect the pain on injection of propofol to develop a strategy to prevent or reduce pain.
det||report-2/NN||this-1/DT	nsubj||describes-3/VBZ||report-2/NN	root||ROOT-0/null||describes-3/VBZ	det||efficacy-5/NN||the-4/DT	dobj||describes-3/VBZ||efficacy-5/NN	prep_of||efficacy-5/NN||sitagliptin-7/NN	num||patients-11/NNS||three-9/CD	amod||patients-11/NNS||japanese-10/JJ	prep_in||sitagliptin-7/NN||patients-11/NNS	nsubj||had-41/VBD||patients-11/NNS	det||woman-16/NN||a-13/DT	amod||woman-16/NN||91-year-old-14/JJ	nn||woman-16/NN||japanese-15/NN	dep||patients-11/NNS||woman-16/NN	prep_with||woman-16/NN||type1diabetes-18/CD	det||man-23/NN||a-20/DT	amod||man-23/NN||54-year-old-21/JJ	nn||man-23/NN||japanese-22/NN	dep||patients-11/NNS||man-23/NN	conj_and||woman-16/NN||man-23/NN	prep_with||man-23/NN||type2diabetes-25/CD	det||man-30/NN||a-27/DT	amod||man-30/NN||30-year-old-28/JJ	nn||man-30/NN||japanese-29/NN	conj_and||woman-16/NN||man-30/NN	conj_and||man-23/NN||man-30/NN	prep_with||man-30/NN||features-32/NNS	det||type-35/NN||both-34/DT	prep_of||features-32/NNS||type-35/NN	num||type-35/NN||1-36/CD	dep||patients-11/NNS||type2diabetes-38/NNS	conj_and||woman-16/NN||type2diabetes-38/NNS	rcmod||patients-11/NNS||had-41/VBD	neg||levels-46/NNS||no-42/DT	amod||levels-46/NNS||detectable-43/JJ	amod||levels-46/NNS||post-meal-44/JJ	amod||levels-46/NNS||c-peptide-45/JJ	dobj||had-41/VBD||levels-46/NNS	type2diabetes-38||sitagliptin-7||yes||this report describes the efficacy of sitagliptin in three japanese patients (a 91-year-old japanese woman with type1diabetes, a 54-year-old japanese man with type2diabetes and a 30-year-old japanese man with features of both type 1 and type2diabetes) who had no detectable post-meal c-peptide levels.
nn||alpha-2/NNS||interferon-1/NN	nsubjpass||used-9/VBN||alpha-2/NNS	nn||±-5/NNP||ifn-î-4/NNP	appos||alpha-2/NNS||±-5/NNP	aux||used-9/VBN||has-7/VBZ	auxpass||used-9/VBN||been-8/VBN	root||ROOT-0/null||used-9/VBN	det||therapy-13/NN||a-11/DT	nn||therapy-13/NN||maintenance-12/NN	prep_as||used-9/VBN||therapy-13/NN	mark||stem-16/VBP||after-14/IN	nsubj||stem-16/VBP||autologous-15/NNS	advcl||used-9/VBN||stem-16/VBP	nn||transplantation-18/NN||cell-17/NN	dobj||stem-16/VBP||transplantation-18/NN	appos||transplantation-18/NN||asct-20/NN	amod||patients-27/NNS||multiplemyeloma-23/JJ	appos||patients-27/NNS||mm-25/NN	prep_for||transplantation-18/NN||patients-27/NNS	multiplemyeloma-23||interferon-1||yes||interferon alpha (ifn-î±) has been used as a maintenance therapy after autologous stem cell transplantation (asct) for multiplemyeloma (mm) patients.
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||compare-8/VB||purpose-2/NN	nsubj||ketamine-21/VB||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||compare-8/VB||to-7/TO	xcomp||was-6/VBD||compare-8/VB	det||combination-10/NN||a-9/DT	dobj||compare-8/VB||combination-10/NN	prep_of||combination-10/NN||lidocaine-12/NN	prep_of||combination-10/NN||ketamine-14/NN	conj_and||lidocaine-12/NN||ketamine-14/NN	amod||pain-17/NN||aquafol-induced-16/JJ	prep_on||compare-8/VB||pain-17/NN	prep_with||compare-8/VB||lidocaine-19/NN	xcomp||was-6/VBD||ketamine-21/VB	conj_or||compare-8/VB||ketamine-21/VB	advmod||ketamine-21/VB||alone-22/RB	det||induction-25/NN||the-24/DT	prep_during||ketamine-21/VB||induction-25/NN	prep_of||induction-25/NN||anesthesia-27/NN	pain-17||ketamine-21||yes||the purpose of this study was to compare a combination of lidocaine and ketamine on aquafol-induced pain with lidocaine or ketamine alone during the induction of anesthesia.
nsubjpass||treated-4/VBN||diarrhea-1/NN	aux||treated-4/VBN||can-2/MD	auxpass||treated-4/VBN||be-3/VB	root||ROOT-0/null||treated-4/VBN	prep_with||treated-4/VBN||loperamide-6/NN	prep_with||treated-4/VBN||diphenoxylate-8/NN	conj_or||loperamide-6/NN||diphenoxylate-8/NN	diarrhea-1||loperamide-6||no||diarrhea can be treated with loperamide or diphenoxylate.
nsubjpass||excluded-6/VBN||patients-1/NNS	amod||tuberculosis-4/NNP||rifampicin-resistant-3/JJ	prep_with||patients-1/NNS||tuberculosis-4/NNP	auxpass||excluded-6/VBN||were-5/VBD	root||ROOT-0/null||excluded-6/VBN	tuberculosis-4||rifampicin--1||yes||patients with rifampicin-resistant tuberculosis were excluded.
expl||are-2/VBP||there-1/EX	root||ROOT-0/null||are-2/VBP	nn||antibodies-5/NNS||mouse-3/NN	nn||antibodies-5/NNS||monoclonal-4/NN	nsubj||are-2/VBP||antibodies-5/NNS	appos||antibodies-5/NNS||mabs-7/NNS	det||f1-11/NNS||the-10/DT	prep_against||antibodies-5/NNS||f1-11/NNS	nsubj||are-2/VBP||v-antigens-14/NNS	conj_and||antibodies-5/NNS||v-antigens-14/NNS	nsubj||protect-18/VB||v-antigens-14/NNS	aux||protect-18/VB||can-16/MD	advmod||protect-18/VB||passively-17/RB	rcmod||v-antigens-14/NNS||protect-18/VB	dobj||protect-18/VB||mice-19/NNS	det||model-23/NN||a-21/DT	amod||model-23/NN||murine-22/JJ	prep_in||protect-18/VB||model-23/NN	prep_of||model-23/NN||plague-25/NNP	advmod||are-30/VBP||however-27/RB	expl||are-30/VBP||there-29/EX	parataxis||are-2/VBP||are-30/VBP	neg||antibodies-35/NNS||no-31/DT	num||yersiniapestis-33/NNS||anti--32/CD	npadvmod||monoclonal-34/JJ||yersiniapestis-33/NNS	amod||antibodies-35/NNS||monoclonal-34/JJ	nsubj||are-30/VBP||antibodies-35/NNS	amod||antibodies-35/NNS||available-36/JJ	amod||treatment-41/NN||prophylactic-38/JJ	conj_or||prophylactic-38/JJ||therapeutic-40/JJ	amod||treatment-41/NN||therapeutic-40/JJ	prep_for||available-36/JJ||treatment-41/NN	prep_in||are-30/VBP||humans-43/NNS	plague-25||yersiniapestis-33||no||there are mouse monoclonal antibodies (mabs) against the f1- and v-antigens that can passively protect mice in a murine model of plague; however, there are no anti- yersiniapestis monoclonal antibodies available for prophylactic or therapeutic treatment in humans.
amod||prophylaxis-3/NNS||non-occupational-1/JJ	amod||prophylaxis-3/NNS||post-exposure-2/JJ	nsubj||use-7/VBP||prophylaxis-3/NNS	appos||prophylaxis-3/NNS||npep-5/NN	root||ROOT-0/null||use-7/VBP	cop||strategy-12/NN||is-8/VBZ	det||strategy-12/NN||an-9/DT	nn||strategy-12/NN||hiv-10/NN	nn||strategy-12/NN||prevention-11/NN	ccomp||use-7/VBP||strategy-12/NN	nsubjpass||recommended-16/VBN||strategy-12/NN	nsubj||prevent-21/VB||strategy-12/NN	aux||recommended-16/VBN||has-14/VBZ	auxpass||recommended-16/VBN||been-15/VBN	rcmod||strategy-12/NN||recommended-16/VBN	det||cdc-19/NN||the-18/DT	agent||recommended-16/VBN||cdc-19/NN	aux||prevent-21/VB||to-20/TO	xcomp||recommended-16/VBN||prevent-21/VB	dobj||prevent-21/VB||hivinfection-22/NN	det||exposure-28/NN||a-24/DT	amod||exposure-28/NN||high-25/JJ	nn||exposure-28/NN||risk-26/NN	amod||exposure-28/NN||sexual-27/JJ	prep_after||prevent-21/VB||exposure-28/NN	prep_since||prevent-21/VB||1997-30/CD	hivinfection-22||hiv-10||no||non-occupational post-exposure prophylaxis (npep) use is an hiv prevention strategy that has been recommended by the cdc to prevent hivinfection after a high risk sexual exposure since 1997.
prep_in||safe-16/JJ||individuals-2/NNS	vmod||individuals-2/NNS||co-infected-3/VBN	nn||filariasis-6/NNS||bancroftian-5/NN	prep_with||co-infected-3/VBN||filariasis-6/NNS	prep_with||co-infected-3/VBN||onchocerciasis-8/NNS	conj_and||filariasis-6/NNS||onchocerciasis-8/NNS	nsubj||safe-16/JJ||treatment-10/NN	nsubj||tolerable-18/JJ||treatment-10/NN	prep_with||treatment-10/NN||ivermectin-12/NN	prep_with||treatment-10/NN||albendazole-14/NN	conj_and||ivermectin-12/NN||albendazole-14/NN	cop||safe-16/JJ||was-15/VBD	root||ROOT-0/null||safe-16/JJ	conj_and||safe-16/JJ||tolerable-18/JJ	onchocerciasis-8||ivermectin-12||yes||in individuals co-infected with bancroftian filariasis and onchocerciasis, treatment with ivermectin and albendazole was safe and tolerable.
nsubj||address-8/VB||efforts-1/NNS	aux||scale-3/VB||to-2/TO	vmod||efforts-1/NNS||scale-3/VB	prt||scale-3/VB||up-4/RP	dobj||scale-3/VB||haart-5/NN	aux||address-8/VB||should-6/MD	advmod||address-8/VB||also-7/RB	root||ROOT-0/null||address-8/VB	dobj||address-8/VB||co-infections-9/NNS	amod||viruses-14/NNS||hepatitisb-11/JJ	conj_and||hepatitisb-11/JJ||c-13/SYM	amod||viruses-14/NNS||c-13/SYM	prep_with||address-8/VB||viruses-14/NNS	hepatitisb-11||viruses-14||no||efforts to scale up haart should also address co-infections with hepatitisb and c viruses.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||investigate-8/VB||aim-2/NN	det||study-5/NN||the-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||investigate-8/VB||to-7/TO	xcomp||was-6/VBD||investigate-8/VB	det||gaps-10/NNS||the-9/DT	dobj||investigate-8/VB||gaps-10/NNS	amod||knowledge-13/NN||nutritional-12/JJ	prep_in||investigate-8/VB||knowledge-13/NN	prep_in||investigate-8/VB||attitudes-15/NNS	conj_and||knowledge-13/NN||attitudes-15/NNS	prep_in||investigate-8/VB||practices-18/NNS	conj_and||knowledge-13/NN||practices-18/NNS	poss||relationship-21/NN||their-20/PRP$	prep_in||investigate-8/VB||relationship-21/NN	conj_and||knowledge-13/NN||relationship-21/NN	amod||characteristics-24/NNS||sociodemographic-23/JJ	prep_with||investigate-8/VB||characteristics-24/NNS	det||population-28/NN||an-26/DT	amod||population-28/NN||urban-27/JJ	prep_in||characteristics-24/NNS||population-28/NN	prep_of||population-28/NN||women-30/NNS	vmod||women-30/NNS||living-31/VBG	prep_with||living-31/VBG||hiv-33/NN	prep_with||living-31/VBG||aids-35/NNS	conj_and||hiv-33/NN||aids-35/NNS	prep_in||living-31/VBG||uganda-37/NN	aids-35||hiv-33||no||the aim of the study was to investigate the gaps in nutritional knowledge, attitudes, and practices and their relationship with sociodemographic characteristics in an urban population of women living with hiv and aids in uganda.
mark||eliminated-5/VBN||although-1/IN	nsubjpass||eliminated-5/VBN||smallpox-2/NN	aux||eliminated-5/VBN||has-3/VBZ	auxpass||eliminated-5/VBN||been-4/VBN	advcl||sought-14/VBN||eliminated-5/VBN	det||environment-8/NN||the-7/DT	prep_from||eliminated-5/VBN||environment-8/NN	nsubjpass||sought-14/VBN||treatments-10/NNS	aux||sought-14/VBN||are-11/VBP	advmod||sought-14/VBN||urgently-12/RB	auxpass||sought-14/VBN||being-13/VBG	root||ROOT-0/null||sought-14/VBN	det||risk-18/NN||the-17/DT	prep_due_to||sought-14/VBN||risk-18/NN	prep_of||risk-18/NN||smallpox-20/NN	auxpass||used-22/VBN||being-21/VBG	vmod||smallpox-20/NN||used-22/VBN	vmod||smallpox-20/NN||used-22/VBN	conj_and||used-22/VBN||used-22/VBN	det||agent-26/NN||a-24/DT	nn||agent-26/NN||bioterrorism-25/NN	prep_as||used-22/VBN||agent-26/NN	nn||virus-30/NN||monkeypox-29/NN	prep_for||used-22/VBN||virus-30/NN	det||disease-34/NN||a-32/DT	amod||disease-34/NN||zoonotic-33/JJ	prep_for||used-22/VBN||disease-34/NN	conj_and||virus-30/NN||disease-34/NN	prep_of||disease-34/NN||africa-36/NN	amod||reactions-40/NNS||adverse-39/JJ	prep_for||used-22/VBN||reactions-40/NNS	conj_and||virus-30/NN||reactions-40/NNS	amod||vaccinations-43/NNS||smallpoxvirus-42/JJ	prep_to||used-22/VBN||vaccinations-43/NNS	smallpox-20||smallpoxvirus-42||no||although smallpox has been eliminated from the environment, treatments are urgently being sought due to the risk of smallpox being used as a bioterrorism agent and for monkeypox virus, a zoonotic disease of africa, and adverse reactions to smallpoxvirus vaccinations.
det||study-4/NN||a-1/DT	amod||cohort-3/JJ||retrospective-2/JJ	amod||study-4/NN||cohort-3/JJ	nsubjpass||employed-6/VBN||study-4/NN	nsubj||compare-8/VB||study-4/NN	auxpass||employed-6/VBN||was-5/VBD	root||ROOT-0/null||employed-6/VBN	aux||compare-8/VB||to-7/TO	xcomp||employed-6/VBN||compare-8/VB	det||survival-10/NN||the-9/DT	dobj||compare-8/VB||survival-10/NN	amod||patients-17/NNS||hivpositive-12/JJ	conj_and||hivpositive-12/JJ||hiv-14/JJ	amod||patients-17/NNS||hiv-14/JJ	amod||patients-17/NNS||negative-15/JJ	nn||patients-17/NNS||tb-16/NN	prep_between||survival-10/NN||patients-17/NNS	dep||patients-17/NNS||370-19/NNP	dep||370-19/NNP||each-20/DT	det||period-33/NN||an-23/DT	num||month-25/NN||eight-24/CD	npadvmod||observed-27/JJ||month-25/NN	advmod||month-25/NN||directly-26/RB	amod||period-33/NN||observed-27/JJ	nn||period-33/NN||treatment-28/NN	nn||period-33/NN||short-course-29/NN	appos||period-33/NN||dots-31/NNP	prep_during||compare-8/VB||period-33/NN	hivpositive-12||hiv-14||no||a retrospective cohort study was employed to compare the survival between hivpositive and hiv negative tb patients (370 each) during an eight month directly observed treatment short-course (dots) period.
aux||investigate-2/VB||to-1/TO	advcl||generated-28/VBN||investigate-2/VB	det||mechanism-4/NN||the-3/DT	dobj||investigate-2/VB||mechanism-4/NN	dep||mechanism-4/NN||s-6/PRP	det||effect-11/NN||the-9/DT	amod||effect-11/NN||inhibitory-10/JJ	prep_of||mechanism-4/NN||effect-11/NN	prep_of||effect-11/NN||asa-13/NN	det||development-16/NN||the-15/DT	prep_on||investigate-2/VB||development-16/NN	amod||inflammation-20/NN||th17-18/JJ	amod||inflammation-20/NN||airway-19/JJ	prep_of||development-16/NN||inflammation-20/NN	det||model-26/NN||a-22/DT	amod||model-26/NN||neutrophilic-23/JJ	nn||model-26/NN||asthma-24/NN	nn||model-26/NN||mouse-25/NN	nsubjpass||generated-28/VBN||model-26/NN	nsubjpass||challenged-41/VBN||model-26/NN	auxpass||generated-28/VBN||was-27/VBD	root||ROOT-0/null||generated-28/VBN	amod||sensitization-31/NN||intranasal-30/JJ	agent||generated-28/VBN||sensitization-31/NN	prep_with||generated-28/VBN||lps-33/NNP	prep_with||generated-28/VBN||ovalbumin-35/NNP	conj_plus||lps-33/NNP||ovalbumin-35/NNP	appos||lps-33/NNP||ova-37/NN	advmod||challenged-41/VBN||then-40/RB	conj_and||generated-28/VBN||challenged-41/VBN	prep_with||challenged-41/VBN||ova-43/NN	advmod||challenged-41/VBN||alone-44/RB	inflammation-20||asa-13||yes||to investigate the mechanism(s) of the inhibitory effect of asa on the development of th17 airway inflammation, a neutrophilic asthma mouse model was generated by intranasal sensitization with lps plus ovalbumin (ova) and then challenged with ova alone.
det||patient-2/NN||the-1/DT	nsubj||received-3/VBD||patient-2/NN	root||ROOT-0/null||received-3/VBD	amod||treatment-6/NN||empirical-4/JJ	amod||treatment-6/NN||anti-tuberculosis-5/JJ	nsubjpass||misinterpreted-13/VBN||treatment-6/NN	det||finding-11/NN||the-8/DT	nn||finding-11/NN||chest-9/NN	nn||finding-11/NN||x-ray-10/NN	conj_and||treatment-6/NN||finding-11/NN	nsubjpass||misinterpreted-13/VBN||finding-11/NN	auxpass||misinterpreted-13/VBN||was-12/VBD	ccomp||received-3/VBD||misinterpreted-13/VBN	prep_as||misinterpreted-13/VBN||tuberculoma-15/NN	tuberculoma-15||tuberculosis--1||no||the patient received empirical anti-tuberculosis treatment and the chest x-ray finding was misinterpreted as tuberculoma.
nsubj||led-5/VBD||investigation-1/NN	amod||incidentalomas-4/NNS||adrenal-3/JJ	prep_of||investigation-1/NN||incidentalomas-4/NNS	root||ROOT-0/null||led-5/VBD	det||discovery-8/NN||the-7/DT	prep_to||led-5/VBD||discovery-8/NN	det||family-11/NN||a-10/DT	prep_of||led-5/VBD||family-11/NN	num||individuals-15/NNS||eight-13/CD	amod||individuals-15/NNS||affected-14/JJ	nsubj||spanning-16/VBG||individuals-15/NNS	parataxis||led-5/VBD||spanning-16/VBG	num||generations-18/NNS||three-17/CD	dobj||spanning-16/VBG||generations-18/NNS	acomp||led-5/VBD||prone-21/JJ	aux||cortisol-23/VB||to-22/TO	xcomp||prone-21/JJ||cortisol-23/VB	nn||adrenalhyperplasia-27/NN||resistance-24/NN	dobj||cortisol-23/VB||bilateral-26/JJ	amod||adrenalhyperplasia-27/NN||bilateral-26/JJ	conj_and||adrenalhyperplasia-27/NN||bilateral-26/JJ	dobj||cortisol-23/VB||adrenalhyperplasia-27/NN	dobj||cortisol-23/VB||arterialhypertension-29/NN	conj_and||adrenalhyperplasia-27/NN||arterialhypertension-29/NN	dobj||cortisol-23/VB||hypokalemia-31/NN	conj_and||adrenalhyperplasia-27/NN||hypokalemia-31/NN	cortisol-23||arterialhypertension-29||no_rel||investigation of adrenal incidentalomas led to the discovery of a family (eight affected individuals spanning three generations), prone to cortisol resistance, bilateral adrenalhyperplasia, arterialhypertension and hypokalemia.
nsubj||demonstrated-2/VBD||we-1/PRP	root||ROOT-0/null||demonstrated-2/VBD	amod||differences-4/NNS||significant-3/JJ	dobj||demonstrated-2/VBD||differences-4/NNS	det||responses-8/NNS||the-6/DT	amod||responses-8/NNS||quantitative-7/JJ	prep_in||demonstrated-2/VBD||responses-8/NNS	nn||³-11/NNP||ifn-î-10/NNP	prep_of||responses-8/NNS||³-11/NNP	aux||mtb-13/VB||to-12/TO	vmod||demonstrated-2/VBD||mtb-13/VB	prep_between||mtb-13/VB||patients-15/NNS	amod||disease-19/NN||active-17/JJ	nn||disease-19/NN||tb-18/NN	prep_with||patients-15/NNS||disease-19/NN	prep_with||patients-15/NNS||those-21/DT	conj_and||disease-19/NN||those-21/DT	prep_with||mtb-13/VB||ltbi-23/NNS	det||study-26/NN||this-25/DT	prep_in||ltbi-23/NNS||study-26/NN	tb-18||mtb-13||no||we demonstrated significant differences in the quantitative responses of ifn-î³ to mtb between patients with active tb disease and those with ltbi in this study.
advmod||bolster-4/VB||additionally-1/RB	nsubj||bolster-4/VB||we-3/PRP	root||ROOT-0/null||bolster-4/VB	poss||reclassification-7/NN||our-5/PRP$	amod||reclassification-7/NN||recent-6/JJ	dobj||bolster-4/VB||reclassification-7/NN	prep_of||reclassification-7/NN||rickettsia-9/NN	prepc_by||bolster-4/VB||identifying-11/VBG	dobj||identifying-11/VBG||ogs-12/NN	nsubj||define-14/VB||ogs-12/NN	rcmod||ogs-12/NN||define-14/VB	det||ag-16/NN||the-15/DT	nsubj||rickettsiae-40/JJ||ag-16/NN	amod||group-19/NN||ancestral-18/JJ	appos||ag-16/NN||group-19/NN	conj_and||ag-16/NN||tg-22/NN	nsubj||rickettsiae-40/JJ||tg-22/NN	amod||group-25/NN||typhus-24/JJ	appos||tg-22/NN||group-25/NN	conj_and||ag-16/NN||trg-28/NN	nsubj||rickettsiae-40/JJ||trg-28/NN	amod||group-31/NN||transitional-30/JJ	appos||trg-28/NN||group-31/NN	conj_and||ag-16/NN||sfg-35/NN	nsubj||rickettsiae-40/JJ||sfg-35/NN	nn||group-38/NN||spottedfever-37/NN	appos||ag-16/NN||group-38/NN	xcomp||define-14/VB||rickettsiae-40/JJ	typhus-24||rickettsia-9||no||additionally, we bolster our recent reclassification of rickettsia by identifying ogs that define the ag (ancestral group), tg (typhus group), trg (transitional group), and sfg (spottedfever group) rickettsiae.
nsubj||shown-4/VBN||we-1/PRP	aux||shown-4/VBN||have-2/VBP	advmod||shown-4/VBN||previously-3/RB	root||ROOT-0/null||shown-4/VBN	mark||protein-10/VBZ||that-5/IN	nsubj||protein-10/VBZ||hepatitisbvirus-6/NNS	appos||hepatitisbvirus-6/NNS||hbv-8/NN	ccomp||shown-4/VBN||protein-10/VBZ	nsubj||leading-25/VBG||x-11/SYM	appos||x-11/SYM||hbx-13/NN	det||protein-18/NN||a-16/DT	amod||protein-18/NN||regulatory-17/JJ	appos||x-11/SYM||protein-18/NN	prep_of||protein-18/NN||hbv-20/NN	amod||stat1-23/NNS||activates-22/JJ	appos||x-11/SYM||stat1-23/NNS	dep||protein-10/VBZ||leading-25/VBG	dep||i-28/NN||type-27/NN	amod||production-33/NN||i-28/NN	nn||production-33/NN||interferon-29/NN	appos||production-33/NN||ifn-31/NN	prep_to||leading-25/VBG||production-33/NN	hbv-20||hepatitisbvirus-6||no||we have previously shown that hepatitisbvirus (hbv) protein x (hbx), a regulatory protein of hbv, activates stat1, leading to type i interferon (ifn) production.
amod||evidence-2/NN||increasing-1/VBG	nsubj||suggest-3/VBP||evidence-2/NN	root||ROOT-0/null||suggest-3/VBP	mark||related-10/VBN||that-4/IN	det||factors-9/NNS||some-5/DT	amod||factors-9/NNS||crucial-6/JJ	amod||factors-9/NNS||nuclear-7/JJ	nn||factors-9/NNS||transcription-8/NN	nsubj||related-10/VBN||factors-9/NNS	ccomp||suggest-3/VBP||related-10/VBN	prep_to||related-10/VBN||hepatitiscvirus-12/NNS	amod||hepatosteatosis-15/NNS||associated-14/VBN	nsubj||hepatitiscvirus-25/VBZ||hepatosteatosis-15/NNS	conj_and||hepatosteatosis-15/NNS||hepatitiscvirusrna-17/NN	nsubj||hepatitiscvirus-25/VBZ||hepatitiscvirusrna-17/NN	nsubjpass||controlled-21/VBN||itself-18/PRP	aux||controlled-21/VBN||can-19/MD	auxpass||controlled-21/VBN||be-20/VB	rcmod||hepatosteatosis-15/NNS||controlled-21/VBN	amod||anti--24/NNS||specific-23/JJ	agent||controlled-21/VBN||anti--24/NNS	parataxis||suggest-3/VBP||hepatitiscvirus-25/VBZ	dobj||hepatitiscvirus-25/VBZ||nutrition-26/NN	hepatitiscvirusrna-17||hepatitiscvirus-25||no||increasing evidence suggest that some crucial nuclear transcription factors related to hepatitiscvirus -associated hepatosteatosis and hepatitiscvirusrna itself can be controlled by specific anti- hepatitiscvirus nutrition.
nsubj||protected-6/VBD||blockade-1/NN	prep_of||blockade-1/NN||il-16-3/JJ	prep_in||il-16-3/JJ||vivo-5/NN	root||ROOT-0/null||protected-6/VBD	prep_against||protected-6/VBD||type1diabetes-8/CD	prepc_by||protected-6/VBD||interfering-10/VBG	prep_with||interfering-10/VBG||recruitment-12/NN	amod||t-cells-16/NNS||cd4-14/JJ	amod||t-cells-16/NNS||+-15/JJ	prep_of||recruitment-12/NN||t-cells-16/NNS	det||pancreas-19/NN||the-18/DT	prep_to||interfering-10/VBG||pancreas-19/NN	det||protection-23/NN||this-22/DT	nsubj||required-24/VBD||protection-23/NN	conj_and||protected-6/VBD||required-24/VBD	det||activity-26/NN||the-25/DT	dobj||required-24/VBD||activity-26/NN	det||ccl4-30/NN||the-28/DT	amod||ccl4-30/NN||chemokine-29/JJ	prep_of||activity-26/NN||ccl4-30/NN	type1diabetes-8||ccl4-30||no_rel||blockade of il-16 in vivo protected against type1diabetes by interfering with recruitment of cd4+ t-cells to the pancreas, and this protection required the activity of the chemokine ccl4.
nsubjpass||associated-58/VBN||quartiles-1/NNS	nsubjpass||related-83/VBN||quartiles-1/NNS	prep_of||quartiles-1/NNS||acr-3/NN	amod||-RSB--8/NNS||median-5/JJ	amod||-RSB--8/NNS||-LSB--6/JJ	nn||-RSB--8/NNS||range-7/NN	dep||quartiles-1/NNS||-RSB--8/NNS	amod||1-11/CD||quartiles-10/JJ	prep_within||-RSB--8/NNS||1-11/CD	npadvmod||-LSB--14/RB||3.0-13/CD	advmod||-RSB--8/NNS||-LSB--14/RB	num||â-16/NN||0.7-15/CD	dep||-RSB--8/NNS||â-16/NN	num||-RSB--20/NNS||$-17/$	num||$-17/$||3.7-19/CD	dep||â-16/NN||-RSB--20/NNS	dep||-RSB--8/NNS||2-22/CD	conj_and||â-16/NN||2-22/CD	num||-RSB--31/NNS||4.6-24/CD	number||3.7-26/CD||-LSB--25/CD	num||-RSB--31/NNS||3.7-26/CD	amod||-RSB--31/NNS||â-27/JJ	num||-RSB--31/NNS||$-28/$	num||$-28/$||5.5-30/CD	appos||2-22/CD||-RSB--31/NNS	dep||-RSB--8/NNS||3-33/CD	conj_and||â-16/NN||3-33/CD	num||-RSB--42/NNS||7.1-35/CD	number||5.5-37/CD||-LSB--36/CD	num||-RSB--42/NNS||5.5-37/CD	amod||-RSB--42/NNS||â-38/JJ	num||-RSB--42/NNS||$-39/$	num||$-39/$||9.7-41/CD	appos||3-33/CD||-RSB--42/NNS	dep||-RSB--8/NNS||4-45/CD	conj_and||â-16/NN||4-45/CD	num||-RSB--54/NNS||16.5-47/CD	number||9.7-49/CD||-LSB--48/CD	num||-RSB--54/NNS||9.7-49/CD	amod||-RSB--54/NNS||â-50/JJ	num||-RSB--54/NNS||$-51/$	num||$-51/$||1,578-53/CD	appos||4-45/CD||-RSB--54/NNS	auxpass||associated-58/VBN||were-56/VBD	advmod||associated-58/VBN||positively-57/RB	root||ROOT-0/null||associated-58/VBN	prep_with||associated-58/VBN||age-60/NN	prep_with||associated-58/VBN||markers-62/NNS	conj_and||age-60/NN||markers-62/NNS	nn||secretion-67/NN||adiposity-64/NN	conj_and||adiposity-64/NN||insulin-66/NN	nn||secretion-67/NN||insulin-66/NN	prep_of||markers-62/NNS||secretion-67/NN	prep_of||markers-62/NNS||resistance-69/NN	conj_and||secretion-67/NN||resistance-69/NN	nn||pressure-72/NN||blood-71/NN	appos||secretion-67/NN||pressure-72/NN	prep_with||associated-58/VBN||use-75/NN	conj_and||age-60/NN||use-75/NN	prep_of||use-75/NN||antihypertensiveagents-77/NNS	amod||effects-80/NNS||antiproteinuric-79/JJ	prep_with||antihypertensiveagents-77/NNS||effects-80/NNS	advmod||related-83/VBN||inversely-82/RB	conj_and||associated-58/VBN||related-83/VBN	amod||sex-86/NN||male-85/JJ	prep_to||related-83/VBN||sex-86/NN	nn||creatinine-89/NN||serum-88/NN	prep_to||related-83/VBN||creatinine-89/NN	conj_and||sex-86/NN||creatinine-89/NN	insulin-66||adiposity-64||no_rel||quartiles of acr (median [range] within quartiles 1, 3.0 [0.7â3.7]; 2, 4.6 [3.7â5.5]; 3, 7.1 [5.5â9.7]; and 4, 16.5 [9.7â1,578]) were positively associated with age, markers of adiposity and insulin secretion and resistance, blood pressure, and use of antihypertensiveagents with antiproteinuric effects and inversely related to male sex and serum creatinine.
nn||dynamics-2/NNS||dm-1/NN	nsubjpass||influenced-5/VBN||dynamics-2/NNS	nsubj||similar-16/JJ||dynamics-2/NNS	auxpass||influenced-5/VBN||is-3/VBZ	neg||influenced-5/VBN||not-4/RB	root||ROOT-0/null||influenced-5/VBN	det||extent-8/NN||the-7/DT	agent||influenced-5/VBN||extent-8/NN	amod||resection-13/NN||conservative-10/JJ	amod||resection-13/NN||primary-11/JJ	nn||resection-13/NN||tumour-12/NN	prep_of||extent-8/NN||resection-13/NN	cop||similar-16/JJ||is-15/VBZ	conj_and||influenced-5/VBN||similar-16/JJ	det||phenotypes-20/NNS||both-18/DT	nn||phenotypes-20/NNS||er-19/NN	prep_for||similar-16/JJ||phenotypes-20/NNS	amod||sites-24/NNS||different-22/JJ	amod||sites-24/NNS||metastatic-23/JJ	prep_across||phenotypes-20/NNS||sites-24/NNS	xcomp||similar-16/JJ||suggesting-26/VBG	amod||mechanisms-28/NNS||similar-27/JJ	dobj||suggesting-26/VBG||mechanisms-28/NNS	nn||development-31/NN||tumour-30/NN	prep_for||mechanisms-28/NNS||development-31/NN	amod||sites-34/NNS||distant-33/JJ	prep_at||suggesting-26/VBG||sites-34/NNS	advmod||different-37/JJ||apparently-36/RB	amod||microenvironments-38/NNS||different-37/JJ	prep_despite||suggesting-26/VBG||microenvironments-38/NNS	tumour-30||dm-1||yes||dm dynamics is not influenced by the extent of conservative primary tumour resection and is similar for both er phenotypes across different metastatic sites, suggesting similar mechanisms for tumour development at distant sites despite apparently different microenvironments.
dep||pain-7/JJ||good-1/JJ	conj_and||pain-7/JJ||moderate-3/JJ	amod||relief-8/NN||moderate-3/JJ	conj_and||pain-7/JJ||mild-6/JJ	amod||relief-8/NN||mild-6/JJ	amod||relief-8/NN||pain-7/JJ	nsubjpass||achieved-10/VBN||relief-8/NN	auxpass||achieved-10/VBN||was-9/VBD	root||ROOT-0/null||achieved-10/VBN	prep_in||achieved-10/VBN||55-12/CD	prep_in||achieved-10/VBN||24-14/CD	conj_and||55-12/CD||24-14/CD	num||%-18/NN||15-17/CD	prep_in||achieved-10/VBN||%-18/NN	conj_and||55-12/CD||%-18/NN	prep_of||%-18/NN||patients-20/NNS	advmod||patients-20/NNS||respectively-22/RB	advmod||patients-20/NNS||on-24/IN	conj_and||respectively-22/RB||on-24/IN	prep_on||respectively-22/RB||amitriptyline-25/NNP	advmod||patients-20/NNS||59-27/CD	conj_and||respectively-22/RB||59-27/CD	conj_and||respectively-22/RB||21-29/CD	conj_and||59-27/CD||21-29/CD	num||%-33/NN||9-32/CD	conj_and||respectively-22/RB||%-33/NN	conj_and||59-27/CD||%-33/NN	prep_of||patients-20/NNS||patients-35/NNS	advmod||achieved-10/VBN||respectively-37/RB	prep_on||achieved-10/VBN||duloxetine-40/NN	pain-7||amitriptyline-25||yes||good, moderate, and mild pain relief was achieved in 55, 24, and 15% of patients, respectively, on amitriptyline and 59, 21, and 9% of patients, respectively, on duloxetine.
advmod||deciphered-5/VBD||there-1/RB	nn||myers-4/NNS||dr.-3/NN	nsubj||deciphered-5/VBD||myers-4/NNS	root||ROOT-0/null||deciphered-5/VBD	dobj||deciphered-5/VBD||many-6/JJ	det||insulin-9/NN||the-8/DT	prep_of||many-6/JJ||insulin-9/NN	vmod||insulin-9/NN||signaling-10/VBG	dobj||signaling-10/VBG||pathways-11/NNS	vmod||pathways-11/NNS||engaged-12/VBN	nn||proteins-17/NNS||insulin-14/NN	nn||proteins-17/NNS||receptor-15/NN	nn||proteins-17/NNS||substrate-16/NN	agent||engaged-12/VBN||proteins-17/NNS	insulin-14||dr--1||no_rel||there , dr. myers deciphered many of the insulin signaling pathways engaged by insulin receptor substrate proteins .
dep||contains-7/VBZ||sera-1/JJ	amod||patients-5/NNS||convalescent-3/JJ	nn||patients-5/NNS||lassafever-4/NN	prep_from||sera-1/JJ||patients-5/NNS	advmod||contains-7/VBZ||often-6/RB	root||ROOT-0/null||contains-7/VBZ	dobj||contains-7/VBZ||antibodies-8/NNS	prep_to||contains-7/VBZ||lassavirus-10/NNS	appos||lassavirus-10/NNS||lasv-12/NNP	nsubj||contains-7/VBZ||glycoprotein-14/NN	num||glycoprotein-14/NN||1-15/CD	appos||glycoprotein-14/NN||gp1-17/NNP	nsubj||contains-7/VBZ||glycoprotein-21/NN	conj_and||glycoprotein-14/NN||glycoprotein-21/NN	num||glycoprotein-21/NN||2-22/CD	appos||glycoprotein-21/NN||gp2-24/NNP	dep||glycoprotein-21/NN||immunization-27/NN	amod||primates-30/NNS||non-human-29/JJ	prep_of||immunization-27/NN||primates-30/NNS	amod||vectors-33/NNS||viral-32/JJ	nsubj||expressing-34/VBG||vectors-33/NNS	prepc_with||contains-7/VBZ||expressing-34/VBG	det||complex-38/NN||the-35/DT	amod||complex-38/NN||arenaviral-36/JJ	nn||complex-38/NN||glycoprotein-37/NN	nsubj||confers-42/VBZ||complex-38/NN	appos||complex-38/NN||gpc-40/NN	ccomp||expressing-34/VBG||confers-42/VBZ	amod||immunity-45/NN||full-43/JJ	amod||immunity-45/NN||protective-44/JJ	dobj||confers-42/VBZ||immunity-45/NN	det||challenge-49/NN||a-47/DT	amod||challenge-49/NN||lethal-48/JJ	prep_against||immunity-45/NN||challenge-49/NN	prep_with||challenge-49/NN||lasv-51/NNP	lassafever-4||lassavirus-10||no||sera from convalescent lassafever patients often contains antibodies to lassavirus (lasv) glycoprotein 1 (gp1), and glycoprotein 2 (gp2); immunization of non-human primates with viral vectors expressing the arenaviral glycoprotein complex (gpc) confers full protective immunity against a lethal challenge with lasv.
amod||minimus-3/NNS||purified-1/JJ	nn||minimus-3/NNS||a.-2/NN	nsubj||cypor-4/VBP||minimus-3/NNS	root||ROOT-0/null||cypor-4/VBP	amod||-rrb--8/NNS||enzyme-5/JJ	amod||-rrb--8/NNS||-lrb--6/JJ	nn||-rrb--8/NNS||ancypor-7/NN	nsubj||partner-14/NN||-rrb--8/NNS	nsubj||loses-19/VBZ||-rrb--8/NNS	cop||partner-14/NN||is-11/VBZ	det||partner-14/NN||the-12/DT	nn||partner-14/NN||redox-13/NN	rcmod||-rrb--8/NNS||partner-14/NN	amod||p450s-17/NNS||cytochrome-16/JJ	prep_of||partner-14/NN||p450s-17/NNS	ccomp||cypor-4/VBP||loses-19/VBZ	amod||-rrb--24/NNS||flavin-adenosine-20/JJ	amod||-rrb--24/NNS||di-nucleotide-21/JJ	amod||-rrb--24/NNS||-lrb--22/JJ	nn||-rrb--24/NNS||fad-23/NN	dobj||loses-19/VBZ||-rrb--24/NNS	amod||cofactors-31/NNS||flavin-26/JJ	amod||cofactors-31/NNS||mono-nucleotide-27/JJ	amod||cofactors-31/NNS||-lrb--28/JJ	nn||cofactors-31/NNS||fmn-29/NN	nn||cofactors-31/NNS||-rrb--30/NN	dobj||loses-19/VBZ||cofactors-31/NNS	conj_and||-rrb--24/NNS||cofactors-31/NNS	nsubj||affect-33/VBP||cofactors-31/NNS	rcmod||cofactors-31/NNS||affect-33/VBP	poss||activity-36/NN||its-34/PRP$	amod||activity-36/NN||enzyme-35/JJ	dobj||affect-33/VBP||activity-36/NN	mono--1||adenosine--1||no_rel||purified a. minimus cypor enzyme -lrb- ancypor -rrb- , which is the redox partner of cytochrome p450s , loses flavin-adenosine di-nucleotide -lrb- fad -rrb- and flavin mono-nucleotide -lrb- fmn -rrb- cofactors that affect its enzyme activity .
nsubj||delayed-2/VBD||time-1/NN	root||ROOT-0/null||delayed-2/VBD	nn||studies-4/NNS||addition-3/NN	dobj||delayed-2/VBD||studies-4/NNS	det||show-9/NN||the-6/DT	amod||show-9/NN||pseudotyped-7/JJ	nn||show-9/NN||viruses-8/NNS	prep_with||delayed-2/VBD||show-9/NN	nsubj||papuamide-11/VBP||show-9/NN	rcmod||show-9/NN||papuamide-11/VBP	det||viralinfection-14/NN||a-12/DT	amod||viralinfection-14/NN||inhibits-13/JJ	dobj||papuamide-11/VBP||viralinfection-14/NN	advmod||papuamide-11/VBP||only-15/RB	det||stage-19/NN||the-17/DT	amod||stage-19/NN||initial-18/JJ	prep_at||papuamide-11/VBP||stage-19/NN	det||cycle-24/NN||the-21/DT	amod||cycle-24/NN||viral-22/JJ	nn||cycle-24/NN||life-23/NN	prep_of||stage-19/NN||cycle-24/NN	viralinfection-14||viruses-8||no||time delayed addition studies with the pseudotyped viruses show that papuamide a inhibits viralinfection only at the initial stage of the viral life cycle.
aux||evaluate-2/VB||to-1/TO	root||ROOT-0/null||evaluate-2/VB	det||efficacy-5/NN||the-3/DT	amod||efficacy-5/NN||long-term-4/JJ	dobj||evaluate-2/VB||efficacy-5/NN	dobj||evaluate-2/VB||safety-7/NN	conj_and||efficacy-5/NN||safety-7/NN	num||combinations-13/NNS||3-9/CD	advmod||available-11/JJ||commercially-10/RB	amod||combinations-13/NNS||available-11/JJ	amod||combinations-13/NNS||fixed-12/VBN	prep_of||efficacy-5/NN||combinations-13/NNS	nn||analogs-16/NNS||prostaglandin-15/NN	prep_of||evaluate-2/VB||analogs-16/NNS	det||prostamide-19/NN||a-18/DT	prep_of||evaluate-2/VB||prostamide-19/NN	conj_or||analogs-16/NNS||prostamide-19/NN	prep_with||evaluate-2/VB||timololmaleate-21/NN	prep_in||timololmaleate-21/NN||patients-23/NNS	amod||openangleglaucoma-26/NN||primary-25/JJ	prep_with||patients-23/NNS||openangleglaucoma-26/NN	prep_with||patients-23/NNS||ocularhypertension-28/NN	conj_or||openangleglaucoma-26/NN||ocularhypertension-28/NN	ocularhypertension-28||prostaglandin-15||no_rel||to evaluate the long-term efficacy and safety of 3 commercially available fixed combinations of prostaglandin analogs or a prostamide with timololmaleate in patients with primary openangleglaucoma or ocularhypertension.
mark||researched-15/VBN||although-1/IN	nsubjpass||researched-15/VBN||work-2/NN	vmod||work-2/NN||related-3/VBN	nn||factors-5/NNS||risk-4/NN	dobj||related-3/VBN||factors-5/NNS	vmod||factors-5/NNS||associated-6/VBN	prep_with||associated-6/VBN||cardiovasculardiseases-8/NNS	appos||work-2/NN||cd-10/NN	aux||researched-15/VBN||have-12/VBP	auxpass||researched-15/VBN||been-13/VBN	advmod||researched-15/VBN||well-14/RB	advcl||is-18/VBZ||researched-15/VBN	expl||is-18/VBZ||there-17/EX	root||ROOT-0/null||is-18/VBZ	neg||knowledge-21/NN||no-19/DT	amod||knowledge-21/NN||detailed-20/JJ	nsubj||is-18/VBZ||knowledge-21/NN	amod||groups-25/NNS||disparate-23/JJ	amod||groups-25/NNS||occupational-24/JJ	prep_regarding||knowledge-21/NN||groups-25/NNS	dep||groups-25/NNS||each-26/DT	det||exposition-31/NN||a-28/DT	amod||exposition-31/NN||different-29/JJ	nn||exposition-31/NN||risk-30/NN	prep_with||groups-25/NNS||exposition-31/NN	cd-10||cardiovasculardiseases-8||no_rel||although work related risk factors associated with cardiovasculardiseases (cd) have been well researched, there is no detailed knowledge regarding disparate occupational groups each with a different risk exposition.
nsubj||standard-5/NN||viralculture-1/NN	cop||standard-5/NN||is-2/VBZ	det||standard-5/NN||the-3/DT	amod||standard-5/NN||gold-4/JJ	root||ROOT-0/null||standard-5/NN	det||diagnosis-8/NN||the-7/DT	prep_for||standard-5/NN||diagnosis-8/NN	prep_of||diagnosis-8/NN||chikungunyafever-10/NN	viralculture-1||chikungunyafever-10||no_rel||viralculture is the gold standard for the diagnosis of chikungunyafever.
nsubjpass||treated-3/VBN||osteomyelitis-1/NNS	auxpass||treated-3/VBN||was-2/VBD	root||ROOT-0/null||treated-3/VBN	amod||teicoplanin-6/NN||parenteral-5/JJ	prep_with||treated-3/VBN||teicoplanin-6/NN	amod||rifampicin-9/NN||oral-8/JJ	prep_with||treated-3/VBN||rifampicin-9/NN	conj_and||teicoplanin-6/NN||rifampicin-9/NN	prep_with||treated-3/VBN||azithromycin-11/NN	conj_and||teicoplanin-6/NN||azithromycin-11/NN	osteomyelitis-1||azithromycin-11||no_rel||osteomyelitis was treated with parenteral teicoplanin, oral rifampicin and azithromycin.
advmod||indicator-12/NN||thus-1/RB	amod||state-4/NN||hypothyroid-3/JJ	nsubj||indicator-12/NN||state-4/NN	nsubj||provoke-19/VB||state-4/NN	amod||period-7/NN||mid-dry-6/JJ	prep_during||state-4/NN||period-7/NN	aux||indicator-12/NN||may-8/MD	cop||indicator-12/NN||be-9/VB	det||indicator-12/NN||an-10/DT	amod||indicator-12/NN||early-11/JJ	root||ROOT-0/null||indicator-12/NN	amod||liver-16/NN||postpartal-14/JJ	amod||liver-16/NN||fatty-15/JJ	prep_of||indicator-12/NN||liver-16/NN	aux||provoke-19/VB||may-18/MD	conj_and||indicator-12/NN||provoke-19/VB	amod||increase-22/NN||t3/t4-20/JJ	nn||increase-22/NN||ratio-21/NN	dobj||provoke-19/VB||increase-22/NN	det||group-25/NN||this-24/DT	prep_in||provoke-19/VB||group-25/NN	prep_of||group-25/NN||cows-27/NNS	hypothyroid-3||t4--1||yes||thus, hypothyroid state during mid-dry period may be an early indicator of postpartal fatty liver and may provoke t3/t4 ratio increase in this group of cows.
nsubj||searched-2/VBD||we-1/PRP	root||ROOT-0/null||searched-2/VBD	ccomp||searched-2/VBD||medline-3/VB	ccomp||searched-2/VBD||pubmed-5/VB	conj_and||medline-3/VB||pubmed-5/VB	dobj||medline-3/VB||terms-6/NNS	nn||stage-9/NN||labour-8/NN	dep||terms-6/NNS||stage-9/NN	dep||stage-9/NN||third-11/JJ	dep||ergonovine-17/NN||ergonovine-15/JJ	dep||medline-3/VB||ergonovine-17/NN	amod||ergonovine-17/NN||tartrate-18/JJ	amod||ergonovine-17/NN||methylergonovine-20/JJ	conj_or||tartrate-18/JJ||methylergonovine-20/JJ	amod||ergonovine-17/NN||oxytocin-22/JJ	conj_or||tartrate-18/JJ||oxytocin-22/JJ	amod||ergonovine-17/NN||oxytocics-24/JJ	conj_or||tartrate-18/JJ||oxytocics-24/JJ	amod||ergonovine-17/NN||misoprostol-26/JJ	conj_or||tartrate-18/JJ||misoprostol-26/JJ	ccomp||searched-2/VBD||and-28/VB	conj_and||medline-3/VB||and-28/VB	parataxis||and-28/VB||postpartumhaemorrhage-30/VB	parataxis||and-28/VB||haemorrhage-32/VB	conj_or||postpartumhaemorrhage-30/VB||haemorrhage-32/VB	conj_and||medline-3/VB||cochrane-35/VB	conj_and||and-28/VB||cochrane-35/VB	dobj||and-28/VB||reviews-36/NNS	det||restriction-40/NN||any-38/DT	nn||restriction-40/NN||language-39/NN	prep_without||and-28/VB||restriction-40/NN	postpartumhaemorrhage-30||ergonovine-17||yes||we searched medline and pubmed terms (labour stage, third) and (ergonovine, ergonovine tartrate, methylergonovine, oxytocin, oxytocics or misoprostol) and (postpartumhaemorrhage or haemorrhage) and cochrane reviews without any language restriction.
nsubj||used-17/VBD||celecoxib-1/NN	conj_and||celecoxib-1/NN||diclofenac-3/NN	nsubj||used-17/VBD||diclofenac-3/NN	conj_and||celecoxib-1/NN||ibuprofen-5/NN	nsubj||used-17/VBD||ibuprofen-5/NN	conj_and||celecoxib-1/NN||nimesulide-8/NN	nsubj||used-17/VBD||nimesulide-8/NN	cop||anti-inflammatorydrugs-11/NNS||are-9/VBP	amod||anti-inflammatorydrugs-11/NNS||nonsteroidal-10/JJ	rcmod||celecoxib-1/NN||anti-inflammatorydrugs-11/NNS	appos||celecoxib-1/NN||nsaids-13/NNS	advmod||commonly-16/RB||very-15/RB	advmod||used-17/VBD||commonly-16/RB	root||ROOT-0/null||used-17/VBD	det||treatment-20/NN||the-19/DT	prep_for||used-17/VBD||treatment-20/NN	amod||mild-24/JJ||moderate-22/JJ	dep||mild-24/JJ||to-23/TO	amod||pain-25/NN||mild-24/JJ	prep_of||treatment-20/NN||pain-25/NN	nn||acetaminophen-31/NN||paracetamol-29/NNP	prep_together_with||used-17/VBD||acetaminophen-31/NN	det||analgesic-38/NN||a-34/DT	advmod||used-37/JJ||very-35/RB	advmod||used-37/JJ||widely-36/RB	amod||analgesic-38/NN||used-37/JJ	appos||acetaminophen-31/NN||analgesic-38/NN	det||effect-43/NN||a-40/DT	amod||effect-43/NN||lesser-41/JJR	amod||effect-43/NN||anti-inflammatory-42/JJ	prep_with||analgesic-38/NN||effect-43/NN	pain-25||acetaminophen-31||yes||celecoxib, diclofenac, ibuprofen, and nimesulide are nonsteroidal anti-inflammatorydrugs (nsaids) very commonly used for the treatment of moderate to mild pain, together with paracetamol (acetaminophen), a very widely used analgesic with a lesser anti-inflammatory effect.
advmod||components-8/NNS||indeed-1/RB	nsubj||components-8/NNS||isoniazid-3/NN	conj_and||isoniazid-3/NN||rifampicin-5/NN	nsubj||components-8/NNS||rifampicin-5/NN	cop||components-8/NNS||are-6/VBP	amod||components-8/NNS||important-7/JJ	root||ROOT-0/null||components-8/NNS	det||regimen-11/NN||any-10/DT	prep_of||components-8/NNS||regimen-11/NN	det||treatment-14/NN||the-13/DT	prep_for||regimen-11/NN||treatment-14/NN	prep_of||treatment-14/NN||drug-16/NN	amod||tb-18/JJ||susceptible-17/JJ	amod||drug-16/NN||tb-18/JJ	tb-18||rifampicin-5||yes||indeed, isoniazid and rifampicin are important components of any regimen for the treatment of drug susceptible tb.
amod||levels-3/NNS||bcar4-1/JJ	nn||levels-3/NNS||mrna-2/NN	nsubjpass||measured-5/VBN||levels-3/NNS	nsubjpass||evaluated-11/VBN||levels-3/NNS	auxpass||measured-5/VBN||were-4/VBD	root||ROOT-0/null||measured-5/VBN	amod||breasttumours-8/NNS||primary-7/JJ	prep_in||measured-5/VBN||breasttumours-8/NNS	conj_and||measured-5/VBN||evaluated-11/VBN	prep_for||evaluated-11/VBN||association-13/NN	amod||survival-16/NN||progression-free-15/JJ	prep_with||evaluated-11/VBN||survival-16/NN	appos||survival-16/NN||pfs-18/NN	amod||benefit-22/NN||clinical-21/JJ	prep_with||evaluated-11/VBN||benefit-22/NN	conj_and||survival-16/NN||benefit-22/NN	prep_in||benefit-22/NN||patients-24/NNS	nn||receptor-27/NN||oestrogen-26/NN	prep_with||patients-24/NNS||receptor-27/NN	nn||±-31/NNS||er-29/NN	nn||±-31/NNS||î-30/NN	appos||receptor-27/NN||±-31/NNS	amod||tumours-35/NNS||positive-34/JJ	dep||benefit-22/NN||tumours-35/NNS	vmod||tumours-35/NNS||receiving-36/VBG	dobj||receiving-36/VBG||tamoxifen-37/NN	amod||monotherapy-40/NN||first-line-39/JJ	prep_as||receiving-36/VBG||monotherapy-40/NN	amod||disease-43/NN||advanced-42/JJ	prep_for||monotherapy-40/NN||disease-43/NN	breasttumours-8||tamoxifen-37||yes||bcar4 mrna levels were measured in primary breasttumours, and evaluated for association with progression-free survival (pfs) and clinical benefit in patients with oestrogen receptor (er î± )-positive tumours receiving tamoxifen as first-line monotherapy for advanced disease.
det||methylphenidate-4/NN||the-1/DT	nn||methylphenidate-4/NN||stimulant-2/NN	nn||methylphenidate-4/NN||drug-3/NN	nsubj||used-19/JJ||methylphenidate-4/NN	dep||methylphenidate-4/NN||mph-6/NN	det||atomoxetine-12/NN||the-9/DT	amod||atomoxetine-12/NN||non-stimulant-10/JJ	nn||atomoxetine-12/NN||drug-11/NN	conj_and||methylphenidate-4/NN||atomoxetine-12/NN	nsubj||used-19/JJ||atomoxetine-12/NN	appos||atomoxetine-12/NN||atx-14/NN	cop||used-19/JJ||are-16/VBP	dep||used-19/JJ||both-17/DT	advmod||used-19/JJ||widely-18/RB	root||ROOT-0/null||used-19/JJ	amod||treatment-22/NN||adhd-21/JJ	prep_for||used-19/JJ||treatment-22/NN	poss||effects-27/NNS||their-25/PRP$	nn||effects-27/NNS||differential-26/NN	nsubj||remain-32/VBP||effects-27/NNS	amod||function-31/NN||human-29/JJ	nn||function-31/NN||brain-30/NN	prep_on||effects-27/NNS||function-31/NN	conj_but||used-19/JJ||remain-32/VBP	acomp||remain-32/VBP||unclear-33/JJ	adhd-21||atomoxetine-12||yes||the stimulant drug methylphenidate (mph) and the non-stimulant drug atomoxetine (atx) are both widely used for adhd treatment, but their differential effects on human brain function remain unclear.
nsubj||produced-12/VBN||blockade-1/NN	prepc_of||blockade-1/NN||signaling-3/VBG	dobj||signaling-3/VBG||pathways-4/NNS	amod||inhibitors-10/NNS||small-6/JJ	nn||inhibitors-10/NNS||molecule-7/NN	nn||inhibitors-10/NNS||tyrosine-8/NN	amod||inhibitors-10/NNS||kinase-9/JJ	prep_with||signaling-3/VBG||inhibitors-10/NNS	aux||produced-12/VBN||has-11/VBZ	root||ROOT-0/null||produced-12/VBN	amod||responses-14/NNS||dramatic-13/JJ	dobj||produced-12/VBN||responses-14/NNS	prep_in||produced-12/VBN||subsets-16/NNS	amod||cancers-19/NNS||other-18/JJ	prep_of||subsets-16/NNS||cancers-19/NNS	cancers-19||tyrosine-8||no_rel||blockade of signaling pathways with small molecule tyrosine kinase inhibitors has produced dramatic responses in subsets of other cancers.
amod||components-3/NNS||individual-2/JJ	prep_among||observed-15/VBN||components-3/NNS	prep_of||components-3/NNS||mets-5/NNS	nsubjpass||observed-15/VBN||differences-7/NNS	prep_between||differences-7/NNS||women-9/NNS	prep_with||women-9/NNS||ra-11/NN	prep_with||women-9/NNS||controls-13/NNS	conj_and||ra-11/NN||controls-13/NNS	auxpass||observed-15/VBN||were-14/VBD	root||ROOT-0/null||observed-15/VBN	prep_for||observed-15/VBN||hypertension-17/NN	appos||hypertension-17/NN||p-19/NNP	number||0.001-21/CD||<-20/CD	num||p-19/NNP||0.001-21/CD	amod||high-25/JJ||low-24/JJ	amod||levels-31/NNS||high-25/JJ	nn||levels-31/NNS||density-26/NN	nn||levels-31/NNS||lipoprotein-cholesterol-27/NN	dep||levels-31/NNS||hdl-c-29/JJ	prep_for||observed-15/VBN||levels-31/NNS	conj_and||hypertension-17/NN||levels-31/NNS	appos||levels-31/NNS||p-33/NNP	number||0.001-35/CD||<-34/CD	num||p-33/NNP||0.001-35/CD	amod||obesity-40/NN||abdominal-39/JJ	prep_for||observed-15/VBN||obesity-40/NN	conj_and||hypertension-17/NN||obesity-40/NN	dep||hypertension-17/NN||p-42/VBN	dep||0.019-44/CD||=-43/SYM	ccomp||p-42/VBN||0.019-44/CD	cholesterol--1||obesity-40||no_rel||among individual components of mets, differences between women with ra and controls were observed for hypertension ( p < 0.001), low high density lipoprotein-cholesterol (hdl-c) levels ( p < 0.001), and abdominal obesity ( p = 0.019).
prep_in||emphasize-15/VB||light-2/NN	det||problem-6/NN||the-4/DT	amod||problem-6/NN||growing-5/VBG	prep_of||light-2/NN||problem-6/NN	prep_of||problem-6/NN||obesity-8/NN	nn||children-11/NNS||malaysian-10/NN	prep_in||obesity-8/NN||children-11/NNS	det||findings-14/NNS||these-13/DT	nsubj||emphasize-15/VB||findings-14/NNS	root||ROOT-0/null||emphasize-15/VB	det||need-18/NN||the-16/DT	amod||need-18/NN||important-17/JJ	dobj||emphasize-15/VB||need-18/NN	amod||interventions-21/NNS||appropriate-20/JJ	prep_for||need-18/NN||interventions-21/NNS	aux||address-23/VB||to-22/TO	vmod||emphasize-15/VB||address-23/VB	det||problems-25/NNS||both-24/DT	dobj||address-23/VB||problems-25/NNS	amod||status-31/NN||obesity-27/JJ	conj_and||obesity-27/JJ||poor-29/JJ	amod||status-31/NN||poor-29/JJ	amod||status-31/NN||vitamind-30/JJ	prep_of||problems-25/NNS||status-31/NN	prep_in||status-31/NN||children-33/NNS	obesity-27||vitamind-30||no_rel||in light of the growing problem of obesity in malaysian children, these findings emphasize the important need for appropriate interventions to address both problems of obesity and poor vitamind status in children.
vmod||shown-15/VBN||utilizing-1/VBG	det||model-4/NN||a-2/DT	nn||model-4/NN||mouse-3/NN	dobj||utilizing-1/VBG||model-4/NN	amod||infection-7/NN||hcmv-6/JJ	prep_of||model-4/NN||infection-7/NN	det||cns-11/NN||the-9/DT	amod||cns-11/NN||developing-10/VBG	prep_of||infection-7/NN||cns-11/NN	nsubj||shown-15/VBN||we-13/PRP	aux||shown-15/VBN||have-14/VBP	root||ROOT-0/null||shown-15/VBN	det||inoculation-18/NN||that-16/DT	amod||inoculation-18/NN||peripheral-17/JJ	dobj||shown-15/VBN||inoculation-18/NN	amod||mice-21/NNS||newborn-20/JJ	prep_of||inoculation-18/NN||mice-21/NNS	amod||results-28/NNS||murine-23/JJ	nn||results-28/NNS||cmv-24/NN	appos||results-28/NNS||mcmv-26/NNP	prep_with||shown-15/VBN||results-28/NNS	nn||infection-31/NN||cns-30/NN	prep_in||results-28/NNS||infection-31/NN	amod||abnormalities-34/NNS||developmental-33/JJ	prep_with||shown-15/VBN||abnormalities-34/NNS	conj_and||results-28/NNS||abnormalities-34/NNS	nsubj||recapitulate-36/VBP||abnormalities-34/NNS	rcmod||abnormalities-34/NNS||recapitulate-36/VBP	amod||features-38/NNS||key-37/JJ	dobj||recapitulate-36/VBP||features-38/NNS	det||infection-42/NN||the-40/DT	amod||infection-42/NN||human-41/JJ	prep_of||features-38/NNS||infection-42/NN	cmv-24||hcmv-6||no||utilizing a mouse model of hcmv infection of the developing cns, we have shown that peripheral inoculation of newborn mice with murine cmv (mcmv) results in cns infection and developmental abnormalities that recapitulate key features of the human infection.
nsubj||focused-4/VBD||treatment-1/NN	prep_with||treatment-1/NN||chlorpromazine-3/NN	root||ROOT-0/null||focused-4/VBD	dobj||focused-4/VBD||attention-5/NN	det||heterogeneity-8/NN||the-7/DT	prep_on||focused-4/VBD||heterogeneity-8/NN	prep_of||heterogeneity-8/NN||schizophrenia-10/NN	prep_in||focused-4/VBD||terms-12/NNS	prep_of||terms-12/NNS||responsiveness-14/NNS	prep_to||responsiveness-14/NNS||treatment-16/NN	schizophrenia-10||chlorpromazine-3||yes||treatment with chlorpromazine focused attention on the heterogeneity of schizophrenia in terms of responsiveness to treatment.
nsubjpass||administered-12/VBN||patients-1/NNS	det||group-5/NN||the-3/DT	nn||group-5/NN||treatment-4/NN	prep_in||patients-1/NNS||group-5/NN	dep||patients-1/NNS||n-7/VBN	dep||80-9/CD||=-8/SYM	ccomp||n-7/VBN||80-9/CD	auxpass||administered-12/VBN||were-11/VBD	root||ROOT-0/null||administered-12/VBN	det||dose-15/NN||a-13/DT	amod||dose-15/NN||20-mg-14/JJ	dobj||administered-12/VBN||dose-15/NN	prep_of||dose-15/NN||omeprazole-17/NN	advmod||daily-19/RB||twice-18/RB	advmod||administered-12/VBN||daily-19/RB	prep_for||administered-12/VBN||1-21/CD	tmod||administered-12/VBN||week-22/NN	advmod||received-35/VBD||then-24/RB	det||groups-29/NNS||the-25/DT	nn||groups-29/NNS||treatment-26/NN	conj_and||treatment-26/NN||control-28/NN	nn||groups-29/NNS||control-28/NN	nsubj||received-35/VBD||groups-29/NNS	nsubj||duodenalulcers-41/VBZ||groups-29/NNS	dep||groups-29/NNS||n-31/VBN	dep||80-33/CD||=-32/SYM	ccomp||n-31/VBN||80-33/CD	conj_and||administered-12/VBN||received-35/VBD	dobj||received-35/VBD||therapy-36/NN	nn||infection-39/NN||hp-38/NN	prep_for||received-35/VBD||infection-39/NN	conj_and||administered-12/VBN||duodenalulcers-41/VBZ	conj_and||received-35/VBD||duodenalulcers-41/VBZ	duodenalulcers-41||omeprazole-17||yes||patients in the treatment group (n=80) were administered a 20-mg dose of omeprazole twice daily for 1 week and then the treatment and control groups (n=80) received therapy for hp infection and duodenalulcers.
det||profile-4/NN||the-1/DT	amod||profile-4/NN||largest-2/JJS	nn||profile-4/NN||mar-3/NN	nsubj||contained-5/VBD||profile-4/NN	nsubjpass||observed-23/VBN||profile-4/NN	root||ROOT-0/null||contained-5/VBD	num||antibiotics-7/NNS||six-6/CD	dobj||contained-5/VBD||antibiotics-7/NNS	dep||antibiotics-7/NNS||penicilling-9/NN	appos||penicilling-9/NN||methicillin-11/NN	appos||penicilling-9/NN||erythromycin-13/NN	conj_and||methicillin-11/NN||erythromycin-13/NN	appos||penicilling-9/NN||ciprofloxacin-15/NN	conj_and||methicillin-11/NN||ciprofloxacin-15/NN	appos||penicilling-9/NN||clindamycin-17/NN	conj_and||methicillin-11/NN||clindamycin-17/NN	appos||penicilling-9/NN||clarithromycin-19/NN	conj_and||methicillin-11/NN||clarithromycin-19/NN	auxpass||observed-23/VBN||was-22/VBD	conj_and||contained-5/VBD||observed-23/VBN	det||isolates-27/NN||the-25/DT	nn||isolates-27/NN||mrsa-26/NN	prep_in||observed-23/VBN||isolates-27/NN	predet||uk-31/NN||both-29/PDT	det||uk-31/NN||the-30/DT	prep_in||isolates-27/NN||uk-31/NN	amod||cohorts-34/NNS||maltese-33/JJ	prep_in||isolates-27/NN||cohorts-34/NNS	conj_and||uk-31/NN||cohorts-34/NNS	mrsa-26||antibiotics-7||no_rel||the largest mar profile contained six antibiotics (penicilling, methicillin, erythromycin, ciprofloxacin, clindamycin and clarithromycin) and was observed in the mrsa isolates in both the uk and maltese cohorts.
nsubjpass||associated-8/VBN||irondeficiencyanaemia-1/NN	amod||supplementation-5/NN||oral-3/JJ	nn||supplementation-5/NN||iron-4/NN	conj_and||irondeficiencyanaemia-1/NN||supplementation-5/NN	nsubjpass||associated-8/VBN||supplementation-5/NN	aux||associated-8/VBN||have-6/VBP	auxpass||associated-8/VBN||been-7/VBN	root||ROOT-0/null||associated-8/VBN	advmod||associated-8/VBN||negatively-9/RB	prep_with||associated-8/VBN||quality-11/NN	prep_of||quality-11/NN||life-13/NN	amod||effects-18/NNS||adverse-17/JJ	prep_with||associated-8/VBN||effects-18/NNS	conj_and||quality-11/NN||effects-18/NNS	advmod||associated-8/VBN||respectively-20/RB	prep_in||associated-8/VBN||subjects-23/NNS	prep_with||subjects-23/NNS||inflammatoryboweldisease-25/NN	appos||inflammatoryboweldisease-25/NN||ibd-27/NN	irondeficiencyanaemia-1||iron-4||yes||irondeficiencyanaemia and oral iron supplementation have been associated negatively with quality of life, and with adverse effects, respectively, in subjects with inflammatoryboweldisease (ibd).
det||aim-2/NN||the-1/DT	nsubj||was-7/VBD||aim-2/NN	nsubj||evaluate-9/VB||aim-2/NN	det||study-6/NN||the-4/DT	amod||study-6/NN||present-5/JJ	prep_of||aim-2/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||evaluate-9/VB||to-8/TO	xcomp||was-7/VBD||evaluate-9/VB	prep_in||evaluate-9/VB||patients-11/NNS	prep_with||patients-11/NNS||polycysticovarysyndrome-13/NN	appos||polycysticovarysyndrome-13/NN||pcos-15/NNS	mark||affects-20/VBZ||whether-17/IN	nn||administration-19/NN||metformin-18/NN	nsubj||affects-20/VBZ||administration-19/NN	ccomp||evaluate-9/VB||affects-20/VBZ	nn||levels-25/NNS||serum-21/NN	conj_and||serum-21/NN||follicular-23/NN	nn||levels-25/NNS||follicular-23/NN	nn||levels-25/NNS||amh-24/NN	dobj||affects-20/VBZ||levels-25/NNS	mark||related-31/VBN||whether-28/IN	nsubjpass||related-31/VBN||this-29/DT	nsubj||ovarian-33/VB||this-29/DT	auxpass||related-31/VBN||is-30/VBZ	ccomp||evaluate-9/VB||related-31/VBN	conj_and||affects-20/VBZ||related-31/VBN	aux||ovarian-33/VB||to-32/TO	xcomp||related-31/VBN||ovarian-33/VB	dobj||ovarian-33/VB||response-34/NN	det||treatment-37/NN||the-36/DT	prep_to||ovarian-33/VB||treatment-37/NN	polycysticovarysyndrome-13||metformin-18||no_rel||the aim of the present study was to evaluate in patients with polycysticovarysyndrome (pcos) whether metformin administration affects serum and follicular amh levels, and whether this is related to ovarian response to the treatment.
nsubj||reduced-10/VBD||induction-1/NN	amod||inflammation-4/NN||neurogenic-3/JJ	prep_of||induction-1/NN||inflammation-4/NN	amod||application-7/NN||topical-6/JJ	prep_by||inflammation-4/NN||application-7/NN	prep_of||application-7/NN||capsaicin-9/NN	root||ROOT-0/null||reduced-10/VBD	xcomp||reduced-10/VBD||licking-11/VBG	dobj||licking-11/VBG||events-12/NNS	amod||mice-15/NNS||skh1-hrhr-14/JJ	prep_in||licking-11/VBG||mice-15/NNS	nsubj||rescued-19/VBD||morphine-18/NN	conj_and||reduced-10/VBD||rescued-19/VBD	det||response-21/NN||this-20/DT	dobj||rescued-19/VBD||response-21/NN	morphine-18||inflammation-4||no_rel||induction of neurogenic inflammation by topical application of capsaicin reduced licking events in skh1-hrhr mice, and morphine rescued this response.
nsubj||member-8/NN||missing-in-metastasis-1/NNS	appos||missing-in-metastasis-1/NNS||mim-3/NN	cop||member-8/NN||is-5/VBZ	det||member-8/NN||a-6/DT	amod||member-8/NN||defining-7/VBG	root||ROOT-0/null||member-8/NN	det||subfamily-17/NN||the-10/DT	amod||subfamily-17/NN||inverse-11/JJ	nn||subfamily-17/NN||bin/amphiphysin/rvs-12/NNS	nn||subfamily-17/NN||domain-13/NN	appos||subfamily-17/NN||i-bar-15/NN	prep_of||member-8/NN||subfamily-17/NN	num||regulators-23/NNS||lipid-19/CD	amod||regulators-23/NNS||binding-20/JJ	amod||regulators-23/NNS||cytoskeletal-22/JJ	prep_of||member-8/NN||regulators-23/NNS	dep||altered-27/VBN||whose-24/WP$	nsubjpass||altered-27/VBN||levels-25/NNS	auxpass||altered-27/VBN||are-26/VBP	dep||regulators-23/NNS||altered-27/VBN	det||number-30/NN||a-29/DT	prep_in||altered-27/VBN||number-30/NN	prep_of||number-30/NN||cancers-32/NNS	i---1||cancers-32||no_rel||missing-in-metastasis (mim) is a defining member of the inverse bin/amphiphysin/rvs domain (i-bar) subfamily of lipid binding, cytoskeletal regulators whose levels are altered in a number of cancers.
det||risk-2/NN||the-1/DT	nsubj||increased-8/VBN||risk-2/NN	amod||emergence-6/NN||adefovirdipivoxil-4/JJ	nn||emergence-6/NN||resistance-5/NN	prep_of||risk-2/NN||emergence-6/NN	aux||increased-8/VBN||has-7/VBZ	root||ROOT-0/null||increased-8/VBN	amod||patients-13/NNS||lamivudine-resistant-10/JJ	amod||patients-13/NNS||hepatitisb-11/JJ	amod||patients-13/NNS||infected-12/JJ	prep_in||increased-8/VBN||patients-13/NNS	hepatitisb-11||adefovirdipivoxil-4||yes||the risk of adefovirdipivoxil resistance emergence has increased in lamivudine-resistant hepatitisb infected patients.
amod||mutants-2/NNS||spontaneous-1/JJ	nsubjpass||isolated-16/VBN||mutants-2/NNS	nsubjpass||found-18/VBN||mutants-2/NNS	prep_of||mutants-2/NNS||mycobacteriumtuberculosis-4/NNS	nsubj||resistant-7/JJ||mycobacteriumtuberculosis-4/NNS	cop||resistant-7/JJ||were-6/VBD	rcmod||mycobacteriumtuberculosis-4/NNS||resistant-7/JJ	det||drugs-11/NNS||the-9/DT	amod||drugs-11/NNS||anti-tuberculosis-10/JJ	prep_to||resistant-7/JJ||drugs-11/NNS	amod||drugs-11/NNS||ethionamide-12/JJ	amod||drugs-11/NNS||isoniazid-14/JJ	conj_and||ethionamide-12/JJ||isoniazid-14/JJ	auxpass||isolated-16/VBN||were-15/VBD	root||ROOT-0/null||isolated-16/VBN	conj_and||isolated-16/VBN||found-18/VBN	prep_to||isolated-16/VBN||map-20/NN	prep_to||isolated-16/VBN||msha-22/NN	det||gene-25/NN||a-24/DT	appos||msha-22/NN||gene-25/NN	vmod||gene-25/NN||encoding-26/VBG	det||enzyme-29/NN||the-27/DT	amod||enzyme-29/NN||first-28/JJ	dobj||encoding-26/VBG||enzyme-29/NN	vmod||enzyme-29/NN||involved-30/VBN	det||biosynthesis-33/NNS||the-32/DT	prep_in||involved-30/VBN||biosynthesis-33/NNS	prep_of||biosynthesis-33/NNS||mycothiol-35/NN	det||thiol-40/NN||a-37/DT	amod||thiol-40/NN||major-38/JJ	amod||thiol-40/NN||low-molecular-weight-39/JJ	appos||mycothiol-35/NN||thiol-40/NN	prep_in||thiol-40/NN||m.tuberculosis-42/NNS	tuberculosis--1||isoniazid-14||yes||spontaneous mutants of mycobacteriumtuberculosis that were resistant to the anti-tuberculosis drugs ethionamide and isoniazid were isolated and found to map to msha , a gene encoding the first enzyme involved in the biosynthesis of mycothiol , a major low-molecular-weight thiol in m.tuberculosis .
amod||size-3/NN||fat-1/JJ	nn||size-3/NN||cell-2/NN	nsubjpass||determined-10/VBN||size-3/NN	conj_and||size-3/NN||expression-5/NN	nsubjpass||determined-10/VBN||expression-5/NN	amod||genes-8/NNS||hypoxia-dependent-7/JJ	prep_of||size-3/NN||genes-8/NNS	auxpass||determined-10/VBN||were-9/VBD	root||ROOT-0/null||determined-10/VBN	prep_in||determined-10/VBN||adipocytes-12/NNS	det||depots-16/NNS||both-14/DT	amod||depots-16/NNS||fat-15/JJ	prep_from||adipocytes-12/NNS||depots-16/NNS	fat-15||hypoxia--1||no_rel||fat cell size and expression of hypoxia-dependent genes were determined in adipocytes from both fat depots.
advmod||associated-2/VBN||dyskinesias-1/RB	root||ROOT-0/null||associated-2/VBN	amod||movements-5/NNS||involuntary-4/JJ	prep_with||associated-2/VBN||movements-5/NNS	amod||contractions-9/NNS||painful-7/JJ	nn||contractions-9/NNS||muscle-8/NN	prep_with||associated-2/VBN||contractions-9/NNS	conj_and||movements-5/NNS||contractions-9/NNS	cop||complication-15/NN||are-10/VBP	det||complication-15/NN||a-11/DT	amod||complication-15/NN||common-12/JJ	conj_and||common-12/JJ||severe-14/JJ	amod||complication-15/NN||severe-14/JJ	auxpass||associated-2/VBN||complication-15/NN	amod||levodopa-18/NN||standard-17/JJ	prep_of||complication-15/NN||levodopa-18/NN	appos||levodopa-18/NN||l-dopa-20/NNP	dep||l-dopa-20/NNP||l-3-22/NN	num||l-3-22/NN||,4-23/CD	dep||l-dopa-20/NNP||dihydroxyphenylalanine-25/NN	nsubjpass||associated-2/VBN||therapy-27/NN	nn||sdisease-31/NN||parkinson-29/NN	prep_for||therapy-27/NN||sdisease-31/NN	parkinson'sdisease--1||l-dopa-20||yes||dyskinesias associated with involuntary movements and painful muscle contractions are a common and severe complication of standard levodopa (l-dopa, l-3,4-dihydroxyphenylalanine) therapy for parkinson'sdisease.
nsubj||studied-3/VBD||we-1/PRP	advmod||studied-3/VBD||here-2/RB	root||ROOT-0/null||studied-3/VBD	det||model-10/NN||the-6/DT	amod||model-10/NN||gold-standard-7/JJ	amod||model-10/NN||non-human-8/JJ	nn||model-10/NN||primate-9/NN	prep_in||studied-3/VBD||model-10/NN	prep_of||model-10/NN||parkinson-12/NN	dep||model-10/NN||sdisease-14/JJ	det||changes-17/NNS||the-16/DT	dep||sdisease-14/JJ||changes-17/NNS	amod||phosphorylation-20/NN||pka-dependent-19/JJ	prep_in||changes-17/NNS||phosphorylation-20/NN	amod||receptor-26/NN||darpp-32-22/JJ	conj_and||darpp-32-22/JJ||glur1-24/JJ	amod||receptor-26/NN||glur1-24/JJ	nn||receptor-26/NN||ampa-25/NN	prep_of||phosphorylation-20/NN||receptor-26/NN	nn||s6-36/NNS||erk-32/NN	conj_and||erk-32/NN||ribosomal-34/JJ	nn||s6-36/NNS||ribosomal-34/JJ	nn||s6-36/NNS||protein-35/NN	prep_in||studied-3/VBD||s6-36/NNS	conj_and||model-10/NN||s6-36/NNS	appos||s6-36/NNS||s6-38/NNP	amod||s6-36/NNS||phosphorylation-40/JJ	vmod||s6-36/NNS||associated-42/VBN	amod||administration-47/NN||acute-44/JJ	conj_and||acute-44/JJ||chronic-46/JJ	amod||administration-47/NN||chronic-46/JJ	prep_to||associated-42/VBN||administration-47/NN	prep_of||administration-47/NN||l-dopa-49/NN	parkinson'sdisease--1||l-dopa-49||yes||we here studied, in the gold-standard non-human primate model of parkinson'sdisease, the changes in pka-dependent phosphorylation of darpp-32 and glur1 ampa receptor, as well as in erk and ribosomal protein s6 (s6) phosphorylation, associated to acute and chronic administration of l-dopa.
nsubj||rare-32/JJ||diseases-1/NNS	vmod||diseases-1/NNS||associated-2/VBN	amod||infections-8/NNS||epstein-barrvirus-4/JJ	appos||infections-8/NNS||ebv-6/NN	prep_with||associated-2/VBN||infections-8/NNS	prep_such_as||associated-2/VBN||infectiousmononucleosis-12/NNS	appos||infectiousmononucleosis-12/NNS||im-14/NN	amod||lymphohistiocytosis-19/NNS||ebv-associated-17/JJ	amod||lymphohistiocytosis-19/NNS||hemophagocytic-18/JJ	prep_such_as||associated-2/VBN||lymphohistiocytosis-19/NNS	conj_and||infectiousmononucleosis-12/NNS||lymphohistiocytosis-19/NNS	appos||lymphohistiocytosis-19/NNS||ebv-hlh-21/NN	amod||ebvinfection-26/NN||chronic-24/JJ	amod||ebvinfection-26/NN||active-25/JJ	prep_such_as||associated-2/VBN||ebvinfection-26/NN	conj_and||infectiousmononucleosis-12/NNS||ebvinfection-26/NN	appos||ebvinfection-26/NN||caebv-28/NNP	cop||rare-32/JJ||are-30/VBP	neg||rare-32/JJ||not-31/RB	root||ROOT-0/null||rare-32/JJ	amod||children-35/NNS||chinese-34/JJ	prep_in||rare-32/JJ||children-35/NNS	ebvinfection-26||ebv-6||no||diseases associated with epstein-barrvirus (ebv) infections, such as infectiousmononucleosis (im), ebv-associated hemophagocytic lymphohistiocytosis (ebv-hlh) and chronic active ebvinfection (caebv) are not rare in chinese children.
nn||granulomas-5/NNS||tuberculosis-1/NNP	appos||granulomas-5/NNS||tb-3/NN	nsubj||collections-8/NNS||granulomas-5/NNS	cop||collections-8/NNS||are-6/VBP	amod||collections-8/NNS||organized-7/VBN	root||ROOT-0/null||collections-8/NNS	amod||cells-11/NNS||immune-10/JJ	prep_of||collections-8/NNS||cells-11/NNS	vmod||cells-11/NNS||comprised-12/VBN	prep_of||comprised-12/VBN||macrophages-14/NNS	prep_of||comprised-12/VBN||lymphocytes-16/NNS	conj_and||macrophages-14/NNS||lymphocytes-16/NNS	amod||cells-19/NNS||other-18/JJ	prep_of||comprised-12/VBN||cells-19/NNS	conj_and||macrophages-14/NNS||cells-19/NNS	nsubj||form-21/VBP||cells-19/NNS	rcmod||cells-19/NNS||form-21/VBP	det||lung-24/NN||the-23/DT	prep_in||form-21/VBP||lung-24/NN	det||result-27/NN||a-26/DT	prep_as||lung-24/NN||result-27/NN	amod||response-30/NN||immune-29/JJ	prep_of||result-27/NN||response-30/NN	nn||infection-36/NN||mycobacteriumtuberculosis-32/NNP	appos||infection-36/NN||mtb-34/NN	prep_to||form-21/VBP||infection-36/NN	tuberculosis-1||mycobacteriumtuberculosis-32||no||tuberculosis (tb) granulomas are organized collections of immune cells comprised of macrophages, lymphocytes and other cells that form in the lung as a result of immune response to mycobacteriumtuberculosis (mtb) infection.
nsubj||show-2/VBP||we-1/PRP	root||ROOT-0/null||show-2/VBP	mark||observed-39/VBN||that-3/IN	mark||correlated-23/JJ||because-4/IN	det||rigidity-7/NN||the-6/DT	prep_of||correlated-23/JJ||rigidity-7/NN	det||bonds-11/NNS||the-9/DT	amod||bonds-11/NNS||covalent-10/JJ	prep_of||rigidity-7/NN||bonds-11/NNS	det||backbones-15/NNS||the-13/DT	amod||backbones-15/NNS||sugar-phosphate-14/JJ	prep_in||bonds-11/NNS||backbones-15/NNS	det||parameters-20/NNS||the-17/DT	nn||parameters-20/NNS||base-18/NN	nn||parameters-20/NNS||pair-19/NN	nsubj||correlated-23/JJ||parameters-20/NNS	cop||correlated-23/JJ||are-21/VBP	advmod||correlated-23/JJ||highly-22/RB	advcl||observed-39/VBN||correlated-23/JJ	advmod||correlated-23/JJ||especially-25/RB	amod||correlation-29/NN||strong-27/JJ	amod||correlation-29/NN||twist-roll-slide-28/JJ	nsubjpass||observed-39/VBN||correlation-29/NN	det||conformation-32/NN||the-31/DT	prep_in||correlation-29/NN||conformation-32/NN	det||dna-36/NN||the-34/DT	amod||dna-36/NN||nucleosomal-35/JJ	prep_of||conformation-32/NN||dna-36/NN	auxpass||observed-39/VBN||is-37/VBZ	advmod||observed-39/VBN||vividly-38/RB	ccomp||show-2/VBP||observed-39/VBN	det||results-43/NNS||the-41/DT	amod||results-43/NNS||calculated-42/JJ	prep_in||observed-39/VBN||results-43/NNS	rigidity-7||base-18||no_rel||we show that because of the rigidity of the covalent bonds in the sugar-phosphate backbones, the base pair parameters are highly correlated, especially, strong twist-roll-slide correlation in the conformation of the nucleosomal dna is vividly observed in the calculated results.
prep||learned-16/VBN||in-1/IN	advmod||years-4/NNS||just-2/RB	num||years-4/NNS||six-3/CD	npadvmod||after-5/IN||years-4/NNS	pcomp||in-1/IN||after-5/IN	det||description-8/NN||the-6/DT	amod||description-8/NN||initial-7/JJ	pobj||after-5/IN||description-8/NN	det||acquiredimmunodeficiencysyndrome-11/NN||the-10/DT	prep_of||description-8/NN||acquiredimmunodeficiencysyndrome-11/NN	nsubjpass||learned-16/VBN||much-13/RB	aux||learned-16/VBN||has-14/VBZ	auxpass||learned-16/VBN||been-15/VBN	root||ROOT-0/null||learned-16/VBN	det||agent-20/NN||the-18/DT	amod||agent-20/NN||etiologic-19/JJ	prep_about||learned-16/VBN||agent-20/NN	det||humanimmunodeficiencyvirus-23/NNS||the-22/DT	appos||agent-20/NN||humanimmunodeficiencyvirus-23/NNS	acquiredimmunodeficiencysyndrome-11||humanimmunodeficiencyvirus-23||no||in just six years after the initial description of the acquiredimmunodeficiencysyndrome, much has been learned about the etiologic agent, the humanimmunodeficiencyvirus.
advmod||investigated-4/VBD||here-1/RB	nsubj||investigated-4/VBD||we-3/PRP	root||ROOT-0/null||investigated-4/VBD	det||response-7/NN||the-5/DT	amod||response-7/NN||immune-6/JJ	dobj||investigated-4/VBD||response-7/NN	amod||infection-10/NN||intranasal-9/JJ	prep_to||investigated-4/VBD||infection-10/NN	det||virus-13/NN||a-12/DT	prep_with||investigated-4/VBD||virus-13/NN	vmod||virus-13/NN||lacking-14/VBG	det||gene-17/NN||the-15/DT	amod||gene-17/NN||n1l-16/JJ	dobj||lacking-14/VBG||gene-17/NN	dep||gene-17/NN||vî-19/VBN	dobj||vî-19/VBN||n1l-21/NNS	prepc_compared_with||gene-17/NN||with-24/IN	nn||viruses-26/NNS||control-25/NN	pobj||gene-17/NN||viruses-26/NNS	vmod||viruses-26/NNS||expressing-27/VBG	dobj||expressing-27/VBG||n1l-28/NNS	virus-13||viruses-26||no||here, we investigated the immune response to intranasal infection with a virus lacking the n1l gene (vîn1l) compared with control viruses expressing n1l .
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||assess-8/VB||purpose-2/NN	det||review-5/NN||this-4/DT	prep_of||purpose-2/NN||review-5/NN	root||ROOT-0/null||was-6/VBD	aux||assess-8/VB||to-7/TO	xcomp||was-6/VBD||assess-8/VB	det||quality-10/NN||the-9/DT	dobj||assess-8/VB||quality-10/NN	amod||literature-15/NN||peer-reviewed-12/JJ	amod||literature-15/NN||published-14/VBN	prep_of||quality-10/NN||literature-15/NN	prep_on||assess-8/VB||timh-17/NN	amod||care-20/NN||hiv/aids-19/JJ	prep_for||assess-8/VB||care-20/NN	prep_for||assess-8/VB||treatment-22/NN	conj_and||care-20/NN||treatment-22/NN	aids--1||hiv--1||no||the purpose of this review was to assess the quality of peer-reviewed, published literature on timh for hiv/aids care and treatment.
det||presence-2/NN||the-1/DT	nsubjpass||associated-9/VBN||presence-2/NN	det||antibodies-6/NNS||these-4/DT	nn||antibodies-6/NNS||auto-5/NN	prep_of||presence-2/NN||antibodies-6/NNS	auxpass||associated-9/VBN||was-7/VBD	advmod||associated-9/VBN||significantly-8/RB	root||ROOT-0/null||associated-9/VBN	advmod||frequent-12/JJ||more-11/RBR	amod||attacks-17/NNS||frequent-12/JJ	advmod||lasting-15/JJ||longer-14/RB	conj_and||frequent-12/JJ||lasting-15/JJ	amod||attacks-17/NNS||lasting-15/JJ	nn||attacks-17/NNS||urticarial-16/NN	prep_with||associated-9/VBN||attacks-17/NNS	urticarial-16||antibodies-6||no_rel||the presence of these auto antibodies was significantly associated with more frequent and longer lasting urticarial attacks.
det||diphtheriae-7/NN||the-1/DT	amod||diphtheriae-7/NN||aerobic-2/JJ	nn||diphtheriae-7/NN||gram-3/NN	amod||diphtheriae-7/NN||positive-4/JJ	nn||diphtheriae-7/NN||bacterium-5/NN	nn||diphtheriae-7/NN||corynebacterium-6/NN	nsubj||causes-8/VBZ||diphtheriae-7/NN	ccomp||characterized-15/VBD||causes-8/VBZ	dobj||causes-8/VBZ||diphtheria-9/NN	det||illness-14/NN||a-11/DT	amod||illness-14/NN||respiratory-12/JJ	nn||illness-14/NN||tract-13/NN	nsubj||characterized-15/VBD||illness-14/NN	nsubj||nasal-36/VBP||illness-14/NN	root||ROOT-0/null||characterized-15/VBD	prep_by||characterized-15/VBD||symptoms-17/NNS	prep_such_as||symptoms-17/NNS||sorethroat-20/NN	amod||fever-23/NN||low-22/JJ	prep_such_as||symptoms-17/NNS||fever-23/NN	conj_and||sorethroat-20/NN||fever-23/NN	det||membrane-28/NN||an-26/DT	amod||membrane-28/NN||adherent-27/JJ	prep_such_as||symptoms-17/NNS||membrane-28/NN	conj_and||sorethroat-20/NN||membrane-28/NN	det||tonsils-31/NNS||the-30/DT	prep_on||characterized-15/VBD||tonsils-31/NNS	appos||tonsils-31/NNS||pharynx-33/NN	conj_and/or||characterized-15/VBD||nasal-36/VBP	advmod||nasal-36/VBP||cavity-37/RB	cavity-37||bacterium-5||no||the aerobic gram positive bacterium corynebacterium diphtheriae causes diphtheria, a respiratory tract illness characterized by symptoms such as sorethroat, low fever, and an adherent membrane on the tonsils, pharynx, and/or nasal cavity.
nsubj||developed-3/VBN||we-1/PRP	aux||developed-3/VBN||have-2/VBP	root||ROOT-0/null||developed-3/VBN	det||model-8/NN||a-4/DT	amod||model-8/NN||reproducible-5/JJ	amod||model-8/NN||large-6/JJ	nn||model-8/NN||animal-7/NN	dobj||developed-3/VBN||model-8/NN	amod||liverfailure-11/NN||acetaminophen-induced-10/JJ	prep_of||model-8/NN||liverfailure-11/NN	nsubj||allows-14/VBZ||liverfailure-11/NN	rcmod||liverfailure-11/NN||allows-14/VBZ	amod||investigation-16/NN||in-depth-15/JJ	dobj||allows-14/VBZ||investigation-16/NN	det||basis-20/NN||the-18/DT	amod||basis-20/NN||pathophysiological-19/JJ	prep_of||investigation-16/NN||basis-20/NN	det||condition-23/NN||this-22/DT	prep_of||basis-20/NN||condition-23/NN	acetaminophen--1||liverfailure-11||no_rel||we have developed a reproducible large animal model of acetaminophen-induced liverfailure, which allows in-depth investigation of the pathophysiological basis of this condition.
nsubjpass||associated-3/VBN||aceruloplasminemia-1/NN	auxpass||associated-3/VBN||was-2/VBD	root||ROOT-0/null||associated-3/VBN	amod||brain-6/NN||severe-5/JJ	prep_with||associated-3/VBN||brain-6/NN	nn||ironoverload-9/NN||liver-8/NN	prep_with||associated-3/VBN||ironoverload-9/NN	conj_and||brain-6/NN||ironoverload-9/NN	advmod||increased-21/VBN||where-11/WRB	amod||expression-14/NN||hepatic-12/JJ	nn||expression-14/NN||mrna-13/NN	nsubjpass||increased-21/VBN||expression-14/NN	det||hepcidin-19/NN||the-16/DT	nn||hepcidin-19/NN||iron-17/NN	nn||hepcidin-19/NN||hormone-18/NN	prep_of||expression-14/NN||hepcidin-19/NN	auxpass||increased-21/VBN||was-20/VBD	rcmod||brain-6/NN||increased-21/VBN	amod||brain-6/NN||corresponding-23/JJ	det||degree-26/NN||the-25/DT	prep_to||corresponding-23/JJ||degree-26/NN	prep_of||degree-26/NN||ironoverload-28/NN	ironoverload-28||iron-17||no||aceruloplasminemia was associated with severe brain and liver ironoverload, where hepatic mrna expression of the iron hormone hepcidin was increased, corresponding to the degree of ironoverload.
nn||analysis-2/NN||sequence-1/NN	nsubj||revealed-6/VBD||analysis-2/NN	det||rnas-5/NNS||these-4/DT	prep_of||analysis-2/NN||rnas-5/NNS	root||ROOT-0/null||revealed-6/VBD	det||organization-9/NN||a-7/DT	amod||organization-9/NN||genome-8/JJ	nsubj||described-13/VBD||organization-9/NN	amod||organization-9/NN||similar-10/JJ	prep||similar-10/JJ||to-11/TO	pobj||to-11/TO||recently-12/RB	ccomp||revealed-6/VBD||described-13/VBD	dobj||described-13/VBD||torradoviruses-14/NNS	det||group-18/NN||a-16/DT	amod||group-18/NN||new-17/JJ	appos||torradoviruses-14/NNS||group-18/NN	amod||viruses-21/NNS||picorna-like-20/JJ	prep_of||group-18/NN||viruses-21/NNS	vmod||viruses-21/NNS||causing-22/VBG	amod||diseases-24/NNS||necrosis-associated-23/JJ	dobj||causing-22/VBG||diseases-24/NNS	prep_of||diseases-24/NNS||tomatoes-26/NNS	amod||-RSB--36/NNS||europe-28/JJ	amod||-RSB--36/NNS||-LSB--29/JJ	nn||-RSB--36/NNS||tomato-30/NN	nn||-RSB--36/NNS||torrado-31/NN	nn||-RSB--36/NNS||virus-32/NN	appos||-RSB--36/NNS||totv-34/NNP	prep_in||tomatoes-26/NNS||-RSB--36/NNS	nn||virus-43/NN||mexico-38/NNP	nn||virus-43/NN||-LSB--39/NNP	nn||virus-43/NN||tomato-40/NNP	nn||virus-43/NN||apex-41/NN	nn||virus-43/NN||necrosis-42/NNS	prep_in||tomatoes-26/NNS||virus-43/NN	conj_and||-RSB--36/NNS||virus-43/NN	appos||virus-43/NN||toanv-45/NNP	nn||virus-50/NN||tomato-48/NN	nn||virus-50/NN||marchitez-49/NN	prep_in||tomatoes-26/NNS||virus-50/NN	conj_and||-RSB--36/NNS||virus-50/NN	appos||virus-50/NN||tomarv-52/NNP	advmod||causing-22/VBG||-RSB--54/RB	virus-50||viruses-21||no||sequence analysis of these rnas revealed a genome organization similar to recently described torradoviruses, a new group of picorna-like viruses causing necrosis-associated diseases of tomatoes in europe [tomato torrado virus (totv)] and mexico [tomato apex necrosis virus (toanv) and tomato marchitez virus (tomarv)].
amod||scores-4/NNS||verbal-1/JJ	amod||scores-4/NNS||analogue-2/JJ	nn||scores-4/NNS||pain-3/NN	nsubj||boluses-9/VBZ||scores-4/NNS	appos||scores-4/NNS||need-6/NN	prep_of||need-6/NN||supplementary/rescue-8/NN	ccomp||recorded-27/VBN||boluses-9/VBZ	dobj||boluses-9/VBZ||dose-10/NN	prep_of||dose-10/NN||bupivacaine-12/NN	vmod||bupivacaine-12/NN||consumed-13/VBN	nsubjpass||recorded-27/VBN||mode-15/NN	prep_of||mode-15/NN||delivery-17/NN	amod||satisfaction-20/NN||maternal-19/JJ	prep_of||mode-15/NN||satisfaction-20/NN	conj_and||delivery-17/NN||satisfaction-20/NN	amod||scores-25/NNS||neonatal-23/JJ	nn||scores-25/NNS||apgar-24/NN	prep_of||mode-15/NN||scores-25/NNS	conj_and||delivery-17/NN||scores-25/NNS	auxpass||recorded-27/VBN||were-26/VBD	root||ROOT-0/null||recorded-27/VBN	pain-3||bupivacaine-12||yes||verbal analogue pain scores, need of supplementary/rescue boluses dose of bupivacaine consumed, mode of delivery, maternal satisfaction, and neonatal apgar scores were recorded.
nsubj||²-6/NN||carvedilol-1/NN	cop||²-6/NN||is-2/VBZ	det||²-6/NN||a-3/DT	amod||²-6/NN||non-selective-4/JJ	nn||²-6/NN||î-5/NN	root||ROOT-0/null||²-6/NN	nsubj||indicated-9/VBD||blocker-8/NN	parataxis||²-6/NN||indicated-9/VBD	det||treatment-12/NN||the-11/DT	prep_in||indicated-9/VBD||treatment-12/NN	nn||failure-17/NN||hypertension-14/NN	conj_and||hypertension-14/NN||heart-16/NN	nn||failure-17/NN||heart-16/NN	prep_of||treatment-12/NN||failure-17/NN	hypertension-14||carvedilol-1||yes||carvedilol is a non-selective î² -blocker indicated in the treatment of hypertension and heart failure.
det||models-4/NNS||both-2/DT	nn||models-4/NNS||mouse-3/NN	nsubj||exhibiting-5/VBG||models-4/NNS	prepc_despite||are-24/VBP||exhibiting-5/VBG	amod||influx-9/NN||increased-6/VBN	amod||influx-9/NN||in-vivo-7/JJ	nn||influx-9/NN||calcium-8/NN	dobj||exhibiting-5/VBG||influx-9/NN	det||stage-13/NN||an-11/DT	amod||stage-13/NN||early-12/JJ	prep_at||exhibiting-5/VBG||stage-13/NN	det||development-16/NN||the-15/DT	prep_in||stage-13/NN||development-16/NN	det||cardiomyopathy-19/NN||the-18/DT	prep_of||development-16/NN||cardiomyopathy-19/NN	prep_before||exhibiting-5/VBG||leftventricularhypertrophy-21/NN	expl||are-24/VBP||there-23/EX	root||ROOT-0/null||are-24/VBP	amod||differences-27/NNS||distinct-25/JJ	amod||differences-27/NNS||phenotypical-26/JJ	nsubj||are-24/VBP||differences-27/NNS	det||models-31/NNS||the-29/DT	num||models-31/NNS||2-30/CD	prep_between||differences-27/NNS||models-31/NNS	prep_in||models-31/NNS||terms-33/NNS	nn||rates-36/NNS||heart-35/NN	prep_of||terms-33/NNS||rates-36/NNS	prep_of||terms-33/NNS||hemodynamics-38/NNS	conj_and||rates-36/NNS||hemodynamics-38/NNS	prep_of||terms-33/NNS||responses-40/NNS	conj_and||rates-36/NNS||responses-40/NNS	nn||inhibitors-44/NNS||calcium-42/NN	nn||inhibitors-44/NNS||channel-43/NN	prep_to||rates-36/NNS||inhibitors-44/NNS	calcium-42||leftventricularhypertrophy-21||no_rel||despite both mouse models exhibiting increased in-vivo calcium influx at an early stage in the development of the cardiomyopathy before leftventricularhypertrophy, there are distinct phenotypical differences between the 2 models in terms of heart rates, hemodynamics and responses to calcium channel inhibitors.
nn||intensity-2/NN||postoperativepain-1/NN	nsubjpass||recorded-9/VBN||intensity-2/NN	conj_and||intensity-2/NN||use-4/NN	nsubjpass||recorded-9/VBN||use-4/NN	amod||analgesia-7/NN||opioid-6/JJ	prep_of||intensity-2/NN||analgesia-7/NN	auxpass||recorded-9/VBN||were-8/VBD	root||ROOT-0/null||recorded-9/VBN	num||hours-12/NNS||72-11/CD	prep_through||recorded-9/VBN||hours-12/NNS	prep_for||hours-12/NNS||comparison-14/NN	advmod||reported-17/VBN||previously-16/RB	amod||data-18/NNS||reported-17/VBN	prep_with||recorded-9/VBN||data-18/NNS	amod||studies-21/NNS||efficacy-20/JJ	prep_from||data-18/NNS||studies-21/NNS	vmod||studies-21/NNS||performed-22/VBN	prep_in||performed-22/VBN||men-24/NNS	vmod||men-24/NNS||undergoing-25/VBG	amod||hernioplasty-28/NN||open-26/JJ	amod||hernioplasty-28/NN||inguinal-27/JJ	dobj||undergoing-25/VBG||hernioplasty-28/NN	opioid-6||postoperativepain-1||no_rel||postoperativepain intensity and use of opioid analgesia were recorded through 72 hours for comparison with previously reported data from efficacy studies performed in men undergoing open inguinal hernioplasty.
amod||reports-2/NNS||recent-1/JJ	nsubj||rendered-26/VBN||reports-2/NNS	amod||levels-5/NNS||substantial-4/JJ	prep_of||reports-2/NNS||levels-5/NNS	amod||activity-8/NN||influenzavirus-7/JJ	prep_of||levels-5/NNS||activity-8/NN	amod||seasonality-11/NN||well-defined-10/JJ	prep_of||reports-2/NNS||seasonality-11/NN	conj_and||levels-5/NNS||seasonality-11/NN	amod||regions-14/NNS||tropical-13/JJ	prep_in||seasonality-11/NN||regions-14/NNS	advmod||persist-22/VBP||where-16/WRB	amod||conditions-20/NNS||warm-17/JJ	conj_and||warm-17/JJ||humid-19/JJ	amod||conditions-20/NNS||humid-19/JJ	nsubj||persist-22/VBP||conditions-20/NNS	advmod||persist-22/VBP||often-21/RB	rcmod||reports-2/NNS||persist-22/VBP	dobj||persist-22/VBP||year-round-23/JJ	aux||rendered-26/VBN||have-25/VBP	root||ROOT-0/null||rendered-26/VBN	amod||hypotheses-28/NNS||previous-27/JJ	nsubj||insufficient-29/JJ||hypotheses-28/NNS	xcomp||rendered-26/VBN||insufficient-29/JJ	prepc_for||insufficient-29/JJ||explaining-31/VBG	amod||patterns-33/NNS||global-32/JJ	dobj||explaining-31/VBG||patterns-33/NNS	prep_of||patterns-33/NNS||influenza-35/NN	influenza-35||influenzavirus-7||no||recent reports of substantial levels of influenzavirus activity and well-defined seasonality in tropical regions, where warm and humid conditions often persist year-round, have rendered previous hypotheses insufficient for explaining global patterns of influenza.
amod||ks-5/NNS||kaposi-1/JJ	amod||ks-5/NNS||ssarcoma-3/JJ	nsubj||rare-12/JJ||ks-5/NNS	nsubj||has-14/VBZ||ks-5/NNS	nsubj||distinguished-17/JJ||ks-5/NNS	amod||patients-10/NNS||hiv-8/JJ	amod||patients-10/NNS||negative-9/JJ	prep_in||ks-5/NNS||patients-10/NNS	cop||rare-12/JJ||is-11/VBZ	root||ROOT-0/null||rare-12/JJ	conj_and||rare-12/JJ||has-14/VBZ	aux||distinguished-17/JJ||to-15/TO	cop||distinguished-17/JJ||be-16/VB	xcomp||has-14/VBZ||distinguished-17/JJ	prep_from||distinguished-17/JJ||aids-19/NNS	vmod||aids-19/NNS||associated-20/VBN	dobj||associated-20/VBN||ks-21/NN	aids-19||hiv-8||no||kaposi'ssarcoma (ks) in hiv negative patients is rare and has to be distinguished from aids associated ks.
nn||tb-3/NN||tuberculosis-1/NNP	nsubj||problem-18/NN||tb-3/NN	vmod||tb-3/NN||caused-6/VBN	agent||caused-6/VBN||mycobacteriumtuberculosis-8/NNS	appos||mycobacteriumtuberculosis-8/NNS||mtb-10/NN	cop||problem-18/NN||is-13/VBZ	det||problem-18/NN||an-14/DT	amod||problem-18/NN||enduring-15/VBG	amod||problem-18/NN||public-16/JJ	nn||problem-18/NN||health-17/NN	root||ROOT-0/null||problem-18/NN	advmod||problem-18/NN||globally-19/RB	advmod||problem-18/NN||particularly-21/RB	amod||africa-24/NN||sub-saharan-23/JJ	prep_in||problem-18/NN||africa-24/NN	tuberculosis-1||mycobacteriumtuberculosis-8||no||tuberculosis (tb), caused by mycobacteriumtuberculosis (mtb), is an enduring public health problem globally, particularly in sub-saharan africa.
vmod||limited-14/VBN||albeit-1/VBG	poss||benefits-4/NNS||its-2/PRP$	amod||benefits-4/NNS||great-3/JJ	dobj||albeit-1/VBG||benefits-4/NNS	prep_as||albeit-1/VBG||immunosuppressant-6/NN	det||use-9/NN||the-8/DT	nsubjpass||limited-14/VBN||use-9/NN	prep_of||use-9/NN||csa-11/NN	aux||limited-14/VBN||has-12/VBZ	auxpass||limited-14/VBN||been-13/VBN	root||ROOT-0/null||limited-14/VBN	amod||effects-18/NNS||undesirable-16/JJ	amod||effects-18/NNS||nephrotoxic-17/JJ	agent||limited-14/VBN||effects-18/NNS	nn||fibrosis-28/NN||sodiumretention-21/NN	dep||fibrosis-28/NN||hypertension-23/NN	dep||fibrosis-28/NN||hyperkalemia-25/NN	amod||fibrosis-28/NN||interstial-27/JJ	prep_including||limited-14/VBN||fibrosis-28/NN	amod||renalfailure-31/NN||progressive-30/JJ	prep_including||limited-14/VBN||renalfailure-31/NN	conj_and||fibrosis-28/NN||renalfailure-31/NN	nn||recipients-34/NNS||transplant-33/NN	prep_in||renalfailure-31/NN||recipients-34/NNS	hypertension-23||csa-11||no||albeit its great benefits as immunosuppressant, the use of csa has been limited by undesirable nephrotoxic effects, including sodiumretention, hypertension, hyperkalemia, interstial fibrosis and progressive renalfailure in transplant recipients.
det||results-2/NNS||the-1/DT	nsubj||inform-7/VB||results-2/NNS	nsubj||optimise-9/VB||results-2/NNS	det||study-5/NN||this-4/DT	prep_from||results-2/NNS||study-5/NN	aux||inform-7/VB||will-6/MD	root||ROOT-0/null||inform-7/VB	conj_and||inform-7/VB||optimise-9/VB	det||management-12/NN||the-10/DT	amod||management-12/NN||clinical-11/JJ	dobj||inform-7/VB||management-12/NN	prep_of||management-12/NN||people-14/NNS	amod||lungdisease-17/NN||interstitial-16/JJ	prep_with||inform-7/VB||lungdisease-17/NN	lungdisease-17||inform-7||no_rel||the results from this study will inform and optimise the clinical management of people with interstitial lungdisease.
det||proportions-2/NNS||the-1/DT	nsubj||%-8/NN||proportions-2/NNS	amod||resistance-5/NN||mono-drug-4/JJ	prep_of||proportions-2/NNS||resistance-5/NN	cop||%-8/NN||were-6/VBD	num||%-8/NN||28.73-7/CD	root||ROOT-0/null||%-8/NN	prep_for||%-8/NN||isoniazid-10/NN	num||%-13/NN||19.41-12/CD	conj_and||%-8/NN||%-13/NN	prep_for||%-13/NN||rifampicin-15/NN	num||%-18/NN||29.33-17/CD	conj_and||%-8/NN||%-18/NN	prep_for||%-18/NN||streptomycin-20/NN	num||%-24/NN||13.98-23/CD	conj_and||%-8/NN||%-24/NN	prep_for||%-24/NN||ethambutol-26/NN	advmod||%-8/NN||respectively-28/RB	mono--1||ethambutol-26||no_rel||the proportions of mono-drug resistance were 28.73% for isoniazid, 19.41% for rifampicin, 29.33% for streptomycin, and 13.98% for ethambutol, respectively.
det||trial-6/NN||a-2/DT	amod||trial-6/NN||randomized-3/JJ	amod||trial-6/NN||double-blind-5/JJ	prep_in||collected-10/VBN||trial-6/NN	nsubjpass||collected-10/VBN||faeces-8/NNS	nsubj||irritablebowelsyndrome-27/JJ||faeces-8/NNS	auxpass||collected-10/VBN||were-9/VBD	root||ROOT-0/null||collected-10/VBN	amod||volunteers-13/NNS||healthy-12/JJ	prep_from||collected-10/VBN||volunteers-13/NNS	prep_from||collected-10/VBN||patients-17/NNS	conj_and||volunteers-13/NNS||patients-17/NNS	amod||cd-20/NN||active-19/JJ	prep_with||patients-17/NNS||cd-20/NN	appos||cd-20/NN||ulcerativecolitis-22/NNS	appos||ulcerativecolitis-22/NNS||uc-24/NN	conj_and||collected-10/VBN||irritablebowelsyndrome-27/JJ	conj_and||collected-10/VBN||irritablebowelsyndrome-27/JJ	conj_and||irritablebowelsyndrome-27/JJ||irritablebowelsyndrome-27/JJ	prep_after||irritablebowelsyndrome-27/JJ||treatment-31/NN	prep_before||irritablebowelsyndrome-27/JJ||treatment-31/NN	cd-20||ulcerativecolitis-22||no_rel||in a randomized, double-blind trial, faeces were collected from healthy volunteers, and from patients with active cd, ulcerativecolitis (uc) and irritablebowelsyndrome before and after treatment.
det||efficacy-3/NN||the-1/DT	amod||efficacy-3/NN||uncertain-2/JJ	nsubj||motivated-20/VBN||efficacy-3/NN	prep_of||efficacy-3/NN||ondansetron-5/NN	amod||patients-9/NNS||pediatric-7/JJ	amod||patients-9/NNS||neurosurgical-8/JJ	prep_for||ondansetron-5/NN||patients-9/NNS	det||effect-14/NN||the-11/DT	amod||effect-14/NN||possible-12/JJ	amod||effect-14/NN||antiemetic-13/JJ	prep_of||efficacy-3/NN||effect-14/NN	conj_or||ondansetron-5/NN||effect-14/NN	amod||dose-17/NN||small-16/JJ	prep_of||effect-14/NN||dose-17/NN	prep_of||dose-17/NN||propofol-19/NN	root||ROOT-0/null||motivated-20/VBN	dobj||motivated-20/VBN||us-21/PRP	nsubj||evaluate-23/VB||us-21/PRP	aux||evaluate-23/VB||to-22/TO	xcomp||motivated-20/VBN||evaluate-23/VB	det||effect-26/NN||the-24/DT	amod||effect-26/NN||preventive-25/JJ	dobj||evaluate-23/VB||effect-26/NN	det||dose-30/NN||a-28/DT	amod||dose-30/NN||subhypnotic-29/JJ	prep_of||effect-26/NN||dose-30/NN	prep_of||dose-30/NN||propofol-32/NN	prep||evaluate-23/VB||combined-33/VBN	pcomp||combined-33/VBN||with-34/IN	pobj||with-34/IN||dexamethasone-35/NN	amod||vomiting-38/NN||postoperative-37/JJ	prep_on||motivated-20/VBN||vomiting-38/NN	appos||vomiting-38/NN||pov-40/NN	advmod||motivated-20/VBN||especially-43/RB	amod||periods-47/NNS||immediate-45/JJ	nn||periods-47/NNS||postoperative-46/NN	prep_during||especially-43/RB||periods-47/NNS	vomiting-38||dexamethasone-35||yes||the uncertain efficacy of ondansetron for pediatric neurosurgical patients or the possible antiemetic effect of small dose of propofol motivated us to evaluate the preventive effect of a subhypnotic dose of propofol combined with dexamethasone on postoperative vomiting (pov), especially during immediate postoperative periods.
det||study-2/NN||this-1/DT	nsubj||aimed-3/VBD||study-2/NN	nsubj||investigate-5/VB||study-2/NN	root||ROOT-0/null||aimed-3/VBD	aux||investigate-5/VB||to-4/TO	xcomp||aimed-3/VBD||investigate-5/VB	mark||had-11/VBD||whether-6/IN	amod||polymorphisms-10/NNS||cyp2b6-7/JJ	conj_or||cyp2b6-7/JJ||cyp3a4-9/JJ	amod||polymorphisms-10/NNS||cyp3a4-9/JJ	nsubj||had-11/VBD||polymorphisms-10/NNS	ccomp||investigate-5/VB||had-11/VBD	dobj||had-11/VBD||effects-12/NNS	nn||efavirenz-15/NN||plasma-14/NN	prep_on||effects-12/NNS||efavirenz-15/NN	nn||concentrations-18/NNS||nevirapine-17/NN	prep_on||effects-12/NNS||concentrations-18/NNS	conj_and||efavirenz-15/NN||concentrations-18/NNS	advmod||co-administered-20/VBN||when-19/WRB	advcl||aimed-3/VBD||co-administered-20/VBN	prep_with||co-administered-20/VBN||rifampicin-22/NN	amod||adults-27/NNS||hiv/tb-24/JJ	amod||adults-27/NNS||co-infected-25/JJ	nn||adults-27/NNS||thai-26/NN	prep_in||rifampicin-22/NN||adults-27/NNS	tb--1||rifampicin-22||yes||this study aimed to investigate whether cyp2b6 or cyp3a4 polymorphisms had effects on plasma efavirenz and nevirapine concentrations when co-administered with rifampicin in hiv/tb co-infected thai adults.
det||study-3/NN||the-2/DT	prep_in||claimed-5/VBD||study-3/NN	nsubj||claimed-5/VBD||we-4/PRP	root||ROOT-0/null||claimed-5/VBD	aux||identify-7/VB||to-6/TO	ccomp||claimed-5/VBD||identify-7/VB	nn||species-9/NNS||brucella-8/NN	dobj||identify-7/VB||species-9/NNS	amod||samples-12/NNS||clinical-11/JJ	prep_from||identify-7/VB||samples-12/NNS	prep_of||samples-12/NNS||patients-14/NNS	amod||brucellosis-17/NNS||active-16/JJ	prep_with||patients-14/NNS||brucellosis-17/NNS	nn||region-20/NN||van-19/NN	prep_from||identify-7/VB||region-20/NN	amod||anatolia-23/NN||eastern-22/JJ	prep_of||region-20/NN||anatolia-23/NN	aux||determine-26/VB||to-25/TO	ccomp||claimed-5/VBD||determine-26/VB	conj_and||identify-7/VB||determine-26/VB	npadvmod||antimicrobial-29/JJ||vitro-28/NN	amod||susceptibilities-30/NNS||antimicrobial-29/JJ	prep_in||determine-26/VB||susceptibilities-30/NNS	det||strains-33/NNS||these-32/DT	prep_of||susceptibilities-30/NNS||strains-33/NNS	advmod||used-36/VBN||commonly-35/RB	amod||agents-38/NNS||used-36/VBN	amod||agents-38/NNS||anti-brucella-37/JJ	prep_to||determine-26/VB||agents-38/NNS	det||tigecycline-44/NN||a-40/DT	amod||tigecycline-44/NN||possible-41/JJ	amod||tigecycline-44/NN||new-42/JJ	nn||tigecycline-44/NN||alternative-43/NN	prep_to||determine-26/VB||tigecycline-44/NN	conj_and||agents-38/NNS||tigecycline-44/NN	brucellosis-17||brucella-8||no||in the study we claimed to identify brucella species from clinical samples of patients with active brucellosis from van region of eastern anatolia and to determine in vitro antimicrobial susceptibilities of these strains to commonly used anti-brucella agents and a possible new alternative tigecycline.
nn||therapy-2/NN||statin-1/NN	nsubjpass||associated-8/VBN||therapy-2/NN	prep_in||therapy-2/NN||patients-4/NNS	prep_with||patients-4/NNS||cardiovasculardisease-6/NN	auxpass||associated-8/VBN||is-7/VBZ	root||ROOT-0/null||associated-8/VBN	amod||incidence-11/NN||reduced-10/VBN	prep_with||associated-8/VBN||incidence-11/NN	prep_of||incidence-11/NN||stroke-13/NN	cardiovasculardisease-6||statin-1||no_rel||statin therapy in patients with cardiovasculardisease is associated with reduced incidence of stroke.
nsubjpass||associated-5/VBN||ca-mrsainfections-1/NNS	aux||associated-5/VBN||have-2/VBP	advmod||associated-5/VBN||mostly-3/RB	auxpass||associated-5/VBN||been-4/VBN	root||ROOT-0/null||associated-5/VBN	amod||strains-8/NNS||staphylococcal-7/JJ	prep_with||associated-5/VBN||strains-8/NNS	vmod||strains-8/NNS||bearing-9/VBG	det||element-17/NN||the-10/DT	amod||element-17/NN||staphylococcal-11/JJ	nn||element-17/NN||cassette-12/NN	nn||element-17/NN||chromosome-13/NN	nn||element-17/NN||mec-14/NN	nn||element-17/NN||type-15/NN	nn||element-17/NN||iv-16/NN	dobj||bearing-9/VBG||element-17/NN	amod||genes-21/NNS||panton-valentine-19/JJ	nn||genes-21/NNS||leukocidin-20/NN	dobj||bearing-9/VBG||genes-21/NNS	conj_and||element-17/NN||genes-21/NNS	mrsa--1||ca--1||no_rel||ca-mrsainfections have mostly been associated with staphylococcal strains bearing the staphylococcal cassette chromosome mec type iv element and panton-valentine leukocidin genes.
aux||assess-2/VB||to-1/TO	advcl||infected-24/VBD||assess-2/VB	det||role-4/NN||the-3/DT	dobj||assess-2/VB||role-4/NN	prep_of||role-4/NN||horses-6/NNS	mark||epizootics-20/VBZ||as-7/IN	nn||hosts-9/NNS||amplification-8/NN	nsubj||epizootics-20/VBZ||hosts-9/NNS	det||1993-12/CD||the-11/DT	prep_during||hosts-9/NNS||1993-12/CD	num||venezuelanequineencephalitis-16/NNS||1996-14/CD	nn||venezuelanequineencephalitis-16/NNS||mexican-15/NN	prep_during||hosts-9/NNS||venezuelanequineencephalitis-16/NNS	conj_and||1993-12/CD||venezuelanequineencephalitis-16/NNS	appos||1993-12/CD||vee-18/NN	advcl||assess-2/VB||epizootics-20/VBZ	nsubj||infected-24/VBD||we-22/PRP	advmod||infected-24/VBD||subcutaneously-23/RB	root||ROOT-0/null||infected-24/VBD	num||horses-26/NNS||10-25/CD	dobj||infected-24/VBD||horses-26/NNS	prepc_by||infected-24/VBD||using-28/VBG	num||isolates-32/NNS||four-29/CD	amod||isolates-32/NNS||different-30/JJ	nn||isolates-32/NNS||equine-31/NN	dobj||using-28/VBG||isolates-32/NNS	venezuelanequineencephalitis-16||vee-18||no||to assess the role of horses as amplification hosts during the 1993 and 1996 mexican venezuelanequineencephalitis (vee) epizootics, we subcutaneously infected 10 horses by using four different equine isolates.
nsubj||tested-5/VBD||samples-1/NNS	amod||plants-4/NNS||symptomatic-3/JJ	prep_from||samples-1/NNS||plants-4/NNS	root||ROOT-0/null||tested-5/VBD	acomp||tested-5/VBD||negative-6/JJ	prep_for||negative-6/JJ||infection-8/NN	amod||virus-13/NN||tomato-10/JJ	amod||virus-13/NN||spotted-11/JJ	nn||virus-13/NN||wilt-12/NN	prep_by||tested-5/VBD||virus-13/NN	nn||virus-17/NN||tobacco-15/NN	nn||virus-17/NN||streak-16/NN	prep_by||tested-5/VBD||virus-17/NN	conj_and||virus-13/NN||virus-17/NN	nn||virus-21/NN||tobacco-19/NN	nn||virus-21/NN||etch-20/NN	prep_by||tested-5/VBD||virus-21/NN	conj_and||virus-13/NN||virus-21/NN	amod||viruses-26/NNS||other-23/JJ	amod||viruses-26/NNS||known-24/JJ	amod||viruses-26/NNS||tomato-infecting-25/JJ	prep_by||tested-5/VBD||viruses-26/NNS	conj_and||virus-13/NN||viruses-26/NNS	virus-21||viruses-26||no||samples from symptomatic plants tested negative for infection by tomato spotted wilt virus, tobacco streak virus, tobacco etch virus and other known tomato-infecting viruses.
poss||knowledge-3/NN||our-2/PRP$	prep_to||case-10/NN||knowledge-3/NN	nsubj||case-10/NN||this-5/DT	cop||case-10/NN||is-6/VBZ	det||case-10/NN||the-7/DT	amod||case-10/NN||first-8/JJ	amod||case-10/NN||reported-9/JJ	root||ROOT-0/null||case-10/NN	prep_of||case-10/NN||bp-12/NN	amod||angiography-16/NN||fundus-14/JJ	nn||angiography-16/NN||fluorescein-15/NN	prep_following||bp-12/NN||angiography-16/NN	det||patient-19/NN||a-18/DT	prep_in||angiography-16/NN||patient-19/NN	amod||albuminsolutionallergy-23/NN||known-21/JJ	amod||albuminsolutionallergy-23/NN||human-22/JJ	prep_with||patient-19/NN||albuminsolutionallergy-23/NN	fluorescein-15||albuminsolutionallergy-23||no_rel||to our knowledge, this is the first reported case of bp following fundus fluorescein angiography in a patient with known human albuminsolutionallergy.
amod||quotient-14/NN||white-1/JJ	nn||quotient-14/NN||blood-2/NN	nn||quotient-14/NN||cell-3/NN	nn||quotient-14/NN||count-4/NN	dep||quotient-14/NN||csf/serum-6/NN	nn||quotient-14/NN||glucose-7/NN	nn||quotient-14/NN||ratio-8/NN	dep||quotient-14/NN||protein-10/NN	dep||quotient-14/NN||csf/serum-12/NN	nn||quotient-14/NN||albumin-13/NN	nsubjpass||analyzed-25/VBN||quotient-14/NN	nn||indices-17/NNS||immunoglobulin-16/NN	conj_and||quotient-14/NN||indices-17/NNS	nsubjpass||analyzed-25/VBN||indices-17/NNS	prep_for||quotient-14/NN||igg-19/NN	prep_for||quotient-14/NN||iga-21/NN	conj_and||igg-19/NN||iga-21/NN	prep_for||quotient-14/NN||igm-23/NN	conj_and||igg-19/NN||igm-23/NN	auxpass||analyzed-25/VBN||were-24/VBD	root||ROOT-0/null||analyzed-25/VBN	num||patients-28/NNS||90-27/CD	prep_in||analyzed-25/VBN||patients-28/NNS	prep_with||patients-28/NNS||bacterialmeningitis-30/NNS	num||patients-33/NNS||117-32/CD	prep_in||analyzed-25/VBN||patients-33/NNS	conj_and||patients-28/NNS||patients-33/NNS	prep_with||patients-33/NNS||viralmeningoencephalitis-35/NNS	num||patients-38/NNS||36-37/CD	prep_in||analyzed-25/VBN||patients-38/NNS	conj_and||patients-28/NNS||patients-38/NNS	prep_with||patients-38/NNS||leptomeningealmetastases-40/NNS	det||total-43/NN||a-42/DT	prep_in||leptomeningealmetastases-40/NNS||total-43/NN	num||samples-47/NNS||480-45/CD	nn||samples-47/NNS||csf-46/NN	prep_of||total-43/NN||samples-47/NNS	bacterialmeningitis-30||albumin-13||no_rel||white blood cell count, csf/serum glucose ratio, protein, csf/serum albumin quotient and immunoglobulin indices for igg, iga and igm were analyzed in 90 patients with bacterialmeningitis, 117 patients with viralmeningoencephalitis and 36 patients with leptomeningealmetastases in a total of 480 csf samples.
nsubjpass||analyzed-16/VBN||oa-1/NN	conj_and||oa-1/NN||ptx-3/NN	nsubjpass||analyzed-16/VBN||ptx-3/NN	num||toxins-6/NNS||two-5/CD	appos||oa-1/NN||toxins-6/NNS	det||mode-11/NN||a-8/DT	advmod||established-10/VBN||better-9/RB	amod||mode-11/NN||established-10/VBN	prep_with||toxins-6/NNS||mode-11/NN	prep_of||mode-11/NN||action-13/NN	auxpass||analyzed-16/VBN||are-15/VBP	root||ROOT-0/null||analyzed-16/VBN	prep_with||analyzed-16/VBN||regard-18/NN	poss||effects-21/NNS||their-20/PRP$	prep_to||analyzed-16/VBN||effects-21/NNS	prep_on||analyzed-16/VBN||development-23/NN	oa-1||toxins-6||no_rel||oa and ptx, two toxins with a better established mode of action, are analyzed with regard to their effects on development.
dep||assess-4/VB||a-1/LS	aux||assess-4/VB||to-3/TO	root||ROOT-0/null||assess-4/VB	det||suitability-6/NN||the-5/DT	dobj||assess-4/VB||suitability-6/NN	det||content-10/NN||the-8/DT	nn||content-10/NN||curriculum-9/NN	prep_of||suitability-6/NN||content-10/NN	amod||quality-13/NN||didactical-12/JJ	nsubj||delivered-16/VBD||quality-13/NN	nsubj||educate-18/VB||quality-13/NN	prep_of||quality-13/NN||information-15/NN	conj_and||assess-4/VB||delivered-16/VBD	aux||educate-18/VB||to-17/TO	xcomp||delivered-16/VBD||educate-18/VB	dobj||educate-18/VB||journalists-19/NNS	det||program-23/NN||the-21/DT	amod||program-23/NN||j2j-22/JJ	prep_in||journalists-19/NNS||program-23/NN	prep_in||journalists-19/NNS||hiv/aids-25/NNS	nn||evaluation-28/NN||process-27/NN	appos||hiv/aids-25/NNS||evaluation-28/NN	prep_in||journalists-19/NNS||b-31/SYM	conj_and||hiv/aids-25/NNS||b-31/SYM	aux||explore-34/VB||to-33/TO	vmod||educate-18/VB||explore-34/VB	det||effects-36/NNS||the-35/DT	dobj||explore-34/VB||effects-36/NNS	amod||programs-39/NNS||such-38/JJ	prep_of||effects-36/NNS||programs-39/NNS	poss||reporting-43/NN||journalists-41/NNS	prep_on||explore-34/VB||reporting-43/NN	amod||related-46/JJ||hiv/aids-45/JJ	amod||information-47/NN||related-46/JJ	prep_of||reporting-43/NN||information-47/NN	nn||evaluation-50/NN||outcome-49/NN	appos||information-47/NN||evaluation-50/NN	aids--1||hiv--1||no||a) to assess the suitability of the curriculum content and didactical quality of information delivered to educate journalists in the j2j program in hiv/aids (process evaluation) and b) to explore the effects of such programs on journalists' reporting of hiv/aids related information (outcome evaluation).
dep||found-18/VBN||independent-1/JJ	det||severity-4/NN||the-3/DT	prep_from||independent-1/JJ||severity-4/NN	det||seasons-9/NNS||the-6/DT	num||seasons-9/NNS||four-7/CD	nn||seasons-9/NNS||epidemic-8/NN	prep_of||severity-4/NN||seasons-9/NNS	num||predictors-12/NNS||seven-11/CD	appos||seasons-9/NNS||predictors-12/NNS	prep_for||predictors-12/NNS||hospitalization-14/NN	prep_for||hospitalization-14/NN||rsvinfection-16/NN	auxpass||found-18/VBN||were-17/VBD	root||ROOT-0/null||found-18/VBN	det||number-23/NN||the-20/DT	amod||number-23/NN||bivariate-21/JJ	nn||number-23/NN||analysis-22/NN	prep_in||found-18/VBN||number-23/NN	prep_of||number-23/NN||children-25/NNS	det||family-28/NN||the-27/DT	prep_in||children-25/NNS||family-28/NN	amod||age-31/NN||chronological-30/JJ	appos||family-28/NN||age-31/NN	det||onset-34/NN||the-33/DT	prep_at||age-31/NN||onset-34/NN	nn||season-37/NN||rsv-36/NN	prep_of||onset-34/NN||season-37/NN	nn||weight-40/NN||birth-39/NN	prep_of||onset-34/NN||weight-40/NN	conj_and||season-37/NN||weight-40/NN	amod||age-43/NN||gestational-42/JJ	prep_of||onset-34/NN||age-43/NN	conj_and||season-37/NN||age-43/NN	nn||order-46/NN||birth-45/NN	nsubjpass||found-18/VBN||order-46/NN	nn||attendance-49/NN||daycare-48/NN	appos||order-46/NN||attendance-49/NN	amod||rsvinfections-52/NNS||previous-51/JJ	appos||attendance-49/NN||rsvinfections-52/NNS	rsvinfections-52||rsv-36||no||independent from the severity of the four epidemic seasons, seven predictors for hospitalization for rsvinfection were found in the bivariate analysis number of children in the family, chronological age at the onset of rsv season, birth weight and gestational age, birth order, daycare attendance, previous rsvinfections.
prep_in||associated-8/VBN||people-2/NNS	amod||mutations-6/NNS||abcb4-4/JJ	nn||mutations-6/NNS||gene-5/NN	nsubjpass||associated-8/VBN||mutations-6/NNS	auxpass||associated-8/VBN||are-7/VBP	root||ROOT-0/null||associated-8/VBN	amod||syndromes-12/NNS||several-10/JJ	nn||syndromes-12/NNS||disease-11/NN	prep_with||associated-8/VBN||syndromes-12/NNS	amod||cholestasis-15/NNS||intrahepatic-14/JJ	prep_including||syndromes-12/NNS||cholestasis-15/NNS	prep_of||cholestasis-15/NNS||pregnancy-17/NN	amod||cholestasis-22/NNS||progressive-19/JJ	amod||cholestasis-22/NNS||familial-20/JJ	amod||cholestasis-22/NNS||intrahepatic-21/JJ	prep_of||cholestasis-15/NNS||cholestasis-22/NNS	conj_and||pregnancy-17/NN||cholestasis-22/NNS	appos||pregnancy-17/NN||type-24/NN	num||type-24/NN||3-25/CD	prep_of||cholestasis-15/NNS||primarybiliarycirrhosis-28/NNS	conj_and||pregnancy-17/NN||primarybiliarycirrhosis-28/NNS	prep_of||cholestasis-15/NNS||cholelithiasis-31/NNS	conj_and||pregnancy-17/NN||cholelithiasis-31/NNS	primarybiliarycirrhosis-28||cholestasis-22||no||in people, abcb4 gene mutations are associated with several disease syndromes including intrahepatic cholestasis of pregnancy, progressive familial intrahepatic cholestasis (type 3), primarybiliarycirrhosis, and cholelithiasis.
amod||proline-2/NN||foliar-applied-1/JJ	nsubj||increased-4/VBD||proline-2/NN	advmod||increased-4/VBD||significantly-3/RB	root||ROOT-0/null||increased-4/VBD	det||content-6/NN||the-5/DT	dobj||increased-4/VBD||content-6/NN	nn||sugar-9/NN||seed-8/NN	prep_of||content-6/NN||sugar-9/NN	appos||sugar-9/NN||oil-11/NN	appos||sugar-9/NN||protein-13/NN	conj_and||oil-11/NN||protein-13/NN	appos||sugar-9/NN||moisture-15/NN	conj_and||oil-11/NN||moisture-15/NN	appos||sugar-9/NN||fiber-17/NN	conj_and||oil-11/NN||fiber-17/NN	appos||sugar-9/NN||ash-19/NN	conj_and||oil-11/NN||ash-19/NN	det||cultivars-23/NNS||both-21/DT	amod||cultivars-23/NNS||maize-22/JJ	prep_in||oil-11/NN||cultivars-23/NNS	advmod||irrigated-26/JJ||well-25/RB	amod||conditions-30/NNS||irrigated-26/JJ	nn||deficit-29/NN||water-28/NN	conj_and||irrigated-26/JJ||deficit-29/NN	amod||conditions-30/NNS||deficit-29/NN	prep_under||increased-4/VBD||conditions-30/NNS	sugar-9||deficit-29||no_rel||foliar-applied proline significantly increased the content of seed sugar, oil, protein, moisture, fiber and ash in both maize cultivars under well irrigated and water deficit conditions.
amod||lines-2/NNS||several-1/JJ	nsubj||support-5/VBP||lines-2/NNS	prep_of||lines-2/NNS||evidence-4/NN	root||ROOT-0/null||support-5/VBP	det||notion-7/NN||the-6/DT	dobj||support-5/VBP||notion-7/NN	mark||predispose-13/VB||that-8/IN	amod||viscosity-11/NN||elevated-9/JJ	nn||viscosity-11/NN||blood-10/NN	nsubj||predispose-13/VB||viscosity-11/NN	aux||predispose-13/VB||may-12/MD	ccomp||support-5/VBP||predispose-13/VB	prep_to||predispose-13/VB||insulinresistance-15/NN	prep_to||predispose-13/VB||type2diabetesmellitus-17/NNS	conj_and||insulinresistance-15/NN||type2diabetesmellitus-17/NNS	prepc_by||predispose-13/VB||limiting-19/VBG	dobj||limiting-19/VBG||delivery-20/NN	prep_of||delivery-20/NN||glucose-22/NN	prep_of||delivery-20/NN||insulin-24/NN	conj_and||glucose-22/NN||insulin-24/NN	prep_of||delivery-20/NN||oxygen-27/NN	conj_and||glucose-22/NN||oxygen-27/NN	advmod||active-30/JJ||metabolically-29/RB	amod||tissues-31/NNS||active-30/JJ	prep_to||glucose-22/NN||tissues-31/NNS	oxygen-27||insulinresistance-15||no_rel||several lines of evidence support the notion that elevated blood viscosity may predispose to insulinresistance and type2diabetesmellitus by limiting delivery of glucose, insulin, and oxygen to metabolically active tissues.
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	amod||parameters-4/NNS||anthropometric-3/JJ	dobj||evaluated-2/VBN||parameters-4/NNS	nn||index-12/NN||height-6/NN	dep||index-12/NN||weight-8/NN	dep||index-12/NN||body-10/NN	nn||index-12/NN||mass-11/NN	dep||parameters-4/NNS||index-12/NN	appos||index-12/NN||bmi-14/NN	appos||index-12/NN||waist-17/NN	nn||circumference-20/NN||hip-19/NN	appos||index-12/NN||circumference-20/NN	conj_and||waist-17/NN||circumference-20/NN	appos||index-12/NN||waist-22/NN	nn||ratio-25/NN||height-24/NN	prep_to||waist-22/NN||ratio-25/NN	dobj||evaluated-2/VBN||additionally-29/RB	advmod||parameters-4/NNS||additionally-29/RB	conj_and||parameters-4/NNS||additionally-29/RB	amod||biomarkers-33/NNS||cardiovascular-31/JJ	nn||biomarkers-33/NNS||risk-32/NN	dobj||evaluated-2/VBN||biomarkers-33/NNS	conj_and||parameters-4/NNS||biomarkers-33/NNS	amod||glucose-37/NN||fasting-35/JJ	nn||glucose-37/NN||plasma-36/NN	dep||biomarkers-33/NNS||glucose-37/NN	dep||biomarkers-33/NNS||hba1c-39/NNS	conj_and||glucose-37/NN||hba1c-39/NNS	dep||biomarkers-33/NNS||triglycerides-41/NNPS	conj_and||glucose-37/NN||triglycerides-41/NNPS	amod||cholesterol-44/NN||total-43/JJ	dep||biomarkers-33/NNS||cholesterol-44/NN	conj_and||glucose-37/NN||cholesterol-44/NN	dep||biomarkers-33/NNS||hdl-46/NN	conj_and||glucose-37/NN||hdl-46/NN	dep||biomarkers-33/NNS||ldl-48/NN	conj_and||glucose-37/NN||ldl-48/NN	dep||biomarkers-33/NNS||lipoprotein-51/NN	conj_and||glucose-37/NN||lipoprotein-51/NN	dep||lipoprotein-51/NN||a-53/SYM	num||patients-59/NNS||81-57/CD	amod||patients-59/NNS||acromegalic-58/JJ	prep_in||evaluated-2/VBN||patients-59/NNS	num||%-62/NN||58-61/CD	dep||patients-59/NNS||%-62/NN	vmod||%-62/NN||cured-63/VBN	prepc_compared_to||evaluated-2/VBN||to-66/TO	num||age-68/NN||320-67/CD	pobj||evaluated-2/VBN||age-68/NN	amod||controls-72/NNS||gender-matched-71/JJ	pobj||evaluated-2/VBN||controls-72/NNS	conj_and||age-68/NN||controls-72/NNS	appos||age-68/NN||ratio-74/NN	num||ratio-74/NN||14-75/CD	dep||evaluated-2/VBN||sampled-78/VBN	det||cohort-84/NN||the-80/DT	amod||cohort-84/NN||primary-81/JJ	nn||cohort-84/NN||care-82/NN	nn||cohort-84/NN||patient-83/NN	prep_from||sampled-78/VBN||cohort-84/NN	ccomp||evaluated-2/VBN||detect-85/VB	cholesterol-44||acromegalic-58||no_rel||we evaluated anthropometric parameters (height, weight, body mass index (bmi), waist and hip circumference, waist to height ratio) and, additionally, cardiovascular risk biomarkers (fasting plasma glucose, hba1c, triglycerides, total cholesterol, hdl, ldl, and lipoprotein (a), in 81 acromegalic patients (58% cured) compared to 320 age- and gender-matched controls (ratio 14), sampled from the primary care patient cohort detect.
amod||adherence-2/NN||sub-optimal-1/JJ	nsubj||places-5/VBZ||adherence-2/NN	prep_to||adherence-2/NN||warfarin-4/NN	root||ROOT-0/null||places-5/VBZ	dobj||places-5/VBZ||millions-6/NNS	prep_of||millions-6/NNS||patients-8/NNS	prep_at||patients-8/NNS||risk-10/NN	nn||complications-15/NNS||stroke-12/NN	conj_and||stroke-12/NN||bleeding-14/NN	nn||complications-15/NNS||bleeding-14/NN	prep_for||risk-10/NN||complications-15/NNS	det||year-17/NN||each-16/DT	tmod||places-5/VBZ||year-17/NN	stroke-12||warfarin-4||yes||sub-optimal adherence to warfarin places millions of patients at risk for stroke and bleeding complications each year.
amod||level-2/NN||pd-1-1/JJ	nsubj||correlated-10/JJ||level-2/NN	amod||tem/temra-7/NN||peripheral-4/JJ	amod||tem/temra-7/NN||cd8-5/JJ	amod||tem/temra-7/NN||+-6/JJ	prep_on||level-2/NN||tem/temra-7/NN	cop||correlated-10/JJ||was-8/VBD	advmod||correlated-10/JJ||highly-9/RB	root||ROOT-0/null||correlated-10/JJ	nn||load-14/NN||hcv-12/NN	amod||load-14/NN||viral-13/JJ	prep_with||correlated-10/JJ||load-14/NN	amod||patients-18/NNS||chronic-16/JJ	amod||patients-18/NNS||hcv-infected-17/JJ	prep_in||load-14/NN||patients-18/NNS	nsubj||made-21/VBD||patients-18/NNS	rcmod||patients-18/NNS||made-21/VBD	amod||indicator-25/NN||pd-1-22/JJ	det||indicator-25/NN||a-23/DT	nn||indicator-25/NN||novel-24/NN	dobj||made-21/VBD||indicator-25/NN	aux||evaluate-27/VB||to-26/TO	vmod||made-21/VBD||evaluate-27/VB	nn||replication-29/NN||hcv-28/NN	dobj||evaluate-27/VB||replication-29/NN	nn||progression-32/NN||disease-31/NN	dobj||evaluate-27/VB||progression-32/NN	conj_and||replication-29/NN||progression-32/NN	amod||patients-35/NNS||chronichepatitisc-34/JJ	prep_in||replication-29/NN||patients-35/NNS	chronichepatitisc-34||hcv-28||no||pd-1 level on peripheral cd8+ tem/temra was highly correlated with hcv viral load in chronic hcv-infected patients, which made pd-1 a novel indicator to evaluate hcv replication and disease progression in chronichepatitisc patients.
nsubj||summarize-2/VBD||we-1/PRP	root||ROOT-0/null||summarize-2/VBD	poss||experience-4/NN||our-3/PRP$	dobj||summarize-2/VBD||experience-4/NN	det||diagnosis-8/NN||the-6/DT	amod||diagnosis-8/NN||pathological-7/JJ	prep_in||summarize-2/VBD||diagnosis-8/NN	amod||complications-11/NNS||late-10/JJ	prep_of||diagnosis-8/NN||complications-11/NNS	nn||transplantation-14/NN||liver-13/NN	prep_of||complications-11/NNS||transplantation-14/NN	appos||transplantation-14/NN||lt-16/NN	aux||understand-20/VB||to-18/TO	advmod||understand-20/VB||better-19/RBR	vmod||summarize-2/VBD||understand-20/VB	det||causes-22/NNS||the-21/DT	dobj||understand-20/VB||causes-22/NNS	amod||dysfunction-26/NN||late-24/JJ	nn||dysfunction-26/NN||allograft-25/NN	prep_of||causes-22/NNS||dysfunction-26/NN	det||population-29/NN||a-28/DT	prep_in||dysfunction-26/NN||population-29/NN	advmod||composed-31/VBN||mostly-30/RB	vmod||population-29/NN||composed-31/VBN	prep_of||composed-31/VBN||patients-33/NNS	nn||infection-39/NN||hepatitisbvirus-35/NNP	appos||infection-39/NN||hbv-37/NN	prep_with||patients-33/NNS||infection-39/NN	hbv-37||hepatitisbvirus-35||no||we summarize our experience in the pathological diagnosis of late complications of liver transplantation (lt) to better understand the causes of late allograft dysfunction in a population mostly composed of patients with hepatitisbvirus (hbv) infection.
nsubjpass||designed-3/VBN||it-1/PRP	nsubj||minimize-5/VB||it-1/PRP	auxpass||designed-3/VBN||is-2/VBZ	root||ROOT-0/null||designed-3/VBN	aux||minimize-5/VB||to-4/TO	xcomp||designed-3/VBN||minimize-5/VB	amod||peaks-8/NNS||high-6/JJ	nn||peaks-8/NNS||glucose-7/NN	dobj||minimize-5/VB||peaks-8/NNS	prepc_while||minimize-5/VB||preventing-10/VBG	dobj||preventing-10/VBG||hypoglycemia-11/NN	hypoglycemia-11||glucose-7||yes||it is designed to minimize high glucose peaks while preventing hypoglycemia.
nn||immunization-5/NN||infection-1/NN	amod||immunization-5/NN||and/or-2/JJ	amod||immunization-5/NN||recombinant-3/JJ	nn||immunization-5/NN||ha-4/NN	nsubj||resulted-13/VBD||immunization-5/NN	nn||pigs-8/NNS||guinea-7/NN	prep_of||immunization-5/NN||pigs-8/NNS	amod||influenzavirus-12/NNS||h3n2-10/JJ	nn||influenzavirus-12/NNS||wyoming-11/NN	prep_with||pigs-8/NNS||influenzavirus-12/NNS	root||ROOT-0/null||resulted-13/VBD	det||production-18/NN||a-15/DT	advmod||rapid-17/JJ||relatively-16/RB	amod||production-18/NN||rapid-17/JJ	nsubj||demonstrating-23/VBG||production-18/NN	amod||antibody-21/NN||viral-specific-20/JJ	prep_of||production-18/NN||antibody-21/NN	advmod||demonstrating-23/VBG||thus-22/RB	prepc_in||resulted-13/VBD||demonstrating-23/VBG	det||immunogenicity-26/NN||the-24/DT	amod||immunogenicity-26/NN||strong-25/JJ	dobj||demonstrating-23/VBG||immunogenicity-26/NN	det||proteins-32/NNS||the-28/DT	amod||proteins-32/NNS||major-29/JJ	amod||proteins-32/NNS||viral-30/JJ	amod||proteins-32/NNS||structural-31/JJ	prep_of||immunogenicity-26/NN||proteins-32/NNS	det||model-36/NN||this-34/DT	nn||model-36/NN||animal-35/NN	prep_in||proteins-32/NNS||model-36/NN	nn||infection-39/NN||influenza-38/NN	prep_for||model-36/NN||infection-39/NN	influenza-38||influenzavirus-12||no||infection and/or recombinant ha immunization of guinea pigs with h3n2 wyoming influenzavirus resulted in a relatively rapid production of viral-specific antibody thus demonstrating the strong immunogenicity of the major viral structural proteins in this animal model for influenza infection.
nn||bovis-2/NNS||m.-1/NN	nsubj||bacille-3/VBP||bovis-2/NNS	root||ROOT-0/null||bacille-3/VBP	nn||-rrb--9/NNP||calmette-guã-4/NNP	nn||-rrb--9/NNP||©-5/NNP	nn||-rrb--9/NNP||rin-6/NNP	nn||-rrb--9/NNP||-lrb--7/NNP	nn||-rrb--9/NNP||bcg-8/NNP	nsubj||fails-22/VBZ||-rrb--9/NNP	nsubj||protect-25/VB||-rrb--9/NNP	advmod||vaccine-15/NN||currently-11/RB	det||vaccine-15/NN||the-12/DT	advmod||available-14/JJ||only-13/RB	amod||vaccine-15/NN||available-14/JJ	appos||-rrb--9/NNP||vaccine-15/NN	nn||-rrb--20/NNP||tuberculosis-17/NNP	nn||-rrb--20/NNP||-lrb--18/NNP	nn||-rrb--20/NNP||tb-19/NNP	prep_against||vaccine-15/NN||-rrb--20/NNP	ccomp||bacille-3/VBP||fails-22/VBZ	aux||protect-25/VB||to-23/TO	advmod||protect-25/VB||adequately-24/RB	xcomp||fails-22/VBZ||protect-25/VB	dobj||protect-25/VB||individuals-26/NNS	amod||infection-32/NN||active-28/JJ	conj_and||active-28/JJ||latent-30/JJ	amod||infection-32/NN||latent-30/JJ	nn||infection-32/NN||tb-31/NN	prep_from||protect-25/VB||infection-32/NN	tuberculosis-17||bcg-8||no||m. bovis bacille calmette-guã © rin -lrb- bcg -rrb- , currently the only available vaccine against tuberculosis -lrb- tb -rrb- , fails to adequately protect individuals from active and latent tb infection .
nsubjpass||studied-4/VBN||liraglutide-1/NN	nsubjpass||studied-4/VBN||liraglutide-1/NN	aux||studied-4/VBN||has-2/VBZ	auxpass||studied-4/VBN||been-3/VBN	root||ROOT-0/null||studied-4/VBN	conj_and||studied-4/VBN||studied-4/VBN	prep_as||studied-4/VBN||monotherapy-6/NN	prep_in||studied-4/VBN||combination-9/NN	prep_with||studied-4/VBN||metformin-11/NN	prep_with||studied-4/VBN||glimepiride-13/NN	conj_and||metformin-11/NN||glimepiride-13/NN	prep_with||studied-4/VBN||rosiglitazone-16/NN	conj_and||metformin-11/NN||rosiglitazone-16/NN	det||treatment-19/NN||the-18/DT	prep_for||metformin-11/NN||treatment-19/NN	prep_of||treatment-19/NN||type2diabetes-21/CD	type2diabetes-21||glimepiride-13||yes||liraglutide has been studied as monotherapy and in combination with metformin, glimepiride, and rosiglitazone for the treatment of type2diabetes.
nsubj||propose-2/VBP||we-1/PRP	root||ROOT-0/null||propose-2/VBP	mark||evolved-8/VBN||that-3/IN	det||viruses-6/NNS||the-4/DT	amod||viruses-6/NNS||ncldv-5/JJ	nsubj||evolved-8/VBN||viruses-6/NNS	aux||evolved-8/VBN||have-7/VBP	ccomp||propose-2/VBP||evolved-8/VBN	amod||growth-11/NN||significant-10/JJ	prep_by||evolved-8/VBN||growth-11/NN	det||virus-16/NN||a-13/DT	amod||virus-16/NN||simple-14/JJ	nn||virus-16/NN||dna-15/NN	prep_of||growth-11/NN||virus-16/NN	nn||acquisition-19/NN||gene-18/NN	prep_by||evolved-8/VBN||acquisition-19/NN	amod||sources-22/NNS||cellular-21/JJ	prep_from||evolved-8/VBN||sources-22/NNS	virus-16||viruses-6||no||we propose that the ncldv viruses have evolved by significant growth of a simple dna virus by gene acquisition from cellular sources.
nsubj||derivative-6/NN||minocycline-1/NN	cop||derivative-6/NN||is-2/VBZ	det||derivative-6/NN||a-3/DT	amod||derivative-6/NN||semi-synthetic-4/JJ	nn||derivative-6/NN||tetracycline-5/NN	root||ROOT-0/null||derivative-6/NN	advmod||used-8/VBN||commonly-7/RB	vmod||derivative-6/NN||used-8/VBN	det||treatment-11/NN||the-10/DT	prep_in||used-8/VBN||treatment-11/NN	prep_of||treatment-11/NN||acne-13/NN	acne-13||tetracycline-5||yes||minocycline is a semi-synthetic tetracycline derivative commonly used in the treatment of acne.
nsubjpass||performed-3/VBN||cmr-1/NN	auxpass||performed-3/VBN||was-2/VBD	root||ROOT-0/null||performed-3/VBN	num||patients-6/NNS||66-5/CD	prep_in||performed-3/VBN||patients-6/NNS	prep_with||patients-6/NNS||chf-8/NN	amod||cardiomyopathy-12/NN||ischemic-11/JJ	prep_due_to||performed-3/VBN||cardiomyopathy-12/NN	appos||cardiomyopathy-12/NN||icm-14/NN	prep_due_to||performed-3/VBN||dilatedcardiomyopathy-18/NN	conj_or||cardiomyopathy-12/NN||dilatedcardiomyopathy-18/NN	appos||dilatedcardiomyopathy-18/NN||dcm-20/NN	number||healthy-24/JJ||32-23/CD	amod||controls-25/NNS||healthy-24/JJ	prep_due_to||performed-3/VBN||controls-25/NNS	conj_and||cardiomyopathy-12/NN||controls-25/NNS	dcm-20||dilatedcardiomyopathy-18||no_rel||cmr was performed in 66 patients with chf due to ischemic cardiomyopathy (icm), or dilatedcardiomyopathy (dcm) and 32 healthy controls.
det||substitution-3/NN||a-1/DT	amod||substitution-3/NN||partial-2/JJ	nsubj||offers-11/VBZ||substitution-3/NN	nn||vaccines-6/NNS||injection-5/NN	prep_of||substitution-3/NN||vaccines-6/NNS	amod||formulations-9/NNS||oral-8/JJ	prep_with||vaccines-6/NNS||formulations-9/NNS	advmod||offers-11/VBZ||still-10/RB	root||ROOT-0/null||offers-11/VBZ	amod||prospects-13/NNS||good-12/JJ	dobj||offers-11/VBZ||prospects-13/NNS	advmod||viable-16/JJ||economically-15/RB	amod||vaccines-21/NNS||viable-16/JJ	amod||anti-hbv-19/JJ||efficacious-18/JJ	conj_and||viable-16/JJ||anti-hbv-19/JJ	amod||vaccines-21/NNS||anti-hbv-19/JJ	amod||vaccines-21/NNS||plant-based-20/JJ	prep_for||prospects-13/NNS||vaccines-21/NNS	hbv--1||vaccines-21||no_rel||a partial substitution of injection vaccines with oral formulations still offers good prospects for economically viable and efficacious anti-hbv plant-based vaccines.
nsubj||assessed-2/VBD||we-1/PRP	root||ROOT-0/null||assessed-2/VBD	nsubj||enrolled-7/VBD||nvp-resistance-3/NN	nn||infants-6/NNS||indian-5/NN	prep_in||nvp-resistance-3/NN||infants-6/NNS	dep||assessed-2/VBD||enrolled-7/VBD	det||transmission-34/NN||the-9/DT	amod||transmission-34/NN||â-10/JJ	amod||transmission-34/NN||$-11/$	dep||$-11/$||six-week-12/JJ	nn||transmission-34/NN||extended-dose-13/NN	dep||$-15/$||nevirapineâ-14/RB	dep||transmission-34/NN||$-15/$	amod||trial-19/NN||swen-17/JJ	npadvmod||of-31/RB||trial-19/NN	npadvmod||nvp-23/JJ||who-20/WP	npadvmod||single-dose-22/JJ||received-21/JJ	amod||who-20/WP||single-dose-22/JJ	advmod||trial-19/NN||nvp-23/JJ	dep||nvp-23/JJ||sd-nvp-25/NN	advmod||trial-19/NN||swen-28/JJ	conj_or||nvp-23/JJ||swen-28/JJ	prep_for||nvp-23/JJ||prevention-30/NN	dep||breast-milk-32/CD||of-31/RB	num||$-15/$||breast-milk-32/CD	amod||transmission-34/NN||hiv-33/JJ	prep_in||enrolled-7/VBD||transmission-34/NN	nsubj||acquired-38/VBD||who-36/WP	advmod||acquired-38/VBD||also-37/RB	dep||assessed-2/VBD||acquired-38/VBD	conj_but||enrolled-7/VBD||acquired-38/VBD	amod||hivinfection-41/NN||subtype-39/JJ	nn||hivinfection-41/NN||c-40/NN	dobj||acquired-38/VBD||hivinfection-41/NN	det||year-45/NN||the-43/DT	amod||year-45/NN||first-44/JJ	prep_during||acquired-38/VBD||year-45/NN	prep_of||year-45/NN||life-47/NN	hivinfection-41||nevirapine--1||yes||we assessed nvp-resistance in indian infants enrolled in the âsix-week extended-dose nevirapineâ? (swen) trial who received single-dose nvp (sd-nvp) or swen for prevention of breast-milk hiv transmission but who also acquired subtype c hivinfection during the first year of life.
root||ROOT-0/null||delayed-1/VBN	nn||results-4/NNS||insulin-2/NN	nn||results-4/NNS||secretion-3/NN	dobj||delayed-1/VBN||results-4/NNS	amod||concentrations-9/NNS||higher-6/JJR	nn||concentrations-9/NNS||peak-7/NN	nn||concentrations-9/NNS||glucose-8/NN	prep_in||results-4/NNS||concentrations-9/NNS	advmod||delayed-1/VBN||particularly-10/RB	advmod||impaired-16/JJ||when-11/WRB	nsubj||impaired-16/JJ||suppression-12/NN	prep_of||suppression-12/NN||glucagon-14/NN	cop||impaired-16/JJ||is-15/VBZ	advcl||delayed-1/VBN||impaired-16/JJ	mark||insulinresistance-19/JJ||whereas-18/IN	advcl||impaired-16/JJ||insulinresistance-19/JJ	dep||delayed-1/VBN||prolongs-20/VBZ	det||duration-22/NN||the-21/DT	nsubj||delayed-1/VBN||duration-22/NN	nsubjpass||marked-29/VBN||duration-22/NN	prep_of||duration-22/NN||hyperglycemia-24/NN	aux||marked-29/VBN||can-27/MD	auxpass||marked-29/VBN||be-28/VB	rcmod||duration-22/NN||marked-29/VBN	advmod||present-37/JJ||when-30/WRB	det||insulinresistance-35/NN||both-31/DT	amod||insulinresistance-35/NN||hepatic-32/JJ	conj_and||hepatic-32/JJ||extra-hepatic-34/JJ	amod||insulinresistance-35/NN||extra-hepatic-34/JJ	nsubj||present-37/JJ||insulinresistance-35/NN	cop||present-37/JJ||are-36/VBP	advcl||marked-29/VBN||present-37/JJ	glucagon-14||insulinresistance-35||no_rel||delayed insulin secretion results in higher peak glucose concentrations particularly when suppression of glucagon is impaired, whereas insulinresistance prolongs the duration of hyperglycemia, which can be marked when both hepatic and extra-hepatic insulinresistance are present.
amod||stimulation-2/NN||insulin-induced-1/JJ	nsubjpass||reduced-12/VBN||stimulation-2/NN	amod||uptake-6/NN||hepatic-4/JJ	nn||uptake-6/NN||glucose-5/NN	prep_of||stimulation-2/NN||uptake-6/NN	amod||synthesis-10/NN||hepatic-8/JJ	nn||synthesis-10/NN||glycogen-9/NN	prep_of||stimulation-2/NN||synthesis-10/NN	conj_and||uptake-6/NN||synthesis-10/NN	auxpass||reduced-12/VBN||are-11/VBP	root||ROOT-0/null||reduced-12/VBN	prep_in||reduced-12/VBN||people-14/NNS	amod||presumably-25/NNS||type2diabetes-16/JJ	advmod||presumably-25/NNS||primarily-17/RB	amod||uptake-21/NN||decreased-20/VBN	prep_due_to||presumably-25/NNS||uptake-21/NN	prep_of||uptake-21/NN||extracellular-23/NN	nn||presumably-25/NNS||glucose-24/NN	prep_with||reduced-12/VBN||presumably-25/NNS	amod||activation-29/NN||inadequate-28/JJ	prep_because_of||presumably-25/NNS||activation-29/NN	amod||glucokinase-32/NN||hepatic-31/JJ	prep_of||activation-29/NN||glucokinase-32/NN	type2diabetes-16||glucose-24||no_rel||insulin-induced stimulation of hepatic glucose uptake and hepatic glycogen synthesis are reduced in people with type2diabetes primarily due to decreased uptake of extracellular glucose presumably because of inadequate activation of hepatic glucokinase.
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||determine-8/VB||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||determine-8/VB||to-7/TO	xcomp||was-6/VBD||determine-8/VB	det||dose-11/NN||the-9/DT	amod||dose-11/NN||optimal-10/JJ	dobj||determine-8/VB||dose-11/NN	prep_of||dose-11/NN||remifentanil-13/NN	prepc_for||determine-8/VB||minimizing-15/VBG	amod||changes-17/NNS||hemodynamic-16/JJ	dobj||minimizing-15/VBG||changes-17/NNS	prep_during||minimizing-15/VBG||intubation-19/NN	prepc_for||determine-8/VB||reducing-21/VBG	conj_and||minimizing-15/VBG||reducing-21/VBG	amod||pain-23/NN||propofol-induced-22/JJ	dobj||reducing-21/VBG||pain-23/NN	amod||patients-26/NNS||elderly-25/JJ	prep_in||reducing-21/VBG||patients-26/NNS	pain-23||propofol--1||yes||the purpose of this study was to determine the optimal dose of remifentanil for minimizing hemodynamic changes during intubation and reducing propofol-induced pain in elderly patients.
nsubj||interesting-4/JJ||it-1/PRP	nsubj||investigate-6/VB||it-1/PRP	aux||interesting-4/JJ||will-2/MD	cop||interesting-4/JJ||be-3/VB	root||ROOT-0/null||interesting-4/JJ	aux||investigate-6/VB||to-5/TO	xcomp||interesting-4/JJ||investigate-6/VB	mark||has-22/VBZ||whether-7/IN	nsubjpass||used-15/VBN||mefloquine-8/NN	nsubj||has-22/VBZ||mefloquine-8/NN	auxpass||used-15/VBN||is-11/VBZ	advmod||used-15/VBN||widely-12/RB	conj_and||widely-12/RB||effectively-14/RB	advmod||used-15/VBN||effectively-14/RB	rcmod||mefloquine-8/NN||used-15/VBN	det||treatment-18/NN||the-17/DT	prep_for||used-15/VBN||treatment-18/NN	prep_of||treatment-18/NN||malaria-20/NN	ccomp||investigate-6/VB||has-22/VBZ	det||impact-24/NN||an-23/DT	dobj||has-22/VBZ||impact-24/NN	prep_on||impact-24/NN||schistosomiasis-26/NNS	prep_in||schistosomiasis-26/NNS||areas-28/NNS	advmod||co-exist-34/VB||where-29/WRB	det||malaria-31/NN||both-30/DT	nsubj||co-exist-34/VB||malaria-31/NN	conj_and||malaria-31/NN||schistosomiasis-33/NNS	nsubj||co-exist-34/VB||schistosomiasis-33/NNS	advcl||interesting-4/JJ||co-exist-34/VB	malaria-31||mefloquine-8||yes||it will be interesting to investigate whether mefloquine, which is widely and effectively used for the treatment of malaria, has an impact on schistosomiasis in areas where both malaria and schistosomiasis co-exist.
amod||artesunate-2/NN||monthly-1/JJ	nsubj||reduced-5/VBD||artesunate-2/NN	prep||artesunate-2/NN||plus-3/CC	pobj||plus-3/CC||amodiaquine-4/NN	root||ROOT-0/null||reduced-5/VBD	det||incidence-7/NN||the-6/DT	dobj||reduced-5/VBD||incidence-7/NN	prep_of||incidence-7/NN||malaria-9/NN	num||%-12/NN||69-11/CD	prep_by||reduced-5/VBD||%-12/NN	number||%-15/NN||95-14/CD	amod||ci-16/NN||%-15/NN	dep||%-12/NN||ci-16/NN	number||%-18/NN||63-17/CD	amod||ci-16/NN||%-18/NN	num||%-21/NN||74-20/CD	appos||ci-16/NN||%-21/NN	prep_by||reduced-5/VBD||anaemia-24/NN	conj_and||%-12/NN||anaemia-24/NN	num||%-27/NN||45-26/CD	prep_by||reduced-5/VBD||%-27/NN	number||%-30/NN||95-29/CD	amod||ci-31/NN||%-30/NN	dep||%-27/NN||ci-31/NN	number||%-33/NN||25-32/CD	amod||ci-31/NN||%-33/NN	num||%-35/NN||,60-34/CD	dep||ci-31/NN||%-35/NN	amod||sulphadoxine-pyrimethamine-39/NN||bimonthly-38/JJ	nsubj||reduced-40/VBD||sulphadoxine-pyrimethamine-39/NN	conj_and||reduced-5/VBD||reduced-40/VBD	det||incidence-42/NN||the-41/DT	dobj||reduced-40/VBD||incidence-42/NN	prep_of||incidence-42/NN||malaria-44/NN	num||%-47/NN||24-46/CD	prep_by||reduced-40/VBD||%-47/NN	number||%-50/NN||95-49/CD	amod||ci-51/NN||%-50/NN	dep||%-47/NN||ci-51/NN	number||%-53/NN||14-52/CD	amod||ci-51/NN||%-53/NN	num||%-55/NN||,33-54/CD	dep||ci-51/NN||%-55/NN	prep_by||reduced-40/VBD||anaemia-58/NN	conj_and||%-47/NN||anaemia-58/NN	num||%-61/NN||30-60/CD	prep_by||reduced-40/VBD||%-61/NN	number||%-64/NN||95-63/CD	amod||ci-65/NN||%-64/NN	dep||%-61/NN||ci-65/NN	number||%-67/NN||6-66/CD	amod||ci-65/NN||%-67/NN	num||%-70/NN||49-69/CD	appos||ci-65/NN||%-70/NN	amod||artesunate-74/NN||bimonthly-73/JJ	nsubj||reduced-77/VBD||artesunate-74/NN	prep||artesunate-74/NN||plus-75/CC	pobj||plus-75/CC||amodiaquine-76/NN	conj_and||reduced-5/VBD||reduced-77/VBD	det||incidence-79/NN||the-78/DT	dobj||reduced-77/VBD||incidence-79/NN	prep_of||incidence-79/NN||malaria-81/NN	num||%-84/NN||17-83/CD	prep_by||reduced-77/VBD||%-84/NN	number||%-87/NN||95-86/CD	amod||ci-88/NN||%-87/NN	dep||%-84/NN||ci-88/NN	number||%-90/NN||6-89/CD	amod||ci-88/NN||%-90/NN	num||%-93/NN||27-92/CD	appos||ci-88/NN||%-93/NN	prep_by||reduced-77/VBD||anaemia-96/NN	conj_and||%-84/NN||anaemia-96/NN	num||%-99/NN||32-98/CD	prep_by||reduced-77/VBD||%-99/NN	number||%-102/NN||95-101/CD	amod||ci-103/NN||%-102/NN	dep||%-99/NN||ci-103/NN	number||%-105/NN||7-104/CD	amod||ci-103/NN||%-105/NN	num||%-108/NN||50-107/CD	appos||ci-103/NN||%-108/NN	prepc_compared_to||reduced-77/VBD||to-111/TO	pobj||reduced-77/VBD||placebo-112/NN	malaria-81||pyrimethamine--1||yes||monthly artesunate plus amodiaquine reduced the incidence of malaria by 69% (95% ci 63%, 74%) and anaemia by 45% (95% ci 25%,60%), bimonthly sulphadoxine-pyrimethamine reduced the incidence of malaria by 24% (95% ci 14%,33%) and anaemia by 30% (95% ci 6%, 49%) and bimonthly artesunate plus amodiaquine reduced the incidence of malaria by 17% (95% ci 6%, 27%) and anaemia by 32% (95% ci 7%, 50%) compared to placebo.
nsubj||assessed-2/VBD||we-1/PRP	root||ROOT-0/null||assessed-2/VBD	det||benefits-5/NNS||the-3/DT	amod||benefits-5/NNS||economic-4/JJ	dobj||assessed-2/VBD||benefits-5/NNS	amod||rifampicin-9/NN||single-7/JJ	nn||rifampicin-9/NN||dose-8/NN	prep_of||benefits-5/NNS||rifampicin-9/NN	appos||rifampicin-9/NN||sdr-11/NN	prep_for||assessed-2/VBD||contacts-14/NNS	amod||intervention-17/NN||chemoprophylactic-16/JJ	prep_as||contacts-14/NNS||intervention-17/NN	det||control-20/NN||the-19/DT	prep_in||assessed-2/VBD||control-20/NN	prep_of||control-20/NN||leprosy-22/NNP	leprosy-22||rifampicin-9||yes||we assessed the economic benefits of single dose rifampicin (sdr) for contacts as chemoprophylactic intervention in the control of leprosy.
nsubj||causes-7/VBZ||streptococcuspneumoniae-1/NN	vmod||streptococcuspneumoniae-1/NN||expressing-2/VBG	dobj||expressing-2/VBG||serogroup-3/NN	num||capsules-5/NNS||6-4/CD	npadvmod||frequently-6/RB||capsules-5/NNS	advmod||causes-7/VBZ||frequently-6/RB	root||ROOT-0/null||causes-7/VBZ	nsubjpass||studied-21/VBN||pneumococcalinfections-8/NNS	det||origins-12/NNS||the-10/DT	amod||origins-12/NNS||evolutionary-11/JJ	conj_and||pneumococcalinfections-8/NNS||origins-12/NNS	nsubjpass||studied-21/VBN||origins-12/NNS	det||strains-17/NNS||the-14/DT	amod||strains-17/NNS||serogroup-15/JJ	num||strains-17/NNS||6-16/CD	prep_of||origins-12/NNS||strains-17/NNS	aux||studied-21/VBN||have-18/VBP	auxpass||studied-21/VBN||been-19/VBN	advmod||studied-21/VBN||extensively-20/RB	ccomp||causes-7/VBZ||studied-21/VBN	pneumococcalinfections-8||streptococcuspneumoniae-1||no||streptococcuspneumoniae expressing serogroup 6 capsules frequently causes pneumococcalinfections and the evolutionary origins of the serogroup 6 strains have been extensively studied.
advmod||induced-9/VBN||furthermore-1/RB	amod||cd40-8/NNS||il-2-3/JJ	punct||±-6/NNP||/-4/:	nn||±-6/NNP||î-5/NNP	dep||cd40-8/NNS||±-6/NNP	nsubj||induced-9/VBN||cd40-8/NNS	root||ROOT-0/null||induced-9/VBN	det||â-13/NN||the-10/DT	amod||â-13/NN||ifn-î-11/JJ	amod||â-13/NN||³-12/JJ	dobj||induced-9/VBN||â-13/NN	dep||â-13/NN||$-14/$	npadvmod||decrease-18/RB||and-16/NNP	advmod||and-16/NNP||no-dependent-17/RB	dep||1-40/CD||decrease-18/RB	nn||metalloproteinase-21/NN||matrix-20/NN	prep_in||decrease-18/RB||metalloproteinase-21/NN	appos||metalloproteinase-21/NN||mmp-23/NN	dep||metalloproteinase-21/NN||expression-25/NN	dep||metalloproteinase-21/NN||activity-27/NN	conj_and||expression-25/NN||activity-27/NN	appos||expression-25/NN||concomitant-29/NN	prep_with||decrease-18/RB||increases-31/NNS	nn||inhibitor-34/NN||tissue-33/NN	prep_in||increases-31/NNS||inhibitor-34/NN	prep_of||inhibitor-34/NN||metalloproteinase-36/NN	appos||metalloproteinase-36/NN||timp-38/NN	num||$-14/$||1-40/CD	amod||expression-43/NN||e-cadherin-42/JJ	dobj||induced-9/VBN||expression-43/NN	conj_and||â-13/NN||expression-43/NN	prep_within||expression-43/NN||tumors-45/NNS	il-2-3||tumors-45||no_rel||furthermore, il-2/î±-cd40 induced the ifn-î³â and no-dependent decrease in matrix metalloproteinase (mmp) expression and activity, concomitant with increases in tissue inhibitor of metalloproteinase (timp) 1 and e-cadherin expression within tumors.
aux||investigate-2/VB||to-1/TO	csubj||synthase-11/VBD||investigate-2/VB	csubj||synthase-11/VBD||investigate-2/VB	det||expression-4/NN||the-3/DT	dobj||investigate-2/VB||expression-4/NN	amod||prostaglandine-7/NN||microsomal-6/JJ	prep_of||expression-4/NN||prostaglandine-7/NN	appos||prostaglandine-7/NN||pge-9/NN	root||ROOT-0/null||synthase-11/VBD	conj_and||synthase-11/VBD||synthase-11/VBD	dobj||synthase-11/VBD||1-12/CD	dep||1-12/CD||mpges-1-14/JJ	dobj||synthase-11/VBD||cyclooxygenase-17/NN	conj_and||1-12/CD||cyclooxygenase-17/NN	appos||cyclooxygenase-17/NN||cox-19/NN	nn||biopsies-23/NNS||muscle-22/NN	prep_in||cyclooxygenase-17/NN||biopsies-23/NNS	prep_from||synthase-11/VBD||patients-25/NNS	prep_with||patients-25/NNS||polymyositis-27/NNS	prep_with||patients-25/NNS||dermatomyositis-29/NNS	conj_or||polymyositis-27/NNS||dermatomyositis-29/NNS	amod||treatment-35/NN||conventional-33/JJ	nn||treatment-35/NN||immunosuppressive-34/NN	prep_after||synthase-11/VBD||treatment-35/NN	prep_before||synthase-11/VBD||treatment-35/NN	polymyositis-27||immunosuppressive-34||no_rel||to investigate the expression of microsomal prostaglandine (pge) synthase 1 (mpges-1) and cyclooxygenase (cox) in muscle biopsies from patients with polymyositis or dermatomyositis before and after conventional immunosuppressive treatment.
det||qpcr-3/NN||this-1/DT	amod||qpcr-3/NN||optimized-2/JJ	nsubjpass||used-7/VBN||qpcr-3/NN	nsubj||assess-9/VB||qpcr-3/NN	advmod||used-7/VBN||assay-4/RB	auxpass||used-7/VBN||was-5/VBD	advmod||used-7/VBN||then-6/RB	root||ROOT-0/null||used-7/VBN	aux||assess-9/VB||to-8/TO	xcomp||used-7/VBN||assess-9/VB	amod||responses-14/NNS||hiv-specific-10/JJ	amod||responses-14/NNS||cellular-11/JJ	nn||responses-14/NNS||t-12/NN	nn||responses-14/NNS||cell-13/NN	dobj||assess-9/VB||responses-14/NNS	amod||cells-19/NNS||cytobrush-derived-16/JJ	amod||cells-19/NNS||cervical-17/JJ	nn||cells-19/NNS||t-18/NN	prep_in||responses-14/NNS||cells-19/NNS	amod||individuals-22/NNS||hivpositive-21/JJ	prep_from||assess-9/VB||individuals-22/NNS	hivpositive-21||hiv--1||no||this optimized qpcr assay was then used to assess hiv-specific cellular t cell responses in cytobrush-derived cervical t cells from hivpositive individuals.
nn||inhibitors-4/NNS||tamoxifen-1/NN	conj_and||tamoxifen-1/NN||aromatase-3/NN	nn||inhibitors-4/NNS||aromatase-3/NN	nsubj||therapies-14/NNS||inhibitors-4/NNS	appos||inhibitors-4/NNS||ais-6/NN	cop||therapies-14/NNS||are-8/VBP	det||therapies-14/NNS||the-9/DT	advmod||common-11/JJ||most-10/RBS	amod||therapies-14/NNS||common-11/JJ	conj_and||common-11/JJ||effective-13/JJ	amod||therapies-14/NNS||effective-13/JJ	root||ROOT-0/null||therapies-14/NNS	prep_for||therapies-14/NNS||patients-16/NNS	nn||±-19/NNS||erî-18/NN	prep_with||patients-16/NNS||±-19/NNS	amod||cancer-23/NN||positive-21/JJ	nn||cancer-23/NN||breast-22/NN	dep||therapies-14/NNS||cancer-23/NN	tamoxifen-1||cancer-23||no_rel||tamoxifen and aromatase inhibitors (ais) are the most common and effective therapies for patients with erî±-positive breast cancer.
vmod||demonstrated-13/VBD||using-1/VBG	amod||administration-3/NN||oral-2/JJ	nsubj||hc-030031-9/JJ||administration-3/NN	det||antagonist-8/NN||the-5/DT	amod||antagonist-8/NN||selective-6/JJ	amod||antagonist-8/NN||trpa1-7/JJ	prep_of||administration-3/NN||antagonist-8/NN	xcomp||using-1/VBG||hc-030031-9/JJ	poss||results-12/NNS||our-11/PRP$	nsubj||demonstrated-13/VBD||results-12/NNS	root||ROOT-0/null||demonstrated-13/VBD	mark||plays-16/VBZ||that-14/IN	nsubj||plays-16/VBZ||trpa1-15/NNS	ccomp||demonstrated-13/VBD||plays-16/VBZ	det||role-19/NN||an-17/DT	amod||role-19/NN||important-18/JJ	dobj||plays-16/VBZ||role-19/NN	det||mechanisms-22/NNS||the-21/DT	prep_in||role-19/NN||mechanisms-22/NNS	amod||role-19/NN||responsible-23/JJ	amod||hypersensitivity-26/NN||mechanical-25/JJ	prep_for||responsible-23/JJ||hypersensitivity-26/NN	vmod||role-19/NN||observed-27/VBN	amod||models-32/NNS||inflammatory-29/JJ	conj_and||inflammatory-29/JJ||neuropathicpain-31/JJ	amod||models-32/NNS||neuropathicpain-31/JJ	prep_in||observed-27/VBN||models-32/NNS	hc--1||hypersensitivity-26||no_rel||using oral administration of the selective trpa1 antagonist hc-030031, our results demonstrated that trpa1 plays an important role in the mechanisms responsible for mechanical hypersensitivity observed in inflammatory and neuropathicpain models.
advmod||considered-18/VBN||as-1/RB	prep_with||as-1/RB||sd-nvp-3/NN	det||value-6/NN||the-5/DT	nsubjpass||considered-18/VBN||value-6/NN	prepc_of||value-6/NN||preventing-8/VBG	dobj||preventing-8/VBG||hivinfection-9/NN	det||number-13/NN||a-11/DT	amod||number-13/NN||large-12/JJ	prep_in||preventing-8/VBG||number-13/NN	prep_of||number-13/NN||infants-15/NNS	aux||considered-18/VBN||should-16/MD	auxpass||considered-18/VBN||be-17/VB	root||ROOT-0/null||considered-18/VBN	det||risk-22/NN||the-20/DT	amod||risk-22/NN||high-21/JJ	prep_alongside||considered-18/VBN||risk-22/NN	prep_of||risk-22/NN||resistance-24/NN	vmod||resistance-24/NN||associated-25/VBN	amod||prophylaxis-29/NNS||extended-27/JJ	nn||prophylaxis-29/NNS||nvp-28/NN	prep_with||associated-25/VBN||prophylaxis-29/NNS	hivinfection-9||nvp-28||yes||as with sd-nvp, the value of preventing hivinfection in a large number of infants should be considered alongside the high risk of resistance associated with extended nvp prophylaxis.
det||interview-4/NN||the-2/DT	amod||interview-4/NN||same-3/JJ	prep_in||conduct-8/VB||interview-4/NN	nsubj||conduct-8/VB||we-6/PRP	aux||conduct-8/VB||will-7/MD	root||ROOT-0/null||conduct-8/VB	amod||exercises-10/NNS||preference-elicitation-9/JJ	dobj||conduct-8/VB||exercises-10/NNS	vmod||exercises-10/NNS||using-11/VBG	det||thermometer-14/NN||the-12/DT	nn||thermometer-14/NN||feeling-13/NN	dobj||using-11/VBG||thermometer-14/NN	aux||identify-16/VB||to-15/TO	vmod||using-11/VBG||identify-16/VB	det||utilities-18/NNS||the-17/DT	dobj||identify-16/VB||utilities-18/NNS	mark||place-21/VBP||that-19/IN	nsubj||place-21/VBP||patients-20/NNS	ccomp||identify-16/VB||place-21/VBP	prepc_on||place-21/VBP||taking-23/VBG	dobj||taking-23/VBG||medication-24/NN	dep||medication-24/NN||warfarin-26/NN	dep||medication-24/NN||aspirin-28/NN	conj_and||warfarin-26/NN||aspirin-28/NN	prepc_on||place-21/VBP||having-33/VBG	conj_and||taking-23/VBG||having-33/VBG	det||stroke-36/NN||a-34/DT	amod||stroke-36/NN||mild-35/JJ	dobj||having-33/VBG||stroke-36/NN	det||stroke-40/NN||a-38/DT	amod||stroke-40/NN||severe-39/JJ	dobj||having-33/VBG||stroke-40/NN	conj_and||stroke-36/NN||stroke-40/NN	det||bleed-45/NN||a-43/DT	amod||bleed-45/NN||major-44/JJ	dobj||having-33/VBG||bleed-45/NN	conj_and||stroke-36/NN||bleed-45/NN	stroke-40||warfarin-26||yes||in the same interview, we will conduct preference-elicitation exercises using the feeling thermometer to identify the utilities that patients place on taking medication (warfarin and aspirin), and on having a mild stroke, a severe stroke, and a major bleed.
nsubj||due-5/JJ||this-1/DT	aux||due-5/JJ||has-2/VBZ	advmod||due-5/JJ||largely-3/RB	cop||due-5/JJ||been-4/VBN	root||ROOT-0/null||due-5/JJ	det||incidence-9/NN||an-7/DT	amod||incidence-9/NN||increased-8/VBN	prep_to||due-5/JJ||incidence-9/NN	amod||candidosis-12/NNS||oral-11/JJ	prep_of||incidence-9/NN||candidosis-12/NNS	det||period-15/NN||this-14/DT	prep_over||incidence-9/NN||period-15/NN	advmod||incidence-9/NN||primarily-17/RB	det||escalation-21/NN||the-20/DT	prep_because_of||incidence-9/NN||escalation-21/NN	prep_in||escalation-21/NN||hiv-infection-23/NN	det||epidemic-27/NN||the-25/DT	nn||epidemic-27/NN||aids-26/NNS	prep_to||due-5/JJ||epidemic-27/NN	conj_and||incidence-9/NN||epidemic-27/NN	aids-26||hiv--1||no||this has largely been due to an increased incidence of oral candidosis over this period, primarily because of the escalation in hiv-infection and the aids epidemic.
aux||estimate-2/VB||to-1/TO	advcl||took-10/VBD||estimate-2/VB	amod||risks-7/NNS||subtype-specific-3/JJ	nn||risks-7/NNS||lifetime-4/NN	nn||risks-7/NNS||breast-5/NN	nn||risks-7/NNS||cancer-6/NN	dobj||estimate-2/VB||risks-7/NNS	nsubj||took-10/VBD||we-9/PRP	root||ROOT-0/null||took-10/VBD	dobj||took-10/VBD||advantage-11/NN	prep_for||available-40/JJ||advantage-11/NN	amod||data-14/NNS||population-based-13/JJ	prep_of||advantage-11/NN||data-14/NNS	nsubj||available-40/JJ||information-17/NN	nn||expression-20/NN||tumor-19/NN	prep_regarding||information-17/NN||expression-20/NN	nn||receptor-23/NN||estrogen-22/NN	prep_of||expression-20/NN||receptor-23/NN	appos||receptor-23/NN||er-25/NN	amod||receptor-29/NN||progesterone-28/JJ	prep_of||expression-20/NN||receptor-29/NN	conj_and||receptor-23/NN||receptor-29/NN	appos||receptor-29/NN||pr-31/NN	prep_of||expression-20/NN||her2/neu-34/NNS	conj_and||receptor-23/NN||her2/neu-34/NNS	appos||her2/neu-34/NNS||her2-36/NNP	cop||available-40/JJ||was-38/VBD	advmod||available-40/JJ||newly-39/RB	rcmod||advantage-11/NN||available-40/JJ	progesterone-28||tumor-19||no_rel||to estimate subtype-specific lifetime breast cancer risks, we took advantage of population-based data for which information regarding tumor expression of estrogen receptor (er), progesterone receptor (pr) and her2/neu (her2) was newly available.
nsubj||showed-5/VBD||smokers-1/NNS	vmod||smokers-1/NNS||treated-2/VBN	prep_with||treated-2/VBN||budesonide/formoterol-4/NN	root||ROOT-0/null||showed-5/VBD	det||increase-7/NN||an-6/DT	dobj||showed-5/VBD||increase-7/NN	det||number-10/NN||the-9/DT	prep_in||showed-5/VBD||number-10/NN	nn||episodes-13/NNS||asthma-12/NN	prep_of||number-10/NN||episodes-13/NNS	parataxis||showed-5/VBD||intercurrent-15/VB	nn||symptoms-17/NNS||asthma-16/NN	dobj||intercurrent-15/VB||symptoms-17/NNS	vmod||symptoms-17/NNS||p-19/VBN	dep||0.016-21/CD||=-20/SYM	ccomp||p-19/VBN||0.016-21/CD	mark||had-26/VBD||while-23/IN	amod||subjects-25/NNS||non-smoking-24/JJ	nsubj||had-26/VBD||subjects-25/NNS	advcl||showed-5/VBD||had-26/VBD	det||decrease-29/NN||a-27/DT	amod||decrease-29/NN||significant-28/JJ	dobj||had-26/VBD||decrease-29/NN	det||episodes-32/NNS||these-31/DT	prep_in||decrease-29/NN||episodes-32/NNS	dep||episodes-32/NNS||p-34/VBN	dep||0.009-36/CD||=-35/SYM	ccomp||p-34/VBN||0.009-36/CD	asthma-16||budesonide--1||no||smokers treated with budesonide/formoterol showed an increase in the number of asthma episodes (intercurrent asthma symptoms, p=0.016) while non-smoking subjects had a significant decrease in these episodes (p=0.009).
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubjpass||recommended-14/VBN||treatment-3/NN	prep_of||treatment-3/NN||malaria-5/NN	prep_in||malaria-5/NN||infants-7/NNS	vmod||infants-7/NNS||using-8/VBG	acomp||using-8/VBG||sulfadoxine-pyrimethamine-9/JJ	appos||treatment-3/NN||sp-ipti-11/NNP	auxpass||recommended-14/VBN||is-13/VBZ	root||ROOT-0/null||recommended-14/VBN	agent||recommended-14/VBN||who-16/WP	prep_for||recommended-14/VBN||implementation-18/NN	prep_in||implementation-18/NN||settings-20/NNS	advmod||high-27/JJ||where-21/WRB	nsubj||high-27/JJ||resistance-22/NN	prep_to||resistance-22/NN||sp-24/NN	cop||high-27/JJ||is-25/VBZ	neg||high-27/JJ||not-26/RB	rcmod||settings-20/NNS||high-27/JJ	malaria-5||pyrimethamine--1||yes||intermittent preventive treatment of malaria in infants using sulfadoxine-pyrimethamine (sp-ipti) is recommended by who for implementation in settings where resistance to sp is not high.
advmod||diagnosed-4/VBN||when-1/WRB	nsubjpass||diagnosed-4/VBN||retinitis-2/NNS	auxpass||diagnosed-4/VBN||is-3/VBZ	advcl||started-10/VBN||diagnosed-4/VBN	nn||therapy-7/NN||haart-6/NN	nsubjpass||started-10/VBN||therapy-7/NN	nsubjpass||improved-12/VBN||therapy-7/NN	aux||started-10/VBN||should-8/MD	auxpass||started-10/VBN||be-9/VB	root||ROOT-0/null||started-10/VBN	conj_or||started-10/VBN||improved-12/VBN	amod||therapy-16/NN||anti-cmv-15/JJ	nsubjpass||administered-30/VBN||therapy-16/NN	amod||valganciclovir-19/NN||oral-18/JJ	prep_with||therapy-16/NN||valganciclovir-19/NN	amod||ganciclovir-22/NN||intravenous-21/JJ	prep_with||therapy-16/NN||ganciclovir-22/NN	conj_or||valganciclovir-19/NN||ganciclovir-22/NN	prep_with||therapy-16/NN||foscarnet-24/NN	conj_or||valganciclovir-19/NN||foscarnet-24/NN	prep_with||therapy-16/NN||cidofovir-27/NN	conj_or||valganciclovir-19/NN||cidofovir-27/NN	aux||administered-30/VBN||should-28/MD	auxpass||administered-30/VBN||be-29/VB	conj_and||started-10/VBN||administered-30/VBN	cmv--1||cidofovir-27||yes||when retinitis is diagnosed, haart therapy should be started or improved, and anti-cmv therapy with oral valganciclovir, intravenous ganciclovir, foscarnet, or cidofovir should be administered.
nsubjpass||reported-7/VBN||cases-1/NNS	amod||pancreatitis-4/NNS||acute-3/JJ	prep_of||cases-1/NNS||pancreatitis-4/NNS	aux||reported-7/VBN||have-5/VBP	auxpass||reported-7/VBN||been-6/VBN	root||ROOT-0/null||reported-7/VBN	prep_in||reported-7/VBN||association-9/NN	prep_with||reported-7/VBN||exenatide-11/NN	prep_with||reported-7/VBN||sitagliptin-13/NN	conj_and||exenatide-11/NN||sitagliptin-13/NN	prep_with||reported-7/VBN||type2diabetes-16/NNS	conj_and||exenatide-11/NN||type2diabetes-16/NNS	prep_without||reported-7/VBN||use-18/NN	det||medications-21/NNS||these-20/DT	prep_of||use-18/NN||medications-21/NNS	type2diabetes-16||sitagliptin-13||yes||cases of acute pancreatitis have been reported in association with exenatide, sitagliptin, and type2diabetes without use of these medications.
amod||weeks-3/NNS||2â-2/JJ	prep_after||developed-16/VBD||weeks-3/NNS	prep_of||weeks-3/NNS||treatment-5/NN	prep_with||treatment-5/NN||meropenem-7/NN	prep_with||treatment-5/NN||erythromycin-9/NN	conj_and||meropenem-7/NN||erythromycin-9/NN	amod||weeks-12/NNS||4â-11/JJ	prep_for||meropenem-7/NN||weeks-12/NNS	det||patient-15/NN||the-14/DT	nsubj||developed-16/VBD||patient-15/NN	root||ROOT-0/null||developed-16/VBD	det||relapse-18/NN||a-17/DT	dobj||developed-16/VBD||relapse-18/NN	nn||jejuni-31/NNS||bacteremia-20/NN	num||months-22/NNS||10â-21/CD	npadvmod||later-23/RBR||months-22/NNS	advmod||resistant-29/NN||later-23/RBR	det||erythromycin-28/NN||a-25/DT	amod||erythromycin-28/NN||high-26/JJ	nn||erythromycin-28/NN||level-27/NN	prep_with||resistant-29/NN||erythromycin-28/NN	amod||jejuni-31/NNS||resistant-29/NN	nn||jejuni-31/NNS||c.-30/NN	prep_of||relapse-18/NN||jejuni-31/NNS	erythromycin-28||bacteremia-20||no_rel||after 2â weeks of treatment with meropenem and erythromycin for 4â weeks , the patient developed a relapse of bacteremia 10â months later with a high level erythromycin resistant c. jejuni .
nsubj||studied-2/VBD||we-1/PRP	root||ROOT-0/null||studied-2/VBD	det||sample-5/NN||a-3/DT	amod||sample-5/NN||cross-sectional-4/JJ	dobj||studied-2/VBD||sample-5/NN	amod||users-10/NNS||adult-7/JJ	nn||users-10/NNS||injection-8/NN	nn||users-10/NNS||drug-9/NN	prep_of||sample-5/NN||users-10/NNS	appos||sample-5/NN||idus-12/NNS	prep_in||studied-2/VBD||kabul-15/NN	appos||kabul-15/NN||afghanistan-17/NN	prep_from||studied-2/VBD||june-20/NNP	num||june-20/NNP||2005-21/CD	prep_through||studied-2/VBD||june-23/NNP	num||june-23/NNP||2006-24/CD	cross--1||idus-12||no_rel||we studied a cross-sectional sample of adult injection drug users (idus) in kabul, afghanistan, from june 2005 through june 2006.
nsubj||compared-3/VBD||we-1/PRP	advmod||compared-3/VBD||directly-2/RB	root||ROOT-0/null||compared-3/VBD	det||efficacy-5/NN||the-4/DT	dobj||compared-3/VBD||efficacy-5/NN	dobj||compared-3/VBD||safety-7/NN	conj_and||efficacy-5/NN||safety-7/NN	num||formulations-12/NNS||two-9/CD	amod||formulations-12/NNS||different-10/JJ	nn||formulations-12/NNS||mesalamine-11/NN	prep_of||efficacy-5/NN||formulations-12/NNS	det||maintenance-15/NN||the-14/DT	prep_in||formulations-12/NNS||maintenance-15/NN	prep_of||maintenance-15/NN||remission-17/NN	prep_in||compared-3/VBD||patients-19/NNS	prep_with||patients-19/NNS||uc-21/NN	uc-21||mesalamine-11||yes||we directly compared the efficacy and safety of two different mesalamine formulations in the maintenance of remission in patients with uc.
nsubjpass||developed-25/VBN||cmx001-1/NNS	det||analog-6/NN||a-3/DT	amod||analog-6/NN||lipophilic-4/JJ	nn||analog-6/NN||nucleotide-5/NN	appos||cmx001-1/NNS||analog-6/NN	vmod||analog-6/NN||formed-7/VBN	advmod||linking-10/VBG||covalently-9/RB	agent||formed-7/VBN||linking-10/VBG	dobj||linking-10/VBG||3-11/CD	appos||propan-1-ol-16/NNS||hexdecyloxy-14/NN	dep||analog-6/NN||propan-1-ol-16/NNS	dep||propan-1-ol-16/NNS||to-17/TO	dep||propan-1-ol-16/NNS||cidofovir-18/NN	appos||cidofovir-18/NN||cdv-20/NN	aux||developed-25/VBN||is-23/VBZ	auxpass||developed-25/VBN||being-24/VBG	root||ROOT-0/null||developed-25/VBN	det||treatment-28/NN||a-27/DT	prep_as||developed-25/VBN||treatment-28/NN	prep_for||treatment-28/NN||smallpox-30/NN	smallpox-30||propan-1-ol-16||no_rel||cmx001, a lipophilic nucleotide analog formed by covalently linking 3-(hexdecyloxy)propan-1-ol to cidofovir (cdv), is being developed as a treatment for smallpox.
det||viruses-2/NNS||the-1/DT	nsubj||detected-3/VBD||viruses-2/NNS	root||ROOT-0/null||detected-3/VBD	cop||virus-8/NN||were-4/VBD	det||virus-8/NN||all-5/DT	nn||virus-8/NN||chlorella-6/NN	nn||virus-8/NN||variabilis-7/NNS	ccomp||detected-3/VBD||virus-8/NN	dep||virus-8/NN||cvv-10/VBN	dep||virus-13/NN||=-11/SYM	amod||virus-13/NN||nc64a-12/JJ	ccomp||cvv-10/VBN||virus-13/NN	virus-13||viruses-2||no||the viruses detected were all chlorella variabilis virus (cvv = nc64a virus).
nsubj||reviewed-2/VBN||we-1/PRP	nsubj||conducted-6/VBN||we-1/PRP	root||ROOT-0/null||reviewed-2/VBN	det||literature-4/NN||the-3/DT	dobj||reviewed-2/VBN||literature-4/NN	conj_and||reviewed-2/VBN||conducted-6/VBN	det||study-8/NN||this-7/DT	dobj||conducted-6/VBN||study-8/NN	aux||assess-10/VB||to-9/TO	vmod||study-8/NN||assess-10/VB	det||impact-12/NN||the-11/DT	dobj||assess-10/VB||impact-12/NN	prepc_of||impact-12/NN||xqlg-14/VBG	det||therapy-18/NN||an-16/DT	amod||therapy-18/NN||add-on-17/JJ	prep_as||xqlg-14/VBG||therapy-18/NN	prep_to||xqlg-14/VBG||treatment-20/NN	amod||seretide-24/NN||fluticasone/salmeterol-22/JJ	prep_with||assess-10/VB||seretide-24/NN	amod||patients-28/NNS||adult-27/JJ	prep_in||seretide-24/NN||patients-28/NNS	amod||asthma-33/NN||mild-to-moderate-30/JJ	amod||asthma-33/NN||persistent-32/JJ	prep_with||assess-10/VB||asthma-33/NN	asthma-33||fluticasone--1||yes||we reviewed the literature and conducted this study to assess the impact of xqlg as an add-on therapy to treatment with fluticasone/salmeterol (seretide) in adult patients with mild-to-moderate, persistent asthma.
vmod||present-16/VBP||using-1/VBG	det||$-10/FW||the-2/DT	nn||$-10/FW||caenorhabditis-3/FW	nn||$-10/FW||elegans-4/FW	nn||$-10/FW||â-5/FW	nn||$-10/FW||$-6/FW	nn||$-10/FW||pseudomonasaeruginosa-8/FW	nn||$-10/FW||hostâ-9/FW	dobj||using-1/VBG||$-10/FW	iobj||using-1/VBG||$-10/FW	nn||system-13/NN||pathogen-12/NN	dep||$-10/FW||system-13/NN	nsubj||present-16/VBP||we-15/PRP	root||ROOT-0/null||present-16/VBP	amod||evidence-18/NN||genetic-17/JJ	dobj||present-16/VBP||evidence-18/NN	mark||required-72/VBN||that-19/IN	det||fat-3-24/NNS||a-20/DT	nn||fat-3-24/NNS||î-21/NN	amod||fat-3-24/NNS||6-desaturase-23/JJ	nsubjpass||required-72/VBN||fat-3-24/NNS	poss||productsâ-30/NNS||its-27/PRP$	num||productsâ-30/NNS||two-28/CD	amod||productsâ-30/NNS||18-carbon-29/JJ	prep_through||fat-3-24/NNS||productsâ-30/NNS	dep||fat-3-24/NNS||$-31/$	num||$-31/$||gamma-linolenicacid-33/CD	dep||$-31/$||gla-35/NN	appos||gla-35/NN||183n6-37/NNS	amod||acid-41/NN||stearidonic-40/JJ	dep||fat-3-24/NNS||acid-41/NN	conj_and||$-31/$||acid-41/NN	dep||acid-41/NN||sda-43/NN	appos||sda-43/NN||184n3-45/NNS	det||acid-54/NN||the-50/DT	num||pufas-52/NNS||20-carbon-51/CD	npadvmod||arachidonic-53/JJ||pufas-52/NNS	amod||acid-54/NN||arachidonic-53/JJ	dep||fat-3-24/NNS||acid-54/NN	conj_negcc||$-31/$||acid-54/NN	dep||acid-54/NN||aa-56/NN	appos||aa-56/NN||204n6-58/NNS	amod||$-69/NNS||eicosapentaenoic-61/JJ	amod||$-69/NNS||acid-62/JJ	dep||$-69/NNS||epa-64/NN	appos||epa-64/NN||205n3-66/NNS	nn||$-69/NNS||â-68/NN	conj_negcc||$-31/$||$-69/NNS	conj_and||acid-54/NN||$-69/NNS	auxpass||required-72/VBN||is-71/VBZ	ccomp||present-16/VBP||required-72/VBN	amod||immunity-76/NN||basal-74/JJ	nn||immunity-76/NN||innate-75/NN	prep_for||required-72/VBN||immunity-76/NN	prep_in||immunity-76/NN||vivo-78/NN	fat--1||gla-35||no_rel||using the caenorhabditis elegans â pseudomonasaeruginosa hostâpathogen system, we present genetic evidence that a î6-desaturase fat-3, through its two 18-carbon productsâgamma-linolenicacid (gla, 183n6) and stearidonic acid (sda, 184n3), but not the 20-carbon pufas arachidonic acid (aa, 204n6) and eicosapentaenoic acid (epa, 205n3)âis required for basal innate immunity in vivo.
amod||settings-3/NNS||resource-limited-2/JJ	prep_in||remains-6/VBZ||settings-3/NNS	nsubj||remains-6/VBZ||hiv/aids-5/NNS	root||ROOT-0/null||remains-6/VBZ	det||threat-9/NN||a-7/DT	amod||threat-9/NN||serious-8/JJ	xcomp||remains-6/VBZ||threat-9/NN	det||well-being-15/NN||the-11/DT	amod||well-being-15/NN||social-12/JJ	conj_and||social-12/JJ||physical-14/JJ	amod||well-being-15/NN||physical-14/JJ	prep_to||remains-6/VBZ||well-being-15/NN	prep_of||well-being-15/NN||women-17/NNS	prepc_of||women-17/NNS||childbearing-19/VBG	dobj||childbearing-19/VBG||age-20/NN	amod||women-23/NNS||pregnant-22/JJ	dobj||childbearing-19/VBG||women-23/NNS	conj_and||age-20/NN||women-23/NNS	dobj||childbearing-19/VBG||mothers-25/NNS	conj_and||age-20/NN||mothers-25/NNS	dobj||childbearing-19/VBG||infants-27/NNS	conj_and||age-20/NN||infants-27/NNS	aids--1||hiv--1||no||in resource-limited settings, hiv/aids remains a serious threat to the social and physical well-being of women of childbearing age, pregnant women, mothers and infants.
nsubj||help-10/VB||knowledge-1/NN	nsubj||contribute-22/VB||knowledge-1/NN	nsubj||evaluate-24/VB||knowledge-1/NN	advmod||circulating-4/VBG||currently-3/RB	prepc_of||knowledge-1/NN||circulating-4/VBG	amod||genotype-6/NN||measlesvirus-5/JJ	dobj||circulating-4/VBG||genotype-6/NN	prep_in||circulating-4/VBG||italy-8/NN	aux||help-10/VB||will-9/MD	root||ROOT-0/null||help-10/VB	prepc_in||help-10/VB||monitoring-12/VBG	det||success-14/NN||the-13/DT	dobj||monitoring-12/VBG||success-14/NN	det||programme-19/NN||the-16/DT	amod||programme-19/NN||measles-17/JJ	nn||programme-19/NN||elimination-18/NN	prep_of||success-14/NN||programme-19/NN	aux||contribute-22/VB||will-21/MD	conj_and||help-10/VB||contribute-22/VB	aux||evaluate-24/VB||to-23/TO	xcomp||contribute-22/VB||evaluate-24/VB	det||effectiveness-26/NN||the-25/DT	dobj||evaluate-24/VB||effectiveness-26/NN	amod||campaigns-30/NNS||future-28/JJ	nn||campaigns-30/NNS||vaccination-29/NN	prep_of||effectiveness-26/NN||campaigns-30/NNS	measles-17||measlesvirus-5||no||knowledge of currently circulating measlesvirus genotype in italy will help in monitoring the success of the measles elimination programme and will contribute to evaluate the effectiveness of future vaccination campaigns.
advmod||outline-3/VBZ||here-1/RB	nsubj||outline-3/VBZ||we-2/PRP	nsubj||discuss-47/VB||we-2/PRP	root||ROOT-0/null||outline-3/VBZ	det||ecology-6/NN||the-4/DT	amod||ecology-6/NN||known-5/JJ	dobj||outline-3/VBZ||ecology-6/NN	det||viruses-12/NNS||the-8/DT	amod||viruses-12/NNS||mosquito-borne-9/JJ	amod||viruses-12/NNS||equine-10/JJ	nn||viruses-12/NNS||encephalitis-11/NN	prep_of||ecology-6/NN||viruses-12/NNS	dep||viruses-12/NNS||weev-14/NNP	dep||viruses-12/NNS||eeev-16/NNP	conj_and||weev-14/NNP||eeev-16/NNP	dep||viruses-12/NNS||veev-19/NNP	conj_and||weev-14/NNP||veev-19/NNP	dobj||outline-3/VBZ||wnv-22/NN	conj_and||ecology-6/NN||wnv-22/NN	conj_and||ecology-6/NN||usuv-24/NNP	conj_and||wnv-22/NN||usuv-24/NNP	conj_and||ecology-6/NN||rvfv-26/NNP	conj_and||wnv-22/NN||rvfv-26/NNP	amod||virus-30/NN||japaneseencephalitis-29/JJ	conj_and||ecology-6/NN||virus-30/NN	conj_and||wnv-22/NN||virus-30/NN	amod||virus-36/NN||tick-borneencephalitis-35/JJ	dobj||outline-3/VBZ||virus-36/NN	conj_and||ecology-6/NN||virus-36/NN	poss||virus-43/NN||its-38/PRP$	nn||virus-43/NN||north-39/NN	num||virus-43/NN||american-40/CD	nn||virus-43/NN||counterpart-41/NN	nn||virus-43/NN||powassan-42/NN	conj_and||ecology-6/NN||virus-43/NN	conj_and||virus-36/NN||virus-43/NN	aux||discuss-47/VB||will-46/MD	conj_and||outline-3/VBZ||discuss-47/VB	det||mode-51/NN||the-48/DT	advmod||likely-50/JJ||most-49/RBS	amod||mode-51/NN||likely-50/JJ	dobj||discuss-47/VB||mode-51/NN	mark||expand-56/VB||that-52/IN	det||viruses-54/NNS||these-53/DT	nsubj||expand-56/VB||viruses-54/NNS	aux||expand-56/VB||could-55/MD	ccomp||discuss-47/VB||expand-56/VB	poss||range-60/NN||their-57/PRP$	amod||range-60/NN||respective-58/JJ	amod||range-60/NN||geographical-59/JJ	dobj||expand-56/VB||range-60/NN	virus-43||viruses-54||no||here we outline the known ecology of the mosquito-borne equine encephalitis viruses (weev, eeev, and veev), wnv, usuv, rvfv, and japaneseencephalitis virus, as well as tick-borneencephalitis virus and its north american counterpart powassan virus, and will discuss the most likely mode that these viruses could expand their respective geographical range.
nsubj||disease-14/NN||tuberculosis-1/NNP	vmod||tuberculosis-1/NNP||caused-3/VBN	agent||caused-3/VBN||mycobacteriumtuberculosis-5/NNS	appos||mycobacteriumtuberculosis-5/NNS||mtb-7/NN	cop||disease-14/NN||is-10/VBZ	det||disease-14/NN||the-11/DT	advmod||notified-13/JJ||most-12/RBS	amod||disease-14/NN||notified-13/JJ	root||ROOT-0/null||disease-14/NN	det||world-17/NN||the-16/DT	prep_in||disease-14/NN||world-17/NN	tuberculosis-1||mtb-7||no||tuberculosis, caused by mycobacteriumtuberculosis (mtb), is the most notified disease in the world.
nsubj||become-5/VBN||gemcitabine-1/NN	prep||gemcitabine-1/NN||plus-2/CC	pobj||plus-2/CC||cisplatin-3/NN	aux||become-5/VBN||has-4/VBZ	root||ROOT-0/null||become-5/VBN	det||standard-8/NN||a-6/DT	amod||standard-8/NN||new-7/JJ	xcomp||become-5/VBN||standard-8/NN	amod||treatment-11/NN||first-line-10/JJ	prep_for||become-5/VBN||treatment-11/NN	amod||cancer-15/NN||advanced-13/JJ	amod||cancer-15/NN||biliary-14/JJ	prep_of||treatment-11/NN||cancer-15/NN	cancer-15||gemcitabine-1||no_rel||gemcitabine plus cisplatin has become a new standard for first-line treatment of advanced biliary cancer.
nsubj||agent-5/NN||francisellatularensis-1/NNS	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||the-3/DT	amod||agent-5/NN||causative-4/JJ	root||ROOT-0/null||agent-5/NN	prep_of||agent-5/NN||tularemia-7/NN	tularemia-7||francisellatularensis-1||no||francisellatularensis is the causative agent of tularemia.
mark||established-11/VBN||although-1/IN	amod||countries-5/NNS||western-4/JJ	prep_in||established-11/VBN||countries-5/NNS	amod||regimens-8/NNS||oxaliplatin-based-7/JJ	nsubjpass||established-11/VBN||regimens-8/NNS	aux||established-11/VBN||have-9/VBP	auxpass||established-11/VBN||been-10/VBN	advcl||accepted-40/VBN||established-11/VBN	det||treatment-16/NN||a-13/DT	amod||treatment-16/NN||gold-14/JJ	amod||treatment-16/NN||standard-15/JJ	prep_as||established-11/VBN||treatment-16/NN	prep_for||treatment-16/NN||patients-18/NNS	nn||iii-21/NN||stage-20/NN	prep_with||patients-18/NNS||iii-21/NN	amod||cancer-28/NN||high-23/JJ	nn||cancer-28/NN||risk-24/NN	nn||cancer-28/NN||stage-25/NN	nn||cancer-28/NN||ii-26/NN	nn||cancer-28/NN||colon-27/NN	prep_with||patients-18/NNS||cancer-28/NN	conj_or||iii-21/NN||cancer-28/NN	amod||resection-31/NN||curative-30/JJ	prep_after||established-11/VBN||resection-31/NN	prep_in||established-11/VBN||japan-34/NN	amod||regimens-36/NNS||fluorouracil-based-35/JJ	nsubjpass||accepted-40/VBN||regimens-36/NNS	nsubjpass||recommended-42/VBN||regimens-36/NNS	aux||accepted-40/VBN||have-37/VBP	auxpass||accepted-40/VBN||been-38/VBN	advmod||accepted-40/VBN||widely-39/RB	root||ROOT-0/null||accepted-40/VBN	conj_and||accepted-40/VBN||recommended-42/VBN	det||guidelines-45/NNS||the-44/DT	prep_in||accepted-40/VBN||guidelines-45/NNS	amod||settings-48/NNS||adjuvant-47/JJ	prep_for||guidelines-45/NNS||settings-48/NNS	prep_in||accepted-40/VBN||patients-50/NNS	nn||cancer-55/NN||stage-52/NN	nn||cancer-55/NN||iii-53/NN	nn||cancer-55/NN||colon-54/NN	prep_with||patients-50/NNS||cancer-55/NN	cancer-55||gold-14||no_rel||although, in western countries, oxaliplatin-based regimens have been established as a gold standard treatment for patients with stage iii or high risk stage ii colon cancer after curative resection, in japan fluorouracil-based regimens have been widely accepted and recommended in the guidelines for adjuvant settings in patients with stage iii colon cancer.
nsubj||autoimmunedisease-4/NN||type1diabetesmellitus-1/NNS	cop||autoimmunedisease-4/NN||is-2/VBZ	det||autoimmunedisease-4/NN||an-3/DT	root||ROOT-0/null||autoimmunedisease-4/NN	dep||autoimmunedisease-4/NN||caused-5/VBN	prep_by||caused-5/VBN||destruction-7/NN	amod||cells-11/NNS||pancreatic-9/JJ	nn||cells-11/NNS||beta-10/NN	prep_of||destruction-7/NN||cells-11/NNS	dep||autoimmunedisease-4/NN||characterized-13/VBN	conj_and||caused-5/VBN||characterized-13/VBN	prep_by||characterized-13/VBN||defect-15/NN	nn||secretion-18/NN||insulin-17/NN	prep_in||defect-15/NN||secretion-18/NN	mark||and/or-27/VBZ||while-19/IN	amod||results-21/NNS||type2diabetesmellitus-20/JJ	nsubj||and/or-27/VBZ||results-21/NNS	prep_from||results-21/NNS||abnormalities-23/NNS	nn||secretion-26/NN||insulin-25/NN	prep_in||abnormalities-23/NNS||secretion-26/NN	advcl||characterized-13/VBN||and/or-27/VBZ	nn||action-29/NN||insulin-28/NN	dobj||and/or-27/VBZ||action-29/NN	dobj||and/or-27/VBZ||both-31/DT	conj_or||action-29/NN||both-31/DT	type2diabetesmellitus-20||insulin-28||yes||type1diabetesmellitus is an autoimmunedisease caused by destruction of pancreatic beta cells and characterized by defect in insulin secretion while type2diabetesmellitus results from abnormalities in insulin secretion and/or insulin action or both.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||case-4/NN||a-3/DT	dobj||report-2/VBP||case-4/NN	amod||syndrome-8/NN||guillain-barrã-6/JJ	amod||syndrome-8/NN||©-7/JJ	prep_of||case-4/NN||syndrome-8/NN	vmod||syndrome-8/NN||presenting-9/VBG	amod||hyponatremia-12/NN||severe-11/JJ	prep_with||presenting-9/VBG||hyponatremia-12/NN	nsubjpass||exacerbated-16/VBN||hyponatremia-12/NN	auxpass||exacerbated-16/VBN||is-14/VBZ	advmod||exacerbated-16/VBN||further-15/RBR	rcmod||hyponatremia-12/NN||exacerbated-16/VBN	nn||therapy-19/NN||intravenousimmuneglobulin-18/NN	agent||exacerbated-16/VBN||therapy-19/NN	guillain-barrã©syndrome--1||intravenousimmuneglobulin-18||yes||we report a case of guillain-barrã©syndrome presenting with severe hyponatremia that is further exacerbated by intravenousimmuneglobulin therapy.
advmod||encode-4/VBP||importantly-1/RB	nsubj||encode-4/VBP||mges-3/NNS	root||ROOT-0/null||encode-4/VBP	amod||factors-7/NNS||putative-5/JJ	nn||factors-7/NNS||virulence-6/NN	dobj||encode-4/VBP||factors-7/NNS	nsubj||confer-11/VBP||factors-7/NNS	dobj||encode-4/VBP||molecules-9/NNS	conj_and||factors-7/NNS||molecules-9/NNS	nsubj||confer-11/VBP||molecules-9/NNS	rcmod||factors-7/NNS||confer-11/VBP	dobj||confer-11/VBP||resistance-12/NN	prep_to||confer-11/VBP||antibiotics-14/NNS	det||gene-18/NN||the-17/DT	prep_including||confer-11/VBP||gene-18/NN	nsubj||confers-20/VBZ||gene-18/NN	rcmod||gene-18/NN||confers-20/VBZ	dobj||confers-20/VBZ||resistance-21/NN	amod||-rrb--29/NNS||beta-lactamantibiotics-23/JJ	amod||s.aureus-26/NNS||methicillin-resistant-25/JJ	prep_in||beta-lactamantibiotics-23/JJ||s.aureus-26/NNS	amod||-rrb--29/NNS||-lrb--27/JJ	nn||-rrb--29/NNS||mrsa-28/NN	prep_to||confers-20/VBZ||-rrb--29/NNS	mrsa-28||s.aureus-26||no||importantly , mges encode putative virulence factors and molecules that confer resistance to antibiotics , including the gene that confers resistance to beta-lactamantibiotics in methicillin-resistant s.aureus -lrb- mrsa -rrb- .
nsubj||prevent-3/VB||this-1/DT	nsubj||eliminate-7/VB||this-1/DT	aux||prevent-3/VB||may-2/MD	root||ROOT-0/null||prevent-3/VB	amod||formation-5/NN||clot-4/JJ	dobj||prevent-3/VB||formation-5/NN	conj_and||prevent-3/VB||eliminate-7/VB	det||risk-9/NN||the-8/DT	dobj||eliminate-7/VB||risk-9/NN	det||thrombo-embolism-13/NN||an-11/DT	amod||thrombo-embolism-13/NN||iatrogenic-12/JJ	prep_of||risk-9/NN||thrombo-embolism-13/NN	embolism--1||clot-4||no_rel||this may prevent clot formation and eliminate the risk of an iatrogenic thrombo-embolism.
amod||existence-2/NN||continuous-1/JJ	nsubjpass||confirmed-11/VBN||existence-2/NN	amod||viruses-5/NNS||pcv2-4/JJ	prep_of||existence-2/NN||viruses-5/NNS	nn||nodes-8/NNS||lymph-7/NN	prep_in||viruses-5/NNS||nodes-8/NNS	aux||confirmed-11/VBN||have-9/VBP	auxpass||confirmed-11/VBN||been-10/VBN	root||ROOT-0/null||confirmed-11/VBN	agent||confirmed-11/VBN||pcr-13/NN	nsubj||took-16/VBD||pcr-13/NN	rcmod||pcr-13/NN||took-16/VBD	quantmod||seven-19/CD||at-17/IN	mwe||at-17/IN||least-18/JJS	pobj||at-17/IN||least-18/JJS	num||days-20/NNS||seven-19/CD	tmod||took-16/VBD||days-20/NNS	det||virus-23/NN||the-22/DT	prep_for||took-16/VBD||virus-23/NN	aux||transferred-26/VBN||to-24/TO	auxpass||transferred-26/VBN||be-25/VB	vmod||virus-23/NN||transferred-26/VBN	amod||organs-29/NNS||other-28/JJ	prep_into||transferred-26/VBN||organs-29/NNS	det||interface-33/NN||the-31/DT	amod||interface-33/NN||primary-32/JJ	prep_from||transferred-26/VBN||interface-33/NN	det||diffusion-37/NN||the-36/DT	nsubj||retarded-42/JJ||diffusion-37/NN	prep_to||diffusion-37/NN||thymus-39/NNS	aux||retarded-42/JJ||had-40/VBD	cop||retarded-42/JJ||been-41/VBN	conj_and||confirmed-11/VBN||retarded-42/JJ	num||days-45/NNS||seven-44/CD	prep_for||retarded-42/JJ||days-45/NNS	virus-23||viruses-5||no||continuous existence of pcv2 viruses in lymph nodes have been confirmed by pcr, which took at least seven days for the virus to be transferred into other organs from the primary interface, and the diffusion to thymus had been retarded for seven days.
nsubj||include-12/VBP||risks-1/NNS	det||spread-4/NN||the-3/DT	prep_for||risks-1/NNS||spread-4/NN	prep_of||spread-4/NN||hiv/aids-6/NNS	amod||people-9/NNS||young-8/JJ	prep_among||hiv/aids-6/NNS||people-9/NNS	prep_in||people-9/NNS||kazakhstan-11/NN	root||ROOT-0/null||include-12/VBP	dobj||include-12/VBP||prostitution-13/NN	dobj||include-12/VBP||prostitution-13/NN	conj_and||prostitution-13/NN||prostitution-13/NN	cc||prostitution-13/NN||well-15/RB	prep_as||prostitution-13/NN||stigmatization-17/NN	det||hivpositive-20/NN||the-19/DT	prep_of||stigmatization-17/NN||hivpositive-20/NN	prep_of||prostitution-13/NN||homosexuals-23/NNS	aids--1||hiv--1||no||risks for the spread of hiv/aids among young people in kazakhstan include prostitution as well as stigmatization of the hivpositive and of homosexuals.
nsubj||compound-5/NN||donepezil-1/NN	cop||compound-5/NN||is-2/VBZ	det||compound-5/NN||the-3/DT	amod||compound-5/NN||leading-4/VBG	root||ROOT-0/null||compound-5/NN	det||treatment-8/NN||the-7/DT	prep_for||compound-5/NN||treatment-8/NN	prepc_of||treatment-8/NN||alzheimerâ-10/VBG	num||disease-14/NN||$-11/$	number||s-13/CD||-12/CD	num||$-11/$||s-13/CD	dobj||alzheimerâ-10/VBG||disease-14/NN	appos||disease-14/NN||ad-16/NN	mwe||than-20/IN||more-19/JJR	quantmod||50-21/CD||than-20/IN	num||countries-22/NNS||50-21/CD	prep_in||alzheimerâ-10/VBG||countries-22/NNS	alzheimer--1||donepezil-1||yes||donepezil is the leading compound for the treatment of alzheimerâs disease (ad) in more than 50 countries.
aux||update-2/VB||to-1/TO	root||ROOT-0/null||update-2/VB	det||programme-7/NN||the-3/DT	amod||programme-7/NN||national-4/JJ	nn||programme-7/NN||malaria-5/NN	nn||programme-7/NN||control-6/NN	dobj||update-2/VB||programme-7/NN	prep_of||programme-7/NN||mali-9/NNS	det||efficacy-12/NN||the-11/DT	prep_on||mali-9/NNS||efficacy-12/NN	prep_of||efficacy-12/NN||chloroquine-14/NN	prep_of||efficacy-12/NN||amodiaquine-16/NN	conj_and||chloroquine-14/NN||amodiaquine-16/NN	prep_of||efficacy-12/NN||sulphadoxine-pyrimethamine-18/NN	conj_and||chloroquine-14/NN||sulphadoxine-pyrimethamine-18/NN	det||treatment-21/NN||the-20/DT	prep_in||update-2/VB||treatment-21/NN	amod||falciparummalaria-24/NN||uncomplicated-23/JJ	prep_of||treatment-21/NN||falciparummalaria-24/NN	malaria-5||chloroquine-14||yes||to update the national malaria control programme of mali on the efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine in the treatment of uncomplicated falciparummalaria.
nn||criteria-2/NNS||eligibility-1/NN	nsubj||randomised-8/VBD||criteria-2/NNS	num||studies-5/NNS||selecting-4/CD	npadvmod||large-6/JJ||studies-5/NNS	amod||scale-7/NN||large-6/JJ	prep_for||criteria-2/NNS||scale-7/NN	root||ROOT-0/null||randomised-8/VBD	amod||trials-10/NNS||controlled-9/JJ	dobj||randomised-8/VBD||trials-10/NNS	mwe||than-13/IN||more-12/JJR	quantmod||200-14/CD||than-13/IN	num||patients-15/NNS||200-14/CD	prep_in||randomised-8/VBD||patients-15/NNS	prep_with||randomised-8/VBD||osteoarthritis-17/NNS	det||knee-20/NN||the-19/DT	prep_of||osteoarthritis-17/NNS||knee-20/NN	nsubj||compared-24/VBD||knee-20/NN	prep_of||osteoarthritis-17/NNS||hip-22/NN	conj_or||knee-20/NN||hip-22/NN	nsubj||compared-24/VBD||hip-22/NN	rcmod||knee-20/NN||compared-24/VBD	dobj||compared-24/VBD||glucosamine-25/NN	dobj||compared-24/VBD||chondroitin-27/NN	conj_or||glucosamine-25/NN||chondroitin-27/NN	poss||combination-31/NN||their-30/PRP$	dobj||compared-24/VBD||combination-31/NN	conj_or||glucosamine-25/NN||combination-31/NN	prep_with||compared-24/VBD||placebo-33/NN	prep_with||compared-24/VBD||head-35/NN	conj_or||placebo-33/NN||head-35/NN	prep_to||compared-24/VBD||head-37/NN	osteoarthritis-17||glucosamine-25||yes||eligibility criteria for selecting studies large scale randomised controlled trials in more than 200 patients with osteoarthritis of the knee or hip that compared glucosamine, chondroitin, or their combination with placebo or head to head.
det||beginning-4/NN||the-3/DT	prep_as_of||includes-16/VBZ||beginning-4/NN	prep_of||beginning-4/NN||2013-6/CD	poss||â-9/NN||our-8/PRP$	appos||2013-6/CD||â-9/NN	amod||â-9/NN||$-10/$	dep||$-10/$||antibodies-11/JJ	aux||watchâ-13/VB||to-12/TO	vmod||beginning-4/NN||watchâ-13/VB	dobj||watchâ-13/VB||$-14/$	num||$-14/$||list-15/CD	root||ROOT-0/null||includes-16/VBZ	num||mabs-19/NNS||28-17/CD	amod||mabs-19/NNS||single-18/JJ	dobj||includes-16/VBZ||mabs-19/NNS	num||mixture-23/NN||one-21/CD	nn||mixture-23/NN||mab-22/NN	dobj||includes-16/VBZ||mixture-23/NN	conj_and||mabs-19/NNS||mixture-23/NN	nsubj||undergoing-26/VBG||mixture-23/NN	aux||undergoing-26/VBG||are-25/VBP	rcmod||mixture-23/NN||undergoing-26/VBG	dobj||undergoing-26/VBG||evaluation-27/NN	prep_in||evaluation-27/NN||phase-29/NN	num||studies-31/NNS||3-30/CD	nsubj||includes-16/VBZ||studies-31/NNS	amod||disorders-36/NNS||inflammatory-33/JJ	conj_or||inflammatory-33/JJ||immunological-35/JJ	amod||disorders-36/NNS||immunological-35/JJ	prep_for||studies-31/NNS||disorders-36/NNS	prep_for||studies-31/NNS||cancers-38/NNS	conj_and||disorders-36/NNS||cancers-38/NNS	amod||cholesterol-41/NN||high-40/JJ	prep_for||studies-31/NNS||cholesterol-41/NN	conj_and||disorders-36/NNS||cholesterol-41/NN	prep_for||studies-31/NNS||osteoporosis-43/NNS	conj_and||disorders-36/NNS||osteoporosis-43/NNS	prep_for||studies-31/NNS||alzheimerdisease-45/NN	conj_and||disorders-36/NNS||alzheimerdisease-45/NN	amod||disease-48/NN||infectious-47/JJ	prep_for||studies-31/NNS||disease-48/NN	conj_and||disorders-36/NNS||disease-48/NN	cholesterol-41||alzheimerdisease-45||no_rel||as of the beginning of 2013, our âantibodies to watchâ? list includes 28 single mabs and one mab mixture that are undergoing evaluation in phase 3 studies for inflammatory or immunological disorders, cancers, high cholesterol, osteoporosis, alzheimerdisease and infectious disease.
nsubj||has-5/VBZ||diabetesmellitus-1/NNS	appos||diabetesmellitus-1/NNS||dm-3/NN	root||ROOT-0/null||has-5/VBZ	det||incidence-8/NN||a-6/DT	amod||incidence-8/NN||growing-7/VBG	dobj||has-5/VBZ||incidence-8/NN	dobj||has-5/VBZ||prevalence-10/NN	conj_and||incidence-8/NN||prevalence-10/NN	amod||societies-13/NNS||modern-12/JJ	prep_in||prevalence-10/NN||societies-13/NNS	vmod||prevalence-10/NN||pushed-15/VBN	det||aging-18/NN||the-17/DT	agent||pushed-15/VBN||aging-18/NN	agent||pushed-15/VBN||change-20/NN	conj_and||aging-18/NN||change-20/NN	nn||styles-23/NNS||life-22/NN	prep_of||aging-18/NN||styles-23/NNS	dm-3||diabetesmellitus-1||no_rel||diabetesmellitus (dm) has a growing incidence and prevalence in modern societies, pushed by the aging and change of life styles.
det||profile-4/NN||the-1/DT	amod||profile-4/NN||largest-2/JJS	nn||profile-4/NN||mar-3/NN	nsubj||contained-5/VBD||profile-4/NN	nsubjpass||observed-23/VBN||profile-4/NN	root||ROOT-0/null||contained-5/VBD	num||antibiotics-7/NNS||six-6/CD	dobj||contained-5/VBD||antibiotics-7/NNS	dep||antibiotics-7/NNS||penicilling-9/NN	appos||penicilling-9/NN||methicillin-11/NN	appos||penicilling-9/NN||erythromycin-13/NN	conj_and||methicillin-11/NN||erythromycin-13/NN	appos||penicilling-9/NN||ciprofloxacin-15/NN	conj_and||methicillin-11/NN||ciprofloxacin-15/NN	appos||penicilling-9/NN||clindamycin-17/NN	conj_and||methicillin-11/NN||clindamycin-17/NN	appos||penicilling-9/NN||clarithromycin-19/NN	conj_and||methicillin-11/NN||clarithromycin-19/NN	auxpass||observed-23/VBN||was-22/VBD	conj_and||contained-5/VBD||observed-23/VBN	det||isolates-27/NN||the-25/DT	nn||isolates-27/NN||mrsa-26/NN	prep_in||observed-23/VBN||isolates-27/NN	predet||uk-31/NN||both-29/PDT	det||uk-31/NN||the-30/DT	prep_in||isolates-27/NN||uk-31/NN	amod||cohorts-34/NNS||maltese-33/JJ	prep_in||isolates-27/NN||cohorts-34/NNS	conj_and||uk-31/NN||cohorts-34/NNS	clindamycin-17||mrsa-26||no_rel||the largest mar profile contained six antibiotics (penicilling, methicillin, erythromycin, ciprofloxacin, clindamycin and clarithromycin) and was observed in the mrsa isolates in both the uk and maltese cohorts.
det||status-3/NN||the-1/DT	nn||status-3/NN||methylation-2/NN	nsubjpass||evaluated-11/VBN||status-3/NN	nsubjpass||matched-34/VBN||status-3/NN	amod||m-9/NN||cst6-5/JJ	nn||m-9/NN||gene-6/NN	amod||m-9/NN||encoding-7/VBG	nn||m-9/NN||cystatin-8/NN	prep_of||status-3/NN||m-9/NN	auxpass||evaluated-11/VBN||was-10/VBD	root||ROOT-0/null||evaluated-11/VBN	ccomp||evaluated-11/VBN||using-12/VBG	amod||reaction-16/NN||methylation-specific-13/JJ	nn||reaction-16/NN||polymerase-14/NN	nn||reaction-16/NN||chain-15/NN	dobj||using-12/VBG||reaction-16/NN	appos||reaction-16/NN||pcr-18/NN	amod||tissues-23/NNS||formalin-fixed-21/JJ	amod||tissues-23/NNS||paraffin-embedded-22/JJ	prep_in||reaction-16/NN||tissues-23/NNS	amod||participants-26/NNS||292-25/JJ	prep_from||using-12/VBG||participants-26/NNS	ccomp||evaluated-11/VBN||using-28/VBG	conj_and||using-12/VBG||using-28/VBG	vmod||using-28/VBG||pyrosequencing-29/VBG	amod||tumor-32/NN||fresh-frozen-31/JJ	prep_in||pyrosequencing-29/VBG||tumor-32/NN	conj_and||evaluated-11/VBN||matched-34/VBN	amod||tissues-36/NNS||normal-35/JJ	dobj||matched-34/VBN||tissues-36/NNS	num||patients-40/NNS||51-38/CD	nn||patients-40/NNS||ibc-39/NN	prep_from||matched-34/VBN||patients-40/NNS	paraffin--1||tumor-32||no_rel||the methylation status of cst6 gene encoding cystatin m was evaluated using methylation-specific polymerase chain reaction (pcr) in formalin-fixed paraffin-embedded tissues from 292 participants and using pyrosequencing in fresh-frozen tumor and matched normal tissues from 51 ibc patients.
det||5-fluorouracil-4/NN||the-1/DT	amod||5-fluorouracil-4/NN||fluorinated-2/JJ	nn||5-fluorouracil-4/NN||pyrimidine-3/NN	nsubj||agent-13/NN||5-fluorouracil-4/NN	dep||5-fluorouracil-4/NN||5-6/CD	dep||5-6/CD||fu-8/NN	cop||agent-13/NN||is-10/VBZ	det||agent-13/NN||an-11/DT	amod||agent-13/NN||anticancer-12/JJ	root||ROOT-0/null||agent-13/NN	vmod||agent-13/NN||used-14/VBN	advmod||adjuvant-17/JJ||most-16/RBS	amod||regimens-21/NNS||adjuvant-17/JJ	conj_and||adjuvant-17/JJ||palliative-19/JJ	amod||regimens-21/NNS||palliative-19/JJ	nn||regimens-21/NNS||treatment-20/NN	prep_in||used-14/VBN||regimens-21/NNS	amod||cancer-24/NN||colorectal-23/JJ	prep_for||regimens-21/NNS||cancer-24/NN	cancer-24||5-fluorouracil-4||no_rel||the fluorinated pyrimidine 5-fluorouracil (5- fu ) is an anticancer agent used in most adjuvant and palliative treatment regimens for colorectal cancer.
det||prevalences-2/NNS||the-1/DT	nsubj||33.1-27/NNP||prevalences-2/NNS	amod||antibody-6/NN||anti-hbv-4/JJ	nn||antibody-6/NN||core-5/NN	prep_of||prevalences-2/NNS||antibody-6/NN	dep||antibody-6/NN||anti-hbc-8/JJ	amod||antigen-14/NN||hepatitisb-11/JJ	nn||antigen-14/NN||virus-12/NN	nn||antigen-14/NN||surface-13/NN	prep_of||prevalences-2/NNS||antigen-14/NN	conj_and||antibody-6/NN||antigen-14/NN	appos||antigen-14/NN||hbsag-16/NN	amod||antibody-22/NN||anti-hbv-20/JJ	nn||antibody-22/NN||surface-21/NN	prep_of||prevalences-2/NNS||antibody-22/NN	conj_and||antibody-6/NN||antibody-22/NN	appos||antibody-22/NN||anti-hbs-24/NNS	cop||33.1-27/NNP||were-26/VBD	root||ROOT-0/null||33.1-27/NNP	conj_and||33.1-27/NNP||10.4-29/CD	num||%-33/NN||56.1-32/CD	conj_and||33.1-27/NNP||%-33/NN	advmod||33.1-27/NNP||respectively-35/RB	hbv--1||hbsag-16||yes||the prevalences of anti-hbv core antibody (anti-hbc), hepatitisb virus surface antigen (hbsag), and anti-hbv surface antibody (anti-hbs) were 33.1, 10.4, and 56.1%, respectively.
det||value-2/NN||the-1/DT	nsubj||important-12/JJ||value-2/NN	nn||leptin-6/NN||monitoring-4/NN	nn||leptin-6/NN||serum-5/NN	prep_of||value-2/NN||leptin-6/NN	advmod||ill-9/JJ||critically-8/RB	amod||patients-10/NNS||ill-9/JJ	prep_in||leptin-6/NN||patients-10/NNS	cop||important-12/JJ||is-11/VBZ	root||ROOT-0/null||important-12/JJ	advmod||diagnosis-15/NN||early-14/RB	prep_for||important-12/JJ||diagnosis-15/NN	prep_for||important-12/JJ||differentiation-17/NN	conj_and||diagnosis-15/NN||differentiation-17/NN	prep_between||diagnosis-15/NN||sepsis-19/NN	amod||sirs-23/NNS||non-infectioussystemicinflammatoryresponsesyndrome-21/JJ	prep_between||diagnosis-15/NN||sirs-23/NNS	conj_and||sepsis-19/NN||sirs-23/NNS	sirs-23||infectioussystemicinflammatoryresponsesyndrome--1||no||the value of monitoring serum leptin in critically ill patients is important for early diagnosis and differentiation between sepsis and non-infectioussystemicinflammatoryresponsesyndrome (sirs).
det||number-2/NN||the-1/DT	nsubj||similar-10/JJ||number-2/NN	nn||copies-5/NNS||virion-4/NN	prep_of||number-2/NN||copies-5/NNS	vmod||copies-5/NNS||shed-6/VBN	prep_per||shed-6/VBN||ml-8/NN	cop||similar-10/JJ||was-9/VBD	root||ROOT-0/null||similar-10/JJ	parataxis||similar-10/JJ||logâ-12/VBG	dobj||logâ-12/VBG||$-13/$	number||3.54-15/CD||-14/CD	num||$-13/$||3.54-15/CD	prep_for||$-13/$||hivpositive-17/NN	prep_versus||hivpositive-17/NN||3.90-19/CD	prep_for||3.90-19/CD||hiv-21/NN	amod||$-13/$||negative-22/JJ	vmod||$-13/$||p-24/VBN	dep||.99-26/CD||=-25/SYM	ccomp||p-24/VBN||.99-26/CD	hivpositive-17||hiv-21||no||the number of virion copies shed per ml was similar (logâ3.54 for hivpositive versus 3.90 for hiv negative, p = .99).
det||study-2/NN||the-1/DT	nsubj||included-3/VBD||study-2/NN	root||ROOT-0/null||included-3/VBD	num||children-6/NNS||2227-4/CD	nn||children-6/NNS||ghanaian-5/NN	dobj||included-3/VBD||children-6/NNS	nsubjpass||given-16/VBN||children-6/NNS	dep||children-6/NNS||3â-8/VBN	num||months-12/NNS||$-9/$	num||$-9/$||59-11/CD	tmod||3â-8/VBN||months-12/NNS	auxpass||given-16/VBN||were-15/VBD	rcmod||children-6/NNS||given-16/VBN	amod||bimonthly-21/NNS||sulphadoxine-pyrimethamine-17/JJ	discourse||bimonthly-21/NNS||sp-19/UH	dobj||given-16/VBN||bimonthly-21/NNS	dobj||given-16/VBN||artesunate-23/NN	dobj||given-16/VBN||amodiaquine-25/NN	conj_plus||artesunate-23/NN||amodiaquine-25/NN	mark||aq-29/VBP||as-27/IN	nsubj||aq-29/VBP||+-28/PRP	dep||amodiaquine-25/NN||aq-29/VBP	dep||amodiaquine-25/NN||monthly-31/JJ	dep||amodiaquine-25/NN||bimonthly-33/JJ	conj_or||monthly-31/JJ||bimonthly-33/JJ	dobj||given-16/VBN||placebo-36/NN	conj_or||artesunate-23/NN||placebo-36/NN	advmod||spanning-41/VBG||monthly-37/JJ	num||months-40/NNS||six-39/CD	prep_for||monthly-37/JJ||months-40/NNS	vmod||placebo-36/NN||spanning-41/VBG	det||season-45/NN||the-42/DT	nn||season-45/NN||malaria-43/NN	nn||season-45/NN||transmission-44/NN	dobj||spanning-41/VBG||season-45/NN	malaria-43||pyrimethamine--1||no||the study included 2227 ghanaian children (3â59 months) who were given sulphadoxine-pyrimethamine (sp) bimonthly, artesunate plus amodiaquine (as+aq) monthly or bimonthly, or placebo monthly for six months spanning the malaria transmission season.
det||study-5/NN||a-2/DT	amod||study-5/NN||randomized-3/JJ	amod||study-5/NN||prospective-4/JJ	prep_in||enrolled-19/VBN||study-5/NN	num||patients-8/NNS||60-7/CD	nsubjpass||enrolled-19/VBN||patients-8/NNS	nsubj||determine-21/VB||patients-8/NNS	nn||i-ii-11/NN||asa-10/NN	dep||patients-8/NNS||i-ii-11/NN	appos||i-ii-11/NN||elder-13/JJR	num||years-16/NNS||65-15/CD	prep_than||elder-13/JJR||years-16/NNS	auxpass||enrolled-19/VBN||were-18/VBD	root||ROOT-0/null||enrolled-19/VBN	aux||determine-21/VB||to-20/TO	xcomp||enrolled-19/VBN||determine-21/VB	dobj||required-37/VBN||which-22/WDT	num||target-25/NN||two-24/CD	prep_of||required-37/VBN||target-25/NN	amod||concentrations-28/NNS||remifentanil-26/JJ	nn||concentrations-28/NNS||blood-27/NN	nsubjpass||required-37/VBN||concentrations-28/NNS	num||ng/ml-31/NN||3-30/CD	dep||concentrations-28/NNS||ng/ml-31/NN	num||ng/ml-34/NN||5-33/CD	appos||ng/ml-31/NN||ng/ml-34/NN	auxpass||required-37/VBN||was-36/VBD	ccomp||determine-21/VB||required-37/VBN	aux||blunt-39/VB||to-38/TO	ccomp||required-37/VBN||blunt-39/VB	amod||changes-41/NNS||hemodynamic-40/JJ	dobj||blunt-39/VB||changes-41/NNS	prep_during||blunt-39/VB||intubation-43/NN	aux||reduce-46/VB||to-45/TO	ccomp||required-37/VBN||reduce-46/VB	conj_and||blunt-39/VB||reduce-46/VB	amod||pain-48/NN||propofol-induced-47/JJ	dobj||reduce-46/VB||pain-48/NN	pain-48||asa-10||yes||in a randomized prospective study, 60 patients (asa i-ii, elder than 65 years) were enrolled to determine which of two target remifentanil blood concentrations (3 ng/ml, 5 ng/ml) was required to blunt hemodynamic changes during intubation and to reduce propofol-induced pain.
amod||feâ-2/NN||defective-1/JJ	poss||synthesis-5/NN||feâ-2/NN	nn||synthesis-5/NN||cluster-4/NN	nsubj||affects-8/VBZ||synthesis-5/NN	nsubj||alters-26/VBZ||synthesis-5/NN	neg||only-7/JJ||not-6/RB	preconj||affects-8/VBZ||only-7/JJ	root||ROOT-0/null||affects-8/VBZ	dobj||affects-8/VBZ||activities-9/NNS	amod||ironâ-12/NN||many-11/JJ	poss||enzymes-15/NNS||ironâ-12/NN	nn||enzymes-15/NNS||ulfur-14/NN	prep_of||activities-9/NNS||enzymes-15/NNS	amod||dehydrogenase-22/NN||aconitase-19/JJ	conj_and||aconitase-19/JJ||succinate-21/JJ	amod||dehydrogenase-22/NN||succinate-21/JJ	prep_such_as||activities-9/NNS||dehydrogenase-22/NN	advmod||alters-26/VBZ||also-25/RB	conj_but||affects-8/VBZ||alters-26/VBZ	det||regulation-28/NN||the-27/DT	dobj||alters-26/VBZ||regulation-28/NN	amod||homeostasis-32/NNS||cellular-30/JJ	nn||homeostasis-32/NNS||iron-31/NN	prep_of||regulation-28/NN||homeostasis-32/NNS	vmod||regulation-28/NN||causing-34/VBG	det||irondeficiency-40/NN||both-35/DT	amod||irondeficiency-40/NN||mitochondrial-36/JJ	amod||irondeficiency-40/NN||ironoverload-37/JJ	conj_and||ironoverload-37/JJ||cytosolic-39/JJ	amod||irondeficiency-40/NN||cytosolic-39/JJ	dobj||causing-34/VBG||irondeficiency-40/NN	irondeficiency-40||iron-31||yes||defective feâs cluster synthesis not only affects activities of many ironâsulfur enzymes, such as aconitase and succinate dehydrogenase, but also alters the regulation of cellular iron homeostasis, causing both mitochondrial ironoverload and cytosolic irondeficiency.
aux||describe-2/VB||to-1/TO	csubj||replaced-24/VBN||describe-2/VB	det||case-management-9/NN||the-3/DT	dep||case-management-9/NN||quality-4/NN	prep_of||quality-4/NN||outpatient-6/NN	amod||case-management-9/NN||paediatric-7/JJ	nn||case-management-9/NN||malaria-8/NN	dobj||describe-2/VB||case-management-9/NN	advmod||4â-11/JJ||approximately-10/RB	amod||case-management-9/NN||4â-11/JJ	num||months-15/NNS||$-12/$	num||$-12/$||6-14/CD	npadvmod||describe-2/VB||months-15/NNS	nn||$-18/NNP||artemetherâ-17/NNP	prep_after||describe-2/VB||$-18/NNP	dep||$-18/NNP||lumefantrine-20/NN	appos||$-18/NNP||al-22/NNP	root||ROOT-0/null||replaced-24/VBN	nn||$-26/NNP||sulfadoxineâ-25/NNP	dep||pyrimethamine-28/NN||$-26/NNP	dep||replaced-24/VBN||pyrimethamine-28/NN	discourse||pyrimethamine-28/NN||sp-30/UH	det||therapy-37/NN||the-33/DT	amod||therapy-37/NN||nationally-34/JJR	amod||therapy-37/NN||recommended-35/VBN	amod||therapy-37/NN||first-line-36/JJ	prep_as||replaced-24/VBN||therapy-37/NN	prep_in||therapy-37/NN||kenya-39/NN	malaria-8||artemether--1||yes||to describe the quality of outpatient paediatric malaria case-management approximately 4â6 months after artemetherâlumefantrine (al) replaced sulfadoxineâpyrimethamine (sp) as the nationally recommended first-line therapy in kenya.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||compare-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||compare-8/VB||to-7/TO	xcomp||was-6/VBD||compare-8/VB	det||outcomes-10/NNS||the-9/DT	dobj||compare-8/VB||outcomes-10/NNS	amod||concomitant-14/NN||postoperative-12/JJ	nn||concomitant-14/NN||adjuvant-13/NN	prep_of||outcomes-10/NNS||concomitant-14/NN	advmod||using-16/VBG||chemoradiotherapy-15/RB	vmod||concomitant-14/NN||using-16/VBG	num||schedules-19/NNS||two-17/CD	amod||schedules-19/NNS||different-18/JJ	dobj||using-16/VBG||schedules-19/NNS	prep_of||schedules-19/NNS||cisplatin-21/NN	prep_for||cisplatin-21/NN||patients-23/NNS	amod||squamouscellcarcinoma-27/NN||high-risk-25/JJ	amod||squamouscellcarcinoma-27/NN||oral-26/JJ	prep_with||patients-23/NNS||squamouscellcarcinoma-27/NN	dep||squamouscellcarcinoma-27/NN||oscc-29/JJ	squamouscellcarcinoma-27||cisplatin-21||no_rel||the aim of this study was to compare the outcomes of postoperative adjuvant concomitant chemoradiotherapy using two different schedules of cisplatin for patients with high-risk oral squamouscellcarcinoma (oscc).
nsubjpass||reported-3/VBN||it-1/PRP	auxpass||reported-3/VBN||was-2/VBD	root||ROOT-0/null||reported-3/VBN	amod||authors-6/NNS||other-5/JJ	agent||reported-3/VBN||authors-6/NNS	mark||relate-10/VB||that-7/IN	nsubj||relate-10/VB||it-8/PRP	nsubj||surfactant-12/VB||it-8/PRP	nsubj||result-16/VB||it-8/PRP	aux||relate-10/VB||may-9/MD	ccomp||reported-3/VBN||relate-10/VB	aux||surfactant-12/VB||to-11/TO	xcomp||relate-10/VB||surfactant-12/VB	dobj||surfactant-12/VB||depletion-13/NN	aux||result-16/VB||may-15/MD	ccomp||reported-3/VBN||result-16/VB	conj_or||relate-10/VB||result-16/VB	amod||damage-20/NN||hypoxic-18/JJ	amod||damage-20/NN||capillary-19/JJ	prep_from||result-16/VB||damage-20/NN	xcomp||result-16/VB||leading-22/VBG	amod||permeability-26/NN||increased-24/VBN	amod||permeability-26/NN||capillary-25/JJ	prep_to||leading-22/VBG||permeability-26/NN	vmod||permeability-26/NN||-LSB--27/VBG	num||-RSB--29/NNS||1,3-28/CD	dobj||-LSB--27/VBG||-RSB--29/NNS	surfactant-12||hypoxic-18||no_rel||it was reported by other authors that it may relate to surfactant depletion or may result from hypoxic capillary damage, leading to increased capillary permeability [1,3].
det||study-2/NN||a-1/DT	nsubjpass||undertaken-4/VBN||study-2/NN	nsubj||estimate-6/VB||study-2/NN	auxpass||undertaken-4/VBN||was-3/VBD	root||ROOT-0/null||undertaken-4/VBN	aux||estimate-6/VB||to-5/TO	xcomp||undertaken-4/VBN||estimate-6/VB	det||seroprevalence-8/NN||the-7/DT	dobj||estimate-6/VB||seroprevalence-8/NN	amod||antigen-12/NN||hepatitisb-10/JJ	nn||antigen-12/NN||surface-11/NN	prep_of||seroprevalence-8/NN||antigen-12/NN	appos||antigen-12/NN||hbsag-14/NN	dobj||estimate-6/VB||antibodies-17/NNS	conj_and||seroprevalence-8/NN||antibodies-17/NNS	prep_to||antibodies-17/NNS||hepatitisc-19/NN	amod||ab-22/NN||anti-hcv-21/JJ	appos||hepatitisc-19/NN||ab-22/NN	prep_to||antibodies-17/NNS||humanimmunodeficiencyvirus-25/NNS	conj_and||hepatitisc-19/NN||humanimmunodeficiencyvirus-25/NNS	amod||ab-28/NN||anti-hiv-27/JJ	appos||hepatitisc-19/NN||ab-28/NN	predet||sexes-33/NNS||both-31/PDT	det||sexes-33/NNS||the-32/DT	prep_in||estimate-6/VB||sexes-33/NNS	amod||groups-37/NNS||different-35/JJ	nn||groups-37/NNS||age-36/NN	prep_in||estimate-6/VB||groups-37/NNS	conj_and||sexes-33/NNS||groups-37/NNS	det||population-41/NN||a-39/DT	amod||population-41/NN||hospital-based-40/JJ	prep_in||estimate-6/VB||population-41/NN	prep_in||population-41/NN||jaipur-43/NN	appos||jaipur-43/NN||rajasthan-45/NN	hepatitisc-19||hcv--1||no||a study was undertaken to estimate the seroprevalence of hepatitisb surface antigen (hbsag) and antibodies to hepatitisc (anti-hcv ab) and humanimmunodeficiencyvirus (anti-hiv ab) in both the sexes and different age groups in a hospital-based population in jaipur, rajasthan.
aux||elucidate-2/VB||to-1/TO	advcl||analyzed-15/VBD||elucidate-2/VB	mark||involved-6/VBN||whether-3/IN	nsubjpass||involved-6/VBN||micrornas-4/NNS	auxpass||involved-6/VBN||are-5/VBP	ccomp||elucidate-2/VB||involved-6/VBN	det||development-9/NN||the-8/DT	prep_in||involved-6/VBN||development-9/NN	amod||resistance-12/NN||fludarabine-11/JJ	prep_of||development-9/NN||resistance-12/NN	nsubj||analyzed-15/VBD||we-14/PRP	root||ROOT-0/null||analyzed-15/VBD	det||expression-17/NN||the-16/DT	dobj||analyzed-15/VBD||expression-17/NN	num||mirnas-21/NNS||723-19/CD	amod||mirnas-21/NNS||human-20/JJ	prep_of||expression-17/NN||mirnas-21/NNS	advmod||mirnas-21/NNS||before-22/RB	advmod||mirnas-21/NNS||5-days-24/JJ	conj_and||before-22/RB||5-days-24/JJ	amod||mono-therapy-27/NN||fludarabine-26/JJ	prep_after||5-days-24/JJ||mono-therapy-27/NN	num||patients-31/NNS||17-29/CD	nn||patients-31/NNS||cll-30/NN	prep_in||analyzed-15/VBD||patients-31/NNS	nsubjpass||classified-34/VBN||patients-31/NNS	nsubj||fludarabine-40/VB||patients-31/NNS	auxpass||classified-34/VBN||were-33/VBD	rcmod||patients-31/NNS||classified-34/VBN	prep_as||classified-34/VBN||responder-36/NN	prep_as||classified-34/VBN||refractory-38/NN	conj_or||responder-36/NN||refractory-38/NN	aux||fludarabine-40/VB||to-39/TO	xcomp||classified-34/VBN||fludarabine-40/VB	dobj||fludarabine-40/VB||treatment-41/NN	prepc_based_on||fludarabine-40/VB||on-43/IN	nn||criteria-45/NNS||nci-44/NN	pobj||fludarabine-40/VB||criteria-45/NNS	cll-30||fludarabine-40||yes||to elucidate whether micrornas are involved in the development of fludarabine resistance, we analyzed the expression of 723 human mirnas before and 5-days after fludarabine mono-therapy in 17 cll patients which were classified as responder or refractory to fludarabine treatment based on nci criteria.
nsubj||represents-10/VBZ||mycobacteriumtuberculosis-1/NNS	det||agent-5/NN||the-3/DT	amod||agent-5/NN||causative-4/JJ	appos||mycobacteriumtuberculosis-1/NNS||agent-5/NN	prep_of||agent-5/NN||tuberculosis-7/NNP	advmod||represents-10/VBZ||still-9/RB	root||ROOT-0/null||represents-10/VBZ	det||threat-15/NN||a-11/DT	amod||threat-15/NN||major-12/JJ	amod||threat-15/NN||public-13/JJ	nn||threat-15/NN||health-14/NN	dobj||represents-10/VBZ||threat-15/NN	amod||countries-18/NNS||many-17/JJ	prep_in||threat-15/NN||countries-18/NNS	tuberculosis-7||mycobacteriumtuberculosis-1||no||mycobacteriumtuberculosis , the causative agent of tuberculosis, still represents a major public health threat in many countries.
nn||levels-2/NNS||glucagon-1/NN	nsubj||remained-3/VBD||levels-2/NNS	root||ROOT-0/null||remained-3/VBD	acomp||remained-3/VBD||suppressed-4/VBN	det||decrease-7/NN||a-6/DT	prep_following||suppressed-4/VBN||decrease-7/NN	amod||insulin-10/NN||zinc-free-9/JJ	prep_in||decrease-7/NN||insulin-10/NN	prep_in||decrease-7/NN||insulin-10/NN	conj_and||insulin-10/NN||insulin-10/NN	prep_with||insulin-10/NN||euglycemia-12/NN	dep||insulin-10/NN||â-14/VB	num||±-17/NN||14-15/CD	nn||±-17/NN||â-16/NN	nsubj||-LSB--20/VBG||±-17/NN	number||pg/ml-19/JJ||3-18/CD	dep||-LSB--20/VBG||pg/ml-19/JJ	xcomp||â-14/VB||-LSB--20/VBG	poss||-RSB--28/NN||â-21/NNP	number||â-24/CD||4.0-23/CD	num||-RSB--28/NN||â-24/CD	nn||-RSB--28/NN||±-25/NN	num||-RSB--28/NN||0.9-26/CD	nn||-RSB--28/NN||pmol/l-27/NN	dobj||-LSB--20/VBG||-RSB--28/NN	amod||hyperinsulinemia-33/NN||sustained-32/VBN	prep_during||insulin-10/NN||hyperinsulinemia-33/NN	prep_with||hyperinsulinemia-33/NN||hypoglycemia-35/NN	nn||±-40/NN||â-37/NN	num||±-40/NN||14-38/CD	nn||±-40/NN||â-39/NN	dep||hypoglycemia-35/NN||±-40/NN	num||-LSB--43/NNS||2-41/CD	amod||-LSB--43/NNS||pg/ml-42/JJ	dep||±-40/NN||-LSB--43/NNS	poss||-RSB--51/NN||â-44/NNP	amod||-RSB--51/NN||4.0-46/JJ	nn||-RSB--51/NN||â-47/NN	nn||-RSB--51/NN||±-48/NN	num||-RSB--51/NN||0.6-49/CD	amod||-RSB--51/NN||pmol/l-50/JJ	dep||-LSB--43/NNS||-RSB--51/NN	acomp||remained-3/VBD||increased-54/VBN	conj_but||suppressed-4/VBN||increased-54/VBN	poss||pg/ml-62/NN||â-56/NNP	number||â-59/CD||3-58/CD	num||pg/ml-62/NN||â-59/CD	amod||pg/ml-62/NN||±-60/JJ	num||pg/ml-62/NN||3-61/CD	prep_to||increased-54/VBN||pg/ml-62/NN	poss||â-67/NN||â-64/NNP	num||â-67/NN||0.9-66/CD	npadvmod||pmol/l-70/JJ||â-67/NN	number||0.9-69/CD||±-68/CD	num||â-67/NN||0.9-69/CD	dep||pg/ml-62/NN||pmol/l-70/JJ	parataxis||increased-54/VBN||p-73/VB	num||0.01-75/CD||<-74/CD	dobj||p-73/VB||0.01-75/CD	det||decrease-79/NN||a-78/DT	prep_following||increased-54/VBN||decrease-79/NN	amod||insulin-82/NN||zinc-free-81/JJ	prep_in||decrease-79/NN||insulin-82/NN	prep_with||insulin-82/NN||hypoglycemia-84/NN	det||min-89/NNS||the-86/DT	amod||min-89/NNS||next-87/JJ	num||min-89/NNS||120-88/CD	prep_over||hypoglycemia-84/NN||min-89/NNS	hypoglycemia-84||glucagon-1||yes||glucagon levels remained suppressed following a decrease in zinc-free insulin with euglycemia (â14 â± 3 pg/ml [â4.0 â± 0.9 pmol/l]) and during sustained hyperinsulinemia with hypoglycemia (â14 â± 2 pg/ml [â4.0 â± 0.6 pmol/l]) but increased to â3 â± 3 pg/ml (â0.9 â± 0.9 pmol/l) ( p < 0.01) following a decrease in zinc-free insulin with hypoglycemia over the next 120 min.
nsubj||mediated-11/JJ||damage-1/NN	amod||mucosa-4/NN||intestinal-3/JJ	prep_to||damage-1/NN||mucosa-4/NN	prep_in||mucosa-4/NN||celiacdisease-6/NN	appos||damage-1/NN||cd-8/NN	cop||mediated-11/JJ||is-10/VBZ	root||ROOT-0/null||mediated-11/JJ	preconj||mediated-11/JJ||both-12/DT	prep_by||mediated-11/JJ||inflammation-14/NN	amod||inflammation-14/NN||due-15/JJ	aux||adaptive-17/VB||to-16/TO	xcomp||due-15/JJ||adaptive-17/VB	xcomp||due-15/JJ||innate-19/VB	conj_and||adaptive-17/VB||innate-19/VB	amod||responses-21/NNS||immune-20/JJ	dobj||adaptive-17/VB||responses-21/NNS	prep_with||responses-21/NNS||il-15-24/CD	det||mediator-28/NN||a-26/DT	amod||mediator-28/NN||major-27/JJ	prep_as||adaptive-17/VB||mediator-28/NN	det||response-33/NN||the-30/DT	amod||response-33/NN||innate-31/JJ	amod||response-33/NN||immune-32/JJ	prep_of||mediator-28/NN||response-33/NN	nsubj||causing-48/VBG||proliferation-37/NN	amod||enterocytes-40/NNS||crypt-39/JJ	prep_of||proliferation-37/NN||enterocytes-40/NNS	det||alteration-44/NN||an-42/DT	amod||alteration-44/NN||early-43/JJ	prep_as||enterocytes-40/NNS||alteration-44/NN	nn||mucosa-47/NN||cd-46/NN	prep_of||alteration-44/NN||mucosa-47/NN	prep_by||mediated-11/JJ||causing-48/VBG	conj_and||inflammation-14/NN||causing-48/VBG	amod||hyperplasia-50/NN||crypts-49/JJ	dobj||causing-48/VBG||hyperplasia-50/NN	cd-46||inflammation-14||no_rel||damage to intestinal mucosa in celiacdisease (cd) is mediated both by inflammation due to adaptive and innate immune responses, with il-15 as a major mediator of the innate immune response, and by proliferation of crypt enterocytes as an early alteration of cd mucosa causing crypts hyperplasia.
aux||address-2/VB||to-1/TO	root||ROOT-0/null||address-2/VB	det||problems-5/NNS||the-3/DT	amod||problems-5/NNS||long-term-4/JJ	dobj||address-2/VB||problems-5/NNS	nn||wear-9/NN||bearing-7/NN	nn||wear-9/NN||surface-8/NN	prep_of||problems-5/NNS||wear-9/NN	prep_of||problems-5/NNS||osteolysis-11/NNS	conj_and||wear-9/NN||osteolysis-11/NNS	vmod||osteolysis-11/NNS||associated-12/VBN	amod||metal-polyethylene-15/NN||conventional-14/JJ	prep_with||associated-12/VBN||metal-polyethylene-15/NN	dep||metal-polyethylene-15/NN||m-pe-17/JJ	amod||arthroplasty-21/NN||total-19/JJ	nn||arthroplasty-21/NN||hip-20/NN	dep||metal-polyethylene-15/NN||arthroplasty-21/NN	appos||metal-polyethylene-15/NN||tha-23/NN	appos||metal-polyethylene-15/NN||metal-metal-26/NN	appos||metal-metal-26/NN||m-m-28/NNP	amod||bearings-36/NNS||ceramic-ceramic-32/JJ	appos||bearings-36/NNS||c-c-34/NNP	nsubjpass||introduced-39/VBN||bearings-36/NNS	aux||introduced-39/VBN||have-37/VBP	auxpass||introduced-39/VBN||been-38/VBN	conj_and||address-2/VB||introduced-39/VBN	osteolysis-11||metal--1||no_rel||to address the long-term problems of bearing surface wear and osteolysis associated with conventional metal-polyethylene (m-pe) total hip arthroplasty (tha), metal-metal (m-m), and ceramic-ceramic (c-c) bearings have been introduced.
aux||investigate-2/VB||to-1/TO	advcl||tested-43/VBD||investigate-2/VB	det||occurrence-5/NN||the-3/DT	amod||occurrence-5/NN||possible-4/JJ	dobj||investigate-2/VB||occurrence-5/NN	iobj||investigate-2/VB||occurrence-5/NN	prep_of||occurrence-5/NN||humanimmunodeficiencyvirus-7/NNS	appos||humanimmunodeficiencyvirus-7/NNS||hiv-9/NN	amod||virus-15/NN||human-12/JJ	amod||virus-15/NN||t-cell-13/JJ	amod||virus-15/NN||lymphotropic-14/JJ	prep_of||occurrence-5/NN||virus-15/NN	conj_or||humanimmunodeficiencyvirus-7/NNS||virus-15/NN	nn||i-18/NNS||type-17/NN	appos||virus-15/NN||i-18/NNS	appos||occurrence-5/NN||htlv-i-20/NNP	dep||occurrence-5/NN||infections-22/NNS	det||states-26/NNS||the-24/DT	amod||states-26/NNS||united-25/VBN	prep_in||infections-22/NNS||states-26/NNS	prep_prior_to||investigate-2/VB||1979-1981-29/CD	advmod||recognized-40/VBN||when-31/WRB	amod||syndrome-34/NN||acquired-32/VBN	amod||syndrome-34/NN||immunedeficiency-33/JJ	nsubjpass||recognized-40/VBN||syndrome-34/NN	appos||syndrome-34/NN||aids-36/NNS	auxpass||recognized-40/VBN||was-38/VBD	advmod||recognized-40/VBN||first-39/RB	advcl||investigate-2/VB||recognized-40/VBN	nsubj||tested-43/VBD||we-42/PRP	root||ROOT-0/null||tested-43/VBD	dobj||tested-43/VBD||sera-44/NN	amod||women-48/NNS||310-46/JJ	amod||women-48/NNS||pregnant-47/JJ	prep_from||tested-43/VBD||women-48/NNS	nsubj||participated-50/VBD||women-48/NNS	rcmod||women-48/NNS||participated-50/VBD	det||project-55/NN||the-52/DT	amod||project-55/NN||collaborative-53/JJ	amod||project-55/NN||perinatal-54/JJ	prep_in||participated-50/VBD||project-55/NN	det||1959-1964-59/NN||the-57/DT	nn||1959-1964-59/NN||period-58/NN	prep_during||participated-50/VBD||1959-1964-59/NN	prep_for||1959-1964-59/NN||hiv-61/NN	prep_for||1959-1964-59/NN||htlv-iantibody-63/NN	conj_and||hiv-61/NN||htlv-iantibody-63/NN	aids-36||humanimmunodeficiencyvirus-7||no||to investigate the possible occurrence of humanimmunodeficiencyvirus (hiv) or human t-cell lymphotropic virus, type i (htlv-i) infections in the united states prior to 1979-1981, when acquired immunedeficiency syndrome (aids) was first recognized, we tested sera from 310 pregnant women who participated in the collaborative perinatal project during the period 1959-1964 for hiv and htlv-iantibody.
amod||factors-3/NNS||numerous-1/JJ	nn||factors-3/NNS||risk-2/NN	nsubjpass||established-11/VBN||factors-3/NNS	det||development-6/NN||the-5/DT	prep_for||factors-3/NNS||development-6/NN	prep_of||development-6/NN||gout-8/NN	aux||established-11/VBN||have-9/VBP	auxpass||established-11/VBN||been-10/VBN	root||ROOT-0/null||established-11/VBN	prep_including||established-11/VBN||hyperuricaemia-14/NN	amod||factors-17/NNS||genetic-16/JJ	prep_including||established-11/VBN||factors-17/NNS	conj_and||hyperuricaemia-14/NN||factors-17/NNS	amod||factors-20/NNS||dietary-19/JJ	prep_including||established-11/VBN||factors-20/NNS	conj_and||hyperuricaemia-14/NN||factors-20/NNS	nn||consumption-23/NN||alcohol-22/NN	prep_including||established-11/VBN||consumption-23/NN	conj_and||hyperuricaemia-14/NN||consumption-23/NN	amod||syndrome-26/NN||metabolic-25/JJ	prep_including||established-11/VBN||syndrome-26/NN	conj_and||hyperuricaemia-14/NN||syndrome-26/NN	prep_including||established-11/VBN||hypertension-28/NN	conj_and||hyperuricaemia-14/NN||hypertension-28/NN	prep_including||established-11/VBN||obesity-30/NN	conj_and||hyperuricaemia-14/NN||obesity-30/NN	amod||use-33/NN||diuretic-32/JJ	prep_including||established-11/VBN||use-33/NN	conj_and||hyperuricaemia-14/NN||use-33/NN	prep_including||established-11/VBN||chronicrenaldisease-35/NN	conj_and||hyperuricaemia-14/NN||chronicrenaldisease-35/NN	alcohol-22||chronicrenaldisease-35||no_rel||numerous risk factors for the development of gout have been established, including hyperuricaemia, genetic factors, dietary factors, alcohol consumption, metabolic syndrome, hypertension, obesity, diuretic use and chronicrenaldisease.
amod||analyses-5/NNS||classical-1/JJ	conj_and||classical-1/JJ||quantitative-3/JJ	amod||analyses-5/NNS||quantitative-3/JJ	nn||analyses-5/NNS||linkage-4/NN	nsubjpass||used-12/VBN||analyses-5/NNS	amod||crosses-8/NNS||genetic-7/JJ	prep_of||analyses-5/NNS||crosses-8/NNS	aux||used-12/VBN||have-9/VBP	advmod||used-12/VBN||traditionally-10/RB	auxpass||used-12/VBN||been-11/VBN	root||ROOT-0/null||used-12/VBN	nn||genes-15/NNS||map-14/NN	prep_to||used-12/VBN||genes-15/NNS	prep_of||genes-15/NNS||interest-17/NN	prep_such_as||genes-15/NNS||those-21/DT	vmod||those-21/DT||conferring-22/VBG	amod||resistance-26/NN||chloroquine-23/JJ	conj_or||chloroquine-23/JJ||quinine-25/JJ	amod||resistance-26/NN||quinine-25/JJ	dobj||conferring-22/VBG||resistance-26/NN	nn||parasites-29/NNS||malaria-28/NN	prep_in||resistance-26/NN||parasites-29/NNS	malaria-28||chloroquine-23||yes||classical and quantitative linkage analyses of genetic crosses have traditionally been used to map genes of interest, such as those conferring chloroquine or quinine resistance in malaria parasites.
det||varicellazostervirus-2/NNS||the-1/DT	nsubj||alpha-herpesvirus-10/NNS||varicellazostervirus-2/NNS	appos||varicellazostervirus-2/NNS||vzv-4/NN	cop||alpha-herpesvirus-10/NNS||is-6/VBZ	det||alpha-herpesvirus-10/NNS||a-7/DT	amod||alpha-herpesvirus-10/NNS||ubiquitous-8/JJ	amod||alpha-herpesvirus-10/NNS||human-9/JJ	root||ROOT-0/null||alpha-herpesvirus-10/NNS	nsubj||agent-15/NN||alpha-herpesvirus-10/NNS	cop||agent-15/NN||is-12/VBZ	det||agent-15/NN||the-13/DT	amod||agent-15/NN||causative-14/JJ	rcmod||alpha-herpesvirus-10/NNS||agent-15/NN	prep_of||agent-15/NN||chickenpox-17/NN	prep_of||agent-15/NN||shingles-19/NNS	conj_and||chickenpox-17/NN||shingles-19/NNS	chickenpox-17||varicellazostervirus-2||yes||the varicellazostervirus (vzv) is a ubiquitous human alpha-herpesvirus that is the causative agent of chickenpox and shingles.
nsubj||reviewed-3/VBN||we-1/PRP	advmod||reviewed-3/VBN||briefly-2/RB	root||ROOT-0/null||reviewed-3/VBN	det||evidence-5/NN||the-4/DT	dobj||reviewed-3/VBN||evidence-5/NN	det||association-8/NN||the-7/DT	prep_on||evidence-5/NN||association-8/NN	amod||infection-14/NN||hepatitisc-10/JJ	appos||infection-14/NN||hcv-12/NN	prep_of||association-8/NN||infection-14/NN	amod||aspects-17/NNS||several-16/JJ	prep_with||infection-14/NN||aspects-17/NNS	amod||health-22/NN||mental-19/JJ	conj_and||mental-19/JJ||psychosocial-21/JJ	amod||health-22/NN||psychosocial-21/JJ	prep_of||aspects-17/NNS||health-22/NN	hepatitisc-10||hcv-12||no||we briefly reviewed the evidence on the association of hepatitisc (hcv) infection with several aspects of mental and psychosocial health.
nn||methods-2/NNS||review-1/NN	nsubj||randomised-3/VBD||methods-2/NNS	root||ROOT-0/null||randomised-3/VBD	amod||trials-5/NNS||controlled-4/JJ	nsubj||eligible-23/JJ||trials-5/NNS	vmod||trials-5/NNS||comparing-6/VBG	dobj||comparing-6/VBG||fibre-7/NN	dobj||comparing-6/VBG||antispasmodics-9/NN	conj_and||fibre-7/NN||antispasmodics-9/NN	dobj||comparing-6/VBG||peppermintoil-12/NN	conj_and||fibre-7/NN||peppermintoil-12/NN	prep_with||comparing-6/VBG||placebo-14/NN	neg||treatment-17/NN||no-16/DT	prep_with||comparing-6/VBG||treatment-17/NN	conj_or||placebo-14/NN||treatment-17/NN	prep_in||comparing-6/VBG||adults-19/NNS	prep_with||adults-19/NNS||irritablebowelsyndrome-21/NN	cop||eligible-23/JJ||were-22/VBD	ccomp||randomised-3/VBD||eligible-23/JJ	prep_for||eligible-23/JJ||inclusion-25/NN	antispasmodics-9||irritablebowelsyndrome-21||no_rel||review methods randomised controlled trials comparing fibre, antispasmodics, and peppermintoil with placebo or no treatment in adults with irritablebowelsyndrome were eligible for inclusion.
nsubj||identified-2/VBD||we-1/PRP	root||ROOT-0/null||identified-2/VBD	num||individuals-4/NNS||425-3/CD	dobj||identified-2/VBD||individuals-4/NNS	vmod||individuals-4/NNS||divided-6/VBN	num||categories-9/NNS||seven-8/CD	prep_into||divided-6/VBN||categories-9/NNS	prepc_according_to||divided-6/VBN||to-11/TO	amod||status-14/NN||carbohydrate-12/JJ	nn||status-14/NN||metabolism-13/NN	pobj||divided-6/VBN||status-14/NN	amod||-RSB--21/NNP||normal-16/JJ	nn||-RSB--21/NNP||glucose-17/NN	nn||-RSB--21/NNP||tolerance-18/NN	nn||-RSB--21/NNP||-LSB--19/NNP	nn||-RSB--21/NNP||ngt-20/FW	dep||individuals-4/NNS||-RSB--21/NNP	amod||glucose-25/NN||impaired-23/VBN	amod||glucose-25/NN||fasting-24/JJ	appos||-RSB--21/NNP||glucose-25/NN	nn||-RSB--30/FW||impairedglucosetolerance-27/FW	nn||-RSB--30/FW||-LSB--28/FW	nn||-RSB--30/FW||igt-29/FW	appos||glucose-25/NN||-RSB--30/FW	advmod||diagnosed-34/VBN||newly-33/RB	amod||type2diabetes-35/NNS||diagnosed-34/VBN	appos||-RSB--21/NNP||type2diabetes-35/NNS	conj_and||glucose-25/NN||type2diabetes-35/NNS	nn||duration-39/NN||diabetes-38/NN	dobj||identified-2/VBD||duration-39/NN	conj_and||individuals-4/NNS||duration-39/NN	dep||duration-39/NN||0â-41/VBN	dobj||0â-41/VBN||$-42/$	num||$-42/$||9-44/CD	amod||$-47/$||10â-46/JJ	appos||$-42/$||$-47/$	num||$-47/$||19-49/CD	amod||-53/NNS||â-52/JJ	appos||$-42/$||-53/NNS	conj_and||$-47/$||-53/NNS	dep||years-56/NNS||¥-54/SYM	num||years-56/NNS||20-55/CD	dep||0â-41/VBN||years-56/NNS	impairedglucosetolerance-27||glucose-25||no_rel||we identified 425 individuals, divided into seven categories according to carbohydrate metabolism status (normal glucose tolerance [ngt], impaired fasting glucose, impairedglucosetolerance [igt], and newly diagnosed type2diabetes) and diabetes duration (0â9, 10â19, and â¥20 years).
nsubj||reduced-2/VBD||bumetanide-1/NN	root||ROOT-0/null||reduced-2/VBD	advmod||reduced-2/VBD||significantly-3/RB	det||scale-8/NN||the-4/DT	nn||scale-8/NN||childhood-5/NN	nn||scale-8/NN||autism-6/NN	nn||scale-8/NN||rating-7/NN	dobj||reduced-2/VBD||scale-8/NN	appos||scale-8/NN||cars-10/NNS	num||'d-14/NNP||d90â-13/CD	dep||scale-8/NN||'d-14/NNP	num||'d-14/NNP||0-15/CD	nn||<-18/NNS||p-17/NN	dep||'d-14/NNP||<-18/NNS	num||placebo-22/NN||0.004-19/CD	amod||placebo-22/NN||treated-20/JJ	nn||placebo-22/NN||vs-21/NN	dep||<-18/NNS||placebo-22/NN	amod||impressions-27/NNS||clinical-25/JJ	amod||impressions-27/NNS||global-26/JJ	dobj||reduced-2/VBD||impressions-27/NNS	dep||impressions-27/NNS||p-29/VBN	number||0.017-31/CD||<-30/CD	dobj||p-29/VBN||0.017-31/CD	vmod||0.017-31/CD||treated-32/VBN	nn||placebo-34/NN||vs-33/NN	dobj||treated-32/VBN||placebo-34/NN	num||values-41/NNS||autism-37/CD	amod||values-41/NNS||diagnostic-38/JJ	nn||values-41/NNS||observation-39/NN	nn||values-41/NNS||schedule-40/NN	dobj||reduced-2/VBD||values-41/NNS	conj_and||impressions-27/NNS||values-41/NNS	tmod||removed-61/VBN||values-41/NNS	advmod||removed-61/VBN||when-42/WRB	det||cases-46/NNS||the-43/DT	advmod||severe-45/JJ||most-44/RBS	amod||cases-46/NNS||severe-45/JJ	nsubjpass||removed-61/VBN||cases-46/NNS	dep||cases-46/NNS||cars-48/NNS	dep||cars-48/NNS||values-49/NNS	det||s.d.-54/NNP||the-51/DT	nn||s.d.-54/NNP||meanâ-52/NNP	nn||s.d.-54/NNP||±-53/NNP	prep_above||values-49/NNS||s.d.-54/NNP	dep||values-49/NNS||n-56/NN	dep||9-58/CD||=-57/SYM	rcmod||n-56/NN||9-58/CD	auxpass||removed-61/VBN||were-60/VBD	rcmod||values-41/NNS||removed-61/VBN	nn||p-65/NN||wilcoxon-63/NN	nn||p-65/NN||test-64/NN	dep||values-41/NNS||p-65/NN	dep||p-65/NN||value-67/NN	dep||0.031-69/CD||=-68/SYM	rcmod||value-67/NN||0.031-69/CD	poss||t-73/NN||student-71/NN	dep||value-67/NN||t-73/NN	dep||t-73/NN||test-75/NN	dep||test-75/NN||p-76/NN	dep||value-67/NN||value-78/NN	dep||0.017-80/CD||=-79/SYM	rcmod||value-78/NN||0.017-80/CD	autism-37||bumetanide-1||no_rel||bumetanide reduced significantly the childhood autism rating scale (cars) (d90âd0; p <0.004 treated vs placebo), clinical global impressions ( p <0.017 treated vs placebo) and autism diagnostic observation schedule values when the most severe cases (cars values above the meanâ±s.d.; n =9) were removed (wilcoxon test p -value=0.031; student's t -test p -value=0.017).
nn||care-2/NN||hiv-1/NN	nsubj||provide-6/VBP||care-2/NN	nn||settings-5/NNS||treatment-4/NN	conj_and||care-2/NN||settings-5/NNS	nsubj||provide-6/VBP||settings-5/NNS	root||ROOT-0/null||provide-6/VBP	det||opportunity-8/NN||an-7/DT	dobj||provide-6/VBP||opportunity-8/NN	nsubj||reach-10/VB||opportunity-8/NN	aux||reach-10/VB||to-9/TO	xcomp||provide-6/VBP||reach-10/VB	dobj||reach-10/VB||people-11/NNS	vmod||people-11/NNS||living-12/VBG	prep_with||living-12/VBG||hiv/aids-14/NNS	appos||hiv/aids-14/NNS||plhiv-16/NNP	nn||messages-20/NNS||prevention-19/NN	prep_with||hiv/aids-14/NNS||messages-20/NNS	prep_with||hiv/aids-14/NNS||services-22/NNS	conj_and||messages-20/NNS||services-22/NNS	aids--1||hiv-1||no||hiv care and treatment settings provide an opportunity to reach people living with hiv/aids (plhiv) with prevention messages and services.
nsubj||did-3/VBD||we-1/PRP	nsubj||analysed-17/VBD||we-1/PRP	advmod||did-3/VBD||also-2/RB	root||ROOT-0/null||did-3/VBD	nn||analyses-5/NNS||follow-up-4/NN	dobj||did-3/VBD||analyses-5/NNS	det||control-9/NN||the-7/DT	amod||control-9/NN||genetic-8/JJ	prep_of||analyses-5/NNS||control-9/NN	det||phenotype-13/NN||the-11/DT	amod||phenotype-13/NN||clinical-12/JJ	prep_of||control-9/NN||phenotype-13/NN	prep_of||phenotype-13/NN||priondisease-15/NN	conj_and||did-3/VBD||analysed-17/VBD	nn||expression-20/NN||candidate-18/NN	nn||expression-20/NN||gene-19/NN	dobj||analysed-17/VBD||expression-20/NN	det||model-25/NN||a-22/DT	nn||model-25/NN||mouse-23/NN	amod||model-25/NN||cellular-24/JJ	prep_in||expression-20/NN||model-25/NN	nn||infection-28/NN||prion-27/NN	prep_of||model-25/NN||infection-28/NN	priondisease-15||prion-27||no||we also did follow-up analyses of the genetic control of the clinical phenotype of priondisease and analysed candidate gene expression in a mouse cellular model of prion infection.
amod||receptor-18/NN||immunostains-1/JJ	prep_for||immunostains-1/JJ||cytokeratins-3/NNS	appos||cytokeratins-3/NNS||ck-5/NN	dep||immunostains-1/JJ||5/6-7/CD	num||5/6-7/CD||14-9/CD	num||5/6-7/CD||8-11/CD	dep||immunostains-1/JJ||18-13/CD	conj_and||5/6-7/CD||18-13/CD	amod||receptor-18/NN||epidermal-15/JJ	nn||receptor-18/NN||growth-16/NN	nn||receptor-18/NN||factor-17/NN	nsubjpass||performed-22/VBN||receptor-18/NN	conj_and||receptor-18/NN||p53-20/NN	nsubjpass||performed-22/VBN||p53-20/NN	auxpass||performed-22/VBN||were-21/VBD	root||ROOT-0/null||performed-22/VBN	nn||sections-25/NNS||paraffin-24/NN	prep_on||performed-22/VBN||sections-25/NNS	nn||microarrays-28/NNS||tissue-27/NN	prep_from||performed-22/VBN||microarrays-28/NNS	vmod||microarrays-28/NNS||containing-29/VBG	det||cancers-31/NNS||these-30/DT	dobj||containing-29/VBG||cancers-31/NNS	cancers-31||paraffin-24||no_rel||immunostains for cytokeratins (ck) 5/6, 14, 8 and 18, epidermal growth factor receptor and p53 were performed on paraffin sections from tissue microarrays containing these cancers.
advmod||2006-11/VB||consecutively-1/RB	csubj||2006-11/VB||admitted-2/VBN	dobj||admitted-2/VBN||patients-3/NNS	det||period-6/NN||the-5/DT	prep_during||admitted-2/VBN||period-6/NN	tmod||admitted-2/VBN||august-7/NNP	num||august-7/NNP||2005-8/CD	prep||admitted-2/VBN||to-9/TO	aux||2006-11/VB||may-10/MD	root||ROOT-0/null||2006-11/VB	det||center-15/NN||the-14/DT	prep_in||recruited-41/VBN||center-15/NN	nn||psychiatry-18/NN||addiction-17/NN	prep_for||center-15/NN||psychiatry-18/NN	amod||institute-21/NN||central-20/JJ	nsubjpass||recruited-41/VBN||institute-21/NN	nsubjpass||administered-46/VBN||institute-21/NN	nn||india-27/NN||psychiatry-23/NN	dep||india-27/NN||ranchi-25/NN	prep_of||institute-21/NN||india-27/NN	amod||diagnosis-34/NN||icd-10-30/JJ	appos||diagnosis-34/NN||dcr-32/NN	prep_with||india-27/NN||diagnosis-34/NN	amod||syndrome-39/NN||alcoholdependencesyndrome-36/JJ	conj_or||alcoholdependencesyndrome-36/JJ||opioiddependence-38/JJ	amod||syndrome-39/NN||opioiddependence-38/JJ	prep_of||diagnosis-34/NN||syndrome-39/NN	auxpass||recruited-41/VBN||were-40/VBD	ccomp||2006-11/VB||recruited-41/VBN	conj_and||2006-11/VB||recruited-41/VBN	det||study-44/NN||the-43/DT	prep_for||recruited-41/VBN||study-44/NN	ccomp||2006-11/VB||administered-46/VBN	conj_and||2006-11/VB||administered-46/VBN	conj_and||recruited-41/VBN||administered-46/VBN	det||drug-51/NN||the-47/DT	nn||drug-51/NN||alcohol-48/NN	conj_or||alcohol-48/NN||other-50/JJ	nn||drug-51/NN||other-50/JJ	dobj||administered-46/VBN||drug-51/NN	dep||drug-51/NN||opioid-53/JJ	punct||drug-51/NN||section-55/,	prep_of||drug-51/NN||ssaga-ii-57/NN	advmod||ssaga-ii-57/NN||respectively-59/RB	det||data-63/NNS||the-62/DT	nsubjpass||entered-65/VBN||data-63/NNS	auxpass||entered-65/VBN||was-64/VBD	conj_and||2006-11/VB||entered-65/VBN	det||sheet-70/NN||the-67/DT	amod||sheet-70/NN||corresponding-68/JJ	nn||sheet-70/NN||tally-69/NN	prep_in||entered-65/VBN||sheet-70/NN	opioiddependence-38||opioid-53||no||consecutively admitted patients during the period august 2005 to may 2006, in the center for addiction psychiatry, central institute of psychiatry, ranchi, india, with icd-10 (dcr) diagnosis of alcoholdependencesyndrome or opioiddependence syndrome were recruited for the study and administered the alcohol or other drug (opioid) section of ssaga-ii, respectively, and the data was entered in the corresponding tally sheet.
advmod||investigated-4/VBD||additionally-1/RB	nsubj||investigated-4/VBD||we-3/PRP	root||ROOT-0/null||investigated-4/VBD	det||role-6/NN||the-5/DT	dobj||investigated-4/VBD||role-6/NN	amod||mice-39/NNS||nf-îºb-8/JJ	nn||infection-11/NN||prion-10/NN	prep_after||nf-îºb-8/JJ||infection-11/NN	amod||â-14/NN||nfkb1-13/JJ	prep_of||infection-11/NN||â-14/NN	amod||mice-39/NNS||$-15/$	punct||$-19/$||/-17/:	dep||$-19/$||â-18/PRP	dep||$-15/$||$-19/$	amod||â-23/NN||nfkb2-22/JJ	dep||$-19/$||â-23/NN	dep||â-23/NN||$-24/$	punct||â-23/NN||/-26/:	dep||â-23/NN||â-27/NN	dep||â-27/NN||$-28/$	amod||â-32/NN||bcl3-31/JJ	dep||â-23/NN||â-32/NN	conj_and||â-27/NN||â-32/NN	dep||â-32/NN||$-33/$	punct||$-19/$||/-35/:	nn||mice-39/NNS||â-36/NN	amod||mice-39/NNS||$-37/$	prep_of||role-6/NN||mice-39/NNS	amod||mice-45/NNS||central-41/JJ	amod||system-specific-43/JJ||nervous-42/JJ	amod||mice-45/NNS||system-specific-43/JJ	amod||mice-45/NNS||p65-deleted-44/JJ	prep_of||role-6/NN||mice-45/NNS	conj_and||mice-39/NNS||mice-45/NNS	vmod||role-6/NN||revealing-46/VBG	det||priondisease-49/NN||an-47/DT	amod||priondisease-49/NN||accelerated-48/VBN	dobj||revealing-46/VBG||priondisease-49/NN	amod||mice-55/NNS||nf-îºb2-51/JJ	conj_and||nf-îºb2-51/JJ||bcl-3-deficient-54/JJ	amod||mice-55/NNS||bcl-3-deficient-54/JJ	prep_in||revealing-46/VBG||mice-55/NNS	nsubj||is-58/VBZ||mice-55/NNS	rcmod||mice-55/NNS||is-58/VBZ	prep_in||is-58/VBZ||line-60/NN	det||activity-65/NN||a-62/DT	amod||activity-65/NN||reduced-63/VBN	nn||activity-65/NN||neuroprotective-64/NN	prep_with||is-58/VBZ||activity-65/NN	nn||infection-68/NN||prion-67/NN	prep_in||activity-65/NN||infection-68/NN	priondisease-49||prion-67||no||additionally, we investigated the role of nf-îºb after prion infection of nfkb1 â/â, nfkb2 â/â and bcl3 â/â mice and central nervous system-specific p65-deleted mice revealing an accelerated priondisease in nf-îºb2- and bcl-3-deficient mice, which is in line with a reduced neuroprotective activity in prion infection.
det||kits-5/NNS||the-1/DT	num||kits-5/NNS||70-2/CD	amod||kits-5/NNS||hbsag-3/JJ	nn||kits-5/NNS||test-4/NN	nsubjpass||evaluated-11/VBN||kits-5/NNS	advmod||world-9/NN||around-7/RB	det||world-9/NN||the-8/DT	prep_from||kits-5/NNS||world-9/NN	auxpass||evaluated-11/VBN||were-10/VBD	root||ROOT-0/null||evaluated-11/VBN	amod||a-f-56/NNS||comparatively-12/RB	poss||sensitivity-16/NN||their-14/PRP$	amod||sensitivity-16/NN||clinical-15/JJ	prep_for||comparatively-12/RB||sensitivity-16/NN	amod||sensitivity-19/NN||analytical-18/JJ	prep_for||comparatively-12/RB||sensitivity-19/NN	conj_and||sensitivity-16/NN||sensitivity-19/NN	prep_for||comparatively-12/RB||sensitivity-21/NN	conj_and||sensitivity-16/NN||sensitivity-21/NN	nn||genotypes-24/NNS||hbv-23/NN	prep_to||sensitivity-21/NN||genotypes-24/NNS	nn||subtypes-27/NNS||hbsag-26/NN	prep_to||sensitivity-21/NN||subtypes-27/NNS	conj_and||genotypes-24/NNS||subtypes-27/NNS	prep_for||comparatively-12/RB||specificity-30/NN	conj_and||sensitivity-16/NN||specificity-30/NN	vmod||specificity-30/NN||using-31/VBG	amod||icbs-43/NNS||394-32/JJ	num||clinical-35/NNS||146-34/CD	dep||icbs-43/NNS||clinical-35/NNS	num||analytical-38/NNS||48-37/CD	conj_and||clinical-35/NNS||analytical-38/NNS	dep||icbs-43/NNS||analytical-38/NNS	num||negative-41/NN||200-40/CD	conj_and||clinical-35/NNS||negative-41/NN	dep||icbs-43/NNS||negative-41/NN	dobj||using-31/VBG||icbs-43/NNS	nn||members-46/NNS||master-44/NN	nn||members-46/NNS||panel-45/NN	dep||specificity-30/NN||members-46/NNS	amod||origin-50/NN||diverse-48/JJ	amod||origin-50/NN||geographical-49/JJ	prep_of||members-46/NNS||origin-50/NN	vmod||origin-50/NN||comprising-51/VBG	det||genotypes-55/NNS||the-52/DT	amod||genotypes-55/NNS||major-53/JJ	nn||genotypes-55/NNS||hbv-54/NN	dobj||comprising-51/VBG||genotypes-55/NNS	dobj||evaluated-11/VBN||a-f-56/NNS	det||subtypes-60/NNS||the-58/DT	amod||subtypes-60/NNS||hbsag-59/VBG	dobj||evaluated-11/VBN||subtypes-60/NNS	conj_and||a-f-56/NNS||subtypes-60/NNS	amod||subtypes-60/NNS||adw2-61/JJ	dep||adw2-61/JJ||,4-62/CD	num||,4-62/CD||adr-64/CD	dep||adw2-61/JJ||ayw1-4-66/CD	conj_and||,4-62/CD||ayw1-4-66/CD	hbv-54||hbsag-59||yes||the 70 hbsag test kits from around the world were evaluated comparatively for their clinical sensitivity, analytical sensitivity, sensitivity to hbv genotypes and hbsag subtypes, and specificity using 394 (146 clinical, 48 analytical and 200 negative) icbs master panel members of diverse geographical origin comprising the major hbv genotypes a-f and the hbsag subtypes adw2,4 , adr and ayw1-4 .
aux||determine-2/VB||to-1/TO	advcl||fed-25/VBN||determine-2/VB	dobj||determine-2/VB||effects-3/NNS	prep_of||effects-3/NNS||irondeficiency-5/NN	nn||activation-8/NN||ampk-7/NN	prep_on||irondeficiency-5/NN||activation-8/NN	prep_on||irondeficiency-5/NN||signaling-10/NN	conj_and||activation-8/NN||signaling-10/NN	det||composition-18/NN||the-15/DT	nn||composition-18/NN||ampk-16/NN	nn||composition-18/NN||subunit-17/NN	prep_of||effects-3/NNS||composition-18/NN	conj_and||irondeficiency-5/NN||composition-18/NN	amod||muscle-21/NN||skeletal-20/JJ	prep_in||composition-18/NN||muscle-21/NN	nsubjpass||fed-25/VBN||rats-23/NNS	auxpass||fed-25/VBN||were-24/VBD	root||ROOT-0/null||fed-25/VBN	det||control-27/NN||a-26/DT	dobj||fed-25/VBN||control-27/NN	iobj||fed-25/VBN||control-27/NN	dep||control-27/NN||c-29/SYM	dep||fe-33/FW||=-30/SYM	amod||fe-33/FW||50-58-31/JJ	nn||fe-33/FW||mg/kg-32/FW	rcmod||c-29/SYM||fe-33/FW	nn||deficient-37/NN||iron-36/NN	dobj||fed-25/VBN||deficient-37/NN	iobj||fed-25/VBN||deficient-37/NN	conj_or||control-27/NN||deficient-37/NN	dep||control-27/NN||id-39/VBN	dep||fe-43/FW||=-40/SYM	amod||fe-43/FW||2-6-41/JJ	nn||fe-43/FW||mg/kg-42/FW	ccomp||id-39/VBN||fe-43/FW	dep||control-27/NN||diet-45/NN	amod||wks-51/NN||6â-47/JJ	amod||wks-51/NN||$-48/$	num||$-48/$||8-50/CD	prep_for||diet-45/NN||wks-51/NN	irondeficiency-5||fe-43||yes||to determine effects of irondeficiency on ampk activation and signaling, as well as the ampk subunit composition in skeletal muscle, rats were fed a control (c=50-58 mg/kg fe) or iron deficient (id=2-6 mg/kg fe) diet for 6â8 wks.
det||effect-3/NN||a-1/DT	amod||effect-3/NN||dual-2/JJ	nsubjpass||observed-8/VBN||effect-3/NN	nn||action-6/NN||insulin-5/NN	prep_on||effect-3/NN||action-6/NN	auxpass||observed-8/VBN||was-7/VBD	root||ROOT-0/null||observed-8/VBN	advmod||exposed-14/VBN||when-9/WRB	nsubjpass||exposed-14/VBN||myotubes-10/NNS	conj_and||myotubes-10/NNS||mice-12/NNS	nsubjpass||exposed-14/VBN||mice-12/NNS	auxpass||exposed-14/VBN||were-13/VBD	advcl||observed-8/VBN||exposed-14/VBN	det||additive-18/NN||this-16/DT	amod||additive-18/NN||cytokine-17/JJ	prep_to||exposed-14/VBN||additive-18/NN	amod||insulin-21/NN||short-term-20/JJ	prep_with||additive-18/NN||insulin-21/NN	amod||uptake-25/NN||increased-23/JJ	nn||uptake-25/NN||glucose-24/NN	dep||insulin-21/NN||uptake-25/NN	amod||sensitivity-29/NN||systemic-27/JJ	nn||sensitivity-29/NN||insulin-28/NN	dep||insulin-21/NN||sensitivity-29/NN	conj_and||uptake-25/NN||sensitivity-29/NN	amod||exposure-33/NN||chronic-32/JJ	nsubj||produced-34/VBD||exposure-33/NN	conj_but||observed-8/VBN||produced-34/VBD	dobj||produced-34/VBD||insulinresistance-35/NN	dep||insulinresistance-35/NN||impaired-37/VBN	amod||translocation-39/NN||glut4-38/JJ	dobj||impaired-37/VBN||translocation-39/NN	nn||membrane-42/NNS||plasma-41/NN	prep_to||impaired-37/VBN||membrane-42/NNS	prep_to||impaired-37/VBN||defects-44/NNS	conj_and||membrane-42/NNS||defects-44/NNS	prep_in||impaired-37/VBN||insulin-46/NN	xcomp||impaired-37/VBN||signaling-47/VBG	det||substrate-52/NN||the-49/DT	nn||substrate-52/NN||insulin-50/NN	nn||substrate-52/NN||receptor-51/NN	nn||level-57/NN||substrate-52/NN	num||-LSB--54/NNS||1-53/CD	npadvmod||irs-1-55/JJ||-LSB--54/NNS	amod||level-57/NN||irs-1-55/JJ	nn||level-57/NN||-RSB--56/NN	prep_at||signaling-47/VBG||level-57/NN	insulin-50||insulinresistance-35||no_rel||a dual effect on insulin action was observed when myotubes and mice were exposed to this cytokine additive with short-term insulin (increased glucose uptake and systemic insulin sensitivity) but chronic exposure produced insulinresistance (impaired glut4 translocation to plasma membrane and defects in insulin signaling at the insulin receptor substrate 1 [irs-1] level).
nsubj||examined-2/VBD||we-1/PRP	root||ROOT-0/null||examined-2/VBD	nsubj||genotypes-17/VBZ||feathers-3/NNS	amod||ducks-6/NNS||domestic-5/JJ	prep_of||feathers-3/NNS||ducks-6/NNS	prep_of||feathers-3/NNS||geese-8/NNS	conj_and||ducks-6/NNS||geese-8/NNS	vmod||ducks-6/NNS||inoculated-9/VBN	num||avianinfluenzavirus-13/NNS||2-11/CD	amod||avianinfluenzavirus-13/NNS||different-12/JJ	prep_with||inoculated-9/VBN||avianinfluenzavirus-13/NNS	appos||avianinfluenzavirus-13/NNS||h5n1-15/NNP	ccomp||examined-2/VBD||genotypes-17/VBZ	h5n1-15||avianinfluenzavirus-13||no||we examined feathers of domestic ducks and geese inoculated with 2 different avianinfluenzavirus (h5n1) genotypes.
nsubj||manifest-13/VB||hypersensitivityreactions-1/NNS	prep_against||hypersensitivityreactions-1/NNS||nonsteroidalantiinflammatorydrugs-3/NNS	appos||nonsteroidalantiinflammatorydrugs-3/NNS||nsaids-5/NNS	prep_like||nonsteroidalantiinflammatorydrugs-3/NNS||diclofenac-8/NN	appos||hypersensitivityreactions-1/NNS||df-10/NN	aux||manifest-13/VB||can-12/MD	root||ROOT-0/null||manifest-13/VB	prep_as||manifest-13/VB||type-15/NN	amod||allergicreactions-17/NNS||i-like-16/JJ	dobj||manifest-13/VB||allergicreactions-17/NNS	amod||anaphylaxis-20/NNS||systemic-19/JJ	prep_including||allergicreactions-17/NNS||anaphylaxis-20/NNS	allergicreactions-17||hypersensitivityreactions-1||no||hypersensitivityreactions against nonsteroidalantiinflammatorydrugs (nsaids) like diclofenac (df) can manifest as type i-like allergicreactions including systemic anaphylaxis.
det||virus-3/NN||the-1/DT	nn||virus-3/NN||aravan-2/NN	nsubj||belong-6/VB||virus-3/NN	aux||belong-6/VB||does-4/VBZ	neg||belong-6/VB||not-5/RB	root||ROOT-0/null||belong-6/VB	prep_to||belong-6/VB||any-8/DT	det||genotypes-13/NNS||the-10/DT	num||genotypes-13/NNS||seven-11/CD	amod||genotypes-13/NNS||known-12/VBN	prep_of||any-8/DT||genotypes-13/NNS	prep_of||genotypes-13/NNS||lyssaviruses-15/NNS	prep_of||any-8/DT||namely-17/RB	advmod||genotypes-13/NNS||namely-17/RB	conj_and||genotypes-13/NNS||namely-17/RB	prep_of||any-8/DT||rabies-19/NNP	conj_and||genotypes-13/NNS||rabies-19/NNP	amod||bat-22/NN||lagos-21/JJ	conj_and||genotypes-13/NNS||bat-22/NN	conj_and||rabies-19/NNP||bat-22/NN	conj_and||genotypes-13/NNS||mokola-24/NN	conj_and||rabies-19/NNP||mokola-24/NN	amod||viruses-28/NNS||duvenhage-27/JJ	conj_and||genotypes-13/NNS||viruses-28/NNS	conj_and||rabies-19/NNP||viruses-28/NNS	amod||lyssavirus-32/NNS||european-30/JJ	nn||lyssavirus-32/NNS||bat-31/NN	conj_and||genotypes-13/NNS||lyssavirus-32/NNS	conj_and||rabies-19/NNP||lyssavirus-32/NNS	dep||lyssavirus-32/NNS||1-33/CD	amod||lyssavirus-37/NNS||european-35/JJ	nn||lyssavirus-37/NNS||bat-36/NN	prep_of||any-8/DT||lyssavirus-37/NNS	conj_and||genotypes-13/NNS||lyssavirus-37/NNS	dep||lyssavirus-37/NNS||2-38/CD	amod||lyssavirus-43/NNS||australian-41/JJ	nn||lyssavirus-43/NNS||bat-42/NN	prep_of||any-8/DT||lyssavirus-43/NNS	conj_and||genotypes-13/NNS||lyssavirus-43/NNS	virus-3||viruses-28||no||the aravan virus does not belong to any of the seven known genotypes of lyssaviruses, namely, rabies, lagos bat, mokola, and duvenhage viruses and european bat lyssavirus 1, european bat lyssavirus 2, and australian bat lyssavirus.
advmod||play-9/VBP||thus-1/RB	amod||species-5/NNS||reactive-3/JJ	nn||species-5/NNS||oxygen-4/NN	nsubj||play-9/VBP||species-5/NNS	nn||molecules-8/NNS||adhesion-7/NN	conj_and||species-5/NNS||molecules-8/NNS	nsubj||play-9/VBP||molecules-8/NNS	root||ROOT-0/null||play-9/VBP	det||role-12/NN||an-10/DT	amod||role-12/NN||important-11/JJ	dobj||play-9/VBP||role-12/NN	det||development-15/NN||the-14/DT	prep_in||role-12/NN||development-15/NN	prep_of||development-15/NN||inflammatoryboweldisease-17/NN	oxygen-4||adhesion-7||no_rel||thus, reactive oxygen species and adhesion molecules play an important role in the development of inflammatoryboweldisease.
amod||hydroxyethylstarch-3/NN||hypertonic-1/JJ	nn||hydroxyethylstarch-3/NN||saline-2/NN	nsubjpass||recommended-9/VBN||hydroxyethylstarch-3/NN	appos||hydroxyethylstarch-3/NN||hh-5/NN	aux||recommended-9/VBN||has-7/VBZ	auxpass||recommended-9/VBN||been-8/VBN	root||ROOT-0/null||recommended-9/VBN	amod||treatment-13/NN||first-11/JJ	nn||treatment-13/NN||line-12/NN	prep_for||recommended-9/VBN||treatment-13/NN	prep_of||treatment-13/NN||hemorrhagicshock-15/NN	hemorrhagicshock-15||hydroxyethylstarch-3||yes||hypertonic saline hydroxyethylstarch (hh) has been recommended for first line treatment of hemorrhagicshock.
amod||vaccines-9/NNS||immunization-1/JJ	amod||swine-6/NNS||1918-like-3/JJ	conj_and||1918-like-3/JJ||classical-5/JJ	amod||swine-6/NNS||classical-5/JJ	prep_with||immunization-1/JJ||swine-6/NNS	amod||vaccines-9/NNS||h1n1-7/JJ	nn||vaccines-9/NNS||virus-8/NN	nsubj||results-10/VBZ||vaccines-9/NNS	root||ROOT-0/null||results-10/VBZ	amod||antibodies-13/NNS||cross-protective-12/JJ	prep_in||results-10/VBZ||antibodies-13/NNS	det||influenza-19/NN||the-15/DT	num||h1n1-17/NNS||2009-16/CD	npadvmod||pandemic-18/JJ||h1n1-17/NNS	amod||influenza-19/NN||pandemic-18/JJ	prep_against||antibodies-13/NNS||influenza-19/NN	xcomp||results-10/VBZ||indicating-21/VBG	amod||similarities-23/NNS||antigenic-22/JJ	dobj||indicating-21/VBG||similarities-23/NNS	det||viruses-26/NNS||these-25/DT	prep_among||indicating-21/VBG||viruses-26/NNS	influenza-19||vaccines-9||no_rel||immunization with 1918-like and classical swine h1n1 virus vaccines results in cross-protective antibodies against the 2009 h1n1 pandemic influenza, indicating antigenic similarities among these viruses.
det||technique-6/NN||the-1/DT	advmod||used-4/VBN||most-2/RBS	advmod||used-4/VBN||commonly-3/RB	amod||technique-6/NN||used-4/VBN	amod||technique-6/NN||current-5/JJ	nsubj||dependent-15/JJ||technique-6/NN	nn||immunoprecipitation-9/NN||chromatin-8/NN	appos||technique-6/NN||immunoprecipitation-9/NN	appos||immunoprecipitation-9/NN||chip-11/NN	cop||dependent-15/JJ||is-14/VBZ	root||ROOT-0/null||dependent-15/JJ	det||antibody-20/NN||a-17/DT	amod||antibody-20/NN||high-18/JJ	nn||antibody-20/NN||quality-19/NN	prep_on||dependent-15/JJ||antibody-20/NN	det||protein-23/NN||each-22/DT	prep_for||antibody-20/NN||protein-23/NN	prep_of||protein-23/NN||interest-25/NN	nsubj||available-31/JJ||interest-25/NN	nsubj||cumbersome-36/JJ||interest-25/NN	nsubj||involving-38/VBG||interest-25/NN	cop||available-31/JJ||is-28/VBZ	neg||available-31/JJ||not-29/RB	advmod||available-31/JJ||always-30/RB	rcmod||interest-25/NN||available-31/JJ	cop||cumbersome-36/JJ||is-34/VBZ	advmod||cumbersome-36/JJ||also-35/RB	rcmod||interest-25/NN||cumbersome-36/JJ	conj_and||available-31/JJ||cumbersome-36/JJ	rcmod||interest-25/NN||involving-38/VBG	conj_and||available-31/JJ||involving-38/VBG	amod||cross-linking-40/NN||sequential-39/JJ	prep_involving||available-31/JJ||cross-linking-40/NN	prep_involving||available-31/JJ||reversal-42/NN	conj_and||cross-linking-40/NN||reversal-42/NN	prep_of||cross-linking-40/NN||cross-linking-44/NN	cross--1||antibody-20||no_rel||the most commonly used current technique, chromatin immunoprecipitation (chip), is dependent on a high quality antibody for each protein of interest, which is not always available, and is also cumbersome, involving sequential cross-linking and reversal of cross-linking.
nsubj||agent-8/NN||humant-celllymphotropicvirustype1-1/JJ	dep||humant-celllymphotropicvirustype1-1/JJ||htlv-1-3/JJ	cop||agent-8/NN||is-5/VBZ	det||agent-8/NN||the-6/DT	amod||agent-8/NN||etiological-7/JJ	root||ROOT-0/null||agent-8/NN	amod||leukemia-12/NN||adult-10/JJ	amod||leukemia-12/NN||t-cell-11/JJ	prep_of||agent-8/NN||leukemia-12/NN	appos||leukemia-12/NN||atl-14/NN	amod||tropicalspasticparaparesis-19/NNS||htlv-1-associatedmyelopathy-17/JJ	amod||tropicalspasticparaparesis-19/NNS||/-18/JJ	prep_of||agent-8/NN||tropicalspasticparaparesis-19/NNS	conj_and||leukemia-12/NN||tropicalspasticparaparesis-19/NNS	appos||leukemia-12/NN||ham/tsp-21/NN	tropicalspasticparaparesis-19||humant-celllymphotropicvirustype1-1||no||humant-celllymphotropicvirustype1 (htlv-1) is the etiological agent of adult t-cell leukemia (atl) and htlv-1-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp).
advmod||decreased-10/VBN||furthermore-1/RB	nn||expression-5/NN||hbz-3/NN	nn||expression-5/NN||mrna-4/NN	nsubjpass||decreased-10/VBN||expression-5/NN	amod||cell-8/NN||htlv-1-infected-7/JJ	prep_per||expression-5/NN||cell-8/NN	auxpass||decreased-10/VBN||was-9/VBD	root||ROOT-0/null||decreased-10/VBN	amod||treatment-14/NN||successful-12/JJ	nn||treatment-14/NN||immunomodulatory-13/NN	prep_after||decreased-10/VBN||treatment-14/NN	prep_for||treatment-14/NN||ham/tsp-16/NN	ham--1||htlv-1--1||no||furthermore, hbz mrna expression per htlv-1-infected cell was decreased after successful immunomodulatory treatment for ham/tsp.
det||study-2/NN||the-1/DT	nsubjpass||made-4/VBN||study-2/NN	nsubj||evaluate-6/VB||study-2/NN	auxpass||made-4/VBN||was-3/VBD	root||ROOT-0/null||made-4/VBN	aux||evaluate-6/VB||to-5/TO	xcomp||made-4/VBN||evaluate-6/VB	nn||turnover-8/NN||bone-7/NN	dobj||evaluate-6/VB||turnover-8/NN	iobj||evaluate-6/VB||turnover-8/NN	amod||lupuserythematosus-11/NNS||systemic-10/JJ	prep_in||turnover-8/NN||lupuserythematosus-11/NNS	appos||turnover-8/NN||sle-13/NN	dep||turnover-8/NN||patients-15/NNS	vmod||patients-15/NNS||undergoing-16/VBG	amod||therapy-19/NN||long-term-17/JJ	amod||therapy-19/NN||glucocorticoid-18/JJ	dobj||undergoing-16/VBG||therapy-19/NN	sle-13||glucocorticoid-18||no_rel||the study was made to evaluate bone turnover in systemic lupuserythematosus (sle) patients undergoing long-term glucocorticoid therapy.
nsubj||±-9/VBZ||mice-1/NNS	det||deletion-5/NN||a-3/DT	amod||deletion-5/NN||whole-body-4/JJ	prep_with||mice-1/NNS||deletion-5/NN	det||î-8/NN||the-7/DT	prep_of||deletion-5/NN||î-8/NN	root||ROOT-0/null||±-9/VBZ	num||subunit-12/NN||2-10/CD	amod||subunit-12/NN||catalytic-11/JJ	dobj||±-9/VBZ||subunit-12/NN	prep_of||subunit-12/NN||ampk-14/NN	dep||±-9/VBZ||ampkî-16/VBG	nn||2â-18/NNP||±-17/NNP	poss||â-21/NNP||2â-18/NNP	nn||â-21/NNP||/-20/NNP	dobj||ampkî-16/VBG||â-21/NNP	poss||littermates-27/NNS||their-25/PRP$	amod||littermates-27/NNS||wild-type-26/JJ	nsubjpass||fed-29/VBN||littermates-27/NNS	auxpass||fed-29/VBN||were-28/VBD	conj_and||±-9/VBZ||fed-29/VBN	advmod||chow-34/NN||either-31/RB	det||chow-34/NN||a-32/DT	amod||chow-34/NN||low-fat-33/JJ	prep_on||fed-29/VBN||chow-34/NN	det||corn-38/NN||a-37/DT	prep_on||fed-29/VBN||corn-38/NN	conj_or||chow-34/NN||corn-38/NN	amod||diet-41/NN||oil-based-39/JJ	amod||diet-41/NN||high-fat-40/JJ	dep||corn-38/NN||diet-41/NN	appos||diet-41/NN||chf-43/NN	det||diet-49/NN||a-47/DT	nn||diet-49/NN||chf-48/NN	prep_on||fed-29/VBN||diet-49/NN	conj_or||chow-34/NN||diet-49/NN	number||%-52/NN||15-51/CD	amod||lipids-53/NNS||%-52/NN	prep_with||diet-49/NN||lipids-53/NNS	vmod||lipids-53/NNS||replaced-54/VBN	amod||concentrate-58/NN||n-3-56/JJ	amod||concentrate-58/NN||lc-pufa-57/JJ	agent||replaced-54/VBN||concentrate-58/NN	nn||f-62/NNP||chf-60/NNP	nn||f-62/NNP||+-61/NNP	appos||concentrate-58/NN||f-62/NNP	chf-60||fat--1||no_rel||mice with a whole-body deletion of the î±2 catalytic subunit of ampk (ampkî±2â/â) and their wild-type littermates were fed on either a low-fat chow, or a corn oil-based high-fat diet (chf), or a chf diet with 15% lipids replaced by n-3 lc-pufa concentrate (chf+f).
nsubj||study-11/NN||this-1/DT	cop||study-11/NN||was-2/VBD	det||study-11/NN||a-3/DT	amod||study-11/NN||12-month-4/JJ	amod||study-11/NN||multicenter-6/JJ	amod||study-11/NN||sham-controlled-8/JJ	amod||study-11/NN||double-masked-10/JJ	root||ROOT-0/null||study-11/NN	prep_with||study-11/NN||eyes-13/NNS	dep||eyes-13/NNS||age-15/NN	number||18-17/CD||>-16/CD	num||years-18/NNS||18-17/CD	dep||age-15/NN||years-18/NNS	appos||age-15/NN||type-20/NN	num||type-20/NN||1-21/CD	num||diabetes-24/NN||2-23/CD	appos||age-15/NN||diabetes-24/NN	conj_or||type-20/NN||diabetes-24/NN	amod||-RSB--47/NNS||central-26/JJ	amod||-RSB--47/NNS||retinal-27/JJ	nn||-RSB--47/NNS||thickness-28/NN	nn||-RSB--47/NNS||-LSB--29/NNP	nn||-RSB--47/NNS||crt-30/NNP	nn||-RSB--47/NNS||-RSB--31/NNP	nn||-RSB--47/NNS||â-32/NNP	nn||-RSB--47/NNS||-33/NNP	nn||-RSB--47/NNS||¥-34/NNP	num||-RSB--47/NNS||300-35/CD	amod||-RSB--47/NNS||î-36/JJ	num||m-38/NN||1/4-37/CD	nn||-RSB--47/NNS||m-38/NN	advmod||acuity-44/JJ||best-41/RB	num||visual-43/NNS||corrected-42/CD	npadvmod||acuity-44/JJ||visual-43/NNS	conj_and||m-38/NN||acuity-44/JJ	nn||-RSB--47/NNS||acuity-44/JJ	amod||-RSB--47/NNS||-LSB--45/JJ	nn||-RSB--47/NNS||bcva-46/NN	appos||age-15/NN||-RSB--47/NNS	prep_of||-RSB--47/NNS||73â-49/CD	dep||-RSB--47/NNS||$-50/$	num||letters-54/NNS||39-52/CD	nn||letters-54/NNS||etdrs-53/NNS	npadvmod||early-56/RB||letters-54/NNS	advmod||letters-54/NNS||-LSB--55/RB	dep||treatment-57/CD||early-56/RB	num||$-50/$||treatment-57/CD	amod||-RSB--60/NNS||diabeticretinopathy-58/JJ	nn||-RSB--60/NNS||study-59/NN	dep||$-50/$||-RSB--60/NNS	advmod||assigned-63/VBN||randomly-62/RB	vmod||study-11/NN||assigned-63/VBN	amod||ranibizumab-66/NN||intravitreal-65/JJ	prep_to||assigned-63/VBN||ranibizumab-66/NN	dep||ranibizumab-66/NN||0.3-68/CD	num||mg-71/NN||0.5-70/CD	dep||ranibizumab-66/NN||mg-71/NN	conj_or||0.3-68/CD||mg-71/NN	dep||0.3-68/CD||n-73/NN	dep||51-75/CD||=-74/SYM	rcmod||n-73/NN||51-75/CD	dep||0.3-68/CD||each-76/DT	prep_to||assigned-63/VBN||sham-79/NN	conj_or||ranibizumab-66/NN||sham-79/NN	dep||study-11/NN||n-81/VBN	dep||49-83/CD||=-82/SYM	ccomp||n-81/VBN||49-83/CD	diabeticretinopathy-58||ranibizumab-66||no_rel||this was a 12-month, multicenter, sham-controlled, double-masked study with eyes (age >18 years, type 1 or 2 diabetes, central retinal thickness [crt] â¥300 î¼m, and best corrected visual acuity [bcva] of 73â39 etdrs letters [early treatment diabeticretinopathy study]) randomly assigned to intravitreal ranibizumab (0.3 or 0.5 mg; n = 51 each) or sham ( n = 49).
nsubj||â-2/VBP||conclusions-1/NNS	root||ROOT-0/null||â-2/VBP	dobj||â-2/VBP||$-3/$	mark||associated-24/VBN||$-3/$	det||data-6/NNS||these-5/DT	nsubj||suggest-7/VBP||data-6/NNS	rcmod||$-3/$||suggest-7/VBP	nsubjpass||associated-24/VBN||polymorphisms-9/NNS	num||components-12/NNS||two-11/CD	prep_in||polymorphisms-9/NNS||components-12/NNS	det||insulin-15/NN||the-14/DT	prep_of||components-12/NNS||insulin-15/NN	vmod||insulin-15/NN||signaling-16/VBG	dobj||signaling-16/VBG||pathway-17/JJ	dobj||signaling-16/VBG||akt2-19/NNS	conj_and||pathway-17/JJ||akt2-19/NNS	dobj||signaling-16/VBG||gsk3b-21/NNS	conj_and||pathway-17/JJ||gsk3b-21/NNS	auxpass||associated-24/VBN||are-23/VBP	ccomp||suggest-7/VBP||associated-24/VBN	prep_with||associated-24/VBN||pcos-26/NNS	insulin-15||pcos-26||no_rel||conclusions âthese data suggest that polymorphisms in two components of the insulin signaling pathway, akt2 and gsk3b , are associated with pcos.
nn||reactivation-5/NNS||hepatitisbvirus-1/NNS	appos||reactivation-5/NNS||hbv-3/NN	nsubj||complication-9/NN||reactivation-5/NNS	cop||complication-9/NN||is-6/VBZ	det||complication-9/NN||the-7/DT	amod||complication-9/NN||frequent-8/JJ	root||ROOT-0/null||complication-9/NN	amod||chemotherapy-12/NN||cytotoxic-11/JJ	prep_after||complication-9/NN||chemotherapy-12/NN	amod||non-hodgkin-15/NN||hbsag-positive-14/JJ	poss||patients-21/NNS||non-hodgkin-15/NN	amod||patients-21/NNS||lymphoma-17/JJ	appos||patients-21/NNS||nhl-19/NN	prep_in||chemotherapy-12/NN||patients-21/NNS	hbv-3||hepatitisbvirus-1||no||hepatitisbvirus (hbv) reactivation is the frequent complication after cytotoxic chemotherapy in hbsag-positive non-hodgkin's lymphoma (nhl) patients.
nsubj||drives-2/VBZ||bcgvaccine-1/NN	root||ROOT-0/null||drives-2/VBZ	det||immunity-9/NN||a-3/DT	amod||immunity-9/NN||strong-4/JJ	nn||immunity-9/NN||t-5/NN	nn||immunity-9/NN||helper-6/NN	num||immunity-9/NN||1-7/CD	amod||immunity-9/NN||cellular-8/JJ	dobj||drives-2/VBZ||immunity-9/NN	nsubj||essential-12/JJ||immunity-9/NN	cop||essential-12/JJ||is-11/VBZ	rcmod||immunity-9/NN||essential-12/JJ	det||protection-15/NN||the-14/DT	prep_for||essential-12/JJ||protection-15/NN	prep_against||protection-15/NN||mycobacteria-17/NN	advmod||suggest-22/VBP||however-19/RB	amod||studies-21/NNS||recent-20/JJ	nsubj||suggest-22/VBP||studies-21/NNS	parataxis||drives-2/VBZ||suggest-22/VBP	mark||have-27/VB||that-23/IN	nn||vaccination-25/NN||bcg-24/NN	nsubj||have-27/VB||vaccination-25/NN	aux||have-27/VB||can-26/MD	ccomp||suggest-22/VBP||have-27/VB	amod||effects-30/NNS||non-specific-28/JJ	amod||effects-30/NNS||beneficial-29/JJ	nsubj||unrelated-31/JJ||effects-30/NNS	xcomp||have-27/VB||unrelated-31/JJ	prep_to||have-27/VB||tuberculosis-33/NNP	tuberculosis-33||bcgvaccine-1||no||bcgvaccine drives a strong t helper 1 cellular immunity which is essential for the protection against mycobacteria, however recent studies suggest that bcg vaccination can have non-specific beneficial effects unrelated to tuberculosis.
nsubj||hypothesized-2/VBN||we-1/PRP	root||ROOT-0/null||hypothesized-2/VBN	mark||associated-41/VBN||that-3/IN	det||decrease-5/NN||the-4/DT	nsubjpass||associated-41/VBN||decrease-5/NN	prep_in||decrease-5/NN||cvl-7/NN	nn||francisco-10/NN||san-9/NN	prep_in||cvl-7/NN||francisco-10/NN	prep_from||francisco-10/NN||2004â-12/CD	dep||decrease-5/NN||$-13/$	npadvmod||of-21/RB||2008-15/NNS	dep||2008-15/NNS||corresponding-17/RB	amod||rates-20/NNS||increased-19/JJ	prep_with||2008-15/NNS||rates-20/NNS	dep||hiv-22/CD||of-21/RB	num||$-13/$||hiv-22/CD	dep||$-13/$||testing-23/NN	amod||therapy-26/NN||antiretroviral-25/JJ	appos||decrease-5/NN||therapy-26/NN	appos||therapy-26/NN||art-28/NN	dep||therapy-26/NN||coverage-30/NN	dep||therapy-26/NN||effectiveness-32/NN	conj_and||coverage-30/NN||effectiveness-32/NN	amod||suppression-37/NN||population-level-35/JJ	amod||suppression-37/NN||virologic-36/JJ	appos||decrease-5/NN||suppression-37/NN	conj_and||therapy-26/NN||suppression-37/NN	aux||associated-41/VBN||would-39/MD	auxpass||associated-41/VBN||be-40/VB	ccomp||hypothesized-2/VBN||associated-41/VBN	det||reduction-44/NN||a-43/DT	prep_with||associated-41/VBN||reduction-44/NN	amod||hivinfections-47/NNS||new-46/JJ	prep_in||reduction-44/NN||hivinfections-47/NNS	hivinfections-47||hiv-22||no||we hypothesized that the decrease in cvl in san francisco from 2004â2008, corresponding with increased rates of hiv testing, antiretroviral therapy (art) coverage and effectiveness, and population-level virologic suppression, would be associated with a reduction in new hivinfections.
nsubj||oncogene-6/NN||lmp1-1/NNS	cop||oncogene-6/NN||is-2/VBZ	det||oncogene-6/NN||the-3/DT	nn||oncogene-6/NN||tumour-4/NN	amod||oncogene-6/NN||predisposing-5/VBG	root||ROOT-0/null||oncogene-6/NN	nsubj||give-16/VBP||oncogene-6/NN	num||series-10/NN||two-8/CD	amod||series-10/NN||different-9/JJ	prep_in||oncogene-6/NN||series-10/NN	amod||mice-13/NNS||transgenic-12/JJ	prep_of||series-10/NN||mice-13/NNS	advmod||give-16/VBP||separately-15/RB	rcmod||oncogene-6/NN||give-16/VBP	dobj||give-16/VBP||rise-17/NN	preconj||b-celllymphomas-20/NNS||either-19/CC	prep_to||give-16/VBP||b-celllymphomas-20/NNS	prep_to||give-16/VBP||carcinomas-22/NNS	conj_or||b-celllymphomas-20/NNS||carcinomas-22/NNS	rise-17||b-celllymphomas-20||no_rel||lmp1 is the tumour predisposing oncogene in two different series of transgenic mice which separately give rise to either b-celllymphomas or carcinomas.
det||treatment-2/NN||the-1/DT	nsubj||evolved-9/VBN||treatment-2/NN	prep_of||treatment-2/NN||chronichepatitisc-4/NN	appos||chronichepatitisc-4/NN||chc-6/NN	aux||evolved-9/VBN||has-8/VBZ	root||ROOT-0/null||evolved-9/VBN	det||years-14/NNS||the-11/DT	amod||years-14/NNS||past-12/JJ	num||years-14/NNS||15-13/CD	prep_in||evolved-9/VBN||years-14/NNS	nsubj||therapy-26/NN||combination-16/NN	amod||interferon-19/NN||pegylated-18/JJ	prep_of||combination-16/NN||interferon-19/NN	prep||interferon-19/NN||plus-20/CC	pobj||plus-20/CC||ribavirin-21/NNP	cop||therapy-26/NN||is-22/VBZ	poss||therapy-26/NN||its-23/PRP$	amod||therapy-26/NN||current-24/JJ	amod||therapy-26/NN||standard-25/JJ	conj_and||evolved-9/VBN||therapy-26/NN	chronichepatitisc-4||interferon-19||yes||the treatment of chronichepatitisc (chc) has evolved in the past 15 years and combination of pegylated interferon plus ribavirin is its current standard therapy.
amod||survivors-2/NNS||thirty-three-1/JJ	nsubjpass||evaluated-15/VBN||survivors-2/NNS	vmod||survivors-2/NNS||treated-3/VBN	prep_with||treated-3/VBN||insulin-5/NN	prep_for||insulin-5/NN||hyperglycemia-7/NN	num||controls-11/NNS||63-9/CD	amod||controls-11/NNS||matched-10/VBN	prep_with||treated-3/VBN||controls-11/NNS	conj_and||insulin-5/NN||controls-11/NNS	prep_without||controls-11/NNS||hyperglycemia-13/NN	auxpass||evaluated-15/VBN||were-14/VBD	root||ROOT-0/null||evaluated-15/VBN	det||age-19/NN||a-17/DT	amod||age-19/NN||corrected-18/VBN	prep_at||evaluated-15/VBN||age-19/NN	num||years-22/NNS||2-21/CD	prep_of||age-19/NN||years-22/NNS	hyperglycemia-13||insulin-5||yes||thirty-three survivors treated with insulin for hyperglycemia and 63 matched controls without hyperglycemia were evaluated at a corrected age of 2 years.
nsubj||accounted-23/VBD||questions-1/NNS	vmod||questions-1/NNS||related-2/VBN	prep_to||related-2/VBN||co-morbidities-4/NNS	prep_in||co-morbidities-4/NNS||hiv/aids-6/NNS	amod||cancers-10/NNS||non-aids-8/JJ	amod||cancers-10/NNS||related-9/JJ	dep||hiv/aids-6/NNS||cancers-10/NNS	amod||diseases-13/NNS||systemic-12/JJ	dep||hiv/aids-6/NNS||diseases-13/NNS	conj_and||cancers-10/NNS||diseases-13/NNS	amod||toxicities-19/NNS||chronic-16/JJ	amod||toxicities-19/NNS||antiretroviral-17/JJ	nn||toxicities-19/NNS||treatment-18/NN	prep_in||co-morbidities-4/NNS||toxicities-19/NNS	conj_and||hiv/aids-6/NNS||toxicities-19/NNS	dep||hiv/aids-6/NNS||metabolicdisorders-21/NNS	root||ROOT-0/null||accounted-23/VBD	advmod||lower-26/JJR||significantly-25/RB	amod||scores-27/NNS||lower-26/JJR	prep_for||accounted-23/VBD||scores-27/NNS	dep||scores-27/NNS||mean-29/NN	num||%-32/NN||41.7-31/CD	appos||mean-29/NN||%-32/NN	num||%-35/NN||95-34/CD	npadvmod||ci-36/RB||%-35/NN	advmod||mean-29/NN||ci-36/RB	num||%-38/NN||39.3-37/CD	dep||mean-29/NN||%-38/NN	quantmod||$-40/$||â-39/RB	num||%-43/NN||$-40/$	num||$-40/$||44-42/CD	dep||%-38/NN||%-43/NN	prepc_compared_to||accounted-23/VBD||to-46/TO	nn||epidemiology-48/NN||hiv/aids-47/NNS	pobj||accounted-23/VBD||epidemiology-48/NN	pobj||accounted-23/VBD||prevention-50/NN	conj_and||epidemiology-48/NN||prevention-50/NN	dep||epidemiology-48/NN||mean-52/VB	num||%-55/NN||65.7-54/CD	nsubj||$-63/VBG||%-55/NN	number||%-58/NN||95-57/CD	amod||ci-59/NN||%-58/NN	appos||%-55/NN||ci-59/NN	num||%-61/NN||63.7-60/CD	npadvmod||â-62/RB||%-61/NN	advmod||$-63/VBG||â-62/RB	ccomp||mean-52/VB||$-63/VBG	num||%-66/NN||67.7-65/CD	dobj||$-63/VBG||%-66/NN	aids--1||hiv--1||no||questions related to co-morbidities in hiv/aids (non-aids related cancers and systemic diseases) and chronic antiretroviral treatment toxicities (metabolicdisorders) accounted for significantly lower scores (mean, 41.7%, 95% ci 39.3%â44%) compared to hiv/aids epidemiology and prevention (mean, 65.7%, 95% ci 63.7%â67.7%).
det||factors-2/NNS||the-1/DT	nsubj||level-16/NN||factors-2/NNS	vmod||factors-2/NNS||associated-3/VBN	det||level-7/NN||a-5/DT	amod||level-7/NN||high-6/JJ	prep_with||associated-3/VBN||level-7/NN	amod||attitudes-10/NNS||such-9/JJ	prep_of||level-7/NN||attitudes-10/NNS	det||hcws-13/NNS||the-12/DT	prep_among||associated-3/VBN||hcws-13/NNS	cop||level-16/NN||were-14/VBD	amod||level-16/NN||high-15/JJ	root||ROOT-0/null||level-16/NN	amod||fear-19/NN||irrational-18/JJ	prep_of||level-16/NN||fear-19/NN	prep_about||fear-19/NN||hiv-21/NN	prep_about||fear-19/NN||aids-23/NNS	conj_and||hiv-21/NN||aids-23/NNS	parataxis||level-16/NN||working-25/VBG	nn||hospital-28/NN||teaching-27/NN	prep_in||working-25/VBG||hospital-28/NN	amod||hospital-33/NN||non-teaching-32/JJ	prep_in||working-25/VBG||hospital-33/NN	conj_negcc||hospital-28/NN||hospital-33/NN	amod||centres-36/NNS||diagnostic-35/JJ	conj_negcc||hospital-28/NN||centres-36/NNS	conj_and||hospital-33/NN||centres-36/NNS	amod||level-39/NN||low-38/JJ	dep||hospital-33/NN||level-39/NN	prep_of||level-39/NN||education-41/NN	cop||male-45/JJ||being-44/VBG	parataxis||level-16/NN||male-45/JJ	conj_and||working-25/VBG||male-45/JJ	aids-23||hiv-21||no||the factors associated with a high level of such attitudes among the hcws were high level of irrational fear about hiv and aids; working in teaching hospital rather than in non-teaching hospital and diagnostic centres; low level of education; and being male.
mark||eliminated-5/VBN||although-1/IN	nsubjpass||eliminated-5/VBN||smallpox-2/NN	aux||eliminated-5/VBN||has-3/VBZ	auxpass||eliminated-5/VBN||been-4/VBN	advcl||sought-14/VBN||eliminated-5/VBN	det||environment-8/NN||the-7/DT	prep_from||eliminated-5/VBN||environment-8/NN	nsubjpass||sought-14/VBN||treatments-10/NNS	aux||sought-14/VBN||are-11/VBP	advmod||sought-14/VBN||urgently-12/RB	auxpass||sought-14/VBN||being-13/VBG	root||ROOT-0/null||sought-14/VBN	det||risk-18/NN||the-17/DT	prep_due_to||sought-14/VBN||risk-18/NN	prep_of||risk-18/NN||smallpox-20/NN	auxpass||used-22/VBN||being-21/VBG	vmod||smallpox-20/NN||used-22/VBN	vmod||smallpox-20/NN||used-22/VBN	conj_and||used-22/VBN||used-22/VBN	det||agent-26/NN||a-24/DT	nn||agent-26/NN||bioterrorism-25/NN	prep_as||used-22/VBN||agent-26/NN	nn||virus-30/NN||monkeypox-29/NN	prep_for||used-22/VBN||virus-30/NN	det||disease-34/NN||a-32/DT	amod||disease-34/NN||zoonotic-33/JJ	prep_for||used-22/VBN||disease-34/NN	conj_and||virus-30/NN||disease-34/NN	prep_of||disease-34/NN||africa-36/NN	amod||reactions-40/NNS||adverse-39/JJ	prep_for||used-22/VBN||reactions-40/NNS	conj_and||virus-30/NN||reactions-40/NNS	amod||vaccinations-43/NNS||smallpoxvirus-42/JJ	prep_to||used-22/VBN||vaccinations-43/NNS	smallpox-20||smallpoxvirus-42||no||although smallpox has been eliminated from the environment, treatments are urgently being sought due to the risk of smallpox being used as a bioterrorism agent and for monkeypox virus, a zoonotic disease of africa, and adverse reactions to smallpoxvirus vaccinations.
nsubj||problem-10/NN||misidentification-1/NN	amod||s.aureus-4/NNS||nosocomial-3/JJ	prep_of||misidentification-1/NN||s.aureus-4/NNS	prep_as||s.aureus-4/NNS||mrsa-6/NN	cop||problem-10/NN||is-7/VBZ	det||problem-10/NN||a-8/DT	amod||problem-10/NN||serious-9/JJ	root||ROOT-0/null||problem-10/NN	nn||hospitals-13/NNS||libyan-12/NN	prep_in||problem-10/NN||hospitals-13/NNS	mrsa-6||s.aureus-4||no||misidentification of nosocomial s.aureus as mrsa is a serious problem in libyan hospitals .
nsubjpass||treated-6/VBN||those-1/DT	nsubjpass||followed-12/VBN||those-1/DT	prep_with||those-1/DT||nephroticsyndrome-3/NN	auxpass||treated-6/VBN||are-4/VBP	advmod||treated-6/VBN||usually-5/RB	root||ROOT-0/null||treated-6/VBN	prep_with||treated-6/VBN||steroids-8/NNS	advmod||treated-6/VBN||initially-9/RB	advmod||followed-12/VBN||often-11/RB	conj_and||treated-6/VBN||followed-12/VBN	amod||agents-15/NNS||alkylating-14/VBG	prep_by||followed-12/VBN||agents-15/NNS	dep||agents-15/NNS||cyclophosphamide-17/JJ	dep||agents-15/NNS||chlorambucil-19/JJ	conj_or||cyclophosphamide-17/JJ||chlorambucil-19/JJ	nephroticsyndrome-3||cyclophosphamide-17||yes||those with nephroticsyndrome are usually treated with steroids initially and often followed by alkylating agents (cyclophosphamide or chlorambucil).
nsubj||equivalent-7/JJ||combination-1/NN	nsubj||leflunomide-9/VB||combination-1/NN	prep_of||combination-1/NN||methotrexate-3/NN	prep_of||combination-1/NN||hydroxychloroquine-5/NN	conj_and||methotrexate-3/NN||hydroxychloroquine-5/NN	cop||equivalent-7/JJ||is-6/VBZ	root||ROOT-0/null||equivalent-7/JJ	aux||leflunomide-9/VB||to-8/TO	xcomp||equivalent-7/JJ||leflunomide-9/VB	prep_in||leflunomide-9/VB||terms-11/NNS	prep_of||terms-11/NNS||efficacy-13/NN	prepc_in||leflunomide-9/VB||reducing-15/VBG	nn||activity-17/NN||disease-16/NN	dobj||reducing-15/VBG||activity-17/NN	det||treatment-21/NN||the-19/DT	amod||treatment-21/NN||initial-20/JJ	prep_in||reducing-15/VBG||treatment-21/NN	amod||rheumatoidarthritis-24/NNS||severe-23/JJ	prep_of||treatment-21/NN||rheumatoidarthritis-24/NNS	rheumatoidarthritis-24||leflunomide-9||yes||combination of methotrexate and hydroxychloroquine is equivalent to leflunomide in terms of efficacy in reducing disease activity in the initial treatment of severe rheumatoidarthritis.
nsubj||analogue-5/NN||adefovir-1/NN	cop||analogue-5/NN||is-2/VBZ	det||analogue-5/NN||an-3/DT	amod||analogue-5/NN||adenosine-4/JJ	dep||shown-34/VBN||analogue-5/NN	vmod||analogue-5/NN||approved-6/VBN	det||administration-12/NN||the-8/DT	nn||administration-12/NN||food-9/NN	conj_and||food-9/NN||drug-11/NN	nn||administration-12/NN||drug-11/NN	agent||approved-6/VBN||administration-12/NN	det||treatment-15/NN||the-14/DT	prep_for||administration-12/NN||treatment-15/NN	nn||mutations-19/NNS||chronichepatitisb-17/NNP	prep_of||treatment-15/NN||mutations-19/NNS	vmod||mutations-19/NNS||occurring-20/VBG	det||transcriptase-28/NN||the-22/DT	amod||transcriptase-28/NN||hepatitisbvirus-23/JJ	nn||transcriptase-28/NN||-lrb--24/NNP	nn||transcriptase-28/NN||hbv-25/NNP	nn||transcriptase-28/NN||-rrb--26/NNP	amod||transcriptase-28/NN||reverse-27/JJ	prep_in||occurring-20/VBG||transcriptase-28/NN	amod||domains-32/NNS||-lrb--29/JJ	nn||domains-32/NNS||rt-30/NN	nn||domains-32/NNS||-rrb--31/NN	nsubjpass||shown-34/VBN||domains-32/NNS	nsubj||confer-36/VB||domains-32/NNS	auxpass||shown-34/VBN||are-33/VBP	root||ROOT-0/null||shown-34/VBN	aux||confer-36/VB||to-35/TO	xcomp||shown-34/VBN||confer-36/VB	dobj||confer-36/VB||resistance-37/NN	prep_to||confer-36/VB||antiviraldrugs-39/NNS	hbv-25||hepatitisbvirus-23||no||adefovir is an adenosine analogue approved by the food and drug administration for the treatment of chronichepatitisb. mutations occurring in the hepatitisbvirus -lrb- hbv -rrb- reverse transcriptase -lrb- rt -rrb- domains are shown to confer resistance to antiviraldrugs .
amod||factors-2/NNS||occupational-1/JJ	nsubjpass||suggested-21/VBN||factors-2/NNS	nn||type-6/NN||job-5/NN	prep_such_as||factors-2/NNS||type-6/NN	prep_such_as||factors-2/NNS||industry-8/NN	conj_and||type-6/NN||industry-8/NN	prep_such_as||factors-2/NNS||exposures-11/NNS	conj_and||type-6/NN||exposures-11/NNS	prep_to||exposures-11/NNS||chemicals-13/NNS	prep_such_as||chemicals-13/NNS||herbicides-16/NNS	prep_such_as||chemicals-13/NNS||chlorophenols-18/NNS	conj_and||herbicides-16/NNS||chlorophenols-18/NNS	aux||suggested-21/VBN||have-19/VBP	auxpass||suggested-21/VBN||been-20/VBN	root||ROOT-0/null||suggested-21/VBN	nn||factors-24/NNS||risk-23/NN	prep_as||suggested-21/VBN||factors-24/NNS	prep_for||factors-24/NNS||sarcomas-26/NNS	sarcomas-26||herbicides-16||no_rel||occupational factors such as job type, industry, and exposures to chemicals such as herbicides and chlorophenols have been suggested as risk factors for sarcomas.
nsubj||piloting-3/VBG||zambia-1/NN	aux||piloting-3/VBG||is-2/VBZ	root||ROOT-0/null||piloting-3/VBG	det||use-5/NN||the-4/DT	dobj||piloting-3/VBG||use-5/NN	prep_of||use-5/NN||artemether-lumefantrine-7/NN	appos||artemether-lumefantrine-7/NN||al-9/NNP	nn||workers-14/NNS||community-12/NN	nn||workers-14/NNS||health-13/NN	prep_by||piloting-3/VBG||workers-14/NNS	appos||workers-14/NNS||chws-16/NNS	aux||treat-19/VB||to-18/TO	vmod||piloting-3/VBG||treat-19/VB	amod||malaria-21/NN||uncomplicated-20/JJ	dobj||treat-19/VB||malaria-21/NN	malaria-21||artemether--1||yes||zambia is piloting the use of artemether-lumefantrine (al) by community health workers (chws) to treat uncomplicated malaria.
det||ability-2/NN||the-1/DT	nsubj||suggests-20/VBZ||ability-2/NN	prep_of||ability-2/NN||ride-4/NN	aux||enhance-6/VB||to-5/TO	vmod||ride-4/NN||enhance-6/VB	dobj||enhance-6/VB||infectivity-7/NN	amod||vzv-10/NN||cell-free-9/JJ	prep_of||infectivity-7/NN||vzv-10/NN	det||range-14/NN||a-12/DT	amod||range-14/NN||wide-13/JJ	prep_over||enhance-6/VB||range-14/NN	nn||times-17/NNS||incubation-16/NN	prep_of||range-14/NN||times-17/NNS	prep_of||range-14/NN||temperatures-19/NNS	conj_and||times-17/NNS||temperatures-19/NNS	root||ROOT-0/null||suggests-20/VBZ	mark||useful-25/JJ||that-21/IN	nsubj||useful-25/JJ||ride-22/NN	aux||useful-25/JJ||may-23/MD	cop||useful-25/JJ||be-24/VB	ccomp||suggests-20/VBZ||useful-25/JJ	prepc_for||useful-25/JJ||increasing-27/VBG	det||stability-29/NN||the-28/DT	dobj||increasing-27/VBG||stability-29/NN	nn||vaccines-34/NNS||varicella-31/NN	conj_or||varicella-31/NN||zoster-33/NN	nn||vaccines-34/NNS||zoster-33/NN	prep_of||stability-29/NN||vaccines-34/NNS	varicella-31||vzv-10||yes||the ability of ride to enhance infectivity of cell-free vzv over a wide range of incubation times and temperatures suggests that ride may be useful for increasing the stability of varicella or zoster vaccines.
det||trial-8/NN||a-2/DT	amod||trial-8/NN||large-3/JJ	amod||trial-8/NN||acute-4/JJ	amod||trial-8/NN||coronary-5/JJ	nn||trial-8/NN||syndrome-6/NN	amod||trial-8/NN||clinical-7/JJ	prep_in||reduced-11/VBD||trial-8/NN	nsubj||reduced-11/VBD||ranolazine-10/NN	root||ROOT-0/null||reduced-11/VBD	det||incidence-13/NN||the-12/DT	dobj||reduced-11/VBD||incidence-13/NN	prep_of||incidence-13/NN||supraventriculartachycardia-15/NN	prep_of||incidence-13/NN||ventriculartachycardia-17/NN	conj_and||supraventriculartachycardia-15/NN||ventriculartachycardia-17/NN	amod||atrialfibrillation-20/NN||new-onset-19/JJ	prep_of||incidence-13/NN||atrialfibrillation-20/NN	conj_and||supraventriculartachycardia-15/NN||atrialfibrillation-20/NN	amod||events-24/NNS||bradycardic-23/JJ	prep_of||incidence-13/NN||events-24/NNS	conj_and||supraventriculartachycardia-15/NN||events-24/NNS	ranolazine-10||atrialfibrillation-20||no_rel||in a large acute coronary syndrome clinical trial, ranolazine reduced the incidence of supraventriculartachycardia, ventriculartachycardia, new-onset atrialfibrillation, and bradycardic events.
num||±-10/NNS||pmlâ-1/CD	amod||±-10/NNS||$-2/$	num||$-2/$||rar-4/CD	amod||receptor-7/NN||retinoicacid-6/JJ	dep||$-2/$||receptor-7/NN	nn||±-10/NNS||î-9/NN	nsubj||protein-14/NN||±-10/NNS	cop||protein-14/NN||is-11/VBZ	det||protein-14/NN||the-12/DT	nn||protein-14/NN||hallmark-13/NN	root||ROOT-0/null||protein-14/NN	prep_of||protein-14/NN||acutepromyelocyticleukaemia-16/NN	det||subtype-21/NN||a-18/DT	advmod||malignant-20/JJ||highly-19/RB	amod||subtype-21/NN||malignant-20/JJ	appos||acutepromyelocyticleukaemia-16/NN||subtype-21/NN	nsubj||accounts-25/VBZ||subtype-21/NN	prep_of||subtype-21/NN||acutemyeloidleukaemia-23/NN	rcmod||subtype-21/NN||accounts-25/VBZ	quantmod||10-28/CD||approximately-27/RB	num||%-29/NN||10-28/CD	prep_for||accounts-25/VBZ||%-29/NN	det||cases-33/NNS||all-31/DT	nn||cases-33/NNS||aml-32/NN	prep_of||%-29/NN||cases-33/NNS	acutepromyelocyticleukaemia-16||retinoicacid-6||yes||pmlârar (retinoicacid receptor) î± is the hallmark protein of acutepromyelocyticleukaemia, a highly malignant subtype of acutemyeloidleukaemia that accounts for approximately 10% of all aml cases.
poss||opinion-3/NN||my-2/PRP$	prep_in||mentioned-8/VBD||opinion-3/NN	det||approaches-7/NNS||the-4/DT	amod||approaches-7/NNS||different-5/JJ	amod||approaches-7/NNS||surgical-6/JJ	nsubj||mentioned-8/VBD||approaches-7/NNS	root||ROOT-0/null||mentioned-8/VBD	advmod||mentioned-8/VBD||above-9/RB	dep||mentioned-8/VBD||cover-10/VB	quantmod||95-12/CD||almost-11/RB	num||%-13/NN||95-12/CD	dobj||cover-10/VB||%-13/NN	dep||tumors-18/NNS||all-15/PDT	nn||tumors-18/NNS||skull-16/NN	nn||tumors-18/NNS||base-17/NN	prep_of||%-13/NN||tumors-18/NNS	prep_of||%-13/NN||lesions-20/NNS	conj_and||tumors-18/NNS||lesions-20/NNS	base-17||tumors-18||no_rel||in my opinion the different surgical approaches mentioned above cover almost 95% of all skull base tumors and lesions.
det||study-3/NN||the-1/DT	nn||study-3/NN||action-2/NN	nsubj||trial-8/NN||study-3/NN	cop||trial-8/NN||is-4/VBZ	det||trial-8/NN||the-5/DT	amod||trial-8/NN||first-6/JJ	amod||trial-8/NN||controlled-7/JJ	root||ROOT-0/null||trial-8/NN	aux||investigate-10/VB||to-9/TO	vmod||trial-8/NN||investigate-10/VB	det||efficacy-12/NN||the-11/DT	dobj||investigate-10/VB||efficacy-12/NN	prep_of||efficacy-12/NN||atomoxetine-14/NN	ccomp||investigate-10/VB||using-15/VBG	amod||cognitive-17/NN||objective-16/JJ	dobj||using-15/VBG||cognitive-17/NN	amod||markers-21/NNS||emotional-19/JJ	nn||markers-21/NNS||function-20/NN	dobj||using-15/VBG||markers-21/NNS	conj_and||cognitive-17/NN||markers-21/NNS	mark||predict-28/VBP||whether-24/IN	det||measures-27/NNS||these-25/DT	amod||measures-27/NNS||objective-26/JJ	nsubj||predict-28/VBP||measures-27/NNS	nsubj||predict-28/VBP||measures-27/NNS	ccomp||investigate-10/VB||predict-28/VBP	conj_and||using-15/VBG||predict-28/VBP	conj_and||using-15/VBG||predict-28/VBP	conj_and||predict-28/VBP||predict-28/VBP	dobj||predict-28/VBP||outcomes-29/NNS	prep_with||predict-28/VBP||atomoxetine-31/NN	prep_in||atomoxetine-31/NN||adhd-33/NN	amod||anxiety-38/NN||comorbid-37/JJ	prep_with||predict-28/VBP||anxiety-38/NN	prep_without||predict-28/VBP||anxiety-38/NN	adhd-33||atomoxetine-31||yes||the action study is the first controlled trial to investigate the efficacy of atomoxetine using objective cognitive and emotional function markers, and whether these objective measures predict outcomes with atomoxetine in adhd with and without comorbid anxiety.
nn||options-2/NNS||treatment-1/NN	nsubj||increased-9/VBN||options-2/NNS	prep_for||options-2/NNS||adhd-4/NN	det||netherlands-7/NNS||the-6/DT	prep_in||adhd-4/NN||netherlands-7/NNS	aux||increased-9/VBN||have-8/VBP	root||ROOT-0/null||increased-9/VBN	det||introduction-12/NN||the-11/DT	prep_with||increased-9/VBN||introduction-12/NN	det||formulations-16/NNS||the-14/DT	amod||formulations-16/NNS||extended-release-15/JJ	prep_of||introduction-12/NN||formulations-16/NNS	prep_of||formulations-16/NNS||methylphenidate-18/NN	nn||er-21/NN||mph-20/NN	appos||methylphenidate-18/NN||er-21/NN	nn||®-24/NNP||concertaâ-23/NNP	dep||er-21/NN||®-24/NNP	prep_in||methylphenidate-18/NN||2003-27/CD	prep_of||formulations-16/NNS||atomoxetine-29/NN	conj_and||methylphenidate-18/NN||atomoxetine-29/NN	appos||atomoxetine-29/NN||atx-31/NN	nn||®-34/NNP||stratteraâ-33/NNP	dep||atx-31/NN||®-34/NNP	prep_in||atomoxetine-29/NN||2005-37/CD	nsubj||scarce-49/JJ||data-40/NNS	det||effect-43/NN||the-42/DT	prep_on||data-40/NNS||effect-43/NN	nn||patterns-47/NNS||drug-45/NN	nn||patterns-47/NNS||usage-46/NN	prep_on||effect-43/NN||patterns-47/NNS	cop||scarce-49/JJ||are-48/VBP	conj_but||increased-9/VBN||scarce-49/JJ	adhd-4||methylphenidate-18||yes||treatment options for adhd in the netherlands have increased with the introduction of the extended-release formulations of methylphenidate (mph er, concertaâ®) in 2003 and atomoxetine (atx, stratteraâ®) in 2005, but data on the effect on drug usage patterns are scarce.
aux||begin-2/VB||to-1/TO	advcl||utilized-23/VBD||begin-2/VB	aux||understand-4/VB||to-3/TO	xcomp||begin-2/VB||understand-4/VB	det||contributions-6/NNS||the-5/DT	dobj||understand-4/VB||contributions-6/NNS	amod||obesity-9/NN||maternal-8/JJ	prep_of||contributions-6/NNS||obesity-9/NN	prep_of||contributions-6/NNS||over-nutrition-11/NN	conj_and||obesity-9/NN||over-nutrition-11/NN	amod||development-14/NN||human-13/JJ	prep_to||understand-4/VB||development-14/NN	det||origins-18/NNS||the-16/DT	amod||origins-18/NNS||early-17/JJ	prep_to||understand-4/VB||origins-18/NNS	conj_and||development-14/NN||origins-18/NNS	prep_of||origins-18/NNS||obesity-20/NN	nsubj||utilized-23/VBD||we-22/PRP	root||ROOT-0/null||utilized-23/VBD	det||model-27/NN||a-24/DT	amod||model-27/NN||non-human-25/JJ	nn||model-27/NN||primate-26/NN	dobj||utilized-23/VBD||model-27/NN	aux||investigate-29/VB||to-28/TO	vmod||utilized-23/VBD||investigate-29/VB	det||effects-31/NNS||the-30/DT	dobj||investigate-29/VB||effects-31/NNS	amod||feeding-35/NN||maternal-33/JJ	amod||feeding-35/NN||high-fat-34/JJ	prep_of||effects-31/NNS||feeding-35/NN	vmod||utilized-23/VBD||obesity-37/VB	conj_and||investigate-29/VB||obesity-37/VB	nn||milk-40/NN||breast-39/NN	prep_on||obesity-37/VB||milk-40/NN	prep_on||obesity-37/VB||maternal-42/NN	conj_and||milk-40/NN||maternal-42/NN	amod||composition-47/NN||fetal-44/JJ	nn||composition-47/NN||plasma-45/NN	nn||composition-47/NN||fattyacid-46/NN	prep_on||obesity-37/VB||composition-47/NN	conj_and||milk-40/NN||composition-47/NN	amod||development-51/NN||fetal-49/JJ	amod||development-51/NN||hepatic-50/JJ	conj_and||milk-40/NN||development-51/NN	conj_and||composition-47/NN||development-51/NN	obesity-37||fattyacid-46||no_rel||to begin to understand the contributions of maternal obesity and over-nutrition to human development and the early origins of obesity, we utilized a non-human primate model to investigate the effects of maternal high-fat feeding and obesity on breast milk, maternal and fetal plasma fattyacid composition and fetal hepatic development.
aux||characterize-3/VB||to-1/TO	advmod||characterize-3/VB||better-2/RBR	dep||tested-14/VBD||characterize-3/VB	dobj||characterize-3/VB||mutations-4/NNS	amod||oncogenes-8/NNP||established-6/VBN	amod||oncogenes-8/NNP||known-7/VBN	prep_in||mutations-4/NNS||oncogenes-8/NNP	nn||genes-12/NNS||tumor-10/NN	nn||genes-12/NNS||suppressor-11/NN	prep_in||mutations-4/NNS||genes-12/NNS	conj_and||oncogenes-8/NNP||genes-12/NNS	nsubj||tested-14/VBD||we-13/PRP	root||ROOT-0/null||tested-14/VBD	det||spectrometric-17/NN||a-15/DT	amod||spectrometric-17/NN||mass-16/JJ	dobj||tested-14/VBD||spectrometric-17/NN	vmod||spectrometric-17/NN||based-18/VBN	dobj||based-18/VBN||platform-19/NN	aux||interrogate-21/VB||to-20/TO	vmod||based-18/VBN||interrogate-21/VB	amod||cancer-23/NN||common-22/JJ	dobj||interrogate-21/VB||cancer-23/NN	vmod||cancer-23/NN||associated-24/VBN	dobj||associated-24/VBN||mutations-25/NNS	det||panel-28/NN||a-27/DT	prep_across||associated-24/VBN||panel-28/NN	num||paraffin-33/NNS||77-30/CD	nn||paraffin-33/NNS||formalin-31/NN	amod||paraffin-33/NNS||fixed-32/VBN	prep_of||panel-28/NN||paraffin-33/NNS	vmod||paraffin-33/NNS||embedded-34/VBN	amod||cases-37/NNS||archived-35/JJ	nn||cases-37/NNS||btc-36/NN	dobj||embedded-34/VBN||cases-37/NNS	paraffin-33||tumor-10||no_rel||to better characterize mutations in established known oncogenes and tumor suppressor genes we tested a mass spectrometric based platform to interrogate common cancer associated mutations across a panel of 77 formalin fixed paraffin embedded archived btc cases.
det||structure-3/NN||the-1/DT	nn||structure-3/NN||crystal-2/NN	nsubj||consists-16/VBZ||structure-3/NN	nsubj||consists-16/VBZ||structure-3/NN	det||compound-7/NN||the-5/DT	nn||compound-7/NN||title-6/NN	prep_of||structure-3/NN||compound-7/NN	nn||-RSB--14/NNP||-LSB--9/NNP	nn||-RSB--14/NNP||zncl2-10/NNP	appos||-RSB--14/NNP||c10h8n2s-12/NNP	appos||structure-3/NN||-RSB--14/NNP	root||ROOT-0/null||consists-16/VBZ	conj_and||consists-16/VBZ||consists-16/VBZ	det||ring-21/NN||a-18/DT	amod||ring-21/NN||six-membered-19/JJ	nn||ring-21/NN||chelate-20/NN	prep_of||consists-16/VBZ||ring-21/NN	prep_in||tetraâhedrally-29/JJ||ring-21/NN	det||atom-26/NN||the-24/DT	nn||atom-26/NN||zn-25/NN	nsubj||tetraâhedrally-29/JJ||atom-26/NN	cop||tetraâhedrally-29/JJ||is-27/VBZ	advmod||tetraâhedrally-29/JJ||approximately-28/RB	rcmod||ring-21/NN||tetraâhedrally-29/JJ	dep||tetraâhedrally-29/JJ||coordinated-30/VBN	num||ions-34/NNS||two-32/CD	nn||ions-34/NNS||chloride-33/NN	prep_by||coordinated-30/VBN||ions-34/NNS	det||atoms-41/NNS||the-37/DT	num||atoms-41/NNS||two-38/CD	amod||atoms-41/NNS||pyridyl-39/JJ	nn||atoms-41/NNS||n-40/NN	prep_by||consists-16/VBZ||atoms-41/NNS	det||sulfide-46/NN||a-43/DT	amod||sulfide-46/NN||single-44/JJ	amod||sulfide-46/NN||di-2-pyridyl-45/JJ	prep_of||atoms-41/NNS||sulfide-46/NN	vmod||sulfide-46/NN||ligand-47/VBN	crystal-2||di--1||no_rel||the crystal structure of the title compound, [zncl2(c10h8n2s)], consists of a six-membered chelate ring in which the zn atom is approximately tetraâ­hedrally coordinated by two chloride ions and by the two pyridyl n atoms of a single di-2-pyridyl sulfide ligand.
amod||dst-3/NN||conventional-2/JJ	agent||classified-8/VBN||dst-3/NN	num||strains-6/NNS||55-5/CD	nsubjpass||classified-8/VBN||strains-6/NNS	auxpass||classified-8/VBN||were-7/VBD	root||ROOT-0/null||classified-8/VBN	prep_as||classified-8/VBN||mdr-tb-10/NN	num||strains-13/NNS||four-12/CD	nsubjpass||rifampicin-15/VBN||strains-13/NNS	auxpass||rifampicin-15/VBN||were-14/VBD	conj_and||classified-8/VBN||rifampicin-15/VBN	xcomp||rifampicin-15/VBN||mono-resistant-16/JJ	num||strains-19/NNS||52-18/CD	nsubj||susceptible-21/JJ||strains-19/NNS	cop||susceptible-21/JJ||were-20/VBD	conj_and||classified-8/VBN||susceptible-21/JJ	det||drugs-25/NNS||all-23/DT	amod||drugs-25/NNS||first-line-24/JJ	prep_to||susceptible-21/JJ||drugs-25/NNS	tb--1||rifampicin-15||yes||by conventional dst, 55 strains were classified as mdr-tb, four strains were rifampicin mono-resistant and 52 strains were susceptible to all first-line drugs.
amod||levels-14/NNS||serum-1/JJ	amod||levels-14/NNS||interleukin-8-2/JJ	dep||interleukin-8-2/JJ||il-8-4/JJ	conj_and||interleukin-8-2/JJ||interferon-alpha-7/JJ	amod||levels-14/NNS||interferon-alpha-7/JJ	dep||interferon-alpha-7/JJ||ifn-9/NN	nn||±-12/NNS||î-11/NN	dep||ifn-9/NN||±-12/NNS	nsubjpass||estimated-17/VBN||levels-14/NNS	aux||estimated-17/VBN||have-15/VBP	auxpass||estimated-17/VBN||been-16/VBN	root||ROOT-0/null||estimated-17/VBN	det||total-20/NN||a-19/DT	prep_from||estimated-17/VBN||total-20/NN	num||individuals-23/NNS||88-22/CD	prep_of||total-20/NN||individuals-23/NNS	prep_of||individuals-30/NNS||individuals-23/NNS	nsubj||individuals-30/NNS||19-26/CD	cop||individuals-30/NNS||were-27/VBD	amod||individuals-30/NNS||disease-free-28/JJ	amod||individuals-30/NNS||healthy-29/JJ	rcmod||individuals-23/NNS||individuals-30/NNS	nsubj||patients-35/NNS||69-33/CD	cop||patients-35/NNS||were-34/VBD	conj_and||estimated-17/VBN||patients-35/NNS	nn||goitre-39/NN||thyroid-37/NN	nn||goitre-39/NN||diseases-38/NNS	prep_with||patients-35/NNS||goitre-39/NN	dep||goitre-39/NN||n-41/VBN	dep||21-43/CD||=-42/SYM	ccomp||n-41/VBN||21-43/CD	prep_with||patients-35/NNS||autoimmunediseases-46/NNS	conj_and||goitre-39/NN||autoimmunediseases-46/NNS	dep||autoimmunediseases-46/NNS||n-48/VBN	dep||16-50/CD||=-49/SYM	ccomp||n-48/VBN||16-50/CD	prep_with||patients-35/NNS||carcinomas-54/NNS	conj_and||goitre-39/NN||carcinomas-54/NNS	dep||carcinomas-54/NNS||n-56/VBN	dep||32-58/CD||=-57/SYM	ccomp||n-56/VBN||32-58/CD	autoimmunediseases-46||interferon--1||no||serum interleukin-8 (il-8) and interferon-alpha (ifn- î± ) levels have been estimated from a total of 88 individuals of which 19 were disease-free healthy individuals, and 69 were patients with thyroid diseases goitre ( n = 21), autoimmunediseases ( n = 16), and carcinomas ( n = 32).
det||increase-2/NN||an-1/DT	nsubjpass||associated-12/VBN||increase-2/NN	nsubjpass||associated-12/VBN||increase-2/NN	amod||adiposity-9/NN||total-4/JJ	conj_and||total-4/JJ||visceral-8/JJ	amod||adiposity-9/NN||visceral-8/JJ	prep_in||increase-2/NN||adiposity-9/NN	auxpass||associated-12/VBN||is-10/VBZ	advmod||associated-12/VBN||probably-11/RB	root||ROOT-0/null||associated-12/VBN	conj_negcc||associated-12/VBN||associated-12/VBN	det||decrease-15/NN||a-14/DT	prep_with||associated-12/VBN||decrease-15/NN	nn||distensibility-18/NN||vascular-17/NN	prep_in||decrease-15/NN||distensibility-18/NN	det||boys-24/NNS||the-20/DT	nn||boys-24/NNS||gujarati-21/NN	nn||boys-24/NNS||indian-22/NN	amod||boys-24/NNS||adolescent-23/JJ	prep_in||distensibility-18/NN||boys-24/NNS	prep_in||associated-12/VBN||girls-28/NNS	advmod||indicating-31/VBG||thus-30/RB	xcomp||associated-12/VBN||indicating-31/VBG	det||role-34/NN||a-32/DT	amod||role-34/NN||protective-33/JJ	dobj||indicating-31/VBG||role-34/NN	amod||estrogen-38/NN||female-36/JJ	nn||estrogen-38/NN||sexhormone-37/NN	prep_of||role-34/NN||estrogen-38/NN	nsubjpass||shown-42/VBN||estrogen-38/NN	nsubj||protect-45/VB||estrogen-38/NN	aux||shown-42/VBN||has-40/VBZ	auxpass||shown-42/VBN||been-41/VBN	rcmod||estrogen-38/NN||shown-42/VBN	advmod||shown-42/VBN||earlier-43/RBR	aux||protect-45/VB||to-44/TO	xcomp||shown-42/VBN||protect-45/VB	det||vasculature-47/NN||the-46/DT	dobj||protect-45/VB||vasculature-47/NN	prep_from||protect-45/VB||atherosclerosis-49/NNS	amod||dysfunction-52/NN||endothelial-51/JJ	appos||atherosclerosis-49/NNS||dysfunction-52/NN	nsubj||occurs-54/VBZ||dysfunction-52/NN	rcmod||dysfunction-52/NN||occurs-54/VBZ	prep_with||occurs-54/VBZ||increase-56/NN	prep_in||increase-56/NN||adiposity-58/NN	adiposity-58||estrogen-38||no_rel||an increase in total as well as visceral adiposity is probably associated with a decrease in vascular distensibility in the gujarati indian adolescent boys but not in girls, thus indicating a protective role of female sexhormone estrogen which has been shown earlier to protect the vasculature from atherosclerosis, endothelial dysfunction which occurs with increase in adiposity.
nsubj||suggest-6/VBP||results-1/NNS	det||study-4/NN||this-3/DT	prep_in||results-1/NNS||study-4/NN	advmod||suggest-6/VBP||also-5/RB	root||ROOT-0/null||suggest-6/VBP	mark||originate-13/VB||that-7/IN	amod||viruses-10/NNS||genotype-8/JJ	nn||viruses-10/NNS||ix-9/NN	nsubj||originate-13/VB||viruses-10/NNS	advmod||likely-12/JJ||most-11/RBS	amod||viruses-10/NNS||likely-12/JJ	ccomp||suggest-6/VBP||originate-13/VB	det||virus-18/NN||a-15/DT	amod||virus-18/NN||genotype-16/JJ	nn||virus-18/NN||iii-17/NN	prep_from||originate-13/VB||virus-18/NN	prep_by||originate-13/VB||insertion-20/NN	det||motif-24/NN||a-22/DT	amod||motif-24/NN||6-nt-23/JJ	prep_of||insertion-20/NN||motif-24/NN	det||5-27/CD||the-26/DT	prep_in||motif-24/NN||5-27/CD	dep||5-27/CD||ncr-30/NN	nsubj||occurred-37/VBN||ncr-30/NN	det||gene-34/NN||the-32/DT	nn||gene-34/NN||np-33/NN	prep_of||ncr-30/NN||gene-34/NN	aux||occurred-37/VBN||had-36/VBD	rcmod||ncr-30/NN||occurred-37/VBN	mark||s-43/VBZ||as-38/IN	advmod||as-40/RB||early-39/RB	nsubj||s-43/VBZ||as-40/RB	prep_in||as-40/RB||1940-42/CD	advcl||occurred-37/VBN||s-43/VBZ	aux||origin-50/NN||might-46/MD	cop||origin-50/NN||be-47/VB	det||origin-50/NN||the-48/DT	amod||origin-50/NN||common-49/JJ	advcl||occurred-37/VBN||origin-50/NN	conj_and||s-43/VBZ||origin-50/NN	amod||viruses-54/NNS||genotype-52/JJ	nn||viruses-54/NNS||v-viii-53/NN	prep_of||origin-50/NN||viruses-54/NNS	virus-18||viruses-54||no||results in this study also suggest that genotype ix viruses most likely originate from a genotype iii virus by insertion of a 6-nt motif in the 5'-ncr of the np gene which had occurred as early as in 1940 s, and might be the common origin of genotype v-viii viruses.
amod||understanding-2/NN||greater-1/JJR	nsubj||help-20/VB||understanding-2/NN	det||interplay-5/NN||the-4/DT	prep_of||understanding-2/NN||interplay-5/NN	det||factors-9/NNS||the-7/DT	amod||factors-9/NNS||key-8/JJ	prep_between||interplay-5/NN||factors-9/NNS	vmod||factors-9/NNS||involved-10/VBN	det||regulation-13/NN||the-12/DT	prep_in||involved-10/VBN||regulation-13/NN	nn||metabolism-16/NN||iron-15/NN	prep_of||regulation-13/NN||metabolism-16/NN	prep_of||regulation-13/NN||erythropoiesis-18/NNS	conj_and||metabolism-16/NN||erythropoiesis-18/NNS	aux||help-20/VB||will-19/MD	root||ROOT-0/null||help-20/VB	xcomp||help-20/VB||develop-21/VB	advmod||effective-23/JJ||more-22/RBR	amod||therapies-24/NNS||effective-23/JJ	dobj||develop-21/VB||therapies-24/NNS	prep_for||develop-21/VB||disorders-26/NNS	nn||irondeficiency-30/NN||ironoverload-28/NN	prep_of||disorders-26/NNS||irondeficiency-30/NN	nn||synthesis-34/NN||hemoglobin-33/NN	prep_of||disorders-26/NNS||synthesis-34/NN	conj_and||irondeficiency-30/NN||synthesis-34/NN	irondeficiency-30||iron-15||yes||greater understanding of the interplay between the key factors involved in the regulation of iron metabolism and erythropoiesis will help develop more effective therapies for disorders of ironoverload, irondeficiency, and hemoglobin synthesis.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||develop-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||develop-8/VB||to-7/TO	xcomp||was-6/VBD||develop-8/VB	det||system-12/NN||a-9/DT	amod||system-12/NN||partial-10/JJ	amod||system-12/NN||closed-loop-11/JJ	dobj||develop-8/VB||system-12/NN	aux||prevent-15/VB||to-13/TO	advmod||prevent-15/VB||safely-14/RB	vmod||develop-8/VB||prevent-15/VB	amod||hypoglycemia-17/NN||nocturnal-16/JJ	dobj||prevent-15/VB||hypoglycemia-17/NN	prepc_by||prevent-15/VB||suspending-19/VBG	nn||delivery-21/NN||insulin-20/NN	dobj||suspending-19/VBG||delivery-21/NN	tmod||predicted-25/VBN||delivery-21/NN	advmod||predicted-25/VBN||when-22/WRB	nsubjpass||predicted-25/VBN||hypoglycemia-23/NN	auxpass||predicted-25/VBN||is-24/VBZ	rcmod||delivery-21/NN||predicted-25/VBN	prep_in||predicted-25/VBN||type1diabetes-27/CD	insulin-20||type1diabetes-27||no_rel||the aim of this study was to develop a partial closed-loop system to safely prevent nocturnal hypoglycemia by suspending insulin delivery when hypoglycemia is predicted in type1diabetes.
amod||infection-7/NN||occult-1/JJ	amod||infection-7/NN||hepatitisb-2/JJ	nn||infection-7/NN||virus-3/NN	appos||infection-7/NN||hbv-5/NN	nsubj||transmit-9/VB||infection-7/NN	aux||transmit-9/VB||might-8/MD	root||ROOT-0/null||transmit-9/VB	amod||units-11/NNS||viremic-10/JJ	dobj||transmit-9/VB||units-11/NNS	det||supply-16/NN||the-13/DT	amod||supply-16/NN||public-14/JJ	nn||supply-16/NN||blood-15/NN	prep_into||transmit-9/VB||supply-16/NN	mark||used-27/VBN||if-17/IN	advmod||antigen-21/NN||only-18/RB	nn||antigen-21/NN||hepatitisb-19/NN	nn||antigen-21/NN||surface-20/NN	nsubjpass||used-27/VBN||antigen-21/NN	appos||antigen-21/NN||hbsag-23/NN	vmod||antigen-21/NN||testing-25/VBG	auxpass||used-27/VBN||is-26/VBZ	advcl||transmit-9/VB||used-27/VBN	nn||screening-30/NN||donor-29/NN	prep_for||used-27/VBN||screening-30/NN	hbv-5||hbsag-23||yes||occult hepatitisb virus (hbv) infection might transmit viremic units into the public blood supply if only hepatitisb surface antigen (hbsag) testing is used for donor screening.
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	det||effects-4/NNS||the-3/DT	iobj||evaluated-2/VBN||effects-4/NNS	det||therapy-8/NN||a-6/DT	amod||therapy-8/NN||combined-7/JJ	prep_of||effects-4/NNS||therapy-8/NN	amod||âµg-18/NN||budesonide-10/JJ	dep||budesonide-10/JJ||200-11/CD	nn||âµg-18/NN||âµg-12/NN	advmod||daily-14/RB||twice-13/RB	advmod||âµg-18/NN||daily-14/RB	conj_and||daily-14/RB||formoterol-16/JJ	advmod||âµg-18/NN||formoterol-16/JJ	dep||formoterol-16/JJ||6-17/CD	prep_of||therapy-8/NN||âµg-18/NN	advmod||daily-20/RB||twice-19/RB	dobj||evaluated-2/VBN||daily-20/RB	prepc_compared_with||evaluated-2/VBN||with-22/IN	amod||âµg-25/NN||budesonide-23/JJ	dep||budesonide-23/JJ||200-24/CD	pobj||evaluated-2/VBN||âµg-25/NN	advmod||âµg-25/NN||twice-26/RB	advmod||alone-28/RB||daily-27/RB	pobj||twice-26/RB||alone-28/RB	nn||questionnaire-32/NN||asthma-30/NN	nn||questionnaire-32/NN||control-31/NN	prep_on||twice-26/RB||questionnaire-32/NN	appos||questionnaire-32/NN||acq-34/NN	nn||quality-38/NN||asthma-37/NN	appos||questionnaire-32/NN||quality-38/NN	nn||questionnaire-41/NN||life-40/NN	prep_of||quality-38/NN||questionnaire-41/NN	appos||quality-38/NN||aqlq-43/NNP	dep||aqlq-43/NNP||juniper-45/NN	amod||function-49/NN||pulmonary-48/JJ	appos||questionnaire-32/NN||function-49/NN	conj_and||quality-38/NN||function-49/NN	amod||inflammation-52/NN||airway-51/JJ	appos||questionnaire-32/NN||inflammation-52/NN	conj_and||quality-38/NN||inflammation-52/NN	det||study-59/NN||a-55/DT	amod||study-59/NN||cross-over-56/JJ	amod||study-59/NN||randomized-57/JJ	amod||study-59/NN||double-blind-58/JJ	prep_in||evaluated-2/VBN||study-59/NN	nn||periods-62/NNS||treatment-61/NN	prep_with||study-59/NN||periods-62/NNS	num||months-65/NNS||two-64/CD	prep_of||periods-62/NNS||months-65/NNS	vmod||months-65/NNS||separated-66/VBN	det||period-71/NN||a-68/DT	amod||period-71/NN||one-month-69/JJ	amod||period-71/NN||wash-out-70/JJ	agent||separated-66/VBN||period-71/NN	asthma-37||budesonide-23||no||we evaluated the effects of a combined therapy of budesonide 200 âµg twice daily and formoterol 6 âµg twice daily compared with budesonide 200 âµg twice daily alone on asthma control questionnaire (acq), asthma quality of life questionnaire (aqlq- juniper), pulmonary function and airway inflammation, in a cross-over randomized double-blind study with treatment periods of two months separated by a one-month wash-out period.
det||aim-2/NN||the-1/DT	nsubj||was-7/VBD||aim-2/NN	nsubj||evaluate-9/VB||aim-2/NN	det||study-6/NN||the-4/DT	amod||study-6/NN||current-5/JJ	prep_of||aim-2/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||evaluate-9/VB||to-8/TO	xcomp||was-7/VBD||evaluate-9/VB	amod||patients-12/NNS||stemi-11/JJ	prep_in||evaluate-9/VB||patients-12/NNS	dep||patients-12/NNS||undergoing-13/VBG	amod||intervention-17/NN||primary-14/JJ	amod||intervention-17/NN||percutaneous-15/JJ	amod||intervention-17/NN||coronary-16/JJ	dobj||undergoing-13/VBG||intervention-17/NN	appos||intervention-17/NN||pci-19/NN	prep_with||intervention-17/NN||abciximab-22/NN	dep||patients-12/NNS||stenting-24/VBG	conj_and||undergoing-13/VBG||stenting-24/VBG	mark||safe-33/JJ||whether-25/IN	amod||reversal-27/NN||immediate-26/JJ	nsubj||safe-33/JJ||reversal-27/NN	prep_of||reversal-27/NN||anticoagulation-29/NN	prep_by||anticoagulation-29/NN||protamine-31/NN	cop||safe-33/JJ||is-32/VBZ	ccomp||stenting-24/VBG||safe-33/JJ	dep||patients-12/NNS||associated-35/JJ	conj_and||undergoing-13/VBG||associated-35/JJ	det||reduction-38/NN||a-37/DT	prep_with||associated-35/JJ||reduction-38/NN	det||occurrence-41/NN||the-40/DT	prep_in||reduction-38/NN||occurrence-41/NN	amod||complications-44/NNS||bleeding-43/VBG	prep_of||occurrence-41/NN||complications-44/NNS	bleeding-43||abciximab-22||no||the aim of the current study was to evaluate in stemi patients undergoing primary percutaneous coronary intervention (pci) with abciximab and stenting whether immediate reversal of anticoagulation by protamine is safe and associated with a reduction in the occurrence of bleeding complications.
advmod||shown-7/VBN||now-1/RB	det||circumcision-4/NN||that-2/DT	amod||circumcision-4/NN||male-3/JJ	nsubjpass||shown-7/VBN||circumcision-4/NN	nsubj||have-9/VB||circumcision-4/NN	aux||shown-7/VBN||has-5/VBZ	auxpass||shown-7/VBN||been-6/VBN	root||ROOT-0/null||shown-7/VBN	aux||have-9/VB||to-8/TO	xcomp||shown-7/VBN||have-9/VB	det||effect-12/NN||a-10/DT	amod||effect-12/NN||protective-11/JJ	dobj||have-9/VB||effect-12/NN	prep_for||effect-12/NN||men-14/NNS	prep_against||men-14/NNS||hivinfection-16/NN	advmod||needs-29/VBZ||when-17/WRB	ccomp||needs-29/VBZ||engaging-18/JJ	amod||intercourse-21/NN||vaginal-20/JJ	prep_in||engaging-18/JJ||intercourse-21/NN	amod||women-24/NNS||hiv-infected-23/JJ	prep_with||engaging-18/JJ||women-24/NNS	det||focus-28/NN||the-26/DT	nn||focus-28/NN||research-27/NN	nsubj||needs-29/VBZ||focus-28/NN	nsubj||shift-31/VB||focus-28/NN	advcl||have-9/VB||needs-29/VBZ	aux||shift-31/VB||to-30/TO	xcomp||needs-29/VBZ||shift-31/VB	det||studies-35/NNS||the-33/DT	amod||studies-35/NNS||operational-34/JJ	prep_towards||shift-31/VB||studies-35/NNS	nsubj||pave-38/VB||studies-35/NNS	aux||pave-38/VB||can-37/MD	rcmod||studies-35/NNS||pave-38/VB	det||way-40/NN||the-39/DT	dobj||pave-38/VB||way-40/NN	amod||implementation-43/NN||effective-42/JJ	prep_for||pave-38/VB||implementation-43/NN	nn||programs-46/NNS||circumcision-45/NN	prep_of||implementation-43/NN||programs-46/NNS	hivinfection-16||hiv--1||no||now that male circumcision has been shown to have a protective effect for men against hivinfection when engaging in vaginal intercourse with hiv-infected women, the research focus needs to shift towards the operational studies that can pave the way for effective implementation of circumcision programs.
amod||concerns-2/NNS||major-1/JJ	nsubj||role-5/NN||concerns-2/NNS	cop||role-5/NN||are-3/VBP	poss||role-5/NN||their-4/PRP$	root||ROOT-0/null||role-5/NN	amod||pathogens-8/NNS||opportunistic-7/JJ	prep_as||role-5/NN||pathogens-8/NNS	amod||infections-11/NNS||hiv/aids-10/JJ	prep_in||pathogens-8/NNS||infections-11/NNS	aids--1||hiv--1||no||major concerns are their role as opportunistic pathogens in hiv/aids infections.
nsubjpass||presented-3/VBN||evidence-1/NN	auxpass||presented-3/VBN||is-2/VBZ	root||ROOT-0/null||presented-3/VBN	mark||involves-7/VBZ||that-4/IN	amod||stress-6/NN||oxidative-5/JJ	nsubj||involves-7/VBZ||stress-6/NN	ccomp||presented-3/VBN||involves-7/VBZ	det||development-9/NN||the-8/DT	dobj||involves-7/VBZ||development-9/NN	det||subset-13/NN||an-11/DT	amod||subset-13/NN||aggressive-12/JJ	prep_of||development-9/NN||subset-13/NN	amod||breasttumours-18/NNS||primary-15/JJ	amod||breasttumours-18/NNS||oestrogen-16/JJ	amod||breasttumours-18/NNS||receptor-positive-17/JJ	prep_of||subset-13/NN||breasttumours-18/NNS	breasttumours-18||oestrogen-16||yes||evidence is presented that oxidative stress involves the development of an aggressive subset of primary oestrogen receptor-positive breasttumours.
det||specimens-2/NNS||the-1/DT	nsubjpass||stored-4/VBN||specimens-2/NNS	auxpass||stored-4/VBN||were-3/VBD	root||ROOT-0/null||stored-4/VBN	num||ml-7/NN||20-6/CD	prep_in||stored-4/VBN||ml-7/NN	det||rinse-11/NN||each-9/DT	nn||rinse-11/NN||mouth-10/NN	prep_of||ml-7/NN||rinse-11/NN	amod||alcohol-free-15/NN||oral-13/JJ	amod||alcohol-free-15/NN||b-14/JJ	dep||rinse-11/NN||alcohol-free-15/NN	amod||rinse-22/NN||listerine-17/JJ	nn||rinse-22/NN||tooth-18/NN	nn||rinse-22/NN||defense-19/NN	nn||rinse-22/NN||anti-cavity-20/NN	nn||rinse-22/NN||fluoride-21/NN	dep||rinse-11/NN||rinse-22/NN	conj_and||alcohol-free-15/NN||rinse-22/NN	dep||rinse-11/NN||klorhex-24/NN	conj_and||alcohol-free-15/NN||klorhex-24/NN	num||hours-28/NNS||12-27/CD	prep_for||rinse-11/NN||hours-28/NNS	cavity--1||fluoride-21||yes||the specimens were stored in 20 ml of each mouth rinse (oral b alcohol-free, listerine tooth defense anti-cavity fluoride rinse and klorhex) for 12 hours.
det||models-4/NNS||the-2/DT	amod||models-4/NNS||three-parameter-3/JJ	prep_for||provided-7/VBD||models-4/NNS	nsubj||provided-7/VBD||hch-1-6/JJ	root||ROOT-0/null||provided-7/VBD	det||fit-10/NN||the-8/DT	amod||fit-10/NN||best-9/JJS	dobj||provided-7/VBD||fit-10/NN	mark||includes-14/VBZ||because-11/IN	det||model-13/NN||the-12/DT	nsubj||includes-14/VBZ||model-13/NN	advcl||provided-7/VBD||includes-14/VBZ	det||parameter-18/NN||a-15/DT	amod||parameter-18/NN||fractional-16/JJ	nn||parameter-18/NN||coverage-17/NN	dobj||includes-14/VBZ||parameter-18/NN	nsubj||accounts-24/VBZ||parameter-18/NN	nn||-21/NNP||ï-20/NNP	appos||parameter-18/NN||-21/NNP	rcmod||parameter-18/NN||accounts-24/VBZ	det||number-27/NN||the-26/DT	prep_for||accounts-24/VBZ||number-27/NN	amod||sites-30/NNS||reactive-29/JJ	prep_of||number-27/NN||sites-30/NNS	vmod||sites-30/NNS||covered-31/VBN	det||enzymes-34/NNS||the-33/DT	agent||covered-31/VBN||enzymes-34/NNS	enzymes-34||fit-10||no_rel||for the three-parameter models, hch-1 provided the best fit because the model includes a fractional coverage parameter (ï) which accounts for the number of reactive sites covered by the enzymes.
nsubj||one-3/CD||irondeficiency-1/NN	cop||one-3/CD||is-2/VBZ	root||ROOT-0/null||one-3/CD	det||disorders-9/NNS||the-5/DT	advmod||nutritional-8/JJ||most-6/RBS	amod||nutritional-8/JJ||common-7/JJ	amod||disorders-9/NNS||nutritional-8/JJ	prep_of||one-3/CD||disorders-9/NNS	advmod||one-3/CD||worldwide-10/RB	nn||donation-13/NN||blood-12/NN	nsubj||cause-15/VB||donation-13/NN	aux||cause-15/VB||may-14/MD	conj_and||one-3/CD||cause-15/VB	nn||depletion-17/NN||iron-16/NN	dobj||cause-15/VB||depletion-17/NN	irondeficiency-1||iron-16||yes||irondeficiency is one of the most common nutritional disorders worldwide and blood donation may cause iron depletion.
advmod||reported-23/VBN||recently-1/RB	det||effectiveness-4/NN||the-3/DT	nsubjpass||reported-23/VBN||effectiveness-4/NN	amod||endoscopic-7/JJ||percutaneous-6/JJ	amod||placement-13/NNS||endoscopic-7/JJ	amod||placement-13/NNS||gastrostomy-8/JJ	appos||placement-13/NNS||peg-10/NNP	nn||placement-13/NNS||tube-12/NN	prep_of||effectiveness-4/NN||placement-13/NNS	amod||bowelobstruction-16/NN||malignant-15/JJ	prep_for||placement-13/NNS||bowelobstruction-16/NN	nn||carcinoma-20/NN||ovarian-19/NN	prep_due_to||placement-13/NNS||carcinoma-20/NN	aux||reported-23/VBN||has-21/VBZ	auxpass||reported-23/VBN||been-22/VBN	root||ROOT-0/null||reported-23/VBN	neg||patients-28/NNS||not-26/RB	det||patients-28/NNS||all-27/DT	nsubj||received-29/VBD||patients-28/NNS	conj_but||reported-23/VBN||received-29/VBD	amod||decompression-31/NN||effective-30/JJ	dobj||received-29/VBD||decompression-31/NN	bowelobstruction-16||peg-10||no||recently, the effectiveness of percutaneous endoscopic gastrostomy (peg) tube placement for malignant bowelobstruction due to ovarian carcinoma has been reported, but not all patients received effective decompression.
amod||mice-3/NNS||balb/c-2/JJ	prep_in||superior-13/JJ||mice-3/NNS	nsubj||superior-13/JJ||administration-5/NN	nsubj||intramuscular-15/VB||administration-5/NN	prep_of||administration-5/NN||rad-7/NN	det||route-11/NN||the-9/DT	amod||route-11/NN||intranasal-10/JJ	prep_via||rad-7/NN||route-11/NN	cop||superior-13/JJ||was-12/VBD	root||ROOT-0/null||superior-13/JJ	aux||intramuscular-15/VB||to-14/TO	xcomp||superior-13/JJ||intramuscular-15/VB	dobj||intramuscular-15/VB||immunization-16/NN	prep_for||intramuscular-15/VB||induction-18/NN	amod||responses-21/NNS||mucosal-20/JJ	prep_of||induction-18/NN||responses-21/NNS	prep_for||intramuscular-15/VB||protection-24/NN	conj_and||induction-18/NN||protection-24/NN	advmod||virulent-27/JJ||highly-26/RB	amod||h1n1-28/NNS||virulent-27/JJ	prep_against||protection-24/NN||h1n1-28/NNS	prep_against||protection-24/NN||h3n2-30/NNS	conj_or||h1n1-28/NNS||h3n2-30/NNS	amod||influenzavirus-34/NNS||h5n1-33/JJ	prep_against||protection-24/NN||influenzavirus-34/NNS	conj_or||h1n1-28/NNS||influenzavirus-34/NNS	pobj||intramuscular-15/VB||challenge-35/NN	h5n1-33||influenzavirus-34||no||in balb/c mice, administration of rad via the intranasal route was superior to intramuscular immunization for induction of mucosal responses and for protection against highly virulent h1n1, h3n2, or h5n1 influenzavirus challenge.
advmod||diminished-13/VBN||moreover-1/RB	amod||responses-4/NNS||anorectic-3/JJ	nsubjpass||diminished-13/VBN||responses-4/NNS	prep_to||responses-4/NNS||leptin-6/NN	prep_to||responses-4/NNS||insulin-8/NN	conj_and||leptin-6/NN||insulin-8/NN	prep_to||responses-4/NNS||glucose-11/NN	conj_and||leptin-6/NN||glucose-11/NN	auxpass||diminished-13/VBN||were-12/VBD	root||ROOT-0/null||diminished-13/VBN	amod||mice-16/NNS||angptl4-null-15/JJ	prep_in||diminished-13/VBN||mice-16/NNS	anorectic-3||glucose-11||no_rel||moreover, anorectic responses to leptin, insulin, and glucose were diminished in angptl4-null mice.
det||compound-4/NN||the-2/DT	nn||compound-4/NN||title-3/NN	prep_in||â-36/NN||compound-4/NN	nsubj||â-36/NN||c20h22n2o5-6/NNS	det||product-10/NN||a-8/DT	amod||product-10/NN||photo-degradation-9/JJ	appos||c20h22n2o5-6/NNS||product-10/NN	det||nisoldipine-15/NN||the-12/DT	nn||nisoldipine-15/NN||hypertension-13/NN	nn||nisoldipine-15/NN||drug-14/NN	prep_of||product-10/NN||nisoldipine-15/NN	det||angle-19/NN||the-17/DT	amod||angle-19/NN||dihedral-18/JJ	appos||c20h22n2o5-6/NNS||angle-19/NN	conj_and||product-10/NN||angle-19/NN	det||ring-23/NN||the-21/DT	amod||ring-23/NN||nitroâsophenyl-22/JJ	prep_between||angle-19/NN||ring-23/NN	det||ring-27/NN||the-25/DT	amod||ring-27/NN||pyridine-26/JJ	appos||c20h22n2o5-6/NNS||ring-27/NN	conj_and||product-10/NN||ring-27/NN	cop||â-36/NN||is-28/VBZ	poss||â-36/NN||75.7-29/NNP	amod||â-36/NN||$-31/$	appos||â-36/NN||3-34/CD	root||ROOT-0/null||â-36/NN	dep||â-36/NN||°-37/SYM	hypertension-13||nisoldipine-15||yes||in the title compound, c20h22n2o5, a photo-degradation product of the hypertension drug nisoldipine, the dihedral angle between the nitroâ­sophenyl ring and the pyridine ring is 75.7â(3)â°.
det||routinely-2/NN||the-1/DT	nsubj||accepted-3/VBD||routinely-2/NN	root||ROOT-0/null||accepted-3/VBD	dobj||accepted-3/VBD||practice-4/NN	aux||start-6/VB||to-5/TO	vmod||accepted-3/VBD||start-6/VB	prep_with||start-6/VB||sulphasalazine-8/NN	appos||sulphasalazine-8/NN||ss-10/NN	mark||proves-24/VBZ||as-12/IN	det||treatment-16/NN||the-13/DT	amod||treatment-16/NN||first-14/JJ	nn||treatment-16/NN||line-15/NN	nsubj||proves-24/VBZ||treatment-16/NN	nsubj||ineffective-27/JJ||treatment-16/NN	prep_in||treatment-16/NN||patients-18/NNS	nn||jia-23/NN||hla-20/NN	amod||jia-23/NN||b27-21/JJ	amod||jia-23/NN||positive-22/JJ	prep_with||patients-18/NNS||jia-23/NN	advcl||start-6/VB||proves-24/VBZ	aux||ineffective-27/JJ||to-25/TO	cop||ineffective-27/JJ||be-26/VB	xcomp||proves-24/VBZ||ineffective-27/JJ	det||proportion-31/NN||a-29/DT	amod||proportion-31/NN||large-30/JJ	prep_in||ineffective-27/JJ||proportion-31/NN	prep_of||proportion-31/NN||children-33/NNS	jia-23||sulphasalazine-8||yes||the routinely accepted practice to start with sulphasalazine (ss) as the first line treatment in patients with hla b27 positive jia proves to be ineffective in a large proportion of children.
amod||nd-3/NN||newcastledisease-1/JJ	nsubj||disease-18/NN||nd-3/NN	vmod||nd-3/NN||caused-5/VBN	amod||virus-9/NN||virulent-7/JJ	nn||virus-9/NN||newcastledisease-8/NN	agent||caused-5/VBN||virus-9/NN	appos||nd-3/NN||ndv-11/NN	cop||disease-18/NN||is-13/VBZ	det||disease-18/NN||a-14/DT	advmod||contagious-16/JJ||highly-15/RB	amod||disease-18/NN||contagious-16/JJ	amod||disease-18/NN||viral-17/JJ	root||ROOT-0/null||disease-18/NN	prep_of||disease-18/NN||poultry-20/NN	newcastledisease-8||ndv-11||no||newcastledisease (nd) caused by virulent newcastledisease virus (ndv) is a highly contagious viral disease of poultry.
nsubj||resulted-2/VBD||this-1/DT	root||ROOT-0/null||resulted-2/VBD	det||guidelines-9/NNS||the-4/DT	amod||guidelines-9/NNS||new-5/JJ	amod||guidelines-9/NNS||national-6/JJ	nn||guidelines-9/NNS||maternity-7/NN	nn||guidelines-9/NNS||care-8/NN	prep_in||resulted-2/VBD||guidelines-9/NNS	auxpass||informed-11/VBN||being-10/VBG	ccomp||resulted-2/VBD||informed-11/VBN	agent||informed-11/VBN||evidence-13/NN	amod||trials-17/NNS||randomised-15/JJ	amod||trials-17/NNS||controlled-16/JJ	prep_from||informed-11/VBN||trials-17/NNS	ccomp||resulted-2/VBD||recommending-19/VBG	conj_and||informed-11/VBN||recommending-19/VBG	advmod||recommending-19/VBG||explicitly-20/RB	det||use-22/NN||the-21/DT	dobj||recommending-19/VBG||use-22/NN	prep_of||use-22/NN||magnesiumsulphate-24/NN	det||management-27/NN||the-26/DT	prep_for||recommending-19/VBG||management-27/NN	prep_of||management-27/NN||eclampsia-29/NN	eclampsia-29||magnesiumsulphate-24||yes||this resulted in the new national maternity care guidelines being informed by evidence from randomised controlled trials and recommending explicitly the use of magnesiumsulphate for the management of eclampsia.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||compare-8/VB||aim-2/NN	det||trial-5/NN||this-4/DT	prep_of||aim-2/NN||trial-5/NN	root||ROOT-0/null||was-6/VBD	aux||compare-8/VB||to-7/TO	xcomp||was-6/VBD||compare-8/VB	amod||treatment-10/NN||on-demand-9/JJ	dobj||compare-8/VB||treatment-10/NN	det||agent-20/NN||a-12/DT	amod||agent-20/NN||pectin-based-13/JJ	amod||agent-20/NN||raft-forming-15/JJ	amod||agent-20/NN||natural-17/JJ	amod||agent-20/NN||anti-reflux-19/JJ	prep_with||treatment-10/NN||agent-20/NN	appos||agent-20/NN||pra-22/NN	prep_with||compare-8/VB||that-25/DT	amod||mg-29/NN||esomeprazole-27/JJ	dep||esomeprazole-27/JJ||20-28/CD	prep_of||that-25/DT||mg-29/NN	appos||mg-29/NN||eso20-31/NNP	prep_in||compare-8/VB||patients-34/NNS	amod||gerd-37/NN||mild/moderate-36/JJ	prep_with||patients-34/NNS||gerd-37/NN	reflux--1||esomeprazole-27||yes||the aim of this trial was to compare on-demand treatment with a pectin-based, raft-forming, natural, anti-reflux agent (pra) with that of esomeprazole 20 mg (eso20) in patients with mild/moderate gerd.
nsubj||caused-2/VBD||thiodicarb-1/NN	root||ROOT-0/null||caused-2/VBD	dobj||caused-2/VBD||hyperglycemia-3/NN	prep_in||caused-2/VBD||rats-5/NNS	advmod||nonsignificant-15/JJ||however-7/RB	nsubj||nonsignificant-15/JJ||increase-9/NN	nn||level-13/NN||plasma-11/NN	nn||level-13/NN||glucose-12/NN	prep_in||increase-9/NN||level-13/NN	cop||nonsignificant-15/JJ||was-14/VBD	parataxis||caused-2/VBD||nonsignificant-15/JJ	hyperglycemia-3||glucose-12||no||thiodicarb caused hyperglycemia in rats; however, increase in plasma glucose level was nonsignificant.
det||results-2/NNS||the-1/DT	nsubj||suggested-7/VBD||results-2/NNS	det||study-6/NN||the-4/DT	amod||study-6/NN||present-5/JJ	prep_of||results-2/NNS||study-6/NN	root||ROOT-0/null||suggested-7/VBD	mark||had-11/VBD||that-8/IN	nn||sinensis-10/NNS||h.-9/NN	nsubj||had-11/VBD||sinensis-10/NNS	ccomp||suggested-7/VBD||had-11/VBD	det||role-14/NN||a-12/DT	amod||role-14/NN||protective-13/JJ	dobj||had-11/VBD||role-14/NN	nn||amnesia-19/NN||age-16/NN	conj_and||age-16/NN||scopolamine-induced-18/JJ	nn||amnesia-19/NN||scopolamine-induced-18/JJ	prep_against||role-14/NN||amnesia-19/NN	vmod||had-11/VBD||indicating-21/VBG	poss||utility-23/NN||its-22/PRP$	dobj||indicating-21/VBG||utility-23/NN	prep_in||indicating-21/VBG||management-25/NN	amod||disorders-28/NNS||cognitive-27/JJ	prep_of||management-25/NN||disorders-28/NNS	amnesia-19||scopolamine--1||no||the results of the present study suggested that h. sinensis had a protective role against age and scopolamine-induced amnesia , indicating its utility in management of cognitive disorders .
det||observations-2/NNS||these-1/DT	nsubj||suggest-3/VBP||observations-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||have-10/VB||that-4/IN	amod||administration-6/NN||oral-5/JJ	nsubj||have-10/VB||administration-6/NN	prep_of||administration-6/NN||egcg-8/NN	aux||have-10/VB||may-9/MD	ccomp||suggest-3/VBP||have-10/VB	amod||effects-13/NNS||significant-11/JJ	amod||effects-13/NNS||beneficial-12/JJ	dobj||have-10/VB||effects-13/NNS	poss||patients-17/NNS||parkinson-15/NN	prep_in||effects-13/NNS||patients-17/NNS	vmod||patients-17/NNS||treated-18/VBN	prep_with||treated-18/VBN||l-dopa-20/NN	prep_with||treated-18/VBN||carbidopa-22/NN	conj_and||l-dopa-20/NN||carbidopa-22/NN	agent||treated-18/VBN||exerting-24/VBG	det||inhibition-27/NN||a-25/DT	amod||inhibition-27/NN||modest-26/JJ	dobj||exerting-24/VBG||inhibition-27/NN	amod||methylation-30/NN||l-dopa-29/JJ	prep_of||inhibition-27/NN||methylation-30/NN	det||neuroprotection-34/NN||a-32/DT	amod||neuroprotection-34/NN||strong-33/JJ	dobj||exerting-24/VBG||neuroprotection-34/NN	conj_plus||inhibition-27/NN||neuroprotection-34/NN	amod||damage-37/NN||oxidative-36/JJ	prep_against||neuroprotection-34/NN||damage-37/NN	prep_against||neuroprotection-34/NN||degeneration-39/NN	conj_and||damage-37/NN||degeneration-39/NN	parkinson's--1||l-dopa-29||yes||these observations suggest that oral administration of egcg may have significant beneficial effects in parkinson's patients treated with l-dopa and carbidopa by exerting a modest inhibition of l-dopa methylation plus a strong neuroprotection against oxidative damage and degeneration.
nsubjpass||recruited-26/VBN||patients-1/NNS	amod||ulcerativecolitis-4/NNS||established-3/VBN	prep_with||patients-1/NNS||ulcerativecolitis-4/NNS	appos||ulcerativecolitis-4/NNS||uc-6/NN	amod||cd-13/NNS||crohn-9/JJ	amod||cd-13/NNS||sdisease-11/JJ	prep_with||patients-1/NNS||cd-13/NNS	conj_and||ulcerativecolitis-4/NNS||cd-13/NNS	nsubj||residents-19/NNS||cd-13/NNS	cop||residents-19/NNS||were-17/VBD	amod||residents-19/NNS||permanent-18/JJ	rcmod||cd-13/NNS||residents-19/NNS	det||districts-23/NNS||these-21/DT	amod||districts-23/NNS||adjoining-22/JJ	prep_of||residents-19/NNS||districts-23/NNS	auxpass||recruited-26/VBN||were-25/VBD	root||ROOT-0/null||recruited-26/VBN	nn||registries-29/NNS||hospital-28/NN	prep_from||recruited-26/VBN||registries-29/NNS	amod||clinics-32/NNS||out-patient-31/JJ	prep_from||recruited-26/VBN||clinics-32/NNS	conj_and||registries-29/NNS||clinics-32/NNS	cd-13||crohn'sdisease--1||no_rel||patients with established ulcerativecolitis (uc) and crohn'sdisease (cd), who were permanent residents of these adjoining districts, were recruited from hospital registries and out-patient clinics.
dep||surprisingly-2/RB||not-1/RB	advmod||was-5/VBD||surprisingly-2/RB	expl||was-5/VBD||there-4/EX	root||ROOT-0/null||was-5/VBD	amod||downregulation-7/NN||clear-6/JJ	nsubj||was-5/VBD||downregulation-7/NN	prep_of||downregulation-7/NN||genes-9/NNS	vmod||genes-9/NNS||associated-10/VBN	nn||synthesis-14/NN||milk-12/NN	amod||synthesis-14/NN||fat-13/JJ	prep_with||associated-10/VBN||synthesis-14/NN	nn||cd36-20/NN||fasn-16/NN	dep||cd36-20/NN||acaca-18/NN	appos||synthesis-14/NN||cd36-20/NN	dep||cd36-20/NN||fabp3-22/NNP	dep||cd36-20/NN||scd-24/NN	amod||regulation-29/NN||lipid-related-27/JJ	nn||regulation-29/NN||transcription-28/NN	prep_with||associated-10/VBN||regulation-29/NN	conj_and||synthesis-14/NN||regulation-29/NN	dep||synthesis-14/NN||srebf1-31/NNS	appos||srebf1-31/NNS||srebf2-33/NNS	scd-24||lipid--1||no_rel||not surprisingly, there was clear downregulation of genes associated with milk fat synthesis ( fasn , acaca , cd36 , fabp3 , scd ) and lipid-related transcription regulation ( srebf1 , srebf2 ).
aux||evaluate-2/VB||to-1/TO	csubj||subjects-25/VBZ||evaluate-2/VB	det||impact-4/NN||the-3/DT	dobj||evaluate-2/VB||impact-4/NN	iobj||evaluate-2/VB||impact-4/NN	amod||intensive-7/NNS||former-6/JJ	prep_of||impact-4/NN||intensive-7/NNS	amod||treatment-11/NN||conventional-9/JJ	nn||treatment-11/NN||insulin-10/NN	prep_versus||intensive-7/NNS||treatment-11/NN	amod||control-14/NN||neuropathyindiabetes-13/JJ	prep_on||treatment-11/NN||control-14/NN	nn||trial-17/NN||complications-16/NNS	prep_on||treatment-11/NN||trial-17/NN	conj_and||control-14/NN||trial-17/NN	dep||impact-4/NN||dcct-19/VBN	amod||treatment-24/NN||intensive-21/JJ	conj_and||intensive-21/JJ||conventional-23/JJ	amod||treatment-24/NN||conventional-23/JJ	dep||impact-4/NN||treatment-24/NN	root||ROOT-0/null||subjects-25/VBZ	amod||13â-28/NNS||type1diabetes-27/JJ	prep_with||subjects-25/VBZ||13â-28/NNS	num||years-32/NNS||$-29/$	num||$-29/$||14-31/CD	npadvmod||subjects-25/VBZ||years-32/NNS	amod||closeout-35/NN||dcct-34/JJ	prep_after||subjects-25/VBZ||closeout-35/NN	det||time-39/NN||closeout-35/NN	prep_during||achieved-44/VBN||time-39/NN	det||groups-42/NNS||the-40/DT	num||groups-42/NNS||two-41/CD	nsubj||achieved-44/VBN||groups-42/NNS	aux||achieved-44/VBN||had-43/VBD	rcmod||closeout-35/NN||achieved-44/VBN	amod||levels-47/NNS||similar-45/JJ	amod||levels-47/NNS||a1c-46/JJ	dobj||achieved-44/VBN||levels-47/NNS	insulin-10||neuropathyindiabetes-13||no_rel||to evaluate the impact of former intensive versus conventional insulin treatment on neuropathyindiabetes control and complications trial (dcct) intensive and conventional treatment subjects with type1diabetes 13â14 years after dcct closeout, during which time the two groups had achieved similar a1c levels.
det||study-3/NN||this-2/DT	prep_in||investigated-6/VBD||study-3/NN	nsubj||investigated-6/VBD||we-5/PRP	root||ROOT-0/null||investigated-6/VBD	det||effect-8/NN||the-7/DT	dobj||investigated-6/VBD||effect-8/NN	det||mixture-12/NN||a-10/DT	amod||mixture-12/NN||lidocaine-11/JJ	prep_of||effect-8/NN||mixture-12/NN	prep_on||investigated-6/VBD||pain-14/NN	dep||pain-14/NN||induced-15/VBN	amod||injection-19/NN||microemulsion-17/JJ	amod||injection-19/NN||propofol-18/JJ	prep_by||induced-15/VBN||injection-19/NN	dep||pain-14/NN||sought-22/VBN	conj_and||induced-15/VBN||sought-22/VBN	aux||determine-24/VB||to-23/TO	xcomp||sought-22/VBN||determine-24/VB	det||dose-27/NN||the-25/DT	amod||dose-27/NN||optimal-26/JJ	dobj||determine-24/VB||dose-27/NN	nsubj||reduce-32/VB||dose-27/NN	prep_of||dose-27/NN||lidocaine-29/NN	aux||reduce-32/VB||could-31/MD	rcmod||dose-27/NN||reduce-32/VB	dobj||reduce-32/VB||pain-33/NN	prepc_on||reduce-32/VB||injecting-35/VBG	det||mixture-38/NN||a-36/DT	amod||mixture-38/NN||propofol-lidocaine-37/JJ	dobj||injecting-35/VBG||mixture-38/NN	pain-33||lidocaine-29||yes||in this study, we investigated the effect of a lidocaine mixture on pain induced by microemulsion propofol injection, and sought to determine the optimal dose of lidocaine that could reduce pain on injecting a propofol-lidocaine mixture.
vmod||increased-9/VBD||reducing-1/VBG	amod||hyperglycemia-3/NN||systemic-2/JJ	dobj||reducing-1/VBG||hyperglycemia-3/NN	prep_to||reducing-1/VBG||euglycemia-5/NN	nsubj||increased-9/VBD||exenatide-7/NN	advmod||increased-9/VBD||still-8/RB	root||ROOT-0/null||increased-9/VBD	amod||turnover-12/NN||total-10/JJ	nn||turnover-12/NN||glucose-11/NN	dobj||increased-9/VBD||turnover-12/NN	nn||saline-19/NN||â-14/NN	number||%-17/NN||1/4-15/CD	number||%-17/NN||20-16/CD	amod||saline-19/NN||%-17/NN	nn||saline-19/NN||-lrb--18/NNP	prep_by||increased-9/VBD||saline-19/NN	num||â-21/NN||13.2-20/CD	dobj||â-31/VBP||â-21/NN	number||1.9-23/CD||±-22/CD	num||â-21/NN||1.9-23/CD	prep||â-21/NN||vs.-24/FW	nn||±-28/NN||exenatide-25/NN	num||±-28/NN||15.6-26/CD	nn||±-28/NN||â-27/NN	pobj||vs.-24/FW||±-28/NN	num||mg-30/NN||2.1-29/CD	nsubj||â-31/VBP||mg-30/NN	rcmod||saline-19/NN||â-31/VBP	nn||kgâ-33/NNP||·-32/NNP	poss||·-37/NN||kgâ-33/NNP	num||·-37/NN||1-35/CD	nn||·-37/NN||â-36/NN	dobj||â-31/VBP||·-37/NN	dep||â-31/VBP||minâ-38/VBG	num||-rrb--45/NNS||1-40/CD	dep||-rrb--45/NNS||p-42/NNP	nn||-rrb--45/NNS||<-43/NNP	num||-rrb--45/NNS||0.05-44/CD	dobj||minâ-38/VBG||-rrb--45/NNS	det||presence-48/NN||the-47/DT	prep_in||-rrb--45/NNS||presence-48/NN	prep_of||presence-48/NN||hyperinsulinemia-50/NN	vmod||presence-48/NN||accompanied-52/VBN	amod||increments-55/NNS||smaller-54/JJR	agent||accompanied-52/VBN||increments-55/NNS	dep||-lrb--59/VBZ||r-57/LS	nsubj||-lrb--59/VBZ||d-58/SYM	nsubj||-rrb--73/JJ||d-58/SYM	prepc_in||minâ-38/VBG||-lrb--59/VBZ	number||%-61/NN||12-60/CD	amod||-rrb--62/NNS||%-61/NN	dobj||-lrb--59/VBZ||-rrb--62/NNS	amod||uptake-66/NN||net-64/JJ	amod||uptake-66/NN||hepatic-65/JJ	dep||-rrb--73/JJ||uptake-66/NN	amod||-lrb--70/NNS||exogenous-68/JJ	nn||-lrb--70/NNS||glucose-69/NN	prep_of||uptake-66/NN||-lrb--70/NNS	num||%-72/NN||45-71/CD	npadvmod||-rrb--73/JJ||%-72/NN	prepc_in||minâ-38/VBG||-rrb--73/JJ	conj_and||-lrb--59/VBZ||-rrb--73/JJ	hyperglycemia-3||glucose-69||no||reducing systemic hyperglycemia to euglycemia , exenatide still increased total glucose turnover by â 1/4 20 % -lrb- saline 13.2 â ± 1.9 vs. exenatide 15.6 â ± 2.1 mg â · kgâ ' 1 â · minâ ' 1 , p < 0.05 -rrb- in the presence of hyperinsulinemia , accompanied by smaller increments in r d -lrb- 12 % -rrb- and net hepatic uptake of exogenous glucose -lrb- 45 % -rrb- .
amod||associations-2/NNS||cross-sectional-1/JJ	nsubjpass||reported-5/VBN||associations-2/NNS	aux||reported-5/VBN||have-3/VBP	auxpass||reported-5/VBN||been-4/VBN	root||ROOT-0/null||reported-5/VBN	prep_for||reported-5/VBN||htlv-1-7/JJ	prep_with||reported-5/VBN||hivinfection-9/NN	det||trends-13/NNS||the-12/DT	nsubj||unknown-23/JJ||trends-13/NNS	prep_in||trends-13/NNS||prevalence-15/NN	amod||associations-20/NNS||htlv-1-17/JJ	conj_and||htlv-1-17/JJ||hiv-19/JJ	amod||associations-20/NNS||hiv-19/JJ	prep_of||prevalence-15/NN||associations-20/NNS	cop||unknown-23/JJ||are-21/VBP	advmod||unknown-23/JJ||largely-22/RB	conj_but||reported-5/VBN||unknown-23/JJ	advmod||unknown-23/JJ||especially-25/RB	nn||africa-29/NN||sub-27/NN	nn||africa-29/NN||saharan-28/NN	prep_in||unknown-23/JJ||africa-29/NN	hivinfection-9||hiv-19||no||cross-sectional associations have been reported for htlv-1 with hivinfection, but the trends in prevalence of htlv-1 and hiv associations are largely unknown, especially in sub saharan africa.
amod||analysis-2/NN||phylogenetic-1/JJ	nsubjpass||retrieved-48/VBN||analysis-2/NN	nsubjpass||used-50/VBN||analysis-2/NN	det||sequences-5/NNS||the-4/DT	prep_of||analysis-2/NN||sequences-5/NNS	prep_from||sequences-5/NNS||india-7/NN	vmod||sequences-5/NNS||published-9/VBN	amod||resource-12/NN||influenzavirus-11/JJ	prep_in||published-9/VBN||resource-12/NN	det||database-15/NN||a-14/DT	dep||analysis-2/NN||database-15/NN	nsubj||integrates-17/VBZ||database-15/NN	rcmod||database-15/NN||integrates-17/VBZ	dobj||integrates-17/VBZ||information-18/NN	vmod||information-18/NN||gathered-19/VBN	det||project-25/NN||the-21/DT	nn||project-25/NN||influenza-22/NN	amod||project-25/NN||genome-23/JJ	amod||project-25/NN||sequencing-24/VBG	prep_from||gathered-19/VBN||project-25/NN	det||institute-29/NN||the-27/DT	amod||institute-29/NN||national-28/JJ	prep_of||project-25/NN||institute-29/NN	nn||diseases-34/NNS||allergy-31/NN	conj_and||allergy-31/NN||infectious-33/JJ	nn||diseases-34/NNS||infectious-33/JJ	prep_of||project-25/NN||diseases-34/NNS	dep||project-25/NN||niaid-36/VBN	det||genbank-40/NN||the-39/DT	prep_from||gathered-19/VBN||genbank-40/NN	conj_and||project-25/NN||genbank-40/NN	det||ncbi-44/NN||the-42/DT	prep_of||genbank-40/NN||ncbi-44/NN	auxpass||retrieved-48/VBN||was-47/VBD	root||ROOT-0/null||retrieved-48/VBN	conj_and||retrieved-48/VBN||used-50/VBN	det||analysis-53/NN||the-52/DT	prep_for||retrieved-48/VBN||analysis-53/NN	influenza-22||influenzavirus-11||no||phylogenetic analysis of the sequences from india, published in influenzavirus resource (a database that integrates information gathered from the influenza genome sequencing project of the national institute of allergy and infectious diseases (niaid) and the genbank of the (ncbi)) was retrieved and used for the analysis.
nsubj||effect-8/NN||bisphosphonate-associatedosteonecrosisofthejaws-1/NNS	appos||bisphosphonate-associatedosteonecrosisofthejaws-1/NNS||bp-onj-3/NNP	cop||effect-8/NN||is-5/VBZ	det||effect-8/NN||an-6/DT	amod||effect-8/NN||adverse-7/JJ	root||ROOT-0/null||effect-8/NN	amod||treatment-11/NN||bisphosphonate-10/JJ	prep_of||effect-8/NN||treatment-11/NN	amod||rates-16/NNS||varying-13/VBG	amod||rates-16/NNS||reported-14/JJ	nn||rates-16/NNS||incidence-15/NN	prep_with||treatment-11/NN||rates-16/NNS	bisphosphonate-10||bisphosphonate-associatedosteonecrosisofthejaws-1||no_rel||bisphosphonate-associatedosteonecrosisofthejaws (bp-onj) is an adverse effect of bisphosphonate treatment with varying reported incidence rates.
nsubj||obstructivepulmonarydisease-21/VBP||objectives-1/NNS	aux||compare-3/VB||to-2/TO	vmod||objectives-1/NNS||compare-3/VB	amod||treatment-8/NN||standard-4/JJ	amod||treatment-8/NN||high-5/JJ	nn||treatment-8/NN||flow-6/NN	nn||treatment-8/NN||oxygen-7/NN	dobj||compare-3/VB||treatment-8/NN	amod||treatment-12/NN||titrated-10/JJ	nn||treatment-12/NN||oxygen-11/NN	prep_with||compare-3/VB||treatment-12/NN	prep_for||treatment-12/NN||patients-14/NNS	det||exacerbation-18/NN||an-16/DT	amod||exacerbation-18/NN||acute-17/JJ	prep_with||compare-3/VB||exacerbation-18/NN	prep_of||exacerbation-18/NN||chronic-20/NN	root||ROOT-0/null||obstructivepulmonarydisease-21/VBP	det||setting-25/NN||the-23/DT	amod||setting-25/NN||prehospital-24/JJ	prep_in||obstructivepulmonarydisease-21/VBP||setting-25/NN	obstructivepulmonarydisease-21||oxygen-11||yes||objectives to compare standard high flow oxygen treatment with titrated oxygen treatment for patients with an acute exacerbation of chronic obstructivepulmonarydisease in the prehospital setting.
nsubjpass||assumed-12/VBN||sorption-1/NN	nsubj||negligible-15/JJ||sorption-1/NN	nsubj||higher-26/JJR||sorption-1/NN	prep_of||sorption-1/NN||venlafaxine-3/NN	prep_of||sorption-1/NN||desmethylvenlafaxine-5/NN	conj_and||venlafaxine-3/NN||desmethylvenlafaxine-5/NN	prep_of||sorption-1/NN||carbamazepine-8/NN	conj_and||venlafaxine-3/NN||carbamazepine-8/NN	prep_on||venlafaxine-3/NN||sludge-10/NN	auxpass||assumed-12/VBN||was-11/VBD	root||ROOT-0/null||assumed-12/VBN	aux||negligible-15/JJ||to-13/TO	cop||negligible-15/JJ||be-14/VB	xcomp||assumed-12/VBN||negligible-15/JJ	dep||negligible-15/JJ||log-17/VB	nn||-20/NNS||kd-18/NN	nn||-20/NNS||â-19/NN	dobj||log-17/VB||-20/NNS	amod||-20/NNS||$-21/$	number||$-21/$||2-22/CD	xcomp||assumed-12/VBN||higher-26/JJR	conj_but||negligible-15/JJ||higher-26/JJR	nn||behavior-28/NN||sorption-27/NN	nsubjpass||expected-31/VBN||behavior-28/NN	aux||expected-31/VBN||can-29/MD	auxpass||expected-31/VBN||be-30/VB	ccomp||higher-26/JJR||expected-31/VBN	prep_for||expected-31/VBN||sertraline-33/NN	dep||negligible-15/JJ||log-35/VB	nn||â-37/NN||kd-36/NN	dobj||log-35/VB||â-37/NN	vmod||â-37/NN||-38/VBG	number||4-40/CD||¥-39/CD	dobj||-38/VBG||4-40/CD	kd-36||venlafaxine-3||no_rel||sorption of venlafaxine, desmethylvenlafaxine, and carbamazepine on sludge was assumed to be negligible (log kd â¤ 2), but higher sorption behavior can be expected for sertraline (log kd â¥ 4).
amod||transcription-3/NN||herv-w-1/JJ	nn||transcription-3/NN||env-2/NN	nsubjpass||found-5/VBN||transcription-3/NN	nsubjpass||elevated-8/VBN||transcription-3/NN	auxpass||found-5/VBN||was-4/VBD	root||ROOT-0/null||found-5/VBN	aux||elevated-8/VBN||to-6/TO	auxpass||elevated-8/VBN||be-7/VB	xcomp||found-5/VBN||elevated-8/VBN	prep_in||elevated-8/VBN||bd-10/NN	nsubj||<-13/VBP||p-12/PRP	dep||elevated-8/VBN||<-13/VBP	amod||$-15/$||10â-14/VBD	dobj||<-13/VBP||$-15/$	num||$-15/$||4-17/CD	prep_in||elevated-8/VBN||sz-21/NN	conj_and||bd-10/NN||sz-21/NN	dep||sz-21/NN||p-23/VBN	dep||0.012-25/CD||=-24/SYM	ccomp||p-23/VBN||0.012-25/CD	advmod||elevated-8/VBN||as-27/RB	prepc_compared_with||elevated-8/VBN||with-29/IN	pobj||elevated-8/VBN||hc-30/NN	xcomp||found-5/VBN||with-33/IN	conj_but||elevated-8/VBN||with-33/IN	amod||values-35/NNS||higher-34/JJR	pobj||with-33/IN||values-35/NNS	prep_in||values-35/NNS||bd-37/NN	prep||bd-37/NN||than-38/IN	pcomp||than-38/IN||in-39/IN	nn||group-41/NN||sz-40/NN	pobj||in-39/IN||group-41/NN	dep||values-35/NNS||p-43/VBN	dep||0.01-45/CD||<-44/SYM	ccomp||p-43/VBN||0.01-45/CD	hc-30||sz-40||no_rel||herv-w env transcription was found to be elevated in bd ( p <10â4) and in sz ( p =0.012) as compared with hc, but with higher values in bd than in sz group ( p <0.01).
amod||asthma-2/NN||aspirin-intolerant-1/JJ	nsubjpass||caused-9/VBN||asthma-2/NN	nsubj||causes-20/VBZ||asthma-2/NN	appos||asthma-2/NN||aia-4/NN	auxpass||caused-9/VBN||is-8/VBZ	rcmod||asthma-2/NN||caused-9/VBN	amod||anti-inflammatorydrugs-12/NNS||non-steroidal-11/JJ	agent||caused-9/VBN||anti-inflammatorydrugs-12/NNS	appos||anti-inflammatorydrugs-12/NNS||nsaids-14/NNS	prep_such_as||anti-inflammatorydrugs-12/NNS||aspirin-18/NN	root||ROOT-0/null||causes-20/VBZ	nn||reduction-25/NN||lunginflammation-21/NN	conj_and||lunginflammation-21/NN||reversal-23/NN	nn||reduction-25/NN||reversal-23/NN	nn||reduction-25/NN||bronchi-24/NN	dobj||causes-20/VBZ||reduction-25/NN	vmod||causes-20/VBZ||leading-27/VBG	prep_to||leading-27/VBG||difficulty-29/NN	prep_in||difficulty-29/NN||breathing-31/NN	asthma-2||aspirin-18||no||aspirin-intolerant asthma (aia), which is caused by non-steroidal anti-inflammatorydrugs (nsaids) such as aspirin, causes lunginflammation and reversal bronchi reduction, leading to difficulty in breathing.
nn||antibodies-2/NNS||bartonella-1/NN	nsubjpass||encountered-4/VBN||antibodies-2/NNS	auxpass||encountered-4/VBN||were-3/VBD	root||ROOT-0/null||encountered-4/VBN	prep_in||encountered-4/VBN||people-6/NNS	vmod||people-6/NNS||living-7/VBG	prepc_across||living-7/VBG||zhejiang-9/VBG	dobj||zhejiang-9/VBG||province-10/NN	det||rate-14/NN||the-12/DT	amod||rate-14/NN||seropositivity-13/JJ	nsubj||higher-23/JJR||rate-14/NN	prep_among||rate-14/NN||those-16/DT	vmod||those-16/DT||exposed-17/VBN	nn||bites-20/NNS||dog-19/NN	prep_to||exposed-17/VBN||bites-20/NNS	cop||higher-23/JJR||was-21/VBD	advmod||higher-23/JJR||significantly-22/RB	conj_and||encountered-4/VBN||higher-23/JJR	prep_than||higher-23/JJR||that-25/DT	nn||donors-28/NNS||blood-27/NN	prep_among||that-25/DT||donors-28/NNS	xcomp||higher-23/JJR||indicating-30/VBG	mark||factor-38/NN||that-31/IN	nn||bites-33/NNS||dog-32/NN	nsubj||factor-38/NN||bites-33/NNS	aux||factor-38/NN||may-34/MD	cop||factor-38/NN||be-35/VB	det||factor-38/NN||a-36/DT	nn||factor-38/NN||risk-37/NN	ccomp||indicating-30/VBG||factor-38/NN	prep_for||factor-38/NN||bartonellainfection-40/NN	bartonellainfection-40||bartonella-1||no||bartonella antibodies were encountered in people living across zhejiang province and the seropositivity rate among those exposed to dog bites was significantly higher than that among blood donors, indicating that dog bites may be a risk factor for bartonellainfection.
mark||occurred-8/VBD||while-1/IN	nsubj||occurred-8/VBD||some-2/DT	det||temperatures-7/NNS||the-4/DT	amod||temperatures-7/NNS||late-5/JJ	amod||temperatures-7/NNS||high-6/JJ	prep_of||some-2/DT||temperatures-7/NNS	advcl||apparent-19/JJ||occurred-8/VBD	det||setting-11/NN||the-10/DT	prep_in||occurred-8/VBD||setting-11/NN	amod||tachycardia-14/NN||marked-13/JJ	prep_of||setting-11/NN||tachycardia-14/NN	nsubj||apparent-19/JJ||it-16/PRP	cop||apparent-19/JJ||was-17/VBD	advmod||apparent-19/JJ||also-18/RB	root||ROOT-0/null||apparent-19/JJ	mark||accompanied-27/VBN||that-20/IN	det||cases-23/NNS||some-22/DT	prep_in||accompanied-27/VBN||cases-23/NNS	nsubjpass||accompanied-27/VBN||fever-24/NN	auxpass||accompanied-27/VBN||was-25/VBD	neg||accompanied-27/VBN||not-26/RB	ccomp||apparent-19/JJ||accompanied-27/VBN	agent||accompanied-27/VBN||tachycardia-29/NN	xcomp||accompanied-27/VBN||making-31/VBG	amod||atropine-33/NN||excessive-32/JJ	dobj||making-31/VBG||atropine-33/NN	amod||infection-36/NN||severe-35/JJ	dobj||making-31/VBG||infection-36/NN	conj_or||atropine-33/NN||infection-36/NN	det||explanation-39/NN||an-37/DT	amod||explanation-39/NN||unlikely-38/JJ	dep||infection-36/NN||explanation-39/NN	predet||fevers-43/NNS||all-41/PDT	det||fevers-43/NNS||the-42/DT	prep_for||making-31/VBG||fevers-43/NNS	tachycardia-29||atropine-33||no||while some of the late high temperatures occurred in the setting of marked tachycardia, it was also apparent that in some cases fever was not accompanied by tachycardia, making excessive atropine or severe infection an unlikely explanation for all the fevers.
nsubj||shows-21/VBZ||propranololhydrochloride-1/NN	appos||propranololhydrochloride-1/NN||one-3/CD	det||²-10/NN||the-5/DT	advmod||used-8/VBN||most-6/RBS	advmod||used-8/VBN||widely-7/RB	amod||²-10/NN||used-8/VBN	nn||²-10/NN||î-9/NN	prep_of||one-3/CD||²-10/NN	dep||²-10/NN||blocker-12/NN	det||treatment-15/NN||the-14/DT	prep_in||blocker-12/NN||treatment-15/NN	prep_of||treatment-15/NN||hypertension-17/NN	prep_since||hypertension-17/NN||1960s-19/CD	root||ROOT-0/null||shows-21/VBZ	det||number-23/NN||a-22/DT	dobj||shows-21/VBZ||number-23/NN	amod||events-29/NNS||serious-25/JJ	conj_and||serious-25/JJ||non-serious-27/JJ	amod||events-29/NNS||non-serious-27/JJ	amod||events-29/NNS||adverse-28/JJ	prep_of||number-23/NN||events-29/NNS	hypertension-17||propranololhydrochloride-1||yes||propranololhydrochloride, one of the most widely used î²-blocker in the treatment of hypertension since 1960s, shows a number of serious and non-serious adverse events.
det||report-4/NN||this-2/DT	nn||report-4/NN||case-3/NN	prep_in||describe-7/VBP||report-4/NN	nsubj||describe-7/VBP||we-6/PRP	nsubj||discuss-21/VB||we-6/PRP	nsubj||chronichepatitis-33/VBZ||we-6/PRP	root||ROOT-0/null||describe-7/VBP	det||knowledge-10/NN||the-8/DT	amod||knowledge-10/NN||current-9/JJ	dobj||describe-7/VBP||knowledge-10/NN	det||history-14/NN||the-12/DT	amod||history-14/NN||natural-13/JJ	prep_on||knowledge-10/NN||history-14/NN	dobj||describe-7/VBP||pathogenesis-16/NNS	conj_and||knowledge-10/NN||pathogenesis-16/NNS	prep_of||pathogenesis-16/NNS||parvovirusb19infection-18/CD	conj_and||describe-7/VBP||discuss-21/VB	det||evidence-24/NN||the-22/DT	amod||evidence-24/NN||existing-23/VBG	dobj||discuss-21/VB||evidence-24/NN	prep_of||evidence-24/NN||parvovirusb19-26/NNS	det||cause-29/NN||a-28/DT	prep_as||parvovirusb19-26/NNS||cause-29/NN	prep_of||cause-29/NN||acute-31/JJ	conj_and||describe-7/VBP||chronichepatitis-33/VBZ	parvovirusb19infection-18||parvovirusb19-26||no||in this case report, we describe the current knowledge on the natural history and pathogenesis of parvovirusb19infection, and discuss the existing evidence of parvovirusb19 as a cause of acute and chronichepatitis.
num||type-3/NN||ten-1/CD	amod||type-3/NN||obese-2/JJ	nsubj||-lrb--11/VBD||type-3/NN	num||patients-6/NNS||2-4/CD	amod||patients-6/NNS||diabetic-5/JJ	nsubjpass||infused-8/VBN||patients-6/NNS	auxpass||infused-8/VBN||were-7/VBD	rcmod||type-3/NN||infused-8/VBN	prep_with||infused-8/VBN||insulin-10/NN	root||ROOT-0/null||-lrb--11/VBD	num||units/h-13/NN||2-12/CD	nsubjpass||infused-34/VBN||units/h-13/NN	nsubjpass||served-51/VBN||units/h-13/NN	num||ml-16/NN||100-15/CD	prep_with||units/h-13/NN||ml-16/NN	number||%-19/NN||5-18/CD	amod||-rrb--21/NNS||%-19/NN	nn||-rrb--21/NNS||dextrose/h-20/NN	prep_of||ml-16/NN||-rrb--21/NNS	number||h.-24/CD||4-23/CD	num||8-26/CD||h.-24/CD	quantmod||8-26/CD||another-25/DT	prep_for||-rrb--21/NNS||8-26/CD	num||type-29/NN||6-28/CD	prep_of||ml-16/NN||type-29/NN	conj_and||-rrb--21/NNS||type-29/NN	num||patients-32/NNS||2-30/CD	amod||patients-32/NNS||diabetic-31/JJ	dep||type-29/NN||patients-32/NNS	auxpass||infused-34/VBN||were-33/VBD	ccomp||-lrb--11/VBD||infused-34/VBN	num||ml-37/NN||100-36/CD	prep_with||infused-34/VBN||ml-37/NN	number||%-40/NN||5-39/CD	amod||dextrose/h-41/NN||%-40/NN	prep_of||ml-37/NN||dextrose/h-41/NN	prep_of||ml-37/NN||saline-43/NN	conj_or||dextrose/h-41/NN||saline-43/NN	num||h-46/NN||4-45/CD	prep_for||ml-37/NN||h-46/NN	advmod||infused-34/VBN||respectively-48/RB	ccomp||-lrb--11/VBD||served-51/VBN	conj_and||infused-34/VBN||served-51/VBN	nn||subjects-54/NNS||control-53/NN	prep_as||served-51/VBN||subjects-54/NNS	insulin-10||ten-1||no_rel||ten obese type 2 diabetic patients were infused with insulin -lrb- 2 units/h with 100 ml of 5 % dextrose/h -rrb- for 4 h. another 8 and 6 type 2 diabetic patients were infused with 100 ml of 5 % dextrose/h or saline for 4 h , respectively , and served as control subjects .
det||study-4/NN||the-2/DT	amod||study-4/NN||current-3/JJ	prep_in||exploited-7/VBN||study-4/NN	nsubj||exploited-7/VBN||we-6/PRP	root||ROOT-0/null||exploited-7/VBN	amod||analysis-10/NN||genome-wide-8/JJ	amod||analysis-10/NN||microarray-9/JJ	dobj||exploited-7/VBN||analysis-10/NN	aux||determine-12/VB||to-11/TO	vmod||analysis-10/NN||determine-12/VB	mark||expressed-22/VBN||that-13/IN	nsubjpass||expressed-22/VBN||genes-14/NNS	nn||sequestration-17/NN||lipid-16/NN	prep_for||genes-14/NNS||sequestration-17/NN	prep_for||genes-14/NNS||metabolism-19/NN	conj_and||sequestration-17/NN||metabolism-19/NN	auxpass||expressed-22/VBN||were-20/VBD	advmod||expressed-22/VBN||highly-21/RB	ccomp||determine-12/VB||expressed-22/VBN	amod||granulomas-26/NNS||caseous-24/JJ	nn||granulomas-26/NNS||tb-25/NN	prep_in||expressed-22/VBN||granulomas-26/NNS	granulomas-26||lipid-16||no_rel||in the current study, we exploited genome-wide microarray analysis to determine that genes for lipid sequestration and metabolism were highly expressed in caseous tb granulomas.
advmod||found-4/VBD||recently-1/RB	nsubj||found-4/VBD||we-3/PRP	root||ROOT-0/null||found-4/VBD	mark||inhibited-12/VBD||that-5/IN	amod||acid-8/NN||acetyl-6/JJ	amod||acid-8/NN||salicylic-7/JJ	nsubj||inhibited-12/VBD||acid-8/NN	appos||acid-8/NN||asa-10/NN	ccomp||found-4/VBD||inhibited-12/VBD	amod||inflammation-15/NN||th17-13/JJ	nn||inflammation-15/NN||airway-14/NN	dobj||inhibited-12/VBD||inflammation-15/NN	det||model-20/NN||an-17/DT	nn||model-20/NN||asthma-18/NN	nn||model-20/NN||mouse-19/NN	prep_in||inhibited-12/VBD||model-20/NN	vmod||model-20/NN||induced-21/VBN	agent||induced-21/VBN||sensitization-23/NN	prep_with||induced-21/VBN||lipopolysaccharide-25/NN	appos||lipopolysaccharide-25/NN||lps-27/NN	dep||lipopolysaccharide-25/NN||containing-30/VBG	dobj||containing-30/VBG||allergens-31/NNS	asthma-18||asa-10||no||recently, we found that acetyl salicylic acid (asa) inhibited th17 airway inflammation in an asthma mouse model induced by sensitization with lipopolysaccharide (lps)-containing allergens.
advmod||observed-11/VBD||however-1/RB	vmod||observed-11/VBD||selecting-3/VBG	amod||models-8/NNS||hyperactive-4/JJ	conj_and||hyperactive-4/JJ||addiction-related-6/JJ	amod||models-8/NNS||addiction-related-6/JJ	nn||models-8/NNS||animal-7/NN	dobj||selecting-3/VBG||models-8/NNS	nsubj||observed-11/VBD||we-10/PRP	nsubj||displayed-23/VBD||we-10/PRP	root||ROOT-0/null||observed-11/VBD	det||mice-13/NNS||that-12/DT	dobj||observed-11/VBD||mice-13/NNS	xcomp||observed-11/VBD||lacking-14/VBG	amod||restriction-18/NN||5-htr1b-15/JJ	amod||restriction-18/NN||self-imposed-16/JJ	nn||restriction-18/NN||food-17/NN	dobj||lacking-14/VBG||restriction-18/NN	prep_after||lacking-14/VBG||deprivation-20/NN	advmod||displayed-23/VBD||still-22/RB	conj_and||observed-11/VBD||displayed-23/VBD	dobj||displayed-23/VBD||anorexia-24/NN	dobj||displayed-23/VBD||hyperactivity-26/NN	conj_and||anorexia-24/NN||hyperactivity-26/NN	prep_after||displayed-23/VBD||ecstasy-28/NN	ecstasy-28||anorexia-24||no_rel||however, selecting hyperactive and addiction-related animal models, we observed that mice lacking 5-htr1b self-imposed food restriction after deprivation and still displayed anorexia and hyperactivity after ecstasy.
nn||rates-8/NNS||hypoglycemia-1/NN	amod||<-4/NNS||bloodglucose-3/JJ	dep||mg/dl-6/JJ||<-4/NNS	number||mg/dl-6/JJ||50-5/CD	dep||rates-8/NNS||mg/dl-6/JJ	nsubj||low-10/JJ||rates-8/NNS	nsubj||comparable-12/JJ||rates-8/NNS	cop||low-10/JJ||were-9/VBD	root||ROOT-0/null||low-10/JJ	conj_and||low-10/JJ||comparable-12/JJ	prep_among||low-10/JJ||groups-14/NNS	hypoglycemia-1||glucose--1||yes||hypoglycemia (bloodglucose <50 mg/dl) rates were low and comparable among groups.
det||decrease-2/NN||the-1/DT	nsubjpass||caused-13/VBN||decrease-2/NN	amod||synthesis-6/NN||mitochondrial-4/JJ	nn||synthesis-6/NN||atp-5/NN	prep_in||decrease-2/NN||synthesis-6/NN	det||patients-10/NNS||the-8/DT	amod||patients-10/NNS||cfs/me-9/JJ	prep_in||synthesis-6/NN||patients-10/NNS	auxpass||caused-13/VBN||is-11/VBZ	neg||caused-13/VBN||not-12/RB	root||ROOT-0/null||caused-13/VBN	det||defect-16/NN||a-15/DT	agent||caused-13/VBN||defect-16/NN	det||complexes-20/NNS||the-18/DT	amod||complexes-20/NNS||enzyme-19/JJ	prep_in||defect-16/NN||complexes-20/NNS	vmod||complexes-20/NNS||catalyzing-21/VBG	amod||phosphorylation-23/NN||oxidative-22/JJ	dobj||catalyzing-21/VBG||phosphorylation-23/NN	det||factor-28/NN||another-27/DT	prep_in||defect-16/NN||factor-28/NN	conj_but||complexes-20/NNS||factor-28/NN	cfs--1||atp-5||no_rel||the decrease in mitochondrial atp synthesis in the cfs/me patients is not caused by a defect in the enzyme complexes catalyzing oxidative phosphorylation, but in another factor.
aux||evaluate-2/VB||to-1/TO	csubj||pcr-15/VBP||evaluate-2/VB	det||performance-4/NN||the-3/DT	dobj||evaluate-2/VB||performance-4/NN	prep_of||performance-4/NN||two-6/CD	nn||pcr-9/NN||house-8/NN	prep_in||evaluate-2/VB||pcr-9/NN	num||reaction-13/NN||polymerase-11/CD	nn||reaction-13/NN||chain-12/NN	appos||pcr-9/NN||reaction-13/NN	root||ROOT-0/null||pcr-15/VBP	amod||methodology-17/NN||dot-blot-16/JJ	dobj||pcr-15/VBP||methodology-17/NN	nn||dot-blot-20/NN||pcr-19/NN	appos||methodology-17/NN||dot-blot-20/NN	amod||electrophoresis-26/NNS||pcr-23/JJ	amod||electrophoresis-26/NNS||agarose-24/JJ	nn||electrophoresis-26/NNS||gel-25/NN	dobj||pcr-15/VBP||electrophoresis-26/NNS	conj_and||methodology-17/NN||electrophoresis-26/NNS	appos||electrophoresis-26/NNS||pcr-ag-28/NN	det||diagnosis-32/NN||the-31/DT	prep_for||electrophoresis-26/NNS||diagnosis-32/NN	prep_of||diagnosis-32/NN||pulmonarytuberculosis-34/NNS	appos||pulmonarytuberculosis-34/NNS||ptb-36/NN	nn||patients-43/NNS||hivseropositive-39/NN	conj_and||hivseropositive-39/NN||hiv-41/NN	nn||patients-43/NNS||hiv-41/NN	nn||patients-43/NNS||seronegative-42/NN	prep_in||pulmonarytuberculosis-34/NNS||patients-43/NNS	hivseropositive-39||hiv-41||no||to evaluate the performance of two in house pcr (polymerase chain reaction) pcr dot-blot methodology (pcr dot-blot) and pcr agarose gel electrophoresis (pcr-ag) for the diagnosis of pulmonarytuberculosis (ptb) in hivseropositive and hiv seronegative patients.
quantmod||20-2/CD||only-1/RB	nsubj||took-10/VBD||20-2/CD	num||%-5/NN||7.8-4/CD	appos||20-2/CD||%-5/NN	det||hcws-9/NNS||the-8/DT	prep_of||20-2/CD||hcws-9/NNS	root||ROOT-0/null||took-10/VBD	amod||prophylaxis-12/NNS||post-exposure-11/JJ	dobj||took-10/VBD||prophylaxis-12/NNS	appos||prophylaxis-12/NNS||pep-14/NN	prep_against||prophylaxis-12/NNS||hiv/aids-17/NNS	poss||injury-20/NN||their-19/PRP$	prep_after||took-10/VBD||injury-20/NN	aids--1||hiv--1||no||only 20 (7.8%) of the hcws took post-exposure prophylaxis (pep) against hiv/aids after their injury.
det||development-2/NN||the-1/DT	nsubjpass||limited-12/VBN||development-2/NN	amod||therapies-5/NNS||effective-4/JJ	prep_of||development-2/NN||therapies-5/NNS	prep_for||therapies-5/NNS||acuteliverfailure-7/NN	appos||development-2/NN||alf-9/NN	auxpass||limited-12/VBN||is-11/VBZ	root||ROOT-0/null||limited-12/VBN	poss||knowledge-15/NN||our-14/PRP$	agent||limited-12/VBN||knowledge-15/NN	det||pathophysiology-18/NN||the-17/DT	prep_of||knowledge-15/NN||pathophysiology-18/NN	det||condition-21/NN||this-20/DT	prep_of||pathophysiology-18/NN||condition-21/NN	det||lack-25/NN||the-24/DT	prep_of||knowledge-15/NN||lack-25/NN	conj_and||pathophysiology-18/NN||lack-25/NN	amod||models-30/NNS||suitable-27/JJ	amod||models-30/NNS||large-28/JJ	nn||models-30/NNS||animal-29/NN	prep_of||lack-25/NN||models-30/NNS	nn||toxicity-33/NN||acetaminophen-32/NN	prep_of||models-30/NNS||toxicity-33/NN	acetaminophen-32||acuteliverfailure-7||no_rel||the development of effective therapies for acuteliverfailure (alf) is limited by our knowledge of the pathophysiology of this condition, and the lack of suitable large animal models of acetaminophen toxicity.
nsubj||describe-2/VBP||we-1/PRP	root||ROOT-0/null||describe-2/VBP	det||case-4/NN||a-3/DT	dobj||describe-2/VBP||case-4/NN	amod||hepatitis-8/NN||acute-6/JJ	amod||hepatitis-8/NN||cholestatic-7/JJ	prep_of||case-4/NN||hepatitis-8/NN	det||man-13/NN||a-10/DT	amod||man-13/NN||68-year-old-11/JJ	amod||man-13/NN||caucasian-12/JJ	prep_in||describe-2/VBP||man-13/NN	nsubj||receiving-16/VBG||man-13/NN	aux||receiving-16/VBG||was-15/VBD	rcmod||man-13/NN||receiving-16/VBG	dobj||receiving-16/VBG||olmesartan-17/NN	dobj||receiving-16/VBG||hydrochlorothiazide-19/NN	conj_and||olmesartan-17/NN||hydrochlorothiazide-19/NN	prep_for||olmesartan-17/NN||arterialhypertension-21/NN	arterialhypertension-21||olmesartan-17||yes||we describe a case of acute cholestatic hepatitis in a 68-year-old caucasian man who was receiving olmesartan and hydrochlorothiazide for arterialhypertension.
det||trial-6/NN||a-2/DT	amod||trial-6/NN||randomized-3/JJ	amod||trial-6/NN||double-blind-5/JJ	prep_in||collected-10/VBN||trial-6/NN	nsubjpass||collected-10/VBN||faeces-8/NNS	nsubj||irritablebowelsyndrome-27/JJ||faeces-8/NNS	auxpass||collected-10/VBN||were-9/VBD	root||ROOT-0/null||collected-10/VBN	amod||volunteers-13/NNS||healthy-12/JJ	prep_from||collected-10/VBN||volunteers-13/NNS	prep_from||collected-10/VBN||patients-17/NNS	conj_and||volunteers-13/NNS||patients-17/NNS	amod||cd-20/NN||active-19/JJ	prep_with||patients-17/NNS||cd-20/NN	appos||cd-20/NN||ulcerativecolitis-22/NNS	appos||ulcerativecolitis-22/NNS||uc-24/NN	conj_and||collected-10/VBN||irritablebowelsyndrome-27/JJ	conj_and||collected-10/VBN||irritablebowelsyndrome-27/JJ	conj_and||irritablebowelsyndrome-27/JJ||irritablebowelsyndrome-27/JJ	prep_after||irritablebowelsyndrome-27/JJ||treatment-31/NN	prep_before||irritablebowelsyndrome-27/JJ||treatment-31/NN	cd-20||irritablebowelsyndrome-27||no_rel||in a randomized, double-blind trial, faeces were collected from healthy volunteers, and from patients with active cd, ulcerativecolitis (uc) and irritablebowelsyndrome before and after treatment.
prep_in||proved-9/VBN||patients-2/NNS	amod||hypertension-5/NN||mild-to-moderate-4/JJ	prep_with||patients-2/NNS||hypertension-5/NN	nsubj||proved-9/VBN||telmisartan-7/NN	aux||proved-9/VBN||has-8/VBZ	root||ROOT-0/null||proved-9/VBN	acomp||proved-9/VBN||superior-10/JJ	amod||antihypertensiveagents-13/NNS||other-12/JJ	prep_to||superior-10/JJ||antihypertensiveagents-13/NNS	dep||antihypertensiveagents-13/NNS||valsartan-15/NN	dep||antihypertensiveagents-13/NNS||losartan-17/NN	conj_and||valsartan-15/NN||losartan-17/NN	dep||antihypertensiveagents-13/NNS||ramipril-19/NN	conj_and||valsartan-15/NN||ramipril-19/NN	dep||antihypertensiveagents-13/NNS||perindopril-21/NN	conj_and||valsartan-15/NN||perindopril-21/NN	dep||antihypertensiveagents-13/NNS||atenolol-24/NN	conj_and||valsartan-15/NN||atenolol-24/NN	amod||pressure-29/NN||controlling-27/JJ	nn||pressure-29/NN||blood-28/NN	prep_in||antihypertensiveagents-13/NNS||pressure-29/NN	advmod||proved-9/VBN||particularly-30/RB	det||end-33/NN||the-32/DT	prep_towards||proved-9/VBN||end-33/NN	det||interval-37/NN||the-35/DT	amod||interval-37/NN||dosing-36/JJ	prep_of||end-33/NN||interval-37/NN	hypertension-5||atenolol-24||yes||in patients with mild-to-moderate hypertension, telmisartan has proved superior to other antihypertensiveagents (valsartan, losartan, ramipril, perindopril, and atenolol) in controlling blood pressure particularly towards the end of the dosing interval.
advmod||used-7/VBN||paradoxically-1/RB	nsubjpass||used-7/VBN||arsenictrioxide-3/NN	nsubj||induce-9/VB||arsenictrioxide-3/NN	aux||used-7/VBN||can-4/MD	advmod||used-7/VBN||also-5/RB	auxpass||used-7/VBN||be-6/VB	root||ROOT-0/null||used-7/VBN	aux||induce-9/VB||to-8/TO	xcomp||used-7/VBN||induce-9/VB	dobj||induce-9/VB||remission-10/NN	prep_in||induce-9/VB||patients-12/NNS	prep_with||patients-12/NNS||acutepromyelocyticleukemia-14/NN	appos||acutepromyelocyticleukemia-14/NN||apl-16/NN	det||rate-21/NN||a-19/DT	nn||rate-21/NN||success-20/NN	prep_with||induce-9/VB||rate-21/NN	quantmod||80-24/CD||approximately-23/RB	num||%-25/NN||80-24/CD	prep_of||rate-21/NN||%-25/NN	acutepromyelocyticleukemia-14||arsenictrioxide-3||yes||paradoxically, arsenictrioxide can also be used to induce remission in patients with acutepromyelocyticleukemia (apl) with a success rate of approximately 80%.
det||probability-3/NN||the-1/DT	amod||probability-3/NN||cumulative-2/JJ	nsubj||%-23/NN||probability-3/NN	prep_of||probability-3/NN||hivinfection-5/NN	nsubjpass||tested-15/VBN||hivinfection-5/NN	prep_among||hivinfection-5/NN||babies-7/NNS	amod||regimen-12/NN||single-9/JJ	nn||regimen-12/NN||dose-10/NN	nn||regimen-12/NN||nevirapine-11/NN	prep_on||babies-7/NNS||regimen-12/NN	auxpass||tested-15/VBN||were-14/VBD	rcmod||hivinfection-5/NN||tested-15/VBN	prepc_at||tested-15/VBN||>-17/VBG	dep||months-20/NNS||=-18/SYM	num||months-20/NNS||18-19/CD	ccomp||>-17/VBG||months-20/NNS	cop||%-23/NN||was-21/VBD	num||%-23/NN||15.0-22/CD	root||ROOT-0/null||%-23/NN	num||%-26/NN||95-25/CD	dep||%-23/NN||%-26/NN	vmod||%-26/NN||ci-27/VBN	num||.1-29/CD||9.8-22-28/CD	dobj||ci-27/VBN||.1-29/CD	prep_in||%-23/NN||2007-32/CD	mark||%-38/NN||whereas-34/IN	nsubj||%-38/NN||it-35/PRP	cop||%-38/NN||was-36/VBD	num||%-38/NN||8.2-37/CD	advcl||%-23/NN||%-38/NN	num||%-41/NN||95-40/CD	dep||%-38/NN||%-41/NN	vmod||%-41/NN||ci-42/VBN	num||.97-44/CD||5.55-11-43/CD	dobj||ci-42/VBN||.97-44/CD	prep_among||%-38/NN||babies-47/NNS	nsubjpass||tested-53/VBN||babies-47/NNS	amod||regimen-50/NN||zidovudine-49/JJ	prep_on||babies-47/NNS||regimen-50/NN	auxpass||tested-53/VBN||were-52/VBD	rcmod||babies-47/NNS||tested-53/VBN	prepc_at||tested-53/VBN||>-55/VBG	dep||days-58/NNS||=-56/SYM	num||days-58/NNS||45-57/CD	ccomp||>-55/VBG||days-58/NNS	prep_in||>-55/VBG||2009-60/CD	hivinfection-5||zidovudine-49||yes||the cumulative probability of hivinfection among babies on single dose nevirapine regimen who were tested at >=18 months was 15.0% (95% ci 9.8-22.1) in 2007, whereas it was 8.2% (95% ci 5.55-11.97) among babies on zidovudine regimen who were tested at >=45 days in 2009.
nn||-rrb--4/NNP||mrsa-1/NN	nn||-rrb--4/NNP||-lrb--2/NN	num||-rrb--4/NNP||346/545-3/CD	nsubj||differ-13/VB||-rrb--4/NNP	nn||patients-10/NNS||mssa-6/NNP	nn||patients-10/NNS||-lrb--7/NNP	num||patients-10/NNS||76/114-8/CD	nn||patients-10/NNS||-rrb--9/NNP	conj_and||-rrb--4/NNP||patients-10/NNS	nsubj||differ-13/VB||patients-10/NNS	aux||differ-13/VB||did-11/VBD	neg||differ-13/VB||not-12/RB	root||ROOT-0/null||differ-13/VB	advmod||differ-13/VB||significantly-14/RB	det||proportion-17/NN||the-16/DT	prep_in||differ-13/VB||proportion-17/NN	vmod||proportion-17/NN||classified-18/VBN	prep_as||classified-18/VBN||ha-20/NN	nsubj||â-30/VBP||s.aureus-22/NNS	det||p-29/NN||the-24/DT	amod||p-29/NN||cdc-25/JJ	amod||p-29/NN||ca-mrsa-26/JJ	nn||p-29/NN||definition-27/NN	nn||p-29/NN||-lrb--28/NN	prep_by||s.aureus-22/NNS||p-29/NN	parataxis||differ-13/VB||â-30/VBP	num||-rrb--38/NNS||$-31/$	number||=-33/CD||-32/CD	num||$-31/$||=-33/CD	amod||-rrb--38/NNS||â-34/JJ	num||-rrb--38/NNS||$-35/$	number||.5-37/CD||0-36/CD	num||$-35/$||.5-37/CD	dobj||â-30/VBP||-rrb--38/NNS	mrsa-1||s.aureus-22||no||mrsa -lrb- 346/545 -rrb- and mssa -lrb- 76/114 -rrb- patients did not differ significantly in the proportion classified as ha - s.aureus by the cdc ca-mrsa definition -lrb- p â $  = â $ 0 .5 -rrb- .
nsubjpass||thought-4/VBN||this-1/DT	nsubj||represent-6/VB||this-1/DT	auxpass||thought-4/VBN||was-2/VBD	advmod||thought-4/VBN||initially-3/RB	root||ROOT-0/null||thought-4/VBN	aux||represent-6/VB||to-5/TO	xcomp||thought-4/VBN||represent-6/VB	det||allergicreaction-8/NN||an-7/DT	dobj||represent-6/VB||allergicreaction-8/NN	aux||dicloxacillin-10/VB||to-9/TO	vmod||allergicreaction-8/NN||dicloxacillin-10/VB	prep_in||dicloxacillin-10/VB||someone-12/NN	det||history-16/NN||a-14/DT	amod||history-16/NN||previous-15/JJ	prep_with||dicloxacillin-10/VB||history-16/NN	nn||hypersensitivity-19/NN||penicillin-18/NN	prep_of||history-16/NN||hypersensitivity-19/NN	hypersensitivity-19||allergicreaction-8||no||this was initially thought to represent an allergicreaction to dicloxacillin in someone with a previous history of penicillin hypersensitivity.
prep_in||inactivated-12/VBN||bacillusanthracis-2/NNS	det||agent-6/NN||the-4/DT	amod||agent-6/NN||causative-5/JJ	appos||bacillusanthracis-2/NNS||agent-6/NN	prep_of||agent-6/NN||anthrax-8/NN	nsubjpass||inactivated-12/VBN||plcr-10/NN	auxpass||inactivated-12/VBN||is-11/VBZ	root||ROOT-0/null||inactivated-12/VBN	agent||inactivated-12/VBN||truncation-14/NN	advmod||expressed-24/VBN||consequently-17/RB	nsubjpass||expressed-24/VBN||genes-18/NNS	vmod||genes-18/NNS||having-19/VBG	amod||sites-22/NNS||plcr-20/JJ	amod||sites-22/NNS||binding-21/VBG	dobj||having-19/VBG||sites-22/NNS	auxpass||expressed-24/VBN||are-23/VBP	conj_and||inactivated-12/VBN||expressed-24/VBN	advmod||low-27/JJ||very-26/RB	amod||levels-28/NNS||low-27/JJ	prep_at||expressed-24/VBN||levels-28/NNS	advmod||compared-30/VBN||when-29/WRB	advcl||expressed-24/VBN||compared-30/VBN	nn||cereus-33/NNS||b.-32/NN	prep_with||compared-30/VBN||cereus-33/NNS	anthrax-8||bacillusanthracis-2||no||in bacillusanthracis , the causative agent of anthrax , plcr is inactivated by truncation , and consequently genes having plcr binding sites are expressed at very low levels when compared with b. cereus .
amod||cytotoxicity-2/NN||cellular-1/JJ	nsubjpass||investigated-11/VBN||cytotoxicity-2/NN	conj_and||cytotoxicity-2/NN||proliferation-4/NN	nsubjpass||investigated-11/VBN||proliferation-4/NN	conj_and||cytotoxicity-2/NN||apoptosis-6/NNS	nsubjpass||investigated-11/VBN||apoptosis-6/NNS	conj_and||cytotoxicity-2/NN||differentiation-8/NNS	nsubjpass||investigated-11/VBN||differentiation-8/NNS	auxpass||investigated-11/VBN||were-9/VBD	advmod||investigated-11/VBN||comprehensively-10/RB	root||ROOT-0/null||investigated-11/VBN	amod||lines-15/NNS||realgar-treated-13/JJ	nn||lines-15/NNS||cell-14/NN	prep_in||investigated-11/VBN||lines-15/NNS	vmod||lines-15/NNS||derived-16/VBN	nn||patient-22/NN||pml-rarî-18/NNP	nn||patient-22/NN||±-19/NNP	nn||patient-22/NN||+-20/NNP	nn||patient-22/NN||apl-21/NN	prep_from||derived-16/VBN||patient-22/NN	det||atra-28/NN||the-25/DT	amod||atra-28/NN||all-transretinoicacid-26/JJ	prep_including||derived-16/VBN||atra-28/NN	amod||nb4-32/JJ||sensitive-31/JJ	dobj||derived-16/VBN||nb4-32/JJ	parataxis||derived-16/VBN||nb4-32/JJ	amod||lines-37/NNS||atra-resistant-34/JJ	amod||lines-37/NNS||mr2-35/JJ	nn||lines-37/NNS||cell-36/NN	dobj||derived-16/VBN||lines-37/NNS	parataxis||derived-16/VBN||lines-37/NNS	conj_and||nb4-32/JJ||lines-37/NNS	apl-21||atra-28||yes||cellular cytotoxicity, proliferation, apoptosis and differentiation were comprehensively investigated in realgar-treated cell lines derived from pml-rarî±+ apl patient, including the all-transretinoicacid (atra)-sensitive nb4 and atra-resistant mr2 cell lines.
det||study-3/NN||this-2/DT	prep_in||is-13/VBZ||study-3/NN	det||prevalence-6/NN||the-5/DT	nsubj||is-13/VBZ||prevalence-6/NN	nn||abnormalities-9/NNS||glucose-8/NN	prep_of||prevalence-6/NN||abnormalities-9/NNS	amod||children-12/NNS||obese-11/JJ	prep_in||abnormalities-9/NNS||children-12/NNS	root||ROOT-0/null||is-13/VBZ	dep||than-15/IN||higher-14/JJR	advmod||is-13/VBZ||than-15/IN	amod||series-18/NN||other-17/JJ	prep_in||is-13/VBZ||series-18/NN	advmod||present-25/JJ||furthermore-20/RB	det||correlation-23/NN||a-22/DT	nsubj||present-25/JJ||correlation-23/NN	cop||present-25/JJ||is-24/VBZ	parataxis||is-13/VBZ||present-25/JJ	prep_between||present-25/JJ||markers-27/NNS	amod||inflammation-32/NN||systemic-29/JJ	conj_and||systemic-29/JJ||intestinal-31/JJ	amod||inflammation-32/NN||intestinal-31/JJ	prep_of||markers-27/NNS||inflammation-32/NN	nn||abnormalities-35/NNS||glucose-34/NN	prep_of||markers-27/NNS||abnormalities-35/NNS	conj_and||inflammation-32/NN||abnormalities-35/NNS	obese-11||glucose-34||no_rel||in this study, the prevalence of glucose abnormalities in obese children is higher than in other series; furthermore, a correlation is present between markers of systemic and intestinal inflammation and glucose abnormalities.
amod||patients-2/NNS||many-1/JJ	nsubj||have-5/VBP||patients-2/NNS	prep_with||patients-2/NNS||aspirin-inducedasthma-4/NN	root||ROOT-0/null||have-5/VBP	amod||hyperresponsiveness-9/NNS||severe-6/JJ	amod||hyperresponsiveness-9/NNS||methacholine-7/JJ	amod||hyperresponsiveness-9/NNS||airway-8/JJ	dobj||have-5/VBP||hyperresponsiveness-9/NNS	appos||hyperresponsiveness-9/NNS||ahr-11/NN	vmod||have-5/VBP||suggesting-14/VBG	det||relationship-16/NN||a-15/DT	dobj||suggesting-14/VBG||relationship-16/NN	prep_between||relationship-16/NN||aspirin-18/NN	prep_between||relationship-16/NN||methacholine-20/NN	conj_and||aspirin-18/NN||methacholine-20/NN	amod||response-23/NN||airway-22/JJ	prep_in||suggesting-14/VBG||response-23/NN	aspirin-inducedasthma-4||aspirin-18||no||many patients with aspirin-inducedasthma have severe methacholine airway hyperresponsiveness (ahr), suggesting a relationship between aspirin and methacholine in airway response.
advmod||shown-8/VBN||however-1/RB	amod||analyses-6/NNS||proteomic-3/JJ	conj_and||proteomic-3/JJ||transcriptomic-5/JJ	amod||analyses-6/NNS||transcriptomic-5/JJ	nsubj||shown-8/VBN||analyses-6/NNS	aux||shown-8/VBN||have-7/VBP	root||ROOT-0/null||shown-8/VBN	mark||upregulated-17/VBN||that-9/IN	det||number-11/NN||a-10/DT	nsubjpass||upregulated-17/VBN||number-11/NN	nsubjpass||upregulated-17/VBN||number-11/NN	nsubjpass||upregulated-17/VBN||number-11/NN	nn||genes-14/NNS||usp-13/NN	prep_of||number-11/NN||genes-14/NNS	auxpass||upregulated-17/VBN||are-15/VBP	advmod||upregulated-17/VBN||significantly-16/RB	ccomp||shown-8/VBN||upregulated-17/VBN	ccomp||shown-8/VBN||upregulated-17/VBN	ccomp||shown-8/VBN||upregulated-17/VBN	conj_and||upregulated-17/VBN||upregulated-17/VBN	conj_and||upregulated-17/VBN||upregulated-17/VBN	amod||conditions-20/NNS||hypoxic-19/JJ	prep_under||upregulated-17/VBN||conditions-20/NNS	prep_in||upregulated-17/VBN||response-23/NN	prep_to||upregulated-17/VBN||nitricoxide-25/NN	prep_to||upregulated-17/VBN||carbonmonoxide-27/NN	conj_and||nitricoxide-25/NN||carbonmonoxide-27/NN	prep_during||upregulated-17/VBN||m.tuberculosisinfection-33/NN	amod||lines-37/NNS||macrophage-35/JJ	nn||lines-37/NNS||cell-36/NN	prep_of||m.tuberculosisinfection-33/NN||lines-37/NNS	nitricoxide-25||hypoxic-19||no_rel||however , proteomic and transcriptomic analyses have shown that a number of usp genes are significantly upregulated under hypoxic conditions and in response to nitricoxide and carbonmonoxide , as well as during m.tuberculosisinfection of macrophage cell lines .
det||doses-3/NNS||the-2/DT	prep_at||lidocaine-13/JJ||doses-3/NNS	vmod||doses-3/NNS||used-4/VBN	nsubj||lidocaine-13/JJ||riluzole-6/NN	nsubj||effective-31/JJ||riluzole-6/NN	cop||lidocaine-13/JJ||was-7/VBD	advmod||lidocaine-13/JJ||at-8/IN	pobj||at-8/IN||least-9/JJS	prep_as||at-8/IN||effective-11/JJ	advmod||lidocaine-13/JJ||as-12/RB	root||ROOT-0/null||lidocaine-13/JJ	prepc_at||lidocaine-13/JJ||reducing-15/VBG	det||number-17/NN||the-16/DT	dobj||reducing-15/VBG||number-17/NN	prep_of||number-17/NN||episodes-19/NNS	amod||vt-22/NN||ischaemic-21/JJ	prep_of||episodes-19/NNS||vt-22/NN	prep_of||episodes-19/NNS||vf-24/NN	conj_or||vt-22/NN||vf-24/NN	prep_in||reducing-15/VBG||pigs-26/NNS	advmod||effective-31/JJ||much-29/RB	advmod||effective-31/JJ||more-30/RBR	conj_and||lidocaine-13/JJ||effective-31/JJ	prepc_at||effective-31/JJ||reducing-33/VBG	det||number-35/NN||the-34/DT	dobj||reducing-33/VBG||number-35/NN	prep_of||number-35/NN||pvcs-37/NNS	vf-24||lidocaine-13||yes||at the doses used, riluzole was at least as effective as lidocaine at reducing the number of episodes of ischaemic vt or vf in pigs, and much more effective at reducing the number of pvcs.
nsubj||result-6/VBP||deficiencies-1/NNS	prep_in||deficiencies-1/NNS||gla-3/FW	prep_in||deficiencies-1/NNS||sda-5/FW	conj_and||gla-3/FW||sda-5/FW	root||ROOT-0/null||result-6/VBP	amod||susceptibility-9/NN||increased-8/VBN	prep_in||result-6/VBP||susceptibility-9/NN	prep_to||susceptibility-9/NN||bacterialinfection-11/NN	nsubjpass||associated-15/VBN||bacterialinfection-11/NN	auxpass||associated-15/VBN||is-14/VBZ	rcmod||bacterialinfection-11/NN||associated-15/VBN	amod||expression-19/NN||reduced-17/VBN	amod||expression-19/NN||basal-18/JJ	prep_with||associated-15/VBN||expression-19/NN	det||number-22/NN||a-21/DT	prep_of||expression-19/NN||number-22/NN	amod||$-26/NNS||immune-specific-24/JJ	amod||$-26/NNS||genesâ-25/JJ	prep_of||number-22/NN||$-26/NNS	dep||â-35/JJ||spp-1-29/JJ	conj_and||â-35/JJ||lys-7-31/JJ	amod||$-36/NNS||lys-7-31/JJ	conj_and||â-35/JJ||lys-2-34/JJ	amod||$-36/NNS||lys-2-34/JJ	amod||$-36/NNS||â-35/JJ	prep_including||$-26/NNS||$-36/NNS	nsubj||encode-39/VBP||$-36/NNS	rcmod||$-36/NNS||encode-39/VBP	amod||peptides-41/NNS||antimicrobial-40/JJ	dobj||encode-39/VBP||peptides-41/NNS	lys--1||sda-5||no_rel||deficiencies in gla and sda result in increased susceptibility to bacterialinfection, which is associated with reduced basal expression of a number of immune-specific genesâincluding spp-1 , lys-7 , and lys-2 âthat encode antimicrobial peptides.
det||study-2/NN||this-1/DT	nsubj||demonstrated-3/VBD||study-2/NN	root||ROOT-0/null||demonstrated-3/VBD	mark||higher-18/JJR||that-4/IN	csubj||higher-18/JJR||circulating-5/VBG	nn||plasmablasts-8/NNS||igg-6/NN	nn||plasmablasts-8/NNS||+-7/NN	dobj||circulating-5/VBG||plasmablasts-8/NNS	amod||secretion-11/NN||spontaneous-10/JJ	dobj||circulating-5/VBG||secretion-11/NN	conj_and||plasmablasts-8/NNS||secretion-11/NN	amod||antibodies-15/NNS||bcg-specific-13/JJ	nn||antibodies-15/NNS||igg-14/NN	prep_of||secretion-11/NN||antibodies-15/NNS	cop||higher-18/JJR||were-16/VBD	advmod||higher-18/JJR||significantly-17/RB	ccomp||demonstrated-3/VBD||higher-18/JJR	prep_in||higher-18/JJR||patients-20/NNS	amod||tb-23/NN||active-22/JJ	prep_with||patients-20/NNS||tb-23/NN	prepc_compared_with||higher-18/JJR||with-25/IN	nn||cases-28/NNS||latent-26/NN	nn||cases-28/NNS||tb-27/NN	pobj||higher-18/JJR||cases-28/NNS	amod||controls-31/NNS||non-tb-30/JJ	pobj||higher-18/JJR||controls-31/NNS	conj_and||cases-28/NNS||controls-31/NNS	tb-27||bcg--1||no||this study demonstrated that circulating igg+ plasmablasts and spontaneous secretion of bcg-specific igg antibodies were significantly higher in patients with active tb compared with latent tb cases and non-tb controls.
amod||time-2/NN||median-1/JJ	nsubj||days-13/NNS||time-2/NN	prep_to||time-2/NN||detection-4/NN	prep_of||detection-4/NN||tuberculosis-6/NNP	det||test-10/NN||the-8/DT	nn||test-10/NN||mtb/rif-9/NN	prep_for||tuberculosis-6/NNP||test-10/NN	cop||days-13/NNS||was-11/VBD	num||days-13/NNS||0-12/CD	root||ROOT-0/null||days-13/NNS	dep||$-17/$||iqr-15/RB	pobj||iqr-15/RB||0â-16/CD	dep||days-13/NNS||$-17/$	num||$-17/$||1-19/CD	prepc_compared_with||days-13/NNS||with-23/IN	num||day-25/NN||1-24/CD	pobj||days-13/NNS||day-25/NN	appos||day-25/NN||0â-27/NNP	num||0â-27/NNP||$-28/$	num||$-28/$||1-30/CD	prep_for||day-25/NN||microscopy-33/NN	num||days-36/NNS||30-35/CD	pobj||days-13/NNS||days-36/NNS	conj_and||day-25/NN||days-36/NNS	appos||days-36/NNS||23â-38/NNP	num||23â-38/NNP||$-39/$	num||$-39/$||43-41/CD	amod||culture-45/NN||solid-44/JJ	prep_for||days-36/NNS||culture-45/NN	num||days-49/NNS||16-48/CD	pobj||days-13/NNS||days-49/NNS	conj_and||day-25/NN||days-49/NNS	appos||days-49/NNS||13â-51/NNP	num||13â-51/NNP||$-52/$	num||$-52/$||21-54/CD	amod||culture-58/NN||liquid-57/JJ	prep_for||days-49/NNS||culture-58/NN	tuberculosis-6||mtb--1||no||median time to detection of tuberculosis for the mtb/rif test was 0 days (iqr 0â1), compared with 1 day (0â1) for microscopy, 30 days (23â43) for solid culture, and 16 days (13â21) for liquid culture.
det||availability-3/NN||the-1/DT	amod||availability-3/NN||limited-2/JJ	nsubj||allografts-22/VBZ||availability-3/NN	amod||pancreata-8/NN||cadaveric-5/JJ	amod||pancreata-8/NN||human-6/JJ	nn||pancreata-8/NN||donor-7/NN	prep_of||availability-3/NN||pancreata-8/NN	det||success-14/NN||the-12/DT	amod||success-14/NN||incomplete-13/JJ	prep_of||availability-3/NN||success-14/NN	conj_and||pancreata-8/NN||success-14/NN	det||protocol-18/NN||the-16/DT	nn||protocol-18/NN||edmonton-17/NN	prep_of||success-14/NN||protocol-18/NN	amod||islet-21/NN||human-20/JJ	prep_for||protocol-18/NN||islet-21/NN	root||ROOT-0/null||allografts-22/VBZ	nn||search-24/NN||fasten-23/NN	nsubj||cells-32/NNS||search-24/NN	amod||sources-27/NNS||new-26/JJ	prep_for||search-24/NN||sources-27/NNS	prep_of||sources-27/NNS||insulin-29/NN	det||cells-32/NNS||the-30/DT	amod||cells-32/NNS||producing-31/VBG	xcomp||allografts-22/VBZ||cells-32/NNS	nn||therapy-36/NN||substitution-34/NN	nn||therapy-36/NN||cell-35/NN	prep_for||cells-32/NNS||therapy-36/NN	prep_of||therapy-36/NN||insulin-dependentdiabetesmellitus-38/NNS	appos||insulin-dependentdiabetesmellitus-38/NNS||t1dm-40/NNP	insulin-dependentdiabetesmellitus-38||insulin-29||yes||the limited availability of cadaveric human donor pancreata as well as the incomplete success of the edmonton protocol for human islet allografts fasten search for new sources of insulin the producing cells for substitution cell therapy of insulin-dependentdiabetesmellitus (t1dm).
det||study-2/NN||this-1/DT	nsubj||suggests-3/VBZ||study-2/NN	root||ROOT-0/null||suggests-3/VBZ	mark||evokes-6/VBZ||that-4/IN	nsubj||evokes-6/VBZ||tadalafil-5/NN	ccomp||suggests-3/VBZ||evokes-6/VBZ	amod||effects-9/NNS||positive-7/JJ	amod||effects-9/NNS||metabolic-8/JJ	dobj||evokes-6/VBZ||effects-9/NNS	amod||women-12/NNS||insulin-resistant-11/JJ	prep_in||effects-9/NNS||women-12/NNS	prep_with||evokes-6/VBZ||type2diabetes-14/CD	type2diabetes-14||insulin--1||yes||this study suggests that tadalafil evokes positive metabolic effects in insulin-resistant women with type2diabetes.
amod||renalcellcarcinoma-4/NN||clear-2/JJ	nn||renalcellcarcinoma-4/NN||cell-3/NN	prep_in||described-12/VBN||renalcellcarcinoma-4/NN	amod||disturbances-6/NNS||many-5/JJ	nsubjpass||described-12/VBN||disturbances-6/NNS	amod||pathway-10/NN||t3-8/JJ	amod||pathway-10/NN||signaling-9/JJ	prep_in||disturbances-6/NNS||pathway-10/NN	auxpass||described-12/VBN||was-11/VBD	root||ROOT-0/null||described-12/VBN	det||type-16/NN||that-15/WDT	prep_in||shown-31/VBN||type-16/NN	prep_of||type-16/NN||cancer-18/NN	advmod||shown-31/VBN||also-19/RB	nsubjpass||shown-31/VBN||expression-20/NN	det||g1-24/NN||some-22/DT	amod||g1-24/NN||key-23/JJ	prep_of||expression-20/NN||g1-24/NN	amod||regulators-29/NNS||s-26/JJ	nn||regulators-29/NNS||phase-27/NN	nn||regulators-29/NNS||progression-28/NN	prep_to||g1-24/NN||regulators-29/NNS	auxpass||shown-31/VBN||was-30/VBD	ccomp||described-12/VBN||shown-31/VBN	t3-8||renalcellcarcinoma-4||no_rel||in clear cell renalcellcarcinoma many disturbances in t3 signaling pathway was described, in that type of cancer also expression of some key g1 to s phase progression regulators was shown.
nsubjpass||studied-4/VBN||liraglutide-1/NN	nsubjpass||studied-4/VBN||liraglutide-1/NN	aux||studied-4/VBN||has-2/VBZ	auxpass||studied-4/VBN||been-3/VBN	root||ROOT-0/null||studied-4/VBN	conj_and||studied-4/VBN||studied-4/VBN	prep_as||studied-4/VBN||monotherapy-6/NN	prep_in||studied-4/VBN||combination-9/NN	prep_with||studied-4/VBN||metformin-11/NN	prep_with||studied-4/VBN||glimepiride-13/NN	conj_and||metformin-11/NN||glimepiride-13/NN	prep_with||studied-4/VBN||rosiglitazone-16/NN	conj_and||metformin-11/NN||rosiglitazone-16/NN	det||treatment-19/NN||the-18/DT	prep_for||metformin-11/NN||treatment-19/NN	prep_of||treatment-19/NN||type2diabetes-21/CD	type2diabetes-21||rosiglitazone-16||yes||liraglutide has been studied as monotherapy and in combination with metformin, glimepiride, and rosiglitazone for the treatment of type2diabetes.
amod||responses-2/NNS||inappropriate-1/JJ	nsubjpass||involved-9/VBN||responses-2/NNS	amod||bacteria-6/NNS||normal-4/JJ	amod||bacteria-6/NNS||intestinal-5/JJ	prep_to||responses-2/NNS||bacteria-6/NNS	aux||involved-9/VBN||may-7/MD	auxpass||involved-9/VBN||be-8/VB	root||ROOT-0/null||involved-9/VBN	det||development-12/NN||the-11/DT	prep_in||involved-9/VBN||development-12/NN	prep_of||development-12/NN||inflammatoryboweldiseases-14/NNS	amod||ibd-16/NN||-lrb--15/JJ	nsubj||ulcerativecolitis-26/VBZ||ibd-16/NN	nn||crohn-19/NNP||e.g.-18/NNP	poss||-rrb--24/NN||crohn-19/NNP	nn||-rrb--24/NN||disease-21/NN	amod||-rrb--24/NN||-lrb--22/JJ	nn||-rrb--24/NN||cd-23/NN	appos||ibd-16/NN||-rrb--24/NN	rcmod||inflammatoryboweldiseases-14/NNS||ulcerativecolitis-26/VBZ	amod||-rrb--30/NNS||-lrb--27/JJ	nn||-rrb--30/NNS||uc-28/NN	amod||-rrb--30/NNS||-rrb--29/JJ	nsubj||mediate-38/VB||-rrb--30/NNS	conj_and||-rrb--30/NNS||variations-32/NNS	nsubj||mediate-38/VB||variations-32/NNS	det||genome-36/NN||the-34/DT	nn||genome-36/NN||host-35/NN	prep_in||-rrb--30/NNS||genome-36/NN	aux||mediate-38/VB||may-37/MD	ccomp||ulcerativecolitis-26/VBZ||mediate-38/VB	det||process-40/NN||this-39/DT	dobj||mediate-38/VB||process-40/NN	cd-23||inflammatoryboweldiseases-14||no_rel||inappropriate responses to normal intestinal bacteria may be involved in the development of inflammatoryboweldiseases -lrb- ibd , e.g. crohn 's disease -lrb- cd -rrb- , ulcerativecolitis -lrb- uc -rrb- -rrb- and variations in the host genome may mediate this process .
nsubj||showed-5/VBD||smokers-1/NNS	vmod||smokers-1/NNS||treated-2/VBN	prep_with||treated-2/VBN||budesonide/formoterol-4/NN	root||ROOT-0/null||showed-5/VBD	det||increase-7/NN||an-6/DT	dobj||showed-5/VBD||increase-7/NN	det||number-10/NN||the-9/DT	prep_in||showed-5/VBD||number-10/NN	nn||episodes-13/NNS||asthma-12/NN	prep_of||number-10/NN||episodes-13/NNS	parataxis||showed-5/VBD||intercurrent-15/VB	nn||symptoms-17/NNS||asthma-16/NN	dobj||intercurrent-15/VB||symptoms-17/NNS	vmod||symptoms-17/NNS||p-19/VBN	dep||0.016-21/CD||=-20/SYM	ccomp||p-19/VBN||0.016-21/CD	mark||had-26/VBD||while-23/IN	amod||subjects-25/NNS||non-smoking-24/JJ	nsubj||had-26/VBD||subjects-25/NNS	advcl||showed-5/VBD||had-26/VBD	det||decrease-29/NN||a-27/DT	amod||decrease-29/NN||significant-28/JJ	dobj||had-26/VBD||decrease-29/NN	det||episodes-32/NNS||these-31/DT	prep_in||decrease-29/NN||episodes-32/NNS	dep||episodes-32/NNS||p-34/VBN	dep||0.009-36/CD||=-35/SYM	ccomp||p-34/VBN||0.009-36/CD	asthma-16||budesonide--1||yes||smokers treated with budesonide/formoterol showed an increase in the number of asthma episodes (intercurrent asthma symptoms, p=0.016) while non-smoking subjects had a significant decrease in these episodes (p=0.009).
amod||challenges-2/NNS||current-1/JJ	nsubj||include-10/VBP||challenges-2/NNS	det||eradication-6/NN||the-4/DT	amod||eradication-6/NN||final-5/JJ	prep_to||challenges-2/NNS||eradication-6/NN	amod||poliomyelitis-9/NNP||paralytic-8/JJ	prep_of||eradication-6/NN||poliomyelitis-9/NNP	root||ROOT-0/null||include-10/VBP	det||transmission-13/NN||the-11/DT	amod||transmission-13/NN||continued-12/VBN	dobj||include-10/VBP||transmission-13/NN	amod||polioviruses-16/NNS||wild-15/JJ	prep_of||transmission-13/NN||polioviruses-16/NNS	amod||reservoirs-19/NNS||endemic-18/JJ	prep_in||polioviruses-16/NNS||reservoirs-19/NNS	dobj||include-10/VBP||reinfection-21/NN	conj_and||transmission-13/NN||reinfection-21/NN	amod||areas-24/NNS||polio-free-23/JJ	prep_of||reinfection-21/NN||areas-24/NNS	appos||areas-24/NNS||outbreaks-26/NNS	prepc_due_to||outbreaks-26/NNS||circulating-29/VBG	amod||polioviruses-31/NNS||vaccine-derived-30/JJ	dobj||circulating-29/VBG||polioviruses-31/NNS	amod||excretion-35/NN||persistent-34/JJ	dobj||include-10/VBP||excretion-35/NN	conj_and||transmission-13/NN||excretion-35/NN	amod||poliovirus-38/NNS||vaccine-derived-37/JJ	prep_of||excretion-35/NN||poliovirus-38/NNS	det||vaccinees-42/NNS||a-40/DT	amod||vaccinees-42/NNS||few-41/JJ	prep_by||poliovirus-38/NNS||vaccinees-42/NNS	amod||immunodeficiencies-45/NNS||b-cell-44/JJ	prep_with||vaccinees-42/NNS||immunodeficiencies-45/NNS	polio--1||poliovirus-38||no||current challenges to the final eradication of paralytic poliomyelitis include the continued transmission of wild polioviruses in endemic reservoirs, reinfection of polio-free areas, outbreaks due to circulating vaccine-derived polioviruses, and persistent excretion of vaccine-derived poliovirus by a few vaccinees with b-cell immunodeficiencies.
det||development-2/NN||the-1/DT	nsubj||step-24/NN||development-2/NN	cc||logic-5/CD||or-4/CC	num||gate-6/NN||logic-5/CD	prep_of||development-2/NN||gate-6/NN	prepc_based_on||gate-6/NN||on-8/IN	amod||strategy-10/NN||dual-aptamer-9/JJ	pobj||gate-6/NN||strategy-10/NN	num||signals-15/NNS||two-12/CD	amod||signals-15/NNS||chemical-13/JJ	nn||signals-15/NNS||input-14/NN	pobj||gate-6/NN||signals-15/NNS	conj_and||strategy-10/NN||signals-15/NNS	dep||gate-6/NN||prpres-17/JJ	dep||gate-6/NN||gdn-hcl-19/JJ	conj_and||prpres-17/JJ||gdn-hcl-19/JJ	cop||step-24/NN||is-21/VBZ	det||step-24/NN||an-22/DT	amod||step-24/NN||important-23/JJ	root||ROOT-0/null||step-24/NN	det||design-27/NN||the-26/DT	prep_toward||step-24/NN||design-27/NN	amod||diagnosis-30/NN||priondiseases-29/JJ	prep_of||design-27/NN||diagnosis-30/NN	nn||systems-33/NNS||therapy-32/NN	prep_of||design-27/NN||systems-33/NNS	conj_and||diagnosis-30/NN||systems-33/NNS	hcl--1||priondiseases-29||no_rel||the development of or logic gate based on dual-aptamer strategy and two chemical input signals (prpres and gdn-hcl) is an important step toward the design of priondiseases diagnosis and therapy systems.
predet||data-3/NNS||all-1/PDT	det||data-3/NNS||these-2/DT	nsubj||corroborate-4/VBP||data-3/NNS	nsubj||confirm-14/VBP||data-3/NNS	nsubj||suggest-26/VBP||data-3/NNS	root||ROOT-0/null||corroborate-4/VBP	det||impact-6/NN||the-5/DT	dobj||corroborate-4/VBP||impact-6/NN	prep_of||impact-6/NN||bvrr/bvrs-8/NNS	nn||modulation-12/NN||cell-10/NN	nn||modulation-12/NN||envelope-11/NN	prep_on||bvrr/bvrs-8/NNS||modulation-12/NN	conj_and||corroborate-4/VBP||confirm-14/VBP	mark||controls-18/VBZ||that-15/IN	det||system-17/NN||this-16/DT	nsubj||controls-18/VBZ||system-17/NN	ccomp||confirm-14/VBP||controls-18/VBZ	det||metabolism-23/NN||the-19/DT	nn||metabolism-23/NN||carbon-20/NN	conj_and||carbon-20/NN||nitrogen-22/NN	nn||metabolism-23/NN||nitrogen-22/NN	dobj||controls-18/VBZ||metabolism-23/NN	conj_and||corroborate-4/VBP||suggest-26/VBP	det||cross-talk-28/NN||a-27/DT	dobj||suggest-26/VBP||cross-talk-28/NN	det||regulators-31/NNS||some-30/DT	prep_among||cross-talk-28/NN||regulators-31/NNS	aux||adjust-33/VB||to-32/TO	vmod||suggest-26/VBP||adjust-33/VB	det||physiology-36/NN||the-34/DT	nn||physiology-36/NN||brucella-35/NN	dobj||adjust-33/VB||physiology-36/NN	det||shift-39/NN||the-38/DT	prep_to||adjust-33/VB||shift-39/NN	vmod||shift-39/NN||expected-40/VBN	aux||occur-42/VB||to-41/TO	xcomp||expected-40/VBN||occur-42/VB	det||transit-45/NN||the-44/DT	prep_during||occur-42/VB||transit-45/NN	det||extracellular-48/NN||the-47/DT	prep_from||transit-45/NN||extracellular-48/NN	det||niche-52/NN||the-50/DT	nn||niche-52/NN||intracellular-51/NN	prep_to||occur-42/VB||niche-52/NN	cross--1||nitrogen-22||no_rel||all these data corroborate the impact of bvrr/bvrs on cell envelope modulation, confirm that this system controls the carbon and nitrogen metabolism, and suggest a cross-talk among some regulators to adjust the brucella physiology to the shift expected to occur during the transit from the extracellular to the intracellular niche.
amod||lymphohistiocytosis-2/NNS||hemophagocytic-1/JJ	nsubjpass||described-8/VBN||lymphohistiocytosis-2/NNS	nsubj||occurs-23/VBZ||lymphohistiocytosis-2/NNS	appos||lymphohistiocytosis-2/NNS||hlh-4/NN	aux||described-8/VBN||has-6/VBZ	auxpass||described-8/VBN||been-7/VBN	root||ROOT-0/null||described-8/VBN	prep_in||described-8/VBN||patients-10/NNS	amod||stages-13/NNS||advanced-12/JJ	prep_with||patients-10/NNS||stages-13/NNS	nn||infection-19/NN||humanimmunodeficiencyvirus-15/NNP	appos||infection-19/NN||hiv-17/NN	prep_of||stages-13/NNS||infection-19/NN	advmod||occurs-23/VBZ||rarely-22/RB	conj_but||described-8/VBN||occurs-23/VBZ	det||stage-27/NN||the-25/DT	nn||stage-27/NN||seroconversion-26/NN	prep_during||occurs-23/VBZ||stage-27/NN	prep_of||stage-27/NN||acutehivinfection-29/NN	acutehivinfection-29||humanimmunodeficiencyvirus-15||no||hemophagocytic lymphohistiocytosis (hlh) has been described in patients with advanced stages of humanimmunodeficiencyvirus (hiv) infection, but rarely occurs during the seroconversion stage of acutehivinfection.
det||people-2/NNS||some-1/DT	nsubj||want-9/VBP||people-2/NNS	nsubj||have-11/VB||people-2/NNS	vmod||people-2/NNS||living-3/VBG	prep_with||living-3/VBG||hiv/aids-5/NNS	appos||hiv/aids-5/NNS||plhiv-7/NNP	root||ROOT-0/null||want-9/VBP	aux||have-11/VB||to-10/TO	xcomp||want-9/VBP||have-11/VB	dobj||have-11/VB||children-12/NNS	mark||want-15/VBP||while-13/IN	nsubj||want-15/VBP||others-14/NNS	nsubj||prevent-17/VB||others-14/NNS	advcl||have-11/VB||want-15/VBP	aux||prevent-17/VB||to-16/TO	xcomp||want-15/VBP||prevent-17/VB	dobj||prevent-17/VB||pregnancies-18/NNS	nsubj||calls-21/VBZ||this-20/DT	nsubj||address-26/VB||this-20/DT	parataxis||want-9/VBP||calls-21/VBZ	amod||services-24/NNS||comprehensive-23/JJ	prep_for||calls-21/VBZ||services-24/NNS	aux||address-26/VB||to-25/TO	xcomp||calls-21/VBZ||address-26/VB	det||needs-28/NNS||both-27/DT	dobj||address-26/VB||needs-28/NNS	aids--1||hiv--1||no||some people living with hiv/aids (plhiv) want to have children while others want to prevent pregnancies; this calls for comprehensive services to address both needs.
mark||shown-6/VBN||although-1/IN	amod||reports-4/NNS||several-2/JJ	amod||reports-4/NNS||recent-3/JJ	nsubj||shown-6/VBN||reports-4/NNS	aux||shown-6/VBN||have-5/VBP	advcl||common-41/JJ||shown-6/VBN	mark||developed-13/VBD||that-7/IN	nn||carcinoma-9/NN||hepatocellular-8/NN	nsubj||developed-13/VBD||carcinoma-9/NN	appos||carcinoma-9/NN||hcc-11/NN	ccomp||shown-6/VBN||developed-13/VBD	prep_in||developed-13/VBD||patients-15/NNS	amod||response-27/NN||chronichepatitisc-17/JJ	dep||response-27/NN||ch-c-19/JJ	amod||response-27/NN||even-21/RB	prepc_after||even-21/RB||having-23/VBG	det||virological-26/NN||a-24/DT	amod||virological-26/NN||sustained-25/JJ	dobj||having-23/VBG||virological-26/NN	prep_with||patients-15/NNS||response-27/NN	appos||response-27/NN||svr-29/NN	nn||therapy-36/NN||interferon-32/NNP	appos||therapy-36/NN||ifn-34/NN	prep_to||developed-13/VBD||therapy-36/NN	nsubj||common-41/JJ||it-38/PRP	nsubj||develop-45/VB||it-38/PRP	cop||common-41/JJ||is-39/VBZ	neg||common-41/JJ||not-40/RB	root||ROOT-0/null||common-41/JJ	prep_for||common-41/JJ||hcc-43/NN	aux||develop-45/VB||to-44/TO	xcomp||common-41/JJ||develop-45/VB	mwe||than-47/IN||more-46/JJR	quantmod||10-48/CD||than-47/IN	num||years-49/NNS||10-48/CD	tmod||develop-45/VB||years-49/NNS	prep_after||develop-45/VB||svr-51/NN	chronichepatitisc-17||ifn-34||yes||although several recent reports have shown that hepatocellular carcinoma (hcc) developed in patients with chronichepatitisc (ch-c) even after having a sustained virological response (svr) to interferon (ifn) therapy, it is not common for hcc to develop more than 10 years after svr.
ccomp||causes-10/VBZ||similar-1/JJ	nn||propofol-5/NN||lipid-3/NN	nn||propofol-5/NN||emulsion-4/NN	prep_to||similar-1/JJ||propofol-5/NN	nn||propofol-8/NN||microemulsion-7/NN	nsubj||causes-10/VBZ||propofol-8/NN	advmod||causes-10/VBZ||also-9/RB	root||ROOT-0/null||causes-10/VBZ	det||incidence-13/NN||a-11/DT	amod||incidence-13/NN||high-12/JJ	dobj||causes-10/VBZ||incidence-13/NN	prep_of||incidence-13/NN||pain-15/NN	amod||injection-18/NN||intravenous-17/JJ	prep_during||causes-10/VBZ||injection-18/NN	pain-15||propofol-8||yes||similar to lipid emulsion propofol, microemulsion propofol also causes a high incidence of pain during intravenous injection.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||case-4/NN||a-3/DT	dobj||report-2/VBP||case-4/NN	amod||lungdisease-8/NN||rheumatoid-6/JJ	amod||lungdisease-8/NN||interstitial-7/JJ	prep_of||case-4/NN||lungdisease-8/NN	vmod||lungdisease-8/NN||presenting-9/VBG	prep_as||presenting-9/VBG||corpulmonale-11/NN	corpulmonale-11||lungdisease-8||no||we report a case of rheumatoid interstitial lungdisease presenting as corpulmonale.
nsubjpass||enrolled-3/VBN||participants-1/NNS	auxpass||enrolled-3/VBN||were-2/VBD	root||ROOT-0/null||enrolled-3/VBN	det||study-7/NN||a-5/DT	amod||study-7/NN||cross-sectional-6/JJ	prep_in||enrolled-3/VBN||study-7/NN	amod||assessment-10/NN||lipoatrophy-9/JJ	prep_with||enrolled-3/VBN||assessment-10/NN	amod||test-15/NN||oral-12/JJ	nn||test-15/NN||glucose-13/NN	nn||test-15/NN||tolerance-14/NN	prep_with||enrolled-3/VBN||test-15/NN	conj_and||assessment-10/NN||test-15/NN	amod||triglycerides-18/NNPS||fasting-17/JJ	prep_with||enrolled-3/VBN||triglycerides-18/NNPS	conj_and||assessment-10/NN||triglycerides-18/NNPS	nn||lactate-22/NN||finger-20/NN	nn||lactate-22/NN||prick-21/NN	prep_with||enrolled-3/VBN||lactate-22/NN	conj_and||assessment-10/NN||lactate-22/NN	amod||concentrations-26/NNS||stavudine-25/JJ	prep_with||enrolled-3/VBN||concentrations-26/NNS	conj_and||assessment-10/NN||concentrations-26/NNS	cross--1||triglycerides-18||no_rel||participants were enrolled in a cross-sectional study with lipoatrophy assessment, oral glucose tolerance test, fasting triglycerides, finger prick lactate, and stavudine concentrations.
amod||studies-2/NNS||recent-1/JJ	nsubj||suggest-3/VBP||studies-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||plays-10/VBZ||that-4/IN	det||induction-6/NN||the-5/DT	nsubj||plays-10/VBZ||induction-6/NN	amod||expression-9/NN||ho-1-8/JJ	prep_of||induction-6/NN||expression-9/NN	ccomp||suggest-3/VBP||plays-10/VBZ	det||role-14/NN||a-11/DT	amod||role-14/NN||critical-12/JJ	amod||role-14/NN||protective-13/JJ	dobj||plays-10/VBZ||role-14/NN	amod||models-18/NNS||intestinal-16/JJ	nn||models-18/NNS||damage-17/NN	prep_in||plays-10/VBZ||models-18/NNS	vmod||models-18/NNS||induced-19/VBN	agent||induced-19/VBN||ischemia-reperfusion-21/NN	agent||induced-19/VBN||indomethacin-23/NN	conj_and||ischemia-reperfusion-21/NN||indomethacin-23/NN	amod||sepsis-26/NN||lipopolysaccharide-associated-25/JJ	agent||induced-19/VBN||sepsis-26/NN	conj_and||ischemia-reperfusion-21/NN||sepsis-26/NN	amod||acid-30/NN||trinitrobenzene-28/JJ	amod||acid-30/NN||sulfonic-29/JJ	agent||induced-19/VBN||acid-30/NN	conj_and||ischemia-reperfusion-21/NN||acid-30/NN	nn||sodium-35/NN||dextran-33/NN	nn||sodium-35/NN||sulfate-34/NN	agent||induced-19/VBN||sodium-35/NN	conj_and||ischemia-reperfusion-21/NN||sodium-35/NN	vmod||plays-10/VBZ||indicating-37/VBG	mark||act-43/VB||that-38/IN	nsubj||act-43/VB||activation-39/NN	nsubj||reduce-50/VB||activation-39/NN	prep_of||activation-39/NN||ho-1-41/CD	aux||act-43/VB||may-42/MD	ccomp||indicating-37/VBG||act-43/VB	det||mechanism-48/NN||an-45/DT	amod||mechanism-48/NN||endogenous-46/JJ	amod||mechanism-48/NN||defensive-47/JJ	prep_as||act-43/VB||mechanism-48/NN	aux||reduce-50/VB||to-49/TO	xcomp||act-43/VB||reduce-50/VB	nn||injury-54/NN||inflammation-51/NN	conj_and||inflammation-51/NN||tissue-53/NN	nn||injury-54/NN||tissue-53/NN	dobj||reduce-50/VB||injury-54/NN	det||tract-58/NN||the-56/DT	amod||tract-58/NN||gastrointestinal-57/JJ	prep_in||reduce-50/VB||tract-58/NN	sepsis-26||dextran-33||no_rel||recent studies suggest that the induction of ho-1 expression plays a critical protective role in intestinal damage models induced by ischemia-reperfusion, indomethacin, lipopolysaccharide-associated sepsis, trinitrobenzene sulfonic acid, and dextran sulfate sodium, indicating that activation of ho-1 may act as an endogenous defensive mechanism to reduce inflammation and tissue injury in the gastrointestinal tract.
nn||total-3/NN||method-1/NN	det||total-3/NN||a-2/DT	nsubjpass||assessed-22/VBN||total-3/NN	num||women-6/NNS||120-5/CD	prep_of||total-3/NN||women-6/NNS	nsubjpass||treated-9/VBN||women-6/NNS	auxpass||treated-9/VBN||were-8/VBD	rcmod||women-6/NNS||treated-9/VBN	prep_for||treated-9/VBN||alcoholaddiction-11/NN	det||hospital-15/NN||the-13/DT	nn||hospital-15/NN||karolinska-14/NN	prep_at||treated-9/VBN||hospital-15/NN	prep_in||hospital-15/NN||stockholm-17/NN	appos||women-6/NNS||sweden-19/NN	auxpass||assessed-22/VBN||were-21/VBD	root||ROOT-0/null||assessed-22/VBN	advmod||assessed-22/VBN||twice-23/RB	det||period-27/NN||a-25/DT	amod||period-27/NN||2-year-26/JJ	prep_over||assessed-22/VBN||period-27/NN	vmod||period-27/NN||using-28/VBG	det||scale-31/NN||the-29/DT	nn||scale-31/NN||depression-30/NN	dobj||using-28/VBG||scale-31/NN	det||checklist-90-35/NN||the-33/DT	nn||checklist-90-35/NN||symptom-34/NN	prep_from||using-28/VBG||checklist-90-35/NN	det||inventory-40/NN||the-37/DT	nn||inventory-40/NN||alcohol-38/NN	nn||inventory-40/NN||use-39/NN	prep_from||using-28/VBG||inventory-40/NN	conj_and||checklist-90-35/NN||inventory-40/NN	det||scale-45/NN||the-42/DT	amod||scale-45/NN||dysfunctional-43/JJ	nn||scale-45/NN||attitude-44/NN	prep_from||using-28/VBG||scale-45/NN	conj_and||checklist-90-35/NN||scale-45/NN	appos||checklist-90-35/NN||das-47/NN	alcoholaddiction-11||alcohol-38||no||method a total of 120 women who were treated for alcoholaddiction at the karolinska hospital in stockholm (sweden) were assessed twice over a 2-year period using the depression scale from the symptom checklist-90, the alcohol use inventory and the dysfunctional attitude scale (das).
det||amplicons-2/NNS||these-1/DT	nsubj||identified-3/VBD||amplicons-2/NNS	root||ROOT-0/null||identified-3/VBD	nsubj||similar-6/JJ||vacciniavirus-4/NNS	advmod||similar-6/JJ||genetically-5/RB	xcomp||identified-3/VBD||similar-6/JJ	prep_to||similar-6/JJ||strains-8/NNS	amod||outbreaks-12/NNS||bovine-10/JJ	nn||outbreaks-12/NNS||vaccinia-11/NN	prep_from||strains-8/NNS||outbreaks-12/NNS	prep_in||outbreaks-12/NNS||brazil-14/NN	vaccinia-11||vacciniavirus-4||no||these amplicons identified vacciniavirus genetically similar to strains from bovine vaccinia outbreaks in brazil.
mark||established-4/VBN||after-1/IN	nsubjpass||established-4/VBN||inflammation-2/NN	auxpass||established-4/VBN||was-3/VBD	advcl||dosed-7/VBN||established-4/VBN	nsubjpass||dosed-7/VBN||mice-5/NNS	auxpass||dosed-7/VBN||were-6/VBD	root||ROOT-0/null||dosed-7/VBN	det||antagonist-11/NN||the-9/DT	amod||antagonist-11/NN||h4r-10/JJ	prep_with||dosed-7/VBN||antagonist-11/NN	number||7777120-14/CD||jnj-13/CD	appos||antagonist-11/NN||7777120-14/CD	amod||antibody-18/NN||anti-il-13-17/JJ	appos||antagonist-11/NN||antibody-18/NN	conj_or||7777120-14/CD||antibody-18/NN	prep_for||antibody-18/NN||comparison-20/NN	antibody-18||inflammation-2||no_rel||after inflammation was established mice were dosed with the h4r antagonist, jnj 7777120, or anti-il-13 antibody for comparison.
amod||imaging-2/NN||bioluminescence-1/JJ	nsubj||exhibited-16/VBD||imaging-2/NN	nn||xenografts-5/NNS||tumor-4/NN	prep_of||imaging-2/NN||xenografts-5/NNS	advmod||expressing-7/VBG||stably-6/RB	vmod||xenografts-5/NNS||expressing-7/VBG	det||sensor-10/NN||the-8/DT	amod||sensor-10/NN||pik3ca-9/JJ	dobj||expressing-7/VBG||sensor-10/NN	amod||cells-15/NNS||pa1-12/JJ	conj_and||pa1-12/JJ||a2780-14/JJ	amod||cells-15/NNS||a2780-14/JJ	prep_in||sensor-10/NN||cells-15/NNS	root||ROOT-0/null||exhibited-16/VBD	amod||activity-18/NN||attenuating-17/JJ	dobj||exhibited-16/VBD||activity-18/NN	det||change-21/NN||any-20/DT	prep_without||exhibited-16/VBD||change-21/NN	amod||tumors-24/NNS||skov3-23/JJ	prep_in||change-21/NN||tumors-24/NNS	xcomp||exhibited-16/VBD||expressing-25/VBG	det||sensor-28/NN||the-26/DT	amod||sensor-28/NN||pik3ca-27/JJ	dobj||expressing-25/VBG||sensor-28/NN	nn||treatment-31/NN||cisplatin-30/NN	prep_after||expressing-25/VBG||treatment-31/NN	tumor-4||cisplatin-30||no_rel||bioluminescence imaging of tumor xenografts stably expressing the pik3ca sensor in pa1 and a2780 cells exhibited attenuating activity without any change in skov3 tumors expressing the pik3ca sensor after cisplatin treatment.
det||study-3/NN||the-1/DT	nn||study-3/NN||validation-2/NN	nsubj||identified-4/VBD||study-3/NN	root||ROOT-0/null||identified-4/VBD	mark||tends-7/VBZ||that-5/IN	nsubj||tends-7/VBZ||va-6/NN	nsubj||overdiagnose-9/VB||va-6/NN	ccomp||identified-4/VBD||tends-7/VBZ	aux||overdiagnose-9/VB||to-8/TO	xcomp||tends-7/VBZ||overdiagnose-9/VB	amod||causes-11/NNS||important-10/JJ	dobj||overdiagnose-9/VB||causes-11/NNS	prep_such_as||causes-11/NNS||diabetes-14/NN	nn||cancer-17/NN||liver-16/NN	prep_such_as||causes-11/NNS||cancer-17/NN	conj_and||diabetes-14/NN||cancer-17/NN	prep_such_as||causes-11/NNS||tuberculosis-20/NNP	conj_and||diabetes-14/NN||tuberculosis-20/NNP	mark||undercounting-23/VBG||while-22/IN	advcl||tends-7/VBZ||undercounting-23/VBG	dobj||undercounting-23/VBG||deaths-24/NNS	prep_from||undercounting-23/VBG||hiv/aids-26/NNS	appos||hiv/aids-26/NNS||liverdiseases-28/NNS	advmod||hiv/aids-26/NNS||genitourinary-30/RB	amod||renal-33/NN||essential-32/JJ	appos||hiv/aids-26/NNS||renal-33/NN	advcl||tends-7/VBZ||digestive-37/VB	conj_and||undercounting-23/VBG||digestive-37/VB	nn||disorders-39/NNS||system-38/NN	dobj||digestive-37/VB||disorders-39/NNS	aids--1||hiv--1||no||the validation study identified that va tends to overdiagnose important causes such as diabetes, liver cancer, and tuberculosis, while undercounting deaths from hiv/aids, liverdiseases, genitourinary (essential renal), and digestive system disorders.
det||time-4/NN||the-2/DT	amod||time-4/NN||same-3/JJ	prep_at||diagnosed-13/VBN||time-4/NN	amod||lungtb-7/NN||miliary-6/JJ	nsubjpass||diagnosed-13/VBN||lungtb-7/NN	vmod||lungtb-7/NN||caused-8/VBN	amod||mycobacteriumtuberculosis-11/NNS||multi-susceptible-10/JJ	agent||caused-8/VBN||mycobacteriumtuberculosis-11/NNS	auxpass||diagnosed-13/VBN||was-12/VBD	root||ROOT-0/null||diagnosed-13/VBN	lungtb-7||mycobacteriumtuberculosis-11||no||at the same time, miliary lungtb caused by multi-susceptible mycobacteriumtuberculosis was diagnosed.
nsubj||conducted-2/VBD||we-1/PRP	root||ROOT-0/null||conducted-2/VBD	det||assessment-7/NN||a-3/DT	amod||assessment-7/NN||quantitative-4/JJ	nn||assessment-7/NN||cancer-5/NN	nn||assessment-7/NN||risk-6/NN	dobj||conducted-2/VBD||assessment-7/NN	prep_for||collected-12/VBD||assessment-7/NN	nsubj||collected-12/VBD||we-11/PRP	rcmod||assessment-7/NN||collected-12/VBD	amod||data-14/NNS||global-13/JJ	dobj||collected-12/VBD||data-14/NNS	amod||levels-18/NNS||food-borne-16/JJ	nn||levels-18/NNS||aflatoxin-17/NN	prep_on||collected-12/VBD||levels-18/NNS	appos||levels-18/NNS||consumption-20/NN	amod||foods-23/NNS||aflatoxin-contaminated-22/JJ	prep_of||consumption-20/NN||foods-23/NNS	nsubj||prevalence-30/VBP||hepatitisbvirus-26/NNS	appos||hepatitisbvirus-26/NNS||hbv-28/NN	conj_and||conducted-2/VBD||prevalence-30/VBP	hbv-28||hepatitisbvirus-26||no||we conducted a quantitative cancer risk assessment, for which we collected global data on food-borne aflatoxin levels, consumption of aflatoxin-contaminated foods, and hepatitisbvirus (hbv) prevalence.
det||types-2/NNS||all-1/DT	nsubjpass||included-8/VBN||types-2/NNS	amod||studies-6/NNS||prospective-4/JJ	amod||studies-6/NNS||clinical-5/JJ	prep_of||types-2/NNS||studies-6/NNS	auxpass||included-8/VBN||were-7/VBD	root||ROOT-0/null||included-8/VBN	mark||used-12/VBN||if-9/IN	nsubjpass||used-12/VBN||magnesiumsulfate-10/NN	nsubj||manage-14/VB||magnesiumsulfate-10/NN	auxpass||used-12/VBN||was-11/VBD	advcl||included-8/VBN||used-12/VBN	aux||manage-14/VB||to-13/TO	xcomp||used-12/VBN||manage-14/VB	dobj||manage-14/VB||pre-eclampsia-15/NN	dobj||manage-14/VB||eclampsia-17/NN	conj_or||pre-eclampsia-15/NN||eclampsia-17/NN	det||study-20/NN||the-19/DT	nsubjpass||conducted-22/VBN||study-20/NN	auxpass||conducted-22/VBN||was-21/VBD	dep||included-8/VBN||conducted-22/VBN	det||country-29/NN||a-24/DT	amod||country-29/NN||low-25/JJ	conj_or||low-25/JJ||middle-income-28/JJ	amod||country-29/NN||middle-income-28/JJ	prep_in||conducted-22/VBN||country-29/NN	det||study-33/NN||the-32/DT	nsubj||included-34/VBD||study-33/NN	conj_and||included-8/VBN||included-34/VBD	det||recording-36/NN||the-35/DT	dobj||included-34/VBD||recording-36/NN	det||incidence-39/NN||the-38/DT	prep_of||recording-36/NN||incidence-39/NN	det||effect-44/NN||any-41/DT	amod||effect-44/NN||adverse-42/JJ	nn||effect-44/NN||side-43/NN	prep_of||incidence-39/NN||effect-44/NN	vmod||effect-44/NN||resulting-45/VBG	amod||use-48/NN||magnesiumsulfate-47/JJ	prep_from||resulting-45/VBG||use-48/NN	eclampsia-17||magnesiumsulfate-47||yes||all types of prospective clinical studies were included if magnesiumsulfate was used to manage pre-eclampsia or eclampsia, the study was conducted in a low- or middle-income country, and the study included the recording of the incidence of any adverse side effect resulting from magnesiumsulfate use.
nsubj||found-3/VBD||we-1/PRP	advmod||found-3/VBD||also-2/RB	root||ROOT-0/null||found-3/VBD	det||infection-6/NN||that-4/DT	amod||infection-6/NN||subcutaneous-5/JJ	dobj||found-3/VBD||infection-6/NN	prep_of||infection-6/NN||animals-8/NNS	amod||results-11/NNS||y.pestis-10/JJ	prep_with||found-3/VBD||results-11/NNS	prep_in||results-11/NNS||bubonicplague-13/NN	prepc_followed_by||found-3/VBD||by-16/IN	pobj||found-3/VBD||pneumonic-17/NN	pobj||found-3/VBD||septicemicplagues-19/NNS	conj_and||pneumonic-17/NN||septicemicplagues-19/NNS	bubonicplague-13||y.pestis-10||no||we also found that subcutaneous infection of animals with y.pestis results in bubonicplague , followed by pneumonic and septicemicplagues .
amod||mutations-2/NNS||activating-1/VBG	nsubj||play-18/VBP||mutations-2/NNS	nn||kinase-7/NN||kit-4/NN	nn||kinase-7/NN||receptor-5/NN	nn||kinase-7/NN||tyrosine-6/NN	prep_in||mutations-2/NNS||kinase-7/NN	det||receptor-14/NN||the-9/DT	amod||receptor-14/NN||related-10/VBN	amod||receptor-14/NN||platelet-derived-11/JJ	nn||receptor-14/NN||growth-12/NN	nn||receptor-14/NN||factor-13/NN	conj_or||mutations-2/NNS||receptor-14/NN	nsubj||play-18/VBP||receptor-14/NN	appos||receptor-14/NN||pdgfr-16/NN	root||ROOT-0/null||play-18/VBP	det||role-21/NN||an-19/DT	amod||role-21/NN||important-20/JJ	dobj||play-18/VBP||role-21/NN	det||pathogenesis-24/NNS||the-23/DT	prep_in||role-21/NN||pathogenesis-24/NNS	amod||tumors-28/NNS||gastrointestinal-26/JJ	amod||tumors-28/NNS||stromal-27/JJ	prep_of||pathogenesis-24/NNS||tumors-28/NNS	appos||tumors-28/NNS||gist-30/NN	tyrosine-6||tumors-28||no_rel||activating mutations in kit receptor tyrosine kinase or the related platelet-derived growth factor receptor (pdgfr) play an important role in the pathogenesis of gastrointestinal stromal tumors (gist).
nsubj||problem-22/NN||tuberculosis-1/NNP	vmod||tuberculosis-1/NNP||caused-2/VBN	agent||caused-2/VBN||multidrug-resistant-4/NN	appos||multidrug-resistant-4/NN||mdr-6/NN	amod||strains-18/NNS||extensively-9/JJ	amod||strains-18/NNS||drug-resistant-10/JJ	appos||strains-18/NNS||xdr-12/NN	nn||strains-18/NNS||mycobacteriumtuberculosis-14/NN	appos||strains-18/NNS||mtb-16/NN	agent||caused-2/VBN||strains-18/NNS	conj_and||multidrug-resistant-4/NN||strains-18/NNS	cop||problem-22/NN||is-19/VBZ	det||problem-22/NN||a-20/DT	amod||problem-22/NN||growing-21/VBG	root||ROOT-0/null||problem-22/NN	amod||countries-25/NNS||many-24/JJ	prep_in||problem-22/NN||countries-25/NNS	tuberculosis-1||mycobacteriumtuberculosis-14||no||tuberculosis caused by multidrug-resistant (mdr) and extensively drug-resistant (xdr) mycobacteriumtuberculosis (mtb) strains is a growing problem in many countries.
det||study-14/NN||a-1/DT	amod||study-14/NN||2-week-2/JJ	amod||study-14/NN||prospective-4/JJ	amod||study-14/NN||randomized-6/JJ	amod||study-14/NN||controlled-8/JJ	amod||study-14/NN||single-center-10/JJ	amod||study-14/NN||parallel-group-12/JJ	nn||study-14/NN||pilot-13/NN	nsubj||administered-29/VBN||study-14/NN	auxpass||carried-16/VBN||was-15/VBD	rcmod||study-14/NN||carried-16/VBN	prt||carried-16/VBN||out-17/RP	aux||determine-19/VB||to-18/TO	xcomp||carried-16/VBN||determine-19/VB	det||efficacy-21/NN||the-20/DT	dobj||determine-19/VB||efficacy-21/NN	dobj||determine-19/VB||safety-23/NN	conj_and||efficacy-21/NN||safety-23/NN	nn||g-27/NN||paracetamol-25/NNP	num||g-27/NN||1-26/CD	prep_of||efficacy-21/NN||g-27/NN	advmod||administered-29/VBN||orally-28/RB	root||ROOT-0/null||administered-29/VBN	det||hours-32/NNS||every-30/DT	num||hours-32/NNS||6-31/CD	dobj||administered-29/VBN||hours-32/NNS	amod||patients-35/NNS||adult-34/JJ	prep_in||administered-29/VBN||patients-35/NNS	amod||openangleglaucoma-40/NN||primary-37/JJ	conj_or||primary-37/JJ||secondary-39/JJ	amod||openangleglaucoma-40/NN||secondary-39/JJ	prep_with||patients-35/NNS||openangleglaucoma-40/NN	prepc_as||administered-29/VBN||compared-42/VBN	pcomp||compared-42/VBN||with-43/IN	amod||levobunolol-45/NN||topical-44/JJ	pobj||with-43/IN||levobunolol-45/NN	number||%-47/NN||0.5-46/CD	amod||levobunolol-45/NN||%-47/NN	advmod||day-50/NN||twice-48/RB	det||day-50/NN||a-49/DT	tmod||with-43/IN||day-50/NN	paracetamol-25||openangleglaucoma-40||no_rel||a 2-week, prospective, randomized, controlled, single-center, parallel-group pilot study was carried out to determine the efficacy and safety of paracetamol 1 g orally administered every 6 hours in adult patients with primary or secondary openangleglaucoma as compared with topical levobunolol 0.5% twice a day.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||examine-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||examine-8/VB||to-7/TO	xcomp||was-6/VBD||examine-8/VB	det||effect-10/NN||the-9/DT	dobj||examine-8/VB||effect-10/NN	prep_of||effect-10/NN||metoprolol-12/NN	prep_versus||metoprolol-12/NN||carvedilol-14/NN	amod||function-17/NN||endothelial-16/JJ	prep_on||examine-8/VB||function-17/NN	amod||function-21/NN||insulin-stimulated-19/JJ	nn||function-21/NN||endothelial-20/NN	prep_on||examine-8/VB||function-21/NN	conj_and||function-17/NN||function-21/NN	prep_in||function-17/NN||patients-23/NNS	prep_with||patients-23/NNS||type2diabetes-25/CD	type2diabetes-25||insulin--1||yes||the aim of this study was to examine the effect of metoprolol versus carvedilol on endothelial function and insulin-stimulated endothelial function in patients with type2diabetes.
nsubj||expresses-10/VBZ||borreliaburgdorferi-1/NNS	det||pathogen-5/NN||the-3/DT	amod||pathogen-5/NN||bacterial-4/JJ	appos||borreliaburgdorferi-1/NNS||pathogen-5/NN	prep_of||pathogen-5/NN||lymeborreliosis-7/NNS	advmod||expresses-10/VBZ||differentially-9/RB	root||ROOT-0/null||expresses-10/VBZ	amod||genes-12/NNS||select-11/JJ	dobj||expresses-10/VBZ||genes-12/NNS	prep_in||expresses-10/VBZ||vivo-14/NN	advmod||contributing-17/VBG||likely-16/RB	vmod||expresses-10/VBZ||contributing-17/VBG	amod||persistence-20/NN||microbial-19/JJ	prep_to||contributing-17/VBG||persistence-20/NN	prep_to||contributing-17/VBG||disease-22/NN	conj_and||persistence-20/NN||disease-22/NN	lymeborreliosis-7||borreliaburgdorferi-1||no||borreliaburgdorferi , the bacterial pathogen of lymeborreliosis, differentially expresses select genes in vivo , likely contributing to microbial persistence and disease.
nsubj||piloting-3/VBG||zambia-1/NN	aux||piloting-3/VBG||is-2/VBZ	root||ROOT-0/null||piloting-3/VBG	det||use-5/NN||the-4/DT	dobj||piloting-3/VBG||use-5/NN	prep_of||use-5/NN||artemether-lumefantrine-7/NN	appos||artemether-lumefantrine-7/NN||al-9/NNP	nn||workers-14/NNS||community-12/NN	nn||workers-14/NNS||health-13/NN	prep_by||piloting-3/VBG||workers-14/NNS	appos||workers-14/NNS||chws-16/NNS	aux||treat-19/VB||to-18/TO	vmod||piloting-3/VBG||treat-19/VB	amod||malaria-21/NN||uncomplicated-20/JJ	dobj||treat-19/VB||malaria-21/NN	malaria-21||lumefantrine--1||yes||zambia is piloting the use of artemether-lumefantrine (al) by community health workers (chws) to treat uncomplicated malaria.
prep_to||approved-7/VBN||date-2/NN	nsubjpass||approved-7/VBN||posaconazole-4/NN	aux||approved-7/VBN||has-5/VBZ	auxpass||approved-7/VBN||been-6/VBN	root||ROOT-0/null||approved-7/VBN	prep_for||approved-7/VBN||prophylaxis-9/NNS	amod||fungalinfections-12/NNS||invasive-11/JJ	prep_of||prophylaxis-9/NNS||fungalinfections-12/NNS	nn||recipients-17/NNS||stem-14/NN	nn||recipients-17/NNS||cell-15/NN	nn||recipients-17/NNS||transplant-16/NN	prep_in||approved-7/VBN||recipients-17/NNS	amod||graftversushostdisease-20/NN||acute-19/JJ	prep_with||recipients-17/NNS||graftversushostdisease-20/NN	dep||recipients-17/NNS||gvhd-22/VBN	amod||patients-26/NNS||neutropenic-25/JJ	prep_in||approved-7/VBN||patients-26/NNS	conj_and||recipients-17/NNS||patients-26/NNS	vmod||patients-26/NNS||receiving-27/VBG	amod||induction-29/NN||intensive-28/JJ	dobj||receiving-27/VBG||induction-29/NN	advmod||receiving-27/VBG||chemotherapy-30/RB	amod||leukemia-34/NN||acute-32/JJ	nn||leukemia-34/NN||myelogenous-33/NNS	prep_for||receiving-27/VBG||leukemia-34/NN	amod||syndrome-37/NN||myelodys-plastic-36/JJ	prep_for||receiving-27/VBG||syndrome-37/NN	conj_and||leukemia-34/NN||syndrome-37/NN	fungalinfections-12||posaconazole-4||yes||to date, posaconazole has been approved for prophylaxis of invasive fungalinfections in stem cell transplant recipients with acute graftversushostdisease (gvhd) and neutropenic patients receiving intensive induction chemotherapy for acute myelogenous leukemia and myelodys-plastic syndrome.
det||rgcs-2/NNS||the-1/DT	nsubj||exposed-3/VBD||rgcs-2/NNS	ccomp||revealed-21/VBD||exposed-3/VBD	prep_to||exposed-3/VBD||hypoxia-5/NN	dep||exposed-3/VBD||either-6/CC	number||%-9/NN||1-8/CD	amod||oxygen-10/NN||%-9/NN	prep_with||exposed-3/VBD||oxygen-10/NN	amod||chloride-13/NN||cobalt-12/JJ	prep_with||exposed-3/VBD||chloride-13/NN	conj_or||oxygen-10/NN||chloride-13/NN	num||î-16/NN||0-400-15/CD	dep||chloride-13/NN||î-16/NN	num||m-18/NN||1/4-17/CD	dep||î-16/NN||m-18/NN	root||ROOT-0/null||revealed-21/VBD	number||30-23/CD||~-22/CD	num||%-24/NN||30-23/CD	dobj||revealed-21/VBD||%-24/NN	num||%-26/NN||-70-25/CD	npadvmod||apoptotic-27/JJ||%-26/NN	amod||%-24/NN||apoptotic-27/JJ	nn||death-29/NN||cell-28/NN	nsubj||revealed-21/VBD||death-29/NN	prep_after||death-29/NN||48-31/CD	num||h-34/NN||72-33/CD	nsubj||revealed-21/VBD||h-34/NN	conj_and||death-29/NN||h-34/NN	prep_of||h-34/NN||exposure-36/NN	oxygen-10||hypoxia-5||no_rel||the rgcs exposed to hypoxia either with 1% oxygen or cobalt chloride (0-400 î¼m), revealed ~30%-70% apoptotic cell death after 48 and 72 h of exposure.
det||research-7/NN||some-1/DT	cc||all-5/DT||not-4/RB	dep||research-7/NN||all-5/DT	nsubj||indicates-8/VBZ||research-7/NN	root||ROOT-0/null||indicates-8/VBZ	mark||linked-20/VBN||that-9/IN	amod||administration-11/NN||antibiotic-10/JJ	nsubjpass||linked-20/VBN||administration-11/NN	prep_in||administration-11/NN||pregnancy-13/NN	prep_in||administration-11/NN||childbirth-15/NN	conj_or||pregnancy-13/NN||childbirth-15/NN	prep_in||administration-11/NN||infancy-17/NN	conj_or||pregnancy-13/NN||infancy-17/NN	aux||linked-20/VBN||may-18/MD	auxpass||linked-20/VBN||be-19/VB	ccomp||indicates-8/VBZ||linked-20/VBN	nn||asthma-23/NN||childhood-22/NN	prep_to||linked-20/VBN||asthma-23/NN	prep_to||linked-20/VBN||eczema-25/NN	conj_and||asthma-23/NN||eczema-25/NN	amod||uncertainty-29/NN||much-28/JJ	nsubj||remains-30/VBZ||uncertainty-29/NN	conj_but||indicates-8/VBZ||remains-30/VBZ	eczema-25||antibiotic-10||no_rel||some, but not all, research indicates that antibiotic administration in pregnancy, childbirth or infancy may be linked to childhood asthma and eczema, but much uncertainty remains.
amod||cases-3/NNS||such-2/JJ	prep_in||helpful-15/JJ||cases-3/NNS	det||evaluation-6/NN||a-4/DT	amod||evaluation-6/NN||thorough-5/JJ	nsubj||helpful-15/JJ||evaluation-6/NN	nsubj||achieve-17/VB||evaluation-6/NN	nn||antibodies-12/NNS||ama-8/NN	nn||antibodies-12/NNS||and/or-9/NN	nn||antibodies-12/NNS||ana-10/NN	amod||antibodies-12/NNS||pbc-specific-11/JJ	prep_for||evaluation-6/NN||antibodies-12/NNS	aux||helpful-15/JJ||could-13/MD	cop||helpful-15/JJ||be-14/VB	root||ROOT-0/null||helpful-15/JJ	aux||achieve-17/VB||to-16/TO	xcomp||helpful-15/JJ||achieve-17/VB	det||diagnosis-22/NN||a-18/DT	amod||diagnosis-22/NN||correct-19/JJ	conj_and||correct-19/JJ||timely-21/JJ	amod||diagnosis-22/NN||timely-21/JJ	dobj||achieve-17/VB||diagnosis-22/NN	antibodies-12||pbc--1||no_rel||in such cases a thorough evaluation for ama and/or ana pbc-specific antibodies could be helpful to achieve a correct and timely diagnosis.
mark||remain-10/VBP||although-1/IN	det||majority-3/NN||the-2/DT	nsubj||remain-10/VBP||majority-3/NN	quantmod||$-6/$||htlv-1â-5/JJ	num||individuals-9/NNS||$-6/$	amod||individuals-9/NNS||infected-8/JJ	prep_of||majority-3/NN||individuals-9/NNS	advcl||develop-26/VB||remain-10/VBP	amod||carriers-12/NNS||asymptomatic-11/JJ	xcomp||remain-10/VBP||carriers-12/NNS	discourse||carriers-12/NNS||ac-14/UH	poss||lifetime-18/NN||their-17/PRP$	prep_during||remain-10/VBP||lifetime-18/NN	nsubj||develop-26/VB||2â-20/NNS	dep||%-24/NN||$-21/$	num||$-21/$||5-23/CD	amod||2â-20/NNS||%-24/NN	aux||develop-26/VB||will-25/MD	root||ROOT-0/null||develop-26/VB	preconj||atl-28/NN||either-27/DT	dobj||develop-26/VB||atl-28/NN	dobj||develop-26/VB||ham/tsp-30/NN	conj_or||atl-28/NN||ham/tsp-30/NN	cc||never-33/RB||but-32/CC	dep||develop-26/VB||never-33/RB	dep||never-33/RB||both-34/DT	ham--1||htlv-1--1||no||although the majority of htlv-1âinfected individuals remain asymptomatic carriers (ac) during their lifetime, 2â5% will develop either atl or ham/tsp, but never both.
det||characteristics-3/NNS||the-1/DT	amod||characteristics-3/NNS||demographic-2/JJ	nsubj||similar-23/JJ||characteristics-3/NNS	prep_of||characteristics-3/NNS||patients-5/NNS	amod||class-10/NN||asa-7/JJ	amod||class-10/NN||physical-8/JJ	nn||class-10/NN||status-9/NN	prep_of||characteristics-3/NNS||class-10/NN	conj_and||patients-5/NNS||class-10/NN	prep_of||characteristics-3/NNS||duration-12/NN	conj_and||patients-5/NNS||duration-12/NN	prep_of||duration-12/NN||surgery-14/NN	det||score-21/NN||the-17/DT	amod||score-21/NN||basal-18/JJ	nn||score-21/NN||vas-19/NN	nn||score-21/NN||pain-20/NN	prep_of||characteristics-3/NNS||score-21/NN	conj_and||patients-5/NNS||score-21/NN	cop||similar-23/JJ||were-22/VBD	root||ROOT-0/null||similar-23/JJ	det||groups-27/NNS||the-25/DT	num||groups-27/NNS||two-26/CD	prep_in||similar-23/JJ||groups-27/NNS	pain-20||asa-7||yes||the demographic characteristics of patients, asa physical status class, duration of surgery, and the basal vas pain score were similar in the two groups.
nsubj||warts-9/NNS||condylomaacuminata-1/NN	cop||warts-9/NNS||are-2/VBP	amod||warts-9/NNS||soft-3/JJ	amod||warts-9/NNS||skin-5/JJ	amod||warts-9/NNS||colored-6/JJ	amod||warts-9/NNS||fleshy-8/JJ	root||ROOT-0/null||warts-9/NNS	nsubjpass||caused-12/VBN||warts-9/NNS	auxpass||caused-12/VBN||are-11/VBP	rcmod||warts-9/NNS||caused-12/VBN	det||humanpapillomavirus-15/NNS||the-14/DT	agent||caused-12/VBN||humanpapillomavirus-15/NNS	appos||humanpapillomavirus-15/NNS||hpv-17/NN	condylomaacuminata-1||hpv-17||no||condylomaacuminata are soft, skin colored, fleshy warts that are caused by the humanpapillomavirus (hpv).
amod||abnormalities-2/NNS||g1/s-1/JJ	nsubj||crucial-4/JJ||abnormalities-2/NNS	cop||crucial-4/JJ||are-3/VBP	root||ROOT-0/null||crucial-4/JJ	det||progression-7/NN||the-6/DT	prep_for||crucial-4/JJ||progression-7/NN	prep_of||progression-7/NN||malignantmelanoma-9/NN	amod||d1-14/NNS||enhanced-12/JJ	nn||d1-14/NNS||cyclin-13/NN	nsubjpass||observed-24/VBN||d1-14/NNS	amod||expression-17/NN||d3-16/JJ	conj_and||d1-14/NNS||expression-17/NN	nsubjpass||observed-24/VBN||expression-17/NN	amod||expression-17/NN||leading-18/VBG	amod||proliferation-22/NN||increased-20/VBN	nn||proliferation-22/NN||melanocyte-21/NN	prep_to||d1-14/NNS||proliferation-22/NN	auxpass||observed-24/VBN||is-23/VBZ	conj_and||crucial-4/JJ||observed-24/VBN	det||melanoma-27/NN||both-26/DT	prep_in||observed-24/VBN||melanoma-27/NN	amod||nevi-30/NNS||dysplastic-29/JJ	prep_in||observed-24/VBN||nevi-30/NNS	conj_and||melanoma-27/NN||nevi-30/NNS	d3-16||malignantmelanoma-9||no_rel||g1/s abnormalities are crucial for the progression of malignantmelanoma, and enhanced cyclin d1 and d3 expression leading to increased melanocyte proliferation is observed in both melanoma and dysplastic nevi.
det||cb-3/NN||the-1/DT	amod||cb-3/NN||high-fat-2/JJ	nsubj||induced-10/VBN||cb-3/NN	conj_and||cb-3/NN||oo-5/NN	nsubj||induced-10/VBN||oo-5/NN	advmod||diets-9/NNS||so-8/RB	conj_and||cb-3/NN||diets-9/NNS	nsubj||induced-10/VBN||diets-9/NNS	root||ROOT-0/null||induced-10/VBN	dobj||induced-10/VBN||hyperglycemia-11/NN	det||increase-15/NN||a-13/DT	amod||increase-15/NN||2-fold-14/JJ	dobj||induced-10/VBN||increase-15/NN	conj_and||hyperglycemia-11/NN||increase-15/NN	amod||content-19/NN||hepatic-17/JJ	amod||content-19/NN||fat-18/JJ	prep_in||induced-10/VBN||content-19/NN	amod||mice-27/NNS||male-21/JJ	neg||female-25/JJ||not-24/RB	conj_but||male-21/JJ||female-25/JJ	amod||mice-27/NNS||female-25/JJ	amod||mice-27/NNS||wild-type-26/JJ	prep_in||content-19/NN||mice-27/NNS	prep_in||content-34/NN||females-30/NNS	amod||content-34/NN||hepatic-32/JJ	amod||content-34/NN||fat-33/JJ	dep||mice-27/NNS||content-34/NN	prep_to||similar-36/JJ||content-34/NN	cop||similar-36/JJ||was-35/VBD	rcmod||content-34/NN||similar-36/JJ	prep_in||that-38/DT||males-40/NNS	vmod||males-40/NNS||fed-41/VBN	det||diet-44/NN||a-42/DT	amod||diet-44/NN||high-fat-43/JJ	dobj||fed-41/VBN||diet-44/NN	hyperglycemia-11||fat-33||no_rel||the high-fat cb, oo, and so diets induced hyperglycemia and a 2-fold increase in hepatic fat content in male, but not female wild-type mice (in females, hepatic fat content was similar to that in males fed a high-fat diet).
prep_in||is-19/VBZ||view-2/NN	det||use-7/NN||the-4/DT	amod||use-7/NN||current-5/JJ	amod||use-7/NN||widespread-6/JJ	prep_of||view-2/NN||use-7/NN	prep||use-7/NN||of-8/IN	prep_of||view-2/NN||reliance-10/NN	conj_and||use-7/NN||reliance-10/NN	det||schistosomicide-14/NN||a-12/DT	amod||schistosomicide-14/NN||single-13/JJ	prep_on||reliance-10/NN||schistosomicide-14/NN	advmod||is-19/VBZ||praziquantel-16/RB	expl||is-19/VBZ||there-18/EX	root||ROOT-0/null||is-19/VBZ	det||need-22/NN||a-20/DT	amod||need-22/NN||pressing-21/JJ	nsubj||is-19/VBZ||need-22/NN	aux||discover-24/VB||to-23/TO	vmod||need-22/NN||discover-24/VB	vmod||need-22/NN||develop-26/VB	conj_and||discover-24/VB||develop-26/VB	amod||drugs-28/NNS||alternative-27/JJ	dobj||discover-24/VB||drugs-28/NNS	prep_for||drugs-28/NNS||schistosomiasis-30/NNS	schistosomiasis-30||praziquantel-16||yes||in view of the current widespread use of and reliance on a single schistosomicide, praziquantel, there is a pressing need to discover and develop alternative drugs for schistosomiasis.
dep||spirochete-6/NN||brachyspirahyodysenteriae-1/JJ	cop||spirochete-6/NN||is-2/VBZ	det||spirochete-6/NN||an-3/DT	amod||spirochete-6/NN||anaerobic-4/JJ	amod||spirochete-6/NN||intestinal-5/JJ	root||ROOT-0/null||spirochete-6/NN	nsubj||colonizes-8/VBZ||spirochete-6/NN	rcmod||spirochete-6/NN||colonizes-8/VBZ	det||intestine-11/NN||the-9/DT	amod||intestine-11/NN||large-10/JJ	dobj||colonizes-8/VBZ||intestine-11/NN	prep_of||intestine-11/NN||pigs-13/NNS	prep_of||intestine-11/NN||causes-15/NNS	conj_and||pigs-13/NNS||causes-15/NNS	nsubj||spirochete-6/NN||swinedysentery-16/NN	det||disease-19/NN||a-18/DT	appos||swinedysentery-16/NN||disease-19/NN	amod||importance-23/NN||significant-21/JJ	amod||importance-23/NN||economic-22/JJ	prep_of||disease-19/NN||importance-23/NN	swinedysentery-16||spirochete-6||no||brachyspirahyodysenteriae is an anaerobic intestinal spirochete that colonizes the large intestine of pigs and causes swinedysentery, a disease of significant economic importance.
amod||advances-2/NNS||newer-1/JJR	nsubj||include-3/VBP||advances-2/NNS	ccomp||revolutionized-63/VBD||include-3/VBP	dobj||include-3/VBP||introduction-4/NN	amod||techniques-7/NNS||newer-6/JJR	prep_of||introduction-4/NN||techniques-7/NNS	amod||epidurals-11/NNS||combined-9/VBN	amod||epidurals-11/NNS||spinal-10/JJ	prep_like||techniques-7/NNS||epidurals-11/NNS	amod||epidurals-14/NNS||low-dose-13/JJ	dobj||include-3/VBP||epidurals-14/NNS	conj_and||introduction-4/NN||epidurals-14/NNS	vmod||epidurals-14/NNS||facilitating-15/VBG	dobj||facilitating-15/VBG||ambulation-16/NN	amod||advances-19/NNS||pharmacological-18/JJ	dobj||include-3/VBP||advances-19/NNS	conj_and||introduction-4/NN||advances-19/NNS	prep_like||advances-19/NNS||introduction-21/NN	prep_of||introduction-21/NN||remifentanil-23/NN	amod||analgesia-27/NN||patient-controlled-25/JJ	amod||analgesia-27/NN||intravenous-26/JJ	prep_for||remifentanil-23/NN||analgesia-27/NN	dobj||include-3/VBP||introduction-29/NN	conj_and||introduction-4/NN||introduction-29/NN	amod||anaesthetics-33/NNS||newer-31/JJR	amod||anaesthetics-33/NNS||local-32/JJ	prep_of||introduction-29/NN||anaesthetics-33/NNS	dobj||include-3/VBP||adjuvants-35/NNS	conj_and||introduction-4/NN||adjuvants-35/NNS	prep_like||adjuvants-35/NNS||ropivacaine-37/JJ	prep_like||adjuvants-35/NNS||levobupivacaine-39/JJ	conj_and||ropivacaine-37/JJ||levobupivacaine-39/JJ	prep_like||adjuvants-35/NNS||sufentanil-41/JJ	conj_and||ropivacaine-37/JJ||sufentanil-41/JJ	prep_like||adjuvants-35/NNS||clonidine-43/JJ	conj_and||ropivacaine-37/JJ||clonidine-43/JJ	prep_like||adjuvants-35/NNS||neostigmine-45/JJ	conj_and||ropivacaine-37/JJ||neostigmine-45/JJ	appos||introduction-4/NN||use-47/NN	amod||agents-50/NNS||inhalational-49/JJ	prep_of||use-47/NN||agents-50/NNS	prep_like||agents-50/NNS||sevoflourane-52/NN	amod||analgesia-56/NN||patient-controlled-54/JJ	amod||analgesia-56/NN||inhalational-55/JJ	prep_for||sevoflourane-52/NN||analgesia-56/NN	vmod||analgesia-56/NN||using-57/VBG	amod||vaporizers-59/NNS||special-58/JJ	dobj||using-57/VBG||vaporizers-59/NNS	nsubj||revolutionized-63/VBD||all-61/DT	aux||revolutionized-63/VBD||have-62/VBP	root||ROOT-0/null||revolutionized-63/VBD	det||practice-65/NN||the-64/DT	dobj||revolutionized-63/VBD||practice-65/NN	nn||management-68/NN||pain-67/NN	prep_of||practice-65/NN||management-68/NN	prepc_in||revolutionized-63/VBD||labouring-70/VBG	dobj||labouring-70/VBG||parturients-71/NNS	pain-67||remifentanil-23||yes||newer advances include introduction of newer techniques like combined spinal epidurals, low-dose epidurals facilitating ambulation, pharmacological advances like introduction of remifentanil for patient-controlled intravenous analgesia, introduction of newer local anaesthetics and adjuvants like ropivacaine, levobupivacaine, sufentanil, clonidine and neostigmine, use of inhalational agents like sevoflourane for patient-controlled inhalational analgesia using special vaporizers, all have revolutionized the practice of pain management in labouring parturients.
amod||development-3/NN||gross-1/JJ	amod||development-3/NN||reproductive-2/JJ	nsubj||normal-5/JJ||development-3/NN	nsubj||testis-10/VBZ||development-3/NN	cop||normal-5/JJ||was-4/VBD	root||ROOT-0/null||normal-5/JJ	nn||mice-8/NNS||smarko-7/NN	prep_in||normal-5/JJ||mice-8/NNS	conj_but||normal-5/JJ||testis-10/VBZ	nsubjpass||reduced-13/VBN||weight-11/NN	auxpass||reduced-13/VBN||was-12/VBD	ccomp||testis-10/VBZ||reduced-13/VBN	prep_in||reduced-13/VBN||adulthood-15/NN	prepc_compared_to||reduced-13/VBN||to-17/TO	nn||littermates-19/NNS||control-18/NN	pobj||reduced-13/VBN||littermates-19/NNS	det||reduction-22/NN||this-21/DT	nsubj||due-25/JJ||reduction-22/NN	nsubj||cause-46/VB||reduction-22/NN	cop||due-25/JJ||was-23/VBD	neg||due-25/JJ||not-24/RB	parataxis||normal-5/JJ||due-25/JJ	det||changes-28/NNS||any-27/DT	prep_to||due-25/JJ||changes-28/NNS	nn||volume-32/NN||germ-30/NN	nn||volume-32/NN||cell-31/NN	prep_in||changes-28/NNS||volume-32/NN	prep_to||due-25/JJ||deficits-35/NNS	conj_or||changes-28/NNS||deficits-35/NNS	nn||concentrations-42/NNS||testosterone-37/NN	conj_or||testosterone-37/NN||lh-39/NN	nn||concentrations-42/NNS||lh-39/NN	conj_or||testosterone-37/NN||fsh-41/NN	nn||concentrations-42/NNS||fsh-41/NN	prep_in||deficits-35/NNS||concentrations-42/NNS	aux||cause-46/VB||did-44/VBD	neg||cause-46/VB||not-45/RB	parataxis||normal-5/JJ||cause-46/VB	conj_and||due-25/JJ||cause-46/VB	dobj||cause-46/VB||infertility-47/NN	testosterone-37||infertility-47||no_rel||gross reproductive development was normal in smarko mice but testis weight was reduced in adulthood compared to control littermates; this reduction was not due to any changes in germ cell volume or to deficits in testosterone, lh or fsh concentrations and did not cause infertility.
num||participants-3/NNS||503-2/CD	prep_of||%-19/NN||participants-3/NNS	det||prevalences-7/NNS||the-5/DT	amod||prevalences-7/NNS||overall-6/JJ	nsubj||%-19/NN||prevalences-7/NNS	nn||infection-10/NN||tb-9/NN	prep_of||prevalences-7/NNS||infection-10/NN	prep_of||prevalences-7/NNS||hivinfection-12/NN	conj_and||infection-10/NN||hivinfection-12/NN	amod||co-infection-16/NN||tb/hiv-15/JJ	prep_of||prevalences-7/NNS||co-infection-16/NN	conj_and||infection-10/NN||co-infection-16/NN	cop||%-19/NN||were-17/VBD	num||%-19/NN||57-18/CD	root||ROOT-0/null||%-19/NN	number||%-22/NN||4.2-21/CD	amod||%-19/NN||%-22/NN	conj_and||%-19/NN||%-22/NN	num||%-26/NN||2.2-25/CD	conj_and||%-19/NN||%-26/NN	advmod||%-19/NN||respectively-28/RB	neg||differences-32/NNS||no-30/DT	amod||differences-32/NNS||significant-31/JJ	nsubj||observed-42/JJ||differences-32/NNS	nn||group-35/NN||risk-34/NN	prep_by||differences-32/NNS||group-35/NN	nn||0.05-39/NNP||p-37/NNP	nn||0.05-39/NNP||>-38/NNP	appos||group-35/NN||0.05-39/NNP	cop||observed-42/JJ||were-41/VBD	parataxis||%-19/NN||observed-42/JJ	infection-10||hiv--1||no||of 503 participants, the overall prevalences of tb infection, hivinfection, and tb/hiv co-infection were 57%, 4.2%, and 2.2%, respectively; no significant differences by risk group (p>0.05) were observed.
nsubj||inform-10/VB||data-1/NNS	prep_on||data-1/NNS||prevalence-3/NN	prep_of||prevalence-3/NN||congenitalmalaria-5/NN	amod||newborns-8/NNS||high-risk-7/JJ	prep_in||congenitalmalaria-5/NN||newborns-8/NNS	aux||inform-10/VB||will-9/MD	root||ROOT-0/null||inform-10/VB	amod||use-13/NN||appropriate-11/JJ	nn||use-13/NN||drug-12/NN	dobj||inform-10/VB||use-13/NN	amod||referral-16/NN||timely-15/JJ	dobj||inform-10/VB||referral-16/NN	conj_and||use-13/NN||referral-16/NN	amod||newborns-19/NNS||sick-18/JJ	prep_of||use-13/NN||newborns-19/NNS	inform-10||congenitalmalaria-5||no_rel||data on prevalence of congenitalmalaria in high-risk newborns will inform appropriate drug use and timely referral of sick newborns.
amod||dyslipidaemia-2/NN||atherogenic-1/JJ	nsubjpass||associated-14/VBN||dyslipidaemia-2/NN	dep||dyslipidaemia-2/NN||characterized-4/VBN	amod||triglycerides-7/NNPS||elevated-6/JJ	prep_by||characterized-4/VBN||triglycerides-7/NNPS	amod||hdl-c-10/NN||low-9/JJ	prep_by||characterized-4/VBN||hdl-c-10/NN	conj_and||triglycerides-7/NNPS||hdl-c-10/NN	auxpass||associated-14/VBN||is-12/VBZ	advmod||associated-14/VBN||strongly-13/RB	root||ROOT-0/null||associated-14/VBN	amod||states-17/NNS||insulin-resistant-16/JJ	prep_with||associated-14/VBN||states-17/NNS	prep_such_as||associated-14/VBN||type2diabetes-21/NNS	det||syndrome-25/NN||the-23/DT	amod||syndrome-25/NN||metabolic-24/JJ	prep_such_as||associated-14/VBN||syndrome-25/NN	conj_and||type2diabetes-21/NNS||syndrome-25/NN	cop||finding-32/NN||is-28/VBZ	advmod||finding-32/NN||also-29/RB	det||finding-32/NN||a-30/DT	amod||finding-32/NN||common-31/JJ	conj_and||associated-14/VBN||finding-32/NN	prep_among||finding-32/NN||patients-34/NNS	xcomp||associated-14/VBN||receiving-35/VBG	dobj||receiving-35/VBG||treatment-36/NN	prep_for||receiving-35/VBG||dyslipidaemia-38/NN	type2diabetes-21||insulin--1||yes||atherogenic dyslipidaemia (characterized by elevated triglycerides and low hdl-c) is strongly associated with insulin-resistant states, such as type2diabetes and the metabolic syndrome, and is also a common finding among patients receiving treatment for dyslipidaemia.
det||future-2/NN||the-1/DT	nsubj||brighter-11/JJ||future-2/NN	det||field-5/NN||the-4/DT	prep_in||future-2/NN||field-5/NN	prep_of||field-5/NN||hiv/aids-7/NNS	aux||brighter-11/JJ||will-8/MD	cop||brighter-11/JJ||be-9/VB	advmod||brighter-11/JJ||much-10/RB	root||ROOT-0/null||brighter-11/JJ	mark||coordinated-17/VBN||if-12/IN	amod||research-14/NN||global-13/JJ	nsubjpass||coordinated-17/VBN||research-14/NN	auxpass||coordinated-17/VBN||is-15/VBZ	advmod||coordinated-17/VBN||appropriately-16/RB	advcl||brighter-11/JJ||coordinated-17/VBN	amod||funds-20/NNS||sufficient-19/JJ	nsubj||available-22/JJ||funds-20/NNS	cop||available-22/JJ||are-21/VBP	advcl||brighter-11/JJ||available-22/JJ	conj_and||coordinated-17/VBN||available-22/JJ	aids--1||hiv--1||no||the future in the field of hiv/aids will be much brighter if global research is appropriately coordinated and sufficient funds are available.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||identify-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||identify-8/VB||to-7/TO	xcomp||was-6/VBD||identify-8/VB	det||presence-10/NN||the-9/DT	dobj||identify-8/VB||presence-10/NN	iobj||identify-8/VB||presence-10/NN	amod||inh-14/NN||isoniazid-12/JJ	prep_of||presence-10/NN||inh-14/NN	prep_of||presence-10/NN||rifampicin-17/NN	conj_and||inh-14/NN||rifampicin-17/NN	appos||presence-10/NN||rif-19/NN	nn||resistance-22/NN||drug-21/NN	dep||presence-10/NN||resistance-22/NN	amod||cases-32/NNS||new-24/JJ	advmod||treated-27/JJ||previously-26/RB	conj_and||new-24/JJ||treated-27/JJ	amod||cases-32/NNS||treated-27/JJ	nn||cases-32/NNS||tuberculosis-28/NNP	appos||cases-32/NNS||tb-30/NN	prep_in||resistance-22/NN||cases-32/NNS	vmod||cases-32/NNS||using-33/VBG	nn||sequencing-35/NN||dna-34/NN	dobj||using-33/VBG||sequencing-35/NN	tb-30||inh-14||yes||the aim of this study was to identify the presence of isoniazid (inh) and rifampicin(rif) drug resistance in new and previously treated tuberculosis (tb) cases using dna sequencing.
nsubj||steroid-5/NN||dhea-1/NN	cop||steroid-5/NN||is-2/VBZ	det||steroid-5/NN||an-3/DT	amod||steroid-5/NN||androgenic-4/JJ	root||ROOT-0/null||steroid-5/NN	vmod||steroid-5/NN||found-6/VBN	amod||levels-9/NNS||low-8/JJ	prep_in||found-6/VBN||levels-9/NNS	det||serum-12/NN||the-11/DT	prep_in||levels-9/NNS||serum-12/NN	amod||patients-15/NNS||lupus-14/JJ	prep_of||serum-12/NN||patients-15/NNS	lupus-14||dhea-1||yes||dhea is an androgenic steroid found in low levels in the serum of lupus patients.
det||therapy-4/NN||the-1/DT	amod||therapy-4/NN||gold-2/JJ	amod||therapy-4/NN||standard-3/JJ	nsubjpass||pegylated-9/VBN||therapy-4/NN	amod||patients-7/NNS||chronichepatitisc-6/JJ	prep_for||therapy-4/NN||patients-7/NNS	auxpass||pegylated-9/VBN||is-8/VBZ	root||ROOT-0/null||pegylated-9/VBN	dobj||pegylated-9/VBN||interferon-10/NN	prep||pegylated-9/VBN||combined-11/VBN	pcomp||combined-11/VBN||with-12/IN	det||drug-15/NN||an-13/DT	amod||drug-15/NN||anti-viral-14/JJ	pobj||with-12/IN||drug-15/NN	appos||drug-15/NN||ribavirin-17/NNP	ribavirin-17||chronichepatitisc-6||no_rel||the gold standard therapy for chronichepatitisc patients is pegylated interferon combined with an anti-viral drug (ribavirin).
det||number-2/NN||the-1/DT	nsubjpass||decreased-9/VBN||number-2/NN	prep_of||number-2/NN||epcs-4/NNS	prep_in||epcs-4/NNS||type2diabetes-6/CD	auxpass||decreased-9/VBN||was-7/VBD	advmod||decreased-9/VBN||significantly-8/RB	root||ROOT-0/null||decreased-9/VBN	prepc_compared_with||decreased-9/VBN||with-11/IN	amod||controls-13/NNS||healthy-12/JJ	pobj||decreased-9/VBN||controls-13/NNS	expl||was-16/VBD||there-15/EX	conj_and||decreased-9/VBN||was-16/VBD	det||correlation-19/NN||an-17/DT	amod||correlation-19/NN||inverse-18/JJ	nsubj||was-16/VBD||correlation-19/NN	det||numbers-23/NNS||the-21/DT	nn||numbers-23/NNS||epc-22/NN	prep_between||correlation-19/NN||numbers-23/NNS	nn||glucose-26/NN||plasma-25/NN	prep_between||correlation-19/NN||glucose-26/NN	conj_and||numbers-23/NNS||glucose-26/NN	nsubj||was-16/VBD||hba1c-31/NNS	conj_and||correlation-19/NN||hba1c-31/NNS	type2diabetes-6||glucose-26||no_rel||the number of epcs in type2diabetes was significantly decreased compared with healthy controls and there was an inverse correlation between the epc numbers and plasma glucose, as well as hba1c.
prep_in||shown-6/VBN||humans-2/NNS	nsubjpass||shown-6/VBN||chemerin-4/NN	nsubjpass||associated-9/VBN||chemerin-4/NN	auxpass||shown-6/VBN||was-5/VBD	root||ROOT-0/null||shown-6/VBN	aux||associated-9/VBN||to-7/TO	auxpass||associated-9/VBN||be-8/VB	xcomp||shown-6/VBN||associated-9/VBN	amod||components-12/NNS||multiple-11/JJ	prep_with||associated-9/VBN||components-12/NNS	det||syndrome-16/NN||the-14/DT	amod||syndrome-16/NN||metabolic-15/JJ	prep_of||components-12/NNS||syndrome-16/NN	prep_including||syndrome-16/NN||bmi-18/NN	prep_including||syndrome-16/NN||triglycerides-20/NNPS	conj_and||bmi-18/NN||triglycerides-20/NNPS	nn||cholesterol-23/NN||hdl-22/NN	prep_including||syndrome-16/NN||cholesterol-23/NN	conj_and||bmi-18/NN||cholesterol-23/NN	prep_including||syndrome-16/NN||hypertension-26/NN	conj_and||bmi-18/NN||hypertension-26/NN	cholesterol-23||hypertension-26||no_rel||in humans, chemerin was shown to be associated with multiple components of the metabolic syndrome including bmi, triglycerides, hdl cholesterol, and hypertension.
det||mtx-12/NN||a-1/DT	amod||mtx-12/NN||24-week-2/JJ	amod||mtx-12/NN||double-blind-4/JJ	amod||mtx-12/NN||double-dummy-6/JJ	amod||mtx-12/NN||randomized-8/JJ	dep||mtx-12/NN||methotrexate-10/NN	root||ROOT-0/null||mtx-12/NN	amod||study-16/NN||controlled-15/JJ	nsubjpass||conducted-18/VBN||study-16/NN	nsubj||evaluate-20/VB||study-16/NN	auxpass||conducted-18/VBN||was-17/VBD	dep||mtx-12/NN||conducted-18/VBN	aux||evaluate-20/VB||to-19/TO	xcomp||conducted-18/VBN||evaluate-20/VB	det||efficacy-22/NN||the-21/DT	dobj||evaluate-20/VB||efficacy-22/NN	dobj||evaluate-20/VB||safety-24/NN	conj_and||efficacy-22/NN||safety-24/NN	prep_of||efficacy-22/NN||ccii-26/NNS	det||treatment-29/NN||the-28/DT	prep_in||ccii-26/NNS||treatment-29/NN	prep_of||treatment-29/NN||rheumatoidarthritis-31/NNS	appos||rheumatoidarthritis-31/NNS||ra-33/NN	rheumatoidarthritis-31||methotrexate-10||yes||a 24-week, double-blind, double-dummy, randomized, methotrexate (mtx)-controlled study was conducted to evaluate the efficacy and safety of ccii in the treatment of rheumatoidarthritis (ra).
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||investigate-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||investigate-8/VB||to-7/TO	xcomp||was-6/VBD||investigate-8/VB	amod||3-13/CD||whether-9/IN	det||3-13/CD||the-10/DT	amod||3-13/CD||vkorc1-11/JJ	number||3-13/CD||*-12/CD	dobj||investigate-8/VB||3-13/CD	nsubj||gâ-16/VBP||rs7294/9041-15/NNS	dep||3-13/CD||gâ-16/VBP	num||â-20/NN||$-17/$	number||>-19/CD||-18/CD	num||$-17/$||>-19/CD	dobj||gâ-16/VBP||â-20/NN	dep||â-20/NN||$-21/$	num||$-21/$||-22/CD	dep||â-20/NN||a-23/SYM	num||*-27/NNP||vkorc1-26/CD	dobj||investigate-8/VB||*-27/NNP	conj_and||3-13/CD||*-27/NNP	num||*-27/NNP||4-28/CD	amod||câ-31/NN||rs17708472/6009-30/JJ	dep||*-27/NNP||câ-31/NN	dep||â-35/NN||$-32/$	num||â-35/NN||-33/CD	amod||â-35/NN||>-34/JJ	dep||câ-31/NN||â-35/NN	dep||â-35/NN||$-36/$	number||t-38/CD||-37/CD	num||$-36/$||t-38/CD	dobj||investigate-8/VB||cyp4f2-42/NNS	conj_and||3-13/CD||cyp4f2-42/NNS	amod||câ-45/NN||rs2108622/1347-44/JJ	dep||cyp4f2-42/NNS||câ-45/NN	dep||â-49/NN||$-46/$	num||â-49/NN||-47/CD	amod||â-49/NN||>-48/JJ	dep||câ-45/NN||â-49/NN	dep||â-49/NN||$-50/$	number||t-52/CD||-51/CD	num||$-50/$||t-52/CD	nsubjpass||associated-56/VBN||polymorphisms-54/NNS	auxpass||associated-56/VBN||were-55/VBD	rcmod||cyp4f2-42/NNS||associated-56/VBN	amod||requirements-62/NNS||elevated-58/JJ	nn||requirements-62/NNS||warfarin-59/NN	nn||requirements-62/NNS||maintenance-60/NN	nn||requirements-62/NNS||dose-61/NN	prep_with||associated-56/VBN||requirements-62/NNS	prep_in||requirements-62/NNS||patients-64/NNS	prep_with||patients-64/NNS||myocardialinfarction-66/NN	dep||3-13/CD||n-68/VBN	dep||105-70/CD||=-69/SYM	ccomp||n-68/VBN||105-70/CD	det||study-77/NN||the-73/DT	amod||study-77/NN||warfarin-74/JJ	nn||study-77/NN||aspirin-75/NN	nn||study-77/NN||reinfarction-76/NN	prep_from||investigate-8/VB||study-77/NN	appos||study-77/NN||waris-ii-79/NNP	myocardialinfarction-66||aspirin-75||yes||the aim of this study was to investigate whether the vkorc1*3 (rs7294/9041 gâ>âa), vkorc1*4 (rs17708472/6009 câ>ât), and cyp4f2 (rs2108622/1347 câ>ât) polymorphisms were associated with elevated warfarin maintenance dose requirements in patients with myocardialinfarction ( n = 105) from the warfarin aspirin reinfarction study (waris-ii).
amod||nsaids-2/NNS||non-selective-1/JJ	nsubj||increase-3/VBP||nsaids-2/NNS	root||ROOT-0/null||increase-3/VBP	det||risk-5/NN||the-4/DT	dobj||increase-3/VBP||risk-5/NN	amod||â-8/NN||pepticulcerdisease-7/JJ	prep_of||risk-5/NN||â-8/NN	number||5-fold-10/JJ||1/4-9/CD	amod||â-8/NN||5-fold-10/JJ	prep_of||risk-5/NN||that-13/DT	conj_and||â-8/NN||that-13/DT	amod||4-fold-17/NNS||upper-15/JJ	amod||4-fold-17/NNS||gibleeding-16/VBG	prep_of||that-13/DT||4-fold-17/NNS	mark||associated-27/VBN||whereas-19/IN	amod||cyclo-oxygenase-2-21/JJ||selective-20/JJ	amod||inhibitors-25/NNS||cyclo-oxygenase-2-21/JJ	dep||cyclo-oxygenase-2-21/JJ||cox-23/NN	nsubjpass||associated-27/VBN||inhibitors-25/NNS	auxpass||associated-27/VBN||are-26/VBP	advcl||increase-3/VBP||associated-27/VBN	det||toxicity-33/NN||a-29/DT	advmod||lower-31/JJR||significantly-30/RB	amod||toxicity-33/NN||lower-31/JJR	nn||toxicity-33/NN||gi-32/NN	prep_with||associated-27/VBN||toxicity-33/NN	amod||agents-36/NNS||non-selective-35/JJ	prep_than||toxicity-33/NN||agents-36/NNS	nsaids-2||pepticulcerdisease-7||no_rel||non-selective nsaids increase the risk of pepticulcerdisease â¼5-fold, and that of upper gibleeding 4-fold, whereas selective cyclo-oxygenase-2 (cox) inhibitors are associated with a significantly lower gi toxicity than non-selective agents.
expl||were-2/VBD||there-1/EX	root||ROOT-0/null||were-2/VBD	num||questions-4/NNS||nine-3/CD	nsubj||were-2/VBD||questions-4/NNS	aux||assess-6/VB||to-5/TO	vmod||questions-4/NNS||assess-6/VB	amod||knowledge-8/NN||hiv/aids-7/JJ	dobj||assess-6/VB||knowledge-8/NN	prep_of||knowledge-8/NN||detainees-10/NNS	num||%-14/NN||35.7-13/CD	nsubj||answered-18/VBD||%-14/NN	prep_of||%-14/NN||those-16/DT	vmod||those-16/DT||surveyed-17/VBN	conj_and||were-2/VBD||answered-18/VBD	det||questions-21/NNS||all-19/DT	num||questions-21/NNS||nine-20/CD	dobj||answered-18/VBD||questions-21/NNS	advmod||answered-18/VBD||correctly-22/RB	aids--1||hiv--1||no||there were nine questions to assess hiv/aids knowledge of detainees, and 35.7% of those surveyed answered all nine questions correctly.
det||test-4/NN||the-1/DT	amod||test-4/NN||xpert-2/JJ	nn||test-4/NN||mtb/rif-3/NN	nsubj||detect-15/VB||test-4/NN	dep||test-4/NN||cepheid-6/VBN	dobj||cepheid-6/VBN||sunnyvale-8/NN	dep||sunnyvale-8/NN||ca-10/MD	appos||sunnyvale-8/NN||usa-12/NN	aux||detect-15/VB||can-14/MD	root||ROOT-0/null||detect-15/VB	dobj||detect-15/VB||tuberculosis-16/NNP	poss||form-20/NN||its-18/PRP$	amod||form-20/NN||multidrug-resistant-19/JJ	dobj||detect-15/VB||form-20/NN	conj_and||tuberculosis-16/NNP||form-20/NN	advmod||high-23/JJ||very-22/RB	amod||sensitivity-24/NN||high-23/JJ	prep_with||detect-15/VB||sensitivity-24/NN	prep_with||detect-15/VB||specificity-26/NN	conj_and||sensitivity-24/NN||specificity-26/NN	amod||studies-29/NNS||controlled-28/JJ	prep_in||detect-15/VB||studies-29/NNS	neg||data-34/NNS||no-32/DT	nn||data-34/NNS||performance-33/NN	nsubj||exist-35/VBP||data-34/NNS	conj_but||detect-15/VB||exist-35/VBP	nn||facilities-41/NNS||district-37/NN	conj_and||district-37/NN||subdistrict-39/NN	nn||facilities-41/NNS||subdistrict-39/NN	nn||facilities-41/NNS||health-40/NN	prep_from||exist-35/VBP||facilities-41/NNS	amod||countries-44/NNS||tuberculosis-endemic-43/JJ	prep_in||exist-35/VBP||countries-44/NNS	tuberculosis-16||mtb--1||no||the xpert mtb/rif test (cepheid, sunnyvale, ca, usa) can detect tuberculosis and its multidrug-resistant form with very high sensitivity and specificity in controlled studies, but no performance data exist from district and subdistrict health facilities in tuberculosis-endemic countries.
nn||testing-2/NN||hiv-1/NN	nsubj||component-8/NN||testing-2/NN	prep_with||testing-2/NN||counseling-4/NN	cop||component-8/NN||is-5/VBZ	det||component-8/NN||an-6/DT	amod||component-8/NN||integral-7/JJ	root||ROOT-0/null||component-8/NN	advmod||hiv-12/NN||most-10/RBS	amod||hiv-12/NN||national-11/JJ	prep_of||component-8/NN||hiv-12/NN	nn||strategies-16/NNS||aids-14/NNS	nn||strategies-16/NNS||prevention-15/NN	prep_of||component-8/NN||strategies-16/NNS	conj_and||hiv-12/NN||strategies-16/NNS	amod||africa-19/NN||southern-18/JJ	prep_in||component-8/NN||africa-19/NN	aids-14||hiv-12||no||hiv testing with counseling is an integral component of most national hiv and aids prevention strategies in southern africa.
amod||agents-3/NNS||multiple-2/JJ	prep_with||imperative-34/JJ||agents-3/NNS	advmod||available-5/JJ||now-4/RB	amod||agents-3/NNS||available-5/JJ	det||treatment-8/NN||the-7/DT	prep_for||agents-3/NNS||treatment-8/NN	amod||rcc-11/NN||advanced-10/JJ	prep_of||treatment-8/NN||rcc-11/NN	nsubj||imperative-34/JJ||identification-13/NN	amod||biomarkers-18/NNS||patient-15/JJ	conj_and||patient-15/JJ||tumor-specific-17/JJ	amod||biomarkers-18/NNS||tumor-specific-17/JJ	prep_of||identification-13/NN||biomarkers-18/NNS	aux||inform-20/VB||to-19/TO	vmod||biomarkers-18/NNS||inform-20/VB	poss||choice-22/NN||our-21/PRP$	dobj||inform-20/VB||choice-22/NN	amod||therapy-25/NN||first-line-24/JJ	prep_of||choice-22/NN||therapy-25/NN	det||sequence-29/NN||the-27/DT	amod||sequence-29/NN||proper-28/JJ	dobj||inform-20/VB||sequence-29/NN	conj_and||choice-22/NN||sequence-29/NN	amod||therapies-32/NNS||subsequent-31/JJ	prep_of||sequence-29/NN||therapies-32/NNS	cop||imperative-34/JJ||is-33/VBZ	root||ROOT-0/null||imperative-34/JJ	tumor--1||inform-20||no_rel||with multiple agents now available for the treatment of advanced rcc, identification of patient and tumor-specific biomarkers to inform our choice of first-line therapy and the proper sequence of subsequent therapies is imperative.
amod||acid-2/NN||tauroursodeoxycholic-1/JJ	nsubjpass||used-16/VBN||acid-2/NN	nsubj||study-18/VB||acid-2/NN	appos||acid-2/NN||tudca-4/NNP	det||chaperone-9/NN||a-7/DT	amod||chaperone-9/NN||chemical-8/JJ	appos||acid-2/NN||chaperone-9/NN	nsubj||alleviates-11/VBZ||chaperone-9/NN	rcmod||chaperone-9/NN||alleviates-11/VBZ	nn||stress-13/NN||er-12/NN	dobj||alleviates-11/VBZ||stress-13/NN	auxpass||used-16/VBN||was-15/VBD	root||ROOT-0/null||used-16/VBN	aux||study-18/VB||to-17/TO	xcomp||used-16/VBN||study-18/VB	det||mechanism-20/NN||the-19/DT	dobj||study-18/VB||mechanism-20/NN	vmod||mechanism-20/NN||underlying-21/VBG	amod||downregulation-24/NN||obesity-induced-22/JJ	nn||downregulation-24/NN||adiponectin-23/NN	dobj||underlying-21/VBG||downregulation-24/NN	amod||mice-27/NNS||db/db-26/JJ	prep_in||underlying-21/VBG||mice-27/NNS	amod||mice-32/NNS||high-fat-29/JJ	amod||mice-32/NNS||diet-induced-30/JJ	nn||mice-32/NNS||obese-31/NN	appos||mice-27/NNS||mice-32/NNS	amod||adipocytes-38/NNS||er-stressed-36/JJ	amod||adipocytes-38/NNS||3t3-l1-37/JJ	prep_in||underlying-21/VBG||adipocytes-38/NNS	conj_and||mice-27/NNS||adipocytes-38/NNS	fat--1||obesity--1||no_rel||tauroursodeoxycholic acid (tudca), a chemical chaperone that alleviates er stress, was used to study the mechanism underlying obesity-induced adiponectin downregulation in db/db mice, high-fat diet-induced obese mice, and in er-stressed 3t3-l1 adipocytes.
nsubj||uses-2/VBZ||australia-1/NN	root||ROOT-0/null||uses-2/VBZ	det||protocol-4/NN||a-3/DT	dobj||uses-2/VBZ||protocol-4/NN	vmod||protocol-4/NN||combining-5/VBG	amod||rabiesimmunoglobulin-7/NN||human-6/JJ	dobj||combining-5/VBG||rabiesimmunoglobulin-7/NN	dep||rabiesimmunoglobulin-7/NN||hrig-9/VBG	dobj||combining-5/VBG||rabiesvaccine-12/NN	conj_and||rabiesimmunoglobulin-7/NN||rabiesvaccine-12/NN	amod||prophylaxis-15/NNS||post-exposure-14/JJ	prep_for||rabiesvaccine-12/NN||prophylaxis-15/NNS	appos||rabiesvaccine-12/NN||pep-17/NN	nn||lyssavirus-24/NNS||rabies-20/NNP	conj_and||rabies-20/NNP||australian-22/NN	nn||lyssavirus-24/NNS||australian-22/NN	nn||lyssavirus-24/NNS||bat-23/NN	prep_of||rabiesvaccine-12/NN||lyssavirus-24/NNS	appos||lyssavirus-24/NNS||ablv-26/NNP	det||aim-31/NN||the-30/DT	prep_with||lyssavirus-24/NNS||aim-31/NN	prepc_of||aim-31/NN||achieving-33/VBG	det||titre-36/NN||an-34/DT	nn||titre-36/NN||antibody-35/NN	dobj||achieving-33/VBG||titre-36/NN	nn||¥-40/NNP||â-38/NNP	nn||¥-40/NNP||-39/NNP	prep_of||titre-36/NN||¥-40/NNP	number||iu/ml-42/JJ||0.5-41/CD	amod||rabiesvaccine-12/NN||iu/ml-42/JJ	dep||world-46/NN||per-45/IN	amod||guidelines-52/NNS||world-46/NN	nn||guidelines-52/NNS||health-47/NN	nn||guidelines-52/NNS||organization-48/NN	dep||guidelines-52/NNS||who-50/WP	prep_as||rabiesvaccine-12/NN||guidelines-52/NNS	advmod||soon-55/RB||as-54/RB	advmod||guidelines-52/NNS||soon-55/RB	prep_as||soon-55/RB||possible-57/JJ	rabies-20||rabiesimmunoglobulin-7||yes||australia uses a protocol combining human rabiesimmunoglobulin (hrig) and rabiesvaccine for post-exposure prophylaxis (pep) of rabies and australian bat lyssavirus (ablv), with the aim of achieving an antibody titre of â¥0.5 iu/ml, as per world health organization (who) guidelines, as soon as possible.
amod||evidence-2/NN||previous-1/JJ	nsubjpass||based-11/VBN||evidence-2/NN	prep_for||evidence-2/NN||elevation-4/NN	prep_of||elevation-4/NN||st-6/NN	nn||cancer-9/NN||ovarian-8/NN	prep_in||st-6/NN||cancer-9/NN	auxpass||based-11/VBN||was-10/VBD	root||ROOT-0/null||based-11/VBN	det||reagent-15/NN||a-13/DT	amod||reagent-15/NN||colorimetric-14/JJ	prep_on||based-11/VBN||reagent-15/NN	nsubj||provide-19/VB||reagent-15/NN	nsubj||react-25/VB||reagent-15/NN	aux||provide-19/VB||does-17/VBZ	neg||provide-19/VB||not-18/RB	rcmod||reagent-15/NN||provide-19/VB	amod||details-21/NNS||structural-20/JJ	dobj||provide-19/VB||details-21/NNS	aux||react-25/VB||can-23/MD	advmod||react-25/VB||also-24/RB	rcmod||reagent-15/NN||react-25/VB	conj_and||provide-19/VB||react-25/VB	amod||lipids-28/NNS||other-27/JJ	prep_with||react-25/VB||lipids-28/NNS	cancer-9||lipids-28||no_rel||previous evidence for elevation of st in ovarian cancer was based on a colorimetric reagent that does not provide structural details and can also react with other lipids.
nsubjpass||used-5/VBN||tetracyclines-1/NNS	conj_and||tetracyclines-1/NNS||cotrimoxazole-3/NN	nsubjpass||used-5/VBN||cotrimoxazole-3/NN	auxpass||used-5/VBN||are-4/VBP	root||ROOT-0/null||used-5/VBN	det||prophylaxis-9/NNS||the-7/DT	amod||prophylaxis-9/NNS||secondary-8/JJ	prep_in||used-5/VBN||prophylaxis-9/NNS	prep_of||prophylaxis-9/NNS||plague-11/NNP	det||case-14/NN||the-13/DT	prep_in||used-5/VBN||case-14/NN	amod||exposure-17/NN||potential-16/JJ	prep_of||case-14/NN||exposure-17/NN	prep_to||used-5/VBN||y.pestis-19/NNS	amod||isolates-23/NNS||cotrimoxazole-resistant-22/JJ	nsubjpass||reported-26/VBN||isolates-23/NNS	aux||reported-26/VBN||have-24/VBP	auxpass||reported-26/VBN||been-25/VBN	conj_but||used-5/VBN||reported-26/VBN	plague-11||y.pestis-19||no||tetracyclines and cotrimoxazole are used in the secondary prophylaxis of plague in the case of potential exposure to y.pestis , but cotrimoxazole-resistant isolates have been reported .
advmod||awaiting-2/VBG||eagerly-1/RB	vmod||become-42/VBN||awaiting-2/VBG	det||results-4/NNS||the-3/DT	dobj||awaiting-2/VBG||results-4/NNS	det||management-7/NN||the-6/DT	prep_of||results-4/NNS||management-7/NN	amod||study-10/NN||myelomeningocele-9/JJ	prep_of||management-7/NN||study-10/NN	dep||management-7/NN||moms-12/VBZ	prep_of||results-4/NNS||with-15/IN	conj_and||management-7/NN||with-15/IN	det||interest-18/NN||an-16/DT	amod||interest-18/NN||increasing-17/VBG	pobj||with-15/IN||interest-18/NN	prepc_in||interest-18/NN||setting-20/VBG	prt||setting-20/VBG||up-21/RP	amod||repair-24/NN||intrauterine-22/JJ	nn||repair-24/NN||myelomeningocele-23/NN	dobj||setting-20/VBG||repair-24/NN	appos||repair-24/NN||iumr-26/NN	det||management-31/NN||the-29/DT	amod||management-31/NN||optimal-30/JJ	nsubj||become-42/VBN||management-31/NN	prep_of||management-31/NN||patients-33/NNS	vmod||patients-33/NNS||suffering-34/VBG	amod||myelomeningocele-37/NN||congenital-36/JJ	prep_from||suffering-34/VBG||myelomeningocele-37/NN	appos||myelomeningocele-37/NN||mmc-39/NN	aux||become-42/VBN||has-41/VBZ	root||ROOT-0/null||become-42/VBN	det||matter-44/NN||a-43/DT	xcomp||become-42/VBN||matter-44/NN	prep_of||matter-44/NN||debate-46/NN	advmod||become-42/VBN||again-47/RB	myelomeningocele-37||mmc-39||no_rel||eagerly awaiting the results of the management of myelomeningocele study (moms) and with an increasing interest in setting up intrauterine myelomeningocele repair (iumr), the optimal management of patients suffering from congenital myelomeningocele (mmc) has become a matter of debate again.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	poss||study-5/NN||our-4/PRP$	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	dep||was-6/VBD||evaluate-8/VB	det||predisposition-10/NN||the-9/DT	dobj||evaluate-8/VB||predisposition-10/NN	prep_to||evaluate-8/VB||autoimmunethyroiditis-12/NNS	prep_in||autoimmunethyroiditis-12/NNS||patients-14/NNS	amod||virus-17/NN||chronichepatitisc-16/JJ	prep_with||patients-14/NNS||virus-17/NN	amod||therapy-20/NN||ifn-alpha-19/JJ	prep_during||evaluate-8/VB||therapy-20/NN	prepc_depending_on||evaluate-8/VB||on-23/IN	det||presence-25/NN||the-24/DT	pobj||evaluate-8/VB||presence-25/NN	prep_of||presence-25/NN||polymorphisms-27/NNS	det||region-31/NN||the-29/DT	nn||region-31/NN||promoter-30/NN	prep_in||polymorphisms-27/NNS||region-31/NN	amod||gene-40/NN||ctla-4c-33/JJ	poss||318-37/NN||â-35/NNP	dep||ctla-4c-33/JJ||318-37/NN	nn||gene-40/NN||t-39/NN	prep_of||region-31/NN||gene-40/NN	dep||was-6/VBD||in-42/IN	conj_and||evaluate-8/VB||in-42/IN	pobj||in-42/IN||exon-43/NN	num||exon-43/NN||1-44/CD	amod||gene-47/NN||a49g-46/JJ	prep_of||exon-43/NN||gene-47/NN	amod||transition-52/NN||c1858t-51/JJ	pobj||in-42/IN||transition-52/NN	conj_and||exon-43/NN||transition-52/NN	amod||gene-55/NN||ptpn22-54/JJ	prep_of||transition-52/NN||gene-55/NN	chronichepatitisc-16||ifn--1||yes||the aim of our study was to evaluate the predisposition to autoimmunethyroiditis in patients with chronichepatitisc virus during ifn-alpha therapy, depending on the presence of polymorphisms in the promoter region of ctla-4c (â318)t gene and in exon 1 of a49g gene as well as c1858t transition of ptpn22 gene.
nsubj||possesses-9/VBZ||mycobacteriumtuberculosis-1/NNS	det||agent-5/NN||the-3/DT	amod||agent-5/NN||etiological-4/JJ	appos||mycobacteriumtuberculosis-1/NNS||agent-5/NN	prep_of||agent-5/NN||tb-7/NN	root||ROOT-0/null||possesses-9/VBZ	det||catabolic-12/NN||a-10/DT	nn||catabolic-12/NN||cholesterol-11/NN	dobj||possesses-9/VBZ||catabolic-12/NN	advmod||implicated-14/VBN||pathway-13/RB	vmod||catabolic-12/NN||implicated-14/VBN	prep_in||implicated-14/VBN||pathogenesis-16/NNS	tb-7||mycobacteriumtuberculosis-1||no||mycobacteriumtuberculosis , the etiological agent of tb, possesses a cholesterol catabolic pathway implicated in pathogenesis.
det||review-3/NN||this-2/DT	prep_in||explore-6/VB||review-3/NN	nsubj||explore-6/VB||we-5/PRP	root||ROOT-0/null||explore-6/VB	det||link-11/NN||a-7/DT	advmod||unrecognised-9/JJ||previously-8/RB	amod||link-11/NN||unrecognised-9/JJ	amod||link-11/NN||genetic-10/JJ	dobj||explore-6/VB||link-11/NN	prep_between||link-11/NN||ts-13/NN	det||series-17/NN||a-15/DT	amod||series-17/NN||competing-16/VBG	dobj||explore-6/VB||series-17/NN	conj_and||link-11/NN||series-17/NN	nsubj||links-56/VBZ||series-17/NN	amod||complexes-20/NNS||trans-synaptic-19/JJ	prep_of||series-17/NN||complexes-20/NNS	dep||series-17/NN||neurexins-22/NNS	appos||neurexins-22/NNS||nrxns-24/NNS	appos||neurexins-22/NNS||neuroligins-27/NNS	appos||neuroligins-27/NNS||nlgns-29/NNS	amod||proteins-35/NNS||leucine-rich-32/JJ	nn||proteins-35/NNS||repeat-33/NN	nn||proteins-35/NNS||transmembrane-34/NN	appos||neurexins-22/NNS||proteins-35/NNS	dep||proteins-35/NNS||lrrtms-37/VBZ	amod||neuronals-43/NNS||leucine-40/JJ	amod||neuronals-43/NNS||rich-41/JJ	nn||neuronals-43/NNS||repeat-42/NN	appos||neurexins-22/NNS||neuronals-43/NNS	appos||neuronals-43/NNS||lrrns-45/NNS	nn||precursor-49/NN||cerebellin-48/NN	dep||series-17/NN||precursor-49/NN	conj_and||neurexins-22/NNS||precursor-49/NN	dep||precursor-49/NN||2-50/CD	appos||2-50/CD||cbln2-52/NNP	rcmod||series-17/NN||links-56/VBZ	dobj||links-56/VBZ||it-57/PRP	nn||disorder-61/NN||autism-59/NN	nn||disorder-61/NN||spectrum-60/NN	prep_with||links-56/VBZ||disorder-61/NN	amod||pathways-64/NNS||neurodevelopmental-63/JJ	prep_through||disorder-61/NN||pathways-64/NNS	leucine-40||autism-59||no_rel||in this review, we explore a previously unrecognised genetic link between ts and a competing series of trans-synaptic complexes (neurexins (nrxns), neuroligins (nlgns), leucine-rich repeat transmembrane proteins (lrrtms), leucine rich repeat neuronals (lrrns) and cerebellin precursor 2 (cbln2)) that links it with autism spectrum disorder through neurodevelopmental pathways.
nsubjpass||found-3/VBN||bmscs-1/NNS	nsubj||reach-6/VB||bmscs-1/NNS	auxpass||found-3/VBN||were-2/VBD	root||ROOT-0/null||found-3/VBN	aux||reach-6/VB||to-4/TO	advmod||reach-6/VB||preferably-5/RB	xcomp||found-3/VBN||reach-6/VB	nsubj||undergoing-8/VBG||sites-7/NNS	dep||reach-6/VB||undergoing-8/VBG	det||process-10/NN||the-9/DT	dobj||undergoing-8/VBG||process-10/NN	nn||proliferation-13/NN||cell-12/NN	prep_of||process-10/NN||proliferation-13/NN	prep_such_as||undergoing-8/VBG||wound-17/NN	prep_such_as||undergoing-8/VBG||tumor-19/NN	conj_and||wound-17/NN||tumor-19/NN	vmod||undergoing-8/VBG||suggesting-21/VBG	mark||used-26/VBN||that-22/IN	nsubjpass||used-26/VBN||bmscs-23/NNS	aux||used-26/VBN||may-24/MD	auxpass||used-26/VBN||be-25/VB	ccomp||suggesting-21/VBG||used-26/VBN	det||vehicle-29/NN||a-28/DT	prep_as||used-26/VBN||vehicle-29/NN	nn||therapy-32/NN||gene-31/NN	prep_for||vehicle-29/NN||therapy-32/NN	prep_of||therapy-32/NN||tumor-34/NN	vehicle-29||tumor-34||no_rel||bmscs were found to preferably reach sites undergoing the process of cell proliferation, such as wound and tumor, suggesting that bmscs may be used as a vehicle for gene therapy of tumor.
nsubj||component-5/NN||nicastrin-1/NN	cop||component-5/NN||is-2/VBZ	det||component-5/NN||an-3/DT	amod||component-5/NN||obligatory-4/JJ	root||ROOT-0/null||component-5/NN	det||³-9/NN||the-7/DT	nn||³-9/NN||î-8/NN	prep_of||component-5/NN||³-9/NN	nsubj||fragments-24/VBZ||secretase-11/NN	det||complex-15/NN||the-13/DT	amod||complex-15/NN||enzyme-14/JJ	dep||secretase-11/NN||complex-15/NN	nsubj||leads-17/VBZ||complex-15/NN	rcmod||complex-15/NN||leads-17/VBZ	det||production-20/NN||the-19/DT	prep_to||leads-17/VBZ||production-20/NN	nn||²-23/NNS||aî-22/NN	prep_of||production-20/NN||²-23/NNS	parataxis||component-5/NN||fragments-24/VBZ	advmod||central-26/JJ||critically-25/RB	acomp||fragments-24/VBZ||central-26/JJ	det||pathogenesis-29/NNS||the-28/DT	prep_to||central-26/JJ||pathogenesis-29/NNS	prep_of||pathogenesis-29/NNS||alzheimer-31/NN	dep||alzheimer-31/NN||sdisease-33/NN	appos||alzheimer-31/NN||ad-35/NN	alzheimer'sdisease--1||enzyme-14||no_rel||nicastrin is an obligatory component of the î³-secretase; the enzyme complex that leads to the production of aî² fragments critically central to the pathogenesis of alzheimer'sdisease (ad).
det||differences-4/NNS||these-1/DT	amod||differences-4/NNS||important-2/JJ	amod||differences-4/NNS||metabolic-3/JJ	nsubj||influence-6/VB||differences-4/NNS	aux||influence-6/VB||could-5/MD	root||ROOT-0/null||influence-6/VB	det||history-9/NN||the-7/DT	amod||history-9/NN||natural-8/JJ	dobj||influence-6/VB||history-9/NN	prep_of||history-9/NN||hyperglycemia-11/NN	nn||dependence-14/NN||insulin-13/NN	prep_of||history-9/NN||dependence-14/NN	conj_and||hyperglycemia-11/NN||dependence-14/NN	amod||outcomes-18/NNS||clinical-17/JJ	prep_of||history-9/NN||outcomes-18/NNS	conj_and||hyperglycemia-11/NN||outcomes-18/NNS	det||youth-21/NN||these-20/DT	prep_in||influence-6/VB||youth-21/NN	hyperglycemia-11||insulin-13||yes||these important metabolic differences could influence the natural history of hyperglycemia, insulin dependence, and clinical outcomes in these youth.
nsubj||shown-4/VBN||we-1/PRP	aux||shown-4/VBN||have-2/VBP	advmod||shown-4/VBN||previously-3/RB	root||ROOT-0/null||shown-4/VBN	mark||improves-10/VBZ||that-5/IN	amod||supplementation-8/NN||dietary-6/JJ	nn||supplementation-8/NN||leucine-7/NN	nsubj||improves-10/VBZ||supplementation-8/NN	advmod||improves-10/VBZ||significantly-9/RB	ccomp||shown-4/VBN||improves-10/VBZ	nn||metabolism-14/NN||glucose-11/NN	conj_and||glucose-11/NN||energy-13/NN	nn||metabolism-14/NN||energy-13/NN	dobj||improves-10/VBZ||metabolism-14/NN	amod||mice-18/NNS||diet-induced-16/JJ	nn||mice-18/NNS||obese-17/NN	prep_in||improves-10/VBZ||mice-18/NNS	vmod||improves-10/VBZ||suggesting-20/VBG	mark||therapy-30/NN||that-21/IN	amod||supplementation-23/NN||leucine-22/JJ	nsubj||therapy-30/NN||supplementation-23/NN	aux||therapy-30/NN||could-24/MD	advmod||therapy-30/NN||potentially-25/RB	cop||therapy-30/NN||be-26/VB	det||therapy-30/NN||a-27/DT	amod||adjuvant-29/JJ||useful-28/JJ	amod||therapy-30/NN||adjuvant-29/JJ	ccomp||suggesting-20/VBG||therapy-30/NN	prep_for||therapy-30/NN||obesity-32/NN	prep_for||therapy-30/NN||type2diabetes-34/NNS	conj_and||obesity-32/NN||type2diabetes-34/NNS	adjuvant-29||obesity-32||no_rel||we have previously shown that dietary leucine supplementation significantly improves glucose and energy metabolism in diet-induced obese mice, suggesting that leucine supplementation could potentially be a useful adjuvant therapy for obesity and type2diabetes.
nn||population-2/NN||patient-1/NN	nsubj||included-3/VBD||population-2/NN	root||ROOT-0/null||included-3/VBD	nn||patients-5/NNS||cll-4/NN	dobj||included-3/VBD||patients-5/NNS	amod||disease-8/NN||relapsed/refractory-7/JJ	prep_with||included-3/VBD||disease-8/NN	nsubj||received-11/VBN||disease-8/NN	aux||received-11/VBN||had-10/VBD	rcmod||disease-8/NN||received-11/VBN	num||lines-16/NNS||one-12/CD	conj_or||one-12/CD||more-14/JJR	num||lines-16/NNS||more-14/JJR	amod||lines-16/NNS||prior-15/JJ	dobj||received-11/VBN||lines-16/NNS	prep_of||lines-16/NNS||treatment-18/NN	preconj||fludarabine-22/NN||either-20/CC	det||fludarabine-22/NN||a-21/DT	prep_including||treatment-18/NN||fludarabine-22/NN	det||regimen-26/NN||an-24/DT	amod||regimen-26/NN||alkylator-based-25/JJ	prep_including||treatment-18/NN||regimen-26/NN	conj_or||fludarabine-22/NN||regimen-26/NN	cll-4||fludarabine-22||yes||patient population included cll patients with relapsed/refractory disease who had received one or more prior lines of treatment including either a fludarabine or an alkylator-based regimen.
det||utilization-5/NN||the-2/DT	nn||utilization-5/NN||diabetes-3/NN	nn||utilization-5/NN||therapy-4/NN	nsubj||researching-6/VBG||utilization-5/NN	prepc_in||exenatide-41/VBP||researching-6/VBG	dobj||researching-6/VBG||changes-7/NNS	nn||weight-11/NN||a1c-9/NNS	nn||factors-14/NNS||weight-11/NN	conj_and||weight-11/NN||other-13/JJ	nn||factors-14/NNS||other-13/JJ	prep_in||changes-7/NNS||factors-14/NNS	prep_through||researching-6/VBG||intervention-16/NN	amod||study-24/NN||exenatide-18/JJ	advmod||exenatide-18/JJ||once-19/RB	amod||study-24/NN||weekly-20/JJ	dep||study-24/NN||duration-1-22/JJ	prep_with||intervention-16/NN||study-24/NN	det||safety-27/NN||the-26/DT	nsubj||exenatide-41/VBP||safety-27/NN	conj_and||safety-27/NN||efficacy-29/NN	nsubj||exenatide-41/VBP||efficacy-29/NN	num||weeks-32/NNS||30-31/CD	prep_of||safety-27/NN||weeks-32/NNS	prep_of||weeks-32/NNS||treatment-34/NN	det||agonist-40/NN||the-36/DT	amod||agonist-40/NN||glucagon-like-37/JJ	amod||agonist-40/NN||peptide-1-38/JJ	nn||agonist-40/NN||receptor-39/NN	prep_with||treatment-34/NN||agonist-40/NN	root||ROOT-0/null||exenatide-41/VBP	mark||compared-52/VBN||once-42/IN	nsubjpass||compared-52/VBN||weekly-43/JJ	amod||qw-46/NN||exenatide-45/JJ	dep||weekly-43/JJ||qw-46/NN	num||mg-49/NN||2-48/CD	dep||qw-46/NN||mg-49/NN	auxpass||compared-52/VBN||was-51/VBD	advcl||exenatide-41/VBP||compared-52/VBN	amod||bid-55/NN||exenatide-54/JJ	prep_with||compared-52/VBN||bid-55/NN	amod||patients-58/NNS||295-57/JJ	prep_in||bid-55/NN||patients-58/NNS	prep_with||compared-52/VBN||type2diabetes-60/CD	type2diabetes-60||exenatide-54||yes||in the diabetes therapy utilization researching changes in a1c, weight and other factors through intervention with exenatide once weekly (duration-1) study, the safety and efficacy of 30 weeks of treatment with the glucagon-like peptide-1 receptor agonist exenatide once weekly (exenatide qw; 2 mg) was compared with exenatide bid in 295 patients with type2diabetes.
nn||studies-2/NNS||animal-1/NN	nsubj||suggest-3/VBP||studies-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||produce-10/VB||that-4/IN	amod||consumption-7/NN||chronic-5/JJ	nn||consumption-7/NN||cannabis-6/NN	nsubj||produce-10/VB||consumption-7/NN	aux||produce-10/VB||may-8/MD	advmod||produce-10/VB||also-9/RB	ccomp||suggest-3/VBP||produce-10/VB	dobj||produce-10/VB||cross-tolerance-11/NN	det||effects-15/NNS||the-13/DT	amod||effects-15/NNS||impairing-14/VBG	prep_for||produce-10/VB||effects-15/NNS	prep_of||effects-15/NNS||alcohol-17/NN	amod||data-21/NNS||supportive-20/JJ	nsubj||scarce-25/JJ||data-21/NNS	prep_in||data-21/NNS||humans-23/NNS	cop||scarce-25/JJ||is-24/VBZ	conj_but||suggest-3/VBP||scarce-25/JJ	cross--1||alcohol-17||no_rel||animal studies suggest that chronic cannabis consumption may also produce cross-tolerance for the impairing effects of alcohol, but supportive data in humans is scarce.
advmod||investigated-25/VBN||sulphadoxine-pyrimethamine-1/RB	dep||investigated-25/VBN||sp-3/VB	det||treatment-8/NN||a-5/DT	advmod||used-7/VBN||widely-6/RB	amod||treatment-8/NN||used-7/VBN	nsubjpass||investigated-25/VBN||treatment-8/NN	amod||malaria-11/NN||uncomplicated-10/JJ	prep_for||treatment-8/NN||malaria-11/NN	prep_for||treatment-8/NN||recommended-13/VBN	conj_and||malaria-11/NN||recommended-13/VBN	amod||treatment-17/NN||intermittent-15/JJ	nn||treatment-17/NN||preventive-16/NN	prep_for||recommended-13/VBN||treatment-17/NN	prep_of||recommended-13/VBN||malaria-19/NN	prep_in||recommended-13/VBN||pregnancy-21/NN	aux||investigated-25/VBN||is-23/VBZ	auxpass||investigated-25/VBN||being-24/VBG	root||ROOT-0/null||investigated-25/VBN	amod||treatment-29/NN||intermittent-27/JJ	nn||treatment-29/NN||preventive-28/NN	prep_for||investigated-25/VBN||treatment-29/NN	prep_of||treatment-29/NN||malaria-31/NN	prep_in||malaria-31/NN||infants-33/NNS	appos||infants-33/NNS||ipti-35/NNP	malaria-31||pyrimethamine--1||yes||sulphadoxine-pyrimethamine (sp) a widely used treatment for uncomplicated malaria and recommended for intermittent preventive treatment of malaria in pregnancy, is being investigated for intermittent preventive treatment of malaria in infants (ipti).
det||kits-5/NNS||the-1/DT	num||kits-5/NNS||70-2/CD	amod||kits-5/NNS||hbsag-3/JJ	nn||kits-5/NNS||test-4/NN	nsubjpass||evaluated-11/VBN||kits-5/NNS	advmod||world-9/NN||around-7/RB	det||world-9/NN||the-8/DT	prep_from||kits-5/NNS||world-9/NN	auxpass||evaluated-11/VBN||were-10/VBD	root||ROOT-0/null||evaluated-11/VBN	amod||a-f-56/NNS||comparatively-12/RB	poss||sensitivity-16/NN||their-14/PRP$	amod||sensitivity-16/NN||clinical-15/JJ	prep_for||comparatively-12/RB||sensitivity-16/NN	amod||sensitivity-19/NN||analytical-18/JJ	prep_for||comparatively-12/RB||sensitivity-19/NN	conj_and||sensitivity-16/NN||sensitivity-19/NN	prep_for||comparatively-12/RB||sensitivity-21/NN	conj_and||sensitivity-16/NN||sensitivity-21/NN	nn||genotypes-24/NNS||hbv-23/NN	prep_to||sensitivity-21/NN||genotypes-24/NNS	nn||subtypes-27/NNS||hbsag-26/NN	prep_to||sensitivity-21/NN||subtypes-27/NNS	conj_and||genotypes-24/NNS||subtypes-27/NNS	prep_for||comparatively-12/RB||specificity-30/NN	conj_and||sensitivity-16/NN||specificity-30/NN	vmod||specificity-30/NN||using-31/VBG	amod||icbs-43/NNS||394-32/JJ	num||clinical-35/NNS||146-34/CD	dep||icbs-43/NNS||clinical-35/NNS	num||analytical-38/NNS||48-37/CD	conj_and||clinical-35/NNS||analytical-38/NNS	dep||icbs-43/NNS||analytical-38/NNS	num||negative-41/NN||200-40/CD	conj_and||clinical-35/NNS||negative-41/NN	dep||icbs-43/NNS||negative-41/NN	dobj||using-31/VBG||icbs-43/NNS	nn||members-46/NNS||master-44/NN	nn||members-46/NNS||panel-45/NN	dep||specificity-30/NN||members-46/NNS	amod||origin-50/NN||diverse-48/JJ	amod||origin-50/NN||geographical-49/JJ	prep_of||members-46/NNS||origin-50/NN	vmod||origin-50/NN||comprising-51/VBG	det||genotypes-55/NNS||the-52/DT	amod||genotypes-55/NNS||major-53/JJ	nn||genotypes-55/NNS||hbv-54/NN	dobj||comprising-51/VBG||genotypes-55/NNS	dobj||evaluated-11/VBN||a-f-56/NNS	det||subtypes-60/NNS||the-58/DT	amod||subtypes-60/NNS||hbsag-59/VBG	dobj||evaluated-11/VBN||subtypes-60/NNS	conj_and||a-f-56/NNS||subtypes-60/NNS	amod||subtypes-60/NNS||adw2-61/JJ	dep||adw2-61/JJ||,4-62/CD	num||,4-62/CD||adr-64/CD	dep||adw2-61/JJ||ayw1-4-66/CD	conj_and||,4-62/CD||ayw1-4-66/CD	hbv-54||hbsag-59||yes||the 70 hbsag test kits from around the world were evaluated comparatively for their clinical sensitivity, analytical sensitivity, sensitivity to hbv genotypes and hbsag subtypes, and specificity using 394 (146 clinical, 48 analytical and 200 negative) icbs master panel members of diverse geographical origin comprising the major hbv genotypes a-f and the hbsag subtypes adw2,4 , adr and ayw1-4 .
prep_in||demonstrated-17/VBD||type1diabetes-2/CD	prepc_compared_with||demonstrated-17/VBD||with-5/IN	pobj||demonstrated-17/VBD||insulinglargine-6/NN	nsubj||demonstrated-17/VBD||ly2605541-8/NNS	nsubj||lowered-39/VBD||ly2605541-8/NNS	det||novel-11/NN||a-10/DT	appos||ly2605541-8/NNS||novel-11/NN	amod||insulin-15/NN||long-acting-13/JJ	amod||insulin-15/NN||basal-14/JJ	appos||novel-11/NN||insulin-15/NN	root||ROOT-0/null||demonstrated-17/VBD	amod||improvements-19/NNS||greater-18/JJR	dobj||demonstrated-17/VBD||improvements-19/NNS	amod||control-22/NN||glycemic-21/JJ	prep_in||demonstrated-17/VBD||control-22/NN	amod||hypoglycemia-26/NN||increased-24/VBN	amod||hypoglycemia-26/NN||total-25/JJ	prep_in||demonstrated-17/VBD||hypoglycemia-26/NN	conj_and||control-22/NN||hypoglycemia-26/NN	amod||hypoglycemia-31/NN||reduced-29/VBN	amod||hypoglycemia-31/NN||nocturnal-30/JJ	prep_in||demonstrated-17/VBD||hypoglycemia-31/NN	conj_and||control-22/NN||hypoglycemia-31/NN	amod||weight-37/NN||reduced-36/VBN	prep_in||demonstrated-17/VBD||weight-37/NN	conj_and||control-22/NN||weight-37/NN	conj_and||demonstrated-17/VBD||lowered-39/VBD	amod||doses-42/NNS||mealtime-40/JJ	nn||doses-42/NNS||insulin-41/NN	dobj||lowered-39/VBD||doses-42/NNS	type1diabetes-2||insulin-41||yes||in type1diabetes, compared with insulinglargine, ly2605541, a novel, long-acting basal insulin, demonstrated greater improvements in glycemic control, increased total hypoglycemia, and reduced nocturnal hypoglycemia, as well as reduced weight and lowered mealtime insulin doses.
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubj||reduces-16/VBZ||treatment-3/NN	prep_of||treatment-3/NN||malaria-5/NN	prep_in||malaria-5/NN||pregnancy-7/NN	appos||pregnancy-7/NN||iptp-9/NN	prep_with||pregnancy-7/NN||sulphadoxine-pyrimethamine-12/NN	appos||treatment-3/NN||sp-14/NN	root||ROOT-0/null||reduces-16/VBZ	det||incidence-18/NN||the-17/DT	dobj||reduces-16/VBZ||incidence-18/NN	amod||birth-weight-21/NN||low-20/JJ	prep_of||incidence-18/NN||birth-weight-21/NN	amod||delivery-24/NN||pre-term-23/JJ	prep_of||incidence-18/NN||delivery-24/NN	conj_and||birth-weight-21/NN||delivery-24/NN	amod||growth-retardation-27/NN||intrauterine-26/JJ	prep_of||incidence-18/NN||growth-retardation-27/NN	conj_and||birth-weight-21/NN||growth-retardation-27/NN	amod||anaemia-30/NN||maternal-29/JJ	prep_of||incidence-18/NN||anaemia-30/NN	conj_and||birth-weight-21/NN||anaemia-30/NN	malaria-5||pyrimethamine--1||yes||intermittent preventive treatment of malaria in pregnancy (iptp) with sulphadoxine-pyrimethamine (sp) reduces the incidence of low birth-weight, pre-term delivery, intrauterine growth-retardation and maternal anaemia.
nn||prevention-3/NN||stroke-2/NN	prep_for||associated-21/VBN||prevention-3/NN	prep_in||prevention-3/NN||patients-5/NNS	vmod||patients-5/NNS||suffering-6/VBG	prep_from||suffering-6/VBG||atrialfibrillation-8/NN	nsubjpass||associated-21/VBN||dabigatran-10/NN	vmod||dabigatran-10/NN||administered-11/VBN	det||dose-14/NN||a-13/DT	prep_at||administered-11/VBN||dose-14/NN	number||mg-17/CD||110-16/CD	prep_of||dose-14/NN||mg-17/CD	advmod||daily-19/JJ||twice-18/RB	advmod||mg-17/CD||daily-19/JJ	auxpass||associated-21/VBN||was-20/VBD	root||ROOT-0/null||associated-21/VBN	prep_with||associated-21/VBN||rates-23/NNS	prep_of||rates-23/NNS||stroke-25/NN	amod||embolism-28/NN||systemic-27/JJ	prep_with||associated-21/VBN||embolism-28/NN	conj_and||rates-23/NNS||embolism-28/NN	nsubj||similar-31/JJ||embolism-28/NN	cop||similar-31/JJ||were-30/VBD	rcmod||embolism-28/NN||similar-31/JJ	prep_to||similar-31/JJ||those-33/DT	vmod||those-33/DT||associated-34/VBN	prep_with||associated-34/VBN||warfarin-36/NN	amod||rates-42/NNS||lower-41/JJR	prep_with||associated-34/VBN||rates-42/NNS	conj_and||warfarin-36/NN||rates-42/NNS	prep_of||rates-42/NNS||hemorrhage-44/NN	stroke-25||warfarin-36||yes||for stroke prevention in patients suffering from atrialfibrillation, dabigatran administered at a dose of 110 mg twice daily was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of hemorrhage.
nsubj||dependent-3/JJ||liverinflammation-1/NN	cop||dependent-3/JJ||was-2/VBD	root||ROOT-0/null||dependent-3/JJ	prep_on||dependent-3/JJ||genotype-5/NN	amod||type-10/NN||apoe2ki-7/JJ	amod||type-10/NN||>-8/JJ	amod||type-10/NN||wild-9/JJ	dep||genotype-5/NN||type-10/NN	prep_on||dependent-3/JJ||gender-13/NN	conj_and||genotype-5/NN||gender-13/NN	amod||male-17/NN||female-15/JJ	amod||male-17/NN||>-16/JJ	appos||gender-13/NN||male-17/NN	nn||content-22/NN||cholesterol-21/NN	prep_on||dependent-3/JJ||content-22/NN	conj_and||genotype-5/NN||content-22/NN	amod||low-26/NN||high-24/JJ	amod||low-26/NN||>-25/JJ	appos||content-22/NN||low-26/NN	det||diet-30/NN||the-29/DT	prep_of||content-22/NN||diet-30/NN	neg||dependent-3/JJ||not-33/RB	advmod||fat-36/JJ||dietary-35/RB	amod||composition-37/NN||fat-36/JJ	prep_on||dependent-3/JJ||composition-37/NN	conj_but||genotype-5/NN||composition-37/NN	liverinflammation-1||fat-36||no_rel||liverinflammation was dependent on genotype (apoe2ki > wild type), gender (female > male), and cholesterol content (high > low) of the diet, but not on dietary fat composition.
nsubj||collected-2/VBD||we-1/PRP	root||ROOT-0/null||collected-2/VBD	amod||records-4/NNS||medical-3/JJ	dobj||collected-2/VBD||records-4/NNS	num||men-8/NNS||170-6/CD	amod||men-8/NNS||adult-7/JJ	prep_of||records-4/NNS||men-8/NNS	dep||men-8/NNS||diagnosed-9/VBN	prep_with||diagnosed-9/VBN||chronichepatitisc-11/NN	nsubj||started-13/VBD||chronichepatitisc-11/NN	rcmod||chronichepatitisc-11/NN||started-13/VBD	dobj||started-13/VBD||treatment-14/NN	det||combination-17/NN||a-16/DT	prep_with||started-13/VBD||combination-17/NN	amod||interferon-alpha-20/NN||pegylated-19/JJ	prep_of||combination-17/NN||interferon-alpha-20/NN	prep_with||started-13/VBD||ribavirin-22/NNP	conj_and||combination-17/NN||ribavirin-22/NNP	prep_between||ribavirin-22/NNP||january-24/NNP	num||january-24/NNP||2003-25/CD	dep||men-8/NNS||june-27/NNP	conj_and||diagnosed-9/VBN||june-27/NNP	num||june-27/NNP||2009-28/CD	det||centre-33/NN||the-30/DT	amod||centre-33/NN||croatian-31/JJ	nn||centre-33/NN||reference-32/NN	prep_at||june-27/NNP||centre-33/NN	amod||hepatitis-36/NN||viral-35/JJ	prep_for||centre-33/NN||hepatitis-36/NN	chronichepatitisc-11||ribavirin-22||yes||we collected medical records of 170 adult men diagnosed with chronichepatitisc who started treatment with a combination of pegylated interferon-alpha and ribavirin between january 2003 and june 2009 at the croatian reference centre for viral hepatitis.
ccomp||evoked-15/VBD||short-2/JJ	number||ms-5/CD||60-4/CD	dep||short-2/JJ||ms-5/CD	amod||pulses-11/NNS||high-8/JJ	nn||pulses-11/NNS||intensity-9/NN	nn||pulses-11/NNS||laser-10/NN	nsubj||evoked-15/VBD||pulses-11/NNS	appos||pulses-11/NNS||sp-13/NN	ccomp||evoked-40/VBD||evoked-15/VBD	xcomp||evoked-15/VBD||monomodal-16/VB	dobj||monomodal-16/VB||pricking-19/NN	dep||pricking-19/NN||pain-22/NN	nsubjpass||enhanced-26/VBN||pain-22/NN	auxpass||enhanced-26/VBN||was-24/VBD	neg||enhanced-26/VBN||not-25/RB	rcmod||pain-22/NN||enhanced-26/VBN	amod||capsaicin-29/NN||topical-28/JJ	agent||enhanced-26/VBN||capsaicin-29/NN	advmod||longer-32/JJR||whereas-31/RB	amod||pricking-19/NN||longer-32/JJR	amod||pulses-36/NNS||lower-34/JJR	nn||pulses-36/NNS||power-35/NN	nsubj||evoked-40/VBD||pulses-36/NNS	appos||pulses-36/NNS||lp-38/NN	root||ROOT-0/null||evoked-40/VBD	xcomp||evoked-40/VBD||monomodal-41/VB	dobj||monomodal-41/VB||burning-44/NN	iobj||monomodal-41/VB||burning-44/NN	dep||burning-44/NN||pain-47/NN	nsubjpass||enhanced-50/VBN||pain-47/NN	auxpass||enhanced-50/VBN||was-49/VBD	rcmod||pain-47/NN||enhanced-50/VBN	amod||capsaicin-53/NN||topical-52/JJ	agent||enhanced-50/VBN||capsaicin-53/NN	pain-47||capsaicin-53||yes||" short (60 ms), high intensity laser pulses (sp) evoked monomodal ""pricking"" pain which was not enhanced by topical capsaicin, whereas longer, lower power pulses (lp) evoked monomodal ""burning"" pain which was enhanced by topical capsaicin."
nn||levels-2/NNS||glucagon-1/NN	nsubj||remained-3/VBD||levels-2/NNS	root||ROOT-0/null||remained-3/VBD	acomp||remained-3/VBD||suppressed-4/VBN	det||decrease-7/NN||a-6/DT	prep_following||suppressed-4/VBN||decrease-7/NN	amod||insulin-10/NN||zinc-free-9/JJ	prep_in||decrease-7/NN||insulin-10/NN	prep_in||decrease-7/NN||insulin-10/NN	conj_and||insulin-10/NN||insulin-10/NN	prep_with||insulin-10/NN||euglycemia-12/NN	dep||insulin-10/NN||â-14/VB	num||±-17/NN||14-15/CD	nn||±-17/NN||â-16/NN	nsubj||-LSB--20/VBG||±-17/NN	number||pg/ml-19/JJ||3-18/CD	dep||-LSB--20/VBG||pg/ml-19/JJ	xcomp||â-14/VB||-LSB--20/VBG	poss||-RSB--28/NN||â-21/NNP	number||â-24/CD||4.0-23/CD	num||-RSB--28/NN||â-24/CD	nn||-RSB--28/NN||±-25/NN	num||-RSB--28/NN||0.9-26/CD	nn||-RSB--28/NN||pmol/l-27/NN	dobj||-LSB--20/VBG||-RSB--28/NN	amod||hyperinsulinemia-33/NN||sustained-32/VBN	prep_during||insulin-10/NN||hyperinsulinemia-33/NN	prep_with||hyperinsulinemia-33/NN||hypoglycemia-35/NN	nn||±-40/NN||â-37/NN	num||±-40/NN||14-38/CD	nn||±-40/NN||â-39/NN	dep||hypoglycemia-35/NN||±-40/NN	num||-LSB--43/NNS||2-41/CD	amod||-LSB--43/NNS||pg/ml-42/JJ	dep||±-40/NN||-LSB--43/NNS	poss||-RSB--51/NN||â-44/NNP	amod||-RSB--51/NN||4.0-46/JJ	nn||-RSB--51/NN||â-47/NN	nn||-RSB--51/NN||±-48/NN	num||-RSB--51/NN||0.6-49/CD	amod||-RSB--51/NN||pmol/l-50/JJ	dep||-LSB--43/NNS||-RSB--51/NN	acomp||remained-3/VBD||increased-54/VBN	conj_but||suppressed-4/VBN||increased-54/VBN	poss||pg/ml-62/NN||â-56/NNP	number||â-59/CD||3-58/CD	num||pg/ml-62/NN||â-59/CD	amod||pg/ml-62/NN||±-60/JJ	num||pg/ml-62/NN||3-61/CD	prep_to||increased-54/VBN||pg/ml-62/NN	poss||â-67/NN||â-64/NNP	num||â-67/NN||0.9-66/CD	npadvmod||pmol/l-70/JJ||â-67/NN	number||0.9-69/CD||±-68/CD	num||â-67/NN||0.9-69/CD	dep||pg/ml-62/NN||pmol/l-70/JJ	parataxis||increased-54/VBN||p-73/VB	num||0.01-75/CD||<-74/CD	dobj||p-73/VB||0.01-75/CD	det||decrease-79/NN||a-78/DT	prep_following||increased-54/VBN||decrease-79/NN	amod||insulin-82/NN||zinc-free-81/JJ	prep_in||decrease-79/NN||insulin-82/NN	prep_with||insulin-82/NN||hypoglycemia-84/NN	det||min-89/NNS||the-86/DT	amod||min-89/NNS||next-87/JJ	num||min-89/NNS||120-88/CD	prep_over||hypoglycemia-84/NN||min-89/NNS	zinc--1||hypoglycemia-84||no_rel||glucagon levels remained suppressed following a decrease in zinc-free insulin with euglycemia (â14 â± 3 pg/ml [â4.0 â± 0.9 pmol/l]) and during sustained hyperinsulinemia with hypoglycemia (â14 â± 2 pg/ml [â4.0 â± 0.6 pmol/l]) but increased to â3 â± 3 pg/ml (â0.9 â± 0.9 pmol/l) ( p < 0.01) following a decrease in zinc-free insulin with hypoglycemia over the next 120 min.
nsubj||treatment-5/NN||vancomycin-1/NN	cop||treatment-5/NN||is-2/VBZ	det||treatment-5/NN||the-3/DT	amod||treatment-5/NN||primary-4/JJ	root||ROOT-0/null||treatment-5/NN	prep_for||treatment-5/NN||infections-7/NNS	vmod||infections-7/NNS||caused-8/VBN	amod||staphylococcusaureus-11/NNS||methicilin-resistant-10/JJ	agent||caused-8/VBN||staphylococcusaureus-11/NNS	appos||staphylococcusaureus-11/NNS||mrsa-13/NNP	mrsa-13||staphylococcusaureus-11||no||vancomycin is the primary treatment for infections caused by methicilin-resistant staphylococcusaureus (mrsa).
det||system-5/NN||a-1/DT	amod||system-5/NN||continuous-2/JJ	nn||system-5/NN||glucose-3/NN	nn||system-5/NN||monitoring-4/NN	nsubj||have-7/VB||system-5/NN	aux||have-7/VB||may-6/MD	root||ROOT-0/null||have-7/VB	dobj||have-7/VB||utility-8/NN	amod||women-11/NNS||pregnant-10/JJ	prep_in||utility-8/NN||women-11/NNS	amod||diabetes-14/NN||insulin-treated-13/JJ	prep_with||have-7/VB||diabetes-14/NN	advmod||for-17/IN||especially-16/RB	dep||have-7/VB||for-17/IN	det||women-19/NNS||those-18/DT	pobj||for-17/IN||women-19/NNS	nsubj||difficult-25/JJ||women-19/NNS	nsubj||control-27/VB||women-19/NNS	nn||sugars-22/NNS||blood-21/NN	prep_with||women-19/NNS||sugars-22/NNS	cop||difficult-25/JJ||are-24/VBP	rcmod||women-19/NNS||difficult-25/JJ	aux||control-27/VB||to-26/TO	xcomp||difficult-25/JJ||control-27/VB	nsubj||experience-30/VBP||who-29/WP	dep||have-7/VB||experience-30/VBP	conj_or||for-17/IN||experience-30/VBP	amod||hypoglycemia-32/NN||nocturnal-31/JJ	dobj||experience-30/VBP||hypoglycemia-32/NN	advmod||need-40/VBP||however-34/RB	amod||systems-39/NNS||continuous-36/JJ	nn||systems-39/NNS||glucose-37/NN	nn||systems-39/NNS||monitoring-38/NN	nsubj||need-40/VBP||systems-39/NNS	parataxis||have-7/VB||need-40/VBP	amod||study-42/NN||additional-41/JJ	dobj||need-40/VBP||study-42/NN	prep_as||need-40/VBP||part-44/NN	amod||trials-49/NNS||larger-46/JJR	amod||trials-49/NNS||randomized-48/JJ	prep_of||part-44/NN||trials-49/NNS	hypoglycemia-32||glucose-37||yes||a continuous glucose monitoring system may have utility in pregnant women with insulin-treated diabetes, especially for those women with blood sugars that are difficult to control or who experience nocturnal hypoglycemia; however, continuous glucose monitoring systems need additional study as part of larger, randomized trials.
advmod||showed-6/VBD||furthermore-1/RB	nn||testing-5/NN||skin-3/NN	nn||testing-5/NN||prick-4/NN	nsubj||showed-6/VBD||testing-5/NN	root||ROOT-0/null||showed-6/VBD	prep||showed-6/VBD||rather-7/RB	amod||cross-reactivity-9/NN||broad-8/JJ	pobj||rather-7/RB||cross-reactivity-9/NN	amod||heparinpreparations-12/NNS||different-11/JJ	prep_among||showed-6/VBD||heparinpreparations-12/NNS	vmod||heparinpreparations-12/NNS||tested-13/VBN	cross--1||heparinpreparations-12||no_rel||furthermore, skin prick testing showed rather broad cross-reactivity among different heparinpreparations tested.
prep_at||produced-7/VBD||week-2/NN	num||week-2/NN||48-3/CD	amod||therapy-6/NN||clevudine-5/JJ	nsubj||produced-7/VBD||therapy-6/NN	root||ROOT-0/null||produced-7/VBD	det||reductions-12/NNS||a-8/DT	advmod||greater-10/JJR||significantly-9/RB	amod||reductions-12/NNS||greater-10/JJR	amod||reductions-12/NNS||mean-11/JJ	dobj||produced-7/VBD||reductions-12/NNS	nn||levels-17/NNS||serum-14/NN	nn||levels-17/NNS||hbv-15/NN	nn||levels-17/NNS||dna-16/NN	prep_in||reductions-12/NNS||levels-17/NNS	prep_from||produced-7/VBD||baseline-19/NN	amod||log10iu/ml-27/NNS||lamivudine-21/JJ	nn||log10iu/ml-27/NNS||therapy-22/NN	nn||log10iu/ml-27/NNS||-lrb--23/NNP	num||log10iu/ml-27/NNS||-5.2-24/CD	amod||log10iu/ml-27/NNS||vs.-25/IN	num||log10iu/ml-27/NNS||-4.2-26/CD	prep_than||baseline-19/NN||log10iu/ml-27/NNS	dep||baseline-19/NN||p-29/NN	dep||-rrb--32/NNS||=-30/SYM	num||-rrb--32/NNS||0.005-31/CD	rcmod||p-29/NN||-rrb--32/NNS	hbv-15||lamivudine-21||yes||at week 48 , clevudine therapy produced a significantly greater mean reductions in serum hbv dna levels from baseline than lamivudine therapy -lrb- -5.2 vs. -4.2 log10iu/ml ; p = 0.005 -rrb- .
nn||rates-2/NNS||success-1/NN	nsubj||%-9/NN||rates-2/NNS	prep_for||rates-2/NNS||daptomycin-4/NN	prep_versus||daptomycin-4/NN||vancomycin/gentamicin-6/NN	cop||%-9/NN||were-7/VBD	num||%-9/NN||45-8/CD	root||ROOT-0/null||%-9/NN	num||%-12/NN||27-11/CD	prep_versus||%-9/NN||%-12/NN	amod||bacteraemia-15/NN||complicated-14/JJ	prep_in||%-12/NN||bacteraemia-15/NN	num||%-18/NN||60-17/CD	prep_versus||%-9/NN||%-18/NN	conj_and||%-12/NN||%-18/NN	num||%-21/NN||45-20/CD	prep_versus||%-18/NN||%-21/NN	amod||bacteraemia-24/NN||uncomplicated-23/JJ	prep_in||%-21/NN||bacteraemia-24/NN	num||%-27/NN||50-26/CD	prep_versus||%-9/NN||%-27/NN	conj_and||%-12/NN||%-27/NN	num||%-30/NN||50-29/CD	prep_versus||%-27/NN||%-30/NN	amod||endocarditis-34/NNS||right-sided-32/JJ	nn||endocarditis-34/NNS||mrsa-33/NN	prep_in||%-30/NN||endocarditis-34/NNS	daptomycin-4||bacteraemia-24||no_rel||success rates for daptomycin versus vancomycin/gentamicin were 45% versus 27% in complicated bacteraemia, 60% versus 45% in uncomplicated bacteraemia and 50% versus 50% in right-sided mrsa endocarditis.
prep_at||similar-11/JJ||baseline-2/NN	det||patients-5/NNS||the-4/DT	nsubj||similar-11/JJ||patients-5/NNS	det||groups-9/NNS||the-7/DT	num||groups-9/NNS||two-8/CD	prep_in||patients-5/NNS||groups-9/NNS	cop||similar-11/JJ||were-10/VBD	root||ROOT-0/null||similar-11/JJ	det||exception-14/NN||the-13/DT	prep_with||similar-11/JJ||exception-14/NN	nn||regimens-18/NNS||hiv-16/NN	nn||regimens-18/NNS||medication-17/NN	prep_of||exception-14/NN||regimens-18/NNS	amod||count-21/NN||cd4-20/JJ	prep_of||exception-14/NN||count-21/NN	conj_and||regimens-18/NNS||count-21/NN	prep_of||exception-14/NN||presence-23/NN	conj_and||regimens-18/NNS||presence-23/NN	amod||malignancy-26/NN||aids-defining-25/JJ	prep_of||presence-23/NN||malignancy-26/NN	aids--1||hiv-16||no||at baseline, the patients in the two groups were similar with the exception of hiv medication regimens, cd4 count and presence of aids-defining malignancy.
mark||used-30/VBN||although-1/IN	amod||strategies-4/NNS||established-2/JJ	amod||strategies-4/NNS||therapeutic-3/JJ	nsubjpass||used-30/VBN||strategies-4/NNS	nsubj||treat-32/VB||strategies-4/NNS	amod||control-10/NN||appropriate-8/JJ	nn||control-10/NN||bloodglucose-9/NN	prep_such_as||strategies-4/NNS||control-10/NN	nn||control-14/NN||blood-12/NN	nn||control-14/NN||pressure-13/NN	appos||control-10/NN||control-14/NN	prepc_with||control-14/NN||reninâ-16/VBG	dobj||reninâ-16/VBG||$-17/$	advmod||with-26/IN||angiotensin-19/RB	nn||blockade-21/NN||system-20/NN	npadvmod||with-26/IN||blockade-21/NN	cc||lowering-25/NNP||and-23/CC	dep||lowering-25/NNP||lipid-24/RB	dep||blockade-21/NN||lowering-25/NNP	dep||statins-27/CD||with-26/IN	num||$-17/$||statins-27/CD	auxpass||used-30/VBN||are-29/VBP	advcl||increased-49/VBN||used-30/VBN	aux||treat-32/VB||to-31/TO	xcomp||used-30/VBN||treat-32/VB	dobj||treat-32/VB||diabetes-33/NN	det||contribution-36/NN||the-35/DT	nsubj||increased-49/VBN||contribution-36/NN	amod||end-stagekidneydisease-39/NN||diabetic-38/JJ	prep_of||contribution-36/NN||end-stagekidneydisease-39/NN	det||number-43/NN||the-41/DT	amod||number-43/NN||total-42/JJ	prep_to||end-stagekidneydisease-39/NN||number-43/NN	prep_of||number-43/NN||cases-45/NNS	vmod||cases-45/NNS||requiring-46/VBG	dobj||requiring-46/VBG||hemodialysis-47/NNS	aux||increased-49/VBN||has-48/VBZ	root||ROOT-0/null||increased-49/VBN	advmod||increased-49/VBN||tremendously-50/RB	det||decades-55/NNS||the-52/DT	amod||decades-55/NNS||past-53/JJ	num||decades-55/NNS||two-54/CD	prep_in||increased-49/VBN||decades-55/NNS	lipid-24||end-stagekidneydisease-39||no_rel||although established therapeutic strategies, such as appropriate bloodglucose control, blood pressure control with reninâangiotensin system blockade, and lipid lowering with statins, are used to treat diabetes, the contribution of diabetic end-stagekidneydisease to the total number of cases requiring hemodialysis has increased tremendously in the past two decades.
nn||±-2/NNP||ifn-î-1/NNP	nsubj||exerts-3/VBZ||±-2/NNP	root||ROOT-0/null||exerts-3/VBZ	amod||effects-5/NNS||multiple-4/JJ	dobj||exerts-3/VBZ||effects-5/NNS	vmod||effects-5/NNS||leading-6/VBG	amod||protection-9/NN||immune-8/JJ	prep_to||leading-6/VBG||protection-9/NN	prep_against||protection-9/NN||pathogens-11/NNS	prep_against||protection-9/NN||cancer-13/NN	conj_and||pathogens-11/NNS||cancer-13/NN	amod||reactions-18/NNS||autoimmune-17/JJ	prep_to||leading-6/VBG||reactions-18/NNS	conj_and||protection-9/NN||reactions-18/NNS	agent||leading-6/VBG||acting-20/VBG	prep_on||acting-20/VBG||monocytes-22/NNS	amod||cells-25/NNS||dendritic-24/JJ	prep_on||acting-20/VBG||cells-25/NNS	conj_and||monocytes-22/NNS||cells-25/NNS	cancer-13||ifn--1||no_rel||ifn-î± exerts multiple effects leading to immune protection against pathogens and cancer as well to autoimmune reactions by acting on monocytes and dendritic cells.
nsubjpass||established-4/VBN||arsenictrioxide-1/NN	aux||established-4/VBN||has-2/VBZ	auxpass||established-4/VBN||been-3/VBN	root||ROOT-0/null||established-4/VBN	det||agent-8/NN||a-6/DT	amod||agent-8/NN||first-line-7/JJ	prep_as||established-4/VBN||agent-8/NN	prepc_for||established-4/VBN||treating-10/VBG	dobj||treating-10/VBG||acutepromyelocyticleukemia-11/NN	acutepromyelocyticleukemia-11||arsenictrioxide-1||yes||arsenictrioxide has been established as a first-line agent for treating acutepromyelocyticleukemia.
mark||correlate-16/VBP||although-1/IN	amod||levels-3/NNS||increased-2/VBN	nsubj||correlate-16/VBP||levels-3/NNS	amod||interferon-8/NN||systemic-5/JJ	nn||interferon-8/NN||type-6/NN	nn||interferon-8/NN||i-7/NN	prep_of||levels-3/NNS||interferon-8/NN	amod||±-11/NN||ifnî-10/JJ	dep||interferon-8/NN||±-11/NN	nn||²-14/NN||î-13/NN	dep||interferon-8/NN||²-14/NN	conj_and||±-11/NN||²-14/NN	advcl||demonstrated-36/VBN||correlate-16/VBP	amod||resolution-19/NN||accelerated-18/VBN	prep_with||correlate-16/VBP||resolution-19/NN	prep_of||resolution-19/NN||rotavirusdisease-21/NN	amod||strains-25/NNS||multiple-23/JJ	nn||strains-25/NNS||rotavirus-24/NNS	nsubjpass||demonstrated-36/VBN||strains-25/NNS	nsubj||antagonize-38/VB||strains-25/NNS	amod||rotavirus-29/NNS||rhesus-28/JJ	prep_including||strains-25/NNS||rotavirus-29/NNS	appos||rotavirus-29/NNS||rrv-31/NN	aux||demonstrated-36/VBN||have-34/VBP	auxpass||demonstrated-36/VBN||been-35/VBN	root||ROOT-0/null||demonstrated-36/VBN	aux||antagonize-38/VB||to-37/TO	xcomp||demonstrated-36/VBN||antagonize-38/VB	nn||production-42/NN||type-39/FW	nn||production-42/NN||i-40/FW	nn||production-42/NN||ifn-41/NN	dobj||antagonize-38/VB||production-42/NN	det||variety-45/NN||a-44/DT	prep_in||production-42/NN||variety-45/NN	amod||types-51/NNS||epithelial-47/JJ	conj_and||epithelial-47/JJ||fibroblast-49/JJ	amod||types-51/NNS||fibroblast-49/JJ	nn||types-51/NNS||cell-50/NN	prep_of||variety-45/NN||types-51/NNS	amod||mechanisms-54/NNS||several-53/JJ	prep_through||antagonize-38/VB||mechanisms-54/NNS	prep_including||antagonize-38/VB||degradation-57/NN	amod||factors-62/NNS||multiple-59/JJ	amod||factors-62/NNS||interferon-60/JJ	amod||factors-62/NNS||regulatory-61/JJ	prep_of||degradation-57/NN||factors-62/NNS	det||protein-67/NN||a-64/DT	amod||protein-67/NN||viral-65/JJ	amod||protein-67/NN||nonstructural-66/JJ	prep_by||factors-62/NNS||protein-67/NN	rotavirusdisease-21||rotavirus-29||no||although increased levels of systemic type i interferon (ifnî± and î²) correlate with accelerated resolution of rotavirusdisease, multiple rotavirus strains, including rhesus rotavirus (rrv), have been demonstrated to antagonize type i ifn production in a variety of epithelial and fibroblast cell types through several mechanisms, including degradation of multiple interferon regulatory factors by a viral nonstructural protein.
amod||testing-3/NN||one-off-1/JJ	nn||testing-3/NN||mtb/rif-2/NN	nsubj||detected-4/VBD||testing-3/NN	root||ROOT-0/null||detected-4/VBD	dobj||detected-4/VBD||933-5/CD	amod||·-8/NNS||90â-7/JJ	dep||933-5/CD||·-8/NNS	num||%-10/NN||3-9/CD	dep||·-8/NNS||%-10/NN	num||cases-15/NNS||1033-13/CD	amod||cases-15/NNS||culture-confirmed-14/JJ	prep_of||933-5/CD||cases-15/NNS	prep_of||cases-15/NNS||tuberculosis-17/NNP	prepc_compared_with||detected-4/VBD||with-20/IN	pobj||detected-4/VBD||699-21/NNP	amod||·-24/NNS||67â-23/JJ	dep||699-21/NNP||·-24/NNS	num||%-26/NN||1-25/CD	dep||·-24/NNS||%-26/NN	prep_of||699-21/NNP||1041-29/CD	prep_for||699-21/NNP||microscopy-31/NN	tuberculosis-17||rif--1||yes||one-off mtb/rif testing detected 933 (90â·3%) of 1033 culture-confirmed cases of tuberculosis, compared with 699 (67â·1%) of 1041 for microscopy.
amod||stimulation-4/NN||chronic-1/JJ	nn||stimulation-4/NN||cb-2/NN	nn||stimulation-4/NN||receptor-3/NN	nsubj||induces-8/VBZ||stimulation-4/NN	nsubj||stimulates-11/VBZ||stimulation-4/NN	nsubj||alters-15/VBZ||stimulation-4/NN	amod||conditions-7/NNS||basal-6/JJ	prep_under||stimulation-4/NN||conditions-7/NNS	root||ROOT-0/null||induces-8/VBZ	dobj||induces-8/VBZ||glucoseintolerance-9/NN	conj_and||induces-8/VBZ||stimulates-11/VBZ	amod||inflammation-13/NN||metabolic-12/JJ	dobj||stimulates-11/VBZ||inflammation-13/NN	conj_and||induces-8/VBZ||alters-15/VBZ	nn||metabolism-17/NN||lipid-16/NN	dobj||alters-15/VBZ||metabolism-17/NN	det||muscles-20/NNS||the-19/DT	prep_in||alters-15/VBZ||muscles-20/NNS	lipid-16||glucoseintolerance-9||no_rel||chronic cb receptor stimulation under basal conditions induces glucoseintolerance, stimulates metabolic inflammation and alters lipid metabolism in the muscles.
det||eye-4/NN||the-2/DT	amod||eye-4/NN||diabetic-3/JJ	prep_in||is-6/VBZ||eye-4/NN	expl||is-6/VBZ||there-5/EX	root||ROOT-0/null||is-6/VBZ	det||impairment-8/NN||an-7/DT	nsubj||is-6/VBZ||impairment-8/NN	nn||homeostasis-11/NNS||iron-10/NN	prep_of||impairment-8/NN||homeostasis-11/NNS	advmod||leading-14/VBG||thus-13/RB	vmod||is-6/VBZ||leading-14/VBG	aux||ironoverload-16/VB||to-15/TO	xcomp||leading-14/VBG||ironoverload-16/VB	ironoverload-16||iron-10||no||in the diabetic eye there is an impairment of iron homeostasis, thus leading to ironoverload.
amod||sepsis-2/NN||severe-1/JJ	nsubj||emerged-4/VBN||sepsis-2/NN	aux||emerged-4/VBN||has-3/VBZ	root||ROOT-0/null||emerged-4/VBN	det||cause-8/NN||a-6/DT	amod||cause-8/NN||common-7/JJ	prep_as||emerged-4/VBN||cause-8/NN	amod||admission-16/NN||intensive-10/JJ	nn||admission-16/NN||care-11/NN	nn||admission-16/NN||unit-12/NN	appos||admission-16/NN||icu-14/NN	prep_of||cause-8/NN||admission-16/NN	det||living-19/NN||those-18/DT	prep_for||emerged-4/VBN||living-19/NN	prep_with||living-19/NN||hiv/aids-21/NNS	aids--1||hiv--1||no||severe sepsis has emerged as a common cause of intensive care unit (icu) admission for those living with hiv/aids.
nsubjpass||used-5/VBN||candesartan-1/NN	aux||used-5/VBN||may-2/MD	auxpass||used-5/VBN||be-3/VB	advmod||used-5/VBN||safely-4/RB	root||ROOT-0/null||used-5/VBN	prep_for||used-5/VBN||patients-7/NNS	prep_with||patients-7/NNS||hypertension-9/NN	nn||metabolism-14/NN||lipid-13/NN	prep_with_respect_to||hypertension-9/NN||metabolism-14/NN	mark||small-25/JJ||because-16/IN	det||effect-18/NN||the-17/DT	nsubj||small-25/JJ||effect-18/NN	prep_of||effect-18/NN||candesartan-20/NN	prep_on||candesartan-20/NN||lipids-22/NNS	aux||small-25/JJ||may-23/MD	cop||small-25/JJ||be-24/VB	advcl||used-5/VBN||small-25/JJ	hypertension-9||candesartan-20||yes||candesartan may be safely used for patients with hypertension with respect to lipid metabolism, because the effect of candesartan on lipids may be small.
advmod||conclude-4/VBP||thus-1/RB	nsubj||conclude-4/VBP||we-3/PRP	root||ROOT-0/null||conclude-4/VBP	mark||was-7/VBD||that-5/IN	expl||was-7/VBD||there-6/EX	ccomp||conclude-4/VBP||was-7/VBD	neg||evidence-10/NN||no-8/DT	amod||evidence-10/NN||serological-9/JJ	nsubj||was-7/VBD||evidence-10/NN	prep_of||evidence-10/NN||infection-12/NN	prep_with||infection-12/NN||hiv-14/NN	prep_with||infection-12/NN||htlv-i-16/NN	conj_or||hiv-14/NN||htlv-i-16/NN	det||women-20/NNS||the-18/DT	amod||women-20/NNS||pregnant-19/JJ	prep_in||evidence-10/NN||women-20/NNS	vmod||women-20/NNS||studied-21/VBN	advmod||present-28/JJ||however-23/RB	nn||antibody-26/NN||hiv-25/NN	nsubj||present-28/JJ||antibody-26/NN	cop||present-28/JJ||was-27/VBD	parataxis||conclude-4/VBP||present-28/JJ	det||patients-32/NNS||all-30/DT	nn||patients-32/NNS||aids-31/NNS	prep_in||present-28/JJ||patients-32/NNS	vmod||patients-32/NNS||tested-33/VBN	nsubjpass||found-38/VBN||htlv-iantibody-36/NN	auxpass||found-38/VBN||was-37/VBD	parataxis||conclude-4/VBP||found-38/VBN	conj_and||present-28/JJ||found-38/VBN	det||majority-41/NN||the-40/DT	prep_in||found-38/VBN||majority-41/NN	prep_of||majority-41/NN||patients-43/NNS	prep_with||patients-43/NNS||tsp-45/NN	aids-31||hiv-25||no||thus, we conclude that there was no serological evidence of infection with hiv or htlv-i in the pregnant women studied; however, hiv antibody was present in all aids patients tested, and htlv-iantibody was found in the majority of patients with tsp.
det||sites-2/NNS||the-1/DT	nsubj||showed-45/VBD||sites-2/NNS	vmod||sites-2/NNS||stratified-3/VBN	prepc_according_to||stratified-3/VBN||to-5/TO	amod||type-8/NN||normal-6/JJ	nn||type-8/NN||tissue-7/NN	pobj||stratified-3/VBN||type-8/NN	amod||fg-12/NN||fibro-glandular-10/JJ	dep||type-8/NN||fg-12/NN	amod||fa-17/NN||fibro-adipose-15/JJ	dep||type-8/NN||fa-17/NN	conj_and||fg-12/NN||fa-17/NN	dep||type-8/NN||adipose-21/NN	conj_and||fg-12/NN||adipose-21/NN	dep||adipose-21/NN||a-23/SYM	nn||type-28/NN||disease-27/NN	pobj||stratified-3/VBN||type-28/NN	conj_or||type-8/NN||type-28/NN	amod||carcinoma-32/NN||invasive-30/JJ	amod||carcinoma-32/NN||ductal-31/JJ	dep||type-8/NN||carcinoma-32/NN	appos||carcinoma-32/NN||idc-34/NN	amod||carcinoma-38/NN||ductal-37/JJ	dep||type-8/NN||carcinoma-38/NN	conj_and||carcinoma-32/NN||carcinoma-38/NN	prep_in||carcinoma-38/NN||situ-40/NN	appos||situ-40/NN||dcis-42/NNS	root||ROOT-0/null||showed-45/VBD	mark||exhibited-48/VBD||that-46/IN	nsubj||exhibited-48/VBD||fg-47/NN	ccomp||showed-45/VBD||exhibited-48/VBD	amod||s-53/NN||increased-49/JJ	nn||s-53/NN||<-50/NN	nn||s-53/NN||î-51/NN	num||s-53/NN||1/4-52/CD	nsubj||showed-58/VBD||s-53/NN	amod||s-53/NN||>-55/JJ	amod||s-53/NN||a-57/DT	conj_and||>-55/JJ||a-57/DT	ccomp||exhibited-48/VBD||showed-58/VBD	amod||²-62/NN||increased-59/VBN	amod||²-62/NN||-LSB--60/JJ	nn||²-62/NN||î-61/NN	dobj||showed-58/VBD||²-62/NN	amod||-RSB--65/NNS||carotene-64/JJ	dep||²-62/NN||-RSB--65/NNS	amod||tissues-68/NNS||normal-67/JJ	prep_within||-RSB--65/NNS||tissues-68/NNS	carotene-64||fa-17||no_rel||the sites stratified according to normal tissue type (fibro-glandular (fg), fibro-adipose (fa), and adipose (a)) or disease type (invasive ductal carcinoma (idc) and ductal carcinoma in situ (dcis)) showed that fg exhibited increased < î¼s' > and a showed increased [î²-carotene] within normal tissues.
aux||investigate-2/VB||to-1/TO	advcl||divided-29/VBN||investigate-2/VB	det||effect-4/NN||the-3/DT	dobj||investigate-2/VB||effect-4/NN	amod||expression-17/NN||budesonide-6/JJ	nn||p-9/NN||substance-8/NN	prep_on||budesonide-6/JJ||p-9/NN	dep||p-9/NN||nk-1-11/JJ	nn||expression-17/NN||receptor-13/NN	dep||expression-17/NN||nk-1r-15/JJ	prep_of||effect-4/NN||expression-17/NN	det||lung-20/NN||the-19/DT	prep_in||investigate-2/VB||lung-20/NN	prep_in||investigate-2/VB||asmcs-22/NNS	conj_and||lung-20/NN||asmcs-22/NNS	num||rats-26/NNS||45-24/CD	nn||rats-26/NNS||wistar-25/NN	nsubjpass||divided-29/VBN||rats-26/NNS	auxpass||divided-29/VBN||were-27/VBD	advmod||divided-29/VBN||randomly-28/RB	root||ROOT-0/null||divided-29/VBN	num||groups-32/NNS||three-31/CD	prep_into||divided-29/VBN||groups-32/NNS	dep||groups-32/NNS||control-33/NN	dep||groups-32/NNS||asthmatic-35/JJ	amod||control-33/NN||asthmatic-35/JJ	conj_and||control-33/NN||asthmatic-35/JJ	amod||treatment-39/NN||budesonide-38/JJ	dep||groups-32/NNS||treatment-39/NN	conj_and||control-33/NN||treatment-39/NN	asthmatic-35||budesonide-38||no||to investigate the effect of budesonide on substance p (nk-1) receptor (nk-1r) expression in the lung and asmcs, 45 wistar rats were randomly divided into three groups control, asthmatic, and budesonide treatment.
det||sites-2/NNS||the-1/DT	nsubj||showed-45/VBD||sites-2/NNS	vmod||sites-2/NNS||stratified-3/VBN	prepc_according_to||stratified-3/VBN||to-5/TO	amod||type-8/NN||normal-6/JJ	nn||type-8/NN||tissue-7/NN	pobj||stratified-3/VBN||type-8/NN	amod||fg-12/NN||fibro-glandular-10/JJ	dep||type-8/NN||fg-12/NN	amod||fa-17/NN||fibro-adipose-15/JJ	dep||type-8/NN||fa-17/NN	conj_and||fg-12/NN||fa-17/NN	dep||type-8/NN||adipose-21/NN	conj_and||fg-12/NN||adipose-21/NN	dep||adipose-21/NN||a-23/SYM	nn||type-28/NN||disease-27/NN	pobj||stratified-3/VBN||type-28/NN	conj_or||type-8/NN||type-28/NN	amod||carcinoma-32/NN||invasive-30/JJ	amod||carcinoma-32/NN||ductal-31/JJ	dep||type-8/NN||carcinoma-32/NN	appos||carcinoma-32/NN||idc-34/NN	amod||carcinoma-38/NN||ductal-37/JJ	dep||type-8/NN||carcinoma-38/NN	conj_and||carcinoma-32/NN||carcinoma-38/NN	prep_in||carcinoma-38/NN||situ-40/NN	appos||situ-40/NN||dcis-42/NNS	root||ROOT-0/null||showed-45/VBD	mark||exhibited-48/VBD||that-46/IN	nsubj||exhibited-48/VBD||fg-47/NN	ccomp||showed-45/VBD||exhibited-48/VBD	amod||s-53/NN||increased-49/JJ	nn||s-53/NN||<-50/NN	nn||s-53/NN||î-51/NN	num||s-53/NN||1/4-52/CD	nsubj||showed-58/VBD||s-53/NN	amod||s-53/NN||>-55/JJ	amod||s-53/NN||a-57/DT	conj_and||>-55/JJ||a-57/DT	ccomp||exhibited-48/VBD||showed-58/VBD	amod||²-62/NN||increased-59/VBN	amod||²-62/NN||-LSB--60/JJ	nn||²-62/NN||î-61/NN	dobj||showed-58/VBD||²-62/NN	amod||-RSB--65/NNS||carotene-64/JJ	dep||²-62/NN||-RSB--65/NNS	amod||tissues-68/NNS||normal-67/JJ	prep_within||-RSB--65/NNS||tissues-68/NNS	carotene-64||carcinoma-38||no_rel||the sites stratified according to normal tissue type (fibro-glandular (fg), fibro-adipose (fa), and adipose (a)) or disease type (invasive ductal carcinoma (idc) and ductal carcinoma in situ (dcis)) showed that fg exhibited increased < î¼s' > and a showed increased [î²-carotene] within normal tissues.
det||study-4/NN||this-1/DT	dep||vitro-3/NN||in-2/IN	amod||study-4/NN||vitro-3/NN	nsubjpass||carried-6/VBN||study-4/NN	nsubj||determine-9/VB||study-4/NN	auxpass||carried-6/VBN||was-5/VBD	root||ROOT-0/null||carried-6/VBN	prt||carried-6/VBN||out-7/RP	aux||determine-9/VB||to-8/TO	xcomp||carried-6/VBN||determine-9/VB	det||activity-12/NN||the-10/DT	amod||activity-12/NN||antimicrobial-11/JJ	dobj||determine-9/VB||activity-12/NN	num||toothpastes-16/NNS||ten-14/CD	amod||toothpastes-16/NNS||iranian-made-15/JJ	prep_of||activity-12/NN||toothpastes-16/NNS	advmod||found-19/VBN||commonly-18/RB	amod||bacteria-20/NNS||found-19/VBN	prep_against||determine-9/VB||bacteria-20/NNS	det||cavity-24/NN||the-22/DT	amod||cavity-24/NN||oral-23/JJ	prep_in||bacteria-20/NNS||cavity-24/NN	cavity-24||bacteria-20||no||this in vitro study was carried out to determine the antimicrobial activity of ten iranian-made toothpastes against commonly found bacteria in the oral cavity.
advmod||frequent-10/JJ||however-1/RB	det||â-4/NN||the-3/DT	poss||variant-7/NN||â-4/NN	amod||variant-7/NN||336a-6/JJ	nsubj||frequent-10/JJ||variant-7/NN	cop||frequent-10/JJ||was-8/VBD	advmod||frequent-10/JJ||more-9/RBR	root||ROOT-0/null||frequent-10/JJ	amod||patients-13/NNS||htlv-1-infected-12/JJ	prep_in||frequent-10/JJ||patients-13/NNS	amod||tropicalspasticparaparesis-17/NNS||-LSB--14/JJ	amod||tropicalspasticparaparesis-17/NNS||htlv-1-associatedmyelopathy-15/JJ	amod||tropicalspasticparaparesis-17/NNS||/-16/JJ	dep||patients-13/NNS||tropicalspasticparaparesis-17/NNS	appos||tropicalspasticparaparesis-17/NNS||ham/tsp-19/NN	quantmod||$-23/$||80â-22/RB	num||%-25/NN||$-23/$	num||$-23/$||-24/CD	appos||tropicalspasticparaparesis-17/NNS||%-25/NN	amod||asymptomatic-28/JJ||healthy-27/JJ	amod||carriers-30/NNS||asymptomatic-28/JJ	amod||carriers-30/NNS||htlv-1-29/JJ	appos||tropicalspasticparaparesis-17/NNS||carriers-30/NNS	amod||-RSB--36/NNS||90â-32/JJ	dep||%-35/NN||$-33/$	num||$-33/$||-34/CD	amod||-RSB--36/NNS||%-35/NN	appos||tropicalspasticparaparesis-17/NNS||-RSB--36/NNS	mark||70â-43/NNS||than-37/IN	det||group-41/NN||the-39/DT	nn||group-41/NN||control-40/NN	prep_in||70â-43/NNS||group-41/NN	dep||-RSB--36/NNS||70â-43/NNS	dep||%-46/NN||$-44/$	num||$-44/$||-45/CD	amod||70â-43/NNS||%-46/NN	dep||70â-43/NNS||-LSB--48/FW	dep||70â-43/NNS||p-49/NN	dep||0.0197-51/CD||=-50/SYM	rcmod||p-49/NN||0.0197-51/CD	nn||ratio-54/NN||odds-53/NNS	appos||tropicalspasticparaparesis-17/NNS||ratio-54/NN	cc||=-58/NNP||or-56/CC	dep||ratio-54/NN||=-58/NNP	num||=-58/NNP||2.511-59/CD	num||=-58/NNP||95â-61/CD	dep||%-64/NN||$-62/$	num||$-62/$||-63/CD	amod||interval-66/NN||%-64/NN	nn||interval-66/NN||confidence-65/NN	nsubj||=-70/VBZ||interval-66/NN	discourse||interval-66/NN||ci-68/UH	rcmod||=-58/NNP||=-70/VBZ	num||â-72/NNS||1.218-71/CD	dobj||=-70/VBZ||â-72/NNS	num||â-72/NNS||$-73/$	num||$-73/$||5.179-75/CD	ham--1||htlv-1-29||no||however, the â336a variant was more frequent in htlv-1-infected patients [htlv-1-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp), 80â%; healthy asymptomatic htlv-1 carriers, 90â%] than in the control group (70â%) [ p =0.0197, odds ratio (or)=2.511, 95â% confidence interval (ci)=1.218â5.179).
nsubj||show-3/VBP||we-1/PRP	advmod||show-3/VBP||now-2/RB	root||ROOT-0/null||show-3/VBP	det||treatment-5/NN||that-4/DT	dobj||show-3/VBP||treatment-5/NN	amod||mice-8/NNS||tumor-bearing-7/JJ	prep_of||treatment-5/NN||mice-8/NNS	amod||cd40-24/NNS||il-2-10/JJ	punct||±-13/NNP||/-11/:	nn||±-13/NNP||î-12/NNP	dep||cd40-24/NNS||±-13/NNP	amod||cd40-24/NNS||cd40-15/JJ	neg||il-2-19/JJ||not-18/RB	dep||cd40-24/NNS||il-2-19/JJ	advmod||±-22/JJ||î-21/RB	conj_or||il-2-19/JJ||±-22/JJ	dep||cd40-24/NNS||±-22/JJ	prep_with||treatment-5/NN||cd40-24/NNS	vmod||treatment-5/NN||induced-26/VBN	amod||synthase-29/NN||significant-27/JJ	nn||synthase-29/NN||nitricoxide-28/NN	nsubj||expression-34/NN||synthase-29/NN	appos||synthase-29/NN||nos-31/NN	num||expression-34/NN||2-33/CD	xcomp||induced-26/VBN||expression-34/NN	amod||macrophages-37/NNS||tumor-associated-36/JJ	prep_in||expression-34/NN||macrophages-37/NNS	il-2-19||tumor--1||no_rel||we now show that treatment of tumor-bearing mice with il-2/î±-cd40, but not il-2 or î±-cd40, induced significant nitricoxide synthase (nos) 2 expression in tumor-associated macrophages.
nn||samples-2/NNS||tumor-1/NN	nsubjpass||obtained-13/VBN||samples-2/NNS	amod||data-5/NNS||clinical-4/JJ	conj_and||samples-2/NNS||data-5/NNS	nsubjpass||obtained-13/VBN||data-5/NNS	num||patients-8/NNS||249-7/CD	prep_from||data-5/NNS||patients-8/NNS	amod||sts-11/NN||non-gist-10/JJ	prep_with||patients-8/NNS||sts-11/NN	auxpass||obtained-13/VBN||were-12/VBD	root||ROOT-0/null||obtained-13/VBN	nn||microarrays-17/NNS||tissue-16/NN	nsubjpass||constructed-22/VBN||microarrays-17/NNS	appos||microarrays-17/NNS||tmas-19/NNS	auxpass||constructed-22/VBN||were-21/VBD	conj_and||obtained-13/VBN||constructed-22/VBN	det||specimen-25/NN||each-24/DT	prep_for||constructed-22/VBN||specimen-25/NN	tumor-1||sts-11||no||tumor samples and clinical data from 249 patients with non-gist sts were obtained, and tissue microarrays (tmas) were constructed for each specimen.
det||absence-3/NN||the-2/DT	prep_in||exhibit-11/VB||absence-3/NN	amod||insulin-6/NN||exogenous-5/JJ	prep_of||absence-3/NN||insulin-6/NN	nsubj||exhibit-11/VB||patients-8/NNS	prep_with||patients-8/NNS||type1diabetes-10/CD	root||ROOT-0/null||exhibit-11/VB	det||variety-13/NN||a-12/DT	nsubj||due-28/JJ||variety-13/NN	amod||abnormalities-16/NNS||metabolic-15/JJ	prep_of||variety-13/NN||abnormalities-16/NNS	prep_including||abnormalities-16/NNS||hyperglycemia-18/NN	prep_including||abnormalities-16/NNS||glycosurea-20/NN	conj_and||hyperglycemia-18/NN||glycosurea-20/NN	amod||ketogenesis-23/NNS||accelerated-22/JJ	prep_including||abnormalities-16/NNS||ketogenesis-23/NNS	conj_and||hyperglycemia-18/NN||ketogenesis-23/NNS	nn||wasting-27/NN||muscle-26/NN	prep_including||abnormalities-16/NNS||wasting-27/NN	conj_and||hyperglycemia-18/NN||wasting-27/NN	xcomp||exhibit-11/VB||due-28/JJ	amod||proteolysis-31/NNS||increased-30/VBN	prep_to||due-28/JJ||proteolysis-31/NNS	type1diabetes-10||insulin-6||yes||in the absence of exogenous insulin, patients with type1diabetes exhibit a variety of metabolic abnormalities including hyperglycemia, glycosurea, accelerated ketogenesis, and muscle wasting due to increased proteolysis.
det||aim-3/NN||the-1/DT	amod||aim-3/NN||main-2/JJ	nsubj||was-7/VBD||aim-3/NN	nsubj||evaluate-9/VB||aim-3/NN	det||study-6/NN||this-5/DT	prep_of||aim-3/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||evaluate-9/VB||to-8/TO	xcomp||was-7/VBD||evaluate-9/VB	det||expression-11/NN||the-10/DT	dobj||evaluate-9/VB||expression-11/NN	amod||mirnas-14/NNS||several-13/JJ	prep_of||expression-11/NN||mirnas-14/NNS	dep||mirnas-14/NNS||mir-1-16/JJ	amod||mir-296-24/JJ||mir-30-18/JJ	amod||mir-296-24/JJ||mir-128-20/JJ	amod||mir-296-24/JJ||mir-196-22/JJ	amod||mirnas-14/NNS||mir-296-24/JJ	amod||cells-30/NNS||peripheral-27/JJ	nn||cells-30/NNS||blood-28/NN	nn||cells-30/NNS||mononuclear-29/NN	prep_in||mirnas-14/NNS||cells-30/NNS	dep||expression-11/NN||pbmcs-32/VBZ	amod||individuals-36/NNS||healthy-35/JJ	conj_and||individuals-36/NNS||individuals-36/NNS	conj_and||individuals-36/NNS||individuals-36/NNS	prep_from||alpha-62/NN||individuals-36/NNS	prep_from||alpha-62/NN||individuals-36/NNS	prep_from||alpha-62/NN||individuals-36/NNS	dep||vitro-39/NN||in-38/IN	amod||ifn-treatment-40/NN||vitro-39/NN	prep_after||individuals-36/NNS||ifn-treatment-40/NN	cc||individuals-36/NNS||and-41/CC	prep_in||individuals-36/NNS||pbmcs-43/NNS	prep_from||pbmcs-43/NNS||patients-45/NNS	amod||chc-49/NN||chronichepatitisc-47/JJ	prep_with||patients-45/NNS||chc-49/NN	advmod||chc-49/NN||before-51/IN	num||hours-54/NNS||12-53/CD	npadvmod||individuals-36/NNS||hours-54/NNS	det||injection-58/NN||the-56/DT	amod||injection-58/NN||first-57/JJ	prep_after||individuals-36/NNS||injection-58/NN	amod||ifn-61/NN||pegylated-60/JJ	prep_of||injection-58/NN||ifn-61/NN	amod||expression-11/NN||alpha-62/NN	chronichepatitisc-47||ifn-61||yes||the main aim of this study was to evaluate the expression of several mirnas (mir-1, mir-30, mir-128, mir-196, mir-296) in peripheral blood mononuclear cells (pbmcs) from healthy individuals after in vitro ifn-treatment and in pbmcs from patients with chronichepatitisc (chc) before and 12 hours after the first injection of pegylated ifn alpha.
advmod||assessing-2/VBG||when-1/WRB	advcl||predominated-17/VBD||assessing-2/VBG	amod||profiles-4/NNS||cytokine-3/JJ	dobj||assessing-2/VBG||profiles-4/NNS	amod||cells-10/NNS||ppd-6/JJ	amod||cells-10/NNS||specific-7/JJ	amod||cells-10/NNS||cd4-8/JJ	nn||cells-10/NNS||t-9/NN	nsubj||predominated-17/VBD||cells-10/NNS	vmod||cells-10/NNS||secreting-11/VBG	preconj||³-14/JJ||both-12/DT	amod||³-14/JJ||ifn-î-13/JJ	dobj||secreting-11/VBG||³-14/JJ	dobj||secreting-11/VBG||il-2-16/JJ	conj_and||³-14/JJ||il-2-16/JJ	root||ROOT-0/null||predominated-17/VBD	prepc_in||predominated-17/VBD||treated-19/VBN	dobj||treated-19/VBN||tb-20/NN	nn||infection-23/NN||latent-22/NN	dobj||treated-19/VBN||infection-23/NN	conj_and||tb-20/NN||infection-23/NN	dobj||treated-19/VBN||bcg-vaccination-25/NN	conj_and||tb-20/NN||bcg-vaccination-25/NN	mark||shifted-35/VBN||whilst-27/IN	amod||tb-30/NN||active-29/JJ	prep_in||shifted-35/VBN||tb-30/NN	det||profile-33/NN||the-31/DT	amod||profile-33/NN||cytokine-32/JJ	nsubjpass||shifted-35/VBN||profile-33/NN	auxpass||shifted-35/VBN||was-34/VBD	dep||treated-19/VBN||shifted-35/VBN	prep_towards||shifted-35/VBN||cells-37/NNS	xcomp||shifted-35/VBN||secreting-38/VBG	amod||³-40/NNS||ifn-î-39/JJ	dobj||secreting-38/VBG||³-40/NNS	advmod||secreting-38/VBG||only-41/RB	dep||secreting-38/VBG||p-43/NNP	number||0.0001-45/CD||<-44/CD	num||p-43/NNP||0.0001-45/CD	tb-30||bcg--1||yes||when assessing cytokine profiles, ppd specific cd4 t cells secreting both ifn-î³ and il-2 predominated in treated tb, latent infection and bcg-vaccination, whilst in active tb the cytokine profile was shifted towards cells secreting ifn-î³ only (p<0.0001).
nsubj||studied-2/VBD||we-1/PRP	root||ROOT-0/null||studied-2/VBD	num||recipients-5/NNS||124-3/CD	nn||recipients-5/NNS||rifampicin-4/NN	dobj||studied-2/VBD||recipients-5/NNS	amod||coinfection-11/NN||concurrent-7/JJ	amod||coinfection-11/NN||hiv-1-8/JJ	amod||coinfection-11/NN||/-9/JJ	nn||coinfection-11/NN||tb-10/NN	prep_with||studied-2/VBD||coinfection-11/NN	vmod||studied-2/VBD||receiving-13/VBG	dobj||receiving-13/VBG||efavirenz-14/NN	num||mg/day-17/NN||600-16/CD	appos||efavirenz-14/NN||mg/day-17/NN	dep||efavirenz-14/NN||n-20/VBN	dep||65-22/CD||=-21/SYM	ccomp||n-20/VBN||65-22/CD	dobj||receiving-13/VBG||nevirapine-25/NN	conj_or||efavirenz-14/NN||nevirapine-25/NN	num||mg/day-28/NN||400-27/CD	appos||nevirapine-25/NN||mg/day-28/NN	dep||nevirapine-25/NN||n-31/VBN	dep||59-33/CD||=-32/SYM	ccomp||n-31/VBN||59-33/CD	vmod||nevirapine-25/NN||based-35/VBN	amod||therapy-37/NN||antiretroviral-36/JJ	dobj||based-35/VBN||therapy-37/NN	appos||nevirapine-25/NN||art-39/NN	tb-10||rifampicin-4||yes||we studied 124 rifampicin recipients with concurrent hiv-1/tb coinfection, receiving efavirenz (600 mg/day) (n = 65) or nevirapine (400 mg/day) (n = 59) based antiretroviral therapy (art).
nsubj||play-2/VBP||families-1/NNS	root||ROOT-0/null||play-2/VBP	amod||roles-4/NNS||central-3/JJ	dobj||play-2/VBP||roles-4/NNS	det||pandemic-8/NN||the-6/DT	amod||pandemic-8/NN||hiv/aids-7/JJ	prep_in||roles-4/NNS||pandemic-8/NN	vmod||play-2/VBP||caring-10/VBG	det||children-14/NNS||both-12/DT	amod||children-14/NNS||orphaned-13/VBN	prep_for||caring-10/VBG||children-14/NNS	det||ill-17/JJ||the-16/DT	prep_for||caring-10/VBG||ill-17/JJ	conj_and||children-14/NNS||ill-17/JJ	aids--1||hiv--1||no||families play central roles in the hiv/aids pandemic, caring for both orphaned children and the ill.
amod||disorders-2/NNS||cognitive-1/JJ	nsubj||emerging-16/VBG||disorders-2/NNS	prep_such_as||disorders-2/NNS||amnesia-5/NN	nn||deficit-8/NN||attention-7/NN	prep_such_as||disorders-2/NNS||deficit-8/NN	conj_and||amnesia-5/NN||deficit-8/NN	prep_such_as||disorders-2/NNS||alzheimerâ-10/NNP	conj_and||amnesia-5/NN||alzheimerâ-10/NNP	num||disease-14/NN||$-11/$	number||s-13/CD||-12/CD	num||$-11/$||s-13/CD	dep||alzheimerâ-10/NNP||disease-14/NN	aux||emerging-16/VBG||are-15/VBP	root||ROOT-0/null||emerging-16/VBG	dobj||emerging-16/VBG||nightmares-17/NNS	det||field-20/NN||the-19/DT	prep_in||nightmares-17/NNS||field-20/NN	prep_of||field-20/NN||medicine-22/NN	mark||exists-27/VBZ||because-23/IN	neg||cure-26/NN||no-24/DT	amod||cure-26/NN||exact-25/JJ	nsubj||exists-27/VBZ||cure-26/NN	advcl||emerging-16/VBG||exists-27/VBZ	prep_for||exists-27/VBZ||them-29/PRP	mark||have-42/VBP||as-31/IN	amod||agents-34/NNS||existing-32/JJ	amod||agents-34/NNS||nootropic-33/JJ	nsubj||have-42/VBP||agents-34/NNS	nn||metrifonate-40/NN||piractam-36/NN	dep||metrifonate-40/NN||tacrine-38/NN	appos||agents-34/NNS||metrifonate-40/NN	advcl||exists-27/VBZ||have-42/VBP	amod||limitations-44/NNS||several-43/JJ	dobj||have-42/VBP||limitations-44/NNS	alzheimer--1||tacrine-38||yes||cognitive disorders such as amnesia, attention deficit and alzheimerâs disease are emerging nightmares in the field of medicine because no exact cure exists for them, as existing nootropic agents (piractam, tacrine, metrifonate) have several limitations.
nsubj||continues-2/VBZ||oxacillin-1/NN	nsubj||agent-7/NN||oxacillin-1/NN	root||ROOT-0/null||continues-2/VBZ	aux||agent-7/NN||to-3/TO	cop||agent-7/NN||be-4/VB	det||agent-7/NN||an-5/DT	amod||agent-7/NN||important-6/JJ	xcomp||continues-2/VBZ||agent-7/NN	det||treatment-10/NN||the-9/DT	prep_in||agent-7/NN||treatment-10/NN	prep_of||treatment-10/NN||staphylococcalinfections-12/NNS	amod||products-16/NNS||many-14/JJ	amod||products-16/NNS||generic-15/JJ	nsubj||available-18/JJ||products-16/NNS	cop||available-18/JJ||are-17/VBP	parataxis||continues-2/VBZ||available-18/JJ	det||requirement-22/NN||the-20/DT	amod||requirement-22/NN||only-21/JJ	nsubj||demonstration-27/NN||requirement-22/NN	poss||approval-25/NN||their-24/PRP$	prep_for||requirement-22/NN||approval-25/NN	cop||demonstration-27/NN||is-26/VBZ	parataxis||continues-2/VBZ||demonstration-27/NN	conj_and||available-18/JJ||demonstration-27/NN	amod||equivalence-30/NNS||pharmaceutical-29/JJ	prep_of||demonstration-27/NN||equivalence-30/NNS	staphylococcalinfections-12||oxacillin-1||yes||oxacillin continues to be an important agent in the treatment of staphylococcalinfections; many generic products are available and the only requirement for their approval is demonstration of pharmaceutical equivalence.
det||total-2/NN||a-1/DT	root||ROOT-0/null||total-2/NN	prep_of||total-2/NN||220-4/CD	num||%-7/NN||30.1-6/CD	appos||220-4/CD||%-7/NN	vmod||220-4/CD||hbsag-9/VBG	amod||donors-11/NNS||negative-10/JJ	nsubj||antihbc-13/JJ||donors-11/NNS	cop||antihbc-13/JJ||were-12/VBD	ccomp||hbsag-9/VBG||antihbc-13/JJ	amod||total-2/NN||positive-14/JJ	prep_of||total-2/NN||them-17/PRP	nsubjpass||hbv-24/VBN||66-18/CD	num||%-21/NN||30-20/CD	appos||66-18/CD||%-21/NN	auxpass||hbv-24/VBN||were-23/VBD	rcmod||total-2/NN||hbv-24/VBN	advmod||positive-26/JJ||dna-25/RB	acomp||hbv-24/VBN||positive-26/JJ	agent||hbv-24/VBN||nat-28/NN	hbv-24||hbsag-9||yes||a total of 220 (30.1%) hbsag negative donors were antihbc positive, of them 66 (30%) were hbv dna positive by nat.
nn||vaccination-2/NN||bcg-1/NN	nsubj||represents-9/VBZ||vaccination-2/NN	vmod||vaccination-2/NN||combined-4/VBN	amod||boosts-7/NNS||adenoviral-delivered-6/JJ	prep_with||combined-4/VBN||boosts-7/NNS	root||ROOT-0/null||represents-9/VBZ	det||strategy-12/NN||a-10/DT	amod||strategy-12/NN||reasonable-11/JJ	dobj||represents-9/VBZ||strategy-12/NN	aux||augment-14/VB||to-13/TO	vmod||strategy-12/NN||augment-14/VB	vmod||strategy-12/NN||broaden-16/VB	conj_and||augment-14/VB||broaden-16/VB	vmod||strategy-12/NN||prolong-18/VB	conj_and||augment-14/VB||prolong-18/VB	amod||protection-20/NN||immune-19/JJ	dobj||augment-14/VB||protection-20/NN	prep_against||augment-14/VB||tuberculosis-22/NNP	appos||tuberculosis-22/NNP||tb-24/NN	tb-24||bcg-1||no||bcg vaccination, combined with adenoviral-delivered boosts, represents a reasonable strategy to augment, broaden and prolong immune protection against tuberculosis (tb).
advmod||demonstrate-3/VBP||here-1/RB	nsubj||demonstrate-3/VBP||we-2/PRP	root||ROOT-0/null||demonstrate-3/VBP	mark||induces-10/VBZ||that-4/IN	nn||cells-8/NNS||breast-6/NN	nn||cells-8/NNS||cancer-7/NN	prep_in||induces-10/VBZ||cells-8/NNS	nsubj||induces-10/VBZ||paclitaxel-9/NN	ccomp||demonstrate-3/VBP||induces-10/VBZ	det||mechanism-14/NN||a-11/DT	nn||mechanism-14/NN||novel-12/NN	nn||mechanism-14/NN||displacement-13/NN	nsubj||prodeath-15/VBP||mechanism-14/NN	nsubj||commit-36/VBP||mechanism-14/NN	ccomp||induces-10/VBZ||prodeath-15/VBP	amod||proteins-17/NNS||bh3-only-16/JJ	iobj||prodeath-15/VBP||proteins-17/NNS	dobj||prodeath-15/VBP||bmf-18/NN	dobj||prodeath-15/VBP||puma-20/NN	conj_and||bmf-18/NN||puma-20/NN	advmod||bmf-18/NN||competitively-21/RB	dep||prodeath-15/VBP||displace-22/VB	amod||bim-26/NN||prodeath-23/JJ	amod||bim-26/NN||bh3-only-24/JJ	nn||bim-26/NN||protein-25/NN	dobj||displace-22/VB||bim-26/NN	amod||proteins-29/NNS||anti-apoptotic-28/JJ	prep_from||bim-26/NN||proteins-29/NNS	amod||bax-32/NN||activate-31/JJ	prep_to||displace-22/VB||bax-32/NN	prep_to||displace-22/VB||bak-34/NN	conj_and||bax-32/NN||bak-34/NN	ccomp||induces-10/VBZ||commit-36/VBP	conj_and||prodeath-15/VBP||commit-36/VBP	det||cell-38/NN||the-37/DT	dobj||commit-36/VBP||cell-38/NN	amod||death-41/NN||apoptotic-40/JJ	prep_to||commit-36/VBP||death-41/NN	cancer-7||paclitaxel-9||no_rel||here we demonstrate that in breast cancer cells paclitaxel induces a novel displacement mechanism prodeath bh3-only proteins bmf and puma competitively displace prodeath bh3-only protein bim from anti-apoptotic proteins to activate bax and bak and commit the cell to apoptotic death.
nsubj||provide-14/VB||lapatinib-1/NN	prep_in||lapatinib-1/NN||combination-4/NN	prep_with||combination-4/NN||non-chemotherapeuticagents-6/NNS	prep_such_as||combination-4/NN||letrozole-10/NN	aux||provide-14/VB||may-12/MD	advmod||provide-14/VB||also-13/RB	root||ROOT-0/null||provide-14/VB	det||option-18/NN||a-15/DT	amod||option-18/NN||chemotherapy-free-16/JJ	nn||option-18/NN||treatment-17/NN	dobj||provide-14/VB||option-18/NN	amod||patients-21/NNS||postmenopausal-20/JJ	prep_for||option-18/NN||patients-21/NNS	nn||cancer-28/NN||estrogen-23/NN	amod||cancer-28/NN||receptor-positive/erbb2-24/JJ	amod||cancer-28/NN||+-25/JJ	amod||cancer-28/NN||metastatic-26/JJ	nn||cancer-28/NN||breast-27/NN	prep_with||provide-14/VB||cancer-28/NN	cancer-28||chemotherapeuticagents--1||no_rel||lapatinib, in combination with non-chemotherapeuticagents, such as letrozole, may also provide a chemotherapy-free treatment option for postmenopausal patients with estrogen receptor-positive/erbb2+ metastatic breast cancer.
nsubj||î-10/VBP||treatment-1/NN	amod||chc-5/NN||chronichepatitisc-3/JJ	prep_of||treatment-1/NN||chc-5/NN	amod||interferon-9/NN||pegylated-8/JJ	prep_with||chc-5/NN||interferon-9/NN	root||ROOT-0/null||î-10/VBP	dobj||î-10/VBP||±-11/NNP	nn||±-14/NNP||pegifnî-13/NNP	appos||±-11/NNP||±-14/NNP	amod||results-18/NNS||ribavirin-17/JJ	dobj||î-10/VBP||results-18/NNS	conj_and||±-11/NNP||results-18/NNS	det||response-22/NN||a-20/DT	amod||response-22/NN||sustained-21/JJ	prep_in||results-18/NNS||response-22/NN	quantmod||half-25/PDT||approximately-24/RB	prep_in||response-22/NN||half-25/PDT	prep_of||half-25/PDT||patients-27/NNS	chronichepatitisc-3||ribavirin-17||yes||treatment of chronichepatitisc (chc) with pegylated interferon î± (pegifnî±) and ribavirin results in a sustained response in approximately half of patients.
prep||recommend-9/VBP||given-1/VBN	det||results-3/NNS||the-2/DT	pobj||given-1/VBN||results-3/NNS	det||study-6/NN||this-5/DT	prep_from||results-3/NNS||study-6/NN	nsubj||recommend-9/VBP||we-8/PRP	root||ROOT-0/null||recommend-9/VBP	dep||vct-14/VBP||1-11/LS	nsubj||vct-14/VBP||making-13/NN	dep||recommend-9/VBP||vct-14/VBP	det||part-17/NN||a-15/DT	amod||part-17/NN||routine-16/JJ	dobj||vct-14/VBP||part-17/NN	nn||services-20/NNS||health-19/NN	prep_of||part-17/NN||services-20/NNS	advmod||vct-14/VBP||especially-22/RB	prep_in||vct-14/VBP||areas-24/NNS	advmod||live-29/VBP||where-25/WRB	amod||individuals-28/NNS||many-26/JJ	amod||individuals-28/NNS||high-risk-27/JJ	nsubj||live-29/VBP||individuals-28/NNS	rcmod||areas-24/NNS||live-29/VBP	prep_in||vct-14/VBP||2-32/CD	conj_and||areas-24/NNS||2-32/CD	dep||2-32/CD||improving-34/VBG	det||sources-37/NNS||the-35/DT	nn||sources-37/NNS||information-36/NN	dobj||improving-34/VBG||sources-37/NNS	dep||2-32/CD||increasing-39/VBG	conj_and||improving-34/VBG||increasing-39/VBG	det||understanding-41/NN||the-40/DT	dobj||increasing-39/VBG||understanding-41/NN	nn||individuals-46/NNS||hiv-43/NN	conj_and||hiv-43/NN||hiv-infected-45/JJ	nn||individuals-46/NNS||hiv-infected-45/JJ	prep_of||understanding-41/NN||individuals-46/NNS	dep||collaboration-53/NN||3-49/LS	amod||collaboration-53/NN||enhancing-51/JJ	amod||collaboration-53/NN||international-52/JJ	prep_in||vct-14/VBP||collaboration-53/NN	conj_and||areas-24/NNS||collaboration-53/NN	amod||planning-56/NN||strategic-55/JJ	prep_in||collaboration-53/NN||planning-56/NN	amod||assistance-59/NN||technical-58/JJ	prep_in||vct-14/VBP||assistance-59/NN	conj_and||areas-24/NNS||assistance-59/NN	prep_in||vct-14/VBP||protocols-62/NNS	conj_and||areas-24/NNS||protocols-62/NNS	aux||translate-64/VB||to-63/TO	vmod||protocols-62/NNS||translate-64/VB	dobj||translate-64/VB||policy-65/NN	amod||action-68/NN||effective-67/JJ	prep_into||translate-64/VB||action-68/NN	dep||chinese-74/VBP||4-71/LS	nsubj||chinese-74/VBP||supporting-73/JJ	parataxis||vct-14/VBP||chinese-74/VBP	amod||organizations-76/NNS||non-government-75/JJ	dobj||chinese-74/VBP||organizations-76/NNS	appos||organizations-76/NNS||ngos-78/NNS	prepc_in||chinese-74/VBP||playing-81/VBG	det||role-84/NN||a-82/DT	amod||role-84/NN||significant-83/JJ	dobj||playing-81/VBG||role-84/NN	det||battle-87/NN||the-86/DT	prep_in||playing-81/VBG||battle-87/NN	prep_against||battle-87/NN||aids-89/NNS	aids-89||hiv-43||no||given the results from this study, we recommend (1) making vct a routine part of health services, especially in areas where many high-risk individuals live; (2) improving the information sources and increasing the understanding of hiv and hiv-infected individuals; (3) enhancing international collaboration in strategic planning, technical assistance, and protocols to translate policy into effective action; (4) supporting chinese non-government organizations (ngos) in playing a significant role in the battle against aids.
expl||is-2/VBZ||there-1/EX	root||ROOT-0/null||is-2/VBZ	amod||consensus-4/NN||widespread-3/JJ	nsubj||is-2/VBZ||consensus-4/NN	mark||hamper-9/VB||that-5/IN	amod||systems-8/NNS||weak-6/JJ	nn||systems-8/NNS||health-7/NN	nsubj||hamper-9/VB||systems-8/NNS	ccomp||is-2/VBZ||hamper-9/VB	det||provision-12/NN||the-10/DT	amod||provision-12/NN||effective-11/JJ	dobj||hamper-9/VB||provision-12/NN	amod||services-15/NNS||hiv/aids-14/JJ	prep_of||provision-12/NN||services-15/NNS	aids--1||hiv--1||no||there is widespread consensus that weak health systems hamper the effective provision of hiv/aids services.
nsubjpass||associated-4/VBN||irondeficiency-1/NN	nsubj||statusepilepticus-42/VBZ||irondeficiency-1/NN	auxpass||associated-4/VBN||was-2/VBD	advmod||associated-4/VBN||neither-3/RB	root||ROOT-0/null||associated-4/VBN	det||risk-8/NN||an-6/DT	amod||risk-8/NN||increased-7/VBN	prep_with||associated-4/VBN||risk-8/NN	amod||seizures-11/NNS||acute-10/JJ	prep_of||risk-8/NN||seizures-11/NNS	num||cases-18/NNS||45/133-13/CD	number||33.8-15/CD||-LSB--14/CD	dep||%-16/NN||33.8-15/CD	dep||cases-18/NNS||%-16/NN	nn||cases-18/NNS||-RSB--17/NN	nsubj||deficient-21/NN||cases-18/NNS	cop||deficient-21/NN||were-19/VBD	nn||deficient-21/NN||iron-20/NN	dep||risk-8/NN||deficient-21/NN	prepc_compared_to||deficient-21/NN||to-23/TO	num||â-36/NNS||36/133-24/CD	number||27.1-26/CD||-LSB--25/CD	dep||%-27/NN||27.1-26/CD	dep||â-36/NNS||%-27/NN	amod||â-36/NNS||-RSB--28/JJ	nn||â-36/NNS||controls-29/NNS	dep||â-36/NNS||p-31/NN	nn||â-36/NNS||â-32/NN	num||â-36/NNS||$-33/$	number||=-35/CD||-34/CD	num||$-33/$||=-35/CD	pobj||deficient-21/NN||â-36/NNS	dep||deficient-21/NN||$-37/$	num||$-37/$||0-38/CD	num||$-37/$||.230-39/CD	conj_nor||associated-4/VBN||statusepilepticus-42/VBZ	nsubj||affect-47/VB||it-44/PRP	aux||affect-47/VB||did-45/VBD	neg||affect-47/VB||not-46/RB	conj_and||associated-4/VBN||affect-47/VB	dobj||affect-47/VB||seizure-48/NN	advmod||affect-47/VB||semiology-49/RB	irondeficiency-1||iron-20||yes||irondeficiency was neither associated with an increased risk of acute seizures (45/133[33.8%] cases were iron deficient compared to 36/133[27.1%] controls, p â=â0.230) nor statusepilepticus and it did not affect seizure semiology.
nsubjpass||involved-3/VBN||nk-1r-1/JJ	auxpass||involved-3/VBN||is-2/VBZ	root||ROOT-0/null||involved-3/VBN	det||pathogenesis-6/NNS||the-5/DT	prep_in||involved-3/VBN||pathogenesis-6/NNS	prep_of||pathogenesis-6/NNS||asthma-8/NN	det||budesonide-11/NN||that-10/DT	nsubj||downregulate-13/VB||budesonide-11/NN	aux||downregulate-13/VB||may-12/MD	conj_and||involved-3/VBN||downregulate-13/VB	det||expression-15/NN||the-14/DT	dobj||downregulate-13/VB||expression-15/NN	prep_of||expression-15/NN||nk-1r-17/CD	det||asmcs-20/NNS||the-19/DT	prep_in||downregulate-13/VB||asmcs-20/NNS	prep_in||downregulate-13/VB||airways-22/NNS	conj_and||asmcs-20/NNS||airways-22/NNS	amod||rats-25/NNS||asthmatic-24/JJ	prep_of||asmcs-20/NNS||rats-25/NNS	nsubj||alleviate-29/VB||rats-25/NNS	aux||alleviate-29/VB||may-28/MD	rcmod||rats-25/NNS||alleviate-29/VB	amod||inflammation-32/NN||neurogenic-30/JJ	nn||inflammation-32/NN||airway-31/NN	dobj||alleviate-29/VB||inflammation-32/NN	asthma-8||budesonide-11||yes||nk-1r is involved in the pathogenesis of asthma and that budesonide may downregulate the expression of nk-1r in the asmcs and airways of asthmatic rats, which may alleviate neurogenic airway inflammation.
aux||identify-2/VB||to-1/TO	dep||meet-8/VBP||identify-2/VB	conj_and||identify-2/VB||implement-4/VB	dep||meet-8/VBP||implement-4/VB	dobj||identify-2/VB||strategies-5/NNS	det||help-7/NN||that-6/DT	nsubj||meet-8/VBP||help-7/NN	root||ROOT-0/null||meet-8/VBP	nn||requirements-11/NNS||safety-9/NN	nn||requirements-11/NNS||monitoring-10/NN	dobj||meet-8/VBP||requirements-11/NNS	det||context-14/NN||the-13/DT	prep_in||requirements-11/NNS||context-14/NN	det||study-18/NN||an-16/DT	amod||study-18/NN||observational-17/JJ	prep_of||context-14/NN||study-18/NN	amod||treatment-27/NN||artemether-lumefantrine-20/JJ	appos||treatment-27/NN||al-22/NNP	amod||treatment-27/NN||administered-24/VBN	prep_as||administered-24/VBN||first-line-26/NN	prep_for||meet-8/VBP||treatment-27/NN	amod||malaria-30/NN||uncomplicated-29/JJ	prep_for||treatment-27/NN||malaria-30/NN	amod||tanzania-33/NN||rural-32/JJ	prep_in||malaria-30/NN||tanzania-33/NN	malaria-30||artemether--1||yes||to identify and implement strategies that help meet safety monitoring requirements in the context of an observational study for artemether-lumefantrine (al) administered as first-line treatment for uncomplicated malaria in rural tanzania.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||significance-5/NN||the-3/DT	amod||significance-5/NN||clinical-4/JJ	dobj||investigated-2/VBD||significance-5/NN	amod||immunoglobulin-9/NN||serum-7/JJ	amod||immunoglobulin-9/NN||specific-8/JJ	prep_of||significance-5/NN||immunoglobulin-9/NN	dep||significance-5/NN||e-10/SYM	appos||significance-5/NN||lge-12/NN	det||enterotoxin-19/NN||the-15/DT	amod||enterotoxin-19/NN||staphylococcal-16/JJ	nn||enterotoxin-19/NN||superantigens-17/NNS	nn||enterotoxin-19/NN||staphylococcal-18/NN	prep_to||investigated-2/VBD||enterotoxin-19/NN	det||sea-22/NN||a-20/DT	dep||enterotoxin-19/NN||sea-22/NN	amod||enterotoxin-26/NN||staphylococcal-25/JJ	prep_to||investigated-2/VBD||enterotoxin-26/NN	conj_and||enterotoxin-19/NN||enterotoxin-26/NN	dep||enterotoxin-26/NN||b-27/SYM	appos||b-27/SYM||seb-29/NN	amod||toxin-34/NN||toxicshocksyndrome-33/JJ	prep_to||investigated-2/VBD||toxin-34/NN	conj_and||enterotoxin-19/NN||toxin-34/NN	appos||toxin-34/NN||tsst-36/NN	dep||toxin-34/NN||-1-38/CD	prep_in||investigated-2/VBD||patients-40/NNS	amod||urticaria-43/NN||chronic-42/JJ	prep_with||patients-40/NNS||urticaria-43/NN	appos||urticaria-43/NN||cu-45/NN	vmod||investigated-2/VBD||focusing-48/VBG	det||differences-51/NNS||the-50/DT	prep_on||focusing-48/VBG||differences-51/NNS	det||prevalences-54/NNS||these-53/DT	prep_in||differences-51/NNS||prevalences-54/NNS	amod||cu-57/NN||aspirin-intolerant-56/JJ	prep_between||prevalences-54/NNS||cu-57/NN	appos||cu-57/NN||aicu-59/NNP	amod||patients-67/NNS||aspirin-tolerant-62/JJ	nn||patients-67/NNS||cu-63/NN	appos||patients-67/NNS||atcu-65/NNP	prep_between||prevalences-54/NNS||patients-67/NNS	conj_and||cu-57/NN||patients-67/NNS	toxin-34||urticaria-43||no_rel||we investigated the clinical significance of serum specific immunoglobulin e (lge) to the staphylococcal superantigens staphylococcal enterotoxin a (sea), staphylococcal enterotoxin b (seb), and toxicshocksyndrome toxin (tsst)-1 in patients with chronic urticaria (cu), focusing on the differences in these prevalences between aspirin-intolerant cu (aicu) and aspirin-tolerant cu (atcu) patients.
nsubjpass||demonstrated-3/VBN||it-1/PRP	auxpass||demonstrated-3/VBN||was-2/VBD	root||ROOT-0/null||demonstrated-3/VBN	mark||effective-10/JJ||that-4/IN	amod||extract-8/NNS||persian-5/JJ	amod||extract-8/NNS||shallot-6/JJ	amod||extract-8/NNS||hydromethanolic-7/JJ	nsubj||effective-10/JJ||extract-8/NNS	cop||effective-10/JJ||was-9/VBD	ccomp||demonstrated-3/VBN||effective-10/JJ	num||species-14/NNS||10-12/CD	amod||species-14/NNS||different-13/JJ	prep_against||effective-10/JJ||species-14/NNS	amod||bacteria-17/NNS||pathogenic-16/JJ	prep_of||species-14/NNS||bacteria-17/NNS	prep_including||bacteria-17/NNS||methicillinresistantstaphylococcusaureus-19/NNS	appos||methicillinresistantstaphylococcusaureus-19/NNS||mrsa-21/NNP	amod||staphylococcusaureus-26/NNS||methicillin-24/JJ	amod||staphylococcusaureus-26/NNS||sensitive-25/JJ	appos||methicillinresistantstaphylococcusaureus-19/NNS||staphylococcusaureus-26/NNS	appos||staphylococcusaureus-26/NNS||mssa-28/NNP	appos||methicillinresistantstaphylococcusaureus-19/NNS||staphylococcusaureus-31/NNS	nn||epidermidis-34/NNS||staphylococcus-33/NN	appos||methicillinresistantstaphylococcusaureus-19/NNS||epidermidis-34/NNS	conj_and||staphylococcusaureus-31/NNS||epidermidis-34/NNS	appos||methicillinresistantstaphylococcusaureus-19/NNS||streptococcuspneumoniae-36/NN	conj_and||staphylococcusaureus-31/NNS||streptococcuspneumoniae-36/NN	appos||methicillinresistantstaphylococcusaureus-19/NNS||escherichiacoli-38/NNS	conj_and||staphylococcusaureus-31/NNS||escherichiacoli-38/NNS	amod||o157h7-41/NNS||escherichiacoli-40/JJ	appos||methicillinresistantstaphylococcusaureus-19/NNS||o157h7-41/NNS	conj_and||staphylococcusaureus-31/NNS||o157h7-41/NNS	appos||methicillinresistantstaphylococcusaureus-19/NNS||salmonellatyphimurium-43/NN	conj_and||staphylococcusaureus-31/NNS||salmonellatyphimurium-43/NN	amod||mirabilis-46/NNS||proteus-45/JJ	appos||methicillinresistantstaphylococcusaureus-19/NNS||mirabilis-46/NNS	conj_and||staphylococcusaureus-31/NNS||mirabilis-46/NNS	nn||pneumoniae-50/NN||klebsiella-49/NN	appos||methicillinresistantstaphylococcusaureus-19/NNS||pneumoniae-50/NN	conj_and||staphylococcusaureus-31/NNS||pneumoniae-50/NN	methicillinresistantstaphylococcusaureus-19||staphylococcusaureus-31||no||it was demonstrated that persian shallot hydromethanolic extract was effective against 10 different species of pathogenic bacteria including methicillinresistantstaphylococcusaureus (mrsa), methicillin sensitive staphylococcusaureus (mssa), staphylococcusaureus , staphylococcus epidermidis , streptococcuspneumoniae , escherichiacoli, escherichiacoli o157h7, salmonellatyphimurium, proteus mirabilis , and klebsiella pneumoniae .
prep_as||included-14/VBD||part-2/NN	det||survey-6/NN||a-4/DT	amod||survey-6/NN||larger-5/JJR	prep_of||part-2/NN||survey-6/NN	vmod||survey-6/NN||assessing-7/VBG	nn||management-9/NN||gp-8/NN	dobj||assessing-7/VBG||management-9/NN	prep_of||management-9/NN||nvaf-11/NN	nsubj||included-14/VBD||we-13/PRP	root||ROOT-0/null||included-14/VBD	dobj||included-14/VBD||questions-15/NNS	aux||explore-17/VB||to-16/TO	vmod||included-14/VBD||explore-17/VB	poss||assessment-21/NN||gps-18/NNP	nn||assessment-21/NN||risk-20/NN	dobj||explore-17/VB||assessment-21/NN	dobj||explore-17/VB||estimates-23/NNS	conj_and||assessment-21/NN||estimates-23/NNS	nn||risk-26/NN||stroke-25/NN	prep_of||estimates-23/NNS||risk-26/NN	poss||perceptions-30/NNS||gps-28/NNP	dobj||explore-17/VB||perceptions-30/NNS	conj_and||assessment-21/NN||perceptions-30/NNS	det||risks-33/NNS||the-32/DT	prep_of||perceptions-30/NNS||risks-33/NNS	prep_of||perceptions-30/NNS||benefits-35/NNS	conj_and||risks-33/NNS||benefits-35/NNS	prep_of||risks-33/NNS||anticoagulation-37/NN	prep_with||anticoagulation-37/NN||warfarin-39/NN	stroke-25||warfarin-39||yes||as part of a larger survey assessing gp management of nvaf, we included questions to explore gps' risk assessment, estimates of stroke risk and gps' perceptions of the risks and benefits of anticoagulation with warfarin.
det||lack-4/NN||the-3/DT	prep_due_to||considered-14/VBN||lack-4/NN	amod||polymorphism-7/NN||cd1b-6/JJ	prep_of||lack-4/NN||polymorphism-7/NN	amod||complexes-11/NNS||m.tuberculosis-9/JJ	amod||complexes-11/NNS||lipid-cd1b-10/JJ	nsubjpass||considered-14/VBN||complexes-11/NNS	aux||considered-14/VBN||could-12/MD	auxpass||considered-14/VBN||be-13/VB	root||ROOT-0/null||considered-14/VBN	amod||markers-18/NNS||universal-16/JJ	nn||markers-18/NNS||tuberculosisinfection-17/NN	prep_as||considered-14/VBN||markers-18/NNS	tuberculosisinfection-17||m.tuberculosis-9||no||due to the lack of cd1b polymorphism , m.tuberculosis lipid-cd1b complexes could be considered as universal tuberculosisinfection markers .
advmod||report-3/VBP||here-1/RB	nsubj||report-3/VBP||we-2/PRP	root||ROOT-0/null||report-3/VBP	det||discovery-5/NN||the-4/DT	dobj||report-3/VBP||discovery-5/NN	num||rnas-10/NNS||34-7/CD	amod||rnas-10/NNS||novel-8/JJ	amod||rnas-10/NNS||small-9/JJ	prep_of||discovery-5/NN||rnas-10/NNS	num||srnas-12/NNS||-lrb--11/CD	npadvmod||-rrb--13/JJ||srnas-12/NNS	amod||rnas-10/NNS||-rrb--13/JJ	det||bcg-19/NN||the-15/DT	amod||bcg-19/NN||tb-complex-16/JJ	nn||bcg-19/NN||m.-17/NN	nn||bcg-19/NN||bovis-18/NNS	prep_in||rnas-10/NNS||bcg-19/NN	vmod||rnas-10/NNS||using-21/VBG	det||combination-23/NN||a-22/DT	dobj||using-21/VBG||combination-23/NN	amod||approaches-28/NNS||experimental-25/JJ	conj_and||experimental-25/JJ||computational-27/JJ	amod||approaches-28/NNS||computational-27/JJ	prep_of||rnas-10/NNS||approaches-28/NNS	tb--1||bcg-19||no||here we report the discovery of 34 novel small rnas -lrb- srnas -rrb- in the tb-complex m. bovis bcg , using a combination of experimental and computational approaches .
prepc_according_to||+-11/VBD||to-2/TO	det||sensitivity-5/NN||the-3/DT	amod||sensitivity-5/NN||different-4/JJ	pobj||+-11/VBD||sensitivity-5/NN	poss||bone-8/NN||their-7/PRP$	prep_of||sensitivity-5/NN||bone-8/NN	nn||cd34-10/NNS||marrow-9/NN	nsubj||+-11/VBD||cd34-10/NNS	root||ROOT-0/null||+-11/VBD	dobj||+-11/VBD||cells-12/NNS	dep||vitro-15/NN||in-14/IN	amod||treatment-16/NN||vitro-15/NN	prep_to||+-11/VBD||treatment-16/NN	nn||patients-26/NNS||etoposide-18/NN	conj_or||etoposide-18/NN||mafosfamide-20/NN	nn||patients-26/NNS||mafosfamide-20/NN	dep||patients-26/NNS||acutemyeloidleukaemia-22/NN	nn||patients-26/NNS||aml-24/NN	prep_with||+-11/VBD||patients-26/NNS	amod||remission-30/NN||apparent-28/JJ	amod||remission-30/NN||complete-29/JJ	prep_in||+-11/VBD||remission-30/NN	appos||remission-30/NN||cr-32/NN	amod||induction-36/NN||chemotherapy-35/JJ	nsubjpass||classified-39/VBN||induction-36/NN	aux||classified-39/VBN||may-37/MD	auxpass||classified-39/VBN||be-38/VB	prepc_after||remission-30/NN||classified-39/VBN	num||groups-42/NNS||three-41/CD	prep_into||classified-39/VBN||groups-42/NNS	appos||groups-42/NNS||i-44/NNP	advmod||responsive-47/JJ||normally-46/RB	amod||groups-42/NNS||responsive-47/JJ	appos||chemoresistant-52/NNS||ii-50/NN	dep||groups-42/NNS||chemoresistant-52/NNS	appos||remission-30/NN||iii-55/NN	advmod||chemosensitive-58/JJ||highly-57/RB	amod||remission-30/NN||chemosensitive-58/JJ	aml-24||etoposide-18||yes||according to the different sensitivity of their bone marrow cd34+ cells to in vitro treatment with etoposide or mafosfamide, acutemyeloidleukaemia (aml) patients in apparent complete remission (cr) after chemotherapy induction may be classified into three groups (i) normally responsive; (ii) chemoresistant; (iii) highly chemosensitive.
amod||toxicity-2/NN||therapy-related-1/JJ	nsubj||comparable-4/JJ||toxicity-2/NN	nsubj||thalidomide-6/VB||toxicity-2/NN	nsubj||included-9/VBD||toxicity-2/NN	cop||comparable-4/JJ||was-3/VBD	root||ROOT-0/null||comparable-4/JJ	aux||thalidomide-6/VB||to-5/TO	xcomp||comparable-4/JJ||thalidomide-6/VB	advmod||thalidomide-6/VB||monotherapy-7/RB	conj_and||comparable-4/JJ||included-9/VBD	dobj||included-9/VBD||somnolence-10/NN	num||%-13/NN||26-12/CD	dep||somnolence-10/NN||%-13/NN	number||%-16/NN||95-15/CD	amod||22â-18/NNS||%-16/NN	nn||22â-18/NNS||ci-17/NN	appos||%-13/NN||22â-18/NNS	dep||%-22/NN||$-19/$	num||$-19/$||31-21/CD	amod||22â-18/NNS||%-22/NN	dobj||included-9/VBD||constipation-25/NN	conj_and||somnolence-10/NN||constipation-25/NN	num||%-28/NN||37-27/CD	dep||constipation-25/NN||%-28/NN	number||%-31/NN||95-30/CD	amod||32â-33/NNS||%-31/NN	nn||32â-33/NNS||ci-32/NN	appos||%-28/NN||32â-33/NNS	dep||%-37/NN||$-34/$	num||$-34/$||42-36/CD	amod||32â-33/NNS||%-37/NN	dobj||included-9/VBD||peripheralneuropathy-40/NN	conj_and||somnolence-10/NN||peripheralneuropathy-40/NN	num||%-43/NN||27-42/CD	dep||somnolence-10/NN||%-43/NN	number||%-46/NN||95-45/CD	amod||23â-48/NNS||%-46/NN	nn||23â-48/NNS||ci-47/NN	appos||%-43/NN||23â-48/NNS	dep||%-52/NN||$-49/$	num||$-49/$||32-51/CD	amod||23â-48/NNS||%-52/NN	peripheralneuropathy-40||thalidomide-6||no||therapy-related toxicity was comparable to thalidomide monotherapy and included somnolence (26%, 95% ci 22â31%), constipation (37%, 95% ci 32â42%) and peripheralneuropathy (27%, 95% ci 23â32%).
amod||abnormalities-3/NNS||striking-1/JJ	nn||abnormalities-3/NNS||baep-2/NN	nsubj||include-7/VBP||abnormalities-3/NNS	nsubj||interpeak-16/VBP||abnormalities-3/NNS	nsubj||lowered-21/VBD||abnormalities-3/NNS	nn||patients-6/NNS||cp-5/NN	prep_in||abnormalities-3/NNS||patients-6/NNS	root||ROOT-0/null||include-7/VBP	dobj||include-7/VBP||prolongation-8/NN	amod||latency-11/NN||absolute-10/JJ	prep_of||prolongation-8/NN||latency-11/NN	nn||v-14/NN||wave-13/NN	prep_of||latency-11/NN||v-14/NN	conj_and||include-7/VBP||interpeak-16/VBP	dobj||interpeak-16/VBP||latencies-17/NNS	prep_of||latencies-17/NNS||iii-v-19/NNP	conj_and||include-7/VBP||lowered-21/VBD	amod||ratio-23/NN||i-v-22/JJ	dobj||lowered-21/VBD||ratio-23/NN	i---1||cp-5||no_rel||striking baep abnormalities in cp patients include prolongation of absolute latency of wave v, interpeak latencies of iii-v and lowered i-v ratio.
nsubj||achieved-4/VBD||treatment-1/NN	prep_with||treatment-1/NN||telavancin-3/NN	root||ROOT-0/null||achieved-4/VBD	amod||rates-7/NNS||higher-5/JJR	nn||rates-7/NNS||cure-6/NN	dobj||achieved-4/VBD||rates-7/NNS	prep_in||achieved-4/VBD||patients-9/NNS	amod||infection-13/NN||monomicrobial-11/JJ	nn||infection-13/NN||s.aureus-12/NNS	prep_with||patients-9/NNS||infection-13/NN	amod||rates-17/NNS||comparable-15/JJ	nn||rates-17/NNS||cure-16/NN	prep_with||patients-9/NNS||rates-17/NNS	conj_and||infection-13/NN||rates-17/NNS	prep_in||achieved-4/VBD||patients-19/NNS	prep_with||patients-19/NNS||mrsainfection-21/NN	prep_in||higher-33/JJR||patients-24/NNS	amod||infections-28/NNS||mixed-26/JJ	amod||infections-28/NNS||gram-positive/gram-negative-27/JJ	prep_with||patients-24/NNS||infections-28/NNS	nn||rates-31/NNS||cure-30/NN	nsubj||higher-33/JJR||rates-31/NNS	cop||higher-33/JJR||were-32/VBD	parataxis||achieved-4/VBD||higher-33/JJR	det||group-37/NN||the-35/DT	nn||group-37/NN||vancomycin-36/NN	prep_in||higher-33/JJR||group-37/NN	mrsainfection-21||s.aureus-12||no||treatment with telavancin achieved higher cure rates in patients with monomicrobial s.aureus infection and comparable cure rates in patients with mrsainfection ; in patients with mixed gram-positive/gram-negative infections , cure rates were higher in the vancomycin group .
det||study-3/NN||this-2/DT	prep_in||investigated-6/VBD||study-3/NN	nsubj||investigated-6/VBD||we-5/PRP	root||ROOT-0/null||investigated-6/VBD	det||effect-8/NN||the-7/DT	dobj||investigated-6/VBD||effect-8/NN	det||mixture-12/NN||a-10/DT	amod||mixture-12/NN||lidocaine-11/JJ	prep_of||effect-8/NN||mixture-12/NN	prep_on||investigated-6/VBD||pain-14/NN	dep||pain-14/NN||induced-15/VBN	amod||injection-19/NN||microemulsion-17/JJ	amod||injection-19/NN||propofol-18/JJ	prep_by||induced-15/VBN||injection-19/NN	dep||pain-14/NN||sought-22/VBN	conj_and||induced-15/VBN||sought-22/VBN	aux||determine-24/VB||to-23/TO	xcomp||sought-22/VBN||determine-24/VB	det||dose-27/NN||the-25/DT	amod||dose-27/NN||optimal-26/JJ	dobj||determine-24/VB||dose-27/NN	nsubj||reduce-32/VB||dose-27/NN	prep_of||dose-27/NN||lidocaine-29/NN	aux||reduce-32/VB||could-31/MD	rcmod||dose-27/NN||reduce-32/VB	dobj||reduce-32/VB||pain-33/NN	prepc_on||reduce-32/VB||injecting-35/VBG	det||mixture-38/NN||a-36/DT	amod||mixture-38/NN||propofol-lidocaine-37/JJ	dobj||injecting-35/VBG||mixture-38/NN	pain-33||lidocaine-29||yes||in this study, we investigated the effect of a lidocaine mixture on pain induced by microemulsion propofol injection, and sought to determine the optimal dose of lidocaine that could reduce pain on injecting a propofol-lidocaine mixture.
prep_in||improved-9/VBD||type1diabetes-2/CD	det||therapy-6/NN||the-4/DT	amod||therapy-6/NN||combined-5/VBN	nsubj||improved-9/VBD||therapy-6/NN	nsubj||decreased-15/VBD||therapy-6/NN	advmod||improved-9/VBD||only-7/RB	advmod||improved-9/VBD||temporarily-8/RB	root||ROOT-0/null||improved-9/VBD	amod||control-11/NN||metabolic-10/JJ	dobj||improved-9/VBD||control-11/NN	advmod||decreased-15/VBD||significantly-14/RB	conj_but||improved-9/VBD||decreased-15/VBD	nn||weight-17/NN||body-16/NN	dobj||decreased-15/VBD||weight-17/NN	nn||levels-22/NNS||low-density-19/NN	nn||levels-22/NNS||lipoprotein-20/NN	nn||levels-22/NNS||cholesterol-21/NN	dobj||decreased-15/VBD||levels-22/NNS	conj_and||weight-17/NN||levels-22/NNS	nn||requirements-26/NNS||insulin-25/NN	dobj||decreased-15/VBD||requirements-26/NNS	conj_and||weight-17/NN||requirements-26/NNS	type1diabetes-2||insulin-25||yes||in type1diabetes, the combined therapy only temporarily improved metabolic control, but significantly decreased body weight, low-density lipoprotein cholesterol levels, and insulin requirements.
mark||shown-5/VBN||although-1/IN	amod||studies-3/NNS||recent-2/JJ	nsubj||shown-5/VBN||studies-3/NNS	aux||shown-5/VBN||have-4/VBP	advcl||suggest-46/VBP||shown-5/VBN	det||decrease-7/NN||a-6/DT	dobj||shown-5/VBN||decrease-7/NN	amod||hepatitis-10/NN||icteric-9/JJ	prep_in||decrease-7/NN||hepatitis-10/NN	prep_after||shown-5/VBN||administration-12/NN	det||types-15/NNS||both-14/DT	prep_of||administration-12/NN||types-15/NNS	nn||³-18/NNS||î-17/NN	prep_of||types-15/NNS||³-18/NNS	parataxis||shown-5/VBN||globulin-20/NN	prep_in||globulin-20/NN||populations-22/NNS	advmod||result-35/NN||where-23/WRB	nsubj||result-35/NN||acquisition-24/NN	amod||virus-27/NN||hepatitisb-26/JJ	prep_of||acquisition-24/NN||virus-27/NN	appos||virus-27/NN||hbv-29/NN	cop||result-35/NN||is-31/VBZ	advmod||likely-33/JJ||most-32/RBS	amod||result-35/NN||likely-33/JJ	det||result-35/NN||the-34/DT	rcmod||populations-22/NNS||result-35/NN	amod||transmission-38/NN||nonparenteral-37/JJ	prep_of||result-35/NN||transmission-38/NN	det||data-41/NNS||the-40/DT	nsubj||suggest-46/VBP||data-41/NNS	nsubj||decreases-56/VBZ||data-41/NNS	vmod||data-41/NNS||pertaining-42/VBG	aux||parenteral-44/VB||to-43/TO	xcomp||pertaining-42/VBG||parenteral-44/VB	dobj||parenteral-44/VB||exposure-45/NN	root||ROOT-0/null||suggest-46/VBP	mark||hbig-48/VBG||that-47/IN	ccomp||suggest-46/VBP||hbig-48/VBG	dobj||hbig-48/VBG||delays-49/NNS	det||period-52/NN||the-50/DT	nn||period-52/NN||incubation-51/NN	dep||hbig-48/VBG||period-52/NN	prep_of||period-52/NN||hbv-54/NN	conj_and||suggest-46/VBP||decreases-56/VBZ	det||development-58/NN||the-57/DT	dobj||decreases-56/VBZ||development-58/NN	amod||immunity-61/NN||passive-active-60/JJ	prep_of||development-58/NN||immunity-61/NN	hbv-54||hbig-48||yes||although recent studies have shown a decrease in icteric hepatitis after administration of both types of î³-globulin in populations where acquisition of hepatitisb virus (hbv) is most likely the result of nonparenteral transmission, the data pertaining to parenteral exposure suggest that hbig delays the incubation period of hbv and decreases the development of passive-active immunity.
det||patient-2/NN||the-1/DT	nsubjpass||admitted-23/VBN||patient-2/NN	det||woman-5/NN||a-4/DT	appos||patient-2/NN||woman-5/NN	vmod||woman-5/NN||aged-6/VBN	num||years-8/NNS||67-7/CD	dep||aged-6/VBN||years-8/NNS	det||history-12/NN||a-10/DT	amod||history-12/NN||long-11/JJ	prep_with||aged-6/VBN||history-12/NN	prep_of||history-12/NN||rheumatoidarthritis-14/NNS	amod||treatment-17/NN||immunosuppressive-16/JJ	prep_under||rheumatoidarthritis-14/NNS||treatment-17/NN	dep||aged-6/VBN||methotrexate-19/JJ	auxpass||admitted-23/VBN||was-22/VBD	root||ROOT-0/null||admitted-23/VBN	poss||department-26/NN||our-25/PRP$	prep_to||admitted-23/VBN||department-26/NN	vmod||department-26/NN||complaining-27/VBG	advmod||complaining-27/VBG||mostly-28/RB	prep_of||complaining-27/VBG||abdominalpain-30/NN	vmod||abdominalpain-30/NN||located-31/VBN	det||epigastrium-34/NN||the-33/DT	prep_in||located-31/VBN||epigastrium-34/NN	det||abdomen-38/NN||the-36/DT	amod||abdomen-38/NN||right-37/JJ	prep_in||located-31/VBN||abdomen-38/NN	conj_and||epigastrium-34/NN||abdomen-38/NN	rheumatoidarthritis-14||methotrexate-19||yes||the patient, a woman aged 67 years with a long history of rheumatoidarthritis under immunosuppressive treatment (methotrexate), was admitted to our department complaining mostly of abdominalpain located in the epigastrium and the right abdomen.
nsubj||included-2/VBD||these-1/DT	root||ROOT-0/null||included-2/VBD	det||role-4/NN||the-3/DT	dobj||included-2/VBD||role-4/NN	prep_of||role-4/NN||statins-6/NNS	det||agent-10/NN||an-8/DT	amod||agent-10/NN||anti-lipid-9/JJ	appos||statins-6/NNS||agent-10/NN	prepc_in||included-2/VBD||reducing-13/VBG	amod||morbidity-15/NN||post-stroke-14/JJ	dobj||reducing-13/VBG||morbidity-15/NN	dobj||reducing-13/VBG||mortality-17/NN	conj_and||morbidity-15/NN||mortality-17/NN	prepc_in||included-2/VBD||decreasing-20/VBG	conj_and||reducing-13/VBG||decreasing-20/VBG	det||plaque-24/NN||the-21/DT	amod||plaque-24/NN||carotid-22/JJ	amod||plaque-24/NN||atherosclerotic-23/JJ	dobj||decreasing-20/VBG||plaque-24/NN	prep_in||plaque-24/NN||middle-26/NN	vmod||middle-26/NN||aged-27/VBN	dobj||aged-27/VBN||patients-28/NNS	amod||risk-31/NN||increased-30/VBN	prep_at||aged-27/VBN||risk-31/NN	prep_of||risk-31/NN||cardiovasculardisease-33/NN	amod||infusion-36/NN||glucose-potassium-insulin-35/JJ	dobj||decreasing-20/VBG||infusion-36/NN	conj_and||plaque-24/NN||infusion-36/NN	amod||acute-39/JJ||hyperglyceamic-38/JJ	amod||patients-41/NNS||acute-39/JJ	nn||patients-41/NNS||stroke-40/NN	prep_in||infusion-36/NN||patients-41/NNS	dep||infusion-36/NN||pioglitazone-43/VB	det||medication-47/NN||an-45/DT	amod||medication-47/NN||anti-diabetic-46/JJ	dobj||pioglitazone-43/VB||medication-47/NN	nsubj||reduce-50/VB||medication-47/NN	aux||reduce-50/VB||to-49/TO	xcomp||pioglitazone-43/VB||reduce-50/VB	dobj||reduce-50/VB||recurrence-51/NN	prep_of||recurrence-51/NN||stroke-53/NN	nn||patients-58/NNS||type-55/NN	num||patients-58/NNS||2-56/CD	nn||patients-58/NNS||diabetic-57/NN	prep_in||reduce-50/VB||patients-58/NNS	parataxis||pioglitazone-43/VB||administration-60/NN	amod||urokinase-63/NN||intra-arterial-62/JJ	prep_of||administration-60/NN||urokinase-63/NN	det||agent-67/NN||a-65/DT	amod||agent-67/NN||thrombolytic-66/JJ	appos||urokinase-63/NN||agent-67/NN	det||role-71/NN||the-70/DT	prep_of||administration-60/NN||role-71/NN	conj_and||urokinase-63/NN||role-71/NN	nn||therapy-74/NN||laser-73/NN	prep_of||role-71/NN||therapy-74/NN	amod||dissolution-77/NN||clot-76/JJ	prep_in||therapy-74/NN||dissolution-77/NN	dep||administration-60/NN||given-78/VBN	mark||is-83/VBZ||that-79/IN	prep_at||is-83/VBZ||present-81/JJ	expl||is-83/VBZ||there-82/EX	pcomp||given-78/VBN||is-83/VBZ	advmod||fda-86/NN||only-84/RB	num||fda-86/NN||one-85/CD	nsubj||is-83/VBZ||fda-86/NN	vmod||fda-86/NN||approved-87/VBN	amod||agent-89/NN||thrombolytic-88/JJ	dobj||approved-87/VBN||agent-89/NN	nn||tpa-92/NN||r-91/NN	dep||administration-60/NN||tpa-92/NN	parataxis||pioglitazone-43/VB||benefit-95/VB	prep_of||benefit-95/VB||warfarin-97/NN	det||anticoagulant-100/NN||an-99/DT	appos||warfarin-97/NN||anticoagulant-100/NN	amod||patients-104/NNS||elderly-103/JJ	prep_in||warfarin-97/NN||patients-104/NNS	prep_with||benefit-95/VB||atrialfibrillation-106/NN	det||community-109/NN||the-108/DT	prep_in||atrialfibrillation-106/NN||community-109/NN	parataxis||pioglitazone-43/VB||nxy-111/VB	det||agent-117/NN||a-113/DT	amod||radical-115/JJ||free-114/JJ	amod||agent-117/NN||radical-115/JJ	amod||agent-117/NN||trapping-116/JJ	dep||nxy-111/VB||agent-117/NN	parataxis||pioglitazone-43/VB||minocycline-120/VB	conj_and||nxy-111/VB||minocycline-120/VB	det||tested-122/NN||both-121/DT	dobj||nxy-111/VB||tested-122/NN	prep_as||nxy-111/VB||neuroprotectants-124/NNS	dobj||decreasing-20/VBG||zoledronate-127/NN	conj_and||plaque-24/NN||zoledronate-127/NN	det||bisphosphonate-131/NN||an-129/DT	amod||bisphosphonate-131/NN||intravenous-130/JJ	appos||zoledronate-127/NN||bisphosphonate-131/NN	aux||prevent-134/VB||to-133/TO	vmod||zoledronate-127/NN||prevent-134/VB	dobj||prevent-134/VB||loss-135/NN	nn||density-139/NN||bone-137/NN	nn||density-139/NN||mineral-138/NN	prep_of||loss-135/NN||density-139/NN	det||extremity-143/NN||the-141/DT	amod||extremity-143/NN||affected-142/VBN	prep_of||density-139/NN||extremity-143/NN	advmod||role-148/NN||finally-146/RB	det||role-148/NN||the-147/DT	prep_of||density-139/NN||role-148/NN	conj_and||extremity-143/NN||role-148/NN	prep_of||role-148/NN||nicardipine-150/NN	det||calciumchannelblocker-153/NN||a-152/DT	appos||nicardipine-150/NN||calciumchannelblocker-153/NN	det||prevention-157/NN||the-156/DT	prep_in||nicardipine-150/NN||prevention-157/NN	prep_of||prevention-157/NN||vasospasm-159/NN	vmod||zoledronate-127/NN||hydrocortisone-162/VB	conj_and||prevent-134/VB||hydrocortisone-162/VB	aux||prevent-164/VB||to-163/TO	xcomp||hydrocortisone-162/VB||prevent-164/VB	dobj||prevent-164/VB||hyponatraemia-165/NN	amod||hemorrhage-168/NN||sub-arachnoid-167/JJ	prep_after||prevent-164/VB||hemorrhage-168/NN	stroke-53||warfarin-97||yes||these included the role of statins (an anti-lipid agent) in reducing post-stroke morbidity and mortality, and decreasing the carotid atherosclerotic plaque in middle aged patients at increased risk of cardiovasculardisease; glucose-potassium-insulin infusion in hyperglyceamic acute stroke patients; pioglitazone (an anti-diabetic medication) to reduce recurrence of stroke in type 2 diabetic patients; administration of intra-arterial urokinase (a thrombolytic agent) and the role of laser therapy in clot dissolution given that at present there is only one fda approved thrombolytic agent (r tpa); benefit of warfarin (an anticoagulant) in elderly patients with atrialfibrillation in the community; nxy (a free radical trapping agent) and minocycline both tested as neuroprotectants; and zoledronate (an intravenous bisphosphonate) to prevent loss of bone mineral density of the affected extremity, and finally the role of nicardipine (a calciumchannelblocker) in the prevention of vasospasm, and hydrocortisone to prevent hyponatraemia after sub-arachnoid hemorrhage.
nsubj||higher-4/JJR||crp-1/NN	cop||higher-4/JJR||was-2/VBD	neg||higher-4/JJR||not-3/RB	root||ROOT-0/null||higher-4/JJR	prep_among||higher-4/JJR||those-6/DT	amod||glucose-10/NN||impaired-8/VBN	amod||glucose-10/NN||fasting-9/JJ	prep_with||those-6/DT||glucose-10/NN	appos||glucose-10/NN||ifg-12/NN	nn||burden-17/NN||pathogen-16/NN	nsubjpass||related-20/VBN||burden-17/NN	auxpass||related-20/VBN||was-18/VBD	neg||related-20/VBN||not-19/RB	conj_and||higher-4/JJR||related-20/VBN	prep_to||related-20/VBN||insulinresistance-22/NN	amod||syndrome-25/NN||metabolic-24/JJ	prep_to||related-20/VBN||syndrome-25/NN	conj_or||insulinresistance-22/NN||syndrome-25/NN	prep_to||related-20/VBN||ifg-28/NN	conj_or||insulinresistance-22/NN||ifg-28/NN	glucose-10||insulinresistance-22||no_rel||crp was not higher among those with impaired fasting glucose (ifg), and pathogen burden was not related to insulinresistance, metabolic syndrome, or ifg.
nsubj||component-5/NN||pyrazinamide-1/NN	nsubj||most-14/JJS||pyrazinamide-1/NN	cop||component-5/NN||is-2/VBZ	det||component-5/NN||an-3/DT	amod||component-5/NN||essential-4/JJ	root||ROOT-0/null||component-5/NN	amod||regimen-10/NN||first-7/JJ	nn||regimen-10/NN||line-8/NN	nn||regimen-10/NN||anti-tuberculosis-9/NNS	prep_of||component-5/NN||regimen-10/NN	conj_and||component-5/NN||most-14/JJS	det||regimens-19/NNS||the-16/DT	amod||regimens-19/NNS||second-17/JJ	nn||regimens-19/NNS||line-18/NN	prep_of||most-14/JJS||regimens-19/NNS	tuberculosis--1||pyrazinamide-1||yes||pyrazinamide is an essential component of first line anti-tuberculosis regimen as well as most of the second line regimens.
nsubj||extended-3/VBN||we-1/PRP	aux||extended-3/VBN||have-2/VBP	ccomp||transferred-17/VBD||extended-3/VBN	det||use-5/NN||the-4/DT	dobj||extended-3/VBN||use-5/NN	amod||therapy-9/NN||nis-mediated-7/JJ	nn||therapy-9/NN||radioiodine-8/NN	prep_of||use-5/NN||therapy-9/NN	amod||types-12/NNS||other-11/JJ	prep_to||extended-3/VBN||types-12/NNS	prep_of||types-12/NNS||cancer-14/NN	nsubj||transferred-17/VBD||we-16/PRP	nsubj||expressed-19/VBD||we-16/PRP	root||ROOT-0/null||transferred-17/VBD	conj_and||transferred-17/VBD||expressed-19/VBD	det||gene-26/NN||the-20/DT	amod||gene-26/NN||sodium-iodide-21/JJ	nn||gene-26/NN||symporter-22/NN	appos||gene-26/NN||nis-24/NN	dobj||expressed-19/VBD||gene-26/NN	prep_into||expressed-19/VBD||prostate-28/NN	prep_into||expressed-19/VBD||colon-30/NN	conj_and||prostate-28/NN||colon-30/NN	nn||cells-35/NNS||breast-33/NN	nn||cells-35/NNS||cancer-34/NN	prep_into||expressed-19/VBD||cells-35/NNS	conj_and||prostate-28/NN||cells-35/NNS	xcomp||expressed-19/VBD||using-36/VBG	amod||vectors-38/NNS||adenoviral-37/JJ	dobj||using-36/VBG||vectors-38/NNS	iodide--1||cancer-34||no_rel||we have extended the use of nis-mediated radioiodine therapy to other types of cancer, we transferred and expressed the sodium-iodide symporter (nis) gene into prostate, colon, and breast cancer cells using adenoviral vectors.
nsubj||bioequivalent-3/JJ||fosaprepitant-1/NN	nsubj||aprepitant-5/VB||fosaprepitant-1/NN	nsubj||offer-9/VB||fosaprepitant-1/NN	cop||bioequivalent-3/JJ||is-2/VBZ	root||ROOT-0/null||bioequivalent-3/JJ	aux||aprepitant-5/VB||to-4/TO	xcomp||bioequivalent-3/JJ||aprepitant-5/VB	aux||offer-9/VB||could-8/MD	conj_and||bioequivalent-3/JJ||offer-9/VB	amod||benefits-11/NNS||potential-10/JJ	dobj||offer-9/VB||benefits-11/NNS	prep_for||offer-9/VB||patients-13/NNS	nsubj||unable-17/JJ||patients-13/NNS	nsubj||tolerate-19/VB||patients-13/NNS	aux||unable-17/JJ||may-15/MD	cop||unable-17/JJ||be-16/VB	rcmod||patients-13/NNS||unable-17/JJ	aux||tolerate-19/VB||to-18/TO	xcomp||unable-17/JJ||tolerate-19/VB	amod||administration-21/NN||oral-20/JJ	dobj||tolerate-19/VB||administration-21/NN	prep_of||administration-21/NN||antiemetics-23/NNS	det||episode-26/NN||an-25/DT	prep_during||tolerate-19/VB||episode-26/NN	prep_of||episode-26/NN||nausea-28/NN	prep_of||episode-26/NN||vomiting-30/NN	conj_or||nausea-28/NN||vomiting-30/NN	vomiting-30||antiemetics-23||no_rel||fosaprepitant is bioequivalent to aprepitant, and could offer potential benefits for patients who may be unable to tolerate oral administration of antiemetics during an episode of nausea or vomiting.
aux||report-2/VB||to-1/TO	root||ROOT-0/null||report-2/VB	det||case-4/NN||a-3/DT	dobj||report-2/VB||case-4/NN	amod||myopia-8/NN||bilateral-6/JJ	amod||myopia-8/NN||acute-7/JJ	prep_of||case-4/NN||myopia-8/NN	prep_of||case-4/NN||angleclosureglaucoma-10/NN	conj_and||myopia-8/NN||angleclosureglaucoma-10/NN	prep_after||report-2/VB||ingestion-12/NN	prep_of||ingestion-12/NN||methazolamide-14/NN	angleclosureglaucoma-10||methazolamide-14||yes||to report a case of bilateral acute myopia and angleclosureglaucoma after ingestion of methazolamide.
vmod||assessed-16/VBD||using-1/VBG	poss||cohort-5/NN||our-2/PRP$	advmod||phenotyped-4/JJ||thoroughly-3/RB	amod||cohort-5/NN||phenotyped-4/JJ	dobj||using-1/VBG||cohort-5/NN	prep_of||cohort-5/NN||subjects-7/NNS	det||risk-11/NN||an-9/DT	amod||risk-11/NN||increased-10/VBN	prep_at||using-1/VBG||risk-11/NN	prep_for||risk-11/NN||type2diabetes-13/CD	nsubj||assessed-16/VBD||we-15/PRP	root||ROOT-0/null||assessed-16/VBD	det||association-18/NN||the-17/DT	dobj||assessed-16/VBD||association-18/NN	amod||variation-22/NN||common-20/JJ	amod||variation-22/NN||genetic-21/JJ	prep_of||association-18/NN||variation-22/NN	det||locus-26/NNS||the-24/DT	amod||locus-26/NNS||mtnr1b-25/JJ	prep_within||assessed-16/VBD||locus-26/NNS	nn||traits-31/NNS||obesity-28/NN	conj_and||obesity-28/NN||prediabetes-30/NN	nn||traits-31/NNS||prediabetes-30/NN	prep_with||locus-26/NNS||traits-31/NNS	advmod||secretion-36/NNS||namely-33/RB	amod||secretion-36/NNS||impaired-34/VBN	nn||secretion-36/NNS||insulin-35/NN	prep_with||locus-26/NNS||secretion-36/NNS	conj_and||traits-31/NNS||secretion-36/NNS	prep_with||locus-26/NNS||insulinresistance-38/NN	conj_and||traits-31/NNS||insulinresistance-38/NN	type2diabetes-13||insulin-35||yes||using our thoroughly phenotyped cohort of subjects at an increased risk for type2diabetes, we assessed the association of common genetic variation within the mtnr1b locus with obesity and prediabetes traits, namely impaired insulin secretion and insulinresistance.
nsubjpass||shown-17/VBN||xaracoll-1/NN	nsubj||reduce-19/VB||xaracoll-1/NN	det||implant-5/NN||a-3/DT	amod||implant-5/NN||collagen-based-4/JJ	appos||xaracoll-1/NN||implant-5/NN	nsubj||delivers-7/VBZ||implant-5/NN	rcmod||implant-5/NN||delivers-7/VBZ	acomp||delivers-7/VBZ||bupivacaine-8/JJ	prep_to||bupivacaine-8/JJ||sites-10/NNS	amod||trauma-13/NN||surgical-12/JJ	prep_of||sites-10/NNS||trauma-13/NN	aux||shown-17/VBN||has-15/VBZ	auxpass||shown-17/VBN||been-16/VBN	root||ROOT-0/null||shown-17/VBN	aux||reduce-19/VB||to-18/TO	xcomp||shown-17/VBN||reduce-19/VB	dobj||reduce-19/VB||postoperativepain-20/NN	dobj||reduce-19/VB||use-22/NN	conj_and||postoperativepain-20/NN||use-22/NN	amod||analgesia-25/NN||opioid-24/JJ	prep_of||postoperativepain-20/NN||analgesia-25/NN	prep_in||reduce-19/VB||patients-27/NNS	vmod||patients-27/NNS||undergoing-28/VBG	amod||surgery-30/NN||open-29/JJ	dobj||undergoing-28/VBG||surgery-30/NN	bupivacaine-8||postoperativepain-20||no_rel||xaracoll, a collagen-based implant that delivers bupivacaine to sites of surgical trauma, has been shown to reduce postoperativepain and use of opioid analgesia in patients undergoing open surgery.
mark||negative-6/JJ||although-1/IN	nsubj||negative-6/JJ||pcr/hsv-2/NNP	prep_of||pcr/hsv-2/NNP||csf-4/NN	cop||negative-6/JJ||was-5/VBD	advcl||treated-12/VBN||negative-6/JJ	det||patient-9/NN||the-8/DT	nsubjpass||treated-12/VBN||patient-9/NN	nsubjpass||showed-17/VBD||patient-9/NN	nsubjpass||discharged-22/VBN||patient-9/NN	auxpass||treated-12/VBN||was-10/VBD	advmod||treated-12/VBN||empirically-11/RB	root||ROOT-0/null||treated-12/VBN	nn||acyclovir-15/NN||iv-14/NN	prep_with||treated-12/VBN||acyclovir-15/NN	conj_and||treated-12/VBN||showed-17/VBD	amod||improvement-19/NN||significant-18/JJ	dobj||showed-17/VBD||improvement-19/NN	auxpass||discharged-22/VBN||was-21/VBD	conj_and||treated-12/VBN||discharged-22/VBN	amod||condition-25/NN||good-24/JJ	prep_in||discharged-22/VBN||condition-25/NN	hsv--1||acyclovir-15||yes||although pcr/hsv of csf was negative, the patient was empirically treated with iv acyclovir and showed significant improvement and was discharged in good condition.
nsubj||agent-8/NN||humant-celllymphotropicvirustype1-1/JJ	dep||humant-celllymphotropicvirustype1-1/JJ||htlv-1-3/JJ	cop||agent-8/NN||is-5/VBZ	det||agent-8/NN||the-6/DT	amod||agent-8/NN||etiological-7/JJ	root||ROOT-0/null||agent-8/NN	amod||leukemia-12/NN||adult-10/JJ	amod||leukemia-12/NN||t-cell-11/JJ	prep_of||agent-8/NN||leukemia-12/NN	appos||leukemia-12/NN||atl-14/NN	amod||tropicalspasticparaparesis-19/NNS||htlv-1-associatedmyelopathy-17/JJ	amod||tropicalspasticparaparesis-19/NNS||/-18/JJ	prep_of||agent-8/NN||tropicalspasticparaparesis-19/NNS	conj_and||leukemia-12/NN||tropicalspasticparaparesis-19/NNS	appos||leukemia-12/NN||ham/tsp-21/NN	tropicalspasticparaparesis-19||htlv-1-3||no||humant-celllymphotropicvirustype1 (htlv-1) is the etiological agent of adult t-cell leukemia (atl) and htlv-1-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp).
nsubj||showed-2/VBD||studies-1/NNS	root||ROOT-0/null||showed-2/VBD	mark||induce-7/VB||that-3/IN	amod||therapy-5/NN||prolonged-4/VBN	nsubj||induce-7/VB||therapy-5/NN	aux||induce-7/VB||could-6/MD	ccomp||showed-2/VBD||induce-7/VB	amod||variants-15/NNS||lamivudine-8/JJ	nn||variants-15/NNS||resistance-9/NN	nn||variants-15/NNS||hepatitisb-10/NN	nn||variants-15/NNS||virus-11/NN	appos||variants-15/NNS||hbv-13/NN	dobj||induce-7/VB||variants-15/NNS	amod||motif-18/NN||ymdd-17/JJ	appos||variants-15/NNS||motif-18/NN	hbv-13||lamivudine-8||yes||studies showed that prolonged therapy could induce lamivudine resistance hepatitisb virus (hbv) variants (ymdd motif).
det||measures-3/NNS||these-1/DT	num||measures-3/NNS||three-2/CD	nsubj||determinants-6/NNS||measures-3/NNS	cop||determinants-6/NNS||are-4/VBP	amod||determinants-6/NNS||underlying-5/VBG	root||ROOT-0/null||determinants-6/NNS	amod||risk-9/NN||sexual-8/JJ	prep_of||determinants-6/NNS||risk-9/NN	prep_of||determinants-6/NNS||hivinfection-11/NN	conj_and||risk-9/NN||hivinfection-11/NN	nsubj||explain-17/VB||they-14/PRP	aux||explain-17/VB||may-15/MD	advmod||explain-17/VB||partially-16/RB	conj_and||determinants-6/NNS||explain-17/VB	det||variation-19/NN||the-18/DT	dobj||explain-17/VB||variation-19/NN	nn||levels-23/NNS||hiv-21/NN	nn||levels-23/NNS||prevalence-22/NN	prep_in||explain-17/VB||levels-23/NNS	det||populations-26/NNS||these-25/DT	prep_between||levels-23/NNS||populations-26/NNS	hivinfection-11||hiv-21||no||these three measures are underlying determinants of sexual risk and hivinfection, and they may partially explain the variation in hiv prevalence levels between these populations.
amod||children-3/NNS||hiv-infected-2/JJ	prep_in||accompanied-13/VBN||children-3/NNS	amod||tb-8/NN||definite-5/JJ	conj_or||definite-5/JJ||probable-7/JJ	amod||tb-8/NN||probable-7/JJ	prep_with||children-3/NNS||tb-8/NN	amod||treatment-11/NN||anti-tuberculosis-10/JJ	nsubjpass||accompanied-13/VBN||treatment-11/NN	auxpass||accompanied-13/VBN||is-12/VBZ	root||ROOT-0/null||accompanied-13/VBN	det||reduction-16/NN||a-15/DT	agent||accompanied-13/VBN||reduction-16/NN	det||magnitude-19/NN||the-18/DT	prep_in||reduction-16/NN||magnitude-19/NN	det||response-25/NN||the-21/DT	amod||response-25/NN||ifn-î-22/JJ	amod||response-25/NN||³-23/JJ	nn||response-25/NN||elispot-24/NN	prep_of||magnitude-19/NN||response-25/NN	prep_to||accompanied-13/VBN||mtb-antigens-27/NNS	tuberculosis--1||mtb--1||no||in hiv-infected children with definite or probable tb, anti-tuberculosis treatment is accompanied by a reduction in the magnitude of the ifn-î³ elispot response to mtb-antigens.
aux||compare-2/VB||to-1/TO	root||ROOT-0/null||compare-2/VB	det||efficacy-4/NN||the-3/DT	dobj||compare-2/VB||efficacy-4/NN	dobj||compare-2/VB||safety-6/NN	conj_and||efficacy-4/NN||safety-6/NN	prep_of||efficacy-4/NN||moclobemide-8/NN	prep_with||compare-2/VB||that-10/DT	prep_of||that-10/DT||imipramine-12/NN	det||antidepressant-16/NN||a-14/DT	amod||antidepressant-16/NN||tricyclic-15/JJ	appos||imipramine-12/NN||antidepressant-16/NN	det||treatment-20/NN||the-19/DT	prep_in||compare-2/VB||treatment-20/NN	amod||depressivedisorder-23/NN||major-22/JJ	prep_of||treatment-20/NN||depressivedisorder-23/NN	depressivedisorder-23||imipramine-12||yes||to compare the efficacy and safety of moclobemide with that of imipramine, a tricyclic antidepressant, in the treatment of major depressivedisorder.
det||range-4/NN||this-2/DT	nn||range-4/NN||dose-3/NN	prep_within||reduced-15/VBD||range-4/NN	det||population-9/NN||this-7/DT	nn||population-9/NN||patients-8/NNS	prep_in||reduced-15/VBD||population-9/NN	amod||dosage-13/NN||increasing-11/JJ	nn||dosage-13/NN||lidocaine-12/NN	nsubj||reduced-15/VBD||dosage-13/NN	nsubj||reduced-15/VBD||dosage-13/NN	advmod||reduced-15/VBD||significantly-14/RB	root||ROOT-0/null||reduced-15/VBD	conj_and||reduced-15/VBD||reduced-15/VBD	dobj||reduced-15/VBD||pain-16/NN	prep_during||reduced-15/VBD||injection-18/NN	nn||propofol-21/NN||microemulsion-20/NN	prep_of||injection-18/NN||propofol-21/NN	pain-16||propofol-21||yes||within this dose range and in this patients population, increasing lidocaine dosage significantly reduced pain during injection of microemulsion propofol.
prep_in||enhanced-7/VBD||summary-2/NN	nsubj||enhanced-7/VBD||c-4/SYM	conj_and||c-4/SYM||ecg-6/NN	nsubj||enhanced-7/VBD||ecg-6/NN	root||ROOT-0/null||enhanced-7/VBD	det||effect-10/NN||the-8/DT	amod||effect-10/NN||antibacterial-9/JJ	dobj||enhanced-7/VBD||effect-10/NN	nn||²-13/NNS||î-12/NN	prep_of||effect-10/NN||²-13/NNS	dep||effect-10/NN||lactamantibiotics-15/NNS	prep_against||lactamantibiotics-15/NNS||mrsa-17/NN	prep_in||enhanced-7/VBD||vitro-19/NN	prep_in||enhanced-7/VBD||in-21/IN	conj_and||vitro-19/NN||in-21/IN	pobj||in-21/IN||vivo-22/NN	nsubjpass||related-27/VBN||vivo-22/NN	aux||related-27/VBN||might-25/MD	auxpass||related-27/VBN||be-26/VB	rcmod||vivo-22/NN||related-27/VBN	det||accumulation-31/NN||the-29/DT	amod||accumulation-31/NN||increased-30/VBN	prep_to||related-27/VBN||accumulation-31/NN	prep_of||accumulation-31/NN||antibiotics-33/NNS	prep_within||antibiotics-33/NNS||mrsa-35/NN	prep_via||mrsa-35/NN||suppression-37/NN	amod||pumpsâ-41/NNS||important-39/JJ	nn||pumpsâ-41/NNS||efflux-40/NN	nn||expression-45/NN||pumpsâ-41/NNS	amod||expression-45/NN||$-42/$	dep||$-42/$||-43/JJ	nn||expression-45/NN||gene-44/NN	prep_of||suppression-37/NN||expression-45/NN	lactamantibiotics-15||mrsa-35||no_rel||in summary, c and ecg enhanced the antibacterial effect of î²-lactamantibiotics against mrsa in vitro and in vivo , which might be related to the increased accumulation of antibiotics within mrsa via suppression of important efflux pumpsâ gene expression.
nn||cancer-2/NN||breast-1/NN	nsubj||cancer-8/NN||cancer-2/NN	cop||cancer-8/NN||is-3/VBZ	advmod||cancer-8/NN||frequently-4/RB	det||cancer-8/NN||a-5/DT	advmod||dependent-7/JJ||hormonally-6/RB	amod||cancer-8/NN||dependent-7/JJ	root||ROOT-0/null||cancer-8/NN	nsubjpass||established-24/VBN||associations-11/NNS	prepc_of||associations-11/NNS||circulating-13/VBG	dobj||circulating-13/VBG||estrogens-14/NNS	dobj||circulating-13/VBG||androgens-16/NNS	conj_and||estrogens-14/NNS||androgens-16/NNS	amod||risk-21/NN||subsequent-18/JJ	nn||risk-21/NN||breast-19/NN	nn||risk-21/NN||cancer-20/NN	prep_with||circulating-13/VBG||risk-21/NN	auxpass||established-24/VBN||are-22/VBP	advmod||established-24/VBN||well-23/RB	conj_and||cancer-8/NN||established-24/VBN	amod||women-27/NNS||postmenopausal-26/JJ	prep_in||established-24/VBN||women-27/NNS	androgens-16||cancer-20||no_rel||breast cancer is frequently a hormonally dependent cancer, and associations of circulating estrogens and androgens with subsequent breast cancer risk are well established in postmenopausal women.
nsubj||linked-2/VBD||we-1/PRP	root||ROOT-0/null||linked-2/VBD	amod||results-5/NNS||positivehiv-3/JJ	nn||results-5/NNS||pcr-4/NN	dobj||linked-2/VBD||results-5/NNS	amod||testing-11/NN||subsequent-7/JJ	nn||testing-11/NN||hiv-8/NN	amod||testing-11/NN||viral-9/JJ	nn||testing-11/NN||load-10/NN	prep_to||linked-2/VBD||testing-11/NN	aux||determine-13/VB||to-12/TO	vmod||linked-2/VBD||determine-13/VB	det||proportion-15/NN||the-14/DT	dobj||determine-13/VB||proportion-15/NN	prep_of||proportion-15/NN||infants-17/NNS	nsubjpass||linked-21/VBN||infants-17/NNS	auxpass||linked-21/VBN||were-19/VBD	advmod||linked-21/VBN||successfully-20/RB	rcmod||infants-17/NNS||linked-21/VBN	nn||care-24/NN||hiv-23/NN	prep_to||linked-21/VBN||care-24/NN	positivehiv-3||hiv-23||no||we linked positivehiv pcr results to subsequent hiv viral load testing to determine the proportion of infants who were successfully linked to hiv care.
det||mechanism-3/NN||the-1/DT	amod||mechanism-3/NN||glucose-dependent-2/JJ	nsubj||holds-11/VBZ||mechanism-3/NN	nn||release-6/NN||insulin-5/NN	prep_of||mechanism-3/NN||release-6/NN	amod||therapy-10/NN||incretin-8/JJ	amod||therapy-10/NN||analog-9/JJ	prep_with||release-6/NN||therapy-10/NN	root||ROOT-0/null||holds-11/VBZ	amod||significance-14/NN||potential-12/JJ	amod||significance-14/NN||clinical-13/JJ	dobj||holds-11/VBZ||significance-14/NN	det||management-17/NN||the-16/DT	prep_in||holds-11/VBZ||management-17/NN	amod||excursions-21/NNS||postprandial-19/JJ	amod||excursions-21/NNS||hyperglycemic-20/JJ	prep_of||management-17/NN||excursions-21/NNS	amod||risk-25/NN||minimal-24/JJ	prep_with||holds-11/VBZ||risk-25/NN	prep_of||risk-25/NN||hypoglycemia-27/NN	advmod||used-29/VBN||when-28/WRB	advcl||holds-11/VBZ||used-29/VBN	amod||medications-32/NNS||non-secretagogue-31/JJ	prep_with||used-29/VBN||medications-32/NNS	hypoglycemia-27||glucose--1||yes||the glucose-dependent mechanism of insulin release with incretin analog therapy holds potential clinical significance in the management of postprandial hyperglycemic excursions, with minimal risk of hypoglycemia when used with non-secretagogue medications.
prep_for||greater-18/JJR||idus-2/NNS	det||risk-5/NN||the-4/DT	nsubj||greater-18/JJR||risk-5/NN	prep_for||risk-5/NN||progression-7/NN	prep_from||progression-7/NN||hiv-9/NN	prep_to||hiv-9/NN||aids-11/NNS	num||years-13/NNS||3-12/CD	dep||aids-11/NNS||years-13/NNS	nn||diagnosis-16/NN||hiv-15/NN	prep_after||aids-11/NNS||diagnosis-16/NN	cop||greater-18/JJR||was-17/VBD	root||ROOT-0/null||greater-18/JJR	prep_for||greater-18/JJR||nonwhites-20/NNS	prep_for||greater-18/JJR||males-22/NNS	conj_and||nonwhites-20/NNS||males-22/NNS	amod||persons-25/NNS||older-24/JJR	prep_for||greater-18/JJR||persons-25/NNS	conj_and||nonwhites-20/NNS||persons-25/NNS	aids-11||hiv-15||no||for idus, the risk for progression from hiv to aids 3 years after hiv diagnosis was greater for nonwhites, males and older persons.
nsubjpass||released-4/VBN||hmgb1-1/NNS	auxpass||released-4/VBN||was-2/VBD	advmod||released-4/VBN||also-3/RB	root||ROOT-0/null||released-4/VBN	amod||carcinoma-11/NN||melanoma-6/JJ	amod||carcinoma-11/NN||small-8/JJ	nn||carcinoma-11/NN||cell-9/NN	nn||carcinoma-11/NN||lung-10/NN	prep_from||released-4/VBN||carcinoma-11/NN	nn||cells-15/NNS||glioma-14/NN	nsubj||treated-16/VBN||cells-15/NNS	conj_and||released-4/VBN||treated-16/VBN	prep_with||treated-16/VBN||radiation-18/NN	prep_with||treated-16/VBN||temozolomide-20/NN	conj_or||radiation-18/NN||temozolomide-20/NN	melanoma-6||temozolomide-20||yes||hmgb1 was also released from melanoma, small cell lung carcinoma, and glioma cells treated with radiation or temozolomide.
amod||scores-4/NNS||verbal-1/JJ	amod||scores-4/NNS||analogue-2/JJ	nn||scores-4/NNS||pain-3/NN	nsubj||need-11/VBP||scores-4/NNS	appos||scores-4/NNS||incidence-6/NN	amod||pain-9/NN||distressing-8/JJ	prep_of||incidence-6/NN||pain-9/NN	ccomp||recorded-28/VBN||need-11/VBP	amod||boluses-14/NNS||supplementary/rescue-13/JJ	prep_of||need-11/VBP||boluses-14/NNS	appos||boluses-14/NNS||dose-16/NN	prep_of||dose-16/NN||bupivacaine-18/NN	vmod||bupivacaine-18/NN||consumed-19/VBN	amod||satisfaction-22/NN||maternal-21/JJ	nsubjpass||recorded-28/VBN||satisfaction-22/NN	amod||scores-26/NNS||neonatal-24/JJ	nn||scores-26/NNS||apgar-25/NN	conj_and||satisfaction-22/NN||scores-26/NNS	nsubjpass||recorded-28/VBN||scores-26/NNS	auxpass||recorded-28/VBN||were-27/VBD	root||ROOT-0/null||recorded-28/VBN	pain-9||bupivacaine-18||yes||verbal analogue pain scores, incidence of distressing pain, need of supplementary/rescue boluses, dose of bupivacaine consumed, maternal satisfaction and neonatal apgar scores were recorded.
det||review-2/NN||this-1/DT	nsubj||considers-3/VBZ||review-2/NN	root||ROOT-0/null||considers-3/VBZ	amod||recommendations-5/NNS||current-4/JJ	dobj||considers-3/VBZ||recommendations-5/NNS	det||treatment-8/NN||the-7/DT	prep_for||recommendations-5/NNS||treatment-8/NN	prep_of||treatment-8/NN||oa-10/NN	det||evidence-15/NN||the-12/DT	advmod||evidence-15/NN||most-13/RBS	amod||evidence-15/NN||recent-14/JJ	dobj||considers-3/VBZ||evidence-15/NN	conj_and||recommendations-5/NNS||evidence-15/NN	det||risks-19/NNS||the-17/DT	amod||risks-19/NNS||cardiovascular-18/JJ	prep_on||evidence-15/NN||risks-19/NNS	vmod||risks-19/NNS||associated-20/VBN	amod||treatments-24/NNS||current-22/JJ	amod||treatments-24/NNS||nsaid-23/JJ	prep_with||associated-20/VBN||treatments-24/NNS	det||potential-28/NN||the-27/DT	dobj||considers-3/VBZ||potential-28/NN	conj_and||recommendations-5/NNS||potential-28/NN	amod||anti-inflammatoryagents-31/NNS||newer-30/JJR	prep_of||potential-28/NN||anti-inflammatoryagents-31/NNS	amod||profiles-35/NNS||improved-33/VBN	amod||profiles-35/NNS||benefit-risk-34/JJ	prep_with||anti-inflammatoryagents-31/NNS||profiles-35/NNS	oa-10||nsaid-23||no_rel||this review considers current recommendations for the treatment of oa, the most recent evidence on the cardiovascular risks associated with current nsaid treatments, and the potential of newer anti-inflammatoryagents with improved benefit-risk profiles.
aux||monitor-2/VB||to-1/TO	advcl||analyzed-27/VBD||monitor-2/VB	amod||influenzaviruses-4/NNS||oseltamivir-resistant-3/JJ	dobj||monitor-2/VB||influenzaviruses-4/NNS	amod||influenzaviruses-4/NNS||a-5/DT	dep||a-5/DT||h1n1-7/CD	appos||influenzaviruses-4/NNS||orvs-10/NNS	prep_with||monitor-2/VB||h275y-13/NNS	prep_in||h275y-13/NNS||neuraminidase-15/NN	appos||neuraminidase-15/NN||na-17/NNP	prep_in||neuraminidase-15/NN||japan-20/NN	num||seasons-24/NNS||2-22/CD	nn||seasons-24/NNS||influenza-23/NN	prep_during||monitor-2/VB||seasons-24/NNS	nsubj||analyzed-27/VBD||we-26/PRP	root||ROOT-0/null||analyzed-27/VBD	num||samples-30/NNS||3,216-28/CD	amod||samples-30/NNS||clinical-29/JJ	dobj||analyzed-27/VBD||samples-30/NNS	amod||and/or-34/NNS||na-32/JJ	nn||and/or-34/NNS||sequencing-33/NN	prep_by||analyzed-27/VBD||and/or-34/NNS	aux||inhibition-36/VB||na-35/TO	vmod||analyzed-27/VBD||inhibition-36/VB	advmod||inhibition-36/VB||assay-37/RB	influenza-23||influenzaviruses-4||no||to monitor oseltamivir-resistant influenzaviruses a (h1n1) (orvs) with h275y in neuraminidase (na) in japan during 2 influenza seasons, we analyzed 3,216 clinical samples by na sequencing and/or na inhibition assay.
det||significance-4/NN||the-1/DT	amod||significance-4/NN||public-2/JJ	nn||significance-4/NN||health-3/NN	nsubjpass||emphasized-10/VBN||significance-4/NN	det||viruses-8/NNS||the-6/DT	amod||viruses-8/NNS||rabies-related-7/JJ	prep_of||significance-4/NN||viruses-8/NNS	auxpass||emphasized-10/VBN||was-9/VBD	root||ROOT-0/null||emphasized-10/VBN	prep_in||emphasized-10/VBN||zimbabwe-12/NN	advmod||became-19/VBD||where-13/WRB	prep_in||became-19/VBD||1981-15/CD	det||virus-18/NN||a-16/DT	amod||virus-18/NN||rabies-related-17/JJ	nsubj||became-19/VBD||virus-18/NN	advcl||emphasized-10/VBN||became-19/VBD	acomp||became-19/VBD||epizootic-20/JJ	det||population-26/NN||the-22/DT	nn||population-26/NN||dog-23/NN	conj_and||dog-23/NN||cat-25/NN	nn||population-26/NN||cat-25/NN	prep_in||became-19/VBD||population-26/NN	virus-18||viruses-8||no||the public health significance of the rabies-related viruses was emphasized in zimbabwe where in 1981 a rabies-related virus became epizootic in the dog and cat population.
advmod||analyzed-25/VBN||however-1/RB	mark||high-9/JJ||since-3/IN	det||statistics-6/NNS||the-4/DT	amod||statistics-6/NNS||calculated-5/JJ	nsubj||high-9/JJ||statistics-6/NNS	cop||high-9/JJ||were-7/VBD	advmod||high-9/JJ||very-8/RB	advcl||analyzed-25/VBN||high-9/JJ	prep||high-9/JJ||albeit-10/IN	neg||albeit-10/IN||not-11/RB	dep||albeit-10/IN||significant-12/JJ	det||possibility-15/NN||the-14/DT	nsubjpass||analyzed-25/VBN||possibility-15/NN	amod||pairing-21/NN||bradycardiaâ-17/JJ	amod||pairing-21/NN||$-18/JJ	amod||pairing-21/NN||propranolol-20/JJ	prep_of||possibility-15/NN||pairing-21/NN	aux||analyzed-25/VBN||should-22/MD	advmod||analyzed-25/VBN||still-23/RB	auxpass||analyzed-25/VBN||be-24/VB	root||ROOT-0/null||analyzed-25/VBN	amod||databases-28/NNS||larger-27/JJR	prep_from||analyzed-25/VBN||databases-28/NNS	bradycardia--1||propranolol-20||no||however, since the calculated statistics were very high albeit not significant, the possibility of bradycardiaâpropranolol pairing should still be analyzed from larger databases.
nn||models-2/NNS||regression-1/NN	nsubjpass||used-4/VBN||models-2/NNS	nsubj||assess-6/VB||models-2/NNS	auxpass||used-4/VBN||were-3/VBD	root||ROOT-0/null||used-4/VBN	aux||assess-6/VB||to-5/TO	xcomp||used-4/VBN||assess-6/VB	det||association-8/NN||the-7/DT	dobj||assess-6/VB||association-8/NN	prep_of||association-8/NN||strength-10/NN	prep_of||strength-10/NN||analgesia-12/NN	prep_of||strength-10/NN||prescription-14/NN	conj_and||analgesia-12/NN||prescription-14/NN	det||nsaid-17/NN||a-16/DT	prep_of||association-8/NN||nsaid-17/NN	det||strength-20/NN||the-19/DT	prep_with||assess-6/VB||strength-20/NN	amod||prescription-23/NN||previous-22/JJ	prep_of||strength-20/NN||prescription-23/NN	det||level-26/NN||the-25/DT	prep_with||assess-6/VB||level-26/NN	conj_and||strength-20/NN||level-26/NN	prep_of||level-26/NN||pain-28/NN	pain-28||nsaid-17||no_rel||regression models were used to assess the association of strength of analgesia and prescription of a nsaid with the strength of previous prescription and the level of pain.
det||review-3/NN||this-2/DT	prep_in||explore-6/VB||review-3/NN	nsubj||explore-6/VB||we-5/PRP	root||ROOT-0/null||explore-6/VB	det||link-11/NN||a-7/DT	advmod||unrecognised-9/JJ||previously-8/RB	amod||link-11/NN||unrecognised-9/JJ	amod||link-11/NN||genetic-10/JJ	dobj||explore-6/VB||link-11/NN	prep_between||link-11/NN||ts-13/NN	det||series-17/NN||a-15/DT	amod||series-17/NN||competing-16/VBG	dobj||explore-6/VB||series-17/NN	conj_and||link-11/NN||series-17/NN	nsubj||links-56/VBZ||series-17/NN	amod||complexes-20/NNS||trans-synaptic-19/JJ	prep_of||series-17/NN||complexes-20/NNS	dep||series-17/NN||neurexins-22/NNS	appos||neurexins-22/NNS||nrxns-24/NNS	appos||neurexins-22/NNS||neuroligins-27/NNS	appos||neuroligins-27/NNS||nlgns-29/NNS	amod||proteins-35/NNS||leucine-rich-32/JJ	nn||proteins-35/NNS||repeat-33/NN	nn||proteins-35/NNS||transmembrane-34/NN	appos||neurexins-22/NNS||proteins-35/NNS	dep||proteins-35/NNS||lrrtms-37/VBZ	amod||neuronals-43/NNS||leucine-40/JJ	amod||neuronals-43/NNS||rich-41/JJ	nn||neuronals-43/NNS||repeat-42/NN	appos||neurexins-22/NNS||neuronals-43/NNS	appos||neuronals-43/NNS||lrrns-45/NNS	nn||precursor-49/NN||cerebellin-48/NN	dep||series-17/NN||precursor-49/NN	conj_and||neurexins-22/NNS||precursor-49/NN	dep||precursor-49/NN||2-50/CD	appos||2-50/CD||cbln2-52/NNP	rcmod||series-17/NN||links-56/VBZ	dobj||links-56/VBZ||it-57/PRP	nn||disorder-61/NN||autism-59/NN	nn||disorder-61/NN||spectrum-60/NN	prep_with||links-56/VBZ||disorder-61/NN	amod||pathways-64/NNS||neurodevelopmental-63/JJ	prep_through||disorder-61/NN||pathways-64/NNS	leucine-40||ts-13||no_rel||in this review, we explore a previously unrecognised genetic link between ts and a competing series of trans-synaptic complexes (neurexins (nrxns), neuroligins (nlgns), leucine-rich repeat transmembrane proteins (lrrtms), leucine rich repeat neuronals (lrrns) and cerebellin precursor 2 (cbln2)) that links it with autism spectrum disorder through neurodevelopmental pathways.
det||results-2/NNS||the-1/DT	nsubj||relevant-28/JJ||results-2/NNS	poss||study-5/NN||our-4/PRP$	prep_of||results-2/NNS||study-5/NN	vmod||results-2/NNS||performed-7/VBN	prep_in||performed-7/VBN||normal-9/JJ	nn||cells-13/NNS||tumor-12/NN	prep_in||performed-7/VBN||cells-13/NNS	conj_negcc||normal-9/JJ||cells-13/NNS	advmod||confound-23/VB||where-14/WRB	amod||alterations-21/NNS||additional-15/JJ	dep||alterations-21/NNS||epi-17/RB	amod||alterations-21/NNS||genetic-20/JJ	nsubj||confound-23/VB||alterations-21/NNS	aux||confound-23/VB||may-22/MD	advcl||performed-7/VBN||confound-23/VB	det||analysis-25/NN||the-24/DT	dobj||confound-23/VB||analysis-25/NN	cop||relevant-28/JJ||are-27/VBP	root||ROOT-0/null||relevant-28/JJ	poss||understanding-31/NN||our-30/PRP$	prep_for||relevant-28/JJ||understanding-31/NN	prep_for||relevant-28/JJ||elucidation-33/NN	conj_and||understanding-31/NN||elucidation-33/NN	det||steps-37/NNS||the-35/DT	amod||steps-37/NNS||initial-36/JJ	prep_of||understanding-31/NN||steps-37/NNS	vmod||steps-37/NNS||underlying-38/VBG	dobj||underlying-38/VBG||smad4-39/NNS	vmod||smad4-39/NNS||driven-41/VBN	amod||tumorigenesis-43/NNS||intestinal-42/JJ	dobj||driven-41/VBN||tumorigenesis-43/NNS	tumor-12||epi-17||no_rel||the results of our study, performed in normal rather than tumor cells where additional (epi-) genetic alterations may confound the analysis, are relevant for our understanding and elucidation of the initial steps underlying smad4 -driven intestinal tumorigenesis.
nsubj||show-2/VBP||results-1/NNS	root||ROOT-0/null||show-2/VBP	mark||induces-8/VBZ||that-3/IN	num||falciparum-7/NN||1-4/CD	amod||falciparum-7/NN||-rrb--5/JJ	nn||falciparum-7/NN||p.-6/NN	nsubj||induces-8/VBZ||falciparum-7/NN	ccomp||show-2/VBP||induces-8/VBZ	det||inflammation-11/NN||a-9/DT	amod||inflammation-11/NN||strong-10/JJ	dobj||induces-8/VBZ||inflammation-11/NN	vmod||inflammation-11/NN||characterized-12/VBN	det||increase-15/NN||an-14/DT	agent||characterized-12/VBN||increase-15/NN	prepc_in||characterized-12/VBN||circulating-17/VBG	dobj||circulating-17/VBG||leukocytes-18/NNS	det||release-21/NN||the-20/DT	dobj||induces-8/VBZ||release-21/NN	conj_and||inflammation-11/NN||release-21/NN	amod||cytokines-24/NNS||inflammatory-23/JJ	prep_of||release-21/NN||cytokines-24/NNS	num||-rrb--27/NNS||2-26/CD	nsubj||induces-37/VBZ||-rrb--27/NNS	prep_in||-rrb--27/NNS||contrast-29/NN	det||yoelii-35/NN||the-31/DT	amod||yoelii-35/NN||rodent-32/JJ	nn||yoelii-35/NN||parasite-33/NN	nn||yoelii-35/NN||p.-34/NN	appos||contrast-29/NN||yoelii-35/NN	conj_and||show-2/VBP||induces-37/VBZ	det||inflammation-42/NN||a-38/DT	advmod||moderate-41/JJ||far-39/RB	advmod||moderate-41/JJ||more-40/RBR	amod||inflammation-42/NN||moderate-41/JJ	dobj||induces-37/VBZ||inflammation-42/NN	number||-rrb--45/CD||3-44/CD	num||cells-49/NNS||-rrb--45/CD	amod||cells-49/NNS||human-46/JJ	amod||cells-49/NNS||red-47/JJ	nn||cells-49/NNS||blood-48/NN	nsubj||induce-54/VB||cells-49/NNS	det||anti-inflammatoryagents-52/NNS||the-51/DT	conj_and||cells-49/NNS||anti-inflammatoryagents-52/NNS	nsubj||induce-54/VB||anti-inflammatoryagents-52/NNS	vmod||anti-inflammatoryagents-52/NNS||employed-53/VBN	conj_and||show-2/VBP||induce-54/VB	amod||inflammation-56/NN||low-grade-55/JJ	dobj||induce-54/VB||inflammation-56/NN	num||macrophages-61/NNS||4-59/CD	amod||macrophages-61/NNS||-rrb--60/JJ	nsubj||seem-62/VBP||macrophages-61/NNS	nsubj||bear-64/VB||macrophages-61/NNS	conj_and||show-2/VBP||seem-62/VBP	aux||bear-64/VB||to-63/TO	xcomp||seem-62/VBP||bear-64/VB	det||function-68/NN||the-65/DT	advmod||critical-67/JJ||most-66/RBS	amod||function-68/NN||critical-67/JJ	dobj||bear-64/VB||function-68/NN	amod||survival-73/NN||controlling-70/JJ	nn||survival-73/NN||p.-71/NN	nn||survival-73/NN||falciparum-72/NN	prep_in||bear-64/VB||survival-73/NN	det||mice-76/NNS||those-75/DT	prep_in||survival-73/NN||mice-76/NNS	mark||have-83/VBP||whereas-78/IN	nn||cells-82/NNS||polymorphonuclear-79/NN	conj_and||polymorphonuclear-79/NN||nk-81/NN	nn||cells-82/NNS||nk-81/NN	nsubj||have-83/VBP||cells-82/NNS	advcl||bear-64/VB||have-83/VBP	advmod||role-87/NN||only-84/RB	det||role-87/NN||a-85/DT	amod||role-87/NN||minor-86/JJ	dobj||have-83/VBP||role-87/NN	anti-inflammatoryagents-52||inflammation-56||no_rel||results show that 1 -rrb- p. falciparum induces a strong inflammation characterized by an increase in circulating leukocytes and the release of inflammatory cytokines ; 2 -rrb- in contrast , the rodent parasite p. yoelii , induces a far more moderate inflammation ; 3 -rrb- human red blood cells and the anti-inflammatoryagents employed induce low-grade inflammation ; and 4 -rrb- macrophages seem to bear the most critical function in controlling p. falciparum survival in those mice , whereas polymorphonuclear and nk cells have only a minor role .
aux||determine-2/VB||to-1/TO	advcl||required-45/VBN||determine-2/VB	mark||associated-6/VBN||if-3/IN	nsubjpass||associated-6/VBN||upregulation-4/NN	auxpass||associated-6/VBN||is-5/VBZ	advcl||determine-2/VB||associated-6/VBN	det||risk-10/NN||an-8/DT	amod||risk-10/NN||increased-9/VBN	prep_with||associated-6/VBN||risk-10/NN	det||acquisition-13/NN||the-12/DT	prep_for||risk-10/NN||acquisition-13/NN	det||hypersensitivityreaction-18/NN||an-15/DT	amod||hypersensitivityreaction-18/NN||adverse-16/JJ	amod||hypersensitivityreaction-18/NN||cm-induced-17/JJ	prep_of||acquisition-13/NN||hypersensitivityreaction-18/NN	mark||associated-23/VBN||if-20/IN	nsubjpass||associated-23/VBN||downregulation-21/NN	auxpass||associated-23/VBN||is-22/VBZ	advcl||determine-2/VB||associated-23/VBN	conj_and||associated-6/VBN||associated-23/VBN	det||risk-26/NN||a-25/DT	prep_without||associated-23/VBN||risk-26/NN	det||acquisition-29/NN||the-28/DT	prep_for||risk-26/NN||acquisition-29/NN	det||hypersensitivityreaction-34/NN||an-31/DT	amod||hypersensitivityreaction-34/NN||adverse-32/JJ	amod||hypersensitivityreaction-34/NN||cm-induced-33/JJ	prep_of||acquisition-29/NN||hypersensitivityreaction-34/NN	amod||studies-37/NNS||further-36/JJ	nsubjpass||required-45/VBN||studies-37/NNS	det||population-41/NN||a-39/DT	amod||population-41/NN||larger-40/JJR	prep_with||studies-37/NNS||population-41/NN	prep_of||population-41/NN||patients-43/NNS	auxpass||required-45/VBN||are-44/VBP	root||ROOT-0/null||required-45/VBN	hypersensitivityreaction-34||hypersensitivityreaction-34||no||to determine if upregulation is associated with an increased risk for the acquisition of an adverse cm-induced hypersensitivityreaction and if downregulation is associated without a risk for the acquisition of an adverse cm-induced hypersensitivityreaction, further studies with a larger population of patients are required.
mark||assess-4/VB||in-1/IN	dep||assess-4/VB||order-2/NN	aux||assess-4/VB||to-3/TO	advcl||study-13/VBP||assess-4/VB	amod||value-7/NN||combined-5/VBN	amod||value-7/NN||diagnostic-6/JJ	dobj||assess-4/VB||value-7/NN	det||tests-10/NNS||these-9/DT	prep_of||value-7/NN||tests-10/NNS	nsubj||study-13/VBP||we-12/PRP	root||ROOT-0/null||study-13/VBP	det||profiles-16/NNS||the-14/DT	amod||profiles-16/NNS||kinetic-15/JJ	dobj||study-13/VBP||profiles-16/NNS	prepc_of||profiles-16/NNS||circulating-18/VBG	amod||igm-22/NN||ns1-19/JJ	amod||igm-22/NN||dengue-21/JJ	dobj||circulating-18/VBG||igm-22/NN	nn||antibodies-25/NNS||igg-24/NN	dobj||circulating-18/VBG||antibodies-25/NNS	conj_and||igm-22/NN||antibodies-25/NNS	det||course-28/NN||the-27/DT	prep_over||igm-22/NN||course-28/NN	det||disease-31/NN||the-30/DT	prep_of||course-28/NN||disease-31/NN	prepc_by||circulating-18/VBG||using-33/VBG	det||denv1-40/NN||an-34/DT	amod||denv1-40/NN||in-house-35/JJ	amod||denv1-40/NN||dengue-36/JJ	nn||denv1-40/NN||type-37/NN	num||denv1-40/NN||1-38/CD	dobj||using-33/VBG||denv1-40/NN	amod||elisa-45/NN||specific-42/JJ	amod||elisa-45/NN||ns1-43/JJ	nn||elisa-45/NN||capture-44/NN	dep||denv1-40/NN||elisa-45/NN	det||igm-51/NN||the-47/DT	amod||igm-51/NN||commercial-48/JJ	nn||igm-51/NN||panbio-49/NN	nn||igm-51/NN||dengue-50/NN	dobj||using-33/VBG||igm-51/NN	conj_and||denv1-40/NN||igm-51/NN	nn||elisas-55/NNS||igg-53/NN	nn||elisas-55/NNS||capture-54/NN	conj_and||denv1-40/NN||elisas-55/NNS	conj_and||igm-51/NN||elisas-55/NNS	dengue-50||antibodies-25||no_rel||in order to assess combined diagnostic value of these tests, we study the kinetic profiles of circulating ns1, dengue igm and igg antibodies over the course of the disease by using an in-house dengue type 1 (denv1) specific ns1 capture elisa and the commercial panbio dengue igm and igg capture elisas.
nn||albumin-2/NN||serum-1/NN	nsubj||predictor-19/NN||albumin-2/NN	det||reactant-7/NN||a-4/DT	amod||reactant-7/NN||negative-5/JJ	amod||reactant-7/NN||acute-phase-6/JJ	appos||albumin-2/NN||reactant-7/NN	appos||albumin-2/NN||marker-9/NN	conj_and||reactant-7/NN||marker-9/NN	amod||malnutrition-14/NN||underlying-11/JJ	nn||malnutrition-14/NN||inflammation-12/NN	nn||malnutrition-14/NN||and/or-13/NN	prep_for||marker-9/NN||malnutrition-14/NN	cop||predictor-19/NN||is-16/VBZ	det||predictor-19/NN||an-17/DT	amod||predictor-19/NN||independent-18/JJ	root||ROOT-0/null||predictor-19/NN	prep_of||predictor-19/NN||cvd-21/NN	prep_of||predictor-19/NN||mortality-23/NN	conj_and||cvd-21/NN||mortality-23/NN	nn||patients-27/NNS||ckd-25/NN	nn||patients-27/NNS||vi-26/NN	prep_in||predictor-19/NN||patients-27/NNS	malnutrition-14||albumin-2||no_rel||serum albumin, a negative acute-phase reactant and marker for underlying inflammation and/or malnutrition, is an independent predictor of cvd and mortality in ckd vi patients.
poss||results-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||results-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||associated-20/VBN||that-4/IN	amod||inflammation-6/NN||colonic-5/JJ	nsubjpass||associated-20/VBN||inflammation-6/NN	amod||mice-12/NNS||il10-8/JJ	dep||mice-12/NNS||/-10/NNP	prep_in||inflammation-6/NN||mice-12/NNS	vmod||inflammation-6/NN||inoculated-13/VBN	prep_with||inoculated-13/VBN||solutions-15/NNS	vmod||solutions-15/NNS||containing-16/VBG	amod||strains-18/NNS||enterococcus-17/JJ	dobj||containing-16/VBG||strains-18/NNS	auxpass||associated-20/VBN||is-19/VBZ	ccomp||suggest-3/VBP||associated-20/VBN	nn||changes-24/NNS||gene-22/NN	nn||changes-24/NNS||expression-23/NN	prep_with||associated-20/VBN||changes-24/NNS	amod||changes-24/NNS||similar-25/JJ	prep_to||similar-25/JJ||those-27/DT	amod||ibd-30/NN||human-29/JJ	prep_of||those-27/DT||ibd-30/NN	advmod||cd-33/VBN||specifically-32/RB	vmod||changes-24/NNS||cd-33/VBN	mark||model-49/NN||that-36/IN	det||inoculum-42/NN||the-38/DT	amod||inoculum-42/NN||efâ-39/JJ	amod||inoculum-42/NN||·-40/JJ	nn||inoculum-42/NN||cif-41/NN	prep_with||model-49/NN||inoculum-42/NN	prep_in||inoculum-42/NN||particular-44/NN	nsubj||model-49/NN||this-45/DT	cop||model-49/NN||is-46/VBZ	det||model-49/NN||an-47/DT	amod||model-49/NN||appropriate-48/JJ	ccomp||suggest-3/VBP||model-49/NN	conj_and||associated-20/VBN||model-49/NN	aux||investigate-51/VB||to-50/TO	vmod||model-49/NN||investigate-51/VB	amod||interactions-53/NNS||food-gene-52/JJ	nsubj||relevant-54/JJ||interactions-53/NNS	xcomp||investigate-51/VB||relevant-54/JJ	amod||cd-57/NN||human-56/JJ	prep_to||relevant-54/JJ||cd-57/NN	cd-57||ibd-30||no_rel||our results suggest that colonic inflammation in il10 -/- mice inoculated with solutions containing enterococcus strains is associated with gene expression changes similar to those of human ibd, specifically cd, and that with the efâ·cif inoculum in particular this is an appropriate model to investigate food-gene interactions relevant to human cd.
prep_for||greater-18/JJR||idus-2/NNS	det||risk-5/NN||the-4/DT	nsubj||greater-18/JJR||risk-5/NN	prep_for||risk-5/NN||progression-7/NN	prep_from||progression-7/NN||hiv-9/NN	prep_to||hiv-9/NN||aids-11/NNS	num||years-13/NNS||3-12/CD	dep||aids-11/NNS||years-13/NNS	nn||diagnosis-16/NN||hiv-15/NN	prep_after||aids-11/NNS||diagnosis-16/NN	cop||greater-18/JJR||was-17/VBD	root||ROOT-0/null||greater-18/JJR	prep_for||greater-18/JJR||nonwhites-20/NNS	prep_for||greater-18/JJR||males-22/NNS	conj_and||nonwhites-20/NNS||males-22/NNS	amod||persons-25/NNS||older-24/JJR	prep_for||greater-18/JJR||persons-25/NNS	conj_and||nonwhites-20/NNS||persons-25/NNS	aids-11||hiv-15||no||for idus, the risk for progression from hiv to aids 3 years after hiv diagnosis was greater for nonwhites, males and older persons.
det||ups-2/NNS||the-1/DT	nsubj||appears-4/VBZ||ups-2/NNS	nsubjpass||involved-7/VBN||ups-2/NNS	nsubj||influence-22/VB||ups-2/NNS	advmod||appears-4/VBZ||also-3/RB	root||ROOT-0/null||appears-4/VBZ	aux||involved-7/VBN||to-5/TO	auxpass||involved-7/VBN||be-6/VB	xcomp||appears-4/VBZ||involved-7/VBN	prepc_in||involved-7/VBN||regulating-9/VBG	nn||synthesis-11/NN||lipid-10/NN	dobj||regulating-9/VBG||synthesis-11/NN	prep_in||synthesis-11/NN||adipocytes-13/NNS	nn||production-16/NN||lipid-15/NN	prep_in||synthesis-11/NN||production-16/NN	conj_and||adipocytes-13/NNS||production-16/NN	det||liver-19/NN||the-18/DT	prep_by||regulating-9/VBG||liver-19/NN	aux||influence-22/VB||could-21/MD	conj_and||appears-4/VBZ||influence-22/VB	det||development-24/NN||the-23/DT	dobj||influence-22/VB||development-24/NN	prep_of||development-24/NN||obesity-26/NN	obesity-26||lipid-15||no_rel||the ups also appears to be involved in regulating lipid synthesis in adipocytes and lipid production by the liver and could influence the development of obesity.
advmod||lower-8/JJR||however-1/RB	det||incidence-4/NN||the-3/DT	nsubj||lower-8/JJR||incidence-4/NN	prep_of||incidence-4/NN||vomiting-6/NN	cop||lower-8/JJR||was-7/VBD	root||ROOT-0/null||lower-8/JJR	det||group-12/NN||the-10/DT	nn||group-12/NN||palonosetron-11/NN	prep_in||lower-8/JJR||group-12/NN	dep||lower-8/JJR||than-13/IN	det||vs.-21/NN||the-15/DT	nn||vs.-21/NN||ondansetron-16/NN	nn||vs.-21/NN||group-17/NN	num||vs.-21/NN||-lrb--18/CD	number||%-20/NN||18-19/CD	amod||vs.-21/NN||%-20/NN	prep_in||lower-8/JJR||vs.-21/NN	number||%-23/NN||4-22/CD	amod||vs.-21/NN||%-23/NN	vmod||vs.-21/NN||p-25/VBN	dep||-rrb--28/NNS||=-26/SYM	num||-rrb--28/NNS||0.025-27/CD	ccomp||p-25/VBN||-rrb--28/NNS	vomiting-6||ondansetron-16||yes||however , the incidence of vomiting was lower in the palonosetron group than in the ondansetron group -lrb- 18 % vs. 4 % , p = 0.025 -rrb- .
det||patients-2/NNS||the-1/DT	nsubjpass||allocated-4/VBN||patients-2/NNS	auxpass||allocated-4/VBN||were-3/VBD	root||ROOT-0/null||allocated-4/VBN	num||groups-7/NNS||two-6/CD	prep_into||allocated-4/VBN||groups-7/NNS	dep||groups-7/NNS||group-8/NN	dep||group-8/NN||a-9/DT	dep||groups-7/NNS||n-11/VBN	dep||60-13/CD||=-12/SYM	ccomp||n-11/VBN||60-13/CD	dobj||discontinued-21/VBN||whom-16/WP	det||agent-19/NN||the-17/DT	nn||agent-19/NN||beta-blocker-18/NN	nsubjpass||discontinued-21/VBN||agent-19/NN	auxpass||discontinued-21/VBN||was-20/VBD	prepc_in||groups-7/NNS||discontinued-21/VBN	prep_for||discontinued-21/VBN||72h-23/CD	prep_before||discontinued-21/VBN||dmpi-25/NN	prep_before||discontinued-21/VBN||groupb-27/NN	conj_and||dmpi-25/NN||groupb-27/NN	dep||discontinued-21/VBN||n-29/VBN	dep||60-31/CD||=-30/SYM	ccomp||n-29/VBN||60-31/CD	prep_without||discontinued-21/VBN||discontinuation-34/NN	prep_of||discontinuation-34/NN||beta-blockers-36/NNS	prep_prior_to||beta-blockers-36/NNS||dmpi-39/NNS	groupb-27||beta-blockers-36||no_rel||the patients were allocated into two groups group a (n=60) in whom the beta-blocker agent was discontinued for 72h before dmpi and groupb (n=60) without discontinuation of beta-blockers prior to dmpi.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	det||study-5/NN||the-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	det||efficacy-10/NN||the-9/DT	dobj||evaluate-8/VB||efficacy-10/NN	dobj||evaluate-8/VB||safety-12/NN	conj_and||efficacy-10/NN||safety-12/NN	prep_of||efficacy-10/NN||ziprasidone-14/NN	prep_versus||ziprasidone-14/NN||risperidone-16/NN	amod||subjects-19/NNS||chinese-18/JJ	prep_in||evaluate-8/VB||subjects-19/NNS	amod||exacerbation-22/NN||acute-21/JJ	prep_with||evaluate-8/VB||exacerbation-22/NN	prep_of||exacerbation-22/NN||schizophrenia-24/NN	schizophrenia-24||ziprasidone-14||yes||the aim of the study was to evaluate the efficacy and safety of ziprasidone versus risperidone in chinese subjects with acute exacerbation of schizophrenia.
amod||-rrb--7/NNP||methicillin-resistantstaphylococcusaureus-1/JJ	nn||-rrb--7/NNP||-lrb--2/NN	nn||-rrb--7/NNP||s.aureus-3/NNS	nn||-rrb--7/NNP||-rrb--4/NNP	nn||-rrb--7/NNP||-lrb--5/NNP	nn||-rrb--7/NNP||mrsa-6/NNP	nsubjpass||reported-18/VBN||-rrb--7/NNP	amod||-rrb--7/NNP||resistant-9/JJ	det||antibiotics-12/NNS||all-11/DT	prep_to||resistant-9/JJ||antibiotics-12/NNS	prep_including||antibiotics-12/NNS||vancomycin-14/NN	aux||reported-18/VBN||has-16/VBZ	auxpass||reported-18/VBN||been-17/VBN	root||ROOT-0/null||reported-18/VBN	prep_in||reported-18/VBN||japan-20/NN	prep_in||reported-18/VBN||usa-22/NN	conj_and||japan-20/NN||usa-22/NN	prep_in||reported-18/VBN||canada-24/NN	conj_and||japan-20/NN||canada-24/NN	prep_in||reported-18/VBN||brazil-26/NN	conj_and||japan-20/NN||brazil-26/NN	methicillin-resistantstaphylococcusaureus-1||s.aureus-3||no||methicillin-resistantstaphylococcusaureus -lrb- s.aureus -rrb- -lrb- mrsa -rrb- , resistant to all antibiotics including vancomycin , has been reported in japan , usa , canada and brazil .
amod||sarcoma-2/NN||soft-tissue-1/JJ	nsubj||group-10/NN||sarcoma-2/NN	appos||sarcoma-2/NN||sts-4/NN	cop||group-10/NN||is-6/VBZ	det||group-10/NN||a-7/DT	advmod||diverse-9/JJ||histopathologically-8/RB	amod||group-10/NN||diverse-9/JJ	root||ROOT-0/null||group-10/NN	prep_of||group-10/NN||tumors-12/NNS	vmod||tumors-12/NNS||accounting-13/VBG	quantmod||10,000-16/CD||approximately-15/RB	num||malignancies-18/NNS||10,000-16/CD	amod||malignancies-18/NNS||new-17/JJ	prep_for||accounting-13/VBG||malignancies-18/NNS	det||us-21/PRP||the-20/DT	prep_in||malignancies-18/NNS||us-21/PRP	det||year-23/NN||each-22/DT	tmod||accounting-13/VBG||year-23/NN	tumors-12||sts-4||no||soft-tissue sarcoma (sts) is a histopathologically diverse group of tumors accounting for approximately 10,000 new malignancies in the us each year.
amod||involvement-2/NN||hepatic-1/JJ	nsubj||uncommon-7/JJ||involvement-2/NN	prep_in||involvement-2/NN||brucellosis-4/NNS	cop||uncommon-7/JJ||is-5/VBZ	neg||uncommon-7/JJ||not-6/RB	root||ROOT-0/null||uncommon-7/JJ	mark||have-18/VB||since-8/IN	num||%-10/NN||10-20-9/CD	nsubj||have-18/VB||%-10/NN	prep_of||%-10/NN||patient-12/NN	vmod||patient-12/NN||infected-13/VBN	nn||species-16/NNS||brucella-15/NN	prep_with||infected-13/VBN||species-16/NNS	aux||have-18/VB||can-17/MD	advcl||uncommon-7/JJ||have-18/VB	amod||tests-22/NNS||abnormal-19/JJ	nn||tests-22/NNS||liver-20/NN	nn||tests-22/NNS||function-21/NN	dobj||have-18/VB||tests-22/NNS	brucellosis-4||brucella-15||no||hepatic involvement in brucellosis is not uncommon since 10-20% of patient infected with brucella species can have abnormal liver function tests.
nsubj||randomized-2/VBD||we-1/PRP	root||ROOT-0/null||randomized-2/VBD	num||adults-4/NNS||52-3/CD	dobj||randomized-2/VBD||adults-4/NNS	amod||type1diabetes-9/NNS||recent-onset-6/JJ	amod||type1diabetes-9/NNS||noninsulin-requiring-8/JJ	prep_with||randomized-2/VBD||type1diabetes-9/NNS	aux||nasal-11/VB||to-10/TO	vmod||randomized-2/VBD||nasal-11/VB	dobj||nasal-11/VB||insulin-12/NN	dobj||nasal-11/VB||placebo-14/NN	conj_or||insulin-12/NN||placebo-14/NN	num||months-17/NNS||12-16/CD	prep_for||nasal-11/VB||months-17/NNS	type1diabetes-9||insulin-12||yes||we randomized 52 adults with recent-onset, noninsulin-requiring type1diabetes to nasal insulin or placebo for 12 months.
nsubj||performed-2/VBD||we-1/PRP	nsubj||determined-28/VBD||we-1/PRP	root||ROOT-0/null||performed-2/VBD	det||analysis-6/NN||a-3/DT	nn||analysis-6/NN||population-4/NN	amod||analysis-6/NN||pharmacokinetic-5/JJ	dobj||performed-2/VBD||analysis-6/NN	prep_of||analysis-6/NN||phenytoin-8/NN	amod||administration-11/NN||intravenous-10/JJ	prep_after||performed-2/VBD||administration-11/NN	prep_of||administration-11/NN||fosphenytoinsodium-13/NN	amod||subjects-21/NNS||healthy-15/JJ	amod||subjects-21/NNS||neurosurgical-17/JJ	conj_and||neurosurgical-17/JJ||epileptic-20/JJ	amod||subjects-21/NNS||epileptic-20/JJ	prep_in||fosphenytoinsodium-13/NN||subjects-21/NNS	amod||patients-25/NNS||pediatric-24/JJ	prep_including||administration-11/NN||patients-25/NNS	conj_and||performed-2/VBD||determined-28/VBD	det||dose-31/NN||the-29/DT	amod||dose-31/NN||optimal-30/JJ	dobj||determined-28/VBD||dose-31/NN	nn||rate-34/NN||infusion-33/NN	dobj||determined-28/VBD||rate-34/NN	conj_and||dose-31/NN||rate-34/NN	prepc_for||determined-28/VBD||achieving-36/VBG	det||range-39/NN||the-37/DT	amod||range-39/NN||therapeutic-38/JJ	dobj||achieving-36/VBG||range-39/NN	epileptic-20||fosphenytoinsodium-13||yes||we performed a population pharmacokinetic analysis of phenytoin after intravenous administration of fosphenytoinsodium in healthy, neurosurgical, and epileptic subjects, including pediatric patients, and determined the optimal dose and infusion rate for achieving the therapeutic range.
prep_in||reduce-33/VB||people-2/NNS	nn||oa-7/NN||hip-4/NN	conj_or||hip-4/NN||knee-6/NN	nn||oa-7/NN||knee-6/NN	prep_with||people-2/NNS||oa-7/NN	dep||reduce-33/VB||walking-9/VBG	det||minimum-11/NN||a-10/DT	dobj||walking-9/VBG||minimum-11/NN	num||steps-14/NNS||3000-13/CD	prep_of||minimum-11/NN||steps-14/NNS	dep||steps-14/NNS||~-16/NNP	num||minutes-18/NNS||30-17/CD	dep||~-16/NNP||minutes-18/NNS	quantmod||3-23/CD||at-21/IN	mwe||at-21/IN||least-22/JJS	pobj||at-21/IN||least-22/JJS	num||days/week-24/NN||3-23/CD	appos||steps-14/NNS||days/week-24/NN	prep_in||steps-14/NNS||combination-27/NN	amod||sulphate-30/NN||glucosamine-29/JJ	prep_with||steps-14/NNS||sulphate-30/NN	aux||reduce-33/VB||may-32/MD	root||ROOT-0/null||reduce-33/VB	nn||symptoms-35/NNS||oa-34/NN	dobj||reduce-33/VB||symptoms-35/NNS	oa-34||glucosamine-29||yes||in people with hip or knee oa, walking a minimum of 3000 steps (~30 minutes), at least 3 days/week, in combination with glucosamine sulphate, may reduce oa symptoms.
det||hbz-3/NN||the-1/DT	amod||hbz-3/NN||htlv-1-2/JJ	nsubj||correlated-12/VBD||hbz-3/NN	nn||load-9/NN||tax-7/NN	nn||load-9/NN||mrna-8/NN	conj_negcc||hbz-3/NN||load-9/NN	nsubj||correlated-12/VBD||load-9/NN	advmod||correlated-12/VBD||positively-11/RB	root||ROOT-0/null||correlated-12/VBD	nn||severity-15/NN||disease-14/NN	prep_with||correlated-12/VBD||severity-15/NN	nn||concentration-19/NN||neopterin-18/NN	prep_with||correlated-12/VBD||concentration-19/NN	conj_and||severity-15/NN||concentration-19/NN	det||fluid-23/NN||the-21/DT	amod||fluid-23/NN||cerebrospinal-22/JJ	prep_in||correlated-12/VBD||fluid-23/NN	nn||patients-26/NNS||ham/tsp-25/NN	prep_of||fluid-23/NN||patients-26/NNS	ham--1||htlv-1-2||no||the htlv-1 hbz, but not tax mrna load, positively correlated with disease severity and with neopterin concentration in the cerebrospinal fluid of ham/tsp patients.
amod||presentation-2/NN||clinical-1/JJ	nsubj||includes-3/VBZ||presentation-2/NN	root||ROOT-0/null||includes-3/VBZ	det||history-5/NN||a-4/DT	dobj||includes-3/VBZ||history-5/NN	prep_of||history-5/NN||asthma-7/NN	prep_after||includes-3/VBZ||ingestion-9/NN	prep_of||ingestion-9/NN||aspirin-11/NN	amod||congestion-14/NN||nasal-13/JJ	prep_of||ingestion-9/NN||congestion-14/NN	conj_and||aspirin-11/NN||congestion-14/NN	amod||rhinorrhea-17/NN||watery-16/JJ	prep_of||ingestion-9/NN||rhinorrhea-17/NN	conj_and||aspirin-11/NN||rhinorrhea-17/NN	prep_of||ingestion-9/NN||nasalpolyposis-19/NNS	conj_and||aspirin-11/NN||nasalpolyposis-19/NNS	asthma-7||aspirin-11||no||clinical presentation includes a history of asthma after ingestion of aspirin, nasal congestion, watery rhinorrhea and nasalpolyposis.
advmod||be-10/VB||however-1/RB	det||use-4/NN||the-3/DT	nsubj||be-10/VB||use-4/NN	amod||vaccines-8/NNS||therapeutic-6/JJ	nn||vaccines-8/NNS||cancer-7/NN	prep_of||use-4/NN||vaccines-8/NNS	aux||be-10/VB||may-9/MD	root||ROOT-0/null||be-10/VB	det||verge-13/NN||the-12/DT	prep_on||be-10/VB||verge-13/NN	prepc_of||verge-13/NN||becoming-15/VBG	det||modality-18/NN||an-16/DT	amod||modality-18/NN||effective-17/JJ	xcomp||becoming-15/VBG||modality-18/NN	cancer-7||vaccines-8||no_rel||however, the use of therapeutic cancer vaccines may be on the verge of becoming an effective modality.
amod||evidence-2/NN||increasing-1/VBG	nsubj||suggests-3/VBZ||evidence-2/NN	root||ROOT-0/null||suggests-3/VBZ	mark||determinants-9/NNS||that-4/IN	amod||responses-6/NNS||innate-5/JJ	nsubj||determinants-9/NNS||responses-6/NNS	cop||determinants-9/NNS||are-7/VBP	amod||determinants-9/NNS||key-8/JJ	ccomp||suggests-3/VBZ||determinants-9/NNS	det||outcome-12/NN||the-11/DT	prep_of||determinants-9/NNS||outcome-12/NN	prep_of||outcome-12/NN||hivinfection-14/NN	vmod||determinants-9/NNS||influencing-16/VBG	amod||events-18/NNS||critical-17/JJ	dobj||influencing-16/VBG||events-18/NNS	det||stages-22/NNS||the-20/DT	amod||stages-22/NNS||earliest-21/JJS	prep_in||influencing-16/VBG||stages-22/NNS	prep_of||stages-22/NNS||infection-24/NN	det||efficiency-27/NN||the-26/DT	prep_including||infection-24/NN||efficiency-27/NN	amod||transmission-31/NN||mucosal-29/JJ	nn||transmission-31/NN||hiv-30/NN	prep_of||efficiency-27/NN||transmission-31/NN	nsubj||replication/spread-42/VBD||establishment-33/NN	amod||foci-36/NNS||initial-35/JJ	prep_of||establishment-33/NN||foci-36/NNS	nn||virus-41/NN||infection-38/NN	conj_and||infection-38/NN||local-40/JJ	nn||virus-41/NN||local-40/JJ	prep_of||foci-36/NNS||virus-41/NN	ccomp||suggests-3/VBZ||replication/spread-42/VBD	conj_and||suggests-3/VBZ||replication/spread-42/VBD	cc||dissemination-47/NN||well-44/RB	nn||dissemination-47/NN||virus-46/NN	dobj||replication/spread-42/VBD||dissemination-47/NN	det||burst-52/NN||the-49/DT	amod||burst-52/NN||ensuing-50/VBG	amod||burst-52/NN||acute-51/JJ	dep||dissemination-47/NN||burst-52/NN	amod||replication-55/NN||viral-54/JJ	prep_of||burst-52/NN||replication-55/NN	det||load-61/NN||the-58/DT	amod||load-61/NN||persisting-59/JJ	amod||load-61/NN||viral-60/JJ	nsubj||established-62/VBD||load-61/NN	conj_and||suggests-3/VBZ||established-62/VBD	hivinfection-14||hiv-30||no||increasing evidence suggests that innate responses are key determinants of the outcome of hivinfection, influencing critical events in the earliest stages of infection including the efficiency of mucosal hiv transmission, establishment of initial foci of infection and local virus replication/spread as well as virus dissemination, the ensuing acute burst of viral replication, and the persisting viral load established.
det||outbreak-6/NN||the-2/DT	num||outbreak-6/NN||2003-3/CD	nn||outbreak-6/NN||toronto-4/NN	nn||outbreak-6/NN||sars-5/NNS	prep_in||transmitted-10/VBN||outbreak-6/NN	nsubjpass||transmitted-10/VBN||sars-cov-8/NNP	auxpass||transmitted-10/VBN||was-9/VBD	root||ROOT-0/null||transmitted-10/VBN	prep_in||transmitted-10/VBN||hospitals-12/NNS	prep_despite||transmitted-10/VBN||adherence-14/NN	nn||procedures-18/NNS||infection-16/NN	nn||procedures-18/NNS||control-17/NN	prep_to||transmitted-10/VBN||procedures-18/NNS	sars-5||sars-cov-8||no||in the 2003 toronto sars outbreak, sars-cov was transmitted in hospitals despite adherence to infection control procedures.
amod||series-2/NN||recent-1/JJ	nsubj||identified-4/VBN||series-2/NN	aux||identified-4/VBN||have-3/VBP	root||ROOT-0/null||identified-4/VBN	det||profile-8/NN||a-5/DT	amod||profile-8/NN||shifting-6/VBG	amod||profile-8/NN||demographic-7/JJ	dobj||identified-4/VBN||profile-8/NN	mark||consume-16/VBP||as-10/IN	amod||numbers-12/NNS||increasing-11/VBG	nsubj||consume-16/VBP||numbers-12/NNS	amod||women-15/NNS||elderly-14/JJ	prep_of||numbers-12/NNS||women-15/NNS	advcl||identified-4/VBN||consume-16/VBP	acomp||consume-16/VBP||calciumcarbonate-17/JJ	det||measure-21/NN||an-19/DT	amod||measure-21/NN||anti-osteoporosis-20/JJ	prep_as||consume-16/VBP||measure-21/NN	osteoporosis--1||calciumcarbonate-17||yes||recent series have identified a shifting demographic profile, as increasing numbers of elderly women consume calciumcarbonate as an anti-osteoporosis measure.
nsubjpass||reported-7/VBN||cases-1/NNS	amod||pancreatitis-4/NNS||acute-3/JJ	prep_of||cases-1/NNS||pancreatitis-4/NNS	aux||reported-7/VBN||have-5/VBP	auxpass||reported-7/VBN||been-6/VBN	root||ROOT-0/null||reported-7/VBN	prep_in||reported-7/VBN||association-9/NN	prep_with||reported-7/VBN||exenatide-11/NN	prep_with||reported-7/VBN||sitagliptin-13/NN	conj_and||exenatide-11/NN||sitagliptin-13/NN	prep_with||reported-7/VBN||type2diabetes-16/NNS	conj_and||exenatide-11/NN||type2diabetes-16/NNS	prep_without||reported-7/VBN||use-18/NN	det||medications-21/NNS||these-20/DT	prep_of||use-18/NN||medications-21/NNS	pancreatitis-4||sitagliptin-13||no_rel||cases of acute pancreatitis have been reported in association with exenatide, sitagliptin, and type2diabetes without use of these medications.
prep_at||made-16/VBN||6â-2/NNS	num||years-6/NNS||$-3/$	num||$-3/$||7-5/CD	npadvmod||6â-2/NNS||years-6/NNS	prep_of||6â-2/NNS||age-8/NN	det||comparison-11/NN||the-10/DT	nsubjpass||made-16/VBN||comparison-11/NN	amod||factors-14/NNS||various-13/JJ	prep_of||comparison-11/NN||factors-14/NNS	auxpass||made-16/VBN||was-15/VBD	root||ROOT-0/null||made-16/VBN	number||lga-19/NN||31-18/CD	amod||children-26/NNS||lga-19/NN	number||appropriate-for-gestational-age-22/NN||34-21/CD	conj_and||lga-19/NN||appropriate-for-gestational-age-22/NN	amod||children-26/NNS||appropriate-for-gestational-age-22/NN	discourse||children-26/NNS||aga-24/UH	prep_between||made-16/VBN||children-26/NNS	dobj||made-16/VBN||fibrinogen-27/NN	dobj||made-16/VBN||antithrombiniii-29/NNS	conj_and||fibrinogen-27/NN||antithrombiniii-29/NNS	nn||c-32/NN||protein-31/NN	dobj||made-16/VBN||c-32/NN	conj_and||fibrinogen-27/NN||c-32/NN	dobj||made-16/VBN||s-34/PRP	conj_and||fibrinogen-27/NN||s-34/PRP	amod||model-43/NN||fasting-36/VBG	nn||model-43/NN||insulin-37/NN	dep||model-43/NN||glucose-39/NN	dep||model-43/NN||homeostasis-41/NN	nn||model-43/NN||assessment-42/NN	dobj||made-16/VBN||model-43/NN	conj_and||fibrinogen-27/NN||model-43/NN	prep_of||model-43/NN||insulinresistance-45/NN	appos||model-43/NN||homa-ir-47/NN	nn||protein-60/NN||index-49/NN	dep||protein-60/NN||adiponectin-51/NN	dep||protein-60/NN||leptin-53/NN	dep||protein-60/NN||visfatin-55/NN	amod||protein-60/NN||igf-1-57/JJ	amod||protein-60/NN||igf-binding-59/JJ	dep||fibrinogen-27/NN||protein-60/NN	appos||protein-60/NN||igfbp-62/NN	nsubj||lipids-68/VBZ||-1-64/CD	amod||-1-64/CD||igfbp-3-66/JJ	rcmod||protein-60/NN||lipids-68/VBZ	det||factors-73/NNS||the-71/DT	amod||factors-73/NNS||genetic-72/JJ	poss||mutation-77/NN||factors-73/NNS	nn||mutation-77/NN||leiden-75/NN	amod||mutation-77/NN||g1691a-76/VBD	dobj||made-16/VBN||mutation-77/NN	conj_and||fibrinogen-27/NN||mutation-77/NN	amod||20210a/g-80/JJ||prothrombin-79/JJ	amod||polymorphism-81/NN||20210a/g-80/JJ	conj_and||fibrinogen-27/NN||polymorphism-81/NN	conj_and||mutation-77/NN||polymorphism-81/NN	conj_and||fibrinogen-27/NN||mutation-84/NN	conj_and||mutation-77/NN||mutation-84/NN	det||gene-89/NN||the-86/DT	amod||5,10-methylenetetrahydrofolate-reductase-88/JJ||enzyme-87/JJ	amod||gene-89/NN||5,10-methylenetetrahydrofolate-reductase-88/JJ	prep_in||mutation-84/NN||gene-89/NN	dep||gene-89/NN||mthfr-c677t-91/JJ	antithrombiniii-29||insulinresistance-45||no_rel||at 6â7 years of age, the comparison of various factors was made between 31 lga and 34 appropriate-for-gestational-age (aga) children fibrinogen, antithrombiniii, protein c and s, fasting insulin, glucose, homeostasis assessment model of insulinresistance (homa-ir) index, adiponectin, leptin, visfatin, igf-1, igf-binding protein (igfbp)-1, igfbp-3, lipids, and the genetic factors v leiden g1691a mutation, prothrombin 20210a/g polymorphism, and mutation in the enzyme 5,10-methylenetetrahydrofolate-reductase gene (mthfr-c677t).
det||review-2/NN||this-1/DT	nsubj||links-16/VBZ||review-2/NN	vmod||review-2/NN||carried-4/VBN	prt||carried-4/VBN||out-5/RP	det||initiative-10/NN||the-7/DT	amod||initiative-10/NN||joint-8/JJ	nn||initiative-10/NN||learning-9/NN	prep_for||carried-4/VBN||initiative-10/NN	prep_on||initiative-10/NN||children-12/NNS	prep_on||initiative-10/NN||aids-14/NNS	conj_and||children-12/NNS||aids-14/NNS	root||ROOT-0/null||links-16/VBZ	det||literature-18/NN||the-17/DT	dobj||links-16/VBZ||literature-18/NN	quantmod||$-21/$||â-20/RB	prep_on||links-16/VBZ||$-21/$	number||$-23/CD||migrationâ-22/CD	num||$-21/$||$-23/CD	prep_on||links-16/VBZ||â-26/NN	dobj||links-16/VBZ||$-27/$	num||$-27/$||hiv-28/CD	advmod||$-31/$||aidsâ-30/RB	dobj||links-16/VBZ||$-31/$	conj_and||$-27/$||$-31/$	num||$-31/$||and-32/CD	quantmod||$-35/$||â-34/RB	prep_on||links-16/VBZ||$-35/$	number||$-37/CD||familiesâ-36/CD	num||$-35/$||$-37/CD	aids-14||hiv--1||no||this review, carried out for the joint learning initiative on children and aids, links the literature on âmigrationâ?, on âhiv and aidsâ? and on âfamiliesâ?.
amod||mtx-3/NN||infliximab-1/JJ	amod||mtx-3/NN||+-2/JJ	nsubj||attenuated-4/VBD||mtx-3/NN	root||ROOT-0/null||attenuated-4/VBD	amod||markers-7/NNS||several-5/JJ	amod||markers-7/NNS||inflammatory-6/JJ	dobj||attenuated-4/VBD||markers-7/NNS	prep_in||attenuated-4/VBD||patients-9/NNS	prep_with||attenuated-4/VBD||jia-11/NN	amod||decreases-14/NNS||larger-13/JJR	nsubjpass||observed-24/VBN||decreases-14/NNS	amod||mmp-3-18/CD||icam-1-16/JJ	prep_in||decreases-14/NNS||mmp-3-18/CD	nn||levels-22/NNS||crp-21/NN	prep_in||decreases-14/NNS||levels-22/NNS	conj_and||mmp-3-18/CD||levels-22/NNS	auxpass||observed-24/VBN||were-23/VBD	parataxis||attenuated-4/VBD||observed-24/VBN	amod||responders-27/NNS||acr-pedi-30-26/JJ	prep_in||observed-24/VBN||responders-27/NNS	prep_versus||responders-27/NNS||nonresponders-29/NNS	jia-11||mtx-3||yes||infliximab + mtx attenuated several inflammatory markers in patients with jia; larger decreases in icam-1, mmp-3, and crp levels were observed in acr-pedi-30 responders versus nonresponders.
amod||sensitivity-2/NN||reduced-1/VBN	nsubj||occurred-10/VBD||sensitivity-2/NN	prepc_for||sensitivity-2/NN||hbsag-4/VBG	amod||diversity-7/NN||genetic-6/JJ	prep_with||hbsag-4/VBG||diversity-7/NN	prep_of||diversity-7/NN||hbv-9/NN	root||ROOT-0/null||occurred-10/VBD	mark||ayw3-15/CD||with-11/IN	dep||d-13/SYM||genotypes/subtypes-12/RB	dep||ayw3-15/CD||d-13/SYM	punct||ayw3-15/CD||/-14/:	advcl||mutants-28/NNS||ayw3-15/CD	dep||ayw4-19/CD||e-17/SYM	punct||ayw4-19/CD||/-18/:	dep||ayw3-15/CD||ayw4-19/CD	nsubj||mutants-28/NNS||f-21/SYM	num||adw4-23/NNS||/-22/CD	dep||f-21/SYM||adw4-23/NNS	dep||f-21/SYM||by-25/IN	conj_and||adw4-23/NNS||by-25/IN	cop||mutants-28/NNS||s-26/VBZ	nn||mutants-28/NNS||gene-27/NN	ccomp||occurred-10/VBD||mutants-28/NNS	hbv-9||hbsag-4||yes||reduced sensitivity for hbsag with genetic diversity of hbv occurred with genotypes/subtypes d/ ayw3 , e/ ayw4 , f/ adw4 and by s gene mutants.
nsubj||endocrinedisease-5/NN||endogenous-1/NNS	advmod||endocrinedisease-5/NN||cushingsyndrome-2/RB	cop||endocrinedisease-5/NN||is-3/VBZ	det||endocrinedisease-5/NN||an-4/DT	root||ROOT-0/null||endocrinedisease-5/NN	vmod||endocrinedisease-5/NN||caused-6/VBN	amod||secretion-9/NN||excessive-8/JJ	agent||caused-6/VBN||secretion-9/NN	nn||hormone-12/NN||adrenocorticotropin-11/NN	prep_of||secretion-9/NN||hormone-12/NN	quantmod||80-15/CD||approximately-14/RB	num||%-16/NN||80-15/CD	prep_in||caused-6/VBN||%-16/NN	prep_of||%-16/NN||cases-18/NNS	advmod||caused-6/VBN||usually-20/RB	det||adenoma-25/NN||a-22/DT	advmod||corticotroph-24/JJ||pituitary-23/RB	amod||adenoma-25/NN||corticotroph-24/JJ	agent||caused-6/VBN||adenoma-25/NN	amod||-RSB--30/NNP||cushingdisease-27/JJ	nn||-RSB--30/NNP||-LSB--28/NNP	nn||-RSB--30/NNP||cd-29/NN	appos||adenoma-25/NN||-RSB--30/NNP	adrenocorticotropin-11||cushingsyndrome-2||no_rel||endogenous cushingsyndrome is an endocrinedisease caused by excessive secretion of adrenocorticotropin hormone in approximately 80% of cases, usually by a pituitary corticotroph adenoma (cushingdisease [cd]).
nsubj||showed-5/VBD||smokers-1/NNS	vmod||smokers-1/NNS||treated-2/VBN	prep_with||treated-2/VBN||budesonide/formoterol-4/NN	root||ROOT-0/null||showed-5/VBD	det||increase-7/NN||an-6/DT	dobj||showed-5/VBD||increase-7/NN	det||number-10/NN||the-9/DT	prep_in||showed-5/VBD||number-10/NN	nn||episodes-13/NNS||asthma-12/NN	prep_of||number-10/NN||episodes-13/NNS	parataxis||showed-5/VBD||intercurrent-15/VB	nn||symptoms-17/NNS||asthma-16/NN	dobj||intercurrent-15/VB||symptoms-17/NNS	vmod||symptoms-17/NNS||p-19/VBN	dep||0.016-21/CD||=-20/SYM	ccomp||p-19/VBN||0.016-21/CD	mark||had-26/VBD||while-23/IN	amod||subjects-25/NNS||non-smoking-24/JJ	nsubj||had-26/VBD||subjects-25/NNS	advcl||showed-5/VBD||had-26/VBD	det||decrease-29/NN||a-27/DT	amod||decrease-29/NN||significant-28/JJ	dobj||had-26/VBD||decrease-29/NN	det||episodes-32/NNS||these-31/DT	prep_in||decrease-29/NN||episodes-32/NNS	dep||episodes-32/NNS||p-34/VBN	dep||0.009-36/CD||=-35/SYM	ccomp||p-34/VBN||0.009-36/CD	asthma-16||budesonide--1||no||smokers treated with budesonide/formoterol showed an increase in the number of asthma episodes (intercurrent asthma symptoms, p=0.016) while non-smoking subjects had a significant decrease in these episodes (p=0.009).
mark||well-known-5/JJ||since-1/IN	nsubj||well-known-5/JJ||cytokines-2/NNS	nsubj||activate-7/VB||cytokines-2/NNS	cop||well-known-5/JJ||are-3/VBP	advmod||well-known-5/JJ||also-4/RB	advcl||examined-12/VBD||well-known-5/JJ	aux||activate-7/VB||to-6/TO	xcomp||well-known-5/JJ||activate-7/VB	acomp||activate-7/VB||nf-îºb-8/JJ	det||study-11/NN||this-10/DT	nsubj||examined-12/VBD||study-11/NN	root||ROOT-0/null||examined-12/VBD	amod||effects-15/NNS||additive/synergistic-14/JJ	prep_for||examined-12/VBD||effects-15/NNS	prep_of||effects-15/NNS||ammonia-17/NN	prep_of||effects-15/NNS||cytokines-19/NNS	conj_and||ammonia-17/NN||cytokines-19/NNS	det||activation-22/NN||the-21/DT	prep_in||examined-12/VBD||activation-22/NN	prep_of||activation-22/NN||nf-îºb-24/NN	poss||role-27/NN||their-26/PRP$	prep_in||examined-12/VBD||role-27/NN	conj_and||activation-22/NN||role-27/NN	prep_in||role-27/NN||astrocyte-29/JJ	amod||astrocyte-29/JJ||swelling-30/VBG	ammonia-17||swelling-30||no_rel||since cytokines are also well-known to activate nf-îºb, this study examined for additive/synergistic effects of ammonia and cytokines in the activation of nf-îºb and their role in astrocyte swelling.
det||ability-2/NN||the-1/DT	nsubj||key-24/JJ||ability-2/NN	aux||subtype-4/VB||to-3/TO	vmod||ability-2/NN||subtype-4/VB	nn||cancer-8/NN||hr-5/NN	num||cancer-8/NN||+-6/CD	nn||cancer-8/NN||breast-7/NN	dobj||subtype-4/VB||cancer-8/NN	det||basis-11/NN||the-10/DT	prep_on||cancer-8/NN||basis-11/NN	amod||predictive-14/NNS||biomarkers-13/JJ	prep_of||basis-11/NN||predictive-14/NNS	prep_of||predictive-14/NNS||response-16/NN	prep_to||subtype-4/VB||ais-18/NN	prep_to||subtype-4/VB||tamoxifen-20/NN	conj_and||ais-18/NN||tamoxifen-20/NN	aux||key-24/JJ||would-21/MD	advmod||key-24/JJ||likely-22/RB	cop||key-24/JJ||be-23/VB	root||ROOT-0/null||key-24/JJ	prepc_to||key-24/JJ||determining-26/VBG	det||treatment-31/NN||the-27/DT	advmod||beneficial-29/JJ||most-28/RBS	amod||treatment-31/NN||beneficial-29/JJ	amod||treatment-31/NN||hormonal-30/JJ	dobj||determining-26/VBG||treatment-31/NN	amod||subpopulations-34/NNS||patient-33/JJ	prep_within||determining-26/VBG||subpopulations-34/NNS	det||process-38/NN||this-37/DT	nsubj||requires-39/VBZ||process-38/NN	conj_but||key-24/JJ||requires-39/VBZ	amod||investigation-41/NN||thorough-40/JJ	dobj||requires-39/VBZ||investigation-41/NN	tamoxifen-20||cancer-8||no_rel||the ability to subtype hr+ breast cancer on the basis of biomarkers predictive of response to ais and tamoxifen would likely be key to determining the most beneficial hormonal treatment within patient subpopulations, but this process requires thorough investigation.
det||benefits-2/NNS||the-1/DT	nsubjpass||discussed-7/VBN||benefits-2/NNS	amod||training-5/NN||physical-4/JJ	prep_of||benefits-2/NNS||training-5/NN	auxpass||discussed-7/VBN||are-6/VBP	root||ROOT-0/null||discussed-7/VBN	prep_along_with||discussed-7/VBN||recommendations-11/NNS	amod||activities-14/NNS||varying-13/VBG	prep_for||recommendations-11/NNS||activities-14/NNS	amod||management-18/NN||pa-associated-16/JJ	nn||management-18/NN||bloodglucose-17/NN	pobj||discussed-7/VBN||management-18/NN	nn||prevention-21/NN||diabetes-20/NN	pobj||discussed-7/VBN||prevention-21/NN	conj_and||management-18/NN||prevention-21/NN	amod||diabetesmellitus-24/NNS||gestational-23/JJ	pobj||discussed-7/VBN||diabetesmellitus-24/NNS	conj_and||management-18/NN||diabetesmellitus-24/NNS	amod||practices-30/NNS||safe-27/JJ	conj_and||safe-27/JJ||effective-29/JJ	amod||practices-30/NNS||effective-29/JJ	pobj||discussed-7/VBN||practices-30/NNS	conj_and||management-18/NN||practices-30/NNS	prep_for||practices-30/NNS||pa-32/NN	prep_with||pa-32/NN||diabetes-relatedcomplications-34/NNS	diabetes-relatedcomplications-34||diabetesmellitus-24||no||the benefits of physical training are discussed, along with recommendations for varying activities, pa-associated bloodglucose management, diabetes prevention, gestational diabetesmellitus, and safe and effective practices for pa with diabetes-relatedcomplications.
amod||levels-3/NNS||s100a12-1/JJ	nn||levels-3/NNS||serum-2/NN	nsubjpass||determined-5/VBN||levels-3/NNS	auxpass||determined-5/VBN||were-4/VBD	root||ROOT-0/null||determined-5/VBN	num||patients-8/NNS||64-7/CD	prep_in||determined-5/VBN||patients-8/NNS	prep_with||patients-8/NNS||ulcerativecolitis-10/NNS	appos||ulcerativecolitis-10/NNS||uc-12/NN	prep_in||determined-5/VBN||64-15/CD	conj_and||patients-8/NNS||64-15/CD	prep_with||64-15/CD||crohn-17/NN	dep||crohn-17/NN||sdisease-19/NN	appos||crohn-17/NN||cd-21/NN	prep_in||determined-5/VBN||73-24/CD	conj_and||patients-8/NNS||73-24/CD	prep_with||73-24/CD||ibs-26/NN	det||assay-34/NN||an-31/DT	amod||assay-34/NN||enzyme-linked-32/JJ	nn||assay-34/NN||immunosorbent-33/NN	prep_by_means_of||determined-5/VBN||assay-34/NN	enzyme--1||ibs-26||no_rel||s100a12 serum levels were determined in 64 patients with ulcerativecolitis (uc), 64 with crohn'sdisease (cd) and 73 with ibs, by means of an enzyme-linked immunosorbent assay.
det||combination-2/NN||the-1/DT	nsubj||reduced-12/VBD||combination-2/NN	amod||propofol-5/NN||cold-4/JJ	prep_of||combination-2/NN||propofol-5/NN	prep_of||combination-2/NN||pretreatment-7/NN	conj_and||propofol-5/NN||pretreatment-7/NN	prep_with||propofol-5/NN||remifentanil-9/NN	advmod||effectively-11/RB||more-10/RBR	advmod||reduced-12/VBD||effectively-11/RB	root||ROOT-0/null||reduced-12/VBD	det||incidence-14/NN||the-13/DT	dobj||reduced-12/VBD||incidence-14/NN	prep_of||incidence-14/NN||pain-16/NN	det||injection-19/NN||the-18/DT	prep_upon||reduced-12/VBD||injection-19/NN	prep_of||injection-19/NN||propofol-21/NN	det||treatment-24/NN||either-23/DT	prep_than||reduced-12/VBD||treatment-24/NN	advmod||reduced-12/VBD||alone-25/RB	pain-16||propofol-21||yes||the combination of cold propofol and pretreatment with remifentanil more effectively reduced the incidence of pain upon the injection of propofol than either treatment alone.
advmod||report-4/VBP||here-1/RB	nsubj||report-4/VBP||we-3/PRP	root||ROOT-0/null||report-4/VBP	mark||stem-27/VBP||that-5/IN	nsubj||stem-27/VBP||treatment-6/NN	amod||diabetes-10/NN||established-8/VBN	amod||diabetes-10/NN||autoimmune-caused-9/JJ	prep_of||treatment-6/NN||diabetes-10/NN	nn||mice-13/NNS||nod-12/NN	prep_in||diabetes-10/NN||mice-13/NNS	num||autologous-16/NNS||purified-15/CD	npadvmod||cd4-17/JJ||autologous-16/NNS	amod||tregs-21/NNS||cd4-17/JJ	amod||tregs-21/NNS||+-18/JJ	amod||tregs-21/NNS||cd62l-19/JJ	amod||tregs-21/NNS||+-20/JJ	prep_with||mice-13/NNS||tregs-21/NNS	vmod||diabetes-10/NN||co-cultured-22/VBN	amod||blood-26/NN||human-24/JJ	nn||blood-26/NN||cord-25/NN	prep_with||co-cultured-22/VBN||blood-26/NN	ccomp||report-4/VBP||stem-27/VBP	nsubj||eliminate-33/VB||cells-28/NNS	nsubj||promote-36/VB||cells-28/NNS	nsubj||reconstitute-55/VB||cells-28/NNS	dep||cells-28/NNS||cb-sc-30/JJ	aux||eliminate-33/VB||can-32/MD	ccomp||stem-27/VBP||eliminate-33/VB	dobj||eliminate-33/VB||hyperglycemia-34/NN	ccomp||stem-27/VBP||promote-36/VB	conj_and||eliminate-33/VB||promote-36/VB	amod||²-39/NNS||islet-37/JJ	nn||²-39/NNS||î-38/NN	dobj||promote-36/VB||²-39/NNS	dep||²-39/NNS||cell-41/NN	vmod||cell-41/NN||regeneration-42/VBN	aux||increase-44/VB||to-43/TO	xcomp||regeneration-42/VBN||increase-44/VB	nn||²-46/NNS||î-45/NN	dobj||increase-44/VB||²-46/NNS	nn||mass-49/NN||cell-48/NN	dep||cell-41/NN||mass-49/NN	nn||production-52/NN||insulin-51/NN	dep||cell-41/NN||production-52/NN	conj_and||mass-49/NN||production-52/NN	ccomp||stem-27/VBP||reconstitute-55/VB	conj_and||eliminate-33/VB||reconstitute-55/VB	amod||architecture-57/NN||islet-56/JJ	dobj||reconstitute-55/VB||architecture-57/NN	hyperglycemia-34||insulin-51||yes||here, we report that treatment of established autoimmune-caused diabetes in nod mice with purified autologous cd4+cd62l+ tregs co-cultured with human cord blood stem cells (cb-sc) can eliminate hyperglycemia, promote islet î²-cell regeneration to increase î²-cell mass and insulin production, and reconstitute islet architecture.
nsubj||believe-2/VBP||we-1/PRP	root||ROOT-0/null||believe-2/VBP	mark||show-46/VBP||that-3/IN	poss||data-8/NNS||our-6/PRP$	amod||data-8/NNS||previous-7/JJ	prep_together_with||infection-22/NN||data-8/NNS	det||prevalence-12/NN||the-10/DT	amod||prevalence-12/NN||high-11/JJ	prep_on||data-8/NNS||prevalence-12/NN	nn||africae-15/NN||r.-14/NN	prep_of||prevalence-12/NN||africae-15/NN	nn||ticks-18/NNS||amblyomma-17/NN	prep_in||africae-15/NN||ticks-18/NNS	nn||felis-21/NNS||r.-20/NN	prep_in||africae-15/NN||felis-21/NNS	conj_and||ticks-18/NNS||felis-21/NNS	nsubj||show-46/VBP||infection-22/NN	prep_in||infection-22/NN||patients-24/NNS	det||results-28/NNS||the-26/DT	amod||results-28/NNS||presented-27/JJ	appos||infection-22/NN||results-28/NNS	det||distribution-31/NN||the-30/DT	prep_on||results-28/NNS||distribution-31/NN	amod||rickettsiae-34/NN||pathogenic-33/JJ	prep_of||distribution-31/NN||rickettsiae-34/NN	prep_in||rickettsiae-34/NN||ticks-36/NNS	det||case-42/NN||the-38/DT	amod||case-42/NN||first-39/JJ	nn||case-42/NN||r.-40/NN	nn||case-42/NN||conorii-41/NN	conj_and||infection-22/NN||case-42/NN	nsubj||show-46/VBP||case-42/NN	amod||africa-45/NN||west-44/JJ	prep_in||case-42/NN||africa-45/NN	ccomp||believe-2/VBP||show-46/VBP	mark||is-53/VBZ||that-47/IN	det||population-50/NN||the-48/DT	amod||population-50/NN||rural-49/JJ	nsubj||is-53/VBZ||population-50/NN	prep_of||population-50/NN||senegal-52/NN	ccomp||show-46/VBP||is-53/VBZ	prep_at||is-53/VBZ||risk-55/NN	amod||tick-bornerickettsioses-58/NNS||other-57/JJ	prep_for||risk-55/NN||tick-bornerickettsioses-58/NNS	nsubj||causes-63/NNS||tick-bornerickettsioses-58/NNS	cop||causes-63/NNS||are-61/VBP	amod||causes-63/NNS||significant-62/JJ	rcmod||tick-bornerickettsioses-58/NNS||causes-63/NNS	amod||disease-66/NN||febrile-65/JJ	prep_of||causes-63/NNS||disease-66/NN	det||area-69/NN||this-68/DT	prep_in||disease-66/NN||area-69/NN	tick-bornerickettsioses-58||rickettsiae-34||no||we believe that together with our previous data on the high prevalence of r. africae in amblyomma ticks and r. felis infection in patients , the presented results on the distribution of pathogenic rickettsiae in ticks and the first r. conorii case in west africa show that the rural population of senegal is at risk for other tick-bornerickettsioses , which are significant causes of febrile disease in this area .
amod||areas-3/NNS||urban-2/JJ	prep_in||become-15/VBN||areas-3/NNS	det||prevalence-8/NN||a-5/DT	amod||prevalence-8/NN||high-6/JJ	nn||prevalence-8/NN||background-7/NN	prep_with||areas-3/NNS||prevalence-8/NN	prep_of||prevalence-8/NN||hiv-10/NN	det||ed-13/NN||the-12/DT	nsubj||become-15/VBN||ed-13/NN	aux||become-15/VBN||has-14/VBZ	root||ROOT-0/null||become-15/VBN	det||site-19/NN||an-16/DT	advmod||important-18/JJ||increasingly-17/RB	amod||site-19/NN||important-18/JJ	xcomp||become-15/VBN||site-19/NN	prepc_for||become-15/VBN||identifying-21/VBG	dobj||identifying-21/VBG||hivinfection-22/NN	hivinfection-22||hiv-10||no||in urban areas with a high background prevalence of hiv, the ed has become an increasingly important site for identifying hivinfection.
amod||tests-2/NNS||statistical-1/JJ	nsubj||indicate-5/VB||tests-2/NNS	aux||indicate-5/VB||did-3/VBD	neg||indicate-5/VB||not-4/RB	root||ROOT-0/null||indicate-5/VB	advmod||indicate-5/VB||heterogeneity-6/RB	det||otitismedia-17/NN||the-8/DT	amod||otitismedia-17/NN||meta-analysis-9/JJ	det||effects-12/NNS||the-11/DT	prep_on||meta-analysis-9/JJ||effects-12/NNS	prep_of||effects-12/NNS||amoxicillin-14/NNP	prep_on||meta-analysis-9/JJ||acute-16/JJ	prep_in||indicate-5/VB||otitismedia-17/NN	dep||otitismedia-17/NN||q-19/NN	dep||q-19/NN||=-20/NNP	num||=-20/NNP||3.29-21/CD	num||=-20/NNP||p-23/CD	dep||0.51-25/CD||=-24/SYM	rcmod||=-20/NNP||0.51-25/CD	dep||=-20/NNP||i2-27/NNS	dep||%-30/NN||=-28/SYM	num||%-30/NN||0-29/CD	rcmod||i2-27/NNS||%-30/NN	dep||=-20/NNP||t2-32/NNS	dep||0-34/CD||=-33/SYM	rcmod||t2-32/NNS||0-34/CD	otitismedia-17||amoxicillin-14||yes||statistical tests did not indicate heterogeneity in the meta-analysis on the effects of amoxicillin on acute otitismedia (q = 3.29, p = 0.51; i2 = 0%; t2 = 0).
det||role-6/NN||the-3/DT	advmod||demonstrated-5/JJ||previously-4/RB	amod||role-6/NN||demonstrated-5/JJ	prep_due_to||suggested-27/VBN||role-6/NN	det||elements-9/NNS||these-8/DT	prep_of||role-6/NN||elements-9/NNS	prepc_in||elements-9/NNS||altering-11/VBG	amod||control-13/NN||transcriptional-12/JJ	dobj||altering-11/VBG||control-13/NN	det||findings-16/NNS||the-15/DT	dobj||altering-11/VBG||findings-16/NNS	conj_and||control-13/NN||findings-16/NNS	prepc_from||altering-11/VBG||comparing-18/VBG	det||sequences-23/NNS||the-19/DT	num||sequences-23/NNS||two-20/CD	amod||sequences-23/NNS||gonococcal-21/JJ	nn||sequences-23/NNS||genome-22/NN	dobj||comparing-18/VBG||sequences-23/NNS	nsubjpass||suggested-27/VBN||it-25/PRP	auxpass||suggested-27/VBN||is-26/VBZ	root||ROOT-0/null||suggested-27/VBN	mark||contribute-34/VBP||that-28/IN	amod||differences-30/NNS||regulatory-29/JJ	nsubj||contribute-34/VBP||differences-30/NNS	nsubj||contribute-34/VBP||differences-30/NNS	vmod||differences-30/NNS||orchestrated-31/VBN	agent||orchestrated-31/VBN||cree-33/NN	ccomp||suggested-27/VBN||contribute-34/VBP	ccomp||suggested-27/VBN||contribute-34/VBP	conj_and||contribute-34/VBP||contribute-34/VBP	det||differences-37/NNS||the-36/DT	prep_to||contribute-34/VBP||differences-37/NNS	prep_between||differences-37/NNS||strains-39/NNS	advmod||contribute-34/VBP||also-41/RB	det||n.gonorrhoeae-50/NN||the-43/DT	advmod||related-45/JJ||closely-44/RB	amod||n.gonorrhoeae-50/NN||related-45/JJ	advmod||distinct-48/JJ||clinically-47/RB	conj_yet||related-45/JJ||distinct-48/JJ	amod||n.gonorrhoeae-50/NN||distinct-48/JJ	nn||n.gonorrhoeae-50/NN||species-49/NN	prep_between||contribute-34/VBP||n.gonorrhoeae-50/NN	prep_between||contribute-34/VBP||neisseriameningitidis-52/NNS	conj_and||n.gonorrhoeae-50/NN||neisseriameningitidis-52/NNS	nn||lactamica-56/NN||neisseria-55/NN	prep_between||contribute-34/VBP||lactamica-56/NN	conj_and||n.gonorrhoeae-50/NN||lactamica-56/NN	gonococcal-21||n.gonorrhoeae-50||no||due to the previously demonstrated role of these elements in altering transcriptional control and the findings from comparing the two gonococcal genome sequences , it is suggested that regulatory differences orchestrated by cree contribute to the differences between strains and also between the closely related yet clinically distinct species n.gonorrhoeae , neisseriameningitidis , and neisseria lactamica .
nsubj||showed-27/VBD||cell-1/NN	amod||cell-1/NN||swelling-2/VBG	auxpass||increased-4/VBN||was-3/VBD	rcmod||cell-1/NN||increased-4/VBN	nn||-rrb--10/NNS||ammonia-6/NNP	nn||-rrb--10/NNS||-lrb--7/NNP	number||%-9/NN||43-8/CD	amod||-rrb--10/NNS||%-9/NN	agent||increased-4/VBN||-rrb--10/NNS	agent||increased-4/VBN||cytokines-13/NNS	conj_and||-rrb--10/NNS||cytokines-13/NNS	vmod||cytokines-13/NNS||-lrb--14/VBG	num||%-16/NN||37-15/CD	dobj||-lrb--14/VBG||%-16/NN	advmod||-lrb--14/VBG||-rrb--17/RB	num||co-treatment-22/NN||24-19/CD	amod||co-treatment-22/NN||h.-20/JJ	amod||co-treatment-22/NN||simultaneous-21/JJ	prep_at||-lrb--14/VBG||co-treatment-22/NN	prep_with||co-treatment-22/NN||cytokines-24/NNS	prep_with||co-treatment-22/NN||ammonia-26/NN	conj_and||cytokines-24/NNS||ammonia-26/NN	root||ROOT-0/null||showed-27/VBD	neg||swelling-30/NN||no-28/DT	amod||swelling-30/NN||additional-29/JJ	dobj||showed-27/VBD||swelling-30/NN	ammonia-26||swelling-30||no_rel||cell swelling was increased by ammonia -lrb- 43 % -rrb- and by cytokines -lrb- 37 % -rrb- at 24 h. simultaneous co-treatment with cytokines and ammonia showed no additional swelling .
det||genes-4/NNS||both-1/DT	amod||genes-4/NNS||early/transient/proliferation-2/JJ	nn||genes-4/NNS||response-3/NN	nsubj||able-9/JJ||genes-4/NNS	nsubj||predict-11/VB||genes-4/NNS	amod||genes-7/NNS||continuous/late/estrogen-response-6/JJ	conj_and||genes-4/NNS||genes-7/NNS	nsubj||able-9/JJ||genes-7/NNS	nsubj||predict-11/VB||genes-7/NNS	cop||able-9/JJ||are-8/VBP	root||ROOT-0/null||able-9/JJ	aux||predict-11/VB||to-10/TO	xcomp||able-9/JJ||predict-11/VB	dobj||predict-11/VB||prognosis-12/NN	amod||breasttumours-15/NNS||primary-14/JJ	prep_of||prognosis-12/NN||breasttumours-15/NNS	det||manner-19/NN||a-17/DT	amod||manner-19/NN||dynamic-18/JJ	prep_in||predict-11/VB||manner-19/NN	breasttumours-15||estrogen--1||yes||both early/transient/proliferation response genes and continuous/late/estrogen-response genes are able to predict prognosis of primary breasttumours in a dynamic manner.
nsubj||calculated-3/VBD||we-2/PRP	ccomp||-lrb--12/VBD||calculated-3/VBD	det||sensitivity-5/NN||the-4/DT	dobj||calculated-3/VBD||sensitivity-5/NN	nn||value-11/NN||specificity-7/NN	amod||value-11/NN||positive-9/JJ	amod||value-11/NN||predictive-10/JJ	nsubj||-lrb--12/VBD||value-11/NN	root||ROOT-0/null||-lrb--12/VBD	number||-rrb--14/CD||ppv-13/CD	dobj||-lrb--12/VBD||-rrb--14/CD	amod||-rrb--22/NNP||negative-17/JJ	amod||-rrb--22/NNP||predictive-18/JJ	nn||-rrb--22/NNP||value-19/NN	nn||-rrb--22/NNP||-lrb--20/NNP	nn||-rrb--22/NNP||npv-21/NNP	dobj||-lrb--12/VBD||-rrb--22/NNP	conj_and||-rrb--14/CD||-rrb--22/NNP	amod||anti-th-25/NN||various-24/JJ	prep_of||-rrb--22/NNP||anti-th-25/NN	cc||anti-th-25/NN||and-26/CC	prep_to||-lrb--12/VBD||titers-29/NNS	vmod||titers-29/NNS||using-30/VBG	amod||cases-33/NNS||culture-confirmed-31/JJ	nn||cases-33/NNS||typhoidfever-32/NN	dobj||using-30/VBG||cases-33/NNS	iobj||using-30/VBG||cases-33/NNS	prep_as||cases-33/NNS||the-35/DT	amod||positives-39/NNS||true-38/JJ	dep||cases-33/NNS||positives-39/NNS	det||children-46/NNS||all-43/DT	amod||children-46/NNS||other-44/JJ	amod||children-46/NNS||febrile-45/JJ	dep||cases-33/NNS||children-46/NNS	conj_and||positives-39/NNS||children-46/NNS	nn||culture-49/NN||blood-48/NN	prep_with||children-46/NNS||culture-49/NN	amod||culture-49/NN||negative-50/JJ	nn||the-54/NNP||s.typhi-52/NNP	amod||the-54/NNP||as-53/IN	prep_for||negative-50/JJ||the-54/NNP	amod||negatives-58/NNS||true-57/JJ	dep||the-54/NNP||negatives-58/NNS	typhoidfever-32||s.typhi-52||no||'' we calculated the sensitivity , specificity , positive predictive value -lrb- ppv -rrb- , and negative predictive value -lrb- npv -rrb- of various anti-th and - to titers using culture-confirmed typhoidfever cases as the '' `` true positives '' '' and all other febrile children with blood culture negative for s.typhi as the '' `` true negatives . '' '' ''
nsubj||lidocaine-4/VBP||pretreatment-1/NN	prep_with||pretreatment-1/NN||iv-3/NN	root||ROOT-0/null||lidocaine-4/VBP	num||mg-6/NNP||40-5/CD	dobj||lidocaine-4/VBP||mg-6/NNP	nn||mg-10/NNS||ketamine-8/NNP	num||mg-10/NNS||25-9/CD	dobj||lidocaine-4/VBP||mg-10/NNS	conj_plus||mg-6/NNP||mg-10/NNS	det||tourniquet-14/NN||a-12/DT	nn||tourniquet-14/NN||rubber-13/NN	prep_with||lidocaine-4/VBP||tourniquet-14/NN	det||min-19/NN||the-16/DT	nn||min-19/NN||forearm-17/NNP	num||min-19/NN||1-18/CD	prep_on||tourniquet-14/NN||min-19/NN	mark||effective-28/JJ||before-20/IN	det||injection-22/NN||the-21/DT	nsubj||effective-28/JJ||injection-22/NN	nn||propofol-25/NN||microemulsion-24/NN	prep_of||injection-22/NN||propofol-25/NN	cop||effective-28/JJ||is-26/VBZ	advmod||effective-28/JJ||more-27/RBR	advcl||lidocaine-4/VBP||effective-28/JJ	nn||mg-32/NN||lidocaine-30/NN	num||mg-32/NN||40-31/CD	prep_than||effective-28/JJ||mg-32/NN	nn||mg-36/NN||ketamine-34/NN	num||mg-36/NN||25-35/CD	prep_than||effective-28/JJ||mg-36/NN	conj_or||mg-32/NN||mg-36/NN	advmod||effective-28/JJ||alone-37/RB	prepc_in||effective-28/JJ||preventing-39/VBG	dobj||preventing-39/VBG||pain-40/NN	det||injection-43/NN||the-42/DT	prep_from||preventing-39/VBG||injection-43/NN	nn||propofol-46/NN||microemulsion-45/NN	prep_of||injection-43/NN||propofol-46/NN	pain-40||lidocaine-30||yes||pretreatment with iv lidocaine 40 mg plus ketamine 25 mg with a rubber tourniquet on the forearm 1 min before the injection of microemulsion propofol is more effective than lidocaine 40 mg or ketamine 25 mg alone in preventing pain from the injection of microemulsion propofol.
advmod||were-4/VBD||consistently-1/RB	expl||were-4/VBD||there-3/EX	root||ROOT-0/null||were-4/VBD	amod||levels-6/NNS||reduced-5/VBN	nsubj||were-4/VBD||levels-6/NNS	amod||cytokines-9/NNS||proinflammatory-8/JJ	prep_of||levels-6/NNS||cytokines-9/NNS	prep_of||levels-6/NNS||chemokines-11/NNS	conj_and||cytokines-9/NNS||chemokines-11/NNS	dep||levels-6/NNS||tnf-î-13/VBN	amod||protein-1-20/NN||±-14/JJ	conj_and||±-14/JJ||il-6-16/JJ	amod||protein-1-20/NN||il-6-16/JJ	conj_and||±-14/JJ||monocyte-18/JJ	amod||protein-1-20/NN||monocyte-18/JJ	nn||protein-1-20/NN||chemoattractant-19/NN	dobj||tnf-î-13/VBN||protein-1-20/NN	amod||levels-24/NNS||increased-23/VBN	nsubj||were-4/VBD||levels-24/NNS	conj_and||levels-6/NNS||levels-24/NNS	det||cytokine-28/NN||the-26/DT	amod||cytokine-28/NN||anti-inflammatory/regulatory-27/JJ	prep_of||levels-24/NNS||cytokine-28/NN	dep||cytokine-28/NN||il-10-30/JJ	prep_in||levels-24/NNS||sera-33/NN	amod||mice-37/NNS||uc-mscs-35/JJ	amod||mice-37/NNS||treated-36/JJ	prep_of||levels-24/NNS||mice-37/NNS	uc--1||anti-inflammatory--1||no_rel||consistently, there were reduced levels of proinflammatory cytokines and chemokines (tnf-î±, il-6 and monocyte chemoattractant protein-1) and increased levels of the anti-inflammatory/regulatory cytokine (il-10) in sera of uc-mscs treated mice.
nsubj||complication-5/NN||pneumomediastinum-1/NN	cop||complication-5/NN||is-2/VBZ	det||complication-5/NN||an-3/DT	amod||complication-5/NN||uncommon-4/JJ	root||ROOT-0/null||complication-5/NN	nsubj||occurs-9/VBZ||complication-5/NN	nsubj||occur-20/VB||complication-5/NN	prep_of||complication-5/NN||cocaineabuse-7/NN	rcmod||complication-5/NN||occurs-9/VBZ	advmod||commonly-11/RB||more-10/RBR	advmod||occurs-9/VBZ||commonly-11/RB	advmod||smoked-15/VBN||when-12/WRB	nsubjpass||smoked-15/VBN||cocaine-13/NN	auxpass||smoked-15/VBN||is-14/VBZ	advcl||commonly-11/RB||smoked-15/VBN	aux||occur-20/VB||can-18/MD	advmod||occur-20/VB||also-19/RB	rcmod||complication-5/NN||occur-20/VB	conj_but||occurs-9/VBZ||occur-20/VB	advmod||insufflated-25/JJ||when-21/WRB	nsubj||insufflated-25/JJ||cocaine-22/NN	cop||insufflated-25/JJ||is-23/VBZ	advmod||insufflated-25/JJ||nasally-24/RB	advcl||occur-20/VB||insufflated-25/JJ	cocaineabuse-7||cocaine-22||no||pneumomediastinum is an uncommon complication of cocaineabuse that occurs more commonly when cocaine is smoked, but can also occur when cocaine is nasally insufflated.
advmod||refractory-22/VBN||conversely-1/RB	det||pc-3-8/NN||the-3/DT	nn||pc-3-8/NN||prostate-4/NN	nn||pc-3-8/NN||cancer-5/NN	nn||pc-3-8/NN||cell-6/NN	nn||pc-3-8/NN||line-7/NN	nsubjpass||refractory-22/VBN||pc-3-8/NN	nsubj||support-31/VB||pc-3-8/NN	amod||negative-12/NN||androgen-10/JJ	nn||negative-12/NN||receptor-11/NN	appos||pc-3-8/NN||negative-12/NN	det||line-19/NN||the-15/DT	amod||line-19/NN||pancreatic-16/JJ	nn||line-19/NN||cancer-17/NN	nn||line-19/NN||cell-18/NN	conj_and||pc-3-8/NN||line-19/NN	nsubjpass||refractory-22/VBN||line-19/NN	amod||line-19/NN||panc-1-20/JJ	auxpass||refractory-22/VBN||were-21/VBD	root||ROOT-0/null||refractory-22/VBN	det||effect-27/NN||the-24/DT	amod||effect-27/NN||viral-25/JJ	amod||effect-27/NN||cytopathic-26/JJ	prep_to||refractory-22/VBN||effect-27/NN	aux||support-31/VB||did-29/VBD	neg||support-31/VB||not-30/RB	conj_and||refractory-22/VBN||support-31/VB	amod||replication-33/NN||viral-32/JJ	dobj||support-31/VB||replication-33/NN	androgen-10||cancer-17||no_rel||conversely, the prostate cancer cell line pc-3 (androgen receptor negative) and the pancreatic cancer cell line panc-1 were refractory to the viral cytopathic effect and did not support viral replication.
nsubjpass||approved-4/VBN||adalimumab-1/NN	auxpass||approved-4/VBN||was-2/VBD	advmod||approved-4/VBN||originally-3/RB	root||ROOT-0/null||approved-4/VBN	prepc_for||approved-4/VBN||treating-6/VBG	dobj||treating-6/VBG||rheumatoidarthritis-7/NNS	rheumatoidarthritis-7||adalimumab-1||yes||adalimumab was originally approved for treating rheumatoidarthritis.
advmod||inhibits-4/VBZ||moreover-1/RB	nsubj||inhibits-4/VBZ||curcumin-3/NN	root||ROOT-0/null||inhibits-4/VBZ	amod||angiogenesis-8/NNS||microvascular-5/JJ	amod||angiogenesis-8/NNS||endothelial-6/JJ	nn||angiogenesis-8/NNS||cell-7/NN	dobj||inhibits-4/VBZ||angiogenesis-8/NNS	prep_through||inhibits-4/VBZ||inhibition-10/NN	amod||expression-13/NN||cox-2-12/JJ	prep_of||inhibition-10/NN||expression-13/NN	amod||production-16/NN||pge2-15/JJ	prep_of||inhibition-10/NN||production-16/NN	conj_and||expression-13/NN||production-16/NN	vmod||inhibits-4/VBZ||suggesting-18/VBG	mark||possesses-23/VBZ||that-19/IN	det||product-22/NN||this-20/DT	amod||product-22/NN||natural-21/JJ	nsubj||possesses-23/VBZ||product-22/NN	ccomp||suggesting-18/VBG||possesses-23/VBZ	amod||properties-25/NNS||antiangiogenic-24/JJ	dobj||possesses-23/VBZ||properties-25/NNS	nsubj||warrants-28/VBZ||properties-25/NNS	rcmod||properties-25/NNS||warrants-28/VBZ	amod||investigation-30/NN||further-29/JJ	dobj||warrants-28/VBZ||investigation-30/NN	amod||treatment-33/NN||adjuvant-32/JJ	prep_as||warrants-28/VBZ||treatment-33/NN	prep_of||treatment-33/NN||ibd-35/NN	prep_of||treatment-33/NN||cancer-37/NN	conj_and||ibd-35/NN||cancer-37/NN	pge2-15||ibd-35||no_rel||moreover, curcumin inhibits microvascular endothelial cell angiogenesis through inhibition of cox-2 expression and pge2 production, suggesting that this natural product possesses antiangiogenic properties, which warrants further investigation as adjuvant treatment of ibd and cancer.
advmod||indicates-5/VBZ||thus-1/RB	poss||study-4/NN||our-3/PRP$	nsubj||indicates-5/VBZ||study-4/NN	root||ROOT-0/null||indicates-5/VBZ	mark||vaccine-13/NN||that-6/IN	nsubj||vaccine-13/NN||pcd685a-7/NNS	aux||vaccine-13/NN||may-8/MD	cop||vaccine-13/NN||be-9/VB	det||vaccine-13/NN||an-10/DT	amod||vaccine-13/NN||efficient-11/JJ	nn||vaccine-13/NN||booster-12/NN	ccomp||indicates-5/VBZ||vaccine-13/NN	prep_against||vaccine-13/NN||tb-15/NN	det||ability-19/NN||a-17/DT	amod||ability-19/NN||strong-18/JJ	prep_with||tb-15/NN||ability-19/NN	aux||enhance-21/VB||to-20/TO	vmod||ability-19/NN||enhance-21/VB	amod||immunity-24/NN||prior-22/JJ	nn||immunity-24/NN||bcg-23/NN	dobj||enhance-21/VB||immunity-24/NN	tb-15||bcg-23||yes||thus, our study indicates that pcd685a may be an efficient booster vaccine against tb with a strong ability to enhance prior bcg immunity.
advmod||shown-8/VBN||however-1/RB	amod||analyses-6/NNS||proteomic-3/JJ	conj_and||proteomic-3/JJ||transcriptomic-5/JJ	amod||analyses-6/NNS||transcriptomic-5/JJ	nsubj||shown-8/VBN||analyses-6/NNS	aux||shown-8/VBN||have-7/VBP	root||ROOT-0/null||shown-8/VBN	mark||upregulated-17/VBN||that-9/IN	det||number-11/NN||a-10/DT	nsubjpass||upregulated-17/VBN||number-11/NN	nsubjpass||upregulated-17/VBN||number-11/NN	nsubjpass||upregulated-17/VBN||number-11/NN	nn||genes-14/NNS||usp-13/NN	prep_of||number-11/NN||genes-14/NNS	auxpass||upregulated-17/VBN||are-15/VBP	advmod||upregulated-17/VBN||significantly-16/RB	ccomp||shown-8/VBN||upregulated-17/VBN	ccomp||shown-8/VBN||upregulated-17/VBN	ccomp||shown-8/VBN||upregulated-17/VBN	conj_and||upregulated-17/VBN||upregulated-17/VBN	conj_and||upregulated-17/VBN||upregulated-17/VBN	amod||conditions-20/NNS||hypoxic-19/JJ	prep_under||upregulated-17/VBN||conditions-20/NNS	prep_in||upregulated-17/VBN||response-23/NN	prep_to||upregulated-17/VBN||nitricoxide-25/NN	prep_to||upregulated-17/VBN||carbonmonoxide-27/NN	conj_and||nitricoxide-25/NN||carbonmonoxide-27/NN	prep_during||upregulated-17/VBN||m.tuberculosisinfection-33/NN	amod||lines-37/NNS||macrophage-35/JJ	nn||lines-37/NNS||cell-36/NN	prep_of||m.tuberculosisinfection-33/NN||lines-37/NNS	tuberculosisinfection--1||carbonmonoxide-27||no_rel||however , proteomic and transcriptomic analyses have shown that a number of usp genes are significantly upregulated under hypoxic conditions and in response to nitricoxide and carbonmonoxide , as well as during m.tuberculosisinfection of macrophage cell lines .
prep_in||involved-16/VBN||addition-2/NN	nsubjpass||involved-16/VBN||transport-4/NN	conj_and||transport-4/NN||diffusion-6/NN	nsubjpass||involved-16/VBN||diffusion-6/NN	prep_of||transport-4/NN||ions-8/NNS	det||epithelium-14/NN||the-10/DT	nn||epithelium-14/NN||bbb-11/NN	conj_and||bbb-11/NN||cp-13/NN	nn||epithelium-14/NN||cp-13/NN	prep_by||ions-8/NNS||epithelium-14/NN	auxpass||involved-16/VBN||are-15/VBP	root||ROOT-0/null||involved-16/VBN	det||formation-19/NN||the-18/DT	prep_in||involved-16/VBN||formation-19/NN	prep_of||formation-19/NN||fluid-21/NN	det||isf-24/NN||the-23/DT	prep_of||formation-19/NN||isf-24/NN	conj_and||fluid-21/NN||isf-24/NN	prep_of||formation-19/NN||csf-26/NN	conj_and||fluid-21/NN||csf-26/NN	advmod||involved-16/VBN||respectively-28/RB	dep||involved-16/VBN||so-30/IN	det||part-33/NN||the-31/DT	amod||part-33/NN||last-32/JJ	nsubj||discusses-37/VBZ||part-33/NN	nsubj||cp-51/VBP||part-33/NN	det||review-36/NN||this-35/DT	prep_of||part-33/NN||review-36/NN	parataxis||involved-16/VBN||discusses-37/VBZ	amod||biology-39/NN||molecular-38/JJ	dobj||discusses-37/VBZ||biology-39/NN	nn||transporters/exchangers-42/NNS||ion-41/NN	prep_of||biology-39/NN||transporters/exchangers-42/NNS	nn||channels-45/NNS||ion-44/NN	prep_of||biology-39/NN||channels-45/NNS	conj_and||transporters/exchangers-42/NNS||channels-45/NNS	det||endothelial-49/NN||the-47/DT	nn||endothelial-49/NN||brain-48/NN	prep_in||discusses-37/VBZ||endothelial-49/NN	parataxis||involved-16/VBN||cp-51/VBP	conj_and||discusses-37/VBZ||cp-51/VBP	amod||cells-53/NNS||epithelial-52/JJ	dobj||cp-51/VBP||cells-53/NNS	ions-8||cp-51||no_rel||in addition, transport and diffusion of ions by the bbb and cp epithelium are involved in the formation of fluid, the isf and csf, respectively, so the last part of this review discusses molecular biology of ion transporters/exchangers and ion channels in the brain endothelial and cp epithelial cells.
csubj||increase-6/NN||compounding-1/VBG	det||problems-3/NNS||these-2/DT	dobj||compounding-1/VBG||problems-3/NNS	cop||increase-6/NN||is-4/VBZ	det||increase-6/NN||the-5/DT	root||ROOT-0/null||increase-6/NN	det||number-9/NN||the-8/DT	prep_in||increase-6/NN||number-9/NN	prep_of||number-9/NN||cases-11/NNS	prep_of||cases-11/NNS||leishmania-13/NN	nn||coinfection-16/NN||hiv-15/NN	dep||increase-6/NN||coinfection-16/NN	det||overlap-21/NN||the-20/DT	prep_due_to||increase-6/NN||overlap-21/NN	det||epidemic-25/NN||the-23/DT	nn||epidemic-25/NN||aids-24/NNS	prep_between||overlap-21/NN||epidemic-25/NN	prep_between||overlap-21/NN||leishmaniasis-27/NNS	conj_and||epidemic-25/NN||leishmaniasis-27/NNS	aids-24||hiv-15||no||compounding these problems is the increase in the number of cases of leishmania -hiv coinfection, due to the overlap between the aids epidemic and leishmaniasis.
nsubjpass||adopted-7/VBN||artemether/lumefantrine-1/NN	appos||artemether/lumefantrine-1/NN||al-3/NNP	aux||adopted-7/VBN||has-5/VBZ	auxpass||adopted-7/VBN||been-6/VBN	root||ROOT-0/null||adopted-7/VBN	det||treatment-10/NN||the-9/DT	prep_as||adopted-7/VBN||treatment-10/NN	prep_of||treatment-10/NN||choice-12/NN	amod||malaria-15/NN||uncomplicated-14/JJ	prep_for||adopted-7/VBN||malaria-15/NN	prep_in||malaria-15/NN||kenya-17/NN	amod||countries-20/NNS||other-19/JJ	prep_for||adopted-7/VBN||countries-20/NNS	conj_and||malaria-15/NN||countries-20/NNS	det||region-23/NN||the-22/DT	prep_in||countries-20/NNS||region-23/NN	malaria-15||lumefantrine--1||yes||artemether/lumefantrine (al) has been adopted as the treatment of choice for uncomplicated malaria in kenya and other countries in the region.
advmod||decreased-9/VBN||notably-1/RB	nn||strains-5/NNS||s.â-3/NN	nn||strains-5/NNS||enterica-4/NN	nsubj||decreased-9/VBN||strains-5/NNS	vmod||strains-5/NNS||lacking-6/VBG	dobj||lacking-6/VBG||rida-7/NN	aux||decreased-9/VBN||have-8/VBP	root||ROOT-0/null||decreased-9/VBN	dobj||decreased-9/VBN||activity-10/NN	det||transaminase-14/NN||the-12/DT	amod||transaminase-14/NN||plp-dependent-13/JJ	prep_of||activity-10/NN||transaminase-14/NN	dep||activity-10/NN||b-15/SYM	amod||ilve-17/JJ||enzyme-16/JJ	amod||activity-10/NN||ilve-17/JJ	det||enzyme-20/NN||an-19/DT	appos||activity-10/NN||enzyme-20/NN	vmod||enzyme-20/NN||involved-21/VBN	amod||biosynthesis-25/NNS||branched-chain-23/JJ	amod||biosynthesis-25/NNS||aminoacid-24/JJ	prep_in||involved-21/VBN||biosynthesis-25/NNS	enzyme-20||rida-7||no_rel||notably, s.â enterica strains lacking rida have decreased activity of the plp-dependent transaminase b enzyme ilve, an enzyme involved in branched-chain aminoacid biosynthesis.
nn||falciparum-2/NN||plasmodium-1/NN	nsubj||evolved-13/VBN||falciparum-2/NN	nsubj||become-15/VB||falciparum-2/NN	det||agent-6/NN||the-4/DT	amod||agent-6/NN||causative-5/JJ	appos||falciparum-2/NN||agent-6/NN	amod||malaria-10/NN||severe-8/JJ	amod||malaria-10/NN||human-9/JJ	prep_of||agent-6/NN||malaria-10/NN	aux||evolved-13/VBN||has-12/VBZ	root||ROOT-0/null||evolved-13/VBN	aux||become-15/VB||to-14/TO	xcomp||evolved-13/VBN||become-15/VB	acomp||become-15/VB||resistant-16/JJ	advmod||successful-19/JJ||previously-18/RB	amod||chemotherapies-21/NNS||successful-19/JJ	amod||chemotherapies-21/NNS||antimalarial-20/JJ	prep_to||resistant-16/JJ||chemotherapies-21/NNS	advmod||notably-24/RB||most-23/RBS	advmod||chemotherapies-21/NNS||notably-24/RB	dep||chemotherapies-21/NNS||chloroquine-25/NN	det||antifolates-28/NNS||the-27/DT	dep||chemotherapies-21/NNS||antifolates-28/NNS	conj_and||chloroquine-25/NN||antifolates-28/NNS	malaria-10||chloroquine-25||yes||plasmodium falciparum , the causative agent of severe human malaria, has evolved to become resistant to previously successful antimalarial chemotherapies, most notably chloroquine and the antifolates.
nsubj||develops-3/VBZ||coldagglutinindisease-1/NN	advmod||develops-3/VBZ||usually-2/RB	root||ROOT-0/null||develops-3/VBZ	mark||directed-16/VBD||as-4/IN	det||result-6/NN||a-5/DT	nsubj||directed-16/VBD||result-6/NN	det||production-9/NN||the-8/DT	prep_of||result-6/NN||production-9/NN	det||auto-antibody-15/NN||a-11/DT	amod||auto-antibody-15/NN||specific-12/JJ	nn||auto-antibody-15/NN||immunoglobulin-13/NN	nn||auto-antibody-15/NN||m-14/NN	prep_of||production-9/NN||auto-antibody-15/NN	advcl||develops-3/VBZ||directed-16/VBD	det||antigens-22/NNS||the-18/DT	nn||antigens-22/NNS||i/i-19/NN	conj_and||i/i-19/NN||h-21/NN	nn||antigens-22/NNS||h-21/NN	prep_against||directed-16/VBD||antigens-22/NNS	appos||antigens-22/NNS||precursors-24/NNS	det||abh-27/NN||the-26/DT	prep_of||precursors-24/NNS||abh-27/NN	nn||substances-32/NNS||lewis-29/NNS	nn||substances-32/NNS||blood-30/NN	nn||substances-32/NNS||group-31/NN	prep_of||precursors-24/NNS||substances-32/NNS	conj_and||abh-27/NN||substances-32/NNS	amod||cells-37/NNS||red-35/JJ	nn||cells-37/NNS||blood-36/NN	prep_on||directed-16/VBD||cells-37/NNS	coldagglutinindisease-1||antibody--1||no||coldagglutinindisease usually develops as a result of the production of a specific immunoglobulin m auto-antibody directed against the i/i and h antigens, precursors of the abh and lewis blood group substances, on red blood cells.
expl||are-2/VBP||there-1/EX	root||ROOT-0/null||are-2/VBP	num||molâecules-7/NNS||two-3/CD	amod||molâecules-7/NNS||uncoordinated-4/JJ	amod||molâecules-7/NNS||acetonitrile-5/JJ	amod||molâecules-7/NNS||solvent-6/JJ	nsubj||are-2/VBP||molâecules-7/NNS	prep_per||molâecules-7/NNS||molâecule-9/NN	nn||compound-12/NN||title-11/NN	prep_of||molâecule-9/NN||compound-12/NN	det||structure-16/NN||the-14/DT	nn||structure-16/NN||crystal-15/NN	prep_in||compound-12/NN||structure-16/NN	uncoordinated-4||solvent-6||no_rel||there are two uncoordinated acetonitrile solvent molâ­ecules per molâ­ecule of title compound in the crystal structure.
nsubj||lower-15/JJR||results-1/NNS	det||intention-4/NN||an-3/DT	prep_in||results-1/NNS||intention-4/NN	aux||treat-6/VB||to-5/TO	vmod||intention-4/NN||treat-6/VB	dobj||treat-6/VB||analysis-7/NN	det||risk-10/NN||the-9/DT	appos||analysis-7/NN||risk-10/NN	prep_of||risk-10/NN||death-12/NN	cop||lower-15/JJR||was-13/VBD	advmod||lower-15/JJR||significantly-14/RB	root||ROOT-0/null||lower-15/JJR	det||arm-20/NN||the-17/DT	amod||arm-20/NN||titrated-18/JJ	nn||arm-20/NN||oxygen-19/NN	prep_in||lower-15/JJR||arm-20/NN	prepc_compared_with||lower-15/JJR||with-22/IN	det||arm-27/NN||the-23/DT	amod||arm-27/NN||high-24/JJ	nn||arm-27/NN||flow-25/NN	nn||arm-27/NN||oxygen-26/NN	pobj||lower-15/JJR||arm-27/NN	det||patients-30/NNS||all-29/DT	prep_for||arm-27/NN||patients-30/NNS	amod||oxygen-34/NN||high-32/JJ	nn||oxygen-34/NN||flow-33/NN	nsubj||n-35/VBP||oxygen-34/NN	dep||arm-27/NN||n-35/VBP	number||226-37/CD||=-36/CD	dobj||n-35/VBP||226-37/CD	amod||n-41/NN||titrated-39/JJ	nn||n-41/NN||oxygen-40/NN	dep||226-37/CD||n-41/NN	number||179-43/CD||=-42/CD	dep||n-41/NN||179-43/CD	det||subgroup-48/NN||the-47/DT	prep_for||arm-27/NN||subgroup-48/NN	conj_and||patients-30/NNS||subgroup-48/NN	prep_of||subgroup-48/NN||patients-50/NNS	amod||obstructivepulmonarydisease-54/NN||confirmed-52/JJ	amod||obstructivepulmonarydisease-54/NN||chronic-53/JJ	prep_with||patients-50/NNS||obstructivepulmonarydisease-54/NN	amod||n-58/NN||high-56/JJ	nn||n-58/NN||flow-57/NN	nsubj||titrated-62/VBD||n-58/NN	number||117-60/CD||=-59/CD	dep||n-58/NN||117-60/CD	dep||subgroup-48/NN||titrated-62/VBD	nsubj||97-65/CD||n-63/NN	dep||97-65/CD||=-64/SYM	ccomp||titrated-62/VBD||97-65/CD	obstructivepulmonarydisease-54||oxygen-40||yes||results in an intention to treat analysis, the risk of death was significantly lower in the titrated oxygen arm compared with the high flow oxygen arm for all patients (high flow oxygen n=226; titrated oxygen n=179) and for the subgroup of patients with confirmed chronic obstructivepulmonarydisease (high flow n=117; titrated n=97).
mark||inform-4/VB||in-1/IN	dep||inform-4/VB||order-2/NN	aux||inform-4/VB||to-3/TO	advcl||analyzed-9/VBD||inform-4/VB	nn||programming-6/NN||prevention-5/NN	dobj||inform-4/VB||programming-6/NN	nsubj||analyzed-9/VBD||we-8/PRP	root||ROOT-0/null||analyzed-9/VBD	dobj||analyzed-9/VBD||hiv-10/NN	amod||hiv-10/NN||discordance-11/JJ	amod||hiv-10/NN||concordance-13/JJ	conj_and||discordance-11/JJ||concordance-13/JJ	prep_within||analyzed-9/VBD||couples-15/NNS	det||survey-21/NN||the-17/DT	nn||survey-21/NN||kenya-18/NN	nn||survey-21/NN||aids-19/NNS	nn||survey-21/NN||indicator-20/NN	prep_in||couples-15/NNS||survey-21/NN	appos||survey-21/NN||kais-23/NNS	dobj||analyzed-9/VBD||2007-25/CD	aids-19||hiv-10||no||in order to inform prevention programming, we analyzed hiv discordance and concordance within couples in the kenya aids indicator survey (kais) 2007.
det||total-2/NN||a-1/DT	root||ROOT-0/null||total-2/NN	num||subjects-5/NNS||95-4/CD	prep_of||total-2/NN||subjects-5/NNS	prep_including||subjects-5/NNS||33-8/CD	amod||hypothyroidism-11/NN||subclinical-10/JJ	prep_with||33-8/CD||hypothyroidism-11/NN	det||hormone-16/NN||an-13/DT	amod||hormone-16/NN||elevated-14/JJ	amod||hormone-16/NN||thyroid-stimulating-15/JJ	dep||hypothyroidism-11/NN||hormone-16/NN	appos||hormone-16/NN||tsh-18/NN	dep||hormone-16/NN||level-20/NN	det||thyroxin-24/NN||a-22/DT	amod||thyroxin-24/NN||normal-23/JJ	dep||hypothyroidism-11/NN||thyroxin-24/NN	conj_and||hormone-16/NN||thyroxin-24/NN	appos||thyroxin-24/NN||ft4-26/NNP	dep||thyroxin-24/NN||level-28/NN	prep_with||33-8/CD||31-31/CD	conj_and||hypothyroidism-11/NN||31-31/CD	amod||hypothyroidism-34/NN||overt-33/JJ	prep_with||31-31/CD||hypothyroidism-34/NN	amod||tsh-37/NN||elevated-36/JJ	dep||hypothyroidism-34/NN||tsh-37/NN	nn||ft4-40/NN||decreased-39/NN	dep||hypothyroidism-34/NN||ft4-40/NN	conj_and||tsh-37/NN||ft4-40/NN	num||controls-46/NNS||31-44/CD	amod||controls-46/NNS||healthy-45/JJ	prep_with||33-8/CD||controls-46/NNS	conj_and||hypothyroidism-11/NN||controls-46/NNS	hypothyroidism-34||thyroxin-24||yes||a total of 95 subjects, including 33 with subclinical hypothyroidism (an elevated thyroid-stimulating hormone (tsh) level and a normal thyroxin (ft4) level), 31 with overt hypothyroidism (elevated tsh and decreased ft4), and 31 healthy controls.
mwe||than-3/IN||more-2/JJR	quantmod||a-4/DT||than-3/IN	num||decade-5/NN||a-4/DT	prep_after||increasing-29/VBG||decade-5/NN	det||epidemic-9/NN||the-7/DT	nn||epidemic-9/NN||aids-8/NNS	prep_of||decade-5/NN||epidemic-9/NN	prep_in||epidemic-9/NN||thailand-11/NN	det||number-14/NN||the-13/DT	nsubj||increasing-29/VBG||number-14/NN	prep_of||number-14/NN||children-16/NNS	poss||parents-18/NNS||children-16/NNS	nsubj||living-20/VBG||parents-18/NNS	nsubj||died-25/VBN||parents-18/NNS	aux||living-20/VBG||are-19/VBP	rcmod||children-16/NNS||living-20/VBG	prep_with||living-20/VBG||hiv-22/NN	aux||died-25/VBN||have-24/VBP	rcmod||children-16/NNS||died-25/VBN	conj_or||living-20/VBG||died-25/VBN	prep_from||died-25/VBN||aids-27/NNS	aux||increasing-29/VBG||is-28/VBZ	root||ROOT-0/null||increasing-29/VBG	advmod||increasing-29/VBG||significantly-30/RB	nsubjpass||reported-35/VBN||it-32/PRP	aux||reported-35/VBN||has-33/VBZ	auxpass||reported-35/VBN||been-34/VBN	conj_and||increasing-29/VBG||reported-35/VBN	mark||discriminated-41/VBN||that-36/IN	det||children-38/NNS||these-37/DT	nsubjpass||discriminated-41/VBN||children-38/NNS	auxpass||discriminated-41/VBN||are-39/VBP	advmod||discriminated-41/VBN||often-40/RB	ccomp||reported-35/VBN||discriminated-41/VBN	prep||discriminated-41/VBN||against-42/IN	pcomp||against-42/IN||by-43/IN	poss||peers-45/NNS||their-44/PRP$	pobj||by-43/IN||peers-45/NNS	aids-27||hiv-22||no||after more than a decade of the aids epidemic in thailand, the number of children whose parents are living with hiv or have died from aids is increasing significantly and it has been reported that these children are often discriminated against by their peers.
nn||hemorrhagicfeverwithrenalsyndrome-3/NN||hantaanvirusinfection-1/NN	amod||hemorrhagicfeverwithrenalsyndrome-3/NN||causing-2/VBG	nsubj||common-8/JJ||hemorrhagicfeverwithrenalsyndrome-3/NN	appos||hemorrhagicfeverwithrenalsyndrome-3/NN||hfrs-5/NNS	cop||common-8/JJ||is-7/VBZ	root||ROOT-0/null||common-8/JJ	amod||korea-11/NN||south-10/JJ	prep_in||common-8/JJ||korea-11/NN	poss||pathogenesis-14/NNS||its-13/PRP$	nsubjpass||suggested-16/VBN||pathogenesis-14/NNS	nsubj||mechanism-21/NN||pathogenesis-14/NNS	auxpass||suggested-16/VBN||is-15/VBZ	conj_and||common-8/JJ||suggested-16/VBN	aux||mechanism-21/NN||to-17/TO	cop||mechanism-21/NN||be-18/VB	det||mechanism-21/NN||an-19/DT	amod||mechanism-21/NN||immunologic-20/JJ	xcomp||suggested-16/VBN||mechanism-21/NN	hfrs-5||hantaanvirus--1||no||hantaanvirusinfection causing hemorrhagicfeverwithrenalsyndrome (hfrs) is common in south korea and its pathogenesis is suggested to be an immunologic mechanism.
det||rate-3/NN||the-1/DT	amod||rate-3/NN||relapse-2/JJ	nsubj||observed-4/VBD||rate-3/NN	root||ROOT-0/null||observed-4/VBD	num||months-7/NNS||12-6/CD	prep_after||observed-4/VBD||months-7/NNS	dobj||observed-4/VBD||treatment-8/NN	prep_with||treatment-8/NN||the-10/DT	nsubj||recommended-12/VBD||the-10/DT	rcmod||the-10/DT||recommended-12/VBD	nn||regimen-15/NN||mdr-13/NN	nn||regimen-15/NN||tb-14/NN	nsubj||equivalent-26/JJ||regimen-15/NN	dep||regimen-15/NN||amikacin-17/NN	appos||amikacin-17/NN||ethionamide-19/NN	appos||amikacin-17/NN||pyrazinamide-21/NN	conj_and||ethionamide-19/NN||pyrazinamide-21/NN	appos||amikacin-17/NN||moxifloxacin-23/NN	conj_and||ethionamide-19/NN||moxifloxacin-23/NN	cop||equivalent-26/JJ||was-25/VBD	ccomp||recommended-12/VBD||equivalent-26/JJ	det||treatment-35/NN||the-28/DT	dep||rate-30/NN||relapse-29/JJ	amod||treatment-35/NN||rate-30/NN	amod||treatment-35/NN||observed-31/JJ	num||months-34/NNS||6-33/CD	prep_after||observed-31/JJ||months-34/NNS	prep_to||equivalent-26/JJ||treatment-35/NN	det||regimen-42/NN||the-37/DT	amod||regimen-42/NN||recommended-38/VBN	nn||regimen-42/NN||drug-39/NN	amod||regimen-42/NN||susceptible-40/VBG	nn||regimen-42/NN||tb-41/NN	prep_with||treatment-35/NN||regimen-42/NN	dep||treatment-35/NN||rifampin-44/NN	dep||rifampin-44/NN||isoniazid-46/JJ	dep||rifampin-44/NN||pyrazinamide-48/JJ	conj_and||isoniazid-46/JJ||pyrazinamide-48/JJ	tb-41||rifampin-44||yes||the relapse rate observed after 12 months treatment with the who recommended mdr tb regimen (amikacin, ethionamide, pyrazinamide and moxifloxacin) was equivalent to the relapse rate observed after 6 months treatment with the recommended drug susceptible tb regimen (rifampin, isoniazid and pyrazinamide).
nsubj||antiemeticdrug-6/NN||ondansetronhydrochloride-1/NN	cop||antiemeticdrug-6/NN||is-2/VBZ	det||antiemeticdrug-6/NN||an-3/DT	advmod||bitter-5/JJ||intensely-4/RB	amod||antiemeticdrug-6/NN||bitter-5/JJ	root||ROOT-0/null||antiemeticdrug-6/NN	vmod||antiemeticdrug-6/NN||used-7/VBN	aux||treat-9/VB||to-8/TO	xcomp||used-7/VBN||treat-9/VB	dobj||treat-9/VB||nausea-10/NN	dobj||treat-9/VB||vomiting-12/NN	conj_and||nausea-10/NN||vomiting-12/NN	prep_following||nausea-10/NN||chemotherapy-14/NN	ondansetronhydrochloride-1||vomiting-12||no_rel||ondansetronhydrochloride is an intensely bitter antiemeticdrug used to treat nausea and vomiting following chemotherapy.
amod||prevalence-2/NN||increasing-1/VBG	nsubj||worsening-17/VBG||prevalence-2/NN	nn||resistance-5/NN||inh-4/NN	prep_of||prevalence-2/NN||resistance-5/NN	advmod||resistance-5/NN||especially-7/RB	amod||tb-12/NN||high-9/JJ	nn||tb-12/NN||tuberculosis-10/NNP	nn||tb-12/NN||-lrb--11/NNP	prep_in||especially-7/RB||tb-12/NN	advmod||prevalent-14/JJ||-rrb--13/RB	amod||countries-15/NNS||prevalent-14/JJ	dep||resistance-5/NN||countries-15/NNS	aux||worsening-17/VBG||is-16/VBZ	root||ROOT-0/null||worsening-17/VBG	det||burden-19/NN||the-18/DT	dobj||worsening-17/VBG||burden-19/NN	nn||programs-23/NNS||tb-21/NN	nn||programs-23/NNS||control-22/NN	prep_of||burden-19/NN||programs-23/NNS	mark||noted-30/VBN||since-25/IN	amod||rates-28/NNS||similar-26/JJ	nn||rates-28/NNS||transmission-27/NN	nsubjpass||noted-30/VBN||rates-28/NNS	auxpass||noted-30/VBN||are-29/VBP	advcl||worsening-17/VBG||noted-30/VBN	nn||strains-37/NNS||inh-32/NN	amod||strains-37/NNS||susceptible-33/JJ	conj_and||susceptible-33/JJ||resistant-35/JJ	amod||strains-37/NNS||resistant-35/JJ	nn||strains-37/NNS||m.tuberculosis-36/NN	prep_for||noted-30/VBN||strains-37/NNS	tb-21||inh-32||yes||increasing prevalence of inh resistance , especially in high tuberculosis -lrb- tb -rrb- prevalent countries is worsening the burden of tb control programs , since similar transmission rates are noted for inh susceptible and resistant m.tuberculosis strains .
nsubjpass||detected-3/VBN||hypothyroidism-1/NN	auxpass||detected-3/VBN||was-2/VBD	root||ROOT-0/null||detected-3/VBN	amod||screening-6/NN||neonatal-5/JJ	agent||detected-3/VBN||screening-6/NN	amod||replacement-9/NN||l-thyroxine-8/JJ	nsubjpass||started-11/VBN||replacement-9/NN	auxpass||started-11/VBN||was-10/VBD	conj_and||detected-3/VBN||started-11/VBN	advmod||started-11/VBN||immediately-12/RB	hypothyroidism-1||l-thyroxine-8||yes||hypothyroidism was detected by neonatal screening and l-thyroxine replacement was started immediately.
amod||responses-3/NNS||rotavirus-induced-1/JJ	amod||responses-3/NNS||immune-2/JJ	nsubjpass||characterized-16/VBN||responses-3/NNS	advmod||t-7/NN||especially-5/RB	det||t-7/NN||the-6/DT	num||responses-11/NNS||t-7/NN	conj_and||t-7/NN||b-9/SYM	num||responses-11/NNS||b-9/SYM	nn||responses-11/NNS||cell-10/NN	appos||responses-3/NNS||responses-11/NNS	aux||characterized-16/VBN||have-13/VBP	auxpass||characterized-16/VBN||been-14/VBN	advmod||characterized-16/VBN||extensively-15/RB	root||ROOT-0/null||characterized-16/VBN	advmod||known-22/VBN||however-18/RB	nsubjpass||known-22/VBN||little-20/RB	auxpass||known-22/VBN||is-21/VBZ	parataxis||characterized-16/VBN||known-22/VBN	amod||mechanisms-26/NNS||innate-24/JJ	amod||mechanisms-26/NNS||immune-25/JJ	prep_about||known-22/VBN||mechanisms-26/NNS	vmod||mechanisms-26/NNS||involved-27/VBN	det||control-30/NN||the-29/DT	prep_in||involved-27/VBN||control-30/NN	prep_of||control-30/NN||rotavirusinfection-32/NN	rotavirusinfection-32||rotavirus--1||no||rotavirus-induced immune responses, especially the t and b cell responses, have been extensively characterized; however, little is known about innate immune mechanisms involved in the control of rotavirusinfection.
prep_in||introduced-10/VBD||2001-2/CD	det||service-6/NN||the-3/DT	amod||service-6/NN||national-4/JJ	nn||service-6/NN||health-5/NN	nsubj||introduced-10/VBD||service-6/NN	det||uk-9/NN||the-8/DT	prep_in||service-6/NN||uk-9/NN	root||ROOT-0/null||introduced-10/VBD	det||scheme-15/NN||a-11/DT	amod||scheme-15/NN||mandatory-12/JJ	nn||scheme-15/NN||bacteraemia-13/NN	nn||scheme-15/NN||surveillance-14/NN	dobj||introduced-10/VBD||scheme-15/NN	det||reporting-18/NN||the-17/DT	prep_for||introduced-10/VBD||reporting-18/NN	prep_of||reporting-18/NN||s.aureus-20/NNS	amod||s.aureus-23/NNS||methicillin-resistant-22/JJ	prep_for||introduced-10/VBD||s.aureus-23/NNS	conj_and||reporting-18/NN||s.aureus-23/NNS	nn||-rrb--26/NNP||-lrb--24/NNP	nn||-rrb--26/NNP||mrsa-25/NNP	dep||s.aureus-23/NNS||-rrb--26/NNP	methicillin--1||mrsa-25||no_rel||in 2001 the national health service in the uk introduced a mandatory bacteraemia surveillance scheme for the reporting of s.aureus and methicillin-resistant s.aureus -lrb- mrsa -rrb- .
amod||trials-4/NNS||several-1/JJ	amod||trials-4/NNS||randomized-2/JJ	amod||trials-4/NNS||controlled-3/JJ	nsubjpass||initiated-6/VBN||trials-4/NNS	nsubj||assess-8/VB||trials-4/NNS	nsubj||assess-8/VB||trials-4/NNS	auxpass||initiated-6/VBN||were-5/VBD	root||ROOT-0/null||initiated-6/VBN	aux||assess-8/VB||to-7/TO	xcomp||initiated-6/VBN||assess-8/VB	xcomp||initiated-6/VBN||assess-8/VB	conj_and||assess-8/VB||assess-8/VB	det||impact-10/NN||the-9/DT	dobj||assess-8/VB||impact-10/NN	amod||therapy-14/NN||hsv-2-12/JJ	nn||therapy-14/NN||suppressive-13/NN	prep_of||impact-10/NN||therapy-14/NN	det||acquisition-17/NN||the-16/DT	prep_on||therapy-14/NN||acquisition-17/NN	prep_of||acquisition-17/NN||hivinfection-19/NN	amod||men-23/NNS||hsv-2-21/JJ	amod||men-23/NNS||infected-22/JJ	prep_by||assess-8/VB||men-23/NNS	prep_by||assess-8/VB||women-25/NNS	conj_and||men-23/NNS||women-25/NNS	det||transmission-31/NN||the-29/DT	amod||transmission-31/NN||onward-30/JJ	prep_on||assess-8/VB||transmission-31/NN	prep_of||transmission-31/NN||hiv-33/NN	amod||men-39/NNS||hsv-2-35/JJ	punct||hiv-37/NN||/-36/:	dep||men-39/NNS||hiv-37/NN	prep_by||assess-8/VB||co-infected-38/JJ	amod||men-39/NNS||co-infected-38/JJ	conj_and||men-39/NNS||co-infected-38/JJ	prep_by||assess-8/VB||men-39/NNS	prep_by||assess-8/VB||women-41/NNS	conj_and||men-39/NNS||women-41/NNS	hivinfection-19||hiv-37||no||several randomized controlled trials were initiated to assess the impact of hsv-2 suppressive therapy on the acquisition of hivinfection by hsv-2 infected men and women, and on the onward transmission of hiv by hsv-2/hiv co-infected men and women.
nn||inhibition-2/NN||microglia-1/NN	nsubj||abolished-4/VBD||inhibition-2/NN	advmod||abolished-4/VBD||also-3/RB	root||ROOT-0/null||abolished-4/VBD	amod||hyperalgesia-6/NN||thermal-5/JJ	dobj||abolished-4/VBD||hyperalgesia-6/NN	det||allodynia-10/NN||the-8/DT	amod||allodynia-10/NN||enhanced-9/JJ	dobj||abolished-4/VBD||allodynia-10/NN	conj_and||hyperalgesia-6/NN||allodynia-10/NN	vmod||allodynia-10/NN||induced-11/VBN	amod||des-arg9-bk-14/NN||intrathecal-13/JJ	agent||induced-11/VBN||des-arg9-bk-14/NN	prepc_without||induced-11/VBN||affecting-16/VBG	dobj||affecting-16/VBG||hyperglycemia-17/NN	nn||rats-20/NNS||stz-19/NN	prep_in||affecting-16/VBG||rats-20/NNS	stz-19||hyperglycemia-17||no_rel||microglia inhibition also abolished thermal hyperalgesia and the enhanced allodynia induced by intrathecal des-arg9-bk without affecting hyperglycemia in stz rats.
amod||binds-4/NNS||î-1/JJ	amod||binds-4/NNS||±-2/JJ	amod||binds-4/NNS||e-catenin-3/JJ	root||ROOT-0/null||binds-4/NNS	det||cellâ-6/NN||the-5/DT	dep||binds-4/NNS||cellâ-6/NN	dep||cellâ-6/NN||$-7/$	advmod||complex-11/NN||cell-9/RB	amod||complex-11/NN||adhesion-10/JJ	dep||²-16/CD||complex-11/NN	prep_of||complex-11/NN||e-cadherin-13/NN	prep_of||complex-11/NN||î-15/NN	conj_and||e-cadherin-13/NN||î-15/NN	num||$-7/$||²-16/CD	dep||binds-4/NNS||catenin-18/NN	nn||²-21/NNS||î-20/NN	dep||catenin-18/NN||²-21/NNS	dep||²-21/NNS||cat-23/NN	nn||dynamics-32/NNS||regulates-26/NNS	nn||dynamics-32/NNS||filamentous-27/NNS	nn||dynamics-32/NNS||actin-28/NN	appos||dynamics-32/NNS||f-actin-30/NN	dep||binds-4/NNS||dynamics-32/NNS	conj_and||catenin-18/NN||dynamics-32/NNS	adhesion-10||f---1||no_rel||î±e-catenin binds the cellâcell adhesion complex of e-cadherin and î²-catenin (î²-cat) and regulates filamentous actin (f-actin) dynamics.
aux||investigate-2/VB||to-1/TO	root||ROOT-0/null||investigate-2/VB	det||effects-4/NNS||the-3/DT	dobj||investigate-2/VB||effects-4/NNS	amod||intraperitoneal-7/JJ||continuous-6/JJ	amod||infusion-9/NN||intraperitoneal-7/JJ	nn||infusion-9/NN||insulin-8/NN	prep_of||effects-4/NNS||infusion-9/NN	appos||infusion-9/NN||cipii-11/NNP	prepc_compared_with||investigate-2/VB||with-14/IN	amod||insulin-16/NN||subcutaneous-15/JJ	pobj||investigate-2/VB||insulin-16/NN	amod||quality-19/NN||health-related-18/JJ	prep_on||insulin-16/NN||quality-19/NN	prep_of||quality-19/NN||life-21/NN	dep||life-21/NN||hrqol-23/JJ	nn||satisfaction-27/NN||treatment-26/NN	prep_of||quality-19/NN||satisfaction-27/NN	conj_and||life-21/NN||satisfaction-27/NN	aux||perform-31/VB||to-30/TO	conj_and||investigate-2/VB||perform-31/VB	det||analysis-34/NN||a-32/DT	nn||analysis-34/NN||cost-33/NN	dobj||perform-31/VB||analysis-34/NN	prep_in||perform-31/VB||type1diabetes-36/CD	type1diabetes-36||insulin-16||yes||to investigate the effects of continuous intraperitoneal insulin infusion (cipii) compared with subcutaneous insulin on health-related quality of life (hrqol) and treatment satisfaction, and to perform a cost analysis in type1diabetes.
det||study-3/NN||this-1/DT	amod||study-3/NN||prospective-2/JJ	nsubj||assessed-4/VBD||study-3/NN	root||ROOT-0/null||assessed-4/VBD	det||effects-6/NNS||the-5/DT	dobj||assessed-4/VBD||effects-6/NNS	amod||function-9/NN||auditory-8/JJ	prep_on||assessed-4/VBD||function-9/NN	det||dose-15/NN||a-11/DT	amod||dose-15/NN||standard-12/JJ	amod||dose-15/NN||3-day-13/JJ	amod||dose-15/NN||oral-14/JJ	prep_of||function-9/NN||dose-15/NN	prep_of||dose-15/NN||artesunate-17/NN	num||mg/kg/day-20/NN||4-19/CD	appos||artesunate-17/NN||mg/kg/day-20/NN	prep||assessed-4/VBD||combined-22/VBN	pcomp||combined-22/VBN||with-23/IN	pobj||with-23/IN||mefloquine-24/NN	num||mg/kg-27/NN||25-26/CD	appos||mefloquine-24/NN||mg/kg-27/NN	prep_in||mefloquine-24/NN||patients-30/NNS	amod||falciparummalaria-34/NN||acute-32/JJ	amod||falciparummalaria-34/NN||uncomplicated-33/JJ	prep_with||patients-30/NNS||falciparummalaria-34/NN	vmod||falciparummalaria-34/NN||treated-35/VBN	det||unit-41/NN||the-37/DT	amod||unit-41/NN||shoklo-38/JJ	nn||unit-41/NN||malaria-39/NN	nn||unit-41/NN||research-40/NN	prep_at||treated-35/VBN||unit-41/NN	det||border-46/NN||the-44/DT	amod||border-46/NN||thai-burmese-45/JJ	prep_on||treated-35/VBN||border-46/NN	falciparummalaria-34||mefloquine-24||yes||this prospective study assessed the effects on auditory function of a standard 3-day oral dose of artesunate (4 mg/kg/day) combined with mefloquine (25 mg/kg) in patients with acute uncomplicated falciparummalaria treated at the shoklo malaria research unit, on the thai-burmese border.
det||duration-5/NN||a-1/DT	amod||duration-5/NN||high-2/JJ	nn||duration-5/NN||dose-3/NN	amod||duration-5/NN||short-4/JJ	nsubj||enrofloxacin-9/VBP||duration-5/NN	dep||duration-5/NN||hdsd-7/VBN	root||ROOT-0/null||enrofloxacin-9/VBP	nsubj||inferior-20/JJ||protocol-10/NN	vmod||protocol-10/NN||administered-11/VBN	prep_to||administered-11/VBN||dogs-13/NNS	amod||uti-16/NN||uncomplicated-15/JJ	prep_with||dogs-13/NNS||uti-16/NN	aux||inferior-20/JJ||will-17/MD	neg||inferior-20/JJ||not-18/RB	cop||inferior-20/JJ||be-19/VB	ccomp||enrofloxacin-9/VBP||inferior-20/JJ	det||regimen-25/NN||a-22/DT	amod||regimen-25/NN||14-day-23/JJ	nn||regimen-25/NN||treatment-24/NN	prep_to||inferior-20/JJ||regimen-25/NN	prep_with||regimen-25/NN||amoxicillin-clavulanicacid-27/NN	amoxicillin-clavulanicacid-27||uti-16||no_rel||a high dose short duration (hdsd) enrofloxacin protocol administered to dogs with uncomplicated uti will not be inferior to a 14-day treatment regimen with amoxicillin-clavulanicacid.
mark||drug-11/NN||although-1/IN	nsubj||drug-11/NN||warfarin-2/NN	cop||drug-11/NN||is-3/VBZ	det||drug-11/NN||an-4/DT	amod||drug-11/NN||effective-5/JJ	amod||drug-11/NN||oral-6/JJ	nn||drug-11/NN||anticoagulation-7/NN	appos||drug-11/NN||oac-9/NN	advcl||scarce-32/JJ||drug-11/NN	aux||reduce-13/VB||to-12/TO	vmod||drug-11/NN||reduce-13/VB	det||risk-15/NN||the-14/DT	dobj||reduce-13/VB||risk-15/NN	prep_of||risk-15/NN||thromboembolism-17/NN	prep_in||reduce-13/VB||patients-19/NNS	amod||atrialfibrillation-22/NN||non-valvular-21/JJ	prep_with||patients-19/NNS||atrialfibrillation-22/NN	appos||atrialfibrillation-22/NN||nvaf-24/NN	amod||data-30/NNS||long-27/JJ	nn||data-30/NNS||term-28/NN	nn||data-30/NNS||follow-up-29/NN	nsubj||scarce-32/JJ||data-30/NNS	nsubj||certain-35/JJ||data-30/NNS	cop||scarce-32/JJ||are-31/VBP	root||ROOT-0/null||scarce-32/JJ	aux||certain-35/JJ||to-33/TO	cop||certain-35/JJ||be-34/VB	xcomp||scarce-32/JJ||certain-35/JJ	mark||maintained-42/VBN||whether-36/IN	det||level-40/NN||the-37/DT	nn||level-40/NN||target-38/NN	nn||level-40/NN||inr-39/NN	nsubjpass||maintained-42/VBN||level-40/NN	auxpass||maintained-42/VBN||is-41/VBZ	ccomp||certain-35/JJ||maintained-42/VBN	amod||patients-45/NNS||warfarin-treated-44/JJ	prep_in||maintained-42/VBN||patients-45/NNS	prep_in||patients-45/NNS||korea-47/NN	thromboembolism-17||warfarin-2||yes||although warfarin is an effective oral anticoagulation (oac) drug to reduce the risk of thromboembolism in patients with non-valvular atrialfibrillation (nvaf), long term follow-up data are scarce to be certain whether the target inr level is maintained in warfarin-treated patients in korea.
det||acquisition-2/NN||the-1/DT	nsubj||has-13/VBZ||acquisition-2/NN	amod||resistance-9/NN||neuraminidase-4/JJ	dep||neuraminidase-4/JJ||na-6/NNP	nn||resistance-9/NN||inhibitor-8/NN	prep_of||acquisition-2/NN||resistance-9/NN	amod||influenzaviruses-12/NNS||h5n1-11/JJ	prep_by||resistance-9/NN||influenzaviruses-12/NNS	root||ROOT-0/null||has-13/VBZ	amod||implications-16/NNS||serious-14/JJ	amod||implications-16/NNS||clinical-15/JJ	dobj||has-13/VBZ||implications-16/NNS	mark||component-27/NN||as-18/IN	det||class-20/NN||this-19/DT	nsubj||component-27/NN||class-20/NN	prep_of||class-20/NN||drugs-22/NNS	aux||component-27/NN||can-23/MD	cop||component-27/NN||be-24/VB	det||component-27/NN||an-25/DT	amod||component-27/NN||essential-26/JJ	advcl||has-13/VBZ||component-27/NN	amod||measures-31/NNS||pandemic-29/JJ	nn||measures-31/NNS||control-30/NN	prep_of||component-27/NN||measures-31/NNS	h5n1-11||influenzaviruses-12||no||the acquisition of neuraminidase (na) inhibitor resistance by h5n1 influenzaviruses has serious clinical implications, as this class of drugs can be an essential component of pandemic control measures.
det||rate-2/NN||the-1/DT	nsubj||ranged-9/VBD||rate-2/NN	prep_of||rate-2/NN||response-4/NN	aux||levofloxacin-6/VB||to-5/TO	vmod||response-4/NN||levofloxacin-6/VB	prep_by||levofloxacin-6/VB||bacterialdisease-8/NN	root||ROOT-0/null||ranged-9/VBD	num||%-12/NN||97.4-11/CD	prep_from||ranged-9/VBD||%-12/NN	prep_in||%-12/NN||keratitis-14/NNS	num||%-17/NN||88.3-16/CD	prep_to||ranged-9/VBD||%-17/NN	prep_in||%-17/NN||dacryocystitis-19/NNS	bacterialdisease-8||levofloxacin-6||yes||the rate of response to levofloxacin by bacterialdisease ranged from 97.4% in keratitis to 88.3% in dacryocystitis.
det||test-4/NN||the-1/DT	amod||test-4/NN||tuberculin-2/JJ	nn||test-4/NN||skin-3/NN	nsubjpass||used-10/VBN||test-4/NN	nsubj||aid-15/VB||test-4/NN	appos||test-4/NN||tst-6/NN	auxpass||used-10/VBN||is-8/VBZ	advmod||used-10/VBN||widely-9/RB	root||ROOT-0/null||used-10/VBN	nn||clinics-13/NNS||tb-12/NN	prep_in||used-10/VBN||clinics-13/NNS	aux||aid-15/VB||to-14/TO	xcomp||used-10/VBN||aid-15/VB	amod||diagnosis-20/NN||mycobacteriumtuberculosis-16/JJ	dep||mycobacteriumtuberculosis-16/JJ||m.tb-18/JJ	dobj||aid-15/VB||diagnosis-20/NN	det||definition-24/NN||the-23/DT	nsubj||unclear-38/JJ||definition-24/NN	det||significance-27/NN||the-26/DT	conj_and||definition-24/NN||significance-27/NN	nsubj||unclear-38/JJ||significance-27/NN	det||test-31/NN||a-29/DT	amod||test-31/NN||positive-30/JJ	prep_of||significance-27/NN||test-31/NN	advmod||young-34/JJ||very-33/RB	amod||children-35/NNS||young-34/JJ	prep_in||test-31/NN||children-35/NNS	cop||unclear-38/JJ||is-36/VBZ	advmod||unclear-38/JJ||still-37/RB	conj_but||used-10/VBN||unclear-38/JJ	tb-12||mycobacteriumtuberculosis-16||no||the tuberculin skin test (tst) is widely used in tb clinics to aid mycobacteriumtuberculosis ( m.tb ) diagnosis, but the definition and the significance of a positive test in very young children is still unclear.
expl||was-2/VBD||there-1/EX	root||ROOT-0/null||was-2/VBD	det||incidence-6/NN||a-3/DT	advmod||lower-5/JJR||significantly-4/RB	amod||incidence-6/NN||lower-5/JJR	nsubj||was-2/VBD||incidence-6/NN	prep_of||incidence-6/NN||microemulsion-8/NN	amod||pain-11/NN||propofol-9/JJ	nn||pain-11/NN||injection-10/NN	npadvmod||than-26/IN||pain-11/NN	dep||pain-11/NN||severity-13/$	num||severity-13/$||2-14/CD	dep||pain-11/NN||more-16/JJR	conj_or||severity-13/$||more-16/JJR	det||group-21/NN||the-19/DT	nn||group-21/NN||combination-20/NN	prep_in||severity-13/$||group-21/NN	num||%-24/NN||12.5-23/CD	appos||pain-11/NN||%-24/NN	advmod||was-2/VBD||than-26/IN	det||groups-32/NNS||the-28/DT	amod||groups-32/NNS||remifentanil-29/JJ	conj_and||remifentanil-29/JJ||lidocaine-31/JJ	amod||groups-32/NNS||lidocaine-31/JJ	prep_in||than-26/IN||groups-32/NNS	num||%-35/NN||90-34/CD	nsubj||p-42/VBP||%-35/NN	num||%-38/NN||65-37/CD	conj_and||%-35/NN||%-38/NN	nsubj||p-42/VBP||%-38/NN	advmod||%-38/NN||respectively-40/RB	dep||groups-32/NNS||p-42/VBP	num||0.05-44/CD||<-43/CD	dobj||p-42/VBP||0.05-44/CD	pain-11||remifentanil-29||yes||there was a significantly lower incidence of microemulsion propofol injection pain (severity 2 or more) in the combination group (12.5%) than in the remifentanil and lidocaine groups (90% and 65%, respectively, p < 0.05).
det||virus-3/NN||the-1/DT	amod||virus-3/NN||htlv-1-2/JJ	nsubj||agent-7/NN||virus-3/NN	cop||agent-7/NN||is-4/VBZ	det||agent-7/NN||a-5/DT	amod||agent-7/NN||known-6/VBN	root||ROOT-0/null||agent-7/NN	vmod||agent-7/NN||involved-8/VBN	det||development-11/NN||the-10/DT	prep_in||involved-8/VBN||development-11/NN	prep_of||development-11/NN||ham/tsp-13/NN	ham--1||htlv-1-2||no||the htlv-1 virus is a known agent involved in the development of ham/tsp.
nsubj||showed-5/VBD||smokers-1/NNS	vmod||smokers-1/NNS||treated-2/VBN	prep_with||treated-2/VBN||budesonide/formoterol-4/NN	root||ROOT-0/null||showed-5/VBD	det||increase-7/NN||an-6/DT	dobj||showed-5/VBD||increase-7/NN	det||number-10/NN||the-9/DT	prep_in||showed-5/VBD||number-10/NN	nn||episodes-13/NNS||asthma-12/NN	prep_of||number-10/NN||episodes-13/NNS	parataxis||showed-5/VBD||intercurrent-15/VB	nn||symptoms-17/NNS||asthma-16/NN	dobj||intercurrent-15/VB||symptoms-17/NNS	vmod||symptoms-17/NNS||p-19/VBN	dep||0.016-21/CD||=-20/SYM	ccomp||p-19/VBN||0.016-21/CD	mark||had-26/VBD||while-23/IN	amod||subjects-25/NNS||non-smoking-24/JJ	nsubj||had-26/VBD||subjects-25/NNS	advcl||showed-5/VBD||had-26/VBD	det||decrease-29/NN||a-27/DT	amod||decrease-29/NN||significant-28/JJ	dobj||had-26/VBD||decrease-29/NN	det||episodes-32/NNS||these-31/DT	prep_in||decrease-29/NN||episodes-32/NNS	dep||episodes-32/NNS||p-34/VBN	dep||0.009-36/CD||=-35/SYM	ccomp||p-34/VBN||0.009-36/CD	asthma-16||formoterol--1||yes||smokers treated with budesonide/formoterol showed an increase in the number of asthma episodes (intercurrent asthma symptoms, p=0.016) while non-smoking subjects had a significant decrease in these episodes (p=0.009).
det||man-4/NN||a-1/DT	amod||man-4/NN||42-year-old-2/JJ	nn||man-4/NN||indian-3/NN	nsubj||received-5/VBD||man-4/NN	root||ROOT-0/null||received-5/VBD	num||rifampicin-8/NN||450-6/CD	nn||rifampicin-8/NN||mg-7/NN	dobj||received-5/VBD||rifampicin-8/NN	appos||rifampicin-8/NN||rif-10/NN	num||mg-14/NN||150-13/CD	dobj||received-5/VBD||mg-14/NN	conj_and||rifampicin-8/NN||mg-14/NN	vmod||mg-14/NN||isoniazid-15/VBN	dep||isoniazid-15/VBN||inh-17/NN	advmod||inh-17/NN||daily-19/RB	auxpass||diagnosed-22/VBN||being-21/VBG	prepc_after||received-5/VBD||diagnosed-22/VBN	det||tuberculosisinfection-26/NN||a-24/DT	nn||tuberculosisinfection-26/NN||latent-25/NN	prep_of||diagnosed-22/VBN||tuberculosisinfection-26/NN	tuberculosisinfection-26||isoniazid-15||yes||a 42-year-old indian man received 450 mg rifampicin (rif) and 150 mg isoniazid (inh) daily after being diagnosed of a latent tuberculosisinfection.
aux||investigate-2/VB||to-1/TO	dep||studied-11/VBD||investigate-2/VB	amod||differences-4/NNS||global-3/JJ	dobj||investigate-2/VB||differences-4/NNS	det||epidemiology-7/NN||the-6/DT	prep_in||investigate-2/VB||epidemiology-7/NN	prep_of||epidemiology-7/NN||chickenpox-9/NN	nsubj||studied-11/VBD||we-10/PRP	root||ROOT-0/null||studied-11/VBD	det||population-13/NN||a-12/DT	dobj||studied-11/VBD||population-13/NN	nn||bissau-16/NN||guinea-15/NN	prep_in||population-13/NN||bissau-16/NN	nsubj||has-25/VBZ||bissau-16/NN	prep_in||has-25/VBZ||contrast-20/NN	amod||countries-24/NNS||other-22/JJ	amod||countries-24/NNS||tropical-23/JJ	prep_to||contrast-20/NN||countries-24/NNS	rcmod||bissau-16/NN||has-25/VBZ	det||age-29/NN||an-26/DT	advmod||early-28/JJ||unexpectedly-27/RB	amod||age-29/NN||early-28/JJ	dobj||has-25/VBZ||age-29/NN	prep_of||age-29/NN||infection-31/NN	prep_with||infection-31/NN||vzv-33/NN	amod||age-29/NN||comparable-35/JJ	aux||temperate-37/VB||to-36/TO	xcomp||comparable-35/JJ||temperate-37/VB	dobj||temperate-37/VB||latitudes-38/NNS	chickenpox-9||vzv-33||yes||to investigate global differences in the epidemiology of chickenpox we studied a population in guinea bissau, which in contrast to other tropical countries has an unexpectedly early age of infection with vzv, comparable to temperate latitudes.
det||study-3/NN||this-2/DT	prep_in||investigated-6/VBD||study-3/NN	nsubj||investigated-6/VBD||we-5/PRP	root||ROOT-0/null||investigated-6/VBD	det||effect-8/NN||the-7/DT	dobj||investigated-6/VBD||effect-8/NN	det||mixture-12/NN||a-10/DT	amod||mixture-12/NN||lidocaine-11/JJ	prep_of||effect-8/NN||mixture-12/NN	prep_on||investigated-6/VBD||pain-14/NN	dep||pain-14/NN||induced-15/VBN	amod||injection-19/NN||microemulsion-17/JJ	amod||injection-19/NN||propofol-18/JJ	prep_by||induced-15/VBN||injection-19/NN	dep||pain-14/NN||sought-22/VBN	conj_and||induced-15/VBN||sought-22/VBN	aux||determine-24/VB||to-23/TO	xcomp||sought-22/VBN||determine-24/VB	det||dose-27/NN||the-25/DT	amod||dose-27/NN||optimal-26/JJ	dobj||determine-24/VB||dose-27/NN	nsubj||reduce-32/VB||dose-27/NN	prep_of||dose-27/NN||lidocaine-29/NN	aux||reduce-32/VB||could-31/MD	rcmod||dose-27/NN||reduce-32/VB	dobj||reduce-32/VB||pain-33/NN	prepc_on||reduce-32/VB||injecting-35/VBG	det||mixture-38/NN||a-36/DT	amod||mixture-38/NN||propofol-lidocaine-37/JJ	dobj||injecting-35/VBG||mixture-38/NN	pain-33||lidocaine-29||yes||in this study, we investigated the effect of a lidocaine mixture on pain induced by microemulsion propofol injection, and sought to determine the optimal dose of lidocaine that could reduce pain on injecting a propofol-lidocaine mixture.
det||fragment-4/NN||the-1/DT	amod||fragment-4/NN||casp8p43-2/JJ	nn||fragment-4/NN||cleavage-3/NN	nsubj||transactivates-6/VBZ||fragment-4/NN	advmod||transactivates-6/VBZ||also-5/RB	root||ROOT-0/null||transactivates-6/VBZ	det||ltr-9/NN||the-7/DT	nn||ltr-9/NN||hiv-8/NN	dobj||transactivates-6/VBZ||ltr-9/NN	prep_through||transactivates-6/VBZ||nf-îºb-11/NN	det||absence-15/NN||the-14/DT	nsubj||inhibits-22/VBZ||absence-15/NN	nn||hivinfection-20/NN||caspase-17/NN	num||hivinfection-20/NN||8-18/CD	nn||hivinfection-20/NN||following-19/NN	prep_of||absence-15/NN||hivinfection-20/NN	advmod||inhibits-22/VBZ||greatly-21/RB	conj_and||transactivates-6/VBZ||inhibits-22/VBZ	nn||replication-24/NN||hiv-23/NN	dobj||inhibits-22/VBZ||replication-24/NN	hivinfection-20||hiv-23||no||the casp8p43 cleavage fragment also transactivates the hiv ltr through nf-îºb, and the absence of caspase 8 following hivinfection greatly inhibits hiv replication.
advmod||recently-2/RB||more-1/RBR	advmod||shown-9/VBN||recently-2/RB	nsubjpass||shown-9/VBN||prasugrel-4/NN	nsubj||provide-11/VB||prasugrel-4/NN	conj_and||prasugrel-4/NN||ticagrelor-6/NN	nsubjpass||shown-9/VBN||ticagrelor-6/NN	nsubj||provide-11/VB||ticagrelor-6/NN	aux||shown-9/VBN||have-7/VBP	auxpass||shown-9/VBN||been-8/VBN	root||ROOT-0/null||shown-9/VBN	aux||provide-11/VB||to-10/TO	xcomp||shown-9/VBN||provide-11/VB	det||action-16/NN||a-12/DT	advmod||powerful-14/JJ||more-13/RBR	amod||action-16/NN||powerful-14/JJ	nn||action-16/NN||antiplatelet-15/NN	dobj||provide-11/VB||action-16/NN	prepc_compared_to||provide-11/VB||to-18/TO	amod||complications-29/NNS||clopidogrel-19/JJ	conj_but||clopidogrel-19/JJ||at-21/IN	amod||complications-29/NNS||at-21/IN	det||cost-23/NN||a-22/DT	pobj||at-21/IN||cost-23/NN	amod||risk-26/NN||higher-25/JJR	prep_of||cost-23/NN||risk-26/NN	prep_of||risk-26/NN||bleeding-28/NN	pobj||provide-11/VB||complications-29/NNS	bleeding-28||clopidogrel-19||no||more recently, prasugrel and ticagrelor have been shown to provide a more powerful antiplatelet action compared to clopidogrel but at a cost of higher risk of bleeding complications.
amod||methods-2/NNS||other-1/JJ	nsubj||helpful-4/JJ||methods-2/NNS	cop||helpful-4/JJ||are-3/VBP	root||ROOT-0/null||helpful-4/JJ	amod||studies-9/NNS||epidemiological-6/JJ	amod||studies-9/NNS||respiratory-7/JJ	nn||studies-9/NNS||health-8/NN	prep_in||helpful-4/JJ||studies-9/NNS	amod||nitricoxide-13/NN||fractional-11/JJ	amod||nitricoxide-13/NN||exhaled-12/JJ	prep_including||studies-9/NNS||nitricoxide-13/NN	appos||nitricoxide-13/NN||feno-15/NNP	amod||percentage-19/NN||eosinophils-18/JJ	prep_including||studies-9/NNS||percentage-19/NN	conj_and||nitricoxide-13/NN||percentage-19/NN	appos||nitricoxide-13/NN||ep-21/NN	amod||markers-28/NNS||nasal-24/JJ	amod||markers-28/NNS||lavage-25/JJ	amod||markers-28/NNS||fluid-26/JJ	nn||markers-28/NNS||measuring-27/NN	prep_in||studies-9/NNS||markers-28/NNS	amod||inflammation-31/NN||airway-30/JJ	prep_for||markers-28/NNS||inflammation-31/NN	det||technique-37/NN||the-34/DT	amod||technique-37/NN||forced-35/VBN	nn||technique-37/NN||oscillatory-36/NN	prep_along_with||studies-9/NNS||technique-37/NN	vmod||technique-37/NN||measuring-38/VBG	amod||resistance-40/NN||airway-39/JJ	dobj||measuring-38/VBG||resistance-40/NN	appos||resistance-40/NN||ar-42/NN	nitricoxide-13||ar-42||no_rel||other methods are helpful in epidemiological respiratory health studies including fractional exhaled nitricoxide (feno) and eosinophils percentage (ep) in nasal lavage fluid measuring markers for airway inflammation along with the forced oscillatory technique measuring airway resistance (ar).
nsubj||give-3/VB||it-1/PRP	nsubj||increase-23/VB||it-1/PRP	aux||give-3/VB||may-2/MD	root||ROOT-0/null||give-3/VB	dobj||give-3/VB||rise-4/NN	amod||quality-7/NN||better-6/JJR	prep_to||give-3/VB||quality-7/NN	prep_of||quality-7/NN||life-9/NN	det||family-13/NN||an-11/DT	amod||family-13/NN||entire-12/JJ	prep_for||life-9/NN||family-13/NN	amod||disappointment-18/NN||bitter-17/JJ	prep_to||give-3/VB||disappointment-18/NN	conj_or||quality-7/NN||disappointment-18/NN	aux||increase-23/VB||may-21/MD	advmod||increase-23/VB||also-22/RB	conj_and||give-3/VB||increase-23/VB	dobj||increase-23/VB||vulnerability-24/NN	prep_to||increase-23/VB||hiv-26/NN	prep_to||increase-23/VB||aids-28/NNS	conj_and||hiv-26/NN||aids-28/NNS	aids-28||hiv-26||no||it may give rise to better quality of life for an entire family, or to bitter disappointment, and may also increase vulnerability to hiv and aids.
det||study-2/NN||this-1/DT	nsubjpass||based-4/VBN||study-2/NN	auxpass||based-4/VBN||is-3/VBZ	root||ROOT-0/null||based-4/VBN	nn||samples-9/NNS||tumor-6/NN	conj_and||tumor-6/NN||serum-8/NN	nn||samples-9/NNS||serum-8/NN	prep_on||based-4/VBN||samples-9/NNS	num||patients-14/NNS||93-11/CD	amod||patients-14/NNS||adult-12/JJ	nn||patients-14/NNS||sts-13/NN	prep_from||based-4/VBN||patients-14/NNS	tumor-6||sts-13||no||this study is based on tumor and serum samples from 93 adult sts patients.
det||involvement-9/NN||a-1/DT	amod||involvement-9/NN||patient-2/JJ	amod||chest-7/NN||extensive-4/JJ	conj_and||extensive-4/JJ||painful-6/JJ	amod||chest-7/NN||painful-6/JJ	prep_with||patient-2/JJ||chest-7/NN	nn||involvement-9/NN||wall-8/NN	nsubjpass||treated-19/VBN||involvement-9/NN	det||cancer-14/NN||a-11/DT	amod||cancer-14/NN||metastatic-12/JJ	nn||cancer-14/NN||borderline-13/NN	prep_from||involvement-9/NN||cancer-14/NN	det||ovary-17/NN||the-16/DT	prep_of||cancer-14/NN||ovary-17/NN	auxpass||treated-19/VBN||was-18/VBD	root||ROOT-0/null||treated-19/VBN	det||carboplatin-22/JJ||a-21/DT	prep_with||treated-19/VBN||carboplatin-22/JJ	amod||regimen-26/NN||paclitaxel-24/JJ	amod||regimen-26/NN||chemotherapy-25/JJ	prep_with||treated-19/VBN||regimen-26/NN	conj_plus||carboplatin-22/JJ||regimen-26/NN	carboplatin-22||painful-6||no_rel||a patient with extensive and painful chest wall involvement from a metastatic borderline cancer of the ovary was treated with a carboplatin plus paclitaxel chemotherapy regimen.
amod||papillomas-5/NNS||immunohistochemically-1/JJ	number||%-3/NN||17.1-2/CD	amod||papillomas-5/NNS||%-3/NN	nn||papillomas-5/NNS||conjunctival-4/NN	nsubj||stained-6/VBD||papillomas-5/NNS	ccomp||negative-16/JJ||stained-6/VBD	acomp||stained-6/VBD||positive-7/JJ	prep_for||stained-6/VBD||hpvantigen-9/NN	det||cases-12/NNS||all-11/DT	nsubj||negative-16/JJ||cases-12/NNS	prep_of||cases-12/NNS||ossn-14/NN	cop||negative-16/JJ||were-15/VBD	root||ROOT-0/null||negative-16/JJ	prep_for||negative-16/JJ||hpv-18/NN	hpvantigen-9||hpv-18||no||immunohistochemically 17.1% conjunctival papillomas stained positive for hpvantigen, all cases of ossn were negative for hpv.
det||incidence-2/NN||the-1/DT	nsubj||disappeared-6/VBD||incidence-2/NN	amod||pain-5/NN||moderate-4/JJ	prep_of||incidence-2/NN||pain-5/NN	root||ROOT-0/null||disappeared-6/VBD	advmod||disappeared-6/VBD||completely-7/RB	det||group-11/NN||the-9/DT	nn||group-11/NN||combination-10/NN	prep_in||disappeared-6/VBD||group-11/NN	num||%-14/NN||0-13/CD	appos||group-11/NN||%-14/NN	prepc_compared_to||disappeared-6/VBD||to-17/TO	pobj||disappeared-6/VBD||that-18/DT	det||group-24/NN||the-20/DT	amod||group-24/NN||remifentanil-21/JJ	conj_and||remifentanil-21/JJ||lidocaine-23/JJ	amod||group-24/NN||lidocaine-23/JJ	prep_in||that-18/DT||group-24/NN	num||%-27/NN||32.5-26/CD	dep||group-24/NN||%-27/NN	num||%-30/NN||20-29/CD	dep||group-24/NN||%-30/NN	conj_and||%-27/NN||%-30/NN	advmod||%-27/NN||respectively-32/RB	nn||0.05-36/NNP||p-34/NNP	nn||0.05-36/NNP||<-35/NNP	appos||%-27/NN||0.05-36/NNP	pain-5||lidocaine-23||yes||the incidence of moderate pain disappeared completely in the combination group (0%) compared to that in the remifentanil and lidocaine group (32.5% and 20%, respectively, p < 0.05).
det||aims-3/NNS||the-1/DT	amod||aims-3/NNS||primary-2/JJ	nsubj||are-4/VBP||aims-3/NNS	nsubj||examine-6/VB||aims-3/NNS	root||ROOT-0/null||are-4/VBP	aux||examine-6/VB||to-5/TO	xcomp||are-4/VBP||examine-6/VB	det||efficacy-8/NN||the-7/DT	dobj||examine-6/VB||efficacy-8/NN	prep_of||efficacy-8/NN||atomoxetine-10/NN	prepc_for||examine-6/VB||improving-12/VBG	amod||function-16/NN||cognition-13/JJ	conj_and||cognition-13/JJ||emotional-15/JJ	amod||function-16/NN||emotional-15/JJ	dep||improving-12/VBG||function-16/NN	prep_in||function-16/NN||adhd-18/NN	mark||pronounced-28/JJ||whether-20/IN	det||improvements-22/NNS||any-21/DT	nsubj||pronounced-28/JJ||improvements-22/NNS	det||outcomes-25/NNS||these-24/DT	prep_in||improvements-22/NNS||outcomes-25/NNS	cop||pronounced-28/JJ||are-26/VBP	advmod||pronounced-28/JJ||more-27/RBR	dep||improving-12/VBG||pronounced-28/JJ	conj_and||function-16/NN||pronounced-28/JJ	prep_in||pronounced-28/JJ||participants-30/NNS	amod||anxiety-33/NN||comorbid-32/JJ	prep_with||participants-30/NNS||anxiety-33/NN	aux||determine-37/VB||to-36/TO	dep||improving-12/VBG||determine-37/VB	conj_and||function-16/NN||determine-37/VB	mark||reliable-47/JJ||if-38/IN	nsubj||reliable-47/JJ||changes-39/NNS	det||outcomes-42/NNS||these-41/DT	prep_in||changes-39/NNS||outcomes-42/NNS	prep_after||outcomes-42/NNS||atomoxetine-44/NN	cop||reliable-47/JJ||are-45/VBP	advmod||reliable-47/JJ||more-46/RBR	advcl||determine-37/VB||reliable-47/JJ	prep_than||reliable-47/JJ||changes-49/NNS	amod||symptoms-52/NNS||diagnostic-51/JJ	prep_in||changes-49/NNS||symptoms-52/NNS	prep_of||symptoms-52/NNS||adhd-54/NN	adhd-54||atomoxetine-44||yes||the primary aims are to examine the efficacy of atomoxetine for improving cognition and emotional function in adhd and whether any improvements in these outcomes are more pronounced in participants with comorbid anxiety; and to determine if changes in these outcomes after atomoxetine are more reliable than changes in diagnostic symptoms of adhd.
advmod||present-4/VBP||here-1/RB	nsubj||present-4/VBP||we-3/PRP	root||ROOT-0/null||present-4/VBP	det||analysis-7/NN||a-5/DT	amod||analysis-7/NN||bioinformatic-6/JJ	dobj||present-4/VBP||analysis-7/NN	amod||populations-10/NNS||hcv-1a-9/JJ	prep_of||analysis-7/NN||populations-10/NNS	vmod||populations-10/NNS||isolated-11/VBN	num||children-14/NNS||23-13/CD	prep_from||isolated-11/VBN||children-14/NNS	prep_with||isolated-11/VBN||chronichepatitisc-16/NN	discourse||chronichepatitisc-16/NN||chc-18/UH	vmod||chronichepatitisc-16/NN||subjected-20/VBN	aux||interferonâ-22/VB||to-21/TO	xcomp||subjected-20/VBN||interferonâ-22/VB	num||therapy-26/NN||$-23/$	num||$-23/$||ribavirin-25/CD	dobj||interferonâ-22/VB||therapy-26/NN	chronichepatitisc-16||interferon--1||yes||here, we present a bioinformatic analysis of hcv-1a populations isolated from 23 children with chronichepatitisc (chc) subjected to interferonâribavirin therapy.
prep_by||olysetâ-25/VBZ||2008-2/CD	dobj||recommended-12/VBD||the-4/DT	nsubj||olysetâ-25/VBZ||the-4/DT	nn||scheme-8/NN||pesticide-6/NN	nn||scheme-8/NN||evaluation-7/NN	nsubj||recommended-12/VBD||scheme-8/NN	appos||scheme-8/NN||whopes-10/NNS	rcmod||the-4/DT||recommended-12/VBD	num||nets-16/NNS||five-13/CD	amod||nets-16/NNS||long-lasting-14/JJ	amod||nets-16/NNS||insecticidal-15/JJ	dobj||recommended-12/VBD||nets-16/NNS	appos||nets-16/NNS||llins-18/NNS	det||prevention-22/NN||the-21/DT	prep_for||recommended-12/VBD||prevention-22/NN	prep_of||prevention-22/NN||malaria-24/NN	root||ROOT-0/null||olysetâ-25/VBZ	amod||®-31/NNS||®-26/JJ	amod||®-31/NNS||permanet-28/JJ	nn||®-31/NNS||2.0-29/NN	nn||®-31/NNS||â-30/NN	dobj||olysetâ-25/VBZ||®-31/NNS	nn||®-34/NNP||netprotectâ-33/NNP	dobj||olysetâ-25/VBZ||®-34/NNP	conj_and||®-31/NNS||®-34/NNP	nn||®-37/NNP||duranetâ-36/NNP	dobj||olysetâ-25/VBZ||®-37/NNP	conj_and||®-31/NNS||®-37/NNP	nn||®-40/NNP||interceptorâ-39/NNP	dobj||olysetâ-25/VBZ||®-40/NNP	conj_and||®-31/NNS||®-40/NNP	pesticide-6||malaria-24||no_rel||by 2008, the who pesticide evaluation scheme (whopes) recommended five long-lasting insecticidal nets (llins) for the prevention of malaria olysetâ®, permanet 2.0â®, netprotectâ®, duranetâ® and interceptorâ®.
det||prevention-3/NN||the-1/DT	nn||prevention-3/NN||stroke-2/NN	nsubj||reduced-33/VBD||prevention-3/NN	amod||reduction-6/NN||aggressive-5/JJ	prep_by||prevention-3/NN||reduction-6/NN	nn||levels-9/NNS||cholesterol-8/NN	prep_of||reduction-6/NN||levels-9/NNS	dep||levels-9/NNS||sparcl-11/JJ	nsubj||showed-14/VBD||trial-13/NN	rcmod||levels-9/NNS||showed-14/VBD	amod||treatment-16/NN||daily-15/JJ	dobj||showed-14/VBD||treatment-16/NN	num||mg-19/NN||80-18/CD	prep_with||showed-14/VBD||mg-19/NN	prep_of||mg-19/NN||atorvastatin-21/NN	prep_in||showed-14/VBD||patients-23/NNS	det||stroke-27/NN||a-25/DT	amod||stroke-27/NN||recent-26/JJ	prep_with||patients-23/NNS||stroke-27/NN	prep_with||patients-23/NNS||transientischemicattack-29/NN	conj_or||stroke-27/NN||transientischemicattack-29/NN	appos||stroke-27/NN||tia-31/NN	root||ROOT-0/null||reduced-33/VBD	det||incidence-35/NN||the-34/DT	dobj||reduced-33/VBD||incidence-35/NN	amod||stroke-40/NN||fatal-37/JJ	conj_or||fatal-37/JJ||nonfatal-39/JJ	amod||stroke-40/NN||nonfatal-39/JJ	prep_of||incidence-35/NN||stroke-40/NN	num||%-43/NN||16-42/CD	prep_by||reduced-33/VBD||%-43/NN	atorvastatin-21||tia-31||no_rel||the stroke prevention by aggressive reduction of cholesterol levels (sparcl) trial showed daily treatment with 80 mg of atorvastatin in patients with a recent stroke or transientischemicattack (tia) reduced the incidence of fatal or nonfatal stroke by 16%.
amod||enzymes-2/NNS||deubiquitylating-1/JJ	nsubj||hydrolyze-7/VB||enzymes-2/NNS	appos||enzymes-2/NNS||dubs-4/NNP	aux||hydrolyze-7/VB||can-6/MD	root||ROOT-0/null||hydrolyze-7/VB	det||bond-16/NN||a-8/DT	amod||bond-16/NN||peptide-9/JJ	conj_or||peptide-9/JJ||amide-11/JJ	amod||bond-16/NN||amide-11/JJ	conj_or||peptide-9/JJ||ester-13/JJ	amod||bond-16/NN||ester-13/JJ	conj_or||peptide-9/JJ||thiolester-15/JJ	amod||bond-16/NN||thiolester-15/JJ	dobj||hydrolyze-7/VB||bond-16/NN	det||c-terminus-19/NNS||the-18/DT	prep_at||hydrolyze-7/VB||c-terminus-19/NNS	prep_of||c-terminus-19/NNS||ubiq-21/NNP	appos||ubiq-21/NNP||ubiquitin-23/NN	det||post-translationally-28/NN||the-27/DT	prep_including||hydrolyze-7/VB||post-translationally-28/NN	vmod||post-translationally-28/NN||formed-29/VBN	amod||bonds-32/NNS||branched-30/JJ	nn||bonds-32/NNS||peptide-31/NN	dobj||formed-29/VBN||bonds-32/NNS	prep_in||formed-29/VBN||mono-34/NN	amod||conjugates-38/NNS||multi-ubiquitylated-37/JJ	prep_in||formed-29/VBN||conjugates-38/NNS	conj_or||mono-34/NN||conjugates-38/NNS	mono-34||ester-13||no_rel||deubiquitylating enzymes (dubs) can hydrolyze a peptide, amide, ester or thiolester bond at the c-terminus of ubiq (ubiquitin), including the post-translationally formed branched peptide bonds in mono- or multi-ubiquitylated conjugates.
det||connection-5/NN||the-3/DT	amod||connection-5/NN||close-4/JJ	prep_because_of||examined-35/VBN||connection-5/NN	prep_of||connection-5/NN||s100b-7/NNS	aux||acth-9/VB||to-8/TO	vmod||s100b-7/NNS||acth-9/VB	vmod||s100b-7/NNS||glutamate-11/VB	conj_and||acth-9/VB||glutamate-11/VB	dobj||acth-9/VB||secretion-12/NN	mark||involved-16/VBN||that-13/IN	nsubjpass||involved-16/VBN||both-14/DT	auxpass||involved-16/VBN||are-15/VBP	ccomp||acth-9/VB||involved-16/VBN	prep_in||involved-16/VBN||neurodegeneration-18/NN	prep_in||involved-16/VBN||symptoms-20/NNS	conj_and||neurodegeneration-18/NN||symptoms-20/NNS	prep_of||neurodegeneration-18/NN||alcoholism-22/NN	det||relationship-24/NN||the-23/DT	nsubjpass||examined-35/VBN||relationship-24/NN	amod||variables-32/NNS||s100b-26/JJ	amod||acute-30/JJ||homocysteine-28/JJ	dep||acute-30/JJ||to-29/TO	conj_and||s100b-26/JJ||acute-30/JJ	amod||variables-32/NNS||acute-30/JJ	nn||variables-32/NNS||withdrawal-31/NN	prep_of||relationship-24/NN||variables-32/NNS	aux||examined-35/VBN||has-33/VBZ	auxpass||examined-35/VBN||been-34/VBN	root||ROOT-0/null||examined-35/VBN	alcoholism-22||acth-9||no_rel||because of the close connection of s100b to acth and glutamate secretion that both are involved in neurodegeneration and symptoms of alcoholism the relationship of s100b and homocysteine to acute withdrawal variables has been examined.
poss||study-3/NN||our-2/PRP$	det||bupivacaine-9/NN||study-3/NN	prep_from||provides-16/VBZ||study-3/NN	nsubjpass||concluded-7/VBN||it-4/PRP	aux||concluded-7/VBN||can-5/MD	auxpass||concluded-7/VBN||be-6/VB	rcmod||study-3/NN||concluded-7/VBN	npadvmod||concluded-7/VBN||bupivacaine-9/NN	prep_along_with||concluded-7/VBN||clonidine-12/NN	amod||doses-15/NNS||low-14/JJ	prep_in||clonidine-12/NN||doses-15/NNS	root||ROOT-0/null||provides-16/VBZ	conj_and||provides-16/VBZ||provides-16/VBZ	amod||sedation-18/NN||good-17/JJ	dobj||provides-16/VBZ||sedation-18/NN	dobj||provides-16/VBZ||analgesia-20/NN	conj_and||sedation-18/NN||analgesia-20/NN	amod||period-25/NN||intraoperative-22/JJ	conj_and||intraoperative-22/JJ||post-operative-24/JJ	amod||period-25/NN||post-operative-24/JJ	prep_in||provides-16/VBZ||period-25/NN	det||abolishes-31/NNS||the-28/DT	amod||abolishes-31/NNS||same-29/JJ	nn||abolishes-31/NNS||time-30/NN	prep_at||provides-16/VBZ||abolishes-31/NNS	nn||pain-34/NN||shoulder-32/NN	nn||pain-34/NN||tip-33/NN	nsubj||provides-16/VBZ||pain-34/NN	nsubj||provides-16/VBZ||pain-34/NN	amod||procedures-37/NNS||laparoscopic-36/JJ	prep_during||pain-34/NN||procedures-37/NNS	pain-34||bupivacaine-9||yes||from our study it can be concluded that bupivacaine along with clonidine in low doses provides good sedation and analgesia in intraoperative and post-operative period and at the same time abolishes shoulder tip pain during laparoscopic procedures.
det||inhibition-4/NN||the-2/DT	amod||inhibition-4/NN||platelet-3/JJ	prep_in||reduced-14/VBD||inhibition-4/NN	amod||outcomes-7/NNS||patient-6/JJ	conj_and||inhibition-4/NN||outcomes-7/NNS	prep_in||reduced-14/VBD||outcomes-7/NNS	appos||outcomes-7/NNS||plato-9/NNP	dep||outcomes-7/NNS||trial-11/NN	nsubj||reduced-14/VBD||ticagrelor-13/NN	root||ROOT-0/null||reduced-14/VBD	det||endpoint-18/NN||the-15/DT	amod||endpoint-18/NN||primary-16/JJ	amod||endpoint-18/NN||composite-17/JJ	dobj||reduced-14/VBD||endpoint-18/NN	amod||death-21/NN||cardiovascular-20/JJ	prep_of||endpoint-18/NN||death-21/NN	prep_of||endpoint-18/NN||myocardialinfarction-23/NN	conj_or||death-21/NN||myocardialinfarction-23/NN	prep_of||endpoint-18/NN||stroke-26/NN	conj_or||death-21/NN||stroke-26/NN	conj_but||reduced-14/VBD||with-29/IN	amod||rates-31/NNS||similar-30/JJ	pobj||with-29/IN||rates-31/NNS	amod||bleeding-34/NN||major-33/JJ	prep_of||rates-31/NNS||bleeding-34/NN	prepc_compared_with||reduced-14/VBD||with-36/IN	pobj||reduced-14/VBD||clopidogrel-37/NN	myocardialinfarction-23||clopidogrel-37||yes||in the platelet inhibition and patient outcomes (plato) trial, ticagrelor reduced the primary composite endpoint of cardiovascular death, myocardialinfarction, or stroke, but with similar rates of major bleeding compared with clopidogrel.
nsubj||intestine-5/NN||coeliacdisease-1/NN	cop||intestine-5/NN||is-2/VBZ	det||intestine-5/NN||a-3/DT	amod||intestine-5/NN||small-4/JJ	root||ROOT-0/null||intestine-5/NN	advmod||caused-7/VBN||enteropathy-6/RB	vmod||intestine-5/NN||caused-7/VBN	amod||intolerance-10/NN||permanent-9/JJ	agent||caused-7/VBN||intolerance-10/NN	nn||gluten-13/NN||wheat-12/NN	prep_to||caused-7/VBN||gluten-13/NN	coeliacdisease-1||gluten-13||no||coeliacdisease is a small intestine enteropathy caused by permanent intolerance to wheat gluten.
nsubj||concurred-2/VBD||hypoglycaemia-1/NN	root||ROOT-0/null||concurred-2/VBD	nn||features-5/NNS||severity-4/NN	prep_with||concurred-2/VBD||features-5/NNS	appos||features-5/NNS||disruption-7/NN	nn||infusion-10/NN||glucose-9/NN	prep_of||disruption-7/NN||infusion-10/NN	prep_of||disruption-7/NN||transfusion-12/NN	conj_and||infusion-10/NN||transfusion-12/NN	hypoglycaemia-1||glucose-9||yes||hypoglycaemia concurred with severity features, disruption of glucose infusion and transfusion.
det||use-3/NN||the-2/DT	prep_through||compared-15/VBD||use-3/NN	amod||gold-6/NN||quantiferon-tb-5/JJ	prep_of||use-3/NN||gold-6/NN	det||assay-12/NN||a-8/DT	amod||assay-12/NN||commercial-9/JJ	nn||assay-12/NN||ifn-î-10/NNP	nn||assay-12/NN||³-11/NNP	appos||gold-6/NN||assay-12/NN	nsubj||compared-15/VBD||we-14/PRP	root||ROOT-0/null||compared-15/VBD	dobj||compared-15/VBD||differences-16/NNS	amod||responses-20/NNS||quantitative-18/JJ	amod||responses-20/NNS||t-cell-19/JJ	prep_in||compared-15/VBD||responses-20/NNS	prep_to||compared-15/VBD||mycobacteriumtuberculosis-22/NNS	appos||mycobacteriumtuberculosis-22/NNS||mtb-24/NN	amod||antigens-28/NNS||specific-27/JJ	nsubj||quantiferon-30/VB||antigens-28/NNS	advmod||quantiferon-30/VB||-LSB--29/RB	parataxis||compared-15/VBD||quantiferon-30/VB	amod||disease-44/NN||tb-2g-31/JJ	dep||disease-44/NN||qft-2g-33/JJ	amod||disease-44/NN||-RSB--35/JJ	prep_between||-RSB--35/JJ||patients-37/NNS	amod||tuberculosis-40/NNP||active-39/JJ	prep_with||patients-37/NNS||tuberculosis-40/NNP	dep||patients-37/NNS||tb-42/VBN	dobj||quantiferon-30/VB||disease-44/NN	dobj||quantiferon-30/VB||those-46/DT	conj_and||disease-44/NN||those-46/DT	nn||infection-50/NN||latent-48/NN	nn||infection-50/NN||tb-49/NN	prep_with||those-46/DT||infection-50/NN	appos||infection-50/NN||ltbi-52/NNP	tb-49||mycobacteriumtuberculosis-22||no||through the use of quantiferon-tb gold, a commercial ifn-î³ assay, we compared differences in quantitative t-cell responses to mycobacteriumtuberculosis (mtb)-specific antigens [quantiferon tb-2g (qft-2g)] between patients with active tuberculosis (tb) disease and those with latent tb infection (ltbi).
nsubj||disease-8/NN||diabetesmellitus-1/NNS	appos||diabetesmellitus-1/NNS||dm-3/NN	cop||disease-8/NN||is-5/VBZ	det||disease-8/NN||a-6/DT	amod||disease-8/NN||complex-7/JJ	root||ROOT-0/null||disease-8/NN	vmod||disease-8/NN||characterized-9/VBN	amod||hyperglycemia-12/NN||chronic-11/JJ	agent||characterized-9/VBN||hyperglycemia-12/NN	det||factor-17/NN||a-14/DT	amod||factor-17/NN||known-15/VBN	nn||factor-17/NN||risk-16/NN	appos||hyperglycemia-12/NN||factor-17/NN	amod||atherosclerosis-20/NNS||accelerated-19/JJ	prep_for||factor-17/NN||atherosclerosis-20/NNS	prep_for||factor-17/NN||vasculardisease-22/NN	conj_and||atherosclerosis-20/NNS||vasculardisease-22/NN	hyperglycemia-12||dm-3||no_rel||diabetesmellitus (dm) is a complex disease characterized by chronic hyperglycemia, a known risk factor for accelerated atherosclerosis and vasculardisease.
nsubj||cause-5/NN||staphylococcusaureus-1/NNS	cop||cause-5/NN||is-2/VBZ	det||cause-5/NN||a-3/DT	amod||cause-5/NN||common-4/JJ	ccomp||-lrb--25/VBD||cause-5/NN	amod||infection-8/NN||human-7/JJ	prep_of||cause-5/NN||infection-8/NN	nsubj||concern-18/NN||emergence-11/NN	amod||s.aureus-14/NNS||vancomycin-resistance-13/JJ	prep_of||emergence-11/NN||s.aureus-14/NNS	cop||concern-18/NN||is-15/VBZ	det||concern-18/NN||a-16/DT	amod||concern-18/NN||great-17/JJ	conj_and||cause-5/NN||concern-18/NN	ccomp||-lrb--25/VBD||concern-18/NN	prep_for||concern-18/NN||treatment-20/NN	amod||s.aureus-23/NNS||methicillin-resistant-22/JJ	prep_of||treatment-20/NN||s.aureus-23/NNS	root||ROOT-0/null||-lrb--25/VBD	nn||-rrb--27/NNS||mrsa-26/NN	dobj||-lrb--25/VBD||-rrb--27/NNS	amod||years-30/NNS||recent-29/JJ	prep_in||-lrb--25/VBD||years-30/NNS	num||-rrb--33/NN||-lrb--31/CD	nn||-rrb--33/NN||mrsa-32/NN	nsubj||-lrb--25/VBD||-rrb--33/NN	mrsa-32||s.aureus-23||no||staphylococcusaureus is a common cause of human infection , and emergence of vancomycin-resistance s.aureus is a great concern for treatment of methicillin-resistant s.aureus , -lrb- mrsa -rrb- in recent years -lrb- mrsa -rrb- .
nsubjpass||developed-15/VBN||dronedarone-1/NN	det||derivative-5/NN||a-3/DT	nn||derivative-5/NN||benzofuran-4/NN	appos||dronedarone-1/NN||derivative-5/NN	det||structure-8/NN||a-7/DT	prep_with||derivative-5/NN||structure-8/NN	amod||amiodarone-11/JJ||similar-9/JJ	dep||amiodarone-11/JJ||to-10/TO	amod||structure-8/NN||amiodarone-11/JJ	aux||developed-15/VBN||has-13/VBZ	auxpass||developed-15/VBN||been-14/VBN	root||ROOT-0/null||developed-15/VBN	det||therapy-19/NN||a-17/DT	amod||therapy-19/NN||potential-18/JJ	prep_as||developed-15/VBN||therapy-19/NN	prep_for||therapy-19/NN||patients-21/NNS	prep_with||patients-21/NNS||atrialfibrillation-23/NN	dronedarone-1||atrialfibrillation-23||no_rel||dronedarone, a benzofuran derivative with a structure similar to amiodarone, has been developed as a potential therapy for patients with atrialfibrillation.
amod||mucins-3/NNS||purified-1/JJ	nn||mucins-3/NNS||salivary-2/NN	nsubj||inhibit-9/VB||mucins-3/NNS	amod||patients-6/NNS||hivpositive-5/JJ	prep_from||mucins-3/NNS||patients-6/NNS	aux||inhibit-9/VB||do-7/VBP	neg||inhibit-9/VB||not-8/RB	root||ROOT-0/null||inhibit-9/VB	det||aidsvirus-11/NNS||the-10/DT	dobj||inhibit-9/VB||aidsvirus-11/NNS	det||assay-16/NN||an-13/DT	dep||vitro-15/NN||in-14/IN	amod||assay-16/NN||vitro-15/NN	prep_in||inhibit-9/VB||assay-16/NN	hivpositive-5||aidsvirus-11||no||purified salivary mucins from hivpositive patients do not inhibit the aidsvirus in an in vitro assay.
nsubj||involved-10/VBD||phase-1/NN	num||phase-1/NN||2-2/CD	prep_from||phase-1/NN||january-5/NNP	prep_to||january-5/NNP||october-7/NNP	num||october-7/NNP||2007-8/CD	root||ROOT-0/null||involved-10/VBD	xcomp||involved-10/VBD||creating-11/VBG	det||platform-14/NN||a-12/DT	amod||platform-14/NN||web-based-13/JJ	dobj||creating-11/VBG||platform-14/NN	aux||host-16/VB||to-15/TO	vmod||creating-11/VBG||host-16/VB	det||system-22/NN||the-17/DT	amod||system-22/NN||integrated-18/VBN	amod||system-22/NN||hiv/aids-19/JJ	nn||system-22/NN||data-20/NN	nn||system-22/NN||collection-21/NN	dobj||host-16/VB||system-22/NN	aids--1||hiv--1||no||phase 2, from january to october 2007, involved creating a web-based platform to host the integrated hiv/aids data collection system.
det||absence-3/NN||the-2/DT	prep_in||exhibit-11/VB||absence-3/NN	amod||insulin-6/NN||exogenous-5/JJ	prep_of||absence-3/NN||insulin-6/NN	nsubj||exhibit-11/VB||patients-8/NNS	prep_with||patients-8/NNS||type1diabetes-10/CD	root||ROOT-0/null||exhibit-11/VB	det||variety-13/NN||a-12/DT	nsubj||due-28/JJ||variety-13/NN	amod||abnormalities-16/NNS||metabolic-15/JJ	prep_of||variety-13/NN||abnormalities-16/NNS	prep_including||abnormalities-16/NNS||hyperglycemia-18/NN	prep_including||abnormalities-16/NNS||glycosurea-20/NN	conj_and||hyperglycemia-18/NN||glycosurea-20/NN	amod||ketogenesis-23/NNS||accelerated-22/JJ	prep_including||abnormalities-16/NNS||ketogenesis-23/NNS	conj_and||hyperglycemia-18/NN||ketogenesis-23/NNS	nn||wasting-27/NN||muscle-26/NN	prep_including||abnormalities-16/NNS||wasting-27/NN	conj_and||hyperglycemia-18/NN||wasting-27/NN	xcomp||exhibit-11/VB||due-28/JJ	amod||proteolysis-31/NNS||increased-30/VBN	prep_to||due-28/JJ||proteolysis-31/NNS	hyperglycemia-18||insulin-6||yes||in the absence of exogenous insulin, patients with type1diabetes exhibit a variety of metabolic abnormalities including hyperglycemia, glycosurea, accelerated ketogenesis, and muscle wasting due to increased proteolysis.
det||results-2/NNS||these-1/DT	nsubj||suggest-3/VBP||results-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||useful-13/JJ||that-4/IN	advmod||culturing-6/VBG||routinely-5/RB	csubj||useful-13/JJ||culturing-6/VBG	prep_for||culturing-6/VBG||m.tuberculosis-8/NNS	prep_during||m.tuberculosis-8/NNS||bronchoscopy-10/NN	cop||useful-13/JJ||is-11/VBZ	advmod||useful-13/JJ||still-12/RB	ccomp||suggest-3/VBP||useful-13/JJ	det||diagnosis-16/NN||the-15/DT	prep_in||useful-13/JJ||diagnosis-16/NN	prep_of||diagnosis-16/NN||pulmonarytuberculosis-18/NNS	det||country-23/NN||an-20/DT	amod||country-23/NN||intermediate-21/JJ	amod||country-23/NN||tuberculosis-burden-22/JJ	prep_in||pulmonarytuberculosis-18/NNS||country-23/NN	pulmonarytuberculosis-18||m.tuberculosis-8||no||these results suggest that routinely culturing for m.tuberculosis during bronchoscopy is still useful in the diagnosis of pulmonarytuberculosis in an intermediate tuberculosis-burden country .
amod||infection-7/NN||occult-1/JJ	amod||infection-7/NN||hepatitisb-2/JJ	nn||infection-7/NN||virus-3/NN	appos||infection-7/NN||hbv-5/NN	nsubj||transmit-9/VB||infection-7/NN	aux||transmit-9/VB||might-8/MD	root||ROOT-0/null||transmit-9/VB	amod||units-11/NNS||viremic-10/JJ	dobj||transmit-9/VB||units-11/NNS	det||supply-16/NN||the-13/DT	amod||supply-16/NN||public-14/JJ	nn||supply-16/NN||blood-15/NN	prep_into||transmit-9/VB||supply-16/NN	mark||used-25/VBN||if-17/IN	advmod||testing-23/NN||only-18/RB	amod||testing-23/NN||hepatitisbsurfaceantigen-19/JJ	nn||testing-23/NN||hbsag-21/NN	nsubjpass||used-25/VBN||testing-23/NN	auxpass||used-25/VBN||is-24/VBZ	advcl||transmit-9/VB||used-25/VBN	nn||screening-28/NN||donor-27/NN	prep_for||used-25/VBN||screening-28/NN	hbv-5||hepatitisbsurfaceantigen-19||yes||occult hepatitisb virus (hbv) infection might transmit viremic units into the public blood supply if only hepatitisbsurfaceantigen (hbsag) testing is used for donor screening.
amod||treatment-2/NN||ionophore-1/JJ	nsubj||had-6/VBD||treatment-2/NN	amod||schizonts-5/NNS||immature-4/JJ	prep_of||treatment-2/NN||schizonts-5/NNS	root||ROOT-0/null||had-6/VBD	det||effect-9/NN||an-7/DT	amod||effect-9/NN||adverse-8/JJ	dobj||had-6/VBD||effect-9/NN	vmod||effect-9/NN||inducing-10/VBG	nsubj||swelling-13/VBG||parasitophorous-11/NNS	nsubj||killing-15/VBG||parasitophorous-11/NNS	dep||swelling-13/VBG||vacuole-12/JJ	xcomp||inducing-10/VBG||swelling-13/VBG	xcomp||inducing-10/VBG||killing-15/VBG	conj_and||swelling-13/VBG||killing-15/VBG	det||parasites-17/NNS||the-16/DT	dobj||swelling-13/VBG||parasites-17/NNS	det||cell-21/NN||the-19/DT	nn||cell-21/NN||host-20/NN	prep_within||swelling-13/VBG||cell-21/NN	ionophore-1||swelling-13||no_rel||ionophore treatment of immature schizonts had an adverse effect inducing parasitophorous vacuole swelling and killing the parasites within the host cell.
mark||contained-8/VBD||while-1/IN	det||diet-4/NN||the-2/DT	amod||diet-4/NN||high-fat-3/JJ	nsubj||contained-8/VBD||diet-4/NN	appos||diet-4/NN||hfd-6/NN	advcl||found-33/VBD||contained-8/VBD	nn||levels-10/NNS||equivalent-9/NN	nsubj||'s-23/VBZ||levels-10/NNS	prep_of||levels-10/NNS||n-3fattyacids-12/JJ	appos||n-3fattyacids-12/JJ||fa-14/NN	possessive||fa-14/NN||'s-15/POS	amod||levels-19/NNS||higher-18/JJR	prep_of||levels-10/NNS||levels-19/NNS	conj_and||n-3fattyacids-12/JJ||levels-19/NNS	amod||fa-22/NN||n-6-21/JJ	prep_of||levels-19/NNS||fa-22/NN	ccomp||contained-8/VBD||'s-23/VBZ	det||diet-27/NN||the-25/DT	nn||diet-27/NN||control-26/NN	prep_than||'s-23/VBZ||diet-27/NN	appos||diet-27/NN||ctr-29/NN	nsubj||found-33/VBD||we-32/PRP	root||ROOT-0/null||found-33/VBD	amod||decreases-35/NNS||significant-34/JJ	nsubj||'s-46/VBZ||decreases-35/NNS	amod||acid-38/NN||docosahexaenoic-37/JJ	prep_in||decreases-35/NNS||acid-38/NN	appos||acid-38/NN||dha-40/NN	amod||fa-45/NN||total-43/JJ	amod||fa-45/NN||n-3-44/JJ	prep_in||decreases-35/NNS||fa-45/NN	conj_and||acid-38/NN||fa-45/NN	ccomp||found-33/VBD||'s-46/VBZ	nn||maternal-49/NN||hfd-48/NN	prep_in||'s-46/VBZ||maternal-49/NN	amod||plasma-52/NN||fetal-51/JJ	prep_in||'s-46/VBZ||plasma-52/NN	conj_and||maternal-49/NN||plasma-52/NN	dha-40||fa-45||no_rel||while the high-fat diet (hfd) contained equivalent levels of n-3fattyacids (fa's) and higher levels of n-6 fa's than the control diet (ctr), we found significant decreases in docosahexaenoic acid (dha) and total n-3 fa's in hfd maternal and fetal plasma.
amod||-rrb--4/NNS||chloroquine-1/JJ	amod||-rrb--4/NNS||-lrb--2/JJ	nn||-rrb--4/NNS||cq-3/NN	nsubj||treatment-9/NN||-rrb--4/NNS	cop||treatment-9/NN||is-5/VBZ	det||treatment-9/NN||the-6/DT	amod||treatment-9/NN||first-7/JJ	nn||treatment-9/NN||line-8/NN	root||ROOT-0/null||treatment-9/NN	amod||vivaxmalaria-13/NN||confirmed-11/JJ	nn||vivaxmalaria-13/NN||p.-12/NN	prep_for||treatment-9/NN||vivaxmalaria-13/NN	det||country-16/NN||the-15/DT	prep_in||vivaxmalaria-13/NN||country-16/NN	chloroquine-1||vivaxmalaria-13||no_rel||chloroquine -lrb- cq -rrb- is the first line treatment for confirmed p. vivaxmalaria in the country .
amod||sleepapnea-2/NN||obstructive-1/JJ	nsubj||common-4/JJ||sleepapnea-2/NN	cop||common-4/JJ||is-3/VBZ	root||ROOT-0/null||common-4/JJ	prep_in||common-4/JJ||patients-6/NNS	prep_with||patients-6/NNS||type2diabetes-8/CD	poss||association-12/NN||its-11/PRP$	nsubjpass||examined-19/VBN||association-12/NN	prep_with||association-12/NN||insulin-14/NN	prep_with||association-12/NN||insulinresistance-16/NN	conj_and||insulin-14/NN||insulinresistance-16/NN	aux||examined-19/VBN||has-17/VBZ	auxpass||examined-19/VBN||been-18/VBN	conj_and||common-4/JJ||examined-19/VBN	amod||studies-22/NNS||cross-sectional-21/JJ	prep_in||examined-19/VBN||studies-22/NNS	type2diabetes-8||insulin-14||yes||obstructive sleepapnea is common in patients with type2diabetes, and its association with insulin and insulinresistance has been examined in cross-sectional studies.
neg||difference-2/NN||no-1/DT	nsubjpass||observed-11/VBN||difference-2/NN	det||group-6/NN||the-4/DT	amod||group-6/NN||tannin-treated-5/JJ	prep_between||difference-2/NN||group-6/NN	det||controls-9/NNS||the-8/DT	prep_between||difference-2/NN||controls-9/NNS	conj_and||group-6/NN||controls-9/NNS	auxpass||observed-11/VBN||was-10/VBD	root||ROOT-0/null||observed-11/VBN	det||number-14/NN||the-13/DT	prep_in||observed-11/VBN||number-14/NN	prep_of||number-14/NN||cells-16/NNS	vmod||cells-16/NNS||seeded-17/VBN	det||bottom-20/NN||the-19/DT	prep_at||seeded-17/VBN||bottom-20/NN	det||wells-23/NNS||the-22/DT	prep_of||bottom-20/NN||wells-23/NNS	tannin--1||wells-23||no_rel||no difference between the tannin-treated group and the controls was observed in the number of cells seeded at the bottom of the wells.
det||patients-4/NNS||the-1/DT	amod||patients-4/NNS||479-2/JJ	amod||patients-4/NNS||evaluable-3/JJ	nsubj||had-11/VBD||patients-4/NNS	prep_with||patients-4/NNS||metastaticcancer-6/NN	amod||sites-10/NNS||other-8/JJ	nn||sites-10/NNS||primarycancer-9/NN	prep_from||metastaticcancer-6/NN||sites-10/NNS	root||ROOT-0/null||had-11/VBD	dobj||had-11/VBD||cr-12/NN	dobj||had-11/VBD||pr-14/NN	conj_and||cr-12/NN||pr-14/NN	amod||rates-20/NNS||cr-17/JJ	amod||rates-20/NNS||+-18/JJ	nn||rates-20/NNS||pr-19/NN	dobj||had-11/VBD||rates-20/NNS	conj_and||cr-12/NN||rates-20/NNS	num||%-23/NN||25-22/CD	prep_of||rates-20/NNS||%-23/NN	num||%-26/NN||27-25/CD	prep_of||rates-20/NNS||%-26/NN	conj_and||%-23/NN||%-26/NN	num||%-30/NN||51-29/CD	prep_of||rates-20/NNS||%-30/NN	conj_and||%-23/NN||%-30/NN	num||weeks-33/NNS||4-32/CD	prep_at||%-30/NN||weeks-33/NNS	num||%-36/NN||26-35/CD	prep_of||rates-20/NNS||%-36/NN	conj_and||%-23/NN||%-36/NN	num||%-39/NN||22-38/CD	prep_of||rates-20/NNS||%-39/NN	conj_and||%-23/NN||%-39/NN	num||%-43/NN||48-42/CD	prep_of||rates-20/NNS||%-43/NN	conj_and||%-23/NN||%-43/NN	num||weeks-46/NNS||8-45/CD	prep_at||%-43/NN||weeks-46/NNS	num||%-50/NN||22-49/CD	prep_of||rates-20/NNS||%-50/NN	conj_and||%-23/NN||%-50/NN	num||%-53/NN||29-52/CD	prep_of||rates-20/NNS||%-53/NN	conj_and||%-23/NN||%-53/NN	num||%-57/NN||51-56/CD	prep_of||rates-20/NNS||%-57/NN	conj_and||%-23/NN||%-57/NN	num||weeks-60/NNS||12-59/CD	prep_at||had-11/VBD||weeks-60/NNS	cr-17||metastaticcancer-6||no_rel||the 479 evaluable patients with metastaticcancer from other primarycancer sites had cr , pr , and cr + pr rates of 25%, 27%, and 51% at 4 weeks; 26%, 22%, and 48% at 8 weeks; and 22%, 29%, and 51% at 12 weeks.
det||woman-3/NN||a-1/DT	amod||woman-3/NN||73-year-old-2/JJ	nsubjpass||given-7/VBN||woman-3/NN	prep_with||woman-3/NN||dementia-5/NN	auxpass||given-7/VBN||was-6/VBD	root||ROOT-0/null||given-7/VBN	acomp||given-7/VBN||clozapine-8/JJ	amod||symptoms-12/NNS||treatment-resistant-10/JJ	amod||symptoms-12/NNS||psychotic-11/JJ	prep_for||given-7/VBN||symptoms-12/NNS	clozapine-8||psychotic-11||no_rel||a 73-year-old woman with dementia was given clozapine for treatment-resistant psychotic symptoms.
det||effort-2/NN||the-1/DT	nsubj||led-25/VBN||effort-2/NN	aux||develop-4/VB||to-3/TO	vmod||effort-2/NN||develop-4/VB	det||rin-20/NN||a-5/DT	nn||rin-20/NN||tuberculosis-6/NNP	appos||tuberculosis-6/NNP||tb-8/NN	nn||rin-20/NN||vaccine-10/NN	advmod||effective-12/JJ||more-11/RBR	amod||rin-20/NN||effective-12/JJ	det||bacille-17/NN||the-14/DT	advmod||used-16/VBN||widely-15/RB	amod||bacille-17/NN||used-16/VBN	prep_than||effective-12/JJ||bacille-17/NN	nn||rin-20/NN||calmette-guã-18/NNP	nn||rin-20/NN||©-19/NNP	dobj||develop-4/VB||rin-20/NN	appos||rin-20/NN||bcg-22/NN	aux||led-25/VBN||has-24/VBZ	root||ROOT-0/null||led-25/VBN	det||development-28/NN||the-27/DT	prep_to||led-25/VBN||development-28/NN	num||vaccines-35/NNS||two-30/CD	nn||vaccines-35/NNS||novel-31/NN	nn||vaccines-35/NNS||fusion-32/NN	nn||vaccines-35/NNS||protein-33/NN	nn||vaccines-35/NNS||subunit-34/NN	prep_of||development-28/NN||vaccines-35/NNS	amod||vaccines-35/NNS||ag85b-esat-6-36/JJ	amod||vaccines-35/NNS||ag85b-tb10-38/JJ	conj_and||ag85b-esat-6-36/JJ||ag85b-tb10-38/JJ	dobj||led-25/VBN||.4-39/CD	tb-8||bcg-22||yes||the effort to develop a tuberculosis (tb) vaccine more effective than the widely used bacille calmette-guã©rin (bcg) has led to the development of two novel fusion protein subunit vaccines ag85b-esat-6 and ag85b-tb10.4.
det||infants-2/NNS||all-1/DT	nsubjpass||tested-7/VBN||infants-2/NNS	det||cohort-5/NN||the-4/DT	prep_in||infants-2/NNS||cohort-5/NN	auxpass||tested-7/VBN||were-6/VBD	root||ROOT-0/null||tested-7/VBN	prep_for||tested-7/VBN||hivinfection-9/NN	xcomp||tested-7/VBN||using-10/VBG	nn||pcr-12/FW||dna-11/FW	dobj||using-10/VBG||pcr-12/FW	amod||visits-16/NNS||multiple-14/JJ	nn||visits-16/NNS||study-15/NN	prep_at||using-10/VBG||visits-16/NNS	det||mo-20/NN||the-18/DT	num||mo-20/NN||24-19/CD	prep_during||using-10/VBG||mo-20/NN	det||study-23/NN||the-22/DT	prep_of||mo-20/NN||study-23/NN	nn||load-29/NN||plasma-26/FW	nn||load-29/NN||rna-27/FW	amod||load-29/NN||viral-28/JJ	nsubjpass||evaluated-38/VBN||load-29/NN	det||infants-36/NNS||all-31/DT	amod||infants-36/NNS||hiv-pcrâ-32/JJ	num||infants-36/NNS||$-33/$	num||$-33/$||positive-35/CD	prep_for||load-29/NN||infants-36/NNS	auxpass||evaluated-38/VBN||was-37/VBD	conj_and||tested-7/VBN||evaluated-38/VBN	advmod||evaluated-38/VBN||retrospectively-39/RB	hivinfection-9||hiv--1||no||all infants in the cohort were tested for hivinfection using dna pcr at multiple study visits during the 24 mo of the study, and plasma rna viral load for all hiv-pcrâpositive infants was evaluated retrospectively.
det||study-2/NN||this-1/DT	nsubj||sheds-3/VBZ||study-2/NN	root||ROOT-0/null||sheds-3/VBZ	dobj||sheds-3/VBZ||light-4/NN	det||needs-7/NNS||the-6/DT	prep_on||sheds-3/VBZ||needs-7/NNS	prep_of||needs-7/NNS||persons-9/NNS	vmod||persons-9/NNS||living-10/VBG	prep_with||living-10/VBG||hiv/aids-12/NNS	det||needs-15/NNS||the-14/DT	prep_with||living-10/VBG||needs-15/NNS	conj_and||hiv/aids-12/NNS||needs-15/NNS	poss||caregivers-20/NNS||their-17/PRP$	amod||caregivers-20/NNS||direct-18/JJ	amod||caregivers-20/NNS||informal-19/JJ	prep_of||needs-15/NNS||caregivers-20/NNS	det||area-24/NN||a-22/DT	amod||area-24/NN||rural-23/JJ	prep_in||living-10/VBG||area-24/NN	det||province-29/NN||the-26/DT	amod||province-29/NN||eastern-27/JJ	nn||province-29/NN||cape-28/NN	prep_of||area-24/NN||province-29/NN	amod||africa-32/NN||south-31/JJ	prep_of||province-29/NN||africa-32/NN	aids--1||hiv--1||no||this study sheds light on the needs of persons living with hiv/aids and the needs of their direct informal caregivers in a rural area of the eastern cape province of south africa.
nsubj||propose-2/VBP||we-1/PRP	root||ROOT-0/null||propose-2/VBP	advmod||propose-2/VBP||thus-3/RB	mark||glucocorticoid-8/VBD||that-4/IN	nn||compromises-7/NNS||gr-5/NN	nn||compromises-7/NNS||haploinsufficiency-6/NN	nsubj||glucocorticoid-8/VBD||compromises-7/NNS	dep||revealed-22/VBD||glucocorticoid-8/VBD	dobj||glucocorticoid-8/VBD||sensitivity-9/NN	aux||represent-12/VB||may-11/MD	ccomp||propose-2/VBP||represent-12/VB	conj_and||revealed-22/VBD||represent-12/VB	det||cause-16/NN||a-13/DT	amod||cause-16/NN||novel-14/JJ	amod||cause-16/NN||genetic-15/JJ	dobj||represent-12/VB||cause-16/NN	amod||hypercortisolism-19/NN||subclinical-18/JJ	prep_of||cause-16/NN||hypercortisolism-19/NN	advmod||revealed-22/VBD||incidentally-21/RB	ccomp||propose-2/VBP||revealed-22/VBD	amod||adrenalhyperplasia-24/NN||bilateral-23/JJ	dobj||revealed-22/VBD||adrenalhyperplasia-24/NN	amod||hypertension-27/NN||mineralocorticoid-independent-26/JJ	dobj||revealed-22/VBD||hypertension-27/NN	conj_and||adrenalhyperplasia-24/NN||hypertension-27/NN	glucocorticoid-8||hypertension-27||no_rel||we propose thus that gr haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical hypercortisolism, incidentally revealed bilateral adrenalhyperplasia and mineralocorticoid-independent hypertension.
nn||mycobacteriumtuberculosis-2/NNS||understanding-1/NN	nsubj||essential-8/JJ||mycobacteriumtuberculosis-2/NNS	nsubj||guide-10/VB||mycobacteriumtuberculosis-2/NNS	appos||mycobacteriumtuberculosis-2/NNS||mtb-4/NN	advmod||essential-8/JJ||transmission-6/RB	cop||essential-8/JJ||is-7/VBZ	root||ROOT-0/null||essential-8/JJ	aux||guide-10/VB||to-9/TO	xcomp||essential-8/JJ||guide-10/VB	amod||strategies-14/NNS||efficient-11/JJ	nn||strategies-14/NNS||tuberculosis-12/NNP	nn||strategies-14/NNS||control-13/NN	dobj||guide-10/VB||strategies-14/NNS	tuberculosis-12||mycobacteriumtuberculosis-2||no||understanding mycobacteriumtuberculosis (mtb) transmission is essential to guide efficient tuberculosis control strategies.
aux||elucidate-2/VB||to-1/TO	advcl||investigated-25/VBD||elucidate-2/VB	nn||mechanisms-4/NNS||novel-3/NN	dobj||elucidate-2/VB||mechanisms-4/NNS	vmod||mechanisms-4/NNS||contributing-5/VBG	det||complex-10/NN||the-7/DT	amod||complex-10/NN||htlv-1-8/JJ	amod||complex-10/NN||neurological-9/JJ	prep_to||contributing-5/VBG||complex-10/NN	poss||presentation-15/NN||its-12/PRP$	amod||presentation-15/NN||classic-13/JJ	amod||presentation-15/NN||neurological-14/JJ	prep_to||contributing-5/VBG||presentation-15/NN	conj_and||complex-10/NN||presentation-15/NN	vmod||presentation-15/NN||called-16/VBN	dobj||called-16/VBN||ham/tsp-17/NN	amod||myelopathy/tropicalspasticparaparesis-21/NNS||htlv-1-19/JJ	amod||myelopathy/tropicalspasticparaparesis-21/NNS||associated-20/JJ	appos||ham/tsp-17/NN||myelopathy/tropicalspasticparaparesis-21/NNS	nsubj||investigated-25/VBD||we-24/PRP	root||ROOT-0/null||investigated-25/VBD	det||expression-27/NN||the-26/DT	dobj||investigated-25/VBD||expression-27/NN	det||receptor-31/NN||the-29/DT	amod||receptor-31/NN||tim-3-30/JJ	prep_of||expression-27/NN||receptor-31/NN	amod||cells-36/NNS||cd8-33/JJ	amod||cells-36/NNS||+-34/JJ	nn||cells-36/NNS||t-35/NN	prep_on||receptor-31/NN||cells-36/NNS	det||cohort-39/NN||a-38/DT	prep_from||investigated-25/VBD||cohort-39/NN	amod||patients-46/NNS||htlv-1-41/JJ	amod||patients-46/NNS||seropositive-42/JJ	amod||patients-46/NNS||asymptomatic-43/JJ	conj_and||asymptomatic-43/JJ||symptomatic-45/JJ	amod||patients-46/NNS||symptomatic-45/JJ	prep_of||cohort-39/NN||patients-46/NNS	ham--1||htlv-1-41||no||to elucidate novel mechanisms contributing to the htlv-1 neurological complex and its classic neurological presentation called ham/tsp (htlv-1 associated myelopathy/tropicalspasticparaparesis), we investigated the expression of the tim-3 receptor on cd8+ t cells from a cohort of htlv-1 seropositive asymptomatic and symptomatic patients.
nsubj||hypothesized-2/VBN||we-1/PRP	root||ROOT-0/null||hypothesized-2/VBN	mark||determinant-9/NN||that-3/IN	nn||duration-5/NN||sleep-4/NN	nsubj||determinant-9/NN||duration-5/NN	cop||determinant-9/NN||is-6/VBZ	advmod||determinant-9/NN||also-7/RB	det||determinant-9/NN||a-8/DT	ccomp||hypothesized-2/VBN||determinant-9/NN	nn||sensitivity-12/NN||insulin-11/NN	prep_of||determinant-9/NN||sensitivity-12/NN	prep_in||sensitivity-12/NN||patients-14/NNS	prep_with||patients-14/NNS||type1diabetes-16/CD	type1diabetes-16||insulin-11||yes||we hypothesized that sleep duration is also a determinant of insulin sensitivity in patients with type1diabetes.
mark||correlated-15/VBD||although-1/IN	preconj||breadth-4/NN||neither-2/CC	det||breadth-4/NN||the-3/DT	nsubj||correlated-15/VBD||breadth-4/NN	det||magnitude-7/NN||the-6/DT	conj_nor||breadth-4/NN||magnitude-7/NN	nsubj||correlated-15/VBD||magnitude-7/NN	det||response-14/NN||the-9/DT	amod||response-14/NN||proteome-wide-10/JJ	amod||response-14/NN||hiv-specific-11/JJ	nn||response-14/NN||ifn-î-12/NN	nn||response-14/NN||³-13/NN	prep_of||magnitude-7/NN||response-14/NN	advcl||associated-24/VBN||correlated-15/VBD	amod||load-18/NN||viral-17/JJ	prep_with||correlated-15/VBD||load-18/NN	amod||progression-22/NN||slow-20/JJ	nn||progression-22/NN||disease-21/NN	nsubjpass||associated-24/VBN||progression-22/NN	auxpass||associated-24/VBN||was-23/VBD	root||ROOT-0/null||associated-24/VBN	prep_with||associated-24/VBN||over-representation-26/NN	nn||hla-31/NN||host-28/NN	amod||hla-31/NN||immunogenetic-29/JJ	amod||hla-31/NN||protective-30/JJ	prep_of||over-representation-26/NN||hla-31/NN	dep||hla-31/NN||b-32/SYM	dep||b-60/VBD||*-33/SYM	nsubj||b-60/VBD||alleles-34/NNS	dep||alleles-34/NNS||10-36/CD	num||sps-39/NN||14-38/CD	prep_of||10-36/CD||sps-39/NN	prep||sps-39/NN||compared-40/VBN	pcomp||compared-40/VBN||to-41/TO	pobj||to-41/TO||0-42/CD	prep_of||0-42/CD||7-44/CD	nn||â-50/NN||pâ-46/NN	amod||â-50/NN||$-47/$	dep||$-47/$||-48/JJ	nn||â-50/NN||=-49/NNP	dep||0-42/CD||â-50/NN	dep||â-50/NN||$-51/$	num||$-51/$||0-52/CD	num||$-51/$||.004-53/CD	appos||0-42/CD||fisher-55/NN	possessive||fisher-55/NN||'s-56/POS	amod||fisher-55/NN||exact-57/JJ	advmod||b-60/VBD||especially-59/RB	dep||hla-31/NN||b-60/VBD	dep||57-62/CD||*-61/SYM	dep||b-60/VBD||57-62/CD	dep||consistent-133/JJ||b-64/SYM	dep||unpaired-126/VBD||*-65/SYM	nsubj||unpaired-126/VBD||5801-66/CD	amod||t-cell-70/NN||multiclade-68/JJ	nn||t-cell-70/NN||gag-69/NN	appos||5801-66/CD||t-cell-70/NN	vmod||t-cell-70/NN||targeting-71/VBG	num||%-74/NN||71-73/CD	dep||t-cell-70/NN||%-74/NN	appos||%-74/NN||10-76/CD	num||sps-79/NN||14-78/CD	prep_of||10-76/CD||sps-79/NN	prep||sps-79/NN||compared-80/VBN	pcomp||compared-80/VBN||to-81/TO	num||%-83/NN||14-82/CD	pobj||to-81/TO||%-83/NN	appos||%-83/NN||1-85/CD	num||rps-88/NN||7-87/CD	prep_of||1-85/CD||rps-88/NN	nn||â-95/NN||pâ-91/NN	amod||â-95/NN||$-92/$	dep||$-92/$||-93/JJ	nn||â-95/NN||=-94/NNP	dep||t-cell-70/NN||â-95/NN	num||â-95/NN||$-96/$	number||.029-98/CD||0-97/CD	num||$-96/$||.029-98/CD	poss||test-103/NN||fisher-100/NN	amod||test-103/NN||exact-102/JJ	dep||t-cell-70/NN||test-103/NN	conj_and||â-95/NN||test-103/NN	amod||virological-106/JJ||evident-105/JJ	amod||control-107/NN||virological-106/JJ	dep||t-cell-70/NN||control-107/NN	conj_and||â-95/NN||control-107/NN	dep||t-cell-70/NN||3.65-109/CD	prepc_compared_to||3.65-109/CD||to-111/TO	num||copies/ml-114/NN||5.46-112/CD	amod||copies/ml-114/NN||log10-113/JJ	pobj||3.65-109/CD||copies/ml-114/NN	prep_in||copies/ml-114/NN||sps-116/NN	prep_in||copies/ml-114/NN||rps-118/NN	conj_and||sps-116/NN||rps-118/NN	advmod||copies/ml-114/NN||respectively-119/RB	dep||t-cell-70/NN||p-122/NN	number||0.001-124/CD||<-123/CD	dep||p-122/NN||0.001-124/CD	advcl||consistent-133/JJ||unpaired-126/VBD	poss||t-test-129/NN||student-127/NN	dobj||unpaired-126/VBD||t-test-129/NN	det||data-131/NNS||these-130/DT	nsubj||consistent-133/JJ||data-131/NNS	cop||consistent-133/JJ||are-132/VBP	dep||hla-31/NN||consistent-133/JJ	conj_and||b-60/VBD||consistent-133/JJ	prep_with||consistent-133/JJ||others-135/NNS	nsubj||associated-137/VBN||others-135/NNS	rcmod||others-135/NNS||associated-137/VBN	dobj||associated-137/VBN||protection-138/NN	prep_from||associated-137/VBN||hivdisease-140/NN	amod||hla-144/NN||inherent-142/JJ	nn||hla-144/NN||host-143/NN	prep_with||associated-137/VBN||hla-144/NN	dep||induce-149/VB||b-145/SYM	amod||ability-147/NN||allele-mediated-146/JJ	nsubj||induce-149/VB||ability-147/NN	aux||induce-149/VB||to-148/TO	ccomp||consistent-133/JJ||induce-149/VB	amod||t-cell-152/NN||broader-150/JJR	nn||t-cell-152/NN||gag-151/NN	dobj||induce-149/VB||t-cell-152/NN	vmod||t-cell-152/NN||targeting-153/VBG	prep||targeting-153/VBG||coupled-154/VBN	pcomp||coupled-154/VBN||with-155/IN	amod||control-158/NN||apparent-156/JJ	amod||control-158/NN||virological-157/JJ	pobj||with-155/IN||control-158/NN	hivdisease-140||hiv--1||no||although neither the breadth nor the magnitude of the proteome-wide hiv-specific ifn-î³ response correlated with viral load, slow disease progression was associated with over-representation of host immunogenetic protective hla b* alleles (10 of 14 sps compared to 0 of 7; pâ=â0.004, fisher's exact) especially b*57 and b*5801, multiclade gag t-cell targeting (71%, 10 of 14 sps compared to 14%, 1 of 7 rps); pâ=â0.029, fisher's exact test and evident virological control (3.65 compared to 5.46 log10 copies/ml in sps and rps respectively); p<0.001, unpaired student's t-test these data are consistent with others that associated protection from hivdisease with inherent host hla b allele-mediated ability to induce broader gag t-cell targeting coupled with apparent virological control.
amod||injection-3/NN||propofol-2/JJ	prep_before||injected-10/VBD||injection-3/NN	prep_for||injection-3/NN||induction-5/NN	prep_of||induction-5/NN||anesthesia-7/NN	nsubj||injected-10/VBD||we-9/PRP	root||ROOT-0/null||injected-10/VBD	number||%-12/NN||1-11/CD	amod||iv-16/NN||%-12/NN	amod||iv-16/NN||lidocaine-13/JJ	num||iv-16/NN||50-14/CD	nn||iv-16/NN||mg-15/NN	dobj||injected-10/VBD||iv-16/NN	nn||relief-19/NN||pain-18/NN	prep_for||iv-16/NN||relief-19/NN	pain-18||propofol-2||yes||before propofol injection for induction of anesthesia, we injected 1% lidocaine 50 mg iv for pain relief.
amod||evidence-3/NN||current-1/JJ	amod||evidence-3/NN||clinical-2/JJ	nsubj||limited-14/JJ||evidence-3/NN	det||use-6/NN||the-5/DT	prep_for||evidence-3/NN||use-6/NN	amod||delivery-9/NN||aerosolized-8/JJ	prep_of||use-6/NN||delivery-9/NN	prepc_in||delivery-9/NN||preventing-11/VBG	dobj||preventing-11/VBG||fungalinfections-12/NNS	cop||limited-14/JJ||is-13/VBZ	root||ROOT-0/null||limited-14/JJ	amod||products-17/NNS||amphotericinb-16/JJ	prep_to||limited-14/JJ||products-17/NNS	mark||voriconazole-22/JJ||although-19/IN	amod||voriconazole-22/JJ||itraconazole-20/JJ	advcl||limited-14/JJ||voriconazole-22/JJ	nsubj||are-26/VBP||caspofungin-25/NN	conj_and||limited-14/JJ||are-26/VBP	prep_under||are-26/VBP||investigation-28/NN	fungalinfections-12||voriconazole-22||yes||current clinical evidence for the use of aerosolized delivery in preventing fungalinfections is limited to amphotericinb products, although itraconazole, voriconazole, and caspofungin are under investigation.
det||effect-4/NN||the-1/DT	amod||effect-4/NN||main-2/JJ	amod||effect-4/NN||biological-3/JJ	nsubj||is-8/VBZ||effect-4/NN	det||substitutions-7/NNS||these-6/DT	prep_of||effect-4/NN||substitutions-7/NNS	root||ROOT-0/null||is-8/VBZ	aux||attenuate-10/VB||to-9/TO	ccomp||is-8/VBZ||attenuate-10/VB	det||consequences-12/NNS||the-11/DT	dobj||attenuate-10/VB||consequences-12/NNS	det||activity-16/NN||the-14/DT	amod||activity-16/NN||mutagenic-15/JJ	prep_of||consequences-12/NNS||activity-16/NN	nn||$-20/NNP||ribavirin-18/NNP	nn||$-20/NNP||â-19/FW	prep_of||activity-16/NN||$-20/NNP	prepc_by||attenuate-10/VB||avoiding-23/VBG	det||repertoire-26/NN||the-24/DT	amod||repertoire-26/NN||biased-25/JJ	dobj||avoiding-23/VBG||repertoire-26/NN	nn||mutations-29/NNS||transition-28/NN	prep_of||repertoire-26/NN||mutations-29/NNS	vmod||mutations-29/NNS||produced-30/VBN	det||$-35/NN||this-32/DT	amod||$-35/NN||purine-33/JJ	amod||$-35/NN||analogueâ-34/JJ	agent||produced-30/VBN||$-35/NN	aux||maintain-39/VB||to-38/TO	ccomp||is-8/VBZ||maintain-39/VB	conj_and||attenuate-10/VB||maintain-39/VB	det||fitness-42/NN||the-40/DT	amod||fitness-42/NN||replicative-41/JJ	dobj||maintain-39/VB||fitness-42/NN	det||virus-45/NN||the-44/DT	prep_of||fitness-42/NN||virus-45/NN	nsubj||able-48/JJ||virus-45/NN	nsubj||escape-50/VB||virus-45/NN	cop||able-48/JJ||is-47/VBZ	rcmod||virus-45/NN||able-48/JJ	aux||escape-50/VB||to-49/TO	xcomp||able-48/JJ||escape-50/VB	dobj||escape-50/VB||extinction-51/NN	prep_by||escape-50/VB||ribavirin-53/NNP	virus-45||ribavirin-53||yes||the main biological effect of these substitutions is to attenuate the consequences of the mutagenic activity of ribavirin âby avoiding the biased repertoire of transition mutations produced by this purine analogueâand to maintain the replicative fitness of the virus which is able to escape extinction by ribavirin.
amod||reactions-2/NNS||pseudotumor-like-1/JJ	nsubjpass||caused-5/VBN||reactions-2/NNS	nsubj||occur-13/VB||reactions-2/NNS	aux||caused-5/VBN||can-3/MD	auxpass||caused-5/VBN||be-4/VB	root||ROOT-0/null||caused-5/VBN	amod||wear-8/NN||high-7/JJ	agent||caused-5/VBN||wear-8/NN	aux||occur-13/VB||may-11/MD	advmod||occur-13/VB||also-12/RB	conj_but||caused-5/VBN||occur-13/VB	prep_around||occur-13/VB||implants-15/NNS	amod||wear-18/NN||low-17/JJ	prep_with||implants-15/NNS||wear-18/NN	advmod||of-22/IN||likely-20/RB	mark||of-22/IN||because-21/IN	advcl||occur-13/VB||of-22/IN	det||hypersensitivityreaction-25/NN||a-23/DT	nn||hypersensitivityreaction-25/NN||metal-24/NN	pobj||of-22/IN||hypersensitivityreaction-25/NN	hypersensitivityreaction-25||metal-24||no_rel||pseudotumor-like reactions can be caused by high wear, but may also occur around implants with low wear, likely because of a metal hypersensitivityreaction.
prep_in||growing-6/VBG||particular-2/JJ	expl||growing-6/VBG||there-4/EX	aux||growing-6/VBG||is-5/VBZ	root||ROOT-0/null||growing-6/VBG	dobj||growing-6/VBG||evidence-7/NN	nsubj||growing-6/VBG||evidence-7/NN	dep||growing-6/VBG||favoring-8/VBG	amod||resection-11/NN||extensive-9/JJ	amod||resection-11/NN||surgical-10/JJ	dobj||favoring-8/VBG||resection-11/NN	dep||growing-6/VBG||increasing-13/VBG	conj_and||favoring-8/VBG||increasing-13/VBG	dobj||increasing-13/VBG||interest-14/NN	det||role-17/NN||the-16/DT	prep_in||increasing-13/VBG||role-17/NN	prep_of||role-17/NN||chemotherapy-19/NN	advmod||temozolomide-22/JJ||especially-21/RB	dep||chemotherapy-19/NN||temozolomide-22/JJ	det||management-26/NN||the-25/DT	prep_in||chemotherapy-19/NN||management-26/NN	det||tumors-29/NNS||these-28/DT	prep_of||management-26/NN||tumors-29/NNS	tumors-29||temozolomide-22||no_rel||in particular, there is growing evidence favoring extensive surgical resection and increasing interest in the role of chemotherapy (especially temozolomide) in the management of these tumors.
nsubjpass||divided-3/VBN||patients-1/NNS	auxpass||divided-3/VBN||were-2/VBD	root||ROOT-0/null||divided-3/VBN	num||groups-6/NNS||two-5/CD	prep_into||divided-3/VBN||groups-6/NNS	prepc_according_to||divided-3/VBN||to-8/TO	det||centre-10/NN||the-9/DT	pobj||divided-3/VBN||centre-10/NN	nn||control-13/NN||disease-12/NN	prep_for||centre-10/NN||control-13/NN	nn||criteria-19/NNS||prevention-15/NN	nn||criteria-19/NNS||cdc-17/NN	prep_for||centre-10/NN||criteria-19/NNS	conj_and||control-13/NN||criteria-19/NNS	amod||patients-24/NNS||aids-related-21/JJ	nn||patients-24/NNS||te-22/NN	nn||patients-24/NNS||aids-23/NNS	prep_for||divided-3/VBN||patients-24/NNS	amod||neurotoxoplasmosis-27/NNS||suspected-26/VBN	prep_with||divided-3/VBN||neurotoxoplasmosis-27/NNS	prep_with||divided-3/VBN||aids-29/NNS	conj_and||neurotoxoplasmosis-27/NNS||aids-29/NNS	amod||patients-32/NNS||hiv-negative-31/JJ	nsubj||confirmed-35/VBD||patients-32/NNS	prep_with||patients-32/NNS||other-34/JJ	conj_and||divided-3/VBN||confirmed-35/VBD	amod||diseases-37/NNS||neurological-36/JJ	dobj||confirmed-35/VBD||diseases-37/NNS	prep||diseases-37/NNS||but-38/CC	neg||suspicions-40/NNS||no-39/DT	pobj||but-38/CC||suspicions-40/NNS	prep_of||suspicions-40/NNS||te-42/NN	aids-29||hiv--1||no||patients were divided into two groups according to the centre for disease control and prevention (cdc) criteria for aids-related te aids patients with suspected neurotoxoplasmosis and aids and hiv-negative patients with other confirmed neurological diseases but no suspicions of te.
aux||compare-2/VB||to-1/TO	root||ROOT-0/null||compare-2/VB	det||efficacy-4/NN||the-3/DT	dobj||compare-2/VB||efficacy-4/NN	dobj||compare-2/VB||safety-6/NN	conj_and||efficacy-4/NN||safety-6/NN	prep_of||efficacy-4/NN||duloxetine-8/NN	dobj||compare-2/VB||amitriptyline-10/NNP	conj_and||efficacy-4/NN||amitriptyline-10/NNP	amod||diabeticneuropathy-13/NN||painful-12/JJ	prep_in||amitriptyline-10/NNP||diabeticneuropathy-13/NN	appos||diabeticneuropathy-13/NN||pdn-15/NN	painful-12||amitriptyline-10||yes||to compare the efficacy and safety of duloxetine and amitriptyline in painful diabeticneuropathy (pdn).
prep_in||carried-46/VBN||response-2/NN	det||suggestion-5/NN||the-4/DT	prep_to||response-2/NN||suggestion-5/NN	mark||attributable-16/JJ||that-6/IN	det||increase-8/NN||an-7/DT	nsubj||attributable-16/JJ||increase-8/NN	det||incidence-11/NN||the-10/DT	prep_in||increase-8/NN||incidence-11/NN	prep_of||incidence-11/NN||celiacdisease-13/NN	aux||attributable-16/JJ||might-14/MD	cop||attributable-16/JJ||be-15/VB	dep||suggestion-5/NN||attributable-16/JJ	det||increase-19/NN||an-18/DT	prep_to||attributable-16/JJ||increase-19/NN	det||content-23/NN||the-21/DT	nn||content-23/NN||gluten-22/NN	prep_in||increase-19/NN||content-23/NN	prep_of||content-23/NN||wheat-25/NN	vmod||wheat-25/NN||resulting-26/VBG	nn||breeding-29/NN||wheat-28/NN	prep_from||resulting-26/VBG||breeding-29/NN	det||survey-32/NN||a-31/DT	nsubjpass||carried-46/VBN||survey-32/NN	prep_of||survey-32/NN||data-34/NNS	det||centuries-40/NNS||the-36/DT	amod||centuries-40/NNS||20th-37/JJ	conj_and||20th-37/JJ||21st-39/JJ	amod||centuries-40/NNS||21st-39/JJ	prep_from||data-34/NNS||centuries-40/NNS	det||states-44/NNS||the-42/DT	amod||states-44/NNS||united-43/VBN	prep_for||centuries-40/NNS||states-44/NNS	auxpass||carried-46/VBN||was-45/VBD	root||ROOT-0/null||carried-46/VBN	prt||carried-46/VBN||out-47/RP	celiacdisease-13||gluten-22||no||in response to the suggestion that an increase in the incidence of celiacdisease might be attributable to an increase in the gluten content of wheat resulting from wheat breeding, a survey of data from the 20th and 21st centuries for the united states was carried out.
det||results-2/NNS||these-1/DT	nsubj||reinforce-3/VBP||results-2/NNS	root||ROOT-0/null||reinforce-3/VBP	det||importance-5/NN||the-4/DT	dobj||reinforce-3/VBP||importance-5/NN	nsubj||reduce-24/VB||importance-5/NN	amod||screening-8/NN||extensive-7/JJ	prep_of||importance-5/NN||screening-8/NN	prep_for||screening-8/NN||hivinfection-10/NN	amod||initiation-13/NN||earlier-12/JJR	prep_of||importance-5/NN||initiation-13/NN	conj_and||screening-8/NN||initiation-13/NN	amod||therapy-16/NN||antiretroviral-15/JJ	prep_of||initiation-13/NN||therapy-16/NN	amod||monitoring-19/NN||stricter-18/JJR	prep_of||importance-5/NN||monitoring-19/NN	conj_and||screening-8/NN||monitoring-19/NN	amod||women-22/NNS||pregnant-21/JJ	prep_of||monitoring-19/NN||women-22/NNS	aux||reduce-24/VB||to-23/TO	xcomp||reinforce-3/VBP||reduce-24/VB	det||risk-26/NN||the-25/DT	dobj||reduce-24/VB||risk-26/NN	amod||rna-30/NN||detectable-28/JJ	nn||rna-30/NN||hiv-29/NN	prep_of||risk-26/NN||rna-30/NN	prep_at||reduce-24/VB||delivery-32/NN	hivinfection-10||hiv-29||no||these results reinforce the importance of extensive screening for hivinfection, earlier initiation of antiretroviral therapy and stricter monitoring of pregnant women to reduce the risk of detectable hiv rna at delivery.
det||results-2/NNS||the-1/DT	nsubj||suggest-17/VBP||results-2/NNS	det||trial-7/NN||an-4/DT	amod||trial-7/NN||open-label-5/JJ	nn||trial-7/NN||pilot-6/NN	prep_of||results-2/NNS||trial-7/NN	amod||patients-10/NNS||injured-9/JJ	prep_of||trial-7/NN||patients-10/NNS	vmod||patients-10/NNS||admitted-11/VBN	det||unit-16/NN||the-13/DT	amod||unit-16/NN||intensive-14/JJ	nn||unit-16/NN||care-15/NN	prep_to||admitted-11/VBN||unit-16/NN	root||ROOT-0/null||suggest-17/VBP	det||supplementation-20/NN||that-18/DT	amod||supplementation-20/NN||omega-3fattyacid-19/JJ	dobj||suggest-17/VBP||supplementation-20/NN	advmod||suggest-17/VBP||immediately-21/RB	mark||reduce-26/VB||after-22/IN	amod||injury-24/NN||accidental-23/JJ	nsubj||reduce-26/VB||injury-24/NN	aux||reduce-26/VB||can-25/MD	advcl||suggest-17/VBP||reduce-26/VB	amod||symptoms-29/NNS||subsequent-27/JJ	amod||symptoms-29/NNS||ptsd-28/JJ	dobj||reduce-26/VB||symptoms-29/NNS	omega-3fattyacid-19||ptsd-28||no_rel||the results of an open-label pilot trial of injured patients admitted to the intensive care unit suggest that omega-3fattyacid supplementation immediately after accidental injury can reduce subsequent ptsd symptoms.
nsubj||agent-5/NN||burkholderiapseudomallei-1/NNS	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||the-3/DT	amod||agent-5/NN||etiologic-4/JJ	root||ROOT-0/null||agent-5/NN	prep_of||agent-5/NN||melioidosis-7/NNS	det||cause-11/NN||a-9/DT	amod||cause-11/NN||significant-10/JJ	appos||melioidosis-7/NNS||cause-11/NN	prep_of||cause-11/NN||morbidity-13/NN	prep_of||cause-11/NN||mortality-15/NN	conj_and||morbidity-13/NN||mortality-15/NN	advmod||endemic-20/JJ||where-16/WRB	det||infection-18/NN||this-17/DT	nsubj||endemic-20/JJ||infection-18/NN	cop||endemic-20/JJ||is-19/VBZ	rcmod||cause-11/NN||endemic-20/JJ	melioidosis-7||burkholderiapseudomallei-1||no||burkholderiapseudomallei is the etiologic agent of melioidosis, a significant cause of morbidity and mortality where this infection is endemic.
root||ROOT-0/null||objectives-1/NNS	aux||study-3/VB||to-2/TO	vmod||objectives-1/NNS||study-3/VB	det||effects-5/NNS||the-4/DT	dobj||study-3/VB||effects-5/NNS	prep_of||effects-5/NNS||metformin-7/NN	det||incidence-10/NN||the-9/DT	prep_on||study-3/VB||incidence-10/NN	amod||deficiency-14/NN||vitamin-12/JJ	amod||deficiency-14/NN||b-12-13/JJ	prep_of||incidence-10/NN||deficiency-14/NN	number||150-17/CD||<-16/CD	num||pmol/l-18/NNS||150-17/CD	appos||objectives-1/NNS||pmol/l-18/NNS	amod||concentrations-22/NNS||low-21/JJ	conj_and||objectives-1/NNS||concentrations-22/NNS	nn||b-12-25/NN||vitamin-24/NN	prep_of||concentrations-22/NNS||b-12-25/NN	num||pmol/l-28/NN||150-220-27/CD	appos||concentrations-22/NNS||pmol/l-28/NN	amod||concentrations-35/NNS||folate-32/JJ	conj_and||folate-32/JJ||homocysteine-34/JJ	amod||concentrations-35/NNS||homocysteine-34/JJ	conj_and||objectives-1/NNS||concentrations-35/NNS	prep_in||concentrations-35/NNS||patients-37/NNS	prep_with||objectives-1/NNS||type2diabetes-39/NNS	vmod||type2diabetes-39/NNS||receiving-40/VBG	dobj||receiving-40/VBG||treatment-41/NN	prep_with||receiving-40/VBG||insulin-43/NN	type2diabetes-39||insulin-43||yes||objectives to study the effects of metformin on the incidence of vitamin b-12 deficiency (<150 pmol/l), low concentrations of vitamin b-12 (150-220 pmol/l), and folate and homocysteine concentrations in patients with type2diabetes receiving treatment with insulin.
nsubj||agent-8/NN||humant-celllymphotropicvirustype1-1/JJ	dep||humant-celllymphotropicvirustype1-1/JJ||htlv-1-3/JJ	cop||agent-8/NN||is-5/VBZ	det||agent-8/NN||the-6/DT	amod||agent-8/NN||etiological-7/JJ	root||ROOT-0/null||agent-8/NN	amod||leukemia-12/NN||adult-10/JJ	amod||leukemia-12/NN||t-cell-11/JJ	prep_of||agent-8/NN||leukemia-12/NN	appos||leukemia-12/NN||atl-14/NN	amod||tropicalspasticparaparesis-19/NNS||htlv-1-associatedmyelopathy-17/JJ	amod||tropicalspasticparaparesis-19/NNS||/-18/JJ	prep_of||agent-8/NN||tropicalspasticparaparesis-19/NNS	conj_and||leukemia-12/NN||tropicalspasticparaparesis-19/NNS	appos||leukemia-12/NN||ham/tsp-21/NN	htlv-1-associatedmyelopathy-17||htlv-1-3||no||humant-celllymphotropicvirustype1 (htlv-1) is the etiological agent of adult t-cell leukemia (atl) and htlv-1-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp).
nsubj||used-4/JJ||arsenictrioxide-1/NN	nsubj||treat-7/VB||arsenictrioxide-1/NN	cop||used-4/JJ||is-2/VBZ	advmod||used-4/JJ||already-3/RB	root||ROOT-0/null||used-4/JJ	advmod||used-4/JJ||clinically-5/RB	aux||treat-7/VB||to-6/TO	xcomp||used-4/JJ||treat-7/VB	dobj||treat-7/VB||acutepromyelocyticleukemia-8/NN	xcomp||treat-7/VB||demonstrating-9/VBG	poss||profile-12/NN||its-10/PRP$	nn||profile-12/NN||safety-11/NN	dobj||demonstrating-9/VBG||profile-12/NN	acutepromyelocyticleukemia-8||arsenictrioxide-1||yes||arsenictrioxide is already used clinically to treat acutepromyelocyticleukemia demonstrating its safety profile.
preconj||entry-5/NN||both-1/DT	nn||entry-5/NN||mv-2/NN	conj_and||mv-2/NN||ev-4/NN	nn||entry-5/NN||ev-4/NN	nsubjpass||inhibited-7/VBN||entry-5/NN	nsubjpass||depended-17/VBN||entry-5/NN	auxpass||inhibited-7/VBN||were-6/VBD	root||ROOT-0/null||inhibited-7/VBN	det||rottlerin-12/NN||the-9/DT	amod||rottlerin-12/NN||macropinocytosis-10/JJ	nn||rottlerin-12/NN||inhibitors-11/NNS	agent||inhibited-7/VBN||rottlerin-12/NN	nn||amiloride-15/NN||dimethyl-14/NN	agent||inhibited-7/VBN||amiloride-15/NN	conj_and||rottlerin-12/NN||amiloride-15/NN	conj_and||inhibited-7/VBN||depended-17/VBN	prep_on||depended-17/VBN||phosphotidylinositol-3-kinase-19/JJ	dep||phosphotidylinositol-3-kinase-19/JJ||pi-21/NN	appos||pi-21/NN||3-23/CD	dep||pi-21/NN||k-25/NN	nsubj||colocalised-30/VBD||both-29/DT	conj_and||inhibited-7/VBN||colocalised-30/VBD	prep_with||colocalised-30/VBD||dextran-32/NN	prep_with||colocalised-30/VBD||transferrin-35/NN	conj_negcc||dextran-32/NN||transferrin-35/NN	ev-4||amiloride-15||no_rel||both mv and ev entry were inhibited by the macropinocytosis inhibitors rottlerin and dimethyl amiloride and depended on phosphotidylinositol-3-kinase (pi(3)k), and both colocalised with dextran but not transferrin.
root||ROOT-0/null||ustekinumabâ-1/VBG	dobj||ustekinumabâ-1/VBG||$-2/$	num||$-2/$||-3/CD	cop||safety-5/NN||s-4/VBZ	aux||ustekinumabâ-1/VBG||safety-5/NN	cc||efficacy-7/RB||and-6/CC	dep||safety-5/NN||efficacy-7/RB	aux||evaluated-10/VBN||has-8/VBZ	auxpass||evaluated-10/VBN||been-9/VBN	ccomp||efficacy-7/RB||evaluated-10/VBN	det||treatment-13/NN||the-12/DT	prep_for||evaluated-10/VBN||treatment-13/NN	amod||plaquepsoriasis-16/NNS||moderate-to-severe-15/JJ	prep_of||treatment-13/NN||plaquepsoriasis-16/NNS	num||phase-19/NN||3-18/CD	prep_in||evaluated-10/VBN||phase-19/NN	vmod||phase-19/NN||iii-20/VBN	amod||trials-22/NNS||clinical-21/JJ	dobj||iii-20/VBN||trials-22/NNS	number||placebo-controlled-25/JJ||2-24/CD	aux||ustekinumabâ-1/VBG||placebo-controlled-25/JJ	conj_and||safety-5/NN||placebo-controlled-25/JJ	dep||safety-5/NN||phoenix-27/VB	dobj||phoenix-27/VB||1-28/CD	dobj||phoenix-27/VB||2-30/CD	conj_and||1-28/CD||2-30/CD	number||comparator-controlled-35/JJ||1-34/CD	aux||ustekinumabâ-1/VBG||comparator-controlled-35/JJ	conj_and||safety-5/NN||comparator-controlled-35/JJ	dep||safety-5/NN||accept-37/VB	nsubj||ustekinumabâ-1/VBG||study-39/NN	nsubj||proved-41/VBD||which-40/WDT	nsubj||failed-50/VBD||which-40/WDT	nsubj||unresponsive-60/JJ||which-40/WDT	nsubj||phototherapy-62/VB||which-40/WDT	nsubj||unable-66/JJ||which-40/WDT	nsubj||use-68/VB||which-40/WDT	ccomp||study-39/NN||proved-41/VBD	acomp||proved-41/VBD||advantageous-42/JJ	prep_in||advantageous-42/JJ||patients-44/NNS	nsubj||treatment-naive-47/JJ||patients-44/NNS	cop||treatment-naive-47/JJ||were-46/VBD	rcmod||patients-44/NNS||treatment-naive-47/JJ	advmod||failed-50/VBD||previously-49/RB	ccomp||study-39/NN||failed-50/VBD	conj_or||proved-41/VBD||failed-50/VBD	amod||medications-53/NNS||other-51/JJ	nn||medications-53/NNS||immunosuppressive-52/NN	dobj||failed-50/VBD||medications-53/NNS	prep_including||medications-53/NNS||cyclosporine-55/NN	prep_including||medications-53/NNS||methotrexate-57/NN	conj_or||cyclosporine-55/NN||methotrexate-57/NN	cop||unresponsive-60/JJ||were-59/VBD	ccomp||study-39/NN||unresponsive-60/JJ	conj_or||proved-41/VBD||unresponsive-60/JJ	aux||phototherapy-62/VB||to-61/TO	xcomp||unresponsive-60/JJ||phototherapy-62/VB	cop||unable-66/JJ||were-65/VBD	ccomp||study-39/NN||unable-66/JJ	conj_or||proved-41/VBD||unable-66/JJ	aux||use-68/VB||to-67/TO	xcomp||unable-66/JJ||use-68/VB	xcomp||unable-66/JJ||tolerate-70/VB	conj_or||use-68/VB||tolerate-70/VB	amod||therapies-72/NNS||other-71/JJ	dobj||use-68/VB||therapies-72/NNS	plaquepsoriasis-16||cyclosporine-55||no_rel||ustekinumabâs safety and efficacy has been evaluated for the treatment of moderate-to-severe plaquepsoriasis in 3 phase iii clinical trials, 2 placebo-controlled (phoenix 1 and 2), and 1 comparator-controlled (accept) study which proved advantageous in patients who were treatment-naive, previously failed other immunosuppressive medications including cyclosporine or methotrexate, were unresponsive to phototherapy, or were unable to use or tolerate other therapies.
det||spectrum-3/NN||a-1/DT	amod||spectrum-3/NN||wide-2/JJ	nsubjpass||observed-7/VBN||spectrum-3/NN	prep_of||spectrum-3/NN||ois-5/NN	auxpass||observed-7/VBN||were-6/VBD	root||ROOT-0/null||observed-7/VBN	amod||patients-10/NNS||hiv-infected-9/JJ	prep_amongst||observed-7/VBN||patients-10/NNS	det||clinic-15/NN||the-12/DT	amod||clinic-15/NN||hiv/aids-13/JJ	nn||clinic-15/NN||apex-14/NN	prep_in||patients-10/NNS||clinic-15/NN	aids--1||hiv--1||no||a wide spectrum of ois were observed amongst hiv-infected patients in the hiv/aids apex clinic.
nsubj||use-11/VBP||patients-1/NNS	vmod||patients-1/NNS||presenting-2/VBG	amod||myocardialinfarction-6/NN||st-segment-4/JJ	nn||myocardialinfarction-6/NN||elevation-5/NN	prep_with||presenting-2/VBG||myocardialinfarction-6/NN	appos||myocardialinfarction-6/NN||stemi-8/NNP	advmod||use-11/VBP||frequently-10/RB	root||ROOT-0/null||use-11/VBP	dobj||use-11/VBP||warfarin-12/NN	myocardialinfarction-6||warfarin-12||yes||patients presenting with st-segment elevation myocardialinfarction (stemi) frequently use warfarin.
advmod||infected-4/VBN||when-1/WRB	nsubjpass||infected-4/VBN||mice-2/NNS	auxpass||infected-4/VBN||were-3/VBD	advcl||observed-16/VBN||infected-4/VBN	det||mc58-278-1220-9/NN||the-6/DT	amod||mc58-278-1220-9/NN||mutant-7/JJ	nn||mc58-278-1220-9/NN||bacteria-8/NNS	prep_with||infected-4/VBN||mc58-278-1220-9/NN	neg||differences-13/NNS||no-11/DT	amod||differences-13/NNS||significant-12/JJ	nsubjpass||observed-16/VBN||differences-13/NNS	aux||observed-16/VBN||could-14/MD	auxpass||observed-16/VBN||be-15/VB	root||ROOT-0/null||observed-16/VBN	det||health-19/NN||the-18/DT	prep_in||observed-16/VBN||health-19/NN	prep_in||observed-16/VBN||survival-21/NN	conj_and||health-19/NN||survival-21/NN	prep_in||observed-16/VBN||bacteraemia-23/NN	conj_and||health-19/NN||bacteraemia-23/NN	amod||production-27/NN||cytokine-26/JJ	prep_in||observed-16/VBN||production-27/NN	conj_and||health-19/NN||production-27/NN	prep_between||production-27/NN||wild-type-29/NN	poss||animals-36/NNS||sr-aâ-31/NNP	amod||animals-36/NNS||/-33/JJ	nn||animals-36/NNS||â-34/NN	prep_in||observed-16/VBN||animals-36/NNS	conj_and||health-19/NN||animals-36/NNS	bacteraemia-23||bacteria-8||no||when mice were infected with the mutant bacteria mc58-278-1220, no significant differences could be observed in the health, survival, bacteraemia, and cytokine production between wild-type and sr-aâ/â animals.
prep_in||shown-6/VBN||oasis-5-2/JJ	nsubjpass||shown-6/VBN||fondaparinux-4/NN	nsubj||noninferior-9/JJ||fondaparinux-4/NN	nsubj||enoxaparin-11/VB||fondaparinux-4/NN	auxpass||shown-6/VBN||was-5/VBD	root||ROOT-0/null||shown-6/VBN	aux||noninferior-9/JJ||to-7/TO	cop||noninferior-9/JJ||be-8/VB	xcomp||shown-6/VBN||noninferior-9/JJ	aux||enoxaparin-11/VB||to-10/TO	xcomp||noninferior-9/JJ||enoxaparin-11/VB	prep_in||enoxaparin-11/VB||terms-13/NNS	nn||mi-17/NN||death-15/NN	nn||ischemia-20/NN||mi-17/NN	conj_or||mi-17/NN||refractory-19/JJ	nn||ischemia-20/NN||refractory-19/JJ	prep_of||terms-13/NNS||ischemia-20/NN	num||days-23/NNS||9-22/CD	prep_at||ischemia-20/NN||days-23/NNS	enoxaparin-11||ischemia-20||no_rel||in oasis-5, fondaparinux was shown to be noninferior to enoxaparin in terms of death, mi or refractory ischemia at 9 days.
advmod||distinctive-4/JJ||apparently-2/RB	advmod||distinctive-4/JJ||quite-3/RB	amod||profiles-7/NNS||distinctive-4/JJ	amod||profiles-7/NNS||venom-5/JJ	nn||profiles-7/NNS||protein-6/NN	prep_despite||observed-10/VBD||profiles-7/NNS	nsubj||observed-10/VBD||we-9/PRP	root||ROOT-0/null||observed-10/VBD	amod||similarity-13/NN||extensive-11/JJ	amod||similarity-13/NN||cross-species-12/JJ	dobj||observed-10/VBD||similarity-13/NN	det||profiles-17/NNS||the-15/DT	amod||profiles-17/NNS||immuno-reactivity-16/JJ	prep_in||observed-10/VBD||profiles-17/NNS	amod||antisera-21/NN||echis-19/JJ	amod||antisera-21/NN||species-specific-20/JJ	prep_of||profiles-17/NNS||antisera-21/NN	venom-5||cross--1||no_rel||despite apparently quite distinctive venom protein profiles, we observed extensive cross-species similarity in the immuno-reactivity profiles of echis species-specific antisera.
det||baseline-3/NN||the-1/DT	amod||baseline-3/NN||lower-2/JJR	nsubj||predicted-6/VBD||baseline-3/NN	vmod||baseline-3/NN||hbsag-4/VBG	dobj||hbsag-4/VBG||level-5/NN	root||ROOT-0/null||predicted-6/VBD	det||decline-9/NN||the-7/DT	amod||decline-9/NN||hbsag-8/VBG	dobj||predicted-6/VBD||decline-9/NN	amod||loss-12/NN||hbsag-11/VBG	dobj||predicted-6/VBD||loss-12/NN	conj_and||decline-9/NN||loss-12/NN	mark||predicted-19/VBD||whereas-14/IN	det||hbv-dna-18/NN||the-15/DT	amod||hbv-dna-18/NN||higher-16/JJR	nn||hbv-dna-18/NN||baseline-17/NN	nsubj||predicted-19/VBD||hbv-dna-18/NN	advcl||predicted-6/VBD||predicted-19/VBD	det||flare-22/NN||the-20/DT	nn||flare-22/NN||hepatitis-21/NN	dobj||predicted-19/VBD||flare-22/NN	hbv--1||hbsag-11||yes||the lower baseline hbsag level predicted the hbsag decline and hbsag loss, whereas the higher baseline hbv-dna predicted the hepatitis flare.
amod||offspring-2/NN||sedentary-1/JJ	nsubj||insulin-resistant-10/JJ||offspring-2/NN	prep_of||offspring-2/NN||patients-4/NNS	prep_with||patients-4/NNS||type2diabetes-6/CD	cop||insulin-resistant-10/JJ||are-7/VBP	advmod||insulin-resistant-10/JJ||often-8/RB	advmod||insulin-resistant-10/JJ||more-9/RBR	root||ROOT-0/null||insulin-resistant-10/JJ	prep_than||insulin-resistant-10/JJ||persons-12/NNS	neg||history-16/NN||no-14/DT	nn||history-16/NN||family-15/NN	prep_with||persons-12/NNS||history-16/NN	prep_of||history-16/NN||diabetes-18/NN	advmod||are-31/VBP||when-21/WRB	amod||offspring-25/NN||active-22/JJ	conj_or||active-22/JJ||fit-24/JJ	amod||offspring-25/NN||fit-24/JJ	nsubj||are-31/VBP||offspring-25/NN	amod||patients-30/NNS||type-27/NN	number||type-27/NN||2-28/CD	amod||patients-30/NNS||diabetic-29/JJ	prep_of||offspring-25/NN||patients-30/NNS	advcl||evident-42/JJ||are-31/VBP	prepc_compared_with||are-31/VBP||with-33/IN	amod||persons-35/NNS||non-diabetic-34/JJ	pobj||are-31/VBP||persons-35/NNS	nsubj||evident-42/JJ||differences-37/NNS	prep_in||differences-37/NNS||insulinresistance-39/NN	cop||evident-42/JJ||are-40/VBP	advmod||evident-42/JJ||less-41/RBR	conj_but||insulin-resistant-10/JJ||evident-42/JJ	type2diabetes-6||insulin--1||yes||sedentary offspring of patients with type2diabetes are often more insulin-resistant than persons with no family history of diabetes, but when active or fit offspring of type 2 diabetic patients are compared with non-diabetic persons, differences in insulinresistance are less evident.
root||ROOT-0/null||artesunateâ-1/VB	dobj||artesunateâ-1/VB||$-2/$	npadvmod||of-10/RB||mefloquine-4/NN	dep||suppression-9/NN||provided-5/RB	det||suppression-9/NN||the-6/DT	dep||post-treatment-8/JJ||greatest-7/JJS	amod||suppression-9/NN||post-treatment-8/JJ	dep||mefloquine-4/NN||suppression-9/NN	dep||malaria-11/CD||of-10/RB	num||$-2/$||malaria-11/CD	malaria-11||mefloquine-4||yes||artesunateâmefloquine provided the greatest post-treatment suppression of malaria.
advmod||present-4/VBP||here-1/RB	nsubj||present-4/VBP||we-3/PRP	root||ROOT-0/null||present-4/VBP	det||study-9/NN||a-5/DT	nn||study-9/NN||combination-6/NN	nn||study-9/NN||chemical-7/NN	amod||study-9/NN||genetic-8/JJ	dobj||present-4/VBP||study-9/NN	aux||explore-11/VB||to-10/TO	vmod||present-4/VBP||explore-11/VB	advmod||work-19/VBP||how-12/WRB	det||sterol-14/NN||the-13/DT	nsubj||work-19/VBP||sterol-14/NN	nsubj||affect-22/VB||sterol-14/NN	nn||pathways-18/NNS||protein-16/NN	nn||pathways-18/NNS||prenylation-17/NN	conj_and||sterol-14/NN||pathways-18/NNS	nsubj||work-19/VBP||pathways-18/NNS	nsubj||affect-22/VB||pathways-18/NNS	ccomp||explore-11/VB||work-19/VBP	advmod||work-19/VBP||together-20/RB	aux||affect-22/VB||to-21/TO	xcomp||work-19/VBP||affect-22/VB	amod||replication-24/NN||hepatitiscviral-23/JJ	dobj||affect-22/VB||replication-24/NN	det||assay-28/NN||a-26/DT	nn||assay-28/NN||replicon-27/NN	prep_in||affect-22/VB||assay-28/NN	hepatitiscviral-23||chemical-7||no_rel||here, we present a combination chemical genetic study to explore how the sterol and protein prenylation pathways work together to affect hepatitiscviral replication in a replicon assay.
det||kinase-4/NN||the-1/DT	nn||kinase-4/NN||receptor-2/NN	nn||kinase-4/NN||tyrosine-3/NN	nsubj||met-5/VBD||kinase-4/NN	root||ROOT-0/null||met-5/VBD	auxpass||involved-7/VBN||is-6/VBZ	ccomp||met-5/VBD||involved-7/VBN	det||progression-10/NN||the-9/DT	prep_in||involved-7/VBN||progression-10/NN	prep_in||involved-7/VBN||metastasis-12/NNS	conj_and||progression-10/NN||metastasis-12/NNS	amod||cancers-16/NNS||numerous-14/JJ	amod||cancers-16/NNS||human-15/JJ	prep_of||progression-10/NN||cancers-16/NNS	cancers-16||tyrosine-3||no_rel||the receptor tyrosine kinase met is involved in the progression and metastasis of numerous human cancers.
det||patients-5/NNS||the-2/DT	num||patients-5/NNS||67-3/CD	amod||patients-5/NNS||b-celllymphoma-4/JJ	nsubj||received-7/VBD||patients-5/NNS	prep_in||had-21/VBD||patients-5/NNS	rcmod||patients-5/NNS||received-7/VBD	advmod||received-7/VBD||chemotherapy-8/RB	num||patients-11/NNS||36-10/CD	nsubj||had-21/VBD||patients-11/NNS	vmod||patients-11/NNS||treated-12/VBN	prep_with||treated-12/VBN||rituximab-14/NN	quantmod||3-18/CD||at-16/IN	mwe||at-16/IN||least-17/JJS	pobj||at-16/IN||least-17/JJS	num||cycles-19/NNS||3-18/CD	appos||patients-11/NNS||cycles-19/NNS	root||ROOT-0/null||had-21/VBD	det||os-24/NN||a-22/DT	amod||os-24/NN||mean-23/JJ	dobj||had-21/VBD||os-24/NN	num||months-27/NNS||72-26/CD	prep_of||os-24/NN||months-27/NNS	num||%-30/NN||95-29/CD	dep||months-27/NNS||%-30/NN	dep||%-30/NN||ci-31/NN	num||ci-31/NN||62-81-32/CD	num||months-36/NNS||62-35/CD	prep_versus||months-27/NNS||months-36/NNS	num||%-39/NN||95-38/CD	dep||months-36/NNS||%-39/NN	dep||%-39/NN||ci-40/NN	num||ci-40/NN||47-76-41/CD	prep_for||months-36/NNS||patients-44/NNS	amod||treatment-47/NN||rituximab-46/JJ	prep_without||had-21/VBD||treatment-47/NN	dep||treatment-47/NN||p-49/VBN	dep||0.021-51/CD||=-50/SYM	ccomp||p-49/VBN||0.021-51/CD	b-celllymphoma-4||rituximab-46||yes||in the 67 b-celllymphoma patients who received chemotherapy, 36 patients treated with rituximab (at least 3 cycles) had a mean os of 72 months (95% ci 62-81) versus 62 months (95% ci 47-76) for patients without rituximab treatment (p = 0.021).
nsubjpass||administered-6/VBN||insulin-1/NN	nsubj||prevent-12/VB||insulin-1/NN	nsubj||stimulates-17/VBZ||insulin-1/NN	nsubj||prevents-21/VBZ||insulin-1/NN	auxpass||administered-6/VBN||is-4/VBZ	advmod||administered-6/VBN||routinely-5/RB	rcmod||insulin-1/NN||administered-6/VBN	advmod||ill-9/JJ||critically-8/RB	amod||patients-10/NNS||ill-9/JJ	prep_to||administered-6/VBN||patients-10/NNS	aux||prevent-12/VB||to-11/TO	xcomp||administered-6/VBN||prevent-12/VB	amod||hyperglycemia-14/NN||excessive-13/JJ	dobj||prevent-12/VB||hyperglycemia-14/NN	advmod||stimulates-17/VBZ||also-16/RB	root||ROOT-0/null||stimulates-17/VBZ	nn||synthesis-19/NN||protein-18/NN	dobj||stimulates-17/VBZ||synthesis-19/NN	conj_and||stimulates-17/VBZ||prevents-21/VBZ	amod||loss-24/NN||whole-body-22/JJ	nn||loss-24/NN||protein-23/NN	dobj||prevents-21/VBZ||loss-24/NN	hyperglycemia-14||insulin-1||yes||insulin, which is routinely administered to critically ill patients to prevent excessive hyperglycemia, also stimulates protein synthesis and prevents whole-body protein loss.
vmod||presented-6/VBD||taken-1/VBN	advmod||taken-1/VBN||together-2/RB	det||arguments-5/NNS||the-4/DT	nsubj||presented-6/VBD||arguments-5/NNS	root||ROOT-0/null||presented-6/VBD	advmod||presented-6/VBD||here-7/RB	dep||presented-6/VBD||lead-8/VB	det||novel-11/NN||a-10/DT	prep_to||lead-8/VB||novel-11/NN	vmod||novel-11/NN||working-12/VBG	dobj||working-12/VBG||hypothesis-13/NNS	amod||epigenetics-17/NNS||molecular-15/JJ	amod||epigenetics-17/NNS||immune-16/JJ	prep_of||hypothesis-13/NNS||epigenetics-17/NNS	mark||pertains-20/VBZ||as-18/IN	nsubj||pertains-20/VBZ||it-19/PRP	advcl||working-12/VBG||pertains-20/VBZ	prep_to||pertains-20/VBZ||hiv/aids-22/NNS	det||immunopathology-26/NN||the-25/DT	prep_to||pertains-20/VBZ||immunopathology-26/NN	conj_and||hiv/aids-22/NNS||immunopathology-26/NN	amod||cells-31/NNS||hiv-1-infected-28/JJ	amod||cells-31/NNS||cd4-29/JJ	nn||cells-31/NNS||+-30/NN	prep_of||immunopathology-26/NN||cells-31/NNS	aids--1||hiv--1||no||taken together, the arguments presented here lead to a novel working hypothesis of molecular immune epigenetics as it pertains to hiv/aids, and the immunopathology of hiv-1-infected cd4+ cells.
nsubj||increased-19/VBD||stimulation-1/NN	amod||dramatically-13/NNS||vvec-3/JJ	prep_with||vvec-3/JJ||extracellular-5/NN	nn||dramatically-13/NNS||atp-6/NN	num||î-9/NN||100-8/CD	dep||dramatically-13/NNS||î-9/NN	num||m-11/NN||1/4-10/CD	dep||î-9/NN||m-11/NN	prep_of||stimulation-1/NN||dramatically-13/NNS	quantmod||ten-fold-17/CD||up-15/IN	dep||ten-fold-17/CD||to-16/TO	dep||dramatically-13/NNS||ten-fold-17/CD	root||ROOT-0/null||increased-19/VBD	nn||formation-23/NN||migration-20/NN	conj_and||migration-20/NN||tube-22/NN	nn||formation-23/NN||tube-22/NN	dobj||increased-19/VBD||formation-23/NN	prep_on||increased-19/VBD||matrigel-25/NN	advmod||observed-36/JJ||however-27/RB	neg||effects-31/NNS||no-29/DT	amod||effects-31/NNS||significant-30/JJ	nsubj||observed-36/JJ||effects-31/NNS	nn||proliferation-34/NN||cell-33/NN	prep_on||effects-31/NNS||proliferation-34/NN	cop||observed-36/JJ||were-35/VBD	parataxis||increased-19/VBD||observed-36/JJ	ten--1||atp-6||no_rel||stimulation of vvec with extracellular atp (100 î¼m) dramatically (up to ten-fold) increased migration and tube formation on matrigel; however, no significant effects on cell proliferation were observed.
mark||analyze-4/VB||in-1/IN	dep||analyze-4/VB||order-2/NN	aux||analyze-4/VB||to-3/TO	advcl||studied-19/VBD||analyze-4/VB	amod||cells-6/NNS||dendritic-5/JJ	dobj||analyze-4/VB||cells-6/NNS	appos||cells-6/NNS||dcs-8/NN	vmod||cells-6/NNS||activation-10/VBN	prep_following||activation-10/VBN||infection-12/NN	amod||strains-16/NNS||different-14/JJ	amod||strains-16/NNS||mycobacterial-15/JJ	prep_with||infection-12/NN||strains-16/NNS	nsubj||studied-19/VBD||we-18/PRP	ccomp||mycobacteriumtuberculosis-36/VBZ||studied-19/VBD	det||profiles-22/NNS||the-20/DT	nn||profiles-22/NNS||expression-21/NN	dobj||studied-19/VBD||profiles-22/NNS	num||genes-25/NNS||165-24/CD	prep_of||profiles-22/NNS||genes-25/NNS	amod||dcs-29/NN||human-27/JJ	amod||dcs-29/NN||monocyte-derived-28/JJ	prep_of||genes-25/NNS||dcs-29/NN	vmod||dcs-29/NN||infected-30/VBN	prep_with||infected-30/VBN||h37rv-32/CD	det||virulent-35/NN||a-34/DT	nsubj||mycobacteriumtuberculosis-36/VBZ||virulent-35/NN	root||ROOT-0/null||mycobacteriumtuberculosis-36/VBZ	dep||mycobacteriumtuberculosis-36/VBZ||mtb-38/NN	nn||strain-41/NN||laboratory-40/NN	dobj||mycobacteriumtuberculosis-36/VBZ||strain-41/NN	dobj||mycobacteriumtuberculosis-36/VBZ||cmt97-43/NNS	conj_and||strain-41/NN||cmt97-43/NNS	det||isolate-48/NN||a-45/DT	amod||isolate-48/NN||clinical-46/JJ	nn||isolate-48/NN||mtb-47/NN	dobj||mycobacteriumtuberculosis-36/VBZ||isolate-48/NN	conj_and||strain-41/NN||isolate-48/NN	amod||bacillus-51/NNS||mycobacteriumbovis-50/JJ	dobj||mycobacteriumtuberculosis-36/VBZ||bacillus-51/NNS	conj_and||strain-41/NN||bacillus-51/NNS	nn||rin-54/NNP||calmette-guã-52/NNP	nn||rin-54/NNP||©-53/NNP	dep||bacillus-51/NNS||rin-54/NNP	appos||rin-54/NNP||bcg-56/NN	amod||pasteur-60/NN||aventis-59/JJ	dobj||mycobacteriumtuberculosis-36/VBZ||pasteur-60/NN	conj_and||strain-41/NN||pasteur-60/NN	nn||japan-64/NN||bcg-63/NN	dobj||mycobacteriumtuberculosis-36/VBZ||japan-64/NN	conj_and||strain-41/NN||japan-64/NN	nsubj||employed-67/VBN||both-66/DT	rcmod||japan-64/NN||employed-67/VBN	prep_as||employed-67/VBN||vaccine-69/NN	prep_against||vaccine-69/NN||tuberculosis-71/NNP	tuberculosis-71||bcg-63||yes||in order to analyze dendritic cells (dcs) activation following infection with different mycobacterial strains, we studied the expression profiles of 165 genes of human monocyte-derived dcs infected with h37rv, a virulent mycobacteriumtuberculosis (mtb) laboratory strain, cmt97, a clinical mtb isolate, mycobacteriumbovis bacillus calmette-guã©rin (bcg), aventis pasteur, and bcg japan, both employed as vaccine against tuberculosis.
amod||dose-3/NN||standard-1/JJ	nn||dose-3/NN||loading-2/NN	nsubj||enough-7/JJ||dose-3/NN	prep_of||dose-3/NN||clopidogrel-5/NN	cop||enough-7/JJ||was-6/VBD	root||ROOT-0/null||enough-7/JJ	amod||patients-11/NNS||asian-9/JJ	nn||patients-11/NNS||ami-10/NN	prep_for||enough-7/JJ||patients-11/NNS	ami-10||clopidogrel-5||yes||standard loading dose of clopidogrel was enough for asian ami patients.
prep||proven-13/VBN||given-1/VBN	advmod||daily-3/JJ||once-2/RB	advmod||at-4/IN||daily-3/JJ	pcomp||given-1/VBN||at-4/IN	num||mg-6/NN||150-5/CD	pobj||at-4/IN||mg-6/NN	num||mg-9/NN||220-8/CD	pobj||at-4/IN||mg-9/NN	conj_or||mg-6/NN||mg-9/NN	nsubj||proven-13/VBN||it-11/PRP	nsubj||competitive-16/JJ||it-11/PRP	aux||proven-13/VBN||has-12/VBZ	root||ROOT-0/null||proven-13/VBN	aux||competitive-16/JJ||to-14/TO	cop||competitive-16/JJ||be-15/VB	xcomp||proven-13/VBN||competitive-16/JJ	prep_with||competitive-16/JJ||enoxaparin-18/NN	det||prevention-21/NN||the-20/DT	prep_in||enoxaparin-18/NN||prevention-21/NN	amod||thromboembolism-24/NN||venous-23/JJ	prep_of||prevention-21/NN||thromboembolism-24/NN	amod||surgery-28/NN||major-26/JJ	amod||surgery-28/NN||orthopedic-27/JJ	prep_after||competitive-16/JJ||surgery-28/NN	det||profile-34/NN||a-31/DT	amod||profile-34/NN||comparable-32/JJ	nn||profile-34/NN||safety-33/NN	prep_with||competitive-16/JJ||profile-34/NN	thromboembolism-24||enoxaparin-18||yes||given once daily at 150 mg or 220 mg, it has proven to be competitive with enoxaparin in the prevention of venous thromboembolism after major orthopedic surgery, with a comparable safety profile.
num||kinds-2/NNS||two-1/CD	nsubj||viruses-7/NNS||kinds-2/NNS	prep_of||kinds-2/NNS||them-4/PRP	cop||viruses-7/NNS||are-5/VBP	amod||viruses-7/NNS||mosquito-borne-6/JJ	root||ROOT-0/null||viruses-7/NNS	nsubj||lead-16/VBP||viruses-7/NNS	nsubj||denguefever/denguehemorrhagicfever-21/VBP||viruses-7/NNS	advmod||virus-11/NN||namely-9/RB	amod||virus-11/NN||japaneseencephalitis-10/JJ	appos||viruses-7/NNS||virus-11/NN	appos||viruses-7/NNS||denguevirus-13/NNS	conj_and||virus-11/NN||denguevirus-13/NNS	rcmod||viruses-7/NNS||lead-16/VBP	prep_to||lead-16/VBP||japaneseencephalitis-18/NNS	rcmod||viruses-7/NNS||denguefever/denguehemorrhagicfever-21/VBP	conj_and||lead-16/VBP||denguefever/denguehemorrhagicfever-21/VBP	advmod||denguefever/denguehemorrhagicfever-21/VBP||respectively-22/RB	det||two-26/CD||the-24/DT	amod||two-26/CD||other-25/JJ	nsubj||viruses-29/NNS||two-26/CD	cop||viruses-29/NNS||are-27/VBP	amod||viruses-29/NNS||tick-borne-28/JJ	parataxis||viruses-7/NNS||viruses-29/NNS	nsubj||contribute-48/VBP||viruses-29/NNS	advmod||virus-33/NN||namely-31/RB	amod||virus-33/NN||tick-borneencephalitis-32/JJ	parataxis||viruses-7/NNS||virus-33/NN	conj_and||viruses-29/NNS||virus-33/NN	nsubj||contribute-48/VBP||virus-33/NN	amod||virus-37/NN||crimean-congo-35/JJ	nn||virus-37/NN||hemorrhagicfever-36/NN	parataxis||viruses-7/NNS||virus-37/NN	conj_and||viruses-29/NNS||virus-37/NN	nsubj||contribute-48/VBP||virus-37/NN	advmod||known-40/VBN||also-39/RB	dep||viruses-29/NNS||known-40/VBN	prepc_as||known-40/VBN||xinjiang-42/VBG	nn||virus-44/NN||hemorrhagicfever-43/NN	dobj||xinjiang-42/VBG||virus-44/NN	rcmod||viruses-29/NNS||contribute-48/VBP	prep_to||contribute-48/VBP||tick-borneencephalitis-50/NNS	nn||hemorrhagicfever-53/NN||xinjiang-52/NN	prep_to||contribute-48/VBP||hemorrhagicfever-53/NN	conj_and||tick-borneencephalitis-50/NNS||hemorrhagicfever-53/NN	advmod||contribute-48/VBP||respectively-54/RB	virus-44||viruses-29||no||two kinds of them are mosquito-borne viruses, namely japaneseencephalitis virus and denguevirus, which lead to japaneseencephalitis, and denguefever/denguehemorrhagicfever respectively; the other two are tick-borne viruses, namely tick-borneencephalitis virus and crimean-congo hemorrhagicfever virus (also known as xinjiang hemorrhagicfever virus), which contribute to tick-borneencephalitis and xinjiang hemorrhagicfever respectively.
nsubjpass||measured-21/VBN||effects-1/NNS	amod||administration-6/NN||intrathecal-3/JJ	amod||administration-6/NN||and/or-4/JJ	amod||administration-6/NN||systemic-5/JJ	prep_of||effects-1/NNS||administration-6/NN	amod||agonist-9/NN||b1r-8/JJ	prep_of||administration-6/NN||agonist-9/NN	dep||agonist-9/NN||des-arg9-bk-11/JJ	prep_of||administration-6/NN||antagonists-14/NNS	conj_and||agonist-9/NN||antagonists-14/NNS	dep||agonist-9/NN||ssr240612-16/JJ	dep||agonist-9/NN||r-715-18/JJ	conj_and||ssr240612-16/JJ||r-715-18/JJ	auxpass||measured-21/VBN||were-20/VBD	root||ROOT-0/null||measured-21/VBN	nn||manifestations-24/NNS||neuropathicpain-23/NN	prep_on||measured-21/VBN||manifestations-24/NNS	des--1||neuropathicpain-23||no_rel||effects of intrathecal and/or systemic administration of b1r agonist (des-arg9-bk) and antagonists (ssr240612 and r-715) were measured on neuropathicpain manifestations.
nsubj||demonstrated-3/VBN||fluoxetine-1/NN	nsubj||effective-7/JJ||fluoxetine-1/NN	aux||demonstrated-3/VBN||has-2/VBZ	root||ROOT-0/null||demonstrated-3/VBN	aux||effective-7/JJ||to-4/TO	cop||effective-7/JJ||be-5/VB	advmod||effective-7/JJ||as-6/RB	xcomp||demonstrated-3/VBN||effective-7/JJ	prep_as||effective-7/JJ||chlomipramine-9/NN	det||treatment-12/NN||the-11/DT	prep_in||effective-7/JJ||treatment-12/NN	prep_of||treatment-12/NN||obsessive-compulsive-disorder-14/NN	appos||obsessive-compulsive-disorder-14/NN||ocd-16/NN	ocd-16||fluoxetine-1||yes||fluoxetine has demonstrated to be as effective as chlomipramine in the treatment of obsessive-compulsive-disorder (ocd).
num||weeks-3/NNS||24-2/CD	prep_within||experienced-16/VBD||weeks-3/NNS	prepc_of||weeks-3/NNS||initiating-5/VBG	amod||treatment-7/NN||antituberculosis-6/JJ	dobj||initiating-5/VBG||treatment-7/NN	num||%-10/NN||40-9/CD	nsubj||experienced-16/VBD||%-10/NN	appos||%-10/NN||117/292-12/CD	prep_of||%-10/NN||patients-15/NNS	root||ROOT-0/null||experienced-16/VBD	amod||deterioration-18/NN||clinical-17/JJ	dobj||experienced-16/VBD||deterioration-18/NN	amod||illness-22/NN||co-morbid-21/JJ	prep_due_to||experienced-16/VBD||illness-22/NN	dep||illness-22/NN||n-24/VBN	dep||70-26/CD||=-25/SYM	ccomp||n-24/VBN||70-26/CD	amod||illness-31/NN||tuberculosis-29/JJ	amod||illness-31/NN||related-30/VBN	prep_due_to||experienced-16/VBD||illness-31/NN	conj_and||illness-22/NN||illness-31/NN	dep||illness-31/NN||n-33/VBN	dep||47-35/CD||=-34/SYM	ccomp||n-33/VBN||47-35/CD	nn||infection-42/NN||non-38/NN	amod||infection-42/NN||aids-defining-39/JJ	amod||infection-42/NN||hiv-1-40/JJ	amod||infection-42/NN||related-41/JJ	prep_due_to||experienced-16/VBD||infection-42/NN	conj_and||illness-22/NN||infection-42/NN	dep||infection-42/NN||n-44/VBN	dep||25-46/CD||=-45/SYM	ccomp||n-44/VBN||25-46/CD	amod||illness-50/NN||aids-defining-49/JJ	prep_due_to||experienced-16/VBD||illness-50/NN	conj_and||illness-22/NN||illness-50/NN	dep||illness-50/NN||n-52/VBN	dep||21-54/CD||=-53/SYM	ccomp||n-52/VBN||21-54/CD	tuberculosis-29||antituberculosis-6||yes||within 24 weeks of initiating antituberculosis treatment, 40% (117/292) of patients experienced clinical deterioration due to co-morbid illness (n = 70), tuberculosis related illness (n = 47), non aids-defining hiv-1 related infection (n = 25) and aids-defining illness (n = 21).
num||percent-2/NN||fourteen-1/CD	nsubj||positive-20/JJ||percent-2/NN	amod||subjects-5/NNS||hivpositive-4/JJ	prep_of||percent-2/NN||subjects-5/NNS	appos||subjects-5/NNS||8/57-7/CD	num||%-11/NN||4.3-10/CD	prep_of||percent-2/NN||%-11/NN	conj_and||subjects-5/NNS||%-11/NN	appos||subjects-5/NNS||14/327-13/CD	amod||subjects-18/NNS||hiv-16/JJ	amod||subjects-18/NNS||negative-17/JJ	prep_of||percent-2/NN||subjects-18/NNS	cop||positive-20/JJ||were-19/VBD	root||ROOT-0/null||positive-20/JJ	prepc_for||positive-20/JJ||hbsag-22/VBG	hbsag-22||hivpositive-4||no_rel||fourteen percent of hivpositive subjects (8/57) and 4.3% (14/327) of hiv negative subjects were positive for hbsag.
amod||ltp-2/NN||spinal-1/JJ	nsubjpass||induced-5/VBN||ltp-2/NN	auxpass||induced-5/VBN||is-3/VBZ	advmod||induced-5/VBN||also-4/RB	root||ROOT-0/null||induced-5/VBN	amod||opioidwithdrawal-8/NN||abrupt-7/JJ	agent||induced-5/VBN||opioidwithdrawal-8/NN	xcomp||induced-5/VBN||making-10/VBG	nsubj||mechanism-14/NN||it-11/PRP	det||mechanism-14/NN||a-12/DT	amod||mechanism-14/NN||possible-13/JJ	xcomp||making-10/VBG||mechanism-14/NN	det||forms-17/NNS||some-16/DT	prep_of||mechanism-14/NN||forms-17/NNS	amod||hyperalgesia-20/NN||opioid-induced-19/JJ	prep_of||forms-17/NNS||hyperalgesia-20/NN	opioidwithdrawal-8||opioid--1||no||spinal ltp is also induced by abrupt opioidwithdrawal, making it a possible mechanism of some forms of opioid-induced hyperalgesia.
det||varicellazostervirus-2/NNS||the-1/DT	nsubj||alpha-herpesvirus-10/NNS||varicellazostervirus-2/NNS	appos||varicellazostervirus-2/NNS||vzv-4/NN	cop||alpha-herpesvirus-10/NNS||is-6/VBZ	det||alpha-herpesvirus-10/NNS||a-7/DT	amod||alpha-herpesvirus-10/NNS||ubiquitous-8/JJ	amod||alpha-herpesvirus-10/NNS||human-9/JJ	root||ROOT-0/null||alpha-herpesvirus-10/NNS	nsubj||agent-15/NN||alpha-herpesvirus-10/NNS	cop||agent-15/NN||is-12/VBZ	det||agent-15/NN||the-13/DT	amod||agent-15/NN||causative-14/JJ	rcmod||alpha-herpesvirus-10/NNS||agent-15/NN	prep_of||agent-15/NN||chickenpox-17/NN	prep_of||agent-15/NN||shingles-19/NNS	conj_and||chickenpox-17/NN||shingles-19/NNS	chickenpox-17||varicellazostervirus-2||no||the varicellazostervirus (vzv) is a ubiquitous human alpha-herpesvirus that is the causative agent of chickenpox and shingles.
nsubj||therapy-9/NN||chloroquine-1/NN	appos||chloroquine-1/NN||cq-3/NN	cop||therapy-9/NN||was-5/VBD	det||therapy-9/NN||the-6/DT	amod||therapy-9/NN||main-7/JJ	nn||therapy-9/NN||malaria-8/NN	root||ROOT-0/null||therapy-9/NN	advmod||therapy-9/NN||worldwide-10/RB	det||1940s-13/NNS||the-12/DT	prep_from||therapy-9/NN||1940s-13/NNS	det||1990s-16/NNS||the-15/DT	prep_until||therapy-9/NN||1990s-16/NNS	malaria-8||chloroquine-1||yes||chloroquine (cq) was the main malaria therapy worldwide from the 1940s until the 1990s.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	det||study-5/NN||the-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	det||effect-10/NN||the-9/DT	dobj||evaluate-8/VB||effect-10/NN	prep_of||effect-10/NN||nitrates-12/NNS	prep_on||nitrates-12/NNS||leftventricularhypertrophy-14/NN	appos||leftventricularhypertrophy-14/NN||lvh-16/NN	amod||patients-20/NNS||hypertensive-19/JJ	prep_in||evaluate-8/VB||patients-20/NNS	amod||dialysis-24/NN||chronic-22/JJ	amod||dialysis-24/NN||peritoneal-23/JJ	prep_on||patients-20/NNS||dialysis-24/NN	appos||dialysis-24/NN||pd-26/NN	leftventricularhypertrophy-14||nitrates-12||no_rel||the aim of the study was to evaluate the effect of nitrates on leftventricularhypertrophy (lvh) in hypertensive patients on chronic peritoneal dialysis (pd).
det||duration-3/NN||the-1/DT	amod||duration-3/NN||longer-2/JJR	nsubjpass||reflected-27/VBN||duration-3/NN	amod||suppression-6/NN||acid-5/JJ	prep_of||duration-3/NN||suppression-6/NN	prep_with||suppression-6/NN||omeprazole-8/NN	dep||suppression-6/NN||particularly-10/RB	det||day-13/NN||the-12/DT	prep_during||suppression-6/NN||day-13/NN	advmod||ingested-18/VBN||when-15/WRB	nsubjpass||ingested-18/VBN||food-16/NN	auxpass||ingested-18/VBN||is-17/VBZ	rcmod||duration-3/NN||ingested-18/VBN	amod||antagonists-21/NNS||h2-receptor-20/JJ	nsubj||effective-24/JJ||antagonists-21/NNS	cop||effective-24/JJ||are-22/VBP	advmod||effective-24/JJ||less-23/RBR	rcmod||duration-3/NN||effective-24/JJ	conj_and||ingested-18/VBN||effective-24/JJ	auxpass||reflected-27/VBN||is-26/VBZ	root||ROOT-0/null||reflected-27/VBN	prep||reflected-27/VBN||in-28/IN	det||superiority-31/NN||the-29/DT	amod||superiority-31/NN||clinical-30/JJ	pobj||in-28/IN||superiority-31/NN	nn||relief-34/NN||symptom-33/NN	prep_for||superiority-31/NN||relief-34/NN	nn||healing-37/NN||ulcer-36/NN	prep_for||superiority-31/NN||healing-37/NN	conj_and||relief-34/NN||healing-37/NN	prep||reflected-27/VBN||especially-39/RB	conj_and||in-28/IN||especially-39/RB	dep||in-28/IN||for-40/IN	det||treatment-42/NN||the-41/DT	pobj||for-40/IN||treatment-42/NN	amod||esophagitis-45/NNS||erosive-44/JJ	prep_of||treatment-42/NN||esophagitis-45/NNS	esophagitis-45||omeprazole-8||yes||the longer duration of acid suppression with omeprazole, particularly during the day, when food is ingested and h2-receptor antagonists are less effective, is reflected in the clinical superiority for symptom relief and ulcer healing and especially for the treatment of erosive esophagitis.
prep_in||increased-10/VBN||response-2/NN	nn||workforces-8/NNS||laboratory-4/NN	conj_and||laboratory-4/NN||client-6/NN	nn||workforces-8/NNS||client-6/NN	nn||workforces-8/NNS||service-7/NN	nsubjpass||increased-10/VBN||workforces-8/NNS	auxpass||increased-10/VBN||were-9/VBD	root||ROOT-0/null||increased-10/VBN	amod||build-out-14/NN||physical-12/JJ	nn||build-out-14/NN||plant-13/NN	nsubjpass||completed-16/VBN||build-out-14/NN	auxpass||completed-16/VBN||was-15/VBD	ccomp||increased-10/VBN||completed-16/VBN	conj_and||increased-10/VBN||completed-16/VBN	nn||paradigms-19/NNS||testing-18/NN	nsubjpass||converted-21/VBN||paradigms-19/NNS	nsubj||viralculture-27/JJ||paradigms-19/NNS	auxpass||converted-21/VBN||were-20/VBD	ccomp||increased-10/VBN||converted-21/VBN	conj_and||increased-10/VBN||converted-21/VBN	amod||tests-25/NNS||routine-23/JJ	nn||tests-25/NNS||screening-24/NN	prep_from||converted-21/VBN||tests-25/NNS	ccomp||increased-10/VBN||viralculture-27/JJ	conj_and||increased-10/VBN||viralculture-27/JJ	conj_and||converted-21/VBN||viralculture-27/JJ	det||assay-32/NN||a-29/DT	amod||assay-32/NN||high-capacity-30/JJ	amod||assay-32/NN||molecular-31/JJ	prep_to||viralculture-27/JJ||assay-32/NN	amod||viruses-35/NNS||respiratory-34/JJ	prep_for||viralculture-27/JJ||viruses-35/NNS	nn||interfaces-40/NNS||laboratory-37/NN	nn||interfaces-40/NNS||information-38/NN	nn||interfaces-40/NNS||system-39/NN	nsubjpass||built-42/VBN||interfaces-40/NNS	auxpass||built-42/VBN||were-41/VBD	ccomp||increased-10/VBN||built-42/VBN	conj_and||increased-10/VBN||built-42/VBN	amod||reports-47/NNS||same-day-45/JJ	amod||reports-47/NNS||epidemiologic-46/JJ	nsubjpass||produced-49/VBN||reports-47/NNS	auxpass||produced-49/VBN||were-48/VBD	conj_and||increased-10/VBN||produced-49/VBN	viralculture-27||viruses-35||no||in response, laboratory and client service workforces were increased, physical plant build-out was completed, testing paradigms were converted from routine screening tests and viralculture to a high-capacity molecular assay for respiratory viruses, laboratory information system interfaces were built, and same-day epidemiologic reports were produced.
aux||begin-2/VB||to-1/TO	advcl||utilized-23/VBD||begin-2/VB	aux||understand-4/VB||to-3/TO	xcomp||begin-2/VB||understand-4/VB	det||contributions-6/NNS||the-5/DT	dobj||understand-4/VB||contributions-6/NNS	amod||obesity-9/NN||maternal-8/JJ	prep_of||contributions-6/NNS||obesity-9/NN	prep_of||contributions-6/NNS||over-nutrition-11/NN	conj_and||obesity-9/NN||over-nutrition-11/NN	amod||development-14/NN||human-13/JJ	prep_to||understand-4/VB||development-14/NN	det||origins-18/NNS||the-16/DT	amod||origins-18/NNS||early-17/JJ	prep_to||understand-4/VB||origins-18/NNS	conj_and||development-14/NN||origins-18/NNS	prep_of||origins-18/NNS||obesity-20/NN	nsubj||utilized-23/VBD||we-22/PRP	root||ROOT-0/null||utilized-23/VBD	det||model-27/NN||a-24/DT	amod||model-27/NN||non-human-25/JJ	nn||model-27/NN||primate-26/NN	dobj||utilized-23/VBD||model-27/NN	aux||investigate-29/VB||to-28/TO	vmod||utilized-23/VBD||investigate-29/VB	det||effects-31/NNS||the-30/DT	dobj||investigate-29/VB||effects-31/NNS	amod||feeding-35/NN||maternal-33/JJ	amod||feeding-35/NN||high-fat-34/JJ	prep_of||effects-31/NNS||feeding-35/NN	vmod||utilized-23/VBD||obesity-37/VB	conj_and||investigate-29/VB||obesity-37/VB	nn||milk-40/NN||breast-39/NN	prep_on||obesity-37/VB||milk-40/NN	prep_on||obesity-37/VB||maternal-42/NN	conj_and||milk-40/NN||maternal-42/NN	amod||composition-47/NN||fetal-44/JJ	nn||composition-47/NN||plasma-45/NN	nn||composition-47/NN||fattyacid-46/NN	prep_on||obesity-37/VB||composition-47/NN	conj_and||milk-40/NN||composition-47/NN	amod||development-51/NN||fetal-49/JJ	amod||development-51/NN||hepatic-50/JJ	conj_and||milk-40/NN||development-51/NN	conj_and||composition-47/NN||development-51/NN	obesity-37||fat--1||no_rel||to begin to understand the contributions of maternal obesity and over-nutrition to human development and the early origins of obesity, we utilized a non-human primate model to investigate the effects of maternal high-fat feeding and obesity on breast milk, maternal and fetal plasma fattyacid composition and fetal hepatic development.
nsubjpass||caused-3/VBN||priondiseases-1/NNS	auxpass||caused-3/VBN||are-2/VBP	root||ROOT-0/null||caused-3/VBN	amod||pathogens-6/NNS||proteinaceous-5/JJ	agent||caused-3/VBN||pathogens-6/NNS	vmod||pathogens-6/NNS||termed-7/VBN	dobj||termed-7/VBN||prions-8/NNS	priondiseases-1||prions-8||no||priondiseases are caused by proteinaceous pathogens termed prions.
nsubjpass||studied-14/VBN||modafinil-1/NN	det||agent-5/NN||a-3/DT	amod||agent-5/NN||wakefulness-promoting-4/JJ	appos||modafinil-1/NN||agent-5/NN	amod||agent-5/NN||unrelated-6/JJ	amod||stimulants-10/NNS||classical-8/JJ	amod||stimulants-10/NNS||sympathomimetic-9/JJ	prep_to||unrelated-6/JJ||stimulants-10/NNS	aux||studied-14/VBN||has-12/VBZ	auxpass||studied-14/VBN||been-13/VBN	root||ROOT-0/null||studied-14/VBN	det||total-17/NN||a-16/DT	prep_in||studied-14/VBN||total-17/NN	num||children-20/NNS||933-19/CD	prep_of||total-17/NN||children-20/NNS	prep_of||total-17/NN||adolescents-22/NNS	conj_and||children-20/NNS||adolescents-22/NNS	det||treatment-25/NN||a-24/DT	prep_as||studied-14/VBN||treatment-25/NN	prep_for||treatment-25/NN||attention-deficit/hyperactivitydisorder-27/NN	dep||treatment-25/NN||adhd-29/VBN	adhd-29||modafinil-1||yes||modafinil, a wakefulness-promoting agent unrelated to classical sympathomimetic stimulants, has been studied in a total of 933 children and adolescents as a treatment for attention-deficit/hyperactivitydisorder (adhd).
det||success-2/NN||the-1/DT	nsubj||sent-11/VBN||success-2/NN	prep_of||success-2/NN||bortezomib-4/NN	det||treatment-7/NN||the-6/DT	prep_in||bortezomib-4/NN||treatment-7/NN	prep_of||treatment-7/NN||multiplemyeloma-9/NN	aux||sent-11/VBN||has-10/VBZ	root||ROOT-0/null||sent-11/VBN	xcomp||sent-11/VBN||encouraging-12/VBG	dobj||encouraging-12/VBG||signals-13/NNS	mark||used-19/VBN||that-14/IN	amod||inhibitors-16/NNS||proteasome-15/JJ	nsubjpass||used-19/VBN||inhibitors-16/NNS	nsubj||treat-21/VB||inhibitors-16/NNS	aux||used-19/VBN||could-17/MD	auxpass||used-19/VBN||be-18/VB	ccomp||encouraging-12/VBG||used-19/VBN	aux||treat-21/VB||to-20/TO	xcomp||used-19/VBN||treat-21/VB	amod||types-23/NNS||other-22/JJ	dobj||treat-21/VB||types-23/NNS	prep_of||types-23/NNS||cancers-25/NNS	multiplemyeloma-9||bortezomib-4||yes||the success of bortezomib in the treatment of multiplemyeloma has sent encouraging signals that proteasome inhibitors could be used to treat other types of cancers.
advmod||compared-4/VBD||here-1/RB	nsubj||compared-4/VBD||we-3/PRP	root||ROOT-0/null||compared-4/VBD	det||characteristics-9/NNS||the-5/DT	nn||characteristics-9/NNS||cell-6/NN	nn||characteristics-9/NNS||culture-7/NN	nn||characteristics-9/NNS||growth-8/NN	dobj||compared-4/VBD||characteristics-9/NNS	nn||viruses-12/NNS||haemorrhagicfever-11/NN	prep_of||characteristics-9/NNS||viruses-12/NNS	appos||viruses-12/NNS||hfv-14/NN	det||arenaviridae-19/NN||the-18/DT	prep_of||viruses-12/NNS||arenaviridae-19/NN	prep_of||viruses-12/NNS||filoviridae-21/NN	conj_and||arenaviridae-19/NN||filoviridae-21/NN	prep_of||viruses-12/NNS||bunyaviridae-23/NN	conj_and||arenaviridae-19/NN||bunyaviridae-23/NN	amod||families-28/NNS||flavivridae-26/JJ	nn||families-28/NNS||virus-27/NN	prep_of||viruses-12/NNS||families-28/NNS	conj_and||arenaviridae-19/NN||families-28/NNS	prepc_by||compared-4/VBD||performing-30/VBG	amod||analysis-32/NN||quantitative-31/JJ	dobj||performing-30/VBG||analysis-32/NN	nn||supernatants-36/NNS||cell-34/NN	nn||supernatants-36/NNS||culture-35/NN	prep_of||analysis-32/NN||supernatants-36/NNS	appos||microscopy-42/NN||i-39/NNP	amod||microscopy-42/NN||electron-41/JJ	prep_by||performing-30/VBG||microscopy-42/NN	det||quantification-45/NN||the-44/DT	prep_for||performing-30/VBG||quantification-45/NN	nn||particles-48/NNS||virus-47/NN	prep_of||quantification-45/NN||particles-48/NNS	appos||particles-48/NNS||ii-51/NN	amod||time-55/NN||quantitative-53/JJ	amod||time-55/NN||real-54/JJ	dep||particles-48/NNS||time-55/NN	vmod||time-55/NN||pcr-56/VBN	det||quantification-59/NN||the-58/DT	prep_for||pcr-56/VBN||quantification-59/NN	prep_of||quantification-59/NN||genomes-61/NNS	amod||determination-67/NN||iii-65/JJ	prep_of||quantification-45/NN||determination-67/NN	conj_and||particles-48/NNS||determination-67/NN	prep_of||determination-67/NN||focus-69/NN	vmod||determination-67/NN||forming-70/VBG	dobj||forming-70/VBG||units-71/NNS	agent||forming-70/VBG||coating-73/VBG	amod||antibodies-75/NNS||fluorescent-74/JJ	dobj||coating-73/VBG||antibodies-75/NNS	amod||monolayers-79/NNS||infected-77/JJ	nn||monolayers-79/NNS||cell-78/NN	prep_to||coating-73/VBG||monolayers-79/NNS	det||quantification-82/NN||the-81/DT	prep_for||determination-67/NN||quantification-82/NN	nn||infectivity-85/NN||virus-84/NN	prep_of||quantification-82/NN||infectivity-85/NN	haemorrhagicfever-11||viruses-12||no||here, we compared the cell culture growth characteristics of haemorrhagicfever viruses (hfv), of the arenaviridae , filoviridae , bunyaviridae , and flavivridae virus families by performing quantitative analysis of cell culture supernatants by (i) electron microscopy for the quantification of virus particles, (ii) quantitative real time pcr for the quantification of genomes, and (iii) determination of focus forming units by coating fluorescent antibodies to infected cell monolayers for the quantification of virus infectivity.
mark||available-7/JJ||although-1/IN	amod||data-4/NNS||cause-specific-2/JJ	nn||data-4/NNS||mortality-3/NN	nsubj||available-7/JJ||data-4/NNS	cop||available-7/JJ||were-5/VBD	neg||available-7/JJ||not-6/RB	advcl||suggests-30/VBZ||available-7/JJ	det||rise-10/NN||the-9/DT	nsubj||suggests-30/VBZ||rise-10/NN	prep_in||rise-10/NN||mortality-12/NN	det||15â-15/NN||the-14/DT	prep_in||mortality-12/NN||15â-15/NN	dep||15â-15/NN||$-16/$	amod||group-20/NN||49-year-18/JJ	nn||group-20/NN||age-19/NN	conj_and||group-20/NN||group-20/NN	npadvmod||closer-26/JJR||group-20/NN	npadvmod||closer-26/JJR||group-20/NN	prep_over||group-20/NN||time-22/NN	prep_in||group-20/NN||areas-25/NNS	dep||strongly-29/CD||closer-26/JJR	prep_to||closer-26/JJR||conurbations-28/NNS	num||$-16/$||strongly-29/CD	root||ROOT-0/null||suggests-30/VBZ	mark||observed-34/VBD||that-31/IN	det||clustering-33/NN||the-32/DT	nsubj||observed-34/VBD||clustering-33/NN	ccomp||suggests-30/VBZ||observed-34/VBD	cop||due-36/JJ||was-35/VBD	ccomp||observed-34/VBD||due-36/JJ	det||development-39/NN||the-38/DT	prep_to||due-36/JJ||development-39/NN	amod||mortality-42/NN||hiv/aids-related-41/JJ	prep_of||development-39/NN||mortality-42/NN	mark||seen-45/VBN||as-44/IN	advcl||due-36/JJ||seen-45/VBN	advmod||seen-45/VBN||similarly-46/RB	advmod||seen-45/VBN||elsewhere-47/RB	amod||africa-50/NN||south-49/JJ	prep_in||seen-45/VBN||africa-50/NN	aids--1||hiv--1||no||although cause-specific mortality data were not available, the rise in mortality in the 15â49-year age group over time and in areas closer to conurbations strongly suggests that the clustering observed was due to the development of hiv/aids-related mortality, as seen similarly elsewhere in south africa.
nsubj||treated-5/VBD||sputum-1/NN	prep_of||sputum-1/NN||215-3/NNP	advmod||treated-5/VBD||previously-4/RB	root||ROOT-0/null||treated-5/VBD	amod||pulmonarytuberculosis-7/NNS||adult-6/JJ	dobj||treated-5/VBD||pulmonarytuberculosis-7/NNS	appos||pulmonarytuberculosis-7/NNS||tb-9/NN	nsubjpass||subjected-18/VBN||patients-11/NNS	det||period-14/NN||a-13/DT	prep_over||patients-11/NNS||period-14/NN	prep_of||period-14/NN||2002-2006-16/CD	auxpass||subjected-18/VBN||were-17/VBD	rcmod||pulmonarytuberculosis-7/NNS||subjected-18/VBN	nn||testing-23/NN||culture-20/NN	conj_and||culture-20/NN||sensitivity-22/NN	nn||testing-23/NN||sensitivity-22/NN	prep_to||subjected-18/VBN||testing-23/NN	amod||antituberculardrugs-26/NNS||common-25/JJ	prep_against||subjected-18/VBN||antituberculardrugs-26/NNS	tb-9||antituberculardrugs-26||yes||sputum of 215 previously treated adult pulmonarytuberculosis (tb) patients over a period of 2002-2006 were subjected to culture and sensitivity testing against common antituberculardrugs.
expl||is-2/VBZ||there-1/EX	root||ROOT-0/null||is-2/VBZ	det||prevalence-5/NN||a-3/DT	amod||prevalence-5/NN||high-4/JJ	nsubj||is-2/VBZ||prevalence-5/NN	amod||tuberculosis-8/NNP||drug-resistant-7/JJ	prep_of||prevalence-5/NN||tuberculosis-8/NNP	prep_in||prevalence-5/NN||children-10/NNS	prepc_in||children-10/NNS||johannesburg-12/VBG	det||setting-15/NN||a-14/DT	prep_in||johannesburg-12/VBG||setting-15/NN	det||prevalence-19/NN||a-17/DT	amod||prevalence-19/NN||high-18/JJ	prep_with||setting-15/NN||prevalence-19/NN	nn||co-infection-22/NN||hiv-21/NN	prep_of||prevalence-19/NN||co-infection-22/NN	mark||found-32/VBN||although-24/IN	neg||association-26/NN||no-25/DT	nsubjpass||found-32/VBN||association-26/NN	prep_between||association-26/NN||hivinfection-28/NN	prep_between||association-26/NN||mdr-tb-30/NN	conj_and||hivinfection-28/NN||mdr-tb-30/NN	auxpass||found-32/VBN||was-31/VBD	advcl||is-2/VBZ||found-32/VBN	det||study-35/NN||this-34/DT	prep_in||found-32/VBN||study-35/NN	hivinfection-28||hiv-21||no||there is a high prevalence of drug-resistant tuberculosis in children in johannesburg in a setting with a high prevalence of hiv co-infection, although no association between hivinfection and mdr-tb was found in this study.
nsubj||adhesin-5/NN||spap-1/NN	cop||adhesin-5/NN||is-2/VBZ	det||adhesin-5/NN||a-3/DT	amod||adhesin-5/NN||1500-residue-4/JJ	root||ROOT-0/null||adhesin-5/NN	vmod||adhesin-5/NN||expressed-6/VBN	det||surface-9/NN||the-8/DT	prep_on||expressed-6/VBN||surface-9/NN	det||mutans-15/NNS||the-11/DT	amod||mutans-15/NNS||caries-implicated-12/JJ	nn||mutans-15/NNS||bacterium-13/NN	nn||mutans-15/NNS||streptococcus-14/NNS	prep_of||surface-9/NN||mutans-15/NNS	caries--1||bacterium-13||no||spap is a 1500-residue adhesin expressed on the surface of the caries-implicated bacterium streptococcus mutans .
mark||knew-4/VBD||although-1/IN	num||%-3/NN||91.4-2/CD	nsubj||knew-4/VBD||%-3/NN	advcl||know-15/VB||knew-4/VBD	nsubjpass||transmitted-7/VBN||tb-5/NN	auxpass||transmitted-7/VBN||was-6/VBD	ccomp||knew-4/VBD||transmitted-7/VBN	prep_via||transmitted-7/VBN||aerosols-9/NNS	quantmod||one-third-12/NN||about-11/RB	nsubj||know-15/VB||one-third-12/NN	aux||know-15/VB||did-13/VBD	neg||know-15/VB||not-14/RB	root||ROOT-0/null||know-15/VB	det||method-17/NN||the-16/DT	dobj||know-15/VB||method-17/NN	prepc_for||know-15/VB||administering-19/VBG	dobj||administering-19/VBG||tuberculin-20/NN	det||vaccine-28/NN||that-23/DT	amod||vaccine-28/NN||bacilluscalmette-guerin-24/JJ	nn||vaccine-28/NN||bcg-26/NN	nsubj||contraindication-32/NN||vaccine-28/NN	cop||contraindication-32/NN||was-29/VBD	neg||contraindication-32/NN||not-30/RB	det||contraindication-32/NN||a-31/DT	conj_or||know-15/VB||contraindication-32/NN	aux||tb-34/VB||to-33/TO	vmod||contraindication-32/NN||tb-34/VB	nn||testing-36/NN||skin-35/NN	dobj||tb-34/VB||testing-36/NN	tb-34||bcg-26||no||although 91.4% knew tb was transmitted via aerosols, about one-third did not know the method for administering tuberculin, or that bacilluscalmette-guerin (bcg) vaccine was not a contraindication to tb skin testing.
nn||treatment-3/NN||statin-2/NN	prep_with||have-9/VBP||treatment-3/NN	amod||patients-6/NNS||such-5/JJ	nsubj||have-9/VBP||patients-6/NNS	neg||longer-8/RB||no-7/RB	advmod||have-9/VBP||longer-8/RB	root||ROOT-0/null||have-9/VBP	det||risk-11/NN||a-10/DT	nsubj||different-15/JJ||risk-11/NN	prep_of||risk-11/NN||myocardialinfarction-13/NN	advmod||different-15/JJ||significantly-14/RB	xcomp||have-9/VBP||different-15/JJ	prep_from||different-15/JJ||that-17/DT	det||population-21/NN||the-19/DT	amod||population-21/NN||general-20/JJ	prep_of||that-17/DT||population-21/NN	myocardialinfarction-13||statin-2||no_rel||with statin treatment, such patients no longer have a risk of myocardialinfarction significantly different from that of the general population.
det||objective-2/NN||the-1/DT	nsubj||was-6/VBD||objective-2/NN	nsubj||assess-8/VB||objective-2/NN	det||study-5/NN||this-4/DT	prep_of||objective-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||assess-8/VB||to-7/TO	xcomp||was-6/VBD||assess-8/VB	dobj||assess-8/VB||adherence-9/NN	dobj||assess-8/VB||persistence-11/NN	conj_and||adherence-9/NN||persistence-11/NN	amod||treatments-14/NNS||mesalamine-13/JJ	prep_to||assess-8/VB||treatments-14/NNS	poss||determinants-18/NNS||their-16/PRP$	amod||determinants-18/NNS||potential-17/JJ	prep_to||assess-8/VB||determinants-18/NNS	conj_and||treatments-14/NNS||determinants-18/NNS	amod||moderate-22/JJ||mild-20/JJ	dep||moderate-22/JJ||to-21/TO	amod||patients-24/NNS||moderate-22/JJ	nn||patients-24/NNS||uc-23/NN	prep_in||assess-8/VB||patients-24/NNS	det||setting-28/NN||a-26/DT	amod||setting-28/NN||real-life-27/JJ	prep_in||patients-24/NNS||setting-28/NN	prep_in||setting-28/NN||quebec-30/NN	appos||quebec-30/NN||canada-32/NN	uc-23||mesalamine-13||yes||the objective of this study was to assess adherence and persistence to mesalamine treatments and their potential determinants in mild to moderate uc patients in a real-life setting in quebec, canada.
det||study-3/NN||this-2/DT	prep_in||sought-6/VBD||study-3/NN	nsubj||sought-6/VBD||we-5/PRP	nsubj||examine-8/VB||we-5/PRP	root||ROOT-0/null||sought-6/VBD	aux||examine-8/VB||to-7/TO	xcomp||sought-6/VBD||examine-8/VB	dobj||examine-8/VB||associations-9/NNS	auxpass||designated-12/VBN||being-11/VBG	prepc_between||associations-9/NNS||designated-12/VBN	det||country-17/NN||a-14/DT	nn||country-17/NN||pepfar-15/NN	nn||country-17/NN||focus-16/NN	prep_as||designated-12/VBN||country-17/NN	cc||receiving-20/VBG||and-19/CC	dep||examine-8/VB||receiving-20/VBG	amod||funding-23/NN||increased-21/JJ	nn||funding-23/NN||pepfar-22/NN	dobj||receiving-20/VBG||funding-23/NN	amod||outcomes-28/NNS||non-hiv-specific-26/JJ	nn||outcomes-28/NNS||health-27/NN	xcomp||sought-6/VBD||outcomes-28/NNS	conj_and||examine-8/VB||outcomes-28/NNS	det||region-38/NN||the-30/DT	nn||organization-33/NN||world-31/NN	nn||organization-33/NN||health-32/NN	nn||region-38/NN||organization-33/NN	dep||organization-33/NN||who-35/WP	nn||region-38/NN||africa-37/NN	prep_in||outcomes-28/NNS||region-38/NN	det||area-41/NN||the-40/DT	appos||region-38/NN||area-41/NN	advmod||affected-43/VBN||most-42/RBS	vmod||area-41/NN||affected-43/VBN	det||epidemic-47/NN||the-45/DT	amod||epidemic-47/NN||hiv/aids-46/JJ	agent||affected-43/VBN||epidemic-47/NN	aids--1||hiv--1||no||in this study, we sought to examine associations between being designated as a pepfar focus country (and receiving increased pepfar funding) and non-hiv-specific health outcomes in the world health organization (who) africa region, the area most affected by the hiv/aids epidemic.
prep_in||unaware-9/JJ||france-2/NN	quantmod||40,000-5/CD||roughly-4/RB	num||persons-7/NNS||40,000-5/CD	amod||persons-7/NNS||hiv-infected-6/JJ	nsubj||unaware-9/JJ||persons-7/NNS	cop||unaware-9/JJ||are-8/VBP	root||ROOT-0/null||unaware-9/JJ	poss||hivinfection-12/NN||their-11/PRP$	prep_of||unaware-9/JJ||hivinfection-12/NN	hivinfection-12||hiv--1||no||in france, roughly 40,000 hiv-infected persons are unaware of their hivinfection.
advmod||diagnosed-3/JJ||newly-2/RB	amod||patients-4/NNS||diagnosed-3/JJ	prep_in||documented-31/VBN||patients-4/NNS	prep_with||patients-4/NNS||hodgkinlymphoma-6/NN	dep||documented-31/VBN||hl-8/VB	det||effect-11/NN||the-10/DT	nsubjpass||documented-31/VBN||effect-11/NN	prep_of||effect-11/NN||doxorubicin-13/NN	prep_of||effect-11/NN||bleomycin-15/NN	conj_and||doxorubicin-13/NN||bleomycin-15/NN	prep_of||effect-11/NN||vinblastine-17/NN	conj_and||doxorubicin-13/NN||vinblastine-17/NN	prep_of||effect-11/NN||dacarbazine-19/NN	conj_and||doxorubicin-13/NN||dacarbazine-19/NN	dep||doxorubicin-13/NN||abvd-21/VBN	amod||neutropenia-25/NN||related-24/VBN	dep||doxorubicin-13/NN||neutropenia-25/NN	amod||delivery-28/NN||chemotherapy-27/JJ	prep_on||neutropenia-25/NN||delivery-28/NN	auxpass||documented-31/VBN||is-29/VBZ	advmod||documented-31/VBN||poorly-30/RB	root||ROOT-0/null||documented-31/VBN	neutropenia-25||vinblastine-17||no||in newly diagnosed patients with hodgkinlymphoma (hl) the effect of doxorubicin, bleomycin, vinblastine and dacarbazine (abvd)-related neutropenia on chemotherapy delivery is poorly documented.
det||analysis-2/NN||the-1/DT	nsubj||included-3/VBD||analysis-2/NN	root||ROOT-0/null||included-3/VBD	num||studies-8/NNS||three-4/CD	amod||studies-8/NNS||randomized-5/JJ	amod||studies-8/NNS||double-blind-7/JJ	dobj||included-3/VBD||studies-8/NNS	prep_in||studies-8/NNS||patients-10/NNS	nn||schizoaffectivedisorder-14/NN||schizophrenia-12/NN	prep_with||patients-10/NNS||schizoaffectivedisorder-14/NN	nn||disorder-18/NN||schizophreniform-17/NN	prep_with||patients-10/NNS||disorder-18/NN	conj_or||schizoaffectivedisorder-14/NN||disorder-18/NN	dep||patients-10/NNS||diagnosed-19/VBN	prepc_according_to||diagnosed-19/VBN||to-21/TO	det||manual-26/NN||the-22/DT	amod||manual-26/NN||diagnostic-23/JJ	conj_and||diagnostic-23/JJ||statistical-25/JJ	amod||manual-26/NN||statistical-25/JJ	pobj||diagnosed-19/VBN||manual-26/NN	amod||disorders-29/NNS||mental-28/JJ	npadvmod||4th-30/JJ||disorders-29/NNS	amod||edition-31/NN||4th-30/JJ	prep_of||manual-26/NN||edition-31/NN	advmod||assigned-34/VBN||randomly-33/RB	dep||patients-10/NNS||assigned-34/VBN	conj_and||diagnosed-19/VBN||assigned-34/VBN	prep_to||assigned-34/VBN||treatment-36/NN	poss||mg/day-43/NN||olanzapine-38/PRP$	amod||mg/day-43/NN||5â-39/JJ	amod||mg/day-43/NN||$-40/$	num||$-40/$||20-42/CD	prep_with||assigned-34/VBN||mg/day-43/NN	det||antipsychotic-46/NN||another-45/DT	prep_with||assigned-34/VBN||antipsychotic-46/NN	conj_or||mg/day-43/NN||antipsychotic-46/NN	amod||2â-49/NNS||haloperidol-48/JJ	dep||antipsychotic-46/NN||2â-49/NNS	num||mg/day-53/NN||$-50/$	num||$-50/$||20-52/CD	dep||2â-49/NNS||mg/day-53/NN	poss||mg/day-60/NN||risperidone-55/PRP$	amod||mg/day-60/NN||2â-56/JJ	amod||mg/day-60/NN||$-57/$	num||$-57/$||10-59/CD	dep||2â-49/NNS||mg/day-60/NN	conj_or||mg/day-53/NN||mg/day-60/NN	poss||mg/day-68/NN||ziprasidone-63/PRP$	amod||mg/day-68/NN||80â-64/JJ	amod||mg/day-68/NN||$-65/$	num||$-65/$||160-67/CD	dep||2â-49/NNS||mg/day-68/NN	conj_or||mg/day-53/NN||mg/day-68/NN	schizophrenia-12||olanzapine-38||yes||the analysis included three randomized, double-blind studies in patients with schizophrenia, schizoaffectivedisorder, or schizophreniform disorder diagnosed according to the diagnostic and statistical manual of mental disorders 4th edition and randomly assigned to treatment with olanzapine 5â20 mg/day or another antipsychotic (haloperidol 2â20 mg/day, risperidone 2â10 mg/day, or ziprasidone 80â160 mg/day).
det||study-2/NN||this-1/DT	nsubjpass||conducted-4/VBN||study-2/NN	nsubj||evaluate-6/VB||study-2/NN	auxpass||conducted-4/VBN||was-3/VBD	root||ROOT-0/null||conducted-4/VBN	aux||evaluate-6/VB||to-5/TO	xcomp||conducted-4/VBN||evaluate-6/VB	det||safety-9/NN||the-7/DT	amod||safety-9/NN||long-term-8/JJ	dobj||evaluate-6/VB||safety-9/NN	amod||inhaler-18/NN||mometasonefuroate/formoterol-11/JJ	appos||inhaler-18/NN||mf/f-13/NN	amod||inhaler-18/NN||administered-15/VBN	prep_through||administered-15/VBN||metered-dose-17/NN	prep_of||safety-9/NN||inhaler-18/NN	appos||inhaler-18/NN||mdi-20/NN	prep_in||evaluate-6/VB||patients-23/NNS	amod||asthma-26/NN||persistent-25/JJ	prep_with||evaluate-6/VB||asthma-26/NN	advmod||asthma-26/NN||previously-27/RB	prep_on||asthma-26/NN||medium-29/NN	amod||ics-33/NN||high-dose-32/JJ	prep_to||asthma-26/NN||ics-33/NN	asthma-26||formoterol--1||no||this study was conducted to evaluate the long-term safety of mometasonefuroate/formoterol (mf/f) administered through metered-dose inhaler (mdi) in patients with persistent asthma previously on medium- to high-dose ics.
prep_in||showed-8/VBD||2011-2/CD	det||tomography-7/NN||the-4/DT	amod||tomography-7/NN||fluoro-deoxy-glucose-positron-5/JJ	nn||tomography-7/NN||emission-6/NN	nsubj||showed-8/VBD||tomography-7/NN	root||ROOT-0/null||showed-8/VBD	det||absence-11/NN||a-9/DT	amod||absence-11/NN||total-10/JJ	nsubj||related-23/VBN||absence-11/NN	amod||activity-15/NN||parasitic-13/JJ	amod||activity-15/NN||metabolic-14/JJ	prep_of||absence-11/NN||activity-15/NN	det||patient-18/NN||the-17/DT	prep_of||absence-11/NN||patient-18/NN	conj_and||activity-15/NN||patient-18/NN	aux||related-23/VBN||had-19/VBD	advmod||related-23/VBN||no-20/RB	amod||symptoms-22/NNS||clinical-21/JJ	pobj||no-20/RB||symptoms-22/NNS	ccomp||showed-8/VBD||related-23/VBN	nn||echinococcosis-26/NNS||alveolar-25/NN	prep_to||related-23/VBN||echinococcosis-26/NNS	echinococcosis-26||glucose--1||no_rel||in 2011, the fluoro-deoxy-glucose-positron emission tomography showed a total absence of parasitic metabolic activity and the patient had no clinical symptoms related to alveolar echinococcosis.
amod||artesunate-2/NN||monthly-1/JJ	nsubj||reduced-5/VBD||artesunate-2/NN	prep||artesunate-2/NN||plus-3/CC	pobj||plus-3/CC||amodiaquine-4/NN	root||ROOT-0/null||reduced-5/VBD	det||incidence-7/NN||the-6/DT	dobj||reduced-5/VBD||incidence-7/NN	prep_of||incidence-7/NN||malaria-9/NN	num||%-12/NN||69-11/CD	prep_by||reduced-5/VBD||%-12/NN	number||%-15/NN||95-14/CD	amod||ci-16/NN||%-15/NN	dep||%-12/NN||ci-16/NN	number||%-18/NN||63-17/CD	amod||ci-16/NN||%-18/NN	num||%-21/NN||74-20/CD	appos||ci-16/NN||%-21/NN	prep_by||reduced-5/VBD||anaemia-24/NN	conj_and||%-12/NN||anaemia-24/NN	num||%-27/NN||45-26/CD	prep_by||reduced-5/VBD||%-27/NN	number||%-30/NN||95-29/CD	amod||ci-31/NN||%-30/NN	dep||%-27/NN||ci-31/NN	number||%-33/NN||25-32/CD	amod||ci-31/NN||%-33/NN	num||%-35/NN||,60-34/CD	dep||ci-31/NN||%-35/NN	amod||sulphadoxine-pyrimethamine-39/NN||bimonthly-38/JJ	nsubj||reduced-40/VBD||sulphadoxine-pyrimethamine-39/NN	conj_and||reduced-5/VBD||reduced-40/VBD	det||incidence-42/NN||the-41/DT	dobj||reduced-40/VBD||incidence-42/NN	prep_of||incidence-42/NN||malaria-44/NN	num||%-47/NN||24-46/CD	prep_by||reduced-40/VBD||%-47/NN	number||%-50/NN||95-49/CD	amod||ci-51/NN||%-50/NN	dep||%-47/NN||ci-51/NN	number||%-53/NN||14-52/CD	amod||ci-51/NN||%-53/NN	num||%-55/NN||,33-54/CD	dep||ci-51/NN||%-55/NN	prep_by||reduced-40/VBD||anaemia-58/NN	conj_and||%-47/NN||anaemia-58/NN	num||%-61/NN||30-60/CD	prep_by||reduced-40/VBD||%-61/NN	number||%-64/NN||95-63/CD	amod||ci-65/NN||%-64/NN	dep||%-61/NN||ci-65/NN	number||%-67/NN||6-66/CD	amod||ci-65/NN||%-67/NN	num||%-70/NN||49-69/CD	appos||ci-65/NN||%-70/NN	amod||artesunate-74/NN||bimonthly-73/JJ	nsubj||reduced-77/VBD||artesunate-74/NN	prep||artesunate-74/NN||plus-75/CC	pobj||plus-75/CC||amodiaquine-76/NN	conj_and||reduced-5/VBD||reduced-77/VBD	det||incidence-79/NN||the-78/DT	dobj||reduced-77/VBD||incidence-79/NN	prep_of||incidence-79/NN||malaria-81/NN	num||%-84/NN||17-83/CD	prep_by||reduced-77/VBD||%-84/NN	number||%-87/NN||95-86/CD	amod||ci-88/NN||%-87/NN	dep||%-84/NN||ci-88/NN	number||%-90/NN||6-89/CD	amod||ci-88/NN||%-90/NN	num||%-93/NN||27-92/CD	appos||ci-88/NN||%-93/NN	prep_by||reduced-77/VBD||anaemia-96/NN	conj_and||%-84/NN||anaemia-96/NN	num||%-99/NN||32-98/CD	prep_by||reduced-77/VBD||%-99/NN	number||%-102/NN||95-101/CD	amod||ci-103/NN||%-102/NN	dep||%-99/NN||ci-103/NN	number||%-105/NN||7-104/CD	amod||ci-103/NN||%-105/NN	num||%-108/NN||50-107/CD	appos||ci-103/NN||%-108/NN	prepc_compared_to||reduced-77/VBD||to-111/TO	pobj||reduced-77/VBD||placebo-112/NN	malaria-81||pyrimethamine--1||yes||monthly artesunate plus amodiaquine reduced the incidence of malaria by 69% (95% ci 63%, 74%) and anaemia by 45% (95% ci 25%,60%), bimonthly sulphadoxine-pyrimethamine reduced the incidence of malaria by 24% (95% ci 14%,33%) and anaemia by 30% (95% ci 6%, 49%) and bimonthly artesunate plus amodiaquine reduced the incidence of malaria by 17% (95% ci 6%, 27%) and anaemia by 32% (95% ci 7%, 50%) compared to placebo.
nn||stover-2/NN||corn-1/NN	nsubj||pretreated-7/VBN||stover-2/NN	nsubj||digested-11/VBN||stover-2/NN	conj_and||stover-2/NN||switchgrass-4/NNS	nsubj||pretreated-7/VBN||switchgrass-4/NNS	conj_and||stover-2/NN||ddgs-6/NNS	nsubj||pretreated-7/VBN||ddgs-6/NNS	root||ROOT-0/null||pretreated-7/VBN	prep_with||pretreated-7/VBN||afex-9/NN	conj_and||pretreated-7/VBN||digested-11/VBN	det||set-15/NN||the-13/DT	amod||set-15/NN||core-14/JJ	prep_with||digested-11/VBN||set-15/NN	vmod||set-15/NN||required-16/VBN	det||proportion-19/NN||a-17/DT	amod||proportion-19/NN||higher-18/JJR	dobj||required-16/VBN||proportion-19/NN	num||ex3-25/NNS||endo-î-21/CD	nn||ex3-25/NNS||²-22/NNP	amod||ex3-25/NNS||1,4-xylanase-23/JJ	prep_of||proportion-19/NN||ex3-25/NNS	det||proportion-30/NN||a-28/DT	amod||proportion-30/NN||lower-29/JJR	prep_of||proportion-19/NN||proportion-30/NN	conj_and||ex3-25/NNS||proportion-30/NN	num||eg1-36/NNS||endo-î-32/CD	nn||eg1-36/NNS||²-33/NNP	amod||eg1-36/NNS||1,4-glucanase-34/JJ	prep_of||proportion-30/NN||eg1-36/NNS	prepc_compared_to||eg1-36/NNS||to-39/TO	det||materials-42/NNS||the-40/DT	amod||materials-42/NNS||same-41/JJ	pobj||eg1-36/NNS||materials-42/NNS	vmod||materials-42/NNS||pretreated-43/VBN	amod||base-46/NN||dilute-45/JJ	prep_with||pretreated-43/VBN||base-46/NN	prep_with||pretreated-43/VBN||ap-48/NN	conj_or||base-46/NN||ap-48/NN	base-46||endo--1||no_rel||corn stover, switchgrass and ddgs pretreated with afex and digested with the core set required a higher proportion of endo-î²1,4-xylanase (ex3) and a lower proportion of endo-î²1,4-glucanase (eg1) compared to the same materials pretreated with dilute base or ap.
det||aim-2/NN||the-1/DT	nsubj||is-6/VBZ||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	det||paper-5/NN||this-4/DT	prep_of||aim-2/NN||paper-5/NN	root||ROOT-0/null||is-6/VBZ	aux||evaluate-8/VB||to-7/TO	xcomp||is-6/VBZ||evaluate-8/VB	det||effect-10/NN||the-9/DT	dobj||evaluate-8/VB||effect-10/NN	prep_of||effect-10/NN||antipsychotics-12/NNS	det||treatment-15/NN||the-14/DT	prep_for||antipsychotics-12/NNS||treatment-15/NN	prep_of||treatment-15/NN||schizophrenia-17/NN	det||community-20/NN||a-19/DT	prep_in||evaluate-8/VB||community-20/NN	vmod||community-20/NN||based-21/VBN	dobj||based-21/VBN||study-22/NN	amod||function-25/NN||sexual-24/JJ	prep_on||based-21/VBN||function-25/NN	nn||levels-28/NNS||prolactin-27/NN	prep_on||based-21/VBN||levels-28/NNS	conj_and||function-25/NN||levels-28/NNS	vmod||function-25/NN||comparing-29/VBG	det||use-31/NN||the-30/DT	dobj||comparing-29/VBG||use-31/NN	prep_of||use-31/NN||aripiprazole-33/NN	prep_of||use-31/NN||standard-35/NN	conj_and||aripiprazole-33/NN||standard-35/NN	prep_of||use-31/NN||care-37/NN	nsubj||choice-46/NN||care-37/NN	appos||care-37/NN||soc-39/NN	cop||choice-46/NN||was-43/VBD	det||choice-46/NN||a-44/DT	amod||choice-46/NN||limited-45/JJ	rcmod||care-37/NN||choice-46/NN	num||antipsychotics-53/NNS||three-48/CD	advmod||used-50/JJ||widely-49/RB	amod||antipsychotics-53/NNS||used-50/JJ	conj_and||used-50/JJ||available-52/JJ	amod||antipsychotics-53/NNS||available-52/JJ	prep_of||choice-46/NN||antipsychotics-53/NNS	dep||antipsychotics-53/NNS||olanzapine-55/NN	dep||olanzapine-55/NN||quetiapine-57/JJ	dep||olanzapine-55/NN||risperidone-59/JJ	conj_or||quetiapine-57/JJ||risperidone-59/JJ	det||trial-64/NN||the-62/DT	nn||trial-64/NN||schizophrenia-63/NN	dep||antipsychotics-53/NNS||trial-64/NN	amod||-RSB--73/NNS||aripiprazole-66/JJ	nn||-RSB--73/NNS||-LSB--67/NNP	nn||-RSB--73/NNS||star-68/NN	nn||-RSB--73/NNS||-RSB--69/NN	nn||-RSB--73/NNS||study-70/NN	nn||-RSB--73/NNS||-LSB--71/NN	amod||-RSB--73/NNS||nct00237913-72/JJ	prep_of||trial-64/NN||-RSB--73/NNS	schizophrenia-63||olanzapine-55||yes||the aim of this paper is to evaluate the effect of antipsychotics for the treatment of schizophrenia in a community based study on sexual function and prolactin levels comparing the use of aripiprazole and standard of care (soc), which was a limited choice of three widely used and available antipsychotics (olanzapine, quetiapine or risperidone) (the schizophrenia trial of aripiprazole [star] study [nct00237913]).
prep_in||reconsidered-48/JJ||light-2/NN	prep_of||light-2/NN||reports-4/NNS	mark||induce-9/VB||that-5/IN	det||cd28-7/NNS||these-6/DT	nsubj||induce-9/VB||cd28-7/NNS	nsubj||â-13/VB||cd28-7/NNS	aux||induce-9/VB||abs-8/MD	dep||reports-4/NNS||induce-9/VB	amod||tregs-11/NNS||immunosuppressive-10/JJ	dobj||induce-9/VB||tregs-11/NNS	dep||reports-4/NNS||â-13/VB	conj_and||induce-9/VB||â-13/VB	dobj||â-13/VB||$-14/$	mark||show-19/VBP||as-16/IN	poss||data-18/NNS||our-17/PRP$	nsubj||show-19/VBP||data-18/NNS	advcl||â-13/VB||show-19/VBP	advmod||show-19/VBP||â-20/RB	dep||show-19/VBP||$-21/VB	mark||inhibitors-26/NNS||that-23/IN	nsubj||inhibitors-26/NNS||they-24/PRP	cop||inhibitors-26/NNS||are-25/VBP	ccomp||$-21/VB||inhibitors-26/NNS	amod||stimulation-31/NN||cd28-28/JJ	nn||stimulation-31/NN||receptor-29/NN	nn||stimulation-31/NN||mediated-30/NN	prep_of||inhibitors-26/NNS||stimulation-31/NN	det||continuation-34/NN||the-33/DT	nsubj||reconsidered-48/JJ||continuation-34/NN	prep_of||continuation-34/NN||therapies-36/NNS	prep_with||therapies-36/NNS||interferons-38/NNS	nn||patients-41/NNS||melanoma-40/NN	prep_in||interferons-38/NNS||patients-41/NNS	vmod||patients-41/NNS||developing-42/VBG	amod||antibodies-44/NNS||cd28-43/JJ	dobj||developing-42/VBG||antibodies-44/NNS	aux||reconsidered-48/JJ||should-45/MD	cop||reconsidered-48/JJ||be-46/VB	advmod||reconsidered-48/JJ||critically-47/RB	root||ROOT-0/null||reconsidered-48/JJ	mark||indicate-53/VBP||since-50/IN	poss||data-52/NNS||our-51/PRP$	nsubj||indicate-53/VBP||data-52/NNS	advcl||reconsidered-48/JJ||indicate-53/VBP	det||outcome-56/NN||a-54/DT	amod||outcome-56/NN||worse-55/JJR	dobj||indicate-53/VBP||outcome-56/NN	prep_of||outcome-56/NN||patients-58/NNS	amod||abs-61/NN||cd28-60/JJ	prep_with||patients-58/NNS||abs-61/NN	melanoma-40||interferons-38||yes||in light of reports that these cd28 abs induce immunosuppressive tregs and â as our data show â that they are inhibitors of cd28 receptor mediated stimulation, the continuation of therapies with interferons in melanoma patients developing cd28 antibodies should be critically reconsidered, since our data indicate a worse outcome of patients with cd28 abs.
nsubj||estimated-3/VBN||we-1/PRP	nsubj||prevent-65/VB||we-1/PRP	aux||estimated-3/VBN||have-2/VBP	root||ROOT-0/null||estimated-3/VBN	mark||have-8/VB||that-4/IN	amod||prophylaxis-6/NNS||lidocaine-5/JJ	nsubj||have-8/VB||prophylaxis-6/NNS	nsubjpass||given-11/VBN||prophylaxis-6/NNS	aux||have-8/VB||would-7/MD	ccomp||estimated-3/VBN||have-8/VB	aux||given-11/VBN||to-9/TO	auxpass||given-11/VBN||be-10/VB	xcomp||have-8/VB||given-11/VBN	quantmod||12-14/CD||about-13/RB	num||patients-15/NNS||12-14/CD	prep_to||given-11/VBN||patients-15/NNS	det||group-20/NN||the-17/DT	amod||group-20/NN||highest-18/JJS	nn||group-20/NN||risk-19/NN	prep_in||given-11/VBN||group-20/NN	dep||group-20/NN||patients-22/NNS	dep||group-20/NN||patients-22/NNS	conj_and||patients-22/NNS||patients-22/NNS	prep_under||patients-22/NNS||age-24/NN	num||age-24/NN||50-25/CD	num||hours-29/NNS||six-28/CD	prep_within||patients-22/NNS||hours-29/NNS	det||onset-32/NN||the-31/DT	prep_of||hours-29/NNS||onset-32/NN	prep_of||onset-32/NN||symptoms-34/NNS	prepc_compared_to||given-11/VBN||to-38/TO	quantmod||400-40/CD||about-39/RB	num||patients-41/NNS||400-40/CD	pobj||given-11/VBN||patients-41/NNS	det||group-46/NN||the-43/DT	amod||group-46/NN||lowest-44/JJS	nn||group-46/NN||risk-45/NN	prep_in||patients-41/NNS||group-46/NN	dep||group-46/NN||patients-48/NNS	prep_above||patients-48/NNS||age-50/NN	num||age-50/NN||70-51/CD	mwe||than-54/IN||more-53/JJR	quantmod||24-55/CD||than-54/IN	num||hours-56/NNS||24-55/CD	dep||group-46/NN||hours-56/NNS	conj_and||patients-48/NNS||hours-56/NNS	det||onset-59/NN||the-58/DT	prep_since||hours-56/NNS||onset-59/NN	prep_of||onset-59/NN||symptoms-61/NNS	aux||prevent-65/VB||to-64/TO	xcomp||estimated-3/VBN||prevent-65/VB	num||episode-67/NN||one-66/CD	dobj||prevent-65/VB||episode-67/NN	amod||ventricularfibrillation-70/NN||primary-69/JJ	prep_of||episode-67/NN||ventricularfibrillation-70/NN	det||group-73/NN||each-72/DT	prep_in||prevent-65/VB||group-73/NN	ventricularfibrillation-70||lidocaine-5||yes||we have estimated that lidocaine prophylaxis would have to be given to about 12 patients in the highest risk group (patients under age 50 and within six hours of the onset of symptoms), compared to about 400 patients in the lowest risk group (patients above age 70 and more than 24 hours since the onset of symptoms), to prevent one episode of primary ventricularfibrillation in each group.
nsubj||treatment-10/NN||chloroquine-1/NNP	conj_plus||chloroquine-1/NNP||primaqine-3/NNP	nsubj||treatment-10/NN||primaqine-3/NNP	cop||treatment-10/NN||is-4/VBZ	det||treatment-10/NN||an-5/DT	amod||treatment-10/NN||inexpensive-6/JJ	advmod||effective-9/JJ||highly-8/RB	conj_and||inexpensive-6/JJ||effective-9/JJ	amod||treatment-10/NN||effective-9/JJ	root||ROOT-0/null||treatment-10/NN	amod||infections-15/NNS||uncomplicated-12/JJ	amod||infections-15/NNS||knowlesi-13/JJ	nn||infections-15/NNS||malaria-14/NN	prep_for||treatment-10/NN||infections-15/NNS	prep_in||infections-15/NNS||humans-17/NNS	expl||is-20/VBZ||there-19/EX	conj_and||treatment-10/NN||is-20/VBZ	neg||evidence-22/NN||no-21/DT	nsubj||is-20/VBZ||evidence-22/NN	nn||resistance-25/NN||drug-24/NN	prep_of||evidence-22/NN||resistance-25/NN	malaria-14||chloroquine-1||yes||chloroquine plus primaqine is an inexpensive and highly effective treatment for uncomplicated knowlesi malaria infections in humans and there is no evidence of drug resistance.
aux||maximize-2/VB||to-1/TO	root||ROOT-0/null||maximize-2/VB	amod||use-4/NN||effective-3/JJ	dobj||maximize-2/VB||use-4/NN	amod||drugs-7/NNS||mydriatic-6/JJ	prep_of||use-4/NN||drugs-7/NNS	prepc_through||maximize-2/VB||comparing-9/VBG	det||effects-12/NNS||the-10/DT	nn||effects-12/NNS||pupillarydilation-11/NN	dobj||comparing-9/VBG||effects-12/NNS	number||%-15/NN||1-14/CD	amod||tropicamide-16/NN||%-15/NN	prep_between||effects-12/NNS||tropicamide-16/NN	number||%-19/NN||2.5-18/CD	amod||phenylephrine-20/NN||%-19/NN	prep_between||effects-12/NNS||phenylephrine-20/NN	conj_and||tropicamide-16/NN||phenylephrine-20/NN	pupillarydilation-11||tropicamide-16||no||to maximize effective use of mydriatic drugs through comparing the pupillarydilation effects between 1% tropicamide and 2.5% phenylephrine.
nn||depletion-2/NN||iron-1/NN	nsubjpass||evaluated-16/VBN||depletion-2/NN	appos||depletion-2/NN||lack-4/NN	nn||stores-7/NNS||iron-6/NN	prep_of||lack-4/NN||stores-7/NNS	advmod||evaluated-16/VBN||irondeficiency-9/RB	amod||anemia-12/NN||irondeficiency-11/JJ	nsubjpass||evaluated-16/VBN||anemia-12/NN	conj_and||anemia-12/NN||anemia-14/NN	nsubjpass||evaluated-16/VBN||anemia-14/NN	auxpass||evaluated-16/VBN||were-15/VBD	root||ROOT-0/null||evaluated-16/VBN	prep_among||evaluated-16/VBN||them-18/PRP	irondeficiency-11||iron-6||yes||iron depletion, lack of iron stores, irondeficiency, irondeficiency anemia and anemia were evaluated among them.
aux||investigate-2/VB||to-1/TO	root||ROOT-0/null||investigate-2/VB	det||effects-4/NNS||the-3/DT	dobj||investigate-2/VB||effects-4/NNS	amod||intraperitoneal-7/JJ||continuous-6/JJ	amod||infusion-9/NN||intraperitoneal-7/JJ	nn||infusion-9/NN||insulin-8/NN	prep_of||effects-4/NNS||infusion-9/NN	appos||infusion-9/NN||cipii-11/NNP	prepc_compared_with||investigate-2/VB||with-14/IN	amod||insulin-16/NN||subcutaneous-15/JJ	pobj||investigate-2/VB||insulin-16/NN	amod||quality-19/NN||health-related-18/JJ	prep_on||insulin-16/NN||quality-19/NN	prep_of||quality-19/NN||life-21/NN	dep||life-21/NN||hrqol-23/JJ	nn||satisfaction-27/NN||treatment-26/NN	prep_of||quality-19/NN||satisfaction-27/NN	conj_and||life-21/NN||satisfaction-27/NN	aux||perform-31/VB||to-30/TO	conj_and||investigate-2/VB||perform-31/VB	det||analysis-34/NN||a-32/DT	nn||analysis-34/NN||cost-33/NN	dobj||perform-31/VB||analysis-34/NN	prep_in||perform-31/VB||type1diabetes-36/CD	type1diabetes-36||insulin-16||yes||to investigate the effects of continuous intraperitoneal insulin infusion (cipii) compared with subcutaneous insulin on health-related quality of life (hrqol) and treatment satisfaction, and to perform a cost analysis in type1diabetes.
amod||treatment-3/NN||titrated-1/JJ	nn||treatment-3/NN||oxygen-2/NN	nsubj||reduced-4/VBD||treatment-3/NN	root||ROOT-0/null||reduced-4/VBD	dobj||reduced-4/VBD||mortality-5/NN	prepc_compared_with||reduced-4/VBD||with-7/IN	amod||oxygen-10/NN||high-8/JJ	nn||oxygen-10/NN||flow-9/NN	pobj||reduced-4/VBD||oxygen-10/NN	num||%-13/NN||58-12/CD	prep_by||oxygen-10/NN||%-13/NN	det||patients-16/NNS||all-15/DT	prep_for||%-13/NN||patients-16/NNS	amod||risk-19/NN||relative-18/JJ	dep||patients-16/NNS||risk-19/NN	num||0.20-26/NNS||0.42-20/CD	num||0.20-26/NNS||95-22/CD	nn||0.20-26/NNS||%-23/NN	nn||0.20-26/NNS||confidence-24/NN	amod||0.20-26/NNS||interval-25/JJ	dep||risk-19/NN||0.20-26/NNS	prep_to||0.20-26/NNS||0.89-28/NNP	dep||0.20-26/NNS||p-30/NN	dep||0.02-32/CD||=-31/SYM	rcmod||p-30/NN||0.02-32/CD	num||%-37/NN||78-36/CD	prep_by||oxygen-10/NN||%-37/NN	conj_and||%-13/NN||%-37/NN	det||patients-40/NNS||the-39/DT	prep_for||%-37/NN||patients-40/NNS	amod||obstructivepulmonarydisease-44/NN||confirmed-42/JJ	amod||obstructivepulmonarydisease-44/NN||chronic-43/JJ	prep_with||patients-40/NNS||obstructivepulmonarydisease-44/NN	dep||obstructivepulmonarydisease-44/NN||0.22-46/CD	appos||0.22-46/CD||0.05-48/CD	prep_to||0.05-48/CD||0.91-50/CD	dep||0.05-48/CD||p-52/NN	dep||0.04-54/CD||=-53/SYM	rcmod||p-52/NN||0.04-54/CD	obstructivepulmonarydisease-44||oxygen-10||yes||titrated oxygen treatment reduced mortality compared with high flow oxygen by 58% for all patients (relative risk 0.42, 95% confidence interval 0.20 to 0.89; p=0.02) and by 78% for the patients with confirmed chronic obstructivepulmonarydisease (0.22, 0.05 to 0.91; p=0.04).
nsubj||aimed-2/VBD||we-1/PRP	nsubj||describe-4/VB||we-1/PRP	nsubj||define-17/VB||we-1/PRP	root||ROOT-0/null||aimed-2/VBD	aux||describe-4/VB||to-3/TO	xcomp||aimed-2/VBD||describe-4/VB	det||features-7/NNS||the-5/DT	amod||features-7/NNS||radiological-6/JJ	dobj||describe-4/VB||features-7/NNS	prep_of||features-7/NNS||patients-9/NNS	vmod||patients-9/NNS||exposed-10/VBN	prep_to||exposed-10/VBN||silica-12/NN	nn||sandblasting-15/NN||denim-14/NN	prep_during||exposed-10/VBN||sandblasting-15/NN	xcomp||aimed-2/VBD||define-17/VB	conj_and||describe-4/VB||define-17/VB	nsubj||related-19/VBN||factors-18/NNS	xcomp||define-17/VB||related-19/VBN	det||development-22/NN||the-21/DT	prep_to||related-19/VBN||development-22/NN	prep_of||development-22/NN||silicosis-24/NNS	silicosis-24||silica-12||no||we aimed to describe the radiological features of patients exposed to silica during denim sandblasting and define factors related to the development of silicosis.
expl||were-2/VBD||there-1/EX	root||ROOT-0/null||were-2/VBD	amod||decreases-4/NNS||significant-3/JJ	nsubj||were-2/VBD||decreases-4/NNS	prep_in||decreases-4/NNS||survival-6/NN	nn||output-9/NN||urine-8/NN	prep_in||decreases-4/NNS||output-9/NN	conj_and||survival-6/NN||output-9/NN	amod||output-12/NN||cardiac-11/JJ	prep_in||decreases-4/NNS||output-12/NN	conj_and||survival-6/NN||output-12/NN	nn||delivery-15/NN||oxygen-14/NN	conj_and||survival-6/NN||delivery-15/NN	conj_and||output-12/NN||delivery-15/NN	amod||min-18/NN||60â-17/JJ	prep_at||output-12/NN||min-18/NN	amod||consumption-21/NN||o2-20/JJ	prep_in||decreases-4/NNS||consumption-21/NN	conj_and||survival-6/NN||consumption-21/NN	amod||min-24/NN||120â-23/JJ	prep_at||consumption-21/NN||min-24/NN	det||group-28/NN||the-26/DT	nn||group-28/NN||pneumonia-27/NN	prep_in||min-24/NN||group-28/NN	prepc_compared_to||group-28/NN||to-30/TO	det||group-35/NN||the-31/DT	amod||group-35/NN||nonâ-32/JJ	amod||group-35/NN||$-33/$	number||$-33/$||pneumonia-34/CD	pobj||group-28/NN||group-35/NN	pneumonia-34||oxygen-14||yes||there were significant decreases in survival, urine output, cardiac output and oxygen delivery at 60â min and o2 consumption at 120â min in the pneumonia group compared to the nonâ?pneumonia group.
det||basis-3/NN||the-2/DT	prep_on||updated-62/VBN||basis-3/NN	det||results-8/NNS||the-5/DT	advmod||published-7/VBN||recently-6/RB	amod||results-8/NNS||published-7/VBN	prep_of||basis-3/NN||results-8/NNS	det||trial-12/NN||a-10/DT	amod||trial-12/NN||clinical-11/JJ	prep_of||results-8/NNS||trial-12/NN	vmod||trial-12/NN||comparing-13/VBG	nn||months-17/NNS||12-14/CD	conj_and||12-14/CD||36â-16/CD	nn||months-17/NNS||36â-16/CD	dobj||comparing-13/VBG||months-17/NNS	prep_of||months-17/NNS||imatinib-19/NN	amod||therapy-22/NN||adjuvant-21/JJ	prep_in||comparing-13/VBG||therapy-22/NN	amod||tumors-26/NNS||gastrointestinal-24/JJ	amod||tumors-26/NNS||stromal-25/JJ	prep_for||therapy-22/NN||tumors-26/NNS	nsubj||demonstrated-32/VBD||tumors-26/NNS	appos||tumors-26/NNS||gists-28/NNS	rcmod||tumors-26/NNS||demonstrated-32/VBD	amod||benefit-34/NN||clinical-33/JJ	dobj||demonstrated-32/VBD||benefit-34/NN	amod||treatment-38/NN||longer-36/JJR	nn||treatment-38/NN||imatinib-37/NN	prep_of||benefit-34/NN||treatment-38/NN	prep_in||treatment-38/NN||terms-40/NNS	prepc_of||terms-40/NNS||delaying-42/VBG	dobj||delaying-42/VBG||recurrences-43/NNS	prepc_of||terms-40/NNS||improving-45/VBG	conj_and||delaying-42/VBG||improving-45/VBG	amod||survival-47/NN||overall-46/JJ	dobj||improving-45/VBG||survival-47/NN	dep||survival-47/NN||both-49/CC	det||us-51/PRP||the-50/DT	conj||survival-47/NN||us-51/PRP	nn||administration-55/NN||food-52/NN	conj_and||food-52/NN||drug-54/NN	nn||administration-55/NN||drug-54/NN	nsubj||updated-62/VBN||administration-55/NN	nsubj||approved-66/VBN||administration-55/NN	det||agency-60/NN||the-57/DT	nn||agency-60/NN||european-58/NN	nn||agency-60/NN||medicines-59/NNS	conj_and||administration-55/NN||agency-60/NN	nsubj||updated-62/VBN||agency-60/NN	aux||updated-62/VBN||have-61/VBP	root||ROOT-0/null||updated-62/VBN	poss||recommendations-64/NNS||their-63/PRP$	dobj||updated-62/VBN||recommendations-64/NNS	conj_and||updated-62/VBN||approved-66/VBN	amod||months-68/NNS||36â-67/JJ	dobj||approved-66/VBN||months-68/NNS	amod||treatment-71/NN||imatinib-70/JJ	prep_of||months-68/NNS||treatment-71/NN	prep_in||approved-66/VBN||patients-73/NNS	amod||homolog-82/NN||v-kit-75/JJ	amod||homolog-82/NN||hardy-zuckerman-76/JJ	dep||hardy-zuckerman-76/JJ||4-77/CD	nn||homolog-82/NN||feline-78/NN	nn||homolog-82/NN||sarcoma-79/NN	amod||homolog-82/NN||viral-80/JJ	nn||homolog-82/NN||oncogene-81/NN	prep_with||patients-73/NNS||homolog-82/NN	appos||homolog-82/NN||kit-84/NN	amod||gists-88/NNS||positive-87/JJ	parataxis||approved-66/VBN||gists-88/NNS	advmod||known-91/VBN||also-90/RB	dep||gists-88/NNS||known-91/VBN	amod||gists-94/NNS||cd117-positive-93/JJ	prep_as||known-91/VBN||gists-94/NNS	amod||risk-98/NN||high-97/JJ	prep_at||gists-88/NNS||risk-98/NN	prep_of||risk-98/NN||recurrence-100/NN	amod||resection-103/NN||surgical-102/JJ	prep_after||updated-62/VBN||resection-103/NN	det||tumor-107/NN||a-105/DT	amod||tumor-107/NN||primary-106/JJ	prep_of||resection-103/NN||tumor-107/NN	tumor-107||adjuvant-21||no_rel||on the basis of the recently published results of a clinical trial comparing 12 and 36â months of imatinib in adjuvant therapy for gastrointestinal stromal tumors (gists), which demonstrated clinical benefit of longer imatinib treatment in terms of delaying recurrences and improving overall survival, both the us food and drug administration and the european medicines agency have updated their recommendations and approved 36â months of imatinib treatment in patients with v-kit hardy-zuckerman 4 feline sarcoma viral oncogene homolog (kit)-positive gists (also known as cd117-positive gists) at high risk of recurrence after surgical resection of a primary tumor.
nsubjpass||associated-4/VBN||fatigue-1/NN	auxpass||associated-4/VBN||was-2/VBD	neg||associated-4/VBN||not-3/RB	root||ROOT-0/null||associated-4/VBN	prep_with||associated-4/VBN||symptoms-6/NNS	prep_of||symptoms-6/NNS||depression-8/NN	nn||quality-11/NN||sleep-10/NN	prep_of||symptoms-6/NNS||quality-11/NN	conj_or||depression-8/NN||quality-11/NN	prep_of||symptoms-6/NNS||gender-13/NN	conj_or||depression-8/NN||gender-13/NN	amod||use-17/NN||supplemental-15/JJ	nn||use-17/NN||oxygen-16/NN	prep_of||symptoms-6/NNS||use-17/NN	conj_or||depression-8/NN||use-17/NN	nn||status-20/NN||smoking-19/NN	prep_of||symptoms-6/NNS||status-20/NN	conj_or||depression-8/NN||status-20/NN	amod||scores-27/NNS||medical-23/JJ	nn||scores-27/NNS||research-24/NN	nn||scores-27/NNS||council-25/NN	nn||scores-27/NNS||dyspnea-26/NN	prep_of||symptoms-6/NNS||scores-27/NNS	conj_or||depression-8/NN||scores-27/NNS	oxygen-16||dyspnea-26||no_rel||fatigue was not associated with symptoms of depression, sleep quality, gender, supplemental oxygen use, smoking status, or medical research council dyspnea scores.
nsubj||active-9/JJ||combinations-1/NNS	prep_of||combinations-1/NNS||capecitabine-3/NN	det||taxane-6/NN||a-5/DT	prep_of||combinations-1/NNS||taxane-6/NN	conj_and||capecitabine-3/NN||taxane-6/NN	cop||active-9/JJ||are-7/VBP	advmod||active-9/JJ||highly-8/RB	root||ROOT-0/null||active-9/JJ	amod||cancer-13/NN||metastatic-11/JJ	nn||cancer-13/NN||breast-12/NN	prep_in||active-9/JJ||cancer-13/NN	nsubjpass||demonstrated-24/VBN||synergy-16/NN	prep_between||synergy-16/NN||capecitabine-18/NN	prep_between||synergy-16/NN||docetaxel-20/NN	conj_and||capecitabine-18/NN||docetaxel-20/NN	aux||demonstrated-24/VBN||has-21/VBZ	advmod||demonstrated-24/VBN||also-22/RB	auxpass||demonstrated-24/VBN||been-23/VBN	conj_and||active-9/JJ||demonstrated-24/VBN	cancer-13||docetaxel-20||no_rel||combinations of capecitabine and a taxane are highly active in metastatic breast cancer, and synergy between capecitabine and docetaxel has also been demonstrated.
prep_in||increased-12/VBD||conclusion-2/NN	nsubj||increased-12/VBD||gip-4/NN	prep_in||gip-4/NN||combination-6/NN	nn||hyperglycemia-11/NN||hyperinsulinemia-8/NN	conj_and||hyperinsulinemia-8/NN||slight-10/JJ	nn||hyperglycemia-11/NN||slight-10/JJ	prep_with||combination-6/NN||hyperglycemia-11/NN	root||ROOT-0/null||increased-12/VBD	amod||flow-16/NN||adipose-13/JJ	nn||flow-16/NN||tissue-14/NN	nn||flow-16/NN||blood-15/NN	dobj||increased-12/VBD||flow-16/NN	nn||uptake-19/NN||glucose-18/NN	dobj||increased-12/VBD||uptake-19/NN	conj_and||flow-16/NN||uptake-19/NN	nn||re-esterification-23/NN||ffa-22/NN	dobj||increased-12/VBD||re-esterification-23/NN	conj_and||flow-16/NN||re-esterification-23/NN	advmod||resulting-26/VBG||thus-25/RB	vmod||increased-12/VBD||resulting-26/VBG	amod||deposition-30/NN||increased-28/VBN	nn||deposition-30/NN||tag-29/NN	prep_in||resulting-26/VBG||deposition-30/NN	amod||tissue-35/NN||abdominal-32/JJ	nn||tissue-35/NN||subcutaneous-33/NN	nn||tissue-35/NN||adipose-34/NN	prep_in||deposition-30/NN||tissue-35/NN	hyperglycemia-11||glucose-18||no||in conclusion, gip in combination with hyperinsulinemia and slight hyperglycemia increased adipose tissue blood flow, glucose uptake, and ffa re-esterification, thus resulting in increased tag deposition in abdominal subcutaneous adipose tissue.
prepc_based_on||is-16/VBZ||on-2/IN	amod||evidence-4/NN||strong-3/JJ	pobj||is-16/VBZ||evidence-4/NN	det||risks-7/NNS||the-6/DT	prep_of||evidence-4/NN||risks-7/NNS	advmod||breastfed-13/JJ||when-8/WRB	nsubj||breastfed-13/JJ||infants-9/NNS	cop||breastfed-13/JJ||are-10/VBP	neg||breastfed-13/JJ||not-11/RB	advmod||breastfed-13/JJ||exclusively-12/RB	rcmod||risks-7/NNS||breastfed-13/JJ	expl||is-16/VBZ||there-15/EX	root||ROOT-0/null||is-16/VBZ	det||need-19/NN||a-17/DT	amod||need-19/NN||great-18/JJ	nsubj||is-16/VBZ||need-19/NN	aux||protect-21/VB||to-20/TO	dep||need-19/NN||protect-21/VB	xcomp||protect-21/VB||breastfeeding-22/VBG	prep_from||breastfeeding-22/VBG||pressures-24/NNS	nn||feeding-27/NN||replacement-26/NN	prep_of||pressures-24/NNS||feeding-27/NN	aux||promote-30/VB||to-29/TO	dep||need-19/NN||promote-30/VB	conj_and||protect-21/VB||promote-30/VB	amod||breastfeeding-32/NN||exclusive-31/JJ	dobj||promote-30/VB||breastfeeding-32/NN	det||option-38/NN||the-34/DT	amod||option-38/NN||best-35/JJS	nn||option-38/NN||infant-36/NN	amod||option-38/NN||feeding-37/VBG	prep_as||promote-30/VB||option-38/NN	prep_for||option-38/NN||hivpositive-40/NN	conj_and||protect-21/VB||hiv-42/VB	conj_and||promote-30/VB||hiv-42/VB	amod||mothers-44/NNS||negative-43/JJ	dobj||hiv-42/VB||mothers-44/NNS	advmod||hiv-42/VB||alike-45/RB	hivpositive-40||hiv-42||no||based on strong evidence of the risks when infants are not exclusively breastfed, there is a great need to protect breastfeeding from pressures of replacement feeding and to promote exclusive breastfeeding as the best infant feeding option for hivpositive and hiv negative mothers alike.
nsubj||represents-5/VBZ||culture-1/NN	prep_of||culture-1/NN||mycobacteriumtuberculosis-3/NNS	advmod||represents-5/VBZ||currently-4/RB	root||ROOT-0/null||represents-5/VBZ	det||â-8/NN||the-6/DT	amod||â-8/NN||closest-7/JJS	dobj||represents-5/VBZ||â-8/NN	amod||â-8/NN||$-9/$	dep||$-9/$||gold-10/JJ	vmod||â-8/NN||standardâ-11/VBG	dobj||standardâ-11/VBG||$-12/$	quantmod||diagnosis-14/CD||for-13/IN	num||$-12/$||diagnosis-14/CD	prep_of||$-12/$||tuberculosis-16/NNP	appos||â-8/NN||tb-18/NN	amod||data-23/NNS||operational-22/JJ	nsubj||scant-25/JJ||data-23/NNS	cop||scant-25/JJ||are-24/VBP	conj_but||represents-5/VBZ||scant-25/JJ	det||impact-28/NN||the-27/DT	prep_on||scant-25/JJ||impact-28/NN	prep_on||scant-25/JJ||cost-effectiveness-30/NNS	conj_and||impact-28/NN||cost-effectiveness-30/NNS	nn||culture-33/NN||tb-32/NN	prep_of||impact-28/NN||culture-33/NN	amod||immunodeficiency-36/NN||human-35/JJ	prep_for||culture-33/NN||immunodeficiency-36/NN	dep||scant-25/JJ||hiv-38/RB	amod||individuals-42/NNS||infected-41/JJ	npadvmod||scant-25/JJ||individuals-42/NNS	amod||settings-45/NNS||resource-limited-44/JJ	prep_in||scant-25/JJ||settings-45/NNS	tb-32||mycobacteriumtuberculosis-3||no||culture of mycobacteriumtuberculosis currently represents the closest âgold standardâ? for diagnosis of tuberculosis (tb), but operational data are scant on the impact and cost-effectiveness of tb culture for human immunodeficiency (hiv-) infected individuals in resource-limited settings.
det||data-2/NNS||these-1/DT	nsubj||demonstrate-3/VBP||data-2/NNS	root||ROOT-0/null||demonstrate-3/VBP	mark||expressed-8/VBN||that-4/IN	nn||proteins-6/NNS||socs-5/NNS	nsubjpass||expressed-8/VBN||proteins-6/NNS	auxpass||expressed-8/VBN||are-7/VBP	ccomp||demonstrate-3/VBP||expressed-8/VBN	amod||lines-13/NNS||human-10/JJ	nn||lines-13/NNS||melanoma-11/NN	nn||lines-13/NNS||cell-12/NN	prep_in||expressed-8/VBN||lines-13/NNS	poss||modulation-16/NN||their-15/PRP$	nsubj||influence-18/VB||modulation-16/NN	aux||influence-18/VB||can-17/MD	conj_and||demonstrate-3/VBP||influence-18/VB	det||responsiveness-20/NNS||the-19/DT	dobj||influence-18/VB||responsiveness-20/NNS	nn||cells-23/NNS||melanoma-22/NN	prep_of||responsiveness-20/NNS||cells-23/NNS	nn||±-26/NNP||ifn-î-25/NNP	prep_to||influence-18/VB||±-26/NNP	nn||³-29/NNP||ifn-î-28/NNP	prep_to||influence-18/VB||³-29/NNP	conj_and||±-26/NNP||³-29/NNP	ifn--1||melanoma-22||no_rel||these data demonstrate that socs proteins are expressed in human melanoma cell lines and their modulation can influence the responsiveness of melanoma cells to ifn-î± and ifn-î³.
det||msm-2/NN||the-1/DT	nsubj||likely-32/JJ||msm-2/NN	nsubj||receive-34/VB||msm-2/NN	vmod||msm-2/NN||sampled-3/VBN	amod||pride-6/NN||gay-5/JJ	prep_at||sampled-3/VBN||pride-6/NN	nsubj||reported-8/VBD||pride-6/NN	rcmod||pride-6/NN||reported-8/VBD	ccomp||reported-8/VBD||engaging-9/VBG	prep_in||engaging-9/VBG||uai-11/NN	aux||used-14/VBN||having-13/VBG	ccomp||reported-8/VBD||used-14/VBN	conj_or||engaging-9/VBG||used-14/VBN	det||stimulant-16/NN||any-15/DT	dobj||used-14/VBN||stimulant-16/NN	dep||stimulant-16/NN||cocaine-18/NN	dep||stimulant-16/NN||crack-cocaine-20/NN	conj_or||cocaine-18/NN||crack-cocaine-20/NN	dep||stimulant-16/NN||methamphetamine-23/NN	conj_or||cocaine-18/NN||methamphetamine-23/NN	det||months-29/NNS||the-26/DT	amod||months-29/NNS||last-27/JJ	num||months-29/NNS||12â-28/CD	prep_in||used-14/VBN||months-29/NNS	cop||likely-32/JJ||were-30/VBD	advmod||likely-32/JJ||more-31/RBR	root||ROOT-0/null||likely-32/JJ	aux||receive-34/VB||to-33/TO	xcomp||likely-32/JJ||receive-34/VB	nn||vaccination-36/NN||hepatitis-35/NN	dobj||receive-34/VB||vaccination-36/NN	advmod||receive-34/VB||on-site-37/JJ	hepatitis-35||cocaine-18||no_rel||the msm sampled at gay pride who reported engaging in uai or having used any stimulant (cocaine, crack-cocaine, or methamphetamine) in the last 12â months were more likely to receive hepatitis vaccination on-site.
amod||aim-3/NN||objective-1/JJ	det||aim-3/NN||the-2/DT	nsubj||was-7/VBD||aim-3/NN	nsubj||assess-9/VB||aim-3/NN	det||analysis-6/NN||this-5/DT	prep_of||aim-3/NN||analysis-6/NN	root||ROOT-0/null||was-7/VBD	aux||assess-9/VB||to-8/TO	xcomp||was-7/VBD||assess-9/VB	det||effect-11/NN||the-10/DT	dobj||assess-9/VB||effect-11/NN	amod||pressurized-14/JJ||budesonide/formoterol-13/JJ	amod||inhaler-16/NN||pressurized-14/JJ	amod||inhaler-16/NN||metered-dose-15/JJ	prep_of||effect-11/NN||inhaler-16/NN	nn||pmdi-19/NNS||bud/fm-18/NN	appos||inhaler-16/NN||pmdi-19/NNS	dobj||assess-9/VB||bud-22/NN	conj_and||effect-11/NN||bud-22/NN	amod||criteria-25/NNS||predefined-24/JJ	prep_on||bud-22/NN||criteria-25/NNS	prep_for||criteria-25/NNS||asthma-27/NN	amod||asthma-27/NN||worsening-28/VBG	det||metric-33/NN||an-30/DT	nn||metric-33/NN||asthma-31/NN	nn||metric-33/NN||control-32/NN	appos||bud-22/NN||metric-33/NN	advmod||aligned-35/VBN||generally-34/RB	vmod||metric-33/NN||aligned-35/VBN	prep_with||aligned-35/VBN||definitions-37/NNS	amod||exacerbations-41/NNS||moderate-39/JJ	nn||exacerbations-41/NNS||asthma-40/NN	prep_of||definitions-37/NNS||exacerbations-41/NNS	num||populations-46/NNS||four-44/CD	amod||populations-46/NNS||different-45/JJ	prep_across||bud-22/NN||populations-46/NNS	asthma-40||formoterol--1||no||objective the aim of this analysis was to assess the effect of budesonide/formoterol pressurized metered-dose inhaler (bud/fm pmdi) and bud on predefined criteria for asthma worsening, an asthma control metric generally aligned with definitions of moderate asthma exacerbations, across four different populations.
amod||symptoms-2/NNS||accompanying-1/VBG	nsubj||increased-18/VBD||symptoms-2/NNS	det||presence-5/NN||the-4/DT	prep_like||symptoms-2/NNS||presence-5/NN	nn||blood-11/NN||fever-7/NN	dep||blood-11/NN||pain-9/NN	prep_of||symptoms-2/NNS||blood-11/NN	det||stool-14/NN||the-13/DT	prep_in||symptoms-2/NNS||stool-14/NN	conj_and||symptoms-2/NNS||vomiting-16/VBG	nsubj||increased-18/VBD||vomiting-16/VBG	advmod||increased-18/VBD||significantly-17/RB	root||ROOT-0/null||increased-18/VBD	amod||prescribing-20/NN||antibiotic-19/JJ	dobj||increased-18/VBD||prescribing-20/NN	vomiting-16||antibiotic-19||no_rel||accompanying symptoms like the presence of fever, pain, blood in the stool and vomiting significantly increased antibiotic prescribing.
amod||+-4/NNS||cd4-1/JJ	amod||+-4/NNS||+-2/JJ	amod||+-4/NNS||cd25hifoxp3-3/JJ	nsubj||immunosuppressive-5/VBP||+-4/NNS	root||ROOT-0/null||immunosuppressive-5/VBP	amod||t-7/NN||regulatory-6/JJ	nn||cells-11/NNS||t-7/NN	appos||cells-11/NNS||treg-9/NN	nsubjpass||implicated-14/VBN||cells-11/NNS	aux||implicated-14/VBN||have-12/VBP	auxpass||implicated-14/VBN||been-13/VBN	ccomp||immunosuppressive-5/VBP||implicated-14/VBN	det||cause-18/NN||a-16/DT	amod||cause-18/NN||possible-17/JJ	prep_as||implicated-14/VBN||cause-18/NN	amod||dysfunction-21/NN||immune-20/JJ	prep_of||cause-18/NN||dysfunction-21/NN	prep_during||implicated-14/VBN||fiv-23/NN	amod||infection-26/NN||hiv-1-25/JJ	prep_during||implicated-14/VBN||infection-26/NN	conj_and||fiv-23/NN||infection-26/NN	mark||capable-31/JJ||as-28/IN	nsubj||capable-31/JJ||they-29/PRP	cop||capable-31/JJ||are-30/VBP	advcl||implicated-14/VBN||capable-31/JJ	prepc_of||capable-31/JJ||modulating-33/VBG	amod||responses-38/NNS||virus-specific-34/JJ	conj_and||virus-specific-34/JJ||inflammatory-36/JJ	amod||responses-38/NNS||inflammatory-36/JJ	amod||responses-38/NNS||immune-37/JJ	dobj||modulating-33/VBG||responses-38/NNS	immunosuppressive-5||virus--1||no_rel||cd4+cd25hifoxp3+ immunosuppressive regulatory t (treg) cells have been implicated as a possible cause of immune dysfunction during fiv and hiv-1 infection, as they are capable of modulating virus-specific and inflammatory immune responses.
amod||rates-2/NNS||prevalence-1/JJ	nsubj||have-34/VBP||rates-2/NNS	amod||virus-5/NN||hepatitisc-4/JJ	prep_of||rates-2/NNS||virus-5/NN	appos||virus-5/NN||hcv-7/NN	dep||virus-5/NN||co-infection-9/NN	det||distribution-12/NN||the-11/DT	prep_of||rates-2/NNS||distribution-12/NN	conj_and||virus-5/NN||distribution-12/NN	nn||genotypes-15/NNS||hcv-14/NN	prep_of||distribution-12/NN||genotypes-15/NNS	det||frequency-19/NN||the-18/DT	prep_of||rates-2/NNS||frequency-19/NN	conj_and||virus-5/NN||frequency-19/NN	amod||resolution-22/NN||spontaneous-21/JJ	prep_of||frequency-19/NN||resolution-22/NN	prep_of||resolution-22/NN||hepatitisc-24/NN	prep_in||hepatitisc-24/NN||patients-26/NNS	vmod||patients-26/NNS||infected-27/VBN	det||humanimmunodeficiencyvirus-30/NNS||the-29/DT	prep_with||infected-27/VBN||humanimmunodeficiencyvirus-30/NNS	appos||humanimmunodeficiencyvirus-30/NNS||hiv-32/NN	root||ROOT-0/null||have-34/VBP	det||disparity-37/NN||a-35/DT	amod||disparity-37/NN||worldwide-36/JJ	dobj||have-34/VBP||disparity-37/NN	hepatitisc-24||hepatitiscvirus--1||no||prevalence rates of hepatitisc virus (hcv) co-infection, the distribution of hcv genotypes, and the frequency of spontaneous resolution of hepatitisc in patients infected with the humanimmunodeficiencyvirus (hiv) have a worldwide disparity.
amod||users-3/NNS||most-1/JJS	nn||users-3/NNS||drug-2/NN	nsubj||answered-9/VBD||users-3/NNS	number||80.6-5/CD||-lrb--4/CD	num||%-6/NN||80.6-5/CD	npadvmod||-rrb--7/JJ||%-6/NN	amod||users-3/NNS||-rrb--7/JJ	advmod||answered-9/VBD||correctly-8/RB	root||ROOT-0/null||answered-9/VBD	mark||make-12/VBP||that-10/IN	nsubj||make-12/VBP||condoms-11/NNS	ccomp||answered-9/VBD||make-12/VBP	nsubj||safer-14/JJR||sex-13/NN	xcomp||make-12/VBP||safer-14/JJR	amod||beliefs-18/NNS||incorrect-17/JJ	nsubj||common-21/JJ||beliefs-18/NNS	cop||common-21/JJ||are-19/VBP	advmod||common-21/JJ||still-20/RB	conj_but||answered-9/VBD||common-21/JJ	nn||e.g.-23/NNP||-lrb--22/NNP	nsubj||reported-37/VBD||e.g.-23/NNP	quantmod||44-25/CD||nearly-24/RB	num||%-26/NN||44-25/CD	nsubj||believed-27/VBD||%-26/NN	rcmod||e.g.-23/NNP||believed-27/VBD	nsubjpass||transmitted-31/VBN||hiv-28/NN	aux||transmitted-31/VBN||can-29/MD	auxpass||transmitted-31/VBN||be-30/VB	ccomp||believed-27/VBD||transmitted-31/VBN	prep_through||transmitted-31/VBN||saliva-33/NN	num||%-36/NN||55-35/CD	prep_through||transmitted-31/VBN||%-36/NN	conj_and||saliva-33/NN||%-36/NN	ccomp||common-21/JJ||reported-37/VBD	mark||transmitted-42/VBN||that-38/IN	nsubjpass||transmitted-42/VBN||hivinfection-39/NN	aux||transmitted-42/VBN||can-40/MD	auxpass||transmitted-42/VBN||be-41/VB	ccomp||reported-37/VBD||transmitted-42/VBN	agent||transmitted-42/VBN||sharing-44/VBG	dobj||sharing-44/VBG||toothbrushes-45/NNS	advmod||sharing-44/VBG||-rrb--46/RB	amod||differences-50/NNS||significant-49/JJ	prep_with||sharing-44/VBG||differences-50/NNS	nsubj||had-55/VBD||differences-50/NNS	nn||users-53/NNS||drug-52/NN	prep_between||differences-50/NNS||users-53/NNS	rcmod||differences-50/NNS||had-55/VBD	nsubjpass||tested-61/VBN||who-57/WP	aux||tested-61/VBN||had-58/VBD	neg||tested-61/VBN||not-59/RB	auxpass||tested-61/VBN||been-60/VBN	ccomp||reported-37/VBD||tested-61/VBN	conj_and||transmitted-42/VBN||tested-61/VBN	prep_for||tested-61/VBN||hiv-63/NN	hivinfection-39||hiv-63||no||most drug users -lrb- 80.6 % -rrb- correctly answered that condoms make sex safer , but incorrect beliefs are still common -lrb- e.g. nearly 44 % believed hiv can be transmitted through saliva and 55 % reported that hivinfection can be transmitted by sharing toothbrushes -rrb- , with significant differences between drug users who had and who had not been tested for hiv .
nsubjpass||performed-3/VBN||cmr-1/NN	auxpass||performed-3/VBN||was-2/VBD	root||ROOT-0/null||performed-3/VBN	num||patients-6/NNS||66-5/CD	prep_in||performed-3/VBN||patients-6/NNS	prep_with||patients-6/NNS||chf-8/NN	amod||cardiomyopathy-12/NN||ischemic-11/JJ	prep_due_to||performed-3/VBN||cardiomyopathy-12/NN	appos||cardiomyopathy-12/NN||icm-14/NN	prep_due_to||performed-3/VBN||dilatedcardiomyopathy-18/NN	conj_or||cardiomyopathy-12/NN||dilatedcardiomyopathy-18/NN	appos||dilatedcardiomyopathy-18/NN||dcm-20/NN	number||healthy-24/JJ||32-23/CD	amod||controls-25/NNS||healthy-24/JJ	prep_due_to||performed-3/VBN||controls-25/NNS	conj_and||cardiomyopathy-12/NN||controls-25/NNS	dcm-20||chf-8||no_rel||cmr was performed in 66 patients with chf due to ischemic cardiomyopathy (icm), or dilatedcardiomyopathy (dcm) and 32 healthy controls.
nsubj||inhibited-25/VBD||amitriptyline-1/NNP	dep||amitriptyline-1/NNP||5-3/CD	num||mg/kg-6/NN||10-5/CD	appos||5-3/CD||mg/kg-6/NN	conj_and||amitriptyline-1/NNP||maprotiline-9/NN	nsubj||inhibited-25/VBD||maprotiline-9/NN	dep||maprotiline-9/NN||10-11/CD	num||mg/kg-14/NN||20-13/CD	appos||10-11/CD||mg/kg-14/NN	conj_and||amitriptyline-1/NNP||fluvoxamine-17/NN	nsubj||inhibited-25/VBD||fluvoxamine-17/NN	dep||amitriptyline-1/NNP||20-19/CD	num||mg/kg-22/NN||30-21/CD	dep||amitriptyline-1/NNP||mg/kg-22/NN	conj_and||20-19/CD||mg/kg-22/NN	advmod||inhibited-25/VBD||effectively-24/RB	root||ROOT-0/null||inhibited-25/VBD	nn||induction-27/NN||pain-26/NN	dobj||inhibited-25/VBD||induction-27/NN	vmod||induction-27/NN||caused-28/VBN	det||phase-32/NN||the-30/DT	amod||phase-32/NN||second-31/JJ	agent||caused-28/VBN||phase-32/NN	det||test-36/NN||the-34/DT	nn||test-36/NN||formalin-35/NN	prep_of||phase-32/NN||test-36/NN	pain-26||amitriptyline-1||yes||amitriptyline (5, 10 mg/kg), maprotiline (10, 20 mg/kg) and fluvoxamine (20 and 30 mg/kg) effectively inhibited pain induction caused by the second phase of the formalin test.
prep_of||considered-7/VBN||these-2/DT	num||subjects-5/NNS||1,607-4/CD	nsubjpass||considered-7/VBN||subjects-5/NNS	nsubj||dopamineagonistâ-10/VBN||subjects-5/NNS	auxpass||considered-7/VBN||were-6/VBD	root||ROOT-0/null||considered-7/VBN	aux||dopamineagonistâ-10/VBN||to-8/TO	aux||dopamineagonistâ-10/VBN||have-9/VB	xcomp||considered-7/VBN||dopamineagonistâ-10/VBN	dobj||dopamineagonistâ-10/VBN||$-11/$	vmod||$-11/$||treated-13/VBN	dobj||treated-13/VBN||hyperprolactinemia-14/NN	prepc_based_on||treated-13/VBN||on-16/IN	det||pattern-19/NN||the-17/DT	amod||pattern-19/NN||prescribing-18/VBG	pobj||treated-13/VBN||pattern-19/NN	hyperprolactinemia-14||dopamineagonist--1||no_rel||of these, 1,607 subjects were considered to have dopamineagonistâtreated hyperprolactinemia based on the prescribing pattern.
amod||reports-2/NNS||several-1/JJ	nsubj||indicate-3/VBP||reports-2/NNS	root||ROOT-0/null||indicate-3/VBP	mark||affects-7/VBZ||that-4/IN	nsubj||affects-7/VBZ||retinoicacid-5/NN	nsubj||alleviates-13/VBZ||retinoicacid-5/NN	advmod||affects-7/VBZ||positively-6/RB	advcl||indicate-3/VBP||affects-7/VBZ	det||progression-9/NN||the-8/DT	dobj||affects-7/VBZ||progression-9/NN	prep_of||progression-9/NN||fibrosis-11/NN	advcl||indicate-3/VBP||alleviates-13/VBZ	conj_and||affects-7/VBZ||alleviates-13/VBZ	det||accumulation-15/NN||the-14/DT	dobj||alleviates-13/VBZ||accumulation-15/NN	det||matrix-19/NN||the-17/DT	nn||matrix-19/NN||extracellular-18/NN	prep_of||accumulation-15/NN||matrix-19/NN	mark||report-24/VBP||whereas-21/IN	amod||studies-23/NNS||other-22/JJ	nsubj||report-24/VBP||studies-23/NNS	dep||affects-7/VBZ||report-24/VBP	det||opposite-26/NN||the-25/DT	dobj||report-24/VBP||opposite-26/NN	mark||exacerbates-30/VBZ||that-28/IN	nsubj||exacerbates-30/VBZ||retinoicacid-29/NN	nsubj||induces-33/VBZ||retinoicacid-29/NN	dep||affects-7/VBZ||exacerbates-30/VBZ	dobj||exacerbates-30/VBZ||fibrosis-31/NN	dep||affects-7/VBZ||induces-33/VBZ	conj_and||exacerbates-30/VBZ||induces-33/VBZ	nn||accumulation-36/NN||extracellular-34/NN	nn||accumulation-36/NN||matrix-35/NN	dobj||induces-33/VBZ||accumulation-36/NN	fibrosis-31||retinoicacid-29||no_rel||several reports indicate that retinoicacid positively affects the progression of fibrosis and alleviates the accumulation of the extracellular matrix, whereas other studies report the opposite; that retinoicacid exacerbates fibrosis and induces extracellular matrix accumulation.
det||study-5/NN||this-2/DT	nn||study-5/NN||retrospective-3/NN	amod||study-5/NN||cross-sectional-4/JJ	prep_in||evaluated-26/VBN||study-5/NN	det||value-8/NN||the-6/DT	amod||value-8/NN||prognostic-7/JJ	nsubjpass||evaluated-26/VBN||value-8/NN	amod||parameters-16/NNS||basic-10/JJ	amod||parameters-16/NNS||cerebrospinal-11/JJ	nn||parameters-16/NNS||fluid-12/NN	appos||parameters-16/NNS||csf-14/NN	prep_of||value-8/NN||parameters-16/NNS	prep_in||parameters-16/NNS||patients-18/NNS	prep_with||patients-18/NNS||bacterialmeningitis-20/NNS	prep_with||patients-18/NNS||viralmeningoencephalitis-22/NNS	conj_and||bacterialmeningitis-20/NNS||viralmeningoencephalitis-22/NNS	prep_with||patients-18/NNS||leptomeningealmetastases-24/NNS	conj_and||bacterialmeningitis-20/NNS||leptomeningealmetastases-24/NNS	auxpass||evaluated-26/VBN||were-25/VBD	root||ROOT-0/null||evaluated-26/VBN	viralmeningoencephalitis-22||basic-10||no_rel||in this retrospective cross-sectional study the prognostic value of basic cerebrospinal fluid (csf) parameters in patients with bacterialmeningitis, viralmeningoencephalitis and leptomeningealmetastases were evaluated.
nsubj||drug-6/NN||praziquantel-1/NN	cop||drug-6/NN||is-2/VBZ	advmod||drug-6/NN||currently-3/RB	det||drug-6/NN||the-4/DT	amod||drug-6/NN||only-5/JJ	root||ROOT-0/null||drug-6/NN	nsubj||effective-9/JJ||drug-6/NN	cop||effective-9/JJ||is-8/VBZ	rcmod||drug-6/NN||effective-9/JJ	det||worms-12/NNS||the-11/DT	prep_against||effective-9/JJ||worms-12/NNS	worms-12||praziquantel-1||yes||praziquantel is currently the only drug that is effective against the worms.
det||results-2/NNS||these-1/DT	nsubj||suggest-3/VBP||results-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||useful-13/JJ||that-4/IN	advmod||culturing-6/VBG||routinely-5/RB	csubj||useful-13/JJ||culturing-6/VBG	prep_for||culturing-6/VBG||m.tuberculosis-8/NNS	prep_during||m.tuberculosis-8/NNS||bronchoscopy-10/NN	cop||useful-13/JJ||is-11/VBZ	advmod||useful-13/JJ||still-12/RB	ccomp||suggest-3/VBP||useful-13/JJ	det||diagnosis-16/NN||the-15/DT	prep_in||useful-13/JJ||diagnosis-16/NN	prep_of||diagnosis-16/NN||pulmonarytuberculosis-18/NNS	det||country-23/NN||an-20/DT	amod||country-23/NN||intermediate-21/JJ	amod||country-23/NN||tuberculosis-burden-22/JJ	prep_in||pulmonarytuberculosis-18/NNS||country-23/NN	tuberculosis--1||m.tuberculosis-8||no||these results suggest that routinely culturing for m.tuberculosis during bronchoscopy is still useful in the diagnosis of pulmonarytuberculosis in an intermediate tuberculosis-burden country .
nsubj||benefit-3/VB||exenatide-1/NN	aux||benefit-3/VB||could-2/MD	root||ROOT-0/null||benefit-3/VB	dobj||benefit-3/VB||type1diabetes-4/NNS	advmod||well-6/RB||as-5/RB	mwe||well-6/RB||as-5/RB	advmod||benefit-3/VB||well-6/RB	type1diabetes-4||exenatide-1||no||exenatide could benefit type1diabetes as well.
nsubj||effective-61/JJ||analysis-1/NN	amod||terbinafine-58/NN||total-3/JJ	num||trials-5/NNS||eight-4/CD	nsubj||state-9/NN||trials-5/NNS	num||patients-8/NNS||1181-7/CD	prep_including||trials-5/NNS||patients-8/NNS	ccomp||total-3/JJ||state-9/NN	mark||likely-17/JJ||that-10/IN	nsubj||likely-17/JJ||treatment-11/NN	nsubj||produce-19/VB||treatment-11/NN	amod||terbinafine-14/NN||continuous-13/JJ	prep_with||treatment-11/NN||terbinafine-14/NN	cop||likely-17/JJ||is-15/VBZ	advmod||likely-17/JJ||more-16/RBR	ccomp||state-9/NN||likely-17/JJ	aux||produce-19/VB||to-18/TO	xcomp||likely-17/JJ||produce-19/VB	amod||cure-23/NN||mycological-20/JJ	conj_and||mycological-20/JJ||clinical-22/JJ	amod||cure-23/NN||clinical-22/JJ	dobj||produce-19/VB||cure-23/NN	prepc_compared_to||produce-19/VB||to-25/TO	amod||itraconazole-27/NN||intermittent-26/JJ	pobj||produce-19/VB||itraconazole-27/NN	nn||2.3-31/NNS||odds-29/NNS	nn||2.3-31/NNS||ratio-30/NN	prep_with||itraconazole-27/NN||2.3-31/NNS	number||%-34/NN||95-33/CD	amod||ci-35/NN||%-34/NN	dep||likely-17/JJ||ci-35/NN	amod||ci-35/NN||1.7-37/CD	num||p-40/NNS||3.0-39/CD	prep_to||ci-35/NN||p-40/NNS	number||0.0001-42/CD||<-41/CD	num||p-40/NNS||0.0001-42/CD	mark||tolerated-51/JJ||though-44/IN	preconj||itraconazole-46/NN||both-45/DT	nsubj||tolerated-51/JJ||itraconazole-46/NN	conj_and||itraconazole-46/NN||terbinafine-48/NN	nsubj||tolerated-51/JJ||terbinafine-48/NN	cop||tolerated-51/JJ||are-49/VBP	advmod||tolerated-51/JJ||well-50/RB	ccomp||likely-17/JJ||tolerated-51/JJ	advmod||effective-54/JJ||highly-53/RB	conj_and||total-3/JJ||effective-54/JJ	amod||terbinafine-58/NN||effective-54/JJ	nn||terbinafine-58/NN||drugs-55/NNS	amod||terbinafine-58/NN||continuous-57/JJ	prep_of||analysis-1/NN||terbinafine-58/NN	cop||effective-61/JJ||is-59/VBZ	advmod||effective-61/JJ||more-60/RBR	root||ROOT-0/null||effective-61/JJ	amod||itraconazole-64/NN||intermittent-63/JJ	prep_than||effective-61/JJ||itraconazole-64/NN	prepc_at||effective-61/JJ||achieving-66/VBG	amod||cure-68/NN||mycological-67/JJ	dobj||achieving-66/VBG||cure-68/NN	amod||onychomycosis-71/NNS||toenail-70/JJ	prep_of||cure-68/NN||onychomycosis-71/NNS	onychomycosis-71||itraconazole-64||yes||analysis of total eight trials including 1181 patients state that treatment with continuous terbinafine is more likely to produce mycological and clinical cure compared to intermittent itraconazole with odds ratio 2.3(95% ci, 1.7 to 3.0 p <0.0001) though both itraconazole and terbinafine are well tolerated and highly effective drugs, continuous terbinafine is more effective than intermittent itraconazole at achieving mycological cure of toenail onychomycosis
det||objective-3/NN||the-1/DT	amod||objective-3/NN||principal-2/JJ	nsubj||was-25/VBD||objective-3/NN	nsubj||develop-27/VB||objective-3/NN	nsubj||implement-29/VB||objective-3/NN	det||studies-7/NNS||these-5/DT	amod||studies-7/NNS||multisite-6/JJ	prep_of||objective-3/NN||studies-7/NNS	dep||studies-7/NNS||florida-9/NN	amod||york-12/NN||new-11/JJ	appos||florida-9/NN||york-12/NN	amod||epicenters-16/NNS||new-14/JJ	nn||epicenters-16/NNS||jersey-15/NN	dep||florida-9/NN||epicenters-16/NNS	amod||-RSB--21/NNS||humanimmunodeficiencyvirus-18/JJ	amod||-RSB--21/NNS||-LSB--19/JJ	nn||-RSB--21/NNS||hiv-20/NN	prep_for||epicenters-16/NNS||-RSB--21/NNS	prep_among||-RSB--21/NNS||women-23/NNS	root||ROOT-0/null||was-25/VBD	aux||develop-27/VB||to-26/TO	xcomp||was-25/VBD||develop-27/VB	xcomp||was-25/VBD||implement-29/VB	conj_and||develop-27/VB||implement-29/VB	amod||combinations-31/NNS||effective-30/JJ	dobj||develop-27/VB||combinations-31/NNS	amod||interventions-34/NNS||behavioral-33/JJ	prep_of||combinations-31/NNS||interventions-34/NNS	aux||optimize-36/VB||to-35/TO	vmod||develop-27/VB||optimize-36/VB	det||status-39/NN||the-37/DT	nn||status-39/NN||health-38/NN	dobj||optimize-36/VB||status-39/NN	det||population-46/NN||the-41/DT	advmod||neglected-43/JJ||most-42/RBS	amod||population-46/NN||neglected-43/JJ	conj_and||neglected-43/JJ||understudied-45/JJ	amod||population-46/NN||understudied-45/JJ	prep_of||status-39/NN||population-46/NN	vmod||population-46/NN||affected-47/VBN	det||epidemic-54/NN||the-49/DT	amod||epidemic-54/NN||acquiredimmunodeficiencysyndrome-50/JJ	appos||epidemic-54/NN||aids-52/NNS	agent||affected-47/VBN||epidemic-54/NN	det||states-58/NNS||the-56/DT	amod||states-58/NNS||united-57/VBN	prep_in||affected-47/VBN||states-58/NNS	amod||women-60/NNS||poor-59/JJ	dep||was-25/VBD||women-60/NNS	prep_of||women-60/NNS||color-62/NN	vmod||color-62/NN||living-63/VBG	prep_with||living-63/VBG||hiv-65/NN	hiv]--1||humanimmunodeficiencyvirus-18||no||the principal objective of these multisite studies (florida, new york, new jersey epicenters for humanimmunodeficiencyvirus [hiv] among women) was to develop and implement effective combinations of behavioral interventions to optimize the health status of the most neglected and understudied population affected by the acquiredimmunodeficiencysyndrome (aids) epidemic in the united states poor women of color living with hiv.
nsubj||remain-2/VBP||uncertainties-1/NNS	root||ROOT-0/null||remain-2/VBP	prepc_as_to||remain-2/VBP||to-4/TO	det||knowledge-6/NN||the-5/DT	pobj||remain-2/VBP||knowledge-6/NN	prep_of||knowledge-6/NN||predictors-8/NNS	amod||pain-11/NN||hz-related-10/JJ	prep_of||predictors-8/NNS||pain-11/NN	det||role-15/NN||the-14/DT	prep_including||knowledge-6/NN||role-15/NN	amod||therapy-18/NN||antiviral-17/JJ	prep_of||role-15/NN||therapy-18/NN	prepc_in||remain-2/VBP||preventing-20/VBG	dobj||preventing-20/VBG||phn-21/NN	amod||practice-25/NN||ordinary-23/JJ	amod||practice-25/NN||clinical-24/JJ	prep_in||preventing-20/VBG||practice-25/NN	phn-21||antiviral-17||no_rel||uncertainties remain as to the knowledge of predictors of hz-related pain, including the role of antiviral therapy in preventing phn in ordinary clinical practice.
aux||evaluate-2/VB||to-1/TO	root||ROOT-0/null||evaluate-2/VB	det||administration-4/NN||the-3/DT	dobj||evaluate-2/VB||administration-4/NN	prep_of||administration-4/NN||antipyretics-6/NNS	prep_to||evaluate-2/VB||children-8/NNS	prep_with||children-8/NNS||upperrespiratorytractinfections-10/NNS	appos||upperrespiratorytractinfections-10/NNS||urti-12/NNP	poss||parents-16/NNS||their-15/PRP$	prep_by||evaluate-2/VB||parents-16/NNS	prep_by||evaluate-2/VB||guardians-18/NNS	conj_or||parents-16/NNS||guardians-18/NNS	prep_without||evaluate-2/VB||consultation-20/NN	prep_with||consultation-20/NN||physicians-22/NNS	conj_and||evaluate-2/VB||compare-25/VB	amod||characteristics-29/NNS||epidemiological-26/JJ	conj_and||epidemiological-26/JJ||clinical-28/JJ	amod||characteristics-29/NNS||clinical-28/JJ	dobj||compare-25/VB||characteristics-29/NNS	prep_of||characteristics-29/NNS||patients-31/NNS	nsubj||received-33/VBD||patients-31/NNS	rcmod||patients-31/NNS||received-33/VBD	dobj||received-33/VBD||antipyretics-34/NNS	dep||evaluate-2/VB||of-36/IN	pcomp||of-36/IN||untreated-37/VBG	dobj||untreated-37/VBG||patients-38/NNS	antipyretics-34||upperrespiratorytractinfections-10||no_rel||to evaluate the administration of antipyretics to children with upperrespiratorytractinfections (urti) by their parents or guardians without consultation with physicians, and compare epidemiological and clinical characteristics of patients who received antipyretics and of untreated patients.
advmod||play-9/VBP||thus-1/RB	amod||species-5/NNS||reactive-3/JJ	nn||species-5/NNS||oxygen-4/NN	nsubj||play-9/VBP||species-5/NNS	nn||molecules-8/NNS||adhesion-7/NN	conj_and||species-5/NNS||molecules-8/NNS	nsubj||play-9/VBP||molecules-8/NNS	root||ROOT-0/null||play-9/VBP	det||role-12/NN||an-10/DT	amod||role-12/NN||important-11/JJ	dobj||play-9/VBP||role-12/NN	det||development-15/NN||the-14/DT	prep_in||role-12/NN||development-15/NN	prep_of||development-15/NN||inflammatoryboweldisease-17/NN	inflammatoryboweldisease-17||oxygen-4||no_rel||thus, reactive oxygen species and adhesion molecules play an important role in the development of inflammatoryboweldisease.
det||prevalence-3/NN||the-1/DT	amod||prevalence-3/NN||high-2/JJ	nsubj||indicates-17/VBZ||prevalence-3/NN	amod||deficits-6/NNS||nutritional-5/JJ	prep_of||prevalence-3/NN||deficits-6/NNS	prep_among||deficits-6/NNS||infants-8/NNS	nn||suggestive-11/NN||symptoms-10/NNS	prep_with||infants-8/NNS||suggestive-11/NN	poss||allergy-16/NN||cow-13/NN	nn||allergy-16/NN||milk-15/NN	prep_of||suggestive-11/NN||allergy-16/NN	root||ROOT-0/null||indicates-17/VBZ	mark||prescribed-24/VBN||that-18/IN	amod||diets-21/NNS||effective-19/JJ	nn||diets-21/NNS||elimination-20/NN	nsubjpass||prescribed-24/VBN||diets-21/NNS	aux||prescribed-24/VBN||should-22/MD	auxpass||prescribed-24/VBN||be-23/VB	ccomp||indicates-17/VBZ||prescribed-24/VBN	aux||control-26/VB||to-25/TO	ccomp||prescribed-24/VBN||control-26/VB	nn||symptoms-28/NNS||allergy-27/NN	dobj||control-26/VB||symptoms-28/NNS	aux||prevent-31/VB||to-30/TO	ccomp||prescribed-24/VBN||prevent-31/VB	conj_and||control-26/VB||prevent-31/VB	conj_and||control-26/VB||treat-33/VB	conj_or||prevent-31/VB||treat-33/VB	dobj||prevent-31/VB||malnutrition-34/NN	allergy-27||allergy-27||no||the high prevalence of nutritional deficits among infants with symptoms suggestive of cow's milk allergy indicates that effective elimination diets should be prescribed to control allergy symptoms and to prevent or treat malnutrition.
amod||dye-3/NNS||evans-1/JJ	amod||dye-3/NNS||blue-2/JJ	nsubj||elicits-7/VBZ||dye-3/NNS	appos||dye-3/NNS||eb-5/NN	root||ROOT-0/null||elicits-7/VBZ	det||fluorescence-10/NN||a-8/DT	nn||fluorescence-10/NN||violet-9/NN	dobj||elicits-7/VBZ||fluorescence-10/NN	prep_by||elicits-7/VBZ||excitation-12/NN	prep_at||excitation-12/NN||345-nm-14/NN	prep_at||excitation-12/NN||emission-16/NN	conj_and||345-nm-14/NN||emission-16/NN	prep_at||elicits-7/VBZ||420-nm-18/JJ	det||reddish-brown-22/NN||a-21/DT	nsubj||fluorescence-23/VBP||reddish-brown-22/NN	conj_and||elicits-7/VBZ||fluorescence-23/VBP	prep_by||fluorescence-23/VBP||excitation-25/NN	prep_at||excitation-25/NN||470-nm-27/NN	prep_at||excitation-25/NN||emission-29/NN	conj_and||470-nm-27/NN||emission-29/NN	amod||characteristic-32/NN||515-nm-31/JJ	prep_at||fluorescence-23/VBP||characteristic-32/NN	prep_of||characteristic-32/NN||oxldl-34/NN	advmod||oxldl-34/NN||only-35/RB	evans-1||nm--1||no_rel||evans blue dye (eb) elicits a violet fluorescence by excitation at 345-nm and emission at 420-nm, and a reddish-brown fluorescence by excitation at 470-nm and emission at 515-nm characteristic of oxldl only.
det||result-3/NN||a-2/DT	prep_as||come-39/VBN||result-3/NN	det||advances-6/NNS||these-5/DT	prep_of||result-3/NN||advances-6/NNS	det||cluster-11/NN||a-8/DT	nn||cluster-11/NN||breast-9/NN	nn||cluster-11/NN||cancer-10/NN	nsubj||come-39/VBN||cluster-11/NN	amod||prognosis-14/NN||poor-13/JJ	prep_with||cluster-11/NN||prognosis-14/NN	nsubj||negative-17/JJ||prognosis-14/NN	cop||negative-17/JJ||is-16/VBZ	rcmod||prognosis-14/NN||negative-17/JJ	det||receptor-21/NN||the-19/DT	nn||receptor-21/NN||estrogen-20/NN	prep_for||negative-17/JJ||receptor-21/NN	appos||receptor-21/NN||esr1-23/NNP	det||receptor-28/NN||the-26/DT	amod||receptor-28/NN||progesterone-27/JJ	prep_for||negative-17/JJ||receptor-28/NN	conj_and||receptor-21/NN||receptor-28/NN	appos||receptor-28/NN||prgr-30/NN	prep_for||negative-17/JJ||erbb2-33/NNS	conj_and||receptor-21/NN||erbb2-33/NNS	quantmod||negative-36/JJ||triple-35/RB	dep||erbb2-33/NNS||negative-36/JJ	aux||come-39/VBN||has-38/VBZ	root||ROOT-0/null||come-39/VBN	det||forefront-42/NN||the-41/DT	prep_to||come-39/VBN||forefront-42/NN	amod||attention-46/NN||medical-44/JJ	amod||attention-46/NN||therapeutic-45/JJ	prep_of||forefront-42/NN||attention-46/NN	cancer-10||estrogen-20||no_rel||as a result of these advances, a breast cancer cluster with poor prognosis that is negative for the estrogen receptor (esr1), the progesterone receptor (prgr) and erbb2 (triple negative) has come to the forefront of medical therapeutic attention.
det||study-2/NN||this-1/DT	nsubj||adopted-3/VBD||study-2/NN	root||ROOT-0/null||adopted-3/VBD	det||model-6/NN||an-4/DT	nn||model-6/NN||fe-5/NN	dobj||adopted-3/VBD||model-6/NN	vmod||adopted-3/VBD||taking-8/VBG	prep_into||taking-8/VBG||account-10/NN	det||asymmetry-13/NN||the-11/DT	amod||asymmetry-13/NN||possible-12/JJ	dobj||taking-8/VBG||asymmetry-13/NN	advmod||existing-15/VBG||inherently-14/RB	amod||asymmetry-13/NN||existing-15/VBG	det||spine-18/NN||the-17/DT	prep_in||existing-15/VBG||spine-18/NN	prep_with||spine-18/NN||respect-20/NN	det||plane-24/NN||the-22/DT	amod||plane-24/NN||sagittal-23/JJ	prep_to||existing-15/VBG||plane-24/NN	det||outline-31/NN||a-27/DT	advmod||geometrically-29/JJ||more-28/RBR	amod||outline-31/NN||geometrically-29/JJ	amod||outline-31/NN||realistic-30/JJ	prep_with||adopted-3/VBD||outline-31/NN	aux||analyze-33/VB||to-32/TO	vmod||outline-31/NN||analyze-33/VB	vmod||outline-31/NN||compare-35/VB	conj_and||analyze-33/VB||compare-35/VB	det||behaviour-38/NN||the-36/DT	amod||behaviour-38/NN||biomechanical-37/JJ	dobj||analyze-33/VB||behaviour-38/NN	det||spine-42/NN||the-40/DT	nn||spine-42/NN||lumbar-41/NN	prep_of||behaviour-38/NN||spine-42/NN	prep_with||analyze-33/VB||regard-44/NN	det||force-48/NN||the-46/DT	amod||force-48/NN||facet-47/JJ	prep_to||adopted-3/VBD||force-48/NN	nsubjpass||associated-55/VBN||force-48/NN	nn||pressure-51/NN||intradiscal-50/NN	prep_to||adopted-3/VBD||pressure-51/NN	conj_and||force-48/NN||pressure-51/NN	nsubjpass||associated-55/VBN||pressure-51/NN	auxpass||associated-55/VBN||are-54/VBP	rcmod||force-48/NN||associated-55/VBN	nn||symptoms-58/NNS||lowbackpain-57/NN	prep_with||associated-55/VBN||symptoms-58/NNS	amod||disorders-62/NNS||other-60/JJ	amod||disorders-62/NNS||spinal-61/JJ	prep_with||associated-55/VBN||disorders-62/NNS	conj_and||symptoms-58/NNS||disorders-62/NNS	lowbackpain-57||fe-5||no_rel||this study adopted an fe model, taking into account the possible asymmetry inherently existing in the spine with respect to the sagittal plane, with a more geometrically realistic outline to analyze and compare the biomechanical behaviour of the lumbar spine with regard to the facet force and intradiscal pressure, which are associated with lowbackpain symptoms and other spinal disorders.
nsubj||herpesvirus-17/NNS||varicella-zostervirus-1/NNS	nsubj||first-24/JJ||varicella-zostervirus-1/NNS	appos||varicella-zostervirus-1/NNS||vzv-3/NN	det||cause-7/NN||the-6/DT	appos||varicella-zostervirus-1/NNS||cause-7/NN	prep_of||cause-7/NN||chickenpox-9/NN	prep_of||cause-7/NN||zoster-11/NN	conj_and||chickenpox-9/NN||zoster-11/NN	cop||herpesvirus-17/NNS||was-13/VBD	det||herpesvirus-17/NNS||the-14/DT	amod||herpesvirus-17/NNS||first-15/JJ	amod||herpesvirus-17/NNS||human-16/JJ	root||ROOT-0/null||herpesvirus-17/NNS	aux||sequenced-20/VBN||to-18/TO	auxpass||sequenced-20/VBN||be-19/VB	vmod||herpesvirus-17/NNS||sequenced-20/VBN	advmod||sequenced-20/VBN||fully-21/RB	det||first-24/JJ||the-23/DT	conj_and||herpesvirus-17/NNS||first-24/JJ	prep_for||licensed-30/VBN||first-24/JJ	nsubjpass||licensed-30/VBN||vaccines-27/NNS	nsubjpass||used-33/VBN||vaccines-27/NNS	aux||licensed-30/VBN||have-28/VBP	auxpass||licensed-30/VBN||been-29/VBN	rcmod||first-24/JJ||licensed-30/VBN	advmod||used-33/VBN||widely-32/RB	rcmod||first-24/JJ||used-33/VBN	conj_and||licensed-30/VBN||used-33/VBN	chickenpox-9||vzv-3||no||varicella-zostervirus (vzv), the cause of chickenpox and zoster, was the first human herpesvirus to be sequenced fully and the first for which vaccines have been licensed and widely used.
dep||hiv/aids-7/VBZ||setting-1/VBG	amod||clinics-5/NNS||public-2/JJ	amod||clinics-5/NNS||primary-3/JJ	nn||clinics-5/NNS||care-4/NN	dobj||setting-1/VBG||clinics-5/NNS	nsubj||hiv/aids-7/VBZ||offering-6/NN	root||ROOT-0/null||hiv/aids-7/VBZ	nn||treatment-11/NN||care-8/NN	amod||treatment-11/NN||antiretroviral-10/JJ	dobj||hiv/aids-7/VBZ||treatment-11/NN	appos||treatment-11/NN||art-13/NN	nn||care-17/NN||tuberculosis-16/NNP	dobj||hiv/aids-7/VBZ||care-17/NN	conj_and||treatment-11/NN||care-17/NN	amod||care-22/NN||ambulatory-20/JJ	amod||care-22/NN||primary-21/JJ	dobj||hiv/aids-7/VBZ||care-22/NN	conj_and||treatment-11/NN||care-22/NN	amod||province-26/NN||free-24/JJ	nn||province-26/NN||state-25/NN	prep_in||care-22/NN||province-26/NN	amod||africa-29/NN||south-28/JJ	appos||province-26/NN||africa-29/NN	aids--1||hiv--1||no||setting public primary care clinics offering hiv/aids care, antiretroviral treatment (art), tuberculosis care, and ambulatory primary care in free state province, south africa.
amod||control-3/NN||tight-1/JJ	nn||control-3/NN||glucose-2/NN	nsubjpass||advocated-18/VBN||control-3/NN	det||care-7/NN||the-5/DT	amod||care-7/NN||acute-6/JJ	prep_during||control-3/NN||care-7/NN	prep_of||care-7/NN||patients-9/NNS	amod||injury-14/NN||severe-11/JJ	amod||injury-14/NN||traumatic-12/JJ	nn||injury-14/NN||brain-13/NN	prep_with||patients-9/NNS||injury-14/NN	aux||advocated-18/VBN||has-15/VBZ	advmod||advocated-18/VBN||recently-16/RB	auxpass||advocated-18/VBN||been-17/VBN	ccomp||is-40/VBZ||advocated-18/VBN	prepc_based_on||advocated-18/VBN||on-20/IN	amod||concerns-22/NNS||experimental-21/JJ	pobj||advocated-18/VBN||concerns-22/NNS	amod||effects-25/NNS||deleterious-24/JJ	prep_about||concerns-22/NNS||effects-25/NNS	prepc_of||effects-25/NNS||presenting-27/VBG	det||brain-30/NN||the-28/DT	amod||brain-30/NN||injured-29/JJ	dobj||presenting-27/VBG||brain-30/NN	det||load-35/NN||a-32/DT	amod||load-35/NN||high-33/JJ	nn||load-35/NN||glucose-34/NN	prep_with||presenting-27/VBG||load-35/NN	advmod||presenting-27/VBG||however-37/RB	expl||is-40/VBZ||there-39/EX	root||ROOT-0/null||is-40/VBZ	dep||worsens-48/VBZ||little-41/JJ	neg||evidence-45/NN||no-43/DT	amod||evidence-45/NN||clinical-44/JJ	conj_or||little-41/JJ||evidence-45/NN	dep||worsens-48/VBZ||evidence-45/NN	mark||worsens-48/VBZ||that-46/IN	nsubj||worsens-48/VBZ||hyperglycemia-47/NN	ccomp||is-40/VBZ||worsens-48/VBZ	amod||injury-50/NN||neurologic-49/JJ	dobj||worsens-48/VBZ||injury-50/NN	hyperglycemia-47||glucose-34||no||tight glucose control during the acute care of patients with severe traumatic brain injury has recently been advocated based on experimental concerns about deleterious effects of presenting the injured brain with a high glucose load, however, there is little or no clinical evidence that hyperglycemia worsens neurologic injury.
mark||shown-5/VBN||although-1/IN	amod||studies-3/NNS||recent-2/JJ	nsubj||shown-5/VBN||studies-3/NNS	aux||shown-5/VBN||have-4/VBP	advcl||suggest-45/VBP||shown-5/VBN	det||decrease-7/NN||a-6/DT	dobj||shown-5/VBN||decrease-7/NN	amod||hepatitis-10/NN||icteric-9/JJ	prep_in||decrease-7/NN||hepatitis-10/NN	prep_after||shown-5/VBN||administration-12/NN	det||types-15/NNS||both-14/DT	prep_of||administration-12/NN||types-15/NNS	nn||³-18/NNS||î-17/NN	prep_of||types-15/NNS||³-18/NNS	parataxis||shown-5/VBN||globulin-20/NN	prep_in||globulin-20/NN||populations-22/NNS	advmod||result-34/NN||where-23/WRB	nsubj||result-34/NN||acquisition-24/NN	prep_of||acquisition-24/NN||hepatitisbvirus-26/NNS	appos||hepatitisbvirus-26/NNS||hbv-28/NN	cop||result-34/NN||is-30/VBZ	advmod||likely-32/JJ||most-31/RBS	amod||result-34/NN||likely-32/JJ	det||result-34/NN||the-33/DT	rcmod||populations-22/NNS||result-34/NN	amod||transmission-37/NN||nonparenteral-36/JJ	prep_of||result-34/NN||transmission-37/NN	det||data-40/NNS||the-39/DT	nsubj||suggest-45/VBP||data-40/NNS	nsubj||decreases-55/VBZ||data-40/NNS	vmod||data-40/NNS||pertaining-41/VBG	aux||parenteral-43/VB||to-42/TO	xcomp||pertaining-41/VBG||parenteral-43/VB	dobj||parenteral-43/VB||exposure-44/NN	root||ROOT-0/null||suggest-45/VBP	mark||hbig-47/VBG||that-46/IN	ccomp||suggest-45/VBP||hbig-47/VBG	dobj||hbig-47/VBG||delays-48/NNS	det||period-51/NN||the-49/DT	nn||period-51/NN||incubation-50/NN	dep||hbig-47/VBG||period-51/NN	prep_of||period-51/NN||hbv-53/NN	conj_and||suggest-45/VBP||decreases-55/VBZ	det||development-57/NN||the-56/DT	dobj||decreases-55/VBZ||development-57/NN	amod||immunity-60/NN||passive-active-59/JJ	prep_of||development-57/NN||immunity-60/NN	hbv-53||hepatitisbvirus-26||no||although recent studies have shown a decrease in icteric hepatitis after administration of both types of î³-globulin in populations where acquisition of hepatitisbvirus (hbv) is most likely the result of nonparenteral transmission, the data pertaining to parenteral exposure suggest that hbig delays the incubation period of hbv and decreases the development of passive-active immunity.
root||ROOT-0/null||accellerase-1/VB	nsubj||superior-4/JJ||1000-2/CD	nsubj||spezyme-6/VB||1000-2/CD	cop||superior-4/JJ||was-3/VBD	dep||accellerase-1/VB||superior-4/JJ	aux||spezyme-6/VB||to-5/TO	xcomp||superior-4/JJ||spezyme-6/VB	dobj||spezyme-6/VB||cp-7/NN	det||set-11/NN||the-9/DT	amod||set-11/NN||core-10/JJ	dobj||spezyme-6/VB||set-11/NN	conj_or||cp-7/NN||set-11/NN	det||mixture-15/NN||the-13/DT	amod||mixture-15/NN||16-component-14/JJ	dobj||spezyme-6/VB||mixture-15/NN	conj_or||cp-7/NN||mixture-15/NN	nn||yield-18/NN||glc-17/NN	prep_for||spezyme-6/VB||yield-18/NN	num||h-21/NN||12-20/CD	prep_at||spezyme-6/VB||h-21/NN	det||set-26/NN||the-24/DT	amod||set-26/NN||16-component-25/JJ	nsubj||effective-29/JJ||set-26/NN	cop||effective-29/JJ||was-27/VBD	advmod||effective-29/JJ||as-28/RB	dep||accellerase-1/VB||effective-29/JJ	conj_but||superior-4/JJ||effective-29/JJ	det||mixtures-34/NNS||the-31/DT	amod||mixtures-34/NNS||commercial-32/JJ	amod||mixtures-34/NNS||enzyme-33/JJ	prep_as||effective-29/JJ||mixtures-34/NNS	num||h.-37/NN||48-36/CD	prep_at||effective-29/JJ||h.-37/NN	cp-7||enzyme-33||no_rel||accellerase 1000 was superior to spezyme cp, the core set or the 16-component mixture for glc yield at 12 h, but the 16-component set was as effective as the commercial enzyme mixtures at 48 h.
nsubjpass||shown-20/VBN||mycophenolatemofetil-1/NN	nsubj||cause-22/VB||mycophenolatemofetil-1/NN	nn||®-4/NNP||cellceptâ-3/NNP	appos||mycophenolatemofetil-1/NN||®-4/NNP	det||drug-11/NN||a-7/DT	advmod||used-9/VBN||commonly-8/RB	amod||drug-11/NN||used-9/VBN	amod||drug-11/NN||immunosuppressive-10/JJ	appos||mycophenolatemofetil-1/NN||drug-11/NN	amod||transplantation-15/NN||solid-13/JJ	nn||transplantation-15/NN||organ-14/NN	prep_in||drug-11/NN||transplantation-15/NN	aux||shown-20/VBN||has-17/VBZ	advmod||shown-20/VBN||recently-18/RB	auxpass||shown-20/VBN||been-19/VBN	root||ROOT-0/null||shown-20/VBN	aux||cause-22/VB||to-21/TO	xcomp||shown-20/VBN||cause-22/VB	dobj||cause-22/VB||graft-versus-hostdisease-23/NN	dep||graft-versus-hostdisease-23/NN||gvhd-25/VBN	prep_like||cause-22/VB||changes-29/NNS	det||tract-33/NN||the-31/DT	amod||tract-33/NN||gastrointestinal-32/JJ	prep_in||changes-29/NNS||tract-33/NN	gvhd-25||mycophenolatemofetil-1||yes||mycophenolatemofetil (cellceptâ®), a commonly used immunosuppressive drug in solid organ transplantation, has recently been shown to cause graft-versus-hostdisease (gvhd)-like changes in the gastrointestinal tract.
nn||models-3/NNS||animal-2/NN	prep_in||attenuated-25/VBN||models-3/NNS	det||number-7/NN||a-5/DT	amod||number-7/NN||limited-6/JJ	conj_and||models-3/NNS||number-7/NN	prep_in||attenuated-25/VBN||number-7/NN	amod||studies-10/NNS||human-9/JJ	prep_of||number-7/NN||studies-10/NNS	vmod||studies-10/NNS||carried-11/VBN	prt||carried-11/VBN||out-12/RP	advmod||far-14/RB||so-13/RB	advmod||carried-11/VBN||far-14/RB	nsubj||attenuated-25/VBN||polyphenols-16/NNS	conj_and||polyphenols-16/NNS||foods-18/NNS	nsubj||attenuated-25/VBN||foods-18/NNS	conj_and||polyphenols-16/NNS||beverages-20/NNS	conj_or||foods-18/NNS||beverages-20/NNS	amod||foods-18/NNS||rich-21/JJ	prep_in||rich-21/JJ||polyphenols-23/NNS	aux||attenuated-25/VBN||have-24/VBP	root||ROOT-0/null||attenuated-25/VBN	amod||responses-28/NNS||postprandial-26/JJ	amod||responses-28/NNS||glycemic-27/JJ	dobj||attenuated-25/VBN||responses-28/NNS	amod||hyperglycemia-31/NN||fasting-30/VBG	dobj||attenuated-25/VBN||hyperglycemia-31/NN	conj_and||responses-28/NNS||hyperglycemia-31/NN	amod||secretion-37/NN||improved-34/VBN	amod||secretion-37/NN||acute-35/JJ	nn||secretion-37/NN||insulin-36/NN	dobj||attenuated-25/VBN||secretion-37/NN	conj_and||responses-28/NNS||secretion-37/NN	nn||sensitivity-40/NN||insulin-39/NN	conj_and||responses-28/NNS||sensitivity-40/NN	conj_and||secretion-37/NN||sensitivity-40/NN	hyperglycemia-31||insulin-39||yes||in animal models and a limited number of human studies carried out so far, polyphenols and foods or beverages rich in polyphenols have attenuated postprandial glycemic responses and fasting hyperglycemia, and improved acute insulin secretion and insulin sensitivity.
amod||chemotherapeutics-2/NNS||first-line-1/JJ	nsubj||dacarbazine-11/NN||chemotherapeutics-2/NNS	vmod||chemotherapeutics-2/NNS||used-3/VBN	nn||therapy-6/NN||melanoma-5/NN	prep_in||used-3/VBN||therapy-6/NN	cop||dacarbazine-11/NN||are-7/VBP	det||dacarbazine-11/NN||the-8/DT	amod||dacarbazine-11/NN||methylating-9/VBG	nn||dacarbazine-11/NN||agents-10/NNS	root||ROOT-0/null||dacarbazine-11/NN	dep||dacarbazine-11/NN||dtic-13/JJ	conj_and||dacarbazine-11/NN||temozolomide-16/NN	appos||temozolomide-16/NN||tmz-18/NN	det||agents-23/NNS||the-21/DT	amod||agents-23/NNS||chloroethylating-22/VBG	conj_and||dacarbazine-11/NN||agents-23/NNS	conj_and||temozolomide-16/NN||agents-23/NNS	amod||agents-23/NNS||bcnu-24/JJ	amod||agents-23/NNS||fotemustine-26/JJ	conj_and||bcnu-24/JJ||fotemustine-26/JJ	melanoma-5||temozolomide-16||yes||first-line chemotherapeutics used in melanoma therapy are the methylating agents dacarbazine (dtic) and temozolomide (tmz) and the chloroethylating agents bcnu and fotemustine.
nsubj||diagnosed-4/VBN||patients-1/NNS	nsubjpass||recruited-20/VBN||patients-1/NNS	nsubjpass||randomized-22/VBN||patients-1/NNS	nsubj||receive-24/VB||patients-1/NNS	aux||diagnosed-4/VBN||have-3/VBP	rcmod||patients-1/NNS||diagnosed-4/VBN	prep_with||diagnosed-4/VBN||rheumatoidarthritis-6/NNS	nn||college-10/NN||american-9/NN	prep_as_per||diagnosed-4/VBN||college-10/NN	advmod||aged-13/VBN||rheumatology-12/RB	amod||years-18/NNS||aged-13/VBN	prep_between||aged-13/VBN||18-15/CD	prep_between||aged-13/VBN||60-17/CD	conj_and||18-15/CD||60-17/CD	prep_of||college-10/NN||years-18/NNS	auxpass||recruited-20/VBN||were-19/VBD	root||ROOT-0/null||recruited-20/VBN	conj_and||recruited-20/VBN||randomized-22/VBN	aux||receive-24/VB||to-23/TO	xcomp||randomized-22/VBN||receive-24/VB	amod||-lrb--26/NNS||leflunomide-25/JJ	dobj||receive-24/VB||-lrb--26/NNS	num||-rrb--30/NNS||10-27/CD	amod||-rrb--30/NNS||mg/day-28/JJ	nn||-rrb--30/NNS||p.o.-29/NN	dep||-lrb--26/NNS||-rrb--30/NNS	det||combination-33/NN||a-32/DT	dobj||receive-24/VB||combination-33/NN	conj_or||-lrb--26/NNS||combination-33/NN	amod||p.o.-41/NN||methotrexate-35/JJ	conj_and||methotrexate-35/JJ||hydroxychloroquine-37/JJ	amod||p.o.-41/NN||hydroxychloroquine-37/JJ	amod||p.o.-41/NN||-lrb--38/JJ	num||p.o.-41/NN||7.5-39/CD	nn||p.o.-41/NN||mg/week-40/NN	prep_of||combination-33/NN||p.o.-41/NN	num||p.o.-45/NN||200-43/CD	amod||p.o.-45/NN||mg/day-44/JJ	prep_of||combination-33/NN||p.o.-45/NN	conj_and||p.o.-41/NN||p.o.-45/NN	advmod||-rrb--48/VBG||respectively-47/RB	vmod||recruited-20/VBN||-rrb--48/VBG	amod||supplementation-52/NN||folate-51/JJ	prep_along_with||-rrb--48/VBG||supplementation-52/NN	num||weeks-55/NNS||12-54/CD	prep_for||supplementation-52/NN||weeks-55/NNS	rheumatoidarthritis-6||leflunomide-25||yes||patients who have diagnosed with rheumatoidarthritis as per american college of rheumatology aged between 18 and 60 years were recruited and randomized to receive leflunomide -lrb- 10 mg/day p.o. -rrb- or a combination of methotrexate and hydroxychloroquine -lrb- 7.5 mg/week p.o. and 200 mg/day p.o. , respectively -rrb- along with folate supplementation for 12 weeks .
amod||mrna-2/NN||nk-1r-1/JJ	nsubj||ratâ-11/VBD||mrna-2/NN	nn||expression-5/NN||protein-4/NN	conj_and||mrna-2/NN||expression-5/NN	nsubj||ratâ-11/VBD||expression-5/NN	det||group-10/NN||the-7/DT	amod||group-10/NN||budesonide-8/JJ	nn||group-10/NN||treatment-9/NN	prep_in||mrna-2/NN||group-10/NN	root||ROOT-0/null||ratâ-11/VBD	num||lung-15/NN||$-12/$	number||s-14/CD||-13/CD	num||$-12/$||s-14/CD	nsubj||less-19/JJR||lung-15/NN	conj_and||lung-15/NN||asmcs-17/NNS	nsubj||less-19/JJR||asmcs-17/NNS	cop||less-19/JJR||were-18/VBD	ccomp||ratâ-11/VBD||less-19/JJR	prep_than||less-19/JJR||that-21/DT	det||groupbut-25/NN||the-23/DT	amod||groupbut-25/NN||asthmatic-24/JJ	prep_in||that-21/DT||groupbut-25/NN	dep||less-19/JJR||greater-26/JJR	prep_than||less-19/JJR||that-28/DT	det||group-32/NN||the-30/DT	nn||group-32/NN||control-31/NN	prep_in||that-28/DT||group-32/NN	asthmatic-24||budesonide-8||yes||nk-1r mrna and protein expression in the budesonide treatment group ratâs lung and asmcs were less than that in the asthmatic groupbut greater than that in the control group.
amod||tension-3/NN||arterial-1/JJ	nn||tension-3/NN||oxygen-2/NN	nsubjpass||recognized-14/VBN||tension-3/NN	nn||delivery-6/NN||oxygen-5/NN	appos||tension-3/NN||delivery-6/NN	prep_to||delivery-6/NN||tissue-8/NN	amod||inflammation-12/NN||systemic-11/JJ	conj_and||tension-3/NN||inflammation-12/NN	nsubjpass||recognized-14/VBN||inflammation-12/NN	auxpass||recognized-14/VBN||are-13/VBP	root||ROOT-0/null||recognized-14/VBN	amod||factors-17/NNS||pivotal-16/JJ	prep_as||recognized-14/VBN||factors-17/NNS	det||progression-20/NN||the-19/DT	prep_in||factors-17/NNS||progression-20/NN	amod||obstructivepulmonarydisease-23/NN||chronic-22/JJ	prep_of||progression-20/NN||obstructivepulmonarydisease-23/NN	dep||progression-20/NN||copd-25/VBN	obstructivepulmonarydisease-23||oxygen-5||yes||arterial oxygen tension, oxygen delivery to tissue, and systemic inflammation are recognized as pivotal factors in the progression of chronic obstructivepulmonarydisease (copd).
root||ROOT-0/null||aim-1/VB	aux||compare-3/VB||to-2/TO	xcomp||aim-1/VB||compare-3/VB	det||effect-5/NN||the-4/DT	dobj||compare-3/VB||effect-5/NN	nn||degludec-8/NN||insulin-7/NN	prep_of||effect-5/NN||degludec-8/NN	conj_and||aim-1/VB||insulinglargine-10/VB	amod||quality-13/NN||health-related-12/JJ	prep_on||insulinglargine-10/VB||quality-13/NN	prep_of||quality-13/NN||life-15/NN	prep_in||life-15/NN||patients-17/NNS	prep_with||patients-17/NNS||type2diabetes-19/CD	prep||insulinglargine-10/VB||starting-20/VBG	pcomp||starting-20/VBG||on-21/IN	nn||therapy-23/NN||insulin-22/NN	pobj||on-21/IN||therapy-23/NN	type2diabetes-19||insulinglargine-10||yes||aim to compare the effect of insulin degludec and insulinglargine on health-related quality of life in patients with type2diabetes starting on insulin therapy.
nn||albumin-2/NN||serum-1/NN	nsubj||predictor-19/NN||albumin-2/NN	det||reactant-7/NN||a-4/DT	amod||reactant-7/NN||negative-5/JJ	amod||reactant-7/NN||acute-phase-6/JJ	appos||albumin-2/NN||reactant-7/NN	appos||albumin-2/NN||marker-9/NN	conj_and||reactant-7/NN||marker-9/NN	amod||malnutrition-14/NN||underlying-11/JJ	nn||malnutrition-14/NN||inflammation-12/NN	nn||malnutrition-14/NN||and/or-13/NN	prep_for||marker-9/NN||malnutrition-14/NN	cop||predictor-19/NN||is-16/VBZ	det||predictor-19/NN||an-17/DT	amod||predictor-19/NN||independent-18/JJ	root||ROOT-0/null||predictor-19/NN	prep_of||predictor-19/NN||cvd-21/NN	prep_of||predictor-19/NN||mortality-23/NN	conj_and||cvd-21/NN||mortality-23/NN	nn||patients-27/NNS||ckd-25/NN	nn||patients-27/NNS||vi-26/NN	prep_in||predictor-19/NN||patients-27/NNS	inflammation-12||albumin-2||no_rel||serum albumin, a negative acute-phase reactant and marker for underlying inflammation and/or malnutrition, is an independent predictor of cvd and mortality in ckd vi patients.
amod||individuals-2/NNS||healthy-1/JJ	nsubjpass||selected-4/VBN||individuals-2/NNS	auxpass||selected-4/VBN||were-3/VBD	root||ROOT-0/null||selected-4/VBN	amod||characteristics-9/NNS||demographic-6/JJ	conj_and||demographic-6/JJ||behavioural-8/JJ	amod||characteristics-9/NNS||behavioural-8/JJ	prep_for||selected-4/VBN||characteristics-9/NNS	amod||sampling-13/NN||stratified-11/JJ	nn||sampling-13/NN||cluster-12/NN	agent||selected-4/VBN||sampling-13/NN	agent||selected-4/VBN||blood-15/NN	conj_and||sampling-13/NN||blood-15/NN	vmod||sampling-13/NN||tested-16/VBN	amod||antigen-20/NN||hepatitisb-18/JJ	nn||antigen-20/NN||surface-19/NN	prep_for||tested-16/VBN||antigen-20/NN	appos||antigen-20/NN||hbsag-22/NN	prep_for||tested-16/VBN||antibody-25/NN	conj_and||antigen-20/NN||antibody-25/NN	nn||antigen-29/NN||hbv-27/NN	nn||antigen-29/NN||core-28/NN	prep_to||antibody-25/NN||antigen-29/NN	dep||antigen-29/NN||anti-hbc-31/JJ	amod||antibodies-36/NNS||anti-hcv-35/JJ	prep_for||tested-16/VBN||antibodies-36/NNS	conj_and||antigen-20/NN||antibodies-36/NNS	appos||antibodies-36/NNS||anti-hcv-38/NNP	hbv-27||hbsag-22||yes||healthy individuals were selected for demographic and behavioural characteristics by stratified cluster sampling and blood tested for hepatitisb surface antigen (hbsag), antibody to hbv core antigen (anti-hbc), and anti-hcv antibodies (anti-hcv).
advmod||feature-11/NN||firstly-1/RB	det||approach-5/NN||a-3/DT	amod||approach-5/NN||developmental-4/JJ	nsubj||feature-11/NN||approach-5/NN	prep_to||approach-5/NN||poverty-7/NN	cop||feature-11/NN||is-8/VBZ	det||feature-11/NN||an-9/DT	amod||feature-11/NN||essential-10/JJ	root||ROOT-0/null||feature-11/NN	prep_of||feature-11/NN||responses-13/NNS	aux||protect-15/VB||to-14/TO	vmod||responses-13/NNS||protect-15/VB	dobj||protect-15/VB||children-16/NNS	vmod||children-16/NNS||affected-17/VBN	agent||affected-17/VBN||hiv-19/NN	agent||affected-17/VBN||aids-21/NNS	conj_and||hiv-19/NN||aids-21/NNS	acomp||protect-15/VB||necessary-23/JJ	aux||safeguard-25/VB||to-24/TO	xcomp||necessary-23/JJ||safeguard-25/VB	poss||capital-28/NN||their-26/PRP$	amod||capital-28/NN||human-27/JJ	dobj||safeguard-25/VB||capital-28/NN	aids-21||hiv-19||no||firstly, a developmental approach to poverty is an essential feature of responses to protect children affected by hiv and aids, necessary to safeguard their human capital.
prep_in||concatenated-7/VBN||addition-2/NN	det||sequences-5/NNS||the-4/DT	nsubjpass||concatenated-7/VBN||sequences-5/NNS	auxpass||concatenated-7/VBN||were-6/VBD	root||ROOT-0/null||concatenated-7/VBN	det||superloci-10/NN||the-9/DT	prep_with||concatenated-7/VBN||superloci-10/NN	num||types-14/NNS||16-12/CD	nn||types-14/NNS||sequence-13/NN	prep_from||superloci-10/NN||types-14/NNS	det||scheme-19/NN||a-16/DT	amod||scheme-19/NN||previous-17/JJ	nn||scheme-19/NN||mlst-18/NN	prep_from||concatenated-7/VBN||scheme-19/NN	vmod||scheme-19/NN||employed-20/VBN	aux||study-22/VB||to-21/TO	xcomp||employed-20/VBN||study-22/VB	det||association-24/NN||the-23/DT	dobj||study-22/VB||association-24/NN	det||clone-28/NN||a-26/DT	amod||clone-28/NN||leptospiral-27/JJ	prep_of||association-24/NN||clone-28/NN	det||outbreak-31/NN||an-30/DT	prep_with||study-22/VB||outbreak-31/NN	amod||leptospirosis-34/NNS||human-33/JJ	prep_of||outbreak-31/NN||leptospirosis-34/NNS	prep_in||study-22/VB||thailand-36/NN	leptospirosis-34||leptospiral-27||no||in addition, the sequences were concatenated with the superloci from 16 sequence types from a previous mlst scheme employed to study the association of a leptospiral clone with an outbreak of human leptospirosis in thailand.
nsubj||taking-3/VBG||he-1/PRP	aux||taking-3/VBG||was-2/VBD	root||ROOT-0/null||taking-3/VBG	amod||mg-6/NN||atenolol-4/JJ	dep||atenolol-4/JJ||100-5/CD	dobj||taking-3/VBG||mg-6/NN	punct||day-8/NN||/-7/:	dep||mg-6/NN||day-8/NN	appos||day-8/NN||amlodipine-10/NN	num||amlodipine-10/NN||10-11/CD	advmod||taking-3/VBG||mg/day-12/RB	det||combination-16/NN||a-15/DT	nsubj||mg/hydrochlorothiazide-20/VBP||combination-16/NN	nsubj||experienced-25/VBD||combination-16/NN	amod||20-19/CD||lisinopril-18/JJ	prep_of||combination-16/NN||20-19/CD	conj_and||taking-3/VBG||mg/hydrochlorothiazide-20/VBP	num||mg-22/NN||12.5-21/CD	dobj||mg/hydrochlorothiazide-20/VBP||mg-22/NN	advmod||mg/hydrochlorothiazide-20/VBP||daily-23/RB	conj_and||taking-3/VBG||experienced-25/VBD	conj_but||mg/hydrochlorothiazide-20/VBP||experienced-25/VBD	amod||peaks-28/NNS||several-26/JJ	nn||peaks-28/NNS||hypertension-27/NN	dobj||experienced-25/VBD||peaks-28/NNS	dobj||experienced-25/VBD||hypotension-30/NN	conj_and||peaks-28/NNS||hypotension-30/NN	hypertension-27||atenolol-4||yes||he was taking atenolol 100 mg /day, amlodipine 10 mg/day, and a combination of lisinopril 20 mg/hydrochlorothiazide 12.5 mg daily but experienced several hypertension peaks and hypotension.
det||center-4/NN||the-1/DT	amod||center-4/NN||hiv/aids-2/JJ	nn||center-4/NN||resource-3/NN	nsubj||harm-8/VBP||center-4/NN	dep||center-4/NN||harc-6/JJ	root||ROOT-0/null||harm-8/VBP	nn||nep-10/NN||reduction-9/NN	nsubj||serves-11/VBZ||nep-10/NN	ccomp||harm-8/VBP||serves-11/VBZ	det||population-14/NN||a-12/DT	amod||population-14/NN||diverse-13/JJ	dobj||serves-11/VBZ||population-14/NN	det||area-19/NN||a-16/DT	amod||area-19/NN||wide-17/JJ	amod||area-19/NN||geographical-18/JJ	prep_from||serves-11/VBZ||area-19/NN	aids--1||hiv--1||no||the hiv/aids resource center (harc) harm reduction nep serves a diverse population from a wide geographical area.
amod||risks-4/NNS||gastrointestinal-3/JJ	prep_because_of||propose-30/VBP||risks-4/NNS	nn||complications-8/NNS||ulcer-7/NN	prep_including||risks-4/NNS||complications-8/NNS	amod||risks-12/NNS||cardiovascular-11/JJ	conj_and||risks-4/NNS||risks-12/NNS	prep_because_of||propose-30/VBP||risks-12/NNS	nn||events-18/NNS||hypertension-15/NN	conj_and||hypertension-15/NN||thrombotic-17/JJ	nn||events-18/NNS||thrombotic-17/JJ	prep_including||risks-12/NNS||events-18/NNS	vmod||events-18/NNS||associated-19/VBN	amod||anti-inflammatorydrugs-22/NNS||nonsteroidal-21/JJ	prep_with||associated-19/VBN||anti-inflammatorydrugs-22/NNS	num||nsaids-24/NNS||-LSB--23/CD	npadvmod||-RSB--25/JJ||nsaids-24/NNS	amod||anti-inflammatorydrugs-22/NNS||-RSB--25/JJ	det||guidelines-29/NNS||these-28/DT	nsubj||propose-30/VBP||guidelines-29/NNS	root||ROOT-0/null||propose-30/VBP	dobj||propose-30/VBP||acetaminophen-31/NN	det||anti-inflammatoryagents-36/NNS||the-33/DT	amod||anti-inflammatoryagents-36/NNS||first-34/JJ	nn||anti-inflammatoryagents-36/NNS||choice-35/NN	prep_as||propose-30/VBP||anti-inflammatoryagents-36/NNS	hypertension-15||nsaids-24||no_rel||because of gastrointestinal risks (including ulcer complications) and cardiovascular risks (including hypertension and thrombotic events associated with nonsteroidal anti-inflammatorydrugs [nsaids]), these guidelines propose acetaminophen as the first choice anti-inflammatoryagents.
det||results-2/NNS||these-1/DT	nsubj||show-3/VBP||results-2/NNS	root||ROOT-0/null||show-3/VBP	mark||emits-9/VBZ||that-4/IN	csubj||emits-9/VBZ||coughing-5/VBG	nn||patients-8/NNS||influenza-7/NN	prep_by||coughing-5/VBG||patients-8/NNS	ccomp||show-3/VBP||emits-9/VBZ	amod||particles-11/NNS||aerosol-10/JJ	dobj||emits-9/VBZ||particles-11/NNS	vmod||particles-11/NNS||containing-12/VBG	dobj||containing-12/VBG||influenzavirus-13/NNS	mark||contained-22/VBN||that-15/IN	nsubjpass||contained-22/VBN||much-16/RB	det||rna-20/NN||the-18/DT	amod||rna-20/NN||viral-19/JJ	prep_of||much-16/RB||rna-20/NN	auxpass||contained-22/VBN||is-21/VBZ	ccomp||show-3/VBP||contained-22/VBN	conj_and||emits-9/VBZ||contained-22/VBN	prep_within||contained-22/VBN||particles-24/NNS	det||range-29/NN||the-26/DT	amod||range-29/NN||respirable-27/JJ	nn||range-29/NN||size-28/NN	prep_in||particles-24/NNS||range-29/NN	influenza-7||influenzavirus-13||no||these results show that coughing by influenza patients emits aerosol particles containing influenzavirus and that much of the viral rna is contained within particles in the respirable size range.
nn||treatment-2/NN||calcitonin-1/NN	nsubj||increased-3/VBD||treatment-2/NN	root||ROOT-0/null||increased-3/VBD	nn||synthesis-7/NN||proteoglycan-4/NN	conj_and||proteoglycan-4/NN||collagen-6/NN	nn||synthesis-7/NN||collagen-6/NN	dobj||increased-3/VBD||synthesis-7/NN	amod||cartilage-11/NN||human-9/JJ	nn||cartilage-11/NN||oa-10/NN	prep_in||increased-3/VBD||cartilage-11/NN	oa-10||calcitonin-1||no_rel||calcitonin treatment increased proteoglycan and collagen synthesis in human oa cartilage.
nsubj||constructed-3/VBN||we-1/PRP	aux||constructed-3/VBN||have-2/VBP	dep||take-52/VB||constructed-3/VBN	det||model-5/NN||a-4/DT	dobj||constructed-3/VBN||model-5/NN	prep_of||model-5/NN||hivinfection-7/NN	mark||types-13/VBZ||that-8/IN	nsubj||types-13/VBZ||differentiates-9/NNS	nsubj||used-17/VBN||differentiates-9/NNS	det||hla-12/NN||these-11/DT	prep_between||differentiates-9/NNS||hla-12/NN	ccomp||constructed-3/VBN||types-13/VBZ	aux||used-17/VBN||have-16/VBP	ccomp||constructed-3/VBN||used-17/VBN	conj_and||types-13/VBZ||used-17/VBN	amod||estimates-19/NNS||reported-18/VBN	dobj||used-17/VBN||estimates-19/NNS	det||number-22/NN||the-21/DT	prep_of||estimates-19/NNS||number-22/NN	prep_of||number-22/NN||people-24/NNS	vmod||people-24/NNS||infected-25/VBN	prep_with||infected-25/VBN||hiv-27/NN	det||rates-31/NNS||the-29/DT	amod||rates-31/NNS||different-30/JJ	prep_with||infected-25/VBN||rates-31/NNS	conj_and||hiv-27/NN||rates-31/NNS	prep_of||rates-31/NNS||progression-33/NN	aux||acquiredimmunodeficiencysyndrome-35/VB||to-34/TO	xcomp||infected-25/VBN||acquiredimmunodeficiencysyndrome-35/VB	dobj||acquiredimmunodeficiencysyndrome-35/VB||aids-37/NNS	nsubj||provide-40/VB||aids-37/NNS	aux||provide-40/VB||to-39/TO	xcomp||acquiredimmunodeficiencysyndrome-35/VB||provide-40/VB	det||estimate-44/NN||a-41/DT	dep||bound-43/VBN||lower-42/JJR	amod||estimate-44/NN||bound-43/VBN	dobj||provide-40/VB||estimate-44/NN	det||length-47/NN||the-46/DT	prep_on||provide-40/VB||length-47/NN	prep_of||length-47/NN||time-49/NN	nsubj||take-52/VB||it-50/PRP	nsubj||impose-56/VB||it-50/PRP	aux||take-52/VB||would-51/MD	root||ROOT-0/null||take-52/VB	prep_for||take-52/VB||hiv-54/NN	aux||impose-56/VB||to-55/TO	xcomp||take-52/VB||impose-56/VB	amod||change-59/NN||major-57/JJ	amod||change-59/NN||genetic-58/JJ	dobj||impose-56/VB||change-59/NN	prep_in||impose-56/VB||humans-61/NNS	aids-37||hiv-54||no||we have constructed a model of hivinfection that differentiates between these hla types, and have used reported estimates of the number of people infected with hiv and the different rates of progression to acquiredimmunodeficiencysyndrome (aids) to provide a lower bound estimate on the length of time it would take for hiv to impose major genetic change in humans.
nsubj||condition-5/NN||hypoparathyroidism-1/NN	cop||condition-5/NN||is-2/VBZ	det||condition-5/NN||a-3/DT	amod||condition-5/NN||chronic-4/JJ	root||ROOT-0/null||condition-5/NN	nsubj||requires-7/VBZ||condition-5/NN	rcmod||condition-5/NN||requires-7/VBZ	det||substitution-10/NN||a-8/DT	amod||substitution-10/NN||lifelong-9/JJ	dobj||requires-7/VBZ||substitution-10/NN	amod||analogues-13/NNS||vitamind-12/JJ	prep_with||requires-7/VBZ||analogues-13/NNS	amod||monitoring-16/NN||careful-15/JJ	prep_with||requires-7/VBZ||monitoring-16/NN	conj_and||analogues-13/NNS||monitoring-16/NN	hypoparathyroidism-1||vitamind-12||yes||hypoparathyroidism is a chronic condition which requires a lifelong substitution with vitamind analogues and careful monitoring.
num||patients-2/NNS||97-1/CD	nsubjpass||recruited-7/VBN||patients-2/NNS	nsubjpass||treated-14/VBN||patients-2/NNS	amod||falciparummalaria-5/NN||uncomplicated-4/JJ	prep_with||patients-2/NNS||falciparummalaria-5/NN	auxpass||recruited-7/VBN||were-6/VBD	root||ROOT-0/null||recruited-7/VBN	prep_from||recruited-7/VBN||april-9/NNP	prep_to||recruited-7/VBN||june-11/NNP	num||june-11/NNP||2006-12/CD	conj_and||recruited-7/VBN||treated-14/VBN	det||al-17/NNP||either-16/DT	prep_with||treated-14/VBN||al-17/NNP	amod||q-21/NN||quinine-19/JJ	prep_with||treated-14/VBN||q-21/NN	conj_or||al-17/NNP||q-21/NN	amod||ap-26/NN||atovaquone/proguanil-24/JJ	prep_with||treated-14/VBN||ap-26/NN	conj_or||al-17/NNP||ap-26/NN	nn||hospital-31/NN||jimma-29/NN	nn||hospital-31/NN||university-30/NN	prep_in||treated-14/VBN||hospital-31/NN	appos||hospital-31/NN||ethiopia-33/NN	falciparummalaria-5||proguanil--1||yes||97 patients with uncomplicated falciparummalaria were recruited from april to june 2006 and treated with either al, quinine (q) or atovaquone/proguanil (ap) in jimma university hospital, ethiopia.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||assess-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||assess-8/VB||to-7/TO	xcomp||was-6/VBD||assess-8/VB	det||knowledge-10/NN||the-9/DT	dobj||assess-8/VB||knowledge-10/NN	prep_of||knowledge-10/NN||hiv/aids-12/NNS	amod||women-15/NNS||iraqi-14/JJ	prep_among||hiv/aids-12/NNS||women-15/NNS	aids--1||hiv--1||no||the aim of this study was to assess the knowledge of hiv/aids among iraqi women.
amod||hypoglycemia-3/NN||progressive-2/JJ	prep_during||demonstrated-7/VBD||hypoglycemia-3/NN	det||subjects-6/NNS||these-5/DT	nsubj||demonstrated-7/VBD||subjects-6/NNS	root||ROOT-0/null||demonstrated-7/VBD	amod||release-10/NN||less-8/JJR	nn||release-10/NN||epinephrine-9/NN	dobj||demonstrated-7/VBD||release-10/NN	dep||release-10/NN||p-12/VBN	dep||0.02-14/CD||=-13/SYM	ccomp||p-12/VBN||0.02-14/CD	amod||impairments-19/NNS||greater-17/JJR	amod||impairments-19/NNS||driving-18/VBG	dobj||demonstrated-7/VBD||impairments-19/NNS	conj_and||release-10/NN||impairments-19/NNS	dep||impairments-19/NNS||p-21/VBN	dep||0.03-23/CD||=-22/SYM	ccomp||p-21/VBN||0.03-23/CD	impairments-19||epinephrine-9||no_rel||during progressive hypoglycemia, these subjects demonstrated less epinephrine release ( p = 0.02) and greater driving impairments ( p = 0.03).
nsubj||gave-11/VBD||analysis-1/NN	amod||lavages-5/NNS||bioassay-positive-3/JJ	amod||lavages-5/NNS||nasal-4/JJ	prep_of||analysis-1/NN||lavages-5/NNS	prep_from||lavages-5/NNS||hamsters-7/NNS	vmod||hamsters-7/NNS||affected-8/VBN	prep_with||affected-8/VBN||transmissibleminkencephalopathy-10/NN	root||ROOT-0/null||gave-11/VBD	amod||values-13/NNS||sd50-12/JJ	iobj||gave-11/VBD||values-13/NNS	num||â-16/NN||103.5-15/CD	prep_of||values-13/NNS||â-16/NN	dobj||gave-11/VBD||$-17/$	npadvmod||that-24/RB||105.7-19/NNP	punct||ml-21/NN||/-20/:	dep||105.7-19/NNP||ml-21/NN	appos||ml-21/NN||showing-23/NN	dep||nasal-25/CD||that-24/RB	num||$-17/$||nasal-25/CD	nsubj||release-27/VBP||cavities-26/NNS	rcmod||$-17/$||release-27/VBP	amod||infectivity-30/NN||substantial-28/JJ	nn||infectivity-30/NN||prion-29/NN	dobj||release-27/VBP||infectivity-30/NN	nsubjpass||detected-35/VBN||infectivity-30/NN	aux||detected-35/VBN||can-32/MD	auxpass||detected-35/VBN||be-33/VB	advmod||detected-35/VBN||rapidly-34/RB	rcmod||infectivity-30/NN||detected-35/VBN	transmissibleminkencephalopathy-10||prion-29||no||analysis of bioassay-positive nasal lavages from hamsters affected with transmissibleminkencephalopathy gave sd50 values of 103.5â105.7/ml, showing that nasal cavities release substantial prion infectivity that can be rapidly detected.
det||inhibitor-3/NN||the-1/DT	amod||inhibitor-3/NN||lysosomotropic-2/JJ	nsubj||suppressed-10/VBD||inhibitor-3/NN	appos||inhibitor-3/NN||chloroquinephosphate-5/NN	prep_of||inhibitor-3/NN||autophagy-8/NN	advmod||suppressed-10/VBD||completely-9/RB	root||ROOT-0/null||suppressed-10/VBD	det||generation-12/NN||the-11/DT	nsubj||spheroid-44/VBD||generation-12/NN	nsubj||abrogated-53/VBD||generation-12/NN	amod||structures-16/NNS||dcis-14/JJ	amod||structures-16/NNS||spheroids/3-d-15/JJ	prep_of||generation-12/NN||structures-16/NNS	nn||invasion-21/NN||suppressed-18/FW	nn||invasion-21/NN||ex-19/FW	nn||invasion-21/NN||vivo-20/NN	appos||structures-16/NNS||invasion-21/NN	amod||stroma-24/NN||autologous-23/JJ	prep_of||invasion-21/NN||stroma-24/NN	amod||apoptosis-27/NNS||induced-26/JJ	appos||invasion-21/NN||apoptosis-27/NNS	vmod||invasion-21/NN||suppressed-29/VBN	amod||proteins-32/NNS||autophagy-30/JJ	amod||proteins-32/NNS||associated-31/JJ	dobj||suppressed-29/VBN||proteins-32/NNS	amod||kinase-37/NN||atg5-34/JJ	prep_including||proteins-32/NNS||akt/pi3-36/JJ	amod||kinase-37/NN||akt/pi3-36/JJ	conj_and||kinase-37/NN||akt/pi3-36/JJ	prep_including||proteins-32/NNS||kinase-37/NN	prep_including||proteins-32/NNS||mtor-39/NN	conj_and||kinase-37/NN||mtor-39/NN	vmod||invasion-21/NN||eliminated-41/VBN	advmod||abnormal-43/JJ||cytogenetically-42/RB	acomp||eliminated-41/VBN||abnormal-43/JJ	ccomp||suppressed-10/VBD||spheroid-44/VBD	xcomp||spheroid-44/VBD||forming-45/VBG	dobj||forming-45/VBG||cells-46/NNS	det||culture-50/NN||the-48/DT	nn||culture-50/NN||organ-49/NN	prep_from||forming-45/VBG||culture-50/NN	ccomp||suppressed-10/VBD||abrogated-53/VBD	conj_and||spheroid-44/VBD||abrogated-53/VBD	amod||formation-56/NN||xenograft-54/JJ	nn||formation-56/NN||tumor-55/NN	dobj||abrogated-53/VBD||formation-56/NN	tumor-55||chloroquinephosphate-5||no_rel||the lysosomotropic inhibitor (chloroquinephosphate) of autophagy completely suppressed the generation of dcis spheroids/3-d structures, suppressed ex vivo invasion of autologous stroma, induced apoptosis, suppressed autophagy associated proteins including atg5, akt/pi3 kinase and mtor, eliminated cytogenetically abnormal spheroid forming cells from the organ culture, and abrogated xenograft tumor formation.
det||study-2/NN||this-1/DT	nsubj||demonstrates-3/VBZ||study-2/NN	root||ROOT-0/null||demonstrates-3/VBZ	det||peptoid-7/NN||the-4/DT	amod||peptoid-7/NN||vegfr2-5/JJ	nn||peptoid-7/NN||antagonist-6/NN	nsubj||enhances-11/VBZ||peptoid-7/NN	appos||peptoid-7/NN||gu81-9/NNS	ccomp||demonstrates-3/VBZ||enhances-11/VBZ	det||activity-14/NN||the-12/DT	amod||activity-14/NN||anti-tumor-13/JJ	dobj||enhances-11/VBZ||activity-14/NN	prep_of||activity-14/NN||doxorubicin-16/NN	amod||breasttumors-21/NNS||spontaneous-18/JJ	amod||breasttumors-21/NNS||murine-19/JJ	amod||breasttumors-21/NNS||mmtv-pymt-20/JJ	prep_in||doxorubicin-16/NN||breasttumors-21/NNS	breasttumors-21||doxorubicin-16||yes||this study demonstrates the vegfr2 antagonist peptoid, gu81, enhances the anti-tumor activity of doxorubicin in spontaneous murine mmtv-pymt breasttumors.
prepc_based_on||tested-28/VBD||on-2/IN	det||premise-4/NN||the-3/DT	pobj||tested-28/VBD||premise-4/NN	mark||receiving-21/VBG||that-5/IN	amod||patients-7/NNS||postabsorptive-6/JJ	nsubj||receiving-21/VBG||patients-7/NNS	prep_with||patients-7/NNS||type1diabetes-9/NNS	vmod||type1diabetes-9/NNS||receiving-10/VBG	amod||insulin-12/NN||intravenous-11/JJ	dobj||receiving-10/VBG||insulin-12/NN	det||dose-15/NN||a-14/DT	prep_in||receiving-10/VBG||dose-15/NN	nsubj||maintains-17/VBZ||dose-15/NN	rcmod||dose-15/NN||maintains-17/VBZ	amod||euglycemia-19/NN||stable-18/JJ	dobj||maintains-17/VBZ||euglycemia-19/NN	aux||receiving-21/VBG||are-20/VBP	dep||premise-4/NN||receiving-21/VBG	advmod||optimal-23/JJ||biologically-22/RB	amod||replacement-25/NN||optimal-23/JJ	nn||replacement-25/NN||insulin-24/NN	dobj||receiving-21/VBG||replacement-25/NN	nsubj||tested-28/VBD||we-27/PRP	root||ROOT-0/null||tested-28/VBD	det||hypothesis-30/NNS||the-29/DT	dobj||tested-28/VBD||hypothesis-30/NNS	mark||supports-33/VBZ||that-31/IN	nsubj||supports-33/VBZ||glucagon-32/NN	ccomp||tested-28/VBD||supports-33/VBZ	amod||concentrations-37/NNS||postabsorptive-34/JJ	nn||concentrations-37/NNS||plasma-35/NN	nn||concentrations-37/NNS||glucose-36/NN	dobj||supports-33/VBZ||concentrations-37/NNS	prep_in||concentrations-37/NNS||humans-39/NNS	type1diabetes-9||insulin-24||yes||based on the premise that postabsorptive patients with type1diabetes receiving intravenous insulin in a dose that maintains stable euglycemia are receiving biologically optimal insulin replacement, we tested the hypothesis that glucagon supports postabsorptive plasma glucose concentrations in humans.
amod||tumors-3/NNS||giant-1/JJ	nn||tumors-3/NNS||cell-2/NN	nsubj||boneneoplasms-9/NNS||tumors-3/NNS	appos||tumors-3/NNS||gcts-5/NNS	cop||boneneoplasms-9/NNS||are-7/VBP	amod||boneneoplasms-9/NNS||primary-8/JJ	root||ROOT-0/null||boneneoplasms-9/NNS	nsubj||involve-12/VBP||boneneoplasms-9/NNS	advmod||involve-12/VBP||rarely-11/RB	rcmod||boneneoplasms-9/NNS||involve-12/VBP	det||base-15/NN||the-13/DT	nn||base-15/NN||skull-14/NN	dobj||involve-12/VBP||base-15/NN	boneneoplasms-9||base-15||no_rel||giant cell tumors (gcts) are primary boneneoplasms that rarely involve the skull base.
det||findings-2/NNS||the-1/DT	nsubj||indicate-3/VBP||findings-2/NNS	root||ROOT-0/null||indicate-3/VBP	det||importance-5/NN||the-4/DT	dobj||indicate-3/VBP||importance-5/NN	prepc_of||importance-5/NN||understanding-7/VBG	det||interplay-9/NN||the-8/DT	dobj||understanding-7/VBG||interplay-9/NN	amod||capital-12/NN||social-11/JJ	prep_between||interplay-9/NN||capital-12/NN	amod||influence-15/NN||religious-14/JJ	prep_between||interplay-9/NN||influence-15/NN	conj_and||capital-12/NN||influence-15/NN	nn||issues-19/NNS||gender-18/NN	prep_between||interplay-9/NN||issues-19/NNS	conj_and||capital-12/NN||issues-19/NNS	amod||strategies-23/NNS||hiv/aids-21/JJ	nn||strategies-23/NNS||preventive-22/NN	prep_in||understanding-7/VBG||strategies-23/NNS	prep_in||strategies-23/NNS||uganda-25/NN	aids--1||hiv--1||no||the findings indicate the importance of understanding the interplay between social capital, religious influence, and gender issues in hiv/aids preventive strategies in uganda.
advmod||are-5/VBP||overall-1/RB	det||findings-4/NNS||the-3/DT	nsubj||are-5/VBP||findings-4/NNS	root||ROOT-0/null||are-5/VBP	prep_in||are-5/VBP||line-7/NN	det||model-10/NN||the-9/DT	prep_with||line-7/NN||model-10/NN	mark||triggers-17/VBZ||that-11/IN	nn||cells-14/NNS||melanoma-13/NN	prep_in||triggers-17/VBZ||cells-14/NNS	amod||o6-methylguanine-16/NNS||tmz-induced-15/JJ	nsubj||triggers-17/VBZ||o6-methylguanine-16/NNS	ccomp||are-5/VBP||triggers-17/VBZ	det||apoptotic-19/NN||the-18/DT	dobj||triggers-17/VBZ||apoptotic-19/NN	cc||necrotic-22/JJ||and-21/CC	dep||apoptotic-19/NN||necrotic-22/JJ	advmod||triggers-17/VBZ||pathway-24/RB	prep_through||triggers-17/VBZ||dsbs-26/NNS	mark||triggered-34/VBN||whereas-28/IN	amod||agents-31/NNS||chloroethylating-30/JJ	prep_for||triggered-34/VBN||agents-31/NNS	nsubjpass||triggered-34/VBN||apoptosis-32/NNS	auxpass||triggered-34/VBN||is-33/VBZ	advcl||triggers-17/VBZ||triggered-34/VBN	det||manner-39/NN||a-36/DT	advmod||complex-38/JJ||more-37/RBR	amod||manner-39/NN||complex-38/JJ	prep_in||triggered-34/VBN||manner-39/NN	melanoma-13||tmz--1||yes||overall, the findings are in line with the model that in melanoma cells tmz-induced o6-methylguanine triggers the apoptotic (and necrotic) pathway through dsbs, whereas for chloroethylating agents apoptosis is triggered in a more complex manner.
nsubjpass||treated-10/VBN||patients-1/NNS	amod||iiia-5/NN||unresectable-3/JJ	nn||iiia-5/NN||stage-4/NN	prep_with||patients-1/NNS||iiia-5/NN	nn||nsclc-8/NN||iiib-7/NN	prep_with||patients-1/NNS||nsclc-8/NN	conj_or||iiia-5/NN||nsclc-8/NN	auxpass||treated-10/VBN||were-9/VBD	root||ROOT-0/null||treated-10/VBN	prep_with||treated-10/VBN||nedaplatin-12/NN	appos||nedaplatin-12/NN||np-14/NN	amod||$-18/$||50â-17/JJ	prep_at||nedaplatin-12/NN||$-18/$	number||mgâ-20/CD||-19/CD	num||$-18/$||mgâ-20/CD	amod||$-18/$||$-21/$	dep||$-21/$||-22/JJ	vmod||$-18/$||mâ-23/VBN	dobj||mâ-23/VBN||2-25/CD	dobj||mâ-23/VBN||irinotecan-27/CD	conj_and||2-25/CD||irinotecan-27/CD	appos||2-25/CD||cpt-29/NN	amod||$-33/$||60â-32/JJ	prep_at||2-25/CD||$-33/$	number||mgâ-35/CD||-34/CD	num||$-33/$||mgâ-35/CD	amod||$-33/$||$-36/$	dep||$-36/$||-37/JJ	vmod||$-33/$||mâ-38/VBN	dobj||mâ-38/VBN||2-40/CD	prep_on||mâ-38/VBN||days-42/NNS	num||days-42/NNS||1-43/CD	prep_on||mâ-38/VBN||8-45/CD	conj_and||days-42/NNS||8-45/CD	det||weeks-48/NNS||every-46/DT	num||weeks-48/NNS||4-47/CD	tmod||mâ-38/VBN||weeks-48/NNS	prep_for||$-33/$||two-50/CD	num||cycles-53/NNS||four-52/CD	prep_to||mâ-23/VBN||cycles-53/NNS	amod||trt-56/NN||concurrent-55/JJ	prep_with||$-18/$||trt-56/NN	amod||$-59/$||2â-58/JJ	dep||nedaplatin-12/NN||$-59/$	number||gy-61/CD||-60/CD	num||$-59/$||gy-61/CD	prep_per||$-59/$||day-63/NN	amod||60â-66/NNS||total-65/JJ	appos||day-63/NN||60â-66/NNS	dep||60â-66/NNS||$-67/$	number||gy-69/CD||-68/CD	num||$-67/$||gy-69/CD	nsclc-8||irinotecan-27||yes||patients with unresectable stage iiia or iiib nsclc were treated with nedaplatin (np) at 50âmgâmâ2 and irinotecan (cpt) at 60âmgâmâ2 on days 1 and 8 every 4 weeks for two to four cycles with concurrent trt (2âgy per day, total 60âgy).
nsubj||sought-2/VBD||we-1/PRP	nsubj||determine-4/VB||we-1/PRP	root||ROOT-0/null||sought-2/VBD	aux||determine-4/VB||to-3/TO	xcomp||sought-2/VBD||determine-4/VB	mark||altered-36/VBN||if-5/IN	nsubjpass||altered-36/VBN||upa-6/NN	nn||inhibitor-9/NN||pa-8/NN	appos||upa-6/NN||inhibitor-9/NN	appos||inhibitor-9/NN||pai-11/NN	dep||inhibitor-9/NN||-1-13/CD	num||expression-20/NN||prostaglandin-15/CD	nn||expression-20/NN||pg-17/NN	amod||expression-20/NN||e2-19/JJ	appos||upa-6/NN||expression-20/NN	conj_and||inhibitor-9/NN||expression-20/NN	amod||fluid-24/NN||nipple-22/JJ	nn||fluid-24/NN||aspirate-23/NN	prep_in||expression-20/NN||fluid-24/NN	appos||fluid-24/NN||naf-26/NN	nn||expression-32/NN||upa-29/NN	conj_and||upa-29/NN||pge2-31/JJ	nn||expression-32/NN||pge2-31/JJ	prep_in||expression-20/NN||expression-32/NN	conj_and||fluid-24/NN||expression-32/NN	prep_in||expression-32/NN||plasma-34/NN	auxpass||altered-36/VBN||were-35/VBD	advcl||determine-4/VB||altered-36/VBN	nn||dose-39/NN||celecoxib-38/NN	agent||altered-36/VBN||dose-39/NN	agent||altered-36/VBN||concentration-41/NN	conj_and||dose-39/NN||concentration-41/NN	prep_in||altered-36/VBN||women-43/NNS	amod||risk-48/NN||increased-45/VBN	nn||risk-48/NN||breast-46/NN	nn||risk-48/NN||cancer-47/NN	prep_at||women-43/NNS||risk-48/NN	cancer-47||prostaglandin-15||no_rel||we sought to determine if upa, pa inhibitor (pai)-1 and prostaglandin (pg)e2 expression in nipple aspirate fluid (naf) and upa and pge2 expression in plasma were altered by celecoxib dose and concentration in women at increased breast cancer risk.
nsubj||causing-8/VBG||vibriocholeraeo1-1/NNS	amod||humans-6/NNS||v.cholerae-3/JJ	amod||humans-6/NNS||o139-4/JJ	amod||humans-6/NNS||infect-5/JJ	conj_and||vibriocholeraeo1-1/NNS||humans-6/NNS	nsubj||causing-8/VBG||humans-6/NNS	root||ROOT-0/null||causing-8/VBG	det||cholera-14/NN||the-9/DT	amod||cholera-14/NN||diarrheal-10/JJ	conj_and||diarrheal-10/JJ||waterborne-12/JJ	amod||cholera-14/NN||waterborne-12/JJ	nn||cholera-14/NN||disease-13/NN	dobj||causing-8/VBG||cholera-14/NN	nsubj||problem-21/NN||cholera-14/NN	cop||problem-21/NN||is-17/VBZ	det||problem-21/NN||a-18/DT	amod||problem-21/NN||worldwide-19/JJ	nn||problem-21/NN||health-20/NN	rcmod||cholera-14/NN||problem-21/NN	cholera-14||vibriocholeraeo1-1||no||vibriocholeraeo1 and v.cholerae o139 infect humans , causing the diarrheal and waterborne disease cholera , which is a worldwide health problem .
det||aqueous-2/NNS||the-1/DT	nsubj||lmw-3/VBP||aqueous-2/NNS	root||ROOT-0/null||lmw-3/VBP	nn||muscles-5/NNS||cod-4/NN	nsubj||extract-6/VB||muscles-5/NNS	ccomp||lmw-3/VBP||extract-6/VB	amod||mortality-8/NN||decreases-7/JJ	dobj||extract-6/VB||mortality-8/NN	det||model-12/NN||the-10/DT	nn||model-12/NN||mouse-11/NN	prep_in||extract-6/VB||model-12/NN	nn||chf-17/NN||dox-14/NN	nn||chf-17/NN||induced-15/NNP	amod||chf-17/NN||acute-16/JJ	prep_of||model-12/NN||chf-17/NN	chf-17||dox-14||no||the aqueous lmw cod muscles extract decreases mortality in the mouse model of dox induced acute chf.
num||piglets-2/NNS||ten-1/CD	nsubjpass||submitted-4/VBN||piglets-2/NNS	auxpass||submitted-4/VBN||were-3/VBD	root||ROOT-0/null||submitted-4/VBN	prep_to||submitted-4/VBN||hi-6/UH	num||min-9/NN||30-8/CD	prep_for||submitted-4/VBN||min-9/NN	vmod||min-9/NN||followed-10/VBN	agent||followed-10/VBN||reoxygenation-12/NN	number||%-15/NN||21-14/CD	amod||o2-16/NNS||%-15/NN	prep_with||followed-10/VBN||o2-16/NNS	num||hours-19/NNS||7-18/CD	prep_for||o2-16/NNS||hours-19/NNS	o2-16||ten-1||no_rel||ten piglets were submitted to hi for 30 min followed by reoxygenation with 21% o2 for 7 hours.
amod||reaction-5/NN||quantitative-1/JJ	amod||reaction-5/NN||real-time-2/JJ	amod||reaction-5/NN||polymerase-3/JJ	nn||reaction-5/NN||chain-4/NN	nsubjpass||employed-10/VBN||reaction-5/NN	nsubj||evaluate-12/VB||reaction-5/NN	appos||reaction-5/NN||pcr-7/NN	auxpass||employed-10/VBN||was-9/VBD	root||ROOT-0/null||employed-10/VBN	aux||evaluate-12/VB||to-11/TO	xcomp||employed-10/VBN||evaluate-12/VB	det||changes-15/NNS||the-13/DT	amod||changes-15/NNS||molecular-14/JJ	dobj||evaluate-12/VB||changes-15/NNS	vmod||changes-15/NNS||associated-16/VBN	amod||dyskinesias-19/NNS||l-dopa-induced-18/JJ	prep_with||associated-16/VBN||dyskinesias-19/NNS	nn||sdisease-23/NN||parkinson-21/NN	prep_in||dyskinesias-19/NNS||sdisease-23/NN	parkinson'sdisease--1||l-dopa--1||yes||quantitative real-time polymerase chain reaction (pcr) was employed to evaluate the molecular changes associated with l-dopa-induced dyskinesias in parkinson'sdisease.
nsubj||agent-5/NN||pioglitazone-1/NN	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||an-3/DT	amod||agent-5/NN||insulin-sensitizing-4/JJ	root||ROOT-0/null||agent-5/NN	amod||agent-5/NN||available-6/JJ	prep_for||available-6/JJ||treatment-8/NN	prep_of||treatment-8/NN||type2diabetes-10/CD	type2diabetes-10||insulin--1||yes||pioglitazone is an insulin-sensitizing agent available for treatment of type2diabetes.
prep_in||assigned-32/VBN||patients-2/NNS	vmod||patients-2/NNS||meeting-3/VBG	det||classification-6/NN||the-4/DT	amod||classification-6/NN||chinese-5/JJ	dobj||meeting-3/VBG||classification-6/NN	amod||criteria-10/NNS||mental-8/JJ	nn||criteria-10/NNS||disorders-9/NNS	prep_of||classification-6/NN||criteria-10/NNS	prep_of||classification-6/NN||criteria-10/NNS	conj_and||criteria-10/NNS||criteria-10/NNS	prep_for||criteria-10/NNS||schizophrenia-12/NN	det||score-25/NN||a-15/DT	amod||score-25/NN||positive-16/JJ	conj_and||positive-16/JJ||negative-18/JJ	amod||score-25/NN||negative-18/JJ	nn||score-25/NN||syndrome-19/NN	nn||score-25/NN||scale-20/NN	dep||score-25/NN||panss-22/NNS	amod||score-25/NN||total-24/JJ	prep_with||criteria-10/NNS||score-25/NN	advmod||meeting-3/VBG||â-26/RB	dep||60-29/CD||-27/SYM	punct||60-29/CD||¥-28/:	dep||meeting-3/VBG||60-29/CD	auxpass||assigned-32/VBN||were-30/VBD	advmod||assigned-32/VBN||randomly-31/RB	root||ROOT-0/null||assigned-32/VBN	num||weeks-35/NNS||six-34/CD	prep_to||assigned-32/VBN||weeks-35/NNS	amod||treatment-38/NN||double-blind-37/JJ	prep_of||weeks-35/NNS||treatment-38/NN	amod||40â-41/NNS||ziprasidone-40/JJ	prep_with||assigned-32/VBN||40â-41/NNS	dep||mg-45/NN||$-42/$	num||$-42/$||80-44/CD	amod||40â-41/NNS||mg-45/NN	advmod||daily-47/JJ||twice-46/RB	nsubjpass||assigned-32/VBN||daily-47/JJ	amod||1â-50/NNS||risperidone-49/JJ	nsubjpass||assigned-32/VBN||1â-50/NNS	conj_or||daily-47/JJ||1â-50/NNS	amod||bid-55/NN||$-51/$	num||$-51/$||3-53/CD	nn||bid-55/NN||mg-54/NN	dep||daily-47/JJ||bid-55/NN	advmod||dosed-58/VBN||flexibly-57/RB	amod||daily-47/JJ||dosed-58/VBN	schizophrenia-12||risperidone-49||yes||in patients meeting the chinese classification of mental disorders criteria for schizophrenia and with a positive and negative syndrome scale (panss) total score â¥60 were randomly assigned to six weeks of double-blind treatment with ziprasidone 40â80 mg twice daily or risperidone 1â3 mg bid, flexibly dosed.
root||ROOT-0/null||epstein-barrvirus-1/NNS	appos||epstein-barrvirus-1/NNS||ebv-3/NN	amod||neoplasms-9/NNS||related-6/JJ	amod||neoplasms-9/NNS||smooth-7/JJ	nn||neoplasms-9/NNS||muscle-8/NN	dep||epstein-barrvirus-1/NNS||neoplasms-9/NNS	nsubjpass||associated-15/VBN||smns-11/NNS	aux||associated-15/VBN||have-13/VBP	auxpass||associated-15/VBN||been-14/VBN	rcmod||neoplasms-9/NNS||associated-15/VBN	amod||dysregulation-18/NN||immune-17/JJ	prep_with||associated-15/VBN||dysregulation-18/NN	advmod||notably-21/RB||most-20/RBS	advmod||associated-15/VBN||notably-21/RB	prep_in||associated-15/VBN||patients-23/NNS	nsubj||undergone-26/VBN||patients-23/NNS	aux||undergone-26/VBN||have-25/VBP	rcmod||patients-23/NNS||undergone-26/VBN	amod||transplantation-29/NN||solid-27/JJ	nn||transplantation-29/NN||organ-28/NN	dobj||undergone-26/VBN||transplantation-29/NN	prep_in||associated-15/VBN||patients-32/NNS	conj_or||patients-23/NNS||patients-32/NNS	nsubj||undergone-26/VBN||patients-32/NNS	prep_with||patients-32/NNS||hiv/aids-34/NNS	aids--1||hiv--1||no||epstein-barrvirus (ebv)-related smooth muscle neoplasms (smns) have been associated with immune dysregulation, most notably in patients who have undergone solid organ transplantation or in patients with hiv/aids.
vmod||hypothesised-23/VBD||using-1/VBG	det||threshold-3/NN||a-2/DT	dobj||using-1/VBG||threshold-3/NN	num||%-6/NN||5-5/CD	prep_of||threshold-3/NN||%-6/NN	prep_above||indicative-15/JJ||%-6/NN	det||prevalence-10/NN||a-9/DT	nsubj||indicative-15/JJ||prevalence-10/NN	amod||vitaminb12-13/NNS||low-12/JJ	prep_of||prevalence-10/NN||vitaminb12-13/NNS	cop||indicative-15/JJ||is-14/VBZ	rcmod||%-6/NN||indicative-15/JJ	det||problem-20/NN||a-17/DT	nn||problem-20/NN||population-18/NN	nn||problem-20/NN||health-19/NN	prep_of||indicative-15/JJ||problem-20/NN	nsubj||hypothesised-23/VBD||we-22/PRP	root||ROOT-0/null||hypothesised-23/VBD	mark||exceeds-26/VBZ||that-24/IN	nsubj||exceeds-26/VBZ||vitaminb12deficiency-25/NNS	nsubj||due-41/JJ||vitaminb12deficiency-25/NNS	ccomp||hypothesised-23/VBD||exceeds-26/VBZ	det||threshold-28/NN||this-27/DT	dobj||exceeds-26/VBZ||threshold-28/NN	amod||refugees-31/NNS||newly-arrived-30/JJ	prep_among||exceeds-26/VBZ||refugees-31/NNS	vmod||refugees-31/NNS||resettling-32/VBG	prep_in||resettling-32/VBG||australia-34/NN	cop||due-41/JJ||is-37/VBZ	advmod||due-41/JJ||higher-38/RBR	prep_among||higher-38/RBR||women-40/NNS	ccomp||hypothesised-23/VBD||due-41/JJ	conj_and||exceeds-26/VBZ||due-41/JJ	poss||risk-45/NN||their-43/PRP$	amod||risk-45/NN||increased-44/VBN	prep_to||due-41/JJ||risk-45/NN	nn||insecurity-48/NN||food-47/NN	prep_of||risk-45/NN||insecurity-48/NN	vitaminb12deficiency-25||vitaminb12-13||yes||using a threshold of 5% above which a prevalence of low vitaminb12 is indicative of a population health problem, we hypothesised that vitaminb12deficiency exceeds this threshold among newly-arrived refugees resettling in australia, and is higher among women due to their increased risk of food insecurity.
amod||results-2/NNS||type1diabetes-1/JJ	nsubj||t-cellâ-5/VBZ||results-2/NNS	prep_from||results-2/NNS||selective-4/JJ	root||ROOT-0/null||t-cellâ-5/VBZ	dobj||t-cellâ-5/VBZ||$-6/$	advmod||destruction-9/JJ||mediated-8/RB	amod||²-14/NNS||destruction-9/JJ	det||î-13/NN||the-11/DT	amod||î-13/NN||insulin-producing-12/JJ	prep_of||destruction-9/JJ||î-13/NN	npadvmod||--15/RB||²-14/NNS	num||$-6/$||cells-16/CD	det||pancreas-19/NN||the-18/DT	prep_in||$-6/$||pancreas-19/NN	type1diabetes-1||insulin--1||yes||type1diabetes results from selective t-cellâmediated destruction of the insulin-producing î²-cells in the pancreas.
nsubjpass||enhanced-4/VBN||cost-effectiveness-1/NNS	aux||enhanced-4/VBN||may-2/MD	auxpass||enhanced-4/VBN||be-3/VB	root||ROOT-0/null||enhanced-4/VBN	agent||enhanced-4/VBN||broadening-6/VBG	det||range-8/NN||the-7/DT	dobj||broadening-6/VBG||range-8/NN	amod||services-11/NNS||srhr-hiv/aids-10/JJ	prep_of||range-8/NN||services-11/NNS	agent||enhanced-4/VBN||adapting-13/VBG	conj_and||broadening-6/VBG||adapting-13/VBG	nn||times-15/NNS||opening-14/NN	dobj||adapting-13/VBG||times-15/NNS	agent||enhanced-4/VBN||expanding-17/VBG	conj_and||broadening-6/VBG||expanding-17/VBG	amod||coverage-19/NN||geographical-18/JJ	dobj||expanding-17/VBG||coverage-19/NN	agent||enhanced-4/VBN||targeting-21/VBG	conj_and||broadening-6/VBG||targeting-21/VBG	amod||marp-23/NN||additional-22/JJ	dobj||targeting-21/VBG||marp-23/NN	aids--1||hiv--1||no||cost-effectiveness may be enhanced by broadening the range of srhr-hiv/aids services, adapting opening times, expanding geographical coverage and targeting additional marp.
nn||items-3/NNS||rating-1/NN	nn||items-3/NNS||scale-2/NN	nsubj||nonresponsive-20/VBP||items-3/NNS	nsubj||â-22/VB||items-3/NNS	det||trial-8/NN||a-5/DT	amod||trial-8/NN||6-week-6/JJ	amod||trial-8/NN||clinical-7/JJ	prep_in||items-3/NNS||trial-8/NN	prep_of||trial-8/NN||olanzapine-10/NN	nn||augmentation-13/NN||placebo-12/NN	prep_versus||olanzapine-10/NN||augmentation-13/NN	prep_in||augmentation-13/NN||patients-15/NNS	amod||bipolardisorder-18/NN||mixed-17/JJ	prep_with||patients-15/NNS||bipolardisorder-18/NN	advmod||nonresponsive-20/VBP||partially-19/RB	root||ROOT-0/null||nonresponsive-20/VBP	aux||â-22/VB||to-21/TO	xcomp||nonresponsive-20/VBP||â-22/VB	nn||¥-24/NNP||-23/NNP	dobj||â-22/VB||¥-24/NNP	num||days-26/NNS||14-25/CD	nsubjpass||analyzed-31/VBN||days-26/NNS	nsubj||characterize-33/VB||days-26/NNS	nn||monotherapy-29/NN||divalproex-28/NN	prep_of||days-26/NNS||monotherapy-29/NN	auxpass||analyzed-31/VBN||were-30/VBD	rcmod||¥-24/NNP||analyzed-31/VBN	aux||characterize-33/VB||to-32/TO	xcomp||analyzed-31/VBN||characterize-33/VB	nn||patterns-35/NNS||symptom-34/NN	dobj||characterize-33/VB||patterns-35/NNS	nsubj||predict-38/VB||patterns-35/NNS	aux||predict-38/VB||could-37/MD	rcmod||patterns-35/NNS||predict-38/VB	dobj||predict-38/VB||remission-39/NN	bipolardisorder-18||divalproex-28||yes||rating scale items in a 6-week clinical trial of olanzapine versus placebo augmentation in patients with mixed bipolardisorder partially nonresponsive to â¥14 days of divalproex monotherapy were analyzed to characterize symptom patterns that could predict remission.
num||subjects-4/NNS||one-1/CD	num||subjects-4/NNS||hundred-2/CD	amod||subjects-4/NNS||fifty-one-3/JJ	nsubj||received-8/VBD||subjects-4/NNS	amod||falciparummalaria-7/NN||uncomplicated-6/JJ	prep_with||subjects-4/NNS||falciparummalaria-7/NN	root||ROOT-0/null||received-8/VBD	advmod||observed-10/JJ||directly-9/RB	amod||therapy-11/NN||observed-10/JJ	dobj||received-8/VBD||therapy-11/NN	num||artesunate-15/NN||12-13/CD	amod||artesunate-15/NN||mg/kg-14/VBG	prep_with||received-8/VBD||artesunate-15/NN	num||days-19/NNS||three-18/CD	prep_over||artesunate-15/NN||days-19/NNS	number||mg/kg-23/JJ||25-22/CD	amod||mefloquine-37/NN||mg/kg-23/JJ	amod||mefloquine-37/NN||mefloquine-24/JJ	amod||mefloquine-37/NN||up-26/IN	det||dose-30/NN||a-28/DT	amod||dose-30/NN||maximum-29/JJ	prep_to||up-26/IN||dose-30/NN	num||mg-33/NN||600-32/CD	prep_of||dose-30/NN||mg-33/NN	amod||mefloquine-37/NN||artesunate/1-34/JJ	num||mefloquine-37/NN||,000-35/CD	nn||mefloquine-37/NN||mg-36/NN	prep_with||received-8/VBD||mefloquine-37/NN	conj_and||artesunate-15/NN||mefloquine-37/NN	falciparummalaria-7||mefloquine-37||yes||one hundred fifty-one subjects with uncomplicated falciparummalaria received directly observed therapy with 12 mg/kg artesunate (over three days) and 25 mg/kg mefloquine, up to a maximum dose of 600 mg artesunate/1,000 mg mefloquine.
det||beginning-4/NN||the-3/DT	prep_as_of||includes-16/VBZ||beginning-4/NN	prep_of||beginning-4/NN||2013-6/CD	poss||â-9/NN||our-8/PRP$	appos||2013-6/CD||â-9/NN	amod||â-9/NN||$-10/$	dep||$-10/$||antibodies-11/JJ	aux||watchâ-13/VB||to-12/TO	vmod||beginning-4/NN||watchâ-13/VB	dobj||watchâ-13/VB||$-14/$	num||$-14/$||list-15/CD	root||ROOT-0/null||includes-16/VBZ	num||mabs-19/NNS||28-17/CD	amod||mabs-19/NNS||single-18/JJ	dobj||includes-16/VBZ||mabs-19/NNS	num||mixture-23/NN||one-21/CD	nn||mixture-23/NN||mab-22/NN	dobj||includes-16/VBZ||mixture-23/NN	conj_and||mabs-19/NNS||mixture-23/NN	nsubj||undergoing-26/VBG||mixture-23/NN	aux||undergoing-26/VBG||are-25/VBP	rcmod||mixture-23/NN||undergoing-26/VBG	dobj||undergoing-26/VBG||evaluation-27/NN	prep_in||evaluation-27/NN||phase-29/NN	num||studies-31/NNS||3-30/CD	nsubj||includes-16/VBZ||studies-31/NNS	amod||disorders-36/NNS||inflammatory-33/JJ	conj_or||inflammatory-33/JJ||immunological-35/JJ	amod||disorders-36/NNS||immunological-35/JJ	prep_for||studies-31/NNS||disorders-36/NNS	prep_for||studies-31/NNS||cancers-38/NNS	conj_and||disorders-36/NNS||cancers-38/NNS	amod||cholesterol-41/NN||high-40/JJ	prep_for||studies-31/NNS||cholesterol-41/NN	conj_and||disorders-36/NNS||cholesterol-41/NN	prep_for||studies-31/NNS||osteoporosis-43/NNS	conj_and||disorders-36/NNS||osteoporosis-43/NNS	prep_for||studies-31/NNS||alzheimerdisease-45/NN	conj_and||disorders-36/NNS||alzheimerdisease-45/NN	amod||disease-48/NN||infectious-47/JJ	prep_for||studies-31/NNS||disease-48/NN	conj_and||disorders-36/NNS||disease-48/NN	cancers-38||antibodies--1||no_rel||as of the beginning of 2013, our âantibodies to watchâ? list includes 28 single mabs and one mab mixture that are undergoing evaluation in phase 3 studies for inflammatory or immunological disorders, cancers, high cholesterol, osteoporosis, alzheimerdisease and infectious disease.
det||microenvironment-3/NN||the-1/DT	nn||microenvironment-3/NN||tumor-2/NN	nsubj||caused-4/VBD||microenvironment-3/NN	root||ROOT-0/null||caused-4/VBD	amod||up-regulation-8/NN||rapid-5/JJ	conj_and||rapid-5/JJ||dramatic-7/JJ	amod||up-regulation-8/NN||dramatic-7/JJ	dobj||caused-4/VBD||up-regulation-8/NN	amod||i-11/FW||arginase-10/JJ	prep_of||up-regulation-8/NN||i-11/FW	amod||synthase-15/NN||inducible-13/JJ	nn||synthase-15/NN||nitricoxide-14/NN	dobj||caused-4/VBD||synthase-15/NN	conj_and||up-regulation-8/NN||synthase-15/NN	prep_in||synthase-15/NN||mdsc-17/NN	nsubjpass||accompanied-21/VBN||mdsc-17/NN	auxpass||accompanied-21/VBN||was-20/VBD	rcmod||mdsc-17/NN||accompanied-21/VBN	agent||accompanied-21/VBN||down-regulation-23/NN	amod||dinucleotide-27/NN||nicotinamide-25/JJ	nn||dinucleotide-27/NN||adenine-26/NN	prep_of||down-regulation-23/NN||dinucleotide-27/NN	vmod||dinucleotide-27/NN||phosphateâ-28/VBG	dobj||phosphateâ-28/VBG||$-29/$	nn||and-32/NNP||oxidase-31/NNP	npadvmod||oxygen-34/RB||and-32/NNP	advmod||and-32/NNP||reactive-33/RB	dep||species-35/CD||oxygen-34/RB	num||$-29/$||species-35/CD	det||cells-38/NNS||these-37/DT	prep_in||$-29/$||cells-38/NNS	adenine-26||tumor-2||no_rel||the tumor microenvironment caused rapid and dramatic up-regulation of arginase i and inducible nitricoxide synthase in mdsc, which was accompanied by down-regulation of nicotinamide adenine dinucleotide phosphateâoxidase and reactive oxygen species in these cells.
det||addition-2/NN||the-1/DT	nsubj||shortens-9/VBZ||addition-2/NN	nsubj||shortens-9/VBZ||addition-2/NN	prep_of||addition-2/NN||acetaminophen-4/NN	aux||lidocaine-6/VB||to-5/TO	vmod||acetaminophen-4/NN||lidocaine-6/VB	prep_for||lidocaine-6/VB||ivra-8/NN	root||ROOT-0/null||shortens-9/VBZ	conj_but||shortens-9/VBZ||shortens-9/VBZ	det||time-12/NN||the-10/DT	nn||time-12/NN||onset-11/NN	dobj||shortens-9/VBZ||time-12/NN	amod||block-15/NN||sensory-14/JJ	prep_of||shortens-9/VBZ||block-15/NN	nn||pain-19/NN||delays-17/NNS	nn||pain-19/NN||tourniquet-18/NN	prep_of||shortens-9/VBZ||pain-19/NN	conj_and||block-15/NN||pain-19/NN	amod||time-21/NN||onset-20/JJ	dep||block-15/NN||time-21/NN	neg||shortens-9/VBZ||not-24/RB	prep_with||shortens-9/VBZ||ketorolac-26/NN	pain-19||acetaminophen-4||yes||the addition of acetaminophen to lidocaine for ivra shortens the onset time of sensory block and delays tourniquet pain onset time, but not with ketorolac.
amod||sepsis-2/NN||severe-1/JJ	nsubj||emerged-4/VBN||sepsis-2/NN	aux||emerged-4/VBN||has-3/VBZ	root||ROOT-0/null||emerged-4/VBN	det||cause-8/NN||a-6/DT	amod||cause-8/NN||major-7/JJ	prep_as||emerged-4/VBN||cause-8/NN	prep_of||cause-8/NN||admission-10/NN	prep_of||cause-8/NN||mortality-12/NN	conj_and||admission-10/NN||mortality-12/NN	amod||patients-16/NNS||hospitalized-14/JJ	nn||patients-16/NNS||hiv/aids-15/NNS	prep_for||admission-10/NN||patients-16/NNS	advmod||affecting-19/VBG||significantly-18/RB	xcomp||emerged-4/VBN||affecting-19/VBG	amod||survival-24/NN||short-20/JJ	conj_and||short-20/JJ||longer-term-23/JJ	amod||survival-24/NN||longer-term-23/JJ	dobj||affecting-19/VBG||survival-24/NN	advmod||ill-27/JJ||critically-26/RB	amod||patients-29/NNS||ill-27/JJ	nn||patients-29/NNS||hiv/aids-28/NN	prep_of||survival-24/NN||patients-29/NNS	aids--1||hiv--1||no||severe sepsis has emerged as a major cause of admission and mortality for hospitalized hiv/aids patients, significantly affecting short- and longer-term survival of critically ill hiv/aids patients.
num||patients-7/NNS||16/47-2/CD	nn||patients-7/NNS||-lrb--3/NNP	num||patients-7/NNS||34.0-4/CD	nn||patients-7/NNS||%-5/NN	nn||patients-7/NNS||-rrb--6/NN	prep_in||suspected-18/VBN||patients-7/NNS	amod||cultures-10/NNS||positive-9/JJ	prep_with||patients-7/NNS||cultures-10/NNS	prep_for||cultures-10/NNS||m.tuberculosis-12/NNS	amod||pulmonarytuberculosis-15/NNS||active-14/JJ	nsubjpass||suspected-18/VBN||pulmonarytuberculosis-15/NNS	auxpass||suspected-18/VBN||was-16/VBD	neg||suspected-18/VBN||not-17/RB	root||ROOT-0/null||suspected-18/VBN	det||time-21/NN||the-20/DT	prep_at||suspected-18/VBN||time-21/NN	prep_of||time-21/NN||bronchoscopy-23/NN	pulmonarytuberculosis-15||m.tuberculosis-12||no||in 16/47 -lrb- 34.0 % -rrb- patients with positive cultures for m.tuberculosis , active pulmonarytuberculosis was not suspected at the time of bronchoscopy .
det||combination-2/NN||a-1/DT	nsubj||treatment-14/NN||combination-2/NN	prep_of||combination-2/NN||levodopa-4/NN	appos||levodopa-4/NN||l-dopa-6/NNP	prep_of||combination-2/NN||carbidopa-9/NN	conj_and||levodopa-4/NN||carbidopa-9/NN	cop||treatment-14/NN||is-10/VBZ	det||treatment-14/NN||the-11/DT	advmod||commonly-used-13/JJ||most-12/RBS	amod||treatment-14/NN||commonly-used-13/JJ	root||ROOT-0/null||treatment-14/NN	nn||management-17/NN||symptom-16/NN	prep_for||treatment-14/NN||management-17/NN	nn||sdisease-21/NN||parkinson-19/NN	prep_in||management-17/NN||sdisease-21/NN	parkinson'sdisease--1||levodopa-4||yes||a combination of levodopa (l-dopa) and carbidopa is the most commonly-used treatment for symptom management in parkinson'sdisease.
det||rate-3/NN||the-1/DT	amod||rate-3/NN||relapse-2/JJ	nsubj||observed-4/VBD||rate-3/NN	root||ROOT-0/null||observed-4/VBD	num||months-7/NNS||12-6/CD	prep_after||observed-4/VBD||months-7/NNS	dobj||observed-4/VBD||treatment-8/NN	prep_with||treatment-8/NN||the-10/DT	nsubj||recommended-12/VBD||the-10/DT	rcmod||the-10/DT||recommended-12/VBD	nn||regimen-15/NN||mdr-13/NN	nn||regimen-15/NN||tb-14/NN	nsubj||equivalent-26/JJ||regimen-15/NN	dep||regimen-15/NN||amikacin-17/NN	appos||amikacin-17/NN||ethionamide-19/NN	appos||amikacin-17/NN||pyrazinamide-21/NN	conj_and||ethionamide-19/NN||pyrazinamide-21/NN	appos||amikacin-17/NN||moxifloxacin-23/NN	conj_and||ethionamide-19/NN||moxifloxacin-23/NN	cop||equivalent-26/JJ||was-25/VBD	ccomp||recommended-12/VBD||equivalent-26/JJ	det||treatment-35/NN||the-28/DT	dep||rate-30/NN||relapse-29/JJ	amod||treatment-35/NN||rate-30/NN	amod||treatment-35/NN||observed-31/JJ	num||months-34/NNS||6-33/CD	prep_after||observed-31/JJ||months-34/NNS	prep_to||equivalent-26/JJ||treatment-35/NN	det||regimen-42/NN||the-37/DT	amod||regimen-42/NN||recommended-38/VBN	nn||regimen-42/NN||drug-39/NN	amod||regimen-42/NN||susceptible-40/VBG	nn||regimen-42/NN||tb-41/NN	prep_with||treatment-35/NN||regimen-42/NN	dep||treatment-35/NN||rifampin-44/NN	dep||rifampin-44/NN||isoniazid-46/JJ	dep||rifampin-44/NN||pyrazinamide-48/JJ	conj_and||isoniazid-46/JJ||pyrazinamide-48/JJ	tb-41||rifampin-44||yes||the relapse rate observed after 12 months treatment with the who recommended mdr tb regimen (amikacin, ethionamide, pyrazinamide and moxifloxacin) was equivalent to the relapse rate observed after 6 months treatment with the recommended drug susceptible tb regimen (rifampin, isoniazid and pyrazinamide).
det||enormity-2/NN||the-1/DT	nsubj||led-6/VBD||enormity-2/NN	amod||sufferings-5/NNS||human-4/JJ	prep_of||enormity-2/NN||sufferings-5/NNS	root||ROOT-0/null||led-6/VBD	dobj||led-6/VBD||clinicians-7/NNS	dobj||led-6/VBD||scientists-9/NNS	conj_and||clinicians-7/NNS||scientists-9/NNS	aux||carry-11/VB||to-10/TO	vmod||led-6/VBD||carry-11/VB	prt||carry-11/VB||out-12/RP	amod||research-14/NN||extensive-13/JJ	dobj||carry-11/VB||research-14/NN	iobj||carry-11/VB||research-14/NN	prep_on||research-14/NN||cholera-16/NN	prep_on||research-14/NN||vibriocholerae-18/NN	conj_and||cholera-16/NN||vibriocholerae-18/NN	det||bacterium-22/NN||the-20/DT	amod||bacterium-22/NN||causative-21/JJ	dep||research-14/NN||bacterium-22/NN	det||disease-25/NN||the-24/DT	prep_of||bacterium-22/NN||disease-25/NN	dep||research-14/NN||leading-27/VBG	nsubj||opened-32/VBD||leading-27/VBG	amod||discoveries-30/NNS||major-29/JJ	prep_to||leading-27/VBG||discoveries-30/NNS	rcmod||leading-27/VBG||opened-32/VBD	prt||opened-32/VBD||up-33/RP	nn||areas-35/NNS||novel-34/NN	dobj||opened-32/VBD||areas-35/NNS	nn||disciplines-40/NNS||research-37/NN	conj_or||research-37/NN||new-39/JJ	nn||disciplines-40/NNS||new-39/JJ	prep_of||areas-35/NNS||disciplines-40/NNS	amod||sciences-43/NNS||biomedical-42/JJ	prep_in||opened-32/VBD||sciences-43/NNS	vibriocholerae-18||bacterium-22||no||the enormity of human sufferings led clinicians and scientists to carry out extensive research on cholera and vibriocholerae (the causative bacterium of the disease) leading to major discoveries that opened up novel areas of research or new disciplines in biomedical sciences.
det||three-2/CD||the-1/DT	nsubjpass||intensified-4/VBN||three-2/CD	auxpass||intensified-4/VBN||are-3/VBP	root||ROOT-0/null||intensified-4/VBN	nn||screening-6/NN||tb-5/NN	dobj||intensified-4/VBN||screening-6/NN	appos||screening-6/NN||icf-8/NN	prep_among||intensified-4/VBN||people-11/NNS	vmod||people-11/NNS||living-12/VBG	prep_with||living-12/VBG||hiv-14/NN	det||provision-17/NN||the-16/DT	appos||hiv-14/NN||provision-17/NN	amod||therapy-21/NN||isoniazid-19/JJ	nn||therapy-21/NN||preventive-20/NN	prep_of||provision-17/NN||therapy-21/NN	appos||therapy-21/NN||ipt-23/NN	nn||control-28/NN||tb-26/NN	nn||control-28/NN||infection-27/NN	prep_of||provision-17/NN||control-28/NN	conj_and||therapy-21/NN||control-28/NN	appos||therapy-21/NN||ic-30/NN	tb-26||isoniazid-19||yes||the three are intensified tb screening (icf) among people living with hiv, the provision of isoniazid preventive therapy (ipt) and tb infection control(ic).
aux||study-2/VB||to-1/TO	advcl||analyzed-18/VBD||study-2/VB	det||effects-4/NNS||the-3/DT	dobj||study-2/VB||effects-4/NNS	amod||growth-7/NN||insulin-like-6/JJ	nn||level-13/NN||growth-7/NN	amod||level-13/NN||factor-1-8/JJ	dep||factor-1-8/JJ||igf-1-10/JJ	nn||level-13/NN||plasma-12/NN	prep_of||effects-4/NNS||level-13/NN	prep_on||study-2/VB||ovaries-15/NNS	nsubj||analyzed-18/VBD||we-17/PRP	root||ROOT-0/null||analyzed-18/VBD	nsubj||isolated-20/VBD||ovaries-19/NNS	ccomp||analyzed-18/VBD||isolated-20/VBD	amod||knockout-25/NN||2-year-old-22/JJ	amod||knockout-25/NN||growthhormone-23/JJ	nn||knockout-25/NN||receptor-24/NN	prep_from||isolated-20/VBD||knockout-25/NN	appos||knockout-25/NN||ghr-ko-27/NNP	amod||mice-31/NNS||laron-29/JJ	nn||mice-31/NNS||dwarf-30/NN	dobj||isolated-20/VBD||mice-31/NNS	advmod||circulating-35/VBG||low-34/JJ	prepc_with||isolated-20/VBD||circulating-35/VBG	nn||levels-37/NNS||plasma-36/NN	dobj||circulating-35/VBG||levels-37/NNS	dep||bovine-43/JJ||igf-1-39/JJ	conj_and||bovine-43/JJ||6-month-old-42/JJ	amod||mice-49/NNS||6-month-old-42/JJ	amod||mice-49/NNS||bovine-43/JJ	amod||mice-49/NNS||growthhormone-44/JJ	amod||mice-49/NNS||transgenic-45/JJ	appos||mice-49/NNS||bghtg-47/NN	prep_of||levels-37/NNS||mice-49/NNS	advmod||circulating-53/VBG||high-52/RB	prepc_with||isolated-20/VBD||circulating-53/VBG	nn||levels-55/NNS||plasma-54/NN	dobj||circulating-53/VBG||levels-55/NNS	prep_of||levels-55/NNS||igf-1-57/CD	dwarf-30||growthhormone-44||yes||to study the effects of insulin-like growth factor-1 (igf-1) plasma level on ovaries, we analyzed ovaries isolated from 2-year-old growthhormone receptor knockout (ghr-ko) laron dwarf mice, with low circulating plasma levels of igf-1, and 6-month-old bovine growthhormone transgenic (bghtg) mice, with high circulating plasma levels of igf-1.
det||objective-2/NN||the-1/DT	nsubj||was-6/VBD||objective-2/NN	nsubj||develop-8/VB||objective-2/NN	det||study-5/NN||this-4/DT	prep_in||objective-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||develop-8/VB||to-7/TO	xcomp||was-6/VBD||develop-8/VB	det||bone-16/NN||an-9/DT	amod||bone-16/NN||osteoconductive-10/JJ	conj_and||osteoconductive-10/JJ||biodegradable-12/JJ	amod||bone-16/NN||biodegradable-12/JJ	conj_and||osteoconductive-10/JJ||rifampicin-14/JJ	amod||bone-16/NN||rifampicin-14/JJ	amod||bone-16/NN||releasing-15/JJ	dobj||develop-8/VB||bone-16/NN	vmod||bone-16/NN||filling-17/VBG	amod||material-19/NN||composite-18/JJ	dobj||filling-17/VBG||material-19/NN	det||treatment-22/NN||the-21/DT	prep_for||filling-17/VBG||treatment-22/NN	prep_of||treatment-22/NN||osteomyelitis-24/NNS	det||bacterialinfection-27/NN||a-26/DT	appos||osteomyelitis-24/NNS||bacterialinfection-27/NN	nsubj||difficult-33/JJ||bacterialinfection-27/NN	nsubj||expensive-35/JJ||bacterialinfection-27/NN	nsubj||treat-37/VB||bacterialinfection-27/NN	prep_of||bacterialinfection-27/NN||bone-29/NN	cop||difficult-33/JJ||is-31/VBZ	advmod||difficult-33/JJ||very-32/RB	rcmod||bacterialinfection-27/NN||difficult-33/JJ	rcmod||bacterialinfection-27/NN||expensive-35/JJ	conj_and||difficult-33/JJ||expensive-35/JJ	aux||treat-37/VB||to-36/TO	xcomp||difficult-33/JJ||treat-37/VB	bacterialinfection-27||rifampicin-14||yes||the objective in this study was to develop an osteoconductive, biodegradable and rifampicin releasing bone filling composite material for the treatment of osteomyelitis, a bacterialinfection of bone that is very difficult and expensive to treat.
det||factors-4/NNS||the-2/DT	nn||factors-4/NNS||risk-3/NN	prep_among||contributed-23/VBD||factors-4/NNS	vmod||factors-4/NNS||identified-5/VBN	amod||levels-8/NNS||low-7/JJ	nsubj||contributed-23/VBD||levels-8/NNS	prep_of||levels-8/NNS||vaccination-10/NN	amod||parity-13/NN||high-12/JJ	prep_of||levels-8/NNS||parity-13/NN	conj_and||vaccination-10/NN||parity-13/NN	amod||levels-17/NNS||low-16/JJ	prep_of||levels-8/NNS||levels-17/NNS	conj_and||vaccination-10/NN||levels-17/NNS	amod||awareness-20/NN||maternal-19/JJ	prep_of||levels-17/NNS||awareness-20/NN	prep_of||awareness-20/NN||vitamina-22/NN	root||ROOT-0/null||contributed-23/VBD	amod||risks-26/NNS||higher-25/JJR	prep_to||contributed-23/VBD||risks-26/NNS	advmod||contributed-23/VBD||ofvitaminadeficiency-27/RB	nn||children-30/NNS||muslim-29/NN	prep_among||contributed-23/VBD||children-30/NNS	ofvitaminadeficiency-27||vitamina-22||yes||among the risk factors identified, low levels of vaccination, high parity, and low levels of maternal awareness of vitamina contributed to higher risks ofvitaminadeficiency among muslim children.
det||study-2/NN||this-1/DT	nsubj||evaluated-3/VBN||study-2/NN	root||ROOT-0/null||evaluated-3/VBN	det||effects-5/NNS||the-4/DT	dobj||evaluated-3/VBN||effects-5/NNS	det||program-10/NN||a-7/DT	amod||program-10/NN||progressive-8/JJ	nn||program-10/NN||walking-9/NN	prep_of||effects-5/NNS||program-10/NN	nn||intake-14/NN||glucosamine-12/NN	nn||intake-14/NN||sulphate-13/NN	prep_of||effects-5/NNS||intake-14/NN	conj_and||program-10/NN||intake-14/NN	nn||symptoms-17/NNS||oa-16/NN	prep_on||evaluated-3/VBN||symptoms-17/NNS	amod||participation-21/NN||physical-19/JJ	nn||participation-21/NN||activity-20/NN	conj_and||evaluated-3/VBN||participation-21/NN	prep_in||participation-21/NN||people-23/NNS	amod||moderate-27/JJ||mild-25/JJ	dep||moderate-27/JJ||to-26/TO	amod||hip-28/NN||moderate-27/JJ	prep_with||people-23/NNS||hip-28/NN	nn||oa-31/NN||knee-30/NN	prep_with||people-23/NNS||oa-31/NN	conj_or||hip-28/NN||oa-31/NN	oa-31||glucosamine-12||yes||this study evaluated the effects of a progressive walking program and glucosamine sulphate intake on oa symptoms and physical activity participation in people with mild to moderate hip or knee oa.
det||article-2/NN||this-1/DT	nsubj||review-4/VB||article-2/NN	aux||review-4/VB||will-3/MD	root||ROOT-0/null||review-4/VB	det||effectiveness-6/NN||the-5/DT	dobj||review-4/VB||effectiveness-6/NN	dobj||review-4/VB||risks-8/NNS	conj_and||effectiveness-6/NN||risks-8/NNS	dobj||review-4/VB||timing-10/NN	conj_and||effectiveness-6/NN||timing-10/NN	amod||uses-13/NNS||clinical-12/JJ	dobj||review-4/VB||uses-13/NNS	conj_and||effectiveness-6/NN||uses-13/NNS	prep_of||uses-13/NNS||teriparatide-15/NN	prep_in||review-4/VB||postmenopausalosteoporosis-17/NNS	postmenopausalosteoporosis-17||teriparatide-15||yes||this article will review the effectiveness, risks, timing and clinical uses of teriparatide in postmenopausalosteoporosis.
nsubj||propose-2/VBP||we-1/PRP	root||ROOT-0/null||propose-2/VBP	mark||allows-17/VBZ||that-3/IN	det||protrusion-5/NN||the-4/DT	nsubj||allows-17/VBZ||protrusion-5/NN	det||portion-8/NN||some-7/DT	prep_of||protrusion-5/NN||portion-8/NN	det||terminus-12/NNS||the-10/DT	nn||terminus-12/NNS||c-11/NN	prep_of||portion-8/NN||terminus-12/NNS	det||shell-16/NN||the-14/DT	amod||shell-16/NN||spherical-15/JJ	prep_above||terminus-12/NNS||shell-16/NN	ccomp||propose-2/VBP||allows-17/VBZ	dobj||allows-17/VBZ||it-18/PRP	nsubj||cross-link-20/VB||it-18/PRP	aux||cross-link-20/VB||to-19/TO	xcomp||allows-17/VBZ||cross-link-20/VB	amod||polypeptides-24/NNS||other-22/JJ	amod||polypeptides-24/NNS||mutant-23/JJ	prep_with||cross-link-20/VB||polypeptides-24/NNS	nn||bridging-27/NNS||iron-26/NN	prep_through||cross-link-20/VB||bridging-27/NNS	xcomp||cross-link-20/VB||leading-29/VBG	amod||precipitation-33/NN||enhanced-31/JJ	amod||precipitation-33/NN||mutant-32/JJ	prep_to||leading-29/VBG||precipitation-33/NN	prep_by||leading-29/VBG||iron-35/NN	cross--1||iron-35||no_rel||we propose that the protrusion of some portion of the c terminus above the spherical shell allows it to cross-link with other mutant polypeptides through iron bridging, leading to enhanced mutant precipitation by iron.
nsubjpass||established-4/VBN||it-1/PRP	aux||established-4/VBN||has-2/VBZ	auxpass||established-4/VBN||been-3/VBN	root||ROOT-0/null||established-4/VBN	mark||reduce-12/VB||that-5/IN	nsubj||reduce-12/VB||dyslipidemia-6/NN	conj_and||dyslipidemia-6/NN||dysglycemia-8/NN	nsubj||reduce-12/VB||dysglycemia-8/NN	vmod||dyslipidemia-6/NN||associated-9/VBN	prep_with||associated-9/VBN||hivdisease-11/NN	ccomp||established-4/VBN||reduce-12/VB	det||survival-15/NN||the-13/DT	amod||survival-15/NN||long-term-14/JJ	dobj||reduce-12/VB||survival-15/NN	det||patients-18/NNS||the-17/DT	prep_of||survival-15/NN||patients-18/NNS	poss||role-22/NN||their-21/PRP$	nsubj||unknown-33/JJ||role-22/NN	prepc_for||role-22/NN||predicting-24/VBG	dobj||predicting-24/VBG||prognosis-25/NN	amod||mortality-28/NN||short-term-27/JJ	prep_of||prognosis-25/NN||mortality-28/NN	nn||patients-31/NNS||hiv-30/NN	prep_in||predicting-24/VBG||patients-31/NNS	cop||unknown-33/JJ||is-32/VBZ	conj_but||established-4/VBN||unknown-33/JJ	hivdisease-11||hiv-30||no||it has been established that dyslipidemia and dysglycemia associated with hivdisease reduce the long-term survival of the patients, but their role for predicting prognosis of short-term mortality in hiv patients is unknown.
nsubj||emerging-12/VBG||il2ra/cd25-1/NNS	det||gene-4/NN||the-3/DT	appos||il2ra/cd25-1/NNS||gene-4/NN	nn||±-9/NNS||interleukin-2-6/NN	nn||±-9/NNS||receptor-7/NN	nn||±-9/NNS||î-8/NN	prep_for||gene-4/NN||±-9/NNS	aux||emerging-12/VBG||is-11/VBZ	root||ROOT-0/null||emerging-12/VBG	det||gene-17/NN||a-14/DT	amod||gene-17/NN||general-15/JJ	nn||gene-17/NN||susceptibility-16/NN	prep_as||emerging-12/VBG||gene-17/NN	prep_for||gene-17/NN||autoimmunediseases-19/NNS	poss||role-23/NN||its-22/PRP$	prep_because_of||autoimmunediseases-19/NNS||role-23/NN	det||development-26/NN||the-25/DT	prep_in||emerging-12/VBG||development-26/NN	prep_in||emerging-12/VBG||function-28/NN	conj_and||development-26/NN||function-28/NN	amod||cells-32/NNS||regulatory-30/JJ	nn||cells-32/NNS||t-31/NN	prep_of||development-26/NN||cells-32/NNS	det||association-35/NN||the-34/DT	prep_in||emerging-12/VBG||association-35/NN	conj_and||development-26/NN||association-35/NN	amod||polymorphisms-38/NNS||single-nucleotide-37/JJ	prep_of||association-35/NN||polymorphisms-38/NNS	parataxis||emerging-12/VBG||snps-40/VBZ	det||gene-44/NN||this-43/DT	prep_within||emerging-12/VBG||gene-44/NN	prep_with||gene-44/NN||type1diabetesmellitus-46/NNS	appos||type1diabetesmellitus-46/NNS||dm-48/NN	poss||disease-53/NN||graves-51/NNS	prep_with||gene-44/NN||disease-53/NN	conj_and||type1diabetesmellitus-46/NNS||disease-53/NN	prep_with||gene-44/NN||rheumatoidarthritis-55/NNS	conj_and||type1diabetesmellitus-46/NNS||rheumatoidarthritis-55/NNS	appos||rheumatoidarthritis-55/NNS||ra-57/NN	prep_with||gene-44/NN||multiplesclerosis-61/NNS	conj_and||type1diabetesmellitus-46/NNS||multiplesclerosis-61/NNS	appos||multiplesclerosis-61/NNS||ms-63/NN	interleukin-2-6||multiplesclerosis-61||no_rel||il2ra/cd25 , the gene for interleukin-2 receptor î±, is emerging as a general susceptibility gene for autoimmunediseases because of its role in the development and function of regulatory t cells and the association of single-nucleotide polymorphisms (snps) within this gene with type1diabetesmellitus (dm), graves' disease, rheumatoidarthritis (ra), and multiplesclerosis (ms).
poss||results-2/NNS||our-1/PRP$	nsubj||demonstrate-3/VBP||results-2/NNS	root||ROOT-0/null||demonstrate-3/VBP	mark||considered-8/VBN||that-4/IN	nsubjpass||considered-8/VBN||lamivudine-5/NN	nsubj||prevent-19/VB||lamivudine-5/NN	aux||considered-8/VBN||should-6/MD	auxpass||considered-8/VBN||be-7/VB	ccomp||demonstrate-3/VBP||considered-8/VBN	advmod||considered-8/VBN||preemptively-9/RB	det||chemotherapy-12/NN||the-11/DT	prep_before||considered-8/VBN||chemotherapy-12/NN	det||patients-17/NNS||all-14/DT	amod||patients-17/NNS||hbsag-positive-15/JJ	nn||patients-17/NNS||nhl-16/NN	prep_for||chemotherapy-12/NN||patients-17/NNS	aux||prevent-19/VB||to-18/TO	xcomp||considered-8/VBN||prevent-19/VB	nn||reactivation-21/NN||hbv-20/NN	dobj||prevent-19/VB||reactivation-21/NN	prep_regardless_of||hbeag-26/VBG||pre-chemotherapy-25/NN	xcomp||considered-8/VBN||hbeag-26/VBG	dobj||hbeag-26/VBG||status-27/NN	hbv-20||lamivudine-5||yes||our results demonstrate that lamivudine should be considered preemptively before the chemotherapy for all hbsag-positive nhl patients to prevent hbv reactivation, regardless of pre-chemotherapy hbeag status.
det||paper-2/NN||this-1/DT	nsubj||explores-3/VBZ||paper-2/NN	root||ROOT-0/null||explores-3/VBZ	det||association-6/NN||the-4/DT	amod||association-6/NN||possible-5/JJ	dobj||explores-3/VBZ||association-6/NN	prep_between||association-6/NN||antibiotics-8/NNS	vmod||antibiotics-8/NNS||prescribed-9/VBN	prep_in||prescribed-9/VBN||infancy-11/NN	prep_in||prescribed-9/VBN||allergicdisorders-13/NNS	conj_and||infancy-11/NN||allergicdisorders-13/NNS	advmod||eczema-16/NN||mainly-15/RB	appos||infancy-11/NN||eczema-16/NN	appos||infancy-11/NN||asthma-18/NN	conj_and||eczema-16/NN||asthma-18/NN	prep_in||prescribed-9/VBN||childhood-21/NN	antibiotics-8||allergicdisorders-13||no_rel||this paper explores the possible association between antibiotics prescribed in infancy and allergicdisorders, mainly eczema and asthma, in childhood.
amod||exercise-2/NN||endurance-1/JJ	nsubj||attenuated-4/VBD||exercise-2/NN	advmod||attenuated-4/VBD||significantly-3/RB	root||ROOT-0/null||attenuated-4/VBD	amod||obesity-7/NN||high-fat-5/JJ	amod||obesity-7/NN||diet-induced-6/JJ	dobj||attenuated-4/VBD||obesity-7/NN	obesity-7||fat--1||no_rel||endurance exercise significantly attenuated high-fat diet-induced obesity.
nsubjpass||defined-6/VBN||irondeficiency-1/NN	appos||irondeficiency-1/NN||id-3/NN	auxpass||defined-6/VBN||was-5/VBD	root||ROOT-0/null||defined-6/VBN	amod||receptor-10/NN||high-soluble-8/JJ	nn||receptor-10/NN||transferrin-9/NN	prep_as||defined-6/VBN||receptor-10/NN	dep||receptor-10/NN||stfr-12/NN	number||8.5-14/CD||>-13/CD	num||â-15/NN||8.5-14/CD	dep||stfr-12/NN||â-15/NN	npadvmod||mg/l-18/JJ||$-16/$	num||$-16/$||-17/CD	amod||â-15/NN||mg/l-18/JJ	prep||receptor-10/NN||plus-20/CC	nn||depletion-22/NN||iron-21/NN	pobj||plus-20/CC||depletion-22/NN	irondeficiency-1||iron-21||yes||irondeficiency (id) was defined as high-soluble transferrin receptor (stfr>8.5âmg/l) plus iron depletion.
nsubj||necessary-9/JJ||methylation-1/NN	det||ar-4/NN||the-3/DT	prep_of||methylation-1/NN||ar-4/NN	amod||632-7/NNS||lysine-6/JJ	prep_on||ar-4/NN||632-7/NNS	cop||necessary-9/JJ||is-8/VBZ	root||ROOT-0/null||necessary-9/JJ	prepc_for||necessary-9/JJ||enhancing-11/VBG	amod||activity-13/NN||transcriptional-12/JJ	dobj||enhancing-11/VBG||activity-13/NN	det||receptor-16/NN||the-15/DT	prep_of||activity-13/NN||receptor-16/NN	prepc_by||enhancing-11/VBG||facilitating-18/VBG	det||communication-21/NN||both-19/DT	amod||communication-21/NN||inter-domain-20/JJ	dobj||facilitating-18/VBG||communication-21/NN	det||n-24/NN||the-23/DT	prep_between||communication-21/NN||n-24/NN	dobj||facilitating-18/VBG||c-termini-27/NN	conj_and||communication-21/NN||c-termini-27/NN	conj_and||communication-21/NN||recruitment-29/NN	conj_and||c-termini-27/NN||recruitment-29/NN	amod||genes-32/NNS||androgen-target-31/JJ	prep_to||c-termini-27/NN||genes-32/NNS	androgen--1||ar-4||no_rel||methylation of the ar on lysine 632 is necessary for enhancing transcriptional activity of the receptor by facilitating both inter-domain communication between the n- and c-termini and recruitment to androgen-target genes.
vmod||invasive-37/JJ||forced-1/VBN	dobj||forced-1/VBN||expression-2/NN	prep_of||expression-2/NN||st6gal-i-4/CD	amod||cells-7/NNS||ov4-6/JJ	prep_in||forced-1/VBN||cells-7/NNS	vmod||forced-1/VBN||resulting-9/VBG	prep_in||resulting-9/VBG||sialylation-11/NN	nn||²-14/NNS||î-13/NN	prep_of||sialylation-11/NN||²-14/NNS	num||integrins-16/NNS||1-15/CD	dobj||resulting-9/VBG||integrins-16/NNS	dep||integrins-16/NNS||induced-18/VBN	amod||adhesion-21/NN||greater-19/JJR	nn||adhesion-21/NN||cell-20/NN	dobj||induced-18/VBN||adhesion-21/NN	prep||induced-18/VBN||to-22/TO	dep||integrins-16/NNS||migration-25/VBN	conj_and||induced-18/VBN||migration-25/VBN	prep||migration-25/VBN||toward-26/IN	vmod||integrins-16/NNS||collagen-28/VBG	dobj||collagen-28/VBG||i.-29/NN	advmod||collagen-28/VBG||similarly-30/RB	amod||cells-34/NNS||st6gal-i-32/JJ	nn||cells-34/NNS||expressing-33/NN	nsubj||invasive-37/JJ||cells-34/NNS	cop||invasive-37/JJ||were-35/VBD	advmod||invasive-37/JJ||more-36/RBR	root||ROOT-0/null||invasive-37/JJ	prep_through||invasive-37/JJ||matrigel-39/NN	adhesion-21||collagen-28||no_rel||forced expression of st6gal-i in ov4 cells , resulting in sialylation of î ² 1 integrins , induced greater cell adhesion to , and migration toward , collagen i. similarly , st6gal-i expressing cells were more invasive through matrigel .
nn||design-2/NN||research-1/NN	nsubj||â-5/VBP||design-2/NN	conj_and||design-2/NN||methods-4/NNS	nsubj||â-5/VBP||methods-4/NNS	root||ROOT-0/null||â-5/VBP	dobj||â-5/VBP||$-6/$	nsubj||measured-9/VBD||we-8/PRP	rcmod||$-6/$||measured-9/VBD	amod||circumference-11/NN||waist-10/JJ	dobj||measured-9/VBD||circumference-11/NN	nn||pressure-14/NN||blood-13/NN	dobj||measured-9/VBD||pressure-14/NN	conj_and||circumference-11/NN||pressure-14/NN	nn||concentrations-21/NNS||glucose-16/NN	conj_and||glucose-16/NN||insulin-18/NN	nn||concentrations-21/NNS||insulin-18/NN	conj_and||glucose-16/NN||lipid-20/NN	nn||concentrations-21/NNS||lipid-20/NN	dobj||measured-9/VBD||concentrations-21/NNS	conj_and||circumference-11/NN||concentrations-21/NNS	det||prevalence-25/NN||the-24/DT	dobj||measured-9/VBD||prevalence-25/NN	conj_and||circumference-11/NN||prevalence-25/NN	amod||syndrome-28/NN||metabolic-27/JJ	prep_of||prevalence-25/NN||syndrome-28/NN	amod||panel-36/NN||national-30/JJ	nn||panel-36/NN||cholesterol-31/NN	nn||panel-36/NN||education-32/NN	nn||panel-36/NN||program-33/NN	nn||panel-36/NN||adult-34/NN	nn||panel-36/NN||treatment-35/NN	dep||syndrome-28/NN||panel-36/NN	dep||syndrome-28/NN||definition-38/NN	conj_iii||panel-36/NN||definition-38/NN	num||men-42/NNS||1,492-41/CD	prep_in||measured-9/VBD||men-42/NNS	prep_in||measured-9/VBD||women-44/NNS	conj_and||men-42/NNS||women-44/NNS	vmod||men-42/NNS||aged-45/VBN	dobj||aged-45/VBN||26â-46/NNS	num||years-50/NNS||$-47/$	num||$-47/$||32-49/CD	npadvmod||aged-45/VBN||years-50/NNS	prep_in||aged-45/VBN||delhi-52/NNS	poss||weight-57/NN||delhi-52/NNS	appos||delhi-52/NNS||india-54/NN	nsubjpass||recorded-61/VBN||weight-57/NN	conj_and||weight-57/NN||height-59/NN	nsubjpass||recorded-61/VBN||height-59/NN	auxpass||recorded-61/VBN||were-60/VBD	rcmod||delhi-52/NNS||recorded-61/VBN	det||months-64/NNS||every-62/DT	num||months-64/NNS||6-63/CD	tmod||recorded-61/VBN||months-64/NNS	prep_throughout||recorded-61/VBN||infancy-66/NN	dep||infancy-66/NN||0â-68/NNS	num||years-72/NNS||$-69/$	num||$-69/$||2-71/CD	dep||0â-68/NNS||years-72/NNS	prep_throughout||recorded-61/VBN||childhood-75/NN	conj_and||infancy-66/NN||childhood-75/NN	dep||childhood-75/NN||2â-77/NNS	num||years-81/NNS||$-78/$	num||$-78/$||11-80/CD	dep||2â-77/NNS||years-81/NNS	prep_throughout||recorded-61/VBN||adolescence-85/NN	conj_and||infancy-66/NN||adolescence-85/NN	num||yearsâ-88/NNS||11-87/CD	dep||adolescence-85/NN||yearsâ-88/NNS	dep||yearsâ-88/NNS||$-89/$	dep||$-89/$||adult-91/NN	glucose-16||delhi-52||no_rel||research design and methods âwe measured waist circumference, blood pressure, glucose, insulin and lipid concentrations, and the prevalence of metabolic syndrome (national cholesterol education program adult treatment panel iii definition) in 1,492 men and women aged 26â32 years in delhi, india, whose weight and height were recorded every 6 months throughout infancy (0â2 years), childhood (2â11 years), and adolescence (11 yearsâadult).
det||report-3/NN||this-1/DT	nn||report-3/NN||case-2/NN	nsubj||demonstrates-4/VBZ||report-3/NN	root||ROOT-0/null||demonstrates-4/VBZ	det||response-7/NN||a-5/DT	amod||response-7/NN||satisfying-6/JJ	nsubj||had-24/VBD||response-7/NN	nsubjpass||discontinued-27/VBN||response-7/NN	aux||topiramate-9/VB||to-8/TO	vmod||response-7/NN||topiramate-9/VB	det||patient-13/NN||a-11/DT	amod||patient-13/NN||79-year-old-12/JJ	prep_in||topiramate-9/VB||patient-13/NN	amod||essentialtremor-16/NN||disabling-15/VBG	prep_with||topiramate-9/VB||essentialtremor-16/NN	nsubj||propranolol-19/VBP||whom-18/WP	nsubj||primidone-23/VBP||whom-18/WP	prepc_in||essentialtremor-16/NN||propranolol-19/VBP	prepc_in||essentialtremor-16/NN||primidone-23/VBP	conj_and||propranolol-19/VBP||primidone-23/VBP	ccomp||demonstrates-4/VBZ||had-24/VBD	aux||discontinued-27/VBN||to-25/TO	auxpass||discontinued-27/VBN||be-26/VB	xcomp||had-24/VBD||discontinued-27/VBN	xcomp||discontinued-27/VBN||due-28/JJ	amod||effects-32/NNS||severe-30/JJ	nn||effects-32/NNS||side-31/NN	prep_to||due-28/JJ||effects-32/NNS	topiramate-9||essentialtremor-16||no_rel||this case report demonstrates a satisfying response to topiramate in a 79-year-old patient with disabling essentialtremor in whom propranolol as well as primidone had to be discontinued due to severe side effects.
nsubj||suggest-2/VBP||we-1/PRP	root||ROOT-0/null||suggest-2/VBP	mark||has-5/VBZ||that-3/IN	nsubj||has-5/VBZ||exenatide-4/NN	ccomp||suggest-2/VBP||has-5/VBZ	amod||potential-7/NN||therapeutic-6/JJ	dobj||has-5/VBZ||potential-7/NN	amod||therapy-10/NN||adjunctive-9/JJ	prep_as||potential-7/NN||therapy-10/NN	prep_in||therapy-10/NN||type1diabetes-12/CD	type1diabetes-12||exenatide-4||no||we suggest that exenatide has therapeutic potential as adjunctive therapy in type1diabetes.
amod||children-2/NNS||forty-eight-1/JJ	nsubjpass||recruited-8/VBN||children-2/NNS	nsubjpass||treated-17/VBN||children-2/NNS	conj_and||children-2/NNS||adolescents-4/NNS	nsubjpass||recruited-8/VBN||adolescents-4/NNS	prep_with||children-2/NNS||ticdisorders-6/NNS	auxpass||recruited-8/VBN||were-7/VBD	root||ROOT-0/null||recruited-8/VBN	det||clinic-12/NN||the-10/DT	nn||clinic-12/NN||outpatient-11/NN	prep_from||recruited-8/VBN||clinic-12/NN	amod||korea-15/NN||south-14/JJ	prep_at||recruited-8/VBN||korea-15/NN	conj_and||recruited-8/VBN||treated-17/VBN	prep_with||treated-17/VBN||aripiprazole-19/NN	amod||dose-22/NN||initial-21/JJ	dep||mg/d-31/VBD||dose-22/NN	num||mg/d-26/NN||5.0-24/CD	nn||mg/d-26/NN||â-25/NN	appos||dose-22/NN||mg/d-26/NN	amod||20â-30/NNS||maximum-28/JJ	nn||20â-30/NNS||dose-29/NN	nsubj||mg/d-31/VBD||20â-30/NNS	dep||aripiprazole-19/NN||mg/d-31/VBD	prep_with||treated-17/VBN||haloperidol-34/NN	conj_or||aripiprazole-19/NN||haloperidol-34/NN	amod||dose-37/NN||initial-36/JJ	dep||haloperidol-34/NN||dose-37/NN	num||â-40/NN||0.75-39/CD	appos||dose-37/NN||â-40/NN	vmod||â-40/NN||mg/d-41/VBN	amod||dose-44/NN||maximum-43/JJ	dep||â-40/NN||dose-44/NN	num||mg/d-48/NN||4.5-46/CD	nn||mg/d-48/NN||â-47/NN	appos||dose-44/NN||mg/d-48/NN	amod||weeks-52/NNS||8â-51/JJ	prep_for||recruited-8/VBN||weeks-52/NNS	ticdisorders-6||haloperidol-34||no_rel||forty-eight children and adolescents with ticdisorders were recruited from the outpatient clinic at south korea and treated with aripiprazole (initial dose, 5.0â mg/d; maximum dose 20â mg/d) or haloperidol (initial dose, 0.75â mg/d; maximum dose, 4.5â mg/d) for 8â weeks.
num||possibility-2/NN||one-1/CD	nsubj||is-3/VBZ||possibility-2/NN	root||ROOT-0/null||is-3/VBZ	prepc_by||is-3/VBZ||signalling-5/VBG	nn||receptors-8/NNS||androgen-7/NN	prep_via||signalling-5/VBG||receptors-8/NNS	appos||receptors-8/NNS||ar-10/NN	vmod||receptors-8/NNS||expressed-12/VBN	amod||arteriole-15/JJ||testicular-14/JJ	amod||cells-18/NNS||arteriole-15/JJ	amod||cells-18/NNS||smooth-16/JJ	nn||cells-18/NNS||muscle-17/NN	prep_in||expressed-12/VBN||cells-18/NNS	androgen-7||ar-10||no_rel||one possibility is by signalling via androgen receptors (ar) expressed in testicular arteriole smooth muscle cells.
mark||likely-14/JJ||since-1/IN	det||part-4/NN||a-2/DT	amod||part-4/NN||significant-3/JJ	nsubj||likely-14/JJ||part-4/NN	nsubj||relate-16/VB||part-4/NN	det||diversity-8/NN||the-6/DT	amod||diversity-8/NN||clinicopathological-7/JJ	prep_of||part-4/NN||diversity-8/NN	vmod||diversity-8/NN||seen-9/VBN	amod||priondisease-12/NN||human-11/JJ	prep_in||seen-9/VBN||priondisease-12/NN	cop||likely-14/JJ||is-13/VBZ	advcl||compared-28/VBN||likely-14/JJ	aux||relate-16/VB||to-15/TO	xcomp||likely-14/JJ||relate-16/VB	det||propagation-19/NN||the-18/DT	prep_to||relate-16/VB||propagation-19/NN	amod||strains-24/NNS||distinct-21/JJ	amod||strains-24/NNS||human-22/JJ	nn||strains-24/NNS||prion-23/NN	prep_of||propagation-19/NN||strains-24/NNS	nsubj||compared-28/VBN||we-26/PRP	aux||compared-28/VBN||have-27/VBP	root||ROOT-0/null||compared-28/VBN	det||properties-31/NNS||the-29/DT	nn||properties-31/NNS||transmission-30/NN	dobj||compared-28/VBN||properties-31/NNS	amod||prions-34/NNS||kuru-33/JJ	prep_of||properties-31/NNS||prions-34/NNS	prep_with||compared-28/VBN||those-36/DT	vmod||those-36/DT||isolated-37/VBN	prep_from||isolated-37/VBN||patients-39/NNS	amod||cjd-46/NN||sporadic-41/JJ	conj_and||sporadic-41/JJ||iatrogenic-43/JJ	amod||cjd-46/NN||iatrogenic-43/JJ	conj_and||sporadic-41/JJ||variant-45/JJ	amod||cjd-46/NN||variant-45/JJ	prep_with||patients-39/NNS||cjd-46/NN	preconj||transgenic-49/JJ||both-48/DT	amod||mice-52/NNS||transgenic-49/JJ	conj_and||transgenic-49/JJ||wild-type-51/JJ	amod||mice-52/NNS||wild-type-51/JJ	prep_in||cjd-46/NN||mice-52/NNS	priondisease-12||prions-34||no||since a significant part of the clinicopathological diversity seen in human priondisease is likely to relate to the propagation of distinct human prion strains, we have compared the transmission properties of kuru prions with those isolated from patients with sporadic, iatrogenic and variant cjd in both transgenic and wild-type mice.
det||cb-3/NN||the-1/DT	amod||cb-3/NN||high-fat-2/JJ	nsubj||induced-10/VBN||cb-3/NN	conj_and||cb-3/NN||oo-5/NN	nsubj||induced-10/VBN||oo-5/NN	advmod||diets-9/NNS||so-8/RB	conj_and||cb-3/NN||diets-9/NNS	nsubj||induced-10/VBN||diets-9/NNS	root||ROOT-0/null||induced-10/VBN	dobj||induced-10/VBN||hyperglycemia-11/NN	det||increase-15/NN||a-13/DT	amod||increase-15/NN||2-fold-14/JJ	dobj||induced-10/VBN||increase-15/NN	conj_and||hyperglycemia-11/NN||increase-15/NN	amod||content-19/NN||hepatic-17/JJ	amod||content-19/NN||fat-18/JJ	prep_in||induced-10/VBN||content-19/NN	amod||mice-27/NNS||male-21/JJ	neg||female-25/JJ||not-24/RB	conj_but||male-21/JJ||female-25/JJ	amod||mice-27/NNS||female-25/JJ	amod||mice-27/NNS||wild-type-26/JJ	prep_in||content-19/NN||mice-27/NNS	prep_in||content-34/NN||females-30/NNS	amod||content-34/NN||hepatic-32/JJ	amod||content-34/NN||fat-33/JJ	dep||mice-27/NNS||content-34/NN	prep_to||similar-36/JJ||content-34/NN	cop||similar-36/JJ||was-35/VBD	rcmod||content-34/NN||similar-36/JJ	prep_in||that-38/DT||males-40/NNS	vmod||males-40/NNS||fed-41/VBN	det||diet-44/NN||a-42/DT	amod||diet-44/NN||high-fat-43/JJ	dobj||fed-41/VBN||diet-44/NN	hyperglycemia-11||fat-33||no_rel||the high-fat cb, oo, and so diets induced hyperglycemia and a 2-fold increase in hepatic fat content in male, but not female wild-type mice (in females, hepatic fat content was similar to that in males fed a high-fat diet).
mark||infect-8/VB||although-1/IN	det||h5n1-6/NNS||the-2/DT	advmod||pathogenic-4/JJ||highly-3/RB	amod||h5n1-6/NNS||pathogenic-4/JJ	nn||h5n1-6/NNS||avianinfluenzavirus-5/NN	nsubj||infect-8/VB||h5n1-6/NNS	nsubj||cause-10/VB||h5n1-6/NNS	aux||infect-8/VB||can-7/MD	advcl||efficient-19/JJ||infect-8/VB	conj_and||infect-8/VB||cause-10/VB	advcl||efficient-19/JJ||cause-10/VB	amod||diseases-12/NNS||severe-11/JJ	dobj||infect-8/VB||diseases-12/NNS	prep_in||diseases-12/NNS||humans-14/NNS	nsubj||efficient-19/JJ||it-16/PRP	cop||efficient-19/JJ||is-17/VBZ	neg||efficient-19/JJ||not-18/RB	root||ROOT-0/null||efficient-19/JJ	prepc_in||efficient-19/JJ||infecting-21/VBG	amod||tract-25/NN||human-22/JJ	amod||tract-25/NN||upper-23/JJ	nn||tract-25/NN||respiratory-24/NN	dobj||infecting-21/VBG||tract-25/NN	h5n1-6||avianinfluenzavirus-5||no||although the highly pathogenic avianinfluenzavirus h5n1 can infect and cause severe diseases in humans, it is not efficient in infecting human upper respiratory tract.
prep_at||score-7/VBP||rest-2/NN	det||pain-6/NN||the-4/DT	nn||pain-6/NN||vas-5/NN	nsubj||score-7/VBP||pain-6/NN	root||ROOT-0/null||score-7/VBP	det||group-11/NN||the-9/DT	amod||group-11/NN||remifentanil-10/JJ	prep_in||score-7/VBP||group-11/NN	num||h-14/NN||2-13/CD	prep_at||group-11/NN||h-14/NN	mark||higher-22/JJR||after-15/IN	nsubj||higher-22/JJR||arrival-16/NN	det||pacu-19/NN||the-18/DT	prep_in||arrival-16/NN||pacu-19/NN	cop||higher-22/JJR||was-20/VBD	advmod||higher-22/JJR||significantly-21/RB	advcl||score-7/VBP||higher-22/JJR	prep_than||higher-22/JJR||those-24/DT	det||groups-29/NNS||the-26/DT	amod||groups-29/NNS||other-27/JJ	num||groups-29/NNS||two-28/CD	prep_in||those-24/DT||groups-29/NNS	pain-6||remifentanil-10||yes||at rest, the vas pain score in the remifentanil group at 2 h after arrival in the pacu was significantly higher than those in the other two groups.
nsubj||genome-5/VBP||sars-coronavirus-1/NNS	appos||sars-coronavirus-1/NNS||sars-cov-3/NNP	root||ROOT-0/null||genome-5/VBP	nsubj||depends-7/VBZ||expression-6/NN	ccomp||genome-5/VBP||depends-7/VBZ	det||synthesis-10/NN||the-9/DT	prep_on||depends-7/VBZ||synthesis-10/NN	det||set-13/NN||a-12/DT	prep_of||synthesis-10/NN||set-13/NN	prep_of||set-13/NN||mrnas-15/NNS	nsubjpass||capped-20/VBN||mrnas-15/NNS	advmod||capped-20/VBN||presumably-18/RB	auxpass||capped-20/VBN||are-19/VBP	rcmod||mrnas-15/NNS||capped-20/VBN	poss||end-26/NN||their-22/PRP$	amod||end-26/NN||5â-23/JJ	amod||end-26/NN||$-24/$	num||$-24/$||²-25/CD	prep_at||capped-20/VBN||end-26/NN	amod||synthesis-30/NN||direct-28/JJ	det||synthesis-30/NN||the-29/DT	prep_at||capped-20/VBN||synthesis-30/NN	conj_and||end-26/NN||synthesis-30/NN	det||proteins-34/NNS||all-32/DT	amod||proteins-34/NNS||viral-33/JJ	prep_of||synthesis-30/NN||proteins-34/NNS	det||cell-38/NN||the-36/DT	amod||cell-38/NN||infected-37/JJ	prep_in||proteins-34/NNS||cell-38/NN	sars--1||coronavirus--1||no||sars-coronavirus (sars-cov) genome expression depends on the synthesis of a set of mrnas, which presumably are capped at their 5â² end and direct the synthesis of all viral proteins in the infected cell.
amod||insights-2/NNS||new-1/JJ	nsubj||broaden-13/VB||insights-2/NNS	det||basis-6/NN||the-4/DT	amod||basis-6/NN||cellular-5/JJ	prep_into||insights-2/NNS||basis-6/NN	amod||toxicity-9/NN||azole-8/JJ	prep_of||basis-6/NN||toxicity-9/NN	prep_in||toxicity-9/NN||fungi-11/NNS	aux||broaden-13/VB||may-12/MD	root||ROOT-0/null||broaden-13/VB	amod||regimens-15/NNS||therapeutic-14/JJ	dobj||broaden-13/VB||regimens-15/NNS	amod||populations-18/NNS||patient-17/JJ	prep_for||broaden-13/VB||populations-18/NNS	vmod||populations-18/NNS||afflicted-19/VBN	amod||fungalinfections-22/NNS||systemic-21/JJ	prep_with||afflicted-19/VBN||fungalinfections-22/NNS	fungalinfections-22||fungi-11||no||new insights into the cellular basis of azole toxicity in fungi may broaden therapeutic regimens for patient populations afflicted with systemic fungalinfections.
advmod||components-8/NNS||indeed-1/RB	nsubj||components-8/NNS||isoniazid-3/NN	conj_and||isoniazid-3/NN||rifampicin-5/NN	nsubj||components-8/NNS||rifampicin-5/NN	cop||components-8/NNS||are-6/VBP	amod||components-8/NNS||important-7/JJ	root||ROOT-0/null||components-8/NNS	det||regimen-11/NN||any-10/DT	prep_of||components-8/NNS||regimen-11/NN	det||treatment-14/NN||the-13/DT	prep_for||regimen-11/NN||treatment-14/NN	prep_of||treatment-14/NN||drug-16/NN	amod||tb-18/JJ||susceptible-17/JJ	amod||drug-16/NN||tb-18/JJ	tb-18||isoniazid-3||yes||indeed, isoniazid and rifampicin are important components of any regimen for the treatment of drug susceptible tb.
nsubj||agent-5/NN||htlv-i-1/NNP	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||the-3/DT	amod||agent-5/NN||causal-4/JJ	root||ROOT-0/null||agent-5/NN	amod||leukemia-10/NN||adult-7/JJ	nn||leukemia-10/NN||t-8/NN	nn||leukemia-10/NN||cell-9/NN	prep_of||agent-5/NN||leukemia-10/NN	dep||leukemia-10/NN||atll-12/JJ	prep_of||agent-5/NN||htlv-i-associatedmyelopathy/tropicalspasticparaparesis-15/NNS	conj_and||leukemia-10/NN||htlv-i-associatedmyelopathy/tropicalspasticparaparesis-15/NNS	appos||leukemia-10/NN||ham/tsp-17/NN	ham--1||htlv-i-1||no||htlv-i is the causal agent of adult t cell leukemia (atll) and htlv-i-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp).
nsubj||agent-5/NN||yersiniapestis-1/NNS	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||the-3/DT	amod||agent-5/NN||causative-4/JJ	root||ROOT-0/null||agent-5/NN	prep_of||agent-5/NN||pneumonicplague-7/NN	advmod||reported-14/VBD||recently-9/RB	nsubj||reported-14/VBD||we-11/PRP	conj_and||we-11/PRP||others-13/NNS	nsubj||reported-14/VBD||others-13/NNS	parataxis||agent-5/NN||reported-14/VBD	dobj||reported-14/VBD||that-15/DT	det||hours-20/NNS||the-17/DT	amod||hours-20/NNS||first-18/JJ	num||hours-20/NNS||24-36-19/CD	prep_during||reported-14/VBD||hours-20/NNS	mark||undetectable-30/JJ||after-21/IN	amod||infection-23/NN||pulmonary-22/JJ	nsubj||undetectable-30/JJ||infection-23/NN	amod||expression-28/NN||y.pestis-25/JJ	amod||expression-28/NN||pro-inflammatory-26/JJ	nn||expression-28/NN||cytokine-27/NN	prep_with||infection-23/NN||expression-28/NN	cop||undetectable-30/JJ||is-29/VBZ	advcl||reported-14/VBD||undetectable-30/JJ	nn||tissues-33/NNS||lung-32/NN	prep_in||undetectable-30/JJ||tissues-33/NNS	pneumonicplague-7||y.pestis-25||no||yersiniapestis is the causative agent of pneumonicplague ; recently , we and others reported that during the first 24-36 hours after pulmonary infection with y.pestis pro-inflammatory cytokine expression is undetectable in lung tissues .
aux||select-2/VB||to-1/TO	advcl||matched-16/VBD||select-2/VB	amod||compartments-4/NNS||cellular-3/JJ	dobj||select-2/VB||compartments-4/NNS	advmod||likely-6/JJ||most-5/RBS	amod||compartments-4/NNS||likely-6/JJ	aux||give-8/VB||to-7/TO	xcomp||likely-6/JJ||give-8/VB	dobj||give-8/VB||rise-9/NN	prep_to||give-8/VB||subgroups-11/NNS	prep_of||subgroups-11/NNS||ependymoma-13/NN	nsubj||matched-16/VBD||we-15/PRP	root||ROOT-0/null||matched-16/VBD	det||transcriptomes-18/NNS||the-17/DT	nsubj||stem-27/VBP||transcriptomes-18/NNS	amod||tumors-21/NNS||human-20/JJ	prep_of||transcriptomes-18/NNS||tumors-21/NNS	prep_to||tumors-21/NNS||those-23/DT	nn||neural-26/NN||mouse-25/NN	prep_of||those-23/DT||neural-26/NN	ccomp||matched-16/VBD||stem-27/VBP	dobj||stem-27/VBP||cells-28/NNS	appos||cells-28/NNS||nscs-30/NNS	vmod||cells-28/NNS||isolated-33/VBN	amod||regions-36/NNS||different-35/JJ	prep_from||isolated-33/VBN||regions-36/NNS	det||cns-39/NN||the-38/DT	prep_of||regions-36/NNS||cns-39/NN	amod||stages-43/NNS||different-41/JJ	amod||stages-43/NNS||developmental-42/JJ	prep_at||cns-39/NN||stages-43/NNS	det||locus-51/NNS||an-46/DT	amod||locus-51/NNS||intact-47/JJ	conj_or||intact-47/JJ||deleted-49/JJ	amod||locus-51/NNS||deleted-49/JJ	amod||locus-51/NNS||ink4a/arf-50/JJ	prep_with||cells-28/NNS||locus-51/NNS	rise-9||ependymoma-13||no_rel||to select cellular compartments most likely to give rise to subgroups of ependymoma, we matched the transcriptomes of human tumors to those of mouse neural stem cells (nscs), isolated from different regions of the cns at different developmental stages, with an intact or deleted ink4a/arf locus.
nsubjpass||shown-3/VBN||fondaparinux-1/NN	nsubj||efficacious-6/JJ||fondaparinux-1/NN	auxpass||shown-3/VBN||was-2/VBD	root||ROOT-0/null||shown-3/VBN	aux||efficacious-6/JJ||to-4/TO	cop||efficacious-6/JJ||be-5/VB	xcomp||shown-3/VBN||efficacious-6/JJ	det||prevention-9/NN||the-8/DT	prep_in||efficacious-6/JJ||prevention-9/NN	amod||heparins-15/NNS||deep-11/JJ	nn||heparins-15/NNS||veinthrombosis-12/NN	nn||heparins-15/NNS||vs-13/NN	amod||heparins-15/NNS||low-molecular-weight-14/JJ	prep_of||prevention-9/NN||heparins-15/NNS	mark||shown-28/VBN||while-17/IN	det||setting-20/NN||the-19/DT	prep_in||shown-28/VBN||setting-20/NN	amod||disease-24/NN||venous-22/JJ	amod||disease-24/NN||thrombo-embolic-23/JJ	prep_of||setting-20/NN||disease-24/NN	nsubjpass||shown-28/VBN||it-26/PRP	nsubj||noninferior-31/JJ||it-26/PRP	auxpass||shown-28/VBN||was-27/VBD	advcl||efficacious-6/JJ||shown-28/VBN	aux||noninferior-31/JJ||to-29/TO	cop||noninferior-31/JJ||be-30/VB	xcomp||shown-28/VBN||noninferior-31/JJ	prep_to||noninferior-31/JJ||enoxaparin-33/NN	prep_to||noninferior-31/JJ||ufh-35/NN	conj_and||enoxaparin-33/NN||ufh-35/NN	enoxaparin-33||veinthrombosis-12||no_rel||fondaparinux was shown to be efficacious in the prevention of deep veinthrombosis vs low-molecular-weight heparins, while in the setting of venous thrombo-embolic disease, it was shown to be noninferior to enoxaparin and ufh.
nn||analysis-3/NN||brain-1/NN	nn||analysis-3/NN||tissue-2/NN	nsubj||indicate-12/VBP||analysis-3/NN	preconj||treated-6/NN||both-5/DT	prep_from||analysis-3/NN||treated-6/NN	prep_from||analysis-3/NN||vehicle-8/NN	conj_and||treated-6/NN||vehicle-8/NN	vmod||treated-6/NN||treated-9/VBN	amod||groups-11/NNS||app/ps1-10/JJ	dobj||treated-9/VBN||groups-11/NNS	ccomp||aî-21/VBP||indicate-12/VBP	neg||differences-15/NNS||no-13/DT	amod||differences-15/NNS||significant-14/JJ	dobj||indicate-12/VBP||differences-15/NNS	amod||burden-19/NN||amyloid-17/JJ	nn||burden-19/NN||plaque-18/NN	prep_in||differences-15/NNS||burden-19/NN	root||ROOT-0/null||aî-21/VBP	nsubj||aî-21/VBP||²-22/NNP	num||²-22/NNP||40/42-23/CD	amod||levels-30/NNS||prpc-25/JJ	conj_or||prpc-25/JJ||aî-27/JJ	amod||levels-30/NNS||aî-27/JJ	amod||levels-30/NNS||²-28/JJ	nn||levels-30/NNS||oligomer-29/NN	appos||²-22/NNP||levels-30/NNS	vehicle-8||plaque-18||no_rel||brain tissue analysis from both treated and vehicle treated app/ps1 groups indicate no significant differences in amyloid plaque burden, aî²40/42, prpc or aî² oligomer levels.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||assess-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||assess-8/VB||to-7/TO	xcomp||was-6/VBD||assess-8/VB	det||association-10/NN||the-9/DT	dobj||assess-8/VB||association-10/NN	prep_of||association-10/NN||strength-12/NN	prep_of||strength-12/NN||pain-reliefmedication-14/NN	vmod||pain-reliefmedication-14/NN||prescribed-15/VBN	det||gp-18/NN||the-17/DT	agent||prescribed-15/VBN||gp-18/NN	det||strength-21/NN||the-20/DT	prep_with||gp-18/NN||strength-21/NN	amod||prescription-24/NN||previous-23/JJ	prep_of||strength-21/NN||prescription-24/NN	nn||level-27/NN||pain-26/NN	prep_of||strength-21/NN||level-27/NN	conj_and||prescription-24/NN||level-27/NN	pain-reliefmedication-14||pain-26||no_rel||the aim of this study was to assess the association of strength of pain-reliefmedication prescribed by the gp with the strength of previous prescription and pain level.
poss||approach-2/NN||our-1/PRP$	nsubjpass||based-4/VBN||approach-2/NN	auxpass||based-4/VBN||was-3/VBD	root||ROOT-0/null||based-4/VBN	prep_on||based-4/VBN||pre-fractionation-6/NN	nn||exchange-9/NN||ion-8/NN	prep_with||based-4/VBN||exchange-9/NN	advmod||coupled-11/VBN||chromatography-10/RB	vmod||exchange-9/NN||coupled-11/VBN	prep_with||coupled-11/VBN||matrix-13/NN	vmod||matrix-13/NN||assisted-14/VBN	nn||desorption-time-16/NN||laser-15/NN	dobj||assisted-14/VBN||desorption-time-16/NN	nn||analysis-21/NN||flight-18/NN	nn||analysis-21/NN||mass-19/NN	nn||analysis-21/NN||spectrometry-20/NN	prep_of||desorption-time-16/NN||analysis-21/NN	vmod||analysis-21/NN||assisted-22/VBN	det||chromatography-26/NN||a-24/DT	amod||chromatography-26/NN||liquid-25/JJ	agent||assisted-22/VBN||chromatography-26/NN	dep||chromatography-26/NN||lc-maldi-tof/tof-28/JJ	tof--1||ion-8||no_rel||our approach was based on pre-fractionation with ion exchange chromatography coupled with matrix assisted laser desorption-time of flight mass spectrometry analysis assisted by a liquid chromatography (lc-maldi-tof/tof).
nsubj||came-2/VBD||nineteen-1/NN	root||ROOT-0/null||came-2/VBD	amod||africa-5/NN||south-4/JJ	prep_from||came-2/VBD||africa-5/NN	det||majority-8/NN||the-7/DT	prep_from||came-2/VBD||majority-8/NN	conj_and||africa-5/NN||majority-8/NN	appos||majority-8/NN||38-10/CD	vmod||majority-8/NN||focused-12/VBN	prep_on||focused-12/VBN||hiv/aids-14/NNS	aids--1||hiv--1||no||nineteen came from south africa and the majority (38) focused on hiv/aids.
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	det||concordance-4/NN||the-3/DT	dobj||evaluated-2/VBN||concordance-4/NN	amod||genotypes-11/NNS||breasttumor-derived-6/JJ	conj_and||breasttumor-derived-6/JJ||normal-8/JJ	amod||genotypes-11/NNS||normal-8/JJ	amod||genotypes-11/NNS||lymph-9/JJ	amod||genotypes-11/NNS||node-derived-10/JJ	prep_between||concordance-4/NN||genotypes-11/NNS	num||enzymes-16/NNS||three-13/CD	amod||enzymes-16/NNS||polymorphic-14/JJ	amod||enzymes-16/NNS||tamoxifen-metabolizing-15/JJ	prep_for||genotypes-11/NNS||enzymes-16/NNS	breasttumor--1||tamoxifen--1||yes||we evaluated the concordance between breasttumor-derived and normal lymph node-derived genotypes for three polymorphic tamoxifen-metabolizing enzymes.
nsubj||cause-5/NN||staphylococcusaureus-1/NNS	cop||cause-5/NN||is-2/VBZ	det||cause-5/NN||a-3/DT	amod||cause-5/NN||common-4/JJ	ccomp||-lrb--25/VBD||cause-5/NN	amod||infection-8/NN||human-7/JJ	prep_of||cause-5/NN||infection-8/NN	nsubj||concern-18/NN||emergence-11/NN	amod||s.aureus-14/NNS||vancomycin-resistance-13/JJ	prep_of||emergence-11/NN||s.aureus-14/NNS	cop||concern-18/NN||is-15/VBZ	det||concern-18/NN||a-16/DT	amod||concern-18/NN||great-17/JJ	conj_and||cause-5/NN||concern-18/NN	ccomp||-lrb--25/VBD||concern-18/NN	prep_for||concern-18/NN||treatment-20/NN	amod||s.aureus-23/NNS||methicillin-resistant-22/JJ	prep_of||treatment-20/NN||s.aureus-23/NNS	root||ROOT-0/null||-lrb--25/VBD	nn||-rrb--27/NNS||mrsa-26/NN	dobj||-lrb--25/VBD||-rrb--27/NNS	amod||years-30/NNS||recent-29/JJ	prep_in||-lrb--25/VBD||years-30/NNS	num||-rrb--33/NN||-lrb--31/CD	nn||-rrb--33/NN||mrsa-32/NN	nsubj||-lrb--25/VBD||-rrb--33/NN	mrsa-32||staphylococcusaureus-1||no||staphylococcusaureus is a common cause of human infection , and emergence of vancomycin-resistance s.aureus is a great concern for treatment of methicillin-resistant s.aureus , -lrb- mrsa -rrb- in recent years -lrb- mrsa -rrb- .
det||mechanism-2/NN||this-1/DT	nsubj||has-9/VBZ||mechanism-2/NN	mark||finds-6/VBZ||if-4/IN	nsubj||finds-6/VBZ||it-5/PRP	dep||mechanism-2/NN||finds-6/VBZ	dobj||finds-6/VBZ||support-7/NN	root||ROOT-0/null||has-9/VBZ	amod||implications-11/NNS||important-10/JJ	dobj||has-9/VBZ||implications-11/NNS	amod||research-14/NN||future-13/JJ	prep_for||implications-11/NNS||research-14/NN	det||hazard-18/NN||the-16/DT	nn||hazard-18/NN||mesothelioma-17/NN	prep_into||has-9/VBZ||hazard-18/NN	prep_into||has-9/VBZ||hazard-18/NN	conj_and||hazard-18/NN||hazard-18/NN	prep_from||hazard-18/NN||harn-20/NN	advmod||hazard-18/NN||also-22/RB	poss||view-26/NN||our-24/PRP$	amod||view-26/NN||current-25/JJ	prep_for||hazard-18/NN||view-26/NN	det||origins-29/NNS||the-28/DT	prep_of||view-26/NN||origins-29/NNS	amod||mesothelioma-33/NN||asbestos-initiated-31/JJ	amod||mesothelioma-33/NN||pleural-32/JJ	prep_of||origins-29/NNS||mesothelioma-33/NN	det||use-37/NN||the-35/DT	amod||use-37/NN||common-36/JJ	prep_of||view-26/NN||use-37/NN	conj_and||origins-29/NNS||use-37/NN	prep_of||use-37/NN||lung-39/NN	amod||burden-43/NN||parenchymal-40/JJ	nn||burden-43/NN||asbestos-41/NN	nn||burden-43/NN||fibre-42/NN	pobj||hazard-18/NN||burden-43/NN	det||correlate-46/NN||a-45/DT	prep_as||has-9/VBZ||correlate-46/NN	det||tumour-49/NN||this-48/DT	prep_of||correlate-46/NN||tumour-49/NN	nsubj||arises-53/VBZ||tumour-49/NN	advmod||arises-53/VBZ||actually-52/RB	rcmod||tumour-49/NN||arises-53/VBZ	det||pleura-57/NN||the-55/DT	amod||pleura-57/NN||parietal-56/JJ	prep_in||arises-53/VBZ||pleura-57/NN	mesothelioma-33||fibre-42||no_rel||this mechanism, if it finds support, has important implications for future research into the mesothelioma hazard from harn and also for our current view of the origins of asbestos-initiated pleural mesothelioma and the common use of lung parenchymal asbestos fibre burden as a correlate of this tumour, which actually arises in the parietal pleura.
det||search-4/NN||a-1/DT	amod||search-4/NN||comprehensive-2/JJ	nn||search-4/NN||literature-3/NN	nsubjpass||carried-6/VBN||search-4/NN	nsubj||identify-9/VB||search-4/NN	auxpass||carried-6/VBN||was-5/VBD	root||ROOT-0/null||carried-6/VBN	prt||carried-6/VBN||out-7/RP	aux||identify-9/VB||to-8/TO	xcomp||carried-6/VBN||identify-9/VB	amod||trials-12/NNS||randomised-10/JJ	amod||trials-12/NNS||controlled-11/JJ	dobj||identify-9/VB||trials-12/NNS	prep_of||trials-12/NNS||polyethyleneglycol-14/NN	appos||polyethyleneglycol-14/NN||peg-16/NNP	prep||identify-9/VB||versus-18/FW	det||placebo-20/NN||either-19/DT	pobj||versus-18/FW||placebo-20/NN	amod||comparator-23/NN||active-22/JJ	pobj||versus-18/FW||comparator-23/NN	conj_or||placebo-20/NN||comparator-23/NN	prep_in||carried-6/VBN||patients-26/NNS	vmod||patients-26/NNS||aged-27/VBN	number||18-29/CD||<-28/CD	num||years-30/NNS||18-29/CD	npadvmod||aged-27/VBN||years-30/NNS	amod||constipation-34/NN||primary-32/JJ	amod||constipation-34/NN||chronic-33/JJ	prep_with||aged-27/VBN||constipation-34/NN	constipation-34||peg-16||yes||a comprehensive literature search was carried out to identify randomised controlled trials of polyethyleneglycol (peg) versus either placebo or active comparator, in patients aged <18 years with primary chronic constipation.
det||approach-2/NN||the-1/DT	nsubjpass||applied-5/VBN||approach-2/NN	aux||applied-5/VBN||has-3/VBZ	auxpass||applied-5/VBN||been-4/VBN	root||ROOT-0/null||applied-5/VBN	det||genome-8/NN||the-7/DT	prep_to||applied-5/VBN||genome-8/NN	prep_of||genome-8/NN||mycobacteriumtuberculosis-10/NNS	appos||mycobacteriumtuberculosis-10/NNS||m.tb-12/NN	det||agent-17/NN||the-15/DT	amod||agent-17/NN||causative-16/JJ	appos||mycobacteriumtuberculosis-10/NNS||agent-17/NN	prep_of||agent-17/NN||one-19/CD	poss||diseases-27/NNS||today-21/NN	advmod||spread-25/JJ||most-23/RBS	advmod||spread-25/JJ||widely-24/RB	amod||diseases-27/NNS||spread-25/JJ	amod||diseases-27/NNS||infectious-26/JJ	prep_of||agent-17/NN||diseases-27/NNS	tb--1||mycobacteriumtuberculosis-10||no||the approach has been applied to the genome of mycobacteriumtuberculosis (m.tb) , the causative agent of one of today's most widely spread infectious diseases.
aux||assess-2/VB||to-1/TO	dep||bimatoprost-33/VBP||assess-2/VB	det||effect-5/NN||the-3/DT	amod||effect-5/NN||additive-4/JJ	dobj||assess-2/VB||effect-5/NN	prep_of||effect-5/NN||dorzolamidehydrochloride-7/NN	number||%-9/NN||2-8/CD	amod||dorzolamidehydrochloride-7/NN||%-9/NN	det||pressure-14/NN||the-11/DT	amod||pressure-14/NN||diurnal-12/JJ	amod||pressure-14/NN||intraocular-13/JJ	prep_on||assess-2/VB||pressure-14/NN	dep||bimatoprost-33/VBP||iop-16/VB	nn||haemodynamics-21/NNS||curve-18/NN	conj_and||curve-18/NN||retrobulbar-20/NN	nn||haemodynamics-21/NNS||retrobulbar-20/NN	nsubj||bimatoprost-33/VBP||haemodynamics-21/NNS	prep_in||haemodynamics-21/NNS||patients-23/NNS	amod||open-angleglaucoma-26/NN||primary-25/JJ	prep_with||patients-23/NNS||open-angleglaucoma-26/NN	dep||patients-23/NNS||poag-28/VBG	vmod||patients-23/NNS||treated-30/VBN	prep_with||treated-30/VBN||morning-dosed-32/JJ	root||ROOT-0/null||bimatoprost-33/VBP	num||%-35/NN||0.03-34/CD	dobj||bimatoprost-33/VBP||%-35/NN	open-angleglaucoma-26||dorzolamidehydrochloride-7||yes||to assess the additive effect of dorzolamidehydrochloride 2% on the diurnal intraocular pressure (iop) curve and retrobulbar haemodynamics in patients with primary open-angleglaucoma (poag) treated with morning-dosed bimatoprost 0.03%.
amod||samples-2/NNS||faecal-1/JJ	nsubjpass||collected-4/VBN||samples-2/NNS	nsubjpass||examined-6/VBN||samples-2/NNS	auxpass||collected-4/VBN||were-3/VBD	root||ROOT-0/null||collected-4/VBN	conj_and||collected-4/VBN||examined-6/VBN	agent||collected-4/VBN||using-8/VBG	amod||katz-13/NN||formalin-ether-9/JJ	nn||katz-13/NN||sedimentation-10/NN	dep||katz-13/NN||kato-12/NN	dobj||using-8/VBG||katz-13/NN	nn||techniques-17/NNS||harada-15/NN	nn||techniques-17/NNS||mori-16/NN	dobj||using-8/VBG||techniques-17/NNS	conj_and||katz-13/NN||techniques-17/NNS	ether--1||harada-15||no_rel||faecal samples were collected and examined by using formalin-ether sedimentation, kato katz and harada mori techniques.
det||study-3/NN||this-2/DT	prep_in||investigated-6/VBD||study-3/NN	nsubj||investigated-6/VBD||we-5/PRP	root||ROOT-0/null||investigated-6/VBD	det||prevalence-8/NN||the-7/DT	dobj||investigated-6/VBD||prevalence-8/NN	amod||mutations-11/NNS||hnf4a-10/JJ	prep_of||prevalence-8/NN||mutations-11/NNS	det||cohort-15/NN||a-13/DT	amod||cohort-15/NN||large-14/JJ	prep_in||investigated-6/VBD||cohort-15/NN	prep_of||cohort-15/NN||patients-17/NNS	amod||responsive-20/JJ||diazoxide-19/JJ	amod||hypoglycemia-22/NN||responsive-20/JJ	amod||hypoglycemia-22/NN||hyperinsulinemic-21/JJ	prep_with||patients-17/NNS||hypoglycemia-22/NN	appos||hypoglycemia-22/NN||hh-24/NN	hypoglycemia-22||diazoxide-19||yes||in this study, we investigated the prevalence of hnf4a mutations in a large cohort of patients with diazoxide responsive hyperinsulinemic hypoglycemia (hh).
det||mainstay-2/NN||the-1/DT	nsubj||represents-5/VBZ||mainstay-2/NN	prep_of||mainstay-2/NN||management-4/NN	root||ROOT-0/null||represents-5/VBZ	dep||represents-5/VBZ||directed-6/VBN	amod||therapy-8/NN||antiviral-7/JJ	dobj||directed-6/VBN||therapy-8/NN	prep_after||directed-6/VBN||evidence-10/NN	prep_of||evidence-10/NN||recurrence-12/NN	prep_of||recurrence-12/NN||chronichepatitisc-14/NNP	vmod||chronichepatitisc-14/NNP||combined-16/VBN	amod||interferon-18/NN||pegylated-17/JJ	dobj||combined-16/VBN||interferon-18/NN	nn||therapy-21/NN||ribavirin-20/NNP	nsubj||treatment-26/NN||therapy-21/NN	cop||treatment-26/NN||is-22/VBZ	det||treatment-26/NN||the-23/DT	amod||treatment-26/NN||current-24/JJ	amod||treatment-26/NN||standard-25/JJ	conj_and||represents-5/VBZ||treatment-26/NN	amod||rates-31/NNS||sustained-28/VBN	amod||rates-31/NNS||viral-29/JJ	nn||rates-31/NNS||response-30/NN	prep_with||treatment-26/NN||rates-31/NNS	number||%-37/NN||25-33/CD	dep||%-37/NN||%-34/NN	dep||%-37/NN||to-35/TO	number||%-37/NN||45-36/CD	prep_of||rates-31/NNS||%-37/NN	chronichepatitisc-14||interferon-18||yes||the mainstay of management represents directed antiviral therapy after evidence of recurrence of chronichepatitisc. combined pegylated interferon and ribavirin therapy is the current standard treatment with sustained viral response rates of 25 % to 45 % .
det||total-2/NN||a-1/DT	nsubjpass||enrolled-17/VBN||total-2/NN	num||volunteers-6/NNS||16-4/CD	amod||volunteers-6/NNS||healthy-5/JJ	prep_of||total-2/NN||volunteers-6/NNS	num||patients-9/NNS||45-8/CD	conj_and||total-2/NN||patients-9/NNS	nsubjpass||enrolled-17/VBN||patients-9/NNS	amod||virus-12/NN||chronichepatitisc-11/JJ	prep_with||patients-9/NNS||virus-12/NN	appos||total-2/NN||hcv-14/NN	auxpass||enrolled-17/VBN||were-16/VBD	root||ROOT-0/null||enrolled-17/VBN	nsubj||n-20/VBZ||f0-19/NNS	parataxis||enrolled-17/VBN||n-20/VBZ	dep||16-22/CD||=-21/SYM	ccomp||n-20/VBZ||16-22/CD	amod||n-25/NN||f1-24/JJ	nsubj||7-27/CD||n-25/NN	dep||7-27/CD||=-26/SYM	ccomp||n-20/VBZ||7-27/CD	amod||n-30/NN||f2-29/JJ	nsubj||17-32/CD||n-30/NN	dep||17-32/CD||=-31/SYM	ccomp||n-20/VBZ||17-32/CD	amod||n-35/NN||f3-34/JJ	nsubj||13-42/CD||n-35/NN	num||n-35/NN||=-36/CD	num||n-35/NN||8-37/CD	amod||n-40/NN||f4-39/JJ	conj_and||n-35/NN||n-40/NN	nsubj||13-42/CD||n-40/NN	dep||13-42/CD||=-41/SYM	ccomp||n-20/VBZ||13-42/CD	prepc_according_to||n-20/VBZ||to-45/TO	det||classification-48/NN||the-46/DT	nn||classification-48/NN||metavir-47/NN	pobj||n-20/VBZ||classification-48/NN	chronichepatitisc-11||hcv-14||no||a total of 16 healthy volunteers and 45 patients with chronichepatitisc virus (hcv) were enrolled (f0 n = 16, f1 n = 7, f2 n = 17, f3 n = 8 and f4 n = 13, according to the metavir classification).
det||findings-3/NNS||the-1/DT	nn||findings-3/NNS||interview-2/NN	nsubj||pointed-4/VBD||findings-3/NNS	root||ROOT-0/null||pointed-4/VBD	prep_to||pointed-4/VBD||obstacles-6/NNS	amod||linkages-9/NNS||strengthening-8/JJ	prep_to||pointed-4/VBD||linkages-9/NNS	nn||planning-12/NN||family-11/NN	prep_between||linkages-9/NNS||planning-12/NN	prep_between||linkages-9/NNS||hiv/aids-14/NNS	conj_and||planning-12/NN||hiv/aids-14/NNS	det||need-18/NN||the-17/DT	prep_including||pointed-4/VBD||need-18/NN	prep_for||need-18/NN||resources-20/NNS	aux||integrate-22/VB||to-21/TO	vmod||resources-20/NNS||integrate-22/VB	nn||planning-24/NN||family-23/NN	dobj||integrate-22/VB||planning-24/NN	vmod||resources-20/NNS||hiv-26/VB	conj_and||integrate-22/VB||hiv-26/VB	dobj||hiv-26/VB||services-27/NNS	dobj||hiv-26/VB||infrastructure-29/NN	conj_or||services-27/NNS||infrastructure-29/NN	dobj||hiv-26/VB||capacity-31/NN	conj_or||services-27/NNS||capacity-31/NN	aux||provide-33/VB||to-32/TO	vmod||hiv-26/VB||provide-33/VB	amod||services-35/NNS||integrated-34/VBN	dobj||provide-33/VB||services-35/NNS	det||level-39/NN||the-37/DT	nn||level-39/NN||facility-38/NN	prep_at||services-35/NNS||level-39/NN	amod||leadership-42/NN||national-41/JJ	dobj||provide-33/VB||leadership-42/NN	conj_and||services-35/NNS||leadership-42/NN	conj_and||services-35/NNS||coordination-44/NN	conj_and||leadership-42/NN||coordination-44/NN	amod||advocacy-48/NN||targeted-47/JJ	dobj||provide-33/VB||advocacy-48/NN	conj_and||services-35/NNS||advocacy-48/NN	amod||decision-makers-51/NNS||key-50/JJ	prep_to||advocacy-48/NN||decision-makers-51/NNS	aids--1||hiv-26||no||the interview findings pointed to obstacles to strengthening linkages between family planning and hiv/aids, including the need for resources to integrate family planning and hiv services, infrastructure or capacity to provide integrated services at the facility level, national leadership and coordination, and targeted advocacy to key decision-makers.
nsubj||treatment-9/NN||intravenousimmunoglobulin-1/NN	appos||intravenousimmunoglobulin-1/NN||ivig-3/NN	cop||treatment-9/NN||is-5/VBZ	det||treatment-9/NN||a-6/DT	amod||treatment-9/NN||proven-7/VBN	amod||treatment-9/NN||effective-8/JJ	root||ROOT-0/null||treatment-9/NN	prep_for||treatment-9/NN||gbs-11/NN	dep||gbs-11/NN||class-13/NN	num||evidence-15/NN||1-14/CD	dep||class-13/NN||evidence-15/NN	gbs-11||ivig-3||yes||intravenousimmunoglobulin (ivig) is a proven effective treatment for gbs (class 1 evidence).
amod||protocol-3/NN||post-transplant-1/JJ	nn||protocol-3/NN||prophylaxis-2/NNS	nsubjpass||based-8/VBN||protocol-3/NN	nsubj||keep-28/VB||protocol-3/NN	nn||recurrence-6/NN||hbv-5/NN	prep_against||protocol-3/NN||recurrence-6/NN	auxpass||based-8/VBN||was-7/VBD	root||ROOT-0/null||based-8/VBN	det||milligrams-12/NNS||a-10/DT	num||milligrams-12/NNS||hundred-11/CD	prep_on||based-8/VBN||milligrams-12/NNS	prep_of||milligrams-12/NNS||lamivudine-14/NN	amod||lamivudine-14/NN||daily-15/JJ	amod||lamivudine-14/NN||plus-16/IN	nn||injections-18/NNS||intramuscular-17/NN	dep||lamivudine-14/NN||injections-18/NNS	prep_of||injections-18/NNS||hepatitisbimmuneglobulin-20/NN	appos||injections-18/NNS||hbig-22/NN	amod||dosage-26/NN||appropriate-25/JJ	prep_with||based-8/VBN||dosage-26/NN	aux||keep-28/VB||to-27/TO	xcomp||based-8/VBN||keep-28/VB	amod||titer-31/NN||anti-hbs-29/JJ	nn||titer-31/NN||antibody-30/NN	dobj||keep-28/VB||titer-31/NN	num||iu/l-34/NN||300-33/CD	prep_above||titer-31/NN||iu/l-34/NN	num||iu/l-37/NN||100-36/CD	prep_above||titer-31/NN||iu/l-37/NN	conj_and||iu/l-34/NN||iu/l-37/NN	prep||keep-28/VB||in-38/IN	det||months-42/NNS||the-39/DT	amod||months-42/NNS||first-40/JJ	num||months-42/NNS||six-41/CD	pobj||in-38/IN||months-42/NNS	prep||keep-28/VB||afterwards-44/RB	conj_and||in-38/IN||afterwards-44/RB	prep||keep-28/VB||respectively-46/RB	conj_and||in-38/IN||respectively-46/RB	hbv-5||lamivudine-14||yes||post-transplant prophylaxis protocol against hbv recurrence was based on a hundred milligrams of lamivudine daily plus intramuscular injections of hepatitisbimmuneglobulin (hbig) with appropriate dosage to keep anti-hbs antibody titer above 300 iu/l and 100 iu/l in the first six months and afterwards, respectively.
det||research-3/NN||the-1/DT	amod||research-3/NN||proposed-2/VBN	nsubj||seeks-4/VBZ||research-3/NN	nsubj||answer-6/VB||research-3/NN	dep||explain-23/VB||seeks-4/VBZ	aux||answer-6/VB||to-5/TO	xcomp||seeks-4/VBZ||answer-6/VB	det||questions-9/NNS||the-7/DT	amod||questions-9/NNS||following-8/JJ	nsubj||i-10/VBZ||questions-9/NNS	parataxis||answer-6/VB||i-10/VBZ	advmod||assessed-13/VBN||when-12/WRB	advcl||answer-6/VB||assessed-13/VBN	advmod||assessed-13/VBN||systematically-14/RB	aux||explain-23/VB||do-16/VBP	nsubj||explain-23/VB||patients-17/NNS	conj_and||patients-17/NNS||clinicians-20/NNS	nsubj||explain-23/VB||clinicians-20/NNS	dep||patients-17/NNS||preferences-22/NNS	root||ROOT-0/null||explain-23/VB	det||utilization-25/NN||the-24/DT	dobj||explain-23/VB||utilization-25/NN	prep_of||utilization-25/NN||warfarin-27/NN	aux||prevent-29/VB||to-28/TO	vmod||explain-23/VB||prevent-29/VB	dobj||prevent-29/VB||strokes-30/NNS	vmod||strokes-30/NNS||associated-31/VBN	prep_with||associated-31/VBN||atrialfibrillation-33/NN	atrialfibrillation-33||warfarin-27||yes||the proposed research seeks to answer the following questions i) when assessed systematically, do patients' and clinicians' preferences explain the utilization of warfarin to prevent strokes associated with atrialfibrillation?
advmod||diagnosed-4/VBN||when-1/WRB	nsubjpass||diagnosed-4/VBN||retinitis-2/NNS	auxpass||diagnosed-4/VBN||is-3/VBZ	advcl||started-10/VBN||diagnosed-4/VBN	nn||therapy-7/NN||haart-6/NN	nsubjpass||started-10/VBN||therapy-7/NN	nsubjpass||improved-12/VBN||therapy-7/NN	aux||started-10/VBN||should-8/MD	auxpass||started-10/VBN||be-9/VB	root||ROOT-0/null||started-10/VBN	conj_or||started-10/VBN||improved-12/VBN	amod||therapy-16/NN||anti-cmv-15/JJ	nsubjpass||administered-30/VBN||therapy-16/NN	amod||valganciclovir-19/NN||oral-18/JJ	prep_with||therapy-16/NN||valganciclovir-19/NN	amod||ganciclovir-22/NN||intravenous-21/JJ	prep_with||therapy-16/NN||ganciclovir-22/NN	conj_or||valganciclovir-19/NN||ganciclovir-22/NN	prep_with||therapy-16/NN||foscarnet-24/NN	conj_or||valganciclovir-19/NN||foscarnet-24/NN	prep_with||therapy-16/NN||cidofovir-27/NN	conj_or||valganciclovir-19/NN||cidofovir-27/NN	aux||administered-30/VBN||should-28/MD	auxpass||administered-30/VBN||be-29/VB	conj_and||started-10/VBN||administered-30/VBN	cmv--1||ganciclovir-22||yes||when retinitis is diagnosed, haart therapy should be started or improved, and anti-cmv therapy with oral valganciclovir, intravenous ganciclovir, foscarnet, or cidofovir should be administered.
mark||shown-5/VBN||although-1/IN	amod||monotherapy-3/NN||docetaxel-2/JJ	nsubj||shown-5/VBN||monotherapy-3/NN	aux||shown-5/VBN||has-4/VBZ	advcl||controversial-38/JJ||shown-5/VBN	amod||benefits-7/NNS||clinical-6/JJ	dobj||shown-5/VBN||benefits-7/NNS	advmod||treated-10/JJ||previously-9/RB	amod||patients-11/NNS||treated-10/JJ	prep_for||shown-5/VBN||patients-11/NNS	amod||non-smallcelllungcancer-14/NN||advanced-13/VBN	prep_with||patients-11/NNS||non-smallcelllungcancer-14/NN	dep||patients-11/NNS||nsclc-16/JJ	det||efficacy-20/NN||the-19/DT	nsubj||controversial-38/JJ||efficacy-20/NN	nn||chemotherapy-24/NN||salvage-22/NN	amod||chemotherapy-24/NN||docetaxel-23/JJ	prep_of||efficacy-20/NN||chemotherapy-24/NN	amod||patients-27/NNS||elderly-26/JJ	prep_for||chemotherapy-24/NN||patients-27/NNS	prep_for||chemotherapy-24/NN||patients-29/NNS	conj_or||patients-27/NNS||patients-29/NNS	amod||status-33/NN||poor-31/JJ	nn||status-33/NN||performance-32/NN	prep_with||patients-27/NNS||status-33/NN	appos||status-33/NN||ps-35/NN	cop||controversial-38/JJ||is-37/VBZ	root||ROOT-0/null||controversial-38/JJ	non-smallcelllungcancer-14||docetaxel-23||yes||although docetaxel monotherapy has shown clinical benefits for previously treated patients with advanced non-smallcelllungcancer (nsclc), the efficacy of salvage docetaxel chemotherapy for elderly patients or patients with poor performance status (ps) is controversial.
amod||response-2/NN||virological-1/JJ	nsubjpass||predicted-15/VBN||response-2/NN	amod||therapy-5/NN||antiviral-4/JJ	prep_to||response-2/NN||therapy-5/NN	prep_in||therapy-5/NN||patients-7/NNS	prep_with||patients-7/NNS||hepatitisc-9/JJ	amod||hepatitisc-9/JJ||recurring-10/VBG	prep_after||hepatitisc-9/JJ||ldlt-12/NN	aux||predicted-15/VBN||can-13/MD	auxpass||predicted-15/VBN||be-14/VB	root||ROOT-0/null||predicted-15/VBN	prep_prior_to||predicted-15/VBN||transplant-18/NN	prepc_based_on||predicted-15/VBN||on-21/IN	amod||levels-25/NNS||pretransplant-22/JJ	nn||levels-25/NNS||serum-23/NN	nn||levels-25/NNS||hcv-rna-24/NN	pobj||predicted-15/VBN||levels-25/NNS	nn||genotype-28/NN||hcv-27/NN	pobj||predicted-15/VBN||genotype-28/NN	conj_and||levels-25/NNS||genotype-28/NN	hepatitisc-9||hcv-27||no||virological response to antiviral therapy in patients with hepatitisc recurring after ldlt can be predicted prior to transplant, based on pretransplant serum hcv-rna levels and hcv genotype.
nsubj||lidocaine-4/VBP||pretreatment-1/NN	prep_with||pretreatment-1/NN||iv-3/NN	root||ROOT-0/null||lidocaine-4/VBP	num||mg-6/NNP||40-5/CD	dobj||lidocaine-4/VBP||mg-6/NNP	nn||mg-10/NNS||ketamine-8/NNP	num||mg-10/NNS||25-9/CD	dobj||lidocaine-4/VBP||mg-10/NNS	conj_plus||mg-6/NNP||mg-10/NNS	det||tourniquet-14/NN||a-12/DT	nn||tourniquet-14/NN||rubber-13/NN	prep_with||lidocaine-4/VBP||tourniquet-14/NN	det||min-19/NN||the-16/DT	nn||min-19/NN||forearm-17/NNP	num||min-19/NN||1-18/CD	prep_on||tourniquet-14/NN||min-19/NN	mark||effective-28/JJ||before-20/IN	det||injection-22/NN||the-21/DT	nsubj||effective-28/JJ||injection-22/NN	nn||propofol-25/NN||microemulsion-24/NN	prep_of||injection-22/NN||propofol-25/NN	cop||effective-28/JJ||is-26/VBZ	advmod||effective-28/JJ||more-27/RBR	advcl||lidocaine-4/VBP||effective-28/JJ	nn||mg-32/NN||lidocaine-30/NN	num||mg-32/NN||40-31/CD	prep_than||effective-28/JJ||mg-32/NN	nn||mg-36/NN||ketamine-34/NN	num||mg-36/NN||25-35/CD	prep_than||effective-28/JJ||mg-36/NN	conj_or||mg-32/NN||mg-36/NN	advmod||effective-28/JJ||alone-37/RB	prepc_in||effective-28/JJ||preventing-39/VBG	dobj||preventing-39/VBG||pain-40/NN	det||injection-43/NN||the-42/DT	prep_from||preventing-39/VBG||injection-43/NN	nn||propofol-46/NN||microemulsion-45/NN	prep_of||injection-43/NN||propofol-46/NN	pain-40||propofol-46||yes||pretreatment with iv lidocaine 40 mg plus ketamine 25 mg with a rubber tourniquet on the forearm 1 min before the injection of microemulsion propofol is more effective than lidocaine 40 mg or ketamine 25 mg alone in preventing pain from the injection of microemulsion propofol.
det||results-2/NNS||these-1/DT	nsubj||advanced-3/VBD||results-2/NNS	nsubj||suggested-12/VBD||results-2/NNS	root||ROOT-0/null||advanced-3/VBD	det||characterization-6/NN||the-4/DT	amod||characterization-6/NN||molecular-5/JJ	dobj||advanced-3/VBD||characterization-6/NN	det||ectoparasite-10/NN||this-8/DT	amod||ectoparasite-10/NN||important-9/JJ	prep_of||characterization-6/NN||ectoparasite-10/NN	conj_and||advanced-3/VBD||suggested-12/VBD	nn||antigens-15/NNS||candidate-13/NN	amod||antigens-15/NNS||protective-14/JJ	dobj||suggested-12/VBD||antigens-15/NNS	det||development-18/NN||the-17/DT	prep_for||suggested-12/VBD||development-18/NN	prep_of||development-18/NN||vaccines-20/NNS	det||control-23/NN||the-22/DT	prep_for||vaccines-20/NNS||control-23/NN	nn||infestations-27/NNS||horn-25/NN	nn||infestations-27/NNS||fly-26/NN	prep_of||control-23/NN||infestations-27/NNS	vaccines-20||infestations-27||no_rel||these results advanced the molecular characterization of this important ectoparasite and suggested candidate protective antigens for the development of vaccines for the control of horn fly infestations.
nsubj||present-2/VBP||we-1/PRP	root||ROOT-0/null||present-2/VBP	dobj||present-2/VBP||images-3/NNS	nn||manifestations-6/NNS||lung-5/NN	prep_of||images-3/NNS||manifestations-6/NNS	prep_of||manifestations-6/NNS||hiv/aids-8/NNS	vmod||present-2/VBP||describing-10/VBG	det||features-13/NNS||the-11/DT	amod||features-13/NNS||salient-12/JJ	dobj||describing-10/VBG||features-13/NNS	det||diagnosis-17/NN||the-15/DT	nn||diagnosis-17/NN||differential-16/NN	dobj||describing-10/VBG||diagnosis-17/NN	conj_and||features-13/NNS||diagnosis-17/NN	aids--1||hiv--1||no||we present images of lung manifestations of hiv/aids, describing the salient features and the differential diagnosis.
num||controls-3/NNS||seventeen-1/CD	amod||controls-3/NNS||healthy-2/JJ	nsubj||participated-27/VBD||controls-3/NNS	appos||controls-3/NNS||hc-5/NN	num||patients-9/NNS||20-8/CD	conj_and||controls-3/NNS||patients-9/NNS	nsubj||participated-27/VBD||patients-9/NNS	amod||disease-15/NN||crohnâ-11/JJ	amod||disease-15/NN||$-12/$	number||s-14/CD||-13/CD	num||$-12/$||s-14/CD	prep_with||patients-9/NNS||disease-15/NN	appos||patients-9/NNS||cd-17/NN	num||patients-21/NNS||22-20/CD	conj_and||controls-3/NNS||patients-21/NNS	nsubj||participated-27/VBD||patients-21/NNS	prep_with||patients-21/NNS||ulcerativecolitis-23/NNS	appos||controls-3/NNS||uc-25/NN	root||ROOT-0/null||participated-27/VBD	det||study-30/NN||the-29/DT	prep_in||participated-27/VBD||study-30/NN	cd-17||crohn--1||no_rel||seventeen healthy controls (hc), 20 patients with crohnâs disease (cd) and 22 patients with ulcerativecolitis (uc) participated in the study.
det||profile-4/NN||the-1/DT	amod||profile-4/NN||largest-2/JJS	nn||profile-4/NN||mar-3/NN	nsubj||contained-5/VBD||profile-4/NN	nsubjpass||observed-23/VBN||profile-4/NN	root||ROOT-0/null||contained-5/VBD	num||antibiotics-7/NNS||six-6/CD	dobj||contained-5/VBD||antibiotics-7/NNS	dep||antibiotics-7/NNS||penicilling-9/NN	appos||penicilling-9/NN||methicillin-11/NN	appos||penicilling-9/NN||erythromycin-13/NN	conj_and||methicillin-11/NN||erythromycin-13/NN	appos||penicilling-9/NN||ciprofloxacin-15/NN	conj_and||methicillin-11/NN||ciprofloxacin-15/NN	appos||penicilling-9/NN||clindamycin-17/NN	conj_and||methicillin-11/NN||clindamycin-17/NN	appos||penicilling-9/NN||clarithromycin-19/NN	conj_and||methicillin-11/NN||clarithromycin-19/NN	auxpass||observed-23/VBN||was-22/VBD	conj_and||contained-5/VBD||observed-23/VBN	det||isolates-27/NN||the-25/DT	nn||isolates-27/NN||mrsa-26/NN	prep_in||observed-23/VBN||isolates-27/NN	predet||uk-31/NN||both-29/PDT	det||uk-31/NN||the-30/DT	prep_in||isolates-27/NN||uk-31/NN	amod||cohorts-34/NNS||maltese-33/JJ	prep_in||isolates-27/NN||cohorts-34/NNS	conj_and||uk-31/NN||cohorts-34/NNS	penicilling-9||mrsa-26||no_rel||the largest mar profile contained six antibiotics (penicilling, methicillin, erythromycin, ciprofloxacin, clindamycin and clarithromycin) and was observed in the mrsa isolates in both the uk and maltese cohorts.
nsubj||changed-5/VBD||duration-1/NN	nn||secretion-4/NN||melatonin-3/NN	prep_of||duration-1/NN||secretion-4/NN	root||ROOT-0/null||changed-5/VBD	prep_in||changed-5/VBD||response-7/NN	prep_to||changed-5/VBD||stroke-9/NN	det||change-13/NN||this-12/DT	nsubjpass||determined-16/VBN||change-13/NN	auxpass||determined-16/VBN||was-14/VBD	advmod||determined-16/VBN||strongly-15/RB	conj_and||changed-5/VBD||determined-16/VBN	det||shift-19/NN||the-18/DT	agent||determined-16/VBN||shift-19/NN	amod||time-23/NN||melatonin-21/JJ	nn||time-23/NN||onset-22/NN	prep_in||shift-19/NN||time-23/NN	melatonin-21||stroke-9||no_rel||duration of melatonin secretion changed in response to stroke, and this change was strongly determined by the shift in melatonin onset time.
amod||influenzaviruses-2/NNS||isolated-1/JJ	nsubjpass||compared-4/VBN||influenzaviruses-2/NNS	auxpass||compared-4/VBN||were-3/VBD	root||ROOT-0/null||compared-4/VBN	amod||influenzaviruses-7/NNS||seasonal-6/JJ	prep_with||compared-4/VBN||influenzaviruses-7/NNS	det||season-12/NN||the-9/DT	num||season-12/NN||2008-10/CD	nn||season-12/NN||influenza-11/NN	prep_from||compared-4/VBN||season-12/NN	influenza-11||influenzaviruses-7||no||isolated influenzaviruses were compared with seasonal influenzaviruses from the 2008 influenza season.
advmod||evident-9/JJ||furthermore-1/RB	amod||inflammation-4/NN||chronic-3/JJ	nsubj||evident-9/JJ||inflammation-4/NN	amod||tissue-7/NN||adipose-6/JJ	prep_in||inflammation-4/NN||tissue-7/NN	cop||evident-9/JJ||was-8/VBD	root||ROOT-0/null||evident-9/JJ	det||expression-13/NN||the-11/DT	nn||expression-13/NN||differential-12/NN	prep_from||evident-9/JJ||expression-13/NN	prep_of||expression-13/NN||genes-15/NNS	vmod||genes-15/NNS||involved-16/VBN	amod||responses-19/NNS||inflammatory-18/JJ	prep_in||involved-16/VBN||responses-19/NNS	prep_in||involved-16/VBN||activation-21/NNS	conj_and||responses-19/NNS||activation-21/NNS	amod||immunity-24/NN||natural-23/JJ	prep_of||responses-19/NNS||immunity-24/NN	num||interferon-28/NN||two-27/CD	prep_including||evident-9/JJ||interferon-28/NN	vmod||interferon-28/NN||regulated-29/VBN	dep||regulated-29/VBN||genes-30/NNS	acomp||regulated-29/VBN||ifit-32/JJ	acomp||regulated-29/VBN||iipg-34/JJ	conj_and||ifit-32/JJ||iipg-34/JJ	nn||genes-42/NNS||mhc-39/NN	nn||genes-42/NNS||class-40/NN	amod||genes-42/NNS||ii-41/JJ	acomp||regulated-29/VBN||genes-42/NNS	conj_and||ifit-32/JJ||genes-42/NNS	interferon-28||inflammation-4||no_rel||furthermore, chronic inflammation in adipose tissue was evident from the differential expression of genes involved in inflammatory responses and activation of natural immunity, including two interferon regulated genes, ifit and iipg , as well as mhc class ii genes.
det||results-2/NNS||these-1/DT	nsubj||provide-3/VBP||results-2/NNS	root||ROOT-0/null||provide-3/VBP	amod||evidence-7/NN||molecular-4/JJ	conj_and||molecular-4/JJ||biochemical-6/JJ	amod||evidence-7/NN||biochemical-6/JJ	dobj||provide-3/VBP||evidence-7/NN	mark||caseation-17/VB||that-8/IN	det||development-10/NN||the-9/DT	nsubj||caseation-17/VB||development-10/NN	det||granuloma-15/NN||the-12/DT	amod||granuloma-15/NN||human-13/JJ	nn||granuloma-15/NN||tb-14/NN	prep_of||development-10/NN||granuloma-15/NN	aux||caseation-17/VB||to-16/TO	ccomp||provide-3/VBP||caseation-17/VB	xcomp||provide-3/VBP||caseation-17/VB	dobj||caseation-17/VB||correlates-18/NNS	amod||dysregulation-21/NN||pathogen-mediated-20/JJ	prep_with||caseation-17/VB||dysregulation-21/NN	nn||metabolism-25/NN||host-23/NN	nn||metabolism-25/NN||lipid-24/NN	prep_of||dysregulation-21/NN||metabolism-25/NN	lipid-24||tb-14||no_rel||these results provide molecular and biochemical evidence that the development of the human tb granuloma to caseation correlates with pathogen-mediated dysregulation of host lipid metabolism.
nn||therapy-3/NN||iron-1/NN	nn||therapy-3/NN||chelation-2/NN	nsubjpass||applied-9/VBN||therapy-3/NN	appos||therapy-3/NN||ict-5/NN	aux||applied-9/VBN||has-7/VBZ	auxpass||applied-9/VBN||been-8/VBN	root||ROOT-0/null||applied-9/VBN	det||patients-12/NNS||the-11/DT	prep_for||applied-9/VBN||patients-12/NNS	amod||dysfunction-16/NN||ironoverload-associated-14/JJ	nn||dysfunction-16/NN||liver-15/NN	prep_with||patients-12/NNS||dysfunction-16/NN	mark||one-20/CD||since-17/IN	nsubj||one-20/CD||it-18/PRP	cop||one-20/CD||is-19/VBZ	advcl||applied-9/VBN||one-20/CD	det||causes-23/NNS||the-22/DT	prep_of||one-20/CD||causes-23/NNS	prep_of||causes-23/NNS||death-25/NN	prep_in||death-25/NN||patients-27/NNS	amod||diseases-31/NNS||intractable-29/JJ	amod||diseases-31/NNS||hematological-30/JJ	prep_with||patients-27/NNS||diseases-31/NNS	vmod||diseases-31/NNS||requiring-32/VBG	amod||transfusions-37/NNS||multiple-33/JJ	amod||transfusions-37/NNS||red-34/JJ	nn||transfusions-37/NNS||blood-35/NN	nn||transfusions-37/NNS||cell-36/NN	dobj||requiring-32/VBG||transfusions-37/NNS	ironoverload--1||iron-1||no||iron chelation therapy (ict) has been applied for the patients with ironoverload-associated liver dysfunction since it is one of the causes of death in patients with intractable hematological diseases requiring multiple red blood cell transfusions.
det||fact-3/NN||the-2/DT	prep_despite||apparent-18/JJ||fact-3/NN	mark||suffer-10/VBP||that-4/IN	nsubj||suffer-10/VBP||men-5/NNS	conj_and||men-5/NNS||women-7/NNS	nsubj||suffer-10/VBP||women-7/NNS	prep_with||men-5/NNS||hiv/aids-9/NNS	dep||fact-3/NN||suffer-10/VBP	det||illness-13/NN||the-11/DT	amod||illness-13/NN||same-12/JJ	dobj||suffer-10/VBP||illness-13/NN	amod||disparities-16/NNS||clear-15/JJ	nsubj||apparent-18/JJ||disparities-16/NNS	cop||apparent-18/JJ||are-17/VBP	root||ROOT-0/null||apparent-18/JJ	det||women-23/NNS||the-20/DT	amod||women-23/NNS||negative-21/JJ	nn||women-23/NNS||reaction-22/NN	prep_in||apparent-18/JJ||women-23/NNS	nn||living-26/NN||men-25/NNS	prep_in||apparent-18/JJ||living-26/NN	conj_and||women-23/NNS||living-26/NN	amod||experience-29/NN||hiv/aids-28/JJ	prep_with||apparent-18/JJ||experience-29/NN	prep_in||experience-29/NN||society-31/NN	aids--1||hiv--1||no||despite the fact that men and women with hiv/aids suffer the same illness, clear disparities are apparent in the negative reaction women and men living with hiv/aids experience in society.
prep_in||enhanced-7/VBD||summary-2/NN	nsubj||enhanced-7/VBD||c-4/SYM	conj_and||c-4/SYM||ecg-6/NN	nsubj||enhanced-7/VBD||ecg-6/NN	root||ROOT-0/null||enhanced-7/VBD	det||effect-10/NN||the-8/DT	amod||effect-10/NN||antibacterial-9/JJ	dobj||enhanced-7/VBD||effect-10/NN	nn||²-13/NNS||î-12/NN	prep_of||effect-10/NN||²-13/NNS	dep||effect-10/NN||lactamantibiotics-15/NNS	prep_against||lactamantibiotics-15/NNS||mrsa-17/NN	prep_in||enhanced-7/VBD||vitro-19/NN	prep_in||enhanced-7/VBD||in-21/IN	conj_and||vitro-19/NN||in-21/IN	pobj||in-21/IN||vivo-22/NN	nsubjpass||related-27/VBN||vivo-22/NN	aux||related-27/VBN||might-25/MD	auxpass||related-27/VBN||be-26/VB	rcmod||vivo-22/NN||related-27/VBN	det||accumulation-31/NN||the-29/DT	amod||accumulation-31/NN||increased-30/VBN	prep_to||related-27/VBN||accumulation-31/NN	prep_of||accumulation-31/NN||antibiotics-33/NNS	prep_within||antibiotics-33/NNS||mrsa-35/NN	prep_via||mrsa-35/NN||suppression-37/NN	amod||pumpsâ-41/NNS||important-39/JJ	nn||pumpsâ-41/NNS||efflux-40/NN	nn||expression-45/NN||pumpsâ-41/NNS	amod||expression-45/NN||$-42/$	dep||$-42/$||-43/JJ	nn||expression-45/NN||gene-44/NN	prep_of||suppression-37/NN||expression-45/NN	mrsa-35||antibacterial-9||no_rel||in summary, c and ecg enhanced the antibacterial effect of î²-lactamantibiotics against mrsa in vitro and in vivo , which might be related to the increased accumulation of antibiotics within mrsa via suppression of important efflux pumpsâ gene expression.
nsubjpass||established-4/VBN||it-1/PRP	nsubj||vibriocholerae-9/VBP||it-1/PRP	auxpass||established-4/VBN||is-2/VBZ	advmod||established-4/VBN||well-3/RB	root||ROOT-0/null||established-4/VBN	nn||coli-7/NNS||e.-6/NN	prep_in||established-4/VBN||coli-7/NNS	conj_and||established-4/VBN||vibriocholerae-9/VBP	mark||unable-24/JJ||that-10/IN	nsubj||unable-24/JJ||strains-11/NNS	nsubj||utilize-26/VB||strains-11/NNS	vmod||strains-11/NNS||harboring-12/VBG	dobj||harboring-12/VBG||mutations-13/NNS	det||-rrb--22/NNP||the-15/DT	amod||-rrb--22/NNP||ferric-16/JJ	amod||-rrb--22/NNP||uptake-17/JJ	nn||-rrb--22/NNP||regulator-18/NN	nn||-rrb--22/NNP||gene-19/NN	nn||-rrb--22/NNP||-lrb--20/NNP	nn||-rrb--22/NNP||fur-21/NN	prep_in||mutations-13/NNS||-rrb--22/NNP	cop||unable-24/JJ||are-23/VBP	ccomp||vibriocholerae-9/VBP||unable-24/JJ	aux||utilize-26/VB||to-25/TO	xcomp||unable-24/JJ||utilize-26/VB	amod||compounds-32/NNS||tricarboxylic-27/JJ	nn||compounds-32/NNS||acid-28/NN	nn||compounds-32/NNS||-lrb--29/NN	nn||compounds-32/NNS||tca-30/NN	nn||compounds-32/NNS||-rrb--31/NN	dobj||utilize-26/VB||compounds-32/NNS	det||down-regulation-37/NN||the-36/DT	prep_due_to||compounds-32/NNS||down-regulation-37/NN	amod||enzymes-42/NNS||key-39/JJ	nn||enzymes-42/NNS||tca-40/NN	nn||enzymes-42/NNS||cycle-41/NN	prep_of||down-regulation-37/NN||enzymes-42/NNS	prep_such_as||compounds-32/NNS||acna-46/NN	prep_such_as||compounds-32/NNS||sdhabcd-48/NN	conj_and||acna-46/NN||sdhabcd-48/NN	vibriocholerae-9||enzymes-42||no_rel||it is well established in e. coli and vibriocholerae that strains harboring mutations in the ferric uptake regulator gene -lrb- fur -rrb- are unable to utilize tricarboxylic acid -lrb- tca -rrb- compounds , due to the down-regulation of key tca cycle enzymes , such as acna and sdhabcd .
nsubj||seems-2/VBZ||it-1/PRP	root||ROOT-0/null||seems-2/VBZ	mark||prominent-19/JJ||that-3/IN	det||impact-5/NN||the-4/DT	nsubj||prominent-19/JJ||impact-5/NN	amod||polymorphism-8/NN||il28b-7/JJ	prep_of||impact-5/NN||polymorphism-8/NN	det||clearance-12/NN||the-10/DT	amod||clearance-12/NN||spontaneous-11/JJ	prep_on||polymorphism-8/NN||clearance-12/NN	nn||genotype-15/NN||hcv-14/NN	prep_of||clearance-12/NN||genotype-15/NN	num||genotype-15/NN||1-16/CD	cop||prominent-19/JJ||is-17/VBZ	advmod||prominent-19/JJ||more-18/RBR	ccomp||seems-2/VBZ||prominent-19/JJ	prep_than||prominent-19/JJ||hcv-21/NN	nsubj||results-25/VBZ||hcv-21/NN	amod||hcv-21/NN||genotype-22/JJ	dep||genotype-22/JJ||3-23/CD	rcmod||hcv-21/NN||results-25/VBZ	det||observation-28/NN||the-27/DT	prep_in||results-25/VBZ||observation-28/NN	amod||rs12979860-31/NNS||higher-30/JJR	prep_of||observation-28/NN||rs12979860-31/NNS	dep||genotype-40/VBP||c-32/SYM	amod||frequency-34/NN||allele-33/JJ	nsubj||genotype-40/VBP||frequency-34/NN	amod||patients-37/NNS||chronichepatitisc-36/JJ	prep_in||frequency-34/NN||patients-37/NNS	prep_with||patients-37/NNS||hcv-39/NN	ccomp||prominent-19/JJ||genotype-40/VBP	dobj||genotype-40/VBP||3-41/CD	nn||genotype-44/NN||hcv-43/NN	prep_than||genotype-40/VBP||genotype-44/NN	num||genotype-44/NN||1-45/CD	chronichepatitisc-36||hcv-43||no||it seems that the impact of il28b polymorphism on the spontaneous clearance of hcv genotype 1 is more prominent than hcv genotype 3 which results in the observation of higher rs12979860 c allele frequency in chronichepatitisc patients with hcv genotype 3 than hcv genotype 1.
nsubj||report-5/NN||this-1/DT	cop||report-5/NN||is-2/VBZ	det||report-5/NN||the-3/DT	amod||report-5/NN||first-4/JJ	root||ROOT-0/null||report-5/NN	aux||demonstrate-7/VB||to-6/TO	vmod||report-5/NN||demonstrate-7/VB	det||effects-9/NNS||the-8/DT	dobj||demonstrate-7/VB||effects-9/NNS	amod||polymorphisms-13/NNS||cyp2b6-11/JJ	amod||polymorphisms-13/NNS||g516t-12/JJ	prep_of||effects-9/NNS||polymorphisms-13/NNS	nn||efavirenz-16/NN||plasma-15/NN	prep_on||demonstrate-7/VB||efavirenz-16/NN	nn||concentrations-19/NNS||nevirapine-18/NN	prep_on||demonstrate-7/VB||concentrations-19/NNS	conj_and||efavirenz-16/NN||concentrations-19/NNS	advmod||co-administered-21/VBN||when-20/WRB	advcl||demonstrate-7/VB||co-administered-21/VBN	prep_with||co-administered-21/VBN||rifampicin-23/NN	amod||adults-28/NNS||hiv/tb-25/JJ	amod||adults-28/NNS||co-infected-26/JJ	nn||adults-28/NNS||thai-27/NN	prep_in||rifampicin-23/NN||adults-28/NNS	tb--1||rifampicin-23||yes||this is the first report to demonstrate the effects of cyp2b6 g516t polymorphisms on plasma efavirenz and nevirapine concentrations when co-administered with rifampicin in hiv/tb co-infected thai adults.
nsubjpass||analyzed-16/VBN||oa-1/NN	conj_and||oa-1/NN||ptx-3/NN	nsubjpass||analyzed-16/VBN||ptx-3/NN	num||toxins-6/NNS||two-5/CD	appos||oa-1/NN||toxins-6/NNS	det||mode-11/NN||a-8/DT	advmod||established-10/VBN||better-9/RB	amod||mode-11/NN||established-10/VBN	prep_with||toxins-6/NNS||mode-11/NN	prep_of||mode-11/NN||action-13/NN	auxpass||analyzed-16/VBN||are-15/VBP	root||ROOT-0/null||analyzed-16/VBN	prep_with||analyzed-16/VBN||regard-18/NN	poss||effects-21/NNS||their-20/PRP$	prep_to||analyzed-16/VBN||effects-21/NNS	prep_on||analyzed-16/VBN||development-23/NN	oa-1||ptx-3||no_rel||oa and ptx, two toxins with a better established mode of action, are analyzed with regard to their effects on development.
mark||cause-7/NN||although-1/IN	nsubj||cause-7/NN||alcoholabuse-2/NN	cop||cause-7/NN||is-3/VBZ	det||cause-7/NN||the-4/DT	advmod||common-6/JJ||most-5/RBS	amod||cause-7/NN||common-6/JJ	advcl||related-30/VBD||cause-7/NN	prep_of||cause-7/NN||livercirrhosis-9/NNS	det||states-13/NNS||the-11/DT	amod||states-13/NNS||united-12/VBN	prep_in||livercirrhosis-9/NNS||states-13/NNS	det||effects-17/NNS||the-15/DT	amod||effects-17/NNS||enhancing-16/JJ	nsubj||related-30/VBD||effects-17/NNS	prep_of||effects-17/NNS||alcohol-19/NN	det||prognosis-23/NN||the-21/DT	amod||prognosis-23/NN||long-term-22/JJ	prep_on||alcohol-19/NN||prognosis-23/NN	amod||virus-26/NN||hepatitisc-25/JJ	prep_of||prognosis-23/NN||virus-26/NN	appos||virus-26/NN||hcv-28/NN	root||ROOT-0/null||related-30/VBD	nsubjpass||clarified-35/VBN||livercirrhosis-31/NNS	aux||clarified-35/VBN||has-32/VBZ	neg||clarified-35/VBN||not-33/RB	auxpass||clarified-35/VBN||been-34/VBN	ccomp||related-30/VBD||clarified-35/VBN	alcoholabuse-2||alcohol-19||no||although alcoholabuse is the most common cause of livercirrhosis in the united states, the enhancing effects of alcohol on the long-term prognosis of hepatitisc virus (hcv) related livercirrhosis has not been clarified.
nsubj||one-3/CD||gonorrhoea-1/NN	cop||one-3/CD||is-2/VBZ	root||ROOT-0/null||one-3/CD	det||sexuallytransmittedinfections-8/NNS||the-5/DT	advmod||common-7/JJ||most-6/RBS	amod||sexuallytransmittedinfections-8/NNS||common-7/JJ	prep_of||one-3/CD||sexuallytransmittedinfections-8/NNS	appos||sexuallytransmittedinfections-8/NNS||stis-10/NNS	amod||countries-14/NNS||developing-13/VBG	prep_in||one-3/CD||countries-14/NNS	det||emergence-18/NN||the-17/DT	nsubj||obstacle-29/NN||emergence-18/NN	prep_of||emergence-18/NN||resistance-20/NN	amod||agents-23/NNS||antimicrobial-22/JJ	prep_to||resistance-20/NN||agents-23/NNS	prep_in||agents-23/NNS||neisseriagonorrhoeae-25/NN	cop||obstacle-29/NN||is-26/VBZ	det||obstacle-29/NN||a-27/DT	amod||obstacle-29/NN||major-28/JJ	conj_and||one-3/CD||obstacle-29/NN	det||control-32/NN||the-31/DT	prep_in||obstacle-29/NN||control-32/NN	prep_of||control-32/NN||gonorrhoea-34/NN	gonorrhoea-34||neisseriagonorrhoeae-25||no||gonorrhoea is one of the most common sexuallytransmittedinfections (stis) in developing countries, and the emergence of resistance to antimicrobial agents in neisseriagonorrhoeae is a major obstacle in the control of gonorrhoea.
amod||analyses-2/NNS||secondary-1/JJ	nsubj||compare-4/VB||analyses-2/NNS	aux||compare-4/VB||will-3/MD	ccomp||hiv-15/VBP||compare-4/VB	det||rates-6/NNS||the-5/DT	dobj||compare-4/VB||rates-6/NNS	prep_of||rates-6/NNS||change-8/NN	amod||count-11/NN||cd4-10/JJ	prep_in||compare-4/VB||count-11/NN	amod||log10-14/NNS||median-13/JJ	nsubj||hiv-15/VBP||log10-14/NNS	root||ROOT-0/null||hiv-15/VBP	amod||load-17/NN||viral-16/JJ	dobj||hiv-15/VBP||load-17/NN	amod||events-21/NNS||drug-related-19/JJ	amod||events-21/NNS||adverse-20/JJ	appos||load-17/NN||events-21/NNS	dobj||hiv-15/VBP||frequency-23/NN	conj_and||load-17/NN||frequency-23/NN	nn||reactivations-26/NNS||hsv-25/NN	prep_of||frequency-23/NN||reactivations-26/NNS	dobj||hiv-15/VBP||rate-28/NN	conj_and||load-17/NN||rate-28/NN	amod||hsv-31/NN||acyclovir-resistant-30/JJ	prep_of||rate-28/NN||hsv-31/NN	dobj||hiv-15/VBP||quality-34/NN	conj_and||load-17/NN||quality-34/NN	prep_of||quality-34/NN||life-36/NN	nn||arms-39/NNS||study-38/NN	prep_between||life-36/NN||arms-39/NNS	hsv-31||acyclovir--1||yes||secondary analyses will compare the rates of change in cd4 count, median log10 hiv viral load, drug-related adverse events, frequency of hsv reactivations, rate of acyclovir-resistant hsv, and quality of life between study arms.
det||objective-2/NN||the-1/DT	nsubj||reported-6/VBD||objective-2/NN	det||study-5/NN||the-4/DT	prep_of||objective-2/NN||study-5/NN	root||ROOT-0/null||reported-6/VBD	nsubj||was-8/VBD||here-7/RB	nsubj||determine-10/VB||here-7/RB	ccomp||reported-6/VBD||was-8/VBD	aux||determine-10/VB||to-9/TO	xcomp||was-8/VBD||determine-10/VB	det||prevalence-12/NN||the-11/DT	dobj||determine-10/VB||prevalence-12/NN	amod||viruses-18/NNS||human-14/JJ	amod||viruses-18/NNS||immunodeficiency-15/JJ	conj_and||immunodeficiency-15/JJ||hepatitisc-17/JJ	amod||viruses-18/NNS||hepatitisc-17/JJ	prep_of||prevalence-12/NN||viruses-18/NNS	dep||hiv-22/NN||respectively-20/RB	appos||viruses-18/NNS||hiv-22/NN	appos||viruses-18/NNS||hcv-24/NNS	conj_and||hiv-22/NN||hcv-24/NNS	det||communities-29/NNS||the-27/DT	amod||communities-29/NNS||earthquake-affected-28/JJ	prep_in||determine-10/VB||communities-29/NNS	prep_of||communities-29/NNS||pakistan-31/NN	hepatitisc-17||hcv-24||no||the objective of the study reported here was to determine the prevalence of human immunodeficiency and hepatitisc viruses (respectively, hiv and hcv) in the earthquake-affected communities of pakistan.
nsubj||present-2/VBP||we-1/PRP	root||ROOT-0/null||present-2/VBP	det||case-4/NN||a-3/DT	dobj||present-2/VBP||case-4/NN	det||woman-8/NN||a-6/DT	amod||woman-8/NN||24-year-old-7/JJ	prep_of||case-4/NN||woman-8/NN	amod||ptld-11/NN||ebv-associated-10/JJ	prep_with||present-2/VBP||ptld-11/NN	nn||transplant-14/NN||lung-13/NN	prep_following||ptld-11/NN||transplant-14/NN	advmod||ptld-20/VBD||where-15/WRB	csubj||ptld-20/VBD||decreasing-16/VBG	csubj||ineffective-23/JJ||decreasing-16/VBG	det||immunosuppression-18/NN||the-17/DT	nsubj||improved-19/VBD||immunosuppression-18/NN	xcomp||decreasing-16/VBG||improved-19/VBD	rcmod||transplant-14/NN||ptld-20/VBD	cop||ineffective-23/JJ||was-22/VBD	rcmod||transplant-14/NN||ineffective-23/JJ	conj_but||ptld-20/VBD||ineffective-23/JJ	prepc_against||ineffective-23/JJ||controlling-25/VBG	det||ebvinfection-27/NN||the-26/DT	dobj||controlling-25/VBG||ebvinfection-27/NN	ebvinfection-27||ebv--1||no||we present a case of a 24-year-old woman with ebv-associated ptld following lung transplant where decreasing the immunosuppression improved ptld but was ineffective against controlling the ebvinfection.
amod||macrophages-2/NNS||peritoneal-1/JJ	nsubj||enhanced-19/VBD||macrophages-2/NNS	vmod||macrophages-2/NNS||obtained-3/VBN	amod||mice-7/NNS||mb49-5/JJ	amod||mice-7/NNS||tumor-bearing-6/JJ	prep_from||obtained-3/VBN||mice-7/NNS	vmod||mice-7/NNS||treated-8/VBN	prep_in||treated-8/VBN||vivo-10/NN	amod||treatment-13/NN||combined-12/VBN	prep_with||treated-8/VBN||treatment-13/NN	prep_of||treatment-13/NN||bcg-15/NN	prep_with||bcg-15/NN||l-name-17/NN	advmod||enhanced-19/VBD||also-18/RB	root||ROOT-0/null||enhanced-19/VBD	amod||proliferation-21/NN||fibroblast-20/JJ	dobj||enhanced-19/VBD||proliferation-21/NN	tumor--1||bcg-15||no_rel||peritoneal macrophages obtained from mb49 tumor-bearing mice treated in vivo with combined treatment of bcg with l-name also enhanced fibroblast proliferation.
nsubj||capable-13/JJ||mycobacteriumtuberculosis-1/NNS	appos||mycobacteriumtuberculosis-1/NNS||m.tb-3/NN	det||pathogen-7/NN||the-6/DT	appos||mycobacteriumtuberculosis-1/NNS||pathogen-7/NN	nsubj||causes-9/VBZ||pathogen-7/NN	rcmod||pathogen-7/NN||causes-9/VBZ	dobj||causes-9/VBZ||tuberculosis-10/NNP	cop||capable-13/JJ||is-12/VBZ	root||ROOT-0/null||capable-13/JJ	prepc_of||capable-13/JJ||staying-15/VBG	advmod||staying-15/VBG||asymptomatically-16/RB	det||form-20/NN||a-18/DT	nn||form-20/NN||latent-19/NN	prep_in||staying-15/VBG||form-20/NN	dep||staying-15/VBG||persisting-22/VBG	prep_for||persisting-22/VBG||years-24/NNS	advmod||low-27/JJ||very-26/RB	amod||state-29/NN||low-27/JJ	amod||state-29/NN||replicating-28/JJ	prep_in||years-24/NNS||state-29/NN	advmod||getting-32/VBG||before-31/RB	dep||staying-15/VBG||getting-32/VBG	advmod||getting-32/VBG||reactivated-33/RB	aux||cause-35/VB||to-34/TO	xcomp||getting-32/VBG||cause-35/VB	amod||infection-37/NN||active-36/JJ	dobj||cause-35/VB||infection-37/NN	tuberculosis-10||mycobacteriumtuberculosis-1||no||mycobacteriumtuberculosis ( m.tb ), the pathogen that causes tuberculosis, is capable of staying asymptomatically in a latent form, persisting for years in very low replicating state, before getting reactivated to cause active infection.
det||group-4/NN||the-2/DT	amod||group-4/NN||overweight/obese-3/JJ	prep_in||times-14/NNS||group-4/NN	nsubj||times-14/NNS||those-6/DT	amod||obesity-9/NN||central-8/JJ	prep_without||those-6/DT||obesity-9/NN	cop||times-14/NNS||were-10/VBD	nn||times-14/NNS||0.53-11/CD	conj_and||0.53-11/CD||0.27-13/CD	nn||times-14/NNS||0.27-13/CD	root||ROOT-0/null||times-14/NNS	advmod||likely-16/JJ||less-15/RBR	amod||times-14/NNS||likely-16/JJ	aux||have-18/VB||to-17/TO	dep||times-14/NNS||have-18/VB	amod||levels-21/NNS||significant-19/JJ	amod||levels-21/NNS||adverse-20/JJ	dobj||have-18/VB||levels-21/NNS	nn||cholesterol-24/NN||hdl-23/NN	prep_of||levels-21/NNS||cholesterol-24/NN	prep_of||levels-21/NNS||homa-ir-26/NN	conj_and||cholesterol-24/NN||homa-ir-26/NN	advmod||have-18/VB||respectively-28/RB	parataxis||have-18/VB||p-30/VB	num||0.05-32/CD||<-31/CD	dobj||p-30/VB||0.05-32/CD	prepc_as||times-14/NNS||compared-36/VBN	pcomp||compared-36/VBN||to-37/TO	pobj||to-37/TO||those-38/DT	amod||obesity-41/NN||central-40/JJ	prep_with||those-38/DT||obesity-41/NN	obese--1||cholesterol-24||no_rel||in the overweight/obese group, those without central obesity were 0.53 and 0.27 times less likely to have significant adverse levels of hdl cholesterol and homa-ir, respectively (p < 0.05), as compared to those with central obesity.
advmod||suggest-5/VBP||moreover-1/RB	det||findings-4/NNS||the-3/DT	nsubj||suggest-5/VBP||findings-4/NNS	root||ROOT-0/null||suggest-5/VBP	mark||barrier-14/NN||that-6/IN	csubj||barrier-14/NN||possessing-7/VBG	amod||hiv/aids-9/JJ||inaccurate-8/JJ	amod||knowledge-10/NN||hiv/aids-9/JJ	dobj||possessing-7/VBG||knowledge-10/NN	aux||barrier-14/NN||may-11/MD	cop||barrier-14/NN||be-12/VB	det||barrier-14/NN||a-13/DT	ccomp||suggest-5/VBP||barrier-14/NN	amod||testing-18/NN||timely-16/JJ	nn||testing-18/NN||hiv-17/NN	prep_to||barrier-14/NN||testing-18/NN	aids--1||hiv-17||no||moreover, the findings suggest that possessing inaccurate hiv/aids knowledge may be a barrier to timely hiv testing.
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||compare-8/VB||purpose-2/NN	nsubj||ketamine-21/VB||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||compare-8/VB||to-7/TO	xcomp||was-6/VBD||compare-8/VB	det||combination-10/NN||a-9/DT	dobj||compare-8/VB||combination-10/NN	prep_of||combination-10/NN||lidocaine-12/NN	prep_of||combination-10/NN||ketamine-14/NN	conj_and||lidocaine-12/NN||ketamine-14/NN	amod||pain-17/NN||aquafol-induced-16/JJ	prep_on||compare-8/VB||pain-17/NN	prep_with||compare-8/VB||lidocaine-19/NN	xcomp||was-6/VBD||ketamine-21/VB	conj_or||compare-8/VB||ketamine-21/VB	advmod||ketamine-21/VB||alone-22/RB	det||induction-25/NN||the-24/DT	prep_during||ketamine-21/VB||induction-25/NN	prep_of||induction-25/NN||anesthesia-27/NN	pain-17||lidocaine-19||yes||the purpose of this study was to compare a combination of lidocaine and ketamine on aquafol-induced pain with lidocaine or ketamine alone during the induction of anesthesia.
nsubjpass||used-11/VBN||indomethacin-1/NN	det||drug-7/NN||a-3/DT	amod||drug-7/NN||potent-4/JJ	amod||drug-7/NN||nonsteroidal-5/JJ	amod||drug-7/NN||anti-inflammatory-6/JJ	appos||indomethacin-1/NN||drug-7/NN	aux||used-11/VBN||has-9/VBZ	auxpass||used-11/VBN||been-10/VBN	root||ROOT-0/null||used-11/VBN	det||treatment-14/NN||the-13/DT	prep_in||used-11/VBN||treatment-14/NN	amod||kinds-17/NNS||various-16/JJ	prep_of||treatment-14/NN||kinds-17/NNS	prep_of||kinds-17/NNS||pains-19/NNS	prep_of||kinds-17/NNS||inflammation-21/NN	conj_and||pains-19/NNS||inflammation-21/NN	prep_of||kinds-17/NNS||arthritis-23/NN	conj_and||pains-19/NNS||arthritis-23/NN	inflammation-21||indomethacin-1||yes||indomethacin, a potent nonsteroidal anti-inflammatory drug, has been used in the treatment of various kinds of pains, inflammation and arthritis.
det||initiative-7/NN||the-1/DT	amod||initiative-7/NN||womenâ-2/JJ	amod||initiative-7/NN||$-3/$	number||s-5/CD||-4/CD	num||$-3/$||s-5/CD	nn||initiative-7/NN||health-6/NN	nsubj||found-8/VBD||initiative-7/NN	root||ROOT-0/null||found-8/VBD	mark||increases-17/VBZ||that-9/IN	nn||estrogen-11/NN||combination-10/NN	nsubj||increases-17/VBZ||estrogen-11/NN	amod||therapy-16/NN||progesterone-13/JJ	nn||therapy-16/NN||hormone-14/NN	nn||therapy-16/NN||replacement-15/NN	conj_and||estrogen-11/NN||therapy-16/NN	nsubj||increases-17/VBZ||therapy-16/NN	ccomp||found-8/VBD||increases-17/VBZ	nn||cancer-19/NN||breast-18/NN	dobj||increases-17/VBZ||cancer-19/NN	nsubj||compelled-25/VBN||cancer-19/NN	nn||risk-22/NN||cardiovasculardisease-21/NN	dobj||increases-17/VBZ||risk-22/NN	conj_and||cancer-19/NN||risk-22/NN	nsubj||compelled-25/VBN||risk-22/NN	rcmod||cancer-19/NN||compelled-25/VBN	amod||women-27/NNS||many-26/JJ	dobj||compelled-25/VBN||women-27/NNS	nsubj||seek-29/VB||women-27/NNS	aux||seek-29/VB||to-28/TO	xcomp||compelled-25/VBN||seek-29/VB	amod||alternatives-31/NNS||herbal-30/JJ	nsubj||extract-35/VB||alternatives-31/NNS	prep_such_as||alternatives-31/NNS||blackcohosh-34/NN	ccomp||seek-29/VB||extract-35/VB	dobj||extract-35/VB||bce-37/NN	nsubj||relieve-40/VB||bce-37/NN	aux||relieve-40/VB||to-39/TO	xcomp||extract-35/VB||relieve-40/VB	poss||symptoms-43/NNS||their-41/PRP$	amod||symptoms-43/NNS||menopausal-42/JJ	dobj||relieve-40/VB||symptoms-43/NNS	progesterone-13||cancer-19||no_rel||the womenâs health initiative found that combination estrogen and progesterone hormone replacement therapy increases breast cancer and cardiovasculardisease risk, which compelled many women to seek herbal alternatives such as blackcohosh extract (bce) to relieve their menopausal symptoms.
nn||guidelines-2/NNS||hypertension-1/NN	nsubj||recommend-3/VBP||guidelines-2/NNS	root||ROOT-0/null||recommend-3/VBP	det||use-5/NN||the-4/DT	dobj||recommend-3/VBP||use-5/NN	prep_of||use-5/NN||thiazidediuretics-7/NNS	amod||therapy-10/NN||first-line-9/JJ	prep_as||thiazidediuretics-7/NNS||therapy-10/NN	amod||hypertension-13/NN||uncomplicated-12/JJ	prep_for||therapy-10/NN||hypertension-13/NN	nsubj||under-prescribed-18/JJ||diuretics-16/NNS	cop||under-prescribed-18/JJ||are-17/VBP	conj_yet||recommend-3/VBP||under-prescribed-18/JJ	nsubj||treated-25/JJ||hypertension-21/NN	cop||treated-25/JJ||is-22/VBZ	advmod||treated-25/JJ||frequently-23/RB	advmod||treated-25/JJ||inadequately-24/RB	conj_yet||recommend-3/VBP||treated-25/JJ	conj_and||under-prescribed-18/JJ||treated-25/JJ	hypertension-21||thiazidediuretics-7||no_rel||hypertension guidelines recommend the use of thiazidediuretics as first-line therapy for uncomplicated hypertension, yet diuretics are under-prescribed, and hypertension is frequently inadequately treated.
amod||particles-3/NNS||microscopic-1/JJ	nn||particles-3/NNS||metal-2/NN	nsubjpass||shown-13/VBN||particles-3/NNS	nsubj||activate-15/VB||particles-3/NNS	det||tissue-7/NN||the-5/DT	amod||tissue-7/NN||soft-6/JJ	prep_from||particles-3/NNS||tissue-7/NN	vmod||tissue-7/NN||surrounding-8/VBG	amod||arthroplasty-10/NN||joint-9/JJ	dobj||surrounding-8/VBG||arthroplasty-10/NN	aux||shown-13/VBN||have-11/VBP	auxpass||shown-13/VBN||been-12/VBN	root||ROOT-0/null||shown-13/VBN	aux||activate-15/VB||to-14/TO	xcomp||shown-13/VBN||activate-15/VB	det||response-18/NN||a-16/DT	amod||response-18/NN||macrophage-17/JJ	dobj||activate-15/VB||response-18/NN	nsubj||leads-20/VBZ||response-18/NN	rcmod||response-18/NN||leads-20/VBZ	nn||resorption-23/NN||bone-22/NN	prep_to||leads-20/VBZ||resorption-23/NN	amod||inflammation-26/NN||increased-25/VBN	prep_to||leads-20/VBZ||inflammation-26/NN	conj_and||resorption-23/NN||inflammation-26/NN	inflammation-26||metal-2||no_rel||microscopic metal particles from the soft tissue surrounding joint arthroplasty have been shown to activate a macrophage response that leads to bone resorption and increased inflammation.
det||aprepitant-6/NN||the-1/DT	amod||aprepitant-6/NN||selective-2/JJ	amod||aprepitant-6/NN||neurokinin-1-3/JJ	nn||aprepitant-6/NN||receptor-4/NN	nn||aprepitant-6/NN||antagonist-5/NN	nsubj||effective-8/JJ||aprepitant-6/NN	cop||effective-8/JJ||is-7/VBZ	root||ROOT-0/null||effective-8/JJ	det||treatment-11/NN||the-10/DT	prep_in||effective-8/JJ||treatment-11/NN	amod||chemotherapy-inducednauseaandvomiting-16/NN||acute-13/JJ	conj_and||acute-13/JJ||delayed-15/JJ	amod||chemotherapy-inducednauseaandvomiting-16/NN||delayed-15/JJ	prep_of||treatment-11/NN||chemotherapy-inducednauseaandvomiting-16/NN	appos||chemotherapy-inducednauseaandvomiting-16/NN||cinv-18/NNP	vmod||chemotherapy-inducednauseaandvomiting-16/NN||associated-20/VBN	det||chemotherapy-27/NN||both-22/DT	advmod||chemotherapy-27/NN||moderately-23/RB	advmod||emetogenic-26/JJ||highly-25/RB	conj_and||moderately-23/RB||emetogenic-26/JJ	advmod||chemotherapy-27/NN||emetogenic-26/JJ	prep_with||associated-20/VBN||chemotherapy-27/NN	chemotherapy-inducednauseaandvomiting-16||emetogenic-26||no_rel||the selective neurokinin-1 receptor antagonist aprepitant is effective in the treatment of acute and delayed chemotherapy-inducednauseaandvomiting (cinv) associated with both moderately and highly emetogenic chemotherapy.
nsubj||cause-5/NN||staphylococcusaureus-1/NNS	cop||cause-5/NN||is-2/VBZ	det||cause-5/NN||a-3/DT	amod||cause-5/NN||common-4/JJ	ccomp||-lrb--25/VBD||cause-5/NN	amod||infection-8/NN||human-7/JJ	prep_of||cause-5/NN||infection-8/NN	nsubj||concern-18/NN||emergence-11/NN	amod||s.aureus-14/NNS||vancomycin-resistance-13/JJ	prep_of||emergence-11/NN||s.aureus-14/NNS	cop||concern-18/NN||is-15/VBZ	det||concern-18/NN||a-16/DT	amod||concern-18/NN||great-17/JJ	conj_and||cause-5/NN||concern-18/NN	ccomp||-lrb--25/VBD||concern-18/NN	prep_for||concern-18/NN||treatment-20/NN	amod||s.aureus-23/NNS||methicillin-resistant-22/JJ	prep_of||treatment-20/NN||s.aureus-23/NNS	root||ROOT-0/null||-lrb--25/VBD	nn||-rrb--27/NNS||mrsa-26/NN	dobj||-lrb--25/VBD||-rrb--27/NNS	amod||years-30/NNS||recent-29/JJ	prep_in||-lrb--25/VBD||years-30/NNS	num||-rrb--33/NN||-lrb--31/CD	nn||-rrb--33/NN||mrsa-32/NN	nsubj||-lrb--25/VBD||-rrb--33/NN	mrsa-32||s.aureus-23||no||staphylococcusaureus is a common cause of human infection , and emergence of vancomycin-resistance s.aureus is a great concern for treatment of methicillin-resistant s.aureus , -lrb- mrsa -rrb- in recent years -lrb- mrsa -rrb- .
amod||curcumin-2/NN||dietary-1/JJ	nsubj||delay-5/VB||curcumin-2/NN	nsubj||sensitize-15/VB||curcumin-2/NN	aux||delay-5/VB||did-3/VBD	neg||delay-5/VB||not-4/RB	root||ROOT-0/null||delay-5/VB	det||engraftment-7/NN||the-6/DT	dobj||delay-5/VB||engraftment-7/NN	dobj||delay-5/VB||growth-9/NN	conj_or||engraftment-7/NN||growth-9/NN	nn||cells-12/NNS||leukemia-11/NN	prep_of||engraftment-7/NN||cells-12/NNS	conj_or||delay-5/VB||sensitize-15/VB	det||cells-17/NNS||the-16/DT	dobj||sensitize-15/VB||cells-17/NNS	nsubj||vincristine-19/VB||cells-17/NNS	aux||vincristine-19/VB||to-18/TO	xcomp||sensitize-15/VB||vincristine-19/VB	leukemia-11||vincristine-19||yes||dietary curcumin did not delay the engraftment or growth of leukemia cells, or sensitize the cells to vincristine.
advmod||hbsag-24/VBG||furthermore-1/RB	mark||expressed-12/VBD||while-3/IN	nsubj||expressed-12/VBD||most-4/JJS	det||controls-7/NNS||the-6/DT	prep_of||most-4/JJS||controls-7/NNS	amod||infection-11/NN||ongoing-9/JJ	nn||infection-11/NN||hbv-10/NN	prep_with||controls-7/NNS||infection-11/NN	advcl||hbsag-24/VBG||expressed-12/VBD	xcomp||expressed-12/VBD||hbsag-13/VBG	det||majority-16/NN||the-15/DT	nsubj||hbsag-24/VBG||majority-16/NN	nn||patients-22/NNS||hcv-18/NN	conj_and||hcv-18/NN||hbv-20/JJ	nn||patients-22/NNS||hbv-20/JJ	amod||patients-22/NNS||positive-21/JJ	prep_of||majority-16/NN||patients-22/NNS	aux||hbsag-24/VBG||were-23/VBD	root||ROOT-0/null||hbsag-24/VBG	amod||positive-29/NN||negative-25/JJ	conj_and||negative-25/JJ||hbv-27/NN	amod||positive-29/NN||hbv-27/NN	nn||positive-29/NN||dna-28/NN	dobj||hbsag-24/VBG||positive-29/NN	hbv-27||hbsag-24||yes||furthermore, while most of the controls with ongoing hbv infection expressed hbsag, the majority of hcv and hbv positive patients were hbsag negative and hbv dna positive.
advmod||evident-2/JJ||as-1/RB	amod||knowledge-11/NN||evident-2/JJ	det||results-5/NNS||the-4/DT	prep_from||evident-2/JJ||results-5/NNS	amod||hiv-8/NN||comprehensive-7/JJ	prep_from||evident-2/JJ||hiv-8/NN	conj_and||results-5/NNS||hiv-8/NN	prep_from||evident-2/JJ||aids-10/NNS	conj_and||results-5/NNS||aids-10/NNS	nsubj||increased-13/VBN||knowledge-11/NN	aux||increased-13/VBN||has-12/VBZ	root||ROOT-0/null||increased-13/VBN	det||period-18/NN||the-15/DT	num||period-18/NN||15-16/CD	nn||period-18/NN||year-17/NN	prep_over||increased-13/VBN||period-18/NN	amod||women-22/NNS||urban-20/JJ	amod||women-22/NNS||young-21/JJ	prep_among||period-18/NN||women-22/NNS	num||%-25/NN||9-24/CD	prep_from||increased-13/VBN||%-25/NN	prep_in||%-25/NN||1993-27/CD	num||%-30/NN||54-29/CD	prep_to||increased-13/VBN||%-30/NN	prep_in||%-30/NN||2008/09-32/CD	aids-10||hiv-8||no||as evident from the results, comprehensive hiv and aids knowledge has increased over the 15 year period among urban young women from 9% in 1993 to 54% in 2008/09.
dep||mp-20/VBP||r-2/LS	conj_or||--4/JJ||racemic-6/JJ	amod||formoterol-17/NN||albuterol-7/JJ	cc||albuterol-7/JJ||and-8/CC	dep||albuterol-7/JJ||r-10/SYM	appos||r-10/SYM||r-12/SYM	conj_or||--14/JJ||racemic-16/JJ	nsubj||mp-20/VBP||formoterol-17/NN	advmod||decreased-19/VBN||significantly-18/RB	vmod||formoterol-17/NN||decreased-19/VBN	root||ROOT-0/null||mp-20/VBP	dobj||mp-20/VBP||levels-21/NNS	amod||cells-27/NNS||normal-23/JJ	conj_and||normal-23/JJ||asthma-25/NN	amod||cells-27/NNS||asthma-25/NN	nn||cells-27/NNS||epithelial-26/NN	prep_in||levels-21/NNS||cells-27/NNS	asthma-25||formoterol-17||no||(r)- or racemic albuterol and (r,r)- or racemic formoterol significantly decreased mp levels in normal and asthma epithelial cells.
amod||analysis-3/NN||multivariate-2/JJ	prep_on||have-22/VBP||analysis-3/NN	det||weight-6/NN||the-4/DT	amod||weight-6/NN||normal-5/JJ	prep_to||likely-20/JJ||weight-6/NN	nsubj||have-22/VBP||weight-6/NN	advmod||obese-8/JJ||centrally-7/RB	amod||children-9/NNS||obese-8/JJ	nsubj||1.66-11/CD||children-9/NNS	nsubj||likely-20/JJ||children-9/NNS	cop||1.66-11/CD||were-10/VBD	rcmod||weight-6/NN||1.66-11/CD	rcmod||weight-6/NN||2.01-13/CD	conj_and||1.66-11/CD||2.01-13/CD	rcmod||weight-6/NN||1.47-15/CD	conj_and||1.66-11/CD||1.47-15/CD	num||times-18/NNS||2.05-17/CD	npadvmod||more-19/RBR||times-18/NNS	advmod||likely-20/JJ||more-19/RBR	rcmod||weight-6/NN||likely-20/JJ	conj_and||1.66-11/CD||likely-20/JJ	root||ROOT-0/null||have-22/VBP	amod||levels-25/NNS||significant-23/JJ	amod||levels-25/NNS||adverse-24/JJ	dobj||have-22/VBP||levels-25/NNS	nn||cholesterol-28/NN||ldl-27/NN	prep_of||levels-25/NNS||cholesterol-28/NN	nn||cholesterol-31/NN||hdl-30/NN	prep_of||levels-25/NNS||cholesterol-31/NN	conj_and||cholesterol-28/NN||cholesterol-31/NN	prep_of||levels-25/NNS||triglycerides-33/NNPS	conj_and||cholesterol-28/NN||triglycerides-33/NNPS	prep_of||levels-25/NNS||insulin-35/NN	conj_and||cholesterol-28/NN||insulin-35/NN	advmod||have-22/VBP||respectively-37/RB	cholesterol-31||obese-8||no_rel||on multivariate analysis the normal weight centrally obese children were 1.66, 2.01, 1.47 and 2.05 times more likely to have significant adverse levels of ldl cholesterol, hdl cholesterol, triglycerides and insulin, respectively.
det||analysis-2/NN||the-1/DT	nsubj||included-3/VBD||analysis-2/NN	root||ROOT-0/null||included-3/VBD	num||studies-8/NNS||three-4/CD	amod||studies-8/NNS||randomized-5/JJ	amod||studies-8/NNS||double-blind-7/JJ	dobj||included-3/VBD||studies-8/NNS	prep_in||studies-8/NNS||patients-10/NNS	nn||schizoaffectivedisorder-14/NN||schizophrenia-12/NN	prep_with||patients-10/NNS||schizoaffectivedisorder-14/NN	nn||disorder-18/NN||schizophreniform-17/NN	prep_with||patients-10/NNS||disorder-18/NN	conj_or||schizoaffectivedisorder-14/NN||disorder-18/NN	dep||patients-10/NNS||diagnosed-19/VBN	prepc_according_to||diagnosed-19/VBN||to-21/TO	det||manual-26/NN||the-22/DT	amod||manual-26/NN||diagnostic-23/JJ	conj_and||diagnostic-23/JJ||statistical-25/JJ	amod||manual-26/NN||statistical-25/JJ	pobj||diagnosed-19/VBN||manual-26/NN	amod||disorders-29/NNS||mental-28/JJ	npadvmod||4th-30/JJ||disorders-29/NNS	amod||edition-31/NN||4th-30/JJ	prep_of||manual-26/NN||edition-31/NN	advmod||assigned-34/VBN||randomly-33/RB	dep||patients-10/NNS||assigned-34/VBN	conj_and||diagnosed-19/VBN||assigned-34/VBN	prep_to||assigned-34/VBN||treatment-36/NN	poss||mg/day-43/NN||olanzapine-38/PRP$	amod||mg/day-43/NN||5â-39/JJ	amod||mg/day-43/NN||$-40/$	num||$-40/$||20-42/CD	prep_with||assigned-34/VBN||mg/day-43/NN	det||antipsychotic-46/NN||another-45/DT	prep_with||assigned-34/VBN||antipsychotic-46/NN	conj_or||mg/day-43/NN||antipsychotic-46/NN	amod||2â-49/NNS||haloperidol-48/JJ	dep||antipsychotic-46/NN||2â-49/NNS	num||mg/day-53/NN||$-50/$	num||$-50/$||20-52/CD	dep||2â-49/NNS||mg/day-53/NN	poss||mg/day-60/NN||risperidone-55/PRP$	amod||mg/day-60/NN||2â-56/JJ	amod||mg/day-60/NN||$-57/$	num||$-57/$||10-59/CD	dep||2â-49/NNS||mg/day-60/NN	conj_or||mg/day-53/NN||mg/day-60/NN	poss||mg/day-68/NN||ziprasidone-63/PRP$	amod||mg/day-68/NN||80â-64/JJ	amod||mg/day-68/NN||$-65/$	num||$-65/$||160-67/CD	dep||2â-49/NNS||mg/day-68/NN	conj_or||mg/day-53/NN||mg/day-68/NN	olanzapine-38||schizophrenia-12||no_rel||the analysis included three randomized, double-blind studies in patients with schizophrenia, schizoaffectivedisorder, or schizophreniform disorder diagnosed according to the diagnostic and statistical manual of mental disorders 4th edition and randomly assigned to treatment with olanzapine 5â20 mg/day or another antipsychotic (haloperidol 2â20 mg/day, risperidone 2â10 mg/day, or ziprasidone 80â160 mg/day).
det||route-4/NN||the-1/DT	amod||route-4/NN||main-2/JJ	nn||route-4/NN||transmission-3/NN	nsubj||mother-12/NN||route-4/NN	nsubj||contributes-17/VBZ||route-4/NN	det||hepatitisbvirus-7/NNS||the-6/DT	prep_of||route-4/NN||hepatitisbvirus-7/NNS	appos||hepatitisbvirus-7/NNS||hbv-9/NN	cop||mother-12/NN||is-11/VBZ	root||ROOT-0/null||mother-12/NN	nn||transmission-15/NN||child-14/NN	prep_to||mother-12/NN||transmission-15/NN	conj_and||mother-12/NN||contributes-17/VBZ	advmod||contributes-17/VBZ||significantly-18/RB	amod||infection-22/NN||chronic-20/JJ	nn||infection-22/NN||hbv-21/NN	prep_to||contributes-17/VBZ||infection-22/NN	hbv-21||hepatitisbvirus-7||no||the main transmission route of the hepatitisbvirus (hbv) is mother to child transmission and contributes significantly to chronic hbv infection.
nn||rates-3/NNS||glucose-1/NN	nn||rates-3/NNS||infusion-2/NN	nsubj||-lrb--4/VBP||rates-3/NNS	root||ROOT-0/null||-lrb--4/VBP	nsubjpass||reduced-12/VBN||girs-5/NNS	dep||reduced-12/VBN||-rrb--6/JJ	det||clamp-10/NN||the-8/DT	amod||clamp-10/NN||euglycemic-9/JJ	prep_during||-rrb--6/JJ||clamp-10/NN	auxpass||reduced-12/VBN||were-11/VBD	xcomp||-lrb--4/VBP||reduced-12/VBN	nn||hypoglycemia-15/NN||morning-14/NN	agent||reduced-12/VBN||hypoglycemia-15/NN	prep_in||reduced-12/VBN||study-17/NN	nsubj||â-24/VBP||2-18/CD	prep||2-18/CD||versus-19/FW	nn||-lrb--22/NN||study-20/NN	num||-lrb--22/NN||1-21/CD	pobj||versus-19/FW||-lrb--22/NN	num||-lrb--22/NN||16.8-23/CD	rcmod||study-17/NN||â-24/VBP	number||2.3-26/CD||±-25/CD	dobj||â-24/VBP||2.3-26/CD	num||±-30/NNS||34.1-28/CD	nn||±-30/NNS||â-29/NN	prep_vs.||2.3-26/CD||±-30/NNS	num||mol/kg/min-34/NN||2.2-31/CD	nn||mol/kg/min-34/NN||î-32/NN	num||mol/kg/min-34/NN||1/4-33/CD	nsubjpass||reduced-12/VBN||mol/kg/min-34/NN	advmod||p-38/VB||respectively-36/RB	ccomp||-lrb--4/VBP||p-38/VB	number||0.001-40/CD||<-39/CD	num||-rrb--41/NNS||0.001-40/CD	dobj||p-38/VB||-rrb--41/NNS	hypoglycemia-15||glucose-1||yes||glucose infusion rates -lrb- girs -rrb- during the euglycemic clamp were reduced by morning hypoglycemia in study 2 versus study 1 -lrb- 16.8 â ± 2.3 vs. 34.1 â ± 2.2 î 1/4 mol/kg/min , respectively , p < 0.001 -rrb- .
det||regions-3/NNS||both-2/DT	prep_in||infected-11/VBN||regions-3/NNS	det||majority-6/NN||the-5/DT	nsubjpass||infected-11/VBN||majority-6/NN	prep_of||majority-6/NN||subjects-8/NNS	aux||infected-11/VBN||had-9/VBD	auxpass||infected-11/VBN||been-10/VBN	root||ROOT-0/null||infected-11/VBN	prep_with||infected-11/VBN||varicella-13/NN	advmod||165-17/CD||only-16/RB	nn||subjects-22/NNS||165-17/CD	num||%-20/NN||5.2-19/CD	appos||subjects-22/NNS||%-20/NN	nsubj||reported-23/VBD||subjects-22/NNS	conj_and||infected-11/VBN||reported-23/VBD	xcomp||reported-23/VBD||receiving-24/VBG	det||vaccination-27/NN||the-25/DT	nn||vaccination-27/NN||vzv-26/NN	dobj||receiving-24/VBG||vaccination-27/NN	varicella-13||vzv-26||no||in both regions, the majority of subjects had been infected with varicella, and only 165 (5.2%) subjects reported receiving the vzv vaccination.
advmod||observed-34/VBN||importantly-1/RB	det||correlation-11/NN||a-3/DT	advmod||significant-5/JJ||highly-4/RB	amod||correlation-11/NN||significant-5/JJ	dep||significant-5/JJ||p-7/VBN	dep||0.000009-9/CD||=-8/SYM	ccomp||p-7/VBN||0.000009-9/CD	nsubjpass||observed-34/VBN||correlation-11/NN	amod||antigen-15/NN||hepatitisb-13/JJ	nn||antigen-15/NN||surface-14/NN	prep_between||correlation-11/NN||antigen-15/NN	appos||antigen-15/NN||hbsag-17/NN	vmod||correlation-11/NN||stimulated-19/VBN	amod||expression-22/NN||il-2-20/JJ	nn||expression-22/NN||gene-21/NN	dobj||stimulated-19/VBN||expression-22/NN	advmod||detectable-25/JJ||as-24/RB	dobj||stimulated-19/VBN||detectable-25/JJ	amod||expression-22/NN||detectable-25/JJ	conj_and||expression-22/NN||detectable-25/JJ	prep_in||detectable-25/JJ||wb-27/NN	amod||titers-32/NNS||specific-30/JJ	nn||titers-32/NNS||antibody-31/NN	dobj||stimulated-19/VBN||titers-32/NNS	conj_and||expression-22/NN||titers-32/NNS	auxpass||observed-34/VBN||was-33/VBD	root||ROOT-0/null||observed-34/VBN	prep_in||observed-34/VBN||donors-36/NNS	vmod||donors-36/NNS||vaccinated-37/VBN	amod||virus-40/NN||hepatitisb-39/JJ	prep_against||vaccinated-37/VBN||virus-40/NN	appos||virus-40/NN||hbv-42/NN	num||months-46/NNS||six-45/CD	prep_between||virus-40/NN||months-46/NNS	num||years-49/NNS||twenty-48/CD	prep_between||virus-40/NN||years-49/NNS	conj_and||months-46/NNS||years-49/NNS	det||tests-52/NNS||the-51/DT	prep_before||vaccinated-37/VBN||tests-52/NNS	hbv-42||antibody-31||no_rel||importantly, a highly significant (p = 0.000009) correlation between hepatitisb surface antigen (hbsag) stimulated il-2 gene expression, as detectable in wb, and specific antibody titers was observed in donors vaccinated against hepatitisb virus (hbv) between six months and twenty years before the tests.
mark||understand-5/VB||in-1/IN	dep||understand-5/VB||order-2/NN	aux||understand-5/VB||to-3/TO	advmod||understand-5/VB||better-4/RBR	advcl||examined-21/VBD||understand-5/VB	det||situation-8/NN||the-6/DT	amod||situation-8/NN||current-7/JJ	dobj||understand-5/VB||situation-8/NN	aux||explore-11/VB||to-10/TO	conj_and||understand-5/VB||explore-11/VB	advcl||examined-21/VBD||explore-11/VB	amod||strategies-13/NNS||possible-12/JJ	dobj||explore-11/VB||strategies-13/NNS	aux||support-15/VB||to-14/TO	vmod||explore-11/VB||support-15/VB	amod||children-17/NNS||hiv-affected-16/JJ	dobj||support-15/VB||children-17/NNS	det||study-20/NN||this-19/DT	nsubj||examined-21/VBD||study-20/NN	nsubj||aids-28/VBZ||study-20/NN	root||ROOT-0/null||examined-21/VBD	poss||attitudes-24/NNS||children-22/NNS	dobj||examined-21/VBD||attitudes-24/NNS	prep_towards||examined-21/VBD||hiv-26/NN	conj_and||examined-21/VBD||aids-28/VBZ	xcomp||aids-28/VBZ||using-29/VBG	dobj||using-29/VBG||questionnaires-30/NNS	nn||discussions-34/NNS||focus-32/NN	nn||discussions-34/NNS||group-33/NN	dobj||using-29/VBG||discussions-34/NNS	conj_and||questionnaires-30/NNS||discussions-34/NNS	prep_with||using-29/VBG||children-36/NNS	prep_in||children-36/NNS||grades-38/NNS	vmod||grades-38/NNS||three-six-39/VBN	num||schools-43/NNS||five-41/CD	amod||schools-43/NNS||primary-42/JJ	prep_in||three-six-39/VBN||schools-43/NNS	det||province-47/NN||a-45/DT	amod||province-47/NN||northern-46/JJ	prep_in||schools-43/NNS||province-47/NN	prep_in||province-47/NN||thailand-49/NN	aids-28||hiv-26||no||in order to better understand the current situation and to explore possible strategies to support hiv-affected children, this study examined children's attitudes towards hiv and aids using questionnaires and focus group discussions with children in grades three-six in five primary schools in a northern province in thailand.
advmod||eligible-2/JJ||forty-1/RB	amod||patients-3/NNS||eligible-2/JJ	nsubjpass||randomized-14/VBN||patients-3/NNS	nsubj||receive-16/VB||patients-3/NNS	nsubj||levofloxacin-32/VB||patients-3/NNS	amod||exacerbation-6/NN||acute-5/JJ	prep_with||patients-3/NNS||exacerbation-6/NN	amod||bronchitis-9/NNS||chronic-8/JJ	prep_of||exacerbation-6/NN||bronchitis-9/NNS	appos||patients-3/NNS||aecb-11/NN	auxpass||randomized-14/VBN||were-13/VBD	root||ROOT-0/null||randomized-14/VBN	aux||receive-16/VB||to-15/TO	xcomp||randomized-14/VBN||receive-16/VB	nn||mg-19/NN||cefditoren-17/NN	num||mg-19/NN||200-18/CD	dobj||receive-16/VB||mg-19/NN	advmod||day-22/NN||twice-20/RB	det||day-22/NN||a-21/DT	npadvmod||receive-16/VB||day-22/NN	num||days-25/NNS||5-24/CD	prep_for||receive-16/VB||days-25/NNS	dep||days-25/NNS||n-27/VBN	dep||20-29/CD||=-28/SYM	ccomp||n-27/VBN||20-29/CD	xcomp||randomized-14/VBN||levofloxacin-32/VB	conj_or||receive-16/VB||levofloxacin-32/VB	num||mg-34/NN||500-33/CD	dobj||levofloxacin-32/VB||mg-34/NN	advmod||daily-36/JJ||once-35/RB	advmod||levofloxacin-32/VB||daily-36/JJ	num||days-39/NNS||7-38/CD	prep_for||daily-36/JJ||days-39/NNS	dep||days-39/NNS||n-41/VBN	dep||20-43/CD||=-42/SYM	ccomp||n-41/VBN||20-43/CD	bronchitis-9||levofloxacin-32||yes||forty eligible patients with acute exacerbation of chronic bronchitis (aecb) were randomized to receive cefditoren 200 mg twice a day for 5 days (n = 20) or levofloxacin 500 mg once daily for 7 days (n = 20).
det||safety-2/NN||the-1/DT	nsubj||+-9/VBD||safety-2/NN	amod||cd-8/NN||chlorproguanil-dapsone-4/JJ	nn||cd-8/NN||+-5/NNP	amod||cd-8/NN||artesunate-6/JJ	amod||cd-8/NN||-lrb--7/JJ	prep_of||safety-2/NN||cd-8/NN	root||ROOT-0/null||+-9/VBD	det||-rrb--20/NN||a-10/DT	amod||-rrb--20/NN||-rrb--11/JJ	conj_and||-rrb--11/JJ||amodiaquine-13/JJ	amod||-rrb--20/NN||amodiaquine-13/JJ	nn||-rrb--20/NN||+-14/NNP	amod||-rrb--20/NN||sulphadoxine-pyrimethamine-15/JJ	nn||-rrb--20/NN||-lrb--16/NN	nn||-rrb--20/NN||aq-17/NN	amod||-rrb--20/NN||+-18/JJ	nn||-rrb--20/NN||sp-19/NN	nsubjpass||evaluated-29/VBN||-rrb--20/NN	det||treatment-23/NN||the-22/DT	prep_for||-rrb--20/NN||treatment-23/NN	amod||falciparummalaria-27/NN||uncomplicated-25/JJ	nn||falciparummalaria-27/NN||p.-26/NN	prep_of||treatment-23/NN||falciparummalaria-27/NN	auxpass||evaluated-29/VBN||was-28/VBD	ccomp||+-9/VBD||evaluated-29/VBN	prepc_according_to||evaluated-29/VBN||to-31/TO	pobj||evaluated-29/VBN||g6pddeficiency-32/NNS	det||analysis-36/NN||a-34/DT	amod||analysis-36/NN||secondary-35/JJ	prep_in||g6pddeficiency-32/NNS||analysis-36/NN	det||trial-43/NN||an-38/DT	amod||trial-43/NN||open-label-39/JJ	amod||trial-43/NN||randomized-41/JJ	amod||trial-43/NN||clinical-42/JJ	prep_of||analysis-36/NN||trial-43/NN	vmod||trial-43/NN||-lsb--44/VBG	number||-rsb--46/CD||1-45/CD	dobj||-lsb--44/VBG||-rsb--46/CD	falciparummalaria-27||pyrimethamine--1||yes||the safety of chlorproguanil-dapsone + artesunate -lrb- cd+a -rrb- and amodiaquine + sulphadoxine-pyrimethamine -lrb- aq+sp -rrb- for the treatment of uncomplicated p. falciparummalaria was evaluated according to g6pddeficiency in a secondary analysis of an open-label , randomized clinical trial -lsb- 1 -rsb- .
aux||assess-2/VB||to-1/TO	advcl||recruited-36/VBN||assess-2/VB	det||efficacy-4/NN||the-3/DT	dobj||assess-2/VB||efficacy-4/NN	prep_of||efficacy-4/NN||exemestane-6/NN	amod||treatment-9/NN||neoadjuvant-8/JJ	prep_as||assess-2/VB||treatment-9/NN	num||women-13/NNS||55-11/CD	amod||women-13/NNS||postmenopausal-12/JJ	nsubjpass||recruited-36/VBN||women-13/NNS	amod||age-16/NN||mean-15/JJ	dep||women-13/NNS||age-16/NN	num||years-18/NNS||76-17/CD	dep||age-16/NN||years-18/NNS	nn||66â-21/NNS||range-20/NN	dep||years-18/NNS||66â-21/NNS	dep||66â-21/NNS||$-22/$	num||$-22/$||86-24/CD	amod||breasttumour-29/NN||oestrogen-positive-27/JJ	amod||breasttumour-29/NN||non-metastatic-28/JJ	prep_with||women-13/NNS||breasttumour-29/NN	conj_and||women-13/NNS||ineligible-31/NN	nsubjpass||recruited-36/VBN||ineligible-31/NN	amod||surgery-34/NN||conservative-33/JJ	prep_for||ineligible-31/NN||surgery-34/NN	auxpass||recruited-36/VBN||were-35/VBD	root||ROOT-0/null||recruited-36/VBN	det||phase-39/NN||this-38/DT	poss||trial-41/NN||phase-39/NN	prep_into||recruited-36/VBN||trial-41/NN	aux||receive-43/VB||to-42/TO	vmod||trial-41/NN||receive-43/VB	amod||exemestane-45/NN||oral-44/JJ	dobj||receive-43/VB||exemestane-45/NN	dep||exemestane-45/NN||25â-47/VBN	dep||dayâ-53/NNP||$-48/$	num||$-48/$||-49/CD	iobj||25â-47/VBN||$-51/$	conj_mgâ||dayâ-53/NNP||$-51/$	num||$-51/$||-52/CD	iobj||25â-47/VBN||dayâ-53/NNP	dobj||25â-47/VBN||1-55/CD	num||months-59/NNS||6-58/CD	prep_for||exemestane-45/NN||months-59/NNS	breasttumour-29||oestrogen--1||no||to assess the efficacy of exemestane as neoadjuvant treatment, 55 postmenopausal women (mean age 76 years; range 66â86) with oestrogen-positive non-metastatic breasttumour and ineligible for conservative surgery were recruited into this phase ii trial to receive oral exemestane (25âmgâdayâ1) for 6 months.
nsubjpass||performed-3/VBN||echocardiography-1/NN	nsubj||verify-21/VB||echocardiography-1/NN	auxpass||performed-3/VBN||was-2/VBD	root||ROOT-0/null||performed-3/VBN	det||subgroups-7/NNS||the-5/DT	amod||subgroups-7/NNS||separate-6/JJ	prep_in||performed-3/VBN||subgroups-7/NNS	nsubj||treated-10/VBD||dox-9/NN	nsubj||controls-15/VBZ||dox-9/NN	parataxis||performed-3/VBN||treated-10/VBD	nsubj||6-13/CD||n-11/NN	dep||6-13/CD||=-12/SYM	ccomp||treated-10/VBD||6-13/CD	parataxis||performed-3/VBN||controls-15/VBZ	conj_and||treated-10/VBD||controls-15/VBZ	nsubj||6-18/CD||n-16/NN	dep||6-18/CD||=-17/SYM	ccomp||controls-15/VBZ||6-18/CD	aux||verify-21/VB||to-20/TO	xcomp||performed-3/VBN||verify-21/VB	det||presence-23/NN||the-22/DT	dobj||verify-21/VB||presence-23/NN	det||grade-26/NN||the-25/DT	dobj||verify-21/VB||grade-26/NN	conj_and||presence-23/NN||grade-26/NN	amod||chf-29/NN||acute-28/JJ	prep_of||grade-26/NN||chf-29/NN	chf-29||dox-9||no||echocardiography was performed in the separate subgroups (dox treated n = 6 and controls n = 6) to verify the presence and the grade of acute chf.
det||combination-2/NN||a-1/DT	nsubj||facilitates-11/VBZ||combination-2/NN	amod||antigen-6/NN||dengue-4/JJ	amod||antigen-6/NN||ns1-5/JJ	prep_of||combination-2/NN||antigen-6/NN	nn||testing-10/NN||igm-8/NN	nn||testing-10/NN||antibody-9/NN	prep_of||combination-2/NN||testing-10/NN	conj_and||antigen-6/NN||testing-10/NN	root||ROOT-0/null||facilitates-11/VBZ	amod||rates-14/NNS||enhanced-12/JJ	nn||rates-14/NNS||diagnosis-13/NN	dobj||facilitates-11/VBZ||rates-14/NNS	dengue-4||antibody-9||no_rel||a combination of dengue ns1 antigen and igm antibody testing facilitates enhanced diagnosis rates.
prep_for||improved-13/VBN||patients-2/NNS	prep_with||patients-2/NNS||type1diabetes-4/CD	nsubj||improved-13/VBN||innovations-6/NNS	nn||formulations-9/NNS||insulin-8/NN	prep_in||innovations-6/NNS||formulations-9/NNS	prep_in||innovations-6/NNS||delivery-11/NN	conj_and||formulations-9/NNS||delivery-11/NN	aux||improved-13/VBN||have-12/VBP	root||ROOT-0/null||improved-13/VBN	det||ability-15/NN||the-14/DT	dobj||improved-13/VBN||ability-15/NN	aux||achieve-17/VB||to-16/TO	vmod||ability-15/NN||achieve-17/VB	amod||control-20/NN||excellent-18/JJ	nn||control-20/NN||bloodglucose-19/NN	dobj||achieve-17/VB||control-20/NN	type1diabetes-4||insulin-8||yes||for patients with type1diabetes, innovations in insulin formulations and delivery have improved the ability to achieve excellent bloodglucose control.
nsubj||demonstration-5/NN||this-1/DT	cop||demonstration-5/NN||is-2/VBZ	det||demonstration-5/NN||the-3/DT	amod||demonstration-5/NN||first-4/JJ	root||ROOT-0/null||demonstration-5/NN	mark||induces-8/VBZ||that-6/IN	nsubj||induces-8/VBZ||stroke-7/NN	ccomp||demonstration-5/NN||induces-8/VBZ	amod||changes-10/NNS||immediate-9/JJ	dobj||induces-8/VBZ||changes-10/NNS	det||timing-13/NN||the-12/DT	prep_in||induces-8/VBZ||timing-13/NN	amod||secretion-17/NN||pineal-15/JJ	nn||secretion-17/NN||melatonin-16/NN	prep_of||timing-13/NN||secretion-17/NN	vmod||induces-8/VBZ||indicating-19/VBG	mark||impacts-26/VBZ||that-20/IN	amod||infarction-25/NNS||cortical-21/JJ	conj_and||cortical-21/JJ||basal-23/JJ	amod||infarction-25/NNS||basal-23/JJ	nn||infarction-25/NNS||ganglia-24/NN	nsubj||impacts-26/VBZ||infarction-25/NNS	ccomp||indicating-19/VBG||impacts-26/VBZ	det||timing-28/NN||the-27/DT	dobj||impacts-26/VBZ||timing-28/NN	nn||rhythms-31/NNS||melatonin-30/NN	prep_of||timing-28/NN||rhythms-31/NNS	melatonin-30||stroke-7||no_rel||this is the first demonstration that stroke induces immediate changes in the timing of pineal melatonin secretion, indicating that cortical and basal ganglia infarction impacts the timing of melatonin rhythms.
det||total-2/NN||a-1/DT	nsubj||received-9/VBD||total-2/NN	number||hospitalized-5/CD||180-4/CD	num||patients-6/NNS||hospitalized-5/CD	prep_of||total-2/NN||patients-6/NNS	prep_with||patients-6/NNS||type2diabetes-8/CD	root||ROOT-0/null||received-9/VBD	det||glulisine-11/NN||either-10/DT	dobj||received-9/VBD||glulisine-11/NN	dep||glulisine-11/NN||n-13/VBN	dep||88-15/CD||=-14/SYM	ccomp||n-13/VBN||88-15/CD	amod||insulin-19/NN||regular-18/JJ	dobj||received-9/VBD||insulin-19/NN	conj_or||glulisine-11/NN||insulin-19/NN	dep||insulin-19/NN||n-21/VBN	dep||92-23/CD||=-22/SYM	ccomp||n-21/VBN||92-23/CD	det||meal-27/NN||each-26/DT	prep_before||received-9/VBD||meal-27/NN	prep_in||meal-27/NN||combination-29/NN	prep_with||received-9/VBD||insulinglargine-31/NN	prep_at||received-9/VBD||bedtime-33/NN	det||fashion-38/NN||a-35/DT	amod||fashion-38/NN||randomized-36/JJ	amod||fashion-38/NN||double-blind-37/JJ	prep_in||bedtime-33/NN||fashion-38/NN	type2diabetes-8||insulinglargine-31||yes||a total of 180 hospitalized patients with type2diabetes received either glulisine ( n = 88) or regular insulin ( n = 92) before each meal in combination with insulinglargine at bedtime in a randomized double-blind fashion.
nn||data-2/NNS||toxicity-1/NN	nsubj||showed-3/VBD||data-2/NNS	root||ROOT-0/null||showed-3/VBD	det||difference-6/NN||a-4/DT	amod||difference-6/NN||significant-5/JJ	dobj||showed-3/VBD||difference-6/NN	prep_in||showed-3/VBD||favour-8/NN	amod||topotecan-11/NN||oral-10/JJ	prep_of||favour-8/NN||topotecan-11/NN	prep_for||topotecan-11/NN||neutropenia-13/NN	dep||topotecan-11/NN||pooled-15/VBN	nn||ratio-17/NN||risk-16/NN	dobj||pooled-15/VBN||ratio-17/NN	dep||0.65-19/NNS||=-18/SYM	rcmod||ratio-17/NN||0.65-19/NNS	num||%-22/NN||95-21/CD	dep||ratio-17/NN||%-22/NN	dep||%-22/NN||ci-23/NN	dep||0.89-27/CD||0.47-25/CD	dep||0.89-27/CD||to-26/TO	advmod||%-22/NN||0.89-27/CD	neutropenia-13||topotecan-11||no||toxicity data showed a significant difference in favour of oral topotecan for neutropenia (pooled risk ratio = 0.65; 95% ci, 0.47 to 0.89).
advmod||approved-7/VBD||recently-1/RB	det||organization-6/NN||the-3/DT	nn||organization-6/NN||world-4/NN	nn||organization-6/NN||health-5/NN	nsubj||approved-7/VBD||organization-6/NN	root||ROOT-0/null||approved-7/VBD	det||africantrypanosomiasis-20/NN||the-8/DT	dep||$-10/$||nifurtimoxâ-9/RB	dep||africantrypanosomiasis-20/NN||$-10/$	amod||combination-13/NN||eflornithine-12/JJ	npadvmod||of-18/RB||combination-13/NN	advmod||combination-13/NN||therapy-14/RB	det||treatment-17/NN||the-16/DT	prep_for||therapy-14/RB||treatment-17/NN	dep||human-19/CD||of-18/RB	num||$-10/$||human-19/CD	dobj||approved-7/VBD||africantrypanosomiasis-20/NN	vmod||approved-7/VBD||renewing-22/VBG	dobj||renewing-22/VBG||interest-23/NN	amod||therapies-26/NNS||nitroheterocycle-25/JJ	prep_in||interest-23/NN||therapies-26/NNS	prep_for||renewing-22/VBG||this-28/DT	amod||diseases-31/NNS||associated-30/VBN	prep_for||renewing-22/VBG||diseases-31/NNS	conj_and||this-28/DT||diseases-31/NNS	africantrypanosomiasis-20||eflornithine-12||yes||recently, the world health organization approved the nifurtimoxâeflornithine combination therapy for the treatment of human africantrypanosomiasis, renewing interest in nitroheterocycle therapies for this and associated diseases.
dep||vitro-2/NN||in-1/IN	amod||studies-3/NNS||vitro-2/NN	nsubj||showed-4/VBD||studies-3/NNS	root||ROOT-0/null||showed-4/VBD	mark||reduces-8/VBZ||that-5/IN	nsubj||reduces-8/VBZ||dha-6/NN	nsubj||promotes-25/VBZ||dha-6/NN	advmod||reduces-8/VBZ||strongly-7/RB	ccomp||showed-4/VBD||reduces-8/VBZ	det||synthesis-13/NN||the-9/DT	nn||synthesis-13/NN||viability-10/NN	conj_and||viability-10/NN||dna-12/NN	nn||synthesis-13/NN||dna-12/NN	dobj||reduces-8/VBZ||synthesis-13/NN	amod||cells-19/NNS||mcf-7-15/JJ	amod||cells-19/NNS||human-16/JJ	nn||cells-19/NNS||breast-17/NN	nn||cells-19/NNS||cancer-18/NN	prep_of||synthesis-13/NN||cells-19/NNS	prep_in||reduces-8/VBZ||culture-21/NN	advmod||promotes-25/VBZ||also-24/RB	ccomp||showed-4/VBD||promotes-25/VBZ	conj_and||reduces-8/VBZ||promotes-25/VBZ	nn||death-27/NN||cell-26/NN	dobj||promotes-25/VBZ||death-27/NN	prep_via||death-27/NN||apoptosis-29/NNS	dha-6||cancer-18||no_rel||in vitro studies showed that dha strongly reduces the viability and dna synthesis of mcf-7 human breast cancer cells in culture, and also promotes cell death via apoptosis.
amod||caseâ-3/NNS||nested-2/JJ	prep_in||observed-19/VBN||caseâ-3/NNS	nsubjpass||observed-19/VBN||$-4/$	nn||analyses-7/NNS||control-6/NN	npadvmod||cumulative-12/RB||analyses-7/NNS	amod||associations-10/NNS||significant-9/JJ	dep||with-11/IN||associations-10/NNS	prep||analyses-7/NNS||with-11/IN	dep||exposure-13/CD||cumulative-12/RB	num||$-4/$||exposure-13/CD	amod||silica-17/NN||respirable-15/JJ	amod||silica-17/NN||free-16/JJ	prep_to||$-4/$||silica-17/NN	auxpass||observed-19/VBN||were-18/VBD	root||ROOT-0/null||observed-19/VBN	prep_for||observed-19/VBN||silicosis-21/NNS	cc||1.13-24/CD||or-23/CC	dep||silicosis-21/NNS||1.13-24/CD	number||%-27/NN||95-26/CD	amod||ci-28/NN||%-27/NN	appos||1.13-24/CD||ci-28/NN	number||1.21-31/CD||1.05-29/CD	dep||1.21-31/CD||to-30/TO	num||ci-28/NN||1.21-31/CD	det||1â-34/NNS||each-33/DT	prep_for||ci-28/NN||1â-34/NNS	dep||ci-28/NN||$-35/$	amod||increase-38/NN||mg/m3-year-37/JJ	npadvmod||ci-53/JJ||increase-38/NN	advmod||exposure-41/NN||in-39/RB	amod||exposure-41/NN||cumulative-40/JJ	dep||increase-38/NN||exposure-41/NN	amod||non-malignant-45/NN||other-44/JJ	conj_and||increase-38/NN||non-malignant-45/NN	npadvmod||ci-53/JJ||non-malignant-45/NN	dep||non-malignant-45/NN||respiratorydisease-46/NN	cc||1.10-49/NN||or-48/CC	dep||increase-38/NN||1.10-49/NN	number||%-52/NN||95-51/CD	num||increase-38/NN||%-52/NN	amod||ci-69/NNS||ci-53/JJ	dep||ci-53/JJ||1.03-54/CD	prep_to||1.03-54/CD||1.16-56/CD	cc||not-59/RB||but-58/CC	dep||ci-53/JJ||not-59/RB	nn||cancer-62/NN||lung-61/NN	prep_for||not-59/RB||cancer-62/NN	prep_for||not-59/RB||0.99-65/CD	conj_or||cancer-62/NN||0.99-65/CD	num||%-68/NN||95-67/CD	dep||not-59/RB||%-68/NN	npadvmod||0.94-70/RB||ci-69/NNS	dep||1.08-100/CD||0.94-70/RB	dep||ci-83/RB||to-71/IN	prep||to-71/IN||1.03-72/IN	amod||cancer-76/NN||kidney-75/JJ	dep||ci-83/RB||cancer-76/NN	conj_or||cancer-76/NN||0.96-79/CD	dep||ci-83/RB||0.96-79/CD	dep||%-82/NN||95-81/CD	advmod||cancer-76/NN||%-82/NN	conj_or||cancer-76/NN||%-82/NN	dep||ci-83/RB||%-82/NN	prep||0.94-70/RB||ci-83/RB	dep||ci-83/RB||0.84-84/JJ	dep||0.84-84/JJ||to-85/IN	dep||to-85/IN||1.09-86/CD	dep||ci-83/RB||non-malignant-89/JJ	conj_or||0.84-84/JJ||non-malignant-89/JJ	dep||0.84-98/IN||kidneydisease-90/NN	conj_or||kidneydisease-90/NN||0.95-93/CD	dep||0.84-98/IN||0.95-93/CD	number||%-96/NN||95-95/CD	amod||ci-97/NN||%-96/NN	dep||0.84-98/IN||ci-97/NN	prep||ci-83/RB||0.84-98/IN	prep||0.94-70/RB||to-99/TO	num||$-35/$||1.08-100/CD	silicosis-21||silica-17||no||in nested caseâcontrol analyses, significant associations with cumulative exposure to respirable free silica were observed for silicosis (or 1.13, 95% ci 1.05 to 1.21 for each 1âmg/m3-year increase in cumulative exposure) and other non-malignant respiratorydisease (or 1.10, 95% ci 1.03 to 1.16) but not for lung cancer (or 0.99, 95% ci 0.94 to 1.03), kidney cancer (or 0.96, 95% ci 0.84 to 1.09) or non-malignant kidneydisease (or 0.95, 95% ci 0.84 to 1.08).
det||strength-2/NN||the-1/DT	nsubj||led-17/VBD||strength-2/NN	det||evidence-5/NN||the-4/DT	prep_of||strength-2/NN||evidence-5/NN	vmod||evidence-5/NN||linking-6/VBG	advmod||linking-6/VBG||concurrency-7/RB	aux||hiv-9/VB||to-8/TO	xcomp||linking-6/VBG||hiv-9/VB	nn||severity-11/NN||epidemic-10/NN	dobj||hiv-9/VB||severity-11/NN	amod||africa-16/NN||southern-13/JJ	conj_and||southern-13/JJ||eastern-15/JJ	amod||africa-16/NN||eastern-15/JJ	prep_in||hiv-9/VB||africa-16/NN	root||ROOT-0/null||led-17/VBD	det||programme-22/NN||the-18/DT	amod||programme-22/NN||joint-19/JJ	amod||programme-22/NN||united-20/JJ	nn||programme-22/NN||nations-21/NNS	dobj||led-17/VBD||programme-22/NN	prep_on||programme-22/NN||hiv/aids-24/NNS	det||community-30/NN||the-26/DT	amod||community-30/NN||southern-27/JJ	nn||community-30/NN||african-28/NN	nn||community-30/NN||development-29/NN	prep_on||programme-22/NN||community-30/NN	conj_and||hiv/aids-24/NNS||community-30/NN	prep_in||led-17/VBD||2006-32/CD	aux||conclude-34/VB||to-33/TO	vmod||led-17/VBD||conclude-34/VB	mark||drivers-57/NNS||that-35/IN	amod||rates-37/NNS||high-36/JJ	nsubj||drivers-57/NNS||rates-37/NNS	amod||partnerships-41/NNS||concurrent-39/JJ	amod||partnerships-41/NNS||sexual-40/JJ	prep_of||rates-37/NNS||partnerships-41/NNS	vmod||rates-37/NNS||combined-43/VBN	amod||rates-46/NNS||low-45/JJ	prep_with||combined-43/VBN||rates-46/NNS	amod||circumcision-49/NN||male-48/JJ	nn||use-53/NN||circumcision-49/NN	conj_and||circumcision-49/NN||infrequent-51/JJ	nn||use-53/NN||infrequent-51/JJ	nn||use-53/NN||condom-52/NN	prep_of||rates-46/NNS||use-53/NN	cop||drivers-57/NNS||are-55/VBP	amod||drivers-57/NNS||major-56/JJ	ccomp||conclude-34/VB||drivers-57/NNS	det||epidemic-61/NN||the-59/DT	nn||epidemic-61/NN||aids-60/NNS	prep_of||drivers-57/NNS||epidemic-61/NN	amod||africa-64/NN||southern-63/JJ	prep_in||epidemic-61/NN||africa-64/NN	aids-60||hiv-9||no||the strength of the evidence linking concurrency to hiv epidemic severity in southern and eastern africa led the joint united nations programme on hiv/aids and the southern african development community in 2006 to conclude that high rates of concurrent sexual partnerships, combined with low rates of male circumcision and infrequent condom use, are major drivers of the aids epidemic in southern africa.
nn||priondiseases-4/NNS||human-1/NN	conj_and||human-1/NN||animal-3/NN	nn||priondiseases-4/NNS||animal-3/NN	nsubj||are-5/VBP||priondiseases-4/NNS	ccomp||understand-24/VBP||are-5/VBP	prep||are-5/VBP||under-6/IN	amod||control-8/NN||genetic-7/JJ	pobj||under-6/IN||control-8/NN	prep||are-5/VBP||apart-11/RB	conj_but||under-6/IN||apart-11/RB	dep||under-6/IN||from-12/IN	pobj||from-12/IN||prnp-13/NN	det||gene-16/NN||the-15/DT	dep||prnp-13/NN||gene-16/NN	nsubj||encodes-18/VBZ||gene-16/NN	rcmod||gene-16/NN||encodes-18/VBZ	det||prionprotein-20/NN||the-19/DT	dobj||encodes-18/VBZ||prionprotein-20/NN	nsubj||understand-24/VBP||we-23/PRP	root||ROOT-0/null||understand-24/VBP	advmod||susceptibility-28/NN||little-25/RB	advmod||susceptibility-28/NN||about-26/RB	amod||susceptibility-28/NN||human-27/JJ	dobj||understand-24/VBP||susceptibility-28/NN	aux||bovinespongiformencephalopathy-30/VB||to-29/TO	vmod||susceptibility-28/NN||bovinespongiformencephalopathy-30/VB	discourse||prions-34/NNS||bse-32/UH	dobj||bovinespongiformencephalopathy-30/VB||prions-34/NNS	det||agent-38/NN||the-36/DT	amod||agent-38/NN||causal-37/JJ	appos||susceptibility-28/NN||agent-38/NN	amod||$-42/NNS||variant-40/JJ	amod||$-42/NNS||creutzfeldtâ-41/JJ	prep_of||agent-38/NN||$-42/NNS	amod||disease-45/NN||jakob-44/JJ	dep||$-42/NNS||disease-45/NN	dep||$-42/NNS||vcjd-47/JJ	priondiseases-4||prionprotein-20||no||human and animal priondiseases are under genetic control, but apart from prnp (the gene that encodes the prionprotein), we understand little about human susceptibility to bovinespongiformencephalopathy (bse) prions, the causal agent of variant creutzfeldtâjakob disease (vcjd).
amod||functions-2/NNS||apoptosis-1/JJ	nsubj||innate-6/VBP||functions-2/NNS	det||host-5/NN||a-4/DT	prep_as||functions-2/NNS||host-5/NN	root||ROOT-0/null||innate-6/VBP	nn||mechanism-8/NN||defence-7/NN	dobj||innate-6/VBP||mechanism-8/NN	prep_against||mechanism-8/NN||viralinfection-10/NN	det||capacity-14/NN||the-13/DT	nsubj||essential-21/JJ||capacity-14/NN	aux||interfere-16/VB||to-15/TO	vmod||capacity-14/NN||interfere-16/VB	det||process-19/NN||this-18/DT	prep_with||interfere-16/VB||process-19/NN	cop||essential-21/JJ||is-20/VBZ	conj_and||innate-6/VBP||essential-21/JJ	det||replication-24/NN||the-23/DT	prep_for||essential-21/JJ||replication-24/NN	amod||viruses-27/NNS||many-26/JJ	prep_of||replication-24/NN||viruses-27/NNS	viralinfection-10||viruses-27||no||apoptosis functions as a host innate defence mechanism against viralinfection, and the capacity to interfere with this process is essential for the replication of many viruses.
nn||counseling-3/NN||hiv-1/NN	amod||counseling-3/NN||voluntary-2/JJ	nsubjpass||considered-10/VBN||counseling-3/NN	conj_and||counseling-3/NN||testing-5/NN	nsubjpass||considered-10/VBN||testing-5/NN	appos||counseling-3/NN||vct-7/NN	auxpass||considered-10/VBN||is-9/VBZ	root||ROOT-0/null||considered-10/VBN	det||method-14/NN||an-11/DT	amod||method-14/NN||effective-12/JJ	nn||method-14/NN||prevention-13/NN	dobj||considered-10/VBN||method-14/NN	prep_of||method-14/NN||hivinfection-16/NN	hivinfection-16||hiv-1||no||hiv voluntary counseling and testing (vct) is considered an effective prevention method of hivinfection.
prepc_after||develop-9/VB||eating-2/VBG	amod||foods-4/NNS||certain-3/JJ	dobj||eating-2/VBG||foods-4/NNS	vmod||eating-2/VBG||containing-5/VBG	dobj||containing-5/VBG||sugars-6/NNS	nsubj||develop-9/VB||he-7/PRP	aux||develop-9/VB||would-8/MD	root||ROOT-0/null||develop-9/VB	dobj||develop-9/VB||angst-10/NN	appos||angst-10/NN||pain-12/NN	poss||fever-17/NN||his-14/PRP$	amod||fever-17/NN||extremities-15/JJ	prep_in||pain-12/NN||fever-17/NN	dep||fever-17/NN||etc.-19/FW	sugars-6||pain-12||no_rel||after eating certain foods containing sugars he would develop angst, pain in his extremities, fever, etc.
det||manuscript-2/NN||this-1/DT	nsubj||reviews-3/VBZ||manuscript-2/NN	root||ROOT-0/null||reviews-3/VBZ	det||benefits-5/NNS||the-4/DT	dobj||reviews-3/VBZ||benefits-5/NNS	amod||control-9/NN||intensive-7/JJ	amod||control-9/NN||glycemic-8/JJ	prep_of||benefits-5/NNS||control-9/NN	amod||goals-14/NNS||type2diabetes-11/JJ	prep_in||control-9/NN||therapeutic-13/JJ	amod||goals-14/NNS||therapeutic-13/JJ	conj_and||goals-14/NNS||therapeutic-13/JJ	prep_in||control-9/NN||goals-14/NNS	prep_in||control-9/NN||guidelines-16/NNS	conj_and||goals-14/NNS||guidelines-16/NNS	dobj||reviews-3/VBZ||advances-18/NNS	conj_and||benefits-5/NNS||advances-18/NNS	nn||therapy-21/NN||insulin-20/NN	prep_in||advances-18/NNS||therapy-21/NN	dobj||reviews-3/VBZ||contribution-24/NN	conj_and||benefits-5/NNS||contribution-24/NN	prep_of||contribution-24/NN||nurses-26/NNS	prepc_in||reviews-3/VBZ||overcoming-28/VBG	dobj||overcoming-28/VBG||barriers-29/NNS	nn||initiation-32/NN||insulin-31/NN	prep_to||overcoming-28/VBG||initiation-32/NN	amod||aspects-35/NNS||related-34/VBN	prep_to||overcoming-28/VBG||aspects-35/NNS	conj_and||initiation-32/NN||aspects-35/NNS	nn||care-38/NN||diabetes-37/NN	prep_of||initiation-32/NN||care-38/NN	type2diabetes-11||insulin-31||yes||this manuscript reviews the benefits of intensive glycemic control in type2diabetes, therapeutic goals and guidelines, advances in insulin therapy, and contribution of nurses in overcoming barriers to insulin initiation and related aspects of diabetes care.
nn||lines-2/NNS||melanoma-1/NN	nsubj||resistant-8/JJ||lines-2/NNS	nsubj||tmz-10/VB||lines-2/NNS	nsubj||fotemustine-12/JJ||lines-2/NNS	vmod||lines-2/NNS||expressing-3/VBG	nn||wild-type-5/NN||p53-4/NN	dobj||expressing-3/VBG||wild-type-5/NN	cop||resistant-8/JJ||were-6/VBD	advmod||resistant-8/JJ||more-7/RBR	root||ROOT-0/null||resistant-8/JJ	aux||tmz-10/VB||to-9/TO	xcomp||resistant-8/JJ||tmz-10/VB	conj_and||resistant-8/JJ||fotemustine-12/JJ	num||lines-17/NNS||p53-14/CD	amod||lines-17/NNS||mutant-15/JJ	nn||lines-17/NNS||melanoma-16/NN	prep_than||fotemustine-12/JJ||lines-17/NNS	nsubj||is-20/VBZ||lines-17/NNS	rcmod||lines-17/NNS||is-20/VBZ	amod||contrast-23/NN||marked-22/JJ	prep_in||is-20/VBZ||contrast-23/NN	amod||data-26/NNS||previous-25/JJ	prep_to||is-20/VBZ||data-26/NNS	vmod||data-26/NNS||reported-27/VBN	nn||cells-30/NNS||glioma-29/NN	prep_for||reported-27/VBN||cells-30/NNS	vmod||cells-30/NNS||treated-31/VBN	prep_with||treated-31/VBN||tmz-33/NN	melanoma-16||tmz-33||yes||melanoma lines expressing p53 wild-type were more resistant to tmz and fotemustine than p53 mutant melanoma lines, which is in marked contrast to previous data reported for glioma cells treated with tmz.
det||varicellazostervirus-2/NNS||the-1/DT	nsubj||alpha-herpesvirus-10/NNS||varicellazostervirus-2/NNS	appos||varicellazostervirus-2/NNS||vzv-4/NN	cop||alpha-herpesvirus-10/NNS||is-6/VBZ	det||alpha-herpesvirus-10/NNS||a-7/DT	amod||alpha-herpesvirus-10/NNS||ubiquitous-8/JJ	amod||alpha-herpesvirus-10/NNS||human-9/JJ	root||ROOT-0/null||alpha-herpesvirus-10/NNS	nsubj||agent-15/NN||alpha-herpesvirus-10/NNS	cop||agent-15/NN||is-12/VBZ	det||agent-15/NN||the-13/DT	amod||agent-15/NN||causative-14/JJ	rcmod||alpha-herpesvirus-10/NNS||agent-15/NN	prep_of||agent-15/NN||chickenpox-17/NN	prep_of||agent-15/NN||shingles-19/NNS	conj_and||chickenpox-17/NN||shingles-19/NNS	chickenpox-17||vzv-4||no||the varicellazostervirus (vzv) is a ubiquitous human alpha-herpesvirus that is the causative agent of chickenpox and shingles.
det||study-2/NN||this-1/DT	nsubj||examined-3/VBD||study-2/NN	root||ROOT-0/null||examined-3/VBD	det||prevention-5/NN||the-4/DT	dobj||examined-3/VBD||prevention-5/NN	prep_of||prevention-5/NN||pain-7/NN	amod||injection-11/NN||microemulsion-9/JJ	amod||injection-11/NN||propofol-10/JJ	prep_during||examined-3/VBD||injection-11/NN	prep_by||examined-3/VBD||pretreatment-13/NN	amod||doses-16/NNS||different-15/JJ	prep_with||examined-3/VBD||doses-16/NNS	prep_of||doses-16/NNS||remifentanil-18/JJ	prep_of||doses-16/NNS||saline-20/JJ	conj_or||remifentanil-18/JJ||saline-20/JJ	prep_of||doses-16/NNS||premixing-23/NN	conj_and||remifentanil-18/JJ||premixing-23/NN	prep_of||premixing-23/NN||lidocaine-25/NN	pain-7||propofol-10||yes||this study examined the prevention of pain during microemulsion propofol injection by pretreatment with different doses of remifentanil or saline, and premixing of lidocaine.
aux||investigate-2/VB||to-1/TO	advcl||divided-29/VBN||investigate-2/VB	det||effect-4/NN||the-3/DT	dobj||investigate-2/VB||effect-4/NN	amod||expression-17/NN||budesonide-6/JJ	nn||p-9/NN||substance-8/NN	prep_on||budesonide-6/JJ||p-9/NN	dep||p-9/NN||nk-1-11/JJ	nn||expression-17/NN||receptor-13/NN	dep||expression-17/NN||nk-1r-15/JJ	prep_of||effect-4/NN||expression-17/NN	det||lung-20/NN||the-19/DT	prep_in||investigate-2/VB||lung-20/NN	prep_in||investigate-2/VB||asmcs-22/NNS	conj_and||lung-20/NN||asmcs-22/NNS	num||rats-26/NNS||45-24/CD	nn||rats-26/NNS||wistar-25/NN	nsubjpass||divided-29/VBN||rats-26/NNS	auxpass||divided-29/VBN||were-27/VBD	advmod||divided-29/VBN||randomly-28/RB	root||ROOT-0/null||divided-29/VBN	num||groups-32/NNS||three-31/CD	prep_into||divided-29/VBN||groups-32/NNS	dep||groups-32/NNS||control-33/NN	dep||groups-32/NNS||asthmatic-35/JJ	amod||control-33/NN||asthmatic-35/JJ	conj_and||control-33/NN||asthmatic-35/JJ	amod||treatment-39/NN||budesonide-38/JJ	dep||groups-32/NNS||treatment-39/NN	conj_and||control-33/NN||treatment-39/NN	asthmatic-35||budesonide-38||yes||to investigate the effect of budesonide on substance p (nk-1) receptor (nk-1r) expression in the lung and asmcs, 45 wistar rats were randomly divided into three groups control, asthmatic, and budesonide treatment.
num||patients-3/NNS||131-2/CD	nsubjpass||hbv-6/VBN||patients-3/NNS	prep_of||did-14/VBD||patients-3/NNS	auxpass||hbv-6/VBN||were-5/VBD	rcmod||patients-3/NNS||hbv-6/VBN	nn||antigen-8/NN||surface-7/NN	nsubj||positive-9/JJ||antigen-8/NN	xcomp||hbv-6/VBN||positive-9/JJ	nsubj||did-14/VBD||55-11/CD	nsubj||receive-18/VB||55-11/CD	conj_and||55-11/CD||76-13/CD	nsubj||did-14/VBD||76-13/CD	root||ROOT-0/null||did-14/VBD	aux||receive-18/VB||did-16/VBD	neg||receive-18/VB||not-17/RB	conj_and||did-14/VBD||receive-18/VB	amod||lamivudine-20/NN||prophylactic-19/JJ	dobj||receive-18/VB||lamivudine-20/NN	advmod||receive-18/VB||respectively-22/RB	hbv-6||lamivudine-20||yes||of 131 patients who were hbv surface antigen positive, 55 and 76 did and did not receive prophylactic lamivudine, respectively.
amod||regimens-2/NNS||current-1/JJ	nsubjpass||thwarted-16/VBN||regimens-2/NNS	vmod||regimens-2/NNS||prescribed-3/VBN	aux||prevent-5/VB||to-4/TO	xcomp||prescribed-3/VBN||prevent-5/VB	amod||diseases-7/NNS||infection-associated-6/JJ	dobj||prevent-5/VB||diseases-7/NNS	prep_such_as||diseases-7/NNS||gastroduodenalulcers-10/NNS	amod||cancer-13/NN||gastric-12/JJ	prep_such_as||diseases-7/NNS||cancer-13/NN	conj_and||gastroduodenalulcers-10/NNS||cancer-13/NN	aux||thwarted-16/VBN||can-14/MD	auxpass||thwarted-16/VBN||be-15/VB	root||ROOT-0/null||thwarted-16/VBN	amod||resistance-19/NN||antibiotic-18/JJ	agent||thwarted-16/VBN||resistance-19/NN	gastroduodenalulcers-10||antibiotic-18||no_rel||current regimens prescribed to prevent infection-associated diseases such as gastroduodenalulcers and gastric cancer can be thwarted by antibiotic resistance.
prep_in||endemic-6/JJ||2008-2/CD	nsubj||endemic-6/JJ||poliomyelitis-3/NNP	cop||endemic-6/JJ||is-4/VBZ	advmod||endemic-6/JJ||still-5/RB	root||ROOT-0/null||endemic-6/JJ	num||countries-9/NNS||4-8/CD	prep_in||endemic-6/JJ||countries-9/NNS	dep||countries-9/NNS||nigeria-11/NN	dep||countries-9/NNS||india-13/NN	conj_and||nigeria-11/NN||india-13/NN	dep||countries-9/NNS||pakistan-15/NN	conj_and||nigeria-11/NN||pakistan-15/NN	dep||countries-9/NNS||afghanistan-18/NN	conj_and||nigeria-11/NN||afghanistan-18/NN	advmod||registered-26/VBN||where-21/WRB	num||cases-24/NNS||1201-22/CD	amod||cases-24/NNS||new-23/JJ	nsubjpass||registered-26/VBN||cases-24/NNS	auxpass||registered-26/VBN||were-25/VBD	rcmod||countries-9/NNS||registered-26/VBN	prep_in||registered-26/VBN||2007-28/CD	num||cases-32/NNS||107-30/CD	amod||cases-32/NNS||sporadic-31/JJ	nsubjpass||notified-35/VBN||cases-32/NNS	auxpass||notified-35/VBN||were-33/VBD	advmod||notified-35/VBN||also-34/RB	parataxis||endemic-6/JJ||notified-35/VBN	prep_in||notified-35/VBN||countries-37/NNS	advmod||endemic-42/JJ||where-38/WRB	nsubj||endemic-42/JJ||poliovirus-39/NNS	cop||endemic-42/JJ||is-40/VBZ	neg||endemic-42/JJ||not-41/RB	rcmod||countries-37/NNS||endemic-42/JJ	poliomyelitis-3||poliovirus-39||no||in 2008 poliomyelitis is still endemic in 4 countries (nigeria, india, pakistan, and afghanistan), where 1201 new cases were registered in 2007; 107 sporadic cases were also notified in countries where poliovirus is not endemic.
amod||mutations-2/NNS||nvp-resistance-1/JJ	nsubj||differ-4/VB||mutations-2/NNS	aux||differ-4/VB||did-3/VBD	root||ROOT-0/null||differ-4/VB	prep_by||differ-4/VB||timing-6/NN	prep_of||timing-6/NN||hivinfection-8/NN	det||variant-12/NN||the-10/DT	amod||variant-12/NN||y181c-11/JJ	nsubj||predominant-14/JJ||variant-12/NN	cop||predominant-14/JJ||was-13/VBD	parataxis||differ-4/VB||predominant-14/JJ	prep_among||predominant-14/JJ||infants-16/NNS	vmod||infants-16/NNS||diagnosed-17/VBN	det||weeks-22/NNS||the-19/DT	amod||weeks-22/NNS||first-20/JJ	num||weeks-22/NNS||six-21/CD	prep_in||diagnosed-17/VBN||weeks-22/NNS	prep_of||weeks-22/NNS||life-24/NN	prepc_compared_to||predominant-14/JJ||to-27/TO	pobj||predominant-14/JJ||y188c/h-28/NNS	amod||transmission-32/NN||late-30/JJ	amod||transmission-32/NN||breast-milk-31/JJ	prep_during||y188c/h-28/NNS||transmission-32/NN	hivinfection-8||nvp--1||yes||nvp-resistance mutations did differ by timing of hivinfection; the y181c variant was predominant among infants diagnosed in the first six weeks of life, compared to y188c/h during late breast-milk transmission.
root||ROOT-0/null||aim-1/VB	aux||compare-3/VB||to-2/TO	xcomp||aim-1/VB||compare-3/VB	det||effect-5/NN||the-4/DT	dobj||compare-3/VB||effect-5/NN	nn||degludec-8/NN||insulin-7/NN	prep_of||effect-5/NN||degludec-8/NN	conj_and||aim-1/VB||insulinglargine-10/VB	amod||quality-13/NN||health-related-12/JJ	prep_on||insulinglargine-10/VB||quality-13/NN	prep_of||quality-13/NN||life-15/NN	prep_in||life-15/NN||patients-17/NNS	prep_with||patients-17/NNS||type2diabetes-19/CD	prep||insulinglargine-10/VB||starting-20/VBG	pcomp||starting-20/VBG||on-21/IN	nn||therapy-23/NN||insulin-22/NN	pobj||on-21/IN||therapy-23/NN	type2diabetes-19||insulin-22||yes||aim to compare the effect of insulin degludec and insulinglargine on health-related quality of life in patients with type2diabetes starting on insulin therapy.
nn||integration-2/NN||methods-1/NNS	nsubjpass||carried-9/VBN||integration-2/NN	amod||systems-7/NNS||separate-4/JJ	nn||systems-7/NNS||hiv/aids-5/NNS	nn||systems-7/NNS||data-6/NNS	prep_of||integration-2/NN||systems-7/NNS	auxpass||carried-9/VBN||was-8/VBD	root||ROOT-0/null||carried-9/VBN	prt||carried-9/VBN||out-10/RP	num||phases-13/NNS||three-12/CD	prep_in||carried-9/VBN||phases-13/NNS	aids--1||hiv--1||no||methods integration of separate hiv/aids data systems was carried out in three phases.
nsubj||found-2/VBD||we-1/PRP	root||ROOT-0/null||found-2/VBD	amod||lidocaine-4/NN||adjunctive-3/JJ	nsubj||decreases-6/VBZ||lidocaine-4/NN	advmod||decreases-6/VBZ||significantly-5/RB	ccomp||found-2/VBD||decreases-6/VBZ	dobj||decreases-6/VBZ||pain-7/NN	prep_during||decreases-6/VBZ||injection-9/NN	prep_during||decreases-6/VBZ||postinjection-11/NN	conj_and||injection-9/NN||postinjection-11/NN	amod||satisfaction-16/NN||corresponding-13/JJ	amod||satisfaction-16/NN||increased-14/JJ	nn||satisfaction-16/NN||patient-15/NN	prep_with||decreases-6/VBZ||satisfaction-16/NN	pain-7||lidocaine-4||yes||we found adjunctive lidocaine significantly decreases pain during injection and postinjection with corresponding increased patient satisfaction.
nsubjpass||mentioned-4/VBN||it-1/PRP	nsubjpass||divided-23/VBN||it-1/PRP	auxpass||mentioned-4/VBN||was-2/VBD	advmod||mentioned-4/VBN||first-3/RB	root||ROOT-0/null||mentioned-4/VBN	agent||mentioned-4/VBN||maurice-6/NN	vmod||maurice-6/NN||raynaud-7/VBN	prep_in||raynaud-7/VBN||1862-9/CD	xcomp||raynaud-7/VBN||describing-10/VBG	quantmod||$-12/$||â-11/RB	num||asphyxia-15/FW||$-12/$	num||$-12/$||a-13/CD	amod||asphyxia-15/FW||local-14/JJ	dobj||describing-10/VBG||asphyxia-15/FW	det||$-19/NN||the-17/DT	amod||$-19/NN||extremitiesâ-18/JJ	prep_of||asphyxia-15/FW||$-19/NN	auxpass||divided-23/VBN||was-21/VBD	advmod||divided-23/VBN||further-22/RBR	conj_and||mentioned-4/VBN||divided-23/VBN	amod||raynaudâ-26/NNS||primary-25/JJ	prep_into||divided-23/VBN||raynaudâ-26/NNS	nsubjpass||related-42/VBN||raynaudâ-26/NNS	num||disease-30/NN||$-27/$	number||s-29/CD||-28/CD	num||$-27/$||s-29/CD	nsubj||phenomenon-37/NN||disease-30/NN	amod||raynaudâ-33/NNS||secondary-32/JJ	conj_and||disease-30/NN||raynaudâ-33/NNS	nsubj||phenomenon-37/NN||raynaudâ-33/NNS	amod||disease-30/NN||$-34/$	number||$-34/$||-35/CD	cop||phenomenon-37/NN||s-36/VBZ	rcmod||raynaudâ-26/NNS||phenomenon-37/NN	auxpass||related-42/VBN||is-40/VBZ	advmod||related-42/VBN||often-41/RB	rcmod||phenomenon-37/NN||related-42/VBN	prep_to||related-42/VBN||connectivetissuediseases-44/NNS	amod||strain-51/NN||physical-48/NN	conj_or||physical-48/NN||chemical-50/NN	amod||strain-51/NN||chemical-50/NN	rcmod||raynaudâ-26/NNS||strain-51/NN	conj_and||phenomenon-37/NN||strain-51/NN	chemical-50||raynaud-7||no_rel||it was first mentioned by maurice raynaud in 1862 describing âa local asphyxia of the extremitiesâ? and was further divided into primary raynaudâs disease and secondary raynaudâs phenomenon, which is often related to connectivetissuediseases, but also physical or chemical strain.
nsubj||agent-5/NN||mycobacteriumtuberculosis-1/NNS	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||the-3/DT	amod||agent-5/NN||etiological-4/JJ	root||ROOT-0/null||agent-5/NN	prep_of||agent-5/NN||tuberculosis-7/NNP	tuberculosis-7||mycobacteriumtuberculosis-1||no||mycobacteriumtuberculosis is the etiological agent of tuberculosis.
det||proportion-2/NN||the-1/DT	nsubj||low-12/JJ||proportion-2/NN	prep_of||proportion-2/NN||disclosure-4/NN	amod||diagnosis-7/NN||hiv/aids-6/JJ	prep_of||disclosure-4/NN||diagnosis-7/NN	amod||children-10/NNS||hiv-infected-9/JJ	prep_to||diagnosis-7/NN||children-10/NNS	cop||low-12/JJ||is-11/VBZ	root||ROOT-0/null||low-12/JJ	aids--1||hiv--1||no||the proportion of disclosure of hiv/aids diagnosis to hiv-infected children is low.
nsubj||appears-3/VBZ||hypersensitivity-1/NN	advmod||appears-3/VBZ||usually-2/RB	root||ROOT-0/null||appears-3/VBZ	amod||infusions-6/NNS||multiple-5/JJ	prep_after||appears-3/VBZ||infusions-6/NNS	xcomp||appears-3/VBZ||suggesting-8/VBG	nn||allergicreactions-11/NNS||type-9/NN	nn||allergicreactions-11/NNS||i-10/NN	dobj||suggesting-8/VBG||allergicreactions-11/NNS	advmod||seem-20/VBP||however-13/RB	amod||types-16/NNS||other-15/JJ	nsubj||seem-20/VBP||types-16/NNS	nsubjpass||implicated-23/VBN||types-16/NNS	prep_of||types-16/NNS||hypersensitivity-18/NN	advmod||seem-20/VBP||also-19/RB	parataxis||appears-3/VBZ||seem-20/VBP	aux||implicated-23/VBN||to-21/TO	auxpass||implicated-23/VBN||be-22/VB	xcomp||seem-20/VBP||implicated-23/VBN	allergicreactions-11||hypersensitivity-18||no||hypersensitivity usually appears after multiple infusions, suggesting type i allergicreactions; however, other types of hypersensitivity also seem to be implicated.
det||epilepsy-7/NN||a-1/DT	amod||epilepsy-7/NN||patient-2/JJ	det||diagnosed-6/NN||an-4/DT	amod||diagnosed-6/NN||early-5/JJ	prep_with||patient-2/JJ||diagnosed-6/NN	nsubj||experienced-13/VBD||epilepsy-7/NN	vmod||epilepsy-7/NN||treated-9/VBN	prep_with||treated-9/VBN||valproicacid-11/NN	root||ROOT-0/null||experienced-13/VBD	det||state-17/NN||an-14/DT	amod||state-17/NN||altered-15/JJ	amod||state-17/NN||mental-16/JJ	dobj||experienced-13/VBD||state-17/NN	amod||days-22/NNS||10â-19/JJ	amod||days-22/NNS||$-20/$	dep||$-20/$||-21/JJ	prep_after||experienced-13/VBD||days-22/NNS	prep_of||days-22/NNS||treatment-24/NN	epilepsy-7||valproicacid-11||yes||a patient with an early diagnosed epilepsy, treated with valproicacid, experienced an altered mental state after 10âdays of treatment.
nn||design-2/NN||research-1/NN	nsubjpass||enrolled-20/VBN||design-2/NN	conj_and||design-2/NN||methods-4/NNS	nsubjpass||enrolled-20/VBN||methods-4/NNS	advmod||hospitalized-10/VBN||â-5/RB	num||patients-9/NNS||$-6/$	num||$-6/$||diabetic-8/CD	pobj||â-5/RB||patients-9/NNS	vmod||design-2/NN||hospitalized-10/VBN	det||department-14/NN||a-12/DT	amod||department-14/NN||diabeticfoot-13/JJ	prep_in||hospitalized-10/VBN||department-14/NN	det||footulcer-17/NN||a-16/DT	prep_with||department-14/NN||footulcer-17/NN	auxpass||enrolled-20/VBN||were-18/VBD	advmod||enrolled-20/VBN||prospectively-19/RB	root||ROOT-0/null||enrolled-20/VBN	mark||free-25/JJ||if-21/IN	nsubj||free-25/JJ||they-22/PRP	aux||free-25/JJ||had-23/VBD	cop||free-25/JJ||been-24/VBN	advcl||enrolled-20/VBN||free-25/JJ	amod||treatment-28/NN||antibiotic-27/JJ	prep_of||free-25/JJ||treatment-28/NN	det||months-33/NNS||the-30/DT	amod||months-33/NNS||previous-31/JJ	num||months-33/NNS||6-32/CD	prep_over||free-25/JJ||months-33/NNS	footulcer-17||antibiotic-27||no_rel||research design and methods âdiabetic patients hospitalized in a diabeticfoot department with a footulcer were prospectively enrolled if they had been free of antibiotic treatment over the previous 6 months.
prep_at||determined-26/VBN||inclusion-2/NN	amod||parameters-6/NNS||steady-state-4/JJ	nn||parameters-6/NNS||pk-5/NN	nsubjpass||determined-26/VBN||parameters-6/NNS	det||form-11/NN||the-8/DT	advmod||active-10/JJ||mmf-9/RB	amod||form-11/NN||active-10/JJ	prep_of||parameters-6/NNS||form-11/NN	prep_of||parameters-6/NNS||mycophenolicacid-13/NN	conj_and||form-11/NN||mycophenolicacid-13/NN	appos||mycophenolicacid-13/NN||mpa-15/NN	poss||metabolite-21/NN||its-19/PRP$	amod||metabolite-21/NN||glucuronide-20/JJ	prep_of||parameters-6/NNS||metabolite-21/NN	conj_and||form-11/NN||metabolite-21/NN	appos||metabolite-21/NN||mpag-23/NN	auxpass||determined-26/VBN||were-25/VBD	root||ROOT-0/null||determined-26/VBN	num||patients-31/NNS||25-28/CD	amod||patients-31/NNS||stable-29/JJ	nn||patients-31/NNS||sle-30/NN	prep_for||determined-26/VBN||patients-31/NNS	amod||manifestations-34/NNS||renal-33/JJ	prep_without||determined-26/VBN||manifestations-34/NNS	mycophenolicacid-13||sle-30||no_rel||at inclusion, steady-state pk parameters of the mmf active form, mycophenolicacid (mpa), and its glucuronide metabolite (mpag) were determined for 25 stable sle patients without renal manifestations.
num||substituent-4/NN||one-1/CD	amod||substituent-4/NN||phenyl-2/JJ	nn||substituent-4/NN||ring-3/NN	nsubj||coplanar-15/JJ||substituent-4/NN	vmod||substituent-4/NN||attached-6/VBN	det||carbon-11/NN||an-8/DT	nn||carbon-11/NN||sp-9/NN	num||carbon-11/NN||2-10/CD	prep_to||attached-6/VBN||carbon-11/NN	cop||coplanar-15/JJ||is-13/VBZ	advmod||coplanar-15/JJ||approximately-14/RB	root||ROOT-0/null||coplanar-15/JJ	det||ring-19/NN||the-17/DT	amod||ring-19/NN||c3pse-18/JJ	prep_with||coplanar-15/JJ||ring-19/NN	mark||lie-36/VBP||whilst-20/IN	det||substituents-24/NNS||the-21/DT	amod||substituents-24/NNS||other-22/JJ	amod||substituents-24/NNS||organic-23/JJ	nsubj||lie-36/VBP||substituents-24/NNS	vmod||substituents-24/NNS||attached-26/VBN	det||3-carbon-30/NN||an-28/DT	nn||3-carbon-30/NN||sp-29/NN	prep_to||attached-26/VBN||3-carbon-30/NN	det||atom-34/NN||a-32/DT	nn||atom-34/NN||pv-33/NN	prep_to||attached-26/VBN||atom-34/NN	conj_and||3-carbon-30/NN||atom-34/NN	ccomp||coplanar-15/JJ||lie-36/VBP	det||side-40/NN||the-38/DT	amod||side-40/NN||same-39/JJ	prep_on||lie-36/VBP||side-40/NN	det||ring-43/NN||the-42/DT	prep_of||side-40/NN||ring-43/NN	pv-33||carbon-11||no_rel||one phenyl ring substituent, attached to an sp 2 carbon, is approximately coplanar with the c3pse ring whilst the other organic substituents, attached to an sp 3-carbon and a pv atom, lie on the same side of the ring.
det||enormity-2/NN||the-1/DT	nsubj||led-6/VBD||enormity-2/NN	amod||sufferings-5/NNS||human-4/JJ	prep_of||enormity-2/NN||sufferings-5/NNS	root||ROOT-0/null||led-6/VBD	dobj||led-6/VBD||clinicians-7/NNS	dobj||led-6/VBD||scientists-9/NNS	conj_and||clinicians-7/NNS||scientists-9/NNS	aux||carry-11/VB||to-10/TO	vmod||led-6/VBD||carry-11/VB	prt||carry-11/VB||out-12/RP	amod||research-14/NN||extensive-13/JJ	dobj||carry-11/VB||research-14/NN	iobj||carry-11/VB||research-14/NN	prep_on||research-14/NN||cholera-16/NN	prep_on||research-14/NN||vibriocholerae-18/NN	conj_and||cholera-16/NN||vibriocholerae-18/NN	det||bacterium-22/NN||the-20/DT	amod||bacterium-22/NN||causative-21/JJ	dep||research-14/NN||bacterium-22/NN	det||disease-25/NN||the-24/DT	prep_of||bacterium-22/NN||disease-25/NN	dep||research-14/NN||leading-27/VBG	nsubj||opened-32/VBD||leading-27/VBG	amod||discoveries-30/NNS||major-29/JJ	prep_to||leading-27/VBG||discoveries-30/NNS	rcmod||leading-27/VBG||opened-32/VBD	prt||opened-32/VBD||up-33/RP	nn||areas-35/NNS||novel-34/NN	dobj||opened-32/VBD||areas-35/NNS	nn||disciplines-40/NNS||research-37/NN	conj_or||research-37/NN||new-39/JJ	nn||disciplines-40/NNS||new-39/JJ	prep_of||areas-35/NNS||disciplines-40/NNS	amod||sciences-43/NNS||biomedical-42/JJ	prep_in||opened-32/VBD||sciences-43/NNS	cholera-16||bacterium-22||no||the enormity of human sufferings led clinicians and scientists to carry out extensive research on cholera and vibriocholerae (the causative bacterium of the disease) leading to major discoveries that opened up novel areas of research or new disciplines in biomedical sciences.
nn||findings-2/NNS||study-1/NN	nsubj||suggest-3/VBP||findings-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||stroke-15/NN||that-4/IN	det||causes-7/NNS||the-5/DT	amod||causes-7/NNS||leading-6/VBG	nsubj||stroke-15/NN||causes-7/NNS	prep_of||causes-7/NNS||death-9/NN	prep_in||death-9/NN||thailand-11/NN	prep_among||thailand-11/NN||males-13/NNS	cop||stroke-15/NN||are-14/VBP	ccomp||suggest-3/VBP||stroke-15/NN	num||%-18/NN||9.4-17/CD	appos||stroke-15/NN||%-18/NN	nn||accidents-22/NNS||transport-21/NN	dep||stroke-15/NN||accidents-22/NNS	num||%-25/NN||8.1-24/CD	appos||accidents-22/NNS||%-25/NN	ccomp||suggest-3/VBP||hiv/aids-28/NNS	conj_and||stroke-15/NN||hiv/aids-28/NNS	num||%-31/NN||7.9-30/CD	appos||hiv/aids-28/NNS||%-31/NN	amod||diseases-36/NNS||ischemic-34/JJ	nn||diseases-36/NNS||heart-35/NN	dep||hiv/aids-28/NNS||diseases-36/NNS	num||%-39/NN||6.4-38/CD	appos||diseases-36/NNS||%-39/NN	amod||lungdiseases-45/NNS||chronic-43/JJ	nn||lungdiseases-45/NNS||obstructive-44/NN	ccomp||suggest-3/VBP||lungdiseases-45/NNS	conj_and||stroke-15/NN||lungdiseases-45/NNS	num||%-48/NN||5.7-47/CD	appos||lungdiseases-45/NNS||%-48/NN	aids--1||hiv--1||no||study findings suggest that the leading causes of death in thailand among males are stroke (9.4%); transport accidents (8.1%); hiv/aids (7.9%); ischemic heart diseases (6.4%); and chronic obstructive lungdiseases (5.7%).
det||analysis-2/NN||this-1/DT	nsubj||included-3/VBD||analysis-2/NN	root||ROOT-0/null||included-3/VBD	dobj||included-3/VBD||participants-4/NNS	det||1999â-7/NNS||the-6/DT	prep_in||included-3/VBD||1999â-7/NNS	dep||included-3/VBD||$-8/$	nsubjpass||aged-19/VBN||$-8/$	det||health-12/NN||2004-10/DT	amod||health-12/NN||national-11/JJ	npadvmod||examination-15/RB||health-12/NN	cc||nutrition-14/RB||and-13/CC	advmod||health-12/NN||nutrition-14/RB	dep||survey-16/CD||examination-15/RB	num||$-8/$||survey-16/CD	auxpass||aged-19/VBN||were-18/VBD	rcmod||$-8/$||aged-19/VBN	number||84-22/CD||20-20/CD	dep||84-22/CD||to-21/TO	num||years-23/NNS||84-22/CD	npadvmod||aged-19/VBN||years-23/NNS	det||diagnosis-26/NN||a-25/DT	prep_without||aged-19/VBN||diagnosis-26/NN	prep_of||diagnosis-26/NN||cardiovasculardisease-28/NN	prep_of||diagnosis-26/NN||hypertension-30/NN	conj_or||cardiovasculardisease-28/NN||hypertension-30/NN	prep_of||diagnosis-26/NN||pregnancy-32/NN	conj_or||cardiovasculardisease-28/NN||pregnancy-32/NN	dep||lower-42/JJR||whose-34/WP$	amod||pressure-37/NN||systolic/diastolic-35/JJ	nn||pressure-37/NN||blood-36/NN	nsubj||lower-42/JJR||pressure-37/NN	appos||pressure-37/NN||sbp/dbp-39/NN	cop||lower-42/JJR||was-41/VBD	dep||diagnosis-26/NN||lower-42/JJR	num||mmhg-45/NN||140/90-44/CD	prep_than||lower-42/JJR||mmhg-45/NN	nsubj||were-48/VBD||mmhg-45/NN	rcmod||mmhg-45/NN||were-48/VBD	dep||were-48/VBD||not-49/RB	dep||not-49/RB||on-50/IN	amod||medication-52/NN||antihypertensive-51/JJ	pobj||on-50/IN||medication-52/NN	nsubj||consumed-56/VBD||who-55/WP	dep||were-48/VBD||consumed-56/VBD	conj_and||not-49/RB||consumed-56/VBD	num||drinks-58/NNS||12-57/CD	dobj||consumed-56/VBD||drinks-58/NNS	cc||more-60/JJR||or-59/CC	num||drinks-58/NNS||more-60/JJR	det||months-65/NNS||the-62/DT	amod||months-65/NNS||past-63/JJ	num||months-65/NNS||12-64/CD	prep_during||consumed-56/VBD||months-65/NNS	dep||months-65/NNS||n-67/VBN	dep||3957-69/CD||=-68/SYM	ccomp||n-67/VBN||3957-69/CD	hypertension-30||antihypertensive-51||no_rel||this analysis included participants in the 1999â2004 national health and nutrition examination survey who were aged 20 to 84 years without a diagnosis of cardiovasculardisease, hypertension or pregnancy, whose systolic/diastolic blood pressure (sbp/dbp) was lower than 140/90 mmhg, who were not on antihypertensive medication, and who consumed 12 drinks or more during the past 12 months (n = 3957).
nsubj||designed-2/VBD||we-1/PRP	root||ROOT-0/null||designed-2/VBD	det||trial-7/NN||a-3/DT	amod||trial-7/NN||four-arm-4/JJ	nn||trial-7/NN||phase-5/NN	nn||trial-7/NN||iii-6/NN	dobj||designed-2/VBD||trial-7/NN	aux||evaluate-9/VB||to-8/TO	vmod||designed-2/VBD||evaluate-9/VB	det||efficacy-11/NN||the-10/DT	dobj||evaluate-9/VB||efficacy-11/NN	dobj||evaluate-9/VB||toxicity-13/NN	conj_and||efficacy-11/NN||toxicity-13/NN	det||combination-16/NN||the-15/DT	prep_of||efficacy-11/NN||combination-16/NN	prep_of||combination-16/NN||docetaxel-18/NN	prep_of||combination-16/NN||carboplatin-20/NN	conj_and||docetaxel-18/NN||carboplatin-20/NN	prep_of||combination-16/NN||bevacizumab-22/NN	conj_and||docetaxel-18/NN||bevacizumab-22/NN	prep_of||combination-16/NN||erlotinib-25/NN	conj_and||docetaxel-18/NN||erlotinib-25/NN	det||treatment-29/NN||the-27/DT	amod||treatment-29/NN||first-line-28/JJ	prep_in||docetaxel-18/NN||treatment-29/NN	prep_of||treatment-29/NN||patients-31/NNS	prep_with||evaluate-9/VB||nsclc-33/NN	nsclc-33||docetaxel-18||yes||we designed a four-arm phase iii trial to evaluate the efficacy and toxicity of the combination of docetaxel, carboplatin, bevacizumab, and erlotinib in the first-line treatment of patients with nsclc.
nsubj||concludes-2/VBZ||it-1/PRP	nsubjpass||incorporated-12/VBN||it-1/PRP	root||ROOT-0/null||concludes-2/VBZ	det||number-5/NN||a-4/DT	prep_with||concludes-2/VBZ||number-5/NN	prep_of||number-5/NN||recommendations-7/NNS	prep_on||recommendations-7/NNS||topics-9/NNS	aux||incorporated-12/VBN||to-10/TO	auxpass||incorporated-12/VBN||be-11/VB	xcomp||concludes-2/VBZ||incorporated-12/VBN	det||agenda-17/NN||the-14/DT	amod||agenda-17/NN||international-15/JJ	nn||agenda-17/NN||research-16/NN	prep_into||incorporated-12/VBN||agenda-17/NN	prep_into||incorporated-12/VBN||policies-19/NNS	conj_and||agenda-17/NN||policies-19/NNS	prep_into||incorporated-12/VBN||programmes-22/NNS	conj_and||agenda-17/NN||programmes-22/NNS	det||field-25/NN||the-24/DT	prep_in||incorporated-12/VBN||field-25/NN	prep_of||field-25/NN||hiv/aids-27/NNS	aids--1||hiv--1||no||it concludes with a number of recommendations on topics to be incorporated into the international research agenda, policies, and programmes in the field of hiv/aids.
det||study-2/NN||this-1/DT	nsubj||gives-3/VBZ||study-2/NN	root||ROOT-0/null||gives-3/VBZ	iobj||gives-3/VBZ||us-4/PRP	det||knowledge-9/NN||an-5/DT	amod||knowledge-9/NN||overview-6/JJ	prep_about||overview-6/JJ||hiv/aids-8/NNS	dobj||gives-3/VBZ||knowledge-9/NN	prep_in||knowledge-9/NN||detention-11/NN	nn||province-14/NN||hunan-13/NN	prep_in||detention-11/NN||province-14/NN	det||sites-19/NNS||all-17/DT	nn||sites-19/NNS||detention-18/NN	nsubj||provided-23/VBD||sites-19/NNS	det||study-22/NN||the-21/DT	prep_in||sites-19/NNS||study-22/NN	conj_and||gives-3/VBZ||provided-23/VBD	amod||services-26/NNS||hiv/aids-24/JJ	nn||services-26/NNS||intervention-25/NN	dobj||provided-23/VBD||services-26/NNS	prep_among||provided-23/VBD||detainees-28/NNS	nsubj||focused-30/VBN||detainees-28/NNS	rcmod||detainees-28/NNS||focused-30/VBN	amod||attitude-35/NN||hiv/aids-32/JJ	nn||attitude-35/NN||knowledge-33/NN	prep_on||focused-30/VBN||attitude-35/NN	nn||behaviors-39/NNS||health-38/NN	prep_on||focused-30/VBN||behaviors-39/NNS	conj_and||attitude-35/NN||behaviors-39/NNS	aids--1||hiv--1||no||this study gives us an overview about hiv/aids knowledge in detention in hunan province, and all detention sites in the study provided hiv/aids intervention services among detainees that focused on hiv/aids knowledge, attitude, and health behaviors.
det||mixture-5/NN||the-1/DT	amod||mixture-5/NN||lidocaine-2/JJ	conj_and||lidocaine-2/JJ||propofol-4/JJ	amod||mixture-5/NN||propofol-4/JJ	nsubj||effective-7/JJ||mixture-5/NN	cop||effective-7/JJ||is-6/VBZ	root||ROOT-0/null||effective-7/JJ	prepc_in||effective-7/JJ||alleviating-9/VBG	dobj||alleviating-9/VBG||pain-10/NN	vmod||pain-10/NN||associated-11/VBN	amod||injection-15/NN||microemulsion-13/JJ	amod||injection-15/NN||propofol-14/JJ	prep_with||associated-11/VBN||injection-15/NN	pain-10||propofol-14||yes||the lidocaine and propofol mixture is effective in alleviating pain associated with microemulsion propofol injection.
det||study-4/NN||a-1/DT	amod||cohort-3/JJ||retrospective-2/JJ	amod||study-4/NN||cohort-3/JJ	nsubjpass||conducted-6/VBN||study-4/NN	auxpass||conducted-6/VBN||was-5/VBD	root||ROOT-0/null||conducted-6/VBN	xcomp||conducted-6/VBN||using-7/VBG	det||center-11/NN||an-8/DT	amod||center-11/NN||academic-9/JJ	nn||center-11/NN||health-10/NN	dobj||using-7/VBG||center-11/NN	amod||record-15/NN||enterprise-wide-12/JJ	amod||record-15/NN||electronic-13/JJ	nn||record-15/NN||health-14/NN	prep||center-11/NN||record-15/NN	appos||record-15/NN||ehr-17/NN	dep||record-15/NN||system-19/NN	aux||identify-21/VB||to-20/TO	vmod||system-19/NN||identify-21/VB	num||patients-23/NNS||11,141-22/CD	dobj||identify-21/VB||patients-23/NNS	prep_with||identify-21/VB||type2diabetes-25/NNS	num||initiators-28/NNS||4,279-27/CD	dep||type2diabetes-25/NNS||initiators-28/NNS	prep_of||initiators-28/NNS||monotherapy-30/NN	prep_with||monotherapy-30/NN||glyburide-32/NN	num||initiators-35/NNS||4,325-34/CD	dep||type2diabetes-25/NNS||initiators-35/NNS	conj_and||initiators-28/NNS||initiators-35/NNS	prep_of||initiators-35/NNS||monotherapy-37/NN	prep_with||monotherapy-37/NN||glipizide-39/NN	num||initiators-43/NNS||2,537-42/CD	dep||type2diabetes-25/NNS||initiators-43/NNS	conj_and||initiators-28/NNS||initiators-43/NNS	prep_of||initiators-43/NNS||monotherapy-45/NN	prep_with||monotherapy-45/NN||glimepiride-47/NN	vmod||system-19/NN||â-50/VB	conj_and||identify-21/VB||â-50/VB	conj_and||identify-21/VB||â-50/VB	conj_and||â-50/VB||â-50/VB	nn||¥-52/NNP||-51/NNP	dobj||â-50/VB||¥-52/NNP	num||years-54/NNS||18-53/CD	npadvmod||¥-52/NNP||years-54/NNS	prep_of||¥-52/NNP||age-56/NN	det||history-61/NN||a-60/DT	prep_with||â-50/VB||history-61/NN	prep_without||â-50/VB||history-61/NN	prep_of||history-61/NN||coronaryarterydisease-63/NN	appos||history-61/NN||cad-65/NN	vmod||system-19/NN||not-68/RB	conj_and||identify-21/VB||not-68/RB	neg||identify-21/VB||not-68/RB	prep_on||not-68/RB||insulin-70/NN	det||noninsulin-73/NN||a-72/DT	prep_on||not-68/RB||noninsulin-73/NN	conj_or||insulin-70/NN||noninsulin-73/NN	vmod||system-19/NN||injectable-74/VB	conj_and||identify-21/VB||injectable-74/VB	prep_at||injectable-74/VB||baseline-76/NN	type2diabetes-25||glipizide-39||yes||a retrospective cohort study was conducted using an academic health center enterprise-wide electronic health record (ehr) system to identify 11,141 patients with type2diabetes (4,279 initiators of monotherapy with glyburide, 4,325 initiators of monotherapy with glipizide, and 2,537 initiators of monotherapy with glimepiride), â¥18 years of age with and without a history of coronaryarterydisease (cad) and not on insulin or a noninsulin injectable at baseline.
nn||cancer-2/NN||prostate-1/NN	nsubj||cancer-8/NN||cancer-2/NN	cop||cancer-8/NN||is-3/VBZ	det||cancer-8/NN||the-4/DT	amod||cancer-8/NN||single-5/JJ	advmod||prevalent-7/JJ||most-6/RBS	amod||cancer-8/NN||prevalent-7/JJ	root||ROOT-0/null||cancer-8/NN	dep||men-11/NNS||us-10/PRP	prep_in||cancer-8/NN||men-11/NNS	poss||standard-14/NN||men-11/NNS	amod||standard-14/NN||gold-13/JJ	nsubj||assessment-19/NN||standard-14/NN	prep_of||standard-14/NN||diagnosis-16/NN	cop||assessment-19/NN||is-17/VBZ	amod||assessment-19/NN||histologic-18/JJ	rcmod||men-11/NNS||assessment-19/NN	prep_of||assessment-19/NN||biopsies-21/NNS	cancer-8||gold-13||no_rel||prostate cancer is the single most prevalent cancer in us men whose gold standard of diagnosis is histologic assessment of biopsies.
amod||users-3/NNS||injecting-1/VBG	nn||users-3/NNS||drug-2/NN	nsubj||remain-7/VBP||users-3/NNS	appos||users-3/NNS||idu-5/NN	root||ROOT-0/null||remain-7/VBP	det||population-10/NN||an-8/DT	amod||population-10/NN||important-9/JJ	xcomp||remain-7/VBP||population-10/NN	prep_at||remain-7/VBP||risk-12/NN	amod||infections-15/NNS||blood-borne-14/JJ	prep_for||risk-12/NN||infections-15/NNS	prep_such_as||infections-15/NNS||humanimmunodeficiencyvirus-18/NNS	appos||humanimmunodeficiencyvirus-18/NNS||hiv-20/NN	prep_such_as||infections-15/NNS||hepatitisbvirus-23/NNS	conj_and||humanimmunodeficiencyvirus-18/NNS||hepatitisbvirus-23/NNS	appos||hepatitisbvirus-23/NNS||hbv-25/NN	amod||virus-29/NN||hepatitisc-28/JJ	prep_such_as||infections-15/NNS||virus-29/NN	conj_and||humanimmunodeficiencyvirus-18/NNS||virus-29/NN	appos||virus-29/NN||hcv-31/NN	hbv-25||hepatitisbvirus-23||no||injecting drug users (idu) remain an important population at risk for blood-borne infections such as humanimmunodeficiencyvirus (hiv), hepatitisbvirus (hbv) and hepatitisc virus (hcv).
det||analysis-2/NN||this-1/DT	nsubjpass||aimed-21/VBN||analysis-2/NN	prep_of||analysis-2/NN||data-4/NNS	num||studies-11/NNS||22-6/CD	amod||studies-11/NNS||double-blind-7/JJ	amod||studies-11/NNS||placebo-controlled-9/JJ	amod||studies-11/NNS||clinical-10/JJ	prep_from||data-4/NNS||studies-11/NNS	prep_of||studies-11/NNS||venlafaxine-13/NN	amod||patients-16/NNS||adult-15/JJ	prep_in||venlafaxine-13/NN||patients-16/NNS	amod||depressivedisorder-19/NN||major-18/JJ	prep_with||patients-16/NNS||depressivedisorder-19/NN	auxpass||aimed-21/VBN||was-20/VBD	root||ROOT-0/null||aimed-21/VBN	prepc_at||aimed-21/VBN||assessing-23/VBG	dobj||assessing-23/VBG||correlations-24/NNS	det||scales-28/NNS||these-26/DT	num||scales-28/NNS||4-27/CD	prep_among||assessing-23/VBG||scales-28/NNS	depressivedisorder-19||venlafaxine-13||yes||this analysis of data from 22 double-blind, placebo-controlled clinical studies of venlafaxine in adult patients with major depressivedisorder was aimed at assessing correlations among these 4 scales.
dep||mp-20/VBP||r-2/LS	conj_or||--4/JJ||racemic-6/JJ	amod||formoterol-17/NN||albuterol-7/JJ	cc||albuterol-7/JJ||and-8/CC	dep||albuterol-7/JJ||r-10/SYM	appos||r-10/SYM||r-12/SYM	conj_or||--14/JJ||racemic-16/JJ	nsubj||mp-20/VBP||formoterol-17/NN	advmod||decreased-19/VBN||significantly-18/RB	vmod||formoterol-17/NN||decreased-19/VBN	root||ROOT-0/null||mp-20/VBP	dobj||mp-20/VBP||levels-21/NNS	amod||cells-27/NNS||normal-23/JJ	conj_and||normal-23/JJ||asthma-25/NN	amod||cells-27/NNS||asthma-25/NN	nn||cells-27/NNS||epithelial-26/NN	prep_in||levels-21/NNS||cells-27/NNS	asthma-25||albuterol-7||yes||(r)- or racemic albuterol and (r,r)- or racemic formoterol significantly decreased mp levels in normal and asthma epithelial cells.
advmod||demonstrated-4/VBD||previously-1/RB	nsubj||demonstrated-4/VBD||we-3/PRP	root||ROOT-0/null||demonstrated-4/VBD	mark||detected-10/VBD||that-5/IN	amod||antibodies-7/NNS||polyclonal-6/JJ	nsubj||detected-10/VBD||antibodies-7/NNS	prep_to||antibodies-7/NNS||proavp-9/NN	ccomp||demonstrated-4/VBD||detected-10/VBD	det||protein-12/NN||that-11/WDT	dobj||examined-18/VBD||protein-12/NN	det||breast-15/NN||all-14/DT	prep_in||protein-12/NN||breast-15/NN	nn||samples-17/NNS||cancer-16/NN	nsubj||examined-18/VBD||samples-17/NNS	ccomp||detected-10/VBD||examined-18/VBD	expl||was-22/VBD||there-21/EX	conj_but||demonstrated-4/VBD||was-22/VBD	neg||reaction-24/NN||no-23/DT	nsubj||was-22/VBD||reaction-24/NN	nn||tissue-27/NN||breast-26/NN	prep_with||reaction-24/NN||tissue-27/NN	vmod||tissue-27/NN||containing-28/VBG	dobj||containing-28/VBG||fibrocysticdisease-29/NN	cancer-16||antibodies-7||no_rel||previously, we demonstrated that polyclonal antibodies to proavp detected that protein in all breast cancer samples examined, but there was no reaction with breast tissue containing fibrocysticdisease.
prep_in||prolonged-11/JJ||addition-2/NN	det||activitiy-6/NN||the-4/DT	amod||activitiy-6/NN||immunosuppressive-5/JJ	nsubj||prolonged-11/JJ||activitiy-6/NN	prep_of||activitiy-6/NN||uc-mscs-8/NNS	aux||prolonged-11/JJ||could-9/MD	cop||prolonged-11/JJ||be-10/VB	root||ROOT-0/null||prolonged-11/JJ	det||participation-14/NN||the-13/DT	prep_by||prolonged-11/JJ||participation-14/NN	prep_of||participation-14/NN||tregs-16/NNS	uc--1||immunosuppressive-5||no_rel||in addition, the immunosuppressive activitiy of uc-mscs could be prolonged by the participation of tregs.
nn||diagnosis-2/NN||pbc-1/NN	nsubjpass||established-4/VBN||diagnosis-2/NN	auxpass||established-4/VBN||was-3/VBD	root||ROOT-0/null||established-4/VBN	prepc_according_to||established-4/VBN||to-6/TO	det||profile-10/NN||the-7/DT	amod||profile-10/NN||cholestatic-8/JJ	amod||profile-10/NN||biochemical-9/JJ	pobj||established-4/VBN||profile-10/NN	amod||antibodies-13/NNS||anti-mitochondrial-12/JJ	appos||profile-10/NN||antibodies-13/NNS	appos||profile-10/NN||ama-15/NN	nn||histology-20/NN||positivity-17/NN	conj_and||positivity-17/NN||liver-19/NN	nn||histology-20/NN||liver-19/NN	dep||profile-10/NN||histology-20/NN	dep||histology-20/NN||first-22/JJ	dep||profile-10/NN||ama-26/NN	conj_and||histology-20/NN||ama-26/NN	conj_and||histology-20/NN||antinuclear-28/NN	conj_and||ama-26/NN||antinuclear-28/NN	appos||ama-26/NN||ana-30/NN	amod||antibodies-33/NNS||pbc-specific-32/JJ	dep||ama-26/NN||antibodies-33/NNS	dep||ama-26/NN||second-35/JJ	antibodies-33||pbc-1||no_rel||pbc diagnosis was established according to the cholestatic biochemical profile, anti-mitochondrial antibodies (ama) positivity and liver histology (first), and ama and antinuclear (ana) pbc-specific antibodies (second).
amod||response-2/NN||t-cell-1/JJ	nsubjpass||evaluated-6/VBN||response-2/NN	prep_to||response-2/NN||rv1985c-4/CD	auxpass||evaluated-6/VBN||was-5/VBD	root||ROOT-0/null||evaluated-6/VBN	amod||elispot-10/NN||ifn-î-8/JJ	amod||elispot-10/NN||³-9/JJ	agent||evaluated-6/VBN||elispot-10/NN	number||tb-13/CD||56-12/CD	num||patients-14/NNS||tb-13/CD	prep_in||elispot-10/NN||patients-14/NNS	num||infection-19/NN||20-16/CD	nn||infection-19/NN||latent-17/NN	nn||infection-19/NN||tb-18/NN	prep_in||elispot-10/NN||infection-19/NN	conj_and||patients-14/NNS||infection-19/NN	appos||infection-19/NN||ltbi-21/NNP	num||controls-26/NNS||30-24/CD	amod||controls-26/NNS||bcg-vaccinated-25/JJ	prep_in||elispot-10/NN||controls-26/NNS	conj_and||patients-14/NNS||controls-26/NNS	prep_in||controls-26/NNS||comparison-28/NN	det||t-spot-32/NN||the-30/DT	amod||t-spot-32/NN||commercial-31/JJ	prep_with||evaluated-6/VBN||t-spot-32/NN	tb-18||bcg--1||yes||t-cell response to rv1985c was evaluated by ifn-î³ elispot in 56 tb patients, 20 latent tb infection (ltbi) and 30 bcg-vaccinated controls in comparison with the commercial t-spot.
nsubj||enzyme-8/NN||glucokinase-1/NN	appos||glucokinase-1/NN||gk-3/NN	cop||enzyme-8/NN||is-5/VBZ	det||enzyme-8/NN||a-6/DT	amod||enzyme-8/NN||glycolytic-7/JJ	root||ROOT-0/null||enzyme-8/NN	nsubj||plays-10/VBZ||enzyme-8/NN	rcmod||enzyme-8/NN||plays-10/VBZ	det||role-13/NN||an-11/DT	amod||role-13/NN||important-12/JJ	dobj||plays-10/VBZ||role-13/NN	prepc_in||plays-10/VBZ||regulating-15/VBG	amod||level-17/NN||bloodglucose-16/JJ	dobj||regulating-15/VBG||level-17/NN	advmod||acting-20/VBG||thus-19/RB	dep||regulating-15/VBG||acting-20/VBG	det||target-25/NN||a-22/DT	advmod||attractive-24/JJ||potentially-23/RB	amod||target-25/NN||attractive-24/JJ	prep_as||acting-20/VBG||target-25/NN	nn||discovery-28/NN||drug-27/NN	prep_for||target-25/NN||discovery-28/NN	det||treatment-31/NN||the-30/DT	prep_in||acting-20/VBG||treatment-31/NN	prep_of||treatment-31/NN||diabetes-33/NN	det||hypoglycemia-42/NN||the-35/DT	amod||hypoglycemia-42/NN||young-36/JJ	dep||hyperinsulinemic-41/JJ||type-37/NN	number||hyperinsulinemic-41/JJ||2-38/CD	conj_and||hyperinsulinemic-41/JJ||persistent-40/JJ	amod||hypoglycemia-42/NN||persistent-40/JJ	amod||hypoglycemia-42/NN||hyperinsulinemic-41/JJ	prep_of||diabetes-33/NN||hypoglycemia-42/NN	prep_of||hypoglycemia-42/NN||infancy-44/NN	hypoglycemia-42||glucose--1||yes||glucokinase (gk) is a glycolytic enzyme that plays an important role in regulating bloodglucose level, thus acting as a potentially attractive target for drug discovery in the treatment of diabetes of the young type 2 and persistent hyperinsulinemic hypoglycemia of infancy.
advmod||investigated-4/VBD||therefore-1/RB	nsubj||investigated-4/VBD||we-3/PRP	root||ROOT-0/null||investigated-4/VBD	mark||associated-19/VBN||whether-5/IN	det||mismatch-7/NN||a-6/DT	nsubjpass||associated-19/VBN||mismatch-7/NN	nn||allotypes-10/NNS||igg-9/NN	prep_in||mismatch-7/NN||allotypes-10/NNS	prep_between||allotypes-10/NNS||adalimumab-12/NN	prep_between||allotypes-10/NNS||igg-14/NN	conj_and||adalimumab-12/NN||igg-14/NN	amod||patients-17/NNS||adalimumab-treated-16/JJ	prep_in||adalimumab-12/NN||patients-17/NNS	auxpass||associated-19/VBN||is-18/VBZ	ccomp||investigated-4/VBD||associated-19/VBN	det||development-22/NN||the-21/DT	prep_with||associated-19/VBN||development-22/NN	prep_of||development-22/NN||aaa-24/NN	aaa-24||adalimumab-12||no_rel||therefore, we investigated whether a mismatch in igg allotypes between adalimumab and igg in adalimumab-treated patients is associated with the development of aaa.
amod||models-4/NNS||cox-1/JJ	amod||models-4/NNS||proportional-2/JJ	nn||models-4/NNS||hazard-3/NN	nsubjpass||built-6/VBN||models-4/NNS	nsubj||compare-8/VB||models-4/NNS	auxpass||built-6/VBN||were-5/VBD	root||ROOT-0/null||built-6/VBN	aux||compare-8/VB||to-7/TO	xcomp||built-6/VBN||compare-8/VB	det||risk-10/NN||the-9/DT	dobj||compare-8/VB||risk-10/NN	amod||pancreatitis-13/NNS||acute-12/JJ	prep_of||risk-10/NN||pancreatitis-13/NNS	amod||subjects-18/NNS||diabetic-15/JJ	conj_and||diabetic-15/JJ||nondiabetic-17/JJ	amod||subjects-18/NNS||nondiabetic-17/JJ	prep_between||compare-8/VB||subjects-18/NNS	nn||sitagliptin-23/NN||exenatide-21/NN	prep_between||compare-8/VB||sitagliptin-23/NN	conj_and||subjects-18/NNS||sitagliptin-23/NN	nn||diabetes-27/NN||control-26/NN	conj_and||subjects-18/NNS||diabetes-27/NN	conj_and||sitagliptin-23/NN||diabetes-27/NN	nn||use-29/NN||medication-28/NN	pobj||compare-8/VB||use-29/NN	pancreatitis-13||sitagliptin-23||no_rel||cox proportional hazard models were built to compare the risk of acute pancreatitis between diabetic and nondiabetic subjects and between exenatide, sitagliptin, and control diabetes medication use.
amod||programs-3/NNS||supervised-1/JJ	nn||programs-3/NNS||toothbrushing-2/NN	nsubj||reduced-8/VBN||programs-3/NNS	vmod||programs-3/NNS||using-4/VBG	nn||dentifrice-6/NN||fluoride-5/NN	dobj||using-4/VBG||dentifrice-6/NN	aux||reduced-8/VBN||have-7/VBP	root||ROOT-0/null||reduced-8/VBN	amod||increment-10/NN||caries-9/JJ	dobj||reduced-8/VBN||increment-10/NN	caries-9||fluoride-5||yes||supervised toothbrushing programs using fluoride dentifrice have reduced caries increment.
nn||influenza-2/NN||duck-1/NN	nsubjpass||believed-8/VBN||influenza-2/NN	advmod||believed-8/VBN||therefore-4/RB	aux||believed-8/VBN||has-6/VBZ	auxpass||believed-8/VBN||been-7/VBN	root||ROOT-0/null||believed-8/VBN	amod||infection-10/NN||inapparent-9/JJ	dobj||believed-8/VBN||infection-10/NN	prepc_with||believed-8/VBN||influenza-12/VBG	det||viruses-14/NNS||a-13/DT	dobj||influenza-12/VBG||viruses-14/NNS	advmod||pathogenic-18/JJ||highly-17/RB	amod||avianinfluenzaviruses-19/NNS||pathogenic-18/JJ	prep_including||believed-8/VBN||avianinfluenzaviruses-19/NNS	appos||avianinfluenzaviruses-19/NNS||hpaivs-21/NNS	prep_in||avianinfluenzaviruses-19/NNS||chickens-24/NNS	influenza-12||influenzaviruses--1||no||duck influenza, therefore, has been believed inapparent infection with influenza a viruses, including highly pathogenic avianinfluenzaviruses (hpaivs) in chickens.
nsubj||assayed-2/VBD||we-1/PRP	root||ROOT-0/null||assayed-2/VBD	amod||dna-5/NN||purified-3/JJ	nn||dna-5/NN||c.botulinum-4/NN	dobj||assayed-2/VBD||dna-5/NN	amod||preparations-9/NNS||crude-7/JJ	nn||preparations-9/NNS||toxin-8/NN	dobj||assayed-2/VBD||preparations-9/NNS	conj_and||dna-5/NN||preparations-9/NNS	dobj||assayed-2/VBD||food-14/NN	conj_and||dna-5/NN||food-14/NN	conj_and||dna-5/NN||stool-16/NN	conj_and||food-14/NN||stool-16/NN	amod||individuals-19/NNS||healthy-18/JJ	prep_from||food-14/NN||individuals-19/NNS	vmod||food-14/NN||spiked-20/VBN	amod||dna-24/NN||purified-22/JJ	nn||dna-24/NN||bont-23/NN	prep_with||spiked-20/VBN||dna-24/NN	num||sample-29/NN||one-27/CD	amod||sample-29/NN||stool-28/JJ	dobj||assayed-2/VBD||sample-29/NN	conj_and||dna-5/NN||sample-29/NN	conj_and||dna-5/NN||sample-29/NN	conj_and||sample-29/NN||sample-29/NN	det||case-32/NN||a-31/DT	prep_from||sample-29/NN||case-32/NN	prep_of||case-32/NN||infantbotulism-34/NN	det||presence-37/NN||the-36/DT	prep_for||infantbotulism-34/NN||presence-37/NN	det||gene-41/NN||the-39/DT	amod||gene-41/NN||ntnh-40/JJ	prep_of||presence-37/NN||gene-41/NN	nsubj||part-45/NN||gene-41/NN	cop||part-45/NN||is-44/VBZ	rcmod||gene-41/NN||part-45/NN	det||cluster-50/NN||the-47/DT	amod||cluster-50/NN||bont-48/JJ	nn||cluster-50/NN||gene-49/NN	prep_of||part-45/NN||cluster-50/NN	det||presence-55/NN||the-54/DT	prep_for||sample-29/NN||presence-55/NN	amod||genes-59/NNS||serotype-specific-57/JJ	nn||genes-59/NNS||bont-58/NN	prep_of||presence-55/NN||genes-59/NNS	infantbotulism-34||c.botulinum-4||no||we assayed purified c.botulinum dna and crude toxin preparations , as well as food and stool from healthy individuals spiked with purified bont dna , and one stool sample from a case of infantbotulism for the presence of the ntnh gene , which is part of the bont gene cluster , and for the presence of serotype-specific bont genes .
amod||movements-2/NNS||involuntary-1/JJ	nsubj||represent-6/VBP||movements-2/NNS	conj_or||movements-2/NNS||dyskinesia-4/NN	nsubj||represent-6/VBP||dyskinesia-4/NN	root||ROOT-0/null||represent-6/VBP	det||complication-9/NN||a-7/DT	amod||complication-9/NN||debilitating-8/JJ	dep||sdisease-16/JJ||complication-9/NN	nn||therapy-12/NN||levodopa-11/NN	prep_of||complication-9/NN||therapy-12/NN	prep_for||therapy-12/NN||parkinson-14/NN	dep||represent-6/VBP||sdisease-16/JJ	parkinson'sdisease--1||levodopa-11||yes||involuntary movements or dyskinesia, represent a debilitating complication of levodopa therapy for parkinson'sdisease.
aux||investigate-2/VB||to-1/TO	root||ROOT-0/null||investigate-2/VB	mark||decrease-7/VB||if-3/IN	amod||analogs-6/NNS||long-acting-4/JJ	nn||analogs-6/NNS||insulin-5/NN	nsubj||decrease-7/VB||analogs-6/NNS	advcl||investigate-2/VB||decrease-7/VB	det||risk-9/NN||the-8/DT	dobj||decrease-7/VB||risk-9/NN	prep_of||risk-9/NN||diabeticketoacidosis-11/NNS	appos||diabeticketoacidosis-11/NNS||dka-13/NN	amod||individuals-17/NNS||young-16/JJ	prep_in||diabeticketoacidosis-11/NNS||individuals-17/NNS	prep_with||individuals-17/NNS||type1diabetes-19/CD	insulin-5||diabeticketoacidosis-11||no_rel||to investigate if long-acting insulin analogs decrease the risk of diabeticketoacidosis (dka) in young individuals with type1diabetes.
det||face-3/NN||the-2/DT	prep_in||attributes-36/NNS||face-3/NN	det||epidemic-7/NN||the-5/DT	amod||epidemic-7/NN||hiv/aids-6/JJ	prep_of||face-3/NN||epidemic-7/NN	nsubj||contributed-10/VBN||epidemic-7/NN	aux||contributed-10/VBN||has-9/VBZ	rcmod||epidemic-7/NN||contributed-10/VBN	det||increase-14/NN||the-12/DT	amod||increase-14/NN||dramatic-13/JJ	prep_to||contributed-10/VBN||increase-14/NN	prep_in||increase-14/NN||orphans-16/NNS	amod||children-19/NNS||abandoned-18/VBN	prep_of||face-3/NN||children-19/NNS	conj_and||epidemic-7/NN||children-19/NNS	nsubj||contributed-10/VBN||children-19/NNS	appos||children-19/NNS||oac-21/NN	advmod||children-19/NNS||worldwide-23/RB	nn||attitudes-26/NNS||caregiver-25/NN	nsubj||attributes-36/NNS||attitudes-26/NNS	prep_about||attitudes-26/NNS||hiv-28/NN	amod||stigma-32/NN||hiv-related-31/JJ	prep_about||attitudes-26/NNS||stigma-32/NN	conj_and||hiv-28/NN||stigma-32/NN	cop||attributes-36/NNS||are-34/VBP	num||attributes-36/NNS||two-35/CD	root||ROOT-0/null||attributes-36/NNS	nsubj||affect-39/VB||attributes-36/NNS	aux||affect-39/VB||may-38/MD	rcmod||attributes-36/NNS||affect-39/VB	dobj||affect-39/VB||caregiving-40/NN	aids--1||hiv-28||no||in the face of the hiv/aids epidemic that has contributed to the dramatic increase in orphans and abandoned children (oac) worldwide, caregiver attitudes about hiv, and hiv-related stigma, are two attributes that may affect caregiving.
amod||coronavirus-2/NNS||severeacuterespiratorysyndrome-associated-1/JJ	nsubj||spreads-6/VBZ||coronavirus-2/NNS	nsubj||has-9/VBZ||coronavirus-2/NNS	appos||coronavirus-2/NNS||sars-cov-4/NNP	root||ROOT-0/null||spreads-6/VBZ	advmod||spreads-6/VBZ||rapidly-7/RB	conj_and||spreads-6/VBZ||has-9/VBZ	det||rate-13/NN||a-10/DT	amod||rate-13/NN||high-11/JJ	amod||rate-13/NN||case-mortality-12/JJ	dobj||has-9/VBZ||rate-13/NN	severeacuterespiratorysyndrome--1||coronavirus-2||no||severeacuterespiratorysyndrome-associated coronavirus (sars-cov) spreads rapidly and has a high case-mortality rate.
nsubj||drug-6/NN||alminoprofen-1/NN	cop||drug-6/NN||is-2/VBZ	det||drug-6/NN||a-3/DT	amod||drug-6/NN||non-steroid-4/JJ	amod||drug-6/NN||anti-inflammatory-5/JJ	root||ROOT-0/null||drug-6/NN	dep||drug-6/NN||nsaid-8/VBN	vmod||drug-6/NN||used-10/VBN	det||analgesic-13/JJ||an-12/DT	prep_as||used-10/VBN||analgesic-13/JJ	prep_for||analgesic-13/JJ||rheumatism-15/NN	anti-inflammatory-5||rheumatism-15||no_rel||alminoprofen is a non-steroid anti-inflammatory drug (nsaid) used as an analgesic for rheumatism.
amod||age-2/NN||increasing-1/VBG	nsubjpass||associated-4/VBN||age-2/NN	auxpass||associated-4/VBN||is-3/VBZ	root||ROOT-0/null||associated-4/VBN	amod||function-8/NN||impaired-6/VBN	amod||function-8/NN||immune-7/JJ	prep_with||associated-4/VBN||function-8/NN	conj_and||associated-4/VBN||in-10/IN	amod||infection-13/NN||chronic-11/JJ	nn||infection-13/NN||hcv-12/NN	pobj||in-10/IN||infection-13/NN	advmod||in-10/IN||specifically-14/RB	amod||fibrosis-18/NN||progressive-17/JJ	prep_with||associated-4/VBN||fibrosis-18/NN	prep_with||associated-4/VBN||liverfailure-20/NN	conj_and||fibrosis-18/NN||liverfailure-20/NN	prep_with||associated-4/VBN||hcc-22/NN	conj_and||fibrosis-18/NN||hcc-22/NN	amod||responses-25/NNS||impaired-24/VBN	prep_with||associated-4/VBN||responses-25/NNS	conj_and||fibrosis-18/NN||responses-25/NNS	amod||therapy-28/NN||antiviral-27/JJ	prep_to||responses-25/NNS||therapy-28/NN	antiviral-27||fibrosis-18||no_rel||increasing age is associated with impaired immune function and in chronic hcv infection specifically, with progressive fibrosis, liverfailure, hcc and impaired responses to antiviral therapy.
nsubj||examined-2/VBD||we-1/PRP	root||ROOT-0/null||examined-2/VBD	dobj||examined-2/VBD||correlates-3/NNS	amod||rna-7/NN||genital-5/JJ	amod||rna-7/NN||hiv-1-6/JJ	prep_of||correlates-3/NNS||rna-7/NN	prep_in||rna-7/NN||women-9/NNS	nsubj||seropositive-12/JJ||who-10/WP	cop||seropositive-12/JJ||were-11/VBD	dep||examined-2/VBD||seropositive-12/JJ	det||-rrb--20/NNP||both-14/DT	amod||-rrb--20/NNP||herpes-15/JJ	nn||-rrb--20/NNP||simplex-16/NN	nn||-rrb--20/NNP||virus-17/NN	nn||-rrb--20/NNP||-lrb--18/NNP	nn||-rrb--20/NNP||hsv-19/NNP	prep_for||seropositive-12/JJ||-rrb--20/NNP	dep||seropositive-12/JJ||-2-21/CD	dep||seropositive-12/JJ||hiv-1-23/CD	conj_and||-2-21/CD||hiv-1-23/CD	dep||enrolled-27/VBN||who-25/WP	auxpass||enrolled-27/VBN||were-26/VBD	dep||examined-2/VBD||enrolled-27/VBN	conj_and||seropositive-12/JJ||enrolled-27/VBN	det||trial-32/NN||a-29/DT	amod||trial-32/NN||randomised-30/JJ	amod||trial-32/NN||controlled-31/JJ	prep_in||enrolled-27/VBN||trial-32/NN	nn||therapy-36/NN||hsv-34/NN	nn||therapy-36/NN||suppressive-35/NN	prep_of||trial-32/NN||therapy-36/NN	num||aciclovir-38/NN||-lrb--37/CD	nsubjpass||enrolled-27/VBN||aciclovir-38/NN	num||-rrb--44/NN||400-39/CD	amod||-rrb--44/NN||mg-40/JJ	amod||-rrb--44/NN||b.i.d-41/JJ	nn||-rrb--44/NN||vs.-42/FW	nn||-rrb--44/NN||placebo-43/FW	dep||enrolled-27/VBN||-rrb--44/NN	prep_in||enrolled-27/VBN||tanzania-46/NN	hsv-34||aciclovir-38||yes||we examined correlates of genital hiv-1 rna in women who were seropositive for both herpes simplex virus -lrb- hsv -rrb- -2 and hiv-1 and who were enrolled in a randomised controlled trial of hsv suppressive therapy -lrb- aciclovir 400 mg b.i.d vs. placebo -rrb- in tanzania .
det||test-4/NN||the-1/DT	amod||test-4/NN||xpert-2/JJ	nn||test-4/NN||mtb/rif-3/NN	nsubj||detect-15/VB||test-4/NN	dep||test-4/NN||cepheid-6/VBN	dobj||cepheid-6/VBN||sunnyvale-8/NN	dep||sunnyvale-8/NN||ca-10/MD	appos||sunnyvale-8/NN||usa-12/NN	aux||detect-15/VB||can-14/MD	root||ROOT-0/null||detect-15/VB	dobj||detect-15/VB||tuberculosis-16/NNP	poss||form-20/NN||its-18/PRP$	amod||form-20/NN||multidrug-resistant-19/JJ	dobj||detect-15/VB||form-20/NN	conj_and||tuberculosis-16/NNP||form-20/NN	advmod||high-23/JJ||very-22/RB	amod||sensitivity-24/NN||high-23/JJ	prep_with||detect-15/VB||sensitivity-24/NN	prep_with||detect-15/VB||specificity-26/NN	conj_and||sensitivity-24/NN||specificity-26/NN	amod||studies-29/NNS||controlled-28/JJ	prep_in||detect-15/VB||studies-29/NNS	neg||data-34/NNS||no-32/DT	nn||data-34/NNS||performance-33/NN	nsubj||exist-35/VBP||data-34/NNS	conj_but||detect-15/VB||exist-35/VBP	nn||facilities-41/NNS||district-37/NN	conj_and||district-37/NN||subdistrict-39/NN	nn||facilities-41/NNS||subdistrict-39/NN	nn||facilities-41/NNS||health-40/NN	prep_from||exist-35/VBP||facilities-41/NNS	amod||countries-44/NNS||tuberculosis-endemic-43/JJ	prep_in||exist-35/VBP||countries-44/NNS	tuberculosis-16||rif--1||yes||the xpert mtb/rif test (cepheid, sunnyvale, ca, usa) can detect tuberculosis and its multidrug-resistant form with very high sensitivity and specificity in controlled studies, but no performance data exist from district and subdistrict health facilities in tuberculosis-endemic countries.
det||contribution-3/NN||the-1/DT	amod||contribution-3/NN||relative-2/JJ	nsubj||unclear-16/JJ||contribution-3/NN	det||components-9/NNS||the-5/DT	amod||components-9/NNS||budesonide-6/JJ	conj_and||budesonide-6/JJ||formoterol-8/JJ	amod||components-9/NNS||formoterol-8/JJ	prep_of||contribution-3/NN||components-9/NNS	det||control-14/NN||the-11/DT	amod||control-14/NN||improved-12/JJ	nn||control-14/NN||asthma-13/NN	prep_to||components-9/NNS||control-14/NN	cop||unclear-16/JJ||is-15/VBZ	root||ROOT-0/null||unclear-16/JJ	asthma-13||budesonide-6||yes||the relative contribution of the budesonide and formoterol components to the improved asthma control is unclear.
det||effect-3/NN||a-1/DT	amod||effect-3/NN||dual-2/JJ	nsubjpass||observed-8/VBN||effect-3/NN	nn||action-6/NN||insulin-5/NN	prep_on||effect-3/NN||action-6/NN	auxpass||observed-8/VBN||was-7/VBD	root||ROOT-0/null||observed-8/VBN	advmod||exposed-14/VBN||when-9/WRB	nsubjpass||exposed-14/VBN||myotubes-10/NNS	conj_and||myotubes-10/NNS||mice-12/NNS	nsubjpass||exposed-14/VBN||mice-12/NNS	auxpass||exposed-14/VBN||were-13/VBD	advcl||observed-8/VBN||exposed-14/VBN	det||additive-18/NN||this-16/DT	amod||additive-18/NN||cytokine-17/JJ	prep_to||exposed-14/VBN||additive-18/NN	amod||insulin-21/NN||short-term-20/JJ	prep_with||additive-18/NN||insulin-21/NN	amod||uptake-25/NN||increased-23/JJ	nn||uptake-25/NN||glucose-24/NN	dep||insulin-21/NN||uptake-25/NN	amod||sensitivity-29/NN||systemic-27/JJ	nn||sensitivity-29/NN||insulin-28/NN	dep||insulin-21/NN||sensitivity-29/NN	conj_and||uptake-25/NN||sensitivity-29/NN	amod||exposure-33/NN||chronic-32/JJ	nsubj||produced-34/VBD||exposure-33/NN	conj_but||observed-8/VBN||produced-34/VBD	dobj||produced-34/VBD||insulinresistance-35/NN	dep||insulinresistance-35/NN||impaired-37/VBN	amod||translocation-39/NN||glut4-38/JJ	dobj||impaired-37/VBN||translocation-39/NN	nn||membrane-42/NNS||plasma-41/NN	prep_to||impaired-37/VBN||membrane-42/NNS	prep_to||impaired-37/VBN||defects-44/NNS	conj_and||membrane-42/NNS||defects-44/NNS	prep_in||impaired-37/VBN||insulin-46/NN	xcomp||impaired-37/VBN||signaling-47/VBG	det||substrate-52/NN||the-49/DT	nn||substrate-52/NN||insulin-50/NN	nn||substrate-52/NN||receptor-51/NN	nn||level-57/NN||substrate-52/NN	num||-LSB--54/NNS||1-53/CD	npadvmod||irs-1-55/JJ||-LSB--54/NNS	amod||level-57/NN||irs-1-55/JJ	nn||level-57/NN||-RSB--56/NN	prep_at||signaling-47/VBG||level-57/NN	insulin-50||insulinresistance-35||no_rel||a dual effect on insulin action was observed when myotubes and mice were exposed to this cytokine additive with short-term insulin (increased glucose uptake and systemic insulin sensitivity) but chronic exposure produced insulinresistance (impaired glut4 translocation to plasma membrane and defects in insulin signaling at the insulin receptor substrate 1 [irs-1] level).
nsubj||anaemia-7/VBN||one-1/CD	nsubj||deficiencyoffolicacid-9/VBN||one-1/CD	det||women-5/NNS||every-3/DT	num||women-5/NNS||three-4/CD	prep_in||one-1/CD||women-5/NNS	aux||anaemia-7/VBN||had-6/VBD	root||ROOT-0/null||anaemia-7/VBN	conj_and||anaemia-7/VBN||deficiencyoffolicacid-9/VBN	mark||had-15/VBD||while-10/IN	nsubj||had-15/VBD||one-11/CD	det||two-14/CD||every-13/DT	prep_in||one-11/CD||two-14/CD	advcl||anaemia-7/VBN||had-15/VBD	dobj||had-15/VBD||irondeficiency-16/NN	vmod||had-15/VBD||suggesting-18/VBG	mark||constitute-26/VBP||that-19/IN	nsubj||constitute-26/VBP||deficiencies-20/NNS	preconj||folicacid-23/NN||both-22/DT	prep_of||deficiencies-20/NNS||folicacid-23/NN	prep_of||deficiencies-20/NNS||iron-25/NN	conj_and||folicacid-23/NN||iron-25/NN	ccomp||suggesting-18/VBG||constitute-26/VBP	det||deficiencies-30/NNS||the-27/DT	amod||deficiencies-30/NNS||major-28/JJ	nn||deficiencies-30/NNS||micronutrient-29/NN	dobj||constitute-26/VBP||deficiencies-30/NNS	nn||women-33/NNS||ethiopian-32/NN	prep_in||deficiencies-30/NNS||women-33/NNS	deficiencyoffolicacid-9||folicacid-23||yes||one in every three women had anaemia and deficiencyoffolicacid while one in every two had irondeficiency, suggesting that deficiencies of both folicacid and iron constitute the major micronutrient deficiencies in ethiopian women.
amod||s.aureus-2/NNS||methicillin-resistant-1/JJ	nsubj||-lrb--3/VBD||s.aureus-2/NNS	root||ROOT-0/null||-lrb--3/VBD	nn||-rrb--5/NNP||mrsa-4/NNP	nsubj||responsible-7/JJ||-rrb--5/NNP	cop||responsible-7/JJ||was-6/VBD	ccomp||-lrb--3/VBD||responsible-7/JJ	num||%-10/NN||28-9/CD	prep_for||responsible-7/JJ||%-10/NN	prep_of||%-10/NN||infections-12/NNS	pobj||of-15/IN||infections-12/NNS	dep||of-15/IN||all-14/DT	nsubj||healthcare-associated-18/JJ||of-15/IN	cop||healthcare-associated-18/JJ||were-17/VBD	rcmod||infections-12/NNS||healthcare-associated-18/JJ	mrsa-4||s.aureus-2||no||methicillin-resistant s.aureus -lrb- mrsa -rrb- was responsible for 28 % of infections , all of which were healthcare-associated .
amod||subjects-2/NNS||forty-nine-1/JJ	nsubjpass||enrolled-66/VBN||subjects-2/NNS	amod||renalcellcarcinoma-5/NN||metastatic-4/JJ	prep_with||subjects-2/NNS||renalcellcarcinoma-5/NN	nsubj||underwent-17/VBD||renalcellcarcinoma-5/NN	num||recipients-10/NNS||21-7/CD	nn||recipients-10/NNS||target-8/NN	nn||recipients-10/NNS||therapy-9/NN	dep||renalcellcarcinoma-5/NN||recipients-10/NNS	num||recipients-14/NNS||28-12/CD	amod||recipients-14/NNS||immunochemotherapy-13/JJ	dep||renalcellcarcinoma-5/NN||recipients-14/NNS	conj_and||recipients-10/NNS||recipients-14/NNS	rcmod||renalcellcarcinoma-5/NN||underwent-17/VBD	det||cycles-20/NNS||either-18/DT	amod||cycles-20/NNS||6-week-19/JJ	dobj||underwent-17/VBD||cycles-20/NNS	amod||treatment-23/NN||sunitinib-22/JJ	prep_of||cycles-20/NNS||treatment-23/NN	dep||subjects-2/NNS||50-25/CD	vmod||50-25/CD||mg-26/VBN	advmod||daily-28/JJ||once-27/RB	advmod||mg-26/VBN||daily-28/JJ	prep||daily-28/JJ||for-29/IN	num||weeks-31/NNS||4-30/CD	npadvmod||on-32/IN||weeks-31/NNS	pcomp||for-29/IN||on-32/IN	num||weeks-35/NNS||2-34/CD	npadvmod||off-36/RB||weeks-35/NNS	advmod||mg-26/VBN||off-36/RB	conj_and||daily-28/JJ||off-36/RB	amod||cycles-40/NNS||8-week-39/JJ	conj_or||subjects-2/NNS||cycles-40/NNS	nsubjpass||enrolled-66/VBN||cycles-40/NNS	prep_of||cycles-40/NNS||immunochemotherapy-42/NN	dep||cycles-40/NNS||combination-44/NN	amod||il-48/NN||interleukin-46/JJ	amod||il-48/NN||-LSB--47/JJ	prep_of||combination-44/NN||il-48/NN	vmod||combination-44/NN||-RSB--49/VBN	dobj||-RSB--49/VBN||-2-50/CD	amod||-RSB--55/NNS||interferon-52/JJ	amod||-RSB--55/NNS||-LSB--53/JJ	nn||-RSB--55/NNS||ifn-54/NN	appos||-2-50/CD||-RSB--55/NNS	amod||-2-50/CD||alpha-57/NN	amod||-2-50/CD||5-fluorouracil-60/VBG	conj_and||alpha-57/NN||5-fluorouracil-60/VBG	amod||-RSB--63/NNS||-LSB--61/JJ	nn||-RSB--63/NNS||fu-62/NN	dobj||5-fluorouracil-60/VBG||-RSB--63/NNS	auxpass||enrolled-66/VBN||were-65/VBD	root||ROOT-0/null||enrolled-66/VBN	renalcellcarcinoma-5||ifn-54||yes||forty-nine subjects with metastatic renalcellcarcinoma (21 target therapy recipients and 28 immunochemotherapy recipients) who underwent either 6-week cycles of sunitinib treatment (50 mg once daily for 4 weeks on and 2 weeks off) or 8-week cycles of immunochemotherapy (combination of interleukin [il]-2, interferon [ifn]-alpha, and 5-fluorouracil [fu]) were enrolled.
nsubj||increased-7/VBD||bortezomib-1/NN	vmod||bortezomib-1/NN||used-2/VBN	amod||treatment-5/NN||first-line-4/JJ	prep_as||used-2/VBN||treatment-5/NN	advmod||increased-7/VBD||significantly-6/RB	root||ROOT-0/null||increased-7/VBD	nn||deposition-9/NN||collagen-8/NN	dobj||increased-7/VBD||deposition-9/NN	prep_in||increased-7/VBD||patients-11/NNS	nn||lesions-16/NNS||multiplemyeloma-13/NN	conj_and||multiplemyeloma-13/NN||osteolytic-15/NN	nn||lesions-16/NNS||osteolytic-15/NN	prep_with||increased-7/VBD||lesions-16/NNS	det||addition-20/NN||the-19/DT	nsubj||inhibited-28/VBD||addition-20/NN	det||transiently-27/NN||a-22/DT	amod||transiently-27/NN||glucocorticoid-23/JJ	det||treatment-26/NN||the-25/DT	prep_to||glucocorticoid-23/JJ||treatment-26/NN	prep_of||addition-20/NN||transiently-27/NN	conj_but||increased-7/VBD||inhibited-28/VBD	det||effect-31/NN||the-29/DT	amod||effect-31/NN||positive-30/JJ	dobj||inhibited-28/VBD||effect-31/NN	prep_of||effect-31/NN||bortezomib-33/NN	vmod||inhibited-28/VBD||suggesting-35/VBG	mark||result-39/VB||that-36/IN	nsubj||result-39/VB||bortezomib-37/NN	aux||result-39/VB||may-38/MD	ccomp||suggesting-35/VBG||result-39/VB	amod||healing-42/NN||better-41/JJR	prep_in||result-39/VB||healing-42/NN	amod||lesions-45/NNS||osteolytic-44/JJ	prep_of||healing-42/NN||lesions-45/NNS	advmod||used-47/VBN||when-46/WRB	advcl||result-39/VB||used-47/VBN	prep_without||used-47/VBN||glucocorticoids-49/NNS	prep_in||glucocorticoids-49/NNS||patients-51/NNS	nsubj||obtained-54/VBN||patients-51/NNS	aux||obtained-54/VBN||have-53/VBP	rcmod||patients-51/NNS||obtained-54/VBN	dobj||obtained-54/VBN||remission-55/NN	det||therapy-59/NN||a-57/DT	amod||therapy-59/NN||previous-58/JJ	prep_with||obtained-54/VBN||therapy-59/NN	multiplemyeloma-13||bortezomib-37||yes||bortezomib used as first-line treatment significantly increased collagen deposition in patients with multiplemyeloma and osteolytic lesions, but the addition of a glucocorticoid to the treatment transiently inhibited the positive effect of bortezomib, suggesting that bortezomib may result in better healing of osteolytic lesions when used without glucocorticoids in patients that have obtained remission with a previous therapy.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||significance-5/NN||the-3/DT	amod||significance-5/NN||clinical-4/JJ	dobj||investigated-2/VBD||significance-5/NN	amod||immunoglobulin-9/NN||serum-7/JJ	amod||immunoglobulin-9/NN||specific-8/JJ	prep_of||significance-5/NN||immunoglobulin-9/NN	dep||significance-5/NN||e-10/SYM	appos||significance-5/NN||lge-12/NN	det||enterotoxin-19/NN||the-15/DT	amod||enterotoxin-19/NN||staphylococcal-16/JJ	nn||enterotoxin-19/NN||superantigens-17/NNS	nn||enterotoxin-19/NN||staphylococcal-18/NN	prep_to||investigated-2/VBD||enterotoxin-19/NN	det||sea-22/NN||a-20/DT	dep||enterotoxin-19/NN||sea-22/NN	amod||enterotoxin-26/NN||staphylococcal-25/JJ	prep_to||investigated-2/VBD||enterotoxin-26/NN	conj_and||enterotoxin-19/NN||enterotoxin-26/NN	dep||enterotoxin-26/NN||b-27/SYM	appos||b-27/SYM||seb-29/NN	amod||toxin-34/NN||toxicshocksyndrome-33/JJ	prep_to||investigated-2/VBD||toxin-34/NN	conj_and||enterotoxin-19/NN||toxin-34/NN	appos||toxin-34/NN||tsst-36/NN	dep||toxin-34/NN||-1-38/CD	prep_in||investigated-2/VBD||patients-40/NNS	amod||urticaria-43/NN||chronic-42/JJ	prep_with||patients-40/NNS||urticaria-43/NN	appos||urticaria-43/NN||cu-45/NN	vmod||investigated-2/VBD||focusing-48/VBG	det||differences-51/NNS||the-50/DT	prep_on||focusing-48/VBG||differences-51/NNS	det||prevalences-54/NNS||these-53/DT	prep_in||differences-51/NNS||prevalences-54/NNS	amod||cu-57/NN||aspirin-intolerant-56/JJ	prep_between||prevalences-54/NNS||cu-57/NN	appos||cu-57/NN||aicu-59/NNP	amod||patients-67/NNS||aspirin-tolerant-62/JJ	nn||patients-67/NNS||cu-63/NN	appos||patients-67/NNS||atcu-65/NNP	prep_between||prevalences-54/NNS||patients-67/NNS	conj_and||cu-57/NN||patients-67/NNS	cu-63||toxicshocksyndrome-33||no_rel||we investigated the clinical significance of serum specific immunoglobulin e (lge) to the staphylococcal superantigens staphylococcal enterotoxin a (sea), staphylococcal enterotoxin b (seb), and toxicshocksyndrome toxin (tsst)-1 in patients with chronic urticaria (cu), focusing on the differences in these prevalences between aspirin-intolerant cu (aicu) and aspirin-tolerant cu (atcu) patients.
mark||activated-4/VBN||although-1/IN	nsubjpass||activated-4/VBN||it-2/PRP	nsubjpass||related-11/VBN||it-2/PRP	auxpass||activated-4/VBN||is-3/VBZ	advcl||same-19/JJ||activated-4/VBN	det||system-8/NN||the-6/DT	amod||system-8/NN||immune-7/JJ	agent||activated-4/VBN||system-8/NN	auxpass||related-11/VBN||is-10/VBZ	conj_and||activated-4/VBN||related-11/VBN	advcl||same-19/JJ||related-11/VBN	prep_to||related-11/VBN||allergicreactions-13/NNS	nsubj||same-19/JJ||it-15/PRP	cop||same-19/JJ||is-16/VBZ	neg||same-19/JJ||not-17/RB	det||same-19/JJ||the-18/DT	root||ROOT-0/null||same-19/JJ	amod||allergicreactions-22/NNS||other-21/JJ	prep_as||same-19/JJ||allergicreactions-22/NNS	allergicreactions-22||allergicreactions-22||no||although it is activated by the immune system and is related to allergicreactions, it is not the same as other allergicreactions.
nn||rates-2/NNS||death-1/NN	nsubj||decreased-3/VBD||rates-2/NNS	root||ROOT-0/null||decreased-3/VBD	prep_over||decreased-3/VBD||time-5/NN	mark||increased-19/VBD||as-6/IN	det||percentage-8/NN||the-7/DT	nsubj||increased-19/VBD||percentage-8/NN	prep_of||percentage-8/NN||people-10/NNS	vmod||people-10/NNS||living-11/VBG	prep_with||living-11/VBG||hiv/aids-13/NNS	vmod||hiv/aids-13/NNS||enrolled-14/VBN	prep_into||enrolled-14/VBN||care-16/NN	prep_into||enrolled-14/VBN||art-18/NN	conj_and||care-16/NN||art-18/NN	advcl||decreased-3/VBD||increased-19/VBD	aids--1||hiv--1||no||death rates decreased over time as the percentage of people living with hiv/aids enrolled into care and art increased.
amod||resonance-4/NN||manganese-enhanced-1/JJ	amod||resonance-4/NN||cardiovascular-2/JJ	amod||resonance-4/NN||magnetic-3/JJ	nsubj||assess-10/VB||resonance-4/NN	appos||resonance-4/NN||mecmr-6/NN	aux||assess-10/VB||can-8/MD	advmod||assess-10/VB||non-invasively-9/RB	root||ROOT-0/null||assess-10/VB	amod||influx-13/NN||myocardial-11/JJ	nn||influx-13/NN||calcium-12/NN	dobj||assess-10/VB||influx-13/NN	nn||levels-17/NNS||calcium-16/NN	nsubjpass||known-19/VBN||levels-17/NNS	nsubjpass||elevated-22/VBN||levels-17/NNS	auxpass||known-19/VBN||are-18/VBP	conj_and||assess-10/VB||known-19/VBN	aux||elevated-22/VBN||to-20/TO	auxpass||elevated-22/VBN||be-21/VB	xcomp||known-19/VBN||elevated-22/VBN	amod||cardiomyopathy-25/NN||musculardystrophy-24/JJ	prep_in||elevated-22/VBN||cardiomyopathy-25/NN	prepc_based_on||elevated-22/VBN||on-27/IN	amod||studies-29/NNS||cellular-28/JJ	pobj||elevated-22/VBN||studies-29/NNS	calcium-16||musculardystrophy-24||no_rel||manganese-enhanced cardiovascular magnetic resonance (mecmr) can non-invasively assess myocardial calcium influx, and calcium levels are known to be elevated in musculardystrophy cardiomyopathy based on cellular studies.
num||infections-3/NNS||three-1/CD	amod||infections-3/NNS||severe-2/JJ	nsubjpass||detected-5/VBN||infections-3/NNS	nsubjpass||detected-5/VBN||infections-3/NNS	nsubjpass||detected-5/VBN||infections-3/NNS	auxpass||detected-5/VBN||were-4/VBD	root||ROOT-0/null||detected-5/VBN	conj_and||detected-5/VBN||detected-5/VBN	conj_and||detected-5/VBN||detected-5/VBN	det||mutation-8/NN||a-7/DT	prep_with||detected-5/VBN||mutation-8/NN	nn||222-12/NNS||ha-10/NN	nn||222-12/NNS||residue-11/NN	prep_at||mutation-8/NN||222-12/NNS	num||viruses-16/NNS||two-15/CD	prep_in||detected-5/VBN||viruses-16/NNS	det||d222g-20/NN||a-18/DT	nn||d222g-20/NN||change-19/NN	prep_with||viruses-16/NNS||d222g-20/NN	num||d222y-26/NNS||one-24/CD	nn||d222y-26/NNS||virus-25/NN	prep_in||detected-5/VBN||d222y-26/NNS	virus-25||viruses-16||no||three severe infections were detected with a mutation at ha residue 222, in two viruses with a change d222g, and in one virus d222y.
nsubj||have-7/VB||efforts-1/NNS	aux||reduce-3/VB||to-2/TO	vmod||efforts-1/NNS||reduce-3/VB	amod||deaths-5/NNS||hiv/aids-4/JJ	dobj||reduce-3/VB||deaths-5/NNS	aux||have-7/VB||could-6/MD	root||ROOT-0/null||have-7/VB	amod||â-9/NN||large-8/JJ	dobj||have-7/VB||â-9/NN	iobj||have-7/VB||â-9/NN	dep||â-9/NN||$-10/$	num||$-10/$||spilloverâ-11/CD	dep||$-10/$||$-12/$	dep||africa-18/CD||benefits-13/NNS	amod||people-16/NNS||elderly-15/JJ	prep_for||benefits-13/NNS||people-16/NNS	prep||benefits-13/NNS||in-17/IN	num||$-12/$||africa-18/CD	aids--1||hiv--1||no||efforts to reduce hiv/aids deaths could have large âspilloverâ? benefits for elderly people in africa.
det||change-3/NN||the-1/DT	amod||change-3/NN||recent-2/JJ	nsubjpass||accompanied-20/VBN||change-3/NN	nn||policy-6/NN||treatment-5/NN	prep_of||change-3/NN||policy-6/NN	amod||malaria-9/NN||uncomplicated-8/JJ	prep_for||policy-6/NN||malaria-9/NN	prep_from||malaria-9/NN||sulfadoxine-pyrime-thamine-11/NN	prep_to||sulfadoxine-pyrime-thamine-11/NN||artemether-lumefantrine-13/NN	appos||artemether-lumefantrine-13/NN||al-15/NNP	prep_in||artemether-lumefantrine-13/NN||kenya-18/NN	auxpass||accompanied-20/VBN||was-19/VBD	root||ROOT-0/null||accompanied-20/VBN	amod||recommendations-25/NNS||revised-22/VBN	nn||recommendations-25/NNS||malaria-23/NN	nn||recommendations-25/NNS||diagnosis-24/NN	nsubj||promoting-26/VBG||recommendations-25/NNS	agent||accompanied-20/VBN||promoting-26/VBG	amod||treatment-29/NN||presumptive-27/JJ	amod||treatment-29/NN||antimalarial-28/JJ	dobj||promoting-26/VBG||treatment-29/NN	amod||children-32/NNS||young-31/JJ	prep_in||treatment-29/NN||children-32/NNS	amod||diagnosis-35/NN||parasitological-34/JJ	dobj||promoting-26/VBG||diagnosis-35/NN	conj_and||treatment-29/NN||diagnosis-35/NN	prep_in||diagnosis-35/NN||patients-37/NNS	num||years-39/NNS||5-38/CD	dep||promoting-26/VBG||years-39/NNS	dep||promoting-26/VBG||older-41/JJR	conj_and||years-39/NNS||older-41/JJR	malaria-23||artemether--1||yes||the recent change of treatment policy for uncomplicated malaria from sulfadoxine-pyrime-thamine to artemether-lumefantrine (al) in kenya was accompanied by revised malaria diagnosis recommendations promoting presumptive antimalarial treatment in young children and parasitological diagnosis in patients 5 years and older.
amod||modulation-2/NN||immune-1/JJ	nsubj||improved-7/VBD||modulation-2/NN	nsubj||resulted-11/VBD||modulation-2/NN	prep||modulation-2/NN||combined-3/VBN	pcomp||combined-3/VBN||with-4/IN	nn||treatment-6/NN||inh-5/NN	pobj||with-4/IN||treatment-6/NN	root||ROOT-0/null||improved-7/VBD	amod||clearance-9/NN||bacillary-8/JJ	dobj||improved-7/VBD||clearance-9/NN	conj_and||improved-7/VBD||resulted-11/VBD	amod||granulomas-14/NNS||smaller-13/JJR	prep_in||resulted-11/VBD||granulomas-14/NNS	amod||pathology-18/NN||less-16/JJR	nn||pathology-18/NN||lung-17/NN	prep_in||resulted-11/VBD||pathology-18/NN	conj_and||granulomas-14/NNS||pathology-18/NN	prepc_compared_to||improved-7/VBD||to-21/TO	pobj||improved-7/VBD||treatment-22/NN	prep_with||treatment-22/NN||inh-24/NN	advmod||inh-24/NN||alone-25/RB	granulomas-14||inh-24||no_rel||immune modulation combined with inh treatment improved bacillary clearance and resulted in smaller granulomas and less lung pathology, compared to treatment with inh alone.
aux||compare-2/VB||to-1/TO	csubj||bloodglucose-11/VBP||compare-2/VB	dobj||compare-2/VB||effects-3/NNS	prep_of||effects-3/NNS||ly2605541-5/NNS	prep_versus||ly2605541-5/NNS||insulinglargine-7/NN	amod||mean-10/NN||daily-9/JJ	prep_on||compare-2/VB||mean-10/NN	root||ROOT-0/null||bloodglucose-11/VBP	prep_as||bloodglucose-11/VBP||part-13/NN	det||regimen-17/NN||a-15/DT	amod||regimen-17/NN||basal-bolus-16/JJ	prep_of||part-13/NN||regimen-17/NN	prep_for||regimen-17/NN||type1diabetes-19/CD	type1diabetes-19||insulinglargine-7||yes||to compare effects of ly2605541 versus insulinglargine on daily mean bloodglucose as part of a basal-bolus regimen for type1diabetes.
nsubj||extended-3/VBN||we-1/PRP	aux||extended-3/VBN||have-2/VBP	ccomp||transferred-17/VBD||extended-3/VBN	det||use-5/NN||the-4/DT	dobj||extended-3/VBN||use-5/NN	amod||therapy-9/NN||nis-mediated-7/JJ	nn||therapy-9/NN||radioiodine-8/NN	prep_of||use-5/NN||therapy-9/NN	amod||types-12/NNS||other-11/JJ	prep_to||extended-3/VBN||types-12/NNS	prep_of||types-12/NNS||cancer-14/NN	nsubj||transferred-17/VBD||we-16/PRP	nsubj||expressed-19/VBD||we-16/PRP	root||ROOT-0/null||transferred-17/VBD	conj_and||transferred-17/VBD||expressed-19/VBD	det||gene-26/NN||the-20/DT	amod||gene-26/NN||sodium-iodide-21/JJ	nn||gene-26/NN||symporter-22/NN	appos||gene-26/NN||nis-24/NN	dobj||expressed-19/VBD||gene-26/NN	prep_into||expressed-19/VBD||prostate-28/NN	prep_into||expressed-19/VBD||colon-30/NN	conj_and||prostate-28/NN||colon-30/NN	nn||cells-35/NNS||breast-33/NN	nn||cells-35/NNS||cancer-34/NN	prep_into||expressed-19/VBD||cells-35/NNS	conj_and||prostate-28/NN||cells-35/NNS	xcomp||expressed-19/VBD||using-36/VBG	amod||vectors-38/NNS||adenoviral-37/JJ	dobj||using-36/VBG||vectors-38/NNS	iodide--1||cancer-34||no_rel||we have extended the use of nis-mediated radioiodine therapy to other types of cancer, we transferred and expressed the sodium-iodide symporter (nis) gene into prostate, colon, and breast cancer cells using adenoviral vectors.
det||use-2/NN||the-1/DT	nsubj||rare-9/JJ||use-2/NN	prep_of||use-2/NN||paracetamol-4/NNP	nn||pain-7/NN||knee-6/NN	prep_for||paracetamol-4/NNP||pain-7/NN	cop||rare-9/JJ||was-8/VBD	root||ROOT-0/null||rare-9/JJ	num||%-12/NN||6-11/CD	dep||rare-9/JJ||%-12/NN	num||%-15/NN||2-14/CD	dep||rare-9/JJ||%-15/NN	conj_versus||%-12/NN||%-15/NN	pain-7||paracetamol-4||yes||the use of paracetamol for knee pain was rare (6% versus 2%).
num||%-2/NN||64-1/CD	nsubj||had-6/VBD||%-2/NN	det||patients-5/NNS||all-4/DT	prep_of||%-2/NN||patients-5/NNS	root||ROOT-0/null||had-6/VBD	det||condition-10/NN||a-7/DT	amod||condition-10/NN||pre-existing-8/JJ	nn||condition-10/NN||immunosuppressive-9/NN	dobj||had-6/VBD||condition-10/NN	num||%-13/NN||10-12/CD	nsubj||hivpositive-15/JJ||%-13/NN	cop||hivpositive-15/JJ||were-14/VBD	conj_and||had-6/VBD||hivpositive-15/JJ	num||%-18/NN||48-17/CD	nsubj||seronegative-21/JJ||%-18/NN	cop||seronegative-21/JJ||were-19/VBD	advmod||seronegative-21/JJ||hiv-20/RB	conj_and||had-6/VBD||seronegative-21/JJ	num||%-24/NN||42-23/CD	nsubj||had-25/VBD||%-24/NN	conj_and||had-6/VBD||had-25/VBD	det||status-29/NN||an-26/DT	amod||status-29/NN||unknown-27/JJ	nn||status-29/NN||hiv-28/NN	dobj||had-25/VBD||status-29/NN	hivpositive-15||hiv-28||no||64% of all patients had a pre-existing immunosuppressive condition; 10% were hivpositive, 48% were hiv seronegative and 42% had an unknown hiv status.
neg||differences-4/NNS||no-1/DT	amod||differences-4/NNS||significant-2/JJ	amod||differences-4/NNS||ethnic-3/JJ	nsubjpass||detected-6/VBN||differences-4/NNS	auxpass||detected-6/VBN||were-5/VBD	root||ROOT-0/null||detected-6/VBN	amod||status-9/NN||node-8/JJ	prep_for||detected-6/VBN||status-9/NN	nn||type-12/NN||tumour-11/NN	prep_for||detected-6/VBN||type-12/NN	conj_or||status-9/NN||type-12/NN	nn||size-15/NN||tumour-14/NN	prep_for||detected-6/VBN||size-15/NN	conj_or||status-9/NN||size-15/NN	amod||receptor-21/NN||human-17/JJ	nn||receptor-21/NN||epidermal-18/NN	nn||receptor-21/NN||growth-19/NN	nn||receptor-21/NN||factor-20/NN	prep_for||detected-6/VBN||receptor-21/NN	conj_or||status-9/NN||receptor-21/NN	nn||receptor-26/NN||oestrogen-23/NN	conj_and||oestrogen-23/NN||progesterone-25/NN	nn||receptor-26/NN||progesterone-25/NN	prep_for||detected-6/VBN||receptor-26/NN	conj_or||status-9/NN||receptor-26/NN	appos||receptor-26/NN||er/pr-28/NN	dep||receptor-26/NN||status-30/NN	prep_for||detected-6/VBN||survival-33/NN	conj_or||status-9/NN||survival-33/NN	progesterone-25||tumour-14||no_rel||no significant ethnic differences were detected for node status, tumour type, tumour size, human epidermal growth factor receptor, oestrogen and progesterone receptor (er/pr) status, or survival.
amod||levels-3/NNS||s100a12-1/JJ	nn||levels-3/NNS||serum-2/NN	nsubjpass||determined-5/VBN||levels-3/NNS	auxpass||determined-5/VBN||were-4/VBD	root||ROOT-0/null||determined-5/VBN	num||patients-8/NNS||64-7/CD	prep_in||determined-5/VBN||patients-8/NNS	prep_with||patients-8/NNS||ulcerativecolitis-10/NNS	appos||ulcerativecolitis-10/NNS||uc-12/NN	prep_in||determined-5/VBN||64-15/CD	conj_and||patients-8/NNS||64-15/CD	prep_with||64-15/CD||crohn-17/NN	dep||crohn-17/NN||sdisease-19/NN	appos||crohn-17/NN||cd-21/NN	prep_in||determined-5/VBN||73-24/CD	conj_and||patients-8/NNS||73-24/CD	prep_with||73-24/CD||ibs-26/NN	det||assay-34/NN||an-31/DT	amod||assay-34/NN||enzyme-linked-32/JJ	nn||assay-34/NN||immunosorbent-33/NN	prep_by_means_of||determined-5/VBN||assay-34/NN	uc-12||cd-21||no_rel||s100a12 serum levels were determined in 64 patients with ulcerativecolitis (uc), 64 with crohn'sdisease (cd) and 73 with ibs, by means of an enzyme-linked immunosorbent assay.
amod||deficiency-3/NN||steroid-1/JJ	amod||deficiency-3/NN||21-hydroxylase-2/JJ	nsubj||accounts-4/VBZ||deficiency-3/NN	root||ROOT-0/null||accounts-4/VBZ	quantmod||95-7/CD||about-6/RB	num||%-8/NN||95-7/CD	prep_for||accounts-4/VBZ||%-8/NN	prep_of||%-8/NN||cases-10/NNS	prep_of||cases-10/NNS||congenitaladrenalhyperplasia-12/NN	appos||congenitaladrenalhyperplasia-12/NN||cah-14/NN	steroid-1||congenitaladrenalhyperplasia-12||no_rel||steroid 21-hydroxylase deficiency accounts for about 95% of cases of congenitaladrenalhyperplasia (cah).
det||bioactivity-2/NN||the-1/DT	nsubj||greater-20/JJR||bioactivity-2/NN	det||fraction-6/NN||the-4/DT	amod||fraction-6/NN||composite-5/JJ	prep_of||bioactivity-2/NN||fraction-6/NN	prepc_in||fraction-6/NN||enhancing-8/VBG	det||effect-11/NN||the-9/DT	amod||effect-11/NN||antibacterial-10/JJ	dobj||enhancing-8/VBG||effect-11/NN	prep_of||effect-11/NN||oxacillin-13/NN	prep_against||oxacillin-13/NN||methicillin-resistantstaphylococcusaureus-15/NNS	appos||methicillin-resistantstaphylococcusaureus-15/NNS||mrsa-17/NNP	cop||greater-20/JJR||was-19/VBD	root||ROOT-0/null||greater-20/JJR	mark||extract-30/VB||than-21/IN	nsubj||extract-30/VB||that-22/DT	det||monomer-26/NN||the-24/DT	amod||monomer-26/NN||individual-25/JJ	prep_of||that-22/DT||monomer-26/NN	det||hawthorn-29/NN||the-28/DT	prep_of||monomer-26/NN||hawthorn-29/NN	ccomp||greater-20/JJR||extract-30/VB	prep_in||extract-30/VB||vitro-32/NN	mrsa-17||oxacillin-13||no_rel||the bioactivity of the composite fraction in enhancing the antibacterial effect of oxacillin against methicillin-resistantstaphylococcusaureus (mrsa) was greater than that of the individual monomer of the hawthorn extract in vitro .
det||study-2/NN||this-1/DT	nsubj||gives-3/VBZ||study-2/NN	root||ROOT-0/null||gives-3/VBZ	iobj||gives-3/VBZ||us-4/PRP	det||knowledge-9/NN||an-5/DT	amod||knowledge-9/NN||overview-6/JJ	prep_about||overview-6/JJ||hiv/aids-8/NNS	dobj||gives-3/VBZ||knowledge-9/NN	prep_in||knowledge-9/NN||detention-11/NN	nn||province-14/NN||hunan-13/NN	prep_in||detention-11/NN||province-14/NN	det||sites-19/NNS||all-17/DT	nn||sites-19/NNS||detention-18/NN	nsubj||provided-23/VBD||sites-19/NNS	det||study-22/NN||the-21/DT	prep_in||sites-19/NNS||study-22/NN	conj_and||gives-3/VBZ||provided-23/VBD	amod||services-26/NNS||hiv/aids-24/JJ	nn||services-26/NNS||intervention-25/NN	dobj||provided-23/VBD||services-26/NNS	prep_among||provided-23/VBD||detainees-28/NNS	nsubj||focused-30/VBN||detainees-28/NNS	rcmod||detainees-28/NNS||focused-30/VBN	amod||attitude-35/NN||hiv/aids-32/JJ	nn||attitude-35/NN||knowledge-33/NN	prep_on||focused-30/VBN||attitude-35/NN	nn||behaviors-39/NNS||health-38/NN	prep_on||focused-30/VBN||behaviors-39/NNS	conj_and||attitude-35/NN||behaviors-39/NNS	aids--1||hiv--1||no||this study gives us an overview about hiv/aids knowledge in detention in hunan province, and all detention sites in the study provided hiv/aids intervention services among detainees that focused on hiv/aids knowledge, attitude, and health behaviors.
nsubjpass||shown-10/VBN||bortezomib-1/NN	nsubj||have-12/VB||bortezomib-1/NN	det||inhibitor-6/NN||the-3/DT	amod||inhibitor-6/NN||first-in-class-4/JJ	nn||inhibitor-6/NN||proteasome-5/NN	appos||bortezomib-1/NN||inhibitor-6/NN	aux||shown-10/VBN||has-8/VBZ	auxpass||shown-10/VBN||been-9/VBN	root||ROOT-0/null||shown-10/VBN	aux||have-12/VB||to-11/TO	xcomp||shown-10/VBN||have-12/VB	det||activity-16/NN||a-13/DT	amod||activity-16/NN||significant-14/JJ	nn||activity-16/NN||antitumor-15/NN	dobj||have-12/VB||activity-16/NN	det||treatment-19/NN||the-18/DT	prep_in||activity-16/NN||treatment-19/NN	amod||patients-22/NNS||relapse/refractory-21/JJ	prep_of||treatment-19/NN||patients-22/NNS	prep_with||have-12/VB||multiplemyeloma-24/NN	multiplemyeloma-24||bortezomib-1||yes||bortezomib, the first-in-class proteasome inhibitor, has been shown to have a significant antitumor activity in the treatment of relapse/refractory patients with multiplemyeloma.
amod||exposure-2/NN||chronic-1/JJ	nsubj||induces-5/VBZ||exposure-2/NN	prep_to||exposure-2/NN||drugsofabuse-4/NN	root||ROOT-0/null||induces-5/VBZ	amod||modifications-7/NNS||important-6/JJ	dobj||induces-5/VBZ||modifications-7/NNS	amod||systems-10/NNS||neuronal-9/JJ	prep_on||modifications-7/NNS||systems-10/NNS	det||system-15/NN||the-13/DT	amod||system-15/NN||dopaminergic-14/JJ	prep_including||modifications-7/NNS||system-15/NN	drugsofabuse-4||dopaminergic-14||no_rel||chronic exposure to drugsofabuse induces important modifications on neuronal systems, including the dopaminergic system.
det||control-3/NN||the-1/DT	amod||control-3/NN||profound-2/JJ	nsubj||oxidant-9/VB||control-3/NN	nsubj||ros-32/VB||control-3/NN	prep_of||control-3/NN||aunps-5/NNS	det||anti-8/NN||the-7/DT	prep_over||aunps-5/NNS||anti-8/NN	root||ROOT-0/null||oxidant-9/VB	dobj||oxidant-9/VB||enzymes-10/NNS	prep_such_as||enzymes-10/NNS||gsh-13/NN	prep_such_as||enzymes-10/NNS||sod-15/NN	conj_and||gsh-13/NN||sod-15/NN	prep_such_as||enzymes-10/NNS||catalase-17/NN	conj_and||gsh-13/NN||catalase-17/NN	prep_such_as||enzymes-10/NNS||gpx-19/NN	conj_and||gsh-13/NN||gpx-19/NN	amod||mice-22/NNS||diabetic-21/JJ	prep_in||oxidant-9/VB||mice-22/NNS	prep_to||oxidant-9/VB||normal-24/JJ	prep_by||oxidant-9/VB||inhibition-27/NN	nn||peroxidation-30/NN||lipid-29/NN	prep_of||inhibition-27/NN||peroxidation-30/NN	conj_and||oxidant-9/VB||ros-32/VB	dobj||ros-32/VB||generation-33/NN	nn||evidence-36/NN||hyperglycemia-35/NN	prep_during||ros-32/VB||evidence-36/NN	poss||effect-39/NN||their-37/PRP$	amod||effect-39/NN||anti-oxidant-38/JJ	dobj||oxidant-9/VB||effect-39/NN	prep_during||oxidant-9/VB||hyperglycemia-41/NN	lipid-29||hyperglycemia-41||no_rel||the profound control of aunps over the anti oxidant enzymes such as gsh, sod, catalase and gpx in diabetic mice to normal, by inhibition of lipid peroxidation and ros generation during hyperglycemia evidence their anti-oxidant effect during hyperglycemia.
nsubj||lidocaine-4/VBP||pretreatment-1/NN	prep_with||pretreatment-1/NN||iv-3/NN	root||ROOT-0/null||lidocaine-4/VBP	num||mg-6/NNP||40-5/CD	dobj||lidocaine-4/VBP||mg-6/NNP	nn||mg-10/NNS||ketamine-8/NNP	num||mg-10/NNS||25-9/CD	dobj||lidocaine-4/VBP||mg-10/NNS	conj_plus||mg-6/NNP||mg-10/NNS	det||tourniquet-14/NN||a-12/DT	nn||tourniquet-14/NN||rubber-13/NN	prep_with||lidocaine-4/VBP||tourniquet-14/NN	det||min-19/NN||the-16/DT	nn||min-19/NN||forearm-17/NNP	num||min-19/NN||1-18/CD	prep_on||tourniquet-14/NN||min-19/NN	mark||effective-28/JJ||before-20/IN	det||injection-22/NN||the-21/DT	nsubj||effective-28/JJ||injection-22/NN	nn||propofol-25/NN||microemulsion-24/NN	prep_of||injection-22/NN||propofol-25/NN	cop||effective-28/JJ||is-26/VBZ	advmod||effective-28/JJ||more-27/RBR	advcl||lidocaine-4/VBP||effective-28/JJ	nn||mg-32/NN||lidocaine-30/NN	num||mg-32/NN||40-31/CD	prep_than||effective-28/JJ||mg-32/NN	nn||mg-36/NN||ketamine-34/NN	num||mg-36/NN||25-35/CD	prep_than||effective-28/JJ||mg-36/NN	conj_or||mg-32/NN||mg-36/NN	advmod||effective-28/JJ||alone-37/RB	prepc_in||effective-28/JJ||preventing-39/VBG	dobj||preventing-39/VBG||pain-40/NN	det||injection-43/NN||the-42/DT	prep_from||preventing-39/VBG||injection-43/NN	nn||propofol-46/NN||microemulsion-45/NN	prep_of||injection-43/NN||propofol-46/NN	pain-40||propofol-46||yes||pretreatment with iv lidocaine 40 mg plus ketamine 25 mg with a rubber tourniquet on the forearm 1 min before the injection of microemulsion propofol is more effective than lidocaine 40 mg or ketamine 25 mg alone in preventing pain from the injection of microemulsion propofol.
nn||concentration-2/NN||muscle-1/NN	nsubj||different-18/JJ||concentration-2/NN	prep_of||concentration-2/NN||acylcarnitines-4/NNS	det||oxidation-14/NN||a-6/DT	dep||oxidation-14/NN||lipid-7/NNP	dep||lipid-7/NNP||intermediate-8/NNP	amod||²-12/NNS||fattyacid-10/JJ	nn||²-12/NNS||î-11/NN	prep_in||lipid-7/NNP||²-12/NNS	appos||concentration-2/NN||oxidation-14/NN	cop||different-18/JJ||was-16/VBD	neg||different-18/JJ||not-17/RB	root||ROOT-0/null||different-18/JJ	det||groups-22/NNS||the-20/DT	amod||groups-22/NNS||hpmc-21/JJ	prep_between||different-18/JJ||groups-22/NNS	nn||control-25/NN||obese-24/NN	prep_between||different-18/JJ||control-25/NN	conj_and||groups-22/NNS||control-25/NN	xcomp||different-18/JJ||suggesting-27/VBG	neg||oxidation-33/NN||no-28/DT	dep||oxidation-33/NN||change-29/NN	prep_in||change-29/NN||muscle-31/NN	amod||oxidation-33/NN||fattyacid-32/JJ	dobj||suggesting-27/VBG||oxidation-33/NN	prep_by||oxidation-33/NN||hpmc-35/NN	fattyacid-32||obese-24||no_rel||muscle concentration of acylcarnitines, a lipid intermediate in fattyacid î²-oxidation, was not different between the hpmc groups and obese control, suggesting no change in muscle fattyacid oxidation by hpmc.
aux||enhance-2/VB||to-1/TO	advcl||generated-22/VBN||enhance-2/VB	det||capabilities-5/NNS||the-3/DT	nn||capabilities-5/NNS||research-4/NN	dobj||enhance-2/VB||capabilities-5/NNS	prep_of||capabilities-5/NNS||investigators-7/NNS	vmod||investigators-7/NNS||interested-8/VBN	prep_in||interested-8/VBN||staphylococcusaureus-10/NNS	det||center-14/NN||the-12/DT	nn||center-14/NN||nebraska-13/NN	nsubj||generated-22/VBN||center-14/NN	amod||research-17/NN||staphylococcal-16/JJ	prep_for||center-14/NN||research-17/NN	appos||center-14/NN||csr-19/NN	aux||generated-22/VBN||has-21/VBZ	root||ROOT-0/null||generated-22/VBN	det||library-27/NN||a-23/DT	amod||library-27/NN||sequence-defined-24/JJ	amod||library-27/NN||transposon-25/JJ	amod||library-27/NN||mutant-26/JJ	dobj||generated-22/VBN||library-27/NN	dep||generated-22/VBN||consisting-28/VBG	num||strains-31/NNS||1,952-30/CD	prep_of||consisting-28/VBG||strains-31/NNS	dobj||consisting-28/VBG||each-33/DT	vmod||each-33/DT||containing-34/VBG	det||mutation-37/NN||a-35/DT	amod||mutation-37/NN||single-36/JJ	dobj||containing-34/VBG||mutation-37/NN	det||gene-41/NN||a-39/DT	amod||gene-41/NN||nonessential-40/JJ	prep_within||containing-34/VBG||gene-41/NN	det||epidemic-44/NN||the-43/DT	prep_of||gene-41/NN||epidemic-44/NN	amod||aureus-48/NN||community-associated-45/JJ	amod||aureus-48/NN||methicillin-resistant-46/JJ	nn||aureus-48/NN||s.â-47/NN	nsubj||isolate-52/VBP||aureus-48/NN	appos||aureus-48/NN||ca-mrsa-50/NNP	dep||containing-34/VBG||isolate-52/VBP	dobj||isolate-52/VBP||usa300-53/NNS	mrsa--1||staphylococcusaureus-10||no||to enhance the research capabilities of investigators interested in staphylococcusaureus , the nebraska center for staphylococcal research (csr) has generated a sequence-defined transposon mutant library consisting of 1,952 strains, each containing a single mutation within a nonessential gene of the epidemic community-associated methicillin-resistant s.â aureus (ca-mrsa) isolate usa300.
mark||observed-9/VBN||although-1/IN	amod||reductions-3/NNS||great-2/JJ	nsubjpass||observed-9/VBN||reductions-3/NNS	amod||schistosomiasis-6/NNS||human-5/JJ	prep_in||reductions-3/NNS||schistosomiasis-6/NNS	aux||observed-9/VBN||have-7/VBP	auxpass||observed-9/VBN||been-8/VBN	advcl||remain-24/VBP||observed-9/VBN	prep_after||observed-9/VBN||praziquantel-11/NN	appos||praziquantel-11/NN||pzq-13/NN	amod||administration-17/NN||mass-15/JJ	nn||administration-17/NN||drug-16/NN	dep||praziquantel-11/NN||administration-17/NN	appos||administration-17/NN||mda-19/NN	det||individuals-23/NNS||some-22/DT	nsubj||remain-24/VBP||individuals-23/NNS	root||ROOT-0/null||remain-24/VBP	acomp||remain-24/VBP||infected-25/VBN	amod||treatments-28/NNS||multiple-27/JJ	prep_after||infected-25/VBN||treatments-28/NNS	schistosomiasis-6||praziquantel-11||yes||although great reductions in human schistosomiasis have been observed after praziquantel (pzq) mass drug administration (mda), some individuals remain infected after multiple treatments.
det||combination-2/NN||a-1/DT	nsubjpass||discovered-35/VBN||combination-2/NN	num||genes-5/NNS||five-4/CD	prep_of||combination-2/NN||genes-5/NNS	nsubj||help-8/VB||genes-5/NNS	nsubj||predict-22/VB||genes-5/NNS	nsubj||contribute-27/VB||genes-5/NNS	aux||help-8/VB||may-7/MD	rcmod||genes-5/NNS||help-8/VB	ccomp||help-8/VB||distinguish-9/VB	nn||grade-11/NN||colonized-10/NN	dobj||distinguish-9/VB||grade-11/NN	num||grade-11/NN||1-12/CD	amod||-17/NNS||infected-14/JJ	nn||-17/NNS||grade-15/NN	nn||-17/NNS||â-16/NN	prep_from||distinguish-9/VB||-17/NNS	number||2-19/CD||¥-18/CD	num||wounds-20/NNS||2-19/CD	dep||distinguish-9/VB||wounds-20/NNS	rcmod||genes-5/NNS||predict-22/VB	conj_and||help-8/VB||predict-22/VB	nn||outcome-24/NN||ulcer-23/NN	dobj||predict-22/VB||outcome-24/NN	rcmod||genes-5/NNS||contribute-27/VB	conj_and||help-8/VB||contribute-27/VB	advmod||appropriate-30/JJ||more-29/RBR	amod||use-31/NN||appropriate-30/JJ	prep_to||contribute-27/VB||use-31/NN	prep_of||use-31/NN||antibiotics-33/NNS	auxpass||discovered-35/VBN||was-34/VBD	root||ROOT-0/null||discovered-35/VBN	ulcer-23||antibiotics-33||no_rel||a combination of five genes that may help distinguish colonized grade 1 from infected grade â¥2 wounds, predict ulcer outcome, and contribute to more appropriate use of antibiotics was discovered.
det||summarizes-3/NNS||this-1/DT	nn||summarizes-3/NNS||review-2/NN	nsubj||experiences-4/VBZ||summarizes-3/NNS	root||ROOT-0/null||experiences-4/VBZ	amod||inhibition-7/NN||dpp-4-6/JJ	prep_with||experiences-4/VBZ||inhibition-7/NN	det||treatment-10/NN||the-9/DT	prep_in||inhibition-7/NN||treatment-10/NN	prep_of||treatment-10/NN||type2diabetes-12/CD	det||focus-16/NN||a-15/DT	prep_with||experiences-4/VBZ||focus-16/NN	prep_on||focus-16/NN||sitagliptin-18/NN	type2diabetes-12||sitagliptin-18||yes||this review summarizes experiences with dpp-4 inhibition in the treatment of type2diabetes, with a focus on sitagliptin.
amod||countries-4/NNS||many-2/JJ	amod||countries-4/NNS||malaria-endemic-3/JJ	prep_in||compromise-10/VB||countries-4/NNS	amod||resistance-7/NN||increasing-6/VBG	nsubj||compromise-10/VB||resistance-7/NN	aux||compromise-10/VB||may-8/MD	advmod||compromise-10/VB||soon-9/RB	root||ROOT-0/null||compromise-10/VB	det||efficacy-12/NN||the-11/DT	dobj||compromise-10/VB||efficacy-12/NN	amod||sp-16/NN||sulphadoxine-pyrimethamine-14/JJ	prep_of||efficacy-12/NN||sp-16/NN	amod||treatment-21/NN||intermittent-19/JJ	amod||treatment-21/NN||preventative-20/JJ	prep_for||sp-16/NN||treatment-21/NN	appos||treatment-21/NN||ipt-23/NN	prep_of||treatment-21/NN||malaria-26/NN	prep_in||compromise-10/VB||pregnancy-28/NN	malaria-26||pyrimethamine--1||yes||in many malaria-endemic countries, increasing resistance may soon compromise the efficacy of sulphadoxine-pyrimethamine (sp) for intermittent preventative treatment (ipt) of malaria in pregnancy.
det||study-3/NN||this-2/DT	prep_in||shown-7/VBN||study-3/NN	nsubj||shown-7/VBN||we-5/PRP	aux||shown-7/VBN||have-6/VBP	root||ROOT-0/null||shown-7/VBN	det||vaccination-11/NN||that-8/DT	amod||vaccination-11/NN||heterologous-9/JJ	amod||vaccination-11/NN||prime-boost-10/JJ	dobj||shown-7/VBN||vaccination-11/NN	nn||tb-15/NN||tuberculosis-13/NNP	prep_against||shown-7/VBN||tb-15/NN	vmod||tb-15/NN||using-17/VBG	amod||priming/dna-hsp-20/NN||intranasal-18/JJ	nn||priming/dna-hsp-20/NN||bcg-19/NN	dobj||using-17/VBG||priming/dna-hsp-20/NN	prep_than||provided-26/VBD||priming/dna-hsp-20/NN	num||boosting-22/NNS||65-21/CD	nsubj||provided-26/VBD||boosting-22/NNS	appos||boosting-22/NNS||bcgin/dna-24/NNP	rcmod||priming/dna-hsp-20/NN||provided-26/VBD	advmod||greater-28/JJR||significantly-27/RB	amod||protection-29/NN||greater-28/JJR	dobj||provided-26/VBD||protection-29/NN	vmod||that-31/DT||afforded-32/VBN	det||subcutaneous-36/NNS||a-34/DT	amod||subcutaneous-36/NNS||single-35/JJ	agent||afforded-32/VBN||subcutaneous-36/NNS	nn||dose-39/NN||intranasal-38/NN	agent||afforded-32/VBN||dose-39/NN	conj_or||subcutaneous-36/NNS||dose-39/NN	prep_of||subcutaneous-36/NNS||bcg-41/NN	tuberculosis-13||bcg-41||no||in this study, we have shown that heterologous prime-boost vaccination against tuberculosis (tb) using intranasal bcg priming/dna-hsp65 boosting (bcgin/dna) provided significantly greater protection than that afforded by a single subcutaneous or intranasal dose of bcg.
nsubj||prescribed-9/VBN||population-1/NN	nsubj||87â-30/JJ||population-1/NN	num||patients-3/NNS||5756-2/CD	dep||aged-4/VBN||patients-3/NNS	amod||population-1/NN||aged-4/VBN	number||49-7/CD||15-5/CD	dep||49-7/CD||to-6/TO	prep||aged-4/VBN||49-7/CD	dep||49-7/CD||years-8/NNS	root||ROOT-0/null||prescribed-9/VBN	dobj||prescribed-9/VBN||isotretinoin-10/NN	amod||acne-13/NN||severe-12/JJ	prep_for||prescribed-9/VBN||acne-13/NN	vmod||acne-13/NN||observed-14/VBN	prepc_for||observed-14/VBN||17â-16/VBG	dobj||17â-16/VBG||$-17/$	num||$-17/$||-18/CD	num||years-21/NNS||197-19/CD	nn||years-21/NNS||person-20/NN	dep||before-22/IN||years-21/NNS	prep||17â-16/VBG||before-22/IN	num||years-26/NNS||2905-24/CD	nn||years-26/NNS||person-25/NN	dep||during-27/IN||years-26/NNS	dep||before-22/IN||during-27/IN	conj_and||prescribed-9/VBN||87â-30/JJ	num||years-35/NNS||$-31/$	number||120-33/CD||-32/CD	num||$-31/$||120-33/CD	nn||years-35/NNS||person-34/NN	npadvmod||87â-30/JJ||years-35/NNS	prep_after||87â-30/JJ||treatment-37/NN	acne-13||isotretinoin-10||yes||population 5756 patients aged 15 to 49 years prescribed isotretinoin for severe acne observed for 17â197 person years before, 2905 person years during, and 87â120 person years after treatment.
aux||use-2/VB||to-1/TO	advcl||necessary-16/JJ||use-2/VB	dobj||use-2/VB||pyrimethamine-3/NN	det||drug-8/NN||an-5/DT	amod||drug-8/NN||alternative-6/JJ	amod||drug-8/NN||anti-malarial-7/JJ	prep_as||use-2/VB||drug-8/NN	amod||parasites-12/NNS||chloroquine-resistant-10/JJ	nn||parasites-12/NNS||malaria-11/NN	prep_for||drug-8/NN||parasites-12/NNS	nsubj||necessary-16/JJ||it-14/PRP	nsubj||determine-18/VB||it-14/PRP	cop||necessary-16/JJ||was-15/VBD	root||ROOT-0/null||necessary-16/JJ	aux||determine-18/VB||to-17/TO	xcomp||necessary-16/JJ||determine-18/VB	det||enzyme-20/NN||the-19/DT	poss||variation-23/NN||enzyme-20/NN	amod||variation-23/NN||genetic-22/JJ	dobj||determine-18/VB||variation-23/NN	amod||syntase-27/NN||dihydrofolate-25/JJ	amod||syntase-27/NN||reductase-thymidylate-26/JJ	prep_in||variation-23/NN||syntase-27/NN	appos||syntase-27/NN||dhfr-ts-29/NNS	nn||strains-33/NNS||korean-32/NN	prep_among||determine-18/VB||strains-33/NNS	malaria-11||chloroquine--1||yes||to use pyrimethamine as an alternative anti-malarial drug for chloroquine-resistant malaria parasites, it was necessary to determine the enzyme's genetic variation in dihydrofolate reductase-thymidylate syntase (dhfr-ts) among korean strains.
nn||mycoplasmosis-2/NNS||avian-1/NN	nsubj||causes-3/VBZ||mycoplasmosis-2/NNS	root||ROOT-0/null||causes-3/VBZ	amod||losses-6/NNS||great-4/JJ	amod||losses-6/NNS||economic-5/JJ	dobj||causes-3/VBZ||losses-6/NNS	det||industry-10/NN||the-8/DT	nn||industry-10/NN||poultry-9/NN	prep_to||causes-3/VBZ||industry-10/NN	nsubj||synovie-21/NN||one-13/CD	det||agents-17/NNS||the-15/DT	amod||agents-17/NNS||major-16/JJ	prep_of||one-13/CD||agents-17/NNS	vmod||agents-17/NNS||involved-18/VBN	cop||synovie-21/NN||is-19/VBZ	nn||synovie-21/NN||mycoplasma-20/NN	conj_and||causes-3/VBZ||synovie-21/NN	appos||synovie-21/NN||ms-23/NN	mycoplasmosis-2||mycoplasma-20||no||avian mycoplasmosis causes great economic losses to the poultry industry, and one of the major agents involved is mycoplasma synovie (ms).
num||cultures-3/NNS||four-1/CD	nn||cultures-3/NNS||sputum-2/NN	nsubj||yielded-8/VBD||cultures-3/NNS	vmod||cultures-3/NNS||-lrb--4/VBG	num||%-6/NN||15.4-5/CD	dobj||-lrb--4/VBG||%-6/NN	advmod||yielded-8/VBD||-rrb--7/RB	root||ROOT-0/null||yielded-8/VBD	amod||colonies-11/NNS||afb-9/JJ	amod||colonies-11/NNS||positive-10/JJ	dobj||yielded-8/VBD||colonies-11/NNS	dobj||m.tuberculosis-16/NNS||which-13/WDT	nsubj||m.tuberculosis-16/NNS||one-14/PRP	cop||m.tuberculosis-16/NNS||was-15/VBD	prepc_among||yielded-8/VBD||m.tuberculosis-16/NNS	num||-rrb--23/NNS||3-18/CD	amod||-rrb--23/NNS||non-tuberculous-19/JJ	nn||-rrb--23/NNS||mycobacteria-20/NN	nn||-rrb--23/NNS||-lrb--21/NN	nn||-rrb--23/NNS||ntm-22/NN	prepc_among||yielded-8/VBD||-rrb--23/NNS	conj_and||m.tuberculosis-16/NNS||-rrb--23/NNS	tuberculous--1||m.tuberculosis-16||no||four sputum cultures -lrb- 15.4 % -rrb- yielded afb positive colonies among which one was m.tuberculosis and 3 non-tuberculous mycobacteria -lrb- ntm -rrb- .
det||initiative-7/NN||the-1/DT	amod||initiative-7/NN||womenâ-2/JJ	amod||initiative-7/NN||$-3/$	number||s-5/CD||-4/CD	num||$-3/$||s-5/CD	nn||initiative-7/NN||health-6/NN	nsubj||found-8/VBD||initiative-7/NN	root||ROOT-0/null||found-8/VBD	mark||increases-17/VBZ||that-9/IN	nn||estrogen-11/NN||combination-10/NN	nsubj||increases-17/VBZ||estrogen-11/NN	amod||therapy-16/NN||progesterone-13/JJ	nn||therapy-16/NN||hormone-14/NN	nn||therapy-16/NN||replacement-15/NN	conj_and||estrogen-11/NN||therapy-16/NN	nsubj||increases-17/VBZ||therapy-16/NN	ccomp||found-8/VBD||increases-17/VBZ	nn||cancer-19/NN||breast-18/NN	dobj||increases-17/VBZ||cancer-19/NN	nsubj||compelled-25/VBN||cancer-19/NN	nn||risk-22/NN||cardiovasculardisease-21/NN	dobj||increases-17/VBZ||risk-22/NN	conj_and||cancer-19/NN||risk-22/NN	nsubj||compelled-25/VBN||risk-22/NN	rcmod||cancer-19/NN||compelled-25/VBN	amod||women-27/NNS||many-26/JJ	dobj||compelled-25/VBN||women-27/NNS	nsubj||seek-29/VB||women-27/NNS	aux||seek-29/VB||to-28/TO	xcomp||compelled-25/VBN||seek-29/VB	amod||alternatives-31/NNS||herbal-30/JJ	nsubj||extract-35/VB||alternatives-31/NNS	prep_such_as||alternatives-31/NNS||blackcohosh-34/NN	ccomp||seek-29/VB||extract-35/VB	dobj||extract-35/VB||bce-37/NN	nsubj||relieve-40/VB||bce-37/NN	aux||relieve-40/VB||to-39/TO	xcomp||extract-35/VB||relieve-40/VB	poss||symptoms-43/NNS||their-41/PRP$	amod||symptoms-43/NNS||menopausal-42/JJ	dobj||relieve-40/VB||symptoms-43/NNS	estrogen-11||cancer-19||no_rel||the womenâs health initiative found that combination estrogen and progesterone hormone replacement therapy increases breast cancer and cardiovasculardisease risk, which compelled many women to seek herbal alternatives such as blackcohosh extract (bce) to relieve their menopausal symptoms.
nsubj||reviewed-3/VBN||we-1/PRP	nsubj||reviewed-3/VBN||we-1/PRP	nsubj||reviewed-3/VBN||we-1/PRP	advmod||reviewed-3/VBN||systematically-2/RB	root||ROOT-0/null||reviewed-3/VBN	conj_and||reviewed-3/VBN||reviewed-3/VBN	conj_and||reviewed-3/VBN||reviewed-3/VBN	amod||studies-5/NNS||published-4/VBN	dobj||reviewed-3/VBN||studies-5/NNS	det||databases-14/NNS||the-8/DT	amod||databases-14/NNS||medline-9/JJ	conj_and||medline-9/JJ||chinese-11/JJ	amod||databases-14/NNS||chinese-11/JJ	amod||databases-14/NNS||biomedical-12/JJ	nn||databases-14/NNS||literature-13/NN	prep_from||reviewed-3/VBN||databases-14/NNS	det||prevalence-18/NN||the-17/DT	prep_on||reviewed-3/VBN||prevalence-18/NN	prep_of||prevalence-18/NN||hivinfection-20/NN	nn||patients-23/NNS||tb-22/NN	prep_among||hivinfection-20/NN||patients-23/NNS	det||prevalence-27/NN||the-26/DT	prep_on||reviewed-3/VBN||prevalence-27/NN	prep_of||prevalence-27/NN||tb-29/NN	amod||population-32/NN||hiv/aids-31/JJ	prep_among||tb-29/NN||population-32/NN	prep_until||reviewed-3/VBN||15-34/CD	tmod||reviewed-3/VBN||april-35/NNP	num||april-35/NNP||2010-36/CD	nsubj||summarized-40/VBD||quantitatively-39/NN	conj_and||reviewed-3/VBN||summarized-40/VBD	det||estimates-42/NNS||the-41/DT	dobj||summarized-40/VBD||estimates-42/NNS	xcomp||summarized-40/VBD||using-43/VBG	dobj||using-43/VBG||meta-analysis-44/NNS	aids--1||hiv--1||no||we systematically reviewed published studies, from the medline and chinese biomedical literature databases, on the prevalence of hivinfection among tb patients and on the prevalence of tb among hiv/aids population until 15 april 2010, and quantitatively summarized the estimates using meta-analysis.
nsubj||arrive-6/VB||patients-1/NNS	nsubj||present-11/VB||patients-1/NNS	det||disorders-4/NNS||both-3/DT	prep_with||patients-1/NNS||disorders-4/NNS	advmod||arrive-6/VB||often-5/RB	root||ROOT-0/null||arrive-6/VB	nn||departments-9/NNS||emergency-8/NN	prep_at||arrive-6/VB||departments-9/NNS	conj_and||arrive-6/VB||present-11/VB	advmod||psychotic-13/JJ||floridly-12/RB	acomp||present-11/VB||psychotic-13/JJ	det||predominance-16/NN||a-15/DT	prep_with||present-11/VB||predominance-16/NN	amod||symptoms-19/NNS||positive-18/JJ	prep_of||predominance-16/NN||symptoms-19/NNS	advmod||prompting-22/VBG||often-21/RB	xcomp||present-11/VB||prompting-22/VBG	dobj||prompting-22/VBG||physicians-23/NNS	nsubj||select-25/VB||physicians-23/NNS	aux||select-25/VB||to-24/TO	xcomp||prompting-22/VBG||select-25/VB	det||medication-29/NN||a-26/DT	amod||medication-29/NN||typical-27/JJ	amod||medication-29/NN||antipsychotic-28/JJ	dobj||select-25/VB||medication-29/NN	prep_such_as||medication-29/NN||haloperidol-32/NN	psychotic-13||haloperidol-32||yes||patients with both disorders often arrive at emergency departments and present floridly psychotic with a predominance of positive symptoms, often prompting physicians to select a typical antipsychotic medication such as haloperidol.
det||method-2/NN||the-1/DT	nsubjpass||optimized-5/VBN||method-2/NN	auxpass||optimized-5/VBN||was-3/VBD	advmod||optimized-5/VBN||first-4/RB	root||ROOT-0/null||optimized-5/VBN	xcomp||optimized-5/VBN||utilizing-6/VBG	amod||strains-9/NNS||borrelia-7/JJ	nn||strains-9/NNS||laboratory-8/NN	dobj||utilizing-6/VBG||strains-9/NNS	advmod||followed-25/VBD||later-12/RB	prepc_by||later-12/RB||demonstrating-14/VBG	dobj||demonstrating-14/VBG||growth-15/NN	prep_of||growth-15/NN||borrelia-17/NN	prep_from||demonstrating-14/VBG||sera-19/NN	amod||seropositive-22/NN||fifty-21/JJ	prep_from||demonstrating-14/VBG||seropositive-22/NN	amod||patients-24/NNS||lymedisease-23/JJ	nsubj||followed-25/VBD||patients-24/NNS	conj_and||optimized-5/VBN||followed-25/VBD	det||cohort-28/NN||another-27/DT	prep_by||followed-25/VBD||cohort-28/NN	num||patients-32/NNS||72-30/CD	amod||patients-32/NNS||lymedisease-31/JJ	prep_of||cohort-28/NN||patients-32/NNS	pobj||of-35/IN||patients-32/NNS	dep||of-35/IN||all-34/DT	nsubj||satisfied-37/VBD||of-35/IN	rcmod||patients-32/NNS||satisfied-37/VBD	det||definition-43/NN||the-38/DT	amod||definition-43/NN||strict-39/JJ	nn||definition-43/NN||cdc-40/NN	nn||definition-43/NN||surveillance-41/NN	nn||definition-43/NN||case-42/NN	dobj||satisfied-37/VBD||definition-43/NN	prep_for||satisfied-37/VBD||lymedisease-45/NN	lymedisease-45||borrelia-17||no||the method was first optimized utilizing borrelia laboratory strains, and later by demonstrating growth of borrelia from sera from fifty seropositive lymedisease patients followed by another cohort of 72 lymedisease patients, all of whom satisfied the strict cdc surveillance case definition for lymedisease.
advmod||hiv-2/NN||as-1/RB	nsubj||share-8/VBP||hiv-2/NN	conj_and||hiv-2/NN||hepatitisc-4/NN	nsubj||share-8/VBP||hepatitisc-4/NN	appos||hiv-2/NN||hcv-6/NN	root||ROOT-0/null||share-8/VBP	det||modes-10/NNS||some-9/DT	nsubj||uncommon-16/JJ||modes-10/NNS	nn||co-infection-13/NN||transmission-12/NN	prep_of||modes-10/NNS||co-infection-13/NN	cop||uncommon-16/JJ||is-14/VBZ	neg||uncommon-16/JJ||not-15/RB	ccomp||share-8/VBP||uncommon-16/JJ	hepatitisc-4||hcv-6||no||as hiv and hepatitisc (hcv) share some modes of transmission co-infection is not uncommon.
nsubj||report-2/VB||we-1/PRP	nsubj||conduct-16/VB||we-1/PRP	root||ROOT-0/null||report-2/VB	det||prevalence-4/NN||the-3/DT	dobj||report-2/VB||prevalence-4/NN	prep_of||prevalence-4/NN||hivinfection-6/NN	amod||studies-9/NNS||descriptive-8/JJ	prep_from||report-2/VB||studies-9/NNS	prep_of||studies-9/NNS||msm-11/NN	prep_with||report-2/VB||lgv-13/NN	conj_and||report-2/VB||conduct-16/VB	det||meta-analysis-18/NNS||a-17/DT	dobj||conduct-16/VB||meta-analysis-18/NNS	nsubj||produce-20/VB||meta-analysis-18/NNS	aux||produce-20/VB||to-19/TO	xcomp||conduct-16/VB||produce-20/VB	det||estimate-23/NN||a-21/DT	nn||estimate-23/NN||summary-22/NN	dobj||produce-20/VB||estimate-23/NN	det||association-26/NN||the-25/DT	prep_of||estimate-23/NN||association-26/NN	prep_between||association-26/NN||lgv-28/NN	prep_between||association-26/NN||hiv-30/NN	conj_and||lgv-28/NN||hiv-30/NN	amod||studies-33/NNS||case-control-32/JJ	prep_from||produce-20/VB||studies-33/NNS	advmod||msm-37/VBN||where-34/WRB	nsubjpass||msm-37/VBN||cases-35/NNS	auxpass||msm-37/VBN||were-36/VBD	advcl||produce-20/VB||msm-37/VBN	prep_with||msm-37/VBN||lgv-39/NN	nsubjpass||msm-43/VBN||controls-41/NNS	auxpass||msm-43/VBN||were-42/VBD	conj_and||report-2/VB||msm-43/VBN	amod||chlamydia-46/NN||rectal-45/JJ	prep_with||msm-43/VBN||chlamydia-46/NN	vmod||chlamydia-46/NN||caused-47/VBN	amod||serovars-50/NNS||non-lgv-49/JJ	agent||caused-47/VBN||serovars-50/NNS	hivinfection-6||hiv-30||no||we report the prevalence of hivinfection from descriptive studies of msm with lgv, and conduct a meta-analysis to produce a summary estimate of the association between lgv and hiv from case-control studies where cases were msm with lgv and controls were msm with rectal chlamydia caused by non-lgv serovars.
amod||outcome-2/NN||main-1/JJ	nsubj||measures-3/VBZ||outcome-2/NN	root||ROOT-0/null||measures-3/VBZ	amod||number-5/NN||monthly-4/JJ	dobj||measures-3/VBZ||number-5/NN	prep_of||number-5/NN||prescriptions-7/NNS	amod||prophylaxis-10/NNS||antibiotic-9/JJ	prep_for||prescriptions-7/NNS||prophylaxis-10/NNS	vmod||prophylaxis-10/NNS||consisting-11/VBG	det||dose-18/NN||a-13/DT	amod||dose-18/NN||single-14/JJ	number||g-16/CD||3-15/CD	num||dose-18/NN||g-16/CD	amod||dose-18/NN||oral-17/JJ	prep_of||consisting-11/VBG||dose-18/NN	prep_of||dose-18/NN||amoxicillin-20/NNP	det||dose-27/NN||a-22/DT	amod||dose-27/NN||single-23/JJ	number||mg-25/CD||600-24/CD	num||dose-27/NN||mg-25/CD	amod||dose-27/NN||oral-26/JJ	dobj||measures-3/VBZ||dose-27/NN	conj_or||number-5/NN||dose-27/NN	prep_of||dose-27/NN||clindamycin-29/NN	amod||number-33/NN||monthly-32/JJ	dobj||measures-3/VBZ||number-33/NN	conj_and||number-5/NN||number-33/NN	prep_of||number-33/NN||cases-35/NNS	prep_of||cases-35/NNS||infectiveendocarditis-37/NNS	amod||deaths-41/NNS||infectiveendocarditis-39/JJ	amod||deaths-41/NNS||related-40/JJ	prep_of||number-33/NN||deaths-41/NNS	conj_or||cases-35/NNS||deaths-41/NNS	prep_in||deaths-41/NNS||hospital-43/NN	prep_of||number-33/NN||cases-46/NNS	conj_or||cases-35/NNS||cases-46/NNS	prep_of||cases-46/NNS||infectiveendocarditis-48/NNS	det||origin-53/NN||a-50/DT	amod||origin-53/NN||possible-51/JJ	amod||origin-53/NN||oral-52/JJ	prep_with||infectiveendocarditis-48/NNS||origin-53/NN	prep_for||origin-53/NN||streptococci-55/NNS	infectiveendocarditis-48||amoxicillin-20||yes||main outcome measures monthly number of prescriptions for antibiotic prophylaxis consisting of a single 3 g oral dose of amoxicillin or a single 600 mg oral dose of clindamycin, and monthly number of cases of infectiveendocarditis, infectiveendocarditis related deaths in hospital, or cases of infectiveendocarditis with a possible oral origin for streptococci.
amod||outcome-2/NN||main-1/JJ	nsubj||measures-3/VBZ||outcome-2/NN	root||ROOT-0/null||measures-3/VBZ	amod||number-5/NN||monthly-4/JJ	dobj||measures-3/VBZ||number-5/NN	prep_of||number-5/NN||prescriptions-7/NNS	amod||prophylaxis-10/NNS||antibiotic-9/JJ	prep_for||prescriptions-7/NNS||prophylaxis-10/NNS	vmod||prophylaxis-10/NNS||consisting-11/VBG	det||dose-18/NN||a-13/DT	amod||dose-18/NN||single-14/JJ	number||g-16/CD||3-15/CD	num||dose-18/NN||g-16/CD	amod||dose-18/NN||oral-17/JJ	prep_of||consisting-11/VBG||dose-18/NN	prep_of||dose-18/NN||amoxicillin-20/NNP	det||dose-27/NN||a-22/DT	amod||dose-27/NN||single-23/JJ	number||mg-25/CD||600-24/CD	num||dose-27/NN||mg-25/CD	amod||dose-27/NN||oral-26/JJ	dobj||measures-3/VBZ||dose-27/NN	conj_or||number-5/NN||dose-27/NN	prep_of||dose-27/NN||clindamycin-29/NN	amod||number-33/NN||monthly-32/JJ	dobj||measures-3/VBZ||number-33/NN	conj_and||number-5/NN||number-33/NN	prep_of||number-33/NN||cases-35/NNS	prep_of||cases-35/NNS||infectiveendocarditis-37/NNS	amod||deaths-41/NNS||infectiveendocarditis-39/JJ	amod||deaths-41/NNS||related-40/JJ	prep_of||number-33/NN||deaths-41/NNS	conj_or||cases-35/NNS||deaths-41/NNS	prep_in||deaths-41/NNS||hospital-43/NN	prep_of||number-33/NN||cases-46/NNS	conj_or||cases-35/NNS||cases-46/NNS	prep_of||cases-46/NNS||infectiveendocarditis-48/NNS	det||origin-53/NN||a-50/DT	amod||origin-53/NN||possible-51/JJ	amod||origin-53/NN||oral-52/JJ	prep_with||infectiveendocarditis-48/NNS||origin-53/NN	prep_for||origin-53/NN||streptococci-55/NNS	infectiveendocarditis-48||clindamycin-29||yes||main outcome measures monthly number of prescriptions for antibiotic prophylaxis consisting of a single 3 g oral dose of amoxicillin or a single 600 mg oral dose of clindamycin, and monthly number of cases of infectiveendocarditis, infectiveendocarditis related deaths in hospital, or cases of infectiveendocarditis with a possible oral origin for streptococci.
nsubj||carotid-50/VBD||methods-1/NNS	aux||test-3/VB||to-2/TO	vmod||methods-1/NNS||test-3/VB	det||hypothesis-5/NNS||this-4/DT	dobj||test-3/VB||hypothesis-5/NNS	nsubj||assessed-8/VBD||we-7/PRP	parataxis||test-3/VB||assessed-8/VBD	det||association-11/NN||the-9/DT	amod||association-11/NN||cross-sectional-10/JJ	dobj||assessed-8/VBD||association-11/NN	nn||lactate-14/NN||plasma-13/NN	prep_of||association-11/NN||lactate-14/NN	det||indicator-17/NN||an-16/DT	dobj||assessed-8/VBD||indicator-17/NN	det||gap-20/NN||the-19/DT	prep_of||indicator-17/NN||gap-20/NN	amod||capacity-23/NN||oxidative-22/JJ	prep_between||gap-20/NN||capacity-23/NN	nn||expenditure-26/NN||energy-25/NN	prep_between||gap-20/NN||expenditure-26/NN	conj_and||capacity-23/NN||expenditure-26/NN	nsubj||taking-35/VBG||type2diabetes-29/NNS	num||adults-33/NNS||1709-31/CD	amod||adults-33/NNS||older-32/JJR	prep_in||type2diabetes-29/NNS||adults-33/NNS	neg||taking-35/VBG||not-34/RB	prepc_with||test-3/VB||taking-35/VBG	dobj||taking-35/VBG||metformin-36/NN	nsubj||participants-40/NNS||metformin-36/NN	cop||participants-40/NNS||were-39/VBD	rcmod||metformin-36/NN||participants-40/NNS	det||risk-44/NN||the-42/DT	amod||risk-44/NN||atherosclerosis-43/JJ	prep_in||participants-40/NNS||risk-44/NN	prep_in||risk-44/NN||communities-46/NNS	dep||communities-46/NNS||aric-48/JJ	root||ROOT-0/null||carotid-50/VBD	nn||study-52/NN||mri-51/NN	dobj||carotid-50/VBD||study-52/NN	type2diabetes-29||metformin-36||yes||methods to test this hypothesis, we assessed the cross-sectional association of plasma lactate, an indicator of the gap between oxidative capacity and energy expenditure, with type2diabetes in 1709 older adults not taking metformin, who were participants in the atherosclerosis risk in communities (aric) carotid mri study.
prep_at||made-16/VBN||6â-2/NNS	num||years-6/NNS||$-3/$	num||$-3/$||7-5/CD	npadvmod||6â-2/NNS||years-6/NNS	prep_of||6â-2/NNS||age-8/NN	det||comparison-11/NN||the-10/DT	nsubjpass||made-16/VBN||comparison-11/NN	amod||factors-14/NNS||various-13/JJ	prep_of||comparison-11/NN||factors-14/NNS	auxpass||made-16/VBN||was-15/VBD	root||ROOT-0/null||made-16/VBN	number||lga-19/NN||31-18/CD	amod||children-26/NNS||lga-19/NN	number||appropriate-for-gestational-age-22/NN||34-21/CD	conj_and||lga-19/NN||appropriate-for-gestational-age-22/NN	amod||children-26/NNS||appropriate-for-gestational-age-22/NN	discourse||children-26/NNS||aga-24/UH	prep_between||made-16/VBN||children-26/NNS	dobj||made-16/VBN||fibrinogen-27/NN	dobj||made-16/VBN||antithrombiniii-29/NNS	conj_and||fibrinogen-27/NN||antithrombiniii-29/NNS	nn||c-32/NN||protein-31/NN	dobj||made-16/VBN||c-32/NN	conj_and||fibrinogen-27/NN||c-32/NN	dobj||made-16/VBN||s-34/PRP	conj_and||fibrinogen-27/NN||s-34/PRP	amod||model-43/NN||fasting-36/VBG	nn||model-43/NN||insulin-37/NN	dep||model-43/NN||glucose-39/NN	dep||model-43/NN||homeostasis-41/NN	nn||model-43/NN||assessment-42/NN	dobj||made-16/VBN||model-43/NN	conj_and||fibrinogen-27/NN||model-43/NN	prep_of||model-43/NN||insulinresistance-45/NN	appos||model-43/NN||homa-ir-47/NN	nn||protein-60/NN||index-49/NN	dep||protein-60/NN||adiponectin-51/NN	dep||protein-60/NN||leptin-53/NN	dep||protein-60/NN||visfatin-55/NN	amod||protein-60/NN||igf-1-57/JJ	amod||protein-60/NN||igf-binding-59/JJ	dep||fibrinogen-27/NN||protein-60/NN	appos||protein-60/NN||igfbp-62/NN	nsubj||lipids-68/VBZ||-1-64/CD	amod||-1-64/CD||igfbp-3-66/JJ	rcmod||protein-60/NN||lipids-68/VBZ	det||factors-73/NNS||the-71/DT	amod||factors-73/NNS||genetic-72/JJ	poss||mutation-77/NN||factors-73/NNS	nn||mutation-77/NN||leiden-75/NN	amod||mutation-77/NN||g1691a-76/VBD	dobj||made-16/VBN||mutation-77/NN	conj_and||fibrinogen-27/NN||mutation-77/NN	amod||20210a/g-80/JJ||prothrombin-79/JJ	amod||polymorphism-81/NN||20210a/g-80/JJ	conj_and||fibrinogen-27/NN||polymorphism-81/NN	conj_and||mutation-77/NN||polymorphism-81/NN	conj_and||fibrinogen-27/NN||mutation-84/NN	conj_and||mutation-77/NN||mutation-84/NN	det||gene-89/NN||the-86/DT	amod||5,10-methylenetetrahydrofolate-reductase-88/JJ||enzyme-87/JJ	amod||gene-89/NN||5,10-methylenetetrahydrofolate-reductase-88/JJ	prep_in||mutation-84/NN||gene-89/NN	dep||gene-89/NN||mthfr-c677t-91/JJ	enzyme-87||insulinresistance-45||no_rel||at 6â7 years of age, the comparison of various factors was made between 31 lga and 34 appropriate-for-gestational-age (aga) children fibrinogen, antithrombiniii, protein c and s, fasting insulin, glucose, homeostasis assessment model of insulinresistance (homa-ir) index, adiponectin, leptin, visfatin, igf-1, igf-binding protein (igfbp)-1, igfbp-3, lipids, and the genetic factors v leiden g1691a mutation, prothrombin 20210a/g polymorphism, and mutation in the enzyme 5,10-methylenetetrahydrofolate-reductase gene (mthfr-c677t).
nsubj||identified-2/VBD||we-1/PRP	root||ROOT-0/null||identified-2/VBD	num||individuals-4/NNS||425-3/CD	dobj||identified-2/VBD||individuals-4/NNS	vmod||individuals-4/NNS||divided-6/VBN	num||categories-9/NNS||seven-8/CD	prep_into||divided-6/VBN||categories-9/NNS	prepc_according_to||divided-6/VBN||to-11/TO	amod||status-14/NN||carbohydrate-12/JJ	nn||status-14/NN||metabolism-13/NN	pobj||divided-6/VBN||status-14/NN	amod||-RSB--21/NNP||normal-16/JJ	nn||-RSB--21/NNP||glucose-17/NN	nn||-RSB--21/NNP||tolerance-18/NN	nn||-RSB--21/NNP||-LSB--19/NNP	nn||-RSB--21/NNP||ngt-20/FW	dep||individuals-4/NNS||-RSB--21/NNP	amod||glucose-25/NN||impaired-23/VBN	amod||glucose-25/NN||fasting-24/JJ	appos||-RSB--21/NNP||glucose-25/NN	nn||-RSB--30/FW||impairedglucosetolerance-27/FW	nn||-RSB--30/FW||-LSB--28/FW	nn||-RSB--30/FW||igt-29/FW	appos||glucose-25/NN||-RSB--30/FW	advmod||diagnosed-34/VBN||newly-33/RB	amod||type2diabetes-35/NNS||diagnosed-34/VBN	appos||-RSB--21/NNP||type2diabetes-35/NNS	conj_and||glucose-25/NN||type2diabetes-35/NNS	nn||duration-39/NN||diabetes-38/NN	dobj||identified-2/VBD||duration-39/NN	conj_and||individuals-4/NNS||duration-39/NN	dep||duration-39/NN||0â-41/VBN	dobj||0â-41/VBN||$-42/$	num||$-42/$||9-44/CD	amod||$-47/$||10â-46/JJ	appos||$-42/$||$-47/$	num||$-47/$||19-49/CD	amod||-53/NNS||â-52/JJ	appos||$-42/$||-53/NNS	conj_and||$-47/$||-53/NNS	dep||years-56/NNS||¥-54/SYM	num||years-56/NNS||20-55/CD	dep||0â-41/VBN||years-56/NNS	impairedglucosetolerance-27||glucose-25||no_rel||we identified 425 individuals, divided into seven categories according to carbohydrate metabolism status (normal glucose tolerance [ngt], impaired fasting glucose, impairedglucosetolerance [igt], and newly diagnosed type2diabetes) and diabetes duration (0â9, 10â19, and â¥20 years).
nsubj||expresses-9/VBZ||mycobacteriumtuberculosis-1/NNS	det||agent-5/NN||the-3/DT	amod||agent-5/NN||causative-4/JJ	appos||mycobacteriumtuberculosis-1/NNS||agent-5/NN	prep_of||agent-5/NN||tuberculosis-7/NNP	root||ROOT-0/null||expresses-9/VBZ	num||members-11/NNS||two-10/CD	dobj||expresses-9/VBZ||members-11/NNS	det||family-15/NN||the-13/DT	nn||family-15/NN||fur-14/NN	prep_of||members-11/NNS||family-15/NN	amod||fura-18/NN||designated-17/VBN	prep_of||members-11/NNS||fura-18/NN	conj_and||family-15/NN||fura-18/NN	prep_of||members-11/NNS||furb-20/NN	conj_and||family-15/NN||furb-20/NN	tuberculosis-7||mycobacteriumtuberculosis-1||no||mycobacteriumtuberculosis , the causative agent of tuberculosis, expresses two members of the fur family, designated fura and furb.
amod||analysis-2/NN||immunohistological-1/JJ	nsubj||confirmed-6/VBD||analysis-2/NN	det||granulomas-5/NNS||these-4/DT	prep_of||analysis-2/NN||granulomas-5/NNS	root||ROOT-0/null||confirmed-6/VBD	det||abundance-9/NN||the-7/DT	amod||abundance-9/NN||disproportionate-8/JJ	dobj||confirmed-6/VBD||abundance-9/NN	det||proteins-12/NNS||the-11/DT	prep_of||abundance-9/NN||proteins-12/NNS	vmod||proteins-12/NNS||involved-13/VBN	nn||metabolism-16/NN||lipid-15/NN	prep_in||involved-13/VBN||metabolism-16/NN	prep_in||involved-13/VBN||cells-18/NNS	vmod||cells-18/NNS||surrounding-19/VBG	det||caseum-21/NN||the-20/DT	dobj||surrounding-19/VBG||caseum-21/NN	advmod||biochemical-36/VBP||namely-23/RB	nn||member-31/NN||adipophilin-25/NN	amod||member-31/NN||acyl-coa-27/JJ	nn||member-31/NN||synthetase-28/NN	amod||member-31/NN||long-chain-29/JJ	nn||member-31/NN||family-30/NN	nsubj||biochemical-36/VBP||member-31/NN	num||member-31/NN||1-32/CD	amod||c.-35/NN||saposin-34/JJ	conj_and||member-31/NN||c.-35/NN	nsubj||biochemical-36/VBP||c.-35/NN	parataxis||confirmed-6/VBD||biochemical-36/VBP	dobj||biochemical-36/VBP||analysis-37/NN	det||species-41/NN||the-39/DT	nn||species-41/NN||lipid-40/NN	prep_of||analysis-37/NN||species-41/NN	det||caseum-44/NN||the-43/DT	prep_within||biochemical-36/VBP||caseum-44/NN	nsubj||implicated-56/VBN||caseum-44/NN	vmod||caseum-44/NN||identified-45/VBN	dobj||identified-45/VBN||cholesterol-46/NN	amod||esters-49/NNS||cholesteryl-48/JJ	dobj||identified-45/VBN||esters-49/NNS	conj_and||cholesterol-46/NN||esters-49/NNS	dobj||identified-45/VBN||triacylglycerols-51/NNS	conj_and||cholesterol-46/NN||triacylglycerols-51/NNS	dobj||identified-45/VBN||lactosylceramide-53/NN	conj_and||cholesterol-46/NN||lactosylceramide-53/NN	rcmod||caseum-44/NN||implicated-56/VBN	amod||lipids-59/NNS||low-density-57/JJ	amod||lipids-59/NNS||lipoprotein-derived-58/JJ	dobj||implicated-56/VBN||lipids-59/NNS	det||source-64/NN||the-61/DT	advmod||likely-63/JJ||most-62/RBS	amod||source-64/NN||likely-63/JJ	prep_as||implicated-56/VBN||source-64/NN	granulomas-5||esters-49||no_rel||immunohistological analysis of these granulomas confirmed the disproportionate abundance of the proteins involved in lipid metabolism in cells surrounding the caseum ; namely , adipophilin , acyl-coa synthetase long-chain family member 1 and saposin c. biochemical analysis of the lipid species within the caseum identified cholesterol , cholesteryl esters , triacylglycerols and lactosylceramide , which implicated low-density lipoprotein-derived lipids as the most likely source .
det||study-2/NN||this-1/DT	nsubj||first-5/JJ||study-2/NN	cop||first-5/JJ||is-3/VBZ	det||first-5/JJ||the-4/DT	root||ROOT-0/null||first-5/JJ	det||uae-8/NN||the-7/DT	prep_in||first-5/JJ||uae-8/NN	aux||report-10/VB||to-9/TO	vmod||uae-8/NN||report-10/VB	amod||levels-13/NNS||such-11/JJ	amod||levels-13/NNS||high-12/JJ	dobj||report-10/VB||levels-13/NNS	prep_of||levels-13/NNS||resistance-15/NN	amod||drugs-18/NNS||anti-tb-17/JJ	prep_to||report-10/VB||drugs-18/NNS	num||%-21/NN||27.7-20/CD	nsubj||are-30/VBP||%-21/NN	nsubj||achieve-35/VB||%-21/NN	amod||drugs-24/NNS||anti-tuberculosis-23/JJ	prep_for||%-21/NN||drugs-24/NNS	prep_such_as||drugs-24/NNS||isoniazid-27/NN	prep_such_as||drugs-24/NNS||pyrazinamide-29/NN	conj_and||isoniazid-27/NN||pyrazinamide-29/NN	parataxis||first-5/JJ||are-30/VBP	amod||significance-33/NN||great-32/JJ	prep_of||are-30/VBP||significance-33/NN	aux||achieve-35/VB||to-34/TO	xcomp||are-30/VBP||achieve-35/VB	amod||treatment-37/NN||proper-36/JJ	dobj||achieve-35/VB||treatment-37/NN	prep_in||achieve-35/VB||m.tuberculosisinfections-39/NNS	prep_in||m.tuberculosisinfections-39/NNS||future-41/NN	tuberculosis--1||m.tuberculosis--1||no||this study is the first in the uae to report such high levels of resistance to anti-tb drugs ; 27.7 % for anti-tuberculosis drugs such as isoniazid and pyrazinamide are of great significance to achieve proper treatment in m.tuberculosisinfections in future .
nsubj||azole-5/NN||posaconazole-1/NN	cop||azole-5/NN||is-2/VBZ	det||azole-5/NN||the-3/DT	amod||azole-5/NN||only-4/JJ	root||ROOT-0/null||azole-5/NN	prep_with||azole-5/NN||activity-7/NN	prep_against||activity-7/NN||zygomycetes-9/NNS	amod||fungi-13/NNS||other-11/JJ	amod||fungi-13/NNS||difficult-to-treat-12/JJ	prep_against||activity-7/NN||fungi-13/NNS	conj_and||zygomycetes-9/NNS||fungi-13/NNS	vmod||azole-5/NN||representing-15/VBG	det||option-19/NN||a-16/DT	amod||option-19/NN||potential-17/JJ	nn||option-19/NN||treatment-18/NN	dobj||representing-15/VBG||option-19/NN	amod||mycosis-23/NNS||refractory-21/JJ	nn||mycosis-23/NNS||invasive-22/NN	prep_for||representing-15/VBG||mycosis-23/NNS	mycosis-23||posaconazole-1||yes||posaconazole is the only azole with activity against zygomycetes and other difficult-to-treat fungi, representing a potential treatment option for refractory invasive mycosis.
amod||aes-2/NN||placebo-adjusted-1/JJ	nsubj||insomnia-9/JJ||aes-2/NN	advmod||common-4/JJ||more-3/RBR	amod||aes-2/NN||common-4/JJ	amod||er-7/NN||paliperidone-6/JJ	prep_with||common-4/JJ||er-7/NN	cop||insomnia-9/JJ||were-8/VBD	ccomp||congestion-36/NN||insomnia-9/JJ	nn||tachycardia-12/NN||sinus-11/NNS	nsubj||congestion-36/NN||tachycardia-12/NN	conj_and||tachycardia-12/NN||tachycardia-14/NN	nsubj||congestion-36/NN||tachycardia-14/NN	advmod||common-17/JJ||more-16/RBR	amod||tachycardia-12/NN||common-17/JJ	prep_with||tachycardia-12/NN||risperidone-19/NN	cop||congestion-36/NN||were-20/VBD	nn||congestion-36/NN||somnolence-21/NN	conj_and||somnolence-21/NN||restlessness-23/NNS	nn||congestion-36/NN||restlessness-23/NNS	conj_and||somnolence-21/NN||nausea-25/NN	nn||congestion-36/NN||nausea-25/NN	conj_and||somnolence-21/NN||anxiety-27/NN	nn||congestion-36/NN||anxiety-27/NN	conj_and||somnolence-21/NN||salivaryhypersecretion-29/NN	nn||congestion-36/NN||salivaryhypersecretion-29/NN	conj_and||somnolence-21/NN||akathisia-31/NN	nn||congestion-36/NN||akathisia-31/NN	conj_and||somnolence-21/NN||dizziness-33/NN	nn||congestion-36/NN||dizziness-33/NN	conj_and||somnolence-21/NN||nasal-35/NN	nn||congestion-36/NN||nasal-35/NN	root||ROOT-0/null||congestion-36/NN	risperidone-19||tachycardia-14||no_rel||placebo-adjusted aes more common with paliperidone er were insomnia, sinus tachycardia and tachycardia; more common with risperidone were somnolence, restlessness, nausea, anxiety, salivaryhypersecretion, akathisia, dizziness and nasal congestion.
nsubj||gave-14/VBD||treatment-1/NN	amod||ketamine-7/NN||intravenous-3/JJ	appos||ketamine-7/NN||iv-5/NN	prep_with||treatment-1/NN||ketamine-7/NN	det||infusion-12/NN||an-9/DT	amod||infusion-12/NN||alternate-10/JJ	nn||infusion-12/NN||day-11/NN	prep_as||ketamine-7/NN||infusion-12/NN	root||ROOT-0/null||gave-14/VBD	amod||remission-16/NN||complete-15/JJ	dobj||gave-14/VBD||remission-16/NN	amod||pain-20/NN||phantom-18/JJ	nn||pain-20/NN||limb-19/NN	prep_of||remission-16/NN||pain-20/NN	pain-20||ketamine-7||yes||treatment with intravenous (iv) ketamine as an alternate day infusion, gave complete remission of phantom limb pain.
det||article-2/NN||this-1/DT	nsubj||reviews-3/VBZ||article-2/NN	nsubj||describes-21/VBZ||article-2/NN	root||ROOT-0/null||reviews-3/VBZ	det||association-5/NN||the-4/DT	dobj||reviews-3/VBZ||association-5/NN	det||development-8/NN||the-7/DT	prep_between||association-5/NN||development-8/NN	amod||squamouscellcarcinoma-11/NN||oral-10/JJ	prep_of||development-8/NN||squamouscellcarcinoma-11/NN	advmod||malignant-14/JJ||potentially-13/RB	amod||lesions-16/NNS||malignant-14/JJ	amod||lesions-16/NNS||oral-15/JJ	prep_in||reviews-3/VBZ||lesions-16/NNS	amod||candidalinfection-19/NN||chronic-18/JJ	prep_with||lesions-16/NNS||candidalinfection-19/NN	conj_and||reviews-3/VBZ||describes-21/VBZ	dobj||describes-21/VBZ||mechanisms-22/NNS	nsubjpass||involved-26/VBN||mechanisms-22/NNS	aux||involved-26/VBN||may-24/MD	auxpass||involved-26/VBN||be-25/VB	rcmod||mechanisms-22/NNS||involved-26/VBN	prep_in||involved-26/VBN||candida-28/NN	vmod||candida-28/NN||associated-30/VBN	amod||transformation-32/NN||malignant-31/JJ	dobj||associated-30/VBN||transformation-32/NN	candidalinfection-19||candida-28||no||this article reviews the association between the development of oral squamouscellcarcinoma in potentially malignant oral lesions with chronic candidalinfection and describes mechanisms that may be involved in candida -associated malignant transformation.
amod||infections-2/NNS||hospital-acquired-1/JJ	nsubj||cause-17/NN||infections-2/NNS	nsubj||impose-23/VB||infections-2/NNS	prep_with||infections-2/NNS||staphylococcusaureus-4/NNS	advmod||s.aureus-8/NNS||especially-6/RB	amod||s.aureus-8/NNS||methicillin-resistant-7/JJ	appos||infections-2/NNS||s.aureus-8/NNS	amod||infections-12/NNS||-lrb--9/JJ	nn||infections-12/NNS||mrsa-10/NN	nn||infections-12/NNS||-rrb--11/NN	dep||s.aureus-8/NNS||infections-12/NNS	cop||cause-17/NN||are-14/VBP	det||cause-17/NN||a-15/DT	amod||cause-17/NN||major-16/JJ	root||ROOT-0/null||cause-17/NN	prep_of||cause-17/NN||illness-19/NN	prep_of||cause-17/NN||death-21/NN	conj_and||illness-19/NN||death-21/NN	conj_and||cause-17/NN||impose-23/VB	amod||costs-26/NNS||serious-24/JJ	amod||costs-26/NNS||economic-25/JJ	dobj||impose-23/VB||costs-26/NNS	prep_on||impose-23/VB||patients-28/NNS	prep_on||impose-23/VB||hospitals-30/NNS	conj_and||patients-28/NNS||hospitals-30/NNS	mrsa-10||staphylococcusaureus-4||no||hospital-acquired infections with staphylococcusaureus , especially methicillin-resistant s.aureus -lrb- mrsa -rrb- infections , are a major cause of illness and death and impose serious economic costs on patients and hospitals .
det||objective-3/NN||the-1/DT	amod||objective-3/NN||main-2/JJ	nsubj||is-8/VBZ||objective-3/NN	nsubj||monitor-10/VB||objective-3/NN	det||study-7/NN||the-5/DT	amod||study-7/NN||current-6/JJ	prep_of||objective-3/NN||study-7/NN	ccomp||â-36/VBP||is-8/VBZ	aux||monitor-10/VB||to-9/TO	xcomp||is-8/VBZ||monitor-10/VB	det||status-13/NN||the-11/DT	amod||status-13/NN||auditory-12/JJ	dobj||monitor-10/VB||status-13/NN	det||group-16/NN||a-15/DT	prep_in||status-13/NN||group-16/NN	prep_of||group-16/NN||adults-18/NNS	prep_with||monitor-10/VB||aids-20/NNS	vmod||monitor-10/VB||receiving-22/VBG	advmod||active-24/JJ||highly-23/RB	amod||therapy-26/NN||active-24/JJ	amod||therapy-26/NN||antiretroviral-25/JJ	dobj||receiving-22/VBG||therapy-26/NN	appos||therapy-26/NN||haart-28/NN	dep||therapy-26/NN||3tc-31/NNP	dep||3tc-31/NNP||lamivudine-33/NN	nsubj||â-36/VBP||d4t-35/NNS	root||ROOT-0/null||â-36/VBP	dobj||â-36/VBP||$-37/$	npadvmod||outpatient-47/JJ||stavudine-39/NN	conj_and||stavudine-39/NN||efavirenz-42/NN	npadvmod||outpatient-47/JJ||efavirenz-42/NN	quantmod||hospital-46/NN||in-44/IN	quantmod||hospital-46/NN||a-45/DT	num||stavudine-39/NN||hospital-46/NN	amod||clinic-48/NNS||outpatient-47/JJ	npadvmod||in-49/RB||clinic-48/NNS	dep||gauteng-50/CD||in-49/RB	num||$-37/$||gauteng-50/CD	aids-20||lamivudine-33||yes||the main objective of the current study is to monitor the auditory status in a group of adults with aids, receiving highly active antiretroviral therapy (haart) (3tc -lamivudine, d4t â stavudine, and efavirenz) in a hospital outpatient clinic in gauteng.
nsubj||identified-2/VBD||we-1/PRP	root||ROOT-0/null||identified-2/VBD	num||individuals-4/NNS||425-3/CD	dobj||identified-2/VBD||individuals-4/NNS	vmod||individuals-4/NNS||divided-6/VBN	num||categories-9/NNS||seven-8/CD	prep_into||divided-6/VBN||categories-9/NNS	prepc_according_to||divided-6/VBN||to-11/TO	amod||status-14/NN||carbohydrate-12/JJ	nn||status-14/NN||metabolism-13/NN	pobj||divided-6/VBN||status-14/NN	amod||-RSB--21/NNP||normal-16/JJ	nn||-RSB--21/NNP||glucose-17/NN	nn||-RSB--21/NNP||tolerance-18/NN	nn||-RSB--21/NNP||-LSB--19/NNP	nn||-RSB--21/NNP||ngt-20/FW	dep||individuals-4/NNS||-RSB--21/NNP	amod||glucose-25/NN||impaired-23/VBN	amod||glucose-25/NN||fasting-24/JJ	appos||-RSB--21/NNP||glucose-25/NN	nn||-RSB--30/FW||impairedglucosetolerance-27/FW	nn||-RSB--30/FW||-LSB--28/FW	nn||-RSB--30/FW||igt-29/FW	appos||glucose-25/NN||-RSB--30/FW	advmod||diagnosed-34/VBN||newly-33/RB	amod||type2diabetes-35/NNS||diagnosed-34/VBN	appos||-RSB--21/NNP||type2diabetes-35/NNS	conj_and||glucose-25/NN||type2diabetes-35/NNS	nn||duration-39/NN||diabetes-38/NN	dobj||identified-2/VBD||duration-39/NN	conj_and||individuals-4/NNS||duration-39/NN	dep||duration-39/NN||0â-41/VBN	dobj||0â-41/VBN||$-42/$	num||$-42/$||9-44/CD	amod||$-47/$||10â-46/JJ	appos||$-42/$||$-47/$	num||$-47/$||19-49/CD	amod||-53/NNS||â-52/JJ	appos||$-42/$||-53/NNS	conj_and||$-47/$||-53/NNS	dep||years-56/NNS||¥-54/SYM	num||years-56/NNS||20-55/CD	dep||0â-41/VBN||years-56/NNS	type2diabetes-35||glucose-25||no_rel||we identified 425 individuals, divided into seven categories according to carbohydrate metabolism status (normal glucose tolerance [ngt], impaired fasting glucose, impairedglucosetolerance [igt], and newly diagnosed type2diabetes) and diabetes duration (0â9, 10â19, and â¥20 years).
det||finding-2/NN||the-1/DT	nsubj||help-11/VB||finding-2/NN	det||function-6/NN||a-4/DT	amod||function-6/NN||non-cell-autonomous-5/JJ	prep_of||finding-2/NN||function-6/NN	amod||cells-9/NNS||mutant-8/JJ	prep_of||function-6/NN||cells-9/NNS	aux||help-11/VB||might-10/MD	root||ROOT-0/null||help-11/VB	xcomp||help-11/VB||explain-12/VB	det||formation-14/NN||the-13/DT	dobj||explain-12/VB||formation-14/NN	nn||hamartomas-17/NNS||brain-16/NN	prep_of||formation-14/NN||hamartomas-17/NNS	amod||malformations-20/NNS||cortical-19/JJ	dobj||explain-12/VB||malformations-20/NNS	conj_and||formation-14/NN||malformations-20/NNS	amod||tsc-23/NN||human-22/JJ	prep_in||malformations-20/NNS||tsc-23/NN	tsc-23||hamartomas-17||no||the finding of a non-cell-autonomous function of mutant cells might help explain the formation of brain hamartomas and cortical malformations in human tsc.
det||pathophysiology-2/NN||the-1/DT	nsubjpass||attributed-7/VBN||pathophysiology-2/NN	prep_of||pathophysiology-2/NN||type2diabetes-4/CD	aux||attributed-7/VBN||has-5/VBZ	auxpass||attributed-7/VBN||been-6/VBN	root||ROOT-0/null||attributed-7/VBN	det||triad-11/NN||the-9/DT	amod||triad-11/NN||classic-10/JJ	prep_to||attributed-7/VBN||triad-11/NN	amod||secretion-15/NN||decreased-13/VBN	nn||secretion-15/NN||insulin-14/NN	prep_of||triad-11/NN||secretion-15/NN	amod||insulinresistance-18/NN||increased-17/VBN	prep_of||triad-11/NN||insulinresistance-18/NN	conj_and||secretion-15/NN||insulinresistance-18/NN	amod||production-24/NN||elevated-21/JJ	amod||production-24/NN||hepatic-22/JJ	nn||production-24/NN||glucose-23/NN	prep_of||triad-11/NN||production-24/NN	conj_and||secretion-15/NN||production-24/NN	type2diabetes-4||insulin-14||yes||the pathophysiology of type2diabetes has been attributed to the classic triad of decreased insulin secretion, increased insulinresistance, and elevated hepatic glucose production.
prep_in||able-7/JJ||addition-2/NN	det||ica-5/NN||the-4/DT	nsubj||able-7/JJ||ica-5/NN	nsubj||detect-9/VB||ica-5/NN	cop||able-7/JJ||was-6/VBD	root||ROOT-0/null||able-7/JJ	aux||detect-9/VB||to-8/TO	xcomp||able-7/JJ||detect-9/VB	num||sample-12/NN||1-10/CD	amod||sample-12/NN||positive-11/JJ	dobj||detect-9/VB||sample-12/NN	dep||detect-9/VB||from-13/IN	num||sera-16/NN||50-15/CD	prep_among||detect-9/VB||sera-16/NN	nsubj||tested-23/VBN||sera-16/NN	amod||patients-20/NNS||acute-18/JJ	nn||patients-20/NNS||hepatitis-19/NN	prep_from||sera-16/NN||patients-20/NNS	aux||tested-23/VBN||had-22/VBD	rcmod||sera-16/NN||tested-23/VBN	acomp||tested-23/VBN||negative-24/JJ	amod||igm-27/NN||anti-hav-26/JJ	prep_for||tested-23/VBN||igm-27/NN	vmod||igm-27/NN||using-28/VBG	det||meia-30/NN||the-29/DT	dobj||using-28/VBG||meia-30/NN	hepatitis-19||anti-hav-26||no_rel||in addition, the ica was able to detect 1 positive sample from among 50 sera from acute hepatitis patients that had tested negative for anti-hav igm using the meia.
det||results-3/NNS||the-1/DT	amod||results-3/NNS||overall-2/JJ	nsubj||show-11/VBP||results-3/NNS	prep_of||results-3/NNS||uri-5/NN	prep_of||results-3/NNS||lri-7/NN	conj_and||uri-5/NN||lri-7/NN	prep_of||results-3/NNS||ip-10/NN	conj_and||uri-5/NN||ip-10/NN	root||ROOT-0/null||show-11/VBP	amod||correlation-13/NN||clear-12/JJ	iobj||show-11/VBP||correlation-13/NN	amod||pm10-19/NNS||so2-15/JJ	conj_and||so2-15/JJ||co-17/NN	amod||pm10-19/NNS||co-17/NN	prep_with||correlation-13/NN||pm10-19/NNS	prep_with||correlation-13/NN||o3-21/NNS	conj_and||pm10-19/NNS||o3-21/NNS	iobj||show-11/VBP||pm10-24/NNS	conj_and||correlation-13/NN||pm10-24/NNS	advmod||pm10-24/NNS||respectively-26/RB	det||etw4-30/NN||the-29/DT	iobj||show-11/VBP||etw4-30/NN	conj_and||correlation-13/NN||etw4-30/NN	amod||temperature-33/NN||effective-32/JJ	appos||etw4-30/NN||temperature-33/NN	predet||the-37/DT||all-36/PDT	prep_for||etw4-30/NN||the-37/DT	num||groups-40/NNS||three-38/CD	nn||groups-40/NNS||disease-39/NN	dobj||show-11/VBP||groups-40/NNS	uri-5||so2-15||no_rel||the overall results of uri, lri, and ip show clear correlation with so2 and co, pm10 and o3, and pm10, respectively, and the etw4 (effective temperature) for all the three disease groups.
nsubj||included-2/VBD||these-1/DT	root||ROOT-0/null||included-2/VBD	det||role-4/NN||the-3/DT	dobj||included-2/VBD||role-4/NN	prep_of||role-4/NN||statins-6/NNS	det||agent-10/NN||an-8/DT	amod||agent-10/NN||anti-lipid-9/JJ	appos||statins-6/NNS||agent-10/NN	prepc_in||included-2/VBD||reducing-13/VBG	amod||morbidity-15/NN||post-stroke-14/JJ	dobj||reducing-13/VBG||morbidity-15/NN	dobj||reducing-13/VBG||mortality-17/NN	conj_and||morbidity-15/NN||mortality-17/NN	prepc_in||included-2/VBD||decreasing-20/VBG	conj_and||reducing-13/VBG||decreasing-20/VBG	det||plaque-24/NN||the-21/DT	amod||plaque-24/NN||carotid-22/JJ	amod||plaque-24/NN||atherosclerotic-23/JJ	dobj||decreasing-20/VBG||plaque-24/NN	prep_in||plaque-24/NN||middle-26/NN	vmod||middle-26/NN||aged-27/VBN	dobj||aged-27/VBN||patients-28/NNS	amod||risk-31/NN||increased-30/VBN	prep_at||aged-27/VBN||risk-31/NN	prep_of||risk-31/NN||cardiovasculardisease-33/NN	amod||infusion-36/NN||glucose-potassium-insulin-35/JJ	dobj||decreasing-20/VBG||infusion-36/NN	conj_and||plaque-24/NN||infusion-36/NN	amod||acute-39/JJ||hyperglyceamic-38/JJ	amod||patients-41/NNS||acute-39/JJ	nn||patients-41/NNS||stroke-40/NN	prep_in||infusion-36/NN||patients-41/NNS	dep||infusion-36/NN||pioglitazone-43/VB	det||medication-47/NN||an-45/DT	amod||medication-47/NN||anti-diabetic-46/JJ	dobj||pioglitazone-43/VB||medication-47/NN	nsubj||reduce-50/VB||medication-47/NN	aux||reduce-50/VB||to-49/TO	xcomp||pioglitazone-43/VB||reduce-50/VB	dobj||reduce-50/VB||recurrence-51/NN	prep_of||recurrence-51/NN||stroke-53/NN	nn||patients-58/NNS||type-55/NN	num||patients-58/NNS||2-56/CD	nn||patients-58/NNS||diabetic-57/NN	prep_in||reduce-50/VB||patients-58/NNS	parataxis||pioglitazone-43/VB||administration-60/NN	amod||urokinase-63/NN||intra-arterial-62/JJ	prep_of||administration-60/NN||urokinase-63/NN	det||agent-67/NN||a-65/DT	amod||agent-67/NN||thrombolytic-66/JJ	appos||urokinase-63/NN||agent-67/NN	det||role-71/NN||the-70/DT	prep_of||administration-60/NN||role-71/NN	conj_and||urokinase-63/NN||role-71/NN	nn||therapy-74/NN||laser-73/NN	prep_of||role-71/NN||therapy-74/NN	amod||dissolution-77/NN||clot-76/JJ	prep_in||therapy-74/NN||dissolution-77/NN	dep||administration-60/NN||given-78/VBN	mark||is-83/VBZ||that-79/IN	prep_at||is-83/VBZ||present-81/JJ	expl||is-83/VBZ||there-82/EX	pcomp||given-78/VBN||is-83/VBZ	advmod||fda-86/NN||only-84/RB	num||fda-86/NN||one-85/CD	nsubj||is-83/VBZ||fda-86/NN	vmod||fda-86/NN||approved-87/VBN	amod||agent-89/NN||thrombolytic-88/JJ	dobj||approved-87/VBN||agent-89/NN	nn||tpa-92/NN||r-91/NN	dep||administration-60/NN||tpa-92/NN	parataxis||pioglitazone-43/VB||benefit-95/VB	prep_of||benefit-95/VB||warfarin-97/NN	det||anticoagulant-100/NN||an-99/DT	appos||warfarin-97/NN||anticoagulant-100/NN	amod||patients-104/NNS||elderly-103/JJ	prep_in||warfarin-97/NN||patients-104/NNS	prep_with||benefit-95/VB||atrialfibrillation-106/NN	det||community-109/NN||the-108/DT	prep_in||atrialfibrillation-106/NN||community-109/NN	parataxis||pioglitazone-43/VB||nxy-111/VB	det||agent-117/NN||a-113/DT	amod||radical-115/JJ||free-114/JJ	amod||agent-117/NN||radical-115/JJ	amod||agent-117/NN||trapping-116/JJ	dep||nxy-111/VB||agent-117/NN	parataxis||pioglitazone-43/VB||minocycline-120/VB	conj_and||nxy-111/VB||minocycline-120/VB	det||tested-122/NN||both-121/DT	dobj||nxy-111/VB||tested-122/NN	prep_as||nxy-111/VB||neuroprotectants-124/NNS	dobj||decreasing-20/VBG||zoledronate-127/NN	conj_and||plaque-24/NN||zoledronate-127/NN	det||bisphosphonate-131/NN||an-129/DT	amod||bisphosphonate-131/NN||intravenous-130/JJ	appos||zoledronate-127/NN||bisphosphonate-131/NN	aux||prevent-134/VB||to-133/TO	vmod||zoledronate-127/NN||prevent-134/VB	dobj||prevent-134/VB||loss-135/NN	nn||density-139/NN||bone-137/NN	nn||density-139/NN||mineral-138/NN	prep_of||loss-135/NN||density-139/NN	det||extremity-143/NN||the-141/DT	amod||extremity-143/NN||affected-142/VBN	prep_of||density-139/NN||extremity-143/NN	advmod||role-148/NN||finally-146/RB	det||role-148/NN||the-147/DT	prep_of||density-139/NN||role-148/NN	conj_and||extremity-143/NN||role-148/NN	prep_of||role-148/NN||nicardipine-150/NN	det||calciumchannelblocker-153/NN||a-152/DT	appos||nicardipine-150/NN||calciumchannelblocker-153/NN	det||prevention-157/NN||the-156/DT	prep_in||nicardipine-150/NN||prevention-157/NN	prep_of||prevention-157/NN||vasospasm-159/NN	vmod||zoledronate-127/NN||hydrocortisone-162/VB	conj_and||prevent-134/VB||hydrocortisone-162/VB	aux||prevent-164/VB||to-163/TO	xcomp||hydrocortisone-162/VB||prevent-164/VB	dobj||prevent-164/VB||hyponatraemia-165/NN	amod||hemorrhage-168/NN||sub-arachnoid-167/JJ	prep_after||prevent-164/VB||hemorrhage-168/NN	atrialfibrillation-106||warfarin-97||yes||these included the role of statins (an anti-lipid agent) in reducing post-stroke morbidity and mortality, and decreasing the carotid atherosclerotic plaque in middle aged patients at increased risk of cardiovasculardisease; glucose-potassium-insulin infusion in hyperglyceamic acute stroke patients; pioglitazone (an anti-diabetic medication) to reduce recurrence of stroke in type 2 diabetic patients; administration of intra-arterial urokinase (a thrombolytic agent) and the role of laser therapy in clot dissolution given that at present there is only one fda approved thrombolytic agent (r tpa); benefit of warfarin (an anticoagulant) in elderly patients with atrialfibrillation in the community; nxy (a free radical trapping agent) and minocycline both tested as neuroprotectants; and zoledronate (an intravenous bisphosphonate) to prevent loss of bone mineral density of the affected extremity, and finally the role of nicardipine (a calciumchannelblocker) in the prevention of vasospasm, and hydrocortisone to prevent hyponatraemia after sub-arachnoid hemorrhage.
nn||predictors-2/NNS||baseline-1/NN	nsubjpass||identified-56/VBN||predictors-2/NNS	prep_of||predictors-2/NNS||level-4/NN	amod||acuity-7/NN||visual-6/JJ	prep_of||level-4/NN||acuity-7/NN	dep||acuity-7/NN||age-9/NN	amod||amd-13/NN||age-relatedmaculardegeneration-11/JJ	dep||acuity-7/NN||amd-13/NN	conj_and||age-9/NN||amd-13/NN	dep||acuity-7/NN||cataract-16/NN	conj_and||age-9/NN||cataract-16/NN	dep||acuity-7/NN||living-18/NN	conj_and||age-9/NN||living-18/NN	advmod||living-18/NN||alone-19/RB	amod||health-23/NN||low-21/JJ	amod||health-23/NN||self-rated-22/JJ	dep||acuity-7/NN||health-23/NN	conj_and||age-9/NN||health-23/NN	amod||life-style-27/NN||sedentary-26/JJ	dep||acuity-7/NN||life-style-27/NN	conj_and||age-9/NN||life-style-27/NN	prep_of||predictors-2/NNS||speed-30/NN	conj_and||level-4/NN||speed-30/NN	amod||loss-34/NN||continued-32/VBN	amod||loss-34/NN||visual-33/JJ	prep_of||speed-30/NN||loss-34/NN	nn||dr-42/NN||age-36/NN	dep||dr-42/NN||amd-38/NN	dep||dr-42/NN||diabeticretinopathy-40/NN	dep||loss-34/NN||dr-42/NN	appos||dr-42/NN||cataract-45/NN	appos||dr-42/NN||living-47/NN	conj_and||cataract-45/NN||living-47/NN	advmod||living-47/NN||alone-48/RB	amod||triglycerides-53/NNPS||high-51/JJ	amod||triglycerides-53/NNPS||fasting-52/VBG	appos||dr-42/NN||triglycerides-53/NNPS	conj_and||cataract-45/NN||triglycerides-53/NNPS	auxpass||identified-56/VBN||were-55/VBD	root||ROOT-0/null||identified-56/VBN	diabeticretinopathy-40||triglycerides-53||no_rel||baseline predictors of level of visual acuity (age, age-relatedmaculardegeneration (amd), cataract, living alone, low self-rated health, and sedentary life-style) and speed of continued visual loss (age, amd, diabeticretinopathy (dr), cataract, living alone, and high fasting triglycerides) were identified.
advmod||cultured-2/VBD||when-1/WRB	advcl||showed-19/VBD||cultured-2/VBD	nn||selenium-7/NN||insulin-4/NN	dep||selenium-7/NN||transferrin-6/NN	prep_in||cultured-2/VBD||selenium-7/NN	nn||media-10/NNS||fibronectin-9/NN	prep_in||cultured-2/VBD||media-10/NNS	conj_and||selenium-7/NN||media-10/NNS	amod||factors-15/NNS||basic-12/JJ	nn||factors-15/NNS||fibroblast-13/NN	nn||factors-15/NNS||growth-14/NN	prep_with||cultured-2/VBD||factors-15/NNS	nn||cells-18/NNS||tumour-17/NN	nsubj||showed-19/VBD||cells-18/NNS	nsubj||phenotypes-23/VBZ||cells-18/NNS	root||ROOT-0/null||showed-19/VBD	amod||morphology-21/NN||neuronal-20/JJ	dobj||showed-19/VBD||morphology-21/NN	conj_and||showed-19/VBD||phenotypes-23/VBZ	basic-12||tumour-17||no_rel||when cultured in insulin, transferrin selenium and fibronectin media with basic fibroblast growth factors, tumour cells showed neuronal morphology and phenotypes.
advmod||dissatisfied-10/VBN||however-1/RB	quantmod||10-4/CD||approximately-3/RB	num||%-5/NN||10-4/CD	nsubjpass||dissatisfied-10/VBN||%-5/NN	amod||patients-8/NNS||hypothyroid-7/JJ	prep_of||%-5/NN||patients-8/NNS	auxpass||dissatisfied-10/VBN||are-9/VBP	root||ROOT-0/null||dissatisfied-10/VBN	det||outcome-13/NN||the-12/DT	prep_with||dissatisfied-10/VBN||outcome-13/NN	amod||monotherapy-16/NN||levothyroxine-15/JJ	prep_of||outcome-13/NN||monotherapy-16/NN	nsubj||continue-20/VBP||physicians-19/NNS	nsubj||report-22/VB||physicians-19/NNS	conj_and||dissatisfied-10/VBN||continue-20/VBP	aux||report-22/VB||to-21/TO	xcomp||continue-20/VBP||report-22/VB	dobj||report-22/VB||benefits-23/NNS	amod||therapy-27/NN||combined-25/VBN	amod||therapy-27/NN||levothyroxine-triidothyronine-26/JJ	prep_from||report-22/VB||therapy-27/NN	det||patients-31/NNS||some-29/DT	amod||patients-31/NNS||hypothyroid-30/JJ	prep_for||therapy-27/NN||patients-31/NNS	hypothyroid-30||levothyroxine-15||yes||however, approximately 10% of hypothyroid patients are dissatisfied with the outcome of levothyroxine monotherapy, and physicians continue to report benefits from combined levothyroxine-triidothyronine therapy for some hypothyroid patients.
advmod||precisely-2/JJ||more-1/RBR	ccomp||was-5/VBD||precisely-2/JJ	expl||was-5/VBD||there-4/EX	root||ROOT-0/null||was-5/VBD	det||decline-8/NN||a-6/DT	amod||decline-8/NN||profound-7/JJ	nsubj||was-5/VBD||decline-8/NN	amod||copies-12/NNS||2-ltr-10/JJ	nn||copies-12/NNS||dna-11/NN	prep_in||decline-8/NN||copies-12/NNS	dep||copies-12/NNS||marker-14/NN	amod||entry-17/NN||nuclear-16/JJ	prep_for||marker-14/NN||entry-17/NN	prep_of||entry-17/NN||hivdna-19/NN	det||level-24/NN||an-22/DT	amod||level-24/NN||unchanged-23/JJ	prep_in||decline-8/NN||level-24/NN	conj_and||copies-12/NNS||level-24/NN	amod||transcription-28/NN||viral-26/JJ	amod||transcription-28/NN||reverse-27/JJ	prep_of||decline-8/NN||transcription-28/NN	amod||cells-32/NNS||ranbp2-ablated-30/JJ	amod||cells-32/NNS||hiv-infected-31/JJ	prep_in||transcription-28/NN||cells-32/NNS	prepc_compared_to||cells-32/NNS||to-34/TO	amod||controls-39/NNS||ranbp3-depleted-35/JJ	conj_or||ranbp3-depleted-35/JJ||non-specific-37/JJ	amod||controls-39/NNS||non-specific-37/JJ	nn||controls-39/NNS||sirna-38/NN	pobj||cells-32/NNS||controls-39/NNS	hivdna-19||hiv--1||no||more precisely, there was a profound decline in 2-ltr dna copies (marker for nuclear entry of hivdna) and an unchanged level of viral reverse transcription in ranbp2-ablated hiv-infected cells compared to ranbp3-depleted or non-specific sirna controls.
nsubj||therapy-7/NN||tamoxifen-1/NN	cop||therapy-7/NN||is-2/VBZ	det||therapy-7/NN||the-3/DT	advmod||prescribed-6/JJ||most-4/RBS	advmod||prescribed-6/JJ||commonly-5/RB	amod||therapy-7/NN||prescribed-6/JJ	root||ROOT-0/null||therapy-7/NN	prep_for||therapy-7/NN||patients-9/NNS	nn||receptor-12/NN||estrogen-11/NN	prep_with||patients-9/NNS||receptor-12/NN	dep||therapy-7/NN||er-14/VBN	nn||±-17/NNS||î-16/NN	dep||therapy-7/NN||±-17/NNS	amod||breasttumors-20/NNS||positive-19/JJ	dep||±-17/NNS||breasttumors-20/NNS	breasttumors-20||tamoxifen-1||yes||tamoxifen is the most commonly prescribed therapy for patients with estrogen receptor (er)î±-positive breasttumors.
amod||peripheralneuropathy-2/NN||bortezomib-associated-1/JJ	nsubjpass||reported-10/VBN||peripheralneuropathy-2/NN	nsubj||appears-12/VBZ||peripheralneuropathy-2/NN	nsubj||resolve-14/VB||peripheralneuropathy-2/NN	prep_in||peripheralneuropathy-2/NN||patients-4/NNS	prep_with||patients-4/NNS||multiplemyeloma-6/NN	aux||reported-10/VBN||has-7/VBZ	auxpass||reported-10/VBN||been-8/VBN	advmod||reported-10/VBN||commonly-9/RB	root||ROOT-0/null||reported-10/VBN	conj_but||reported-10/VBN||appears-12/VBZ	aux||resolve-14/VB||to-13/TO	xcomp||appears-12/VBZ||resolve-14/VB	det||majority-17/NN||a-16/DT	prep_in||resolve-14/VB||majority-17/NN	det||patients-20/NNS||these-19/DT	prep_of||majority-17/NN||patients-20/NNS	nn||reduction-23/NN||dose-22/NN	prep_after||resolve-14/VB||reduction-23/NN	prep_after||resolve-14/VB||discontinuation-25/NN	conj_or||reduction-23/NN||discontinuation-25/NN	multiplemyeloma-6||bortezomib--1||yes||bortezomib-associated peripheralneuropathy in patients with multiplemyeloma has been commonly reported but appears to resolve in a majority of these patients after dose reduction or discontinuation.
nsubj||found-2/VBD||we-1/PRP	root||ROOT-0/null||found-2/VBD	neg||correlation-4/NN||no-3/DT	dobj||found-2/VBD||correlation-4/NN	amod||rates-8/NNS||high-6/JJ	nn||rates-8/NNS||mdr-7/NN	prep_between||correlation-4/NN||rates-8/NNS	nn||incidence-11/NN||tb-10/NN	dobj||found-2/VBD||incidence-11/NN	conj_and||correlation-4/NN||incidence-11/NN	amod||rates-15/NNS||hiv/tb-13/JJ	amod||rates-15/NNS||co-infection-14/JJ	appos||incidence-11/NN||rates-15/NNS	dobj||found-2/VBD||year-18/NN	conj_or||correlation-4/NN||year-18/NN	prep_of||year-18/NN||introduction-20/NN	prep_of||introduction-20/NN||rifampin-22/NN	tb-10||rifampin-22||yes||we found no correlation between high mdr rates and tb incidence, hiv/tb co-infection rates, or year of introduction of rifampin.
prep_in||associated-8/VBN||people-2/NNS	amod||mutations-6/NNS||abcb4-4/JJ	nn||mutations-6/NNS||gene-5/NN	nsubjpass||associated-8/VBN||mutations-6/NNS	auxpass||associated-8/VBN||are-7/VBP	root||ROOT-0/null||associated-8/VBN	amod||syndromes-12/NNS||several-10/JJ	nn||syndromes-12/NNS||disease-11/NN	prep_with||associated-8/VBN||syndromes-12/NNS	amod||cholestasis-15/NNS||intrahepatic-14/JJ	prep_including||syndromes-12/NNS||cholestasis-15/NNS	prep_of||cholestasis-15/NNS||pregnancy-17/NN	amod||cholestasis-22/NNS||progressive-19/JJ	amod||cholestasis-22/NNS||familial-20/JJ	amod||cholestasis-22/NNS||intrahepatic-21/JJ	prep_of||cholestasis-15/NNS||cholestasis-22/NNS	conj_and||pregnancy-17/NN||cholestasis-22/NNS	appos||pregnancy-17/NN||type-24/NN	num||type-24/NN||3-25/CD	prep_of||cholestasis-15/NNS||primarybiliarycirrhosis-28/NNS	conj_and||pregnancy-17/NN||primarybiliarycirrhosis-28/NNS	prep_of||cholestasis-15/NNS||cholelithiasis-31/NNS	conj_and||pregnancy-17/NN||cholelithiasis-31/NNS	primarybiliarycirrhosis-28||cholestasis-22||no||in people, abcb4 gene mutations are associated with several disease syndromes including intrahepatic cholestasis of pregnancy, progressive familial intrahepatic cholestasis (type 3), primarybiliarycirrhosis, and cholelithiasis.
amod||analyses-2/NNS||hydrogeological-1/JJ	nsubj||revealed-3/VBD||analyses-2/NNS	root||ROOT-0/null||revealed-3/VBD	mark||influenced-7/VBN||that-4/IN	nsubjpass||influenced-7/VBN||dentalfluorosis-5/NNS	auxpass||influenced-7/VBN||is-6/VBZ	ccomp||revealed-3/VBD||influenced-7/VBN	det||concentration-10/NN||the-9/DT	agent||influenced-7/VBN||concentration-10/NN	prep_of||concentration-10/NN||fluoride-12/NN	cc||%-18/NN||or-14/CC	nn||2.59-16/FW||=-15/FW	dep||%-18/NN||2.59-16/FW	num||%-18/NN||ci95-17/CD	dep||fluoride-12/NN||%-18/NN	num||â-20/NN||1.07-19/CD	dep||%-18/NN||â-20/NN	dep||â-20/NN||$-21/$	npadvmod||=-26/RB||6.27-23/NNS	dep||6.27-23/NNS||p-25/NN	dep||0.073-27/CD||=-26/RB	num||$-21/$||0.073-27/CD	prep_of||concentration-10/NN||bicarbonate-30/NN	conj_and||fluoride-12/NN||bicarbonate-30/NN	cc||%-36/NN||or-32/CC	dep||%-36/NN||=-33/RB	num||%-36/NN||1.02-34/CD	num||%-36/NN||ci95-35/CD	dep||fluoride-12/NN||%-36/NN	num||â-38/NN||1.01-37/CD	dep||%-36/NN||â-38/NN	dep||â-38/NN||$-39/$	npadvmod||=-44/RB||1.03-41/NNS	dep||1.03-41/NNS||p-43/NN	dep||0.060-45/CD||=-44/RB	num||$-39/$||0.060-45/CD	det||water-49/NN||the-48/DT	prep_in||influenced-7/VBN||water-49/NN	amod||wells-52/NNS||deep-51/JJ	prep_of||water-49/NN||wells-52/NNS	dentalfluorosis-5||fluoride-12||no||hydrogeological analyses revealed that dentalfluorosis is influenced by the concentration of fluoride (or = 2.59 ci95% 1.07â6.27; p = 0.073) and bicarbonate (or = 1.02 ci95% 1.01â1.03; p = 0.060) in the water of deep wells.
prep_in||proved-9/VBN||patients-2/NNS	amod||hypertension-5/NN||mild-to-moderate-4/JJ	prep_with||patients-2/NNS||hypertension-5/NN	nsubj||proved-9/VBN||telmisartan-7/NN	aux||proved-9/VBN||has-8/VBZ	root||ROOT-0/null||proved-9/VBN	acomp||proved-9/VBN||superior-10/JJ	amod||antihypertensiveagents-13/NNS||other-12/JJ	prep_to||superior-10/JJ||antihypertensiveagents-13/NNS	dep||antihypertensiveagents-13/NNS||valsartan-15/NN	dep||antihypertensiveagents-13/NNS||losartan-17/NN	conj_and||valsartan-15/NN||losartan-17/NN	dep||antihypertensiveagents-13/NNS||ramipril-19/NN	conj_and||valsartan-15/NN||ramipril-19/NN	dep||antihypertensiveagents-13/NNS||perindopril-21/NN	conj_and||valsartan-15/NN||perindopril-21/NN	dep||antihypertensiveagents-13/NNS||atenolol-24/NN	conj_and||valsartan-15/NN||atenolol-24/NN	amod||pressure-29/NN||controlling-27/JJ	nn||pressure-29/NN||blood-28/NN	prep_in||antihypertensiveagents-13/NNS||pressure-29/NN	advmod||proved-9/VBN||particularly-30/RB	det||end-33/NN||the-32/DT	prep_towards||proved-9/VBN||end-33/NN	det||interval-37/NN||the-35/DT	amod||interval-37/NN||dosing-36/JJ	prep_of||end-33/NN||interval-37/NN	hypertension-5||perindopril-21||yes||in patients with mild-to-moderate hypertension, telmisartan has proved superior to other antihypertensiveagents (valsartan, losartan, ramipril, perindopril, and atenolol) in controlling blood pressure particularly towards the end of the dosing interval.
det||time-4/NN||the-2/DT	amod||time-4/NN||first-3/JJ	prep_for||brings-16/VBZ||time-4/NN	det||supplement-7/NN||this-6/DT	nsubj||brings-16/VBZ||supplement-7/NN	det||journal-10/NN||the-9/DT	prep_to||supplement-7/NN||journal-10/NN	det||society-15/NN||the-12/DT	amod||society-15/NN||international-13/JJ	nn||society-15/NN||aids-14/NNS	prep_of||journal-10/NN||society-15/NN	root||ROOT-0/null||brings-16/VBZ	prt||brings-16/VBZ||together-17/RP	num||place-20/NN||one-19/CD	prep_in||brings-16/VBZ||place-20/NN	det||rationale-22/NN||the-21/DT	dobj||brings-16/VBZ||rationale-22/NN	amod||services-25/NNS||family-centred-24/JJ	prep_for||rationale-22/NN||services-25/NNS	prep_for||services-25/NNS||children-27/NNS	vmod||children-27/NNS||affected-28/VBN	agent||affected-28/VBN||hiv-30/NN	agent||affected-28/VBN||aids-32/NNS	conj_and||hiv-30/NN||aids-32/NNS	prep_for||rationale-22/NN||some-34/DT	conj_and||services-25/NNS||some-34/DT	det||evidence-38/NN||the-36/DT	amod||evidence-38/NN||available-37/JJ	prep_of||some-34/DT||evidence-38/NN	det||effectiveness-41/NN||the-40/DT	prep_for||evidence-38/NN||effectiveness-41/NN	prepc_of||effectiveness-41/NN||doing-43/VBG	advmod||doing-43/VBG||so-44/RB	aids-32||hiv-30||no||for the first time, this supplement to the journal of the international aids society brings together in one place the rationale for family-centred services for children affected by hiv and aids and some of the available evidence for the effectiveness of doing so.
advmod||produced-2/VBN||endogenously-1/RB	amod||autacoids-4/NNS||produced-2/VBN	nn||autacoids-4/NNS||lipid-3/NN	nsubj||acting-7/VBG||autacoids-4/NNS	aux||acting-7/VBG||are-5/VBP	advmod||acting-7/VBG||locally-6/RB	root||ROOT-0/null||acting-7/VBG	amod||mediators-10/NNS||small-8/JJ	nn||mediators-10/NNS||molecule-9/NN	dobj||acting-7/VBG||mediators-10/NNS	nsubj||play-12/VBP||mediators-10/NNS	rcmod||mediators-10/NNS||play-12/VBP	det||role-15/NN||a-13/DT	amod||role-15/NN||central-14/JJ	dobj||play-12/VBP||role-15/NN	det||regulation-18/NN||the-17/DT	prep_in||role-15/NN||regulation-18/NN	nn||homeostasis-23/NNS||inflammation-20/NN	conj_and||inflammation-20/NN||tissue-22/NN	nn||homeostasis-23/NNS||tissue-22/NN	prep_of||regulation-18/NN||homeostasis-23/NNS	lipid-3||inflammation-20||no_rel||endogenously produced lipid autacoids are locally acting small molecule mediators that play a central role in the regulation of inflammation and tissue homeostasis.
nsubj||unknown-3/JJ||it-1/PRP	cop||unknown-3/JJ||is-2/VBZ	root||ROOT-0/null||unknown-3/JJ	mark||associated-18/VBN||whether-4/IN	amod||activation-7/NN||t-5/JJ	nn||activation-7/NN||cell-6/NN	nsubjpass||associated-18/VBN||activation-7/NN	conj_and||activation-7/NN||senescence-9/NN	nsubjpass||associated-18/VBN||senescence-9/NN	num||sequelae-13/NN||2-11/CD	amod||sequelae-13/NN||immunologic-12/JJ	appos||activation-7/NN||sequelae-13/NN	prep_of||sequelae-13/NN||hivinfection-15/NN	auxpass||associated-18/VBN||are-17/VBP	ccomp||unknown-3/JJ||associated-18/VBN	prep_with||associated-18/VBN||vasculardisease-20/NN	amod||adults-23/NNS||hiv-infected-22/JJ	prep_among||associated-18/VBN||adults-23/NNS	hivinfection-15||hiv--1||no||it is unknown whether t cell activation and senescence, 2 immunologic sequelae of hivinfection, are associated with vasculardisease among hiv-infected adults.
det||potential-7/NN||an-1/DT	advmod||high-3/JJ||unexpectedly-2/RB	amod||potential-7/NN||high-3/JJ	amod||potential-7/NN||seroprevalence-4/JJ	conj_and||seroprevalence-4/JJ||pathogenic-6/JJ	amod||potential-7/NN||pathogenic-6/JJ	nsubjpass||observed-16/VBN||potential-7/NN	amod||parvovirusb19-10/NNS||human-9/JJ	prep_of||potential-7/NN||parvovirusb19-10/NNS	appos||potential-7/NN||b19v-12/NNP	aux||observed-16/VBN||have-14/VBP	auxpass||observed-16/VBN||been-15/VBN	root||ROOT-0/null||observed-16/VBN	amod||countries-20/NNS||certain-18/JJ	amod||countries-20/NNS||malaria-endemic-19/JJ	prep_in||observed-16/VBN||countries-20/NNS	prep_in||countries-20/NNS||parallel-22/NN	amod||use-25/NN||local-24/JJ	prep_with||observed-16/VBN||use-25/NN	prep_of||use-25/NN||chloroquine-27/NN	appos||chloroquine-27/NN||cq-29/NN	amod||treatment-33/NN||first-line-32/JJ	prep_as||observed-16/VBN||treatment-33/NN	prep_for||treatment-33/NN||malaria-35/NN	malaria-35||chloroquine-27||yes||an unexpectedly high seroprevalence and pathogenic potential of human parvovirusb19 (b19v) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (cq) as first-line treatment for malaria.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||significance-5/NN||the-3/DT	amod||significance-5/NN||clinical-4/JJ	dobj||investigated-2/VBD||significance-5/NN	amod||immunoglobulin-9/NN||serum-7/JJ	amod||immunoglobulin-9/NN||specific-8/JJ	prep_of||significance-5/NN||immunoglobulin-9/NN	dep||significance-5/NN||e-10/SYM	appos||significance-5/NN||lge-12/NN	det||enterotoxin-19/NN||the-15/DT	amod||enterotoxin-19/NN||staphylococcal-16/JJ	nn||enterotoxin-19/NN||superantigens-17/NNS	nn||enterotoxin-19/NN||staphylococcal-18/NN	prep_to||investigated-2/VBD||enterotoxin-19/NN	det||sea-22/NN||a-20/DT	dep||enterotoxin-19/NN||sea-22/NN	amod||enterotoxin-26/NN||staphylococcal-25/JJ	prep_to||investigated-2/VBD||enterotoxin-26/NN	conj_and||enterotoxin-19/NN||enterotoxin-26/NN	dep||enterotoxin-26/NN||b-27/SYM	appos||b-27/SYM||seb-29/NN	amod||toxin-34/NN||toxicshocksyndrome-33/JJ	prep_to||investigated-2/VBD||toxin-34/NN	conj_and||enterotoxin-19/NN||toxin-34/NN	appos||toxin-34/NN||tsst-36/NN	dep||toxin-34/NN||-1-38/CD	prep_in||investigated-2/VBD||patients-40/NNS	amod||urticaria-43/NN||chronic-42/JJ	prep_with||patients-40/NNS||urticaria-43/NN	appos||urticaria-43/NN||cu-45/NN	vmod||investigated-2/VBD||focusing-48/VBG	det||differences-51/NNS||the-50/DT	prep_on||focusing-48/VBG||differences-51/NNS	det||prevalences-54/NNS||these-53/DT	prep_in||differences-51/NNS||prevalences-54/NNS	amod||cu-57/NN||aspirin-intolerant-56/JJ	prep_between||prevalences-54/NNS||cu-57/NN	appos||cu-57/NN||aicu-59/NNP	amod||patients-67/NNS||aspirin-tolerant-62/JJ	nn||patients-67/NNS||cu-63/NN	appos||patients-67/NNS||atcu-65/NNP	prep_between||prevalences-54/NNS||patients-67/NNS	conj_and||cu-57/NN||patients-67/NNS	enterotoxin-26||toxicshocksyndrome-33||no_rel||we investigated the clinical significance of serum specific immunoglobulin e (lge) to the staphylococcal superantigens staphylococcal enterotoxin a (sea), staphylococcal enterotoxin b (seb), and toxicshocksyndrome toxin (tsst)-1 in patients with chronic urticaria (cu), focusing on the differences in these prevalences between aspirin-intolerant cu (aicu) and aspirin-tolerant cu (atcu) patients.
nsubj||effect-9/NN||pain-1/NN	amod||injection-4/NN||propofol-3/JJ	prep_on||pain-1/NN||injection-4/NN	cop||effect-9/NN||is-5/VBZ	det||effect-9/NN||a-6/DT	amod||effect-9/NN||well-known-7/JJ	amod||effect-9/NN||adverse-8/JJ	root||ROOT-0/null||effect-9/NN	pain-1||propofol-3||yes||pain on propofol injection is a well-known adverse effect.
nsubjpass||computed-10/VBN||association-1/NN	amod||survival-4/NN||overall-3/JJ	prep_between||association-1/NN||survival-4/NN	nn||levels-8/NNS||serum-6/NN	nn||levels-8/NNS||25ohd-7/NNS	prep_between||association-1/NN||levels-8/NNS	conj_and||survival-4/NN||levels-8/NNS	auxpass||computed-10/VBN||were-9/VBD	ccomp||adjuvant-49/VBD||computed-10/VBN	xcomp||computed-10/VBN||using-11/VBG	det||model-16/NN||the-12/DT	amod||model-16/NN||cox-13/JJ	amod||model-16/NN||proportional-14/JJ	nn||model-16/NN||hazard-15/NN	dobj||using-11/VBG||model-16/NN	vmod||model-16/NN||adjusted-17/VBN	prep_for||adjusted-17/VBN||month-19/NN	nn||sampling-22/NN||serum-21/NN	prep_of||month-19/NN||sampling-22/NN	dobj||using-11/VBG||age-26/NN	conj_and||model-16/NN||age-26/NN	prep_at||age-26/NN||diagnosis-28/NN	nsubj||adjuvant-49/VBD||gender-30/NN	nn||stage-33/NN||cancer-32/NN	appos||gender-30/NN||stage-33/NN	amod||tumor-36/NN||residual-35/JJ	appos||gender-30/NN||tumor-36/NN	prep_after||tumor-36/NN||surgery-38/NN	nn||period-41/NN||time-40/NN	appos||gender-30/NN||period-41/NN	prep_of||period-41/NN||surgery-43/NN	appos||gender-30/NN||location-45/NN	prep_of||location-45/NN||tumor-47/NN	root||ROOT-0/null||adjuvant-49/VBD	dobj||adjuvant-49/VBD||chemotherapy-50/NN	dobj||adjuvant-49/VBD||number-52/NN	conj_and||chemotherapy-50/NN||number-52/NN	nn||nodes-55/NNS||lymph-54/NN	prep_of||chemotherapy-50/NN||nodes-55/NNS	prep_with||adjuvant-49/VBD||metastasis-57/NNS	prep_at||metastasis-57/NNS||surgery-59/NN	tumor-47||adjuvant-49||no_rel||association between overall survival and serum 25ohd levels were computed using the cox proportional hazard model adjusted for month of serum sampling as well as age at diagnosis, gender, cancer stage, residual tumor after surgery, time period of surgery, location of tumor, adjuvant chemotherapy and number of lymph nodes with metastasis at surgery.
nn||rates-2/NNS||success-1/NN	nsubj||%-9/NN||rates-2/NNS	prep_for||rates-2/NNS||daptomycin-4/NN	prep_versus||daptomycin-4/NN||vancomycin/gentamicin-6/NN	cop||%-9/NN||were-7/VBD	num||%-9/NN||45-8/CD	root||ROOT-0/null||%-9/NN	num||%-12/NN||27-11/CD	prep_versus||%-9/NN||%-12/NN	amod||bacteraemia-15/NN||complicated-14/JJ	prep_in||%-12/NN||bacteraemia-15/NN	num||%-18/NN||60-17/CD	prep_versus||%-9/NN||%-18/NN	conj_and||%-12/NN||%-18/NN	num||%-21/NN||45-20/CD	prep_versus||%-18/NN||%-21/NN	amod||bacteraemia-24/NN||uncomplicated-23/JJ	prep_in||%-21/NN||bacteraemia-24/NN	num||%-27/NN||50-26/CD	prep_versus||%-9/NN||%-27/NN	conj_and||%-12/NN||%-27/NN	num||%-30/NN||50-29/CD	prep_versus||%-27/NN||%-30/NN	amod||endocarditis-34/NNS||right-sided-32/JJ	nn||endocarditis-34/NNS||mrsa-33/NN	prep_in||%-30/NN||endocarditis-34/NNS	daptomycin-4||bacteraemia-24||no_rel||success rates for daptomycin versus vancomycin/gentamicin were 45% versus 27% in complicated bacteraemia, 60% versus 45% in uncomplicated bacteraemia and 50% versus 50% in right-sided mrsa endocarditis.
det||review-3/NN||this-2/DT	prep_in||summarise-6/VBP||review-3/NN	nsubj||summarise-6/VBP||we-5/PRP	root||ROOT-0/null||summarise-6/VBP	cc||critically-8/RB||and-7/CC	dep||summarise-6/VBP||critically-8/RB	ccomp||critically-8/RB||evaluate-9/VB	det||data-12/NNS||the-10/DT	amod||data-12/NNS||existing-11/VBG	dobj||evaluate-9/VB||data-12/NNS	det||link-16/NN||the-14/DT	amod||link-16/NN||possible-15/JJ	prep_on||data-12/NNS||link-16/NN	prep_between||link-16/NN||vitamind-18/NN	prep_between||link-16/NN||multiplesclerosis-20/NNS	conj_and||vitamind-18/NN||multiplesclerosis-20/NNS	prep_in||data-12/NNS||light-22/NN	det||question-26/NN||the-24/DT	amod||question-26/NN||crucial-25/JJ	prep_of||light-22/NN||question-26/NN	mark||impact-33/VB||whether-27/IN	nsubj||impact-33/VB||optimization-28/NN	amod||status-31/NN||vitamind-30/JJ	prep_of||optimization-28/NN||status-31/NN	aux||impact-33/VB||may-32/MD	ccomp||summarise-6/VBP||impact-33/VB	det||risk-35/NN||the-34/DT	dobj||impact-33/VB||risk-35/NN	vmod||risk-35/NN||and/or-36/VBG	det||course-38/NN||the-37/DT	dobj||and/or-36/VBG||course-38/NN	prep_of||course-38/NN||multiplesclerosis-40/NNS	vitamind-30||multiplesclerosis-40||no_rel||in this review, we summarise and critically evaluate the existing data on the possible link between vitamind and multiplesclerosis in light of the crucial question whether optimization of vitamind status may impact the risk and/or the course of multiplesclerosis.
det||trial-4/NN||a-2/DT	amod||trial-4/NN||clinical-3/JJ	prep_in||-rrb--38/VBZ||trial-4/NN	nn||doxycycline-10/NNP||chloroquine-6/NNP	conj_vs.||chloroquine-6/NNP||chloroquine-8/NNP	nn||doxycycline-10/NNP||chloroquine-8/NNP	amod||doxycycline-10/NNP||plus-9/IN	prep_of||trial-4/NN||doxycycline-10/NNP	prep_of||trial-4/NN||doxycycline-12/NNP	conj_vs.||doxycycline-10/NNP||doxycycline-12/NNP	advmod||n-26/VBN||alone-13/RB	nn||vivax-16/NN||plasmodium-15/NN	nn||n-18/NN||vivax-16/NN	amod||n-18/NN||-lrb--17/JJ	prep_against||alone-13/RB||n-18/NN	dep||-rrb--21/JJ||=-19/SYM	number||-rrb--21/JJ||64-20/CD	dep||n-18/NN||-rrb--21/JJ	amod||-lrb--25/NNS||plasmodium-23/JJ	nn||-lrb--25/NNS||falciparum-24/NN	dep||n-18/NN||-lrb--25/NNS	conj_or||-rrb--21/JJ||-lrb--25/NNS	vmod||doxycycline-10/NNP||n-26/VBN	dep||malaria-30/NN||=-27/SYM	num||malaria-30/NN||98-28/CD	amod||malaria-30/NN||-rrb--29/JJ	ccomp||n-26/VBN||malaria-30/NN	det||wcc-37/NN||the-32/DT	amod||wcc-37/NN||total-33/JJ	amod||wcc-37/NN||white-34/JJ	nn||wcc-37/NN||cell-35/NN	nn||wcc-37/NN||-lrb--36/NN	nsubj||-rrb--38/VBZ||wcc-37/NN	nsubj||platelet-40/VBD||wcc-37/NN	root||ROOT-0/null||-rrb--38/VBZ	conj_and||-rrb--38/VBZ||platelet-40/VBD	amod||counts-44/NNS||-lrb--41/JJ	nn||counts-44/NNS||plt-42/NN	nn||counts-44/NNS||-rrb--43/NN	nsubj||measured-46/JJ||counts-44/NNS	cop||measured-46/JJ||were-45/VBD	ccomp||platelet-40/VBD||measured-46/JJ	prep_on||measured-46/JJ||days-48/NNS	dep||measured-46/JJ||0-49/CD	num||0-49/CD||3-51/CD	num||0-49/CD||7-53/CD	dep||measured-46/JJ||28-55/CD	conj_and||0-49/CD||28-55/CD	num||papuans-59/NNS||57-57/CD	amod||papuans-59/NNS||indigenous-58/JJ	prep_in||measured-46/JJ||papuans-59/NNS	prep_with||papuans-59/NNS||life-61/NN	amod||exposure-64/NN||long-62/JJ	nn||exposure-64/NN||malaria-63/NN	dobj||-rrb--38/VBZ||exposure-64/NN	num||immigrants-69/NNS||105-66/CD	nn||immigrants-69/NNS||non-67/NN	nn||immigrants-69/NNS||papuan-68/NN	dobj||-rrb--38/VBZ||immigrants-69/NNS	conj_and||exposure-64/NN||immigrants-69/NNS	amod||parts-72/NNS||other-71/JJ	prep_from||-rrb--38/VBZ||parts-72/NNS	prep_of||parts-72/NNS||indonesia-74/NN	amod||exposure-78/NN||limited-76/VBN	nn||exposure-78/NN||malaria-77/NN	prep_with||-rrb--38/VBZ||exposure-78/NN	malaria-77||chloroquine-8||yes||in a clinical trial of chloroquine vs. chloroquine plus doxycycline vs. doxycycline alone against plasmodium vivax -lrb- n = 64 -rrb- or plasmodium falciparum -lrb- n = 98 -rrb- malaria , the total white cell -lrb- wcc -rrb- and platelet -lrb- plt -rrb- counts were measured on days 0 , 3 , 7 and 28 in 57 indigenous papuans with life long malaria exposure and 105 non papuan immigrants from other parts of indonesia with limited malaria exposure .
nsubj||lifesaving-5/JJ||vasopressin-1/NN	aux||lifesaving-5/JJ||might-2/MD	cop||lifesaving-5/JJ||be-3/VB	advmod||lifesaving-5/JJ||potentially-4/RB	root||ROOT-0/null||lifesaving-5/JJ	amod||cardiacarrest-9/NN||blunt-7/JJ	nn||cardiacarrest-9/NN||trauma-8/NN	prep_in||lifesaving-5/JJ||cardiacarrest-9/NN	prepc_compared_to||cardiacarrest-9/NN||to-11/TO	amod||treatment-13/NN||standard-12/JJ	pobj||cardiacarrest-9/NN||treatment-13/NN	prep_with||treatment-13/NN||epinephrine-15/NN	cardiacarrest-9||epinephrine-15||yes||vasopressin might be potentially lifesaving in blunt trauma cardiacarrest compared to standard treatment with epinephrine.
neg||differences-2/NNS||no-1/DT	nsubjpass||seen-4/VBN||differences-2/NNS	auxpass||seen-4/VBN||were-3/VBD	root||ROOT-0/null||seen-4/VBN	amod||patients-10/NNS||hivpositive-6/JJ	conj_and||hivpositive-6/JJ||hiv-8/JJ	amod||patients-10/NNS||hiv-8/JJ	amod||patients-10/NNS||negative-9/JJ	prep_between||seen-4/VBN||patients-10/NNS	hivpositive-6||hiv-8||no||no differences were seen between hivpositive and hiv negative patients.
prep_in||correlated-8/VBN||addition-2/NN	amod||concentration-5/NN||formate-4/JJ	nsubjpass||correlated-8/VBN||concentration-5/NN	nsubjpass||correlated-38/VBN||concentration-5/NN	auxpass||correlated-8/VBN||was-6/VBD	advmod||correlated-8/VBN||negatively-7/RB	root||ROOT-0/null||correlated-8/VBN	amod||pc20-11/NNS||methacholine-10/JJ	prep_with||correlated-8/VBN||pc20-11/NNS	num||0.39-21/NNS||râ-13/CD	amod||0.39-21/NNS||$-14/$	number||=-16/CD||-15/CD	num||$-14/$||=-16/CD	amod||0.39-21/NNS||â-17/JJ	amod||0.39-21/NNS||$-18/$	dep||$-18/$||â-19/JJ	nsubj||asthmatics-32/VBZ||0.39-21/NNS	nn||â-27/NN||pâ-23/NN	amod||â-27/NN||$-24/$	dep||$-24/$||-25/JJ	nn||â-27/NN||=-26/NNP	appos||0.39-21/NNS||â-27/NN	dep||â-27/NN||$-28/$	num||$-28/$||0-29/CD	num||$-28/$||.002-30/CD	dep||pc20-11/NNS||asthmatics-32/VBZ	advmod||asthmatics-32/VBZ||only-33/RB	advmod||correlated-38/VBN||positively-37/RB	conj_and||correlated-8/VBN||correlated-38/VBN	det||nitrite-43/NN||the-40/DT	amod||nitrite-43/NN||no-derived-41/JJ	nn||nitrite-43/NN||ion-42/NN	prep_with||correlated-38/VBN||nitrite-43/NN	dep||nitrite-43/NN||râ-45/VBN	dobj||râ-45/VBN||$-46/$	number||=-48/CD||-47/CD	num||$-46/$||=-48/CD	dep||râ-45/VBN||â-49/VB	dobj||â-49/VB||$-50/$	number||.46-52/CD||0-51/CD	num||$-50/$||.46-52/CD	appos||$-50/$||p-54/NN	number||0.0001-56/CD||<-55/CD	dep||p-54/NN||0.0001-56/CD	amod||ige-64/NN||total-62/JJ	nn||ige-64/NN||serum-63/NN	prep_with||correlated-38/VBN||ige-64/NN	conj_and||nitrite-43/NN||ige-64/NN	dep||ige-64/NN||râ-66/VBN	num||â-70/NN||$-67/$	number||=-69/CD||-68/CD	num||$-67/$||=-69/CD	dobj||râ-66/VBN||â-70/NN	nsubj||asthmatics-84/VBZ||$-71/$	num||$-71/$||0-72/CD	num||$-71/$||.28-73/CD	nn||â-79/NN||pâ-75/NN	amod||â-79/NN||$-76/$	dep||$-76/$||-77/JJ	nn||â-79/NN||=-78/NNP	appos||$-71/$||â-79/NN	dep||â-79/NN||$-80/$	num||$-80/$||0-81/CD	num||$-80/$||.016-82/CD	rcmod||â-70/NN||asthmatics-84/VBZ	advmod||asthmatics-84/VBZ||only-85/RB	methacholine-10||asthmatics-84||no_rel||in addition, formate concentration was negatively correlated with methacholine pc20 (râ=ââ0.39, pâ=â0.002, asthmatics only), and positively correlated with the no-derived ion nitrite (râ=â0.46, p<0.0001) as well as with total serum ige (râ=â0.28, pâ=â0.016, asthmatics only).
amod||evidence-3/NN||current-1/JJ	amod||evidence-3/NN||clinical-2/JJ	nsubj||limited-14/JJ||evidence-3/NN	det||use-6/NN||the-5/DT	prep_for||evidence-3/NN||use-6/NN	amod||delivery-9/NN||aerosolized-8/JJ	prep_of||use-6/NN||delivery-9/NN	prepc_in||delivery-9/NN||preventing-11/VBG	dobj||preventing-11/VBG||fungalinfections-12/NNS	cop||limited-14/JJ||is-13/VBZ	root||ROOT-0/null||limited-14/JJ	amod||products-17/NNS||amphotericinb-16/JJ	prep_to||limited-14/JJ||products-17/NNS	mark||voriconazole-22/JJ||although-19/IN	amod||voriconazole-22/JJ||itraconazole-20/JJ	advcl||limited-14/JJ||voriconazole-22/JJ	nsubj||are-26/VBP||caspofungin-25/NN	conj_and||limited-14/JJ||are-26/VBP	prep_under||are-26/VBP||investigation-28/NN	fungalinfections-12||voriconazole-22||yes||current clinical evidence for the use of aerosolized delivery in preventing fungalinfections is limited to amphotericinb products, although itraconazole, voriconazole, and caspofungin are under investigation.
det||study-2/NN||this-1/DT	nsubj||investigated-3/VBD||study-2/NN	root||ROOT-0/null||investigated-3/VBD	det||effects-5/NNS||the-4/DT	dobj||investigated-3/VBD||effects-5/NNS	amod||ea-8/NN||low-frequency-7/JJ	prep_of||effects-5/NNS||ea-8/NN	amod||action-11/NN||metabolic-10/JJ	prep_on||investigated-3/VBD||action-11/NN	advmod||obese-14/JJ||genetically-13/RB	amod||mice-20/NNS||obese-14/JJ	npadvmod||diabetic-18/JJ||type-16/NN	num||type-16/NN||2-17/CD	conj_and||obese-14/JJ||diabetic-18/JJ	amod||mice-20/NNS||diabetic-18/JJ	nn||mice-20/NNS||db/db-19/NN	prep_in||action-11/NN||mice-20/NNS	obese-14||ea-8||no_rel||this study investigated the effects of low-frequency ea on metabolic action in genetically obese and type 2 diabetic db/db mice.
mark||condition-7/NN||although-1/IN	amod||cancer-3/NN||cervical-2/JJ	nsubj||condition-7/NN||cancer-3/NN	cop||condition-7/NN||is-4/VBZ	det||condition-7/NN||an-5/DT	amod||condition-7/NN||aids-defining-6/JJ	advcl||increase-18/VB||condition-7/NN	nsubj||increase-18/VB||infection-9/NN	prep_with||infection-9/NN||humanimmunodeficiencyvirus-11/NNS	appos||humanimmunodeficiencyvirus-11/NNS||hiv-13/NN	aux||increase-18/VB||may-15/MD	advmod||modestly-17/RB||only-16/RB	advmod||increase-18/VB||modestly-17/RB	root||ROOT-0/null||increase-18/VB	det||risk-20/NN||the-19/DT	dobj||increase-18/VB||risk-20/NN	amod||cancer-23/NN||cervical-22/JJ	prep_of||risk-20/NN||cancer-23/NN	hiv)--1||humanimmunodeficiencyvirus-11||no||although cervical cancer is an aids-defining condition, infection with humanimmunodeficiencyvirus (hiv) may only modestly increase the risk of cervical cancer.
num||antigonist-4/NN||î-1/CD	amod||antigonist-4/NN||²-2/JJ	amod||antigonist-4/NN||2-ar-3/JJ	nsubj||abrogated-6/VBD||antigonist-4/NN	advmod||abrogated-6/VBD||effectively-5/RB	root||ROOT-0/null||abrogated-6/VBD	amod||expression-9/NN||isoproterenol-induced-7/JJ	amod||expression-9/NN||mmp-7-8/JJ	dobj||abrogated-6/VBD||expression-9/NN	ar--1||isoproterenol--1||no_rel||î²2-ar antigonist effectively abrogated isoproterenol-induced mmp-7 expression.
det||combination-3/NN||the-1/DT	amod||combination-3/NN||budesonide/formoterol-2/JJ	nsubjpass||used-6/VBN||combination-3/NN	auxpass||used-6/VBN||is-4/VBZ	advmod||used-6/VBN||successfully-5/RB	root||ROOT-0/null||used-6/VBN	amod||relief-9/NN||fast-8/JJ	prep_for||used-6/VBN||relief-9/NN	nn||symptoms-12/NNS||asthma-11/NN	prep_of||relief-9/NN||symptoms-12/NNS	prep_in||symptoms-12/NNS||addition-14/NN	poss||use-17/NN||its-16/PRP$	prep_to||used-6/VBN||use-17/NN	nn||therapy-20/NN||maintenance-19/NN	prep_as||used-6/VBN||therapy-20/NN	asthma-11||formoterol--1||yes||the budesonide/formoterol combination is successfully used for fast relief of asthma symptoms in addition to its use as maintenance therapy.
nsubj||cause-4/VBP||burkholderiapseudomallei-1/NNS	conj_and||burkholderiapseudomallei-1/NNS||burkholderiamallei-3/NNS	nsubj||cause-4/VBP||burkholderiamallei-3/NNS	root||ROOT-0/null||cause-4/VBP	det||diseases-6/NNS||the-5/DT	nsubj||melioidosis-7/VBZ||diseases-6/NNS	nsubj||glanders-9/VBZ||diseases-6/NNS	ccomp||cause-4/VBP||melioidosis-7/VBZ	ccomp||cause-4/VBP||glanders-9/VBZ	conj_and||melioidosis-7/VBZ||glanders-9/VBZ	advmod||cause-4/VBP||respectively-11/RB	glanders-9||burkholderiamallei-3||no||burkholderiapseudomallei and burkholderiamallei cause the diseases melioidosis and glanders, respectively.
amod||virus-3/NN||feline-1/JJ	nn||virus-3/NN||immunodeficiency-2/NN	nsubj||lentivirus-9/NNS||virus-3/NN	appos||virus-3/NN||fiv-5/NN	cop||lentivirus-9/NNS||is-7/VBZ	det||lentivirus-9/NNS||a-8/DT	root||ROOT-0/null||lentivirus-9/NNS	dep||lentivirus-9/NNS||associated-10/VBN	amod||illnesses-13/NNS||aids-like-12/JJ	prep_with||associated-10/VBN||illnesses-13/NNS	prep_in||illnesses-13/NNS||cats-15/NNS	aux||used-19/VBN||has-17/VBZ	auxpass||used-19/VBN||been-18/VBN	dep||lentivirus-9/NNS||used-19/VBN	conj_and||associated-10/VBN||used-19/VBN	det||model-22/NN||a-21/DT	prep_as||used-19/VBN||model-22/NN	det||study-25/NN||the-24/DT	prep_for||model-22/NN||study-25/NN	prep_of||study-25/NN||humanimmunodeficiencyvirus-27/NNS	appos||humanimmunodeficiencyvirus-27/NNS||hiv-29/NN	aids--1||humanimmunodeficiencyvirus-27||no||feline immunodeficiency virus (fiv) is a lentivirus associated with aids-like illnesses in cats and has been used as a model for the study of humanimmunodeficiencyvirus (hiv).
prep_in||developed-37/VBN||addition-2/NN	det||advent-6/NN||the-5/DT	prep_with||developed-37/VBN||advent-6/NN	amod||numbers-9/NNS||increasing-8/VBG	prep_of||advent-6/NN||numbers-9/NNS	prep_of||numbers-9/NNS||children-11/NNS	vmod||children-11/NNS||infected-12/VBN	prep_with||infected-12/VBN||hiv-14/NN	vmod||hiv-14/NN||surviving-15/VBG	amod||adulthood-20/NN||adolescence-17/JJ	conj_and||adolescence-17/JJ||young-19/JJ	amod||adulthood-20/NN||young-19/JJ	prep_into||surviving-15/VBG||adulthood-20/NN	det||intervention-26/NN||a-22/DT	amod||intervention-26/NN||champ-23/JJ	amod||intervention-26/NN||+-24/JJ	amod||intervention-26/NN||family-based-25/JJ	nsubjpass||developed-37/VBN||intervention-26/NN	nsubj||mitigate-39/VB||intervention-26/NN	vmod||intervention-26/NN||using-28/VBG	det||principles-31/NNS||the-29/DT	amod||principles-31/NNS||founding-30/JJ	dobj||using-28/VBG||principles-31/NNS	prep_of||principles-31/NNS||champ-33/NN	aux||developed-37/VBN||has-35/VBZ	auxpass||developed-37/VBN||been-36/VBN	root||ROOT-0/null||developed-37/VBN	aux||mitigate-39/VB||to-38/TO	xcomp||developed-37/VBN||mitigate-39/VB	det||influences-42/NNS||the-40/DT	nn||influences-42/NNS||risk-41/NN	dobj||mitigate-39/VB||influences-42/NNS	vmod||influences-42/NNS||associated-43/VBN	cop||hivpositive-46/JJ||being-45/VBG	prepc_with||associated-43/VBN||hivpositive-46/JJ	hivpositive-46||hiv-14||no||in addition, with the advent of increasing numbers of children infected with hiv surviving into adolescence and young adulthood, a champ+ family-based intervention, using the founding principles of champ, has been developed to mitigate the risk influences associated with being hivpositive.
nsubj||seems-2/VBZ||it-1/PRP	root||ROOT-0/null||seems-2/VBZ	mark||prominent-19/JJ||that-3/IN	det||impact-5/NN||the-4/DT	nsubj||prominent-19/JJ||impact-5/NN	amod||polymorphism-8/NN||il28b-7/JJ	prep_of||impact-5/NN||polymorphism-8/NN	det||clearance-12/NN||the-10/DT	amod||clearance-12/NN||spontaneous-11/JJ	prep_on||polymorphism-8/NN||clearance-12/NN	nn||genotype-15/NN||hcv-14/NN	prep_of||clearance-12/NN||genotype-15/NN	num||genotype-15/NN||1-16/CD	cop||prominent-19/JJ||is-17/VBZ	advmod||prominent-19/JJ||more-18/RBR	ccomp||seems-2/VBZ||prominent-19/JJ	prep_than||prominent-19/JJ||hcv-21/NN	nsubj||results-25/VBZ||hcv-21/NN	amod||hcv-21/NN||genotype-22/JJ	dep||genotype-22/JJ||3-23/CD	rcmod||hcv-21/NN||results-25/VBZ	det||observation-28/NN||the-27/DT	prep_in||results-25/VBZ||observation-28/NN	amod||rs12979860-31/NNS||higher-30/JJR	prep_of||observation-28/NN||rs12979860-31/NNS	dep||genotype-40/VBP||c-32/SYM	amod||frequency-34/NN||allele-33/JJ	nsubj||genotype-40/VBP||frequency-34/NN	amod||patients-37/NNS||chronichepatitisc-36/JJ	prep_in||frequency-34/NN||patients-37/NNS	prep_with||patients-37/NNS||hcv-39/NN	ccomp||prominent-19/JJ||genotype-40/VBP	dobj||genotype-40/VBP||3-41/CD	nn||genotype-44/NN||hcv-43/NN	prep_than||genotype-40/VBP||genotype-44/NN	num||genotype-44/NN||1-45/CD	chronichepatitisc-36||hcv-43||no||it seems that the impact of il28b polymorphism on the spontaneous clearance of hcv genotype 1 is more prominent than hcv genotype 3 which results in the observation of higher rs12979860 c allele frequency in chronichepatitisc patients with hcv genotype 3 than hcv genotype 1.
nsubj||show-3/VBP||we-1/PRP	advmod||show-3/VBP||here-2/RB	root||ROOT-0/null||show-3/VBP	mark||higher-25/JJR||that-4/IN	det||frequency-7/NN||the-5/DT	amod||frequency-7/NN||average-6/JJ	nsubj||higher-25/JJR||frequency-7/NN	amod||cells-14/NNS||total-9/JJ	conj_and||total-9/JJ||cd8-11/JJ	amod||cells-14/NNS||cd8-11/JJ	amod||cells-14/NNS||+-12/JJ	nn||cells-14/NNS||nkt-13/NN	prep_of||frequency-7/NN||cells-14/NNS	prep_in||cells-14/NNS||pbmcs-16/NNS	num||subjects-22/NNS||128-18/CD	amod||latent-20/JJ||healthy-19/JJ	amod||subjects-22/NNS||latent-20/JJ	amod||subjects-22/NNS||ebv-infected-21/JJ	prep_from||pbmcs-16/NNS||subjects-22/NNS	cop||higher-25/JJR||is-23/VBZ	advmod||higher-25/JJR||significantly-24/RB	ccomp||show-3/VBP||higher-25/JJR	prep||higher-25/JJR||than-26/IN	pcomp||than-26/IN||in-27/IN	num||patients-32/NNS||17-28/CD	amod||patients-32/NNS||acute-29/JJ	nn||patients-32/NNS||ebv-30/NN	nn||patients-32/NNS||infectiousmononucleosis-31/NN	pobj||in-27/IN||patients-32/NNS	num||patients-37/NNS||16-34/CD	amod||patients-37/NNS||ebv-associated-35/JJ	nn||patients-37/NNS||hodgkinlymphoma-36/NN	pobj||in-27/IN||patients-37/NNS	conj_and||patients-32/NNS||patients-37/NNS	num||subjects-44/NNS||16-40/CD	amod||subjects-44/NNS||ebv-negative-41/JJ	amod||subjects-44/NNS||normal-42/JJ	nn||subjects-44/NNS||control-43/NN	pobj||in-27/IN||subjects-44/NNS	conj_and||patients-32/NNS||subjects-44/NNS	infectiousmononucleosis-31||ebv-30||no||we here show that the average frequency of total and cd8+ nkt cells in pbmcs from 128 healthy latent ebv-infected subjects is significantly higher than in 17 acute ebv infectiousmononucleosis patients, 16 ebv-associated hodgkinlymphoma patients, and 16 ebv-negative normal control subjects.
nsubj||curves-2/VBZ||survival-1/NN	root||ROOT-0/null||curves-2/VBZ	csubj||showed-14/VBD||monitoring-4/VBG	det||percentage-6/NN||the-5/DT	dobj||monitoring-4/VBG||percentage-6/NN	amod||cells-10/NNS||human-8/JJ	nn||cells-10/NNS||leukemia-9/NN	prep_of||percentage-6/NN||cells-10/NNS	amod||blood-13/NN||peripheral-12/JJ	prep_in||monitoring-4/VBG||blood-13/NN	conj_and||curves-2/VBZ||showed-14/VBD	mark||inhibit-19/VB||that-15/IN	nsubj||inhibit-19/VB||resveratrol-16/NN	nsubj||influence-24/VB||resveratrol-16/NN	aux||inhibit-19/VB||did-17/VBD	neg||inhibit-19/VB||not-18/RB	ccomp||showed-14/VBD||inhibit-19/VB	nn||growth-22/NN||leukemia-20/NN	nn||growth-22/NN||cell-21/NN	dobj||inhibit-19/VB||growth-22/NN	ccomp||showed-14/VBD||influence-24/VB	conj_or||inhibit-19/VB||influence-24/VB	det||activity-26/NN||the-25/DT	dobj||influence-24/VB||activity-26/NN	prep_of||activity-26/NN||vincristine-28/NN	leukemia-20||vincristine-28||yes||survival curves and monitoring the percentage of human leukemia cells in peripheral blood showed that resveratrol did not inhibit leukemia cell growth or influence the activity of vincristine.
nsubj||carried-2/VBD||we-1/PRP	root||ROOT-0/null||carried-2/VBD	prt||carried-2/VBD||out-3/RP	det||study-6/NN||this-4/DT	amod||study-6/NN||preliminary-5/JJ	dobj||carried-2/VBD||study-6/NN	aux||analyze-8/VB||to-7/TO	vmod||study-6/NN||analyze-8/VB	det||predicted-10/NN||the-9/DT	nsubj||undetectable-22/JJ||predicted-10/NN	vmod||predicted-10/NN||hbsag-11/VBG	nn||changes-13/NNS||conformation-12/NN	dobj||hbsag-11/VBG||changes-13/NNS	nn||variants-16/NNS||hbv-15/NN	prep_of||changes-13/NNS||variants-16/NNS	vmod||variants-16/NNS||isolated-17/VBN	amod||donors-21/NNS||indonesian-19/JJ	nn||donors-21/NNS||blood-20/NN	prep_from||isolated-17/VBN||donors-21/NNS	xcomp||analyze-8/VB||undetectable-22/JJ	prepc_by||undetectable-22/JJ||hbsag-24/VBG	dobj||hbsag-24/VBG||assays-25/NNS	poss||significance-28/NN||its-27/PRP$	dobj||hbsag-24/VBG||significance-28/NN	conj_and||assays-25/NNS||significance-28/NN	prepc_compared_to||carried-2/VBD||to-31/TO	amod||variants-34/NNS||other-32/JJ	amod||variants-34/NNS||previously-reported-33/JJ	pobj||carried-2/VBD||variants-34/NNS	nsubjpass||associated-37/VBN||variants-34/NNS	auxpass||associated-37/VBN||were-36/VBD	rcmod||variants-34/NNS||associated-37/VBN	amod||failure-40/NN||diagnostic-39/JJ	prep_with||associated-37/VBN||failure-40/NN	hbv-15||hbsag-24||yes||we carried out this preliminary study to analyze the predicted hbsag conformation changes of hbv variants isolated from indonesian blood donors undetectable by hbsag assays and its significance, compared to other previously-reported variants that were associated with diagnostic failure.
det||study-5/NN||a-2/DT	amod||study-5/NN||randomized-3/JJ	amod||study-5/NN||prospective-4/JJ	prep_in||enrolled-19/VBN||study-5/NN	num||patients-8/NNS||60-7/CD	nsubjpass||enrolled-19/VBN||patients-8/NNS	nsubj||determine-21/VB||patients-8/NNS	nn||i-ii-11/NN||asa-10/NN	dep||patients-8/NNS||i-ii-11/NN	appos||i-ii-11/NN||elder-13/JJR	num||years-16/NNS||65-15/CD	prep_than||elder-13/JJR||years-16/NNS	auxpass||enrolled-19/VBN||were-18/VBD	root||ROOT-0/null||enrolled-19/VBN	aux||determine-21/VB||to-20/TO	xcomp||enrolled-19/VBN||determine-21/VB	dobj||required-37/VBN||which-22/WDT	num||target-25/NN||two-24/CD	prep_of||required-37/VBN||target-25/NN	amod||concentrations-28/NNS||remifentanil-26/JJ	nn||concentrations-28/NNS||blood-27/NN	nsubjpass||required-37/VBN||concentrations-28/NNS	num||ng/ml-31/NN||3-30/CD	dep||concentrations-28/NNS||ng/ml-31/NN	num||ng/ml-34/NN||5-33/CD	appos||ng/ml-31/NN||ng/ml-34/NN	auxpass||required-37/VBN||was-36/VBD	ccomp||determine-21/VB||required-37/VBN	aux||blunt-39/VB||to-38/TO	ccomp||required-37/VBN||blunt-39/VB	amod||changes-41/NNS||hemodynamic-40/JJ	dobj||blunt-39/VB||changes-41/NNS	prep_during||blunt-39/VB||intubation-43/NN	aux||reduce-46/VB||to-45/TO	ccomp||required-37/VBN||reduce-46/VB	conj_and||blunt-39/VB||reduce-46/VB	amod||pain-48/NN||propofol-induced-47/JJ	dobj||reduce-46/VB||pain-48/NN	pain-48||remifentanil-26||yes||in a randomized prospective study, 60 patients (asa i-ii, elder than 65 years) were enrolled to determine which of two target remifentanil blood concentrations (3 ng/ml, 5 ng/ml) was required to blunt hemodynamic changes during intubation and to reduce propofol-induced pain.
det||spread-2/NN||the-1/DT	nsubj||suggests-23/VBZ||spread-2/NN	det||h1n1influenzavirus-6/NNS||the-4/DT	num||h1n1influenzavirus-6/NNS||2009-5/CD	prep_of||spread-2/NN||h1n1influenzavirus-6/NNS	det||population-9/NN||the-8/DT	prep_in||h1n1influenzavirus-6/NNS||population-9/NN	advmod||population-9/NN||worldwide-10/RB	det||number-17/NN||the-15/DT	amod||number-17/NN||large-16/JJ	prep_in_addition_to||spread-2/NN||number-17/NN	prep_of||number-17/NN||individuals-19/NNS	advmod||vaccinated-21/VBN||already-20/RB	vmod||individuals-19/NNS||vaccinated-21/VBN	root||ROOT-0/null||suggests-23/VBZ	mark||have-32/VBP||that-24/IN	det||proportion-27/NN||a-25/DT	amod||proportion-27/NN||large-26/JJ	nsubj||have-32/VBP||proportion-27/NN	det||population-30/NN||the-29/DT	prep_of||proportion-27/NN||population-30/NN	advmod||have-32/VBP||now-31/RB	ccomp||suggests-23/VBZ||have-32/VBP	amod||antibodies-34/NNS||cross-protective-33/JJ	dobj||have-32/VBP||antibodies-34/NNS	det||virus-38/NN||the-36/DT	num||virus-38/NN||1918-37/CD	prep_against||antibodies-34/NNS||virus-38/NN	advmod||alleviating-41/VBG||greatly-40/RB	vmod||antibodies-34/NNS||alleviating-41/VBG	dobj||alleviating-41/VBG||concerns-42/NNS	dobj||alleviating-41/VBG||fears-44/NNS	conj_and||concerns-42/NNS||fears-44/NNS	det||exposure/release-48/NN||the-46/DT	amod||exposure/release-48/NN||accidental-47/JJ	prep_regarding||concerns-42/NNS||exposure/release-48/NN	det||virus-52/NN||the-50/DT	num||virus-52/NN||1918-51/CD	prep_of||exposure/release-48/NN||virus-52/NN	det||laboratory-55/NN||the-54/DT	prep_from||virus-52/NN||laboratory-55/NN	det||use-58/NN||the-57/DT	prep_of||exposure/release-48/NN||use-58/NN	conj_and||virus-52/NN||use-58/NN	det||virus-61/NN||the-60/DT	prep_of||use-58/NN||virus-61/NN	det||agent-65/NN||a-63/DT	amod||agent-65/NN||bioterrorist-64/JJ	prep_as||virus-61/NN||agent-65/NN	virus-61||antibodies-34||no_rel||the spread of the 2009 h1n1influenzavirus in the population worldwide, in addition to the large number of individuals already vaccinated, suggests that a large proportion of the population now have cross-protective antibodies against the 1918 virus, greatly alleviating concerns and fears regarding the accidental exposure/release of the 1918 virus from the laboratory and the use of the virus as a bioterrorist agent.
det||treatment-3/NN||the-1/DT	amod||treatment-3/NN||standard-2/JJ	nsubjpass||based-8/VBN||treatment-3/NN	prep_of||treatment-3/NN||apl-5/NN	aux||based-8/VBN||has-6/VBZ	auxpass||based-8/VBN||been-7/VBN	root||ROOT-0/null||based-8/VBN	det||administration-12/NN||the-10/DT	amod||administration-12/NN||combined-11/VBN	prep_on||based-8/VBN||administration-12/NN	prep_of||administration-12/NN||all-transretinoicacid-14/NN	prep_of||administration-12/NN||chemotherapy-16/NN	conj_and||all-transretinoicacid-14/NN||chemotherapy-16/NN	prep_including||administration-12/NN||anthracyclins-18/NNS	prep_including||administration-12/NN||cytarabine-20/NN	conj_and||anthracyclins-18/NNS||cytarabine-20/NN	apl-5||all-transretinoicacid-14||yes||the standard treatment of apl has been based on the combined administration of all-transretinoicacid and chemotherapy including anthracyclins and cytarabine.
amod||studies-2/NNS||previous-1/JJ	nsubj||demonstrate-3/VBP||studies-2/NNS	root||ROOT-0/null||demonstrate-3/VBP	mark||improves-12/VBZ||that-4/IN	amod||release-7/NN||tolterodine-5/JJ	amod||release-7/NN||extended-6/JJ	nsubj||improves-12/VBZ||release-7/NN	appos||release-7/NN||er-9/NN	advmod||improves-12/VBZ||significantly-11/RB	ccomp||demonstrate-3/VBP||improves-12/VBZ	nn||episodes-18/NNS||urgency-13/NN	nn||episodes-18/NNS||urinaryincontinence-14/NN	appos||episodes-18/NNS||uui-16/NN	dobj||improves-12/VBZ||episodes-18/NNS	urinaryincontinence-14||tolterodine-5||yes||previous studies demonstrate that tolterodine extended release (er) significantly improves urgency urinaryincontinence (uui) episodes.
nsubj||allowed-15/VBD||inhibition-1/NN	amod||growth-5/NN||postembryonic-3/JJ	nn||growth-5/NN||root-4/NN	prep_of||inhibition-1/NN||growth-5/NN	amod||glutathione-9/NN||depleting-8/VBG	prep_by||inhibition-1/NN||glutathione-9/NN	advmod||genetically-11/RB||either-10/RB	amod||glutathione-9/NN||genetically-11/RB	amod||glutathione-9/NN||chemically-13/RB	advmod||genetically-11/RB||chemically-13/RB	conj_or||genetically-11/RB||chemically-13/RB	root||ROOT-0/null||allowed-15/VBD	dobj||allowed-15/VBD||seedlings-16/NNS	nsubj||escape-18/VB||seedlings-16/NNS	aux||escape-18/VB||to-17/TO	xcomp||allowed-15/VBD||escape-18/VB	nn||arrest-20/NN||shoot-19/NN	dobj||escape-18/VB||arrest-20/NN	chemically-13||arrest-20||no_rel||inhibition of postembryonic root growth, by depleting glutathione either genetically or chemically, allowed seedlings to escape shoot arrest.
prep_in||reduced-11/VBD||rats-2/NNS	prep_with||rats-2/NNS||chronicrenalfailure-4/NN	nn||carbonate-7/NN||lanthanum-6/NN	nsubj||reduced-11/VBD||carbonate-7/NN	nn||hydroxide-10/NNS||aluminum-9/NN	conj_and||carbonate-7/NN||hydroxide-10/NNS	nsubj||reduced-11/VBD||hydroxide-10/NNS	root||ROOT-0/null||reduced-11/VBD	advmod||phosphate-13/JJ||urinary-12/RB	amod||excretion-14/NN||phosphate-13/JJ	dobj||reduced-11/VBD||excretion-14/NN	det||degree-18/NN||a-16/DT	amod||degree-18/NN||greater-17/JJR	prep_to||reduced-11/VBD||degree-18/NN	advmod||rapidly-21/RB||more-20/RBR	conj_and||reduced-11/VBD||rapidly-21/RB	prep_than||rapidly-21/RB||calciumcarbonate-23/NN	nsubj||effective-30/JJ||calciumcarbonate-23/NN	prep_in||effective-30/JJ||turn-27/NN	cop||effective-30/JJ||was-28/VBD	advmod||effective-30/JJ||more-29/RBR	rcmod||calciumcarbonate-23/NN||effective-30/JJ	nn||hydrochloride-33/NN||sevelamer-32/NN	prep_than||effective-30/JJ||hydrochloride-33/NN	chronicrenalfailure-4||calciumcarbonate-23||yes||in rats with chronicrenalfailure, lanthanum carbonate and aluminum hydroxide reduced urinary phosphate excretion to a greater degree and more rapidly than calciumcarbonate, which in turn was more effective than sevelamer hydrochloride.
det||aggressive-2/JJ||the-1/DT	nsubj||precludes-6/VBZ||aggressive-2/JJ	det||tumor-5/NN||the-4/DT	prep_of||aggressive-2/JJ||tumor-5/NN	root||ROOT-0/null||precludes-6/VBZ	amod||whenever-9/NNS||radical-7/JJ	nn||whenever-9/NNS||therapy-8/NN	nsubj||possible-10/JJ||whenever-9/NNS	xcomp||precludes-6/VBZ||possible-10/JJ	mark||seems-15/VBZ||since-12/IN	nn||therapy-14/NN||adjuvant-13/NN	nsubj||seems-15/VBZ||therapy-14/NN	nsubj||have-17/VB||therapy-14/NN	advcl||precludes-6/VBZ||seems-15/VBZ	aux||have-17/VB||to-16/TO	xcomp||seems-15/VBZ||have-17/VB	amod||effect-19/NN||little-18/JJ	dobj||have-17/VB||effect-19/NN	tumor-5||adjuvant-13||no_rel||the aggressive of the tumor precludes radical therapy whenever possible, since adjuvant therapy seems to have little effect.
aux||strengthen-2/VB||to-1/TO	advcl||identified-13/VBD||strengthen-2/VB	dobj||strengthen-2/VB||support-3/NN	nn||planning-6/NN||family-5/NN	prep_for||support-3/NN||planning-6/NN	nn||prevention-9/NN||hiv-8/NN	prep_as||strengthen-2/VB||prevention-9/NN	nsubj||identified-13/VBD||we-11/PRP	nsubj||sought-35/VBD||we-11/PRP	nsubj||determine-37/VB||we-11/PRP	advmod||identified-13/VBD||systematically-12/RB	root||ROOT-0/null||identified-13/VBD	amod||individuals-15/NNS||key-14/JJ	dobj||identified-13/VBD||individuals-15/NNS	det||field-18/NN||the-17/DT	prep_in||identified-13/VBD||field-18/NN	amod||hiv/aids-21/NNS||international-20/JJ	prep_of||field-18/NN||hiv/aids-21/NNS	advmod||field-18/NN||â-22/RB	pobj||â-22/RB||$-23/$	dep||field-18/NN||those-25/DT	nsubj||influence-29/VB||those-25/DT	aux||influence-29/VB||could-27/MD	advmod||influence-29/VB||potentially-28/RB	rcmod||those-25/DT||influence-29/VB	det||$-32/$||the-30/DT	amod||$-32/$||issueâ-31/JJ	dobj||influence-29/VB||$-32/$	conj_and||identified-13/VBD||sought-35/VBD	aux||determine-37/VB||to-36/TO	xcomp||sought-35/VBD||determine-37/VB	poss||perceptions-39/NNS||their-38/PRP$	dobj||determine-37/VB||perceptions-39/NNS	prep_of||perceptions-39/NNS||barriers-41/NNS	aux||facilitators-44/NNS||to-42/TO	cc||facilitators-44/NNS||and-43/CC	vmod||determine-37/VB||facilitators-44/NNS	prepc_for||facilitators-44/NNS||implementing-46/VBG	det||strategy-49/NN||this-47/DT	amod||strategy-49/NN||pmtct-48/JJ	dobj||implementing-46/VBG||strategy-49/NN	aids--1||hiv-8||no||to strengthen support for family planning as hiv prevention, we systematically identified key individuals in the field of international hiv/aidsâthose who could potentially influence the issueâand sought to determine their perceptions of barriers to and facilitators for implementing this pmtct strategy.
num||patients-2/NNS||50-1/CD	nsubjpass||included-20/VBN||patients-2/NNS	nsubjpass||subjected-23/VBN||patients-2/NNS	det||sex-5/NN||either-4/DT	prep_of||patients-2/NNS||sex-5/NN	vmod||sex-5/NN||aged-6/VBN	num||years-9/NNS||35-65-8/CD	prep_between||aged-6/VBN||years-9/NNS	vmod||years-9/NNS||presenting-10/VBG	prep_with||presenting-10/VBG||features-12/NNS	nn||pain-18/NN||cervical-14/NN	conj_and||cervical-14/NN||lumbar-16/NN	nn||pain-18/NN||lumbar-16/NN	amod||pain-18/NN||radiculopathic-17/JJ	prep_of||features-12/NNS||pain-18/NN	auxpass||included-20/VBN||were-19/VBD	root||ROOT-0/null||included-20/VBN	auxpass||subjected-23/VBN||were-22/VBD	conj_and||included-20/VBN||subjected-23/VBN	amod||injection-28/NN||single-25/JJ	nn||injection-28/NN||lumbar-26/NN	nn||injection-28/NN||epidural-27/NN	prep_to||subjected-23/VBN||injection-28/NN	amod||anaesthetic-31/NN||local-30/JJ	prep_of||injection-28/NN||anaesthetic-31/NN	amod||injection-28/NN||tramadol-33/JJ	amod||injection-28/NN||methylprednisolone-35/JJ	conj_and||tramadol-33/JJ||methylprednisolone-35/JJ	det||position-40/NN||the-38/DT	amod||position-40/NN||lateral-39/JJ	prep_in||injection-28/NN||position-40/NN	pain-18||tramadol-33||yes||50 patients of either sex aged between 35-65 years presenting with features of cervical and lumbar radiculopathic pain were included and were subjected to single lumbar epidural injection of local anaesthetic, tramadol and methylprednisolone, in the lateral position.
nn||status-2/NN||bmi-1/NN	nsubjpass||studied-4/VBN||status-2/NN	auxpass||studied-4/VBN||was-3/VBD	dep||reported-12/VBD||studied-4/VBN	advmod||studied-4/VBN||cross-sectionally-5/RB	prep_in||studied-4/VBN||relation-7/NN	det||parental-11/NN||the-9/DT	amod||parental-11/NN||following-10/JJ	prep_to||studied-4/VBN||parental-11/NN	root||ROOT-0/null||reported-12/VBD	dobj||reported-12/VBD||outcomes-13/NNS	det||index-17/NN||a-14/DT	amod||index-17/NN||general-15/JJ	nn||index-17/NN||health-16/NN	nsubj||reported-12/VBD||index-17/NN	nn||visits-20/NNS||gp-19/NN	appos||index-17/NN||visits-20/NNS	nn||absenteeism-23/NN||school-22/NN	appos||visits-20/NNS||absenteeism-23/NN	prep_due_to||absenteeism-23/NN||illness-26/NN	amod||limitations-30/NNS||health-related-28/JJ	amod||limitations-30/NNS||functional-29/JJ	prep_due_to||absenteeism-23/NN||limitations-30/NNS	conj_and||illness-26/NN||limitations-30/NNS	nn||respiratoryinfections-34/NNS||doctor-32/NN	nn||respiratoryinfections-34/NNS||diagnosed-33/NN	prep_due_to||absenteeism-23/NN||respiratoryinfections-34/NNS	conj_and||illness-26/NN||respiratoryinfections-34/NNS	prep_due_to||absenteeism-23/NN||use-36/NN	conj_and||illness-26/NN||use-36/NN	prep_of||use-36/NN||antibiotics-38/NNS	cross--1||antibiotics-38||no_rel||bmi status was studied cross-sectionally in relation to the following parental reported outcomes a general health index, gp visits, school absenteeism due to illness, health-related functional limitations, doctor diagnosed respiratoryinfections and use of antibiotics.
nsubj||identified-2/VBD||we-1/PRP	root||ROOT-0/null||identified-2/VBD	num||patients-4/NNS||50-3/CD	dobj||identified-2/VBD||patients-4/NNS	amod||influenzapneumonia-7/NN||suspected-6/VBN	prep_with||patients-4/NNS||influenzapneumonia-7/NN	det||presence-10/NN||the-9/DT	nsubjpass||confirmed-14/VBN||presence-10/NN	prep_of||presence-10/NN||influenzavirus-12/NNS	auxpass||confirmed-14/VBN||was-13/VBD	parataxis||identified-2/VBD||confirmed-14/VBN	num||11-17/CD||18-16/CD	prep_in||confirmed-14/VBN||11-17/CD	amod||h1n1-21/NNS||pandemic-19/JJ	prep_with||confirmed-14/VBN||h1n1-21/NNS	num||virus-24/NN||2009-23/CD	dep||h1n1-21/NNS||virus-24/NN	prep_with||confirmed-14/VBN||5-26/CD	conj_and||h1n1-21/NNS||5-26/CD	amod||influenza-29/NN||unsubtypeable-28/JJ	prep_with||5-26/CD||influenza-29/NN	det||virus-31/NN||a-30/DT	dep||5-26/CD||virus-31/NN	prep_with||confirmed-14/VBN||1-33/CD	conj_and||h1n1-21/NNS||1-33/CD	amod||influenza-36/NN||seasonal-35/JJ	prep_with||1-33/CD||influenza-36/NN	det||virus-38/NN||a-37/DT	dep||influenza-36/NN||virus-38/NN	appos||influenza-36/NN||h3n2-40/NNP	prep_with||confirmed-14/VBN||1-44/CD	conj_and||h1n1-21/NNS||1-44/CD	prep_in||positive-59/JJ||1-44/CD	amod||results-48/NNS||assay-47/JJ	nsubj||positive-59/JJ||results-48/NNS	prep_for||results-48/NNS||seasonal-50/JJ	amod||h1n1-54/NNS||pandemic-52/JJ	prep_for||results-48/NNS||h1n1-54/NNS	conj_and||seasonal-50/JJ||h1n1-54/NNS	num||viruses-57/NNS||2009-56/CD	dep||h1n1-54/NNS||viruses-57/NNS	cop||positive-59/JJ||were-58/VBD	rcmod||1-44/CD||positive-59/JJ	influenzapneumonia-7||influenzavirus-12||no||we identified 50 patients with suspected influenzapneumonia; the presence of influenzavirus was confirmed in 18 11 with pandemic (h1n1) 2009 virus, 5 with unsubtypeable influenza a virus, 1 with seasonal influenza a virus (h3n2), and 1 in whom assay results for seasonal and pandemic (h1n1) 2009 viruses were positive.
det||three-dose-4/NN||the-1/DT	advmod||three-dose-4/NN||once-2/RB	amod||three-dose-4/NN||daily-3/JJ	nsubj||superior-14/JJ||three-dose-4/NN	nsubj||six-dose-16/VB||three-dose-4/NN	amod||suspension-7/NN||artemether-lumefantrine-6/JJ	prep_of||three-dose-4/NN||suspension-7/NN	nn||®-10/NNP||co-artesianeâ-9/NNP	appos||three-dose-4/NN||®-10/NNP	cop||superior-14/JJ||was-12/VBD	neg||superior-14/JJ||not-13/RB	root||ROOT-0/null||superior-14/JJ	aux||six-dose-16/VB||to-15/TO	xcomp||superior-14/JJ||six-dose-16/VB	amod||tablets-18/NNS||artemether-lumefantrine-17/JJ	dobj||six-dose-16/VB||tablets-18/NNS	nn||®-21/NNP||coartemâ-20/NNP	appos||tablets-18/NNS||®-21/NNP	det||treatment-25/NN||the-24/DT	prep_for||six-dose-16/VB||treatment-25/NN	amod||malaria-28/NN||uncomplicated-27/JJ	prep_of||treatment-25/NN||malaria-28/NN	prep_in||malaria-28/NN||children-30/NNS	num||years-33/NNS||five-32/CD	prep_below||six-dose-16/VB||years-33/NNS	prep_of||years-33/NNS||age-35/NN	amod||kenya-38/NN||western-37/JJ	prep_in||age-35/NN||kenya-38/NN	malaria-28||lumefantrine--1||yes||the once daily three-dose of artemether-lumefantrine suspension (co-artesianeâ®) was not superior to six-dose artemether-lumefantrine tablets (coartemâ®) for the treatment of uncomplicated malaria in children below five years of age in western kenya.
mark||identify-4/VB||in-1/IN	dep||identify-4/VB||order-2/NN	aux||identify-4/VB||to-3/TO	advcl||treated-15/VBD||identify-4/VB	dobj||identify-4/VB||genes-5/NNS	nsubjpass||regulated-9/VBN||genes-5/NNS	auxpass||regulated-9/VBN||are-7/VBP	advmod||regulated-9/VBN||epigenetically-8/RB	rcmod||genes-5/NNS||regulated-9/VBN	nn||tumors-12/NNS||neuroblastoma-11/NN	prep_in||regulated-9/VBN||tumors-12/NNS	nsubj||treated-15/VBD||we-14/PRP	root||ROOT-0/null||treated-15/VBD	num||lines-19/NNS||four-16/CD	nn||lines-19/NNS||neuroblastoma-17/NN	nn||lines-19/NNS||cell-18/NN	dobj||treated-15/VBD||lines-19/NNS	det||agent-23/NN||the-21/DT	amod||agent-23/NN||demethylating-22/JJ	prep_with||lines-19/NNS||agent-23/NN	amod||agent-23/NN||5-aza-2-24/JJ	dep||agent-23/NN||deoxycytidine-27/NN	dep||agent-23/NN||5-aza-dc-29/JJ	dep||lines-19/NNS||either-31/DT	dep||either-31/DT||separately-32/RB	dep||lines-19/NNS||in-34/IN	conj_or||either-31/DT||in-34/IN	pobj||in-34/IN||conjunction-35/NN	det||inhibitor-40/NN||the-37/DT	amod||inhibitor-40/NN||histone-38/JJ	nn||inhibitor-40/NN||deacetylase-39/NN	prep_with||conjunction-35/NN||inhibitor-40/NN	vmod||inhibitor-40/NN||trichostatin-41/VBN	det||tsa-44/NN||a-42/DT	dep||trichostatin-41/VBN||tsa-44/NN	neuroblastoma-17||aza--1||no_rel||in order to identify genes that are epigenetically regulated in neuroblastoma tumors, we treated four neuroblastoma cell lines with the demethylating agent 5-aza-2'-deoxycytidine (5-aza-dc) either separately or in conjunction with the histone deacetylase inhibitor trichostatin a (tsa).
mark||expressed-8/VBD||while-1/IN	det||lines-7/NNS||the-2/DT	num||lines-7/NNS||three-3/CD	amod||lines-7/NNS||cervical-4/JJ	nn||lines-7/NNS||cancer-5/NN	nn||lines-7/NNS||cell-6/NN	nsubj||expressed-8/VBD||lines-7/NNS	advcl||enzymes-24/NNS||expressed-8/VBD	num||mmps-11/NNS||10-14-9/CD	amod||mmps-11/NNS||different-10/JJ	dobj||expressed-8/VBD||mmps-11/NNS	det||expression-15/NN||the-13/DT	amod||expression-15/NN||median-14/JJ	nsubj||enzymes-24/NNS||expression-15/NN	nn||cells-20/NNS||endometrial-17/NN	conj_and||endometrial-17/NN||choriocarcinoma-19/NN	nn||cells-20/NNS||choriocarcinoma-19/NN	prep_in||expression-15/NN||cells-20/NNS	cop||enzymes-24/NNS||was-21/VBD	num||enzymes-24/NNS||7-22/CD	amod||enzymes-24/NNS||different-23/JJ	root||ROOT-0/null||enzymes-24/NNS	enzymes-24||choriocarcinoma-19||no_rel||while the three cervical cancer cell lines expressed 10-14 different mmps, the median expression in endometrial and choriocarcinoma cells was 7 different enzymes.
nn||gain-3/NN||body-1/NN	nn||gain-3/NN||weight-2/NN	nsubjpass||suppressed-20/VBN||gain-3/NN	amod||accumulation-7/NN||fat-5/JJ	nn||accumulation-7/NN||pad-6/NN	conj_and||gain-3/NN||accumulation-7/NN	nsubjpass||suppressed-20/VBN||accumulation-7/NN	det||development-10/NN||the-9/DT	conj_and||gain-3/NN||development-10/NN	nsubjpass||suppressed-20/VBN||development-10/NN	prep_of||development-10/NN||hyperlipidemia-12/NN	conj_and||gain-3/NN||hyperglycemia-14/NN	nsubjpass||suppressed-20/VBN||hyperglycemia-14/NN	conj_and||gain-3/NN||insulinresistance-17/NN	nsubjpass||suppressed-20/VBN||insulinresistance-17/NN	auxpass||suppressed-20/VBN||were-18/VBD	advmod||suppressed-20/VBN||significantly-19/RB	root||ROOT-0/null||suppressed-20/VBN	amod||polyphenols-23/NNS||lemon-22/JJ	agent||suppressed-20/VBN||polyphenols-23/NNS	fat-5||insulinresistance-17||no_rel||body weight gain, fat pad accumulation, the development of hyperlipidemia, hyperglycemia, and insulinresistance were significantly suppressed by lemon polyphenols.
det||study-2/NN||this-1/DT	nsubj||compared-3/VBD||study-2/NN	root||ROOT-0/null||compared-3/VBD	det||efficacy-5/NN||the-4/DT	dobj||compared-3/VBD||efficacy-5/NN	nn||monotherapy-8/NN||metformin-7/NN	prep_of||efficacy-5/NN||monotherapy-8/NN	nn||overweight-12/NN||normal-weight-10/NN	prep_among||compared-3/VBD||overweight-12/NN	nn||patients-16/NNS||obese-15/NN	prep_among||compared-3/VBD||patients-16/NNS	conj_and||overweight-12/NN||patients-16/NNS	advmod||diagnosed-19/JJ||newly-18/RB	amod||type2diabetes-20/NNS||diagnosed-19/JJ	prep_with||compared-3/VBD||type2diabetes-20/NNS	type2diabetes-20||metformin-7||yes||this study compared the efficacy of metformin monotherapy among normal-weight, overweight, and obese patients with newly diagnosed type2diabetes.
nn||antibodies-2/NNS||igg-1/NN	nsubjpass||measured-6/VBN||antibodies-2/NNS	prep_against||antibodies-2/NNS||mog-4/NN	auxpass||measured-6/VBN||were-5/VBD	root||ROOT-0/null||measured-6/VBN	agent||measured-6/VBN||elisa-8/NN	amod||fluid-13/NN||sera-10/JJ	conj_and||sera-10/JJ||cerebrospinal-12/JJ	amod||fluid-13/NN||cerebrospinal-12/JJ	prep_in||elisa-8/NN||fluid-13/NN	appos||fluid-13/NN||csf-15/NN	num||patients-20/NNS||65-18/CD	amod||patients-20/NNS||hiv-positive-19/JJ	prep_of||elisa-8/NN||patients-20/NNS	prep_with||patients-20/NNS||hand-22/NN	dep||elisa-8/NN||n-24/VBN	dep||14-26/CD||=-25/SYM	ccomp||n-24/VBN||14-26/CD	amod||infections-31/NNS||cerebral-29/JJ	amod||infections-31/NNS||opportunistic-30/JJ	appos||elisa-8/NN||infections-31/NNS	dep||infections-31/NNS||hivoi-33/NNS	vmod||hivoi-33/NNS||n-35/VBN	dep||25-37/CD||=-36/SYM	ccomp||n-35/VBN||25-37/CD	amod||hivinfection-41/NN||primary-40/JJ	agent||measured-6/VBN||hivinfection-41/NN	conj_and||elisa-8/NN||hivinfection-41/NN	dep||hivinfection-41/NN||hivm-43/NN	appos||hivm-43/NN||n-45/NN	dep||5-47/CD||=-46/SYM	rcmod||n-45/NN||5-47/CD	amod||patients-51/NNS||asymptomatic-50/JJ	agent||measured-6/VBN||patients-51/NNS	conj_and||elisa-8/NN||patients-51/NNS	dep||patients-51/NNS||hivasy-53/NN	appos||hivasy-53/NN||n-55/NN	dep||21-57/CD||=-56/SYM	rcmod||n-55/NN||21-57/CD	hivinfection-41||hiv--1||no||igg antibodies against mog were measured by elisa in sera and cerebrospinal fluid (csf) of 65 hiv-positive patients with hand (n = 14), cerebral opportunistic infections (hivoi, n = 25), primary hivinfection (hivm, n = 5) and asymptomatic patients (hivasy, n = 21).
expl||were-2/VBD||there-1/EX	root||ROOT-0/null||were-2/VBD	amod||cases-4/NNS||295-3/JJ	nsubj||were-2/VBD||cases-4/NNS	prep_of||diagnosed-31/VBN||cases-4/NNS	prep_of||cases-4/NNS||ibd-6/NN	dep||cases-4/NNS||uc-8/VBN	dep||240-10/CD||=-9/SYM	ccomp||uc-8/VBN||240-10/CD	ccomp||uc-8/VBN||cd-12/VB	dep||55-14/CD||=-13/SYM	ccomp||cd-12/VB||55-14/CD	nsubjpass||diagnosed-31/VBN||34-19/CD	dep||34-19/CD||uc-21/VBN	dep||30-23/CD||=-22/SYM	ccomp||uc-21/VBN||30-23/CD	ccomp||uc-21/VBN||cd-25/VB	dep||4-27/CD||=-26/SYM	ccomp||cd-25/VB||4-27/CD	auxpass||diagnosed-31/VBN||were-29/VBD	advmod||diagnosed-31/VBN||newly-30/RB	rcmod||cases-4/NNS||diagnosed-31/VBN	det||year-35/NN||the-33/DT	nn||year-35/NN||study-34/NN	prep_during||diagnosed-31/VBN||year-35/NN	uc-21||cd-25||no_rel||there were 295 cases of ibd (uc = 240, cd = 55), of which 34 (uc = 30, cd = 4) were newly diagnosed during the study year.
nsubj||increased-8/VBD||animals-1/NNS	vmod||animals-1/NNS||primed-2/VBN	prep||primed-2/VBN||with-3/IN	nsubj||showed-5/VBD||afro-1-4/JJ	parataxis||primed-2/VBN||showed-5/VBD	dobj||showed-5/VBD||i-6/FW	root||ROOT-0/null||increased-8/VBD	amod||production-11/NN||ag85b-specific-9/JJ	amod||production-11/NN||ifn-gamma-10/JJ	dobj||increased-8/VBD||production-11/NN	det||assay-15/NN||the-13/DT	nn||assay-15/NN||wba-14/NN	prep_in||production-11/NN||assay-15/NN	amod||pg/ml-20/NN||median-17/JJ	amod||pg/ml-20/NN||>-18/JJ	num||pg/ml-20/NN||400-19/CD	dep||assay-15/NN||pg/ml-20/NN	num||animals-23/NNS||6-22/CD	prep_for||pg/ml-20/NN||animals-23/NNS	num||week-26/NN||one-25/CD	dep||assay-15/NN||week-26/NN	det||boost-30/NN||the-28/DT	amod||boost-30/NN||first-29/JJ	prep_after||increased-8/VBD||boost-30/NN	amod||tb-antigens-33/NNS||adenoviral-delivered-32/JJ	prep_with||boost-30/NN||tb-antigens-33/NNS	prep||increased-8/VBD||as-34/IN	prep||increased-8/VBD||compared-35/VBN	pcomp||compared-35/VBN||to-36/TO	pobj||to-36/TO||animals-37/NNS	vmod||animals-37/NNS||primed-38/VBN	prep_with||primed-38/VBN||bcg-40/NN	number||200-43/CD||<-42/CD	num||pg/ml-44/NNS||200-43/CD	appos||bcg-40/NN||pg/ml-44/NNS	dobj||primed-38/VBN||ii-47/NN	amod||proliferation-52/NN||stronger-49/JJR	nn||proliferation-52/NN||t-50/NN	nn||proliferation-52/NN||cell-51/NN	npadvmod||primed-38/VBN||proliferation-52/NN	det||subset-59/NN||the-54/DT	amod||subset-59/NN||cd8alpha/alpha-55/JJ	amod||subset-59/NN||+-56/JJ	nn||subset-59/NN||t-57/NN	nn||subset-59/NN||cell-58/NN	prep_in||primed-38/VBN||subset-59/NN	amod||index-62/NN||proliferative-61/JJ	dep||subset-59/NN||index-62/NN	num||%-64/NN||17-63/CD	dep||index-62/NN||%-64/NN	prepc_as||subset-59/NN||compared-67/VBN	pcomp||compared-67/VBN||to-68/TO	amod||animals-70/NNS||bcg-primed-69/JJ	pobj||to-68/TO||animals-70/NNS	amod||index-73/NN||proliferative-72/JJ	dep||subset-59/NN||index-73/NN	number||%-75/NN||5-74/CD	amod||index-73/NN||%-75/NN	amod||cells-80/NNS||cd8alpha/alpha-77/JJ	amod||cells-80/NNS||+-78/JJ	nn||cells-80/NNS||t-79/NN	prep_in||index-73/NN||cells-80/NNS	tb--1||bcg-40||yes||animals primed with afro-1 showed i) increased ag85b-specific ifn-gamma production in the wba assay (median >400 pg/ml for 6 animals) one week after the first boost with adenoviral-delivered tb-antigens as compared to animals primed with bcg (<200 pg/ml), ii) stronger t cell proliferation in the cd8alpha/alpha+ t cell subset (proliferative index 17%) as compared to bcg-primed animals (proliferative index 5% in cd8alpha/alpha+ t cells).
nn||injection-2/NN||lps-1/NN	root||ROOT-0/null||injection-2/NN	vmod||injection-2/NN||induced-3/VBN	det||increase-6/NN||a-4/DT	amod||increase-6/NN||rapid-5/JJ	dobj||induced-3/VBN||increase-6/NN	nn||concentrations-9/NNS||plasma-8/NN	prep_in||increase-6/NN||concentrations-9/NNS	amod||metabolites-12/NNS||nitricoxide-11/JJ	prep_of||concentrations-9/NNS||metabolites-12/NNS	amod||concentrations-9/NNS||nitrite-14/JJ	amod||concentrations-9/NNS||nitrate-16/JJ	conj_and||nitrite-14/JJ||nitrate-16/JJ	appos||concentrations-9/NNS||nom-18/NN	amod||acidâ-23/NNS||thiobarbituric-22/JJ	dobj||induced-3/VBN||acidâ-23/NNS	conj_and||increase-6/NN||acidâ-23/NNS	dep||acidâ-23/NNS||$-24/$	advmod||substances-27/RB||reacting-26/RB	dep||generation-41/CD||substances-27/RB	pobj||substances-27/RB||tbars-29/NN	det||increase-33/NN||an-32/DT	appos||tbars-29/NN||increase-33/NN	amod||species-37/NNS||reactive-35/JJ	nn||species-37/NNS||oxygen-36/NN	prep_in||increase-33/NN||species-37/NNS	appos||species-37/NNS||ros-39/NN	num||$-24/$||generation-41/CD	nn||leukocytes-44/NNS||polymorphonuclear-43/NN	agent||induced-3/VBN||leukocytes-44/NNS	dep||injection-2/NN||pmnls-46/NNS	amod||increases-51/NNS||marked-50/VBN	conj_and||injection-2/NN||increases-51/NNS	amod||fattyacids-55/NNS||plasma-53/JJ	amod||fattyacids-55/NNS||free-54/JJ	prep_in||increases-51/NNS||fattyacids-55/NNS	nn||necrosis-58/NNS||tumor-57/NN	appos||fattyacids-55/NNS||necrosis-58/NNS	nn||±-60/NNP||factor-î-59/NNP	dep||injection-2/NN||±-60/NNP	nn||±-63/NNP||tnf-î-62/NNP	appos||±-60/NNP||±-63/NNP	dep||injection-2/NN||interleukin-6-66/JJ	conj_and||±-60/NNP||interleukin-6-66/JJ	dep||interleukin-6-66/JJ||il-6-68/JJ	amod||protein-1-73/NN||monocyte-71/JJ	nn||protein-1-73/NN||chemoattractant-72/NN	dep||injection-2/NN||protein-1-73/NN	conj_and||±-60/NNP||protein-1-73/NN	dep||protein-1-73/NN||mcp-1-75/JJ	amod||factor-81/NN||macrophage-78/JJ	nn||factor-81/NN||migration-79/NN	nn||factor-81/NN||inhibition-80/NN	appos||protein-1-73/NN||factor-81/NN	appos||factor-81/NN||mif-83/NN	amod||protein-87/NN||c-reactive-86/JJ	appos||protein-1-73/NN||protein-87/NN	appos||protein-87/NN||resistin-89/NN	vmod||protein-1-73/NN||visfatin-91/VBN	nn||protein-95/NN||lipopolysaccharide-93/NN	amod||protein-95/NN||binding-94/VBG	appos||protein-1-73/NN||protein-95/NN	appos||protein-95/NN||lbp-97/NN	advmod||group-b1-102/JJ||high-100/RB	advmod||group-b1-102/JJ||mobility-101/RB	dep||injection-2/NN||group-b1-102/JJ	amod||±-60/NNP||group-b1-102/JJ	conj_and||±-60/NNP||group-b1-102/JJ	dep||group-b1-102/JJ||hmg-b1-104/JJ	nn||concentrations-109/NNS||myoglobin-108/NN	dep||injection-2/NN||concentrations-109/NNS	conj_and||±-60/NNP||concentrations-109/NNS	tumor-57||mcp--1||no_rel||lps injection induced a rapid increase in plasma concentrations of nitricoxide metabolites, nitrite and nitrate (nom), and thiobarbituric acidâreacting substances (tbars), an increase in reactive oxygen species (ros) generation by polymorphonuclear leukocytes (pmnls), and marked increases in plasma free fattyacids, tumor necrosis factor-î± (tnf-î±), interleukin-6 (il-6), monocyte chemoattractant protein-1 (mcp-1), macrophage migration inhibition factor (mif), c-reactive protein, resistin, visfatin, lipopolysaccharide binding protein (lbp), high mobility group-b1 (hmg-b1), and myoglobin concentrations.
det||efficacy-3/NN||the-1/DT	amod||efficacy-3/NN||analgesic-2/JJ	nsubjpass||assessed-8/VBN||efficacy-3/NN	det||block-6/NN||the-5/DT	prep_of||efficacy-3/NN||block-6/NN	auxpass||assessed-8/VBN||was-7/VBD	root||ROOT-0/null||assessed-8/VBN	amod||anesthetics-11/NNS||intraoperative-10/JJ	prep_with||assessed-8/VBN||anesthetics-11/NNS	appos||anesthetics-11/NNS||desflurane-13/NN	appos||anesthetics-11/NNS||numbers-16/NNS	prep_of||numbers-16/NNS||patients-18/NNS	vmod||patients-18/NNS||needing-19/VBG	amod||analgesics-21/NNS||postoperative-20/JJ	dobj||needing-19/VBG||analgesics-21/NNS	det||time-24/NN||the-23/DT	appos||anesthetics-11/NNS||time-24/NN	conj_and||numbers-16/NNS||time-24/NN	det||analgesics-28/NNS||the-26/DT	amod||analgesics-28/NNS||first-27/JJ	prep_to||time-24/NN||analgesics-28/NNS	vmod||analgesics-28/NNS||required-29/VBN	nn||intensity-33/NN||pain-32/NN	appos||anesthetics-11/NNS||intensity-33/NN	conj_and||numbers-16/NNS||intensity-33/NN	amod||scale-37/NN||visual-35/JJ	amod||scale-37/NN||analog-36/JJ	prep_by||intensity-33/NN||scale-37/NN	appos||scale-37/NN||vas-39/NN	pain-32||desflurane-13||yes||the analgesic efficacy of the block was assessed with intraoperative anesthetics (desflurane), numbers of patients needing postoperative analgesics, the time to the first analgesics required, and pain intensity by visual analog scale (vas).
nsubj||had-2/VBD||most-1/JJS	root||ROOT-0/null||had-2/VBD	det||level-5/NN||a-3/DT	amod||level-5/NN||fair-4/JJ	dobj||had-2/VBD||level-5/NN	prep_of||level-5/NN||knowledge-7/NN	prep_on||had-2/VBD||hiv/aids-9/NNS	det||score-16/NN||the-12/DT	amod||score-16/NN||highest-13/JJS	amod||score-16/NN||mean-14/JJ	nn||score-16/NN||knowledge-15/NN	prep_with||had-2/VBD||score-16/NN	det||msm-19/NN||the-18/DT	prep_among||score-16/NN||msm-19/NN	prep_from||msm-19/NN||jiamusi-21/NNS	appos||jiamusi-21/NNS||those-23/DT	nn||rmb/month-27/NN||income-25/NN	num||rmb/month-27/NN||2000-3000-26/CD	prep_with||those-23/DT||rmb/month-27/NN	appos||those-23/DT||those-29/DT	vmod||those-29/DT||searching-30/VBG	amod||partners-32/NNS||sexual-31/JJ	dobj||searching-30/VBG||partners-32/NNS	prep_via||partners-32/NNS||internet-34/NN	dobj||searching-30/VBG||those-36/DT	conj_and||partners-32/NNS||those-36/DT	vmod||those-36/DT||performed-37/VBN	nn||testing-39/NN||hiv-38/NN	dobj||performed-37/VBN||testing-39/NN	prep||performed-37/VBN||over-40/IN	num||year-42/NN||1-41/CD	npadvmod||ago-43/RB||year-42/NN	pcomp||over-40/IN||ago-43/RB	aids--1||hiv-38||no||most had a fair level of knowledge on hiv/aids, with the highest mean knowledge score among the msm from jiamusi, those with income 2000-3000 rmb/month, those searching sexual partners via internet and those performed hiv testing over 1 year ago).
nsubjpass||performed-3/VBN||bioassay-1/NN	auxpass||performed-3/VBN||were-2/VBD	root||ROOT-0/null||performed-3/VBN	prep_on||performed-3/VBN||adults-5/NNS	vmod||adults-5/NNS||collected-6/VBN	det||field-9/NN||the-8/DT	prep_from||collected-6/VBN||field-9/NN	aux||assess-11/VB||to-10/TO	xcomp||collected-6/VBN||assess-11/VB	det||susceptibility-13/NN||the-12/DT	dobj||assess-11/VB||susceptibility-13/NN	nn||vectors-16/NNS||malaria-15/NN	prep_of||susceptibility-13/NN||vectors-16/NNS	amod||papers-19/NNS||insecticide-impregnated-18/JJ	prep_to||assess-11/VB||papers-19/NNS	dep||performed-3/VBN||permethrin-21/VB	num||%-23/NN||0.75-22/CD	dobj||permethrin-21/VB||%-23/NN	dep||performed-3/VBN||delthamethrin-25/VB	conj_and||permethrin-21/VB||delthamethrin-25/VB	num||%-27/NN||0.05-26/CD	dobj||delthamethrin-25/VB||%-27/NN	dep||performed-3/VBN||ddt-29/VB	conj_and||permethrin-21/VB||ddt-29/VB	num||%-31/NN||4-30/CD	dobj||ddt-29/VB||%-31/NN	dep||performed-3/VBN||bendiocarb-34/VB	conj_and||permethrin-21/VB||bendiocarb-34/VB	num||%-36/NN||0.1-35/CD	dobj||bendiocarb-34/VB||%-36/NN	amod||guidelines-40/NNS||whopes-39/JJ	prep_following||performed-3/VBN||guidelines-40/NNS	insecticide--1||malaria-15||no_rel||bioassay were performed on adults collected from the field to assess the susceptibility of malaria vectors to insecticide-impregnated papers (permethrin 0.75%, delthamethrin 0.05%, ddt 4%, and bendiocarb 0.1%) following whopes guidelines.
nsubj||â-2/VBP||results-1/NNS	root||ROOT-0/null||â-2/VBP	dobj||â-2/VBP||$-3/$	det||patients-8/NNS||the-5/DT	advmod||obese-7/JJ||morbidly-6/RB	amod||patients-8/NNS||obese-7/JJ	nsubj||had-11/VBD||patients-8/NNS	prep_with||patients-8/NNS||diabetes-10/NN	rcmod||$-3/$||had-11/VBD	advmod||higher-13/JJR||significantly-12/RB	amod||levels-14/NNS||higher-13/JJR	dobj||had-11/VBD||levels-14/NNS	prep_of||levels-14/NNS||oxldl-16/NN	prepc_compared_with||had-11/VBD||with-18/IN	det||patients-22/NNS||the-19/DT	advmod||obese-21/JJ||morbidly-20/RB	amod||patients-22/NNS||obese-21/JJ	pobj||had-11/VBD||patients-22/NNS	amod||glucose-26/NN||normal-24/JJ	nn||glucose-26/NN||fasting-25/NN	prep_with||patients-22/NNS||glucose-26/NN	det||subjects-30/NNS||the-28/DT	nn||subjects-30/NNS||control-29/NN	prep_with||patients-22/NNS||subjects-30/NNS	conj_and||glucose-26/NN||subjects-30/NNS	advmod||lower-33/JJR||significantly-32/RB	amod||levels-34/NNS||lower-33/JJR	pobj||had-11/VBD||levels-34/NNS	conj_and||patients-22/NNS||levels-34/NNS	amod||antibodies-38/NNS||igm-36/JJ	amod||antibodies-38/NNS||anti-oxldl-37/JJ	prep_of||levels-34/NNS||antibodies-38/NNS	obese-21||antibodies-38||no_rel||results âthe morbidly obese patients with diabetes had significantly higher levels of oxldl compared with the morbidly obese patients with normal fasting glucose and the control subjects and significantly lower levels of igm anti-oxldl antibodies.
det||beginning-4/NN||the-3/DT	prep_as_of||includes-16/VBZ||beginning-4/NN	prep_of||beginning-4/NN||2013-6/CD	poss||â-9/NN||our-8/PRP$	appos||2013-6/CD||â-9/NN	amod||â-9/NN||$-10/$	dep||$-10/$||antibodies-11/JJ	aux||watchâ-13/VB||to-12/TO	vmod||beginning-4/NN||watchâ-13/VB	dobj||watchâ-13/VB||$-14/$	num||$-14/$||list-15/CD	root||ROOT-0/null||includes-16/VBZ	num||mabs-19/NNS||28-17/CD	amod||mabs-19/NNS||single-18/JJ	dobj||includes-16/VBZ||mabs-19/NNS	num||mixture-23/NN||one-21/CD	nn||mixture-23/NN||mab-22/NN	dobj||includes-16/VBZ||mixture-23/NN	conj_and||mabs-19/NNS||mixture-23/NN	nsubj||undergoing-26/VBG||mixture-23/NN	aux||undergoing-26/VBG||are-25/VBP	rcmod||mixture-23/NN||undergoing-26/VBG	dobj||undergoing-26/VBG||evaluation-27/NN	prep_in||evaluation-27/NN||phase-29/NN	num||studies-31/NNS||3-30/CD	nsubj||includes-16/VBZ||studies-31/NNS	amod||disorders-36/NNS||inflammatory-33/JJ	conj_or||inflammatory-33/JJ||immunological-35/JJ	amod||disorders-36/NNS||immunological-35/JJ	prep_for||studies-31/NNS||disorders-36/NNS	prep_for||studies-31/NNS||cancers-38/NNS	conj_and||disorders-36/NNS||cancers-38/NNS	amod||cholesterol-41/NN||high-40/JJ	prep_for||studies-31/NNS||cholesterol-41/NN	conj_and||disorders-36/NNS||cholesterol-41/NN	prep_for||studies-31/NNS||osteoporosis-43/NNS	conj_and||disorders-36/NNS||osteoporosis-43/NNS	prep_for||studies-31/NNS||alzheimerdisease-45/NN	conj_and||disorders-36/NNS||alzheimerdisease-45/NN	amod||disease-48/NN||infectious-47/JJ	prep_for||studies-31/NNS||disease-48/NN	conj_and||disorders-36/NNS||disease-48/NN	cholesterol-41||cancers-38||no_rel||as of the beginning of 2013, our âantibodies to watchâ? list includes 28 single mabs and one mab mixture that are undergoing evaluation in phase 3 studies for inflammatory or immunological disorders, cancers, high cholesterol, osteoporosis, alzheimerdisease and infectious disease.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||determine-8/VB||aim-2/NN	nsubj||prednisone-22/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||determine-8/VB||to-7/TO	xcomp||was-6/VBD||determine-8/VB	mark||pharmacokinetics-14/VBZ||whether-9/IN	nsubj||pharmacokinetics-14/VBZ||mycophenolatemofetil-10/NN	appos||mycophenolatemofetil-10/NN||mmf-12/NN	ccomp||determine-8/VB||pharmacokinetics-14/VBZ	dep||pharmacokinetics-14/VBZ||pk-16/NN	amod||mmf-20/NN||combined-19/VBN	prep_under||pharmacokinetics-14/VBZ||mmf-20/NN	xcomp||was-6/VBD||prednisone-22/VB	conj_and||determine-8/VB||prednisone-22/VB	amod||therapy-24/NN||remission-maintenance-23/JJ	nsubj||predict-26/VB||therapy-24/NN	aux||predict-26/VB||can-25/MD	ccomp||prednisone-22/VB||predict-26/VB	dobj||predict-26/VB||systemiclupuserythematosus-27/NNS	appos||systemiclupuserythematosus-27/NNS||sle-29/NN	amod||flares-32/NNS||clinical-31/JJ	dobj||determine-8/VB||flares-32/NNS	mycophenolatemofetil-10||systemiclupuserythematosus-27||no_rel||the aim of this study was to determine whether mycophenolatemofetil (mmf) pharmacokinetics (pk) under combined mmf and prednisone remission-maintenance therapy can predict systemiclupuserythematosus (sle) clinical flares.
det||polymorphism-4/NN||a-1/DT	amod||polymorphism-4/NN||single-2/JJ	nn||polymorphism-4/NN||nucleotide-3/NN	nsubjpass||shown-36/VBN||polymorphism-4/NN	nsubj||determinant-40/NN||polymorphism-4/NN	appos||polymorphism-4/NN||snp-6/NN	prep_in||polymorphism-4/NN||codon-9/NN	num||codon-9/NN||129-10/CD	det||gene-15/NN||the-12/DT	amod||gene-15/NN||human-13/JJ	nn||gene-15/NN||prion-14/NN	prep_of||codon-9/NN||gene-15/NN	vmod||shown-36/VBN||leading-17/VBG	det||change-20/NN||a-19/DT	prep_to||leading-17/VBG||change-20/NN	prep_from||change-20/NN||methionine-22/NN	aux||valine-24/VB||to-23/TO	xcomp||leading-17/VBG||valine-24/VB	prep_at||valine-24/VB||residue-26/NN	num||residue-26/NN||129-27/CD	prep_of||residue-26/NN||prionprotein-29/NN	appos||prionprotein-29/NN||prp-31/NN	aux||shown-36/VBN||has-34/VBZ	auxpass||shown-36/VBN||been-35/VBN	root||ROOT-0/null||shown-36/VBN	aux||determinant-40/NN||to-37/TO	cop||determinant-40/NN||be-38/VB	det||determinant-40/NN||a-39/DT	xcomp||shown-36/VBN||determinant-40/NN	det||susceptibility-43/NN||the-42/DT	prep_in||determinant-40/NN||susceptibility-43/NN	aux||priondisease-45/VB||to-44/TO	vmod||susceptibility-43/NN||priondisease-45/VB	priondisease-45||prionprotein-29||no||a single nucleotide polymorphism (snp) in codon 129 of the human prion gene, leading to a change from methionine to valine at residue 129 of prionprotein (prp), has been shown to be a determinant in the susceptibility to priondisease.
aux||use-2/VB||to-1/TO	advcl||necessary-16/JJ||use-2/VB	dobj||use-2/VB||pyrimethamine-3/NN	det||drug-8/NN||an-5/DT	amod||drug-8/NN||alternative-6/JJ	amod||drug-8/NN||anti-malarial-7/JJ	prep_as||use-2/VB||drug-8/NN	amod||parasites-12/NNS||chloroquine-resistant-10/JJ	nn||parasites-12/NNS||malaria-11/NN	prep_for||drug-8/NN||parasites-12/NNS	nsubj||necessary-16/JJ||it-14/PRP	nsubj||determine-18/VB||it-14/PRP	cop||necessary-16/JJ||was-15/VBD	root||ROOT-0/null||necessary-16/JJ	aux||determine-18/VB||to-17/TO	xcomp||necessary-16/JJ||determine-18/VB	det||enzyme-20/NN||the-19/DT	poss||variation-23/NN||enzyme-20/NN	amod||variation-23/NN||genetic-22/JJ	dobj||determine-18/VB||variation-23/NN	amod||syntase-27/NN||dihydrofolate-25/JJ	amod||syntase-27/NN||reductase-thymidylate-26/JJ	prep_in||variation-23/NN||syntase-27/NN	appos||syntase-27/NN||dhfr-ts-29/NNS	nn||strains-33/NNS||korean-32/NN	prep_among||determine-18/VB||strains-33/NNS	malaria-11||pyrimethamine-3||no||to use pyrimethamine as an alternative anti-malarial drug for chloroquine-resistant malaria parasites, it was necessary to determine the enzyme's genetic variation in dihydrofolate reductase-thymidylate syntase (dhfr-ts) among korean strains.
poss||findings-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||findings-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||prominent-16/JJ||that-4/IN	det||influence-6/NN||the-5/DT	nsubj||prominent-16/JJ||influence-6/NN	prepc_of||influence-6/NN||treg-8/VBG	nn||suppression-10/NN||cell-9/NN	dobj||treg-8/VBG||suppression-10/NN	nn||pathogenesis-13/NNS||fiv-12/NN	prep_during||treg-8/VBG||pathogenesis-13/NNS	cop||prominent-16/JJ||is-14/VBZ	advmod||prominent-16/JJ||most-15/RBS	ccomp||suggest-3/VBP||prominent-16/JJ	mark||activated-21/VBN||after-17/IN	amod||cells-19/NNS||treg-18/VBG	nsubjpass||activated-21/VBN||cells-19/NNS	auxpass||activated-21/VBN||are-20/VBP	ccomp||prominent-16/JJ||activated-21/VBN	det||environment-24/NN||the-23/DT	prep_in||activated-21/VBN||environment-24/NN	amod||fivinfection-27/NN||established-26/VBN	prep_of||environment-24/NN||fivinfection-27/NN	fivinfection-27||fiv-12||no||our findings suggest that the influence of treg cell suppression during fiv pathogenesis is most prominent after treg cells are activated in the environment of established fivinfection.
det||evidence-2/NN||the-1/DT	nsubj||parasitophorous-4/VBZ||evidence-2/NN	nsubj||suggests-23/VBZ||evidence-2/NN	rcmod||evidence-2/NN||parasitophorous-4/VBZ	amod||swelling-6/NNS||vacuole-5/JJ	nsubj||dependent-15/JJ||swelling-6/NNS	det||stage-9/NN||a-8/DT	appos||swelling-6/NNS||stage-9/NN	amod||egress-12/NNS||unaffected-11/JJ	prep_of||stage-9/NN||egress-12/NNS	cop||dependent-15/JJ||is-14/VBZ	ccomp||parasitophorous-4/VBZ||dependent-15/JJ	det||rise-18/NN||a-17/DT	prep_upon||dependent-15/JJ||rise-18/NN	amod||+-22/NNS||intracellular-20/JJ	amod||+-22/NNS||ca2-21/JJ	prep_in||rise-18/NN||+-22/NNS	root||ROOT-0/null||suggests-23/VBZ	det||mechanism-25/NN||a-24/DT	dobj||suggests-23/VBZ||mechanism-25/NN	amod||egress-28/NNS||ionophore-inducible-27/JJ	prep_for||mechanism-25/NN||egress-28/NNS	det||target-32/NN||a-30/DT	amod||target-32/NN||new-31/JJ	dobj||suggests-23/VBZ||target-32/NN	conj_and||mechanism-25/NN||target-32/NN	amod||+-35/NNS||ca2-34/JJ	prep_for||target-32/NN||+-35/NNS	det||programme-38/NN||the-37/DT	npadvmod||liberating-39/JJ||programme-38/NN	amod||parasites-40/NNS||liberating-39/JJ	prep_in||+-35/NNS||parasites-40/NNS	det||cell-44/NN||the-42/DT	nn||cell-44/NN||host-43/NN	prep_from||suggests-23/VBZ||cell-44/NN	ionophore--1||swelling-6||no_rel||the evidence that parasitophorous vacuole swelling, a stage of unaffected egress, is dependent upon a rise in intracellular ca2+ suggests a mechanism for ionophore-inducible egress and a new target for ca2+ in the programme liberating parasites from the host cell.
poss||recommendations-2/NNS||their-1/PRP$	nsubj||included-3/VBD||recommendations-2/NNS	root||ROOT-0/null||included-3/VBD	dep||make-12/VB||1-5/LS	det||country-10/NN||every-7/DT	amod||country-10/NN||dengue-8/JJ	amod||country-10/NN||endemic-9/JJ	nsubj||make-12/VB||country-10/NN	aux||make-12/VB||should-11/MD	dep||included-3/VBD||make-12/VB	dobj||make-12/VB||reporting-13/NN	amod||cases-16/NNS||dengue-15/JJ	prep_of||reporting-13/NN||cases-16/NNS	det||government-19/NN||the-18/DT	prep_to||make-12/VB||government-19/NN	amod||government-19/NN||mandatory-20/JJ	dep||developed-30/VBN||2-23/LS	amod||systems-27/NNS||electronic-25/JJ	nn||systems-27/NNS||reporting-26/NN	nsubjpass||developed-30/VBN||systems-27/NNS	nsubjpass||used-32/VBN||systems-27/NNS	aux||developed-30/VBN||should-28/MD	auxpass||developed-30/VBN||be-29/VB	parataxis||make-12/VB||developed-30/VBN	parataxis||make-12/VB||used-32/VBN	conj_and||developed-30/VBN||used-32/VBN	nsubj||include-43/VB||3-35/NNP	amod||data-41/NNS||minimum-38/JJ	nn||data-41/NNS||dengue-39/NN	nn||data-41/NNS||surveillance-40/NN	prep_at||3-35/NNP||data-41/NNS	aux||include-43/VB||should-42/MD	conj_and||included-3/VBD||include-43/VB	dobj||include-43/VB||incidence-44/NN	nn||rates-47/NNS||hospitalization-46/NN	appos||incidence-44/NN||rates-47/NNS	appos||rates-47/NNS||deaths-49/NNS	nn||group-52/NN||age-51/NN	prep_by||include-43/VB||group-52/NN	dep||completed-61/VBN||4-55/LS	amod||studies-58/NNS||additional-57/JJ	nsubjpass||completed-61/VBN||studies-58/NNS	nsubj||check-63/VB||studies-58/NNS	aux||completed-61/VBN||should-59/MD	auxpass||completed-61/VBN||be-60/VB	conj_and||included-3/VBD||completed-61/VBN	aux||check-63/VB||to-62/TO	xcomp||completed-61/VBN||check-63/VB	det||sensitivity-65/NN||the-64/DT	dobj||check-63/VB||sensitivity-65/NN	det||system-68/NN||the-67/DT	prep_of||sensitivity-65/NN||system-68/NN	dep||share-75/VB||5-71/CD	nsubj||share-75/VB||laboratories-73/NNS	aux||share-75/VB||should-74/MD	conj_and||included-3/VBD||share-75/VB	dobj||share-75/VB||expertise-76/NN	dobj||share-75/VB||data-78/NNS	conj_and||expertise-76/NN||data-78/NNS	appos||tests-83/NNS||6-81/CD	dep||expertise-76/NN||tests-83/NNS	nsubj||identify-85/VBP||tests-83/NNS	rcmod||tests-83/NNS||identify-85/VBP	nsubjpass||used-89/VBN||denguevirus-86/NNS	aux||used-89/VBN||should-87/MD	auxpass||used-89/VBN||be-88/VB	ccomp||identify-85/VBP||used-89/VBN	prep_in||used-89/VBN||patients-91/NNS	prep_with||patients-91/NNS||fever-93/NN	num||days-96/NNS||four-95/CD	prep_for||fever-93/NN||days-96/NNS	cc||less-98/JJR||or-97/CC	num||days-96/NNS||less-98/JJR	nn||tests-101/NNS||antibody-100/NN	nsubjpass||used-104/VBN||tests-101/NNS	nsubj||diagnose-109/VB||tests-101/NNS	aux||used-104/VBN||should-102/MD	auxpass||used-104/VBN||be-103/VB	conj_and||included-3/VBD||used-104/VBN	prep_after||used-104/VBN||day-106/NN	num||day-106/NN||4-107/CD	aux||diagnose-109/VB||to-108/TO	xcomp||used-104/VBN||diagnose-109/VB	dobj||diagnose-109/VB||dengue-110/NN	appos||detection-117/NN||7-114/CD	amod||detection-117/NN||early-116/JJ	nsubj||goals-125/NNS||detection-117/NN	conj_and||detection-117/NN||prediction-119/NN	nsubj||goals-125/NNS||prediction-119/NN	amod||outbreaks-122/NNS||dengue-121/JJ	prep_of||prediction-119/NN||outbreaks-122/NNS	aux||goals-125/NNS||should-123/MD	cop||goals-125/NNS||be-124/VB	conj_and||included-3/VBD||goals-125/NNS	amod||systems-129/NNS||national-127/JJ	nn||systems-129/NNS||surveillance-128/NN	prep_for||goals-125/NNS||systems-129/NNS	dengue-121||denguevirus-86||no||their recommendations included (1) every dengue endemic country should make reporting of dengue cases to the government mandatory; (2) electronic reporting systems should be developed and used; (3) at minimum dengue surveillance data should include incidence, hospitalization rates, deaths by age group; (4) additional studies should be completed to check the sensitivity of the system; (5) laboratories should share expertise and data; (6) tests that identify denguevirus should be used in patients with fever for four days or less and antibody tests should be used after day 4 to diagnose dengue; and (7) early detection and prediction of dengue outbreaks should be goals for national surveillance systems.
nsubj||anesthetic-7/NN||ketamine-1/NN	cop||anesthetic-7/NN||is-2/VBZ	det||anesthetic-7/NN||a-3/DT	advmod||used-5/VBN||widely-4/RB	amod||anesthetic-7/NN||used-5/VBN	nn||anesthetic-7/NN||dissociative-6/NN	root||ROOT-0/null||anesthetic-7/NN	nsubj||induce-10/VB||which-8/WDT	aux||induce-10/VB||can-9/MD	ccomp||anesthetic-7/NN||induce-10/VB	det||symptoms-13/NNS||some-11/DT	amod||symptoms-13/NNS||psychotic-like-12/JJ	dobj||induce-10/VB||symptoms-13/NNS	nn||deficits-16/NNS||memory-15/NN	dobj||induce-10/VB||deficits-16/NNS	conj_and||symptoms-13/NNS||deficits-16/NNS	det||patients-19/NNS||some-18/DT	prep_in||induce-10/VB||patients-19/NNS	det||period-23/NN||the-21/DT	amod||period-23/NN||post-operative-22/JJ	prep_during||induce-10/VB||period-23/NN	psychotic--1||ketamine-1||no||ketamine is a widely used dissociative anesthetic which can induce some psychotic-like symptoms and memory deficits in some patients during the post-operative period.
amod||reports-2/NNS||several-1/JJ	nsubj||indicate-3/VBP||reports-2/NNS	root||ROOT-0/null||indicate-3/VBP	mark||affects-7/VBZ||that-4/IN	nsubj||affects-7/VBZ||retinoicacid-5/NN	nsubj||alleviates-13/VBZ||retinoicacid-5/NN	advmod||affects-7/VBZ||positively-6/RB	advcl||indicate-3/VBP||affects-7/VBZ	det||progression-9/NN||the-8/DT	dobj||affects-7/VBZ||progression-9/NN	prep_of||progression-9/NN||fibrosis-11/NN	advcl||indicate-3/VBP||alleviates-13/VBZ	conj_and||affects-7/VBZ||alleviates-13/VBZ	det||accumulation-15/NN||the-14/DT	dobj||alleviates-13/VBZ||accumulation-15/NN	det||matrix-19/NN||the-17/DT	nn||matrix-19/NN||extracellular-18/NN	prep_of||accumulation-15/NN||matrix-19/NN	mark||report-24/VBP||whereas-21/IN	amod||studies-23/NNS||other-22/JJ	nsubj||report-24/VBP||studies-23/NNS	dep||affects-7/VBZ||report-24/VBP	det||opposite-26/NN||the-25/DT	dobj||report-24/VBP||opposite-26/NN	mark||exacerbates-30/VBZ||that-28/IN	nsubj||exacerbates-30/VBZ||retinoicacid-29/NN	nsubj||induces-33/VBZ||retinoicacid-29/NN	dep||affects-7/VBZ||exacerbates-30/VBZ	dobj||exacerbates-30/VBZ||fibrosis-31/NN	dep||affects-7/VBZ||induces-33/VBZ	conj_and||exacerbates-30/VBZ||induces-33/VBZ	nn||accumulation-36/NN||extracellular-34/NN	nn||accumulation-36/NN||matrix-35/NN	dobj||induces-33/VBZ||accumulation-36/NN	fibrosis-31||retinoicacid-29||no_rel||several reports indicate that retinoicacid positively affects the progression of fibrosis and alleviates the accumulation of the extracellular matrix, whereas other studies report the opposite; that retinoicacid exacerbates fibrosis and induces extracellular matrix accumulation.
det||objective-2/NN||the-1/DT	nsubj||was-6/VBD||objective-2/NN	nsubj||determine-8/VB||objective-2/NN	det||study-5/NN||this-4/DT	prep_of||objective-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||determine-8/VB||to-7/TO	xcomp||was-6/VBD||determine-8/VB	mark||collected-16/VBD||whether-9/IN	amod||levels-13/NNS||estradiol-10/JJ	conj_and||estradiol-10/JJ||testosterone-12/JJ	amod||levels-13/NNS||testosterone-12/JJ	nsubj||collected-16/VBD||levels-13/NNS	prep_in||levels-13/NNS||serum-15/NN	ccomp||determine-8/VB||collected-16/VBD	mark||associated-20/VBN||before-17/IN	nsubjpass||associated-20/VBN||menopause-18/NN	auxpass||associated-20/VBN||are-19/VBP	advcl||collected-16/VBD||associated-20/VBN	amod||risk-25/NN||subsequent-22/JJ	nn||risk-25/NN||breast-23/NN	nn||risk-25/NN||cancer-24/NN	prep_with||associated-20/VBN||risk-25/NN	testosterone-12||cancer-24||no_rel||the objective of this study was to determine whether estradiol and testosterone levels in serum collected before menopause are associated with subsequent breast cancer risk.
nsubjpass||administered-23/VBN||questionnaires-1/NNS	aux||ascertain-3/VB||to-2/TO	vmod||questionnaires-1/NNS||ascertain-3/VB	det||presence-5/NN||the-4/DT	dobj||ascertain-3/VB||presence-5/NN	amod||conditions-8/NNS||atopy-associated-7/JJ	prep_of||presence-5/NN||conditions-8/NNS	prep_such_as||conditions-8/NNS||hayfever-11/NN	prep_such_as||conditions-8/NNS||atopicdermatitis-13/NNS	conj_and||hayfever-11/NN||atopicdermatitis-13/NNS	prep_such_as||conditions-8/NNS||asthma-15/NN	conj_and||hayfever-11/NN||asthma-15/NN	amod||rhinitis-18/NNS||allergic-17/JJ	prep_such_as||conditions-8/NNS||rhinitis-18/NNS	conj_and||hayfever-11/NN||rhinitis-18/NNS	prep_such_as||conditions-8/NNS||allergicconjunctivitis-21/NNS	conj_and||hayfever-11/NN||allergicconjunctivitis-21/NNS	auxpass||administered-23/VBN||were-22/VBD	root||ROOT-0/null||administered-23/VBN	det||parents-26/NNS||the-25/DT	prep_to||administered-23/VBN||parents-26/NNS	num||pupils-29/NNS||128-28/CD	prep_of||parents-26/NNS||pupils-29/NNS	det||3rd-32/NNS||the-31/DT	prep_in||pupils-29/NNS||3rd-32/NNS	amod||grades-35/NNS||6th-34/JJ	prep_to||administered-23/VBN||grades-35/NNS	amod||school-38/NN||elementary-37/JJ	prep_of||grades-35/NNS||school-38/NN	allergicconjunctivitis-21||atopy--1||no||questionnaires to ascertain the presence of atopy-associated conditions such as hayfever, atopicdermatitis, asthma, allergic rhinitis, and allergicconjunctivitis were administered to the parents of 128 pupils in the 3rd to 6th grades of elementary school.
nsubj||reported-3/VBN||we-1/PRP	aux||reported-3/VBN||have-2/VBP	root||ROOT-0/null||reported-3/VBN	det||rate-11/NN||a-4/DT	amod||rate-11/NN||promising-5/JJ	amod||rate-11/NN||complete-6/JJ	nn||rate-11/NN||remission-7/NN	num||rate-11/NN||-lrb--8/CD	nn||rate-11/NN||cr-9/NN	nn||rate-11/NN||-rrb--10/NN	dobj||reported-3/VBN||rate-11/NN	advmod||diagnosed-14/JJ||newly-13/RB	amod||patients-16/NNS||diagnosed-14/JJ	nn||patients-16/NNS||myeloma-15/NN	prep_for||rate-11/NN||patients-16/NNS	vmod||patients-16/NNS||treated-17/VBN	det||approach-21/NN||a-19/DT	amod||approach-21/NN||staged-20/JJ	agent||treated-17/VBN||approach-21/NN	prep_in||underwent-27/VBD||approach-21/NN	amod||patients-26/NNS||chemosensitive-25/JJ	nsubj||underwent-27/VBD||patients-26/NNS	rcmod||approach-21/NN||underwent-27/VBD	nsubj||stem-30/VB||autologous-28/NNS	dep||stem-30/VB||haematopoietic-29/JJ	xcomp||underwent-27/VBD||stem-30/VB	nn||-rrb--35/NNS||cell-31/NN	nn||-rrb--35/NNS||transplantation-32/NN	nn||-rrb--35/NNS||-lrb--33/NN	nn||-rrb--35/NNS||auto-hsct-34/NN	dobj||stem-30/VB||-rrb--35/NNS	mark||received-40/VBD||while-36/IN	amod||patients-39/NNS||less-37/JJR	nn||patients-39/NNS||chemosensitive-38/NN	nsubj||received-40/VBD||patients-39/NNS	advcl||stem-30/VB||received-40/VBD	nn||therapy-42/NN||salvage-41/NN	dobj||received-40/VBD||therapy-42/NN	prep_with||received-40/VBD||bortezomib/thalidomide/dexamethasone-44/NN	prep_prior_to||received-40/VBD||auto-hsct-47/NN	malaria--1||mefloquine--1||yes||we have reported a promising complete remission -lrb- cr -rrb- rate for newly diagnosed myeloma patients treated by a staged approach , in which chemosensitive patients underwent autologous haematopoietic stem cell transplantation -lrb- auto-hsct -rrb- while less chemosensitive patients received salvage therapy with bortezomib/thalidomide/dexamethasone prior to auto-hsct .
amod||nanotube-4/NN||single-1/JJ	nn||nanotube-4/NN||wall-2/NN	nn||nanotube-4/NN||carbon-3/NN	nn||constructs-8/NNS||nanotube-4/NN	appos||constructs-8/NNS||swcnt-6/NN	nsubjpass||appended-11/VBN||constructs-8/NNS	auxpass||appended-11/VBN||were-9/VBD	advmod||appended-11/VBN||covalently-10/RB	root||ROOT-0/null||appended-11/VBN	amod||chelates-14/NNS||radiometal-ion-13/JJ	prep_with||appended-11/VBN||chelates-14/NNS	amod||,4,7,10-17/CD||1,4,7,10-tetraazacyclododecane-1-16/JJ	dep||chelates-14/NNS||,4,7,10-17/CD	amod||-RSB--23/NNP||tetraacetic-19/JJ	amod||-RSB--23/NNP||acid-20/JJ	nn||-RSB--23/NNP||-LSB--21/NNP	nn||-RSB--23/NNP||dota-22/NNP	dep||,4,7,10-17/CD||-RSB--23/NNP	amod||-RSB--28/NNS||desferrioxamineb-25/JJ	amod||-RSB--28/NNS||-LSB--26/JJ	nn||-RSB--28/NNS||dfo-27/NN	dep||,4,7,10-17/CD||-RSB--28/NNS	conj_or||-RSB--23/NNP||-RSB--28/NNS	det||tumor-32/NN||the-31/DT	prep_with||appended-11/VBN||tumor-32/NN	conj_and||chelates-14/NNS||tumor-32/NN	amod||e4g10-35/NNS||neovascular-targeting-33/JJ	nn||e4g10-35/NNS||antibody-34/NN	dep||tumor-32/NN||e4g10-35/NNS	antibody-34||tumor-32||no_rel||single wall carbon nanotube (swcnt) constructs were covalently appended with radiometal-ion chelates (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid [dota] or desferrioxamineb [dfo]) and the tumor neovascular-targeting antibody e4g10.
mark||suggested-6/VBN||although-1/IN	det||studies-4/NNS||some-2/DT	amod||studies-4/NNS||previous-3/JJ	nsubj||suggested-6/VBN||studies-4/NNS	aux||suggested-6/VBN||have-5/VBP	advcl||examined-24/VBN||suggested-6/VBN	mark||comprised-14/VBN||that-7/IN	amod||growth-9/NN||posttraumatic-8/JJ	nsubjpass||comprised-14/VBN||growth-9/NN	appos||growth-9/NN||ptg-11/NN	auxpass||comprised-14/VBN||is-13/VBZ	ccomp||suggested-6/VBN||comprised-14/VBN	amod||factors-17/NNS||several-16/JJ	prep_of||comprised-14/VBN||factors-17/NNS	amod||properties-20/NNS||different-19/JJ	prep_with||comprised-14/VBN||properties-20/NNS	nsubj||examined-24/VBN||few-22/JJ	aux||examined-24/VBN||have-23/VBP	root||ROOT-0/null||examined-24/VBN	predet||association-27/NN||both-25/PDT	det||association-27/NN||the-26/DT	dobj||examined-24/VBN||association-27/NN	prep_between||examined-24/VBN||ptg-29/NN	prep_between||examined-24/VBN||posttraumaticstressdisorder-31/NN	conj_and||ptg-29/NN||posttraumaticstressdisorder-31/NN	dep||examined-24/VBN||ptsd-33/VBN	prep_between||examined-24/VBN||ptg-37/NN	conj_and||ptg-29/NN||ptg-37/NN	conj_and||ptg-29/NN||resilience-39/NN	conj_and||ptg-37/NN||resilience-39/NN	vmod||ptg-37/NN||focusing-41/VBG	prep_on||focusing-41/VBG||each-43/DT	det||factors-46/NNS||the-45/DT	prep_of||each-43/DT||factors-46/NNS	prep_of||factors-46/NNS||ptg-48/NN	ptsd-33||ptg-48||no_rel||although some previous studies have suggested that posttraumatic growth (ptg) is comprised of several factors with different properties, few have examined both the association between ptg and posttraumaticstressdisorder (ptsd) and between ptg and resilience, focusing on each of the factors of ptg.
det||study-4/NN||a-1/DT	amod||study-4/NN||cross-2/JJ	amod||study-4/NN||sectional-3/JJ	nsubjpass||conducted-6/VBN||study-4/NN	auxpass||conducted-6/VBN||was-5/VBD	root||ROOT-0/null||conducted-6/VBN	amod||hospital-11/NN||tikur-8/JJ	nn||hospital-11/NN||anbessa-9/NN	amod||hospital-11/NN||specialized-10/JJ	prep_in||conducted-6/VBN||hospital-11/NN	appos||hospital-11/NN||tash-13/NN	amod||center-18/NN||teklehaymanot-16/JJ	nn||center-18/NN||health-17/NN	prep_in||conducted-6/VBN||center-18/NN	conj_and||hospital-11/NN||center-18/NN	appos||hospital-11/NN||thc-20/NN	prep_from||conducted-6/VBN||november-23/NNP	num||november-23/NNP||2010-24/CD	prep_to||conducted-6/VBN||april-26/NNP	num||april-26/NNP||2011-27/CD	cross-2||thc-20||no_rel||a cross sectional study was conducted in tikur anbessa specialized hospital (tash) and teklehaymanot health center (thc) from november 2010 to april 2011.
det||paper-4/NN||the-2/DT	amod||paper-4/NN||present-3/JJ	prep_in||review-7/VBP||paper-4/NN	nsubj||review-7/VBP||we-6/PRP	nsubj||review-7/VBP||we-6/PRP	root||ROOT-0/null||review-7/VBP	conj_or||review-7/VBP||review-7/VBP	amod||developments-9/NNS||recent-8/JJ	dobj||review-7/VBP||developments-9/NNS	det||use-12/NN||the-11/DT	prep_in||review-7/VBP||use-12/NN	prep_of||use-12/NN||enzymes-14/NNS	prep_as||enzymes-14/NNS||additives-16/NNS	amod||aids-20/NNS||processing-19/VBG	prep_as||review-7/VBP||aids-20/NNS	det||industry-25/NN||the-22/DT	nn||industry-25/NN||food-23/NN	nn||industry-25/NN||biotechnology-24/NN	prep_in||aids-20/NNS||industry-25/NN	amod||gluten-28/NN||detoxify-27/JJ	prep_to||industry-25/NN||gluten-28/NN	enzymes-14||aids-20||no_rel||in the present paper, we review recent developments in the use of enzymes as additives or as processing aids in the food biotechnology industry to detoxify gluten.
amod||analyses-5/NNS||case-control-2/JJ	conj_and||case-control-2/JJ||case-series-4/JJ	amod||analyses-5/NNS||case-series-4/JJ	prep_in||examined-8/VBD||analyses-5/NNS	nsubj||examined-8/VBD||we-7/PRP	root||ROOT-0/null||examined-8/VBD	nn||concentrations-10/NNS||serum-9/NN	dobj||examined-8/VBD||concentrations-10/NNS	amod||25ohd-14/NNS||25-hydroxyvitamind-12/JJ	prep_of||concentrations-10/NNS||25ohd-14/NNS	prep_in||25ohd-14/NNS||relation-17/NN	nn||characteristics-22/NNS||breast-19/NN	nn||characteristics-22/NNS||cancer-20/NN	amod||characteristics-22/NNS||prognostic-21/JJ	prep_to||examined-8/VBD||characteristics-22/NNS	amod||grade-26/NN||histologic-25/JJ	prep_including||examined-8/VBD||grade-26/NN	nn||receptor-29/NN||estrogen-28/NN	appos||grade-26/NN||receptor-29/NN	appos||receptor-29/NN||er-31/NN	amod||subtypes-36/NNS||molecular-35/JJ	nsubj||enrolled-67/VBD||subtypes-36/NNS	vmod||subtypes-36/NNS||defined-37/VBN	agent||defined-37/VBN||er-39/NN	amod||pr-44/NN||progesterone-41/JJ	nn||pr-44/NN||receptor-42/NN	agent||defined-37/VBN||pr-44/NN	conj_and||er-39/NN||pr-44/NN	agent||defined-37/VBN||her2-47/NNS	conj_and||er-39/NN||her2-47/NNS	num||women-51/NNS||579-50/CD	prep_among||defined-37/VBN||women-51/NNS	nn||cancer-55/NN||incident-53/NN	nn||cancer-55/NN||breast-54/NN	prep_with||women-51/NNS||cancer-55/NN	num||controls-58/NNS||574-57/CD	prep_among||defined-37/VBN||controls-58/NNS	conj_and||women-51/NNS||controls-58/NNS	vmod||controls-58/NNS||matched-59/VBN	prep_on||matched-59/VBN||age-61/NN	prep_on||matched-59/VBN||time-63/NN	conj_and||age-61/NN||time-63/NN	nn||draw-66/NN||blood-65/NN	prep_of||age-61/NN||draw-66/NN	conj_and||examined-8/VBD||enrolled-67/VBD	det||institute-73/NN||the-69/DT	amod||institute-73/NN||roswell-70/JJ	nn||institute-73/NN||park-71/NN	nn||institute-73/NN||cancer-72/NN	prep_in||enrolled-67/VBD||institute-73/NN	num||2008-77/CD||2003-75/CD	dep||2008-77/CD||to-76/TO	prep_from||enrolled-67/VBD||2008-77/CD	estrogen-28||cancer-72||no_rel||in case-control and case-series analyses, we examined serum concentrations of 25-hydroxyvitamind (25ohd) in relation to breast cancer prognostic characteristics, including histologic grade, estrogen receptor (er), and molecular subtypes defined by er, progesterone receptor (pr) and her2, among 579 women with incident breast cancer and 574 controls matched on age and time of blood draw enrolled in the roswell park cancer institute from 2003 to 2008.
amod||individuals-5/NNS||fifty-three-1/JJ	num||individuals-5/NNS||-lrb--2/CD	num||individuals-5/NNS||53-3/CD	amod||individuals-5/NNS||-rrb--4/JJ	nsubjpass||tested-33/VBN||individuals-5/NNS	amod||hivinfection-8/NN||early-7/JJ	prep_with||individuals-5/NNS||hivinfection-8/NN	num||non-reactive-16/NN||-lrb--10/CD	amod||non-reactive-16/NN||i.e.-11/JJ	amod||non-reactive-16/NN||3rd-12/JJ	nn||non-reactive-16/NN||generation-13/NN	amod||non-reactive-16/NN||anti-hiv-14/JJ	nn||non-reactive-16/NN||eia-15/NN	prep_with||individuals-5/NNS||non-reactive-16/NN	conj_or||hivinfection-8/NN||non-reactive-16/NN	prep_with||individuals-5/NNS||reactive-18/NN	conj_or||hivinfection-8/NN||reactive-18/NN	amod||non-reactive-23/NN||hiv-1-20/JJ	amod||non-reactive-23/NN||western-21/JJ	nn||non-reactive-23/NN||blot-22/NN	conj_or||hivinfection-8/NN||non-reactive-23/NN	conj_or||reactive-18/NN||non-reactive-23/NN	amod||-rrb--31/NNS||indeterminate-25/JJ	conj_and||indeterminate-25/JJ||hiv-1-27/JJ	amod||-rrb--31/NNS||hiv-1-27/JJ	amod||-rrb--31/NNS||p24-28/JJ	nn||-rrb--31/NNS||antigen-29/NN	nn||-rrb--31/NNS||reactive-30/NN	conj_or||hivinfection-8/NN||-rrb--31/NNS	conj_or||reactive-18/NN||-rrb--31/NNS	auxpass||tested-33/VBN||were-32/VBD	root||ROOT-0/null||tested-33/VBN	agent||tested-33/VBN||institm-35/NN	hivinfection-8||hiv--1||no||fifty-three -lrb- 53 -rrb- individuals with early hivinfection , -lrb- i.e. 3rd generation anti-hiv eia non-reactive or reactive , hiv-1 western blot non-reactive or indeterminate and hiv-1 p24 antigen reactive -rrb- were tested by institm .
amod||studies-4/NNS||previous-1/JJ	amod||studies-4/NNS||genome-wide-2/JJ	nn||studies-4/NNS||association-3/NN	nsubj||confirmed-10/VBN||studies-4/NNS	amod||genes-8/NNS||type2diabetes-6/JJ	nn||genes-8/NNS||susceptibility-7/NN	prep_for||studies-4/NNS||genes-8/NNS	aux||confirmed-10/VBN||have-9/VBP	root||ROOT-0/null||confirmed-10/VBN	mark||associated-31/VBN||that-11/IN	det||variant-14/NN||a-12/DT	amod||variant-14/NN||common-13/JJ	nsubjpass||associated-31/VBN||variant-14/NN	appos||variant-14/NN||rs9939609-16/NNS	det||mass-21/NN||the-19/DT	amod||mass-21/NN||fat-20/JJ	prep_in||variant-14/NN||mass-21/NN	advmod||region-29/NN||obesity-23/RB	amod||region-29/NN||associated-24/JJ	appos||region-29/NN||fto-26/NN	nn||region-29/NN||gene-28/NN	prep_in||variant-14/NN||region-29/NN	conj_and||mass-21/NN||region-29/NN	auxpass||associated-31/VBN||is-30/VBZ	ccomp||confirmed-10/VBN||associated-31/VBN	nn||index-35/NN||body-33/NN	nn||index-35/NN||mass-34/NN	prep_with||associated-31/VBN||index-35/NN	appos||index-35/NN||bmi-37/NN	nn||children-41/NNS||european-40/NN	prep_in||index-35/NN||children-41/NNS	prep_in||index-35/NN||adults-43/NNS	conj_and||children-41/NNS||adults-43/NNS	obesity-23||fat-20||no_rel||previous genome-wide association studies for type2diabetes susceptibility genes have confirmed that a common variant, rs9939609, in the fat mass and obesity associated ( fto ) gene region is associated with body mass index (bmi) in european children and adults.
nsubjpass||developed-25/VBN||cmx001-1/NNS	det||analog-6/NN||a-3/DT	amod||analog-6/NN||lipophilic-4/JJ	nn||analog-6/NN||nucleotide-5/NN	appos||cmx001-1/NNS||analog-6/NN	vmod||analog-6/NN||formed-7/VBN	advmod||linking-10/VBG||covalently-9/RB	agent||formed-7/VBN||linking-10/VBG	dobj||linking-10/VBG||3-11/CD	appos||propan-1-ol-16/NNS||hexdecyloxy-14/NN	dep||analog-6/NN||propan-1-ol-16/NNS	dep||propan-1-ol-16/NNS||to-17/TO	dep||propan-1-ol-16/NNS||cidofovir-18/NN	appos||cidofovir-18/NN||cdv-20/NN	aux||developed-25/VBN||is-23/VBZ	auxpass||developed-25/VBN||being-24/VBG	root||ROOT-0/null||developed-25/VBN	det||treatment-28/NN||a-27/DT	prep_as||developed-25/VBN||treatment-28/NN	prep_for||treatment-28/NN||smallpox-30/NN	smallpox-30||cidofovir-18||no_rel||cmx001, a lipophilic nucleotide analog formed by covalently linking 3-(hexdecyloxy)propan-1-ol to cidofovir (cdv), is being developed as a treatment for smallpox.
nsubj||inform-4/VB||it-1/PRP	nsubj||describe-14/VB||it-1/PRP	aux||inform-4/VB||will-2/MD	advmod||inform-4/VB||further-3/RBR	root||ROOT-0/null||inform-4/VB	det||debate-6/NN||the-5/DT	dobj||inform-4/VB||debate-6/NN	det||effectiveness-9/NN||the-8/DT	prep_about||inform-4/VB||effectiveness-9/NN	nn||screening-12/NN||ipv-11/NN	prep_of||effectiveness-9/NN||screening-12/NN	conj_and||inform-4/VB||describe-14/VB	nn||prevalence-16/NN||ipv-15/NN	dobj||describe-14/VB||prevalence-16/NN	det||community-19/NN||a-18/DT	prep_in||describe-14/VB||community-19/NN	vmod||community-19/NN||based-20/VBN	amod||population-25/NN||post-partum-21/JJ	conj_and||post-partum-21/JJ||early-23/JJ	amod||population-25/NN||early-23/JJ	nn||population-25/NN||infant-24/NN	dobj||based-20/VBN||population-25/NN	ipv-15||inform-4||no_rel||it will further inform the debate about the effectiveness of ipv screening and describe ipv prevalence in a community based post-partum and early infant population.
prep_in||-9/VBD||comparison-2/NN	amod||virus-5/NN||wild-type-4/JJ	prep_to||comparison-2/NN||virus-5/NN	amod||ï-8/NN||apoptosis-defective-7/JJ	nsubj||-9/VBD||ï-8/NN	root||ROOT-0/null||-9/VBD	amod||viruses-11/NNS||mutant-10/JJ	nsubj||display-12/VBP||viruses-11/NNS	ccomp||-9/VBD||display-12/VBP	amod||neurovirulence-14/NN||diminished-13/JJ	dobj||display-12/VBP||neurovirulence-14/NN	amod||inoculation-17/NN||intracranial-16/JJ	prep_following||neurovirulence-14/NN||inoculation-17/NN	amod||mice-20/NNS||newborn-19/JJ	prep_of||inoculation-17/NN||mice-20/NNS	virus-5||viruses-11||no||in comparison to wild-type virus, apoptosis-defective ï mutant viruses display diminished neurovirulence following intracranial inoculation of newborn mice.
amod||as2o3-3/NNS||arsenictrioxide-1/JJ	nsubj||triggers-11/VBZ||as2o3-3/NNS	vmod||as2o3-3/NNS||used-6/VBN	aux||treat-8/VB||to-7/TO	xcomp||used-6/VBN||treat-8/VB	dobj||treat-8/VB||promyelocyticleukemia-9/NN	root||ROOT-0/null||triggers-11/VBZ	nn||death-13/NN||cell-12/NN	dobj||triggers-11/VBZ||death-13/NN	amod||mechanisms-16/NNS||unknown-15/JJ	prep_via||death-13/NN||mechanisms-16/NNS	promyelocyticleukemia-9||arsenictrioxide-1||yes||arsenictrioxide (as2o3), used to treat promyelocyticleukemia, triggers cell death via unknown mechanisms.
poss||results-2/NNS||our-1/PRP$	nsubj||showed-3/VBD||results-2/NNS	root||ROOT-0/null||showed-3/VBD	mark||sensitive-22/JJ||that-4/IN	det||patients-8/NNS||the-5/DT	amod||patients-8/NNS||younger-6/JJR	nn||patients-8/NNS||age-7/NN	nsubj||sensitive-22/JJ||patients-8/NNS	det||patients-11/NNS||the-10/DT	appos||patients-8/NNS||patients-11/NNS	det||site-16/NN||a-13/DT	amod||site-16/NN||peripheral-14/JJ	nn||site-16/NN||iv-15/NN	prep_with||patients-11/NNS||site-16/NN	amod||patients-19/NNS||female-18/JJ	prep_with||patients-11/NNS||patients-19/NNS	conj_and||site-16/NN||patients-19/NNS	cop||sensitive-22/JJ||are-20/VBP	advmod||sensitive-22/JJ||more-21/RBR	ccomp||showed-3/VBD||sensitive-22/JJ	prep_to||sensitive-22/JJ||pain-24/NN	det||injection-27/NN||the-26/DT	prep_on||pain-24/NN||injection-27/NN	prep_of||injection-27/NN||propofol-29/NN	pain-24||propofol-29||yes||our results showed that the younger age patients, the patients with a peripheral iv site and female patients are more sensitive to pain on the injection of propofol.
prep_conclusionsâ||demonstrate-6/VBP||$-2/$	det||studies-5/NNS||these-4/DT	nsubj||demonstrate-6/VBP||studies-5/NNS	root||ROOT-0/null||demonstrate-6/VBP	det||variety-9/NN||a-8/DT	prep_in||demonstrate-6/VBP||variety-9/NN	amod||models-12/NNS||rodent-11/JJ	prep_of||variety-9/NN||models-12/NNS	mark||/-19/VBZ||that-13/IN	amod||delivery-15/NN||systemic-14/JJ	nsubj||/-19/VBZ||delivery-15/NN	num||.2-18/CD||kir6-17/CD	prep_of||delivery-15/NN||.2-18/CD	ccomp||demonstrate-6/VBP||/-19/VBZ	amod||$-21/NNS||sur-1â-20/JJ	dobj||/-19/VBZ||$-21/NNS	amod||kcos-24/NNS||selective-23/JJ	nsubj||enhance-25/VB||kcos-24/NNS	dep||/-19/VBZ||enhance-25/VB	det||response-29/NN||the-26/DT	nn||response-29/NN||glucose-27/NN	nn||response-29/NN||counterregulatory-28/NN	dobj||enhance-25/VB||response-29/NN	amod||hypoglycemia-32/NN||insulin-induced-31/JJ	prep_to||enhance-25/VB||hypoglycemia-32/NN	hypoglycemia-32||glucose-27||yes||conclusionsâ these studies demonstrate in a variety of rodent models that systemic delivery of kir6.2/sur-1âselective kcos enhance the glucose counterregulatory response to insulin-induced hypoglycemia.
nsubj||hypothesized-2/VBN||we-1/PRP	root||ROOT-0/null||hypothesized-2/VBN	mark||have-18/VB||that-3/IN	amod||infection-16/NN||macrophages-4/JJ	prep_from||macrophages-4/JJ||individuals-6/NNS	amod||manifestations-10/NNS||different-8/JJ	amod||manifestations-10/NNS||clinical-9/JJ	prep_with||individuals-6/NNS||manifestations-10/NNS	prep_of||manifestations-10/NNS||mycobacteriumtuberculosis-12/NNS	appos||mycobacteriumtuberculosis-12/NNS||mtb-14/NN	nsubj||have-18/VB||infection-16/NN	aux||have-18/VB||would-17/MD	ccomp||hypothesized-2/VBN||have-18/VB	amod||profiles-22/NNS||distinct-19/JJ	nn||profiles-22/NNS||gene-20/NN	nn||profiles-22/NNS||expression-21/NN	dobj||have-18/VB||profiles-22/NNS	mark||associated-32/VBN||that-24/IN	nsubjpass||associated-32/VBN||polymorphisms-25/NNS	det||genes-28/NNS||these-27/DT	prep_in||polymorphisms-25/NNS||genes-28/NNS	aux||associated-32/VBN||may-29/MD	advmod||associated-32/VBN||also-30/RB	auxpass||associated-32/VBN||be-31/VB	ccomp||hypothesized-2/VBN||associated-32/VBN	conj_and||have-18/VB||associated-32/VBN	prep_with||associated-32/VBN||susceptibility-34/NN	prep_to||associated-32/VBN||tb-36/NN	tb-36||mycobacteriumtuberculosis-12||no||we hypothesized that macrophages from individuals with different clinical manifestations of mycobacteriumtuberculosis ( mtb ) infection would have distinct gene expression profiles and that polymorphisms in these genes may also be associated with susceptibility to tb.
det||models-4/NNS||both-2/DT	nn||models-4/NNS||mouse-3/NN	nsubj||exhibiting-5/VBG||models-4/NNS	prepc_despite||are-24/VBP||exhibiting-5/VBG	amod||influx-9/NN||increased-6/VBN	amod||influx-9/NN||in-vivo-7/JJ	nn||influx-9/NN||calcium-8/NN	dobj||exhibiting-5/VBG||influx-9/NN	det||stage-13/NN||an-11/DT	amod||stage-13/NN||early-12/JJ	prep_at||exhibiting-5/VBG||stage-13/NN	det||development-16/NN||the-15/DT	prep_in||stage-13/NN||development-16/NN	det||cardiomyopathy-19/NN||the-18/DT	prep_of||development-16/NN||cardiomyopathy-19/NN	prep_before||exhibiting-5/VBG||leftventricularhypertrophy-21/NN	expl||are-24/VBP||there-23/EX	root||ROOT-0/null||are-24/VBP	amod||differences-27/NNS||distinct-25/JJ	amod||differences-27/NNS||phenotypical-26/JJ	nsubj||are-24/VBP||differences-27/NNS	det||models-31/NNS||the-29/DT	num||models-31/NNS||2-30/CD	prep_between||differences-27/NNS||models-31/NNS	prep_in||models-31/NNS||terms-33/NNS	nn||rates-36/NNS||heart-35/NN	prep_of||terms-33/NNS||rates-36/NNS	prep_of||terms-33/NNS||hemodynamics-38/NNS	conj_and||rates-36/NNS||hemodynamics-38/NNS	prep_of||terms-33/NNS||responses-40/NNS	conj_and||rates-36/NNS||responses-40/NNS	nn||inhibitors-44/NNS||calcium-42/NN	nn||inhibitors-44/NNS||channel-43/NN	prep_to||rates-36/NNS||inhibitors-44/NNS	calcium-42||cardiomyopathy-19||no_rel||despite both mouse models exhibiting increased in-vivo calcium influx at an early stage in the development of the cardiomyopathy before leftventricularhypertrophy, there are distinct phenotypical differences between the 2 models in terms of heart rates, hemodynamics and responses to calcium channel inhibitors.
num||strains-2/NNS||208-1/CD	nsubjpass||studied-16/VBN||strains-2/NNS	prep_of||strains-2/NNS||staphylococcusaureus-4/NNS	dobj||isolated-8/VBN||staphylococcusaureus-4/NNS	nsubjpass||isolated-8/VBN||we-6/PRP	auxpass||isolated-8/VBN||were-7/VBD	rcmod||staphylococcusaureus-4/NNS||isolated-8/VBN	prep_from||isolated-8/VBN||gorgan-10/NN	advmod||isolated-8/VBN||north-12/RB	prep_of||north-12/RB||iran-14/NN	auxpass||studied-16/VBN||were-15/VBD	ccomp||mrsa-34/NN||studied-16/VBN	amod||cases-19/NNS||121-18/JJ	nsubj||mrsa-34/NN||cases-19/NNS	prep_from||cases-19/NNS||patients-21/NNS	num||cases-24/NNS||87-23/CD	prep_from||cases-19/NNS||cases-24/NNS	conj_and||patients-21/NNS||cases-24/NNS	amod||carriers-27/NNS||healthy-26/JJ	prep_from||cases-24/NNS||carriers-27/NNS	npadvmod||out-30/IN||59-29/CD	advmod||carriers-27/NNS||out-30/IN	prep_of||cases-24/NNS||them-32/PRP	cop||mrsa-34/NN||were-33/VBD	root||ROOT-0/null||mrsa-34/NN	num||mssa-37/NN||149-36/CD	conj_and||mrsa-34/NN||mssa-37/NN	mrsa-34||staphylococcusaureus-4||no||208 strains of staphylococcusaureus which we were isolated from gorgan, north of iran were studied, 121 cases from patients and 87 cases from healthy carriers, 59 out of them were mrsa and 149 mssa .
advmod||diminishing-8/VBG||however-1/RB	nn||options-4/NNS||treatment-3/NN	nsubj||diminishing-8/VBG||options-4/NNS	prep_for||options-4/NNS||gonorrhea-6/NN	aux||diminishing-8/VBG||are-7/VBP	root||ROOT-0/null||diminishing-8/VBG	mark||developed-12/VBN||as-9/IN	nsubj||developed-12/VBN||neisseriagonorrhoeae-10/NN	aux||developed-12/VBN||have-11/VBP	advcl||diminishing-8/VBG||developed-12/VBN	dobj||developed-12/VBN||resistance-13/NN	amod||drugs-17/NNS||several-15/JJ	amod||drugs-17/NNS||antimicrobial-16/JJ	prep_to||developed-12/VBN||drugs-17/NNS	prep_such_as||drugs-17/NNS||sulfonamides-20/NNS	prep_such_as||drugs-17/NNS||penicillin-22/NNS	conj_and||sulfonamides-20/NNS||penicillin-22/NNS	prep_such_as||drugs-17/NNS||tetracyclines-24/NNS	conj_and||sulfonamides-20/NNS||tetracyclines-24/NNS	prep_such_as||drugs-17/NNS||quinolones-26/NNS	conj_and||sulfonamides-20/NNS||quinolones-26/NNS	gonorrhea-6||neisseriagonorrhoeae-10||no||however, treatment options for gonorrhea are diminishing as neisseriagonorrhoeae have developed resistance to several antimicrobial drugs such as sulfonamides, penicillin, tetracyclines and quinolones.
nsubj||reduced-9/VBD||prevention-1/NN	amod||reabsorption-5/NN||renal-3/JJ	nn||reabsorption-5/NN||glucose-4/NN	prep_of||prevention-1/NN||reabsorption-5/NN	amod||deletion-8/NN||sglt2-7/JJ	prep_by||reabsorption-5/NN||deletion-8/NN	root||ROOT-0/null||reduced-9/VBD	dobj||reduced-9/VBD||hfd-10/NN	amod||hyperglycemia-14/NN||obesity-associated-13/JJ	dobj||reduced-9/VBD||hyperglycemia-14/NN	conj_and||hfd-10/NN||hyperglycemia-14/NN	amod||glucoseintolerance-17/NN||improved-16/VBN	conj_and||hfd-10/NN||glucoseintolerance-17/NN	conj_and||hyperglycemia-14/NN||glucoseintolerance-17/NN	amod||secretion-23/NN||increased-20/VBN	amod||secretion-23/NN||glucose-stimulated-21/JJ	nn||secretion-23/NN||insulin-22/NN	conj_and||hfd-10/NN||secretion-23/NN	conj_and||hyperglycemia-14/NN||secretion-23/NN	prep_in||secretion-23/NN||vivo-25/NN	hyperglycemia-14||glucose-4||no||prevention of renal glucose reabsorption by sglt2 deletion reduced hfd- and obesity-associated hyperglycemia, improved glucoseintolerance, and increased glucose-stimulated insulin secretion in vivo.
num||injection-4/NN||10-2/CD	nn||injection-4/NN||units-3/NNS	prep_after||lower-44/JJR||injection-4/NN	nsubj||lower-44/JJR||time-6/NN	nn||peak-10/NN||lispro-8/NN	nn||peak-10/NN||plasma-9/NN	prep_to||time-6/NN||peak-10/NN	amod||-rrb--14/NNS||-lrb--11/JJ	nn||-rrb--14/NNS||t-12/NN	nn||-rrb--14/NNS||max-13/NN	nsubj||similar-16/JJ||-rrb--14/NNS	cop||similar-16/JJ||was-15/VBD	rcmod||peak-10/NN||similar-16/JJ	number||48.3-18/CD||-lrb--17/CD	dep||similar-16/JJ||48.3-18/CD	prep||similar-16/JJ||vs.-19/FW	number||min-21/CD||55.7-20/CD	pobj||vs.-19/FW||min-21/CD	nn||subjects-24/NNS||control-23/NN	dep||min-21/CD||subjects-24/NNS	nn||-rrb--30/NN||type-26/NN	num||-rrb--30/NN||2-27/CD	nn||-rrb--30/NN||diabetic-28/NN	nn||-rrb--30/NN||subjects-29/NNS	prep_versus||subjects-24/NNS||-rrb--30/NN	mark||-lrb--35/VBD||although-32/IN	amod||concentration-34/NN||maximal-33/JJ	nsubj||-lrb--35/VBD||concentration-34/NN	advcl||similar-16/JJ||-lrb--35/VBD	dep||max-37/NN||c-36/SYM	dep||dose-40/NN||max-37/NN	num||max-37/NN||-rrb--38/CD	punct||dose-40/NN||/-39/:	dep||-lrb--35/VBD||dose-40/NN	cop||lower-44/JJR||was-41/VBD	num||%-43/NN||41-42/CD	npadvmod||lower-44/JJR||%-43/NN	root||ROOT-0/null||lower-44/JJR	prep_in||lower-44/JJR||subjects-46/NNS	prep_with||lower-44/JJR||type2diabetes-48/CD	amod||-rrb--79/NNS||lower-51/JJR	conj_and||lower-51/JJR||delayed-53/VBN	amod||-rrb--79/NNS||delayed-53/VBN	amod||rate-57/NN||maximal-54/JJ	nn||rate-57/NN||glucose-55/NN	nn||rate-57/NN||infusion-56/NN	nsubj||-lrb--58/VB||rate-57/NN	ccomp||delayed-53/VBN||-lrb--58/VB	dobj||-lrb--58/VB||girmax-59/NN	num||girmax-59/NN||9.0-60/CD	num||mg/kg/min-63/NN||0.6-62/CD	prep_vs.||girmax-59/NN||mg/kg/min-63/NN	dep||-lrb--58/VB||p-65/VB	dobj||p-65/VB||<-66/NNP	num||<-66/NNP||0.0001-67/CD	num||<-66/NNP||69-69/CD	num||min-72/NN||130-71/CD	prep_vs.||<-66/NNP||min-72/NN	dep||-lrb--58/VB||p-74/VB	number||0.0001-76/CD||<-75/CD	dobj||p-74/VB||0.0001-76/CD	advmod||0.0001-76/CD||respectively-78/RB	prep_with||lower-44/JJR||-rrb--79/NNS	type2diabetes-48||lispro-8||yes||after 10 units injection , time to lispro plasma peak -lrb- t max -rrb- was similar -lrb- 48.3 vs. 55.7 min ; control subjects versus type 2 diabetic subjects -rrb- , although maximal concentration -lrb- c max -rrb- / dose was 41 % lower in subjects with type2diabetes , with lower and delayed maximal glucose infusion rate -lrb- girmax 9.0 vs. 0.6 mg/kg/min , p < 0.0001 , 69 vs. 130 min , p < 0.0001 , respectively -rrb- .
amod||co-trimoxazole-2/NN||oral-1/JJ	nsubj||reduce-5/VB||co-trimoxazole-2/NN	aux||reduce-5/VB||did-3/VBD	neg||reduce-5/VB||not-4/RB	root||ROOT-0/null||reduce-5/VB	dobj||reduce-5/VB||relapses-6/NNS	advmod||reduce-5/VB||significantly-7/RB	nn||sgranulomatosis-11/NNS||wegener-9/NN	prep_in||reduce-5/VB||sgranulomatosis-11/NNS	wegener'sgranulomatosis--1||co-trimoxazole-2||no_rel||oral co-trimoxazole did not reduce relapses significantly in wegener'sgranulomatosis.
prep_in||analyzed-29/VBN||total-2/NN	num||strains-6/NNS||32-4/CD	amod||strains-6/NNS||aeromonas-5/JJ	nsubjpass||analyzed-29/VBN||strains-6/NNS	vmod||strains-6/NNS||isolated-7/VBN	amod||specimens-10/NNS||stool-9/JJ	prep_from||isolated-7/VBN||specimens-10/NNS	vmod||specimens-10/NNS||collected-11/VBN	amod||patients-14/NNS||hiv/aids-13/JJ	prep_from||collected-11/VBN||patients-14/NNS	vmod||patients-14/NNS||suffering-15/VBG	prep_from||suffering-15/VBG||gastroenteritis-17/NNS	poss||drinking-water-21/NN||their-19/PRP$	nn||drinking-water-21/NN||household-20/NN	prep_from||suffering-15/VBG||drinking-water-21/NN	conj_and||gastroenteritis-17/NNS||drinking-water-21/NN	vmod||drinking-water-21/NN||stored-22/VBN	amod||containers-27/NNS||20-l-24/JJ	conj_and||20-l-24/JJ||25-l-26/JJ	amod||containers-27/NNS||25-l-26/JJ	prep_in||stored-22/VBN||containers-27/NNS	auxpass||analyzed-29/VBN||were-28/VBD	root||ROOT-0/null||analyzed-29/VBN	amod||pcr-35/NN||random-31/JJ	amod||pcr-35/NN||amplified-32/VBN	amod||pcr-35/NN||polymorphic-33/JJ	nn||pcr-35/NN||dna-34/NN	agent||analyzed-29/VBN||pcr-35/NN	dep||pcr-35/NN||rapd-37/VBN	aids--1||hiv--1||no||in total, 32 aeromonas strains isolated from stool specimens collected from hiv/aids patients suffering from gastroenteritis and their household drinking-water stored in 20-l and 25-l containers were analyzed by random amplified polymorphic dna pcr (rapd).
advmod||find-4/VBP||similarly-1/RB	nsubj||find-4/VBP||we-3/PRP	root||ROOT-0/null||find-4/VBP	neg||suppression-6/NN||no-5/DT	dobj||find-4/VBP||suppression-6/NN	prepc_of||suppression-6/NN||silencing-8/VBG	dobj||silencing-8/VBG||pathways-9/NNS	prep_in||pathways-9/NNS||cells-11/NNS	prepc_with||silencing-8/VBG||replicating-13/VBG	dobj||replicating-13/VBG||virus-14/NN	vmod||find-4/VBP||suggesting-16/VBG	mark||reduce-29/VB||that-17/IN	amod||products-19/NNS||viral-18/JJ	nsubj||reduce-29/VB||products-19/NNS	det||elements-25/NNS||the-22/DT	nn||elements-25/NNS||tar-23/NN	nn||elements-25/NNS||rna-24/NN	prep_such_as||products-19/NNS||elements-25/NNS	advmod||reduce-29/VB||also-26/RB	aux||reduce-29/VB||do-27/VBP	neg||reduce-29/VB||not-28/RB	ccomp||suggesting-16/VBG||reduce-29/VB	det||efficacy-31/NN||the-30/DT	dobj||reduce-29/VB||efficacy-31/NN	amod||rna-34/NN||cellular-33/JJ	prep_of||efficacy-31/NN||rna-34/NN	amod||rna-34/NN||silencing-35/VBG	tar-23||virus-14||no_rel||similarly, we find no suppression of silencing pathways in cells with replicating virus, suggesting that viral products such as the tar rna elements also do not reduce the efficacy of cellular rna silencing.
amod||glucose-2/NN||high-1/JJ	nsubj||reduced-5/VBD||glucose-2/NN	conj_and||glucose-2/NN||hyperglycemia-4/NN	nsubj||reduced-5/VBD||hyperglycemia-4/NN	dep||challenged-30/VBD||reduced-5/VBD	dobj||reduced-5/VBD||upregulation-6/NN	det||inhibitory-10/NN||the-8/DT	amod||inhibitory-10/NN||nf-îºb-9/JJ	prep_of||upregulation-6/NN||inhibitory-10/NN	amod||a20-14/NNS||atheroprotective-12/JJ	nn||a20-14/NNS||protein-13/NN	prep_of||upregulation-6/NN||a20-14/NNS	conj_and||inhibitory-10/NN||a20-14/NNS	amod||endothelial-18/NN||human-16/JJ	amod||endothelial-18/NN||coronary-17/JJ	prep_in||reduced-5/VBD||endothelial-18/NN	appos||endothelial-18/NN||ec-20/NN	amod||cultures-29/NNS||smooth-23/JJ	nn||cultures-29/NNS||muscle-24/NN	nn||cultures-29/NNS||cell-25/NN	appos||cultures-29/NNS||smc-27/NN	prep_in||reduced-5/VBD||cultures-29/NNS	conj_and||endothelial-18/NN||cultures-29/NNS	root||ROOT-0/null||challenged-30/VBD	nn||necrosis-33/NNS||tumor-32/NN	prep_with||challenged-30/VBD||necrosis-33/NNS	nn||alpha-35/NNS||factor-34/NN	nsubj||challenged-30/VBD||alpha-35/NNS	appos||alpha-35/NNS||tnf-37/NN	appos||alpha-35/NNS||aortae-40/NN	amod||mice-43/NNS||diabetic-42/JJ	prep_of||aortae-40/NN||mice-43/NNS	amod||injection-49/NN||lipopolysaccharide-45/JJ	appos||injection-49/NN||lps-47/NN	prep_following||mice-43/NNS||injection-49/NN	vmod||injection-49/NN||used-50/VBN	vmod||injection-49/NN||used-50/VBN	conj_and||used-50/VBN||used-50/VBN	det||insult-54/NN||an-52/DT	amod||insult-54/NN||inflammatory-53/JJ	prep_as||used-50/VBN||insult-54/NN	amod||vein-grafts-58/NNS||failed-57/VBN	prep_in||used-50/VBN||vein-grafts-58/NNS	amod||patients-61/NNS||diabetic-60/JJ	prep_of||vein-grafts-58/NNS||patients-61/NNS	hyperglycemia-4||glucose-2||no||high glucose and hyperglycemia reduced upregulation of the nf-îºb inhibitory and atheroprotective protein a20 in human coronary endothelial (ec) and smooth muscle cell (smc) cultures challenged with tumor necrosis factor alpha (tnf), aortae of diabetic mice following lipopolysaccharide (lps) injection used as an inflammatory insult and in failed vein-grafts of diabetic patients.
advmod||methods-6/NNS||all-1/RB	det||methods-6/NNS||the-2/DT	amod||reversible-4/JJ||available-3/JJ	amod||methods-6/NNS||reversible-4/JJ	nn||methods-6/NNS||contraceptive-5/NN	nsubjpass||used-10/VBN||methods-6/NNS	aux||used-10/VBN||can-7/MD	advmod||used-10/VBN||generally-8/RB	auxpass||used-10/VBN||be-9/VB	root||ROOT-0/null||used-10/VBN	agent||used-10/VBN||women-12/NNS	prep_at||women-12/NNS||risk-14/NN	prep_of||risk-14/NN||hivinfection-16/NN	amod||women-20/NNS||hiv-infected-19/JJ	agent||used-10/VBN||women-20/NNS	conj_and||women-12/NNS||women-20/NNS	hivinfection-16||hiv--1||no||all the available reversible contraceptive methods can generally be used by women at risk of hivinfection and by hiv-infected women.
det||group-5/NN||the-1/DT	amod||group-5/NN||empirical-2/JJ	nn||group-5/NN||pain-3/NN	nn||group-5/NN||relief-4/NN	nsubj||included-15/VBD||group-5/NN	det||group-9/NN||the-7/DT	nn||group-9/NN||control-8/NN	dep||group-5/NN||group-9/NN	appos||group-9/NN||n-11/NN	dep||120-13/CD||=-12/SYM	rcmod||n-11/NN||120-13/CD	root||ROOT-0/null||included-15/VBD	det||patients-17/NNS||the-16/DT	dobj||included-15/VBD||patients-17/NNS	nsubj||received-19/VBD||patients-17/NNS	nsubj||meperidine-23/VBP||patients-17/NNS	rcmod||patients-17/NNS||received-19/VBD	amod||sulpyrin-21/NN||intravenous-20/JJ	dobj||received-19/VBD||sulpyrin-21/NN	rcmod||patients-17/NNS||meperidine-23/VBP	conj_and/or||received-19/VBD||meperidine-23/VBP	advmod||meperidine-23/VBP||postoperatively-24/RB	pain-3||meperidine-23||yes||the empirical pain relief group (the control group, n = 120) included the patients that received intravenous sulpyrin and/or meperidine postoperatively.
nsubj||critical-6/JJ||restoration-1/NN	nn||secretion-4/NN||insulin-3/NN	prep_of||restoration-1/NN||secretion-4/NN	cop||critical-6/JJ||is-5/VBZ	root||ROOT-0/null||critical-6/JJ	det||treatment-9/NN||the-8/DT	prep_for||critical-6/JJ||treatment-9/NN	prep_of||treatment-9/NN||type2diabetes-11/CD	type2diabetes-11||insulin-3||yes||restoration of insulin secretion is critical for the treatment of type2diabetes.
nsubj||identified-12/VBD||analyses-1/NNS	amod||data-4/NNS||phosphoproteomic-3/JJ	prep_of||analyses-1/NNS||data-4/NNS	nn||samples-11/NNS||breast-6/NN	conj_and||breast-6/NN||lung-8/NN	nn||samples-11/NNS||lung-8/NN	nn||samples-11/NNS||cancer-9/NN	amod||samples-11/NNS||patient-10/JJ	prep_from||data-4/NNS||samples-11/NNS	root||ROOT-0/null||identified-12/VBD	det||subset-14/NN||a-13/DT	dobj||identified-12/VBD||subset-14/NN	det||sites-19/NNS||the-16/DT	amod||sites-19/NNS||src-dependent-17/JJ	nn||sites-19/NNS||phosphorylation-18/NN	prep_of||subset-14/NN||sites-19/NNS	auxpass||correlated-23/VBN||being-21/VBG	advmod||correlated-23/VBN||strongly-22/RB	prepc_as||identified-12/VBD||correlated-23/VBN	nn||activation-26/NN||src-25/NN	prep_with||correlated-23/VBN||activation-26/NN	nsubj||represent-29/VBP||activation-26/NN	rcmod||activation-26/NN||represent-29/VBP	nn||markers-31/NNS||candidate-30/NN	dobj||represent-29/VBP||markers-31/NNS	nn||downstream-35/NNS||src-33/NN	nn||downstream-35/NNS||activation-34/NN	prep_of||markers-31/NNS||downstream-35/NNS	nn||kinases-39/NNS||receptor-37/NN	nn||kinases-39/NNS||tyrosine-38/NN	prep_of||downstream-35/NNS||kinases-39/NNS	amod||tumors-42/NNS||human-41/JJ	prep_in||kinases-39/NNS||tumors-42/NNS	tyrosine-38||tumors-42||no_rel||analyses of phosphoproteomic data from breast and lung cancer patient samples identified a subset of the src-dependent phosphorylation sites as being strongly correlated with src activation, which represent candidate markers of src activation downstream of receptor tyrosine kinases in human tumors.
det||data-3/NNS||the-1/DT	amod||data-3/NNS||published-2/VBN	nsubj||support-4/VBP||data-3/NNS	root||ROOT-0/null||support-4/VBP	det||use-6/NN||the-5/DT	dobj||support-4/VBP||use-6/NN	prep_of||use-6/NN||levofloxacin-8/NN	amod||urinarytractinfections-11/NNS||complicated-10/JJ	prep_in||support-4/VBP||urinarytractinfections-11/NNS	amod||pyelonephritis-14/NNS||acute-13/JJ	prep_in||support-4/VBP||pyelonephritis-14/NNS	conj_and||urinarytractinfections-11/NNS||pyelonephritis-14/NNS	urinarytractinfections-11||levofloxacin-8||yes||the published data support the use of levofloxacin in complicated urinarytractinfections and acute pyelonephritis.
det||discovery-2/NN||the-1/DT	nsubj||highlights-6/VBZ||discovery-2/NN	nn||virus-5/NN||kampar-4/NN	prep_of||discovery-2/NN||virus-5/NN	root||ROOT-0/null||highlights-6/VBZ	det||trend-9/NN||the-7/DT	amod||trend-9/NN||increasing-8/VBG	dobj||highlights-6/VBZ||trend-9/NN	prep_of||trend-9/NN||emergence-11/NN	nn||viruses-15/NNS||bat-13/NN	nn||viruses-15/NNS||zoonotic-14/NN	prep_of||trend-9/NN||viruses-15/NNS	det||need-18/NN||the-17/DT	dobj||highlights-6/VBZ||need-18/NN	conj_and||trend-9/NN||need-18/NN	aux||expand-20/VB||to-19/TO	vmod||need-18/NN||expand-20/VB	poss||understanding-22/NN||our-21/PRP$	dobj||expand-20/VB||understanding-22/NN	prep_of||understanding-22/NN||bats-24/NNS	det||source-27/NN||a-26/DT	prep_as||expand-20/VB||source-27/NN	amod||viruses-31/NNS||many-29/JJ	amod||viruses-31/NNS||unknown-30/JJ	prep_of||source-27/NN||viruses-31/NNS	virus-5||viruses-31||no||the discovery of kampar virus highlights the increasing trend of emergence of bat zoonotic viruses and the need to expand our understanding of bats as a source of many unknown viruses.
mark||used-12/VBN||although-1/IN	det||vaccine-5/NN||an-2/DT	amod||vaccine-5/NN||attenuated-3/JJ	nn||vaccine-5/NN||vzv-4/NN	nsubjpass||used-12/VBN||vaccine-5/NN	appos||vaccine-5/NN||v-oka-7/NNP	aux||used-12/VBN||has-9/VBZ	auxpass||used-12/VBN||been-10/VBN	advmod||used-12/VBN||widely-11/RB	advcl||seen-24/VBN||used-12/VBN	prep_in||used-12/VBN||children-14/NNS	det||states-18/NNS||the-16/DT	amod||states-18/NNS||united-17/VBN	prep_in||children-14/NNS||states-18/NNS	nn||outbreaks-21/NNS||chickenpox-20/NN	nsubjpass||seen-24/VBN||outbreaks-21/NNS	auxpass||seen-24/VBN||are-22/VBP	advmod||seen-24/VBN||still-23/RB	root||ROOT-0/null||seen-24/VBN	det||vaccine-29/NN||the-27/DT	nn||vaccine-29/NN||shingles-28/NNS	nsubj||reduces-31/VBZ||vaccine-29/NN	advmod||reduces-31/VBZ||only-30/RB	conj_and||seen-24/VBN||reduces-31/VBZ	det||risk-33/NN||the-32/DT	dobj||reduces-31/VBZ||risk-33/NN	prep_of||risk-33/NN||shingles-35/NNS	num||%-38/NN||50-37/CD	prep_by||reduces-31/VBZ||%-38/NN	shingles-35||vzv-4||no||although an attenuated vzv vaccine (v-oka) has been widely used in children in the united states, chickenpox outbreaks are still seen, and the shingles vaccine only reduces the risk of shingles by 50%.
prep_in||decreased-18/VBN||comparison-2/NN	det||group-6/NN||the-4/DT	nn||group-6/NN||control-5/NN	prep_to||comparison-2/NN||group-6/NN	det||capacity-11/NN||the-8/DT	nn||capacity-11/NN||insulin-9/NN	nn||capacity-11/NN||secretory-10/NN	nsubjpass||decreased-18/VBN||capacity-11/NN	nsubj||more-21/JJR||capacity-11/NN	det||states-16/NNS||the-13/DT	num||states-16/NNS||two-14/CD	amod||states-16/NNS||hyperglycemic-15/JJ	prep_in||capacity-11/NN||states-16/NNS	auxpass||decreased-18/VBN||was-17/VBD	root||ROOT-0/null||decreased-18/VBN	conj_and||decreased-18/VBN||more-21/JJR	amod||hyperglycemia-24/NN||intermittent-23/JJ	prep_with||more-21/JJR||hyperglycemia-24/NN	prep||more-21/JJR||than-25/IN	pcomp||than-25/IN||with-26/IN	amod||hyperglycemia-28/NN||chronic-27/JJ	pobj||with-26/IN||hyperglycemia-28/NN	hyperglycemia-28||insulin-9||yes||in comparison to the control group, the insulin secretory capacity in the two hyperglycemic states was decreased, and more with intermittent hyperglycemia than with chronic hyperglycemia.
det||data-2/NNS||these-1/DT	nsubj||open-3/VBP||data-2/NNS	root||ROOT-0/null||open-3/VBP	amod||perspectives-5/NNS||new-4/JJ	dobj||open-3/VBP||perspectives-5/NNS	det||possibility-8/NN||the-7/DT	prep_on||open-3/VBP||possibility-8/NN	aux||use-10/VB||to-9/TO	vmod||possibility-8/NN||use-10/VB	xcomp||use-10/VB||sap-11/VB	det||component-16/NN||a-13/DT	amod||component-16/NN||potential-14/JJ	nn||component-16/NN||vaccine-15/NN	prep_as||sap-11/VB||component-16/NN	vmod||component-16/NN||inducing-17/VBG	amod||antibodies-20/NNS||functional-18/JJ	amod||antibodies-20/NNS||cross-reacting-19/JJ	dobj||inducing-17/VBG||antibodies-20/NNS	vmod||antibodies-20/NNS||interfering-21/VBG	prep_with||interfering-21/VBG||streptococcalinfections-23/NNS	cross--1||antibodies-20||no_rel||these data open new perspectives on the possibility to use sap as a potential vaccine component inducing functional cross-reacting antibodies interfering with streptococcalinfections.
nsubj||effective-61/JJ||analysis-1/NN	amod||terbinafine-58/NN||total-3/JJ	num||trials-5/NNS||eight-4/CD	nsubj||state-9/NN||trials-5/NNS	num||patients-8/NNS||1181-7/CD	prep_including||trials-5/NNS||patients-8/NNS	ccomp||total-3/JJ||state-9/NN	mark||likely-17/JJ||that-10/IN	nsubj||likely-17/JJ||treatment-11/NN	nsubj||produce-19/VB||treatment-11/NN	amod||terbinafine-14/NN||continuous-13/JJ	prep_with||treatment-11/NN||terbinafine-14/NN	cop||likely-17/JJ||is-15/VBZ	advmod||likely-17/JJ||more-16/RBR	ccomp||state-9/NN||likely-17/JJ	aux||produce-19/VB||to-18/TO	xcomp||likely-17/JJ||produce-19/VB	amod||cure-23/NN||mycological-20/JJ	conj_and||mycological-20/JJ||clinical-22/JJ	amod||cure-23/NN||clinical-22/JJ	dobj||produce-19/VB||cure-23/NN	prepc_compared_to||produce-19/VB||to-25/TO	amod||itraconazole-27/NN||intermittent-26/JJ	pobj||produce-19/VB||itraconazole-27/NN	nn||2.3-31/NNS||odds-29/NNS	nn||2.3-31/NNS||ratio-30/NN	prep_with||itraconazole-27/NN||2.3-31/NNS	number||%-34/NN||95-33/CD	amod||ci-35/NN||%-34/NN	dep||likely-17/JJ||ci-35/NN	amod||ci-35/NN||1.7-37/CD	num||p-40/NNS||3.0-39/CD	prep_to||ci-35/NN||p-40/NNS	number||0.0001-42/CD||<-41/CD	num||p-40/NNS||0.0001-42/CD	mark||tolerated-51/JJ||though-44/IN	preconj||itraconazole-46/NN||both-45/DT	nsubj||tolerated-51/JJ||itraconazole-46/NN	conj_and||itraconazole-46/NN||terbinafine-48/NN	nsubj||tolerated-51/JJ||terbinafine-48/NN	cop||tolerated-51/JJ||are-49/VBP	advmod||tolerated-51/JJ||well-50/RB	ccomp||likely-17/JJ||tolerated-51/JJ	advmod||effective-54/JJ||highly-53/RB	conj_and||total-3/JJ||effective-54/JJ	amod||terbinafine-58/NN||effective-54/JJ	nn||terbinafine-58/NN||drugs-55/NNS	amod||terbinafine-58/NN||continuous-57/JJ	prep_of||analysis-1/NN||terbinafine-58/NN	cop||effective-61/JJ||is-59/VBZ	advmod||effective-61/JJ||more-60/RBR	root||ROOT-0/null||effective-61/JJ	amod||itraconazole-64/NN||intermittent-63/JJ	prep_than||effective-61/JJ||itraconazole-64/NN	prepc_at||effective-61/JJ||achieving-66/VBG	amod||cure-68/NN||mycological-67/JJ	dobj||achieving-66/VBG||cure-68/NN	amod||onychomycosis-71/NNS||toenail-70/JJ	prep_of||cure-68/NN||onychomycosis-71/NNS	onychomycosis-71||terbinafine-58||yes||analysis of total eight trials including 1181 patients state that treatment with continuous terbinafine is more likely to produce mycological and clinical cure compared to intermittent itraconazole with odds ratio 2.3(95% ci, 1.7 to 3.0 p <0.0001) though both itraconazole and terbinafine are well tolerated and highly effective drugs, continuous terbinafine is more effective than intermittent itraconazole at achieving mycological cure of toenail onychomycosis
advmod||expressed-10/VBN||therefore-1/RB	det||number-4/NN||a-3/DT	nsubjpass||expressed-10/VBN||number-4/NN	nsubj||cp-17/VBP||number-4/NN	amod||proteins-8/NNS||specific-6/JJ	nn||proteins-8/NNS||transport-7/NN	prep_of||number-4/NN||proteins-8/NNS	auxpass||expressed-10/VBN||are-9/VBP	root||ROOT-0/null||expressed-10/VBN	nn||cells-15/NNS||brain-12/NN	nn||cells-15/NNS||capillary-13/NN	nn||cells-15/NNS||endothelial-14/NN	prep_in||expressed-10/VBN||cells-15/NNS	conj_and||expressed-10/VBN||cp-17/VBP	amod||cells-19/NNS||epithelial-18/JJ	dobj||cp-17/VBP||cells-19/NNS	nsubj||provide-21/VBP||cells-19/NNS	rcmod||cells-19/NNS||provide-21/VBP	dobj||provide-21/VBP||transport-22/NN	prep_of||transport-22/NN||nutrients-24/NNS	prep_of||transport-22/NN||ions-26/NNS	conj_and||nutrients-24/NNS||ions-26/NNS	det||cns-29/NN||the-28/DT	prep_into||cp-17/VBP||cns-29/NN	prep_into||cp-17/VBP||removal-31/NN	conj_and||cns-29/NN||removal-31/NN	nn||products-34/NNS||waste-33/NN	prep_of||cns-29/NN||products-34/NNS	prep_of||cns-29/NN||ions-36/NNS	conj_and||products-34/NNS||ions-36/NNS	det||csf-39/NN||the-38/DT	prep_from||cp-17/VBP||csf-39/NN	ions-36||cp-17||no_rel||therefore, a number of specific transport proteins are expressed in brain capillary endothelial cells and cp epithelial cells that provide transport of nutrients and ions into the cns and removal of waste products and ions from the csf.
nsubj||equivalent-7/JJ||combination-1/NN	nsubj||leflunomide-9/VB||combination-1/NN	prep_of||combination-1/NN||methotrexate-3/NN	prep_of||combination-1/NN||hydroxychloroquine-5/NN	conj_and||methotrexate-3/NN||hydroxychloroquine-5/NN	cop||equivalent-7/JJ||is-6/VBZ	root||ROOT-0/null||equivalent-7/JJ	aux||leflunomide-9/VB||to-8/TO	xcomp||equivalent-7/JJ||leflunomide-9/VB	prep_in||leflunomide-9/VB||terms-11/NNS	prep_of||terms-11/NNS||efficacy-13/NN	prepc_in||leflunomide-9/VB||reducing-15/VBG	nn||activity-17/NN||disease-16/NN	dobj||reducing-15/VBG||activity-17/NN	det||treatment-21/NN||the-19/DT	amod||treatment-21/NN||initial-20/JJ	prep_in||reducing-15/VBG||treatment-21/NN	amod||rheumatoidarthritis-24/NNS||severe-23/JJ	prep_of||treatment-21/NN||rheumatoidarthritis-24/NNS	rheumatoidarthritis-24||hydroxychloroquine-5||yes||combination of methotrexate and hydroxychloroquine is equivalent to leflunomide in terms of efficacy in reducing disease activity in the initial treatment of severe rheumatoidarthritis.
det||study-2/NN||this-1/DT	nsubj||aims-3/VBZ||study-2/NN	nsubj||investigate-5/VB||study-2/NN	root||ROOT-0/null||aims-3/VBZ	aux||investigate-5/VB||to-4/TO	xcomp||aims-3/VBZ||investigate-5/VB	det||effects-7/NNS||the-6/DT	dobj||investigate-5/VB||effects-7/NNS	nn||proliferation-11/NN||rapa-9/NN	amod||proliferation-11/NN||suppressing-10/VBG	prep_of||effects-7/NNS||proliferation-11/NN	amod||cells-16/NNS||pancreatic-13/JJ	amod||cells-16/NNS||carcinoma-14/JJ	amod||cells-16/NNS||pc-2-15/JJ	prep_of||proliferation-11/NN||cells-16/NNS	prep_in||cells-16/NNS||vitro-18/NNP	poss||mechanism-22/NN||its-20/PRP$	amod||mechanism-22/NN||molecular-21/JJ	prep_of||effects-7/NNS||mechanism-22/NN	conj_and||proliferation-11/NN||mechanism-22/NN	vmod||mechanism-22/NN||involved-23/VBN	nn||activities-26/NNS||antitumor-25/NN	prep_in||involved-23/VBN||activities-26/NNS	rapa-9||carcinoma-14||no_rel||this study aims to investigate the effects of rapa suppressing proliferation of pancreatic carcinoma pc-2 cells in vitro and its molecular mechanism involved in antitumor activities.
nsubj||examined-3/VBD||we-1/PRP	advmod||examined-3/VBD||therefore-2/RB	root||ROOT-0/null||examined-3/VBD	det||integrity-7/NN||the-4/DT	amod||integrity-7/NN||synovial-5/JJ	nn||integrity-7/NN||lining-6/NN	nsubj||wear-19/VBP||integrity-7/NN	amod||infiltrates-11/NNS||inflammatory-9/JJ	nn||infiltrates-11/NNS||cell-10/NN	conj_and||integrity-7/NN||infiltrates-11/NNS	nsubj||wear-19/VBP||infiltrates-11/NNS	nn||organization-14/NN||tissue-13/NN	conj_and||integrity-7/NN||organization-14/NN	nsubj||wear-19/VBP||organization-14/NN	conj_and||integrity-7/NN||necrosis-16/NNS	nsubj||wear-19/VBP||necrosis-16/NNS	conj_and||integrity-7/NN||metal-18/NN	nsubj||wear-19/VBP||metal-18/NN	ccomp||examined-3/VBD||wear-19/VBP	nsubj||causes-37/VBZ||particles-20/NNS	amod||tissues-23/NNS||pseudotumor-like-22/JJ	prep_of||particles-20/NNS||tissues-23/NNS	amod||hips-26/NNS||m-m-25/JJ	prep_from||tissues-23/NNS||hips-26/NNS	vmod||hips-26/NNS||revised-27/VBN	amod||wear-31/NN||suspected-29/VBN	amod||wear-31/NN||high-30/JJ	prep_for||revised-27/VBN||wear-31/NN	amod||wear-31/NN||related-32/VBN	amod||metal-35/NN||suspected-34/VBN	prep_for||revised-27/VBN||metal-35/NN	conj_and||wear-31/NN||metal-35/NN	advmod||causes-37/VBZ||hypersensitivity-36/RB	ccomp||wear-19/VBP||causes-37/VBZ	metal-35||hypersensitivity-36||no_rel||we therefore examined the synovial lining integrity, inflammatory cell infiltrates, tissue organization, necrosis and metal wear particles of pseudotumor-like tissues from m-m hips revised for suspected high wear related and suspected metal hypersensitivity causes.
nsubjpass||affected-5/VBN||cows-1/NNS	nsubjpass||hypothyroid-12/VBN||cows-1/NNS	auxpass||affected-5/VBN||were-4/VBD	rcmod||cows-1/NNS||affected-5/VBN	amod||liver-9/NN||severe-7/JJ	amod||liver-9/NN||fatty-8/JJ	prep_with||affected-5/VBN||liver-9/NN	auxpass||hypothyroid-12/VBN||were-11/VBD	root||ROOT-0/null||hypothyroid-12/VBN	prep_prior_to||hypothyroid-12/VBN||development-15/NN	det||condition-18/NN||the-17/DT	prep_of||development-15/NN||condition-18/NN	acomp||hypothyroid-12/VBN||due-19/JJ	amod||concentrations-23/NNS||lower-21/JJR	amod||concentrations-23/NNS||t4-22/JJ	prep_to||due-19/JJ||concentrations-23/NNS	acomp||hypothyroid-12/VBN||had-26/VBD	conj_and||due-19/JJ||had-26/VBD	advmod||lower-28/JJR||significantly-27/RB	amod||concentration-29/NN||lower-28/JJR	dobj||had-26/VBD||concentration-29/NN	prep_of||concentration-29/NN||t3-31/NNS	amod||ratios-35/NNS||higher-33/JJR	amod||ratios-35/NNS||t3/t4-34/JJ	prep_of||concentration-29/NN||ratios-35/NNS	conj_and||t3-31/NNS||ratios-35/NNS	prep_than||had-26/VBD||cows-37/NNS	amod||liver-43/NN||mild-39/JJ	conj_and||mild-39/JJ||moderate-41/JJ	amod||liver-43/NN||moderate-41/JJ	nn||liver-43/NN||fatty-42/NN	prep_with||cows-37/NNS||liver-43/NN	hypothyroid-12||t4-22||yes||cows, that were affected with severe fatty liver, were hypothyroid prior to development of the condition due to lower t4 concentrations, and had significantly lower concentration of t3 and higher t3/t4 ratios than cows with mild and moderate fatty liver.
det||indices-3/NNS||the-1/DT	amod||indices-3/NNS||insulinresistance-2/JJ	nsubj||value-8/NN||indices-3/NNS	vmod||indices-3/NNS||used-4/VBN	cop||value-8/NN||were-5/VBD	det||value-8/NN||the-6/DT	nn||value-8/NN||m-7/NN	root||ROOT-0/null||value-8/NN	nsubj||rate-17/NN||value-8/NN	cop||rate-17/NN||is-11/VBZ	det||rate-17/NN||the-12/DT	amod||rate-17/NN||total-13/JJ	nn||rate-17/NN||body-14/NN	nn||rate-17/NN||glucose-15/NN	nn||rate-17/NN||disposal-16/NN	rcmod||value-8/NN||rate-17/NN	det||value-22/NN||the-20/DT	nn||value-22/NN||m/i-21/NN	conj_and||value-8/NN||value-22/NN	nsubj||value-28/NN||value-22/NN	cop||value-28/NN||is-25/VBZ	det||value-28/NN||the-26/DT	nn||value-28/NN||m-27/NN	rcmod||value-22/NN||value-28/NN	vmod||value-28/NN||adjusted-29/VBN	det||level-36/NN||the-31/DT	amod||level-36/NN||steady-32/JJ	nn||level-36/NN||state-33/NN	nn||level-36/NN||plasma-34/NN	nn||level-36/NN||insulin-35/NN	prep_for||adjusted-29/VBN||level-36/NN	insulinresistance-2||glucose-15||no_rel||the insulinresistance indices used were the m value, which is the total body glucose disposal rate, and the m/i value, which is the m value adjusted for the steady state plasma insulin level.
amod||classes-2/NNS||major-1/JJ	nsubj||include-8/VBP||classes-2/NNS	prep_of||classes-2/NNS||medication-4/NN	nn||management-7/NN||asthma-6/NN	prep_in||medication-4/NN||management-7/NN	root||ROOT-0/null||include-8/VBP	xcomp||include-8/VBP||bronchodilating-9/VBG	nn||2-agonists-12/NN||î-10/NN	nn||2-agonists-12/NN||²-11/NN	dobj||bronchodilating-9/VBG||2-agonists-12/NN	amod||corticosteroids-16/NNS||anti-inflammatory-14/JJ	amod||corticosteroids-16/NNS||inhaled-15/JJ	dobj||bronchodilating-9/VBG||corticosteroids-16/NNS	conj_and||2-agonists-12/NN||corticosteroids-16/NNS	amod||modifiers-19/NNS||leukotriene-18/JJ	dobj||bronchodilating-9/VBG||modifiers-19/NNS	conj_and||2-agonists-12/NN||modifiers-19/NNS	dobj||bronchodilating-9/VBG||theophyllines-21/NNS	conj_and||2-agonists-12/NN||theophyllines-21/NNS	asthma-6||theophyllines-21||yes||major classes of medication in asthma management include bronchodilating î²2-agonists, anti-inflammatory inhaled corticosteroids, leukotriene modifiers and theophyllines.
det||case-2/NN||this-1/DT	nsubj||suggests-3/VBZ||case-2/NN	root||ROOT-0/null||suggests-3/VBZ	mark||offer-7/VB||that-4/IN	nsubj||offer-7/VB||bivalirudin-5/NN	aux||offer-7/VB||could-6/MD	ccomp||suggests-3/VBZ||offer-7/VB	dobj||offer-7/VB||promise-8/NN	prep_for||promise-8/NN||use-10/NN	prep_in||offer-7/VB||patients-12/NNS	amod||thrombocytopaenia-15/NN||heparin-induced-14/JJ	prep_with||offer-7/VB||thrombocytopaenia-15/NN	dep||offer-7/VB||hit-17/VBN	prep_after||offer-7/VB||thrombolysis-20/NNS	amod||pulmonaryembolism-23/NN||massive-22/JJ	prep_for||thrombolysis-20/NNS||pulmonaryembolism-23/NN	pulmonaryembolism-23||heparin--1||yes||this case suggests that bivalirudin could offer promise for use in patients with heparin-induced thrombocytopaenia (hit) after thrombolysis for massive pulmonaryembolism.
amod||anticoagulation-2/NN||oral-1/JJ	nsubj||prevents-3/VBZ||anticoagulation-2/NN	root||ROOT-0/null||prevents-3/VBZ	dobj||prevents-3/VBZ||strokes-4/NNS	prep_in||strokes-4/NNS||patients-6/NNS	prep_with||patients-6/NNS||atrialfibrillation-8/NN	nsubj||remain-14/VBP||reasons-12/NNS	prep_for||receive-26/VBP||reasons-12/NNS	rcmod||reasons-12/NNS||remain-14/VBP	acomp||remain-14/VBP||unclear-15/JJ	mwe||than-18/IN||less-17/JJR	quantmod||40-19/CD||than-18/IN	num||%-20/NN||40-19/CD	nsubj||receive-26/VBP||%-20/NN	det||patients-23/NNS||all-22/DT	prep_of||%-20/NN||patients-23/NNS	prep_with||patients-23/NNS||atrialfibrillation-25/NN	conj_but||prevents-3/VBZ||receive-26/VBP	dobj||receive-26/VBP||warfarin-27/NN	strokes-4||warfarin-27||yes||oral anticoagulation prevents strokes in patients with atrialfibrillation but, for reasons that remain unclear, less than 40% of all patients with atrialfibrillation receive warfarin.
det||results-2/NNS||these-1/DT	nsubj||suggest-3/VBP||results-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||have-11/VBP||that-4/IN	det||combination-6/NN||the-5/DT	nsubj||have-11/VBP||combination-6/NN	prep_of||combination-6/NN||desloratadine-8/NN	prep_of||combination-6/NN||mometasonefuroate-10/NN	conj_and||desloratadine-8/NN||mometasonefuroate-10/NN	ccomp||suggest-3/VBP||have-11/VBP	det||effect-15/NN||a-12/DT	amod||effect-15/NN||greater-13/JJR	nn||effect-15/NN||antinflammatory-14/NN	dobj||have-11/VBP||effect-15/NN	det||model-20/NN||an-17/DT	dep||vitro-19/NN||in-18/IN	amod||model-20/NN||vitro-19/NN	prep_in||effect-15/NN||model-20/NN	amod||inflammation-23/NN||eosinophil-22/JJ	prep_of||model-20/NN||inflammation-23/NN	det||drugs-26/NNS||those-25/DT	prep_than||have-11/VBP||drugs-26/NNS	vmod||drugs-26/NNS||administered-27/VBN	advmod||administered-27/VBN||alone-28/RB	inflammation-23||mometasonefuroate-10||yes||these results suggest that the combination of desloratadine and mometasonefuroate have a greater antinflammatory effect in an in vitro model of eosinophil inflammation than those drugs administered alone.
det||extracts-2/NNS||all-1/DT	nsubj||showed-9/VBD||extracts-2/NNS	nn||flower-7/NN||samanea-5/NN	nn||flower-7/NN||saman-6/NN	prep_except||extracts-2/NNS||flower-7/NN	root||ROOT-0/null||showed-9/VBD	amod||activity-11/NN||antibacterial-10/JJ	dobj||showed-9/VBD||activity-11/NN	num||strains-14/NNS||two-13/CD	prep_against||showed-9/VBD||strains-14/NNS	prep_of||strains-14/NNS||methicillinresistantstaphylococcusaureus-16/NNS	appos||methicillinresistantstaphylococcusaureus-16/NNS||mrsa-18/NNP	amod||values-22/NNS||mid-21/JJ	prep_with||showed-9/VBD||values-22/NNS	vmod||values-22/NNS||ranging-23/VBG	num||î-31/NNS||100-25/CD	number||1/4-27/CD||î-26/CD	num||î-31/NNS||1/4-27/CD	amod||î-31/NNS||g/disc-28/JJ	cc||500-30/CD||and-29/CC	num||î-31/NNS||500-30/CD	prep_between||ranging-23/VBG||î-31/NNS	number||g/disc-33/JJ||1/4-32/CD	amod||î-31/NNS||g/disc-33/JJ	methicillinresistantstaphylococcusaureus-16||antibacterial-10||no_rel||all extracts (except samanea saman flower) showed antibacterial activity against two strains of methicillinresistantstaphylococcusaureus (mrsa) with mid values ranging between 100 î¼g/disc and 500 î¼g/disc.
nsubj||include-5/VBP||advantages-1/NNS	det||therapies-4/NNS||these-3/DT	prep_of||advantages-1/NNS||therapies-4/NNS	root||ROOT-0/null||include-5/VBP	amod||enhancement-7/NN||glucose-dependent-6/JJ	dobj||include-5/VBP||enhancement-7/NN	nn||secretion-10/NN||insulin-9/NN	prep_of||enhancement-7/NN||secretion-10/NN	amod||instances-13/NNS||infrequent-12/JJ	dobj||include-5/VBP||instances-13/NNS	conj_and||enhancement-7/NN||instances-13/NNS	prep_of||instances-13/NNS||hypoglycemia-15/NN	nn||loss-18/NN||weight-17/NN	dobj||include-5/VBP||loss-18/NN	conj_and||enhancement-7/NN||loss-18/NN	amod||agonists-22/NNS||glp-1-20/JJ	nn||agonists-22/NNS||receptor-21/NN	prep_with||loss-18/NN||agonists-22/NNS	nn||maintenance-25/NN||weight-24/NN	dobj||include-5/VBP||maintenance-25/NN	conj_and||enhancement-7/NN||maintenance-25/NN	amod||inhibitors-28/NNS||dpp-iv-27/JJ	prep_with||maintenance-25/NN||inhibitors-28/NNS	amod||pressure-32/NN||decreased-30/JJ	nn||pressure-32/NN||blood-31/NN	dobj||include-5/VBP||pressure-32/NN	conj_and||enhancement-7/NN||pressure-32/NN	appos||pressure-32/NN||improvements-34/NNS	prep_in||improvements-34/NNS||dyslipidemia-36/NN	amod||effects-41/NNS||potential-39/JJ	amod||effects-41/NNS||beneficial-40/JJ	dobj||include-5/VBP||effects-41/NNS	conj_and||enhancement-7/NN||effects-41/NNS	nn||function-44/NN||cv-43/NN	prep_on||effects-41/NNS||function-44/NN	hypoglycemia-15||glucose--1||yes||advantages of these therapies include glucose-dependent enhancement of insulin secretion, infrequent instances of hypoglycemia, weight loss with glp-1 receptor agonists, weight maintenance with dpp-iv inhibitors, decreased blood pressure, improvements in dyslipidemia, and potential beneficial effects on cv function.
nn||venereum-2/NN||lymphogranuloma-1/NN	nn||proctitis-6/NNS||venereum-2/NN	appos||proctitis-6/NNS||lgv-4/NN	nsubjpass||caused-8/VBN||proctitis-6/NNS	nsubj||endemic-18/JJ||proctitis-6/NNS	auxpass||caused-8/VBN||is-7/VBZ	root||ROOT-0/null||caused-8/VBN	agent||caused-8/VBN||chlamydiatrachomatis-10/NNS	appos||chlamydiatrachomatis-10/NNS||ct-12/NN	amod||l-15/NN||genotype-14/JJ	dobj||caused-8/VBN||l-15/NN	cop||endemic-18/JJ||is-17/VBZ	conj_and||caused-8/VBN||endemic-18/JJ	prep_among||endemic-18/JJ||men-20/NNS	nsubj||have-22/VBP||men-20/NNS	rcmod||men-20/NNS||have-22/VBP	dobj||have-22/VBP||sex-23/NN	prep_with||have-22/VBP||men-25/NNS	appos||men-25/NNS||msm-27/NN	amod||society-31/NN||western-30/JJ	prep_in||men-25/NNS||society-31/NN	lgv-4||chlamydiatrachomatis-10||no||lymphogranuloma venereum (lgv) proctitis is caused by chlamydiatrachomatis (ct) genotype l and is endemic among men who have sex with men (msm) in western society.
nsubj||play-3/VB||vitamind-1/NN	aux||play-3/VB||may-2/MD	root||ROOT-0/null||play-3/VB	det||role-5/NN||a-4/DT	dobj||play-3/VB||role-5/NN	det||pathogenesis-8/NNS||the-7/DT	prep_in||play-3/VB||pathogenesis-8/NNS	prep_of||pathogenesis-8/NNS||type2diabetes-10/CD	mark||d-17/VBD||as-12/IN	nsubj||d-17/VBD||25-13/CD	discourse||25-13/CD||oh-15/UH	advcl||play-3/VB||d-17/VBD	nsubjpass||associated-21/VBN||concentration-18/NN	auxpass||associated-21/VBN||was-19/VBD	advmod||associated-21/VBN||independently-20/RB	ccomp||d-17/VBD||associated-21/VBN	preconj||sensitivity-25/NN||both-23/DT	nn||sensitivity-25/NN||insulin-24/NN	prep_with||associated-21/VBN||sensitivity-25/NN	nn||²-28/NN||î-27/NN	prep_with||associated-21/VBN||²-28/NN	conj_and||sensitivity-25/NN||²-28/NN	nsubj||function-31/VBP||cell-30/NN	parataxis||play-3/VB||function-31/VBP	prep_among||function-31/VBP||individuals-33/NNS	prep_at||individuals-33/NNS||risk-35/NN	prep_of||risk-35/NN||type2diabetes-37/CD	type2diabetes-37||insulin-24||yes||vitamind may play a role in the pathogenesis of type2diabetes, as 25(oh)d concentration was independently associated with both insulin sensitivity and î²-cell function among individuals at risk of type2diabetes.
amod||options-2/NNS||several-1/JJ	nsubjpass||licensed-10/VBN||options-2/NNS	det||treatment-5/NN||the-4/DT	prep_for||options-2/NNS||treatment-5/NN	prep_of||treatment-5/NN||hepatitisb-7/NN	aux||licensed-10/VBN||have-8/VBP	auxpass||licensed-10/VBN||been-9/VBN	root||ROOT-0/null||licensed-10/VBN	det||interferon-15/NN||the-12/DT	amod||interferon-15/NN||last-13/JJ	nn||interferon-15/NN||years-14/NNS	prep_in||licensed-10/VBN||interferon-15/NN	amod||interferon-18/NN||pegylated-17/JJ	prep_in||licensed-10/VBN||interferon-18/NN	conj_and||interferon-15/NN||interferon-18/NN	prep_in||licensed-10/VBN||lamivudine-20/NN	conj_and||interferon-15/NN||lamivudine-20/NN	prep_in||licensed-10/VBN||adefovir-22/NN	conj_and||interferon-15/NN||adefovir-22/NN	prep_in||licensed-10/VBN||entecavir-24/NN	conj_and||interferon-15/NN||entecavir-24/NN	prep_in||licensed-10/VBN||telbivudine-27/NN	conj_and||interferon-15/NN||telbivudine-27/NN	hepatitisb-7||lamivudine-20||yes||several options for the treatment of hepatitisb have been licensed in the last years interferon, pegylated interferon, lamivudine, adefovir, entecavir, and telbivudine.
prepc_based_on||standard-16/NN||on-2/IN	amod||studies-6/NNS||multiple-3/JJ	nn||studies-6/NNS||phase-4/NN	nn||studies-6/NNS||iii-5/NN	pobj||standard-16/NN||studies-6/NNS	conj_and||studies-6/NNS||meta-analyses-8/NNS	pobj||standard-16/NN||meta-analyses-8/NNS	amod||chemoradiotherapy-12/NN||concurrent-10/JJ	amod||chemoradiotherapy-12/NN||cisplatin-based-11/JJ	nsubj||standard-16/NN||chemoradiotherapy-12/NN	cop||standard-16/NN||is-13/VBZ	det||standard-16/NN||the-14/DT	amod||standard-16/NN||current-15/JJ	root||ROOT-0/null||standard-16/NN	prep_of||standard-16/NN||care-18/NN	advmod||advanced-21/JJ||locally-20/RB	amod||disease-22/NN||advanced-21/JJ	prep_for||care-18/NN||disease-22/NN	amod||committee-26/NN||american-24/JJ	amod||committee-26/NN||joint-25/JJ	dep||disease-22/NN||committee-26/NN	nn||ivb-38/NNP||cancer-28/NN	nn||ivb-38/NNP||manual-29/NN	nn||ivb-38/NNP||-LSB--30/NNP	amod||ivb-38/NNP||7th-31/JJ	nn||ivb-38/NNP||edition-32/NN	nn||ivb-38/NNP||-RSB--33/FW	nn||ivb-38/NNP||stages-34/FW	nn||ivb-38/NNP||iiâ-35/FW	nn||ivb-38/NNP||$-36/NNP	prep_on||committee-26/NN||ivb-38/NNP	cancer-28||cisplatin--1||no_rel||based on multiple phase iii studies and meta-analyses, concurrent cisplatin-based chemoradiotherapy is the current standard of care for locally advanced disease (american joint committee on cancer manual [7th edition] stages iiâivb).
det||case-4/NN||the-2/DT	amod||case-4/NN||presented-3/JJ	prep_in||suggested-16/VBD||case-4/NN	nsubj||suggested-16/VBD||history-6/NN	conj_and||history-6/NN||symptoms-8/NNS	nsubj||suggested-16/VBD||symptoms-8/NNS	conj_and||history-6/NN||results-11/NNS	nsubj||suggested-16/VBD||results-11/NNS	nn||testing-14/NN||skin-13/NN	prep_of||results-11/NNS||testing-14/NN	advmod||suggested-16/VBD||strongly-15/RB	root||ROOT-0/null||suggested-16/VBD	det||hypersensitivity-20/NN||an-17/DT	amod||hypersensitivity-20/NN||ige-mediated-18/JJ	amod||hypersensitivity-20/NN||allergic-19/JJ	dobj||suggested-16/VBD||hypersensitivity-20/NN	amod||heparins-23/NNS||different-22/JJ	prep_against||suggested-16/VBD||heparins-23/NNS	heparins-23||hypersensitivity-20||no_rel||in the presented case, history, symptoms, and results of skin testing strongly suggested an ige-mediated allergic hypersensitivity against different heparins.
amod||ph-2/NN||fecal-1/JJ	nsubjpass||measured-13/VBN||ph-2/NN	nsubjpass||compared-15/VBN||ph-2/NN	amod||acids-6/NNS||fecal-4/JJ	amod||acids-6/NNS||organic-5/JJ	conj_and||ph-2/NN||acids-6/NNS	nsubjpass||measured-13/VBN||acids-6/NNS	amod||counts-11/NNS||fecal-9/JJ	nn||counts-11/NNS||bacteria-10/NNS	conj_and||ph-2/NN||counts-11/NNS	nsubjpass||measured-13/VBN||counts-11/NNS	auxpass||measured-13/VBN||were-12/VBD	root||ROOT-0/null||measured-13/VBN	conj_and||measured-13/VBN||compared-15/VBN	amod||group-18/NN||survived-17/JJ	agent||measured-13/VBN||group-18/NN	amod||group-21/NN||nonsurvived-20/JJ	agent||measured-13/VBN||group-21/NN	conj_and||group-18/NN||group-21/NN	nn||group-25/NN||nonbacteremia-24/NN	agent||measured-13/VBN||group-25/NN	conj_or||group-18/NN||group-25/NN	nn||group-28/NN||bacteremia-27/NN	conj_or||group-18/NN||group-28/NN	conj_and||group-25/NN||group-28/NN	bacteremia-27||bacteria-10||no||fecal ph, fecal organic acids, and fecal bacteria counts were measured and compared by survived group and nonsurvived group, or nonbacteremia group and bacteremia group.
det||study-4/NN||a-1/DT	amod||cohort-3/JJ||retrospective-2/JJ	amod||study-4/NN||cohort-3/JJ	nsubjpass||conducted-6/VBN||study-4/NN	auxpass||conducted-6/VBN||was-5/VBD	root||ROOT-0/null||conducted-6/VBN	xcomp||conducted-6/VBN||using-7/VBG	det||center-11/NN||an-8/DT	amod||center-11/NN||academic-9/JJ	nn||center-11/NN||health-10/NN	dobj||using-7/VBG||center-11/NN	amod||record-15/NN||enterprise-wide-12/JJ	amod||record-15/NN||electronic-13/JJ	nn||record-15/NN||health-14/NN	prep||center-11/NN||record-15/NN	appos||record-15/NN||ehr-17/NN	dep||record-15/NN||system-19/NN	aux||identify-21/VB||to-20/TO	vmod||system-19/NN||identify-21/VB	num||patients-23/NNS||11,141-22/CD	dobj||identify-21/VB||patients-23/NNS	prep_with||identify-21/VB||type2diabetes-25/NNS	num||initiators-28/NNS||4,279-27/CD	dep||type2diabetes-25/NNS||initiators-28/NNS	prep_of||initiators-28/NNS||monotherapy-30/NN	prep_with||monotherapy-30/NN||glyburide-32/NN	num||initiators-35/NNS||4,325-34/CD	dep||type2diabetes-25/NNS||initiators-35/NNS	conj_and||initiators-28/NNS||initiators-35/NNS	prep_of||initiators-35/NNS||monotherapy-37/NN	prep_with||monotherapy-37/NN||glipizide-39/NN	num||initiators-43/NNS||2,537-42/CD	dep||type2diabetes-25/NNS||initiators-43/NNS	conj_and||initiators-28/NNS||initiators-43/NNS	prep_of||initiators-43/NNS||monotherapy-45/NN	prep_with||monotherapy-45/NN||glimepiride-47/NN	vmod||system-19/NN||â-50/VB	conj_and||identify-21/VB||â-50/VB	conj_and||identify-21/VB||â-50/VB	conj_and||â-50/VB||â-50/VB	nn||¥-52/NNP||-51/NNP	dobj||â-50/VB||¥-52/NNP	num||years-54/NNS||18-53/CD	npadvmod||¥-52/NNP||years-54/NNS	prep_of||¥-52/NNP||age-56/NN	det||history-61/NN||a-60/DT	prep_with||â-50/VB||history-61/NN	prep_without||â-50/VB||history-61/NN	prep_of||history-61/NN||coronaryarterydisease-63/NN	appos||history-61/NN||cad-65/NN	vmod||system-19/NN||not-68/RB	conj_and||identify-21/VB||not-68/RB	neg||identify-21/VB||not-68/RB	prep_on||not-68/RB||insulin-70/NN	det||noninsulin-73/NN||a-72/DT	prep_on||not-68/RB||noninsulin-73/NN	conj_or||insulin-70/NN||noninsulin-73/NN	vmod||system-19/NN||injectable-74/VB	conj_and||identify-21/VB||injectable-74/VB	prep_at||injectable-74/VB||baseline-76/NN	type2diabetes-25||glyburide-32||yes||a retrospective cohort study was conducted using an academic health center enterprise-wide electronic health record (ehr) system to identify 11,141 patients with type2diabetes (4,279 initiators of monotherapy with glyburide, 4,325 initiators of monotherapy with glipizide, and 2,537 initiators of monotherapy with glimepiride), â¥18 years of age with and without a history of coronaryarterydisease (cad) and not on insulin or a noninsulin injectable at baseline.
nsubj||determine-3/VB||objectives-1/NNS	nsubj||support-11/VB||objectives-1/NNS	aux||determine-3/VB||to-2/TO	root||ROOT-0/null||determine-3/VB	det||relation-5/NN||the-4/DT	dobj||determine-3/VB||relation-5/NN	det||epidemic-9/NN||the-7/DT	amod||epidemic-9/NN||hiv/aids-8/JJ	prep_between||relation-5/NN||epidemic-9/NN	conj_and||determine-3/VB||support-11/VB	amod||people-15/NNS||dependent-13/JJ	amod||people-15/NNS||elderly-14/JJ	prep_for||support-11/VB||people-15/NNS	prep_in||people-15/NNS||africa-17/NN	aids--1||hiv--1||no||objectives to determine the relation between the hiv/aids epidemic and support for dependent elderly people in africa.
det||risk-2/NN||the-1/DT	nsubj||increased-8/VBN||risk-2/NN	amod||emergence-6/NN||adefovirdipivoxil-4/JJ	nn||emergence-6/NN||resistance-5/NN	prep_of||risk-2/NN||emergence-6/NN	aux||increased-8/VBN||has-7/VBZ	root||ROOT-0/null||increased-8/VBN	amod||patients-13/NNS||lamivudine-resistant-10/JJ	amod||patients-13/NNS||hepatitisb-11/JJ	amod||patients-13/NNS||infected-12/JJ	prep_in||increased-8/VBN||patients-13/NNS	hepatitisb-11||lamivudine--1||yes||the risk of adefovirdipivoxil resistance emergence has increased in lamivudine-resistant hepatitisb infected patients.
mark||condition-7/NN||although-1/IN	amod||cancer-3/NN||cervical-2/JJ	nsubj||condition-7/NN||cancer-3/NN	cop||condition-7/NN||is-4/VBZ	det||condition-7/NN||an-5/DT	amod||condition-7/NN||aids-defining-6/JJ	advcl||increase-18/VB||condition-7/NN	nsubj||increase-18/VB||infection-9/NN	prep_with||infection-9/NN||humanimmunodeficiencyvirus-11/NNS	appos||humanimmunodeficiencyvirus-11/NNS||hiv-13/NN	aux||increase-18/VB||may-15/MD	advmod||modestly-17/RB||only-16/RB	advmod||increase-18/VB||modestly-17/RB	root||ROOT-0/null||increase-18/VB	det||risk-20/NN||the-19/DT	dobj||increase-18/VB||risk-20/NN	amod||cancer-23/NN||cervical-22/JJ	prep_of||risk-20/NN||cancer-23/NN	aids--1||humanimmunodeficiencyvirus-11||no||although cervical cancer is an aids-defining condition, infection with humanimmunodeficiencyvirus (hiv) may only modestly increase the risk of cervical cancer.
advmod||greater-2/JJR||significantly-1/RB	amod||reductions-3/NNS||greater-2/JJR	nsubjpass||observed-9/VBN||reductions-3/NNS	nsubjpass||observed-9/VBN||reductions-3/NNS	amod||bp-7/NN||seated-5/JJ	amod||bp-7/NN||diastolic-6/JJ	prep_in||reductions-3/NNS||bp-7/NN	auxpass||observed-9/VBN||were-8/VBD	root||ROOT-0/null||observed-9/VBN	conj_and||observed-9/VBN||observed-9/VBN	prep_between||observed-9/VBN||baseline-11/NN	num||weeks-15/NNS||eight-14/CD	prep_after||observed-9/VBN||weeks-15/NNS	prep_of||weeks-15/NNS||treatment-17/NN	prep_with||observed-9/VBN||olmesartan/amlodipine-19/NN	prepc_compared_with||observed-9/VBN||with-22/IN	nn||doses-24/NNS||equivalent-23/NN	pobj||observed-9/VBN||doses-24/NNS	amod||monotherapy-29/NN||olmesartan-26/JJ	conj_or||olmesartan-26/JJ||amolodipine-28/JJ	amod||monotherapy-29/NN||amolodipine-28/JJ	prep_of||doses-24/NNS||monotherapy-29/NN	appos||monotherapy-29/NN||p-31/NNP	number||0.001-33/CD||<-32/CD	num||p-31/NNP||0.001-33/CD	det||combination-39/NN||the-37/DT	amod||combination-39/NN||factorial-38/JJ	prep_in||observed-9/VBN||combination-39/NN	nn||trial-50/NN||olmesartanmedoxomil-41/NN	conj_and||olmesartanmedoxomil-41/NN||amlodipinebesylate-43/JJ	nn||trial-50/NN||amlodipinebesylate-43/JJ	amod||highbloodpressure-46/NN||controlling-45/VBG	prep_in||amlodipinebesylate-43/JJ||highbloodpressure-46/NN	appos||highbloodpressure-46/NN||coach-48/NN	prep_of||combination-39/NN||trial-50/NN	highbloodpressure-46||olmesartanmedoxomil-41||yes||significantly greater reductions in seated diastolic bp were observed between baseline and after eight weeks of treatment with olmesartan/amlodipine, compared with equivalent doses of olmesartan or amolodipine monotherapy ( p < 0.001), in the factorial combination of olmesartanmedoxomil and amlodipinebesylate in controlling highbloodpressure (coach) trial.
nsubj||revealed-6/VBD||studies-1/NNS	vmod||studies-1/NNS||conducted-2/VBN	poss||laboratory-5/NN||our-4/PRP$	prep_in||conducted-2/VBN||laboratory-5/NN	root||ROOT-0/null||revealed-6/VBD	mark||affected-22/VBN||that-7/IN	det||bm-hscs-12/NNS||the-8/DT	amod||bm-hscs-12/NNS||primitive-9/JJ	amod||bm-hscs-12/NNS||sca-1-10/JJ	nn||bm-hscs-12/NNS||+-11/NN	nsubjpass||affected-22/VBN||bm-hscs-12/NNS	nn||marrow-15/NN||bone-14/NN	dep||bm-hscs-12/NNS||marrow-15/NN	amod||cell-18/NN||hematopoietic-16/JJ	nn||cell-18/NN||stem-17/NN	dep||marrow-15/NN||cell-18/NN	auxpass||affected-22/VBN||are-20/VBP	advmod||affected-22/VBN||significantly-21/RB	ccomp||revealed-6/VBD||affected-22/VBN	amod||animals-26/NNS||experimental-24/JJ	amod||animals-26/NNS||aplastic-25/JJ	prep_in||affected-22/VBN||animals-26/NNS	vmod||animals-26/NNS||pretreated-27/VBN	amod||drugs-30/NNS||chemotherapeutic-29/JJ	prep_with||pretreated-27/VBN||drugs-30/NNS	dep||drugs-30/NNS||busulfan-32/JJ	dep||drugs-30/NNS||cyclophosphamide-34/JJ	conj_and||busulfan-32/JJ||cyclophosphamide-34/JJ	expl||is-38/VBZ||there-37/EX	ccomp||revealed-6/VBD||is-38/VBZ	conj_and||affected-22/VBN||is-38/VBZ	amod||activity-41/NN||increased-39/VBN	amod||activity-41/NN||caspase-3-40/JJ	nsubj||is-38/VBZ||activity-41/NN	amod||high-44/JJ||consecutive-43/JJ	amod||population-58/NN||high-44/JJ	amod||population-58/NN||annexin-v-45/JJ	advmod||leading-47/JJ||positivity-46/RB	amod||population-58/NN||leading-47/JJ	amod||apoptosis-50/NNS||premature-49/JJ	prep_to||leading-47/JJ||apoptosis-50/NNS	det||marrow-54/NN||the-52/DT	nn||marrow-54/NN||bone-53/NN	prep_in||apoptosis-50/NNS||marrow-54/NN	amod||population-58/NN||hematopoietic-55/JJ	nn||population-58/NN||stem-56/NN	nn||population-58/NN||cell-57/NN	prep_with||activity-41/NN||population-58/NN	amod||condition-61/NN||aplastic-60/JJ	prep_in||activity-41/NN||condition-61/NN	busulfan-32||sca--1||no_rel||studies conducted in our laboratory revealed that the primitive sca-1+ bm-hscs (bone marrow hematopoietic stem cell) are significantly affected in experimental aplastic animals pretreated with chemotherapeutic drugs (busulfan and cyclophosphamide) and there is increased caspase-3 activity with consecutive high annexin-v positivity leading to premature apoptosis in the bone marrow hematopoietic stem cell population in aplastic condition.
amod||agents-4/NNS||recommended-1/VBN	amod||agents-4/NNS||parenteral-2/JJ	nn||agents-4/NNS||anticoagulant-3/NN	nsubj||include-16/VBP||agents-4/NNS	amod||indications-7/NNS||different-6/JJ	prep_with||agents-4/NNS||indications-7/NNS	det||prevention-10/NN||the-9/DT	prep_for||indications-7/NNS||prevention-10/NN	prep_for||indications-7/NNS||treatment-12/NN	conj_and||prevention-10/NN||treatment-12/NN	amod||thromboembolism-15/NN||venous-14/JJ	prep_of||prevention-10/NN||thromboembolism-15/NN	root||ROOT-0/null||include-16/VBP	dobj||include-16/VBP||unfractionatedheparin-17/NN	amod||heparins-20/NNS||low-molecular-weight-19/JJ	dobj||include-16/VBP||heparins-20/NNS	conj_and||unfractionatedheparin-17/NN||heparins-20/NNS	dobj||include-16/VBP||fondaparinux-22/NN	conj_and||unfractionatedheparin-17/NN||fondaparinux-22/NN	thromboembolism-15||unfractionatedheparin-17||yes||recommended parenteral anticoagulant agents with different indications for the prevention and treatment of venous thromboembolism include unfractionatedheparin, low-molecular-weight heparins and fondaparinux.
nn||department-2/NN||emergency-1/NN	nsubjpass||treated-15/VBN||department-2/NN	dep||treated-15/VBN||ed-4/NN	nsubjpass||treated-15/VBN||patients-6/NNS	amod||thromboembolism-9/NN||venous-8/JJ	prep_with||patients-6/NNS||thromboembolism-9/NN	appos||patients-6/NNS||vte-11/NN	auxpass||treated-15/VBN||are-13/VBP	advmod||treated-15/VBN||eventually-14/RB	root||ROOT-0/null||treated-15/VBN	det||dose-19/NN||a-17/DT	amod||dose-19/NN||standard-18/JJ	prep_with||treated-15/VBN||dose-19/NN	prep_of||dose-19/NN||warfarin-21/NN	det||fact-24/NN||the-23/DT	prep_despite||treated-15/VBN||fact-24/NN	mark||known-31/VBN||that-25/IN	det||number-27/NN||a-26/DT	nsubjpass||known-31/VBN||number-27/NN	nsubj||sensitive-34/JJ||number-27/NN	nsubj||warfarin-36/VB||number-27/NN	nsubj||experience-39/VB||number-27/NN	prep_of||number-27/NN||patients-29/NNS	auxpass||known-31/VBN||are-30/VBP	ccomp||treated-15/VBN||known-31/VBN	aux||sensitive-34/JJ||to-32/TO	cop||sensitive-34/JJ||be-33/VB	xcomp||known-31/VBN||sensitive-34/JJ	aux||warfarin-36/VB||to-35/TO	xcomp||sensitive-34/JJ||warfarin-36/VB	aux||experience-39/VB||may-38/MD	ccomp||treated-15/VBN||experience-39/VB	conj_and||known-31/VBN||experience-39/VB	amod||inrs-41/NNS||supra-therapeutic-40/JJ	dobj||experience-39/VB||inrs-41/NNS	amod||events-45/NNS||adverse-43/JJ	amod||events-45/NNS||bleeding-44/VBG	dobj||experience-39/VB||events-45/NNS	conj_and||inrs-41/NNS||events-45/NNS	thromboembolism-9||warfarin-36||yes||emergency department (ed) patients with venous thromboembolism (vte) are eventually treated with a standard dose of warfarin despite the fact that a number of patients are known to be sensitive to warfarin and may experience supra-therapeutic inrs and adverse bleeding events.
nsubj||searched-2/VBD||we-1/PRP	root||ROOT-0/null||searched-2/VBD	ccomp||searched-2/VBD||medline-3/VB	ccomp||searched-2/VBD||pubmed-5/VB	conj_and||medline-3/VB||pubmed-5/VB	dobj||medline-3/VB||terms-6/NNS	nn||stage-9/NN||labour-8/NN	dep||terms-6/NNS||stage-9/NN	dep||stage-9/NN||third-11/JJ	dep||ergonovine-17/NN||ergonovine-15/JJ	dep||medline-3/VB||ergonovine-17/NN	amod||ergonovine-17/NN||tartrate-18/JJ	amod||ergonovine-17/NN||methylergonovine-20/JJ	conj_or||tartrate-18/JJ||methylergonovine-20/JJ	amod||ergonovine-17/NN||oxytocin-22/JJ	conj_or||tartrate-18/JJ||oxytocin-22/JJ	amod||ergonovine-17/NN||oxytocics-24/JJ	conj_or||tartrate-18/JJ||oxytocics-24/JJ	amod||ergonovine-17/NN||misoprostol-26/JJ	conj_or||tartrate-18/JJ||misoprostol-26/JJ	ccomp||searched-2/VBD||and-28/VB	conj_and||medline-3/VB||and-28/VB	parataxis||and-28/VB||postpartumhaemorrhage-30/VB	parataxis||and-28/VB||haemorrhage-32/VB	conj_or||postpartumhaemorrhage-30/VB||haemorrhage-32/VB	conj_and||medline-3/VB||cochrane-35/VB	conj_and||and-28/VB||cochrane-35/VB	dobj||and-28/VB||reviews-36/NNS	det||restriction-40/NN||any-38/DT	nn||restriction-40/NN||language-39/NN	prep_without||and-28/VB||restriction-40/NN	postpartumhaemorrhage-30||ergonovine-17||yes||we searched medline and pubmed terms (labour stage, third) and (ergonovine, ergonovine tartrate, methylergonovine, oxytocin, oxytocics or misoprostol) and (postpartumhaemorrhage or haemorrhage) and cochrane reviews without any language restriction.
root||ROOT-0/null||study-1/VB	det||effects-3/NNS||the-2/DT	dobj||study-1/VB||effects-3/NNS	iobj||study-1/VB||effects-3/NNS	prep_of||effects-3/NNS||exenatide-5/NN	appos||exenatide-5/NN||exe-7/NN	amod||effects-3/NNS||plus-9/IN	amod||rosi-12/NNS||rosiglitazone-10/JJ	dep||effects-3/NNS||rosi-12/NNS	nn||²-16/NNS||î-15/NN	prep_on||rosi-12/NNS||²-16/NNS	nn||function-19/NN||cell-18/NN	dep||rosi-12/NNS||function-19/NN	nn||sensitivity-22/NN||insulin-21/NN	dep||rosi-12/NNS||sensitivity-22/NN	conj_and||function-19/NN||sensitivity-22/NN	vmod||function-19/NN||using-23/VBG	amod||techniques-29/NNS||hyperglycemic-24/JJ	conj_and||hyperglycemic-24/JJ||euglycemic-26/JJ	amod||techniques-29/NNS||euglycemic-26/JJ	nn||techniques-29/NNS||insulin-27/NN	nn||techniques-29/NNS||clamp-28/NN	dobj||using-23/VBG||techniques-29/NNS	prep_in||techniques-29/NNS||participants-31/NNS	prep_with||participants-31/NNS||type2diabetes-33/NNS	prep_on||type2diabetes-33/NNS||metformin-35/NN	insulin-27||type2diabetes-33||no_rel||study the effects of exenatide (exe) plus rosiglitazone (rosi) on î²-cell function and insulin sensitivity using hyperglycemic and euglycemic insulin clamp techniques in participants with type2diabetes on metformin.
det||plague-2/NN||the-1/DT	nsubj||disease-6/NN||plague-2/NN	cop||disease-6/NN||is-3/VBZ	det||disease-6/NN||a-4/DT	amod||disease-6/NN||zoonotic-5/JJ	root||ROOT-0/null||disease-6/NN	vmod||disease-6/NN||caused-7/VBN	det||yersiniapestis-11/NNS||the-9/DT	nn||yersiniapestis-11/NNS||bacterium-10/NN	agent||caused-7/VBN||yersiniapestis-11/NNS	plague-2||yersiniapestis-11||no||the plague is a zoonotic disease caused by the bacterium yersiniapestis .
det||female-3/NN||a-1/DT	amod||female-3/NN||72-year-old-2/JJ	nsubj||treated-11/VBN||female-3/NN	det||male-7/NN||a-5/DT	amod||male-7/NN||57-year-old-6/JJ	conj_and||female-3/NN||male-7/NN	nsubj||treated-11/VBN||male-7/NN	prep_with||male-7/NN||chronichepatitisc-9/NN	aux||treated-11/VBN||were-10/VBD	root||ROOT-0/null||treated-11/VBN	det||therapy-15/NN||a-13/DT	nn||therapy-15/NN||combination-14/NN	prep_with||treated-11/VBN||therapy-15/NN	amod||-rrb--21/NNS||pegylated-17/JJ	nn||-rrb--21/NNS||interferon-18/NN	nn||-rrb--21/NNS||-lrb--19/NN	amod||-rrb--21/NNS||peg-ifn-20/JJ	prep_of||therapy-15/NN||-rrb--21/NNS	dep||treated-11/VBN||î-23/VBN	amod||s.c.-31/NN||±-24/JJ	amod||s.c.-31/NN||2a-25/JJ	number||180-27/CD||-lrb--26/CD	num||s.c.-31/NN||180-27/CD	nn||s.c.-31/NN||î-28/NN	num||s.c.-31/NN||1/4-29/CD	nn||s.c.-31/NN||g-30/NN	dobj||î-23/VBN||s.c.-31/NN	advmod||week-34/NN||once-32/RB	det||week-34/NN||a-33/DT	tmod||î-23/VBN||week-34/NN	nn||-rrb--43/NNS||-rrb--35/NNP	conj_and||-rrb--35/NNP||ribavirin-37/NNP	nn||-rrb--43/NNS||ribavirin-37/NNP	nn||-rrb--43/NNS||-lrb--38/NNP	num||-rrb--43/NNS||1,000-39/CD	amod||-rrb--43/NNS||mg-40/JJ	nn||-rrb--43/NNS||orally-41/NN	amod||-rrb--43/NNS||daily-42/JJ	dobj||treated-11/VBN||-rrb--43/NNS	chronichepatitisc-9||interferon-18||yes||a 72-year-old female and a 57-year-old male with chronichepatitisc were treated with a combination therapy of pegylated interferon -lrb- peg-ifn -rrb- - î ± 2a -lrb- 180 î 1/4 g s.c. once a week -rrb- and ribavirin -lrb- 1,000 mg orally daily -rrb- .
poss||findings-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||findings-2/NNS	nsubj||improve-18/VB||findings-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||used-9/VBN||that-4/IN	amod||signatures-6/NNS||molecular-5/JJ	nsubjpass||used-9/VBN||signatures-6/NNS	nsubj||characterize-11/VB||signatures-6/NNS	aux||used-9/VBN||can-7/MD	auxpass||used-9/VBN||be-8/VB	ccomp||suggest-3/VBP||used-9/VBN	aux||characterize-11/VB||to-10/TO	xcomp||used-9/VBN||characterize-11/VB	amod||responses-13/NNS||immune-12/JJ	dobj||characterize-11/VB||responses-13/NNS	prep_to||characterize-11/VB||viruses-15/NNS	aux||improve-18/VB||may-17/MD	conj_and||suggest-3/VBP||improve-18/VB	poss||understanding-20/NN||our-19/PRP$	dobj||improve-18/VB||understanding-20/NN	prep_of||understanding-20/NN||susceptibility-22/NN	aux||viralinfection-24/VB||to-23/TO	vmod||improve-18/VB||viralinfection-24/VB	amod||implications-27/NNS||possible-26/JJ	prep_with||viralinfection-24/VB||implications-27/NNS	nn||development-30/NN||vaccine-29/NN	prep_for||implications-27/NNS||development-30/NN	viralinfection-24||viruses-15||no||our findings suggest that molecular signatures can be used to characterize immune responses to viruses and may improve our understanding of susceptibility to viralinfection with possible implications for vaccine development.
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubj||reduces-11/VBZ||treatment-3/NN	prep_in||treatment-3/NN||infants-5/NNS	prep_with||infants-5/NNS||sulphadoxine-pyrimethamine-7/NN	appos||treatment-3/NN||ipti-sp-9/NN	root||ROOT-0/null||reduces-11/VBZ	nn||morbidity-13/NN||malaria-12/NN	dobj||reduces-11/VBZ||morbidity-13/NN	number||%-19/NN||20-15/CD	dep||%-19/NN||%-16/NN	dep||%-19/NN||to-17/TO	number||%-19/NN||33-18/CD	prep_by||reduces-11/VBZ||%-19/NN	malaria-12||pyrimethamine--1||yes||intermittent preventive treatment in infants with sulphadoxine-pyrimethamine (ipti-sp) reduces malaria morbidity by 20% to 33%.
det||contrary-3/NN||the-2/DT	prep_on||tgf-î-40/VBZ||contrary-3/NN	amod||injections-7/NNS||triple-5/JJ	nn||injections-7/NNS||i.p.-6/NN	nsubj||tgf-î-40/VBZ||injections-7/NNS	num||hours-10/NNS||24-9/CD	npadvmod||apart-11/RB||hours-10/NNS	advmod||injections-7/NNS||apart-11/RB	num||î-15/NN||10-14/CD	prep_of||injections-7/NNS||î-15/NN	num||ejhe-18/NN||1/4-16/CD	nn||ejhe-18/NN||g-17/NN	nsubj||increased-19/VBD||ejhe-18/NN	rcmod||î-15/NN||increased-19/VBD	advmod||ifn-î-21/JJ||significantly-20/RB	amod||production-23/NN||ifn-î-21/JJ	amod||production-23/NN||³-22/JJ	dobj||increased-19/VBD||production-23/NN	det||p-28/NN||the-25/DT	amod||p-28/NN||spleen-26/JJ	amod||p-28/NN||-lrb--27/JJ	prep_in||increased-19/VBD||p-28/NN	vmod||p-28/NN||<-29/VBG	num||-rrb--31/NNS||0.02-30/CD	dobj||<-29/VBG||-rrb--31/NNS	mark||increased-35/VBD||while-32/IN	advmod||ejhe-wr-34/NN||only-33/RB	nsubj||increased-35/VBD||ejhe-wr-34/NN	advcl||<-29/VBG||increased-35/VBD	advmod||ifn-î-37/JJ||significantly-36/RB	amod||³-38/NNS||ifn-î-37/JJ	dobj||increased-35/VBD||³-38/NNS	root||ROOT-0/null||tgf-î-40/VBZ	number||1-42/CD||²-41/CD	dobj||tgf-î-40/VBZ||1-42/CD	amod||<-47/NNS||il-17-44/JJ	amod||<-47/NNS||-lrb--45/JJ	nn||<-47/NNS||p-46/NN	dobj||tgf-î-40/VBZ||<-47/NNS	conj_and||1-42/CD||<-47/NNS	dep||<-47/NNS||0.03-48/CD	num||production-52/NN||0.005-50/CD	amod||production-52/NN||-rrb--51/JJ	dep||<-47/NNS||production-52/NN	det||microenvironment-56/NN||the-54/DT	nn||microenvironment-56/NN||tumor-55/NN	prep_within||production-52/NN||microenvironment-56/NN	amod||fibrosarcoma-59/NN||meth-a-58/JJ	prep_of||microenvironment-56/NN||fibrosarcoma-59/NN	ifn--1||fibrosarcoma-59||no_rel||on the contrary , triple i.p. injections , 24 hours apart ; of 10 î 1/4 g ejhe increased significantly ifn-î ³ production in the spleen -lrb- p < 0.02 -rrb- while only ejhe-wr increased significantly ifn-î ³ , tgf-î ² 1 and il-17 -lrb- p < 0.03 - 0.005 -rrb- production within the tumor microenvironment of meth-a fibrosarcoma .
nsubj||product-6/NN||c-peptide-1/NN	cop||product-6/NN||is-2/VBZ	det||product-6/NN||a-3/DT	amod||product-6/NN||proinsulin-4/JJ	nn||product-6/NN||cleavage-5/NN	root||ROOT-0/null||product-6/NN	vmod||product-6/NN||released-7/VBN	det||pancreas-10/NN||the-9/DT	prep_from||released-7/VBN||pancreas-10/NN	nn||equimolar-13/NN||amounts-12/NNS	prep_in||pancreas-10/NN||equimolar-13/NN	prep_to||released-7/VBN||insulin-15/NN	amod||levels-19/NNS||elevated-18/JJ	nsubjpass||found-24/VBN||levels-19/NNS	prep_of||levels-19/NNS||c-peptide-21/NN	aux||found-24/VBN||have-22/VBP	auxpass||found-24/VBN||been-23/VBN	conj_and||product-6/NN||found-24/VBN	prep_in||found-24/VBN||patients-26/NNS	amod||type2diabetesmellitus-31/NNS||insulinresistance-28/JJ	conj_and||insulinresistance-28/JJ||early-30/JJ	amod||type2diabetesmellitus-31/NNS||early-30/JJ	prep_with||patients-26/NNS||type2diabetesmellitus-31/NNS	type2diabetesmellitus-31||insulin-15||yes||c-peptide is a proinsulin cleavage product released from the pancreas in amounts equimolar to insulin, and elevated levels of c-peptide have been found in patients with insulinresistance and early type2diabetesmellitus.
prep_since||administered-14/VBN||1986-2/CD	nsubjpass||administered-14/VBN||interferon-alfa-4/NN	dep||interferon-alfa-4/NN||ifn-6/NN	nn||±-9/NNS||î-8/NN	dep||ifn-6/NN||±-9/NNS	advmod||administered-14/VBN||monotherapy-11/RB	aux||administered-14/VBN||has-12/VBZ	auxpass||administered-14/VBN||been-13/VBN	root||ROOT-0/null||administered-14/VBN	prep_for||administered-14/VBN||patients-16/NNS	prep_with||patients-16/NNS||chronichepatitisc-18/NN	appos||chronichepatitisc-18/NN||chc-20/NN	chronichepatitisc-18||ifn-6||yes||since 1986, interferon-alfa (ifn- î± ) monotherapy has been administered for patients with chronichepatitisc (chc).
vmod||experience-12/VBP||living-1/VBG	det||depth-4/NN||a-3/DT	prep_at||living-1/VBG||depth-4/NN	quantmod||2500-7/CD||approximately-6/RB	num||meters-8/NNS||2500-7/CD	prep_of||depth-4/NN||meters-8/NNS	det||worms-11/NNS||these-10/DT	nsubj||experience-12/VBP||worms-11/NNS	root||ROOT-0/null||experience-12/VBP	amod||conditions-15/NNS||extreme-13/JJ	amod||conditions-15/NNS||environmental-14/JJ	dobj||experience-12/VBP||conditions-15/NNS	amod||temperature-19/NN||high-18/JJ	prep_including||conditions-15/NNS||temperature-19/NN	prep_including||conditions-15/NNS||pressure-21/NN	conj_and||temperature-19/NN||pressure-21/NN	amod||levels-26/NNS||high-25/JJ	dobj||experience-12/VBP||levels-26/NNS	conj_and||conditions-15/NNS||levels-26/NNS	prep_of||levels-26/NNS||sulfide-28/NN	prep_of||levels-26/NNS||heavymetals-30/NNS	conj_and||sulfide-28/NN||heavymetals-30/NNS	sulfide-28||worms-11||no_rel||living at a depth of approximately 2500 meters, these worms experience extreme environmental conditions, including high temperature and pressure as well as high levels of sulfide and heavymetals.
amod||approaches-4/NNS||current-1/JJ	amod||approaches-4/NNS||conventional-2/JJ	nn||approaches-4/NNS||vaccination-3/NN	nsubj||induce-7/VB||approaches-4/NNS	aux||induce-7/VB||do-5/VBP	neg||induce-7/VB||not-6/RB	root||ROOT-0/null||induce-7/VB	amod||responses-11/NNS||potent-8/JJ	amod||responses-11/NNS||cd8-9/JJ	amod||responses-11/NNS||t-cell-10/JJ	dobj||induce-7/VB||responses-11/NNS	prepc_for||induce-7/VB||fighting-13/VBG	advmod||viraldiseases-16/NNS||mostly-14/RB	amod||viraldiseases-16/NNS||variable-15/JJ	dobj||fighting-13/VBG||viraldiseases-16/NNS	prep_such_as||viraldiseases-16/NNS||influenza-19/NN	prep_such_as||viraldiseases-16/NNS||avianinfluenzaviruses-21/NNS	conj_or||influenza-19/NN||avianinfluenzaviruses-21/NNS	prep_such_as||viraldiseases-16/NNS||hiv-23/NN	conj_or||influenza-19/NN||hiv-23/NN	influenza-19||avian--1||no||current conventional vaccination approaches do not induce potent cd8 t-cell responses for fighting mostly variable viraldiseases such as influenza, avianinfluenzaviruses or hiv.
amod||reports-2/NNS||several-1/JJ	nsubj||indicate-3/VBP||reports-2/NNS	root||ROOT-0/null||indicate-3/VBP	mark||affects-7/VBZ||that-4/IN	nsubj||affects-7/VBZ||retinoicacid-5/NN	nsubj||alleviates-13/VBZ||retinoicacid-5/NN	advmod||affects-7/VBZ||positively-6/RB	advcl||indicate-3/VBP||affects-7/VBZ	det||progression-9/NN||the-8/DT	dobj||affects-7/VBZ||progression-9/NN	prep_of||progression-9/NN||fibrosis-11/NN	advcl||indicate-3/VBP||alleviates-13/VBZ	conj_and||affects-7/VBZ||alleviates-13/VBZ	det||accumulation-15/NN||the-14/DT	dobj||alleviates-13/VBZ||accumulation-15/NN	det||matrix-19/NN||the-17/DT	nn||matrix-19/NN||extracellular-18/NN	prep_of||accumulation-15/NN||matrix-19/NN	mark||report-24/VBP||whereas-21/IN	amod||studies-23/NNS||other-22/JJ	nsubj||report-24/VBP||studies-23/NNS	dep||affects-7/VBZ||report-24/VBP	det||opposite-26/NN||the-25/DT	dobj||report-24/VBP||opposite-26/NN	mark||exacerbates-30/VBZ||that-28/IN	nsubj||exacerbates-30/VBZ||retinoicacid-29/NN	nsubj||induces-33/VBZ||retinoicacid-29/NN	dep||affects-7/VBZ||exacerbates-30/VBZ	dobj||exacerbates-30/VBZ||fibrosis-31/NN	dep||affects-7/VBZ||induces-33/VBZ	conj_and||exacerbates-30/VBZ||induces-33/VBZ	nn||accumulation-36/NN||extracellular-34/NN	nn||accumulation-36/NN||matrix-35/NN	dobj||induces-33/VBZ||accumulation-36/NN	fibrosis-31||retinoicacid-29||no_rel||several reports indicate that retinoicacid positively affects the progression of fibrosis and alleviates the accumulation of the extracellular matrix, whereas other studies report the opposite; that retinoicacid exacerbates fibrosis and induces extracellular matrix accumulation.
nn||scores-2/NNS||nausea-1/NN	nsubj||severe-12/JJ||scores-2/NNS	nsubj||similar-14/JJ||scores-2/NNS	prep_at||scores-2/NNS||baseline-4/NN	conj_and||scores-2/NNS||0â-6/NNS	nsubj||severe-12/JJ||0â-6/NNS	num||minutes-10/NNS||$-7/$	num||$-7/$||30-9/CD	dep||0â-6/NNS||minutes-10/NNS	cop||severe-12/JJ||were-11/VBD	root||ROOT-0/null||severe-12/JJ	conj_and||severe-12/JJ||similar-14/JJ	prep_between||severe-12/JJ||groups-16/NNS	advmod||had-35/VBD||however-18/RB	amod||$-22/$||31â-21/JJ	prep_at||had-35/VBD||$-22/$	num||$-22/$||60-24/CD	conj_and||$-22/$||61â-26/NNS	prep_at||had-35/VBD||61â-26/NNS	num||minutes-30/NNS||$-27/$	num||$-27/$||120-29/CD	dep||61â-26/NNS||minutes-30/NNS	nsubj||had-35/VBD||patients-32/NNS	vmod||patients-32/NNS||receiving-33/VBG	dobj||receiving-33/VBG||prochlorperazine-34/NN	parataxis||severe-12/JJ||had-35/VBD	amod||control-37/NN||better-36/JJR	dobj||had-35/VBD||control-37/NN	nn||=-47/FW||nausea-39/FW	nn||=-47/FW||-lrb--40/FW	nn||=-47/FW||24.9-41/FW	nn||=-47/FW||vs.-42/FW	nn||=-47/FW||43.7-43/FW	nn||=-47/FW||mm-44/FW	dep||=-47/FW||p-46/FW	prep_of||control-37/NN||=-47/FW	dep||=-47/FW||0.03-48/CD	nn||=-56/FW||16.8-50/FW	nn||=-56/FW||vs.-51/FW	nn||=-56/FW||34.3-52/FW	nn||=-56/FW||mm-53/FW	dep||=-56/FW||p-55/FW	dep||=-47/FW||=-56/FW	num||-rrb--58/NNS||0.05-57/CD	dep||=-56/FW||-rrb--58/NNS	nausea-39||prochlorperazine-34||yes||nausea scores at baseline and 0â $ `` 30 minutes were severe and similar between groups ; however , at 31â $ `` 60 and 61â $ `` 120 minutes , patients receiving prochlorperazine had better control of nausea -lrb- 24.9 vs. 43.7 mm , p = 0.03 ; 16.8 vs. 34.3 mm , p = 0.05 -rrb- .
prepc_based_on||used-14/VBN||on-2/IN	det||study-4/NN||this-3/DT	pobj||used-14/VBN||study-4/NN	nsubjpass||used-14/VBN||ceftriaxone-6/NN	conj_and||ceftriaxone-6/NN||cefixime-8/NN	nsubjpass||used-14/VBN||cefixime-8/NN	conj_and||ceftriaxone-6/NN||spectinomycin-11/NN	nsubjpass||used-14/VBN||spectinomycin-11/NN	aux||used-14/VBN||can-12/MD	auxpass||used-14/VBN||be-13/VB	root||ROOT-0/null||used-14/VBN	det||therapy-19/NN||an-16/DT	amod||therapy-19/NN||empirical-17/JJ	amod||therapy-19/NN||first-line-18/JJ	prep_as||used-14/VBN||therapy-19/NN	prep_for||therapy-19/NN||gonorrhoea-21/NN	nn||pakistan-25/NN||india-23/NN	prep_in||used-14/VBN||pakistan-25/NN	prep_in||used-14/VBN||bhutan-28/NN	conj_and||pakistan-25/NN||bhutan-28/NN	mark||be-43/VB||whereas-30/IN	nsubj||be-43/VB||ciprofloxacin-31/NN	appos||ciprofloxacin-31/NN||penicilling-33/NN	appos||ciprofloxacin-31/NN||tetracycline-35/NN	conj_and||penicilling-33/NN||tetracycline-35/NN	appos||ciprofloxacin-31/NN||erythromycin-37/NN	conj_and||penicilling-33/NN||erythromycin-37/NN	appos||ciprofloxacin-31/NN||azithromycin-40/NN	conj_and||penicilling-33/NN||azithromycin-40/NN	aux||be-43/VB||should-41/MD	neg||be-43/VB||not-42/RB	rcmod||pakistan-25/NN||be-43/VB	gonorrhoea-21||azithromycin-40||no_rel||based on this study, ceftriaxone, cefixime, and spectinomycin can be used as an empirical first-line therapy for gonorrhoea in india, pakistan, and bhutan, whereas ciprofloxacin, penicilling, tetracycline, erythromycin, and azithromycin should not be.
nsubj||increases-2/VBZ||this-1/DT	root||ROOT-0/null||increases-2/VBZ	xcomp||increases-2/VBZ||circulating-3/VBG	dobj||circulating-3/VBG||levels-4/NNS	amod||secretion-11/NN||active-6/JJ	amod||stimulates-9/JJ||glp-1-7/JJ	amod||secretion-11/NN||stimulates-9/JJ	nn||secretion-11/NN||insulin-10/NN	prep_of||levels-4/NNS||secretion-11/NN	nsubj||results-18/VBZ||secretion-11/NN	amod||secretion-15/NN||inhibits-13/JJ	nn||secretion-15/NN||glucagon-14/NN	prep_of||levels-4/NNS||secretion-15/NN	conj_and||secretion-11/NN||secretion-15/NN	nsubj||results-18/VBZ||secretion-15/NN	rcmod||secretion-11/NN||results-18/VBZ	prepc_in||results-18/VBZ||lowering-20/VBG	nn||levels-23/NNS||glucose-22/NN	prep_of||lowering-20/VBG||levels-23/NNS	prep_of||lowering-20/VBG||improvement-25/NN	conj_and||levels-23/NNS||improvement-25/NN	det||control-29/NN||the-27/DT	amod||control-29/NN||glycemic-28/JJ	prep_of||levels-23/NNS||control-29/NN	prep_in||control-29/NN||patients-31/NNS	prep_with||patients-31/NNS||type2diabetes-33/CD	type2diabetes-33||insulin-10||yes||this increases circulating levels of active glp-1, stimulates insulin secretion and inhibits glucagon secretion, which results in lowering of glucose levels and improvement of the glycemic control in patients with type2diabetes.
det||rate-3/NN||the-1/DT	amod||rate-3/NN||relapse-2/JJ	nsubj||observed-4/VBD||rate-3/NN	root||ROOT-0/null||observed-4/VBD	num||months-7/NNS||12-6/CD	prep_after||observed-4/VBD||months-7/NNS	dobj||observed-4/VBD||treatment-8/NN	prep_with||treatment-8/NN||the-10/DT	nsubj||recommended-12/VBD||the-10/DT	rcmod||the-10/DT||recommended-12/VBD	nn||regimen-15/NN||mdr-13/NN	nn||regimen-15/NN||tb-14/NN	nsubj||equivalent-26/JJ||regimen-15/NN	dep||regimen-15/NN||amikacin-17/NN	appos||amikacin-17/NN||ethionamide-19/NN	appos||amikacin-17/NN||pyrazinamide-21/NN	conj_and||ethionamide-19/NN||pyrazinamide-21/NN	appos||amikacin-17/NN||moxifloxacin-23/NN	conj_and||ethionamide-19/NN||moxifloxacin-23/NN	cop||equivalent-26/JJ||was-25/VBD	ccomp||recommended-12/VBD||equivalent-26/JJ	det||treatment-35/NN||the-28/DT	dep||rate-30/NN||relapse-29/JJ	amod||treatment-35/NN||rate-30/NN	amod||treatment-35/NN||observed-31/JJ	num||months-34/NNS||6-33/CD	prep_after||observed-31/JJ||months-34/NNS	prep_to||equivalent-26/JJ||treatment-35/NN	det||regimen-42/NN||the-37/DT	amod||regimen-42/NN||recommended-38/VBN	nn||regimen-42/NN||drug-39/NN	amod||regimen-42/NN||susceptible-40/VBG	nn||regimen-42/NN||tb-41/NN	prep_with||treatment-35/NN||regimen-42/NN	dep||treatment-35/NN||rifampin-44/NN	dep||rifampin-44/NN||isoniazid-46/JJ	dep||rifampin-44/NN||pyrazinamide-48/JJ	conj_and||isoniazid-46/JJ||pyrazinamide-48/JJ	tb-41||ethionamide-19||yes||the relapse rate observed after 12 months treatment with the who recommended mdr tb regimen (amikacin, ethionamide, pyrazinamide and moxifloxacin) was equivalent to the relapse rate observed after 6 months treatment with the recommended drug susceptible tb regimen (rifampin, isoniazid and pyrazinamide).
det||summarizes-3/NNS||this-1/DT	nn||summarizes-3/NNS||protocol-2/NN	root||ROOT-0/null||summarizes-3/NNS	det||rationale-5/NN||the-4/DT	dep||summarizes-3/NNS||rationale-5/NN	dep||summarizes-3/NNS||design-7/NN	conj_and||rationale-5/NN||design-7/NN	det||ii-11/NN||a-9/DT	nn||ii-11/NN||phase-10/NN	prep_of||rationale-5/NN||ii-11/NN	amod||blinded-14/JJ||randomized-12/JJ	amod||summarizes-3/NNS||blinded-14/JJ	amod||trial-17/NN||placebo-controlled-16/JJ	appos||summarizes-3/NNS||trial-17/NN	det||infusion-22/NN||a-19/DT	amod||infusion-22/NN||low-dose-20/JJ	amod||infusion-22/NN||continuous-21/JJ	prep_of||trial-17/NN||infusion-22/NN	prep_of||infusion-22/NN||furosemide-24/NN	vmod||summarizes-3/NNS||titrated-26/VBN	det||parameter-30/NN||the-28/DT	amod||parameter-30/NN||physiology-29/JJ	prep_to||titrated-26/VBN||parameter-30/NN	nn||output-33/NN||urine-32/NN	prep_of||parameter-30/NN||output-33/NN	advmod||ill-37/JJ||critically-36/RB	amod||patients-38/NNS||ill-37/JJ	prep_in||summarizes-3/NNS||patients-38/NNS	amod||aki-41/NN||early-40/JJ	prep_with||patients-38/NNS||aki-41/NN	aki-41||furosemide-24||yes||this protocol summarizes the rationale and design of a phase ii randomized, blinded, placebo-controlled trial of a low-dose continuous infusion of furosemide, titrated to the physiology parameter of urine output, in critically ill patients with early aki.
amod||dissemination-3/NN||postoperatively-1/JJ	nn||dissemination-3/NN||tumor-2/NN	nsubjpass||controlled-5/VBN||dissemination-3/NN	auxpass||controlled-5/VBN||was-4/VBD	root||ROOT-0/null||controlled-5/VBN	amod||chemotherapy-8/NN||adjuvant-7/JJ	prep_with||controlled-5/VBN||chemotherapy-8/NN	tumor-2||adjuvant-7||no_rel||postoperatively tumor dissemination was controlled with adjuvant chemotherapy.
nn||analysis-2/NN||meta-1/NN	nsubj||showed-3/VBD||analysis-2/NN	root||ROOT-0/null||showed-3/VBD	mark||higher-59/JJR||that-4/IN	det||rate-6/NN||the-5/DT	nsubj||higher-59/JJR||rate-6/NN	amod||dna-11/NN||undetected-8/JJ	nn||dna-11/NN||serum-9/NN	nn||dna-11/NN||hbv-10/NN	prep_of||rate-6/NN||dna-11/NN	amod||risk-14/NN||relative-13/JJ	dep||dna-11/NN||risk-14/NN	amod||risk-14/NN||1.73-16/CD	number||%-19/NN||95-18/CD	amod||interval-21/NN||%-19/NN	nn||interval-21/NN||confidence-20/NN	dep||risk-14/NN||interval-21/NN	num||.17-24/CD||1.38-2-23/CD	dep||risk-14/NN||.17-24/CD	conj_and||interval-21/NN||.17-24/CD	dep||0.00001-28/CD||p-26/RB	number||0.00001-28/CD||<-27/CD	dep||.17-24/CD||0.00001-28/CD	dep||risk-14/NN||that-31/DT	conj_and||interval-21/NN||that-31/DT	nn||normalization-35/NN||serum-33/NN	nn||normalization-35/NN||alt-34/NN	prep_of||that-31/DT||normalization-35/NN	amod||risk-38/NN||relative-37/JJ	dep||normalization-35/NN||risk-38/NN	dep||risk-38/NN||1.25-40/CD	number||%-43/NN||95-42/CD	amod||interval-45/NN||%-43/NN	nn||interval-45/NN||confidence-44/NN	dep||risk-14/NN||interval-45/NN	num||.49-48/CD||1.06-1-47/CD	appos||interval-45/NN||.49-48/CD	dep||risk-14/NN||p-50/NN	dep||0.009-52/CD||=-51/SYM	rcmod||p-50/NN||0.009-52/CD	det||group-57/NN||the-55/DT	nn||group-57/NN||entecavir-56/NN	prep_in||dna-11/NN||group-57/NN	cop||higher-59/JJR||were-58/VBD	ccomp||showed-3/VBD||higher-59/JJR	prep_than||higher-59/JJR||those-61/DT	det||group-65/NN||the-63/DT	nn||group-65/NN||adefovir-64/NN	prep_in||those-61/DT||group-65/NN	hbv-10||adefovir-64||yes||meta analysis showed that the rate of undetected serum hbv dna (relative risk, 1.73; 95% confidence interval, 1.38-2.17; p < 0.00001) and that of serum alt normalization (relative risk, 1.25; 95% confidence interval, 1.06-1.49; p = 0.009) in the entecavir group were higher than those in the adefovir group.
nsubj||occurs-18/VBZ||infection-1/NN	nsubj||occurs-18/VBZ||infection-1/NN	amod||titers-4/NNS||high-3/JJ	prep_with||infection-1/NN||titers-4/NNS	prep_of||titers-4/NNS||ebv-6/NN	amod||cells-12/NNS||mixed-8/JJ	amod||cells-12/NNS||primary-10/JJ	amod||cells-12/NNS||b-11/JJ	prep_of||ebv-6/NN||cells-12/NNS	amod||stages-15/NNS||different-14/JJ	prep_in||cells-12/NNS||stages-15/NNS	prep_of||stages-15/NNS||differentiation-17/NN	root||ROOT-0/null||occurs-18/VBZ	conj_and||occurs-18/VBZ||occurs-18/VBZ	amod||ebvinfection-21/NN||primary-20/JJ	prep_during||occurs-18/VBZ||ebvinfection-21/NN	det||setting-25/NN||the-24/DT	prep_in||occurs-18/VBZ||setting-25/NN	nsubj||predisposes-30/VBZ||setting-25/NN	nn||cell-immunocompromise-28/NN||t-27/NN	prep_of||setting-25/NN||cell-immunocompromise-28/NN	rcmod||setting-25/NN||predisposes-30/VBZ	prep_to||predisposes-30/VBZ||development-32/NN	amod||diseases-35/NNS||ebv-lymphoproliferative-34/JJ	prep_of||development-32/NN||diseases-35/NNS	ebvinfection-21||ebv-6||no||infection with high titers of ebv of mixed, primary b cells in different stages of differentiation occurs during primary ebvinfection and in the setting of t cell-immunocompromise that predisposes to development of ebv-lymphoproliferative diseases.
aux||evaluate-2/VB||to-1/TO	root||ROOT-0/null||evaluate-2/VB	det||doseâ-4/NN||the-3/DT	dobj||evaluate-2/VB||doseâ-4/NN	dep||doseâ-4/NN||$-5/$	advmod||of-9/IN||response-7/RB	npadvmod||of-9/IN||relationship-8/NN	dep||lixisenatide-10/CD||of-9/IN	num||$-5/$||lixisenatide-10/CD	appos||$-5/$||ave0010-12/NNP	det||agonist-22/NN||a-15/DT	amod||agonist-22/NN||glucagon-like-16/JJ	amod||agonist-22/NN||peptide-1-17/JJ	dep||agonist-22/NN||glp-1-19/JJ	nn||agonist-22/NN||receptor-21/NN	appos||doseâ-4/NN||agonist-22/NN	amod||patients-26/NNS||metformin-treated-25/JJ	prep_in||evaluate-2/VB||patients-26/NNS	prep_with||evaluate-2/VB||type2diabetes-28/CD	type2diabetes-28||metformin--1||yes||to evaluate the doseâresponse relationship of lixisenatide (ave0010), a glucagon-like peptide-1 (glp-1) receptor agonist, in metformin-treated patients with type2diabetes.
nsubj||drug-8/NN||ablc-1/NN	cop||drug-8/NN||is-2/VBZ	det||drug-8/NN||a-3/DT	amod||drug-8/NN||safe-4/JJ	conj_and||safe-4/JJ||effective-6/JJ	amod||drug-8/NN||effective-6/JJ	amod||drug-8/NN||broad-spectrum-7/JJ	root||ROOT-0/null||drug-8/NN	det||treatment-11/NN||the-10/DT	prep_in||drug-8/NN||treatment-11/NN	amod||fungalinfections-14/NNS||invasive-13/JJ	prep_of||treatment-11/NN||fungalinfections-14/NNS	prep_in||fungalinfections-14/NNS||patients-16/NNS	nn||refractory-19/NNS||infection-18/NN	prep_with||patients-16/NNS||refractory-19/NNS	prep_with||patients-16/NNS||refractory-19/NNS	conj_or||refractory-19/NNS||refractory-19/NNS	nn||deoxycholate-22/NN||amb-21/NN	prep_to||refractory-19/NNS||deoxycholate-22/NN	nn||intolerant-26/NN||patients-25/NNS	prep_in||refractory-19/NNS||intolerant-26/NN	det||formulation-30/NN||the-28/DT	amod||formulation-30/NN||same-29/JJ	prep_of||intolerant-26/NN||formulation-30/NN	fungalinfections-14||amb-21||yes||ablc is a safe and effective broad-spectrum drug in the treatment of invasive fungalinfections in patients with infection refractory to amb deoxycholate or in patients intolerant of the same formulation.
nsubj||propose-2/VBP||we-1/PRP	root||ROOT-0/null||propose-2/VBP	det||model-5/NN||a-3/DT	nn||model-5/NN||threshold-4/NN	dobj||propose-2/VBP||model-5/NN	det||development-8/NN||the-7/DT	prep_for||model-5/NN||development-8/NN	prep_of||development-8/NN||celiacdisease-10/NN	prep_in||determines-24/VBZ||celiacdisease-10/NN	det||efficiency-15/NN||the-14/DT	nsubj||determines-24/VBZ||efficiency-15/NN	nn||presentation-18/NN||gluten-17/NN	prep_of||efficiency-15/NN||presentation-18/NN	amod||cells-23/NNS||cd4-20/JJ	amod||cells-23/NNS||+-21/JJ	nn||cells-23/NNS||t-22/NN	prep_to||presentation-18/NN||cells-23/NNS	rcmod||celiacdisease-10/NN||determines-24/VBZ	det||likelihood-26/NN||the-25/DT	dobj||determines-24/VBZ||likelihood-26/NN	amod||celiacdisease-29/NN||developing-28/VBG	prep_of||likelihood-26/NN||celiacdisease-29/NN	poss||complications-32/NNS||its-31/PRP$	prep_of||likelihood-26/NN||complications-32/NNS	conj_and||celiacdisease-29/NN||complications-32/NNS	celiacdisease-29||gluten-17||no||we propose a threshold model for the development of celiacdisease, in which the efficiency of gluten presentation to cd4+ t cells determines the likelihood of developing celiacdisease and its complications.
mark||indicated-2/VBD||while-1/IN	advcl||extends-20/VBZ||indicated-2/VBD	prep_for||indicated-2/VBD||schizophrenia-4/NN	amod||mania-7/NN||acute-6/JJ	prep_for||indicated-2/VBD||mania-7/NN	conj_and||schizophrenia-4/NN||mania-7/NN	amod||base-14/NN||ziprasidoneâ-9/JJ	amod||base-14/NN||$-10/$	dep||$-10/$||-11/JJ	nn||base-14/NN||s-12/NN	nn||base-14/NN||evidence-13/NN	nsubj||extends-20/VBZ||base-14/NN	conj_and||base-14/NN||use-16/NN	nsubj||extends-20/VBZ||use-16/NN	amod||practice-19/NN||clinical-18/JJ	prep_in||base-14/NN||practice-19/NN	root||ROOT-0/null||extends-20/VBZ	det||approvals-24/NNS||these-22/DT	amod||approvals-24/NNS||regulatory-23/JJ	prep_beyond||extends-20/VBZ||approvals-24/NNS	ziprasidone--1||schizophrenia-4||no_rel||while indicated for schizophrenia and acute mania, ziprasidoneâs evidence base and use in clinical practice extends beyond these regulatory approvals.
expl||discussion-5/NN||there-1/EX	aux||discussion-5/NN||has-2/VBZ	cop||discussion-5/NN||been-3/VBN	amod||discussion-5/NN||little-4/JJ	root||ROOT-0/null||discussion-5/NN	det||importance-8/NN||the-7/DT	prep_about||discussion-5/NN||importance-8/NN	amod||management-11/NN||oral-10/JJ	prep_of||importance-8/NN||management-11/NN	amod||therapy-17/NN||interferon-13/JJ	appos||therapy-17/NN||ifn-15/NN	prep_about||discussion-5/NN||therapy-17/NN	conj_and||importance-8/NN||therapy-17/NN	mark||documented-31/VBN||although-19/IN	nsubjpass||documented-31/VBN||management-20/NN	det||effects-24/NNS||the-22/DT	nn||effects-24/NNS||side-23/NN	prep_of||management-20/NN||effects-24/NNS	prep_of||effects-24/NNS||therapy-26/NN	prep_for||therapy-26/NN||chronichepatitisc-28/NN	aux||documented-31/VBN||has-29/VBZ	auxpass||documented-31/VBN||been-30/VBN	advcl||discussion-5/NN||documented-31/VBN	chronichepatitisc-28||ifn-15||yes||there has been little discussion about the importance of oral management and interferon (ifn) therapy, although management of the side effects of therapy for chronichepatitisc has been documented.
amod||subjects-2/NNS||adult-1/JJ	nsubj||underwent-5/VBD||subjects-2/NNS	prep_with||subjects-2/NNS||type1diabetes-4/CD	root||ROOT-0/null||underwent-5/VBD	num||study-8/NN||one-6/CD	amod||study-8/NN||closed-loop-7/JJ	dobj||underwent-5/VBD||study-8/NN	prep_with||study-8/NN||insulin-10/NN	dobj||underwent-5/VBD||placebo-12/NN	conj_plus||study-8/NN||placebo-12/NN	num||study-15/NN||one-14/CD	conj_plus||study-8/NN||study-15/NN	conj_and||placebo-12/NN||study-15/NN	prep_with||underwent-5/VBD||insulin-17/NN	prep||insulin-17/NN||plus-18/CC	pobj||plus-18/CC||glucagon-19/NN	prep||underwent-5/VBD||given-21/VBN	pcomp||given-21/VBN||at-22/IN	pobj||at-22/IN||times-23/NNS	amod||hypoglycemia-26/NN||impending-25/JJ	prep_of||times-23/NNS||hypoglycemia-26/NN	type1diabetes-4||insulin-17||yes||adult subjects with type1diabetes underwent one closed-loop study with insulin plus placebo and one study with insulin plus glucagon, given at times of impending hypoglycemia.
prep_in||found-9/VBN||contrast-2/NN	nsubjpass||found-9/VBN||mutations-4/NNS	prep_in||mutations-4/NNS||pfcyt-b-6/NN	auxpass||found-9/VBN||were-7/VBD	neg||found-9/VBN||not-8/RB	root||ROOT-0/null||found-9/VBN	num||patients-12/NNS||three-11/CD	prep_in||found-9/VBN||patients-12/NNS	vmod||patients-12/NNS||treated-13/VBN	prep_with||treated-13/VBN||atovaquone-proguanil-15/NN	nsubj||exhibited-17/VBD||atovaquone-proguanil-15/NN	rcmod||atovaquone-proguanil-15/NN||exhibited-17/VBD	amod||clearance-19/NN||delayed-18/JJ	dobj||exhibited-17/VBD||clearance-19/NN	det||infection-23/NN||the-21/DT	amod||infection-23/NN||primary-22/JJ	prep_of||clearance-19/NN||infection-23/NN	dobj||exhibited-17/VBD||in-26/IN	conj_nor||clearance-19/NN||in-26/IN	pobj||in-26/IN||two-27/CD	xcomp||exhibited-17/VBD||returning-28/VBG	dobj||returning-28/VBG||travellers-29/NNS	prep_with||returning-28/VBG||malaria-31/NN	nsubj||used-34/VBN||malaria-31/NN	aux||used-34/VBN||had-33/VBD	rcmod||malaria-31/NN||used-34/VBN	det||combination-36/NN||the-35/DT	dobj||used-34/VBN||combination-36/NN	prep_for||combination-36/NN||prophylaxis-38/NNS	malaria-31||proguanil--1||yes||in contrast, mutations in pfcyt-b were not found in three patients treated with atovaquone-proguanil who exhibited delayed clearance of the primary infection, nor in two returning travellers with malaria who had used the combination for prophylaxis.
det||intervention-5/NN||the-1/DT	amod||intervention-5/NN||spinal-2/JJ	nn||intervention-5/NN||osteoporosis-3/NN	amod||intervention-5/NN||therapeutic-4/JJ	nsubj||trial-18/NN||intervention-5/NN	appos||intervention-5/NN||soti-7/NNP	cop||trial-18/NN||was-9/VBD	det||trial-18/NN||an-10/DT	amod||trial-18/NN||international-11/JJ	amod||trial-18/NN||double-13/JJ	amod||trial-18/NN||blind-14/JJ	amod||trial-18/NN||placebo-16/JJ	amod||trial-18/NN||controlled-17/JJ	root||ROOT-0/null||trial-18/NN	vmod||trial-18/NN||supporting-20/VBG	det||efficacy-22/NN||the-21/DT	dobj||supporting-20/VBG||efficacy-22/NN	amod||2-25/CD||strontiumranelate-24/JJ	prep_of||efficacy-22/NN||2-25/CD	advmod||supporting-20/VBG||g/day-26/RB	prepc_in||supporting-20/VBG||reducing-28/VBG	det||risk-30/NN||the-29/DT	dobj||reducing-28/VBG||risk-30/NN	amod||fractures-33/NNS||vertebral-32/JJ	prep_of||risk-30/NN||fractures-33/NNS	amod||women-36/NNS||postmenopausal-35/JJ	prep_in||fractures-33/NNS||women-36/NNS	prep_with||reducing-28/VBG||osteoporosis-38/NNS	det||fracture-43/NN||a-40/DT	amod||vertebral-42/JJ||prevalent-41/JJ	amod||fracture-43/NN||vertebral-42/JJ	prep_with||reducing-28/VBG||fracture-43/NN	conj_and||osteoporosis-38/NNS||fracture-43/NN	osteoporosis-38||strontiumranelate-24||no_rel||the spinal osteoporosis therapeutic intervention (soti) was an international, double blind, placebo controlled trial, supporting the efficacy of strontiumranelate 2 g/day in reducing the risk of vertebral fractures in postmenopausal women with osteoporosis and a prevalent vertebral fracture.
nsubj||triple-5/VBZ||a-2/SYM	ccomp||includes-19/VBZ||triple-5/VBZ	dobj||triple-5/VBZ||therapy-6/NN	dobj||triple-5/VBZ||approach-9/NN	aux||address-11/VB||to-10/TO	vmod||approach-9/NN||address-11/VB	dobj||address-11/VB||stigma-12/NN	dobj||address-11/VB||discrimination-14/NN	conj_and||stigma-12/NN||discrimination-14/NN	auxpass||discussed-16/VBN||is-15/VBZ	rcmod||stigma-12/NN||discussed-16/VBN	nsubj||includes-19/VBZ||which-18/WDT	root||ROOT-0/null||includes-19/VBZ	amod||acceptance-21/NN||greater-20/JJR	dobj||includes-19/VBZ||acceptance-21/NN	prep_of||acceptance-21/NN||people-23/NNS	dep||people-23/NNS||living-24/VBG	prep_with||living-24/VBG||hiv-26/NN	prep_with||living-24/VBG||aids-28/NNS	conj_and||hiv-26/NN||aids-28/NNS	appos||hiv-26/NN||plwha-30/NNP	dep||people-23/NNS||improving-33/VBG	conj_and||living-24/VBG||improving-33/VBG	amod||laws-35/NNS||relevant-34/JJ	dobj||improving-33/VBG||laws-35/NNS	dobj||improving-33/VBG||policies-37/NNS	conj_and||laws-35/NNS||policies-37/NNS	dep||people-23/NNS||involving-40/VBG	conj_and||living-24/VBG||involving-40/VBG	nn||users-42/NNS||prevention-41/NN	dobj||involving-40/VBG||users-42/NNS	dep||people-23/NNS||working-44/VBG	dep||people-23/NNS||working-44/VBG	conj_negcc||working-44/VBG||working-44/VBG	prep_with||working-44/VBG||people-46/NNS	prep_for||working-44/VBG||people-50/NNS	aids-28||hiv-26||no||" a ""triple therapy"" approach to address stigma and discrimination is discussed, which includes greater acceptance of people living with hiv and aids (plwha), improving relevant laws and policies, and involving prevention users- working with people rather than for people- ."
advmod||investigated-4/VBD||here-1/RB	nsubj||investigated-4/VBD||we-3/PRP	root||ROOT-0/null||investigated-4/VBD	det||ability-6/NN||the-5/DT	dobj||investigated-4/VBD||ability-6/NN	prep_of||ability-6/NN||quercetin-8/NN	aux||sensitise-10/VB||to-9/TO	vmod||investigated-4/VBD||sensitise-10/VB	vmod||investigated-4/VBD||sensitise-10/VB	conj_and||sensitise-10/VB||sensitise-10/VB	amod||cells-12/NNS||primary-11/JJ	dobj||sensitise-10/VB||cells-12/NNS	amod||leukaemia-16/NN||chronic-14/JJ	amod||leukaemia-16/NN||lymphocytic-15/JJ	prep_from||sensitise-10/VB||leukaemia-16/NN	appos||leukaemia-16/NN||cll-18/NN	nn||agonists-26/NNS||death-21/NN	nn||agonists-26/NNS||receptor-22/NN	nn||agonists-26/NNS||dr-24/NN	prep_to||leukaemia-16/NN||agonists-26/NNS	amod||ligand-30/NN||recombinant-28/JJ	amod||ligand-30/NN||tnf-related-apoptosis-inducing-29/JJ	prep_from||sensitise-10/VB||ligand-30/NN	conj_and||leukaemia-16/NN||ligand-30/NN	dep||ligand-30/NN||rtrail-32/JJ	prep_from||sensitise-10/VB||anti-cd95-35/JJ	conj_and||leukaemia-16/NN||anti-cd95-35/JJ	prep_to||sensitise-10/VB||fludarabine-39/NN	det||drug-45/NN||a-41/DT	advmod||used-43/VBN||widely-42/RB	amod||drug-45/NN||used-43/VBN	amod||drug-45/NN||chemotherapeutic-44/JJ	appos||fludarabine-39/NN||drug-45/NN	prep_against||investigated-4/VBD||cll-47/NN	cll-47||fludarabine-39||yes||here, we investigated the ability of quercetin to sensitise primary cells from chronic lymphocytic leukaemia (cll) to death receptor (dr) agonists, recombinant tnf-related-apoptosis-inducing ligand (rtrail) and anti-cd95, and to fludarabine, a widely used chemotherapeutic drug against cll.
nsubj||measured-2/VBD||we-1/PRP	root||ROOT-0/null||measured-2/VBD	nn||concentrations-5/NNS||plasma-3/NN	nn||concentrations-5/NNS||glucagon-4/NN	dobj||measured-2/VBD||concentrations-5/NNS	prep_in||measured-2/VBD||patients-7/NNS	prep_with||measured-2/VBD||type1diabetes-9/NNS	vmod||type1diabetes-9/NNS||infused-10/VBN	det||glulisine-15/NN||the-12/DT	amod||glulisine-15/NN||zinc-free-13/JJ	nn||glulisine-15/NN||insulin-14/NN	prep_with||infused-10/VBN||glulisine-15/NN	num||occasions-18/NNS||three-17/CD	prep_on||glulisine-15/NN||occasions-18/NNS	type1diabetes-9||glucagon-4||no_rel||we measured plasma glucagon concentrations in patients with type1diabetes infused with the zinc-free insulin glulisine on three occasions.
nn||fixation-2/NN||formaldehyde-1/NN	nsubj||remains-5/VBZ||fixation-2/NN	conj_and||fixation-2/NN||paraffin-embedding-4/NN	nsubj||remains-5/VBZ||paraffin-embedding-4/NN	root||ROOT-0/null||remains-5/VBZ	det||technique-10/NN||the-6/DT	advmod||used-9/VBN||most-7/RBS	advmod||used-9/VBN||widely-8/RB	amod||technique-10/NN||used-9/VBN	xcomp||remains-5/VBZ||technique-10/NN	amod||specimens-15/NNS||processing-12/VBG	nn||specimens-15/NNS||cancer-13/NN	nn||specimens-15/NNS||tissue-14/NN	prep_for||technique-10/NN||specimens-15/NNS	amod||examination-18/NN||pathologic-17/JJ	prep_for||specimens-15/NNS||examination-18/NN	det||study-21/NN||the-20/DT	prep_for||technique-10/NN||study-21/NN	conj_and||specimens-15/NNS||study-21/NN	nn||morphology-24/NN||tissue-23/NN	prep_of||study-21/NN||morphology-24/NN	amod||preservation-28/NN||archival-27/JJ	prep_for||technique-10/NN||preservation-28/NN	conj_and||specimens-15/NNS||preservation-28/NN	cancer-13||paraffin--1||no_rel||formaldehyde fixation and paraffin-embedding remains the most widely used technique for processing cancer tissue specimens for pathologic examination, the study of tissue morphology, and archival preservation.
nsubj||yeast-5/NN||cryptococcusneoformans-1/NNS	cop||yeast-5/NN||is-2/VBZ	det||yeast-5/NN||an-3/DT	amod||yeast-5/NN||encapsulated-4/JJ	root||ROOT-0/null||yeast-5/NN	det||species-11/NN||the-7/DT	advmod||frequent-9/JJ||most-8/RBS	amod||species-11/NN||frequent-9/JJ	amod||species-11/NN||cryptococcal-10/JJ	conj_and||yeast-5/NN||species-11/NN	vmod||species-11/NN||found-12/VBN	prep_in||found-12/VBN||humans-14/NNS	cryptococcusneoformans-1||cryptococcal-10||no||cryptococcusneoformans is an encapsulated yeast and the most frequent cryptococcal species found in humans.
det||man-4/NN||a-1/DT	amod||man-4/NN||42-year-old-2/JJ	nn||man-4/NN||indian-3/NN	nsubj||received-5/VBD||man-4/NN	root||ROOT-0/null||received-5/VBD	num||rifampicin-8/NN||450-6/CD	nn||rifampicin-8/NN||mg-7/NN	dobj||received-5/VBD||rifampicin-8/NN	appos||rifampicin-8/NN||rif-10/NN	num||mg-14/NN||150-13/CD	dobj||received-5/VBD||mg-14/NN	conj_and||rifampicin-8/NN||mg-14/NN	vmod||mg-14/NN||isoniazid-15/VBN	dep||isoniazid-15/VBN||inh-17/NN	advmod||inh-17/NN||daily-19/RB	auxpass||diagnosed-22/VBN||being-21/VBG	prepc_after||received-5/VBD||diagnosed-22/VBN	det||tuberculosisinfection-26/NN||a-24/DT	nn||tuberculosisinfection-26/NN||latent-25/NN	prep_of||diagnosed-22/VBN||tuberculosisinfection-26/NN	tuberculosisinfection-26||inh-17||yes||a 42-year-old indian man received 450 mg rifampicin (rif) and 150 mg isoniazid (inh) daily after being diagnosed of a latent tuberculosisinfection.
amod||factors-3/NNS||independent-1/JJ	nn||factors-3/NNS||risk-2/NN	nsubj||weight-18/NN||factors-3/NNS	det||development-6/NN||the-5/DT	prep_for||factors-3/NNS||development-6/NN	prep_of||development-6/NN||diabetes-8/NN	nn||women-11/NNS||korean-10/NN	prep_in||diabetes-8/NN||women-11/NNS	amod||gdm-14/NN||previous-13/JJ	prep_with||women-11/NNS||gdm-14/NN	cop||weight-18/NN||are-15/VBP	amod||weight-18/NN||pre-pregnancy-16/JJ	nn||weight-18/NN||body-17/NN	root||ROOT-0/null||weight-18/NN	amod||age-21/NN||gestational-20/JJ	appos||weight-18/NN||age-21/NN	prep_at||age-21/NN||diagnosis-23/NN	nn||hyperglycemia-26/NN||antepartum-25/NN	conj_and||weight-18/NN||hyperglycemia-26/NN	amod||test-31/NN||oral-28/JJ	nn||test-31/NN||glucose-29/NN	nn||test-31/NN||tolerance-30/NN	prep_on||hyperglycemia-26/NN||test-31/NN	amod||response-35/NN||low-33/JJ	nn||response-35/NN||insulin-34/NN	conj_and||weight-18/NN||response-35/NN	amod||load-39/NN||oral-37/JJ	nn||load-39/NN||glucose-38/NN	prep_to||response-35/NN||load-39/NN	nn||history-43/NN||family-42/NN	conj_and||weight-18/NN||history-43/NN	prep_of||history-43/NN||diabetes-45/NN	hyperglycemia-26||glucose-38||no||independent risk factors for the development of diabetes in korean women with previous gdm are pre-pregnancy body weight, gestational age at diagnosis, antepartum hyperglycemia on oral glucose tolerance test, low insulin response to oral glucose load, and family history of diabetes.
aux||compare-2/VB||to-1/TO	csubj||ort-22/VBP||compare-2/VB	det||efficacy-4/NN||the-3/DT	dobj||compare-2/VB||efficacy-4/NN	prep_of||efficacy-4/NN||ondansetron-6/NN	prep_of||efficacy-4/NN||domperidone-8/NN	conj_and||ondansetron-6/NN||domperidone-8/NN	det||treatment-12/NN||the-10/DT	amod||treatment-12/NN||symptomatic-11/JJ	prep_for||compare-2/VB||treatment-12/NN	nsubj||failed-21/VBN||treatment-12/NN	prep_of||treatment-12/NN||vomiting-14/NN	prep_in||vomiting-14/NN||children-16/NNS	prep_with||children-16/NNS||ag-18/NN	aux||failed-21/VBN||have-20/VBP	rcmod||treatment-12/NN||failed-21/VBN	root||ROOT-0/null||ort-22/VBP	ondansetron-6||vomiting-14||no_rel||to compare the efficacy of ondansetron and domperidone for the symptomatic treatment of vomiting in children with ag who have failed ort.
det||guideline-3/NN||the-1/DT	amod||guideline-3/NN||national-2/JJ	nsubj||recommends-4/VBZ||guideline-3/NN	root||ROOT-0/null||recommends-4/VBZ	num||diagnosis-7/NN||three-5/CD	amod||diagnosis-7/NN||different-6/JJ	dep||recommends-4/VBZ||diagnosis-7/NN	nn||strategies-10/NNS||treatment-9/NN	dep||recommends-4/VBZ||strategies-10/NNS	conj_and||diagnosis-7/NN||strategies-10/NNS	nn||i-15/NNS||health-12/NN	nn||i-15/NNS||post-13/NN	nn||i-15/NNS||level-14/NN	prep_at||diagnosis-7/NN||i-15/NNS	det||use-18/NN||the-17/DT	dobj||recommends-4/VBZ||use-18/NN	det||p.falciparum-21/NN||a-20/DT	prep_of||use-18/NN||p.falciparum-21/NN	punct||rdt-25/NN||/-22/:	amod||rdt-25/NN||vivax-23/JJ	amod||rdt-25/NN||specific-24/JJ	dep||use-18/NN||rdt-25/NN	nn||tool-28/NN||diagnosis-27/NN	prep_as||rdt-25/NN||tool-28/NN	aux||treat-31/VB||to-30/TO	prep_as||rdt-25/NN||treat-31/VB	conj_and||tool-28/NN||treat-31/VB	vmod||tool-28/NN||treat-31/VB	prep_with||treat-31/VB||artemether-lumefantrine-33/NN	appos||artemether-lumefantrine-33/NN||al-35/NNP	amod||cq-40/NN||chloroquine-38/JJ	prep_with||treat-31/VB||cq-40/NN	conj_or||artemether-lumefantrine-33/NN||cq-40/NN	prep_with||treat-31/VB||referral-43/NN	conj_or||artemether-lumefantrine-33/NN||referral-43/NN	mark||diagnosed-48/VBN||if-44/IN	det||patient-46/NN||the-45/DT	nsubjpass||diagnosed-48/VBN||patient-46/NN	auxpass||diagnosed-48/VBN||was-47/VBD	advcl||treat-31/VB||diagnosed-48/VBN	prep_with||diagnosed-48/VBN||p.falciparum-50/NN	prep_with||diagnosed-48/VBN||p.vivax-52/NN	conj_or||p.falciparum-50/NN||p.vivax-52/NN	neg||malaria-55/NN||no-54/DT	prep_with||diagnosed-48/VBN||malaria-55/NN	conj_or||p.falciparum-50/NN||malaria-55/NN	dep||rdt-25/NN||respectively-57/RB	nn||pan/pf-60/NN||parascreen-59/NN	dep||use-18/NN||pan/pf-60/NN	vmod||pan/pf-60/NN||based-61/VBN	dobj||based-61/VBN||strategy-62/NN	csubj||diagnosed-101/VBD||ii-65/VB	det||use-68/NN||the-67/DT	dobj||ii-65/VB||use-68/NN	det||rdt-73/NN||a-70/DT	amod||rdt-73/NN||p.falciparum-71/JJ	amod||rdt-73/NN||specific-72/JJ	prep_of||ii-65/VB||rdt-73/NN	prep_of||ii-65/VB||al-75/NNP	conj_and||rdt-73/NN||al-75/NNP	nn||cases-78/NNS||p.falciparum-77/NN	prep_for||al-75/NNP||cases-78/NNS	prep_for||al-75/NNP||cq-80/NN	conj_and||cases-78/NNS||cq-80/NN	det||rest-83/NN||the-82/DT	prep_for||cases-78/NNS||rest-83/NN	nn||pf-86/NN||paracheck-85/NN	dep||cases-78/NNS||pf-86/NN	vmod||pf-86/NN||based-87/VBN	dobj||based-87/VBN||strategy-88/NN	conj_and||ii-65/VB||iii-92/VB	csubj||diagnosed-101/VBD||iii-92/VB	det||use-95/NN||the-94/DT	dobj||iii-92/VB||use-95/NN	prep_of||iii-92/VB||al-97/NNP	det||cases-100/NNS||all-99/DT	prep_for||al-97/NNP||cases-100/NNS	parataxis||recommends-4/VBZ||diagnosed-101/VBD	advmod||diagnosed-101/VBD||presumptively-102/RB	prep_as||diagnosed-101/VBD||malaria-104/NN	dep||malaria-104/NN||presumptive-106/NN	vmod||presumptive-106/NN||based-107/VBN	dobj||based-107/VBN||strategy-108/NN	malaria-104||lumefantrine--1||yes||the national guideline recommends three different diagnosis and treatment strategies at health post level i) the use of a p.falciparum / vivax specific rdt as diagnosis tool and to treat with artemether-lumefantrine (al), chloroquine (cq) or referral if the patient was diagnosed with p.falciparum , p.vivax or no malaria, respectively (parascreen pan/pf based strategy); ii) the use of a p.falciparum specific rdt and al for p.falciparum cases and cq for the rest (paracheck pf based strategy); and iii) the use of al for all cases diagnosed presumptively as malaria (presumptive based strategy).
prepc_according_to||+-11/VBD||to-2/TO	det||sensitivity-5/NN||the-3/DT	amod||sensitivity-5/NN||different-4/JJ	pobj||+-11/VBD||sensitivity-5/NN	poss||bone-8/NN||their-7/PRP$	prep_of||sensitivity-5/NN||bone-8/NN	nn||cd34-10/NNS||marrow-9/NN	nsubj||+-11/VBD||cd34-10/NNS	root||ROOT-0/null||+-11/VBD	dobj||+-11/VBD||cells-12/NNS	dep||vitro-15/NN||in-14/IN	amod||treatment-16/NN||vitro-15/NN	prep_to||+-11/VBD||treatment-16/NN	nn||patients-26/NNS||etoposide-18/NN	conj_or||etoposide-18/NN||mafosfamide-20/NN	nn||patients-26/NNS||mafosfamide-20/NN	dep||patients-26/NNS||acutemyeloidleukaemia-22/NN	nn||patients-26/NNS||aml-24/NN	prep_with||+-11/VBD||patients-26/NNS	amod||remission-30/NN||apparent-28/JJ	amod||remission-30/NN||complete-29/JJ	prep_in||+-11/VBD||remission-30/NN	appos||remission-30/NN||cr-32/NN	amod||induction-36/NN||chemotherapy-35/JJ	nsubjpass||classified-39/VBN||induction-36/NN	aux||classified-39/VBN||may-37/MD	auxpass||classified-39/VBN||be-38/VB	prepc_after||remission-30/NN||classified-39/VBN	num||groups-42/NNS||three-41/CD	prep_into||classified-39/VBN||groups-42/NNS	appos||groups-42/NNS||i-44/NNP	advmod||responsive-47/JJ||normally-46/RB	amod||groups-42/NNS||responsive-47/JJ	appos||chemoresistant-52/NNS||ii-50/NN	dep||groups-42/NNS||chemoresistant-52/NNS	appos||remission-30/NN||iii-55/NN	advmod||chemosensitive-58/JJ||highly-57/RB	amod||remission-30/NN||chemosensitive-58/JJ	cr-32||aml-24||no_rel||according to the different sensitivity of their bone marrow cd34+ cells to in vitro treatment with etoposide or mafosfamide, acutemyeloidleukaemia (aml) patients in apparent complete remission (cr) after chemotherapy induction may be classified into three groups (i) normally responsive; (ii) chemoresistant; (iii) highly chemosensitive.
nsubj||factors-8/NNS||acidogenicity-1/NN	conj_and||acidogenicity-1/NN||aciduricity-3/NN	nsubj||factors-8/NNS||aciduricity-3/NN	cop||factors-8/NNS||are-4/VBP	det||factors-8/NNS||the-5/DT	amod||factors-8/NNS||main-6/JJ	nn||factors-8/NNS||virulence-7/NN	root||ROOT-0/null||factors-8/NNS	det||mutans-14/NNS||the-10/DT	amod||mutans-14/NNS||cavity-causing-11/JJ	nn||mutans-14/NNS||bacterium-12/NN	nn||mutans-14/NNS||streptococcus-13/NNS	prep_of||factors-8/NNS||mutans-14/NNS	cavity--1||bacterium-12||no||acidogenicity and aciduricity are the main virulence factors of the cavity-causing bacterium streptococcus mutans .
nsubj||agent-6/NN||mycobacteriumtuberculosis-1/NNS	cop||agent-6/NN||is-2/VBZ	det||agent-6/NN||the-3/DT	amod||agent-6/NN||principal-4/JJ	amod||agent-6/NN||etiologic-5/JJ	root||ROOT-0/null||agent-6/NN	amod||-rrb--12/NNP||human-8/JJ	nn||-rrb--12/NNP||tuberculosis-9/NNP	nn||-rrb--12/NNP||-lrb--10/NNP	nn||-rrb--12/NNP||tb-11/NNP	prep_of||agent-6/NN||-rrb--12/NNP	det||member-15/NN||a-14/DT	conj_and||agent-6/NN||member-15/NN	det||-rrb--22/NNS||the-17/DT	amod||complex-19/JJ||m.tuberculosis-18/JJ	amod||-rrb--22/NNS||complex-19/JJ	amod||-rrb--22/NNS||-lrb--20/JJ	nn||-rrb--22/NNS||mtc-21/NN	prep_of||member-15/NN||-rrb--22/NNS	tuberculosis-9||m.tuberculosis-18||no||mycobacteriumtuberculosis is the principal etiologic agent of human tuberculosis -lrb- tb -rrb- and a member of the m.tuberculosis complex -lrb- mtc -rrb- .
amod||urbanisation-2/NN||rapid-1/JJ	nsubj||altered-26/VBN||urbanisation-2/NN	amod||africa-5/NN||sub-saharan-4/JJ	prep_in||urbanisation-2/NN||africa-5/NN	appos||africa-5/NN||ssa-7/NN	vmod||urbanisation-2/NN||fuelled-10/VBN	prep_in||fuelled-10/VBN||part-12/NN	agent||fuelled-10/VBN||ruralâ-14/VBG	dobj||ruralâ-14/VBG||$-15/$	advmod||migration-18/RB||urban-17/RB	dep||epidemic-23/CD||migration-18/RB	dep||migration-18/RB||and-19/NNP	det||hiv/aids-22/NNS||a-20/DT	amod||hiv/aids-22/NNS||devastating-21/JJ	dep||migration-18/RB||hiv/aids-22/NNS	num||$-15/$||epidemic-23/CD	aux||altered-26/VBN||has-25/VBZ	root||ROOT-0/null||altered-26/VBN	det||status-28/NN||the-27/DT	dobj||altered-26/VBN||status-28/NN	amod||people-31/NNS||older-30/JJR	prep_of||status-28/NN||people-31/NNS	amod||societies-35/NNS||many-33/JJ	nn||societies-35/NNS||ssa-34/NN	prep_in||people-31/NNS||societies-35/NNS	aids--1||hiv--1||no||rapid urbanisation in sub-saharan africa (ssa), fuelled in part by ruralâurban migration and a devastating hiv/aids epidemic, has altered the status of older people in many ssa societies.
det||2003-3/CD||the-2/DT	prep_during||randomised-26/VBN||2003-3/CD	num||seasons-8/NNS||2004-5/CD	nn||seasons-8/NNS||malaria-6/NN	nn||seasons-8/NNS||transmission-7/NN	conj_and||2003-3/CD||seasons-8/NNS	prep_during||randomised-26/VBN||seasons-8/NNS	num||children-12/NNS||1200-10/CD	nn||children-12/NNS||gambian-11/NN	nsubjpass||randomised-26/VBN||children-12/NNS	nsubj||receive-28/VB||children-12/NNS	amod||anaemia-17/NN||moderate-14/JJ	conj_or||moderate-14/JJ||severe-16/JJ	amod||anaemia-17/NN||severe-16/JJ	prep_with||children-12/NNS||anaemia-17/NN	nn||<-21/NNS||hb-19/NN	nn||<-21/NNS||concentration-20/NN	dep||g/dl-23/JJ||<-21/NNS	number||g/dl-23/JJ||7-22/CD	dep||anaemia-17/NN||g/dl-23/JJ	auxpass||randomised-26/VBN||were-25/VBD	root||ROOT-0/null||randomised-26/VBN	aux||receive-28/VB||to-27/TO	xcomp||randomised-26/VBN||receive-28/VB	det||sulfadoxine-pyrimethamine-31/NN||either-29/DT	amod||sulfadoxine-pyrimethamine-31/NN||monthly-30/JJ	dobj||receive-28/VB||sulfadoxine-pyrimethamine-31/NN	appos||sulfadoxine-pyrimethamine-31/NN||sp-33/NN	dobj||receive-28/VB||placebo-36/NN	conj_or||sulfadoxine-pyrimethamine-31/NN||placebo-36/NN	det||end-39/NN||the-38/DT	prep_until||receive-28/VB||end-39/NN	det||season-44/NN||the-41/DT	nn||season-44/NN||malaria-42/NN	nn||season-44/NN||transmission-43/NN	prep_of||end-39/NN||season-44/NN	prep_in||enrolled-49/VBN||season-44/NN	nsubjpass||enrolled-49/VBN||they-47/PRP	auxpass||enrolled-49/VBN||were-48/VBD	rcmod||season-44/NN||enrolled-49/VBN	det||trial-54/NN||a-52/DT	amod||trial-54/NN||double-blind-53/JJ	prep_in||enrolled-49/VBN||trial-54/NN	malaria-42||pyrimethamine--1||no||during the 2003 and 2004 malaria transmission seasons, 1200 gambian children with moderate or severe anaemia (hb concentration <7 g/dl) were randomised to receive either monthly sulfadoxine-pyrimethamine (sp) or placebo until the end of the malaria transmission season in which they were enrolled, in a double-blind trial.
nsubjpass||studied-22/VBN||correlation-1/NN	prep_of||correlation-1/NN||adiponectin-3/NN	nn||levels-6/NNS||plasma-5/NN	prep_with||adiponectin-3/NN||levels-6/NNS	nn||anthropometry-14/NN||insulin-8/NN	dep||anthropometry-14/NN||proinsulin-10/NN	dep||anthropometry-14/NN||insulinresistance-12/NN	prep_of||levels-6/NNS||anthropometry-14/NN	nn||history-18/NN||family-17/NN	prep_of||levels-6/NNS||history-18/NN	conj_and||anthropometry-14/NN||history-18/NN	prep_of||levels-6/NNS||diabetes-20/NN	auxpass||studied-22/VBN||were-21/VBD	root||ROOT-0/null||studied-22/VBN	insulin-8||insulinresistance-12||no_rel||correlation of adiponectin with plasma levels of insulin, proinsulin, insulinresistance, anthropometry, and family history of diabetes were studied.
mark||drugs-5/NNS||although-1/IN	nsubj||drugs-5/NNS||ppis-2/NNS	nsubj||effective-7/JJ||ppis-2/NNS	cop||drugs-5/NNS||are-3/VBP	amod||drugs-5/NNS||safe-4/JJ	advcl||shown-22/VBN||drugs-5/NNS	amod||drugs-5/NNS||effective-7/JJ	conj_and||drugs-5/NNS||effective-7/JJ	advcl||shown-22/VBN||effective-7/JJ	nn||esophagitis-11/NNS||healing-9/NN	nn||esophagitis-11/NNS||erosive-10/NN	prep_in||effective-7/JJ||esophagitis-11/NNS	conj_and||drugs-5/NNS||in-14/IN	advcl||shown-22/VBN||in-14/IN	amod||symptoms-16/NNS||relieving-15/VBG	pobj||in-14/IN||symptoms-16/NNS	nsubj||shown-22/VBN||studies-18/NNS	prep_with||studies-18/NNS||esomeprazole-20/NN	aux||shown-22/VBN||have-21/VBP	root||ROOT-0/null||shown-22/VBN	mark||has-26/VBZ||that-23/IN	det||drug-25/NN||this-24/DT	nsubj||has-26/VBZ||drug-25/NN	ccomp||shown-22/VBN||has-26/VBZ	prep_as||has-26/VBZ||powerful-28/JJ	det||ability-30/NN||an-29/DT	dobj||has-26/VBZ||ability-30/NN	aux||inhibit-32/VB||to-31/TO	vmod||ability-30/NN||inhibit-32/VB	amod||secretion-34/NN||acid-33/JJ	dobj||inhibit-32/VB||secretion-34/NN	prep_as||inhibit-32/VB||omeprazole-36/NN	esophagitis-11||esomeprazole-20||yes||although ppis are safe drugs, effective in healing erosive esophagitis, and in relieving symptoms, studies with esomeprazole have shown that this drug has as powerful an ability to inhibit acid secretion as omeprazole.
det||trial-5/NN||a-2/DT	amod||trial-5/NN||randomized-3/JJ	amod||trial-5/NN||clinical-4/JJ	prep_as||confirmed-20/VBD||trial-5/NN	num||patients-10/NNS||one-7/CD	num||patients-10/NNS||hundred-8/CD	num||patients-10/NNS||twenty-9/CD	nsubj||confirmed-20/VBD||patients-10/NNS	num||male-13/NN||103-12/CD	dep||patients-10/NNS||male-13/NN	num||female-16/NN||17-15/CD	dep||patients-10/NNS||female-16/NN	conj_and||male-13/NN||female-16/NN	prep_with||patients-10/NNS||angiographically-19/NN	root||ROOT-0/null||confirmed-20/VBD	dobj||confirmed-20/VBD||cad-21/NN	nsubj||were-23/VBD||cad-21/NN	rcmod||cad-21/NN||were-23/VBD	amod||therapy-27/NN||long-term-25/JJ	nn||therapy-27/NN||betablocker-26/NN	prep_on||were-23/VBD||therapy-27/NN	nn||¥-31/NNP||â-29/NNP	nn||¥-31/NNP||-30/NNP	dep||therapy-27/NN||¥-31/NNP	num||months-33/NNS||3-32/CD	dep||¥-31/NNP||months-33/NNS	vmod||therapy-27/NN||enrolled-35/VBN	det||study-41/NN||a-37/DT	amod||study-41/NN||randomized-38/JJ	amod||study-41/NN||clinical-39/JJ	nn||study-41/NN||trial-40/NN	prep_in||enrolled-35/VBN||study-41/NN	betablocker-26||cad-21||no_rel||as a randomized clinical trial, one hundred twenty patients (103 male and 17 female) with angiographically confirmed cad who were on long-term betablocker therapy (â¥3 months) enrolled in a randomized clinical trial study.
nn||$-2/NNP||conclusionsâ-1/NNP	nn||infusion-5/NN||$-2/NNP	nn||infusion-5/NN||ghrelin-4/NN	nsubj||induces-7/VBZ||infusion-5/NN	nsubj||insulinresistance-10/VBP||infusion-5/NN	advmod||induces-7/VBZ||acutely-6/RB	root||ROOT-0/null||induces-7/VBZ	dobj||induces-7/VBZ||lipolysis-8/NNS	conj_and||induces-7/VBZ||insulinresistance-10/VBP	advmod||insulinresistance-10/VBP||independently-11/RB	prep_of||insulinresistance-10/VBP||gh-13/NN	prep_of||insulinresistance-10/VBP||cortisol-15/NN	conj_and||gh-13/NN||cortisol-15/NN	cortisol-15||insulinresistance-10||no_rel||conclusionsâ ghrelin infusion acutely induces lipolysis and insulinresistance independently of gh and cortisol.
amod||sensitivity-3/NN||mtb/rif-1/JJ	nn||sensitivity-3/NN||test-2/NN	nsubj||·-6/NNS||sensitivity-3/NN	cop||·-6/NNS||was-4/VBD	amod||·-6/NNS||76â-5/JJ	root||ROOT-0/null||·-6/NNS	number||%-8/NN||9-7/CD	amod||·-6/NNS||%-8/NN	amod||patients-13/NNS||smear-negative-10/JJ	amod||patients-13/NNS||culture-positive-12/JJ	prep_in||·-6/NNS||patients-13/NNS	number||385-17/CD||296-15/CD	quantmod||385-17/CD||of-16/IN	num||samples-18/NNS||385-17/CD	appos||patients-13/NNS||samples-18/NNS	amod||·-23/NNS||99â-22/JJ	prep_in||·-6/NNS||·-23/NNS	conj_and||patients-13/NNS||·-23/NNS	num||%-25/NN||0-24/CD	npadvmod||specific-26/JJ||%-25/NN	amod||·-23/NNS||specific-26/JJ	dep||specific-26/JJ||2846-28/CD	num||samples-32/NNS||2876-30/CD	amod||samples-32/NNS||non-tuberculosis-31/JJ	prep_of||2846-28/CD||samples-32/NNS	tuberculosis--1||rif--1||yes||mtb/rif test sensitivity was 76â·9% in smear-negative, culture-positive patients (296 of 385 samples), and 99â·0% specific (2846 of 2876 non-tuberculosis samples).
nn||manifestations-2/NNS||ocular-1/NN	nsubj||occur-4/VB||manifestations-2/NNS	aux||occur-4/VB||can-3/MD	root||ROOT-0/null||occur-4/VB	quantmod||50-8/CD||up-6/IN	dep||50-8/CD||to-7/TO	num||%-9/NN||50-8/CD	prep_in||occur-4/VB||%-9/NN	amod||patients-20/NNS||humanimmunodeficiencyvirus-11/JJ	appos||patients-20/NNS||hiv-13/NN	amod||patients-20/NNS||/-15/JJ	amod||patients-20/NNS||acquiredimmunedeficiencysyndrome-16/JJ	dep||acquiredimmunedeficiencysyndrome-16/JJ||aids-18/NNS	prep_of||%-9/NN||patients-20/NNS	nn||involvement-24/NN||posterior-22/NN	nn||involvement-24/NN||segment-23/NN	nsubj||presentation-29/NN||involvement-24/NN	cop||presentation-29/NN||is-25/VBZ	det||presentation-29/NN||the-26/DT	advmod||common-28/JJ||most-27/RBS	amod||presentation-29/NN||common-28/JJ	conj_and||occur-4/VB||presentation-29/NN	acquiredimmunedeficiencysyndrome-16||humanimmunodeficiencyvirus-11||no||ocular manifestations can occur in up to 50% of humanimmunodeficiencyvirus (hiv)/acquiredimmunedeficiencysyndrome (aids) patients and posterior segment involvement is the most common presentation.
nn||lines-2/NNS||melanoma-1/NN	nsubj||resistant-8/JJ||lines-2/NNS	nsubj||tmz-10/VB||lines-2/NNS	nsubj||fotemustine-12/JJ||lines-2/NNS	vmod||lines-2/NNS||expressing-3/VBG	nn||wild-type-5/NN||p53-4/NN	dobj||expressing-3/VBG||wild-type-5/NN	cop||resistant-8/JJ||were-6/VBD	advmod||resistant-8/JJ||more-7/RBR	root||ROOT-0/null||resistant-8/JJ	aux||tmz-10/VB||to-9/TO	xcomp||resistant-8/JJ||tmz-10/VB	conj_and||resistant-8/JJ||fotemustine-12/JJ	num||lines-17/NNS||p53-14/CD	amod||lines-17/NNS||mutant-15/JJ	nn||lines-17/NNS||melanoma-16/NN	prep_than||fotemustine-12/JJ||lines-17/NNS	nsubj||is-20/VBZ||lines-17/NNS	rcmod||lines-17/NNS||is-20/VBZ	amod||contrast-23/NN||marked-22/JJ	prep_in||is-20/VBZ||contrast-23/NN	amod||data-26/NNS||previous-25/JJ	prep_to||is-20/VBZ||data-26/NNS	vmod||data-26/NNS||reported-27/VBN	nn||cells-30/NNS||glioma-29/NN	prep_for||reported-27/VBN||cells-30/NNS	vmod||cells-30/NNS||treated-31/VBN	prep_with||treated-31/VBN||tmz-33/NN	melanoma-16||tmz-33||yes||melanoma lines expressing p53 wild-type were more resistant to tmz and fotemustine than p53 mutant melanoma lines, which is in marked contrast to previous data reported for glioma cells treated with tmz.
advmod||achieved-25/VBN||moreover-1/RB	advmod||added-6/VBN||when-3/WRB	nsubjpass||added-6/VBN||thioridazine-4/NN	auxpass||added-6/VBN||was-5/VBD	advcl||achieved-25/VBN||added-6/VBN	det||regimen-9/NN||a-8/DT	prep_to||added-6/VBN||regimen-9/NN	vmod||regimen-9/NN||containing-10/VBG	dobj||containing-10/VBG||rifampicin-11/NN	dobj||containing-10/VBG||isoniazid-13/NN	conj_and||rifampicin-11/NN||isoniazid-13/NN	dobj||containing-10/VBG||pyrazinamide-15/NN	conj_and||rifampicin-11/NN||pyrazinamide-15/NN	nn||tuberculosis-18/NNP||susceptible-17/NNP	prep_for||containing-10/VBG||tuberculosis-18/NNP	det||effect-23/NN||a-20/DT	amod||effect-23/NN||significant-21/JJ	amod||effect-23/NN||synergistic-22/JJ	nsubjpass||achieved-25/VBN||effect-23/NN	auxpass||achieved-25/VBN||was-24/VBD	root||ROOT-0/null||achieved-25/VBN	poss||â-31/NNP||â-27/NNP	nn||â-31/NNP||6.2-29/NNP	nn||â-31/NNP||vs-30/NNP	poss||cfu-35/NN||â-31/NNP	number||log-34/CD||5.9-33/CD	num||cfu-35/NN||log-34/CD	dep||achieved-25/VBN||cfu-35/NN	nn||0.01-39/NNP||p-37/NNP	nn||0.01-39/NNP||<-38/NNP	appos||cfu-35/NN||0.01-39/NNP	tuberculosis-18||pyrazinamide-15||yes||moreover, when thioridazine was added to a regimen containing rifampicin, isoniazid and pyrazinamide for susceptible tuberculosis, a significant synergistic effect was achieved (â6.2 vs â5.9 log cfu, p<0.01).
det||trial-8/NN||a-2/DT	amod||trial-8/NN||large-3/JJ	amod||trial-8/NN||acute-4/JJ	amod||trial-8/NN||coronary-5/JJ	nn||trial-8/NN||syndrome-6/NN	amod||trial-8/NN||clinical-7/JJ	prep_in||reduced-11/VBD||trial-8/NN	nsubj||reduced-11/VBD||ranolazine-10/NN	root||ROOT-0/null||reduced-11/VBD	det||incidence-13/NN||the-12/DT	dobj||reduced-11/VBD||incidence-13/NN	prep_of||incidence-13/NN||supraventriculartachycardia-15/NN	prep_of||incidence-13/NN||ventriculartachycardia-17/NN	conj_and||supraventriculartachycardia-15/NN||ventriculartachycardia-17/NN	amod||atrialfibrillation-20/NN||new-onset-19/JJ	prep_of||incidence-13/NN||atrialfibrillation-20/NN	conj_and||supraventriculartachycardia-15/NN||atrialfibrillation-20/NN	amod||events-24/NNS||bradycardic-23/JJ	prep_of||incidence-13/NN||events-24/NNS	conj_and||supraventriculartachycardia-15/NN||events-24/NNS	ventriculartachycardia-17||ranolazine-10||no_rel||in a large acute coronary syndrome clinical trial, ranolazine reduced the incidence of supraventriculartachycardia, ventriculartachycardia, new-onset atrialfibrillation, and bradycardic events.
amod||services-3/NNS||family-centred-2/JJ	nsubj||acknowledge-9/VBP||services-3/NNS	nsubj||include-23/VBP||services-3/NNS	advmod||acknowledge-9/VBP||in-4/IN	det||context-6/NN||the-5/DT	pobj||in-4/IN||context-6/NN	prep_of||in-4/IN||hiv/aids-8/NNS	root||ROOT-0/null||acknowledge-9/VBP	det||view-12/NN||a-10/DT	amod||view-12/NN||broad-11/JJ	dobj||acknowledge-9/VBP||view-12/NN	iobj||acknowledge-9/VBP||view-12/NN	prep||view-12/NN||of-13/IN	dep||of-13/IN||a-14/SYM	nn||system-18/NN||family-17/NN	dep||view-12/NN||system-18/NN	advmod||include-23/VBP||ideally-22/RB	conj_and||acknowledge-9/VBP||include-23/VBP	amod||treatment-25/NN||comprehensive-24/JJ	dobj||include-23/VBP||treatment-25/NN	dobj||include-23/VBP||care-27/NN	conj_and||treatment-25/NN||care-27/NN	nn||agencies-30/NNS||community-29/NN	dobj||include-23/VBP||agencies-30/NNS	conj_and||treatment-25/NN||agencies-30/NNS	amod||management-34/NN||coordinated-32/JJ	nn||management-34/NN||case-33/NN	dobj||include-23/VBP||management-34/NN	conj_and||treatment-25/NN||management-34/NN	aids--1||hiv--1||no||" family-centred services in the context of hiv/aids acknowledge a broad view of a ""family system"" and ideally include comprehensive treatment and care, community agencies and coordinated case management."
nsubj||compound-8/NN||praziquantel-1/NN	appos||praziquantel-1/NN||pzq-3/NN	cop||compound-8/NN||is-5/VBZ	det||compound-8/NN||the-6/DT	nn||compound-8/NN||drug-7/NN	root||ROOT-0/null||compound-8/NN	prep_of||compound-8/NN||choice-10/NN	det||control-13/NN||the-12/DT	prep_in||choice-10/NN||control-13/NN	prep_in||choice-10/NN||treatment-15/NN	conj_and||control-13/NN||treatment-15/NN	prep_of||control-13/NN||schistosomiasis-17/NNS	schistosomiasis-17||praziquantel-1||yes||praziquantel (pzq) is the drug compound of choice in the control and treatment of schistosomiasis.
advmod||assessed-5/VBD||therefore-1/RB	nsubj||assessed-5/VBD||we-3/PRP	advmod||assessed-5/VBD||directly-4/RB	root||ROOT-0/null||assessed-5/VBD	det||efficacy-7/NN||the-6/DT	dobj||assessed-5/VBD||efficacy-7/NN	amod||inhibition-10/NN||c-met-9/JJ	prep_of||efficacy-7/NN||inhibition-10/NN	nn||ablation-13/NN||androgen-12/NN	prep_during||assessed-5/VBD||ablation-13/NN	det||growth-16/NN||the-15/DT	prep_on||assessed-5/VBD||growth-16/NN	prep_on||assessed-5/VBD||progression-18/NN	conj_and||growth-16/NN||progression-18/NN	nn||cancer-21/NN||prostate-20/NN	prep_of||growth-16/NN||cancer-21/NN	androgen-12||cancer-21||no_rel||therefore, we directly assessed the efficacy of c-met inhibition during androgen ablation on the growth and progression of prostate cancer.
amod||mutations-2/NNS||nvp-resistance-1/JJ	nsubj||differ-4/VB||mutations-2/NNS	aux||differ-4/VB||did-3/VBD	root||ROOT-0/null||differ-4/VB	prep_by||differ-4/VB||timing-6/NN	prep_of||timing-6/NN||hivinfection-8/NN	det||variant-12/NN||the-10/DT	amod||variant-12/NN||y181c-11/JJ	nsubj||predominant-14/JJ||variant-12/NN	cop||predominant-14/JJ||was-13/VBD	parataxis||differ-4/VB||predominant-14/JJ	prep_among||predominant-14/JJ||infants-16/NNS	vmod||infants-16/NNS||diagnosed-17/VBN	det||weeks-22/NNS||the-19/DT	amod||weeks-22/NNS||first-20/JJ	num||weeks-22/NNS||six-21/CD	prep_in||diagnosed-17/VBN||weeks-22/NNS	prep_of||weeks-22/NNS||life-24/NN	prepc_compared_to||predominant-14/JJ||to-27/TO	pobj||predominant-14/JJ||y188c/h-28/NNS	amod||transmission-32/NN||late-30/JJ	amod||transmission-32/NN||breast-milk-31/JJ	prep_during||y188c/h-28/NNS||transmission-32/NN	hivinfection-8||nvp--1||yes||nvp-resistance mutations did differ by timing of hivinfection; the y181c variant was predominant among infants diagnosed in the first six weeks of life, compared to y188c/h during late breast-milk transmission.
num||days-2/NNS||two-1/CD	npadvmod||developed-17/VBD||days-2/NNS	amod||administration-5/NN||intravenous-4/JJ	prep_after||developed-17/VBD||administration-5/NN	det||course-9/NN||a-7/DT	amod||course-9/NN||first-8/JJ	prep_of||administration-5/NN||course-9/NN	amod||mg/m2-13/NNS||bortezomib-11/JJ	dep||bortezomib-11/JJ||1-12/CD	prep_of||course-9/NN||mg/m2-13/NNS	det||patient-16/NN||the-15/DT	nsubj||developed-17/VBD||patient-16/NN	root||ROOT-0/null||developed-17/VBD	amod||numbness-19/NNS||rapidly-progressive-18/JJ	dobj||developed-17/VBD||numbness-19/NNS	dobj||developed-17/VBD||pain-21/NN	conj_and||numbness-19/NNS||pain-21/NN	nn||weakness-24/NN||muscle-23/NN	dobj||developed-17/VBD||weakness-24/NN	conj_and||numbness-19/NNS||weakness-24/NN	det||upper-28/JJ||the-26/DT	amod||upper-28/JJ||bilateral-27/JJ	prep_in||developed-17/VBD||upper-28/JJ	amod||limbs-31/NNS||lower-30/JJR	prep_in||developed-17/VBD||limbs-31/NNS	conj_and||upper-28/JJ||limbs-31/NNS	pain-21||bortezomib-11||no_rel||two days after intravenous administration of a first course of bortezomib 1 mg/m2, the patient developed rapidly-progressive numbness, pain and muscle weakness in the bilateral upper and lower limbs.
amod||factors-3/NNS||numerous-1/JJ	nn||factors-3/NNS||risk-2/NN	nsubjpass||established-11/VBN||factors-3/NNS	det||development-6/NN||the-5/DT	prep_for||factors-3/NNS||development-6/NN	prep_of||development-6/NN||gout-8/NN	aux||established-11/VBN||have-9/VBP	auxpass||established-11/VBN||been-10/VBN	root||ROOT-0/null||established-11/VBN	prep_including||established-11/VBN||hyperuricaemia-14/NN	amod||factors-17/NNS||genetic-16/JJ	prep_including||established-11/VBN||factors-17/NNS	conj_and||hyperuricaemia-14/NN||factors-17/NNS	amod||factors-20/NNS||dietary-19/JJ	prep_including||established-11/VBN||factors-20/NNS	conj_and||hyperuricaemia-14/NN||factors-20/NNS	nn||consumption-23/NN||alcohol-22/NN	prep_including||established-11/VBN||consumption-23/NN	conj_and||hyperuricaemia-14/NN||consumption-23/NN	amod||syndrome-26/NN||metabolic-25/JJ	prep_including||established-11/VBN||syndrome-26/NN	conj_and||hyperuricaemia-14/NN||syndrome-26/NN	prep_including||established-11/VBN||hypertension-28/NN	conj_and||hyperuricaemia-14/NN||hypertension-28/NN	prep_including||established-11/VBN||obesity-30/NN	conj_and||hyperuricaemia-14/NN||obesity-30/NN	amod||use-33/NN||diuretic-32/JJ	prep_including||established-11/VBN||use-33/NN	conj_and||hyperuricaemia-14/NN||use-33/NN	prep_including||established-11/VBN||chronicrenaldisease-35/NN	conj_and||hyperuricaemia-14/NN||chronicrenaldisease-35/NN	alcohol-22||hypertension-28||no_rel||numerous risk factors for the development of gout have been established, including hyperuricaemia, genetic factors, dietary factors, alcohol consumption, metabolic syndrome, hypertension, obesity, diuretic use and chronicrenaldisease.
det||sensitivity-2/NN||the-1/DT	nsubjpass||evaluated-12/VBN||sensitivity-2/NN	conj_and||sensitivity-2/NN||specificity-4/NN	nsubjpass||evaluated-12/VBN||specificity-4/NN	det||elisa-8/NN||the-6/DT	amod||elisa-8/NN||epitope-blocking-7/JJ	prep_of||sensitivity-2/NN||elisa-8/NN	prep_for||elisa-8/NN||h5n1-10/CD	auxpass||evaluated-12/VBN||were-11/VBD	root||ROOT-0/null||evaluated-12/VBN	xcomp||evaluated-12/VBN||using-13/VBG	nn||antisera-15/NN||chicken-14/NN	dobj||using-13/VBG||antisera-15/NN	amod||clades-19/NNS||multiple-17/JJ	nn||clades-19/NNS||virus-18/NN	prep_to||using-13/VBG||clades-19/NNS	amod||subtypes-23/NNS||other-21/JJ	nn||subtypes-23/NNS||influenza-22/NN	prep_to||using-13/VBG||subtypes-23/NNS	conj_and||clades-19/NNS||subtypes-23/NNS	nn||samples-28/NNS||serum-27/NN	prep_to||using-13/VBG||samples-28/NNS	conj_and||clades-19/NNS||samples-28/NNS	prep_from||samples-28/NNS||individuals-30/NNS	advmod||infected-32/VBN||naturally-31/RB	vmod||individuals-30/NNS||infected-32/VBN	amod||influenzaviruses-37/NNS||h5n1-34/JJ	conj_or||h5n1-34/JJ||seasonal-36/JJ	amod||influenzaviruses-37/NNS||seasonal-36/JJ	prep_with||infected-32/VBN||influenzaviruses-37/NNS	influenza-22||influenzaviruses-37||no||the sensitivity and specificity of the epitope-blocking elisa for h5n1 were evaluated using chicken antisera to multiple virus clades and other influenza subtypes as well as serum samples from individuals naturally infected with h5n1 or seasonal influenzaviruses.
det||review-3/NN||this-2/DT	prep_in||present-6/VB||review-3/NN	nsubj||present-6/VB||we-5/PRP	nsubj||activation-14/VB||we-5/PRP	nsubj||discuss-32/VB||we-5/PRP	root||ROOT-0/null||present-6/VB	amod||knowledge-8/NN||current-7/JJ	dobj||present-6/VB||knowledge-8/NN	amod||recognition-12/NN||innate-10/JJ	amod||recognition-12/NN||immune-11/JJ	prep_on||present-6/VB||recognition-12/NN	conj_and||present-6/VB||activation-14/VB	prep_during||activation-14/VB||hivinfection-16/NN	prepc_based_on||activation-14/VB||on-18/IN	pobj||activation-14/VB||studies-19/NNS	nn||culture-22/NN||cell-21/NN	prep_in||studies-19/NNS||culture-22/NN	amod||primates-25/NNS||non-human-24/JJ	prep_in||studies-19/NNS||primates-25/NNS	conj_and||culture-22/NN||primates-25/NNS	amod||individuals-29/NNS||hiv-infected-28/JJ	prep_in||studies-19/NNS||individuals-29/NNS	conj_and||culture-22/NN||individuals-29/NNS	conj_and||present-6/VB||discuss-32/VB	det||implications-34/NNS||the-33/DT	dobj||discuss-32/VB||implications-34/NNS	det||understanding-37/NN||the-36/DT	prep_for||discuss-32/VB||understanding-37/NN	nn||immunopathogenesis-40/NNS||hiv-39/NN	prep_of||understanding-37/NN||immunopathogenesis-40/NNS	hivinfection-16||hiv-39||no||in this review, we present current knowledge on innate immune recognition and activation during hivinfection based on studies in cell culture, non-human primates, and hiv-infected individuals, and discuss the implications for the understanding of hiv immunopathogenesis.
nsubj||used-2/VBD||we-1/PRP	root||ROOT-0/null||used-2/VBD	nn||rip-chip-4/NN||hur-3/NN	dobj||used-2/VBD||rip-chip-4/NN	det||method-10/NN||a-6/DT	amod||method-10/NN||comprehensive-7/JJ	conj_and||comprehensive-7/JJ||systematic-9/JJ	amod||method-10/NN||systematic-9/JJ	prep_as||used-2/VBD||method-10/NN	aux||survey-12/VB||to-11/TO	vmod||used-2/VBD||survey-12/VB	nn||genes-16/NNS||breast-13/NN	nn||genes-16/NNS||cancer-14/NN	nn||genes-16/NNS||target-15/NN	dobj||survey-12/VB||genes-16/NNS	det||lines-41/NNS||both-18/DT	amod||lines-41/NNS||mcf-7-19/JJ	nn||positive-23/NN||estrogen-21/NN	nn||positive-23/NN||receptor-22/NN	dep||mcf-7-19/JJ||positive-23/NN	nn||+-26/NNS||er-25/NN	appos||positive-23/NN||+-26/NNS	conj_and||mcf-7-19/JJ||mda-mb-231-29/JJ	amod||lines-41/NNS||mda-mb-231-29/JJ	num||receptor-32/NN||estrogen-31/CD	npadvmod||negative-33/JJ||receptor-32/NN	dep||er-35/NN||negative-33/JJ	dep||mda-mb-231-29/JJ||er-35/NN	nn||lines-41/NNS||breast-38/NN	nn||lines-41/NNS||cancer-39/NN	nn||lines-41/NNS||cell-40/NN	prep_in||genes-16/NNS||lines-41/NNS	cancer-39||estrogen-31||no_rel||we used hur rip-chip as a comprehensive and systematic method to survey breast cancer target genes in both mcf-7 (estrogen receptor positive, er+) and mda-mb-231 (estrogen receptor negative, er-) breast cancer cell lines.
amod||bacteraemia-2/NN||s.aureus-1/JJ	nsubj||associated-5/JJ||bacteraemia-2/NN	aux||associated-5/JJ||is-3/VBZ	advmod||associated-5/JJ||frequently-4/RB	root||ROOT-0/null||associated-5/JJ	prep_with||associated-5/JJ||exposure-7/NN	nn||settings-10/NNS||healthcare-9/NN	prep_to||associated-5/JJ||settings-10/NNS	prep_with||associated-5/JJ||mrsa-12/NN	vmod||mrsa-12/NN||causing-13/VBG	det||burden-16/NN||a-14/DT	amod||burden-16/NN||considerable-15/JJ	dobj||causing-13/VBG||burden-16/NN	prep_of||burden-16/NN||disease-18/NN	mrsa-12||s.aureus-1||no||s.aureus bacteraemia is frequently associated with exposure to healthcare settings with mrsa causing a considerable burden of disease .
det||purpose-2/NN||the-1/DT	nsubj||is-6/VBZ||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||is-6/VBZ	aux||investigate-8/VB||to-7/TO	ccomp||is-6/VBZ||investigate-8/VB	det||prevalence-10/NN||the-9/DT	dobj||investigate-8/VB||prevalence-10/NN	prep_of||prevalence-10/NN||hiv-12/NN	prep_among||hiv-12/NN||msm-14/NN	prepc_in||investigate-8/VB||heilongjiang-16/VBG	dobj||heilongjiang-16/VBG||province-17/NN	aux||assess-20/VB||to-19/TO	ccomp||is-6/VBZ||assess-20/VB	conj_and||investigate-8/VB||assess-20/VB	poss||levels-23/NNS||their-21/PRP$	nn||levels-23/NNS||knowledge-22/NN	dobj||assess-20/VB||levels-23/NNS	nn||behaviors-26/NNS||risk-25/NN	dobj||assess-20/VB||behaviors-26/NNS	conj_and||levels-23/NNS||behaviors-26/NNS	advmod||assess-20/VB||related-27/VBN	prep_to||related-27/VBN||hiv/aids-29/NNS	aux||explore-33/VB||to-32/TO	ccomp||is-6/VBZ||explore-33/VB	conj_and||investigate-8/VB||explore-33/VB	poss||associations-35/NNS||their-34/PRP$	dobj||explore-33/VB||associations-35/NNS	nn||resources-38/NNS||information-37/NN	prep_with||explore-33/VB||resources-38/NNS	aids--1||hiv-12||no||the purpose of this study is to investigate the prevalence of hiv among msm in heilongjiang province, to assess their knowledge levels and risk behaviors related to hiv/aids, and to explore their associations with information resources.
nsubj||cause-5/NN||it-1/PRP	cop||cause-5/NN||is-2/VBZ	det||cause-5/NN||a-3/DT	amod||cause-5/NN||major-4/JJ	root||ROOT-0/null||cause-5/NN	det||transition-8/NN||the-7/DT	prep_of||cause-5/NN||transition-8/NN	det||infection-11/NN||the-10/DT	prep_from||transition-8/NN||infection-11/NN	amod||tuberculosis-16/NNP||active-13/JJ	nn||tuberculosis-16/NNP||disease-14/NN	nn||tuberculosis-16/NNP||-lrb--15/NNP	prep_to||infection-11/NN||tuberculosis-16/NNP	nn||-rrb--19/NNS||tb-18/NN	appos||tuberculosis-16/NNP||-rrb--19/NNS	det||transmission-24/NN||the-23/DT	conj_and||cause-5/NN||transmission-24/NN	prep_of||transmission-24/NN||m.tuberculosis-26/NNS	amod||persons-29/NNS||other-28/JJ	prep_to||m.tuberculosis-26/NNS||persons-29/NNS	tb-18||m.tuberculosis-26||no||it is a major cause of the transition from the infection to active disease -lrb- tuberculosis , tb -rrb- as well as the transmission of m.tuberculosis to other persons .
aux||evaluate-2/VB||to-1/TO	csubj||differing-10/VBD||evaluate-2/VB	csubj||differing-10/VBD||evaluate-2/VB	det||effects-4/NNS||the-3/DT	dobj||evaluate-2/VB||effects-4/NNS	num||diets-9/NNS||two-6/CD	amod||diets-9/NNS||low-fat-7/JJ	amod||diets-9/NNS||hypocaloric-8/JJ	prep_of||effects-4/NNS||diets-9/NNS	root||ROOT-0/null||differing-10/VBD	conj_and||differing-10/VBD||differing-10/VBD	det||ratio-14/NN||the-12/DT	amod||ratio-14/NN||carbohydrate-to-protein-13/JJ	prep_in||differing-10/VBD||ratio-14/NN	nn||training-21/NN||resistance-19/NN	nn||training-21/NN||exercise-20/NN	prep_with||differing-10/VBD||training-21/NN	prep_without||differing-10/VBD||training-21/NN	appos||training-21/NN||rt-23/NN	nn||loss-28/NN||weight-27/NN	prep_on||differing-10/VBD||loss-28/NN	nn||composition-31/NN||body-30/NN	prep_on||differing-10/VBD||composition-31/NN	conj_and||loss-28/NN||composition-31/NN	amod||outcomes-39/NNS||cardiovasculardisease-34/JJ	dep||cardiovasculardisease-34/JJ||cvd-36/NN	nn||outcomes-39/NNS||risk-38/NN	prep_on||differing-10/VBD||outcomes-39/NNS	conj_and||loss-28/NN||outcomes-39/NNS	amod||patients-42/NNS||overweight/obese-41/JJ	prep_in||outcomes-39/NNS||patients-42/NNS	prep_with||patients-42/NNS||type2diabetes-44/CD	type2diabetes-44||fat--1||no_rel||to evaluate the effects of two low-fat hypocaloric diets differing in the carbohydrate-to-protein ratio, with and without resistance exercise training (rt), on weight loss, body composition, and cardiovasculardisease (cvd) risk outcomes in overweight/obese patients with type2diabetes.
det||prevalence-2/NN||the-1/DT	nsubjpass||investigated-29/VBN||prevalence-2/NN	prep_of||prevalence-2/NN||hepatitisbvirus-4/NNS	appos||hepatitisbvirus-4/NNS||hbv-6/NN	amod||virus-10/NN||hepatitisc-9/JJ	prep_of||prevalence-2/NN||virus-10/NN	conj_and||hepatitisbvirus-4/NNS||virus-10/NN	appos||hepatitisbvirus-4/NNS||hcv-12/NN	poss||factors-18/NNS||its-15/PRP$	amod||factors-18/NNS||associated-16/VBN	nn||factors-18/NNS||risk-17/NN	conj_and||prevalence-2/NN||factors-18/NNS	nsubjpass||investigated-29/VBN||factors-18/NNS	amod||patients-24/NNS||haemodialysis-20/JJ	appos||patients-24/NNS||hd-22/NN	prep_among||factors-18/NNS||patients-24/NNS	nn||strip-27/NN||gaza-26/NN	prep_in||factors-18/NNS||strip-27/NN	auxpass||investigated-29/VBN||was-28/VBD	root||ROOT-0/null||investigated-29/VBN	xcomp||investigated-29/VBN||using-30/VBG	amod||techniques-34/NNS||serological-31/JJ	conj_and||serological-31/JJ||molecular-33/JJ	amod||techniques-34/NNS||molecular-33/JJ	dobj||using-30/VBG||techniques-34/NNS	hbv-6||hepatitisbvirus-4||no||the prevalence of hepatitisbvirus (hbv) and hepatitisc virus (hcv) and its associated risk factors among haemodialysis (hd) patients in gaza strip was investigated using serological and molecular techniques.
nsubj||effect-9/NN||pain-1/NN	amod||injection-4/NN||propofol-3/JJ	prep_on||pain-1/NN||injection-4/NN	cop||effect-9/NN||is-5/VBZ	det||effect-9/NN||a-6/DT	amod||effect-9/NN||well-known-7/JJ	amod||effect-9/NN||adverse-8/JJ	root||ROOT-0/null||effect-9/NN	pain-1||propofol-3||yes||pain on propofol injection is a well-known adverse effect.
det||mechanism-2/NN||this-1/DT	nsubj||has-9/VBZ||mechanism-2/NN	mark||finds-6/VBZ||if-4/IN	nsubj||finds-6/VBZ||it-5/PRP	dep||mechanism-2/NN||finds-6/VBZ	dobj||finds-6/VBZ||support-7/NN	root||ROOT-0/null||has-9/VBZ	amod||implications-11/NNS||important-10/JJ	dobj||has-9/VBZ||implications-11/NNS	amod||research-14/NN||future-13/JJ	prep_for||implications-11/NNS||research-14/NN	det||hazard-18/NN||the-16/DT	nn||hazard-18/NN||mesothelioma-17/NN	prep_into||has-9/VBZ||hazard-18/NN	prep_into||has-9/VBZ||hazard-18/NN	conj_and||hazard-18/NN||hazard-18/NN	prep_from||hazard-18/NN||harn-20/NN	advmod||hazard-18/NN||also-22/RB	poss||view-26/NN||our-24/PRP$	amod||view-26/NN||current-25/JJ	prep_for||hazard-18/NN||view-26/NN	det||origins-29/NNS||the-28/DT	prep_of||view-26/NN||origins-29/NNS	amod||mesothelioma-33/NN||asbestos-initiated-31/JJ	amod||mesothelioma-33/NN||pleural-32/JJ	prep_of||origins-29/NNS||mesothelioma-33/NN	det||use-37/NN||the-35/DT	amod||use-37/NN||common-36/JJ	prep_of||view-26/NN||use-37/NN	conj_and||origins-29/NNS||use-37/NN	prep_of||use-37/NN||lung-39/NN	amod||burden-43/NN||parenchymal-40/JJ	nn||burden-43/NN||asbestos-41/NN	nn||burden-43/NN||fibre-42/NN	pobj||hazard-18/NN||burden-43/NN	det||correlate-46/NN||a-45/DT	prep_as||has-9/VBZ||correlate-46/NN	det||tumour-49/NN||this-48/DT	prep_of||correlate-46/NN||tumour-49/NN	nsubj||arises-53/VBZ||tumour-49/NN	advmod||arises-53/VBZ||actually-52/RB	rcmod||tumour-49/NN||arises-53/VBZ	det||pleura-57/NN||the-55/DT	amod||pleura-57/NN||parietal-56/JJ	prep_in||arises-53/VBZ||pleura-57/NN	asbestos-41||mesothelioma-33||no_rel||this mechanism, if it finds support, has important implications for future research into the mesothelioma hazard from harn and also for our current view of the origins of asbestos-initiated pleural mesothelioma and the common use of lung parenchymal asbestos fibre burden as a correlate of this tumour, which actually arises in the parietal pleura.
mark||indicate-4/VBP||although-1/IN	det||data-3/NNS||these-2/DT	nsubj||indicate-4/VBP||data-3/NNS	advcl||found-37/VBN||indicate-4/VBP	mark||acquired-14/VBN||that-5/IN	amod||resistance-8/NN||methylating-6/VBG	nn||resistance-8/NN||drug-7/NN	nsubjpass||acquired-14/VBN||resistance-8/NN	nn||cells-11/NNS||melanoma-10/NN	prep_of||resistance-8/NN||cells-11/NNS	aux||acquired-14/VBN||can-12/MD	auxpass||acquired-14/VBN||be-13/VB	ccomp||indicate-4/VBP||acquired-14/VBN	agent||acquired-14/VBN||down-regulation-16/NN	nn||repair-19/NN||mismatch-18/NN	prep_of||down-regulation-16/NN||repair-19/NN	det||correlation-22/NN||a-21/DT	nsubjpass||found-37/VBN||correlation-22/NN	amod||expression-27/NN||msh2-24/JJ	conj_and||msh2-24/JJ||msh6-26/JJ	amod||expression-27/NN||msh6-26/JJ	prep_between||correlation-22/NN||expression-27/NN	det||lines-31/NNS||the-29/DT	amod||lines-31/NNS||different-30/JJ	prep_in||expression-27/NN||lines-31/NNS	nn||sensitivity-34/NN||tmz-33/NN	prep_in||expression-27/NN||sensitivity-34/NN	conj_and||lines-31/NNS||sensitivity-34/NN	auxpass||found-37/VBN||was-35/VBD	neg||found-37/VBN||not-36/RB	root||ROOT-0/null||found-37/VBN	melanoma-10||tmz-33||yes||although these data indicate that methylating drug resistance of melanoma cells can be acquired by down-regulation of mismatch repair, a correlation between msh2 and msh6 expression in the different lines and tmz sensitivity was not found.
nsubj||disease-6/NN||lymedisease-1/NN	cop||disease-6/NN||is-2/VBZ	det||disease-6/NN||a-3/DT	amod||disease-6/NN||common-4/JJ	amod||disease-6/NN||vector-borne-5/JJ	root||ROOT-0/null||disease-6/NN	vmod||disease-6/NN||caused-7/VBN	det||borreliaburgdorferi-11/NN||the-9/DT	amod||borreliaburgdorferi-11/NN||spirochete-10/JJ	agent||caused-7/VBN||borreliaburgdorferi-11/NN	nsubj||manifests-17/VBZ||borreliaburgdorferi-11/NN	appos||borreliaburgdorferi-11/NN||bb-13/NN	rcmod||borreliaburgdorferi-11/NN||manifests-17/VBZ	amod||inflammation-23/NNS||systemic-19/JJ	conj_and||systemic-19/JJ||targeted-21/JJ	amod||inflammation-23/NNS||targeted-21/JJ	nn||inflammation-23/NNS||tissue-22/NN	prep_as||manifests-17/VBZ||inflammation-23/NNS	lymedisease-1||borreliaburgdorferi-11||no||lymedisease is a common vector-borne disease caused by the spirochete borreliaburgdorferi ( bb ), which manifests as systemic and targeted tissue inflammation.
nsubjpass||increased-11/VBN||hepcidin-1/NN	det||regulator-5/NN||a-3/DT	amod||regulator-5/NN||key-4/JJ	appos||hepcidin-1/NN||regulator-5/NN	nn||homeostasis-8/NNS||iron-7/NN	prep_of||regulator-5/NN||homeostasis-8/NNS	auxpass||increased-11/VBN||is-10/VBZ	root||ROOT-0/null||increased-11/VBN	prep_in||increased-11/VBN||response-13/NN	prep_to||increased-11/VBN||inflammation-15/NN	det||infections-18/NNS||some-17/DT	prep_to||increased-11/VBN||infections-18/NNS	conj_and||inflammation-15/NN||infections-18/NNS	nsubj||unclear-37/JJ||the-21/DT	prep_in||role-24/NN||vivo-23/NN	rcmod||the-21/DT||role-24/NN	prep_of||role-24/NN||hepcidin-26/NN	advmod||role-24/NN||particularly-28/RB	prep_in||role-24/NN||children-30/NNS	prep_with||children-30/NNS||irondeficiencyanemia-32/NN	appos||the-21/DT||ida-34/NN	cop||unclear-37/JJ||is-36/VBZ	conj_but||increased-11/VBN||unclear-37/JJ	irondeficiencyanemia-32||iron-7||yes||hepcidin, a key regulator of iron homeostasis, is increased in response to inflammation and some infections, but the in vivo role of hepcidin, particularly in children with irondeficiencyanemia (ida) is unclear.
nsubj||immunomodulator-5/NN||tacrolimus-1/NNS	cop||immunomodulator-5/NN||is-2/VBZ	det||immunomodulator-5/NN||a-3/DT	amod||immunomodulator-5/NN||potent-4/JJ	root||ROOT-0/null||immunomodulator-5/NN	nsubj||effective-8/JJ||immunomodulator-5/NN	cop||effective-8/JJ||is-7/VBZ	rcmod||immunomodulator-5/NN||effective-8/JJ	det||treatment-11/NN||the-10/DT	prep_in||effective-8/JJ||treatment-11/NN	prep_of||treatment-11/NN||inflammatoryboweldisease-13/NN	appos||inflammatoryboweldisease-13/NN||ibd-15/NN	immunomodulator-5||inflammatoryboweldisease-13||no_rel||tacrolimus is a potent immunomodulator that is effective in the treatment of inflammatoryboweldisease (ibd).
det||extracts-3/NNS||the-1/DT	num||extracts-3/NNS||three-2/CD	nsubj||effective-6/JJ||extracts-3/NNS	cop||effective-6/JJ||were-4/VBD	advmod||effective-6/JJ||also-5/RB	ccomp||micrococcus-15/VBZ||effective-6/JJ	det||bacteria-10/NNS||all-8/DT	amod||bacteria-10/NNS||gram-positive-9/JJ	prep_against||effective-6/JJ||bacteria-10/NNS	vmod||bacteria-10/NNS||tested-11/VBN	amod||cereus-13/NNS||bacillus-12/JJ	dobj||tested-11/VBN||cereus-13/NNS	root||ROOT-0/null||micrococcus-15/VBZ	nsubj||micrococcus-15/VBZ||luteus-16/NNS	amod||staphylococcusaureus-19/NNS||methicillin-susceptible-18/JJ	appos||luteus-16/NNS||staphylococcusaureus-19/NNS	appos||staphylococcusaureus-19/NNS||mssa-21/NNP	appos||luteus-16/NNS||methicillin-resistantstaphylococcusaureus-24/NNS	conj_and||staphylococcusaureus-19/NNS||methicillin-resistantstaphylococcusaureus-24/NNS	appos||methicillin-resistantstaphylococcusaureus-24/NNS||mrsa-26/NNP	amod||epidermidis-30/NNS||stapylococcus-29/JJ	appos||luteus-16/NNS||epidermidis-30/NNS	conj_and||staphylococcusaureus-19/NNS||epidermidis-30/NNS	amod||g/ml-39/NN||minimum-32/JJ	nn||g/ml-39/NN||inhibitory-33/NN	nn||g/ml-39/NN||concentration-34/NN	nn||g/ml-39/NN||mic-35/NN	num||g/ml-39/NN||15.6-250-36/CD	amod||g/ml-39/NN||î-37/JJ	num||g/ml-39/NN||1/4-38/CD	dep||epidermidis-30/NNS||g/ml-39/NN	amod||g/ml-48/NN||minimum-41/JJ	nn||g/ml-48/NN||bactericidal-42/NN	nn||g/ml-48/NN||concentration-43/NN	nn||g/ml-48/NN||mbc-44/NN	num||g/ml-48/NN||15.6-250-45/CD	amod||g/ml-48/NN||î-46/JJ	num||g/ml-48/NN||1/4-47/CD	dep||g/ml-39/NN||g/ml-48/NN	methicillin-resistantstaphylococcusaureus-24||staphylococcusaureus-19||no||the three extracts were also effective against all gram-positive bacteria tested bacillus cereus, micrococcus luteus , methicillin-susceptible staphylococcusaureus (mssa), methicillin-resistantstaphylococcusaureus (mrsa) and stapylococcus epidermidis (minimum inhibitory concentration mic 15.6-250 î¼g/ml; minimum bactericidal concentration mbc 15.6-250 î¼g/ml).
advmod||sustains-8/VBZ||however-1/RB	det||increase-5/NN||the-3/DT	amod||increase-5/NN||adaptive-4/JJ	nsubj||sustains-8/VBZ||increase-5/NN	prep_in||increase-5/NN||adh3-7/CD	root||ROOT-0/null||sustains-8/VBZ	nn||metabolism-10/NN||alcohol-9/NN	dobj||sustains-8/VBZ||metabolism-10/NN	advmod||sustains-8/VBZ||even-12/RB	prep_in||sustains-8/VBZ||patients-14/NNS	prep_with||patients-14/NNS||alcoholiclivercirrhosis-16/NNS	nsubj||makes-19/VBZ||alcoholiclivercirrhosis-16/NNS	rcmod||alcoholiclivercirrhosis-16/NNS||makes-19/VBZ	nsubj||drink-25/VB||it-20/PRP	dep||drink-25/VB||possible-21/JJ	mark||drink-25/VB||for-22/IN	nsubj||drink-25/VB||them-23/PRP	aux||drink-25/VB||to-24/TO	xcomp||makes-19/VBZ||drink-25/VB	dobj||drink-25/VB||themselves-26/PRP	prep_to||drink-25/VB||death-28/NN	alcoholiclivercirrhosis-16||alcohol-9||no||however, the adaptive increase in adh3 sustains alcohol metabolism, even in patients with alcoholiclivercirrhosis, which makes it possible for them to drink themselves to death.
nsubj||examined-2/VBD||we-1/PRP	root||ROOT-0/null||examined-2/VBD	det||mechanisms-6/NNS||the-3/DT	amod||mechanisms-6/NNS||possible-4/JJ	amod||mechanisms-6/NNS||anti-inflammatory-5/JJ	dobj||examined-2/VBD||mechanisms-6/NNS	prep_of||mechanisms-6/NNS||gabapentin-8/NN	det||attenuation-11/NN||the-10/DT	prep_in||examined-2/VBD||attenuation-11/NN	prep_of||attenuation-11/NN||neuropathicpain-13/NN	det||interaction-16/NN||the-15/DT	prep_in||examined-2/VBD||interaction-16/NN	conj_and||attenuation-11/NN||interaction-16/NN	det||effects-20/NNS||the-18/DT	amod||effects-20/NNS||anti-allodynic-19/JJ	prep_between||interaction-16/NN||effects-20/NNS	prep_of||effects-20/NNS||gabapentin-22/NN	amod||expression-28/NN||interleukin-10-24/JJ	dep||expression-28/NN||il-10-26/JJ	prep_between||interaction-16/NN||expression-28/NN	conj_and||effects-20/NNS||expression-28/NN	det||model-32/NN||a-30/DT	nn||model-32/NN||rat-31/NN	prep_in||expression-28/NN||model-32/NN	prep_of||model-32/NN||neuropathicpain-34/NN	gabapentin-22||neuropathicpain-34||no_rel||we examined the possible anti-inflammatory mechanisms of gabapentin in the attenuation of neuropathicpain and the interaction between the anti-allodynic effects of gabapentin and interleukin-10 (il-10) expression in a rat model of neuropathicpain.
nsubj||impact-13/VB||aim-1/NN	nn||gain-4/NN||weight-3/NN	prep_as||aim-1/NN||gain-4/NN	prep_as||aim-1/NN||hypoglycaemia-6/NN	conj_and||gain-4/NN||hypoglycaemia-6/NN	vmod||aim-1/NN||associated-7/VBN	amod||therapy-10/NN||glimepiride-9/JJ	prep_with||associated-7/VBN||therapy-10/NN	aux||impact-13/VB||can-11/MD	advmod||impact-13/VB||negatively-12/RB	ccomp||investigated-28/VBD||impact-13/VB	nn||perceptions-15/NNS||weight-14/NN	dobj||impact-13/VB||perceptions-15/NNS	amod||well-being-18/NN||psychological-17/JJ	dobj||impact-13/VB||well-being-18/NN	conj_and||perceptions-15/NNS||well-being-18/NN	amod||quality-21/NN||overall-20/JJ	dobj||impact-13/VB||quality-21/NN	conj_and||perceptions-15/NNS||quality-21/NN	prep_of||quality-21/NN||life-23/NN	prep_in||impact-13/VB||type2diabetes-25/CD	nsubj||investigated-28/VBD||we-27/PRP	root||ROOT-0/null||investigated-28/VBD	mark||improve-33/VB||whether-29/IN	amod||treatment-31/NN||liraglutide-30/JJ	nsubj||improve-33/VB||treatment-31/NN	aux||improve-33/VB||could-32/MD	ccomp||investigated-28/VBD||improve-33/VB	det||factors-35/NNS||these-34/DT	dobj||improve-33/VB||factors-35/NNS	type2diabetes-25||glimepiride-9||yes||aim as weight gain and hypoglycaemia associated with glimepiride therapy can negatively impact weight perceptions, psychological well-being and overall quality of life in type2diabetes, we investigated whether liraglutide treatment could improve these factors.
nsubj||studied-2/VBD||we-1/PRP	root||ROOT-0/null||studied-2/VBD	det||expression-4/NN||the-3/DT	dobj||studied-2/VBD||expression-4/NN	nn||i-vi-7/NN||prx-6/NN	prep_of||expression-4/NN||i-vi-7/NN	poss||relationship-10/NN||their-9/PRP$	prep_of||expression-4/NN||relationship-10/NN	conj_and||i-vi-7/NN||relationship-10/NN	amod||survival-13/NN||patient-12/JJ	prep_to||studied-2/VBD||survival-13/NN	num||grade-16/NN||383-15/CD	npadvmod||ii-iv-17/JJ||grade-16/NN	amod||braintumors-20/NNS||ii-iv-17/JJ	amod||braintumors-20/NNS||diffuse-18/JJ	amod||braintumors-20/NNS||astrocytic-19/JJ	prep_in||survival-13/NN||braintumors-20/NNS	i---1||braintumors-20||no_rel||we studied the expression of prx i-vi and their relationship to patient survival in 383 grade ii-iv diffuse astrocytic braintumors.
poss||case-2/NN||our-1/PRP$	nsubj||report-7/NN||case-2/NN	cop||report-7/NN||is-3/VBZ	advmod||report-7/NN||also-4/RB	det||report-7/NN||a-5/DT	amod||report-7/NN||first-6/JJ	root||ROOT-0/null||report-7/NN	nn||complex-11/NN||mycobacteria-9/NN	nn||complex-11/NN||avium-10/NN	prep_of||report-7/NN||complex-11/NN	nn||gordonae-14/NN||mycobacteria-13/NN	prep_of||report-7/NN||gordonae-14/NN	conj_and||complex-11/NN||gordonae-14/NN	vmod||complex-11/NN||isolated-15/VBN	advmod||isolated-15/VBN||simultaneously-16/RB	amod||patient-19/NN||individual-18/JJ	prep_from||isolated-15/VBN||patient-19/NN	amod||mycobacterialdisease-22/NN||nontuberculous-21/JJ	prep_with||isolated-15/VBN||mycobacterialdisease-22/NN	mycobacterialdisease-22||mycobacteria-13||no||our case is also a first report of mycobacteria avium complex and mycobacteria gordonae isolated simultaneously from individual patient with nontuberculous mycobacterialdisease.
det||patient-2/NN||the-1/DT	nsubjpass||treated-4/VBN||patient-2/NN	auxpass||treated-4/VBN||was-3/VBD	ccomp||dipropionate-20/VBP||treated-4/VBN	amod||mg-9/NN||oral-6/JJ	amod||mg-9/NN||methylprednisolone-7/JJ	dep||methylprednisolone-7/JJ||48-8/CD	prep_with||treated-4/VBN||mg-9/NN	nn||®-12/NNP||prednolâ-11/NNP	dep||mg-9/NN||®-12/NNP	nn||nevzat-15/NN||mustafa-14/NN	dep||®-12/NNP||nevzat-15/NN	amod||clobetasol-19/NN||topical-18/JJ	nsubj||dipropionate-20/VBP||clobetasol-19/NN	root||ROOT-0/null||dipropionate-20/VBP	num||cream-23/NN||0.05-21/CD	nn||cream-23/NN||%-22/NN	dobj||dipropionate-20/VBP||cream-23/NN	nn||®-26/NNP||dermovateâ-25/NNP	dep||cream-23/NN||®-26/NNP	nn||smithkline-29/NN||glaxo-28/NN	dep||®-26/NNP||smithkline-29/NN	amod||urea-36/NN||topical-33/JJ	number||%-35/NN||4-34/CD	amod||urea-36/NN||%-35/NN	dobj||dipropionate-20/VBP||urea-36/NN	conj_and||cream-23/NN||urea-36/NN	dep||cream-23/NN||lotion-37/NN	amod||®-41/NNS||excipial-39/JJ	amod||®-41/NNS||lipoâ-40/JJ	dep||lotion-37/NN||®-41/NNS	dep||®-41/NNS||orva-43/NN	amod||bullouspemphigoid-47/NN||presumptive-46/JJ	prep_for||lotion-37/NN||bullouspemphigoid-47/NN	bullouspemphigoid-47||clobetasol-19||no_rel||the patient was treated with oral methylprednisolone 48 mg (prednolâ®; mustafa nevzat), topical clobetasol dipropionate 0.05% cream (dermovateâ®; glaxo smithkline), and topical 4% urea lotion (excipial lipoâ®; orva) for presumptive bullouspemphigoid.
amod||2b-3/NNS||high-dose-1/JJ	amod||2b-3/NNS||interferon-alpha-2/JJ	nsubj||therapy-14/NN||2b-3/NNS	num||2b-7/NNS||ifn-î-5/CD	nn||2b-7/NNS||±-6/NNP	appos||2b-3/NNS||2b-7/NNS	cop||therapy-14/NN||is-9/VBZ	det||therapy-14/NN||the-10/DT	advmod||therapy-14/NN||only-11/RB	amod||therapy-14/NN||approved-12/VBN	amod||therapy-14/NN||systemic-13/JJ	root||ROOT-0/null||therapy-14/NN	det||states-18/NNS||the-16/DT	amod||states-18/NNS||united-17/VBN	prep_in||therapy-14/NN||states-18/NNS	det||treatment-22/NN||the-20/DT	amod||treatment-22/NN||adjuvant-21/JJ	prep_for||states-18/NNS||treatment-22/NN	prep_of||treatment-22/NN||melanoma-24/NN	melanoma-24||interferon--1||yes||high-dose interferon-alpha 2b (ifn-î± 2b) is the only approved systemic therapy in the united states for the adjuvant treatment of melanoma.
mark||occurred-8/VBD||while-1/IN	nsubj||occurred-8/VBD||some-2/DT	det||temperatures-7/NNS||the-4/DT	amod||temperatures-7/NNS||late-5/JJ	amod||temperatures-7/NNS||high-6/JJ	prep_of||some-2/DT||temperatures-7/NNS	advcl||apparent-19/JJ||occurred-8/VBD	det||setting-11/NN||the-10/DT	prep_in||occurred-8/VBD||setting-11/NN	amod||tachycardia-14/NN||marked-13/JJ	prep_of||setting-11/NN||tachycardia-14/NN	nsubj||apparent-19/JJ||it-16/PRP	cop||apparent-19/JJ||was-17/VBD	advmod||apparent-19/JJ||also-18/RB	root||ROOT-0/null||apparent-19/JJ	mark||accompanied-27/VBN||that-20/IN	det||cases-23/NNS||some-22/DT	prep_in||accompanied-27/VBN||cases-23/NNS	nsubjpass||accompanied-27/VBN||fever-24/NN	auxpass||accompanied-27/VBN||was-25/VBD	neg||accompanied-27/VBN||not-26/RB	ccomp||apparent-19/JJ||accompanied-27/VBN	agent||accompanied-27/VBN||tachycardia-29/NN	xcomp||accompanied-27/VBN||making-31/VBG	amod||atropine-33/NN||excessive-32/JJ	dobj||making-31/VBG||atropine-33/NN	amod||infection-36/NN||severe-35/JJ	dobj||making-31/VBG||infection-36/NN	conj_or||atropine-33/NN||infection-36/NN	det||explanation-39/NN||an-37/DT	amod||explanation-39/NN||unlikely-38/JJ	dep||infection-36/NN||explanation-39/NN	predet||fevers-43/NNS||all-41/PDT	det||fevers-43/NNS||the-42/DT	prep_for||making-31/VBG||fevers-43/NNS	tachycardia-29||atropine-33||no||while some of the late high temperatures occurred in the setting of marked tachycardia, it was also apparent that in some cases fever was not accompanied by tachycardia, making excessive atropine or severe infection an unlikely explanation for all the fevers.
det||initiative-7/NN||the-1/DT	amod||initiative-7/NN||womenâ-2/JJ	amod||initiative-7/NN||$-3/$	number||s-5/CD||-4/CD	num||$-3/$||s-5/CD	nn||initiative-7/NN||health-6/NN	nsubj||found-8/VBD||initiative-7/NN	root||ROOT-0/null||found-8/VBD	mark||increases-17/VBZ||that-9/IN	nn||estrogen-11/NN||combination-10/NN	nsubj||increases-17/VBZ||estrogen-11/NN	amod||therapy-16/NN||progesterone-13/JJ	nn||therapy-16/NN||hormone-14/NN	nn||therapy-16/NN||replacement-15/NN	conj_and||estrogen-11/NN||therapy-16/NN	nsubj||increases-17/VBZ||therapy-16/NN	ccomp||found-8/VBD||increases-17/VBZ	nn||cancer-19/NN||breast-18/NN	dobj||increases-17/VBZ||cancer-19/NN	nsubj||compelled-25/VBN||cancer-19/NN	nn||risk-22/NN||cardiovasculardisease-21/NN	dobj||increases-17/VBZ||risk-22/NN	conj_and||cancer-19/NN||risk-22/NN	nsubj||compelled-25/VBN||risk-22/NN	rcmod||cancer-19/NN||compelled-25/VBN	amod||women-27/NNS||many-26/JJ	dobj||compelled-25/VBN||women-27/NNS	nsubj||seek-29/VB||women-27/NNS	aux||seek-29/VB||to-28/TO	xcomp||compelled-25/VBN||seek-29/VB	amod||alternatives-31/NNS||herbal-30/JJ	nsubj||extract-35/VB||alternatives-31/NNS	prep_such_as||alternatives-31/NNS||blackcohosh-34/NN	ccomp||seek-29/VB||extract-35/VB	dobj||extract-35/VB||bce-37/NN	nsubj||relieve-40/VB||bce-37/NN	aux||relieve-40/VB||to-39/TO	xcomp||extract-35/VB||relieve-40/VB	poss||symptoms-43/NNS||their-41/PRP$	amod||symptoms-43/NNS||menopausal-42/JJ	dobj||relieve-40/VB||symptoms-43/NNS	cancer-19||hormone-14||no_rel||the womenâs health initiative found that combination estrogen and progesterone hormone replacement therapy increases breast cancer and cardiovasculardisease risk, which compelled many women to seek herbal alternatives such as blackcohosh extract (bce) to relieve their menopausal symptoms.
det||understanding-3/NN||a-1/DT	amod||understanding-3/NN||better-2/JJR	nsubj||help-12/VB||understanding-3/NN	nsubj||develop-14/VB||understanding-3/NN	det||anorexia-10/NN||the-5/DT	amod||anorexia-10/NN||neurobiological-6/JJ	nn||anorexia-10/NN||mechanisms-7/NNP	amod||anorexia-10/NN||underlying-8/JJ	amod||anorexia-10/NN||inflammation-associated-9/JJ	prep_of||understanding-3/NN||anorexia-10/NN	aux||help-12/VB||will-11/MD	root||ROOT-0/null||help-12/VB	aux||develop-14/VB||to-13/TO	xcomp||help-12/VB||develop-14/VB	nn||stimulants-16/NNS||appetite-15/NN	dobj||develop-14/VB||stimulants-16/NNS	nn||patients-21/NNS||cancer-18/NN	conj_and||cancer-18/NN||aids-20/NNS	nn||patients-21/NNS||aids-20/NNS	prep_for||develop-14/VB||patients-21/NNS	stimulants-16||inflammation--1||no_rel||a better understanding of the neurobiological mechanisms underlying inflammation-associated anorexia will help to develop appetite stimulants for cancer and aids patients.
mark||regards-2/VBZ||with-1/IN	advcl||different-29/JJ||regards-2/VBZ	prep_to||regards-2/VBZ||culture-4/NN	det||rate-8/NN||the-6/DT	nn||rate-8/NN||conversion-7/NN	nsubj||different-29/JJ||rate-8/NN	det||period-12/NN||the-10/DT	amod||period-12/NN||whole-11/JJ	prep_during||rate-8/NN||period-12/NN	det||treatment-15/NN||the-14/DT	prep_of||period-12/NN||treatment-15/NN	dep||treatment-15/NN||2-17/CD	amod||2-17/CD||8-19/CD	nn||weeks-24/NNS||12-21/CD	conj_and||12-21/CD||20-23/CD	nn||weeks-24/NNS||20-23/CD	appos||2-17/CD||weeks-24/NNS	cop||different-29/JJ||were-26/VBD	neg||different-29/JJ||not-27/RB	advmod||different-29/JJ||significantly-28/RB	root||ROOT-0/null||different-29/JJ	amod||patients-35/NNS||hivpositive-31/JJ	conj_and||hivpositive-31/JJ||hiv-33/JJ	amod||patients-35/NNS||hiv-33/JJ	amod||patients-35/NNS||negative-34/JJ	prep_between||different-29/JJ||patients-35/NNS	hivpositive-31||hiv-33||no||with regards to culture, the conversion rate during the whole period of the treatment (2, 8, 12 and 20 weeks) were not significantly different between hivpositive and hiv negative patients.
amod||epidemic-6/NN||chikungunyavirus-2/JJ	appos||epidemic-6/NN||chikv-4/NNP	prep_during||identified-13/VBD||epidemic-6/NN	prep_in||epidemic-6/NN||nagpur-8/NN	appos||nagpur-8/NN||india-10/NN	nsubj||identified-13/VBD||we-12/PRP	root||ROOT-0/null||identified-13/VBD	det||patients-17/NNS||some-14/DT	amod||patients-17/NNS||suspected-15/VBN	nn||patients-17/NNS||chikungunya-16/NN	dobj||identified-13/VBD||patients-17/NNS	amod||complications-20/NNS||neurological-19/JJ	prep_with||identified-13/VBD||complications-20/NNS	chikungunya-16||chikungunyavirus-2||no||during chikungunyavirus (chikv) epidemic in nagpur, india, we identified some suspected chikungunya patients with neurological complications.
nsubj||leads-3/VBZ||gr-1/NN	nsubj||hypertension-5/VB||gr-1/NN	nsubj||hypertension-5/VB||gr-1/NN	advmod||leads-3/VBZ||haploinsufficiency-2/RB	root||ROOT-0/null||leads-3/VBZ	aux||hypertension-5/VB||to-4/TO	xcomp||leads-3/VBZ||hypertension-5/VB	xcomp||leads-3/VBZ||hypertension-5/VB	conj_negcc||hypertension-5/VB||hypertension-5/VB	acomp||hypertension-5/VB||due-6/JJ	amod||occupation-9/NN||illicit-8/JJ	prep_to||due-6/JJ||occupation-9/NN	amod||receptor-13/NN||renal-11/JJ	amod||receptor-13/NN||mineralocorticoid-12/JJ	prep_of||occupation-9/NN||receptor-13/NN	amod||cortisol-16/NN||elevated-15/JJ	prep_by||hypertension-5/VB||cortisol-16/NN	amod||production-22/NN||increased-20/VBN	amod||production-22/NN||mineralocorticoid-21/JJ	prep_to||hypertension-5/VB||production-22/NN	vmod||production-22/NN||reported-23/VBN	amod||resistance-27/NN||primary-25/JJ	amod||resistance-27/NN||glucocorticoid-26/JJ	prep_in||reported-23/VBN||resistance-27/NN	glucocorticoid-26||hypertension-5||no_rel||gr haploinsufficiency leads to hypertension due to illicit occupation of renal mineralocorticoid receptor by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.
prep_in||tb-7/NN||children-2/NNS	prep_in||accompanied-24/VBN||children-2/NNS	amod||tb-7/NN||definite-4/JJ	conj_or||definite-4/JJ||probable-6/JJ	amod||tb-7/NN||probable-6/JJ	prep_with||positive-17/JJ||tb-7/NN	det||result-15/NN||the-10/DT	amod||result-15/NN||ifn-î-11/JJ	amod||result-15/NN||³-12/JJ	nn||result-15/NN||elispot-13/NN	nn||result-15/NN||assay-14/NN	nsubj||positive-17/JJ||result-15/NN	cop||positive-17/JJ||was-16/VBD	rcmod||children-2/NNS||positive-17/JJ	prep_at||positive-17/JJ||presentation-19/NN	amod||treatment-22/NN||anti-tuberculous-21/JJ	nsubjpass||accompanied-24/VBN||treatment-22/NN	auxpass||accompanied-24/VBN||was-23/VBD	root||ROOT-0/null||accompanied-24/VBN	det||decrease-28/NN||a-26/DT	amod||decrease-28/NN||significant-27/JJ	agent||accompanied-24/VBN||decrease-28/NN	preconj||magnitude-32/NN||both-30/PDT	det||magnitude-32/NN||the-31/DT	prep_in||decrease-28/NN||magnitude-32/NN	det||response-37/NN||the-34/DT	amod||response-37/NN||ifn-î-35/JJ	amod||response-37/NN||³-36/JJ	prep_of||magnitude-32/NN||response-37/NN	prep_to||response-37/NN||individual-39/NN	amod||antigens-43/NNS||combined-41/VBN	amod||antigens-43/NNS||mtb-specific-42/JJ	prep_in||decrease-28/NN||antigens-43/NNS	conj_or||magnitude-32/NN||antigens-43/NNS	advmod||esat-6-45/JJ||-lrb--44/RB	amod||antigens-43/NNS||esat-6-45/JJ	amod||-rrb--53/NN||median-46/JJ	num||sfcs/106-48/NNS||110-47/CD	npadvmod||pbmc-49/JJ||sfcs/106-48/NNS	amod||-rrb--53/NN||pbmc-49/JJ	nn||-rrb--53/NN||-lrb--50/NN	nn||-rrb--53/NN||iqr-51/NN	num||-rrb--53/NN||65-305-52/CD	dep||antigens-43/NNS||-rrb--53/NN	prep_at||-rrb--53/NN||presentation-55/NN	prep_vs.||presentation-55/NN||15-57/CD	vmod||presentation-55/NN||-lrb--58/VBG	num||-lrb--118/NNS||10-115-59/CD	conj_and||-rrb--60/JJ||-rrb--60/JJ	amod||-lrb--118/NNS||-rrb--60/JJ	amod||-lrb--118/NNS||-rrb--60/JJ	num||months-63/NNS||six-62/CD	prep_at||-rrb--60/JJ||months-63/NNS	vmod||months-63/NNS||p-65/VBN	dep||0.04-67/CD||=-66/SYM	ccomp||p-65/VBN||0.04-67/CD	amod||-rrb--73/NNS||cfp-10-69/JJ	dep||cfp-10-69/JJ||177-70/CD	amod||-rrb--73/NNS||-lrb--71/JJ	amod||-rrb--73/NNS||48-508-72/JJ	dep||months-63/NNS||-rrb--73/NNS	prep_vs.||-rrb--73/NNS||20-75/CD	amod||-rrb--73/NNS||-lrb--76/JJ	num||-rrb--78/NNS||5-165-77/CD	dep||-lrb--76/JJ||-rrb--78/NNS	vmod||-rrb--73/NNS||p-80/VBN	dep||0.004-82/CD||=-81/SYM	ccomp||p-80/VBN||0.004-82/CD	amod||iqr-92/NNS||esat-6-84/JJ	conj_or||esat-6-84/JJ||cfp-10-86/JJ	amod||iqr-92/NNS||cfp-10-86/JJ	nn||iqr-92/NNS||median-87/NN	amod||iqr-92/NNS||250-88/VBD	amod||iqr-92/NNS||sfcs/106-89/JJ	amod||iqr-92/NNS||pbmc-90/JJ	nn||iqr-92/NNS||-lrb--91/NN	appos||-rrb--73/NNS||iqr-92/NNS	num||-rrb--94/NNS||94-508-93/CD	dep||-rrb--73/NNS||-rrb--94/NNS	num||-rrb--99/NNS||25-96/CD	amod||-rrb--99/NNS||-lrb--97/VBG	num||-rrb--99/NNS||10-165-98/CD	prep_vs.||-rrb--94/NNS||-rrb--99/NNS	vmod||months-63/NNS||p-101/VBN	dep||-rrb--104/NNS||=-102/SYM	num||-rrb--104/NNS||0.004-103/CD	ccomp||p-101/VBN||-rrb--104/NNS	det||proportion-108/NN||the-107/DT	prep_in||-rrb--60/JJ||proportion-108/NN	prep_of||proportion-108/NN||children-110/NNS	det||ifn-î-114/NN||a-112/DT	amod||ifn-î-114/NN||positive-113/JJ	prep_with||children-110/NNS||ifn-î-114/NN	amod||-lrb--118/NNS||³-115/JJ	amod||-lrb--118/NNS||elispot-116/JJ	nn||-lrb--118/NNS||assay-117/NN	dobj||-lrb--58/VBG||-lrb--118/NNS	poss||vs-125/NN||fisher-119/NN	amod||vs-125/NN||exact-121/JJ	nn||vs-125/NN||test-122/NN	nn||vs-125/NN||esat-6-123/NN	num||vs-125/NN||15/0-124/CD	dep||-lrb--118/NNS||vs-125/NN	dep||-lrb--118/NNS||5/11-126/CD	vmod||5/11-126/CD||p-128/VBN	dep||0.0002-130/CD||=-129/SYM	ccomp||p-128/VBN||0.0002-130/CD	amod||-lrb--118/NNS||cfp-10-132/JJ	dep||cfp-10-132/JJ||22/0-133/CD	amod||-rrb--53/NN||vs-134/JJ	dep||vs-134/JJ||8/17-135/CD	vmod||-rrb--53/NN||p-137/VBN	dep||0.0001-139/CD||=-138/SYM	ccomp||p-137/VBN||0.0001-139/CD	amod||-rrb--53/NN||esat-6-141/JJ	amod||-rrb--53/NN||cfp-10-143/JJ	conj_or||esat-6-141/JJ||cfp-10-143/JJ	dep||-rrb--53/NN||22/0-144/CD	prep_vs.||22/0-144/CD||9/17-146/CD	vmod||22/0-144/CD||p-148/VBN	dep||-rrb--151/NNS||=-149/SYM	num||-rrb--151/NNS||0.002-150/CD	ccomp||p-148/VBN||-rrb--151/NNS	tuberculous--1||mtb--1||no||in children with definite or probable tb in whom the ifn-î ³ elispot assay result was positive at presentation , anti-tuberculous treatment was accompanied by a significant decrease in both the magnitude of the ifn-î ³ response to individual or combined mtb-specific antigens -lrb- esat-6 median 110 sfcs/106 pbmc -lrb- iqr 65-305 -rrb- at presentation vs. 15 -lrb- 10-115 -rrb- at six months , p = 0.04 ; cfp-10 177 -lrb- 48-508 -rrb- vs. 20 -lrb- 5-165 -rrb- , p = 0.004 , esat-6 or cfp-10 median 250 sfcs/106 pbmc -lrb- iqr 94-508 -rrb- vs. 25 -lrb- 10-165 -rrb- , p = 0.004 -rrb- and in the proportion of children with a positive ifn-î ³ elispot assay -lrb- fisher 's exact test esat-6 15/0 vs 5/11 , p = 0.0002 , cfp-10 22/0 vs 8/17 , p = 0.0001 , esat-6 or cfp-10 22/0 vs. 9/17 , p = 0.002 -rrb- .
nn||concentrations-2/NNS||serum-1/NN	nsubjpass||measured-50/VBN||concentrations-2/NNS	amod||cytokines-5/NNS||proinflammatory-4/JJ	prep_of||concentrations-2/NNS||cytokines-5/NNS	amod||interleukin-6-8/JJ||interleukin-1alpha-6/JJ	amod||cytokines-5/NNS||interleukin-6-8/JJ	nn||necrosis-11/NNS||tumor-10/NN	prep_of||concentrations-2/NNS||necrosis-11/NNS	conj_and||cytokines-5/NNS||necrosis-11/NNS	amod||colonystimulatingfactor-15/NN||factor-alpha-12/JJ	amod||colonystimulatingfactor-15/NN||granulocyte-macrophage-14/JJ	dep||necrosis-11/NNS||colonystimulatingfactor-15/NN	dep||colonystimulatingfactor-15/NN||gm-csf-17/JJ	det||markers-22/NNS||some-20/DT	amod||markers-22/NNS||biochemical-21/JJ	prep_of||concentrations-2/NNS||markers-22/NNS	conj_and||cytokines-5/NNS||markers-22/NNS	prep_of||markers-22/NNS||osteoporosis-24/NN	nn||alkaline-31/NN||osteocalcin-26/NN	conj_and||osteocalcin-26/NN||total-28/NN	nn||alkaline-31/NN||total-28/NN	conj_and||osteocalcin-26/NN||bone-30/NN	nn||alkaline-31/NN||bone-30/NN	dep||concentrations-2/NNS||alkaline-31/NN	amod||telopeptides-41/NNS||phosphatase-32/JJ	amod||telopeptides-41/NNS||procollagen-34/JJ	nn||telopeptides-41/NNS||type-35/NN	amod||telopeptides-41/NNS||i-36/JJ	amod||telopeptides-41/NNS||carboxyterminal-37/JJ	amod||telopeptides-41/NNS||propeptide-38/JJ	amod||telopeptides-41/NNS||carboxyterminal-40/JJ	dep||alkaline-31/NN||telopeptides-41/NNS	nn||collagen-45/NN||type-43/FW	nn||collagen-45/NN||i-44/FW	prep_of||telopeptides-41/NNS||collagen-45/NN	dep||collagen-45/NN||ctx-47/NN	auxpass||measured-50/VBN||were-49/VBD	root||ROOT-0/null||measured-50/VBN	ctx-47||tumor-10||no_rel||serum concentrations of proinflammatory cytokines interleukin-1alpha, interleukin-6, tumor necrosis factor-alpha, granulocyte-macrophage colonystimulatingfactor (gm-csf) and some biochemical markers of osteoporosis (osteocalcin, total and bone alkaline phosphatase, procollagen type i carboxyterminal propeptide, carboxyterminal telopeptides of type i collagen--ctx) were measured.
amod||organizations-2/NNS||professional-1/JJ	nsubj||updated-4/VBN||organizations-2/NNS	aux||updated-4/VBN||have-3/VBP	root||ROOT-0/null||updated-4/VBN	poss||guidelines-6/NNS||their-5/PRP$	dobj||updated-4/VBN||guidelines-6/NNS	prep_for||updated-4/VBN||t2d-8/CD	aux||include-10/VB||to-9/TO	vmod||updated-4/VBN||include-10/VB	det||inhibitor-13/NN||a-11/DT	amod||inhibitor-13/NN||dpp-4-12/JJ	dobj||include-10/VB||inhibitor-13/NN	det||$-19/NNP||an-15/DT	amod||$-19/NNP||early-16/JJ	nn||$-19/NNP||treatment-17/NN	nn||$-19/NNP||optionâ-18/NNP	prep_as||include-10/VB||$-19/NNP	preconj||include-10/VB||either-21/CC	amod||therapy-24/NN||initial-23/JJ	prep_as||include-10/VB||therapy-24/NN	conj_or||$-19/NNP||therapy-24/NN	prep_in||therapy-24/NN||combination-26/NN	prep_with||combination-26/NN||metformin-28/NN	amod||therapy-33/NN||add-on-32/JJ	prep_as||include-10/VB||therapy-33/NN	conj_or||$-19/NNP||therapy-33/NN	prep_for||include-10/VB||patients-35/NNS	poss||glycemia-37/NNS||patients-35/NNS	nsubjpass||controlled-40/VBN||glycemia-37/NNS	auxpass||controlled-40/VBN||is-38/VBZ	advmod||controlled-40/VBN||inadequately-39/RB	rcmod||patients-35/NNS||controlled-40/VBN	det||drug-46/NN||a-42/DT	amod||drug-46/NN||single-43/JJ	amod||drug-46/NN||oral-44/JJ	amod||drug-46/NN||antidiabetic-45/JJ	agent||controlled-40/VBN||drug-46/NN	t2d-8||metformin-28||yes||professional organizations have updated their guidelines for t2d to include a dpp-4 inhibitor as an early treatment optionâeither as initial therapy in combination with metformin, or as add-on therapy for patients whose glycemia is inadequately controlled by a single oral antidiabetic drug.
poss||efficacy-4/NN||its-2/PRP$	amod||efficacy-4/NN||well-established-3/JJ	prep_despite||is-22/VBZ||efficacy-4/NN	prepc_in||efficacy-4/NN||reducing-6/VBG	amod||death-8/NN||cardiac-related-7/JJ	dobj||reducing-6/VBG||death-8/NN	dobj||reducing-6/VBG||myocardialinfarction-10/NN	conj_and||death-8/NN||myocardialinfarction-10/NN	dobj||reducing-6/VBG||stroke-13/NN	conj_and||death-8/NN||stroke-13/NN	amod||therapy-17/NN||dual-15/JJ	nn||therapy-17/NN||antiplatelet-16/NN	nsubj||is-22/VBZ||therapy-17/NN	prep_with||therapy-17/NN||aspirin-19/NN	prep_with||therapy-17/NN||clopidogrel-21/NN	conj_and||aspirin-19/NN||clopidogrel-21/NN	root||ROOT-0/null||is-22/VBZ	neg||is-22/VBZ||not-23/RB	prep_without||is-22/VBZ||shortcomings-25/NNS	myocardialinfarction-10||aspirin-19||yes||despite its well-established efficacy in reducing cardiac-related death, myocardialinfarction, and stroke, dual antiplatelet therapy with aspirin and clopidogrel is not without shortcomings.
det||sequencing-5/NN||the-1/DT	nn||sequencing-5/NN||isolation-2/NN	conj_and||isolation-2/NN||genome-4/NN	nn||sequencing-5/NN||genome-4/NN	nsubj||enable-15/VB||sequencing-5/NN	amod||viruses-8/NNS||uncultivated-7/JJ	prep_of||sequencing-5/NN||viruses-8/NNS	vmod||viruses-8/NNS||using-9/VBG	amod||approaches-13/NNS||single-10/JJ	nn||approaches-13/NNS||virus-11/NN	nn||approaches-13/NNS||genomics-12/NNS	dobj||using-9/VBG||approaches-13/NNS	aux||enable-15/VB||will-14/MD	root||ROOT-0/null||enable-15/VB	dobj||enable-15/VB||researchers-16/NNS	nsubj||address-18/VB||researchers-16/NNS	aux||address-18/VB||to-17/TO	xcomp||enable-15/VB||address-18/VB	dobj||address-18/VB||questions-19/NNS	nsubj||unattainable-32/JJ||questions-19/NNS	amod||diversity-22/NN||viral-21/JJ	prep_about||questions-19/NNS||diversity-22/NN	prep_about||questions-19/NNS||evolution-24/NN	conj_and||diversity-22/NN||evolution-24/NN	prep_about||questions-19/NNS||adaptation-26/NN	conj_and||diversity-22/NN||adaptation-26/NN	prep_about||questions-19/NNS||ecology-28/NN	conj_and||diversity-22/NN||ecology-28/NN	cop||unattainable-32/JJ||were-30/VBD	advmod||unattainable-32/JJ||previously-31/RB	rcmod||questions-19/NNS||unattainable-32/JJ	virus-11||viruses-8||no||the isolation and genome sequencing of uncultivated viruses using single virus genomics approaches will enable researchers to address questions about viral diversity, evolution, adaptation and ecology that were previously unattainable.
det||study-6/NN||the-1/DT	amod||study-6/NN||chinese-2/JJ	nn||study-6/NN||hypertension-3/NN	nn||study-6/NN||intervention-4/NN	nn||study-6/NN||efficacy-5/NN	nsubj||randomized-13/NN||study-6/NN	appos||study-6/NN||chief-8/NN	cop||randomized-13/NN||is-10/VBZ	det||randomized-13/NN||a-11/DT	amod||randomized-13/NN||multi-centre-12/JJ	root||ROOT-0/null||randomized-13/NN	dep||randomized-13/NN||controlled-14/VBN	amod||trial-16/NN||clinical-15/JJ	dobj||controlled-14/VBN||trial-16/NN	xcomp||controlled-14/VBN||comparing-17/VBG	det||effects-19/NNS||the-18/DT	dobj||comparing-17/VBG||effects-19/NNS	amod||blocker-26/NN||amlodipine-21/JJ	nn||blocker-26/NN||+-22/NNP	nn||blocker-26/NN||angiotensin-23/NN	nn||blocker-26/NN||ii-24/NN	nn||blocker-26/NN||receptor-25/NN	prep_of||effects-19/NNS||blocker-26/NN	nn||diuretics-30/NNS||amlodipine-28/NN	nn||diuretics-30/NNS||+-29/NN	prep_of||effects-19/NNS||diuretics-30/NNS	conj_and||blocker-26/NN||diuretics-30/NNS	det||incidence-33/NN||the-32/DT	prep_on||comparing-17/VBG||incidence-33/NN	amod||events-36/NNS||cardiovascular-35/JJ	prep_of||incidence-33/NN||events-36/NNS	dep||controlled-14/VBN||represented-38/VBN	det||composite-41/NN||a-40/DT	prep_as||represented-38/VBN||composite-41/NN	amod||stroke-44/NN||non-fatal-43/JJ	prep_of||composite-41/NN||stroke-44/NN	amod||myocardialinfarction-47/NN||non-fatal-46/JJ	dobj||controlled-14/VBN||myocardialinfarction-47/NN	amod||events-51/NNS||cardiovascular-49/JJ	nn||events-51/NNS||death-50/NN	dobj||controlled-14/VBN||events-51/NNS	conj_and||myocardialinfarction-47/NN||events-51/NNS	amod||patients-56/NNS||high-risk-53/JJ	nn||patients-56/NNS||chinese-54/NN	nn||patients-56/NNS||hypertensive-55/NN	prep_in||myocardialinfarction-47/NN||patients-56/NNS	hypertension-3||amlodipine-28||yes||the chinese hypertension intervention efficacy study (chief) is a multi-centre randomized controlled clinical trial comparing the effects of amlodipine+angiotensin ii receptor blocker and amlodipine+diuretics on the incidence of cardiovascular events, represented as a composite of non-fatal stroke, non-fatal myocardialinfarction and cardiovascular death events in high-risk chinese hypertensive patients.
advmod||see-3/VBP||here-1/RB	nsubj||see-3/VBP||we-2/PRP	root||ROOT-0/null||see-3/VBP	mark||occurs-10/VBZ||that-4/IN	amod||patients-7/NNS||obese-6/JJ	prep_in||occurs-10/VBZ||patients-7/NNS	nsubj||occurs-10/VBZ||hyperandrogenism-9/NN	ccomp||see-3/VBP||occurs-10/VBZ	det||result-13/NN||a-12/DT	prep_as||occurs-10/VBZ||result-13/NN	prep_of||result-13/NN||hyperinsulinemia-15/NN	amod||conversion-20/NN||peripheral-19/JJ	prep_as||occurs-10/VBZ||conversion-20/NN	conj_and||result-13/NN||conversion-20/NN	prep_of||conversion-20/NN||estrogens-22/NNS	prep_into||occurs-10/VBZ||androgens-24/NNS	det||tissue-29/NN||the-26/DT	amod||tissue-29/NN||excessive-27/JJ	nn||tissue-29/NN||adipose-28/NN	prep_in||androgens-24/NNS||tissue-29/NN	obese-6||estrogens-22||no_rel||here we see that in obese patients, hyperandrogenism occurs as a result of hyperinsulinemia as well as peripheral conversion of estrogens into androgens in the excessive adipose tissue.
nsubj||resulted-13/VBD||phagocytosis-1/NNS	prep_of||phagocytosis-1/NNS||cvb3-infected-3/JJ	amod||islets-12/NNS||mock-infected-7/JJ	conj_and||mock-infected-7/JJ||human-9/JJ	amod||islets-12/NNS||human-9/JJ	conj_and||mock-infected-7/JJ||porcine-11/JJ	amod||islets-12/NNS||porcine-11/JJ	prep_of||phagocytosis-1/NNS||islets-12/NNS	conj_negcc||cvb3-infected-3/JJ||islets-12/NNS	root||ROOT-0/null||resulted-13/VBD	prep_in||resulted-13/VBD||induction-15/NN	prep_of||induction-15/NN||isgs-17/NNS	prep_in||resulted-13/VBD||dcs-19/NN	det||rig-29/NN||the-22/DT	nn||rig-29/NN||retinoicacidâ-23/NNP	nn||rig-29/NN||$-24/NNP	nn||rig-29/NN||inducible-26/NN	nn||rig-29/NN||gene-27/NN	prep_including||resulted-13/VBD||rig-29/NN	prep_including||resulted-13/VBD||iâ-32/RB	advmod||rig-29/NN||iâ-32/RB	conj_and||rig-29/NN||iâ-32/RB	pobj||iâ-32/RB||$-33/$	prep_like||iâ-32/RB||helicases-36/NNS	dep||helicases-36/NNS||rlhs-38/NNS	prep_including||resulted-13/VBD||rig-i-41/NN	conj_and||rig-29/NN||rig-i-41/NN	nn||mda5-52/NN||melanoma-44/NNP	nn||mda5-52/NN||differentiationâ-45/NNP	nn||mda5-52/NN||$-46/NNP	amod||mda5-52/NN||associated-48/JJ	nn||mda5-52/NN||gene-49/NN	num||mda5-52/NN||5-50/CD	prep_including||resulted-13/VBD||mda5-52/NN	conj_and||rig-29/NN||mda5-52/NN	melanoma-44||rig-29||no_rel||phagocytosis of cvb3-infected, but not mock-infected, human and porcine islets resulted in induction of isgs in dcs, including the retinoicacidâinducible gene (rig)-iâlike helicases (rlhs), rig-i, and melanoma differentiationâassociated gene 5 (mda5).
nsubj||pump-22/VBP||objective-1/NN	aux||compare-3/VB||to-2/TO	vmod||objective-1/NN||compare-3/VB	det||safety-5/NN||the-4/DT	dobj||compare-3/VB||safety-5/NN	dobj||compare-3/VB||efficacy-7/NN	conj_and||safety-5/NN||efficacy-7/NN	amod||delivery-12/NN||overnight-9/JJ	amod||delivery-12/NN||closed-10/VBN	nn||delivery-12/NN||loop-11/NN	prep_of||safety-5/NN||delivery-12/NN	prep_of||delivery-12/NN||insulin-14/NN	amod||pancreas-17/NN||artificial-16/JJ	appos||objective-1/NN||pancreas-17/NN	amod||insulin-21/NN||conventional-20/JJ	prep_with||objective-1/NN||insulin-21/NN	root||ROOT-0/null||pump-22/VBP	dobj||pump-22/VBP||therapy-23/NN	prep_in||pump-22/VBP||adults-25/NNS	prep_with||adults-25/NNS||type1diabetes-27/CD	type1diabetes-27||insulin-21||yes||objective to compare the safety and efficacy of overnight closed loop delivery of insulin (artificial pancreas) with conventional insulin pump therapy in adults with type1diabetes.
det||data-2/NNS||these-1/DT	nsubj||established-4/VBN||data-2/NNS	aux||established-4/VBN||have-3/VBP	root||ROOT-0/null||established-4/VBN	mark||prion-9/VBN||that-5/IN	amod||prions-7/NNS||kuru-6/JJ	nsubj||prion-9/VBN||prions-7/NNS	aux||prion-9/VBN||have-8/VBP	ccomp||established-4/VBN||prion-9/VBN	nn||properties-11/NNS||strain-10/NN	nsubj||equivalent-12/JJ||properties-11/NNS	xcomp||prion-9/VBN||equivalent-12/JJ	prep_to||equivalent-12/JJ||those-14/DT	amod||prions-29/NNS||classical-16/JJ	dep||prions-29/NNS||sporadic-18/JJ	conj_and||sporadic-18/JJ||iatrogenic-20/JJ	dep||prions-29/NNS||iatrogenic-20/JJ	amod||prions-29/NNS||cjd-22/JJ	nn||prions-29/NNS||prions-23/NNS	conj_but||prions-23/NNS||distinct-25/JJ	nn||prions-29/NNS||distinct-25/JJ	amod||cjd-28/NN||variant-27/JJ	prep_from||distinct-25/JJ||cjd-28/NN	prep_of||those-14/DT||prions-29/NNS	kuru-6||prions-29||no_rel||these data have established that kuru prions have prion strain properties equivalent to those of classical (sporadic and iatrogenic) cjd prions but distinct from variant cjd prions.
nsubj||associated-3/VBN||sch-1/PRP	aux||associated-3/VBN||was-2/VBD	root||ROOT-0/null||associated-3/VBN	amod||prevalence-6/NN||greater-5/JJR	prep_with||associated-3/VBN||prevalence-6/NN	amod||4.15-20/NNS||diabeticretinopathy-8/JJ	advmod||stdr-11/JJR||especially-10/RB	amod||4.15-20/NNS||stdr-11/JJR	nn||4.15-20/NNS||-LSB--12/NN	nn||4.15-20/NNS||odds-13/NNS	nn||4.15-20/NNS||ratio-14/NN	num||%-17/NN||95-16/CD	npadvmod||ci-18/JJ||%-17/NN	dep||4.15-20/NNS||ci-18/JJ	prep_of||prevalence-6/NN||4.15-20/NNS	dep||4.15-20/NNS||2.17-22/CD	dep||4.15-20/NNS||$-24/$	conj_â||2.17-22/CD||$-24/$	num||$-24/$||7.96-26/CD	dep||associated-3/VBN||p-29/VBN	dep||-RSB--32/NNS||=-30/SYM	num||-RSB--32/NNS||0.000-31/CD	ccomp||p-29/VBN||-RSB--32/NNS	det||adjustment-35/NN||an-34/DT	prep_after||p-29/VBN||adjustment-35/NN	prep_for||adjustment-35/NN||age-37/NN	appos||age-37/NN||sex-39/NN	dobj||associated-3/VBN||duration-41/NN	nn||hypertension-49/NN||diabetes-43/NN	dep||hypertension-49/NN||a1c-45/NN	dep||hypertension-49/NN||bmi-47/NN	prep_of||duration-41/NN||hypertension-49/NN	nn||cholesterol-53/NN||ldl-52/NN	prep_of||duration-41/NN||cholesterol-53/NN	conj_and||hypertension-49/NN||cholesterol-53/NN	cholesterol-53||hypertension-49||no_rel||sch was associated with greater prevalence of diabeticretinopathy, especially stdr [odds ratio (95% ci) 4.15 (2.17â7.96), p = 0.000] after an adjustment for age, sex, duration of diabetes, a1c, bmi, hypertension, and ldl cholesterol.
aux||assess-2/VB||to-1/TO	advcl||obtained-84/VBN||assess-2/VB	dobj||assess-2/VB||gender-3/NN	dep||assess-2/VB||pubertal-6/NN	amod||differences-10/NNS||age-related-9/JJ	nsubjpass||obtained-84/VBN||differences-10/NNS	prep_in||differences-10/NNS||change-12/NN	amod||hsds-22/NNS||baseline-14/JJ	nn||hsds-22/NNS||height-15/NN	nn||hsds-22/NNS||standard-16/NN	nn||hsds-22/NNS||deviation-17/NN	nn||hsds-22/NNS||score-18/NN	nn||hsds-22/NNS||î-20/NN	prep_from||differences-10/NNS||hsds-22/NNS	conj_and||differences-10/NNS||data-25/NNS	nsubjpass||obtained-84/VBN||data-25/NNS	num||patients-36/NNS||5,797-27/CD	amod||patients-36/NNS||growthhormone-28/JJ	appos||patients-36/NNS||gh-30/NN	nn||patients-36/NNS||naã-32/NN	nn||patients-36/NNS||¯-33/NNP	nn||patients-36/NNS||ve-34/NNP	amod||patients-36/NNS||pediatric-35/JJ	prep_from||data-25/NNS||patients-36/NNS	number||18-39/CD||<-38/CD	num||years-40/NNS||18-39/CD	appos||patients-36/NNS||years-40/NNS	amod||deficiency-44/NN||growthhormone-43/JJ	prep_with||data-25/NNS||deficiency-44/NN	appos||data-25/NNS||ghd-46/NN	amod||deficiency-52/NN||multiple-49/JJ	amod||deficiency-52/NN||pituitary-50/JJ	nn||deficiency-52/NN||hormone-51/NN	conj_and||differences-10/NNS||deficiency-52/NN	nsubjpass||obtained-84/VBN||deficiency-52/NN	dep||deficiency-52/NN||mphd-54/JJ	nn||syndrome-58/NN||turner-57/NN	conj_and||differences-10/NNS||syndrome-58/NN	nsubjpass||obtained-84/VBN||syndrome-58/NN	appos||syndrome-58/NN||ts-60/NN	conj_and||differences-10/NNS||small-63/JJ	nsubjpass||obtained-84/VBN||small-63/JJ	amod||age-66/NN||gestational-65/JJ	prep_for||small-63/JJ||age-66/NN	appos||small-63/JJ||sga-68/NN	nn||syndrome-72/NN||noonan-71/NN	conj_and||differences-10/NNS||syndrome-72/NN	nsubjpass||obtained-84/VBN||syndrome-72/NN	appos||syndrome-72/NN||ns-74/NN	amod||shortstature-79/NN||idiopathic-78/JJ	conj_and||differences-10/NNS||shortstature-79/NN	nsubjpass||obtained-84/VBN||shortstature-79/NN	appos||differences-10/NNS||iss-81/NN	auxpass||obtained-84/VBN||were-83/VBD	root||ROOT-0/null||obtained-84/VBN	det||program-95/NN||the-86/DT	nn||program-95/NN||answer-87/NN	amod||studies-91/NNS||american-89/JJ	nn||studies-91/NNS||norditropin-90/NN	dep||program-95/NN||studies-91/NNS	amod||research-93/NN||web-enabled-92/JJ	dep||studies-91/NNS||research-93/NN	prep_from||obtained-84/VBN||program-95/NN	advmod||obtained-84/VBN||registry-96/RB	shortstature-79||growthhormone-43||yes||to assess gender-, pubertal-, age-related differences in change from baseline height standard deviation score (îhsds), data from 5,797 growthhormone (gh) naã¯ve pediatric patients (<18 years) with growthhormone deficiency (ghd), multiple pituitary hormone deficiency (mphd), turner syndrome (ts), small for gestational age (sga), noonan syndrome (ns), and idiopathic shortstature (iss) were obtained from the answer (american norditropin studies web-enabled research) program registry.
det||training-3/NN||the-1/DT	amod||training-3/NN||district-led-2/JJ	nsubj||improved-5/VBD||training-3/NN	advmod||improved-5/VBD||significantly-4/RB	ccomp||right-30/JJ||improved-5/VBD	dobj||improved-5/VBD||knowledge-6/NN	vmod||knowledge-6/NN||relating-7/VBG	prep_to||relating-7/VBG||hiv/aids-9/NNS	prep_to||relating-7/VBG||puberty-11/NN	conj_and||hiv/aids-9/NNS||puberty-11/NN	dep||knowledge-6/NN||rr-13/NN	vmod||rr-13/NN||ranged-14/VBN	number||2.0-18/CD||1.06-16/CD	dep||2.0-18/CD||to-17/TO	prep_from||ranged-14/VBN||2.0-18/CD	nsubj||right-30/JJ||attitudes-21/NNS	nn||confidentiality-25/NN||condoms-23/NNS	nn||people-28/NNS||confidentiality-25/NN	conj_and||confidentiality-25/NN||young-27/JJ	nn||people-28/NNS||young-27/JJ	prep_towards||attitudes-21/NNS||people-28/NNS	cop||right-30/JJ||'s-29/VBZ	root||ROOT-0/null||right-30/JJ	prep_to||right-30/JJ||treatment-32/NN	nsubj||range-35/VBP||rr-34/NN	dep||treatment-32/NN||range-35/VBP	num||.36-37/CD||1.23-1-36/CD	dobj||range-35/VBP||.36-37/CD	aids--1||hiv--1||no||the district-led training significantly improved knowledge relating to hiv/aids and puberty (rr ranged from 1.06 to 2.0), attitudes towards condoms, confidentiality and young people's right to treatment (rr range 1.23-1.36).
advmod||determinant-7/NN||therefore-1/RB	nn||duration-4/NN||sleep-3/NN	nsubj||determinant-7/NN||duration-4/NN	cop||determinant-7/NN||is-5/VBZ	det||determinant-7/NN||a-6/DT	root||ROOT-0/null||determinant-7/NN	nn||sensitivity-10/NN||insulin-9/NN	prep_of||determinant-7/NN||sensitivity-10/NN	prep_in||sensitivity-10/NN||patients-12/NNS	prep_with||patients-12/NNS||type1diabetes-14/CD	type1diabetes-14||insulin-9||yes||therefore, sleep duration is a determinant of insulin sensitivity in patients with type1diabetes.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||investigate-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||investigate-8/VB||to-7/TO	xcomp||was-6/VBD||investigate-8/VB	det||effect-10/NN||the-9/DT	dobj||investigate-8/VB||effect-10/NN	amod||polyphenols-14/NNS||dietary-12/JJ	amod||polyphenols-14/NNS||lemon-13/JJ	prep_of||effect-10/NN||polyphenols-14/NNS	amod||obesity-18/NN||high-fat-16/JJ	amod||obesity-18/NN||diet-induced-17/JJ	prep_on||investigate-8/VB||obesity-18/NN	prep_in||obesity-18/NN||mice-20/NNS	det||regulation-25/NN||the-24/DT	prep_on||investigate-8/VB||regulation-25/NN	conj_and||obesity-18/NN||regulation-25/NN	det||expression-28/NN||the-27/DT	prep_of||regulation-25/NN||expression-28/NN	det||genes-31/NNS||the-30/DT	prep_of||expression-28/NN||genes-31/NNS	vmod||genes-31/NNS||involved-32/VBN	nn||metabolism-35/NN||lipid-34/NN	prep_in||involved-32/VBN||metabolism-35/NN	aux||elucidate-37/VB||to-36/TO	xcomp||involved-32/VBN||elucidate-37/VB	det||mechanisms-39/NNS||the-38/DT	dobj||elucidate-37/VB||mechanisms-39/NNS	fat--1||obesity-18||no_rel||the aim of this study was to investigate the effect of dietary lemon polyphenols on high-fat diet-induced obesity in mice, and on the regulation of the expression of the genes involved in lipid metabolism to elucidate the mechanisms.
det||overview-2/NN||an-1/DT	nsubjpass||provided-4/VBN||overview-2/NN	auxpass||provided-4/VBN||is-3/VBZ	root||ROOT-0/null||provided-4/VBN	det||benefits-8/NNS||the-6/DT	amod||benefits-8/NNS||clinical-7/JJ	prep_of||provided-4/VBN||benefits-8/NNS	amod||detection-11/NN||early-10/JJ	prep_of||benefits-8/NNS||detection-11/NN	amod||intervention-14/NN||prompt-13/JJ	prep_of||provided-4/VBN||intervention-14/NN	conj_and||benefits-8/NNS||intervention-14/NN	amod||levels-17/NNS||highbloodpressure-16/JJ	prep_of||intervention-14/NN||levels-17/NNS	det||analysis-22/NN||a-20/DT	amod||analysis-22/NN||closer-21/JJR	prep_with||provided-4/VBN||analysis-22/NN	amod||trials-26/NNS||recent-24/JJ	amod||trials-26/NNS||clinical-25/JJ	prep_of||analysis-22/NN||trials-26/NNS	vmod||analysis-22/NN||performed-28/VBN	prep_with||performed-28/VBN||olmesartanmedoxomil-30/NN	amod||subjects-33/NNS||young-32/JJ	prep_in||olmesartanmedoxomil-30/NN||subjects-33/NNS	prep_with||performed-28/VBN||hypertension-35/NN	highbloodpressure-16||olmesartanmedoxomil-30||yes||an overview is provided of the clinical benefits of early detection and prompt intervention of highbloodpressure levels, with a closer analysis of recent clinical trials, performed with olmesartanmedoxomil in young subjects with hypertension.
amod||response-2/NN||t-cell-1/JJ	nsubjpass||evaluated-6/VBN||response-2/NN	prep_to||response-2/NN||rv1985c-4/CD	auxpass||evaluated-6/VBN||was-5/VBD	root||ROOT-0/null||evaluated-6/VBN	amod||elispot-10/NN||ifn-î-8/JJ	amod||elispot-10/NN||³-9/JJ	agent||evaluated-6/VBN||elispot-10/NN	number||tb-13/CD||56-12/CD	num||patients-14/NNS||tb-13/CD	prep_in||elispot-10/NN||patients-14/NNS	num||infection-19/NN||20-16/CD	nn||infection-19/NN||latent-17/NN	nn||infection-19/NN||tb-18/NN	prep_in||elispot-10/NN||infection-19/NN	conj_and||patients-14/NNS||infection-19/NN	appos||infection-19/NN||ltbi-21/NNP	num||controls-26/NNS||30-24/CD	amod||controls-26/NNS||bcg-vaccinated-25/JJ	prep_in||elispot-10/NN||controls-26/NNS	conj_and||patients-14/NNS||controls-26/NNS	prep_in||controls-26/NNS||comparison-28/NN	det||t-spot-32/NN||the-30/DT	amod||t-spot-32/NN||commercial-31/JJ	prep_with||evaluated-6/VBN||t-spot-32/NN	tb-18||bcg--1||no||t-cell response to rv1985c was evaluated by ifn-î³ elispot in 56 tb patients, 20 latent tb infection (ltbi) and 30 bcg-vaccinated controls in comparison with the commercial t-spot.
amod||models-4/NNS||cox-1/JJ	amod||models-4/NNS||proportional-2/JJ	nn||models-4/NNS||hazard-3/NN	nsubjpass||built-6/VBN||models-4/NNS	nsubj||compare-8/VB||models-4/NNS	auxpass||built-6/VBN||were-5/VBD	root||ROOT-0/null||built-6/VBN	aux||compare-8/VB||to-7/TO	xcomp||built-6/VBN||compare-8/VB	det||risk-10/NN||the-9/DT	dobj||compare-8/VB||risk-10/NN	amod||pancreatitis-13/NNS||acute-12/JJ	prep_of||risk-10/NN||pancreatitis-13/NNS	amod||subjects-18/NNS||diabetic-15/JJ	conj_and||diabetic-15/JJ||nondiabetic-17/JJ	amod||subjects-18/NNS||nondiabetic-17/JJ	prep_between||compare-8/VB||subjects-18/NNS	nn||sitagliptin-23/NN||exenatide-21/NN	prep_between||compare-8/VB||sitagliptin-23/NN	conj_and||subjects-18/NNS||sitagliptin-23/NN	nn||diabetes-27/NN||control-26/NN	conj_and||subjects-18/NNS||diabetes-27/NN	conj_and||sitagliptin-23/NN||diabetes-27/NN	nn||use-29/NN||medication-28/NN	pobj||compare-8/VB||use-29/NN	exenatide-21||pancreatitis-13||no_rel||cox proportional hazard models were built to compare the risk of acute pancreatitis between diabetic and nondiabetic subjects and between exenatide, sitagliptin, and control diabetes medication use.
nsubj||represents-37/VBZ||vigabatrin-1/NN	det||agent-6/NN||the-3/DT	amod||agent-6/NN||first-4/JJ	amod||agent-6/NN||therapeutic-5/JJ	appos||vigabatrin-1/NN||agent-6/NN	aux||approved-9/VBN||to-7/TO	auxpass||approved-9/VBN||be-8/VB	vmod||agent-6/NN||approved-9/VBN	vmod||agent-6/NN||approved-9/VBN	conj_and||approved-9/VBN||approved-9/VBN	det||administration-15/NN||the-11/DT	nn||administration-15/NN||food-12/NN	conj_and||food-12/NN||drug-14/NN	nn||administration-15/NN||drug-14/NN	agent||approved-9/VBN||administration-15/NN	det||treatment-18/NN||the-17/DT	prep_for||administration-15/NN||treatment-18/NN	amod||spasms-21/NNS||infantile-20/JJ	prep_of||treatment-18/NN||spasms-21/NNS	amod||use-28/NN||adjunctive-27/JJ	prep_for||approved-9/VBN||use-28/NN	det||treatment-31/NN||the-30/DT	prep_in||use-28/NN||treatment-31/NN	amod||partialepilepsy-35/NN||refractory-33/JJ	amod||partialepilepsy-35/NN||complex-34/JJ	prep_of||treatment-31/NN||partialepilepsy-35/NN	root||ROOT-0/null||represents-37/VBZ	det||advance-40/NN||an-38/DT	amod||advance-40/NN||important-39/JJ	dobj||represents-37/VBZ||advance-40/NN	prep_for||advance-40/NN||patients-42/NNS	amod||epilepsy-45/NN||difficult-to-manage-44/JJ	prep_with||patients-42/NNS||epilepsy-45/NN	epilepsy-45||vigabatrin-1||yes||vigabatrin, the first therapeutic agent to be approved by the food and drug administration for the treatment of infantile spasms, as well as for adjunctive use in the treatment of refractory complex partialepilepsy, represents an important advance for patients with difficult-to-manage epilepsy.
det||vaccine-3/NN||the-1/DT	nn||vaccine-3/NN||wv-2/NN	nsubj||useful-12/JJ||vaccine-3/NN	vmod||vaccine-3/NN||prepared-4/VBN	det||influenzavirus-7/NNS||an-6/DT	prep_from||prepared-4/VBN||influenzavirus-7/NNS	det||library-10/NN||the-9/DT	prep_in||influenzavirus-7/NNS||library-10/NN	cop||useful-12/JJ||is-11/VBZ	root||ROOT-0/null||useful-12/JJ	det||vaccine-16/NN||an-14/DT	nn||vaccine-16/NN||emergency-15/NN	prep_as||useful-12/JJ||vaccine-16/NN	det||phase-20/NN||the-18/DT	amod||phase-20/NN||early-19/JJ	prep_in||vaccine-16/NN||phase-20/NN	amod||influenza-23/NN||pandemic-22/JJ	prep_of||phase-20/NN||influenza-23/NN	influenza-23||influenzavirus-7||no||the wv vaccine prepared from an influenzavirus in the library is useful as an emergency vaccine in the early phase of pandemic influenza.
nsubj||case-4/NN||this-1/DT	cop||case-4/NN||is-2/VBZ	det||case-4/NN||the-3/DT	root||ROOT-0/null||case-4/NN	amod||mycobacteriumtuberculosis-7/NNS||automated-6/JJ	prep_for||case-4/NN||mycobacteriumtuberculosis-7/NNS	appos||case-4/NN||mtb-9/NN	amod||systems-13/NNS||liquid-11/JJ	nn||systems-13/NNS||culture-12/NN	dep||case-4/NN||systems-13/NNS	nsubjpass||developed-20/VBN||systems-13/NNS	nsubjpass||used-24/VBN||systems-13/NNS	nsubjpass||beginning-32/VBG||systems-13/NNS	nsubjpass||applied-35/VBN||systems-13/NNS	nn||detection-17/NN||tuberculosis-15/NNP	nn||detection-17/NN||case-16/NN	prep_for||systems-13/NNS||detection-17/NN	auxpass||developed-20/VBN||were-19/VBD	rcmod||systems-13/NNS||developed-20/VBN	auxpass||used-24/VBN||are-22/VBP	advmod||used-24/VBN||widely-23/RB	rcmod||systems-13/NNS||used-24/VBN	conj_and||developed-20/VBN||used-24/VBN	amod||settings-28/NNS||low-26/JJ	nn||settings-28/NNS||burden-27/NN	prep_in||used-24/VBN||settings-28/NNS	aux||beginning-32/VBG||are-30/VBP	advmod||beginning-32/VBG||only-31/RB	rcmod||systems-13/NNS||beginning-32/VBG	conj_but||developed-20/VBN||beginning-32/VBG	aux||applied-35/VBN||to-33/TO	auxpass||applied-35/VBN||be-34/VB	xcomp||beginning-32/VBG||applied-35/VBN	det||scale-39/NN||a-37/DT	amod||scale-39/NN||large-38/JJ	prep_on||applied-35/VBN||scale-39/NN	amod||settings-43/NNS||high-41/JJ	nn||settings-43/NNS||burden-42/NN	prep_in||scale-39/NN||settings-43/NNS	tuberculosis-15||mycobacteriumtuberculosis-7||no||this is the case for automated mycobacteriumtuberculosis (mtb) liquid culture systems for tuberculosis case detection which were developed and are widely used in low burden settings but are only beginning to be applied on a large scale in high burden settings.
det||prevention-3/NN||the-1/DT	nn||prevention-3/NN||stroke-2/NN	nsubj||reduced-33/VBD||prevention-3/NN	amod||reduction-6/NN||aggressive-5/JJ	prep_by||prevention-3/NN||reduction-6/NN	nn||levels-9/NNS||cholesterol-8/NN	prep_of||reduction-6/NN||levels-9/NNS	dep||levels-9/NNS||sparcl-11/JJ	nsubj||showed-14/VBD||trial-13/NN	rcmod||levels-9/NNS||showed-14/VBD	amod||treatment-16/NN||daily-15/JJ	dobj||showed-14/VBD||treatment-16/NN	num||mg-19/NN||80-18/CD	prep_with||showed-14/VBD||mg-19/NN	prep_of||mg-19/NN||atorvastatin-21/NN	prep_in||showed-14/VBD||patients-23/NNS	det||stroke-27/NN||a-25/DT	amod||stroke-27/NN||recent-26/JJ	prep_with||patients-23/NNS||stroke-27/NN	prep_with||patients-23/NNS||transientischemicattack-29/NN	conj_or||stroke-27/NN||transientischemicattack-29/NN	appos||stroke-27/NN||tia-31/NN	root||ROOT-0/null||reduced-33/VBD	det||incidence-35/NN||the-34/DT	dobj||reduced-33/VBD||incidence-35/NN	amod||stroke-40/NN||fatal-37/JJ	conj_or||fatal-37/JJ||nonfatal-39/JJ	amod||stroke-40/NN||nonfatal-39/JJ	prep_of||incidence-35/NN||stroke-40/NN	num||%-43/NN||16-42/CD	prep_by||reduced-33/VBD||%-43/NN	cholesterol-8||stroke-40||no_rel||the stroke prevention by aggressive reduction of cholesterol levels (sparcl) trial showed daily treatment with 80 mg of atorvastatin in patients with a recent stroke or transientischemicattack (tia) reduced the incidence of fatal or nonfatal stroke by 16%.
advmod||patients-3/NNS||only-1/RB	det||patients-3/NNS||those-2/DT	nsubjpass||included-36/VBN||patients-3/NNS	amod||acutehepatitise-6/NN||sporadic-5/JJ	prep_of||patients-3/NNS||acutehepatitise-6/NN	nsubj||were-8/VBD||acutehepatitise-6/NN	nsubj||followed-16/VBD||acutehepatitise-6/NN	rcmod||acutehepatitise-6/NN||were-8/VBD	poss||week-12/NN||their-10/PRP$	amod||week-12/NN||first-11/JJ	prep_in||were-8/VBD||week-12/NN	prep_of||week-12/NN||illness-14/NN	rcmod||acutehepatitise-6/NN||followed-16/VBD	conj_and||were-8/VBD||followed-16/VBD	prt||followed-16/VBD||up-17/RP	advmod||followed-16/VBD||weekly-18/RB	nn||tests-22/NNS||liver-20/NN	nn||tests-22/NNS||function-21/NN	prep_for||followed-16/VBD||tests-22/NNS	nn||antibody-27/NN||igm-24/NN	nn||antibody-27/NN||anti-25/NN	nn||antibody-27/NN||hev-26/NN	appos||tests-22/NNS||antibody-27/NN	nn||rna-30/NN||hev-29/NN	appos||tests-22/NNS||rna-30/NN	conj_and||antibody-27/NN||rna-30/NN	prep_in||antibody-27/NN||sera-32/NN	prep_in||antibody-27/NN||stool-34/NN	conj_and||sera-32/NN||stool-34/NN	auxpass||included-36/VBN||were-35/VBD	root||ROOT-0/null||included-36/VBN	acutehepatitise-6||hev-29||no||only those patients of sporadic acutehepatitise who were in their first week of illness and followed up weekly for liver function tests, igm anti hev antibody and hev rna in sera and stool were included.
amod||administration-5/NN||intranasal-1/JJ	nn||administration-5/NN||-lrb--2/NN	nn||administration-5/NN||i.n-3/NN	nn||administration-5/NN||-rrb--4/NN	nsubj||immunogenic-9/JJ||administration-5/NN	prep_of||administration-5/NN||plc-7/NN	cop||immunogenic-9/JJ||was-8/VBD	root||ROOT-0/null||immunogenic-9/JJ	amod||level-14/NN||mucosal-11/JJ	conj_and||mucosal-11/JJ||systemic-13/JJ	amod||level-14/NN||systemic-13/JJ	prep_at||immunogenic-9/JJ||level-14/NN	prep_vs.||level-14/NN||v.cholerae-16/NN	advmod||proven-31/VBN||however-18/RB	det||potential-21/NN||the-19/DT	amod||potential-21/NN||adjuvant-20/JJ	nsubjpass||proven-31/VBN||potential-21/NN	det||structure-24/NN||this-23/DT	prep_of||potential-21/NN||structure-24/NN	amod||antigens-27/NNS||non-cholera-26/JJ	prep_for||structure-24/NN||antigens-27/NNS	aux||proven-31/VBN||has-28/VBZ	neg||proven-31/VBN||not-29/RB	auxpass||proven-31/VBN||been-30/VBN	parataxis||immunogenic-9/JJ||proven-31/VBN	advmod||proven-31/VBN||yet-32/RB	cholera--1||v.cholerae-16||no||intranasal -lrb- i.n -rrb- administration of plc was immunogenic at mucosal and systemic level vs. v.cholerae ; however the adjuvant potential of this structure for non-cholera antigens has not been proven yet .
agent||formed-32/VBN||conjugating-2/VBG	amod||antibodies-4/NNS||anti-h5n1-3/JJ	dobj||conjugating-2/VBG||antibodies-4/NNS	det||chemistry-19/NN||the-6/DT	amod||chemistry-19/NN||ps@pdav-7/JJ	prep_via||ps@pdav-7/JJ||n-9/NN	dep||n-9/NN||hydroxysuccinimide-11/JJ	dep||n-9/NN||1-ethyl3-13/JJ	conj_and||hydroxysuccinimide-11/JJ||1-ethyl3-13/JJ	dep||n-9/NN||3-dimethylaminopropyl-16/JJ	nn||chemistry-19/NN||carbodiimide-18/NN	prep_to||conjugating-2/VBG||chemistry-19/NN	det||microsphere-27/NN||a-21/DT	amod||microsphere-27/NN||stable-22/JJ	amod||microsphere-27/NN||blue-23/JJ	amod||microsphere-27/NN||complex-24/JJ	amod||microsphere-27/NN||anti-h5n1-26/JJ	nsubjpass||formed-32/VBN||microsphere-27/NN	dep||microsphere-27/NN||ps@pdav-anti-h5n1-29/JJ	auxpass||formed-32/VBN||was-31/VBD	root||ROOT-0/null||formed-32/VBN	antibodies-4||h5n1--1||no_rel||by conjugating anti-h5n1 antibodies to the ps@pdav via n -hydroxysuccinimide and 1-ethyl3-(3-dimethylaminopropyl) carbodiimide chemistry, a stable blue complex, anti-h5n1 microsphere (ps@pdav-anti-h5n1) was formed.
amod||trials-3/NNS||published-1/VBN	amod||trials-3/NNS||double-blind-2/JJ	nsubj||show-4/VBP||trials-3/NNS	root||ROOT-0/null||show-4/VBP	mark||achieves-12/VBZ||that-5/IN	amod||therapy-7/NN||budesonide/formoterol-6/JJ	nsubj||achieves-12/VBZ||therapy-7/NN	vmod||therapy-7/NN||delivered-8/VBN	amod||fashion-11/NN||smart-10/JJ	prep_in||delivered-8/VBN||fashion-11/NN	ccomp||show-4/VBP||achieves-12/VBZ	amod||outcomes-15/NNS||better-13/JJR	nn||outcomes-15/NNS||asthma-14/NN	dobj||achieves-12/VBZ||outcomes-15/NNS	amod||monotherapy-18/NN||budesonide-17/JJ	prep_than||achieves-12/VBZ||monotherapy-18/NN	amod||doses-21/NNS||lower-20/JJR	prep_than||achieves-12/VBZ||doses-21/NNS	conj_or||monotherapy-18/NN||doses-21/NNS	amod||therapy-24/NN||budesonide/formoterol-23/JJ	prep_of||doses-21/NNS||therapy-24/NN	vmod||therapy-24/NN||delivered-25/VBN	amod||dosage-28/NN||constant-27/JJ	prep_in||delivered-25/VBN||dosage-28/NN	asthma-14||formoterol--1||yes||published double-blind trials show that budesonide/formoterol therapy delivered in smart fashion achieves better asthma outcomes than budesonide monotherapy or lower doses of budesonide/formoterol therapy delivered in constant dosage.
dep||make-6/VB||not-1/RB	advmod||make-6/VB||only-2/RB	aux||make-6/VB||did-3/VBD	amod||systems-5/NNS||such-4/JJ	dobj||make-6/VB||systems-5/NNS	root||ROOT-0/null||make-6/VB	acomp||make-6/VB||possible-7/JJ	det||isolation-10/NN||the-8/DT	amod||isolation-10/NN||direct-9/JJ	nsubj||make-6/VB||isolation-10/NN	nsubj||make-6/VB||identification-12/NN	conj_and||isolation-10/NN||identification-12/NN	prep_of||isolation-10/NN||viruses-14/NNS	det||production-19/NN||the-18/DT	nsubj||make-6/VB||production-19/NN	conj_and||isolation-10/NN||production-19/NN	amod||reagents-23/NNS||viral-21/JJ	amod||reagents-23/NNS||diagnostic-22/JJ	prep_of||production-19/NN||reagents-23/NNS	amod||diagnosis-26/NN||rapid-25/JJ	prep_for||reagents-23/NNS||diagnosis-26/NN	det||evaluation-29/NN||the-28/DT	nsubj||make-6/VB||evaluation-29/NN	conj_and||isolation-10/NN||evaluation-29/NN	prep_of||evaluation-29/NN||antiviralagents-31/NNS	det||production-35/NN||the-34/DT	nsubj||make-6/VB||production-35/NN	conj_and||isolation-10/NN||production-35/NN	prep_of||production-35/NN||vaccines-37/NNS	det||control-40/NN||the-39/DT	prep_for||vaccines-37/NNS||control-40/NN	prep_of||control-40/NN||viraldiseases-42/NNS	viraldiseases-42||viruses-14||no||not only did such systems make possible the direct isolation and identification of viruses, but also the production of viral diagnostic reagents for rapid diagnosis, the evaluation of antiviralagents, and the production of vaccines for the control of viraldiseases.
det||emergence-2/NN||the-1/DT	nsubj||reveals-14/VBZ||emergence-2/NN	det||threat-6/NN||the-4/DT	amod||threat-6/NN||global-5/JJ	prep_of||emergence-2/NN||threat-6/NN	advmod||drug-resistant-9/JJ||extensively-8/RB	amod||mycobacteriumtuberculosis-13/NNS||drug-resistant-9/JJ	appos||mycobacteriumtuberculosis-13/NNS||xdr-11/NN	prep_of||threat-6/NN||mycobacteriumtuberculosis-13/NNS	root||ROOT-0/null||reveals-14/VBZ	dobj||reveals-14/VBZ||weaknesses-15/NNS	nn||management-18/NN||tuberculosis-17/NNP	prep_in||weaknesses-15/NNS||management-18/NN	amod||services-21/NNS||diagnostic-20/JJ	prep_in||weaknesses-15/NNS||services-21/NNS	conj_and||management-18/NN||services-21/NNS	tuberculosis-17||mycobacteriumtuberculosis-13||no||the emergence of the global threat of extensively drug-resistant (xdr) mycobacteriumtuberculosis reveals weaknesses in tuberculosis management and diagnostic services.
det||ratio-4/NN||the-1/DT	nn||ratio-4/NN||food-2/NN	nn||ratio-4/NN||efficiency-3/NN	nsubj||greater-6/JJR||ratio-4/NN	cop||greater-6/JJR||was-5/VBD	root||ROOT-0/null||greater-6/JJR	amod||feeding-9/NN||hpmc-8/JJ	prep_with||greater-6/JJR||feeding-9/NN	prepc_compared_to||greater-6/JJR||to-11/TO	det||control-14/NN||the-12/DT	amod||control-14/NN||obese-13/JJ	pobj||greater-6/JJR||control-14/NN	amod||excretion-17/NN||urinary-16/JJ	nsubjpass||reduced-24/VBN||excretion-17/NN	nn||bodies-22/NNS||glucose-19/NN	conj_and||glucose-19/NN||ketone-21/NN	nn||bodies-22/NNS||ketone-21/NN	prep_of||excretion-17/NN||bodies-22/NNS	auxpass||reduced-24/VBN||was-23/VBD	conj_and||greater-6/JJR||reduced-24/VBN	obese-13||ketone-21||no_rel||the food efficiency ratio was greater with hpmc feeding compared to the obese control and urinary excretion of glucose and ketone bodies was reduced.
nsubjpass||treated-11/VBN||patients-1/NNS	nn||sdisease-5/NN||alzheimer-3/NN	prep_with||patients-1/NNS||sdisease-5/NN	appos||patients-1/NNS||ad-7/NN	auxpass||treated-11/VBN||are-9/VBP	advmod||treated-11/VBN||currently-10/RB	root||ROOT-0/null||treated-11/VBN	amod||inhibitors-14/NNS||cholinesterase-13/JJ	prep_with||treated-11/VBN||inhibitors-14/NNS	prep_such_as||inhibitors-14/NNS||galantamine-18/NN	amod||knowledge-22/NN||actual-21/JJ	prep_without||treated-11/VBN||knowledge-22/NN	poss||concentration-25/NN||its-24/PRP$	prep_of||knowledge-22/NN||concentration-25/NN	prep_in||concentration-25/NN||plasma-27/NN	alzheimer'sdisease--1||galantamine-18||yes||patients with alzheimer'sdisease (ad) are currently treated with cholinesterase inhibitors, such as galantamine, without actual knowledge of its concentration in plasma.
nsubj||sought-2/VBD||we-1/PRP	nsubj||investigate-4/VB||we-1/PRP	root||ROOT-0/null||sought-2/VBD	aux||investigate-4/VB||to-3/TO	xcomp||sought-2/VBD||investigate-4/VB	det||effect-6/NN||the-5/DT	dobj||investigate-4/VB||effect-6/NN	nn||repletion-10/NN||iv-8/NN	nn||repletion-10/NN||iron-9/NN	prep_of||effect-6/NN||repletion-10/NN	amod||counts-16/NNS||platelet-12/JJ	appos||counts-16/NNS||plt-14/NN	prep_on||repletion-10/NN||counts-16/NNS	nn||patients-19/NNS||ckd-18/NN	prep_in||investigate-4/VB||patients-19/NNS	prep_with||investigate-4/VB||irondeficiencyanemia-21/NN	appos||irondeficiencyanemia-21/NN||ida-23/NN	irondeficiencyanemia-21||iron-9||yes||we sought to investigate the effect of iv iron repletion on platelet (plt) counts in ckd patients with irondeficiencyanemia (ida).
nsubj||manifest-13/VB||hypersensitivityreactions-1/NNS	prep_against||hypersensitivityreactions-1/NNS||nonsteroidalantiinflammatorydrugs-3/NNS	appos||nonsteroidalantiinflammatorydrugs-3/NNS||nsaids-5/NNS	prep_like||nonsteroidalantiinflammatorydrugs-3/NNS||diclofenac-8/NN	appos||hypersensitivityreactions-1/NNS||df-10/NN	aux||manifest-13/VB||can-12/MD	root||ROOT-0/null||manifest-13/VB	prep_as||manifest-13/VB||type-15/NN	amod||allergicreactions-17/NNS||i-like-16/JJ	dobj||manifest-13/VB||allergicreactions-17/NNS	amod||anaphylaxis-20/NNS||systemic-19/JJ	prep_including||allergicreactions-17/NNS||anaphylaxis-20/NNS	hypersensitivityreactions-1||allergicreactions-17||no||hypersensitivityreactions against nonsteroidalantiinflammatorydrugs (nsaids) like diclofenac (df) can manifest as type i-like allergicreactions including systemic anaphylaxis.
det||group-2/NN||this-1/DT	nsubj||showed-4/VBD||group-2/NN	advmod||showed-4/VBD||also-3/RB	root||ROOT-0/null||showed-4/VBD	det||imbalance-8/NN||a-5/DT	amod||imbalance-8/NN||significant-6/JJ	amod||imbalance-8/NN||metabolic-7/JJ	dobj||showed-4/VBD||imbalance-8/NN	nn||levels-13/NNS||glucose-10/NN	conj_and||glucose-10/NN||insulin-12/NN	nn||levels-13/NNS||insulin-12/NN	prep_with||showed-4/VBD||levels-13/NNS	nn||profile-16/NN||lipid-15/NN	prep_with||showed-4/VBD||profile-16/NN	conj_and||levels-13/NNS||profile-16/NN	det||ranges-19/NNS||the-18/DT	prep_outside||showed-4/VBD||ranges-19/NNS	vmod||ranges-19/NNS||considered-20/VBN	acomp||considered-20/VBN||safe-21/JJ	aux||prevent-23/VB||to-22/TO	xcomp||safe-21/JJ||prevent-23/VB	det||development-25/NN||the-24/DT	dobj||prevent-23/VB||development-25/NN	prep_of||development-25/NN||cardiovasculardisease-27/NN	prep_of||development-25/NN||t2d-29/NNS	conj_and||cardiovasculardisease-27/NN||t2d-29/NNS	t2d-29||insulin-12||yes||this group also showed a significant metabolic imbalance with glucose and insulin levels and lipid profile outside the ranges considered safe to prevent the development of cardiovasculardisease and t2d.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||role-4/NN||the-3/DT	dobj||investigated-2/VBD||role-4/NN	amod||reductase-10/NN||polyol-6/JJ	nn||reductase-10/NN||pathway-7/NN	nn||reductase-10/NN||enzymes-8/NNS	nn||reductase-10/NN||aldose-9/NN	prep_of||role-4/NN||reductase-10/NN	appos||reductase-10/NN||ar-12/NN	amod||dehydrogenase-16/NN||sorbitol-15/JJ	prep_of||role-4/NN||dehydrogenase-16/NN	conj_and||reductase-10/NN||dehydrogenase-16/NN	appos||reductase-10/NN||sdh-18/NN	prepc_in||investigated-2/VBD||mediating-21/VBG	dobj||mediating-21/VBG||injury-22/NN	amod||ischemia-reperfusion-25/JJ||due-23/JJ	dep||ischemia-reperfusion-25/JJ||to-24/TO	amod||injury-22/NN||ischemia-reperfusion-25/JJ	appos||injury-22/NN||ir-27/NN	amod||hearts-35/NNS||type-30/NN	number||type-30/NN||2-31/CD	amod||hearts-35/NNS||diabetic-32/JJ	amod||hearts-35/NNS||bbz-33/JJ	nn||hearts-35/NNS||rat-34/NN	prep_in||mediating-21/VBG||hearts-35/NNS	enzymes-8||ischemia--1||no_rel||we investigated the role of polyol pathway enzymes aldose reductase (ar) and sorbitol dehydrogenase (sdh) in mediating injury due to ischemia-reperfusion (ir) in type 2 diabetic bbz rat hearts.
det||study-2/NN||a-1/DT	nsubj||assess-4/VB||study-2/NN	nsubj||identify-23/VB||study-2/NN	aux||assess-4/VB||to-3/TO	root||ROOT-0/null||assess-4/VB	det||susceptibility-6/NN||the-5/DT	dobj||assess-4/VB||susceptibility-6/NN	prep_of||susceptibility-6/NN||nursing-8/NN	amod||students-11/NNS||medical-10/JJ	dobj||assess-4/VB||students-11/NNS	conj_and||susceptibility-6/NN||students-11/NNS	prep_towards||students-11/NNS||varicellainfection-13/NN	prepc_by||assess-4/VB||screening-15/VBG	nn||antibodies-18/NNS||igg-17/NN	prep_for||screening-15/VBG||antibodies-18/NNS	prep_against||antibodies-18/NNS||varicellavirus-20/NNS	aux||identify-23/VB||to-22/TO	conj_and||assess-4/VB||identify-23/VB	det||factors-26/NNS||any-24/DT	nn||factors-26/NNS||risk-25/NN	dobj||identify-23/VB||factors-26/NNS	det||same-29/JJ||the-28/DT	prep_for||identify-23/VB||same-29/JJ	varicellainfection-13||varicellavirus-20||no||a study to assess the susceptibility of nursing and medical students towards varicellainfection by screening for igg antibodies against varicellavirus and to identify any risk factors for the same.
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubjpass||recommended-12/VBN||treatment-3/NN	prep_of||treatment-3/NN||malaria-5/NN	prep_with||malaria-5/NN||sulphadoxine-pyrimethamine-7/NN	appos||treatment-3/NN||sp-9/NN	auxpass||recommended-12/VBN||is-11/VBZ	root||ROOT-0/null||recommended-12/VBN	det||prevention-15/NN||the-14/DT	prep_for||recommended-12/VBN||prevention-15/NN	prep_of||prevention-15/NN||malaria-17/NN	prep_in||recommended-12/VBN||pregnancy-19/NN	amod||africa-22/NN||sub-saharan-21/JJ	prep_in||pregnancy-19/NN||africa-22/NN	malaria-17||pyrimethamine--1||yes||intermittent preventive treatment of malaria with sulphadoxine-pyrimethamine (sp) is recommended for the prevention of malaria in pregnancy in sub-saharan africa.
amod||hypertension-2/NN||aldosterone-salt-1/JJ	nsubjpass||prevented-4/VBN||hypertension-2/NN	auxpass||prevented-4/VBN||was-3/VBD	root||ROOT-0/null||prevented-4/VBN	advmod||prevented-4/VBN||completely-5/RB	agent||prevented-4/VBN||spironolactone-7/NN	advmod||prevented-4/VBN||modestly-9/RB	agent||prevented-4/VBN||losartan-11/NN	conj_and||spironolactone-7/NN||losartan-11/NN	conj_and||spironolactone-7/NN||apocynin-13/NN	conj_and||losartan-11/NN||apocynin-13/NN	hypertension-2||spironolactone-7||yes||aldosterone-salt hypertension was prevented completely by spironolactone and modestly by losartan and apocynin.
vmod||confirmed-8/VBD||using-1/VBG	acomp||using-1/VBG||3-nitrotyrosine-2/JJ	det||parameter-5/NN||a-4/DT	prep_as||using-1/VBG||parameter-5/NN	nsubj||confirmed-8/VBD||we-7/PRP	root||ROOT-0/null||confirmed-8/VBD	mark||increases-14/VBZ||that-9/IN	det||diet-12/NN||the-10/DT	amod||diet-12/NN||fishoil-supplemented-11/JJ	nsubj||increases-14/VBZ||diet-12/NN	advmod||increases-14/VBZ||significantly-13/RB	ccomp||confirmed-8/VBD||increases-14/VBZ	amod||stress-16/NN||oxidative-15/JJ	dobj||increases-14/VBZ||stress-16/NN	nn||cells-19/NNS||tumor-18/NN	prep_in||increases-14/VBZ||cells-19/NNS	prep_in||cells-19/NNS||vivo-21/NN	fishoil--1||tumor-18||no_rel||using 3-nitrotyrosine as a parameter, we confirmed that the fishoil-supplemented diet significantly increases oxidative stress in tumor cells in vivo .
amod||genes-2/NNS||upregulated-1/JJ	nsubj||transduction-30/NN||genes-2/NNS	cop||transduction-30/NN||were-3/VBD	advmod||transduction-30/NN||mostly-4/RB	det||transduction-30/NN||those-5/DT	amod||transduction-30/NN||related-6/VBN	nn||matrix-9/NN||extracellular-8/NN	prep_to||related-6/VBN||matrix-9/NN	amod||collagens-12/NNS||different-11/JJ	appos||matrix-9/NN||collagens-12/NNS	nn||adhesion-16/NN||cell-15/NN	prep_to||related-6/VBN||adhesion-16/NN	conj_and||matrix-9/NN||adhesion-16/NN	appos||adhesion-16/NN||fibronectin-18/NN	nn||development-22/NN||muscle-21/NN	prep_to||related-6/VBN||development-22/NN	conj_and||matrix-9/NN||development-22/NN	dep||development-22/NN||myosins-24/NNS	dep||development-22/NN||melusin-26/NN	conj_and||myosins-24/NNS||melusin-26/NN	prep_to||related-6/VBN||signal-29/NN	conj_and||matrix-9/NN||signal-29/NN	root||ROOT-0/null||transduction-30/NN	collagens-12||adhesion-16||no_rel||upregulated genes were mostly those related to extracellular matrix (different collagens), cell adhesion (fibronectin), muscle development (myosins and melusin) and signal transduction.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||effects-4/NNS||the-3/DT	dobj||investigated-2/VBD||effects-4/NNS	prep_on||effects-4/NNS||hemodynamics-6/NNS	nn||exchange-9/NN||gas-8/NN	prep_on||effects-4/NNS||exchange-9/NN	conj_and||hemodynamics-6/NNS||exchange-9/NN	det||emulsion-13/NN||a-11/DT	nn||emulsion-13/NN||lipid-12/NN	prep_of||effects-4/NNS||emulsion-13/NN	vmod||emulsion-13/NN||enriched-14/VBN	prep_with||enriched-14/VBN||omega-3fattyacids-16/JJ	prep_in||omega-3fattyacids-16/JJ||patients-18/NNS	prep_with||patients-18/NNS||ards-20/NNS	ards-20||omega-3fattyacids-16||no_rel||we investigated the effects on hemodynamics and gas exchange of a lipid emulsion enriched with omega-3fattyacids in patients with ards.
nsubj||prototype-12/NN||mimivirus-1/NNS	det||virus-6/NN||a-3/DT	amod||virus-6/NN||giant-4/JJ	nn||virus-6/NN||dsdna-5/NN	appos||mimivirus-1/NNS||virus-6/NN	vmod||virus-6/NN||infecting-7/VBG	dobj||infecting-7/VBG||acanthamoeba-8/NN	cop||prototype-12/NN||is-10/VBZ	det||prototype-12/NN||the-11/DT	root||ROOT-0/null||prototype-12/NN	det||family-16/NN||the-14/DT	amod||family-16/NN||mimiviridae-15/JJ	prep_of||prototype-12/NN||family-16/NN	det||addition-20/NN||the-18/DT	amod||addition-20/NN||latest-19/JJS	appos||prototype-12/NN||addition-20/NN	det||family-23/NN||the-22/DT	prep_to||addition-20/NN||family-23/NN	det||viruses-29/NNS||the-25/DT	amod||viruses-29/NNS||nucleocytoplasmic-26/JJ	amod||viruses-29/NNS||large-27/JJ	nn||viruses-29/NNS||dna-28/NN	prep_of||family-23/NN||viruses-29/NNS	dep||prototype-12/NN||ncldvs-31/VBZ	virus-6||viruses-29||no||mimivirus, a giant dsdna virus infecting acanthamoeba , is the prototype of the mimiviridae family, the latest addition to the family of the nucleocytoplasmic large dna viruses (ncldvs).
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	num||hypotheses-4/NNS||two-3/CD	dobj||investigated-2/VBD||hypotheses-4/NNS	appos||hypotheses-4/NNS||1-6/CD	mark||result-18/VB||that-8/IN	amod||inoculation-10/NN||oral-9/JJ	nsubj||result-18/VB||inoculation-10/NN	amod||mice-16/NNS||il10-12/JJ	dep||mice-16/NNS||/-14/NNP	prep_of||inoculation-10/NN||mice-16/NNS	aux||result-18/VB||would-17/MD	ccomp||investigated-2/VBD||result-18/VB	amod||inflammation-25/NN||greater-20/JJR	advmod||consistent-23/JJ||more-22/RBR	conj_and||greater-20/JJR||consistent-23/JJ	amod||inflammation-25/NN||consistent-23/JJ	amod||inflammation-25/NN||intestinal-24/JJ	prep_in||result-18/VB||inflammation-25/NN	mark||observed-28/VBD||than-26/IN	nsubj||observed-28/VBD||that-27/DT	advcl||result-18/VB||observed-28/VBD	ccomp||result-18/VB||observed-28/VBD	amod||mice-34/NNS||il10-30/JJ	dep||mice-34/NNS||/-32/NNP	prep_in||observed-28/VBD||mice-34/NNS	prep||observed-28/VBD||not-35/RB	pcomp||not-35/RB||receiving-36/VBG	det||inoculation-38/NN||this-37/DT	dobj||receiving-36/VBG||inoculation-38/NN	dep||observed-28/VBD||2-42/CD	mark||associated-49/VBN||that-44/IN	det||inflammation-46/NN||this-45/DT	nsubjpass||associated-49/VBN||inflammation-46/NN	aux||associated-49/VBN||would-47/MD	auxpass||associated-49/VBN||be-48/VB	advcl||result-18/VB||associated-49/VBN	ccomp||result-18/VB||associated-49/VBN	conj_and||observed-28/VBD||associated-49/VBN	prep_with||associated-49/VBN||changes-51/NNS	nn||levels-56/NNS||colon-53/NN	nn||levels-56/NNS||gene-54/NN	nn||levels-56/NNS||expression-55/NN	prep_in||changes-51/NNS||levels-56/NNS	dep||associated-49/VBN||similar-57/JJ	prep_to||similar-57/JJ||those-59/DT	advmod||observed-61/VBN||previously-60/RB	vmod||those-59/DT||observed-61/VBN	amod||studies-64/NNS||human-63/JJ	prep_in||observed-61/VBN||studies-64/NNS	det||mice-68/NNS||these-67/DT	nsubj||model-74/NN||mice-68/NNS	aux||model-74/NN||would-69/MD	advmod||model-74/NN||therefore-70/RB	cop||model-74/NN||be-71/VB	det||model-74/NN||an-72/DT	amod||model-74/NN||appropriate-73/JJ	conj_and||investigated-2/VBD||model-74/NN	amod||cd-77/NN||human-76/JJ	prep_for||model-74/NN||cd-77/NN	cd-77||inflammation-46||no_rel||we investigated two hypotheses (1) that oral inoculation of il10 -/- mice would result in greater and more consistent intestinal inflammation than that observed in il10 -/- mice not receiving this inoculation, and (2) that this inflammation would be associated with changes in colon gene expression levels similar to those previously observed in human studies, and these mice would therefore be an appropriate model for human cd.
det||investigation-2/NN||an-1/DT	nsubjpass||carried-4/VBN||investigation-2/NN	auxpass||carried-4/VBN||was-3/VBD	root||ROOT-0/null||carried-4/VBN	prt||carried-4/VBN||out-5/RP	prep_during||carried-4/VBN||october-7/NNP	num||october-7/NNP||2005â-8/CD	dobj||carried-4/VBN||$-9/$	npadvmod||in-19/RB||september-11/NNP	advmod||september-11/NNP||2006-12/CD	advmod||prevalence-16/NN||determine-14/RB	det||prevalence-16/NN||the-15/DT	prep_to||2006-12/CD||prevalence-16/NN	prep_of||prevalence-16/NN||bloodstreaminfections-18/NNS	dep||patients-20/CD||in-19/RB	num||$-9/$||patients-20/CD	vmod||$-9/$||attending-21/VBG	det||department-24/NN||the-22/DT	nn||department-24/NN||outpatient-23/NN	dobj||attending-21/VBG||department-24/NN	det||clinic-28/NN||the-26/DT	amod||clinic-28/NN||hiv/aids-27/JJ	prep_of||department-24/NN||clinic-28/NN	det||hospital-34/NN||the-30/DT	amod||hospital-34/NN||lagos-31/JJ	nn||hospital-34/NN||university-32/NN	nn||hospital-34/NN||teaching-33/NN	prep_at||carried-4/VBN||hospital-34/NN	prep_in||hospital-34/NN||nigeria-36/NN	aids--1||hiv--1||no||an investigation was carried out during october 2005âseptember 2006 to determine the prevalence of bloodstreaminfections in patients attending the outpatient department of the hiv/aids clinic at the lagos university teaching hospital in nigeria.
amod||monitoring-2/NN||detailed-1/JJ	nsubj||contribute-18/VB||monitoring-2/NN	det||arsenic-6/NN||the-4/DT	amod||arsenic-6/NN||therapeutic-5/JJ	prep_of||monitoring-2/NN||arsenic-6/NN	poss||metabolites-9/NNS||its-8/PRP$	prep_of||monitoring-2/NN||metabolites-9/NNS	conj_and||arsenic-6/NN||metabolites-9/NNS	amod||specimens-13/NNS||various-11/JJ	amod||specimens-13/NNS||accessible-12/JJ	prep_in||metabolites-9/NNS||specimens-13/NNS	nn||patients-16/NNS||apl-15/NN	prep_of||specimens-13/NNS||patients-16/NNS	aux||contribute-18/VB||can-17/MD	root||ROOT-0/null||contribute-18/VB	prepc_to||contribute-18/VB||improving-20/VBG	dobj||improving-20/VBG||treatment-21/NN	advmod||improving-20/VBG||efficacy-22/RB	prepc_to||contribute-18/VB||minimizing-24/VBG	conj_and||improving-20/VBG||minimizing-24/VBG	amod||effects-27/NNS||arsenic-induced-25/JJ	nn||effects-27/NNS||side-26/NN	dobj||minimizing-24/VBG||effects-27/NNS	apl-15||arsenic-6||yes||detailed monitoring of the therapeutic arsenic and its metabolites in various accessible specimens of apl patients can contribute to improving treatment efficacy and minimizing arsenic-induced side effects.
det||results-2/NNS||these-1/DT	nsubj||suggest-3/VBP||results-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||used-12/VBN||that-4/IN	amod||plasmablasts-8/NNS||bcg-specific-5/JJ	amod||plasmablasts-8/NNS||igg-secreting-6/JJ	amod||plasmablasts-8/NNS||peripheral-7/JJ	nsubjpass||used-12/VBN||plasmablasts-8/NNS	nsubj||improve-18/VB||plasmablasts-8/NNS	nsubj||facilitate-32/VB||plasmablasts-8/NNS	aux||used-12/VBN||could-9/MD	auxpass||used-12/VBN||be-10/VB	advmod||used-12/VBN||successfully-11/RB	ccomp||suggest-3/VBP||used-12/VBN	det||biomarker-16/NN||a-14/DT	amod||biomarker-16/NN||host-specific-15/JJ	prep_as||used-12/VBN||biomarker-16/NN	aux||improve-18/VB||to-17/TO	xcomp||used-12/VBN||improve-18/VB	dobj||improve-18/VB||diagnosis-19/NN	amod||tb-22/NN||active-21/JJ	prep_of||diagnosis-19/NN||tb-22/NN	advmod||improve-18/VB||particularly-24/RB	prep_in||improve-18/VB||people-26/NNS	nsubj||hivpositive-29/JJ||people-26/NNS	cop||hivpositive-29/JJ||are-28/VBP	rcmod||people-26/NNS||hivpositive-29/JJ	xcomp||used-12/VBN||facilitate-32/VB	conj_and||improve-18/VB||facilitate-32/VB	dobj||facilitate-32/VB||administration-33/NN	amod||treatment-36/NN||effective-35/JJ	prep_of||administration-33/NN||treatment-36/NN	prep_to||facilitate-32/VB||patients-38/NNS	tb-22||bcg--1||no||these results suggest that bcg-specific igg-secreting peripheral plasmablasts could be successfully used as a host-specific biomarker to improve diagnosis of active tb, particularly in people who are hivpositive, and facilitate administration of effective treatment to patients.
nsubj||indicates-15/VBZ||increased-1/VBN	amod||increased-1/VBN||binding-2/VBG	amod||neurons-10/NNS||tf-4/JJ	det||purkinje-8/NN||the-6/DT	nn||purkinje-8/NN||cerebellar-7/NN	prep_to||tf-4/JJ||purkinje-8/NN	nn||neurons-10/NNS||cell-9/NN	prep_of||increased-1/VBN||neurons-10/NNS	amod||brains-13/NNS||scjd-12/JJ	prep_of||neurons-10/NNS||brains-13/NNS	advmod||indicates-15/VBZ||further-14/RB	root||ROOT-0/null||indicates-15/VBZ	dobj||indicates-15/VBZ||upregulation-16/NN	prep_of||upregulation-16/NN||tfr-18/NN	det||phenotype-21/NN||a-20/DT	dobj||indicates-15/VBZ||phenotype-21/NN	conj_and||upregulation-16/NN||phenotype-21/NN	amod||irondeficiency-24/NN||neuronal-23/JJ	prep_of||phenotype-21/NN||irondeficiency-24/NN	amod||brains-27/NNS||diseased-26/JJ	prep_in||irondeficiency-24/NN||brains-27/NNS	amod||levels-31/NNS||increased-29/VBN	nn||levels-31/NNS||iron-30/NN	prep_despite||indicates-15/VBZ||levels-31/NNS	irondeficiency-24||iron-30||yes||increased binding of tf to the cerebellar purkinje cell neurons of scjd brains further indicates upregulation of tfr and a phenotype of neuronal irondeficiency in diseased brains despite increased iron levels.
amod||causes-2/NNS||potential-1/JJ	nsubj||include-12/VBP||causes-2/NNS	amod||deterioration-5/NN||clinical-4/JJ	prep_for||causes-2/NNS||deterioration-5/NN	prep_in||deterioration-5/NN||settings-7/NNS	amod||prevalence-11/NN||high-9/JJ	amod||prevalence-11/NN||hiv-1-10/JJ	prep_of||settings-7/NNS||prevalence-11/NN	root||ROOT-0/null||include-12/VBP	npadvmod||resistant-14/JJ||drug-13/NN	amod||mycobacteriumtuberculosis-15/NNS||resistant-14/JJ	dobj||include-12/VBP||mycobacteriumtuberculosis-15/NNS	appos||mycobacteriumtuberculosis-15/NNS||m.tb-17/NN	amod||illnesses-21/NNS||co-morbid-20/JJ	dobj||include-12/VBP||illnesses-21/NNS	conj_and||mycobacteriumtuberculosis-15/NNS||illnesses-21/NNS	amod||adherence-24/NN||poor-23/JJ	dobj||include-12/VBP||adherence-24/NN	conj_and||mycobacteriumtuberculosis-15/NNS||adherence-24/NN	nn||syndrome-32/NN||therapy-26/NN	nn||syndrome-32/NN||tuberculosis-28/NNP	amod||syndrome-32/NN||associated-immune-29/JJ	amod||syndrome-32/NN||reconstitution-30/JJ	amod||syndrome-32/NN||inflammatory-31/JJ	prep_to||adherence-24/NN||syndrome-32/NN	appos||syndrome-32/NN||tb-iris-34/NNS	amod||levels-40/NNS||subtherapeutic-37/JJ	nn||levels-40/NNS||antitubercular-38/NN	nn||levels-40/NNS||drug-39/NN	dobj||include-12/VBP||levels-40/NNS	conj_and||mycobacteriumtuberculosis-15/NNS||levels-40/NNS	tb--1||antitubercular-38||yes||potential causes for clinical deterioration in settings of high hiv-1 prevalence include drug resistant mycobacteriumtuberculosis (m.tb) , co-morbid illnesses, poor adherence to therapy, tuberculosis associated-immune reconstitution inflammatory syndrome (tb-iris) and subtherapeutic antitubercular drug levels.
amod||prevalence-2/NN||increasing-1/VBG	nsubj||worsening-17/VBG||prevalence-2/NN	nn||resistance-5/NN||inh-4/NN	prep_of||prevalence-2/NN||resistance-5/NN	advmod||resistance-5/NN||especially-7/RB	amod||tb-12/NN||high-9/JJ	nn||tb-12/NN||tuberculosis-10/NNP	nn||tb-12/NN||-lrb--11/NNP	prep_in||especially-7/RB||tb-12/NN	advmod||prevalent-14/JJ||-rrb--13/RB	amod||countries-15/NNS||prevalent-14/JJ	dep||resistance-5/NN||countries-15/NNS	aux||worsening-17/VBG||is-16/VBZ	root||ROOT-0/null||worsening-17/VBG	det||burden-19/NN||the-18/DT	dobj||worsening-17/VBG||burden-19/NN	nn||programs-23/NNS||tb-21/NN	nn||programs-23/NNS||control-22/NN	prep_of||burden-19/NN||programs-23/NNS	mark||noted-30/VBN||since-25/IN	amod||rates-28/NNS||similar-26/JJ	nn||rates-28/NNS||transmission-27/NN	nsubjpass||noted-30/VBN||rates-28/NNS	auxpass||noted-30/VBN||are-29/VBP	advcl||worsening-17/VBG||noted-30/VBN	nn||strains-37/NNS||inh-32/NN	amod||strains-37/NNS||susceptible-33/JJ	conj_and||susceptible-33/JJ||resistant-35/JJ	amod||strains-37/NNS||resistant-35/JJ	nn||strains-37/NNS||m.tuberculosis-36/NN	prep_for||noted-30/VBN||strains-37/NNS	tb-21||inh-32||yes||increasing prevalence of inh resistance , especially in high tuberculosis -lrb- tb -rrb- prevalent countries is worsening the burden of tb control programs , since similar transmission rates are noted for inh susceptible and resistant m.tuberculosis strains .
nsubjpass||decreased-9/VBN||mortality-1/NN	prep_among||mortality-1/NN||idus-3/NNS	vmod||idus-3/NNS||living-4/VBG	prep_with||living-4/VBG||aids-6/NNS	aux||decreased-9/VBN||might-7/MD	auxpass||decreased-9/VBN||be-8/VB	root||ROOT-0/null||decreased-9/VBN	agent||decreased-9/VBN||reducing-11/VBG	amod||inequality-14/NN||metropolitan-12/JJ	nn||inequality-14/NN||income-13/NN	dobj||reducing-11/VBG||inequality-14/NN	agent||decreased-9/VBN||increasing-16/VBG	conj_and||reducing-11/VBG||increasing-16/VBG	amod||expenditures-19/NNS||public-17/JJ	nn||expenditures-19/NNS||health-18/NN	dobj||increasing-16/VBG||expenditures-19/NNS	advmod||increasing-23/VBG||perhaps-22/RB	agent||decreased-9/VBN||increasing-23/VBG	conj_and||reducing-11/VBG||increasing-23/VBG	nn||treatment-26/NN||drug-24/NN	nn||treatment-26/NN||abuse-25/NN	dobj||increasing-23/VBG||treatment-26/NN	nn||services-30/NNS||hiv-28/NN	nn||services-30/NNS||testing-29/NN	dobj||increasing-23/VBG||services-30/NNS	conj_and||treatment-26/NN||services-30/NNS	aids-6||hiv-28||no||mortality among idus living with aids might be decreased by reducing metropolitan income inequality, increasing public health expenditures, and perhaps increasing drug abuse treatment and hiv testing services.
nn||rhythms-2/NNS||melatonin-1/NN	nsubj||displayed-3/VBD||rhythms-2/NNS	root||ROOT-0/null||displayed-3/VBD	amod||instability-5/NN||prolonged-4/JJ	dobj||displayed-3/VBD||instability-5/NN	amod||days-7/NNS||several-6/JJ	tmod||displayed-3/VBD||days-7/NNS	prep_after||displayed-3/VBD||stroke-9/NN	det||majority-13/NN||a-12/DT	prep_with||displayed-3/VBD||majority-13/NN	prep_of||majority-13/NN||rats-15/NNS	vmod||rats-15/NNS||showing-16/VBG	det||alternation-19/NN||a-17/DT	amod||alternation-19/NN||day-to-day-18/JJ	dobj||showing-16/VBG||alternation-19/NN	prep_between||alternation-19/NN||advance-21/NN	prep_between||alternation-19/NN||delay-23/NN	conj_and||advance-21/NN||delay-23/NN	nn||onset-26/NN||melatonin-25/NN	prep_in||showing-16/VBG||onset-26/NN	prep_in||showing-16/VBG||duration-28/NN	conj_and||onset-26/NN||duration-28/NN	stroke-9||melatonin-25||no_rel||melatonin rhythms displayed prolonged instability several days after stroke, with a majority of rats showing a day-to-day alternation between advance and delay in melatonin onset and duration.
nsubj||drug-6/NN||bivalirudin-1/NN	cop||drug-6/NN||is-2/VBZ	det||drug-6/NN||a-3/DT	amod||drug-6/NN||synthetic-4/JJ	nn||drug-6/NN||anticoagulant-5/NN	root||ROOT-0/null||drug-6/NN	nsubj||cause-21/VB||drug-6/NN	advmod||employed-8/VBN||sometimes-7/RB	vmod||drug-6/NN||employed-8/VBN	det||substitute-11/NN||a-10/DT	prep_as||employed-8/VBN||substitute-11/NN	prep_for||substitute-11/NN||heparin-13/NN	det||anticoagulant-18/NN||a-15/DT	advmod||used-17/VBN||commonly-16/RB	amod||anticoagulant-18/NN||used-17/VBN	appos||heparin-13/NN||anticoagulant-18/NN	aux||cause-21/VB||can-20/MD	rcmod||drug-6/NN||cause-21/VB	det||heparin-inducedthrombocytopenia-25/NN||a-22/DT	nn||heparin-inducedthrombocytopenia-25/NN||condition-23/NN	amod||heparin-inducedthrombocytopenia-25/NN||called-24/VBN	dobj||cause-21/VB||heparin-inducedthrombocytopenia-25/NN	dep||heparin-inducedthrombocytopenia-25/NN||hit-27/VBN	hit-27||heparin-13||no||bivalirudin is a synthetic anticoagulant drug sometimes employed as a substitute for heparin, a commonly used anticoagulant that can cause a condition called heparin-inducedthrombocytopenia (hit).
det||extent-3/NN||the-2/DT	prep_to||suggests-26/VBZ||extent-3/NN	mark||mimics-11/VBZ||that-4/IN	det||nicotine-7/NN||the-5/DT	amod||nicotine-7/NN||combined-6/VBN	nsubj||mimics-11/VBZ||nicotine-7/NN	nn||sensitization-10/NN||pcp-9/NN	conj_and||nicotine-7/NN||sensitization-10/NN	nsubj||mimics-11/VBZ||sensitization-10/NN	dep||extent-3/NN||mimics-11/VBZ	amod||nicotineaddiction-13/NN||comorbid-12/JJ	dobj||mimics-11/VBZ||nicotineaddiction-13/NN	prep_in||nicotineaddiction-13/NN||schizophrenia-15/NN	det||effect-20/NN||the-17/DT	amod||effect-20/NN||preferential-18/JJ	nn||effect-20/NN||inhibitory-19/NN	nsubj||suggests-26/VBZ||effect-20/NN	prep_of||effect-20/NN||iptakalim-22/NN	amod||hyperlocomotion-25/NN||nicotine-induced-24/JJ	prep_on||iptakalim-22/NN||hyperlocomotion-25/NN	root||ROOT-0/null||suggests-26/VBZ	mark||drug-34/NN||that-27/IN	nsubj||drug-34/NN||iptakalim-28/NN	aux||drug-34/NN||may-29/MD	cop||drug-34/NN||be-30/VB	det||drug-34/NN||a-31/DT	amod||drug-34/NN||potential-32/JJ	amod||drug-34/NN||useful-33/JJ	ccomp||suggests-26/VBZ||drug-34/NN	det||abuse-39/NN||the-36/DT	nn||abuse-39/NN||treatment-37/NN	nn||abuse-39/NN||nicotine-38/NN	prep_for||drug-34/NN||abuse-39/NN	prep_in||abuse-39/NN||schizophrenia-41/NN	nicotineaddiction-13||nicotine-38||no||to the extent that the combined nicotine and pcp sensitization mimics comorbid nicotineaddiction in schizophrenia, the preferential inhibitory effect of iptakalim on nicotine-induced hyperlocomotion suggests that iptakalim may be a potential useful drug for the treatment nicotine abuse in schizophrenia.
det||procedures-3/NNS||the-2/DT	nsubj||eliminated-13/VBD||procedures-3/NNS	nsubj||vaccinated-75/VBD||procedures-3/NNS	prep_by||eliminated-13/VBD||which-5/WDT	amod||vaccine-8/NN||oral-6/JJ	amod||vaccine-8/NN||polio-7/JJ	npadvmod||rapidly-12/RB||vaccine-8/NN	appos||vaccine-8/NN||opv-10/NN	advmod||eliminated-13/VBD||rapidly-12/RB	root||ROOT-0/null||eliminated-13/VBD	dobj||eliminated-13/VBD||all-14/DT	dobj||eliminated-13/VBD||almost-16/RB	advmod||all-14/DT||almost-16/RB	conj_or||all-14/DT||almost-16/RB	det||disease-19/NN||all-17/DT	amod||disease-19/NN||paralytic-18/JJ	dep||all-14/DT||disease-19/NN	vmod||disease-19/NN||caused-20/VBN	agent||caused-20/VBN||polioviruses-22/NNS	det||temperate-27/NN||the-24/DT	advmod||developed-26/JJ||economically-25/RB	amod||temperate-27/NN||developed-26/JJ	prep_from||caused-20/VBN||temperate-27/NN	nn||countries-29/NNS||climate-28/NN	nsubj||inadequate-32/JJ||countries-29/NNS	aux||inadequate-32/JJ||have-30/VBP	cop||inadequate-32/JJ||been-31/VBN	rcmod||temperate-27/NN||inadequate-32/JJ	amod||countries-37/NNS||tropical-34/JJ	conj_and||tropical-34/JJ||subtropical-36/JJ	amod||countries-37/NNS||subtropical-36/JJ	prep_in||inadequate-32/JJ||countries-37/NNS	dep||inadequate-32/JJ||except-39/IN	det||countries-43/NNS||some-41/DT	amod||countries-43/NNS||small-42/JJ	prep_in||inadequate-32/JJ||countries-43/NNS	amod||services-47/NNS||good-45/JJ	nn||services-47/NNS||health-46/NN	prep_with||countries-43/NNS||services-47/NNS	advmod||is-52/VBZ||largely-49/RB	mark||is-52/VBZ||because-50/IN	expl||is-52/VBZ||there-51/EX	advcl||inadequate-32/JJ||is-52/VBZ	advmod||more-54/JJR||much-53/RB	amod||circulation-56/NN||more-54/JJR	amod||circulation-56/NN||year-round-55/JJ	iobj||is-52/VBZ||circulation-56/NN	nsubj||is-52/VBZ||circulation-56/NN	prep_of||circulation-56/NN||wild-60/NN	dep||circulation-56/NN||polioviruses-63/NNS	nsubj||continue-65/VBP||polioviruses-63/NNS	nsubj||produce-67/VB||polioviruses-63/NNS	rcmod||polioviruses-63/NNS||continue-65/VBP	aux||produce-67/VB||to-66/TO	xcomp||continue-65/VBP||produce-67/VB	det||disease-69/NN||the-68/DT	dobj||produce-67/VB||disease-69/NN	det||unvaccinated-72/NN||the-71/DT	prep_in||disease-69/NN||unvaccinated-72/NN	advmod||vaccinated-75/VBD||incompletely-74/RB	conj_and||eliminated-13/VBD||vaccinated-75/VBD	dobj||vaccinated-75/VBD||children-76/NNS	polio-7||polioviruses-63||no||" the procedures by which oral polio vaccine (opv) rapidly eliminated all or almost all paralytic disease caused by polioviruses from the economically developed temperate climate countries have been inadequate in tropical and subtropical countries, except in some small countries with good health services, largely because there is much more year-round circulation of ""wild"" polioviruses which continue to produce the disease in the unvaccinated and incompletely vaccinated children."
nsubj||represents-9/VBZ||pulmonarytuberculosis-1/NNS	vmod||pulmonarytuberculosis-1/NNS||caused-3/VBN	agent||caused-3/VBN||mycobacteriumtuberculosis-5/NNS	appos||mycobacteriumtuberculosis-5/NNS||m.tb-7/NN	root||ROOT-0/null||represents-9/VBZ	det||concern-14/NN||a-10/DT	amod||concern-14/NN||leading-11/VBG	amod||concern-14/NN||global-12/JJ	nn||concern-14/NN||health-13/NN	dobj||represents-9/VBZ||concern-14/NN	number||million-18/CD||8.7-17/CD	num||cases-21/NNS||million-18/CD	advmod||emerging-20/JJ||newly-19/RB	amod||cases-21/NNS||emerging-20/JJ	prep_with||concern-14/NN||cases-21/NNS	number||million-25/CD||1.4-24/CD	num||deaths-27/NNS||million-25/CD	amod||deaths-27/NNS||reported-26/VBN	dobj||represents-9/VBZ||deaths-27/NNS	conj_and||concern-14/NN||deaths-27/NNS	advmod||deaths-27/NNS||annually-28/RB	tb--1||mycobacteriumtuberculosis-5||no||pulmonarytuberculosis, caused by mycobacteriumtuberculosis (m.tb) represents a leading global health concern, with 8.7 million newly emerging cases, and 1.4 million reported deaths annually.
det||effect-3/NN||the-1/DT	amod||effect-3/NN||limited-2/JJ	nsubj||led-11/VBD||effect-3/NN	amod||abscess-7/NNS||percutaneous-5/JJ	amod||abscess-7/NNS||transhepatic-6/JJ	prep_of||effect-3/NN||abscess-7/NNS	amod||abscess-7/NNS||drainage-8/JJ	amod||abscess-7/NNS||antibiotics-10/JJ	conj_and||drainage-8/JJ||antibiotics-10/JJ	root||ROOT-0/null||led-11/VBD	dobj||led-11/VBD||us-12/PRP	nsubj||perform-14/VB||us-12/PRP	aux||perform-14/VB||to-13/TO	xcomp||led-11/VBD||perform-14/VB	amod||resection-16/NN||radical-15/JJ	dobj||perform-14/VB||resection-16/NN	det||abscess-19/NNS||the-18/DT	prep_of||resection-16/NN||abscess-19/NNS	abscess-19||antibiotics-10||no_rel||the limited effect of percutaneous transhepatic abscess drainage and antibiotics led us to perform radical resection of the abscess.
amod||analysis-2/NN||proteomic-1/JJ	nsubj||identified-3/VBD||analysis-2/NN	root||ROOT-0/null||identified-3/VBD	dobj||identified-3/VBD||rela-4/NN	dobj||identified-3/VBD||stat5-6/NNS	conj_and||rela-4/NN||stat5-6/NNS	num||proteins-10/NNS||two-8/CD	amod||proteins-10/NNS||major-9/JJ	prep_as||identified-3/VBD||proteins-10/NNS	vmod||proteins-10/NNS||associated-11/VBN	nn||resistance-14/NN||carboplatin-13/NN	prep_with||associated-11/VBN||resistance-14/NN	prep_in||resistance-14/NN||ovariantumors-16/NNS	ovariantumors-16||carboplatin-13||yes||proteomic analysis identified rela and stat5 as two major proteins associated with carboplatin resistance in ovariantumors.
nsubj||studied-2/VBD||we-1/PRP	root||ROOT-0/null||studied-2/VBD	num||adults-5/NNS||16-3/CD	amod||adults-5/NNS||nondiabetic-4/JJ	dobj||studied-2/VBD||adults-5/NNS	num||subjects-8/NNS||16-7/CD	dobj||studied-2/VBD||subjects-8/NNS	conj_and||adults-5/NNS||subjects-8/NNS	prep_with||studied-2/VBD||type1diabetes-10/CD	prep_during||studied-2/VBD||euglycemia-12/NN	npadvmod||mmol/l-16/JJ||bloodglucose-14/NN	num||bloodglucose-14/NN||4.5-15/CD	dep||euglycemia-12/NN||mmol/l-16/JJ	prep_during||studied-2/VBD||hypoglycemia-19/NN	conj_and||euglycemia-12/NN||hypoglycemia-19/NN	npadvmod||mmol/l-23/JJ||bloodglucose-21/NN	num||bloodglucose-21/NN||2.5-22/CD	dep||euglycemia-12/NN||mmol/l-23/JJ	hypoglycemia-19||glucose--1||yes||we studied 16 nondiabetic adults and 16 subjects with type1diabetes during euglycemia (bloodglucose 4.5 mmol/l) and hypoglycemia (bloodglucose 2.5 mmol/l).
amod||melphalan-2/NN||high-dose-1/JJ	nsubj||stem-9/VBP||melphalan-2/NN	num||mg/m2-5/NNS||200-4/CD	appos||melphalan-2/NN||mg/m2-5/NNS	prep_with||melphalan-2/NN||autologous-8/NNS	root||ROOT-0/null||stem-9/VBP	nn||transplantation-11/NN||cell-10/NN	nsubj||treatment-18/NN||transplantation-11/NN	appos||transplantation-11/NN||asct-13/NN	cop||treatment-18/NN||is-15/VBZ	det||treatment-18/NN||the-16/DT	amod||treatment-18/NN||standard-17/JJ	ccomp||stem-9/VBP||treatment-18/NN	amod||patients-21/NNS||young-20/JJ	prep_for||treatment-18/NN||patients-21/NNS	prep_with||patients-21/NNS||multiplemyeloma-23/NN	appos||multiplemyeloma-23/NN||mm-25/NN	multiplemyeloma-23||melphalan-2||yes||high-dose melphalan (200 mg/m2) with autologous stem cell transplantation (asct) is the standard treatment for young patients with multiplemyeloma (mm).
det||patients-2/NNS||all-1/DT	nsubjpass||treated-4/VBN||patients-2/NNS	auxpass||treated-4/VBN||were-3/VBD	root||ROOT-0/null||treated-4/VBN	amod||debridement-7/NN||surgical-6/JJ	agent||treated-4/VBN||debridement-7/NN	vmod||debridement-7/NN||followed-8/VBN	det||combination-11/NN||a-10/DT	agent||followed-8/VBN||combination-11/NN	nsubj||died-31/VBD||combination-11/NN	prep_of||combination-11/NN||antibiotics-13/NNS	dep||combination-11/NN||ceftazidime-16/NN	appos||ceftazidime-16/NN||amoxy-clavulanicacid-18/NN	appos||ceftazidime-16/NN||co-trimoxazole-20/NN	conj_and||amoxy-clavulanicacid-18/NN||co-trimoxazole-20/NN	appos||ceftazidime-16/NN||doxycycline-22/NN	conj_and||amoxy-clavulanicacid-18/NN||doxycycline-22/NN	num||months-26/NNS||six-25/CD	prep_for||ceftazidime-16/NN||months-26/NNS	prepc_except_for||months-26/NNS||for-28/IN	pobj||months-26/NNS||one-29/CD	rcmod||combination-11/NN||died-31/VBD	acomp||died-31/VBD||due-32/JJ	aux||fulminant-34/VB||to-33/TO	xcomp||due-32/JJ||fulminant-34/VB	dobj||fulminant-34/VB||septicemia-35/NN	septicemia-35||clavulanicacid--1||no_rel||all patients were treated by surgical debridement followed by a combination of antibiotics; (ceftazidime, amoxy-clavulanicacid, co-trimoxazole and doxycycline) for six months except for one who died due to fulminant septicemia.
amod||therapy-2/NN||lamivudine-1/JJ	nsubj||had-3/VBD||therapy-2/NN	root||ROOT-0/null||had-3/VBD	det||effect-6/NN||a-4/DT	amod||effect-6/NN||significant-5/JJ	dobj||had-3/VBD||effect-6/NN	amod||seroconversion-9/NN||hbeag-8/JJ	prep_on||effect-6/NN||seroconversion-9/NN	nn||disappearance-12/NN||hbv-dna-11/NN	prep_on||effect-6/NN||disappearance-12/NN	conj_and||seroconversion-9/NN||disappearance-12/NN	nn||normalization-16/NN||alt-15/NN	dobj||had-3/VBD||normalization-16/NN	conj_and||effect-6/NN||normalization-16/NN	nn||children-19/NNS||korean-18/NN	prep_for||normalization-16/NN||children-19/NNS	prep_with||had-3/VBD||chronichepatitisb-21/NN	hbv--1||lamivudine-1||yes||lamivudine therapy had a significant effect on hbeag seroconversion and hbv-dna disappearance, and alt normalization for korean children with chronichepatitisb.
aux||determine-2/VB||to-1/TO	csubj||factor-16/VBZ||determine-2/VB	mark||explains-9/VBZ||whether-3/IN	amod||provasopressin-5/NN||c-terminal-4/JJ	nsubj||explains-9/VBZ||provasopressin-5/NN	appos||provasopressin-5/NN||copeptin-7/NN	ccomp||determine-2/VB||explains-9/VBZ	det||importance-12/NN||the-10/DT	amod||importance-12/NN||prognostic-11/JJ	dobj||explains-9/VBZ||importance-12/NN	nn||growth-15/NN||insulin-14/NN	prep_of||importance-12/NN||growth-15/NN	root||ROOT-0/null||factor-16/VBZ	amod||protein-1-18/NN||binding-17/VBG	dobj||factor-16/VBZ||protein-1-18/NN	dep||protein-1-18/NN||igfbp-1-20/JJ	prep_in||protein-1-18/NN||patients-23/NNS	prep_with||patients-23/NNS||myocardialinfarction-25/NN	prep_with||patients-23/NNS||type2diabetes-27/NNS	conj_and||myocardialinfarction-25/NN||type2diabetes-27/NNS	type2diabetes-27||insulin-14||yes||to determine whether c-terminal provasopressin (copeptin) explains the prognostic importance of insulin growth factor binding protein-1 (igfbp-1) in patients with myocardialinfarction and type2diabetes.
nsubj||carried-2/VBD||we-1/PRP	root||ROOT-0/null||carried-2/VBD	prt||carried-2/VBD||out-3/RP	det||study-6/NN||this-4/DT	amod||study-6/NN||preliminary-5/JJ	dobj||carried-2/VBD||study-6/NN	aux||analyze-8/VB||to-7/TO	vmod||study-6/NN||analyze-8/VB	det||predicted-10/NN||the-9/DT	nsubj||undetectable-22/JJ||predicted-10/NN	vmod||predicted-10/NN||hbsag-11/VBG	nn||changes-13/NNS||conformation-12/NN	dobj||hbsag-11/VBG||changes-13/NNS	nn||variants-16/NNS||hbv-15/NN	prep_of||changes-13/NNS||variants-16/NNS	vmod||variants-16/NNS||isolated-17/VBN	amod||donors-21/NNS||indonesian-19/JJ	nn||donors-21/NNS||blood-20/NN	prep_from||isolated-17/VBN||donors-21/NNS	xcomp||analyze-8/VB||undetectable-22/JJ	prepc_by||undetectable-22/JJ||hbsag-24/VBG	dobj||hbsag-24/VBG||assays-25/NNS	poss||significance-28/NN||its-27/PRP$	dobj||hbsag-24/VBG||significance-28/NN	conj_and||assays-25/NNS||significance-28/NN	prepc_compared_to||carried-2/VBD||to-31/TO	amod||variants-34/NNS||other-32/JJ	amod||variants-34/NNS||previously-reported-33/JJ	pobj||carried-2/VBD||variants-34/NNS	nsubjpass||associated-37/VBN||variants-34/NNS	auxpass||associated-37/VBN||were-36/VBD	rcmod||variants-34/NNS||associated-37/VBN	amod||failure-40/NN||diagnostic-39/JJ	prep_with||associated-37/VBN||failure-40/NN	hbv-15||hbsag-24||yes||we carried out this preliminary study to analyze the predicted hbsag conformation changes of hbv variants isolated from indonesian blood donors undetectable by hbsag assays and its significance, compared to other previously-reported variants that were associated with diagnostic failure.
nsubjpass||collected-3/VBN||strains-1/NNS	nsubjpass||tested-19/VBN||strains-1/NNS	auxpass||collected-3/VBN||were-2/VBD	root||ROOT-0/null||collected-3/VBN	num||patients-11/NNS||1824-5/CD	amod||patients-11/NNS||diagnosed-6/JJ	nn||patients-11/NNS||sputum-7/NN	amod||patients-11/NNS||smear-8/JJ	amod||patients-11/NNS||positive-9/JJ	nn||patients-11/NNS||pulmonarytb-10/NN	prep_from||collected-3/VBN||patients-11/NNS	amod||province-14/NN||jiangsu-13/JJ	prep_in||patients-11/NNS||province-14/NN	prep_of||province-14/NN||china-16/NN	advmod||tested-19/VBN||then-18/RB	conj_and||collected-3/VBN||tested-19/VBN	nn||susceptibility-22/NN||drug-21/NN	prep_for||tested-19/VBN||susceptibility-22/NN	prep_against||susceptibility-22/NN||rifampicin-24/NN	prep_against||susceptibility-22/NN||isoniazid-26/NN	conj_and||rifampicin-24/NN||isoniazid-26/NN	prep_against||susceptibility-22/NN||ethambutol-28/NN	conj_and||rifampicin-24/NN||ethambutol-28/NN	prep_against||susceptibility-22/NN||streptomycin-30/NN	conj_and||rifampicin-24/NN||streptomycin-30/NN	pulmonarytb-10||isoniazid-26||no_rel||strains were collected from 1824 diagnosed sputum smear positive pulmonarytb patients in jiangsu province of china and then tested for drug susceptibility against rifampicin, isoniazid, ethambutol and streptomycin.
nsubj||group-4/NN||brucella-1/NN	cop||group-4/NN||is-2/VBZ	det||group-4/NN||a-3/DT	root||ROOT-0/null||group-4/NN	prep_of||group-4/NN||bacteria-6/NNS	nsubj||causes-8/VBZ||bacteria-6/NNS	rcmod||bacteria-6/NNS||causes-8/VBZ	dobj||causes-8/VBZ||brucellosis-9/NNS	nsubj||affect-13/VB||brucellosis-9/NNS	aux||affect-13/VB||can-12/MD	rcmod||brucellosis-9/NNS||affect-13/VB	nn||health-15/NN||population-14/NN	dobj||affect-13/VB||health-15/NN	amod||success-18/NN||reproductive-17/JJ	dobj||affect-13/VB||success-18/NN	conj_and||health-15/NN||success-18/NN	amod||mammals-22/NNS||many-20/JJ	amod||mammals-22/NNS||marine-21/JJ	prep_in||health-15/NN||mammals-22/NNS	brucellosis-9||brucella-1||no||brucella is a group of bacteria that causes brucellosis, which can affect population health and reproductive success in many marine mammals.
nsubj||appears-3/VBZ||hypersensitivity-1/NN	advmod||appears-3/VBZ||usually-2/RB	root||ROOT-0/null||appears-3/VBZ	amod||infusions-6/NNS||multiple-5/JJ	prep_after||appears-3/VBZ||infusions-6/NNS	xcomp||appears-3/VBZ||suggesting-8/VBG	nn||allergicreactions-11/NNS||type-9/NN	nn||allergicreactions-11/NNS||i-10/NN	dobj||suggesting-8/VBG||allergicreactions-11/NNS	advmod||seem-20/VBP||however-13/RB	amod||types-16/NNS||other-15/JJ	nsubj||seem-20/VBP||types-16/NNS	nsubjpass||implicated-23/VBN||types-16/NNS	prep_of||types-16/NNS||hypersensitivity-18/NN	advmod||seem-20/VBP||also-19/RB	parataxis||appears-3/VBZ||seem-20/VBP	aux||implicated-23/VBN||to-21/TO	auxpass||implicated-23/VBN||be-22/VB	xcomp||seem-20/VBP||implicated-23/VBN	hypersensitivity-18||allergicreactions-11||no||hypersensitivity usually appears after multiple infusions, suggesting type i allergicreactions; however, other types of hypersensitivity also seem to be implicated.
neg||differences-4/NNS||no-1/DT	amod||differences-4/NNS||significant-2/JJ	amod||differences-4/NNS||ethnic-3/JJ	nsubjpass||detected-6/VBN||differences-4/NNS	auxpass||detected-6/VBN||were-5/VBD	root||ROOT-0/null||detected-6/VBN	amod||status-9/NN||node-8/JJ	prep_for||detected-6/VBN||status-9/NN	nn||type-12/NN||tumour-11/NN	prep_for||detected-6/VBN||type-12/NN	conj_or||status-9/NN||type-12/NN	nn||size-15/NN||tumour-14/NN	prep_for||detected-6/VBN||size-15/NN	conj_or||status-9/NN||size-15/NN	amod||receptor-21/NN||human-17/JJ	nn||receptor-21/NN||epidermal-18/NN	nn||receptor-21/NN||growth-19/NN	nn||receptor-21/NN||factor-20/NN	prep_for||detected-6/VBN||receptor-21/NN	conj_or||status-9/NN||receptor-21/NN	nn||receptor-26/NN||oestrogen-23/NN	conj_and||oestrogen-23/NN||progesterone-25/NN	nn||receptor-26/NN||progesterone-25/NN	prep_for||detected-6/VBN||receptor-26/NN	conj_or||status-9/NN||receptor-26/NN	appos||receptor-26/NN||er/pr-28/NN	dep||receptor-26/NN||status-30/NN	prep_for||detected-6/VBN||survival-33/NN	conj_or||status-9/NN||survival-33/NN	oestrogen-23||tumour-14||no_rel||no significant ethnic differences were detected for node status, tumour type, tumour size, human epidermal growth factor receptor, oestrogen and progesterone receptor (er/pr) status, or survival.
nsubj||disease-7/NN||melioidosis-1/NNS	cop||disease-7/NN||is-2/VBZ	det||disease-7/NN||a-3/DT	advmod||fatal-5/JJ||frequently-4/RB	amod||disease-7/NN||fatal-5/JJ	amod||disease-7/NN||infectious-6/JJ	root||ROOT-0/null||disease-7/NN	vmod||disease-7/NN||caused-8/VBN	det||burkholderiapseudomallei-15/NN||the-10/DT	nn||burkholderiapseudomallei-15/NN||soil-11/NN	nn||burkholderiapseudomallei-15/NN||dwelling-12/NN	amod||burkholderiapseudomallei-15/NN||gram-negative-13/JJ	nn||burkholderiapseudomallei-15/NN||bacterium-14/NN	agent||caused-8/VBN||burkholderiapseudomallei-15/NN	melioidosis-1||burkholderiapseudomallei-15||no||melioidosis is a frequently fatal infectious disease caused by the soil dwelling gram-negative bacterium burkholderiapseudomallei .
mark||occurred-5/VBD||though-1/IN	neg||hypoglycemia-4/NN||no-2/DT	amod||hypoglycemia-4/NN||insulin-induced-3/JJ	nsubj||occurred-5/VBD||hypoglycemia-4/NN	advcl||1â-12/VBD||occurred-5/VBD	amod||glucose-8/NN||cerebral-7/JJ	nsubj||1â-12/VBD||glucose-8/NN	vmod||glucose-8/NN||decreased-9/VBN	prep_on||decreased-9/VBN||days-11/NNS	root||ROOT-0/null||1â-12/VBD	dobj||1â-12/VBD||$-13/$	num||$-13/$||4-15/CD	nn||onset-18/NN||insulin-17/NN	prep_after||1â-12/VBD||onset-18/NN	prepc_without||1â-12/VBD||reaching-20/VBG	amod||levels-22/NNS||critical-21/JJ	dobj||reaching-20/VBG||levels-22/NNS	hypoglycemia-4||glucose-8||yes||though no insulin-induced hypoglycemia occurred, cerebral glucose decreased on days 1â4 after insulin onset without reaching critical levels.
nsubj||calmetteâ-7/VBD||data-1/NNS	amod||exposure-4/NN||tuberculosis-3/JJ	prep_on||data-1/NNS||exposure-4/NN	prep_on||data-1/NNS||bacillus-6/NNS	conj_and||exposure-4/NN||bacillus-6/NNS	root||ROOT-0/null||calmetteâ-7/VBD	nsubjpass||obtained-18/VBN||$-8/NN	nn||$-8/NN||guã-10/FW	nn||$-8/NN||©-11/FW	dep||$-8/NN||rin-12/FW	discourse||$-8/NN||bcg-14/UH	advmod||obtained-18/VBN||vaccination-16/RB	auxpass||obtained-18/VBN||were-17/VBD	ccomp||calmetteâ-7/VBD||obtained-18/VBN	tuberculosis-3||bcg-14||no||data on tuberculosis exposure and bacillus calmetteâguã©rin (bcg) vaccination were obtained.
nsubjpass||treated-27/VBN||individuals-1/NNS	dep||individuals-1/NNS||n-3/VBN	dep||113-5/CD||=-4/SYM	ccomp||n-3/VBN||113-5/CD	amod||depressivedisorder-22/NN||dsm-iv-8/JJ	amod||manual-13/NN||diagnostic-10/JJ	conj_and||diagnostic-10/JJ||statistical-12/JJ	amod||manual-13/NN||statistical-12/JJ	dep||dsm-iv-8/JJ||manual-13/NN	amod||disorders-16/NNS||mental-15/JJ	prep_of||manual-13/NN||disorders-16/NNS	amod||edition-19/NN||fourth-18/JJ	appos||disorders-16/NNS||edition-19/NN	amod||depressivedisorder-22/NN||major-21/JJ	prep_with||individuals-1/NNS||depressivedisorder-22/NN	appos||depressivedisorder-22/NN||mdd-24/NN	auxpass||treated-27/VBN||were-26/VBD	root||ROOT-0/null||treated-27/VBN	prep_with||treated-27/VBN||escitalopram-29/NN	appos||escitalopram-29/NN||esc-31/NN	prep_with||treated-27/VBN||venlafaxine-34/NN	conj_or||escitalopram-29/NN||venlafaxine-34/NN	appos||escitalopram-29/NN||ven-36/NN	num||weeks-40/NNS||8-39/CD	prep_over||treated-27/VBN||weeks-40/NNS	venlafaxine-34||depressivedisorder-22||no_rel||individuals ( n =113) with dsm-iv (diagnostic and statistical manual of mental disorders, fourth edition) major depressivedisorder (mdd) were treated with escitalopram (esc) or venlafaxine (ven) over 8 weeks.
amod||outcomes-2/NNS||secondary-1/JJ	nsubj||include-3/VBP||outcomes-2/NNS	root||ROOT-0/null||include-3/VBP	amod||measures-5/NNS||anthropometric-4/JJ	dobj||include-3/VBP||measures-5/NNS	nn||pressure-8/NN||blood-7/NN	dobj||include-3/VBP||pressure-8/NN	conj_and||measures-5/NNS||pressure-8/NN	nn||profile-12/NN||blood-10/NN	nn||profile-12/NN||lipid-11/NN	dobj||include-3/VBP||profile-12/NN	conj_and||measures-5/NNS||profile-12/NN	amod||measures-15/NNS||psychosocial-14/JJ	dobj||include-3/VBP||measures-15/NNS	conj_and||measures-5/NNS||measures-15/NNS	dobj||include-3/VBP||measures-19/NNS	conj_and||measures-5/NNS||measures-19/NNS	prep_of||measures-19/NNS||diet-21/NN	amod||activity-24/NN||physical-23/JJ	prep_of||measures-19/NNS||activity-24/NN	conj_and||diet-21/NN||activity-24/NN	amod||monitoring-27/NN||bloodglucose-26/JJ	prep_of||measures-19/NNS||monitoring-27/NN	conj_and||diet-21/NN||monitoring-27/NN	nn||care-30/NN||foot-29/NN	prep_of||measures-19/NNS||care-30/NN	conj_and||diet-21/NN||care-30/NN	nn||taking-33/NN||medication-32/NN	prep_of||measures-19/NNS||taking-33/NN	conj_and||diet-21/NN||taking-33/NN	secondary-1||glucose--1||no_rel||secondary outcomes include anthropometric measures, blood pressure, blood lipid profile, psychosocial measures as well as measures of diet, physical activity, bloodglucose monitoring, foot care and medication taking.
num||controls-3/NNS||seventeen-1/CD	amod||controls-3/NNS||healthy-2/JJ	nsubj||participated-27/VBD||controls-3/NNS	appos||controls-3/NNS||hc-5/NN	num||patients-9/NNS||20-8/CD	conj_and||controls-3/NNS||patients-9/NNS	nsubj||participated-27/VBD||patients-9/NNS	amod||disease-15/NN||crohnâ-11/JJ	amod||disease-15/NN||$-12/$	number||s-14/CD||-13/CD	num||$-12/$||s-14/CD	prep_with||patients-9/NNS||disease-15/NN	appos||patients-9/NNS||cd-17/NN	num||patients-21/NNS||22-20/CD	conj_and||controls-3/NNS||patients-21/NNS	nsubj||participated-27/VBD||patients-21/NNS	prep_with||patients-21/NNS||ulcerativecolitis-23/NNS	appos||controls-3/NNS||uc-25/NN	root||ROOT-0/null||participated-27/VBD	det||study-30/NN||the-29/DT	prep_in||participated-27/VBD||study-30/NN	ulcerativecolitis-23||hc-5||yes||seventeen healthy controls (hc), 20 patients with crohnâs disease (cd) and 22 patients with ulcerativecolitis (uc) participated in the study.
det||group-3/NN||the-1/DT	amod||group-3/NN||whole-2/JJ	nsubj||presented-8/VBD||group-3/NN	num||patients-7/NNS||81-5/CD	amod||patients-7/NNS||acromegalic-6/JJ	prep_of||group-3/NN||patients-7/NNS	root||ROOT-0/null||presented-8/VBD	advmod||higher-11/JJR||significantly-10/RB	amod||biomarkers-32/NNS||higher-11/JJR	amod||biomarkers-32/NNS||anthropometric-12/JJ	nn||biomarkers-32/NNS||parameters-13/NNS	nn||circumference-24/NNS||weight-17/NN	conj_and||weight-17/NN||bmi-19/NN	nn||circumference-24/NNS||bmi-19/NN	conj_and||weight-17/NN||waist-21/NN	nn||circumference-24/NNS||waist-21/NN	conj_and||weight-17/NN||hip-23/NN	nn||circumference-24/NNS||hip-23/NN	prep_such_as||parameters-13/NNS||circumference-24/NNS	conj_but||parameters-13/NNS||with-27/IN	nn||biomarkers-32/NNS||with-27/IN	advmod||favourable-29/JJ||more-28/RBR	pobj||with-27/IN||favourable-29/JJ	amod||biomarkers-32/NNS||cardiovascular-30/JJ	nn||biomarkers-32/NNS||risk-31/NN	prep_with||presented-8/VBD||biomarkers-32/NNS	amod||glucose-38/NN||fasting-36/JJ	nn||glucose-38/NN||plasma-37/NN	prep_such_as||biomarkers-32/NNS||glucose-38/NN	amod||cholesterol-41/NN||total-40/JJ	prep_such_as||biomarkers-32/NNS||cholesterol-41/NN	conj_and||glucose-38/NN||cholesterol-41/NN	prep_such_as||biomarkers-32/NNS||triglycerides-43/NNPS	conj_and||glucose-38/NN||triglycerides-43/NNPS	nn||levels-46/NNS||hdl-45/NN	prep_such_as||biomarkers-32/NNS||levels-46/NNS	conj_and||glucose-38/NN||levels-46/NNS	prep_in||presented-8/VBD||comparison-49/NN	poss||controls-53/NNS||their-51/PRP$	amod||controls-53/NNS||respective-52/JJ	prep_to||presented-8/VBD||controls-53/NNS	cholesterol-41||acromegalic-6||no_rel||the whole group of 81 acromegalic patients presented with significantly higher anthropometric parameters, such as weight, bmi, waist and hip circumference, but with more favourable cardiovascular risk biomarkers, such as fasting plasma glucose, total cholesterol, triglycerides and hdl levels, in comparison to their respective controls.
amod||drugs-2/NNS||several-1/JJ	nsubj||lead-16/VB||drugs-2/NNS	vmod||drugs-2/NNS||used-3/VBN	det||management-6/NN||the-5/DT	prep_in||used-3/VBN||management-6/NN	prep_of||management-6/NN||aids-8/NNS	prep_such_as||aids-8/NNS||nevirapine-11/NN	prep_such_as||aids-8/NNS||indinavir-13/NN	conj_or||nevirapine-11/NN||indinavir-13/NN	aux||lead-16/VB||can-14/MD	advmod||lead-16/VB||themselves-15/PRP	root||ROOT-0/null||lead-16/VB	amod||inflammation-19/NN||severe-18/JJ	prep_to||lead-16/VB||inflammation-19/NN	det||segment-23/NN||the-21/DT	nn||segment-23/NN||anterior-22/NN	prep_in||lead-16/VB||segment-23/NN	prep_in||lead-16/VB||adnexa-25/NN	conj_and||segment-23/NN||adnexa-25/NN	det||eye-28/NN||the-27/DT	prep_of||segment-23/NN||eye-28/NN	aids-8||indinavir-13||yes||several drugs used in the management of aids such as nevirapine or indinavir can themselves lead to severe inflammation in the anterior segment and adnexa of the eye.
det||zn-3/NN||a-1/DT	amod||zn-3/NN||size-controlled-2/JJ	nsubjpass||used-10/VBN||zn-3/NN	nsubj||explain-16/VB||zn-3/NN	discourse||zn-3/NN||oh-5/UH	number||template-8/JJ||2-7/CD	amod||zn-3/NN||template-8/JJ	auxpass||used-10/VBN||is-9/VBZ	root||ROOT-0/null||used-10/VBN	det||study-14/NN||a-12/DT	nn||study-14/NN||case-13/NN	prep_as||used-10/VBN||study-14/NN	aux||explain-16/VB||to-15/TO	xcomp||used-10/VBN||explain-16/VB	det||strategy-19/NN||the-17/DT	amod||strategy-19/NN||chemical-18/JJ	dobj||explain-16/VB||strategy-19/NN	nsubjpass||executed-23/VBN||strategy-19/NN	aux||executed-23/VBN||can-21/MD	auxpass||executed-23/VBN||be-22/VB	rcmod||strategy-19/NN||executed-23/VBN	advmod||engineering-26/VBG||chemically-25/RB	prepc_to||executed-23/VBN||engineering-26/VBG	amod||cavities-29/NNS||various-27/JJ	nn||cavities-29/NNS||nanoscale-28/NN	dobj||engineering-26/VBG||cavities-29/NNS	chemical-18||cavities-29||no_rel||a size-controlled zn(oh)2 template is used as a case study to explain the chemical strategy that can be executed to chemically engineering various nanoscale cavities.
root||ROOT-0/null||saturated-1/VBN	acomp||saturated-1/VBN||fat-2/JJ	nsubj||induce-21/VB||carbohydrates-4/NNS	appos||carbohydrates-4/NNS||components-6/NNS	det||meal-10/NN||the-8/DT	amod||meal-10/NN||hfhc-9/JJ	prep_of||components-6/NNS||meal-10/NN	vmod||meal-10/NN||known-12/VBN	aux||induce-14/VB||to-13/TO	xcomp||known-12/VBN||induce-14/VB	amod||stress-16/NN||oxidative-15/JJ	dobj||induce-14/VB||stress-16/NN	dobj||induce-14/VB||inflammation-18/NN	conj_and||stress-16/NN||inflammation-18/NN	advmod||induce-21/VB||also-20/RB	conj_and||saturated-1/VBN||induce-21/VB	det||increase-23/NN||an-22/DT	dobj||induce-21/VB||increase-23/NN	prep_in||induce-21/VB||lps-25/NN	prep_in||induce-21/VB||tlr-4-27/JJ	conj_and||lps-25/NN||tlr-4-27/JJ	prep_in||induce-21/VB||socs3-30/NNS	conj_and||lps-25/NN||socs3-30/NNS	inflammation-18||fat-2||no_rel||saturated fat and carbohydrates, components of the hfhc meal, known to induce oxidative stress and inflammation, also induce an increase in lps, tlr-4, and socs3.
nsubj||causes-2/VBZ||varicella-zostervirus-1/NNS	nsubj||shingles-8/VBZ||varicella-zostervirus-1/NNS	root||ROOT-0/null||causes-2/VBZ	dobj||causes-2/VBZ||chickenpox-3/NN	amod||infection-6/NN||primary-5/JJ	prep_upon||causes-2/VBZ||infection-6/NN	conj_and||causes-2/VBZ||shingles-8/VBZ	prep_after||shingles-8/VBZ||reactivation-10/NN	chickenpox-3||varicella-zostervirus-1||no||varicella-zostervirus causes chickenpox upon primary infection and shingles after reactivation.
amod||admissions-2/NNS||ninety-four-1/JJ	nsubj||met-3/VBD||admissions-2/NNS	root||ROOT-0/null||met-3/VBD	det||criteria-5/NNS||the-4/DT	dobj||met-3/VBD||criteria-5/NNS	prep_for||criteria-5/NNS||hiv-7/NN	prep_for||criteria-5/NNS||aids-9/NNS	conj_or||hiv-7/NN||aids-9/NNS	conj_or||hiv-7/NN||pancreatitis-11/NNS	conj_and||aids-9/NNS||pancreatitis-11/NNS	num||patients-15/NNS||67-13/CD	amod||patients-15/NNS||unique-14/JJ	dep||criteria-5/NNS||patients-15/NNS	vmod||patients-15/NNS||comprised-16/VBN	det||cohort-18/NN||the-17/DT	dobj||comprised-16/VBN||cohort-18/NN	aids-9||hiv-7||no||ninety-four admissions met the criteria for hiv or aids and pancreatitis; 67 unique patients comprised the cohort.
amod||receptor-3/NN||peroxisome-1/JJ	amod||receptor-3/NN||proliferator-activated-2/JJ	nsubj||î-4/VBP||receptor-3/NN	root||ROOT-0/null||î-4/VBP	number||1-6/CD||³-5/CD	dobj||î-4/VBP||1-6/CD	appos||1-6/CD||pparî-8/NNP	number||1-10/CD||³-9/CD	num||pparî-8/NNP||1-10/CD	nn||±-17/NNP||liver-13/NNP	dep||±-17/NNP||x-14/SYM	nn||±-17/NNP||receptor-15/NNP	nn||±-17/NNP||î-16/NNPS	nsubj||receptors-24/NNS||±-17/NNP	nn||±-20/NNP||lxrî-19/NNP	dep||receptors-24/NNS||±-20/NNP	cop||receptors-24/NNS||are-22/VBP	amod||receptors-24/NNS||nuclear-23/JJ	conj_and||î-4/VBP||receptors-24/NNS	nsubj||play-26/VBP||receptors-24/NNS	rcmod||receptors-24/NNS||play-26/VBP	amod||roles-28/NNS||pivotal-27/JJ	dobj||play-26/VBP||roles-28/NNS	amod||homeostasis-32/NNS||macrophage-30/JJ	nn||homeostasis-32/NNS||cholesterol-31/NN	prep_in||play-26/VBP||homeostasis-32/NNS	prep_in||play-26/VBP||inflammation-34/NN	conj_and||homeostasis-32/NNS||inflammation-34/NN	amod||processes-38/NNS||key-36/JJ	amod||processes-38/NNS||biological-37/JJ	dep||receptors-24/NNS||processes-38/NNS	prep_in||processes-38/NNS||atherogenesis-40/NNS	cholesterol-31||inflammation-34||no_rel||peroxisome proliferator-activated receptor î³1 (pparî³1) and liver x receptor î± (lxrî±) are nuclear receptors that play pivotal roles in macrophage cholesterol homeostasis and inflammation; key biological processes in atherogenesis.
det||strength-2/NN||the-1/DT	nsubj||led-17/VBD||strength-2/NN	det||evidence-5/NN||the-4/DT	prep_of||strength-2/NN||evidence-5/NN	vmod||evidence-5/NN||linking-6/VBG	advmod||linking-6/VBG||concurrency-7/RB	aux||hiv-9/VB||to-8/TO	xcomp||linking-6/VBG||hiv-9/VB	nn||severity-11/NN||epidemic-10/NN	dobj||hiv-9/VB||severity-11/NN	amod||africa-16/NN||southern-13/JJ	conj_and||southern-13/JJ||eastern-15/JJ	amod||africa-16/NN||eastern-15/JJ	prep_in||hiv-9/VB||africa-16/NN	root||ROOT-0/null||led-17/VBD	det||programme-22/NN||the-18/DT	amod||programme-22/NN||joint-19/JJ	amod||programme-22/NN||united-20/JJ	nn||programme-22/NN||nations-21/NNS	dobj||led-17/VBD||programme-22/NN	prep_on||programme-22/NN||hiv/aids-24/NNS	det||community-30/NN||the-26/DT	amod||community-30/NN||southern-27/JJ	nn||community-30/NN||african-28/NN	nn||community-30/NN||development-29/NN	prep_on||programme-22/NN||community-30/NN	conj_and||hiv/aids-24/NNS||community-30/NN	prep_in||led-17/VBD||2006-32/CD	aux||conclude-34/VB||to-33/TO	vmod||led-17/VBD||conclude-34/VB	mark||drivers-57/NNS||that-35/IN	amod||rates-37/NNS||high-36/JJ	nsubj||drivers-57/NNS||rates-37/NNS	amod||partnerships-41/NNS||concurrent-39/JJ	amod||partnerships-41/NNS||sexual-40/JJ	prep_of||rates-37/NNS||partnerships-41/NNS	vmod||rates-37/NNS||combined-43/VBN	amod||rates-46/NNS||low-45/JJ	prep_with||combined-43/VBN||rates-46/NNS	amod||circumcision-49/NN||male-48/JJ	nn||use-53/NN||circumcision-49/NN	conj_and||circumcision-49/NN||infrequent-51/JJ	nn||use-53/NN||infrequent-51/JJ	nn||use-53/NN||condom-52/NN	prep_of||rates-46/NNS||use-53/NN	cop||drivers-57/NNS||are-55/VBP	amod||drivers-57/NNS||major-56/JJ	ccomp||conclude-34/VB||drivers-57/NNS	det||epidemic-61/NN||the-59/DT	nn||epidemic-61/NN||aids-60/NNS	prep_of||drivers-57/NNS||epidemic-61/NN	amod||africa-64/NN||southern-63/JJ	prep_in||epidemic-61/NN||africa-64/NN	aids-60||hiv-9||no||the strength of the evidence linking concurrency to hiv epidemic severity in southern and eastern africa led the joint united nations programme on hiv/aids and the southern african development community in 2006 to conclude that high rates of concurrent sexual partnerships, combined with low rates of male circumcision and infrequent condom use, are major drivers of the aids epidemic in southern africa.
nsubj||fungaldisease-5/NN||histoplasmosis-1/NNS	cop||fungaldisease-5/NN||is-2/VBZ	det||fungaldisease-5/NN||a-3/DT	amod||fungaldisease-5/NN||systemic-4/JJ	root||ROOT-0/null||fungaldisease-5/NN	advmod||known-8/VBN||also-7/RB	vmod||fungaldisease-5/NN||known-8/VBN	nn||sdisease-12/NN||darling-10/NN	prep_as||known-8/VBN||sdisease-12/NN	rcmod||fungaldisease-5/NN||caused-14/VBN	det||histoplasmacapsulatum-19/NN||the-16/DT	amod||histoplasmacapsulatum-19/NN||dimorphic-17/JJ	nn||histoplasmacapsulatum-19/NN||fungus-18/NN	prep_by||caused-14/VBN||histoplasmacapsulatum-19/NN	fungaldisease-5||fungus-18||no||histoplasmosis is a systemic fungaldisease, also known as darling'sdisease, caused by the dimorphic fungus histoplasmacapsulatum .
advmod||evaluated-12/VBN||here-1/RB	amod||effects-5/NNS||potential-3/JJ	nn||effects-5/NNS||immunosuppressive-4/NN	nsubjpass||evaluated-12/VBN||effects-5/NNS	amod||uc-mscs-8/NNS||human-7/JJ	prep_of||effects-5/NNS||uc-mscs-8/NNS	prep_in||uc-mscs-8/NNS||ra-10/NN	auxpass||evaluated-12/VBN||were-11/VBD	root||ROOT-0/null||evaluated-12/VBN	uc--1||immunosuppressive-4||no_rel||here, potential immunosuppressive effects of human uc-mscs in ra were evaluated.
det||use-3/NN||the-1/DT	amod||use-3/NN||combined-2/VBN	nsubjpass||associated-23/VBN||use-3/NN	prep_of||use-3/NN||propofol-5/NN	prep_of||use-3/NN||remifentanil-7/NN	conj_and||propofol-5/NN||remifentanil-7/NN	det||infusion-11/NN||a-9/DT	amod||infusion-11/NN||continuous-10/JJ	prep_as||use-3/NN||infusion-11/NN	prep_as||use-3/NN||infusion-11/NN	conj_and||infusion-11/NN||infusion-11/NN	prep_before||infusion-11/NN||performance-13/NN	det||block-16/NN||the-15/DT	prep_of||performance-13/NN||block-16/NN	amod||surgery-21/NN||lengthy-19/JJ	amod||surgery-21/NN||vitreo-retinal-20/JJ	prep_during||infusion-11/NN||surgery-21/NN	auxpass||associated-23/VBN||was-22/VBD	root||ROOT-0/null||associated-23/VBN	det||incidence-27/NN||a-25/DT	amod||incidence-27/NN||lower-26/JJR	prep_with||associated-23/VBN||incidence-27/NN	amod||discomfort-30/NN||patient-29/JJ	prep_of||incidence-27/NN||discomfort-30/NN	nn||pain-33/NN||breakthrough-32/NN	prep_of||incidence-27/NN||pain-33/NN	conj_and||discomfort-30/NN||pain-33/NN	amod||movement-37/NN||patient-36/JJ	prep_of||incidence-27/NN||movement-37/NN	conj_and||discomfort-30/NN||movement-37/NN	amod||degree-41/NN||high-40/JJ	prep_along_with||incidence-27/NN||degree-41/NN	prepc_of||degree-41/NN||surgeonsâ-43/VBG	nn||stability-49/NN||$-44/$	number||satisfaction-46/CD||-45/CD	num||$-44/$||satisfaction-46/CD	conj_and||$-44/$||hemodynamic-48/JJ	nn||stability-49/NN||hemodynamic-48/JJ	dobj||surgeonsâ-43/VBG||stability-49/NN	pain-33||remifentanil-7||yes||the combined use of propofol and remifentanil as a continuous infusion before performance of the block and during lengthy vitreo-retinal surgery was associated with a lower incidence of patient discomfort, breakthrough pain, and patient movement along with high degree of surgeonsâ satisfaction and hemodynamic stability.
amod||countries-3/NNS||western-2/JJ	prep_in||resulted-18/VBN||countries-3/NNS	det||introduction-6/NN||the-5/DT	nsubj||resulted-18/VBN||introduction-6/NN	nn||therapy-10/NN||combination-8/NN	amod||therapy-10/NN||antiretroviral-9/JJ	prep_of||introduction-6/NN||therapy-10/NN	appos||therapy-10/NN||cart-12/NN	amod||chemotherapeuticagents-16/NNS||new-15/JJ	prep_of||introduction-6/NN||chemotherapeuticagents-16/NNS	conj_and||therapy-10/NN||chemotherapeuticagents-16/NNS	aux||resulted-18/VBN||has-17/VBZ	root||ROOT-0/null||resulted-18/VBN	amod||incidence-21/NN||decreased-20/VBN	prep_in||resulted-18/VBN||incidence-21/NN	amod||prognosis-24/NN||improved-23/VBN	prep_in||resulted-18/VBN||prognosis-24/NN	conj_and||incidence-21/NN||prognosis-24/NN	nn||ssarcoma-28/NN||aids-associatedkaposi-26/NN	prep_of||prognosis-24/NN||ssarcoma-28/NN	aids-associatedkaposi'ssarcoma--1||chemotherapeuticagents-16||no_rel||in western countries, the introduction of combination antiretroviral therapy (cart) and new chemotherapeuticagents has resulted in decreased incidence and improved prognosis of aids-associatedkaposi'ssarcoma.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||significance-5/NN||the-3/DT	amod||significance-5/NN||clinical-4/JJ	dobj||investigated-2/VBD||significance-5/NN	amod||immunoglobulin-9/NN||serum-7/JJ	amod||immunoglobulin-9/NN||specific-8/JJ	prep_of||significance-5/NN||immunoglobulin-9/NN	dep||significance-5/NN||e-10/SYM	appos||significance-5/NN||lge-12/NN	det||enterotoxin-19/NN||the-15/DT	amod||enterotoxin-19/NN||staphylococcal-16/JJ	nn||enterotoxin-19/NN||superantigens-17/NNS	nn||enterotoxin-19/NN||staphylococcal-18/NN	prep_to||investigated-2/VBD||enterotoxin-19/NN	det||sea-22/NN||a-20/DT	dep||enterotoxin-19/NN||sea-22/NN	amod||enterotoxin-26/NN||staphylococcal-25/JJ	prep_to||investigated-2/VBD||enterotoxin-26/NN	conj_and||enterotoxin-19/NN||enterotoxin-26/NN	dep||enterotoxin-26/NN||b-27/SYM	appos||b-27/SYM||seb-29/NN	amod||toxin-34/NN||toxicshocksyndrome-33/JJ	prep_to||investigated-2/VBD||toxin-34/NN	conj_and||enterotoxin-19/NN||toxin-34/NN	appos||toxin-34/NN||tsst-36/NN	dep||toxin-34/NN||-1-38/CD	prep_in||investigated-2/VBD||patients-40/NNS	amod||urticaria-43/NN||chronic-42/JJ	prep_with||patients-40/NNS||urticaria-43/NN	appos||urticaria-43/NN||cu-45/NN	vmod||investigated-2/VBD||focusing-48/VBG	det||differences-51/NNS||the-50/DT	prep_on||focusing-48/VBG||differences-51/NNS	det||prevalences-54/NNS||these-53/DT	prep_in||differences-51/NNS||prevalences-54/NNS	amod||cu-57/NN||aspirin-intolerant-56/JJ	prep_between||prevalences-54/NNS||cu-57/NN	appos||cu-57/NN||aicu-59/NNP	amod||patients-67/NNS||aspirin-tolerant-62/JJ	nn||patients-67/NNS||cu-63/NN	appos||patients-67/NNS||atcu-65/NNP	prep_between||prevalences-54/NNS||patients-67/NNS	conj_and||cu-57/NN||patients-67/NNS	enterotoxin-26||toxicshocksyndrome-33||no_rel||we investigated the clinical significance of serum specific immunoglobulin e (lge) to the staphylococcal superantigens staphylococcal enterotoxin a (sea), staphylococcal enterotoxin b (seb), and toxicshocksyndrome toxin (tsst)-1 in patients with chronic urticaria (cu), focusing on the differences in these prevalences between aspirin-intolerant cu (aicu) and aspirin-tolerant cu (atcu) patients.
advmod||show-5/VBP||altogether-1/RB	det||data-4/NNS||the-3/DT	nsubj||show-5/VBP||data-4/NNS	root||ROOT-0/null||show-5/VBP	mark||tool-15/NN||that-6/IN	det||xmrk-11/NN||the-7/DT	nn||xmrk-11/NN||receptor-8/NN	nn||xmrk-11/NN||tyrosine-9/NN	nn||xmrk-11/NN||kinase-10/NN	nsubj||tool-15/NN||xmrk-11/NN	cop||tool-15/NN||is-12/VBZ	det||tool-15/NN||a-13/DT	amod||tool-15/NN||useful-14/JJ	ccomp||show-5/VBP||tool-15/NN	nsubjpass||expressed-25/VBN||tool-15/NN	det||identification-18/NN||the-17/DT	prep_in||tool-15/NN||identification-18/NN	nn||genes-21/NNS||target-20/NN	prep_of||identification-18/NN||genes-21/NNS	auxpass||expressed-25/VBN||are-23/VBP	advmod||expressed-25/VBN||commonly-24/RB	rcmod||tool-15/NN||expressed-25/VBN	amod||melanocytes-28/NNS||xmrk-transgenic-27/JJ	prep_in||expressed-25/VBN||melanocytes-28/NNS	nn||lines-32/NNS||melanoma-30/NN	nn||lines-32/NNS||cell-31/NN	prep_in||expressed-25/VBN||lines-32/NNS	conj_and||melanocytes-28/NNS||lines-32/NNS	melanoma-30||tyrosine-9||no_rel||altogether, the data show that the receptor tyrosine kinase xmrk is a useful tool in the identification of target genes that are commonly expressed in xmrk-transgenic melanocytes and melanoma cell lines.
mwe||than-2/IN||more-1/JJR	quantmod||million-4/CD||than-2/IN	number||million-4/CD||25-3/CD	num||lives-5/NNS||million-4/CD	nsubjpass||claimed-8/VBN||lives-5/NNS	aux||claimed-8/VBN||have-6/VBP	auxpass||claimed-8/VBN||been-7/VBN	root||ROOT-0/null||claimed-8/VBN	agent||claimed-8/VBN||aids-10/NNS	number||million-13/CD||33.2-12/CD	num||people-14/NNS||million-13/CD	nsubjpass||estimated-16/VBN||people-14/NNS	nsubj||have-18/VB||people-14/NNS	auxpass||estimated-16/VBN||are-15/VBP	conj_and||claimed-8/VBN||estimated-16/VBN	aux||have-18/VB||to-17/TO	xcomp||estimated-16/VBN||have-18/VB	dobj||have-18/VB||hiv-19/NN	prep_of||majority-22/NN||hiv-19/NN	det||majority-22/NN||the-21/DT	nsubj||living-26/VBG||majority-22/NN	aux||living-26/VBG||are-25/VBP	rcmod||hiv-19/NN||living-26/VBG	det||countries-30/NNS||the-28/DT	amod||countries-30/NNS||underdeveloped-29/JJ	prep_in||living-26/VBG||countries-30/NNS	aids-10||hiv-19||no||more than 25 million lives have been claimed by aids and 33.2 million people are estimated to have hiv, the majority of which are living in the underdeveloped countries.
det||studies-2/NNS||these-1/DT	nsubj||indicate-3/VBP||studies-2/NNS	root||ROOT-0/null||indicate-3/VBP	mark||useful-11/JJ||that-4/IN	amod||responses-6/NNS||anti-htlv-iantibody-5/JJ	nsubj||useful-11/JJ||responses-6/NNS	nsubj||suggest-15/VBP||responses-6/NNS	vmod||responses-6/NNS||detected-7/VBN	agent||detected-7/VBN||lips-9/NNS	cop||useful-11/JJ||are-10/VBP	ccomp||indicate-3/VBP||useful-11/JJ	prep_for||useful-11/JJ||diagnosis-13/NN	ccomp||indicate-3/VBP||suggest-15/VBP	conj_and||useful-11/JJ||suggest-15/VBP	mark||feature-23/NN||that-16/IN	amod||antibodies-19/NNS||elevated-17/JJ	amod||antibodies-19/NNS||anti-env-18/JJ	nsubj||feature-23/NN||antibodies-19/NNS	cop||feature-23/NN||are-20/VBP	det||feature-23/NN||a-21/DT	amod||feature-23/NN||common-22/JJ	ccomp||suggest-15/VBP||feature-23/NN	vmod||feature-23/NN||found-24/VBN	nn||patients-27/NNS||ham/tsp-26/NN	prep_in||found-24/VBN||patients-27/NNS	antibodies-19||ham--1||no_rel||these studies indicate that anti-htlv-iantibody responses detected by lips are useful for diagnosis and suggest that elevated anti-env antibodies are a common feature found in ham/tsp patients.
nsubj||fungaldisease-5/NN||histoplasmosis-1/NNS	cop||fungaldisease-5/NN||is-2/VBZ	det||fungaldisease-5/NN||a-3/DT	amod||fungaldisease-5/NN||systemic-4/JJ	root||ROOT-0/null||fungaldisease-5/NN	advmod||known-8/VBN||also-7/RB	vmod||fungaldisease-5/NN||known-8/VBN	nn||sdisease-12/NN||darling-10/NN	prep_as||known-8/VBN||sdisease-12/NN	rcmod||fungaldisease-5/NN||caused-14/VBN	det||histoplasmacapsulatum-19/NN||the-16/DT	amod||histoplasmacapsulatum-19/NN||dimorphic-17/JJ	nn||histoplasmacapsulatum-19/NN||fungus-18/NN	prep_by||caused-14/VBN||histoplasmacapsulatum-19/NN	darling'sdisease--1||histoplasmacapsulatum-19||no||histoplasmosis is a systemic fungaldisease, also known as darling'sdisease, caused by the dimorphic fungus histoplasmacapsulatum .
det||relationship-4/NN||a-1/DT	amod||relationship-4/NN||quantitative-2/JJ	nn||relationship-4/NN||structureâactivity-3/NN	nsubj||study-8/VBP||relationship-4/NN	appos||relationship-4/NN||qsar-6/NN	dep||made-11/VBN||study-8/VBP	aux||made-11/VBN||has-9/VBZ	auxpass||made-11/VBN||been-10/VBN	root||ROOT-0/null||made-11/VBN	det||series-14/NN||some-13/DT	prep_on||made-11/VBN||series-14/NN	prep_of||series-14/NN||antiâhepatitisbvirus-16/NNS	appos||antiâhepatitisbvirus-16/NNS||hbv-18/NN	nsubjpass||made-11/VBN||agents-20/NNS	advmod||agents-20/NNS||namely-22/RB	det||series-25/NN||a-24/DT	nsubjpass||made-11/VBN||series-25/NN	conj_and||agents-20/NNS||series-25/NN	amod||prodrugs-33/NNS||novel-27/JJ	amod||prodrugs-33/NNS||bis-28/JJ	dep||prodrugs-33/NNS||lâaminoacid-30/JJ	nn||prodrugs-33/NNS||ester-32/NN	prep_of||series-25/NN||prodrugs-33/NNS	prep_of||prodrugs-33/NNS||9â-35/CD	amod||â-39/NN||-LSB--37/JJ	amod||â-39/NN||2â-38/JJ	nsubjpass||made-11/VBN||â-39/NN	conj_and||agents-20/NNS||â-39/NN	appos||â-39/NN||phosphonomethoxy-41/NN	amod||adenine-45/NN||ethyl-43/JJ	amod||adenine-45/NN||-RSB--44/JJ	dep||â-39/NN||adenine-45/NN	det||series-49/NN||a-47/DT	amod||series-49/NN||similar-48/JJ	nsubjpass||made-11/VBN||series-49/NN	conj_and||agents-20/NNS||series-49/NN	amod||comprising-52/NNS||compounds-51/JJ	prep_of||series-49/NN||comprising-52/NNS	prep_of||comprising-52/NNS||2â-54/CD	amod||-LSB--57/NNS||aminoâ6âarylthioâ9â-56/JJ	nsubjpass||made-11/VBN||-LSB--57/NNS	conj_and||agents-20/NNS||-LSB--57/NNS	dep||-LSB--57/NNS||2â-58/NNS	nsubjpass||made-11/VBN||phosphonoethoxy-61/NN	conj_and||agents-20/NNS||phosphonoethoxy-61/NN	amod||esters-72/NNS||ethyl-63/JJ	amod||esters-72/NNS||-RSB--64/JJ	nn||esters-72/NNS||purine-65/NN	nn||esters-72/NNS||bis-66/NN	num||trifluoroethyl-70/NN||2,2,2-68/CD	nn||trifluoroethyl-70/NN||â-69/NN	appos||esters-72/NNS||trifluoroethyl-70/NN	dep||phosphonoethoxy-61/NN||esters-72/NNS	det||series-76/NN||a-75/DT	nsubjpass||made-11/VBN||series-76/NN	conj_and||agents-20/NNS||series-76/NN	amod||benzimidazoles-80/NNS||1â-78/JJ	amod||benzimidazoles-80/NNS||isopropylsulfonylâ2âamine-79/JJ	prep_of||series-76/NN||benzimidazoles-80/NNS	hbv-18||hepatitisbvirus--1||no||a quantitative structureâ­activity relationship (qsar) study has been made on some series of antiâ­hepatitisbvirus (hbv) agents, namely, a series of novel bis(lâ­aminoacid) ester prodrugs of 9â­[2â­â­(phosphonomethoxy)ethyl]adenine, a similar series of compounds comprising of 2â­ aminoâ­6â­arylthioâ­9â­[2â­(phosphonoethoxy)ethyl] purine bis(2,2,2â­ trifluoroethyl) esters, and a series of 1â­isopropylsulfonylâ­2â­amine benzimidazoles.
nsubj||been-17/VBN||gay-1/JJ	conj_and||gay-1/JJ||bisexual-3/NN	nsubj||been-17/VBN||bisexual-3/NN	amod||men-7/NNS||other-6/JJ	conj_and||gay-1/JJ||men-7/NNS	nsubj||have-9/VBP||men-7/NNS	nsubj||been-17/VBN||men-7/NNS	rcmod||men-7/NNS||have-9/VBP	dobj||have-9/VBP||sex-10/NN	prep_with||have-9/VBP||men-12/NNS	appos||gay-1/JJ||msm-14/NN	aux||been-17/VBN||have-16/VBP	root||ROOT-0/null||been-17/VBN	det||populations-22/NNS||the-19/DT	advmod||affected-21/JJ||most-20/RBS	amod||populations-22/NNS||affected-21/JJ	prep_among||been-17/VBN||populations-22/NNS	prep_by||been-17/VBN||hiv-24/NN	mark||identified-31/VBN||since-25/IN	det||pandemic-28/NN||the-26/DT	nn||pandemic-28/NN||aids-27/NNS	nsubjpass||identified-31/VBN||pandemic-28/NN	auxpass||identified-31/VBN||was-29/VBD	advmod||identified-31/VBN||first-30/RB	advcl||been-17/VBN||identified-31/VBN	det||1980s-34/NNS||the-33/DT	prep_in||identified-31/VBN||1980s-34/NNS	aids-27||hiv-24||no||gay, bisexual, and other men who have sex with men (msm) have been among the most affected populations by hiv since the aids pandemic was first identified in the 1980s.
det||efficacy-3/NN||the-1/DT	amod||efficacy-3/NN||variable-2/JJ	nsubj||necessitates-28/VBZ||efficacy-3/NN	quantmod||$-6/$||0â-5/RB	num||%-9/NN||$-6/$	num||$-6/$||80-8/CD	appos||efficacy-3/NN||%-9/NN	nn||©-16/FW||mycobacteriumbovis-12/FW	nn||©-16/FW||bacille-13/FW	nn||©-16/FW||calmette-14/FW	nn||©-16/FW||gurã-15/FW	prep_of||efficacy-3/NN||©-16/FW	discourse||vaccine-21/NN||bcg-19/UH	prep_in||©-16/FW||vaccine-21/NN	amod||tuberculosis-24/NNP||adult-23/JJ	prep_against||efficacy-3/NN||tuberculosis-24/NNP	discourse||efficacy-3/NN||tb-26/UH	root||ROOT-0/null||necessitates-28/VBZ	dobj||necessitates-28/VBZ||development-29/NN	amod||candidates-33/NNS||alternative-31/JJ	nn||candidates-33/NNS||vaccine-32/NN	prep_of||development-29/NN||candidates-33/NNS	tuberculosis-24||bcg-19||no||the variable efficacy (0â80%) of mycobacteriumbovis bacille calmette gurã©in (bcg) vaccine against adult tuberculosis (tb) necessitates development of alternative vaccine candidates.
det||microassay-3/NN||this-1/DT	amod||microassay-3/NN||robust-2/JJ	nsubj||improve-5/VB||microassay-3/NN	aux||improve-5/VB||will-4/MD	root||ROOT-0/null||improve-5/VB	poss||understanding-7/NN||our-6/PRP$	dobj||improve-5/VB||understanding-7/NN	det||immunity-12/NN||the-9/DT	amod||immunity-12/NN||protective-10/JJ	amod||immunity-12/NN||humoral-11/JJ	prep_of||understanding-7/NN||immunity-12/NN	mark||confer-16/VBP||that-13/IN	amod||rabiesvaccines-15/NNS||current-14/JJ	nsubj||confer-16/VBP||rabiesvaccines-15/NNS	nsubj||applicable-24/JJ||rabiesvaccines-15/NNS	ccomp||improve-5/VB||confer-16/VBP	amod||lyssaviruses-19/NNS||emerging-18/VBG	prep_against||confer-16/VBP||lyssaviruses-19/NNS	aux||applicable-24/JJ||will-22/MD	cop||applicable-24/JJ||be-23/VB	ccomp||improve-5/VB||applicable-24/JJ	conj_and||confer-16/VBP||applicable-24/JJ	nn||studies-27/NNS||surveillance-26/NN	prep_to||applicable-24/JJ||studies-27/NNS	advmod||helping-30/VBG||thus-29/RB	xcomp||applicable-24/JJ||helping-30/VBG	aux||control-32/VB||to-31/TO	xcomp||helping-30/VBG||control-32/VB	det||spread-34/NN||the-33/DT	dobj||control-32/VB||spread-34/NN	prep_of||spread-34/NN||rabies-36/NNP	rabies-36||rabiesvaccines-15||yes||this robust microassay will improve our understanding of the protective humoral immunity that current rabiesvaccines confer against emerging lyssaviruses, and will be applicable to surveillance studies, thus helping to control the spread of rabies.
det||study-2/NN||this-1/DT	nsubjpass||conducted-4/VBN||study-2/NN	nsubj||evaluate-6/VB||study-2/NN	auxpass||conducted-4/VBN||was-3/VBD	root||ROOT-0/null||conducted-4/VBN	aux||evaluate-6/VB||to-5/TO	xcomp||conducted-4/VBN||evaluate-6/VB	det||effects-9/NNS||the-7/DT	amod||effects-9/NNS||protective-8/JJ	dobj||evaluate-6/VB||effects-9/NNS	amod||supplementation-12/NN||oliveoil-11/JJ	prep_of||effects-9/NNS||supplementation-12/NN	prep_against||evaluate-6/VB||osteoporosis-14/NNS	amod||rats-20/NNS||ovariectomized-16/JJ	appos||rats-20/NNS||ovx-18/NN	prep_in||osteoporosis-14/NNS||rats-20/NNS	osteoporosis-14||oliveoil-11||no_rel||this study was conducted to evaluate the protective effects of oliveoil supplementation against osteoporosis in ovariectomized (ovx) rats.
det||regimen-3/NN||a-1/DT	nn||regimen-3/NN||novel-2/NN	nsubj||is-12/VBZ||regimen-3/NN	vmod||regimen-3/NN||consisting-4/VBG	prep_of||consisting-4/VBG||bortezomib-6/NN	prep_of||consisting-4/VBG||doxorubicin-8/NN	conj_and||bortezomib-6/NN||doxorubicin-8/NN	prep_of||consisting-4/VBG||dexamethasone-11/NN	conj_and||bortezomib-6/NN||dexamethasone-11/NN	root||ROOT-0/null||is-12/VBZ	advmod||is-12/VBZ||currently-13/RB	amod||evaluation-16/NN||active-15/JJ	prep_under||is-12/VBZ||evaluation-16/NN	det||treatment-19/NN||the-18/DT	prep_for||evaluation-16/NN||treatment-19/NN	prep_of||treatment-19/NN||multiplemyeloma-21/NN	multiplemyeloma-21||bortezomib-6||yes||a novel regimen consisting of bortezomib, doxorubicin, and dexamethasone is currently under active evaluation for the treatment of multiplemyeloma.
num||trials-6/NNS||two-2/CD	amod||trials-6/NNS||pivotal-3/JJ	nn||trials-6/NNS||phase-4/NN	nn||trials-6/NNS||iii-5/NN	prep_in||dosages-22/VBZ||trials-6/NNS	prep_in||trials-6/NNS||stably-8/NN	vmod||stably-8/NN||treated-9/VBN	dobj||treated-9/VBN||patients-10/NNS	amod||immunodeficiency-13/NN||primary-12/JJ	prep_with||treated-9/VBN||immunodeficiency-13/NN	nn||subcutaneous-16/NNS||immuneglobulin-15/NN	nsubj||dosages-22/VBZ||subcutaneous-16/NNS	nsubj||produced-48/VBD||subcutaneous-16/NNS	number||%-18/NN||20-17/CD	amod||subcutaneous-16/NNS||%-18/NN	amod||subcutaneous-21/NNS||weekly-20/JJ	prep_at||subcutaneous-16/NNS||subcutaneous-21/NNS	root||ROOT-0/null||dosages-22/VBZ	det||therapy-36/NN||either-23/DT	amod||therapy-36/NN||equivalent-24/JJ	det||intravenous-32/NN||each-26/DT	amod||intravenous-32/NN||patientâ-27/JJ	amod||intravenous-32/NN||$-28/$	number||s-30/CD||-29/CD	num||$-28/$||s-30/CD	amod||intravenous-32/NN||previous-31/JJ	prep_to||equivalent-24/JJ||intravenous-32/NN	prep_to||equivalent-24/JJ||subcutaneous-34/NNS	conj_or||intravenous-32/NN||subcutaneous-34/NNS	nn||therapy-36/NN||replacement-35/NN	dobj||dosages-22/VBZ||therapy-36/NN	xcomp||produced-48/VBD||providing-39/VBG	amod||exposure-42/NN||equivalent-40/JJ	amod||exposure-42/NN||systemic-41/JJ	dobj||providing-39/VBG||exposure-42/NN	amod||therapy-46/NN||previous-44/JJ	amod||therapy-46/NN||intravenous-45/JJ	prep_to||providing-39/VBG||therapy-46/NN	conj_or||dosages-22/VBZ||produced-48/VBD	ccomp||produced-48/VBD||mean-49/VB	amod||levels-53/NNS||serum-50/JJ	nn||levels-53/NNS||igg-51/NN	nn||levels-53/NNS||trough-52/NN	nsubj||equal-54/JJ||levels-53/NNS	ccomp||mean-49/VB||equal-54/JJ	cc||greater-57/JJR||or-56/CC	prep_to||equal-54/JJ||greater-57/JJR	amod||levels-60/NNS||pre-study-59/JJ	prep_than||equal-54/JJ||levels-60/NNS	immunodeficiency-13||immuneglobulin-15||yes||in two pivotal phase iii trials in stably treated patients with primary immunodeficiency, immuneglobulin subcutaneous 20% at weekly subcutaneous dosages either equivalent to each patientâs previous intravenous or subcutaneous replacement therapy, or providing equivalent systemic exposure to previous intravenous therapy, produced mean serum igg trough levels equal to or greater than pre-study levels.
num||women-2/NNS||three-1/CD	nsubjpass||admitted-5/VBN||women-2/NNS	auxpass||admitted-5/VBN||were-3/VBD	advmod||admitted-5/VBN||consecutively-4/RB	root||ROOT-0/null||admitted-5/VBN	poss||unit-11/NN||our-7/PRP$	amod||unit-11/NN||medical-8/JJ	amod||unit-11/NN||intensive-9/JJ	nn||unit-11/NN||care-10/NN	prep_to||admitted-5/VBN||unit-11/NN	prep_for||unit-11/NN||thyrotoxicosis-13/NNS	det||ingestion-16/NN||the-15/DT	nsubj||containing-21/VBG||ingestion-16/NN	amod||pills-19/NNS||dietary-18/JJ	prep_of||ingestion-16/NN||pills-19/NNS	advmod||containing-21/VBG||accidentally-20/RB	prepc_after||admitted-5/VBN||containing-21/VBG	amod||levels-23/NNS||high-22/JJ	dobj||containing-21/VBG||levels-23/NNS	prep_of||levels-23/NNS||thyroxin-25/NN	thyrotoxicosis-13||thyroxin-25||no||three women were consecutively admitted to our medical intensive care unit for thyrotoxicosis after the ingestion of dietary pills accidentally containing high levels of thyroxin.
aux||investigate-2/VB||to-1/TO	advcl||divided-29/VBN||investigate-2/VB	det||effect-4/NN||the-3/DT	dobj||investigate-2/VB||effect-4/NN	amod||expression-17/NN||budesonide-6/JJ	nn||p-9/NN||substance-8/NN	prep_on||budesonide-6/JJ||p-9/NN	dep||p-9/NN||nk-1-11/JJ	nn||expression-17/NN||receptor-13/NN	dep||expression-17/NN||nk-1r-15/JJ	prep_of||effect-4/NN||expression-17/NN	det||lung-20/NN||the-19/DT	prep_in||investigate-2/VB||lung-20/NN	prep_in||investigate-2/VB||asmcs-22/NNS	conj_and||lung-20/NN||asmcs-22/NNS	num||rats-26/NNS||45-24/CD	nn||rats-26/NNS||wistar-25/NN	nsubjpass||divided-29/VBN||rats-26/NNS	auxpass||divided-29/VBN||were-27/VBD	advmod||divided-29/VBN||randomly-28/RB	root||ROOT-0/null||divided-29/VBN	num||groups-32/NNS||three-31/CD	prep_into||divided-29/VBN||groups-32/NNS	dep||groups-32/NNS||control-33/NN	dep||groups-32/NNS||asthmatic-35/JJ	amod||control-33/NN||asthmatic-35/JJ	conj_and||control-33/NN||asthmatic-35/JJ	amod||treatment-39/NN||budesonide-38/JJ	dep||groups-32/NNS||treatment-39/NN	conj_and||control-33/NN||treatment-39/NN	asthmatic-35||budesonide-38||no||to investigate the effect of budesonide on substance p (nk-1) receptor (nk-1r) expression in the lung and asmcs, 45 wistar rats were randomly divided into three groups control, asthmatic, and budesonide treatment.
nsubj||antipsychoticdrug-5/NN||aripiprazole-1/NN	cop||antipsychoticdrug-5/NN||is-2/VBZ	det||antipsychoticdrug-5/NN||an-3/DT	amod||antipsychoticdrug-5/NN||atypical-4/JJ	root||ROOT-0/null||antipsychoticdrug-5/NN	vmod||antipsychoticdrug-5/NN||approved-6/VBN	det||treatment-9/NN||the-8/DT	prep_for||approved-6/VBN||treatment-9/NN	amod||disorders-12/NNS||psychiatric-11/JJ	prep_of||treatment-9/NN||disorders-12/NNS	nn||depressivedisorder-20/NN||schizophrenia-15/NN	prep_such_as||disorders-12/NNS||bipolardisorder-17/NN	conj_and||depressivedisorder-20/NN||bipolardisorder-17/NN	prep_such_as||disorders-12/NNS||major-19/JJ	amod||depressivedisorder-20/NN||major-19/JJ	conj_and||depressivedisorder-20/NN||major-19/JJ	prep_such_as||disorders-12/NNS||depressivedisorder-20/NN	prep_such_as||disorders-12/NNS||autism-22/NN	conj_and||depressivedisorder-20/NN||autism-22/NN	depressivedisorder-20||aripiprazole-1||no_rel||aripiprazole is an atypical antipsychoticdrug approved for the treatment of psychiatric disorders such as schizophrenia, bipolardisorder, major depressivedisorder and autism.
prep_in||correlated-8/VBN||addition-2/NN	amod||concentration-5/NN||formate-4/JJ	nsubjpass||correlated-8/VBN||concentration-5/NN	nsubjpass||correlated-38/VBN||concentration-5/NN	auxpass||correlated-8/VBN||was-6/VBD	advmod||correlated-8/VBN||negatively-7/RB	root||ROOT-0/null||correlated-8/VBN	amod||pc20-11/NNS||methacholine-10/JJ	prep_with||correlated-8/VBN||pc20-11/NNS	num||0.39-21/NNS||râ-13/CD	amod||0.39-21/NNS||$-14/$	number||=-16/CD||-15/CD	num||$-14/$||=-16/CD	amod||0.39-21/NNS||â-17/JJ	amod||0.39-21/NNS||$-18/$	dep||$-18/$||â-19/JJ	nsubj||asthmatics-32/VBZ||0.39-21/NNS	nn||â-27/NN||pâ-23/NN	amod||â-27/NN||$-24/$	dep||$-24/$||-25/JJ	nn||â-27/NN||=-26/NNP	appos||0.39-21/NNS||â-27/NN	dep||â-27/NN||$-28/$	num||$-28/$||0-29/CD	num||$-28/$||.002-30/CD	dep||pc20-11/NNS||asthmatics-32/VBZ	advmod||asthmatics-32/VBZ||only-33/RB	advmod||correlated-38/VBN||positively-37/RB	conj_and||correlated-8/VBN||correlated-38/VBN	det||nitrite-43/NN||the-40/DT	amod||nitrite-43/NN||no-derived-41/JJ	nn||nitrite-43/NN||ion-42/NN	prep_with||correlated-38/VBN||nitrite-43/NN	dep||nitrite-43/NN||râ-45/VBN	dobj||râ-45/VBN||$-46/$	number||=-48/CD||-47/CD	num||$-46/$||=-48/CD	dep||râ-45/VBN||â-49/VB	dobj||â-49/VB||$-50/$	number||.46-52/CD||0-51/CD	num||$-50/$||.46-52/CD	appos||$-50/$||p-54/NN	number||0.0001-56/CD||<-55/CD	dep||p-54/NN||0.0001-56/CD	amod||ige-64/NN||total-62/JJ	nn||ige-64/NN||serum-63/NN	prep_with||correlated-38/VBN||ige-64/NN	conj_and||nitrite-43/NN||ige-64/NN	dep||ige-64/NN||râ-66/VBN	num||â-70/NN||$-67/$	number||=-69/CD||-68/CD	num||$-67/$||=-69/CD	dobj||râ-66/VBN||â-70/NN	nsubj||asthmatics-84/VBZ||$-71/$	num||$-71/$||0-72/CD	num||$-71/$||.28-73/CD	nn||â-79/NN||pâ-75/NN	amod||â-79/NN||$-76/$	dep||$-76/$||-77/JJ	nn||â-79/NN||=-78/NNP	appos||$-71/$||â-79/NN	dep||â-79/NN||$-80/$	num||$-80/$||0-81/CD	num||$-80/$||.016-82/CD	rcmod||â-70/NN||asthmatics-84/VBZ	advmod||asthmatics-84/VBZ||only-85/RB	methacholine-10||asthmatics-84||no_rel||in addition, formate concentration was negatively correlated with methacholine pc20 (râ=ââ0.39, pâ=â0.002, asthmatics only), and positively correlated with the no-derived ion nitrite (râ=â0.46, p<0.0001) as well as with total serum ige (râ=â0.28, pâ=â0.016, asthmatics only).
nsubjpass||shown-12/VBN||reduction-1/NN	amod||layer-6/NN||retinal-3/JJ	nn||layer-6/NN||nerve-4/NN	nn||layer-6/NN||fibre-5/NN	prep_of||reduction-1/NN||layer-6/NN	dep||reduction-1/NN||rnfl-8/JJ	advmod||shown-12/VBN||thickness-10/RB	auxpass||shown-12/VBN||was-11/VBD	root||ROOT-0/null||shown-12/VBN	prep_as||shown-12/VBN||part-14/NN	det||process-18/NN||the-16/DT	amod||process-18/NN||neurodegenerative-17/JJ	prep_of||part-14/NN||process-18/NN	det||range-21/NN||a-20/DT	prep_in||shown-12/VBN||range-21/NN	amod||pathologies-25/NNS||different-23/JJ	nn||pathologies-25/NNS||neurodegenerative-24/NN	prep_of||range-21/NN||pathologies-25/NNS	amod||disease-31/NN||alzheimerâ-27/JJ	dep||alzheimerâ-27/JJ||$-28/$	number||s-30/CD||²-29/CD	num||$-28/$||s-30/CD	prep_including||pathologies-25/NNS||disease-31/NN	appos||disease-31/NN||ad-33/NN	amod||parkinsonâ-37/NNS||idiopathic-36/JJ	prep_including||pathologies-25/NNS||parkinsonâ-37/NNS	conj_and||disease-31/NN||parkinsonâ-37/NNS	num||disease-41/NN||$-38/$	number||s-40/CD||-39/CD	num||$-38/$||s-40/CD	dep||parkinsonâ-37/NNS||disease-41/NN	appos||disease-41/NN||pd-43/NN	nn||ataxia-47/NN||spinocerebellar-46/NN	prep_including||pathologies-25/NNS||ataxia-47/NN	conj_and||disease-31/NN||ataxia-47/NN	appos||ataxia-47/NN||sca-49/NN	amod||atrophy-54/NN||multiple-52/JJ	nn||atrophy-54/NN||system-53/NN	prep_including||pathologies-25/NNS||atrophy-54/NN	conj_and||disease-31/NN||atrophy-54/NN	appos||atrophy-54/NN||msa-56/NN	msa-56||alzheimer--1||no_rel||reduction of retinal nerve fibre layer (rnfl) thickness was shown as part of the neurodegenerative process in a range of different neurodegenerative pathologies including alzheimerâ²s disease (ad), idiopathic parkinsonâs disease (pd), spinocerebellar ataxia (sca) and multiple system atrophy (msa).
det||encoding-3/NN||the-1/DT	nn||encoding-3/NN||gene-2/NN	nsubj||mycobacteriumleprae-4/VBP||encoding-3/NN	root||ROOT-0/null||mycobacteriumleprae-4/VBP	amod||-rrb--11/NNP||small-5/JJ	nn||-rrb--11/NNP||heat-6/NN	nn||-rrb--11/NNP||shock-7/NN	nn||-rrb--11/NNP||protein-8/NN	nn||-rrb--11/NNP||-lrb--9/NNP	nn||-rrb--11/NNP||shsp18-10/NNP	nsubjpass||amplified-13/VBN||-rrb--11/NNP	nsubjpass||cloned-22/VBN||-rrb--11/NNP	auxpass||amplified-13/VBN||was-12/VBD	ccomp||mycobacteriumleprae-4/VBP||amplified-13/VBN	amod||material-16/NN||biopsy-15/JJ	prep_from||amplified-13/VBN||material-16/NN	nn||patients-19/NNS||leprosy-18/NNP	prep_of||material-16/NN||patients-19/NNS	ccomp||mycobacteriumleprae-4/VBP||cloned-22/VBN	conj_and||amplified-13/VBN||cloned-22/VBN	conj_and||amplified-13/VBN||expressed-24/VBN	conj_and||cloned-22/VBN||expressed-24/VBN	nn||coli-27/NNS||e.-26/NN	prep_in||cloned-22/VBN||coli-27/NNS	leprosy-18||mycobacteriumleprae-4||no||the gene encoding mycobacteriumleprae small heat shock protein -lrb- shsp18 -rrb- was amplified from biopsy material of leprosy patients , and cloned and expressed in e. coli .
mark||have-3/VBP||because-1/IN	nsubj||have-3/VBP||mice-2/NNS	advcl||exposed-15/VBN||have-3/VBP	amod||levels-6/NNS||higher-4/JJR	nn||levels-6/NNS||glucose-5/NN	dobj||have-3/VBP||levels-6/NNS	prep_than||have-3/VBP||humans-8/NNS	det||cells-13/NNS||the-10/DT	amod||cells-13/NNS||transplanted-11/VBN	nn||cells-13/NNS||beta-12/NN	nsubjpass||exposed-15/VBN||cells-13/NNS	auxpass||exposed-15/VBN||were-14/VBD	root||ROOT-0/null||exposed-15/VBN	amod||hyperglycemia-18/NN||mild-17/JJ	prep_to||exposed-15/VBN||hyperglycemia-18/NN	det||environment-22/NN||the-20/DT	amod||environment-22/NN||abnormal-21/JJ	prep_to||exposed-15/VBN||environment-22/NN	conj_and||hyperglycemia-18/NN||environment-22/NN	det||site-26/NN||the-24/DT	nn||site-26/NN||transplant-25/NN	prep_of||environment-22/NN||site-26/NN	hyperglycemia-18||glucose-5||no||because mice have higher glucose levels than humans, the transplanted beta cells were exposed to mild hyperglycemia and the abnormal environment of the transplant site.
det||consensus-2/NN||some-1/DT	nsubjpass||reached-4/VBN||consensus-2/NN	auxpass||reached-4/VBN||was-3/VBD	root||ROOT-0/null||reached-4/VBN	det||probability-7/NN||the-6/DT	prep_around||reached-4/VBN||probability-7/NN	mark||progress-18/VB||that-8/IN	nsubj||progress-18/VB||patients-9/NNS	amod||settings-13/NNS||higher-11/JJR	nn||settings-13/NNS||transmission-12/NN	prep_from||patients-9/NNS||settings-13/NNS	amod||malaria-16/NN||untreated-15/JJ	prep_with||settings-13/NNS||malaria-16/NN	aux||progress-18/VB||would-17/MD	ccomp||reached-4/VBN||progress-18/VB	amod||disease-21/NN||severe-20/JJ	prep_to||progress-18/VB||disease-21/NN	dep||disease-21/NN||median-23/NN	num||%-25/NN||3-24/CD	dep||median-23/NN||%-25/NN	amod||1â-32/NNS||inter-quartile-27/JJ	nn||1â-32/NNS||range-28/NN	discourse||1â-32/NNS||iqr-30/UH	appos||%-25/NN||1â-32/NNS	dep||%-36/NN||$-33/$	num||$-33/$||5-35/CD	amod||1â-32/NNS||%-36/NN	det||probability-41/NN||the-40/DT	prep_to||progress-18/VB||probability-41/NN	conj_and||disease-21/NN||probability-41/NN	mark||required-46/VBD||that-42/IN	det||illness-45/NN||a-43/DT	amod||illness-45/NN||non-malaria-44/JJ	nsubj||required-46/VBD||illness-45/NN	ccomp||progress-18/VB||required-46/VBD	dobj||required-46/VBD||antibiotics-47/NNS	prep_in||required-46/VBD||areas-49/NNS	amod||prevalence-53/NN||low-51/JJ	nn||prevalence-53/NN||hiv-52/NN	prep_of||areas-49/NNS||prevalence-53/NN	number||20-56/CD||median-55/CD	num||%-57/NN||20-56/CD	appos||prevalence-53/NN||%-57/NN	malaria-16||antibiotics-47||no_rel||some consensus was reached around the probability that patients from higher transmission settings with untreated malaria would progress to severe disease (median 3%, inter-quartile range (iqr) 1â5%), and the probability that a non-malaria illness required antibiotics in areas of low hiv prevalence (median 20%).
det||mito-mice-3/NN||the-2/DT	prep_in||induced-10/VBN||mito-mice-3/NN	nsubj||induced-10/VBN||accumulation-5/NN	nn||mtdna-9/NN||î-7/NN	prep_of||accumulation-5/NN||mtdna-9/NN	root||ROOT-0/null||induced-10/VBN	amod||defects-13/NNS||mitochondrial-11/JJ	nn||defects-13/NNS||respiration-12/NN	dobj||induced-10/VBN||defects-13/NNS	amod||tissues-16/NNS||various-15/JJ	prep_in||defects-13/NNS||tissues-16/NNS	vmod||induced-10/VBN||resulting-18/VBG	amod||phenotypes-22/NNS||mitochondrial-20/JJ	nn||phenotypes-22/NNS||disease-21/NN	prep_in||resulting-18/VBG||phenotypes-22/NNS	amod||weight-28/NN||low-26/JJ	nn||weight-28/NN||body-27/NN	prep_such_as||phenotypes-22/NNS||weight-28/NN	amod||acidosis-31/NNS||lactic-30/JJ	prep_such_as||phenotypes-22/NNS||acidosis-31/NNS	conj_and||weight-28/NN||acidosis-31/NNS	prep_such_as||phenotypes-22/NNS||ischemia-33/NN	conj_and||weight-28/NN||ischemia-33/NN	prep_such_as||phenotypes-22/NNS||myopathy-35/NN	conj_and||weight-28/NN||myopathy-35/NN	nn||block-38/NN||heart-37/NN	prep_such_as||phenotypes-22/NNS||block-38/NN	conj_and||weight-28/NN||block-38/NN	prep_such_as||phenotypes-22/NNS||deafness-40/NNS	conj_and||weight-28/NN||deafness-40/NNS	prep_such_as||phenotypes-22/NNS||maleinfertility-42/NN	conj_and||weight-28/NN||maleinfertility-42/NN	prep_such_as||phenotypes-22/NNS||renalfailure-45/NN	conj_and||weight-28/NN||renalfailure-45/NN	mito--1||renalfailure-45||no_rel||in the mito-mice, accumulation of îmtdna induced mitochondrial respiration defects in various tissues, resulting in mitochondrial disease phenotypes, such as low body weight, lactic acidosis, ischemia, myopathy, heart block, deafness, maleinfertility, and renalfailure.
det||review-2/NN||this-1/DT	nsubj||focuses-3/VBZ||review-2/NN	root||ROOT-0/null||focuses-3/VBZ	amod||asthma-6/NN||aspirin-exacerbated-5/JJ	prep_on||focuses-3/VBZ||asthma-6/NN	appos||asthma-6/NN||aea-8/NN	asthma-6||aspirin--1||no||this review focuses on aspirin-exacerbated asthma (aea).
nsubjpass||caused-3/VBN||type2diabetes-1/NNS	auxpass||caused-3/VBN||is-2/VBZ	root||ROOT-0/null||caused-3/VBN	agent||caused-3/VBN||defects-5/NNS	preconj||signaling-9/NN||both-7/DT	nn||signaling-9/NN||insulin-8/NN	prep_in||defects-5/NNS||signaling-9/NN	nn||secretion-12/NN||insulin-11/NN	prep_in||defects-5/NNS||secretion-12/NN	conj_and||signaling-9/NN||secretion-12/NN	type2diabetes-1||insulin-11||yes||type2diabetes is caused by defects in both insulin signaling and insulin secretion.
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||determine-8/VB||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||determine-8/VB||to-7/TO	xcomp||was-6/VBD||determine-8/VB	det||dose-11/NN||the-9/DT	amod||dose-11/NN||optimal-10/JJ	dobj||determine-8/VB||dose-11/NN	prep_of||dose-11/NN||remifentanil-13/NN	prepc_for||determine-8/VB||minimizing-15/VBG	amod||changes-17/NNS||hemodynamic-16/JJ	dobj||minimizing-15/VBG||changes-17/NNS	prep_during||minimizing-15/VBG||intubation-19/NN	prepc_for||determine-8/VB||reducing-21/VBG	conj_and||minimizing-15/VBG||reducing-21/VBG	amod||pain-23/NN||propofol-induced-22/JJ	dobj||reducing-21/VBG||pain-23/NN	amod||patients-26/NNS||elderly-25/JJ	prep_in||reducing-21/VBG||patients-26/NNS	pain-23||remifentanil-13||yes||the purpose of this study was to determine the optimal dose of remifentanil for minimizing hemodynamic changes during intubation and reducing propofol-induced pain in elderly patients.
aux||compare-2/VB||to-1/TO	csubj||treated-14/VBN||compare-2/VB	det||incidence-4/NN||the-3/DT	dobj||compare-2/VB||incidence-4/NN	amod||events-7/NNS||cardiovascular-6/JJ	prep_of||incidence-4/NN||events-7/NNS	prep_of||incidence-4/NN||mortality-9/NN	conj_and||events-7/NNS||mortality-9/NN	prep_in||compare-2/VB||patients-11/NNS	prep_with||patients-11/NNS||type2diabetesmellitus-13/CD	root||ROOT-0/null||treated-14/VBN	nn||comparators-19/NNS||sitagliptin-16/NN	conj_or||sitagliptin-16/NN||non-sitagliptin-18/NN	nn||comparators-19/NNS||non-sitagliptin-18/NN	prep_with||treated-14/VBN||comparators-19/NNS	type2diabetesmellitus-13||sitagliptin-16||yes||to compare the incidence of cardiovascular events and mortality in patients with type2diabetesmellitus treated with sitagliptin or non-sitagliptin comparators.
poss||guidelines-4/NNS||afghanistan-1/NN	amod||guidelines-4/NNS||national-3/JJ	nsubj||recommend-5/VBP||guidelines-4/NNS	root||ROOT-0/null||recommend-5/VBP	acomp||recommend-5/VBP||chloroquine-6/JJ	det||treatment-9/NN||the-8/DT	prep_for||chloroquine-6/JJ||treatment-9/NN	nn||infection-13/NN||plasmodium-11/NN	nn||infection-13/NN||vivax-12/NN	prep_of||treatment-9/NN||infection-13/NN	det||parasite-16/NN||the-15/DT	appos||infection-13/NN||parasite-16/NN	dep||recommend-5/VBP||responsible-17/JJ	det||majority-20/NN||the-19/DT	prep_for||responsible-17/JJ||majority-20/NN	poss||burden-24/NN||its-22/PRP$	nn||burden-24/NN||malaria-23/NN	prep_of||majority-20/NN||burden-24/NN	malaria-23||chloroquine-6||yes||afghanistan's national guidelines recommend chloroquine for the treatment of plasmodium vivax infection, the parasite responsible for the majority of its malaria burden.
det||patients-2/NNS||the-1/DT	nsubj||group-8/NN||patients-2/NNS	cop||group-8/NN||were-3/VBD	amod||group-8/NN||divided-4/VBN	num||groups-7/NNS||5-6/CD	prep_into||divided-4/VBN||groups-7/NNS	root||ROOT-0/null||group-8/NN	dep||diabetic-12/NN||1-10/LS	dep||group-8/NN||diabetic-12/NN	amod||levels-16/NNS||normal-14/JJ	amod||levels-16/NNS||glycemic-15/JJ	prep_with||diabetic-12/NN||levels-16/NNS	aux||american-19/VB||to-18/TO	dep||n-27/VBN||american-19/VB	nn||criteria-22/NNS||diabetes-20/NN	nn||criteria-22/NNS||association-21/NN	dobj||american-19/VB||criteria-22/NNS	amod||patients-25/NNS||in-hospital-24/JJ	prep_for||american-19/VB||patients-25/NNS	prep_according||levels-16/NNS||n-27/VBN	dep||123-29/CD||=-28/SYM	ccomp||n-27/VBN||123-29/CD	conj_and||group-8/NN||group-32/NN	dep||diabetics-36/NNS||2-34/LS	dep||group-32/NN||diabetics-36/NNS	prep_with||diabetics-36/NNS||hyperglycemia-38/NN	dep||group-32/NN||n-40/VBN	dep||76-42/CD||=-41/SYM	ccomp||n-40/VBN||76-42/CD	conj_and||group-8/NN||group-45/NN	dep||non-diabetics-49/NNS||3-47/LS	dep||group-45/NN||non-diabetics-49/NNS	prep_with||non-diabetics-49/NNS||hyperglycemia-51/NN	dep||group-45/NN||n-53/VBN	dep||225-55/CD||=-54/SYM	ccomp||n-53/VBN||225-55/CD	conj_and||group-8/NN||group-58/NN	dep||diabetics-62/NNS||4-60/LS	dep||group-58/NN||diabetics-62/NNS	dep||group-58/NN||non-diabetics-64/NNS	conj_and||diabetics-62/NNS||non-diabetics-64/NNS	amod||hyperglycemia-67/NN||persistent-66/JJ	prep_with||diabetics-62/NNS||hyperglycemia-67/NN	num||days-71/NNS||3-69/CD	amod||days-71/NNS||consecutive-70/JJ	prep_during||hyperglycemia-67/NN||days-71/NNS	dep||group-58/NN||n-73/VBN	dep||57-75/CD||=-74/SYM	ccomp||n-73/VBN||57-75/CD	conj_and||group-8/NN||group-78/NN	appos||group-78/NN||5-80/CD	dep||group-78/NN||those-82/DT	amod||control-86/NN||normal-84/JJ	nn||control-86/NN||glucose-85/NN	prep_with||group-78/NN||control-86/NN	dep||control-86/NN||n-88/VBN	dep||298-90/NNS||=-89/SYM	ccomp||n-88/VBN||298-90/NNS	hyperglycemia-67||glucose-85||no||the patients were divided into 5 groups group (1) diabetic with normal glycemic levels according to american diabetes association criteria for in-hospital patients (n = 123); group (2) diabetics with hyperglycemia (n = 76); group (3) non-diabetics with hyperglycemia (n = 225); group (4)diabetics and non-diabetics with persistent hyperglycemia during 3 consecutive days (n = 57) and group (5) those with normal glucose control (n = 298).
poss||aim-2/NN||our-1/PRP$	nsubj||was-3/VBD||aim-2/NN	nsubj||determine-5/VB||aim-2/NN	root||ROOT-0/null||was-3/VBD	aux||determine-5/VB||to-4/TO	xcomp||was-3/VBD||determine-5/VB	det||efficacy-7/NN||the-6/DT	dobj||determine-5/VB||efficacy-7/NN	det||vaccine-14/NN||a-9/DT	amod||vaccine-14/NN||trivalent-10/JJ	amod||vaccine-14/NN||inactivated-11/JJ	nn||vaccine-14/NN||split-12/NN	nn||vaccine-14/NN||virusinfluenza-13/NN	prep_of||efficacy-7/NN||vaccine-14/NN	appos||efficacy-7/NN||tiv-16/NN	amod||influenza-20/NN||culture-confirmed-19/JJ	prep_against||efficacy-7/NN||influenza-20/NN	det||and/or-22/NN||a-21/DT	dep||influenza-20/NN||and/or-22/NN	dep||efficacy-7/NN||b-23/SYM	prep_in||determine-5/VB||adults-25/NNS	number||64-28/CD||18-26/CD	dep||64-28/CD||to-27/TO	num||years-29/NNS||64-28/CD	npadvmod||adults-25/NNS||years-29/NNS	prep_of||adults-25/NNS||age-31/NN	det||season-35/NN||the-33/DT	num||season-35/NN||2005/2006-34/CD	prep_during||determine-5/VB||season-35/NN	det||republic-39/NN||the-37/DT	amod||republic-39/NN||czech-38/JJ	prep_in||season-35/NN||republic-39/NN	influenza-20||virusinfluenza-13||no||our aim was to determine the efficacy of a trivalent inactivated split virusinfluenza vaccine (tiv) against culture-confirmed influenza a and/or b in adults 18 to 64 years of age during the 2005/2006 season in the czech republic.
nn||analysis-2/NN||sequence-1/NN	nsubj||revealed-6/VBD||analysis-2/NN	det||rnas-5/NNS||these-4/DT	prep_of||analysis-2/NN||rnas-5/NNS	root||ROOT-0/null||revealed-6/VBD	det||organization-9/NN||a-7/DT	amod||organization-9/NN||genome-8/JJ	nsubj||described-13/VBD||organization-9/NN	amod||organization-9/NN||similar-10/JJ	prep||similar-10/JJ||to-11/TO	pobj||to-11/TO||recently-12/RB	ccomp||revealed-6/VBD||described-13/VBD	dobj||described-13/VBD||torradoviruses-14/NNS	det||group-18/NN||a-16/DT	amod||group-18/NN||new-17/JJ	appos||torradoviruses-14/NNS||group-18/NN	amod||viruses-21/NNS||picorna-like-20/JJ	prep_of||group-18/NN||viruses-21/NNS	vmod||viruses-21/NNS||causing-22/VBG	amod||diseases-24/NNS||necrosis-associated-23/JJ	dobj||causing-22/VBG||diseases-24/NNS	prep_of||diseases-24/NNS||tomatoes-26/NNS	amod||-RSB--36/NNS||europe-28/JJ	amod||-RSB--36/NNS||-LSB--29/JJ	nn||-RSB--36/NNS||tomato-30/NN	nn||-RSB--36/NNS||torrado-31/NN	nn||-RSB--36/NNS||virus-32/NN	appos||-RSB--36/NNS||totv-34/NNP	prep_in||tomatoes-26/NNS||-RSB--36/NNS	nn||virus-43/NN||mexico-38/NNP	nn||virus-43/NN||-LSB--39/NNP	nn||virus-43/NN||tomato-40/NNP	nn||virus-43/NN||apex-41/NN	nn||virus-43/NN||necrosis-42/NNS	prep_in||tomatoes-26/NNS||virus-43/NN	conj_and||-RSB--36/NNS||virus-43/NN	appos||virus-43/NN||toanv-45/NNP	nn||virus-50/NN||tomato-48/NN	nn||virus-50/NN||marchitez-49/NN	prep_in||tomatoes-26/NNS||virus-50/NN	conj_and||-RSB--36/NNS||virus-50/NN	appos||virus-50/NN||tomarv-52/NNP	advmod||causing-22/VBG||-RSB--54/RB	virus-50||viruses-21||no||sequence analysis of these rnas revealed a genome organization similar to recently described torradoviruses, a new group of picorna-like viruses causing necrosis-associated diseases of tomatoes in europe [tomato torrado virus (totv)] and mexico [tomato apex necrosis virus (toanv) and tomato marchitez virus (tomarv)].
det||findings-2/NNS||the-1/DT	nsubj||show-3/VBP||findings-2/NNS	root||ROOT-0/null||show-3/VBP	dep||exposed-13/VBN||1-4/LS	neg||facility-8/NN||no-6/DT	nn||facility-8/NN||health-7/NN	nsubjpass||exposed-13/VBN||facility-8/NN	nn||worker-11/NN||health-10/NN	conj_or||facility-8/NN||worker-11/NN	nsubjpass||exposed-13/VBN||worker-11/NN	auxpass||exposed-13/VBN||was-12/VBD	dep||show-3/VBP||exposed-13/VBN	det||components-16/NNS||all-15/DT	prep_to||exposed-13/VBN||components-16/NNS	det||intervention-19/NN||the-18/DT	prep_of||components-16/NNS||intervention-19/NN	dep||proportion-24/NN||2-21/LS	det||proportion-24/NN||the-23/DT	dep||intervention-19/NN||proportion-24/NN	nn||workers-27/NNS||health-26/NN	prep_of||proportion-24/NN||workers-27/NNS	nsubj||received-29/VBD||workers-27/NNS	rcmod||workers-27/NNS||received-29/VBD	det||training-33/NN||the-30/DT	amod||training-33/NN||enhanced-31/JJ	amod||training-33/NN||in-service-32/JJ	nsubj||%-36/NN||training-33/NN	cop||%-36/NN||was-34/VBD	num||%-36/NN||67-35/CD	ccomp||received-29/VBD||%-36/NN	dep||proportion-41/NN||3-38/LS	det||proportion-41/NN||the-40/DT	prep_of||proportion-24/NN||proportion-41/NN	conj_and||workers-27/NNS||proportion-41/NN	nsubj||received-29/VBD||proportion-41/NN	amod||children-44/NNS||febrile-43/JJ	prep_of||proportion-41/NN||children-44/NNS	amod||malaria-47/NN||uncomplicated-46/JJ	prep_with||children-44/NNS||malaria-47/NN	vmod||malaria-47/NN||treated-48/VBN	det||drug-53/NN||the-50/DT	amod||drug-53/NN||first-line-51/JJ	amod||drug-53/NN||anti-malarial-52/JJ	prep_with||treated-48/VBN||drug-53/NN	appos||drug-53/NN||artemether-lumefantrine-55/NN	appos||artemether-lumefantrine-55/NN||al-57/NNP	nn||facilities-62/NNS||health-61/NN	prep_at||treated-48/VBN||facilities-62/NNS	advmod||was-65/VBD||where-63/WRB	nsubj||was-65/VBD||al-64/NNP	advcl||treated-48/VBN||was-65/VBD	prep_in||was-65/VBD||stock-67/NN	vmod||stock-67/NN||increased-68/VBN	num||%-71/NN||76.9-70/CD	prep_from||increased-68/VBN||%-71/NN	num||%-74/NN||95-73/CD	dep||%-71/NN||%-74/NN	dep||%-74/NN||ci-75/NNP	num||ci-75/NNP||69.4-76/CD	num||ci-75/NNP||83.1-78/CD	num||%-82/NN||87.6-81/CD	prep_to||increased-68/VBN||%-82/NN	num||%-85/NN||95-84/CD	dep||%-82/NN||%-85/NN	number||82.5-87/CD||ci-86/CD	num||%-85/NN||82.5-87/CD	amod||%-85/NN||91.5-89/CD	dep||were-95/VBD||4-92/LS	expl||were-95/VBD||there-94/EX	parataxis||was-65/VBD||were-95/VBD	amod||improvements-99/NNS||modest-96/JJ	conj_but||modest-96/JJ||non-significant-98/JJ	amod||improvements-99/NNS||non-significant-98/JJ	nsubj||were-95/VBD||improvements-99/NNS	prepc_in||were-95/VBD||dispensing-101/VBG	prepc_in||were-95/VBD||counseling-103/VBG	conj_and||dispensing-101/VBG||counseling-103/VBG	dobj||dispensing-101/VBG||practices-104/NNS	prep_of||proportion-24/NN||5-107/CD	conj_and||workers-27/NNS||5-107/CD	nsubj||received-29/VBD||5-107/CD	advmod||restricted-113/VBN||when-109/WRB	det||analyses-111/NNS||the-110/DT	nsubjpass||restricted-113/VBN||analyses-111/NNS	auxpass||restricted-113/VBN||were-112/VBD	advcl||exposed-13/VBN||restricted-113/VBN	nn||workers-116/NNS||health-115/NN	prep_to||restricted-113/VBN||workers-116/NNS	nsubj||received-118/VBD||workers-116/NNS	nsubj||received-125/VBN||workers-116/NNS	rcmod||workers-116/NNS||received-118/VBD	det||training-122/NN||the-119/DT	amod||training-122/NN||enhanced-120/JJ	amod||training-122/NN||in-service-121/JJ	dobj||received-118/VBD||training-122/NN	aux||received-125/VBN||had-124/VBD	rcmod||workers-116/NNS||received-125/VBN	conj_and/or||received-118/VBD||received-125/VBN	amod||guidelines-127/NNS||new-126/JJ	dobj||received-125/VBN||guidelines-127/NNS	nn||aids-130/NNS||job-129/NN	nsubjpass||observed-140/VBN||aids-130/NNS	neg||improvements-134/NNS||no-132/DT	amod||improvements-134/NNS||significant-133/JJ	appos||aids-130/NNS||improvements-134/NNS	amod||tasks-138/NNS||reported-136/JJ	amod||tasks-138/NNS||case-management-137/JJ	prep_in||improvements-134/NNS||tasks-138/NNS	auxpass||observed-140/VBN||were-139/VBD	dep||show-3/VBP||observed-140/VBN	conj_and||exposed-13/VBN||observed-140/VBN	prepc_compared_to||observed-140/VBN||to-142/TO	pobj||observed-140/VBN||baseline-143/NN	malaria-47||artemether--1||yes||the findings show 1) no health facility or health worker was exposed to all components of the intervention; 2) the proportion of health workers who received the enhanced in-service training was 67%; 3) the proportion of febrile children with uncomplicated malaria treated with the first-line anti-malarial drug, artemether-lumefantrine (al), at health facilities where al was in stock increased from 76.9% (95%ci 69.4, 83.1) to 87.6% (95% ci 82.5, 91.5); 4) there were modest but non-significant improvements in dispensing and counseling practices; and 5) when the analyses were restricted to health workers who received the enhanced in-service training and/or had received new guidelines and job aids, no significant improvements in reported case-management tasks were observed compared to baseline.
amod||controversy-2/NN||much-1/JJ	nsubj||exists-3/VBZ||controversy-2/NN	root||ROOT-0/null||exists-3/VBZ	xcomp||exists-3/VBZ||concerning-4/VBG	det||efficacy-6/NN||the-5/DT	nsubj||due-21/JJ||efficacy-6/NN	amod||cardioverter-defibrillators-11/NNS||primary-8/JJ	amod||cardioverter-defibrillators-11/NNS||prophylactic-9/JJ	nn||cardioverter-defibrillators-11/NNS||implantable-10/NN	prep_of||efficacy-6/NN||cardioverter-defibrillators-11/NNS	appos||cardioverter-defibrillators-11/NNS||icds-13/NNS	prep_in||cardioverter-defibrillators-11/NNS||patients-16/NNS	amod||fraction-20/NN||low-18/JJ	nn||fraction-20/NN||ejection-19/NN	prep_with||patients-16/NNS||fraction-20/NN	xcomp||concerning-4/VBG||due-21/JJ	prep_to||due-21/JJ||coronaryarterydisease-23/NN	appos||coronaryarterydisease-23/NN||cad-25/NN	prep_to||due-21/JJ||dilatedcardiomyopathy-28/NN	conj_or||coronaryarterydisease-23/NN||dilatedcardiomyopathy-28/NN	appos||coronaryarterydisease-23/NN||dcm-30/NN	dcm-30||coronaryarterydisease-23||no_rel||much controversy exists concerning the efficacy of primary prophylactic implantable cardioverter-defibrillators (icds) in patients with low ejection fraction due to coronaryarterydisease (cad) or dilatedcardiomyopathy (dcm).
det||study-3/NN||this-2/DT	prep_in||compared-21/VBD||study-3/NN	det||variation-7/NN||the-4/DT	nn||variation-7/NN||spa-5/NN	nn||variation-7/NN||gene-6/NN	nsubjpass||studied-17/VBN||variation-7/NN	prep_in||variation-7/NN||s.aureus-9/NNS	vmod||s.aureus-9/NNS||isolated-10/VBN	amod||carriers-13/NNS||healthy-12/JJ	prep_from||isolated-10/VBN||carriers-13/NNS	prep_from||isolated-10/VBN||patients-15/NNS	conj_and||carriers-13/NNS||patients-15/NNS	auxpass||studied-17/VBN||was-16/VBD	rcmod||study-3/NN||studied-17/VBN	nsubj||compared-21/VBD||we-19/PRP	advmod||compared-21/VBD||also-20/RB	root||ROOT-0/null||compared-21/VBD	det||variation-23/NN||this-22/DT	dobj||compared-21/VBD||variation-23/NN	prep_among||compared-21/VBD||mrsa-25/NN	nn||strains-28/NNS||mssa-27/NN	prep_with||compared-21/VBD||strains-28/NNS	mrsa-25||s.aureus-9||no||in this study the spa gene variation in s.aureus isolated from healthy carriers and patients was studied , we also compared this variation among mrsa with mssa strains .
det||study-2/NN||this-1/DT	nsubjpass||designed-5/VBN||study-2/NN	nsubj||investigate-7/VB||study-2/NN	aux||designed-5/VBN||has-3/VBZ	auxpass||designed-5/VBN||been-4/VBN	root||ROOT-0/null||designed-5/VBN	aux||investigate-7/VB||to-6/TO	xcomp||designed-5/VBN||investigate-7/VB	mark||alternative-15/NN||whether-8/IN	det||admixture-10/NN||this-9/DT	nsubj||alternative-15/NN||admixture-10/NN	aux||alternative-15/NN||can-11/MD	cop||alternative-15/NN||be-12/VB	det||alternative-15/NN||a-13/DT	amod||alternative-15/NN||suitable-14/JJ	ccomp||investigate-7/VB||alternative-15/NN	aux||propofol-17/VB||to-16/TO	vmod||alternative-15/NN||propofol-17/VB	prep_in||designed-5/VBN||relation-20/NN	aux||ease-22/VB||to-21/TO	vmod||relation-20/NN||ease-22/VB	prep_of||ease-22/VB||insertion-24/NN	det||pain-35/NN||the-26/DT	nn||stability-30/NN||lma-27/NN	amod||stability-30/NN||haemodynamic-29/JJ	dep||pain-35/NN||stability-30/NN	nn||containment-33/NN||cost-32/NN	dep||stability-30/NN||containment-33/NN	prep_of||insertion-24/NN||pain-35/NN	prep_on||pain-35/NN||injection-37/NN	prep_on||pain-35/NN||recovery-39/NN	conj_and||injection-37/NN||recovery-39/NN	prep_in||ease-22/VB||children-41/NNS	pain-35||propofol-17||yes||this study has been designed to investigate whether this admixture can be a suitable alternative to propofol, in relation to ease of insertion of the lma, haemodynamic stability, cost containment, pain on injection and recovery in children.
amod||ligands-2/NNS||nonribose-1/JJ	nsubjpass||represented-4/VBN||ligands-2/NNS	auxpass||represented-4/VBN||are-3/VBP	root||ROOT-0/null||represented-4/VBN	amod||dicarbonitrilepyridines-8/NNS||conveniently-6/JJ	amod||dicarbonitrilepyridines-8/NNS||substituted-7/JJ	agent||represented-4/VBN||dicarbonitrilepyridines-8/NNS	dobj||is-65/VBZ||which-11/WDT	num||-LSB--14/CD||2-12/CD	nsubj||is-65/VBZ||-LSB--14/CD	amod||-LSB--14/CD||6-amino-3-15/JJ	dep||6-amino-3-15/JJ||,5-16/CD	dep||-LSB--14/CD||dicyano-4-18/JJ	number||4-21/CD||-LSB--20/CD	dep||dicyano-4-18/JJ||4-21/CD	appos||-RSB--27/NN||cyclopropylmethoxy-24/NN	amod||-RSB--27/NN||phenyl-26/JJ	dep||-LSB--14/CD||-RSB--27/NN	amod||acetamide-30/NN||pyridin-2-ylsulfanyl-28/JJ	amod||acetamide-30/NN||-RSB--29/JJ	dep||-RSB--27/NN||acetamide-30/NN	dep||-LSB--14/CD||bay-60â-32/JJ	dep||bay-60â-32/JJ||$-33/$	nn||ha2a-39/NN||6583-35/NNP	dep||ha2a-39/NN||ha1-37/NNS	npadvmod||=-58/RB||ha2a-39/NN	dep||î-50/NNS||ha3-41/RB	num||î-50/NNS||ec50â-42/CD	amod||î-50/NNS||$-43/$	number||>-45/CD||-44/CD	num||$-43/$||>-45/CD	amod||î-50/NNS||â-46/JJ	num||î-50/NNS||$-47/$	number||10â-49/CD||-48/CD	num||$-47/$||10â-49/CD	dep||ha2a-39/NN||î-50/NNS	num||m-52/NN||1/4-51/CD	dep||î-50/NNS||m-52/NN	amod||ec50â-55/NNS||ha2b-54/JJ	dep||î-50/NNS||ec50â-55/NNS	dep||î-50/NNS||$-56/$	num||$-56/$||-57/CD	dep||â-59/CD||=-58/RB	num||$-33/$||â-59/CD	dep||nm-63/NN||$-60/$	num||nm-63/NN||-61/CD	amod||nm-63/NN||3â-62/JJ	dep||$-33/$||nm-63/NN	prepc_among||represented-4/VBN||is-65/VBZ	advmod||is-65/VBZ||currently-66/RB	amod||investigation-69/NN||preclinical-phase-68/JJ	prep_under||is-65/VBZ||investigation-69/NN	prepc_for||is-65/VBZ||treating-71/VBG	dobj||treating-71/VBG||coronaryarterydisorders-72/NNS	dobj||treating-71/VBG||atherosclerosis-74/NNS	conj_and||coronaryarterydisorders-72/NNS||atherosclerosis-74/NNS	nm-63||atherosclerosis-74||no_rel||nonribose ligands are represented by conveniently substituted dicarbonitrilepyridines, among which 2-[6-amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-ylsulfanyl]acetamide ( bay-60â6583 , ha1, ha2a, ha3 ec50â>â10â î¼m; ha2b ec50â=â3â nm) is currently under preclinical-phase investigation for treating coronaryarterydisorders and atherosclerosis.
aux||evaluate-2/VB||to-1/TO	root||ROOT-0/null||evaluate-2/VB	det||level-4/NN||the-3/DT	dobj||evaluate-2/VB||level-4/NN	prep_of||level-4/NN||pain-6/NN	prep_during||evaluate-2/VB||phacoemulsification-8/NN	amod||implantation-13/NN||foldable-10/JJ	amod||implantation-13/NN||intraocular-11/JJ	nn||implantation-13/NN||lens-12/NN	prep_during||evaluate-2/VB||implantation-13/NN	conj_and||phacoemulsification-8/NN||implantation-13/NN	prep_under||evaluate-2/VB||instillation-15/NN	amod||eyedrops-20/NNS||tetracaine-17/JJ	number||%-19/NN||0.5-18/CD	amod||eyedrops-20/NNS||%-19/NN	prep_of||instillation-15/NN||eyedrops-20/NNS	det||combination-23/NN||a-22/DT	prep_versus||eyedrops-20/NNS||combination-23/NN	dep||%-27/NN||lidocaine-25/JJ	number||%-27/NN||2-26/CD	amod||gel-28/NN||%-27/NN	prep_of||combination-23/NN||gel-28/NN	prep_of||combination-23/NN||instillation-30/NN	conj_and||gel-28/NN||instillation-30/NN	amod||eyedrops-33/NNS||tetracaine-32/JJ	prep_of||eyedrops-20/NNS||eyedrops-33/NNS	pain-6||tetracaine-32||yes||to evaluate the level of pain during phacoemulsification and foldable intraocular lens implantation under instillation of tetracaine 0.5% eyedrops versus a combination of lidocaine 2% gel and instillation of tetracaine eyedrops.
amod||prevalence-2/NN||increasing-1/VBG	nsubj||worsening-17/VBG||prevalence-2/NN	nn||resistance-5/NN||inh-4/NN	prep_of||prevalence-2/NN||resistance-5/NN	advmod||resistance-5/NN||especially-7/RB	amod||tb-12/NN||high-9/JJ	nn||tb-12/NN||tuberculosis-10/NNP	nn||tb-12/NN||-lrb--11/NNP	prep_in||especially-7/RB||tb-12/NN	advmod||prevalent-14/JJ||-rrb--13/RB	amod||countries-15/NNS||prevalent-14/JJ	dep||resistance-5/NN||countries-15/NNS	aux||worsening-17/VBG||is-16/VBZ	root||ROOT-0/null||worsening-17/VBG	det||burden-19/NN||the-18/DT	dobj||worsening-17/VBG||burden-19/NN	nn||programs-23/NNS||tb-21/NN	nn||programs-23/NNS||control-22/NN	prep_of||burden-19/NN||programs-23/NNS	mark||noted-30/VBN||since-25/IN	amod||rates-28/NNS||similar-26/JJ	nn||rates-28/NNS||transmission-27/NN	nsubjpass||noted-30/VBN||rates-28/NNS	auxpass||noted-30/VBN||are-29/VBP	advcl||worsening-17/VBG||noted-30/VBN	nn||strains-37/NNS||inh-32/NN	amod||strains-37/NNS||susceptible-33/JJ	conj_and||susceptible-33/JJ||resistant-35/JJ	amod||strains-37/NNS||resistant-35/JJ	nn||strains-37/NNS||m.tuberculosis-36/NN	prep_for||noted-30/VBN||strains-37/NNS	tb-21||inh-32||yes||increasing prevalence of inh resistance , especially in high tuberculosis -lrb- tb -rrb- prevalent countries is worsening the burden of tb control programs , since similar transmission rates are noted for inh susceptible and resistant m.tuberculosis strains .
amod||syphilis-2/NNS||venereal-1/JJ	nsubj||multi-stage-5/NN||syphilis-2/NNS	cop||multi-stage-5/NN||is-3/VBZ	det||multi-stage-5/NN||a-4/DT	root||ROOT-0/null||multi-stage-5/NN	advmod||disease-9/NN||sexually-7/RB	amod||disease-9/NN||transmitted-8/JJ	appos||multi-stage-5/NN||disease-9/NN	vmod||disease-9/NN||caused-10/VBN	det||treponemapallidum-15/NN||the-12/DT	amod||treponemapallidum-15/NN||spirochetal-13/JJ	nn||treponemapallidum-15/NN||bacterium-14/NN	agent||caused-10/VBN||treponemapallidum-15/NN	appos||treponemapallidum-15/NN||tp-17/NN	syphilis-2||treponemapallidum-15||no||venereal syphilis is a multi-stage, sexually transmitted disease caused by the spirochetal bacterium treponemapallidum (tp) .
det||phase-3/NN||this-1/DT	amod||phase-3/NN||multi-centre-2/JJ	nsubj||ii-4/VBP||phase-3/NN	root||ROOT-0/null||ii-4/VBP	amod||trial-6/NN||clinical-5/JJ	nsubj||evaluation-11/NN||trial-6/NN	cop||evaluation-11/NN||is-7/VBZ	det||evaluation-11/NN||the-8/DT	amod||evaluation-11/NN||first-9/JJ	amod||evaluation-11/NN||prospective-10/JJ	ccomp||ii-4/VBP||evaluation-11/NN	nsubj||failed-24/VBD||evaluation-11/NN	prep_of||evaluation-11/NN||radioembolisation-13/NN	prep_of||radioembolisation-13/NN||patients-15/NNS	amod||metastases-19/NNS||colorectal-17/JJ	nn||metastases-19/NNS||liver-18/NN	prep_with||patients-15/NNS||metastases-19/NNS	dep||evaluation-11/NN||mcrc-21/JJ	rcmod||evaluation-11/NN||failed-24/VBD	amod||oxaliplatin-26/NN||previous-25/JJ	dobj||failed-24/VBD||oxaliplatin-26/NN	amod||regimens-32/NNS||irinotecan-based-29/JJ	amod||regimens-32/NNS||systemic-30/JJ	amod||regimens-32/NNS||chemotherapy-31/JJ	dobj||failed-24/VBD||regimens-32/NNS	conj_and||oxaliplatin-26/NN||regimens-32/NNS	metastases-19||irinotecan--1||yes||this multi-centre phase ii clinical trial is the first prospective evaluation of radioembolisation of patients with colorectal liver metastases (mcrc) who failed previous oxaliplatin- and irinotecan-based systemic chemotherapy regimens.
amod||risks-4/NNS||gastrointestinal-3/JJ	prep_because_of||propose-29/VBP||risks-4/NNS	nn||complications-8/NNS||ulcer-7/NN	prep_including||risks-4/NNS||complications-8/NNS	amod||risks-12/NNS||cardiovascular-11/JJ	conj_and||risks-4/NNS||risks-12/NNS	prep_because_of||propose-29/VBP||risks-12/NNS	nn||events-18/NNS||hypertension-15/NN	conj_and||hypertension-15/NN||thrombotic-17/JJ	nn||events-18/NNS||thrombotic-17/JJ	prep_including||risks-12/NNS||events-18/NNS	vmod||events-18/NNS||associated-19/VBN	amod||-RSB--24/NNS||nonsteroidalanti-inflammatorydrugs-21/JJ	amod||-RSB--24/NNS||-LSB--22/JJ	nn||-RSB--24/NNS||nsaids-23/NNS	prep_with||associated-19/VBN||-RSB--24/NNS	det||guidelines-28/NNS||these-27/DT	nsubj||propose-29/VBP||guidelines-28/NNS	root||ROOT-0/null||propose-29/VBP	dobj||propose-29/VBP||acetaminophen-30/NN	det||anti-inflammatoryagents-35/NNS||the-32/DT	amod||anti-inflammatoryagents-35/NNS||first-33/JJ	nn||anti-inflammatoryagents-35/NNS||choice-34/NN	prep_as||propose-29/VBP||anti-inflammatoryagents-35/NNS	nonsteroidalanti-inflammatorydrugs-21||hypertension-15||no_rel||because of gastrointestinal risks (including ulcer complications) and cardiovascular risks (including hypertension and thrombotic events associated with nonsteroidalanti-inflammatorydrugs [nsaids]), these guidelines propose acetaminophen as the first choice anti-inflammatoryagents.
nsubj||studied-2/VBD||we-1/PRP	root||ROOT-0/null||studied-2/VBD	num||adults-5/NNS||16-3/CD	amod||adults-5/NNS||nondiabetic-4/JJ	dobj||studied-2/VBD||adults-5/NNS	num||subjects-8/NNS||16-7/CD	dobj||studied-2/VBD||subjects-8/NNS	conj_and||adults-5/NNS||subjects-8/NNS	prep_with||studied-2/VBD||type1diabetes-10/CD	prep_during||studied-2/VBD||euglycemia-12/NN	npadvmod||mmol/l-16/JJ||bloodglucose-14/NN	num||bloodglucose-14/NN||4.5-15/CD	dep||euglycemia-12/NN||mmol/l-16/JJ	prep_during||studied-2/VBD||hypoglycemia-19/NN	conj_and||euglycemia-12/NN||hypoglycemia-19/NN	npadvmod||mmol/l-23/JJ||bloodglucose-21/NN	num||bloodglucose-21/NN||2.5-22/CD	dep||euglycemia-12/NN||mmol/l-23/JJ	hypoglycemia-19||glucose--1||yes||we studied 16 nondiabetic adults and 16 subjects with type1diabetes during euglycemia (bloodglucose 4.5 mmol/l) and hypoglycemia (bloodglucose 2.5 mmol/l).
nsubj||antibody-5/NN||rituximab-1/NN	cop||antibody-5/NN||is-2/VBZ	det||antibody-5/NN||a-3/DT	amod||antibody-5/NN||monoclonal-4/JJ	root||ROOT-0/null||antibody-5/NN	det||cd20-10/NNS||the-7/DT	amod||cd20-10/NNS||b-cell-8/JJ	nn||cd20-10/NNS||marker-9/NN	prep_to||antibody-5/NN||cd20-10/NNS	cop||agent-16/NN||is-12/VBZ	det||agent-16/NN||a-13/DT	amod||agent-16/NN||common-14/JJ	amod||agent-16/NN||biologic-15/JJ	conj_and||antibody-5/NN||agent-16/NN	advmod||used-18/VBN||widely-17/RB	vmod||agent-16/NN||used-18/VBN	det||treatment-21/NN||the-20/DT	prep_for||used-18/VBN||treatment-21/NN	amod||disorders-26/NNS||b-celllymphoma-23/JJ	amod||disorders-26/NNS||lymphoproliferative-25/JJ	prep_of||treatment-21/NN||disorders-26/NNS	amod||conditions-30/NNS||inflammatory-29/JJ	conj_and||antibody-5/NN||conditions-30/NNS	conj_and||agent-16/NN||conditions-30/NNS	nsubj||refractory-33/JJ||conditions-30/NNS	cop||refractory-33/JJ||are-32/VBP	rcmod||conditions-30/NNS||refractory-33/JJ	amod||treatment-36/NN||conventional-35/JJ	prep_to||refractory-33/JJ||treatment-36/NN	prep_including||treatment-36/NN||rheumatoidarthritis-39/NNS	det||vasculitides-42/NNS||some-41/DT	prep_including||treatment-36/NN||vasculitides-42/NNS	conj_and||rheumatoidarthritis-39/NNS||vasculitides-42/NNS	b-celllymphoma-23||rituximab-1||yes||rituximab is a monoclonal antibody to the b-cell marker cd20 and is a common biologic agent widely used for the treatment of b-celllymphoma, lymphoproliferative disorders, and inflammatory conditions that are refractory to conventional treatment, including rheumatoidarthritis and some vasculitides.
nsubjpass||shown-3/VBN||fondaparinux-1/NN	nsubj||efficacious-6/JJ||fondaparinux-1/NN	auxpass||shown-3/VBN||was-2/VBD	root||ROOT-0/null||shown-3/VBN	aux||efficacious-6/JJ||to-4/TO	cop||efficacious-6/JJ||be-5/VB	xcomp||shown-3/VBN||efficacious-6/JJ	det||prevention-9/NN||the-8/DT	prep_in||efficacious-6/JJ||prevention-9/NN	amod||heparins-15/NNS||deep-11/JJ	nn||heparins-15/NNS||veinthrombosis-12/NN	nn||heparins-15/NNS||vs-13/NN	amod||heparins-15/NNS||low-molecular-weight-14/JJ	prep_of||prevention-9/NN||heparins-15/NNS	mark||shown-28/VBN||while-17/IN	det||setting-20/NN||the-19/DT	prep_in||shown-28/VBN||setting-20/NN	amod||disease-24/NN||venous-22/JJ	amod||disease-24/NN||thrombo-embolic-23/JJ	prep_of||setting-20/NN||disease-24/NN	nsubjpass||shown-28/VBN||it-26/PRP	nsubj||noninferior-31/JJ||it-26/PRP	auxpass||shown-28/VBN||was-27/VBD	advcl||efficacious-6/JJ||shown-28/VBN	aux||noninferior-31/JJ||to-29/TO	cop||noninferior-31/JJ||be-30/VB	xcomp||shown-28/VBN||noninferior-31/JJ	prep_to||noninferior-31/JJ||enoxaparin-33/NN	prep_to||noninferior-31/JJ||ufh-35/NN	conj_and||enoxaparin-33/NN||ufh-35/NN	veinthrombosis-12||heparins-15||yes||fondaparinux was shown to be efficacious in the prevention of deep veinthrombosis vs low-molecular-weight heparins, while in the setting of venous thrombo-embolic disease, it was shown to be noninferior to enoxaparin and ufh.
advmod||assessed-17/VBN||here-1/RB	det||significance-5/NN||the-3/DT	amod||significance-5/NN||prognostic-4/JJ	nsubjpass||assessed-17/VBN||significance-5/NN	det||marker-9/NN||this-7/DT	amod||marker-9/NN||epigenetic-8/JJ	prep_of||significance-5/NN||marker-9/NN	amod||toxicity-15/NN||severe-13/JJ	amod||toxicity-15/NN||5-fu-14/JJ	prep_with_respect_to||marker-9/NN||toxicity-15/NN	auxpass||assessed-17/VBN||was-16/VBD	root||ROOT-0/null||assessed-17/VBN	num||patients-21/NNS||27-19/CD	nn||patients-21/NNS||cancer-20/NN	prep_in||assessed-17/VBN||patients-21/NNS	vmod||patients-21/NNS||receiving-22/VBG	dobj||receiving-22/VBG||5-fu-23/JJ	vmod||5-fu-23/JJ||based-24/VBN	advmod||based-24/VBN||chemotherapy-25/RB	num||patients-29/NNS||17-28/CD	prep_including||based-24/VBN||patients-29/NNS	vmod||patients-29/NNS||experiencing-30/VBG	amod||effects-34/NNS||severe-31/JJ	amod||effects-34/NNS||toxic-32/JJ	nn||effects-34/NNS||side-33/NN	dobj||experiencing-30/VBG||effects-34/NNS	nn||administration-37/NN||drug-36/NN	prep_following||effects-34/NNS||administration-37/NN	prep_of||none-39/NN||administration-37/NN	nsubj||carriers-43/NNS||none-39/NN	cop||carriers-43/NNS||were-42/VBD	rcmod||administration-37/NN||carriers-43/NNS	det||mutation-49/NN||a-45/DT	amod||mutation-49/NN||known-46/JJ	amod||mutation-49/NN||deleterious-47/JJ	amod||mutation-49/NN||dpyd-48/JJ	prep_of||carriers-43/NNS||mutation-49/NN	num||patients-54/NNS||ten-52/CD	nn||patients-54/NNS||control-53/NN	dobj||receiving-22/VBG||patients-54/NNS	conj_and||5-fu-23/JJ||patients-54/NNS	5-fu-23||cancer-20||no_rel||here, the prognostic significance of this epigenetic marker with respect to severe 5-fu toxicity was assessed in 27 cancer patients receiving 5-fu based chemotherapy, including 17 patients experiencing severe toxic side effects following drug administration, none of which were carriers of a known deleterious dpyd mutation, and ten control patients.
nsubjpass||approved-3/VBN||interferon-1/NN	auxpass||approved-3/VBN||is-2/VBZ	root||ROOT-0/null||approved-3/VBN	amod||treatment-6/NN||adjuvant-5/JJ	prep_for||approved-3/VBN||treatment-6/NN	prep_of||treatment-6/NN||patients-8/NNS	nn||melanoma-12/NN||stage-10/NN	nn||melanoma-12/NN||iib/iii-11/NN	prep_with||patients-8/NNS||melanoma-12/NN	melanoma-12||interferon-1||yes||interferon is approved for adjuvant treatment of patients with stage iib/iii melanoma.
nsubjpass||demonstrated-3/VBN||it-1/PRP	auxpass||demonstrated-3/VBN||was-2/VBD	ccomp||methicillin-26/VBP||demonstrated-3/VBN	mark||effective-10/JJ||that-4/IN	amod||extract-8/NNS||persian-5/JJ	amod||extract-8/NNS||shallot-6/JJ	amod||extract-8/NNS||hydromethanolic-7/JJ	nsubj||effective-10/JJ||extract-8/NNS	cop||effective-10/JJ||was-9/VBD	ccomp||demonstrated-3/VBN||effective-10/JJ	num||species-14/NNS||10-12/CD	amod||species-14/NNS||different-13/JJ	prep_against||effective-10/JJ||species-14/NNS	amod||bacteria-17/NNS||pathogenic-16/JJ	prep_of||species-14/NNS||bacteria-17/NNS	amod||resistant-20/JJ||methicillin-19/JJ	amod||staphylococcusaureus-21/NNS||resistant-20/JJ	prep_including||bacteria-17/NNS||staphylococcusaureus-21/NNS	appos||staphylococcusaureus-21/NNS||mrsa-23/NNP	root||ROOT-0/null||methicillin-26/VBP	acomp||methicillin-26/VBP||sensitive-27/JJ	nsubj||methicillin-26/VBP||staphylococcusaureus-28/NNS	appos||staphylococcusaureus-28/NNS||mssa-30/NNP	appos||staphylococcusaureus-28/NNS||staphylococcusaureus-33/NNS	nn||epidermidis-36/NNS||staphylococcus-35/NN	appos||staphylococcusaureus-28/NNS||epidermidis-36/NNS	conj_and||staphylococcusaureus-33/NNS||epidermidis-36/NNS	appos||staphylococcusaureus-28/NNS||streptococcuspneumoniae-38/NN	conj_and||staphylococcusaureus-33/NNS||streptococcuspneumoniae-38/NN	appos||staphylococcusaureus-28/NNS||escherichiacoli-40/NNS	conj_and||staphylococcusaureus-33/NNS||escherichiacoli-40/NNS	amod||o157h7-43/NNS||escherichiacoli-42/JJ	appos||staphylococcusaureus-28/NNS||o157h7-43/NNS	conj_and||staphylococcusaureus-33/NNS||o157h7-43/NNS	appos||staphylococcusaureus-28/NNS||salmonellatyphimurium-45/NN	conj_and||staphylococcusaureus-33/NNS||salmonellatyphimurium-45/NN	amod||mirabilis-48/NNS||proteus-47/JJ	appos||staphylococcusaureus-28/NNS||mirabilis-48/NNS	conj_and||staphylococcusaureus-33/NNS||mirabilis-48/NNS	nn||pneumoniae-52/NN||klebsiella-51/NN	appos||staphylococcusaureus-28/NNS||pneumoniae-52/NN	conj_and||staphylococcusaureus-33/NNS||pneumoniae-52/NN	mrsa-23||staphylococcusaureus-33||no||it was demonstrated that persian shallot hydromethanolic extract was effective against 10 different species of pathogenic bacteria including methicillin resistant staphylococcusaureus (mrsa), methicillin sensitive staphylococcusaureus (mssa), staphylococcusaureus , staphylococcus epidermidis , streptococcuspneumoniae , escherichiacoli, escherichiacoli o157h7, salmonellatyphimurium, proteus mirabilis , and klebsiella pneumoniae .
amod||expression-3/NN||increased-1/VBN	amod||expression-3/NN||mmp-7-2/JJ	nsubjpass||identified-5/VBN||expression-3/NN	auxpass||identified-5/VBN||was-4/VBD	root||ROOT-0/null||identified-5/VBN	preconj||levels-11/NNS||both-7/DT	nn||levels-11/NNS||mrna-8/NN	conj_and||mrna-8/NN||protein-10/NN	nn||levels-11/NNS||protein-10/NN	prep_at||identified-5/VBN||levels-11/NNS	det||cells-16/NNS||the-13/DT	amod||cells-16/NNS||gastric-14/JJ	nn||cells-16/NNS||cancer-15/NN	prep_in||identified-5/VBN||cells-16/NNS	prep_in||cells-16/NNS||response-18/NN	amod||stimulation-21/NN||isoproterenol-20/JJ	prep_to||identified-5/VBN||stimulation-21/NN	cancer-15||isoproterenol-20||no_rel||increased mmp-7 expression was identified at both mrna and protein levels in the gastric cancer cells in response to isoproterenol stimulation.
det||medication-2/NN||the-1/DT	nsubjpass||registered-12/VBN||medication-2/NN	vmod||medication-2/NN||used-3/VBN	prep_for||used-3/VBN||diabetes-5/NN	prep_for||used-3/VBN||arterialhypertension-7/NN	conj_and||diabetes-5/NN||arterialhypertension-7/NN	prep_for||used-3/VBN||hyperlipidemia-9/NN	conj_and||diabetes-5/NN||hyperlipidemia-9/NN	aux||registered-12/VBN||will-10/MD	auxpass||registered-12/VBN||be-11/VB	root||ROOT-0/null||registered-12/VBN	prep_together_with||registered-12/VBN||antiplateletdrugs-16/NNS	antiplateletdrugs-16||arterialhypertension-7||no_rel||the medication used for diabetes, arterialhypertension and hyperlipidemia will be registered, together with antiplateletdrugs.
amod||influenzaviruses-3/NNS||avian-1/JJ	amod||influenzaviruses-3/NNS||h5n1-2/JJ	nsubj||cause-4/VBP||influenzaviruses-3/NNS	root||ROOT-0/null||cause-4/VBP	amod||disease-6/NN||severe-5/JJ	dobj||cause-4/VBP||disease-6/NN	amod||mortality-9/NN||high-8/JJ	dobj||cause-4/VBP||mortality-9/NN	conj_and||disease-6/NN||mortality-9/NN	amod||humans-12/NNS||infected-11/JJ	prep_in||disease-6/NN||humans-12/NNS	h5n1-2||influenzaviruses-3||no||avian h5n1 influenzaviruses cause severe disease and high mortality in infected humans.
nsubj||increased-2/VBD||vitamine-1/NN	root||ROOT-0/null||increased-2/VBD	nn||risk-4/NN||pneumonia-3/NN	dobj||increased-2/VBD||risk-4/NN	num||%-7/NN||79-6/CD	prep_by||increased-2/VBD||%-7/NN	num||%-10/NN||95-9/CD	nsubj||ci-11/VBP||%-10/NN	parataxis||increased-2/VBD||ci-11/VBP	number||%-16/NN||27-12/CD	dep||%-16/NN||%-13/NN	dep||%-16/NN||to-14/TO	number||%-16/NN||150-15/CD	dobj||ci-11/VBP||%-16/NN	prep_among||increased-2/VBD||those-19/DT	nsubj||had-21/VBD||those-19/DT	nsubj||exercise-30/VB||those-19/DT	rcmod||those-19/DT||had-21/VBD	det||exposure-24/NN||the-22/DT	amod||exposure-24/NN||highest-23/JJS	dobj||had-21/VBD||exposure-24/NN	prep_to||exposure-24/NN||smoking-26/NN	aux||exercise-30/VB||did-28/VBD	neg||exercise-30/VB||not-29/RB	rcmod||those-19/DT||exercise-30/VB	conj_and||had-21/VBD||exercise-30/VB	pneumonia-3||vitamine-1||no_rel||vitamine increased pneumonia risk by 79% (95% ci 27% to 150%) among those who had the highest exposure to smoking and did not exercise.
nsubj||infection-9/NN||pertussis-1/NN	cop||infection-9/NN||is-2/VBZ	det||infection-9/NN||a-3/DT	advmod||contagious-5/JJ||highly-4/RB	amod||infection-9/NN||contagious-5/JJ	amod||infection-9/NN||respiratory-6/JJ	nn||infection-9/NN||tract-7/NN	nn||infection-9/NN||diseasecausedbybordetellapertussis-8/NN	root||ROOT-0/null||infection-9/NN	diseasecausedbybordetellapertussis-8||pertussis-1||yes||pertussis is a highly contagious respiratory tract diseasecausedbybordetellapertussis infection.
det||epidemic-3/NN||the-1/DT	nn||epidemic-3/NN||hiv/aids-2/NNS	nsubj||evolved-5/VBN||epidemic-3/NN	aux||evolved-5/VBN||has-4/VBZ	root||ROOT-0/null||evolved-5/VBN	det||burden-9/NN||an-7/DT	amod||burden-9/NN||increasing-8/VBG	prep_with||evolved-5/VBN||burden-9/NN	amod||adults-12/NNS||older-11/JJR	prep_in||burden-9/NN||adults-12/NNS	aids--1||hiv--1||no||the hiv/aids epidemic has evolved with an increasing burden in older adults.
prepc_compared_with||had-11/VBD||with-2/IN	nn||subjects-4/NNS||control-3/NN	pobj||had-11/VBD||subjects-4/NNS	amod||patients-7/NNS||type2diabetes-low-6/JJ	conj_and||subjects-4/NNS||patients-7/NNS	pobj||had-11/VBD||patients-7/NNS	amod||patients-10/NNS||type2diabetes-high-9/JJ	nsubj||had-11/VBD||patients-10/NNS	root||ROOT-0/null||had-11/VBD	det||perfusion-16/NN||the-12/DT	amod||perfusion-16/NN||lowest-13/JJS	amod||perfusion-16/NN||hepatic-14/JJ	amod||perfusion-16/NN||parenchymal-15/JJ	dobj||had-11/VBD||perfusion-16/NN	dep||perfusion-16/NN||p-18/VBN	dep||0.004-20/CD||=-19/SYM	ccomp||p-18/VBN||0.004-20/CD	amod||uptake-26/NN||insulin-stimulated-23/JJ	amod||uptake-26/NN||hepatic-24/JJ	nn||uptake-26/NN||glucose-25/NN	dobj||had-11/VBD||uptake-26/NN	conj_and||perfusion-16/NN||uptake-26/NN	dep||uptake-26/NN||p-28/VBN	dep||0.013-30/CD||=-29/SYM	ccomp||p-28/VBN||0.013-30/CD	type2diabetes--1||glucose-25||no_rel||compared with control subjects and type2diabetes-low patients, type2diabetes-high patients had the lowest hepatic parenchymal perfusion ( p = 0.004) and insulin-stimulated hepatic glucose uptake ( p = 0.013).
det||report-2/NN||this-1/DT	nsubj||describes-3/VBZ||report-2/NN	root||ROOT-0/null||describes-3/VBZ	det||efficacy-5/NN||the-4/DT	dobj||describes-3/VBZ||efficacy-5/NN	prep_of||efficacy-5/NN||sitagliptin-7/NN	num||patients-11/NNS||three-9/CD	amod||patients-11/NNS||japanese-10/JJ	prep_in||sitagliptin-7/NN||patients-11/NNS	nsubj||had-41/VBD||patients-11/NNS	det||woman-16/NN||a-13/DT	amod||woman-16/NN||91-year-old-14/JJ	nn||woman-16/NN||japanese-15/NN	dep||patients-11/NNS||woman-16/NN	prep_with||woman-16/NN||type1diabetes-18/CD	det||man-23/NN||a-20/DT	amod||man-23/NN||54-year-old-21/JJ	nn||man-23/NN||japanese-22/NN	dep||patients-11/NNS||man-23/NN	conj_and||woman-16/NN||man-23/NN	prep_with||man-23/NN||type2diabetes-25/CD	det||man-30/NN||a-27/DT	amod||man-30/NN||30-year-old-28/JJ	nn||man-30/NN||japanese-29/NN	conj_and||woman-16/NN||man-30/NN	conj_and||man-23/NN||man-30/NN	prep_with||man-30/NN||features-32/NNS	det||type-35/NN||both-34/DT	prep_of||features-32/NNS||type-35/NN	num||type-35/NN||1-36/CD	dep||patients-11/NNS||type2diabetes-38/NNS	conj_and||woman-16/NN||type2diabetes-38/NNS	rcmod||patients-11/NNS||had-41/VBD	neg||levels-46/NNS||no-42/DT	amod||levels-46/NNS||detectable-43/JJ	amod||levels-46/NNS||post-meal-44/JJ	amod||levels-46/NNS||c-peptide-45/JJ	dobj||had-41/VBD||levels-46/NNS	type1diabetes-18||sitagliptin-7||no||this report describes the efficacy of sitagliptin in three japanese patients (a 91-year-old japanese woman with type1diabetes, a 54-year-old japanese man with type2diabetes and a 30-year-old japanese man with features of both type 1 and type2diabetes) who had no detectable post-meal c-peptide levels.
nn||number-2/NN||otu-1/NN	nsubjpass||reduced-5/VBN||number-2/NN	auxpass||reduced-5/VBN||was-3/VBD	advmod||reduced-5/VBN||significantly-4/RB	root||ROOT-0/null||reduced-5/VBN	prep_in||reduced-5/VBN||cd-7/NN	num||±-11/NNP||7.7-9/CD	nn||±-11/NNP||â-10/NNP	dep||cd-7/NN||±-11/NNP	num||±-11/NNP||3.7-12/CD	nn||sd-16/NNP||meanâ-14/NNP	nn||sd-16/NNP||±-15/NNP	appos||±-11/NNP||sd-16/NNP	prep_in||reduced-5/VBN||uc-19/NN	conj_and||cd-7/NN||uc-19/NN	num||3.0-24/NNS||9.0-21/CD	nn||3.0-24/NNS||â-22/NNP	nn||3.0-24/NNS||±-23/NN	appos||cd-7/NN||3.0-24/NNS	prepc_compared_to||reduced-5/VBN||to-27/TO	pobj||reduced-5/VBN||hc-28/NN	num||2.2-33/NNS||11.9-30/CD	nn||2.2-33/NNS||â-31/NNP	nn||2.2-33/NNS||±-32/NN	appos||hc-28/NN||2.2-33/NNS	dep||hc-28/NN||p-36/VBN	dep||0.0005-38/CD||=-37/SYM	ccomp||p-36/VBN||0.0005-38/CD	uc-19||hc-28||yes||otu number was significantly reduced in cd (7.7â±3.7, meanâ±sd) and uc (9.0â±3.0) compared to hc (11.9â±2.2) (p=0.0005).
det||microenvironment-3/NN||the-1/DT	nn||microenvironment-3/NN||tumor-2/NN	nsubj||caused-4/VBD||microenvironment-3/NN	root||ROOT-0/null||caused-4/VBD	amod||up-regulation-8/NN||rapid-5/JJ	conj_and||rapid-5/JJ||dramatic-7/JJ	amod||up-regulation-8/NN||dramatic-7/JJ	dobj||caused-4/VBD||up-regulation-8/NN	amod||i-11/FW||arginase-10/JJ	prep_of||up-regulation-8/NN||i-11/FW	amod||synthase-15/NN||inducible-13/JJ	nn||synthase-15/NN||nitricoxide-14/NN	dobj||caused-4/VBD||synthase-15/NN	conj_and||up-regulation-8/NN||synthase-15/NN	prep_in||synthase-15/NN||mdsc-17/NN	nsubjpass||accompanied-21/VBN||mdsc-17/NN	auxpass||accompanied-21/VBN||was-20/VBD	rcmod||mdsc-17/NN||accompanied-21/VBN	agent||accompanied-21/VBN||down-regulation-23/NN	amod||dinucleotide-27/NN||nicotinamide-25/JJ	nn||dinucleotide-27/NN||adenine-26/NN	prep_of||down-regulation-23/NN||dinucleotide-27/NN	vmod||dinucleotide-27/NN||phosphateâ-28/VBG	dobj||phosphateâ-28/VBG||$-29/$	nn||and-32/NNP||oxidase-31/NNP	npadvmod||oxygen-34/RB||and-32/NNP	advmod||and-32/NNP||reactive-33/RB	dep||species-35/CD||oxygen-34/RB	num||$-29/$||species-35/CD	det||cells-38/NNS||these-37/DT	prep_in||$-29/$||cells-38/NNS	oxygen-34||tumor-2||no_rel||the tumor microenvironment caused rapid and dramatic up-regulation of arginase i and inducible nitricoxide synthase in mdsc, which was accompanied by down-regulation of nicotinamide adenine dinucleotide phosphateâoxidase and reactive oxygen species in these cells.
amod||inhibitor-3/NN||urinary-1/JJ	nn||inhibitor-3/NN||trypsin-2/NN	nsubjpass||used-16/VBN||inhibitor-3/NN	appos||inhibitor-3/NN||uti-5/NN	det||inhibitor-11/NN||a-8/DT	amod||inhibitor-11/NN||serine-9/JJ	nn||inhibitor-11/NN||protease-10/NN	appos||inhibitor-3/NN||inhibitor-11/NN	aux||used-16/VBN||has-13/VBZ	auxpass||used-16/VBN||been-14/VBN	advmod||used-16/VBN||widely-15/RB	root||ROOT-0/null||used-16/VBN	prep_in||used-16/VBN||japan-18/NN	det||drug-21/NN||a-20/DT	prep_as||used-16/VBN||drug-21/NN	prep_for||drug-21/NN||patients-23/NNS	amod||inflammatory-26/JJ||acute-25/JJ	amod||disorders-27/NNS||inflammatory-26/JJ	prep_with||patients-23/NNS||disorders-27/NNS	prep_such_as||disorders-27/NNS||disseminatedintravascularcoagulation-30/NN	appos||disseminatedintravascularcoagulation-30/NN||dic-32/NN	prep_such_as||disorders-27/NNS||shock-35/NN	conj_and||disseminatedintravascularcoagulation-30/NN||shock-35/NN	prep_such_as||disorders-27/NNS||pancreatitis-38/NNS	conj_and||disseminatedintravascularcoagulation-30/NN||pancreatitis-38/NNS	shock-35||trypsin-2||no_rel||urinary trypsin inhibitor (uti), a serine protease inhibitor, has been widely used in japan as a drug for patients with acute inflammatory disorders such as disseminatedintravascularcoagulation (dic), shock, and pancreatitis.
aux||evaluate-2/VB||to-1/TO	csubj||subjects-25/VBZ||evaluate-2/VB	det||impact-4/NN||the-3/DT	dobj||evaluate-2/VB||impact-4/NN	iobj||evaluate-2/VB||impact-4/NN	amod||intensive-7/NNS||former-6/JJ	prep_of||impact-4/NN||intensive-7/NNS	amod||treatment-11/NN||conventional-9/JJ	nn||treatment-11/NN||insulin-10/NN	prep_versus||intensive-7/NNS||treatment-11/NN	amod||control-14/NN||neuropathyindiabetes-13/JJ	prep_on||treatment-11/NN||control-14/NN	nn||trial-17/NN||complications-16/NNS	prep_on||treatment-11/NN||trial-17/NN	conj_and||control-14/NN||trial-17/NN	dep||impact-4/NN||dcct-19/VBN	amod||treatment-24/NN||intensive-21/JJ	conj_and||intensive-21/JJ||conventional-23/JJ	amod||treatment-24/NN||conventional-23/JJ	dep||impact-4/NN||treatment-24/NN	root||ROOT-0/null||subjects-25/VBZ	amod||13â-28/NNS||type1diabetes-27/JJ	prep_with||subjects-25/VBZ||13â-28/NNS	num||years-32/NNS||$-29/$	num||$-29/$||14-31/CD	npadvmod||subjects-25/VBZ||years-32/NNS	amod||closeout-35/NN||dcct-34/JJ	prep_after||subjects-25/VBZ||closeout-35/NN	det||time-39/NN||closeout-35/NN	prep_during||achieved-44/VBN||time-39/NN	det||groups-42/NNS||the-40/DT	num||groups-42/NNS||two-41/CD	nsubj||achieved-44/VBN||groups-42/NNS	aux||achieved-44/VBN||had-43/VBD	rcmod||closeout-35/NN||achieved-44/VBN	amod||levels-47/NNS||similar-45/JJ	amod||levels-47/NNS||a1c-46/JJ	dobj||achieved-44/VBN||levels-47/NNS	type1diabetes-27||insulin-10||yes||to evaluate the impact of former intensive versus conventional insulin treatment on neuropathyindiabetes control and complications trial (dcct) intensive and conventional treatment subjects with type1diabetes 13â14 years after dcct closeout, during which time the two groups had achieved similar a1c levels.
nsubj||one-11/CD||tb-1/NN	vmod||tb-1/NN||caused-3/VBN	agent||caused-3/VBN||mycobacteriumtuberculosis-5/NNS	appos||mycobacteriumtuberculosis-5/NNS||mtb-7/NN	cop||one-11/CD||is-10/VBZ	root||ROOT-0/null||one-11/CD	det||diseases-17/NNS||the-13/DT	amod||diseases-17/NNS||major-14/JJ	amod||diseases-17/NNS||global-15/JJ	amod||diseases-17/NNS||infectious-16/JJ	prep_of||one-11/CD||diseases-17/NNS	tb-1||mycobacteriumtuberculosis-5||no||tb, caused by mycobacteriumtuberculosis (mtb), is one of the major global infectious diseases.
amod||activity-2/NN||epileptic-1/JJ	nsubjpass||induced-5/VBN||activity-2/NN	auxpass||induced-5/VBN||is-3/VBZ	advmod||induced-5/VBN||generally-4/RB	root||ROOT-0/null||induced-5/VBN	amod||models-8/NNS||experimental-7/JJ	prep_in||induced-5/VBN||models-8/NNS	amod||application-11/NN||local-10/JJ	agent||induced-5/VBN||application-11/NN	amod||drugs-14/NNS||epileptogenic-13/JJ	prep_of||application-11/NN||drugs-14/NNS	prep_including||induced-5/VBN||pentylenetetrazol-17/NN	appos||pentylenetetrazol-17/NN||ptz-19/NN	advmod||used-23/VBN||widely-22/RB	vmod||pentylenetetrazol-17/NN||used-23/VBN	preconj||vertebrate-26/JJ||both-25/DT	amod||neurons-29/NNS||vertebrate-26/JJ	conj_and||vertebrate-26/JJ||invertebrate-28/JJ	amod||neurons-29/NNS||invertebrate-28/JJ	prep_on||used-23/VBN||neurons-29/NNS	epileptic-1||pentylenetetrazol-17||no||epileptic activity is generally induced in experimental models by local application of epileptogenic drugs, including pentylenetetrazol (ptz), widely used on both vertebrate and invertebrate neurons.
amod||risks-4/NNS||gastrointestinal-3/JJ	prep_because_of||propose-30/VBP||risks-4/NNS	nn||complications-8/NNS||ulcer-7/NN	prep_including||risks-4/NNS||complications-8/NNS	amod||risks-12/NNS||cardiovascular-11/JJ	conj_and||risks-4/NNS||risks-12/NNS	prep_because_of||propose-30/VBP||risks-12/NNS	nn||events-18/NNS||hypertension-15/NN	conj_and||hypertension-15/NN||thrombotic-17/JJ	nn||events-18/NNS||thrombotic-17/JJ	prep_including||risks-12/NNS||events-18/NNS	vmod||events-18/NNS||associated-19/VBN	amod||anti-inflammatorydrugs-22/NNS||nonsteroidal-21/JJ	prep_with||associated-19/VBN||anti-inflammatorydrugs-22/NNS	num||nsaids-24/NNS||-LSB--23/CD	npadvmod||-RSB--25/JJ||nsaids-24/NNS	amod||anti-inflammatorydrugs-22/NNS||-RSB--25/JJ	det||guidelines-29/NNS||these-28/DT	nsubj||propose-30/VBP||guidelines-29/NNS	root||ROOT-0/null||propose-30/VBP	dobj||propose-30/VBP||acetaminophen-31/NN	det||anti-inflammatoryagents-36/NNS||the-33/DT	amod||anti-inflammatoryagents-36/NNS||first-34/JJ	nn||anti-inflammatoryagents-36/NNS||choice-35/NN	prep_as||propose-30/VBP||anti-inflammatoryagents-36/NNS	anti-inflammatoryagents-36||hypertension-15||no_rel||because of gastrointestinal risks (including ulcer complications) and cardiovascular risks (including hypertension and thrombotic events associated with nonsteroidal anti-inflammatorydrugs [nsaids]), these guidelines propose acetaminophen as the first choice anti-inflammatoryagents.
det||ratio-4/NN||the-2/DT	nn||ratio-4/NN||benefit/risk-3/NN	prep_in||be-21/VB||ratio-4/NN	det||use-7/NN||the-6/DT	nsubj||be-21/VB||use-7/NN	nn||unsaponifiables-17/NNS||chondroitinsulfate-9/NN	prep_of||use-7/NN||diacereine-11/NN	conj_and||unsaponifiables-17/NNS||diacereine-11/NN	prep_of||use-7/NN||glucosamine-13/NN	conj_and||unsaponifiables-17/NNS||glucosamine-13/NN	nn||unsaponifiables-17/NNS||sulfate-14/NN	prep_of||use-7/NN||avocado/soybean-16/NN	conj_and||unsaponifiables-17/NNS||avocado/soybean-16/NN	prep_of||use-7/NN||unsaponifiables-17/NNS	prep_of||use-7/NN||hyaluronicacid-19/NN	conj_and||unsaponifiables-17/NNS||hyaluronicacid-19/NN	aux||be-21/VB||could-20/MD	root||ROOT-0/null||be-21/VB	amod||interest-24/NN||potential-23/JJ	prep_of||be-21/VB||interest-24/NN	det||management-28/NN||the-26/DT	amod||management-28/NN||symptomatic-27/JJ	prep_for||be-21/VB||management-28/NN	prep_of||management-28/NN||oa-30/NN	oa-30||chondroitinsulfate-9||yes||in the benefit/risk ratio, the use of chondroitinsulfate, diacereine, glucosamine sulfate, avocado/soybean unsaponifiables and hyaluronicacid could be of potential interest for the symptomatic management of oa.
advmod||was-8/VBD||therefore-1/RB	det||aim-4/NN||the-3/DT	nsubj||was-8/VBD||aim-4/NN	nsubj||assess-10/VB||aim-4/NN	det||study-7/NN||this-6/DT	prep_of||aim-4/NN||study-7/NN	root||ROOT-0/null||was-8/VBD	aux||assess-10/VB||to-9/TO	xcomp||was-8/VBD||assess-10/VB	det||effectiveness-12/NN||the-11/DT	dobj||assess-10/VB||effectiveness-12/NN	amod||-rrb--43/NN||chloroquine-14/JJ	nn||strains-18/NNS||p.-16/NN	nn||strains-18/NNS||vivax-17/NN	prep_against||chloroquine-14/JJ||strains-18/NNS	prep_in||strains-18/NNS||one-20/CD	det||areas-25/NNS||the-22/DT	amod||areas-25/NNS||malaria-23/JJ	amod||areas-25/NNS||endemic-24/JJ	prep_of||one-20/CD||areas-25/NNS	nn||district-31/NN||ethiopia-27/NN	advmod||district-31/NN||namely-29/RB	nn||district-31/NN||halaba-30/NN	prep_of||areas-25/NNS||district-31/NN	vmod||strains-18/NNS||located-33/VBN	amod||nations-36/NNS||south-35/JJ	prep_in||located-33/VBN||nations-36/NNS	prep_in||located-33/VBN||nationalities-38/NNS	conj_and||nations-36/NNS||nationalities-38/NNS	nn||-rrb--43/NN||peoples-39/NNS	nn||-rrb--43/NN||region-40/NN	amod||-rrb--43/NN||-lrb--41/VBG	nn||-rrb--43/NN||snnpr-42/NN	prep_of||effectiveness-12/NN||-rrb--43/NN	amod||ethiopia-46/NN||south-45/JJ	prep_of||effectiveness-12/NN||ethiopia-46/NN	num||patients-50/NNS||87-48/CD	nn||patients-50/NNS||malaria-49/NN	prep_among||ethiopia-46/NN||patients-50/NNS	vmod||patients-50/NNS||enrolled-51/VBN	det||study-54/NN||the-53/DT	prep_in||enrolled-51/VBN||study-54/NN	quantmod||80-57/CD||only-56/RB	appos||study-54/NN||80-57/CD	prep_of||80-57/CD||them-59/PRP	vmod||80-57/CD||completed-60/VBN	det||follow-up-63/NN||the-61/DT	amod||follow-up-63/NN||28-days-62/JJ	dobj||completed-60/VBN||follow-up-63/NN	malaria-49||chloroquine-14||yes||therefore , the aim of this study was to assess the effectiveness of chloroquine against p. vivax strains in one of the malaria endemic areas of ethiopia , namely halaba district , located in south nations and nationalities peoples region -lrb- snnpr -rrb- of south ethiopia among 87 malaria patients enrolled in the study , only 80 of them completed the 28-days follow-up .
aux||prevent-2/VB||to-1/TO	advcl||added-23/VBN||prevent-2/VB	dobj||prevent-2/VB||hyperinsulinemia-3/NN	nsubj||cause-7/VB||hyperinsulinemia-3/NN	aux||cause-7/VB||may-6/MD	rcmod||hyperinsulinemia-3/NN||cause-7/VB	dobj||cause-7/VB||atherosclerosis-8/NNS	nsubjpass||added-23/VBN||thiazolidinediones-10/NNS	appos||thiazolidinediones-10/NNS||tzds-12/NNS	advmod||known-16/VBN||also-15/RB	vmod||thiazolidinediones-10/NNS||known-16/VBN	nn||sensitizers-19/NNS||insulin-18/NN	prep_as||known-16/VBN||sensitizers-19/NNS	auxpass||added-23/VBN||are-21/VBP	advmod||added-23/VBN||often-22/RB	root||ROOT-0/null||added-23/VBN	det||regimen-27/NN||the-25/DT	amod||regimen-27/NN||therapeutic-26/JJ	prep_to||added-23/VBN||regimen-27/NN	prep_of||regimen-27/NN||patients-29/NNS	prep_with||added-23/VBN||type2diabetes-31/NNS	nsubj||receiving-34/VBG||type2diabetes-31/NNS	aux||receiving-34/VBG||are-33/VBP	rcmod||type2diabetes-31/NNS||receiving-34/VBG	dobj||receiving-34/VBG||insulin-35/NN	atherosclerosis-8||thiazolidinediones-10||no_rel||to prevent hyperinsulinemia, which may cause atherosclerosis, thiazolidinediones (tzds), also known as insulin sensitizers, are often added to the therapeutic regimen of patients with type2diabetes who are receiving insulin.
mark||factor-6/NN||since-1/IN	nsubj||factor-6/NN||angiogenesis-2/NNS	cop||factor-6/NN||is-3/VBZ	det||factor-6/NN||an-4/DT	amod||factor-6/NN||essential-5/JJ	advcl||assessment-33/NN||factor-6/NN	amod||progression-10/NN||solid-8/JJ	nn||progression-10/NN||tumor-9/NN	prep_in||factor-6/NN||progression-10/NN	amod||factor-15/NN||vascular-12/JJ	amod||factor-15/NN||endothelial-13/JJ	nn||factor-15/NN||growth-14/NN	nsubj||factor-22/NN||factor-15/NN	appos||factor-15/NN||vegf-17/NN	cop||factor-22/NN||is-19/VBZ	det||factor-22/NN||an-20/DT	amod||factor-22/NN||important-21/JJ	conj_and||factor-6/NN||factor-22/NN	advcl||assessment-33/NN||factor-22/NN	prep_in||factor-22/NN||angiogenesis-24/NNS	det||aim-27/NN||the-26/DT	nsubj||assessment-33/NN||aim-27/NN	det||study-30/NN||this-29/DT	prep_of||aim-27/NN||study-30/NN	cop||assessment-33/NN||is-31/VBZ	det||assessment-33/NN||the-32/DT	root||ROOT-0/null||assessment-33/NN	amod||changes-44/NNS||angiogenic-35/JJ	nn||changes-44/NNS||factor-36/NN	conj_and||factor-36/NN||vegf-38/NN	nn||changes-44/NNS||vegf-38/NN	conj_and||factor-36/NN||serum-40/NN	nn||changes-44/NNS||serum-40/NN	conj_and||factor-36/NN||urine-42/NN	nn||changes-44/NNS||urine-42/NN	nn||changes-44/NNS||level-43/NN	prep_of||assessment-33/NN||changes-44/NNS	amod||immunotherapy-48/NN||superficial-46/JJ	nn||immunotherapy-48/NN||bladdertumor-47/NN	prep_in||assessment-33/NN||immunotherapy-48/NN	amod||bcg-51/NN||intravesical-50/JJ	prep_by||immunotherapy-48/NN||bcg-51/NN	bladdertumor-47||bcg-51||yes||since angiogenesis is an essential factor in solid tumor progression and vascular endothelial growth factor (vegf) is an important factor in angiogenesis, the aim of this study is the assessment of angiogenic factor, vegf, serum and urine level changes in superficial bladdertumor immunotherapy by intravesical bcg.
amod||´-3/NNS||vitamine-1/JJ	nn||´-3/NNS||î-2/NN	dep||shown-8/VBN||´-3/NNS	nsubjpass||shown-8/VBN||tocotrienol-5/NN	nsubj||have-10/VB||tocotrienol-5/NN	aux||shown-8/VBN||has-6/VBZ	auxpass||shown-8/VBN||been-7/VBN	root||ROOT-0/null||shown-8/VBN	aux||have-10/VB||to-9/TO	xcomp||shown-8/VBN||have-10/VB	nn||activity-12/NN||antitumor-11/NN	dobj||have-10/VB||activity-12/NN	det||mechanism-18/NN||the-15/DT	amod||mechanism-18/NN||precise-16/JJ	amod||mechanism-18/NN||molecular-17/JJ	prep_by||inhibits-22/VBZ||mechanism-18/NN	nsubj||remains-28/VBZ||mechanism-18/NN	nsubj||inhibits-22/VBZ||it-21/PRP	rcmod||mechanism-18/NN||inhibits-22/VBZ	det||proliferation-24/NN||the-23/DT	dobj||inhibits-22/VBZ||proliferation-24/NN	nn||cells-27/NNS||cancer-26/NN	prep_of||proliferation-24/NN||cells-27/NNS	conj_but||shown-8/VBN||remains-28/VBZ	acomp||remains-28/VBZ||unclear-29/JJ	cancer-26||vitamine-1||no_rel||vitamine î´-tocotrienol has been shown to have antitumor activity, but the precise molecular mechanism by which it inhibits the proliferation of cancer cells remains unclear.
nsubj||shown-4/VBN||we-1/PRP	aux||shown-4/VBN||have-2/VBP	advmod||shown-4/VBN||previously-3/RB	root||ROOT-0/null||shown-4/VBN	mark||improves-10/VBZ||that-5/IN	amod||supplementation-8/NN||dietary-6/JJ	nn||supplementation-8/NN||leucine-7/NN	nsubj||improves-10/VBZ||supplementation-8/NN	advmod||improves-10/VBZ||significantly-9/RB	ccomp||shown-4/VBN||improves-10/VBZ	nn||metabolism-14/NN||glucose-11/NN	conj_and||glucose-11/NN||energy-13/NN	nn||metabolism-14/NN||energy-13/NN	dobj||improves-10/VBZ||metabolism-14/NN	amod||mice-18/NNS||diet-induced-16/JJ	nn||mice-18/NNS||obese-17/NN	prep_in||improves-10/VBZ||mice-18/NNS	vmod||improves-10/VBZ||suggesting-20/VBG	mark||therapy-30/NN||that-21/IN	amod||supplementation-23/NN||leucine-22/JJ	nsubj||therapy-30/NN||supplementation-23/NN	aux||therapy-30/NN||could-24/MD	advmod||therapy-30/NN||potentially-25/RB	cop||therapy-30/NN||be-26/VB	det||therapy-30/NN||a-27/DT	amod||adjuvant-29/JJ||useful-28/JJ	amod||therapy-30/NN||adjuvant-29/JJ	ccomp||suggesting-20/VBG||therapy-30/NN	prep_for||therapy-30/NN||obesity-32/NN	prep_for||therapy-30/NN||type2diabetes-34/NNS	conj_and||obesity-32/NN||type2diabetes-34/NNS	adjuvant-29||type2diabetes-34||no_rel||we have previously shown that dietary leucine supplementation significantly improves glucose and energy metabolism in diet-induced obese mice, suggesting that leucine supplementation could potentially be a useful adjuvant therapy for obesity and type2diabetes.
prep_on||6â-3/VBD||days-2/NNS	root||ROOT-0/null||6â-3/VBD	dobj||6â-3/VBD||$-4/$	dep||dextrose-23/NN||8-6/CD	nn||therapy-9/NN||levofloxacin-8/NN	prep_of||8-6/CD||therapy-9/NN	det||hypoglycaemia-15/NN||the-11/DT	amod||experienced-13/JJ||patient-12/JJ	amod||hypoglycaemia-15/NN||experienced-13/JJ	nn||hypoglycaemia-15/NN||recurrent-14/NN	appos||therapy-9/NN||hypoglycaemia-15/NN	amod||nutrition-19/NN||total-17/JJ	amod||nutrition-19/NN||parenteral-18/JJ	prep_despite||8-6/CD||nutrition-19/NN	number||%-22/NN||10-21/CD	amod||dextrose-23/NN||%-22/NN	npadvmod||fluids-25/JJR||dextrose-23/NN	num||dextrose-23/NN||containing-24/CD	amod||insulin-29/NNS||fluids-25/JJR	conj_and||fluids-25/JJR||cessation-27/JJ	amod||insulin-29/NNS||cessation-27/JJ	dep||cessation-27/JJ||of-28/IN	npadvmod||therapy-30/RB||insulin-29/NNS	dep||3-31/CD||therapy-30/RB	num||$-4/$||3-31/CD	nsubj||6â-3/VBD||days-32/NNS	det||episode-38/NN||the-35/DT	amod||episode-38/NN||first-36/JJ	amod||episode-38/NN||hypoglycaemic-37/JJ	prep_prior_to||days-32/NNS||episode-38/NN	hypoglycaemia-15||dextrose-23||yes||on days 6â8 of levofloxacin therapy, the patient experienced recurrent hypoglycaemia despite total parenteral nutrition, 10% dextrose containing fluids and cessation of insulin therapy 3 days prior to the first hypoglycaemic episode.
poss||pharmacokinetics-4/NNS||their-2/PRP$	amod||pharmacokinetics-4/NNS||long-acting-3/JJ	prep_despite||associated-14/VBN||pharmacokinetics-4/NNS	det||use-7/NN||the-6/DT	nsubjpass||associated-14/VBN||use-7/NN	prep_of||use-7/NN||insulinglargine-9/NN	prep_of||use-7/NN||detemir-11/NN	conj_or||insulinglargine-9/NN||detemir-11/NN	auxpass||associated-14/VBN||is-12/VBZ	neg||associated-14/VBN||not-13/RB	root||ROOT-0/null||associated-14/VBN	det||incidence-18/NN||a-16/DT	amod||incidence-18/NN||lower-17/JJR	prep_with||associated-14/VBN||incidence-18/NN	prep_of||incidence-18/NN||dka-20/NN	prepc_compared_with||associated-14/VBN||with-22/IN	pobj||associated-14/VBN||nphinsulin-23/NN	insulinglargine-9||dka-20||no_rel||despite their long-acting pharmacokinetics, the use of insulinglargine or detemir is not associated with a lower incidence of dka compared with nphinsulin.
amod||antigen-3/NN||hepatitisb-1/JJ	nn||antigen-3/NN||surface-2/NN	nsubj||served-9/VBN||antigen-3/NN	nsubjpass||detected-18/VBN||antigen-3/NN	appos||antigen-3/NN||hbsag-5/NN	rcmod||antigen-3/NN||served-9/VBN	det||marker-12/NN||the-11/DT	prep_as||served-9/VBN||marker-12/NN	nn||infection-15/NN||hbv-14/NN	prep_of||marker-12/NN||infection-15/NN	auxpass||detected-18/VBN||was-17/VBD	root||ROOT-0/null||detected-18/VBN	det||sandwich-23/NN||a-20/DT	amod||sandwich-23/NN||double-21/JJ	nn||sandwich-23/NN||antibody-22/NN	prep_in||detected-18/VBN||sandwich-23/NN	vmod||sandwich-23/NN||using-24/VBG	num||antibodies-27/NNS||two-25/CD	amod||antibodies-27/NNS||monoclonal-26/JJ	dobj||using-24/VBG||antibodies-27/NNS	appos||antibodies-27/NNS||mabs-29/NNS	nsubj||biotinylated-34/VBD||one-32/PRP	nsubj||capture-36/VB||one-32/PRP	advmod||biotinylated-34/VBD||chemically-33/RB	ccomp||detected-18/VBN||biotinylated-34/VBD	conj_and||detected-18/VBN||biotinylated-34/VBD	aux||capture-36/VB||to-35/TO	xcomp||biotinylated-34/VBD||capture-36/VB	det||other-40/JJ||the-39/DT	nsubj||labeled-41/VBD||other-40/JJ	nsubj||reveal-48/VB||other-40/JJ	conj_and||detected-18/VBN||labeled-41/VBD	amod||nanoparticles-45/NNS||eu3-43/JJ	amod||nanoparticles-45/NNS||+-44/JJ	prep_with||labeled-41/VBD||nanoparticles-45/NNS	aux||reveal-48/VB||to-47/TO	xcomp||labeled-41/VBD||reveal-48/VB	hbv-14||hbsag-5||yes||hepatitisb surface antigen (hbsag), which served as the marker of hbv infection, was detected in a double antibody sandwich using two monoclonal antibodies (mabs), one chemically biotinylated to capture, and the other labeled with eu3+ nanoparticles, to reveal.
det||study-2/NN||this-1/DT	nsubjpass||conducted-4/VBN||study-2/NN	nsubj||compare-6/VB||study-2/NN	auxpass||conducted-4/VBN||was-3/VBD	root||ROOT-0/null||conducted-4/VBN	aux||compare-6/VB||to-5/TO	xcomp||conducted-4/VBN||compare-6/VB	det||efficacy-8/NN||the-7/DT	dobj||compare-6/VB||efficacy-8/NN	det||combination-11/NN||a-10/DT	prep_of||efficacy-8/NN||combination-11/NN	prep_of||combination-11/NN||ondansetron-13/NN	prep_of||combination-11/NN||dexamethasone-15/NN	conj_and||ondansetron-13/NN||dexamethasone-15/NN	prep_with||compare-6/VB||that-17/DT	nn||analgesia-36/NN||metoclopramide-19/NN	conj_and||metoclopramide-19/NN||dexamethasone-21/JJ	nn||analgesia-36/NN||dexamethasone-21/JJ	prep_for||dexamethasone-21/JJ||prevention-23/NN	prepc_of||prevention-23/NN||postoperativenauseaandvomiting-25/VBG	dobj||postoperativenauseaandvomiting-25/VBG||ponv-27/NNP	amod||patients-31/NNS||gynecologic-30/JJ	prep_in||ponv-27/NNP||patients-31/NNS	vmod||patients-31/NNS||receiving-32/VBG	amod||analgesia-36/NN||fentanyl-33/JJ	amod||analgesia-36/NN||iv-patient-34/JJ	amod||analgesia-36/NN||controlled-35/VBN	prep_of||that-17/DT||analgesia-36/NN	postoperativenauseaandvomiting-25||metoclopramide-19||yes||this study was conducted to compare the efficacy of a combination of ondansetron and dexamethasone with that of metoclopramide and dexamethasone for prevention of postoperativenauseaandvomiting (ponv) in gynecologic patients receiving fentanyl iv-patient controlled analgesia.
amod||findings-2/NNS||above-1/JJ	nsubj||facilitate-4/VB||findings-2/NNS	nsubj||further-26/VB||findings-2/NNS	aux||facilitate-4/VB||might-3/MD	root||ROOT-0/null||facilitate-4/VB	det||application-7/NN||the-5/DT	amod||application-7/NN||prophylactic-6/JJ	dobj||facilitate-4/VB||application-7/NN	amod||products-10/NNS||natural-9/JJ	prep_of||application-7/NN||products-10/NNS	det||realization-13/NN||the-12/DT	dobj||facilitate-4/VB||realization-13/NN	conj_and||application-7/NN||realization-13/NN	amod||drugs-17/NNS||novel-15/JJ	amod||drugs-17/NNS||anti-influenza-16/JJ	prep_of||realization-13/NN||drugs-17/NNS	prepc_based_on||facilitate-4/VB||on-19/IN	amod||acids-21/NNS||caffeoylquinic-20/JJ	pobj||facilitate-4/VB||acids-21/NNS	conj_and||facilitate-4/VB||further-26/VB	det||understanding-28/NN||the-27/DT	dobj||further-26/VB||understanding-28/NN	amod||mechanisms-32/NNS||cytoprotective-30/JJ	nn||mechanisms-32/NNS||intracellular-31/NN	prep_of||understanding-28/NN||mechanisms-32/NNS	amod||cells-35/NNS||influenzavirus-infected-34/JJ	prep_in||further-26/VB||cells-35/NNS	influenza--1||influenzavirus--1||no||above findings might facilitate the prophylactic application of natural products and the realization of novel anti-influenza drugs based on caffeoylquinic acids, as well as further the understanding of cytoprotective intracellular mechanisms in influenzavirus-infected cells.
nsubjpass||diagnosed-4/VBN||she-1/PRP	nsubjpass||given-9/VBN||she-1/PRP	auxpass||diagnosed-4/VBN||was-2/VBD	advmod||diagnosed-4/VBN||erroneously-3/RB	root||ROOT-0/null||diagnosed-4/VBN	amod||tuberculosis-7/NNP||abdominal-6/JJ	prep_as||diagnosed-4/VBN||tuberculosis-7/NNP	conj_and||diagnosed-4/VBN||given-9/VBN	iobj||given-9/VBN||antituberculosis-10/NNS	dobj||given-9/VBN||drugs-11/NNS	prep_with||showed-15/VBD||drugs-11/NNS	nsubj||showed-15/VBD||she-14/PRP	rcmod||drugs-11/NNS||showed-15/VBD	neg||improvement-17/NN||no-16/DT	dobj||showed-15/VBD||improvement-17/NN	tuberculosis-7||antituberculosis-10||yes||she was erroneously diagnosed as abdominal tuberculosis and given antituberculosis drugs with which she showed no improvement.
det||study-2/NN||this-1/DT	nsubj||demonstrated-3/VBD||study-2/NN	root||ROOT-0/null||demonstrated-3/VBD	mark||higher-18/JJR||that-4/IN	csubj||higher-18/JJR||circulating-5/VBG	nn||plasmablasts-8/NNS||igg-6/NN	nn||plasmablasts-8/NNS||+-7/NN	dobj||circulating-5/VBG||plasmablasts-8/NNS	amod||secretion-11/NN||spontaneous-10/JJ	dobj||circulating-5/VBG||secretion-11/NN	conj_and||plasmablasts-8/NNS||secretion-11/NN	amod||antibodies-15/NNS||bcg-specific-13/JJ	nn||antibodies-15/NNS||igg-14/NN	prep_of||secretion-11/NN||antibodies-15/NNS	cop||higher-18/JJR||were-16/VBD	advmod||higher-18/JJR||significantly-17/RB	ccomp||demonstrated-3/VBD||higher-18/JJR	prep_in||higher-18/JJR||patients-20/NNS	amod||tb-23/NN||active-22/JJ	prep_with||patients-20/NNS||tb-23/NN	prepc_compared_with||higher-18/JJR||with-25/IN	nn||cases-28/NNS||latent-26/NN	nn||cases-28/NNS||tb-27/NN	pobj||higher-18/JJR||cases-28/NNS	amod||controls-31/NNS||non-tb-30/JJ	pobj||higher-18/JJR||controls-31/NNS	conj_and||cases-28/NNS||controls-31/NNS	tb-27||bcg--1||yes||this study demonstrated that circulating igg+ plasmablasts and spontaneous secretion of bcg-specific igg antibodies were significantly higher in patients with active tb compared with latent tb cases and non-tb controls.
amod||management-2/NN||obstetric-1/JJ	nsubj||focuses-6/VBZ||management-2/NN	amod||pre-eclampsia-5/NN||severe-4/JJ	prep_of||management-2/NN||pre-eclampsia-5/NN	root||ROOT-0/null||focuses-6/VBZ	amod||management-9/NN||medical-8/JJ	prep_on||focuses-6/VBZ||management-9/NN	nn||pressure-12/NN||blood-11/NN	prep_of||management-9/NN||pressure-12/NN	prep_of||management-9/NN||prevention-14/NN	conj_and||pressure-12/NN||prevention-14/NN	prep_of||management-9/NN||seizures-16/NNS	vmod||seizures-16/NNS||using-17/VBG	dobj||using-17/VBG||magnesiumsulfate-18/NN	det||cure-23/NN||the-21/DT	amod||cure-23/NN||ultimate-22/JJ	nsubj||remains-24/VBZ||cure-23/NN	conj_but||focuses-6/VBZ||remains-24/VBZ	xcomp||remains-24/VBZ||delivery-25/NN	det||fetus-28/NN||the-27/DT	prep_of||delivery-25/NN||fetus-28/NN	prep_of||delivery-25/NN||placenta-30/NN	conj_and||fetus-28/NN||placenta-30/NN	seizures-16||magnesiumsulfate-18||yes||obstetric management of severe pre-eclampsia focuses on medical management of blood pressure and prevention of seizures using magnesiumsulfate, but the ultimate cure remains delivery of the fetus and placenta.
poss||laboratory-3/NN||our-2/PRP$	prep_in||address-6/VBP||laboratory-3/NN	nsubj||address-6/VBP||we-5/PRP	root||ROOT-0/null||address-6/VBP	advmod||unsettled-8/VBN||still-7/RB	amod||questions-9/NNS||unsettled-8/VBN	nsubj||ellipticine-47/VBP||questions-9/NNS	nsubj||mechanism-51/NN||questions-9/NNS	prep_of||ellipticine-47/VBP||mechanisms-13/NNS	prep_of||mechanisms-13/NNS||action-15/NN	amod||drugs-18/NNS||dna-damaging-17/JJ	prep_of||action-15/NN||drugs-18/NNS	nsubj||use-21/VBP||both-19/DT	advmod||use-21/VBP||currently-20/RB	rcmod||mechanisms-13/NNS||use-21/VBP	prep_for||use-21/VBP||treatment-23/NN	amod||neuroblastomas-26/NNS||human-25/JJ	prep_of||treatment-23/NN||neuroblastomas-26/NNS	dep||mechanisms-13/NNS||doxorubicin-28/NN	dep||mechanisms-13/NNS||cis-platin-30/NN	conj_and||doxorubicin-28/NN||cis-platin-30/NN	dep||mechanisms-13/NNS||cyclophosphamide-32/NN	conj_and||doxorubicin-28/NN||cyclophosphamide-32/NN	dep||mechanisms-13/NNS||etoposide-34/NN	conj_and||doxorubicin-28/NN||etoposide-34/NN	det||growth-41/NN||another-37/DT	amod||growth-41/NN||anticancer-38/JJ	nn||growth-41/NN||agent-39/NN	amod||growth-41/NN||decreasing-40/VBG	conj_and||mechanisms-13/NNS||growth-41/NN	prep_of||ellipticine-47/VBP||growth-41/NN	prep_of||growth-41/NN||neuroblastomas-43/NNS	prep_in||neuroblastomas-43/NNS||vitro-45/NNP	rcmod||questions-9/NNS||ellipticine-47/VBP	cop||mechanism-51/NN||are-49/VBP	amod||mechanism-51/NN||predominant-50/JJ	ccomp||address-6/VBP||mechanism-51/NN	dep||mechanism-51/NN||s-53/PRP	amod||mechanism-51/NN||responsible-55/JJ	poss||action-59/NN||their-57/PRP$	nn||action-59/NN||antitumor-58/NN	prep_for||responsible-55/JJ||action-59/NN	nn||lines-63/NNS||neuroblastoma-61/NN	nn||lines-63/NNS||cell-62/NN	prep_in||mechanism-51/NN||lines-63/NNS	prep_in||mechanism-51/NN||vitro-65/NN	neuroblastomas-43||cyclophosphamide-32||yes||in our laboratory, we address still unsettled questions, which of mechanisms of action of dna-damaging drugs both currently use for treatment of human neuroblastomas (doxorubicin, cis-platin, cyclophosphamide and etoposide) and another anticancer agent decreasing growth of neuroblastomas in vitro , ellipticine, are predominant mechanism(s) responsible for their antitumor action in neuroblastoma cell lines in vitro .
nsubjpass||detected-5/VBN||immunoreactivity-1/NN	prep_against||immunoreactivity-1/NN||hbz-3/NN	auxpass||detected-5/VBN||was-4/VBD	root||ROOT-0/null||detected-5/VBN	prep_in||detected-5/VBN||subsets-7/NNS	det||individuals-11/NNS||all-9/DT	amod||individuals-11/NNS||htlv-1-infected-10/JJ	prep_of||subsets-7/NNS||individuals-11/NNS	det||test-14/NN||the-13/DT	nsubj||did-15/VBD||test-14/NN	conj_but||detected-5/VBN||did-15/VBD	neg||discriminate-17/JJ||not-16/RB	dobj||did-15/VBD||discriminate-17/JJ	prep_between||discriminate-17/JJ||ac-19/NN	prep_between||discriminate-17/JJ||atl-21/NN	conj_and||ac-19/NN||atl-21/NN	prep_between||discriminate-17/JJ||ham/tsp-23/NN	conj_and||ac-19/NN||ham/tsp-23/NN	ham--1||htlv-1--1||no||immunoreactivity against hbz was detected in subsets of all htlv-1-infected individuals but the test did not discriminate between ac, atl and ham/tsp.
aux||compare-2/VB||to-1/TO	csubj||adjuncts-16/VBZ||compare-2/VB	conj_and||compare-2/VB||evaluate-4/VB	csubj||adjuncts-16/VBZ||evaluate-4/VB	det||effect-6/NN||the-5/DT	dobj||compare-2/VB||effect-6/NN	prepc_of||effect-6/NN||adding-8/VBG	npadvmod||as-15/RB||ketamine-9/NN	conj_or||ketamine-9/NN||nitroglycerin-11/NN	npadvmod||as-15/RB||nitroglycerin-11/NN	appos||ketamine-9/NN||ntg-13/NN	advmod||adding-8/VBG||as-15/RB	root||ROOT-0/null||adjuncts-16/VBZ	aux||lidocaine-18/VB||to-17/TO	xcomp||adjuncts-16/VBZ||lidocaine-18/VB	amod||anesthesia-22/NN||intravenous-20/JJ	amod||anesthesia-22/NN||regional-21/JJ	prep_for||lidocaine-18/VB||anesthesia-22/NN	appos||anesthesia-22/NN||ivra-24/NNP	prep_on||anesthesia-22/NN||intraoperative-27/NN	xcomp||adjuncts-16/VBZ||postoperative-29/VB	conj_and||lidocaine-18/VB||postoperative-29/VB	nn||times-37/NNS||analgesia-30/NN	conj_and||analgesia-30/NN||sensorial-32/NN	nn||times-37/NNS||sensorial-32/NN	conj_and||analgesia-30/NN||motor-34/NN	nn||times-37/NNS||motor-34/NN	nn||times-37/NNS||block-35/NN	nn||times-37/NNS||onset-36/NN	dobj||postoperative-29/VB||times-37/NNS	xcomp||adjuncts-16/VBZ||tourniquet-40/VB	conj_and||lidocaine-18/VB||tourniquet-40/VB	dobj||tourniquet-40/VB||pain-41/NN	pain-41||ketamine-9||yes||to compare and evaluate the effect of adding ketamine or nitroglycerin (ntg) as adjuncts to lidocaine for intravenous regional anesthesia (ivra) on intraoperative and postoperative analgesia, sensorial and motor block onset times, and tourniquet pain.
amod||lines-2/NNS||several-1/JJ	nsubj||support-5/VBP||lines-2/NNS	prep_of||lines-2/NNS||evidence-4/NN	root||ROOT-0/null||support-5/VBP	det||notion-7/NN||the-6/DT	dobj||support-5/VBP||notion-7/NN	mark||predispose-13/VB||that-8/IN	amod||viscosity-11/NN||elevated-9/JJ	nn||viscosity-11/NN||blood-10/NN	nsubj||predispose-13/VB||viscosity-11/NN	aux||predispose-13/VB||may-12/MD	ccomp||support-5/VBP||predispose-13/VB	prep_to||predispose-13/VB||insulinresistance-15/NN	prep_to||predispose-13/VB||type2diabetesmellitus-17/NNS	conj_and||insulinresistance-15/NN||type2diabetesmellitus-17/NNS	prepc_by||predispose-13/VB||limiting-19/VBG	dobj||limiting-19/VBG||delivery-20/NN	prep_of||delivery-20/NN||glucose-22/NN	prep_of||delivery-20/NN||insulin-24/NN	conj_and||glucose-22/NN||insulin-24/NN	prep_of||delivery-20/NN||oxygen-27/NN	conj_and||glucose-22/NN||oxygen-27/NN	advmod||active-30/JJ||metabolically-29/RB	amod||tissues-31/NNS||active-30/JJ	prep_to||glucose-22/NN||tissues-31/NNS	type2diabetesmellitus-17||insulin-24||yes||several lines of evidence support the notion that elevated blood viscosity may predispose to insulinresistance and type2diabetesmellitus by limiting delivery of glucose, insulin, and oxygen to metabolically active tissues.
advmod||less-5/JJR||however-1/RB	nsubj||less-5/JJR||sodiumretention-3/NN	cop||less-5/JJR||is-4/VBZ	root||ROOT-0/null||less-5/JJR	advmod||restricted-15/VBN||when-6/WRB	csubjpass||restricted-15/VBN||given-7/VBN	amod||intake-12/NN||sodiumbicarbonate-9/JJ	conj_and||sodiumbicarbonate-9/JJ||sodiumchloride-11/JJ	amod||intake-12/NN||sodiumchloride-11/JJ	prep_as||given-7/VBN||intake-12/NN	auxpass||restricted-15/VBN||is-13/VBZ	advmod||restricted-15/VBN||concomitantly-14/RB	advcl||less-5/JJR||restricted-15/VBN	sodiumretention-3||sodiumbicarbonate-9||no||however, sodiumretention is less when given as sodiumbicarbonate and sodiumchloride intake is concomitantly restricted.
det||study-2/NN||this-1/DT	nsubj||aimed-3/VBD||study-2/NN	nsubj||investigate-5/VB||study-2/NN	root||ROOT-0/null||aimed-3/VBD	aux||investigate-5/VB||to-4/TO	xcomp||aimed-3/VBD||investigate-5/VB	mark||had-11/VBD||whether-6/IN	amod||polymorphisms-10/NNS||cyp2b6-7/JJ	conj_or||cyp2b6-7/JJ||cyp3a4-9/JJ	amod||polymorphisms-10/NNS||cyp3a4-9/JJ	nsubj||had-11/VBD||polymorphisms-10/NNS	ccomp||investigate-5/VB||had-11/VBD	dobj||had-11/VBD||effects-12/NNS	nn||efavirenz-15/NN||plasma-14/NN	prep_on||effects-12/NNS||efavirenz-15/NN	nn||concentrations-18/NNS||nevirapine-17/NN	prep_on||effects-12/NNS||concentrations-18/NNS	conj_and||efavirenz-15/NN||concentrations-18/NNS	advmod||co-administered-20/VBN||when-19/WRB	advcl||aimed-3/VBD||co-administered-20/VBN	prep_with||co-administered-20/VBN||rifampicin-22/NN	amod||adults-27/NNS||hiv/tb-24/JJ	amod||adults-27/NNS||co-infected-25/JJ	nn||adults-27/NNS||thai-26/NN	prep_in||rifampicin-22/NN||adults-27/NNS	tb--1||rifampicin-22||yes||this study aimed to investigate whether cyp2b6 or cyp3a4 polymorphisms had effects on plasma efavirenz and nevirapine concentrations when co-administered with rifampicin in hiv/tb co-infected thai adults.
nsubj||ovarian-10/VBP||a2780cis-1/NNS	appos||a2780cis-1/NNS||cisplatin-resistant-3/NN	conj_and||a2780cis-1/NNS||a2780-6/NNS	nsubj||ovarian-10/VBP||a2780-6/NNS	dep||a2780-6/NNS||cisplatin-sensitive-8/JJ	root||ROOT-0/null||ovarian-10/VBP	nn||lines-13/NNS||carcinoma-11/NN	nn||lines-13/NNS||cell-12/NN	nsubjpass||used-15/VBN||lines-13/NNS	auxpass||used-15/VBN||were-14/VBD	ccomp||ovarian-10/VBP||used-15/VBN	carcinoma-11||cisplatin--1||no_rel||a2780cis (cisplatin-resistant) and a2780 (cisplatin-sensitive) ovarian carcinoma cell lines were used.
root||ROOT-0/null||adding-1/VBG	acomp||adding-1/VBG||trastuzumab-2/JJ	prep_to||trastuzumab-2/JJ||chemotherapy-4/NN	dep||adding-1/VBG||improved-5/VBD	det||survival-7/NN||the-6/DT	dobj||improved-5/VBD||survival-7/NN	prep_of||survival-7/NN||patients-9/NNS	amod||cancer-13/NN||advanced-11/VBN	amod||cancer-13/NN||gastric-12/JJ	prep_with||improved-5/VBD||cancer-13/NN	vmod||cancer-13/NN||overexpressing-14/VBG	amod||receptor-19/NN||human-15/JJ	nn||receptor-19/NN||epidermal-16/NN	nn||receptor-19/NN||growth-17/NN	nn||receptor-19/NN||factor-18/NN	dobj||overexpressing-14/VBG||receptor-19/NN	nsubj||adding-1/VBG||2-20/CD	cancer-13||trastuzumab-2||no_rel||adding trastuzumab to chemotherapy improved the survival of patients with advanced gastric cancer overexpressing human epidermal growth factor receptor 2.
poss||results-2/NNS||our-1/PRP$	nsubj||suggest-14/VBP||results-2/NNS	vmod||results-2/NNS||based-4/VBN	prep_on||based-4/VBN||analysis-6/NN	prep_of||analysis-6/NN||s.aureus-8/NNS	vmod||s.aureus-8/NNS||isolated-9/VBN	amod||samples-12/NNS||nasopharyngeal-11/JJ	prep_from||isolated-9/VBN||samples-12/NNS	root||ROOT-0/null||suggest-14/VBP	mark||remains-27/VBZ||that-15/IN	prep_in||remains-27/VBZ||portugal-17/NN	det||prevalence-19/NN||the-18/DT	nsubj||remains-27/VBZ||prevalence-19/NN	amod||carriage-22/NN||ca-mrsa-21/JJ	prep_of||prevalence-19/NN||carriage-22/NN	amod||children-26/NNS||healthy-24/JJ	amod||children-26/NNS||young-25/JJ	prep_in||carriage-22/NN||children-26/NNS	ccomp||suggest-14/VBP||remains-27/VBZ	advmod||low-29/JJ||extremely-28/RB	acomp||remains-27/VBZ||low-29/JJ	xcomp||remains-27/VBZ||favoring-30/VBG	det||exclusion-32/NN||the-31/DT	dobj||favoring-30/VBG||exclusion-32/NN	det||group-35/NN||this-34/DT	prep_of||exclusion-32/NN||group-35/NN	det||reservoir-38/NN||a-37/DT	prep_as||favoring-30/VBG||reservoir-38/NN	amod||isolates-41/NNS||such-40/JJ	prep_of||reservoir-38/NN||isolates-41/NNS	mrsa--1||s.aureus-8||no||our results , based on analysis of s.aureus isolated from nasopharyngeal samples , suggest that in portugal the prevalence of ca-mrsa carriage in healthy young children remains extremely low favoring the exclusion of this group as a reservoir of such isolates .
amod||reactivation-2/NN||pharmacological-1/JJ	nsubjpass||suggested-23/VBN||reactivation-2/NN	nsubj||eradicate-28/VB||reactivation-2/NN	amod||expression-8/NN||humanimmunodeficiencyvirus-4/JJ	appos||expression-8/NN||hiv-6/NN	prep_of||reactivation-2/NN||expression-8/NN	nn||proviruses-11/NNS||latent-10/NN	prep_from||expression-8/NN||proviruses-11/NNS	vmod||proviruses-11/NNS||coupled-12/VBN	advmod||suppressive-15/JJ||fully-14/RB	amod||therapy-17/NN||suppressive-15/JJ	amod||therapy-17/NN||antiretroviral-16/JJ	prep_with||coupled-12/VBN||therapy-17/NN	appos||therapy-17/NN||art-19/NN	aux||suggested-23/VBN||has-21/VBZ	auxpass||suggested-23/VBN||been-22/VBN	root||ROOT-0/null||suggested-23/VBN	det||strategy-26/NN||a-25/DT	prep_as||suggested-23/VBN||strategy-26/NN	aux||eradicate-28/VB||to-27/TO	xcomp||suggested-23/VBN||eradicate-28/VB	dobj||eradicate-28/VB||hivinfection-29/NN	hivinfection-29||hiv-6||no||pharmacological reactivation of humanimmunodeficiencyvirus (hiv) expression from latent proviruses coupled with fully suppressive antiretroviral therapy (art) has been suggested as a strategy to eradicate hivinfection.
det||discovery-2/NN||the-1/DT	nsubj||provides-42/VBZ||discovery-2/NN	mark||1-12/CD||that-3/IN	det||inhibitor-7/NN||the-4/DT	amod||inhibitor-7/NN||renin-angiotensin-5/JJ	nn||inhibitor-7/NN||system-6/NN	nsubj||1-12/CD||inhibitor-7/NN	nn||type-11/NN||angiotensin-9/NN	nn||type-11/NN||ii-10/NN	conj_and||inhibitor-7/NN||type-11/NN	nsubj||1-12/CD||type-11/NN	dep||discovery-2/NN||1-12/CD	appos||1-12/CD||at1-14/NNP	nn||blocker-17/NN||receptor-16/NN	nsubj||activate-26/VB||blocker-17/NN	appos||blocker-17/NN||arb-19/NN	appos||blocker-17/NN||telmisartan-22/NN	aux||activate-26/VB||can-24/MD	advmod||activate-26/VB||selectively-25/RB	rcmod||1-12/CD||activate-26/VB	det||³-31/NN||the-27/DT	amod||³-31/NN||peroxisome-28/JJ	amod||³-31/NN||proliferator-activated-29/JJ	amod||³-31/NN||receptor-î-30/JJ	dobj||activate-26/VB||³-31/NN	nn||³-34/NNP||pparî-33/NNP	dep||1-12/CD||³-34/NNP	det||target-40/NN||an-36/DT	amod||target-40/NN||established-37/JJ	amod||target-40/NN||antidiabetic-38/JJ	nn||target-40/NN||drug-39/NN	appos||³-34/NNP||target-40/NN	root||ROOT-0/null||provides-42/VBZ	det||opportunity-45/NN||the-43/DT	amod||opportunity-45/NN||unique-44/JJ	dobj||provides-42/VBZ||opportunity-45/NN	aux||prevent-47/VB||to-46/TO	vmod||opportunity-45/NN||prevent-47/VB	vmod||opportunity-45/NN||treat-49/VB	conj_and||prevent-47/VB||treat-49/VB	amod||complications-51/NNS||cardiovascular-50/JJ	dobj||prevent-47/VB||complications-51/NNS	amod||patients-55/NNS||high-risk-53/JJ	amod||patients-55/NNS||elderly-54/JJ	prep_in||complications-51/NNS||patients-55/NNS	nn||diabetes-60/NN||hypertension-57/NN	conj_and||hypertension-57/NN||new-onset-59/NN	nn||diabetes-60/NN||new-onset-59/NN	prep_with||prevent-47/VB||diabetes-60/NN	hypertension-57||telmisartan-22||yes||the discovery that the renin-angiotensin system inhibitor and angiotensin ii type 1 (at1) receptor blocker (arb), telmisartan, can selectively activate the peroxisome proliferator-activated receptor-î³ (pparî³, an established antidiabetic drug target) provides the unique opportunity to prevent and treat cardiovascular complications in high-risk elderly patients with hypertension and new-onset diabetes.
det||dose-3/NN||the-2/DT	prep_at||able-10/JJ||dose-3/NN	num||mg/kg-6/NN||15-5/CD	prep_of||dose-3/NN||mg/kg-6/NN	nsubj||able-10/JJ||mq-8/NN	nsubj||rescue-12/VB||mq-8/NN	cop||able-10/JJ||was-9/VBD	root||ROOT-0/null||able-10/JJ	aux||rescue-12/VB||to-11/TO	xcomp||able-10/JJ||rescue-12/VB	nsubj||tested-14/VBD||all-13/DT	ccomp||rescue-12/VB||tested-14/VBD	dobj||tested-14/VBD||aspects-15/NNS	amod||impairment-18/NN||cognitive-17/JJ	prep_of||aspects-15/NNS||impairment-18/NN	amod||memory-29/NN||spatial-20/JJ	conj_and||spatial-20/JJ||episodic-22/JJ	amod||memory-29/NN||episodic-22/JJ	conj_and||spatial-20/JJ||aversive-24/JJ	amod||memory-29/NN||aversive-24/JJ	conj_and||spatial-20/JJ||short-26/JJ	amod||memory-29/NN||short-26/JJ	conj_and||spatial-20/JJ||long-term-28/JJ	amod||memory-29/NN||long-term-28/JJ	prep_including||impairment-18/NN||memory-29/NN	det||models-40/NNS||both-31/DT	amod||models-40/NNS||scopolamine-32/JJ	advmod||²-36/JJ||aî-35/RB	conj_and||scopolamine-32/JJ||²-36/JJ	amod||models-40/NNS||²-36/JJ	amod||models-40/NNS||induced-38/JJ	nn||models-40/NNS||amnesia-39/NN	prep_in||memory-29/NN||models-40/NNS	amnesia-39||scopolamine-32||no||at the dose of 15 mg/kg, mq was able to rescue all tested aspects of cognitive impairment including spatial, episodic, aversive, short and long-term memory in both scopolamine- and aî²-induced amnesia models.
det||study-3/NN||this-2/DT	prep_in||characterized-6/VBD||study-3/NN	nsubj||characterized-6/VBD||we-5/PRP	root||ROOT-0/null||characterized-6/VBD	amod||changes-9/NNS||early-7/JJ	amod||changes-9/NNS||biochemical-8/JJ	dobj||characterized-6/VBD||changes-9/NNS	vmod||changes-9/NNS||associated-10/VBN	nn||administration-15/NN||sertraline-12/NN	conj_and||sertraline-12/NN||placebo-14/NN	nn||administration-15/NN||placebo-14/NN	prep_with||associated-10/VBN||administration-15/NN	dobj||characterized-6/VBD||changes-17/NNS	conj_and||changes-9/NNS||changes-17/NNS	vmod||changes-17/NNS||associated-18/VBN	det||reduction-21/NN||a-20/DT	prep_with||associated-18/VBN||reduction-21/NN	amod||symptoms-24/NNS||depressive-23/JJ	prep_in||reduction-21/NN||symptoms-24/NNS	prep_in||associated-18/VBN||patients-26/NNS	amod||depressivedisorder-29/NN||major-28/JJ	prep_with||patients-26/NNS||depressivedisorder-29/NN	appos||depressivedisorder-29/NN||mdd-31/NN	depressivedisorder-29||sertraline-12||yes||in this study, we characterized early biochemical changes associated with sertraline and placebo administration and changes associated with a reduction in depressive symptoms in patients with major depressivedisorder (mdd).
det||study-2/NN||this-1/DT	nsubj||anopheles-14/VBZ||study-2/NN	vmod||study-2/NN||used-3/VBN	det||bassiana-7/NN||the-4/DT	nn||bassiana-7/NN||fungus-5/NN	nn||bassiana-7/NN||beauveria-6/NN	dobj||used-3/VBN||bassiana-7/NN	aux||infect-9/VB||to-8/TO	vmod||used-3/VBN||infect-9/VB	det||vector-13/NN||the-10/DT	amod||vector-13/NN||insecticide-resistant-11/JJ	nn||vector-13/NN||malaria-12/NN	dobj||infect-9/VB||vector-13/NN	root||ROOT-0/null||anopheles-14/VBZ	amod||s.s-16/NN||gambiae-15/JJ	nsubj||vkper-21/VBP||s.s-16/NN	nn||culicidae-19/NN||diptera-18/NN	appos||s.s-16/NN||culicidae-19/NN	ccomp||anopheles-14/VBZ||vkper-21/VBP	nn||strain-24/NN||laboratory-22/NN	nn||strain-24/NN||colony-23/NN	dobj||vkper-21/VBP||strain-24/NN	insecticide--1||malaria-12||no_rel||this study used the fungus beauveria bassiana to infect the insecticide-resistant malaria vector anopheles gambiae s.s (diptera culicidae) vkper laboratory colony strain.
nsubj||reported-3/VBD||we-1/PRP	advmod||reported-3/VBD||previously-2/RB	root||ROOT-0/null||reported-3/VBD	amod||aggregation-5/NN||familial-4/JJ	dobj||reported-3/VBD||aggregation-5/NN	amod||response-8/NN||flush-7/JJ	prep_in||reported-3/VBD||response-8/NN	aux||niacin-10/VB||to-9/TO	vmod||reported-3/VBD||niacin-10/VB	nn||patch-12/NN||skin-11/NN	dobj||niacin-10/VB||patch-12/NN	nn||patients-15/NNS||schizophrenia-14/NN	prep_among||niacin-10/VB||patients-15/NNS	poss||relatives-19/NNS||their-17/PRP$	amod||relatives-19/NNS||nonpsychotic-18/JJ	prep_among||niacin-10/VB||relatives-19/NNS	conj_and||patients-15/NNS||relatives-19/NNS	flush-7||niacin-10||no||we previously reported familial aggregation in flush response to niacin skin patch among schizophrenia patients and their nonpsychotic relatives.
nsubjpass||evaluated-3/VBN||subjects-1/NNS	auxpass||evaluated-3/VBN||were-2/VBD	root||ROOT-0/null||evaluated-3/VBN	prep_for||evaluated-3/VBN||diabeticnephropathy-5/NN	amod||rate-11/NN||24-h-7/JJ	nn||rate-11/NN||urinary-8/NN	nn||rate-11/NN||albumin-9/NN	nn||rate-11/NN||excretion-10/NN	dep||diabeticnephropathy-5/NN||rate-11/NN	prep_for||evaluated-3/VBN||diabeticretinopathy-14/NN	conj_and||diabeticnephropathy-5/NN||diabeticretinopathy-14/NN	dep||diabeticretinopathy-14/NN||classified-16/VBN	prepc_according_to||classified-16/VBN||to-18/TO	det||group-22/NN||the-19/DT	amod||group-22/NN||global-20/JJ	nn||group-22/NN||diabeticretinopathy-21/NN	pobj||classified-16/VBN||group-22/NN	diabeticretinopathy-21||albumin-9||no_rel||subjects were evaluated for diabeticnephropathy (24-h urinary albumin excretion rate) and diabeticretinopathy (classified according to the global diabeticretinopathy group).
advmod||was-9/VBD||therefore-1/RB	det||aim-4/NN||the-3/DT	nsubj||was-9/VBD||aim-4/NN	nsubj||assess-11/VB||aim-4/NN	det||study-8/NN||the-6/DT	amod||study-8/NN||present-7/JJ	prep_of||aim-4/NN||study-8/NN	root||ROOT-0/null||was-9/VBD	aux||assess-11/VB||to-10/TO	xcomp||was-9/VBD||assess-11/VB	det||effects-13/NNS||the-12/DT	dobj||assess-11/VB||effects-13/NNS	prep_of||effects-13/NNS||pioglitazone-15/NN	nn||mass-18/NN||cetp-17/NN	prep_on||assess-11/VB||mass-18/NN	prep_in||assess-11/VB||patients-20/NNS	prep_with||patients-20/NNS||type2diabetes-22/CD	type2diabetes-22||pioglitazone-15||yes||therefore, the aim of the present study was to assess the effects of pioglitazone on cetp mass in patients with type2diabetes.
nsubj||protein-6/NN||adiponectin-1/NN	cop||protein-6/NN||is-2/VBZ	det||protein-6/NN||an-3/DT	advmod||related-5/VBN||obesity-4/RB	amod||protein-6/NN||related-5/VBN	root||ROOT-0/null||protein-6/NN	nsubj||mediates-8/VBZ||that-7/WDT	ccomp||protein-6/NN||mediates-8/VBZ	det||risk-10/NN||the-9/DT	dobj||mediates-8/VBZ||risk-10/NN	prep_of||risk-10/NN||type2diabetes-12/NNS	amod||individuals-15/NNS||obese-14/JJ	prep_in||type2diabetes-12/NNS||individuals-15/NNS	poss||anti-inflammatory-18/NN||its-17/PRP$	prep_with||mediates-8/VBZ||anti-inflammatory-18/NN	nn||properties-21/NNS||insulin-sensitizing-20/NN	prep_with||mediates-8/VBZ||properties-21/NNS	conj_and||anti-inflammatory-18/NN||properties-21/NNS	insulin--1||obese-14||no_rel||adiponectin is an obesity related protein that mediates the risk of type2diabetes in obese individuals with its anti-inflammatory and insulin-sensitizing properties.
nn||-rrb--4/NNP||mrsa-1/NN	nn||-rrb--4/NNP||-lrb--2/NN	num||-rrb--4/NNP||346/545-3/CD	nsubj||differ-13/VB||-rrb--4/NNP	nn||patients-10/NNS||mssa-6/NNP	nn||patients-10/NNS||-lrb--7/NNP	num||patients-10/NNS||76/114-8/CD	nn||patients-10/NNS||-rrb--9/NNP	conj_and||-rrb--4/NNP||patients-10/NNS	nsubj||differ-13/VB||patients-10/NNS	aux||differ-13/VB||did-11/VBD	neg||differ-13/VB||not-12/RB	root||ROOT-0/null||differ-13/VB	advmod||differ-13/VB||significantly-14/RB	det||proportion-17/NN||the-16/DT	prep_in||differ-13/VB||proportion-17/NN	vmod||proportion-17/NN||classified-18/VBN	prep_as||classified-18/VBN||ha-20/NN	nsubj||â-30/VBP||s.aureus-22/NNS	det||p-29/NN||the-24/DT	amod||p-29/NN||cdc-25/JJ	amod||p-29/NN||ca-mrsa-26/JJ	nn||p-29/NN||definition-27/NN	nn||p-29/NN||-lrb--28/NN	prep_by||s.aureus-22/NNS||p-29/NN	parataxis||differ-13/VB||â-30/VBP	num||-rrb--38/NNS||$-31/$	number||=-33/CD||-32/CD	num||$-31/$||=-33/CD	amod||-rrb--38/NNS||â-34/JJ	num||-rrb--38/NNS||$-35/$	number||.5-37/CD||0-36/CD	num||$-35/$||.5-37/CD	dobj||â-30/VBP||-rrb--38/NNS	mrsa-1||s.aureus-22||no||mrsa -lrb- 346/545 -rrb- and mssa -lrb- 76/114 -rrb- patients did not differ significantly in the proportion classified as ha - s.aureus by the cdc ca-mrsa definition -lrb- p â $  = â $ 0 .5 -rrb- .
det||results-2/NNS||the-1/DT	nsubj||come-3/VBP||results-2/NNS	nsubj||aids-21/VBZ||results-2/NNS	root||ROOT-0/null||come-3/VBP	det||study-8/NN||a-5/DT	amod||study-8/NN||qualitative-6/JJ	amod||study-8/NN||phenomenological-7/JJ	prep_from||come-3/VBP||study-8/NN	vmod||study-8/NN||using-9/VBG	amod||interviews-11/NNS||in-depth-10/JJ	dobj||using-9/VBG||interviews-11/NNS	num||caregivers-15/NNS||21-13/CD	nn||caregivers-15/NNS||family-14/NN	prep_with||using-9/VBG||caregivers-15/NNS	advmod||ill-18/JJ||chronically-17/RB	amod||hiv-19/NN||ill-18/JJ	prep_of||caregivers-15/NNS||hiv-19/NN	conj_and||come-3/VBP||aids-21/VBZ	dobj||aids-21/VBZ||patients-22/NNS	num||district-25/NN||one-24/CD	prep_in||aids-21/VBZ||district-25/NN	prep_in||district-25/NN||lesotho-27/NN	aids-21||hiv-19||no||the results come from a qualitative phenomenological study using in-depth interviews with 21 family caregivers of chronically ill hiv and aids patients in one district in lesotho.
prepc_by||prevents-13/VBZ||inhibiting-2/VBG	det||current-7/NN||the-3/DT	amod||current-7/NN||late-4/JJ	amod||current-7/NN||inward-5/JJ	nn||current-7/NN||sodium-6/NN	dobj||inhibiting-2/VBG||current-7/NN	appos||current-7/NN||ina-9/NN	nsubj||prevents-13/VBZ||ranolazine-12/NN	root||ROOT-0/null||prevents-13/VBZ	amod||accumulation-17/NN||pathologic-14/JJ	nn||accumulation-17/NN||intracellular-15/NN	nn||accumulation-17/NN||calcium-16/NN	dobj||prevents-13/VBZ||accumulation-17/NN	nsubj||leads-19/VBZ||accumulation-17/NN	rcmod||accumulation-17/NN||leads-19/VBZ	prep_to||leads-19/VBZ||ischemia-21/NN	amod||dysfunction-24/NN||myocardial-23/JJ	prep_to||leads-19/VBZ||dysfunction-24/NN	conj_and||ischemia-21/NN||dysfunction-24/NN	amod||instability-28/NN||electrical-27/JJ	prep_to||leads-19/VBZ||instability-28/NN	conj_and||ischemia-21/NN||instability-28/NN	ranolazine-12||ischemia-21||no_rel||by inhibiting the late inward sodium current (ina), ranolazine prevents pathologic intracellular calcium accumulation that leads to ischemia, myocardial dysfunction, and electrical instability.
det||experiment-3/NN||this-2/DT	prep_in||transduced-10/VBN||experiment-3/NN	amod||cells-8/NNS||human-5/JJ	amod||cells-8/NNS||mesenchymal-6/JJ	nn||cells-8/NNS||stem-7/NN	nsubjpass||transduced-10/VBN||cells-8/NNS	auxpass||transduced-10/VBN||were-9/VBD	root||ROOT-0/null||transduced-10/VBN	prep_with||transduced-10/VBN||aav-12/NN	nsubj||containing-15/VBG||aav-12/NN	aux||containing-15/VBG||is-14/VBZ	rcmod||aav-12/NN||containing-15/VBG	amod||gene-19/NN||furin-cleavable-16/JJ	amod||gene-19/NN||human-17/JJ	nn||gene-19/NN||preproinsulin-18/NN	dobj||containing-15/VBG||gene-19/NN	aux||generate-21/VB||to-20/TO	vmod||containing-15/VBG||generate-21/VB	amod||cells-23/NNS||insulin-producing-22/JJ	dobj||generate-21/VB||cells-23/NNS	amod||²-27/NNS||surrogate-25/JJ	nn||²-27/NNS||î-26/NN	prep_as||generate-21/VB||²-27/NNS	dep||aav-12/NN||cells-29/NNS	det||therapy-33/NN||the-31/DT	amod||therapy-33/NN||type1diabetes-32/JJ	prep_for||cells-29/NNS||therapy-33/NN	type1diabetes-32||insulin--1||yes||in this experiment, human mesenchymal stem cells were transduced with aav which is containing furin-cleavable human preproinsulin gene to generate insulin-producing cells as surrogate î²-cells for the type1diabetes therapy.
det||report-4/NN||this-2/DT	nn||report-4/NN||case-3/NN	prep_through||discussed-17/VBN||report-4/NN	det||points-8/NNS||the-6/DT	nn||points-8/NNS||differential-7/NN	nsubjpass||discussed-17/VBN||points-8/NNS	nsubjpass||focused-20/VBN||points-8/NNS	amod||imbalances-13/NNS||nephrocalcinosis-10/JJ	conj_and||nephrocalcinosis-10/JJ||electrolyte-12/JJ	amod||imbalances-13/NNS||electrolyte-12/JJ	prep_of||points-8/NNS||imbalances-13/NNS	prep_between||imbalances-13/NNS||them-15/PRP	auxpass||discussed-17/VBN||are-16/VBP	root||ROOT-0/null||discussed-17/VBN	conj_and||discussed-17/VBN||focused-20/VBN	advmod||focused-20/VBN||more-21/RBR	amod||tests-24/NNS||diagnostic-23/JJ	prep_on||focused-20/VBN||tests-24/NNS	prep_on||focused-20/VBN||managements-26/NNS	conj_and||tests-24/NNS||managements-26/NNS	nn||rta-30/NN||type-28/NN	num||rta-30/NN||1-29/CD	prep_of||tests-24/NNS||rta-30/NN	nephrocalcinosis-10||electrolyte-12||no_rel||through this case report, the differential points of nephrocalcinosis and electrolyte imbalances between them are discussed, and focused more on diagnostic tests and managements of type 1 rta.
amod||hyperglycemia-2/NN||postprandial-1/JJ	nsubj||showed-8/VBD||hyperglycemia-2/NN	advmod||levels-7/NNS||especially-4/RB	amod||levels-7/NNS||30-minute-5/JJ	nn||levels-7/NNS||glucose-6/NN	nsubj||showed-8/VBD||levels-7/NNS	root||ROOT-0/null||showed-8/VBD	amod||correlation-10/NN||significant-9/JJ	dobj||showed-8/VBD||correlation-10/NN	prep_with||showed-8/VBD||bapwv-12/NNP	prep_in||showed-8/VBD||subjects-14/NNS	amod||hyperglycemia-17/NN||fasting-16/JJ	prep_with||subjects-14/NNS||hyperglycemia-17/NN	hyperglycemia-17||glucose-6||no||postprandial hyperglycemia, especially 30-minute glucose levels showed significant correlation with bapwv in subjects with fasting hyperglycemia.
num||%-2/NN||18.1-1/CD	nsubj||performed-11/VBN||%-2/NN	appos||%-2/NN||799/4416-4/CD	det||respondents-8/NNS||the-7/DT	prep_of||%-2/NN||respondents-8/NNS	aux||performed-11/VBN||had-9/VBD	advmod||performed-11/VBN||ever-10/RB	root||ROOT-0/null||performed-11/VBN	det||self-test-13/NN||a-12/DT	dobj||performed-11/VBN||self-test-13/NN	det||tests-19/NNS||the-15/DT	advmod||frequently-17/RB||most-16/RBS	advmod||used-18/VBN||frequently-17/RB	amod||tests-19/NNS||used-18/VBN	appos||self-test-13/NN||tests-19/NNS	aux||those-21/DT||being-20/VBG	vmod||tests-19/NNS||those-21/DT	prep_for||those-21/DT||diabetes-23/NN	num||%-26/NN||5.3-25/CD	appos||diabetes-23/NN||%-26/NN	prep_for||those-21/DT||kidneydisease-29/NN	conj_and||diabetes-23/NN||kidneydisease-29/NN	num||%-32/NN||4.9-31/CD	appos||kidneydisease-29/NN||%-32/NN	prep_for||those-21/DT||cholesterol-35/NN	conj_and||diabetes-23/NN||cholesterol-35/NN	num||%-38/NN||4.5-37/CD	appos||cholesterol-35/NN||%-38/NN	prep_for||those-21/DT||urinarytractinfection-41/NN	conj_and||diabetes-23/NN||urinarytractinfection-41/NN	num||%-44/NN||1.9-43/CD	appos||urinarytractinfection-41/NN||%-44/NN	prep_for||those-21/DT||hiv/aids-47/NNS	conj_and||diabetes-23/NN||hiv/aids-47/NNS	conj_and||diabetes-23/NN||chlamydia-49/NNS	conj_and||hiv/aids-47/NNS||chlamydia-49/NNS	dep||%-53/NN||both-51/DT	number||%-53/NN||1.6-52/CD	dep||hiv/aids-47/NNS||%-53/NN	kidneydisease-29||cholesterol-35||no_rel||18.1% (799/4416) of the respondents had ever performed a self-test, the most frequently used tests being those for diabetes (5.3%), kidneydisease (4.9%), cholesterol (4.5%), urinarytractinfection (1.9%) and hiv/aids and chlamydia (both 1.6%).
vmod||indicate-6/VBP||taken-1/VBN	advmod||taken-1/VBN||together-2/RB	det||data-5/NNS||these-4/DT	nsubj||indicate-6/VBP||data-5/NNS	root||ROOT-0/null||indicate-6/VBP	mark||is-9/VBZ||that-7/IN	expl||is-9/VBZ||there-8/EX	ccomp||indicate-6/VBP||is-9/VBZ	det||downregulation-12/NN||a-10/DT	amod||downregulation-12/NN||systematic-11/JJ	nsubj||is-9/VBZ||downregulation-12/NN	amod||levels-15/NNS||tim-3-14/JJ	prep_of||downregulation-12/NN||levels-15/NNS	nsubj||allow-35/VB||levels-15/NNS	nn||cells-18/NNS||t-17/NN	prep_on||levels-15/NNS||cells-18/NNS	prep_in||levels-15/NNS||htlv-1infection-20/CD	vmod||levels-15/NNS||sustaining-22/VBG	det||population-27/NN||a-23/DT	advmod||active-26/JJ||profoundly-24/RB	advmod||active-26/JJ||highly-25/RB	amod||population-27/NN||active-26/JJ	dobj||sustaining-22/VBG||population-27/NN	advmod||pathogenic-30/JJ||potentially-29/RB	amod||cells-32/NNS||pathogenic-30/JJ	nn||cells-32/NNS||t-31/NN	prep_of||population-27/NN||cells-32/NNS	aux||allow-35/VB||may-34/MD	rcmod||levels-15/NNS||allow-35/VB	det||development-38/NN||the-37/DT	prep_for||allow-35/VB||development-38/NN	amod||complications-41/NNS||htlv-1-40/JJ	prep_of||development-38/NN||complications-41/NNS	htlv-1infection-20||htlv-1-40||no||taken together, these data indicate that there is a systematic downregulation of tim-3 levels on t cells in htlv-1infection, sustaining a profoundly highly active population of potentially pathogenic t cells that may allow for the development of htlv-1 complications.
amod||therapy-4/NN||multiple-dose-1/JJ	amod||therapy-4/NN||metronidazole-2/JJ	amod||therapy-4/NN||oral-3/JJ	nsubj||treatment-9/NN||therapy-4/NN	cop||treatment-9/NN||is-5/VBZ	advmod||treatment-9/NN||currently-6/RB	det||treatment-9/NN||the-7/DT	nn||treatment-9/NN||reference-8/NN	root||ROOT-0/null||treatment-9/NN	prep_for||treatment-9/NN||bacterialvaginosis-11/NNS	appos||bacterialvaginosis-11/NNS||bv-13/NN	bacterialvaginosis-11||metronidazole-2||yes||multiple-dose metronidazole oral therapy is currently the reference treatment for bacterialvaginosis (bv).
det||study-6/NN||the-1/DT	amod||study-6/NN||alpha-tocopherol-2/JJ	amod||study-6/NN||beta-carotene-3/JJ	nn||study-6/NN||cancer-4/NN	nn||study-6/NN||prevention-5/NN	nsubj||examined-7/VBD||study-6/NN	root||ROOT-0/null||examined-7/VBD	det||effects-9/NNS||the-8/DT	dobj||examined-7/VBD||effects-9/NNS	amod||carotene-22/NN||vitamine-11/JJ	num||mg-14/NN||50-13/CD	dep||vitamine-11/JJ||mg-14/NN	prep_per||mg-14/NN||day-16/NN	npadvmod||²-20/JJ||î-19/NN	conj_and||vitamine-11/JJ||²-20/JJ	amod||carotene-22/NN||²-20/JJ	prep_of||effects-9/NNS||carotene-22/NN	num||mg-25/NN||20-24/CD	dep||carotene-22/NN||mg-25/NN	prep_per||mg-25/NN||day-27/NN	nn||cancer-31/NN||lung-30/NN	prep_on||examined-7/VBD||cancer-31/NN	num||smokers-35/NNS||29,133-33/CD	amod||smokers-35/NNS||male-34/JJ	prep_in||cancer-31/NN||smokers-35/NNS	vmod||smokers-35/NNS||aged-36/VBN	xcomp||aged-36/VBN||50â-37/VBG	num||years-41/NNS||$-38/$	num||$-38/$||69-40/CD	tmod||50â-37/VBG||years-41/NNS	vmod||50â-37/VBG||using-42/VBG	det||ã-45/NN||a-43/DT	num||ã-45/NN||2-44/CD	dobj||using-42/VBG||ã-45/NN	num||design-49/NN||2-47/CD	amod||design-49/NN||factorial-48/JJ	dep||ã-45/NN||design-49/NN	cancer-31||beta-carotene-3||no_rel||the alpha-tocopherol beta-carotene cancer prevention study examined the effects of vitamine (50 mg per day) and î²-carotene (20 mg per day) on lung cancer in 29,133 male smokers aged 50â69 years using a 2 ã 2 factorial design.
amod||survivors-2/NNS||thirty-three-1/JJ	nsubjpass||evaluated-15/VBN||survivors-2/NNS	vmod||survivors-2/NNS||treated-3/VBN	prep_with||treated-3/VBN||insulin-5/NN	prep_for||insulin-5/NN||hyperglycemia-7/NN	num||controls-11/NNS||63-9/CD	amod||controls-11/NNS||matched-10/VBN	prep_with||treated-3/VBN||controls-11/NNS	conj_and||insulin-5/NN||controls-11/NNS	prep_without||controls-11/NNS||hyperglycemia-13/NN	auxpass||evaluated-15/VBN||were-14/VBD	root||ROOT-0/null||evaluated-15/VBN	det||age-19/NN||a-17/DT	amod||age-19/NN||corrected-18/VBN	prep_at||evaluated-15/VBN||age-19/NN	num||years-22/NNS||2-21/CD	prep_of||age-19/NN||years-22/NNS	hyperglycemia-13||insulin-5||yes||thirty-three survivors treated with insulin for hyperglycemia and 63 matched controls without hyperglycemia were evaluated at a corrected age of 2 years.
advmod||suggest-15/VBP||indeed-1/RB	amod||lines-4/NNS||several-3/JJ	nsubj||suggest-15/VBP||lines-4/NNS	prep_of||lines-4/NNS||evidence-6/NN	prep_including||evidence-6/NN||epidemiologic-8/NN	prep_including||evidence-6/NN||preclinical-10/JJ	conj_and||epidemiologic-8/NN||preclinical-10/JJ	amod||data-14/NNS||clinical-13/JJ	prep_including||evidence-6/NN||data-14/NNS	conj_and||epidemiologic-8/NN||data-14/NNS	root||ROOT-0/null||suggest-15/VBP	mark||and/or-20/VBD||that-16/IN	amod||levels-19/NNS||reduced-17/VBN	amod||levels-19/NNS||vitamind-18/JJ	nsubj||and/or-20/VBD||levels-19/NNS	ccomp||suggest-15/VBP||and/or-20/VBD	nsubj||factor-28/NN||dysregulation-21/NN	amod||homeostasis-24/NNS||vitamind-23/JJ	prep_of||dysregulation-21/NN||homeostasis-24/NNS	cop||factor-28/NN||is-25/VBZ	det||factor-28/NN||a-26/DT	nn||factor-28/NN||risk-27/NN	ccomp||and/or-20/VBD||factor-28/NN	det||development-31/NN||the-30/DT	prep_for||factor-28/NN||development-31/NN	prep_of||development-31/NN||multiplesclerosis-33/NNS	det||hand-37/NN||the-35/DT	num||hand-37/NN||one-36/CD	prep_on||multiplesclerosis-33/NNS||hand-37/NN	mark||associated-46/VBN||that-40/IN	amod||levels-43/NNS||vitamind-41/JJ	nn||levels-43/NNS||serum-42/NN	nsubjpass||associated-46/VBN||levels-43/NNS	auxpass||associated-46/VBN||are-44/VBP	advmod||associated-46/VBN||inversely-45/RB	ccomp||suggest-15/VBP||associated-46/VBN	conj_and||and/or-20/VBD||associated-46/VBN	nn||activity-49/NN||disease-48/NN	prep_with||associated-46/VBN||activity-49/NN	prep_with||associated-46/VBN||progression-51/NN	conj_and||activity-49/NN||progression-51/NN	det||hand-55/NN||the-53/DT	amod||hand-55/NN||other-54/JJ	prep_on||associated-46/VBN||hand-55/NN	multiplesclerosis-33||vitamind-41||no_rel||indeed, several lines of evidence including epidemiologic, preclinical, and clinical data suggest that reduced vitamind levels and/or dysregulation of vitamind homeostasis is a risk factor for the development of multiplesclerosis on the one hand, and that vitamind serum levels are inversely associated with disease activity and progression on the other hand.
mark||respond-6/NN||while-1/IN	amod||patients-3/NNS||many-2/JJ	nsubj||respond-6/NN||patients-3/NNS	prep_with||patients-3/NNS||ocd-5/NN	advcl||remains-19/VBZ||respond-6/NN	prep_to||respond-6/NN||ssris-8/NNS	prep_to||respond-6/NN||clomipramine-10/NN	conj_or||ssris-8/NNS||clomipramine-10/NN	det||treatment-13/NN||the-12/DT	nsubj||remains-19/VBZ||treatment-13/NN	prep_of||treatment-13/NN||those-15/DT	amod||ocd-18/NN||refractory-17/JJ	prep_with||those-15/DT||ocd-18/NN	root||ROOT-0/null||remains-19/VBZ	acomp||remains-19/VBZ||challenging-20/JJ	ocd-18||clomipramine-10||yes||while many patients with ocd respond to ssris or clomipramine, the treatment of those with refractory ocd remains challenging.
nsubj||predicts-16/VBZ||modeling-1/NN	prepc_of||modeling-1/NN||expanding-3/VBG	amod||treatment-5/NN||antiretroviral-4/JJ	dobj||expanding-3/VBG||treatment-5/NN	det||adults-9/NNS||all-7/DT	amod||adults-9/NNS||hiv-infected-8/JJ	prep_to||expanding-3/VBG||adults-9/NNS	advmod||expanding-3/VBG||already-10/RB	prep_in||expanding-3/VBG||care-12/NN	nn||francisco-15/NN||san-14/NN	prep_in||care-12/NN||francisco-15/NN	root||ROOT-0/null||predicts-16/VBZ	dobj||predicts-16/VBZ||reductions-17/NNS	amod||hivinfection-20/NN||new-19/JJ	prep_in||reductions-17/NNS||hivinfection-20/NN	num||years-23/NNS||5-22/CD	prep_at||predicts-16/VBZ||years-23/NNS	num||%-26/NN||59-25/CD	prep_of||years-23/NNS||%-26/NN	prep_among||%-26/NN||men-28/NNS	nsubj||have-30/VBP||men-28/NNS	rcmod||men-28/NNS||have-30/VBP	dobj||have-30/VBP||sex-31/NN	prep_with||have-30/VBP||men-33/NNS	hivinfection-20||hiv--1||no||modeling of expanding antiretroviral treatment to all hiv-infected adults already in care in san francisco predicts reductions in new hivinfection at 5 years of 59% among men who have sex with men.
advmod||approved-17/VBN||finally-1/RB	det||conference-6/NN||the-4/DT	amod||conference-6/NN||present-5/JJ	prep_at||approved-17/VBN||conference-6/NN	nsubjpass||approved-17/VBN||expansion-8/NN	det||indications-11/NNS||the-10/DT	prep_of||expansion-8/NN||indications-11/NNS	prep_of||indications-11/NNS||mtx-13/NN	prep_for||mtx-13/NN||jia-15/NN	auxpass||approved-17/VBN||was-16/VBD	root||ROOT-0/null||approved-17/VBN	prep_in||approved-17/VBN||japan-19/NN	jia-15||mtx-13||yes||finally, at the present conference, expansion of the indications of mtx for jia was approved in japan.
det||number-2/NN||the-1/DT	nsubjpass||expected-7/VBN||number-2/NN	nsubj||rise-9/VB||number-2/NN	amod||mothers-5/NNS||diabetic-4/JJ	prep_of||number-2/NN||mothers-5/NNS	auxpass||expected-7/VBN||is-6/VBZ	root||ROOT-0/null||expected-7/VBN	aux||rise-9/VB||to-8/TO	xcomp||expected-7/VBN||rise-9/VB	mark||progresses-27/VBZ||as-11/IN	nsubj||progresses-27/VBZ||more-12/JJR	nsubj||childbearing-29/VB||more-12/JJR	conj_and||more-12/JJR||more-14/JJR	nsubj||progresses-27/VBZ||more-14/JJR	nsubj||childbearing-29/VB||more-14/JJR	det||population-20/NN||the-16/DT	amod||population-20/NN||obese-17/JJ	amod||population-20/NN||pediatric-18/JJ	amod||population-20/NN||female-19/JJ	prep_of||more-12/JJR||population-20/NN	prep_in||population-20/NN||developed-22/JJ	det||countries-26/NNS||some-24/DT	amod||countries-26/NNS||developing-25/VBG	prep_of||more-12/JJR||countries-26/NNS	conj_and||population-20/NN||countries-26/NNS	advcl||expected-7/VBN||progresses-27/VBZ	aux||childbearing-29/VB||to-28/TO	xcomp||progresses-27/VBZ||childbearing-29/VB	dobj||childbearing-29/VB||age-30/NN	obese-17||rise-9||no_rel||the number of diabetic mothers is expected to rise, as more and more of the obese pediatric female population in developed and some developing countries progresses to childbearing age.
nsubj||found-2/VBD||we-1/PRP	nsubj||observed-19/VBD||we-1/PRP	nsubj||promoted-38/VBD||we-1/PRP	root||ROOT-0/null||found-2/VBD	det||correlation-4/NN||a-3/DT	dobj||found-2/VBD||correlation-4/NN	amod||expression-7/NN||erbb2-6/JJ	prep_between||correlation-4/NN||expression-7/NN	prep_between||correlation-4/NN||activation-9/NN	conj_and||expression-7/NN||activation-9/NN	prep_of||correlation-4/NN||pak-11/NN	amod||samples-17/NNS||estrogen-receptor-13/JJ	amod||samples-17/NNS||positive-14/JJ	amod||samples-17/NNS||human-15/JJ	nn||samples-17/NNS||breasttumor-16/NN	prep_in||found-2/VBD||samples-17/NNS	conj_and||found-2/VBD||observed-19/VBD	dobj||observed-19/VBD||that-20/DT	amod||cultures-23/NNS||3d-22/JJ	prep_in||that-20/DT||cultures-23/NNS	appos||cultures-23/NNS||activation-25/NN	amod||pathway-28/NN||rac-pak1-27/JJ	prep_of||activation-25/NN||pathway-28/NN	amod||homodimers-31/NNS||erbb2-30/JJ	prep_by||observed-19/VBD||homodimers-31/NNS	vmod||homodimers-31/NNS||induced-32/VBN	nn||factor-34/NN||growth-33/NN	dobj||induced-32/VBN||factor-34/NN	amod||proliferation-36/NN||independent-35/JJ	dobj||found-2/VBD||proliferation-36/NN	conj_and||found-2/VBD||promoted-38/VBD	dobj||promoted-38/VBD||disruption-39/NN	amod||structures-44/NNS||three-dimensional-41/JJ	amod||structures-44/NNS||mammary-42/JJ	amod||structures-44/NNS||acinar-like-43/JJ	prep_of||disruption-39/NN||structures-44/NNS	prep_through||promoted-38/VBD||activation-46/NN	det||pathways-52/NNS||the-48/DT	nn||pathways-52/NNS||erk-49/NN	conj_and||erk-49/NN||akt-51/NN	nn||pathways-52/NNS||akt-51/NN	prep_of||activation-46/NN||pathways-52/NNS	breasttumor-16||estrogen--1||no||we found a correlation between erbb2 expression and activation of pak in estrogen-receptor positive human breasttumor samples and observed that in 3d cultures, activation of rac-pak1 pathway by erbb2 homodimers induced growth factor independent proliferation and promoted disruption of three-dimensional mammary acinar-like structures through activation of the erk and akt pathways.
det||avian-4/NN||the-1/DT	amod||avian-4/NN||recent-2/JJ	amod||avian-4/NN||h5n1-3/JJ	nsubj||influenzavirus-8/VBZ||avian-4/NN	amod||swine-origin-7/NN||h1n1-6/JJ	conj_and||avian-4/NN||swine-origin-7/NN	nsubj||influenzavirus-8/VBZ||swine-origin-7/NN	root||ROOT-0/null||influenzavirus-8/VBZ	nsubj||reaffirm-10/VB||outbreaks-9/NNS	ccomp||influenzavirus-8/VBZ||reaffirm-10/VB	mark||real-21/JJ||that-11/IN	det||threat-13/NN||the-12/DT	nsubj||real-21/JJ||threat-13/NN	nsubj||ever-present-23/JJ||threat-13/NN	det||pandemic-18/NN||a-15/DT	amod||pandemic-18/NN||world-wide-16/JJ	nn||pandemic-18/NN||influenza-17/NN	prep_of||threat-13/NN||pandemic-18/NN	cop||real-21/JJ||is-19/VBZ	preconj||real-21/JJ||both-20/DT	ccomp||reaffirm-10/VB||real-21/JJ	ccomp||reaffirm-10/VB||ever-present-23/JJ	conj_and||real-21/JJ||ever-present-23/JJ	influenza-17||influenzavirus-8||no||the recent h5n1 avian and h1n1 swine-origin influenzavirus outbreaks reaffirm that the threat of a world-wide influenza pandemic is both real and ever-present.
nsubj||drugs-14/NNS||chondroitinsulfate-1/NN	appos||chondroitinsulfate-1/NN||cs-3/NN	amod||sulfate-7/NN||glucosamine-6/JJ	conj_and||chondroitinsulfate-1/NN||sulfate-7/NN	nsubj||drugs-14/NNS||sulfate-7/NN	appos||sulfate-7/NN||gs-9/NN	cop||drugs-14/NNS||are-11/VBP	amod||drugs-14/NNS||symptomatic-12/JJ	amod||drugs-14/NNS||slow-acting-13/JJ	root||ROOT-0/null||drugs-14/NNS	prep_for||drugs-14/NNS||osteoarthritis-16/NNS	appos||osteoarthritis-16/NNS||oa-18/NN	advmod||used-21/VBN||widely-20/RB	vmod||osteoarthritis-16/NNS||used-21/VBN	prep_in||used-21/VBN||clinic-23/NN	osteoarthritis-16||glucosamine-6||yes||chondroitinsulfate (cs) and glucosamine sulfate (gs) are symptomatic slow-acting drugs for osteoarthritis (oa) widely used in clinic.
nsubj||aimed-2/VBD||we-1/PRP	nsubj||compare-4/VB||we-1/PRP	root||ROOT-0/null||aimed-2/VBD	aux||compare-4/VB||to-3/TO	xcomp||aimed-2/VBD||compare-4/VB	det||effects-6/NNS||the-5/DT	dobj||compare-4/VB||effects-6/NNS	prep_of||effects-6/NNS||sufentanil-8/NN	amod||doses-11/NNS||analgesic-10/JJ	prep_in||sufentanil-8/NN||doses-11/NNS	prepc_for||compare-4/VB||reducing-13/VBG	det||pain-16/NN||the-14/DT	nn||pain-16/NN||injection-15/NN	dobj||reducing-13/VBG||pain-16/NN	nn||propofol-19/NN||microemulsion-18/NN	prep_of||pain-16/NN||propofol-19/NN	pain-16||propofol-19||yes||we aimed to compare the effects of sufentanil in analgesic doses for reducing the injection pain of microemulsion propofol.
nsubj||antibody-8/NN||panitumumab-1/NN	cop||antibody-8/NN||is-2/VBZ	det||antibody-8/NN||the-3/DT	amod||antibody-8/NN||first-4/JJ	advmod||human-6/JJ||fully-5/RB	amod||antibody-8/NN||human-6/JJ	nn||antibody-8/NN||monoclonal-7/NN	root||ROOT-0/null||antibody-8/NN	aux||epidermal-10/VB||to-9/TO	vmod||antibody-8/NN||epidermal-10/VB	nn||receptor-13/NN||growth-11/NN	nn||receptor-13/NN||factor-12/NN	dobj||epidermal-10/VB||receptor-13/NN	nsubj||enter-18/VB||receptor-13/NN	appos||receptor-13/NN||egfr-15/NN	aux||enter-18/VB||to-17/TO	xcomp||epidermal-10/VB||enter-18/VB	amod||trials-20/NNS||clinical-19/JJ	dobj||enter-18/VB||trials-20/NNS	det||treatment-23/NN||the-22/DT	prep_for||enter-18/VB||treatment-23/NN	amod||tumors-26/NNS||solid-25/JJ	prep_of||treatment-23/NN||tumors-26/NNS	antibody-8||tumors-26||no_rel||panitumumab is the first fully human monoclonal antibody to epidermal growth factor receptor (egfr) to enter clinical trials for the treatment of solid tumors.
mark||understand-4/VB||in-1/IN	dep||understand-4/VB||order-2/NN	aux||understand-4/VB||to-3/TO	advcl||analysed-27/VBD||understand-4/VB	mark||serve-9/VB||whether-5/IN	det||snp-7/NN||this-6/DT	nsubj||serve-9/VB||snp-7/NN	nsubj||evaluate-11/VB||snp-7/NN	aux||serve-9/VB||may-8/MD	ccomp||understand-4/VB||serve-9/VB	aux||evaluate-11/VB||to-10/TO	xcomp||serve-9/VB||evaluate-11/VB	det||contribution-13/NN||the-12/DT	dobj||evaluate-11/VB||contribution-13/NN	det||gene-17/NN||the-15/DT	amod||gene-17/NN||ccl2-16/JJ	prep_of||contribution-13/NN||gene-17/NN	det||expression-20/NN||the-19/DT	prep_to||evaluate-11/VB||expression-20/NN	nn||disease-23/NN||tb-22/NN	prep_of||expression-20/NN||disease-23/NN	nsubj||analysed-27/VBD||we-25/PRP	advmod||analysed-27/VBD||further-26/RB	root||ROOT-0/null||analysed-27/VBD	dobj||analysed-27/VBD||distribution-28/NN	poss||alleles-31/NNS||its-30/PRP$	prep_of||distribution-28/NN||alleles-31/NNS	prep_of||distribution-28/NN||genotypes-33/NNS	conj_and||alleles-31/NNS||genotypes-33/NNS	num||cases-37/NNS||301-35/CD	nn||cases-37/NNS||tb-36/NN	prep_in||analysed-27/VBD||cases-37/NNS	num||controls-41/NNS||338-39/CD	amod||controls-41/NNS||non-infected-40/JJ	prep_versus||cases-37/NNS||controls-41/NNS	det||bcg-44/NN||all-43/DT	dep||controls-41/NNS||bcg-44/NN	vmod||bcg-44/NN||vaccinated-45/VBN	vmod||controls-41/NNS||representing-47/VBG	det||population-51/NN||a-48/DT	amod||population-51/NN||high-risk-49/JJ	amod||population-51/NN||pediatric-50/JJ	dobj||representing-47/VBG||population-51/NN	nn||china-54/NN||north-53/NN	prep_of||population-51/NN||china-54/NN	tb-36||bcg-44||no||in order to understand whether this snp may serve to evaluate the contribution of the ccl2 gene to the expression of tb disease, we further analysed distribution of its alleles and genotypes in 301 tb cases versus 338 non-infected controls (all bcg vaccinated) representing a high-risk pediatric population of north china.
det||study-3/NN||the-1/DT	amod||study-3/NN||current-2/JJ	nsubjpass||initiated-5/VBN||study-3/NN	nsubj||define-7/VB||study-3/NN	auxpass||initiated-5/VBN||was-4/VBD	root||ROOT-0/null||initiated-5/VBN	aux||define-7/VB||to-6/TO	xcomp||initiated-5/VBN||define-7/VB	det||effects-9/NNS||the-8/DT	dobj||define-7/VB||effects-9/NNS	det||sitagliptin-14/NN||the-11/DT	amod||sitagliptin-14/NN||dpp-iv-12/JJ	nn||sitagliptin-14/NN||inhibitor-13/NN	prep_of||effects-9/NNS||sitagliptin-14/NN	appos||sitagliptin-14/NN||mk0431-16/NNP	amod||survival-21/NN||transplanted-19/VBN	amod||survival-21/NN||islet-20/JJ	prep_on||define-7/VB||survival-21/NN	amod||diabetic-24/JJ||nonobese-23/JJ	amod||mice-28/NNS||diabetic-24/JJ	appos||mice-28/NNS||nod-26/NN	prep_in||survival-21/NN||mice-28/NNS	det||model-33/NN||an-30/DT	amod||model-33/NN||autoimmune-31/JJ	amod||model-33/NN||type1diabetes-32/JJ	appos||survival-21/NN||model-33/NN	type1diabetes-32||sitagliptin-14||no||the current study was initiated to define the effects of the dpp-iv inhibitor sitagliptin (mk0431) on transplanted islet survival in nonobese diabetic (nod) mice, an autoimmune type1diabetes model.
agent||decreased-29/VBN||elimination-2/VBG	amod||factors-7/NNS||local-4/JJ	conj_and||local-4/JJ||systemic-6/JJ	amod||factors-7/NNS||systemic-6/JJ	prep_of||elimination-2/VBG||factors-7/NNS	amod||patients-10/NNS||diabetic-9/JJ	prep_in||elimination-2/VBG||patients-10/NNS	conj_and||elimination-2/VBG||improving-12/VBG	agent||decreased-29/VBN||improving-12/VBG	poss||care-16/NN||their-13/PRP$	amod||care-16/NN||oral-14/JJ	nn||care-16/NN||health-15/NN	dobj||improving-12/VBG||care-16/NN	nn||colonization-19/NN||candida-18/NN	nsubjpass||decreased-29/VBN||colonization-19/NN	det||risk-22/NN||the-21/DT	conj_and||colonization-19/NN||risk-22/NN	nsubjpass||decreased-29/VBN||risk-22/NN	prep_of||risk-22/NN||oral-24/JJ	prep_of||risk-22/NN||systemiccandidiasis-26/NNS	conj_and||oral-24/JJ||systemiccandidiasis-26/NNS	aux||decreased-29/VBN||will-27/MD	auxpass||decreased-29/VBN||be-28/VB	root||ROOT-0/null||decreased-29/VBN	systemiccandidiasis-26||candida-18||no||by elimination of local and systemic factors in diabetic patients and improving their oral health care, candida colonization and the risk of oral and systemiccandidiasis will be decreased.
mark||randomised-6/VBD||as-1/IN	nsubj||randomised-6/VBD||part-2/NN	det||cluster-5/NN||a-4/DT	prep_of||part-2/NN||cluster-5/NN	advcl||assessed-11/VBD||randomised-6/VBD	amod||trial-8/NN||controlled-7/JJ	dobj||randomised-6/VBD||trial-8/NN	nsubj||assessed-11/VBD||we-10/PRP	root||ROOT-0/null||assessed-11/VBD	det||prevalence-14/NN||the-12/DT	amod||prevalence-14/NN||baseline-13/JJ	dobj||assessed-11/VBD||prevalence-14/NN	prep||prevalence-14/NN||of-15/IN	nn||factors-19/NNS||risk-18/NN	dobj||assessed-11/VBD||factors-19/NNS	conj_and||prevalence-14/NN||factors-19/NNS	prep||assessed-11/VBD||for-20/IN	nn||infection-26/NN||activetrachoma-22/NN	conj_and||activetrachoma-22/NN||ocular-24/NN	nn||infection-26/NN||ocular-24/NN	nn||infection-26/NN||c.trachomatis-25/NNS	dobj||assessed-11/VBD||infection-26/NN	advmod||children-30/NNS||randomly-28/RB	amod||children-30/NNS||selected-29/VBN	prep_in||infection-26/NN||children-30/NNS	vmod||children-30/NNS||aged-31/VBN	dobj||aged-31/VBN||0â-32/NNS	num||years-36/NNS||$-33/$	num||$-33/$||5-35/CD	npadvmod||aged-31/VBN||years-36/NNS	num||gambian-39/NN||48-38/CD	prep_from||aged-31/VBN||gambian-39/NN	num||communities-43/NNS||36-41/CD	amod||communities-43/NNS||tanzanian-42/JJ	prep_from||aged-31/VBN||communities-43/NNS	conj_and||gambian-39/NN||communities-43/NNS	activetrachoma-22||c.trachomatis-25||no||as part of a cluster randomised controlled trial , we assessed the baseline prevalence of , and risk factors for , activetrachoma and ocular c.trachomatis infection in randomly selected children aged 0â $ `` 5 years from 48 gambian and 36 tanzanian communities .
nsubj||protein-6/NN||adiponectin-1/NN	cop||protein-6/NN||is-2/VBZ	det||protein-6/NN||an-3/DT	advmod||related-5/VBN||obesity-4/RB	amod||protein-6/NN||related-5/VBN	root||ROOT-0/null||protein-6/NN	nsubj||mediates-8/VBZ||that-7/WDT	ccomp||protein-6/NN||mediates-8/VBZ	det||risk-10/NN||the-9/DT	dobj||mediates-8/VBZ||risk-10/NN	prep_of||risk-10/NN||type2diabetes-12/NNS	amod||individuals-15/NNS||obese-14/JJ	prep_in||type2diabetes-12/NNS||individuals-15/NNS	poss||anti-inflammatory-18/NN||its-17/PRP$	prep_with||mediates-8/VBZ||anti-inflammatory-18/NN	nn||properties-21/NNS||insulin-sensitizing-20/NN	prep_with||mediates-8/VBZ||properties-21/NNS	conj_and||anti-inflammatory-18/NN||properties-21/NNS	type2diabetes-12||insulin--1||yes||adiponectin is an obesity related protein that mediates the risk of type2diabetes in obese individuals with its anti-inflammatory and insulin-sensitizing properties.
amod||adhesion-3/NN||several-1/JJ	nn||adhesion-3/NN||cell-2/NN	nsubj||transmembrane-4/VBP||adhesion-3/NN	root||ROOT-0/null||transmembrane-4/VBP	amod||repeat-6/NN||leucine-rich-5/JJ	nn||proteins-10/NNS||repeat-6/NN	appos||proteins-10/NNS||lrr-8/NN	nsubjpass||expressed-13/VBN||proteins-10/NNS	nsubjpass||thought-20/VBN||proteins-10/NNS	nsubj||regulators-24/NNS||proteins-10/NNS	auxpass||expressed-13/VBN||are-11/VBP	advmod||expressed-13/VBN||highly-12/RB	ccomp||transmembrane-4/VBP||expressed-13/VBN	det||system-17/NN||the-15/DT	amod||system-17/NN||nervous-16/JJ	prep_in||expressed-13/VBN||system-17/NN	auxpass||thought-20/VBN||are-19/VBP	ccomp||transmembrane-4/VBP||thought-20/VBN	conj_and||expressed-13/VBN||thought-20/VBN	aux||regulators-24/NNS||to-21/TO	cop||regulators-24/NNS||be-22/VB	amod||regulators-24/NNS||key-23/JJ	xcomp||thought-20/VBN||regulators-24/NNS	poss||development-27/NN||its-26/PRP$	prep_of||regulators-24/NNS||development-27/NN	leucine--1||adhesion-3||no_rel||several cell adhesion transmembrane leucine-rich repeat (lrr) proteins are highly expressed in the nervous system and are thought to be key regulators of its development.
det||effect-4/NN||the-1/DT	amod||effect-4/NN||acute-2/JJ	amod||effect-4/NN||protective-3/JJ	nsubjpass||tested-9/VBN||effect-4/NN	amod||budesonide-7/NN||inhaled-6/JJ	prep_of||effect-4/NN||budesonide-7/NN	auxpass||tested-9/VBN||was-8/VBD	root||ROOT-0/null||tested-9/VBN	det||model-12/NN||a-11/DT	prep_in||tested-9/VBN||model-12/NN	advmod||increased-15/JJ||temporarily-14/RB	amod||inflammation-17/NN||increased-15/JJ	nn||inflammation-17/NN||airway-16/NN	prep_of||model-12/NN||inflammation-17/NN	amod||challenges-22/NNS||repeated-19/VBN	amod||challenges-22/NNS||indirect-20/JJ	nn||challenges-22/NNS||airway-21/NN	prep_with||tested-9/VBN||challenges-22/NNS	vmod||challenges-22/NNS||mimicking-24/VBG	det||exacerbation-28/NN||an-25/DT	amod||exacerbation-28/NN||acute-26/JJ	nn||exacerbation-28/NN||asthma-27/NN	dobj||mimicking-24/VBG||exacerbation-28/NN	asthma-27||budesonide-7||yes||the acute protective effect of inhaled budesonide was tested in a model of temporarily increased airway inflammation with repeated indirect airway challenges, mimicking an acute asthma exacerbation.
nn||abnormalities-2/NNS||glucose-1/NN	nsubjpass||documented-4/VBN||abnormalities-2/NNS	auxpass||documented-4/VBN||were-3/VBD	root||ROOT-0/null||documented-4/VBN	num||%-7/NN||71-6/CD	prep_in||documented-4/VBN||%-7/NN	nn||type2diabetes-10/NNS||patients-9/NNS	prep_of||%-7/NN||type2diabetes-10/NNS	num||%-13/NN||29-12/CD	prep_in||documented-4/VBN||%-13/NN	amod||glucose-17/NN||impaired-15/VBN	amod||glucose-17/NN||fasting-16/JJ	appos||%-13/NN||glucose-17/NN	appos||glucose-17/NN||ifg-19/NN	num||%-23/NN||58-22/CD	prep_in||glucose-17/NN||%-23/NN	prep_in||glucose-17/NN||impairedglucosetolerance-26/NN	conj_and||%-23/NN||impairedglucosetolerance-26/NN	appos||%-23/NN||igt-28/NN	num||%-32/NN||37.5-31/CD	prep_in||glucose-17/NN||%-32/NN	impairedglucosetolerance-26||glucose-17||no_rel||glucose abnormalities were documented in 71% of patients type2diabetes in 29%, impaired fasting glucose (ifg) in 58%, and impairedglucosetolerance (igt) in 37.5%.
amod||trials-3/NNS||published-1/VBN	amod||trials-3/NNS||double-blind-2/JJ	nsubj||show-4/VBP||trials-3/NNS	root||ROOT-0/null||show-4/VBP	mark||achieves-12/VBZ||that-5/IN	amod||therapy-7/NN||budesonide/formoterol-6/JJ	nsubj||achieves-12/VBZ||therapy-7/NN	vmod||therapy-7/NN||delivered-8/VBN	amod||fashion-11/NN||smart-10/JJ	prep_in||delivered-8/VBN||fashion-11/NN	ccomp||show-4/VBP||achieves-12/VBZ	amod||outcomes-15/NNS||better-13/JJR	nn||outcomes-15/NNS||asthma-14/NN	dobj||achieves-12/VBZ||outcomes-15/NNS	amod||monotherapy-18/NN||budesonide-17/JJ	prep_than||achieves-12/VBZ||monotherapy-18/NN	amod||doses-21/NNS||lower-20/JJR	prep_than||achieves-12/VBZ||doses-21/NNS	conj_or||monotherapy-18/NN||doses-21/NNS	amod||therapy-24/NN||budesonide/formoterol-23/JJ	prep_of||doses-21/NNS||therapy-24/NN	vmod||therapy-24/NN||delivered-25/VBN	amod||dosage-28/NN||constant-27/JJ	prep_in||delivered-25/VBN||dosage-28/NN	asthma-14||budesonide-17||yes||published double-blind trials show that budesonide/formoterol therapy delivered in smart fashion achieves better asthma outcomes than budesonide monotherapy or lower doses of budesonide/formoterol therapy delivered in constant dosage.
det||study-2/NN||this-1/DT	nsubj||aims-3/VBZ||study-2/NN	nsubj||identify-5/VB||study-2/NN	root||ROOT-0/null||aims-3/VBZ	aux||identify-5/VB||to-4/TO	xcomp||aims-3/VBZ||identify-5/VB	det||distribution-8/NN||the-6/DT	amod||distribution-8/NN||genotypic-7/JJ	dobj||identify-5/VB||distribution-8/NN	prep_of||distribution-8/NN||hbv-10/NN	num||patients-14/NNS||40-12/CD	amod||patients-14/NNS||hbsag-positive-13/JJ	prep_in||identify-5/VB||patients-14/NNS	amod||nia-18/NN||rondã-16/JJ	amod||nia-18/NN||´-17/JJ	prep_from||patients-14/NNS||nia-18/NN	acomp||identify-5/VB||brazil-20/JJ	hbv-10||hbsag--1||yes||this study aims to identify the genotypic distribution of hbv in 40 hbsag-positive patients from rondã´nia, brazil.
num||questionnaires-2/NNS||nine-1/CD	nsubjpass||sent-4/VBN||questionnaires-2/NNS	nsubjpass||sent-4/VBN||questionnaires-2/NNS	auxpass||sent-4/VBN||were-3/VBD	root||ROOT-0/null||sent-4/VBN	conj_and||sent-4/VBN||sent-4/VBN	det||states-9/NNS||all-6/DT	num||states-9/NNS||31-7/CD	nn||states-9/NNS||member-8/NN	prep_to||sent-4/VBN||states-9/NNS	nn||countries-12/NNS||eee/efta-11/NN	prep_to||sent-4/VBN||countries-12/NNS	conj_and||states-9/NNS||countries-12/NNS	vmod||states-9/NNS||requesting-13/VBG	dobj||requesting-13/VBG||data-14/NNS	det||behavioural-18/NN||the-16/DT	amod||behavioural-18/NN||overall-17/JJ	prep_on||requesting-13/VBG||behavioural-18/NN	amod||system-23/NN||second-20/JJ	nn||system-23/NN||generation-21/NN	nn||system-23/NN||surveillance-22/NN	prep_on||requesting-13/VBG||system-23/NN	conj_and||behavioural-18/NN||system-23/NN	prep_on||sent-4/VBN||surveillance-26/NN	det||population-30/NN||the-28/DT	amod||population-30/NN||general-29/JJ	prep_in||surveillance-26/NN||population-30/NN	appos||population-30/NN||youth-32/NN	appos||population-30/NN||men-34/NNS	vmod||men-34/NNS||having-35/VBG	dobj||having-35/VBG||sex-36/NN	prep_with||sex-36/NN||men-38/NNS	appos||population-30/NN||msm-40/NN	amod||users-45/NNS||injecting-43/VBG	nn||users-45/NNS||drug-44/NN	appos||population-30/NN||users-45/NNS	appos||users-45/NNS||idu-47/NN	nn||workers-51/NNS||sex-50/NN	appos||population-30/NN||workers-51/NNS	appos||workers-51/NNS||sw-53/NN	appos||workers-51/NNS||migrants-56/NNS	appos||population-30/NN||people-58/NNS	vmod||people-58/NNS||living-59/VBG	prep_with||living-59/VBG||hiv/aids-61/NNS	appos||hiv/aids-61/NNS||plwha-63/NNP	prep_with||living-59/VBG||sexuallytransmittedinfection-67/NN	conj_and||hiv/aids-61/NNS||sexuallytransmittedinfection-67/NN	appos||sexuallytransmittedinfection-67/NN||sti-69/NN	nn||patients-72/NNS||clinics-71/NNS	dep||sexuallytransmittedinfection-67/NN||patients-72/NNS	aids--1||hiv--1||no||nine questionnaires were sent to all 31 member states and eee/efta countries requesting data on the overall behavioural and second generation surveillance system and on surveillance in the general population, youth, men having sex with men (msm), injecting drug users (idu), sex workers (sw), migrants, people living with hiv/aids (plwha), and sexuallytransmittedinfection (sti) clinics patients.
amod||cmr-3/NN||adenosine-1/JJ	nn||cmr-3/NN||stress-2/NN	nsubj||techniques-14/NNS||cmr-3/NN	amod||analyses-11/NNS||qualitative-6/JJ	conj_and||qualitative-6/JJ||semi-quantitative-8/JJ	amod||analyses-11/NNS||semi-quantitative-8/JJ	amod||analyses-11/NNS||normalized-9/JJ	nn||analyses-11/NNS||upslope-10/NN	prep_by||cmr-3/NN||analyses-11/NNS	cop||techniques-14/NNS||are-12/VBP	amod||techniques-14/NNS||reproducible-13/JJ	root||ROOT-0/null||techniques-14/NNS	det||patients-17/NNS||both-16/DT	prep_in||techniques-14/NNS||patients-17/NNS	amod||cad-20/NN||multi-vessel-19/JJ	prep_with||techniques-14/NNS||cad-20/NN	prep_with||techniques-14/NNS||those-22/DT	conj_and||cad-20/NN||those-22/DT	amod||cad-25/NN||known-24/VBN	prep_without||techniques-14/NNS||cad-25/NN	adenosine-1||cad-25||no_rel||adenosine stress cmr, by qualitative and semi-quantitative normalized upslope analyses are reproducible techniques in both patients with multi-vessel cad and those without known cad.
det||role-2/NN||the-1/DT	nsubj||topic-14/NN||role-2/NN	prep_of||role-2/NN||viralinfections-4/NNS	det||development-7/NN||the-6/DT	prep_in||viralinfections-4/NNS||development-7/NN	prep_of||development-7/NN||type1diabetes-9/CD	cop||topic-14/NN||is-10/VBZ	det||topic-14/NN||a-11/DT	advmod||interesting-13/JJ||rather-12/RB	amod||topic-14/NN||interesting-13/JJ	root||ROOT-0/null||topic-14/NN	mark||appear-20/VBP||because-15/IN	amod||models-18/NNS||experimental-17/JJ	prep_in||appear-20/VBP||models-18/NNS	nsubj||appear-20/VBP||viruses-19/NNS	advcl||topic-14/NN||appear-20/VBP	acomp||appear-20/VBP||capable-21/JJ	advmod||accelerating-24/VBG||both-23/DT	prepc_of||capable-21/JJ||accelerating-24/VBG	prepc_of||capable-21/JJ||decelerating-28/VBG	conj_and||accelerating-24/VBG||decelerating-28/VBG	det||processes-31/NNS||the-29/DT	amod||processes-31/NNS||immunological-30/JJ	dobj||decelerating-28/VBG||processes-31/NNS	vmod||processes-31/NNS||leading-32/VBG	prep_to||leading-32/VBG||type1diabetes-34/CD	viralinfections-4||viruses-19||no||the role of viralinfections in the development of type1diabetes is a rather interesting topic because in experimental models viruses appear capable of both accelerating as well as decelerating the immunological processes leading to type1diabetes.
det||expression-2/NN||the-1/DT	nsubjpass||analyzed-25/VBN||expression-2/NN	nn||receptor-5/NN||estrogen-4/NN	prep_of||expression-2/NN||receptor-5/NN	appos||receptor-5/NN||er-7/NN	amod||pr-13/NN||progesterone-10/JJ	nn||pr-13/NN||receptor-11/NN	prep_of||expression-2/NN||pr-13/NN	conj_and||receptor-5/NN||pr-13/NN	prep_of||expression-2/NN||her2-16/NNS	conj_and||receptor-5/NN||her2-16/NNS	prep_of||expression-2/NN||her4-18/NNS	conj_and||receptor-5/NN||her4-18/NNS	nn||m-22/NN||cystatin-21/NN	prep_of||expression-2/NN||m-22/NN	conj_and||receptor-5/NN||m-22/NN	auxpass||analyzed-25/VBN||was-23/VBD	advmod||analyzed-25/VBN||retrospectively-24/RB	root||ROOT-0/null||analyzed-25/VBN	xcomp||analyzed-25/VBN||using-26/VBG	advmod||using-26/VBG||immunohistochemistry-27/RB	num||patients-30/NNS||117-29/CD	prep_in||using-26/VBG||patients-30/NNS	amod||carcinoma-33/NN||ductal-32/JJ	prep_with||patients-30/NNS||carcinoma-33/NN	prep_in||carcinoma-33/NN||situ-35/NN	appos||situ-35/NN||dcis-37/NNS	num||patients-42/NNS||175-41/CD	prep_in||using-26/VBG||patients-42/NNS	conj_and||patients-30/NNS||patients-42/NNS	amod||cancer-46/NN||invasive-44/JJ	nn||cancer-46/NN||breast-45/NN	prep_with||patients-42/NNS||cancer-46/NN	appos||cancer-46/NN||ibc-48/NN	progesterone-10||cancer-46||no_rel||the expression of estrogen receptor (er), progesterone receptor (pr), her2, her4, and cystatin m was retrospectively analyzed using immunohistochemistry in 117 patients with ductal carcinoma in situ (dcis) and in 175 patients with invasive breast cancer (ibc).
mwe||than-2/IN||more-1/JJR	quantmod||50-3/CD||than-2/IN	num||%-4/NN||50-3/CD	nsubj||ribavirin-25/VBZ||%-4/NN	amod||viruses-7/NNS||hepatitisc-6/JJ	prep_of||%-4/NN||viruses-7/NNS	appos||viruses-7/NNS||hcv-9/NN	amod||patients-13/NNS||infected-12/JJ	nsubj||respond-16/VB||patients-13/NNS	aux||respond-16/VB||do-14/VBP	neg||respond-16/VB||not-15/RB	parataxis||ribavirin-25/VBZ||respond-16/VB	det||interferon-20/NN||the-18/DT	amod||interferon-20/NN||classical-19/JJ	prep_to||respond-16/VB||interferon-20/NN	appos||interferon-20/NN||ifn-22/NN	punct||respond-16/VB||/-24/:	root||ROOT-0/null||ribavirin-25/VBZ	dep||ribavirin-25/VBZ||rbv-27/NN	nn||therapy-30/NN||combination-29/NN	dobj||ribavirin-25/VBZ||therapy-30/NN	hepatitisc-6||ribavirin-25||no_rel||more than 50% of hepatitisc viruses (hcv)-infected patients do not respond to the classical interferon (ifn)/ribavirin (rbv) combination therapy.
amod||virus-2/NN||duckplague-1/JJ	nsubj||agent-9/NN||virus-2/NN	appos||virus-2/NN||dpv-4/NN	cop||agent-9/NN||is-6/VBZ	det||agent-9/NN||the-7/DT	amod||agent-9/NN||causative-8/JJ	root||ROOT-0/null||agent-9/NN	nsubj||causes-16/VBZ||agent-9/NN	prep_of||agent-9/NN||duckplague-11/NN	appos||agent-9/NN||dp-13/NN	rcmod||agent-9/NN||causes-16/VBZ	amod||morbidity-18/NN||significant-17/JJ	dobj||causes-16/VBZ||morbidity-18/NN	dobj||causes-16/VBZ||mortality-20/NN	conj_and||morbidity-18/NN||mortality-20/NN	amod||areas-23/NNS||duck-producing-22/JJ	prep_throughout||causes-16/VBZ||areas-23/NNS	det||world-26/NN||the-25/DT	prep_of||areas-23/NNS||world-26/NN	duckplague-11||duckplaguevirus--1||no||duckplague virus (dpv) is the causative agent of duckplague (dp) that causes significant morbidity and mortality throughout duck-producing areas of the world.
aux||evaluate-2/VB||to-1/TO	advcl||etoposide-23/VBP||evaluate-2/VB	dobj||evaluate-2/VB||tolerability-3/NN	dobj||evaluate-2/VB||maintenance-5/NN	conj_and||tolerability-3/NN||maintenance-5/NN	nn||intensity-8/NN||dose-7/NN	prep_of||tolerability-3/NN||intensity-8/NN	num||treatment-12/NN||2-10/CD	amod||treatment-12/NN||weekly-11/JJ	prep_of||intensity-8/NN||treatment-12/NN	prep_with||treatment-12/NN||vincristine-14/NN	nsubj||etoposide-23/VBP||doxorubicin-16/NN	appos||doxorubicin-16/NN||cyclophosphamide-18/NN	vmod||cyclophosphamide-18/NN||alternating-19/VBG	prep_with||alternating-19/VBG||ifosfamide-21/NN	root||ROOT-0/null||etoposide-23/VBP	parataxis||etoposide-23/VBP||vdc/ie-25/VB	prep_in||etoposide-23/VBP||patients-28/NNS	amod||sarcomas-34/NNS||advanced-30/JJ	amod||sarcomas-34/NNS||small-31/JJ	nn||sarcomas-34/NNS||round-32/NN	nn||sarcomas-34/NNS||cell-33/NN	prep_with||patients-28/NNS||sarcomas-34/NNS	amod||tumours-38/NNS||ewing-36/JJ	nn||tumours-38/NNS||family-37/NN	prep_including||etoposide-23/VBP||tumours-38/NNS	appos||tumours-38/NNS||eft-40/NN	amod||tumours-47/NNS||desmoplastic-43/JJ	amod||tumours-47/NNS||small-44/JJ	nn||tumours-47/NNS||round-45/NN	nn||tumours-47/NNS||cell-46/NN	prep_including||etoposide-23/VBP||tumours-47/NNS	conj_and||tumours-38/NNS||tumours-47/NNS	appos||tumours-47/NNS||dsrct-49/NN	amod||sarcomas-57/NNS||undifferentiated-52/JJ	amod||sarcomas-57/NNS||high-53/JJ	nn||sarcomas-57/NNS||grade-54/NN	nn||sarcomas-57/NNS||round-55/NN	nn||sarcomas-57/NNS||cell-56/NN	prep_including||etoposide-23/VBP||sarcomas-57/NNS	conj_and||tumours-38/NNS||sarcomas-57/NNS	appos||sarcomas-57/NNS||uhgrcs-59/NNS	sarcomas-57||ifosfamide-21||yes||to evaluate tolerability and maintenance of dose intensity of 2 weekly treatment with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide, etoposide (vdc/ie) in patients with advanced small round cell sarcomas including ewing family tumours (eft), desmoplastic small round cell tumours (dsrct) and undifferentiated high grade round cell sarcomas (uhgrcs).
det||mechanism-2/NN||this-1/DT	nsubj||has-9/VBZ||mechanism-2/NN	mark||finds-6/VBZ||if-4/IN	nsubj||finds-6/VBZ||it-5/PRP	dep||mechanism-2/NN||finds-6/VBZ	dobj||finds-6/VBZ||support-7/NN	root||ROOT-0/null||has-9/VBZ	amod||implications-11/NNS||important-10/JJ	dobj||has-9/VBZ||implications-11/NNS	amod||research-14/NN||future-13/JJ	prep_for||implications-11/NNS||research-14/NN	det||hazard-18/NN||the-16/DT	nn||hazard-18/NN||mesothelioma-17/NN	prep_into||has-9/VBZ||hazard-18/NN	prep_into||has-9/VBZ||hazard-18/NN	conj_and||hazard-18/NN||hazard-18/NN	prep_from||hazard-18/NN||harn-20/NN	advmod||hazard-18/NN||also-22/RB	poss||view-26/NN||our-24/PRP$	amod||view-26/NN||current-25/JJ	prep_for||hazard-18/NN||view-26/NN	det||origins-29/NNS||the-28/DT	prep_of||view-26/NN||origins-29/NNS	amod||mesothelioma-33/NN||asbestos-initiated-31/JJ	amod||mesothelioma-33/NN||pleural-32/JJ	prep_of||origins-29/NNS||mesothelioma-33/NN	det||use-37/NN||the-35/DT	amod||use-37/NN||common-36/JJ	prep_of||view-26/NN||use-37/NN	conj_and||origins-29/NNS||use-37/NN	prep_of||use-37/NN||lung-39/NN	amod||burden-43/NN||parenchymal-40/JJ	nn||burden-43/NN||asbestos-41/NN	nn||burden-43/NN||fibre-42/NN	pobj||hazard-18/NN||burden-43/NN	det||correlate-46/NN||a-45/DT	prep_as||has-9/VBZ||correlate-46/NN	det||tumour-49/NN||this-48/DT	prep_of||correlate-46/NN||tumour-49/NN	nsubj||arises-53/VBZ||tumour-49/NN	advmod||arises-53/VBZ||actually-52/RB	rcmod||tumour-49/NN||arises-53/VBZ	det||pleura-57/NN||the-55/DT	amod||pleura-57/NN||parietal-56/JJ	prep_in||arises-53/VBZ||pleura-57/NN	asbestos-41||mesothelioma-33||no_rel||this mechanism, if it finds support, has important implications for future research into the mesothelioma hazard from harn and also for our current view of the origins of asbestos-initiated pleural mesothelioma and the common use of lung parenchymal asbestos fibre burden as a correlate of this tumour, which actually arises in the parietal pleura.
nsubj||result-6/VBP||mutations-1/NNS	nsubj||produce-11/VB||mutations-1/NNS	det||gene-5/NN||the-3/DT	nn||gene-5/NN||hfe-4/NN	prep_in||mutations-1/NNS||gene-5/NN	ccomp||characterized-22/VBD||result-6/VBP	prep_in||result-6/VBP||ironoverload-8/NN	aux||produce-11/VB||can-10/MD	conj_and||result-6/VBP||produce-11/VB	ccomp||characterized-22/VBD||produce-11/VB	dobj||produce-11/VB||hereditaryhemochromatosis-12/NNS	appos||hereditaryhemochromatosis-12/NNS||hh-14/NN	det||disorder-18/NN||a-17/DT	nsubj||characterized-22/VBD||disorder-18/NN	nn||metabolism-21/NN||iron-20/NN	prep_of||disorder-18/NN||metabolism-21/NN	root||ROOT-0/null||characterized-22/VBD	amod||absorption-27/NN||increased-24/VBN	amod||absorption-27/NN||intestinal-25/JJ	nn||absorption-27/NN||iron-26/NN	prep_by||characterized-22/VBD||absorption-27/NN	ironoverload-8||iron-26||no||mutations in the hfe gene result in ironoverload and can produce hereditaryhemochromatosis (hh), a disorder of iron metabolism characterized by increased intestinal iron absorption.
det||patients-2/NNS||the-1/DT	nsubj||group-8/NN||patients-2/NNS	cop||group-8/NN||were-3/VBD	amod||group-8/NN||divided-4/VBN	num||groups-7/NNS||5-6/CD	prep_into||divided-4/VBN||groups-7/NNS	root||ROOT-0/null||group-8/NN	dep||diabetic-12/NN||1-10/LS	dep||group-8/NN||diabetic-12/NN	amod||levels-16/NNS||normal-14/JJ	amod||levels-16/NNS||glycemic-15/JJ	prep_with||diabetic-12/NN||levels-16/NNS	aux||american-19/VB||to-18/TO	dep||n-27/VBN||american-19/VB	nn||criteria-22/NNS||diabetes-20/NN	nn||criteria-22/NNS||association-21/NN	dobj||american-19/VB||criteria-22/NNS	amod||patients-25/NNS||in-hospital-24/JJ	prep_for||american-19/VB||patients-25/NNS	prep_according||levels-16/NNS||n-27/VBN	dep||123-29/CD||=-28/SYM	ccomp||n-27/VBN||123-29/CD	conj_and||group-8/NN||group-32/NN	dep||diabetics-36/NNS||2-34/LS	dep||group-32/NN||diabetics-36/NNS	prep_with||diabetics-36/NNS||hyperglycemia-38/NN	dep||group-32/NN||n-40/VBN	dep||76-42/CD||=-41/SYM	ccomp||n-40/VBN||76-42/CD	conj_and||group-8/NN||group-45/NN	dep||non-diabetics-49/NNS||3-47/LS	dep||group-45/NN||non-diabetics-49/NNS	prep_with||non-diabetics-49/NNS||hyperglycemia-51/NN	dep||group-45/NN||n-53/VBN	dep||225-55/CD||=-54/SYM	ccomp||n-53/VBN||225-55/CD	conj_and||group-8/NN||group-58/NN	dep||diabetics-62/NNS||4-60/LS	dep||group-58/NN||diabetics-62/NNS	dep||group-58/NN||non-diabetics-64/NNS	conj_and||diabetics-62/NNS||non-diabetics-64/NNS	amod||hyperglycemia-67/NN||persistent-66/JJ	prep_with||diabetics-62/NNS||hyperglycemia-67/NN	num||days-71/NNS||3-69/CD	amod||days-71/NNS||consecutive-70/JJ	prep_during||hyperglycemia-67/NN||days-71/NNS	dep||group-58/NN||n-73/VBN	dep||57-75/CD||=-74/SYM	ccomp||n-73/VBN||57-75/CD	conj_and||group-8/NN||group-78/NN	appos||group-78/NN||5-80/CD	dep||group-78/NN||those-82/DT	amod||control-86/NN||normal-84/JJ	nn||control-86/NN||glucose-85/NN	prep_with||group-78/NN||control-86/NN	dep||control-86/NN||n-88/VBN	dep||298-90/NNS||=-89/SYM	ccomp||n-88/VBN||298-90/NNS	hyperglycemia-67||glucose-85||no||the patients were divided into 5 groups group (1) diabetic with normal glycemic levels according to american diabetes association criteria for in-hospital patients (n = 123); group (2) diabetics with hyperglycemia (n = 76); group (3) non-diabetics with hyperglycemia (n = 225); group (4)diabetics and non-diabetics with persistent hyperglycemia during 3 consecutive days (n = 57) and group (5) those with normal glucose control (n = 298).
nsubjpass||prompted-35/VBN||reports-1/NNS	mark||abundant-17/JJ||that-2/IN	nsubj||abundant-17/JJ||bacteria-3/NNS	det||phylum-7/NN||the-5/DT	amod||phylum-7/NN||firmicutes-6/JJ	prep_within||bacteria-3/NNS||phylum-7/NN	advmod||phylum-7/NN||especially-9/RB	det||prausnitzii-13/NN||the-10/DT	nn||prausnitzii-13/NN||species-11/NN	nn||prausnitzii-13/NN||faecalibacterium-12/NN	dep||phylum-7/NN||prausnitzii-13/NN	cop||abundant-17/JJ||are-15/VBP	advmod||abundant-17/JJ||less-16/RBR	dep||reports-1/NNS||abundant-17/JJ	poss||patients-25/NNS||crohn-19/NN	nn||patients-25/NNS||disease-21/NN	nn||patients-25/NNS||-lrb--22/NN	nn||patients-25/NNS||cd-23/NN	nn||patients-25/NNS||-rrb--24/NN	prep_in||abundant-17/JJ||patients-25/NNS	prep_in||abundant-17/JJ||supernatants-27/NNS	conj_and||patients-25/NNS||supernatants-27/NNS	prep_from||abundant-17/JJ||cultures-29/NNS	det||bacterium-32/NN||this-31/DT	prep_of||cultures-29/NNS||bacterium-32/NN	auxpass||prompted-35/VBN||are-33/VBP	advmod||prompted-35/VBN||anti-inflammatory-34/RB	root||ROOT-0/null||prompted-35/VBN	det||investigation-37/NN||the-36/DT	dobj||prompted-35/VBN||investigation-37/NN	det||correlations-41/NNS||the-39/DT	amod||correlations-41/NNS||possible-40/JJ	prep_of||investigation-37/NN||correlations-41/NNS	det||abundance-44/NN||the-43/DT	prep_between||correlations-41/NNS||abundance-44/NN	nn||prausnitzii-47/NNS||f.-46/NN	prep_of||abundance-44/NN||prausnitzii-47/NNS	det||response-50/NN||the-49/DT	prep_of||abundance-44/NN||response-50/NN	conj_and||prausnitzii-47/NNS||response-50/NN	prep_to||prompted-35/VBN||treatment-52/NN	prep_in||prompted-35/VBN||patients-54/NNS	nn||diseases-57/NNS||gut-56/NN	prep_with||patients-54/NNS||diseases-57/NNS	amod||controls-60/NNS||healthy-59/JJ	prep_with||patients-54/NNS||controls-60/NNS	conj_and||diseases-57/NNS||controls-60/NNS	anti-inflammatory-34||crohn's disease--1||no_rel||reports that bacteria within the firmicutes phylum , especially the species faecalibacterium prausnitzii , are less abundant in crohn 's disease -lrb- cd -rrb- patients and supernatants from cultures of this bacterium are anti-inflammatory prompted the investigation of the possible correlations between the abundance of f. prausnitzii and the response to treatment in patients with gut diseases and healthy controls .
nsubj||exerts-2/VBZ||adiponectin-1/NN	root||ROOT-0/null||exerts-2/VBZ	amod||effects-5/NNS||multiple-3/JJ	amod||effects-5/NNS||protective-4/JJ	dobj||exerts-2/VBZ||effects-5/NNS	prep_against||exerts-2/VBZ||cardiovasculardisease-7/NN	acomp||exerts-2/VBZ||independent-9/JJ	poss||activity-13/NN||its-11/PRP$	amod||activity-13/NN||insulin-sensitizing-12/JJ	prep_of||independent-9/JJ||activity-13/NN	insulin--1||cardiovasculardisease-7||no_rel||adiponectin exerts multiple protective effects against cardiovasculardisease, independent of its insulin-sensitizing activity.
amod||causes-2/NNS||potential-1/JJ	nsubj||include-12/VBP||causes-2/NNS	amod||deterioration-5/NN||clinical-4/JJ	prep_for||causes-2/NNS||deterioration-5/NN	prep_in||deterioration-5/NN||settings-7/NNS	amod||prevalence-11/NN||high-9/JJ	amod||prevalence-11/NN||hiv-1-10/JJ	prep_of||settings-7/NNS||prevalence-11/NN	root||ROOT-0/null||include-12/VBP	npadvmod||resistant-14/JJ||drug-13/NN	amod||mycobacteriumtuberculosis-15/NNS||resistant-14/JJ	dobj||include-12/VBP||mycobacteriumtuberculosis-15/NNS	appos||mycobacteriumtuberculosis-15/NNS||m.tb-17/NN	amod||illnesses-21/NNS||co-morbid-20/JJ	dobj||include-12/VBP||illnesses-21/NNS	conj_and||mycobacteriumtuberculosis-15/NNS||illnesses-21/NNS	amod||adherence-24/NN||poor-23/JJ	dobj||include-12/VBP||adherence-24/NN	conj_and||mycobacteriumtuberculosis-15/NNS||adherence-24/NN	nn||syndrome-32/NN||therapy-26/NN	nn||syndrome-32/NN||tuberculosis-28/NNP	amod||syndrome-32/NN||associated-immune-29/JJ	amod||syndrome-32/NN||reconstitution-30/JJ	amod||syndrome-32/NN||inflammatory-31/JJ	prep_to||adherence-24/NN||syndrome-32/NN	appos||syndrome-32/NN||tb-iris-34/NNS	amod||levels-40/NNS||subtherapeutic-37/JJ	nn||levels-40/NNS||antitubercular-38/NN	nn||levels-40/NNS||drug-39/NN	dobj||include-12/VBP||levels-40/NNS	conj_and||mycobacteriumtuberculosis-15/NNS||levels-40/NNS	tuberculosis-28||mycobacteriumtuberculosis-15||no||potential causes for clinical deterioration in settings of high hiv-1 prevalence include drug resistant mycobacteriumtuberculosis (m.tb) , co-morbid illnesses, poor adherence to therapy, tuberculosis associated-immune reconstitution inflammatory syndrome (tb-iris) and subtherapeutic antitubercular drug levels.
det||sample-6/NN||any-1/DT	amod||sample-6/NN||patient-2/JJ	prep_with||patient-2/JJ||one-4/CD	nn||sample-6/NN||blood-5/NN	nsubj||received-15/VBD||sample-6/NN	vmod||sample-6/NN||containing-7/VBG	quantmod||than-9/IN||more-8/JJR	num||genomes-12/NNS||than-9/IN	num||cytomegalovirus-11/NNS||3000-10/CD	dep||than-9/IN||cytomegalovirus-11/NNS	dobj||containing-7/VBG||genomes-12/NNS	prep_per||genomes-12/NNS||ml-14/NN	root||ROOT-0/null||received-15/VBD	dobj||received-15/VBD||ganciclovir-16/NN	num||measurements-23/NNS||two-18/CD	amod||measurements-23/NNS||consecutive-19/JJ	amod||measurements-23/NNS||undetectable-20/JJ	nn||measurements-23/NNS||cytomegalovirus-21/NN	nn||measurements-23/NNS||dna-22/NN	prep_until||received-15/VBD||measurements-23/NNS	cytomegalovirus-21||ganciclovir-16||yes||any patient with one blood sample containing more than 3000 cytomegalovirus genomes per ml received ganciclovir until two consecutive undetectable cytomegalovirus dna measurements.
det||data-4/NNS||an-1/DT	amod||data-4/NNS||availably-2/JJ	amod||data-4/NNS||statistical-3/JJ	nsubjpass||used-8/VBN||data-4/NNS	nsubj||assess-10/VB||data-4/NNS	nsubjpass||obtained-24/VBN||data-4/NNS	auxpass||used-8/VBN||are-7/VBP	rcmod||data-4/NNS||used-8/VBN	aux||assess-10/VB||to-9/TO	xcomp||used-8/VBN||assess-10/VB	det||capability-13/NN||the-11/DT	nn||capability-13/NN||detection-12/NN	dobj||assess-10/VB||capability-13/NN	prep_of||capability-13/NN||networks-15/NNS	prep_on||networks-15/NNS||avianinfluenzavirus-17/NNS	appos||avianinfluenzavirus-17/NNS||h5n1-19/NNP	aux||obtained-24/VBN||can-22/MD	auxpass||obtained-24/VBN||be-23/VB	root||ROOT-0/null||obtained-24/VBN	advmod||easily-26/RB||relatively-25/RB	advmod||obtained-24/VBN||easily-26/RB	prep_through||obtained-24/VBN||implementation-28/NN	det||panel-31/NN||the-30/DT	prep_of||implementation-28/NN||panel-31/NN	prep_on||panel-31/NN||networks-33/NNS	h5n1-19||avianinfluenzavirus-17||no||an availably statistical data, which are used to assess the detection capability of networks on avianinfluenzavirus (h5n1), can be obtained relatively easily through implementation of the panel on networks.
amod||scores-4/NNS||verbal-1/JJ	amod||scores-4/NNS||analogue-2/JJ	nn||scores-4/NNS||pain-3/NN	nsubj||boluses-9/VBZ||scores-4/NNS	appos||scores-4/NNS||need-6/NN	prep_of||need-6/NN||supplementary/rescue-8/NN	ccomp||recorded-27/VBN||boluses-9/VBZ	dobj||boluses-9/VBZ||dose-10/NN	prep_of||dose-10/NN||bupivacaine-12/NN	vmod||bupivacaine-12/NN||consumed-13/VBN	nsubjpass||recorded-27/VBN||mode-15/NN	prep_of||mode-15/NN||delivery-17/NN	amod||satisfaction-20/NN||maternal-19/JJ	prep_of||mode-15/NN||satisfaction-20/NN	conj_and||delivery-17/NN||satisfaction-20/NN	amod||scores-25/NNS||neonatal-23/JJ	nn||scores-25/NNS||apgar-24/NN	prep_of||mode-15/NN||scores-25/NNS	conj_and||delivery-17/NN||scores-25/NNS	auxpass||recorded-27/VBN||were-26/VBD	root||ROOT-0/null||recorded-27/VBN	pain-3||bupivacaine-12||yes||verbal analogue pain scores, need of supplementary/rescue boluses dose of bupivacaine consumed, mode of delivery, maternal satisfaction, and neonatal apgar scores were recorded.
det||duplication-5/NN||the-1/DT	amod||duplication-5/NN||flt3-2/JJ	amod||duplication-5/NN||internal-3/JJ	nn||duplication-5/NN||tandem-4/NN	nsubjpass||analyzed-23/VBN||duplication-5/NN	nsubjpass||analyzed-23/VBN||duplication-5/NN	appos||duplication-5/NN||itd-7/NN	det||mutation-13/NN||the-10/DT	amod||mutation-13/NN||d835-11/JJ	amod||mutation-13/NN||activating-12/VBG	conj_and||duplication-5/NN||mutation-13/NN	nsubjpass||analyzed-23/VBN||mutation-13/NN	det||domain-18/NN||the-15/DT	amod||domain-18/NN||tyrosine-16/JJ	nn||domain-18/NN||kinase-17/NN	prep_in||mutation-13/NN||domain-18/NN	dep||mutation-13/NN||tkd-20/VBN	auxpass||analyzed-23/VBN||were-22/VBD	root||ROOT-0/null||analyzed-23/VBN	conj_and||analyzed-23/VBN||analyzed-23/VBN	nn||reaction-27/NN||polymerase-25/NN	nn||reaction-27/NN||chain-26/NN	agent||analyzed-23/VBN||reaction-27/NN	appos||reaction-27/NN||pcr-29/NN	det||dna-34/NN||the-32/DT	amod||dna-34/NN||genomic-33/JJ	prep_in||reaction-27/NN||dna-34/NN	nn||patients-37/NNS||korean-36/NN	prep_of||dna-34/NN||patients-37/NNS	prep_with||analyzed-23/VBN||aml-39/NN	prep_at||analyzed-23/VBN||diagnosis-41/NN	prep_during||analyzed-23/VBN||follow-up-44/NN	aml-39||tyrosine-16||no_rel||the flt3 internal tandem duplication (itd) and the d835 activating mutation in the tyrosine kinase domain (tkd) were analyzed by polymerase chain reaction (pcr) in the genomic dna of korean patients with aml at diagnosis and during follow-up.
